nonylphenol	B-C1254354
diethoxylate	I-C1254354
inhibits	B-C3463820
apoptosis	B-C0162638
induced	B-C0205263
in	O
pc12	B-C0085262
cells	I-C0085262
nonylphenol	B-C1254354
and	O
short-chain	B-C1254354
nonylphenol	I-C1254354
ethoxylates	I-C1254354
such	O
as	O
np2	B-C1254354
eo	I-C1254354
are	O
present	B-C0150312
in	O
aquatic	B-C0563034
environment	I-C0563034
as	O
wastewater	B-C3494254
contaminants	B-C2827365
,	O
and	O
their	O
toxic	B-C0600688
effects	I-C0600688
on	O
aquatic	B-C0596121
species	I-C0596121
have	O
been	O
reported	O
.	O
	
apoptosis	B-C0162638
has	O
been	O
shown	O
to	O
be	O
induced	B-C0205263
by	O
serum	B-C0229671
deprivation	B-C0871712
or	O
copper	B-C0009968
treatment	B-C1522326
.	O
	
to	O
understand	O
the	O
toxicity	B-C0040539
of	O
nonylphenol	B-C1254354
diethoxylate	I-C1254354
,	O
we	O
investigated	O
the	O
effects	B-C1704420
of	I-C1704420
np2	B-C1254354
eo	I-C1254354
on	O
apoptosis	B-C0162638
induced	B-C0205263
by	O
serum	B-C0229671
deprivation	B-C0871712
and	O
copper	B-C0009968
by	O
using	O
pc12	B-C0085262
cell	I-C0085262
system	I-C0085262
.	O
	
nonylphenol	B-C1254354
diethoxylate	I-C1254354
itself	O
showed	O
no	O
toxicity	O
and	O
recovered	O
cell	B-C0007620
viability	I-C0007620
from	O
apoptosis	B-C0162638
.	O
	
in	O
addition	O
,	O
nonylphenol	B-C1254354
diethoxylate	I-C1254354
decreased	B-C0205216
dna	B-C0376669
fragmentation	I-C0376669
caused	O
by	O
apoptosis	B-C0162638
in	O
pc12	B-C0085262
cells	I-C0085262
.	O
	
this	O
phenomenon	B-C1882365
was	O
confirmed	O
after	O
treating	B-C1522326
apoptotic	B-C1516044
pc12	B-C0085262
cells	I-C0085262
with	O
nonylphenol	B-C1254354
diethoxylate	I-C1254354
,	O
whereas	O
the	O
cytochrome	B-C0010749
c	I-C0010749
release	O
into	O
the	O
cytosol	B-C1383501
decreased	B-C0205216
as	O
compared	O
to	O
that	O
in	O
apoptotic	B-C0007634
cells	I-C0007634
not	O
treated	B-C1522326
with	O
nonylphenol	B-C1254354
diethoxylate	I-C1254354
s	O
.	O
	
furthermore	O
,	O
bax	B-C0219474
contents	B-C0456205
in	O
apoptotic	B-C0007634
cells	I-C0007634
were	O
reduced	B-C0392756
after	O
exposure	B-C0332157
to	I-C0332157
nonylphenol	B-C1254354
diethoxylate	I-C1254354
.	O
	
thus	O
,	O
nonylphenol	B-C1254354
diethoxylate	I-C1254354
has	O
the	O
opposite	B-C1280500
effect	I-C1280500
on	O
apoptosis	B-C0162638
in	O
pc12	B-C0085262
cells	I-C0085262
compared	O
to	O
nonylphenol	B-C1254354
,	O
which	O
enhances	B-C2349975
apoptosis	B-C0162638
induced	B-C0205263
by	O
serum	B-C0229671
deprivation	B-C0871712
.	O
	
the	O
difference	B-C1705242
in	O
structure	B-C0678594
of	O
the	O
two	O
compounds	B-C0220806
is	O
hypothesized	B-C1512571
to	O
be	O
responsible	O
for	O
this	O
phenomenon	B-C1882365
.	O
	
these	O
results	B-C2825142
indicated	O
that	O
nonylphenol	B-C1254354
diethoxylate	I-C1254354
has	O
capability	B-C2698977
to	O
affect	O
cell	B-C0007589
differentiation	I-C0007589
and	O
development	B-C0243107
and	O
has	O
potentially	B-C3245505
harmful	B-C0600688
effect	I-C0600688
on	O
organisms	B-C0029235
because	O
of	O
its	O
unexpected	O
impact	B-C4049986
on	O
apoptosis	B-C0162638
.	O
	
ezh2	B-C1333368
and	O
zfx	B-C1421578
oncogenes	B-C0029016
in	O
malignant	B-C0205282
behaviour	I-C0205282
of	O
parathyroid	B-C0030521
neoplasms	I-C0030521
several	O
studies	B-C0008972
reported	O
somatic	B-C0544886
mutations	I-C0544886
of	O
many	O
genes	B-C0017337
men1	B-C0694884
,	O
ctnnb1	B-C1332803
,	O
cdkis	B-C0919539
and	O
others	O
in	O
parathyroid	B-C0262587
adenoma	I-C0262587
,	O
although	O
with	O
different	B-C1705242
prevalence	B-C0220900
.	O
	
recently	O
,	O
activating	B-C1879547
mutations	B-C0026882
of	O
the	O
ezh2	B-C1333368
and	O
zfx	B-C1421578
oncogenes	B-C0029016
were	O
identified	O
in	O
benign	B-C0205183
parathyroid	B-C0262587
adenoma	I-C0262587
by	O
whole	B-C3640077
exome	I-C3640077
sequencing	I-C3640077
.	O
	
the	O
same	O
mutations	B-C0026882
had	O
been	O
found	O
in	O
blood	B-C0005767
and	O
ovary	B-C0029939
malignant	B-C0006826
tumours	I-C0006826
.	O
	
on	O
one	O
hand	O
,	O
this	O
result	O
raised	O
the	O
hypothesis	B-C1512571
that	O
these	O
oncogenes	B-C0029016
may	O
play	O
a	O
role	O
in	O
the	O
onset	B-C0332162
of	O
parathyroid	B-C0030521
tumour	I-C0030521
,	O
but	O
it	O
would	O
also	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
malignant	B-C0205282
,	O
rather	O
benign	B-C0205183
,	O
parathyroid	B-C0030521
neoplasm	I-C0030521
.	O
	
our	O
aim	B-C1947946
was	O
to	O
verify	O
the	O
occurrence	B-C2745955
of	O
selected	O
mutations	B-C0026882
of	O
the	O
ezh2	B-C1333368
and	O
zfx	B-C1421578
genes	I-C1421578
in	O
an	O
italian	B-C0337810
cohort	B-C0599755
of	O
23	O
sporadic	B-C0205422
parathyroid	B-C0687150
carcinomas	I-C0687150
,	O
12	O
atypical	B-C0205182
and	O
45	O
typical	B-C3538928
adenomas	B-C0001430
.	O
	
dna	B-C0012854
was	O
extracted	B-C0185115
from	O
paraffin-embedded	B-C1519524
tissues	I-C1519524
,	O
pcr	B-C0032520
amplified	B-C1521871
and	O
directly	O
sequenced	B-C1561491
.	O
	
no	B-C0205160
mutations	B-C0026882
were	O
detected	B-C0442726
in	O
the	O
coding	B-C0015295
sequence	I-C0015295
and	O
boundaries	B-C1136191
of	O
both	O
genes	B-C0017337
in	O
any	O
of	O
the	O
samples	B-C0370003
.	O
	
two	O
polymorphisms	B-C0678951
of	O
the	O
ezh2	B-C1333368
gene	I-C1333368
were	O
identified	B-C0205396
with	O
different	B-C1705242
prevalence	B-C0033105
the	O
rs2072407	B-C0678941
variant	I-C0678941
was	O
present	B-C0150312
in	O
the	O
30	O
%	O
of	O
the	O
samples	B-C0370003
,	O
in	O
keeping	O
with	O
the	O
overall	B-C1561607
frequency	B-C0439603
in	O
larger	B-C0549177
populations	B-C0032659
,	O
while	O
the	O
rs78589034	B-C0678941
variant	I-C0678941
,	O
located	O
close	O
to	O
the	O
5'	B-C1254348
end	I-C1254348
of	O
the	O
exon	B-C0015295
16	I-C0015295
,	O
was	O
detected	B-C0442726
in	O
only	O
one	O
proband	B-C1948021
with	O
familial	B-C0241888
isolated	B-C0205409
hyperparathyroidism	B-C0020502
we	O
investigated	B-C1292732
the	O
possible	O
outcome	B-C1274040
on	O
the	O
splicing	B-C0035687
process	I-C0035687
.	O
	
ezh2	B-C1333368
and	O
zfx	B-C1421578
genes	I-C1421578
do	O
not	O
seem	O
to	O
have	O
an	O
impact	B-C4049986
on	O
the	O
onset	B-C0332162
of	O
most	O
parathyroid	B-C0030521
tumours	I-C0030521
,	O
both	O
benign	B-C0205183
and	O
malignant	B-C0205282
,	O
though	O
further	O
studies	O
on	O
larger	B-C0549177
cohorts	B-C0599755
of	O
different	B-C1705242
ethnicity	B-C0243103
patient	B-C0030705
-	O
physician	B-C0031831
discordance	B-C1705242
in	O
global	B-C0281858
assessment	I-C0281858
in	O
rheumatoid	B-C0003873
arthritis	I-C0003873
a	O
systematic	B-C0220922
literature	B-C0282441
review	I-C0282441
with	O
meta-analysis	B-C0920317
the	O
integration	O
of	O
the	O
patient	B-C0030705
in	O
therapeutic	B-C0302350
decision-making	B-C0011109
is	O
important	O
in	O
the	O
management	B-C0376636
of	O
rheumatoid	B-C0003873
arthritis	I-C0003873
ra	B-C0003873
,	O
but	O
the	O
patient	B-C0030705
opinion	B-C0871010
regarding	O
disease	B-C0012634
status	B-C0449438
may	O
differ	O
from	O
the	O
physician's	B-C0031831
opinion	B-C0871010
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
assess	B-C1516048
in	O
the	O
published	B-C0023866
literature	I-C0023866
the	O
frequency	B-C0376249
and	O
drivers	O
of	O
patient	B-C0030705
-	O
physician	B-C0031831
discordance	B-C1705242
in	O
global	B-C0281858
assessment	I-C0281858
in	O
ra	B-C0003873
.	O
	
a	O
systematic	B-C0220922
literature	B-C0282441
review	I-C0282441
of	O
all	O
articles	B-C1706852
published	B-C0034037
up	O
to	O
january	O
2015	O
in	O
medline	B-C0025141
or	O
embase	B-C0282574
,	O
reporting	O
discordance	B-C1705242
in	O
ra	B-C0003873
,	O
was	O
conducted	O
by	O
2	O
investigators	B-C0035173
.	O
	
discordance	B-C1705242
was	O
defined	O
based	O
on	O
the	O
absolute	B-C1705242
difference	I-C1705242
of	O
patient	B-C4054229
global	I-C4054229
pga	B-C4054229
and	O
physician	B-C0281858
global	I-C0281858
assessments	I-C0281858
phga	B-C0281858
on	O
0-10-cm	O
scales	O
.	O
	
the	O
frequency	B-C0376249
of	O
discordance	B-C1705242
and	O
its	O
predictors	B-C0035648
were	O
collected	O
in	O
each	O
study	B-C2603343
.	O
	
frequencies	B-C0376249
of	O
discordance	B-C1705242
were	O
pooled	B-C2349200
by	O
meta-analysis	B-C0920317
using	O
random	B-C0439605
effect	B-C1280500
.	O
	
in	O
all	O
,	O
12	O
studies	B-C2603343
were	O
selected	O
i.e	O
,	O
11	O
patients	B-C0030705
weighted	B-C0444504
mean	I-C0444504
sd	O
age	B-C0001779
was	O
55.1	O
13.9	O
years	B-C0439234
,	O
weighted	B-C0444504
mean	I-C0444504
sd	O
disease	B-C0872146
duration	I-C0872146
was	O
10.4	O
9.3	O
years	B-C0439234
,	O
and	O
80.7	O
were	O
women	B-C0043210
.	O
	
the	O
value	B-C1522609
of	O
the	O
difference	B-C1705241
|	O
pga	B-C4054229
-	O
phga	B-C0281858
|	O
defining	O
discordance	B-C1705242
varied	O
between	O
0.5	O
cm	O
n	O
=	O
2	O
studies	O
to	O
3	O
cm	O
n	O
=	O
5	O
studies	O
the	O
weighted	B-C0444504
mean	I-C0444504
value	I-C0444504
was	O
2.7	O
cm	O
.	O
	
the	O
pooled	B-C2349200
percentage	B-C0439165
of	O
patients	B-C0030705
with	O
discordance	B-C1705242
was	O
43%	O
95%	O
confidence	B-C0009667
interval	I-C0009667
36%-51%	O
range	B-C1514721
25%-76%	O
.	O
	
pga	B-C4054229
was	O
usually	O
higher	B-C0205250
than	O
phga	B-C0281858
.	O
	
the	O
drivers	O
of	O
pga	B-C4054229
were	O
pain	B-C0030193
and	O
functional	B-C0205245
incapacity	B-C3176592
,	O
whereas	O
drivers	O
of	O
phga	B-C0281858
were	O
joint	B-C0282574
counts	I-C0282574
and	O
acute-phase	B-C0001347
reactants	I-C0001347
.	O
	
discordance	B-C1705242
in	O
global	B-C0281858
assessment	I-C0281858
was	O
most	O
frequently	B-C0332183
defined	O
as	O
a	O
difference	B-C1705242
of	O
3	O
points	O
or	O
more	O
even	O
with	O
such	O
a	O
stringent	O
definition	O
,	O
up	O
to	O
half	B-C2825407
the	O
patients	B-C0030705
were	O
found	O
to	O
be	O
discordant	B-C1705242
.	O
	
the	O
long-term	B-C0443252
consequences	B-C0686907
of	O
this	O
discordance	B-C1705242
a	O
randomized	B-C0206035
controlled	I-C0206035
noninferiority	I-C0206035
trial	I-C0206035
of	O
single	B-C0178602
dose	I-C0178602
of	O
oral	B-C0360528
dexamethasone	I-C0360528
versus	O
5	O
days	B-C0439228
of	O
oral	B-C3216040
prednisone	I-C3216040
in	O
acute	O
adult	B-C0001675
asthma	B-C0004096
oral	B-C0360528
dexamethasone	I-C0360528
demonstrates	B-C3687625
bioavailability	B-C0005508
similar	B-C2348205
to	O
that	O
of	O
oral	B-C3216040
prednisone	I-C3216040
but	O
has	O
a	O
longer	O
half-life	B-C0018517
.	O
	
we	O
evaluate	O
whether	O
a	O
single	B-C0178602
dose	I-C0178602
of	O
oral	B-C0360528
dexamethasone	I-C0360528
plus	B-C0332287
4	O
days	B-C0439228
of	O
placebo	B-C1696465
is	O
not	O
inferior	B-C0542339
to	O
5	O
days	B-C0439228
of	O
oral	B-C3216040
prednisone	I-C3216040
in	O
treatment	B-C1522326
of	O
adults	B-C0001675
with	O
mild	B-C0581124
to	O
moderate	B-C0581125
asthma	B-C0349790
exacerbations	I-C0349790
to	O
prevent	B-C1292733
relapse	B-C0035020
defined	O
as	O
an	O
unscheduled	B-C3854240
return	O
visit	O
for	O
additional	B-C1706712
treatment	I-C1706712
for	O
persistent	B-C3266628
or	O
worsening	B-C0332271
asthma	B-C0004096
within	O
14	O
days	B-C0439228
.	O
	
adult	B-C0001675
emergency	B-C3840745
department	I-C3840745
patients	B-C0030705
aged	B-C0001779
18	O
to	O
55	O
years	B-C0439234
were	O
randomized	B-C0034656
to	O
receive	B-C1514756
either	O
a	O
single	B-C0178602
dose	I-C0178602
of	O
12	O
mg	O
of	O
oral	B-C0360528
dexamethasone	I-C0360528
with	O
4	O
days	B-C0439228
of	O
placebo	B-C1696465
or	O
a	O
5-	O
day	B-C0439228
course	B-C0750729
of	O
oral	B-C3216040
prednisone	I-C3216040
60	O
mg	O
a	O
day	B-C0439228
.	O
	
outcomes	B-C1274040
including	B-C0332257
relapse	B-C0035020
were	O
assessed	B-C1516048
by	O
a	O
follow-up	B-C0178941
telephone	I-C0178941
interview	I-C0178941
at	O
2	O
weeks	B-C0439230
.	O
	
one	O
hundred	B-C0392762
seventy-three	I-C0392762
dexamethasone	B-C0011777
and	O
203	O
prednisone	B-C0032952
subjects	B-C0681850
completed	B-C0205197
the	O
study	O
regimen	O
and	O
telephone	B-C0178941
follow-up	I-C0178941
.	O
	
the	O
dexamethasone	B-C0011777
group	B-C0681860
by	O
a	O
small	O
margin	O
surpassed	O
the	O
preset	O
8%	O
difference	B-C1705242
between	O
groups	B-C0681860
for	O
noninferiority	B-C0205556
in	O
relapse	B-C0035020
rates	B-C1521828
within	O
14	O
days	B-C0439228
12.1	O
versus	O
9.8	O
difference	B-C1705242
2.3	O
95%	O
confidence	B-C0009667
interval	I-C0009667
-4	O
to	O
8.6	O
.	O
	
subjects	B-C0681850
in	O
the	O
2	O
groups	B-C0681860
had	O
similar	O
rates	B-C1521828
of	O
hospitalization	B-C0019993
for	O
their	O
relapse	B-C0035020
visit	B-C1512346
dexamethasone	B-C0011777
3.4	O
versus	O
prednisone	B-C0032952
2.9	O
difference	B-C1705242
0.5	O
95%	O
confidence	B-C0009667
interval	I-C0009667
-4	O
to	O
3.1	O
.	O
	
adverse	B-C1280500
effect	I-C1280500
rates	B-C1521828
were	O
generally	O
the	O
same	O
in	O
the	O
2	O
groups	B-C0681860
.	O
	
a	O
single	B-C0178602
dose	I-C0178602
of	O
oral	B-C0360528
dexamethasone	I-C0360528
did	O
not	O
demonstrate	B-C3687625
noninferiority	B-C0205556
to	O
prednisone	B-C0032952
for	O
5	O
days	B-C0439228
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	B-C1522326
of	O
adults	B-C0001675
with	O
mild	B-C0581124
to	O
moderate	B-C0581125
asthma	B-C0349790
exacerbations	I-C0349790
.	O
	
enhanced	B-C2349975
compliance	B-C3714738
and	O
convenience	B-C3831015
may	O
support	O
the	O
use	B-C0457083
of	O
dexamethasone	B-C0011777
malignancy	B-C4282132
is	O
associated	B-C0332281
with	I-C0332281
microcalcification	B-C0521174
and	O
higher	B-C0456603
ap/t	I-C0456603
ratio	I-C0456603
in	O
ultrasonography	B-C0041618
,	O
but	O
not	O
with	O
hashimoto's	B-C0677607
thyroiditis	I-C0677607
in	O
histopathology	B-C0430445
in	O
patients	B-C0030705
with	O
thyroid	B-C0040137
nodules	I-C0040137
evaluated	O
as	O
bethesda	B-C0040137
category	I-C0040137
iii	I-C0040137
aus	B-C0522580
/	O
flus	B-C1272585
in	O
cytology	B-C1305671
the	O
predictors	B-C0683956
of	O
malignancy	B-C4282132
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	B-C0376636
in	O
nodules	B-C0040137
with	O
atypia	B-C0522580
of	I-C0522580
undetermined	I-C0522580
significance	I-C0522580
/	O
follicular	B-C1272585
lesion	I-C1272585
of	I-C1272585
undetermined	I-C1272585
significance	I-C1272585
aus	B-C0522580
/	O
flus	B-C1272585
.	O
	
our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	B-C0683956
,	O
clinical	B-C0683956
,	O
and	O
biochemical	B-C0683956
predictors	I-C0683956
of	O
malignancy	B-C4282132
in	O
these	O
patients	B-C0030705
.	O
	
a	O
total	O
of	O
427	O
patients	B-C0030705
with	O
cytologically	B-C0040137
bethesda	I-C0040137
category	I-C0040137
iii	I-C0040137
aus	B-C0522580
/	O
flus	B-C1272585
thyroid	B-C0040137
nodules	I-C0040137
were	O
included	O
in	O
this	O
retrospective	B-C0035363
study	I-C0035363
.	O
	
we	O
divided	O
the	O
nodules	B-C0040137
into	O
two	O
subgroups	B-C1257890
according	O
to	O
the	O
histopathology	B-C0430445
as	O
benign	B-C0205183
and	O
malignant	B-C0205282
,	O
and	O
compared	O
the	O
preoperative	B-C0445204
ultrasonographical	B-C1720195
,	O
clinical	B-C3854293
,	O
and	O
biochemical	B-C0243095
findings	I-C0243095
.	O
	
in	O
overall	O
,	O
427	O
patients	B-C0030705
with	O
449	O
aus	B-C0522580
/	O
flus	B-C1272585
nodules	B-C0040137
who	O
had	O
undergone	O
surgery	B-C0543467
,	O
the	O
rate	O
of	O
malignancy	B-C4282132
was	O
23.4	O
%	O
105/449	O
.	O
	
when	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	B-C4282132
was	O
25.8	O
%	O
in	O
nodules	B-C0040137
with	O
aus	B-C0522580
82/318	O
and	O
17.6	O
%	O
in	O
nodules	B-C0040137
with	O
flus	B-C1272585
23/131	O
p	O
=	O
0.061	O
.	O
	
the	O
vast	O
majority	O
of	O
malignant	B-C2347026
specimens	I-C2347026
in	O
histopathology	B-C0430445
consisted	O
of	O
papillary	B-C0238463
thyroid	I-C0238463
carcinoma	I-C0238463
ptc	B-C0238463
n	O
=	O
91	O
,	O
86.7	O
%	O
.	O
	
preoperative	B-C0445204
ultrasonographic	B-C1720195
features	I-C1720195
of	O
105	O
malignant	B-C0040137
nodules	I-C0040137
in	O
histopathology	B-C0430445
were	O
compared	O
with	O
the	O
344	O
benign	B-C0749467
nodules	I-C0749467
in	O
histopathology	B-C0430445
.	O
	
anteroposterior/transverse	B-C0456603
ap/t	I-C0456603
ratio	I-C0456603
was	O
significantly	O
higher	O
in	O
malignant	B-C1257890
group	I-C1257890
compared	O
to	O
benign	B-C1257890
group	I-C1257890
p	O
=	O
0.013	O
.	O
	
in	O
multiple	B-C0936012
logistic	I-C0936012
analysis	I-C0936012
,	O
we	O
found	O
that	O
higher	B-C0456603
ap/t	I-C0456603
ratio	I-C0456603
and	O
microcalcification	B-C0521174
were	O
independently	O
associated	B-C0332281
with	I-C0332281
malignancy	B-C4282132
p	O
<	O
0.05	O
.	O
	
the	O
malignancy	B-C4282132
-associated	O
cut-off	O
value	O
of	O
ap/t	B-C0456603
ratio	I-C0456603
at	O
maximum	O
sensitivity	B-C0036668
and	I-C0036668
specificity	I-C0036668
was	O
0.81	O
.	O
	
we	O
did	O
not	O
find	O
any	O
correlation	B-C1707520
between	O
malignancy	B-C4282132
and	O
hashimoto's	B-C0677607
thyroiditis	I-C0677607
in	O
histopathology	B-C0430445
in	O
multivariate	B-C0026777
analysis	I-C0026777
p	O
>	O
0.05	O
.	O
	
in	O
bethesda	B-C0040137
category	I-C0040137
iii	I-C0040137
nodules	I-C0040137
with	O
higher	B-C0456603
ap/t	I-C0456603
ratio	I-C0456603
and	O
microcalcification	B-C0521174
,	O
surgery	B-C0543467
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine-needle	B-C1510483
aspiration	I-C1510483
biopsy	I-C1510483
or	O
impact	B-C4049986
of	O
cofactor	B-C0178555
-	O
binding	B-C0682969
loop	I-C0682969
mutations	B-C0026882
on	O
thermotolerance	B-C3544386
and	O
activity	B-C0243102
of	O
e	B-C0014834
.	O
	
coli	I-C0014834
transketolase	B-C0040709
improvement	B-C2986411
of	O
thermostability	B-C0597571
in	O
engineered	B-C0014442
enzymes	I-C0014442
can	O
allow	O
biocatalysis	B-C2350294
on	O
substrates	B-C3891814
with	O
poor	O
aqueous	B-C0599956
solubility	B-C0037628
.	O
	
denaturation	B-C0033627
of	O
the	O
cofactor	B-C0178555
-	O
binding	B-C0682969
loops	I-C0682969
of	O
escherichia	B-C0014834
coli	I-C0014834
transketolase	B-C0040709
tk	B-C0040709
was	O
previously	O
linked	O
to	O
the	O
loss	B-C1517945
of	O
enzyme	B-C0243102
activity	I-C0243102
under	O
conditions	B-C0348080
of	O
high	B-C0205250
ph	B-C0020283
or	O
urea	B-C0041942
.	O
	
incubation	B-C0022885
at	O
temperatures	B-C0039476
just	O
below	O
the	O
thermal	B-C1254365
melting	I-C1254365
transition	I-C1254365
,	O
above	O
which	O
the	O
protein	B-C0033684
aggregates	B-C0332621
,	O
was	O
also	O
found	O
to	O
anneal	B-C0205245
the	O
enzyme	B-C0014442
to	O
give	O
an	O
increased	B-C0205217
specific	O
activity	B-C0243102
.	O
	
the	O
potential	O
role	B-C1705810
of	O
cofactor	B-C0178555
-	O
binding	B-C0682969
loop	I-C0682969
instability	B-C1444783
in	O
this	O
process	O
remained	O
unclear	O
.	O
	
in	O
this	O
work	O
,	O
the	O
two	O
cofactor	B-C0178555
-	O
binding	B-C0682969
loops	I-C0682969
residues	B-C0002518
185-192	I-C0002518
and	O
382-392	B-C0002518
were	O
progressively	O
mutated	O
towards	O
the	O
equivalent	O
sequence	B-C0004793
from	O
the	O
thermostable	B-C0205556
thermus	B-C0085475
thermophilus	I-C0085475
tk	B-C0040709
and	O
variants	B-C0678941
assessed	B-C1516048
for	O
their	O
impact	B-C4049986
on	O
both	O
thermostability	B-C0597571
and	O
activity	B-C0441655
.	O
	
cofactor-binding	B-C0004793
loop	I-C0004793
2	I-C0004793
variants	B-C0678941
had	O
detrimental	B-C1280500
effects	I-C1280500
on	O
specific	O
activity	B-C0441655
at	O
elevated	B-C3163633
temperatures	B-C0039476
,	O
whereas	O
the	O
h192p	B-C0026882
mutation	I-C0026882
in	O
cofactor-binding	B-C0004793
loop	I-C0004793
1	I-C0004793
resulted	O
in	O
a	O
two-fold	O
improved	O
stability	B-C0597571
to	O
inactivation	B-C0544461
at	O
elevated	B-C3163633
temperatures	B-C0039476
,	O
and	O
increased	B-C0205217
the	O
critical	B-C0039476
onset	I-C0039476
temperature	I-C0039476
for	O
aggregation	B-C0332621
.	O
	
the	O
specific	O
activity	B-C0441655
of	O
h192p	B-C0026882
was	O
3-fold	O
and	O
19-fold	O
higher	B-C0205250
than	O
that	O
for	O
wild-type	B-C1883559
at	O
60	O
and	O
65	O
respectively	O
,	O
and	O
also	O
remained	O
2.7	O
fold	O
higher	B-C0205250
after	O
re-cooling	B-C0678568
from	O
pre-incubations	B-C0022885
at	O
either	O
55	O
or	O
60	O
for	O
1h	O
.	O
	
interestingly	O
,	O
h192p	B-C0026882
was	O
also	O
2-times	O
more	O
active	B-C0205177
than	O
wild-type	B-C1883559
tk	B-C0040709
at	O
25	O
.	O
	
optimal	B-C2698651
activity	B-C0441655
was	O
achieved	O
at	O
60	O
for	O
h192p	B-C0026882
compared	O
to	O
55	O
for	O
wild	B-C1883559
type	I-C1883559
.	O
	
these	O
results	O
show	O
that	O
cofactor-binding	B-C0004793
loop	I-C0004793
1	I-C0004793
,	O
plays	O
a	O
pivotal	O
role	B-C1705810
in	O
partial	B-C0728938
denaturation	B-C0033627
and	O
aggregation	B-C0332621
at	O
elevated	B-C3163633
temperatures	B-C0039476
.	O
	
furthermore	O
,	O
a	O
single	B-C0026882
rigidifying	I-C0026882
mutation	I-C0026882
within	O
this	O
loop	B-C0004793
can	O
significantly	O
improve	O
the	O
enzyme	B-C0243102
specific	I-C0243102
activity	I-C0243102
,	O
as	O
well	O
as	O
the	O
stability	B-C0597571
to	O
thermal	B-C0018837
denaturation	B-C0033627
and	O
aggregation	B-C0332621
,	O
to	O
give	O
an	O
increased	B-C0205217
temperature	B-C0039476
optimum	B-C2698651
for	O
safety	B-C1705187
of	O
transradial	B-C2041518
diagnostic	I-C2041518
cardiac	I-C2041518
catheterization	I-C2041518
in	O
patients	B-C0030705
under	O
oral	B-C0442027
anticoagulant	B-C0150457
therapy	I-C0150457
cardiac	B-C0018795
catheterization	I-C0018795
in	O
anticoagulated	B-C0741134
patients	B-C0030705
is	O
usually	O
performed	B-C0884358
after	O
the	O
anticoagulation	B-C0003281
has	O
been	O
withdrawn	B-C1707825
,	O
at	O
least	O
in	O
the	O
previous	O
48h	O
,	O
and	O
sometimes	O
bridging	B-C3873426
therapy	I-C3873426
with	I-C3873426
heparin	I-C3873426
is	O
used	O
.	O
	
a	O
prospective	O
observational	B-C1518527
study	I-C1518527
including	O
489	O
patients	B-C0030705
undergoing	O
transradial	B-C0018795
catheterization	I-C0018795
was	O
conducted	O
.	O
	
a	O
total	O
of	O
140	O
patients	B-C0030705
were	O
under	O
acenocoumarol	B-C0000956
group	B-C0441835
a	I-C0441835
and	O
they	O
were	O
compared	B-C1707455
with	O
the	O
remainder	B-C1527428
group	B-C0441836
b	I-C0441836
for	O
complications	B-C0009566
after	O
the	O
procedure	B-C0018795
bleeding	B-C0019080
and	O
vascular	B-C0920165
access	I-C0920165
complications	I-C0920165
.	O
	
patients	B-C0030705
in	O
group	B-C0441835
a	I-C0441835
were	O
older	B-C1518563
74	O
years	O
vs	O
.	O
	
68	O
years	O
,	O
p<0	O
and	O
the	O
main	O
indication	B-C3146298
for	O
anticoagulation	B-C0003281
was	O
atrial	B-C0004238
fibrillation	I-C0004238
58.6	O
.	O
	
no	B-C1513916
complications	B-C0009566
occurred	O
during	O
the	O
procedures	B-C0018795
.	O
	
there	O
were	O
no	B-C1513916
acute	B-C0333276
bleedings	I-C0333276
just	O
after	B-C0687676
the	O
bandage	B-C0004726
removal	B-C1883720
.	O
	
during	O
the	O
first	O
24h	O
,	O
only	O
3	O
2.1	O
radial	B-C1110554
occlusions	I-C1110554
in	O
group	B-C0441835
a	I-C0441835
and	O
2	O
0.6	O
in	O
group	B-C0441836
b	I-C0441836
p=0	O
were	O
recorded	B-C2355580
.	O
	
hematomas	B-C0018944
between	O
5	O
and	O
10cm	O
appeared	O
in	O
5%	O
of	O
the	O
group	B-C0441835
a	I-C0441835
vs	O
.	O
	
4.6	O
in	O
group	B-C0441836
b	I-C0441836
.	O
	
during	O
the	O
1-month	B-C1442451
follow-up	B-C1522577
period	B-C1948053
,	O
one	O
more	O
radial	B-C1110554
occlusion	I-C1110554
in	O
each	O
group	B-C0441833
was	O
recorded	B-C2355580
and	O
there	O
were	O
4	O
1.1	O
additional	O
mild	B-C2945599
hematomas	B-C0018944
in	O
group	B-C0441836
b	I-C0441836
and	O
none	O
in	O
group	B-C0441835
a	I-C0441835
p=0	O
.	O
	
performing	B-C0884358
a	O
transradial	B-C2041518
diagnostic	I-C2041518
cardiac	I-C2041518
catheterization	I-C2041518
without	B-C0332288
removal	B-C1883720
of	O
the	O
oral	B-C0442027
chronic	B-C0694554
anticoagulation	I-C0694554
appears	O
safe	B-C3266157
in	O
patients	B-C0030705
under	O
acenocumarol	B-C0000956
therapy	B-C0087111
.	O
	
does	O
infrared	B-C0181645
visualization	B-C0234621
improve	O
selection	B-C1707391
of	O
venipuncture	B-C0600406
sites	B-C0205145
for	O
indwelling	B-C0439848
needle	B-C0027551
at	O
the	O
forearm	B-C0016536
in	O
second-year	O
nursing	B-C0038496
students	I-C0038496
to	O
evaluate	O
the	O
effectiveness	B-C1280519
of	O
a	O
vein	B-C0025080
visualization	I-C0025080
display	I-C0025080
system	I-C0025080
using	O
near-infrared	B-C1289901
light	I-C1289901
""""	O
vein	B-C0025080
display	I-C0025080
""""	O
for	O
the	O
safe	O
and	O
proper	O
selection	B-C1707391
of	O
venipuncture	B-C0600406
sites	B-C0205145
for	O
indwelling	B-C0439848
needle	B-C0027551
placement	O
in	O
the	O
forearm	B-C0016536
.	O
	
ten	O
second	O
year	O
nursing	B-C0038496
students	I-C0038496
were	O
recruited	O
to	O
apply	O
an	O
indwelling	B-C0439848
needle	B-C0027551
line	O
with	O
and	O
without	O
vein	B-C0042449
display	B-C0870432
.	O
	
another	O
ten	O
participants	B-C0679646
were	O
recruited	O
from	O
various	O
faculty	B-C0015535
to	O
serve	O
as	O
patients	B-C0030705
.	O
	
the	O
quality	O
of	O
the	O
venipuncture	B-C0600406
procedure	I-C0600406
at	O
various	O
selected	O
sites	B-C0205145
was	O
evaluated	O
according	O
to	O
a	O
scale	B-C0349674
developed	O
by	O
the	O
authors	B-C3812881
.	O
	
time	B-C0040223
,	O
scores	B-C0449820
and	O
patterns	B-C0332307
of	O
puncture	B-C0600406
-	O
site	B-C0205145
selection	B-C1707391
were	O
compared	O
with	O
respect	O
to	O
three	O
different	O
methods	O
1	O
attempt	O
1	O
tourniquet	B-C0040519
only	O
,	O
2	O
attempt	O
2	O
vein	B-C0025080
display	I-C0025080
only	O
and	O
3	O
attempt	O
3	O
both	O
.	O
	
to	O
validate	O
the	O
effectiveness	B-C1280519
of	O
vein	B-C0042449
display	B-C0870432
,	O
52	O
trials	O
were	O
conducted	O
in	O
total	O
.	O
	
we	O
found	O
that	O
venipuncture	B-C0600406
site	B-C0205145
selection	B-C1707391
time	O
was	O
significantly	O
improved	O
with	O
the	O
vein	B-C0025080
display	I-C0025080
,	O
particularly	O
in	O
the	O
case	O
of	O
difficult	O
to	O
administer	B-C1621583
venipuncture	B-C0600406
sites	B-C0205145
.	O
	
overall	O
,	O
we	O
found	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
venipuncture	B-C0600406
quality	B-C0332306
,	O
as	O
determined	O
by	O
our	O
scale	B-C0349674
.	O
	
these	O
results	O
suggest	O
that	O
equipment	O
such	O
as	O
the	O
vein	B-C0025080
display	I-C0025080
can	O
contribute	O
immensely	O
to	O
the	O
improvement	O
of	O
practical	B-C0008973
skills	I-C0008973
,	O
such	O
as	O
venipuncture	B-C0600406
,	O
especially	O
in	O
the	O
context	O
of	O
elderly	B-C0001792
patients	B-C0030705
.	O
	
elective	B-C0206058
nephron	B-C0194086
sparing	I-C0194086
surgery	I-C0194086
decreases	B-C0205216
other	B-C0476465
cause	I-C0476465
mortality	I-C0476465
relative	B-C0205345
to	O
radical	B-C0401181
nephrectomy	I-C0401181
only	O
in	O
specific	B-C0205369
subgroups	B-C1515021
of	O
patients	B-C0030705
with	O
renal	B-C0007134
cell	I-C0007134
carcinoma	I-C0007134
there	O
is	O
no	O
consensus	B-C0376298
regarding	O
a	O
protective	B-C1545588
effect	I-C1545588
on	O
mortality	B-C0205848
due	O
to	O
a	O
cause	O
other	O
than	O
cancer	B-C0006826
in	O
patients	B-C0030705
treated	B-C0332293
with	I-C0332293
elective	B-C0206058
nephron	B-C0194086
sparing	I-C0194086
surgery	I-C0194086
relative	B-C0205345
to	O
their	O
radical	B-C0401181
nephrectomy	I-C0401181
counterparts	O
.	O
	
we	O
test	B-C0039593
whether	O
the	O
protective	B-C1545588
effect	I-C1545588
of	O
nephron	B-C0194086
sparing	I-C0194086
surgery	I-C0194086
relative	B-C0205345
to	O
radical	B-C0401181
nephrectomy	I-C0401181
is	O
universal	B-C0175671
or	O
present	O
in	O
specific	B-C0205369
subgroups	B-C1515021
of	O
patients	B-C0030705
.	O
	
a	O
collaborative	B-C0392762
database	B-C0242356
of	O
5	O
institutions	B-C1272753
was	O
queried	B-C1522634
to	O
evaluate	B-C0220825
1	O
patients	B-C0030705
without	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
diagnosed	B-C0011900
with	O
a	O
clinical	B-C0205210
t1	B-C2217020
renal	I-C2217020
mass	I-C2217020
that	O
was	O
treated	B-C0332293
with	I-C0332293
nephron	B-C0194086
sparing	I-C0194086
surgery	I-C0194086
or	O
radical	B-C0401181
nephrectomy	I-C0401181
.	O
	
multivariable	B-C0034980
cox	I-C0034980
regression	I-C0034980
analysis	I-C0034980
was	O
done	O
to	O
assess	B-C0184514
the	O
impact	B-C4049986
of	O
surgery	B-C0543467
type	O
nephron	B-C0194086
sparing	I-C0194086
surgery	I-C0194086
vs	O
radical	B-C0401181
nephrectomy	I-C0401181
on	O
other	B-C0476465
cause	I-C0476465
mortality	I-C0476465
after	O
adjustment	O
for	O
patient	B-C0030705
and	O
cancer	B-C0006826
characteristics	B-C1521970
.	O
	
interaction	B-C1704675
terms	O
were	O
used	O
to	O
test	B-C0039593
the	O
hypothesis	O
that	O
the	O
impact	B-C4049986
of	O
surgery	B-C0543467
type	O
varies	O
according	O
to	O
specific	B-C0205369
subcohorts	B-C0599755
of	O
patients	B-C0030705
.	O
	
ten-year	B-C1254367
other	B-C0476465
cause	I-C0476465
mortality	I-C0476465
-free	O
survival	B-C0038954
rates	I-C0038954
were	O
90%	O
and	O
88%	O
after	O
nephron	B-C0194086
sparing	I-C0194086
surgery	I-C0194086
and	O
radical	B-C0401181
nephrectomy	I-C0401181
,	O
respectively	O
.	O
	
in	O
the	O
overall	B-C1561607
population	B-C1257890
radical	B-C0401181
nephrectomy	I-C0401181
was	O
not	O
associated	B-C0332281
with	I-C0332281
an	O
increased	B-C0205217
risk	B-C0035647
of	O
other	B-C0476465
cause	I-C0476465
mortality	I-C0476465
on	O
multivariable	B-C0026777
analysis	I-C0026777
compared	O
to	O
nephron	B-C0194086
sparing	I-C0194086
surgery	I-C0194086
hr	B-C2985465
0.91	O
,	O
95%	O
ci	B-C0009667
0.6	O
,	O
p	O
=	O
0.6	O
.	O
	
however	O
,	O
radical	B-C0401181
nephrectomy	I-C0401181
increased	B-C0205217
the	O
risk	B-C0035647
of	O
other	B-C0476465
cause	I-C0476465
mortality	I-C0476465
according	O
to	O
the	O
increasing	B-C0205217
baseline	B-C1442488
charlson	B-C3714916
comorbidity	I-C3714916
index	I-C3714916
interaction	B-C1704675
test	B-C0039593
p	O
=	O
0.0008	O
.	O
	
for	O
example	O
,	O
in	O
a	O
patient	B-C0030705
with	O
a	O
charlson	B-C3714916
comorbidity	I-C3714916
index	I-C3714916
of	O
4	O
the	O
probability	B-C0033204
of	O
10-year	B-C1254367
other	B-C0476465
cause	I-C0476465
mortality	I-C0476465
-free	O
survival	B-C0038952
was	O
86%	O
after	O
nephron	B-C0194086
sparing	I-C0194086
surgery	I-C0194086
and	O
60%	O
after	O
radical	B-C0401181
nephrectomy	I-C0401181
.	O
	
elective	B-C0206058
nephron	B-C0194086
sparing	I-C0194086
surgery	I-C0194086
does	O
not	O
improve	B-C0184511
other	O
cause	O
survival	B-C0038952
relative	B-C0205345
to	O
radical	B-C0401181
nephrectomy	I-C0401181
consistently	O
in	O
all	O
patients	B-C0030705
with	O
kidney	B-C0740457
cancer	I-C0740457
.	O
	
patients	B-C0030705
who	O
are	O
more	O
ill	B-C0221423
with	O
relevant	B-C2347946
comorbidities	B-C0009488
are	O
those	O
who	O
benefit	B-C0814225
the	O
most	O
from	O
nephron	B-C0194086
sparing	I-C0194086
surgery	I-C0194086
in	O
terms	O
of	O
other	B-C0476465
cause	I-C0476465
mortality	I-C0476465
.	O
	
prospective	O
study	O
of	O
dietary	B-C0012155
non	B-C4049177
enzymatic	I-C4049177
antioxidant	I-C4049177
capacity	I-C4049177
on	O
the	O
risk	B-C0035647
of	O
hip	B-C0019557
fracture	I-C0019557
in	O
the	O
elderly	B-C0001792
dietary	B-C0729311
antioxidants	I-C0729311
may	O
play	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
bone	B-C0029453
loss	I-C0029453
and	O
associated	O
fractures	B-C0016658
by	O
reducing	O
levels	O
of	O
oxidative	B-C0242606
stress	I-C0242606
.	O
	
we	O
prospectively	O
investigated	O
the	O
association	O
between	O
dietary	B-C0012155
non	B-C4049177
enzymatic	I-C4049177
antioxidant	I-C4049177
capacity	I-C4049177
neac	B-C4049177
and	O
the	O
risk	B-C0035647
of	O
hip	B-C0019557
fracture	I-C0019557
and	O
whether	O
this	O
effect	O
was	O
modified	O
by	O
smoking	B-C0037369
.	O
	
in	O
the	O
swedish	B-C0599755
national	I-C0599755
march	I-C0599755
cohort	I-C0599755
13	O
men	B-C0025266
and	O
women	B-C0043210
over	O
the	O
age	O
of	O
55	O
who	O
had	O
not	O
experienced	O
cancer	B-C0006826
,	O
cardiovascular	B-C0007222
disease	I-C0007222
or	O
hip	B-C0019557
fracture	I-C0019557
,	O
were	O
followed	O
through	O
record-linkages	B-C0025101
from	O
1997	O
through	O
2010	O
.	O
	
neac	B-C4049177
was	O
assessed	O
by	O
a	O
validated	O
food	B-C2986698
frequency	I-C2986698
questionnaire	I-C2986698
collected	O
at	O
baseline	B-C1442488
.	O
	
we	O
categorized	O
the	O
distribution	O
of	O
neac	B-C4049177
into	O
sex	B-C0079399
-	O
specific	B-C0205369
quartiles	B-C2828255
and	O
used	O
multivariable	B-C0033489
adjusted	I-C0033489
cox	I-C0033489
proportional	I-C0033489
hazards	I-C0033489
regression	I-C0033489
models	I-C0033489
to	O
estimate	O
hazard	B-C2985465
ratios	I-C2985465
hrs	B-C2985465
with	O
95%	O
confidence	B-C0009667
intervals	I-C0009667
95%	O
ci	B-C0009667
.	O
	
during	O
a	O
mean	O
follow-up	B-C1522577
time	B-C0040223
of	O
12.4years	O
,	O
we	O
identified	O
491	O
incident	O
cases	O
of	O
first	O
hip	B-C0019557
fracture	I-C0019557
.	O
	
subjects	O
in	O
the	O
highest	O
quartile	B-C2828255
of	O
dietary	B-C0012155
neac	B-C4049177
had	O
a	O
39%	O
lower	B-C3843763
risk	I-C3843763
of	O
incident	O
hip	B-C0019557
fracture	I-C0019557
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	B-C2828255
hr	B-C2985465
0.61	O
95%	O
ci	B-C0009667
0.44	O
.	O
	
the	O
association	O
was	O
non-linear	O
p	O
for	O
non-linearity	O
0.004	O
with	O
a	O
potential	O
threshold	O
between	O
the	O
first	O
and	O
the	O
second	O
quartile	B-C2828255
and	O
no	O
further	O
risk	B-C1137094
reduction	I-C1137094
at	O
higher	O
levels	O
of	O
dietary	B-C0012155
neac	B-C4049177
.	O
	
due	O
to	O
a	O
low	O
smoking	O
prevalence	O
in	O
our	O
study	O
population	O
,	O
we	O
had	O
limited	O
power	O
to	O
detect	O
effect	O
modification	O
between	O
dietary	B-C0012155
neac	B-C4049177
and	O
smoking	B-C0037369
on	O
a	O
multiplicative	B-C2911648
or	O
additive	B-C0392762
scale	I-C0392762
.	O
	
higher	O
dietary	O
neac	B-C4049177
intake	O
is	O
associated	O
with	O
lower	O
risk	B-C0035647
of	O
hip	B-C0019557
fracture	I-C0019557
function	B-C0563143
and	O
clinical	B-C0205210
meaningfulness	B-C1280519
of	O
treatments	B-C0087111
for	O
mild	B-C2945599
alzheimer's	B-C0002395
disease	I-C0002395
effectiveness	B-C1280519
of	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
treatments	B-C0087111
is	O
commonly	O
evaluated	O
with	O
coprimary	B-C1274040
outcomes	I-C1274040
cognition	B-C0009240
with	O
function	B-C0563143
to	O
ensure	O
clinical	B-C0205210
meaningfulness	B-C1280519
of	O
a	O
cognitive	B-C0009240
effect	B-C1280500
.	O
	
we	O
reviewed	B-C1709940
the	O
literature	B-C0023866
for	O
functional	B-C0563143
outcomes	B-C1274040
in	O
mild	B-C2945599
ad	B-C0002395
or	O
mild	B-C1270972
cognitive	I-C1270972
impairment	I-C1270972
mci	B-C1270972
patients	B-C0030705
distinct	O
from	O
combined	O
mild-moderate	B-C1299392
/	O
severe	B-C0205082
ad	B-C0002395
treated	B-C0332293
with	I-C0332293
approved	O
ad	B-C0002395
drugs	B-C0013227
.	O
	
cognitive	B-C0009244
and	O
functional	B-C0563143
treatment	B-C0087111
differences	O
in	O
mild	B-C2945599
ad	B-C0002395
patients	B-C0030705
in	O
solanezumab	B-C2935150
expedition	B-C0015315
/	O
expedition2	B-C0015315
studies	B-C2603343
were	O
compared	B-C1707455
across	O
time	B-C0040223
.	O
	
seven	O
publications	B-C0034036
provided	O
mci	B-C1270972
/	O
mild	B-C2945599
ad	B-C0002395
functional	B-C0563143
outcomes	B-C1274040
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	B-C0563143
treatment	B-C1518681
effect	I-C1518681
.	O
	
secondary	B-C0683944
analyses	I-C0683944
of	O
expedition	B-C0015315
studies	B-C2603343
suggested	O
a	O
smaller	O
functional	B-C0563143
effect	B-C1280500
of	O
solanezumab	B-C2935150
relative	O
to	O
cognition	B-C0009240
.	O
	
an	O
increasing	B-C0442808
effect	B-C1280500
of	O
solanezumab	B-C2935150
over	O
18	O
months	B-C0439231
was	O
shown	O
for	O
cognition	B-C0009240
and	O
function	B-C0563143
.	O
	
function	B-C0563143
as	O
the	O
sole	O
measure	B-C0079809
to	O
demonstrate	O
clinical	B-C0205210
meaningfulness	B-C1280519
of	O
cognitive	B-C0009240
effects	B-C1280500
in	O
mild	B-C2945599
ad	B-C0002395
may	O
have	O
limitations	B-C0449295
.	O
	
for	O
disease	B-C0012634
-	O
modifying	B-C0392747
treatments	B-C0087111
,	O
point	O
differences	O
on	O
cognitive	B-C0009240
and	O
functional	B-C0563143
scales	B-C0349674
should	O
be	O
qualified	O
with	O
duration	B-C0444921
of	I-C0444921
treatment	I-C0444921
.	O
	
in	O
search	O
of	O
the	O
e	B-C0014834
.	O
	
coli	I-C0014834
compounds	B-C0574031
that	O
change	O
the	O
antibiotic	B-C0003232
production	B-C0205245
pattern	O
of	O
streptomyces	B-C0995741
coelicolor	I-C0995741
during	O
inter-species	B-C0870742
interaction	I-C0870742
the	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	B-C1292732
the	O
interaction	B-C1704675
between	O
e.coli	B-C0014834
and	O
streptomyces	B-C1449847
coelicolor	I-C1449847
a3	I-C1449847
2	I-C1449847
for	O
the	O
increased	B-C0205217
production	B-C0205245
of	O
undecylprodigiosin	B-C0077826
and	O
identify	O
the	O
e	B-C0014834
.	O
	
coli	I-C0014834
actives	B-C0205177
mediating	B-C0086597
this	O
inter-species	B-C0870742
interaction	I-C0870742
.	O
	
the	O
antibiotics	B-C0003232
of	O
interest	O
were	O
the	O
red-pigmented	B-C0526040
undecylprodigiosin	I-C0526040
and	O
blue-pigmented	B-C0333610
actinorhodin	B-C0050663
.	O
	
pure	O
cultures	B-C0430402
of	O
s	B-C0995741
.	O
	
coelicolor	I-C0995741
in	O
a	O
defined	O
medium	B-C0010454
produced	O
higher	O
concentrations	B-C1264643
of	O
actinorhodin	B-C0050663
compared	B-C1707455
to	O
those	O
of	O
undecylprodigiosin	B-C0077826
.	O
	
the	O
latter	O
however	O
,	O
is	O
more	O
important	O
due	O
to	O
its	O
immunosuppressive	B-C0021080
and	O
antitumor	B-C1516031
properties	I-C1516031
.	O
	
as	O
a	O
strategy	O
to	O
increase	B-C0442805
undecylprodigiosin	B-C0077826
production	B-C0205245
,	O
we	O
added	O
separately	O
,	O
live	B-C1441322
cells	I-C1441322
and	O
heat-killed	B-C1522240
cells	B-C0007634
of	O
e	B-C0014834
.	O
	
coli	I-C0014834
c600	I-C0014834
,	O
and	O
the	O
cell-free	B-C1550101
supernatant	I-C1550101
of	O
e	B-C0014834
.	O
	
coli	I-C0014834
culture	B-C0430402
to	O
s	B-C0995741
.	O
	
coelicolor	I-C0995741
cultures	B-C3179108
in	I-C3179108
shake	I-C3179108
flasks	I-C3179108
.	O
	
the	O
interaction	B-C1704675
with	O
live	B-C1441322
cells	I-C1441322
of	O
e	B-C0014834
.	O
	
coli	I-C0014834
altered	O
the	O
antibiotic	B-C0003232
production	B-C0205245
pattern	O
and	O
undecylprodigiosin	B-C0077826
production	B-C0205245
was	O
enhanced	B-C2349975
by	O
3.5	O
compared	O
to	O
the	O
pure	B-C0430402
cultures	I-C0430402
of	O
s	B-C0995741
.	O
	
coelicolor	I-C0995741
and	O
actinorhodin	B-C0050663
decreased	B-C0205216
by	O
15-fold	O
.	O
	
the	O
heat-killed	B-C1522240
cells	B-C0007634
of	O
e	B-C0014834
.	O
	
coli	I-C0014834
however	O
,	O
had	O
no	B-C1301751
effect	I-C1301751
on	O
antibiotic	B-C0003232
production	B-C0205245
.	O
	
in	O
all	O
cases	O
,	O
growth	B-C0178747
and	O
glucose	B-C0556133
consumption	I-C0556133
of	O
s	B-C0995741
.	O
	
coelicolor	I-C0995741
remained	O
almost	O
the	O
same	B-C0445247
as	O
those	O
observed	B-C1441672
in	O
the	O
pure	B-C0430402
culture	I-C0430402
indicating	O
that	O
the	O
changes	B-C0392747
in	O
antibiotic	B-C0003232
production	B-C0205245
were	O
not	O
due	O
to	O
nutritional	B-C1442959
stress	B-C0038435
.	O
	
results	B-C1274040
with	O
cell-free	B-C1550101
supernatant	I-C1550101
of	O
e	B-C0014834
.	O
	
coli	I-C0014834
culture	B-C0430402
indicated	O
that	O
the	O
interaction	B-C1704675
between	O
s	B-C0995741
.	O
	
coelicolor	I-C0995741
and	O
e	B-C0014834
.	O
	
coli	I-C0014834
was	O
mediated	B-C0086597
via	O
diffusible	B-C0574031
molecule	I-C0574031
.	O
	
using	O
a	O
set	O
of	O
extraction	B-C0684295
procedures	I-C0684295
and	O
agar-well	B-C0005507
diffusion	I-C0005507
bioassays	I-C0005507
,	O
we	O
isolated	B-C0205409
and	O
preliminarily	O
identified	B-C0205396
a	O
class	B-C0574031
of	I-C0574031
compounds	I-C0574031
.	O
	
for	O
the	O
preliminary	O
verification	B-C1711411
,	O
we	O
added	O
the	O
compound	B-C0574031
which	O
was	O
the	O
common	O
chemical	B-C1254350
structural	I-C1254350
moiety	I-C1254350
in	O
this	O
class	B-C0574031
of	I-C0574031
compounds	I-C0574031
to	O
the	O
pure	O
s	B-C0995741
.	O
	
coelicolor	I-C0995741
cultures	B-C1331092
.	O
	
we	O
observed	O
similar	O
effects	B-C1280500
on	O
antibiotic	B-C0003232
production	B-C0205245
as	O
with	O
the	O
live	O
e	B-C0014834
.	O
	
coli	I-C0014834
cells	B-C0007634
and	O
their	O
supernatant	B-C1550101
indicating	O
that	O
this	O
class	B-C0574031
of	I-C0574031
compounds	I-C0574031
secreted	B-C1327616
by	O
e	B-C0014834
.	O
	
coli	I-C0014834
indeed	O
could	O
act	O
as	O
actives	B-C0205177
during	O
interspecies	B-C0870742
interaction	I-C0870742
and	O
increase	B-C0442805
the	O
production	B-C0205245
of	O
group	B-C0026845
iii/iv	I-C0026845
muscle	I-C0026845
afferents	B-C0027883
limit	B-C0439801
the	O
intramuscular	B-C0442117
metabolic	B-C0311400
perturbation	B-C0332453
during	O
whole	B-C0444584
body	I-C0444584
exercise	B-C0015259
in	O
humans	B-C0086418
the	O
purpose	B-C1285529
of	O
this	O
study	B-C2603343
was	O
to	O
determine	B-C1148554
the	O
role	B-C1705810
of	O
group	B-C0026845
iii/iv	I-C0026845
muscle	I-C0026845
afferents	B-C0027883
in	O
limiting	B-C0439801
the	O
endurance	B-C0518031
exercise	B-C0015259
-	O
induced	B-C0205263
metabolic	B-C0311400
perturbation	B-C0332453
assayed	B-C1510438
in	O
muscle	B-C0026845
biopsy	B-C0677862
samples	I-C0677862
taken	O
from	O
locomotor	B-C0023946
muscle	B-C0026845
.	O
	
lumbar	B-C0024090
intrathecal	B-C1370196
fentanyl	B-C0015846
was	O
used	O
to	O
attenuate	B-C0599946
the	O
central	B-C0205099
projection	B-C0348018
of	O
μ-opioid	B-C0066908
receptor	I-C0066908
-	O
sensitive	B-C0332324
locomotor	B-C0023946
muscle	B-C0026845
afferents	B-C0027883
during	O
a	O
5	O
km	O
cycling	B-C1511572
time	B-C0040223
trial	B-C0008976
.	O
	
the	O
findings	B-C0243095
suggest	O
that	O
the	O
central	B-C0205099
projection	B-C0348018
of	O
group	B-C0026845
iii/iv	I-C0026845
muscle	I-C0026845
afferent	B-C0027883
feedback	B-C0678663
constrains	B-C1707494
voluntary	B-C0439656
neural	B-C3714606
'	O
drive	B-C0013126
'	O
to	O
working	B-C0205177
locomotor	B-C0023946
muscle	B-C0026845
and	O
limits	B-C0439801
the	O
exercise	B-C0015259
-	O
induced	B-C0205263
intramuscular	B-C0442117
metabolic	B-C0311400
perturbation	B-C0332453
.	O
	
therefore	O
,	O
the	O
cns	B-C3714787
might	O
regulate	B-C1327622
the	O
degree	B-C0449286
of	O
metabolic	B-C0311400
perturbation	B-C0332453
within	O
locomotor	B-C0023946
muscle	B-C0026845
and	O
thereby	O
limit	B-C0439801
peripheral	B-C0205100
fatigue	B-C0015672
.	O
	
it	O
appears	B-C0700364
that	O
the	O
group	B-C0026845
iii/iv	I-C0026845
muscle	I-C0026845
afferents	B-C0027883
are	O
an	O
important	B-C3898777
neural	B-C3714606
link	B-C0178718
in	O
this	O
regulatory	B-C1327622
mechanism	B-C0441712
,	O
which	O
probably	B-C0750492
serves	O
to	O
protect	B-C1545588
locomotor	B-C0023946
muscle	B-C0026845
from	O
the	O
potentially	B-C3245505
severe	B-C0205082
functional	B-C4062321
impairment	I-C4062321
as	O
a	O
consequence	B-C0686907
of	O
severe	B-C0205082
intramuscular	B-C0442117
metabolic	B-C0311400
disturbance	B-C2699787
.	O
	
to	O
investigate	B-C1292732
the	O
role	B-C1705810
of	O
metabo	B-C0025519
-	O
and	O
mechanosensitive	B-C1522640
group	B-C0026845
iii/iv	I-C0026845
muscle	I-C0026845
afferents	B-C0027883
in	O
limiting	B-C0439801
the	O
intramuscular	B-C0442117
metabolic	B-C0311400
perturbation	B-C0332453
during	O
whole	B-C0444584
body	I-C0444584
endurance	B-C0518031
exercise	B-C0015259
,	O
eight	O
subjects	B-C0681850
performed	B-C0884358
5	O
km	O
cycling	B-C1511572
time	B-C0040223
trials	B-C0008976
under	B-C2911690
control	I-C2911690
conditions	I-C2911690
ctrl	B-C2911690
and	O
with	O
lumbar	B-C0024090
intrathecal	B-C1370196
fentanyl	B-C0015846
impairing	B-C0221099
lower	B-C0023216
limb	I-C0023216
muscle	B-C0026845
afferent	B-C0027883
feedback	B-C0678663
fent	B-C0678663
.	O
	
vastus	B-C0224444
lateralis	I-C0224444
muscle	B-C0026845
biopsies	B-C0677862
were	O
obtained	B-C1301820
before	B-C0332152
and	O
immediately	B-C0205253
after	B-C0687676
exercise	B-C0015259
.	O
	
motoneuronal	B-C0026609
output	B-C0204709
was	I-C0204709
estimated	I-C0204709
through	O
vastus	B-C0224444
lateralis	I-C0224444
surface	I-C0224444
electromyography	B-C0013839
emg	B-C0013839
.	O
	
exercise	B-C0015259
-	O
induced	B-C0205263
changes	B-C0392747
in	O
intramuscular	B-C0442117
metabolites	B-C0870883
were	O
determine	B-C1148554
d	O
using	O
liquid	B-C0302908
and	O
gas	B-C1720784
chromatography-mass	I-C1720784
spectrometry	I-C1720784
.	O
	
quadriceps	B-C0224440
fatigue	B-C0015672
was	O
quantified	B-C1709793
by	O
pre	B-C0332152
-	O
to	O
post	B-C0687676
-	O
exercise	B-C0015259
changes	B-C0392747
in	O
potentiated	B-C0376590
quadriceps	I-C0376590
twitch	I-C0376590
torque	I-C0376590
δqtsingle	B-C0376590
evoked	B-C1444748
by	O
electrical	B-C0442828
femoral	B-C0015808
nerve	I-C0015808
stimulation	B-C1292856
.	O
	
although	O
motoneuronal	B-C0026609
output	B-C0441655
was	O
21	O
12%	O
higher	B-C0205250
during	O
fent	B-C0678663
compared	B-C1707455
to	O
ctrl	B-C2911690
p	O
<	O
0.05	O
,	O
time	B-C0040223
to	O
complete	B-C0205197
the	O
time	B-C0040223
trial	B-C0008976
was	O
similar	B-C2348205
8.8	O
min	O
.	O
	
compared	B-C1707455
to	O
ctrl	B-C2911690
,	O
power	B-C0445194
output	I-C0445194
during	O
fent	B-C0678663
was	O
10	O
4%	O
higher	B-C0205250
in	O
the	O
first	B-C3843058
half	I-C3843058
of	O
the	O
time	B-C0040223
trial	B-C0008976
,	O
but	O
11	O
5%	O
lower	B-C0205251
in	O
the	O
second	B-C3843057
half	I-C3843057
both	O
p	O
<	O
0.01	O
.	O
	
the	O
exercise	B-C0015259
-	O
induced	B-C0205263
increase	B-C0442805
in	O
intramuscular	B-C0442117
inorganic	B-C0031603
phosphate	I-C0031603
,	O
h	B-C0033727
,	O
adenosine	B-C0001459
diphosphate	I-C0001459
,	O
lactate	B-C0022924
and	O
phosphocreatine	B-C0031634
depletion	B-C0333668
was	O
55	O
30	O
,	O
62	O
18	O
,	O
129	O
63	O
,	O
47	O
14	O
p	O
<	O
0.001	O
and	O
27	O
14%	O
p	O
<	O
0.01	O
greater	B-C1704243
in	O
fent	B-C0678663
than	O
ctrl	B-C2911690
.	O
	
δqtsingle	B-C0376590
was	O
greater	B-C1704243
following	O
fent	B-C0678663
than	O
ctrl	B-C2911690
-52	O
2	O
vs	O
-31	O
1%	O
,	O
p	O
<	O
0.001	O
and	O
this	O
difference	B-C1705241
was	O
positively	B-C1446409
correlated	B-C1707520
with	O
the	O
difference	B-C1705241
in	O
inorganic	B-C0031603
phosphate	I-C0031603
r	O
=	O
0.79	O
p	O
<	O
0.01	O
and	O
h	O
r	O
=	O
0.92	O
p	O
<	O
0.01	O
.	O
	
in	O
conclusion	B-C1707478
,	O
during	O
whole	B-C0444584
body	I-C0444584
exercise	B-C0015259
,	O
group	B-C0026845
iii/iv	I-C0026845
muscle	I-C0026845
afferents	B-C0027883
provide	B-C1999230
feedback	B-C0678663
to	O
the	O
cns	B-C3714787
which	O
,	O
in	O
turn	O
,	O
constrains	B-C1707494
motoneuronal	B-C0026609
output	B-C0441655
to	O
the	O
active	B-C0205177
skeletal	B-C0242692
muscle	I-C0242692
.	O
	
this	O
regulatory	B-C1327622
mechanism	B-C0441712
limits	B-C0439801
the	O
exercise	B-C0015259
-	O
induced	B-C0205263
intramuscular	B-C0442117
metabolic	B-C0311400
perturbation	B-C0332453
,	O
preventing	O
an	O
abnormal	B-C4022950
homeostatic	I-C4022950
challenge	B-C0805586
and	O
excessive	B-C0442802
peripheral	B-C0205100
fatigue	B-C0015672
.	O
	
the	O
effects	B-C1704420
of	I-C1704420
paternal	B-C0337493
high-fat	B-C0012155
diet	I-C0012155
exposure	B-C0332157
on	O
offspring	B-C0680063
metabolism	B-C0025519
with	O
epigenetic	B-C1516924
changes	I-C1516924
in	O
the	O
mouse	O
adiponectin	B-C1540187
and	O
leptin	B-C1416825
gene	B-C0314621
promoters	I-C0314621
recent	O
studies	B-C2603343
have	O
demonstrated	O
that	O
epigenetic	B-C1516924
changes	I-C1516924
resulting	O
from	O
malnutrition	B-C0162429
might	O
play	O
important	O
roles	B-C1705810
in	O
transgenerational	B-C0871541
links	I-C0871541
with	O
metabolic	B-C0025517
diseases	I-C0025517
.	O
	
previously	O
,	O
we	O
observed	B-C1441672
that	O
exposure	B-C0332157
to	O
a	O
high-fat	B-C0012155
diet	I-C0012155
hfd	B-C0012155
in	B-C1708480
utero	I-C1708480
caused	B-C0015127
a	O
metabolic	B-C0311400
syndrome	B-C0039082
-like	O
phenomenon	B-C1882365
through	B-C0332273
epigenetic	B-C1516924
modifications	I-C1516924
of	O
the	O
adiponectin	B-C1540187
and	O
leptin	B-C1416825
genes	I-C1416825
that	O
persisted	O
for	O
multiple	B-C0439064
generations	B-C0079411
.	O
	
recent	O
etiological	B-C0015127
studies	B-C2603343
indicated	B-C1444656
that	O
paternal	B-C0337493
bmi	B-C1305855
had	O
effects	B-C1280500
on	O
offspring	B-C0680063
bmi	B-C1305855
that	O
were	O
independent	B-C0332291
of	I-C0332291
but	O
additive	B-C0442796
to	O
maternal	B-C1858460
bmi	B-C1305855
effects	B-C1280500
.	O
	
thus	O
,	O
we	O
examined	O
whether	O
paternal	B-C0337493
hfd	B-C0012155
-	O
induced	B-C0205263
obesity	B-C0028754
affected	B-C1280500
the	O
metabolic	B-C0311400
status	B-C0449438
of	O
offspring	B-C0680063
through	B-C0332273
epigenetic	B-C1516924
changes	I-C1516924
in	O
the	O
adiponectin	B-C1540187
and	O
leptin	B-C1416825
genes	I-C1416825
.	O
	
additionally	O
,	O
we	O
investigated	B-C1292732
whether	O
a	O
normal	B-C0184625
diet	I-C0184625
during	B-C0347984
subsequent	B-C1136186
generations	I-C1136186
abolished	B-C1947925
the	O
epigenetic	B-C1516924
changes	I-C1516924
associated	B-C0332281
with	I-C0332281
paternal	B-C0337493
hfd	B-C0012155
exposure	B-C0332157
before	B-C0332152
conception	B-C0009637
.	O
	
we	O
observed	B-C1441672
the	O
effects	B-C1704420
of	I-C1704420
paternal	B-C0337493
hfd	B-C0012155
exposure	B-C0332157
before	B-C0332152
conception	B-C0009637
over	O
multiple	B-C0439064
generations	B-C0079411
on	O
offspring	B-C0680063
metabolic	B-C0311400
traits	B-C0599883
,	O
including	B-C0332257
weight	B-C0043094
and	O
fat	B-C0015677
gain	B-C1517378
,	O
glucose	B-C0271650
intolerance	I-C0271650
,	O
hypertriglyceridemia	B-C0020557
,	O
abnormal	B-C1955907
adipocytokine	I-C1955907
levels	B-C0441889
,	O
hypertension	B-C0020538
,	O
and	O
adiponectin	B-C1540187
and	O
leptin	B-C1416825
gene	I-C1416825
expression	B-C0017262
and	O
epigenetic	B-C1516924
changes	I-C1516924
.	O
	
normal	B-C0184625
diet	I-C0184625
consumption	O
by	O
male	O
offspring	B-C0680063
during	O
the	O
subsequent	O
generation	O
following	O
paternal	B-C0337493
hfd	B-C0012155
exposure	B-C0332157
diminished	B-C0205216
whereas	O
consumption	B-C2983605
for	O
two	O
generations	B-C0079411
completely	O
abolished	B-C1947925
the	O
effect	B-C1280500
of	O
paternal	B-C0337493
hfd	B-C0012155
exposure	B-C0332157
on	O
metabolic	B-C0311400
traits	B-C0599883
and	O
adipocytokine	B-C1955907
promoter	O
epigenetic	B-C1516924
changes	I-C1516924
in	O
the	O
offspring	B-C0680063
.	O
	
the	O
effects	B-C1704420
of	I-C1704420
paternal	B-C0337493
hfd	B-C0012155
exposure	B-C0332157
on	O
offspring	B-C0680063
were	O
relatively	O
weaker	B-C1762617
than	O
those	O
following	B-C0332282
hfd	B-C0012155
exposure	B-C0332157
in	B-C1708480
utero	I-C1708480
.	O
	
however	O
,	O
paternal	B-C0337493
hfd	B-C0012155
exposure	B-C0332157
had	O
an	O
additive	B-C0442796
metabolic	B-C0311400
effect	B-C1280500
for	O
two	O
generations	B-C0079411
,	O
suggesting	O
that	O
both	O
paternal	B-C0337493
and	O
maternal	B-C1858460
nutrition	B-C1442959
might	O
affect	B-C1280500
offspring	B-C0680063
metabolism	B-C0025519
through	B-C0332273
epigenetic	B-C1516924
modifications	I-C1516924
of	O
adipocytokine	B-C0017337
genes	I-C0017337
for	O
multiple	B-C0439064
generations	B-C0079411
.	O
	
study	B-C0947630
of	O
the	O
microfocus	B-C0205234
x-ray	B-C0184486
tube	I-C0184486
based	O
on	O
a	O
point-like	B-C1521840
target	I-C1521840
used	O
for	O
micro-computed	B-C2350281
tomography	I-C2350281
for	O
a	O
micro-computed	B-C2350281
tomography	I-C2350281
micro-ct	I-C2350281
system	I-C2350281
,	O
the	O
microfocus	B-C0205234
x-ray	B-C0184486
tube	I-C0184486
is	O
an	O
essential	B-C0205224
component	O
because	O
the	O
spatial	B-C1254362
resolution	B-C1706463
of	O
ct	B-C0040405
images	B-C1704254
,	O
in	O
theory	B-C0871935
,	O
is	O
mainly	O
determined	O
by	O
the	O
size	B-C0456389
and	O
stability	B-C0205360
of	O
the	O
x-ray	B-C0043299
focal	B-C0205146
spot	I-C0205146
of	O
the	O
microfocus	B-C0205234
x-ray	B-C0184486
tube	I-C0184486
.	O
	
however	O
,	O
many	O
factors	B-C1521761
,	O
including	O
voltage	B-C0598352
fluctuations	B-C0231241
,	O
mechanical	B-C0376706
vibrations	B-C0459800
,	O
and	O
temperature	B-C0450031
changes	I-C0450031
,	O
can	O
cause	B-C0085978
the	O
size	B-C0456389
and	O
the	O
stability	B-C0205360
of	O
the	O
x-ray	B-C0043299
focal	B-C0205146
spot	I-C0205146
to	O
degrade	B-C1254366
.	O
	
a	O
new	O
microfocus	B-C0205234
x-ray	B-C0184486
tube	I-C0184486
based	O
on	O
a	O
point-like	B-C1521840
micro-target	I-C1521840
in	O
which	O
the	O
x-ray	B-C0043299
target	B-C1521840
is	O
irradiated	B-C1254366
with	O
an	O
unfocused	O
electron	B-C0013840
beam	I-C0013840
was	O
investigated	B-C1292732
.	O
	
egs4	B-C0026507
monte	I-C0026507
carlo	I-C0026507
simulation	I-C0026507
code	I-C0026507
was	O
employed	O
for	O
the	O
calculation	B-C1441506
of	O
the	O
x-ray	B-C0043299
intensity	B-C0596836
produced	O
from	O
the	O
point-like	B-C1521840
micro-target	I-C1521840
and	O
the	O
substrate	B-C3891814
.	O
	
the	O
effects	B-C1704420
of	I-C1704420
several	O
arrangements	O
of	O
the	O
target	B-C1521840
material	B-C0520510
,	O
target	B-C1521840
and	O
beam	B-C0013840
size	B-C0456389
were	O
studied	B-C0947630
.	O
	
the	O
simulation	B-C0679083
results	B-C1274040
demonstrated	O
that	O
if	O
the	O
intensity	B-C0596836
of	O
x-rays	B-C0043299
generated	B-C2346631
at	O
the	O
point-like	B-C1521840
target	I-C1521840
is	O
greater	B-C0439093
than	I-C0439093
half	O
of	O
the	O
x-ray	B-C0043299
intensity	B-C0596836
produced	O
on	O
the	O
substrate	B-C3891814
,	O
the	O
x-ray	B-C0043299
focal	B-C0205146
spot	I-C0205146
is	O
determined	O
in	O
part	O
by	O
the	O
point-like	B-C1521840
target	I-C1521840
rather	O
than	O
by	O
the	O
electron	B-C0013840
beam	I-C0013840
in	O
the	O
conventional	B-C0439858
x-ray	B-C0184486
tube	I-C0184486
.	O
	
in	O
theory	B-C0871935
,	O
since	O
it	O
is	O
able	O
to	O
reduce	B-C0392756
those	O
unfavorable	O
effects	B-C1280500
such	O
as	O
the	O
electron	B-C0243095
beam	I-C0243095
trajectory	I-C0243095
swinging	I-C0243095
and	O
the	O
beam	B-C0013840
size	B-C0456389
changing	B-C0392747
for	O
the	O
microfocus	B-C0205234
x-ray	B-C0184486
tube	I-C0184486
,	O
it	O
could	O
alleviate	B-C0392756
ct	B-C0040405
image	B-C1704254
artifacts	B-C0085089
caused	B-C0085978
by	O
the	O
x-ray	B-C0043299
focal	B-C0205146
spot	I-C0205146
shift	B-C3845720
and	O
size	B-C0541591
change	I-C0541591
.	O
	
early	B-C1279919
assessment	B-C0220825
of	O
bilateral	B-C0198737
inguinal	I-C0198737
hernia	I-C0198737
repair	I-C0198737
a	O
comparison	B-C1707455
between	O
the	O
laparoscopic	B-C0087111
total	I-C0087111
extraperitoneal	I-C0087111
and	O
stoppa	B-C0087111
approaches	I-C0087111
the	O
present	B-C0521116
clinical	B-C0008976
trial	I-C0008976
was	O
designed	O
to	O
compare	B-C1707455
the	O
results	B-C1274040
of	O
bilateral	B-C0198737
inguinal	I-C0198737
hernia	I-C0198737
repair	I-C0198737
between	O
patients	B-C0030705
who	O
underwent	O
the	O
conventional	B-C0443177
stoppa	B-C0087111
technique	I-C0087111
and	O
laparoscopic	B-C0521293
total	I-C0521293
extraperitoneal	I-C0521293
repair	I-C0521293
lte	B-C0521293
with	O
a	O
single	O
mesh	B-C0181805
and	O
without	O
staple	B-C1293125
fixation	I-C1293125
.	O
	
this	O
controlled	O
,	O
randomised	B-C0034656
clinical	B-C0008976
trial	I-C0008976
was	O
conducted	O
at	O
general	B-C1708333
surgery	I-C1708333
and	I-C1708333
trauma	I-C1708333
of	I-C1708333
the	I-C1708333
clinics	I-C1708333
hospital	I-C1708333
,	O
medical	B-C1708333
school	I-C1708333
,	O
the	O
university	B-C1708333
of	I-C1708333
sγo	I-C1708333
paulo	I-C1708333
between	O
september	O
2010	O
and	O
february	O
2011	O
.	O
	
totally	O
,	O
50	O
male	B-C0086582
patients	B-C0030705
,	O
with	O
a	O
bilateral	B-C0267672
inguinal	I-C0267672
hernia	I-C0267672
,	O
older	O
than	O
25	O
years	B-C0439234
were	O
considered	O
eligible	B-C1548635
for	O
the	O
study	B-C2603343
.	O
	
the	O
following	O
parameters	B-C0549193
were	O
analysed	B-C0936012
during	O
the	O
early	B-C1279919
post-operative	B-C0032790
period	I-C0032790
1	O
the	O
intensity	B-C0522510
of	O
surgical	B-C4060629
trauma	I-C4060629
,	O
operation	B-C3494201
time	I-C3494201
,	O
c-reactive	B-C0006560
protein	I-C0006560
crp	B-C0006560
levels	B-C0441889
,	O
white	B-C0023508
blood	I-C0023508
cell	I-C0023508
count	I-C0023508
,	O
bleeding	B-C0019080
and	O
pain	B-C1320357
intensity	I-C1320357
2	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
assessment	B-C0220825
and	O
3	O
post-operative	B-C0032787
complications	I-C0032787
.	O
	
lte	B-C0521293
procedure	I-C0521293
was	O
longer	B-C0205166
than	O
the	O
stoppa	B-C0087111
procedure	I-C0087111
134.6	O
min	O
38.3	O
vs	O
.	O
	
90.6	O
min	O
41.3	O
p	O
<	O
0.05	O
.	O
	
the	O
levels	B-C0441889
of	O
crp	B-C0006560
were	O
higher	B-C0205250
in	O
the	O
stoppa	B-C0087111
group	B-C0441833
p	O
<	O
0.05	O
but	O
the	O
number	O
of	O
leucocytes	B-C0023516
,	O
haematocrit	B-C0518014
,	O
and	O
haemoglobin	B-C0019046
were	O
similar	B-C2348205
between	O
the	O
groups	B-C0441833
p	O
>	O
0.05	O
.	O
	
there	O
was	O
no	B-C3842396
difference	I-C3842396
in	O
pain	B-C0030193
during	O
the	O
1	O
st	O
and	O
7	O
th	O
post-operative	B-C0241311
,	O
physical	B-C0516981
functioning	I-C0516981
,	O
physical	B-C0449295
limitation	I-C0449295
,	O
the	O
impact	B-C4049986
of	O
pain	B-C0030193
on	O
daily	B-C0871707
activities	I-C0871707
,	O
and	O
the	O
carolinas	B-C0349674
comfort	I-C0349674
scale	I-C0349674
during	O
the	O
7	O
th	O
and	O
15	O
th	O
post-operative	B-C0241311
p	O
>	O
0.05	O
.	O
	
complications	B-C0009566
occurred	O
in	O
88%	O
of	O
stoppa	B-C0087111
group	B-C0441833
22	O
patients	B-C0030705
and	O
64%	O
in	O
lte	B-C0521293
group	B-C0441833
16	O
patients	B-C0030705
p	O
<	O
0.05	O
.	O
	
the	O
comparative	B-C1579762
study	I-C1579762
between	O
the	O
stoppa	B-C0087111
and	O
lte	B-C0521293
approaches	O
for	O
the	O
bilateral	B-C0198737
inguinal	I-C0198737
hernia	I-C0198737
repair	I-C0198737
demonstrated	O
that	O
1	O
the	O
lte	B-C0521293
approach	O
showed	O
less	O
surgical	B-C4060629
trauma	I-C4060629
despite	O
the	O
longer	B-C0205166
operation	B-C3494201
time	I-C3494201
2	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
during	O
the	O
early	B-C1279919
post-operative	B-C0032790
period	I-C0032790
were	O
similar	B-C2348205
and	O
3	O
complication	B-C0009566
rates	B-C1521828
were	O
higher	B-C0205250
in	O
the	O
stoppa	B-C0087111
group	B-C0441833
.	O
	
morphological	B-C0543482
characteristics	B-C1521970
regulating	O
phallic	B-C0227948
glans	I-C0227948
engorgement	B-C0020452
in	O
the	O
american	B-C0327167
alligator	I-C0327167
the	O
distal	B-C0205108
part	I-C0205108
of	O
the	O
crocodilian	B-C0327160
phallus	B-C0030851
consists	O
of	O
a	O
bulbous	B-C0227948
glans	I-C0227948
containing	O
well-developed	O
vascular	B-C1511228
tissues	I-C1511228
that	O
can	O
inflate	O
before	O
or	O
during	O
sexual	B-C0036864
activity	I-C0036864
,	O
enlarging	B-C0442800
and	O
elaborating	O
the	O
glans	B-C1550261
into	O
a	O
complex	B-C0439855
,	O
though	O
still	O
functionally	B-C0205245
undefined	B-C0750600
,	O
copulatory	B-C1325873
structure	O
.	O
	
an	O
enlarged	B-C0442800
glans	B-C1550261
putatively	O
interacts	B-C1704675
with	O
the	O
female	B-C0086287
cloaca	B-C0008987
and	O
may	O
change	B-C0392747
the	O
shape	B-C0332479
of	O
her	B-C0700038
reproductive	I-C0700038
tract	I-C0700038
to	O
facilitate	O
insemination	B-C0021586
and	O
increase	B-C0442805
the	O
probability	B-C0033204
of	O
fertilization	B-C0015914
.	O
	
here	O
,	O
we	O
investigated	O
the	O
cellular-level	B-C0007613
properties	I-C0007613
of	O
the	O
glans	B-C1550261
and	O
other	O
inflatable	B-C0040300
phallic	I-C0040300
tissues	I-C0040300
associated	O
with	O
the	O
sperm	B-C0037868
-conducting	O
sulcus	B-C1184482
spermaticus	B-C0037855
in	O
the	O
american	B-C0327167
alligator	I-C0327167
alligator	B-C0327167
mississippiensis	I-C0327167
.	O
	
using	O
histochemical	B-C0200825
staining	I-C0200825
,	O
we	O
visualized	O
and	O
defined	O
collagen	B-C0009325
and	O
elastin	B-C0230899
fiber	I-C0230899
densities	B-C0178587
and	O
orientations	B-C1704322
in	O
these	O
tissues	B-C0040300
.	O
	
extracellular	B-C0015350
matrix	I-C0015350
architectures	O
provided	O
insights	O
about	O
phallic	B-C0227948
glans	I-C0227948
material	O
properties	O
and	O
how	O
they	O
may	O
affect	B-C0392760
tissue	B-C0040300
strength	B-C0237897
and	O
flexibility	B-C0242808
during	O
inflation	O
and	O
in	O
response	O
to	O
copulatory	B-C1325873
forces	B-C0441722
.	O
	
we	O
also	O
investigated	O
the	O
potential	B-C3245505
sources	O
of	O
fluids	B-C0302908
that	O
induce	B-C0205263
inflation	O
in	O
alligator	B-C0002123
phalli	B-C0030851
.	O
	
combining	O
serial	B-C0022885
sectioning	I-C0022885
and	O
three-dimensional	B-C0022885
reconstruction	I-C0022885
,	O
we	O
identified	O
a	O
pair	O
of	O
supracrucal	B-C0501402
plexus	I-C0501402
vascular	I-C0501402
bodies	B-C1995017
at	O
the	O
proximal	O
end	O
of	O
the	O
alligator	B-C0002123
phallus	B-C0030851
that	O
extend	O
distally	B-C1254362
adjacent	I-C1254362
to	O
ventro-medial	B-C0040300
sulcus	I-C0040300
tissues	I-C0040300
.	O
	
together	O
,	O
our	O
gross	B-C0439806
and	O
histological	B-C0449575
examination	I-C0449575
of	O
the	O
american	B-C0327167
alligator	I-C0327167
phallic	B-C0227948
glans	I-C0227948
suggests	O
that	O
its	O
tissues	B-C0040300
are	O
arranged	O
in	O
a	O
manner	O
that	O
would	O
allow	O
vascular	B-C0005847
inflation	O
to	O
expand	O
the	O
glans	B-C1550261
to	O
a	O
specific	O
and	O
repeatable	O
shape	B-C0332479
,	O
and	O
potentially	B-C3245505
release	O
secretory	B-C0243092
products	I-C0243092
into	O
the	O
female	B-C0700038
reproductive	I-C0700038
tract	I-C0700038
.	O
	
both	O
elements	O
could	O
play	O
roles	O
in	O
postcopulatory	B-C1325873
sexual	B-C1720879
selection	I-C1720879
,	O
by	O
mechanically	B-C0443254
and/or	O
chemically	O
affecting	B-C1517151
female	I-C1517151
reproductive	I-C1517151
physiology	I-C1517151
.	O
	
a	O
novel	O
role	B-C1705810
for	O
poly	B-C0242210
binding	I-C0242210
proteins	I-C0242210
in	O
programmed	B-C0282572
ribosomal	I-C0282572
frameshifting	I-C0282572
translational	B-C1519614
control	B-C0243148
through	O
programmed	B-C0282572
ribosomal	I-C0282572
frameshifting	I-C0282572
prf	B-C0282572
is	O
exploited	O
widely	O
by	O
viruses	B-C0042776
and	O
increasingly	O
documented	O
in	O
cellular	B-C0007634
genes	B-C0017337
.	O
	
frameshifting	B-C0282572
is	O
induced	B-C0205263
by	O
mrna	B-C0035696
secondary	I-C0035696
structures	I-C0035696
that	O
compromise	O
ribosome	B-C0035553
fidelity	B-C0007613
during	O
decoding	B-C0205245
of	O
a	O
heptanucleotide	B-C0004793
'slippery'	I-C0004793
sequence	I-C0004793
.	O
	
the	O
nsp2	B-C0033684
prf	B-C0282572
signal	B-C0037080
of	O
porcine	B-C0376536
reproductive	I-C0376536
and	I-C0376536
respiratory	I-C0376536
syndrome	I-C0376536
virus	I-C0376536
is	O
distinctive	O
in	O
directing	O
both	O
-2	B-C0282572
and	O
-1	B-C0282572
prf	I-C0282572
and	O
in	O
its	O
requirement	B-C1514873
for	O
a	O
trans-acting	B-C0033684
protein	I-C0033684
factor	I-C0033684
,	O
the	O
viral	B-C0042776
replicase	B-C0033684
subunit	I-C0033684
nsp1β	I-C0033684
.	O
	
here	O
we	O
show	O
that	O
the	O
the	O
trans-activation	B-C0040624
of	O
frameshifting	B-C0282572
is	O
carried	O
out	O
by	O
a	O
protein	B-C1180347
complex	I-C1180347
composed	O
of	O
nsp1β	B-C0033684
and	O
a	O
cellular	B-C0007634
poly	B-C0242210
binding	I-C0242210
protein	I-C0242210
pcbp	B-C0242210
.	O
	
from	O
the	O
results	O
of	O
in	B-C1533691
vitro	I-C1533691
translation	B-C1519614
and	O
electrophoretic	B-C0949632
mobility	I-C0949632
shift	I-C0949632
assays	I-C0949632
,	O
we	O
demonstrate	O
that	O
a	O
pcbp	B-C0242210
/	O
nsp1β	B-C0033684
complex	B-C1180347
binds	O
to	O
a	O
c-rich	B-C0004793
sequence	I-C0004793
downstream	B-C0522506
of	O
the	O
slippery	B-C0004793
sequence	I-C0004793
and	O
here	O
mimics	O
the	O
activity	B-C0441655
of	O
a	O
structured	O
mrna	B-C0035696
stimulator	B-C0574031
of	O
prf	B-C0282572
.	O
	
this	O
is	O
the	O
first	O
description	O
of	O
a	O
role	B-C1705810
for	O
a	O
trans-acting	B-C0033684
cellular	I-C0033684
protein	I-C0033684
in	O
prf	B-C0282572
.	O
	
the	O
discovery	O
broadens	O
the	O
repertoire	O
of	O
activities	B-C0441655
associated	B-C0332281
with	I-C0332281
poly	B-C0242210
binding	I-C0242210
proteins	I-C0242210
and	O
prototypes	B-C0205556
a	O
new	O
class	O
of	O
virus	B-C0042776
-	O
host	B-C1167395
interactions	B-C1704675
.	O
	
production	O
of	O
bioactive	B-C3714412
conjugated	B-C1257880
linoleic	I-C1257880
acid	I-C1257880
by	O
the	O
multifunctional	B-C3658346
enolase	B-C0031691
from	O
lactobacillus	B-C0317608
plantarum	I-C0317608
lactobacillus	B-C0317608
plantarum	I-C0317608
α-enolase	B-C2364020
,	O
a	O
multifunctional	B-C3658346
-anchorless-	O
surface	B-C0025252
protein	I-C0025252
belonging	O
to	O
the	O
conserved	O
family	O
of	O
enolases	B-C0031691
with	O
a	O
central	O
role	O
in	O
glycolytic	B-C0017952
metabolism	B-C0025519
,	O
was	O
characterized	B-C1880022
to	O
have	O
a	O
side	O
role	O
in	O
the	O
intricate	B-C0025519
metabolism	I-C0025519
of	O
biohydrogenation	B-C0020286
of	O
linoleic	B-C0023749
acid	I-C0023749
,	O
catalyzing	B-C0007382
the	O
formation	B-C1522492
of	O
bioactive	B-C3714412
9-cis-11-trans-cla	B-C1609806
through	O
dehydration	B-C0598133
and	O
isomerization	B-C0596342
of	O
10-hydroxy-12-cis-octadecenoic	B-C0620518
acid	I-C0620518
.	O
	
the	O
identity	O
of	O
the	O
enolase	B-C0031691
was	O
confirmed	O
through	O
mass	B-C0037813
spectrometric	I-C0037813
analysis	I-C0037813
that	O
showed	O
the	O
characteristic	O
442	O
amino	B-C0002518
acid	I-C0002518
sequence	I-C0002518
with	O
a	O
molecular	B-C3152252
mass	I-C3152252
of	O
48.03	O
kda	B-C1532717
.	O
	
the	O
enolase	B-C0031691
was	O
not	O
capable	O
of	O
using	O
linoleic	B-C0023749
acid	I-C0023749
directly	O
as	O
a	O
substrate	B-C3891814
but	O
instead	O
uses	O
its	O
hydroxyl	B-C0700307
derivative	B-C1527240
10-hydroxi-12-cis-octadecenoic	B-C0620518
acid	I-C0620518
to	O
finally	O
form	O
bioactive	B-C3714412
conjugated	B-C0050156
linoleic	I-C0050156
acid	I-C0050156
.	O
	
biochemical	B-C0205474
optimization	B-C2698650
studies	B-C2603343
were	O
carried	O
out	O
to	O
elucidate	O
the	O
conditions	O
for	O
maximum	O
production	O
of	O
9-cis-11-trans-cla	B-C1609806
and	O
maximum	O
stability	B-C0014439
of	O
α-enolase	B-C2364020
when	O
catalyzing	B-C0007382
this	O
reaction	B-C0596319
.	O
	
furthermore	O
,	O
through	O
structural	B-C0204514
analysis	I-C0204514
of	O
the	O
protein	B-C0033684
,	O
we	O
propose	O
the	O
binding	B-C0005456
sites	I-C0005456
of	O
substrate	B-C3891814
and	O
product	B-C1514468
molecules	B-C0567416
that	O
were	O
characterized	B-C1880022
as	O
two	O
hydrophobic	B-C0598629
superficial	O
pockets	O
located	O
at	O
opposite	O
ends	O
of	O
the	O
enolase	B-C0031691
connected	O
through	O
a	O
channel	B-C0022009
where	O
the	O
catalysis	B-C0007382
of	O
dehydration	B-C0598133
and	O
isomerization	B-C0596342
might	O
occur	O
.	O
	
these	O
results	O
prove	O
that	O
multifunctional	B-C3658346
α-enolase	B-C2364020
also	O
plays	O
a	O
role	O
in	O
cell	B-C4235382
detoxification	I-C4235382
from	O
polyunsaturated	B-C0032615
fatty	I-C0032615
acids	I-C0032615
such	O
as	O
linoleic	B-C0023749
acid	I-C0023749
,	O
along	O
with	O
the	O
linoleate	B-C0312354
isomerase	I-C0312354
complex	B-C1704241
.	O
	
associations	B-C0439849
of	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
and	O
physical	B-C0026606
activity	I-C0026606
with	O
sexual	B-C0549622
dysfunction	I-C0549622
in	O
breast	B-C0678222
cancer	I-C0678222
survivors	B-C0206194
sexual	B-C0549622
dysfunction	I-C0549622
is	O
a	O
common	O
and	O
distressing	B-C0231303
consequence	B-C0686907
of	I-C0686907
breast	B-C0678222
cancer	I-C0678222
bc	B-C0678222
treatment	B-C0087111
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
we	O
investigated	O
the	O
sexual	B-C0278092
functioning	I-C0278092
of	O
bc	B-C0678222
patients	B-C0030705
and	O
its	O
association	B-C0004083
with	O
women's	B-C0043210
personal	B-C1519021
characteristics	B-C1521970
and	O
cancer	B-C0920425
treatments	I-C0920425
.	O
	
in	O
this	O
cross-sectional	B-C0010362
study	I-C0010362
,	O
sexual	B-C0278092
function	I-C0278092
was	O
assessed	O
using	O
the	O
female	B-C4289276
sexual	I-C4289276
function	I-C4289276
index	I-C4289276
fsfi	B-C4289276
.	O
	
the	O
health-related	B-C4279947
quality	I-C4279947
of	I-C4279947
life	I-C4279947
hrqol	B-C4279947
was	O
measured	O
using	O
the	O
european	B-C1516985
organization	I-C1516985
for	I-C1516985
research	I-C1516985
and	I-C1516985
treatment	I-C1516985
of	I-C1516985
cancer	I-C1516985
eortc	B-C1516985
qlq-c30	B-C3641780
and	O
its	O
breast	B-C0282574
module	I-C0282574
br-23	I-C0282574
.	O
	
of	O
the	O
235	O
participants	B-C0679646
approached	O
,	O
216	O
participants	B-C0679646
were	O
included	O
in	O
the	O
study	O
.	O
	
of	O
these	O
,	O
63	O
patients	B-C0030705
reported	O
no	B-C3840693
sexual	I-C3840693
activity	I-C3840693
in	O
the	O
last	O
month	B-C0439231
and	O
thus	O
were	O
analyzed	O
only	O
in	O
relation	O
to	O
the	O
sexual	B-C0023618
desire	I-C0023618
domain	B-C1880389
of	O
fsfi	B-C4289276
.	O
	
a	O
total	O
of	O
154	O
71.3	O
%	O
patients	B-C0030705
were	O
classified	O
with	O
hypoactive	B-C0020594
sexual	I-C0020594
desire	I-C0020594
disorder	I-C0020594
hsdd	B-C0020594
.	O
	
from	O
those	O
patients	B-C0030705
reporting	O
sexual	B-C0036864
activity	I-C0036864
in	O
the	O
last	O
month	B-C0439231
,	O
63.3	O
%	O
97	O
out	O
of	O
153	O
were	O
classified	O
with	O
sexual	B-C0549622
dysfunction	I-C0549622
.	O
	
using	O
hierarchical	B-C0206031
logistic	I-C0206031
regression	I-C0206031
,	O
the	O
variance	O
explained	O
change	O
in	O
r	O
2	O
by	O
the	O
addition	O
of	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
and	O
mild	O
to	O
moderate	O
physical	B-C0026606
activity	I-C0026606
in	O
the	O
prediction	B-C0681842
models	B-C3161035
of	O
sexual	B-C0549622
dysfunction	I-C0549622
and	O
hsdd	B-C0020594
were	O
6.8	O
and	O
7.2	O
%	O
,	O
respectively	O
.	O
	
age	B-C0001779
,	O
bmi	B-C1305855
,	O
and	O
physical	B-C0026606
activity	I-C0026606
were	O
independently	O
associated	O
with	O
sexual	B-C0549622
dysfunction	I-C0549622
and	O
hsdd	B-C0020594
.	O
	
additionally	O
,	O
bc	B-C0678222
patients	B-C0030705
with	O
sexual	B-C0549622
dysfunction	I-C0549622
reported	O
lower	B-C1611820
scores	B-C0449820
on	O
global	O
hrqol	B-C4279947
,	O
role	O
functioning	B-C0205245
,	O
and	O
fatigue	B-C0015672
.	O
	
based	O
on	O
our	O
findings	B-C0243095
,	O
bc	B-C0678222
survivors	B-C0206194
should	O
be	O
encouraged	O
to	O
practice	B-C0032893
regular	O
physical	B-C0026606
activity	I-C0026606
and	O
to	O
lose	B-C0418839
weight	I-C0418839
in	O
order	O
to	O
avoid	O
sexual	B-C0549622
dysfunction	I-C0549622
.	O
	
however	O
,	O
future	O
clinical	B-C0008976
trials	I-C0008976
are	O
needed	O
to	O
confirm	O
these	O
combination	B-C0013162
of	O
telmisartan	B-C0248719
with	O
sildenafil	B-C0529793
ameliorate	B-C0205556
progression	B-C0242656
of	O
diabetic	B-C0011881
nephropathy	I-C0011881
in	O
streptozotocin	B-C0038432
-	O
induced	B-C0205263
diabetic	B-C0241863
model	O
diabetic	B-C0011881
nephropathy	I-C0011881
dn	B-C0011881
is	O
a	O
leading	O
cause	O
of	O
end-stage	B-C0022661
renal	I-C0022661
disease	I-C0022661
in	O
the	O
world	O
.	O
	
several	O
signaling	B-C0037080
pathways	I-C0037080
are	O
involved	O
in	O
the	O
pathogenesis	B-C0699748
of	O
dn	B-C0011881
including	O
elevation	B-C0702240
in	O
level	O
of	O
angiotensin	B-C0003009
ii	I-C0003009
,	O
formation	B-C1522492
of	O
advanced	B-C0162574
glycation	I-C0162574
end	I-C0162574
products	I-C0162574
age	B-C0162574
,	O
activation	B-C1819041
of	O
protein	B-C0033634
kinase	I-C0033634
c	I-C0033634
pkc	B-C0033634
,	O
and	O
lipid	B-C0333574
accumulation	I-C0333574
.	O
	
these	O
pathways	B-C0037080
activate	B-C1879547
one	O
another	O
mutually	O
leading	O
to	O
oxidative	B-C0242606
stress	I-C0242606
,	O
increasing	O
expression	B-C1171362
of	O
transforming	B-C1704256
growth	I-C1704256
factor	I-C1704256
beta-1	I-C1704256
tgf-β	B-C1704256
1	I-C1704256
and	O
release	B-C1283071
of	O
interleukins	B-C0021764
and	O
adhesion	B-C0007578
molecules	I-C0007578
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	B-C3816499
pathway	B-C1705987
to	O
ameliorate	B-C0205556
the	O
progression	B-C0242656
of	O
dn	B-C0011881
.	O
	
in	O
the	O
present	O
study	B-C0008972
,	O
white	B-C0684072
male	I-C0684072
rats	I-C0684072
n=48	O
were	O
divided	O
into	O
six	O
groups	O
8	O
rats	B-C0684072
each	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	B-C0009932
control	I-C0009932
and	O
a	O
control	B-C0009932
vehicle	I-C0009932
group	I-C0009932
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	B-C0241863
by	O
a	O
single	O
intraperitoneal	B-C0021493
injection	I-C0021493
of	O
streptozotocin	B-C0038432
stz	B-C0038432
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
dn	B-C0011881
.	O
	
thereafter	O
,	O
the	O
rats	B-C0684072
were	O
divided	O
into	O
dn	B-C0011881
group	O
,	O
dn	B-C0011881
group	O
receiving	O
telmisartan	B-C0248719
or	O
sildenafil	B-C0529793
or	O
telmisartan	B-C0248719
sildenafil	B-C0529793
combination	B-C0013162
.	O
	
after	O
the	O
specified	B-C0205369
treatment	B-C0039798
period	B-C1948053
,	O
urine	B-C1610733
samples	I-C1610733
were	O
collected	B-C1516695
using	O
metabolic	B-C3273359
cages	I-C3273359
to	O
measure	O
proteinuria	B-C0033687
,	O
animals	B-C0003062
were	O
then	O
euthanized	B-C0162665
,	O
blood	B-C0178913
and	O
tissue	B-C1292533
samples	I-C1292533
were	O
collected	B-C1516695
for	O
measurement	B-C0392201
of	I-C0392201
blood	I-C0392201
glucose	I-C0392201
,	O
bun	B-C0005845
,	O
s.cr	B-C0201976
,	O
ldl	B-C0202117
,	O
no	B-C3810607
,	O
tgf-β1	B-C3889969
,	O
il-1β	B-C3815172
,	O
ageps	B-C0022885
,	O
and	O
sod	B-C0022885
.	O
	
the	O
combination	B-C0013218
therapy	I-C0013218
showed	O
significant	O
decrease	O
in	O
bun	B-C0600137
,	O
s.cr	B-C0010294
,	O
ldl	B-C0023823
,	O
tgf-β1	B-C1704256
,	O
il-1β	B-C0021753
,	O
proteinuria	B-C0033687
and	O
ageps	B-C0162574
and	O
significant	O
increase	O
in	O
sod	B-C0038838
and	O
no	B-C0028128
.	O
	
the	O
findings	O
showed	O
that	O
combination	B-C0013218
therapy	I-C0013218
was	O
able	O
to	O
ameliorate	B-C0205556
dn	B-C0011881
and	O
that	O
the	O
effects	O
were	O
superior	B-C0205556
to	O
the	O
single	O
drugs	B-C0013227
analysis	B-C0936012
of	O
low-biomass	B-C0005535
microbial	B-C0445623
communities	I-C0445623
in	O
the	O
deep	B-C0681784
biosphere	I-C0681784
over	O
the	O
past	O
few	B-C2981279
decades	I-C2981279
,	O
the	O
subseafloor	B-C0681784
biosphere	I-C0681784
has	O
been	O
explored	O
by	O
scientific	B-C0205245
ocean	I-C0205245
drilling	I-C0205245
to	O
depths	B-C0205125
of	O
about	O
2.5km	O
below	O
the	O
seafloor	B-C0681784
.	O
	
although	O
organic-rich	B-C0871648
anaerobic	I-C0871648
sedimentary	I-C0871648
habitats	I-C0871648
in	O
the	O
ocean	B-C1254362
margins	I-C1254362
harbor	I-C1254362
large	O
numbers	O
of	O
microbial	B-C0445623
cells	I-C0445623
,	O
microbial	B-C0445623
populations	I-C0445623
in	O
ultraoligotrophic	B-C0871648
aerobic	I-C0871648
sedimentary	I-C0871648
habitats	I-C0871648
in	O
the	O
open	O
ocean	B-C0205245
gyres	I-C0205245
are	O
several	O
orders	O
of	O
magnitude	B-C1704240
less	O
abundant	B-C2346714
.	O
	
despite	O
advances	O
in	O
cultivation-independent	B-C0449851
molecular	I-C0449851
ecological	I-C0449851
techniques	I-C0449851
,	O
exploring	O
the	O
low-biomass	B-C0005535
environment	B-C0014406
remains	O
technologically	B-C0332218
challenging	I-C0332218
,	O
especially	O
in	O
the	O
deep	B-C0681784
subseafloor	I-C0681784
biosphere	I-C0681784
.	O
	
reviewing	B-C1704362
the	O
historical	B-C1552723
background	I-C1552723
of	O
deep-biosphere	B-C0681784
analytical	B-C0178476
methods	I-C0178476
,	O
the	O
importance	B-C3898777
of	O
obtaining	O
clean	B-C0370003
samples	I-C0370003
and	O
tracing	B-C0243095
contamination	B-C2349974
,	O
as	O
well	O
as	O
methods	B-C0025663
for	O
detecting	B-C0243095
microbial	B-C0599840
life	B-C0376558
,	O
technological	B-C0681539
aspects	I-C0681539
of	O
molecular	B-C0025952
microbiology	I-C0025952
,	O
and	O
detecting	B-C0243095
subseafloor	B-C0681784
metabolic	B-C0025519
activity	I-C0025519
the	O
sensitivity	B-C0036668
and	I-C0036668
specifity	I-C0036668
of	O
dr-70	B-C0041365
immunoassay	B-C0020980
as	O
a	O
tumor	B-C0041365
marker	I-C0041365
for	O
non-small	B-C0007131
cell	I-C0007131
lung	I-C0007131
cancer	I-C0007131
lung	B-C0242379
cancer	I-C0242379
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	B-C1516192
related	I-C1516192
mortality	I-C1516192
.	O
	
patients	B-C0030705
with	O
lung	B-C0242379
cancer	I-C0242379
are	O
usually	O
diagnosed	B-C0430022
at	O
advanced	B-C0005898
or	O
locally	B-C0005898
advanced	I-C0005898
stage	I-C0005898
,	O
for	O
this	O
reason	O
early	B-C0596473
diagnosis	I-C0596473
of	O
lung	B-C0242379
cancer	I-C0242379
is	O
very	O
important	O
.	O
	
for	O
early	B-C0596473
detection	I-C0596473
of	O
lung	B-C0242379
cancer	I-C0242379
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low-dose	B-C0040405
computed	I-C0040405
tomography	I-C0040405
or	O
tumor	B-C0041366
biomarkers	I-C0041366
.	O
	
in	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	B-C0220825
dr-70	B-C0041365
sensitivity	B-C0036668
and	I-C0036668
specificity	I-C0036668
as	O
a	O
tumor	B-C0041365
marker	I-C0041365
in	O
detection	B-C1511790
of	O
non-small	B-C0007131
cell	I-C0007131
lung	I-C0007131
cancers	I-C0007131
.	O
	
between	O
may	B-C3812381
2013	O
and	O
april	B-C3715024
2014	O
,	O
the	O
serum	B-C1550100
samples	I-C1550100
from	O
88	O
non	B-C0006826
lung	I-C0006826
cancer	I-C0006826
patients	B-C0030705
,	O
86	O
patients	B-C0030705
with	O
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disesase	I-C0024117
were	O
obtained	O
.	O
	
blood	B-C0178913
samples	I-C0178913
from	O
each	O
participant	B-C0679646
were	O
analyzed	B-C0936012
for	O
dr-70	B-C0041365
level	B-C0441889
.	O
	
totally	O
174	O
patients	B-C0030705
were	O
enrolled	O
to	O
the	O
study	B-C2603343
152	O
male	B-C0025266
,	O
22	O
female	B-C0043210
.	O
	
histopathologically	B-C0243140
47	O
patients	B-C0030705
were	O
diagnosed	B-C0430022
with	O
squamous	B-C0149782
cell	I-C0149782
lung	I-C0149782
cancer	I-C0149782
,	O
34	O
38.6	O
with	O
adenocarcinoma	B-C0001418
,	O
and	O
7	O
8%	O
with	O
non-small	B-C0007131
cell	I-C0007131
lung	I-C0007131
cancer	I-C0007131
.	O
	
the	O
mean	B-C0041365
serum	I-C0041365
dr-70	I-C0041365
levels	B-C0441889
in	O
lung	B-C0242379
cancer	I-C0242379
patients	B-C0030705
2.43	O
1.82	O
µg/ml	O
was	O
significantly	B-C0243095
higher	I-C0243095
compared	B-C1707455
to	O
the	O
86	O
non-cancerous	B-C0243095
subjects	B-C2349001
1.15	O
0.70	O
µg/ml	O
p<	O
0.01	O
.	O
	
dr-70	B-C0041365
exhibited	O
clinical	B-C0205210
sensitivity	B-C0036668
and	I-C0036668
specificity	I-C0036668
of	O
54.5	O
and	O
83.7	O
,	O
respectively	O
,	O
at	O
an	O
optimal	B-C2698651
cut	B-C1442160
off	I-C1442160
at	O
1.98	O
µg/ml	O
.	O
	
it	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	B-C0012634
is	O
6.171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
dr-70	B-C0041365
level	B-C0441889
is	O
1.98	O
µg/ml	O
and	O
higher	O
.	O
	
dr-70	B-C0041365
,	O
a	O
marker	B-C0041365
used	O
to	O
measure	B-C0079809
fibrin	B-C0163275
degradation	I-C0163275
products	I-C0163275
,	O
generated	O
by	O
all	O
major	O
cancers	B-C0006826
,	O
may	O
helps	O
to	O
find	O
high	B-C0332167
risk	I-C0332167
lung	B-C0242379
cancer	I-C0242379
patients	B-C0030705
.	O
	
catastrophic	B-C0015318
expenditure	I-C0015318
and	O
impoverishment	B-C0392762
of	O
patients	B-C0030705
affected	O
by	O
7	O
rare	B-C0678236
diseases	I-C0678236
in	O
china	B-C0008115
china	B-C0008115
is	O
actively	O
promoting	B-C0033414
regulation	O
of	O
rare	B-C0678236
diseases	I-C0678236
,	O
rare	B-C0678236
disease	I-C0678236
and	O
orphan	B-C0013232
drugs	I-C0013232
have	O
been	O
formally	O
incorporated	O
into	O
the	O
national	B-C0679910
planning	I-C0679910
.	O
	
however	O
,	O
few	O
studies	B-C2603343
have	O
been	O
done	O
to	O
evaluate	O
the	O
affordability	B-C0814630
of	O
rare	B-C0678236
disease	I-C0678236
patients	B-C0030705
in	O
china	B-C0008115
.	O
	
this	O
study	O
aims	O
to	O
provide	O
policy	B-C0242456
recommendations	B-C0034866
for	O
the	O
establishment	B-C0443211
of	O
social	B-C0282574
security	I-C0282574
mechanism	I-C0282574
for	O
rare	B-C0678236
diseases	I-C0678236
in	O
china	B-C0008115
,	O
so	O
as	O
to	O
address	O
the	O
problem	O
of	O
poverty	B-C0032854
caused	O
by	O
these	O
diseases	B-C0012634
.	O
	
a	O
total	O
of	O
7	O
rare	B-C0678236
diseases	I-C0678236
were	O
selected	O
by	O
delphi	B-C0011216
method	I-C0011216
.	O
	
affordability	B-C0814630
of	O
treatment	B-C0087111
for	O
the	O
7	O
rare	B-C0678236
diseases	I-C0678236
was	O
assessed	B-C1516048
through	O
annual	B-C0021162
per	I-C0021162
capital	I-C0021162
income	I-C0021162
,	O
catastrophic	B-C0015318
expenditure	I-C0015318
and	O
impoverishment	B-C0392762
expenditure	B-C0015316
among	O
urban	B-C1257890
and	O
rural	B-C1257890
residents	I-C1257890
in	O
china	B-C0008115
.	O
	
assessed	B-C1516048
through	O
annual	B-C0021162
per	I-C0021162
capital	I-C0021162
income	I-C0021162
,	O
health	B-C0015318
expenditure	I-C0015318
for	O
the	O
7	O
rare	B-C0678236
diseases	I-C0678236
are	O
all	O
rather	O
high	O
.	O
	
the	O
highest	O
health	B-C0015318
expenditure	I-C0015318
is	O
equivalent	O
to	O
income	B-C0021162
of	O
69.34	O
years	B-C0439234
of	O
one	O
urban	B-C1257890
resident	I-C1257890
,	O
and	O
the	O
burden	O
is	O
heavier	O
for	O
rural	B-C1257890
residents	I-C1257890
.	O
	
through	O
catastrophic	B-C0015318
expenditure	I-C0015318
assessment	B-C1516048
,	O
proportions	B-C1709707
of	O
the	O
population	B-C1257890
experiencing	O
catastrophic	B-C0015318
expenditure	I-C0015318
caused	O
by	O
the	O
7	O
rare	B-C0678236
diseases	I-C0678236
are	O
all	O
under	O
0.167	O
however	O
,	O
once	O
one	O
is	O
ill	B-C0221423
and	O
taking	O
medications	B-C4284232
,	O
he	O
will	O
suffer	O
from	O
catastrophic	B-C0015318
health	I-C0015318
expenditure	I-C0015318
.	O
	
through	O
impoverishment	B-C0392762
expenditure	B-C0015316
assessment	B-C1516048
,	O
the	O
proportions	B-C1709707
of	O
impoverishment	B-C0392762
payment	B-C0680264
are	O
low	O
among	O
both	O
urban	B-C1257890
and	O
rural	B-C1257890
residents	I-C1257890
,	O
but	O
the	O
7	O
rare	B-C0678236
diseases	I-C0678236
could	O
lead	O
nearly	O
4.6	O
million	O
people	B-C1257890
into	O
poverty	B-C0032854
on	O
a	O
national	O
scale	O
.	O
	
the	O
affordability	B-C0814630
of	O
treatment	B-C0087111
for	O
rare	B-C0678236
disease	I-C0678236
as	O
well	O
as	O
orphan	B-C0013232
drugs	I-C0013232
is	O
rather	O
poor	B-C0542537
.	O
	
residents	B-C2347958
of	O
different	O
income	B-C0870689
levels	I-C0870689
all	O
have	O
difficulties	O
to	O
afford	O
the	O
treatment	B-C0087111
for	O
rare	B-C0678236
diseases	I-C0678236
,	O
so	O
poverty	B-C0032854
caused	O
by	O
rare	B-C0678236
diseases	I-C0678236
is	O
quite	O
widespread	B-C0205391
.	O
	
therefore	O
,	O
social	B-C0282574
security	I-C0282574
mechanism	I-C0282574
for	O
rare	B-C0678236
disease	I-C0678236
patients	B-C0030705
should	O
be	O
established	O
and	O
specific	O
payment	B-C0680264
pattern	O
for	O
orphan	B-C0013232
drugs	I-C0013232
experimental	B-C0681814
study	I-C0681814
in	O
pulmonary	B-C0034052
artery	I-C0034052
sealing	B-C1963784
with	O
a	O
vessel-sealing	B-C0025080
device	I-C0025080
the	O
development	O
of	O
vessel-sealing	B-C0025080
devices	I-C0025080
will	O
facilitate	O
safety	B-C0036043
in	O
video-assisted	B-C0752151
thoracoscopic	I-C0752151
surgery	I-C0752151
.	O
	
our	O
objective	O
was	O
to	O
evaluate	O
the	O
feasibility	B-C0205556
and	O
safety	B-C0036043
of	O
sealing	B-C1963784
pulmonary	B-C0034052
arteries	I-C0034052
with	O
the	O
enseal	B-C0025080
tissue-sealing	I-C0025080
device	I-C0025080
.	O
	
pulmonary	B-C0034052
arteries	I-C0034052
from	O
beagle	B-C1296765
dogs	I-C1296765
mean	O
body	O
weight	O
13.1	O
kg	O
,	O
range	O
10.5	O
kg	O
were	O
divided	O
into	O
3	O
groups	B-C1642385
according	O
to	O
the	O
in-vivo	B-C1515655
sealing	B-C0449371
method	I-C0449371
used	O
enseal	B-C0025080
,	O
ligation	B-C0189722
,	O
and	O
proximal	B-C0205107
ligation	B-C0189722
plus	O
distal	B-C0205108
enseal	B-C0025080
and	O
extracted	O
to	O
evaluate	O
the	O
pressure	B-C0033095
tolerance	B-C1704410
up	O
to	O
75	O
mm	O
hg	O
at	O
the	O
sealed	B-C0587267
end	B-C0444930
.	O
	
a	O
left	O
lower	O
lobectomy	B-C0023928
was	O
performed	O
to	O
evaluate	O
chronic-phase	B-C0457343
durability	O
of	O
the	O
sealed	B-C0025080
stumps	I-C0025080
in	O
a	O
survival	B-C0599779
model	I-C0599779
.	O
	
two	O
or	O
three	O
branches	O
of	O
the	O
pulmonary	B-C0034052
arteries	I-C0034052
in	O
each	O
dog	B-C0012984
were	O
allocated	O
to	O
each	O
of	O
the	O
3	O
groups	B-C1642385
.	O
	
after	O
the	O
scheduled	O
survival	B-C0038952
period	B-C1948053
,	O
the	O
pulmonary	B-C0034052
arteries	I-C0034052
were	O
sampled	O
.	O
	
pressure	B-C0033095
tolerance	B-C1704410
at	O
the	O
sealed	B-C0587267
end	B-C0444930
was	O
evaluated	O
in	O
91	O
pulmonary	B-C0034052
artery	I-C0034052
sections	O
.	O
	
all	O
sealed	B-C0587267
ends	B-C0444930
showed	O
pressure	B-C0033095
tolerance	B-C1704410
>75	O
mm	O
hg	O
.	O
	
a	O
left	O
lower	O
lobectomy	B-C0023928
was	O
performed	O
in	O
13	O
dogs	B-C0012984
in	O
which	O
35	O
pulmonary	B-C0034052
artery	I-C0034052
sections	O
had	O
been	O
allocated	O
into	O
the	O
3	O
groups	B-C1642385
.	O
	
no	B-C1513916
sealing	B-C1963784
failure	B-C0231174
was	O
found	O
,	O
and	O
pathological	B-C1521733
findings	B-C0243095
showed	O
healing	B-C0043240
and	O
persistent	B-C0205322
hemostasis	B-C0019116
at	O
all	O
sealed	B-C0587267
ends	B-C0444930
of	O
the	O
pulmonary	B-C0034052
arteries	I-C0034052
after	O
2	O
and	O
4	O
weeks	B-C0439230
of	O
the	O
survival	B-C0038952
period	B-C1948053
.	O
	
pulmonary	B-C0034052
arteries	I-C0034052
sealed	B-C0587267
in	B-C1515655
vivo	I-C1515655
with	O
the	O
enseal	B-C0025080
device	I-C0025080
showed	O
pressure	B-C0033095
tolerance	B-C1704410
>75	O
mm	O
hg	O
in	O
the	O
acute	B-C0439557
phase	I-C0439557
,	O
and	O
persistent	B-C0205322
hemostasis	B-C0019116
after	O
2	O
or	O
4	O
weeks	B-C0439230
.	O
	
pulmonary	B-C0034052
artery	I-C0034052
sealing	B-C1963784
with	O
the	O
enseal	B-C0025080
device	I-C0025080
is	O
feasible	B-C0205556
and	O
safe	B-C0036043
in	O
thoracic	B-C0524832
surgery	I-C0524832
pathophysiology	B-C0031847
,	O
treatment	B-C0087111
and	O
prevention	B-C0199176
of	O
ovarian	B-C0085083
hyperstimulation	I-C0085083
syndrome	I-C0085083
severe	B-C0205082
ovarian	B-C0085083
hyperstimulation	I-C0085083
syndrome	I-C0085083
ohss	B-C0085083
is	O
an	O
iatrogenic	B-C0439669
condition	B-C0348080
that	O
affects	B-C4054723
1%	O
of	O
women	B-C0043210
that	O
undergo	O
treatment	B-C0087111
with	O
assisted	B-C0872104
reproductive	I-C0872104
technology	I-C0872104
.	O
	
the	O
review	B-C0282443
aims	B-C1947946
to	O
summarize	B-C1706244
recent	B-C0332185
evidence	B-C3887511
on	O
pathophysiology	B-C0031847
,	O
treatment	B-C0087111
,	O
and	O
prevention	B-C0199176
of	O
ohss	B-C0085083
.	O
	
the	O
pathophysiology	B-C0031847
is	O
still	O
not	O
completely	B-C0205197
understood	B-C0162340
however	O
,	O
vascular	B-C0078058
endothelial	I-C0078058
growth	I-C0078058
factor	I-C0078058
is	O
likely	O
to	O
be	O
an	O
important	B-C3898777
mediator	O
.	O
	
human	B-C1141639
chorionic	I-C1141639
gonadotropin	I-C1141639
was	O
previously	O
thought	B-C0039869
to	O
be	O
necessary	O
for	O
ohss	B-C0085083
to	O
occur	B-C1709305
however	O
,	O
recent	B-C0007320
case	I-C0007320
reports	I-C0007320
have	O
proven	B-C0456369
otherwise	O
.	O
	
the	O
contribution	B-C1880177
of	O
an	O
attenuated	B-C0599946
anti-mullerian	B-C0066928
hormone	I-C0066928
signalling	B-C0037083
pathway	I-C0037083
and	O
cd11c	B-C0023395
+	O
hla-dr	B-C0019764
+	O
dendritic	B-C0011306
cells	I-C0011306
and	O
associated	B-C0332281
interleukins	B-C0021764
has	O
been	O
explored	O
recently	B-C0332185
as	O
contributors	B-C1880177
to	O
pathogenesis	B-C0699748
.	O
	
treatment	B-C0087111
is	O
largely	O
supportive	B-C0344211
and	O
is	O
based	B-C1705938
mainly	O
on	O
consensus	B-C0376298
statements	B-C1710187
rather	O
than	O
evidence	B-C3887511
.	O
	
therefore	O
,	O
it	O
is	O
important	B-C3898777
to	O
prevent	B-C1292733
this	O
condition	B-C0348080
by	O
identifying	B-C1269815
women	B-C0043210
at	B-C1444641
risk	I-C1444641
,	O
allowing	B-C0683607
the	O
clinician	B-C0871685
to	O
implement	B-C1708476
preventive	B-C0679716
strategies	I-C0679716
,	O
including	B-C0332257
the	O
use	O
of	O
gnrh	B-C1268855
antagonist	I-C1268855
cycles	B-C0001289
with	O
agonist	B-C2987634
triggers	O
.	O
	
more	O
research	B-C0035168
is	O
required	B-C1514873
to	O
elucidate	O
the	O
pathophysiology	B-C0031847
behind	O
the	O
condition	B-C0348080
.	O
	
clinicians	B-C0871685
should	O
employ	B-C0457083
strategies	B-C0679199
to	O
prevent	B-C0679698
ohss	B-C0085083
.	O
	
eosinophilic	B-C1262481
gastroenteritis	I-C1262481
as	O
a	O
rare	B-C0522498
cause	B-C0015127
of	O
recurrent	B-C0743544
epigastric	I-C0743544
pain	I-C0743544
eosinophilic	B-C1262481
gastroenteritis	I-C1262481
ege	B-C1262481
is	O
a	O
rare	O
inflammatory	B-C1290884
disorder	I-C1290884
of	O
gastrointestinal	B-C0017189
tract	I-C0017189
characterized	B-C1880022
by	O
eosinophilic	B-C0333390
infiltration	I-C0333390
of	O
the	O
bowel	B-C0021853
wall	I-C0021853
.	O
	
it	O
can	O
mimic	O
many	O
gastrointestinal	B-C0017178
disorders	I-C0017178
due	O
to	O
its	O
wide	B-C0243095
spectrum	I-C0243095
of	I-C0243095
presentations	I-C0243095
.	O
	
diagnose	B-C0011900
is	O
mostly	O
based	O
on	O
excluding	B-C0332196
other	B-C0205394
disorders	B-C0012634
and	O
a	O
high	B-C0205250
suspicion	B-C0242114
.	O
	
here	O
we	O
report	B-C0007320
a	I-C0007320
case	I-C0007320
of	O
26	O
year	B-C0439234
old	B-C0580836
man	B-C0025266
with	O
a	O
history	B-C0262926
of	O
sever	B-C0232493
epigastric	I-C0232493
pain	I-C0232493
followed	O
by	O
nausea	B-C0027497
,	O
vomiting	B-C0042963
since	O
a	O
few	B-C0205388
days	B-C0439228
before	B-C0332152
admission	B-C0030673
with	O
final	O
diagnosis	B-C0011900
of	O
comparison	O
of	O
sonoelastography	B-C1955929
with	O
sonourethrography	B-C0581495
and	O
retrograde	B-C0845989
urethrography	I-C0845989
in	O
the	O
evaluation	B-C0220825
of	O
male	B-C0086582
anterior	B-C1720814
urethral	I-C1720814
strictures	I-C1720814
retrograde	B-C0845989
urethrography	I-C0845989
rug	B-C0845989
is	O
the	O
most	O
common	O
and	O
preferred	O
imaging	B-C1275506
modality	I-C1275506
for	O
imaging	B-C0011923
of	O
the	O
anterior	B-C1720814
urethral	I-C1720814
strictures	I-C1720814
despite	O
its	O
well-known	O
limitations	B-C0449295
and	O
disadvantages	O
.	O
	
sonourethrography	B-C0581495
sug	B-C0581495
was	O
introduced	O
in	O
1988	O
to	O
overcome	B-C2983310
the	O
limitations	B-C0449295
of	O
rug	B-C0845989
and	O
to	O
provide	O
more	O
accurate	B-C0598285
results	I-C0598285
.	O
	
as	O
proper	O
selection	O
of	O
imaging	B-C1275506
modality	I-C1275506
is	O
very	O
important	O
for	O
planning	B-C0599880
the	I-C0599880
treatment	I-C0599880
,	O
various	O
advances	O
in	O
this	O
area	O
are	O
required	O
.	O
	
one	O
of	O
the	O
major	O
factors	O
for	O
recurrence	B-C0034897
of	O
stricture	B-C0041974
disease	I-C0041974
is	O
spongiofibrosis	B-C0016059
.	O
	
sonoelastography	B-C1955929
se	B-C1955929
is	O
a	O
newer	B-C1519842
technique	I-C1519842
,	O
tried	O
in	O
various	O
other	O
pathologies	B-C0030664
.	O
	
in	O
this	O
study	O
,	O
we	O
have	O
used	O
this	O
technique	O
for	O
the	O
first	O
time	O
to	O
assess	O
its	O
efficacy	B-C2348251
in	O
the	O
evaluation	O
of	O
anterior	B-C1720814
urethral	I-C1720814
stricture	I-C1720814
disease	I-C1720814
by	O
comparison	O
with	O
rug	B-C0845989
and	O
sug	B-C0581495
.	O
	
between	O
august	O
2014	O
and	O
may	O
2015	O
,	O
77	O
patients	B-C0030705
with	O
clinical	O
features	O
of	O
anterior	B-C1720814
urethral	I-C1720814
stricture	I-C1720814
disease	I-C1720814
were	O
included	O
in	O
the	O
study	O
and	O
evaluated	O
by	O
rug	B-C0845989
followed	O
by	O
sug	B-C0581495
and	O
se	B-C1955929
for	O
stricture	B-C1389955
location	B-C0450429
,	O
length	B-C1444754
,	O
depth	B-C1827571
of	O
spongiofibrosis	B-C0016059
and	O
periurethral	B-C3828581
pathologies	B-C0030664
.	O
	
the	O
results	O
were	O
then	O
correlated	O
with	O
operative	O
and	O
histopathological	B-C0243140
findings	I-C0243140
.	O
	
overall	O
diagnostic	B-C0598285
accuracy	I-C0598285
of	O
se	B-C1955929
,	O
sug	B-C0581495
,	O
and	O
rgu	B-C0845989
for	O
the	O
estimation	O
of	O
stricture	B-C1389955
location	B-C0450429
,	O
and	O
length	B-C1444754
were	O
estimated	O
92.68	O
vs	O
.	O
	
91.54	O
,	O
79%	O
vs	O
.	O
	
78.87	O
and	O
80.48	O
vs	O
.	O
	
43.66	O
,	O
respectively	O
,	O
while	O
for	O
depth	B-C1827571
of	O
spongiofibrosis	B-C0016059
se	B-C1955929
,	O
and	O
sug	B-C0581495
had	O
accuracy	B-C0443131
rates	I-C0443131
of	O
87.3	O
,	O
48%	O
,	O
respectively	O
.	O
	
the	O
mean	O
length	O
measured	O
on	O
se	B-C1955929
was	O
nearest	O
to	O
the	O
mean	O
intra-operative	B-C0456904
stricture	B-C1389955
length	B-C1444754
21.34	O
mm	O
.	O
	
se	B-C1955929
findings	O
significantly	O
correlated	O
with	O
the	O
colour	B-C0475705
of	I-C0475705
bladder	I-C0475705
mucosa	I-C0475705
on	O
cystoscopic	B-C0401483
examination	I-C0401483
p=0	O
whereas	O
the	O
association	O
was	O
non-significant	O
p=0	O
for	O
difficulty	O
in	O
incision	B-C0184898
.	O
	
while	O
a	O
nonsignificant	O
correlation	O
existed	O
between	O
sug	B-C0581495
findings	O
related	O
both	O
to	O
the	O
colour	B-C0475705
of	I-C0475705
the	I-C0475705
bladder	I-C0475705
mucosa	I-C0475705
and	O
difficulty	O
in	O
incision	B-C0184898
on	O
cystoscopy	B-C0010702
,	O
se	B-C1955929
findings	O
had	O
a	O
significant	O
association	O
p<0	O
with	O
histopathology	B-C0243140
findings	I-C0243140
for	O
severe	O
degree	B-C4285457
of	I-C4285457
fibrosis	I-C4285457
.	O
	
sonoelastography	B-C1955929
estimates	O
stricture	B-C1254362
site	I-C1254362
and	I-C1254362
length	I-C1254362
better	O
in	O
comparison	O
with	O
rug	B-C0845989
and	O
sug	B-C0581495
.	O
	
it	O
estimates	O
degree	O
of	O
spongiofibrosis	B-C0016059
which	O
serves	O
as	O
an	O
important	O
prognostic	B-C1514474
factor	I-C1514474
for	O
stricture	B-C0034897
recurrence	I-C0034897
more	O
accurately	B-C0443131
than	O
changes	B-C0392747
in	O
risk	B-C0035648
factors	I-C0035648
for	O
young	B-C0332239
male	B-C0086582
suicide	B-C0038661
in	O
newcastle	B-C0017446
upon	I-C0017446
tyne	I-C0017446
,	O
1961-2009	O
aims	B-C1947946
and	O
method	B-C0025663
to	O
ascertain	O
differences	B-C1705242
in	O
patterns	B-C0038661
of	I-C0038661
suicide	I-C0038661
in	O
young	B-C0332239
men	B-C0025266
over	O
three	O
decades	B-C2981279
1960s	O
,	O
1990s	O
and	O
2000s	O
and	O
discuss	O
implications	B-C0205556
for	O
suicide	B-C0038661
prevention	B-C2700409
.	O
	
data	B-C1511726
on	O
suicides	B-C0038661
and	O
open	B-C0680738
verdicts	I-C0680738
in	O
men	B-C0025266
aged	O
15-34	O
were	O
obtained	O
from	O
coroner's	B-C0282574
records	I-C0282574
in	O
newcastle	B-C0017446
upon	I-C0017446
tyne	I-C0017446
and	O
analysed	B-C0936012
using	O
spss	B-C0037585
software	I-C0037585
.	O
	
results	B-C1274040
an	O
increase	B-C0442805
in	O
suicide	B-C1822575
rates	I-C1822575
from	O
the	O
first	O
to	O
the	O
second	O
decade	B-C2981279
was	O
followed	O
by	O
a	O
fall	O
in	O
the	O
third	O
decade	B-C2981279
.	O
	
this	O
was	O
associated	B-C0332281
with	I-C0332281
an	O
increasing	B-C0442808
proportion	B-C1709707
of	O
single	B-C0205171
men	B-C0025266
,	O
those	O
living	B-C0260794
alone	I-C0260794
,	O
unemployment	B-C0041674
,	O
consumption	B-C0001948
of	I-C0001948
alcohol	I-C0001948
,	O
use	O
of	O
hanging	B-C0544691
,	O
previous	B-C0205156
suicide	B-C0038663
attempt	I-C0038663
and	O
history	B-C0814462
of	I-C0814462
treatment	I-C0814462
for	O
mental	B-C0004936
illness	I-C0004936
.	O
	
clinical	B-C0205210
implications	B-C0205556
this	O
study	B-C2603343
highlights	O
the	O
need	O
for	O
more	O
interventions	B-C0184661
and	O
focus	B-C0589098
to	O
be	O
given	O
to	O
young	B-C0332239
males	B-C0086582
in	O
the	O
suicide	B-C0038661
prevention	B-C2700409
area	I-C2700409
and	O
is	O
of	O
high	O
importance	O
in	O
the	O
field	B-C3244304
of	I-C3244304
public	I-C3244304
health	I-C3244304
.	O
	
areas	O
that	O
could	O
be	O
tackled	O
include	O
reducing	B-C0392756
access	B-C0444454
to	O
means	B-C1704970
of	O
suicide	B-C0038661
,	O
reducing	B-C0392756
alcohol	B-C0001948
use	I-C0001948
,	O
support	B-C1521721
for	O
relationship	B-C0439849
difficulties	B-C0332218
,	O
engagement	B-C3508152
with	O
mental	B-C0025355
health	I-C0025355
services	I-C0025355
and	O
management	B-C0376636
of	O
chronic	B-C0008679
illness	I-C0008679
.	O
	
social	B-C0871381
cognition	I-C0871381
in	O
schizophrenia	B-C0036341
factor	B-C0870541
structure	I-C0870541
of	O
emotion	B-C0013987
processing	B-C0025361
and	O
theory	B-C0935573
of	I-C0935573
mind	I-C0935573
factor	B-C0085801
analytic	I-C0085801
studies	I-C0085801
examining	O
social	B-C0871381
cognition	I-C0871381
in	O
schizophrenia	B-C0036341
have	O
yielded	O
inconsistent	O
results	B-C1274040
most	O
likely	O
due	O
to	O
the	O
varying	O
number	O
and	O
quality	B-C3242457
of	I-C3242457
measures	I-C3242457
.	O
	
with	O
the	O
recent	O
conclusion	O
of	O
phase	B-C0439561
3	I-C0439561
of	O
the	O
social	B-C0871381
cognition	I-C0871381
psychometric	B-C0033920
evaluation	I-C0033920
scope	I-C0033920
study	I-C0033920
,	O
the	O
most	O
psychometrically	B-C0033920
sound	B-C0430022
measures	I-C0430022
of	O
social	B-C0871381
cognition	I-C0871381
have	O
been	O
identified	O
.	O
	
therefore	O
,	O
the	O
aims	O
of	O
the	O
present	O
study	B-C2603343
were	O
to	O
1	O
examine	B-C0332128
the	O
factor	B-C0870541
structure	I-C0870541
of	O
social	B-C0871381
cognition	I-C0871381
in	O
schizophrenia	B-C0036341
through	O
the	O
utilization	O
of	O
psychometrically	B-C0033920
sound	B-C0430022
measures	I-C0430022
,	O
2	O
examine	B-C0332128
the	O
stability	B-C0205360
of	O
the	O
factor	B-C0870541
structure	I-C0870541
across	O
two	O
study	B-C2603343
visits	O
,	O
3	O
compare	O
the	O
factor	B-C0870541
structure	I-C0870541
of	O
social	B-C0871381
cognition	I-C0871381
in	O
schizophrenia	B-C0036341
to	O
that	O
in	O
healthy	B-C2986479
controls	I-C2986479
,	O
and	O
4	O
examine	B-C0332128
the	O
relationship	O
between	O
the	O
factors	B-C0870541
and	O
relevant	O
outcome	B-C0086749
measures	I-C0086749
including	O
social	B-C0037395
functioning	I-C0037395
and	O
symptoms	B-C1457887
.	O
	
results	B-C1274040
supported	O
a	O
one-factor	B-C0282574
model	I-C0282574
for	O
the	O
patient	B-C0030705
and	O
healthy	B-C2986479
control	I-C2986479
samples	O
at	O
both	O
visits	B-C1512346
.	O
	
this	O
single	O
factor	O
was	O
significantly	O
associated	O
with	O
negative	O
symptoms	O
in	O
the	O
schizophrenia	O
sample	O
and	O
with	O
social	O
functioning	O
in	O
both	O
groups	O
at	O
both	O
study	O
visits	B-C1512346
assessment	B-C0220825
of	O
residual	B-C0543478
disease	I-C0543478
with	O
molecular	B-C2985547
breast	I-C2985547
imaging	I-C2985547
in	O
patients	B-C0030705
undergoing	O
neoadjuvant	B-C0600558
therapy	I-C0600558
association	O
with	O
molecular	B-C1521991
subtypes	B-C0449560
assessment	B-C0220825
of	O
residual	B-C0543478
disease	I-C0543478
after	O
neoadjuvant	B-C0600558
therapy	I-C0600558
for	O
breast	B-C0006142
cancer	I-C0006142
is	O
an	O
ongoing	O
challenge	O
of	O
breast	B-C0006141
imaging	B-C0011923
.	O
	
this	O
study	B-C2603343
evaluates	B-C0220825
the	O
accuracy	B-C0443131
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	B-C2985547
breast	I-C2985547
imaging	I-C2985547
mbi	B-C2985547
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	B-C1258740
zinc	I-C1258740
telluride	I-C1258740
detectors	B-C0180392
in	O
assessing	O
residual	B-C0543478
disease	I-C0543478
after	O
neoadjuvant	B-C0600558
therapy	I-C0600558
in	O
patients	B-C0030705
with	O
breast	B-C0006142
cancer	I-C0006142
.	O
	
clinical	B-C1516606
data	I-C1516606
,	O
imaging	B-C0011923
,	O
surgical	B-C0038895
,	O
and	O
pathological	B-C1521733
findings	B-C0243095
of	O
51	O
women	B-C0043210
with	O
breast	B-C0006142
cancer	I-C0006142
undergoing	O
neoadjuvant	B-C0600558
therapy	I-C0600558
were	O
recorded	O
.	O
	
mbi	B-C2985547
findings	B-C0243095
were	O
correlated	B-C1707520
with	O
surgical	B-C1710255
pathology	I-C1710255
results	I-C1710255
.	O
	
accuracy	B-C0443131
of	O
mbi	B-C2985547
in	O
predicting	O
complete	B-C4050242
pathological	I-C4050242
response	I-C4050242
and	O
size	B-C0456389
of	O
residual	B-C0543478
disease	I-C0543478
was	O
assessed	O
according	O
to	O
molecular	B-C1521991
subtypes	B-C0449560
.	O
	
the	O
size	B-C0456389
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
mbi	B-C2985547
correlated	B-C1707520
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	B-C0205469
r	O
=	O
0.55	O
p	O
<	O
001	O
.	O
	
this	O
correlation	B-C1707520
was	O
stronger	O
for	O
triple	B-C3539878
negative	I-C3539878
and	O
her2/neu	B-C2348909
positive	I-C2348909
subtypes	B-C0449560
r	O
=	O
0.92	O
and	O
0.62	O
,	O
respectively	O
.	O
	
sixteen	O
patients	B-C0030705
31%	O
had	O
complete	B-C4050242
pathological	I-C4050242
response	I-C4050242
.	O
	
the	O
sensitivity	B-C1511883
and	O
specificity	B-C0037791
of	O
mbi	B-C2985547
for	O
detecting	O
residual	B-C0543478
disease	I-C0543478
were	O
83%	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
,	O
66-93	O
and	O
69%	O
95%	O
ci	B-C0009667
,	O
42-88	O
,	O
respectively	O
.	O
	
for	O
triple	B-C3539878
negative	I-C3539878
or	O
her2/neu	B-C2348909
positive	I-C2348909
disease	O
the	O
sensitivity	B-C1511883
and	O
specificity	B-C0037791
were	O
88%	O
95%	O
ci	B-C0009667
,	O
62-98	O
and	O
75%	O
95%	O
ci	B-C0009667
,	O
43-93	O
,	O
respectively	O
.	O
	
the	O
accuracy	B-C0443131
of	O
mbi	B-C2985547
in	O
assessing	O
residual	B-C0543478
disease	I-C0543478
after	O
neoadjuvant	B-C0600558
treatment	I-C0600558
might	O
be	O
related	O
to	O
the	O
molecular	B-C1521991
subtype	B-C0449560
.	O
	
accuracy	B-C0443131
is	O
highest	O
in	O
the	O
triple	B-C3539878
negative	I-C3539878
and	O
her2/neu	B-C2348909
positive	I-C2348909
subtypes	B-C0449560
.	O
	
the	O
relationship	B-C0439849
between	O
histological	B-C0205462
prostatitis	B-C0033581
and	O
lower	B-C0574785
urinary	I-C0574785
tract	I-C0574785
symptoms	I-C0574785
and	O
sexual	B-C0278092
function	I-C0278092
this	O
prospective	B-C0033522
analysis	I-C0033522
assessed	B-C1516048
the	O
effect	B-C1280500
of	O
histological	B-C0205462
prostatitis	B-C0033581
on	O
lower	B-C0729866
urinary	I-C0729866
tract	I-C0729866
functions	B-C0542341
and	O
sexual	B-C0278092
function	I-C0278092
.	O
	
the	O
patients	B-C0030705
were	O
separated	B-C0443299
into	O
two	O
groups	B-C0441833
as	O
histologically	B-C0205462
observed	B-C1441672
prostatitis	B-C0033581
group	B-C0441833
a	I-C0441833
and	O
no	B-C0243095
prostatitis	I-C0243095
group	B-C0441833
b	I-C0441833
according	O
to	O
the	O
biopsy	B-C0005558
outcomes	B-C1274040
.	O
	
international	B-C1998280
prostate	I-C1998280
symptom	I-C1998280
score	I-C1998280
,	O
international	B-C2959364
index	I-C2959364
of	I-C2959364
erectile	I-C2959364
function-5	I-C2959364
scores	I-C2959364
,	O
maximal	B-C0429784
and	O
average	B-C0429785
flow	I-C0429785
rate	I-C0429785
,	O
and	O
residual	B-C0429774
urine	I-C0429774
volumes	I-C0429774
were	O
compared	B-C1707455
statistically	O
between	O
groups	B-C0441833
.	O
	
there	O
was	O
no	O
significant	B-C0237881
difference	B-C1705242
p>0	O
in	O
baseline	B-C1442488
age	B-C0001779
t=0	O
,	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
value	I-C1305855
t=0	O
,	O
prostate	B-C1441416
volume	I-C1441416
t=0	O
,	O
prostate-specific	B-C0201544
antigen	I-C0201544
levels	I-C0201544
t=0	O
,	O
maximal	B-C0429784
t=0	O
and	O
average	B-C0429785
flow	I-C0429785
rate	I-C0429785
t=0	O
,	O
and	O
post-void	B-C1439885
residual	B-C0429774
urine	I-C0429774
volume	I-C0429774
t=0	O
.	O
	
mean	B-C0444504
international	B-C1998280
prostate	I-C1998280
symptom	I-C1998280
score	I-C1998280
in	O
patients	B-C0030705
with	O
prostatitis	B-C0033581
was	O
numerically	B-C0243174
but	O
not	O
significantly	B-C4055637
higher	I-C4055637
than	O
that	O
in	O
those	O
without	B-C0332288
prostatitis	B-C0033581
t=0	O
,	O
p=0	O
.	O
	
mean	B-C0444504
international	B-C2959364
index	I-C2959364
of	I-C2959364
erectile	I-C2959364
function-5	I-C2959364
score	I-C2959364
in	O
the	O
prostatitis	B-C0033581
group	B-C0441833
was	O
significantly	B-C4055638
lower	I-C4055638
than	O
that	O
in	O
those	O
without	B-C0332288
prostatitis	B-C0033581
t=1	O
,	O
p=0	O
.	O
	
histological	B-C0205462
prostatitis	B-C0033581
notably	O
affected	B-C0392760
sexual	B-C0278092
function	I-C0278092
of	O
patients	B-C0030705
and	O
may	O
serve	O
as	O
a	O
major	B-C0205164
risk	B-C0035648
factor	I-C0035648
for	O
sexual	B-C0549622
dysfunction	I-C0549622
while	O
having	O
little	O
effect	B-C1280500
on	O
lower	B-C0574785
urinary	I-C0574785
tract	I-C0574785
symptoms	I-C0574785
.	O
	
beyond	O
""""	O
median	B-C0876920
waiting	B-C0814636
time	I-C0814636
""""	O
development	B-C1527148
and	O
validation	B-C1519941
of	O
a	O
competing	O
risk	B-C0679713
model	I-C0679713
to	O
predict	B-C0681842
outcomes	B-C1274040
on	O
the	O
kidney	B-C0022646
transplant	B-C3272315
waiting	I-C3272315
list	I-C3272315
median	B-C0876920
historical	B-C0019659
time	B-C0040223
to	O
kidney	B-C0022671
transplant	I-C0022671
is	O
misleading	O
because	O
it	O
does	O
not	O
convey	O
the	O
competing	O
risks	B-C0035647
of	O
death	B-C0011065
or	O
removal	B-C0420299
from	I-C0420299
the	I-C0420299
waiting	I-C0420299
list	I-C0420299
.	O
	
we	O
developed	O
and	O
validated	O
a	O
competing	O
risk	B-C0679713
model	I-C0679713
to	O
calculate	B-C1441506
likelihood	O
of	O
outcomes	B-C0085415
for	O
kidney	B-C0022671
transplant	I-C0022671
candidates	B-C0524355
and	O
demonstrate	O
how	O
this	O
information	B-C1533716
differs	B-C1705242
from	O
median	B-C0876920
time	B-C0814636
to	O
transplant	B-C0022671
.	O
	
data	B-C1511726
were	O
obtained	B-C1301820
from	O
the	O
us	B-C0034975
scientific	I-C0034975
registry	I-C0034975
of	O
transplant	B-C0376387
recipients	I-C0376387
.	O
	
the	O
retrospective	B-C2985505
cohort	I-C2985505
included	O
163	O
636	O
adults	B-C0001675
listed	O
for	O
kidney	B-C0022671
transplant	I-C0022671
before	O
december	O
31	O
,	O
2011	O
.	O
	
predictors	B-C0035648
were	O
age	B-C0001779
,	O
sex	B-C0079399
,	O
blood	B-C1383165
type	I-C1383165
,	O
calculated	B-C1443182
panel-reactive	B-C1141951
antibodies	I-C1141951
,	O
donation	B-C0411257
service	B-C0007403
area	I-C0007403
,	O
dialysis	B-C0011946
duration	B-C0449238
,	O
comorbid	B-C1275743
conditions	I-C1275743
,	O
and	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
.	O
	
outcomes	B-C0085415
were	O
deceased	O
or	O
living	B-C0348050
donor	I-C0348050
transplant	B-C0022671
,	O
death	B-C0011065
or	O
removal	B-C0420299
from	I-C0420299
the	I-C0420299
list	I-C0420299
due	B-C0678226
to	I-C0678226
deteriorating	B-C0332271
medical	B-C0205476
condition	B-C0348080
,	O
or	O
removal	B-C0420299
due	B-C0678226
to	I-C0678226
other	B-C3840932
reasons	I-C3840932
.	O
	
we	O
calculated	B-C0444686
hazards	B-C0598697
for	O
the	O
possible	B-C0332149
outcomes	B-C0085415
,	O
then	O
the	O
cumulative	B-C1511559
incidence	B-C0021149
function	B-C0031843
for	O
a	O
given	O
candidate	B-C0524355
using	O
competing	O
risk	B-C0035647
methodology	B-C3266812
.	O
	
discrimination	B-C0012632
and	O
calibration	B-C0006751
were	O
assessed	B-C1516048
through	B-C0332273
c	B-C0681933
statistics	I-C0681933
and	O
calibration	B-C0006751
plots	B-C1301732
for	O
each	B-C1457900
cause	B-C0015127
-	O
specific	B-C0205369
cox	B-C0018623
proportional	I-C0018623
hazard	I-C0018623
model	I-C0018623
.	O
	
c	B-C0681933
statistics	I-C0681933
ranged	O
from	O
0.64	O
to	O
0.73	O
.	O
	
calibration	B-C0006751
plots	B-C1301732
showed	O
good	B-C0205170
calibration	B-C0006751
.	O
	
the	O
competing	O
risk	B-C0679713
model	I-C0679713
shows	O
probability	B-C0033204
of	O
all	O
possible	B-C0332149
outcomes	B-C0085415
for	O
up	O
to	O
12	B-C0439234
years	I-C0439234
given	O
a	O
candidate's	B-C0524355
characteristics	B-C1521970
,	O
contrasted	O
with	O
the	O
median	B-C0876920
waiting	B-C0814636
time	I-C0814636
for	O
that	O
candidate's	B-C0524355
donation	B-C0411257
service	B-C0007403
area	I-C0007403
.	O
	
a	O
competing	O
risk	B-C0679713
model	I-C0679713
conveys	O
more	O
relevant	B-C2347946
information	B-C1533716
than	O
the	O
median	B-C0876920
waiting	B-C0814636
time	I-C0814636
for	O
a	O
given	B-C1442162
transplant	B-C1708333
center	I-C1708333
.	O
	
this	O
model	B-C0033204
will	O
be	O
updated	B-C1519814
to	O
create	B-C1706214
a	O
calculator	O
reflecting	O
the	O
most	O
recent	B-C0332185
outcomes	B-C0085415
and	O
changes	B-C0392747
in	O
allocation	B-C1706778
policy	B-C0242456
.	O
	
it	O
illustrates	O
the	O
conversations	B-C0871703
that	O
should	O
be	O
initiated	B-C1704686
with	O
transplant	B-C0022671
candidates	B-C0524355
.	O
	
tead1	B-C1420679
regulates	O
the	O
expression	B-C0017262
of	O
peripheral	B-C1418677
myelin	I-C1418677
protein	I-C1418677
22	I-C1418677
during	O
schwann	B-C1817645
cell	I-C1817645
development	I-C1817645
schwann	B-C0036387
cells	I-C0036387
are	O
myelinating	B-C0027836
glia	I-C0027836
in	O
the	O
peripheral	B-C0206417
nervous	I-C0206417
system	I-C0206417
that	O
form	O
the	O
myelin	B-C0026973
sheath	I-C0026973
.	O
	
a	O
major	O
cause	O
of	O
peripheral	B-C0031117
neuropathy	I-C0031117
is	O
a	O
copy	B-C1511518
number	I-C1511518
variant	I-C1511518
involving	O
the	O
peripheral	B-C1418677
myelin	I-C1418677
protein	I-C1418677
22	I-C1418677
pmp22	I-C1418677
gene	I-C1418677
,	O
which	O
is	O
located	O
within	O
a	O
1.4	O
duplication	B-C0017261
on	O
chromosome	B-C0008659
17	I-C0008659
associated	O
with	O
the	O
most	O
common	O
form	O
of	O
charcot-marie-tooth	B-C0007959
disease	I-C0007959
cmt1a	B-C0007959
.	O
	
rodent	B-C1519106
models	I-C1519106
of	O
cmt1a	B-C0007959
have	O
been	O
used	O
to	O
show	O
that	O
reducing	O
pmp22	B-C1418677
overexpression	B-C0017262
mitigates	O
several	O
aspects	O
of	O
a	O
cmt1a	B-C0007959
-related	O
phenotype	B-C0031437
.	O
	
mechanistic	B-C0441712
studies	B-C2603343
of	O
pmp22	B-C1418677
regulation	B-C0017263
identified	O
enhancers	B-C0014290
regulated	O
by	O
the	O
sox10	B-C1571654
sry	B-C1571654
sex	I-C1571654
determining	I-C1571654
region	I-C1571654
y-box	I-C1571654
10	I-C1571654
and	O
egr2	B-C0064419
/	O
krox20	B-C0064419
early	B-C0064419
growth	I-C0064419
response	I-C0064419
protein	I-C0064419
2	I-C0064419
transcription	B-C0040648
factors	I-C0040648
in	O
myelinated	B-C0027750
nerves	I-C0027750
.	O
	
however	O
,	O
relatively	O
little	O
is	O
known	O
regarding	O
how	O
other	O
transcription	B-C0040648
factors	I-C0040648
induce	B-C0205263
pmp22	B-C1418677
expression	B-C0017262
during	O
schwann	B-C1817645
cell	I-C1817645
development	I-C1817645
and	O
myelination	B-C0596991
.	O
	
here	O
,	O
we	O
examined	O
pmp22	B-C1418677
enhancers	B-C0014290
as	O
a	O
function	O
of	O
cell	B-C1148560
type-specificity	I-C1148560
,	O
nerve	B-C0161479
injury	I-C0161479
and	O
development	B-C1527148
.	O
	
while	O
pmp22	B-C1418677
enhancers	B-C0014290
marked	O
by	O
active	B-C0205177
histone	B-C1156199
modifications	I-C1156199
were	O
lost	B-C0745777
or	O
remodeled	O
after	O
injury	B-C3263723
,	O
we	O
found	O
that	O
these	O
enhancers	B-C0014290
were	O
permissive	O
in	O
early	O
development	B-C1527148
prior	O
to	O
pmp22	B-C1418677
upregulation	B-C0041904
.	O
	
pmp22	B-C1418677
enhancers	B-C0014290
contain	O
binding	B-C1956035
motifs	I-C1956035
for	O
tea	B-C0220134
domain	I-C0220134
tead	B-C0220134
transcription	B-C0040648
factors	I-C0040648
of	O
the	O
hippo	B-C3158583
signaling	I-C3158583
pathway	I-C3158583
.	O
	
we	O
discovered	O
that	O
tead1	B-C1420679
and	O
co-activators	O
yap	B-C1424135
and	O
taz	B-C1336578
are	O
required	O
for	O
pmp22	B-C1418677
expression	B-C0017262
,	O
as	O
well	O
as	O
for	O
the	O
expression	B-C0017262
of	O
egr2	B-C1414315
tead1	B-C1420679
directly	O
binds	O
pmp22	B-C1418677
and	O
egr2	B-C1414315
enhancers	B-C0014290
early	O
in	O
development	B-C1527148
and	O
tead1	B-C1420679
binding	B-C1167622
is	O
induced	B-C0205263
during	O
myelination	B-C0596991
,	O
correlating	O
with	O
pmp22	B-C1418677
expression	B-C0017262
.	O
	
the	O
data	B-C1511726
identify	O
tead1	B-C1420679
as	O
a	O
novel	O
regulator	B-C0017362
of	O
pmp22	B-C1418677
expression	B-C0017262
during	O
development	B-C1527148
in	O
concert	O
with	O
sox10	B-C1420317
and	O
neutrophil	B-C1870887
gelatinase-associated	I-C1870887
lipocalin	I-C1870887
in	O
a	O
triphasic	B-C0205185
rat	B-C0599779
model	I-C0599779
of	O
adenine	B-C0001407
-	O
induced	B-C0205263
kidney	B-C0160420
injury	I-C0160420
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
ngal	B-C1870887
,	O
given	O
its	O
advantages	O
over	O
traditional	O
biomarkers	B-C0005516
,	O
can	O
be	O
used	O
to	O
describe	O
the	O
dynamic	O
characteristics	O
of	O
the	O
renal	B-C0041349
tubulointerstitial	I-C0041349
insult	I-C0041349
caused	O
by	O
adenine	B-C0001407
.	O
	
subsequently	O
,	O
it	O
will	O
be	O
possible	O
to	O
assess	O
ngal	B-C1870887
as	O
a	O
biomarker	B-C0005516
of	O
any	O
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
,	O
on	O
top	O
of	O
chronic	B-C0238304
interstitial	I-C0238304
disease	I-C0238304
,	O
if	O
ngal	B-C1870887
levels	B-C0441889
are	O
stable	B-C0205360
through	B-C0332273
the	O
chronic	B-C0457343
phase	I-C0457343
of	O
our	O
adenine	B-C0599779
model	I-C0599779
.	O
	
study	B-C2348561
group	I-C2348561
rats	B-C0034693
were	O
fed	O
an	O
adenine	B-C0001407
diet	B-C0012155
,	O
and	O
control	B-C0009932
group	I-C0009932
rats	B-C0034693
were	O
fed	O
a	O
regular	B-C0184625
diet	I-C0184625
only	O
.	O
	
blood	B-C0178913
and	O
urine	B-C1610733
samples	I-C1610733
for	O
urea	B-C0041942
,	O
creatinine	B-C0010294
and	O
ngal	B-C1870887
were	O
drawn	O
from	O
each	O
rat	B-C0034693
at	O
the	O
beginning	B-C0439659
of	O
the	O
study	B-C0008972
and	O
after	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
and	O
8	O
weeks	O
.	O
	
kidney	B-C0022646
slices	B-C1519355
from	O
these	O
rats	B-C0034693
were	O
stained	B-C0487602
with	O
hematoxylin-eosin	B-C0523207
he	B-C0523207
and	O
β-actin	B-C0005186
stainings	B-C0487602
.	O
	
serum	B-C2945624
urea	I-C2945624
,	O
creatinine	B-C0201975
and	O
ngal	B-C1870887
levels	B-C0441889
and	O
urinary	B-C1316828
ngal/creatinine	I-C1316828
ratio	I-C1316828
in	O
the	O
study	O
group	O
were	O
higher	O
than	O
baseline	B-C1442488
and	O
than	O
in	O
the	O
control	B-C0009932
group	I-C0009932
these	O
differences	O
were	O
statistically	B-C0237881
significant	I-C0237881
in	O
some	O
of	O
the	O
intervals	B-C1272706
.	O
	
tubulointerstitial	B-C0041349
changes	O
and	O
adenine	B-C0001407
crystals	O
were	O
evident	O
in	O
the	O
study	O
group	O
rats	B-C0034693
.	O
	
in	O
the	O
rats	B-C0034693
fed	O
adenine	B-C0001407
,	O
serum	B-C2945624
urea	I-C2945624
,	O
creatinine	B-C1318439
and	O
ngal	B-C1870887
levels	B-C0441889
and	O
urinary	B-C1316828
ngal/creatinine	I-C1316828
ratio	I-C1316828
followed	O
a	O
triphasic	B-C1336825
pattern	I-C1336825
of	O
kidney	B-C0160420
injury	I-C0160420
an	O
acute	B-C0439557
phase	I-C0439557
while	O
on	O
the	O
adenine	B-C0001407
diet	B-C0012155
,	O
a	O
partial	B-C0728938
recovery	B-C2004454
phase	B-C0205390
after	O
switching	O
to	O
the	O
regular	B-C0184625
diet	I-C0184625
and	O
a	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
phase	B-C0205390
after	O
stabilization	O
of	O
renal	B-C0232804
function	I-C0232804
.	O
	
ngal	B-C1870887
can	O
serve	O
a	O
biomarker	B-C0005516
for	O
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
and	O
possibly	O
for	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
in	O
the	O
tubulointerstitial	B-C0041349
rat	B-C0599779
model	I-C0599779
.	O
	
talking	B-C0234856
or	O
keeping	B-C0443304
silent	I-C0443304
about	O
parental	B-C0030551
mental	B-C1446377
health	I-C1446377
problems	I-C1446377
-a	O
grounded	B-C1510611
theory	I-C1510611
of	O
parents	B-C0030551
'	O
decision	B-C0011109
making	I-C0011109
and	O
experiences	B-C0596545
with	O
their	O
children	B-C0008059
this	O
grounded	B-C1510611
theory	I-C1510611
study	B-C2603343
explored	O
parents	B-C0030551
'	O
experiences	B-C0596545
of	O
responding	O
to	O
their	O
children's	B-C0008059
need	O
for	O
understanding	O
parental	B-C0030551
mental	B-C0025353
health	I-C0025353
concerns	B-C2699424
.	O
	
fifteen	O
parents	B-C0030551
with	O
severe	B-C0205082
and	O
enduring	O
mental	B-C1446377
health	I-C1446377
difficulties	I-C1446377
participated	O
in	O
the	O
study	B-C2603343
.	O
	
the	O
findings	B-C0243095
suggest	O
four	O
main	O
social	B-C0871384
processes	I-C0871384
that	O
influence	O
parents	B-C0030551
'	O
talk	B-C0234856
with	O
their	O
children	B-C0008059
about	O
parental	B-C0030551
mental	B-C1446377
health	I-C1446377
issues	I-C1446377
,	O
namely	O
""""	O
protecting	B-C3146231
and	O
being	B-C3146231
protected	I-C3146231
""""	O
""""	O
responding	B-C0871261
to	O
children's	B-C0008059
search	B-C1706202
for	O
understanding	B-C0162340
""""	O
""""	O
prioritizing	B-C0549179
family	B-C0015608
life	I-C0015608
""""	O
and	O
""""	O
relating	B-C0004927
to	I-C0004927
others	I-C0004927
""""	O
implications	O
of	O
the	O
findings	B-C0243095
for	O
clinical	B-C1254363
practice	I-C1254363
and	O
future	O
research	B-C0035168
are	O
considered	O
.	O
	
in	O
particular	O
,	O
the	O
need	O
for	O
more	O
family-orientated	B-C1254363
services	I-C1254363
where	O
parents	B-C0030551
experience	B-C0596545
parental	B-C0030551
mental	B-C1446377
health	I-C1446377
problems	I-C1446377
a	O
case	B-C1706256
of	O
bilateral	B-C0238767
pneumothoraces	B-C0032326
resulting	O
from	O
tracheostomy	B-C0040590
for	O
advanced	B-C0679246
laryngeal	B-C0007107
cancer	I-C0007107
pneumothorax	B-C0032326
is	O
a	O
possible	O
complication	B-C0009566
of	O
tracheostomy	B-C0040590
.	O
	
we	O
report	B-C0700287
a	O
rare	O
case	O
of	O
bilateral	B-C0238767
pneumothoraces	B-C0032326
resulting	O
from	O
tracheostomy	B-C0040590
in	O
an	O
advanced	B-C0679246
laryngeal	B-C0007107
cancer	I-C0007107
patient	B-C0030705
.	O
	
a	O
59-year-old	O
man	B-C0086582
was	O
referred	O
to	O
our	O
clinic	B-C0442592
for	O
evaluation	B-C0220825
and	O
treatment	B-C0087111
of	O
laryngeal	B-C0023055
tumor	I-C0023055
.	O
	
laryngeal	B-C0023072
endoscopy	I-C0023072
showed	O
limited	B-C0243095
movement	I-C0243095
of	O
bilateral	B-C0459363
vocal	I-C0459363
cords	I-C0459363
,	O
and	O
computed	B-C0040405
tomography	I-C0040405
revealed	O
a	O
tumor	B-C0027651
lesion	B-C0221198
extending	O
from	O
the	O
vocal	B-C0042930
cords	I-C0042930
to	O
the	O
subglottic	B-C0456475
area	I-C0456475
.	O
	
three	O
days	B-C0439228
after	O
the	O
first	B-C4287881
visit	I-C4287881
,	O
the	O
patient	B-C0030705
developed	O
respiratory	B-C0013404
difficulty	I-C0013404
,	O
and	O
we	O
elected	O
to	O
perform	O
emergency	B-C0498305
tracheostomy	I-C0498305
for	O
airway	B-C0150126
management	I-C0150126
.	O
	
immediately	O
after	O
the	O
start	O
of	O
the	O
procedure	B-C0543467
,	O
he	O
began	O
hyperventilating	B-C0020578
,	O
and	O
complained	O
of	O
respiratory	B-C4062414
discomfort	I-C4062414
and	O
chest	B-C0008031
pain	I-C0008031
.	O
	
we	O
then	O
recognized	O
a	O
mediastinal	B-C0025066
air	B-C2242512
leak	I-C2242512
,	O
and	O
we	O
suspected	B-C0332147
pneumothorax	B-C0032326
resulting	O
from	O
the	O
tracheostomy	B-C0040590
.	O
	
chest	B-C0039985
x-ray	I-C0039985
showed	O
bilateral	B-C0238767
pneumothoraces	B-C0032326
therefore	O
,	O
we	O
inserted	B-C0441587
bilateral	B-C0238767
chest	B-C0817096
drainage	B-C0184114
tubes	I-C0184114
,	O
which	O
stabilized	B-C0184512
his	O
respiratory	B-C4062804
condition	I-C4062804
.	O
	
we	O
speculated	O
that	O
the	O
pathogenesis	B-C0699748
of	O
the	O
bilateral	B-C0238767
pneumothoraces	B-C0032326
was	O
weakened	B-C1762617
alveolar	B-C0225695
walls	I-C0225695
secondary	O
to	O
long-term	B-C0443252
smoking	B-C0037369
,	O
and	O
a	O
significant	O
rise	B-C0442805
in	O
airway	B-C0428719
pressure	I-C0428719
because	O
of	O
airway	B-C0231818
constriction	I-C0231818
by	O
the	O
neck-extended	B-C0577754
position	I-C0577754
and	O
hyperventilation	B-C0020578
,	O
during	O
arsenic	B-C0596621
triglutathione	I-C0596621
as	B-C0596621
transport	B-C0005528
by	O
multidrug	B-C1451297
resistance	I-C1451297
protein	I-C1451297
1	I-C1451297
mrp1	B-C1451297
/	O
abcc1	B-C1451297
is	O
selectively	O
modified	B-C0392747
by	O
phosphorylation	B-C1158886
of	O
tyr920/ser921	B-C0002518
and	O
glycosylation	B-C0376322
of	O
asn19/asn23	B-C0002518
the	O
atp-binding	B-C0242738
cassette	I-C0242738
abc	I-C0242738
transporter	I-C0242738
multidrug	B-C1451297
resistance	I-C1451297
protein	I-C1451297
1	I-C1451297
mrp1	B-C1451297
/	O
abcc1	B-C1451297
is	O
responsible	O
for	O
the	O
cellular	B-C0007634
export	B-C0699789
of	O
a	O
chemically	O
diverse	B-C1880371
array	B-C1510941
of	O
xenobiotics	B-C0043335
and	O
endogenous	B-C0205227
compounds	B-C0439861
.	O
	
arsenic	B-C0003818
,	O
a	O
human	B-C0086418
carcinogen	B-C0007090
,	O
is	O
a	O
high-affinity	B-C0205556
mrp1	B-C1451297
substrate	B-C3891814
as	O
arsenic	B-C0596621
triglutathione	I-C0596621
as	B-C0596621
.	O
	
in	O
this	O
study	O
,	O
marked	O
differences	O
in	O
as	B-C0596621
transport	B-C0005528
kinetics	B-C2825046
were	O
observed	O
between	O
mrp1	B-C1451297
-enriched	O
membrane	B-C0596901
vesicles	B-C1622418
prepared	B-C1521827
from	O
human	B-C0086418
embryonic	B-C0013935
kidney	B-C0022646
293	B-C2936239
hek	I-C2936239
km	B-C1706312
3.8	O
µm	O
and	O
vmax	B-C1710637
307	O
pmol/mg	O
per	O
minute	O
and	O
hela	B-C0018873
km	B-C1706312
0.32	O
µm	O
and	O
vmax	B-C1710637
42	O
pmol/mg	O
per	O
minute	O
cells	B-C0007634
.	O
	
mutant	B-C1564139
mrp1	B-C1451297
lacking	O
n-linked	O
glycosylation	B-C0376322
asn19/23/1006gln	B-C0002518
sugar-free	O
sf	B-C1451297
expressed	B-C1171362
in	O
either	O
hek293	B-C2936239
or	O
hela	B-C0018873
cells	I-C0018873
had	O
low	O
km	B-C1706312
and	O
vmax	B-C1710637
values	O
for	O
as	B-C0596621
,	O
similar	B-C2348205
to	O
hela	B-C0018873
wild-type	I-C0018873
wt	O
mrp1	B-C1451297
.	O
	
when	O
prepared	B-C1521827
in	O
the	O
presence	B-C0150312
of	O
phosphatase	B-C0597217
inhibitors	I-C0597217
,	O
both	O
wt-	B-C1451297
and	O
sf-mrp1	B-C1451297
-enriched	O
membrane	B-C0596901
vesicles	B-C1622418
had	O
a	O
high	O
km	B-C1706312
value	O
for	O
as	B-C0596621
3-6	O
µm	O
,	O
regardless	O
of	O
the	O
cell	B-C0682523
line	I-C0682523
.	O
	
kinetic	B-C0449381
parameters	I-C0449381
of	O
as	B-C0596621
for	O
hek	B-C2936239
-	O
asn19/23gln-mrp1	B-C1451297
were	O
similar	B-C2348205
to	O
those	O
of	O
hela	B-C0018873
/	O
hek	B-C2936239
-	O
sf-mrp1	B-C1451297
and	O
hela-wt	B-C0018873
-	O
mrp1	B-C1451297
,	O
whereas	O
those	O
of	O
single	B-C0205171
glycosylation	B-C0376322
mutants	B-C1564139
were	O
like	O
those	O
of	O
hek-wt	B-C2936239
-mrp1	O
.	O
	
mutation	B-C0026882
of	O
19	O
potential	B-C3245505
mrp1	O
phosphorylation	B-C1158886
sites	B-C0205145
revealed	O
that	O
hek	B-C2936239
-	O
tyr920phe/ser921ala-mrp1	B-C1451297
transported	B-C0005528
as	B-C0596621
like	O
hela-wt	B-C0018873
-	O
mrp1	B-C1451297
,	O
whereas	O
individual	O
hek	B-C2936239
-	O
tyr920phe-	B-C1451297
and	O
-	O
ser921ala-mrp1	B-C1451297
mutants	B-C1564139
were	O
similar	B-C2348205
to	O
hek-wt	B-C2936239
-	O
mrp1	B-C1451297
.	O
	
together	O
,	O
these	O
results	B-C0683954
suggest	O
that	O
asn19/asn23	B-C0002518
glycosylation	B-C0376322
and	O
tyr920/ser921	B-C0002518
phosphorylation	B-C1158886
are	O
responsible	O
for	O
altering	B-C0392747
the	O
kinetics	B-C2825046
of	O
mrp1	B-C1451297
-mediated	O
as	B-C0596621
transport	B-C0005528
.	O
	
the	O
kinetics	B-C2825046
of	O
as	B-C0596621
transport	B-C0005528
by	O
hek	B-C2936239
-	O
asn19/23gln/tyr920glu/ser921glu	B-C0002518
were	O
similar	B-C2348205
to	O
hek-wt	B-C2936239
-	O
mrp1	B-C1451297
,	O
indicating	O
that	O
the	O
phosphorylation	B-C1158886
-mimicking	O
substitutions	O
abrogated	O
the	O
influence	B-C4054723
of	O
asn19/23gln	B-C0002518
glycosylation	B-C0376322
.	O
	
overall	O
,	O
these	O
data	O
suggest	O
that	O
cross-talk	O
between	O
mrp1	B-C1451297
glycosylation	B-C0376322
and	O
phosphorylation	B-C1158886
occurs	O
and	O
that	O
phosphorylation	B-C1158886
of	O
tyr920	B-C0002518
and	O
ser921	B-C0002518
can	O
switch	O
mrp1	B-C1451297
to	O
a	O
lower-affinity	B-C0205556
,	O
higher-capacity	B-C0205556
as	B-C0596621
transporter	B-C0596902
,	O
allowing	O
arsenic	B-C0003818
detoxification	B-C4235382
over	O
a	O
broad	B-C0332464
concentration	B-C1446561
range	B-C1514721
.	O
	
naphthohydroquinones	B-C1254351
,	O
naphthoquinones	B-C0027388
,	O
anthraquinones	B-C0003174
,	O
and	O
a	O
naphthohydroquinone	B-C1254351
dimer	B-C0596448
isolated	B-C0205409
from	O
the	O
aerial	B-C1136056
parts	I-C1136056
of	O
morinda	B-C1474894
parvifolia	I-C1474894
and	O
their	O
cytotoxic	B-C0596402
effects	I-C0596402
through	O
up-regulation	B-C0162493
of	O
p53	B-C0079419
five	O
unknown	B-C0439673
compounds	B-C1254351
,	O
morindaparvins	B-C1254351
c-g	I-C1254351
,	O
consisting	O
of	O
naphthohydroquinones	B-C1254351
,	O
a	O
naphthoquinone	B-C0027388
,	O
an	O
anthraquinone	B-C0003174
,	O
and	O
a	O
naphthohydroquinone	B-C1254351
dimer	B-C0596448
,	O
together	O
with	O
three	O
known	O
quinones	B-C0034435
and	O
seven	O
other	O
known	O
compounds	B-C1254351
,	O
were	O
isolated	B-C0205409
from	O
the	O
aerial	B-C1136056
parts	I-C1136056
of	O
morinda	B-C1474894
parvifolia	I-C1474894
.	O
	
the	O
structures	O
of	O
morindaparvins	B-C1254351
c	I-C1254351
,	O
d	B-C1254351
,	O
e	B-C1254351
,	O
f	B-C1254351
,	O
and	O
g	B-C1254351
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	B-C0037812
or	O
x-ray	B-C0599643
diffraction	I-C0599643
analysis	I-C0599643
as	O
methyl	B-C1254351
4-hydroxy-1	I-C1254351
,	O
methyl	B-C1254351
4	I-C1254351
,	O
3-amino-6-methoxy-2-methoxycarbonyl-1	B-C1254351
,	O
1	B-C1254351
,	O
and	O
dimethyl	B-C1254351
1	I-C1254351
,	O
respectively	O
.	O
	
naphthoquinones	B-C0027388
and	O
naphthohydroquinone	B-C1254351
dimers	B-C0596448
were	O
previously	O
unknown	B-C0439673
in	O
the	O
genus	B-C1708235
morinda	B-C1010821
.	O
	
in	O
addition	O
,	O
the	O
compounds	B-C1254351
were	O
tested	B-C0039593
for	O
cytotoxicity	B-C0596402
against	O
four	O
human	B-C0086418
cancer	B-C0085983
cell	I-C0085983
lines	I-C0085983
hela	B-C0018873
,	O
a2780	B-C0085983
,	O
ketr3	B-C0085983
and	O
mcf-7	B-C0596890
and	O
their	O
effects	B-C1280500
on	O
p53	B-C0079419
-	O
activated	B-C1879547
transcription	B-C0040649
.	O
	
three	O
naphthoquinones	B-C0027388
had	O
moderate	B-C1881878
cytotoxic	B-C0596402
effects	I-C0596402
with	O
ic50	B-C0600495
values	O
ranging	B-C1514721
from	O
1.51	O
to	O
9.56	O
μm	O
,	O
through	O
up-regulation	B-C0162493
of	O
p53	B-C0079419
transcriptional	B-C0162493
activity	I-C0162493
.	O
	
identification	B-C0020792
and	O
sar	B-C0038477
evaluation	B-C0220825
of	O
hemozoin	B-C0062496
-	O
inhibiting	B-C3463820
benzamides	B-C0005029
active	B-C0205177
against	O
plasmodium	B-C0032150
falciparum	I-C0032150
quinoline	B-C0034423
antimalarials	B-C0003374
target	B-C1521840
hemozoin	B-C0062496
formation	B-C1522492
causing	O
a	O
cytotoxic	B-C1511636
accumulation	B-C4055506
of	O
ferriprotoporphyrin	B-C0015877
ix	I-C0015877
fe	B-C0015877
.	O
	
well-developed	O
sar	B-C0038477
models	B-C3161035
exist	O
for	O
β-hematin	B-C0062496
inhibition	B-C3463820
,	O
parasite	B-C0030498
activity	B-C0441655
,	O
and	O
cellular	B-C1148560
mechanisms	I-C1148560
for	O
this	O
compound	B-C0456387
class	I-C0456387
,	O
but	O
no	O
comparably	O
detailed	O
investigations	B-C0243095
exist	O
for	O
other	O
hemozoin	B-C0062496
inhibiting	B-C3463820
chemotypes	B-C1254351
.	O
	
here	O
,	O
benzamide	B-C0053139
analogues	B-C0002776
based	O
on	O
previous	O
hts	B-C2718003
hits	O
have	O
been	O
purchased	B-C0870238
or	O
synthesized	B-C1883254
.	O
	
only	O
derivatives	B-C0243072
containing	I-C0243072
an	I-C0243072
electron	I-C0243072
deficient	I-C0243072
aromatic	I-C0243072
ring	I-C0243072
and	O
capable	O
of	O
adopting	O
flat	B-C0026377
conformations	I-C0026377
,	O
optimal	O
for	O
π-π	B-C1704675
interactions	I-C1704675
with	O
fe	B-C0015877
,	O
inhibited	B-C0311403
β-hematin	B-C0062496
formation	B-C1522492
.	O
	
the	O
two	O
most	O
potent	O
analogues	B-C0002776
showed	O
nanomolar	B-C0439282
parasite	B-C0030498
activity	B-C0441655
,	O
with	O
little	O
cq	B-C0008269
cross-resistance	B-C2363980
,	O
low	O
cytotoxicity	B-C0596402
,	O
and	O
high	O
in	B-C1533691
vitro	I-C1533691
microsomal	B-C1979928
stability	B-C0205360
.	O
	
selected	O
analogues	B-C0002776
inhibited	B-C0311403
hemozoin	B-C0062496
formation	B-C1522492
in	O
plasmodium	B-C0032150
falciparum	I-C0032150
causing	O
high	O
levels	B-C0441889
of	O
free	O
heme	B-C0018966
.	O
	
in	O
contrast	O
to	O
quinolines	B-C0034424
,	O
introduction	B-C0579004
of	O
amine	B-C1254350
side	I-C1254350
chains	I-C1254350
did	O
not	O
lead	O
to	O
benzamide	B-C0053139
accumulation	B-C4055506
in	O
the	O
parasite	B-C0030498
.	O
	
these	O
data	B-C1511726
reveal	O
complex	O
relationships	B-C0439849
between	O
heme	B-C1148616
binding	I-C1148616
,	O
free	O
heme	B-C0018966
levels	B-C0441889
,	O
cellular	B-C0007613
accumulation	I-C0007613
,	O
and	O
in	B-C1533691
vitro	I-C1533691
activity	B-C0441655
of	O
potential	O
novel	B-C0205314
antimalarials	B-C0003374
.	O
	
shear	B-C0392762
modulus	I-C0392762
of	O
structured	B-C0678594
electrorheological	B-C1704353
fluid	I-C1704353
mixtures	B-C0439962
some	O
immiscible	B-C0439861
blends	I-C0439861
under	O
a	O
strong	O
electric	B-C0337037
field	I-C0337037
often	O
exhibit	O
periodic	B-C0332182
structures	B-C0678594
,	O
bridging	O
the	O
gap	O
between	O
two	O
electrodes	B-C0013812
.	O
	
upon	O
shear	B-C3825679
,	O
the	O
structures	B-C0678594
tilt	B-C1711426
,	O
and	O
exhibit	O
an	O
elastic	B-C0681018
response	O
which	O
is	O
mostly	O
governed	O
by	O
the	O
electric	B-C0013790
energy	I-C0013790
.	O
	
assuming	O
a	O
two-dimensional	B-C0439534
stripe	B-C0678594
structure	I-C0678594
,	O
we	O
calculate	O
the	O
maxwell	B-C0038442
stress	I-C0038442
,	O
and	O
derive	O
an	O
expression	B-C2911684
for	O
the	O
shear	B-C0392762
modulus	I-C0392762
,	O
demonstrating	O
how	O
it	O
depends	O
on	O
the	O
external	O
electric	B-C0337037
field	I-C0337037
,	O
the	O
composition	B-C1882370
,	O
and	O
the	O
dielectric	B-C0596437
properties	I-C0596437
of	O
the	O
blend	B-C0439861
.	O
	
we	O
also	O
suggest	O
the	O
notion	O
of	O
effective	O
interfacial	B-C2713544
tension	I-C2713544
,	O
which	O
renormalizes	O
the	O
effect	B-C1704420
of	I-C1704420
the	O
electric	B-C0337037
field	I-C0337037
.	O
	
this	O
leads	O
to	O
a	O
simple	O
derivation	B-C1441547
of	O
the	O
scaling	B-C1947938
law	I-C1947938
for	O
the	O
selection	O
of	O
the	O
wavelength	B-C0449819
of	O
the	O
structure	B-C0678594
formed	O
under	O
an	O
electric	B-C0337037
field	I-C0337037
.	O
	
sequence-specific	B-C1624609
dna	I-C1624609
binding	I-C1624609
by	O
long	B-C1254350
hairpin	I-C1254350
pyrrole-imidazole	B-C0029224
polyamides	I-C0029224
containing	O
an	O
8-amino-3	B-C0029224
acid	I-C0029224
unit	O
with	O
the	O
aim	O
of	O
improving	O
aqueous	B-C0597682
solubility	I-C0597682
,	O
we	O
designed	B-C1707689
and	O
synthesized	B-C1883254
five	O
n-methylpyrrole	B-C0029224
py	I-C0029224
im	I-C0029224
polyamides	I-C0029224
capable	O
of	O
recognizing	O
9-bp	B-C0004793
sequences	I-C0004793
.	O
	
their	O
dna-binding	B-C1148673
affinities	B-C1510827
and	O
sequence	B-C0004793
specificities	B-C0037791
were	O
evaluated	O
by	O
spr	B-C0597731
and	O
bind-n-seq	B-C0936012
analyses	I-C0936012
.	O
	
the	O
design	B-C1707689
of	O
polyamide	B-C0029224
1	I-C0029224
was	O
based	O
on	O
a	O
conventional	O
model	B-C3161035
,	O
with	O
three	O
consecutive	O
py	B-C0383659
or	O
im	B-C0044472
rings	O
separated	O
by	O
a	O
β-alanine	B-C0000392
to	O
match	O
the	O
curvature	O
and	O
twist	B-C0231467
of	O
long	O
dna	B-C0012854
helices	B-C1254362
.	O
	
polyamides	B-C0029224
2	I-C0029224
and	I-C0029224
3	I-C0029224
contained	O
an	O
8-amino-3	B-C0029224
acid	I-C0029224
ao	B-C0029224
unit	O
,	O
which	O
has	O
previously	O
only	O
been	O
used	O
as	O
a	O
linker	B-C0029224
within	O
linear	O
py-im	B-C0029224
polyamides	I-C0029224
or	O
between	O
py	B-C0383659
-	O
im	O
hairpin	O
motifs	O
for	O
tandem	O
hairpin	O
.	O
	
it	O
is	O
demonstrated	O
herein	O
that	O
ao	O
also	O
functions	O
as	O
a	O
linker	O
element	O
that	O
can	O
extend	O
to	O
2-bp	O
in	O
hairpin	O
motifs	O
.	O
	
notably	O
,	O
although	O
the	O
ao	O
-containing	O
unit	O
can	O
fail	O
to	O
bind	O
the	O
expected	O
sequence	O
,	O
polyamide	O
4	O
,	O
which	O
has	O
two	O
ao	O
units	O
facing	O
each	O
other	O
in	O
a	O
hairpin	O
form	O
,	O
successfully	O
showed	O
the	O
expected	O
motif	O
and	O
a	O
kd	O
value	O
of	O
16nm	O
was	O
recorded	O
.	O
	
polyamide	O
5	O
,	O
containing	O
a	O
β-alanine-β-alanine	O
unit	O
instead	O
of	O
the	O
ao	O
of	O
polyamide	O
2	O
,	O
was	O
synthesized	O
for	O
comparison	O
.	O
	
the	O
aqueous	O
solubilities	O
and	O
nuclear	O
localization	O
of	O
three	O
of	O
the	O
polyamides	O
were	O
also	O
examined	O
.	O
	
the	O
results	O
suggest	O
the	O
possibility	O
of	O
applying	O
the	O
ao	O
unit	O
in	O
the	O
core	O
of	O
py-im	O
polyamide	O
compounds	I-C0029224
causes	B-C0007465
of	I-C0007465
death	I-C0007465
among	O
children	B-C0008059
aged	B-C0001779
5	O
to	O
14	O
years	B-C1510829
old	B-C0580836
from	O
2008	O
to	O
2013	O
in	O
kersa	O
health	O
and	O
demographic	O
surveillance	O
system	O
kersa	O
hdss	O
,	O
ethiopia	B-C0015024
the	O
global	O
burden	O
of	O
mortality	B-C0008083
among	I-C0008083
children	I-C0008083
is	O
still	O
very	O
huge	O
though	O
its	O
trend	B-C1521798
has	O
started	O
declining	O
following	O
the	O
improvements	B-C2986411
in	O
the	O
living	B-C0080190
standard	I-C0080190
.	O
	
it	O
presents	O
serious	O
challenges	B-C0805586
to	O
the	O
well-being	O
of	O
children	B-C0008059
in	O
many	O
african	B-C0454695
countries	I-C0454695
.	O
	
today	O
,	O
sub-saharan	B-C0001738
africa	I-C0001738
alone	O
accounts	O
for	O
about	O
50%	O
of	O
global	B-C2348867
child	B-C0008083
mortality	I-C0008083
.	O
	
the	O
overall	O
objective	B-C0018017
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
magnitude	B-C1704240
and	O
distribution	B-C1704711
of	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
among	O
children	B-C0008059
aged	B-C0001779
5	O
to	O
14	O
year	O
olds	O
in	O
the	O
population	B-C1257890
of	O
kersa	O
hdss	O
using	O
verbal	B-C0439824
autopsy	B-C0004398
method	O
for	O
the	O
period	B-C1948053
2008	O
to	O
2013	O
.	O
	
kersa	O
health	O
and	O
demographic	O
surveillance	O
system	O
kersa	O
hdss	O
was	O
established	O
in	O
september	B-C3828193
2007	O
.	O
	
the	O
center	O
consists	O
of	O
10	O
rural	B-C0178837
and	O
2	O
urban	B-C0178876
kebeles	B-C1257890
which	O
were	O
selected	O
randomly	O
from	O
38	O
kebeles	B-C1257890
in	O
the	O
district	B-C0001567
.	O
	
thus	O
this	O
study	O
was	O
conducted	O
in	O
kersa	O
hdss	O
and	O
data	B-C1511726
was	O
taken	O
from	O
kersa	B-C0282574
hdss	I-C0282574
database	I-C0282574
.	O
	
the	O
study	B-C2603343
population	B-C1257890
included	O
all	O
children	B-C0008059
aged	B-C0001779
5	O
to	O
14	O
years	O
registered	O
during	O
the	O
period	B-C1948053
of	O
2008	O
to	O
2013	O
in	O
kersa	O
hdss	O
using	O
age	B-C0001779
specific	O
va	O
questionnaires	B-C0034394
.	O
	
data	B-C1511726
were	O
extracted	O
from	O
spss	B-C0282574
database	I-C0282574
and	O
analyzed	O
using	O
stata	B-C0282574
.	O
	
a	O
total	O
of	O
229	O
deaths	B-C1306577
were	O
recorded	O
over	O
the	O
period	B-C1948053
of	O
six	O
years	O
with	O
a	O
crude	O
death	B-C0205848
rate	I-C0205848
of	O
219.6	O
per	O
100	O
population	B-C1257890
of	O
this	O
age	B-C0027362
group	I-C0027362
over	O
the	O
study	B-C2603343
period	B-C1948053
.	O
	
this	O
death	B-C0205848
rate	I-C0205848
was	O
217.5	O
and	O
221.5	O
per	O
100	O
populations	B-C1257890
for	O
females	B-C0086287
and	O
males	B-C0086582
,	O
respectively	O
.	O
	
75%	O
of	O
deaths	B-C1306577
took	O
place	O
at	O
home	O
.	O
	
the	O
study	B-C2603343
identified	O
severe	O
malnutrition	B-C0162429
33.9	O
,	O
intestinal	B-C0178238
infectious	I-C0178238
diseases	I-C0178238
13.8	O
and	O
acute	B-C0238990
lower	I-C0238990
respiratory	I-C0238990
infections	I-C0238990
9.2	O
to	O
be	O
the	O
three	O
most	O
leading	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
.	O
	
in	O
broad	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
classification	B-C0008902
,	O
injuries	B-C0043251
have	O
been	O
found	O
to	O
be	O
the	O
second	O
most	O
cause	B-C0007465
of	I-C0007465
death	I-C0007465
next	O
to	O
communicable	B-C0009450
diseases	I-C0009450
56.3	O
attributing	O
to	O
13.1	O
of	O
the	O
total	O
deaths	B-C1306577
.	O
	
in	O
specific	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
classification	B-C0008902
severe	O
malnutrition	B-C0162429
,	O
intestinal	B-C0178238
infectious	I-C0178238
diseases	I-C0178238
and	O
acute	B-C0238990
lower	I-C0238990
respiratory	I-C0238990
infections	I-C0238990
were	O
the	O
three	O
leading	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
where	O
,	O
in	O
broad	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
communicable	B-C0009450
diseases	I-C0009450
and	O
injuries	B-C0043251
were	O
among	O
the	O
leading	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
.	O
	
hence	O
,	O
concerned	O
bodies	O
should	O
take	O
measures	O
to	O
avert	O
the	O
situation	O
of	O
mortality	B-C0008083
from	O
these	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
and	O
further	O
inferential	B-C0936012
analysis	I-C0936012
into	O
the	O
prevention	B-C0033144
and	O
management	B-C0376636
of	O
infectious	B-C0009450
diseases	I-C0009450
naïve	B-C3641721
cd8	B-C0242629
t	I-C0242629
cell	I-C0242629
derived	O
tumor	B-C0027651
-	O
specific	B-C0205369
cytotoxic	B-C3641722
effectors	I-C3641722
as	O
a	O
potential	O
remedy	B-C1880198
for	O
overcoming	O
tgf-β	B-C0040690
immunosuppression	B-C4048329
in	O
the	O
tumor	B-C2936626
microenvironment	I-C2936626
despite	O
of	O
the	O
potential	O
implications	O
for	O
cancer	B-C0278348
immunotherapy	I-C0278348
,	O
conventional	B-C0439858
approaches	B-C1292724
using	O
in	B-C1533691
vitro	I-C1533691
expanded	B-C0205229
cd8	B-C0242629
t	I-C0242629
cells	I-C0242629
have	O
suboptimal	B-C2984009
outcomes	B-C0085415
,	O
mostly	O
due	O
to	O
loss	B-C1517945
of	O
functionality	B-C0542341
from	O
cellular	B-C0007634
exhaustion	B-C0678684
.	O
	
we	O
therefore	O
investigated	O
the	O
phenotypic	B-C0031437
and	O
functional	B-C0205245
differences	B-C1705242
among	O
in	B-C1533691
vitro	I-C1533691
activated	B-C1879547
cd8	B-C0242629
t	I-C0242629
cells	I-C0242629
of	O
three	O
different	O
sources	B-C0449416
,	O
namely	O
naïve	B-C3641721
nteff	B-C3641721
,	O
memory	B-C0682639
mteff	B-C0682639
and	O
tumor-infiltrating	B-C0079722
lymphocytes	I-C0079722
tileff	B-C0079722
from	O
human	B-C0086418
and	O
mice	B-C0025929
,	O
to	O
better	O
understand	O
mechanisms	B-C0441712
behind	O
potent	O
effector	B-C3641722
functions	B-C0542341
and	O
potential	O
for	O
overcoming	O
current	O
limitations	B-C0449295
.	O
	
in	O
line	O
with	O
the	O
greater	O
proliferation	B-C0596873
activity	B-C0441655
and	O
longer	O
telomere	B-C0085187
lengths	B-C1444754
of	O
nteff	B-C3641721
populations	I-C3641721
,	O
cells	B-C0007634
of	O
naïve	B-C0439659
origin	I-C0439659
exhibited	O
significantly	O
less	O
amounts	O
of	O
t	B-C0039194
cell	I-C0039194
exhaustion	B-C0678684
markers	B-C0005516
than	O
those	O
of	O
mteff	B-C0682639
and	O
tileff	B-C0079722
,	O
and	O
moreover	O
,	O
acquired	O
distinct	O
expression	B-C1171362
patterns	I-C1171362
of	O
memory-promoting	B-C0040648
transcription	I-C0040648
factors	I-C0040648
,	O
t-bet	B-C0913648
and	O
eomes	B-C1454790
,	O
induced	B-C0205263
in	O
a	O
rapid	B-C0456962
and	O
sustainable	B-C0443318
manner	B-C0205245
.	O
	
nteff	B-C3641721
cells	I-C3641721
appeared	O
to	O
have	O
lower	O
expression	B-C1171362
of	O
foxp1	B-C3273485
and	O
were	O
refractory	O
to	O
apoptosis	B-C0162638
upon	O
tgf-β	B-C0040690
conditioning	B-C0205245
,	O
implying	O
better	O
survival	B-C0007620
potential	B-C3245505
and	O
resistance	B-C4281815
to	O
tumor	B-C0027651
-	O
induced	B-C0205263
immune	B-C4048329
suppression	I-C4048329
.	O
	
of	O
cd8	B-C0242629
t	I-C0242629
cell	I-C0242629
pools	O
activated	B-C1879547
to	O
tumor	B-C0027651
-	O
specific	B-C0205369
ctls	B-C0039195
,	O
naïve	B-C3641721
cell	I-C3641721
generated	B-C3146294
effectors	B-C3641722
possessed	O
the	O
most	O
potent	O
cytotoxic	B-C0243095
activity	I-C0243095
,	O
validating	O
implications	O
for	O
use	O
in	O
rational	O
design	B-C1707689
of	O
adoptive	B-C0079613
immunotherapy	I-C0079613
.	O
	
antiadipogenic	B-C0243095
activity	I-C0243095
of	O
γ-oryzanol	B-C0061081
and	O
its	O
stability	B-C0205360
in	O
pigmented	B-C0333610
rice	B-C0035567
γ-oryzanol	B-C0061081
,	O
a	O
prevalent	O
compound	O
in	O
pigmented	B-C0333610
rice	B-C0035567
varieties	B-C0332307
,	O
has	O
been	O
reported	O
to	O
ameliorate	O
obesity-associated	B-C1285391
metabolic	I-C1285391
disorders	I-C1285391
.	O
	
antiadipogenic	B-C0243095
activities	I-C0243095
of	O
γ-oryzanol	B-C0061081
were	O
determined	O
in	O
human	B-C0086418
adipose	B-C0001527
-	O
derived	B-C1550535
mesenchymal	B-C1257975
stem	I-C1257975
cells	I-C1257975
and	O
mouse	B-C1522424
-	O
derived	B-C1550535
3t3-l1	B-C1257743
cells	I-C1257743
.	O
	
γ-oryzanol	B-C0061081
significantly	O
decreased	B-C0205216
lipid	B-C3810056
accumulation	I-C3810056
and	O
reduced	B-C0392756
glycerol-3-phosphate	B-C1151278
dehydrogenase	I-C1151278
activities	I-C1151278
in	O
both	O
adipocytes	B-C0206131
.	O
	
in	O
addition	O
,	O
γ-oryzanol	B-C0061081
in	O
four	O
pigmented	B-C0333610
rice	B-C0035567
varieties	B-C0332307
black	B-C0035567
with	I-C0035567
giant	I-C0035567
embryo	I-C0035567
,	O
brown	B-C0452710
,	O
sugary	B-C0035567
brown	I-C0035567
,	O
and	O
red	B-C0452711
was	O
stable	B-C0205360
when	O
stored	B-C1698986
at	O
4	O
and	O
also	O
at	O
room	B-C2348236
temperature	I-C2348236
for	O
22	O
weeks	O
,	O
whereas	O
other	O
bioactives	B-C3714412
such	O
as	O
lutein	B-C0043328
and	O
β-carotene	B-C0053396
were	O
stable	B-C0205360
only	O
at	O
-80	O
.	O
	
furthermore	O
,	O
the	O
yield	B-C1265611
of	O
γ-oryzanol	B-C0061081
from	O
these	O
rice	B-C0035567
varieties	B-C0332307
was	O
significantly	O
increased	O
through	O
steaming	B-C1522240
and	O
roasting	B-C1522240
processes	I-C1522240
.	O
	
therefore	O
,	O
γ-oryzanol	B-C0061081
exerts	O
antiadipogenic	B-C0243095
activity	I-C0243095
by	O
suppressing	B-C1260953
adipocyte	B-C1159884
differentiations	I-C1159884
and	O
is	O
stable	B-C0205360
in	O
pigmented	B-C0333610
rice	B-C0035567
for	O
an	O
extended	B-C0231448
period	B-C1948053
of	I-C1948053
time	I-C1948053
during	O
storage	B-C1698986
and	O
after	B-C0687676
cooking	B-C0335326
.	O
	
thus	O
,	O
the	O
intake	B-C1512806
of	O
pigmented	B-C0333610
rice	B-C0035567
may	O
be	O
a	O
useful	O
strategy	O
for	O
preventing	B-C1292733
obesity	B-C0028754
.	O
	
impact	B-C4049986
of	O
chemotherapy	B-C3665472
on	O
diet	B-C0012155
and	O
nutritional	B-C0392209
status	I-C0392209
of	O
women	B-C0043210
with	O
breast	B-C0006142
cancer	I-C0006142
a	O
prospective	B-C0033522
study	I-C0033522
certain	O
food	B-C0016452
groups	I-C0016452
are	O
often	O
rejected	B-C1548437
during	O
chemotherapy	B-C3665472
ct	B-C3665472
due	O
to	O
the	O
side	B-C0879626
effects	I-C0879626
of	I-C0879626
treatment	I-C0879626
,	O
which	O
may	O
interfere	B-C0521102
with	I-C0521102
adequate	B-C0547809
diet	I-C0547809
and	O
nutritional	B-C0392209
status	I-C0392209
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	B-C0220825
the	O
treatment	B-C0039798
impact	B-C4049986
on	O
the	O
diet	B-C0012155
and	O
nutritional	B-C0392209
status	I-C0392209
of	O
women	B-C0043210
with	O
breast	B-C0006142
cancer	I-C0006142
bc	B-C0006142
.	O
	
in	O
this	O
prospective	B-C0033522
longitudinal	I-C0033522
study	I-C0033522
,	O
conducted	O
in	O
2014-2015	O
,	O
55	O
women	B-C0043210
diagnosed	O
with	O
bc	B-C0006142
,	O
with	O
a	O
mean	O
age	B-C0001779
51.5	O
years	B-C0439234
,	O
were	O
followed	O
and	O
data	B-C1511726
were	O
collected	O
at	O
three	O
different	O
times	O
.	O
	
anthropometric	B-C0815129
and	O
dietary	B-C0814244
assessments	I-C0814244
were	O
performed	O
,	O
the	O
latter	O
by	O
applying	O
nine	O
24h	O
dietary	B-C0566508
recall	I-C0566508
s	O
,	O
by	O
using	O
the	O
brazilian	B-C0282574
healthy	I-C0282574
eating	I-C0282574
index	I-C0282574
revised	I-C0282574
bhei-r	B-C0282574
,	O
and	O
calculating	B-C1441506
the	O
prevalence	B-C0220900
of	O
inadequacy	B-C0205412
by	O
the	O
ear	B-C0282574
cut-off	I-C0282574
point	I-C0282574
method	I-C0282574
.	O
	
regarding	O
the	O
bhei-r	B-C0282574
analysis	B-C0936012
,	O
the	O
majority	O
of	O
women	B-C0043210
had	O
a	O
""""	O
diet	B-C0012155
requires	O
modification	B-C3840684
'	O
,	O
both	O
at	O
the	O
beginning	B-C0439659
t0	O
,	O
58.2	O
,	O
n	O
=	O
32	O
and	O
during	B-C2709058
treatment	I-C2709058
t1	O
,	O
54.5	O
,	O
n	O
=	O
30	O
.	O
	
however	O
,	O
after	O
the	O
end	O
of	O
the	O
ct	B-C3665472
,	O
the	O
greater	B-C0439165
percentage	I-C0439165
of	O
patients	B-C0030705
t2	O
,	O
49.1	O
,	O
n	O
=	O
27	O
were	O
classified	O
as	O
having	O
an	O
""""	O
inadequate	B-C0522060
diet	I-C0522060
""""	O
,	O
since	O
the	O
total	B-C0439810
fruit	B-C0016767
consumption	B-C0441655
as	O
well	O
as	O
the	O
dark	B-C2348898
green	I-C2348898
and	O
orange	B-C0016452
vegetable	I-C0016452
and	O
legume	B-C0023263
consumption	B-C0441655
decreased	B-C0205216
significantly	I-C0205216
during	B-C2709058
treatment	I-C2709058
p	O
=	O
0.043	O
and	O
p	O
=	O
0.026	O
,	O
respectively	O
.	O
	
there	O
was	O
a	O
significant	B-C0392756
reduction	I-C0392756
in	O
the	O
intake	B-C1512806
of	O
macro	B-C2346926
and	O
micronutrients	B-C0282575
,	O
with	O
a	O
high	O
prevalence	B-C0220900
of	O
inadequacy	B-C0205412
,	O
of	O
up	O
to	O
100%	O
,	O
for	O
calcium	B-C0006726
,	O
iron	B-C0376520
,	O
phosphorus	B-C0080014
,	O
magnesium	B-C2348270
,	O
niacin	B-C0027996
,	O
riboflavin	B-C0035527
,	O
thiamin	B-C0039840
,	O
vitamin	B-C0087162
b6	I-C0087162
,	O
vitamin	B-C0003968
c	I-C0003968
and	O
zinc	B-C2348288
.	O
	
assessment	B-C0028708
of	O
the	O
nutritional	B-C0392209
status	I-C0392209
indicated	O
that	O
56%	O
n	O
=	O
31	O
of	O
patients	B-C0030705
were	O
overweight	B-C0497406
at	O
these	O
three	O
different	O
times	O
.	O
	
weight	B-C0005910
,	O
bmi	B-C1305855
and	O
waist	B-C0455829
circumference	I-C0455829
increased	B-C0205217
significantly	I-C0205217
,	O
indicating	O
a	O
worse	B-C1457868
nutritional	B-C0392209
status	I-C0392209
,	O
and	O
there	O
was	O
a	O
correlation	B-C1707520
between	O
poor	B-C0332306
diet	I-C0332306
quality	I-C0332306
and	O
higher	B-C0042295
values	I-C0042295
for	O
bmi	B-C1305855
,	O
waist-hip	B-C0205682
ratio	I-C0205682
and	O
waist-to-height	B-C1821269
ratio	I-C1821269
.	O
	
chemotherapy	B-C3665472
interferes	B-C0521102
in	O
the	O
patients	B-C0030705
'	O
diet	B-C0012155
generating	O
a	O
negative	B-C4049986
impact	I-C4049986
on	O
the	O
quality	B-C0332306
and	O
intake	B-C1512806
of	O
micro	B-C0282575
and	O
macronutrients	B-C2346926
,	O
as	O
well	O
as	O
an	O
impact	B-C4049986
on	O
their	O
nutritional	B-C0392209
status	I-C0392209
,	O
with	O
an	O
increase	O
in	O
anthropometric	B-C0815129
measurements	I-C0815129
.	O
	
benefit	O
and	O
risk	B-C0035649
in	O
short	O
term	O
after	O
total	B-C0040508
hip	I-C0040508
arthroplasty	I-C0040508
by	O
direct	B-C0205511
anterior	I-C0205511
approach	I-C0205511
combined	O
with	O
dual	B-C0025080
mobility	I-C0025080
cup	I-C0025080
no	O
previous	O
reports	O
have	O
described	O
the	O
benefits	O
and	O
risks	B-C0035649
associated	O
with	O
the	O
dual	B-C0025080
mobility	I-C0025080
cup	I-C0025080
dmc	B-C0025080
in	O
primary	O
tha	B-C0040508
via	O
direct	B-C0205511
anterior	I-C0205511
approach	I-C0205511
daa	B-C0205511
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
compare	O
the	O
safety	B-C1705187
and	O
rate	O
of	O
early	O
postoperative	B-C0032787
complication	I-C0032787
of	O
the	O
daa	B-C0205511
with	O
the	O
dmc	B-C0025080
for	O
tha	B-C0040508
with	O
those	O
of	O
the	O
daa	B-C0205511
with	O
a	O
single	B-C0025080
standard	I-C0025080
cup	I-C0025080
,	O
and	O
to	O
investigate	O
the	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
dmc	B-C0025080
on	O
intra	B-C0456904
-	O
and	O
perioperative	B-C1518988
outcomes	B-C1274040
.	O
	
we	O
retrospectively	O
investigated	O
60	O
hips	B-C0019552
treated	B-C0087111
in	O
the	O
single-	O
daa	B-C0205511
group	B-C0441833
and	O
60	O
hips	B-C0019552
treated	B-C0087111
in	O
the	O
dual-	O
daa	B-C0205511
group	B-C0441833
.	O
	
a	O
primary	B-C0205225
/	O
secondary	B-C0205436
outcome	B-C1274040
variable	O
was	O
the	O
presence	O
of	O
any	O
intra	B-C0021890
-	O
or	O
perioperative	B-C1518988
complication	B-C0009566
within	O
the	O
first	O
6	O
months	B-C0439231
/the	O
operative	B-C3494201
time	I-C3494201
and	O
hip	O
function	O
at	O
6	O
months	B-C0439231
postoperatively	B-C0032790
.	O
	
we	O
also	O
analyzed	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
dmc	B-C0025080
on	O
intra	B-C0456904
-	O
and	O
perioperative	B-C1518988
outcomes	B-C1274040
.	O
	
no	B-C1513916
intraoperative	B-C0021890
complications	I-C0021890
were	O
observed	O
in	O
either	O
group	B-C0441833
.	O
	
one	O
anterior	B-C1265658
dislocation	I-C1265658
and	O
one	O
periprosthetic	B-C4040051
hip	I-C4040051
fracture	I-C4040051
were	O
occurred	O
in	O
the	O
single-	O
daa	B-C0205511
group	B-C0441833
.	O
	
the	O
surgical	B-C3494201
times	I-C3494201
in	O
the	O
single-	O
daa	B-C0205511
and	O
dual-	O
daa	B-C0205511
groups	B-C0441833
were	O
112.0	O
20.9	O
and	O
121.0	O
26.9	O
min	O
p	O
<	O
0.001	O
.	O
	
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
6-	O
month	B-C0439231
postoperative	B-C0032790
hip	B-C0449820
function	I-C0449820
scores	I-C0449820
between	O
the	O
two	O
groups	B-C0441833
.	O
	
there	O
was	O
no	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
dmc	B-C0025080
on	O
intra	B-C0456904
-	O
and	O
perioperative	B-C1518988
outcomes	B-C1274040
.	O
	
we	O
have	O
demonstrated	O
the	O
short-term	O
safety	B-C1705187
and	O
lack	O
of	O
inferiority	O
of	O
using	O
the	O
dmc	B-C0025080
in	O
the	O
daa	B-C0205511
compared	O
with	O
the	O
standard	B-C0025080
single	I-C0025080
mobility	I-C0025080
cup	I-C0025080
.	O
	
diffuse	B-C2832047
traumatic	I-C2832047
brain	I-C2832047
injury	I-C2832047
affects	O
chronic	B-C0205191
corticosterone	B-C0010124
function	B-C0542341
in	O
the	O
rat	B-C0034721
as	O
many	O
as	O
20-55%	O
of	O
patients	B-C0030705
with	O
a	O
history	B-C0332119
of	O
traumatic	B-C0876926
brain	I-C0876926
injury	I-C0876926
tbi	B-C0876926
experience	O
chronic	B-C0205191
endocrine	B-C1397856
dysfunction	I-C1397856
,	O
leading	O
to	O
impaired	B-C4049260
quality	I-C4049260
of	I-C4049260
life	I-C4049260
,	O
impaired	B-C0221099
rehabilitation	B-C0034992
efforts	B-C1516084
and	O
lowered	B-C1504437
life	I-C1504437
expectancy	I-C1504437
.	O
	
endocrine	B-C1397856
dysfunction	I-C1397856
after	O
tbi	B-C0876926
is	O
thought	O
to	O
result	B-C1274040
from	O
acceleration	B-C0000894
-	O
deceleration	B-C0011100
forces	B-C0441722
to	O
the	O
brain	B-C0006104
within	O
the	O
skull	B-C2951888
,	O
creating	O
enduring	O
hypothalamic	B-C0020663
and	O
pituitary	B-C0032005
neuropathology	B-C1540677
,	O
and	O
subsequent	O
hypothalamic	B-C0020663
-pituitary	O
endocrine	O
hpe	O
dysfunction	O
.	O
	
these	O
experiments	O
were	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
single	O
diffuse	O
tbi	O
results	O
in	O
chronic	O
dysfunction	O
of	O
corticosterone	O
cort	O
,	O
a	O
glucocorticoid	O
released	O
in	O
response	O
to	O
stress	O
and	O
testosterone	O
.	O
	
we	O
used	O
a	O
rodent	O
model	O
of	O
diffuse	O
tbi	O
induced	O
by	O
midline	O
fluid	O
percussion	O
injury	O
mfpi	O
.	O
	
at	O
2	O
months	O
postinjury	O
compared	O
with	O
uninjured	O
control	O
animals	O
,	O
circulating	O
levels	O
of	O
cort	O
were	O
evaluated	O
at	O
rest	O
,	O
under	O
restraint	O
stress	O
and	O
in	O
response	O
to	O
dexamethasone	O
,	O
a	O
synthetic	O
glucocorticoid	O
commonly	O
used	O
to	O
test	O
hpe	O
axis	O
regulation	O
.	O
	
testosterone	O
was	O
evaluated	O
at	O
rest	O
.	O
	
further	O
,	O
we	O
assessed	O
changes	O
in	O
injury	O
-	O
induced	O
neuron	O
morphology	O
golgi	O
stain	O
,	O
neuropathology	O
silver	O
stain	O
and	O
activated	O
astrocytes	O
gfap	O
in	O
the	O
paraventricular	O
nucleus	O
pvn	O
of	O
the	O
hypothalamus	O
.	O
	
resting	O
plasma	O
cort	O
levels	O
were	O
decreased	O
at	O
2	O
months	O
postinjury	O
and	O
there	O
was	O
a	O
blunted	O
cort	O
increase	O
in	O
response	O
to	O
restraint	O
induced	O
stress	O
.	O
	
no	O
changes	O
in	O
testosterone	O
were	O
measured	O
.	O
	
these	O
changes	O
in	O
cort	O
were	O
observed	O
concomitantly	O
with	O
altered	O
complexity	O
of	O
neuron	O
processes	O
in	O
the	O
pvn	O
over	O
time	O
,	O
devoid	O
of	O
neuropathology	O
or	O
astrocytosis	O
.	O
	
results	O
provide	O
evidence	O
that	O
a	O
single	O
moderate	O
diffuse	O
tbi	O
leads	O
to	O
changes	O
in	O
cort	O
function	O
,	O
which	O
can	O
contribute	O
to	O
the	O
persistence	O
of	O
symptoms	O
related	O
to	O
endocrine	O
dysfunction	O
.	O
	
future	O
experiments	O
aim	O
to	O
evaluate	O
additional	O
hp-related	O
hormones	O
and	O
endocrine	O
circuit	O
pathology	O
following	O
diffuse	O
tbi	I-C2832047
methamphetamine	B-C0025611
,	O
3	B-C0115471
mdma	B-C0115471
and	O
3	B-C2974592
mdpv	B-C2974592
induce	B-C0205263
differential	B-C0443199
cytotoxic	B-C0596402
effects	I-C0596402
in	O
bovine	B-C0007452
brain	B-C0006104
microvessel	B-C2350570
endothelial	B-C0225336
cells	I-C0225336
designer	B-C0011684
drugs	I-C0011684
such	O
as	O
synthetic	B-C0304403
psychostimulants	I-C0304403
are	O
indicative	O
of	O
a	O
worldwide	O
problem	B-C0033213
of	O
drug	B-C0013146
abuse	I-C0013146
and	O
addiction	B-C1510472
.	O
	
in	O
addition	O
to	O
methamphetamine	B-C0025611
meth	B-C0025611
,	O
these	O
drugs	B-C0011684
include	O
3	B-C0115471
mdma	B-C0115471
and	O
commercial	B-C0680536
preparations	B-C1521827
of	O
synthetic	B-C0054876
cathinones	I-C0054876
including	O
3	B-C2974592
mdpv	B-C2974592
,	O
typically	O
referred	O
to	O
as	O
""""	O
bath	B-C0771243
salts	I-C0771243
""""	O
these	O
psychostimulants	B-C0304403
exert	O
neurotoxic	B-C0235032
effects	I-C0235032
by	O
altering	B-C1515926
monoamine	B-C0815020
systems	I-C0815020
in	O
the	O
brain	B-C0006104
.	O
	
additionally	O
,	O
meth	B-C0025611
and	O
mdma	B-C0115471
adversely	B-C0879626
affect	I-C0879626
the	O
integrity	B-C1947912
of	O
the	O
blood-brain	B-C0005854
barrier	I-C0005854
bbb	B-C0005854
there	O
are	O
no	O
current	O
reports	B-C0684224
on	O
the	O
effects	B-C1704420
of	I-C1704420
mdpv	B-C2974592
on	O
the	O
bbb	B-C0005854
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
compare	B-C1707455
the	O
effects	B-C1704420
of	I-C1704420
meth	B-C0025611
,	O
mdma	B-C0115471
and	O
mdpv	B-C2974592
on	O
bovine	B-C0007452
brain	B-C0006104
microvessel	B-C2350570
endothelial	B-C0225336
cells	I-C0225336
bbmvecs	B-C0225336
,	O
an	O
accepted	O
in	B-C1515654
vitro	I-C1515654
model	I-C1515654
of	O
the	O
bbb	B-C0005854
.	O
	
confluent	B-C0205200
bbmvec	B-C0225336
monolayers	B-C0934502
were	O
treated	B-C1522326
with	O
meth	B-C0025611
,	O
mdma	B-C0115471
and	O
mdpv	B-C2974592
0.5mm	O
for	O
24h	O
.	O
	
meth	B-C0025611
and	O
mdma	B-C0115471
increased	B-C0205217
lactate	B-C0022917
dehydrogenase	I-C0022917
release	B-C1283071
only	O
at	O
the	O
highest	B-C1522410
concentration	B-C1446561
2.5mm	O
,	O
whereas	O
mdpv	B-C2974592
induced	B-C0205263
cytotoxicity	B-C0596402
at	O
all	O
concentration	B-C1446561
s	O
.	O
	
mdma	B-C0115471
and	O
meth	B-C0025611
decreased	B-C0205216
cellular	B-C0596290
proliferation	I-C0596290
only	O
at	O
2.5mm	O
,	O
with	O
similar	O
effects	B-C1280500
observed	O
after	O
mdpv	B-C2974592
exposures	B-C0332157
starting	O
at	O
1mm	O
.	O
	
only	O
mdpv	B-C2974592
increased	B-C0205217
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
production	B-C1883254
at	O
all	O
concentrations	B-C1446561
tested	B-C0039593
whereas	O
all	O
3	O
drugs	B-C0011684
increased	B-C0205217
nitric	B-C0028128
oxide	I-C0028128
production	B-C1883254
.	O
	
morphological	B-C0936012
analysis	I-C0936012
revealed	O
different	B-C1705242
patterns	O
of	O
compound	B-C1706082
-	O
induced	B-C0205263
cell	B-C0599732
damage	I-C0599732
.	O
	
meth	B-C0025611
induced	B-C0205263
vacuole	B-C0042219
formatio	B-C1522492
n	O
at	O
1mm	O
and	O
disruption	B-C0332453
of	O
the	O
monolayer	B-C0934502
at	O
2.5mm	O
.	O
	
mdma	B-C0115471
induced	B-C0205263
disruption	B-C0332453
of	O
the	O
endothelial	B-C0225336
monolayer	B-C0934502
from	O
1mm	O
without	O
vacuolization	B-C0010840
.	O
	
on	O
the	O
other	O
hand	O
,	O
mdpv	B-C2974592
induced	B-C0205263
monolayer	B-C0934502
disruption	B-C0332453
at	O
doses	B-C0178602
0.5mm	O
without	O
vacuole	B-C0042219
formation	B-C1522492
at	O
2.5mm	O
,	O
the	O
few	O
remaining	O
cells	B-C0007634
lacked	O
endothelial	B-C0332437
morphology	I-C0332437
.	O
	
these	O
data	B-C1511726
suggest	O
that	O
even	O
though	O
these	O
synthetic	B-C0304403
psychostimulants	I-C0304403
alter	O
monoaminergic	B-C0815020
systems	I-C0815020
,	O
they	O
each	O
induce	B-C0205263
bbb	B-C0005854
toxicity	B-C0013221
by	O
different	B-C1705242
mechanisms	B-C0441712
with	O
mdpv	B-C2974592
being	O
the	O
most	O
alleviation	B-C0392756
of	O
hepatic	B-C0205054
fat	B-C0333574
accumulation	I-C0333574
by	O
betaine	B-C0005304
involves	O
reduction	B-C0392756
of	O
homocysteine	B-C0019878
via	O
up-regulation	B-C0041904
of	O
betaine-homocysteine	B-C0053518
methyltransferase	I-C0053518
bhmt	B-C0053518
we	O
investigated	B-C1292732
the	O
anti-lipogenic	B-C0205245
effect	I-C0205245
of	O
betaine	B-C0005304
in	O
rats	B-C0086893
fed	O
methionine	B-C0025646
and	O
choline	B-C0008405
-	O
deficient	B-C0332268
diet	B-C0012155
mcd	B-C0012155
.	O
	
intake	O
of	O
mcd	B-C0012155
for	O
3	O
wk	O
resulted	O
in	O
a	O
significant	B-C0750502
accumulation	B-C0333574
of	O
hepatic	B-C0205054
lipids	B-C0023779
,	O
which	O
was	O
prevented	B-C2700409
by	O
betaine	B-C0005304
supplementation	B-C0242297
in	O
drinking	B-C0599638
water	I-C0599638
1%	O
.	O
	
phosphorylation	B-C1158886
of	O
amp-activated	B-C2350345
protein	I-C2350345
kinase	I-C2350345
ampk	B-C2350345
,	O
acetyl-coa	B-C0001022
carboxylase	I-C0001022
acc	B-C0001022
,	O
sterol	B-C0537474
regulatory	I-C0537474
element-binding	I-C0537474
protein	I-C0537474
1c	I-C0537474
srebp-1c	B-C0537474
,	O
and	O
liver	B-C1431123
kinase	I-C1431123
b1	I-C1431123
lkb1	B-C1431123
was	O
inhibited	B-C0311403
by	O
mcd	B-C0012155
intake	B-C1512806
,	O
and	O
these	O
changes	O
were	O
all	O
inhibited	B-C0311403
by	O
betaine	B-C0005304
feeding	B-C3714845
.	O
	
meanwhile	O
,	O
betaine	B-C0005304
supplementation	B-C0242297
reversed	B-C1555029
the	O
reduction	B-C0392756
of	O
methionine	B-C1325080
and	I-C1325080
s-adenosylmethionine	I-C1325080
sam	B-C1325080
,	O
and	O
the	O
elevation	B-C3163633
of	O
homocysteine	B-C2242817
levels	I-C2242817
in	O
the	O
liver	B-C0023884
,	O
which	O
could	O
be	O
attributable	O
to	O
the	O
induction	B-C0014431
of	O
betaine-homocysteine	B-C0053518
methyltransfease	I-C0053518
bhmt	B-C0053518
and	O
methionine	B-C0025647
adenosyltransferase	I-C0025647
mat	B-C0025647
.	O
	
different	B-C1705242
cell	B-C0007634
lines	I-C0007634
were	O
used	O
to	O
clarify	O
the	O
role	O
of	O
homocysteine	B-C0019878
on	O
activation	B-C0014429
of	O
the	O
ampk	B-C2350345
pathway	B-C0598390
.	O
	
homocysteine	B-C0019878
treatment	B-C1522326
decreased	B-C0205216
pampk	B-C2350345
,	O
pacc	B-C0001022
,	O
psrebp-1c	B-C0537474
and	O
plkb1	B-C1431123
in	O
hepg2	B-C2717940
cells	I-C2717940
.	O
	
metformin	B-C0025598
-	O
induced	B-C0205263
activation	B-C0014429
of	O
ampk	B-C2350345
was	O
also	O
inhibited	B-C0311403
by	O
homocysteine	B-C0019878
.	O
	
treatment	B-C1522326
with	O
hydroxylamine	B-C0020362
,	O
a	O
cystathionine	B-C0010641
β-synthase	I-C0010641
inhibitor	B-C0014432
,	O
resulted	O
in	O
a	O
reduction	B-C0392756
of	O
pampk	B-C2350345
,	O
pacc	B-C0001022
and	O
psrebp-1c	B-C0537474
,	O
accompanied	O
by	O
an	O
elevation	B-C3163633
of	O
intracellular	B-C0178719
homocysteine	B-C0019878
.	O
	
betaine	B-C0005304
treatment	B-C0087111
prevented	B-C2700409
the	O
homocysteine	B-C0019878
-	O
induced	B-C0205263
reduction	B-C0392756
of	O
pampk	B-C2350345
,	O
pacc	B-C0001022
,	O
psrebp-1c	B-C0537474
and	O
plkb1	B-C1431123
in	O
h4iie	B-C0007634
cells	I-C0007634
,	O
but	O
not	O
in	O
hepg2	B-C2717940
cells	I-C2717940
.	O
	
also	O
the	O
elevation	B-C3163633
of	O
cellular	O
homocysteine	B-C0019878
and	O
inhibition	B-C3463820
of	O
protein	B-C1171362
expression	I-C1171362
of	O
bhmt	B-C0053518
were	O
prevented	B-C2700409
by	O
betaine	B-C0005304
only	O
in	O
h4iie	B-C0007634
cells	I-C0007634
which	O
express	B-C1171362
bhmt	B-C0053518
.	O
	
the	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
betaine	B-C0005304
against	O
hepatic	B-C0205054
lipid	B-C0023779
accumulation	B-C0333574
may	O
be	O
attributed	B-C0449234
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
depletion	B-C0333668
of	O
homocysteine	B-C0019878
via	O
up-regulation	B-C0041904
of	O
bhmt	B-C0053518
in	O
dual-color	B-C0026018
sted	I-C0026018
microscopy	I-C0026018
reveals	O
a	O
sandwich	B-C0678594
structure	I-C0678594
of	O
bassoon	B-C1454967
and	O
piccolo	B-C1452991
in	O
active	B-C3541837
zones	I-C3541837
of	O
adult	B-C0001675
and	O
aged	B-C0001779
mice	B-C0025929
presynaptic	B-C3541837
active	I-C3541837
zones	I-C3541837
play	O
a	O
pivotal	O
role	O
as	O
synaptic	B-C0039065
vesicle	I-C0039065
release	B-C0005898
sites	I-C0005898
for	O
synaptic	B-C0027793
transmission	I-C0027793
,	O
but	O
the	O
molecular	B-C1254362
architecture	I-C1254362
of	O
active	B-C3541837
zones	I-C3541837
in	O
mammalian	B-C0024660
neuromuscular	B-C0027869
junctions	I-C0027869
nmjs	B-C0027869
at	O
sub-diffraction	B-C2699488
limited	I-C2699488
resolution	I-C2699488
remains	O
unknown	O
.	O
	
bassoon	B-C1454967
and	O
piccolo	B-C1452991
are	O
active	B-C3541837
zone	I-C3541837
specific	O
cytosolic	B-C1383501
proteins	B-C0033684
essential	O
for	O
active	B-C3896009
zone	I-C3896009
assembly	I-C3896009
in	O
nmjs	B-C0027869
,	O
ribbon	B-C1179874
synapses	I-C1179874
,	O
and	O
brain	B-C0006104
synapses	B-C0039062
.	O
	
these	O
proteins	B-C0033684
are	O
thought	O
to	O
colocalize	B-C0392752
and	O
share	O
some	O
functions	O
at	O
active	B-C3541837
zones	I-C3541837
.	O
	
here	O
,	O
we	O
report	O
an	O
unexpected	O
finding	O
of	O
non-overlapping	B-C0597704
localization	I-C0597704
of	O
these	O
two	O
proteins	B-C0033684
in	O
mouse	B-C0025929
nmjs	B-C0027869
revealed	O
using	O
dual-color	B-C1254365
stimulated	I-C1254365
emission	I-C1254365
depletion	I-C1254365
sted	B-C1254365
super	B-C0026018
resolution	I-C0026018
microscopy	I-C0026018
.	O
	
piccolo	B-C1452991
puncta	B-C0243095
sandwiched	O
bassoon	B-C1454967
puncta	B-C0243095
and	O
aligned	B-C1706765
in	O
a	O
piccolo	B-C1452991
-	O
bassoon	B-C1454967
-	O
piccolo	B-C1452991
structure	B-C0678594
in	O
adult	B-C0001675
nmjs	B-C0027869
.	O
	
p/q-type	B-C0814022
voltage-gated	I-C0814022
calcium	I-C0814022
channel	I-C0814022
vgcc	B-C0814022
puncta	B-C0243095
colocalized	B-C0392752
with	O
bassoon	B-C1454967
puncta	B-C0243095
.	O
	
the	O
p/q-type	B-C0814022
vgcc	I-C0814022
and	O
bassoon	B-C1454967
protein	B-C0428479
levels	I-C0428479
decreased	B-C0205216
significantly	O
in	O
nmjs	B-C0027869
from	O
aged	B-C0001779
mouse	B-C0025929
.	O
	
in	O
contrast	O
,	O
the	O
piccolo	B-C1452991
levels	B-C0428479
in	O
nmjs	B-C0027869
from	O
aged	B-C0001779
mice	B-C0025929
were	O
comparable	O
to	O
levels	B-C0428479
in	O
adult	B-C0001675
mice	B-C0025929
.	O
	
this	O
study	O
revealed	O
the	O
molecular	B-C1254362
architecture	I-C1254362
of	O
active	B-C3541837
zones	I-C3541837
in	O
mouse	B-C0025929
nmjs	B-C0027869
at	O
sub-diffraction	B-C2699488
limited	I-C2699488
resolution	I-C2699488
,	O
and	O
described	O
the	O
selective	B-C0007613
degeneration	I-C0007613
mechanism	I-C0007613
of	O
active	B-C3541837
zone	I-C3541837
proteins	B-C0033684
in	O
nmjs	B-C0027869
from	O
aged	B-C0001779
mice	B-C0025929
.	O
	
interestingly	O
,	O
the	O
localization	B-C0597704
pattern	I-C0597704
of	O
active	B-C3541837
zone	I-C3541837
proteins	B-C0033684
described	O
herein	O
is	O
similar	O
to	O
active	B-C3541837
zone	I-C3541837
structures	B-C0678594
described	O
using	O
electron	B-C2350255
microscope	I-C2350255
tomography	I-C2350255
.	O
	
molecular	B-C1521991
serum	B-C0229671
signature	B-C0005516
of	O
treatment	B-C2063866
resistant	I-C2063866
depression	I-C2063866
a	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	B-C1269683
depressive	I-C1269683
disorder	I-C1269683
mdd	B-C1269683
do	O
not	O
respond	O
to	O
multiple	B-C0439064
trials	B-C0008976
of	O
anti-depressants	B-C0003289
,	O
develop	O
a	O
chronic	B-C0205191
course	B-C0242656
of	I-C0242656
disease	I-C0242656
and	O
become	O
treatment	B-C0087111
resistant	B-C1514892
.	O
	
most	O
of	O
the	O
studies	O
investigating	O
molecular	B-C1521991
changes	B-C0392747
in	O
treatment-resistant	B-C2063866
depression	I-C2063866
trd	B-C2063866
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	B-C0017337
.	O
	
consequently	O
,	O
biomarkers	B-C0005516
associated	O
with	O
trd	B-C2063866
are	O
still	O
lacking	O
.	O
	
this	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high-throughput	B-C0872252
proteomic	I-C0872252
platforms	I-C0872252
to	O
identify	O
peripheral	B-C0205100
biomarkers	B-C0005516
of	O
trd	B-C2063866
defined	O
by	O
two	O
staging	B-C0449394
models	I-C0449394
,	O
the	O
thase	B-C0449394
and	I-C0449394
rush	I-C0449394
staging	I-C0449394
model	I-C0449394
trm	B-C0449394
and	O
the	O
maudsley	B-C0449394
staging	I-C0449394
model	I-C0449394
msm	B-C0449394
.	O
	
serum	B-C0229671
collected	O
from	O
an	O
inpatient	B-C0021562
cohort	O
of	O
65	O
individuals	B-C0027361
suffering	O
from	O
mdd	B-C1269683
was	O
analysed	O
using	O
two	O
different	O
mass	B-C0037813
spectrometric-based	I-C0037813
platforms	I-C0037813
,	O
label-free	B-C0872318
liquid	I-C0872318
chromatography	I-C0872318
mass	I-C0872318
spectrometry	I-C0872318
lc-ms	B-C0872318
and	O
selective	B-C2826902
reaction	I-C2826902
monitoring	I-C2826902
srm	B-C2826902
,	O
as	O
well	O
as	O
a	O
multiplex	B-C0020980
bead	I-C0020980
based	I-C0020980
assay	I-C0020980
.	O
	
in	O
the	O
lc-ms	B-C0872318
analysis	I-C0872318
,	O
proteins	B-C0033684
involved	O
in	O
the	O
acute	B-C0001349
phase	I-C0001349
response	I-C0001349
and	O
complement	B-C0009528
activation	I-C0009528
and	O
coagulation	B-C1328723
were	O
significantly	O
different	O
between	O
the	O
staging	B-C0449394
groups	I-C0449394
in	O
both	O
models	B-C0449394
.	O
	
in	O
the	O
multiplex	B-C0020980
bead-based	I-C0020980
assay	I-C0020980
analysis	O
tnf-α	B-C1168005
levels	I-C1168005
log	B-C0023956
=	O
-4	O
,	O
p	O
=	O
0.045	O
were	O
significantly	B-C0237881
different	B-C1705242
in	O
the	O
trm	B-C0449394
comparison	B-C1707455
.	O
	
using	O
srm	B-C2826902
,	O
significant	B-C0237881
changes	B-C0392747
of	O
three	O
apolipoproteins	B-C0085201
a-i	I-C0085201
β	O
=	O
0.029	O
,	O
p	O
=	O
0.035	O
,	O
m	B-C1438565
β	O
=	O
-0	O
,	O
p	O
=	O
0.009	O
and	O
f	B-C0052208
β	O
=	O
-0	O
,	O
p	O
=	O
0.024	O
were	O
associated	O
with	O
the	O
trm	B-C0449394
but	O
not	O
the	O
msm	B-C0449394
.	O
	
overall	O
,	O
our	O
findings	B-C0243095
suggest	O
that	O
proteins	B-C0033684
,	O
which	O
are	O
involved	O
in	O
immune	B-C1155000
and	O
complement	B-C0009528
activation	I-C0009528
,	O
may	O
represent	O
potential	O
biomarkers	B-C0005516
that	O
could	O
be	O
used	O
by	O
clinicians	B-C0871685
to	O
identify	O
high-risk	B-C0332167
patients	B-C0030705
.	O
	
nevertheless	O
,	O
given	O
that	O
the	O
molecular	B-C1521991
changes	B-C0392747
between	O
the	O
staging	B-C0449394
groups	I-C0449394
were	O
subtle	O
,	O
the	O
results	O
need	O
to	O
be	O
interpreted	B-C1285553
benchmark	O
study	B-C2603343
on	O
fine-mode	B-C0001712
aerosol	I-C0001712
in	O
a	O
big	B-C0814837
urban	I-C0814837
area	I-C0814837
and	O
relevant	B-C0178602
doses	I-C0178602
deposited	B-C0333562
in	O
the	O
human	B-C0086418
respiratory	B-C0282335
tract	I-C0282335
it	O
is	O
well-known	O
that	O
the	O
health	B-C0018684
effects	B-C1280500
of	O
pm	B-C1510837
increase	O
as	O
particle	B-C0030608
size	I-C0030608
decreases	O
particularly	O
,	O
great	O
concern	O
has	O
risen	O
on	O
the	O
role	O
of	O
ultrafine	B-C0597177
particles	I-C0597177
ufps	B-C0597177
.	O
	
starting	O
from	O
the	O
knowledge	O
that	O
the	O
main	O
fraction	B-C1264633
of	I-C1264633
atmospheric	B-C0004178
aerosol	B-C0001712
in	O
rome	B-C0035831
is	O
characterized	O
by	O
significant	O
levels	B-C0441889
of	O
pm2.5	B-C1510837
almost	O
75%	O
of	O
pm10	B-C1510837
fraction	O
is	O
pm2.5	B-C1510837
,	O
the	O
paper	O
is	O
focused	O
on	O
submicron	B-C0597177
particles	I-C0597177
in	O
such	O
great	B-C0814837
urban	I-C0814837
area	I-C0814837
.	O
	
the	O
daytime	B-C0332169
/	O
nighttime	B-C3844540
,	O
work-	B-C0680192
/	O
weekdays	B-C0680189
and	O
cold	B-C0009264
/	O
hot	B-C2350229
seasonal	B-C0036497
trends	I-C0036497
of	O
submicron	B-C0597177
particles	I-C0597177
will	O
be	O
investigated	O
and	O
discussed	O
along	O
with	O
nox	B-C0028167
and	O
total	O
pah	B-C0032458
drifts	O
demonstrating	O
the	O
primary	O
origin	O
of	O
ufps	B-C0597177
from	O
combustion	B-C1522240
processes	I-C1522240
.	O
	
furthermore	O
,	O
moving	O
from	O
these	O
data	O
,	O
the	O
total	O
dose	B-C0178602
of	O
submicron	B-C0597177
particles	I-C0597177
deposited	B-C0333562
in	O
the	O
respiratory	B-C0035237
system	I-C0035237
i.e	O
,	O
head	B-C0018670
,	O
tracheobronchial	B-C0458580
and	O
alveolar	B-C1440080
regions	I-C1440080
in	O
different	O
lung	B-C0225752
lobes	I-C0225752
has	O
been	O
estimated	O
.	O
	
dosimeter	B-C0180488
estimates	B-C0750572
were	O
performed	O
with	O
the	O
multiple-path	B-C3161035
particle	I-C3161035
dosimetry	I-C3161035
model	I-C3161035
mppd	B-C3161035
v.2	I-C3161035
.	O
	
the	O
paper	O
discusses	O
the	O
aerosol	B-C0001712
doses	B-C0178602
deposited	B-C0333562
in	O
the	O
respiratory	B-C0035237
system	I-C0035237
of	O
individuals	B-C0237401
exposed	B-C0332157
in	O
proximity	O
of	O
traffic	B-C3840880
.	O
	
during	O
traffic	B-C3840880
peak	O
hours	B-C0439227
,	O
about	O
6.6	O
10	O
particles	B-C0597177
are	O
deposited	B-C0333562
into	O
the	O
respiratory	B-C0035237
system	I-C0035237
.	O
	
such	O
dose	B-C0178602
is	O
almost	O
entirely	O
made	O
of	O
ufps	B-C0597177
.	O
	
according	O
to	O
the	O
greater	O
dose	B-C0178602
estimated	B-C0750572
,	O
right	B-C0446959
lung	I-C0446959
lobes	I-C0446959
are	O
expected	O
to	O
be	O
more	O
susceptible	B-C0231204
to	O
respiratory	B-C0521346
pathologies	B-C0677042
than	O
left	B-C0446960
lobes	I-C0446960
.	O
	
international	B-C0162791
liver	I-C0162791
transplant	I-C0162791
society	I-C0162791
practice	I-C0162791
guidelines	I-C0162791
diagnosis	B-C0011900
and	O
management	B-C0376636
of	O
hepatopulmonary	B-C0600452
syndrome	I-C0600452
and	O
portopulmonary	B-C1868851
hypertension	I-C1868851
two	O
distinct	O
pulmonary	B-C0854416
vascular	I-C0854416
disorders	I-C0854416
,	O
hepatopulmonary	B-C0600452
syndrome	I-C0600452
hps	B-C0600452
and	O
portopulmonary	B-C1868851
hypertension	I-C1868851
poph	B-C1868851
may	O
occur	O
as	O
a	O
consequence	B-C0686907
of	I-C0686907
hepatic	B-C0736268
parenchymal	I-C0736268
or	O
vascular	B-C0241657
abnormalities	I-C0241657
.	O
	
hps	B-C0600452
and	O
poph	B-C1868851
have	O
major	O
clinical	B-C0205210
implications	B-C0243095
for	O
liver	B-C0023911
transplantation	I-C0023911
.	O
	
a	O
european	B-C0162458
respiratory	I-C0162458
society	I-C0162458
task	I-C0162458
force	I-C0162458
on	O
pulmonary-hepatic	B-C0012634
disorders	I-C0012634
convened	O
in	O
2002	O
to	O
standardize	O
the	O
diagnosis	B-C0011900
and	O
guide	B-C0162791
management	I-C0162791
of	O
these	O
disorders	B-C0012634
.	O
	
these	O
international	B-C0162791
liver	I-C0162791
transplant	I-C0162791
society	I-C0162791
diagnostic	I-C0162791
and	I-C0162791
management	I-C0162791
guidelines	I-C0162791
are	O
based	O
on	O
that	O
task	B-C0162458
force	I-C0162458
consensus	O
and	O
should	O
continue	O
to	O
evolve	O
as	O
clinical	B-C0205210
experience	O
dictates	O
.	O
	
based	O
on	O
a	O
review	O
of	O
over	O
1000	O
published	O
hps	B-C0600452
and	O
poph	B-C1868851
articles	O
identified	O
via	O
a	O
medline	B-C0242356
search	I-C0242356
1985-2015	O
,	O
clinical	B-C0282451
guidelines	I-C0282451
were	O
based	O
on	O
,	O
selected	B-C0700287
single	I-C0700287
care	I-C0700287
reports	I-C0700287
,	O
small	B-C0205549
series	I-C0205549
,	O
registries	B-C0034975
,	O
databases	B-C0242356
,	O
and	O
expert	B-C0600219
opinion	I-C0600219
.	O
	
the	O
paucity	O
of	O
randomized	B-C0206035
,	O
controlled	I-C0206035
trials	I-C0206035
in	O
either	O
of	O
these	O
disorders	B-C0012634
was	O
noted	O
.	O
	
guidelines	B-C0282451
are	O
presented	O
in	O
5	O
parts	O
i	O
.	O
	
definitions	B-C0679227
/	O
diagnostic	B-C0679228
criteria	I-C0679228
ii	O
.	O
	
hepatopulmonary	B-C0600452
syndrome	I-C0600452
iii	O
.	O
	
portopulmonary	B-C1868851
hypertension	I-C1868851
iv	O
.	O
	
implications	B-C0243095
for	O
liver	B-C0023911
transplantation	I-C0023911
and	O
v	O
.	O
	
suggestions	B-C1705535
for	O
future	O
clinical	B-C0008972
research	I-C0008972
.	O
	
uveitis	B-C0042164
in	O
children	B-C0008059
the	O
review	O
provides	O
updates	O
on	O
novel	B-C0205314
risk	B-C1519104
markers	I-C1519104
for	O
the	O
development	B-C1527148
of	O
pediatric	B-C1521725
inflammatory	B-C0042164
uveitis	I-C0042164
and	O
a	O
severe	B-C0242656
disease	I-C0242656
course	I-C0242656
,	O
on	O
treatment	B-C0087111
of	O
refractory	B-C1514815
disease	I-C1514815
,	O
and	O
on	O
the	O
measurement	B-C0242485
of	O
visual	B-C1274040
outcomes	I-C1274040
.	O
	
there	O
are	O
several	O
new	O
genetic	B-C0017393
markers	I-C0017393
,	O
biomarkers	B-C0005516
,	O
and	O
clinical	B-C0205210
factors	B-C1521761
that	O
may	O
influence	O
a	O
child's	B-C0008059
uveitis	B-C0042164
disease	B-C0242656
course	I-C0242656
.	O
	
it	O
is	O
important	O
to	O
identify	O
children	B-C0008059
at	O
risk	B-C0035647
for	O
poor	B-C1274040
visual	I-C1274040
outcomes	I-C1274040
and	O
who	O
are	O
refractory	B-C0332325
to	O
traditional	B-C3650840
therapy	I-C3650840
.	O
	
racial	B-C0243095
disparities	I-C0243095
have	O
recently	O
been	O
reported	B-C0684224
.	O
	
we	O
describe	O
agents	B-C0450442
of	O
potential	B-C0814225
benefit	I-C0814225
.	O
	
in	O
addition	O
,	O
we	O
discuss	O
the	O
importance	O
of	O
patient	B-C2987124
reported	I-C2987124
outcomes	I-C2987124
in	O
this	O
population	B-C0030705
.	O
	
uveitis	B-C0042164
can	O
lead	O
to	O
vision-threatening	B-C0009566
complications	I-C0009566
.	O
	
timely	B-C0087111
and	I-C0087111
aggressive	I-C0087111
treatment	I-C0087111
of	O
children	B-C0008059
identified	O
to	O
be	O
at	O
risk	B-C0035647
for	O
a	O
severe	B-C0242656
uveitis	I-C0242656
course	I-C0242656
may	O
lead	O
to	O
improved	B-C1274040
outcomes	I-C1274040
.	O
	
utility	B-C0457083
of	O
a	O
mhealth	B-C3658310
app	I-C3658310
for	O
self-management	B-C0086969
and	O
education	B-C0013621
of	O
cardiac	B-C0018799
diseases	I-C0018799
in	O
spanish	B-C0037747
urban	B-C0017446
and	I-C0017446
rural	I-C0017446
areas	I-C0017446
analyze	B-C0936012
the	O
utility	B-C0457083
of	O
a	O
mobile	B-C3658310
health	I-C3658310
app	I-C3658310
named	O
heartkeeper	B-C3827995
in	O
several	B-C1257890
groups	I-C1257890
of	I-C1257890
population	I-C1257890
and	O
obtain	B-C1301820
conclusions	B-C1707703
to	O
be	O
applied	B-C4048755
to	O
other	B-C3658310
similar	I-C3658310
apps	I-C3658310
.	O
	
a	O
questionnaire	B-C0034394
has	O
been	O
designed	B-C1707689
to	O
evaluate	O
the	O
usage	B-C0457083
and	O
utility	B-C0457083
of	O
the	O
heartkeeper	B-C3658310
app	I-C3658310
.	O
	
the	O
questionnaire	B-C0034394
information	B-C1533716
was	O
collected	B-C1516698
by	O
collaborating	O
cardiologists	B-C0175906
from	O
32	O
patients	B-C0030705
before	B-C0150091
and	I-C0150091
after	I-C0150091
they	O
used	B-C0457083
the	O
app	B-C3658310
.	O
	
patients	B-C0030705
were	O
randomly	B-C0150105
selected	I-C0150105
with	O
established	O
quotas	B-C2347740
within	O
interest	B-C1705429
groups	I-C1705429
,	O
so	O
that	O
men	B-C0025266
and	O
women	B-C0043210
,	O
patients	B-C0030705
older	B-C0001792
or	O
younger	B-C0332239
than	O
60	O
years	B-C0439234
old	I-C0439234
and	O
patients	B-C0030705
living	O
in	O
urban	B-C0017446
or	I-C0017446
rural	I-C0017446
areas	I-C0017446
were	O
equally	B-C1882932
represented	I-C1882932
.	O
	
using	O
the	O
appropriate	O
statistical	B-C1710191
techniques	I-C1710191
we	O
see	O
that	O
the	O
heartkeeper	B-C3658310
app	I-C3658310
was	O
useful	O
for	O
patients	B-C0030705
as	O
they	O
qualify	B-C1548635
with	O
70	O
points	O
out	O
of	O
100	O
the	O
overall	B-C3272903
opinion	I-C3272903
of	O
the	O
app	B-C3658310
,	O
it	O
helps	O
them	O
remember	B-C0034770
more	O
easily	O
taking	O
their	O
pills	B-C0994475
with	O
a	O
mean	O
improvement	B-C2986411
of	O
20.94	O
points	O
p	O
<	O
0.001	O
and	O
they	O
perceive	O
a	O
global	B-C2986411
improvement	I-C2986411
of	O
their	O
health	O
8.28	O
points	O
,	O
p	O
<	O
0.001	O
.	O
	
we	O
also	O
observe	B-C1441672
that	O
these	O
improvements	B-C2986411
do	O
not	O
depend	O
,	O
in	O
general	O
,	O
on	O
the	O
area	B-C0017446
urban	I-C0017446
or	I-C0017446
rural	I-C0017446
where	O
the	O
patient	B-C0030705
comes	O
from	O
or	O
on	O
their	O
sex	B-C0079399
.	O
	
although	O
older	B-C1518563
patients	I-C1518563
needed	B-C0027552
more	O
help	O
to	O
use	B-C0457083
the	O
app	B-C3658310
and	O
used	B-C0457083
it	O
slightly	O
less	B-C0205213
frequently	I-C0205213
,	O
the	O
improvements	B-C2986411
on	O
several	B-C0079809
measures	I-C0079809
considered	O
,	O
such	O
as	O
remembering	B-C0034770
taking	O
pills	B-C0994475
,	O
breathing	B-C0497337
problems	I-C0497337
or	O
trouble	B-C0858854
developing	I-C0858854
activities	I-C0858854
,	O
depend	O
significantly	O
p	O
<	O
0.05	O
on	O
age	O
with	O
older	B-C1518563
patients	I-C1518563
reporting	O
higher	B-C0205250
improvements	B-C2986411
than	O
younger	B-C0238598
ones	I-C0238598
.	O
	
the	O
results	B-C1274040
obtained	O
with	O
the	O
sample	B-C0079809
of	O
patients	B-C0030705
considered	O
in	O
this	O
research	B-C0035168
prove	O
the	O
utility	B-C0457083
of	O
the	O
heartkeeper	B-C3658310
app	I-C3658310
.	O
	
this	O
utility	B-C0457083
is	O
similar	O
in	O
urban	B-C0017446
and	I-C0017446
rural	I-C0017446
areas	I-C0017446
and	O
for	O
patients	B-C0030705
of	O
both	B-C0079399
sexes	I-C0079399
and	O
,	O
to	B-C1555600
some	I-C1555600
extent	I-C1555600
,	O
depends	O
on	O
the	O
age	B-C0027362
of	O
the	O
patient	B-C0030705
with	O
older	B-C1518563
patients	I-C1518563
reporting	O
slightly	B-C0205213
lower	I-C0205213
frequency	I-C0205213
of	O
use	B-C0457083
but	O
higher	B-C0205250
health	B-C2986411
improvements	I-C2986411
than	O
younger	B-C0238598
ones	I-C0238598
.	O
	
a	O
holistic	B-C0683249
approach	I-C0683249
to	O
age	B-C0001779
estimation	B-C0680844
in	O
refugee	B-C0034961
children	B-C0008059
many	O
refugee	B-C0034961
children	B-C0008059
arriving	O
in	O
australia	B-C0004340
have	O
an	O
inaccurately	B-C0443236
documented	B-C1301725
date	B-C2348576
of	I-C2348576
birth	I-C2348576
dob	B-C2348576
.	O
	
a	O
medical	B-C0582103
assessment	I-C0582103
of	O
a	O
child's	B-C0001779
age	I-C0001779
is	O
often	O
requested	O
when	O
there	O
is	O
a	O
concern	B-C2699424
that	O
their	O
documented	B-C1301725
dob	B-C2348576
is	O
incorrect	B-C3827420
.	O
	
this	O
study's	O
aim	O
was	O
to	O
assess	B-C0184514
the	O
accuracy	B-C0443131
a	O
holistic	B-C0037589
age	I-C0037589
assessment	I-C0037589
tool	I-C0037589
aat	B-C0037589
in	O
estimating	B-C0680844
the	O
age	B-C0001779
of	O
refugee	B-C0034961
children	B-C0008059
newly	O
settled	O
in	O
australia	B-C0004340
.	O
	
a	O
holistic	B-C0037589
aat	I-C0037589
that	O
combines	O
medical	B-C0679624
and	O
non-medical	B-C1254370
approaches	I-C1254370
was	O
used	O
to	O
estimate	B-C0680844
the	O
ages	B-C0001779
of	O
60	O
refugee	B-C0034961
children	B-C0008059
with	O
a	O
known	O
dob	B-C2348576
.	O
	
the	O
tool	B-C0037589
used	O
four	O
components	B-C1705248
to	O
assess	B-C0184514
age	B-C0001779
an	O
oral	B-C0442027
narrative	B-C1135957
,	O
developmental	B-C0458003
assessment	B-C0220825
,	O
anthropometric	B-C2598146
measures	I-C2598146
and	O
pubertal	B-C1627769
assessment	B-C0220825
.	O
	
assessors	B-C0401803
were	O
blinded	B-C0150108
to	O
the	O
true	B-C0205238
age	B-C0001779
of	O
the	O
child	B-C0008059
.	O
	
correlation	B-C0392762
coefficients	I-C0392762
for	O
the	O
actual	B-C0237400
and	O
estimated	B-C0680844
age	B-C0001779
were	O
calculated	B-C1441506
for	O
the	O
tool	B-C0037589
overall	B-C1705248
and	I-C1705248
individual	I-C1705248
components	I-C1705248
.	O
	
the	O
correlation	B-C0392762
coefficient	I-C0392762
between	O
the	O
actual	B-C0237400
and	O
estimated	B-C0680844
age	B-C0001779
from	O
the	O
aat	B-C0037589
was	O
very	O
strong	O
at	O
0.9802	O
boys	B-C0870221
0.9748	O
,	O
girls	B-C0870604
0.9876	O
.	O
	
the	O
oral	B-C0442027
narrative	B-C1135957
component	B-C1705248
of	O
the	O
tool	B-C0037589
performed	O
best	O
r	O
=	O
0.9603	O
.	O
	
overall	O
,	O
86.7	O
of	O
age	B-C0001779
estimates	B-C0680844
were	O
within	O
1	O
year	B-C0439234
of	O
the	O
true	B-C0205238
age	B-C0001779
.	O
	
the	O
range	O
of	O
differences	O
was	O
-1	O
to	O
3.92	O
years	B-C0439234
with	O
a	O
standard	B-C0871420
deviation	I-C0871420
of	O
0.77	O
years	B-C0439234
9.24	O
months	B-C0439231
.	O
	
the	O
aat	B-C0037589
is	O
a	O
holistic	B-C1254370
,	O
simple	B-C0205352
and	O
safe	B-C0814103
instrument	O
that	O
can	O
be	O
used	O
to	O
estimate	B-C0680844
age	B-C0001779
in	O
refugee	B-C0034961
children	B-C0008059
with	O
results	O
comparable	O
with	O
radiological	B-C0039431
methods	I-C0039431
caged-opossum	B-C0037589
motif	B-C0936012
enrichment	I-C0936012
analysis	I-C0936012
from	O
cage	B-C0150098
-derived	O
tsss	B-C0949639
with	O
the	O
emergence	O
of	O
large-scale	B-C0150098
cap	I-C0150098
analysis	I-C0150098
of	I-C0150098
gene	I-C0150098
expression	I-C0150098
cage	I-C0150098
datasets	I-C0150098
from	O
individual	B-C0022877
labs	I-C0022877
and	O
the	O
fantom	B-C1709701
consortium	I-C1709701
,	O
one	O
can	O
now	O
analyze	O
the	O
cis-regulatory	B-C0034987
regions	I-C0034987
associated	O
with	O
gene	B-C0040649
transcription	I-C0040649
at	O
an	O
unprecedented	B-C0205556
level	I-C0205556
of	I-C0205556
refinement	I-C0205556
.	O
	
by	O
coupling	O
transcription	B-C3158211
factor	I-C3158211
binding	I-C3158211
site	I-C3158211
tfbs	B-C3158211
enrichment	B-C0936012
analysis	I-C0936012
with	O
cage	B-C0150098
-derived	O
genomic	B-C0598659
regions	I-C0598659
,	O
caged-opossum	B-C0037589
can	O
identify	B-C0205396
tfs	B-C0040648
that	O
act	O
as	O
key	B-C1706198
regulators	B-C1704735
of	O
genes	B-C0017337
involved	O
in	O
specific	B-C0205369
mammalian	B-C1512977
cell	I-C1512977
and	O
tissue	B-C2713035
types	I-C2713035
.	O
	
the	O
webtool	B-C0037589
allows	O
for	O
the	O
analysis	B-C0936012
of	O
cage	B-C0150098
-derived	O
transcription	B-C0949639
start	I-C0949639
sites	I-C0949639
tsss	B-C0949639
either	O
provided	O
by	O
the	O
user	B-C1706077
or	O
selected	O
from	O
1300	O
mammalian	B-C0024660
samples	B-C0370003
from	O
the	O
fantom5	B-C1709701
project	I-C1709701
with	O
pre-computed	B-C1880157
tfbs	B-C3158211
predicted	O
with	O
jaspar	B-C0242356
tf	I-C0242356
binding	I-C0242356
profiles	I-C0242356
.	O
	
the	O
tool	B-C0242356
helps	O
power	O
insights	B-C0233820
into	O
the	O
regulation	B-C0017263
of	I-C0017263
genes	I-C0017263
through	O
the	O
study	B-C2603343
of	O
the	O
specific	B-C0205369
usage	B-C0457083
of	O
tsss	B-C0949639
within	O
specific	B-C0205369
cell	B-C0449475
types	I-C0449475
and/or	O
under	O
specific	B-C0348080
conditions	I-C0348080
.	O
	
the	O
caged-oposum	B-C0037589
web	I-C0037589
tool	I-C0037589
is	O
implemented	O
in	O
perl	B-C0037589
,	O
mysql	B-C1710218
and	O
apache	B-C0243030
and	O
is	O
available	O
at	O
http	B-C2349146
contacts	O
anthony.mathelier	B-C1705961
or	O
wyeth	B-C1705961
supplementary	B-C2936424
information	I-C2936424
supplementary	B-C2936424
data	I-C2936424
are	O
available	O
at	O
bioinformatics	B-C0282420
online	B-C0029038
.	O
	
self-assembled	B-C0872376
polymeric	B-C0032521
vectors	B-C0085104
mixtures	B-C0439962
characterization	B-C1880022
of	O
the	O
polymorphism	B-C1882417
and	O
existence	O
of	O
synergistic	B-C2986495
effects	B-C1280500
in	O
photodynamic	B-C0031740
therapy	I-C0031740
the	O
objective	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
relation	O
between	O
the	O
purity	B-C1882508
of	O
polymeric	B-C0032521
self-assemblies	B-C0872376
vectors	B-C0085104
solution	B-C0037633
and	O
their	O
photodynamic	B-C0031740
therapeutic	I-C0031740
efficiency	B-C0013682
.	O
	
for	O
this	O
,	O
several	O
amphiphilic	B-C0002671
block	B-C0596383
copolymers	I-C0596383
of	O
poly	B-C1258138
have	O
been	O
used	O
to	O
form	O
self-assemblies	B-C0872376
with	O
different	O
morphologies	B-C0332437
micelles	B-C0025938
,	O
worm-like	B-C0025938
micelles	I-C0025938
or	O
vesicles	B-C0332437
.	O
	
in	O
a	O
first	O
step	O
,	O
controlled	B-C0439962
mixtures	I-C0439962
of	O
preformed	O
micelles	B-C0025938
and	O
vesicles	B-C0332437
have	O
been	O
characterized	O
both	O
by	O
dynamic	B-C1882368
light	I-C1882368
scattering	I-C1882368
and	O
asymmetrical	B-C1135847
flow	I-C1135847
field	I-C1135847
flow	I-C1135847
fractionation	I-C1135847
asflfff	B-C1135847
.	O
	
for	O
this	O
,	O
a	O
custom-made	B-C1880202
program	B-C0037585
,	O
storms	B-C0037585
,	O
was	O
developed	O
to	O
analyze	O
dls	B-C1882368
data	B-C1511726
in	O
a	O
thorough	O
manner	O
by	O
providing	O
a	O
large	O
set	O
of	O
fitting	O
parameters	B-C0549193
.	O
	
this	O
showed	O
that	O
dls	B-C1882368
only	O
sensed	O
the	O
larger	B-C0549177
vesicles	B-C0332437
when	O
the	O
micelles	B-C0025938
/	O
vesicles	B-C0332437
ratio	B-C0456603
was	O
80/20	O
w/w	O
.	O
	
on	O
the	O
other	O
hand	O
,	O
asflfff	B-C1135847
allowed	O
clear	O
detection	B-C0442726
of	O
the	O
presence	O
of	O
micelles	B-C0025938
when	O
this	O
same	O
ratio	B-C0456603
was	O
as	O
low	O
as	O
10/90	O
.	O
	
subsequently	O
,	O
the	O
photodynamic	B-C0031740
therapy	I-C0031740
efficiency	B-C0013682
of	O
various	O
controlled	B-C0439962
mixtures	I-C0439962
was	O
assessed	O
using	O
multicellular	O
spheroids	B-C1844596
when	O
a	O
photosensitizer	B-C0162713
,	O
pheophorbide	B-C0070716
a	I-C0070716
,	O
was	O
encapsulated	B-C0205223
in	O
the	O
polymer	B-C0032521
self-assemblies	B-C0872376
.	O
	
some	O
mixtures	O
were	O
shown	O
to	O
be	O
as	O
efficient	B-C0442799
as	O
monomorphous	B-C0700329
systems	I-C0700329
.	O
	
in	O
some	O
cases	O
,	O
mixtures	B-C0439962
were	O
found	O
to	O
exhibit	O
a	O
higher	O
pdt	B-C0031740
efficiency	B-C0013682
compared	O
to	O
the	O
individual	O
nano	B-C1553036
-	O
objects	B-C0347997
,	O
revealing	O
a	O
synergistic	B-C2986495
effect	B-C1280500
for	O
the	O
efficient	O
delivery	B-C3850077
of	O
the	O
photosensitizer	B-C0162713
.	O
	
polymorphous	B-C1882417
vectors	B-C0085104
can	O
therefore	O
be	O
superior	O
in	O
therapeutic	B-C0039798
applications	I-C0039798
.	O
	
fuzheng	B-C0574031
qingjie	I-C0574031
granules	I-C0574031
inhibit	B-C3463820
growth	B-C0220844
of	O
hepatoma	B-C0677626
cells	I-C0677626
via	O
inducing	B-C0205263
mitochondria	B-C0026237
-mediated	O
apoptosis	B-C0162638
and	O
enhancing	B-C2349975
immune	B-C1817756
function	I-C1817756
fuzheng	B-C0574031
qingjie	I-C0574031
fzqj	B-C0574031
granules	I-C0574031
,	O
a	O
compound	B-C1706082
chinese	B-C0025123
medicine	I-C0025123
,	O
have	O
been	O
used	O
as	O
an	O
adjuvant	B-C0677850
therapy	I-C0677850
for	O
alimentary	B-C0017189
tract	I-C0017189
cancers	B-C0006826
.	O
	
however	O
,	O
the	O
underlying	O
anticancer	B-C0243095
mechanisms	B-C0441712
are	O
still	O
not	O
well	O
understood	O
.	O
	
in	O
the	O
present	B-C0521116
study	B-C2603343
,	O
hepg2	B-C2717940
cells	I-C2717940
were	O
treated	B-C1522326
with	O
fzqj	B-C0574031
-	O
containing	B-C2700400
serum	B-C0229671
.	O
	
cell	B-C0596290
proliferation	I-C0596290
was	O
evaluated	B-C0220825
using	O
mtt	B-C2986858
assay	I-C2986858
.	O
	
apoptosis	B-C0162638
was	O
analyzed	B-C0936012
using	O
a	O
flow	B-C0180279
cytometer	I-C0180279
.	O
	
cell	B-C3825563
ultrastructure	I-C3825563
was	O
observed	B-C1441672
under	O
a	O
transmission	B-C0262880
electron	I-C0262880
microscope	I-C0262880
.	O
	
the	O
mitochondrial	B-C1720920
membrane	I-C1720920
potential	I-C1720920
δψ	B-C1720920
was	O
examined	B-C0332128
with	O
jc-1	B-C0013343
dye	I-C0013343
.	O
	
in	O
h22	B-C1512411
tumor-bearing	I-C1512411
mice	I-C1512411
,	O
cd4	B-C0039215
t	I-C0039215
cells	I-C0039215
,	O
cd8	B-C0242629
t	I-C0242629
cells	I-C0242629
,	O
cd3	B-C1267816
t	I-C1267816
cells	I-C1267816
,	O
and	O
natural	B-C0022688
killer	I-C0022688
cells	I-C0022688
nk	B-C0022688
in	O
peripheral	B-C0229664
blood	I-C0229664
were	O
evaluated	O
cytometrically	B-C0180279
.	O
	
interleukin	B-C0021756
il	I-C0021756
and	O
tumor	B-C0041368
necrosis	I-C0041368
factor	I-C0041368
tnf	B-C0041368
levels	B-C0441889
were	O
measured	B-C0444706
using	O
radioimmunoassay	B-C0034580
the	O
mrna	B-C0035696
levels	B-C0441889
of	O
bax	B-C0812198
and	O
bcl-2	B-C0376515
were	O
examined	B-C0332128
by	O
reverse	B-C0599161
transcription-polymerase	I-C0599161
chain	I-C0599161
reaction	I-C0599161
.	O
	
the	O
protein	B-C0033684
levels	B-C0441889
of	O
bax	B-C0219474
,	O
bcl-2	B-C0210955
,	O
cytochrome	B-C0010749
c	I-C0010749
,	O
caspase	B-C0291573
3	I-C0291573
and	O
9	B-C0910167
,	O
parp	B-C0032405
,	O
and	O
cd69	B-C0108800
were	O
examined	B-C0332128
by	O
western	B-C0005863
blotting	I-C0005863
.	O
	
the	O
apoptotic	B-C1516044
cells	B-C0007634
in	O
tissues	B-C0040300
were	O
observed	B-C1441672
using	O
tunel	B-C0872284
method	I-C0872284
.	O
	
alanine	B-C0001899
transaminase	I-C0001899
alt	B-C0001899
,	O
aspartate	B-C0004002
transaminase	I-C0004002
ast	B-C0004002
,	O
blood	B-C0600137
urea	I-C0600137
nitrogen	I-C0600137
bun	B-C0600137
,	O
and	O
creatinine	B-C0010294
cre	B-C0010294
were	O
detected	B-C0442726
by	O
an	O
automatic	B-C0205554
biochemical	B-C0205474
analyzer	B-C0179038
.	O
	
the	O
results	B-C1274040
showed	O
that	O
fzqj	B-C0574031
-	O
containing	B-C2700400
serum	B-C0229671
remarkably	O
inhibited	B-C3463820
proliferation	B-C0596290
of	O
hepg2	B-C2717940
cells	I-C2717940
in	O
dose	B-C1512045
-	O
and	O
time	B-C0040223
-	O
dependent	B-C0851827
manners	O
,	O
induced	B-C0205263
hepg2	B-C2717940
cell	I-C2717940
apoptosis	B-C0162638
and	O
caused	O
a	O
decrease	B-C0547047
of	O
δψ	B-C1720920
.	O
	
analysis	B-C0936012
of	O
tumor	B-C0475358
tissue	I-C0475358
showed	O
that	O
fzqj	B-C0574031
-	O
induced	B-C0205263
apoptosis	B-C0162638
was	O
accompanied	O
by	O
downregulation	B-C0013081
of	O
bcl-2	B-C0210955
and	O
upregulation	B-C0041904
of	O
bax	B-C0219474
,	O
release	B-C1283071
of	O
cytochrome	B-C0010749
c	I-C0010749
,	O
activation	B-C0014429
of	O
caspase	B-C0291573
3	I-C0291573
and	O
9	B-C0910167
,	O
and	O
cleavage	B-C0597304
of	O
parp	B-C0032405
.	O
	
in	O
addition	O
,	O
fzqj	B-C0574031
increased	B-C0205217
the	O
percentages	B-C0439165
of	O
cd4	B-C0039215
t	I-C0039215
and	O
nk	B-C0022688
cells	I-C0022688
,	O
the	O
ratio	B-C0456603
of	O
cd4	B-C0039215
/	O
cd8	B-C0242629
t	I-C0242629
cells	I-C0242629
as	O
well	O
as	O
the	O
levels	B-C0441889
of	O
serum	B-C0229671
tnf-α	B-C0041368
.	O
	
fzqj	B-C0574031
also	O
increased	B-C0205217
cd69	B-C0108800
expression	B-C1171362
in	O
tumor	B-C0475358
tissue	I-C0475358
.	O
	
no	B-C0243095
hepatorenal	I-C0243095
toxicity	I-C0243095
was	O
observed	B-C1441672
in	O
h22	B-C1512411
tumor-bearing	I-C1512411
mice	I-C1512411
.	O
	
these	O
results	B-C1274040
indicated	B-C1444656
that	O
fzqj	B-C0574031
could	O
inhibit	B-C3463820
the	O
growth	B-C0220844
of	O
hepatoma	B-C0677626
cells	I-C0677626
via	O
regulating	O
immune	B-C1817756
function	I-C1817756
and	O
inducing	B-C0205263
mitochondria	B-C0026237
mediated	O
professional	B-C0282574
reinventions	I-C0282574
swedish	B-C1710263
psychologists	B-C0033908
,	O
1990-2010	O
since	O
the	O
early	O
20th	B-C0681748
century	I-C0681748
,	O
the	O
swedish	B-C1710263
psychology	B-C0033909
profession	I-C0033909
has	O
undergone	O
several	O
changes	B-C0392747
in	O
its	O
essential	B-C0441655
tasks	I-C0441655
,	O
epistemological	B-C0376553
foundations	I-C0376553
,	O
and	O
social	B-C0035820
roles	I-C0035820
.	O
	
these	O
changes	B-C0392747
occurred	B-C1709305
through	O
an	O
ongoing	O
"""tuning"""	O
with	O
swedish	B-C1710263
society	B-C0037455
,	O
in	O
which	O
the	O
profession	B-C0028811
strove	O
to	O
appear	O
relevant	O
to	O
society's	B-C0037455
concerns	B-C2699424
and	O
problems	B-C0033213
as	O
well	O
as	O
enroll	O
others	O
to	O
share	O
the	O
profession's	B-C0028811
goals	B-C0018017
and	O
aims	B-C1947946
.	O
	
studying	O
the	O
history	B-C0019665
of	O
the	O
profession	B-C0028811
can	O
thus	O
shed	O
light	O
on	O
the	O
changing	B-C0392747
definitions	B-C1704788
and	O
contours	B-C0876954
of	O
the	O
psychology	B-C0033909
profession	I-C0033909
itself	O
as	O
well	O
as	O
on	O
the	O
organization	B-C1300196
of	O
the	O
society	B-C0037455
in	O
which	O
it	O
acts	O
.	O
	
this	O
article	B-C1706852
examines	O
the	O
history	B-C0019665
of	O
the	O
swedish	B-C1710263
psychology	B-C0033909
profession	I-C0033909
from	O
1990	O
to	O
2010	O
,	O
through	O
an	O
analysis	B-C0936012
of	O
the	O
discussions	B-C2584313
and	O
debates	B-C0870392
taking	O
place	O
in	O
the	O
swedish	B-C1710263
psychological	B-C0162443
association's	I-C0162443
journal	I-C0162443
.	O
	
the	O
analytical	B-C1254372
framework	I-C1254372
used	O
draws	O
on	O
work	O
done	O
within	O
actor-network	B-C0683613
theory	I-C0683613
and	O
science	B-C0242481
studies	I-C0242481
.	O
	
we	O
argue	O
that	O
the	O
profession's	B-C0028811
institutional	B-C0439849
connections	I-C0439849
,	O
defining	O
tasks	B-C0441655
,	O
epistemological	B-C0376553
underpinnings	B-C1254370
,	O
and	O
social	B-C0680375
position	I-C0680375
have	O
changed	B-C0392747
in	O
major	O
ways	O
during	O
these	O
2	O
decades	B-C2981279
.	O
	
overall	O
,	O
as	O
a	O
result	O
of	O
an	O
increasingly	O
felt	O
insecurity	B-C0233497
,	O
the	O
profession	B-C0028811
has	O
turned	O
outward	O
and	O
tried	O
to	O
find	O
new	O
ways	O
to	O
legitimize	B-C1552821
itself	O
to	O
politicians	B-C0682232
,	O
the	O
media	B-C0009458
,	O
patients	B-C0030705
,	O
and	O
customers	B-C2981734
through	O
means	O
such	O
as	O
a	O
more	O
economized	B-C0013557
vocabulary	B-C0042926
and	O
novel	B-C0205314
forms	O
of	O
empirical	B-C0376367
research	I-C0376367
.	O
	
these	O
changes	B-C0392747
have	O
led	O
to	O
a	O
more	O
socialized	B-C2371613
profession	B-C0028811
,	O
now	O
more	O
closely	O
tuned	O
to	O
other	O
actors	B-C0335083
in	O
swedish	B-C1710263
society	B-C0037455
,	O
leading	O
to	O
conflicts	B-C1705242
within	O
the	O
profession	B-C0028811
over	O
whether	O
this	O
is	O
an	O
opportunity	O
to	O
better	O
control	B-C0243148
their	O
own	O
destiny	O
or	O
if	O
it	O
will	O
lead	O
to	O
a	O
loss	B-C4061233
of	I-C4061233
autonomy	I-C4061233
.	O
	
psycinfo	B-C0242356
database	I-C0242356
record	I-C0242356
personally	B-C2945764
meaningful	I-C2945764
rituals	I-C2945764
a	O
way	O
to	O
increase	B-C0442805
compassion	B-C0242270
and	O
decrease	B-C0547047
burnout	B-C0476644
among	O
hospice	B-C0085555
staff	B-C0851286
and	O
volunteers	B-C3661466
rituals	B-C2945764
can	O
increase	B-C0442805
a	O
sense	B-C0814552
of	I-C0814552
connectedness	I-C0814552
,	O
meaning	B-C0876919
,	O
and	O
support	B-C0037438
,	O
especially	O
after	O
the	O
death	B-C0011065
of	O
those	O
for	O
whom	O
we	O
care	O
.	O
	
hospice	B-C0085555
staff	B-C1547600
may	O
benefit	O
from	O
the	O
use	O
of	O
personal	B-C2945764
rituals	I-C2945764
as	O
they	O
cope	B-C0009967
with	I-C0009967
the	O
frequent	B-C0205848
deaths	I-C0205848
of	O
their	O
patients	B-C0030705
,	O
ultimately	O
aiming	O
to	O
provide	O
compassionate	B-C1947933
care	I-C1947933
while	O
minimizing	O
burnout	B-C0476644
.	O
	
this	O
study	O
investigated	O
the	O
role	O
of	O
personally	B-C2945764
meaningful	I-C2945764
rituals	I-C2945764
in	O
increasing	B-C0442805
compassion	B-C0242270
and	O
decreasing	B-C0392756
burnout	B-C0476644
among	O
hospice	B-C0085555
staff	B-C1547600
and	O
volunteers	B-C3661466
.	O
	
an	O
online	B-C0038951
survey	I-C0038951
was	O
completed	O
by	O
members	O
of	O
the	O
national	B-C4035207
hospice	I-C4035207
and	I-C4035207
palliative	I-C4035207
care	I-C4035207
organization	I-C4035207
nhpco	O
which	O
inquired	O
about	O
personal	O
ritual	O
practices	O
,	O
and	O
included	O
the	O
professional	O
quality	O
of	O
life	O
proqol	O
scale	O
to	O
measure	O
current	O
levels	O
of	O
compassion	O
satisfaction	O
,	O
burnout	O
,	O
and	O
secondary	O
traumatic	O
stress	O
.	O
	
three	O
hundred	O
ninety	O
hospice	O
staff	O
and	O
volunteers	O
from	O
across	O
38	O
states	O
completed	O
the	O
online	O
survey	O
.	O
	
the	O
majority	O
of	O
participants	O
were	O
caucasian	O
and	O
female	O
,	O
with	O
an	O
average	O
of	O
nine	O
years	O
of	O
experience	O
in	O
hospice	O
and	O
palliative	O
care	O
.	O
	
the	O
majority	O
of	O
hospice	O
staff	O
and	O
volunteers	O
used	O
personally	O
meaningful	O
rituals	O
after	O
the	O
death	O
of	O
their	O
patients	O
to	O
help	O
them	O
cope	O
71%	O
.	O
	
those	O
who	O
used	O
rituals	O
demonstrated	O
significantly	O
higher	O
compassion	O
satisfaction	O
and	O
significantly	O
lower	O
burnout	O
as	O
measured	O
by	O
the	O
proqol	O
,	O
with	O
professional	O
support	O
,	O
social	O
support	O
,	O
and	O
age	O
playing	O
significant	O
roles	O
as	O
well	O
.	O
	
rituals	O
may	O
be	O
an	O
important	O
way	O
to	O
increase	O
compassion	O
and	O
decrease	O
burnout	O
among	O
hospice	O
staff	O
and	O
volunteers	O
.	O
	
organizations	O
may	O
benefit	O
from	O
providing	O
training	O
and	O
support	O
for	O
personalized	O
rituals	O
among	O
team	O
members	O
,	O
especially	O
new	O
staff	O
who	O
may	O
be	O
at	O
greater	O
risk	O
for	O
burnout	B-C0476644
activation	B-C1879547
of	O
the	O
orphan	B-C2002138
receptor	I-C2002138
gpr55	I-C2002138
by	O
lysophosphatidylinositol	B-C0065391
promotes	B-C0033414
metastasis	B-C0027627
in	O
triple-negative	B-C3539878
breast	I-C3539878
cancer	I-C3539878
the	O
orphan	B-C0682972
g	I-C0682972
protein-coupled	I-C0682972
receptor	I-C0682972
gpr55	B-C2002138
has	O
been	O
directly	B-C1947931
or	O
indirectly	B-C0439852
related	B-C0439849
to	O
basic	O
alterations	B-C1515926
that	O
drive	O
malignant	B-C0205282
growth	B-C0018270
uncontrolled	B-C0205318
cancer	O
cell	B-C0596290
proliferation	I-C0596290
,	O
sustained	B-C0302600
angiogenesis	I-C0302600
,	O
and	O
cancer	O
cell	B-C0007577
adhesion	I-C0007577
and	O
migration	B-C1254366
.	O
	
however	O
,	O
little	B-C0700321
is	O
known	B-C0205309
about	O
the	O
involvement	B-C1314939
of	O
this	O
receptor	B-C0597357
in	O
metastasis	B-C0027627
.	O
	
here	O
,	O
we	O
show	O
that	O
elevated	B-C3163633
gpr55	B-C0597360
expression	I-C0597360
in	O
human	B-C0086418
tumors	B-C0027651
is	O
associated	B-C0332281
with	I-C0332281
the	O
aggressive	B-C0027671
basal	I-C0027671
/	O
triple-negative	B-C3539878
breast	I-C3539878
cancer	I-C3539878
population	B-C1257890
,	O
higher	B-C0033204
probability	I-C0033204
to	O
develop	O
metastases	B-C0027627
,	O
and	O
therefore	O
poor	B-C2700379
patient	B-C0030705
prognosis	B-C0033325
.	O
	
activation	B-C1879547
of	O
gpr55	B-C2002138
by	O
its	O
proposed	O
endogenous	B-C0205227
ligand	B-C0023688
lysophosphatidylinositol	B-C0065391
confers	O
pro-invasive	B-C0205281
features	B-C2348519
on	O
breast	B-C1512505
cancer	I-C1512505
cells	I-C1512505
both	O
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
.	O
	
specifically	O
,	O
this	O
effect	B-C1280500
is	O
elicited	B-C0449265
by	I-C0449265
coupling	B-C1948027
to	O
gq/11	B-C2975447
heterotrimeric	I-C2975447
proteins	I-C2975447
and	O
the	O
subsequent	B-C0332282
activation	B-C1879547
,	O
through	O
erk	B-C0600388
,	O
of	O
the	O
transcription	B-C1333479
factor	I-C1333479
etv4	I-C1333479
/	O
pea3	B-C0084827
.	O
	
together	B-C1883357
,	O
these	O
data	B-C1511726
show	O
that	O
gpr55	B-C2002138
promotes	B-C0033414
breast	B-C0678222
cancer	I-C0678222
metastasis	B-C0027627
,	O
and	O
supports	B-C1521721
the	O
notion	O
that	O
this	O
orphan	B-C0597357
receptor	I-C0597357
may	O
constitute	O
a	O
new	B-C0205314
therapeutic	B-C0302350
target	B-C1521840
and	O
potential	B-C3245505
biomarker	B-C0005516
in	O
the	O
highly	O
aggressive	B-C1519691
triple-negative	I-C1519691
subtype	I-C1519691
.	O
	
effect	B-C1280500
of	O
ultrasonic	B-C0220934
processing	B-C1709694
on	O
the	O
changes	O
in	O
activity	B-C1537044
,	O
aggregation	B-C0332621
and	O
the	O
secondary	B-C0162807
and	O
tertiary	B-C0162808
structure	I-C0162808
of	O
polyphenol	B-C0012524
oxidase	I-C0012524
in	O
oriental	B-C0017446
sweet	B-C0440285
melon	I-C0440285
cucumis	B-C0947370
melo	I-C0947370
var	I-C0947370
.	O
	
makuwa	I-C0947370
makino	I-C0947370
polyphenol	B-C0012524
oxidase	I-C0012524
ppo	B-C0012524
mainly	O
contributes	B-C1880177
to	O
the	O
browning	B-C0085927
reaction	I-C0085927
of	O
fruits	B-C0016767
and	O
vegetables	B-C0042440
and	O
causes	O
serious	B-C0205404
damage	B-C1883709
to	O
the	O
quality	B-C0332306
of	O
sweet	B-C0440285
melon	I-C0440285
products	B-C1514468
.	O
	
however	O
,	O
traditional	B-C0443324
methods	B-C0449851
to	O
inactivate	B-C0544461
browning	B-C0085927
may	O
induce	B-C0205263
more	O
unexpected	B-C4055646
risks	B-C0035647
than	O
ultrasonic	B-C0220934
processing	B-C1709694
.	O
	
meanwhile	O
,	O
there	O
are	O
no	O
reports	B-C0684224
on	O
the	O
effect	B-C1280500
of	O
ultrasound	B-C1456803
on	O
ppo	B-C0012524
directly	O
purified	B-C1998793
from	O
sweet	B-C0440285
melon	I-C0440285
.	O
	
the	O
ppo	B-C0012524
in	O
the	O
original	B-C0205313
juice	B-C1268568
was	O
less	O
inactivated	B-C0544461
than	O
the	O
purified	B-C1998793
form	O
when	O
treated	B-C0332293
with	I-C0332293
ultrasound	B-C1456803
.	O
	
as	O
for	O
purified	B-C1998793
ppo	B-C0012524
,	O
superior	O
to	O
thermal	B-C0454527
treatment	I-C0454527
,	O
less	O
heat	B-C0018837
was	O
needed	O
to	O
inactivate	B-C0544461
the	O
ppo	B-C0012524
with	O
ultrasonic	B-C0220934
treatment	B-C0087111
.	O
	
at	O
intensity	B-C2173560
lower	I-C2173560
than	O
200	O
w	O
,	O
ultrasound	B-C1456803
did	O
not	O
significantly	B-C0750502
affect	O
the	O
structure	B-C0678594
and	O
activity	B-C1561536
of	O
ppo	B-C0012524
p	O
>	O
0.05	O
,	O
and	O
latent	B-C0205275
ppo	B-C0012524
was	O
activated	B-C1879547
.	O
	
at	O
intensity	B-C2173560
higher	I-C2173560
than	O
200	O
w	O
,	O
ultrasound	B-C1456803
inactivated	B-C0544461
ppo	B-C0012524
,	O
induced	B-C0205263
aggregation	B-C0332621
and	O
dissociation	B-C0301643
of	O
ppo	B-C0012524
particles	B-C0597177
and	O
significantly	B-C4055638
decreased	I-C4055638
the	O
α-helix	B-C0162805
structure	I-C0162805
content	O
.	O
	
low-frequency	B-C0205213
high-intensity	B-C4081854
ultrasound	B-C1456803
caused	O
an	O
inactivation	B-C0544461
effect	B-C1280500
and	O
conformational	B-C0301641
changes	I-C0301641
of	O
purified	B-C1998793
ppo	B-C0012524
from	O
oriental	B-C0017446
sweet	B-C0440285
melons	I-C0440285
.	O
	
changes	B-C0392747
in	O
the	O
ppo	B-C0012524
structure	B-C0678594
induced	B-C0205263
by	O
ultrasound	B-C1456803
eventually	O
inactivated	B-C0544461
the	O
enzyme	B-C0014442
.	O
	
ultrasound	B-C1456803
may	O
be	O
a	O
potential	B-C3245505
method	B-C0449851
to	O
inactivate	B-C0544461
ppo	B-C0012524
in	O
oriental	B-C0017446
sweet	B-C0440285
melons	I-C0440285
.	O
	
phylogeography	B-C2936603
of	O
the	O
spanish	B-C0086409
moon	B-C0026593
moth	I-C0026593
graellsia	B-C1024524
isabellae	I-C1024524
lepidoptera	B-C0023338
,	O
saturniidae	B-C3102349
geographic	B-C0017444
and	O
demographic	B-C0011292
factors	I-C0011292
as	O
well	O
as	O
specialisation	B-C0037776
to	O
a	O
new	O
host-plant	B-C0868970
may	O
lead	O
to	O
host	B-C0868970
-	O
associated	B-C0332281
differentiation	B-C2945687
in	O
plant	B-C0032098
-feeding	O
insects	B-C0021585
.	O
	
we	O
explored	O
the	O
phylogeography	B-C2936603
of	O
a	O
protected	B-C0205245
moth	B-C0026593
,	O
graellsia	B-C1024524
isabellae	I-C1024524
,	O
and	O
its	O
two	O
recognised	O
host-plant	B-C0868970
species	B-C1705920
pinus	B-C0996613
sylvestris	I-C0996613
and	O
p	B-C1670069
.	O
	
nigra	I-C1670069
in	O
order	O
to	O
seek	O
for	O
any	O
concordance	O
useful	O
to	O
disentangle	O
the	O
evolutionary	B-C0019665
history	I-C0019665
of	O
this	O
iconic	O
lepidopteran	B-C0023338
.	O
	
dna	B-C0012854
variation	B-C0042333
in	O
one	O
mitochondrial	B-C0026237
marker	B-C0012872
and	O
nine	O
nuclear	B-C0007610
microsatellite	B-C0678933
loci	I-C0678933
revealed	O
a	O
strong	O
phylogeographic	B-C0243095
pattern	I-C0243095
across	O
28	O
populations	O
of	O
g	B-C1024524
.	O
	
isabellae	I-C1024524
studied	O
in	O
spain	B-C0037747
and	O
france	B-C0016674
comprising	O
six	O
groups	B-C0441833
mostly	O
distributed	B-C1704711
along	O
different	B-C1705242
mountain	B-C0442533
ranges	I-C0442533
.	O
	
reanalysis	B-C0936012
of	O
a	O
previously	O
published	O
chloroplast	B-C0008266
microsatellite	B-C0150098
dataset	I-C0150098
revealed	B-C0443289
a	O
three	O
and	O
two-	O
group	B-C0018266
structure	I-C0018266
for	O
spanish	B-C0086409
p	B-C0996613
.	O
	
sylvestris	I-C0996613
and	O
p	B-C1670069
.	O
	
nigra	I-C1670069
,	O
respectively	O
.	O
	
overall	O
,	O
the	O
population	O
groupings	O
of	O
this	O
protected	B-C0205245
moth	B-C0026593
did	O
not	O
match	B-C1708943
the	O
ones	O
of	O
p	B-C0996613
.	O
	
sylvestris	I-C0996613
and	O
p	B-C1670069
.	O
	
nigra	I-C1670069
.	O
	
there	O
was	O
no	B-C0332125
evidence	I-C0332125
of	I-C0332125
host	B-C0868970
-	O
associated	B-C0332281
differentiation	B-C2945687
between	O
populations	O
using	O
p	B-C0996613
.	O
	
sylvestris	I-C0996613
and	O
the	O
ones	O
inhabiting	B-C0205245
p	B-C1670069
.	O
	
nigra	I-C1670069
.	O
	
the	O
two	O
major	B-C0205164
mitochondrial	B-C0026237
clades	B-C0441833
of	O
g	B-C1024524
.	O
	
isabellae	I-C1024524
likely	O
diverged	O
before	O
the	O
last	B-C1254367
glacial	I-C1254367
maximum	I-C1254367
and	O
geographically	B-C1517526
separated	B-C0443299
the	O
species	B-C1705920
into	O
a	O
""""	O
southern	B-C1710133
""""	O
central	B-C1704332
and	I-C1704332
southern	I-C1704332
iberian	I-C1704332
clusters	I-C1704332
and	O
a	O
""""	O
northern	B-C1709269
""""	O
lineage	B-C1881379
eastern	B-C1704332
iberian	I-C1704332
,	O
pyrenean	B-C1704332
and	O
french	B-C1704332
alpine	I-C1704332
clusters	I-C1704332
.	O
	
the	O
eastern	B-C1704332
iberian	I-C1704332
system	I-C1704332
,	O
where	O
this	O
insect	B-C0021585
uses	O
both	O
host-plants	B-C0868970
,	O
harboured	O
the	O
highest	B-C1522410
level	B-C0441889
of	O
genetic	B-C0314603
diversity	B-C1880371
.	O
	
such	O
a	O
group	B-C0441833
independently	O
colonised	B-C4289767
the	O
west	B-C1705493
and	O
east	B-C1707877
parts	I-C1707877
of	O
the	O
pyrenees	B-C0681784
.	O
	
our	O
results	O
point	O
to	O
a	O
native	B-C0302891
origin	B-C0439659
for	O
the	O
french	B-C0032659
populations	I-C0032659
occurring	B-C2745955
in	O
the	O
alps	B-C0442533
,	O
genetically	B-C0314603
related	O
to	O
the	O
eastern	B-C0681784
iberian	I-C0681784
and	O
pyrenean	B-C0681784
sites	I-C0681784
.	O
	
the	O
central	B-C0441833
iberian	I-C0441833
group	I-C0441833
derived	O
from	O
southern	B-C0681784
iberian	I-C0681784
ancestors	B-C0870134
.	O
	
secondary	B-C0205436
contacts	B-C0205556
were	O
inferred	O
between	O
the	O
southern/central	B-C0032659
iberian	I-C0032659
populations	I-C0032659
and	O
eastern	B-C1704332
iberian	I-C1704332
cluster	I-C1704332
as	O
well	O
as	O
between	O
the	O
two	O
pyrenean	B-C1704332
ones	I-C1704332
.	O
	
the	O
mito-nuclear	B-C0392762
discordance	I-C0392762
observed	O
with	O
regard	O
to	O
the	O
eastern	B-C1704332
iberian	I-C1704332
cluster	I-C1704332
is	O
congruent	B-C0439853
with	O
a	O
secondary	B-C0205436
contact	B-C0205556
after	O
the	O
evolution	B-C0015219
of	O
mito-nuclear	B-C0205556
incompatibilities	I-C0205556
in	O
geographically	B-C0681784
isolated	I-C0681784
areas	I-C0681784
.	O
	
prevalence	B-C0220900
of	O
physical	B-C0026606
activity	I-C0026606
and	O
sitting	B-C2584297
time	B-C0040223
among	O
south	B-C1556095
korean	I-C1556095
adolescents	B-C0205653
results	B-C0683954
from	O
the	O
korean	B-C1556095
national	B-C0376344
health	I-C0376344
and	I-C0376344
nutrition	I-C0376344
examination	I-C0376344
survey	I-C0376344
,	O
2013	O
this	O
study	O
aimed	O
to	O
describe	O
physical	B-C0026606
activity	I-C0026606
pa	B-C0026606
and	O
sitting	B-C2584297
time	B-C0040223
,	O
and	O
to	O
examine	O
associations	B-C0439849
between	O
sociodemographic	B-C0011292
factors	I-C0011292
,	O
weight	B-C0005910
status	B-C0449438
,	O
pa	B-C0026606
,	O
and	O
sitting	B-C2584297
time	B-C0040223
among	O
south	B-C1556095
korean	I-C1556095
adolescents	B-C0205653
12-18	O
years	B-C1510829
.	O
	
findings	B-C2607943
are	O
based	O
on	O
self-report	B-C2700446
data	I-C2700446
from	O
638	O
participants	B-C0679646
in	O
the	O
2013	O
korea	B-C0022771
national	B-C0376344
health	I-C0376344
and	I-C0376344
nutrition	I-C0376344
examination	I-C0376344
survey	I-C0376344
.	O
	
only	O
4.9	O
of	O
adolescents	B-C0205653
accumulated	O
60	O
minutes	B-C0439232
of	O
moderate-to-vigorous	B-C0026606
pa	I-C0026606
daily	B-C0332173
.	O
	
adolescents	B-C0205653
spent	O
532.4	O
9.3	O
mins/d	B-C0556973
sitting	B-C2584297
.	O
	
after	O
controlling	O
for	O
age	B-C0001779
and	O
sex	B-C0079399
,	O
individuals	B-C0027361
in	O
higher	B-C0019532
income	I-C0019532
groups	I-C0019532
compared	B-C1707455
with	O
the	O
lowest	B-C0024045
income	I-C0024045
group	I-C0024045
,	O
living	B-C2982691
in	O
nonmetro	B-C1254362
seoul	B-C3850150
compared	B-C1707455
with	O
metro	B-C0599587
seoul	B-C3850150
,	O
and	O
who	O
were	O
overweight	B-C0497406
compared	B-C1707455
with	O
nonoverweight	B-C0005910
were	O
more	O
likely	O
to	O
meet	O
pa	B-C0026606
guidelines	B-C0162791
.	O
	
participants	B-C0679646
in	O
the	O
highest	B-C0019532
income	I-C0019532
group	I-C0019532
compared	B-C1707455
with	O
lowest	B-C0024045
income	I-C0024045
group	I-C0024045
,	O
and	O
residing	B-C2982691
in	O
nonmetro	B-C1254362
seoul	B-C3850150
compared	B-C1707455
with	O
metro	B-C0599587
seoul	B-C3850150
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
high	O
sitting	B-C2584297
time	B-C0040223
group	B-C0441833
>720	O
min/d	B-C0556973
p	O
<	O
05	O
.	O
	
increasing	B-C0442808
pa	B-C0026606
and	O
reducing	B-C0392756
sitting	B-C2584297
should	O
be	O
a	O
public	B-C3244304
health	I-C3244304
priority	B-C0549179
in	O
south	B-C0022773
korea	I-C0022773
.	O
	
graphene	B-C2936695
/	O
nafion	B-C0068361
composite	B-C1561572
film	I-C1561572
modified	O
glassy	B-C0522500
carbon	B-C3874229
electrode	I-C3874229
for	O
simultaneous	B-C0521115
determination	B-C1148554
of	O
paracetamol	B-C0000970
,	O
aspirin	B-C0004057
and	O
caffeine	B-C0006644
in	O
pharmaceutical	B-C1705957
formulations	I-C1705957
a	O
graphene	B-C2936695
-	O
nafion	B-C0068361
composite	B-C1561572
film	I-C1561572
was	O
fabricated	B-C0870840
on	O
the	O
glassy	B-C0522500
carbon	B-C3874229
electrode	I-C3874229
gr-nf/gce	B-C3874229
,	O
and	O
used	O
for	O
simultaneous	B-C0521115
determination	B-C1148554
of	O
paracetamol	B-C0000970
par	B-C0000970
,	O
aspirin	B-C0004057
asa	B-C0004057
and	O
caffeine	B-C0006644
caf	B-C0006644
.	O
	
the	O
electrochemical	B-C0205556
behaviors	I-C0205556
of	O
par	B-C0000970
,	O
asa	B-C0004057
and	O
caf	B-C0006644
were	O
investigated	B-C1292732
by	O
cyclic	B-C0683134
voltammetry	I-C0683134
and	O
square-wave	B-C0201748
adsorptive	I-C0201748
anodic	I-C0201748
stripping	I-C0201748
voltammetry	I-C0201748
.	O
	
by	O
using	O
stripping	B-C0201748
one	O
for	O
simultaneous	B-C0521115
determination	B-C1148554
of	O
par	B-C0000970
,	O
asa	B-C0004057
and	O
caf	B-C0006644
,	O
their	O
electrochemical	B-C0444505
oxidation	I-C0444505
peaks	I-C0444505
appeared	B-C0700364
at	O
+0	O
,	O
1.04	O
and	O
1.44v	O
,	O
and	O
good	B-C0205170
linear	B-C0205556
current	I-C0205556
responses	I-C0205556
were	O
obtained	B-C1301820
with	O
the	O
detection	B-C2718050
limits	I-C2718050
of	O
18ngml	O
1.2	O
,	O
11.7ngml	O
6.5	O
and	O
7.3ngml	O
3.8	O
,	O
respectively	O
.	O
	
finally	O
,	O
the	O
proposed	B-C1705535
electrochemical	B-C0183210
sensor	I-C0183210
was	O
successfully	B-C1272703
applied	B-C4048755
for	O
quantifying	B-C1709793
par	B-C0000970
,	O
asa	B-C0004057
and	O
caf	B-C0006644
in	O
commercial	B-C0680536
tablet	B-C1705957
formulations	I-C1705957
.	O
	
long-term	B-C0443252
antibiofilm	B-C0441655
activity	I-C0441655
of	O
carboxymethyl	B-C1744331
chitosan	I-C1744331
on	O
mixed	B-C0081786
biofilm	I-C0081786
on	O
silicone	B-C0037114
silicone	B-C0037114
voice	B-C0087165
prostheses	I-C0087165
are	O
most	O
frequently	B-C0332183
used	O
in	O
voice	B-C0199531
rehabilitation	I-C0199531
of	O
laryngectomized	B-C0023065
patients	B-C0030705
.	O
	
however	O
,	O
the	O
functional	B-C1385354
device	I-C1385354
lifetimes	B-C4071830
are	O
limited	B-C0439801
due	B-C0678226
to	I-C0678226
formation	B-C1522492
of	O
mixed	B-C0081786
biofilms	I-C0081786
.	O
	
existing	O
in	B-C1515654
vitro	I-C1515654
models	I-C1515654
simulating	O
biofilm	B-C1325881
formation	I-C1325881
are	O
restricted	B-C0443288
to	O
only	O
short-term	B-C0443303
periods	B-C1948053
.	O
	
the	O
goal	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
determine	O
the	O
effect	B-C1280500
of	O
carboxymethyl	B-C1744331
chitosan	I-C1744331
on	O
mixed	B-C1325881
biofilm	I-C1325881
formation	I-C1325881
of	O
fungi	B-C0016832
and	O
bacteria	B-C0004611
on	O
silicone	B-C0037114
over	O
a	O
long-term	B-C0443252
period	B-C1948053
.	O
	
mixed	O
species	B-C1705920
biofilms	B-C0081786
of	O
candida	B-C0006837
albicans	I-C0006837
,	O
candida	B-C0319882
tropicalis	I-C0319882
,	O
lactobacillus	B-C0317620
gasseri	I-C0317620
,	O
streptococcus	B-C0318179
salivarius	I-C0318179
,	O
rothia	B-C0318071
dentocariosa	I-C0318071
,	O
and	O
staphylococcus	B-C0038174
epidermidis	I-C0038174
were	O
cultivated	B-C1254366
on	O
the	O
surfaces	B-C0205148
of	O
medical-grade	B-C0037114
silicone	I-C0037114
with	O
and	O
without	O
addition	O
of	O
carboxymethyl	B-C1744331
chitosan	I-C1744331
.	O
	
biofilm	B-C0022702
kinetics	I-C0022702
was	O
monitored	O
using	O
specially	O
designed	B-C3203922
image	I-C3203922
analysis	I-C3203922
software	I-C3203922
to	O
calculate	B-C1441506
the	O
percentual	B-C0205245
surface	I-C0205245
covering	I-C0205245
of	O
each	O
platelet	B-C0005821
.	O
	
biofilm	B-C1254362
architecture	I-C1254362
was	O
investigated	B-C1292732
by	O
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
.	O
	
a	O
cover	B-C1999244
of	O
living	B-C0376558
mixed	B-C0081786
biofilm	I-C0081786
could	O
be	O
generated	O
over	O
22	O
days	B-C0439228
on	O
silicone	B-C0037114
and	O
the	O
maximum	B-C0806909
of	O
22%	O
biofilm	B-C0081786
surface	B-C0205245
covering	I-C0205245
at	O
day	B-C0439228
22	O
.	O
	
however	O
,	O
less	B-C0439092
than	I-C0439092
4%	O
surface	B-C1999244
coverage	I-C1999244
was	O
observed	B-C1441672
on	O
the	O
carboxymethyl	B-C1744331
chitosan	I-C1744331
-	O
treated	B-C1522326
plates	O
in	O
the	O
testing	B-C0039593
period	B-C1948053
.	O
	
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
confirms	B-C0750484
that	O
,	O
on	O
surfaces	B-C0205148
treated	B-C1522326
by	O
carboxymethyl	B-C1744331
chitosan	I-C1744331
,	O
the	O
biofilm	B-C0081786
was	O
less	B-C0547044
dense	B-C0439794
.	O
	
in	O
addition	O
,	O
there	O
were	O
fewer	B-C0205388
layers	O
of	O
cells	B-C0007634
and	O
profuse	B-C4055264
cellular	I-C4055264
debris	I-C4055264
,	O
together	B-C1883357
with	O
degrading	O
and	O
morphologically	B-C1260954
altered	I-C1260954
yeast	B-C0043393
cells	O
.	O
	
carboxymethyl	O
chitosan	O
may	O
serve	O
as	O
a	O
possible	O
antibiofilm	O
agent	O
to	O
limit	O
biofilm	O
formation	O
on	O
voice	O
prostheses	O
.	O
	
na	O
laryngoscope	O
,	O
126	O
,	O
spectral	B-C0037812
fingerprints	I-C0037812
of	O
large-scale	O
cortical	B-C0007776
dynamics	B-C3826426
during	B-C0347984
ambiguous	B-C0237467
motion	B-C0026598
perception	I-C0026598
ambiguous	B-C1274012
stimuli	B-C0234402
have	O
been	O
widely	O
used	O
to	O
study	O
the	O
neuronal	B-C0027882
correlates	B-C1707520
of	O
consciousness	B-C0234421
.	O
	
recently	O
,	O
it	O
has	O
been	O
suggested	O
that	O
conscious	B-C0234421
perception	B-C0030971
might	O
arise	O
from	O
the	O
dynamic	B-C0729333
interplay	O
of	O
functionally	O
specialized	O
but	O
widely	O
distributed	O
cortical	B-C0007776
areas	I-C0007776
.	O
	
while	O
previous	O
research	O
mainly	O
focused	O
on	O
phase	B-C4042905
coupling	I-C4042905
as	O
a	O
correlate	B-C1707520
of	O
cortical	B-C0007776
communication	O
,	O
more	O
recent	O
findings	O
indicated	O
that	O
additional	O
coupling	B-C4042905
modes	I-C4042905
might	O
coexist	O
and	O
possibly	O
subserve	O
distinct	O
cortical	B-C0234393
functions	I-C0234393
.	O
	
here	O
,	O
we	O
studied	O
two	O
coupling	B-C4042905
modes	I-C4042905
,	O
namely	O
phase	B-C4042905
and	I-C4042905
envelope	I-C4042905
coupling	I-C4042905
,	O
which	O
might	O
differ	O
in	O
their	O
origins	O
,	O
putative	O
functions	O
and	O
dynamics	B-C3826426
.	O
	
therefore	O
,	O
we	O
recorded	O
128-channel	O
eeg	B-C0013819
while	O
participants	B-C0679646
performed	O
a	O
bistable	B-C0025365
motion	I-C0025365
task	I-C0025365
and	O
utilized	O
state-of-the-art	O
source-space	O
connectivity	B-C1707489
analysis	B-C0936012
techniques	B-C0449851
to	O
study	O
the	O
functional	B-C2700217
relevance	I-C2700217
of	O
different	O
coupling	B-C4042905
modes	I-C4042905
for	O
cortical	B-C0007776
communication	O
.	O
	
our	O
results	O
indicate	O
that	O
gamma-band	B-C4042905
phase	I-C4042905
coupling	I-C4042905
in	O
extrastriate	B-C3498366
visual	B-C0042817
cortex	I-C0042817
might	O
mediate	O
the	O
integration	O
of	O
visual	B-C0031734
tokens	I-C0031734
into	O
a	O
moving	B-C0560560
stimulus	B-C0234402
during	O
ambiguous	B-C0237467
visual	B-C0031734
stimulation	I-C0031734
.	O
	
furthermore	O
,	O
our	O
results	O
suggest	O
that	O
long-range	O
fronto-occipital	O
gamma-band	O
envelope	B-C4042905
coupling	I-C4042905
sustains	O
the	O
horizontal	O
percept	O
during	O
ambiguous	B-C0237467
motion	B-C0026598
perception	I-C0026598
.	O
	
additionally	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
local	B-C1518897
parieto-occipital	I-C1518897
alpha-band	B-C4042905
phase	I-C4042905
coupling	I-C4042905
controls	O
the	O
inter-	O
hemispheric	B-C0205139
information	B-C0205245
transfer	I-C0205245
.	O
	
these	O
findings	O
provide	O
correlative	B-C1707520
evidence	B-C3887511
for	O
the	O
notion	O
that	O
synchronized	B-C0439580
oscillatory	O
brain	B-C0443158
activity	I-C0443158
reflects	O
the	O
processing	B-C1327511
of	I-C1327511
sensory	I-C1327511
input	O
as	O
well	O
as	O
the	O
information	B-C0679019
integration	I-C0679019
across	O
several	O
spatiotemporal	B-C3494293
scales	I-C3494293
.	O
	
the	O
results	O
indicate	O
that	O
distinct	B-C0392762
coupling	I-C0392762
modes	I-C0392762
are	O
involved	O
in	O
different	O
cortical	B-C0007776
computations	B-C1880157
and	O
that	O
the	O
rich	O
spatiotemporal	B-C3494293
correlation	I-C3494293
structure	B-C0006104
of	I-C0006104
the	I-C0006104
brain	I-C0006104
might	O
constitute	O
the	O
functional	B-C0205245
architecture	O
for	O
cortical	B-C0007776
beneficial	B-C0683156
effects	I-C0683156
of	O
voglibose	B-C0532578
administration	B-C1533734
on	O
body	B-C0005910
weight	I-C0005910
and	O
lipid	B-C0598783
metabolism	I-C0598783
via	O
gastrointestinal	B-C0012240
bile	B-C0005390
acid	I-C0005390
modification	B-C0579005
this	O
study	B-C0008972
was	O
designed	O
with	O
the	O
goal	B-C0018017
of	O
examining	O
the	O
effects	B-C0728866
of	O
voglibose	B-C0532578
administration	B-C1533734
on	O
body	B-C0005910
weight	I-C0005910
and	O
lipid	B-C0598783
metabolism	I-C0598783
and	O
underlying	O
mechanism	B-C0441712
high	B-C0521974
fat	I-C0521974
diet	I-C0521974
-induced	O
obese	B-C0025933
mice	I-C0025933
.	O
	
male	B-C0086582
c57bl/6	B-C1521751
mice	I-C1521751
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	B-C1642385
a	O
control	B-C0009932
diet	I-C0009932
ctl	B-C0009932
,	O
high-fat	B-C1642385
diet	I-C1642385
hf	B-C1642385
,	O
high-fat	B-C1642385
diet	I-C1642385
supplemented	I-C1642385
with	I-C1642385
voglibose	I-C1642385
vo	B-C1642385
,	O
and	O
high	B-C1642385
fat	I-C1642385
diet	I-C1642385
pair-fed	I-C1642385
group	I-C1642385
pf	B-C1642385
.	O
	
after	O
12	O
weeks	B-C0439230
,	O
the	O
following	O
characteristics	B-C1521970
were	O
investigated	O
serum	B-C0428462
lipid	I-C0428462
and	O
glucose	B-C0583332
levels	I-C0583332
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	B-C3244092
levels	I-C3244092
of	O
genes	B-C0017337
involved	O
in	O
lipid	B-C0598783
and	O
bile	B-C0678714
acid	I-C0678714
metabolism	I-C0678714
.	O
	
in	O
addition	O
,	O
pyrosequencing	B-C2732543
was	O
used	O
to	O
analyze	O
the	O
composition	B-C0486616
of	O
gut	B-C2985398
microbiota	I-C2985398
found	O
in	O
feces	B-C0015733
.	O
	
total	B-C0043094
body	I-C0043094
weight	I-C0043094
gain	I-C0043094
was	O
significantly	B-C4055638
lower	I-C4055638
in	O
the	O
vo	B-C1642385
group	I-C1642385
than	O
in	O
the	O
ctl	B-C0009932
,	O
hf	B-C1642385
,	O
and	O
pf	B-C1642385
groups	I-C1642385
.	O
	
the	O
vo	B-C1642385
group	I-C1642385
exhibited	O
improved	O
metabolic	B-C3853758
profiles	I-C3853758
including	O
those	O
of	O
blood	B-C0392201
glucose	I-C0392201
,	O
triglyceride	B-C0428475
,	O
and	O
total	B-C0428466
cholesterol	I-C0428466
levels	I-C0428466
.	O
	
the	O
12-	O
week	B-C0439230
voglibose	B-C0532578
administration	B-C1533734
decreased	O
the	O
ratio	O
of	O
firmicutes	B-C1254144
to	O
bacteroidetes	B-C0995456
found	O
in	O
feces	B-C0015733
.	O
	
circulating	O
levels	B-C0441889
of	O
taurocholic	B-C0039358
and	O
cholic	B-C0055568
acid	I-C0055568
were	O
significantly	B-C4055637
higher	I-C4055637
in	O
the	O
vo	B-C1642385
group	I-C1642385
than	O
in	O
the	O
hf	B-C1642385
and	O
ctl	B-C0009932
groups	I-C0009932
.	O
	
deoxycholic	B-C0011479
acid	I-C0011479
levels	B-C0441889
tended	O
to	O
be	O
higher	O
in	O
the	O
vo	B-C1642385
group	I-C1642385
than	O
in	O
the	O
hf	B-C1642385
group	I-C1642385
.	O
	
voglibose	B-C0532578
administration	B-C1533734
downregulated	B-C0013081
expression	B-C3244092
levels	I-C3244092
of	O
cyp8b1	B-C1413895
and	O
hnf4α	B-C1415629
genes	I-C1415629
and	O
upregulated	B-C0041904
those	O
of	O
pgc1α	B-C1418779
,	O
whereas	O
fxrα	B-C1417825
was	O
not	O
affected	O
.	O
	
voglibose	B-C0532578
administration	B-C1533734
elicits	O
changes	O
in	O
the	O
composition	B-C0486616
of	O
the	O
intestinal	B-C2985398
microbiota	I-C2985398
and	O
circulating	B-C0870883
metabolites	I-C0870883
,	O
which	O
ultimately	O
has	O
systemic	B-C0678788
effects	I-C0678788
on	O
body	B-C0005910
weight	I-C0005910
and	O
lipid	B-C0598783
metabolism	I-C0598783
in	O
supramolecular	B-C0599844
recognition	I-C0599844
of	O
amino	B-C0002520
acids	I-C0002520
by	O
twisted	B-C1737934
cucurbit	I-C1737934
binding	B-C1167622
interactions	B-C1704675
between	B-C0205103
twisted	B-C1737934
cucurbit	I-C1737934
tq	B-C1737934
and	O
twenty	O
standard	B-C1442989
amino	B-C0002520
acids	I-C0002520
aas	B-C0002520
have	O
been	O
investigated	B-C1292732
by	O
nmr	B-C0877853
spectroscopy	I-C0877853
and	O
isothermal	B-C0006779
titration	I-C0006779
calorimetry	I-C0006779
itc	B-C0006779
in	O
aqueous	B-C0043047
hcl	B-C0020259
solutions	I-C0020259
and	O
in	O
dmso	B-C0012403
.	O
	
the	O
results	B-C1274040
showed	O
that	O
tq	B-C1737934
displays	B-C0870432
clear	O
binding	B-C1167622
affinity	B-C1510827
for	O
aas	B-C0002520
with	O
a	O
positively	B-C1254350
charged	I-C1254350
side	I-C1254350
chain	I-C1254350
or	O
containing	B-C0332256
an	O
aromatic	B-C0020245
ring	I-C0020245
,	O
but	O
weaker	B-C1762617
binding	B-C1167622
affinity	B-C1510827
for	O
aas	B-C0002520
with	O
hydrophobic	B-C1254355
or	O
polar	B-C1254355
side	I-C1254355
chains	I-C1254355
,	O
with	O
the	O
binding	B-C1167622
mode	B-C1513371
depending	O
on	O
the	O
type	O
of	O
side	B-C1254350
chain	I-C1254350
present	O
in	O
the	O
comparison	B-C1707455
of	O
alkaline	B-C1149888
phosphatase	I-C1149888
activity	I-C1149888
of	O
mc3t3-e1	B-C0007600
cells	I-C0007600
cultured	O
on	O
different	O
ti	B-C0040302
surfaces	B-C0205148
modified	O
sandblasted	B-C1254366
with	O
large	O
grit	B-C0440273
and	O
acid-etched	B-C1254366
msla	B-C0040302
,	O
laser-treated	B-C1254366
,	O
and	O
laser	B-C1254366
and	I-C1254366
acid-treated	I-C1254366
ti	B-C0040302
surfaces	B-C0205148
in	O
this	O
study	B-C2603343
,	O
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	B-C0220825
the	O
effect	O
of	O
implant	O
surface	B-C0205148
treatment	O
on	O
cell	B-C0007589
differentiation	I-C0007589
of	O
osteoblast	B-C0029418
cells	I-C0029418
.	O
	
for	O
this	O
purpose	O
,	O
three	O
surfaces	B-C0205148
were	O
compared	O
1	O
a	O
modified	O
sla	O
msla	O
sand-blasted	O
with	O
large	O
grit	B-C0440273
,	O
acid-etched	O
,	O
and	O
immersed	O
in	O
0.9	O
nacl	B-C0037494
,	O
2	O
a	O
laser	B-C1254366
treatment	I-C1254366
lt	B-C1254366
laser	B-C1254366
treatment	I-C1254366
titanium	B-C0040302
surface	B-C0205148
and	O
3	O
a	O
laser	B-C1254366
and	I-C1254366
acid-treated	I-C1254366
lat	O
laser	B-C1254366
treatment	I-C1254366
,	O
acid-etched	I-C1254366
titanium	B-C0040302
surface	B-C0205148
.	O
	
the	O
msla	B-C0040302
surfaces	B-C0205148
were	O
considered	O
as	O
the	O
control	B-C0009932
group	I-C0009932
,	O
and	O
lt	B-C0040302
and	O
lat	B-C0040302
surfaces	B-C0205148
as	O
test	B-C0441833
groups	I-C0441833
.	O
	
alkaline	B-C0002059
phosphatase	I-C0002059
expression	B-C1171362
alp	B-C0002059
was	O
used	O
to	O
quantify	O
osteoblastic	B-C1159974
differentiation	I-C1159974
of	O
mc3t3-e1	B-C0007600
cell	I-C0007600
.	O
	
surface	B-C0205148
roughness	B-C0205556
was	O
evaluated	B-C0220825
by	O
a	O
contact	B-C0025080
profilometer	I-C0025080
urfpak-sv	O
mitutoyo	O
,	O
kawasaki	O
,	O
japan	B-C0022341
and	O
characterized	O
by	O
two	O
parameters	O
mean	B-C0205556
roughness	I-C0205556
ra	B-C0205556
and	O
maximum	B-C0392762
peak-to-valley	I-C0392762
height	I-C0392762
rt	B-C0392762
.	O
	
scanning	B-C0262878
electron	I-C0262878
microscope	I-C0262878
revealed	O
that	O
msla	O
control	B-C0009932
group	I-C0009932
surface	B-C0205148
was	O
not	O
as	O
rough	B-C0205556
as	O
lt	B-C0040302
,	O
lat	B-C0040302
surface	B-C0205148
test	B-C0441833
groups	I-C0441833
.	O
	
alkaline	B-C0002059
phosphatase	I-C0002059
expression	B-C1171362
,	O
the	O
measure	O
of	O
osteoblastic	B-C1159974
differentiation	I-C1159974
,	O
and	O
total	O
alp	B-C0002059
expression	B-C1171362
by	O
surface-adherent	B-C0007634
cells	I-C0007634
were	O
found	O
to	O
be	O
highest	O
at	O
21	O
days	B-C0439228
for	O
all	O
three	O
surfaces	B-C0205148
tested	O
p<	O
.	O
	
furthermore	O
,	O
alp	B-C0002059
expression	B-C1171362
levels	B-C0441889
of	O
msla	B-C0040302
and	O
lat	B-C0040302
surfaces	B-C0205148
were	O
significantly	O
higher	O
than	O
expression	B-C1171362
levels	B-C0441889
of	O
lt	B-C0040302
surface-adherent	B-C0007634
cells	I-C0007634
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	B-C0439228
,	O
respectively	O
p<	O
.	O
	
however	O
,	O
alp	B-C0002059
expression	B-C1171362
levels	B-C0441889
between	O
msla	B-C0040302
and	O
lat	B-C0040302
surface	B-C0205148
were	O
equal	O
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	B-C0439228
p>	O
.	O
	
this	O
study	B-C2603343
suggested	O
that	O
msla	B-C0040302
and	O
lat	B-C0040302
surfaces	B-C0205148
exhibited	O
more	O
favorable	B-C3640814
environment	B-C0014406
for	O
osteoblast	B-C1159974
differentiation	I-C1159974
when	O
compared	O
with	O
lt	B-C0040302
surface	B-C0205148
,	O
the	O
results	O
that	O
are	O
important	O
for	O
implant	B-C0021102
surface	B-C0205148
modification	B-C0392747
studies	B-C2603343
.	O
	
overcoming	B-C2983310
structural	B-C0678594
inequalities	B-C0242503
in	O
oral	B-C0029162
health	I-C0029162
the	O
role	O
of	O
dental	B-C0011365
curricula	B-C0010478
to	O
date	O
the	O
role	O
of	O
health	B-C0036376
professional	I-C0036376
schools	I-C0036376
in	O
addressing	O
oral	B-C0029162
health	I-C0029162
inequalities	B-C0242503
have	O
been	O
minimal	O
,	O
as	O
attempts	B-C1516084
have	O
focused	B-C1285542
principally	O
upon	O
systemic	B-C0205373
reform	B-C0870472
and	O
broader	O
societal	B-C0028761
obligations	I-C0028761
.	O
	
professionalism	B-C4046065
is	O
a	O
broad	O
competency	B-C0086035
that	O
is	O
taught	O
throughout	O
dental	B-C0036376
schools	I-C0036376
and	O
encompasses	O
a	O
range	B-C1514721
of	O
attributes	O
.	O
	
professionalism	B-C4046065
as	O
a	O
competency	B-C0086035
draws	O
some	O
debate	B-C0870392
and	O
appears	O
to	O
be	O
a	O
shifting	B-C0392747
phenomenon	I-C0392747
.	O
	
we	O
may	O
ask	O
if	O
professionalism	B-C4046065
in	O
the	O
dental	B-C0011365
curricula	B-C0010478
may	O
be	O
better	O
addressed	O
by	O
social	B-C0037394
accountability	I-C0037394
social	B-C0037394
accountability	I-C0037394
directs	O
oral	B-C0029162
health	I-C0029162
professional	B-C0010478
curricula	I-C0010478
education	B-C0013622
,	O
research	B-C0035168
,	O
and	O
service	B-C1254363
activities	I-C1254363
towards	O
addressing	O
the	O
priority	B-C0549179
health	B-C0018684
concerns	B-C2699424
of	O
the	O
community	B-C0009462
,	O
in	O
our	O
case	O
oral	B-C0029162
health	I-C0029162
inequalities	B-C0242503
.	O
	
although	O
working	O
toward	O
dental	B-C0036376
schools	I-C0036376
becoming	O
more	O
socially	B-C0037394
accountable	I-C0037394
seems	O
like	O
a	O
sensible	O
way	O
to	O
address	B-C0376649
oral	B-C0029162
health	I-C0029162
inequalities	B-C0242503
,	O
it	O
might	O
have	O
limitations	O
.	O
	
we	O
will	O
consider	O
some	O
of	O
the	O
challenges	O
in	O
the	O
dental	B-C0011365
curricula	B-C0010478
by	O
considering	O
some	O
of	O
the	O
political	B-C0032380
,	O
structural	B-C0678594
,	O
social	B-C0337460
and	O
ethical	B-C0026531
factors	B-C1521761
that	O
influence	B-C4054723
our	O
institutions	B-C2607850
and	O
our	O
function	B-C0542341
analysis	B-C0936012
of	O
mef2c	B-C1417102
promoter	B-C0086860
in	O
muscle	B-C1326080
differentiation	I-C1326080
regeneration	B-C2752380
of	I-C2752380
adult	I-C2752380
skeletal	I-C2752380
muscle	I-C2752380
following	O
injury	B-C3263722
occurs	O
through	O
the	O
activation	B-C1326120
of	O
satellite	B-C0599856
cells	I-C0599856
,	O
that	O
proliferates	B-C0596290
,	O
differentiates	B-C0007589
,	O
and	O
fuses	B-C1261468
with	O
injured	B-C0332664
myofibers	B-C3899956
.	O
	
myocyte	B-C3658245
enhancer	I-C3658245
factor	I-C3658245
2	I-C3658245
mef2	I-C3658245
proteins	I-C3658245
are	O
reported	O
that	O
they	O
have	O
the	O
potential	O
contributions	O
to	O
adult	B-C0001675
muscle	B-C1850849
regeneration	I-C1850849
.	O
	
in	O
order	O
to	O
further	O
understand	O
mef2c	B-C1417102
gene	I-C1417102
,	O
the	O
promoter	B-C0086860
of	O
pig	B-C0039005
mef2c	B-C1417102
gene	I-C1417102
was	O
analyzed	O
in	O
this	O
paper	O
.	O
	
quantitative	B-C3179034
real-time	I-C3179034
pcr	I-C3179034
qrt-pcr	B-C3179034
revealed	O
the	O
expression	B-C0017262
pattern	O
of	O
mef2c	B-C1417102
gene	I-C1417102
in	O
muscle	B-C0026845
of	O
eight	O
tissues	B-C0040300
.	O
	
the	O
mef2c	B-C1417102
promoter	B-C0086860
had	O
the	O
higher	O
transcriptional	B-C0040649
activity	I-C0040649
in	O
differentiated	B-C0007589
c2c12	B-C0007634
cells	I-C0007634
than	O
that	O
in	O
proliferating	B-C0596290
c2c12	B-C0007634
cells	I-C0007634
,	O
which	O
was	O
accompanied	O
by	O
the	O
up-regulation	B-C0162493
of	O
mrna	B-C1515670
expression	I-C1515670
of	O
mef2c	B-C1417102
gene	I-C1417102
.	O
	
function	B-C0542341
deletion	B-C0017260
and	O
mutation	B-C0026882
analyses	B-C0936012
showed	O
that	O
myod	B-C0165230
and	O
mef2	B-C3658245
binding	B-C1514535
sites	I-C1514535
within	O
the	O
mef2c	B-C1417102
promoter	B-C0086860
were	O
responsible	O
for	O
the	O
regulation	B-C1158770
of	O
mef2c	B-C1417102
transcription	B-C0040649
.	O
	
mef2c	B-C1417102
could	O
up-regulate	B-C0162493
the	I-C0162493
transcriptional	I-C0162493
activities	I-C0162493
of	O
mef2c	B-C1417102
promoter	B-C0086860
constructs	I-C0086860
which	O
contained	O
a	O
3'-end	B-C0314659
nucleotide	I-C0314659
sequence	I-C0314659
with	O
p300	B-C1530358
binding	B-C0004793
site	I-C0004793
.	O
	
the	O
electrophoretic	B-C0949632
mobility	I-C0949632
shift	I-C0949632
assays	I-C0949632
emsa	B-C0949632
and	O
chromatin	B-C1328856
immunoprecipitation	I-C1328856
chip	I-C1328856
assays	I-C1328856
determined	O
the	O
myod	B-C0165230
binding	B-C1514535
site	I-C1514535
in	O
mef2c	B-C1417102
promoter	B-C0086860
.	O
	
these	O
results	O
advanced	O
our	O
knowledge	O
of	O
the	O
promoter	B-C0086860
of	O
the	O
pig	B-C0039005
mef2c	B-C1417102
gene	I-C1417102
.	O
	
and	O
the	O
study	O
of	O
mef2c	B-C1417102
promoter	B-C0086860
regulator	O
elements	O
helped	O
to	O
elucidating	O
the	O
regulation	B-C1158770
mechanisms	I-C1158770
of	O
mef2c	B-C1417102
in	O
muscle	B-C1326080
differentiation	I-C1326080
or	O
muscle	B-C0185414
repair	I-C0185414
and	O
regeneration	B-C1850849
.	O
	
novel	O
insights	O
into	O
development	O
of	O
diabetic	B-C0241863
bladder	B-C0005686
disorder	I-C0005686
provided	O
by	O
metabolomic	B-C1328813
analysis	I-C1328813
of	O
the	O
rat	B-C0034721
nondiabetic	O
and	O
diabetic	B-C0241863
detrusor	B-C1180419
and	O
urothelial	B-C0227692
layer	I-C0227692
there	O
are	O
at	O
present	O
no	O
published	O
studies	O
providing	O
a	O
global	O
overview	O
of	O
changes	B-C0392747
in	O
bladder	B-C0005682
metabolism	B-C0025519
resulting	O
from	O
diabetes	B-C0011847
.	O
	
such	O
studies	O
have	O
the	O
potential	O
to	O
provide	O
mechanistic	O
insight	O
into	O
the	O
development	O
of	O
diabetic	B-C0241863
bladder	B-C0005686
disorder	I-C0005686
dbd	I-C0005686
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
compared	O
the	O
metabolome	B-C2350399
of	O
detrusor	B-C1180419
and	O
urothelial	B-C0227692
layer	I-C0227692
in	O
a	O
1-mo	O
streptozotocin	B-C0038432
-induced	O
rat	B-C0034721
model	B-C0012644
of	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
with	O
nondiabetic	B-C0009932
controls	I-C0009932
.	O
	
our	O
studies	O
revealed	O
that	O
diabetes	B-C0011847
caused	O
both	O
common	O
and	O
differential	O
changes	B-C0392747
in	O
the	O
detrusor	B-C1180419
and	O
urothelial	B-C0227692
layer's	I-C0227692
metabolome	B-C2350399
.	O
	
diabetes	B-C0011847
resulted	O
in	O
similar	O
changes	B-C0392747
in	O
the	O
levels	O
of	O
previously	O
described	O
diabetic	B-C0011847
markers	B-C0005516
in	O
both	O
tissues	B-C0040300
,	O
such	O
as	O
glucose	B-C0017725
,	O
lactate	B-C0064582
,	O
2-hydroxybutyrate	B-C0046188
,	O
branched-chain	B-C3494275
amino	I-C3494275
acid	I-C3494275
degradation	I-C3494275
products	I-C3494275
,	O
bile	B-C0005390
acids	I-C0005390
,	O
and	O
1	B-C0044029
,	O
as	O
well	O
as	O
markers	B-C0005516
of	O
oxidative	B-C0242606
stress	I-C0242606
.	O
	
in	O
the	O
detrusor	B-C1180419
but	O
not	O
the	O
urothelial	B-C0227692
layer	I-C0227692
,	O
diabetes	B-C0011847
caused	O
activation	O
of	O
the	O
pentose-phosphate	B-C0030893
and	O
polyol	B-C0071629
pathways	B-C1704259
,	O
concomitant	O
with	O
a	O
reduction	O
in	O
the	O
tca	B-C1516586
cycle	I-C1516586
and	O
β-oxidation	B-C1158368
.	O
	
changes	B-C0392747
in	O
detrusor	B-C1180419
energy-generating	B-C1158271
pathways	I-C1158271
resulted	O
in	O
an	O
accumulation	O
of	O
sorbitol	B-C0037688
that	O
,	O
through	O
generation	O
of	O
advanced	B-C0162574
glycation	I-C0162574
end	I-C0162574
products	I-C0162574
,	O
is	O
likely	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
of	O
dbd	B-C0005686
.	O
	
in	O
the	O
diabetic	B-C0241863
urothelial	B-C0227692
layer	I-C0227692
there	O
was	O
decreased	O
flux	B-C2348693
of	O
glucose	B-C0017725
via	O
glycolysis	B-C0017952
and	O
changes	B-C0392747
in	O
lipid	O
metabolism	O
,	O
particularly	O
prostaglandin	O
synthesis	O
,	O
which	O
also	O
potentially	O
contributes	O
to	O
detrusor	O
dysfunction	B-C0277785
proximal	B-C0022885
soil	I-C0022885
sensing	I-C0022885
-	O
a	O
contribution	B-C1880177
for	O
species	B-C1705920
habitat	B-C0871648
distribution	B-C1704711
modelling	B-C0870071
of	O
earthworms	B-C0086194
in	O
agricultural	B-C0562975
soils	B-C0037592
earthworms	B-C0086194
are	O
important	O
for	O
maintaining	O
soil	B-C0037592
ecosystem	B-C0162358
functioning	B-C0542341
and	O
serve	O
as	O
indicators	B-C0021212
of	O
soil	B-C0037592
fertility	B-C0205556
.	O
	
however	O
,	O
detection	O
of	O
earthworms	B-C0086194
is	O
time-consuming	B-C3827829
,	O
which	O
hinders	O
the	O
assessment	B-C1516048
of	O
earthworm	B-C0086194
abundances	B-C2346714
with	O
high	O
sampling	B-C0870078
density	B-C0178587
over	O
entire	O
fields	B-C0562975
.	O
	
recent	O
developments	O
of	O
mobile	B-C0183210
terrestrial	I-C0183210
sensor	I-C0183210
platforms	I-C0183210
for	O
proximal	B-C0022885
soil	I-C0022885
sensing	I-C0022885
pss	B-C0022885
provided	O
new	O
tools	B-C0336791
for	O
collecting	O
dense	O
spatial	O
information	B-C1533716
of	O
soils	B-C0037592
using	O
various	O
sensing	B-C0282574
principles	I-C0282574
.	O
	
yet	O
,	O
the	O
potential	O
of	O
pss	B-C0022885
for	O
assessing	B-C1516048
earthworm	B-C0086194
habitats	B-C0871648
is	O
largely	O
unexplored	O
.	O
	
this	O
study	B-C2603343
investigates	B-C1292732
whether	O
pss	B-C0022885
data	B-C1511726
contribute	O
to	O
the	O
spatial	O
prediction	B-C0681842
of	O
earthworm	B-C0086194
abundances	B-C2346714
in	O
species	B-C1705920
distribution	B-C1704711
models	B-C3161035
of	O
agricultural	B-C0562975
soils	B-C0037592
.	O
	
proximal	B-C0022885
soil	I-C0022885
sensing	I-C0022885
data	B-C1511726
,	O
e.g	O
,	O
soil	B-C0037592
electrical	B-C0013777
conductivity	I-C0013777
ec	B-C0013777
,	O
ph	B-C0020283
,	O
and	O
near	B-C0376519
infrared	I-C0376519
absorbance	I-C0376519
nir	B-C0376519
,	O
were	O
collected	B-C1516695
in	O
real-time	B-C1550177
in	O
a	O
field	B-C0562975
with	O
two	O
management	B-C0680830
strategies	I-C0680830
reduced	B-C0392756
tillage	B-C1254366
/	O
conventional	O
tillage	B-C1254366
and	O
sandy	B-C0037592
to	O
loam	B-C0037592
soils	I-C0037592
.	O
	
pss	B-C0022885
was	O
related	O
to	O
observations	B-C0302523
from	O
a	O
long-term	B-C0443252
11	O
years	B-C0439234
earthworm	B-C0086194
observation	B-C0552617
study	I-C0552617
conducted	O
at	O
42	O
plots	B-C0562975
.	O
	
earthworms	B-C0086194
were	O
sampled	B-C0870078
from	O
0.5	O
x	O
0.5	O
x	O
0.2	O
m³	O
soil	B-C0037592
blocks	O
and	O
identified	B-C0205396
to	O
species	B-C1705920
level	B-C0441889
.	O
	
sensor	B-C0600364
data	B-C1511726
were	O
highly	O
correlated	O
with	O
earthworm	B-C0086194
abundances	B-C2346714
observed	B-C1441672
in	O
reduced	B-C0392756
tillage	B-C1254366
but	O
less	O
correlated	B-C1707520
with	O
earthworm	B-C0086194
abundances	B-C2346714
observed	B-C1441672
in	O
conventional	B-C1254366
tillage	I-C1254366
.	O
	
this	O
may	O
indicate	O
that	O
management	B-C1273870
influences	B-C4054723
the	O
sensor	B-C0600364
-	O
earthworm	B-C0086194
relationship	O
.	O
	
generalized	O
additive	O
models	B-C3161035
and	O
state-space	B-C3161035
models	I-C3161035
showed	O
that	O
modelling	B-C0870071
based	O
on	O
data	B-C1511726
fusion	O
from	O
ec	B-C0013777
,	O
ph	B-C0020283
,	O
and	O
nir	B-C0376519
sensors	B-C0600364
produced	O
better	O
results	B-C0683954
than	O
modelling	B-C0870071
without	O
sensor	B-C0600364
data	B-C1511726
or	O
data	B-C1511726
from	O
just	O
a	O
single	O
sensor	B-C0600364
.	O
	
regarding	O
the	O
individual	O
earthworm	B-C0086194
species	B-C1705920
,	O
particular	O
sensor	B-C0600364
combinations	O
were	O
more	O
appropriate	O
than	O
others	O
due	O
to	O
the	O
different	O
habitat	B-C0871648
requirements	B-C1514873
of	O
the	O
earthworms	B-C0086194
.	O
	
earthworm	B-C0086194
species	B-C1705920
with	O
soil	B-C0037592
-specific	O
habitat	B-C0871648
preferences	B-C0558295
were	O
spatially	O
predicted	O
with	O
higher	O
accuracy	B-C0443131
by	O
pss	B-C0022885
than	O
more	O
ubiquitous	B-C2348867
species	B-C1705920
.	O
	
our	O
findings	B-C0243095
suggest	O
that	O
pss	B-C0022885
contributes	O
to	O
the	O
spatial	O
modelling	B-C0870071
of	O
earthworm	B-C0086194
abundances	B-C2346714
at	O
field	B-C0814860
scale	I-C0814860
and	O
that	O
it	O
will	O
support	O
species	B-C1705920
distribution	B-C1704711
modelling	B-C0870071
in	O
the	O
attempt	O
to	O
understand	O
the	O
soil	B-C0037592
-	O
earthworm	B-C0086194
relationships	O
in	O
size	B-C0870226
matters	O
to	O
function	O
brain	B-C1113695
volume	I-C1113695
correlates	B-C1707520
with	O
intrinsic	B-C0205102
brain	B-C0443158
activity	I-C0443158
across	O
healthy	B-C3898900
individuals	B-C0027361
a	O
fundamental	O
issue	O
in	O
neuroscience	B-C0027910
is	O
to	O
understand	O
the	O
structural	B-C0678594
substrates	B-C1521761
of	O
neural	O
activities	O
.	O
	
intrinsic	B-C0205102
brain	B-C0443158
activity	I-C0443158
has	O
been	O
increasingly	O
recognized	O
as	O
an	O
important	O
functional	O
activity	O
mode	O
and	O
is	O
tightly	O
linked	O
with	O
various	O
cognitive	B-C0392335
functions	I-C0392335
.	O
	
structurally	O
,	O
cognitive	B-C0392335
functions	I-C0392335
have	O
also	O
shown	O
a	O
relation	O
with	O
brain	B-C1113695
volume	I-C1113695
/	O
size	B-C0870226
.	O
	
therefore	O
,	O
an	O
association	B-C0439849
between	O
intrinsic	B-C0205102
brain	B-C0443158
activities	I-C0443158
and	O
brain	B-C1113695
volume	I-C1113695
/	O
size	B-C0870226
can	O
be	O
hypothesized	O
,	O
and	O
brain	B-C1113695
volume	I-C1113695
/	O
size	B-C0870226
may	O
impact	B-C4049986
intrinsic	B-C0205102
brain	B-C0443158
activity	I-C0443158
in	O
human	B-C0086418
brains	B-C0006104
.	O
	
the	O
present	O
study	B-C2603343
aimed	O
to	O
explicitly	O
investigate	B-C1292732
this	O
brain	B-C0006104
structure	I-C0006104
-	O
function	B-C0031843
relationship	B-C0439849
using	O
two	O
large	O
independent	O
cohorts	B-C0599755
of	O
176	O
and	O
236	O
young	B-C0238598
adults	I-C0238598
.	O
	
structural	B-C0678594
-	O
mri	B-C0024485
was	O
performed	B-C0884358
to	O
estimate	B-C0750572
the	O
brain	B-C1113695
volume	I-C1113695
,	O
and	O
resting-state	B-C4288291
functional-mri	I-C4288291
was	O
applied	O
to	O
extract	O
the	O
amplitude	B-C0392762
of	I-C0392762
low-frequency	I-C0392762
fluctuations	I-C0392762
alff	B-C0392762
,	O
an	O
imaging	O
measure	O
of	O
intrinsic	B-C0205102
brain	B-C0443158
activity	I-C0443158
.	O
	
intriguingly	O
,	O
our	O
results	O
revealed	O
a	O
robust	O
linear	B-C0205132
correlation	B-C1707520
between	O
whole-brain	B-C0870226
size	I-C0870226
and	O
alff	B-C0392762
.	O
	
moreover	O
,	O
specific	B-C0205369
brain	B-C0228179
lobes	I-C0228179
/	O
regions	B-C1273723
,	O
including	O
the	O
frontal	B-C0016733
lobe	I-C0016733
,	O
the	O
left	B-C2338540
middle	I-C2338540
frontal	I-C2338540
gyrus	I-C2338540
,	O
anterior	B-C0175190
cingulate	I-C0175190
gyrus	I-C0175190
,	O
rolandic	B-C0228265
operculum	I-C0228265
,	O
and	O
insula	B-C0021640
,	O
also	O
showed	O
a	O
reliable	B-C0205556
,	O
positive	B-C1446409
volume	B-C1113695
-	O
alff	B-C0392762
correlation	B-C1707520
in	O
the	O
two	O
cohorts	B-C0599755
.	O
	
these	O
findings	O
offer	O
direct	B-C1947931
,	O
empirical	B-C1880496
evidence	B-C0332120
of	I-C0332120
a	O
strong	B-C0442821
association	B-C0439849
between	O
brain	B-C0870226
size	I-C0870226
/	O
volume	B-C1113695
and	O
intrinsic	B-C0205102
brain	B-C0443158
activity	I-C0443158
,	O
as	O
well	O
as	O
provide	O
novel	O
insight	O
into	O
the	O
structural	B-C0678594
substrates	B-C1521761
of	O
the	O
intrinsic	B-C0205102
brain	B-C0443158
activity	I-C0443158
of	O
the	O
human	B-C0086418
brain	B-C0006104
.	O
	
on	O
the	O
control	B-C2587213
of	O
social	B-C0728831
approach-avoidance	B-C0562433
behavior	I-C0562433
neural	B-C3714606
and	O
endocrine	B-C0521425
mechanisms	B-C0441712
the	O
ability	B-C0085732
to	O
control	B-C2587213
our	O
automatic	B-C0205554
action	B-C3266814
tendencies	B-C0750492
is	O
crucial	B-C1511545
for	O
adequate	B-C0205411
social	B-C0037420
interactions	I-C0037420
.	O
	
emotional	B-C0849912
events	B-C0441471
trigger	B-C1444748
automatic	B-C0205554
approach	B-C0562433
and	I-C0562433
avoidance	I-C0562433
tendencies	B-C0750492
.	O
	
although	O
these	O
actions	B-C3266814
may	O
be	O
generally	O
adaptive	B-C0231193
,	O
the	O
capacity	B-C1516240
to	O
override	B-C1547671
these	O
emotional	B-C0221736
reactions	I-C0221736
may	O
be	O
key	B-C1706198
to	O
flexible	B-C0443220
behavior	B-C0004927
during	O
social	B-C0037420
interaction	I-C0037420
.	O
	
the	O
present	B-C0521116
chapter	B-C1552857
provides	B-C1999230
a	O
review	B-C1552617
of	O
the	O
neuroendocrine	B-C0027912
mechanisms	B-C0441712
underlying	O
this	O
ability	B-C0085732
and	O
their	O
relation	B-C0439849
to	O
social	B-C0728831
psychopathologies	B-C0033927
.	O
	
aberrant	B-C0443127
social	B-C0037397
behavior	I-C0037397
,	O
such	O
as	O
observed	B-C1441672
in	O
social	B-C4237417
anxiety	I-C4237417
or	O
psychopathy	B-C0031212
,	O
is	O
marked	B-C1706089
by	O
abnormalities	B-C1704258
in	O
approach-avoidance	B-C0562433
tendencies	B-C0750492
and	O
the	O
ability	B-C0085732
to	O
control	B-C2587213
them	O
.	O
	
key	B-C1706198
neural	B-C3714606
regions	B-C0205147
involved	B-C1314939
in	O
the	O
regulation	B-C1327622
of	O
approach-avoidance	B-C0562433
behavior	I-C0562433
are	O
the	O
amygdala	B-C0002708
,	O
widely	O
implicated	B-C4049986
in	O
automatic	B-C0205554
emotional	B-C0849912
processing	B-C0025361
,	O
and	O
the	O
anterior	B-C0205094
prefrontal	B-C0162783
cortex	I-C0162783
,	O
which	O
exerts	B-C0015264
control	B-C2587213
over	O
the	O
amygdala	B-C0002708
.	O
	
hormones	B-C0019932
,	O
especially	O
testosterone	B-C0039601
and	O
cortisol	B-C0020268
,	O
have	O
been	O
shown	O
to	O
affect	B-C0001721
approach-avoidance	B-C0562433
behavior	I-C0562433
and	O
the	O
associated	B-C0332281
neural	B-C3714606
mechanisms	B-C0441712
.	O
	
the	O
present	B-C0521116
chapter	B-C1552857
also	O
discusses	O
ways	O
to	O
directly	B-C1947931
influence	B-C4054723
social	B-C0728831
approach	B-C0562433
and	I-C0562433
avoidance	I-C0562433
behavior	I-C0562433
and	O
will	O
end	O
with	O
a	O
research	B-C0035168
agenda	B-C0681473
to	O
further	O
advance	B-C1527148
this	O
important	B-C3898777
research	B-C0035168
field	I-C0035168
.	O
	
control	B-C2587213
over	O
approach-avoidance	B-C0562433
tendencies	B-C0750492
may	O
serve	O
as	O
an	O
exemplar	B-C3161035
of	O
emotional	B-C0849912
action	B-C3266814
regulation	B-C1327622
and	O
might	O
have	O
a	O
great	B-C1704243
value	B-C3827682
in	O
understanding	B-C0162340
the	O
underlying	O
mechanisms	B-C0441712
of	O
the	O
development	B-C1527148
of	O
affective	B-C0001723
disorders	I-C0001723
.	O
	
high	O
occurrence	O
of	O
non-clear	B-C0007134
cell	I-C0007134
renal	I-C0007134
cell	I-C0007134
carcinoma	I-C0007134
in	O
oman	B-C0028971
it	O
is	O
conventionally	O
accepted	O
that	O
renal	B-C0007134
cell	I-C0007134
carcinoma	I-C0007134
rcc	B-C0007134
occurs	O
in	O
older	B-C0030705
patients	I-C0030705
and	O
the	O
clear	B-C0279702
cell	I-C0279702
type	I-C0279702
is	O
the	O
most	O
common	O
histology	B-C0019638
.	O
	
however	O
,	O
ethnic	B-C0205419
variations	I-C0205419
exist	O
and	O
this	O
study	B-C2603343
was	O
carried	O
out	O
to	O
determine	O
the	O
epidemiological	B-C0681682
pattern	I-C0681682
of	O
rcc	B-C0007134
in	O
oman	B-C0028971
.	O
	
ninety	O
rcc	B-C0007134
patients	B-C0030705
who	O
presented	B-C0449450
to	O
a	O
tertiary	B-C0587437
care	I-C0587437
center	I-C0587437
in	O
the	O
sultanate	B-C0017446
of	I-C0017446
oman	I-C0017446
from	O
2010	O
to	O
2014	O
were	O
studied	B-C2603343
.	O
	
the	O
main	B-C0243095
findings	I-C0243095
were	O
that	O
the	O
median	B-C0001779
age	I-C0001779
of	O
presentation	B-C0449450
was	O
low	B-C0205251
,	O
more	O
patients	B-C0030705
presented	B-C0449450
with	O
localized	B-C0392752
stage	B-C1306673
,	O
and	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
non-clear	B-C0007134
especially	O
papillary	B-C1306837
histology	B-C0019638
.	O
	
data	B-C1511726
from	O
other	O
gulf	B-C0454664
countries	I-C0454664
patient	B-C2094221
mobility	I-C2094221
for	O
elective	B-C0814500
secondary	B-C0018747
health	I-C0018747
care	I-C0018747
services	I-C0018747
in	O
response	B-C2911692
to	O
patient	B-C0600591
choice	I-C0600591
policies	I-C0600591
a	O
systematic	B-C1955832
review	I-C1955832
our	O
review	O
establishes	O
the	O
empirical	B-C1880496
evidence	B-C3887511
for	O
patient	B-C2094221
mobility	I-C2094221
for	O
elective	B-C3494402
secondary	I-C3494402
care	I-C3494402
services	I-C3494402
in	O
countries	B-C0454664
that	O
allow	O
patients	B-C0030705
to	O
choose	O
their	O
health	B-C1999121
care	I-C1999121
provider	I-C1999121
.	O
	
pubmed	B-C1138432
and	O
embase	B-C0282574
were	O
searched	O
for	O
relevant	O
articles	B-C1706852
between	O
1990	O
and	O
2015	O
.	O
	
of	O
5	O
titles	B-C1705823
/	O
abstracts	B-C0600678
reviewed	B-C1709940
,	O
26	O
studies	B-C0008972
were	O
included	O
.	O
	
the	O
studies	B-C0008972
used	O
three	O
main	O
methodological	B-C0025662
models	B-C3161035
to	O
establish	O
mobility	B-C0425245
.	O
	
variation	B-C0205419
in	O
the	O
extent	O
of	O
patient	B-C2094221
mobility	I-C2094221
was	O
observed	O
across	O
the	O
studies	O
.	O
	
mobility	B-C0425245
was	O
positively	O
associated	B-C0332281
with	I-C0332281
lower	B-C0814636
waiting	I-C0814636
times	I-C0814636
,	O
indicators	B-C1522602
of	O
better	B-C0034379
service	I-C0034379
quality	I-C0034379
,	O
and	O
access	O
to	O
advanced	B-C1510819
technology	I-C1510819
.	O
	
it	O
was	O
negatively	O
associated	O
with	O
advanced	B-C0001792
age	I-C0001792
or	O
lower	O
socioeconomic	B-C0748878
backgrounds	O
.	O
	
from	O
a	O
policy	B-C0242456
perspective	B-C0032670
we	O
demonstrate	O
that	O
a	O
significant	O
proportion	B-C1709707
of	O
patients	B-C0030705
are	O
prepared	O
to	O
travel	B-C0040802
beyond	O
their	O
nearest	O
provider	B-C1999121
for	O
elective	B-C0814500
services	I-C0814500
.	O
	
as	O
a	O
consequence	O
,	O
some	O
providers	B-C1999121
are	O
likely	O
to	O
be	O
""""	O
winners	B-C0511302
""""	O
and	O
others	O
""""	O
losers	B-C0243095
""""	O
which	O
could	O
result	O
in	O
overall	O
decreased	B-C0205216
provider	B-C1999121
capacity	B-C1516240
or	O
inefficient	B-C0231185
utilization	O
of	O
existing	O
services	B-C0018747
.	O
	
equity	B-C4042901
new	B-C0205314
breast	B-C0024902
pain	I-C0024902
chart	B-C0007963
for	O
objective	B-C0034869
record	I-C0034869
of	O
mastalgia	B-C0024902
mastalgia	B-C0024902
is	O
the	O
commonest	B-C0205214
affliction	B-C0018235
of	O
mammary	B-C0929301
gland	I-C0929301
among	O
ladies	B-C0043210
of	O
the	O
reproductive	B-C0035156
age	B-C0027362
group	I-C0027362
.	O
	
since	O
etiopathogenesis	B-C1510540
and	O
therapy	B-C0087111
are	O
different	B-C1705242
for	O
cyclical	B-C0405472
and	O
noncyclical	B-C0405473
pain	I-C0405473
,	O
it	O
is	O
imperative	O
to	O
ascertain	O
the	O
exact	O
type	O
correctly	O
.	O
	
this	O
is	O
usually	O
done	O
in	O
the	O
breast	B-C3810844
clinics	I-C3810844
by	O
advising	O
the	O
patient	B-C0030705
to	O
fill	O
a	O
pain	B-C0451366
diary	I-C0451366
over	O
a	O
period	B-C1948053
of	O
2	O
months	B-C0439231
over	O
two	O
menstrual	B-C0025329
cycles	I-C0025329
.	O
	
the	O
cardiff	B-C0007963
pain	I-C0007963
chart	I-C0007963
records	I-C0007963
the	O
severity	B-C0439793
of	O
pain	B-C0030193
in	O
the	O
form	O
of	O
a	O
triangle	B-C0205119
for	O
mild	B-C2945599
to	O
moderate	B-C0278139
pain	I-C0278139
and	O
a	O
square	B-C0205120
for	O
severe	B-C0278140
pain	I-C0278140
.	O
	
moreover	O
,	O
cardiff	B-C0007963
pain	I-C0007963
chart	I-C0007963
does	O
not	O
allow	O
a	O
patient	B-C0030705
to	O
record	B-C2355580
the	O
severity	B-C0439793
of	O
pain	B-C0030193
on	O
days	B-C0439228
of	O
menses	B-C0025344
,	O
as	O
she	O
has	O
to	O
put	O
the	O
letter	O
"""p"""	O
in	O
the	O
box	O
.	O
	
these	O
problems	B-C0033213
have	O
been	O
resolved	B-C2699488
in	O
the	O
new	B-C0205314
breast	B-C0024902
pain	I-C0024902
chart	B-C0007963
.	O
	
in	O
the	O
new	B-C0205314
pain	B-C0007963
chart	I-C0007963
,	O
the	O
lady	B-C0043210
records	B-C2355580
pain	B-C0030193
severity	B-C0439793
in	O
the	O
form	O
of	O
visual	B-C2960751
linear	I-C2960751
analogue	I-C2960751
scale	I-C2960751
score	I-C2960751
on	O
every	B-C0332173
day	I-C0332173
of	O
menstrual	B-C0025329
cycle	I-C0025329
.	O
	
she	O
enters	O
her	O
menstrual	B-C0025329
experience	B-C0596545
on	O
a	O
separate	O
part	O
of	O
chart	B-C0007963
,	O
which	O
allows	O
us	O
to	O
visualize	B-C0449911
the	O
full	O
month's	B-C0439231
pain	B-C0030193
severity	B-C0439793
the	O
demand	O
for	O
cigarettes	B-C0677453
in	O
tanzania	B-C0039298
and	O
implications	B-C0814846
for	O
tobacco	B-C0040329
taxation	B-C0681007
policy	I-C0681007
the	O
study	B-C2603343
attempts	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	B-C0677453
in	O
tanzania	B-C0039298
and	O
presents	O
simulation	B-C0679083
results	B-C1274040
on	O
the	O
effect	B-C1280500
of	O
the	O
cigarette	B-C0677453
excise	B-C0681045
tax	I-C0681045
on	O
smoking	B-C0037369
participation	B-C0679823
,	O
government	B-C0681043
revenue	I-C0681043
,	O
and	O
related	O
topics	O
.	O
	
after	O
briefly	O
summarizing	O
the	O
magnitude	B-C1704240
and	O
spread	O
of	O
cigarette	B-C0459840
consumption	I-C0459840
in	O
the	O
country	B-C0454664
,	O
the	O
paper	O
reviews	O
some	O
empirical	O
estimates	O
from	O
african	B-C0454695
and	O
other	O
countries	B-C0454664
.	O
	
the	O
2008	O
tanzanian	B-C0039298
household	B-C0006347
budget	I-C0006347
survey	B-C0038951
was	O
used	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	B-C0677453
in	O
tanzania	B-C0039298
.	O
	
the	O
descriptive	O
statistics	O
suggest	O
that	O
the	O
smoking	B-C0037369
prevalence	O
for	O
tanzania	B-C0039298
is	O
15.35	O
percent	O
with	O
low	O
variability	O
across	O
expenditure	B-C0681860
income	I-C0681860
groups	I-C0681860
.	O
	
smoking	B-C0037369
intensity	O
and	O
per	B-C0681013
capita	I-C0681013
consumption	I-C0681013
were	O
estimated	O
at	O
7.08	O
cigarettes	B-C0677453
and	O
1.33	O
cigarettes	B-C0677453
,	O
respectively	O
,	O
a	O
relatively	O
low	O
value	O
.	O
	
a	O
two-part	B-C3161035
demand	I-C3161035
equation	I-C3161035
model	I-C3161035
was	O
used	O
to	O
estimate	O
various	O
elasticities	B-C0680960
.	O
	
for	O
the	O
overall	O
equation	B-C0552449
,	O
the	O
price	B-C0814751
elasticities	I-C0814751
of	O
smoking	B-C0037369
participation	B-C0679823
,	O
smoking	B-C0037369
intensity	O
,	O
and	O
total	O
elasticity	B-C0680960
were	O
estimated	O
at	O
-0	O
,	O
-0	O
,	O
and	O
-1	O
,	O
respectively	O
.	O
	
compared	O
to	O
similar	O
results	O
in	O
other	O
developing	B-C0011750
countries	I-C0011750
,	O
the	O
estimates	O
appear	O
quite	O
high	O
.	O
	
when	O
estimated	O
by	O
expenditure	B-C0681860
income	I-C0681860
groups	I-C0681860
,	O
the	O
magnitude	B-C1704240
of	O
the	O
elasticity	B-C0680960
appears	O
higher	O
among	O
high	B-C0681860
expenditure	I-C0681860
groups	I-C0681860
than	O
among	O
low	B-C0681860
expenditure	I-C0681860
groups	I-C0681860
.	O
	
two	O
simulation	B-C0679083
exercises	O
were	O
undertaken	O
.	O
	
first	O
,	O
the	O
effect	B-C1280500
of	O
different	O
excise	B-C0681045
rates	B-C1521828
on	O
smoking	B-C0037369
participation	B-C1521828
rate	I-C1521828
,	O
cigarette	B-C0459840
consumption	I-C0459840
,	O
tax	B-C0681043
revenue	I-C0681043
,	O
and	O
related	O
responses	O
was	O
estimated	O
and	O
highlighted	O
.	O
	
second	O
,	O
the	O
same	O
exercise	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	B-C1280500
of	O
a	O
given	O
increase	B-C0442805
in	O
the	O
cigarette	B-C0677453
excise	B-C0681045
tax	I-C0681045
on	O
various	O
expenditure	B-C0681860
groups	I-C0681860
.	O
	
the	O
overall	O
results	B-C1274040
suggest	O
that	O
an	O
increase	B-C0442805
in	O
the	O
excise	B-C0681045
tax	I-C0681045
on	O
cigarettes	B-C0677453
in	O
tanzania	B-C0039298
would	O
reduce	O
cigarette	B-C0459840
consumption	I-C0459840
and	O
increase	B-C0442805
government	B-C0681043
tax	I-C0681043
revenue	I-C0681043
.	O
	
physicians'	B-C0031831
knowledge	O
on	O
the	O
work-related	B-C0871617
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disease	I-C0024117
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disease	I-C0024117
copd	B-C0024117
may	O
be	O
induced	O
by	O
the	O
work	B-C0162579
environment	I-C0162579
conditions	B-C0348080
.	O
	
according	O
to	O
the	O
estimates	B-C0750572
,	O
10-20%	O
of	O
all	O
copd	B-C0024117
cases	B-C0868928
are	O
associated	B-C0332281
with	I-C0332281
occupational	B-C0028798
exposure	I-C0028798
to	O
dusts	B-C0013330
and	O
irritant	B-C0022108
gases	B-C0017110
.	O
	
however	O
,	O
in	O
2014	O
,	O
only	O
11	O
cases	B-C0868928
of	O
work-related	B-C0871617
copd	B-C0024117
were	O
recognized	O
in	O
poland	B-C0032356
.	O
	
the	O
aim	O
of	O
the	O
study	B-C2603343
was	O
to	O
analyze	B-C0936012
the	O
reasons	O
for	O
the	O
low	B-C0205251
incidence	B-C0021149
of	O
work-related	B-C0871617
copd	B-C0024117
in	O
the	O
context	B-C0449255
of	O
pulmonologists	B-C0586859
'	O
knowledge	O
about	O
occupational	B-C0521127
risk	B-C0035648
factors	I-C0035648
and	O
procedures	B-C2700391
on	O
reporting	B-C0700287
suspected	B-C0277540
occupational	B-C0028797
diseases	I-C0028797
.	O
	
a	O
survey	B-C0038951
included	O
94	O
pulmonologists	B-C0586859
randomly	B-C0439605
selected	O
out	O
of	O
225	O
specialists	B-C0920580
registered	O
at	O
the	O
local	B-C1708333
physicians	I-C1708333
chamber	I-C1708333
in	O
łódź	B-C0681784
.	O
	
the	O
study	B-C2603343
was	O
performed	B-C0884358
anonymously	B-C2346787
with	O
the	O
use	O
of	O
original	O
questionnaire	B-C0034394
.	O
	
more	O
than	O
a	O
half	O
of	O
the	O
surveyed	B-C0038951
pulmonologists	B-C0586859
identified	B-C0205396
environmental	B-C0014406
risk	B-C0035648
factors	I-C0035648
for	O
copd	B-C0024117
correctly	O
,	O
while	O
only	O
23.4	O
properly	O
identified	B-C0205396
the	O
main	O
occupational	B-C0521127
risk	B-C0035648
factors	I-C0035648
as	O
the	O
cause	B-C0085978
of	O
copd	B-C0024117
.	O
	
only	O
58.5	O
of	O
the	O
pulmonologists	B-C0586859
always	O
asked	O
their	O
patients	B-C0030705
suffering	B-C0231303
from	O
copd	B-C0024117
about	O
their	O
job	B-C0028811
/	O
profession	B-C0028811
and	O
60.6	O
of	O
them	O
did	O
not	O
have	O
any	O
knowledge	O
about	O
procedures	B-C2700391
on	O
reporting	B-C0700287
suspected	B-C0277540
occupational	B-C0028797
diseases	I-C0028797
.	O
	
the	O
physicians	B-C0031831
rarely	B-C0522498
ask	O
patients	B-C0030705
suffering	B-C0231303
from	O
copd	B-C0024117
about	O
their	O
job	B-C0028811
/	O
profession	B-C0028811
and	O
the	O
relationship	B-C0439849
between	O
their	O
ailments	B-C0221423
and	O
occupational	B-C0028798
exposure	I-C0028798
.	O
	
what	O
is	O
more	O
,	O
they	O
do	O
not	O
know	O
legal	B-C0680575
regulations	I-C0680575
on	O
proper	O
referral	B-C0034927
of	I-C0034927
a	I-C0034927
patient	I-C0034927
with	O
a	O
suspected	B-C0277540
case	B-C0868928
of	O
occupational	B-C0028797
disease	I-C0028797
.	O
	
the	O
results	B-C1274040
of	O
the	O
study	B-C2603343
clearly	O
indicate	B-C3146298
that	O
there	O
is	O
an	O
urgent	O
need	O
for	O
increasing	B-C0442808
pulmonologists	B-C0586859
'	O
knowledge	O
on	O
work-related	B-C0871617
copd	B-C0024117
.	O
	
case	B-C0085973
report	I-C0085973
of	O
necrotizing	B-C0238124
fasciitis	I-C0238124
associated	B-C0332281
with	I-C0332281
streptococcus	B-C0038410
pneumoniae	I-C0038410
necrotizing	B-C0238124
fasciitis	I-C0238124
,	O
caused	O
by	O
streptococcus	B-C0038410
pneumoniae	I-C0038410
,	O
is	O
an	O
extremely	B-C0522498
rare	I-C0522498
and	O
life-threatening	B-C2826244
bacterial	B-C0004611
soft	B-C0149778
tissue	I-C0149778
infection	I-C0149778
.	O
	
we	O
report	B-C0700287
a	O
case	B-C0868928
of	O
early	O
necrotizing	B-C0238124
fasciitis	I-C0238124
associated	B-C0332281
with	I-C0332281
streptococcus	B-C0038410
pneumoniae	I-C0038410
infection	B-C3714514
in	O
a	O
26-	O
year	B-C0439234
-old	O
man	B-C0025266
who	O
was	O
immunocompromised	B-C0085393
with	O
mixed	B-C0026272
connective	I-C0026272
tissue	I-C0026272
disease	I-C0026272
.	O
	
the	O
patient	B-C0030705
presented	O
with	O
acute	B-C0205178
,	O
painful	B-C0030193
,	O
erythematous	B-C0332476
,	O
and	O
edematous	B-C0521464
skin	I-C0521464
lesions	B-C0221198
of	O
his	O
right	B-C0817923
lower	I-C0817923
back	I-C0817923
,	O
which	O
rapidly	O
progressed	B-C1280477
to	O
the	O
right	B-C0230431
knee	I-C0230431
.	O
	
the	O
patient	B-C0030705
underwent	O
surgical	B-C0184899
exploration	I-C0184899
,	O
and	O
a	O
diagnosis	B-C0011900
of	O
necrotizing	B-C0238124
fasciitis	I-C0238124
was	O
confirmed	O
by	O
pathological	B-C1521733
evidence	B-C3887511
of	O
necrosis	B-C0027540
of	O
the	O
fascia	B-C0015641
and	O
neutrophil	B-C0751982
infiltration	I-C0751982
in	O
tissue	B-C3864006
biopsies	I-C3864006
.	O
	
cultures	B-C3826495
of	O
fascial	B-C0015450
tissue	B-C3864006
biopsies	I-C3864006
and	O
blood	B-C0178913
samples	I-C0178913
were	O
positive	B-C1446409
for	O
streptococcus	B-C0038410
pneumoniae	I-C0038410
.	O
	
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	B-C0700287
of	O
necrotizing	B-C0238124
fasciitis	I-C0238124
resulting	O
from	O
streptococcus	B-C0038410
pneumoniae	I-C0038410
diagnosed	B-C0011900
at	O
early	O
phase	B-C0205390
the	O
patient	B-C1115804
recovered	I-C1115804
well	O
without	O
surgical	B-C0455097
debridement	I-C0455097
.	O
	
a	O
comparative	B-C1579762
study	I-C1579762
of	O
the	O
efficacy	B-C1280519
of	O
iv	B-C0348016
dexketoprofen	B-C0772505
,	O
lornoxicam	B-C0055477
,	O
and	O
diclophenac	B-C1254351
sodium	I-C1254351
on	O
postoperative	B-C0853389
analgesia	I-C0853389
and	O
tramadol	B-C0040610
consumption	B-C0678263
in	O
patients	B-C0030705
receiving	O
patient-controlled	B-C0078944
tramadol	B-C0040610
this	O
study	B-C2603343
was	O
designed	B-C1707689
to	O
compare	B-C1707455
the	O
effects	B-C1704420
of	I-C1704420
dexketoprofen	B-C0772505
,	O
lornoxicam	B-C0055477
,	O
and	O
diclophenac	B-C1254351
sodium	I-C1254351
on	O
postoperative	B-C0853389
analgesia	I-C0853389
and	O
tramadol	B-C0040610
consumption	B-C0678263
in	O
patients	B-C0030705
receiving	O
postoperative	B-C0032790
patient-controlled	B-C0078944
tramadol	B-C0040610
after	O
a	O
major	B-C0205164
abdominal	B-C0198482
surgery	I-C0198482
.	O
	
eighty	O
patients	B-C0030705
were	O
randomized	B-C3815594
to	O
receive	O
one	O
of	O
the	O
four	O
study	B-C2603343
drugs	B-C1254351
.	O
	
patients	B-C0030705
in	O
group	B-C0441833
dexketoprofen	B-C0772505
dt	B-C0772505
received	O
iv	B-C0348016
50	O
mg	O
dexketoprofen	B-C0772505
,	O
group	B-C0441833
lornoxicam	B-C0055477
lr	B-C0055477
received	O
iv	B-C0348016
8	O
mg	O
lornoxicam	B-C0055477
,	O
group	B-C0441833
diclophenac	B-C1254351
sodium	I-C1254351
ds	B-C1254351
received	O
75	O
mg	O
iv	B-C0348016
diclophenac	B-C1254351
sodium	I-C1254351
and	O
group	B-C0441833
saline	B-C0036082
s	B-C0036082
received	O
0.9	O
saline	B-C0036082
in	O
2	O
ml	O
syringes	B-C0039142
,	O
20	O
min	B-C0439232
before	O
the	O
end	O
of	O
anaesthesia	B-C0002903
.	O
	
a	O
standardized	B-C1442989
1	O
mg	O
kg	O
dose	B-C0178602
of	O
tramadol	B-C0040610
was	O
routinely	B-C0205547
administered	B-C1621583
to	O
all	O
patients	B-C0030705
as	O
the	O
loading	B-C3714444
dose	I-C3714444
at	O
the	O
end	O
of	O
surgery	B-C0543467
.	O
	
postoperatively	B-C0032790
,	O
whenever	O
patients	B-C0030705
requested	O
,	O
they	O
were	O
allowed	O
to	O
use	O
a	O
tramadol	B-C0040610
patient-controlled	B-C3266095
analgesia	I-C3266095
device	I-C3266095
giving	O
a	O
bolus	B-C1511237
dose	I-C1511237
0.2	O
mg	O
kg	O
of	O
tramadol	B-C0040610
.	O
	
pain	B-C0030193
,	O
discomfort	B-C0231218
,	O
and	O
sedation	B-C0235195
scores	B-C0449820
,	O
cumulative	B-C1511559
tramadol	B-C0040610
consumption	B-C0678263
,	O
supplemental	B-C2348609
meperidine	B-C0025376
requirement	B-C1514873
,	O
and	O
side	B-C0879626
effects	I-C0879626
were	O
recorded	O
.	O
	
visual	B-C0681889
rating	I-C0681889
scale	I-C0681889
and	O
patient	B-C0030705
discomfort	B-C0231218
scores	B-C0449820
were	O
significantly	B-C0750502
lower	B-C2003888
in	O
dt	B-C0772505
,	O
lr	B-C0055477
and	O
ds	B-C1254351
groups	B-C0441833
compared	O
to	O
those	O
in	O
in	O
group	B-C0441833
s	B-C0036082
p<0	O
.	O
	
cumulative	B-C1511559
tramadol	B-C0040610
consumption	B-C0678263
was	O
significantly	B-C0750502
lower	B-C2003888
in	O
non-steroidal	B-C3536840
anti-inflammatory	I-C3536840
drug	I-C3536840
nsaid	B-C3536840
treated	B-C1522326
groups	B-C0441833
at	O
each	O
study	B-C2347804
period	I-C2347804
after	O
the	O
second	O
postoperative	B-C0032790
hour	B-C0439227
than	O
in	O
group	B-C0441833
s	B-C0036082
p<0	O
.	O
	
supplemental	B-C2348609
meperidine	B-C0025376
requirement	B-C1514873
was	O
significantly	B-C0750502
higher	O
in	O
group	B-C0441833
s	B-C0036082
at	O
each	O
study	B-C2347804
period	I-C2347804
after	O
postoperative	B-C0032790
30	O
min	B-C0439232
than	O
in	O
nsaid	B-C3536840
-	O
treated	B-C1522326
groups	B-C0441833
p<0	O
.	O
	
after	O
major	B-C0205164
abdominal	B-C0198482
surgery	I-C0198482
,	O
adding	O
iv	B-C0348016
diclophenac	B-C0012091
,	O
lornoxicam	B-C0055477
or	O
dexketoprofen	B-C0772505
to	O
patient-controlled	B-C0078944
tramadol	B-C0040610
resulted	O
in	O
lower	B-C2003888
pain	B-C0030193
scores	B-C0449820
,	O
smaller	B-C0547044
tramadol	B-C0040610
consumption	B-C0678263
,	O
less	O
rescue	O
supplemental	B-C2348609
analgesic	B-C0002771
requirement	B-C1514873
,	O
and	O
fewer	O
side	B-C0879626
effects	I-C0879626
compared	O
with	O
the	O
tramadol	B-C0040610
alone	O
perioperative	B-C0150706
management	I-C0150706
of	O
severe	B-C4013784
hypertension	I-C4013784
during	O
laparoscopic	B-C0751429
surgery	I-C0751429
for	O
pheochromocytoma	B-C0031511
phaeochromocytoma	B-C0031511
is	O
a	O
catecholamine-secreting	B-C1325901
vascular	B-C0282607
tumour	I-C0282607
that	O
is	O
derived	O
from	O
chromaffin	B-C0376604
cell	I-C0376604
.	O
	
lethal	B-C3151529
cardiovascular	B-C0161816
complications	I-C0161816
,	O
such	O
as	O
serious	O
hypertension	B-C0020538
,	O
myocardial	B-C0027051
infarction	I-C0027051
and	O
aortic	B-C0340643
dissection	I-C0340643
,	O
may	O
occur	O
because	O
of	O
uncontrolled	B-C0271748
catecholamine	I-C0271748
release	I-C0271748
.	O
	
each	O
stage	B-C0205390
of	O
anaesthesia	B-C1300200
management	I-C1300200
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive	B-C0271748
catecholamine	I-C0271748
secretion	I-C0271748
that	O
may	O
occur	O
during	O
induction	B-C0857127
,	O
perioperative	B-C1518988
stage	I-C1518988
and	O
surgical	B-C0185111
manipulation	I-C0185111
.	O
	
in	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	B-C0150706
preparation	I-C0150706
and	O
severe	B-C1254363
,	O
persistent	I-C1254363
hypertension	I-C1254363
attack	I-C1254363
management	I-C1254363
with	O
a	O
combination	O
of	O
α-adrenergic	B-C3536752
blockade	I-C3536752
,	O
β-adrenergic	B-C3536830
blockade	I-C3536830
,	O
sodium	B-C0037533
nitroprusside	I-C0037533
and	O
remifentanil	B-C0246631
in	O
a	O
patient	B-C0030705
who	O
underwent	O
laparoscopic	B-C0751429
surgery	I-C0751429
for	O
a	O
case	B-C0868928
based	O
reflection	B-C0243095
on	O
communicating	B-C0205196
end	I-C0205196
of	O
life	B-C0376558
information	B-C1533716
in	O
non-english	B-C1546417
speaking	I-C1546417
patients	B-C0030705
mr	O
x	O
was	O
a	O
56	O
year	B-C1510829
old	I-C1510829
chinese	B-C0152035
man	B-C0025266
non-english	B-C1546417
speaking	I-C1546417
,	O
who	O
presented	O
to	O
the	O
emergency	B-C0562508
department	I-C0562508
with	O
a	O
range	O
of	O
non-specific	B-C0205370
symptoms	B-C1457887
.	O
	
on	O
full	O
workup	O
,	O
he	O
was	O
diagnosed	B-C0011900
with	O
an	O
advanced	B-C0235974
cancer	I-C0235974
of	I-C0235974
the	I-C0235974
pancreas	I-C0235974
.	O
	
it	O
was	O
an	O
aggressive	B-C2945759
,	O
highly	O
treatment	B-C0871547
resistant	I-C0871547
cancer	I-C0871547
,	O
with	O
an	O
alarmingly	O
poor	B-C0278252
prognosis	I-C0278252
.	O
	
before	O
the	O
diagnosis	B-C0011900
had	O
been	O
made	O
,	O
the	O
family	B-C0015576
had	O
informed	O
our	O
team	B-C0086390
that	O
we	O
were	O
not	O
to	O
discuss	O
medical	B-C0205476
issues	B-C0033213
with	O
mr	O
x	O
directly	O
,	O
and	O
that	O
upon	O
arriving	O
on	O
a	O
diagnosis	B-C0011900
we	O
were	O
to	O
come	O
to	O
them	O
first	O
and	O
they	O
would	O
subsequently	O
inform	O
him	O
.	O
	
they	O
reported	O
that	O
mr	O
x	O
was	O
in	O
support	B-C1521721
of	O
this	O
arrangement	O
.	O
	
eventually	O
we	O
told	O
the	O
family	B-C0015576
about	O
mr	O
x's	O
diagnosis	B-C0011900
,	O
and	O
they	O
asserted	O
their	O
collective	B-C0680341
will	I-C0680341
to	O
keep	O
this	O
information	B-C1533716
from	O
him	O
,	O
reaffirming	O
that	O
all	O
medical	B-C0205476
discussion	B-C0557061
go	O
through	O
them	O
.	O
	
however	O
,	O
the	O
doctor	B-C0031831
in	I-C0031831
charge	I-C0031831
explained	O
the	O
diagnosis	B-C0011900
to	O
mr	O
x	O
using	O
an	O
interpreter	B-C0150646
while	O
his	O
family	B-C0015576
were	O
away	O
from	O
his	O
bed	B-C0004916
.	O
	
in	O
this	O
discussion	O
,	O
i	O
consider	O
this	O
case	B-C0868928
from	O
the	O
perspective	O
of	O
respecting	B-C1279750
patients'	I-C1279750
and	I-C1279750
families'	I-C1279750
preferences	I-C1279750
around	O
medical	B-C0237726
treatment	I-C0237726
and	I-C0237726
care	I-C0237726
.	O
	
difference-in-differences	B-C1710191
method	I-C1710191
in	O
comparative	B-C2718022
effectiveness	I-C2718022
research	I-C2718022
utility	O
with	O
unbalanced	B-C0681860
groups	I-C0681860
comparative	B-C2718022
effectiveness	I-C2718022
research	I-C2718022
cer	B-C2718022
often	O
includes	O
observational	B-C3658316
studies	I-C3658316
utilizing	O
administrative	B-C1320722
data	I-C1320722
.	O
	
multiple	O
conditioning	O
methods	O
can	O
be	O
used	O
for	O
cer	B-C2718022
to	O
adjust	O
for	O
group	B-C0681860
differences	B-C1705242
,	O
including	O
difference-in-differences	B-C1710191
did	I-C1710191
estimation	I-C1710191
.	O
	
this	O
study	O
presents	O
did	B-C1710191
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	B-C0025663
to	O
estimate	O
treatment	B-C0085415
outcomes	I-C0085415
in	O
the	O
cer	B-C2718022
setting	O
by	O
utilizing	O
the	O
marketscan	B-C0242356
databases	I-C0242356
for	O
multiple	B-C0026769
sclerosis	I-C0026769
ms	B-C0026769
patients	B-C0030705
receiving	O
different	O
therapies	B-C0087111
.	O
	
the	O
sample	O
included	O
6762	O
patients	B-C0030705
,	O
with	O
363	O
in	O
the	O
test	B-C2348484
cohort	I-C2348484
glatiramer	B-C0289884
acetate	I-C0289884
ga	B-C0289884
switched	B-C2936279
to	O
fingolimod	B-C1699926
fty	B-C1699926
and	O
6399	O
in	O
the	O
control	B-C0009932
cohort	I-C0009932
ga	B-C0289884
only	O
,	O
no	B-C0243095
switch	I-C0243095
from	O
a	O
us	B-C0242356
administrative	I-C0242356
claims	I-C0242356
database	I-C0242356
.	O
	
a	O
trend	B-C0681702
analysis	I-C0681702
was	O
conducted	O
to	O
rule	O
out	O
concerns	O
regarding	O
regression	B-C0034980
to	O
the	O
mean	B-C0444504
and	O
to	O
compare	O
relapse	B-C0035020
rates	O
among	O
treatment	B-C2348484
cohorts	I-C2348484
.	O
	
did	B-C1710191
analysis	I-C1710191
was	O
used	O
to	O
enable	O
comparisons	B-C1707455
among	O
the	O
test	B-C2348484
and	O
control	B-C0009932
cohorts	I-C0009932
.	O
	
logistic	B-C0206031
regression	I-C0206031
was	O
used	O
to	O
estimate	O
the	O
probability	B-C0033204
of	O
relapse	B-C0035020
after	O
switching	B-C2936279
from	O
ga	B-C0289884
to	O
fty	B-C1699926
,	O
and	O
to	O
compare	B-C1707455
group	B-C0681860
differences	B-C1705242
in	O
the	O
pre	B-C0332152
-	O
and	O
post	B-C0687676
-	O
index	B-C1948053
periods	I-C1948053
.	O
	
crude	O
did	B-C1710191
analysis	I-C1710191
showed	O
that	O
in	O
the	O
pre	B-C0332152
-	O
index	B-C1948053
period	I-C1948053
more	O
patients	B-C0030705
in	O
the	O
test	B-C2348484
cohort	I-C2348484
experienced	O
an	O
ms	B-C0026769
relapse	B-C0035020
and	O
had	O
a	O
higher	O
mean	B-C0444504
number	I-C0444504
of	O
relapses	B-C0035020
than	O
in	O
the	O
control	B-C0009932
cohort	I-C0009932
.	O
	
during	O
the	O
pre	B-C0332152
-	O
index	B-C1948053
period	I-C1948053
,	O
numeric	B-C1704455
and	O
relative	O
data	O
for	O
ms	B-C0026769
relapses	B-C0035020
in	O
patients	B-C0030705
in	O
the	O
test	B-C2348484
cohort	I-C2348484
were	O
significantly	O
higher	O
than	O
in	O
the	O
control	B-C0009932
cohort	I-C0009932
,	O
while	O
no	B-C1273937
significant	I-C1273937
between-	O
group	B-C0681860
differences	B-C1705242
emerged	O
during	O
the	O
post	B-C0687676
-	O
index	B-C1948053
period	I-C1948053
.	O
	
generalized	O
linear	B-C0023732
modeling	I-C0023732
with	O
did	B-C1710191
regression	B-C0681925
estimation	I-C0681925
showed	O
that	O
the	O
mean	O
number	O
of	O
ms	B-C0026769
relapses	B-C0035020
decreased	O
significantly	O
in	O
the	O
post	B-C0687676
-	O
index	B-C1948053
period	I-C1948053
among	O
patients	B-C0030705
in	O
the	O
test	B-C2348484
cohort	I-C2348484
compared	O
with	O
patients	B-C0030705
in	O
the	O
control	B-C0009932
cohort	I-C0009932
.	O
	
in	O
this	O
study	O
,	O
an	O
ms	B-C0026769
population	B-C1257890
was	O
utilized	O
to	O
demonstrate	O
how	O
did	B-C1710191
can	O
be	O
applied	O
to	O
estimate	O
treatment	B-C1518681
effects	I-C1518681
in	O
a	O
heterogeneous	B-C0019409
population	B-C1257890
,	O
where	O
the	O
test	B-C2348484
and	O
control	B-C0009932
cohorts	I-C0009932
varied	O
greatly	O
.	O
	
the	O
results	O
show	O
that	O
did	B-C1710191
offers	O
a	O
robust	O
method	O
for	O
comparing	B-C1707455
diverse	B-C1880371
cohorts	B-C0599755
when	O
other	O
risk-adjustment	B-C0600568
methods	I-C0600568
metabolomic	B-C1328813
analysis	B-C1524024
of	O
glycerophospholipid	B-C0162448
signatures	O
of	O
inflammation	B-C0021368
treated	B-C0332293
with	I-C0332293
non-steroidal	B-C0003211
anti-inflammatory	I-C0003211
drugs	I-C0003211
-induced-	O
raw264.7	B-C0024432
cells	I-C0024432
using	O
1	B-C0877853
nmr	I-C0877853
and	O
u-hplc	B-C0008562
/	O
q-tof-ms	B-C0599827
non-destructive	B-C0877853
proton	I-C0877853
nuclear	I-C0877853
magnetic	I-C0877853
resonance	I-C0877853
1	I-C0877853
nmr	I-C0877853
spectroscopy	I-C0877853
and	O
highly	B-C0439822
sensitive	I-C0439822
ultra-performance	B-C0008562
liquid	I-C0008562
chromatography	I-C0008562
quadrupole	B-C0599827
time-of-flight	I-C0599827
mass	I-C0599827
spectrometry	I-C0599827
u-hplc	B-C0008562
/	O
q-tof-ms	B-C0599827
coupled	O
to	O
data	B-C0868941
processing	I-C0868941
methods	B-C0025663
were	O
applied	O
to	O
analyze	O
the	O
metabolic	B-C1328813
profiling	I-C1328813
changes	O
of	O
glycerophospholipids	B-C0162448
gpls	B-C0162448
in	O
raw264.7	B-C0024432
cells	I-C0024432
from	O
inflammation	B-C0021368
to	O
prognosis	B-C0033325
.	O
	
analysis	B-C0936012
of	O
1	B-C0877853
nmr	I-C0877853
was	O
shown	O
that	O
the	O
models	B-C3161035
were	O
grouped	B-C1522242
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	B-C1705242
.	O
	
based	O
on	O
the	O
highly	B-C0205352
simple	I-C0205352
,	O
accurate	B-C0443131
,	O
non-targeted	O
and	O
non-destructively	O
advantages	O
of	O
1	B-C0877853
nmr	I-C0877853
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti-inflammatory	B-C0003209
drugs	I-C0003209
in	O
the	O
metabolic	B-C1328813
profiling	I-C1328813
of	O
gpls	B-C0162448
.	O
	
58	O
gpls	B-C0162448
were	O
identified	B-C0205396
by	O
u-hplc	B-C0008562
/	O
q-tof-ms	B-C0599827
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	B-C0205396
in	O
this	O
study	B-C2603343
compared	O
with	O
our	O
previous	O
results	O
.	O
	
in	O
addition	O
,	O
ten	O
potential	B-C3245505
biomarkers	B-C0005516
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	B-C1959616
pc	B-C1959616
16	O
and	O
18	O
changed	B-C0443172
consistently	O
in	O
three	O
drug-induced	B-C0458082
groups	B-C0441833
and	O
might	O
be	O
the	O
important	O
biomarkers	B-C0005516
.	O
	
compared	O
with	O
1	B-C0877853
nmr	I-C0877853
,	O
u-hplc	B-C0008562
/	O
q-tof-ms	B-C0599827
showed	O
higher	B-C0205250
sensitivity	B-C0036668
and	I-C0036668
specificity	I-C0036668
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	B-C1148554
of	O
biomarkers	B-C0005516
apart	O
from	O
the	O
deficiency	B-C2987487
of	O
time-consuming	B-C3827829
sample	B-C1720914
preparation	I-C1720914
steps	I-C1720914
and	O
unambiguous	O
metabolite	B-C0870883
identification	B-C0205396
.	O
	
therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	B-C1705241
of	O
gpls	B-C0162448
during	O
inflammation	B-C0021368
by	O
combining	O
1	B-C0877853
nmr	I-C0877853
spectroscopy	I-C0877853
with	O
u-hplc	B-C0008562
/	O
q-tof-ms	B-C0599827
.	O
	
the	O
metabolic	B-C1328813
profiling	I-C1328813
of	O
gpls	B-C0162448
provides	O
valuable	O
evidence	B-C3887511
for	O
inflammation	B-C0021368
diagnosis	B-C0011900
and	O
prognosis	B-C0033325
,	O
and	O
might	O
unravel	O
the	O
mechanisms	B-C0441712
involved	O
in	O
inflammation	B-C0021368
progression	B-C0242656
.	O
	
characterization	B-C1880022
of	O
novel	B-C0205314
deor-family	B-C0035147
member	B-C1551024
from	O
the	O
streptomyces	B-C1937901
ahygroscopicus	I-C1937901
strain	B-C1518614
ck-15	I-C1518614
that	O
acts	O
as	O
a	O
repressor	B-C1336789
of	O
morphological	B-C0543482
development	B-C1527148
wuyiencin	B-C0031253
is	O
produced	B-C0441655
by	O
streptomyces	B-C1937901
ahygroscopicus	I-C1937901
var	I-C1937901
.	O
	
wuyiensis	I-C1937901
,	O
which	O
has	O
been	O
widely	O
used	O
in	O
china	B-C0008115
as	O
an	O
industrially	B-C0007983
produced	B-C0033268
biopesticide	B-C0031253
to	O
control	B-C0243148
various	O
fungal	B-C0026946
diseases	I-C0026946
.	O
	
although	O
its	O
mechanism	B-C0441712
of	O
action	B-C3266814
,	O
breeding	B-C0006159
,	O
and	O
fermentation	B-C0015852
had	O
been	O
extensively	O
characterized	B-C1880022
,	O
less	O
is	O
known	O
about	O
the	O
regulatory	B-C1817179
functions	I-C1817179
that	O
affect	O
its	O
biosynthesis	B-C0005572
or	O
morphological	B-C0543482
development	B-C1527148
.	O
	
the	O
wysr3	B-C0017337
gene	I-C0017337
of	O
s	B-C1937901
.	O
	
ahygroscopicus	I-C1937901
strain	B-C1518614
ck-15	I-C1518614
,	O
a	O
novel	B-C0205314
member	B-C1551024
of	O
the	O
deor	B-C0035147
family	I-C0035147
of	O
regulatory	B-C0017362
genes	I-C0017362
,	O
was	O
assessed	B-C1516048
to	O
determine	O
its	O
function	B-C0542341
by	O
gene	B-C2350567
knockdown	I-C2350567
.	O
	
herein	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
deor	B-C0035147
family	I-C0035147
proteins	I-C0035147
derived	O
from	O
the	O
same	O
source	B-C0449416
are	O
likely	O
to	O
be	O
a	O
single	B-C0205171
branch	B-C1253959
in	O
a	O
phylogenetic	B-C0205556
tree	I-C0205556
and	O
show	O
that	O
wysr3	B-C0017337
acts	O
as	O
a	O
repressor	B-C1336789
for	O
its	O
morphological	B-C0543482
development	B-C1527148
without	O
effecting	O
wuyiencin	B-C0031253
production	B-C0441655
.	O
	
we	O
found	O
that	O
the	O
δwysr3	B-C0017337
strain	B-C1518614
can	O
grow	O
quickly	O
to	O
reach	O
a	O
plateau	B-C2964353
stage	B-C1306673
of	O
maximum	O
biomass	B-C0005535
at	O
60	O
h	O
,	O
which	O
is	O
12	O
h	O
faster	B-C0456962
than	O
the	O
wild-type	B-C1883559
strain	B-C1518614
.	O
	
in	O
the	O
industrial	B-C0007983
fermentation	B-C0015852
production	B-C0033268
process	B-C1522240
,	O
the	O
δwysr3	B-C0017337
strain	B-C1518614
can	O
reduce	B-C0392756
consumption	B-C0009830
and	O
save	O
both	O
time	B-C0040223
and	O
targeting	B-C1521840
the	O
ecology	B-C0013546
within	O
the	O
role	B-C1705810
of	O
the	O
gut-brain	B-C1522496
axis	I-C1522496
and	O
human	B-C0086418
microbiota	B-C3887843
in	O
drug	B-C1510472
addiction	I-C1510472
despite	O
major	B-C3854260
advances	I-C3854260
in	O
our	O
understanding	B-C0162340
of	O
the	O
brain	B-C0006104
using	B-C1524063
traditional	B-C0027910
neuroscience	I-C0027910
,	O
reliable	B-C3858758
and	O
efficacious	B-C1704419
treatments	B-C0087111
for	O
drug	B-C1510472
addiction	I-C1510472
have	O
remained	B-C0243095
elusive	I-C0243095
.	O
	
hence	O
,	O
the	O
time	B-C0040223
has	O
come	O
to	O
utilize	B-C0042153
novel	B-C0205314
approaches	B-C0449445
,	O
particularly	O
those	O
drawing	B-C0205556
upon	O
contemporary	B-C1254367
advances	B-C3854260
in	O
fields	B-C1521738
outside	O
of	O
established	B-C0443211
neuroscienc	B-C0027910
e	O
and	O
psychiatry	B-C0033873
.	O
	
put	O
another	O
way	O
,	O
the	O
time	B-C0040223
has	O
come	O
for	O
a	O
paradigm	B-C0681797
shift	I-C0681797
in	O
the	O
addiction	B-C0085281
sciences	B-C0036397
.	O
	
apropos	B-C1548787
,	O
a	O
revolution	B-C0205245
in	O
the	O
area	B-C0205146
of	O
human	B-C0086418
health	B-C0018684
is	O
underway	B-C1272688
,	O
which	O
is	O
occurring	B-C1709305
at	O
the	O
nexus	B-C0205556
between	O
enteric	B-C1304890
microbiology	B-C0025952
and	O
neuroscience	B-C0027910
.	O
	
it	O
has	O
become	O
increasingly	B-C0442805
clear	B-C2963144
that	O
the	O
human	B-C0086418
microbiota	B-C3887843
the	O
vast	O
ecology	B-C0013546
of	O
bacteria	B-C0004611
residing	B-C2982691
within	O
the	O
human	B-C0086418
organism	B-C0029235
,	O
plays	O
an	O
important	B-C3898777
role	B-C1705810
in	O
health	B-C0018684
and	O
disease	B-C0012634
.	O
	
this	O
is	O
not	O
surprising	O
,	O
as	O
it	O
has	O
been	O
estimated	B-C0750572
that	O
bacteria	B-C0004611
living	B-C2982691
in	O
the	O
human	B-C0242821
body	I-C0242821
approximately	B-C0332232
1kg	O
of	O
mass	B-C1306372
,	O
roughly	O
equivalent	B-C0205163
to	O
that	O
of	O
the	O
human	B-C0086418
brain	B-C0006104
outnumber	O
human	B-C0427861
cells	I-C0427861
10	O
to	O
1	O
.	O
	
while	O
advances	O
in	O
the	O
understanding	B-C0162340
of	O
the	O
role	B-C1705810
of	O
microbiota	B-C3887843
in	O
other	O
areas	B-C0205146
of	O
human	B-C0086418
health	B-C0018684
have	O
yielded	B-C0392762
intriguing	B-C0205556
results	B-C1274040
e.g	O
,	O
clostridium	B-C1411966
difficile	I-C1411966
,	O
irritable	B-C0022104
bowel	I-C0022104
syndrome	I-C0022104
,	O
autism	B-C0004352
,	O
etc	O
,	O
to	O
date	B-C0011008
,	O
no	O
systematic	B-C0220922
programs	B-C3484370
of	O
research	B-C0035168
have	O
examined	B-C0332128
the	O
role	B-C1705810
of	O
microbiota	B-C3887843
in	O
drug	B-C1510472
addiction	I-C1510472
.	O
	
the	O
current	B-C0521116
hypothesis	B-C1512571
,	O
therefore	O
,	O
is	O
that	O
gut	B-C4287543
dysbiosis	I-C4287543
plays	O
a	O
key	O
role	B-C1705810
in	O
addictive	B-C0085281
disorders	B-C0012634
.	O
	
in	O
the	O
context	B-C0449255
of	O
this	O
hypothesis	B-C1512571
,	O
this	O
paper	B-C0282420
provides	B-C1999230
a	O
rationale	B-C2699007
for	O
future	B-C0016884
research	B-C0035168
to	O
target	B-C1521840
the	O
""""	O
gut	B-C0699819
-	O
brain	B-C0006104
axis	B-C1522496
""""	O
in	O
addiction	B-C0085281
.	O
	
a	O
brief	O
background	B-C1706907
of	O
the	O
gut	B-C0699819
-	O
brain	B-C0006104
axis	B-C1522496
is	O
provided	B-C1999230
,	O
along	O
with	O
a	O
series	B-C0205549
of	O
hypothesis-driven	B-C1512571
ideas	B-C1947946
outlining	O
potential	B-C3245505
treatments	B-C0087111
for	O
addiction	B-C0085281
via	O
manipulations	B-C0243095
of	O
the	O
""""	O
ecology	B-C0013546
homogeneous	B-C1881065
synthesis	B-C1883254
of	O
ag	B-C1721060
nanoparticles	I-C1721060
-doped	O
water-soluble	B-C0050505
cellulose	I-C0050505
acetate	I-C0050505
for	O
versatile	B-C0205556
applications	B-C4048755
we	O
report	B-C0684224
a	O
facile	B-C0205352
and	O
efficient	B-C0442799
approach	B-C0449445
for	O
synthesis	B-C1883254
of	O
well-dispersed	B-C0332624
and	O
stable	B-C0205360
silver	B-C1721060
nanoparticles	I-C1721060
ag	B-C1721060
nps	I-C1721060
using	O
water-soluble	B-C0050505
cellulose	I-C0050505
acetate	I-C0050505
ca	B-C0050505
as	O
both	O
reductant	B-C0376446
and	O
stabilizer	B-C1550603
.	O
	
partially	B-C0728938
substituted	O
ca	B-C0050505
with	O
highly	B-C0205250
active	B-C0205177
hydroxyl	B-C0700307
groups	I-C0700307
and	O
excellent	B-C1961136
water-solubility	B-C0597682
is	O
able	B-C1299581
to	O
reduce	B-C0301630
silver	B-C0022023
ions	I-C0022023
in	O
homogeneous	B-C1881065
aqueous	B-C0599956
medium	B-C1705217
effectively	B-C1704419
.	O
	
the	O
synthesized	B-C1883254
ag	B-C1721060
nps	I-C1721060
were	O
characterized	B-C1880022
by	O
uv-vis	B-C0037812
spectroscopy	I-C0037812
,	O
x-ray	B-C0043301
diffraction	I-C0043301
,	O
x-ray	B-C2700282
photoelectron	I-C2700282
spectroscopy	I-C2700282
,	O
transmission	B-C0678118
electron	I-C0678118
microscopy	I-C0678118
and	O
energy	B-C2699997
dispersive	I-C2699997
x-ray	I-C2699997
spectroscope	I-C2699997
analysis	B-C0002778
.	O
	
the	O
as-	O
prepared	B-C4082130
ag	B-C1721060
nps	I-C1721060
were	O
well-dispersed	B-C0332624
,	O
showing	O
a	O
surface	B-C0597731
plasmon	I-C0597731
resonance	I-C0597731
peak	B-C0444505
at	O
426	O
nm	B-C0439202
.	O
	
the	O
resulted	O
ag	B-C1721060
nps	I-C1721060
ca	B-C0050505
nanohybrids	B-C1721059
exhibit	O
high	B-C0205250
catalytic	B-C1264638
activity	I-C1264638
for	O
the	O
reduction	B-C0301630
of	O
4-nitrophenol	B-C0048581
to	O
4-aminophenol	B-C0048047
in	O
the	O
presence	O
of	O
nabh4	B-C0074728
.	O
	
meanwhile	O
,	O
the	O
nanohybrids	B-C1721059
are	O
also	O
effective	B-C1704419
in	O
inhibiting	B-C3463820
the	O
growth	B-C0018270
of	O
bacterial	B-C0004611
.	O
	
this	O
environmentally	B-C2350566
friendly	I-C2350566
method	I-C2350566
promotes	B-C0033414
the	O
use	B-C1524063
of	I-C1524063
renewable	B-C0027492
natural	I-C0027492
resources	I-C0027492
to	O
prepare	B-C1521827
a	O
variety	B-C2346866
of	O
inorganic-organic	B-C0520510
materials	I-C0520510
for	O
catalysis	B-C0007382
,	O
antibacterial	B-C0279516
,	O
sensors	B-C0183210
and	O
other	O
isx-9	B-C0022266
can	O
potentiate	O
cell	B-C0596290
proliferation	I-C0596290
and	O
neuronal	B-C0027882
commitment	B-C1160036
in	O
the	O
rat	B-C0086893
dentate	B-C0152314
gyrus	I-C0152314
adult	B-C0001675
hippocampal	B-C0019564
neurogenesis	B-C0814002
can	O
be	O
modulated	B-C0443264
by	O
various	O
physiological	B-C1254359
and	O
pathological	B-C0752135
conditions	I-C0752135
,	O
including	O
stress	B-C0038435
,	O
affective	B-C0525045
disorders	I-C0525045
,	O
and	O
several	O
neurological	B-C0205494
conditions	B-C0348080
.	O
	
given	O
the	O
proposed	O
role	O
of	O
this	O
form	O
of	O
structural	B-C1254358
plasticity	I-C1254358
in	O
the	O
functioning	B-C0031843
of	O
the	O
hippocampus	B-C0019564
namely	O
learning	B-C0023185
and	O
memory	B-C0025260
and	O
affective	B-C0243150
behaviors	B-C0004927
,	O
it	O
is	O
believed	O
that	O
alterations	B-C1515926
in	O
hippocampal	B-C0019564
neurogenesis	B-C0814002
might	O
underlie	O
some	O
of	O
the	O
behavioral	B-C0004927
deficits	B-C2987487
associated	B-C0332281
with	I-C0332281
these	O
psychiatric	B-C0205487
and	O
neurological	B-C0205494
conditions	B-C0348080
.	O
	
thus	O
,	O
the	O
search	B-C1706202
for	O
compounds	B-C1254351
that	O
can	O
reverse	B-C1555029
these	O
deficits	B-C2987487
with	O
minimal	B-C0547040
side	B-C0879626
effects	I-C0879626
has	O
become	O
a	O
recognized	O
priority	O
.	O
	
in	O
the	O
present	O
study	B-C0008972
we	O
tested	B-C0039593
the	O
pro-neurogenic	B-C0205494
effects	B-C1280500
of	O
isoxazole	B-C0022266
9	I-C0022266
isx-9	B-C0022266
,	O
a	O
small	O
synthetic	B-C1883254
molecule	B-C0567416
that	O
has	O
been	O
recently	O
identified	B-C0205396
through	O
the	O
screening	B-C0373483
of	I-C0373483
chemical	I-C0373483
libraries	I-C0373483
in	O
stem	B-C0009385
cell-based	I-C0009385
assays	I-C0009385
.	O
	
we	O
found	O
that	O
administration	B-C1533734
of	O
isx-9	B-C0022266
for	O
14days	O
was	O
able	O
to	O
potentiate	O
cell	B-C0596290
proliferation	I-C0596290
and	O
increase	B-C0442805
the	O
number	B-C0237753
of	O
immature	B-C0205252
neurons	B-C0027882
in	O
the	O
hippocampal	B-C0019564
dg	B-C0152314
of	O
adult	B-C0001675
rats	B-C0086893
.	O
	
in	B-C0332287
addition	I-C0332287
,	O
isx-9	B-C0022266
treatment	B-C0087111
was	O
able	O
to	O
completely	B-C0205197
reverse	B-C1555029
the	O
marked	B-C1706089
reduction	B-C0392756
in	O
these	O
initial	B-C0205265
stages	B-C0205390
of	O
the	O
neurogenic	B-C1518289
process	I-C1518289
observed	B-C1441672
in	O
vehicle	B-C0042444
-	O
treated	B-C1522326
animals	B-C0003062
which	O
were	O
submitted	O
to	O
repeated	B-C0205341
handling	B-C0037793
and	O
exposure	B-C0332157
to	I-C0332157
daily	B-C0332173
intraperitoneal	B-C0021493
injections	I-C0021493
.	O
	
based	O
on	O
these	O
results	B-C1254595
,	O
we	O
recommend	O
that	O
future	O
neurogenesis	B-C0814002
studies	B-C0008972
that	O
require	O
repeated	B-C0205341
handling	B-C0037793
and	O
manipulation	B-C0947647
of	O
animals	B-C0003062
should	O
include	O
a	O
naïve	O
non-manipulated	O
control	B-C0243148
to	O
determine	O
the	O
baseline	B-C1442488
levels	B-C0441889
of	O
hippocampal	B-C0019564
cell	B-C0596290
proliferation	I-C0596290
and	O
neuronal	B-C0027882
differentiation	B-C0007589
.	O
	
overall	O
,	O
these	O
findings	B-C2825141
demonstrate	O
that	O
isx-9	B-C0022266
is	O
a	O
promising	O
synthetic	B-C1883254
compound	B-C1254351
for	O
the	O
mitigation	B-C1553901
of	O
stress	B-C0038435
-	O
induced	B-C0205263
deficits	B-C2987487
in	O
adult	B-C0001675
hippocampal	B-C0019564
neurogenesis	B-C0814002
.	O
	
future	O
studies	B-C0008972
are	O
thus	O
warranted	O
to	O
evaluate	B-C0220825
the	O
pro-neurogenic	B-C0205494
properties	B-C0871161
of	O
isx-9	B-C0022266
in	O
animal	B-C0599779
models	I-C0599779
of	O
affective	B-C0525045
and	O
neurological	B-C0027765
disorders	I-C0027765
associated	B-C0332281
with	I-C0332281
impaired	B-C0221099
hippocampal	B-C0019564
structural	B-C1254358
plasticity	I-C1254358
.	O
	
changes	B-C0392747
in	O
parenting	B-C0085092
strategies	B-C0679199
after	O
a	O
young	B-C0332239
person's	B-C0027361
self-harm	B-C0424366
a	O
qualitative	B-C0949415
study	I-C0949415
when	O
faced	O
with	O
the	O
discovery	B-C1880355
of	O
their	O
child's	B-C0008059
self-harm	B-C0424366
,	O
mothers	B-C0026591
and	O
fathers	B-C0015671
may	O
re-evaluate	B-C0220825
their	O
parenting	B-C0085092
strategies	B-C0679199
.	O
	
this	O
can	O
include	O
changes	B-C0392747
to	O
the	O
amount	O
of	O
support	B-C0037438
they	O
provide	O
their	O
child	B-C0008059
and	O
changes	B-C0392747
to	O
the	O
degree	B-C0449286
to	O
which	O
they	O
control	B-C0243148
and	O
monitor	B-C0441655
their	O
child	B-C0008059
.	O
	
we	O
conducted	O
an	O
in-depth	B-C0949415
qualitative	I-C0949415
study	I-C0949415
with	O
37	O
parents	B-C0030551
of	O
young	B-C0332239
people	B-C0027361
who	O
had	O
self-harmed	B-C0424366
in	O
which	O
we	O
explored	O
how	O
and	O
why	O
their	O
parenting	B-C0085092
changed	B-C0392747
after	O
the	O
discovery	B-C1880355
of	O
self-harm	B-C0424366
.	O
	
early	B-C1279919
on	O
,	O
parents	B-C0030551
often	O
found	O
themselves	O
"""walking"	O
on	O
"eggshells"""	O
so	O
as	O
not	O
to	O
upset	B-C3887804
their	O
child	B-C0008059
,	O
but	O
later	O
they	O
felt	O
more	O
able	O
to	O
take	O
some	O
control	B-C0243148
.	O
	
parents	B-C0030551
'	O
reactions	B-C0443286
to	O
the	O
self-harm	B-C0424366
often	O
depended	O
on	O
how	O
they	O
conceptualised	O
it	O
as	O
part	O
of	O
adolescence	B-C0001578
,	O
as	O
a	O
mental	B-C4061796
health	I-C4061796
issue	I-C4061796
or	O
as	O
""""	O
naughty	B-C0004927
behaviour	I-C0004927
""""	O
.	O
	
parenting	B-C0085092
of	O
other	O
children	B-C0008059
in	O
the	O
family	B-C0015576
could	O
also	O
be	O
affected	O
,	O
with	O
parents	B-C0030551
worrying	O
about	O
less	O
of	O
their	O
time	B-C0040223
being	O
available	O
for	O
siblings	B-C0037047
.	O
	
many	O
parents	B-C0030551
developed	O
specific	O
strategies	B-C0679199
they	O
felt	O
helped	O
them	O
to	O
be	O
more	O
effective	O
parents	B-C0030551
,	O
such	O
as	O
learning	B-C0023185
to	O
avoid	O
blaming	B-C0870209
themselves	O
or	O
their	O
child	B-C0008059
for	O
the	O
self-harm	B-C0424366
and	O
developing	O
new	O
ways	O
to	O
communicate	B-C0566001
with	O
their	O
child	B-C0008059
.	O
	
parents	B-C0030551
were	O
generally	O
eager	O
to	O
pass	O
their	O
knowledge	B-C0376554
on	O
to	O
other	O
people	B-C0027361
in	O
the	O
same	O
situation	B-C0868928
.	O
	
parents	B-C0030551
reported	O
changes	B-C0392747
in	O
their	O
parenting	B-C0085092
behaviours	B-C0004927
after	O
the	O
discovery	B-C1880355
of	O
a	O
child	B-C0008059
's	O
self-harm	B-C0424366
.	O
	
professionals	B-C0679924
involved	O
in	O
the	O
care	B-C1947933
of	O
young	B-C0332239
people	B-C0027361
who	O
self-harm	B-C0424366
might	O
use	O
this	O
information	B-C1533716
in	O
supporting	B-C1521721
and	O
advising	B-C1828381
parents	B-C0030551
.	O
	
optimizing	B-C2698650
survival	B-C0220921
of	O
patients	B-C0030705
with	O
marginally	B-C0205188
operable	I-C0205188
stage	B-C0278983
iiia	I-C0278983
non-small-cell	I-C0278983
lung	I-C0278983
cancer	I-C0278983
receiving	O
chemoradiotherapy	B-C0436307
with	B-C0038895
or	O
without	B-C0332288
surgery	B-C0038895
for	O
marginally	B-C0205188
operable	I-C0205188
stage	B-C0278983
iiia	I-C0278983
non-small-cell	I-C0278983
lung	I-C0278983
cancer	I-C0278983
nsclc	B-C0278983
,	O
surgery	B-C0038895
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	B-C0600558
concurrent	B-C3178775
chemoradiotherapy	I-C3178775
ccrt	B-C3178775
for	O
reasons	O
unresectable	B-C1519810
or	O
medically	B-C0205187
inoperable	I-C0205187
conditions	B-C0348080
,	O
or	O
patient	B-C0040809
refusal	I-C0040809
.	O
	
this	O
study	B-C2603343
aims	O
to	O
investigate	B-C1292732
the	O
outcomes	B-C1274040
of	O
a	O
phased	B-C0040808
ccrt	I-C0040808
protocol	I-C0040808
established	O
to	O
maximize	O
the	O
operability	B-C0205245
of	O
marginally	B-C0205188
operable	I-C0205188
stage	B-C0278983
iiia	I-C0278983
nsclc	I-C0278983
and	O
to	O
care	O
for	O
reassessed	B-C1516048
inoperable	B-C0030705
patients	I-C0030705
,	O
in	O
comparison	O
with	O
continuous-course	B-C3178775
definitive	I-C3178775
ccrt	I-C3178775
.	O
	
forty-seven	O
patients	B-C0030705
with	O
marginally	B-C0205188
operable	I-C0205188
stage	B-C0278983
iiia	I-C0278983
nsclc	I-C0278983
receiving	O
ccrt	B-C3178775
were	O
included	O
.	O
	
twenty-eight	O
patients	B-C0030705
were	O
treated	B-C1522326
with	O
our	O
phased	B-C0040808
ccrt	I-C0040808
protocol	I-C0040808
,	O
including	O
neoadjuvant	B-C0600558
ccrt	B-C3178775
followed	O
by	O
surgery	B-C0038895
group	B-C0441833
a	I-C0441833
,	O
n	O
=	O
16	O
or	O
,	O
for	O
reassessed	B-C1516048
inoperable	B-C0030705
patients	I-C0030705
,	O
maintenance	O
chemotherapy	O
and	O
split-course	O
ccrt	O
boost	O
group	O
b	O
,	O
n	O
=	O
12	O
.	O
	
the	O
other	O
19	O
were	O
treated	O
with	O
continuous-course	O
definitive	O
ccrt	O
group	O
c	O
.	O
	
overall	O
survival	O
os	O
and	O
progression-free	O
survival	O
pfs	O
were	O
analyzed	O
.	O
	
among	O
all	O
,	O
median	O
os	O
and	O
pfs	O
were	O
35.6	O
and	O
12.8	O
months	O
,	O
respectively	O
median	O
follow-up	O
,	O
22.3	O
months	O
.	O
	
the	O
median	O
os	O
of	O
group	O
a	O
not	O
reached	O
was	O
better	O
than	O
that	O
of	O
group	O
b	O
34.4	O
months	O
and	O
group	O
c	O
15.2	O
months	O
p	O
=	O
009	O
.	O
	
on	O
multivariate	O
analysis	O
,	O
performance	O
status	O
0	O
to	O
1	O
hazard	O
ratio	O
hr	O
,	O
0.026	O
p	O
<	O
001	O
,	O
adenocarcinoma	O
hr	O
,	O
0.156	O
p	O
=	O
003	O
,	O
and	O
group	O
a	O
hr	O
,	O
0.199	O
p	O
=	O
033	O
were	O
independent	O
prognostic	O
factors	O
.	O
	
the	O
os	O
of	O
group	O
b	O
hr	O
,	O
0.450	O
95%	O
confidence	O
interval	O
,	O
0.118	O
p	O
=	O
243	O
was	O
not	O
statistically	O
different	O
from	O
that	O
of	O
group	O
c	O
.	O
	
for	O
marginally	O
operable	O
stage	O
iiia	O
nsclc	O
,	O
our	O
phased	O
ccrt	O
strategy	O
may	O
optimize	O
survival	O
by	O
maximizing	O
operability	O
and	O
maintain	O
an	O
acceptable	O
survival	O
for	O
reassessed	O
inoperable	O
patients	B-C0030705
by	O
split-course	O
ccrt	O
boost	O
following	O
maintenance	B-C0481504
chemotherapy	I-C0481504
.	O
	
evaluation	O
of	O
three	B-C0205449
protein-extraction	B-C3827821
methods	I-C3827821
for	O
proteome	B-C0751973
analysis	B-C0002778
of	O
maize	B-C0010028
leaf	B-C0242724
midrib	B-C2698828
,	O
a	O
compound	B-C1514137
tissue	I-C1514137
rich	O
in	O
sclerenchyma	B-C1514137
cells	I-C1514137
leaf	B-C0242724
morphology	B-C0332437
is	O
closely	O
related	O
to	O
the	O
growth	B-C0018271
and	I-C0018271
development	I-C0018271
of	O
maize	B-C0010028
zea	I-C0010028
mays	I-C0010028
l	I-C0010028
plants	I-C0010028
and	O
final	O
kernel	B-C0043137
production	O
.	O
	
as	O
an	O
important	O
part	O
of	O
the	O
maize	B-C0010028
leaf	B-C0242724
,	O
the	O
midrib	B-C2698828
holds	O
leaf	B-C0242724
blades	O
in	O
the	O
aerial	B-C1136056
position	I-C1136056
for	O
maximum	O
sunlight	B-C0038817
capture	O
.	O
	
leaf	B-C0242724
midrib	B-C2698828
s	O
of	O
adult	B-C0205286
plants	B-C0010028
contain	O
substantial	O
sclerenchyma	B-C1514137
cells	I-C1514137
with	O
heavily	B-C1280412
thickened	I-C1280412
and	O
lignified	B-C0023705
secondary	B-C0918262
walls	I-C0918262
and	O
have	O
a	O
high	O
amount	O
of	O
phenolics	B-C0359916
,	O
making	O
protein	B-C3827821
extraction	I-C3827821
and	O
proteome	B-C0751973
analysis	B-C0002778
difficult	O
in	O
leaf	B-C0242724
midrib	B-C2698828
tissue	O
.	O
	
in	O
the	O
present	O
study	O
,	O
three	O
protein-extraction	B-C3827821
methods	I-C3827821
that	O
are	O
commonly	O
used	O
in	O
plant	B-C0032098
proteomics	B-C0872252
,	O
i.e	O
,	O
phenol	B-C0070570
extraction	B-C0684295
,	O
tca	B-C0040900
/	O
acetone	B-C0001002
extraction	B-C0684295
,	O
and	O
tca	B-C0040900
/	O
acetone	B-C0001002
/	O
phenol	B-C0070570
extraction	B-C0684295
,	O
were	O
qualitatively	B-C0034375
and	O
quantitatively	B-C0034384
evaluated	I-C0034384
based	O
on	O
2de	O
maps	O
and	O
ms/ms	B-C0037813
analysis	I-C0037813
using	O
the	O
midribs	B-C2698828
of	O
the	O
10th	O
newly	O
expanded	O
leaves	B-C0242724
of	O
maize	B-C0010028
plants	I-C0010028
.	O
	
microscopy	B-C0026018
revealed	O
the	O
existence	O
of	O
substantial	O
amounts	O
of	O
sclerenchyma	B-C1514137
underneath	O
maize	B-C0010028
midrib	B-C2698828
epidermises	B-C0376608
particularly	O
abaxial	B-C1254362
epidermises	B-C0376608
.	O
	
the	O
spot-number	O
order	O
obtained	O
via	O
2de	B-C0013860
mapping	I-C0013860
was	O
as	O
follows	O
phenol	B-C0070570
extraction	B-C0684295
655	O
>	O
tca	B-C0040900
/	O
acetone	B-C0001002
extraction	B-C0684295
589	O
>	O
tca	B-C0040900
/	O
acetone	B-C0001002
/	O
phenol	B-C0070570
extraction	B-C0684295
545	O
.	O
	
ms/ms	B-C0037813
analysis	I-C0037813
identified	O
a	O
total	O
of	O
17	O
spots	B-C1705203
that	O
exhibited	O
2-fold	O
changes	O
in	O
abundance	O
among	O
the	O
three	B-C0205449
methods	O
using	O
phenol	B-C0070570
extraction	B-C0684295
as	O
a	O
control	B-C0009932
.	O
	
sixteen	O
of	O
the	O
proteins	B-C0032089
identified	O
were	O
hydrophilic	B-C0475370
,	O
with	O
gravy	B-C0392762
values	I-C0392762
ranging	O
from	O
-0	O
to	O
-0	O
.	O
	
for	O
all	O
three	B-C0205449
methods	O
,	O
we	O
were	O
able	O
to	O
obtain	O
high-quality	O
protein	B-C0032089
samples	O
and	O
good	O
2de	B-C0013860
maps	I-C0013860
for	O
the	O
maize	B-C0010028
leaf	B-C0242724
midrib	B-C2698828
.	O
	
however	O
,	O
phenol	B-C0070570
extraction	B-C0684295
produced	O
a	O
better	O
2de	B-C0013860
map	I-C0013860
with	O
greater	O
resolution	B-C2699488
between	O
spots	B-C1705203
,	O
and	O
tca	B-C0040900
/	O
acetone	B-C0001002
extraction	B-C0684295
produced	O
higher	O
protein	B-C0032089
yields	B-C0392762
.	O
	
thus	O
,	O
this	O
paper	O
includes	O
a	O
discussion	O
regarding	O
the	O
possible	O
reasons	O
for	O
differential	B-C0443199
protein	B-C3827821
extraction	I-C3827821
among	O
the	O
three	B-C0205449
methods	O
.	O
	
this	O
study	O
provides	O
useful	O
information	O
that	O
can	O
be	O
used	O
to	O
select	O
suitable	O
protein	B-C3827821
extraction	I-C3827821
methods	O
for	O
the	O
proteome	B-C0751973
analysis	B-C0002778
of	O
recalcitrant	O
plant	B-C1514137
tissues	I-C1514137
that	O
are	O
rich	O
in	O
sclerenchyma	B-C1514137
cells	I-C1514137
.	O
	
dominant	B-C0429283
and	O
non-	O
dominant	B-C0429283
frequency	B-C0376249
structure	O
of	O
evoked	B-C1444748
ventricular	B-C0042510
fibrillation	I-C0042510
in	O
dogs	B-C0012984
with	O
myocardial	B-C0151744
ischemia	I-C0151744
the	O
first	O
10	O
min	O
of	O
electrically	B-C3517066
provoked	I-C3517066
ventricular	B-C0042510
fibrillation	I-C0042510
in	O
dogs	B-C0012984
with	O
ischemic	B-C0151744
heart	I-C0151744
disease	I-C0151744
were	O
characterized	B-C1880022
by	O
organized	B-C1300196
myocardial	B-C1254358
activity	I-C1254358
evidenced	O
by	O
the	O
dominant	B-C0429283
ecg	I-C0429283
frequency	I-C0429283
structure	O
.	O
	
during	O
the	O
first	O
2	O
min	O
of	O
ventricular	B-C0042510
fibrillation	I-C0042510
,	O
low-frequency	B-C0205556
oscillations	I-C0205556
4-7	O
hz	O
dominated	O
,	O
while	O
on	O
min	O
3	O
to	O
10	O
after	O
the	O
onset	O
of	O
fibrillation	B-C0042510
,	O
the	O
dominant	B-C0429283
frequencies	I-C0429283
were	O
low	B-C0205251
and	O
medium	B-C0439536
4-12	O
hz	O
.	O
	
after	O
10-min	O
fibrillation	B-C0042510
,	O
the	O
oscillations	B-C0695434
became	O
non-	O
dominant	B-C0429283
.	O
	
thus	O
,	O
ischemic	B-C2919051
myocardium	I-C2919051
maintains	B-C0024501
the	O
organized	B-C0449236
structure	I-C0449236
of	O
ventricular	B-C0042510
fibrillation	I-C0042510
for	O
the	O
first	O
10	O
min	O
,	O
which	O
is	O
important	O
for	O
the	O
development	B-C1527148
of	O
automatic	B-C0011905
diagnostics	I-C0011905
of	O
abnormal	B-C4062482
cardiac	I-C4062482
activity	I-C4062482
in	O
adverse	B-C0877248
events	I-C0877248
risk	B-C0035647
associated	B-C0332281
with	I-C0332281
angiogenesis	B-C0596087
inhibitors	I-C0596087
addition	O
to	O
therapy	B-C0087111
in	O
ovarian	B-C0029925
cancer	I-C0029925
a	O
meta-analysis	B-C0920317
of	O
randomized	B-C0206035
controlled	I-C0206035
trials	I-C0206035
inhibition	B-C1510884
of	I-C1510884
angiogenesis	I-C1510884
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	B-C0087111
strategy	I-C0087111
for	O
advanced	B-C0029925
or	O
recurrent	B-C0278689
ovarian	I-C0278689
cancer	I-C0278689
.	O
	
we	O
conduct	O
this	O
meta-analysis	B-C0920317
to	O
investigate	B-C1292732
the	O
risk	B-C0035647
of	O
adverse	B-C0877248
events	I-C0877248
of	O
special	O
interest	O
related	O
to	O
angiogenesis	B-C0596087
inhibitors	I-C0596087
ais	B-C0596087
in	O
ovarian	B-C0029925
cancer	I-C0029925
.	O
	
databases	B-C0242356
from	O
pubmed	B-C1138432
,	O
web	B-C0282574
of	I-C0282574
science	I-C0282574
and	O
cochrane	B-C0023621
library	I-C0023621
up	O
to	O
december	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	B-C2347946
studies	B-C2603343
.	O
	
eligible	O
studies	B-C2603343
included	O
prospective	B-C0206035
randomized	I-C0206035
controlled	I-C0206035
phase	I-C0206035
ii/iii	I-C0206035
clinical	I-C0206035
trials	I-C0206035
evaluating	B-C0557980
therapy	B-C0087111
with	O
or	O
without	O
ais	B-C0596087
for	O
ovarian	B-C0029925
cancer	I-C0029925
.	O
	
summary	O
relative	B-C0242492
risk	I-C0242492
rr	B-C0242492
and	O
95%	O
confidence	B-C0009667
intervals	I-C0009667
cis	B-C0009667
were	O
calculated	B-C1441506
using	O
random-effects	B-C0205556
or	O
fixed-effects	B-C0205556
according	O
to	O
the	O
heterogeneity	B-C0019409
among	O
included	O
trials	B-C0008976
.	O
	
a	O
total	O
of	O
7	O
patients	B-C0030705
from	O
ten	O
clinical	B-C0008976
trials	I-C0008976
were	O
included	O
in	O
the	O
meta-analysis	B-C0920317
.	O
	
pooled	B-C2349200
rr	B-C0242492
showed	O
that	O
the	O
use	B-C1524063
of	I-C1524063
ais	B-C0596087
was	O
associated	B-C0332281
with	I-C0332281
a	O
statistically	O
increased	B-C0205217
risk	B-C0035647
in	O
four	O
of	O
the	O
adverse	B-C0001688
outcomes	B-C0085415
studied	O
arterial	B-C3544094
thromboembolic	I-C3544094
events	B-C0441471
rr	B-C0242492
=	O
2.0	O
,	O
gastrointestinal	B-C0151664
gi	I-C0151664
perforation	I-C0151664
rr	B-C0242492
=	O
3.86	O
,	O
proteinuria	B-C0033687
rr	B-C0242492
=	O
2.44	O
,	O
and	O
hypertension	B-C0020538
rr	B-C0242492
=	O
5.39	O
.	O
	
no	B-C3694175
statistically	I-C3694175
significant	I-C3694175
differences	B-C1705242
were	O
found	O
for	O
hemorrhagic	B-C0019080
events	B-C0441471
p	O
=	O
0.07	O
,	O
venous	B-C1861172
thromboembolic	I-C1861172
events	B-C0441471
p	O
=	O
0.13	O
,	O
or	O
fatal	B-C1302234
adverse	B-C0877248
events	I-C0877248
p	O
=	O
0.26	O
.	O
	
the	O
addition	O
of	O
ais	B-C0596087
to	O
therapy	B-C0087111
in	O
ovarian	B-C0029925
cancer	I-C0029925
did	O
significantly	O
increase	B-C0442805
the	O
risk	B-C0035647
of	O
arterial	B-C3544094
thromboembolic	I-C3544094
events	B-C0441471
,	O
gi	B-C0151664
perforation	I-C0151664
,	O
proteinuria	B-C0033687
and	O
hypertension	B-C0020538
,	O
but	O
not	O
for	O
venous	B-C1861172
thromboembolic	I-C1861172
events	B-C0441471
,	O
hemorrhagic	B-C0019080
events	B-C0441471
,	O
or	O
fatal	B-C1302234
adverse	B-C0877248
events	I-C0877248
.	O
	
relationship	B-C0439849
between	O
lrrk2	B-C1425650
r1628p	B-C0752046
polymorphism	I-C0752046
and	O
parkinson's	B-C0030567
disease	I-C0030567
in	O
asian	B-C0078988
populations	I-C0078988
although	O
the	O
leucine-rich	B-C1425650
repeat	I-C1425650
kinase	I-C1425650
2	I-C1425650
lrrk2	B-C1425650
r1628p	B-C0752046
polymorphism	I-C0752046
has	O
been	O
associated	B-C0332281
with	I-C0332281
the	O
risk	B-C0035647
of	O
parkinson's	B-C0030567
disease	I-C0030567
pd	B-C0030567
in	O
taiwan	B-C0039260
,	O
china	B-C0008115
,	O
and	O
singapore	B-C0037173
,	O
there	O
are	O
conflicting	O
findings	O
regarding	O
this	O
relationship	B-C0439849
.	O
	
thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
meta-analysis	B-C0920317
was	O
to	O
evaluate	O
the	O
associations	B-C0439849
between	O
the	O
lrrk2	B-C1425650
r1628p	B-C0752046
polymorphism	I-C0752046
rs33949390	B-C0752046
and	O
pd	B-C0030567
in	O
asian	B-C0078988
populations	I-C0078988
.	O
	
a	O
search	O
for	O
eligible	O
studies	B-C2603343
was	O
performed	O
in	O
pubmed	B-C1138432
,	O
embase	B-C0079198
,	O
sinomed	B-C0079198
,	O
and	O
the	O
china	B-C0242356
knowledge	I-C0242356
resource	I-C0242356
integrated	I-C0242356
database	I-C0242356
,	O
and	O
pooled	O
odds	O
ratios	O
and	O
95%	O
confidence	B-C0009667
intervals	I-C0009667
were	O
used	O
to	O
evaluate	O
the	O
strength	O
of	O
the	O
association	B-C0439849
between	O
the	O
r1628p	B-C0752046
polymorphism	I-C0752046
and	O
pd	B-C0030567
.	O
	
this	O
meta-analysis	B-C0920317
assessed	O
19	O
studies	B-C2603343
from	O
14	O
papers	O
that	O
involved	O
a	O
total	O
of	O
9	O
pd	B-C0030567
patients	B-C0030705
and	O
8	O
controls	B-C0009932
and	O
found	O
that	O
the	O
r1628p	B-C0752046
polymorphism	I-C0752046
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
the	O
risk	B-C0035647
of	O
pd	B-C0030567
in	O
asian	B-C0078988
populations	I-C0078988
.	O
	
moreover	O
,	O
stratification	B-C1514983
analyses	I-C1514983
indicated	O
that	O
the	O
r1628p	B-C0752046
polymorphism	I-C0752046
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
an	O
increased	O
risk	B-C0035647
of	O
pd	B-C0030567
among	O
chinese	B-C0152035
as	O
well	O
as	O
non-chinese	B-C0078988
asian	I-C0078988
populations	I-C0078988
and	O
an	O
increased	O
risk	B-C0035647
of	O
pd	B-C0030567
in	O
chinese	B-C0030705
patients	I-C0030705
from	O
china	B-C0008115
,	O
taiwan	B-C0039260
,	O
and	O
singapore	B-C0037173
.	O
	
in	O
a	O
stratified	B-C1514983
analysis	I-C1514983
conducted	O
according	O
to	O
age	B-C0001779
,	O
significant	O
associations	B-C0439849
were	O
found	O
for	O
both	O
late-onset	O
pd	B-C0030567
and	O
early-onset	O
pd	B-C0030567
.	O
	
the	O
present	O
data	O
indicate	O
that	O
the	O
r1628p	B-C0752046
polymorphism	I-C0752046
of	O
the	O
lrrk2	B-C1425650
gene	I-C1425650
contributes	O
to	O
pd	B-C0030567
susceptibility	B-C0012655
in	O
asian	B-C0078988
,	O
especially	O
chinese	B-C0152035
,	O
populations	B-C1257890
.	O
	
efficacy	B-C1280519
and	O
safety	B-C0678800
of	O
cisplatin	B-C0008838
,	O
dexamethasone	B-C0011777
,	O
gemcitabine	B-C0045093
and	O
pegaspargase	B-C0071568
ddgp	B-C1254351
regimen	B-C0040808
in	O
newly	B-C1518321
diagnosed	I-C1518321
,	O
advanced-stage	B-C0205179
extranodal	B-C1955906
natural	I-C1955906
killer/t-cell	I-C1955906
lymphoma	I-C1955906
interim	B-C2827738
analysis	B-C0936012
of	O
a	O
phase	B-C0439562
4	I-C0439562
study	B-C2603343
nct01501149	O
to	O
explore	O
a	O
more	O
effective	B-C1704419
treatment	B-C0039798
for	O
newly	B-C1518321
diagnosed	I-C1518321
,	O
advanced-stage	B-C0205179
extranodal	B-C0392788
natural	I-C0392788
killer/t-cell	I-C0392788
lymphoma	I-C0392788
,	O
nasal	I-C0392788
type	I-C0392788
enktl	B-C0392788
,	O
we	O
conducted	O
a	O
phase	B-C0439562
4	I-C0439562
study	B-C2603343
of	O
the	O
cisplatin	B-C0008838
,	O
dexamethasone	B-C0011777
,	O
gemcitabine	B-C0045093
,	O
pegaspargase	B-C0071568
ddgp	B-C1254351
regimen	B-C0040808
.	O
	
the	O
primary	O
end	B-C2349179
point	I-C2349179
was	O
the	O
2-year	O
progression-free	B-C0242792
survival	I-C0242792
pfs	B-C0242792
after	O
the	O
protocol	B-C0040808
treatment	I-C0040808
.	O
	
secondary	O
endpoints	B-C2349179
included	O
response	B-C0237629
rate	I-C0237629
rr	B-C0237629
,	O
overall	B-C4086681
survival	I-C4086681
os	B-C4086681
and	O
median	B-C2986586
survival	I-C2986586
time	I-C2986586
mst	B-C2986586
.	O
	
the	O
interim	B-C2827738
analysis	B-C0936012
included	O
data	B-C1511726
only	O
from	O
march	O
2011	O
to	O
september	O
2013	O
,	O
who	O
received	B-C1514756
six	O
cycles	O
of	O
ddgp	B-C1254351
chemotherapy	B-C3665472
.	O
	
a	O
total	O
of	O
25	O
eligible	B-C1548635
patients	B-C0030705
were	O
enrolled	O
.	O
	
seventeen	O
patients	B-C0030705
17/24	O
,	O
70.83	O
achieved	O
complete	B-C1275810
response	I-C1275810
cr	B-C1275810
and	O
four	O
4/24	O
,	O
16.67	O
achieved	O
partial	B-C1521726
response	I-C1521726
pr	B-C1521726
,	O
three	O
3/24	O
,	O
12.50	O
had	O
progressive	B-C1335499
disease	I-C1335499
pd	B-C1335499
.	O
	
the	O
rr	B-C0237629
after	O
treatment	B-C0039798
was	O
87.50	O
.	O
	
after	O
a	O
median	B-C0876920
follow-up	B-C1522577
duration	B-C0449238
of	O
24.67	O
months	B-C0439231
range	O
4-48	O
months	B-C0439231
.	O
	
the	O
2-year	O
pfs	B-C0242792
and	O
os	B-C0038954
rate	I-C0038954
were	O
61.80	O
95%	O
ci	B-C0009667
,	O
42.00	O
to	O
81.60	O
and	O
68.50	O
%	O
95%	O
ci	B-C0009667
,	O
48.70	O
to	O
88.30	O
,	O
respectively	O
.	O
	
the	O
mst	B-C2986586
was	O
36.55	O
months	B-C0439231
95%	O
ci	B-C0009667
,	O
29.41	O
months	B-C0439231
to	O
43.70	O
months	B-C0439231
.	O
	
grade	B-C0441800
3/4	O
leukopenia	B-C0023530
occurred	B-C2745955
in	O
fourteen	O
patients	B-C0030705
58.33	O
and	O
grade	B-C0441800
3/4	O
thrombocytopenia	B-C0040034
occurred	B-C2745955
in	O
eleven	O
patients	B-C0030705
45.83	O
.	O
	
twelve	O
patients	B-C0030705
50.00	O
experienced	O
activated	B-C0030605
partial	I-C0030605
phromboplastin	I-C0030605
ptime	I-C0030605
aptt	B-C0030605
elongation	B-C0240671
and	O
fourteen	O
patients	B-C0030705
58.33	O
experienced	O
hypofibrinogenemia	B-C0553681
.	O
	
in	O
conclusion	O
,	O
ddgp	B-C1254351
regimen	B-C0040808
is	O
an	O
effective	B-C1704419
and	O
tolerated	B-C0013220
treatment	B-C0039798
for	O
newly	B-C1518321
diagnosed	I-C1518321
,	O
advanced-stage	B-C0205179
enktl	B-C0392788
.	O
	
this	O
trial	B-C0008976
was	O
registered	B-C1514821
at	O
www.clinicaltrials	B-C2349146
effect	B-C1280500
of	O
hepatitis	B-C1698259
c	I-C1698259
virus	I-C1698259
coinfection	I-C1698259
on	O
the	O
content	O
of	O
cd4	B-C0483191
and	I-C0483191
cd8	I-C0483191
t	B-C0039194
cell	I-C0039194
subpopulations	B-C0079720
in	O
hiv	B-C0019682
-	O
infected	B-C0439663
patients	B-C0030705
receiving	B-C1514756
antiretroviral	B-C1963724
therapy	I-C1963724
we	O
studied	O
the	O
effect	B-C1280500
of	O
hepatitis	B-C1698259
c	I-C1698259
virus	I-C1698259
coinfection	I-C1698259
on	O
t	B-C0039194
cell	I-C0039194
subpopulations	B-C0079720
in	O
hiv	B-C0019682
-	O
infected	B-C0439663
patients	B-C0030705
receiving	O
antiretroviral	B-C1963724
therapy	I-C1963724
.	O
	
coinfection	B-C0275524
with	O
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
was	O
followed	O
by	O
a	O
decrease	B-C0547047
in	O
the	O
number	O
of	O
naive	B-C3273372
cd4	I-C3273372
t	I-C3273372
cells	I-C3273372
and	O
an	O
increase	B-C0442805
in	O
the	O
count	B-C0750480
of	O
central	O
cd8	B-C0242629
memory	I-C0242629
t	I-C0242629
cells	I-C0242629
in	O
these	O
patients	B-C0030705
.	O
	
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
had	O
no	B-C1301751
effect	I-C1301751
on	O
the	O
number	O
of	O
cd4	B-C3273371
memory	I-C3273371
t	I-C3273371
cells	I-C3273371
main	O
target	O
for	O
hiv	B-C0019682
.	O
	
this	O
can	O
explain	O
the	O
absence	O
of	O
strong	O
negative	B-C0205160
effect	B-C1280500
of	O
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
on	O
the	O
course	B-C0750729
of	O
hiv	B-C0019682
infection	B-C3714514
.	O
	
examining	B-C1292732
the	O
contribution	B-C1880177
of	O
motor	B-C1513492
movement	I-C1513492
and	O
language	B-C0023008
dominance	B-C0870441
to	O
increased	B-C0205217
left	B-C0205091
lateralization	B-C0013010
during	O
sign	B-C0037078
generation	B-C3146294
in	O
native	B-C0302891
signers	B-C1257890
the	O
neural	B-C0027763
systems	I-C0027763
supporting	O
speech	B-C0037817
and	O
sign	B-C1547188
processing	B-C0025361
are	O
very	O
similar	B-C2348205
,	O
although	O
not	O
identical	O
.	O
	
in	O
a	O
previous	O
ftcd	B-C2603343
study	I-C2603343
of	O
hearing	B-C0025361
native	B-C0302891
signers	B-C1257890
gutierrez-sigut	O
,	O
daws	O
,	O
et	O
al	O
,	O
2015	O
we	O
found	O
stronger	O
left	B-C0205091
lateralization	B-C0013010
for	O
sign	B-C1547188
than	O
speech	B-C0037817
.	O
	
given	O
that	O
this	O
increased	B-C0205217
lateralization	B-C0013010
could	O
not	O
be	O
explained	O
by	O
hand	B-C0018563
movement	B-C0026649
alone	O
,	O
the	O
contribution	O
of	O
motor	B-C1513492
movement	I-C1513492
versus	O
'	O
linguistic	B-C0023008
'	O
processes	B-C0025361
to	O
the	O
strength	B-C0808080
of	O
hemispheric	B-C0205139
lateralization	B-C0013010
during	O
sign	B-C1547188
production	B-C0025361
remains	O
unclear	O
.	O
	
here	O
we	O
directly	O
contrast	B-C1979874
lateralization	B-C0013010
strength	B-C0808080
of	O
covert	B-C0871315
versus	O
overt	B-C2963144
signing	B-C1547188
during	O
phonological	B-C0542341
and	O
semantic	B-C0036612
fluency	B-C0870569
tasks	B-C0542341
.	O
	
to	O
address	O
the	O
possibility	O
that	O
hearing	B-C0025361
native	B-C0302891
signers	B-C1257890
'	O
elevated	B-C3163633
lateralization	B-C0392762
indices	I-C0392762
lis	B-C0392762
were	O
due	O
to	O
performing	O
a	O
task	B-C0542341
in	O
their	O
less	O
dominant	B-C1527180
language	B-C0023008
,	O
here	O
we	O
test	O
deaf	B-C0525064
native	B-C0302891
signers	B-C1257890
,	O
whose	O
dominant	B-C1527180
language	B-C0023008
is	O
british	B-C3874914
sign	I-C3874914
language	I-C3874914
bsl	B-C3874914
.	O
	
signers	B-C1257890
were	O
more	O
strongly	O
left	B-C0205091
lateralized	B-C0013010
for	O
overt	B-C2963144
than	O
covert	B-C0871315
sign	B-C1547188
generation	O
.	O
	
however	O
,	O
the	O
strength	B-C0808080
of	O
lateralization	B-C0013010
was	O
not	O
correlated	B-C1707520
with	O
the	O
amount	O
of	O
time	O
producing	O
movements	B-C0026649
of	O
the	O
right	B-C0230370
hand	I-C0230370
.	O
	
comparisons	B-C1707455
with	O
previous	O
data	B-C1511726
from	O
hearing	B-C0025361
native	B-C0302891
english	B-C0376245
speakers	B-C1257890
suggest	O
stronger	O
laterality	B-C0392762
indices	I-C0392762
for	O
sign	B-C1547188
than	O
speech	B-C0037817
in	O
both	O
covert	B-C0871315
and	O
overt	B-C2963144
tasks	B-C0542341
.	O
	
this	O
increased	B-C0205217
left	B-C0205091
lateralization	B-C0013010
may	O
be	O
driven	O
by	O
specific	O
properties	B-C0871161
of	O
sign	B-C1547188
production	B-C0025361
such	O
as	O
the	O
increased	B-C0205217
use	B-C0457083
of	O
self-monitoring	B-C0237864
mechanisms	B-C0441712
or	O
the	O
nature	B-C0349590
of	O
phonological	B-C0679058
encoding	I-C0679058
of	O
hard	B-C0598741
ticks	I-C0598741
acari	B-C0598741
ixodidae	I-C0598741
of	O
livestock	B-C2936506
in	O
nicaragua	B-C0028002
,	O
with	O
notes	B-C1317574
about	O
distribution	B-C1704711
we	O
document	B-C0920316
the	O
species	B-C1705920
of	O
ticks	B-C0040203
that	O
parasitize	B-C1384353
livestock	B-C2936506
in	O
nicaragua	B-C0028002
.	O
	
the	O
study	B-C2603343
was	O
based	O
on	O
tick	B-C0040203
collection	B-C1516698
on	O
cattle	B-C0007452
and	O
horses	B-C0019944
from	O
437	O
farms	B-C0557759
in	O
nine	O
departments	B-C1704729
.	O
	
of	O
4841	O
animals	B-C0003062
examined	O
4481	O
cows	B-C0007452
and	O
360	O
horses	B-C0019944
,	O
3299	O
were	O
parasitized	B-C1384353
,	O
which	O
represent	O
68	O
%	O
of	O
the	O
bovines	B-C3667982
and	O
67	O
%	O
of	O
the	O
equines	B-C0019944
in	O
study	B-C2603343
59	O
cows	B-C0007452
and	O
25	O
horses	B-C0019944
were	O
parasitized	B-C1384353
by	O
more	O
than	O
one	O
species	B-C1705920
.	O
	
in	O
addition	O
,	O
280	O
specimens	B-C0370003
of	O
the	O
entomological	B-C0014386
museum	B-C0026863
in	O
león	B-C3814077
were	O
examined	O
.	O
	
the	O
ticks	B-C0040203
found	O
on	O
cattle	B-C0007452
were	O
rhipicephalus	B-C0323515
microplus	I-C0323515
75.2	O
%	O
of	O
the	O
ticks	B-C0040203
collected	B-C1516698
,	O
amblyomma	B-C3989620
mixtum	I-C3989620
20.8	O
%	O
,	O
a	B-C1667898
.	O
	
parvum	I-C1667898
2.6	O
%	O
,	O
a	B-C1690769
.	O
	
tenellum	I-C1690769
0.7	O
%	O
,	O
a	B-C0323501
.	O
	
maculatum	I-C0323501
0.7	O
%	O
.	O
	
while	O
the	O
ticks	B-C0040203
collected	B-C1516698
from	O
the	O
horses	B-C0019944
were	O
dermacentor	B-C0323524
nitens	I-C0323524
41.5	O
%	O
,	O
a	B-C3989620
.	O
	
mixtum	I-C3989620
31.7	O
%	O
,	O
r	B-C0323515
.	O
	
microplus	I-C0323515
13.8	O
%	O
,	O
a	B-C1667898
.	O
	
parvum	I-C1667898
6.5	O
%	O
,	O
a	B-C1690769
.	O
	
tenellum	I-C1690769
3.3	O
%	O
,	O
d	B-C0011595
.	O
	
dissimilis	I-C0011595
2.4	O
%	O
and	O
a	B-C0323501
.	O
	
maculatum	I-C0323501
assessment	B-C0220825
the	O
exposure	B-C0332157
level	B-C0441889
of	O
rare	B-C0025556
earth	I-C0025556
elements	I-C0025556
in	O
workers	B-C1527116
producing	B-C0033268
cerium	B-C0007828
,	O
lanthanum	B-C0534702
oxide	I-C0534702
ultrafine	B-C0077801
and	O
nanoparticles	B-C1450054
in	O
order	O
to	O
assess	B-C0184514
occupational	B-C0521127
exposure	B-C0332157
level	B-C0441889
of	O
15	O
rare	B-C0025556
earth	I-C0025556
elements	I-C0025556
rees	B-C0025556
and	O
identify	B-C0205396
the	O
associated	B-C0332281
influence	B-C4054723
,	O
we	O
used	O
inductively	B-C1553183
coupled	I-C1553183
plasma	I-C1553183
mass	I-C1553183
spectrometry	I-C1553183
icp-ms	B-C1553183
based	B-C1527178
on	O
closed	B-C0587267
-	O
vessel	B-C3273359
microwave	B-C0026051
-	O
assisted	B-C1269765
wet	B-C2700391
digestion	I-C2700391
procedure	I-C2700391
to	O
determinate	B-C1148554
the	O
concentration	B-C1446561
of	O
y	B-C0043432
,	O
la	B-C0534702
,	O
ce	B-C0007828
,	O
pr	B-C0032904
,	O
nd	B-C0027599
,	O
sm	B-C0036147
,	O
eu	B-C0015180
,	O
gd	B-C0016911
,	O
tb	B-C0039541
,	O
dy	B-C0013407
,	O
ho	B-C0019846
,	O
er	B-C0014688
,	O
tm	B-C0040066
,	O
yb	B-C0043431
and	O
lu	B-C0024170
in	O
urinary	B-C1610733
samples	I-C1610733
obtained	B-C1301820
from	O
workers	B-C1527116
producing	B-C0033268
ultrafine	B-C0077801
and	O
nanoparticles	B-C1450054
containing	O
cerium	B-C0007828
and	O
lanthanum	B-C0534702
oxide	I-C0534702
.	O
	
the	O
results	B-C1254595
suggest	B-C1705535
that	O
la	B-C0534702
and	O
ce	B-C0007828
were	O
the	O
primary	B-C0205225
component	B-C1705248
,	O
together	O
accounting	B-C0680857
for	O
97	O
%	O
of	O
total	O
rees	B-C0025556
in	O
workers	B-C1527116
.	O
	
the	O
urinary	B-C1610733
levels	B-C0441889
of	O
la	B-C0534702
,	O
and	O
ce	B-C0007828
among	O
the	O
workers	B-C1527116
6.36	O
,	O
15.32	O
μg.g	O
creatinine	B-C0010294
,	O
respectively	O
were	O
significantly	B-C0750502
enriched	B-C0205556
compared	B-C1707455
to	O
those	O
levels	B-C0441889
measured	B-C0444706
in	O
the	O
control	B-C0009932
subjects	B-C0681850
1.52	O
,	O
4.04	O
μg.g	O
creatinine	B-C0010294
,	O
respectively	O
p	O
<	O
0.05	O
.	O
	
this	O
study	B-C2603343
simultaneously	B-C0521115
identified	B-C0205396
the	O
associated	B-C0332281
individual	B-C0237401
factors	B-C1521761
,	O
the	O
results	B-C1254595
indicate	B-C3146298
that	O
the	O
concentrations	B-C1446561
in	O
over	O
5	O
years	O
group	B-C0441833
11.64	O
10.93	O
for	O
la	B-C0534702
,	O
27.83	O
24.38	O
for	O
ce	B-C0007828
were	O
significantly	B-C0750502
elevated	B-C3163633
compared	B-C1707455
to	O
1-5	O
years	O
group	B-C0441833
2.58	O
1.51	O
for	O
la	B-C0534702
,	O
6.87	O
3.90	O
for	O
ce	B-C0007828
p	O
<	O
0.05	O
.	O
	
compared	B-C1707455
the	O
urinary	B-C1610733
levels	B-C0441889
of	O
la	B-C0534702
and	O
ce	B-C0007828
at	O
the	O
separation	B-C0445406
and	O
packaging	B-C0030176
locations	B-C0450429
9.10	O
9.51	O
for	O
la	B-C0534702
,	O
22.29	O
21.01	O
for	O
ce	B-C0007828
with	O
the	O
other	O
locations	B-C0450429
2.85	O
0.98	O
for	O
la	B-C0534702
,	O
6.37	O
2.12	O
for	O
ce	B-C0007828
,	O
the	O
results	B-C1254595
show	O
urinary	B-C1610733
concentrations	B-C1446561
were	O
significantly	B-C0750502
higher	B-C0205250
in	O
workers	B-C1527116
at	O
separation	B-C0445406
and	O
packaging	B-C0030176
locations	B-C0450429
p	O
<	O
0.01	O
.	O
	
inter	B-C1548610
-	O
individual	B-C0237401
variation	B-C0205419
in	O
levels	B-C0441889
of	O
la	B-C0534702
and	O
ce	B-C0007828
in	O
urine	B-C0042036
is	O
the	O
result	B-C1274040
of	O
multi-factorial	B-C0015483
comprehensive	B-C1880156
action	B-C3266814
.	O
	
further	O
researches	B-C0035173
should	O
focus	B-C1285542
on	O
the	O
multiple	B-C0439064
factors	B-C1521761
contributing	B-C1880177
to	O
the	O
rees	B-C0025556
levels	B-C0441889
of	O
the	O
occupationally	B-C0521127
exposed	B-C0332157
workers	B-C1527116
.	O
	
two	O
known	B-C0205309
and	O
one	O
new	B-C0205314
species	B-C1705920
of	O
draconematidae	B-C2992016
and	O
epsilonematida	B-C2287919
nematoda	B-C0027581
,	O
desmodorida	B-C1030325
from	O
the	O
white	B-C0036493
sea	I-C0036493
,	O
north	B-C0035970
russia	I-C0035970
morphological	B-C0543482
descriptions	B-C0678257
of	O
three	O
""""	O
walking	B-C1704319
nematode	I-C1704319
""""	O
species	B-C1705920
found	O
for	O
the	O
first	O
time	O
in	O
the	O
white	B-C0036493
sea	I-C0036493
are	O
presented	O
.	O
	
draconema	B-C4111696
ophicephalum	I-C4111696
claparède	B-C0805191
,	O
1863	O
draconematidae	B-C2992016
and	O
epsilonema	B-C4093458
steineri	I-C4093458
chitwood	B-C0805191
,	O
1935	O
epsilonematidae	B-C2287919
,	O
both	O
known	O
from	O
insufficient	B-C0231180
material	O
and	O
females	B-C0086287
only	O
,	O
are	O
re-described	O
and	O
problems	B-C0033213
of	O
their	O
taxonomic	B-C0008903
identification	B-C0205396
as	O
well	O
as	O
species	B-C1705920
compositions	B-C0486616
of	O
respective	O
genera	B-C1708235
are	O
discussed	O
.	O
	
the	O
new	B-C0205314
species	B-C1705920
prochaetosoma	B-C2992020
marisalbi	I-C2992020
sp	I-C2992020
.	O
	
n	O
.	O
	
draconematidae	B-C2992016
differs	O
from	O
other	O
prochaetosoma	B-C2992020
species	I-C2992020
except	O
p	B-C2992020
.	O
	
longicapitatum	I-C2992020
allgén	B-C0805191
,	O
1935	O
in	O
that	O
the	O
pharyngeal	B-C0031354
bulb	B-C1947952
lumen	B-C0524461
is	O
not	B-C0243095
cuticularised	I-C0243095
,	O
from	O
p	B-C2992020
.	O
	
longicapitatum	I-C2992020
by	O
shape	B-C1268086
of	I-C1268086
body	I-C1268086
and	O
rostrum	B-C0243092
,	O
greater	B-C1704243
number	O
of	O
cephalic	B-C0205096
adhesive	B-C0243092
tubes	I-C0243092
,	O
and	O
from	O
p	B-C2992020
.	O
	
maertensi	I-C2992020
decraemer	B-C0805191
,	O
1989	O
by	O
having	O
a	O
relatively	O
longer	B-C0205166
tail	B-C0039259
,	O
fewer	O
anterior	B-C0205094
adhesive	B-C0243092
tubes	I-C0243092
and	O
longer	B-C0205166
spicules	B-C2826618
,	O
besides	O
lacking	O
cuticular	B-C1160234
thickening	I-C1160234
in	O
the	O
pharyngeal	B-C0031354
bulb	B-C1947952
.	O
	
draconema	B-C2992018
hoonsooi	I-C2992018
,	O
d	B-C2992018
.	O
	
youngeouni	I-C2992018
,	O
p.rochaetosoma	B-C2992020
beomseomense	I-C2992020
,	O
p	B-C2992020
.	O
	
brevicaudatum	I-C2992020
,	O
p	B-C2992020
.	O
	
byungilli	I-C2992020
,	O
p	B-C2992020
.	O
	
cracense	I-C2992020
,	O
p	B-C2992020
.	O
	
saheungi	I-C2992020
,	O
p	B-C2992020
.	O
	
sujungi	I-C2992020
,	O
p	B-C2992020
.	O
	
supseomense	I-C2992020
erected	B-C0443211
by	O
rho	B-C0805191
min	B-C0805191
2011	O
are	O
considered	O
as	O
invalid	B-C3245471
species	B-C1705920
while	O
prochaetosoma	B-C2992020
arcticum	I-C2992020
,	O
p	B-C2992020
.	O
	
lugubre	I-C2992020
and	O
epsilonema	B-C2287919
cygnoides	I-C2287919
are	O
assumed	O
as	O
species	B-C1705920
inquirenda	I-C1705920
.	O
	
from	O
a	O
phylogenetic	B-C1519068
tree	I-C1519068
based	O
on	O
the	O
18s	B-C0035899
rrna	I-C0035899
gene	I-C0035899
,	O
all	O
three	O
white	B-C0036493
sea	I-C0036493
species	B-C1705920
adjoin	B-C0205107
to	O
unidentified	B-C0205427
species	B-C1705920
of	O
their	O
respective	O
differential	B-C0443199
effects	B-C1704420
of	I-C1704420
crude	B-C0031264
oil	I-C0031264
on	O
denitrification	B-C0598972
and	O
anammox	B-C1158281
,	O
and	O
the	O
impact	B-C4049986
on	O
n2o	B-C0028215
production	B-C1254365
denitrification	B-C0598972
and	O
anammox	B-C1158281
are	O
key	O
processes	B-C1522240
for	O
reducing	B-C0392756
the	O
external	B-C0205101
nitrogen	B-C0028158
loads	O
delivered	B-C1705822
to	O
coastal	B-C0557760
ecosystems	B-C0162358
,	O
and	O
these	O
processes	B-C1522240
can	O
be	O
affected	B-C0392760
by	O
pollutants	B-C0599786
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
investigated	B-C1292732
the	O
effect	B-C1704420
of	I-C1704420
crude	B-C0031264
oil	I-C0031264
on	O
denitrification	B-C0598972
and	O
anammox	B-C1158281
.	O
	
controlled	B-C0681814
laboratory	I-C0681814
experiments	I-C0681814
were	O
performed	O
using	O
sediment	B-C1550099
slurries	B-C1550099
from	O
the	O
lima	B-C0017446
estuary	B-C3494468
nw	B-C1254362
portugal	B-C0032729
.	O
	
anammox	B-C1158281
and	O
denitrification	B-C0598972
rates	B-C0392762
were	O
measured	O
using	O
15	B-C0028162
no3	B-C0699857
,	O
and	O
the	O
production	B-C1254365
of	O
29	B-C0028158
and	O
30	B-C0028158
quantified	O
by	O
membrane	B-C0037813
inlet	I-C0037813
mass	I-C0037813
spectrometry	I-C0037813
.	O
	
results	O
revealed	O
that	O
while	O
denitrification	B-C0598972
rates	B-C0392762
were	O
stimulated	O
between	O
10	O
and	O
25	O
000	O
times	O
after	O
crude	B-C0031264
oil	I-C0031264
amendment	B-C0680532
,	O
anammox	B-C1158281
activity	B-C0441655
was	O
partially	O
between	O
2	O
and	O
5	O
times	O
or	O
completely	B-C0205197
inhibited	B-C0311403
by	O
the	O
addition	B-C1883712
of	O
crude	B-C0031264
oil	I-C0031264
when	O
comparing	O
to	O
rates	B-C0392762
in	O
unamended	B-C1882979
controls	I-C1882979
.	O
	
similar	O
results	O
were	O
observed	O
across	O
four	O
estuarine	B-C1254362
sediment	B-C1550099
types	B-C0332307
,	O
despite	O
their	O
different	O
physical-chemical	B-C1521970
characteristics	I-C1521970
.	O
	
moreover	O
,	O
n2o	B-C0028215
production	B-C1254365
was	O
reduced	B-C0392756
by	O
2-36	O
times	O
following	O
crude	B-C0031264
oil	I-C0031264
addition	B-C1883712
.	O
	
further	O
work	O
is	O
required	O
to	O
fully	O
understand	O
the	O
mechanism	B-C0441712
of	O
the	O
observed	B-C1441672
reduction	B-C0392756
in	O
n2o	B-C0028215
production	B-C1254365
.	O
	
this	O
study	B-C2603343
represents	O
one	O
of	O
the	O
first	O
contributions	B-C1880177
to	O
the	O
understanding	O
of	O
the	O
impact	B-C4049986
of	O
crude	B-C0031264
oil	I-C0031264
pollution	B-C0392355
on	O
denitrification	B-C0598972
and	O
anammox	B-C1158281
,	O
with	O
profound	O
implications	O
for	O
the	O
management	B-C1273870
of	O
aquatic	B-C0563034
ecosystems	B-C0162358
regarding	O
eutrophication	B-C0015191
n-removal	B-C1883720
.	O
	
shining	O
the	O
light	O
on	O
the	O
dark	O
side	O
of	O
medical	B-C0205476
leadership	B-C0023181
-	O
a	O
qualitative	B-C0949415
study	I-C0949415
in	O
australia	B-C0004340
purpose	O
the	O
paper	O
aims	B-C1947946
to	O
explore	O
the	O
beliefs	B-C0004951
of	O
doctors	B-C0031831
in	O
leadership	B-C0023181
roles	O
of	O
the	O
concept	B-C0178566
of	O
"""the"	O
dark	O
"side"""	O
,	O
using	O
data	B-C1511726
collected	O
from	O
interviews	B-C0021822
carried	O
out	O
with	O
45	O
doctors	B-C0031831
in	O
medical	B-C0205476
leadership	B-C0023181
roles	O
across	O
australia	B-C0004340
.	O
	
the	O
paper	O
looks	O
at	O
the	O
beliefs	B-C0004951
from	O
the	O
perspectives	B-C1254370
of	O
doctors	B-C0031831
who	O
are	O
already	O
in	O
leadership	B-C0023181
roles	O
themselves	O
to	O
identify	O
potential	O
barriers	B-C4063003
they	O
might	O
have	O
encountered	O
and	O
to	O
arrive	O
at	O
better-informed	O
strategies	O
to	O
engage	O
more	O
doctors	B-C0031831
in	O
the	O
leadership	B-C0023181
of	O
the	O
australian	B-C0238711
health	B-C1456613
system	I-C1456613
.	O
	
the	O
research	B-C0035168
question	O
is	O
"""what"	O
are	O
the	O
beliefs	B-C0004951
of	O
medical	B-C0205476
leaders	B-C0557558
that	O
form	O
the	O
key	O
themes	B-C0869035
or	O
dimensions	B-C0439534
of	O
the	O
negative	O
perception	O
of	O
the	O
'dark	O
side'	O
.	O
	
design/methodology/approach	O
the	O
paper	O
analysed	O
data	B-C1511726
from	O
two	O
similar	O
qualitative	B-C0949415
studies	I-C0949415
examining	O
medical	B-C0205476
leadership	B-C0023181
and	O
engagement	O
in	O
australia	B-C0004340
by	O
the	O
same	O
author	O
,	O
in	O
collaboration	B-C0282116
with	O
other	O
researchers	B-C0035173
,	O
which	O
used	O
in-depth	O
semi-structured	B-C0681913
interviews	I-C0681913
with	O
45	O
purposively	O
sampled	O
senior	O
medical	B-C0205476
leaders	B-C0557558
in	O
leadership	B-C0023181
roles	O
across	O
australia	B-C0004340
in	O
health	B-C0018747
services	I-C0018747
,	O
private	B-C0033173
and	O
public	B-C0020022
hospitals	I-C0020022
,	O
professional	B-C0680403
associations	I-C0680403
and	O
health	B-C1514958
departments	I-C1514958
.	O
	
the	O
data	B-C1511726
were	O
analysed	O
using	O
deductive	O
and	O
inductive	O
approaches	B-C0449445
through	O
a	O
coding	B-C0009219
framework	O
based	O
on	O
the	O
interview	B-C0021822
data	B-C1511726
and	O
literature	B-C0282441
review	I-C0282441
,	O
with	O
all	O
sections	O
of	O
coded	B-C0009219
data	B-C1511726
grouped	B-C0441833
into	O
themes	B-C0869035
.	O
	
findings	O
medical	B-C0205476
leaders	B-C0557558
had	O
four	O
key	O
beliefs	B-C0004951
about	O
the	O
"""dark"	O
"side"""	O
as	O
perceived	O
through	O
the	O
eyes	B-C0015392
of	O
their	O
own	O
past	O
clinical	B-C0008973
experience	I-C0008973
and/or	O
their	O
clinical	B-C0205210
colleagues	B-C0681088
.	O
	
these	O
four	O
beliefs	B-C0004951
or	O
dimensions	B-C0439534
of	O
the	O
negative	O
perception	O
colloquially	O
known	O
as	O
"""the"	O
dark	O
"side"""	O
are	O
the	O
belief	B-C0004951
that	O
they	O
lack	O
both	O
managerial	B-C0402281
and	O
clinical	B-C0205210
credibility	B-C0870373
,	O
they	O
have	O
confused	O
identities	O
,	O
they	O
may	O
be	O
in	O
conflict	B-C0079152
with	O
clinicians	B-C0871685
,	O
their	O
clinical	B-C0205210
colleagues	B-C0681088
lack	O
insight	O
into	O
the	O
complexities	O
of	O
medical	B-C0205476
leadership	B-C0023181
and	O
,	O
as	O
a	O
result	O
,	O
doctors	B-C0031831
are	O
actively	O
discouraged	O
from	O
making	O
the	O
transition	O
from	O
clinical	B-C0008973
practice	I-C0008973
to	O
medical	B-C0205476
leadership	B-C0023181
roles	O
in	O
the	O
first	O
place	O
.	O
	
research	O
limitations/implications	O
this	O
research	B-C0035168
was	O
conducted	O
within	O
the	O
western	B-C1705493
developed-nation	B-C0282613
setting	O
of	O
australia	B-C0004340
and	O
only	O
involved	O
interviews	B-C0021822
with	O
doctors	B-C0031831
in	O
medical	B-C0205476
leadership	B-C0023181
roles	O
.	O
	
the	O
findings	O
are	O
therefore	O
limited	O
to	O
the	O
doctors	B-C0031831
'	O
own	O
perceptions	O
of	O
themselves	O
based	O
on	O
their	O
past	O
experiences	O
and	O
beliefs	B-C0004951
.	O
	
future	O
research	B-C0035168
involving	O
doctors	B-C0031831
who	O
have	O
not	O
chosen	O
to	O
transition	B-C2700061
to	O
leadership	B-C0023181
roles	O
,	O
or	O
other	O
health	B-C1552267
practitioners	I-C1552267
in	O
other	O
settings	O
,	O
may	O
provide	O
a	O
broader	O
perspective	B-C1254370
.	O
	
also	O
,	O
this	O
research	B-C0035168
was	O
exploratory	O
and	O
descriptive	B-C0437940
in	O
nature	O
using	O
qualitative	B-C0681940
methods	I-C0681940
,	O
and	O
quantitative	B-C1510569
research	I-C1510569
can	O
be	O
carried	O
out	O
in	O
the	O
future	O
to	O
extend	O
this	O
research	B-C0035168
for	O
statistical	B-C0871424
generalisation	I-C0871424
.	O
	
practical	O
implications	O
the	O
paper	O
includes	O
implications	O
for	O
health	B-C0018720
organisations	I-C0018720
,	O
training	O
providers	O
,	O
medical	B-C0205476
employers	B-C1274022
and	O
health	B-C1514958
departments	I-C1514958
and	O
describes	O
a	O
multi-prong	O
strategy	O
to	O
address	O
this	O
important	O
issue	O
.	O
	
originality/value	O
this	O
paper	O
fulfils	O
an	O
identified	O
need	O
to	O
study	B-C2603343
the	O
concept	B-C0178566
of	O
"""moving"	O
to	O
the	O
dark	O
"side"""	O
as	O
a	O
negative	O
perception	O
of	O
medical	B-C0205476
leadership	B-C0023181
and	O
contributes	O
to	O
the	O
evidence	B-C3887511
in	O
this	O
under-	O
researched	B-C0035168
area	O
.	O
	
this	O
paper	O
has	O
used	O
data	B-C1511726
from	O
two	O
similar	O
studies	B-C2603343
,	O
combined	O
together	O
for	O
the	O
first	O
time	O
,	O
with	O
new	O
analysis	B-C0936012
and	O
coding	B-C0009219
,	O
looking	O
at	O
the	O
concept	B-C0178566
erlotinib	B-C1135135
plus	O
gemcitabine	B-C0045093
versus	O
gemcitabine	B-C0045093
for	O
pancreatic	B-C0235974
cancer	I-C0235974
real	B-C0237400
-	O
world	B-C2700280
analysis	B-C0936012
of	O
korean	B-C0022771
national	B-C0015737
database	B-C0242356
a	O
randomized	B-C0206034
clinical	I-C0206034
trial	I-C0206034
has	O
found	O
that	O
the	O
addition	B-C0596304
of	O
erlotinib	B-C1135135
to	O
gemcitabine	B-C0045093
gem	B-C0045093
-	O
e	B-C1135135
for	O
pancreatic	B-C0235974
cancer	I-C0235974
led	O
to	O
a	O
modest	B-C0205081
increase	B-C0442805
in	O
survival	B-C0038952
.	O
	
the	O
aim	B-C1947946
of	O
this	O
national	B-C0681788
population	B-C1257890
-	O
based	B-C1527178
retrospective	B-C0035363
study	I-C0035363
was	O
to	O
compare	B-C1707455
the	O
effectiveness	B-C1280519
of	O
gem	B-C0045093
-	O
e	B-C1135135
to	O
gem	B-C0045093
alone	O
for	O
pancreatic	B-C0235974
cancer	I-C0235974
patients	B-C0030705
in	O
real	B-C0205897
clinical	I-C0205897
practice	I-C0205897
.	O
	
patients	B-C0030705
with	O
pancreatic	B-C0235974
cancer	I-C0235974
icd-10	B-C1137110
c25	O
with	O
prescription	B-C1521941
claims	O
of	O
gemcitabine	B-C0045093
or	O
erlotinib	B-C1135135
between	O
jan	O
1	O
,	O
2007	O
and	O
dec	O
31	O
,	O
2012	O
were	O
retrospectively	B-C1514923
identified	B-C0205396
from	O
the	O
korean	B-C0022771
health	B-C0027452
insurance	I-C0027452
claims	O
database	B-C0242356
.	O
	
to	O
be	O
included	O
in	O
the	O
study	B-C2603343
population	B-C1257890
,	O
patients	B-C0030705
were	O
required	B-C1514873
to	O
have	O
had	O
a	O
histological	B-C0679557
or	O
cytological	B-C1298647
diagnosis	I-C1298647
within	O
one	O
year	O
before	O
chemotherapy	B-C3665472
.	O
	
patients	B-C0030705
treated	B-C0332154
with	I-C0332154
prior	O
radiotherapy	B-C1522449
,	O
surgery	B-C2081627
,	O
or	O
chemotherapy	B-C3665472
were	O
excluded	B-C1554077
to	O
reduce	B-C0441610
heterogeneity	B-C0019409
.	O
	
overall	O
survival	B-C0038952
from	O
the	O
initiation	B-C1704686
of	O
therapy	B-C0087111
and	O
the	O
medical	B-C0086600
costs	I-C0086600
of	O
gem	B-C0045093
-	O
e	B-C1135135
and	O
gem	B-C0045093
were	O
compared	B-C1707455
.	O
	
a	O
total	O
of	O
4	O
patients	B-C0030705
were	O
included	O
in	O
the	O
analysis	B-C0936012
.	O
	
overall	O
survival	B-C0038952
was	O
not	O
significantly	B-C0750502
longer	B-C0205166
in	O
patients	B-C0030705
treated	B-C0332154
with	O
gem	B-C0045093
-	O
e	B-C1135135
median	B-C0876920
6.77	O
months	O
for	O
gem	B-C0045093
-	O
e	B-C1135135
vs	O
.	O
	
6.68	O
months	O
for	O
gem	B-C0045093
,	O
p	O
=	O
0.0977	O
.	O
	
there	O
was	O
also	O
no	B-C3694175
significant	I-C3694175
difference	B-C1705241
in	O
the	O
respective	O
one-year	O
survival	B-C0038954
rates	I-C0038954
27.0	O
%	O
vs	O
.	O
	
27.3	O
%	O
p	O
=	O
0.5988	O
.	O
	
multivariate	B-C0026777
analysis	I-C0026777
using	O
age	B-C0001779
,	O
gender	B-C0079399
,	O
and	O
comorbidities	B-C0009488
as	O
covariates	B-C0814913
did	O
not	O
reveal	B-C0443289
any	O
significant	B-C0750502
differences	B-C1705241
in	O
survival	B-C0038952
.	O
	
based	B-C1527178
on	O
this	O
relative	B-C0035023
effectiveness	I-C0035023
,	O
the	O
incremental	B-C1705117
cost	B-C0010186
per	O
life	B-C0376558
year	B-C0439234
gained	B-C1517378
over	O
gem	B-C0045093
was	O
estimated	B-C0750572
at	O
usd	B-C1555442
70	O
for	O
gem	B-C0045093
-	O
e	B-C1135135
.	O
	
gem	B-C0045093
-	O
e	B-C1135135
for	O
pancreatic	B-C0235974
cancer	I-C0235974
is	O
not	O
more	O
effective	B-C1704419
than	O
gem	B-C0045093
in	O
a	O
real	B-C0237400
-	O
world	B-C2700280
setting	B-C1552652
,	O
and	O
it	O
does	O
not	O
provide	B-C1999230
reasonable	B-C0566251
cost-effectiveness	B-C0010181
over	O
development	O
of	O
a	O
novel	O
quantitative	B-C0887819
structure-activity	I-C0887819
relationship	I-C0887819
model	B-C3161035
to	O
accurately	O
predict	O
pulmonary	B-C3852990
absorption	I-C3852990
and	O
replace	O
routine	O
use	O
of	O
the	O
isolated	B-C0205409
perfused	B-C1549542
respiring	B-C0035203
rat	B-C1882727
lung	I-C1882727
model	B-C3161035
we	O
developed	O
and	O
tested	O
a	O
novel	O
quantitative	B-C0887819
structure-activity	I-C0887819
relationship	I-C0887819
qsar	B-C0887819
model	B-C3161035
to	O
better	O
understand	O
the	O
physicochemical	B-C2350461
drivers	O
of	O
pulmonary	B-C3852990
absorption	I-C3852990
,	O
and	O
to	O
facilitate	O
compound	B-C0013171
design	I-C0013171
through	O
improved	O
prediction	B-C0681842
of	O
absorption	B-C2347023
.	O
	
the	O
model	B-C3161035
was	O
tested	O
using	O
a	O
large	O
array	O
of	O
both	O
existing	O
and	O
newly	O
designed	O
compounds	B-C0013227
.	O
	
pulmonary	B-C3852990
absorption	I-C3852990
data	O
was	O
generated	O
using	O
the	O
isolated	B-C0205409
perfused	B-C1549542
respiring	B-C0035203
rat	B-C1882727
lung	I-C1882727
iprlu	B-C1882727
model	B-C3161035
for	O
82	O
drug	B-C0920472
discovery	I-C0920472
compounds	B-C0013227
and	O
17	O
marketed	B-C1254351
drugs	I-C1254351
.	O
	
this	O
dataset	O
was	O
used	O
to	O
build	O
a	O
novel	O
qsar	B-C0887819
model	B-C3161035
based	O
on	O
calculated	O
physicochemical	B-C2350461
properties	I-C2350461
.	O
	
a	O
further	O
9	O
compounds	B-C0013227
were	O
used	O
to	O
test	O
the	O
model's	B-C3161035
predictive	O
capability	B-C2698977
.	O
	
the	O
qsar	B-C0887819
model	B-C3161035
performed	O
well	O
on	O
the	O
9	O
compounds	B-C0013227
in	O
the	O
""""	O
test	B-C0150098
set	I-C0150098
""""	O
with	O
a	O
predicted	O
versus	O
observed	O
correlation	B-C0010100
of	O
r	O
=	O
0.85	O
,	O
and	O
>65%	O
of	O
compounds	B-C0013227
correctly	O
categorised	O
.	O
	
calculated	O
descriptors	O
associated	O
with	O
permeability	B-C0031164
and	O
hydrophobicity	B-C0598629
positively	O
correlated	O
with	O
pulmonary	B-C3852990
absorption	I-C3852990
,	O
whereas	O
those	O
associated	O
with	O
charge	B-C0205556
,	O
ionisation	B-C0596801
and	O
size	B-C0456389
negatively	O
correlated	O
.	O
	
the	O
novel	O
qsar	B-C0887819
model	B-C3161035
described	O
here	O
can	O
replace	O
routine	O
generation	O
of	O
iprlu	B-C1882727
model	B-C3161035
data	O
for	O
ranking	B-C0699794
and	O
classifying	B-C0008902
compounds	B-C0013227
prior	O
to	O
synthesis	B-C1883254
.	O
	
it	O
will	O
also	O
provide	O
scientists	O
working	O
in	O
the	O
field	O
of	O
inhaled	B-C0920472
drug	I-C0920472
discovery	I-C0920472
with	O
a	O
deeper	O
understanding	O
of	O
the	O
physicochemical	B-C2350461
drivers	O
of	O
pulmonary	B-C3852990
absorption	I-C3852990
based	O
on	O
a	O
relevant	O
respiratory	O
compound	B-C0013227
dataset	B-C0150098
.	O
	
the	O
epiderm	B-C0282574
3d	B-C1511123
human	I-C1511123
reconstructed	I-C1511123
skin	I-C1511123
micronucleus	I-C1511123
rsmn	I-C1511123
assay	I-C1511123
historical	B-C3850080
control	I-C3850080
data	B-C1511726
and	O
proof	B-C0565962
of	O
principle	B-C2603343
studies	I-C2603343
for	O
mechanistic	B-C1510438
assay	I-C1510438
adaptations	O
the	O
in	B-C1511123
vitro	I-C1511123
human	I-C1511123
reconstructed	I-C1511123
skin	I-C1511123
micronucleus	I-C1511123
rsmn	I-C1511123
assay	I-C1511123
in	O
epiderm	B-C0282574
is	O
a	O
promising	O
novel	O
animal	B-C0003059
alternative	I-C0003059
for	O
evaluating	O
genotoxicity	B-C0598309
of	O
topically	B-C0683174
applied	I-C0683174
chemicals	B-C0220806
.	O
	
it	O
is	O
particularly	O
useful	O
for	O
assessing	B-C0184514
cosmetic	B-C0456611
ingredients	I-C0456611
that	O
can	O
no	O
longer	O
be	O
tested	B-C0039593
using	O
in	B-C1515655
vivo	I-C1515655
assays	B-C1510438
.	O
	
to	O
advance	O
the	O
use	O
of	O
this	O
test	B-C0392366
especially	O
for	O
regulatory	B-C0220905
decision-making	B-C0011109
,	O
we	O
have	O
established	O
the	O
rsmn	B-C1511123
assay	I-C1511123
in	O
our	O
laboratory	B-C0022877
according	O
to	O
good	B-C2983608
laboratory	I-C2983608
practice	I-C2983608
and	O
following	O
the	O
principles	O
of	O
the	O
oecd	B-C3850013
test	B-C0162791
guideline	I-C0162791
487	I-C0162791
in	B-C1533691
vitro	I-C1533691
mammalian	B-C1512977
cell	I-C1512977
micronucleus	B-C0026006
test	I-C0026006
.	O
	
proficiency	O
with	O
the	O
assay	B-C1510438
was	O
established	O
by	O
correctly	O
identifying	O
direct-acting	B-C0026879
genotoxins	I-C0026879
and	O
genotoxins	B-C0026879
requiring	O
metabolism	B-C0025519
,	O
as	O
well	O
as	O
non-genotoxic	B-C0243095
/	O
non-carcinogenic	B-C0243095
chemicals	B-C0220806
.	O
	
we	O
also	O
report	B-C0684224
the	O
analysis	B-C0936012
of	O
our	O
historical	B-C3850080
control	I-C3850080
data	B-C1511726
that	O
demonstrate	O
vehicle	O
control	O
and	O
positive	B-C1883676
control	I-C1883676
values	B-C0392762
for	O
%	O
micronuclei	B-C4048301
in	O
binucleated	B-C0333909
cells	I-C0333909
are	O
in	O
the	O
ranges	O
reported	O
previously	O
.	O
	
technical	B-C1710348
issues	I-C1710348
including	O
evaluating	O
various	O
solvents	B-C0037638
with	O
both	O
48h	O
and	O
72h	O
treatment	B-C0040808
regimens	I-C0040808
were	O
investigated	B-C1292732
.	O
	
for	O
the	O
first	O
time	O
,	O
mechanistic	B-C2698671
studies	I-C2698671
using	O
crest	B-C0242481
analysis	I-C0242481
revealed	O
that	O
the	O
rsmn	B-C1510438
assay	I-C1510438
is	O
suitable	O
for	O
distinguishing	O
aneugens	B-C0949641
and	O
clastogens	B-C0008904
.	O
	
moreover	O
,	O
the	O
assay	B-C1510438
is	O
also	O
suitable	O
for	O
measuring	O
cytokines	B-C0079189
as	O
markers	B-C0162489
for	O
proliferative	B-C0334094
and	O
toxic	B-C0600688
effects	I-C0600688
of	O
wnt-5a	B-C4255015
/	O
frizzled9	B-C1438694
receptor	B-C1514762
signaling	I-C1514762
through	O
the	O
gαo	B-C3884317
/	O
gβγ	B-C0596637
complex	I-C0596637
regulates	B-C1327622
dendritic	B-C0872341
spine	I-C0872341
formation	B-C0007613
wnt	B-C0033684
ligands	I-C0033684
play	O
crucial	O
roles	O
in	O
the	O
development	B-C1254358
and	O
regulation	B-C1325905
of	I-C1325905
synapse	I-C1325905
structure	I-C1325905
and	I-C1325905
function	I-C1325905
.	O
	
specifically	O
,	O
wnt-5a	B-C4255015
acts	O
as	O
a	O
secreted	B-C0018284
growth	I-C0018284
factor	I-C0018284
that	O
regulates	B-C1327622
dendritic	B-C0872341
spine	I-C0872341
formation	B-C0007613
in	O
rodent	B-C0035804
hippocampal	B-C0019564
neurons	B-C0027882
,	O
resulting	O
in	O
postsynaptic	B-C1167384
development	B-C1254358
that	O
promotes	O
the	O
clustering	B-C3269066
of	I-C3269066
the	I-C3269066
postsynaptic	I-C3269066
density	I-C3269066
protein-95	I-C3269066
psd-95	I-C3269066
.	O
	
here	O
,	O
we	O
focused	O
on	O
the	O
early	B-C1279919
events	B-C0441471
occurring	O
after	O
the	O
interaction	B-C0872079
between	O
wnt-5a	B-C4255015
and	O
its	O
frizzled	B-C1564903
receptor	I-C1564903
at	O
the	O
neuronal	B-C0027882
cell	B-C0699040
surface	I-C0699040
.	O
	
additionally	O
,	O
we	O
studied	O
the	O
role	B-C1705810
of	O
heterotrimeric	B-C0752348
g	I-C0752348
proteins	I-C0752348
in	O
wnt-5a	B-C4255015
-dependent	O
synaptic	B-C0039063
development	B-C1254358
.	O
	
we	O
report	O
that	O
frizzled9	B-C1438694
fzd9	B-C1438694
,	O
a	O
wnt	B-C4255015
receptor	B-C1564903
related	O
to	O
williams'	B-C0175702
syndrome	I-C0175702
,	O
is	O
localized	O
in	O
the	O
postsynaptic	B-C0682686
region	I-C0682686
,	O
where	O
it	O
interacts	B-C0872079
with	O
wnt-5a	B-C4255015
.	O
	
functionally	O
,	O
fzd9	B-C1438694
is	O
required	O
for	O
the	O
wnt-5a	B-C4255015
-mediated	O
increase	B-C0442805
in	O
dendritic	B-C0872341
spine	I-C0872341
density	I-C0872341
.	O
	
fzd9	B-C1438694
forms	O
a	O
pre-coupled	B-C3893600
complex	I-C3893600
with	O
gαo	B-C3884317
under	O
basal	B-C1254365
conditions	I-C1254365
that	O
dissociates	B-C0301643
after	O
wnt-5a	B-C4255015
stimulation	B-C1148560
.	O
	
accordingly	O
,	O
we	O
found	O
that	O
g-protein	B-C0007613
inhibition	I-C0007613
abrogates	I-C0007613
wnt-5a	B-C4255015
-dependent	O
pathway	B-C1704259
in	O
hippocampal	B-C0019564
neurons	B-C0027882
.	O
	
in	O
particular	O
,	O
the	O
activation	B-C1879547
of	O
gαo	B-C3884317
appears	O
to	O
be	O
a	O
key	O
factor	O
controlling	B-C2239193
the	O
wnt-5a	B-C4255015
-	O
induced	B-C0205263
dendritic	B-C0872341
spine	I-C0872341
density	I-C0872341
.	O
	
in	O
addition	O
,	O
we	O
found	O
that	O
gβγ	B-C0596637
is	O
required	O
for	O
the	O
wnt-5a	B-C4255015
-mediated	O
increase	B-C0442805
in	O
cytosolic	B-C1383501
calcium	B-C0006675
levels	B-C0441889
and	O
spinogenesis	B-C0007613
.	O
	
our	O
findings	B-C2607943
reveal	O
that	O
fzd9	B-C1438694
and	O
heterotrimeric	B-C0752348
g	I-C0752348
proteins	I-C0752348
regulate	B-C1327622
wnt-5a	B-C4255015
signaling	B-C0037080
and	O
dendritic	B-C0872341
spines	I-C0872341
in	O
cultured	B-C0007635
hippocampal	B-C0019564
neurons	B-C0027882
.	O
	
a	O
delayed	B-C0205421
diagnosis	B-C0011900
of	O
chronic	B-C0311262
mesenteric	I-C0311262
ischaemia	I-C0311262
the	O
role	O
of	O
clinicians	B-C0871685
'	O
cognitive	B-C1516691
errors	B-C0743559
chronic	B-C0205191
diarrhoeal	B-C1290807
illnesses	I-C1290807
with	O
nausea	B-C0027497
and	O
weight	B-C1262477
loss	I-C1262477
are	O
a	O
common	B-C0205214
indication	B-C3146298
for	O
gastroenterology	B-C0017163
review	B-C1552617
.	O
	
while	O
many	O
such	O
cases	O
have	O
intra-luminal	B-C0442115
aetiologies	B-C1314792
,	O
such	O
as	O
inflammatory	B-C0021390
bowel	I-C0021390
disease	I-C0021390
,	O
coeliac	B-C0007570
disease	I-C0007570
or	O
other	O
malabsorptive	B-C3280502
conditions	I-C3280502
,	O
with	O
many	O
other	O
cases	O
due	O
to	O
functional	B-C0205245
gut	B-C0699819
disorders	B-C0012634
or	O
systemic	B-C0205373
malignancy	B-C4282132
,	O
clinicians	B-C0871685
must	O
also	O
keep	O
vascular	B-C0042373
disorders	I-C0042373
in	O
mind	O
.	O
	
here	O
we	O
report	O
a	O
patient	B-C0030705
with	O
a	O
delayed	B-C0205421
diagnosis	B-C0011900
of	O
chronic	B-C0311262
mesenteric	I-C0311262
ischaemia	I-C0311262
after	O
6	O
months	B-C0439231
of	O
gastrointestinal	B-C0426576
symptoms	I-C0426576
strongly	O
mimicking	O
an	O
alternative	B-C1523987
diagnosis	B-C0011900
such	O
as	O
inflammatory	B-C0021390
bowel	I-C0021390
disease	I-C0021390
due	O
an	O
atypical	B-C0205182
predominance	B-C1527180
of	O
nausea	B-C0027497
and	O
diarrhoea	B-C0011991
rather	O
than	O
pain	B-C0030193
.	O
	
we	O
briefly	O
review	B-C1552617
the	O
literature	B-C0023866
on	O
treatment	B-C1522326
of	O
this	O
condition	B-C0012634
but	O
also	O
discuss	O
with	O
particular	O
attention	O
the	O
sequence	B-C1519249
of	O
cognitive	B-C1516691
errors	B-C0743559
made	O
by	O
clinicians	B-C0871685
that	O
led	O
to	O
a	O
diagnostic	B-C0011900
delay	B-C0205421
,	O
inviting	O
readers	O
to	O
thus	O
reflect	O
on	O
how	O
such	O
errors	B-C0743559
can	O
be	O
minimised	B-C0392756
in	O
their	O
evaluation	B-C0220825
of	O
choroidal	B-C0008520
thickness	B-C1280412
in	O
patients	B-C0030705
with	O
pseudoexfoliation	B-C0206368
syndrome	I-C0206368
and	O
pseudoexfoliation	B-C0206368
glaucoma	I-C0206368
purpose	B-C1285529
.	O
	
to	O
compare	B-C1707455
the	O
macular	B-C0332574
and	O
peripapillary	B-C0442163
choroidal	B-C0008520
thickness	B-C1280412
in	O
eyes	B-C0015392
with	O
pseudoexfoliation	B-C0206368
pex	I-C0206368
syndrome	I-C0206368
and	O
pex	B-C0206368
glaucoma	I-C0206368
with	O
the	O
normal	B-C0205307
eyes	B-C0015392
of	O
healthy	B-C3898900
controls	B-C0009932
.	O
	
materials	O
and	O
methods	O
.	O
	
in	O
this	O
prospective	B-C0033522
study	I-C0033522
,	O
30	O
eyes	B-C0015392
of	O
30	O
patients	B-C0030705
with	O
pex	B-C0206368
syndrome	I-C0206368
,	O
28	O
eyes	B-C0015392
of	O
28	O
patients	B-C0030705
with	O
pex	B-C0206368
glaucoma	I-C0206368
,	O
and	O
30	O
eyes	B-C0015392
of	O
30	O
age	B-C0001779
-matched	O
healthy	B-C3898900
subjects	B-C0681850
were	O
enrolled	O
.	O
	
choroidal	B-C0008520
thicknesses	B-C1280412
in	O
the	O
macular	B-C0332574
and	O
peripapillary	B-C0442163
areas	B-C0205146
were	O
measured	B-C0444706
by	O
using	O
spectral	B-C3876157
domain	I-C3876157
optical	I-C3876157
coherence	I-C3876157
tomography	I-C3876157
.	O
	
results	O
.	O
	
gender	B-C0079399
,	O
age	B-C0001779
,	O
and	O
axial	B-C2936396
length	I-C2936396
did	O
not	B-C1273937
significantly	I-C1273937
differ	O
between	O
the	O
groups	B-C0681860
all	O
,	O
p	O
>	O
0.05	O
.	O
	
the	O
mean	B-C0444504
values	I-C0444504
of	O
choroidal	B-C0008520
thickness	B-C1280412
in	O
the	O
macular	B-C0332574
and	O
peripapillary	B-C0442163
areas	B-C0205146
except	B-C0332300
the	O
superior	B-C1282910
quadrant	B-C1631280
in	O
the	O
patients	B-C0030705
with	O
pex	B-C0206368
syndrome	I-C0206368
and	O
pex	B-C0206368
glaucoma	I-C0206368
were	O
lower	B-C2003888
compared	B-C1707455
with	O
controls	B-C0009932
all	O
p	O
<	O
0.05	O
.	O
	
the	O
mean	B-C0444504
values	I-C0444504
of	O
the	O
macular	B-C0332574
and	O
peripapillary	B-C0442163
choroidal	B-C0008520
thickness	B-C1280412
in	O
the	O
pex	B-C0206368
glaucoma	I-C0206368
group	B-C0681860
were	O
lower	B-C2003888
compared	B-C1707455
with	O
pex	B-C0206368
syndrome	I-C0206368
group	B-C0681860
however	O
this	O
difference	B-C1705242
was	O
not	B-C1273937
significant	I-C1273937
.	O
	
conclusions	O
.	O
	
the	O
findings	B-C0243095
of	O
this	O
study	B-C2603343
revealed	B-C0443289
that	O
macular	B-C0332574
and	O
peripapillary	B-C0442163
choroidal	B-C0008520
thicknesses	B-C1280412
were	O
decreased	B-C0205216
in	O
pex	B-C0206368
syndrome	I-C0206368
and	O
pex	B-C0206368
glaucoma	I-C0206368
cases	B-C0868928
.	O
	
the	O
role	O
of	O
choroid	B-C0008520
in	O
the	O
development	B-C1527148
of	O
glaucomatous	B-C0017601
damage	B-C1883709
in	O
patients	B-C0030705
with	O
pex	B-C0206368
syndrome	I-C0206368
remains	O
clinical	B-C0037088
features	I-C0037088
and	O
complications	B-C0009566
of	O
the	O
hla-b27	B-C0019740
-associated	O
acute	B-C0701807
anterior	I-C0701807
uveitis	I-C0701807
a	O
metanalysis	B-C0920317
in	O
this	O
article	B-C1706852
,	O
we	O
report	O
a	O
literature-based	B-C0023866
metanalysis	B-C0920317
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	B-C0037088
features	I-C0037088
of	O
the	O
hla-b27	B-C0019740
acute	B-C0701807
anterior	I-C0701807
uveitis	I-C0701807
aau	B-C0701807
.	O
	
the	O
examined	B-C0332128
material	O
was	O
based	O
on	O
observational	B-C1518527
studies	I-C1518527
in	O
which	O
participants	B-C0679646
were	O
affected	O
by	O
acute	B-C0701807
anterior	I-C0701807
uveitis	I-C0701807
and	O
divided	O
into	O
hla	B-C0239961
b27+	I-C0239961
and	O
hla	B-C0587081
b27-	I-C0587081
.	O
	
we	O
performed	O
a	O
search	O
on	O
articles	B-C1706852
with	O
the	O
words	O
""""	O
hla	B-C0042164
b27	I-C0042164
uveitis	I-C0042164
""""	O
dated	O
before	O
may	O
2014	O
.	O
	
among	O
these	O
,	O
29	O
articles	B-C1706852
were	O
selected	O
for	O
a	O
second	O
review	B-C1552617
.	O
	
after	O
a	O
further	O
evaluation	O
,	O
22	O
articles	B-C1706852
were	O
analyzed	B-C0936012
.	O
	
the	O
clinical	B-C0683325
characteristics	I-C0683325
studied	O
in	O
the	O
metanalysis	B-C0920317
were	O
1	O
systemic	B-C0442893
disease	I-C0442893
2	O
sex	B-C0036878
distribution	I-C0036878
3	O
laterality	B-C0023114
4	O
visual	B-C0042812
acuity	I-C0042812
5	O
hypopion	B-C0020641
6	O
anterior	B-C0015982
chamber's	I-C0015982
fibrin	I-C0015982
7	O
elevated	B-C0234708
intraocular	I-C0234708
pressure	I-C0234708
iop	B-C0021888
during	O
inflammation	B-C0021368
8	O
glaucoma	B-C0017601
9	O
posterior	B-C0152253
synechiae	I-C0152253
10	O
cataract	B-C0086543
11	O
cystoid	B-C0024440
macular	I-C0024440
edema	I-C0024440
12	O
papillitis	B-C0030353
.	O
	
we	O
have	O
calculated	O
a	O
relative	B-C0242492
risk	I-C0242492
rr	B-C0242492
for	O
each	O
outcome	B-C0086749
measured	I-C0086749
.	O
	
the	O
results	B-C1274040
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
hla	B-C0019740
b27	I-C0019740
acute	B-C0701807
anterior	I-C0701807
uveitis	I-C0701807
,	O
such	O
as	O
strong	O
association	B-C0332281
with	I-C0332281
ankylosing	B-C0038013
spondylitis	I-C0038013
rr	B-C0242492
=	O
6.80	O
and	O
systemic	B-C0442893
diseases	I-C0442893
rr	B-C0242492
=	O
9.9	O
,	O
male	B-C0086582
prevalence	B-C0220900
rr	B-C0242492
=	O
1.2	O
,	O
unilateral	B-C0205092
rr	B-C0242492
=	O
1.1	O
or	O
alternating	O
bilateral	B-C0238767
rr	B-C0242492
=	O
2.2	O
involvement	B-C1314939
,	O
hypopion	B-C0020641
rr	B-C0242492
=	O
5.5	O
,	O
fibrinous	B-C0033684
reaction	B-C0443286
and	O
even	O
papillitis	B-C0030353
r	O
=	O
7.7	O
.	O
	
simultaneous	O
bilateral	B-C0238767
rr	B-C0242492
=	O
0.3	O
aau	B-C0701807
is	O
more	O
frequent	B-C0332183
in	O
hla-b27	B-C0019740
negative	B-C0205160
form	O
.	O
	
we	O
report	O
higher	O
risk	B-C0035647
of	O
elevated	B-C0234708
iop	I-C0234708
and	O
glaucoma	B-C0017601
rr	B-C0242492
=	O
0.6	O
in	O
b27-	B-C0701807
acute	I-C0701807
anterior	I-C0701807
uveitis	I-C0701807
.	O
	
no	O
significant	O
difference	O
between	O
hla	B-C4285788
b	I-C4285788
27	I-C4285788
positive	I-C4285788
and	O
negative	B-C0205160
aau	B-C0701807
was	O
observed	B-C1441672
according	O
to	O
final	O
visual	B-C0042812
acuity	I-C0042812
and	O
complications	B-C0009566
such	O
as	O
posterior	B-C0152253
synechiae	I-C0152253
,	O
cataract	B-C0086543
,	O
and	O
maculare	B-C0024440
edema	I-C0024440
.	O
	
we	O
trust	O
that	O
this	O
will	O
inform	O
on	O
the	O
clinical	B-C4084924
evaluation	I-C4084924
and	O
therapeutic	B-C0302350
decision	B-C0679006
in	O
addressing	O
a	O
still	O
ill-defined	O
ophthalmologic	B-C0205481
condition	B-C0348080
.	O
	
a	O
case	O
presenting	O
with	O
splenic	B-C0037998
infarct	I-C0037998
diagnosed	B-C0011900
as	O
primary	B-C0005953
bone	I-C0005953
marrow	I-C0005953
cd5	B-C0882892
positive	I-C0882892
dlbcl	B-C0079744
a	O
clinicopathological	B-C1707520
correlation	I-C1707520
de	B-C1515568
novo	I-C1515568
cd5+	B-C0882892
diffuse	B-C0011900
large	I-C0011900
b	I-C0011900
cell	I-C0011900
lymphoma	I-C0011900
dlbcl	B-C0079744
is	O
a	O
rare	B-C0522498
and	O
aggressive	B-C0243095
subtype	I-C0243095
of	O
dlbcl	B-C0079744
.	O
	
it	O
is	O
a	O
distinct	O
clinicopathologic	B-C0243095
entity	B-C1551338
with	O
complex	B-C1704864
molecular	I-C1704864
profile	I-C1704864
and	O
poor	B-C0278252
prognosis	I-C0278252
.	O
	
a	O
59	O
year	B-C0439234
old	O
female	B-C0086287
presented	B-C0150312
with	I-C0150312
pyrexia	B-C0015970
of	I-C0015970
unknown	I-C0015970
origin	I-C0015970
since	O
1	O
month	B-C0439231
.	O
	
on	O
examination	B-C0031809
,	O
there	O
was	O
severe	B-C0030232
pallor	I-C0030232
,	O
hepatosplenomegaly	B-C0019214
and	O
no	B-C0522499
palpable	I-C0522499
lymphadenopathy	B-C0497156
.	O
	
complete	B-C0009555
blood	I-C0009555
count	I-C0009555
revealed	B-C0443289
bicytopenia	B-C1142446
with	O
normal	B-C0438221
total	I-C0438221
leucocyte	I-C0438221
count	I-C0438221
.	O
	
liver	B-C0023901
and	O
renal	B-C0022662
function	I-C0022662
tests	I-C0022662
were	O
normal	B-C0205307
.	O
	
ultrasonography	B-C0203464
abdomen	I-C0203464
revealed	B-C0443289
splenic	B-C0038002
enlargement	I-C0038002
with	O
two	B-C0243095
focal	I-C0243095
lesions	I-C0243095
attributed	O
to	O
either	O
splenic	B-C0272412
abscess	I-C0272412
or	O
infarcts	B-C0037998
.	O
	
patient	B-C0030705
was	O
being	O
managed	O
as	O
splenic	B-C0037998
infarct	I-C0037998
but	O
continued	O
to	O
have	O
bicytopenia	B-C1142446
.	O
	
further	O
investigation	B-C0220825
showed	O
elevated	B-C0241013
serum	I-C0241013
ferritin	I-C0241013
,	O
triglycerides	B-C0813230
and	O
ldh	B-C1275604
.	O
	
with	O
a	O
clinical	B-C0205210
suspicion	B-C0242114
of	O
infection	B-C3714514
and	O
haemophagocytic	B-C0024291
lymphohistiocytosis	I-C0024291
bone	B-C0398523
marrow	I-C0398523
aspiration	I-C0398523
bma	O
and	O
biopsy	O
bmbx	O
was	O
done	O
.	O
	
bma	O
showed	O
extensive	O
haemophagocytosis	O
and	O
7.4	O
%	O
large	O
lymphoma-like	O
cells	O
.	O
	
on	O
this	O
basis	O
pet-ct	O
was	O
suggested	O
which	O
showed	O
enlarged	O
spleen	O
with	O
diffuse	O
uptake	O
.	O
	
bmbx	O
showed	O
nodular	O
and	O
intrasinusoidal	O
collection	O
of	O
abnormal	O
lymphoid	O
cells	O
.	O
	
on	O
immunohistochemistry	O
,	O
these	O
cells	O
were	O
positive	O
for	O
cd20	O
,	O
cd5	O
,	O
mum1	O
,	O
bcl-2	O
,	O
bcl-6	O
and	O
negative	O
for	O
cd3	O
,	O
cd10	O
and	O
cd23	O
.	O
	
cd34	O
highlighted	O
focal	O
intrasinusoidal	O
pattern	O
.	O
	
the	O
complete	O
clinicopathological	O
profile	O
suggested	O
the	O
diagnosis	O
of	O
de	O
novo	O
cd5+	O
dlbcl	O
,	O
with	O
primary	O
hepatosplenic	O
pattern	O
of	O
involvement	O
.	O
	
cd5+	O
dlbcl	O
presenting	O
as	O
splenic	O
infarct	O
is	O
very	O
rare	O
.	O
	
this	O
case	O
was	O
unusual	O
as	O
the	O
diagnosis	O
of	O
a	O
primary	O
aggressive	O
lymphoma	O
with	O
haemophagocytosis	O
was	O
established	O
in	O
a	O
patient	O
who	O
presented	O
with	O
fever	O
and	O
splenic	O
infarct	O
without	O
lymphadenopathy	O
.	O
	
this	O
indicates	O
the	O
importance	O
of	O
good	O
morphological	O
assessment	O
of	O
a	O
bone	B-C0005954
marrow	I-C0005954
aspirate	O
and	O
biopsy	O
to	O
make	O
a	O
correct	O
diagnosis	B-C0011900
the	O
cost-effectiveness	B-C0010181
of	O
family	B-C0015576
/	O
family-based	B-C0087111
therapy	I-C0087111
for	O
treatment	B-C1522326
of	O
externalizing	B-C0004936
disorders	I-C0004936
,	O
substance	B-C0038586
use	I-C0038586
disorders	I-C0038586
and	O
delinquency	B-C0522174
a	O
systematic	O
review	B-C0282443
family	B-C0087111
therapy	I-C0087111
and	O
family-based	B-C1522326
treatment	I-C1522326
has	O
been	O
commonly	O
applied	O
in	O
children	B-C0008059
and	O
adolescents	B-C0205653
in	O
mental	B-C0184643
health	I-C0184643
care	I-C0184643
and	O
has	O
been	O
proven	O
to	O
be	O
effective	O
.	O
	
there	O
is	O
an	O
increased	O
interest	O
in	O
economic	B-C0150099
evaluations	I-C0150099
of	O
these	O
,	O
often	O
expensive	O
,	O
interventions	B-C0184661
.	O
	
the	O
aim	O
of	O
this	O
systematic	O
review	B-C0282443
is	O
to	O
summarize	O
and	O
evaluate	B-C0220825
the	O
evidence	O
on	O
cost-effectiveness	B-C0010181
of	O
family	B-C0015576
/	O
family-based	B-C0087111
therapy	I-C0087111
for	O
externalizing	B-C0004936
disorders	I-C0004936
,	O
substance	B-C0038586
use	I-C0038586
disorders	I-C0038586
and	O
delinquency	B-C0522174
.	O
	
a	O
systematic	O
literature	O
search	O
was	O
performed	O
in	O
pubmed	B-C1138432
,	O
education	B-C1449627
resource	I-C1449627
information	I-C1449627
centre	I-C1449627
eric	B-C1449627
,	O
psycinfo	B-C1140129
and	O
cochrane	B-C0242356
reviews	B-C0282443
including	O
studies	B-C0947630
conducted	O
after	O
1990	O
and	O
before	O
the	O
first	O
of	O
august	O
of	O
2013	O
.	O
	
full	O
economic	B-C0150099
evaluations	I-C0150099
investigating	O
family	B-C0015576
/	O
family-based	B-C0184661
interventions	I-C0184661
for	O
adolescents	B-C0205653
between	O
10	O
and	O
20	O
years	B-C0439234
treated	B-C1522326
for	O
substance	B-C0038586
use	I-C0038586
disorders	I-C0038586
,	O
delinquency	B-C0522174
or	O
externalizing	B-C0004936
disorders	I-C0004936
were	O
included	O
.	O
	
seven	O
hundred	O
thirty-one	O
articles	B-C1706852
met	O
the	O
search	O
criteria	O
and	O
51	O
studies	B-C0947630
were	O
initially	O
selected	O
.	O
	
the	O
final	O
selection	O
resulted	O
in	O
the	O
inclusion	O
of	O
11	O
studies	B-C0947630
.	O
	
the	O
quality	B-C0332306
of	O
these	O
studies	B-C0947630
was	O
assessed	B-C1516048
.	O
	
within	O
the	O
identified	O
studies	B-C0947630
,	O
there	O
was	O
great	O
variation	O
in	O
the	O
specific	O
type	O
of	O
family	B-C0015576
/	O
family-based	B-C0184661
interventions	I-C0184661
and	O
disorders	B-C0012634
.	O
	
according	O
to	O
the	O
outcomes	B-C0085565
of	O
the	O
checklists	O
,	O
the	O
overall	O
quality	B-C0332306
of	O
the	O
economic	B-C0150099
evaluations	I-C0150099
was	O
low	O
.	O
	
results	O
varied	O
by	O
study	B-C0947630
.	O
	
due	O
to	O
the	O
variations	O
in	O
setting	O
,	O
design	O
and	O
outcome	O
it	O
was	O
not	O
feasible	O
to	O
pool	O
results	O
using	O
a	O
meta-analysis	B-C0920317
.	O
	
the	O
quality	B-C0332306
of	O
the	O
identified	O
economic	B-C0150099
evaluations	I-C0150099
of	O
family	B-C0015576
/	O
family-based	B-C0087111
therapy	I-C0087111
for	O
treatment	B-C1522326
of	O
externalizing	B-C0004936
disorders	I-C0004936
,	O
adolescent	B-C0205653
substance	B-C0038586
use	I-C0038586
disorders	I-C0038586
and	O
delinquency	B-C0522174
was	O
insufficient	O
to	O
determine	O
the	O
cost-effectiveness	B-C0010181
.	O
	
although	O
commonly	O
applied	O
,	O
family	B-C0015576
/	O
family-based	B-C0087111
therapy	I-C0087111
is	O
costly	O
and	O
more	O
research	O
of	O
higher	O
quality	B-C0332306
regulation	B-C0017263
of	O
abca1	B-C1412058
and	O
abcg1	B-C1412096
gene	B-C0017262
expression	I-C0017262
in	O
the	O
intraabdominal	B-C1563739
adipose	I-C1563739
tissue	I-C1563739
tissue	B-C1519516
specific	I-C1519516
expression	I-C1519516
of	I-C1519516
genes	I-C1519516
encoding	B-C2700640
cholesterol	B-C0008377
transporters	B-C0007292
abca1	B-C3711161
and	O
abcg1	B-C0963751
as	O
well	O
as	O
genes	B-C0017337
encoding	B-C2700640
the	O
most	O
important	O
transcriptional	B-C0040649
regulators	B-C0815047
of	O
adipogenesis	B-C0596843
-	O
lxra	B-C0297439
,	O
lxrb	B-C0754148
,	O
pparg	B-C3887582
and	O
rora	B-C0284080
has	O
been	O
investigated	B-C1292732
in	O
intraabdominal	B-C1563739
adipose	I-C1563739
tissue	I-C1563739
iat	B-C1563739
samples	B-C0370003
a	O
direct	O
correlation	B-C1707520
between	O
the	O
content	O
of	O
abca1	B-C3711161
and	O
abcg1	B-C0963751
proteins	I-C0963751
with	O
rora	B-C0284080
protein	I-C0284080
level	B-C0441889
r=0	O
,	O
p<0	O
r=0	O
,	O
p<0	O
,	O
respectively	O
suggests	B-C1705535
the	O
role	O
of	O
the	O
transcription	B-C0040648
factor	I-C0040648
rora	B-C0284080
in	O
the	O
regulation	B-C1327622
of	O
iat	B-C1563739
abca1	B-C3711161
and	O
abcg1	B-C0963751
protein	I-C0963751
levels	B-C0441889
.	O
	
abca1	B-C1412058
and	O
abcg1	B-C1412096
gene	B-C0017262
expression	I-C0017262
positively	O
correlated	B-C1707520
with	O
obesity	B-C0028754
indicators	B-C0021212
such	O
as	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
r=0	O
,	O
p=0	O
r=0	O
,	O
p=0	O
,	O
respectively	O
and	O
waist	B-C0455829
circumference	I-C0455829
r=0	O
,	O
p=0	O
r=0	O
,	O
p=0	O
,	O
respectively	O
.	O
	
the	O
development	B-C1527148
of	O
obesity	B-C0028754
is	O
associated	B-C0332281
with	I-C0332281
decreased	B-C0205216
iat	B-C1563739
levels	B-C0441889
of	O
rora	B-C1335634
and	O
lxrb	B-C1417823
mrna	B-C0035696
p=0	O
and	O
p=0	O
,	O
respectively	O
.	O
	
these	O
data	B-C1511726
suggest	B-C1705535
that	O
the	O
nuclear	B-C0284080
factor	I-C0284080
rora	I-C0284080
can	O
play	O
a	O
significant	B-C0750502
role	O
in	O
the	O
regulation	B-C1327622
of	O
cholesterol	B-C1156530
metabolism	I-C1156530
and	O
control	B-C0243148
iat	B-C1563739
expression	B-C1171362
of	O
abca1	B-C3711161
and	O
abcg1	B-C0963751
,	O
while	O
the	O
level	B-C0441889
of	O
iat	B-C1563739
lxrb	B-C1417823
gene	B-C0017262
expression	I-C0017262
may	O
be	O
an	O
important	O
factor	O
associated	B-C0332281
with	I-C0332281
the	O
development	B-C1527148
of	O
triterpenoids	B-C1519655
from	O
the	O
stems	B-C0242767
of	O
tripterygium	B-C1059497
regelii	I-C1059497
three	O
new	O
triterpenoids	B-C1519655
,	O
triregelolides	B-C1519655
a	O
,	O
b	O
1	O
,	O
2	O
,	O
and	O
triregeloic	B-C1519655
acid	I-C1519655
3	O
,	O
were	O
isolated	B-C0205409
from	O
the	O
stems	B-C0242767
of	O
tripterygium	B-C1059497
regelii	I-C1059497
along	O
with	O
twenty	O
known	O
triterpene	B-C0041113
analogues	B-C0002776
4-23	O
.	O
	
the	O
structures	O
of	O
three	O
new	O
compounds	B-C0041113
were	O
identified	O
by	O
analyzing	O
their	O
nmr	B-C0877853
spectroscopic	I-C0877853
and	O
hresims	B-C0596495
data	O
.	O
	
compounds	B-C0041113
4	B-C0041113
,	O
7	B-C0041113
,	O
8	B-C0041113
,	O
10	B-C0041113
,	O
13	B-C0041113
,	O
14	B-C0041113
,	O
17	B-C0041113
,	O
21-23	B-C0041113
were	O
isolated	B-C0205409
from	O
t	B-C1059497
.	O
	
regelii	I-C1059497
for	O
the	O
first	O
time	O
.	O
	
compounds	B-C1519655
3	B-C1519655
,	O
5	B-C0041113
,	O
6	B-C0041113
,	O
8	B-C0041113
,	O
9	B-C0041113
,	O
10	B-C0041113
,	O
14	B-C0041113
and	O
16	B-C0041113
showed	O
inhibitory	B-C1156236
effects	I-C1156236
on	I-C1156236
the	I-C1156236
proliferation	I-C1156236
of	O
human	B-C1512505
breast	I-C1512505
cancer	I-C1512505
cells	I-C1512505
mcf-7	B-C0596890
by	O
24.1	O
,	O
69.6	O
,	O
72.8	O
,	O
21.6	O
,	O
23.1	O
,	O
43.3	O
,	O
25.5	O
and	O
23.5	O
p<0	O
at	O
a	O
concentration	B-C0392762
biochemical	B-C0205474
evidence	O
for	O
a	O
mitochondrial	B-C0026237
genetic	B-C0314603
modifier	B-C3178895
in	O
the	O
phenotypic	B-C0031437
manifestation	B-C0205319
of	O
leber's	B-C0917796
hereditary	I-C0917796
optic	I-C0917796
neuropathy	I-C0917796
-associated	O
mitochondrial	B-C0948444
dna	I-C0948444
mutation	I-C0948444
leber's	B-C0917796
hereditary	I-C0917796
optic	I-C0917796
neuropathy	I-C0917796
lhon	B-C0917796
is	O
the	O
most	O
common	O
mitochondrial	B-C0751651
disease	I-C0751651
.	O
	
mitochondrial	B-C0026237
modifiers	B-C3178895
are	O
proposed	O
to	O
modify	O
the	O
phenotypic	B-C0031437
expression	I-C0031437
of	O
primary	O
lhon	B-C0917796
-associated	O
mitochondrial	B-C0012929
dna	I-C0012929
mtdna	B-C0012929
mutations	B-C0948444
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
demonstrated	O
that	O
the	O
lhon	B-C0917796
susceptibility	B-C0012655
allele	B-C0002085
m.14502t	B-C0002085
>	I-C0002085
c	I-C0002085
,	O
p	B-C0002085
.	O
	
58i	I-C0002085
>	I-C0002085
v	I-C0002085
in	O
the	O
nd6	B-C1537995
gene	I-C1537995
modulated	B-C0443264
the	O
phenotypic	B-C0031437
expression	I-C0031437
of	O
primary	O
lhon	B-C0917796
-associated	O
m.11778g	B-C0026882
>	I-C0026882
a	I-C0026882
mutation	I-C0026882
.	O
	
twenty-two	O
han	B-C0814942
chinese	I-C0814942
pedigrees	B-C0030761
carrying	O
m.14502t	B-C0026882
>	I-C0026882
c	I-C0026882
and	O
m.11778g	B-C0026882
>	I-C0026882
a	I-C0026882
mutations	I-C0026882
exhibited	O
significantly	O
higher	O
penetrance	B-C0524899
of	O
optic	B-C3887709
neuropathy	I-C3887709
than	O
those	O
carrying	O
only	O
m.11778g	B-C0026882
>	I-C0026882
a	I-C0026882
mutation	I-C0026882
.	O
	
we	O
performed	O
functional	B-C0205245
assays	B-C0005507
using	O
the	O
cybrid	B-C0007600
cell	I-C0007600
models	I-C0007600
,	O
generated	O
by	O
fusing	O
mtdna-less	B-C0007634
ρ	I-C0007634
cells	I-C0007634
with	O
enucleated	B-C0007634
cells	I-C0007634
from	O
lhon	B-C0917796
patients	B-C0030705
carrying	O
both	O
m.11778g	B-C0026882
>	I-C0026882
a	I-C0026882
and	O
m.14502t	B-C0026882
>	I-C0026882
c	I-C0026882
mutations	I-C0026882
,	O
only	O
m.14502t	B-C0026882
>	I-C0026882
c	I-C0026882
or	O
m.11778g	B-C0026882
>	I-C0026882
a	I-C0026882
mutation	I-C0026882
and	O
a	O
control	O
belonging	O
to	O
the	O
same	O
mtdna	B-C0012929
haplogroup	B-C0018591
.	O
	
these	O
cybrids	B-C0007600
cell	I-C0007600
lines	I-C0007600
bearing	O
m.14502t	B-C0026882
>	I-C0026882
c	I-C0026882
mutation	I-C0026882
exhibited	O
mild	O
effects	B-C1280500
on	O
mitochondrial	B-C0026237
functions	B-C0542341
compared	O
with	O
those	O
carrying	O
only	O
m.11778g	B-C0026882
>	I-C0026882
a	I-C0026882
mutation	I-C0026882
.	O
	
however	O
,	O
more	O
severe	O
mitochondrial	B-C0026237
dysfunctions	B-C3887504
were	O
observed	O
in	O
cell	B-C0007600
lines	I-C0007600
bearing	O
both	O
m.14502t	B-C0026882
>	I-C0026882
c	I-C0026882
and	O
m.11778g	B-C0026882
>	I-C0026882
a	I-C0026882
mutations	I-C0026882
than	O
those	O
carrying	O
only	O
m.11778g	B-C0026882
>	I-C0026882
a	I-C0026882
or	O
m.14502t	B-C0026882
>	I-C0026882
c	I-C0026882
mutation	I-C0026882
.	O
	
in	O
particular	O
,	O
the	O
m.14502t	B-C0026882
>	I-C0026882
c	I-C0026882
mutation	I-C0026882
altered	O
assemble	O
of	O
complex	B-C0171406
i	I-C0171406
,	O
thereby	O
aggravating	O
the	O
respiratory	B-C0521346
phenotypes	B-C0031437
associated	O
with	O
m.11778g	B-C0026882
>	I-C0026882
a	I-C0026882
mutation	I-C0026882
,	O
resulted	O
in	O
a	O
more	O
defective	B-C0332452
complex	B-C0171406
i	I-C0171406
.	O
	
furthermore	O
,	O
more	O
reductions	O
in	O
the	O
levels	O
of	O
mitochondrial	B-C0026237
atp	B-C0001480
and	O
increasing	O
production	O
of	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
were	O
also	O
observed	O
in	O
mutant	B-C0596988
cells	B-C0007634
bearing	O
both	O
m.14502t	B-C0026882
>	I-C0026882
c	I-C0026882
and	O
m.11778g	B-C0026882
>	I-C0026882
a	I-C0026882
mutation	I-C0026882
than	O
those	O
carrying	O
only	O
11778g	B-C0026882
>	I-C0026882
a	I-C0026882
mutation	I-C0026882
.	O
	
our	O
findings	O
provided	O
new	O
insights	O
into	O
the	O
pathophysiology	B-C0031847
of	O
lhon	B-C0917796
that	O
were	O
manifested	B-C1280444
by	I-C1280444
interaction	O
between	O
primary	O
and	O
secondary	O
mtdna	B-C0012929
mutations	B-C0948444
.	O
	
improving	B-C1272745
care	B-C4019079
transitions	I-C4019079
across	O
healthcare	B-C0086388
settings	B-C1254362
through	O
a	O
human	B-C4035944
factors	I-C4035944
approach	O
after	O
more	O
than	O
two	O
decades	B-C2981279
of	O
research	B-C0035168
focused	O
on	O
care	B-C4019079
transition	I-C4019079
improvement	B-C2986411
and	O
intervention	B-C0184661
development	B-C1527148
,	O
unfavorable	B-C1519790
outcome	I-C1519790
measures	B-C1879489
associated	B-C0332281
with	I-C0332281
care	B-C4019079
transitions	I-C4019079
across	O
healthcare	B-C0086388
settings	B-C1254362
persist	O
.	O
	
readmissions	B-C0745042
rates	B-C1264674
remain	O
an	O
important	O
outcome	B-C1274040
to	O
target	B-C1521840
for	O
intervention	B-C0184661
,	O
adverse	B-C0877248
events	I-C0877248
associated	B-C0332281
with	I-C0332281
care	B-C4019079
transitions	I-C4019079
continue	O
to	O
be	O
an	O
issue	B-C0033213
,	O
and	O
patients	B-C0030705
are	O
often	O
dissatisfied	B-C0870433
with	O
the	O
quality	B-C0332306
of	O
their	O
care	B-C1947933
.	O
	
currently	O
,	O
interventions	B-C0184661
to	O
improve	O
care	B-C4019079
transitions	I-C4019079
are	O
disease	B-C0012634
specific	B-C0205369
,	O
require	O
substantial	B-C0205556
financial	B-C3826621
investments	I-C3826621
in	O
training	B-C0220931
allied	B-C0002122
healthcare	I-C0002122
professionals	I-C0002122
,	O
or	O
focus	O
primarily	O
on	O
hospital-based	B-C1563179
discharge	I-C1563179
planning	I-C1563179
with	O
mixed	O
results	O
.	O
	
this	O
complex	B-C0205556
situation	I-C0205556
requires	O
a	O
method	B-C2911685
of	I-C2911685
evaluation	I-C2911685
that	O
can	O
provide	O
a	O
comprehensive	B-C1880156
,	O
in-depth	B-C0205125
,	O
and	O
context-driven	B-C1254370
investigation	B-C0220825
of	O
potential	B-C0035648
risks	I-C0035648
to	O
safe	O
care	B-C4019079
transitions	I-C4019079
across	O
healthcare	B-C0086388
settings	B-C1254362
,	O
which	O
can	O
lead	O
to	O
the	O
creation	B-C1706214
of	O
effective	B-C1704419
,	O
usable	B-C0205556
,	O
and	O
sustainable	B-C0443318
interventions	B-C0184661
.	O
	
a	O
systems'	O
approach	O
known	O
as	O
human	B-C0020120
factors	I-C0020120
and	I-C0020120
ergonomics	I-C0020120
hfe	B-C0020120
evaluates	B-C1550545
the	O
factors	B-C1521761
in	O
a	O
system	O
that	O
affect	O
human	B-C0020115
performance	I-C0020115
.	O
	
this	O
article	B-C1706852
describes	O
how	O
hfe	B-C0020120
can	O
complement	O
and	O
further	O
strengthen	O
efforts	O
to	O
improve	B-C1272745
care	B-C4019079
transitions	I-C4019079
.	O
	
adenosine	B-C0001443
and	O
the	O
adenosine	B-C2936552
a2a	I-C2936552
receptor	I-C2936552
agonist	I-C2936552
,	O
cgs21680	B-C0055233
,	O
upregulate	B-C0949479
cd39	B-C0108783
and	O
cd73	B-C0000530
expression	B-C0597360
through	O
e2f-1	B-C1384539
and	O
creb	B-C0056695
in	O
regulatory	B-C0039198
t	I-C0039198
cells	I-C0039198
isolated	B-C0205409
from	O
septic	B-C0333534
mice	B-C0025929
the	O
number	O
of	O
regulatory	B-C0039198
t	I-C0039198
cells	I-C0039198
treg	B-C0039198
cells	I-C0039198
and	O
the	O
expression	B-C0597360
of	O
ectonucleoside	B-C0108783
triphosphate	I-C0108783
diphosphohydrolase	I-C0108783
1	I-C0108783
entpd1	B-C0108783
also	O
known	O
as	O
cd39	B-C0108783
and	O
5'-ectonucleotidase	B-C0000530
nt5e	B-C0000530
also	O
known	O
as	O
cd73	B-C0000530
on	O
the	O
treg	B-C0039198
cell	I-C0039198
surface	B-C0205148
are	O
increased	B-C0205217
during	O
sepsis	B-C0243026
.	O
	
in	O
this	O
study	O
,	O
to	O
determine	O
the	O
factors	B-C0005515
leading	O
to	O
the	O
high	B-C0205250
expression	B-C0597360
of	O
cd39	B-C0108783
and	O
cd73	B-C0000530
,	O
and	O
the	O
regulation	B-C1327622
of	I-C1327622
the	O
cd39	B-C0108783
/	O
cd73	B-C0000530
/	O
adenosine	B-C0001443
pathway	B-C1705987
in	O
treg	B-C0039198
cells	I-C0039198
under	O
septic	B-C0333534
conditions	O
,	O
we	O
constructed	O
a	O
mouse	B-C2986594
model	I-C2986594
of	O
sepsis	B-C0243026
and	O
separated	O
the	O
treg	B-C0039198
cells	I-C0039198
using	O
a	O
flow	B-C0180279
cytometer	I-C0180279
.	O
	
the	O
treg	B-C0039198
cells	I-C0039198
isolated	B-C0205409
from	O
the	O
peritoneal	B-C0031148
lavage	I-C0031148
and	O
splenocytes	B-C1519477
of	O
the	O
mice	B-C0025929
were	O
treated	B-C0332293
with	I-C0332293
adenosine	B-C0001443
or	O
the	O
specific	O
adenosine	B-C2936552
a2a	I-C2936552
receptor	I-C2936552
agonist	I-C2936552
,	O
cgs21680	B-C0055233
,	O
and	O
were	O
transfected	B-C0040669
with	O
specific	O
sirna	B-C1099354
targeting	B-C1521840
e2f	B-C1384539
transcription	I-C1384539
factor	I-C1384539
1	I-C1384539
e2f-1	B-C1384539
or	O
cyclic	B-C0056695
adenosine	I-C0056695
monophosphate	I-C0056695
camp	I-C0056695
response	I-C0056695
element-binding	I-C0056695
protein	I-C0056695
creb	B-C0056695
,	O
which	O
are	O
predicted	O
transcription	B-C0040648
regulatory	I-C0040648
factors	I-C0040648
of	O
cd39	B-C0108783
or	O
cd73	B-C0000530
.	O
	
the	O
regulatory	B-C1327622
relationships	O
among	O
these	O
factors	B-C0005515
were	O
then	O
determined	O
by	O
western	B-C0949466
blot	I-C0949466
analysis	I-C0949466
and	O
dual-luciferase	B-C0022885
reporter	I-C0022885
assay	I-C0022885
.	O
	
in	O
addition	O
,	O
changes	B-C0392747
in	O
adenosine	B-C1158592
metabolism	I-C1158592
were	O
measured	O
in	O
the	O
treated	B-C1522326
cells	B-C0007634
.	O
	
the	O
results	O
revealed	O
that	O
adenosine	B-C0001443
and	O
cgs21680	B-C0055233
significantly	O
upregulated	B-C0949479
cd39	B-C0108783
and	O
cd73	B-C0000530
expression	B-C0597360
p<0	O
.	O
	
e2f-1	B-C1384539
and	O
creb	B-C0056695
induced	O
cd39	B-C0108783
and	O
cd73	B-C0000530
expression	B-C0597360
,	O
and	O
were	O
upregulated	B-C0949479
by	O
adenosine	B-C0001443
and	O
cgs21680	B-C0055233
.	O
	
adenosine	B-C1510699
triphosphate	I-C1510699
atp	I-C1510699
hydrolysis	I-C1510699
and	O
adenosine	B-C0001443
generation	B-C3146294
were	O
inhibited	B-C3463820
by	O
the	O
knockdown	B-C0849355
of	O
e2f-1	B-C1384539
or	O
creb	B-C0056695
,	O
and	O
were	O
accelerated	B-C0521110
in	O
the	O
presence	O
of	O
cgs21680	B-C0055233
.	O
	
based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
inferred	O
that	O
adenosine	B-C0001443
,	O
the	O
adenosine	B-C2936552
a2a	I-C2936552
receptor	I-C2936552
agonist	I-C2936552
,	O
e2f-1	B-C1384539
and	O
creb	B-C0056695
are	O
the	O
possible	O
factors	B-C0005515
contributing	O
to	O
the	O
high	B-C0205250
expression	B-C0597360
of	O
cd39	B-C0108783
and	O
cd73	B-C0000530
on	O
the	O
treg	B-C0039198
cell	I-C0039198
surface	B-C0205148
during	O
sepsis	B-C0243026
.	O
	
adenosine	B-C0001443
and	O
its	O
a2a	B-C2936552
receptor	I-C2936552
agonist	I-C2936552
served	O
as	O
the	O
signal	B-C1152628
transducer	I-C1152628
factors	B-C0005515
of	O
the	O
cd39	B-C0108783
/	O
cd73	B-C0000530
/	O
adenosine	B-C0001443
pathway	B-C1705987
,	O
accelerating	B-C0521110
adenosine	B-C0001443
generation	B-C3146294
.	O
	
our	O
study	O
may	O
benefit	O
further	O
research	B-C0035168
on	O
adenosine	B-C1158592
metabolism	I-C1158592
for	O
the	O
treatment	B-C0087111
of	O
exploring	O
consumer	B-C1707496
and	O
patient	B-C0030705
knowledge	B-C0376554
,	O
behavior	B-C0004927
,	O
and	O
attitude	B-C0004271
toward	B-C3875150
medicinal	B-C0013227
and	O
lifestyle	B-C3273359
products	I-C3273359
purchased	B-C0870238
from	O
the	O
internet	B-C0282111
a	O
web	B-C0282111
-	O
based	B-C1527178
survey	B-C0038951
in	O
recent	O
years	O
,	O
lifestyle	B-C3273359
products	I-C3273359
have	O
emerged	O
to	O
help	O
improve	B-C0184511
people's	B-C0027361
physical	B-C2607857
and	O
mental	B-C0025361
performance	B-C0597198
.	O
	
the	O
internet	B-C0282111
plays	O
a	O
major	B-C0205164
role	B-C1705810
in	O
the	O
spread	B-C0332261
of	O
these	O
products	B-C1514468
.	O
	
however	O
,	O
the	O
literature	B-C0023866
has	O
reported	O
issues	O
regarding	O
the	O
authenticity	B-C0205556
of	O
medicines	B-C0013227
purchased	B-C0870238
from	O
the	O
internet	B-C0282111
and	O
the	O
impact	B-C4049986
of	O
counterfeit	B-C2936336
medicines	I-C2936336
on	O
public	B-C0678367
health	B-C0018684
.	O
	
little	O
or	O
no	B-C1546437
data	I-C1546437
are	I-C1546437
available	I-C1546437
on	O
the	O
authenticity	B-C0205556
of	O
lifestyle	B-C3273359
products	I-C3273359
and	O
actual	O
toxicity	B-C0040539
associated	B-C0332281
with	I-C0332281
their	O
use	B-C1524063
and	O
misuse	B-C0549649
.	O
	
our	O
aim	O
was	O
to	O
investigate	B-C1292732
consumer	B-C0680971
and	O
patient	B-C0870289
attitudes	I-C0870289
toward	B-C3875150
the	O
purchase	B-C0870238
of	O
lifestyle	B-C3273359
products	I-C3273359
from	O
the	O
internet	B-C0282111
,	O
their	O
knowledge	B-C0376554
of	O
product	B-C1514468
authenticity	B-C0205556
and	O
toxicity	B-C0040539
,	O
and	O
their	O
experiences	B-C0596545
with	O
counterfeit	B-C0205556
lifestyle	B-C3273359
products	I-C3273359
.	O
	
a	O
web	B-C0282111
-	O
based	B-C1527178
study	B-C2603343
was	O
performed	B-C0884358
between	O
may	O
2014	O
and	O
may	O
2015	O
.	O
	
uniform	B-C0205375
collection	B-C0010995
of	I-C0010995
data	I-C0010995
was	O
performed	B-C0884358
through	B-C0332273
an	O
anonymous	B-C2346787
online	B-C0029038
questionnaire	B-C0034394
.	O
	
participants	B-C0679646
were	O
invited	O
worldwide	B-C0332464
via	O
email	B-C0013849
,	O
social	B-C3179065
media	I-C3179065
,	O
or	O
personal	B-C0086792
communication	I-C0086792
to	O
complete	B-C0205197
the	O
online	B-C0029038
questionnaire	B-C0034394
.	O
	
a	O
total	B-C0439810
of	O
320	O
participants	B-C0679646
completed	B-C0205197
the	O
questionnaire	B-C0034394
.	O
	
the	O
results	B-C1274040
of	O
the	O
questionnaire	B-C0034394
showed	O
that	O
208	O
65.0	O
participants	B-C0679646
purchased	B-C0870238
lifestyle	B-C3273359
products	I-C3273359
from	O
the	O
internet	B-C0282111
mainly	B-C1542147
due	B-C0678226
to	I-C0678226
convenience	B-C3831015
and	O
reduced	B-C0392756
cost	B-C0010186
.	O
	
more	B-C0439093
than	I-C0439093
half	B-C2825407
55.6	O
,	O
178/320	O
of	O
participants	B-C0679646
purchased	B-C0870238
cosmetic	B-C0010164
products	I-C0010164
,	O
whereas	O
only	O
a	O
minority	B-C0205165
purchased	B-C0870238
medicinal	B-C0013227
products	I-C0013227
.	O
	
yet	O
,	O
62.8	O
201/320	O
of	O
participants	B-C0679646
were	O
aware	B-C0004448
of	O
the	O
presence	B-C0150312
of	O
counterfeit	B-C0205556
lifestyle	B-C3273359
products	I-C3273359
from	O
the	O
internet	B-C0282111
,	O
and	O
11.9	O
38/320	O
experienced	B-C0596545
counterfeit	B-C0205556
products	B-C1514468
.	O
	
in	O
only	O
0.9	O
3/320	O
of	O
those	O
cases	B-C0868928
were	O
counterfeit	B-C0205556
lifestyle	B-C3273359
products	I-C3273359
reported	B-C0700287
to	O
authorities	B-C1708333
.	O
	
moreover	O
,	O
7.2	O
23/320	O
of	O
the	O
participants	B-C0679646
experienced	B-C0596545
adverse	B-C0879626
effects	I-C0879626
due	O
to	O
counterfeit	B-C0205556
lifestyle	B-C3273359
products	I-C3273359
.	O
	
in	O
summary	O
,	O
patients	B-C0030705
experienced	B-C0596545
counterfeit	B-C0205556
lifestyle	B-C3273359
products	I-C3273359
that	O
resulted	B-C0332294
in	I-C0332294
adverse	B-C0879626
effects	I-C0879626
on	O
their	O
health	B-C0018684
.	O
	
although	O
certain	O
adverse	B-C0879626
effects	I-C0879626
were	O
reported	B-C0700287
in	O
this	O
study	B-C2603343
,	O
counterfeit	B-C0205556
products	B-C1514468
were	O
underreported	B-C0700287
to	O
authorities	B-C1708333
.	O
	
further	O
public	B-C0679750
awareness	I-C0679750
campaigns	I-C0679750
and	O
patient	B-C0030688
education	I-C0030688
are	O
it's	O
not	O
all	O
doom	O
and	O
gloom	O
prune	B-C0033770
belly	I-C0033770
syndrome	I-C0033770
associated	B-C1735591
with	I-C1735591
vacterl	I-C1735591
prune	B-C0033770
belly	I-C0033770
syndrome	I-C0033770
is	O
a	O
rare	B-C0522498
abnormality	B-C1704258
its	O
association	B-C1735591
with	I-C1735591
vacterl	I-C1735591
is	O
even	O
rarer	B-C0522498
.	O
	
this	O
association	B-C1735591
has	O
been	O
reported	B-C0700287
in	O
literature	B-C0023866
a	O
few	O
times	O
since	O
first	O
reported	B-C0700287
in	O
1993	O
and	O
so	O
far	O
the	O
majority	B-C0680220
have	O
either	O
been	O
stillbirths	B-C1850556
or	I-C1850556
died	I-C1850556
shortly	I-C1850556
after	I-C1850556
birth	I-C1850556
.	O
	
we	O
present	O
a	O
case	B-C1706256
of	O
prune	B-C0033770
belly	I-C0033770
syndrome	I-C0033770
associated	B-C1735591
with	I-C1735591
vacterl	I-C1735591
changes	B-C0392747
in	O
cardiovascular	B-C3887460
health	B-C0018759
status	I-C0018759
and	O
the	O
risk	B-C0035647
of	I-C0035647
new-onset	B-C0745129
hypertension	I-C0745129
in	O
kailuan	B-C1257890
cohort	B-C0009247
study	I-C0009247
american	B-C0002458
heart	I-C0002458
association	I-C0002458
cardiovascular	B-C3887460
health	B-C0282574
metrics	I-C0282574
are	O
intimately	O
related	O
to	O
cardiovascular	B-C0007222
diseases	I-C0007222
.	O
	
acting	O
as	O
a	O
key	B-C3898777
independent	O
risk	B-C0035648
factor	I-C0035648
for	O
high	B-C0205250
morbidity	B-C0026538
and	O
mortality	B-C0681679
of	O
cardiovascular	B-C0007222
diseases	I-C0007222
,	O
hypertension	B-C0020538
and	O
its	O
relationship	B-C0439849
between	O
health	B-C0018759
status	I-C0018759
get	O
urgent	O
attention	B-C0004268
.	O
	
while	O
the	O
influence	B-C4054723
of	O
individual	B-C0027361
health	B-C0018759
status	I-C0018759
changes	B-C0392747
and	O
the	O
future	O
risk	B-C0035647
of	I-C0035647
new-onset	B-C0745129
hypertension	I-C0745129
is	O
rarely	O
understood	O
,	O
the	O
present	O
study	O
applied	O
this	O
construct	O
to	O
assess	B-C0184514
the	O
changes	B-C0392747
of	O
cardiovascular	B-C3887460
health	B-C0018759
status	I-C0018759
and	O
the	O
morbidity	B-C0026538
of	O
hypertension	B-C0020538
in	O
kailuan	B-C1257890
cohort	B-C0009247
study	I-C0009247
in	O
north	B-C1709269
china	B-C0008115
.	O
	
the	O
cardiovascular	B-C3887460
health	B-C0449820
score	I-C0449820
chs	B-C0449820
was	O
evaluated	B-C0220825
by	O
the	O
follow-ups	B-C3274571
of	O
2006-2007	O
,	O
2008-2009	O
,	O
2010-2011	O
and	O
2012-2013	O
.	O
	
the	O
study	B-C2348561
population	I-C2348561
n	O
=	O
19381	O
was	O
divided	B-C0332849
into	O
5	O
groups	B-C0441833
based	O
on	O
the	O
changes	B-C0392747
in	O
their	O
chs	B-C0449820
score	I-C0449820
between	O
the	O
first	O
two	O
follow-ups	B-C3274571
chs	O
of	O
2006-2007	O
and	O
2008-2009	O
-2	O
,	O
-1	O
,	O
0	O
,	O
1	O
,	O
2	O
.	O
	
the	O
morbidity	B-C0026538
of	O
hypertension	B-C0020538
was	O
collected	B-C1516698
during	B-C0347984
2010-2011	O
and	O
2012-2013	O
follow-ups	B-C3274571
.	O
	
data	B-C0010992
analysis	I-C0010992
showed	O
that	O
during	B-C0347984
a	O
median	B-C0876920
follow-up	B-C3274571
of	O
3.79	O
years	O
,	O
morbidity	B-C0026538
of	O
hypertension	B-C0020538
had	O
a	O
graded	O
relationship	B-C0439849
with	O
chs	O
.	O
	
as	O
chs	O
scored	O
from	O
low	O
to	O
high	O
,	O
the	O
standardized	B-C1255664
morbidity	B-C0026538
of	O
hypertension	B-C0020538
for	O
all	O
participants	B-C0679646
were	O
81.40	O
,	O
75.47	O
,	O
68.37	O
,	O
71.43	O
and	O
83.13	O
per	O
1000	O
person-year	O
,	O
respectively	O
.	O
	
an	O
increased	B-C0205217
chs	O
score	O
of	O
1	O
was	O
associated	O
with	O
a	O
10%	O
decrease	B-C0547047
in	O
the	O
future	B-C0016884
risk	B-C0035647
of	I-C0035647
new-onset	B-C0745129
hypertension	I-C0745129
hr	O
0.90	O
,	O
95%	O
ci	B-C0009667
0.88	O
.	O
	
in	O
conclusion	O
,	O
there	O
was	O
a	O
strong	O
inverse	O
relationship	B-C0439849
between	O
the	O
incidence	O
of	O
new-onset	B-C0745129
hypertension	I-C0745129
and	O
elevation	B-C3163633
of	O
cardiovascular	B-C3887460
health	B-C0282574
metrics	I-C0282574
.	O
	
population	B-C1257890
-wide	O
prevention	B-C2700409
,	O
especially	O
the	O
promotion	B-C0018738
of	O
lifestyle	B-C0023676
improvements	B-C2986411
,	O
is	O
critical	B-C1511545
to	O
reducing	B-C0392756
the	O
morbidity	B-C0026538
of	O
new-onset	B-C0745129
hypertension	I-C0745129
.	O
	
an	O
hiv	B-C0019682
-	O
tailored	B-C2986593
quit	B-C1947925
-	O
smoking	B-C0037369
counselling	B-C0010210
pilot	B-C0031928
intervention	B-C0184661
targeting	B-C1521840
depressive	B-C0086132
symptoms	I-C0086132
plus	O
nicotine	B-C1278444
replacement	I-C1278444
therapy	I-C1278444
cardiovascular	B-C0007222
disease	I-C0007222
cvd	B-C0007222
rates	B-C0026538
among	O
people	B-C0027361
living	B-C2963182
with	I-C2963182
hiv/aids	I-C2963182
phas	B-C2963182
are	O
high	B-C0205250
.	O
	
rates	B-C1521828
of	O
cigarette	B-C0700219
smoking	I-C0700219
,	O
a	O
leading	B-C1522538
contributor	B-C1880177
to	O
cvd	B-C0007222
among	O
phas	B-C2963182
,	O
are	O
40-70%	O
2-3	O
times	O
higher	B-C0205250
than	O
the	O
general	B-C0683971
population	I-C0683971
.	O
	
furthermore	O
,	O
phas	B-C2963182
have	O
high	B-C0205250
rates	B-C1521828
of	O
depression	B-C0011570
40-60%	O
,	O
a	O
risk	B-C0035648
factor	I-C0035648
for	O
smoking	B-C0037369
cessation	B-C1880019
relapse	B-C0035020
.	O
	
the	O
current	O
pilot	B-C0031928
study	I-C0031928
examined	B-C0332128
the	O
effectiveness	B-C1280519
of	O
a	O
specifically	O
tailored	B-C2986593
5-	O
session	B-C1883016
smoking	B-C0037369
cessation	B-C1880019
counselling	B-C0010210
programme	I-C0010210
for	O
phas	B-C2963182
,	O
which	O
addressed	O
depression	B-C0011570
,	O
in	O
combination	O
with	O
nicotine	B-C1278444
replacement	I-C1278444
therapy	I-C1278444
nrt	B-C1278444
in	O
a	O
cohort	B-C0599755
of	O
pha	B-C2963182
smokers	B-C0337664
n	O
=	O
50	O
.	O
	
at	O
6-	O
month	B-C0439231
follow-up	B-C1522577
,	O
28%	O
of	O
participants	B-C0679646
demonstrated	O
biochemically	B-C0205474
verified	B-C1711411
abstinence	B-C3843422
from	O
smoking	B-C0037369
.	O
	
this	O
result	B-C2825142
compares	B-C1707455
favourably	O
to	O
other	O
quit	B-C1947925
-	O
smoking	B-C0037369
intervention	B-C0184661
studies	B-C0008972
,	O
particularly	O
given	O
the	O
high	B-C0205250
percentage	B-C0439165
of	O
hiv+	B-C0019699
smokers	B-C0337664
with	O
depression	B-C0011570
.	O
	
at	O
study	B-C0008972
baseline	B-C1442488
,	O
52%	O
of	O
hiv+	B-C0019699
smokers	B-C0337664
scored	O
above	O
the	O
clinical	B-C0205210
cut-off	B-C1442160
for	O
depression	B-C0011570
on	O
the	O
centre	B-C0679604
for	I-C0679604
epidemiological	I-C0679604
studies	I-C0679604
-	I-C0679604
depression	I-C0679604
ces-d	I-C0679604
scale	I-C0679604
.	O
	
hiv+	B-C0019699
smokers	B-C0337664
with	O
depression	B-C0011570
at	O
study	B-C0008972
baseline	B-C1442488
demonstrated	O
quantitatively	B-C0392762
lower	B-C2003888
depression	B-C0011570
at	O
6-	O
month	B-C0439231
follow-up	B-C1522577
with	O
a	O
large	B-C0549177
effect	B-C0814843
size	I-C0814843
d	O
=	O
1	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	B-C0237881
significance	I-C0237881
p	O
=	O
058	O
.	O
	
furthermore	O
,	O
those	O
with	O
depression	B-C0011570
were	O
no	O
more	O
likely	O
to	O
relapse	B-C0035020
than	O
those	O
without	O
depression	B-C0011570
p	O
=	O
33	O
,	O
suggesting	O
that	O
our	O
counselling	B-C0010210
programme	I-C0010210
adequately	B-C0205411
addressed	O
this	O
significant	B-C0750502
barrier	B-C0679881
to	O
smoking	B-C0037369
cessation	B-C1880019
among	O
phas	B-C2963182
.	O
	
our	O
pilot	B-C0031928
study	I-C0031928
indicates	O
the	O
importance	B-C3898777
of	O
tailored	B-C2986593
programmes	I-C2986593
to	O
help	O
phas	B-C2963182
quit	B-C1947925
smoking	B-C0037369
,	O
the	O
significance	B-C0750502
of	O
addressing	O
depressive	B-C0086132
symptoms	I-C0086132
,	O
and	O
the	O
need	O
for	O
tailored	B-C2986593
counselling	I-C2986593
programmes	I-C2986593
to	O
enhance	B-C2349975
quit	B-C1947925
rates	B-C1521828
among	O
effects	B-C1704420
of	I-C1704420
complex	B-C0439855
life	B-C0023675
cycles	I-C0023675
on	O
genetic	B-C0042333
diversity	I-C0042333
cyclical	B-C0030596
parthenogenesis	I-C0030596
neutral	O
patterns	O
of	O
population	B-C1257890
genetic	B-C0042333
diversity	I-C0042333
in	O
species	B-C1705920
with	O
complex	B-C0439855
life	B-C0023675
cycles	I-C0023675
are	O
difficult	O
to	O
anticipate	B-C0681842
.	O
	
cyclical	B-C0030596
parthenogenesis	I-C0030596
cp	B-C0030596
,	O
in	O
which	O
organisms	B-C0029235
undergo	O
several	O
rounds	O
of	O
clonal	B-C1522642
reproduction	B-C0035150
followed	O
by	O
a	O
sexual	B-C0036864
event	I-C0036864
,	O
is	O
one	O
such	O
life	B-C0023675
cycle	I-C0023675
.	O
	
many	O
species	B-C1705920
,	O
including	O
crop	B-C0242775
pests	B-C0869004
aphids	B-C0003562
,	O
human	B-C0585165
parasites	I-C0585165
trematodes	B-C3889286
or	O
models	B-C3161035
used	O
in	O
evolutionary	B-C0017398
science	I-C0017398
daphnia	B-C0010979
,	O
are	O
cyclical	B-C0029235
parthenogens	I-C0029235
.	O
	
it	O
is	O
therefore	O
crucial	O
to	O
understand	O
the	O
impact	O
of	O
such	O
a	O
life	B-C0023675
cycle	I-C0023675
on	O
neutral	O
genetic	B-C0042333
diversity	I-C0042333
.	O
	
in	O
this	O
paper	O
,	O
we	O
describe	O
distributions	B-C1704711
of	O
genetic	B-C0042333
diversity	I-C0042333
under	O
conditions	B-C0348080
of	O
cp	B-C0030596
with	O
various	O
clonal	B-C1522642
phase	B-C0205390
lengths	B-C1444754
.	O
	
using	O
a	O
markov	B-C0024828
chain	I-C0024828
model	I-C0024828
of	O
cp	B-C0030596
for	O
a	O
single	B-C0205171
locus	B-C1708726
and	O
individual-based	O
simulations	B-C0679083
for	O
two	B-C0205448
loci	B-C1708726
,	O
our	O
analysis	O
first	O
demonstrates	O
that	O
strong	O
departures	B-C1706081
from	O
full	O
sexuality	B-C0036915
are	O
observed	O
after	O
only	O
a	O
few	O
generations	B-C0079411
of	O
clonality	B-C1704387
.	O
	
the	O
convergence	B-C2700387
towards	O
predictions	B-C0681842
made	O
under	O
conditions	O
of	O
full	O
clonality	B-C1704387
during	O
the	O
clonal	B-C1522642
phase	B-C0205390
depends	O
on	O
the	O
balance	O
between	O
mutations	B-C0026882
and	O
genetic	B-C0917892
drift	I-C0917892
.	O
	
second	O
,	O
the	O
sexual	B-C0036864
event	I-C0036864
of	O
cp	B-C0030596
usually	O
resets	O
the	O
genetic	B-C0042333
diversity	I-C0042333
at	O
a	O
single	B-C0205171
locus	B-C1708726
towards	O
predictions	B-C0681842
made	O
under	O
full	O
sexuality	B-C0036915
.	O
	
however	O
,	O
this	O
single	O
recombination	B-C0034865
event	O
is	O
insufficient	O
to	O
reshuffle	O
gametic	B-C0007613
phases	I-C0007613
towards	O
full-sexuality	B-C0036915
predictions	B-C0681842
.	O
	
finally	O
,	O
for	O
similar	O
levels	O
of	O
clonality	B-C1704387
,	O
cp	B-C0030596
and	O
acyclic	O
partial	B-C0728938
clonality	B-C1704387
wherein	O
a	O
fixed	O
proportion	O
of	O
individuals	B-C0237401
are	O
clonally	B-C1704387
produced	O
within	O
each	O
generation	B-C0079411
differentially	O
affect	O
the	O
distribution	B-C1704711
of	O
genetic	B-C0042333
diversity	I-C0042333
.	O
	
overall	O
,	O
this	O
work	O
provides	O
solid	O
predictions	B-C0681842
of	O
neutral	O
genetic	B-C0042333
diversity	I-C0042333
that	O
may	O
serve	O
as	O
a	O
null	B-C3161035
model	I-C3161035
in	O
detecting	O
the	O
action	O
of	O
common	O
evolutionary	B-C0015219
or	O
demographic	B-C0011298
processes	B-C1522240
in	O
cyclical	B-C0029235
parthenogens	I-C0029235
recent	B-C0332185
advances	B-C1519201
in	O
chitosan	B-C0162969
-based	O
nanoparticulate	B-C1450054
pulmonary	B-C0024109
drug	B-C0085104
delivery	I-C0085104
the	O
advent	O
of	O
biodegradable	B-C0597998
polymer	I-C0597998
-	O
encapsulated	B-C0205223
drug	B-C1254351
nanoparticles	B-C1450054
has	O
made	O
the	O
pulmonary	B-C0024109
route	B-C0013153
of	I-C0013153
administration	I-C0013153
an	O
exciting	O
area	O
of	O
drug	B-C0085104
delivery	I-C0085104
research	B-C0035168
.	O
	
chitosan	B-C0162969
,	O
a	O
natural	B-C0205296
biodegradable	B-C0597998
and	O
biocompatible	B-C0005479
polysaccharide	B-C0032594
has	O
received	B-C1514756
enormous	O
attention	O
as	O
a	O
carrier	B-C0013161
for	O
drug	B-C0085104
delivery	I-C0085104
.	O
	
recently	O
,	O
nanoparticles	B-C1450054
of	O
chitosan	B-C0162969
cs	B-C0162969
and	O
its	O
synthetic	B-C0162969
derivatives	I-C0162969
have	O
been	O
investigated	B-C1292732
for	O
the	O
encapsulation	B-C2348438
and	O
delivery	B-C0205245
of	O
many	O
drugs	B-C1254351
with	O
improved	B-C0184511
targeting	B-C1521840
and	O
controlled	B-C0868939
release	I-C0868939
.	O
	
herein	O
,	O
recent	B-C0332185
advances	B-C1519201
in	O
the	O
preparation	B-C1521827
and	O
use	B-C1524063
of	I-C1524063
micro-	B-C4085688
/	O
nanoparticles	B-C1450054
of	O
chitosan	B-C0162969
and	O
its	O
derivatives	B-C0162969
for	O
pulmonary	B-C0024109
delivery	B-C0205245
of	O
various	O
therapeutic	B-C0304231
agents	I-C0304231
drugs	B-C1254351
,	O
genes	B-C0017337
,	O
vaccines	B-C0042210
are	O
reviewed	B-C1709940
.	O
	
although	O
chitosan	B-C0162969
has	O
wide	O
applications	B-C0205245
in	O
terms	O
of	O
formulations	B-C0524527
and	O
routes	B-C0013153
of	I-C0013153
drug	I-C0013153
delivery	I-C0013153
,	O
this	O
review	B-C0282443
is	O
focused	O
on	O
pulmonary	B-C0024109
delivery	B-C1881966
of	I-C1881966
drug-encapsulated	I-C1881966
nanoparticles	I-C1881966
of	O
chitosan	B-C0162969
and	O
its	O
derivatives	B-C0162969
.	O
	
in	O
addition	O
,	O
the	O
controversial	B-C1254370
toxicological	B-C0600688
effects	I-C0600688
of	O
chitosan	B-C0162969
nanoparticles	B-C1450054
for	O
lung	B-C0024109
delivery	B-C0205245
form	B-C0348078
and	O
function	B-C0542341
in	O
gene	B-C1720950
regulatory	I-C1720950
networks	I-C1720950
the	O
structure	B-C0678594
of	O
network	B-C0205556
motifs	I-C0205556
determines	O
fundamental	B-C0871161
properties	I-C0871161
of	O
their	O
dynamical	B-C1254362
state	I-C1254362
space	I-C1254362
network	B-C0205556
motifs	I-C0205556
have	O
been	O
studied	O
extensively	O
over	O
the	O
past	O
decade	O
,	O
and	O
certain	O
motifs	B-C0205556
,	O
such	O
as	O
the	O
feed-forward	B-C0205556
loop	I-C0205556
,	O
play	O
an	O
important	O
role	O
in	O
regulatory	B-C1720950
networks	I-C1720950
.	O
	
recent	B-C0332185
studies	B-C2603343
have	O
used	O
boolean	B-C1552663
network	B-C1882071
motifs	B-C0205556
to	O
explore	O
the	O
link	O
between	O
form	B-C0348078
and	O
function	B-C0542341
in	O
gene	B-C1720950
regulatory	I-C1720950
networks	I-C1720950
and	O
have	O
found	O
that	O
the	O
structure	B-C0678594
of	O
a	O
motif	B-C0205556
does	O
not	O
strongly	O
determine	O
its	O
function	B-C0542341
,	O
if	O
this	O
is	O
defined	O
in	O
terms	O
of	O
the	O
gene	B-C0017262
expression	I-C0017262
patterns	B-C0449774
the	O
motif	B-C0205556
can	O
produce	O
.	O
	
here	O
,	O
we	O
offer	O
a	O
different	O
,	O
higher	B-C0205250
-	O
level	B-C0441889
definition	B-C1704788
of	O
the	O
'	O
function	B-C0542341
'	O
of	O
a	O
motif	B-C0205556
,	O
in	O
terms	O
of	O
two	O
fundamental	B-C0871161
properties	I-C0871161
of	O
its	O
dynamical	B-C1254362
state	I-C1254362
space	I-C1254362
as	O
a	O
boolean	B-C1552663
network	B-C1882071
.	O
	
one	O
is	O
the	O
basin	B-C4068571
entropy	I-C4068571
,	O
which	O
is	O
a	O
complexity	B-C0237523
measure	B-C0079809
of	O
the	O
dynamics	B-C3826426
of	O
boolean	B-C1552663
networks	B-C1882071
.	O
	
the	O
other	O
is	O
the	O
diversity	B-C1880371
of	O
cyclic	B-C1444754
attractor	I-C1444754
lengths	I-C1444754
that	O
a	O
given	O
motif	B-C0205556
can	O
produce	O
.	O
	
using	O
these	O
two	O
measures	B-C0079809
,	O
we	O
examine	O
all	O
104	O
topologically	O
distinct	O
three-node	B-C2697524
motifs	B-C0205556
and	O
show	O
that	O
the	O
structural	B-C0678594
properties	B-C0871161
of	O
a	O
motif	B-C0205556
,	O
such	O
as	O
the	O
presence	O
of	O
feedback	B-C0205556
loops	I-C0205556
and	O
feed-forward	B-C0205556
loops	I-C0205556
,	O
predict	O
fundamental	B-C1521970
characteristics	I-C1521970
of	O
its	O
dynamical	B-C1254362
state	I-C1254362
space	I-C1254362
,	O
which	O
in	O
turn	O
determine	O
aspects	O
of	O
its	O
functional	B-C0205245
versatility	I-C0205245
.	O
	
we	O
also	O
show	O
that	O
these	O
higher	B-C0205250
-	O
level	B-C0441889
properties	B-C0871161
have	O
a	O
direct	O
bearing	O
on	O
real	O
regulatory	B-C1720950
networks	I-C1720950
,	O
as	O
both	O
basin	B-C4068571
entropy	I-C4068571
and	O
cycle	B-C1444754
length	I-C1444754
diversity	B-C1880371
show	O
a	O
close	O
correspondence	O
with	O
the	O
prevalence	B-C0220900
,	O
in	O
neural	B-C0598941
and	O
genetic	B-C1720950
regulatory	I-C1720950
networks	I-C1720950
,	O
of	O
the	O
13	O
connected	O
motifs	B-C0205556
without	O
self-interactions	B-C1704675
that	O
have	O
been	O
studied	O
extensively	O
in	O
the	O
jak1	B-C0169658
-	O
stat3	B-C0253050
signals	B-C0037083
are	O
essential	B-C0205224
effectors	B-C0599560
of	O
the	O
usp6	B-C1175888
/	O
tre17	B-C1175888
oncogene	I-C1175888
in	O
tumorigenesis	B-C0596263
bone	B-C0005967
and	O
soft	B-C0037579
tissue	I-C0037579
tumors	I-C0037579
bstt	B-C0027651
are	O
relatively	O
poorly	O
understood	O
,	O
hampering	O
the	O
development	B-C1527148
of	O
effective	B-C1704419
therapies	B-C0087111
.	O
	
here	O
we	O
report	B-C0684224
a	O
role	O
for	O
the	O
ubiquitin-specific	B-C1175888
protease	I-C1175888
6	I-C1175888
usp6	B-C1175888
tre17	B-C1175888
oncogene	I-C1175888
,	O
which	O
is	O
overexpressed	B-C1514559
upon	O
chromosome	B-C0040715
translocation	I-C0040715
in	O
various	O
human	B-C0086418
tumors	B-C0027651
,	O
including	O
aneurysmal	B-C0152244
bone	I-C0152244
cyst	I-C0152244
abc	B-C0152244
,	O
and	O
the	O
related	O
benign	B-C0205183
lesion	B-C0221198
nodular	B-C0410005
fasciitis	I-C0410005
.	O
	
ectopic	B-C1512167
expression	I-C1512167
of	O
usp6	B-C1175888
is	O
known	O
to	O
drive	O
formation	B-C1522492
of	O
tumors	B-C0027651
,	O
which	O
recapitulate	O
key	B-C2348519
features	I-C2348519
of	O
abc	B-C0152244
and	O
nodular	B-C0410005
fasciitis	I-C0410005
however	O
,	O
the	O
identity	B-C0017390
of	O
usp6's	B-C1175888
relevant	O
substrates	B-C0178623
has	O
been	O
obscure	O
.	O
	
here	O
we	O
report	B-C0684224
that	O
the	O
jak1	B-C0169658
-	O
stat3	B-C0253050
signaling	B-C0037080
pathway	I-C0037080
serves	O
as	O
an	O
essential	B-C0205224
effector	B-C0599560
of	O
usp6	B-C1175888
in	O
bstt	B-C0027651
formation	B-C1522492
.	O
	
we	O
found	O
that	O
usp6	B-C1175888
directly	O
deubiquitinated	B-C1157996
jak1	B-C0169658
,	O
leading	B-C1522538
to	O
its	O
stabilization	B-C0184512
and	O
activation	B-C0599177
of	O
stat3	B-C0253050
.	O
	
the	O
tumorigenic	B-C0007621
potential	B-C3245505
of	O
usp6	B-C1175888
was	O
attenuated	B-C0332161
significantly	I-C0332161
by	I-C0332161
crispr	B-C3658200
-mediated	O
deletion	B-C0017260
of	O
jak1	B-C1334290
or	O
stat3	B-C1367307
,	O
or	O
by	O
administration	B-C1621583
of	O
a	O
jak	B-C0597721
family	I-C0597721
inhibitor	B-C1999216
.	O
	
analysis	B-C0936012
of	O
primary	B-C2347026
clinical	I-C2347026
samples	I-C2347026
of	O
nodular	B-C0410005
fasciitis	I-C0410005
confirmed	B-C0750484
the	O
activation	B-C0599177
of	O
a	O
jak1	B-C0169658
-	O
stat3	B-C0253050
gene	B-C1708225
signature	I-C1708225
in	B-C0681829
vivo	I-C0681829
together	O
,	O
our	O
studies	B-C0947630
highlight	O
jak1	B-C0169658
as	O
the	O
first	O
identified	O
substrate	B-C0178623
for	O
usp6	B-C1175888
,	O
and	O
they	O
offer	O
a	O
mechanistic	B-C2699007
rationale	I-C2699007
for	O
the	O
clinical	B-C1261322
investigation	I-C1261322
of	O
jak	B-C0597721
and	O
stat3	B-C0253050
inhibitors	B-C1999216
as	O
therapeutics	B-C0302350
for	O
the	O
treatment	B-C0087111
of	O
bone	B-C0005967
and	O
soft	B-C0037579
tissue	I-C0037579
tumors	I-C0037579
along	O
with	O
other	O
neoplasms	B-C0027651
driven	O
by	O
usp6	B-C1175888
overexpression	B-C1514559
.	O
	
the	O
evidence	B-C3887511
behind	O
integrating	B-C1881786
palliative	B-C0030231
care	I-C0030231
into	O
oncology	B-C0027651
practice	B-C0033284
palliative	B-C0587605
care	I-C0587605
services	I-C0587605
provided	B-C1999230
alongside	O
traditional	B-C0443324
oncology	B-C3244201
care	I-C3244201
have	O
been	O
shown	O
to	O
be	O
beneficial	B-C0205556
to	O
patients	B-C0030705
and	O
families	B-C0015576
.	O
	
this	O
article	B-C1706852
provides	O
a	O
brief	B-C1879313
history	B-C0019664
of	O
palliative	B-C0030231
care	I-C0030231
,	O
a	O
pathway	O
to	O
implementing	B-C1705848
these	O
services	B-C0557854
into	O
currently	B-C0521116
established	B-C0443211
oncology	B-C1516732
programs	I-C1516732
,	O
and	O
a	O
brief	O
discussion	B-C2584313
of	O
common	B-C4045969
barriers	I-C4045969
.	O
	
secondary	B-C1184751
ossification	I-C1184751
center	I-C1184751
appearance	B-C0700364
and	O
closure	B-C1293215
in	I-C1293215
the	I-C1293215
pelvis	I-C1293215
and	O
proximal	B-C0448190
femur	I-C0448190
variable	O
ossification	B-C0029433
patterns	B-C0449774
of	O
the	O
pelvis	B-C0030797
in	O
skeletally	B-C0037253
immature	B-C0205252
patients	B-C0030705
can	O
make	O
the	O
interpretation	O
of	O
pelvic	B-C0030797
radiographs	B-C1306645
challenging	O
.	O
	
inconsistencies	O
among	O
prior	O
studies	O
and	O
lack	O
of	O
sex	B-C1522384
comparisons	B-C1707455
underscore	O
the	O
need	O
for	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
secondary	B-C1184751
ossification	I-C1184751
centers	I-C1184751
.	O
	
this	O
study	O
evaluates	B-C0220825
the	O
chronology	B-C0008717
and	O
sex	B-C0036866
differences	I-C0036866
for	O
appearance	B-C0700364
and	O
closure	B-C1293215
of	I-C1293215
pelvic	I-C1293215
and	O
proximal	B-C0448190
femoral	I-C0448190
secondary	B-C1184751
ossification	I-C1184751
centers	I-C1184751
using	O
computed	B-C0040405
tomography	I-C0040405
ct	B-C0040405
.	O
	
patients	B-C0030705
who	O
underwent	O
abdominal	B-C0412620
and	O
pelvic	B-C3842376
ct	I-C3842376
scans	I-C3842376
between	O
january	O
2009	O
and	O
december	O
2014	O
at	O
2	O
tertiary	O
level	O
1	O
trauma	B-C0040786
centers	I-C0040786
were	O
retrospectively	B-C1514923
reviewed	B-C1709940
.	O
	
patients	B-C0030705
between	O
the	O
ages	B-C0001779
of	O
2	O
and	O
32	O
years	O
with	O
adequate	O
imaging	B-C0011923
of	O
the	O
pelvis	B-C0030797
and	O
proximal	B-C0448190
femurs	I-C0448190
were	O
included	O
.	O
	
patients	B-C0030705
with	O
a	O
history	O
of	O
orthopaedic	B-C1274117
trauma	I-C1274117
or	O
pathology	B-C0030664
affecting	B-C0392760
ossification	B-C0029433
were	O
excluded	O
.	O
	
ct	B-C0040405
scans	I-C0040405
were	O
assessed	B-C1516048
for	O
the	O
appearance	B-C0700364
and	O
closure	B-C0185003
of	O
the	O
following	O
secondary	B-C1184751
ossification	I-C1184751
centers	I-C1184751
anterior	B-C0223645
inferior	I-C0223645
iliac	I-C0223645
spine	I-C0223645
aiis	B-C0223645
,	O
anterior	B-C0223644
superior	I-C0223644
iliac	I-C0223644
spine	I-C0223644
asis	B-C0223644
,	O
femoral	B-C0015813
head	I-C0015813
fh	B-C0015813
,	O
greater	B-C0223865
trochanter	I-C0223865
gt	B-C0223865
,	O
iliac	B-C0223651
crest	I-C0223651
ic	B-C0223651
,	O
ischial	B-C0223656
tuberosity	I-C0223656
it	B-C0223656
,	O
lesser	B-C0223866
trochanter	I-C0223866
lt	B-C0223866
,	O
posterior	B-C0223646
superior	I-C0223646
iliac	I-C0223646
spine	I-C0223646
psis	B-C0223646
,	O
symphysis	B-C0034015
pubis	I-C0034015
sp	B-C0034015
,	O
and	O
triradiate	B-C0007301
cartilage	I-C0007301
trc	B-C0007301
.	O
	
basic	O
descriptive	O
statistics	O
are	O
reported	O
.	O
	
a	O
total	O
of	O
496	O
ct	B-C0040405
scans	I-C0040405
met	O
inclusion	B-C1512693
criteria	I-C1512693
240	O
males	B-C0086582
and	O
256	O
females	B-C0086287
.	O
	
the	O
order	O
of	O
appearance	B-C0700364
of	O
the	O
secondary	B-C1184751
ossification	I-C1184751
centers	I-C1184751
was	O
male	B-C0086582
gt	B-C0223865
,	O
lt	B-C0223866
,	O
aiis	B-C0223645
,	O
it	B-C0223656
,	O
asis	B-C0223644
,	O
psis	B-C0223646
,	O
ic	B-C0223651
,	O
and	O
sp	B-C0034015
female	B-C0086287
gt	B-C0223865
,	O
lt	B-C0223866
,	O
it	B-C0223656
,	O
aiis	B-C0223645
,	O
psis	B-C0223646
,	O
ic	B-C0223651
,	O
asis	B-C0223644
,	O
and	O
sp	B-C0034015
.	O
	
the	O
order	O
of	O
closure	B-C0185003
was	O
similar	O
male	B-C0086582
trc	B-C0007301
,	O
lt	B-C0223866
,	O
fh	B-C0015813
,	O
aiis	B-C0223645
,	O
gt	B-C0223865
,	O
asis	B-C0223644
,	O
psis	B-C0223646
,	O
it	B-C0223656
,	O
ic	B-C0223651
,	O
and	O
sp	B-C0034015
female	B-C0086287
lt	B-C0223866
,	O
trc	B-C0007301
,	O
aiis	B-C0223645
,	O
fh	B-C0015813
,	O
gt	B-C0223865
,	O
asis	B-C0223644
,	O
psis	B-C0223646
,	O
it	B-C0223656
,	O
ic	B-C0223651
,	O
and	O
sp	B-C0034015
.	O
	
female	B-C0086287
ossification	B-C1184744
centers	I-C1184744
appeared	O
1	O
to	O
2	O
years	O
before	O
males	B-C0086582
in	O
all	O
locations	B-C1515974
.	O
	
female	B-C0086287
ossification	B-C1184744
centers	I-C1184744
closed	O
1	O
to	O
2	O
years	O
before	O
males	B-C0086582
in	O
all	O
locations	B-C1515974
except	O
trc	B-C0007301
,	O
ic	B-C0223651
,	O
and	O
sp	B-C0034015
.	O
	
the	O
appearance	B-C0700364
and	O
closure	B-C1293215
of	I-C1293215
the	I-C1293215
pelvis	I-C1293215
and	O
proximal	B-C0448190
femur	I-C0448190
secondary	B-C1184751
ossification	I-C1184751
centers	I-C1184751
follow	O
a	O
predictable	O
pattern	O
of	O
development	O
,	O
occurring	O
slightly	O
earlier	O
in	O
females	B-C0086287
than	O
males	B-C0086582
.	O
	
knowledge	O
of	O
more	O
precise	O
ages	B-C1821962
of	I-C1821962
developmen	I-C1821962
t	O
and	O
sex	B-C0036866
differences	I-C0036866
better	O
characterize	O
this	O
complex	O
skeletal	B-C1160401
development	I-C1160401
.	O
	
future	O
studies	O
may	O
use	O
secondary	B-C1184751
ossification	I-C1184751
centers	I-C1184751
to	O
further	O
evaluate	B-C0220825
skeletal	B-C3825673
maturity	I-C3825673
,	O
assess	O
pediatric	B-C0030755
pathology	B-C0030664
,	O
and	O
aid	O
surgical	B-C1515089
management	I-C1515089
.	O
	
pediatric	B-C0008059
orthopaedic	B-C0037253
trauma	B-C3714660
and	O
associated	B-C3263723
injuries	I-C3263723
of	O
snowmobile	B-C2063141
,	O
atv	B-C0683911
,	O
and	O
dirtbike	B-C0683911
accidents	I-C0683911
a	O
19-year	B-C0439234
experience	O
at	O
a	O
level	O
1	O
pediatric	B-C0008059
trauma	B-C0040786
center	I-C0040786
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	O
the	O
type	B-C0332307
and	O
severity	B-C0439793
of	O
orthopaedic	B-C0597457
and	O
associated	B-C0412812
injuries	I-C0412812
for	O
snowmobile	B-C2063141
,	O
all-terrain	B-C0683911
vehicles	I-C0683911
atv	B-C0683911
and	O
motorized	B-C0683911
dirtbike	I-C0683911
accidents	I-C0683911
in	O
a	O
pediatric	B-C0008059
patient	B-C0030705
population	I-C0030705
.	O
	
a	O
total	O
of	O
758	O
patients	B-C0030705
who	O
presented	O
following	O
either	O
snowmobile	B-C3714660
n=87	O
,	O
atv-related	B-C3714660
n=308	O
or	O
dirtbike	B-C3714660
n=363	I-C3714660
trauma	I-C3714660
at	O
our	O
institution	B-C2607850
between	O
1996	O
and	O
2015	O
were	O
retrospectively	O
reviewed	B-C1709940
.	O
	
a	O
total	O
of	O
441	O
axial	B-C0016658
and	O
appendicular	B-C0016658
fractures	I-C0016658
occurred	O
requiring	O
533	O
procedures	B-C2700391
.	O
	
snowmobile	B-C2063141
and	O
dirtbike	B-C0683911
accidents	I-C0683911
were	O
associated	B-C0332281
with	I-C0332281
a	O
higher	O
rate	O
of	O
fractures	B-C0016658
63%	O
,	O
64%	O
than	O
the	O
atv	B-C1257890
group	I-C1257890
50%	O
p=0	O
.	O
	
snowmobile	B-C0412812
injuries	I-C0412812
had	O
the	O
highest	O
rate	O
of	O
spinal	B-C0080179
23%	O
and	O
lower	B-C1542178
extremity	I-C1542178
fractures	I-C1542178
53%	O
p=0	O
.	O
	
snowmobile	B-C0599755
and	O
dirtbike	B-C0599755
cohorts	I-C0599755
had	O
higher	O
rate	O
of	O
femur	B-C0015802
fractures	I-C0015802
22%	O
,	O
17%	O
,	O
p=0	O
whereas	O
the	O
atv	B-C0599755
cohort	I-C0599755
had	O
higher	O
rates	O
of	O
upper	B-C1140618
extremity	I-C1140618
18%	O
,	O
hand	B-C0018563
11%	O
,	O
scapula	B-C0036277
4.6	O
,	O
and	O
open	B-C0016662
fractures	I-C0016662
28.6	O
p<0	O
.	O
	
head	B-C0018674
trauma	I-C0018674
was	O
the	O
most	O
commonly	O
associated	B-C0412812
injury	I-C0412812
in	O
275	O
patients	B-C0030705
with	O
the	O
highest	O
rate	O
in	O
the	O
atv	B-C1257890
group	I-C1257890
44%	O
who	O
also	O
had	O
the	O
highest	O
rate	O
of	O
no	O
helmet	O
use	O
76%	O
.	O
	
snowmobile	B-C0030705
and	O
atv	B-C0030705
patients	I-C0030705
had	O
higher	O
injury	B-C0021504
severity	I-C0021504
score	I-C0021504
11.3	O
,	O
9.6	O
than	O
dirtbike	B-C0030705
patients	I-C0030705
7.8	O
p=0	O
.	O
	
atv	B-C0030705
patients	I-C0030705
were	O
found	O
to	O
be	O
younger	B-C0332239
11.8	O
y	O
compared	O
with	O
snowmobile	B-C0030705
13.2	O
y	O
and	O
dirtbike	B-C0030705
13.5	O
y	O
p<0	O
.	O
	
pediatric	B-C0008059
snowmobile	B-C2063141
,	O
atv	B-C0683911
and	O
dirtbike	B-C0683911
accidents	I-C0683911
result	O
in	O
severe	B-C0205082
orthopaedic	B-C0597457
and	O
associated	B-C0412812
injuries	I-C0412812
with	O
each	O
vehicle	B-C0348005
demonstrating	O
significantly	O
different	O
injury	B-C3263723
patterns	B-C0449774
.	O
	
injury	B-C0150638
prevention	I-C0150638
should	O
focus	O
on	O
improved	O
safety	B-C0150755
mechanisms	I-C0150755
,	O
protective	B-C3840637
gear	I-C3840637
,	O
safe	O
areas	O
for	O
off-road	B-C0028892
vehicle	I-C0028892
use	O
and	O
strict	B-C0023150
laws	I-C0023150
with	O
minimum	O
age	B-C0001779
hospitalist	B-C0600620
co-management	B-C1273870
of	O
pediatric	B-C1521725
orthopaedic	B-C0524852
surgical	B-C0871463
patients	I-C0871463
at	O
a	O
community	B-C0020003
hospital	I-C0020003
the	O
benefits	O
of	O
hospitalist	B-C0600620
co-management	B-C1273870
of	O
pediatric	B-C1521725
surgical	B-C0871463
patients	I-C0871463
include	O
bettering	B-C0332272
patient	B-C1113679
safety	I-C1113679
,	O
decreasing	B-C0442797
negative	B-C3853545
patient	B-C1547647
outcomes	I-C1547647
,	O
providing	O
comprehensive	B-C0009586
medical	I-C0009586
care	I-C0009586
,	O
and	O
establishing	O
a	O
dedicated	B-C0035201
resource	I-C0035201
to	O
patients	B-C0030705
for	O
postoperative	B-C0032786
care	I-C0032786
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
characterize	B-C1880022
the	O
nature	B-C0349590
of	O
patients	B-C0030705
co-managed	O
by	O
a	O
pediatric	B-C1521725
hospitalist	B-C0600620
.	O
	
the	O
authors	B-C3812881
hypothesize	B-C1512571
that	O
hospitalist	B-C0600620
co-management	B-C1273870
is	O
safe	B-C3266157
and	O
efficacious	B-C1280519
in	O
pediatric	B-C1521725
orthopaedic	B-C0524852
surgical	B-C0871463
patients	I-C0871463
who	O
are	O
admitted	B-C0184666
to	O
a	O
community	B-C0020003
hospital	I-C0020003
.	O
	
a	O
retrospective	B-C0035363
review	I-C0035363
was	O
performed	O
of	O
all	O
pediatric	B-C1521725
orthopaedic	B-C0524852
surgical	B-C0871463
patients	I-C0871463
admitted	B-C0184666
to	O
a	O
community	B-C0020003
hospital	I-C0020003
who	O
were	O
co-managed	O
by	O
a	O
pediatric	B-C1521725
hospitalist	B-C0600620
.	O
	
indications	O
for	O
hospitalization	B-C0019993
included	O
pain	B-C1304888
control	I-C1304888
,	O
antibiotic	B-C0199779
infusion	I-C0199779
,	O
and	O
need	O
for	O
neurovascular	B-C1828265
monitoring	I-C1828265
.	O
	
parameters	B-C0549193
of	O
postoperative	B-C0032786
care	I-C0032786
and	O
co-management	B-C1273870
were	O
assessed	B-C1516048
,	O
including	O
presence	B-C0150312
of	O
complications	B-C2362589
,	O
medication	B-C1293116
introduction	I-C1293116
or	O
adjustment	O
by	O
the	O
hospitalist	B-C0600620
,	O
follow-up	B-C1522577
adherence	B-C1510802
,	O
and	O
readmission	B-C0030700
/	O
complication	B-C2362589
rates	B-C1521828
after	O
discharge	B-C0030685
.	O
	
thirty-two	O
patients	B-C0030705
were	O
assessed	B-C1516048
with	O
an	O
average	B-C0001779
age	I-C0001779
of	O
8.8	O
years	B-C0439234
.	O
	
twenty-five	O
percent	B-C0439165
of	O
patients	B-C0030705
had	O
an	O
associated	B-C0009488
comorbidity	I-C0009488
,	O
including	O
asthma	B-C0004096
,	O
attention	B-C0041671
deficit	I-C0041671
disorder	I-C0041671
,	O
and/or	O
autism	B-C0004352
.	O
	
the	O
pediatric	B-C1521725
hospitalist	B-C0600620
added	O
pain	B-C0508321
medication	I-C0508321
to	O
the	O
original	O
postoperative	B-C0032786
orders	I-C0032786
placed	O
by	O
the	O
orthopaedics	B-C0334954
team	I-C0334954
in	O
44	O
percent	B-C0439165
of	O
patients	B-C0030705
14	O
of	O
the	O
32	O
either	O
for	O
breakthrough	B-C1135120
pain	I-C1135120
or	O
better	O
long-term	O
coverage	O
.	O
	
additionally	O
,	O
25	O
percent	B-C0439165
of	O
patients	B-C0030705
had	O
pain	B-C0508321
medication	I-C0508321
adjusted	O
from	O
the	O
original	O
dosing	B-C0178602
and	O
schedule	B-C0030703
.	O
	
the	O
hospitalist	B-C0600620
team	B-C0871489
contacted	O
the	O
surgeon	B-C0582175
about	O
the	O
four	O
patients	B-C0030705
12.5	O
percent	B-C0439165
.	O
	
in	O
three	O
of	O
the	O
cases	O
,	O
the	O
surgeon	B-C0582175
was	O
contacted	O
to	O
discuss	O
pain	B-C0508321
medication	I-C0508321
,	O
and	O
one	O
patient	B-C0030705
woke	O
up	O
agitated	O
from	O
anesthesia	B-C0002903
,	O
necessitating	O
a	O
visit	O
from	O
the	O
surgeon	B-C0582175
on	O
the	O
pediatrics	O
floor	O
.	O
	
the	O
length	O
of	O
stay	O
was	O
one	O
day	O
for	O
all	O
patients	B-C0030705
.	O
	
the	O
hospitalists	B-C0600620
rounded	O
on	O
and	O
discharged	B-C0030685
patients	I-C0030685
the	O
subsequent	O
morning	O
.	O
	
all	O
patients	B-C0030705
were	O
given	O
a	O
follow-up	B-C0184760
appointment	I-C0184760
and	I-C0184760
schedule	I-C0184760
by	O
the	O
hospitalist	B-C0600620
team	O
,	O
and	O
every	B-C0030705
patient	I-C0030705
followed	B-C1522577
up	I-C1522577
accordingly	O
within	O
ten	O
days	B-C0439228
of	O
discharge	B-C0030685
.	O
	
no	O
complications	B-C2362589
or	O
hospital	B-C0600290
readmissions	I-C0600290
occurred	O
within	O
thirty	O
days	B-C0439228
of	O
discharge	B-C0030685
.	O
	
hospitalist	B-C0600620
co-management	B-C1273870
of	O
pediatric	B-C1521725
orthopaedic	B-C0524852
surgical	B-C0871463
patients	I-C0871463
in	O
a	O
community	O
hospital	O
allows	O
for	O
better	O
medical	O
comorbidity	O
and	O
medication	O
management	O
.	O
	
hospitalist	O
s	O
can	O
provide	O
closer	O
observation	O
during	O
the	O
inpatient	O
stay	O
and	O
help	O
streamline	O
communication	O
between	O
providers	O
and	O
patients	B-C0030705
while	O
allowing	O
the	O
surgeon	O
the	O
ability	O
to	O
be	O
more	O
mobile	O
.	O
	
co-management	O
is	O
safe	O
and	O
efficacious	O
in	O
pediatric	O
orthopaedic	O
surgical	O
patients	O
who	O
are	O
admitted	O
to	O
a	O
community	B-C0020003
hospital	I-C0020003
.	O
	
extra	O
carbohydrate	B-C0108401
binding	I-C0108401
module	I-C0108401
contributes	B-C1880177
to	O
the	O
processivity	B-C0205556
and	O
catalytic	B-C0243102
activity	I-C0243102
of	O
a	O
non-modular	B-C0020289
hydrolase	I-C0020289
family	O
5	B-C0384886
endoglucanase	I-C0384886
from	O
fomitiporia	B-C1225186
mediterranea	I-C1225186
mf3/22	I-C1225186
fmeg	B-C0384886
from	O
fomitiporia	B-C1225186
mediterranea	I-C1225186
is	O
a	O
non-modular	B-C0384886
endoglucanase	I-C0384886
composed	O
of	O
a	O
24-amino	B-C0002520
acids	I-C0002520
extension	B-C0231448
and	O
13-amino	B-C0002520
acids	I-C0002520
linker-like	B-C0030956
peptide	I-C0030956
at	O
the	O
n-terminus	B-C1514562
and	O
a	O
312-amino	B-C0002520
acids	I-C0002520
gh5	B-C0600499
catalytic	I-C0600499
domain	I-C0600499
cd	B-C0600499
at	O
the	O
c-terminus	B-C1514562
.	O
	
in	O
this	O
study	O
,	O
six	O
fmeg	B-C0384886
derivatives	O
with	O
deletion	B-C1880274
of	O
n-terminal	B-C0030935
fragments	I-C0030935
or	O
fusion	B-C0162768
with	O
an	O
extra	O
family	B-C0108401
1	I-C0108401
carbohydrate-binding	I-C0108401
module	I-C0108401
cbm1	B-C0108401
was	O
constructed	O
in	O
order	O
to	O
evaluate	O
the	O
contribution	B-C1880177
of	O
cbm1	B-C0108401
to	O
fmeg	B-C0384886
processivity	B-C0205556
and	O
catalytic	B-C0243102
activity	I-C0243102
.	O
	
fmeg	B-C0384886
showed	O
a	O
weak	O
processivity	B-C0205556
and	O
released	O
cellobiose	B-C0007630
g2	B-C0007630
and	O
cellotriose	B-C1690565
g3	B-C1690565
as	O
main	B-C1514468
end	I-C1514468
products	I-C1514468
,	O
and	O
cellotriose	B-C1690565
g4	B-C1690565
as	O
minor	B-C1514468
end	I-C1514468
product	I-C1514468
from	O
filter	B-C0180859
paper	I-C0180859
fp	B-C0180859
,	O
but	O
more	O
amount	O
of	O
g4	B-C1690565
was	O
released	O
from	O
regenerated	B-C0007648
amorphous	I-C0007648
cellulose	I-C0007648
rac	B-C0007648
.	O
	
all	O
derivatives	B-C1690565
had	O
similar	O
activity	O
on	O
carboxymethylcellulose	B-C0007068
cmc	B-C0007068
with	O
the	O
same	B-C2698651
optimal	I-C2698651
ph	B-C0020283
7.0	O
and	O
temperature	B-C0039476
50	O
.	O
	
however	O
,	O
fusing	O
an	O
extra	O
cbm1	B-C0108401
to	O
fmeg	B-C0384886
or	O
fmeg	B-C0384886
with	O
flexible	B-C0030956
peptide	I-C0030956
significantly	O
improved	O
its	O
processivity	B-C0205556
and	O
catalytic	B-C1264638
activity	I-C1264638
to	O
fp	B-C0180859
and	O
rac	B-C0007648
.	O
	
overall	O
,	O
1.79	O
and	O
1.84	O
increases	O
in	O
the	O
soluble	B-C1948047
/insoluble	O
product	O
ratio	B-C0456603
on	O
fp	B-C0180859
,	O
and	O
1.38	O
and	O
1.39	O
increases	O
on	O
rac	B-C0007648
,	O
compared	O
to	O
fmeg	B-C0384886
,	O
were	O
recorded	O
for	O
cbm1	B-C0108401
-	O
fmeg	B-C0384886
and	O
cbm1	B-C0108401
-linker-	O
fmeg	B-C0384886
,	O
respectively	O
.	O
	
meanwhile	O
,	O
they	O
displayed	O
2.64	O
and	O
2.67	B-C0243095
more	I-C0243095
activity	I-C0243095
on	O
rac	B-C0007648
,	O
and	O
1.68	O
and	O
1.77	O
on	O
fp	B-C0180859
,	O
respectively	O
.	O
	
similar	O
improvement	O
was	O
also	O
obtained	O
for	O
cbm1	B-C0108401
-linker-	O
fmeg	B-C0384886
as	O
compared	O
with	O
fmeg	B-C0384886
.	O
	
interestingly	O
,	O
fusion	O
of	O
an	O
extra	O
cbm1	B-C0108401
with	O
fmeg	B-C0384886
also	O
caused	O
an	O
alteration	B-C1515926
of	O
cleavage	B-C0596311
pattern	I-C0596311
on	O
insoluble	B-C0007648
celluloses	I-C0007648
.	O
	
our	O
results	O
suggest	O
that	O
such	O
improvements	O
in	O
processivity	B-C0205556
and	O
catalytic	B-C1264638
activity	I-C1264638
may	O
arise	O
from	O
cbm1	B-C0108401
binding	B-C0033618
affinity	I-C0033618
.	O
	
the	O
n-terminal	B-C0002520
24-	I-C0002520
or	I-C0002520
37-amino	I-C0002520
acids	I-C0002520
may	O
serve	O
as	O
linker	O
for	O
sufficient	O
spatial	B-C1254362
separation	I-C1254362
of	O
the	O
two	B-C1514562
domains	I-C1514562
required	O
for	O
processivity	B-C0205556
and	O
catalytic	B-C1264638
activity	I-C1264638
.	O
	
in	O
addition	O
,	O
deletion	B-C1880274
of	O
the	O
n-terminal	B-C0002520
24-	I-C0002520
or	I-C0002520
37-amino	I-C0002520
acids	I-C0002520
led	O
to	O
significant	B-C0392756
reduction	I-C0392756
in	O
thermostability	B-C0597571
but	O
not	O
the	O
enzymatic	B-C0243102
activity	I-C0243102
.	O
	
overnight	B-C0439583
switching	B-C2936279
from	O
oxcarbazepine	B-C0069751
to	O
eslicarbazepine	B-C2725262
acetate	I-C2725262
an	O
observational	B-C1518527
study	I-C1518527
there	O
are	O
clinical	B-C0013956
situations	I-C0013956
where	O
it	O
might	O
be	O
appropriate	B-C1548787
to	O
switch	B-C2936279
patients	B-C0030705
from	O
immediate-release	B-C1708470
oxcarbazepine	B-C0069751
oxc	B-C0069751
to	O
eslicarbazepine	B-C2725262
acetate	I-C2725262
esl	B-C2725262
.	O
	
we	O
investigated	B-C1292732
the	O
effects	B-C1704420
of	I-C1704420
transitioning	O
patients	B-C0030705
overnight	B-C0439583
from	O
oxc	B-C0069751
to	O
esl	B-C2725262
.	O
	
a	O
retrospective	B-C0035363
,	O
single-center	B-C2603343
study	I-C2603343
was	O
conducted	O
in	O
which	O
patients	B-C0030705
with	O
drug-resistant	B-C0013203
focal	B-C0014547
epilepsy	I-C0014547
on	O
a	O
stable	O
dose	B-C0678766
of	O
immediate-release	B-C1708470
oxc	B-C0069751
for	O
at	O
least	O
4	B-C1442465
weeks	I-C1442465
were	O
switched	B-C2936279
overnight	B-C0439583
to	O
esl	B-C2725262
.	O
	
patients	B-C0030705
were	O
switched	B-C2936279
because	O
they	O
experienced	O
persistent	B-C0205322
seizures	B-C0036572
with	O
oxc	B-C0069751
but	O
were	O
unable	B-C1299582
to	O
tolerate	B-C4053931
increased	O
oxc	B-C0069751
dosing	B-C0678766
due	O
to	O
adverse	B-C0041755
events	I-C0041755
.	O
	
tolerability	B-C4053931
was	O
assessed	B-C1516048
using	O
the	O
adverse	B-C0282574
events	I-C0282574
profile	I-C0282574
aep	B-C0282574
,	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
was	O
assessed	B-C1516048
using	O
the	O
quality	B-C0282574
of	I-C0282574
life	I-C0282574
in	I-C0282574
epilepsy	I-C0282574
inventory	I-C0282574
10	I-C0282574
qolie-10	B-C0282574
,	O
and	O
alertness	B-C1443086
was	O
assessed	B-C1516048
as	O
reaction	B-C0034746
time	I-C0034746
using	O
a	O
subtest	O
of	O
the	O
test	B-C0037585
battery	I-C0037585
for	I-C0037585
attention	I-C0037585
performance	I-C0037585
version	I-C0037585
2.3	I-C0037585
.	O
	
assessments	B-C1261322
were	O
performed	B-C0884358
immediately	B-C0205548
prior	B-C0332152
to	I-C0332152
and	O
5	B-C1442466
days	I-C1442466
after	O
switching	B-C2936279
from	O
oxc	B-C0069751
to	O
esl	B-C2725262
days	B-C0439228
0	O
and	O
5	O
,	O
respectively	O
.	O
	
the	O
analysis	B-C0936012
included	O
21	O
patients	B-C0030705
12	O
women	B-C0043210
,	O
9	O
men	B-C0025266
mean	B-C0243095
age	I-C0243095
36	I-C0243095
years	I-C0243095
.	O
	
after	O
switching	B-C2936279
from	O
oxc	B-C0069751
to	O
esl	B-C2725262
,	O
there	O
were	O
significant	O
improvements	B-C2986411
in	O
mean	B-C0449820
scores	I-C0449820
for	O
aep	B-C0282574
p<	O
,	O
qolie-10	B-C0282574
p=	O
,	O
and	O
alertness	B-C1443086
p<	O
.	O
	
adverse	B-C0282574
events	I-C0282574
profile	I-C0282574
total	B-C0449820
scores	I-C0449820
improved	B-C0184511
for	O
21/21	O
100.0	O
patients	B-C0030705
,	O
qolie-10	B-C0282574
total	B-C0449820
scores	I-C0449820
improved	B-C0184511
for	O
17/21	O
81.0	O
patients	B-C0030705
,	O
and	O
alertness	B-C1443086
scores	B-C0449820
improved	B-C0184511
for	O
16/21	O
76.2	O
patients	B-C0030705
.	O
	
in	O
this	O
short-term	B-C0443303
,	O
single-center	B-C2603343
study	I-C2603343
,	O
an	O
overnight	B-C0439583
switch	B-C2936279
from	O
twice-daily	B-C0585361
oxc	B-C0069751
to	O
once-daily	B-C0556983
esl	B-C2725262
in	O
patients	B-C0030705
with	O
drug-resistant	B-C0013203
focal	B-C0014547
epilepsies	I-C0014547
resulted	B-C2825142
in	O
improvements	B-C2986411
in	O
side	B-C0041755
effects	I-C0041755
,	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
,	O
and	O
complete	B-C0205197
genome	B-C0017428
sequences	B-C0162326
of	O
three	O
outbreak	B-C0012652
-associated	O
legionella	B-C0023238
pneumophila	I-C0023238
isolates	B-C1764827
we	O
report	O
here	O
the	O
complete	B-C0205197
genome	B-C0017428
sequences	B-C0162326
of	O
three	O
legionella	B-C0023238
pneumophila	I-C0023238
isolates	B-C1764827
that	O
are	O
associated	B-C0332281
with	I-C0332281
a	O
legionnaires'	B-C0023241
disease	I-C0023241
outbreak	B-C0012652
in	O
new	B-C0027976
york	I-C0027976
in	O
2012	O
.	O
	
two	O
clinical	B-C0205210
isolates	B-C1764827
d7630	B-C0023238
and	O
d7632	B-C0023238
and	O
one	O
environmental	B-C0014406
isolate	B-C1764827
d7631	B-C0023238
were	O
recovered	B-C0521108
from	O
this	O
outbreak	B-C0012652
.	O
	
a	O
single	O
isolate-specific	B-C1764827
virulence	B-C0042765
gene	B-C0017337
was	O
found	O
in	O
d7632	B-C0023238
.	O
	
these	O
isolates	B-C1764827
were	O
included	O
in	O
a	O
large	O
study	O
evaluating	B-C0220825
the	O
genomic	B-C0017428
resolution	B-C2699488
of	O
various	O
bioinformatics	B-C1140694
approaches	B-C1292724
for	O
l	B-C0023238
.	O
	
pneumophila	I-C0023238
serogroup	B-C0449543
1	I-C0449543
isolates	B-C1764827
.	O
	
complete	O
genome	B-C3854164
sequence	I-C3854164
analysis	I-C3854164
of	O
a	O
naturally	O
reassorted	O
infectious	B-C0021338
bursal	I-C0021338
disease	I-C0021338
virus	I-C0021338
from	O
india	B-C0021201
the	O
novel	O
infectious	B-C0021338
bursal	I-C0021338
disease	I-C0021338
virus	I-C0021338
ibdv	B-C0021338
isolate	B-C3494870
bge14/abt1/mvc/india	B-C0021338
is	O
a	O
very	O
virulent	B-C1520022
ibdv	B-C0021338
that	O
was	O
isolated	B-C3494870
from	O
broiler	B-C0005595
flocks	I-C0005595
in	O
southern	O
parts	O
of	O
india	B-C0021201
during	O
2014	O
.	O
	
here	O
,	O
we	O
report	O
,	O
for	O
the	O
first	O
time	O
in	O
india	B-C0021201
,	O
the	O
complete	O
genome	B-C0017428
sequence	I-C0017428
of	O
bge14/abt1/mvc/india	B-C0021338
,	O
a	O
reassortment	O
strain	B-C1518614
with	O
segments	B-C0017428
a	I-C0017428
and	I-C0017428
b	I-C0017428
derived	O
from	O
a	O
very	O
virulent	B-C1520022
ibdv	B-C0021338
strain	B-C1518614
and	O
an	O
attenuated	B-C0599946
ibdv	B-C0021338
,	O
respectively	O
.	O
	
the	O
findings	O
from	O
this	O
study	O
provide	O
additional	O
insight	O
into	O
the	O
genetic	B-C1749881
exchange	I-C1749881
between	O
attenuated	B-C0599946
and	O
very	O
virulent	B-C1520022
strains	B-C1518614
of	O
ibdv	B-C0021338
circulating	B-C0175630
in	B-C3539073
the	I-C3539073
field	I-C3539073
.	O
	
patient	B-C0030702
satisfaction	I-C0030702
with	O
postpartum	B-C0086839
teaching	B-C0220924
methods	B-C0025663
postpartum	B-C0086839
discharge	B-C4282220
instructions	I-C4282220
are	O
a	O
crucial	O
part	O
of	O
a	O
mother's	B-C0026591
birth	B-C0005615
experience	B-C0596545
.	O
	
finding	B-C0243095
the	O
method	B-C0025663
to	O
provide	O
those	O
discharge	B-C4282220
instructions	I-C4282220
in	O
a	O
manner	O
that	O
increases	B-C0442805
the	O
mother's	B-C0026591
satisfaction	B-C0242428
with	O
her	O
hospital	B-C0019994
experience	B-C0596545
is	O
important	O
.	O
	
this	O
quasi-experimental	B-C2985410
study	I-C2985410
examined	B-C0332128
the	O
relationship	B-C0439849
between	O
new	B-C0205314
mothers'	B-C0026591
interaction	B-C0037420
with	O
nurses	B-C0028661
providing	O
postpartum	B-C0086839
instructions	B-C1442085
by	O
the	O
traditional	B-C0443324
and	O
class	O
methods	B-C0025663
and	O
their	O
satisfaction	B-C0242428
with	O
discharge	B-C0514209
teaching	I-C0514209
.	O
	
the	O
results	O
indicated	O
new	B-C0205314
mothers	B-C0026591
were	O
satisfied	B-C0242428
with	O
both	O
methods	B-C0025663
of	O
discharge	B-C0514209
teaching	I-C0514209
however	O
,	O
they	O
were	O
more	O
likely	O
to	O
report	O
stronger	O
agreement	B-C0680240
with	O
overall	O
satisfaction	B-C0242428
with	O
the	O
traditional	B-C0443324
method	B-C0025663
of	O
discharge	B-C0514209
teaching	I-C0514209
than	O
with	O
attending	B-C1999232
the	O
discharge	B-C0514209
class	I-C0514209
.	O
	
splicing	B-C0035687
variants	O
of	O
adar2	B-C0001457
and	O
adar2	B-C0001457
-mediated	O
rna	B-C0162782
editing	I-C0162782
in	O
glioma	B-C0017638
the	O
roles	O
of	O
alternative	B-C0002345
splicing	I-C0002345
and	O
rna	B-C0162782
editing	I-C0162782
in	O
gene	B-C0017263
regulation	I-C0017263
and	O
transcriptome	B-C3178810
diversity	O
are	O
well	O
documented	O
.	O
	
adenosine	B-C0001457
deaminases	I-C0001457
acting	O
on	O
rna	B-C0035668
adars	B-C0001457
are	O
responsible	O
for	O
adenosine-to-inosine	B-C1158747
a-to-i	I-C1158747
editing	I-C1158747
and	O
exemplify	O
the	O
complex	O
association	O
between	O
rna	B-C0162782
editing	I-C0162782
and	O
alternative	B-C0002345
splicing	I-C0002345
.	O
	
the	O
self-editing	B-C0162782
activity	O
of	O
adar2	B-C0001457
,	O
which	O
acts	O
on	O
its	O
own	O
pre-mrna	B-C0026661
,	O
leads	O
to	O
its	O
alternative	B-C0002345
splicing	I-C0002345
.	O
	
alternative	B-C0002345
splicing	I-C0002345
occurs	O
independently	O
at	O
nine	O
splicing	B-C0035687
sites	O
on	O
adar2	B-C0001457
pre-mrna	B-C0026661
,	O
generating	O
numerous	O
alternative	B-C0002345
splicing	I-C0002345
variants	O
with	O
various	O
catalytic	B-C0243102
activities	I-C0243102
.	O
	
a-to-i	B-C1158747
rna	I-C1158747
editing	I-C1158747
is	O
important	O
in	O
a	O
range	O
of	O
physiological	B-C0031845
processes	I-C0031845
in	O
humans	B-C0086418
and	O
is	O
associated	O
with	O
several	O
diseases	B-C0012634
,	O
including	O
amyotrophic	B-C0002736
lateral	I-C0002736
sclerosis	I-C0002736
,	O
mood	B-C0525045
disorders	I-C0525045
,	O
epilepsy	B-C0014544
and	O
glioma	B-C0017638
.	O
	
reduced	O
editing	B-C0162782
at	O
the	O
glutamine	B-C0017797
/	O
arginine	B-C0003765
site	O
of	O
the	O
ampa	B-C0536483
receptor	I-C0536483
subunit	I-C0536483
glua2	I-C0536483
in	O
glioma	B-C0017638
,	O
without	O
any	O
alteration	O
in	O
adar2	B-C0001457
expression	B-C1171362
,	O
is	O
a	O
notable	O
phenomenon	O
.	O
	
several	O
studies	O
have	O
tried	O
to	O
explain	O
this	O
alteration	B-C1515926
in	O
the	O
catalytic	B-C0243102
activity	I-C0243102
of	O
adar2	B-C0001457
however	O
,	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O
	
the	O
present	O
review	B-C0282443
summarizes	O
the	O
relevant	O
literature	B-C0023866
and	O
shares	O
experimental	B-C2825142
results	I-C2825142
concerning	O
adar2	B-C0001457
alternative	B-C0002345
splicing	I-C0002345
.	O
	
in	O
particular	O
,	O
the	O
present	O
review	B-C0282443
demonstrates	O
that	O
shifts	O
in	O
the	O
relative	O
abundance	O
of	O
the	O
active	O
and	O
inactive	O
splicing	B-C0035687
variants	O
of	O
adar2	B-C0001457
may	O
reduce	O
the	O
adar2	B-C0001457
editing	B-C0162782
activity	O
in	O
glioma	B-C0017638
.	O
	
dominant	O
expression	B-C1171362
of	O
adar2	B-C0001457
splicing	B-C0035687
variant	O
with	O
low	O
enzyme	B-C0243102
activity	I-C0243102
causes	O
reduced	O
rna	B-C0162782
editing	I-C0162782
of	O
glua2	B-C0536483
subunit	I-C0536483
at	O
the	O
glutamine	B-C0017797
/	O
arginine	B-C0003765
site	O
in	O
heat-shock	B-C0109272
protein	I-C0109272
60	I-C0109272
of	O
porphyromonas	B-C0085478
gingivalis	I-C0085478
may	O
induce	O
dysfunction	B-C3887504
of	O
human	B-C3179121
umbilical	I-C3179121
endothelial	I-C3179121
cells	I-C3179121
via	O
regulation	B-C1327622
of	O
endothelial-nitric	B-C0669365
oxide	I-C0669365
synthase	I-C0669365
and	O
vascular	B-C0300423
endothelial-cadherin	I-C0300423
accumulating	O
evidence	O
has	O
established	O
that	O
periodontitis	B-C0031099
was	O
an	O
independent	O
risk	B-C0035648
factor	I-C0035648
for	O
coronary	B-C0010068
heart	I-C0010068
disease	I-C0010068
cad	B-C0010068
.	O
	
porphyromonus	B-C0085478
gingivalis	I-C0085478
p	B-C0085478
.	O
	
gingivalis	I-C0085478
,	O
a	O
major	O
periodontal	B-C0332275
pathogen	B-C0450254
,	O
has	O
already	O
been	O
shown	O
to	O
have	O
a	O
significant	O
role	O
in	O
the	O
inflammatory	B-C1155266
response	I-C1155266
of	O
cad	B-C0010068
in	B-C1515655
vivo	I-C1515655
.	O
	
the	O
aim	O
of	O
the	O
present	O
study	B-C2603343
was	O
to	O
identify	O
whether	O
p	B-C0085478
.	O
	
gingivalis	I-C0085478
heat-shock	B-C0109272
protein	I-C0109272
60	I-C0109272
hsp60	B-C0109272
induced	O
the	O
dysfunction	B-C3887504
of	O
human	B-C3179121
umbilical	I-C3179121
vein	I-C3179121
endothelial	I-C3179121
cells	I-C3179121
huvecs	B-C3179121
in	B-C1533691
vitro	I-C1533691
.	O
	
huvecs	B-C3179121
were	O
stimulated	B-C1948023
with	O
a	O
range	O
of	O
p	B-C0085478
.	O
	
gingivalis	I-C0085478
hsp60	B-C0109272
concentrations	B-C0392762
1	O
,	O
10	O
and	O
100	O
ng/l	O
at	O
different	O
time-points	B-C2348792
.	O
	
the	O
levels	B-C0441889
of	O
vascular	B-C0300423
endothelial	I-C0300423
ve	I-C0300423
,	O
endothelial	B-C0669365
nitric	I-C0669365
oxide	I-C0669365
synthase	I-C0669365
enos	B-C0669365
and	O
cysteinyl	B-C0291573
aspartate-specific	I-C0291573
protease-3	I-C0291573
caspase-3	B-C0291573
were	O
measured	O
using	O
western	B-C0949466
blot	I-C0949466
analysis	B-C0936012
.	O
	
the	O
apoptotic	B-C0162638
rate	B-C1521828
of	O
huvecs	B-C3179121
was	O
detected	O
using	O
flow	B-C0016263
cytometry	I-C0016263
.	O
	
p	B-C0085478
.	O
	
gingivalis	I-C0085478
hsp60	B-C0109272
at	O
a	O
concentration	B-C0392762
of	O
10	O
ng/l	O
significantly	O
decreased	O
the	O
expression	B-C1171362
levels	B-C0441889
of	O
ve-cadherin	B-C0300423
and	O
enos	B-C0669365
protein	I-C0669365
at	O
24	O
h	B-C0439227
stimulation	B-C1948023
,	O
whereas	O
no	O
difference	O
in	O
these	O
proteins	B-C0033684
was	O
identified	O
following	O
a	O
low	B-C0445550
dose	I-C0445550
of	O
p	B-C0085478
.	O
	
gingivalis	I-C0085478
hsp60	B-C0109272
1	O
ng/l	O
.	O
	
p	B-C0085478
.	O
	
gingivalis	I-C0085478
hsp60	B-C0109272
at	O
100	O
ng/l	O
significantly	O
downregulated	B-C0013081
the	O
expression	B-C1171362
levels	B-C0441889
of	O
ve-cadherin	B-C0300423
and	O
enos	B-C0669365
protein	I-C0669365
at	O
12	O
h	O
in	O
huvecs	B-C3179121
.	O
	
however	O
,	O
the	O
cleavage	B-C0596311
of	O
caspase-3	B-C0291573
showed	O
an	O
opposing	O
change	O
at	O
different	O
concentrations	B-C0392762
.	O
	
consistently	O
,	O
p	B-C0085478
.	O
	
gingivalis	I-C0085478
hsp60	B-C0109272
induced	O
apoptosis	B-C0162638
of	O
huvecs	B-C3179121
in	O
a	O
concentration	B-C0392762
-	O
dependent	B-C3244310
manner	O
.	O
	
these	O
results	B-C1274040
indicated	O
that	O
p	B-C0085478
.	O
	
gingivalis	I-C0085478
hsp60	B-C0109272
may	O
induce	O
dysfunction	B-C3887504
and	O
apoptosis	B-C0162638
in	O
huvecs	B-C3179121
via	O
downregulating	B-C0013081
the	O
expression	B-C1171362
levels	B-C0441889
of	O
ve-cadherin	B-C0300423
and	O
enos	B-C0669365
,	O
and	O
promoting	O
the	O
cleavage	B-C0596311
of	O
estradiol	B-C0014912
prodrugs	B-C0033262
ep	B-C0033262
for	O
efficient	O
oral	B-C0001563
estrogen	B-C3173348
treatment	I-C3173348
and	O
abolished	O
effects	O
on	O
estrogen	B-C0014939
modulated	O
liver	B-C0232741
functions	I-C0232741
oral	B-C0001563
compared	O
to	O
parenteral	B-C0259961
estrogen	B-C3173348
administration	I-C3173348
is	O
characterized	O
by	O
reduced	O
systemic	B-C0205373
but	O
prominent	O
hepatic	B-C0205054
estrogenic	B-C0877035
effects	I-C0877035
on	O
lipids	B-C0023779
,	O
hemostatic	B-C0019116
factors	I-C0019116
,	O
gh	B-C0037663
-/	O
igf	B-C0021665
i	I-C0021665
axis	O
,	O
angiotensinogen	B-C0003017
.	O
	
in	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	B-C2945675
effects	I-C2945675
of	O
oral	B-C0001563
treatment	I-C0001563
,	O
estradiol	B-C0014912
e2	B-C0014912
prodrugs	B-C0033262
ep	B-C0033262
were	O
designed	O
which	O
bypass	O
the	O
liver	B-C0736268
tissue	I-C0736268
as	O
inactive	O
molecules	O
.	O
	
carbone17-oh	B-C1254350
sulfonamide	I-C1254350
-o2-nh2	I-C1254350
substituted	I-C1254350
esters	I-C1254350
of	O
e2	B-C0014912
ec508	B-C0014912
,	O
others	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	B-C0007034
anhydrase	I-C0007034
ii	I-C0007034
ca-ii	B-C0007034
binding	B-C1149286
.	O
	
ca	B-C0007034
ii	I-C0007034
in	O
erythrocytes	B-C0014792
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
ep	B-C0033262
from	O
portal	B-C2324289
vein	I-C2324289
blood	I-C2324289
during	O
liver	B-C0023884
passage	B-C0439799
.	O
	
ovariectomized	B-C3687559
ovx	B-C3687559
,	O
day	O
minus	O
14	O
rats	B-C0034721
were	O
orally	B-C0001563
treated	I-C0001563
once	O
daily	O
from	O
day	O
1-3	O
.	O
	
sacrifice	O
day	O
4	O
.	O
	
uteri	B-C0042149
were	O
dissected	B-C0205239
and	O
weighed	B-C3827964
.	O
	
cholesterol	B-C0201950
fractions	I-C0201950
and	O
angiotensinogen	B-C0523500
were	O
determined	O
in	O
plasma	B-C0032105
.	O
	
oral	B-C0360514
e2	I-C0360514
and	O
ethinyl	B-C0015011
estradiol	I-C0015011
ee	B-C0015011
generated	O
dose	O
related	O
uterine	B-C0042149
growth	B-C0018270
and	O
important	O
hepatic	B-C0205054
estrogenic	B-C0877035
effects	I-C0877035
.	O
	
ep	B-C0033262
induced	O
uterine	B-C1326619
growth	I-C1326619
at	O
about	O
hundred-fold	O
lower	O
doses	O
.	O
	
this	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	B-C0032105
cholesterol	B-C0008377
or	O
angiotensinogen	B-C0003017
.	O
	
preliminary	O
pharmacokinetic	B-C0201734
studies	I-C0201734
with	O
ec508	B-C0014912
used	O
intravenous	B-C0013125
and	O
oral	B-C0001563
administration	I-C0001563
in	O
male	B-C0086582
rats	B-C0034721
.	O
	
resulting	O
blood	O
levels	O
revealed	O
complete	O
oral	B-C0001563
bioavailability	B-C0005508
.	O
	
further	O
high	O
blood	B-C0005767
-	O
but	O
low	O
plasma	B-C0032105
concentrations	O
indicated	O
erythrocyte	B-C0014792
binding	B-C1145667
of	O
ec508	B-C0014912
in	B-C1515655
vivo	I-C1515655
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	B-C0023884
passage	B-C0439799
.	O
	
very	O
high	O
systemic	B-C0205373
estrogenicity	B-C0014939
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	B-C0205054
estrogenic	B-C0877035
effects	I-C0877035
is	O
evidence	O
for	O
a	O
systemic	B-C0205373
release	O
of	O
e2	B-C0014912
from	O
sulfonamide	B-C0033262
ep	I-C0033262
.	O
	
in	O
conclusion	O
,	O
tested	O
oral	B-C0001563
ep	B-C0033262
bypass	O
the	O
liver	B-C0023884
in	O
erythrocytes	B-C0014792
furnishing	O
systemic	B-C0205373
estradiol	B-C0014912
at	O
hydrolysis	B-C0020291
.	O
	
this	O
mechanism	O
avoids	O
the	O
hepatic	B-C0205054
estrogenic	B-C0720298
impact	O
of	O
conventional	O
oral	B-C0001563
estrogen	B-C0279494
therapy	I-C0279494
.	O
	
differences	B-C1705242
in	O
pain	B-C0030193
experience	B-C0596545
and	O
cooperation	B-C1321605
between	O
consecutive	B-C0543467
surgeries	I-C0543467
in	O
patients	B-C0030705
undergoing	O
phacoemulsification	B-C0282545
the	O
purpose	O
of	O
this	O
study	B-C2603343
is	O
to	O
compare	O
pain	B-C0030193
experience	B-C0596545
and	O
cooperation	B-C1321605
between	O
consecutive	B-C0543467
surgeries	I-C0543467
in	O
patients	B-C0030705
undergoing	O
phacoemulsification	B-C0282545
in	O
both	O
eyes	B-C0015392
,	O
using	O
sub-tenon's	B-C0002921
local	I-C0002921
anesthesia	I-C0002921
without	O
sedation	B-C0344106
.	O
	
in	O
this	O
study	B-C2603343
,	O
268	O
patients	B-C0030705
with	O
bilateral	B-C3864031
senile	I-C3864031
cataracts	I-C3864031
were	O
recruited	O
.	O
	
all	O
operations	B-C0543467
were	O
performed	O
without	O
sedation	B-C0344106
,	O
using	O
a	O
clear	O
corneal	B-C0010031
phacoemulsification	B-C0282545
technique	I-C0282545
and	O
sub-tenon's	B-C0002921
local	I-C0002921
anesthesia	I-C0002921
,	O
by	O
one	O
of	O
four	O
surgeons	B-C0582175
.	O
	
the	O
first	O
surgery	B-C0543467
was	O
performed	O
on	O
the	O
eye	B-C0015392
with	O
the	O
higher	O
grade	O
cataract	B-C0086543
.	O
	
the	O
other	O
eye	B-C0015392
was	O
operated	B-C3241922
on	O
within	O
3	B-C1442461
months	I-C1442461
by	O
the	O
same	O
surgeon	B-C0582175
mean	O
interval	O
1.9	O
1.1	O
months	B-C0439231
.	O
	
all	O
patients	B-C0030705
were	O
asked	O
to	O
grade	O
their	O
pain	B-C0030193
experience	B-C0596545
during	O
induction	B-C0857127
and	O
maintenance	B-C0024501
of	O
anesthesia	B-C0002903
and	O
also	O
during	O
the	O
phacoemulsification	B-C0282545
surgery	I-C0282545
,	O
using	O
a	O
visual	B-C0042815
analogue	I-C0042815
scale	I-C0042815
vas	B-C0042815
from	O
0	O
no	B-C3891813
pain	I-C3891813
to	O
10	O
unbearable	B-C3640014
pain	I-C3640014
administered	O
after	O
the	O
surgery	B-C0543467
.	O
	
the	O
cooperation	B-C1321605
of	O
the	O
patient	B-C0030705
was	O
graded	O
from	O
0	O
no	O
event	O
to	O
3	O
markedeye	B-C0015413
and	O
head	B-C0376591
movement	I-C0376591
and	O
lid	B-C0850674
squeezing	I-C0850674
by	O
the	O
attending	O
surgeon	B-C0582175
.	O
	
the	O
vas	B-C2732809
scores	I-C2732809
and	O
cooperation	B-C1321605
scores	B-C0449820
of	O
the	O
patients	B-C0030705
were	O
the	O
outcome	B-C0086749
measurements	I-C0086749
.	O
	
the	O
mean	B-C0582148
pain	I-C0582148
score	I-C0582148
was	O
2.11	O
0.79	O
in	O
the	O
first	O
eye	B-C0015392
and	O
3.33	O
0.80	O
in	O
the	O
second	O
eye	B-C0015392
during	O
the	O
administration	B-C1533734
of	O
sub-tenon's	B-C0002921
anesthesia	I-C0002921
,	O
and	O
1.50	O
0.60	O
in	O
the	O
first	O
eye	B-C0015392
and	O
2.10	O
0.57	O
in	O
the	O
second	O
eye	B-C0015392
during	O
the	O
phacoemulsification	B-C0282545
surgery	I-C0282545
.	O
	
the	O
patient	B-C1321605
cooperation	I-C1321605
score	B-C0449820
was	O
1.60	O
0.75	O
in	O
the	O
first	O
surgery	B-C0543467
and	O
2.08	O
0.72	O
in	O
the	O
second	O
surgery	B-C0543467
.	O
	
the	O
differences	B-C1705242
between	O
the	O
first	O
and	O
second	O
surgeries	B-C0543467
were	O
statistically	O
significant	O
for	O
all	O
outcome	B-C0086749
measures	I-C0086749
p	O
<	O
0.01	O
.	O
	
patients	B-C0030705
who	O
previously	O
underwent	O
phaco	B-C0282545
surgery	I-C0282545
in	O
one	O
eye	B-C0015392
experienced	O
more	O
pain	B-C0030193
and	O
showed	O
worse	B-C1457868
cooperation	B-C1321605
during	O
the	O
phaco	B-C0282545
surgery	I-C0282545
in	O
the	O
second	O
eye	B-C0015392
,	O
especially	O
if	O
there	O
was	O
a	O
short	O
time	O
between	O
the	O
surgeries	B-C0543467
,	O
viz	O
,	O
less	O
than	O
3	O
months	B-C0439231
.	O
	
therefore	O
,	O
if	O
the	O
surgeon	B-C0582175
has	O
difficulty	B-C0332218
in	O
the	O
first	O
operation	B-C0543467
gaining	O
the	O
patient's	B-C1321605
cooperation	I-C1321605
,	O
the	O
surgeon	B-C0582175
must	O
be	O
careful	O
if	O
contralateral	B-C0038901
eye	I-C0038901
surgery	I-C0038901
is	O
required	O
,	O
the	O
addition	O
of	O
sedation	B-C0344106
/	O
analgesia	B-C3202977
should	O
be	O
considered	O
or	O
the	O
surgery	B-C0543467
postponed	O
for	O
a	O
while	O
to	O
abolish	O
the	O
influence	B-C4054723
of	O
recent	B-C0233792
memory	I-C0233792
on	O
the	O
patient's	B-C0030705
subsequent	O
pain	B-C0030193
experience	B-C0596545
.	O
	
co-chip	B-C1328856
enables	O
genome-wide	B-C0079435
mapping	I-C0079435
of	O
histone	B-C1257775
mark	I-C1257775
co-occurrence	B-C2745955
at	O
single-molecule	B-C2699488
resolution	I-C2699488
histone	B-C1156199
modifications	I-C1156199
play	O
an	O
important	B-C3898777
role	B-C1705810
in	O
chromatin	B-C1156187
organization	I-C1156187
and	O
transcriptional	B-C1158770
regulation	I-C1158770
,	O
but	O
despite	O
the	O
large	B-C3869890
amount	I-C3869890
of	O
genome-wide	B-C0017428
histone	B-C1156199
modification	I-C1156199
data	B-C1511726
collected	B-C1516695
in	O
different	B-C1705242
cells	B-C0007634
and	O
tissues	B-C0040300
,	O
little	O
is	O
known	O
about	O
co-occurrence	B-C2745955
of	O
modifications	B-C1156199
on	O
the	O
same	O
nucleosome	B-C0028623
.	O
	
here	O
we	O
present	B-C0449450
a	O
genome-wide	B-C1510568
quantitative	I-C1510568
method	I-C1510568
for	O
combinatorial	B-C0918012
indexed	I-C0918012
chromatin	B-C1328856
immunoprecipitation	I-C1328856
co-chip	B-C1328856
to	O
characterize	O
co-occurrence	B-C2745955
of	O
histone	B-C1156199
modifications	I-C1156199
on	O
nucleosomes	B-C0028623
.	O
	
using	O
co-chip	B-C1328856
,	O
we	O
study	B-C0681814
the	O
genome-wide	B-C0017428
co-occurrence	B-C2745955
of	O
14	O
chromatin	B-C1257775
marks	I-C1257775
70	O
pairwise	B-C0205195
combinations	I-C0205195
,	O
and	O
find	O
previously	O
undescribed	O
co-occurrence	B-C2745955
patterns	B-C0449774
,	O
including	O
the	O
co-occurrence	B-C2745955
of	O
h3k9me1	B-C0314621
and	O
h3k27ac	B-C0314621
in	O
super-enhancers	B-C0004793
.	O
	
finally	O
,	O
we	O
apply	B-C4048755
co-chip	B-C1328856
to	O
measure	B-C0079809
the	O
distribution	B-C1704711
of	O
the	O
bivalent	B-C0392762
h3k4me3	B-C0314621
-	O
h3k27me3	B-C0314621
domains	B-C1514562
in	O
two	O
distinct	O
mouse	B-C4042879
embryonic	I-C4042879
stem	I-C4042879
cell	I-C4042879
mesc	B-C4042879
states	O
and	O
in	O
four	O
adult	B-C0040300
tissues	I-C0040300
.	O
	
we	O
observe	B-C1441672
dynamic	B-C0729333
changes	B-C0443172
in	O
5	O
regions	O
and	O
discover	B-C1880355
both	O
loss	B-C1517945
and	O
de	B-C1515568
novo	I-C1515568
gain	B-C1517378
of	O
bivalency	B-C0392762
in	O
key	O
tissue-specific	B-C1955394
regulatory	B-C0017362
genes	I-C0017362
,	O
suggesting	B-C1705535
a	O
functional	B-C1705810
role	I-C1705810
for	O
bivalent	B-C0392762
domains	B-C1514562
during	O
different	O
stages	B-C1306673
of	O
development	B-C1527148
.	O
	
these	O
results	B-C0683954
show	O
that	O
co-chip	B-C1328856
can	O
reveal	B-C0443289
the	O
complex	B-C1704675
interactions	I-C1704675
between	O
histone	B-C1156199
modifications	I-C1156199
.	O
	
hand-assisted	B-C2936499
laparoscopic	I-C2936499
versus	O
standard	B-C1517722
laparoscopic	I-C1517722
colectomy	I-C1517722
are	O
outcomes	B-C0085415
and	O
operative	B-C3494201
time	I-C3494201
different	O
hal	B-C2936499
colectomy	B-C0009274
is	O
a	O
technique	B-C0449851
perceived	O
to	O
provide	O
the	O
benefits	O
of	O
laparoscopic	B-C0751429
surgery	I-C0751429
while	O
improving	O
tactile	O
feedback	O
and	O
operative	B-C3494201
time	I-C3494201
.	O
	
published	O
data	B-C1511726
are	O
largely	O
limited	O
to	O
small	O
,	O
single-institution	B-C2603343
studies	I-C2603343
.	O
	
the	O
2012-2013	O
national	B-C0242193
surgical	I-C0242193
quality	I-C0242193
improvement	I-C0242193
program	I-C0242193
participant	I-C0242193
data	I-C0242193
use	I-C0242193
file	I-C0242193
was	O
queried	O
for	O
patients	B-C0030705
undergoing	O
elective	O
sl	B-C1517722
or	O
hal	B-C2936499
colectomy	B-C0009274
.	O
	
patients	B-C0030705
underwent	O
1	O
propensity	O
matching	O
and	O
had	O
outcomes	B-C0085415
compared	O
.	O
	
an	O
additional	O
subgroup	B-C0936012
analysis	I-C0936012
was	O
performed	O
for	O
patients	B-C0030705
undergoing	O
segmental	B-C0205122
resections	B-C0015252
only	O
.	O
	
13	O
patients	B-C0030705
were	O
identified	O
,	O
of	O
whom	O
6084	O
43.6	O
%	O
underwent	O
hal	B-C2936499
colectomy	B-C0009274
.	O
	
patients	B-C0030705
undergoing	O
hal	B-C2936499
versus	O
sl	B-C1517722
colectomy	I-C1517722
had	O
higher	O
rates	B-C1521828
of	O
postoperative	B-C0400877
ileus	I-C0400877
8.7	O
vs	O
.	O
	
6.3	O
%	O
,	O
p	O
<	O
0.001	O
,	O
wound	B-C1096106
complication	I-C1096106
8.8	O
vs	O
.	O
	
6.8	O
%	O
,	O
p	O
=	O
0.006	O
,	O
and	O
30-	O
day	B-C0439228
readmission	B-C0030700
7.5	O
vs	O
.	O
	
6.0	O
%	O
,	O
p	O
=	O
0.002	O
,	O
without	O
any	O
differences	O
in	O
operative	B-C3494201
time	I-C3494201
156	O
vs	O
.	O
	
157	O
min	O
,	O
p	O
=	O
0.713	O
.	O
	
amongst	O
segmental	B-C0205122
colectomies	B-C0009274
,	O
hal	B-C2936499
remained	O
associated	O
with	O
higher	O
rates	B-C1521828
of	O
wound	B-C1096106
complications	I-C1096106
8.6	O
vs	O
.	O
	
6.5	O
%	O
,	O
p	O
=	O
0.016	O
,	O
postoperative	B-C0400877
ileus	I-C0400877
8.9	O
vs	O
.	O
	
6.3	O
%	O
,	O
p	O
<	O
0.001	O
,	O
and	O
30-	O
day	B-C0439228
readmission	B-C0030700
7.1	O
vs	O
.	O
	
5.9	O
%	O
,	O
p	O
=	O
0.041	O
with	O
no	O
difference	O
in	O
operative	B-C3494201
time	I-C3494201
between	O
hal	B-C2936499
and	O
sl	O
145	O
vs	O
.	O
	
145	O
min	O
,	O
p	O
=	O
0.334	O
.	O
	
use	O
of	O
hal	B-C2936499
colectomy	B-C0009274
is	O
associated	O
with	O
increased	O
risk	B-C0086930
of	O
wound	B-C1096106
complications	I-C1096106
,	O
postoperative	B-C0400877
ileus	I-C0400877
,	O
and	O
readmissions	B-C0030700
.	O
	
importantly	O
,	O
this	O
technique	B-C0449851
is	O
not	O
associated	O
with	O
any	O
decrease	O
in	O
operative	B-C3494201
time	I-C3494201
.	O
	
safety	B-C0036043
and	O
immunogenecity	B-C4054739
of	O
a	O
live	O
attenuated	B-C0042211
rift	B-C1548485
valley	I-C1548485
fever	I-C1548485
vaccine	I-C1548485
cl13t	B-C1548485
in	O
camels	B-C0006801
rift	B-C0035613
valley	I-C0035613
fever	I-C0035613
is	O
an	O
emerging	O
zoonotic	B-C1628327
viral	B-C0042769
disease	I-C0042769
,	O
enzootic	B-C0277551
and	O
endemic	B-C0277550
in	O
africa	B-C0001737
and	O
the	O
arabian	B-C0003671
peninsula	I-C0003671
,	O
which	O
poses	O
a	O
significant	B-C0750502
threat	B-C0749385
to	O
both	O
human	B-C0086418
and	O
animal	B-C0003062
health	B-C3534575
.	O
	
the	O
disease	B-C0035613
is	O
most	O
severe	B-C0205082
in	O
ruminants	B-C0035950
causing	B-C0678227
abortions	B-C0149814
in	O
pregnant	B-C0032961
animals	B-C0003062
,	O
especially	O
sheep	B-C0036945
animals	I-C0036945
and	O
high	O
mortality	B-C0205848
in	O
young	B-C0332239
populations	B-C1257890
.	O
	
high	O
mortality	B-C0205848
rates	I-C0205848
and	O
severe	B-C0205082
clinical	B-C0205210
manifestation	B-C1280464
have	O
also	O
been	O
reported	B-C0684224
among	O
camel	B-C0006801
populations	B-C1257890
in	O
africa	B-C0001737
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	B-C0521116
available	B-C0470187
live	B-C0042211
vaccines	I-C0042211
against	O
rvf	B-C0035613
have	O
been	O
tested	B-C0039593
for	O
safety	B-C0036043
and	O
efficacy	B-C1280519
in	O
this	O
species	B-C1705920
.	O
	
in	O
this	O
study	B-C2603343
,	O
the	O
safety	B-C0036043
and	O
efficacy	B-C1280519
through	O
a	O
neutralizing	B-C0475463
antibody	I-C0475463
response	B-C0871261
of	O
the	O
thermostable	B-C0042211
live	I-C0042211
attenuated	I-C0042211
rvf	B-C1548485
cl13t	I-C1548485
vaccine	I-C1548485
were	O
evaluated	B-C0220825
in	O
camels	B-C0006801
in	O
two	O
different	B-C1705242
preliminary	B-C0439611
experiments	B-C0681814
involving	O
16	O
camels	B-C0006801
,	O
that	O
12	O
camels	B-C0006801
and	O
4	O
pregnant	B-C0032961
camels	B-C0006801
.	O
	
the	O
study	B-C2603343
revealed	B-C0443289
that	O
the	O
cl13t	B-C1548485
vaccine	I-C1548485
was	O
safe	B-C0036043
to	O
use	B-C0457083
in	O
camels	B-C0006801
and	O
no	O
abortions	B-C0149814
or	O
teratogenic	B-C0232910
effects	I-C0232910
were	O
observed	B-C1441672
.	O
	
the	O
single	O
dose	B-C0178602
of	O
the	O
vaccine	B-C0042211
stimulated	O
a	O
strong	B-C0442821
and	O
long-lasting	O
neutralizing	B-C0475463
antibody	I-C0475463
response	B-C0871261
for	O
up	O
to	O
12	O
months	B-C0439231
.	O
	
the	O
presence	B-C0150312
of	O
neutralization	B-C0475463
antibodies	I-C0475463
is	O
likely	O
to	O
correlate	B-C0332281
with	I-C0332281
protection	B-C1545588
however	O
protection	B-C1545588
would	O
need	O
to	O
be	O
confirmed	B-C0521093
by	I-C0521093
challenge	O
experiments	B-C0681814
using	O
the	O
virulent	B-C1520022
rvf	B-C0035614
virus	I-C0035614
.	O
	
autoantibodies	B-C0004358
to	O
mog	B-C0069428
in	O
a	O
distinct	O
subgroup	B-C1515021
of	O
adult	B-C0001675
multiple	B-C0026769
sclerosis	I-C0026769
to	O
evaluate	B-C0220825
the	O
presence	O
of	O
antibodies	B-C0003241
to	O
conformation	B-C0033625
-intact	O
myelin	B-C0069428
oligodendrocyte	I-C0069428
glycoprotein	I-C0069428
mog	B-C0069428
in	O
a	O
subgroup	B-C1515021
of	O
adult	B-C0001675
patients	B-C0030705
with	O
clinically	B-C0205210
definite	O
multiple	B-C0026769
sclerosis	I-C0026769
ms	B-C0026769
preselected	O
for	O
a	O
specific	O
clinical	B-C0205210
phenotype	B-C0031437
including	O
severe	B-C0205082
spinal	B-C0037925
cord	I-C0037925
,	O
optic	B-C0029130
nerve	I-C0029130
,	O
and	O
brainstem	B-C0006121
involvement	O
.	O
	
antibodies	B-C0003241
to	O
mog	B-C0069428
were	O
investigated	B-C1292732
using	O
a	O
cell-based	B-C0005507
assay	I-C0005507
in	O
3	O
groups	B-C1257890
of	O
patients	B-C0030705
104	O
preselected	O
patients	B-C0030705
with	O
ms	B-C0026769
group	B-C1257890
1	I-C1257890
,	O
55	O
age	B-C0001779
-	O
and	O
sex	B-C0079399
-matched	O
,	O
otherwise	O
unselected	O
patients	B-C0030705
with	O
ms	B-C0026769
group	B-C1257890
2	I-C1257890
,	O
and	O
in	O
22	O
brain-biopsied	B-C0740294
patients	B-C0030705
with	O
demyelinating	B-C0011303
diseases	I-C0011303
of	O
the	O
cns	B-C3714787
n	O
=	O
19	O
with	O
ms	B-C0026769
,	O
4	O
of	O
whom	O
classified	B-C0008902
as	O
ms	B-C0026769
type	I-C0026769
ii	I-C0026769
group	B-C1257890
3	I-C1257890
.	O
	
recognized	O
epitopes	B-C0003316
were	O
identified	O
with	O
mutated	B-C0596611
variants	B-C0678941
of	O
mog	B-C1417228
.	O
	
antibodies	B-C0003241
to	O
mog	B-C0069428
were	O
found	O
in	O
about	O
5%	O
5/104	O
of	O
preselected	O
adult	B-C0001675
patients	B-C0030705
with	O
ms	B-C0026769
.	O
	
in	O
contrast	O
,	O
in	O
groups	B-C1257890
2	I-C1257890
and	O
3	B-C1257890
,	O
none	O
of	O
the	O
patients	B-C0030705
tested	B-C0039593
positive	O
for	O
mog	B-C0069428
antibodies	B-C0003241
.	O
	
patients	B-C0030705
with	O
ms	B-C0026769
with	O
antibodies	B-C0003241
to	O
mog	B-C0069428
predominantly	O
manifested	B-C0205319
with	O
concomitant	B-C0521115
severe	B-C0205082
brainstem	B-C0006121
and	O
spinal	B-C0037925
cord	I-C0037925
involvement	O
and	O
had	O
a	O
severe	B-C0205082
disease	B-C0242656
course	I-C0242656
with	O
high	O
relapse	B-C0035020
rates	B-C1521828
and	O
failure	B-C0162643
to	O
several	O
disease-modifying	B-C0087111
therapies	I-C0087111
.	O
	
three	O
of	O
them	O
had	O
been	O
treated	B-C0332293
with	I-C0332293
plasma	B-C0032113
exchange	I-C0032113
with	O
a	O
favorable	B-C0221607
response	I-C0221607
.	O
	
all	O
anti-mog	B-C1291777
-positive	O
patients	B-C0030705
with	O
ms	B-C0026769
showed	O
typical	O
ms	B-C0026769
lesions	B-C0221198
on	O
brain	B-C0412675
mri	I-C0412675
.	O
	
longitudinal	B-C0815265
analysis	I-C0815265
up	O
to	O
9	O
years	B-C0439234
revealed	O
fluctuations	B-C0231239
and	O
reappearance	O
of	O
anti-mog	B-C1621287
reactivity	I-C1621287
.	O
	
epitope	B-C0242831
mapping	I-C0242831
indicated	O
interindividual	B-C0019409
heterogeneity	I-C0019409
,	O
yet	O
intraindividual	B-C0205360
stability	I-C0205360
of	O
the	O
antibody	B-C0003261
response	I-C0003261
.	O
	
antibodies	B-C0003241
to	O
mog	B-C0069428
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	B-C1515021
of	O
adult	B-C0001675
ms	B-C0026769
with	O
a	O
specific	O
clinical	B-C0205210
phenotype	B-C0031437
and	O
may	O
indicate	O
disease	B-C0012634
heterogeneity	B-C0019409
.	O
	
acute	B-C4289946
ph-negative	I-C4289946
lymphoblastic	I-C4289946
leukemias	I-C4289946
in	O
adults	B-C0001675
risk	B-C0035648
factors	I-C0035648
in	O
the	O
use	O
of	O
the	O
all-2009	B-C2348563
protocol	I-C2348563
to	O
analyze	O
well-known	O
risk	B-C0035648
factors	I-C0035648
rfs	B-C0035648
,	O
such	O
as	O
age	B-C0001779
,	O
immunophenotype	B-C0079611
,	O
baseline	B-C1442488
leukocytosis	B-C0023518
,	O
enhanced	B-C2349975
lactate	B-C0022917
dehydrogenase	I-C0022917
ldh	B-C0022917
activity	B-C0243102
,	O
time	O
to	O
achieve	O
complete	O
remission	B-C0544452
,	O
a	O
risk	B-C0684030
group	I-C0684030
,	O
and	O
cytogenetic	B-C0008625
abnormalities	I-C0008625
in	O
patients	B-C0030705
with	O
acute	B-C0023449
lymphoblastic	I-C0023449
leukemia	I-C0023449
all	B-C0023449
in	O
the	O
use	O
of	O
the	O
all-2009	B-C2348563
protocol	I-C2348563
.	O
	
the	O
protocol	B-C2348563
covered	O
298	O
patients	B-C0030705
137	O
women	B-C0043210
including	B-C0332257
13	O
pregnant	B-C0033011
women	I-C0033011
and	O
161	O
men	B-C0025266
aged	O
15	O
to	O
55	O
years	O
median	O
age	O
28	O
years	O
with	O
ph-negative	B-C4289946
all	I-C4289946
.	O
	
the	O
phenotype	B-C0031437
was	O
unknown	O
in	O
6	O
patients	B-C0030705
.	O
	
three	O
1%	O
were	O
ascertained	O
to	O
have	O
a	O
biphenotypic	O
variant	O
.	O
	
182	O
62.4	O
patients	B-C0030705
were	O
found	O
to	O
have	O
b-cell	B-C0279593
all	I-C0279593
early	O
pre-b	B-C0279593
all	I-C0279593
n=51	O
common	O
all	B-C0023449
n=92	O
,	O
and	O
pre-b	B-C0279593
all	I-C0279593
n=39	O
107	O
36.6	O
patients	B-C0030705
had	O
t-cell	B-C0279592
all	I-C0279592
early	O
t-all	B-C0279592
n=56	O
thymic	B-C0040113
t-all	B-C0279592
n=41	O
,	O
and	O
mature	B-C0205286
t-all	B-C0279592
n=10	O
.	O
	
according	O
to	O
the	O
baseline	B-C1442488
clinical	B-C0205210
and	O
laboratory	B-C0022877
parameters	B-C0449381
leukocytosis	B-C0023518
of	O
30	O
and	O
more	O
for	O
b-all	B-C0279593
and	O
that	O
of	O
100	O
and	O
more	O
for	O
t-all	B-C0279592
phenotype	B-C0031437
в-i	O
for	O
b-all	B-C0279593
,	O
phenotype	B-C0031437
т-i-ii-iv	O
for	O
t-all	B-C0279592
ldh	B-C0022917
activity	B-C0243102
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
the	O
presence	B-C0150312
of	O
translocation	B-C0040715
t	I-C0040715
,	O
the	O
high-risk	B-C0684030
group	I-C0684030
included	B-C0332257
most	O
patients	B-C0030705
with	O
b-all	B-C0279593
n=110	O
72.8	O
and	O
t-all	B-C0279592
n=76	O
76%	O
.	O
	
thirty-five	O
patients	B-C0030705
with	O
t-all	B-C0279592
underwent	O
autologous	B-C0194037
bone	I-C0194037
marrow	I-C0194037
transplantation	I-C0194037
bmt	B-C0005961
.	O
	
allogeneic	B-C0149615
bmt	I-C0149615
was	O
performed	B-C0884358
in	O
18	O
7%	O
of	O
the	O
258	O
patients	B-C0030705
who	O
had	O
undergone	O
an	O
induction	B-C4049995
phase	I-C4049995
.	O
	
five-year	O
overall	B-C4086681
survival	I-C4086681
for	O
all	O
the	O
patients	B-C0030705
included	B-C0332257
in	O
the	O
investigation	B-C0220825
was	O
59%	O
relapse-free	B-C0679867
survival	O
was	O
65%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	B-C0030705
with	O
b-all	B-C0279593
and	O
in	O
those	O
with	O
t-all	B-C0279592
the	O
overall	B-C0038954
survival	I-C0038954
rates	I-C0038954
were	O
53.3	O
and	O
67.5	O
p=0	O
the	O
relapse-free	O
survival	O
was	O
56	O
and	O
79%	O
p=0	O
,	O
respectively	O
.	O
	
multivariate	B-C0026777
analysis	I-C0026777
including	B-C0332257
the	O
well-known	O
rfs	B-C0035648
demonstrated	O
that	O
the	O
latter	O
for	O
t-all	B-C0279592
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient's	B-C0030705
age	B-C0001779
was	O
identified	O
for	O
b-all	B-C0279593
p=0	O
.	O
	
a	O
lower	O
chemotherapeutic	B-C0729502
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	B-C0149615
bmts	I-C0149615
did	O
not	O
affect	O
total	O
positive	O
treatment	B-C0087111
results	B-C0456984
in	O
adult	B-C0001675
patients	B-C0030705
with	O
all	B-C0023449
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	B-C0010858
effects	B-C1280500
and	O
by	O
preserving	B-C0728887
the	O
total	O
cytostatic	B-C0010858
loading	B-C3714444
dose	I-C3714444
.	O
	
the	O
results	B-C0456984
of	O
the	O
russian	B-C0035970
investigation	B-C0220825
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	B-C0149615
bmts	I-C0149615
in	O
adult	B-C0001675
patients	B-C0030705
with	O
multidetector	B-C3179130
ct	I-C3179130
of	O
expected	B-C1517001
findings	B-C0243095
and	O
complications	B-C0009566
after	O
contemporary	B-C1254367
inguinal	B-C0021446
hernia	I-C0021446
repair	I-C0021446
surgery	B-C0543467
inguinal	B-C0021446
hernia	I-C0021446
repair	I-C0021446
ihr	B-C0021446
with	O
prosthetic	B-C0175649
mesh	B-C0181805
implantation	B-C0021107
is	O
the	O
most	O
common	O
procedure	B-C0087111
in	O
general	B-C2242991
surgery	I-C2242991
,	O
and	O
may	O
be	O
performed	B-C0884358
using	O
either	O
an	O
open	B-C0348025
or	O
laparoscopic	B-C0393360
approach	I-C0393360
.	O
	
this	O
paper	B-C0030351
provides	O
an	O
overview	B-C0814812
of	O
contemporary	B-C1254367
tension-free	O
ihr	B-C0021446
techniques	B-C0449851
and	O
materials	B-C0520510
,	O
and	O
illustrates	O
the	O
expected	B-C1517001
postoperative	B-C0231287
imaging	B-C1287399
findings	I-C1287399
and	O
iatrogenic	B-C0854404
injuries	I-C0854404
.	O
	
emphasis	O
is	O
placed	O
on	O
multidetector	B-C3179130
ct	I-C3179130
,	O
which	O
represents	O
the	O
ideal	B-C1512612
modality	B-C0695347
to	O
comprehensively	O
visualize	O
the	O
operated	B-C0205245
groin	B-C1279151
region	I-C1279151
and	O
deeper	B-C0205125
intra-abdominal	B-C0588044
structures	I-C0588044
.	O
	
ct	B-C0040405
consistently	O
depicts	O
seroma	B-C0262627
,	O
mesh	B-C3888473
infections	I-C3888473
,	O
hemorrhages	B-C0019080
,	O
bowel	B-C0021853
complications	B-C0009566
and	O
urinary	B-C0005682
bladder	I-C0005682
injuries	B-C0403677
,	O
and	O
thus	O
generally	O
provides	O
a	O
consistent	B-C0332290
basis	O
for	O
therapeutic	B-C0302350
choice	B-C1707391
.	O
	
since	O
radiologists	B-C0334907
are	O
increasingly	B-C0442808
requested	O
to	O
investigate	B-C1292732
suspected	B-C0750491
iatrogenic	B-C0439669
complications	B-C0009566
,	O
this	O
paper	B-C0030351
aims	O
to	O
provide	O
an	O
increased	B-C0205217
familiarity	B-C0600269
with	O
early	B-C1279919
ct	B-C0040405
studies	B-C1881134
after	O
ihr	B-C0021446
,	O
including	O
complications	B-C0009566
and	O
normal	B-C0205307
postoperative	B-C0231287
appearances	B-C0700364
such	O
as	O
focal	B-C0205234
pseudolesions	B-C1261287
,	O
in	O
order	O
to	O
avoid	B-C1254363
misinterpretation	I-C1254363
and	O
inappropriate	B-C1548788
management	B-C0376636
.	O
	
the	O
transcription	B-C0040648
factors	I-C0040648
ms188	B-C4277090
and	O
ams	B-C1434242
form	O
a	O
complex	B-C0439855
to	O
activate	B-C1515877
the	O
expression	B-C1171362
of	O
cyp703a2	B-C2000791
for	O
sporopollenin	B-C2755351
biosynthesis	I-C2755351
in	O
arabidopsis	B-C0162740
thaliana	I-C0162740
the	O
sexine	B-C1820011
layer	I-C1820011
of	O
pollen	B-C0032385
grain	I-C0032385
is	O
mainly	O
composed	O
of	O
sporopollenins	B-C0075041
.	O
	
the	O
sporophytic	B-C2717770
secretory	I-C2717770
tapetum	I-C2717770
is	O
required	B-C1514873
for	O
the	O
biosynthesis	B-C2755351
of	I-C2755351
sporopollenin	I-C2755351
.	O
	
although	O
several	O
enzymes	B-C0014442
involved	B-C1314939
in	O
sporopollenin	B-C2755351
biosynthesis	I-C2755351
have	O
been	O
reported	O
,	O
the	O
regulatory	B-C1152521
mechanism	I-C1152521
of	O
these	O
enzymes	B-C0014442
in	O
tapetal	B-C2717770
layer	I-C2717770
remains	O
elusive	O
.	O
	
aborted	B-C1434242
microspores	I-C1434242
ams	B-C1434242
and	O
male	B-C4277090
sterile	I-C4277090
188	I-C4277090
/	O
myb103	B-C0769095
/	O
myb80	B-C0769095
ms188	B-C4277090
/	O
myb103	B-C0769095
/	O
myb80	B-C0769095
are	O
two	O
tapetal	B-C2717770
cell	I-C2717770
-specific	O
transcription	B-C0040648
factors	I-C0040648
required	B-C1514873
for	O
pollen	B-C1326804
wall	I-C1326804
formation	I-C1326804
.	O
	
ams	B-C1434242
functions	B-C0542341
upstream	B-C0522505
of	O
ms188	B-C4277090
.	O
	
here	O
we	O
report	O
that	O
ams	B-C1434242
and	O
ms188	B-C4277090
target	B-C1521840
the	O
cyp703a2	B-C1333195
gene	I-C1333195
,	O
which	O
is	O
involved	B-C1314939
in	O
sporopollenin	B-C2755351
biosynthesis	I-C2755351
.	O
	
we	O
found	O
that	O
ams	B-C1434242
and	O
ms188	B-C4277090
were	O
localized	B-C0392752
in	O
tapetum	B-C2717770
while	O
cyp703a2	B-C2000791
was	O
localized	B-C0392752
in	O
both	O
tapetum	B-C2717770
and	O
locule	B-C1136229
.	O
	
chromatin	B-C1328856
immunoprecipitation	I-C1328856
chip	B-C1328856
showed	O
that	O
ms188	B-C4277090
directly	O
bound	B-C1145667
to	O
the	O
promoter	B-C0086860
of	O
cyp703a2	B-C1333195
and	O
luciferase-inducible	B-C0024075
assay	B-C1510438
showed	O
that	O
ms188	B-C4277090
activated	B-C1879547
the	O
expression	B-C1171362
of	O
cyp703a2	B-C2000791
.	O
	
yeast	B-C1961118
two-hybrid	I-C1961118
and	O
electrophoretic	B-C0949632
mobility	I-C0949632
shift	I-C0949632
assays	I-C0949632
emsas	B-C0949632
further	O
demonstrated	O
that	O
ms188	B-C4277090
complexed	B-C0439855
with	O
ams	B-C1434242
.	O
	
the	O
expression	B-C1171362
of	O
cyp703a2	B-C1333195
could	O
be	O
partially	O
restored	O
by	O
the	O
elevated	B-C3163633
levels	I-C3163633
of	O
ms188	B-C4277090
in	O
the	O
ams	B-C1434242
mutant	B-C0596988
.	O
	
therefore	O
,	O
our	O
data	B-C1511726
reveal	B-C0443289
that	O
ms188	B-C4277090
coordinates	B-C0700114
with	O
ams	B-C1434242
to	O
activate	B-C1515877
cyp703a2	B-C2000791
in	O
sporopollenin	B-C2755351
biosynthesis	I-C2755351
of	O
plant	B-C0032098
tapetum	B-C2717770
.	O
	
activation	B-C1879547
of	O
ephrinb-ephb	B-C2984386
receptor	I-C2984386
signalling	I-C2984386
in	O
rat	B-C1882864
spinal	I-C1882864
cord	I-C1882864
contributes	O
to	O
maintenance	B-C0024501
of	O
diabetic	B-C0241863
neuropathic	B-C3714625
pain	I-C3714625
diabetic	B-C0241863
neuropathic	B-C3714625
pain	I-C3714625
dnp	B-C3714625
is	O
severe	B-C0205082
and	O
intractable	B-C0205269
in	O
clinic	B-C0442592
.	O
	
the	O
specific	B-C0205369
cellular	B-C0007613
and	O
molecular	B-C1148560
mechanisms	B-C0441712
underlying	O
dnp	B-C3714625
remain	O
elusive	O
and	O
its	O
treatment	B-C0039798
are	O
limited	B-C0439801
.	O
	
we	O
investigated	B-C1292732
roles	B-C1705810
of	O
ephb1	B-C0907648
receptor	I-C0907648
in	O
the	O
development	O
of	O
dnp	B-C3714625
.	O
	
diabetic	B-C0241863
neuropathic	B-C3714625
pain	I-C3714625
was	O
produced	O
in	O
male	B-C0086582
,	O
adult	B-C0001675
,	O
sprague-dawley	B-C0034715
rats	I-C0034715
by	O
a	O
single	O
i.p	O
.	O
	
streptozotocin	B-C0038432
stz	B-C0038432
or	O
alloxan	B-C0002151
.	O
	
western	B-C0949466
blot	I-C0949466
analysis	I-C0949466
and	O
immunohistochemistry	B-C0021044
were	O
used	O
to	O
analyse	O
expression	B-C1171362
of	O
ephb1	B-C0907648
receptor	I-C0907648
as	O
well	O
as	O
the	O
activation	B-C1879547
of	O
the	O
glial	B-C0027836
cells	I-C0027836
and	O
the	O
pro-inflammatory	B-C0079189
cytokines	I-C0079189
in	O
the	O
spinal	B-C0037925
cord	I-C0037925
.	O
	
dnp	B-C3714625
manifested	B-C0205319
as	O
mechanical	B-C2936719
allodynia	I-C2936719
,	O
which	O
was	O
determined	O
by	O
measuring	B-C0444706
incidence	B-C0021149
of	O
foot	B-C0016504
withdrawal	B-C0441655
in	O
response	B-C0871261
to	O
mechanical	B-C0332467
indentation	I-C0332467
of	O
the	O
hind	B-C2983612
paw	B-C0687080
by	O
an	O
electro	B-C3273359
von	I-C3273359
frey	I-C3273359
filament	I-C3273359
.	O
	
diabetic	B-C0241863
neuropathic	B-C3714625
pain	I-C3714625
and	O
high	B-C2919432
blood	I-C2919432
glucose	I-C2919432
were	O
exhibited	O
simultaneously	B-C0521115
in	O
around	O
70%	O
of	O
animals	B-C0003062
that	O
received	O
i.p	O
.	O
	
stz	B-C0038432
or	O
alloxan	B-C0002151
.	O
	
phosphorylation	B-C0031715
of	O
ephb1	B-C0907648
,	O
activation	B-C1879547
of	O
the	O
astrocytes	B-C0004112
and	O
microglial	B-C0206116
cells	I-C0206116
,	O
and	O
level	B-C0441889
of	O
tumour	B-C1456820
necrosis	I-C1456820
factor	I-C1456820
tnf	B-C1456820
and	O
interleukin	B-C0021753
il	I-C0021753
in	O
the	O
spinal	B-C0037925
cord	I-C0037925
were	O
significantly	O
increased	O
in	O
rats	B-C0034721
with	O
dnp	B-C3714625
.	O
	
spinal	B-C0521329
blocking	B-C0332206
ephb1	B-C0907648
receptor	I-C0907648
activation	B-C1879547
in	O
the	O
late	O
phase	O
after	O
stz	B-C0038432
injection	B-C1533685
significantly	O
suppressed	B-C1260953
the	O
established	O
mechanical	B-C2936719
allodynia	I-C2936719
as	O
well	O
as	O
activation	B-C1879547
of	O
the	O
astrocytes	B-C0004112
and	O
microglial	B-C0206116
cells	I-C0206116
and	O
activity	B-C0441655
of	O
tnf-α	B-C1456820
and	O
il-1β	B-C0021753
.	O
	
however	O
,	O
spinal	B-C0521329
treatment	B-C0039798
of	O
ephb1	B-C0907648
-	O
fc	B-C0034805
in	O
the	O
early	B-C0814494
phase	I-C0814494
after	O
stz	B-C0038432
injection	B-C1533685
did	O
not	O
prevent	O
the	O
induction	B-C0205263
of	O
dnp	B-C3714625
.	O
	
ephb1	B-C0907648
receptor	I-C0907648
activation	B-C1879547
in	O
the	O
spinal	B-C0037925
cord	I-C0037925
is	O
critical	B-C1511545
to	O
the	O
maintenance	B-C0024501
,	O
but	O
not	O
induction	B-C0205263
of	O
diabetic	B-C0241863
pain	B-C0030193
.	O
	
ephb1	B-C0907648
receptor	I-C0907648
may	O
be	O
a	O
potential	B-C3245505
target	B-C1521840
for	O
relieving	B-C0002766
the	O
established	O
diabetic	B-C0241863
pain	B-C0030193
.	O
	
activation	B-C1879547
of	O
ephb1	B-C0907648
receptor	I-C0907648
in	O
the	O
spinal	B-C0037925
cord	I-C0037925
is	O
critical	B-C1511545
to	O
maintaining	B-C1314677
the	O
established	O
diabetic	B-C0241863
neuropathic	B-C3714625
pain	I-C3714625
,	O
but	O
not	O
to	O
diabetic	B-C0241863
pain	B-C0030193
induction	B-C0205263
.	O
	
spinal	B-C0521329
blocking	B-C0332206
ephb1	B-C0907648
receptor	I-C0907648
activation	B-C1879547
suppresses	B-C1260953
ongoing	O
diabetic	B-C0241863
neuropathic	B-C3714625
pain	I-C3714625
.	O
	
conservation	B-C2347858
of	O
the	O
red	B-C0325557
kite	I-C0325557
milvus	B-C0325557
milvus	I-C0325557
aves	B-C0005595
accipitriformes	B-C3669511
is	O
not	O
affected	B-C0392760
by	O
the	O
establishment	O
of	O
a	O
broad	O
hybrid	B-C0020205
zone	B-C1710706
with	O
the	O
black	B-C1016933
kite	I-C1016933
milvus	B-C1016933
migrans	I-C1016933
migrans	I-C1016933
in	O
central	B-C0682369
europe	I-C0682369
among	O
accipitriformes	B-C3669511
sensu	O
stricto	O
,	O
only	O
a	O
few	O
species	B-C1705920
have	O
been	O
reported	B-C0684224
to	O
form	O
hybrid	B-C0020205
zones	B-C1710706
these	O
include	O
the	O
red	B-C0325557
kite	I-C0325557
milvus	B-C0325557
milvus	I-C0325557
and	O
black	B-C1016933
kite	I-C1016933
milvus	B-C1016933
migrans	I-C1016933
migrans	I-C1016933
.	O
	
m	B-C0325557
.	O
	
milvus	I-C0325557
is	O
endemic	B-C0302891
to	O
the	O
western	B-C0681784
palearctic	I-C0681784
and	O
has	O
an	O
estimated	O
total	O
population	B-C0032659
of	O
20-24	O
breeding	B-C0006159
pairs	B-C1709450
.	O
	
the	O
species	B-C1705920
was	O
in	O
decline	O
until	O
the	O
1970s	O
due	O
to	O
persecution	B-C0871062
and	O
has	O
declined	O
again	O
since	O
the	O
1990s	O
due	O
to	O
ingestion	B-C0232478
of	O
rodenticide-treated	B-C0035805
baits	I-C0035805
,	O
illegal	B-C3242151
poisoning	B-C0032343
and	O
changes	O
in	O
agricultural	B-C0001829
practices	I-C0001829
,	O
particularly	O
in	O
its	O
core	B-C0444669
range	B-C1514721
.	O
	
whereas	O
f1	B-C0314650
m	B-C0325557
.	O
	
milvus	I-C0325557
m	B-C1016933
.	O
	
migr	I-C1016933
.	O
	
migrans	I-C1016933
hybrid	B-C0020205
offspring	B-C0680063
have	O
been	O
found	O
,	O
f2	B-C0314651
and	O
f3	B-C0680063
hybrids	B-C0020205
have	O
only	O
rarely	O
been	O
reported	B-C0684224
,	O
with	O
low	O
nesting	B-C0027776
success	B-C0597535
rates	B-C1521828
of	O
f1	B-C0314650
hybrids	B-C0020205
and	O
partial	B-C0728938
hybrid	B-C0020205
sterility	O
likely	O
playing	O
a	O
role	O
.	O
	
here	O
,	O
we	O
analyzed	B-C0936012
the	O
mitochondrial	B-C0026237
co1	B-C1537985
and	O
cytb	B-C1537988
and	O
nuclear	B-C0007610
myc	B-C0086661
dna	B-C0012854
loci	B-C1708726
of	O
184	O
m	B-C0325557
.	O
	
milvus	I-C0325557
,	O
124	O
m	B-C1016933
.	O
	
migr	I-C1016933
.	O
	
migrans	I-C1016933
and	O
3	O
f1	B-C0314650
hybrid	B-C0020205
individuals	O
collected	O
across	O
central	B-C0682369
europe	I-C0682369
.	O
	
in	O
agreement	B-C4255373
with	O
previous	O
studies	B-C2603343
,	O
we	O
found	O
low	O
heterozygosity	B-C0019425
in	O
m	B-C0325557
.	O
	
milvus	I-C0325557
regardless	O
of	O
locus	B-C1708726
.	O
	
we	O
found	O
that	O
populations	B-C0032659
of	O
both	O
examined	B-C0332128
species	B-C1705920
were	O
characterized	B-C1880022
by	O
a	O
high	O
gene	B-C1565556
flow	I-C1565556
within	O
populations	B-C0032659
,	O
with	O
all	O
of	O
the	O
major	O
haplotypes	B-C0018591
distributed	O
across	O
the	O
entire	O
examined	B-C0332128
area	B-C0017446
.	O
	
few	O
haplotypes	B-C0018591
displayed	O
statistically	B-C0237881
significant	I-C0237881
aggregation	B-C0332621
in	O
one	O
region	B-C0017446
over	O
another	O
.	O
	
we	O
did	O
not	O
find	O
mitochondrial	B-C0012929
dna	I-C0012929
of	O
one	O
species	B-C1705920
in	O
individuals	O
with	O
the	O
plumage	B-C0015731
of	O
the	O
other	O
species	B-C1705920
,	O
except	O
in	O
f1	B-C0314650
hybrids	B-C0020205
,	O
which	O
agrees	O
with	O
haldane	B-C0870077
rule	I-C0870077
.	O
	
it	O
remains	O
to	O
be	O
investigated	B-C1292732
by	O
genomic	B-C0017428
methods	B-C0025664
whether	O
occasional	O
gene	B-C1565556
flow	I-C1565556
occurs	O
through	O
the	O
paternal	B-C0337493
line	O
,	O
as	O
the	O
examined	B-C0332128
myc	B-C0086661
gene	I-C0086661
displayed	O
only	O
marginal	O
divergence	B-C0443204
between	O
m	B-C0325557
.	O
	
milvus	I-C0325557
and	O
m	B-C1016933
.	O
	
migr	I-C1016933
.	O
	
migrans	I-C1016933
.	O
	
the	O
central	B-C0682369
europe	I-C0682369
an	O
population	B-C0032659
of	O
m	B-C0325557
.	O
	
milvus	I-C0325557
is	O
clearly	O
subject	O
to	O
free	O
intraspecific	O
gene	B-C1565556
flow	I-C1565556
,	O
which	O
has	O
direct	O
implications	O
when	O
considering	O
the	O
origin	B-C0439659
of	O
individuals	O
in	O
m	B-C0325557
.	O
	
milvus	I-C0325557
extracellular	B-C0521119
potassium	B-C0032821
and	O
seizures	B-C0036572
excitation	B-C0549255
,	O
inhibition	B-C3463820
and	O
the	O
role	O
of	O
ih	B-C1956068
seizure	B-C0036572
activity	I-C0036572
leads	O
to	O
increases	O
in	O
extracellular	B-C0521119
potassium	B-C0032821
concentration	B-C1264643
k	B-C0597277
formula	O
see	O
text	O
,	O
which	O
can	O
result	O
in	O
changes	O
in	O
neuronal	B-C0027882
passive	B-C3686820
and	O
active	B-C0205177
membrane	B-C3161472
properties	O
as	O
well	O
as	O
in	O
population	B-C1257890
activities	B-C0441655
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
examined	O
how	O
extracellular	B-C0521119
potassium	B-C0032821
modulates	O
seizure	B-C0036572
activities	I-C0036572
using	O
an	O
acute	O
4-ap	B-C0000477
induced	O
seizure	B-C0036572
model	B-C3161035
in	O
the	O
neocortex	B-C0175173
,	O
both	O
in	B-C1515655
vivo	I-C1515655
and	O
in	B-C1533691
vitro	I-C1533691
.	O
	
moderately	O
elevated	O
k	B-C0597277
formula	O
see	O
text	O
up	O
to	O
9	O
see	O
text	O
prolonged	B-C0439590
seizure	B-C0036572
durations	B-C0449238
and	O
shortened	B-C1254367
interictal	I-C1254367
intervals	I-C1254367
as	O
well	O
as	O
depolarized	B-C1395184
the	O
neuronal	B-C0027882
resting	B-C0025251
membrane	I-C0025251
potential	I-C0025251
rmp	B-C0025251
.	O
	
however	O
,	O
when	O
k	B-C0597277
formula	O
see	O
text	O
reached	O
higher	O
than	O
9	O
see	O
text	O
,	O
seizure	B-C0036572
like	I-C0036572
events	I-C0036572
sles	B-C0036572
were	O
blocked	B-C0332206
and	O
neurons	B-C0027882
went	O
into	O
a	O
depolarization	B-C1395184
-	O
blocked	B-C0332206
state	O
.	O
	
spreading	B-C0332261
depression	B-C0011570
was	O
never	O
observed	O
as	O
the	O
blockade	O
of	O
ictal	B-C0036572
events	I-C0036572
could	O
be	O
reversed	O
within	O
1-2	O
see	O
text	O
after	O
the	O
raised	O
k	B-C0597277
formula	O
see	O
text	O
was	O
changed	O
back	O
to	O
control	O
levels	O
.	O
	
this	O
concentration	B-C1264643
-dependent	O
dual	O
effect	O
of	O
k	B-C0597277
formula	O
see	O
text	O
was	O
observed	O
using	O
in	B-C1515655
vivo	I-C1515655
and	O
in	B-C1533691
vitro	I-C1533691
mouse	B-C1521713
brain	I-C1521713
preparations	I-C1521713
as	O
well	O
as	O
in	O
human	B-C0086418
neocortical	B-C0175173
tissue	B-C0040300
resected	O
during	O
epilepsy	B-C0014544
surgery	B-C0543467
.	O
	
blocking	B-C0332206
the	O
ih	O
current	O
,	O
mediated	O
by	O
hyperpolarization-activated	B-C1956068
cyclic	I-C1956068
nucleotide-gated	I-C1956068
hcn	I-C1956068
channels	I-C1956068
,	O
modulated	O
the	O
elevated	O
k	B-C0597277
formula	O
see	O
text	O
influence	B-C4054723
on	O
sles	B-C0036572
by	O
promoting	O
the	O
high	O
k	B-C0597277
formula	O
see	O
text	O
inhibitory	B-C3463820
actions	I-C3463820
.	O
	
these	O
results	O
demonstrate	O
biphasic	O
actions	O
of	O
raised	O
k	B-C0597277
formula	O
see	O
text	O
on	O
neuronal	B-C0027882
excitability	B-C0235169
and	O
seizure	B-C0036572
activity	I-C0036572
.	O
	
activation	B-C0014429
of	O
general	B-C2354171
control	I-C2354171
nonderepressible	I-C2354171
2	I-C2354171
kinase	I-C2354171
protects	B-C1545588
human	B-C0086418
glomerular	B-C1182791
endothelial	I-C1182791
cells	I-C1182791
from	O
harmful	O
high-glucose	B-C0860803
-	O
induced	B-C0205263
molecular	B-C1704259
pathways	I-C1704259
considering	O
the	O
referred	O
beneficial	O
effects	O
of	O
protein	B-C0033684
restriction	B-C0443288
on	O
diabetic	B-C0011881
nephropathy	I-C0011881
dn	B-C0011881
and	O
the	O
role	O
of	O
renal	B-C0022646
endothelium	B-C0014257
in	O
its	O
pathogenesis	B-C0699748
,	O
we	O
evaluated	B-C0220825
the	O
effect	O
of	O
general	B-C2354171
control	I-C2354171
nonderepressible	I-C2354171
2	I-C2354171
gcn2	I-C2354171
kinase	I-C2354171
activation	B-C0014429
,	O
a	O
sensor	B-C0600364
of	O
amino	B-C0002520
acid	I-C0002520
deprivation	B-C0871712
,	O
on	O
known	O
detrimental	O
molecular	B-C1704259
pathways	I-C1704259
in	O
primary	O
human	B-C0086418
glomerular	B-C1182791
endothelial	I-C1182791
cells	I-C1182791
genc	B-C1182791
.	O
	
genc	B-C1182791
were	O
cultured	B-C0430400
under	O
normal	O
or	O
high	B-C0205250
-glucose	O
conditions	O
in	O
the	O
presence	O
or	O
not	O
of	O
the	O
gcn2	O
kinase	O
activator	O
,	O
tryptophanol	O
.	O
	
glucose	O
transporter	O
1	O
glut1	O
expression	O
was	O
assessed	O
by	O
western	O
blotting	O
and	O
reactive	O
oxygen	O
species	O
ros	O
using	O
a	O
fluorogenic	O
probe	O
.	O
	
activities	O
of	O
glyceraldehyde	O
3-phosphate	O
dehydrogenase	O
gapdh	O
and	O
protein	O
kinase	O
c	O
pkc	O
were	O
assessed	O
by	O
commercial	O
activity	O
assays	O
,	O
sorbitol	O
colorimetrically	O
,	O
methylglyoxal	O
by	O
elisa	O
and	O
o-linked	O
β-n-acetyl	O
glucosamine	O
o-glcnac	O
proteins	O
by	O
western	O
blotting	O
.	O
	
high	O
glucose	O
induced	O
glut1	O
expression	O
,	O
increased	O
ros	O
and	O
inhibited	O
gapdh	O
.	O
	
also	O
it	O
increased	O
the	O
polyol	O
pathway	O
product	O
sorbitol	O
,	O
pkc	O
activity	O
,	O
the	O
level	O
of	O
the	O
o-glcnac-modified	O
proteins	O
that	O
produced	O
by	O
the	O
hexosamine	O
pathway	O
and	O
the	O
advanced	O
glycation	O
endproducts'	O
precursor	O
methylglyoxal	O
.	O
	
co-treatment	O
of	O
genc	O
with	O
tryptophanol	O
restored	O
the	O
above	O
high-glucose	O
-	O
induced	O
alterations	O
.	O
	
activation	O
of	O
gcn2	O
kinase	O
protects	O
genc	O
from	O
high-glucose	O
-	O
induced	O
harmful	O
molecular	O
pathways	O
.	O
	
by	O
inhibiting	O
concurrently	O
many	O
pathways	O
involved	O
in	O
dn	O
pathogenesis	O
,	O
gcn2	O
kinase	O
may	O
serve	O
as	O
a	O
pharmaceutical	O
target	O
for	O
the	O
treatment	O
of	O
dn	B-C0011881
juicer	B-C0037589
provides	B-C1999230
a	O
one-click	O
system	O
for	O
analyzing	B-C0936012
loop-resolution	B-C0200892
hi-c	I-C0200892
experiments	I-C0200892
hi-c	B-C0200892
experiments	I-C0200892
explore	O
the	O
3d	B-C0026377
structure	I-C0026377
of	O
the	O
genome	B-C0017428
,	O
generating	B-C3146294
terabases	B-C0150098
of	I-C0150098
data	I-C0150098
to	O
create	O
high-resolution	B-C1719039
contact	B-C0814036
maps	I-C0814036
.	O
	
here	O
,	O
we	O
introduce	O
juicer	B-C0037589
,	O
an	O
open-source	B-C0037589
tool	I-C0037589
for	O
analyzing	O
terabase-scale	B-C0392762
hi-c	B-C0150098
datasets	I-C0150098
.	O
	
juicer	B-C0037589
allows	O
users	B-C1706077
without	B-C0332288
a	O
computational	B-C1880157
background	B-C1706907
to	O
transform	B-C1705163
raw	B-C0026382
sequence	I-C0026382
data	I-C0026382
into	O
normalized	O
contact	B-C0814036
maps	I-C0814036
with	O
one	O
click	O
.	O
	
juicer	B-C0037589
produces	O
a	O
hic	B-C0242193
file	I-C0242193
containing	O
compressed	B-C0332260
contact	B-C1704640
matrices	I-C1704640
at	O
many	O
resolutions	B-C1706463
,	O
facilitating	O
visualization	B-C0175631
and	O
analysis	B-C0936012
at	O
multiple	B-C0392762
scales	I-C0392762
.	O
	
structural	B-C0026377
features	I-C0026377
,	O
such	O
as	O
loops	B-C1516509
and	O
domains	B-C0599845
,	O
are	O
automatically	B-C0004374
annotated	B-C1552720
.	O
	
juicer	B-C0037589
is	O
available	O
as	O
open	B-C1996904
source	B-C0011001
software	B-C0037585
bjn	B-C0004446
awards	I-C0004446
2016	O
iv	B-C0455142
therapy	I-C0455142
claire	O
rickard	O
professor	B-C0015535
of	O
nursing	B-C0028661
,	O
national	O
health	O
and	O
medical	O
research	O
council	O
nhmrc	O
centre	B-C1516383
of	I-C1516383
research	I-C1516383
excellence	I-C1516383
in	O
nursing	B-C0028661
,	O
griffith	O
university	O
,	O
was	O
awarded	B-C0004446
second	O
place	O
in	O
the	O
bjn	B-C0004446
awards	I-C0004446
2016	O
for	O
iv	B-C0455142
therapy	I-C0455142
nurse	B-C0028661
of	O
the	O
year	B-C0439234
.	O
	
here	O
she	O
talks	O
about	O
the	O
she	O
has	O
done	O
to	O
be	O
recognised	O
in	O
this	O
stressful	B-C0231297
life	B-C0557155
events	I-C0557155
and	O
leucocyte	B-C1836777
telomere	I-C1836777
length	I-C1836777
do	O
lifestyle	B-C1517875
factors	I-C1517875
,	O
somatic	B-C2986476
and	O
mental	B-C0025353
health	I-C0025353
,	O
or	O
low	B-C0021368
grade	I-C0021368
inflammation	I-C0021368
mediate	O
this	O
relationship	B-C0439849
results	O
from	O
a	O
cohort	B-C0599755
of	O
danish	B-C0025266
men	I-C0025266
born	B-C0005615
in	O
1953	O
exposure	B-C0332157
to	I-C0332157
psychosocial	B-C0542298
stress	B-C0038435
is	O
associated	B-C0332281
with	I-C0332281
increased	O
risk	B-C0035647
of	O
a	O
number	O
of	O
somatic	B-C2986476
and	O
mental	B-C0004936
disorders	I-C0004936
with	O
relation	B-C0439849
to	O
immune	O
system	O
functioning	O
.	O
	
we	O
aimed	O
to	O
explore	O
whether	O
stressful	O
events	O
in	O
early	O
and	O
recent	O
life	O
was	O
associated	O
with	O
leucocyte	O
telomere	O
length	O
tl	O
,	O
which	O
is	O
assumed	O
to	O
reflect	O
the	O
accumulated	O
burden	O
of	O
inflammation	O
and	O
oxidative	O
stress	O
occurring	O
during	O
the	O
life	O
course	O
.	O
	
we	O
specifically	O
aimed	O
to	O
address	O
whether	O
childhood	O
constitutes	O
a	O
sensitive	O
period	O
and	O
how	O
much	O
of	O
the	O
relation	B-C0439849
between	O
stressful	O
life	O
events	O
and	O
tl	O
is	O
mediated	O
through	O
somatic	O
and	O
mental	O
health	O
,	O
lifestyle	O
,	O
and	O
markers	O
of	O
low-grade	O
inflammation	O
.	O
	
a	O
cohort	O
of	O
danish	O
men	O
born	O
in	O
1953	O
has	O
been	O
followed	O
since	O
birth	O
in	O
the	O
metropolit	O
cohort	O
.	O
	
these	O
men	O
underwent	O
a	O
health	O
examination	O
including	O
blood	O
sampling	O
in	O
2010	O
and	O
a	O
subset	O
of	O
324	O
also	O
had	O
a	O
quantitative	O
pcr-based	O
measurement	O
of	O
tl	O
.	O
	
the	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
tl	O
was	O
analysed	O
using	O
structural	O
equation	O
modelling	O
,	O
which	O
also	O
provided	O
an	O
estimate	O
of	O
the	O
proportion	O
of	O
the	O
total	O
effect	O
mediated	O
by	O
somatic	O
and	O
mental	O
health	O
cardiovascular	O
disease	O
,	O
body	O
mass	O
and	O
depressive	O
mood	O
,	O
lifestyle	O
factors	O
,	O
and	O
low	O
grade	O
inflammation	O
c-reactive	O
protein	O
crp	O
,	O
interleukin	O
il	O
and	O
il-10	O
.	O
	
total	O
number	O
of	O
stressful	O
events	O
experienced	O
during	O
the	O
life	O
course	O
was	O
not	O
associated	O
with	O
tl	O
.	O
	
in	O
terms	O
of	O
sensitive	O
periods	O
,	O
we	O
found	O
that	O
number	O
of	O
stressful	O
events	O
in	O
childhood	O
was	O
associated	O
with	O
shorter	O
tl	O
βper	O
number	O
stressful	O
events	O
in	O
childhood	O
=-0	O
p=0	O
.	O
	
this	O
relation	O
was	O
particularly	O
strong	O
for	O
being	O
placed	O
away	O
from	O
home	O
β=-0	O
p<0	O
.	O
	
thirty	O
percent	O
of	O
the	O
total	O
effect	O
of	O
stressful	O
events	O
in	O
childhood	O
on	O
tl	O
was	O
mediated	O
by	O
the	O
included	O
variables	O
,	O
with	O
the	O
largest	O
proportion	O
being	O
mediated	O
through	O
depressive	O
mood	O
16%	O
and	O
crp	O
9%	O
.	O
	
this	O
study	O
suggests	O
that	O
stressful	O
events	O
in	O
childhood	O
are	O
associated	O
with	O
shorter	O
tl	O
in	O
middle-aged	O
men	O
and	O
that	O
part	O
of	O
this	O
relation	O
is	O
explained	O
by	O
depressive	O
mood	O
and	O
low	O
grade	O
inflammation	B-C0021368
description	B-C0678257
of	O
ancylomarina	B-C0004611
subtilis	I-C0004611
gen	I-C0004611
.	O
	
nov	I-C0004611
,	O
sp	I-C0004611
.	O
	
nov	I-C0004611
,	O
isolated	B-C0205409
from	O
coastal	B-C0557760
sediment	I-C0557760
,	O
proposal	B-C1555306
of	O
marinilabiliales	B-C0004611
ord	I-C0004611
.	O
	
nov	I-C0004611
.	O
	
and	O
transfer	B-C3244299
of	O
marinilabiliaceae	B-C3557298
,	O
prolixibacteraceae	B-C3800560
and	O
marinifilaceae	B-C3986640
to	O
the	O
order	B-C1705177
marinilabiliales	B-C0004611
a	O
gram-stain-negative	B-C0018150
,	O
facultatively	B-C1532741
anaerobic	I-C1532741
,	O
moderately	B-C0599691
halophilic	I-C0599691
,	O
filamentous	B-C1979891
,	O
non-motile	B-C1301466
bacterium	I-C1301466
,	O
designated	B-C1524084
fa102t	B-C0018149
,	O
was	O
isolated	B-C0205409
from	O
marine	B-C0282589
sediment	I-C0282589
of	O
the	O
coast	B-C0442544
of	O
weihai	B-C0008115
,	O
china	I-C0008115
.	O
	
phylogenetic	B-C1519068
analysis	I-C1519068
based	B-C1527178
on	O
16s	B-C3537372
rrna	I-C3537372
gene	I-C3537372
sequences	I-C3537372
showed	B-C0870432
that	O
strain	B-C0456178
fa102t	B-C0018149
formed	O
a	O
distinct	B-C2963144
evolutionary	B-C0015219
lineage	B-C1881379
within	O
the	O
family	B-C1704727
marinifilaceae	B-C3986640
and	O
its	O
closest	B-C1821461
relative	I-C1821461
was	O
marinifilum	B-C2990363
fragile	I-C2990363
jcm	I-C2990363
15579t	I-C2990363
93.2	O
sequence	B-C1710052
similarity	I-C1710052
.	O
	
the	O
dna	B-C0012854
g+c	B-C1135899
content	I-C1135899
of	O
the	O
novel	B-C0205314
strain	B-C0456178
was	O
36.5	O
mol%	O
.	O
	
the	O
predominant	B-C1542147
cellular	B-C0007634
fatty	B-C0015684
acids	I-C0015684
and	O
respiratory	B-C0521346
quinone	B-C0034435
were	O
iso-c15	B-C0044840
and	O
iso-c15	B-C0754432
3-oh	I-C0754432
,	O
and	O
mk-7	B-C0078382
,	O
respectively	B-C1548787
.	O
	
on	O
the	O
basis	B-C1527178
of	O
the	O
phylogenetic	B-C0683236
,	O
phenotypic	B-C0031437
and	O
physiological	B-C0205463
data	B-C1511726
,	O
strain	B-C0456178
fa102t	B-C0018149
represents	B-C1882932
a	O
novel	B-C0205314
genus	B-C1708235
and	O
species	B-C1705920
,	O
for	O
which	O
the	O
name	O
ancylomarina	B-C0004611
subtilis	I-C0004611
gen	I-C0004611
.	O
	
nov	I-C0004611
,	O
sp	I-C0004611
.	O
	
nov	I-C0004611
.	O
	
is	O
proposed	B-C1553874
.	O
	
the	O
type	B-C0332307
strain	B-C0456178
of	O
ancylomarina	B-C0018149
subtilis	I-C0018149
is	O
fa102t	B-C0018149
=	O
kctc	B-C0004611
42257t	I-C0004611
=	O
dsm	B-C0004611
28825t	I-C0004611
=	O
cicc	B-C0004611
10902t	I-C0004611
.	O
	
furthermore	O
,	O
a	O
new	B-C0205314
order	B-C1705177
named	O
marinilabiliales	B-C0004611
is	O
proposed	B-C1553874
to	O
accommodate	B-C1832072
three	O
families	B-C1704727
previously	B-C0205156
classified	B-C0008902
in	O
the	O
order	B-C1705177
bacteroidales	B-C1080663
.	O
	
marinilabiliales	B-C0004611
ord	I-C0004611
.	O
	
nov	I-C0004611
.	O
	
encompasses	O
the	O
families	B-C1704727
marinilabiliaceae	B-C3557298
,	O
prolixibacteraceae	B-C3800560
and	O
treatment	B-C0087111
for	O
rheumatoid	B-C0003873
arthritis	I-C0003873
and	O
risk	B-C1281905
of	O
alzheimer's	B-C0002395
disease	I-C0002395
a	O
nested	B-C0027775
case-control	I-C0027775
analysis	I-C0027775
it	O
is	O
increasingly	B-C0442808
becoming	O
accepted	B-C1272684
that	O
inflammation	B-C0021368
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-C0699748
of	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
,	O
as	O
several	B-C0443302
immune	B-C0020962
-related	O
genes	B-C0017337
have	O
been	O
associated	B-C0332281
with	I-C0332281
ad	B-C0002395
.	O
	
among	O
these	O
is	O
tumor	B-C1456820
necrosis	I-C1456820
factor	I-C1456820
tnf	I-C1456820
,	O
a	O
proinflammatory	B-C0079189
cytokine	I-C0079189
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	B-C0004364
disorders	I-C0004364
,	O
including	O
rheumatoid	B-C0003873
arthritis	I-C0003873
ra	B-C0003873
.	O
	
although	O
ad	B-C0002395
and	O
ra	B-C0003873
appear	O
to	O
involve	O
similar	B-C2348205
pathological	B-C0030660
mechanisms	I-C0030660
through	O
the	O
production	B-C0003261
of	O
tnf-α	B-C1456820
,	O
the	O
relationship	B-C0439849
between	O
ad	B-C0002395
and	O
ra	B-C0003873
remains	O
unknown	B-C0439673
.	O
	
to	O
determine	O
the	O
relative	B-C0242492
risk	I-C0242492
of	O
ad	B-C0002395
among	O
ra	B-C0003873
patients	B-C0030705
and	O
non-	O
ra	B-C0003873
patients	B-C0030705
,	O
and	O
whether	O
anti-tnf	B-C0281481
therapy	I-C0281481
for	O
ra	B-C0003873
was	O
associated	B-C0332281
with	I-C0332281
a	O
lower	B-C0205251
risk	B-C1281905
of	O
ad	B-C0002395
in	O
ra	B-C0003873
patients	B-C0030705
.	O
	
we	O
performed	O
a	O
nested	B-C0027775
case-control	I-C0027775
study	I-C0027775
of	O
more	O
than	O
8.5	O
million	O
commercially	O
insured	B-C1548605
adults	B-C0001675
aged	O
18	O
years	O
in	O
all	O
50	O
us	B-C0041703
states	I-C0041703
,	O
puerto	B-C0034044
rico	I-C0034044
,	O
and	O
us	B-C0042752
virgin	I-C0042752
islands	I-C0042752
in	O
the	O
verisk	B-C0242356
health	I-C0242356
claims	I-C0242356
database	I-C0242356
.	O
	
we	O
derived	O
a	O
sub-cohort	B-C0599755
of	O
subjects	O
with	O
a	O
diagnosis	B-C0011900
of	O
ra	B-C0003873
controls	B-C0009932
,	O
or	O
ra	B-C0003873
and	O
ad	B-C0002395
cases	B-C1706256
,	O
matching	B-C0150103
cases	B-C1706256
and	O
controls	O
based	O
on	O
age	B-C0001779
,	O
sex	B-C0079399
,	O
exposure	B-C1545382
assessment	I-C1545382
period	I-C1545382
,	O
and	O
methotrexate	B-C0746573
treatment	I-C0746573
.	O
	
we	O
also	O
assessed	B-C0086930
relative	I-C0086930
risk	I-C0086930
of	O
ad	B-C0002395
following	O
exposure	B-C0332157
to	I-C0332157
standard	B-C1442989
ra	B-C0003873
therapies	B-C0087111
,	O
including	O
anti-tnf	B-C1562242
agents	I-C1562242
infliximab	B-C0666743
,	O
adalimumab	B-C1122087
,	O
etanercept	B-C0717758
,	O
methotrexate	B-C0025677
,	O
prednisone	B-C0032952
,	O
sulfasalazine	B-C0036078
,	O
and	O
rituximab	B-C0393022
.	O
	
odds	B-C0028873
ratios	I-C0028873
were	O
adjusted	O
for	O
comorbidities	B-C0009488
,	O
including	O
coronary	B-C0010068
artery	I-C0010068
disease	I-C0010068
,	O
diabetes	B-C0011849
mellitus	I-C0011849
,	O
and	O
peripheral	B-C0085096
vascular	I-C0085096
disease	I-C0085096
.	O
	
ad	B-C0002395
was	O
more	O
prevalent	B-C1542147
p	O
<	O
0.0001	O
among	O
ra	B-C0003873
patients	B-C0030705
0.79	O
%	O
than	O
among	O
those	O
without	B-C0332288
ra	B-C0003873
0.11	O
%	O
.	O
	
chronic	B-C4315615
conditions	I-C4315615
such	O
as	O
coronary	B-C0010068
artery	I-C0010068
disease	I-C0010068
odds	B-C0028873
ratio	I-C0028873
or	B-C0028873
1.48	O
95	O
%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
1.04	O
p	O
=	O
0.03	O
,	O
diabetes	B-C0011847
or	B-C0028873
1.86	O
95	O
%	O
ci	B-C0009667
1.32	O
p	O
=	O
0.0004	O
,	O
and	O
peripheral	B-C0085096
vascular	I-C0085096
disease	I-C0085096
or	B-C0028873
1.61	O
95	O
%	O
ci	B-C0009667
1.06	O
p	O
=	O
0.02	O
significantly	O
increased	O
the	O
relative	B-C0242492
risk	I-C0242492
of	O
ad	B-C0002395
among	O
ra	B-C0003873
patients	B-C0030705
.	O
	
exposure	B-C0332157
to	I-C0332157
anti-tnf	B-C1562242
agents	I-C1562242
as	O
a	O
class	B-C1547013
,	O
but	O
not	O
other	O
immunosuppressive	B-C0021081
drugs	I-C0021081
studied	O
,	O
was	O
associated	B-C0332281
with	I-C0332281
lowered	B-C1272755
risk	B-C1281905
of	O
ad	B-C0002395
among	O
ra	B-C0003873
patients	B-C0030705
unadjusted	O
or	B-C0028873
0.44	O
95	O
%	O
ci	B-C0009667
0.22	O
p	O
=	O
0.02	O
adjusted	O
or	B-C0028873
0.45	O
95	O
%	O
ci	B-C0009667
0.23	O
p	O
=	O
0.02	O
.	O
	
sub-group	B-C2347789
analysis	I-C2347789
demonstrated	O
that	O
of	O
the	O
three	O
anti-tnf	B-C1562242
agents	I-C1562242
studied	O
,	O
only	O
etanercept	B-C0717758
unadjusted	O
or	B-C0028873
,	O
0.33	O
95	O
%	O
ci	B-C0009667
0.08	O
p	O
=	O
0.03	O
adjusted	O
or	B-C0028873
0.30	O
95	O
%	O
ci	B-C0009667
0.08	O
p	O
=	O
0.02	O
was	O
associated	B-C0332281
with	I-C0332281
a	O
decreased	B-C0205216
risk	B-C1281905
of	O
ad	B-C0002395
in	O
ra	B-C0003873
patients	B-C0030705
.	O
	
there	O
is	O
an	O
increased	B-C0205217
risk	B-C1281905
of	O
ad	B-C0002395
in	O
the	O
studied	O
ra	B-C0003873
population	B-C0032659
.	O
	
the	O
relative	B-C0242492
risk	I-C0242492
of	O
ad	B-C0002395
among	O
ra	B-C0003873
subjects	O
was	O
lowered	B-C1272755
in	O
those	O
exposed	B-C0332157
to	I-C0332157
etanercept	B-C0717758
.	O
	
anti-tnf	B-C0281481
therapy	I-C0281481
with	O
etanercept	B-C0717758
shows	O
promise	B-C1555307
as	O
a	O
potential	B-C3245505
treatment	B-C0087111
for	O
dimerization	B-C2350408
of	O
egfr	B-C0034802
and	O
her2	B-C0069515
induces	O
breast	B-C0006142
cancer	I-C0006142
cell	B-C0007608
motility	I-C0007608
through	O
stat1	B-C0287920
-dependent	O
acta2	B-C2716282
induction	B-C0205263
the	O
dimerization	B-C2350408
of	O
egfr	B-C0034802
and	O
her2	B-C0069515
is	O
associated	O
with	O
poor	O
prognosis	B-C0033325
such	O
as	O
induction	B-C0205263
of	O
tumor	B-C0598934
growth	I-C0598934
and	O
cell	B-C2699153
invasion	I-C2699153
compared	B-C1707455
to	O
when	O
egfr	B-C0034802
remains	O
as	O
a	O
homodimer	B-C0596448
.	O
	
however	O
,	O
the	O
mechanism	B-C0441712
for	O
events	O
after	O
dimerization	B-C2350408
in	O
breast	B-C0006142
cancer	I-C0006142
models	B-C0026336
is	O
not	O
clear	O
.	O
	
we	O
found	O
that	O
expressions	B-C1171362
of	O
alpha-smooth	B-C2716282
muscle	I-C2716282
actin	I-C2716282
acta2	B-C2716282
and	O
signal	B-C0287920
transducer	I-C0287920
and	I-C0287920
activator	I-C0287920
of	I-C0287920
transcription	I-C0287920
1	I-C0287920
stat1	B-C0287920
significantly	O
increased	B-C0205217
with	O
transient	O
or	O
stable	O
overexpression	B-C1514559
of	O
her2	B-C0069515
in	O
egfr	B-C0034802
-	O
positive	B-C1446409
breast	B-C0006142
cancer	I-C0006142
cells	B-C0007634
.	O
	
acta2	B-C2716282
and	O
stat1	B-C0287920
expression	B-C1171362
was	O
also	O
increased	B-C0205217
in	O
her2	B-C0069515
-	O
positive	B-C1446409
breast	B-C0006142
cancer	I-C0006142
patients	B-C0030705
.	O
	
in	O
contrast	O
,	O
acta2	B-C2716282
expression	B-C1171362
was	O
decreased	B-C0205216
by	O
her2	B-C1099354
sirna	I-C1099354
.	O
	
next	O
,	O
we	O
investigated	O
the	O
co-relation	O
between	O
stat1	B-C0287920
and	O
acta2	B-C2716282
expression	B-C1171362
.	O
	
basal	O
acta2	B-C2716282
expression	B-C1171362
was	O
significantly	O
decreased	B-C0205216
by	O
treatment	B-C0087111
with	O
the	O
stat1	B-C1254351
inhibitor	I-C1254351
fludarabine	B-C0059985
or	O
the	O
jak2	B-C1254351
inhibitor	I-C1254351
ag490	B-C0381241
.	O
	
in	O
contrast	O
,	O
acta2	B-C2716282
expression	B-C1171362
was	O
increased	B-C0205217
by	O
stat1	B-C0287920
overexpression	B-C1514559
.	O
	
levels	O
of	O
acta2	B-C2716282
,	O
stat1	B-C0287920
,	O
and	O
her2	B-C0069515
were	O
increased	B-C0205217
and	O
relapse	O
free	B-C0242793
survival	I-C0242793
was	O
decreased	B-C0205216
in	O
high-risk	B-C0332167
breast	B-C0006142
cancer	I-C0006142
patients	B-C0030705
.	O
	
we	O
also	O
investigated	B-C1292732
the	O
effect	O
of	O
acta2	B-C2716282
on	O
cell	B-C0007608
motility	I-C0007608
,	O
which	O
was	O
suppressed	B-C1260953
by	O
acta2	B-C2930586
shrna	I-C2930586
overexpression	B-C1514559
in	O
mda-mb231	B-C1512505
her2	B-C0069515
and	O
4t1	B-C1512505
mammary	I-C1512505
carcinoma	I-C1512505
cells	I-C1512505
.	O
	
the	O
number	O
of	O
lung	B-C0034079
metastatic	I-C0034079
nodules	I-C0034079
was	O
significantly	O
decreased	B-C0205216
in	O
acta2	B-C2716282
knockdown	B-C0206745
mice	I-C0206745
.	O
	
taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
induction	B-C0205263
of	O
acta2	B-C2716282
by	O
egfr	B-C0034802
and	O
her2	B-C0069515
dimerization	B-C2350408
was	O
regulated	O
through	O
a	O
jak2	B-C0169661
/	O
stat1	B-C0287920
signaling	B-C0037080
pathway	I-C0037080
,	O
and	O
aberrant	O
acta2	B-C2716282
expression	B-C1171362
accelerated	O
the	O
invasiveness	O
and	O
metastasis	O
of	O
breast	O
cancer	O
cells	B-C0007634
intensive	O
social	B-C0728831
cognitive	B-C0009244
treatment	I-C0009244
can	O
do	O
treatment	B-C1522326
with	O
participation	B-C0679823
of	O
support	O
partners	B-C3887537
in	O
persons	B-C0027361
with	O
relapsing	B-C0751967
remitting	I-C0751967
multiple	I-C0751967
sclerosis	I-C0751967
observation	B-C0700325
of	O
improved	B-C0184511
self-efficacy	B-C0600564
,	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
,	O
anxiety	B-C0003467
and	O
depression	B-C0011570
1	O
year	B-C0439234
later	O
in	O
persons	B-C0027361
with	O
multiple	B-C0026769
sclerosis	I-C0026769
ms	B-C0026769
self-efficacy	B-C0600564
positively	B-C1446409
affects	O
health-related	B-C4279947
quality	I-C4279947
of	I-C4279947
life	I-C4279947
hrqol	B-C4279947
and	O
physical	B-C0026606
activity	I-C0026606
.	O
	
in	O
a	O
previous	O
study	O
we	O
observed	B-C1441672
that	O
6	O
months	B-C0439231
after	O
an	O
intensive	O
3-	O
day	B-C0439228
social	B-C0728831
cognitive	B-C0009244
treatment	I-C0009244
can	O
do	O
treatment	B-C1522326
with	O
the	O
participation	B-C0679823
of	O
support	O
partners	B-C3887537
,	O
self-efficacy	B-C0600564
and	O
hrqol	B-C4279947
had	O
improved	B-C0184511
in	O
persons	B-C0027361
with	O
relapsing	B-C0751967
remitting	I-C0751967
ms	I-C0751967
rrms	B-C0751967
.	O
	
given	O
the	O
chronic	B-C0205191
nature	B-C0449786
of	I-C0449786
the	I-C0449786
disease	I-C0449786
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
these	O
beneficial	B-C0814225
changes	B-C0392747
may	O
last	O
.	O
	
can	O
do	O
treatment	B-C1522326
was	O
given	O
to	O
60	O
persons	B-C0027361
with	O
ms	B-C0026769
and	O
their	O
support	O
partners	B-C3887537
.	O
	
at	O
baseline	B-C1442488
and	O
12	O
months	B-C0439231
after	O
treatment	B-C0087111
self-efficacy	B-C0600564
control	B-C2587213
,	O
self-efficacy	B-C0600564
function	B-C0542341
,	O
physical	B-C0205485
and	O
mental	B-C0025353
hrqol	B-C4279947
,	O
anxiety	B-C0003467
,	O
depression	B-C0011570
and	O
fatigue	B-C0015672
were	O
assessed	B-C1516048
via	O
self-report	B-C2700446
questionnaires	B-C0034394
.	O
	
differences	B-C1705242
were	O
tested	B-C0039593
via	O
a	O
paired	B-C1709451
t	I-C1709451
test	I-C1709451
.	O
	
of	O
the	O
57	O
persons	B-C0027361
with	O
ms	B-C0026769
that	O
completed	B-C0205197
the	O
baseline	B-C1442488
assessment	B-C1516048
and	O
the	O
3-	O
day	B-C0439228
treatment	B-C1522326
,	O
38	O
filled	O
in	O
the	O
12th	O
month	B-C0439231
questionnaires	B-C0034394
response	B-C1704632
rate	B-C1521828
66.7	O
%	O
,	O
22	O
with	O
rrms	B-C0751967
and	O
14	O
with	O
progressive	B-C0205329
ms	B-C0026769
.	O
	
in	O
the	O
rr	B-C0751967
group	B-C0441833
self-efficacy	B-C0600564
control	B-C2587213
had	O
increased	B-C0205217
by	O
20.2	O
%	O
and	O
physical	B-C0205485
hrqol	B-C4279947
by	O
15.0	O
%	O
,	O
and	O
depression	B-C0011570
and	O
anxiety	B-C0003467
had	O
decreased	B-C0205216
by	O
29.8	O
and	O
25.9	O
%	O
,	O
respectively	O
all	O
p	O
<	O
0.05	O
the	O
changes	B-C0392747
in	O
mental	B-C0025353
hrqol	B-C4279947
+17	O
%	O
and	O
fatigue	B-C0015672
-20	O
%	O
failed	B-C0231175
to	O
be	O
statistically	B-C0237881
significant	I-C0237881
p	O
=	O
0.087	O
,	O
p	O
=	O
0.080	O
,	O
respectively	O
.	O
	
in	O
the	O
progressive	B-C0205329
group	B-C0441833
no	O
changes	B-C0392747
suggestive	B-C0332299
of	I-C0332299
improvement	B-C2986411
were	O
seen	O
.	O
	
the	O
findings	B-C2607943
suggest	B-C1705535
that	O
a	O
3-	O
day	B-C0439228
intensive	O
social	B-C0728831
cognitive	B-C0009244
treatment	I-C0009244
can	O
do	O
treatment	B-C1522326
with	O
the	O
participation	B-C0679823
of	O
support	O
partners	B-C3887537
may	O
have	O
long	B-C1254367
lasting	I-C1254367
beneficial	B-C0814225
effects	B-C1280500
on	O
the	O
self-efficacy	B-C0600564
and	O
hrqol	B-C4279947
in	O
persons	B-C0027361
with	O
rrms	B-C0751967
and	O
that	O
improvements	B-C2986411
in	O
anxiety	B-C0003467
and	O
depression	B-C0011570
,	O
not	O
seen	O
in	O
the	O
6-	O
month	B-C0439231
study	O
,	O
may	O
yet	O
develop	B-C1527148
at	O
12	O
perineal	B-C3544174
injuries	I-C3544174
and	O
birth	B-C0243095
positions	I-C0243095
among	O
2992	O
women	B-C0043210
with	O
a	O
low	B-C0404841
risk	I-C0404841
pregnancy	I-C0404841
who	O
opted	O
for	O
a	O
homebirth	B-C0419367
whether	O
certain	O
birth	B-C0243095
positions	I-C0243095
are	O
associated	B-C0332281
with	I-C0332281
perineal	B-C3544174
injuries	I-C3544174
and	O
severe	B-C0559034
perineal	I-C0559034
trauma	I-C0559034
spt	B-C0559034
is	O
still	O
unclear	B-C3845108
.	O
	
the	O
objective	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
describe	O
the	O
prevalence	B-C0220900
of	O
perineal	B-C3544174
injuries	I-C3544174
of	O
different	O
severity	B-C0439793
in	O
a	O
low-risk	B-C3538919
population	B-C1257890
of	O
women	B-C0043210
who	O
planned	O
to	O
give	O
birth	B-C0419367
at	I-C0419367
home	I-C0419367
and	O
to	O
compare	O
the	O
prevalence	B-C0220900
of	O
perineal	B-C3544174
injuries	I-C3544174
,	O
spt	B-C0559034
and	O
episiotomy	B-C0014586
in	O
different	O
birth	B-C0243095
positions	I-C0243095
in	O
four	O
nordic	B-C0036273
countries	I-C0036273
.	O
	
a	O
population	B-C1257890
-based	O
prospective	B-C1709709
cohort	I-C1709709
study	I-C1709709
of	O
planned	O
home	B-C0419367
births	I-C0419367
in	O
four	O
nordic	B-C0036273
countries	I-C0036273
.	O
	
to	O
assess	B-C3824997
medical	I-C3824997
outcomes	I-C3824997
a	O
questionnaire	B-C0034394
completed	O
after	O
birth	B-C0005615
by	O
the	O
attending	O
midwife	B-C0026083
was	O
used	O
.	O
	
descriptive	B-C1710191
statistics	I-C1710191
,	O
bivariate	B-C0681927
analysis	I-C0681927
and	O
logistic	B-C0206031
regression	I-C0206031
were	O
used	O
to	O
analyze	O
the	O
data	B-C1511726
.	O
	
two	O
thousand	O
nine	O
hundred	O
ninety-two	O
women	B-C0043210
with	O
planned	O
home	B-C0419367
births	I-C0419367
,	O
who	O
birthed	O
spontaneously	O
at	O
home	B-C0442519
or	O
after	O
transfer	B-C0184736
to	I-C0184736
hospital	I-C0184736
,	O
between	O
2008	O
and	O
2013	O
were	O
included	O
.	O
	
the	O
prevalence	B-C0220900
of	O
spt	B-C0559034
was	O
0.7	O
%	O
and	O
the	O
prevalence	B-C0220900
of	O
episiotomy	B-C0014586
was	O
1.0	O
%	O
.	O
	
there	O
were	O
differences	O
between	O
the	O
countries	O
regarding	O
all	O
maternal	B-C1858460
characteristics	B-C1521970
.	O
	
no	O
association	O
between	O
flexible	B-C0443220
sacrum	B-C3669209
positions	B-C0733755
and	O
sutured	B-C0205368
perineal	B-C3544174
injuries	I-C3544174
was	O
found	O
or	B-C0028873
1.02	O
95	O
%	O
ci	B-C0009667
0.86	O
or	O
spt	B-C0559034
or	B-C0028873
0.68	O
ci	B-C0009667
95	O
%	O
0.26	O
.	O
	
flexible	B-C0443220
sacrum	B-C3669209
positions	B-C0733755
were	O
associated	B-C0332281
with	I-C0332281
fewer	O
episiotomies	B-C0014586
or	B-C0028873
0.20	O
ci	B-C0009667
95	O
%	O
0.10	O
.	O
	
a	O
low	O
prevalence	B-C0220900
of	O
spt	B-C0559034
and	O
episiotomy	B-C0014586
was	O
found	O
among	O
women	B-C0043210
opting	O
for	O
a	O
home	B-C0419367
birth	I-C0419367
in	O
four	O
nordic	B-C0036273
countries	I-C0036273
.	O
	
women	B-C0043210
used	O
a	O
variety	O
of	O
birth	B-C0243095
positions	I-C0243095
and	O
a	O
majority	O
gave	O
birth	B-C0005615
in	O
flexible	B-C0443220
sacrum	B-C3669209
positions	B-C0733755
.	O
	
no	O
associations	O
were	O
found	O
between	O
flexible	B-C0443220
sacrum	B-C3669209
positions	B-C0733755
and	O
spt	B-C0559034
.	O
	
flexible	B-C0443220
sacrum	B-C3669209
positions	B-C0733755
were	O
associated	B-C0332281
with	I-C0332281
fewer	O
parallel-processing	B-C0597171
continuous-flow	B-C0179969
device	I-C0179969
for	O
optimization	B-C2698650
-	O
free	B-C0332296
polymerase	B-C0032520
chain	I-C0032520
reaction	I-C0032520
a	O
parallel-processing	B-C0597171
four-station	B-C0032520
polymerase	I-C0032520
chain	I-C0032520
reaction	I-C0032520
pcr	B-C0032520
device	B-C0699733
has	O
been	O
developed	O
,	O
which	O
performs	B-C0884358
continuous-flow	B-C0806140
pcr	B-C0032520
without	O
optimization	B-C2698650
of	O
the	O
annealing	B-C0920681
temperature	B-C0039476
.	O
	
since	O
the	O
annealing	B-C0920681
temperature	B-C0039476
of	O
each	O
station	B-C1883167
can	O
be	O
controlled	B-C2587213
independently	B-C0332291
,	O
the	O
device	B-C0699733
covers	B-C1999244
an	O
annealing	B-C0920681
temperature	B-C0039476
range	B-C1514721
of	O
50-68	O
c	O
,	O
which	O
is	O
wide	B-C0332464
enough	O
to	O
perform	B-C0884358
pcr	B-C0032520
for	O
any	O
dna	B-C0684192
fragment	I-C0684192
regardless	O
of	O
its	O
optimum	B-C2698651
annealing	B-C0920681
condition	B-C0348080
.	O
	
this	O
arrangement	B-C0870432
lets	O
us	O
continuously	B-C0549178
obtain	B-C1301820
an	O
amplified	B-C1521871
amount	B-C1265611
of	O
a	O
dna	B-C0684192
fragment	I-C0684192
at	O
least	O
from	O
one	O
of	O
the	O
stations	B-C1883167
.	O
	
the	O
device	B-C0699733
consists	O
of	O
four	O
identical	B-C0205280
cylindrical	B-C0205114
stations	B-C1883167
diameter	B-C1301886
20	O
mm	O
,	O
height	B-C0489786
55	O
mm	O
.	O
	
a	O
polytetrafluoroethylene	B-C0032611
capillary	B-C0376432
reactor	I-C0376432
length	B-C1444754
2	O
m	O
,	O
i.d	O
.	O
	
100	O
μm	O
,	O
o.d	O
.	O
	
400	O
μm	O
is	O
wound	B-C0231467
helically	I-C0231467
up	B-C1282911
around	B-C0750503
each	O
station	B-C1883167
.	O
	
the	O
whole	O
assembly	B-C1706853
is	O
designed	B-C1707689
to	O
minimize	B-C1524031
the	O
number	B-C0237753
of	O
heating	B-C0181153
blocks	I-C0181153
for	O
providing	B-C1999230
temperatures	B-C0039476
of	O
denaturation	B-C0301642
,	O
annealing	B-C0920681
,	O
and	O
extension	B-C0231448
to	O
be	O
seven	O
and	O
to	O
shape	B-C0332479
a	O
compact	B-C1333134
cube	B-C1880194
height	B-C0489786
55	O
mm	O
,	O
base	B-C1626935
60	O
mm	O
60	O
mm	O
.	O
	
the	O
reproducibility	B-C1514863
for	O
continuous-flow	B-C0806140
pcr	B-C0032520
is	O
reasonably	O
high	B-C0205250
run	B-C1704688
-to-	O
run	B-C1704688
and	O
station	B-C1883167
-to-	O
station	B-C1883167
relative	O
standard	B-C0871420
deviation	I-C0871420
of	O
their	O
amplification	B-C0683230
is	O
lower	O
than	O
6	O
%	O
and	O
about	O
4	O
%	O
,	O
respectively	O
.	O
	
performance	B-C1882330
on	O
the	O
optimization	B-C2698650
-	O
free	B-C0332296
dna	B-C0683230
amplification	I-C0683230
has	O
been	O
evaluated	B-C0220825
with	O
four	O
dna	B-C0444245
samples	I-C0444245
with	O
different	B-C1705242
annealing	B-C0920681
conditions	B-C0348080
and	O
product	B-C1514468
sizes	B-C0456389
323	O
,	O
608	O
,	O
828	O
,	O
and	O
1101	O
bp	O
,	O
which	O
has	O
demonstrated	B-C0443289
that	O
in	O
all	O
cases	B-C0868928
,	O
pcr	B-C0032520
is	O
successful	B-C1272703
at	O
least	O
on	O
one	O
station	B-C1883167
.	O
	
in	O
addition	B-C0332287
,	O
three	O
dna	B-C0684192
fragment	I-C0684192
s	O
with	O
different	B-C1705242
lengths	B-C1444754
323	O
,	O
1101	O
,	O
and	O
2836	O
bp	O
have	O
been	O
successfully	B-C1272703
amplified	B-C1521871
in	O
a	O
segmented	B-C0442059
-	O
flow	B-C0806140
mode	B-C1513371
without	O
the	O
carry-over	O
contamination	B-C2349974
between	O
segments	B-C0442059
.	O
	
this	O
result	B-C1274040
suggests	O
that	O
this	O
device	B-C0699733
could	O
serve	O
as	O
the	O
pcr	B-C0032520
module	B-C1709061
of	O
a	O
continuous-flow	B-C0806140
high-throughput	B-C0872186
on-line	I-C0872186
total	I-C0872186
dna	I-C0872186
analysis	I-C0872186
system	B-C0449913
integrating	B-C0205195
all	O
necessary	O
modules	B-C1709061
from	O
cell	B-C0007634
lysis	B-C0024348
/	O
dna	B-C3839098
extraction	I-C3839098
to	O
pcr	B-C0032520
product	B-C1514468
analysis	B-C0936012
.	O
	
assessing	B-C1516048
sex-differences	B-C0036866
and	O
the	O
effect	B-C1280500
of	O
timing	B-C0449243
of	O
vaccination	B-C0042196
on	O
immunogenicity	B-C4277607
,	O
reactogenicity	B-C1691781
and	O
efficacy	B-C3242199
of	I-C3242199
vaccines	I-C3242199
in	O
young	B-C0332239
children	B-C0008059
study	B-C2348563
protocol	I-C2348563
for	O
an	O
individual	B-C0237401
participant	B-C0679646
data	B-C1511726
meta-analysis	B-C0920317
of	O
randomised	B-C0206035
controlled	I-C0206035
trials	I-C0206035
disease	B-C0012634
incidence	B-C0021149
differs	O
between	O
males	B-C0086582
and	O
females	B-C0086287
for	O
some	O
infectious	B-C0009450
or	O
inflammatory	B-C1290884
diseases	I-C1290884
.	O
	
sex-differences	B-C0036866
in	O
immune	B-C0301872
responses	I-C0301872
to	O
some	O
vaccines	B-C0042210
have	O
also	O
been	O
observed	O
,	O
mostly	O
to	O
viral	B-C0042742
vaccines	I-C0042742
in	O
adults	B-C0001675
.	O
	
little	O
evidence	B-C3887511
is	O
available	B-C0470187
on	O
whether	O
sex-differences	B-C0036866
occur	O
in	O
response	B-C1704632
to	O
immunisation	B-C0020971
in	O
infancy	B-C0231330
even	O
though	O
this	O
is	O
the	O
age	B-C0027362
group	I-C0027362
in	O
which	O
most	O
vaccines	B-C0042210
are	O
administered	B-C1521801
.	O
	
factors	B-C1521761
other	O
than	O
sex	B-C1522384
,	O
such	O
as	O
timing	B-C0449243
or	O
coadministration	B-C1533734
of	O
other	O
vaccines	B-C0042210
,	O
can	O
also	O
influence	B-C4054723
the	O
immune	B-C0301872
response	I-C0301872
to	O
vaccination	B-C0042196
.	O
	
individual	B-C0237401
participant	B-C0679646
data	B-C1511726
meta-analysis	B-C0920317
of	O
randomised	B-C0206035
controlled	I-C0206035
trials	I-C0206035
of	O
vaccines	B-C0042210
in	O
healthy	O
infants	B-C0021270
and	O
young	B-C0332239
children	B-C0008059
will	O
be	O
conducted	O
.	O
	
fully	O
anonymised	O
data	B-C1511726
from	O
170	O
randomised	B-C0206035
controlled	I-C0206035
trials	I-C0206035
of	O
v	O
accines	B-C0042210
for	O
diphtheria	B-C0012546
,	O
tetanus	B-C0039614
,	O
bordetella	B-C0006017
pertussis	I-C0006017
,	O
polio	B-C0032371
,	O
haemophilus	B-C0121772
influenzae	I-C0121772
type	I-C0121772
b	I-C0121772
,	O
hepatitis	B-C0019163
b	I-C0019163
,	O
streptococcus	B-C0038410
pneumoniae	I-C0038410
,	O
neisseria	B-C0027575
meningitidis	I-C0027575
,	O
measles	B-C0025007
,	O
mumps	B-C0026780
,	O
rubella	B-C0035920
,	O
varicella	B-C0008049
and	O
rotavirus	B-C0035870
will	O
be	O
combined	O
for	O
analysis	B-C0936012
.	O
	
outcomes	B-C1274040
include	O
measures	B-C1879489
of	O
immunogenicity	B-C4277607
immunoglobulins	B-C0021027
,	O
reactogenicity	B-C1691781
,	O
safety	B-C0036043
and	O
disease	B-C0012634
-specific	O
clinical	B-C3850123
efficacy	I-C3850123
.	O
	
data	B-C1511726
from	O
trials	B-C0008976
of	O
vaccines	B-C0042210
containing	O
similar	O
components	B-C0449432
will	O
be	O
combined	O
in	O
hierarchical	B-C0699032
models	B-C3161035
and	O
the	O
effect	B-C1280500
of	O
sex	B-C1522384
and	O
timing	B-C0449243
of	O
vaccinations	B-C0042196
estimated	O
for	O
each	O
outcome	B-C1274040
separately	O
.	O
	
systematic	B-C1955832
reviews	I-C1955832
of	O
published	B-C0034037
estimates	O
of	O
sex-differences	B-C0036866
cannot	O
adequately	O
answer	B-C0508431
questions	I-C0508431
in	O
this	O
field	B-C1521738
since	O
such	O
comparisons	B-C1707455
are	O
never	O
the	O
main	O
purpose	B-C1285529
of	O
a	O
clinical	B-C0008976
trial	I-C0008976
,	O
thus	O
a	O
large	B-C0549177
degree	B-C0449286
of	O
reporting	B-C0700287
bias	B-C0242568
exists	B-C2987476
in	O
the	O
published	B-C0034037
literature	B-C0023866
.	O
	
recent	O
improvements	B-C2986411
in	O
the	O
widespread	B-C0205391
availability	B-C0470187
of	I-C0470187
individual	B-C0237401
participant	B-C0679646
data	B-C1511726
from	O
randomised	B-C0206035
controlled	I-C0206035
trials	I-C0206035
makes	O
it	O
feasible	O
to	O
conduct	O
extensive	B-C0205231
individual	B-C0237401
participant	B-C0679646
data	B-C1511726
meta-analyses	B-C0920317
which	O
were	O
previously	B-C0205156
impossible	B-C0243095
,	O
thereby	O
reducing	B-C0392756
the	O
effect	B-C1280500
of	O
publication	B-C0034036
or	O
reporting	B-C0700287
bias	B-C0242568
on	O
the	O
understanding	B-C0162340
of	O
the	O
infant	B-C0021270
immune	B-C0301872
response	I-C0301872
.	O
	
preliminary	B-C1548161
results	I-C1548161
will	O
be	O
available	B-C0470187
in	O
2016	O
with	O
final	O
results	B-C1274040
available	B-C0470187
in	O
2019	O
.	O
	
no	B-C0332197
ethics	B-C0015000
review	B-C0282443
is	O
required	O
for	O
secondary	B-C0683944
analyses	I-C0683944
of	O
anonymised	O
an	O
ultrasensitive	B-C0332324
electrochemiluminescence	B-C3830326
sensor	B-C0183210
based	O
on	O
reduced	B-C2936695
graphene	I-C2936695
oxide	I-C2936695
-	O
copper	B-C0389357
sulfide	I-C0389357
composite	B-C0205199
coupled	O
with	O
capillary	B-C0201699
electrophoresis	I-C0201699
for	O
determination	B-C1148554
of	O
amlodipine	B-C0354468
besylate	I-C0354468
in	O
mice	B-C0025929
plasma	B-C0032105
a	O
new	O
electrochemiluminescence	B-C3830326
ecl	B-C3830326
sensor	B-C0183210
based	O
on	O
reduced	B-C2936695
graphene	I-C2936695
oxide	I-C2936695
-	O
copper	B-C0389357
sulfide	I-C0389357
rgo	B-C2936695
-	O
cus	B-C0389357
composite	B-C0205199
coupled	O
with	O
capillary	B-C0201699
electrophoresis	I-C0201699
ce	B-C0201699
was	O
constructed	O
for	O
the	O
ultrasensitive	B-C0332324
detection	B-C1511790
of	O
amlodipine	B-C0354468
besylate	I-C0354468
aml	B-C0354468
for	O
the	O
first	O
time	O
.	O
	
in	O
this	O
work	O
,	O
rgo	B-C2936695
-	O
cus	B-C0389357
composite	B-C0205199
was	O
synthesized	O
by	O
one-pot	O
hydrothermal	B-C0449851
method	I-C0449851
and	O
used	O
for	O
electrode	B-C0013812
modification	B-C3840684
.	O
	
the	O
electrochemical	B-C2350499
and	O
ecl	B-C3830326
behaviors	O
of	O
the	O
sensor	B-C0183210
were	O
investigated	B-C1292732
.	O
	
more	O
than	O
5-fold	O
enhance	B-C2349975
in	O
ecl	B-C3830326
intensity	B-C0871362
was	O
observed	B-C1441672
after	O
modified	O
with	O
rgo	B-C2936695
-	O
cus	B-C0389357
composite	B-C0205199
.	O
	
the	O
results	B-C0456984
can	O
be	O
ascribed	O
to	O
the	O
presence	B-C3854307
of	O
rgo	B-C2936695
-	O
cus	B-C0389357
composite	B-C0205199
on	O
the	O
electrode	B-C0013812
surface	B-C0205148
that	O
facilitates	O
the	O
electron	B-C1521828
transfer	I-C1521828
rate	I-C1521828
between	O
the	O
electroactive	B-C0205177
center	B-C0205099
of	O
ru	B-C1704241
and	O
the	O
electrode	B-C0013812
.	O
	
the	O
ecl	B-C3830326
sensor	B-C0183210
was	O
coupled	B-C1948027
with	O
ce	B-C0201699
to	O
improve	O
the	O
selectivity	B-C1254595
and	O
the	O
ce	B-C0201699
-	O
ecl	B-C3830326
parameters	B-C0449381
that	O
affect	O
separation	B-C0678621
and	O
detection	B-C1511790
were	O
optimized	O
.	O
	
under	O
the	O
optimum	B-C2698651
conditions	O
,	O
the	O
linear	B-C1514721
ranges	I-C1514721
for	O
aml	B-C0354468
was	O
0.008	O
with	O
a	O
detection	B-C2718050
limit	I-C2718050
of	O
2.8ng	O
s/n=3	O
.	O
	
the	O
method	B-C0871511
displayed	O
the	O
advantages	O
of	O
high	B-C2346484
sensitivity	I-C2346484
,	O
good	B-C1254595
selectivity	I-C1254595
,	O
wide	O
linear	B-C1514721
range	I-C1514721
,	O
low	O
detection	B-C2718050
limit	I-C2718050
and	O
fine	B-C1514863
reproducibility	I-C1514863
,	O
and	O
was	O
used	O
to	O
analyze	O
aml	B-C0354468
in	O
mice	B-C0025929
plasma	B-C0032105
with	O
a	O
satisfactory	O
result	B-C0456984
,	O
which	O
holds	O
a	O
great	O
potential	B-C3245505
in	O
the	O
field	O
of	O
pharmaceutical	B-C0936012
analysis	I-C0936012
.	O
	
estrogen	B-C0014939
and	O
progesterone	B-C0033308
hormone	B-C0019932
receptor	B-C0597360
expression	I-C0597360
in	O
oral	B-C0151546
cavity	I-C0151546
cancer	I-C0151546
recent	O
studies	O
have	O
shown	O
an	O
increase	B-C0442805
in	O
the	O
incidence	B-C0021149
of	O
oral	B-C0585362
squamous	I-C0585362
cell	I-C0585362
carcinoma	I-C0585362
oscc	B-C0585362
in	O
younger	B-C0332239
patients	B-C0030705
.	O
	
the	O
hypothesis	B-C1512571
that	O
tumors	B-C0027651
could	O
be	O
hormonally	B-C0019932
induced	B-C0205263
during	O
pregnancy	B-C0032961
or	O
in	O
young	B-C0332239
female	B-C0086287
patients	B-C0030705
without	O
the	O
well-known	O
risk	B-C0035648
factors	I-C0035648
alcohol	B-C0085762
or	O
tobacco	B-C0040336
abuse	I-C0040336
seems	O
to	O
be	O
plausible	O
.	O
	
estrogen	B-C0665341
receptor	I-C0665341
alpha	I-C0665341
erα	B-C0665341
and	O
progesterone	B-C0034833
receptor	I-C0034833
pr	B-C0034833
expression	B-C0597360
were	O
analyzed	B-C0936012
in	O
normal	O
oral	B-C0026639
mucosa	I-C0026639
n=5	O
,	O
oral	B-C0221198
precursor	I-C0221198
lesions	I-C0221198
simple	B-C0456483
hyperplasia	I-C0456483
,	O
n=11	O
squamous	B-C1302751
intraepithelial	I-C1302751
neoplasia	I-C1302751
,	O
sin	B-C1302751
i-iii	I-C1302751
,	O
n=35	O
,	O
and	O
oscc	B-C0585362
specimen	B-C0370003
.	O
	
osccs	B-C0585362
were	O
stratified	B-C0205363
in	O
a	O
young	B-C0332239
female	B-C0086287
n=7	O
study	O
cohort	B-C0599755
and	O
older	B-C3826770
patients	B-C0030705
n=46	O
.	O
	
in	O
the	O
young	B-C0332239
female	B-C0086287
study	O
cohort	B-C0599755
three	O
patients	B-C0030705
n=3/7	O
developed	O
oscc	B-C0585362
during	O
or	O
shortly	O
after	O
pregnancy	B-C0032961
.	O
	
breast	B-C0678222
cancer	I-C0678222
tissues	B-C0040300
were	O
used	O
as	O
positive	B-C1883676
control	I-C1883676
for	O
erα	B-C0665341
and	O
pr	B-C0034833
expression	B-C0597360
.	O
	
erα	B-C0665341
expression	B-C0597360
was	O
found	O
in	O
four	O
oral	B-C0221198
precursor	I-C0221198
lesions	I-C0221198
squamous	B-C1302751
intraepithelial	I-C1302751
neoplasia	I-C1302751
,	O
sin	B-C1302751
i-iii	I-C1302751
,	O
n=4/35	O
,	O
11%	O
and	O
in	O
five	O
oscc	B-C0585362
specimen	B-C0370003
n=5/46	O
,	O
11%	O
.	O
	
the	O
five	O
erα	B-C0665341
positive	B-C1446409
oscc	B-C0585362
samples	B-C0370003
were	O
older	B-C3826770
male	B-C0086582
patients	B-C0030705
.	O
	
all	O
patients	B-C0030705
within	O
the	O
young	B-C0332239
female	B-C0086287
study	O
cohort	B-C0599755
were	O
negatively	B-C0205160
stained	O
for	O
both	O
erα	B-C0665341
and	O
pr	B-C0034833
.	O
	
er	B-C0034804
expression	B-C0597360
could	O
be	O
regarded	O
as	O
a	O
seldom	B-C0522498
risk	B-C0035648
factor	I-C0035648
for	O
oscc	B-C0585362
.	O
	
pr	B-C0034833
expression	B-C0597360
seems	O
to	O
be	O
not	O
relevant	B-C2347946
for	O
the	O
development	B-C1527148
of	O
studying	B-C0681814
neuroprotective	B-C0815279
effect	I-C0815279
of	O
atorvastatin	B-C0286651
as	O
a	O
small	B-C1328819
molecule	I-C1328819
drug	B-C1254351
on	O
high	B-C0860803
glucose	I-C0860803
-	O
induced	B-C0205263
neurotoxicity	B-C0235032
in	O
undifferentiated	B-C0205618
pc12	B-C0085262
cells	I-C0085262
role	B-C1705810
of	O
nadph	B-C0068355
oxidase	I-C0068355
overproduction	B-C0205556
of	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
ros	B-C0162772
by	O
nadph	B-C0068355
oxidase	I-C0068355
nox	B-C0068355
activation	B-C0014429
has	O
been	O
considered	B-C0750591
the	O
essential	B-C0205224
mechanism	B-C0441712
induced	B-C0205263
by	O
hyperglycemia	B-C0020456
in	O
various	O
tissues	B-C0040300
.	O
	
however	O
,	O
there	O
is	O
no	B-C0205556
comprehensive	I-C0205556
study	B-C0681814
on	O
the	O
role	B-C1705810
of	O
noxs	B-C0068355
in	O
high	B-C0860803
glucose	I-C0860803
hg	B-C0860803
induced	B-C0205263
toxic	B-C0600688
effect	I-C0600688
in	O
neural	B-C0027757
tissues	I-C0027757
.	O
	
recently	O
,	O
a	O
therapeutic	B-C0302350
strategy	B-C0679199
in	O
oxidative	B-C0311404
related	B-C0439849
pathologies	B-C0030664
has	O
been	O
introduced	B-C1292748
by	O
blocking	B-C0332206
the	O
undesirable	B-C3266814
actions	I-C3266814
of	O
nox	B-C0068355
enzymes	I-C0068355
by	O
small	B-C1328819
molecules	I-C1328819
.	O
	
the	O
protective	B-C1545588
roles	B-C1705810
of	O
statins	B-C0360714
in	O
ameliorating	B-C0205556
oxidative	B-C0242606
stress	I-C0242606
by	O
nox	B-C0068355
inhibition	B-C1524081
have	O
been	O
shown	O
in	O
some	O
tissues	B-C0040300
except	O
neural	B-C0027757
.	O
	
we	O
hypothesized	B-C1512571
then	O
,	O
that	O
different	B-C1705242
noxs	B-C0068355
may	O
have	O
role	B-C1705810
in	O
hg	B-C0860803
-	O
induced	B-C0205263
neural	B-C0599732
cell	I-C0599732
injury	I-C0599732
.	O
	
furthermore	O
,	O
we	O
postulate	B-C1705535
that	O
atorvastatin	B-C0286651
as	O
a	O
small	B-C1328819
molecule	I-C1328819
may	O
modulate	B-C0443264
this	O
noxs	B-C1151146
activity	I-C1151146
to	O
protect	B-C1545588
neural	B-C0027882
cells	I-C0027882
.	O
	
undifferentiated	B-C0205618
pc12	B-C0085262
cells	I-C0085262
were	O
treated	B-C0332293
with	I-C0332293
hg	B-C0860803
140	O
mm/	O
24	B-C0456696
h	I-C0456696
in	O
the	O
presence	B-C0150312
and	O
absence	B-C0332197
of	O
atorvastatin	B-C0286651
1	O
μm/	O
96	B-C0439227
h	I-C0439227
.	O
	
the	O
cell	B-C0007620
viability	I-C0007620
was	O
measured	B-C0444706
by	O
mtt	B-C2986858
assay	I-C2986858
and	O
the	O
gene	B-C1956267
and	O
protein	B-C3463810
expressions	I-C3463810
profile	I-C3463810
of	O
nox	B-C0068355
1-4	O
were	O
determined	B-C0521095
by	I-C0521095
rt-pcr	B-C0599161
and	O
western	B-C0005863
blotting	I-C0005863
,	O
respectively	O
.	O
	
levels	B-C0441889
of	O
ros	B-C0162772
and	O
malondialdehyde	B-C0024643
mda	B-C0024643
were	O
also	O
evaluated	B-C1516048
.	O
	
gene	B-C0017262
and	O
protein	B-C1171362
expression	I-C1171362
levels	B-C0441889
of	O
nox	B-C0068355
1-4	O
and	O
consequently	B-C3845876
ros	B-C0162772
and	O
mda	B-C0024643
levels	B-C0441889
were	O
elevated	B-C3163633
in	O
hg	B-C0860803
-	O
treated	B-C1522326
pc12	B-C0085262
cells	I-C0085262
.	O
	
atorvastatin	B-C0286651
could	O
significantly	B-C0750502
decrease	B-C0547047
hg	B-C0860803
-	O
induced	B-C0205263
noxs	B-C0068355
,	O
ros	B-C0162772
and	O
mda	B-C0024643
elevation	B-C0702240
and	O
improve	B-C0184511
impaired	B-C0221099
cell	B-C0007620
viability	I-C0007620
.	O
	
it	O
can	O
be	O
concluded	B-C1707478
that	O
hg	B-C0860803
could	O
elevate	B-C3163633
noxs	B-C1151146
activity	I-C1151146
,	O
ros	B-C0162772
and	O
mda	B-C0024643
levels	B-C0441889
in	O
neural	B-C0027757
tissues	I-C0027757
and	O
atorvastatin	B-C0286651
as	O
a	O
small	B-C1328819
molecule	I-C1328819
nox	B-C1254351
inhibitor	I-C1254351
drug	I-C1254351
may	O
prevent	B-C2700409
and	O
delay	B-C0205421
diabetic	B-C0342257
complications	I-C0342257
,	O
particularly	O
intravascular	B-C0442123
inflammation	B-C0021368
triggers	B-C1444748
intracerebral	B-C0442111
activated	B-C1879547
microglia	B-C0206116
and	O
contributes	O
to	O
secondary	B-C0270611
brain	I-C0270611
injury	I-C0270611
after	O
experimental	B-C1517586
subarachnoid	B-C0038525
hemorrhage	I-C0038525
esah	B-C0038525
activation	B-C1879547
of	O
innate	B-C0020969
immunity	I-C0020969
contributes	O
to	O
secondary	B-C0270611
brain	I-C0270611
injury	I-C0270611
after	O
experimental	B-C1517586
subarachnoid	B-C0038525
hemorrhage	I-C0038525
esah	B-C0038525
.	O
	
microglia	B-C0206116
accumulation	B-C4055506
and	O
activation	B-C1879547
within	O
the	O
brain	B-C0006104
has	O
recently	O
been	O
shown	O
to	O
induce	O
neuronal	B-C2754100
cell	I-C2754100
death	I-C2754100
after	O
esah	B-C0038525
.	O
	
in	O
isolated	B-C0205409
mouse	B-C0025929
brain	B-C0006104
capillaries	B-C0935624
after	O
esah	B-C0038525
,	O
we	O
show	O
a	O
significantly	O
increased	O
gene	B-C0017262
expression	I-C0017262
for	O
intercellular	B-C1334074
adhesion	I-C1334074
molecule-1	I-C1334074
icam-1	B-C1334074
and	O
p-selectin	B-C1335809
.	O
	
hence	O
,	O
we	O
hypothesized	B-C1512571
that	O
extracerebral	B-C1254362
intravascular	B-C0442123
inflammatory	B-C1155266
processes	I-C1155266
might	O
initiate	O
the	O
previously	O
reported	B-C0700287
microglia	B-C0206116
accumulation	B-C4055506
within	O
the	O
brain	B-C0459385
tissue	I-C0459385
.	O
	
we	O
therefore	O
induced	O
esah	B-C0038525
in	O
knockout	B-C0206745
mice	I-C0206745
for	O
icam-1	B-C1334074
icam-1	B-C1334074
and	O
p-selectin	B-C1419941
glycoprotein	I-C1419941
ligand-1	I-C1419941
psgl-1	B-C1419941
to	O
find	O
a	O
significant	O
decrease	O
in	O
neutrophil	B-C0027950
-	O
endothelial	B-C0225336
interaction	B-C0007582
within	O
the	O
first	O
7	O
days	O
after	O
the	O
bleeding	B-C0019080
in	O
a	O
chronic	B-C0205191
cranial	B-C3163632
window	B-C0026339
model	I-C0026339
.	O
	
this	O
inhibition	B-C3463820
of	O
neutrophil	B-C0751982
recruitment	I-C0751982
to	O
the	O
endothelium	B-C0225336
results	O
in	O
significantly	O
ameliorated	B-C0243095
microglia	B-C0206116
accumulation	B-C4055506
and	O
neuronal	B-C2754100
cell	I-C2754100
death	I-C2754100
in	O
knockout	B-C1171353
animals	I-C1171353
in	O
comparison	O
to	O
controls	O
.	O
	
our	O
results	O
suggest	O
an	O
outside-in	O
activation	B-C1879547
of	O
the	O
cns	B-C3714787
innate	I-C3714787
immune	B-C0020962
system	I-C0020962
at	O
the	O
vessel	B-C0042591
/	O
brain	B-C0006104
interface	O
following	O
esah	B-C0038525
.	O
	
microglia	B-C0206116
cells	B-C0007634
,	O
as	O
part	O
of	O
the	O
brain's	B-C0006104
innate	B-C0020969
immune	I-C0020969
system	I-C0020969
,	O
are	O
triggered	B-C1444748
by	O
an	O
inflammatory	B-C0021368
reaction	I-C0021368
in	O
the	O
microvasculature	B-C0243079
after	O
esah	B-C0038525
,	O
thus	O
contributing	O
to	O
neuronal	B-C2754100
cell	I-C2754100
death	I-C2754100
.	O
	
this	O
finding	O
offers	O
a	O
whole	O
range	O
of	O
new	O
research	B-C0035168
targets	B-C1521840
,	O
as	O
well	O
as	O
possible	O
therapy	B-C0039798
options	O
for	O
patients	B-C0030705
suffering	O
from	O
amphetamine	B-C0236665
withdrawal	I-C0236665
differentially	O
increases	O
the	O
expression	B-C1171362
of	O
organic	B-C1453697
cation	I-C1453697
transporter	I-C1453697
3	I-C1453697
and	O
serotonin	B-C0170657
transporter	I-C0170657
in	O
limbic	B-C0023715
brain	B-C0006104
regions	I-C0006104
amphetamine	B-C0236665
withdrawal	I-C0236665
increases	O
anxiety	B-C0003467
and	O
stress	B-C0038435
sensitivity	O
related	O
to	O
blunted	B-C1997138
ventral	B-C1704448
hippocampus	B-C0019564
vhipp	B-C0019564
and	O
enhances	O
the	O
central	B-C0175219
nucleus	I-C0175219
of	I-C0175219
the	I-C0175219
amygdala	I-C0175219
cea	B-C0175219
serotonin	B-C0036751
responses	B-C0871261
.	O
	
extracellular	B-C0521119
serotonin	B-C0036751
levels	B-C0441889
are	O
regulated	O
by	O
the	O
serotonin	B-C0170657
transporter	I-C0170657
sert	B-C0170657
and	O
organic	B-C1453697
cation	I-C1453697
transporter	I-C1453697
3	I-C1453697
oct3	B-C1453697
,	O
and	O
vhipp	B-C0019564
oct3	B-C1453697
expression	B-C1171362
is	O
enhanced	O
during	O
24	B-C1442770
hours	I-C1442770
of	O
amphetamine	B-C0236665
withdrawal	I-C0236665
,	O
while	O
sert	B-C0170657
expression	B-C1171362
is	O
unaltered	O
.	O
	
here	O
,	O
we	O
tested	O
whether	O
oct3	B-C1453697
and	O
sert	B-C0170657
expression	B-C1171362
in	O
the	O
cea	B-C0175219
is	O
also	O
affected	O
during	O
acute	O
withdrawal	B-C2825032
to	O
explain	O
opposing	O
regional	O
alterations	O
in	O
limbic	B-C0023715
serotonergic	B-C2262837
neurotransmission	I-C2262837
and	O
if	O
respective	O
changes	O
continued	O
with	O
two	B-C4082118
weeks	I-C4082118
of	O
withdrawal	B-C2825032
.	O
	
we	O
also	O
determined	O
whether	O
changes	O
in	O
transporter	B-C0596902
expression	B-C1171362
were	O
confined	O
to	O
these	O
regions	O
.	O
	
male	B-C0086582
rats	B-C0004728
received	O
amphetamine	B-C0002658
or	O
saline	B-C0036082
for	O
two	B-C4082118
weeks	I-C4082118
followed	O
by	O
24	B-C1442770
hours	I-C1442770
or	O
two	B-C4082118
weeks	I-C4082118
of	O
withdrawal	B-C2825032
,	O
with	O
transporter	B-C0596902
expression	B-C1171362
measured	O
using	O
western	B-C0949466
immunoblot	I-C0949466
.	O
	
oct3	B-C1453697
and	O
sert	B-C0170657
expression	B-C1171362
increased	O
in	O
the	O
cea	B-C0175219
at	O
both	O
withdrawal	B-C2825032
timepoints	O
.	O
	
in	O
the	O
vhipp	B-C0019564
,	O
oct3	B-C1453697
expression	B-C1171362
increased	O
only	O
at	O
24	B-C1442770
hours	I-C1442770
of	O
withdrawal	B-C2825032
,	O
with	O
an	O
equivalent	O
pattern	O
seen	O
in	O
the	O
dorsomedial	B-C0013055
hypothalamus	I-C0013055
.	O
	
no	B-C0442739
changes	I-C0442739
were	O
evident	O
in	O
any	O
other	O
regions	B-C0005898
sampled	O
.	O
	
these	O
regionally	O
specific	O
changes	O
in	O
limbic	B-C0023715
oct3	B-C1453697
and	O
sert	B-C0170657
expression	B-C1171362
may	O
partially	O
contribute	O
to	O
the	O
serotonergic	B-C0036751
imbalance	B-C1397014
and	O
negative	B-C1513916
affect	I-C1513916
during	O
amphetamine	B-C0236665
withdrawal	I-C0236665
.	O
	
nutritional	B-C0868998
aspects	I-C0868998
of	O
night	B-C0240526
eating	B-C0013470
and	O
its	O
association	B-C0332281
with	I-C0332281
weight	B-C0005910
status	B-C0449438
among	O
korean	B-C1556095
adolescents	B-C0205653
a	O
growing	B-C0205245
body	O
of	O
research	B-C0035168
has	O
indicated	O
that	O
night	B-C0240526
eating	B-C0013470
could	O
be	O
associated	B-C0332281
with	I-C0332281
poor	B-C0588012
diet	I-C0588012
quality	B-C0332306
and	O
negative	B-C0205160
health	B-C1550208
outcomes	I-C1550208
.	O
	
this	O
study	B-C0085973
examined	O
the	O
nutritional	B-C0868998
aspects	I-C0868998
of	O
night	B-C0240526
eating	B-C0013470
,	O
its	O
related	O
factors	B-C1521761
,	O
and	O
the	O
association	B-C0439849
between	O
night	B-C0240526
eating	B-C0013470
and	O
body	B-C0005910
weight	I-C0005910
among	O
korean	B-C1556095
adolescents	B-C0205653
.	O
	
this	O
study	B-C0085973
analysed	O
the	O
data	B-C1511726
from	O
a	O
one	O
day	B-C0439228
24-hour	O
dietary	B-C0242481
recall	I-C0242481
as	O
well	O
as	O
a	O
demographic	B-C0011296
survey	I-C0011296
of	O
1	O
korean	B-C1556095
adolescents	B-C0205653
aged	O
12	O
to	O
18-	O
years	B-C0439234
-old	O
obtained	O
from	O
the	O
2010-2012	O
korea	B-C0022771
national	B-C0376344
health	I-C0376344
and	I-C0376344
nutrition	I-C0376344
examination	I-C0376344
survey	I-C0376344
.	O
	
'	O
night	B-C0240526
eating	B-C0013470
'	O
was	O
defined	O
as	O
consuming	O
25%	O
or	O
more	O
of	O
one's	O
daily	B-C0564415
energy	I-C0564415
intake	I-C0564415
between	O
21	O
and	O
06	O
.	O
	
subjects	B-C0080105
complying	O
with	O
the	O
preceding	O
condition	B-C0348080
were	O
classified	O
as	O
'	O
night	B-C0240526
eaters	B-C1257890
'	O
,	O
whereas	O
the	O
rest	O
were	O
considered	O
'	O
non-night	B-C1257890
eaters	I-C1257890
'	O
.	O
	
logistic	B-C0681925
regression	I-C0681925
analysis	I-C0681925
examined	O
factors	B-C1521761
related	O
to	O
night	B-C0240526
eating	B-C0013470
.	O
	
multiple	B-C0023733
linear	I-C0023733
regression	I-C0023733
analyses	I-C0023733
were	O
used	O
to	O
examine	O
the	O
relationship	B-C0439849
between	O
night	B-C0240526
eating	B-C0013470
and	O
bmi	B-C1305855
z-scores	B-C0871421
,	O
whereas	O
multinomial	B-C0681925
logistic	I-C0681925
regression	I-C0681925
analysis	I-C0681925
was	O
used	O
to	O
examine	O
the	O
relationship	B-C0439849
between	O
night	B-C0240526
eating	B-C0013470
and	O
weight	B-C0005910
status	B-C0449438
.	O
	
about	O
21%	O
of	O
korean	B-C1556095
adolescents	B-C0205653
appeared	O
to	O
be	O
night	B-C0240526
eaters	B-C1257890
.	O
	
night	B-C0240526
eaters	B-C1257890
showed	O
increased	B-C0205217
breakfast	B-C2698559
skipping	B-C0560435
p	O
=	O
0.001	O
,	O
higher	O
energy	B-C0006777
intake	I-C0006777
from	O
snacks	B-C0453863
p	O
<	O
0.001	O
,	O
greater	O
proportion	B-C0564429
of	I-C0564429
energy	I-C0564429
intake	I-C0564429
from	I-C0564429
fat	I-C0564429
p	O
=	O
0.029	O
,	O
and	O
lower	B-C0449820
dietary	I-C0449820
diversity	I-C0449820
scores	I-C0449820
p	O
=	O
0.008	O
than	O
non-night	B-C1257890
eaters	I-C1257890
.	O
	
male	B-C0086582
adolescents	B-C0205653
presented	O
1.9	O
times	B-C1632851
higher	O
odds	O
of	O
being	O
night	B-C0240526
eaters	B-C1257890
than	O
females	B-C0086287
.	O
	
adolescents	B-C0205653
whose	O
both	O
parents	B-C0030551
were	O
night	B-C0240526
eaters	B-C1257890
were	O
4.4	O
times	B-C1632851
as	O
likely	O
to	O
be	O
night	B-C0240526
eaters	B-C1257890
as	O
those	O
whose	O
neither	O
parents	B-C0030551
were	O
.	O
	
female	B-C0086287
adolescents	B-C0205653
showed	O
a	O
significant	O
relationship	B-C0439849
between	O
night	B-C0240526
eating	B-C0013470
and	O
bmi	B-C1305855
z-scores	B-C0871421
β	O
=	O
0.28	O
,	O
p	O
=	O
0.004	O
.	O
	
however	O
,	O
night	B-C0240526
eating	B-C0013470
did	O
not	O
increase	B-C0442805
odds	O
of	O
being	O
overweight	B-C0497406
or	O
obese	B-C0028754
in	O
adolescents	B-C0205653
.	O
	
night	B-C0240526
eating	B-C0013470
in	O
korean	B-C1556095
adolescents	B-C0205653
was	O
related	O
to	O
undesirable	B-C4019289
dietary	I-C4019289
behaviours	I-C4019289
and	O
low	B-C2136285
diet	I-C2136285
quality	I-C2136285
in	O
general	O
as	O
well	O
as	O
higher	O
bmi	B-C1305855
z-scores	B-C0871421
in	O
females	B-C0086287
.	O
	
male	B-C0086582
gender	B-C0079399
and	O
parental	B-C0030551
night	B-C0240526
eating	B-C0013470
appeared	O
to	O
be	O
the	O
factors	B-C1521761
that	O
significantly	O
increased	B-C0205217
odds	O
of	O
night	B-C0240526
eating	B-C0013470
.	O
	
these	O
results	O
suggest	O
that	O
night	B-C0240526
eating	B-C0013470
should	O
be	O
considered	O
when	O
designing	O
nutrition	B-C0204934
education	I-C0204934
or	O
intervention	B-C0599917
programs	I-C0599917
targeting	O
a	O
randomized	B-C0206034
trial	I-C0206034
of	O
plasma-lyte	B-C0071213
a	I-C0071213
and	O
0.9	B-C1725399
%	I-C1725399
sodium	I-C1725399
chloride	I-C1725399
in	O
acute	B-C0267446
pediatric	I-C0267446
gastroenteritis	I-C0267446
compare	O
the	O
efficacy	B-C1280519
and	O
safety	O
of	O
plasma-lyte	B-C0071213
a	I-C0071213
pla	B-C0071213
versus	O
0.9	B-C1725399
%	I-C1725399
sodium	I-C1725399
chloride	I-C1725399
nacl	B-C1725399
intravenous	B-C0559692
iv	I-C0559692
fluid	I-C0559692
replacement	I-C0559692
in	O
children	B-C0008059
with	O
moderate	O
to	O
severe	B-C3472181
dehydration	I-C3472181
secondary	O
to	O
acute	B-C0267446
gastroenteritis	I-C0267446
age	B-C0267446
.	O
	
prospective	B-C0033522
,	O
randomized	B-C0034656
,	O
double-blind	B-C0013072
study	I-C0013072
conducted	O
at	O
eight	O
pediatric	B-C1521725
emergency	B-C0562508
departments	I-C0562508
eds	B-C0562508
in	O
the	O
us	B-C0041703
and	O
canada	B-C0006823
nct	O
.	O
	
the	O
primary	B-C3274433
outcome	I-C3274433
measure	I-C3274433
was	O
serum	B-C1261426
bicarbonate	I-C1261426
level	I-C1261426
at	O
4	O
h	O
.	O
	
secondary	B-C3274440
outcomes	I-C3274440
included	O
safety	O
and	O
tolerability	B-C3274448
.	O
	
the	O
hypothesis	B-C1512571
was	O
that	O
pla	B-C0071213
would	O
be	O
superior	O
to	O
0.9	B-C1725399
%	I-C1725399
nacl	I-C1725399
in	O
improvement	B-C0202059
of	I-C0202059
4-h	I-C0202059
bicarbonate	I-C0202059
.	O
	
patients	B-C0030705
n	O
=	O
100	O
aged	O
6	O
months	O
to	O
<11	O
years	O
with	O
age	B-C0267446
-induced	O
moderate-to-	O
severe	B-C3472181
dehydration	I-C3472181
were	O
enrolled	O
.	O
	
patients	B-C0030705
with	O
a	O
baseline	B-C1442488
bicarbonate	B-C0428196
level	I-C0428196
22	O
meq/l	O
formed	B-C0205431
the	O
modified	B-C0392747
intent	B-C1292734
to	I-C1292734
treat	I-C1292734
mitt	B-C1292734
group	B-C1257890
.	O
	
at	O
baseline	B-C1442488
,	O
the	O
treatment	B-C0087111
groups	B-C1257890
were	O
comparable	O
except	O
that	O
the	O
pla	B-C0071213
group	B-C1257890
was	O
older	O
.	O
	
at	O
hour	O
4	O
,	O
the	O
pla	B-C0071213
group	B-C1257890
had	O
greater	O
increases	B-C0858078
in	I-C0858078
serum	I-C0858078
bicarbonate	I-C0858078
from	O
baseline	B-C1442488
than	O
did	O
the	O
0.9	B-C1725399
%	I-C1725399
nacl	I-C1725399
group	B-C1257890
mean	O
sd	O
at	O
4	O
h	O
18	O
3.74	O
vs	O
18.0	O
3.67	O
change	O
from	O
baseline	B-C1442488
of	O
1.6	O
and	O
0.0	O
,	O
respectively	O
p	O
=	O
004	O
.	O
	
both	O
treatment	B-C0087111
groups	B-C1257890
received	O
similar	O
fluid	B-C0449971
volumes	I-C0449971
.	O
	
the	O
pla	B-C0071213
group	B-C1257890
had	O
less	O
abdominal	B-C0000737
pain	I-C0000737
and	O
better	O
dehydration	B-C0011175
scores	O
at	O
hour	O
2	O
both	O
p	O
=	O
03	O
but	O
not	O
at	O
hour	O
4	O
p	O
=	O
0.15	O
and	O
0.08	O
,	O
respectively	O
.	O
	
no	O
patient	B-C0030705
experienced	O
clinically	B-C1546960
relevant	I-C1546960
worsening	I-C1546960
of	O
laboratory	B-C0587081
findings	I-C0587081
or	O
physical	B-C0031809
examination	I-C0031809
,	O
and	O
hospital	B-C0598610
admission	I-C0598610
rates	I-C0598610
were	O
similar	B-C2348205
.	O
	
one	O
patient	B-C0030705
in	O
each	O
treatment	B-C0087111
group	B-C1257890
developed	O
hyponatremia	B-C0020625
.	O
	
four	O
patients	B-C0030705
developed	O
hyperkalemia	B-C0020461
pla	B-C0071213
1	O
,	O
0.9	B-C1725399
%	I-C1725399
nacl	I-C1725399
3	O
.	O
	
in	O
comparison	B-C1707455
with	O
0.9	B-C1725399
%	I-C1725399
nacl	I-C1725399
,	O
pla	B-C0071213
for	O
rehydration	B-C0034997
in	O
children	B-C0008059
with	O
age	B-C0267446
was	O
well	O
tolerated	O
and	O
led	O
to	O
more	O
rapid	O
improvement	B-C0428301
in	I-C0428301
serum	I-C0428301
bicarbonate	I-C0428301
and	O
dehydration	B-C0011175
the	O
relationships	B-C0439849
between	O
symptoms	B-C1457887
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
over	O
the	O
course	B-C0750729
of	O
cognitive-behavioral	B-C0009244
therapy	I-C0009244
for	O
panic	B-C0030319
disorder	I-C0030319
in	O
japan	B-C0022341
this	O
study	B-C2603343
examined	B-C0332128
the	O
relationships	B-C0439849
between	O
changes	B-C0392747
in	O
symptoms	B-C1457887
and	O
changes	B-C0392747
in	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
qol	B-C0034380
during	O
cognitive-behavioral	B-C0009244
therapy	I-C0009244
cbt	B-C0009244
for	O
panic	B-C0030319
disorder	I-C0030319
pd	B-C0030319
.	O
	
we	O
treated	B-C1522326
198	O
pd	B-C0030319
patients	B-C0030705
with	O
group	O
cbt	B-C0009244
in	O
japan	B-C0022341
.	O
	
using	O
multiple	B-C0034980
regression	I-C0034980
analysis	I-C0034980
,	O
we	O
examined	B-C0332128
the	O
associations	B-C0439849
between	O
changes	B-C0392747
in	O
qol	B-C0034380
and	O
changes	B-C0392747
in	O
pd	B-C0030319
symptoms	B-C1457887
or	O
comorbid	B-C0233397
psychological	I-C0233397
symptoms	I-C0233397
during	O
cbt	B-C0009244
.	O
	
changes	B-C0392747
in	O
anticipatory	B-C0231397
anxiety	I-C0231397
,	O
agoraphobic	B-C0233702
fear	I-C0233702
/	O
avoidance	B-C0870186
,	O
and	O
somatization	B-C0149779
were	O
significant	O
predictors	B-C2698872
of	O
changes	B-C0392747
in	O
some	O
aspects	O
of	O
qol	B-C0034380
.	O
	
it	O
might	O
be	O
useful	O
to	O
decrease	O
somatization	B-C0149779
,	O
anticipatory	B-C0231397
anxiety	I-C0231397
,	O
and	O
agoraphobic	B-C0233702
fear	I-C0233702
to	O
improve	O
qol	B-C0034380
in	O
cbt	B-C0009244
for	O
coupling	B-C1948027
of	O
trpv6	B-C1452353
and	O
tmem16a	B-C2976269
in	O
epithelial	B-C0014597
principal	I-C0014597
cells	I-C0014597
of	O
the	O
rat	B-C1882657
epididymis	I-C1882657
the	O
epididymis	B-C0014533
establishes	O
a	O
congenial	B-C1524057
environment	B-C0014406
for	O
sperm	B-C0037846
maturation	I-C0037846
and	O
protection	B-C1545588
.	O
	
its	O
fluid	B-C0005889
is	O
acidic	B-C0920750
,	O
and	O
the	O
calcium	B-C0006675
concentration	B-C1446561
is	O
low	B-C0205251
and	O
declines	O
along	O
the	O
length	B-C1444754
of	O
the	O
epididymal	B-C0014533
tubule	I-C0014533
.	O
	
however	O
,	O
our	O
knowledge	O
of	O
ionic	B-C0162585
currents	I-C0162585
and	O
mechanisms	B-C0441712
of	O
calcium	B-C1156269
homeostasis	I-C1156269
in	O
rat	B-C1882657
epididymal	I-C1882657
epithelial	B-C0014597
cells	I-C0014597
remains	O
enigmatic	O
.	O
	
in	O
this	O
study	B-C2603343
,	O
to	O
better	O
understand	O
calcium	B-C1156269
regulation	I-C1156269
in	O
the	O
epididymis	B-C0014533
,	O
we	O
use	O
the	O
patch-clamp	B-C0242625
method	I-C0242625
to	O
record	O
from	O
single	O
rat	B-C0034693
cauda	B-C0228024
epididymal	I-C0228024
principal	B-C0007634
cells	I-C0007634
.	O
	
we	O
detect	B-C0442726
a	O
constitutively	O
active	B-C0205177
ca	B-C0596235
current	B-C0162585
with	O
characteristics	B-C1521970
that	O
match	O
the	O
epithelial	B-C0014609
calcium	B-C0006685
channel	I-C0006685
trpv6	B-C1452353
.	O
	
electrophysiological	B-C0850293
and	O
pharmacological	B-C1831759
data	I-C1831759
also	O
reveal	O
a	O
constitutively	O
active	B-C1956140
calcium-activated	I-C1956140
chloride	I-C1956140
conductance	I-C1956140
cacc	B-C1956140
.	O
	
removal	O
of	O
extracellular	B-C0521119
calcium	B-C0006675
attenuates	B-C0599946
not	O
only	O
the	O
trpv6	B-C1452353
-like	O
conductance	B-C0678840
,	O
but	O
also	O
the	O
cacc	B-C1956140
.	O
	
lanthanide	B-C0205838
block	B-C0332206
is	O
time	B-C0040223
dependent	B-C0851827
such	O
that	O
the	O
trpv6	B-C1452353
-like	O
component	O
is	O
inhibited	B-C1516145
first	O
,	O
followed	O
by	O
the	O
cacc	B-C1956140
.	O
	
the	O
putative	O
cacc	B-C1956140
blocker	B-C0870261
niflumic	B-C0028067
acid	I-C0028067
partially	O
inhibits	B-C1516145
whole-cell	B-C0007634
currents	B-C0162585
,	O
whereas	O
la	B-C0534702
almost	O
abolishes	O
whole-cell	B-C0007634
currents	B-C0162585
in	O
principal	B-C0007634
cells	I-C0007634
.	O
	
membrane	B-C0025251
potential	I-C0025251
measurements	B-C0242485
reveal	O
an	O
interplay	O
between	O
la	B-C0534702
-	O
sensitive	B-C0022009
ion	I-C0022009
channels	I-C0022009
and	O
those	O
that	O
are	O
sensitive	B-C0332324
to	O
the	O
specific	B-C1552740
tmem16a	B-C2976269
inhibitor	B-C0243077
tannic	B-C0039294
acid	I-C0039294
.	O
	
in	B-C1515655
vivo	I-C1515655
perfusion	B-C0031001
of	O
the	O
cauda	B-C0228024
epididymal	I-C0228024
tubule	I-C0228024
shows	O
a	O
substantial	O
rate	O
of	O
ca	B-C0596235
reabsorption	B-C3852988
from	O
the	O
luminal	B-C0524462
side	I-C0524462
,	O
which	O
is	O
dose-dependently	O
suppressed	B-C1260953
by	O
ruthenium	B-C0035975
red	I-C0035975
,	O
a	O
putative	O
blocker	B-C0870261
of	O
epithelial	B-C0014609
ca	B-C0006685
channels	I-C0006685
and	O
cacc	B-C1956140
.	O
	
finally	O
,	O
we	O
discover	O
messenger	B-C0035696
rna	I-C0035696
for	O
both	O
trpv6	B-C1452353
and	O
tmem16a	B-C2976269
in	O
the	O
rat	B-C1882657
epididymis	I-C1882657
and	O
show	O
that	O
their	O
proteins	B-C0033684
colocalize	B-C0392752
in	O
the	O
apical	B-C0596119
membrane	I-C0596119
of	O
principal	B-C0007634
cells	I-C0007634
.	O
	
collectively	O
,	O
these	O
data	B-C1511726
provide	O
evidence	B-C3887511
for	O
a	O
coupling	B-C1948027
mechanism	B-C0441712
between	O
trpv6	B-C1452353
and	O
tmem16a	B-C2976269
in	O
principal	B-C0007634
cells	I-C0007634
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	B-C1156269
of	I-C1156269
calcium	I-C1156269
homeostasis	I-C1156269
in	O
the	O
voices	O
a	O
conversation	B-C0871703
with	O
allen	B-C0086418
j	I-C0086418
.	O
	
wilcox	I-C0086418
allen	B-C0086418
james	I-C0086418
wilcox	I-C0086418
was	O
born	O
on	O
30	O
september	O
1946	O
in	O
columbus	B-C3831044
,	O
oh	I-C3831044
.	O
	
he	O
studied	O
medicine	B-C0025118
at	O
the	O
university	B-C0041740
of	I-C0041740
michigan	I-C0041740
,	O
graduated	O
in	O
1973	O
,	O
and	O
after	O
a	O
rotating	O
internship	B-C0237690
,	O
he	O
completed	B-C2030948
a	I-C2030948
master's	I-C2030948
degree	I-C2030948
in	O
maternal	B-C4035700
and	I-C4035700
child	I-C4035700
health	I-C4035700
1976	O
and	O
a	O
phd	B-C1512022
in	O
epidemiology	B-C0014507
1979	O
at	O
the	O
university	B-C0041740
of	I-C0041740
north	I-C0041740
carolina	I-C0041740
in	O
chapel	B-C0017446
hill	I-C0017446
.	O
	
after	O
graduation	B-C1711333
,	O
he	O
went	O
to	O
work	B-C0043227
at	O
the	O
national	B-C1955979
institute	I-C1955979
of	I-C1955979
environmental	I-C1955979
health	I-C1955979
sciences	I-C1955979
niehs	B-C1955979
,	O
one	O
of	O
the	O
us	B-C0027468
national	I-C0027468
institutes	I-C0027468
of	I-C0027468
health	I-C0027468
in	O
durham	B-C3830368
,	O
nc	I-C3830368
,	O
where	O
he	O
has	O
spent	O
his	O
career	B-C0178534
.	O
	
he	O
developed	O
a	O
research	B-C0683935
program	I-C0683935
in	O
reproductive	O
and	O
perinatal	B-C1518977
epidemiology	I-C1518977
,	O
a	O
relatively	O
unexplored	O
area	O
at	O
the	O
time	O
.	O
	
his	O
studies	O
include	O
the	O
early	B-C0747845
pregnancy	I-C0747845
study	O
,	O
which	O
documented	B-C1301725
the	O
extent	O
of	O
subclinical	B-C0205211
pregnancy	B-C0687675
loss	I-C0687675
in	O
humans	B-C0086418
and	O
established	B-C0443211
the	O
fertile	B-C0015894
days	I-C0015894
of	O
a	O
woman's	B-C0043210
menstrual	B-C0025329
cycle	I-C0025329
.	O
	
he	O
served	O
as	O
the	O
chief	B-C1706996
of	I-C1706996
the	O
epidemiology	B-C0014507
branch	B-C1706131
from	O
1991	O
to	O
2001	O
,	O
and	O
as	O
editor-in-chief	B-C1522486
of	O
the	O
journal	B-C0162443
epidemiology	B-C0014507
from	O
2001	O
to	O
2014	O
.	O
	
his	O
textbook	B-C0039712
,	O
fertility	B-C0039712
and	I-C0039712
pregnancy-an	I-C0039712
epidemiologic	I-C0039712
perspective	I-C0039712
,	O
was	O
published	B-C0034037
by	O
oxford	B-C1552679
university	I-C1552679
press	I-C1552679
in	O
2010	O
.	O
	
he	O
was	O
elected	B-C0682233
to	O
the	O
american	B-C1708333
epidemiological	I-C1708333
society	I-C1708333
in	O
1989	O
,	O
and	O
served	O
as	O
its	O
president	B-C0028811
in	O
2003	O
.	O
	
he	O
also	O
served	O
as	O
president	B-C0028811
of	O
the	O
society	B-C1708333
of	I-C1708333
pediatric	I-C1708333
and	I-C1708333
perinatal	I-C1708333
epidemiological	I-C1708333
research	I-C1708333
1996	O
and	O
the	O
president	B-C0028811
of	O
the	O
society	B-C1708333
of	I-C1708333
epidemiological	I-C1708333
research	I-C1708333
1998	O
.	O
	
he	O
holds	O
adjunct	O
teaching	B-C0220924
appointments	B-C0003629
at	O
the	O
university	B-C0041740
of	I-C0041740
north	I-C0041740
carolina	I-C0041740
,	O
harvard	B-C0041740
university	I-C0041740
,	O
and	O
the	O
university	B-C0041740
of	I-C0041740
bergen	I-C0041740
norway	B-C0028423
,	O
which	O
awarded	B-C0004446
him	O
an	O
honorary	B-C2985253
doctoral	B-C1512027
degree	I-C1512027
evaluation	B-C0220825
of	O
spontaneous	B-C0205359
bone	B-C0005972
regeneration	I-C0005972
after	O
enucleation	B-C0014392
of	O
large	B-C0549177
cysts	B-C0010709
of	O
the	O
jaws	B-C0022359
using	O
radiographic	B-C0444708
computed	B-C1441526
software	B-C0037585
spontaneous	B-C0205359
regeneration	B-C0005972
of	I-C0005972
bone	I-C0005972
is	O
commonly	B-C0205214
seen	O
in	O
the	O
small	B-C0700321
surgical	B-C0543467
defects	B-C1457869
caused	O
by	O
enucleation	B-C0014392
of	O
cysts	B-C0010709
.	O
	
however	O
,	O
in	O
case	O
of	O
large	B-C0549177
surgical	B-C0543467
defects	B-C1457869
caused	O
by	O
the	O
enucleation	B-C0014392
,	O
spontaneous	B-C0205359
regeneration	B-C0005972
of	I-C0005972
bone	I-C0005972
is	O
a	O
rare	B-C0522498
phenomenon	B-C1882365
and	O
it	O
depends	B-C1701901
on	O
factors	B-C1521761
,	O
such	O
as	O
age	B-C0001779
of	O
the	O
patient	B-C0030705
,	O
intact	B-C0205266
periosteum	B-C0031110
,	O
and	O
proper	O
stabilization	B-C1293130
.	O
	
the	O
study	B-C2603343
included	B-C0332257
16	O
patients	B-C0030705
,	O
who	O
reported	B-C0700287
to	O
the	O
department	B-C0019961
of	I-C0019961
oral	I-C0019961
and	I-C0019961
maxillofacial	I-C0019961
surgery	I-C0019961
with	O
the	O
complaint	B-C0012634
of	O
pain	B-C0030193
and	O
swelling	B-C0038999
in	O
the	O
jaws	B-C0022359
diagnosed	B-C0011900
as	O
cyst	B-C0010709
.	O
	
the	O
sample	B-C2347026
included	B-C0332257
equal	O
numbers	B-C0237753
of	O
male	B-C0086582
and	O
female	B-C0086287
subjects	B-C0681850
aged	B-C0001779
between	O
15	O
and	O
40	O
years	O
.	O
	
panoramic	B-C0034579
radiographs	I-C0034579
were	O
taken	O
pre-	B-C0445204
and	O
postoperatively	B-C0032790
on	O
day	O
2	O
of	O
the	O
enucleation	B-C0014392
.	O
	
the	O
dimensions	B-C0439534
of	O
the	O
cyst	B-C0010709
were	O
evaluated	B-C0220825
on	O
the	O
radiograph	B-C1306645
according	O
to	O
the	O
proforma	B-C0205245
.	O
	
subsequent	B-C0332282
radiographs	B-C1306645
were	O
taken	O
at	O
regular	B-C0205272
intervals	B-C1272706
of	O
1.5	O
,	O
3	O
,	O
and	O
6	O
months	O
using	O
standard	B-C0034925
parameters	B-C0549193
and	O
were	O
analyzed	B-C0936012
using	O
mcid	B-C3203917
analysis	I-C3203917
software	B-C0037585
of	O
imaging	B-C1881134
research	I-C1881134
.	O
	
mean	B-C0444504
reduction	B-C0441610
was	O
seen	O
in	O
up	O
to	O
39	O
and	O
60%	O
in	O
the	O
cystic	B-C0205207
cavity	B-C1510420
size	B-C0456389
and	O
increase	B-C0442805
in	O
the	O
mean	B-C0444504
density	B-C0178587
up	O
to	O
59	O
and	O
90.2	O
at	O
3	O
and	O
6	O
months	O
intervals	B-C1272706
respectively	O
.	O
	
spontaneous	B-C0205359
bone	B-C0005972
regeneration	I-C0005972
was	O
seen	O
even	O
after	O
primary	B-C0205225
closure	B-C0185003
of	O
the	O
large	B-C0549177
cystic	B-C0205207
defect	B-C1457869
without	O
the	O
need	B-C0027552
for	O
placement	B-C0441587
of	O
foreign	B-C0729652
substances	I-C0729652
or	O
grafts	B-C0181074
and	O
it	O
also	O
eliminated	B-C0849355
the	O
complications	B-C0009566
resulting	B-C0678226
from	I-C0678226
placement	B-C0441587
of	O
foreign	B-C0729652
substance	I-C0729652
.	O
	
further	O
studies	B-C2603343
are	O
required	B-C1514873
in	O
a	O
larger	B-C0549177
sample	B-C2347026
with	O
longer	B-C0205166
follow-up	B-C1522577
durations	B-C0449238
to	O
confirm	B-C1456348
the	O
outcome	B-C0085415
of	I-C0085415
the	I-C0085415
present	I-C0085415
work	I-C0085415
for	O
the	O
benefit	B-C0814225
of	O
patients	B-C0030705
.	O
	
the	O
present	B-C0521116
study	B-C2603343
depicted	O
that	O
spontaneous	B-C0205359
bone	B-C0005972
regeneration	I-C0005972
can	O
occur	O
with	O
accepted	B-C1272684
results	B-C0808233
after	O
simple	B-C0205352
enucleation	B-C0014392
of	O
jaw	B-C0022359
cyst	B-C0010709
without	O
the	O
aid	B-C1269765
of	O
any	O
graft	B-C0181074
material	I-C0181074
.	O
	
hence	O
,	O
simple	B-C0205352
enucleation	B-C0014392
may	O
be	O
considered	B-C0750591
as	O
a	O
first	B-C1708063
line	I-C1708063
of	I-C1708063
treatment	I-C1708063
modality	B-C0695347
for	O
cystic	B-C0205207
lesion	B-C0221198
of	O
the	O
jaws	B-C0022359
.	O
	
this	O
simplifies	O
the	O
surgical	B-C0543467
procedure	I-C0543467
,	O
decreases	B-C0547047
the	O
economic	B-C0013557
and	O
biologic	B-C0205460
costs	B-C0010186
,	O
and	O
reduces	B-C0441610
the	O
risk	B-C0035647
of	O
postoperative	B-C0032787
complications	I-C0032787
.	O
	
follow-up	B-C1522577
is	O
necessary	O
along	O
with	O
patient's	B-C0030705
compliance	B-C1321605
for	O
the	O
success	B-C0679864
of	I-C0679864
treatment	I-C0679864
.	O
	
membrane	B-C1621323
protein	I-C1621323
solubilization	I-C1621323
and	O
composition	B-C0243176
of	O
protein	B-C0033684
detergent	B-C0011740
complexes	B-C1704241
membrane	B-C0025252
proteins	I-C0025252
are	O
typically	B-C1171362
expressed	I-C1171362
in	O
heterologous	B-C0439860
systems	B-C0449913
with	O
a	O
view	O
to	O
in	B-C0681828
vitro	I-C0681828
characterization	B-C1880022
.	O
	
a	O
critical	B-C1261552
step	I-C1261552
in	O
the	O
preparation	B-C1521827
of	O
membrane	B-C0025252
proteins	I-C0025252
after	O
expression	B-C1171362
in	O
any	O
system	B-C0449913
is	O
the	O
solubilization	B-C1621323
of	I-C1621323
the	I-C1621323
protein	I-C1621323
in	O
aqueous	B-C3255993
solution	I-C3255993
,	O
typically	O
using	O
detergents	B-C0011740
and	O
lipids	B-C0023779
,	O
to	O
obtain	O
the	O
protein	B-C0033684
in	O
a	O
form	O
suitable	B-C3900053
for	O
purification	B-C0243114
,	O
structural	B-C0204514
or	O
functional	B-C0205245
analysis	B-C0936012
.	O
	
this	O
process	B-C1522240
is	O
particularly	O
difficult	O
as	O
the	O
objective	O
is	O
to	O
prepare	O
the	O
protein	B-C0033684
in	O
an	O
unnatural	B-C0522502
environment	B-C0014406
,	O
a	O
protein	B-C0033684
detergent	B-C0011740
complex	B-C1704241
,	O
separating	O
it	O
from	O
its	O
natural	B-C0205296
lipid	B-C0023779
partners	O
while	O
causing	O
the	O
minimum	B-C1524031
destabilization	B-C1622120
or	O
modification	B-C3840684
of	O
the	O
structure	B-C0678594
.	O
	
although	O
the	O
process	B-C1522240
is	O
difficult	B-C0332218
,	O
and	O
relatively	O
hard	O
to	O
master	O
,	O
an	O
increasing	B-C0442808
number	O
of	O
membrane	B-C0025252
proteins	I-C0025252
have	O
been	O
successfully	B-C0205409
isolated	I-C0205409
after	O
expression	B-C1171362
in	O
a	O
wide	O
variety	O
of	O
systems	B-C0449913
.	O
	
in	O
this	O
chapter	O
we	O
give	O
a	O
general	B-C2348563
protocol	I-C2348563
for	O
preparing	O
protein	B-C0033684
detergent	B-C0011740
complexes	B-C1704241
that	O
is	O
aimed	O
at	O
guiding	O
the	O
reader	O
through	O
the	O
different	O
critical	B-C1261552
steps	I-C1261552
.	O
	
in	O
the	O
second	O
part	O
of	O
the	O
chapter	O
we	O
illustrate	O
how	O
to	O
analyze	B-C0936012
the	O
composition	B-C0243176
of	O
protein	B-C0033684
detergent	B-C0011740
complexes	B-C1704241
this	O
analysis	B-C0936012
is	O
important	O
as	O
it	O
has	O
been	O
found	O
that	O
compositional	B-C0243176
variation	B-C0205419
can	O
we	O
predict	B-C0681842
burnout	B-C0006433
among	O
student	B-C0038496
nurses	I-C0038496
an	O
exploration	O
of	O
the	O
icwr-1	B-C0026347
model	I-C0026347
of	O
individual	B-C0237401
psychological	B-C0683253
resilience	I-C0683253
the	O
nature	O
of	O
nursing	B-C0028677
work	I-C0028677
is	O
demanding	B-C0441516
and	O
can	O
be	O
stressful	B-C0231297
.	O
	
previous	O
studies	O
have	O
shown	O
a	O
high	B-C0205250
rate	B-C1521828
of	O
burnout	B-C0006433
among	O
employed	B-C0557351
nurses	B-C0028661
.	O
	
recently	O
,	O
efforts	O
have	O
been	O
made	O
to	O
understand	O
the	O
role	O
of	O
resilience	B-C0683253
in	O
determining	O
the	O
psychological	B-C0683269
adjustment	I-C0683269
of	O
employed	B-C0557351
nurses	B-C0028661
.	O
	
a	O
theoretical	B-C0026350
model	I-C0026350
of	O
resilience	B-C0683253
was	O
proposed	O
recently	O
that	O
includes	B-C0332257
several	B-C0443302
constructs	B-C2827421
identified	O
in	O
the	O
literature	B-C0023866
related	O
to	O
resilience	B-C0683253
and	O
to	O
psychological	B-C0233398
functioning	I-C0233398
.	O
	
as	O
nursing	B-C0038496
students	I-C0038496
are	O
the	O
future	B-C0016884
of	O
the	O
nursing	B-C0028677
workforce	B-C2700616
it	O
is	O
important	B-C3898777
to	O
advance	B-C3854260
our	O
understanding	O
of	O
the	O
determinants	B-C1521761
of	O
resilience	B-C0683253
in	O
this	O
population	B-C1257890
.	O
	
student	B-C0038496
nurses	I-C0038496
who	O
had	O
completed	B-C1556116
their	O
final	B-C3853528
practicum	B-C0032929
were	O
invited	O
to	O
participate	O
in	O
an	O
online	B-C0038951
survey	I-C0038951
measuring	B-C0444706
the	O
key	O
constructs	B-C2827421
of	O
the	O
icwr-1	B-C0026347
model	I-C0026347
.	O
	
422	O
students	B-C0038496
from	O
across	O
australia	B-C0004340
and	O
canada	B-C0006823
completed	B-C1556116
the	O
survey	B-C0038951
between	O
july	O
2014	O
and	O
july	O
2015	O
.	O
	
as	O
well	O
as	O
several	B-C0443302
key	O
demographics	B-C1704791
,	O
trait	B-C0233849
negative	I-C0233849
affect	I-C0233849
,	O
mindfulness	B-C3542996
,	O
self-efficacy	B-C0600564
,	O
coping	B-C0009967
,	O
resilience	B-C0683253
,	O
and	O
burnout	B-C0006433
were	O
measured	B-C0444706
.	O
	
we	O
used	O
structural	B-C0681947
equation	I-C0681947
modeling	I-C0681947
and	O
found	O
support	O
for	O
the	O
major	B-C0205164
pathways	B-C1705987
of	O
the	O
model	B-C0026347
namely	O
that	O
resilience	B-C0683253
had	O
a	O
significant	B-C0750502
influence	B-C4054723
on	O
the	O
relationship	B-C0439849
between	O
mindfulness	B-C3542996
,	O
self-efficacy	B-C0600564
and	O
coping	B-C0009967
,	O
and	O
psychological	B-C0683269
adjustment	I-C0683269
burnout	B-C0006433
scores	B-C0449820
.	O
	
furthermore	O
,	O
as	O
predicted	B-C0681842
,	O
neuroticism	B-C1842981
moderated	O
the	O
relationship	B-C0439849
between	O
coping	B-C0009967
and	O
burnout	B-C0006433
.	O
	
results	O
are	O
discussed	O
in	O
terms	O
of	O
potential	B-C3245505
approaches	B-C1292724
to	O
supporting	O
nursing	B-C0038496
students	I-C0038496
who	O
may	O
be	O
at	B-C1444641
risk	I-C1444641
of	O
medication	B-C2735670
intervention	I-C2735670
for	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
patients	B-C0030705
transitioning	B-C2700061
from	O
hospital	B-C0019994
to	O
home	B-C0442519
study	B-C0035171
design	I-C0035171
and	O
baseline	B-C1442488
characteristics	B-C1521970
the	O
hospital	B-C0600290
readmission	I-C0600290
rate	B-C1521828
in	O
the	O
population	B-C1257890
with	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
ckd	B-C1561643
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	B-C0035647
are	O
urgently	O
needed	B-C0027552
.	O
	
the	O
ckd	B-C1561643
-	O
medication	B-C2735670
intervention	I-C2735670
trial	I-C2735670
ckd	B-C1561643
-	O
mit	B-C2735670
www.clinicaltrials	B-C4287891
ncto1459770	I-C4287891
is	O
a	O
single-blind	B-C0037181
investigators	B-C0008961
,	O
randomized	B-C0034656
,	O
clinical	B-C0008976
trial	I-C0008976
conducted	O
at	O
providence	B-C0086388
health	I-C0086388
care	I-C0086388
in	O
spokane	B-C3827207
,	O
washington	I-C3827207
.	O
	
study	B-C0681850
participants	I-C0681850
are	O
hospitalized	B-C0870668
patients	I-C0870668
with	O
ckd	B-C1561643
stages	B-C1306673
3-5	O
not	O
treated	B-C0332293
with	I-C0332293
kidney	B-C0206074
replacement	I-C0206074
therapy	I-C0206074
and	O
acute	B-C4061114
illness	I-C4061114
.	O
	
the	O
study	B-C1096775
intervention	I-C1096775
is	O
a	O
pharmacist-led	B-C1449564
,	O
home-based	B-C0338059
,	O
medication	B-C0150270
management	I-C0150270
intervention	B-C0184661
delivered	B-C1705822
within	O
7	O
days	B-C0439228
after	O
hospital	B-C0586003
discharge	I-C0586003
.	O
	
the	O
primary	B-C1274040
outcome	I-C1274040
is	O
a	O
composite	O
of	O
hospital	B-C0600290
readmissions	I-C0600290
and	O
visits	O
to	O
emergency	B-C0562508
departments	I-C0562508
and	O
urgent	B-C1710587
care	I-C1710587
centers	I-C1710587
for	O
90	O
days	B-C0439228
following	O
hospital	B-C0586003
discharge	I-C0586003
.	O
	
secondary	B-C1274040
outcomes	I-C1274040
are	O
achievements	B-C0683272
of	O
guideline-based	B-C0162791
targets	B-C1521840
for	O
ckd	B-C1561643
risk	B-C0035648
factors	I-C0035648
and	O
complications	B-C0009566
.	O
	
enrollment	B-C1516879
began	O
in	O
february	B-C3830166
2012	O
and	O
ended	O
in	O
may	B-C3812381
2015	O
.	O
	
at	O
baseline	B-C1442488
,	O
the	O
age	B-C0001779
of	O
participants	B-C0679646
was	O
69	O
11	O
years	B-C0439234
mean	O
sd	O
,	O
50%	O
77	O
of	O
155	O
were	O
women	B-C0043210
,	O
83%	O
117	O
of	O
141	O
had	O
hypertension	B-C0020538
and	O
56%	O
79	O
of	O
141	O
had	O
diabetes	B-C0011847
.	O
	
at	O
baseline	B-C1442488
,	O
the	O
estimated	B-C3811844
glomerular	I-C3811844
filtration	I-C3811844
rate	B-C1521828
was	O
41	O
14	O
ml/min/1	O
m2	O
and	O
urine	B-C0455271
albumin-to-creatinine	I-C0455271
ratio	I-C0455271
was	O
43	O
mg/g	O
interquartile	B-C1711350
range	I-C1711350
8-528	O
mg/g	O
.	O
	
the	O
most	O
frequent	O
diagnosis	B-C1550395
category	I-C1550395
for	O
the	O
index	O
hospital	B-C0184666
admission	I-C0184666
was	O
cardiovascular	B-C0007222
diseases	I-C0007222
at	O
34%	O
53	O
of	O
155	O
,	O
but	O
the	O
most	O
common	O
single	B-C0011900
diagnosis	I-C0011900
for	O
admission	B-C0030673
was	O
community-acquired	B-C0456394
acute	B-C0022660
kidney	I-C0022660
injury	I-C0022660
at	O
10%	O
16	O
of	O
155	O
.	O
	
participants	B-C0679646
in	O
ckd	B-C1561643
-	O
mit	B-C2735670
are	O
typical	O
of	O
acutely	B-C4061114
ill	I-C4061114
hospitalized	B-C0870668
patients	I-C0870668
with	O
ckd	B-C1561643
.	O
	
a	O
medication	B-C0150270
management	I-C0150270
intervention	B-C0184661
after	O
hospital	B-C0586003
discharge	I-C0586003
is	O
under	O
study	B-C2603343
to	O
reduce	B-C0392756
post	B-C0687676
-	O
hospitalization	B-C0019993
acute	B-C0679878
care	I-C0679878
utilization	B-C0042153
and	O
to	O
improve	O
ckd	B-C1561643
management	B-C0376636
.	O
	
direct	B-C1947931
repair	B-C1705181
of	O
lumbar	B-C3874316
pars	I-C3874316
interarticularis	I-C3874316
defects	B-C1457869
by	O
utilizing	B-C0042153
intraoperative	B-C0392304
o-arm-based	I-C0392304
navigation	I-C0392304
and	O
microendoscopic	B-C0014245
techniques	I-C0014245
a	O
retrospective	B-C0035363
analysis	I-C0035363
of	O
the	O
clinical	B-C2985631
outcomes	I-C2985631
of	O
eight	O
patients	B-C0030705
with	O
the	O
lumbar	B-C3874316
pars	I-C3874316
interarticulars	I-C3874316
defects	B-C1457869
treated	B-C0332154
by	O
direct	B-C1947931
repair	B-C1705181
with	O
the	O
aid	B-C1269765
of	O
intraoperative	B-C0392304
o-arm	I-C0392304
based	I-C0392304
navigation	I-C0392304
and	O
microendoscopic	B-C0014245
techniques	I-C0014245
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
the	O
efficacy	B-C1280519
and	O
safety	B-C0036043
of	O
direct	B-C1947931
screw	B-C0301559
repair	B-C1705181
by	O
using	B-C0457083
minimally	B-C0282624
invasive	I-C0282624
surgery	I-C0282624
for	O
the	O
lumbar	B-C3874316
pars	I-C3874316
interarticulars	I-C3874316
defects	B-C1457869
in	O
a	O
pilot	B-C2603343
study	I-C2603343
.	O
	
direct	B-C1947931
repair	B-C1705181
of	O
pars	B-C3874316
interarticulars	I-C3874316
defects	B-C1457869
has	O
been	O
used	B-C0457083
to	O
treat	B-C0087111
young	B-C0238598
adult	I-C0238598
patients	B-C0030705
.	O
	
reports	B-C0684224
concerning	B-C2699424
direct	B-C1947931
repair	B-C1705181
by	O
minimally	B-C0282624
invasive	I-C0282624
techniques	I-C0282624
for	O
pars	B-C3874316
interarticulars	I-C3874316
defects	B-C1457869
are	O
quite	O
rare	B-C0522498
.	O
	
review	B-C1552617
of	O
medical	B-C0025102
records	I-C0025102
identified	B-C0205396
eight	O
consecutive	B-C1707491
patients	B-C0030705
treated	B-C0332154
with	O
intraoperative	B-C0392304
o-arm	I-C0392304
based	I-C0392304
navigation	I-C0392304
and	O
microendoscopic	B-C0014245
techniques	I-C0014245
.	O
	
debridement	B-C0011079
and	O
autograft	B-C0040736
of	O
pars	B-C3874316
interarticularis	I-C3874316
defects	B-C1457869
was	O
performed	B-C0884358
under	O
microendoscopic	B-C0014245
procedure	I-C0014245
.	O
	
then	O
,	O
percutaneous	B-C0522523
bilateral	B-C0238767
intralaminar	B-C0205274
screws	B-C0301559
were	O
inserted	B-C0441587
by	O
utilizing	B-C0042153
intraoperative	B-C0392304
navigation	I-C0392304
.	O
	
the	O
clinical	B-C1516606
and	O
radiological	B-C0039431
data	B-C1511726
were	O
collected	B-C1516695
and	O
analyzed	B-C0936012
retrospectively	B-C1514923
.	O
	
eight	O
patients	B-C0030705
had	O
a	O
mean	B-C0444504
age	B-C0001779
of	O
28.4	O
years	O
,	O
and	O
five	O
were	O
30	O
years	O
or	O
younger	B-C0332239
at	O
the	O
time	B-C0040223
of	O
treatment	B-C0087111
.	O
	
symptoms	B-C1457887
included	B-C2700399
axial	B-C0205131
back	B-C0004604
pain	I-C0004604
in	O
100%	O
of	O
patients	B-C0030705
without	O
concomitant	B-C0521115
radiculopathy	B-C0700594
.	O
	
autograft	B-C0040736
was	O
used	B-C0457083
in	O
all	O
cases	B-C1706256
.	O
	
the	O
average	B-C1510992
follow-up	B-C1522577
duration	B-C0449238
was	O
27.4	O
months	O
with	O
a	O
range	B-C1514721
of	O
20	O
to	O
33	O
months	O
.	O
	
symptoms	B-C1457887
resolved	B-C3714811
completely	B-C0205197
or	O
partially	B-C0728938
in	O
all	O
patients	B-C0030705
.	O
	
low	B-C0024031
back	I-C0024031
pain	I-C0024031
visual	B-C2960751
analog	I-C2960751
scores	I-C2960751
decrease	B-C0547047
from	O
preoperative	B-C0445204
6.8	O
to	O
postoperative	B-C0032790
1.4	O
of	O
eight	O
cases	B-C1706256
.	O
	
of	O
16	O
pars	B-C0229962
defects	B-C1457869
,	O
healing	B-C2004454
was	O
observed	B-C1441672
in	O
13	O
81.3	O
at	O
last	O
radiological	B-C0039431
follow-up	B-C1522577
.	O
	
one	O
patient	B-C0030705
with	O
bilateral	B-C0332917
fusion	I-C0332917
failure	I-C0332917
refused	B-C1705116
revision	B-C0035110
surgery	I-C0035110
because	O
of	O
mild	B-C0436343
complaint	I-C0436343
.	O
	
no	B-C4032686
complications	I-C4032686
such	O
as	O
dural	B-C1504340
tear	I-C1504340
,	O
nerve	B-C0854396
root	I-C0854396
injury	I-C0854396
,	O
and	O
infection	B-C3714514
occurred	B-C1709305
.	O
	
minimally	B-C0282624
invasive	I-C0282624
direct	B-C1947931
repair	B-C1705181
of	O
the	O
pars	B-C3874316
interarticularis	I-C3874316
defects	B-C1457869
with	O
intralaminar	B-C0205274
screws	B-C0301559
by	O
using	B-C0457083
microendoscopic	B-C0014245
system	I-C0014245
and	O
navigation	B-C0392304
procedure	I-C0392304
can	O
provide	B-C1999230
safe	O
and	O
effective	B-C1704419
treatment	B-C0087111
of	O
spondylolysis	B-C0038018
with	O
satisfactory	B-C0205410
clinical	B-C0205210
and	O
radiological	B-C0039431
outcomes	B-C1274040
,	O
which	O
need	B-C0027552
some	O
special	B-C0025080
tools	I-C0025080
with	O
steep	B-C0332218
learning	B-C0023185
curve	I-C0023185
.	O
	
evidence	B-C3887511
-based	O
review	B-C0282443
and	O
survey	B-C0038951
of	O
expert	B-C0600219
opinion	I-C0600219
of	O
reconstruction	B-C0524865
of	O
metastatic	B-C0684550
spine	I-C0684550
tumors	I-C0684550
systematic	B-C0220922
review	B-C0282443
and	O
consensus	B-C0376298
expert	B-C0600219
opinion	I-C0600219
.	O
	
to	O
provide	O
surgeons	B-C0582175
and	O
other	O
health	B-C0018724
care	I-C0018724
professionals	I-C0018724
with	O
guidelines	B-C0162791
for	O
surgical	B-C0524865
reconstruction	I-C0524865
of	O
metastatic	B-C0027627
spine	B-C0037933
disease	I-C0037933
based	O
on	O
evidence	B-C3887511
and	O
expert	B-C0600219
opinion	I-C0600219
.	O
	
the	O
surgical	B-C0543467
treatment	I-C0543467
of	O
spinal	B-C0684550
metastases	I-C0684550
is	O
controversial	O
.	O
	
specifically	O
two	O
aspects	O
of	O
surgical	B-C0524865
reconstruction	I-C0524865
are	O
addressed	O
in	O
this	O
study	O
i	O
choice	O
of	O
bone	B-C0005976
graft	I-C0005976
used	O
during	B-C0347984
surgery	B-C0543467
for	O
metastatic	B-C0684550
spine	I-C0684550
tumors	I-C0684550
and	O
ii	O
the	O
design	B-C1707689
of	O
reconstruction	B-C0524865
or	O
construct	B-C0005479
to	O
stabilize	B-C0184512
.	O
	
a	O
systematic	B-C0220922
review	B-C0282443
of	O
the	O
available	B-C0470187
medical	B-C0205476
literature	B-C0023866
from	O
1980	O
to	O
2015	O
was	O
conducted	O
,	O
and	O
combined	B-C0205195
with	O
consensus	B-C0376298
expert	B-C0600219
opinion	I-C0600219
from	O
a	O
recent	O
survey	B-C0038951
of	O
spine	B-C0037949
surgeons	B-C0582175
who	O
treat	B-C0087111
metastatic	B-C0684550
spine	I-C0684550
tumors	I-C0684550
.	O
	
there	O
is	O
very	O
little	O
evidence	B-C3887511
in	O
the	O
literature	B-C0023866
to	O
provide	O
guidance	B-C0150600
on	O
the	O
use	B-C1524063
of	I-C1524063
bone	B-C0005976
graft	I-C0005976
in	O
metastatic	B-C0027627
tumor	I-C0027627
reconstruction	B-C0524865
.	O
	
there	O
is	O
little	O
evidence	B-C3887511
in	O
the	O
literature	B-C0023866
to	O
support	O
the	O
preferential	O
use	B-C1524063
of	I-C1524063
one	O
graft	B-C0449494
type	I-C0449494
over	O
the	O
other	O
.	O
	
approximately	O
,	O
41%	O
of	O
respondents	B-C0282122
said	O
they	O
used	O
bone	B-C0005976
graft	I-C0005976
or	O
bone	B-C0005976
graft	I-C0005976
substitutes	B-C0243003
to	O
accomplish	O
fusion	B-C1293131
.	O
	
there	O
were	O
17	O
studies	B-C0008972
that	O
described	O
the	O
use	B-C1524063
of	I-C1524063
a	O
prefabricated	B-C0175649
prosthetic	I-C0175649
,	O
10	O
studies	B-C0008972
describing	O
the	O
use	B-C1524063
of	I-C1524063
polymethyl	B-C0005533
methacrylate	I-C0005533
pmma	B-C0005533
bone	B-C0005934
cement	I-C0005934
,	O
and	O
only	O
three	O
studies	B-C0008972
describing	O
the	O
use	B-C1524063
of	I-C1524063
bone	B-C0005976
graft	I-C0005976
for	O
anterior	B-C0205094
column	B-C0037949
reconstruction	B-C0524865
.	O
	
the	O
use	B-C1524063
of	I-C1524063
structural	B-C2367546
allograft	I-C2367546
was	O
most	O
popular	O
among	O
the	O
experts	B-C0009817
for	O
anterior	B-C0205094
reconstruction	B-C0524865
,	O
followed	B-C0332283
by	I-C0332283
cage	B-C0441239
reconstruction	B-C0524865
,	O
and	O
pmma	B-C0005533
bone	B-C0005934
cement	I-C0005934
.	O
	
achieving	O
bony	B-C0391889
union	I-C0391889
may	O
be	O
of	O
importance	B-C3898777
for	O
the	O
maintenance	B-C0024501
of	O
spinal	B-C0037949
stability	B-C0205360
in	O
the	O
long	B-C0443252
term	I-C0443252
after	O
reconstruction	B-C0524865
.	O
	
whether	O
bony	B-C0391889
union	I-C0391889
is	O
required	B-C1514873
for	O
patients	B-C0030705
with	O
shorter	B-C1806781
life	B-C0023671
expectancies	I-C0023671
is	O
debatable	O
.	O
	
the	O
literature	B-C0023866
supports	O
the	O
use	B-C1524063
of	I-C1524063
anterior	B-C0205094
reconstruction	B-C0524865
with	O
either	O
a	O
prefabricated	B-C0175649
prosthetic	I-C0175649
or	O
pmma	B-C0005533
bone	B-C0005934
cement	I-C0005934
.	O
	
it	O
also	O
supports	O
the	O
use	B-C1524063
of	I-C1524063
an	O
anterior	B-C0205094
construct	B-C0005479
reinforced	O
with	O
bilateral	B-C0238767
posterior	B-C0205095
instrumentation	B-C0021632
when	O
performing	B-C0450010
a	O
three-column	B-C0524865
reconstruction	I-C0524865
.	O
	
the	O
value	O
of	O
transesophageal	B-C0206054
echocardiography	I-C0206054
for	O
embolic	B-C3888970
strokes	I-C3888970
of	I-C3888970
undetermined	I-C3888970
source	I-C3888970
our	O
aim	O
was	O
to	O
evaluate	O
the	O
diagnostic	B-C0011933
yield	I-C0011933
of	O
transesophageal	B-C0206054
echocardiography	I-C0206054
tee	B-C0206054
in	O
consecutive	O
patients	B-C0030705
with	O
ischemic	B-C0948008
stroke	I-C0948008
is	B-C0948008
fulfilling	O
the	O
diagnostic	B-C0679228
criteria	I-C0679228
of	O
embolic	B-C3888970
strokes	I-C3888970
of	I-C3888970
undetermined	I-C3888970
source	I-C3888970
esus	B-C3888970
.	O
	
we	O
prospectively	O
evaluated	O
consecutive	O
patients	B-C0030705
with	O
acute	O
is	B-C0948008
satisfying	O
esus	B-C3888970
criteria	O
who	O
underwent	O
in-	O
hospital	B-C0019994
tee	B-C0206054
examination	I-C0206054
in	O
3	O
tertiary	B-C0587437
care	I-C0587437
stroke	I-C0587437
centers	I-C0587437
during	B-C1254367
a	I-C1254367
12-month	I-C1254367
period	I-C1254367
.	O
	
we	O
also	O
performed	O
a	O
systematic	B-C1955832
review	I-C1955832
and	O
meta-analysis	B-C0920317
estimating	I-C0920317
the	O
cumulative	O
effect	O
of	O
tee	B-C0206054
findings	B-C0243095
on	O
therapeutic	B-C0039798
management	I-C0039798
for	O
secondary	B-C1277289
stroke	I-C1277289
prevention	I-C1277289
among	O
different	O
is	B-C0948008
subgroups	O
.	O
	
we	O
identified	O
61	O
patients	B-C0030705
with	O
esus	B-C3888970
who	O
underwent	B-C1261322
investigation	I-C1261322
with	O
tee	B-C0206054
mean	O
age	O
44	O
12	O
years	O
,	O
49%	O
men	B-C0025266
,	O
median	O
nih	B-C4028214
stroke	I-C4028214
scale	I-C4028214
score	I-C4028214
=	O
5	O
points	O
interquartile	B-C1711350
range	I-C1711350
3-8	O
.	O
	
tee	B-C0206054
revealed	O
additional	O
findings	B-C0243095
in	O
52%	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
40%-65%	O
of	O
the	O
study	B-C2348561
population	I-C2348561
.	O
	
tee	B-C0206054
findings	B-C0243095
changed	O
management	O
initiation	B-C1704686
of	O
anticoagulation	B-C0003281
therapy	I-C0003281
,	O
administration	B-C1533734
of	O
iv	B-C0338237
antibiotic	I-C0338237
therapy	I-C0338237
,	O
and	O
patent	B-C0189967
foramen	I-C0189967
ovale	I-C0189967
closure	I-C0189967
in	O
10	O
16%	O
95%	O
ci	B-C0009667
9%-28%	O
patients	B-C0030705
.	O
	
the	O
pooled	B-C1521828
rate	I-C1521828
of	O
reported	O
anticoagulation	B-C0003281
therapy	I-C0003281
attributed	O
to	O
abnormal	B-C0205161
tee	B-C0206054
findings	B-C0243095
among	O
3	O
acute	O
is	B-C0948008
patients	B-C0030705
included	O
in	O
the	O
meta-analysis	B-C0920317
12	O
studies	O
was	O
8.7	O
95%	O
ci	B-C0009667
7.3	O
.	O
	
in	O
subgroup	B-C0936012
analysis	I-C0936012
,	O
the	O
rates	O
of	O
initiation	B-C1704686
of	O
anticoagulation	B-C0003281
therapy	I-C0003281
on	O
the	O
basis	O
of	O
tee	B-C0206054
investigation	O
did	O
not	O
differ	O
p	O
=	O
0.315	O
among	O
patients	B-C0030705
with	O
cryptogenic	B-C0332240
stroke	I-C0332240
6.9	O
95%	O
ci	B-C0009667
4.9	O
,	O
esus	B-C3888970
8.1	O
95%	O
ci	B-C0009667
3.4	O
,	O
and	O
is	B-C0948008
9.4	O
95%	O
ci	B-C0009667
7.5	O
.	O
	
abnormal	O
tee	B-C0206054
findings	B-C0243095
may	O
decisively	O
affect	O
the	O
selection	O
of	O
appropriate	B-C1548787
therapeutic	B-C0087111
strategy	I-C0087111
in	O
approximately	O
1	O
of	O
7	O
patients	B-C0030705
with	O
simultaneous	B-C0521115
thrombosis	B-C0040053
of	O
multiple	B-C0205042
coronary	I-C0205042
arteries	I-C0205042
in	O
a	O
patient	B-C0030705
with	O
rheumatoid	B-C0003873
arthritis	I-C0003873
we	O
present	O
a	O
case	B-C0868928
of	O
simultaneous	B-C0521115
coronary	B-C0264689
thrombosis	I-C0264689
of	I-C0264689
the	I-C0264689
left	I-C0264689
main	I-C0264689
,	O
the	O
left	B-C0226032
anterior	I-C0226032
descending	I-C0226032
artery	I-C0226032
and	O
the	O
right	B-C0226042
coronary	I-C0226042
artery	I-C0226042
in	O
a	O
patient	B-C0030705
,	O
recently	O
diagnosed	B-C0430022
with	O
rheumatoid	B-C0003873
arthritis	I-C0003873
.	O
	
unintentional	B-C0151736
injuries	I-C0151736
in	O
children	B-C0008059
up	O
to	O
six	O
years	B-C1510829
of	O
age	B-C0001779
and	O
related	O
parental	B-C0030551
knowledge	B-C0376554
,	O
attitudes	B-C0004271
,	O
and	O
behaviors	B-C0004927
in	O
italy	B-C0022277
to	O
describe	O
risk	B-C0035648
factors	I-C0035648
associated	B-C0332281
with	I-C0332281
unintentional	B-C0151736
injuries	I-C0151736
among	O
children	B-C0008059
aged	O
<6	O
years	B-C1510829
and	O
to	O
examine	O
parents	B-C0030551
'	O
level	O
of	O
knowledge	B-C0376554
,	O
attitudes	B-C0004271
,	O
and	O
behaviors	B-C0004927
about	O
pediatric	B-C1521725
injuries	B-C3263723
and	O
related	O
preventive	B-C0814446
measures	I-C0814446
.	O
	
a	O
cross-sectional	B-C0010362
survey	I-C0010362
was	O
conducted	O
between	O
may	B-C3812381
and	O
july	B-C3829447
2015	O
on	O
a	O
random	B-C0150105
sample	I-C0150105
of	O
794	O
parents	B-C0030551
of	O
3-	O
to	O
6-year-old	O
children	B-C0008059
through	O
a	O
self-administered	B-C1519231
anonymous	B-C0034394
questionnaire	I-C0034394
.	O
	
a	O
total	O
of	O
409	O
parents	B-C0030551
participated	O
.	O
	
two-thirds	O
of	O
the	O
children	B-C0008059
had	O
experienced	O
at	O
least	O
1	O
unintentional	B-C0151736
injury	I-C0151736
in	O
the	O
previous	O
12	O
months	B-C0439231
.	O
	
more	O
than	O
one-half	O
of	O
these	O
children	B-C0008059
were	O
boys	B-C0870221
.	O
	
the	O
leading	B-C0552510
cause	I-C0552510
was	O
falls	B-C0000921
the	O
injuries	B-C3263723
occurred	O
mainly	O
at	O
home	B-C0442519
,	O
and	O
only	O
9.2	O
were	O
brought	O
for	O
attention	O
to	O
an	O
emergency	B-C0562508
department	I-C0562508
.	O
	
parents	B-C0030551
who	O
did	O
not	O
believe	O
that	O
it	O
is	O
possible	O
to	O
prevent	O
unintentional	B-C0151736
injuries	I-C0151736
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
child	B-C0008059
injured	B-C0332664
.	O
	
approximately	O
70%	O
of	O
respondents	B-C0282122
were	O
aware	B-C0004448
of	O
security	B-C0036547
measures	I-C0036547
to	O
prevent	O
pediatric	B-C1521725
injuries	B-C3263723
,	O
and	O
this	O
knowledge	B-C0376554
was	O
more	O
prevalent	O
in	O
older	O
parents	B-C0030551
and	O
in	O
those	O
with	O
at	O
least	O
a	O
college	B-C0013652
level	I-C0013652
of	I-C0013652
education	I-C0013652
compared	O
with	O
those	O
with	O
a	O
middle	B-C0870891
school	I-C0870891
education	I-C0870891
.	O
	
the	O
perceived	B-C0030971
utility	O
of	O
education	B-C0013621
about	O
preventive	B-C0814446
measures	I-C0814446
of	O
pediatric	B-C1521725
injuries	B-C3263723
had	O
a	O
mean	B-C0444504
value	I-C0444504
of	O
8.9	O
on	O
a	O
likert	B-C0451267
scale	I-C0451267
of	O
1-10	O
1	O
,	O
not	O
useful	O
,	O
to	O
10	O
,	O
very	O
useful	O
and	O
was	O
significantly	O
higher	O
in	O
mothers	B-C0026591
.	O
	
this	O
study	O
highlights	O
a	O
clear	O
need	O
for	O
public	B-C0699943
health	I-C0699943
educational	B-C0150562
programs	I-C0150562
for	O
parents	B-C0030551
regarding	O
prevention	B-C0814446
of	O
unintentional	B-C0151736
injuries	I-C0151736
in	O
children	B-C0008059
as	O
a	O
valuable	O
tool	O
to	O
increase	O
safety	B-C0036043
and	O
injury	B-C0150638
prevention	I-C0150638
and	O
to	O
reduce	B-C0547047
risks	B-C0035647
,	O
because	O
the	O
majority	O
of	O
such	O
injuries	B-C3263723
occur	O
at	O
truncated	B-C0007452
bovine	I-C0007452
integrin	B-C0166814
alpha-v/beta-6	I-C0166814
as	O
a	O
universal	B-C1749457
capture	I-C1749457
ligand	I-C1749457
for	O
fmd	B-C0016514
diagnosis	B-C0011900
foot-and-mouth	B-C0016514
disease	I-C0016514
fmd	B-C0016514
is	O
endemic	B-C0277550
in	O
many	O
regions	B-C0205147
of	O
the	O
world	B-C2700280
and	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
epizootic	B-C0598393
animal	B-C0003047
diseases	I-C0003047
.	O
	
fmd	B-C0016514
affects	O
livestock	B-C2936506
,	O
such	O
as	O
cattle	B-C0007452
,	O
sheep	B-C0036945
,	O
goats	B-C1510458
and	O
pigs	B-C0039005
,	O
and	O
causes	O
enormous	B-C0681022
economic	I-C0681022
losses	I-C0681022
due	O
to	O
reduced	O
productivity	B-C0033269
and	O
trade	B-C0443288
restrictions	I-C0443288
.	O
	
preparedness	B-C1318963
and	O
early	B-C0596473
diagnosis	I-C0596473
are	O
essential	B-C0205224
for	O
effective	B-C0085557
control	I-C0085557
of	O
fmd	B-C0016514
.	O
	
many	O
diagnostic	B-C1510438
assays	I-C1510438
are	O
dependent	B-C0851827
on	O
raising	O
high-affinity	B-C0205556
,	O
anti-fmd	B-C0949945
virus	I-C0949945
fmdv	B-C0949945
serotype-specific	B-C0443640
antibodies	I-C0443640
in	O
small	O
animals	B-C0003062
rabbits	B-C3887509
and	O
guinea	B-C0085979
pigs	I-C0085979
that	O
give	O
broad	O
virus	B-C0042776
coverage	O
.	O
	
here	O
we	O
show	O
that	O
soluble	B-C1948047
,	O
truncated	B-C0348078
forms	I-C0348078
of	O
bovine	B-C0007452
αvβ6	B-C0166814
bind	B-C1167622
fmdv	B-C0949945
in	O
an	O
authentic	O
rgd	B-C0052350
and	O
divalent	B-C1372999
cation	I-C1372999
dependent	I-C1372999
interaction	I-C1372999
and	O
can	O
be	O
used	O
as	O
the	O
trapping	B-C0034760
reagent	I-C0034760
in	O
a	O
fmdv	B-C0949945
sandwich	B-C0014441
elisa	I-C0014441
.	O
	
in	O
addition	O
,	O
inclusion	B-C1512693
of	O
flag	B-C0251594
or	O
his	B-C0019602
tags	I-C0019602
facilitates	O
simple	O
purification	B-C0597301
without	O
the	O
loss	B-C1517945
of	O
virus	B-C1721019
binding	I-C1721019
.	O
	
we	O
also	O
provide	O
evidence	B-C3887511
that	O
when	O
combined	B-C0205195
with	O
a	O
guinea	B-C0085979
pig	I-C0085979
polyclonal	B-C0229671
serum	I-C0229671
,	O
or	O
serotype-specific	B-C0003250
monoclonal	I-C0003250
antibodies	I-C0003250
,	O
the	O
integrin	B-C0021701
can	O
be	O
used	O
to	O
detect	B-C0442726
viruses	B-C0042776
representative	O
of	O
all	O
fmdv	B-C0884162
serotypes	I-C0884162
.	O
	
we	O
also	O
show	O
that	O
recombinant	B-C0597363
fmdv	I-C0597363
empty	B-C0006933
capsids	I-C0006933
,	O
with	O
stabilising	B-C0596391
disulphide	I-C0596391
bonds	I-C0596391
,	O
can	O
serve	O
as	O
an	O
antigen	B-C0003320
in	O
the	O
elisa	B-C0014441
and	O
can	O
therefore	O
replace	O
inactivated	B-C0003320
virus	I-C0003320
antigen	I-C0003320
as	O
a	O
positive	B-C1883676
control	I-C1883676
for	O
the	O
assay	B-C1510438
.	O
	
our	O
results	B-C0456984
demonstrate	O
the	O
potential	B-C3245505
use	O
of	O
bovine	B-C0007452
αvβ6	B-C0166814
and	O
fmdv	B-C0949945
empty	B-C0006933
capsids	I-C0006933
in	O
fmd	B-C0016514
diagnostic	B-C1510438
assays	I-C1510438
.	O
	
stress	B-C0038443
and	O
binge	B-C0556346
drinking	I-C0556346
a	O
toxic	B-C0600688
combination	O
for	O
the	O
teenage	B-C0001578
brain	B-C0006104
young	B-C0238598
adult	I-C0238598
university	B-C0597615
students	I-C0597615
frequently	O
binge	B-C0556346
on	O
alcohol	B-C0001948
and	O
have	O
high	B-C0205250
stress	B-C1319127
levels	I-C1319127
.	O
	
based	O
on	O
findings	O
in	O
rodents	B-C0035804
,	O
we	O
predicted	O
that	O
heavy	B-C2030272
current	I-C2030272
alcohol	I-C2030272
use	I-C2030272
and	O
elevated	B-C3163633
stress	B-C0038443
and	O
depression	B-C3483981
scores	I-C3483981
would	O
be	O
associated	B-C0332281
with	I-C0332281
deficits	B-C2987487
on	O
high	B-C0205250
interference	B-C0521102
memory	B-C0025260
tasks	B-C3540678
,	O
while	O
early	B-C1833334
onset	I-C1833334
,	O
prolonged	O
binge	B-C0556346
patterns	B-C0556328
would	O
lead	O
to	O
broader	O
cognitive	B-C0009241
deficits	I-C0009241
on	O
tests	O
of	O
associative	B-C0679058
encoding	I-C0679058
and	O
executive	B-C0935584
functions	I-C0935584
.	O
	
we	O
developed	O
the	O
concentration	B-C0086045
memory	B-C0025260
task	B-C3540678
,	O
a	O
novel	O
computerized	B-C0009609
version	I-C0009609
of	O
the	O
concentration	B-C0086045
card	B-C0870328
game	I-C0870328
with	O
a	O
high	B-C0205250
degree	O
of	O
interference	B-C0521102
.	O
	
we	O
found	O
that	O
young	B-C0238598
adults	I-C0238598
with	O
elevated	B-C3163633
stress	B-C4296662
,	O
depression	B-C3483981
,	O
and	O
alcohol	B-C0449820
consumption	I-C0449820
scores	I-C0449820
were	O
impaired	B-C0221099
in	O
the	O
concentration	B-C0086045
memory	B-C0025260
task	B-C3540678
.	O
	
we	O
also	O
analyzed	B-C0010992
data	I-C0010992
from	O
a	O
previous	O
study	O
,	O
and	O
found	O
that	O
higher	B-C0205250
alcohol	B-C0449820
consumption	I-C0449820
scores	I-C0449820
were	O
associated	B-C0332281
with	I-C0332281
impaired	B-C0221099
performance	B-C0597198
on	O
another	O
high	B-C0205250
interference	B-C0521102
memory	B-C0025260
task	B-C3540678
,	O
based	O
on	O
kirwan	B-C0392366
and	I-C0392366
stark's	I-C0392366
mnemonic	I-C0392366
similarity	I-C0392366
test	I-C0392366
.	O
	
on	O
the	O
other	O
hand	O
,	O
adolescent	B-C0205653
onset	B-C0206132
of	O
binge	B-C0556346
drinking	I-C0556346
predicted	O
poorer	B-C2700379
performance	B-C0597198
on	O
broader	O
range	O
of	O
memory	B-C0025260
tests	B-C0392366
,	O
including	O
a	O
more	O
systematic	B-C0451414
test	I-C0451414
of	I-C0451414
spatial	I-C0451414
recognition	I-C0451414
memory	I-C0451414
,	O
and	O
an	O
associative	B-C0023185
learning	I-C0023185
task	B-C3540678
.	O
	
our	O
results	B-C0683954
are	O
broadly	O
consistent	B-C0332290
with	I-C0332290
findings	O
in	O
rodents	B-C0035804
that	O
acute	B-C4038778
alcohol	I-C4038778
and	O
stress	B-C0038443
exposure	O
suppress	B-C1260953
neurogenesis	B-C0814002
in	O
the	O
adult	B-C0001675
hippocampus	B-C0019564
,	O
which	O
in	O
turn	O
impairs	B-C0221099
performance	B-C0597198
in	O
high	B-C0205250
interference	B-C0521102
memory	B-C0025260
tasks	B-C3540678
,	O
while	O
adolescent	B-C0205653
onset	B-C0206132
binge	B-C0556346
drinking	I-C0556346
causes	O
more	O
extensive	B-C0205231
brain	B-C0270611
damage	I-C0270611
and	O
cognitive	B-C0009241
deficits	I-C0009241
.	O
	
of	O
kindlins	B-C0033684
and	O
cancer	B-C0006826
kindlins	B-C0033684
are	O
4.1	B-C1514562
ferm	I-C1514562
domain	I-C1514562
containing	O
proteins	B-C0033684
.	O
	
there	O
are	O
three	O
kindlins	B-C0033684
in	O
mammals	B-C0024660
,	O
which	O
share	O
high	B-C0205250
sequence	B-C0002518
identity	O
.	O
	
kindlin-1	B-C0033684
is	O
expressed	B-C1171362
primarily	O
in	O
epithelial	B-C0014597
cells	I-C0014597
,	O
kindlin-2	B-C0033684
is	O
widely	O
distributed	B-C1704711
and	O
is	O
particularly	O
abundant	B-C2346714
in	O
adherent	B-C0007634
cells	I-C0007634
,	O
and	O
kindlin-3	B-C0033684
is	O
expressed	B-C1171362
primarily	O
in	O
hematopoietic	B-C2323499
cells	I-C2323499
.	O
	
these	O
distributions	B-C1704711
are	O
not	O
exclusive	B-C1548966
some	O
cells	B-C0007634
express	B-C1171362
multiple	B-C0439064
kindlins	B-C0033684
,	O
and	O
transformed	B-C0007634
cells	I-C0007634
often	B-C0332183
exhibit	O
aberrant	B-C0443127
expression	B-C1171362
,	O
both	O
in	O
the	O
isoforms	B-C0597298
and	O
the	O
levels	B-C0441889
of	O
kindlins	B-C0033684
.	O
	
great	O
interest	O
in	O
the	O
kindlins	B-C0033684
has	O
emerged	O
from	O
the	O
recognition	O
that	O
they	O
play	O
major	B-C0205164
roles	B-C1705810
in	O
controlling	B-C2239193
integrin	B-C0021701
function	B-C1527118
.	O
	
in	B-C0681828
vitro	I-C0681828
studies	I-C0681828
,	O
in	B-C0681829
vivo	I-C0681829
studies	I-C0681829
of	O
mice	B-C0025929
deficient	B-C0011155
in	O
kindlins	B-C0033684
,	O
and	O
studies	B-C0681814
of	O
patients	B-C0030705
with	O
genetic	B-C0314603
deficiencies	B-C0011155
of	O
kindlins	B-C0033684
have	O
clearly	O
established	B-C0443211
that	O
they	O
regulate	O
the	O
capacity	B-C1516240
of	O
integrins	B-C0021701
to	O
mediate	B-C0205556
their	O
functions	B-C0542341
.	O
	
kindlins	B-C0033684
are	O
adaptor	B-C0033684
proteins	I-C0033684
their	O
function	B-C0542341
emanate	B-C0700364
from	O
their	O
interaction	B-C1704675
with	O
binding	B-C1167622
partners	O
,	O
including	O
the	O
cytoplasmic	B-C0521449
tails	I-C0521449
of	O
integrins	B-C0021701
and	O
components	O
of	O
the	O
actin	B-C0025979
cytoskeleton	I-C0025979
.	O
	
the	O
purpose	B-C1285529
of	O
this	O
review	B-C0282443
is	O
to	O
provide	O
a	O
brief	B-C1879313
overview	B-C0814812
of	O
kindlin	B-C0033684
structure	B-C1510464
and	O
function	B-C1527118
,	O
a	O
consideration	B-C0518609
of	O
their	O
binding	B-C1167622
partners	O
,	O
and	O
then	O
to	O
focus	O
on	O
the	O
relationship	B-C0439849
of	O
each	O
kindlin	B-C0033684
family	B-C1335532
member	B-C1551024
with	O
cancer	B-C0006826
.	O
	
in	O
view	B-C0449911
of	O
many	O
correlations	B-C1707520
of	O
kindlin	B-C0033684
expression	B-C1171362
levels	B-C0441889
and	O
neoplasia	B-C0027651
and	O
the	O
known	O
association	B-C0439849
of	O
integrins	B-C0021701
with	O
tumor	B-C0178874
progression	I-C0178874
and	O
metastasis	B-C0027627
,	O
we	O
consider	B-C0750591
whether	O
regulation	O
of	O
kindlins	B-C0033684
or	O
their	O
function	B-C0542341
would	O
be	O
attractive	B-C2346874
targets	B-C1521840
for	O
treatment	B-C0920425
of	I-C0920425
cancer	I-C0920425
.	O
	
preclinical	B-C1709630
fibrinolysis	B-C0016017
in	O
patients	B-C0030705
with	O
st-segment	B-C1536220
elevation	I-C1536220
myocardial	I-C1536220
infarction	I-C1536220
in	O
a	O
rural	B-C0178837
region	I-C0178837
in	O
the	O
current	B-C4291682
guidelines	I-C4291682
for	O
the	O
treatment	B-C0087111
of	O
patients	B-C0030705
with	O
st-segment	B-C1536220
elevation	I-C1536220
myocardial	I-C1536220
infarction	I-C1536220
stemi	B-C1536220
,	O
the	O
european	O
society	O
of	O
cardiology	O
esc	O
recommends	B-C0034866
preclinical	B-C1709630
fibrinolysis	B-C0016017
as	O
a	O
reperfusion	B-C0035124
therapy	I-C0035124
if	O
,	O
due	O
to	O
long	O
transportation	B-C1554194
times	B-C0040223
,	O
no	O
cardiac	B-C0018795
catheterisation	I-C0018795
is	O
available	B-C0470187
within	O
90-120	O
min	B-C0439232
.	O
	
however	O
,	O
there	O
is	O
little	O
remaining	B-C1527428
in-depth	O
expertise	B-C0870520
in	O
this	O
method	B-C0449851
because	O
fibrinolysis	B-C0016017
is	O
presently	B-C0750528
only	O
rarely	B-C0522498
indicated	B-C1444656
.	O
	
in	O
a	O
rural	B-C0178837
area	I-C0178837
in	O
southwestern	B-C1710136
germany	B-C0017480
,	O
where	O
an	O
emergency	B-C1532297
primary	I-C1532297
percutaneous	I-C1532297
coronary	I-C1532297
intervention	I-C1532297
was	O
not	O
routinely	B-C0205547
available	B-C0470187
within	O
90-120	O
min	B-C0439232
,	O
156	O
stemi	B-C1536220
patients	B-C0030705
underwent	O
fibrinolysis	B-C0016017
with	O
the	O
plasminogen	B-C0256103
activator	I-C0256103
reteplase	I-C0256103
,	O
performed	B-C1550369
by	I-C1550369
trained	O
emergency	B-C0013956
physicians	B-C0031831
.	O
	
the	O
practicality	B-C0205556
of	O
the	O
treatment	B-C0087111
,	O
as	O
well	O
as	O
complications	B-C0009566
and	O
the	O
mortality	B-C0205848
of	O
the	O
patients	B-C0030705
in	O
the	O
preclinical	B-C1709630
phase	B-C0205390
until	O
arrival	B-C1706079
at	O
the	O
hospital	B-C0019994
,	O
were	O
retrospectively	B-C0035363
studied	I-C0035363
.	O
	
the	O
mean	B-C0040223
time	I-C0040223
from	O
onset	B-C0332162
of	I-C0332162
the	O
symptoms	B-C1457887
to	O
first	O
medical	B-C0582446
contact	I-C0582446
was	O
114	O
116	O
min	B-C0439232
.	O
	
the	O
mean	B-C1272706
interval	I-C1272706
to	O
the	O
start	B-C0439659
of	O
fibrinolysis	B-C0016017
of	O
13.5	O
6.4	O
min	B-C0439232
was	O
within	O
the	O
30	O
min	B-C0439232
mandated	B-C0520248
by	O
the	O
esc	O
.	O
	
patients	B-C0030705
with	O
inferior	B-C2882099
stemi	I-C2882099
represented	B-C1882932
the	O
largest	B-C0443228
subgroup	B-C1515021
.	O
	
occurring	O
in	O
39	O
cases	B-C0681850
25	O
%	O
,	O
complications	B-C0009566
due	O
to	O
infarction	B-C0021308
were	O
relatively	O
common	B-C0205214
during	O
the	O
prehospital	B-C2735050
phase	B-C0205390
,	O
including	O
15	O
cases	B-C0681850
9.6	O
%	O
of	O
cardiogenic	B-C0036980
shock	I-C0036980
,	O
but	O
in	O
all	O
cases	B-C0681850
the	O
complications	B-C0009566
were	O
manageable	B-C0243095
.	O
	
no	O
patient	B-C0030705
died	B-C1306577
before	O
arrival	B-C1706079
at	O
the	O
hospital	B-C0019994
.	O
	
as	O
lysis	B-C0024348
-	O
associated	B-C0332281
adverse	B-C0879626
effects	I-C0879626
,	O
merely	O
two	O
uncomplicated	B-C0443334
mucosal	B-C0854375
haemorrhages	I-C0854375
and	O
one	O
case	O
of	O
mild	B-C0863090
allergic	I-C0863090
skin	I-C0863090
reactions	I-C0863090
were	O
seen	B-C0205397
.	O
	
in	O
emergency	B-C0013956
situations	I-C0013956
with	O
long	O
transportation	B-C1554194
times	B-C0040223
to	O
the	O
nearest	O
suitable	B-C3900053
cardiac	B-C0018795
catheterisation	I-C0018795
laboratory	B-C0022877
,	O
preclinical	B-C1709630
fibrinolysis	B-C0016017
in	O
stemi	B-C1536220
still	O
represents	O
a	O
workable	B-C0449851
method	I-C0449851
.	O
	
success	B-C0597535
of	O
this	O
strategy	B-C0679199
requires	O
particularly	O
strong	B-C0220931
training	I-C0220931
of	O
the	O
emergency	B-C0013956
physicians	B-C0031831
in	O
ecg	B-C1623258
and	O
lysis	B-C0024348
therapy	B-C0087111
,	O
and	O
co-operation	B-C0392337
with	O
nearby	O
cardiac	B-C0475309
centres	I-C0475309
.	O
	
a	O
method	B-C0449851
of	O
providing	B-C1999230
engaging	O
formative	B-C4042837
feedback	I-C4042837
to	O
large	B-C0549177
cohort	B-C0599755
first-year	B-C1254367
physiology	B-C0031842
and	O
anatomy	B-C0002808
students	B-C0038492
a	O
growing	O
body	O
of	O
evidence	B-C3887511
demonstrates	B-C3687625
a	O
critical	B-C1511545
role	O
for	O
effective	B-C1704419
,	O
meaningful	B-C0205556
feedback	B-C2911691
to	O
enhance	B-C2349975
student	B-C0038492
learning	B-C0023185
.	O
	
effective	B-C1704419
feedback	B-C2911691
can	O
become	O
part	B-C1292711
of	I-C1292711
the	O
learning	B-C0023185
cycle	B-C1511572
that	O
is	O
not	O
only	O
a	O
learning	B-C0023185
opportunity	B-C0683937
for	O
the	O
student	B-C0038492
but	O
can	O
also	O
be	O
used	O
to	O
inform	B-C1552002
the	O
teacher	B-C0221457
and	O
ongoing	B-C0549178
curriculum	B-C0681362
development	I-C0681362
.	O
	
feedback	B-C2911691
is	O
considered	B-C0750591
particularly	O
important	B-C3898777
during	B-C0347984
the	O
first	B-C1254367
year	I-C1254367
of	O
university	B-C0041740
and	O
can	O
even	O
be	O
viewed	O
as	O
a	O
retention	B-C0333117
strategy	O
that	O
can	O
help	O
attenuate	B-C0599946
student	B-C0038492
performance	B-C0458631
anxieties	I-C0458631
and	O
solidify	B-C0205556
perceptions	B-C0030971
of	O
academic	B-C0000875
support	I-C0000875
.	O
	
unfortunately	O
,	O
the	O
provision	O
of	O
individualized	B-C1881197
,	O
timely	B-C3827828
feedback	B-C2911691
can	O
be	O
particularly	O
challenging	O
in	O
first-year	B-C1254367
courses	B-C0681364
as	O
they	O
tend	O
to	O
be	O
large	B-C0549177
and	O
diverse	B-C1880371
cohort	B-C0599755
classes	B-C0456387
that	O
pose	O
challenges	O
of	O
time	B-C0040223
and	O
logistics	B-C0242415
.	O
	
various	O
forms	O
of	O
generic	O
feedback	B-C2911691
can	O
provide	B-C1999230
rapid	B-C0456962
and	O
cost-effect	B-C0010181
feedback	B-C2911691
to	O
large	B-C0549177
cohorts	B-C0599755
but	O
may	O
be	O
of	O
limited	B-C0439801
benefit	B-C0814225
to	O
students	B-C0038492
other	O
than	O
signaling	O
weaknesses	B-C0243095
in	O
knowledge	B-C0376554
.	O
	
the	O
present	B-C0150312
study	B-C2603343
describes	B-C1552738
a	O
method	B-C0449851
that	O
was	O
used	O
to	O
provide	B-C1999230
formative	B-C4042837
task-related	I-C4042837
feedback	I-C4042837
to	O
a	O
large	B-C0549177
cohort	B-C0599755
of	O
first-year	B-C1254367
physiology	B-C0031842
and	O
anatomy	B-C0002808
students	B-C0038492
.	O
	
based	O
on	O
student	B-C0038492
evaluations	B-C0220825
presented	B-C0449450
in	O
this	O
study	B-C2603343
,	O
this	O
method	B-C0449851
provided	B-C1999230
feedback	B-C2911691
in	O
a	O
manner	O
that	O
engaged	O
students	B-C0038492
,	O
uncovered	B-C0439845
underlying	B-C0243095
misconceptions	I-C0243095
,	O
facilitated	O
peer	B-C0679739
discussion	B-C2584313
,	O
and	O
provided	B-C1999230
opportunity	O
for	O
new	B-C0205314
instruction	B-C0039401
while	O
allowing	B-C0683607
the	O
lecturer	B-C0920339
to	O
recognize	B-C0524637
common	B-C0205214
gaps	B-C3887622
in	O
knowledge	B-C0376554
and	O
inform	O
ongoing	B-C0549178
curriculum	B-C0681362
development	I-C0681362
.	O
	
sirt2	B-C2720168
deacetylates	B-C2246982
and	O
inhibits	B-C3893923
the	I-C3893923
peroxidase	I-C3893923
activity	I-C3893923
of	O
peroxiredoxin-1	B-C0672553
to	O
sensitize	B-C1512505
breast	I-C1512505
cancer	I-C1512505
cells	I-C1512505
to	O
oxidant	B-C0242606
stress	I-C0242606
-	O
inducing	B-C0205263
agents	O
sirt2	B-C2720168
is	O
a	O
protein	B-C2246982
deacetylase	I-C2246982
with	O
tumor	B-C1325410
suppressor	I-C1325410
activity	I-C1325410
in	O
breast	B-C0006142
and	O
liver	B-C0345904
tumors	I-C0345904
where	O
it	O
is	O
mutated	B-C1705285
however	O
,	O
the	O
critical	O
substrates	B-C3891814
mediating	O
its	O
antitumor	B-C0243095
activity	I-C0243095
are	O
not	O
fully	O
defined	O
.	O
	
here	O
we	O
demonstrate	O
that	O
sirt2	B-C2720168
binds	B-C1149286
,	O
deacetylates	B-C1511737
,	O
and	O
inhibits	B-C3893923
the	I-C3893923
peroxidase	I-C3893923
activity	I-C3893923
of	O
the	O
antioxidant	B-C0672553
protein	I-C0672553
peroxiredoxin	I-C0672553
prdx-1	B-C0672553
in	O
breast	B-C1512505
cancer	I-C1512505
cells	I-C1512505
.	O
	
ectopic	B-C0574895
overexpression	B-C0017262
of	O
sirt2	B-C2720168
,	O
but	O
not	O
its	O
catalytically	B-C0596988
dead	I-C0596988
mutant	I-C0596988
,	O
increased	B-C0205217
intracellular	B-C0178719
levels	I-C0178719
of	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
ros	B-C0162772
induced	B-C0020281
by	I-C0020281
hydrogen	I-C0020281
peroxide	I-C0020281
,	O
which	O
led	O
to	O
increased	B-C0205217
levels	B-C0441889
of	O
an	O
overoxidized	B-C0672553
and	I-C0672553
multimeric	I-C0672553
form	I-C0672553
of	I-C0672553
prdx-1	I-C0672553
with	O
activity	B-C0243041
as	I-C0243041
a	I-C0243041
molecular	I-C0243041
chaperone	I-C0243041
.	O
	
elevated	B-C3163633
levels	B-C0441889
of	O
sirt2	B-C1420071
sensitized	B-C1512505
breast	I-C1512505
cancer	I-C1512505
cells	I-C1512505
to	O
intracellular	B-C0012860
dna	I-C0012860
damage	I-C0012860
and	O
cell	B-C3894015
death	I-C3894015
induced	I-C3894015
by	I-C3894015
oxidative	I-C3894015
stress	I-C3894015
,	O
as	O
associated	O
with	O
increased	B-C0205217
levels	B-C0441889
of	O
nuclear	B-C1333633
foxo3a	I-C1333633
and	O
the	O
proapoptotic	B-C4282114
bim	I-C4282114
protein	I-C4282114
.	O
	
in	O
addition	O
,	O
elevated	B-C3163633
levels	B-C0441889
of	O
sirt2	B-C2720168
sensitized	B-C1512505
breast	I-C1512505
cancer	I-C1512505
cells	I-C1512505
to	O
arsenic	B-C0052416
trioxide	I-C0052416
,	O
an	O
approved	O
therapeutic	B-C0304231
agent	I-C0304231
,	O
along	O
with	O
other	O
intracellular	B-C0162772
ros	I-C0162772
-	O
inducing	B-C1254351
agents	I-C1254351
.	O
	
conversely	O
,	O
antisense	B-C0080124
rna	I-C0080124
-	O
mediated	B-C0599946
attenuation	I-C0599946
of	O
sirt2	B-C2720168
reversed	B-C1555029
ros	B-C0162772
-	O
induced	B-C1516457
toxicity	I-C1516457
as	O
demonstrated	O
in	O
a	O
zebrafish	B-C0043457
embryo	B-C0013935
model	I-C0013935
system	I-C0013935
.	O
	
collectively	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
tumor	B-C1325410
suppressor	I-C1325410
activity	I-C1325410
of	O
sirt2	B-C2720168
requires	O
its	O
ability	O
to	O
restrict	B-C0443288
the	O
antioxidant	B-C1148564
activity	I-C1148564
of	O
prdx-1	B-C0672553
,	O
thereby	O
sensitizing	B-C1512505
breast	I-C1512505
cancer	I-C1512505
cells	I-C1512505
to	O
ros	B-C0162772
-	O
induced	B-C0012860
dna	I-C0012860
damage	I-C0012860
and	O
cell	B-C0596402
cytotoxicity	I-C0596402
.	O
	
on	O
the	O
development	B-C1527148
of	O
conjunctival	B-C1761613
hyperemia	I-C1761613
computer-assisted	B-C0011905
diagnosis	I-C0011905
tools	I-C0011905
influence	O
of	O
feature	B-C2348519
selection	B-C1707391
and	O
class	B-C0282574
imbalance	I-C0282574
in	O
automatic	O
gradings	O
the	O
sudden	O
increase	O
of	O
blood	B-C0232338
flow	I-C0232338
in	O
the	O
bulbar	B-C0229275
conjunctiva	I-C0229275
,	O
known	O
as	O
hyperemia	B-C0020452
,	O
is	O
associated	O
to	O
a	O
red	B-C0678581
hue	I-C0678581
of	O
variable	B-C0439828
intensity	B-C0205556
.	O
	
experts	O
measure	O
hyperemia	B-C0020452
using	O
levels	O
in	O
a	O
grading	B-C0282574
scale	I-C0282574
,	O
a	O
procedure	O
that	O
is	O
subjective	O
,	O
non-repeatable	O
and	O
time	B-C3827829
consuming	I-C3827829
,	O
thus	O
creating	O
a	O
need	O
for	O
its	O
automatisation	B-C0004376
.	O
	
however	O
,	O
the	O
task	O
is	O
far	O
from	O
straightforward	B-C1272701
due	O
to	O
data	O
issues	O
such	O
as	O
class	B-C0282574
imbalance	I-C0282574
or	O
correlated	B-C1707520
features	B-C2348519
.	O
	
in	O
this	O
paper	O
,	O
we	O
study	O
the	O
specific	O
features	B-C2348519
of	O
hyperemia	B-C0020452
and	O
propose	O
various	O
approaches	O
to	O
address	O
these	O
problems	O
in	O
the	O
context	O
of	O
an	O
automatic	B-C0282574
framework	I-C0282574
for	O
hyperemia	B-C0020452
grading	B-C0243095
.	O
	
oversampling	B-C0282574
,	O
undersampling	B-C0282574
and	O
smote	B-C0282574
approaches	I-C0282574
were	O
applied	O
in	O
order	O
to	O
tackle	O
the	O
problem	O
of	O
class	B-C0282574
imbalance	I-C0282574
.	O
	
25	O
features	O
were	O
computed	O
for	O
each	O
image	O
and	O
regression	B-C0034980
methods	I-C0034980
were	O
then	O
used	O
to	O
transform	O
them	O
into	O
a	O
value	O
on	O
the	O
grading	B-C0282574
scale	I-C0282574
.	O
	
the	O
values	O
and	O
relationships	O
among	O
features	B-C2348519
and	O
experts'	B-C0243095
values	I-C0243095
were	O
analysed	O
,	O
and	O
five	O
feature	B-C2348519
selection	B-C1707391
techniques	O
were	O
subsequently	O
studied	O
.	O
	
the	O
lowest	B-C0392762
mean	I-C0392762
square	I-C0392762
error	I-C0392762
mse	B-C0392762
for	O
the	O
regression	B-C0034980
systems	I-C0034980
trained	O
with	O
individual	O
features	O
is	O
below	O
0.1	O
for	O
both	O
scales	O
.	O
	
multi-layer	B-C0870951
perceptron	I-C0870951
mlp	B-C0870951
obtains	O
the	O
best	O
values	O
,	O
but	O
is	O
less	O
consistent	O
than	O
the	O
random	B-C0282574
forest	I-C0282574
rf	I-C0282574
method	I-C0282574
.	O
	
when	O
all	O
features	O
are	O
combined	O
,	O
the	O
best	O
results	O
for	O
both	O
scales	O
are	O
achieved	O
with	O
mlp	B-C0870951
.	O
	
correlation	B-C0282574
based	I-C0282574
feature	I-C0282574
selection	I-C0282574
cfs	B-C0282574
and	O
m5	O
provide	O
the	O
best	O
results	O
,	O
mse	B-C0392762
=0	O
and	O
mse	B-C0392762
=0	O
respectively	O
.	O
	
finally	O
,	O
the	O
class	B-C0282574
imbalance	I-C0282574
problem	I-C0282574
is	O
minimised	O
with	O
the	O
smote	B-C0282574
approach	I-C0282574
for	O
both	O
scales	O
mse	B-C0392762
<0	O
.	O
	
machine	B-C0376284
learning	I-C0376284
methods	O
are	O
able	O
to	O
perform	O
an	O
objective	O
assessment	O
of	O
hyperemia	B-C0020452
grading	B-C0243095
,	O
removing	O
both	O
intra-	B-C0205556
and	I-C0205556
inter-expert	I-C0205556
subjectivity	I-C0205556
while	O
providing	O
a	O
gain	O
in	O
computation	B-C1880157
time	B-C0040223
.	O
	
smote	B-C0282574
and	O
oversampling	B-C0282574
approaches	I-C0282574
minimise	O
the	O
class	B-C0282574
imbalance	I-C0282574
problem	I-C0282574
,	O
while	O
feature	B-C2348519
selection	B-C1707391
reduces	O
the	O
number	O
of	O
features	B-C2348519
from	O
25	O
to	O
3-5	O
without	O
worsening	O
the	O
mse	B-C0392762
.	O
	
as	O
the	O
differences	O
between	O
the	O
system	B-C0015324
and	O
a	O
human	B-C0031831
expert	I-C0031831
are	O
similar	O
to	O
the	O
differences	O
between	O
experts	B-C0031831
,	O
we	O
can	O
therefore	O
conclude	O
that	O
the	O
system	B-C0015324
behaves	O
like	O
an	O
medication	B-C2081612
,	O
rehabilitation	B-C0034992
and	O
health	B-C0814514
care	I-C0814514
consumption	I-C0814514
in	O
adults	B-C0001675
with	O
cerebral	B-C0007789
palsy	I-C0007789
a	O
population	B-C1709599
based	I-C1709599
study	I-C1709599
to	O
evaluate	O
medication	B-C2081612
,	O
rehabilitation	B-C0034992
and	O
healthcare	B-C0814514
consumption	I-C0814514
in	O
adults	B-C0001675
with	O
cp	B-C0007789
as	O
a	O
function	B-C0542341
of	O
gross	B-C3873236
motor	I-C3873236
function	I-C3873236
classification	I-C3873236
system	I-C3873236
gmfcs	B-C3873236
level	O
.	O
	
questionnaire	B-C0034394
-based	O
cross-sectional	B-C0010362
study	I-C0010362
.	O
	
brittany	B-C0017446
,	O
a	O
french	B-C0079170
county	I-C0079170
.	O
	
adults	B-C0001675
with	O
cerebral	B-C0007789
palsy	I-C0007789
.	O
	
questionnaires	B-C0034394
relating	O
to	O
drugs	B-C0013227
,	O
orthotic	B-C0029365
devices	I-C0029365
,	O
mobility	B-C3495449
aids	I-C3495449
,	O
rehabilitation	B-C0034992
and	O
medical	B-C0496675
input	I-C0496675
were	O
sent	B-C1519246
to	O
435	O
members	B-C0680022
of	O
a	O
unique	B-C1710548
regional	B-C0017446
french	I-C0017446
network	B-C1882071
dedicated	O
to	O
adults	B-C0001675
with	O
cerebral	B-C0007789
palsy	I-C0007789
.	O
	
the	O
questionnaire	B-C0034394
was	O
completed	B-C0205197
by	O
the	O
participant	B-C0679646
or	O
a	O
helper	B-C0682221
if	O
necessary	O
.	O
	
of	O
the	O
282	O
responders	B-C0919876
,	O
7.8	O
had	O
a	O
gmfcs	B-C3873236
level	I-C3873236
of	O
i	O
,	O
14.2	O
ii	O
,	O
17.7	O
iii	O
,	O
29.1	O
iv	O
and	O
31.2	O
v	O
.	O
	
participants	B-C0679646
consumed	O
a	O
large	B-C0814514
amount	I-C0814514
of	I-C0814514
healthcare	I-C0814514
.	O
	
almost	B-C2825406
three-quarters	I-C2825406
took	O
orally	B-C0013227
administered	I-C0013227
drugs	I-C0013227
,	O
of	O
which	O
antispastic	B-C4020576
and	O
antiepileptic	B-C0003299
drugs	I-C0003299
were	O
among	O
the	O
most	B-C0332183
frequent	I-C0332183
.	O
	
nearly	O
all	O
patients	B-C0030705
had	O
at	O
least	O
one	O
type	O
of	O
rehabilitation	B-C0034992
,	O
87.2	O
had	O
physiotherapy	B-C0949766
,	O
78%	O
used	O
at	O
least	O
one	O
mobility	B-C3495449
aid	I-C3495449
and	O
69.5	O
used	O
at	O
least	O
one	O
orthotic	B-C0029365
device	I-C0029365
.	O
	
the	O
frequency	B-C0439603
of	O
numerous	O
inputs	O
increased	O
with	O
gmfcs	B-C3873236
level	I-C3873236
.	O
	
specificities	B-C0037791
were	O
found	B-C0150312
for	O
each	O
gmfcs	B-C3873236
level	I-C3873236
,	O
e.g	O
.	O
	
participants	B-C0679646
with	O
gmfcs	B-C3873236
level	I-C3873236
iv	O
and	O
v	O
had	O
a	O
high	B-C0441889
level	I-C0441889
of	O
medical	B-C0496675
input	I-C0496675
and	O
a	O
greater	B-C1524063
use	I-C1524063
of	I-C1524063
trunk-supporting	B-C0025080
devices	I-C0025080
,	O
antireflux	B-C0399651
and	O
laxative	B-C0282090
.	O
	
profiles	B-C0237801
could	O
be	O
established	O
based	O
on	O
gmfcs	B-C3873236
levels	I-C3873236
.	O
	
adults	B-C0001675
with	O
cerebral	B-C0007789
palsy	I-C0007789
use	O
a	O
large	B-C3869890
amount	I-C3869890
of	O
drugs	B-C0013227
,	O
mobility	B-C3495449
aids	I-C3495449
,	O
orthotic	B-C0029365
devices	I-C0029365
,	O
rehabilitation	B-C0034992
and	O
medical	B-C0496675
input	I-C0496675
.	O
	
healthcare	B-C0086388
is	O
targeted	B-C1521840
at	O
cerebral	B-C0007789
palsy	I-C0007789
-related	O
issues	O
.	O
	
gmfcs	O
is	O
a	O
determinant	O
of	O
healthcare	O
consumption	O
and	O
thus	O
a	O
useful	O
tool	O
for	O
clinical	O
practice	O
to	O
target	O
care	O
appropriately	B-C1548787
transcriptome	B-C4086963
sequencing	I-C4086963
and	O
de	B-C1515568
novo	I-C1515568
characterization	B-C1880022
of	O
korean	B-C0022771
endemic	O
land	B-C0037378
snail	I-C0037378
,	O
koreanohadra	B-C0037378
kurodana	I-C0037378
for	O
functional	O
transcripts	B-C1519595
and	O
ssr	B-C1519302
markers	B-C0017393
the	O
korean	B-C0022771
endemic	O
land	B-C0037378
snail	I-C0037378
koreanohadra	B-C0037378
kurodana	I-C0037378
gastropoda	B-C0324023
bradybaenidae	B-C1040093
found	O
in	O
humid	B-C0563027
areas	I-C0563027
of	O
broadleaf	B-C0086312
forests	I-C0086312
and	O
shrubs	B-C0446286
have	O
been	O
considered	O
vulnerable	O
as	O
the	O
number	O
of	O
individuals	B-C0237401
are	O
declining	O
in	O
recent	O
years	B-C0439234
.	O
	
the	O
species	B-C0684063
is	O
poorly	O
characterized	O
at	O
the	O
genomic	B-C0017428
level	I-C0017428
that	O
limits	O
the	O
understanding	O
of	O
functions	B-C0542341
at	O
the	O
molecular	B-C1521991
and	O
genetics	B-C0314603
level	I-C0314603
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
we	O
performed	O
de	B-C1515568
novo	I-C1515568
transcriptome	B-C4086963
sequencing	I-C4086963
to	O
produce	O
a	O
comprehensive	O
transcript	B-C1519595
dataset	B-C0150098
of	O
visceral	B-C0040300
mass	I-C0040300
tissue	I-C0040300
of	O
k	B-C0037378
.	O
	
kurodana	I-C0037378
by	O
the	O
illumina	B-C1513384
paired-end	I-C1513384
sequencing	I-C1513384
technology	I-C1513384
.	O
	
over	O
234	O
million	O
quality	O
reads	O
were	O
assembled	O
to	O
a	O
total	O
of	O
315	O
contigs	B-C1511491
and	O
191	O
unigenes	B-C1710539
,	O
with	O
an	O
average	O
and	O
n50	B-C0028630
length	B-C1444754
of	O
585.6	O
and	O
715	O
bp	O
and	O
678	O
and	O
927	O
bp	O
,	O
respectively	O
.	O
	
overall	O
,	O
36.32	O
%	O
of	O
the	O
unigenes	B-C1710539
found	O
matches	O
to	O
known	O
protein	B-C0002518
/	O
nucleotide	B-C0004793
sequences	I-C0004793
in	O
the	O
public	B-C0242356
databases	I-C0242356
.	O
	
the	O
direction	B-C0449738
of	O
the	O
unigenes	B-C1710539
to	O
functional	O
categories	O
was	O
determined	O
using	O
cog	B-C0242356
,	O
go	B-C1138831
,	O
kegg	B-C0242356
,	O
and	O
interproscan	B-C2826595
protein	B-C1514562
domain	I-C1514562
search	B-C1706202
.	O
	
the	O
go	B-C1138831
analysis	B-C0936012
search	O
resulted	O
in	O
22	O
unigenes	B-C1710539
12.02	O
%	O
being	O
categorized	O
into	O
40	O
functional	B-C0598132
groups	I-C0598132
.	O
	
the	O
kegg	B-C0242356
annotation	I-C0242356
revealed	O
that	O
metabolism	B-C1291081
pathway	I-C1291081
genes	B-C0017337
were	O
enriched	O
.	O
	
the	O
most	O
prominent	O
protein	B-C1514562
motifs	I-C1514562
include	O
the	O
zinc	B-C0080347
finger	I-C0080347
,	O
ribonuclease	B-C0085431
h	I-C0085431
,	O
reverse	B-C0035379
transcriptase	I-C0035379
,	O
and	O
ankyrin	B-C1956127
repeat	I-C1956127
domains	I-C1956127
.	O
	
the	O
simple	B-C1519302
sequence	I-C1519302
repeats	I-C1519302
ssrs	B-C1519302
identified	O
from	O
>1	O
kb	O
length	B-C1444754
of	O
unigenes	B-C1710539
show	O
a	O
dominancy	O
of	O
dinucleotide	B-C0282524
repeat	I-C0282524
motifs	I-C0282524
followed	O
with	O
tri-	B-C0282537
and	O
tetranucleotide	B-C0282521
motifs	I-C0282521
.	O
	
a	O
number	O
of	O
unigenes	B-C1710539
were	O
putatively	O
assessed	O
to	O
belong	O
to	O
adaptation	B-C0392673
and	O
defense	B-C0011142
mechanisms	I-C0011142
including	O
heat	B-C0243043
shock	I-C0243043
proteins	I-C0243043
70	I-C0243043
,	O
toll-like	B-C1411976
receptor	I-C1411976
4	I-C1411976
,	O
amp-activated	B-C2350345
protein	I-C2350345
kinase	I-C2350345
,	O
aquaporin-2	B-C0213238
,	O
etc	O
.	O
	
our	O
data	O
provide	O
a	O
rich	O
source	O
for	O
the	O
identification	B-C0205396
and	O
functional	O
characterization	B-C1880022
of	O
new	O
genes	B-C0017337
and	O
candidate	O
polymorphic	B-C1882417
ssr	B-C1519302
markers	B-C0017393
in	O
k	B-C0037378
.	O
	
kurodana	I-C0037378
.	O
	
the	O
availability	O
of	O
transcriptome	B-C3178810
information	O
http	B-C0872179
would	O
promote	O
the	O
utilization	O
of	O
the	O
resources	O
for	O
phylogenetics	B-C1519068
study	I-C1519068
and	O
genetic	B-C0042333
diversity	I-C0042333
assessment	B-C1516048
.	O
	
prediction	B-C0681842
of	O
estrogenic	B-C0014939
bioactivity	B-C0441655
of	O
environmental	B-C0220806
chemical	I-C0220806
metabolites	B-C0870883
the	O
us	B-C0041712
environmental	I-C0041712
protection	I-C0041712
agency's	I-C0041712
epa	B-C0041712
endocrine	B-C1254363
disruptor	I-C1254363
screening	I-C1254363
program	I-C1254363
edsp	B-C1254363
is	O
using	O
in	B-C1511726
vitro	I-C1511726
data	I-C1511726
generated	O
from	O
toxcast	B-C0282574
/	O
tox21	B-C0282574
high-throughput	B-C2718002
screening	I-C2718002
assays	I-C2718002
to	O
assess	O
the	O
endocrine	B-C0014136
activity	B-C0441655
of	O
environmental	B-C0220806
chemicals	I-C0220806
.	O
	
considering	O
that	O
in	B-C3850137
vitro	I-C3850137
assays	I-C3850137
may	O
have	O
limited	O
metabolic	B-C0025520
capacity	I-C0025520
,	O
inactive	B-C0220806
chemicals	I-C0220806
that	O
are	O
biotransformed	B-C0005576
into	O
metabolites	B-C0870883
with	O
endocrine	B-C0014136
bioactivity	B-C0441655
may	O
be	O
missed	O
for	O
further	O
screening	B-C1305399
and	O
testing	B-C0039593
.	O
	
therefore	O
,	O
there	O
is	O
a	O
value	O
in	O
developing	O
novel	O
approaches	O
to	O
account	O
for	O
metabolism	B-C0025519
and	O
endocrine	B-C0014136
activity	B-C0441655
of	O
both	O
parent	B-C0220806
chemicals	I-C0220806
and	O
their	O
associated	O
metabolites	B-C0870883
.	O
	
we	O
used	O
commercially	O
available	O
software	B-C0037585
to	O
predict	O
metabolites	B-C0870883
of	O
50	O
parent	B-C1706082
compounds	I-C1706082
,	O
out	O
of	O
which	O
38	O
chemicals	B-C0220806
are	O
known	O
to	O
have	O
estrogenic	B-C0014939
metabolites	B-C0870883
,	O
and	O
12	O
compounds	B-C1706082
and	O
their	O
metabolites	B-C0870883
are	O
negative	O
for	O
estrogenic	B-C0014939
activity	B-C0441655
.	O
	
three	O
er	B-C0034804
qsar	B-C0887819
models	B-C3161035
were	O
used	O
to	O
determine	O
potential	O
estrogen	B-C0014939
bioactivity	B-C0441655
of	O
the	O
parent	B-C1706082
compounds	I-C1706082
and	O
predicted	O
metabolites	B-C0870883
,	O
the	O
outputs	O
of	O
the	O
models	B-C3161035
were	O
averaged	O
,	O
and	O
the	O
chemicals	B-C0220806
were	O
then	O
ranked	O
based	O
on	O
the	O
total	O
estrogenicity	B-C0205245
of	O
the	O
parent	B-C0220806
chemical	I-C0220806
and	O
metabolites	B-C0870883
.	O
	
the	O
metabolite	B-C0037585
prediction	I-C0037585
software	I-C0037585
correctly	O
identified	O
known	O
estrogenic	B-C0014939
metabolites	B-C0870883
for	O
26	O
out	O
of	O
27	O
parent	B-C0220806
chemicals	I-C0220806
with	O
associated	O
metabolite	B-C0870883
data	O
,	O
and	O
39	O
out	O
of	O
46	O
estrogenic	B-C0014939
metabolites	B-C0870883
were	O
predicted	O
as	O
potential	O
biotransformation	B-C0005576
products	B-C0005522
derived	O
from	O
the	O
parent	B-C0220806
chemical	I-C0220806
.	O
	
the	O
qsar	B-C0887819
models	B-C3161035
estimated	O
stronger	O
estrogenic	B-C0014939
activity	B-C0441655
for	O
the	O
majority	O
of	O
the	O
known	O
estrogenic	B-C0014939
metabolites	B-C0870883
compared	O
to	O
their	O
parent	B-C0220806
chemicals	I-C0220806
.	O
	
finally	O
,	O
the	O
three	O
models	B-C3161035
identified	O
a	O
similar	O
set	O
of	O
parent	B-C1706082
compounds	I-C1706082
as	O
top	O
ranked	O
chemicals	B-C0220806
based	O
on	O
the	O
estrogenicity	B-C0205245
of	O
putative	O
metabolites	B-C0870883
.	O
	
this	O
proposed	O
in	B-C3489666
silico	I-C3489666
approach	O
is	O
an	O
inexpensive	O
and	O
rapid	O
strategy	O
for	O
the	O
detection	B-C0442726
of	O
chemicals	B-C0220806
with	O
estrogenic	B-C0014939
metabolites	B-C0870883
and	O
may	O
reduce	O
potential	O
false	B-C0205558
negative	I-C0205558
results	O
from	O
in	B-C3850137
vitro	I-C3850137
assays	I-C3850137
.	O
	
effects	B-C1704420
of	I-C1704420
application	B-C4048755
of	O
social	B-C0037424
marketing	I-C0037424
theory	B-C0871935
and	O
the	O
health	B-C3714363
belief	I-C3714363
model	I-C3714363
in	O
promoting	B-C0033414
cervical	B-C0281187
cancer	I-C0281187
screening	I-C0281187
among	O
targeted	B-C1521840
women	B-C0043210
in	O
sisaket	B-C1514578
province	I-C1514578
,	O
thailand	B-C0039725
cervical	B-C4048328
cancer	I-C4048328
is	O
a	O
major	B-C0205164
public	B-C0033213
health	I-C0033213
problem	I-C0033213
in	O
thailand	B-C0039725
,	O
being	O
ranked	B-C0699794
second	O
only	O
to	O
breast	B-C0678222
cancer	I-C0678222
.	O
	
thai	B-C0337910
women	B-C0043210
have	O
been	O
reported	B-C0700287
to	O
have	O
a	O
low	B-C0205251
rate	B-C1521828
of	O
cervical	B-C0281187
cancer	I-C0281187
screening	I-C0281187
27.7	O
of	O
the	O
80%	O
goal	B-C0018017
of	O
who	B-C0043237
.	O
	
we	O
therefore	O
aimed	B-C1947946
to	O
apply	B-C4048755
the	O
social	B-C0037424
marketing	I-C0037424
theory	B-C0871935
and	O
health	B-C3714363
belief	I-C3714363
model	I-C3714363
in	O
promoting	B-C0033414
cervical	B-C0281187
cancer	I-C0281187
screening	I-C0281187
in	O
kanthararom	B-C0017446
district	I-C0017446
,	O
sisaket	B-C1514578
province	I-C1514578
.	O
	
a	O
total	B-C0439810
of	O
92	O
from	O
974	O
targeted	B-C1521840
women	B-C0043210
aged	B-C0001779
3060	O
years	B-C0439234
were	O
randomly	B-C0034656
divided	B-C0332849
into	O
two	O
groups	B-C0441833
.	O
	
the	O
experimental	B-C1257890
group	I-C1257890
underwent	O
application	B-C4048755
of	O
social	B-C0037424
marketing	I-C0037424
theory	B-C0871935
and	O
a	O
health	B-C3714363
belief	I-C3714363
model	I-C3714363
program	B-C3484370
promoting	B-C0033414
cervical	B-C0281187
cancer	I-C0281187
screening	I-C0281187
while	O
the	O
control	B-C0009932
group	I-C0009932
received	B-C1514756
normal	B-C1254363
services	I-C1254363
.	O
	
two	O
research	B-C1516602
tools	I-C1516602
were	O
used	O
1	O
application	B-C4048755
of	O
social	B-C0037424
marketing	I-C0037424
theory	B-C0871935
and	O
health	B-C3714363
belief	I-C3714363
model	I-C3714363
program	B-C3484370
and	O
2	O
questionnaire	B-C0034394
used	O
to	O
evaluate	B-C1516048
perceptions	B-C0030971
of	O
cervical	B-C4048328
cancer	I-C4048328
.	O
	
descriptive	B-C0678257
and	O
inferential	B-C0002780
statistics	I-C0002780
including	B-C0332257
paired	B-C1709450
sample	B-C0392366
ttest	I-C0392366
and	O
independent	B-C0332291
ttest	B-C0392366
were	O
used	O
to	O
analyze	B-C0010992
the	I-C0010992
data	I-C0010992
.	O
	
after	O
the	O
program	B-C3484370
had	O
been	O
used	O
,	O
the	O
mean	B-C3533236
score	I-C3533236
of	O
perception	B-C0030971
of	O
cervical	B-C4048328
cancer	I-C4048328
of	O
experimental	B-C1257890
group	I-C1257890
was	O
at	O
a	O
higher	B-C0205250
level	B-C0441889
x=4	O
s.d	B-C0871420
.	O
	
=0	O
,	O
than	O
in	O
the	O
control	B-C0009932
group	I-C0009932
x=3	O
s.d	B-C0871420
.	O
	
=0	O
with	O
statistical	B-C0237881
significance	I-C0237881
p<0	O
.	O
	
this	O
research	B-C0035168
demonstrated	O
an	O
appropriate	B-C1548787
communication	B-C0009452
process	B-C1522240
in	O
behavioral	B-C0004927
modification	B-C0392747
to	O
prevent	O
cervical	B-C4048328
cancer	I-C4048328
.	O
	
it	O
can	O
be	O
recommended	B-C0034866
that	O
this	O
program	B-C3484370
featuring	B-C2348519
social	B-C0037424
marketing	I-C0037424
and	O
the	O
health	B-C3714363
belief	I-C3714363
model	I-C3714363
be	O
used	O
to	O
promote	B-C0033414
cervical	B-C0281187
cancer	I-C0281187
screening	I-C0281187
in	O
targeted	B-C1521840
women	B-C0043210
and	O
it	O
can	O
be	O
promoted	B-C0033414
as	O
a	O
guideline	B-C0162791
for	O
other	O
health	B-C0018747
services	I-C0018747
,	O
especially	O
in	O
health	B-C0018738
promotion	I-C0018738
and	O
disease	B-C0679698
prevention	I-C0679698
.	O
	
visualization	B-C0011923
of	O
the	O
intimal	B-C0038925
flap	I-C0038925
in	O
intracranial	B-C3665731
arterial	I-C3665731
dissection	I-C3665731
using	O
high-resolution	B-C1719039
3t	B-C0024485
mri	I-C0024485
presence	B-C0150312
of	O
an	O
intimal	B-C0038925
flap	I-C0038925
is	O
a	O
critical	B-C1511545
imaging	B-C1287399
finding	I-C1287399
in	O
diagnosing	B-C0011900
intracranial	B-C3665731
artery	I-C3665731
dissection	I-C3665731
icad	B-C3665731
.	O
	
recent	O
reports	B-C0684224
showed	O
that	O
high-resolution	B-C1719039
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
mri	B-C0024485
was	O
better	B-C0332272
at	O
identifying	O
intimal	B-C0038925
flaps	I-C0038925
as	O
compared	B-C1707455
with	O
routine	O
mri	B-C0024485
techniques	I-C0024485
used	O
in	O
clinical	B-C3176918
settings	I-C3176918
.	O
	
however	O
,	O
no	O
current	O
standardized	O
sequence	B-C1519249
for	O
high-resolution	B-C1719039
mri	B-C0024485
without	O
gadolinium	B-C0016911
enhancement	B-C2349975
produces	O
images	B-C1551337
of	O
satisfactory	O
quality	B-C0332306
with	O
clinically	O
tolerable	O
scanning	B-C0441633
times	B-C0040223
.	O
	
this	O
study	O
evaluated	B-C0220825
a	O
nonenhanced	B-C0024485
high-resolution	I-C0024485
fast	I-C0024485
spin	I-C0024485
echo	I-C0024485
hr-fse	I-C0024485
mri	I-C0024485
sequence	B-C1519249
for	O
visualizing	O
intimal	B-C0038925
flaps	I-C0038925
in	O
patients	B-C0030705
with	O
icad	B-C3665731
.	O
	
three	O
patients	B-C0030705
with	O
icad	B-C3665731
underwent	O
plain	O
mri	B-C0024485
examination	O
using	O
a	O
2-dimensional	B-C1705052
t2-weighted	B-C0011923
fse	I-C0011923
imaging	I-C0011923
sequence	B-C1519249
optimized	O
for	O
our	O
3t	B-C0449913
system	I-C0449913
in-plane	O
pixel	O
size	O
,	O
23	O
mm	O
23	O
mm	O
slice	O
thickness	O
3	O
mm	O
with	O
no	O
interslice	O
gap	O
,	O
as	O
well	O
as	O
scanning	B-C0441633
with	O
conventional	B-C0439858
modalities	B-C0695347
,	O
including	O
ct	B-C1536105
angiography	I-C1536105
,	O
magnetic	B-C0243032
resonance	I-C0243032
angiography	I-C0243032
,	O
and	O
digital	B-C0002979
subtraction	I-C0002979
angiography	I-C0002979
.	O
	
we	O
assessed	B-C1516048
whether	O
these	O
imaging	B-C1275506
methods	I-C1275506
could	O
visualize	O
an	O
intimal	B-C0038925
flap	I-C0038925
and/or	O
double	B-C0243095
lumen	I-C0243095
sign	I-C0243095
in	O
the	O
participants	B-C0679646
and	O
compared	B-C1707455
the	O
results	B-C0683954
between	O
hr-fse	B-C0024485
and	O
the	O
other	O
modalities	B-C0695347
.	O
	
hr-fse	B-C0024485
images	B-C1551337
clearly	O
showed	O
intimal	B-C0038925
flaps	I-C0038925
and	O
double	B-C0243095
lumen	I-C0243095
signs	I-C0243095
in	O
all	O
3	O
patients	B-C0030705
,	O
whereas	O
the	O
conventional	B-C0439858
modalities	B-C0695347
identified	B-C0205396
a	O
double	B-C0243095
lumen	I-C0243095
sign	I-C0243095
in	O
only	O
2	O
of	O
the	O
3	O
patients	B-C0030705
.	O
	
the	O
present	O
method	O
of	O
optimized	O
hr-fse	B-C0024485
imaging	I-C0024485
with	O
a	O
3t	B-C0449913
system	I-C0449913
improved	B-C0184511
visualization	B-C0011923
of	O
intimal	B-C0038925
flaps	I-C0038925
and	O
should	O
thus	O
be	O
considered	O
for	O
assessing	B-C1516048
patients	B-C0030705
with	O
suspected	B-C0750491
icad	B-C3665731
that	O
cannot	O
be	O
definitively	O
diagnosed	B-C0011900
by	O
conventional	B-C0439858
imaging	B-C1275506
modalities	I-C1275506
.	O
	
quantification	B-C1709793
of	O
intact	B-C0205266
plasma	B-C0032105
agt	B-C0003017
consisting	O
of	O
oxidized	O
and	O
reduced	B-C0033625
conformations	I-C0033625
using	O
a	O
modified	O
elisa	B-C0014441
the	O
pleiotropic	B-C3266814
actions	I-C3266814
of	O
the	O
renin-angiotensin	B-C0035096
system	I-C0035096
ras	B-C0035096
depend	O
on	O
the	O
availability	B-C0470187
of	I-C0470187
angiotensinogen	B-C0003017
agt	B-C0003017
which	O
generates	B-C3146294
angiotensin	B-C0003006
i	I-C0003006
ang	B-C0003006
i	I-C0003006
when	O
cleaved	B-C0205242
by	O
renin	B-C0035094
.	O
	
thus	O
,	O
quantification	B-C1709793
of	O
the	O
intact	B-C0205266
agt	B-C0003017
iagt	B-C0003017
concentrations	B-C1264643
is	O
important	B-C3898777
to	O
evaluate	O
the	O
actual	B-C0237400
renin	B-C0003017
substrate	I-C0003017
available	B-C0470187
.	O
	
the	O
iagt	B-C0003017
conformation	B-C0033625
exists	O
as	O
oxidized	B-C0003017
agt	I-C0003017
oxi-agt	B-C0003017
and	O
reduced	B-C0003017
agt	I-C0003017
red-agt	B-C0003017
in	O
a	O
disulfide	B-C1511997
bond	I-C1511997
,	O
and	O
oxi-agt	B-C0003017
has	O
a	O
higher	B-C0205250
affinity	B-C1510827
for	O
renin	B-C0035094
,	O
which	O
may	O
exacerbate	O
ras	B-C0035096
-	O
associated	B-C0243083
diseases	I-C0243083
.	O
	
accordingly	O
,	O
we	O
determined	B-C0521095
iagt	B-C0003017
,	O
oxi-agt	B-C0003017
,	O
and	O
red-agt	B-C0003017
levels	B-C0441889
in	O
plasma	B-C0032105
from	O
rats	B-C0034693
and	O
mice	B-C0025929
.	O
	
blood	B-C0178913
samples	I-C0178913
were	O
obtained	B-C1301820
by	O
cardiac	B-C0022885
puncture	I-C0022885
and	O
then	O
immediately	B-C0205253
mixed	B-C0205430
with	O
an	O
inhibitor	B-C0243077
solution	B-C0037633
containing	B-C0332256
a	O
renin	B-C1960108
inhibitor	I-C1960108
.	O
	
total	B-C0439810
agt	B-C0003017
tagt	B-C0003017
levels	B-C0441889
were	O
measured	B-C0444706
by	O
tagt	B-C0003017
elisa	B-C0014441
which	O
detects	B-C0442726
both	O
cleaved	B-C0205242
and	O
iagt	B-C0003017
.	O
	
iagt	B-C0003017
levels	B-C0441889
were	O
determined	B-C0521095
by	I-C0521095
iagt	B-C0003017
elisa	B-C0014441
which	O
was	O
found	O
to	O
only	O
detect	B-C0442726
red-agt	B-C0003017
.	O
	
thus	O
,	O
it	O
was	O
necessary	O
to	O
treat	O
samples	B-C0178913
with	O
dithiothreitol	B-C0012789
,	O
a	O
reducing	B-C0376446
agent	I-C0376446
,	O
to	O
quantify	B-C1709793
total	B-C0439810
iagt	B-C0003017
concentration	B-C1264643
.	O
	
tagt	B-C0003017
levels	B-C0441889
in	O
rat	B-C0034693
and	O
mouse	B-C0025929
plasma	B-C0032105
were	O
1	O
139	O
and	O
1	O
77	O
ng/ml	O
,	O
respectively	O
.	O
	
iagt	B-C0003017
levels	B-C0441889
were	O
53%	O
of	O
tagt	B-C0003017
in	O
rat	B-C0034693
plasma	B-C0032105
but	O
only	O
22%	O
in	O
mouse	B-C0025929
plasma	B-C0032105
,	O
probably	O
reflecting	O
the	O
greater	B-C1704243
plasma	B-C0032105
renin	B-C0035094
activity	B-C0243102
in	O
mice	B-C0025929
.	O
	
the	O
ratios	B-C0456603
of	O
oxi-agt	B-C0003017
and	O
red-agt	B-C0003017
were	O
4	O
rat	B-C0034693
and	O
16	O
mouse	B-C0025929
.	O
	
plasma	B-C0032105
iagt	B-C0003017
consists	O
of	O
oxi-agt	B-C0003017
and	O
red-agt	B-C0003017
,	O
suggesting	B-C1705535
that	O
oxidative	B-C0242606
stress	I-C0242606
can	O
influence	B-C4054723
ang	B-C0003006
i	I-C0003006
generation	B-C3146294
by	O
the	O
agt	B-C0003017
conformation	B-C0033625
switch	O
.	O
	
furthermore	O
,	O
the	O
lower	B-C2003888
availability	B-C0470187
of	I-C0470187
plasma	B-C0032105
iagt	B-C0003017
in	O
mice	B-C0025929
suggests	B-C1705535
that	O
it	O
may	O
serve	O
as	O
a	O
limiting	B-C0439801
factor	B-C1521761
in	O
ang	B-C0003006
i	I-C0003006
formation	B-C1522492
in	O
this	O
carbon	B-C0007018
monoxide	I-C0007018
improves	B-C0184511
efficacy	B-C1280519
of	O
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
during	B-C0347984
sepsis	B-C0243026
by	O
production	O
of	O
specialized	B-C1704211
proresolving	B-C0243095
lipid	B-C0599745
mediators	I-C0599745
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
are	O
being	O
investigated	B-C1292732
as	O
a	O
cell-based	B-C3658313
therapy	I-C3658313
for	O
a	O
number	O
of	O
disease	B-C0030660
processes	I-C0030660
,	O
with	O
promising	O
results	B-C2825142
in	O
animal	B-C0599779
models	I-C0599779
of	O
systemic	B-C3646020
inflammation	I-C3646020
and	O
sepsis	B-C0243026
.	O
	
studies	B-C2603343
are	O
ongoing	O
to	O
determine	O
ways	O
to	O
further	O
improve	B-C0184511
the	O
therapeutic	B-C0302350
potential	B-C3245505
of	O
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
.	O
	
a	O
gas	B-C0017110
molecule	B-C0567416
that	O
improves	B-C0184511
outcome	B-C1274040
in	O
experimental	B-C1517586
sepsis	B-C0243026
is	O
carbon	B-C0007018
monoxide	I-C0007018
.	O
	
we	O
hypothesized	O
that	O
preconditioning	B-C0205245
of	O
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
with	O
carbon	B-C0007018
monoxide	I-C0007018
ex	B-C2348480
vivo	I-C2348480
would	O
promote	B-C0033414
further	O
therapeutic	B-C0302350
benefit	B-C0814225
when	O
cells	B-C0007634
are	O
administered	B-C1521801
in	B-C1515655
vivo	I-C1515655
after	O
the	O
onset	B-C0332162
of	I-C0332162
polymicrobial	B-C0275524
sepsis	B-C0243026
in	O
mice	B-C0025929
.	O
	
animal	B-C0683949
study	I-C0683949
and	O
primary	B-C1449562
cell	I-C1449562
culture	I-C1449562
.	O
	
laboratory	B-C0022877
investigation	B-C0220825
.	O
	
balb/c	B-C0025919
mice	I-C0025919
.	O
	
polymicrobial	B-C0275524
sepsis	B-C0243026
was	O
induced	B-C0205263
by	O
cecal	B-C0007531
ligation	B-C0023690
and	O
puncture	B-C0034117
.	O
	
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
,	O
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
-	O
conditioned	B-C0205556
with	O
carbon	B-C0007018
monoxide	I-C0007018
,	O
fibroblasts	B-C0016030
,	O
or	O
fibroblasts	B-C0016030
-	O
conditioned	B-C0205556
with	O
carbon	B-C0007018
monoxide	I-C0007018
were	O
delivered	B-C1705822
by	O
tail	B-C2985205
vein	I-C2985205
injections	B-C1533685
to	O
septic	B-C0333534
mice	B-C0025929
.	O
	
the	O
mice	B-C0025929
were	O
assessed	B-C1516048
for	O
survival	B-C0038952
,	O
bacterial	B-C0521009
clearance	B-C0449297
,	O
and	O
the	O
inflammatory	B-C1155266
response	I-C1155266
during	B-C0347984
sepsis	B-C0243026
in	O
each	O
of	O
the	O
groups	B-C0441833
.	O
	
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
were	O
also	O
assessed	B-C1516048
for	O
their	O
ability	B-C0085732
to	O
promote	B-C0033414
bacterial	B-C0521009
phagocytosis	B-C0031308
by	O
neutrophils	B-C0027950
,	O
the	O
production	O
of	O
specialized	B-C1704211
proresolving	B-C0243095
lipid	B-C0599745
mediators	I-C0599745
,	O
and	O
their	O
importance	O
for	O
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
function	B-C0031843
using	O
gene	B-C0598496
silencing	I-C0598496
.	O
	
ex	B-C2348480
vivo	I-C2348480
preconditioning	B-C0205245
with	O
carbon	B-C0007018
monoxide	I-C0007018
allowed	O
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
to	O
be	O
administered	B-C1521801
later	O
after	O
the	O
onset	B-C0332162
of	I-C0332162
sepsis	B-C0243026
6	O
hr	O
,	O
and	O
yet	O
maintain	O
their	O
therapeutic	B-C1527144
effect	I-C1527144
with	O
increased	B-C0205217
survival	B-C0038952
.	O
	
carbon	B-C0007018
monoxide	I-C0007018
preconditioned	B-C0205217
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
were	O
also	O
able	O
to	O
alleviate	O
organ	B-C0332675
injury	I-C0332675
,	O
improve	B-C0184511
bacterial	B-C0521009
clearance	B-C0449297
,	O
and	O
promote	B-C0033414
the	O
resolution	B-C1514893
of	O
inflammation	B-C0021368
.	O
	
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
exposed	B-C0332157
to	I-C0332157
carbon	B-C0007018
monoxide	I-C0007018
,	O
with	O
docosahexaenoic	B-C0556150
acid	I-C0556150
substrate	B-C3891814
,	O
produced	O
specialized	B-C1704211
proresolving	B-C0243095
lipid	B-C0599745
mediators	I-C0599745
,	O
particularly	O
d-series	B-C0205556
resolvins	B-C4288292
,	O
which	O
promoted	B-C0033414
survival	B-C0038952
.	O
	
silencing	B-C0598496
of	O
lipoxygenase	B-C1157322
pathways	I-C1157322
5-lipoxygenase	B-C1151570
and	O
12	B-C1151569
/	O
15-lipoxygenase	B-C1324412
,	O
which	O
are	O
important	B-C3898777
enzymes	B-C0014442
for	O
specialized	B-C1704211
proresolving	B-C0243095
lipid	B-C0599745
mediator	I-C0599745
biosynthesis	B-C0005572
,	O
resulted	B-C1274040
in	O
a	O
loss	O
of	O
therapeutic	B-C0302350
benefit	B-C0814225
bestowed	O
on	O
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
by	O
carbon	B-C0007018
monoxide	I-C0007018
.	O
	
taken	O
together	O
,	O
these	O
data	B-C1511726
suggest	O
that	O
production	O
of	O
specialized	B-C1704211
proresolving	B-C0243095
lipid	B-C0599745
mediators	I-C0599745
contribute	B-C1880177
to	O
improved	B-C0184511
mesenchymal	B-C3178844
stromal	I-C3178844
cell	I-C3178844
efficacy	B-C1280519
when	O
exposed	B-C0332157
to	I-C0332157
carbon	B-C0007018
monoxide	I-C0007018
,	O
resulting	O
in	O
an	O
improved	B-C0184511
therapeutic	B-C0521982
response	I-C0521982
during	B-C0347984
sepsis	B-C0243026
.	O
	
effect	B-C1280500
of	O
primary	B-C0033137
health	I-C0033137
care	I-C0033137
reforms	B-C2986411
in	O
turkey	B-C0041400
on	O
health	B-C0030672
service	I-C0030672
utilization	I-C0030672
and	O
user	B-C3650764
satisfaction	I-C3650764
strengthening	B-C1704419
primary	B-C0033137
health	I-C0033137
care	I-C0033137
phc	B-C0033137
is	O
considered	O
a	O
priority	O
for	O
efficient	B-C0442799
and	O
responsive	B-C0205342
health	B-C0018696
systems	I-C0018696
,	O
but	O
empirical	B-C1880496
evidence	B-C3887511
from	O
low-	O
and	O
middle-	O
income	B-C0021162
countries	B-C0454664
is	O
limited	B-C0439801
.	O
	
the	O
stepwise	B-C1293116
introduction	I-C1293116
of	O
family	B-C0015607
medicine	I-C0015607
across	O
all	O
81	O
provinces	B-C1514578
of	O
turkey	B-C0041400
a	O
middle-income	B-C0870890
country	B-C0454664
between	O
2005	O
and	O
2010	O
,	O
aimed	O
at	O
phc	B-C0033137
strengthening	B-C1704419
,	O
presents	O
a	O
natural	B-C0681814
experiment	I-C0681814
for	O
assessing	B-C1516048
the	O
effect	B-C1280500
of	O
family	B-C0015607
medicine	I-C0015607
on	O
health	B-C0030672
service	I-C0030672
utilization	I-C0030672
and	O
user	B-C3650764
satisfaction	I-C3650764
the	O
effect	B-C1280500
of	O
health	B-C0018696
system	I-C0018696
reforms	B-C2986411
,	O
that	O
introduced	O
family	B-C0015607
medicine	I-C0015607
,	O
on	O
utilization	B-C0042153
was	O
assessed	B-C1516048
using	O
longitudinal	B-C0023981
,	O
province-level	B-C0035168
data	I-C0035168
for	O
12	O
years	B-C0439234
and	O
multivariate	B-C0026336
regression	I-C0026336
models	I-C0026336
adjusting	O
for	O
supply-side	B-C0439828
variables	I-C0439828
,	O
demographics	B-C0681669
,	O
socio-economic	B-C0086996
development	I-C0086996
and	O
underlying	O
yearly	B-C0439234
trends	B-C0040833
.	O
	
user	B-C3650764
satisfaction	I-C3650764
with	O
primary	B-C0033137
and	O
secondary	B-C3494402
care	I-C3494402
services	B-C0018747
was	O
explored	O
using	O
data	B-C1511726
from	O
annual	B-C0038951
life	I-C0038951
satisfaction	I-C0038951
surveys	I-C0038951
.	O
	
trends	B-C0040833
in	O
preferred	O
first	O
point	O
of	O
contact	B-C0332158
primary	B-C0033137
vs	O
secondary	B-C3494402
,	O
public	B-C0020022
vs	O
.	O
	
private	B-C0033173
,	O
reason	B-C0008300
for	I-C0008300
choice	I-C0008300
and	O
health	B-C0018747
services	I-C0018747
issues	B-C0744349
,	O
were	O
described	B-C1552738
and	O
stratified	B-C0205363
by	O
patient	B-C0815172
characteristics	I-C0815172
,	O
provider	B-C2706153
type	I-C2706153
,	O
and	O
rural/urban	B-C0017446
settings	I-C0017446
between	O
2002	O
and	O
2013	O
,	O
the	O
average	B-C0449788
number	I-C0449788
of	O
phc	B-C0033137
consultations	B-C0009818
increased	B-C0205217
from	O
1.75	O
to	O
2.83	O
per	O
person	B-C0027361
per	O
year	B-C0439234
.	O
	
in	O
multivariate	B-C0026336
models	I-C0026336
,	O
family	B-C0015607
medicine	I-C0015607
introduction	B-C1293116
was	O
associated	B-C0332281
with	I-C0332281
an	O
increase	B-C0442805
of	O
0.37	O
phc	B-C0033137
consultations	B-C0009818
per	O
person	B-C0027361
p	O
<	O
0.001	O
,	O
and	O
slower	B-C0439834
annual	B-C2911660
growth	I-C2911660
in	O
phc	B-C0033137
and	O
secondary	B-C3494402
care	I-C3494402
consultations	B-C0009818
.	O
	
following	O
family	B-C0015607
medicine	I-C0015607
introduction	B-C1293116
,	O
the	O
growth	B-C2911660
of	O
phc	B-C0033137
and	O
secondary	B-C3494402
care	I-C3494402
consultations	B-C0009818
per	O
person	B-C0027361
was	O
0.08	O
and	O
0.30	O
,	O
respectively	O
,	O
a	O
year	B-C0439234
.	O
	
phc	B-C0033137
increased	B-C0205217
as	O
preferred	O
provider	B-C2706153
by	O
9.5	O
over	O
7	O
years	B-C0439234
with	O
the	O
reasons	O
of	O
proximity	B-C1514583
and	O
service	B-C3650764
satisfaction	I-C3650764
,	O
which	O
increased	B-C0205217
by	O
14.9	O
and	O
11.8	O
,	O
respectively	O
.	O
	
reporting	B-C0700287
of	O
poor	B-C0745076
facility	I-C0745076
hygiene	I-C0745076
,	O
difficulty	B-C1822076
getting	I-C1822076
an	I-C1822076
appointment	I-C1822076
,	O
poor	B-C2700379
physician	B-C0031831
behaviour	B-C0004927
and	O
high	B-C0205250
costs	B-C0085552
of	I-C0085552
health	I-C0085552
care	I-C0085552
all	O
declined	B-C1511741
p	O
<	O
0.001	O
in	O
phc	B-C0033137
settings	B-C0017446
,	O
but	O
remained	O
higher	B-C0205250
among	O
urban	B-C2700386
,	O
low-income	B-C1331016
and	O
working-age	B-C0001779
populations	B-C1257890
.	O
	
laparoscopic	B-C0031150
radical	B-C0193854
lymph	I-C0193854
node	I-C0193854
dissection	I-C0193854
for	O
advanced	B-C4016406
colon	I-C4016406
cancer	I-C4016406
close	O
to	O
the	O
hepatic	B-C0227385
flexure	I-C0227385
complete	B-C0728940
mesocolic	I-C0728940
excision	I-C0728940
is	O
currently	O
recognized	O
as	O
a	O
standard	B-C0184661
procedure	I-C0184661
for	O
colon	B-C0699790
cancer	I-C0699790
.	O
	
gastroepiploic	B-C0447070
,	O
infrapyloric	B-C0229779
,	O
and	O
superficial	B-C0229783
pancreatic	I-C0229783
head	I-C0229783
lymph	I-C0229783
node	I-C0229783
metastases	B-C0024232
in	O
the	O
gastrocolic	B-C0230229
ligament	I-C0230229
have	O
been	O
reported	O
for	O
colon	B-C0699790
cancer	I-C0699790
close	O
to	O
the	O
hepatic	B-C0227385
flexure	I-C0227385
.	O
	
we	O
sought	O
to	O
investigate	O
metastases	B-C0024232
in	O
the	O
gastrocolic	B-C0230229
ligament	I-C0230229
in	O
colon	B-C0699790
cancer	I-C0699790
close	O
to	O
the	O
hepatic	B-C0227385
flexure	I-C0227385
.	O
	
this	O
was	O
a	O
single-center	B-C0035363
retrospective	I-C0035363
study	I-C0035363
.	O
	
all	O
patients	B-C0030705
with	O
t2	B-C0475373
or	O
deeper	O
invasive	B-C0205281
colon	B-C0699790
cancer	I-C0699790
in	O
the	O
relevant	O
tumor	B-C3897292
location	I-C3897292
who	O
underwent	O
laparoscopic	B-C0585464
right	I-C0585464
hemicolectomy	I-C0585464
or	O
extended	B-C0400043
right	I-C0400043
hemicolectomy	I-C0400043
at	O
our	O
institution	B-C0018704
between	O
1	O
april	B-C3715024
2011	O
and	O
31	O
march	B-C3829202
2015	O
were	O
included	O
.	O
	
lymph	B-C0242382
node	I-C0242382
dissection	I-C0242382
in	O
the	O
gastrocolic	B-C0230229
ligament	I-C0230229
was	O
performed	O
in	O
35	O
cases	O
.	O
	
complications	B-C0009566
occurred	O
in	O
11	O
patients	B-C0030705
31%	O
and	O
were	O
grades	O
i	O
and	O
ii	O
according	O
to	O
the	O
clavien-dindo	B-C4055231
classification	I-C4055231
.	O
	
lymph	B-C0024232
node	I-C0024232
metastases	I-C0024232
in	O
the	O
gastrocolic	B-C0230229
ligament	I-C0230229
were	O
found	O
in	O
only	O
three	O
patients	B-C0030705
9%	O
.	O
	
each	O
metastasis	B-C0024232
was	O
larger	O
than	O
9	O
mm	B-C0439200
.	O
	
metastases	B-C0024232
in	O
the	O
gastrocolic	B-C0230229
ligament	I-C0230229
occurred	O
in	O
9%	O
of	O
patients	B-C0030705
with	O
t2	B-C0475373
or	O
deeper	O
invasive	B-C0205281
colon	B-C0699790
cancer	I-C0699790
close	O
to	O
the	O
hepatic	B-C0227385
flexure	I-C0227385
.	O
	
laparoscopy	B-C1883297
was	O
feasible	O
and	O
useful	O
during	O
gastrocolic	B-C0728940
ligament	I-C0728940
resection	I-C0728940
.	O
	
this	O
study	B-C2603343
included	O
a	O
small	O
sample	B-C0370003
and	O
lacked	O
an	O
extended	B-C0231449
follow-up	B-C1522577
.	O
	
further	O
studies	B-C2603343
are	O
needed	O
to	O
determine	O
the	O
clinical	B-C2347946
relevance	I-C2347946
of	O
this	O
finding	B-C0243095
,	O
particularly	O
in	O
terms	O
of	O
recurrence	B-C0034897
and	O
long-term	B-C0443252
survival	B-C0038952
.	O
	
smartphone	B-C3204335
-based	O
psychotherapeutic	B-C0033968
micro-interventions	B-C0184661
to	O
improve	O
mood	B-C0026516
in	O
a	O
real-world	B-C1254367
setting	I-C1254367
using	O
mobile	B-C1136360
communication	B-C0681426
technology	I-C0681426
as	O
new	O
personalized	O
approach	B-C0449445
to	O
treat	B-C0087111
mental	B-C0004936
disorders	I-C0004936
or	O
to	O
more	O
generally	O
improve	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
is	O
highly	O
promising	O
.	O
	
knowledge	B-C0376554
about	O
intervention	B-C0184661
components	B-C0449432
that	O
target	O
key	O
psychopathological	B-C0033927
processes	B-C1522240
in	O
terms	O
of	O
transdiagnostic	O
psychotherapy	B-C0033968
approaches	B-C0449445
is	O
urgently	O
needed	O
.	O
	
we	O
explored	O
the	O
use	O
of	O
smartphone	B-C3204335
-based	O
micro-interventions	B-C0184661
based	O
on	O
psychotherapeutic	B-C0237915
techniques	I-C0237915
,	O
guided	O
by	O
short	O
video-clips	B-C3463807
,	O
to	O
elicit	O
mood	B-C0085633
changes	I-C0085633
.	O
	
as	O
part	O
of	O
a	O
larger	O
neurofeedback	B-C2713543
study	B-C2603343
,	O
all	O
subjects	B-C0080105
-after	O
being	O
randomly	O
assigned	O
to	O
an	O
experimental	O
or	O
control	O
neurofeedback	B-C2713543
condition	B-C0348080
-underwent	O
daily	B-C0332173
smartphone	B-C3204335
-based	O
micro-interventions	B-C0184661
for	O
13	O
consecutive	O
days	B-C0439228
.	O
	
they	O
were	O
free	O
to	O
choose	O
out	O
of	O
provided	O
techniques	B-C0449851
,	O
including	O
viscerosensory	B-C0445254
attention	B-C0004268
,	O
emotional	B-C0849912
imagery	B-C0175631
,	O
facial	B-C0015457
expression	I-C0015457
,	O
and	O
contemplative	B-C1277196
repetition	B-C0205341
.	O
	
changes	B-C0392747
in	O
mood	B-C0026516
were	O
assessed	O
in	O
real	O
world	O
using	O
the	O
multidimensional	B-C0451394
mood	I-C0451394
state	I-C0451394
questionnaire	I-C0451394
scales	O
good	B-C0205170
-	O
bad	B-C0205169
,	O
gb	O
awake	B-C0234422
-	O
tired	B-C0557875
,	O
at	O
and	O
calm	B-C0522165
-	O
nervous	B-C0027769
,	O
cn	O
.	O
	
twenty-seven	O
men	B-C0025266
participated	O
on	O
at	O
least	O
11	O
days	B-C0439228
and	O
were	O
thus	O
included	O
in	O
the	O
analyses	B-C0936012
.	O
	
altogether	O
,	O
they	O
underwent	O
335	O
,	O
generally	O
well-tolerated	O
,	O
micro-intervention	B-C0679644
sessions	I-C0679644
,	O
with	O
viscerosensory	B-C0445254
attention	B-C0004268
178	O
sessions	B-C0679644
,	O
53.13	O
and	O
contemplative	B-C1277196
repetition	B-C0205341
68	O
sessions	B-C0679644
,	O
20.30	O
being	O
the	O
most	O
frequently	O
applied	O
techniques	B-C0449851
.	O
	
mixed	O
models	B-C3161035
indicated	O
that	O
subjects	B-C0080105
showed	O
better	O
mood	B-C0026516
gb	O
b	O
=	O
0.464	O
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
0.068	O
,	O
0.860	O
,	O
t	O
613.3	O
=	O
2.298	O
,	O
p	O
=	O
0.022	O
and	O
became	O
more	O
awake	B-C0234422
at	O
b	O
=	O
0.514	O
,	O
95%	O
ci	B-C0009667
0.103	O
,	O
0.925	O
,	O
t	O
612.4	O
=	O
2.456	O
,	O
p	O
=	O
0.014	O
and	O
calmer	B-C0522165
cn	O
b	O
=	O
0.685	O
,	O
95%	O
ci	B-C0009667
0.360	O
,	O
1.010	O
,	O
t	O
612.3	O
=	O
4.137	O
,	O
p	O
<	O
0.001	O
from	O
pre	B-C1254367
-	O
to	O
post-micro-intervention	B-C1254367
.	O
	
these	O
mood	B-C0026516
improvements	B-C2986411
from	O
pre	B-C1254367
-	O
to	O
post-micro-intervention	B-C1254367
were	O
associated	O
with	O
changes	B-C0085633
in	I-C0085633
mood	I-C0085633
from	O
the	O
1st	O
day	B-C0439228
until	O
the	O
last	O
day	B-C0439228
with	O
regard	O
to	O
gb	B-C0026516
mood	I-C0026516
r	O
=	O
0.614	O
,	O
95%	O
ci	B-C0009667
0.297	O
,	O
0.809	O
,	O
p	O
<	O
0.001	O
,	O
but	O
not	O
at	B-C0026516
mood	I-C0026516
r	O
=	O
0.279	O
,	O
95%	O
ci	B-C0009667
-0	O
,	O
0.602	O
,	O
p	O
=	O
0.167	O
and	O
cn	B-C0026516
mood	I-C0026516
r	O
=	O
0.277	O
,	O
95%	O
ci	B-C0009667
0.124	O
,	O
0.601	O
,	O
p	O
=	O
0.170	O
.	O
	
our	O
findings	B-C0243095
provide	O
evidence	O
for	O
the	O
applicability	O
of	O
smartphone	B-C3204335
-based	O
micro-interventions	B-C0184661
eliciting	O
short-term	B-C0443303
mood	B-C0085633
changes	I-C0085633
,	O
based	O
on	O
techniques	B-C0449851
used	O
in	O
psychotherapeutic	B-C0033968
approaches	B-C0449445
,	O
such	O
as	O
mindfulness	B-C3542996
-based	O
psychotherapy	B-C0033968
,	O
transcendental	B-C0150814
meditation	I-C0150814
,	O
and	O
other	O
contemplative	B-C1277196
therapies	B-C0087111
.	O
	
the	O
results	O
encourage	O
exploring	O
these	O
techniques	B-C0449851
'	O
capability	B-C2698977
to	O
improve	O
mood	B-C0026516
in	O
randomized	O
controlled	B-C0681867
studies	I-C0681867
and	O
patients	B-C0030705
.	O
	
smartphone	B-C3204335
-based	O
micro-interventions	B-C0184661
are	O
promising	O
to	O
modify	O
mood	B-C0026516
in	O
real-world	B-C1254367
settings	I-C1254367
,	O
complementing	O
other	O
psychotherapeutic	B-C0582386
interventions	I-C0582386
,	O
in	O
line	O
with	O
the	O
precision	B-C1547902
medicine	B-C0679624
approach	I-C0679624
.	O
	
the	O
here	O
presented	O
data	B-C1511726
were	O
collected	O
within	O
a	O
randomized	B-C0206034
trial	I-C0206034
,	O
primary	B-C0205225
pituitary	B-C0032005
diffuse	B-C0079744
large	I-C0079744
b-cell	I-C0079744
lymphoma	I-C0079744
with	O
somatotroph	B-C0342369
hyperplasia	I-C0342369
and	O
acromegaly	B-C0001206
case	B-C0085973
report	I-C0085973
diffuse	B-C0079744
large	I-C0079744
b-cell	I-C0079744
lymphoma	I-C0079744
dlbcl	B-C0079744
is	O
the	O
most	O
common	B-C0205214
type	B-C0332307
of	O
non-hodgkin	B-C0024305
lymphoma	I-C0024305
and	O
comprises	O
approximately	O
30%	O
of	O
all	O
lymphomas	B-C0024299
.	O
	
patients	B-C0030705
typically	O
present	B-C0150312
with	O
a	O
nonpainful	B-C0234226
mass	B-C0577559
in	O
the	O
neck	B-C0027530
,	O
groin	B-C0018246
,	O
or	O
abdomen	B-C0000726
associated	B-C0332281
with	I-C0332281
constitutional	B-C0009812
symptoms	I-C0009812
.	O
	
in	O
this	O
report	B-C0684224
,	O
however	O
,	O
the	O
authors	B-C3812881
describe	O
a	O
rare	B-C0522498
case	B-C0868928
of	O
a	O
61-	O
year	B-C1510829
-old	O
woman	B-C0043210
with	O
hyperprolactinemia	B-C0020514
,	O
hypothyroidism	B-C0020676
,	O
and	O
acromegaly	B-C0001206
elevation	B-C0205250
of	O
insulin-like	B-C0021665
growth	I-C0021665
factor-1	I-C0021665
igf-1	B-C0021665
with	O
elevated	B-C0205250
growth	B-C0037668
hormone-releasing	I-C0037668
hormone	I-C0037668
ghrh	B-C0037668
in	O
whom	O
an	O
mri	B-C0024485
demonstrated	B-C0443289
diffuse	B-C0877018
enlargement	I-C0877018
of	I-C0877018
the	I-C0877018
pituitary	I-C0877018
gland	I-C0877018
.	O
	
despite	O
medical	B-C0418981
treatment	I-C0418981
,	O
the	O
patient	B-C0030705
had	O
persistent	B-C0205322
elevation	B-C0205250
of	O
igf-1	B-C0021665
.	O
	
she	O
underwent	O
a	O
transsphenoidal	B-C0176118
biopsy	I-C0176118
,	O
which	O
yielded	B-C1999230
a	O
diagnosis	B-C0011900
of	O
dlbcl	B-C0079744
with	O
an	O
activated	B-C1879547
b-cell	B-C0004561
immunophenotype	B-C0079611
with	O
somatotroph	B-C0342369
hyperplasia	I-C0342369
.	O
	
after	O
stereo-tactic	B-C3896609
radiation	I-C3896609
therapy	I-C3896609
in	O
combination	B-C0205195
with	O
chemotherapy	B-C3665472
,	O
she	O
is	O
currently	B-C0521116
in	O
remission	B-C0687702
from	O
her	O
lymphoma	B-C0024299
and	O
has	O
normalized	B-C1882115
igf-1	B-C0021665
levels	B-C0441889
without	O
medical	B-C0418981
therapy	I-C0418981
,	O
8	O
months	B-C0439231
after	O
her	O
histopathological	B-C0243140
diagnosis	B-C0011900
.	O
	
this	O
is	O
the	O
only	O
reported	B-C0684224
case	B-C0868928
of	O
its	O
kind	O
and	O
displays	O
the	O
importance	O
of	O
a	O
broad	O
differential	B-C0011906
diagnosis	I-C0011906
,	O
multidisciplinary	B-C0729737
evaluation	I-C0729737
,	O
and	O
critical	B-C1511545
intraoperative	B-C0456904
decision-making	B-C0011109
when	O
treating	B-C1522326
atypical	O
sellar	B-C0036609
lesions	B-C0221198
.	O
	
doctor	B-C0031831
competence	B-C0086035
and	O
the	O
demand	B-C0441516
for	O
healthcare	B-C0086388
evidence	B-C3887511
from	O
rural	B-C0008115
china	I-C0008115
the	O
agency	B-C0237463
problem	B-C0033213
between	O
patients	B-C0030705
and	O
doctors	B-C0031831
has	O
long	O
been	O
emphasised	O
in	O
the	O
health	B-C0023866
economics	I-C0023866
literature	I-C0023866
,	O
but	O
the	O
empirical	B-C1880496
evidence	B-C3887511
on	O
whether	O
patients	B-C0030705
can	O
evaluate	B-C1516048
and	O
respond	O
to	O
better	B-C0332272
quality	B-C0034379
care	I-C0034379
remains	O
mixed	B-C0205430
and	O
inconclusive	B-C1629507
.	O
	
using	O
household	B-C0020052
data	B-C1511726
linked	O
to	O
an	O
assessment	B-C1516048
of	O
village	B-C0562518
doctors'	B-C0031831
clinical	B-C0008956
competence	I-C0008956
in	O
rural	B-C0008115
china	I-C0008115
,	O
we	O
show	O
that	O
there	O
is	O
no	B-C0205556
correlation	I-C0205556
between	O
doctor	B-C0031831
competence	B-C0086035
and	O
patients'	B-C0030705
healthcare	B-C0086388
utilisation	B-C0042153
,	O
with	O
confidence	B-C0009667
intervals	I-C0009667
reasonably	O
tight	O
around	O
zero	O
.	O
	
household	B-C0020052
perceptions	B-C0030971
of	O
quality	B-C0332306
are	O
an	O
important	B-C3898777
determinant	B-C1521761
of	O
care-seeking	B-C0018695
behaviour	I-C0018695
,	O
yet	O
patients	B-C0030705
appear	B-C0700364
unable	B-C1299582
to	O
recognise	B-C0205396
more	O
competent	B-C0086035
doctors	B-C0031831
-	O
there	O
is	O
no	O
relationship	B-C0439849
between	O
doctor	B-C0031831
competence	B-C0086035
and	O
perceptions	B-C0030971
of	O
quality	B-C0332306
.	O
	
unintentional	B-C1283932
insecticide	B-C0413048
poisoning	I-C0413048
by	O
age	B-C0001779
an	O
analysis	B-C0936012
of	O
queensland	O
poisons	O
information	O
centre	O
calls	B-C0302186
data	B-C1511726
from	O
the	O
queensland	O
poisons	O
information	O
centre	O
qpic	O
was	O
assessed	B-C1516048
to	O
determine	B-C0205258
mechanisms	B-C0441712
of	O
acute	O
insecticide	B-C0413048
poisoning	I-C0413048
in	O
young	B-C0728836
children	I-C0728836
<5	B-C0439234
years	I-C0439234
and	O
whether	O
age	B-C0001779
affects	B-C0001721
insecticide-poisoning	B-C0413048
patterns	B-C0449774
.	O
	
records	B-C0034869
of	O
all	O
insecticide-related	B-C0302186
calls	I-C0302186
placed	O
to	O
qpic	O
in	O
2014	O
were	O
obtained	B-C1301820
.	O
	
a	O
stratified	B-C0205363
analysis	B-C0936012
of	O
call	B-C0302186
patterns	B-C0449774
by	O
age	B-C0001779
was	O
conducted	B-C0205245
.	O
	
of	O
743	O
insecticide-related	B-C0302186
calls	I-C0302186
received	B-C1709850
by	I-C1709850
qpic	O
364	O
49.0	O
were	O
for	O
young	B-C0728836
children	I-C0728836
.	O
	
the	O
number	O
of	O
calls	B-C0302186
peaked	B-C0444505
in	O
children	B-C0008059
aged	B-C4082117
one	I-C4082117
.	O
	
ant	B-C0003455
and	O
cockroach	B-C0009208
baits	B-C1254354
accounted	B-C0392762
for	O
39.0	O
of	O
calls	B-C0302186
.	O
	
sprays	B-C1154182
,	O
which	O
were	O
found	B-C0150312
to	O
contain	O
not	O
only	O
pyrethroids	B-C0597329
,	O
pyrethrins	B-C0034245
and/or	O
piperonly	B-C0031962
butoxide	I-C0031962
but	O
also	O
the	O
organophosphate	B-C0012013
diazinon	I-C0012013
,	O
accounted	B-C0392762
for	O
25.8	O
of	O
calls	B-C0302186
.	O
	
mouthing	B-C2584309
or	O
ingesting	B-C0232478
a	O
pest-control	B-C0031253
product	I-C0031253
and	O
consuming	B-C0441655
an	O
item/insect	O
after	O
treatment	B-C0039798
were	O
common	O
mechanisms	B-C0441712
for	O
children	B-C0008059
under	O
the	O
age	B-C0439234
of	I-C0439234
two	I-C0439234
.	O
	
topical	B-C0332237
exposure	B-C0332157
to	I-C0332157
sprays	B-C1154182
,	O
via	O
direct	B-C1947931
application	B-C1524063
,	O
typically	O
by	O
the	O
child	B-C0008059
or	O
an	O
older	B-C0337511
sibling	I-C0337511
,	O
peaked	B-C0444505
in	O
children	B-C0008059
aged	B-C0439234
two	I-C0439234
.	O
	
in	O
12.3	O
of	O
calls	B-C0302186
medical	B-C0948564
attention	I-C0948564
for	O
the	O
child	B-C0008059
was	O
already	O
sought	B-C0743213
or	O
advised	B-C0418832
by	I-C0418832
qpic	O
.	O
	
normal	B-C0004927
behaviours	I-C0004927
associated	B-C0332281
with	I-C0332281
child	B-C0008071
development	I-C0008071
,	O
particularly	O
mouthing	B-C2584309
behaviours	B-C0004927
,	O
explained	O
the	O
peak	B-C0332157
of	I-C0332157
exposure	I-C0332157
in	O
one-year	B-C4082117
-	O
olds	B-C0008059
.	O
	
this	O
finding	B-C0243095
should	O
guide	O
strategies	B-C0679199
to	O
minimise	B-C1524031
poisonings	B-C0032343
in	O
this	O
vulnerable	B-C0949366
population	I-C0949366
.	O
	
investigating	O
synthetic	B-C0597550
oligonucleotide	B-C0028953
targeting	O
of	O
mir31	B-C2607480
in	O
duchenne	B-C0013264
muscular	I-C0013264
dystrophy	I-C0013264
exon-skipping	B-C0035687
via	O
synthetic	B-C0597550
antisense	B-C0079925
oligonucleotides	I-C0079925
represents	O
one	O
of	O
the	O
most	O
promising	O
potential	O
therapies	B-C0087111
for	O
duchenne	B-C0013264
muscular	I-C0013264
dystrophy	I-C0013264
dmd	B-C0013264
,	O
yet	O
this	O
approach	O
is	O
highly	O
sequence-specific	B-C1624609
and	O
thus	O
each	O
oligonucleotide	B-C0028953
is	O
of	O
benefit	O
to	O
only	O
a	O
subset	O
of	O
patients	B-C0030705
.	O
	
the	O
discovery	B-C1880355
that	O
dystrophin	B-C0079259
mrna	B-C0035696
is	O
subject	O
to	O
translational	B-C1519619
suppression	I-C1519619
by	O
the	O
microrna	B-C1101610
mir31	B-C2607480
,	O
and	O
that	O
mir31	B-C2607480
is	O
elevated	O
in	O
the	O
muscle	B-C0026845
of	O
dmd	B-C0013264
patients	B-C0030705
,	O
raises	O
the	O
possibility	O
that	O
the	O
same	O
oligonucleotide	B-C0028953
chemistries	O
employed	O
for	O
exon	B-C0035687
skipping	I-C0035687
could	O
be	O
directed	O
toward	O
relieving	O
this	O
translational	B-C1519619
block	I-C1519619
.	O
	
this	O
approach	O
would	O
act	O
synergistically	B-C2986495
with	O
exon	B-C0035687
skipping	I-C0035687
where	O
possible	O
,	O
but	O
by	O
targeting	O
the	O
3'utr	B-C0600600
it	O
would	O
further	O
be	O
of	O
benefit	O
to	O
the	O
many	O
dmd	B-C0013264
patients	B-C0030705
who	O
express	O
low	O
levels	O
of	O
in-frame	B-C0080089
transcript	B-C1519595
.	O
	
we	O
here	O
present	O
investigations	B-C1261322
into	O
the	O
feasibility	O
of	O
combining	O
exon	B-C0035687
skipping	I-C0035687
with	O
several	O
different	O
strategies	O
for	O
mir31	B-C2607480
-	O
modulation	B-C0678672
,	O
using	O
both	O
in	B-C3850137
vitro	I-C3850137
models	B-C0026339
and	O
the	O
mdx	B-C0206535
mouse	I-C0206535
the	O
classical	O
animal	B-C0599779
model	I-C0599779
of	O
dmd	B-C0013264
,	O
and	O
monitoring	B-C1283169
effects	B-C1280500
on	O
dystrophin	B-C0079259
at	O
the	O
transcriptional	B-C0040649
and	O
translational	B-C1519614
level	O
.	O
	
we	O
show	O
that	O
despite	O
promising	O
results	O
from	O
our	O
cell	B-C0007585
culture	I-C0007585
model	B-C0026339
,	O
our	O
in	B-C1515655
vivo	I-C1515655
data	B-C1511726
failed	O
to	O
demonstrate	O
similarly	O
reproducible	O
enhancement	B-C2349975
of	O
dystrophin	B-C0079259
translation	B-C1519614
,	O
suggesting	O
that	O
mir31	B-C2607480
-	O
modulation	B-C0678672
may	O
not	O
be	O
practical	O
under	O
current	O
oligonucleotide	B-C0028953
approaches	O
.	O
	
possible	O
explanations	O
for	O
this	O
disappointing	O
outcome	B-C0085415
are	O
discussed	O
,	O
along	O
with	O
suggestions	O
for	O
future	O
undisclosed	B-C0439673
hiv	B-C0019693
infection	I-C0019693
and	O
art	B-C1963724
use	B-C0457083
in	O
the	O
kenya	B-C0038951
aids	I-C0038951
indicator	I-C0038951
survey	I-C0038951
2012	I-C0038951
relevance	B-C2347946
to	O
targets	B-C1521840
for	O
hiv	B-C0920550
diagnosis	I-C0920550
and	O
treatment	B-C0087111
in	O
kenya	B-C0022558
to	O
assess	B-C0184514
the	O
impact	B-C4049986
of	O
undisclosed	B-C0439673
hiv	B-C0019693
infection	I-C0019693
and	O
antiretroviral	B-C1963724
arv	I-C1963724
therapy	I-C1963724
art	B-C1963724
on	O
national	B-C0681788
estimates	B-C0750572
of	O
diagnosed	B-C2186509
hiv	I-C2186509
and	O
art	B-C1963724
coverage	B-C1999244
in	O
kenya	B-C0022558
.	O
	
hiv-positive	B-C2186509
dried	B-C0178913
blood	I-C0178913
spot	I-C0178913
samples	I-C0178913
from	O
kenya's	B-C0038951
second	I-C0038951
aids	I-C0038951
indicator	I-C0038951
survey	I-C0038951
were	O
tested	B-C0039593
for	O
an	O
arv	B-C1979629
biomarker	B-C0005516
by	O
liquid	B-C4049918
chromatography-tandem	I-C4049918
mass	I-C4049918
spectrometry	I-C4049918
.	O
	
estimates	B-C0750572
of	O
diagnosed	B-C2186509
hiv	I-C2186509
and	O
art	B-C1963724
use	B-C0457083
based	O
on	O
self-report	B-C2700446
were	O
compared	B-C1707455
with	O
those	O
corrected	O
for	O
undisclosed	B-C0439673
hiv	B-C0019693
infection	I-C0019693
and	O
art	B-C1963724
use	B-C0457083
based	O
on	O
arv	B-C1979629
testing	O
.	O
	
multivariate	B-C0026777
analysis	I-C0026777
determined	B-C0521095
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
undisclosed	B-C0439673
hiv	B-C0019693
infection	I-C0019693
and	O
art	B-C1963724
use	B-C0457083
among	O
persons	B-C0027361
on	O
art	B-C1963724
.	O
	
among	O
559	O
hiv-positive	B-C2186509
samples	B-C0178913
,	O
the	O
arv	B-C1979629
biomarker	B-C0005516
was	O
detected	B-C0442726
in	O
42.5	O
ci	O
37.4	O
.	O
	
arv	B-C0599685
drugs	I-C0599685
were	O
present	O
in	O
90.7	O
ci	O
86.1	O
reporting	B-C2186509
hiv-positive	I-C2186509
status	O
and	O
receiving	B-C1514756
art	B-C1963724
,	O
66.7	O
ci	O
59.9	O
reporting	B-C2186509
hiv-positive	I-C2186509
status	O
irrespective	O
of	O
art	B-C1963724
use	B-C0457083
,	O
21.0	O
ci	O
13.4	O
reporting	B-C0700287
hiv-negative	B-C0854048
status	I-C0854048
,	O
and	O
19.3	O
ci	O
9.0	O
reporting	B-C0700287
no	B-C1513916
previous	B-C0205156
hiv	B-C1321876
test	I-C1321876
.	O
	
after	O
correcting	O
for	O
undisclosed	B-C0439673
hiv	B-C0019693
infection	I-C0019693
and	O
art	B-C1963724
use	B-C0457083
,	O
diagnosed	B-C2186509
hiv	I-C2186509
increased	B-C0205217
from	O
46.9	O
to	O
57.2	O
and	O
art	B-C1963724
coverage	B-C1999244
increased	B-C0205217
from	O
31.8	O
to	O
42.8	O
.	O
	
undisclosed	B-C0439673
hiv	B-C0019693
infection	I-C0019693
on	O
art	B-C1963724
was	O
associated	B-C0332281
with	I-C0332281
being	O
aged	B-C0001792
25-39	O
years	O
and	O
not	O
visiting	O
a	O
health	B-C0018724
provider	I-C0018724
in	O
the	O
past	O
year	O
,	O
while	O
younger	B-C4061789
age	I-C4061789
and	O
higher	B-C0699759
wealth	I-C0699759
was	O
associated	B-C0332281
with	I-C0332281
undisclosed	B-C0439673
art	B-C1963724
use	B-C0457083
.	O
	
substantial	B-C0750502
levels	B-C0441889
of	O
undisclosed	B-C0439673
hiv	B-C0019693
infection	I-C0019693
and	O
art	B-C1963724
use	B-C0457083
while	O
on	O
art	B-C1963724
were	O
observed	B-C1441672
,	O
resulting	B-C0332294
in	I-C0332294
diagnosed	B-C2186509
hiv	I-C2186509
underestimated	O
by	O
112	O
persons	B-C0027361
and	O
art	B-C1963724
coverage	B-C1999244
by	O
131	O
persons	B-C0027361
.	O
	
supplementing	O
self-reported	B-C2700446
art	B-C1963724
status	B-C0449438
with	O
objective	B-C0870410
measures	I-C0870410
of	O
art	B-C1963724
use	B-C0457083
in	O
national	B-C0681788
population	B-C1257890
-based	O
sero-surveys	B-C0019700
can	O
improve	B-C0184511
monitoring	B-C1283169
of	O
treatment	B-C0087111
targets	B-C1521840
in	O
differential	O
control	B-C0243148
and	O
function	B-C0542341
of	O
arabidopsis	B-C0162741
prodh1	B-C1418945
and	O
prodh2	B-C1424903
genes	I-C1424903
on	O
infection	B-C3714514
with	O
biotrophic	B-C0243095
and	O
necrotrophic	B-C0243095
pathogens	B-C0450254
arabidopsis	B-C0162741
contains	O
two	O
proline	B-C1418945
dehydrogenase	I-C1418945
prodh	I-C1418945
genes	I-C1418945
,	O
prodh1	B-C1418945
and	O
prodh2	B-C1424903
,	O
encoding	B-C2700640
for	O
homologous	B-C1512488
and	O
functional	B-C0205245
isoenzymes	B-C0022173
.	O
	
although	O
prodh1	B-C1418945
has	O
been	O
studied	O
extensively	O
,	O
especially	O
under	O
abiotic	B-C0449430
stress	I-C0449430
,	O
prodh2	B-C1424903
has	O
only	O
started	O
to	O
be	O
analysed	O
in	O
recent	O
years	B-C0439234
.	O
	
these	O
genes	B-C0017337
display	O
distinctive	O
expression	B-C0017262
patterns	B-C0449774
and	O
show	O
weak	B-C1762617
transcriptional	B-C1158770
co-regulation	I-C1158770
,	O
but	O
are	O
both	O
activated	B-C1879547
in	O
pathogen	B-C0450254
-	O
infected	B-C0439663
tissues	B-C0040300
.	O
	
we	O
have	O
demonstrated	O
previously	O
that	O
arabidopsis	B-C0162741
plants	I-C0162741
with	O
silenced	B-C0598496
prodh1	B-C1418945
/	O
2	B-C1424903
expression	B-C0017262
fail	B-C0231175
to	O
trigger	O
defences	B-C1154988
against	O
the	O
hemibiotrophic	B-C0243095
bacterial	B-C0004611
pathogen	B-C0450254
pseudomonas	B-C0317966
syringae	I-C0317966
pv	I-C0317966
.	O
	
tomato	I-C0317966
avrrpm1	I-C0317966
pst-avrrpm1	B-C0317966
,	O
and	O
that	O
prodh1	B-C1418945
and	O
prodh2	B-C1424903
are	O
differentially	O
regulated	B-C0851285
by	O
salicylic	B-C0036079
acid	I-C0036079
sa	B-C0036079
.	O
	
in	O
the	O
current	O
work	O
,	O
we	O
used	O
prodh1	B-C0162741
and	O
prodh2	B-C0162741
single-	O
mutant	B-C0596988
plants	B-C0032098
to	O
assess	O
the	O
particular	O
contribution	O
of	O
each	O
gene	B-C0017337
to	O
resistance	B-C4281815
against	O
pst-avrrpm1	B-C0317966
and	O
the	O
necrotrophic	B-C0243095
fungal	B-C3826297
pathogen	I-C3826297
botrytis	B-C0579190
cinerea	I-C0579190
.	O
	
in	O
addition	O
,	O
we	O
studied	O
the	O
sensitivity	B-C0332324
of	O
prodh1	B-C1418945
and	O
prodh2	B-C1424903
to	O
the	O
jasmonic	B-C0064138
acid	I-C0064138
ja	B-C0064138
defence	B-C1154988
pathway	B-C1704259
.	O
	
we	O
found	O
that	O
prodh1	B-C3657000
and	O
prodh2	B-C3657000
are	O
both	O
necessary	O
to	O
achieve	O
maximum	O
resistance	B-C4281815
against	O
pst-avrrpm1	B-C0317966
and	O
b	B-C0579190
.	O
	
cinerea	I-C0579190
.	O
	
however	O
,	O
prodh2	B-C3657000
has	O
a	O
major	O
effect	O
on	O
early	O
restriction	B-C0443288
of	O
b	B-C0579190
.	O
	
cinerea	I-C0579190
growth	B-C0018270
.	O
	
interestingly	O
,	O
prodh1	B-C1418945
is	O
up-regulated	B-C0041904
by	O
sa	B-C0036079
and	O
ja	B-C0064138
,	O
whereas	O
prodh2	B-C1424903
is	O
only	O
activated	B-C1879547
by	O
ja	B-C0064138
,	O
and	O
both	O
genes	B-C0017337
display	O
transcriptional	B-C1158770
inter-regulation	I-C1158770
at	O
basal	B-C0205112
and	O
infection	B-C3714514
conditions	B-C0348080
.	O
	
these	O
studies	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
contribution	O
of	O
prodh2	B-C1424903
to	O
disease	B-C1136180
resistance	I-C1136180
,	O
and	O
describe	O
the	O
differential	O
regulation	B-C0851285
and	O
non-redundant	O
but	O
complementary	B-C0542341
function	I-C0542341
of	O
both	O
enzyme	B-C0022173
isoforms	I-C0022173
in	O
infected	B-C0439663
tissues	B-C0040300
,	O
providing	O
support	O
for	O
a	O
fundamental	O
role	O
of	O
prodh	B-C1418945
in	O
the	O
control	O
of	O
biotrophic	B-C0243095
and	O
necrotrophic	B-C0243095
pathogens	B-C0450254
.	O
	
effect	B-C1280500
of	O
protein	B-C0033684
repetitiveness	B-C0205341
on	O
protein-protein	B-C0872079
interaction	I-C0872079
prediction	B-C0681842
results	B-C1274040
using	O
support	B-C2699740
vector	I-C2699740
machines	I-C2699740
there	O
are	O
many	O
computational	B-C1516769
approaches	I-C1516769
to	O
predict	O
the	O
protein-protein	B-C0872079
interactions	I-C0872079
using	O
support	B-C2699740
vector	I-C2699740
machines	I-C2699740
svms	B-C2699740
with	O
high	O
performance	O
.	O
	
in	O
fact	O
,	O
performance	O
of	O
currently	O
reported	O
methods	B-C0025663
are	O
significantly	O
over-estimated	O
and	O
affected	O
by	O
the	O
object	O
repetitiveness	B-C0205341
in	O
the	O
datasets	B-C0150098
used	O
.	O
	
to	O
study	B-C2603343
the	O
effect	O
of	O
object	O
repetitiveness	B-C0205341
of	O
datasets	B-C0150098
on	O
predicting	B-C0681842
results	B-C1274040
.	O
	
we	O
present	O
novel	O
methods	B-C0025663
to	O
construct	O
different	O
positive	B-C1446409
datasets	B-C0150098
with	O
or	O
without	O
repeating	O
proteins	B-C0033684
using	O
graph	B-C0681493
maximum	O
matching	O
in	O
the	O
protein-protein	B-C0872079
interaction	I-C0872079
datasets	B-C0150098
and	O
corresponding	O
series	O
of	O
negative	B-C0205160
datasets	B-C0150098
with	O
different	O
proteins	B-C0033684
repetitiveness	B-C0205341
are	O
constructed	O
using	O
graph	B-C0681493
adjacency	B-C1879629
matrix	I-C1879629
.	O
	
the	O
relationship	B-C0439849
between	O
the	O
svm	B-C2699740
prediction	B-C0681842
results	B-C1274040
and	O
the	O
repeated	B-C0205341
proteins	B-C0033684
repeat	O
numbers	O
and	O
repeat	O
rates	O
and	O
the	O
distributions	B-C1704711
of	O
repeated	B-C0205341
proteins	B-C0033684
in	O
the	O
datasets	B-C0150098
are	O
analyzed	O
.	O
	
protein	B-C0033684
repetitiveness	B-C0205341
of	O
positive	B-C1446409
and	O
negative	B-C0205160
datasets	B-C0150098
can	O
affect	O
the	O
prediction	B-C0681842
result	B-C1274040
high	O
protein	B-C0033684
repetitiveness	B-C0205341
of	O
positive	B-C1446409
or	O
negative	B-C0205160
datasets	B-C0150098
yield	O
high	O
performance	O
prediction	O
result	B-C1274040
.	O
	
this	O
indicate	O
that	O
dealing	O
with	O
object	O
repetitiveness	B-C0205341
of	O
datasets	B-C0150098
is	O
a	O
key	O
issue	O
in	O
protein-protein	B-C0872079
interactions	I-C0872079
prediction	B-C0681842
using	O
svms	B-C2699740
since	O
real	O
world	O
data	B-C1511726
contain	O
certain	O
degrees	O
of	O
repeat	B-C0205341
proteins	B-C0033684
.	O
	
from	O
'	O
sense	B-C0596887
of	I-C0596887
number	I-C0596887
'	O
to	O
'	O
sense	B-C0424215
of	I-C0424215
magnitude	B-C1704240
'	O
-	O
the	O
role	O
of	O
continuous	B-C0549178
magnitudes	B-C1704240
in	O
numerical	B-C0237753
cognition	B-C0009240
in	O
this	O
review	O
,	O
we	O
are	O
pitting	B-C0205323
two	O
theories	B-C0871935
against	O
each	O
other	O
the	O
more	O
accepted	O
theory	B-C0871935
-the	O
'	O
number	B-C0596887
sense	I-C0596887
'	O
theory	B-C0871935
-suggesting	O
that	O
a	O
sense	B-C0596887
of	I-C0596887
number	I-C0596887
is	O
innate	B-C0021619
and	O
non-symbolic	B-C0871836
numerosity	I-C0871836
is	O
being	O
processed	O
independently	O
of	O
continuous	B-C0549178
magnitudes	B-C1704240
e.g	O
,	O
size	B-C0456389
,	O
area	B-C0205146
,	O
density	B-C0178587
and	O
the	O
newly	O
emerging	O
theory	B-C0871935
suggesting	O
that	O
1	O
both	O
numerosities	B-C0871836
and	O
continuous	B-C0549178
magnitudes	B-C1704240
are	O
processed	O
holistically	O
when	O
comparing	O
numerosities	B-C0871836
,	O
and	O
2	O
a	O
sense	B-C0596887
of	I-C0596887
number	I-C0596887
might	O
not	O
be	O
innate	B-C0021619
.	O
	
in	O
the	O
first	O
part	O
of	O
this	O
review	O
,	O
we	O
discuss	O
the	O
'	O
number	B-C0596887
sense	I-C0596887
'	O
theory	B-C0871935
.	O
	
against	O
this	O
background	O
,	O
we	O
demonstrate	O
how	O
the	O
natural	O
correlation	B-C1707520
between	O
numerosities	B-C0871836
and	O
continuous	B-C0549178
magnitudes	B-C1704240
makes	O
it	O
nearly	O
impossible	O
to	O
study	O
non-symbolic	B-C0871836
numerosity	I-C0871836
processing	I-C0871836
in	O
isolation	O
from	O
continuous	B-C0549178
magnitudes	B-C1704240
,	O
and	O
therefore	O
the	O
results	O
of	O
behavioral	B-C0004939
and	O
imaging	B-C1881134
studies	I-C1881134
with	O
infants	B-C0021270
,	O
adults	B-C0001675
and	O
animals	B-C0003062
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
relying	O
on	O
continuous	B-C0549178
magnitudes	B-C1704240
.	O
	
in	O
the	O
second	O
part	O
,	O
we	O
explain	O
the	O
'	O
sense	B-C0424215
of	I-C0424215
magnitude	B-C1704240
'	O
theory	B-C0871935
and	O
review	O
studies	O
that	O
directly	O
demonstrate	O
that	O
continuous	O
magnitudes	O
are	O
more	O
automatic	O
and	O
basic	O
than	O
numerosities	O
.	O
	
finally	O
,	O
we	O
present	O
outstanding	O
questions	O
.	O
	
our	O
conclusion	O
is	O
that	O
there	O
is	O
not	O
enough	O
convincing	O
evidence	O
to	O
support	O
the	O
number	O
sense	O
theory	B-C0871935
anymore	O
.	O
	
therefore	O
,	O
we	O
encourage	O
researchers	O
not	O
to	O
assume	O
that	O
number	O
sense	O
is	O
simply	O
innate	O
,	O
but	O
to	O
put	O
this	O
hypothesis	O
to	O
the	O
test	O
,	O
and	O
to	O
consider	O
if	O
such	O
an	O
assumption	O
is	O
even	O
testable	O
in	O
light	O
of	O
the	O
correlation	O
of	O
numerosity	O
and	O
continuous	B-C0549178
magnitudes	B-C1704240
.	O
	
how	O
integrated	B-C0022885
management	I-C0022885
strategies	I-C0022885
promote	B-C0033414
protein	B-C0033684
quality	B-C0332306
of	O
cotton	B-C0010197
embryos	I-C0010197
high	B-C0205250
levels	B-C0441889
of	O
soil	B-C0037592
available	B-C0470187
n	B-C0028158
,	O
n	B-C0028158
assimilation	B-C1254365
and	O
protein	B-C0033684
accumulation	B-C4055506
rate	B-C1521828
cottonseed	B-C0010197
is	O
widely	O
used	O
as	O
a	O
source	B-C0449416
of	O
ruminant	B-C0035950
feed	B-C0003050
and	O
for	O
industrial	B-C0021267
purposes	B-C1285529
.	O
	
therefore	O
,	O
there	O
is	O
a	O
tremendous	O
need	O
to	O
improve	B-C0184511
the	O
nutritional	B-C0028722
value	I-C0028722
of	O
cotton	B-C0010197
embryos	I-C0010197
.	O
	
in	O
this	O
study	B-C2603343
,	O
a	O
conventional	B-C0022885
management	I-C0022885
cm	B-C0022885
and	O
two	O
integrated	O
cotton	B-C0010197
management	B-C0022885
strategies	I-C0022885
ims1	B-C0022885
,	O
ims2	B-C0022885
were	O
performed	B-C0884358
at	O
two	O
soil	B-C0037592
fertility	B-C0243095
levels	B-C0441889
to	O
study	B-C2603343
the	O
relationships	B-C0439849
among	O
soil	B-C0037592
n	B-C0028158
,	O
n	B-C0028158
assimilation	B-C1254365
,	O
embryonic	B-C0036563
protein	B-C0033684
accumulation	B-C4055506
and	O
protein	B-C0033684
quality	B-C0332306
.	O
	
the	O
levels	B-C0202202
of	I-C0202202
proteins	I-C0202202
,	O
essential	B-C0201874
amino	I-C0201874
acids	I-C0201874
,	O
and	O
semi-essential	B-C0201874
amino	I-C0201874
acids	I-C0201874
,	O
especially	O
those	O
of	O
glutamate	B-C0523665
,	O
lysine	B-C0523760
,	O
and	O
methionine	B-C0428210
,	O
were	O
higher	B-C0205250
in	O
ims1	B-C0022885
and	O
ims2	B-C0022885
embryos	B-C0036563
than	O
in	O
cm	B-C0022885
embryos	B-C0036563
.	O
	
these	O
changes	B-C0392747
were	O
significantly	O
positively	B-C1446409
correlated	B-C1707520
with	O
the	O
soil	B-C0037592
-	O
available	B-C0470187
n	B-C0523793
content	I-C0523793
,	O
glutamine	B-C1150667
synthetase	I-C1150667
activity	I-C1150667
and	O
peak	B-C0444505
value	O
of	O
protein	B-C0033684
accumulation	B-C4055506
rate	B-C1521828
and	O
were	O
negatively	B-C1513916
correlated	B-C1707520
with	O
the	O
free	B-C1996904
amino	B-C1328436
acid	I-C1328436
level	I-C1328436
.	O
	
these	O
results	B-C0683954
illustrated	O
that	O
integrated	B-C0022885
management	I-C0022885
strategies	I-C0022885
,	O
especially	O
the	O
rates	B-C1521828
and	O
timing	B-C0449243
of	O
n	B-C0028158
application	B-C4048755
,	O
raise	B-C0442805
the	O
level	B-C0441889
of	O
soil	B-C0037592
available	B-C0470187
n	B-C0028158
,	O
which	O
is	O
beneficial	O
for	O
n	B-C0028158
assimilation	B-C1254365
in	O
developing	O
cotton	B-C0010197
embryos	I-C0010197
.	O
	
the	O
protein	B-C0202202
content	I-C0202202
was	O
limited	B-C0439801
by	O
the	O
rate	B-C1521828
of	O
protein	B-C0033684
accumulation	B-C4055506
rather	O
than	O
by	O
the	O
free	B-C1996904
amino	B-C0201874
acid	I-C0201874
content	I-C0201874
.	O
	
the	O
combination	B-C0205195
of	O
target	B-C0392762
yield	I-C0392762
fertilization	B-C1254365
,	O
a	O
growth	B-C0597252
-driven	O
n	B-C0028158
application	B-C4048755
schedule	O
,	O
a	O
high	B-C0205250
plant	B-C0032098
density	B-C0178587
and	O
the	O
seedling	B-C0242437
raising	O
with	O
bio-organic	B-C1289928
fertilizer	I-C1289928
can	O
substantially	O
improve	B-C0184511
protein	B-C0033684
quality	B-C0332306
in	O
cotton	B-C0010197
embryos	I-C0010197
,	O
especially	O
at	O
a	O
soil	B-C0037592
with	O
low	O
soil	B-C0037592
organic	B-C0029224
matter	I-C0029224
and	O
total	B-C0439810
nitrogen	B-C0028158
.	O
	
help	O
end	O
the	O
hiv	B-C0019682
epidemic	B-C0014499
after	O
many	O
delays	O
,	O
the	O
public	B-C0886172
consultation	I-C0886172
on	O
hiv	B-C0150413
prevention	I-C0150413
tool	B-C0282574
prep	B-C3850098
pre-exposure	B-C3850098
prophylaxis	I-C3850098
is	O
finally	O
here	O
.	O
	
now	O
is	O
the	O
time	O
to	O
mobilise	O
-	O
help	O
end	O
the	O
hiv	B-C0019682
epidemic	B-C0014499
by	O
responding	O
to	O
this	O
nhs	B-C1254363
england	I-C1254363
consultation	I-C1254363
before	O
23	O
osseointegration	B-C0079949
behavior	O
of	O
novel	B-C0205314
ti-nb-zr-ta-si	B-C0011323
alloy	I-C0011323
for	O
dental	B-C0011373
implants	I-C0011373
an	O
in	B-C1515655
vivo	I-C1515655
study	B-C2603343
this	O
study	O
aimed	O
to	O
evaluate	B-C0220825
the	O
effects	B-C1704420
of	I-C1704420
ti-nb-zr-ta-si	B-C0011323
alloy	I-C0011323
implants	B-C0011373
on	O
mineral	B-C1521828
apposition	I-C1521828
rate	I-C1521828
and	O
new	O
bic	B-C0392762
contact	I-C0392762
in	O
rabbits	B-C3887509
.	O
	
twelve	O
ti-nb-zr-ta-si	B-C0011323
alloy	I-C0011323
implants	B-C0011373
were	O
fabricated	B-C0205245
and	O
placed	B-C1533810
into	O
the	O
right	B-C0444532
femur	B-C0015811
sites	B-C1515974
in	O
six	O
rabbits	B-C3887509
,	O
and	O
commercially	O
pure	O
titanium	B-C0040302
implants	B-C0011373
were	O
used	O
as	O
controls	B-C0009932
in	O
the	O
left	B-C0443246
femur	B-C0015811
.	O
	
tetracycline	B-C0039644
and	O
alizarin	B-C0051165
red	I-C0051165
were	O
administered	O
3	O
weeks	B-C0439230
and	O
1	O
week	B-C0439230
before	O
euthanization	B-C1136183
,	O
respectively	O
.	O
	
at	O
4	O
weeks	B-C0439230
and	O
8	O
weeks	B-C0439230
after	O
implantation	B-C0011370
,	O
animals	B-C0003062
were	O
euthanized	B-C3686530
,	O
respectively	O
.	O
	
surface	B-C0205148
characterization	B-C1880022
and	O
implant-bone	B-C0392762
contact	I-C0392762
surface	B-C0205148
analysis	B-C0936012
were	O
performed	B-C0884358
by	O
using	O
a	O
scanning	B-C0262878
electron	I-C0262878
microscope	I-C0262878
and	O
an	O
energy	B-C0025080
dispersive	I-C0025080
x-ray	I-C0025080
detector	I-C0025080
.	O
	
mineral	B-C1521828
apposition	I-C1521828
rate	I-C1521828
was	O
evaluated	B-C0220825
using	O
a	O
confocal	B-C0242841
laser	I-C0242841
scanning	I-C0242841
microscope	I-C0242841
.	O
	
toluidine	B-C0523203
blue	I-C0523203
staining	I-C0523203
was	O
performed	B-C0884358
on	O
undecalcified	B-C0243095
sections	B-C1522472
for	O
histology	B-C0019638
and	O
histomorphology	B-C0332437
evaluation	O
.	O
	
scanning	B-C0262878
electron	I-C0262878
microscope	I-C0262878
and	O
histomorphology	B-C0332437
observation	B-C1554188
revealed	B-C0443289
a	O
direct	B-C0332158
contact	I-C0332158
between	O
implants	B-C0011373
and	O
bone	B-C0262950
of	O
all	O
groups	B-C0441833
.	O
	
after	O
a	O
healing	B-C0043240
period	B-C1948053
of	O
4	O
weeks	B-C0439230
,	O
ti-nb-zr-ta-si	B-C0011323
alloy	I-C0011323
implants	B-C0011373
showed	O
significantly	O
higher	O
mineral	B-C1521828
apposition	I-C1521828
rate	I-C1521828
compared	O
to	O
commercially	O
pure	O
titanium	B-C0040302
implants	B-C0011373
p	O
<	O
0.05	O
,	O
whereas	O
there	O
was	O
no	B-C1273937
significant	I-C1273937
difference	O
between	O
ti-nb-zr-ta-si	B-C0011323
alloy	I-C0011323
implants	B-C0011373
and	O
commercially	O
pure	O
titanium	B-C0040302
implants	B-C0011373
p	O
>	O
0.05	O
at	O
8	O
weeks	B-C0439230
.	O
	
no	B-C1273937
significant	I-C1273937
difference	O
of	O
bone-to-implant	B-C0392762
contact	I-C0392762
was	O
observed	B-C1441672
between	O
ti-nb-zr-ta-si	B-C0011323
alloy	I-C0011323
implants	B-C0011373
and	O
commercially	O
pure	O
titanium	B-C0040302
implants	B-C0011373
implants	B-C0011373
after	O
a	O
healing	B-C0043240
period	B-C1948053
of	O
4	O
weeks	B-C0439230
and	O
8	O
weeks	B-C0439230
.	O
	
this	O
study	O
showed	O
that	O
ti-nb-zr-ta-si	B-C0011323
alloy	I-C0011323
implants	B-C0011373
could	O
establish	O
a	O
close	B-C0332158
direct	I-C0332158
contact	I-C0332158
comparedto	O
commercially	O
pure	O
titanium	B-C0040302
implants	B-C0011373
implants	B-C0011373
,	O
improved	B-C0184511
mineral	B-C1521828
matrix	I-C1521828
apposition	I-C1521828
rate	I-C1521828
,	O
and	O
may	O
someday	O
be	O
an	O
alternative	B-C1523987
as	O
a	O
material	B-C0520510
for	O
dental	B-C0011373
implants	I-C0011373
.	O
	
simultaneous	B-C0521115
edited	B-C1711200
mrs	B-C0024487
of	O
gaba	B-C0016904
and	O
glutathione	B-C0017817
edited	B-C1711200
mrs	B-C0024487
allows	O
the	O
detection	B-C1511790
of	O
low	B-C0205251
-	O
concentration	B-C1446561
metabolites	B-C0870883
,	O
whose	O
signals	B-C1710082
are	O
not	B-C1518422
resolved	B-C2699488
in	O
the	O
mr	B-C0024487
spectrum	I-C0024487
.	O
	
tailored	B-C1706701
acquisitions	I-C1706701
can	O
be	O
designed	B-C0920454
to	O
detect	B-C1511790
,	O
for	O
example	B-C1707959
,	O
the	O
inhibitory	B-C3463820
neurotransmitter	B-C0027908
γ-aminobutyric	B-C0016904
acid	I-C0016904
gaba	B-C0016904
,	O
or	O
the	O
reduction-oxidation	B-C0030012
redox	B-C0030012
compound	O
glutathione	B-C0017817
gsh	B-C0017817
,	O
and	O
single	B-C0205171
-	O
voxel	B-C2700259
edited	B-C1711200
experiments	B-C0681814
are	O
generally	O
acquired	O
at	O
a	O
rate	B-C1521828
of	O
one	B-C0205447
metabolite	B-C0870883
-	O
per-experiment	B-C0681814
.	O
	
we	O
demonstrate	O
that	O
simultaneous	B-C0521115
detection	B-C1511790
of	O
the	O
overlapping	B-C1948020
signals	B-C1710082
of	O
gaba	B-C0016904
and	O
gsh	B-C0017817
is	O
possible	O
using	B-C1524063
hadamard	B-C0022885
encoding	I-C0022885
and	I-C0022885
reconstruction	I-C0022885
of	I-C0022885
mega-edited	I-C0022885
spectroscopy	I-C0022885
hermes	B-C0022885
.	O
	
hermes	B-C0022885
applies	B-C4048755
orthogonal	B-C2700640
editing	I-C2700640
encoding	I-C2700640
following	B-C0332282
a	O
hadamard	B-C1519193
scheme	I-C1519193
,	O
such	O
that	O
gsh-	B-C0017817
and	O
gaba	B-C0016904
-	O
edited	B-C1711200
difference	B-C1705242
spectra	B-C2827424
can	O
be	O
reconstructed	O
from	O
a	O
single	B-C0681814
multiplexed	I-C0681814
experiment	I-C0681814
.	O
	
at	O
a	O
te	B-C2826100
of	O
80ms	O
,	O
20-ms	O
editing	B-C1711200
pulses	B-C1947910
are	O
applied	B-C4048755
at	O
4.56ppm	O
on	O
gsh	B-C0017817
on	O
gaba	B-C0016904
,	O
both	B-C1706086
offsets	B-C1711330
using	O
a	O
dual-lobe	B-C1947910
cosine-modulated	I-C1947910
pulse	I-C1947910
or	O
neither	O
.	O
	
hadamard	B-C0282574
combinations	I-C0282574
of	O
the	O
four	O
sub-experiments	B-C0681814
yield	O
gaba	B-C0016904
and	O
gsh	B-C0017817
difference	B-C1705242
spectra	B-C2827424
.	O
	
it	O
is	O
shown	O
that	O
hermes	B-C0022885
gives	O
excellent	B-C1961136
separation	B-C0443299
of	O
the	O
edited	B-C1711200
gaba	B-C0016904
and	O
gsh	B-C0017817
signals	B-C1710082
in	O
phantoms	B-C0282611
,	O
and	O
resulting	O
edited	B-C1711200
lineshapes	B-C0348078
agree	B-C3641827
well	B-C0205170
with	O
separate	B-C0443299
mescher-garwood	B-C0022885
point-resolved	I-C0022885
spectroscopy	I-C0022885
mega-press	B-C0022885
acquisitions	B-C1706701
.	O
	
in	B-C1515655
vivo	I-C1515655
,	O
the	O
quality	B-C0332306
and	O
signal-to-noise	B-C2986823
ratio	I-C2986823
snr	B-C2986823
of	O
hermes	B-C0022885
spectra	B-C2827424
are	O
similar	B-C2348205
to	O
those	O
of	O
sequentially	B-C1705294
acquired	B-C0439661
mega-press	B-C0022885
spectra	B-C2827424
,	O
with	O
the	O
benefit	B-C0814225
of	O
saving	O
half	O
the	O
acquisition	B-C1706701
time	B-C0040223
.	O
	
chitosan	B-C0162969
-functionalised	O
poly	B-C0032509
methacrylate	I-C0032509
core-shell	B-C0013161
microgels	I-C0013161
as	O
drug	B-C0085104
delivery	I-C0085104
carriers	I-C0085104
salicylic	B-C0036079
acid	I-C0036079
loading	B-C0205245
and	I-C0205245
release	I-C0205245
this	O
work	O
presents	O
the	O
evaluation	O
of	O
chitosan	B-C0162969
-functionalised	O
poly	B-C0032509
methacrylate	I-C0032509
cs	B-C0162969
/	O
phema	B-C0032509
core-shell	B-C0013161
microgels	I-C0013161
as	O
drug	B-C0085104
delivery	I-C0085104
carriers	I-C0085104
.	O
	
cs	B-C0162969
/	O
phema	B-C0032509
microgels	B-C0013161
were	O
prepared	O
by	O
emulsifier-free	B-C0314672
emulsion	I-C0314672
polymerisation	I-C0314672
with	O
n	B-C0067314
'-methylenebisacrylamide	I-C0067314
mba	B-C0067314
as	O
a	O
crosslinker	B-C0029224
.	O
	
the	O
study	B-C0013175
on	I-C0013175
drug	I-C0013175
loading	I-C0013175
,	O
using	O
salicylic	B-C0036079
acid	I-C0036079
sa	B-C0036079
as	O
a	O
model	B-C1254351
drug	I-C1254351
,	O
was	O
performed	O
.	O
	
the	O
results	O
showed	O
that	O
the	O
encapsulation	B-C2348438
efficiency	I-C2348438
ee	B-C2348438
increased	O
as	O
drug	B-C1254351
-to-	O
microgel	O
ratio	B-C0456603
was	O
increased	O
.	O
	
higher	O
ee	B-C2348438
can	O
be	O
achieved	O
with	O
the	O
increase	O
in	O
degree	O
of	O
crosslinking	B-C1254366
,	O
by	O
increasing	O
the	O
amount	O
of	O
mba	B-C0067314
from	O
0.01	O
g	O
to	O
0.03	O
g	O
.	O
	
in	O
addition	O
,	O
the	O
highest	O
ee	B-C2348438
61.1	O
was	O
observed	O
at	O
ph	B-C0020283
3	O
.	O
	
the	O
highest	O
release	B-C3850077
of	I-C3850077
sa	I-C3850077
60%	O
was	O
noticed	O
at	O
ph	B-C0020283
2.4	O
,	O
while	O
the	O
lowest	O
one	O
49.4	O
was	O
obtained	O
at	O
ph	B-C0020283
7.4	O
.	O
	
moreover	O
,	O
the	O
highest	O
release	B-C3850077
of	I-C3850077
sa	I-C3850077
was	O
enhanced	O
by	O
the	O
presence	O
of	O
0.2	O
m	O
nacl	B-C0037494
.	O
	
the	O
ph	B-C0020283
-	O
and	O
ionic-sensitivity	B-C0205556
of	O
cs	B-C0162969
/	O
phema	B-C0032509
could	O
be	O
useful	O
as	O
a	O
sustained	B-C1135768
release	I-C1135768
delivery	I-C1135768
device	I-C1135768
,	O
especially	O
for	O
oral	B-C0302620
delivery	I-C0302620
.	O
	
breast	B-C0191925
augmentation	I-C0191925
after	O
conservation	B-C0917927
surgery	I-C0917927
and	O
radiation	B-C1522449
therapy	I-C1522449
there	O
is	O
a	O
paucity	O
of	O
data	O
regarding	O
outcomes	O
for	O
patients	B-C0030705
undergoing	O
breast	B-C0191925
augmentation	I-C0191925
with	O
implants	B-C0021102
after	O
breast	B-C0917927
conservation	I-C0917927
surgery	I-C0917927
bcs	B-C0917927
and	O
radiotherapy	B-C1522449
.	O
	
this	O
retrospective	B-C0035363
study	I-C0035363
examined	O
outcomes	O
for	O
patients	B-C0030705
with	O
breast	B-C0179412
implant	I-C0179412
-only	O
augmentation	B-C0191925
after	O
bcs	B-C0917927
and	O
radiotherapy	B-C1522449
.	O
	
between	O
june	O
1998	O
and	O
december	O
2010	O
,	O
671	O
women	B-C0043210
underwent	O
prosthetic	B-C0179412
breast	B-C0085076
reconstruction	I-C0085076
.	O
	
nineteen	O
patients	B-C0030705
2.8	O
underwent	O
an	O
augmentation	B-C0191925
after	O
bcs	B-C0917927
and	O
radiotherapy	B-C1522449
.	O
	
the	O
mean	B-C0444504
age	B-C0001779
was	O
55.8	O
years	B-C1510829
range	B-C1514721
,	O
40-69	O
years	B-C1510829
.	O
	
sixteen	O
of	O
these	O
patients	B-C0030705
underwent	O
one-stage	B-C0021107
implant	I-C0021107
-only	O
breast	B-C0191925
augmentation	I-C0191925
,	O
whereas	O
3	O
patients	B-C0030705
underwent	O
two-stage	B-C0021107
expander	I-C0021107
and	O
then	O
implant	B-C0191925
augmentation	I-C0191925
.	O
	
all	O
surgeries	B-C0543467
were	O
successful	O
.	O
	
the	O
average	O
size	O
of	O
breast	B-C0179412
implant	I-C0179412
used	O
was	O
258.7	O
.	O
	
seven	O
patients	B-C0030705
also	O
received	O
contralateral	B-C0441988
augmentation	B-C0191925
with	O
an	O
average	O
implant	O
size	O
of	O
232.2	O
.	O
	
one	O
patient	B-C0030705
received	O
oral	B-C1527415
antibiotics	B-C0003232
for	O
minor	O
wound	B-C0043241
infection	I-C0043241
.	O
	
patients	B-C0030705
were	O
judged	O
to	O
have	O
an	O
excellent	O
14/19	O
73.7	O
,	O
good	O
3/19	O
15.8	O
,	O
or	O
fair	O
2/19	O
10.5	O
cosmetic	B-C1390444
result	B-C1274040
.	O
	
the	O
breasts	B-C0006141
of	O
selected	O
patients	B-C0030705
with	O
breast	B-C0006142
cancer	I-C0006142
after	O
bcs	B-C0917927
and	O
radiotherapy	B-C1522449
.	O
	
with	O
asymmetry	O
can	O
be	O
adequately	O
augmented	B-C0205217
with	O
breast	B-C0179412
implants	I-C0179412
mitochondrial	B-C1418818
pyruvate	I-C1418818
dehydrogenase	I-C1418818
phosphatase	I-C1418818
1	I-C1418818
regulates	O
the	O
early	O
differentiation	B-C1817118
of	I-C1817118
cardiomyocytes	I-C1817118
from	O
mouse	B-C4042879
embryonic	I-C4042879
stem	I-C4042879
cells	I-C4042879
mitochondria	B-C0026237
are	O
crucial	O
for	O
maintaining	O
the	O
properties	O
of	O
embryonic	B-C0596508
stem	I-C0596508
cells	I-C0596508
escs	B-C0596508
and	O
for	O
regulating	O
their	O
subsequent	O
differentiation	B-C0007589
into	O
diverse	O
cell	B-C0282637
lineages	I-C0282637
,	O
including	O
cardiomyocytes	B-C0225828
.	O
	
however	O
,	O
mitochondrial	B-C0574031
regulators	I-C0574031
that	O
manage	O
the	O
rate	B-C1521828
of	I-C1521828
differentiation	I-C1521828
or	O
cell	B-C1540661
fate	I-C1540661
have	O
been	O
rarely	O
identified	O
.	O
	
this	O
study	O
aimed	O
to	O
determine	O
the	O
potential	O
mitochondrial	B-C0033684
factor	I-C0033684
that	O
controls	O
the	O
differentiation	B-C1514964
of	I-C1514964
escs	I-C1514964
into	O
cardiac	B-C0225828
myocytes	I-C0225828
.	O
	
we	O
induced	O
cardiomyocyte	B-C1817118
differentiation	I-C1817118
from	O
mouse	B-C4042879
escs	I-C4042879
mescs	B-C4042879
and	O
performed	O
microarray	B-C1449575
assays	I-C1449575
to	O
assess	O
messenger	B-C0035696
rna	I-C0035696
mrna	B-C0035696
expression	B-C0040649
changes	O
at	O
differentiation	B-C0243095
day	I-C0243095
8	I-C0243095
d8	B-C0243095
compared	O
with	O
undifferentiated	B-C0205618
mescs	B-C4042879
d0	O
.	O
	
among	O
the	O
differentially	O
expressed	B-C0017337
genes	I-C0017337
,	O
pdp1	B-C1418818
expression	B-C0017262
was	O
significantly	O
decreased	O
27-fold	O
on	O
d8	B-C0243095
compared	O
to	O
d0	B-C0205618
,	O
which	O
was	O
accompanied	O
by	O
suppressed	B-C1260953
mitochondrial	B-C0026237
indices	B-C0918012
,	O
including	O
atp	B-C0001480
levels	O
,	O
membrane	B-C1156295
potential	I-C1156295
,	O
ros	B-C3894464
and	O
mitochondrial	B-C1658623
ca	I-C1658623
.	O
	
notably	O
,	O
pdp1	B-C1418818
overexpression	B-C0017262
significantly	O
enhanced	O
the	O
mitochondrial	B-C0026237
indices	B-C0918012
and	O
pyruvate	B-C1151688
dehydrogenase	I-C1151688
activity	I-C1151688
and	O
reduced	O
the	O
expression	B-C0040649
of	O
cardiac	B-C2247990
differentiation	I-C2247990
marker	B-C0872263
mrna	I-C0872263
and	O
the	O
cardiac	B-C2247990
differentiation	I-C2247990
rate	B-C1521828
compared	O
to	O
a	O
mock	O
control	O
.	O
	
in	O
confirmation	O
of	O
this	O
,	O
a	O
knockdown	B-C2350567
of	O
the	O
pdp1	B-C1418818
gene	I-C1418818
promoted	O
the	O
expression	B-C0040649
of	O
cardiac	B-C2247990
differentiation	I-C2247990
marker	B-C0872263
mrna	I-C0872263
and	O
the	O
cardiac	B-C2247990
differentiation	I-C2247990
rate	B-C1521828
.	O
	
in	O
conclusion	O
,	O
our	O
results	O
suggest	O
that	O
mitochondrial	B-C1418818
pdp1	I-C1418818
is	O
a	O
potential	O
regulator	O
that	O
controls	O
cardiac	B-C2247990
differentiation	I-C2247990
at	O
an	O
early	O
differentiation	B-C1254367
stage	I-C1254367
in	O
thermo-reversible	B-C1254366
capture	I-C1254366
and	I-C1254366
release	I-C1254366
of	O
dna	B-C0012854
by	O
zwitterionic	B-C0038891
surfactants	I-C0038891
the	O
thermo-reversible	B-C1254366
capture	I-C1254366
and	I-C1254366
release	I-C1254366
of	O
dna	B-C0012854
were	O
studied	O
by	O
the	O
protonation	B-C0178812
and	O
deprotonation	B-C0599225
of	O
alkyldimethylamine	B-C0029224
oxide	I-C0029224
cndmao	B-C0029224
,	O
n	O
=	O
10	O
,	O
12	O
and	O
14	O
in	O
tris-hcl	B-C1254353
buffer	B-C3190981
solution	I-C3190981
.	O
	
dna	B-C0012854
/	O
c14dmao	B-C0029224
in	O
tris-hcl	B-C1254353
buffer	B-C3190981
solution	I-C3190981
with	O
ph	B-C0020283
=	O
7.2	O
is	O
transparent	B-C0522503
at	O
25	O
c	O
,	O
indicating	O
that	O
dna	B-C0012854
molecules	B-C0567416
exist	O
mainly	O
in	O
individuals	B-C0237401
and	O
the	O
binding	B-C1167622
of	O
c14dmao	B-C0029224
is	O
weak	B-C1762617
.	O
	
with	O
the	O
increase	B-C0442805
of	O
temperature	B-C0039476
,	O
the	O
ph	B-C0020283
of	O
the	O
buffer	B-C3190981
solution	I-C3190981
continuously	O
decreases	B-C0547047
,	O
which	O
leads	O
to	O
protonation	B-C0178812
of	O
c14dmao	B-C0029224
c14dmao	B-C0029224
+	O
h	B-C0033727
c14dmaoh	B-C0029224
and	O
an	O
obvious	O
increase	B-C0301634
of	I-C0301634
the	I-C0301634
turbidity	I-C0301634
of	O
the	O
samples	B-C0439861
.	O
	
this	O
indicates	O
a	O
stronger	O
binding	B-C1167622
of	O
the	O
protonated	B-C0178812
c14dmaoh	B-C0029224
to	O
dna	B-C0012854
.	O
	
further	O
investigations	O
demonstrated	O
the	O
formation	B-C1522492
of	O
dna	B-C0012854
/	O
c14dmaoh	B-C0029224
complexes	B-C1704241
,	O
in	O
which	O
the	O
stretched	O
dna	B-C0012854
molecules	B-C0567416
are	O
effectively	O
compacted	B-C1333134
as	O
evidenced	O
from	O
uv-vis	B-C1883416
absorptions	O
,	O
circular	O
dichroism	O
cd	O
measurements	O
,	O
atomic	O
force	O
microscopy	O
afm	O
observations	O
,	O
dynamic	O
light	O
scattering	O
dls	O
measurements	O
and	O
agarose	O
gel	O
electrophoresis	O
age	O
.	O
	
interestingly	O
,	O
when	O
the	O
temperature	O
is	O
turned	O
back	O
to	O
25	O
c	O
,	O
the	O
compacted	O
dna	O
molecules	O
can	O
fully	O
recover	O
to	O
the	O
stretched	O
conformation	O
.	O
	
this	O
cycle	O
can	O
be	O
repeated	O
several	O
times	O
without	O
obvious	O
loss	O
of	O
efficiency	O
.	O
	
the	O
effect	O
of	O
the	O
chain	O
length	O
of	O
cndmao	O
has	O
also	O
been	O
investigated	O
.	O
	
when	O
c14dmao	O
was	O
replaced	O
by	O
c12dmao	O
,	O
similar	O
phenomena	O
can	O
be	O
observed	O
with	O
a	O
slightly	O
higher	O
critical	O
surfactant	O
concentration	O
for	O
dna	O
compaction	O
and	O
a	O
slightly	O
lower	O
ph	O
of	O
tris-hcl	O
buffer	O
solution	O
with	O
ph	O
=	O
6.8	O
.	O
	
for	O
the	O
dna	O
/	O
c10dmao	O
system	O
,	O
however	O
,	O
no	O
dna	O
compaction	O
was	O
observed	O
even	O
in	O
tris-hcl	O
buffer	O
solution	O
with	O
a	O
much	O
lower	O
ph	O
and	O
a	O
much	O
higher	O
c10dmao	O
concentration	O
.	O
	
the	O
negative	O
charges	O
of	O
dna	O
molecules	O
can	O
easily	O
be	O
neutralized	O
by	O
positive	O
charges	O
of	O
cationic	O
cndmaoh	O
n	O
=	O
12	O
and	O
14	O
micelles	O
.	O
	
dna	O
was	O
compacted	O
and	O
then	O
insoluble	O
dna	O
/	O
cndmaoh	O
complexes	O
were	O
formed	O
.	O
	
because	O
of	O
the	O
much	O
higher	O
critical	O
micelle	O
concentration	O
cmc	O
of	O
the	O
shorter	O
chain	O
length	O
c10dmaoh	O
,	O
cationic	O
c10dmaoh	O
micelles	O
cannot	O
form	O
under	O
the	O
studied	O
condition	O
to	O
compact	O
dna	O
.	O
	
the	O
strategy	O
may	O
provide	O
an	O
efficient	O
and	O
alternative	O
approach	O
for	O
stimuli-responsive	O
gene	O
therapy	O
and	O
drug	O
release	I-C3850077
collaborating	B-C0282116
for	O
systems	B-C0449913
change	B-C0392747
a	O
social	B-C0596159
science	I-C0596159
framework	I-C0596159
for	O
academic	B-C0683838
roles	I-C0683838
in	O
community	B-C0680453
partnerships	I-C0680453
environmental	B-C0014413
health	I-C0014413
researchers	B-C0035173
,	O
government	B-C0018105
agencies	I-C0018105
,	O
and	O
community	B-C0683986
groups	I-C0683986
have	O
endorsed	O
long-term	O
community	B-C0009462
-	O
academic	B-C0683838
partnerships	B-C1711206
as	O
an	O
effective	B-C0679199
strategy	I-C0679199
to	O
support	B-C1521721
science	B-C0036397
-based	O
improvements	B-C2986411
in	O
environmental	B-C0014413
health	I-C0014413
.	O
	
social	B-C0037434
sciences	I-C0037434
concepts	B-C0178566
,	O
approaches	B-C1254370
,	O
and	O
methods	B-C0025663
are	O
fundamental	O
to	O
these	O
translational	B-C1711206
partnerships	I-C1711206
.	O
	
however	O
,	O
appropriate	B-C1548787
roles	B-C0086939
for	O
academic	B-C0683838
partners	B-C3887537
vary	O
throughout	O
the	O
process	B-C1522240
of	O
changing	B-C0392747
systems	B-C0449913
policies	B-C0242456
,	O
practices	B-C0033284
,	O
programs	B-C3484370
,	O
etc	O
.	O
	
this	O
can	O
complicate	O
planning	B-C0086960
,	O
evaluating	B-C1550157
,	O
and	O
sustaining	B-C0443318
such	O
partnerships	B-C1711206
.	O
	
we	O
set	O
forth	O
a	O
conceptual	B-C1254370
framework	I-C1254370
for	O
academic	B-C0683838
partners	B-C3887537
'	O
roles	O
at	O
different	B-C1306673
stages	I-C1306673
of	O
systems	B-C0449913
change	B-C0392747
.	O
	
we	O
apply	O
this	O
framework	B-C1254370
to	O
three	O
longstanding	O
academic	B-C0683838
-	O
community	B-C0009462
partnerships	B-C1711206
involving	O
national	B-C1955979
institute	I-C1955979
of	I-C1955979
environmental	I-C1955979
health	I-C1955979
sciences	I-C1955979
community	B-C1522486
outreach	I-C1522486
and	I-C1522486
engagement	I-C1522486
cores	I-C1522486
.	O
	
we	O
conclude	O
by	O
discussing	O
how	O
the	O
framework	B-C1254370
can	O
help	O
academic	B-C0683838
partners	B-C3887537
tap	O
appropriate	B-C1548787
expertise	B-C0870520
,	O
redefine	O
their	O
roles	O
,	O
and	O
evaluate	O
their	O
contributions	O
to	O
community	B-C0009462
efforts	O
to	O
improve	B-C0184511
environmental	B-C0014413
health	I-C0014413
.	O
	
a	O
novel	B-C0205314
mechanical	B-C0183309
simulator	I-C0183309
for	O
cannulation	B-C0917707
and	O
sphincterotomy	B-C0748895
after	O
billroth	B-C0192444
ii	I-C0192444
or	O
roux-en-y	B-C0372024
reconstruction	I-C0372024
in	O
patients	B-C0030705
with	O
billroth	B-C0192444
ii	I-C0192444
b	B-C0192444
ii	I-C0192444
or	O
roux-en-y	B-C0372024
anatomy	B-C0700276
,	O
endoscopic	B-C0008310
retrograde	I-C0008310
cholangiopancreatography	I-C0008310
ercp	B-C0008310
is	O
demanding	O
.	O
	
here	O
,	O
we	O
describe	O
a	O
novel	B-C0205314
simulator	B-C0183309
with	O
simulated	B-C0679083
fluoroscopy	B-C0016356
for	O
cannulation	B-C0917707
and	O
sphincterotomy	B-C0748895
training	B-C0220931
in	O
such	O
situations	O
.	O
	
a	O
custom-made	O
simulation	B-C4075558
system	I-C4075558
was	O
built	B-C1706853
based	O
upon	O
a	O
common	B-C0205214
chassis	B-C1707356
of	O
a	O
series	B-C0205549
of	O
previously	B-C0205156
described	O
ercp	B-C0008310
simulators	B-C0183309
.	O
	
the	O
papilla	B-C3714556
is	O
made	O
out	O
of	O
organic	B-C0747055
material	B-C0520510
and	O
can	O
be	O
cut	B-C1883724
by	O
high	B-C0205212
frequency	I-C0205212
current	B-C1705970
.	O
	
the	O
advancement	B-C1280477
of	O
guidewires	B-C1708264
and	O
other	O
instruments	B-C0348000
within	O
transparent	B-C0522503
mock	O
bile	B-C0005400
ducts	I-C0005400
can	O
be	O
viewed	O
in	O
the	O
window	B-C1704674
of	O
the	O
simulator	B-C0183309
without	O
the	O
need	O
for	O
fluoroscopy	B-C0016356
.	O
	
the	O
ercp	B-C0008310
b	B-C0192444
ii	I-C0192444
/	O
roux-en-y	B-C0372024
simulation	B-C4075558
system	I-C4075558
was	O
first	O
evaluated	B-C0220825
during	O
an	O
ercp	B-C0008310
course	B-C0750729
.	O
	
there	O
were	O
no	O
technical	B-C1710348
problems	I-C1710348
related	O
to	O
the	O
novel	B-C0205314
simulator	B-C0183309
during	O
the	O
course	B-C0750729
.	O
	
after	O
sphincterotomy	B-C0748895
,	O
the	O
organic	B-C0747055
papillae	B-C3714556
could	O
easily	O
be	O
exchanged	B-C0205245
within	O
a	O
few	O
seconds	B-C0457385
.	O
	
overall	O
,	O
the	O
novel	B-C0205314
b	B-C0192444
ii	I-C0192444
/	O
roux-en-y	B-C0372024
simulator	B-C0183309
achieved	O
favorable	B-C3640814
results	B-C1274040
by	O
trainees	B-C1522486
and	O
expert	B-C1611835
endoscopists	B-C1522486
in	O
all	O
categories	B-C0683312
assessed	B-C1516048
.	O
	
the	O
new	O
b	B-C0192444
ii	I-C0192444
/	O
roux-en-y	B-C0372024
mechanical	B-C0183309
simulator	I-C0183309
is	O
simple	B-C0205352
and	O
practicable	B-C0205556
.	O
	
a	O
first	O
evaluation	B-C0220825
during	O
an	O
ercp	B-C0008310
course	B-C0750729
showed	O
promising	O
a	O
thermophilic	B-C0597570
-like	O
ene-reductase	B-C0030016
originating	O
from	O
an	O
acidophilic	B-C0333931
iron	B-C0004611
oxidizer	I-C0004611
ene-reductases	B-C0030016
originating	O
from	O
extremophiles	B-C4277715
are	O
gaining	O
importance	O
in	O
the	O
field	O
of	O
biocatalysis	B-C2350294
due	O
to	O
higher	B-C0205250
-	O
stability	B-C0205360
properties	B-C0871161
.	O
	
the	O
genome	B-C0017428
of	O
the	O
acidophilic	B-C0333931
iron-oxidizing	B-C0004611
bacterium	I-C0004611
""""	O
"ferrovum"""	B-C3908921
sp	I-C3908921
.	O
	
ja12	I-C3908921
was	O
found	O
to	O
harbor	O
a	O
thermophilic	B-C0597570
-like	O
ene-reductase	B-C0030016
foye-1	B-C0030016
.	O
	
the	O
foye-1	B-C0017337
gene	I-C0017337
was	O
ligated	O
into	O
a	O
pet16bp	B-C0032136
expression	B-C0017262
vector	B-C0017397
system	I-C0017397
,	O
and	O
the	O
enzyme	B-C0014442
was	O
produced	O
in	O
escherichia	B-C0014834
coli	I-C0014834
bl21	B-C0007634
de3	I-C0007634
plyss	I-C0007634
cells	I-C0007634
in	O
yields	O
of	O
10	O
mg	O
l	O
.	O
	
foye-1	B-C0030016
showed	O
remarkable	O
activity	B-C0243102
and	O
rates	B-C1521828
on	O
n-phenylmaleimide	B-C0068268
and	O
n-phenyl-2-methylmaleimide	B-C0029224
up	O
to	O
89	O
u	O
mg	O
,	O
>97	O
%	O
conversion	B-C0439836
,	O
95	O
%	O
r	O
with	O
both	O
nicotinamide	B-C0009235
cofactors	I-C0009235
,	O
nadph	B-C0027303
and	O
nadh	B-C0027289
.	O
	
the	O
catalytic	B-C0007382
efficiency	B-C0013682
with	O
nadph	B-C0027303
was	O
27	O
times	O
higher	B-C0205250
compared	O
to	O
nadh	B-C0027289
.	O
	
at	O
the	O
temperature	B-C0039476
maximum	B-C0806909
50	O
c	O
and	O
ph	B-C0020283
optimum	I-C0020283
6.5	O
,	O
activity	B-C0243102
was	O
almost	O
doubled	B-C1705764
to	O
160	O
u	O
mg	O
.	O
	
these	O
findings	B-C0243095
accomplish	O
foye-1	B-C0030016
for	O
a	O
valuable	O
biocatalyst	B-C0175921
in	O
the	O
synthesis	B-C1883254
of	O
succinimides	B-C0038623
.	O
	
the	O
appearance	O
of	O
a	O
thermophilic	B-C0597570
-like	O
ene-reductase	B-C0030016
in	O
an	O
acidic	B-C0871648
habitat	I-C0871648
is	O
discussed	O
with	O
respect	O
to	O
its	O
phylogenetic	O
placement	O
and	O
to	O
the	O
genomic	B-C0017428
neighborhood	B-C0014406
of	O
the	O
encoding	B-C2700640
gene	B-C0017337
,	O
awarding	O
foye-1	B-C0030016
a	O
putative	O
involvement	O
in	O
a	O
quorum-sensing	B-C1154599
a	O
tanshinone	B-C0075810
i	I-C0075810
derivative	B-C1527240
enhances	O
the	O
activities	B-C3714634
of	O
antibiotics	B-C0003232
against	O
staphylococcus	B-C0038172
aureus	I-C0038172
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
infections	B-C3714514
caused	O
by	O
staphylococcus	B-C0038172
aureus	I-C0038172
are	O
prevalent	O
.	O
	
the	O
dramatically	O
reduced	O
discovery	B-C1880355
of	O
new	O
antibiotics	B-C0003232
,	O
as	O
well	O
as	O
the	O
persistent	O
emergence	O
of	O
resistant	B-C1444090
bacteria	I-C1444090
,	O
represents	O
a	O
major	O
health	B-C0018684
problem	B-C0033213
in	O
both	O
hospital	B-C0019994
and	O
community	B-C1274109
settings	I-C1274109
.	O
	
using	O
antibiotic	B-C0003232
enhancers	O
to	O
rescue	O
existing	O
classes	O
of	O
antibiotics	B-C0003232
is	O
an	O
attractive	O
strategy	O
.	O
	
in	O
this	O
study	B-C2603343
,	O
16-aldehyde	B-C1254351
tanshinone	I-C1254351
i	I-C1254351
alt	B-C1254351
was	O
synthesized	B-C1883254
and	O
bacteriostatic	B-C3714634
activity	I-C3714634
was	O
explored	O
.	O
	
in	O
addition	O
,	O
synergistic	B-C2986495
or	O
additive	B-C0442796
activity	B-C3714634
between	O
alt	B-C1254351
and	O
aminoglycoside	B-C0003233
antibiotics	I-C0003233
or	O
β-lactam	B-C0026458
antibiotics	I-C0026458
in	B-C1533691
vitro	I-C1533691
was	O
identified	O
.	O
	
moreover	O
,	O
alt	B-C1254351
was	O
documented	O
to	O
augment	O
clearance	O
of	O
streptomycin	B-C0038425
str	B-C0038425
and	O
ampicillin	B-C0002680
amp	B-C0002680
against	O
s	B-C0038172
.	O
	
aureus	I-C0038172
in	O
a	O
murine	B-C2986594
infection	I-C2986594
model	I-C2986594
.	O
	
primary	O
mechanistic	B-C0678659
insight	I-C0678659
indicated	O
that	O
alt	B-C1254351
could	O
damage	B-C1883709
the	O
bacterial	B-C0004611
cell	B-C3161472
membrane	I-C3161472
,	O
leading	O
to	O
accumulation	B-C4055506
of	O
antibiotics	B-C0003232
inside	O
bacterial	B-C0563199
cells	I-C0563199
.	O
	
this	O
finding	O
might	O
be	O
useful	O
for	O
treating	B-C1522326
infections	B-C3714514
caused	O
by	O
s	B-C0038172
.	O
	
aureus	I-C0038172
and	O
expand	O
the	O
scope	O
of	O
application	B-C4048755
of	O
investigation	O
of	O
argyrophilic	B-C0682551
nucleolar	B-C0028609
organizing	I-C0028609
region	I-C0028609
ischemia/reperfusion	B-C0035126
i/r	I-C0035126
injury	I-C0035126
is	O
a	O
complex	B-C0441471
event	I-C0441471
frequently	O
observed	B-C1441672
in	O
vascular	B-C0042381
surgery	I-C0042381
and	O
can	O
cause	O
functional	B-C0007613
and	O
structural	B-C0243092
cell	B-C0599732
damage	I-C0599732
.	O
	
nucleolar-organizing	B-C0028609
regions	I-C0028609
nors	B-C0028609
are	O
sites	B-C0205145
of	O
the	O
ribosomal	B-C0035899
genes	I-C0035899
located	O
on	O
chromosomes	B-C0008633
and	O
can	O
be	O
stained	B-C0487602
with	O
silver	B-C0037125
when	O
they	O
are	O
active	B-C0205177
.	O
	
thus	O
these	O
proteins	B-C0033684
are	O
named	O
as	O
argyrophilic-nor	B-C1571148
agnor	I-C1571148
proteins	I-C1571148
.	O
	
we	O
aimed	O
to	O
investigate	O
any	O
possible	O
effects	B-C1704420
of	I-C1704420
renal	B-C0022646
i/r	B-C0035126
injury	I-C0035126
on	O
the	O
nor	B-C1571149
protein	I-C1571149
synthesis	B-C0597295
and	O
association	O
between	O
the	O
agnor	B-C1571148
proteins	I-C1571148
amount	B-C1265611
and	O
histopathological	B-C2825141
injuring	I-C2825141
score	I-C2825141
.	O
	
nine	O
female	B-C0086287
wistar-albino	B-C0086893
rats	I-C0086893
with	O
weight	O
of	O
200-250g	O
were	O
included	O
into	O
the	O
study	O
.	O
	
the	O
animals	B-C0003062
were	O
randomly	B-C0439605
divided	B-C0332849
in	O
two	O
groups	B-C0441833
,	O
a	O
control	B-C0009932
group	I-C0009932
and	O
an	O
i/r	B-C0035126
group	B-C0441833
.	O
	
in	O
i/r	B-C0035126
group	B-C0441833
,	O
rats	B-C0086893
were	O
subjected	O
to	O
45	O
minutes	O
of	O
renal	B-C0733948
pedicle	I-C0733948
occlusion	B-C0028778
followed	O
by	O
24	O
hours	O
of	O
reperfusion	B-C0684253
.	O
	
in	O
the	O
control	B-C0009932
group	I-C0009932
no	O
drug	B-C0392877
injections	I-C0392877
or	O
ischemia	B-C0035126
reperfusion	I-C0035126
were	O
performed	B-C0884358
in	O
animals	B-C0003062
.	O
	
then	O
histopathological	B-C2825141
injury	I-C2825141
score	I-C2825141
,	O
mean	B-C0243095
agnor	I-C0243095
number	I-C0243095
and	O
total	B-C0243095
agnor	I-C0243095
area	I-C0243095
/	O
nuclear	B-C0243095
area	I-C0243095
taa	B-C0243095
/	O
na	B-C0243095
were	O
detected	B-C0442726
for	O
each	O
rat	B-C0086893
.	O
	
the	O
differences	O
between	O
control	B-C0009932
and	O
i/r	B-C0035126
groups	B-C0441833
were	O
significant	B-C0750502
for	O
histopathological	B-C2825141
injury	I-C2825141
scores	I-C2825141
p	O
=	O
0.016	O
.	O
	
also	O
the	O
differences	O
between	O
control	B-C0009932
group	I-C0009932
and	O
i/r	B-C0035126
group	B-C0441833
were	O
significant	B-C0750502
for	O
mean	B-C0243095
agnor	I-C0243095
number	I-C0243095
p	O
=	O
0.000	O
and	O
taa/na	B-C0456603
ratio	I-C0456603
p	O
=	O
0.000	O
.	O
	
additionally	O
,	O
there	O
was	O
a	O
positive	B-C1707520
correlation	I-C1707520
between	O
taa/na	B-C0456603
ratio	I-C0456603
and	O
histopathological	B-C2825141
injury	I-C2825141
score	I-C2825141
r	O
=	O
0.728	O
p	O
=	O
0.026	O
and	O
between	O
mean	B-C0243095
agnor	I-C0243095
number	I-C0243095
and	O
histopathological	B-C2825141
injury	I-C2825141
score	I-C2825141
r	O
=	O
0.670	O
p	O
=	O
0.048	O
.	O
	
the	O
detection	B-C1511790
of	O
agnor	B-C1571148
proteins	I-C1571148
amount	B-C1265611
may	O
be	O
used	O
as	O
an	O
indicator	B-C1522602
to	O
obtain	O
information	B-C1533716
about	O
the	O
cellular	B-C0007613
behaviour	I-C0007613
self-protective	B-C0524828
mechanism	O
of	O
tubular	B-C1266872
epithelial	I-C1266872
cells	I-C1266872
against	O
i/r	B-C0035126
injury	I-C0035126
and	O
cellular	B-C0599732
damage	I-C0599732
levels	B-C0441889
when	O
emotion	B-C0013987
and	O
expression	B-C0015457
diverge	O
the	O
social	B-C0814661
costs	I-C0814661
of	O
parkinson's	B-C0030567
disease	I-C0030567
patients	B-C0030705
with	O
parkinson's	B-C0030567
disease	I-C0030567
pd	B-C0030567
are	O
perceived	B-C0030971
more	O
negatively	B-C0205160
than	O
their	O
healthy	B-C3898900
peers	B-C0679739
,	O
yet	O
it	O
remains	O
unclear	O
what	O
factors	B-C1521761
contribute	B-C1880177
to	O
this	O
negative	B-C0205160
social	B-C0037427
perception	I-C0037427
.	O
	
based	O
on	O
a	O
cohort	B-C0599755
of	O
17	O
pd	B-C0030567
patients	B-C0030705
and	O
20	O
healthy	B-C2986479
controls	I-C2986479
,	O
we	O
assessed	B-C1516048
how	O
naïve	O
raters	O
judge	O
the	O
emotion	B-C0013987
and	O
emotional	B-C0849912
intensity	B-C0522510
displayed	B-C0870432
in	O
dynamic	B-C0729333
facial	B-C0015457
expressions	I-C0015457
as	O
adults	B-C0001675
with	O
and	O
without	O
pd	B-C0030567
watched	B-C2371283
emotionally	B-C0013987
evocative	O
films	B-C4019020
experiment	B-C0681814
1	O
,	O
and	O
how	O
age	B-C0001779
-matched	O
peers	B-C0679739
naïve	O
to	O
patients	B-C0030705
'	O
disease	B-C0012634
status	O
judge	O
their	O
social	B-C0037408
desirability	I-C0037408
along	O
various	O
dimensions	B-C0439534
from	O
audiovisual	B-C2936644
stimuli	B-C0234402
interview	B-C0021821
excerpts	I-C0021821
recorded	O
after	O
certain	O
films	B-C4019020
experiment	B-C0681814
2	O
.	O
	
in	O
experiment	B-C0681814
1	O
,	O
participants	B-C0679646
with	O
pd	B-C0030567
were	O
rated	B-C0871208
as	O
significantly	B-C4055637
more	I-C4055637
facially	B-C0015457
expressive	I-C0015457
than	O
healthy	B-C2986479
controls	I-C2986479
moreover	O
,	O
ratings	B-C0871208
demonstrated	O
that	O
pd	B-C0030567
patients	B-C0030705
were	O
routinely	O
mistaken	O
for	O
experiencing	B-C0596545
a	O
negative	B-C0205160
emotion	B-C0013987
,	O
whereas	O
controls	B-C0243148
were	O
rated	B-C0871208
as	O
displaying	B-C0870432
a	O
more	O
positive	B-C1446409
emotion	B-C0013987
than	O
they	O
reported	B-C0700287
feeling	B-C1527305
.	O
	
in	O
experiment	B-C0681814
2	O
,	O
results	B-C0456984
showed	O
that	O
age-peers	B-C0679739
rated	B-C0871208
pd	B-C0030567
patients	B-C0030705
as	O
significantly	B-C4055638
less	I-C4055638
socially	B-C0037408
desirable	I-C0037408
than	O
control	B-C0243148
participants	B-C0679646
.	O
	
specifically	O
,	O
pd	B-C0030567
patients	B-C0030705
were	O
rated	B-C0871208
as	O
less	O
involved	B-C1314939
,	O
interested	B-C0543488
,	O
friendly	B-C2700214
,	O
intelligent	O
,	O
optimistic	B-C0564470
,	O
attentive	O
,	O
and	O
physically	B-C2346874
attractive	I-C2346874
than	O
healthy	B-C2986479
controls	I-C2986479
.	O
	
taken	O
together	O
,	O
our	O
results	B-C0456984
point	O
to	O
a	O
disconnect	O
between	O
how	O
pd	B-C0030567
patients	B-C0030705
report	B-C0700287
feeling	B-C1527305
and	O
attributions	B-C0596130
that	O
others	O
make	O
about	O
their	O
emotions	B-C0013987
and	O
social	B-C0037401
characteristics	I-C0037401
,	O
underlining	O
significant	B-C0750502
social	B-C0699806
challenges	I-C0699806
of	O
the	O
disease	B-C0012634
.	O
	
in	O
particular	O
,	O
changes	B-C0392747
in	O
the	O
ability	B-C0085732
to	O
modulate	B-C0443264
the	O
expression	B-C0015457
of	O
negative	B-C0205160
emotions	B-C0013987
may	O
contribute	B-C1880177
to	O
the	O
negative	B-C0205160
social	B-C0728831
impressions	B-C0596764
that	O
many	O
pd	B-C0030567
patients	B-C0030705
establishing	O
in-	O
hospital	B-C0019994
geriatrics	B-C4041524
services	I-C4041524
in	O
africa	B-C0001737
insights	O
from	O
the	O
university	B-C0019994
of	I-C0019994
benin	I-C0019994
teaching	I-C0019994
hospital	I-C0019994
geriatrics	B-C0017469
project	B-C1709701
unawareness	O
of	O
the	O
peculiar	O
healthcare	B-C0086388
needs	B-C0027552
of	O
the	O
elderly	B-C0001792
and	O
resource	B-C0035201
constraints	B-C0443288
may	O
be	O
some	O
reasons	O
why	O
until	O
recently	O
,	O
nigerian	B-C0028075
hospitals	B-C0019994
have	O
not	O
been	O
equipped	O
with	O
the	O
human	B-C0700103
and	O
infrastructural	B-C0392762
resources	I-C0392762
required	O
to	O
meet	O
older	B-C0001792
adults	I-C0001792
'	O
special	O
healthcare	B-C0086388
needs	B-C0027552
.	O
	
there	O
is	O
paucity	O
of	O
specialized	O
health	B-C0557829
services	I-C0557829
for	O
the	O
elderly	B-C0001792
in	O
africa	B-C0001737
.	O
	
nigeria	B-C0028075
,	O
with	O
a	O
population	B-C1257890
of	O
over	O
170	O
million	O
,	O
did	O
not	O
have	O
any	O
healthcare	B-C0018704
facility	I-C0018704
with	O
dedicated	O
services	B-C1704289
for	O
the	O
elderly	B-C0001792
until	O
2012	O
.	O
	
the	O
university	B-C0019994
of	I-C0019994
benin	I-C0019994
teaching	I-C0019994
hospital	I-C0019994
ubth	B-C0019994
in	O
nigeria	B-C0028075
was	O
established	O
in	O
1973	O
and	O
created	O
its	O
geriatrics	B-C0017469
unit	O
in	O
october	O
2013	O
.	O
	
a	O
prepared	O
environment	O
and	O
trained	B-C0086390
interdisciplinary	I-C0086390
teams	I-C0086390
are	O
pivotal	O
in	O
providing	O
effective	O
healthcare	B-C0557829
services	I-C0557829
for	O
the	O
elderly	B-C0001792
.	O
	
the	O
ongoing	O
ubth	B-C0019994
geriatrics	B-C0017469
project	B-C1709701
aims	O
to	O
provide	O
specialized	O
interdisciplinary	B-C0597720
health	B-C0018747
services	I-C0018747
to	O
older	B-C0001792
adults	I-C0001792
and	O
to	O
provide	O
training	B-C0220931
and	O
continuing	O
professional	B-C0871147
development	I-C0871147
in	O
geriatrics	B-C0017469
for	O
healthcare	B-C0557570
staff	I-C0557570
.	O
	
in	O
developing	O
our	O
inpatient	B-C0021562
services	B-C1704289
,	O
we	O
adopted	O
the	O
acute	B-C0683810
care	I-C0683810
for	I-C0683810
elders	I-C0683810
ace	B-C0683810
model	B-C0596657
and	O
worked	O
in	O
tandem	O
with	O
the	O
"""abcs"""	O
of	O
implementing	O
ace	B-C0596657
units	I-C0596657
.	O
	
in	O
the	O
face	O
of	O
limited	O
resources	B-C0035201
,	O
it	O
was	O
possible	O
to	O
establish	O
a	O
functional	O
geriatrics	B-C0017469
unit	I-C0017469
with	O
a	O
trained	O
interdisciplinary	B-C0086390
team	I-C0086390
.	O
	
family	B-C0015576
participation	B-C0679823
is	O
central	O
in	O
our	O
practice	B-C0086343
.	O
	
since	O
october	O
2013	O
,	O
residents	B-C2347958
and	O
house	B-C0401975
officers	I-C0401975
in	O
internal	B-C0013227
medicine	I-C0013227
have	O
been	O
undertaking	O
4-	O
and	O
12-	O
weekly	B-C0332174
rotations	B-C0035868
,	O
respectively	O
.	O
	
there	O
is	O
also	O
a	O
robust	O
academic	B-C3844065
program	I-C3844065
,	O
which	O
includes	O
once-	O
weekly	B-C0332174
geriatric	B-C1704440
pharmacotherapy	B-C0013216
seminars	B-C2029815
,	O
once-	O
weekly	B-C0332174
interdisciplinary	O
seminars	B-C2029815
,	O
and	O
2-	O
weekly	B-C0332174
journal	B-C0556656
club	I-C0556656
meetings	I-C0556656
alternating	O
with	O
seminars	B-C2029815
on	O
geriatric	B-C2585718
assessment	I-C2585718
tools	I-C2585718
.	O
	
it	O
is	O
possible	O
to	O
establish	O
geriatric	B-C4041524
services	I-C4041524
and	O
achieve	O
best	O
practices	B-C0086343
in	O
resource-limited	O
settings	O
by	O
investing	O
on	O
improving	O
available	O
human	B-C0700103
resources	I-C0700103
and	O
infrastructure	B-C1514880
.	O
	
we	O
also	O
make	O
recommendations	O
for	O
setting	O
up	O
similar	O
services	B-C0557829
in	O
other	O
parts	O
of	O
engaging	B-C2937292
adolescent	B-C0001588
girls	I-C0001588
in	O
transactional	B-C0033595
sex	I-C0033595
through	B-C0332273
compensated	B-C0205432
dating	B-C0237553
transactional	B-C0033595
sex	I-C0033595
through	B-C0332273
so-called	O
compensated	B-C0205432
dating	B-C0237553
in	O
adolescent	B-C0001588
girls	I-C0001588
is	O
a	O
problem	B-C0033213
in	O
need	B-C0027552
of	O
public	B-C0678367
concern	B-C2699424
.	O
	
compensated	B-C0205432
dating	B-C0237553
typically	O
involves	O
the	O
use	B-C1524063
of	I-C1524063
information	B-C0683867
communication	I-C0683867
technology	I-C0683867
to	O
advertise	B-C0001690
,	O
search	B-C1706202
,	O
bargain	B-C0871661
,	O
and	O
eventually	O
arrange	O
for	O
transactional	B-C0033595
sex	I-C0033595
.	O
	
the	O
technology	B-C0683867
enables	B-C1171285
the	O
sexual	B-C0036911
partners	I-C0036911
to	O
maintain	B-C0024501
privacy	B-C0080048
and	O
secrecy	B-C0871315
in	O
transactional	B-C0033595
sex	I-C0033595
.	O
	
such	O
secrecy	B-C0871315
necessitates	B-C0027552
the	O
girls	B-C0043210
'	O
disclosure	B-C0012625
about	O
their	O
life	B-C0023672
experiences	I-C0023672
in	O
order	B-C1705176
to	O
address	O
the	O
concern	B-C2699424
.	O
	
the	O
disclosure	B-C0012625
is	O
the	O
focus	B-C1285542
of	O
the	O
present	O
qualitative	B-C0949415
study	I-C0949415
of	O
27	O
girls	B-C0043210
practicing	B-C0237607
the	O
dating	B-C0237553
in	O
hong	B-C0019907
kong	I-C0019907
,	O
china	B-C0008115
.	O
	
based	B-C1527178
on	O
the	O
disclosure	B-C0012625
,	O
the	O
study	B-C2603343
presents	O
a	O
grounded	B-C1510611
theory	I-C1510611
that	O
epitomizes	O
engagement	B-C2937292
in	O
compensated	B-C0205432
dating	B-C0237553
by	O
referential	B-C0008300
choice	I-C0008300
.	O
	
such	O
a	O
referential	B-C0871935
choice	I-C0871935
theory	I-C0871935
unravels	O
that	O
choice	B-C0008300
with	O
reference	B-C0205543
to	O
the	O
family	B-C0015576
push	B-C0441722
and	O
social	B-C0237750
norms	I-C0237750
sustains	B-C0443318
the	O
engagement	B-C2937292
.	O
	
meanwhile	O
,	O
the	O
choice	B-C0008300
rests	O
on	O
expectancy	B-C0679138
and	O
reinforcement	B-C0442805
from	O
experiential	B-C0243012
learning	I-C0243012
about	O
compensated	B-C0205432
dating	B-C0237553
.	O
	
the	O
theory	B-C0871935
thus	O
implies	O
ways	O
to	O
undercut	O
the	O
engagement	B-C2937292
through	B-C0332273
diverting	B-C0743226
the	O
referential	B-C0008300
choice	I-C0008300
of	O
the	O
numerical	B-C0679083
simulation	I-C0679083
of	O
emitted	B-C0597177
particle	I-C0597177
characteristics	B-C1521970
and	O
airway	B-C0458827
deposition	B-C0333562
distribution	B-C1378698
of	O
symbicort	B-C1735945
turbuhaler	I-C1735945
dry	B-C0032861
powder	I-C0032861
fixed	O
combination	B-C0013162
aerosol	B-C1112870
drug	I-C1112870
one	O
of	O
the	O
most	O
widespread	O
dry	B-C0032861
powder	I-C0032861
fixed	O
combinations	B-C0013162
used	O
in	O
asthma	B-C0004096
and	O
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disease	I-C0024117
copd	B-C0024117
management	B-C0376636
is	O
symbicort	B-C1735945
turbuhaler	I-C1735945
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
simulate	B-C0679083
the	O
deposition	B-C0333562
distribution	B-C1378698
of	O
both	O
components	B-C0184498
of	O
this	O
drug	B-C1254351
within	O
the	O
airways	B-C0458827
based	O
on	O
realistic	O
airflow	B-C0678216
measurements	I-C0678216
.	O
	
breathing	B-C0004048
parameters	B-C0549193
of	O
25	O
healthy	B-C0686750
adults	I-C0686750
11	O
females	B-C0086287
and	O
14	O
males	B-C0086582
were	O
acquired	B-C0439661
while	O
inhaling	B-C0004048
through	O
turbuhaler	B-C1553479
.	O
	
individual	B-C0027361
specific	O
emitted	B-C0178602
doses	I-C0178602
and	O
particle	B-C0030608
size	I-C0030608
distributions	B-C1378698
of	O
symbicort	B-C1735945
turbuhaler	I-C1735945
were	O
determined	B-C0521095
.	O
	
a	O
self-developed	O
particle	B-C0597177
deposition	B-C0333562
model	B-C3161035
was	O
adapted	B-C0205245
and	O
validated	B-C0205245
to	O
simulate	B-C0679083
the	O
deposition	B-C0333562
of	O
budesonide	B-C0054201
inhaled	B-C1629043
corticosteroid	I-C1629043
ics	B-C1629043
and	O
formoterol	B-C0060657
long	B-C2987634
acting	I-C2987634
β2	I-C2987634
agonist	I-C2987634
laba	B-C2987634
in	O
the	O
upper	B-C0225377
airways	I-C0225377
and	O
lungs	B-C0024109
of	O
the	O
healthy	B-C1708335
volunteers	I-C1708335
.	O
	
based	O
on	O
current	B-C0521116
simulations	B-C0679083
the	O
emitted	B-C0178602
doses	I-C0178602
varied	O
between	O
50.4	O
and	O
92.5	O
of	O
the	O
metered	O
dose	B-C0178602
for	O
the	O
ics	B-C1629043
,	O
and	O
between	O
38%	O
and	O
96.1	O
in	O
case	O
of	O
laba	B-C2987634
component	B-C0184498
depending	O
on	O
the	O
individual	B-C0027361
inhalation	B-C0231832
flow	I-C0231832
rate	I-C0231832
.	O
	
this	O
variability	B-C2827666
induced	B-C0205263
a	O
notable	O
inter-	O
individual	B-C0027361
spread	B-C0332261
of	O
the	O
deposited	B-C0333562
lung	B-C0024109
doses	B-C0178602
mean	O
33.6	O
,	O
range	B-C1514721
20.4	O
for	O
budesonide	B-C0054201
and	O
mean	O
29.8	O
,	O
range	B-C1514721
16.4	O
for	O
formoterol	B-C0060657
.	O
	
significant	B-C0750502
inter-gender	B-C0079399
differences	B-C1705242
were	O
also	O
observed	B-C1441672
.	O
	
average	O
lung	B-C0024109
dose	B-C0178602
of	O
budesonide	B-C0054201
was	O
29.2	O
of	O
the	O
metered	O
dose	B-C0178602
for	O
females	B-C0086287
and	O
37%	O
for	O
males	B-C0086582
,	O
while	O
formoterol	B-C0060657
deposited	B-C0333562
with	O
26.4	O
efficiency	B-C0013682
for	O
females	B-C0086287
and	O
32.5	O
for	O
males	B-C0086582
.	O
	
present	O
results	B-C1274040
also	O
highlighted	O
the	O
importance	B-C3898777
of	O
breath-holding	B-C0235744
after	O
inhalation	B-C0004048
of	O
the	O
drug	B-C1254351
.	O
	
about	O
a	O
half	O
of	O
the	O
total	O
lung	B-C0024109
deposition	B-C0333562
occurred	B-C1709305
during	O
breath-hold	B-C0235744
at	O
9.6s	O
average	O
breath-hold	B-C0235744
time	B-C0040223
.	O
	
calculated	O
depositions	B-C0333562
confirmed	B-C0521093
appropriate	B-C1548787
lung	B-C0024109
deposition	B-C0333562
of	O
symbicort	B-C1735945
turbuhaler	I-C1735945
for	O
both	O
genders	B-C0079399
,	O
however	O
more	O
effort	O
for	O
optimal	B-C1998547
inhalation	I-C1998547
technique	I-C1998547
is	O
advised	B-C0034866
for	O
persons	B-C0027361
with	O
low	B-C0476408
vital	I-C0476408
capacity	I-C0476408
.	O
	
this	O
study	B-C2603343
demonstrated	O
the	O
possibility	O
of	O
personalized	B-C1709510
prediction	B-C0681842
of	O
airway	B-C0458827
deposition	B-C0333562
of	O
aerosol	B-C1112870
drugs	I-C1112870
by	O
numerical	B-C0679083
simulations	I-C0679083
.	O
	
the	O
methodology	B-C3266812
developed	O
in	O
this	O
study	B-C2603343
will	O
be	O
applicable	B-C1706839
also	O
to	O
other	O
marketed	B-C3640197
drugs	B-C1254351
in	O
the	O
nutrient	B-C0558027
intake	I-C0558027
of	O
infants	B-C0021270
and	O
toddlers	B-C0682053
in	O
the	O
united	B-C0041698
arab	I-C0041698
emirates	I-C0041698
the	O
feeding	O
infants	B-C0021270
and	O
toddlers	B-C0682053
study	O
this	O
descriptive	O
study	O
evaluated	O
the	O
nutrient	B-C0006777
adequacy	I-C0006777
of	O
the	O
diet	B-C0012155
of	O
infants	B-C0021270
aged	O
6-11	O
months	O
and	O
toddlers	B-C0682053
aged	O
12-24	O
months	O
in	O
the	O
united	B-C0041698
arab	I-C0041698
emirates	I-C0041698
.	O
	
a	O
random	O
sample	O
of	O
1000	O
infants	B-C0021270
and	O
toddlers	B-C0682053
was	O
recruited	O
from	O
2	O
cities	O
al	B-C0041698
ain	I-C0041698
and	O
dubai	B-C0041698
from	O
march	B-C3829202
2011	O
to	O
february	B-C3830166
2012	O
and	O
their	O
usual	O
nutrient	B-C0558027
intake	I-C0558027
was	O
determined	O
using	O
24-hour	O
recall	O
.	O
	
in	O
all	O
,	O
54.2	O
of	O
infants	B-C0021270
and	O
25.2	O
of	O
toddlers	B-C0682053
were	O
breastfeeding	B-C0006147
.	O
	
mean	O
energy	B-C0006777
intake	I-C0006777
of	O
infant	B-C0870604
girls	I-C0870604
in	O
al	B-C0041698
ain	I-C0041698
and	O
dubai	B-C0041698
was	O
747	O
sd	O
189	O
kcal	B-C0439259
and	O
773	O
sd	O
215	O
kcal	B-C0439259
respectively	O
and	O
810.5	O
sd	O
232.2	O
kcal	B-C0439259
and	O
821.9	O
sd	O
262	O
kcal	B-C0439259
for	O
boys	B-C0870221
.	O
	
in	O
toddlers	B-C0682053
,	O
mean	O
energy	B-C0006777
intake	I-C0006777
for	O
girls	B-C0870604
in	O
al	O
ain	O
and	O
dubai	O
was	O
1032.8	O
sd	O
252	O
kcal	B-C0439259
and	O
1013	O
sd	O
339.1	O
kcal	B-C0439259
respectively	O
and	O
1057.2	O
sd	O
201.8	O
kcal	B-C0439259
and	O
1030.3	O
sd	O
341.7	O
kcal	B-C0439259
for	O
boys	B-C0870221
.	O
	
iron	B-C0518043
intake	I-C0518043
was	O
low	B-C0205251
in	O
both	O
groups	O
.	O
	
mean	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
and	O
body	B-C0005910
weight	I-C0005910
and	O
height	B-C0005890
were	O
similar	O
to	O
world	B-C0043237
health	I-C0043237
organization	I-C0043237
figures	O
but	O
significant	O
numbers	O
of	O
infants	B-C0021270
and	O
toddlers	B-C0682053
of	O
both	O
sexes	O
were	O
over	B-C0497406
-	O
or	O
underweight	B-C0041667
.	O
	
although	O
mean	O
energy	O
and	O
macronutrient	B-C2346926
intakes	B-C0558027
were	O
comparable	O
to	O
the	O
rda	B-C0524787
,	O
significant	O
numbers	O
were	O
over	B-C1257763
-	O
or	O
estimation	O
of	O
the	O
hiv-1	B-C0019704
backward	B-C0439784
mutation	B-C3178846
rate	I-C3178846
from	O
transmitted	B-C0013203
drug-resistant	I-C0013203
strains	B-C1518614
one	O
of	O
the	O
serious	O
threats	B-C0749385
facing	O
the	O
administration	O
of	O
antiretroviral	B-C1963724
therapy	I-C1963724
to	O
human	B-C0019704
immunodeficiency	I-C0019704
virus	I-C0019704
hiv-1	B-C0019704
infected	B-C2363741
patients	B-C0030705
is	O
the	O
reported	O
increasing	B-C1512456
prevalence	I-C1512456
of	O
transmitted	B-C0013203
drug	I-C0013203
resistance	I-C0013203
.	O
	
however	O
,	O
given	O
that	O
hiv-1	B-C0019704
drug-resistant	B-C0013203
strains	B-C1518614
are	O
often	O
less	O
fit	O
than	O
the	O
wild-type	B-C1883559
strains	B-C1518614
,	O
it	O
is	O
expected	O
that	O
drug-resistant	B-C0013203
strains	B-C1518614
that	O
are	O
present	O
during	O
the	O
primary	B-C0205225
phase	B-C0205390
of	O
the	O
hiv-1	B-C2363741
infection	I-C2363741
are	O
replaced	B-C0559956
by	O
the	O
fitter	O
wild-type	B-C1883559
strains	B-C1518614
.	O
	
this	O
replacement	B-C0559956
of	O
hiv-1	B-C1836231
resistant	I-C1836231
mutations	B-C0026882
involves	O
the	O
emergence	O
of	O
wild-type	B-C1883559
strains	B-C1518614
by	O
a	O
process	B-C1522240
of	O
backward	B-C0439784
mutation	B-C0026882
.	O
	
how	O
quickly	O
the	O
replacement	B-C0559956
happens	O
is	O
dependent	B-C3244310
on	O
the	O
class	O
of	O
hiv-1	B-C0019704
mutation	B-C0026882
group	B-C0441833
.	O
	
we	O
estimate	O
the	O
backward	B-C0439784
mutation	B-C3178846
rates	I-C3178846
and	O
relative	O
fitness	O
of	O
various	O
mutational	B-C0026882
groups	B-C0441833
known	O
to	O
confer	O
hiv-1	B-C0019704
drug	B-C0013203
resistance	I-C0013203
.	O
	
we	O
do	O
this	O
by	O
fitting	O
a	O
stochastic	B-C0871922
model	I-C0871922
to	O
data	B-C1511726
for	O
individuals	B-C0237401
who	O
were	O
originally	O
infected	B-C0439663
by	O
an	O
hiv-1	B-C0019704
strain	B-C1518614
carrying	O
any	O
one	O
of	O
the	O
known	O
drug	B-C0013203
resistance	I-C0013203
-conferring	O
mutations	B-C0026882
and	O
observed	O
over	O
a	O
period	B-C3259132
of	I-C3259132
time	I-C3259132
to	O
see	O
whether	O
the	O
resistant	B-C0332325
strain	B-C1518614
is	O
replaced	B-C0559956
.	O
	
to	O
do	O
this	O
,	O
we	O
seek	O
a	O
distribution	B-C1704711
,	O
generated	O
from	O
simulations	B-C0679083
of	O
the	O
stochastic	B-C0871922
model	I-C0871922
,	O
that	O
best	O
describes	O
the	O
observed	B-C1441672
clinical	B-C1516606
data	I-C1516606
replacement	B-C0559956
times	B-C1632851
of	O
a	O
given	O
mutation	B-C0026882
.	O
	
we	O
found	O
that	O
lamivudine/emtricitabine	B-C1977395
-associated	O
mutations	B-C0026882
have	O
a	O
distinctly	O
higher	O
,	O
backward	B-C0439784
mutation	B-C3178846
rate	I-C3178846
and	O
low	O
relative	B-C0205345
fitness	B-C1456706
compared	O
to	O
the	O
other	O
classes	B-C0456387
as	O
has	O
been	O
reported	O
before	O
while	O
protease	B-C0033607
inhibitors	I-C0033607
-associated	O
mutations	B-C0026882
have	O
a	O
slower	O
backward	B-C0439784
mutation	B-C3178846
rate	I-C3178846
and	O
high	O
relative	B-C0205345
fitness	B-C1456706
.	O
	
for	O
the	O
other	O
mutation	B-C0026882
classes	B-C0456387
,	O
we	O
found	O
more	O
uncertainty	O
in	O
their	O
modeling	B-C0870071
the	O
hospital	B-C0019994
safety	B-C0036043
partnership	B-C3826012
preferences	B-C0376409
of	I-C0376409
patients	I-C0376409
and	O
their	O
families	B-C0015576
a	O
discrete	B-C0443299
choice	B-C0008300
conjoint	B-C0681814
experiment	I-C0681814
patients	B-C0030705
and	O
their	O
families	B-C0015576
play	O
an	O
important	O
role	B-C1705810
in	O
efforts	O
to	O
improve	B-C2986411
health	B-C0018747
service	I-C0018747
safety	B-C0036043
.	O
	
the	O
objective	B-C0018017
of	O
this	O
study	B-C2603343
is	O
to	O
understand	O
the	O
safety	B-C0036043
partnership	B-C3826012
preferences	B-C0376409
of	I-C0376409
patients	I-C0376409
and	O
their	O
families	B-C0015576
.	O
	
we	O
used	O
a	O
discrete	B-C0443299
choice	B-C0008300
conjoint	B-C0681814
experiment	I-C0681814
to	O
model	O
the	O
safety	B-C0036043
partnership	B-C3826012
preferences	B-C0376409
of	O
1	O
patients	B-C0030705
or	O
those	O
such	O
as	O
parents	B-C0030551
acting	O
on	O
their	O
behalf	O
.	O
	
participants	B-C0679646
made	O
choices	B-C0008300
between	O
hypothetical	O
safety	B-C0036043
partnerships	B-C3826012
composed	O
by	O
experimentally	O
varying	O
15	O
four-level	O
partnership	B-C3826012
design	B-C1707689
attributes	B-C0037401
.	O
	
participants	B-C0679646
preferred	B-C0558295
an	O
approach	B-C0449445
to	O
safety	B-C0036043
based	O
on	O
partnerships	B-C3826012
between	O
patients	B-C0030705
and	O
staff	B-C0025106
rather	O
than	O
a	O
model	O
delegating	O
responsibility	B-C0678341
for	O
safety	B-C0036043
to	O
hospital	B-C0025109
staff	I-C0025109
.	O
	
they	O
valued	O
the	O
opportunity	B-C0814559
to	I-C0814559
participate	I-C0814559
in	O
point	O
of	O
service	O
safety	B-C0036043
partnerships	B-C3826012
,	O
such	O
as	O
identity	O
and	O
medication	B-C1254363
double	I-C1254363
checks	I-C1254363
,	O
that	O
might	O
afford	O
an	O
immediate	B-C0205253
risk	B-C1137094
reduction	I-C1137094
.	O
	
latent	O
class	O
analysis	B-C0936012
yielded	O
two	O
segments	O
.	O
	
actively	B-C0679646
engaged	I-C0679646
participants	I-C0679646
73.3	O
comprised	O
outpatients	B-C0029921
with	O
higher	B-C2584301
education	I-C2584301
,	O
who	O
anticipated	B-C3840775
more	O
benefits	B-C0814225
to	O
safety	B-C0036043
partnerships	B-C3826012
,	O
were	O
more	B-C3840600
confident	I-C3840600
in	O
their	O
ability	B-C0085732
to	O
contribute	B-C1880177
,	O
and	O
were	O
more	O
intent	B-C1283828
on	O
participating	B-C0679823
.	O
	
they	O
were	O
more	O
likely	O
to	O
prefer	B-C0376409
a	O
personal	O
engagement	B-C3508152
strategy	B-C0679199
,	O
valued	O
scientific	B-C3887511
evidence	I-C3887511
,	O
preferred	B-C0558295
a	O
more	O
active	O
approach	B-C0449445
to	O
safety	B-C1272340
education	I-C1272340
,	O
and	O
advocated	O
disclosure	B-C4046003
of	I-C4046003
errors	I-C4046003
.	O
	
the	O
passively	O
engaged	O
segment	O
26.7	O
anticipated	B-C3840775
fewer	B-C0205388
benefits	B-C0814225
,	O
were	O
less	O
confident	B-C0558095
in	O
their	O
ability	B-C0085732
to	O
contribute	B-C1880177
,	O
and	O
were	O
less	O
intent	O
on	O
participating	B-C0679823
.	O
	
they	O
were	O
more	O
likely	O
to	O
prefer	O
an	O
engagement	B-C3508152
strategy	B-C0679199
based	O
on	O
signage	B-C4054026
.	O
	
they	O
preferred	B-C0558295
that	O
staff	B-C0025106
explain	O
why	O
they	O
thought	O
patients	B-C0030705
should	O
help	O
make	O
care	B-C0086388
safer	O
and	O
decide	O
whether	O
errors	B-C0376531
were	O
disclosed	O
.	O
	
inpatients	B-C0021562
,	O
those	O
with	O
immigrant	B-C2242882
backgrounds	I-C2242882
,	O
and	O
those	O
with	O
less	B-C0013658
education	I-C0013658
were	O
more	O
likely	O
to	O
be	O
in	O
this	O
segment	O
.	O
	
health	B-C0018747
services	I-C0018747
need	O
to	O
communicate	O
information	B-C1533716
regarding	O
risks	B-C0035647
,	O
ask	O
about	O
partnership	B-C3826012
preferences	B-C0376409
,	O
create	O
opportunities	B-C0814559
respecting	O
individual	B-C0021228
differences	I-C0021228
,	O
and	O
ensure	O
a	O
positive	B-C1514241
response	I-C1514241
when	O
patients	B-C0030705
raise	O
safety	B-C0036043
concerns	B-C2699424
.	O
	
influence	O
of	O
ozone	B-C0030106
and	O
paracetic	B-C0030968
acid	I-C0030968
disinfection	B-C0012683
on	O
adhesion	B-C0175633
of	I-C0175633
resilient	B-C0440188
liners	I-C0440188
to	O
acrylic	B-C0001222
resin	I-C0001222
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
paracetic	B-C0030968
acid	I-C0030968
paa	B-C0030968
and	O
ozone	B-C0030106
disinfection	B-C0012683
on	O
the	O
tensile	B-C0039526
bond	I-C0039526
strength	I-C0039526
tbs	B-C0039526
of	O
silicone-based	B-C0037114
resilient	B-C0440188
liners	I-C0440188
to	O
acrylic	B-C0001222
resins	I-C0001222
.	O
	
one	O
hundred	O
and	O
twenty	O
dumbbell	B-C0686912
shaped	I-C0686912
heat-polymerized	B-C0314672
acrylic	B-C0001222
resins	I-C0001222
were	O
prepared	O
.	O
	
from	O
the	O
mid	O
segment	O
of	O
the	O
specimens	B-C0370003
,	O
3	O
mm	O
of	O
acrylic	B-C0001222
were	O
grinded	O
off	O
and	O
separated	O
parts	O
were	O
reattached	O
by	O
resilient	B-C0440188
liners	I-C0440188
.	O
	
the	O
specimens	B-C0370003
were	O
divided	O
into	O
2	B-C0370003
control	I-C0370003
control1	B-C0370003
,	O
control7	B-C0370003
and	O
4	O
test	O
groups	O
of	O
paa	B-C0030968
and	O
ozone	B-C0030106
disinfection	B-C0012683
paa1	B-C0030968
,	O
paa7	B-C0030968
,	O
ozone1	B-C0030106
and	O
ozone7	B-C0030106
n=10	O
.	O
	
while	O
control	O
groups	O
were	O
immersed	O
in	O
distilled	B-C0790233
water	I-C0790233
for	O
10	O
min	O
control1	B-C0370003
and	O
7	O
days	O
control7	B-C0370003
,	O
test	O
groups	O
were	O
subjected	O
to	O
paa	B-C0030968
16	O
g/l	O
or	O
ozone	B-C0030106
rich	O
water	B-C0043047
4	O
mg/l	O
for	O
1	O
cycle	O
10	O
min	O
for	O
paa	B-C0030968
and	O
60	O
min	O
for	O
ozone	B-C0030106
per	O
day	O
for	O
7	O
days	O
prior	O
to	O
tensile	B-C0039526
tests	B-C0022885
.	O
	
measurements	O
of	O
the	O
tbs	B-C0039526
were	O
analyzed	O
using	O
3-way	O
anova	B-C0002780
and	O
tukey's	B-C0022885
hsd	I-C0022885
test	I-C0022885
.	O
	
adhesive	B-C0001516
strength	B-C0808080
of	O
mollosil	B-C1436546
decreased	O
significantly	O
by	O
application	O
of	O
ozone	B-C0030106
disinfection	B-C0012683
.	O
	
paa	B-C0030968
disinfection	B-C0012683
had	O
no	O
negative	O
effect	O
on	O
the	O
tbs	B-C0039526
values	O
of	O
mollosil	B-C1436546
and	O
molloplast	B-C0128823
b	I-C0128823
to	O
acrylic	B-C0001222
resin	I-C0001222
.	O
	
single	O
application	O
of	O
ozone	B-C0030106
disinfection	B-C0012683
did	O
not	O
have	O
any	O
negative	O
effect	O
on	O
tbs	B-C0039526
values	O
of	O
molloplast	B-C0128823
b	I-C0128823
,	O
but	O
prolonged	B-C0439590
exposure	B-C0240618
to	I-C0240618
ozone	I-C0240618
decreased	O
its	O
adhesive	B-C0001516
strength	B-C0808080
.	O
	
the	O
adhesion	B-C0175633
of	O
resilient	B-C0440188
liners	I-C0440188
to	O
acrylic	O
was	O
not	O
adversely	O
affected	O
by	O
paa	B-C0030968
disinfection	B-C0012683
.	O
	
immersion	O
in	O
ozonated	B-C3640178
water	B-C0043047
significantly	O
decreased	O
tbs	B-C0039526
of	O
mollosil	B-C1436546
.	O
	
prolonged	O
exposure	O
to	O
ozone	B-C0030106
negatively	O
affects	O
adhesion	B-C0175633
of	O
molloplast	B-C0128823
b	I-C0128823
to	O
denture	B-C3504513
base	I-C3504513
materials	I-C3504513
.	O
	
the	O
construction	B-C1521827
of	O
three-dimensional	B-C0450363
composite	B-C0009570
fibrous	B-C0439709
macrostructures	B-C0678594
with	B-C0449582
nanotextures	I-C0449582
for	O
biomedical	B-C1879848
applications	B-C4048755
the	O
development	O
of	O
modern	O
biomedical	B-C1879848
nanotechnology	B-C0872323
requires	O
three-dimensional	B-C0450363
macrostructures	B-C0678594
with	B-C0449582
nanotextures	I-C0449582
to	O
meet	O
the	O
requirements	O
for	O
practical	O
applications	B-C4048755
in	O
intricate	O
biological	B-C0460002
systems	I-C0460002
.	O
	
additionally	O
,	O
the	O
restoration	B-C0678689
and	O
regeneration	B-C0815081
of	O
some	O
specific	O
body	B-C0040300
tissues	I-C0040300
and	O
organs	B-C0178784
rely	O
on	O
the	O
function	O
of	O
conductive	B-C0032521
polymers	I-C0032521
,	O
which	O
can	O
provide	O
electrical	B-C0442828
cues	B-C0010439
for	O
cells	B-C0007634
.	O
	
in	O
this	O
study	O
,	O
we	O
fabricated	O
three-dimensional	B-C0450363
composite	B-C0009570
nanofibre	B-C1881960
macrostructures	B-C0678594
of	O
polycaprolactone	B-C0137734
pcl	B-C0137734
with	O
different	O
concentrations	B-C1446561
of	O
polyaniline	B-C0962453
pani	B-C0962453
by	O
employing	O
an	O
improved	O
electrospinning	B-C0449851
technology	I-C0449851
with	O
a	O
specially	O
designed	O
collector	O
.	O
	
the	O
3d	B-C0450363
structures	B-C0678594
possessed	O
cap-like	B-C0678594
macrostructures	I-C0678594
with	O
centimetre-scale	B-C0475210
thickness	B-C1280412
and	O
interconnected	O
pore	B-C0449582
nanotextures	I-C0449582
with	O
nanometre-scale	B-C0439202
nanofibres	B-C1881960
.	O
	
to	O
estimate	O
the	O
biocompatibility	B-C0596177
of	O
the	O
3d	B-C0450363
pcl	B-C0137734
/	O
pani	B-C0962453
composite	B-C0009570
nanofibre	B-C1881960
macrostructures	B-C0678594
,	O
mouse	B-C0025929
myoblasts	B-C0596995
c2c12	B-C0596995
cells	I-C0596995
were	O
cultured	O
as	O
model	B-C2986594
cells	B-C0007634
.	O
	
the	O
initial	O
responses	O
of	O
c2c12	B-C0596995
cells	I-C0596995
to	O
the	O
3d	B-C0450363
pcl	B-C0137734
/	O
pani	B-C0962453
composite	B-C0009570
macrostructures	B-C0678594
were	O
significantly	O
superior	O
to	O
those	O
to	O
pure	O
pcl	B-C0137734
,	O
that	O
is	O
,	O
the	O
cells	B-C0007634
exhibited	O
typical	O
myoblast-like	B-C0332437
morphologies	I-C0332437
with	O
obvious	O
pseudopodia	B-C0033827
and	O
the	O
moderate	O
incorporation	O
less	O
than	O
2.0	O
wt%	O
of	O
conductive	O
pani	B-C0962453
facilitated	O
cell	B-C0596290
proliferation	I-C0596290
,	O
which	O
indicated	O
that	O
pani	B-C0962453
has	O
appreciable	O
cell	B-C3714634
affinity	I-C3714634
.	O
	
moreover	O
,	O
the	O
addition	O
of	O
conductive	B-C0205556
pani	B-C0962453
to	O
the	O
3d	B-C0450363
composite	B-C0009570
nanofibre	B-C1881960
macrostructures	B-C0678594
considerably	O
enhanced	O
myoblast	B-C1159966
differentiation	I-C1159966
and	O
myotube	B-C2265916
maturation	I-C2265916
.	O
	
these	O
results	O
suggest	O
that	O
electrospun	B-C0205556
3d	B-C0450363
pcl	B-C0137734
/	O
pani	B-C0962453
composite	B-C0009570
nanofibre	B-C1881960
macrostructures	B-C0678594
would	O
have	O
promising	O
applications	O
in	O
tissue	O
engineering	I-C0596171
mechanisms	B-C0441712
of	O
replacement	B-C0559956
of	O
circulating	B-C0175630
viruses	B-C0042776
by	O
seasonal	B-C4304723
and	O
pandemic	B-C0029347
influenza	I-C0029347
a	I-C0029347
viruses	I-C0029347
seasonal	B-C4304723
influenza	I-C4304723
causes	O
annual	O
epidemics	B-C0014499
by	O
the	O
accumulation	B-C4055506
of	O
antigenic	B-C0003319
changes	I-C0003319
.	O
	
pandemic	B-C4304383
influenza	I-C4304383
occurs	O
through	O
a	O
major	O
antigenic	B-C0003319
change	I-C0003319
of	O
the	O
influenza	B-C0029347
a	I-C0029347
virus	I-C0029347
,	O
which	O
can	O
originate	B-C0439659
from	O
other	O
hosts	B-C1167395
.	O
	
although	O
new	O
antigenic	B-C0003319
variants	I-C0003319
of	O
the	O
influenza	B-C0029347
a	I-C0029347
virus	I-C0029347
replace	O
formerly	O
circulating	B-C0175630
seasonal	B-C0042776
and	O
pandemic	B-C0042776
viruses	I-C0042776
,	O
replacement	B-C0559956
mechanisms	B-C0441712
remain	O
poorly	O
understood	O
.	O
	
a	O
stochastic	B-C0282574
individual-based	I-C0282574
seir	I-C0282574
susceptible-exposed-infectious-recovered	I-C0282574
model	I-C0282574
with	O
two	O
viral	B-C1518614
strains	I-C1518614
formerly	O
circulating	B-C0175630
old	B-C1518614
strain	I-C1518614
and	O
newly	B-C1518614
emerged	I-C1518614
strain	I-C1518614
was	O
developed	O
for	O
simulations	B-C0679083
to	O
elucidate	O
the	O
replacement	B-C0559956
mechanisms	B-C0441712
.	O
	
factors	B-C1521761
and	O
conditions	B-C0348080
of	O
virus	B-C0042776
and	O
host	B-C1167395
populations	O
affecting	O
the	O
replacement	B-C0559956
were	O
identified	O
.	O
	
replacement	O
is	O
more	O
likely	O
to	O
occur	O
in	O
tropical	B-C0017446
regions	I-C0017446
than	O
temperate	B-C0017446
regions	I-C0017446
.	O
	
the	O
magnitude	B-C1704240
of	O
the	O
ongoing	O
epidemic	B-C0014499
by	O
the	O
old	B-C1518614
strain	I-C1518614
,	O
herd	B-C1135927
immunity	I-C1135927
against	O
the	O
old	B-C1518614
strain	I-C1518614
,	O
and	O
timing	B-C0449243
of	O
appearance	B-C0700364
of	O
the	O
new	B-C1518614
strain	I-C1518614
are	O
not	O
that	O
important	O
for	O
replacement	B-C0559956
.	O
	
it	O
is	O
probable	O
that	O
the	O
frequency	O
of	O
replacement	B-C0559956
by	O
a	O
pandemic	B-C0042776
virus	I-C0042776
is	O
higher	O
than	O
a	O
seasonal	B-C0042776
virus	I-C0042776
because	O
of	O
the	O
high	O
initial	O
susceptibility	B-C1264642
and	O
high	O
basic	O
reproductive	B-C0035150
number	O
of	O
the	O
pandemic	B-C0042776
virus	I-C0042776
.	O
	
the	O
findings	O
of	O
this	O
study	O
on	O
replacement	B-C0559956
mechanisms	B-C0441712
could	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
virus	B-C1160716
transmission	I-C1160716
dynamics	B-C3826426
and	O
may	O
possibly	O
be	O
helpful	O
in	O
establishing	O
an	O
effective	B-C1704419
strategy	O
to	O
mitigate	B-C1553901
the	O
impact	O
of	O
seasonal	B-C4304723
and	O
pandemic	B-C4304383
influenza	I-C4304383
.	O
	
request	B-C1272683
and	O
fulfillment	B-C3242069
of	O
postpartum	B-C0086839
tubal	B-C0520483
ligation	I-C0520483
in	O
patients	B-C0030705
after	O
high-risk	B-C0242786
pregnancy	I-C0242786
female	B-C0015787
sterilization	I-C0015787
is	O
one	O
of	O
the	O
most	O
prevalent	O
methods	B-C0025663
of	O
contraception	B-C0700589
in	O
the	O
united	B-C0041703
states	I-C0041703
.	O
	
prior	O
studies	B-C2603343
have	O
shown	O
that	O
nearly	O
half	O
of	O
postpartum	B-C0086839
tubal	B-C0520483
ligation	I-C0520483
pptl	B-C0520483
requests	B-C1272683
go	O
unfulfilled	B-C0205245
.	O
	
this	O
study	B-C2603343
seeks	O
to	O
establish	O
whether	O
obstetric	B-C0205484
or	O
medical	B-C0035647
risk	I-C0035647
status	B-C0449438
influences	O
patients	B-C0030705
'	O
request	B-C1272683
for	O
or	O
subsequent	O
completion	B-C0205197
of	O
pptl	B-C0520483
.	O
	
this	O
study	B-C2603343
was	O
a	O
retrospective	B-C2985505
cohort	I-C2985505
study	I-C2985505
of	O
women	B-C0043210
delivering	B-C0005615
at	O
a	O
university	B-C0020028
hospital	I-C0020028
in	O
2009-2010	O
who	O
received	O
prenatal	B-C0033052
care	I-C0033052
in	O
the	O
faculty	B-C0015535
and	O
resident	B-C0442592
clinics	I-C0442592
.	O
	
high-risk	B-C0332167
status	B-C0449438
was	O
defined	O
by	O
society	B-C2945690
for	I-C2945690
maternal-fetal	I-C2945690
medicine	I-C2945690
guidelines	I-C2945690
.	O
	
documentation	B-C0920316
of	O
contraceptive	B-C0599880
plan	I-C0599880
and	O
administration	B-C1533734
of	O
contraceptive	B-C0700589
methods	I-C0700589
was	O
abstracted	B-C3259344
from	O
patient	B-C0025102
records	I-C0025102
.	O
	
subsequent	O
pregnancies	B-C0032961
through	O
march	O
1	O
,	O
2013	O
,	O
were	O
abstracted	B-C3259344
.	O
	
of	O
3063	O
participants	B-C0679646
2048	O
low	B-C3538919
risk	I-C3538919
and	O
1015	O
high	B-C0332167
risk	I-C0332167
,	O
231	O
requested	B-C1272683
pptl	B-C0520483
7.5	O
.	O
	
this	O
was	O
more	O
likely	O
among	O
high-risk	B-C0332167
patients	B-C0030705
than	O
low-risk	B-C3538919
patients	B-C0030705
10.0	O
vs	O
.	O
	
6.3	O
,	O
p<	O
,	O
those	O
with	O
public	B-C0021672
insurance	I-C0021672
13.8	O
vs	O
.	O
	
3.2	O
,	O
p<	O
and	O
those	O
with	O
an	O
unintended	B-C0041747
index	I-C0041747
pregnancy	I-C0041747
13.8	O
vs	O
.	O
	
4.1	O
,	O
p<	O
.	O
	
of	O
the	O
patients	B-C0030705
requesting	B-C1272683
pptl	B-C0520483
,	O
118	O
51.1	O
underwent	O
the	O
procedure	B-C0087111
immediately	O
postpartum	B-C0086839
.	O
	
completion	B-C0205197
was	O
not	O
associated	O
with	O
high-risk	B-C0332167
status	B-C0449438
54.0	O
,	O
or	O
with	O
race	B-C0034510
,	O
insurance	B-C0376629
status	I-C0376629
or	O
parity	B-C0030563
.	O
	
among	O
113	O
women	B-C0043210
with	O
an	O
unfulfilled	B-C0205245
pptl	B-C0520483
request	B-C1272683
,	O
there	O
were	O
17	O
subsequent	O
pregnancies	B-C0032961
15.0	O
during	O
the	O
27	O
months	B-C0439231
of	O
follow-up	B-C1522577
.	O
	
though	O
women	B-C0043210
with	O
high-risk	B-C0242786
pregnancies	I-C0242786
were	O
more	O
likely	O
to	O
request	B-C1272683
pptl	B-C0520483
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	B-C0205197
the	O
procedure	B-C0087111
.	O
	
over	O
one	O
third	O
of	O
high-risk	B-C0332167
patients	B-C0030705
'	O
requests	B-C1272683
were	O
unfulfilled	B-C0205245
,	O
indicating	O
that	O
significant	O
barriers	O
may	O
remain	O
.	O
	
though	O
women	B-C0043210
with	O
high-risk	B-C0242786
pregnancies	I-C0242786
were	O
more	O
likely	O
to	O
request	B-C1272683
pptl	B-C0520483
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	B-C0205197
the	O
procedure	B-C0087111
.	O
	
providers	O
should	O
consider	O
these	O
procedures	B-C0087111
urgent	B-C0439609
,	O
especially	O
in	O
high-risk	B-C0332167
women	B-C0043210
,	O
and	O
advocate	O
for	O
their	O
patients	B-C0030705
'	O
access	O
to	O
this	O
gut	B-C2985398
microbiota	I-C2985398
after	O
roux-en-y	B-C0585179
gastric	I-C0585179
bypass	I-C0585179
and	O
sleeve	B-C3160799
gastrectomy	I-C3160799
in	O
a	O
diabetic	B-C0011847
rat	B-C0034721
model	B-C0012644
increased	O
diversity	B-C1880371
and	O
associations	O
of	O
discriminant	B-C0205235
genera	B-C1708235
with	O
metabolic	B-C0025519
changes	B-C0392747
recent	O
work	O
with	O
gut	B-C2985398
microbiota	I-C2985398
after	O
bariatric	B-C1456587
surgery	I-C1456587
is	O
limited	O
,	O
and	O
the	O
results	O
have	O
not	O
been	O
in	O
agreement	O
.	O
	
given	O
the	O
role	O
of	O
the	O
gut	B-C2985398
microbiota	I-C2985398
in	O
regulating	O
host	B-C1167395
metabolism	B-C0025519
,	O
we	O
explored	O
the	O
effect	O
of	O
roux-en-y	B-C0585179
gastric	I-C0585179
bypass	I-C0585179
rygb	B-C0585179
and	O
sleeve	B-C3160799
gastrectomy	I-C3160799
sg	B-C3160799
on	O
the	O
modifications	O
of	O
gut	B-C2985398
microbiota	I-C2985398
with	O
regard	O
to	O
the	O
potential	O
influence	O
of	O
food	B-C0016452
intake	B-C1512806
and/or	O
weight	B-C0005910
loss	B-C1517945
and	O
examined	O
their	O
links	O
with	O
host	O
metabolism	O
.	O
	
zucker	O
diabetic	O
fatty	O
rats	O
were	O
divided	O
into	O
the	O
following	O
groups	O
rygb	O
sham-operated	O
with	O
pair-fed	O
as	O
rygb	O
sham-operated	O
fed	O
ad	O
libitum	O
and	O
sg	O
.	O
	
the	O
metabolic	O
effects	O
and	O
gut	O
microbiota	O
profile	O
were	O
analyzed	O
10	O
weeks	O
postoperatively	O
.	O
	
associations	O
between	O
discriminating	O
genera	O
and	O
metabolic	O
markers	O
after	O
rygb	O
were	O
explored	O
.	O
	
the	O
2	O
procedures	O
induced	O
similar	O
glucose	O
improvement	O
and	O
increased	O
flora	O
diversity	O
after	O
10	O
weeks	O
compared	O
with	O
sham-operated	O
groups	O
.	O
	
rygb	O
induced	O
a	O
marked	O
higher	O
relative	O
abundance	O
of	O
proteobacteria	O
/	O
gammaproteobacteria	O
and	O
betaproteobacteria	O
and	O
increased	O
emergence	O
of	O
fusobacteria	O
and	O
clostridium	O
,	O
whereas	O
sg	O
resulted	O
in	O
more	O
abundant	O
actinobacteria	O
compared	O
with	O
other	O
groups	O
.	O
	
most	O
of	O
the	O
12	O
discriminant	O
genera	O
correlated	O
with	O
changes	O
in	O
metabolic	O
phenotype	O
,	O
but	O
only	O
28.6	O
of	O
these	O
correlations	O
were	O
independent	O
of	O
weight	O
,	O
and	O
4	O
discriminant	O
genera	O
still	O
negatively	O
correlated	O
with	O
serum	O
insulin	O
level	O
independent	O
of	O
food	O
intake	O
and	O
weight	O
loss	B-C1517945
after	O
rygb	O
.	O
	
these	O
data	O
demonstrate	O
that	O
rygb	O
and	O
sg	O
surgery	O
produced	O
similar	O
diversity	O
but	O
different	O
microbiota	O
compositions	O
changes	O
in	O
zucker	O
diabetic	O
fatty	O
rats	O
.	O
	
these	O
findings	O
stimulate	O
deeper	O
explorations	O
of	O
functions	O
of	O
the	O
discriminate	O
microbiota	O
and	O
the	O
mechanisms	O
linking	O
postsurgical	O
modulation	O
of	O
gut	O
microbiota	O
and	O
improvements	O
in	O
insulin	O
resistance	I-C0021655
ocular	B-C1262036
toxicity	I-C1262036
of	O
auy922	B-C2348996
in	O
pigmented	B-C0034700
and	O
albino	B-C0684072
rats	I-C0684072
auy922	B-C2348996
,	O
a	O
heat	B-C0243044
shock	I-C0243044
protein	I-C0243044
90	I-C0243044
inhibitor	B-C1999216
is	O
associated	O
with	O
ocular	B-C0015392
adverse	B-C0877248
events	I-C0877248
aes	B-C0877248
.	O
	
to	O
provide	O
a	O
better	O
understanding	O
of	O
ocular	B-C0015392
aes	B-C0877248
in	O
patients	B-C0030705
,	O
4	O
investigative	B-C2603343
studies	I-C2603343
were	O
performed	O
in	O
a	O
step-wise	B-C0449445
approach	I-C0449445
to	O
assess	O
retinal	B-C0035298
structure	I-C0035298
and	O
function	O
in	O
pigmented	B-C0034700
brown	B-C0034700
norway	I-C0034700
and	O
albino	B-C0684072
wistar	I-C0684072
rats	I-C0684072
.	O
	
in	O
rats	O
administered	O
30mg/kg	O
of	O
auy922	O
,	O
the	O
auc	O
0-24	O
h	O
and	O
cmax	O
are	O
comparable	O
to	O
that	O
in	O
patients	O
at	O
70mg/m	O
.	O
	
auy922	O
at	O
30mg/kg	O
was	O
poorly	O
tolerated	O
by	O
rats	O
with	O
morbidity	O
or	O
mortality	O
generally	O
after	O
the	O
third	O
weekly	O
treatment	O
.	O
	
electroretinography	O
erg	O
changes	O
were	O
observed	O
at	O
doses	O
30mg/kg	O
.	O
	
the	O
erg	O
changes	O
were	O
dose	O
dependent	O
,	O
consistent	O
with	O
an	O
effect	O
on	O
the	O
photoreceptors	O
,	O
and	O
fully	O
reversible	O
.	O
	
the	O
erg	O
effects	O
could	O
not	O
be	O
minimized	O
by	O
decreasing	O
the	O
cmax	O
while	O
maintaining	O
auc	O
.	O
	
histopathological	O
changes	O
were	O
seen	O
mainly	O
when	O
rats	O
were	O
administered	O
auy922	O
at	O
100mg/kg	O
.	O
	
the	O
2-	O
hour	O
infusion	O
of	O
auy922	O
at	O
100mg/kg	O
caused	O
disorganization	O
of	O
the	O
outer	O
segment	O
photoreceptor	O
morphology	O
in	O
male	O
brown	O
norway	O
rats	O
the	O
severity	O
of	O
the	O
disorganization	O
increased	O
with	O
the	O
number	O
of	O
administrations	O
,	O
but	O
was	O
reversible	O
during	O
a	O
4-	O
week	O
posttreatment	O
period	O
.	O
	
there	O
was	O
no	O
major	O
difference	O
in	O
ocular	O
response	O
between	O
brown	O
norway	O
and	O
wistar	B-C0034716
rats	B-C0034721
.	O
	
no	O
changes	O
in	O
serum	O
iron	O
levels	O
,	O
and	O
no	O
changes	O
in	O
rhodopsin	O
,	O
pde6α	O
,	O
β-transducin	O
concentrations	O
,	O
or	O
retinal	O
pigment	O
epithelium-specific	O
protein	O
rpe65	O
expression	O
were	O
observed	O
after	O
single	O
and	O
multiple	O
infusions	O
of	O
auy922	O
at	O
100mg/kg	O
compared	O
to	O
vehicle-treated	O
controls	O
.	O
	
auy922	O
retinal	O
toxicity	O
in	O
rats	O
recapitulates	O
and	O
further	O
characterizes	O
that	O
reported	O
in	O
patients	O
and	O
is	O
shown	O
to	O
be	O
reversible	O
,	O
while	O
a	O
precise	O
molecular	O
mechanism	O
for	O
the	O
effect	O
was	O
not	O
assessment	B-C0220825
of	O
cerebral	B-C0006104
blood	B-C0599705
perfusion	I-C0599705
reserve	O
with	O
acetazolamide	B-C0000981
using	O
3d	B-C3891302
spiral	I-C3891302
asl	I-C3891302
mri	I-C3891302
preliminary	O
experience	O
in	O
pediatric	B-C1521725
patients	B-C0030705
to	O
demonstrate	O
the	O
clinical	B-C0015730
feasibility	I-C0015730
of	O
a	O
new	O
non-cartesian	B-C3891302
cylindrically-distributed	I-C3891302
spiral	I-C3891302
3d	I-C3891302
pseudo-continuous	I-C3891302
arterial	I-C3891302
spin	I-C3891302
labeling	I-C3891302
pcasl	I-C3891302
magnetic	I-C3891302
resonance	I-C3891302
imaging	I-C3891302
mri	I-C3891302
pulse	B-C3828438
sequence	I-C3828438
in	O
pediatric	B-C1521725
patients	B-C0030705
in	O
quantifying	B-C1709793
cerebral	B-C0428714
blood	I-C0428714
flow	I-C0428714
cbf	B-C0428714
response	O
to	O
an	O
acetazolamide	B-C0042402
acz	I-C0042402
vasodilator	I-C0042402
challenge	O
.	O
	
mri	B-C0024485
exams	I-C0024485
were	O
performed	O
on	O
two	O
3	B-C3273359
tesla	I-C3273359
philips	I-C3273359
ingenia	I-C3273359
systems	I-C3273359
using	I-C3273359
32	I-C3273359
channel	I-C3273359
head	I-C3273359
coil	I-C3273359
arrays	I-C3273359
.	O
	
after	O
local	O
institutional	B-C2346499
review	I-C2346499
board	I-C2346499
approval	I-C2346499
,	O
the	O
3d	B-C3891302
spiral-based	I-C3891302
pcasl	I-C3891302
technique	I-C3891302
was	O
added	O
to	O
a	O
standard	O
brain	B-C0412675
mri	I-C0412675
exam	I-C0412675
and	O
evaluated	O
in	O
13	O
pediatric	B-C1521725
patients	B-C0030705
average	O
age	O
11.7	O
,	O
range	O
1.4	O
.	O
	
all	O
patients	B-C0030705
were	O
administered	B-C3469597
acz	B-C0000981
for	O
clinically	B-C2985739
indicated	I-C2985739
reasons	O
.	O
	
quantitative	O
whole-brain	B-C0005776
cbf	I-C0005776
measurements	I-C0005776
were	O
computed	O
pre	B-C0332152
-	O
and	O
post	B-C0687676
-	O
acz	B-C0000981
to	O
assess	O
cerebrovascular	B-C0007818
reserve	I-C0007818
.	O
	
3d	B-C3891302
spiral	I-C3891302
pcasl	I-C3891302
data	B-C1511726
were	O
successfully	O
reconstructed	O
in	O
all	O
13	O
cases	B-C0150093
.	O
	
in	O
11	O
patients	B-C0030705
,	O
cbf	B-C0428714
increased	O
2.8	O
to	O
93.2	O
after	O
administration	B-C3469597
of	I-C3469597
acz	B-C0000981
.	O
	
in	O
the	O
two	O
remaining	O
patients	B-C0030705
,	O
cbf	B-C0428714
decreased	O
by	O
2.4	O
to	O
6.0	O
after	O
acz	B-C0000981
.	O
	
the	O
group	O
average	O
change	O
in	O
cbf	B-C0428714
due	O
to	O
acz	B-C0000981
was	O
approximately	O
25.0	O
and	O
individual	O
changes	O
were	O
statistically	B-C0237881
significant	I-C0237881
p<0	O
in	O
all	O
patients	B-C0030705
using	O
a	O
paired	O
t-test	B-C0871472
analysis	I-C0871472
.	O
	
cbf	B-C0428714
perfusion	B-C0599705
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
mr	B-C1636167
angiography	I-C1636167
and	O
clinical	B-C0455712
findings	I-C0455712
.	O
	
3d	B-C3891302
cylindrically-distributed	I-C3891302
spiral	I-C3891302
pcasl	I-C3891302
mri	I-C3891302
provides	O
a	O
robust	O
approach	O
to	O
assess	B-C0184514
cerebral	B-C0428714
blood	I-C0428714
flow	I-C0428714
and	O
reserve	O
in	O
pediatric	B-C1521725
patients	B-C0030705
.	O
	
assessing	B-C0184514
the	O
learning	B-C0023185
potential	B-C3245505
of	O
an	O
interactive	B-C0815244
digital	B-C0870328
game	I-C0870328
versus	O
an	O
interactive-style	B-C0815244
didactic	B-C0205556
lecture	B-C0376683
the	O
continued	O
importance	O
of	O
didactic	B-C0205556
teaching	B-C0039401
in	O
medical	B-C0038495
student	I-C0038495
education	B-C0013621
games	B-C0150593
with	O
educational	B-C0013621
intent	O
offer	O
a	O
possible	B-C0332149
advantage	O
of	O
being	O
more	O
interactive	B-C0815244
and	O
increasing	B-C0205217
learner	B-C1257890
satisfaction	B-C0242428
.	O
	
we	O
conducted	O
a	O
two-armed	B-C0681814
experiment	I-C0681814
to	O
evaluate	B-C0220825
student	B-C0038492
satisfaction	B-C0242428
and	O
content	B-C0456205
mastery	B-C0870851
for	O
an	O
introductory	O
pediatric	B-C1518934
radiology	I-C1518934
topic	B-C1555712
,	O
taught	B-C0348054
by	O
either	O
an	O
interactive	B-C0815244
digital	B-C0870328
game	I-C0870328
or	O
with	O
a	O
traditional	B-C0443324
didactic	B-C0205556
lecture	B-C0376683
.	O
	
medical	B-C0038495
students	I-C0038495
participating	B-C0679823
in	O
a	O
fourth-year	O
radiology	B-C0034599
elective	B-C0439608
were	O
invited	O
to	O
participate	B-C0679823
.	O
	
student	B-C0038492
cohorts	B-C0599755
were	O
alternatively	B-C1523987
given	O
a	O
faculty	B-C0015535
-	O
supervised	B-C0039401
1h	O
session	B-C1883017
playing	B-C0032214
a	O
simple	O
interactive	B-C0815244
digital	B-C1883674
tic-tac-toe	B-C0150593
quiz	B-C1709061
module	I-C1709061
on	O
pediatric	B-C0203054
gastrointestinal	I-C0203054
radiology	I-C0203054
or	O
a	O
1h	O
didactic	B-C0205556
introductory	O
lecture	B-C0376683
on	O
the	O
same	O
topic	B-C1555712
.	O
	
survey	B-C0038951
questions	B-C1522634
assessed	B-C1516048
the	O
learners'	B-C1257890
perceived	B-C0030971
ability	B-C1718058
to	I-C1718058
recall	I-C1718058
the	O
material	B-C0520510
as	O
well	O
as	O
their	O
satisfaction	B-C0242428
with	O
the	O
educational	B-C0013621
experience	B-C0596545
.	O
	
results	O
of	O
an	O
end-of-rotation	B-C1254367
exam	B-C4284036
were	O
reviewed	B-C1709940
to	O
evaluate	B-C0220825
a	O
quantitative	B-C0034384
measure	I-C0034384
of	O
learning	B-C0023185
between	O
groups	B-C0441833
.	O
	
survey	B-C0038951
responses	B-C2911692
were	O
analyzed	B-C0936012
with	O
a	O
chi-squared	B-C0008041
test	I-C0008041
.	O
	
exam	B-C4284036
results	O
for	O
both	O
groups	B-C0441833
were	O
analyzed	B-C0936012
with	O
a	O
paired	O
student's	B-C0871453
t-test	I-C0871453
.	O
	
students	B-C0038492
in	O
the	O
lecture	B-C0376683
group	B-C0441833
had	O
higher	B-C0205250
test	B-C0237855
scores	I-C0237855
compared	B-C1707455
to	O
students	B-C0038492
in	O
the	O
game	B-C0150593
group	B-C0441833
4.0	O
versus	O
3.6	O
,	O
p	O
=	O
0.045	O
.	O
	
students	B-C0038492
in	O
the	O
lecture	B-C0376683
group	B-C0441833
reported	B-C0700287
greater	B-C1704243
understanding	B-C0162340
and	O
recall	B-C0034770
of	O
the	O
material	B-C0520510
than	O
students	B-C0038492
in	O
the	O
game	B-C0150593
group	B-C0441833
p	O
<	O
0.001	O
and	O
p	O
=	O
0.004	O
,	O
respectively	O
.	O
	
students	B-C0038492
in	O
the	O
lecture	B-C0376683
group	B-C0441833
perceived	B-C0030971
the	O
lecture	B-C0376683
to	O
be	O
more	O
enjoyable	B-C3843343
and	O
a	O
better	O
use	O
of	O
their	O
time	B-C0040223
compared	B-C1707455
to	O
those	O
in	O
the	O
game	B-C0150593
group	B-C0441833
p	O
=	O
0.04	O
and	O
p	O
<	O
0.001	O
,	O
respectively	O
.	O
	
there	O
was	O
no	O
statistically	B-C0237881
significant	I-C0237881
difference	B-C3842396
between	O
the	O
lecture	B-C0376683
and	O
game	B-C0150593
group	B-C0441833
in	O
ability	B-C0085732
to	O
maintain	O
interest	B-C0162400
p	O
=	O
0.187	O
.	O
	
in	O
comparison	O
to	O
pre-survey	B-C1254367
results	O
,	O
there	O
was	O
a	O
statistically	B-C0237881
significant	I-C0237881
decrease	B-C0547047
in	O
interest	B-C0162400
for	O
further	O
digital	B-C1883674
interactive	B-C0815244
materials	B-C0520510
reported	B-C0700287
by	O
students	B-C0038492
in	O
the	O
game	B-C0150593
group	B-C0441833
p	O
=	O
0.146	O
.	O
	
our	O
experience	B-C0596545
supported	O
the	O
use	O
of	O
a	O
traditional	B-C0443324
lecture	B-C0376683
over	O
a	O
digital	B-C0870328
game	I-C0870328
module	O
.	O
	
while	O
these	O
results	O
might	O
be	O
affected	B-C0392760
by	O
the	O
specific	B-C0205369
lecture	B-C0376683
and	O
digital	B-C1883674
content	B-C0456205
in	O
any	O
given	O
comparison	B-C1707455
,	O
a	O
digital	B-C1883674
module	B-C1709061
predictors	B-C2698872
of	O
30-	O
day	B-C0439228
mortality	B-C0205848
in	O
patients	B-C0030705
with	O
spontaneous	B-C0205359
primary	B-C0205225
intracerebral	B-C2937358
hemorrhage	I-C2937358
intracerebral	B-C2937358
hemorrhage	I-C2937358
ich	B-C2937358
is	O
a	O
life	B-C2826244
threatening	I-C2826244
entity	O
,	O
and	O
an	O
early	B-C0029909
outcome	I-C0029909
assessment	I-C0029909
is	O
mandatory	O
for	O
optimizing	O
therapeutic	B-C0087111
efforts	I-C0087111
.	O
	
we	O
retrospectively	B-C1514923
analyzed	B-C0936012
data	B-C1511726
from	O
342	O
patients	B-C0030705
with	O
spontaneous	B-C0205359
primary	B-C0205225
ich	B-C2937358
to	O
evaluate	O
possible	O
predictors	B-C2698872
of	O
30-	O
day	B-C0439228
mortality	B-C0205848
considering	O
clinical	B-C0205210
,	O
radiological	B-C0205483
,	O
and	O
therapeutical	B-C0302350
parameters	B-C0549193
.	O
	
we	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome	B-C0282574
grading	I-C0282574
scoring	I-C0282574
systems	I-C0282574
ich	B-C0449820
score	I-C0449820
,	O
func	B-C0449820
score	I-C0449820
and	O
intracerebral	B-C0349674
hemorrhage	I-C0349674
grading	I-C0349674
scale	I-C0349674
ich-gs	B-C0349674
on	O
our	O
population	B-C1257890
to	O
evaluate	O
the	O
correlation	B-C1707520
of	O
these	O
scores	B-C0449820
with	O
the	O
30-	O
day	B-C0439228
mortality	B-C0205848
in	O
our	O
study	B-C2603343
.	O
	
we	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome	B-C0282574
grading	I-C0282574
scoring	I-C0282574
systems	I-C0282574
ich	B-C0449820
score	I-C0449820
,	O
func	B-C0449820
score	I-C0449820
and	O
intracerebral	B-C0349674
hemorrhage	I-C0349674
grading	I-C0349674
scale	I-C0349674
ich-gs	B-C0349674
on	O
our	O
population	B-C1257890
to	O
evaluate	O
the	O
correlation	B-C1707520
of	O
these	O
scores	B-C0449820
with	O
the	O
30-	O
day	B-C0439228
mortality	B-C0205848
in	O
our	O
study	B-C2603343
.	O
	
from	O
342	O
patients	B-C0030705
mean	O
age	B-C0001779
67	O
years	B-C0439234
,	O
mean	O
glasgow	B-C0017594
coma	I-C0017594
scale	I-C0017594
gcs	B-C0017594
on	O
admission	B-C0184666
9	O
,	O
mean	O
ich	B-C2937358
volume	B-C0449468
62.19	O
ml	O
,	O
most	O
common	O
hematoma	B-C0018944
location	B-C1515974
basal	B-C0004781
ganglia	I-C0004781
43.9	O
,	O
102	O
received	O
surgical	B-C0543467
and	O
240	O
conservative	B-C0459914
treatment	I-C0459914
.	O
	
the	O
30-	O
day	B-C0439228
mortality	B-C0205848
was	O
25.15	O
.	O
	
in	O
a	O
multivariate	B-C0026777
analysis	I-C0026777
,	O
gcs	B-C0017594
odds	B-C0028873
ratio	I-C0028873
or	B-C0028873
=0	O
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
=0	O
,	O
p	O
<	O
0.001	O
,	O
bleeding	B-C0019080
volume	B-C0449468
or	B-C0028873
=	O
1.012	O
per	O
ml	O
,	O
95%	O
ci	B-C0009667
=	O
1.007	O
-	O
1.017	O
,	O
p	O
<	O
0.001	O
,	O
and	O
infratentorial	B-C0441939
hematoma	B-C0018944
location	B-C1515974
or	B-C0028873
=	O
5.381	O
,	O
95%	O
ci	B-C0009667
=	O
2.166	O
,	O
p	O
=	O
0.009	O
were	O
significant	O
predictors	B-C2698872
for	O
the	O
30-	O
day	B-C0439228
mortality	B-C0205848
.	O
	
after	O
receiver	B-C0034772
operating	I-C0034772
characteristics	I-C0034772
analysis	B-C0936012
,	O
we	O
defined	O
a	O
""""	O
high-risk	B-C0684030
group	I-C0684030
""""	O
for	O
an	O
unfavorable	O
short-term	B-C0443303
outcome	B-C1274040
with	O
gcs	B-C0017594
<11	O
and	O
ich	B-C2937358
volume	B-C0449468
>32	O
ml	O
supratentorially	B-C0441938
or	O
21	O
ml	O
infratentorially	B-C0441939
.	O
	
using	O
pearson	B-C1709490
correlation	I-C1709490
,	O
we	O
found	O
a	O
correlation	B-C1707520
of	O
0.986	O
between	O
ich	B-C0449820
score	I-C0449820
and	O
30-	O
day	B-C0439228
mortality	B-C0205848
p	O
<	O
0.001	O
,	O
0.853	O
between	O
func	B-C0449820
score	I-C0449820
and	O
30-	O
day	B-C0439228
mortality	B-C0205848
p	O
=	O
0.001	O
,	O
and	O
0.924	O
between	O
ich-gs	B-C0349674
and	O
30-	O
day	B-C0439228
mortality	B-C0205848
p	O
=	O
0.001	O
.	O
	
gcs	B-C0017594
score	B-C0449820
on	O
admission	B-C0184666
together	O
with	O
the	O
baseline	B-C1442488
volume	B-C0449468
and	O
localization	B-C0475264
of	O
the	O
hemorrhage	B-C0019080
are	O
strong	O
predictors	B-C2698872
for	O
30-	O
day	B-C0439228
mortality	B-C0205848
in	O
patients	B-C0030705
with	O
spontaneous	B-C0205359
primary	B-C0205225
intracerebral	B-C2937358
hemorrhage	I-C2937358
,	O
and	O
by	O
relying	O
on	O
them	O
it	O
is	O
possible	O
to	O
identify	O
high-risk	B-C0332167
patients	B-C0030705
with	O
poor	O
short-term	B-C0443303
outcome	B-C1274040
.	O
	
the	O
ich	B-C0449820
score	I-C0449820
and	O
the	O
ich-gs	B-C0349674
accurately	B-C0443131
predict	B-C2698872
the	O
30-	O
day	B-C0439228
mortality	B-C0205848
.	O
	
gga-mir-21	B-C1101610
inhibits	B-C0311403
chicken	B-C0008051
pre-adipocyte	B-C0206131
proliferation	B-C0596290
in	O
part	O
by	O
down-regulating	B-C0013081
kruppel-like	B-C1416661
factor	I-C1416661
5	I-C1416661
gga-mir-21	B-C1101610
is	O
abundantly	O
expressed	B-C0017262
in	O
chicken	B-C0008051
pre-adipocytes	B-C0206131
,	O
but	O
its	O
role	O
is	O
unclear	O
.	O
	
the	O
present	O
study	O
investigated	B-C1292732
the	O
role	O
of	O
gga-mir-21	B-C1101610
in	O
chicken	B-C0008051
pre-adipocyte	B-C0206131
proliferation	B-C0596290
.	O
	
cell	B-C3899698
proliferation	I-C3899698
assay	I-C3899698
and	O
gene	B-C1880945
expression	I-C1880945
analysis	I-C1880945
of	O
proliferating	B-C1366837
cell	I-C1366837
nuclear	I-C1366837
antigen	I-C1366837
pcna	B-C1366837
showed	O
that	O
the	O
gga-mir-21	B-C1101610
mimic	B-C0441655
inhibited	B-C0311403
pre-adipocyte	B-C0206131
proliferation	B-C0596290
.	O
	
in	O
contrast	O
,	O
the	O
gga-mir-21	B-C1101610
inhibitor	B-C1999216
enhanced	B-C2349975
pre-adipocyte	B-C0206131
proliferation	B-C0596290
.	O
	
the	O
subsequent	O
investigation	B-C1292732
identified	O
kruppel-like	B-C1416661
factor	I-C1416661
5	I-C1416661
klf5	B-C1416661
mrna	B-C0035696
as	O
a	O
target	B-C1521840
of	O
gga-mir-21	B-C1101610
.	O
	
the	O
gga-mir-21	B-C1101610
mimic	B-C0441655
inhibited	B-C0311403
klf5	B-C1416661
3	B-C0600600
reporter	B-C0206414
activity	B-C0441655
and	O
decreased	B-C0205216
endogenous	B-C0205227
klf5	B-C1416661
expression	B-C0017262
in	O
primary	B-C0205225
pre-adipocytes	B-C0206131
.	O
	
klf5	B-C1416661
knockdown	B-C2350567
using	O
rnai	B-C1136031
had	O
a	O
similar	O
effect	B-C1280500
to	O
that	O
of	O
the	O
gga-mir-21	B-C1101610
mimic	B-C0441655
on	O
cell	B-C0596290
proliferation	I-C0596290
.	O
	
the	O
promoting	B-C0033414
effect	B-C1280500
of	O
the	O
gga-mir-21	B-C1101610
inhibitor	B-C1999216
on	O
pre-adipocyte	B-C0206131
proliferation	B-C0596290
was	O
partially	O
attenuated	B-C0332161
by	O
klf5	B-C1416661
knockdown	B-C2350567
.	O
	
taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
mir-21	B-C1101610
inhibits	O
chicken	B-C0008051
pre-adipocyte	B-C0206131
proliferation	B-C0596290
,	O
at	O
least	O
in	O
part	O
,	O
by	O
targeting	B-C0242613
klf5	B-C1416661
.	O
	
the	O
application	B-C4048755
of	O
heterogeneous	B-C1704332
cluster	I-C1704332
grouping	I-C1704332
to	O
reflective	B-C0043266
writing	I-C0043266
for	O
medical	B-C0020157
humanities	I-C0020157
literature	B-C2603343
study	I-C2603343
to	O
enhance	B-C2349975
students'	B-C0038492
empathy	B-C0013989
,	O
critical	B-C4279941
thinking	I-C4279941
,	O
and	O
reflective	B-C0043266
writing	I-C0043266
to	O
facilitate	O
interdisciplinary	B-C0597720
collaboration	I-C0597720
and	O
to	O
make	O
connections	B-C0449379
between	O
patients'	B-C0030705
diseases	B-C0012634
and	O
their	O
social	B-C0728831
/	O
cultural	B-C0220814
contexts	I-C0220814
,	O
the	O
study	B-C2603343
examined	B-C0332128
whether	O
the	O
use	O
of	O
heterogeneous	B-C1704332
cluster	I-C1704332
grouping	I-C1704332
in	O
reflective	B-C0043266
writing	I-C0043266
for	O
medical	B-C0020157
humanities	I-C0020157
literature	O
acquisition	B-C1706701
could	O
have	O
positive	B-C1280500
effects	I-C1280500
on	O
medical	B-C0000872
university	I-C0000872
students	B-C0038492
in	O
terms	O
of	O
empathy	B-C0013989
,	O
critical	B-C4279941
thinking	I-C4279941
,	O
and	O
reflective	B-C0043266
writing	I-C0043266
.	O
	
a	O
15-week	B-C0439230
quasi-experimental	B-C0815255
design	I-C0815255
was	O
conducted	O
to	O
investigate	B-C1292732
the	O
learning	B-C1274040
outcomes	I-C1274040
.	O
	
after	O
conducting	O
cluster	B-C0002045
algorithms	I-C0002045
,	O
heterogeneous	B-C1704332
learning	I-C1704332
clusters	I-C1704332
experimental	B-C0681860
group	I-C0681860
n	O
=	O
43	O
and	O
non-heterogeneous	B-C1704332
learning	I-C1704332
clusters	I-C1704332
control	B-C0009932
group	I-C0009932
n	O
=	O
43	O
were	O
derived	O
for	O
a	O
medical	B-C0020157
humanities	I-C0020157
literature	B-C2603343
study	I-C2603343
.	O
	
before	O
and	O
after	O
the	O
intervention	B-C0184661
,	O
an	O
empathy	B-C0349674
scale	I-C0349674
in	O
patient	B-C0017313
care	I-C0017313
es	B-C0349674
-	O
pc	B-C0017313
,	O
a	O
critical	B-C0220825
thinking	I-C0220825
disposition	I-C0220825
assessment	I-C0220825
ctda-r	B-C0220825
,	O
and	O
a	O
reflective	B-C1254363
writing	I-C1254363
test	I-C1254363
were	O
administered	B-C1521801
to	O
both	O
groups	B-C0441833
.	O
	
the	O
findings	O
showed	O
that	O
on	O
the	O
empathy	B-C0349674
scale	I-C0349674
,	O
significant	O
differences	O
in	O
the	O
""""	O
behavioral	B-C0013989
empathy	I-C0013989
""""	O
""""	O
affective	B-C0013989
empathy	I-C0013989
""""	O
and	O
overall	O
sections	O
existed	O
between	O
the	O
post-test	B-C3533236
mean	I-C3533236
scores	I-C3533236
of	O
the	O
experimental	B-C0681860
group	I-C0681860
and	O
those	O
of	O
the	O
control	B-C0009932
group	I-C0009932
,	O
but	O
such	O
differences	O
did	O
not	O
exist	O
in	O
""""	O
intelligent	B-C0013989
empathy	I-C0013989
""""	O
regarding	O
critical	B-C4279941
thinking	I-C4279941
,	O
there	O
were	O
significant	O
differences	O
in	O
""""	O
systematicity	B-C0220922
and	O
analyticity	B-C0936012
""""	O
""""	O
skepticism	B-C1510638
and	O
well-informed	B-C1254363
""""	O
""""	O
maturity	B-C0449989
and	O
skepticism	B-C1510638
""""	O
and	O
overall	O
sections	O
.	O
	
as	O
for	O
reflective	B-C0043266
writing	I-C0043266
,	O
significant	O
differences	O
existed	O
in	O
""""	O
ideas	B-C1254370
""""	O
""""	O
voice	B-C0042939
and	O
point	B-C1254370
of	I-C1254370
view	I-C1254370
""""	O
""""	O
critical	B-C4279941
thinking	I-C4279941
and	O
representation	B-C1882932
""""	O
""""	O
depth	B-C0025361
of	I-C0025361
reflection	I-C0025361
on	O
personal	B-C0871850
growth	I-C0871850
""""	O
and	O
overall	O
sections	O
,	O
but	O
not	O
in	O
""""	O
focus	B-C1285542
and	O
context	B-C0449255
structure	I-C0449255
""""	O
and	O
""""	O
language	B-C0023008
and	O
conventions	B-C0086047
""""	O
this	O
study	B-C2603343
outlined	O
an	O
alternative	O
for	O
using	O
heterogeneous	B-C1704332
cluster	I-C1704332
grouping	I-C1704332
in	O
reflective	B-C0043266
writing	I-C0043266
about	O
medical	B-C0020157
humanities	I-C0020157
literature	O
to	O
facilitate	O
interdisciplinary	B-C0392337
cooperation	I-C0392337
to	O
provide	O
more	O
humanizing	O
medical	B-C0496675
care	I-C0496675
.	O
	
the	O
usefulness	O
of	O
employing	B-C0557351
an	O
electronic	B-C0183817
traction	I-C0183817
table	I-C0183817
to	O
determine	O
flexibility	B-C0242808
in	O
adolescent	B-C0410702
idiopathic	I-C0410702
scoliosis	I-C0410702
the	O
aim	O
of	O
the	O
study	B-C2603343
was	O
to	O
develop	B-C1527148
new	O
equipment	B-C0014672
for	O
the	O
assessment	B-C0220825
of	O
the	O
flexibility	B-C0242808
of	O
the	O
spine	B-C0037949
with	O
different	O
forces	B-C0441722
.	O
	
this	O
new	O
system	B-C0449913
should	O
provide	O
a	O
different	O
perspective	O
to	O
adolescent	B-C0410702
idiopathic	I-C0410702
scoliosis	I-C0410702
ais	B-C0410702
for	O
the	O
selection	B-C1707391
of	O
fusion	B-C0441889
levels	I-C0441889
and	O
surgical	B-C0543467
success	B-C0679864
.	O
	
eighteen	O
patients	B-C0030705
suffering	O
from	O
ais	B-C0410702
who	O
were	O
scheduled	O
to	O
undergo	O
posterior	B-C0205095
instrumented	B-C0919636
spinal	I-C0919636
fusion	I-C0919636
in	O
our	O
clinic	B-C0442592
were	O
recruited	O
in	O
this	O
study	B-C2603343
.	O
	
the	O
electronic	B-C0183817
traction	I-C0183817
table	I-C0183817
ett	B-C0183817
that	O
was	O
designed	O
in	O
our	O
clinic	B-C0442592
was	O
used	O
to	O
evaluate	O
the	O
radiogical	B-C0549193
and	O
clinical	B-C0205210
parameters	B-C0549193
of	O
the	O
spine	B-C0037949
.	O
	
the	O
significant	O
prescriptive	B-C0205556
angle	I-C0205556
of	O
major	O
cobb	B-C0563192
angles	I-C0563192
between	O
postoperative	B-C0205556
angles	I-C0205556
were	O
longitudinal	B-C0205127
traction	B-C0040597
and	O
lateral	B-C0563192
pushing	I-C0563192
cobb	I-C0563192
angles	I-C0563192
.	O
	
longitudinal	B-C0205127
traction	B-C0040597
and	O
lateral	B-C0563192
pushing	I-C0563192
angles	I-C0563192
were	O
more	O
correlated	O
with	O
correction	B-C0456603
ratios	I-C0456603
.	O
	
there	O
was	O
a	O
significant	B-C0750502
difference	O
between	O
longitudinal	B-C0205127
traction	B-C0040597
minor	O
cobb	B-C0563192
angle	I-C0563192
,	O
longitudinal	B-C0205127
traction	B-C0040597
lateral	B-C0563192
pushing	I-C0563192
minor	I-C0563192
cobb	I-C0563192
angle	I-C0563192
and	O
postoperative	B-C0563192
minor	I-C0563192
cobb	I-C0563192
angles	I-C0563192
.	O
	
the	O
deformity	B-C0302142
is	O
needed	O
to	O
balance	O
both	O
tractional	B-C0040597
and	O
rotational	B-C0035868
forces	O
and	O
useful	O
technique	O
to	O
evaluate	O
curve	O
flexibility	O
before	O
the	O
operation	O
.	O
	
electronic	O
traction	O
table	O
is	O
a	O
new	O
device	O
for	O
determining	O
preoperative	O
flexibility	O
with	O
longitudinal	O
traction	O
and	O
lateral	O
pushing	O
radiographs	O
.	O
	
it	O
can	O
be	O
useful	O
for	O
choosing	O
selective	O
fusion	O
levels	O
at	O
the	O
proximal	O
and	O
distal	O
end	O
of	O
the	O
vertebral	O
column	I-C0037949
the	O
messaging	B-C1254363
for	I-C1254363
diabetes	I-C1254363
intervention	B-C0184661
reduced	O
barriers	B-C0679881
to	O
medication	B-C2364172
adherence	I-C2364172
among	O
low-income	B-C1331016
,	O
diverse	O
adults	B-C0001675
with	O
type	B-C0011860
2	I-C0011860
nonadherence	B-C0746935
to	O
diabetes	B-C0011847
medication	B-C2081612
is	O
prevalent	O
and	O
costly	O
.	O
	
messaging	B-C1254363
for	I-C1254363
diabetes	I-C1254363
med	B-C1254363
,	O
a	O
mobile	B-C2718080
health	I-C2718080
mhealth	B-C2718080
intervention	B-C0184661
,	O
identified	O
and	O
addressed	O
user	B-C1706077
-specific	O
barriers	B-C0679881
to	O
medication	B-C2364172
adherence	I-C2364172
.	O
	
we	O
assessed	O
whether	O
med	B-C1254363
reduced	O
users	B-C1706077
'	O
targeted	O
barriers	B-C0679881
and	O
if	O
barrier	B-C0679881
reductions	O
were	O
associated	O
with	O
within-participant	B-C0679646
improvements	O
in	O
adherence	B-C1510802
or	O
glycemic	B-C0205556
control	I-C0205556
hba1c	B-C0019018
.	O
	
adults	B-C0001675
n	O
=	O
80	O
with	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
completed	O
self-report	O
measures	O
identifying	O
barriers	B-C0679881
to	O
adherence	B-C1510802
at	O
baseline	O
and	O
monthly	B-C0332177
for	O
3	O
months	B-C0439231
.	O
	
at	O
each	O
assessment	B-C0220825
,	O
17	O
barriers	B-C0679881
were	O
assessed	O
and	O
ranked	O
for	O
each	O
user	B-C1706077
.	O
	
each	O
subsequent	O
month	B-C0439231
,	O
users	B-C1706077
received	O
daily	O
text	B-C3178910
messages	I-C3178910
addressing	O
their	O
3	O
highest	O
ranked	O
barriers	B-C0679881
.	O
	
targeted	O
barriers	B-C0679881
were	O
different	O
for	O
each	O
participant	B-C0679646
and	O
could	O
change	O
monthly	B-C0332177
.	O
	
paired	O
t-tests	B-C0871472
assessed	O
within-participant	B-C0679646
improvement	O
in	O
targeted	O
barriers	B-C0679881
each	O
month	B-C0439231
,	O
and	O
nested	O
regression	B-C3161035
models	I-C3161035
assessed	O
if	O
changes	O
in	O
a	O
participant's	B-C0679646
barrier	O
scores	O
were	O
associated	O
with	O
improvements	O
in	O
adherence	B-C1510802
and	O
hba1c	B-C0019018
.	O
	
participants	B-C0679646
were	O
69%	O
non-white	O
and	O
82%	O
had	O
incomes	O
<	O
.	O
	
average	O
hba1c	B-C0019018
was	O
8.2	O
2.0	O
.	O
	
assessment	O
completion	O
rates	O
were	O
100%	O
at	O
baseline	O
,	O
59%	O
at	O
1	O
month	B-C0439231
,	O
30%	O
at	O
2	O
months	B-C0439231
,	O
and	O
65%	O
at	O
3	O
months	B-C0439231
.	O
	
the	O
most	O
commonly	O
reported	O
barriers	B-C0679881
were	O
the	O
cost	B-C0010186
of	O
medications	B-C2081612
76%	O
,	O
believing	O
medications	B-C2081612
are	O
harmful	O
58%	O
,	O
and	O
lacking	O
information	O
about	O
medications	B-C2081612
53%	O
.	O
	
participants	B-C0679646
'	O
barrier	B-C0679881
scores	O
improved	O
each	O
month	B-C0439231
and	O
barrier	B-C0679881
improvement	O
predicted	O
adherence	B-C1510802
assessed	O
via	O
nightly	O
adherence	B-C1510802
assessment	O
text	B-C3178910
messages	I-C3178910
p	O
<	O
001	O
.	O
	
among	O
participants	B-C0679646
who	O
completed	O
assessments	O
each	O
month	B-C0439231
,	O
barrier	B-C0679881
improvement	O
in	O
months	B-C0439231
2	O
and	O
3	O
p	O
<	O
05	O
predicted	O
hba1c	B-C0019018
improvement	O
.	O
	
iterative	O
,	O
individual	O
tailoring	O
may	O
overcome	O
users	B-C1706077
'	O
barriers	B-C0679881
to	O
adherence	B-C1510802
.	O
	
attrition	O
is	O
a	O
challenge	O
for	O
mhealth	B-C2718080
interventions	B-C0184661
among	O
low-income	B-C1331016
patients	B-C0030705
.	O
	
macular	B-C0332574
ganglion	B-C0228071
cell	I-C0228071
-	O
inner	B-C1512785
plexiform	I-C1512785
layer	I-C1512785
thickness	B-C1280412
is	O
associated	B-C0332281
with	I-C0332281
clinical	B-C0242656
progression	I-C0242656
in	O
mild	B-C1719378
cognitive	I-C1719378
impairment	I-C1719378
and	O
alzheimers	B-C0002395
disease	I-C0002395
we	O
investigated	O
the	O
association	O
of	O
the	O
macular	B-C0332574
ganglion	B-C0228071
cell	I-C0228071
-	O
inner	B-C1512785
plexiform	I-C1512785
layer	I-C1512785
gcipl	B-C1512785
and	O
peripapillary	B-C1517753
retinal	I-C1517753
nerve	I-C1517753
fiber	I-C1517753
layer	I-C1517753
rnfl	B-C1517753
thicknesses	B-C1280412
with	O
disease	B-C0242656
progression	I-C0242656
in	O
mild	B-C1719378
cognitive	I-C1719378
impairment	I-C1719378
mci	B-C1719378
and	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
.	O
	
we	O
recruited	O
42	O
patients	B-C0030705
with	O
ad	B-C0002395
,	O
26	O
with	O
mci	B-C1719378
,	O
and	O
66	O
normal	O
elderly	B-C0009932
controls	I-C0009932
.	O
	
the	O
thicknesses	B-C1280412
of	O
the	O
rnfl	B-C1517753
and	O
gcipl	B-C1512785
were	O
measured	O
via	O
spectral-domain	B-C3876157
optic	I-C3876157
coherent	I-C3876157
tomography	I-C3876157
in	O
all	O
participants	B-C0679646
at	O
baseline	B-C1442488
.	O
	
the	O
patients	B-C0030705
with	O
mci	B-C1719378
or	O
ad	B-C0002395
underwent	O
clinical	B-C0205210
and	O
neuropsychological	B-C0027902
tests	I-C0027902
at	O
baseline	B-C1442488
and	O
once	B-C1254367
every	I-C1254367
year	I-C1254367
thereafter	I-C1254367
for	I-C1254367
2	I-C1254367
years	I-C1254367
.	O
	
the	O
clinical	B-C3827230
dementia	I-C3827230
rating	I-C3827230
scale-sum	I-C3827230
of	I-C3827230
boxes	I-C3827230
cdr-sb	B-C3827230
score	B-C0449820
exhibited	O
significant	O
negative	B-C0205160
relationships	B-C0439849
with	O
the	O
average	B-C1512785
gcipl	I-C1512785
thickness	B-C1280412
β	O
=	O
-0	O
,	O
p	O
<	O
0.05	O
and	O
the	O
gcipl	B-C1512785
thickness	B-C1280412
in	O
the	O
superotemporal	B-C1275875
,	O
superonasal	B-C1275872
,	O
and	O
inferonasal	B-C1275873
sectors	I-C1275873
.	O
	
the	O
composite	B-C0449820
memory	I-C0449820
score	I-C0449820
exhibited	O
significant	O
positive	B-C1446409
associations	B-C0439849
with	O
the	O
average	B-C1512785
gcipl	I-C1512785
thickness	B-C1280412
and	O
the	O
gcipl	B-C1512785
thickness	B-C1280412
in	O
the	O
superotemporal	B-C1275875
,	O
inferonasal	B-C1275873
,	O
and	O
inferotemporal	B-C1275868
sectors	I-C1275868
.	O
	
the	O
temporal	B-C1517753
rnfl	I-C1517753
thickness	B-C1280412
,	O
the	O
average	O
and	O
minimum	O
gcipl	B-C1512785
thicknesses	B-C1280412
,	O
and	O
the	O
gcipl	B-C1512785
thickness	B-C1280412
in	O
the	O
inferonasal	B-C1275873
,	O
inferior	B-C0005898
,	O
and	O
inferotemporal	B-C1275868
sectors	I-C1275868
at	O
baseline	B-C1442488
were	O
significantly	O
reduced	B-C0392756
in	O
mci	B-C1719378
patients	B-C0030705
who	O
were	O
converted	O
to	O
ad	B-C0002395
compared	O
to	O
stable	O
mci	B-C1719378
patients	B-C0030705
.	O
	
the	O
change	O
of	O
cdr-sb	B-C3827230
from	O
baseline	B-C1442488
to	O
2	O
years	B-C0439234
exhibited	O
significant	O
negative	B-C0205160
associations	B-C0439849
with	O
the	O
average	O
β	O
=	O
-0	O
,	O
p	O
=	O
0.006	O
and	O
minimum	B-C1512785
gcipl	I-C1512785
thicknesses	B-C1280412
as	O
well	O
as	O
gcipl	B-C1512785
thickness	B-C1280412
in	O
the	O
superotemporal	B-C1275875
,	O
superior	B-C0005898
,	O
superonasal	B-C1275872
,	O
and	O
inferonasal	B-C1275873
sectors	I-C1275873
at	O
baseline	B-C1442488
.	O
	
our	O
data	O
suggest	O
that	O
macular	O
gcipl	B-C1512785
thickness	B-C1280412
represents	O
a	O
promising	O
biomarker	B-C0005516
for	O
monitoring	O
the	O
progression	B-C0242656
of	O
mci	B-C1719378
and	O
green	B-C2350565
and	O
rapid	B-C0456962
synthesis	B-C1883254
of	O
silver	B-C0037125
nanoparticles	B-C1721060
using	O
borago	B-C0522465
officinalis	I-C0522465
leaf	B-C0242724
extract	B-C0032081
anticancer	B-C0243095
and	O
antibacterial	B-C0243095
activities	I-C0243095
this	O
study	O
highlights	O
the	O
facile	O
,	O
reliable	O
,	O
cost	B-C0010186
effective	B-C1704419
,	O
and	O
ecofriendly	B-C2350565
synthesis	B-C1883254
of	O
silver	B-C0037125
nanoparticles	B-C1721060
agnps	B-C1721060
using	O
borago	B-C0522465
officinalis	I-C0522465
leaves	B-C0242724
extract	B-C0032081
efficiently	B-C0442799
.	O
	
the	O
biosynthesis	B-C1883254
of	O
agnps	B-C1721060
was	O
verified	B-C1547321
by	O
uv-vis	B-C1883416
spectrum	I-C1883416
which	O
showed	O
the	O
surface	B-C0597731
plasmon	I-C0597731
resonance	I-C0597731
spr	B-C0597731
band	O
at	O
422	O
nm	O
.	O
	
transmission	B-C0678118
electron	I-C0678118
microscope	I-C0678118
tem	I-C0678118
analysis	I-C0678118
revealed	O
that	O
the	O
particles	B-C1721060
were	O
spherical	B-C0332501
,	O
hexagonal	B-C1708361
,	O
and	O
irregular	B-C0205271
in	O
shape	B-C0332479
and	O
had	O
size	B-C0030608
ranging	B-C1514721
from	O
30	O
to	O
80	O
nm	O
.	O
	
the	O
energy	B-C2699997
dispersive	I-C2699997
x-ray	I-C2699997
spectroscopy	I-C2699997
edx	B-C2699997
and	O
elemental	B-C0022885
mapping	I-C0022885
have	O
displayed	O
the	O
purity	B-C1882508
and	O
maximum	B-C0806909
distribution	B-C1704711
of	O
silver	B-C0037125
in	O
the	O
agnps	B-C0037125
.	O
	
the	O
crystalline	B-C0444626
nature	O
of	O
agnps	B-C0037125
had	O
been	O
identified	B-C0205396
using	O
x-ray	B-C0043301
diffraction	I-C0043301
xrd	B-C0043301
and	O
selected	B-C0022885
area	I-C0022885
diffraction	I-C0022885
pattern	I-C0022885
saed	O
.	O
	
the	O
particle	B-C0030608
size	I-C0030608
analysis	B-C1524024
revealed	O
that	O
the	O
z-average	B-C1510992
diameter	B-C1301886
of	O
the	O
agnps	B-C0037125
was	O
50.86	O
nm	O
with	O
polydispersity	B-C1882415
index	I-C1882415
pdi	B-C1882415
0.136	O
.	O
	
zeta	B-C0597697
potential	I-C0597697
analysis	B-C1524024
displayed	O
the	O
colloidal	B-C0205556
stability	I-C0205556
of	O
agnps	B-C0037125
.	O
	
this	O
work	O
also	O
showed	O
the	O
efficacy	B-C1280519
of	O
agnps	B-C1721060
against	O
lung	B-C0024109
cancer	B-C0085983
cell	I-C0085983
lines	I-C0085983
a549	B-C4277577
and	O
cervical	B-C0007874
cancer	B-C0085983
cell	I-C0085983
line	I-C0085983
hela	B-C0018873
,	O
in	B-C1533691
vitro	I-C1533691
.	O
	
the	O
agnps	B-C1721060
showed	O
cytotoxicity	B-C0596402
to	O
the	O
a549	B-C4277577
and	O
hela	B-C0018873
cancer	B-C0085983
cell	I-C0085983
line	I-C0085983
at	O
the	O
concentrations	B-C1446561
5	O
and	O
2	O
μg/ml	O
.	O
	
the	O
agnps	B-C0037125
were	O
also	O
explored	O
for	O
the	O
antibacterial	B-C0243095
activity	I-C0243095
including	O
biofilm	B-C0081786
inhibition	B-C3463820
against	O
pathogenic	B-C3816499
bacteria	B-C0004611
.	O
	
the	O
b	B-C0522465
.	O
	
officinalis	I-C0522465
leaves	B-C0242724
extract	B-C0032081
can	O
be	O
used	O
efficiently	B-C0442799
for	O
green	O
synthesis	B-C1883254
agnps	B-C0037125
.	O
	
the	O
biosynthesized	O
agnps	B-C0037125
demonstrated	O
potentials	B-C3245505
as	O
anticancer	B-C0003392
and	O
antibacterial	B-C0279516
agents	I-C0279516
.	O
	
this	O
work	O
provides	O
helpful	O
insight	O
into	O
the	O
development	B-C1527148
of	O
new	O
anticancer	B-C0003392
and	O
antimicrobial	B-C1136254
agents	I-C1136254
.	O
	
genotyping	B-C3178894
of	O
staphylococcus	B-C0038172
aureus	I-C0038172
in	O
bovine	B-C0024895
mastitis	I-C0024895
and	O
correlation	O
to	O
phenotypic	B-C0031437
characteristics	B-C1521970
reducing	O
the	O
prevalence	O
of	O
mastitis	B-C0024895
caused	O
by	O
staphylococcus	B-C0038172
aureus	I-C0038172
s	B-C0038172
.	O
	
aureus	I-C0038172
is	O
essential	O
to	O
improve	O
animal	B-C0003062
health	B-C0018684
and	O
reduce	O
economic	O
losses	O
for	O
farmers	B-C0221460
.	O
	
the	O
clinical	O
outcome	O
of	O
acute	B-C0024895
mastitis	I-C0024895
and	O
risk	B-C0035647
of	O
progression	O
to	O
persistent	B-C0205322
mastitis	B-C0024895
can	O
,	O
at	O
least	O
to	O
some	O
extent	O
,	O
be	O
related	O
to	O
genetic	B-C0678941
variants	I-C0678941
of	O
the	O
strain	B-C1518614
causing	O
the	O
infection	B-C3714514
.	O
	
in	O
the	O
present	O
study	B-C2603343
we	O
have	O
used	O
microarrays	B-C1709016
to	O
investigate	O
the	O
presence	O
of	O
virulence	B-C0042765
genes	B-C0017337
in	O
s	B-C0038172
.	O
	
aureus	I-C0038172
isolates	O
from	O
dairy	B-C0175925
cows	I-C0175925
with	O
acute	B-C0024895
clinical	I-C0024895
mastitis	I-C0024895
n=70	O
and	O
correlated	O
the	O
findings	B-C0243095
to	O
other	O
genotypic	B-C0017431
and	O
phenotypic	B-C0031437
characteristics	B-C1521970
.	O
	
among	O
the	O
most	O
commonly	O
found	O
virulence	B-C1136170
factors	I-C1136170
were	O
genes	B-C0017337
encoding	B-C2700640
several	O
hemolysin	B-C0019053
types	B-C0332307
,	O
leukocidins	B-C0023504
d	I-C0023504
and	O
lukm	B-C0293523
/	O
lukf-p83	B-C0033684
,	O
clumping	B-C1871029
factors	I-C1871029
a	I-C1871029
and	O
b	B-C0969304
,	O
fibrinogen	B-C1437844
binding	I-C1437844
protein	I-C1437844
and	O
fibronectin-binding	B-C2976610
protein	I-C2976610
a	I-C2976610
.	O
	
some	O
virulence	B-C1136170
factors	I-C1136170
e.g	O
.	O
	
fibronectin-binding	B-C2976609
protein	I-C2976609
b	I-C2976609
and	O
staphylococcus	B-C0038172
aureus	I-C0038172
surface	B-C0025252
protein	I-C0025252
g	I-C0025252
were	O
less	O
common	O
.	O
	
genes	B-C0017337
coding	O
for	O
several	O
staphylococcal	B-C0597508
enterotoxins	I-C0597508
and	O
toxic	B-C1617068
shock	I-C1617068
syndrome	I-C1617068
toxin-1	I-C1617068
tsst-1	B-C1617068
were	O
commonly	O
found	O
,	O
especially	O
in	O
one	O
major	O
pulsotype	B-C1518614
.	O
	
no	B-C1513916
beta-lactamase	B-C0017337
genes	I-C0017337
were	O
found	O
in	O
any	O
common	O
pulsotype	B-C1518614
,	O
while	O
present	O
in	O
some	O
rare	O
pulsotypes	B-C1518614
,	O
indicated	O
to	O
be	O
of	O
human	B-C4287933
origin	I-C4287933
.	O
	
production	O
of	O
tsst-1	B-C1617068
,	O
enterotoxins	B-C0014372
,	O
hemolysins	B-C0019053
and	O
beta-lactamase	B-C0597979
could	O
all	O
be	O
positively	O
correlated	O
to	O
presence	O
of	O
the	O
corresponding	O
genes	B-C0017337
.	O
	
this	O
study	B-C2603343
reveals	O
a	O
number	O
of	O
genotypic	B-C0017431
differences	B-C1705242
and	O
similarities	B-C2348205
among	O
common	O
and	O
rare	O
pulsotypes	B-C1518614
of	O
s	B-C0038172
.	O
	
aureus	I-C0038172
from	O
cases	O
of	O
mastitis	B-C0024895
in	O
sweden	B-C0038995
.	O
	
the	O
results	O
could	O
help	O
the	O
design	O
of	O
diagnostic	B-C0949688
tools	I-C0949688
to	O
guide	O
on-farm	O
interventions	O
according	O
to	O
the	O
expected	O
impact	O
on	O
udder	B-C0242386
health	B-C0018684
from	O
a	O
specific	O
s	B-C0038172
.	O
	
aureus	I-C0038172
genotype	B-C0017431
.	O
	
uveitis	B-C0042164
in	O
spondyloarthritis	B-C0949690
patients	B-C0030705
and	O
its	O
association	B-C0332281
with	I-C0332281
hla-b27	B-C0019740
histocompatibility	I-C0019740
antigen	I-C0019740
prospective	B-C0033522
study	I-C0033522
t	O
o	O
perform	O
a	O
prospective	B-C0033522
study	I-C0033522
of	O
clinical	B-C2708283
presentation	I-C2708283
and	O
course	B-C0750729
of	O
uveitis	B-C0042164
in	O
spondyloarthritis	B-C0949690
spa	B-C0949690
patients	B-C0030705
as	O
well	O
as	O
its	O
association	B-C0332281
with	I-C0332281
the	O
hla-b27	B-C0019740
histocompatibility	I-C0019740
antigen	I-C0019740
.	O
	
the	O
study	B-C2603343
included	O
219	O
patients	B-C0030705
with	O
uveitis	B-C0042164
,	O
all	O
tested	B-C0039593
for	O
hla-b27	B-C0019740
antigen	I-C0019740
and	O
various	O
infections	B-C3714514
viral	B-C0042769
,	O
bacterial	B-C0004623
,	O
and	O
parasitic	B-C0747256
as	O
well	O
as	O
examined	B-C0332128
for	O
locomotive	B-C0026860
system	I-C0026860
involvement	B-C1314939
.	O
	
the	O
presence	B-C0150312
of	O
the	O
hla-b27	B-C0019740
antigen	I-C0019740
was	O
determined	B-C0521095
in	O
142	O
64.8	O
out	O
of	O
219	O
patients	B-C0030705
,	O
of	O
them	O
87	O
were	O
diagnosed	B-C0011900
with	O
an	O
entity	B-C1551338
of	O
the	O
spa	B-C0949690
group	B-C0441833
.	O
	
the	O
remaining	B-C1527428
77	O
35.2	O
patients	B-C0030705
appeared	O
to	O
be	O
hla-b27	B-C0019740
-	O
negative	B-C0205160
,	O
but	O
13	O
were	O
still	O
diagnosed	B-C0011900
with	O
an	O
entity	B-C1551338
of	O
the	O
spa	B-C0949690
group	B-C0441833
.	O
	
there	O
were	O
10	O
4.6	O
patients	B-C0030705
with	O
2	O
or	O
more	O
diseases	B-C0012634
from	O
the	O
spa	B-C0949690
group	B-C0441833
clinical	O
decussation	O
.	O
	
when	O
comparing	B-C1707455
the	O
two	O
groups	B-C0441833
of	O
hla-b27-positive	B-C0239961
and	O
negative	B-C0205160
patients	B-C0030705
having	O
both	O
spa	B-C0949690
and	O
uveitis	B-C0042164
,	O
no	O
statistically	B-C0237881
significant	I-C0237881
difference	B-C1705242
was	O
found	O
as	O
to	O
the	O
age	B-C0206132
of	I-C0206132
onset	I-C0206132
,	O
site	B-C1515974
,	O
frequency	B-C0439603
of	I-C0439603
attacks	I-C0439603
,	O
and	O
uni	B-C0205092
-	O
or	O
bilateral	B-C0238767
involvement	B-C1314939
p>0	O
.	O
	
we	O
also	O
performed	B-C0884358
a	O
comparison	B-C1707455
of	O
hla-b27-positive	B-C0239961
and	O
negative	B-C0205160
patients	B-C0030705
with	O
no	O
account	O
to	O
their	O
spa	B-C0949690
status	B-C0449438
and	O
revealed	B-C0443289
a	O
higher	B-C0205250
complication	B-C0009566
rate	B-C1521828
in	O
those	O
that	O
were	O
negative	B-C0205160
p<0	O
,	O
which	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
hla-b27	B-C0019740
-	O
negative	B-C0205160
patients	B-C0030705
often	O
have	O
autoimmune	B-C3888523
or	O
infectious	B-C0042164
uveitis	I-C0042164
of	O
different	B-C1705242
origin	O
notable	O
for	O
long	B-C0205166
attacks	O
and	O
short	B-C1806781
remissions	B-C0544452
.	O
	
assessing	B-C0184514
the	O
site	B-C1515974
and	O
course	B-C0750729
of	O
uveitis	B-C0042164
as	O
well	O
as	O
hla-b27	B-C0019740
testing	B-C0039593
of	O
uveitis	B-C0042164
patients	B-C0030705
has	O
proved	O
important	B-C3898777
for	O
etiological	B-C1314792
diagnosis	B-C0011900
.	O
	
diseases	B-C0012634
of	O
the	O
spa	B-C0949690
group	B-C0441833
have	O
been	O
shown	O
to	O
be	O
6.7	O
times	B-C1632851
more	O
common	O
in	O
hla-b27-positive	B-C0239961
patients	B-C0030705
as	O
compared	B-C1707455
to	O
hla-b27	B-C0019740
-	O
negative	B-C0205160
ones	O
.	O
	
clinical	B-C2708283
presentation	I-C2708283
of	O
uveitis	B-C0042164
in	O
the	O
presence	B-C0150312
of	O
spa	B-C0949690
in	O
both	O
hla-b27-positive	B-C0239961
and	O
negative	B-C0205160
patients	B-C0030705
resembles	O
that	O
of	O
idiopathic	B-C0042164
uveitis	I-C0042164
-	O
an	O
independent	O
hla-b27	B-C0019740
-	O
associated	B-C0332281
syndrome	B-C0039082
р>0	O
.	O
	
cases	O
of	O
decussation	O
between	O
entities	B-C1551338
of	O
the	O
spa	B-C0949690
group	B-C0441833
are	O
usually	O
more	O
severe	B-C0205082
in	O
terms	O
of	O
clinical	B-C2708283
presentation	I-C2708283
and	O
course	B-C0750729
of	O
uveitis	B-C0042164
and	O
are	O
associated	B-C0332281
with	I-C0332281
a	O
worse	B-C0278252
prognosis	I-C0278252
.	O
	
complications	B-C0009566
of	O
uveitis	B-C0042164
are	O
more	O
likely	O
to	O
be	O
found	O
in	O
non-spa	B-C0243095
hla-b27	B-C0019740
-	O
negative	B-C0205160
patients	B-C0030705
human	B-C0086418
brucellosis	B-C0006309
in	O
south	B-C0037712
africa	I-C0037712
public	B-C3244304
health	I-C3244304
and	O
diagnostic	B-C0679836
pitfalls	I-C0679836
human	B-C0086418
brucellosis	B-C0006309
in	O
south	B-C0037712
africa	I-C0037712
sa	B-C0037712
is	O
under-diagnosed	B-C0679837
and	O
under-reported	B-C0243095
.	O
	
this	O
is	O
because	O
many	O
clinicians	B-C0871685
have	O
little	O
or	O
no	O
experience	O
in	O
managing	O
affected	B-C0522476
patients	I-C0522476
,	O
and	O
in	O
part	O
because	O
of	O
the	O
nonspecific	B-C0750540
and	O
insidious	B-C1288298
nature	B-C0449786
of	I-C0449786
the	I-C0449786
disease	I-C0449786
.	O
	
a	O
case	B-C0868928
of	O
human	B-C0086418
brucellosis	B-C0006309
caused	O
by	O
brucella	B-C0006305
melitensis	I-C0006305
in	O
a	O
patient	B-C0030705
from	O
the	O
western	B-C0681784
cape	I-C0681784
province	I-C0681784
of	O
sa	B-C0037712
is	O
described	B-C1552738
,	O
and	O
the	O
resulting	B-C0332294
exposure	O
of	O
staff	B-C1552089
members	I-C1552089
at	O
two	O
medical	B-C0022877
microbiology	I-C0022877
laboratories	I-C0022877
,	O
as	O
well	O
as	O
the	O
public	B-C1827659
health	I-C1827659
investigation	I-C1827659
that	O
was	O
conducted	O
,	O
are	O
discussed	O
.	O
	
this	O
article	B-C0282420
aims	B-C1947946
to	O
highlight	O
the	O
need	O
for	O
strengthening	O
integration	B-C0243126
between	O
public	B-C3244304
health	I-C3244304
,	O
medical	B-C0199168
and	O
veterinary	B-C0042615
services	B-C0557854
and	O
exposing	B-C0011155
deficiencies	I-C0011155
in	O
public	B-C3244304
health	I-C3244304
,	O
veterinary	B-C0042615
and	O
laboratory	B-C0022877
survey	B-C0038951
of	O
trichinella	B-C0856687
infection	I-C0856687
from	O
domestic	B-C1136016
pigs	I-C1136016
in	O
the	O
historical	B-C2004062
endemic	B-C0205146
areas	I-C0205146
of	O
henan	B-C1514578
province	I-C1514578
,	O
central	B-C0008115
china	I-C0008115
the	O
aim	B-C1947946
of	O
this	O
work	B-C0043227
was	O
to	O
investigate	B-C1292732
the	O
current	B-C0150312
situation	I-C0150312
of	O
trichinella	B-C0856687
infection	I-C0856687
from	O
domestic	B-C1136016
pigs	I-C1136016
in	O
the	O
historical	B-C2004062
endemic	B-C0205146
areas	I-C0205146
of	O
henan	B-C1514578
province	I-C1514578
,	O
central	B-C0008115
china	I-C0008115
.	O
	
a	O
total	O
of	O
823	O
diaphragm	B-C3687538
samples	I-C3687538
from	O
the	O
indoor-raised	B-C1136016
pigs	I-C1136016
were	O
collected	B-C1516698
in	O
five	B-C0205451
cities	B-C0008848
of	O
henan	B-C1514578
during	O
2014-2015	O
and	O
examined	B-C0332128
by	O
artificial	B-C0025664
digestion	I-C0025664
method	I-C0025664
.	O
	
the	O
overall	B-C1707459
prevalence	I-C1707459
of	O
trichinella	B-C0856687
infection	I-C0856687
in	O
pigs	B-C0039005
was	O
0.61	O
%	O
5/823	O
.	O
	
trichinella	B-C0546803
larvae	I-C0546803
were	O
detected	B-C0442726
in	O
0.91	O
%	O
5/550	O
of	O
pigs	B-C0039005
from	O
nanyang	B-C0008848
city	I-C0008848
of	O
henan	B-C1514578
.	O
	
the	O
larval	B-C0023047
burden	B-C2828008
in	O
infected	B-C0237158
animals	I-C0237158
was	O
0.03	O
larvae	B-C0023047
per	O
gram	O
lpg	O
of	O
muscles	B-C0026845
with	O
a	O
range	B-C1514721
from	O
0.02	O
to	O
0.05	O
lpg	O
.	O
	
the	O
larvae	B-C0546803
were	O
identified	B-C0205396
as	O
trichinella	B-C0040892
spiralis	I-C0040892
by	O
multiple	B-C3179032
pcr	I-C3179032
.	O
	
our	O
study	B-C2603343
confirms	B-C0521093
the	O
existence	B-C2987476
of	O
swine	B-C0039005
trichinellosis	B-C0040896
in	O
henan	B-C1514578
,	O
but	O
the	O
infection	B-C3714514
level	B-C0441889
was	O
under	O
the	O
minimum	B-C0441889
level	I-C0441889
for	O
defining	O
infectious	B-C0314732
sources	I-C0314732
for	O
humans	B-C0086418
.	O
	
however	O
,	O
the	O
prevalence	B-C0220900
of	O
swine	B-C0039005
trichinella	B-C0856687
infection	I-C0856687
in	O
henan	B-C1514578
need	O
to	O
be	O
further	O
evaluated	B-C0220825
with	O
a	O
large	B-C0549177
scale	I-C0549177
of	O
pork	B-C3687765
samples	I-C3687765
for	O
ensuring	O
meat	B-C0025017
food	B-C1456535
safety	I-C1456535
.	O
	
voriconazole	B-C0393080
metabolism	B-C0683140
is	O
influenced	B-C4054723
by	O
severe	B-C0205082
inflammation	B-C0021368
a	O
prospective	B-C0033522
study	I-C0033522
during	O
an	O
infection	B-C3714514
or	O
inflammation	B-C0021368
,	O
several	B-C0443302
drug	B-C1254351
-	O
metabolizing	B-C0683140
enzymes	B-C0014442
in	O
the	O
liver	B-C0023884
are	O
down-regulated	B-C1327624
,	O
including	O
cytochrome	B-C0010762
p450	I-C0010762
iso-enzymes	I-C0010762
.	O
	
since	O
voriconazole	B-C0393080
is	O
extensively	B-C0205231
metabolized	B-C0683140
by	O
cytochrome	B-C0010762
p450	I-C0010762
iso-enzymes	I-C0010762
,	O
the	O
metabolism	B-C0683140
of	O
voriconazole	B-C0393080
can	O
be	O
influenced	B-C4054723
during	O
inflammation	B-C0021368
via	O
reduced	B-C0392756
clearance	B-C0683151
of	I-C0683151
the	I-C0683151
drug	I-C0683151
,	O
resulting	O
in	O
higher	B-C0205250
voriconazole	B-C0393080
trough	B-C3640757
concentrations	I-C3640757
.	O
	
to	O
investigate	O
prospectively	O
the	O
influence	B-C4054723
of	O
inflammation	B-C0021368
on	O
voriconazole	B-C0393080
metabolism	B-C0683140
and	O
voriconazole	B-C0393080
trough	B-C3640757
concent	I-C3640757
ratio	I-C3640757
ns	I-C3640757
.	O
	
a	O
prospective	O
observational	O
study	O
was	O
performed	O
at	O
the	O
university	O
medical	O
center	O
groningen	O
.	O
	
patients	O
were	O
eligible	O
for	O
inclusion	O
if	O
they	O
were	O
18	O
years	O
old	O
and	O
treated	O
with	O
voriconazole	O
.	O
	
voriconazole	O
and	O
voriconazole-n-oxide	O
concentrations	O
were	O
determined	O
in	O
discarded	O
blood	O
samples	O
.	O
	
to	O
determine	O
the	O
degree	O
of	O
inflammation	O
,	O
c-reactive	O
protein	O
crp	O
concentrations	O
were	O
used	O
.	O
	
subsequently	O
,	O
a	O
longitudinal	O
data	O
analysis	O
was	O
performed	O
to	O
assess	O
the	O
effect	O
of	O
inflammation	O
on	O
the	O
metabolic	O
ratio	B-C0456603
and	O
voriconazole	O
trough	O
concentration	O
.	O
	
thirty-four	O
patients	O
were	O
included	O
.	O
	
in	O
total	O
489	O
voriconazole	O
trough	O
concentrations	O
were	O
included	O
in	O
the	O
longitudinal	O
data	O
analysis	O
.	O
	
this	O
analysis	O
showed	O
that	O
inflammation	O
,	O
reflected	O
by	O
crp	O
concentrations	O
,	O
significantly	O
influence	O
d	O
the	O
metabolic	O
ratio	O
,	O
voriconazole	O
trough	O
concentration	O
and	O
voriconazole-n-oxide	O
concentration	O
all	O
p	O
<	O
0.001	O
,	O
when	O
corrected	O
for	O
other	O
factors	O
that	O
could	O
influence	O
voriconazole	O
metabolism	O
.	O
	
the	O
metabolic	O
ratio	O
was	O
decreased	O
by	O
0.99229	O
and	O
the	O
voriconazole-n-oxide	O
concentration	O
by	O
0.99775	O
,	O
while	O
the	O
voriconazole	O
trough	O
concentration	O
was	O
increased	O
by	O
1.005321	O
,	O
where	O
n	O
is	O
the	O
difference	O
in	O
crp	O
units	O
in	O
mg/l	O
.	O
	
this	O
study	O
shows	O
that	O
voriconazole	O
metabolism	O
is	O
decreased	O
during	O
inflammation	O
,	O
resulting	O
in	O
higher	O
voriconazole	O
trough	O
concentration	O
s	O
.	O
	
therefore	O
,	O
frequent	O
monitoring	O
of	O
voriconazole	O
serum	O
concentrations	O
is	O
recommended	O
during	O
and	O
following	O
severe	O
inflammation	B-C0021368
neoadjuvant	B-C4272610
chemotherapy	I-C4272610
of	O
ovarian	B-C0029925
cancer	I-C0029925
results	O
in	O
three	O
patterns	O
of	O
tumor-infiltrating	B-C0079722
lymphocyte	I-C0079722
response	B-C0301909
with	O
distinct	O
implications	O
for	O
immunotherapy	B-C0278348
purpose	O
some	O
forms	O
of	O
chemotherapy	B-C0392920
can	O
enhance	O
antitumor	B-C2986475
immunity	B-C0020964
through	O
immunogenic	B-C0872192
cell	B-C0007587
death	I-C0007587
,	O
resulting	O
in	O
increased	O
t-cell	B-C1155065
activation	I-C1155065
and	O
tumor	B-C4060690
infiltration	I-C4060690
.	O
	
such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	B-C0027651
to	O
immunotherapies	B-C0278348
,	O
including	O
checkpoint	B-C1155873
blockade	I-C1155873
.	O
	
we	O
investigated	O
whether	O
platinum	B-C0032207
-	O
and	O
taxane	B-C0215136
-based	O
chemotherapy	B-C0392920
for	O
ovarian	B-C0029925
cancer	I-C0029925
induces	O
immunologic	B-C0205470
changes	O
consistent	O
with	O
this	O
possibility	O
.	O
	
experimental	B-C0015320
design	I-C0015320
matched	O
pre	B-C0332152
-	O
and	O
post	B-C0687676
-	O
neoadjuvant	B-C4272610
chemotherapy	I-C4272610
tumor	B-C0475358
samples	I-C0475358
from	O
26	O
high-grade	B-C3839280
serous	I-C3839280
carcinoma	I-C3839280
hgsc	B-C3839280
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	B-C0021044
ihc	B-C0021044
for	O
a	O
large	O
panel	O
of	O
immune	B-C0312740
cells	I-C0312740
and	O
associated	O
factors	O
.	O
	
the	O
prognostic	O
significance	O
of	O
post	B-C0687676
-	O
chemotherapy	B-C0392920
til	B-C0079722
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	B-C0599755
n	O
=	O
90	O
neoadjuvant	B-C4272610
chemotherapy	I-C4272610
was	O
associated	O
with	O
increased	O
densities	O
of	O
cd3	B-C0108779
+	O
,	O
cd8	B-C0085358
+	O
,	O
cd8	B-C0085358
+	O
tia-1	B-C1429678
+	O
,	O
pd-1	B-C2986635
+	O
and	O
cd20	B-C0054946
+	O
til	B-C0079722
.	O
	
other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
cd79a	B-C0286618
+	O
cd138	B-C1609943
+	O
plasma	B-C0032112
cells	I-C0032112
,	O
cd68	B-C0108799
+	O
macrophages	B-C0024432
,	O
and	O
mhc	B-C0019629
class	I-C0019629
i	I-C0019629
on	O
tumor	B-C0597032
cells	I-C0597032
.	O
	
immunosuppressive	B-C4048329
cell	B-C0007634
types	O
were	O
also	O
unchanged	O
,	O
including	O
foxp3	B-C4282118
+	O
pd-1	B-C2986635
+	O
cells	B-C0039198
putative	O
regulatory	B-C0039198
t	I-C0039198
cells	I-C0039198
,	O
ido-1	B-C3529891
+	O
cells	O
,	O
and	O
pd-l1	B-C4300350
+	O
cells	O
both	O
macrophages	B-C0024432
and	O
tumor	B-C0597032
cells	I-C0597032
.	O
	
hierarchical	B-C1881045
clustering	I-C1881045
revealed	O
three	O
response	O
patterns	O
i	O
til	B-C0079722
high	O
tumors	B-C0027651
showed	O
increases	O
in	O
multiple	O
immune	B-C0162489
markers	I-C0162489
after	O
chemotherapy	B-C4272610
ii	O
til	B-C0079722
low	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
and	O
iii	O
til	B-C0079722
negative	B-C0205160
cases	O
generally	O
remained	O
negative	B-C0205160
.	O
	
despite	O
the	O
dramatic	O
increases	O
seen	O
in	O
the	O
first	O
two	O
patterns	O
,	O
post-	O
chemotherapy	B-C0392920
til	B-C0079722
showed	O
limited	O
prognostic	O
significance.conclusions	O
chemotherapy	B-C4272610
augments	O
pre-existing	O
til	B-C0079722
responses	B-C0301909
but	O
fails	O
to	O
relieve	O
major	O
immune-suppressive	B-C1840264
mechanisms	I-C1840264
or	O
confer	O
significant	O
prognostic	O
benefit	O
.	O
	
our	O
findings	O
provide	O
rationale	O
for	O
multipronged	O
approaches	O
to	O
immunotherapy	B-C0278348
tailored	O
to	O
the	O
baseline	O
features	O
of	O
the	O
tumor	B-C2936626
microenvironment	I-C2936626
.	O
	
the	O
adder	B-C0206298
vipera	B-C0206298
berus	I-C0206298
in	O
southern	B-C0442533
altay	I-C0442533
mountains	I-C0442533
population	B-C0032661
characteristics	I-C0032661
,	O
distribution	B-C0037775
,	O
morphology	B-C0332437
and	O
phylogenetic	B-C1519069
position	I-C1519069
as	O
the	O
most	O
widely	O
distributed	B-C0037775
snake	B-C0037382
in	O
eurasia	B-C0017446
,	O
the	O
adder	B-C0206298
vipera	B-C0206298
berus	I-C0206298
has	O
been	O
extensively	B-C0205231
investigated	B-C1292732
in	O
europe	B-C0015176
but	O
poorly	O
understood	O
in	O
asia	B-C0003980
.	O
	
the	O
southern	B-C0442533
altay	I-C0442533
mountains	I-C0442533
represent	O
the	O
adder's	B-C0206298
southern	B-C1710133
distribution	B-C0037775
limit	B-C0439801
in	O
central	B-C0003982
asia	I-C0003982
,	O
whereas	O
its	O
population	B-C0032671
status	I-C0032671
has	O
never	O
been	O
assessed	B-C1516048
.	O
	
we	O
conducted	O
,	O
for	O
the	O
first	O
time	O
,	O
field	B-C1517184
surveys	I-C1517184
for	O
the	O
adder	B-C0206298
at	O
two	O
areas	B-C0205146
of	O
southern	B-C0442533
altay	I-C0442533
mountains	I-C0442533
using	O
a	O
combination	B-C0205195
of	O
line	B-C0242481
transects	I-C0242481
and	O
random	B-C0439605
searches	B-C1706202
.	O
	
we	O
also	O
described	O
the	O
morphological	B-C0332437
characteristics	I-C0332437
of	O
the	O
collected	B-C0200345
specimens	I-C0200345
and	O
conducted	O
analyses	B-C0936012
of	O
external	B-C0205101
morphology	B-C0332437
and	O
molecular	B-C0031797
phylogeny	I-C0031797
.	O
	
the	O
results	B-C0683954
showed	O
that	O
the	O
adder	B-C0206298
distributed	B-C0037775
in	O
both	O
survey	B-C0011296
sites	B-C0205145
and	O
we	O
recorded	B-C0034869
a	O
total	O
of	O
34	O
sightings	B-C1947978
.	O
	
in	O
kanas	B-C0563004
river	I-C0563004
valley	I-C0563004
,	O
the	O
estimated	B-C0750572
encounter	B-C1947978
rate	B-C1521828
over	O
a	O
total	O
of	O
137	O
km	O
transects	B-C0242481
was	O
0.15	O
0.05	O
sightings	B-C1947978
/km	O
.	O
	
the	O
occurrence	B-C2745955
of	O
melanism	B-C0025209
was	O
only	O
17%	O
.	O
	
the	O
small	B-C0748864
size	I-C0748864
was	O
typical	B-C3538928
for	O
the	O
adders	B-C0206298
in	O
southern	B-C0442533
altay	I-C0442533
mountains	I-C0442533
in	O
contrast	O
to	O
other	O
geographic	B-C0032659
populations	I-C0032659
of	O
the	O
nominate	B-C1707391
subspecies	B-C1883207
.	O
	
a	O
phylogenetic	B-C1519069
tree	I-C1519069
obtained	B-C1301820
by	O
bayesian	B-C0242196
inference	I-C0242196
based	O
on	O
dna	B-C0162326
sequences	I-C0162326
of	O
the	O
mitochondrial	B-C0010744
cytochrome	I-C0010744
b	I-C0010744
1	O
bp	O
grouped	B-C0439745
them	O
within	O
the	O
northern	B-C0032659
clade	I-C0032659
of	O
the	O
species	B-C1705920
but	O
failed	O
to	O
separate	B-C0443299
them	O
from	O
the	O
subspecies	B-C1883207
v	B-C0206298
.	O
	
b	I-C0206298
.	O
	
sachalinensis	I-C0206298
.	O
	
our	O
discovery	B-C1880355
extends	O
the	O
distribution	B-C0037775
range	B-C1514721
of	O
v	B-C0206298
.	O
	
berus	I-C0206298
and	O
provides	O
a	O
basis	B-C1527178
for	O
further	O
researches	B-C0035168
.	O
	
we	O
discuss	O
the	O
hypothesis	B-C1512571
that	O
the	O
adder	B-C0206298
expands	B-C0205229
its	O
distribution	B-C0037775
border	B-C2828371
to	O
the	O
southwest	B-C1710136
along	O
the	O
mountains	B-C0442533
'	O
elevation	B-C0702240
gradient	B-C0812409
,	O
but	O
the	O
population	B-C1257890
abundance	B-C2346714
declines	B-C0547047
gradually	B-C0439833
due	O
to	O
a	O
drying	B-C0681771
climate	I-C0681771
.	O
	
binding	B-C1145667
of	O
pollutants	B-C0599786
to	O
biomolecules	B-C0574031
a	O
simulation	B-C0679083
study	I-C0679083
a	O
number	O
of	O
cases	B-C0868928
around	O
the	O
world	B-C2700280
have	O
been	O
reported	O
where	O
animals	B-C0003062
were	O
found	B-C0476463
dead	I-C0476463
or	O
dying	B-C0184532
with	O
symptoms	B-C1457887
resembling	O
a	O
thiamine	B-C0039841
vitamin	B-C0042850
b	I-C0042850
deficiency	I-C0042850
,	O
and	O
for	O
some	O
of	O
these	O
,	O
a	O
link	O
to	O
pollutants	B-C0599786
has	O
been	O
suggested	O
.	O
	
here	O
,	O
we	O
investigate	B-C0220825
whether	O
biomolecules	B-C0574031
involved	O
in	O
thiamin	B-C1523455
binding	I-C1523455
and	O
transport	B-C1159805
could	O
be	O
blocked	B-C0332206
by	O
a	O
range	O
of	O
different	O
pollutants	B-C0599786
.	O
	
we	O
used	O
in	B-C3489666
silico	I-C3489666
docking	B-C1522290
of	O
five	O
compound	B-C0574031
classes	B-C0456387
25	O
compounds	B-C0574031
in	O
total	O
to	O
each	O
of	O
five	O
targets	O
prion	B-C4082486
protein	I-C4082486
,	O
ecf-type	B-C3158987
abc	I-C3158987
transporter	I-C3158987
,	O
thi-box	B-C2936590
riboswitch	I-C2936590
receptor	I-C2936590
,	O
thiamin	B-C0039850
pyrophosphokinase	I-C0039850
,	O
and	O
ykof	B-C0033684
protein	I-C0033684
and	O
subsequently	O
performed	O
molecular	B-C2717775
dynamics	I-C2717775
md	I-C2717775
simulations	I-C2717775
to	O
assess	O
the	O
stability	B-C0205360
of	O
the	O
complexes	B-C1704241
.	O
	
the	O
compound	B-C0574031
classes	B-C0456387
were	O
thiamin	B-C0039840
analogues	B-C0002776
control	B-C1550141
,	O
pesticides	B-C0031253
,	O
veterinary	B-C0042614
medicines	B-C0013227
,	O
polychlorinated	B-C0032447
biphenyls	I-C0032447
,	O
and	O
dioxins	B-C0012503
,	O
all	O
of	O
which	O
are	O
prevalent	B-C0220900
in	O
the	O
environment	B-C0014406
to	O
some	O
extent	O
.	O
	
a	O
few	O
anthropogenic	O
compounds	B-C0574031
were	O
found	O
to	O
bind	B-C1167622
the	O
ecf-type	B-C3158987
abc	I-C3158987
transporter	I-C3158987
,	O
but	O
none	B-C0243095
binds	I-C0243095
stably	I-C0243095
to	O
prion	B-C4082486
protein	I-C4082486
.	O
	
for	O
the	O
riboswitch	B-C2936590
,	O
most	O
compounds	B-C0574031
remained	O
in	O
their	O
binding	B-C1254355
pockets	I-C1254355
during	O
50	O
ns	O
of	O
md	B-C2717775
simulation	I-C2717775
,	O
indicating	O
that	O
rna	B-C0035668
provides	O
a	O
promiscuous	O
binding	B-C0005456
site	I-C0005456
.	O
	
in	O
both	O
ykof	B-C0033684
and	O
thiamin	B-C0039850
pyrophosphokinase	I-C0039850
tpk	B-C0039850
,	O
most	O
compounds	B-C0574031
remain	O
tightly	B-C1145667
bound	I-C1145667
.	O
	
however	O
,	O
tpk	B-C0039850
biomolecules	B-C0574031
undergo	O
pollutant	B-C0599786
-	O
induced	B-C0205263
conformational	B-C0301641
changes	I-C0301641
.	O
	
although	O
most	O
compounds	B-C0574031
are	O
found	O
to	O
bind	O
to	O
some	O
of	O
these	O
targets	O
,	O
a	O
larger	O
data	O
set	O
is	O
needed	O
along	O
with	O
more	O
quantitative	B-C1510568
methods	I-C1510568
like	O
free	B-C0678592
energy	I-C0678592
perturbation	I-C0678592
calculations	B-C1441506
before	O
firm	O
conclusions	B-C1707478
can	O
be	O
drawn	O
.	O
	
this	O
study	B-C2603343
is	O
in	O
part	O
a	O
test	O
bed	O
for	O
large-scale	O
quantitative	B-C0034384
computational	B-C4297010
screening	I-C4297010
of	O
interactions	B-C1704675
between	O
biological	B-C0574031
entities	I-C0574031
and	O
pollutant	B-C0599786
molecules	I-C0599786
.	O
	
characterisation	B-C1880022
of	O
methicillin-resistant	B-C1265292
staphylococcus	I-C1265292
aureus	I-C1265292
clinical	B-C0205210
isolates	B-C1764827
from	O
animals	B-C0003062
in	O
new	B-C0027978
zealand	I-C0027978
,	O
2012-2013	O
,	O
and	O
subclinical	B-C0205211
colonisation	B-C2242741
in	O
dogs	B-C0012984
and	O
cats	B-C0007450
in	O
auckland	B-C0681784
to	O
characterise	B-C1880022
methicillin-resistant	B-C1265292
staphylococcus	I-C1265292
aureus	I-C1265292
mrsa	B-C1265292
isolates	B-C1764827
from	O
infection	B-C0578491
sites	I-C0578491
in	O
animals	B-C0003062
in	O
new	B-C0027978
zealand	I-C0027978
and	O
assess	O
the	O
prevalence	B-C0220900
of	O
subclinical	B-C0205211
mrsa	B-C2242741
colonisation	I-C2242741
in	O
dogs	B-C0012984
and	O
cats	B-C0007450
attending	O
veterinary	B-C2936717
clinics	I-C2936717
in	O
auckland	B-C0681784
.	O
	
mrsa	B-C1265292
isolates	B-C1764827
from	O
clinical	B-C0205210
specimens	B-C0370003
obtained	O
by	O
the	O
main	O
new	B-C0027978
zealand	I-C0027978
veterinary	B-C0022877
diagnostic	I-C0022877
laboratories	I-C0022877
between	O
june	B-C3829443
2012	O
and	O
june	B-C3829443
2013	O
,	O
were	O
genotypically	B-C1880022
characterised	I-C1880022
by	O
dna	B-C1522053
microarray	I-C1522053
hybridisation	I-C1522053
analysis	I-C1522053
and	O
spa	B-C0038164
typing	B-C0087124
.	O
	
in	O
addition	O
,	O
nasal	B-C0222095
or	O
perineal	B-C0222176
skin	I-C0222176
swabs	B-C0183753
collected	O
from	O
a	O
cross-sectional	B-C0370003
sample	I-C0370003
of	O
dogs	B-C0012984
n=361	O
and	O
cats	B-C0007450
n=225	O
attending	O
29	O
veterinary	B-C2936717
clinics	I-C2936717
in	O
auckland	B-C0681784
during	O
the	O
same	O
period	B-C1948053
were	O
analysed	B-C0936012
for	O
mrsa	B-C1265292
by	O
culture	B-C2242979
.	O
	
eight	O
mrsa	B-C1265292
clinical	B-C0205210
isolates	B-C1764827
were	O
submitted	O
for	O
characterisation	B-C1880022
by	O
the	O
participating	O
laboratories	B-C0022877
.	O
	
the	O
isolates	B-C1764827
originated	O
from	O
five	O
dogs	B-C0012984
,	O
including	O
two	O
isolates	B-C1764827
from	O
the	O
same	O
dog	B-C0012984
,	O
one	O
foal	B-C3669731
,	O
and	O
one	O
isolate	B-C1764827
had	O
no	O
identification	O
of	O
the	O
source	B-C0449416
.	O
	
the	O
strain	B-C1518614
-	O
types	B-C0332307
identified	B-C0205396
were	O
ak3	B-C1265292
st-5	I-C1265292
sccmeciv	I-C1265292
t045	O
n=1	O
,	O
usa500	B-C1265292
st8	I-C1265292
sccmeciv	I-C1265292
t064	O
n=1	O
,	O
wspp	B-C1265292
st30	I-C1265292
sccmeciv	I-C1265292
t019	O
n=1	O
,	O
rhine	B-C1265292
hesse	I-C1265292
st5	I-C1265292
sccmecii	I-C1265292
t002	O
n=2	O
,	O
and	O
emrsa-15	B-C1265292
st22	I-C1265292
sccmeciv	I-C1265292
t032	O
n=3	O
.	O
	
no	O
mrsa	B-C1265292
were	O
isolated	B-C0205409
from	O
586	O
cultured	B-C0183753
swabs	I-C0183753
.	O
	
methicillin-susceptible	B-C1265292
s	I-C1265292
.	O
	
aureus	I-C1265292
were	O
detected	B-C0442726
in	O
9/257	O
3.5	O
swabs	B-C0183753
and	O
non-aureus	B-C0038170
staphylococci	I-C0038170
in	O
22/257	O
8.5	O
swabs	B-C0183753
.	O
	
the	O
estimated	O
true	O
mrsa	B-C1265292
subclinical	B-C0205211
colonisation	B-C2242741
prevalence	B-C0220900
was	O
0%	O
,	O
with	O
an	O
upper	O
95%	O
ci	B-C0009667
boundary	O
of	O
1.9	O
for	O
cats	B-C0007450
and	O
1.4	O
for	O
dogs	B-C0012984
.	O
	
the	O
modest	B-C0237753
number	I-C0237753
of	O
mrsa	B-C1265292
isolates	B-C1764827
submitted	O
for	O
this	O
study	B-C0085973
by	O
the	O
participating	O
laboratories	B-C0022877
suggests	O
clinical	B-C0205210
mrsa	B-C0343401
infection	I-C0343401
in	O
animals	B-C0003062
in	O
new	B-C0027978
zealand	I-C0027978
continues	O
to	O
be	O
sporadic	B-C0205422
.	O
	
the	O
wide	O
variety	O
of	O
strain	B-C1518614
-	O
types	B-C0332307
found	O
mirrored	O
the	O
evolving	O
strain	B-C1518614
-	O
type	B-C0332307
diversity	B-C1880371
observed	O
in	O
humans	B-C0086418
.	O
	
we	O
cannot	O
rule	O
out	O
bias	B-C0242568
due	O
to	O
the	O
non-random	B-C0150105
sampling	I-C0150105
of	O
dogs	B-C0012984
and	O
cats	B-C0007450
,	O
but	O
the	O
apparent	O
colonisation	B-C4289767
prevalence	B-C0220900
of	O
0%	O
was	O
consistent	B-C0332290
with	I-C0332290
the	O
low	O
prevalence	B-C0220900
of	O
subclinical	B-C0205211
colonisation	B-C2242741
in	O
humans	B-C0086418
in	O
new	B-C0027978
zealand	I-C0027978
.	O
	
these	O
similarities	B-C2348205
indicate	O
the	O
epidemiology	B-C0014507
of	O
animal	B-C0003062
and	O
human	B-C0086418
mrsa	B-C0343401
infections	I-C0343401
are	O
linked	O
.	O
	
in	O
the	O
last	O
decade	B-C2981279
,	O
the	O
prevalence	B-C0220900
of	O
human	B-C0086418
mrsa	B-C0343401
infections	I-C0343401
in	O
new	B-C0027978
zealand	I-C0027978
has	O
steadily	O
increased	B-C0205217
.	O
	
this	O
is	O
the	O
second	O
published	O
study	B-C0085973
of	O
mrsa	B-C1265292
in	O
animals	B-C0003062
in	O
new	B-C0027978
zealand	I-C0027978
.	O
	
the	O
results	O
indicate	O
clinical	B-C0205210
mrsa	B-C0343401
infection	I-C0343401
in	O
animals	B-C0003062
remains	O
sporadic	B-C0205422
,	O
but	O
the	O
diversification	B-C0680948
of	O
the	O
strain	B-C1518614
-	O
types	B-C0332307
may	O
pose	O
new	O
therapeutic	B-C0302350
challenges	O
to	O
veterinarians	B-C0242856
,	O
due	O
to	O
their	O
diverse	O
cloud-based	B-C0037589
motifsim	I-C0037589
detecting	B-C0442726
similarity	B-C2348205
in	O
large	O
dna	B-C3178798
motif	I-C3178798
data	B-C0150098
sets	I-C0150098
we	O
developed	O
the	O
cloud-based	B-C0037589
motifsim	I-C0037589
on	O
amazon	B-C1710664
web	I-C1710664
services	I-C1710664
aws	B-C1710664
cloud	B-C4042841
.	O
	
the	O
tool	B-C0037589
is	O
an	O
extended	O
version	B-C0333052
from	O
our	O
web-based	B-C0037589
tool	I-C0037589
version	I-C0037589
2.0	I-C0037589
,	O
which	O
was	O
developed	O
based	O
on	O
a	O
novel	O
algorithm	B-C0002045
for	O
detecting	B-C0442726
similarity	B-C2348205
in	O
multiple	O
dna	B-C3178798
motif	I-C3178798
data	B-C0150098
sets	I-C0150098
.	O
	
this	O
cloud	B-C4042841
-based	O
version	B-C0333052
further	O
allows	O
researchers	B-C0035173
to	O
exploit	O
the	O
computing	B-C0035201
resources	I-C0035201
available	O
from	O
aws	B-C1710664
to	O
detect	B-C0442726
similarity	B-C2348205
in	O
multiple	O
large-scale	O
dna	B-C3178798
motif	I-C3178798
data	B-C0150098
sets	I-C0150098
resulting	O
from	O
the	O
next-generation	B-C2936622
sequencing	I-C2936622
technology	I-C2936622
.	O
	
the	O
tool	B-C0037589
is	O
highly	O
scalable	O
with	O
expandable	O
utilization	B-C0042153
and	O
outcomes	B-C0086750
of	O
sentinel	B-C0796693
lymph	I-C0796693
node	I-C0796693
biopsy	I-C0796693
for	O
vulvar	B-C0375071
cancer	I-C0375071
to	O
examine	O
the	O
use	O
and	O
predictors	O
of	O
sentinel	B-C0796693
node	I-C0796693
biopsy	I-C0796693
in	O
women	B-C0043210
with	O
vulvar	B-C0375071
cancer	I-C0375071
.	O
	
the	O
perspective	B-C0242356
database	I-C0242356
,	O
an	O
all-payer	B-C0242356
database	I-C0242356
that	O
collects	B-C0010995
data	I-C0010995
from	O
more	O
than	O
500	O
hospitals	B-C0019994
,	O
was	O
used	O
to	O
perform	O
a	O
retrospective	B-C2985505
cohort	I-C2985505
study	I-C2985505
of	O
women	B-C0043210
with	O
vulvar	B-C0375071
cancer	I-C0375071
who	O
underwent	O
vulvectomy	B-C0195066
and	O
lymph	B-C0193842
node	I-C0193842
assessment	I-C0193842
from	O
2006	O
to	O
2015	O
.	O
	
multivariable	B-C0026336
models	I-C0026336
were	O
used	O
to	O
determine	O
factors	B-C0679238
associated	O
with	O
sentinel	B-C0796693
node	I-C0796693
biopsy	I-C0796693
.	O
	
length	B-C0023303
of	I-C0023303
stay	I-C0023303
and	O
cost	B-C0087112
were	O
compared	O
between	O
women	B-C0043210
who	O
underwent	O
sentinel	B-C0796693
node	I-C0796693
biopsy	I-C0796693
and	O
lymphadenectomy	B-C0024203
.	O
	
among	O
2	O
women	B-C0043210
,	O
sentinel	B-C0796693
node	I-C0796693
biopsy	I-C0796693
was	O
utilized	O
in	O
618	O
27.2	O
and	O
1	O
72.8	O
underwent	O
inguinofemoral	B-C0398408
lymphadenectomy	I-C0398408
.	O
	
performance	O
of	O
sentinel	B-C0796693
node	I-C0796693
biopsy	I-C0796693
increased	O
from	O
17.0	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
12.0	O
in	O
2006	O
to	O
39.1	O
95%	O
ci	B-C0009667
27.1	O
in	O
2015	O
.	O
	
in	O
a	O
multivariable	B-C0026336
model	I-C0026336
,	O
women	B-C0043210
treated	B-C1522326
more	O
recently	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
sentinel	B-C0796693
node	I-C0796693
biopsy	I-C0796693
,	O
whereas	O
women	B-C0043210
with	O
more	O
comorbidities	B-C0009488
and	O
those	O
treated	B-C1522326
at	O
rural	B-C0020023
hospitals	I-C0020023
were	O
less	O
likely	O
to	O
have	O
undergone	O
the	O
procedure	B-C0796693
.	O
	
the	O
median	B-C2939193
length	B-C0023303
of	I-C0023303
stay	I-C0023303
was	O
shorter	O
for	O
those	O
undergoing	O
sentinel	B-C0796693
node	I-C0796693
biopsy	I-C0796693
median	B-C2939193
2	O
days	O
,	O
interquartile	B-C1711350
range	I-C1711350
1-3	O
compared	O
with	O
women	B-C0043210
who	O
underwent	O
inguinofemoral	B-C0398408
lymphadenectomy	I-C0398408
median	O
3	O
days	O
,	O
interquartile	B-C1711350
range	I-C1711350
2-4	O
.	O
	
the	O
cost	O
of	O
sentinel	B-C0796693
node	I-C0796693
biopsy	I-C0796693
was	O
7	O
interquartile	B-C1711350
range	I-C1711350
5	O
compared	O
with	O
8	O
interquartile	B-C1711350
range	I-C1711350
5	O
for	O
lymphadenectomy	B-C0024203
.	O
	
the	O
use	O
of	O
sentinel	B-C0796693
node	I-C0796693
biopsy	I-C0796693
for	O
vulvar	B-C0375071
cancer	I-C0375071
has	O
more	O
than	O
doubled	O
since	O
2006	O
.	O
	
sentinel	B-C0796693
lymph	I-C0796693
node	I-C0796693
biopsy	I-C0796693
is	O
associated	O
with	O
a	O
shorter	B-C3489408
hospital	I-C3489408
stay	I-C3489408
and	O
decreased	B-C0010187
cost	I-C0010187
compared	O
with	O
inguinofemoral	B-C0398408
lymphadenectomy	I-C0398408
.	O
	
condition	B-C0348080
-	O
dependent	B-C0851827
co-regulation	B-C1327622
of	O
genomic	B-C0017258
clusters	I-C0017258
of	O
virulence	B-C1136170
factors	I-C1136170
in	O
the	O
grapevine	B-C0012634
trunk	I-C0012634
pathogen	B-C0450254
neofusicoccum	B-C2269732
parvum	I-C2269732
the	O
ascomycete	B-C0003965
neofusicoccum	B-C2269732
parvum	I-C2269732
,	O
one	O
of	O
the	O
causal	B-C0449411
agents	I-C0449411
of	O
botryosphaeria	B-C1011772
dieback	I-C1011772
,	O
is	O
a	O
destructive	O
wood	B-C0043217
-	O
infecting	B-C0439663
fungus	B-C0016832
and	O
a	O
serious	O
threat	B-C0749385
to	O
grape	B-C0018208
production	O
worldwide	B-C2700280
.	O
	
the	O
capability	B-C2698977
of	O
colonizing	B-C4289767
woody	B-C1514137
tissue	I-C1514137
combined	B-C0205195
with	O
the	O
secretion	B-C0036536
of	O
phytotoxic	B-C1407029
compounds	B-C1706082
is	O
thought	O
to	O
underlie	O
its	O
pathogenicity	B-C1136169
and	O
virulence	B-C0042765
.	O
	
here	O
,	O
we	O
describe	O
the	O
repertoire	O
of	O
virulence	B-C1136170
factors	I-C1136170
and	O
their	O
transcriptional	B-C0040649
dynamics	B-C3826426
as	O
the	O
fungus	B-C0016832
feeds	B-C0016452
on	O
different	O
substrates	B-C3891814
and	O
colonizes	B-C4289767
the	O
woody	B-C2699642
stem	I-C2699642
.	O
	
we	O
assembled	B-C1706853
and	O
annotated	B-C1552720
a	O
highly	B-C0205250
contiguous	B-C0205283
genome	B-C0017428
using	O
single	B-C0687728
molecule	I-C0687728
real-time	I-C0687728
dna	I-C0687728
sequencing	I-C0687728
.	O
	
transcriptome	B-C0752248
profiling	I-C0752248
by	O
rna-sequencing	B-C0917793
determined	O
the	O
genome	B-C0017428
-wide	O
patterns	B-C0449774
of	O
expression	B-C0017262
of	O
virulence	B-C1136170
factors	I-C1136170
both	O
in	B-C0681828
vitro	I-C0681828
potato	B-C0032846
dextrose	B-C3266617
agar	I-C3266617
or	O
medium	B-C0010454
amended	B-C1691222
with	O
grape	B-C0018208
wood	B-C0043217
as	O
substrate	B-C3891814
and	O
in	O
planta	B-C0032098
.	O
	
pairwise	B-C0237913
statistical	I-C0237913
testing	I-C0237913
of	O
differential	B-C1705242
expression	B-C0017262
followed	O
by	O
co-expression	B-C1880945
network	I-C1880945
analysis	I-C1880945
revealed	O
that	O
physically	B-C0205485
clustered	B-C0017258
genes	I-C0017258
coding	B-C0017380
for	O
putative	O
virulence	B-C0042765
functions	B-C0542341
were	O
induced	O
depending	O
on	O
substrate	B-C3891814
or	O
stage	B-C1306673
of	O
plant	B-C0032098
infection	B-C3714514
.	O
	
co-expressed	B-C0017262
gene	B-C0017258
clusters	I-C0017258
were	O
significantly	O
enriched	O
not	O
only	O
in	O
genes	B-C0017337
associated	B-C0332281
with	I-C0332281
secondary	B-C0260000
metabolism	I-C0260000
,	O
but	O
also	O
with	O
cell	B-C1157855
wall	I-C1157855
degradation	I-C1157855
,	O
suggesting	O
that	O
dynamic	B-C0729333
co-regulation	B-C1327622
of	O
transcriptional	B-C1720950
networks	I-C1720950
contribute	O
to	O
multiple	O
aspects	O
of	O
n	B-C2269732
.	O
	
parvum	I-C2269732
virulence	B-C0042765
.	O
	
in	O
most	O
of	O
the	O
co-expressed	B-C0017262
clusters	B-C0017258
,	O
all	O
genes	B-C0017337
shared	O
at	O
least	O
a	O
common	O
motif	O
in	O
their	O
promoter	B-C0033413
region	I-C0033413
indicative	O
of	O
co-regulation	B-C1327622
by	O
the	O
same	O
transcription	B-C0040648
factor	I-C0040648
.	O
	
co-expression	B-C1880945
analysis	I-C1880945
also	O
identified	O
chromatin	B-C0008546
regulators	B-C1704735
with	O
correlated	B-C1707520
expression	B-C0017262
with	O
inducible	B-C0205263
clusters	B-C0017258
of	O
virulence	B-C1136170
factors	I-C1136170
,	O
suggesting	O
a	O
complex	O
,	O
multi-layered	O
regulation	B-C1327622
of	O
the	O
virulence	B-C0042765
repertoire	O
of	O
n	B-C2269732
.	O
	
parvum	I-C2269732
.	O
	
congenital	B-C0000768
anomalies	I-C0000768
following	O
use	O
of	O
isotretinoin	B-C0022265
emphasis	O
on	O
its	O
legal	B-C0022433
aspects	I-C0022433
we	O
described	O
a	O
neonate	B-C0021289
with	O
severe	B-C0205082
and	O
multiple	B-C0000772
abnormalities	I-C0000772
following	O
use	O
of	O
isotretinoin	B-C0022265
,	O
in	O
spite	O
of	O
the	O
mother	B-C0026591
's	O
previous	O
knowledge	B-C0376554
of	O
drug	B-C1393201
complications	I-C1393201
.	O
	
initial	O
physical	B-C0031809
examination	I-C0031809
after	O
delivery	B-C0011209
showed	O
congenital	B-C0332907
absence	I-C0332907
of	O
both	B-C0229118
eyes	I-C0229118
and	O
both	O
auricles	B-C0928075
as	O
well	O
as	O
anal	B-C0003466
atresia	I-C0003466
and	O
a	O
cleft	B-C0008925
palate	I-C0008925
.	O
	
due	O
to	O
severe	B-C0205082
respiratory	B-C0476273
distress	I-C0476273
and	O
atresia	B-C0243066
of	O
the	O
anus	B-C0003461
,	O
the	O
neonate	B-C0021289
was	O
admitted	O
to	O
a	O
neonatal	B-C0021289
intensive	B-C0021708
care	I-C0021708
unit	I-C0021708
and	O
underwent	O
reconstructive	B-C0524865
surgery	I-C0524865
.	O
	
the	O
drug	B-C1254351
should	O
not	O
have	O
been	O
used	O
during	O
pregnancy	B-C0032961
.	O
	
using	O
this	O
drug	B-C1254351
within	O
pregnancy	B-C0032961
with	O
awareness	O
of	O
its	O
side	B-C0041755
effects	I-C0041755
may	O
have	O
legal	B-C1301860
consequences	B-C0686907
.	O
	
functional	B-C0392673
adaptation	I-C0392673
of	O
crustacean	B-C1704306
exoskeletal	B-C0596796
elements	B-C0013879
through	O
structural	B-C0678594
and	O
compositional	B-C0005885
diversity	B-C0282469
a	O
combined	B-C0205195
experimental	B-C0681814
and	O
theoretical	B-C0039778
study	I-C0039778
the	O
crustacean	B-C1704306
cuticle	B-C2699479
is	O
a	O
composite	B-C0205199
material	B-C0520510
that	O
covers	O
the	O
whole	O
animal	B-C0003062
and	O
forms	O
the	O
continuous	B-C0596796
exoskeleton	I-C0596796
.	O
	
nano-fibers	B-C1881960
composed	O
of	O
chitin	B-C0008141
and	O
protein	B-C0033684
molecules	I-C0033684
form	O
most	O
of	O
the	O
organic	B-C0747055
matrix	B-C4050026
of	O
the	O
cuticle	B-C2699479
that	O
,	O
at	O
the	O
macroscale	B-C0392762
,	O
is	O
organized	O
in	O
up	O
to	O
eight	O
hierarchical	B-C0699032
levels	B-C0441889
.	O
	
at	O
least	O
two	O
of	O
them	O
,	O
the	O
exo-	B-C2699479
and	O
endocuticle	B-C2699479
,	O
contain	O
a	O
mineral	B-C0026162
phase	I-C0026162
of	O
mainly	O
mg	B-C0024467
-	O
calcite	B-C0205686
,	O
amorphous	B-C1979848
calcium	B-C0006681
carbonate	I-C0006681
and	O
phosphate	B-C0031603
.	O
	
the	O
high	O
number	O
of	O
hierarchical	B-C0699032
levels	B-C0441889
and	O
the	O
compositional	B-C0005885
diversity	B-C0282469
provide	O
a	O
high	O
degree	B-C0205556
of	I-C0205556
freedom	I-C0205556
for	O
varying	B-C0392747
the	O
physical	B-C1998468
,	O
in	O
particular	O
mechanical	B-C0205245
,	O
properties	B-C0871161
of	O
the	O
material	B-C0520510
.	O
	
this	O
makes	O
the	O
cuticle	B-C2699479
a	O
versatile	B-C0520510
material	I-C0520510
ideally	O
suited	O
to	O
form	O
a	O
variety	O
of	O
skeletal	B-C0521324
elements	B-C0013879
that	O
are	O
adapted	B-C0392673
to	O
different	O
functions	B-C0542341
and	O
the	O
eco-physiological	B-C1518614
strains	I-C1518614
of	O
individual	B-C1705920
species	I-C1705920
.	O
	
this	O
review	B-C0282443
presents	O
our	O
recent	O
analytical	B-C0178476
,	O
experimental	B-C0681814
and	O
theoretical	B-C0039778
studies	I-C0039778
on	O
the	O
cuticle	B-C2699479
,	O
summarising	O
at	O
which	O
hierarchical	B-C0699032
levels	B-C0441889
structure	B-C0678594
and	O
composition	B-C0005885
are	O
modified	O
to	O
achieve	O
the	O
required	O
physical	B-C1998468
properties	I-C1998468
.	O
	
we	O
describe	O
our	O
multi-scale	B-C0026336
hierarchical	I-C0026336
modeling	I-C0026336
approach	I-C0026336
based	O
on	O
the	O
results	B-C1274040
from	O
these	O
studies	B-C2603343
,	O
aiming	O
at	O
systematically	B-C0220922
predicting	B-C0681842
the	O
structure	B-C0678594
-	O
composition	B-C0005885
-	O
property	B-C0871161
relations	B-C0439849
of	O
cuticle	B-C2699479
composites	B-C0205199
from	O
the	O
molecular	B-C1521991
level	B-C0441889
to	O
the	O
macro-scale	B-C0392762
.	O
	
this	O
modeling	B-C0026336
approach	I-C0026336
provides	O
a	O
tool	O
to	O
facilitate	O
the	O
development	B-C1527148
of	O
optimized	O
biomimetic	B-C1136386
materials	I-C1136386
within	O
a	O
knowledge-based	B-C0026336
design	I-C0026336
approach	I-C0026336
.	O
	
draft	B-C2348746
genome	I-C2348746
sequences	I-C2348746
of	O
15	O
isolates	B-C3494793
of	O
listeria	B-C3472320
monocytogenes	I-C3472320
serotype	I-C3472320
1/2a	I-C3472320
,	O
subgroup	B-C1515021
st204	B-C1518614
listeria	B-C0023861
monocytogenes	I-C0023861
sequence	B-C1518614
type	I-C1518614
204	I-C1518614
st204	I-C1518614
strains	I-C1518614
have	O
been	O
isolated	B-C0205409
from	O
a	O
range	B-C0016452
of	I-C0016452
food	I-C0016452
,	O
environmental	B-C0014406
,	O
and	O
clinical	B-C0205210
sources	B-C0449416
in	O
australia	B-C0004340
.	O
	
this	O
study	O
describes	O
the	O
draft	B-C2348746
genome	I-C2348746
sequences	I-C2348746
of	O
15	O
isolates	O
collected	O
from	O
meat	B-C0025017
and	O
dairy	B-C0010947
associated	I-C0010947
sources	I-C0010947
.	O
	
high	O
transferability	B-C0205556
of	O
homoeolog-specific	B-C0017393
markers	I-C0017393
between	O
bread	B-C0006138
wheat	B-C0043137
and	O
newly	O
synthesized	B-C1883254
hexaploid	B-C0043137
wheat	I-C0043137
lines	I-C0043137
bread	B-C0006138
wheat	B-C0043137
triticum	B-C1123020
aestivum	I-C1123020
,	O
2n	O
=	O
6x	O
=	O
42	O
,	O
aabbdd	O
has	O
a	O
complex	O
allohexaploid	B-C0017428
genome	I-C0017428
,	O
which	O
makes	O
it	O
difficult	O
to	O
differentiate	B-C2945687
between	O
the	O
homoeologous	B-C0162774
sequences	I-C0162774
and	O
assign	O
them	O
to	O
the	O
chromosome	B-C0008633
a	I-C0008633
,	O
b	B-C0008633
,	O
or	O
d	B-C0008633
subgenomes	B-C0017428
.	O
	
the	O
chromosome	B-C0008633
-based	O
draft	O
genome	B-C0017428
sequence	B-C0004793
of	O
the	O
'	O
chinese	B-C0043137
spring	I-C0043137
'	O
common	O
wheat	B-C0043137
cultivar	I-C0043137
enables	O
the	O
large-scale	O
development	B-C1527148
of	O
polymerase	B-C0032520
chain	I-C0032520
reaction	I-C0032520
pcr	B-C0032520
markers	B-C0017393
specific	O
for	O
homoeologs	O
.	O
	
based	O
on	O
high-confidence	O
'	O
chinese	B-C0043137
spring	I-C0043137
'	O
genes	B-C0017337
with	O
known	O
functions	O
,	O
we	O
developed	O
183	O
putative	O
homoeolog-specific	B-C0017393
markers	I-C0017393
for	O
chromosomes	B-C0008633
4b	I-C0008633
and	O
7b	B-C0008633
.	O
	
these	O
markers	B-C0017393
were	O
used	O
in	O
pcr	B-C0032520
assays	I-C0032520
for	O
the	O
4b	B-C0008633
and	O
7b	B-C0008633
nullisomes	O
and	O
their	O
euploid	O
synthetic	B-C0043137
hexaploid	I-C0043137
wheat	I-C0043137
shw	I-C0043137
line	I-C0043137
that	O
was	O
newly	O
generated	O
from	O
a	O
hybridization	B-C0376343
between	O
triticum	B-C0997189
turgidum	I-C0997189
aabb	O
and	O
the	O
wild	O
diploid	B-C1257909
species	I-C1257909
aegilops	B-C1007013
tauschii	I-C1007013
dd	O
.	O
	
up	O
to	O
64%	O
of	O
the	O
markers	B-C0017393
for	O
chromosomes	B-C0008633
4b	I-C0008633
or	O
7b	B-C0008633
in	O
the	O
shw	B-C0043137
background	O
were	O
confirmed	O
to	O
be	O
homoeolog-specific	O
.	O
	
thus	O
,	O
these	O
markers	B-C0017393
were	O
highly	O
transferable	O
between	O
the	O
'	O
chinese	B-C0043137
spring	I-C0043137
'	O
bread	B-C0006138
wheat	B-C0043137
and	O
shw	B-C0043137
lines	I-C0043137
.	O
	
homoeolog-specific	B-C0017393
markers	I-C0017393
designed	O
using	O
genes	B-C0017337
with	O
known	O
functions	O
may	O
be	O
useful	O
for	O
genetic	B-C0796344
investigations	I-C0796344
involving	O
homoeologous	O
chromosome	B-C0008633
tracking	O
and	O
homoeolog	O
expression	B-C0017262
participation	B-C0679823
in	O
and	O
adherence	B-C1510802
to	O
physical	B-C0015259
exercise	I-C0015259
after	O
completion	B-C0205197
of	O
primary	B-C1306459
cancer	I-C1306459
treatment	B-C0087111
the	O
purpose	B-C1285529
of	O
this	O
study	B-C2603343
was	O
to	O
identify	B-C0020792
demographic	B-C0011292
,	O
clinical	B-C0205210
,	O
psychosocial	B-C0542298
,	O
physical	B-C0205485
and	O
environmental	B-C0014406
factors	B-C1521761
that	O
are	O
associated	B-C0332281
with	I-C0332281
participation	B-C0679823
in	O
and	O
adherence	B-C1510802
to	O
a	O
combined	B-C0205195
resistance	B-C4281815
and	O
endurance	B-C0419120
exercise	I-C0419120
program	B-C3484370
among	O
cancer	B-C1516231
survivors	I-C1516231
,	O
shortly	O
after	O
completion	B-C0205197
of	O
primary	B-C1306459
cancer	I-C1306459
treatment	B-C0087111
.	O
	
data	B-C1511726
from	O
the	O
randomized	B-C3815594
controlled	B-C2587213
resistance	B-C0282574
and	I-C0282574
endurance	I-C0282574
exercise	I-C0282574
after	I-C0282574
chemotherapy	I-C0282574
react	B-C0282574
study	B-C2603343
were	O
used	O
for	O
this	O
study	B-C2603343
.	O
	
the	O
participants	B-C0679646
of	O
the	O
react	B-C0282574
study	B-C2603343
were	O
randomly	B-C0439605
allocated	B-C1706778
to	O
either	O
a	O
high	B-C4081854
intensity	I-C4081854
hi	B-C4081854
or	O
low	B-C0205251
-to-	O
moderate	B-C4081855
intensity	I-C4081855
lmi	B-C0522510
exercise	B-C0015259
program	B-C3484370
.	O
	
patients	B-C0030705
'	O
participation	B-C0679823
rate	B-C1521828
was	O
defined	O
as	O
the	O
cancer	B-C1516231
survivors	I-C1516231
'	O
decision	O
to	O
participate	B-C0679823
in	O
the	O
react	B-C0282574
study	B-C2603343
.	O
	
exercise	B-C0015259
adherence	B-C1510802
reflected	B-C0558058
participants	B-C0679646
'	O
attendance	B-C2827364
to	O
the	O
scheduled	B-C0205539
exercise	B-C0015259
sessions	B-C1883016
and	O
their	O
compliance	B-C1321605
to	O
the	O
prescribed	B-C0278329
exercises	B-C0015259
.	O
	
high	B-C0205250
session	B-C1883016
attendance	B-C2827364
rates	B-C1521828
were	O
defined	O
as	O
attending	B-C1999232
at	O
least	O
80	O
%	O
of	O
the	O
sessions	B-C1883016
.	O
	
high	B-C0205250
compliance	B-C1321605
rates	B-C1521828
were	O
defined	O
as	O
performing	B-C0884358
at	O
least	O
of	O
90	O
%	O
of	O
the	O
prescribed	B-C0278329
exercise	B-C0015259
across	O
all	O
sessions	B-C1883016
.	O
	
correlates	B-C1707520
of	O
exercise	B-C0015259
adherence	B-C1510802
were	O
studied	B-C2603343
separately	B-C0443299
for	O
hi	B-C4081854
and	O
lmi	B-C0522510
exercise	B-C0015259
.	O
	
demographic	B-C0011292
,	O
clinical	B-C0205210
,	O
and	O
physical	B-C0205485
factors	B-C1521761
were	O
assessed	B-C1516048
using	O
self-reported	B-C0681906
questionnaires	B-C0034394
.	O
	
relevant	B-C2347946
clinical	B-C2708733
information	I-C2708733
was	O
extracted	B-C1301820
from	O
medical	B-C0025102
records	I-C0025102
.	O
	
multivariable	B-C0681925
logistic	I-C0681925
regression	I-C0681925
analyses	I-C0681925
were	O
applied	B-C4048755
to	O
identify	B-C0020792
correlates	B-C1707520
that	O
were	O
significantly	B-C0750502
associated	B-C0332281
with	I-C0332281
participation	B-C0679823
,	O
high	B-C0205250
session	B-C1883016
attendance	B-C2827364
,	O
high	B-C0205250
compliance	B-C1321605
with	O
resistance	B-C4281815
and	O
high	B-C0205250
compliance	B-C1321605
with	O
endurance	B-C0419120
exercises	I-C0419120
.	O
	
participants	B-C0679646
were	O
more	B-C3840799
likely	I-C3840799
to	O
have	O
higher	B-C0424933
education	I-C0424933
,	O
be	O
non-smokers	B-C0337672
,	O
have	O
lower	B-C0205251
psychological	B-C0815107
distress	I-C0815107
,	O
higher	B-C0205250
outcome	B-C0085415
expectations	B-C0679138
,	O
and	O
perceive	B-C0030971
more	B-C0205172
exercise	B-C0015259
barriers	B-C0679881
than	O
non-participants	B-C1257890
.	O
	
in	O
hi	B-C4081854
exercise	B-C0015259
,	O
higher	B-C0205250
self-efficacy	B-C0600564
was	O
significantly	B-C0750502
associated	B-C0332281
with	I-C0332281
high	B-C0205250
session	B-C1883016
attendance	B-C2827364
and	O
high	B-C0205250
compliance	B-C1321605
with	O
endurance	B-C0419120
exercises	I-C0419120
,	O
and	O
lower	B-C0205251
psychological	B-C0815107
distress	I-C0815107
was	O
significantly	B-C0750502
associated	B-C0332281
with	I-C0332281
high	B-C0205250
compliance	B-C1321605
with	O
resistance	B-C4281815
exercise	B-C0015259
s	O
.	O
	
in	O
lmi	B-C0522510
exercise	B-C0015259
,	O
being	O
a	O
non-smoker	B-C0337672
was	O
significantly	B-C0750502
associated	B-C0332281
with	I-C0332281
high	B-C0205250
compliance	B-C1321605
with	O
resistance	B-C4281815
exercises	B-C0015259
and	O
higher	B-C0205250
bmi	B-C1305855
was	O
significantly	B-C0750502
associated	B-C0332281
with	I-C0332281
high	B-C0205250
compliance	B-C1321605
with	O
resistance	B-C4281815
and	O
endurance	B-C0419120
exercises	I-C0419120
.	O
	
furthermore	O
,	O
breast	B-C1516231
cancer	I-C1516231
survivors	I-C1516231
were	O
less	B-C0439092
likely	B-C0750492
to	O
report	B-C0700287
high	B-C0205250
compliance	B-C1321605
with	O
resistance	B-C4281815
and	O
endurance	B-C0419120
exercises	I-C0419120
in	O
lmi	B-C0522510
exercise	B-C0015259
compared	B-C1707455
to	O
survivors	B-C0206194
of	O
other	O
types	O
of	O
cancer	B-C0006826
.	O
	
the	O
discriminative	B-C0012632
ability	B-C0085732
of	O
the	O
multivariable	B-C0439828
models	B-C3161035
ranged	B-C1514721
from	O
0.62	O
to	O
0.75	O
.	O
	
several	O
demographic	B-C0011292
,	O
clinical	B-C0205210
and	O
psychosocial	B-C0542298
factors	B-C1521761
were	O
associated	B-C0332281
with	I-C0332281
participation	B-C0679823
in	O
and	O
adherence	B-C1510802
to	O
exercise	B-C0015259
among	O
cancer	B-C1516231
survivors	I-C1516231
.	O
	
psychosocial	B-C0542298
factors	B-C1521761
were	O
more	B-C0205172
strongly	B-C0442821
associated	B-C0332281
with	I-C0332281
adherence	B-C1510802
in	O
hi	B-C4081854
than	O
lmi	B-C0522510
exercise	B-C0015259
.	O
	
this	O
study	B-C2603343
was	O
registered	B-C0684224
at	O
the	O
netherlands	B-C0034975
trial	I-C0034975
register	I-C0034975
ntr2153	B-C0034975
in	B-C0444498
situ	I-C0444498
stabilization	B-C0205360
of	O
heavy	B-C0347988
metals	I-C0347988
in	O
multiple-	O
metal	B-C0025552
contaminated	B-C0205279
paddy	B-C1083174
soil	B-C0037592
using	O
different	O
steel	B-C0038239
slag	B-C0885779
-based	O
silicon	B-C0037107
fertilizer	B-C0015919
steel	B-C0038239
slag	B-C0885779
has	O
been	O
widely	O
used	O
as	O
amendment	O
and	O
silicon	B-C0037107
fertilizer	B-C0015919
to	O
alleviate	O
the	O
mobility	B-C0425245
and	O
bioavailability	B-C0005508
of	O
heavy	B-C0347988
metals	I-C0347988
in	O
soil	B-C0037592
.	O
	
the	O
objective	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	B-C0220825
the	O
influence	B-C4054723
of	O
particle	B-C0030608
size	I-C0030608
,	O
composition	B-C0243176
,	O
and	O
application	O
rate	O
of	O
slag	B-C0885779
on	O
metal	B-C0025552
immobilization	B-C0205245
in	O
acidic	B-C0001128
soil	B-C0037592
,	O
metals	B-C0025552
uptake	B-C0243144
by	O
rice	B-C1140671
and	O
rice	B-C1140671
growth	B-C0220844
.	O
	
the	O
results	O
indicated	O
that	O
application	O
of	O
slag	B-C0885779
increased	O
soil	B-C0037592
ph	B-C0020283
,	O
plant	B-C0032098
-available	O
silicon	B-C0037107
concentrations	B-C1446561
in	O
soil	B-C0037592
,	O
and	O
decreased	B-C0205216
the	O
bioavailability	B-C0005508
of	O
metals	B-C0025552
compared	O
with	O
control	B-C0243148
treatment	I-C0243148
,	O
whereas	O
pulverous	B-C0885779
slag	I-C0885779
s1	B-C0885779
was	O
more	B-C1704419
effective	I-C1704419
than	O
granular	B-C0205248
slag	B-C0885779
s2	O
and	O
s3	O
.	O
	
the	O
acid	B-C0001128
-	O
extractable	B-C1264633
fraction	I-C1264633
of	I-C1264633
cd	B-C0006632
in	O
the	O
spiked	O
soil	B-C0037592
was	O
significantly	O
decreased	B-C0205216
with	O
application	O
of	O
s1	B-C0885779
at	O
rates	O
of	O
1	O
and	O
3	O
%	O
,	O
acid-extractable	O
fractions	O
of	O
cu	B-C0009968
and	O
zn	B-C0043481
were	O
decreased	B-C0205216
when	O
treated	B-C1522326
at	O
3	O
%	O
.	O
	
use	O
of	O
s1	B-C0885779
at	O
both	O
rates	O
resulted	O
in	O
significantly	B-C4055638
lower	I-C4055638
cd	B-C0006632
,	O
cu	B-C0009968
,	O
and	O
zn	B-C0043481
concentrations	B-C1446561
in	O
rice	B-C1140671
tissues	B-C1514137
than	O
in	O
controls	B-C0009932
by	O
82.6	O
,	O
88.4	O
,	O
and	O
67.4	O
%	O
,	O
respectively	O
.	O
	
however	O
,	O
use	O
of	O
pulverous	B-C0885779
slag	I-C0885779
at	O
1	O
%	O
significantly	O
promotes	B-C0033414
rice	B-C1140671
growth	B-C0220844
,	O
restricted	O
rice	B-C1140671
growth	B-C0220844
when	O
treated	B-C1522326
at	O
3	O
%	O
.	O
	
thus	O
,	O
the	O
results	O
explained	O
that	O
reduced	B-C0392756
particle	B-C0030608
size	I-C0030608
and	O
suitable	O
application	O
rate	O
of	O
slag	B-C0885779
could	O
be	O
beneficial	O
to	O
rice	B-C1140671
growth	B-C0220844
and	O
metals	B-C0025552
stabilization	B-C0205360
.	O
	
plasmodium	B-C0032150
falciparum	I-C0032150
choline	B-C0008415
kinase	I-C0008415
inhibition	B-C3463820
leads	O
to	O
a	O
major	O
decrease	B-C0547047
in	O
phosphatidylethanolamine	B-C1450468
causing	O
parasite	B-C0030498
death	B-C0011065
malaria	B-C0024530
is	O
a	O
life-threatening	B-C2826244
disease	B-C0012634
caused	O
by	O
different	O
species	B-C1705920
of	O
the	O
protozoan	B-C0585171
parasite	I-C0585171
plasmodium	B-C0032148
,	O
with	O
p	B-C0032150
.	O
	
falciparum	I-C0032150
being	O
the	O
deadliest	O
.	O
	
increasing	B-C0442808
parasitic	B-C0521066
resistance	B-C4281815
to	O
existing	O
antimalarials	B-C0003374
makes	O
the	O
necessity	O
of	O
novel	B-C0205314
avenues	O
to	O
treat	B-C0087111
this	O
disease	B-C0012634
an	O
urgent	O
priority	O
.	O
	
the	O
enzymes	B-C0014442
responsible	O
for	O
the	O
synthesis	B-C1883254
of	O
phosphatidylcholine	B-C1959616
and	O
phosphatidylethanolamine	B-C1450468
are	O
attractive	O
drug	B-C1521840
targets	I-C1521840
to	O
treat	B-C0087111
malaria	B-C0024530
as	O
their	O
selective	O
inhibition	B-C3463820
leads	O
to	O
an	O
arrest	O
of	O
the	O
parasite's	B-C0030498
growth	B-C0018270
and	O
cures	B-C0679252
malaria	B-C0024530
in	O
a	O
mouse	B-C2986594
model	I-C2986594
.	O
	
we	O
present	O
here	O
a	O
detailed	O
study	B-C2603343
that	O
reveals	O
a	O
mode	B-C1524059
of	I-C1524059
action	I-C1524059
for	O
two	O
p	B-C0032150
.	O
	
falciparum	I-C0032150
choline	B-C0008415
kinase	I-C0008415
inhibitors	B-C0243077
both	O
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
.	O
	
the	O
compounds	B-C0205198
present	O
distinct	O
binding	B-C1167622
modes	O
to	O
the	O
choline	B-C0008405
/	O
ethanolamine	B-C0059696
-	O
binding	B-C0005456
site	I-C0005456
of	O
p	B-C0032150
.	O
	
falciparum	I-C0032150
choline	B-C0008415
kinase	I-C0008415
,	O
reflecting	O
different	O
types	O
of	O
inhibition	B-C3463820
.	O
	
strikingly	O
,	O
these	O
compounds	B-C0205198
primarily	O
inhibit	O
the	O
ethanolamine	B-C1150468
kinase	I-C1150468
activity	I-C1150468
of	O
the	O
p	B-C0032150
.	O
	
falciparum	I-C0032150
choline	B-C0008415
kinase	I-C0008415
,	O
leading	O
to	O
a	O
severe	O
decrease	B-C0547047
in	O
the	O
phosphatidylethanolamine	B-C1450468
levels	B-C0441889
within	O
p	B-C0032150
.	O
	
falciparum	I-C0032150
,	O
which	O
explains	O
the	O
resulting	O
growth	B-C0031437
phenotype	I-C0031437
and	O
the	O
parasites	B-C0030498
death	B-C0011065
.	O
	
these	O
studies	O
provide	O
an	O
understanding	O
of	O
the	O
mode	B-C1524059
of	I-C1524059
action	I-C1524059
,	O
and	O
act	O
as	O
a	O
springboard	O
for	O
continued	O
antimalarial	B-C0243107
development	I-C0243107
efforts	O
selectively	O
targeting	O
p	B-C0032150
.	O
	
falciparum	I-C0032150
choline	B-C0008415
kinase	I-C0008415
.	O
	
anti-cd45rb	B-C0003250
and	O
donor-specific	B-C0199960
spleen	I-C0199960
cells	I-C0199960
transfusion	I-C0199960
inhibition	B-C3463820
allograft	B-C2891288
skin	I-C2891288
rejection	I-C2891288
mediated	O
by	O
memory	B-C0682639
t	I-C0682639
cells	I-C0682639
donor-reactive	O
memory	B-C0682639
t	I-C0682639
tm	I-C0682639
mediate	O
accelerated	O
rejection	B-C0018129
,	O
which	O
is	O
known	O
as	O
a	O
barrier	O
to	O
the	O
survival	O
of	O
transplanted	B-C0524930
organs	I-C0524930
.	O
	
selective	O
interference	O
with	O
the	O
anti-cd45rb	B-C0003250
monoclonal	I-C0003250
antibody	I-C0003250
α-cd45rb	I-C0003250
reliably	O
induces	O
donor	B-C0013018
-	O
specific	B-C0205369
tolerance	B-C0887937
.	O
	
in	O
this	O
study	B-C2603343
,	O
pre-sensitization	B-C1254367
to	O
female	B-C0086287
c57bl/6	B-C1521751
mice	I-C1521751
with	O
the	O
skin	B-C1123023
of	O
female	B-C0086287
blab/c	B-C0026809
mice	I-C0026809
generated	O
a	O
large	O
number	O
of	O
tm	B-C0682639
cells	I-C0682639
and	O
resulted	O
in	O
rapid	O
rejection	B-C0018129
of	O
the	O
secondly	B-C0205436
transplanted	B-C0700106
allografts	B-C0450127
.	O
	
α-cd45rb	B-C0003250
did	O
induce	O
the	O
tolerance	B-C0887937
to	O
skin	B-C0440814
allograft	I-C0440814
primarily	B-C0205225
transplanted	B-C0700106
but	O
failed	O
to	O
induce	O
tolerance	B-C0887937
in	O
the	O
pre-sensitized	B-C0026809
mice	I-C0026809
.	O
	
donor-specific	B-C0199960
spleen	I-C0199960
cell	I-C0199960
transfusion	I-C0199960
dst	B-C0199960
alone	O
also	O
failed	O
to	O
induce	O
the	O
tolerance	B-C0887937
in	O
the	O
pre-sensitized	B-C1254367
recipients	B-C0376387
.	O
	
interestingly	O
,	O
combination	O
of	O
α-cd45rb	B-C0003250
with	O
dst	B-C0199960
inhibited	O
the	O
rejection	B-C0018129
induced	O
by	O
memory	B-C0682639
t	I-C0682639
cells	I-C0682639
in	O
the	O
pre-sensitized	B-C0026809
mice	I-C0026809
.	O
	
cd25+	B-C0039194
t-cell	I-C0039194
depletion	B-C0677960
in	O
α-cd45rb	B-C0003250
combined	O
with	O
dst	B-C0199960
therapy	B-C0087111
recipients	B-C0376387
could	O
prevent	O
skin	B-C0440814
allograft	I-C0440814
tolerance	B-C0887937
from	O
establishing	O
.	O
	
in	O
addition	O
,	O
adoptive	B-C0376518
transfer	I-C0376518
of	O
donor	B-C0013018
-primed	O
memory	B-C0682639
t	I-C0682639
cells	I-C0682639
into	O
the	O
tolerant	B-C0887937
recipients	B-C0376387
markedly	O
broke	O
the	O
established	O
tolerance	B-C0887937
.	O
	
our	O
findings	B-C0243095
indicate	O
that	O
α-cd45rb	B-C0003250
and	O
dst	B-C0199960
can	O
synergistically	O
inhibit	O
the	O
accelerated	O
rejection	B-C0018129
mediated	O
by	O
memory	B-C0682639
t	I-C0682639
cells	I-C0682639
and	O
induce	O
long-term	O
skin	B-C0440814
allograft	I-C0440814
acceptance	B-C0301944
in	O
recruitment	B-C2949735
of	O
minority	B-C0026192
adolescents	B-C0205653
and	O
young	B-C0238598
adults	I-C0238598
into	O
randomised	B-C0206035
clinical	I-C0206035
trials	I-C0206035
testing	B-C0039593
the	O
design	B-C1707689
of	O
the	O
technology	B-C0886296
enhanced	I-C0886296
community	I-C0886296
health	I-C0886296
nursing	I-C0886296
tech-n	B-C0886296
pelvic	B-C0242172
inflammatory	I-C0242172
disease	I-C0242172
trial	O
pelvic	B-C0242172
inflammatory	I-C0242172
disease	I-C0242172
pid	B-C0242172
disproportionately	B-C0205350
affects	O
adolescent	B-C0205653
and	O
young	B-C0238598
adult	I-C0238598
aya	B-C0027362
women	B-C0043210
and	O
can	O
negatively	O
influence	B-C4054723
reproductive	B-C0242667
health	I-C0242667
trajectories	O
.	O
	
few	O
randomized	B-C0206035
controlled	I-C0206035
trials	I-C0206035
rcts	B-C0206035
have	O
focused	O
on	O
strategies	O
to	O
improve	B-C0184511
outpatient	B-C0029921
adherence	B-C1510802
or	O
to	O
reduce	B-C0392756
reproductive	B-C0035150
morbidity	B-C0026538
in	O
this	O
population	B-C1257890
.	O
	
this	O
paper	O
describes	O
the	O
research	B-C0086912
methods	I-C0086912
and	O
preliminary	B-C0439611
effectiveness	B-C1280519
of	O
recruitment	B-C2949735
,	O
retention	B-C0679857
,	O
and	O
intervention	B-C0886296
strategies	O
employed	O
in	O
a	O
novel	O
rct	B-C0206035
designed	O
to	O
test	O
a	O
technology-enhanced	B-C0886296
community-health	I-C0886296
nursing	I-C0886296
tech-n	B-C0886296
intervention	B-C0886296
among	O
urban	O
aya	B-C0027362
with	O
pid	B-C0242172
.	O
	
aya	B-C0027362
women	B-C0043210
aged	B-C0001779
13-25	O
years	B-C1510829
were	O
recruited	B-C2949735
during	O
acute	B-C0149959
pid	I-C0149959
visits	B-C1512346
in	O
outpatient	B-C0002424
clinics	I-C0002424
and	O
emergency	B-C0562508
departments	I-C0562508
ed	B-C0562508
to	O
participate	B-C0030699
in	O
this	O
irb-approved	B-C2346499
trial	O
.	O
	
participants	B-C0679646
completed	B-C0205197
an	O
audio-computerized	B-C0021822
self-interview	I-C0021822
acasi	B-C0021822
,	O
provided	O
vaginal	B-C0586773
specimens	I-C0586773
,	O
and	O
were	O
randomized	B-C0034656
to	O
standard	B-C1442989
treatment	B-C0087111
or	O
the	O
intervention	B-C0886296
.	O
	
intervention	B-C0886296
participants	B-C0679646
received	B-C1514756
text-messaging	B-C3178908
support	B-C1521721
for	O
30	O
days	B-C0439228
and	O
a	O
community	B-C1522710
health	I-C1522710
nurse	I-C1522710
chn	I-C1522710
interventionist	I-C1522710
performed	B-C0884358
a	O
home	B-C2046813
visit	I-C2046813
with	I-C2046813
clinical	I-C2046813
assessment	I-C2046813
within	O
5	O
days	B-C0439228
after	O
enrollment	B-C1516879
.	O
	
all	O
patients	B-C0030705
received	O
a	O
full	O
course	B-C0750729
of	O
medications	B-C1254363
and	O
completed	B-C0205197
research	O
visits	B-C0848616
at	O
14-	O
days	B-C0439228
adherence	B-C1510802
,	O
30	O
days	B-C0439228
and	O
90	O
days	B-C0439228
with	O
by	O
an	O
outreach	B-C0586969
worker	I-C0586969
.	O
	
sti	B-C0036916
testing	B-C0039593
performed	B-C0884358
at	O
the	O
30-and	O
90-	O
day	B-C0439228
visits	B-C1512346
.	O
	
exploratory	B-C0936012
analyses	I-C0936012
using	O
descriptive	B-C1710191
statistics	I-C1710191
were	O
conducted	O
to	O
examine	O
recruitment	B-C2949735
,	O
retention	B-C0679857
,	O
and	O
follow-up	B-C1522577
data	B-C1511726
to	O
test	O
the	O
overall	O
design	B-C1707689
of	O
the	O
intervention	B-C0886296
.	O
	
in	O
the	O
first	O
48	O
months	B-C0439231
,	O
64%	O
of	O
463	O
patients	B-C0030705
were	O
eligible	B-C1548635
for	O
the	O
study	O
and	O
81.2	O
of	O
293	O
eligible	B-C1548635
patients	B-C0030705
were	O
recruited	B-C2949735
for	O
the	O
study	O
63.3	O
238	O
81.2	O
of	O
eligible	B-C1548635
patients	B-C0030705
were	O
enrolled	B-C1516879
.	O
	
most	O
participants	B-C0679646
were	O
african	B-C0085756
american	I-C0085756
95.6	O
with	O
a	O
mean	B-C0444504
age	B-C0001779
of	O
18.6	O
2.3	O
.	O
	
ninety-four	O
percent	O
of	O
individuals	B-C0027361
assigned	O
to	O
the	O
tech-n	B-C0886296
intervention	I-C0886296
completed	B-C0205197
the	O
nursing	B-C0848616
visits	I-C0848616
.	O
	
all	O
completed	B-C0205197
visits	B-C0848616
have	O
been	O
within	O
the	O
5-	O
day	B-C0439228
window	B-C1272706
and	O
over	O
90%	O
of	O
patients	B-C0030705
in	O
both	O
arms	O
have	O
been	O
retained	B-C0333118
over	O
the	O
3-	O
month	B-C0439231
follow-up	B-C1522577
period	B-C1948053
.	O
	
biological	B-C0205460
data	B-C1511726
suggests	O
a	O
shift	B-C0001398
in	I-C0001398
the	I-C0001398
biological	I-C0001398
milieu	I-C0001398
with	O
the	O
predominance	O
of	O
chlamydia	B-C0518948
trachomatis	I-C0518948
,	O
mycoplasma	B-C3854370
genitalium	I-C3854370
,	O
and	O
trichomonas	B-C0040923
vaginalis	I-C0040923
infections	I-C0040923
.	O
	
preliminary	B-C0439611
data	B-C1511726
from	O
the	O
tech-n	B-C0886296
study	O
demonstrated	O
that	O
urban	B-C0442529
,	O
low-income	B-C1331016
,	O
minority	B-C0026192
aya	B-C0027362
with	O
pid	B-C0242172
can	O
effectively	O
be	O
recruited	B-C2949735
and	O
retained	B-C0333118
to	O
participate	B-C0030699
in	O
sexual	B-C2362326
and	O
reproductive	B-C0242667
health	I-C0242667
rcts	B-C0206035
with	O
sufficient	B-C0205410
investment	B-C0021953
in	O
the	O
design	B-C1707689
and	O
infrastructure	B-C1514880
of	I-C1514880
the	I-C1514880
study	I-C1514880
.	O
	
community	B-C0009462
-based	O
sexual	B-C2362326
health	I-C2362326
interventions	B-C0184661
appear	O
to	O
be	O
both	O
feasible	B-C0205556
and	O
acceptable	B-C1879533
in	O
this	O
extended	O
use	O
of	O
prostate	B-C4084801
health	I-C4084801
index	I-C4084801
and	O
percentage	O
of	O
-2	B-C3710767
antigen	I-C3710767
in	O
chinese	B-C0152035
men	B-C0025266
with	O
prostate	B-C0138741
specific	I-C0138741
antigen	I-C0138741
10-20	O
ng/ml	O
and	O
normal	B-C0205307
digital	B-C1384593
rectal	I-C1384593
examination	I-C1384593
we	O
investigated	O
the	O
extended	O
use	O
of	O
prostate	B-C4084801
health	I-C4084801
index	I-C4084801
phi	B-C4084801
and	O
percentage	O
of	O
-2	B-C3710767
antigen	I-C3710767
%p2psa	B-C3710767
in	O
chinese	B-C0152035
men	B-C0025266
with	O
prostate-specific	B-C0138741
antigen	I-C0138741
psa	B-C0138741
10-20	O
ng/ml	O
and	O
normal	B-C0205307
digital	B-C1384593
rectal	I-C1384593
examination	I-C1384593
dre	B-C1384593
.	O
	
all	O
consecutive	O
chinese	B-C0152035
men	B-C0025266
with	O
psa	B-C0138741
10-20	O
ng/ml	O
and	O
normal	B-C0205307
dre	B-C1384593
who	O
agreed	O
for	O
transrectal	B-C0373345
ultrasound	I-C0373345
trus	B-C0373345
10-core	O
prostate	B-C0194804
biopsy	I-C0194804
were	O
recruited	O
.	O
	
blood	B-C0178913
samples	I-C0178913
were	O
taken	O
immediately	O
before	O
trus	B-C0373345
-guided	O
prostate	B-C0194804
biopsy	I-C0194804
.	O
	
the	O
performances	O
of	O
total	B-C2986589
psa	I-C2986589
tpsa	B-C2986589
,	O
%	O
free-to-total	B-C2207083
psa	I-C2207083
%	O
fpsa	B-C2207083
,	O
%p2psa	B-C3710767
,	O
and	O
phi	B-C4084801
were	O
compared	O
using	O
logistic	B-C0206031
regression	I-C0206031
,	O
receiver	B-C0034772
operating	I-C0034772
characteristic	I-C0034772
,	O
and	O
decision	B-C0936012
curve	I-C0936012
analyses	I-C0936012
dca	B-C0936012
.	O
	
from	O
2008	O
to	O
2015	O
,	O
312	O
consecutive	O
chinese	B-C0152035
men	B-C0025266
were	O
included	O
.	O
	
among	O
them	O
,	O
53	O
out	O
of	O
312	O
17.0	O
men	B-C0025266
were	O
diagnosed	B-C0011900
to	O
have	O
prostate	B-C0376358
cancer	I-C0376358
on	O
biopsy	B-C0005558
.	O
	
the	O
proportions	O
of	O
men	B-C0025266
with	O
positive	B-C1514241
biopsies	I-C1514241
were	O
6.7	O
in	O
phi	O
<35	O
,	O
22.8	O
in	O
phi	O
35-55	O
,	O
and	O
54.5	O
in	O
phi	O
>55	O
chi-square	O
test	O
,	O
p<0	O
.	O
	
the	O
area	O
under	O
curves	O
auc	O
of	O
the	O
base	O
model	O
including	O
age	O
,	O
tpsa	O
and	O
status	O
of	O
initial/repeated	O
biopsy	O
was	O
0.64	O
.	O
	
adding	O
%p2psa	O
and	O
phi	O
to	O
the	O
base	O
model	O
improved	O
the	O
auc	O
to	O
0.79	O
p<0	O
and	O
0.78	O
p<0	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
dca	O
.	O
	
the	O
positive	O
biopsy	O
rates	O
of	O
gleason	O
7	O
or	O
above	O
prostate	O
cancers	O
were	O
2.2	O
for	O
phi	O
<35	O
,	O
7.9	O
for	O
phi	O
35-55	O
,	O
and	O
36.4	O
for	O
phi	O
>55	O
chi-square	O
test	O
,	O
p<0	O
.	O
	
by	O
utilizing	O
the	O
phi	O
cutoff	O
of	O
35	O
to	O
men	O
with	O
psa	O
10-20	O
ng/ml	O
and	O
normal	O
dre	O
,	O
57.1	O
178	O
of	O
312	O
biopsies	B-C0005558
could	O
be	O
avoided	O
.	O
	
both	O
phi	B-C4084801
and	O
%p2psa	O
performed	O
well	O
in	O
predicting	O
prostate	O
cancer	O
and	O
high	O
grade	O
prostate	O
cancer	O
.	O
	
the	O
use	O
of	O
phi	B-C4084801
and	O
%p2psa	O
should	O
be	O
extended	O
to	O
chinese	O
men	O
with	O
psa	O
10-20	O
ng/ml	O
and	O
normal	O
dre	B-C1384593
a	O
pilot	B-C0031928
study	I-C0031928
exploring	O
the	O
relationship	B-C0439849
between	O
self	B-C0036588
-	O
compassion	B-C0242270
,	O
self	B-C0036588
-	O
judgement	B-C0022423
,	O
self	B-C0036588
-	O
kindness	B-C0871641
,	O
compassion	B-C0242270
,	O
professional	B-C0034380
quality	I-C0034380
of	I-C0034380
life	I-C0034380
and	O
wellbeing	B-C0031206
among	O
uk	B-C0041700
community	B-C0557521
nurses	I-C0557521
compassion	B-C4042834
fatigue	I-C4042834
and	O
burnout	B-C0006433
can	O
impact	B-C4049986
on	O
performance	B-C1882330
of	O
nurses	B-C0557521
.	O
	
this	O
paper	O
explores	O
the	O
relationship	B-C0439849
between	O
self	B-C0036588
-	O
compassion	B-C0242270
,	O
self	B-C0036588
-	O
judgement	B-C0022423
,	O
self	B-C0036588
-	O
kindness	B-C0871641
,	O
compassion	B-C0242270
,	O
professional	B-C0034380
quality	I-C0034380
of	I-C0034380
life	I-C0034380
,	O
and	O
wellbeing	B-C0031206
among	O
community	B-C0557521
nurses	I-C0557521
.	O
	
to	O
measure	B-C0079809
associations	B-C0332281
between	O
self	B-C0036588
-	O
compassion	B-C0242270
,	O
compassion	B-C4042834
fatigue	I-C4042834
,	O
wellbeing	B-C0031206
,	O
and	O
burnout	B-C0006433
in	O
community	B-C0557521
nurses	I-C0557521
.	O
	
quantitative	B-C0392762
data	B-C1511726
were	O
collected	B-C1516698
using	O
standardised	B-C1442989
psychometric	B-C0034394
questionnaires	I-C0034394
1	O
professional	B-C0451401
quality	I-C0451401
of	I-C0451401
life	I-C0451401
scale	I-C0451401
2	O
self-compassion	B-C0392762
scale	I-C0392762
3	O
short	B-C4075266
warwick	I-C4075266
edinburgh	I-C4075266
mental	I-C4075266
wellbeing	I-C4075266
scale	I-C4075266
4	O
compassion	B-C0392762
for	I-C0392762
others	I-C0392762
scale	I-C0392762
,	O
used	O
to	O
measure	B-C0079809
relationships	B-C0439849
between	O
self	B-C0036588
-	O
compassion	B-C0242270
,	O
compassion	B-C4042834
fatigue	I-C4042834
,	O
wellbeing	B-C0031206
,	O
and	O
burnout	B-C0006433
.	O
	
a	O
cross	B-C0010362
sectional	I-C0010362
sample	O
of	O
registered	B-C0687673
community	I-C0687673
nurses	I-C0687673
n=37	O
studying	O
for	O
a	O
postgraduate	B-C2983146
diploma	B-C4035742
at	O
a	O
university	B-C0041740
in	O
the	O
north	B-C0014282
of	I-C0014282
england	I-C0014282
took	O
part	O
in	O
this	O
study	B-C0031928
.	O
	
results	B-C1274040
show	O
that	O
community	B-C0557521
nurses	I-C0557521
who	O
score	B-C0449820
high	B-C0205250
on	O
measures	B-C0079809
of	O
self	B-C0036588
-	O
compassion	B-C0242270
and	O
wellbeing	B-C0031206
,	O
also	O
report	O
less	B-C0547044
burnout	B-C0006433
.	O
	
greater	B-C1704243
compassion	B-C0242270
satisfaction	B-C0242428
was	O
also	O
positively	B-C1446409
associated	B-C0332281
with	I-C0332281
compassion	B-C0242270
for	O
others	O
,	O
and	O
wellbeing	B-C0031206
,	O
whilst	O
also	O
being	O
negatively	B-C0205160
correlated	B-C1707520
with	O
burnout	B-C0006433
.	O
	
high	B-C0205250
levels	B-C0441889
of	O
self	B-C0036588
-	O
compassion	B-C0242270
were	O
linked	O
with	O
lower	B-C2003888
levels	B-C0441889
of	O
burnout	B-C0006433
.	O
	
furthermore	O
when	O
community	B-C0557521
nurses	I-C0557521
have	O
greater	B-C1704243
compassion	B-C0242270
satisfaction	B-C0242428
they	O
also	O
report	O
more	O
compassion	B-C0242270
for	O
others	O
,	O
increased	B-C0205217
wellbeing	B-C0031206
,	O
and	O
less	B-C0547044
burnout	B-C0006433
.	O
	
the	O
implications	B-C0205245
of	O
this	O
are	O
discussed	O
alongside	O
suggestions	B-C1705535
for	O
the	O
promotion	B-C0033414
of	O
greater	B-C1704243
compassion	B-C0242270
cd169	B-C1608815
identifies	B-C0243095
an	O
activated	B-C1515879
cd8	B-C0242629
t	I-C0242629
cell	I-C0242629
subset	B-C0079720
in	O
regional	B-C1179441
lymph	I-C1179441
nodes	I-C1179441
that	O
predicts	B-C0681842
favorable	B-C3640814
prognosis	B-C0033325
in	O
colorectal	B-C1527249
cancer	I-C1527249
patients	B-C0030705
cd169	B-C1608815
was	O
first	O
identified	O
on	O
macrophages	B-C0024432
mϕ	B-C0024432
and	O
linked	O
to	O
antigen	B-C0206431
presentation	I-C0206431
.	O
	
here	O
,	O
we	O
showed	O
cd169	B-C0017262
expression	I-C0017262
on	O
some	O
cd8	B-C0242629
t	I-C0242629
lymphocytes	I-C0242629
in	O
regional	B-C1179441
lymph	I-C1179441
nodes	I-C1179441
lns	B-C1179441
and	O
investigated	B-C1292732
the	O
function	B-C0031843
and	O
clinical	B-C0243095
relevance	I-C0243095
of	O
cd169	B-C0039194
t	I-C0039194
cells	I-C0039194
in	O
tumor-draining	B-C0024204
lns	I-C0024204
of	O
colorectal	B-C1527249
cancer	I-C1527249
crc	B-C1527249
patients	B-C0030705
.	O
	
fresh	B-C0440747
tumor-draining	I-C0440747
ln	I-C0440747
tissues	I-C0440747
from	O
39	O
randomly	B-C0439605
enrolled	B-C4316108
patients	I-C4316108
were	O
assessed	B-C1516048
by	O
flow	B-C0016263
cytometry	I-C0016263
for	O
activation	B-C1440937
and	O
differentiation	B-C0007589
of	O
cd169	B-C0039194
t	I-C0039194
cells	I-C0039194
and	O
t	B-C1523368
cell-mediated	I-C1523368
killing	I-C1523368
of	I-C1523368
tumor	I-C1523368
cells	I-C1523368
.	O
	
in	O
total	O
,	O
114	O
tumor-draining	B-C0024204
ln	I-C0024204
paraffin	O
sections	O
from	O
crc	B-C1527249
patients	B-C0030705
were	O
analyzed	O
by	O
multiple-color	B-C0016318
immunofluorescence	I-C0016318
for	O
cd169	B-C0039194
t	I-C0039194
cell	I-C0039194
distribution	B-C1704711
and	O
clinical	O
values	O
.	O
	
the	O
prognostic	B-C0220901
significance	B-C0205556
of	O
cd169	B-C0039194
t	I-C0039194
cells	I-C0039194
was	O
evaluated	B-C0220825
by	O
kaplan-meier	B-C1720943
analysis	I-C1720943
.	O
	
a	O
fraction	B-C1264633
of	I-C1264633
cd8	B-C0242629
t	I-C0242629
cells	I-C0242629
in	O
regional	B-C1179441
lns	I-C1179441
,	O
but	O
not	O
peripheral	B-C0229664
blood	I-C0229664
,	O
tonsils	B-C0836921
,	O
or	O
tumors	B-C0027651
,	O
expressed	B-C1608815
surface	I-C1608815
cd169	I-C1608815
.	O
	
in	B-C0444498
situ	I-C0444498
detection	B-C1511790
of	O
draining	B-C0024204
lns	I-C0024204
revealed	B-C0443289
preferential	O
localization	B-C0475264
of	O
cd169	B-C0039194
t	I-C0039194
cells	I-C0039194
to	O
subcapsular	B-C1518052
sinus	I-C1518052
and	O
interfollicular	B-C1512836
regions	I-C1512836
,	O
closely	O
associated	B-C0332281
with	I-C0332281
cd169	B-C0024432
mϕ	I-C0024432
.	O
	
cd169	B-C0039194
t	I-C0039194
cell	I-C0039194
ratios	B-C0456603
were	O
significantly	O
lower	O
in	O
peri-tumor	B-C1254362
lns	B-C0024204
than	O
distant-tumor	B-C1254362
lns	B-C0024204
.	O
	
cd169	B-C0039194
t	I-C0039194
cells	I-C0039194
predominantly	B-C0205556
expressed	O
activation	B-C0005516
markers	I-C0005516
cd69	B-C0108800
,	O
hla-dr	B-C0019764
,	O
pd-1	B-C0135710
with	O
slightly	O
lower	O
cd45ra	B-C0108789
and	O
cd62l	B-C0125090
levels	B-C0441889
.	O
	
they	O
produced	O
high	B-C0205250
granzyme	B-C0061878
b	I-C0061878
,	O
perforin	B-C0070410
,	O
tnf-α	B-C1456820
,	O
and	O
ifnγ	B-C3539881
levels	B-C0441889
,	O
and	O
promoted	O
tumor-killing	B-C1446301
efficiency	I-C1446301
ex	B-C1254362
vitro	I-C1254362
.	O
	
moreover	O
,	O
cd169	B-C0039194
t	I-C0039194
cells	I-C0039194
infiltrating	B-C0332448
tumor-draining	B-C0024204
lns	I-C0024204
decreased	B-C0205216
with	O
disease	B-C0242656
progression	I-C0242656
and	O
were	O
strongly	O
associated	B-C0332281
with	I-C0332281
crc	B-C1527249
patient	B-C0030705
survival	B-C0038952
.	O
	
we	O
identified	B-C0205396
novel	O
activated	B-C1440937
/	O
cytolytic	B-C0039195
cd169	I-C0039195
t	I-C0039195
cells	I-C0039195
selectively	O
present	O
in	O
regional	B-C1179441
lns	I-C1179441
,	O
potentially	O
serving	O
as	O
a	O
powerful	O
prognostic	B-C1514474
factor	I-C1514474
and	O
indicator	B-C1522602
for	O
selecting	B-C1707391
patients	B-C0030705
for	O
appearance	B-C0700364
differences	B-C1705242
between	O
lots	B-C3272563
and	O
brands	B-C0592503
of	O
similar	O
shade	B-C0009393
designations	B-C0600091
of	O
dental	B-C0891703
composite	I-C0891703
resins	I-C0891703
the	O
purposes	B-C1285529
of	O
this	O
study	B-C2603343
were	O
to	O
investigate	B-C1292732
differences	B-C1705242
in	O
two	O
inherent	B-C2347662
appearance	B-C0700364
characteristics	B-C1521970
between	O
lots	B-C3272563
of	O
an	O
enamel	B-C0891703
dental	I-C0891703
composite	I-C0891703
resin	I-C0891703
of	O
the	O
same	O
shade	B-C0009393
and	O
brand	B-C0592503
,	O
and	O
to	O
further	O
compare	B-C1707455
these	O
differences	B-C1705242
to	O
those	O
of	O
similar	O
shade	B-C0009393
designation	B-C0600091
of	O
a	O
different	B-C1705242
brand	B-C0592503
of	O
dental	B-C0891703
composite	I-C0891703
resins	I-C0891703
.	O
	
appearance	B-C0700364
analyses	B-C0936012
proceeded	B-C0439659
for	O
three	O
different	O
lots	B-C3272563
of	O
shades	B-C0009393
a1	B-C0008902
,	O
b2	B-C0008902
,	O
and	O
d3	B-C0008902
manufactured	B-C0870840
by	O
one	O
company	B-C0683757
and	O
for	O
one	O
lot	B-C3272563
of	O
shade	B-C0009393
ea1	B-C0008902
manufactured	B-C0870840
by	O
another	O
.	O
	
samples	B-C0370003
were	O
measured	B-C0444706
on	O
black	B-C0439541
,	O
white	B-C0220938
,	O
and	O
gray	B-C1269776
backings	B-C1706907
using	O
spectroradiometry	B-C0034603
.	O
	
kubelka-munk	B-C0871935
theory	I-C0871935
was	O
used	O
to	O
determine	O
reflectivity	B-C4054089
of	O
each	O
lot	B-C3272563
studied	B-C2603343
.	O
	
cielab	B-C0042295
values	I-C0042295
and	O
color	B-C0009393
differences	B-C1705242
between	O
shades	B-C0009393
and	O
lots	B-C3272563
were	O
analyzed	B-C0936012
.	O
	
translucency	B-C0522503
indicators	B-C0021212
were	O
compared	B-C1707455
between	O
lots	B-C3272563
over	O
thicknesses	B-C1280412
from	O
0.5	O
to	O
3.0	O
mm	O
.	O
	
differences	B-C1705242
in	O
inherent	B-C2347662
color	B-C0009393
between	O
some	O
lots	B-C3272563
of	O
same	O
shade	B-C0009393
designations	B-C0600091
within	O
a	O
brand	B-C0592503
were	O
found	O
to	O
be	O
above	O
the	O
acceptability	B-C0814633
threshold	B-C0449864
.	O
	
color	B-C0009393
difference	B-C1705242
between	O
an	O
enamel	B-C0891703
composite	I-C0891703
resin	I-C0891703
of	O
shade	B-C0009393
a1	B-C0008902
and	O
a	O
composite	B-C0891703
resin	I-C0891703
of	O
shade	B-C0009393
ea1	B-C0008902
was	O
also	O
above	O
the	O
acceptability	B-C0814633
threshold	B-C0449864
.	O
	
statistically	B-C0237881
significant	I-C0237881
differences	B-C1705242
in	O
the	O
translucency	B-C0522503
were	O
found	O
between	O
some	O
lots	B-C3272563
of	O
one	O
shade	B-C0009393
over	O
the	O
entire	O
range	B-C1514721
of	O
thicknesses	B-C1280412
studied	B-C2603343
.	O
	
appearance	B-C0700364
analyses	B-C0936012
indicate	B-C3146298
substantial	O
variation	B-C0205419
between	O
lots	B-C3272563
of	O
same	O
shade	B-C0009393
designations	B-C0600091
as	O
well	O
as	O
between	O
brands	B-C0592503
of	O
similar	O
shade	B-C0009393
designations	B-C0600091
.	O
	
optical	B-C0029144
principles	O
applied	B-C4048755
to	O
important	B-C3898777
clinical	B-C0205210
appearance	B-C0700364
attributes	O
are	O
described	O
which	O
characterize	B-C1880022
inherent	B-C2347662
appearance	B-C0700364
attributes	O
and	O
provide	O
aid	B-C1269765
in	O
the	O
appearance	B-C0700364
matching	B-C1708943
process	B-C1522240
for	O
dental	B-C0891703
composite	I-C0891703
resins	I-C0891703
used	O
in	O
restorative	B-C0204217
and	O
operative	B-C0543467
dental	I-C0543467
procedures	I-C0543467
.	O
	
patient	B-C0376409
preferences	I-C0376409
in	O
treatment	B-C0087111
choices	B-C1707391
for	O
early-stage	B-C2363430
lung	B-C0242379
cancer	I-C0242379
decision-making	B-C0011109
for	O
lung	B-C0242379
cancer	I-C0242379
treatment	B-C0087111
can	O
be	O
complex	B-C0439855
because	O
it	O
involves	O
both	O
provider	B-C0031831
recommendations	B-C0034866
based	O
on	O
the	O
patient's	B-C0030705
clinical	B-C0205210
condition	B-C0348080
and	O
patient	B-C0376409
preferences	I-C0376409
.	O
	
this	O
study	B-C2603343
describes	O
the	O
relative	O
importance	O
of	O
several	O
considerations	B-C0518609
in	O
lung	B-C0242379
cancer	I-C0242379
treatment	B-C0087111
from	O
the	O
patient's	B-C0030705
perspective	B-C0871010
.	O
	
a	O
conjoint	B-C0681814
preference	I-C0681814
experiment	I-C0681814
began	O
by	O
asking	O
respondents	B-C0282122
to	O
imagine	O
that	O
they	O
had	O
just	O
been	O
diagnosed	B-C0011900
with	O
lung	B-C0242379
cancer	I-C0242379
.	O
	
respondents	B-C0282122
then	O
chose	B-C1707391
among	O
procedures	B-C0087111
that	O
differed	O
regarding	O
treatment	B-C0087111
modalities	B-C3889585
,	O
the	O
potential	O
for	O
treatment	B-C0087111
-related	O
complications	B-C0009566
,	O
the	O
likelihood	B-C0033204
of	O
recurrence	B-C0034897
,	O
provider	B-C0031831
case	B-C0868928
volume	B-C0449468
,	O
and	O
distance	B-C0012751
needed	B-C1514873
to	O
travel	B-C0040802
for	O
treatment	B-C0087111
.	O
	
conjoint	B-C0681814
analysis	I-C0681814
derived	O
relative	O
weights	O
for	O
these	O
attributes	B-C1521970
.	O
	
a	O
total	O
of	O
225	O
responses	B-C1706817
were	O
analyzed	B-C0936012
.	O
	
respondents	B-C0282122
were	O
most	O
willing	O
to	O
accept	O
minimally	B-C0547040
invasive	B-C4048276
operations	I-C4048276
for	O
treatment	B-C0087111
of	O
their	O
hypothetical	O
lung	B-C0242379
cancer	I-C0242379
,	O
followed	O
by	O
stereotactic	B-C3896609
body	I-C3896609
radiation	I-C3896609
therapy	I-C3896609
sbrt	B-C3896609
they	O
were	O
least	O
willing	O
to	O
accept	O
thoracotomy	B-C0039991
.	O
	
treatment	B-C0087111
type	O
and	O
risk	B-C2986492
of	I-C2986492
recurrence	I-C2986492
were	O
the	O
most	O
important	O
attributes	B-C1521970
from	O
the	O
conjoint	B-C0681814
experiment	I-C0681814
each	O
with	O
a	O
relative	O
weight	O
of	O
0.23	O
,	O
followed	O
by	O
provider	B-C0031831
volume	B-C0449468
relative	O
weight	O
of	O
0.21	O
,	O
risk	B-C0035647
of	O
major	O
complications	B-C0009566
relative	O
weight	O
of	O
0.18	O
,	O
and	O
distance	B-C0012751
needed	B-C1514873
to	O
travel	B-C0040802
for	O
treatment	B-C0087111
relative	O
weight	O
of	O
0.15	O
.	O
	
procedural	B-C0087111
and	O
treatment	B-C0087111
preferences	B-C0558295
did	O
not	O
vary	O
with	O
demographics	B-C1521970
,	O
self-reported	B-C2700446
health	B-C0018759
status	I-C0018759
,	O
or	O
familiarity	B-C0600269
with	O
the	O
procedures	B-C0087111
.	O
	
survey	B-C0038951
respondents	B-C0282122
preferred	O
minimally	B-C0547040
invasive	B-C4048276
operations	I-C4048276
over	O
sbrt	B-C3896609
or	O
thoracotomy	B-C0039991
for	O
treatment	B-C0087111
of	O
early-stage	B-C2363430
non-small	B-C0007131
cell	I-C0007131
lung	I-C0007131
cancer	I-C0007131
.	O
	
treatment	B-C0087111
modality	B-C3889585
and	O
risk	B-C0035647
of	O
cancer	B-C0920420
recurrence	I-C0920420
were	O
the	O
most	O
important	O
factors	O
associated	O
with	O
treatment	B-C0087111
preferences	B-C0558295
.	O
	
provider	B-C0031831
experience	B-C0596545
outweighed	O
the	O
potential	O
need	B-C1514873
to	O
travel	B-C0040802
for	O
lung	B-C0242379
cancer	I-C0242379
treatment	B-C0087111
.	O
	
suppressed	B-C1260953
translation	B-C0597295
and	O
ulk1	B-C1313678
degradation	B-C0597297
as	O
potential	B-C3245505
mechanisms	B-C0441712
of	O
autophagy	B-C0004391
limitation	O
under	O
prolonged	B-C0439590
starvation	B-C0038187
macroautophagy	B-C1155604
/	O
autophagy	B-C0004391
is	O
a	O
well-organized	O
process	O
of	O
intracellular	B-C1523935
degradation	I-C1523935
,	O
which	O
is	O
rapidly	O
activated	B-C1879547
under	O
starvation	B-C0038187
conditions	O
.	O
	
recent	O
data	B-C1511726
demonstrate	O
a	O
transcriptional	B-C0040649
upregulation	B-C0041904
of	O
several	O
autophagy	B-C0004391
genes	B-C0017337
as	O
a	O
mechanism	B-C0441712
that	O
controls	B-C2587213
autophagy	B-C0004391
in	O
response	O
to	O
starvation	B-C0038187
.	O
	
here	O
we	O
report	O
that	O
despite	O
the	O
significant	O
upregulation	B-C0041904
of	O
mrna	B-C0035696
of	O
the	O
essential	O
autophagy	B-C0004391
initiation	B-C0017337
gene	I-C0017337
ulk1	B-C1421350
,	O
its	O
protein	B-C1313678
level	B-C0441889
is	O
rapidly	O
reduced	B-C0392756
under	O
starvation	B-C0038187
.	O
	
although	O
both	O
autophagic	B-C0004391
and	O
proteasomal	B-C0033684
systems	I-C0033684
contribute	O
to	O
the	O
degradation	B-C0597297
of	O
ulk1	B-C1313678
,	O
under	O
prolonged	B-C0439590
nitrogen	B-C0028158
deprivation	B-C0871712
,	O
its	O
level	B-C0441889
was	O
still	O
reduced	B-C0392756
in	O
atg7	B-C1825498
knockout	B-C0007634
cells	I-C0007634
,	O
and	O
only	O
initially	O
stabilized	O
in	O
cells	B-C0007634
treated	B-C1522326
with	O
the	O
lysosomal	B-C0024369
or	O
proteasomal	B-C1443643
inhibitors	I-C1443643
.	O
	
we	O
demonstrate	O
that	O
under	O
starvation	B-C0038187
,	O
protein	B-C0597295
translation	I-C0597295
is	O
rapidly	O
diminished	B-C0205216
and	O
,	O
similar	O
to	O
treatments	B-C0087111
with	O
the	O
proteosynthesis	B-C0033671
inhibitors	I-C0033671
cycloheximide	B-C0010572
or	O
anisomycin	B-C0003082
,	O
is	O
associated	O
with	O
a	O
significant	O
reduction	B-C0392756
of	O
ulk1	B-C1313678
.	O
	
furthermore	O
,	O
it	O
was	O
found	O
that	O
inhibition	B-C3463820
of	O
the	O
mitochondrial	B-C0026237
respiratory	B-C4235129
complexes	I-C4235129
or	O
the	O
mitochondrial	B-C0026237
atp	B-C2250396
synthase	I-C2250396
function	I-C2250396
that	O
could	O
also	O
take	O
place	O
in	O
the	O
absence	B-C0332197
of	O
substrates	B-C3891814
,	O
promote	O
upregulation	B-C0041904
of	O
ulk1	B-C0035696
mrna	I-C0035696
and	O
protein	B-C1171362
expression	I-C1171362
in	O
an	O
ampk	B-C2350345
-	O
dependent	B-C3244310
manner	O
in	O
u1810	B-C0597032
lung	I-C0597032
cancer	I-C0597032
cells	I-C0597032
growing	O
in	O
complete	O
culture	B-C0010454
medium	I-C0010454
.	O
	
these	O
inhibitors	B-C1999216
could	O
also	O
drastically	O
increase	B-C0442805
the	O
ulk1	B-C1313678
protein	I-C1313678
in	O
u1810	B-C0597032
cells	I-C0597032
with	O
knockout	O
of	O
atg13	B-C3146638
,	O
where	O
the	O
ulk1	B-C1313678
expression	B-C1171362
is	O
significantly	O
diminished	B-C0205216
.	O
	
however	O
,	O
such	O
upregulation	B-C0041904
of	O
ulk1	B-C1313678
protein	I-C1313678
is	O
negligible	O
under	O
starvation	B-C0038187
conditions	O
,	O
further	O
signifying	O
the	O
contribution	O
of	O
translation	B-C0597295
and	O
suggesting	O
that	O
transcriptional	B-C0040649
upregulation	B-C0041904
of	O
ulk1	B-C1313678
protein	I-C1313678
will	O
be	O
diminished	B-C0205216
under	O
such	O
conditions	O
.	O
	
thus	O
,	O
we	O
propose	O
a	O
model	B-C0026336
where	O
inhibition	B-C3463820
of	O
protein	B-C0597295
translation	I-C0597295
,	O
together	O
with	O
the	O
degradation	B-C0597297
systems	O
,	O
limit	O
autophagy	B-C0004391
during	O
neuroprotective	B-C0815279
role	I-C0815279
of	O
microrna-22	B-C1537720
in	O
a	O
6-hydroxydopamine	B-C0085196
-	O
induced	B-C0205263
cell	B-C0007634
model	B-C0684309
of	O
parkinson's	B-C0030567
disease	I-C0030567
via	O
regulation	B-C0017263
of	O
its	O
target	B-C1521840
gene	B-C0017337
trpm7	B-C1425224
parkinson's	B-C0030567
disease	I-C0030567
pd	B-C0030567
,	O
the	O
second	O
most	O
prevalent	B-C0205391
neurodegenerative	B-C0524851
disorder	I-C0524851
with	O
only	O
symptomatic	B-C0231220
treatment	B-C0087111
available	B-C0470187
,	O
is	O
characterized	B-C1880022
by	O
a	O
progressive	B-C0205329
loss	B-C1517945
of	O
dopaminergic	B-C1512035
neurons	I-C1512035
in	O
the	O
midbrain	B-C0025462
.	O
	
ample	O
evidence	O
indicated	O
that	O
micrornas	B-C1101610
mirs	B-C1101610
could	O
regulate	B-C1514248
post-transcriptional	I-C1514248
gene	B-C0017262
expression	I-C0017262
and	O
neuronal	B-C0027765
disease	I-C0027765
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
we	O
have	O
evaluated	O
the	O
effects	B-C1280500
and	O
mechanism	B-C0441712
of	O
mir-22	B-C1537720
in	O
pc12	B-C0085262
pheochromocytoma	I-C0085262
cells	I-C0085262
treated	B-C1522326
with	O
6-hydroxydopamine	B-C0085196
6-ohda	B-C0085196
to	O
mimic	O
pd	B-C0030567
.	O
	
rt-pcr	B-C0599161
results	B-C1274040
showed	O
that	O
the	O
expression	B-C0017262
of	O
mir-22	B-C1537720
is	O
downregulated	B-C0013081
in	O
6-ohda	B-C0085196
-	O
treated	B-C1522326
pc12	B-C0085262
cells	I-C0085262
,	O
and	O
the	O
overexpression	B-C0017262
of	O
mir-22	B-C1537720
significantly	O
promoted	B-C0033414
the	O
survival	B-C0007620
and	O
proliferation	B-C0596290
of	O
6-ohda	B-C0085196
-	O
induced	B-C0205263
pc12	B-C0085262
cells	I-C0085262
,	O
whereas	O
mir-22	B-C1537720
inhibitor	B-C1999216
reversed	B-C1555029
these	O
effects	B-C1280500
.	O
	
in	O
addition	O
,	O
pc12	B-C0085262
cells	I-C0085262
were	O
treated	B-C1522326
with	O
mir-22	B-C1537720
mimics	I-C1537720
or	O
inhibitor	B-C1999216
following	B-C0332282
6-ohda	B-C0085196
administration	B-C1533734
,	O
which	O
medicated	O
ros	B-C0162772
production	B-C1148560
and	O
upregulation	B-C0041904
or	O
downregulation	B-C0013081
of	O
caspase-3	B-C1150132
activity	I-C1150132
,	O
respectively	O
.	O
	
a	O
luciferase	B-C0024075
reporter	O
assay	B-C2717977
revealed	B-C0443289
that	O
transient	B-C1425224
receptor	I-C1425224
potential	I-C1425224
melastatin	I-C1425224
7	I-C1425224
trpm7	B-C1425224
is	O
a	O
direct	B-C1947931
target	B-C1521840
gene	B-C0017337
of	O
mir-22	B-C1537720
,	O
and	O
mir-22	B-C1537720
overexpression	B-C0017262
markedly	O
downregulated	B-C0013081
the	O
level	B-C0441889
of	O
trpm7	B-C1425224
.	O
	
strikingly	O
,	O
further	O
analysis	B-C0936012
showed	O
that	O
mir-22	B-C1537720
mediated	O
6-ohda	B-C0085196
-	O
induced	B-C0205263
pc12	B-C0085262
cell	B-C0007620
survival	I-C0007620
and	O
proliferation	B-C0596290
by	O
targeting	B-C1521840
trpm7	B-C1425224
.	O
	
taken	O
together	O
,	O
the	O
present	O
study	B-C2603343
showed	O
that	O
mir-22	B-C1537720
overexpression	B-C0017262
exhibited	O
neuroprotective	B-C0815279
and	O
reversal	B-C1555029
effects	B-C1280500
on	O
the	O
6-ohda	B-C0085196
-	O
induced	B-C0205263
pc12	B-C0085262
cell	B-C0007595
growth	I-C0007595
and	O
apoptosis	B-C0162638
by	O
targeting	B-C1521840
trpm7	B-C1425224
.	O
	
obstacle	B-C0038039
course	I-C0038039
runs	I-C0038039
review	B-C0282443
of	O
acquired	O
injuries	B-C3263723
and	O
illnesses	B-C0221423
at	O
a	O
series	B-C0205549
of	O
canadian	B-C0238884
events	B-C0441471
race	B-C0038039
the	O
growing	O
popularity	O
of	O
obstacle	B-C0038039
course	I-C0038039
runs	I-C0038039
ocrs	B-C0038039
has	O
led	O
to	O
significant	B-C0750502
concerns	B-C2699424
regarding	O
their	O
safety	B-C0036043
.	O
	
the	O
influx	O
of	O
injuries	B-C3263723
and	O
illnesses	B-C0221423
in	O
rural	B-C0178837
areas	I-C0178837
where	O
ocrs	B-C0038039
are	O
often	O
held	O
can	O
impose	O
a	O
large	O
burden	O
on	O
emergency	B-C0013961
medical	I-C0013961
services	I-C0013961
ems	B-C0013961
and	O
local	O
eds	O
.	O
	
literature	B-C0023866
concerning	B-C2699424
the	O
safety	B-C0036043
of	O
these	O
events	B-C0441471
is	O
minimal	B-C0547040
and	O
mostly	O
consists	O
of	O
media	B-C0009458
reports	B-C0684224
.	O
	
we	O
sought	O
to	O
characterise	B-C1880022
the	O
injury	B-C3263723
and	O
illness	B-C0221423
profile	O
of	O
ocrs	B-C0038039
and	O
the	O
level	B-C0441889
of	O
medical	B-C0237078
care	I-C0237078
required	O
.	O
	
this	O
study	B-C2603343
analysed	B-C0936012
ocr	B-C0038039
events	B-C0441471
occurring	O
in	O
eight	O
locations	O
across	O
canada	B-C0006823
from	O
may	O
to	O
august	O
2015	O
total	O
45	O
285	O
participants	B-C0679646
.	O
	
data	B-C1511726
were	O
extracted	B-C0677145
from	O
event	B-C0441471
medical	B-C0007963
charts	I-C0007963
of	O
patients	B-C0030705
presenting	O
to	O
the	O
onsite	B-C0450429
medical	B-C0086390
team	I-C0086390
,	O
including	O
injury	B-C3263723
or	O
illness	B-C0221423
type	O
,	O
onsite	O
treatment	B-C0087111
and	O
disposition	B-C0743223
.	O
	
there	O
were	O
557	O
race	B-C0679646
participants	I-C0679646
treated	B-C1522326
at	O
eight	O
ocr	B-C0038039
events	B-C0441471
1.2	O
of	O
all	O
participants	B-C0679646
.	O
	
there	O
were	O
609	O
medical	B-C0025102
complaints	I-C0025102
in	O
total	O
.	O
	
three	O
quarters	O
of	O
injuries	B-C3263723
were	O
musculoskeletal	B-C0497254
in	O
nature	O
.	O
	
eighty-nine	O
per	O
cent	O
returned	O
to	O
the	O
event	B-C0441471
with	O
no	O
need	O
for	O
further	O
medical	B-C0237078
care	I-C0237078
.	O
	
the	O
majority	O
of	O
treatments	B-C0087111
were	O
completed	O
with	O
first	B-C0016143
aid	I-C0016143
and	O
basic	O
medical	B-C0025080
equipment	I-C0025080
.	O
	
eleven	O
patients	B-C0030705
2%	O
of	O
patients	B-C0030705
required	O
transfer	O
to	O
hospital	B-C0019994
by	O
ems	B-C0013961
for	O
presentations	O
including	O
fracture	B-C0016658
,	O
dislocation	B-C0012691
,	O
head	B-C0018674
injury	I-C0018674
,	O
chest	B-C0008031
pain	I-C0008031
,	O
fall	B-C1997329
from	I-C1997329
height	I-C1997329
,	O
and	O
abdominal	B-C0000737
pain	I-C0000737
.	O
	
we	O
found	O
that	O
1.2	O
of	O
race	B-C0679646
participants	I-C0679646
presented	O
to	O
onsite	O
medical	B-C0199168
services	I-C0199168
.	O
	
the	O
majority	O
of	O
complaints	O
were	O
minor	B-C0332673
and	O
musculoskeletal	B-C0272448
in	O
nature	O
.	O
	
only	O
2%	O
of	O
those	O
treated	B-C1522326
were	O
transferred	O
to	O
hospital	B-C0019994
through	O
ems	B-C0013961
.	O
	
this	O
is	O
consistent	B-C0332290
with	I-C0332290
other	O
types	O
of	O
mass	B-C3841750
gathering	I-C3841750
events	B-C0441471
.	O
	
is	O
modern	B-C0242324
medical	B-C1444483
management	I-C1444483
changing	B-C0392747
ultimate	O
patient	B-C1547647
outcomes	I-C1547647
in	O
inflammatory	B-C0021390
bowel	I-C0021390
disease	I-C0021390
the	O
impact	B-C4049986
of	O
modern	B-C0242324
medical	B-C1444483
management	I-C1444483
of	O
inflammatory	B-C0021390
bowel	I-C0021390
disease	I-C0021390
ibd	B-C0021390
on	O
surgical	B-C0587668
necessity	I-C0587668
and	O
outcomes	B-C1274040
remains	O
unclear	B-C3845108
.	O
	
we	O
hypothesized	O
that	O
surgery	B-C0543467
rates	B-C1521828
have	O
decreased	B-C0205216
while	O
outcomes	B-C1274040
have	O
worsened	B-C1457868
due	O
to	O
operating	B-C0543467
on	O
""""	O
sicker	B-C0221423
""""	O
patients	B-C0030705
since	O
the	O
introduction	B-C0579004
of	O
biologic	B-C1531518
medications	I-C1531518
.	O
	
the	O
nationwide	O
inpatient	B-C0021562
sample	B-C0370003
and	O
icd-9-cm	B-C1137112
codes	I-C1137112
were	O
used	O
to	O
identify	O
inpatient	B-C0021562
admissions	B-C0184666
for	O
crohn's	B-C0010346
disease	I-C0010346
and	O
ulcerative	B-C0009324
colitis	I-C0009324
.	O
	
trends	B-C1521798
in	O
ibd	B-C0021390
nutrition	B-C0392209
,	O
surgeries	B-C0543467
,	O
and	O
postoperative	B-C0032787
complications	I-C0032787
were	O
determined	O
.	O
	
there	O
were	O
191	O
admissions	B-C0184666
for	O
ibd	B-C0021390
during	O
the	O
study	B-C2603343
period	B-C1948053
.	O
	
surgery	B-C0543467
rates	B-C1521828
were	O
largely	O
unchanged	B-C0442739
over	O
the	O
study	B-C2603343
period	B-C1948053
,	O
ranging	O
from	O
9	O
to	O
12	O
%	O
of	O
admissions	B-C0184666
in	O
both	O
crohn's	B-C0010346
disease	I-C0010346
and	O
ulcerative	B-C0009324
colitis	I-C0009324
.	O
	
the	O
rate	B-C1521828
of	O
poor	B-C0162429
nutrition	I-C0162429
increased	B-C0205217
by	O
67	O
%	O
in	O
ulcerative	B-C0009324
colitis	I-C0009324
and	O
by	O
83	O
%	O
in	O
crohn's	B-C0010346
disease	I-C0010346
.	O
	
rates	B-C1521828
of	O
postoperative	B-C0032790
anastomotic	B-C0919691
leak	I-C0919691
10.2	O
%	O
were	O
unchanged	B-C0442739
over	O
the	O
years	O
.	O
	
postoperative	B-C0392618
infection	I-C0392618
rates	B-C1521828
decreased	B-C0205216
by	O
17	O
%	O
in	O
crohn's	B-C0010346
disease	I-C0010346
18	O
%	O
in	O
2003	O
to	O
15	O
%	O
in	O
2012	O
p	O
<	O
0.001	O
but	O
did	O
not	O
show	O
a	O
trend	B-C1545470
in	O
any	O
direction	O
in	O
ulcerative	B-C0009324
colitis	I-C0009324
.	O
	
rates	B-C1521828
of	O
ibd	B-C0021390
surgery	B-C0038894
have	O
remained	O
stable	B-C0205360
while	O
postoperative	B-C0032787
infectious	I-C0032787
complications	I-C0032787
have	O
remained	O
stable	B-C0205360
or	O
decreased	B-C0205216
since	O
the	O
implementation	B-C0018726
of	O
biologic	B-C1531518
therapies	I-C1531518
.	O
	
we	O
identified	O
an	O
increase	B-C0442805
in	O
poor	B-C0162429
nutrition	I-C0162429
in	O
surgical	B-C0871463
patients	I-C0871463
.	O
	
clinical	B-C0205210
experience	B-C0023672
with	O
the	O
subcutaneous	B-C3694431
implantable	I-C3694431
cardioverter-defibrillator	I-C3694431
in	O
adults	B-C0001675
with	O
congenital	B-C0152021
heart	I-C0152021
disease	I-C0152021
sudden	B-C0085298
cardiac	I-C0085298
death	I-C0085298
is	O
a	O
major	O
contributor	O
to	O
mortality	B-C0205848
for	O
adults	B-C0001675
with	O
congenital	B-C0152021
heart	I-C0152021
disease	I-C0152021
.	O
	
the	O
subcutaneous	B-C0443315
implantable	B-C0162589
cardioverter-defibrillator	I-C0162589
icd	B-C0162589
has	O
emerged	O
as	O
a	O
novel	B-C0205314
tool	B-C0336791
for	O
prevention	B-C2700409
of	O
sudden	B-C0085298
cardiac	I-C0085298
death	I-C0085298
,	O
but	O
clinical	B-C3266594
performance	I-C3266594
data	B-C1511726
for	O
adults	B-C0001675
with	O
congenital	B-C0152021
heart	I-C0152021
disease	I-C0152021
are	O
limited	O
.	O
	
a	O
retrospective	B-C0035363
study	I-C0035363
involving	O
7	O
centers	O
over	O
a	O
5-	O
year	B-C0439234
period	B-C1948053
beginning	O
in	O
2011	O
was	O
performed	B-C0884358
.	O
	
twenty-one	O
patients	B-C0030705
median	B-C2347635
33.9	O
years	B-C0439234
were	O
identified	O
.	O
	
the	O
most	O
common	O
diagnosis	B-C0011900
was	O
single	B-C0152424
ventricle	I-C0152424
physiology	B-C0031843
52%	O
,	O
9	O
palliated	B-C1274136
by	O
fontan	B-C0190010
operation	I-C0190010
and	O
2	O
by	O
aortopulmonary	B-C0397538
shunts	I-C0397538
d-transposition	B-C1275836
of	I-C1275836
the	I-C1275836
great	I-C1275836
arteries	I-C1275836
after	O
mustard	B-C1306542
/	O
senning	B-C0339890
n=2	O
,	O
tetralogy	B-C0039685
of	I-C0039685
fallot	I-C0039685
n=2	O
,	O
aortic	B-C1260873
valve	I-C1260873
disease	I-C1260873
n=2	O
,	O
and	O
other	O
biventricular	B-C0699808
surgery	B-C0543467
n=4	O
.	O
	
a	O
prior	O
cardiac	B-C0018825
device	I-C0018825
had	O
been	O
implanted	B-C0948629
in	O
7	O
33%	O
.	O
	
the	O
icd	B-C0162589
indication	B-C3146298
was	O
primary	B-C0033144
prevention	I-C0033144
in	O
67%	O
and	O
secondary	B-C0679699
in	O
33%	O
patient	B-C0030705
s	I-C0030705
.	O
	
the	O
most	O
common	O
reason	O
for	O
subcutaneous	B-C0443315
icd	B-C0162589
placement	B-C0441587
was	O
limited	O
transvenous	B-C0522521
access	I-C0522521
for	O
ventricular	B-C2825199
lead	I-C2825199
placement	B-C0441587
n=10	O
followed	O
by	O
intracardiac	B-C0489644
right-to-left	I-C0489644
shunt	I-C0489644
n=5	O
.	O
	
ventricular	B-C0085612
arrhythmia	I-C0085612
was	O
induced	B-C0205263
in	O
17	O
81%	O
and	O
was	O
converted	O
with	O
80	O
joules	B-C0439256
in	O
all	O
.	O
	
there	O
was	O
one	O
implant	B-C0085073
complication	I-C0085073
related	I-C0085073
to	I-C0085073
infection	I-C0085073
,	O
not	B-C0332288
requiring	O
device	B-C0752250
removal	I-C0752250
.	O
	
over	O
a	O
median	B-C2347635
follow-up	B-C1522577
of	O
14	O
months	B-C0439231
,	O
4	O
patients	B-C0030705
21%	O
received	O
inappropriate	B-C0340944
and	O
1	O
5%	O
patient	B-C0030705
received	O
appropriate	B-C0036984
shocks	I-C0036984
.	O
	
there	O
was	O
one	O
arrhythmic	B-C3844298
death	I-C3844298
related	O
to	O
asystole	B-C0018790
in	O
a	O
single	B-C0152424
ventricle	I-C0152424
patient	B-C0030705
.	O
	
subcutaneous	B-C0443315
icd	B-C0162589
implantation	B-C0021107
is	O
feasible	O
for	O
adults	B-C0001675
with	O
congenital	B-C0152021
heart	I-C0152021
disease	I-C0152021
patients	B-C0030705
.	O
	
most	O
candidates	B-C0030705
have	O
single	B-C0152424
ventricle	I-C0152424
heart	B-C0018799
disease	I-C0018799
and	O
limited	O
transvenous	B-C0522521
options	I-C0522521
for	O
icd	B-C0162589
placement	B-C0441587
.	O
	
despite	O
variable	B-C0439828
anatomy	B-C1384516
,	O
this	O
study	B-C2603343
demonstrates	O
successful	B-C1272703
conversion	B-C0439836
of	O
induced	B-C0205263
ventricular	B-C0085612
arrhythmia	I-C0085612
and	O
reasonable	B-C0184784
rhythm	B-C0232187
discrimination	B-C0234412
during	O
interaction	B-C1704675
of	O
multiple	B-C0439064
gene	B-C0678941
variants	I-C0678941
and	O
their	O
effects	B-C1280500
on	O
schizophrenia	B-C0036341
phenotypes	B-C0031437
schizophrenia	B-C0036341
is	O
a	O
clinically	B-C0205210
heterogeneous	B-C1858576
disorder	I-C1858576
and	O
may	O
be	O
explained	O
by	O
its	O
complex	O
genetic	B-C0314603
architecture	I-C0314603
.	O
	
many	O
schizophrenia	B-C0036341
susceptibility	B-C0012655
genes	B-C0017337
were	O
identified	B-C0205396
but	O
the	O
picture	O
remains	O
unclear	O
due	O
to	O
inconsistent	B-C0442809
or	O
contradictory	B-C0205556
genetic	B-C2717878
association	I-C2717878
studies	I-C2717878
.	O
	
this	O
confusion	O
may	O
,	O
in	O
part	O
,	O
be	O
because	O
symptoms	B-C1457887
result	O
from	O
the	O
combined	O
interaction	B-C1704675
of	O
many	O
genes	B-C0017337
and	O
these	O
interacting	B-C1704675
genes	B-C0017337
are	O
associated	B-C0332281
with	I-C0332281
specific	B-C0205369
sub-phenotypes	B-C0031437
of	O
schizophrenia	B-C0036341
rather	O
than	O
schizophrenia	B-C0036341
as	O
a	O
whole	O
.	O
	
this	O
study	O
investigates	B-C1292732
the	O
relationship	B-C0439849
between	O
schizophrenia	B-C0036341
susceptibility	B-C0012655
genes	B-C0017337
and	O
schizophrenia	B-C0036341
sub-phenotypes	B-C0031437
by	O
identifying	B-C0205396
multiple	B-C0439064
gene	B-C0678941
variant	I-C0678941
interactions	B-C1704675
.	O
	
fifty	O
snps	B-C0752046
from	O
21	O
genes	B-C0017337
were	O
genotyped	B-C3178894
in	O
235	O
australian	B-C0238711
participants	B-C0679646
with	O
schizophrenia	B-C0036341
screened	B-C0220908
for	O
various	O
phenotypes	B-C0031437
.	O
	
schizophrenia	B-C0036341
participants	B-C0679646
were	O
grouped	O
into	O
relevant	B-C2347946
phenotype	B-C0031437
clusters	B-C1704332
using	O
cluster	B-C0009085
analysis	I-C0009085
and	O
normalized	B-C1882115
phenotype	B-C0031437
cluster	B-C1704332
scores	B-C0449820
were	O
calculated	O
for	O
each	O
patient	B-C0030705
.	O
	
the	O
relationship	B-C0439849
between	O
genotypes	B-C0017431
and	O
normalized	B-C1882115
phenotype	B-C0031437
cluster	B-C1704332
scores	B-C0449820
were	O
analyzed	O
by	O
linear	B-C0034980
regression	I-C0034980
analysis	I-C0034980
.	O
	
three	O
phenotype	B-C0031437
clusters	B-C1704332
were	O
identified	B-C0205396
.	O
	
there	O
was	O
some	O
overlap	O
in	O
symptoms	B-C1457887
between	O
phenotype	B-C0031437
clusters	B-C1704332
,	O
particularly	O
for	O
depression	B-C0011570
.	O
	
however	O
,	O
cluster	B-C1704332
1	I-C1704332
appears	O
to	O
be	O
characterized	O
by	O
speech	B-C0037822
disorder	I-C0037822
and	O
affective	O
behavior	B-C2039359
symptoms	I-C2039359
,	O
cluster	B-C1704332
2	I-C1704332
has	O
predominantly	O
hallucination	B-C0018524
symptoms	B-C1457887
and	O
cluster	B-C1704332
3	I-C1704332
has	O
mainly	O
delusion	B-C0011253
symptoms	B-C1457887
.	O
	
interaction	B-C1704675
of	O
five	O
snps	B-C0752046
was	O
found	O
to	O
have	O
an	O
effect	O
on	O
cluster	B-C1704332
1	I-C1704332
symptoms	B-C1457887
ten	O
snps	B-C0752046
on	O
cluster	B-C1704332
2	I-C1704332
symptoms	B-C1457887
and	O
eight	O
snps	B-C0752046
on	O
cluster	B-C1704332
3	I-C1704332
symptoms	B-C1457887
.	O
	
the	O
interaction	B-C1704675
of	O
specific	B-C0205369
susceptibility	B-C0012655
genes	B-C0017337
is	O
likely	O
to	O
lead	O
to	O
specific	B-C0205369
clinical	B-C0205210
sub-phenotypes	B-C0031437
of	O
schizophrenia	B-C0036341
.	O
	
larger	O
patient	B-C0030705
cohorts	B-C0599755
with	O
more	O
extensive	O
clinical	B-C0205210
data	B-C1511726
will	O
improve	O
the	O
detection	B-C0442726
of	O
gene	B-C0596610
interactions	I-C0596610
and	O
the	O
resultant	O
schizophrenia	B-C0036341
clinical	B-C0205210
phenotypes	B-C0031437
.	O
	
evaluation	O
of	O
dnmt1	B-C1414121
gene	B-C1956267
expression	I-C1956267
profile	I-C1956267
and	O
methylation	B-C0025723
of	O
its	O
promoter	B-C0033413
region	I-C0033413
in	O
patients	B-C0030705
with	O
ankylosing	B-C0038013
spondylitis	I-C0038013
ankylosing	B-C0038013
spondylitis	I-C0038013
as	B-C0038013
is	O
an	O
autoimmune	B-C0004364
disease	I-C0004364
with	O
a	O
chronic	B-C0003864
inflammatory	I-C0003864
arthritis	I-C0003864
.	O
	
the	O
critical	O
role	O
of	O
methylation	B-C0025723
in	O
the	O
biology	B-C0005532
of	O
immunocytes	B-C0312737
has	O
increasingly	O
been	O
surveyed	B-C0038951
to	O
discover	O
disease	B-C0012634
etiology	B-C1314792
.	O
	
dna	B-C1621352
methyltransferase	I-C1621352
1	I-C1621352
dnmt1	B-C1621352
is	O
an	O
enzyme	B-C0014442
,	O
which	O
establishes	O
and	O
regulates	B-C1327622
patterns	B-C0449774
of	O
methylated	B-C0010843
cytosine	I-C0010843
residues	O
.	O
	
the	O
aim	B-C1947946
of	O
the	O
current	O
investigation	B-C0220825
was	O
to	O
unveil	O
if	O
methylation	B-C0025723
circumstances	O
of	O
cpg	B-C0056912
sites	B-C0205145
in	O
dnmt1	B-C1414121
promoter	B-C0086860
could	O
affect	O
the	O
mrna	B-C1515670
expression	I-C1515670
level	B-C0441889
of	O
this	O
gene	B-C0017337
in	O
peripheral	B-C1321301
blood	I-C1321301
mononuclear	I-C1321301
cells	I-C1321301
pbmcs	B-C1321301
from	O
as	B-C0038013
patients	B-C0030705
.	O
	
pbmcs	B-C1321301
were	O
isolated	O
from	O
whole	B-C0370231
blood	I-C0370231
of	O
40	O
as	B-C0038013
patients	B-C0030705
and	O
40	O
healthy	B-C3898900
individuals	B-C0027361
.	O
	
total	O
rna	B-C0035668
and	O
dna	B-C0012854
contents	O
of	O
leukocytes	B-C0023516
were	O
extracted	B-C0185115
.	O
	
afterward	O
,	O
quantitative	B-C0034384
analysis	I-C0034384
was	O
carried	O
out	O
by	O
real-time	B-C1709846
pcr	I-C1709846
using	O
the	O
sybr	B-C0282574
green	I-C0282574
pcr	I-C0282574
master	I-C0282574
mix	I-C0282574
.	O
	
finally	O
,	O
to	O
determine	O
the	O
methylation	B-C0025723
level	B-C0441889
,	O
pcr	B-C0032520
products	B-C0012854
of	O
bisulfite-treated	B-C0012854
dna	I-C0012854
from	O
patients	B-C0030705
and	O
controls	B-C0009932
were	O
sequenced	B-C1294197
.	O
	
compared	O
with	O
healthy	B-C3898900
controls	B-C0009932
,	O
expression	B-C0017262
level	I-C0017262
of	O
dnmt1	B-C1414121
in	O
as	B-C0038013
patients	B-C0030705
was	O
significantly	O
downregulated	B-C0013081
.	O
	
methylation	B-C0025723
of	O
dnmt1	B-C1414121
promoter	B-C0086860
was	O
significantly	O
higher	O
in	O
as	B-C0038013
patients	B-C0030705
in	O
comparison	O
to	O
controls	B-C0009932
.	O
	
while	O
a	O
negative	B-C0205160
correlation	B-C1707520
between	O
methylation	B-C0025723
and	O
expression	B-C0017262
level	I-C0017262
of	O
dnmt1	B-C1414121
was	O
observed	O
in	O
as	B-C0038013
patients	B-C0030705
,	O
both	O
methylation	B-C0025723
and	O
expression	B-C0017262
level	I-C0017262
of	O
dnmt1	B-C1414121
did	O
not	O
correlate	B-C1707520
with	O
clinical	B-C0205210
manifestations	B-C0205319
.	O
	
considering	O
the	O
observation	O
that	O
decreased	B-C0205216
expression	B-C0017262
level	I-C0017262
of	O
dnmt1	B-C1414121
was	O
associated	O
with	O
hypermethylation	B-C1512554
of	O
dnmt1	B-C1414121
promoter	B-C0086860
in	O
pbmcs	B-C1321301
from	O
as	B-C0038013
patients	B-C0030705
,	O
this	O
survey	B-C0038951
suggests	O
that	O
dysregulation	O
of	O
dnmt1	B-C1414121
expression	B-C0017262
through	O
altered	B-C0392747
methylation	B-C0025723
level	B-C0441889
of	O
other	O
target	B-C1521840
genes	B-C0017337
would	O
probably	O
contribute	O
to	O
as	B-C0038013
antibacterial	B-C0279516
activity	B-C0441655
of	O
polyaniline	B-C0962453
coated	B-C1522408
silver	B-C0037125
nanoparticles	B-C1721060
synthesized	B-C1883254
from	O
piper	B-C3643364
betle	I-C3643364
leaves	I-C3643364
extract	I-C3643364
plants	B-C0032098
or	O
natural	B-C0027492
resources	I-C0027492
have	O
been	O
found	O
to	O
be	O
a	O
good	O
alternative	B-C1523987
method	B-C0449851
for	O
nanoparticles	B-C1450054
synthesis	B-C1883254
.	O
	
in	O
this	O
study	B-C2603343
,	O
polyaniline	B-C0962453
coated	B-C1522408
silver	B-C0037125
nanoparticles	B-C1721060
agnps	B-C1721060
synthesized	B-C1883254
from	O
piper	B-C3643364
betle	I-C3643364
leaves	I-C3643364
extract	I-C3643364
were	O
investigated	O
for	O
their	O
antibacterial	B-C0279516
activity	B-C0441655
.	O
	
silver	O
nanoparticles	O
were	O
prepared	O
from	O
the	O
reduction	O
of	O
silver	O
nitrate	O
and	O
nabh4	O
was	O
used	O
as	O
reducing	O
agent	O
.	O
	
silver	O
nanoparticles	O
and	O
extracts	O
were	O
mixed	O
thoroughly	O
and	O
then	O
coated	O
by	O
polyaniline	O
.	O
	
prepared	O
nanoparticles	O
were	O
characterized	O
by	O
visual	O
inspection	O
,	O
ultraviolet-visible	O
spectroscopy	O
uv	O
,	O
fourier	O
transform	O
infrared	O
spectroscopy	O
ft-ir	O
,	O
transmission	O
electron	O
microscopy	O
tem	O
techniques	O
.	O
	
antibacterial	O
activities	O
of	O
the	O
synthesized	O
silver	O
nanoparticles	O
were	O
tested	O
against	O
staphylococcus	O
aureus	O
atcc	O
25923	O
,	O
salmonella	O
typhi	O
atcc	O
14028	O
,	O
escherichia	O
coli	O
atcc	O
25922	O
and	O
pseudomonas	O
aeruginosa	O
atcc	O
27853	O
.	O
	
uv-vis	O
spectrum	O
of	O
reaction	O
mixture	O
showed	O
strong	O
absorption	O
peak	O
with	O
centering	O
at	O
400	O
nm	O
.	O
	
the	O
ft-ir	O
results	O
imply	O
that	O
ag-nps	O
were	O
successfully	O
synthesized	O
and	O
capped	O
with	O
bio-compounds	O
present	O
in	O
p	O
.	O
	
betle	O
.	O
	
tem	O
image	O
showed	O
that	O
ag-nps	O
formed	O
were	O
well	O
dispersed	O
with	O
a	O
spherical	O
structures	O
and	O
particle	O
size	O
ranging	O
from	O
10	O
to	O
30	O
nm	O
.	O
	
the	O
result	O
revealed	O
that	O
ag-extract	O
nps	O
showed	O
32.78	O
mm	O
zone	O
of	O
inhibition	O
against	O
s	O
.	O
	
aureus	O
,	O
whereas	O
norfloxacin	O
positive	O
control	O
showed	O
maximum	O
32.15	O
mm	O
zone	O
of	O
inhibition	O
for	O
s	O
.	O
	
aureus	O
.	O
	
again	O
,	O
maximum	O
zone	O
of	O
inhibition	O
29.55	O
mm	O
was	O
found	O
for	O
s	O
.	O
	
typhi	O
,	O
27.12	O
mm	O
for	O
e	O
.	O
	
coli	O
and	O
21.95	O
mm	O
for	O
p	O
.	O
	
aeruginosa	O
.	O
	
the	O
results	O
obtained	O
by	O
this	O
study	O
can't	O
be	O
directly	O
extrapolated	O
to	O
human	O
so	O
further	O
studies	O
should	O
be	O
undertaken	O
to	O
established	O
the	O
strong	O
antimicrobial	O
activity	B-C0441655
of	O
ag-extract	O
nps	O
for	O
drug	O
development	O
program	I-C0872152
clinical	B-C2708733
pearls	I-C2708733
in	O
tremor	B-C0040822
and	O
other	O
hyperkinetic	B-C0424295
movement	I-C0424295
disorders	B-C0004936
hyperkinetic	B-C0424295
movements	I-C0424295
,	O
such	O
as	O
tremor	B-C0040822
,	O
myoclonus	B-C0027066
,	O
chorea	B-C0008489
,	O
and	O
dystonia	B-C0013421
,	O
occur	O
in	O
many	O
neurologic	B-C0524851
and	O
medical	B-C0012634
conditions	I-C0012634
.	O
	
accurate	O
clinical	B-C4084924
evaluation	I-C4084924
is	O
the	O
important	O
first	O
step	O
for	O
the	O
proper	O
diagnosis	B-C1704656
and	O
treatment	B-C0087111
of	O
patients	B-C0030705
with	O
abnormal	B-C0013384
movements	I-C0013384
.	O
	
tracking	O
children	B-C0008059
with	O
acute	B-C0023449
lymphoblastic	I-C0023449
leukemia	I-C0023449
who	O
abandoned	B-C1272694
therapy	B-C0087111
experience	B-C0596545
,	O
challenges	B-C0805586
,	O
parental	B-C0030551
perspectives	B-C0449911
,	O
and	O
impact	O
of	O
treatment	B-C0087111
subsidies	B-C0038574
and	O
intensified	B-C0010210
counseling	I-C0010210
refusal	B-C0040809
for	I-C0040809
treatment	I-C0040809
and	O
therapy	B-C0087111
abandonment	B-C0452129
are	O
important	O
reasons	O
for	O
unfavorable	O
outcome	O
of	O
childhood	B-C0231335
acute	B-C0023449
lymphoblastic	I-C0023449
leukemia	I-C0023449
all	B-C0023449
in	O
resource	B-C0018741
-poor	O
countries	B-C0454664
.	O
	
the	O
present	O
study	B-C2603343
,	O
conducted	O
on	O
children	B-C0008059
with	O
all	B-C0023449
whose	O
treatment	B-C0087111
was	O
abandoned	B-C1272694
,	O
attempted	O
to	O
track	O
all	O
these	O
children	B-C0008059
to	O
ascertain	O
the	O
causes	O
and	O
outcome	B-C1274040
of	O
therapy	B-C0087111
abandonment	B-C0452129
/	O
refusal	B-C0040809
.	O
	
in	O
order	O
to	O
improve	O
outcome	B-C1274040
of	O
all	B-C0023449
,	O
measures	O
to	O
prevent	O
abandonment	B-C0452129
were	O
introduced	O
in	O
the	O
form	O
of	O
treatment	B-C0087111
subsidies	B-C0038574
and	O
intensified	B-C0010210
multistage	I-C0010210
counseling	I-C0010210
.	O
	
of	O
the	O
77	O
of	O
418	O
children	B-C0008059
abandoning	O
therapy	B-C0087111
,	O
17	O
22%	O
refused	B-C1705116
upfront	I-C1705116
,	O
whereas	O
the	O
rest	O
abandoned	B-C1272694
during	O
various	O
phases	O
of	O
chemotherapy	B-C3665472
.	O
	
only	O
39	O
50.6	O
of	O
these	O
77	O
families	B-C0015576
could	O
be	O
subsequently	O
contacted	O
.	O
	
financial	B-C0549106
problems	I-C0549106
,	O
too	O
many	O
dependents	B-C1962923
at	O
home	B-C0442519
,	O
and	O
wrong	O
perceptions	B-C0030971
about	O
cancer	B-C0006826
led	O
to	O
abandonment	B-C0452129
in	O
majority	O
.	O
	
children	B-C0243095
abandoning	I-C0243095
treatment	I-C0243095
before	O
completion	O
of	O
induction	B-C0857127
had	O
a	O
significantly	O
shorter	O
survival	B-C0038952
than	O
who	O
abandoned	B-C1272694
post	B-C1254367
induction	I-C1254367
p	O
<	O
0001	O
.	O
	
intensified	B-C0010210
preabandonment	I-C0010210
counseling	I-C0010210
and	O
subsidized	O
treatment	B-C0087111
led	O
to	O
significant	O
reduction	B-C0392756
in	O
abandonment	B-C1521828
rates	I-C1521828
effect	B-C1280500
of	O
new-onset	B-C0746890
left	B-C0023211
bundle	I-C0023211
branch	I-C0023211
block	I-C0023211
after	O
transcatheter	B-C3509486
aortic	I-C3509486
valve	I-C3509486
implantation	I-C3509486
corevalve	B-C0184252
on	O
mortality	B-C0205848
,	O
frequency	B-C0439603
of	O
re-hospitalization	B-C0019993
,	O
and	O
need	O
for	O
pacemaker	B-C0030163
new-onset	B-C0746890
conduction	B-C0232219
disturbances	I-C0232219
are	O
common	O
after	O
transcatheter	B-C3509486
aortic	I-C3509486
valve	I-C3509486
implantation	I-C3509486
tavi	B-C3509486
.	O
	
the	O
most	O
common	O
complication	B-C0009566
is	O
left	B-C0023211
bundle	I-C0023211
branch	I-C0023211
block	I-C0023211
lbbb	B-C0023211
.	O
	
the	O
clinical	B-C0205210
impact	B-C4049986
of	O
new-onset	B-C0746890
lbbb	B-C0023211
after	O
tavi	B-C3509486
remains	O
controversial	B-C0680243
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
clinical	B-C0205210
impact	B-C4049986
of	O
new-onset	B-C0746890
lbbb	B-C0023211
in	O
terms	O
of	O
mortality	B-C0205848
and	O
morbidity	B-C0178685
need	O
for	O
pacemakers	B-C0030163
and	O
admissions	B-C0030673
for	O
heart	B-C0018801
failure	I-C0018801
at	O
long-term	B-C1517942
follow-up	I-C1517942
.	O
	
from	O
april	O
2008	O
to	O
december	O
2014	O
,	O
220	O
patients	B-C0030705
who	O
had	O
severe	O
aortic	B-C0003507
stenosis	I-C0003507
were	O
treated	B-C0332293
with	I-C0332293
the	O
implantation	B-C0021107
of	O
a	O
corevalve	B-C0184252
prosthesis	I-C0184252
.	O
	
sixty-seven	O
of	O
these	O
patients	B-C0030705
were	O
excluded	O
from	O
the	O
analysis	B-C0936012
,	O
including	O
22	O
patients	B-C0030705
with	O
pre-existing	B-C2347662
lbbb	B-C0023211
and	O
45	O
with	O
a	O
permanent	B-C0281945
pacemaker	I-C0281945
,	O
implanted	B-C0021102
previously	O
or	O
within	O
72	O
hours	B-C0439227
of	O
implantation	B-C0021107
.	O
	
the	O
remaining	O
153	O
patients	B-C0030705
were	O
divided	O
into	O
2	O
groups	B-C0441833
group	B-C0441833
1	O
n	O
=	O
80	O
,	O
those	O
with	O
persistent	B-C0205322
new-onset	B-C0746890
lbbb	B-C0023211
,	O
and	O
group	B-C0441833
2	O
n	O
=	O
73	O
,	O
those	O
without	O
conduction	B-C0232219
disturbances	I-C0232219
after	O
treatment	B-C0087111
.	O
	
both	O
groups	B-C0441833
were	O
followed	B-C1522577
up	I-C1522577
at	O
1	O
month	B-C0439231
,	O
6	O
months	B-C0439231
,	O
12	O
months	B-C0439231
,	O
and	O
yearly	B-C0332181
thereafter	O
.	O
	
persistent	B-C0205322
new-onset	B-C0746890
lbbb	B-C0023211
occurred	O
in	O
80	O
patients	B-C0030705
36%	O
immediately	O
after	O
tavi	B-C3509486
73	O
patients	B-C0030705
33%	O
did	O
not	O
develop	O
conduction	B-C0232219
disturbances	I-C0232219
.	O
	
the	O
mean	O
follow-up	B-C1522577
time	B-C0040223
of	O
both	O
groups	B-C0441833
was	O
32	O
22	O
months	B-C0439231
range	O
3	O
to	O
82	O
months	B-C0439231
,	O
and	O
there	O
were	O
no	O
differences	O
in	O
time	B-C0040223
between	O
the	O
groups	B-C0441833
.	O
	
there	O
were	O
no	O
differences	O
in	O
mortality	B-C0205848
between	O
the	O
groups	B-C0441833
39%	O
vs	O
48%	O
,	O
p	O
=	O
0.58	O
.	O
	
no	O
differences	O
were	O
observed	O
between	O
the	O
groups	B-C0441833
in	O
re-hospitalizations	B-C0019993
for	O
heart	B-C0018801
failure	I-C0018801
11%	O
vs	O
16%	O
,	O
p	O
=	O
0.55	O
.	O
	
group	B-C0441833
1	O
did	O
not	O
require	O
pacemaker	B-C0189842
implantation	I-C0189842
more	O
often	O
at	O
follow-up	B-C1522577
10%	O
vs	O
13%	O
,	O
p	O
=	O
0.38	O
than	O
group	B-C0441833
2	O
.	O
	
in	O
conclusion	O
,	O
new-onset	B-C0746890
lbbb	B-C0023211
was	O
not	O
associated	B-C0332281
with	I-C0332281
a	O
higher	B-C0205250
incidence	B-C0021149
of	O
late	O
need	O
for	O
a	O
permanent	B-C0281945
pacemaker	I-C0281945
after	O
corevalve	B-C0184252
implantation	B-C0021107
.	O
	
in	O
addition	O
,	O
it	O
was	O
not	O
associated	B-C0332281
with	I-C0332281
a	O
higher	O
risk	O
of	O
late	O
mortality	B-C0205848
or	O
the	O
relationship	B-C0439849
between	O
polymorphisms	B-C0032529
of	O
bdnfos	B-C1538322
and	O
bdnf	B-C1332408
genes	I-C1332408
and	O
heroin	B-C0019337
addiction	I-C0019337
in	O
the	O
han	B-C0814942
chinese	I-C0814942
population	I-C0814942
the	O
number	O
of	O
heroin	B-C0011892
addicts	B-C0858354
is	O
increasing	B-C0442808
in	O
the	O
world	B-C2700280
.	O
	
both	O
environmental	B-C0686732
and	O
genetic	B-C0814299
factors	I-C0814299
both	O
play	O
critical	B-C1511545
roles	O
in	O
the	O
process	B-C1522240
of	O
heroin	B-C0019337
addiction	I-C0019337
.	O
	
we	O
aimed	B-C1947946
to	O
investigate	B-C1292732
the	O
associations	B-C0439849
between	O
single	B-C0752046
nucleotide	I-C0752046
polymorphisms	I-C0752046
snps	B-C0752046
in	O
lin7c	B-C1425077
,	O
bdnfos	B-C1538322
and	O
bdnf	B-C1332408
genes	I-C1332408
and	O
drug	B-C1510472
addiction	I-C1510472
in	O
the	O
han	B-C0814942
chinese	I-C0814942
population	I-C0814942
.	O
	
we	O
conducted	O
a	O
case-control	B-C0007328
study	I-C0007328
among	O
692	O
cases	B-C0868928
and	O
700	O
healthy	B-C2986479
controls	I-C2986479
from	O
xi'an	B-C0681784
,	O
china	B-C0008115
.	O
	
eight	O
snps	B-C0752046
were	O
selected	B-C1707391
and	O
genotyped	B-C1285573
using	O
massarray	B-C0282574
technology	I-C0282574
sequenom	B-C0683757
,	O
san	B-C3828258
diego	I-C3828258
,	O
ca	I-C3828258
,	O
usa	B-C0041703
.	O
	
odds	B-C0028873
ratios	I-C0028873
or	B-C0028873
and	O
95%	O
confidence	B-C0009667
intervals	I-C0009667
cis	B-C0009667
were	O
calculated	B-C1441506
by	O
unconditional	B-C0206031
logistic	I-C0206031
regression	I-C0206031
adjusting	O
for	O
age	B-C0001779
and	O
sex	B-C0079399
.	O
	
using	O
the	O
chi-squared	B-C0008041
test	I-C0008041
,	O
we	O
found	O
that	O
rs7481311	B-C0678941
or	B-C0028873
=1	O
,	O
95%	O
ci	B-C0009667
=	O
1.087	O
,	O
p	O
=	O
0.009	O
and	O
rs11030096	B-C0678941
or	B-C0028873
=1	O
,	O
95%	O
ci	B-C0009667
=	O
1.049	O
,	O
p	O
=	O
0.011	O
in	O
the	O
bndfos	B-C1538322
were	O
associated	B-C0332281
with	I-C0332281
an	O
increased	B-C0205217
risk	B-C0035647
of	O
heroin	B-C0019337
addiction	I-C0019337
.	O
	
by	O
contrast	O
,	O
rs988712	B-C0678941
located	O
in	O
bdnfos	B-C1538322
showed	O
a	O
decreased	B-C0205216
risk	B-C0035647
of	O
heroin	B-C0019337
addiction	I-C0019337
or	B-C0028873
=0	O
,	O
95%	O
ci	B-C0009667
=	O
0.582	O
,	O
p	O
=	O
0.003	O
.	O
	
by	O
genetic	B-C0026343
model	I-C0026343
analysis	B-C0936012
,	O
we	O
found	O
that	O
the	O
't'	B-C0002085
allele	I-C0002085
of	O
rs988712	B-C0678941
in	O
bdnfos	B-C1538322
had	O
a	O
protective	O
role	O
for	O
heroin	B-C0019337
addiction	I-C0019337
in	O
the	O
additive	B-C0026343
model	I-C0026343
and	O
dominant	B-C0026343
model	I-C0026343
p	O
<	O
0.05	O
.	O
	
by	O
contrast	O
,	O
the	O
allele	B-C0002085
't'	I-C0002085
of	O
rs7481311	B-C0678941
in	O
bdnfos	B-C1538322
significantly	O
elevated	B-C3163633
the	O
risk	B-C0035647
of	O
heroin	B-C0019337
addiction	I-C0019337
in	O
the	O
additive	B-C0026343
model	I-C0026343
,	O
recessive	B-C0026343
model	I-C0026343
and	O
dominant	B-C0026343
model	I-C0026343
p	O
<	O
0.05	O
.	O
	
we	O
also	O
found	O
that	O
allele	B-C0002085
'c	I-C0002085
'	O
of	O
rs11030096	B-C0678941
was	O
associated	B-C0332281
with	I-C0332281
an	O
increased	B-C0205217
risk	B-C0035647
of	O
addiction	B-C0019337
in	O
the	O
dominant	B-C0026343
model	I-C0026343
and	O
additive	B-C0026343
model	I-C0026343
p	O
<	O
0.05	O
.	O
	
additionally	O
,	O
we	O
found	O
that	O
rs6265	B-C0678941
,	O
rs11030104	B-C0678941
and	O
rs10767664	B-C0678941
in	O
bdnf	B-C1332408
were	O
associated	B-C0332281
with	I-C0332281
a	O
decreased	B-C0205216
risk	B-C0035647
of	O
heroin	B-C0019337
addiction	I-C0019337
p	O
<	O
0.05	O
.	O
	
however	O
,	O
only	O
rs7481311	B-C0678941
in	O
bdnfos	B-C1538322
remained	O
significant	B-C0750502
after	O
bonferroni	B-C2347434
correction	I-C2347434
p	O
<	O
0.00625	O
.	O
	
these	O
results	B-C2825142
suggest	O
that	O
polymorphisms	B-C0032529
of	O
bdnfos	B-C1538322
play	O
an	O
important	B-C3898777
role	O
in	O
heroin	B-C0019337
addiction	I-C0019337
susceptibility	B-C1264642
in	O
the	O
chinese	B-C0814942
han	I-C0814942
population	I-C0814942
.	O
	
risk	B-C0814287
and	I-C0814287
protective	I-C0814287
factors	I-C0814287
associated	B-C0332281
with	I-C0332281
adolescent	B-C0001588
girls'	I-C0001588
substance	B-C0237123
use	I-C0237123
data	B-C1511726
from	O
a	O
nationwide	O
facebook	B-C3179065
sample	O
despite	O
overall	O
reductions	B-C0547047
in	O
teenage	B-C0001578
substance	B-C0237123
use	I-C0237123
,	O
adolescent	B-C0001588
girls	I-C0001588
'	O
rates	B-C1521828
of	O
substance	B-C0237123
use	I-C0237123
remain	O
unacceptably	B-C1299351
high	I-C1299351
.	O
	
this	O
article	B-C1706852
examines	O
whether	O
girls	B-C0043210
'	O
substance	B-C0237123
use	I-C0237123
is	O
associated	B-C0332281
with	I-C0332281
general	O
risk	B-C0814287
and	I-C0814287
protective	I-C0814287
factors	I-C0814287
goal	B-C0025361
setting	I-C0025361
,	O
problem	B-C0033211
solving	I-C0033211
,	O
refusal	B-C0683255
skills	I-C0683255
,	O
peer	B-C0683549
use	I-C0683549
,	O
and	O
self-efficacy	B-C0600564
and	O
gender	B-C0079399
-	O
specific	B-C0205369
risk	B-C0814287
and	I-C0814287
protective	I-C0814287
factors	I-C0814287
communication	B-C0178556
style	I-C0178556
,	O
coping	B-C0086059
skills	I-C0086059
,	O
self-esteem	B-C0036597
,	O
body	B-C0005891
image	I-C0005891
,	O
perceived	B-C0038443
stress	I-C0038443
,	O
anxiety	B-C0003469
,	O
and	O
depression	B-C0011570
.	O
	
cross-sectional	B-C0010362
data	I-C0010362
were	O
collected	O
in	O
2013	O
via	O
online	B-C0178803
surveys	I-C0178803
from	O
a	O
nationwide	O
sample	O
of	O
adolescent	B-C0001588
girls	I-C0001588
n	O
=	O
788	O
,	O
aged	O
13	O
and	O
14	O
years	O
,	O
who	O
were	O
recruited	O
through	O
facebook	B-C3179065
.	O
	
in	O
multivariate	B-C0026777
analyses	I-C0026777
,	O
controlling	O
for	O
correlates	B-C0871178
of	O
adolescent	B-C0205653
substance	B-C0237123
use	I-C0237123
,	O
11	O
of	O
the	O
13	O
general	O
and	O
gender	B-C0079399
-	O
specific	B-C0205369
risk	B-C0814287
and	I-C0814287
protective	I-C0814287
factors	I-C0814287
were	O
consistently	O
associated	B-C0332281
with	I-C0332281
past-month	O
alcohol	B-C0001948
,	O
cigarette	B-C0694535
,	O
and	O
other	O
drug	B-C0242510
use	I-C0242510
in	O
the	O
expected	O
direction	O
past-month	B-C0871810
marijuana	I-C0871810
use	I-C0871810
was	O
associated	B-C0332281
with	I-C0332281
8	O
of	O
the	O
13	O
factors	B-C1521761
.	O
	
refusal	B-C0683255
skill	I-C0683255
s	O
,	O
peer	B-C0683549
use	I-C0683549
,	O
coping	B-C0009967
,	O
and	O
depressive	B-C0344315
mood	I-C0344315
were	O
most	O
consistently	O
and	O
strongly	O
associated	B-C0332281
with	I-C0332281
substance	B-C0237123
use	I-C0237123
.	O
	
substance	B-C1171221
abuse	I-C1171221
prevention	I-C1171221
programs	B-C0043113
targeting	O
adolescent	B-C0001588
girls	I-C0001588
should	O
focus	O
on	O
such	O
general	O
risk	B-C0814287
and	I-C0814287
protective	I-C0814287
factors	I-C0814287
as	O
problem	B-C0033211
solving	I-C0033211
,	O
refusal	B-C0683255
skill	I-C0683255
s	O
,	O
peer	B-C0683549
influences	I-C0683549
,	O
and	O
self-efficacy	B-C0600564
,	O
as	O
well	O
as	O
such	O
gender	B-C0079399
-	O
specific	B-C0205369
risk	B-C0814287
and	I-C0814287
protective	I-C0814287
factors	I-C0814287
as	O
communication	B-C0178556
style	I-C0178556
,	O
coping	B-C0009967
,	O
self-esteem	B-C0036597
,	O
body	B-C0005891
image	I-C0005891
,	O
perceived	B-C0038443
stress	I-C0038443
,	O
and	O
mood	B-C0262715
management	I-C0262715
.	O
	
ethics	B-C0015000
hype	B-C0683753
there	O
has	O
been	O
growing	O
concern	B-C2699424
about	O
the	O
phenomenon	B-C1882365
of	O
science	B-C0036397
hype	B-C0683753
,	O
the	O
tendency	O
to	O
exaggerate	B-C0442801
the	O
value	O
or	O
near	B-C1706276
-	O
future	B-C0016884
application	B-C4048755
of	O
research	B-C0683954
results	I-C0683954
.	O
	
although	O
this	O
is	O
a	O
problem	B-C0033213
that	O
touches	O
every	O
area	B-C1879848
of	I-C1879848
biomedicine	I-C1879848
,	O
the	O
topic	B-C1555712
of	O
genetics	B-C0017398
seems	O
to	O
be	O
particularly	O
prone	O
to	O
enthusiastic	B-C0558083
predictions	B-C0681842
.	O
	
the	O
world	B-C2700280
has	O
been	O
told	O
for	O
over	O
two	O
decades	B-C1254367
-by	O
the	O
media	B-C0009458
,	O
researchers	B-C0035173
,	O
politicians	B-C0682232
,	O
and	O
the	O
biotech	B-C0005574
industry	B-C0021267
-that	O
a	O
genome	B-C0017428
-driven	O
health	B-C0086388
care	I-C0086388
revolution	B-C0441716
is	O
just	O
around	O
the	O
corner	O
.	O
	
and	O
while	O
the	O
revolution	B-C0441716
never	O
seems	O
to	O
arrive	O
,	O
the	O
hopeful	O
rhetoric	B-C0814791
continues	O
.	O
	
it	O
has	O
been	O
suggested	O
that	O
this	O
unrelenting	O
""""	O
genohype	B-C0683753
""""	O
is	O
having	O
a	O
range	O
of	O
adverse	B-C0243095
social	B-C0037397
consequences	I-C0037397
,	O
including	O
misleading	O
the	O
public	B-C0162592
and	O
hurting	B-C3640015
the	O
long-term	B-C0443252
legitimacy	B-C0023262
of	O
the	O
field	B-C1521738
.	O
	
while	O
we	O
need	O
more	O
good	O
data	B-C1511726
on	O
the	O
nature	B-C0349590
and	O
magnitude	B-C1704240
of	O
these	O
possible	O
harms	B-C0680558
,	O
few	O
would	O
argue	O
with	O
the	O
proposition	B-C0035174
that	O
sustained	B-C0443318
science	B-C0036397
hype	B-C0683753
is	O
a	O
bad	O
thing	O
.	O
	
we	O
all	O
benefit	B-C0814225
from	O
robust	B-C2986815
science	B-C0036397
and	O
accurate	B-C0443131
public	B-C0162592
representations	B-C1882932
of	O
biomedical	B-C0005540
research	I-C0005540
.	O
	
but	O
,	O
to	O
date	O
,	O
there	O
has	O
been	O
very	O
little	O
consideration	B-C0518609
of	O
the	O
degree	B-C0449286
to	O
which	O
the	O
scholarship	B-C0036365
on	O
the	O
related	O
ethical	B-C0086264
,	O
legal	B-C0680513
,	O
and	O
social	B-C0683653
issues	I-C0683653
has	O
been	O
hyped	O
.	O
	
are	O
the	O
conclusions	B-C1707478
from	O
elsi	B-C0036365
scholarship	I-C0036365
also	O
lubiprostone	B-C1684405
accelerates	B-C0521110
intestinal	B-C0232484
transit	I-C0232484
and	O
alleviates	B-C0205245
small	B-C3160854
intestinal	I-C3160854
bacterial	I-C3160854
overgrowth	I-C3160854
in	O
patients	B-C0030705
with	O
chronic	B-C0401149
constipation	I-C0401149
lubiprostone	B-C1684405
is	O
an	O
effective	B-C1704419
treatment	B-C1522326
for	O
chronic	B-C0401149
constipation	I-C0401149
cc	B-C0401149
.	O
	
the	O
mechanism	B-C1524059
of	I-C1524059
action	I-C1524059
of	O
lubiprostone	B-C1684405
is	O
through	O
increasing	B-C0442808
fluid	B-C2263233
secretion	I-C2263233
and	O
lubrication	B-C0024069
of	O
the	O
intestinal	B-C0545876
lumen	I-C0545876
.	O
	
the	O
effects	B-C1280500
of	O
lubiprostone	B-C1684405
on	O
gastrointestinal	B-C0232484
transit	I-C0232484
and	O
small	B-C3160854
intestinal	I-C3160854
bacterial	I-C3160854
overgrowth	I-C3160854
sibo	B-C3160854
have	O
not	O
been	O
adequately	O
explored	O
.	O
	
the	O
current	O
study	B-C2603343
was	O
designed	O
to	O
investigate	B-C1292732
whether	O
lubiprostone	B-C1684405
1	O
alters	O
gastrointestinal	B-C0232484
transit	I-C0232484
and	O
2	O
affects	O
sibo	B-C3160854
in	O
patients	B-C0030705
with	O
constipation	B-C0009806
.	O
	
a	O
total	O
of	O
29	O
female	B-C0150905
patients	I-C0150905
mean	B-C0001779
age	I-C0001779
=	O
39	O
years	B-C0439234
range	B-C1514721
19-64	O
with	O
cc	B-C0401149
received	B-C1514756
2	O
weeks	B-C0439230
of	O
lubiprostone	B-C1684405
24mcg	O
b.i	O
,	O
p.o	O
.	O
	
stool	B-C0426740
consistency	I-C0426740
based	O
on	O
bristol	B-C4084861
stool	I-C4084861
scale	I-C4084861
and	O
the	O
frequency	B-C0426642
of	I-C0426642
bowel	I-C0426642
movements	I-C0426642
bms	B-C0011135
were	O
recorded	O
.	O
	
gastric	B-C1954153
emptying	I-C1954153
time	I-C1954153
,	O
small	B-C1254358
bowel	I-C1254358
transit	I-C1254358
time	I-C1254358
,	O
colon	B-C0009368
transit	B-C1254358
time	I-C1254358
ctt	B-C1254358
,	O
combined	O
small	B-C0232688
and	I-C0232688
large	I-C0232688
bowel	I-C0232688
transit	I-C0232688
time	I-C0232688
slbtt	B-C0232688
and	O
whole	O
gut	B-C0699819
transit	B-C1254358
time	I-C1254358
were	O
measured	B-C0444706
using	O
wireless	B-C0430022
motility	I-C0430022
capsule	I-C0430022
.	O
	
the	O
sibo	B-C3160854
status	B-C0449438
was	O
assessed	O
by	O
the	O
lactulose	B-C0344439
breath	I-C0344439
test	I-C0344439
.	O
	
data	B-C1511726
were	O
analyzed	B-C0936012
using	O
wilcoxon	B-C0242931
rank	I-C0242931
,	O
mann-whitney	B-C0242927
u	I-C0242927
,	O
spearman	B-C0242929
rank	I-C0242929
correlation	I-C0242929
and	O
chi-square	B-C0008041
tests	I-C0008041
.	O
	
lubiprostone	B-C1684405
significantly	O
softened	B-C0870079
the	O
stool	B-C0015733
and	O
increased	B-C0205217
the	O
frequency	B-C0426642
of	I-C0426642
bm	I-C0426642
from	O
median	B-C0876920
of	O
2	O
to	O
4	O
times	B-C1632851
per	O
week	B-C0439230
.	O
	
the	O
ctt	B-C1254358
and	O
slbtt	B-C0232688
were	O
significantly	O
shorter	B-C1282927
in	O
responders	B-C1257890
to	O
lubiprostone	B-C1684405
i.e	O
,	O
those	O
with	O
2	O
times	B-C1632851
increase	B-C0442805
in	O
the	O
number	B-C0237753
of	O
their	O
weekly	B-C0332174
bm	B-C0011135
compared	B-C1707455
with	O
nonresponders	B-C1257890
.	O
	
the	O
higher	B-C0205250
frequency	B-C0426642
of	I-C0426642
bm	I-C0426642
after	O
treatment	B-C1522326
was	O
significantly	O
correlated	B-C1707520
with	O
the	O
acceleration	B-C0000894
of	O
ctt	B-C1254358
,	O
slbtt	B-C0232688
and	O
whole	O
gut	B-C0699819
transit	B-C1254358
time	I-C1254358
.	O
	
in	O
all	O
,	O
17	O
out	O
of	O
25	O
68%	O
patients	B-C0030705
,	O
who	O
were	O
tested	B-C0039593
for	O
sibo	B-C3160854
at	O
baseline	B-C1442488
,	O
were	O
positive	B-C1446409
.	O
	
in	O
addition	O
,	O
7	O
out	O
of	O
17	O
41%	O
sibo	B-C3160854
-	O
positive	B-C1446409
patients	B-C0030705
became	O
sibo	B-C3160854
-	O
negative	B-C0205160
after	O
lubiprostone	B-C1684405
treatment	B-C1522326
p	O
<	O
0.05	O
.	O
	
in	O
cc	B-C0401149
,	O
lubiprostone	B-C1684405
improves	O
the	O
frequency	B-C0426642
of	I-C0426642
bms	I-C0426642
,	O
softens	B-C0870079
the	O
stool	B-C0015733
,	O
accelerates	B-C0521110
intestinal	B-C0232484
transit	I-C0232484
and	O
decreases	B-C0547047
accompanying	O
sibo	B-C3160854
.	O
	
the	O
improvement	B-C2986411
of	O
sibo	B-C3160854
could	O
be	O
explained	O
by	O
the	O
cleansing	B-C1947930
effect	B-C1280500
of	O
increased	B-C0205217
intestinal	B-C0232671
fluid	I-C0232671
and	O
mucus	B-C0026727
combined	O
with	O
enhanced	B-C2349975
intestinal	B-C0021838
motility	I-C0021838
with	O
minimally	B-C0282624
invasive	I-C0282624
treatment	I-C0282624
of	O
difficult	O
bleeding	B-C0019080
lesions	B-C0221198
of	O
the	O
small	B-C0021852
bowel	I-C0021852
bleeding	B-C0019080
lesions	B-C0221198
of	O
the	O
small	B-C0021852
bowel	I-C0021852
are	O
often	O
difficult	O
to	O
identify	B-C0205396
due	O
to	O
the	O
obscure	B-C3844685
symptomatology	B-C1457887
.	O
	
localizing	B-C0392752
these	O
lesions	B-C0221198
requires	O
specific	B-C0205369
techniques	B-C0449851
.	O
	
the	O
double-balloon	B-C2936452
enteroscopy	I-C2936452
dbe	B-C2936452
could	O
be	O
used	O
to	O
precisely	O
localize	B-C0392752
and	O
mark	O
lesions	B-C0221198
,	O
so	O
that	O
a	O
minimally	B-C0282624
invasive	I-C0282624
surgical	I-C0282624
treatment	I-C0282624
could	O
be	O
performed	O
.	O
	
twenty	O
robot	B-C0336537
-	O
assisted	B-C1269765
small	B-C3865550
bowel	I-C3865550
procedures	I-C3865550
are	O
presented	O
using	O
a	O
combination	B-C0205195
of	O
dbe	B-C2936452
for	O
localization	B-C0392752
and	O
robotic	B-C4038855
resection	I-C4038855
.	O
	
there	O
were	O
10	O
jejunal	B-C3837064
resections	I-C3837064
and	O
10	O
ileal	B-C3837066
resections	I-C3837066
.	O
	
mean	O
age	B-C0001779
was	O
58.7	O
years	B-C0439234
.	O
	
mean	O
operative	B-C3494201
time	I-C3494201
was	O
153.4	O
minutes	B-C0439232
,	O
mean	O
blood	B-C3163616
loss	I-C3163616
of	O
46	O
ml	O
.	O
	
no	O
conversion-to-open	B-C3494226
and	O
there	O
were	O
4	O
post-operative	B-C0032790
complications	B-C0009566
.	O
	
the	O
90-	O
day	B-C0439228
mortality	B-C0205848
was	O
nil	O
and	O
the	O
median	O
length	B-C0023303
of	I-C0023303
stay	I-C0023303
was	O
4.1	O
days	B-C0439228
.	O
	
final	O
pathology	B-C0807321
was	O
consistent	B-C0332290
with	I-C0332290
malignancy	B-C4282132
in	O
10	O
cases	B-C0868928
.	O
	
the	O
combination	B-C0205195
of	O
double-balloon	B-C2936452
enteroscopy	I-C2936452
and	O
robotic	B-C4038855
technology	I-C4038855
allows	O
accurate	B-C0443131
identification	B-C0205396
and	O
selective	O
treatment	B-C1522326
of	O
lesions	B-C0221198
that	O
could	O
be	O
otherwise	O
difficult	O
to	O
treat	B-C1522326
in	O
a	O
minimally	B-C0282624
invasive	I-C0282624
fashion	I-C0282624
.	O
	
kinematic	B-C0600169
and	O
emg	B-C0013839
responses	B-C0871261
to	O
pelvis	B-C0030797
and	O
leg	B-C1140621
assistance	B-C1521721
force	B-C0336996
during	O
treadmill	B-C2712999
walking	I-C2712999
in	O
children	B-C0008059
with	O
cerebral	B-C0007789
palsy	I-C0007789
treadmill	B-C2107089
training	I-C2107089
has	O
been	O
used	O
for	O
improving	O
locomotor	B-C0023946
function	I-C0023946
in	O
children	B-C0008059
with	O
cerebral	B-C0007789
palsy	I-C0007789
cp	B-C0007789
,	O
but	O
the	O
functional	O
gains	O
are	O
relatively	O
small	O
,	O
suggesting	O
a	O
need	O
to	O
improve	O
current	O
paradigms	B-C0681797
.	O
	
the	O
understanding	O
of	O
the	O
kinematic	B-C0600169
and	O
emg	B-C0013839
responses	B-C0871261
to	O
force	B-C0336996
s	O
applied	O
to	O
the	O
body	B-C1268086
of	O
subjects	O
during	O
treadmill	B-C2712999
walking	I-C2712999
is	O
crucial	O
for	O
improving	O
current	O
paradigms	B-C0681797
.	O
	
the	O
objective	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
determine	O
the	O
kinematic	B-C0600169
s	O
and	O
emg	B-C0013839
responses	B-C0871261
to	O
the	O
pelvis	B-C0030797
and/or	O
leg	B-C1140621
assistance	B-C1521721
force	B-C0336996
.	O
	
ten	O
children	B-C0008059
with	O
spastic	B-C0338596
cp	I-C0338596
were	O
recruited	O
to	O
participate	B-C0030699
in	O
this	O
study	B-C2603343
.	O
	
a	O
controlled	O
assistance	B-C1521721
force	B-C0336996
was	O
applied	O
to	O
the	O
pelvis	B-C0030797
and/or	O
legs	B-C1140621
during	O
stance	B-C2019827
and	O
swing	B-C2039052
phase	I-C2039052
of	I-C2039052
gait	I-C2039052
through	O
a	O
custom	O
designed	O
robotic	B-C1738367
system	I-C1738367
during	O
walking	B-C0080331
.	O
	
muscle	B-C0026845
activities	B-C0441655
and	O
spatial	B-C1254362
-	O
temporal	B-C2362314
gait	B-C0016928
parameters	I-C0016928
were	O
measured	O
at	O
different	O
loading	B-C4279935
conditions	I-C4279935
during	O
walking	B-C0080331
.	O
	
in	O
addition	O
,	O
the	O
spatial-temporal	B-C0016928
gait	I-C0016928
parameters	I-C0016928
during	O
overground	O
walking	B-C0080331
before	O
and	O
after	O
treadmill	B-C2107089
training	I-C2107089
were	O
also	O
collected	O
.	O
	
applying	O
pelvis	B-C0030797
assistance	B-C1521721
improved	B-C0184511
step	B-C0427127
height	I-C0427127
and	O
applying	O
leg	B-C1140621
assistance	B-C1521721
improved	B-C0184511
step	B-C0427126
length	I-C0427126
during	O
walking	B-C0080331
,	O
but	O
applying	O
leg	B-C1140621
assistance	B-C1521721
also	O
reduced	B-C0392756
muscle	B-C0026845
activation	B-C1879547
of	O
ankle	B-C0581542
flexor	I-C0581542
during	O
the	O
swing	B-C2039052
phase	I-C2039052
of	I-C2039052
gait	I-C2039052
.	O
	
in	O
addition	O
,	O
step	B-C0427126
length	I-C0427126
and	O
self-selected	O
walking	B-C2009910
speed	I-C2009910
significantly	O
improved	B-C0184511
after	O
one	O
session	B-C1883016
of	O
treadmill	B-C2107089
training	I-C2107089
with	O
combined	O
pelvis	B-C0030797
and	O
leg	B-C1140621
assistance	B-C1521721
.	O
	
outlining	O
a	O
population	B-C0242444
"""at"	I-C0242444
"risk"""	I-C0242444
of	O
parkinson's	B-C0030567
disease	I-C0030567
evidence	B-C3887511
from	O
a	O
case-control	B-C0007328
study	I-C0007328
the	O
multifactorial	B-C0699748
pathogenesis	I-C0699748
of	O
parkinson's	B-C0030567
disease	I-C0030567
pd	B-C0030567
requires	O
a	O
careful	O
identification	O
of	O
populations	B-C0242444
"""at"	I-C0242444
"risk"""	I-C0242444
of	O
developing	O
the	O
disease	B-C0030567
.	O
	
in	O
this	O
case-control	B-C0007328
study	I-C0007328
we	O
analyzed	B-C0936012
a	O
large	O
italian	B-C0022277
population	B-C1257890
,	O
in	O
an	O
attempt	O
to	O
outline	O
general	B-C0243161
criteria	I-C0243161
to	O
define	O
a	O
population	B-C0242444
"""at"	I-C0242444
"risk"""	I-C0242444
of	O
pd	B-C0030567
.	O
	
we	O
enrolled	O
300	O
pd	B-C0030567
patients	B-C0030705
and	O
300	O
controls	B-C0009932
,	O
gender	B-C0079399
and	O
age	B-C0001779
matched	B-C0024908
,	O
from	O
the	O
same	O
urban	B-C2700386
geographical	B-C0681784
area	I-C0681784
.	O
	
all	O
subjects	B-C0080105
were	O
interviewed	B-C0021822
on	O
demographics	B-C0011298
,	O
family	B-C0241889
history	I-C0241889
of	O
pd	B-C0030567
,	O
occupational	B-C0149685
and	I-C0149685
environmental	I-C0149685
toxicants	I-C0149685
exposure	I-C0149685
,	O
smoking	B-C1519386
status	I-C1519386
,	O
and	O
alcohol	B-C0001948
consumption	I-C0001948
.	O
	
a	O
sample	O
of	O
65	O
patients	B-C0030705
and	O
65	O
controls	B-C0009932
also	O
underwent	O
serum	B-C1550100
dosing	B-C0178602
of	O
iron	B-C0337439
,	O
copper	B-C0373587
,	O
mercury	B-C0428257
,	O
and	O
manganese	B-C0373677
by	O
means	O
of	O
inductively	B-C1553183
coupled-plasma-mass-spectrometry	I-C1553183
icp-ms	B-C1553183
.	O
	
positive	B-C1446409
family	B-C0241889
history	I-C0241889
,	O
toxicants	B-C0040537
exposure	I-C0040537
,	O
non-current-smoker	B-C3496610
,	O
and	O
alcohol	B-C0425322
nonconsumer	I-C0425322
status	I-C0425322
occurred	O
as	O
significant	O
risk	B-C0035648
factors	I-C0035648
in	O
our	O
population	B-C1257890
.	O
	
the	O
number	O
of	O
concurring	B-C0035648
risk	I-C0035648
factors	I-C0035648
overlapping	B-C1948020
in	O
the	O
same	B-C0080105
subject	I-C0080105
impressively	O
increased	B-C0205217
the	O
overall	B-C1444641
risk	I-C1444641
.	O
	
no	B-C3842396
significant	I-C3842396
differences	I-C3842396
were	O
measured	B-C0444706
in	O
the	O
metal	B-C0025552
serum	B-C1550100
levels	B-C0441889
.	O
	
our	O
findings	B-C0243095
indicate	O
that	O
combination	O
of	O
three	O
to	O
four	O
concurrent	B-C0205420
pd	B-C0030567
-	O
risk	B-C0035648
factors	I-C0035648
defines	O
a	O
condition	O
""""	O
at	B-C1444641
risk	I-C1444641
""""	O
of	O
pd	B-C0030567
.	O
	
a	O
simple	O
stratification	B-C1514983
,	O
based	O
on	O
these	O
questionnaires	B-C0034394
,	O
might	O
be	O
of	O
help	O
in	O
identifying	B-C0949543
subjects	I-C0949543
suitable	O
for	O
neuroprotective	B-C0679199
strategies	I-C0679199
.	O
	
work	B-C0043227
process	B-C1522240
,	O
performance	B-C1286385
and	O
professional	B-C0679924
profile	I-C0679924
of	O
a	O
hearing	B-C0018747
health	I-C0018747
network	I-C0018747
reference	B-C1561577
for	O
satisfaction	B-C0242428
to	O
analyze	B-C0936012
the	O
correlation	B-C1707520
between	O
the	O
satisfaction	B-C0022397
of	O
professionals	B-C0679924
from	O
the	O
hearing	B-C0018747
health	I-C0018747
care	I-C0018747
network	I-C0018747
in	O
two	O
micro	B-C3811161
-	O
regions	B-C0205147
of	O
minas	B-C0681784
gerais	I-C0681784
state	I-C0681784
and	O
the	O
sociodemographic	B-C2003903
profile	I-C2003903
,	O
work	B-C0043227
process	B-C1522240
,	O
and	O
work	B-C1286385
performance	I-C1286385
in	O
the	O
health	B-C0018747
service	I-C0018747
.	O
	
this	O
is	O
a	O
cross-sectional	B-C0010362
,	O
observational	B-C1518527
,	O
analytic	B-C0009247
study	I-C0009247
with	O
a	O
non-probabilistic	B-C4288587
sample	I-C4288587
including	O
34	O
professionals	B-C0679924
from	O
the	O
hearing	B-C0018747
health	I-C0018747
care	I-C0018747
services	I-C0018747
.	O
	
data	B-C0010995
collection	I-C0010995
occurred	O
through	O
individual	B-C0237401
interviews	B-C0021822
in	O
the	O
municipality	B-C0600182
of	O
professional	B-C0033284
practice	I-C0033284
.	O
	
associations	B-C0439849
between	O
the	O
professional	B-C0022397
satisfaction	I-C0022397
variable	B-C0439828
and	O
the	O
explanatory	B-C0681841
variables	B-C0439828
sociodemographic	B-C1511726
data	I-C1511726
,	O
work	B-C0205547
routine	I-C0205547
,	O
and	O
developed	B-C0332253
actions	B-C3266814
were	O
conducted	O
.	O
	
professionals	B-C0679924
with	O
graduate	B-C0013630
studies	I-C0013630
were	O
more	O
satisfied	B-C4084799
with	O
the	O
human	B-C0162791
resources	I-C0162791
policy	I-C0162791
and	O
the	O
activities	B-C0441655
developed	B-C0332253
,	O
whereas	O
health	B-C0086388
civil	B-C0401892
servants	I-C0401892
showed	O
more	O
satisfaction	B-C0242428
with	O
the	O
wage	B-C0036064
policy	B-C0242456
and	O
the	O
work	B-C0237852
schedule	I-C0237852
.	O
	
the	O
correlation	B-C0010101
analysis	I-C0010101
between	O
work	B-C0043227
process	B-C1522240
and	O
satisfaction	B-C0022397
revealed	B-C0443289
a	O
moderate	B-C1510992
positive	B-C1514241
correlation	B-C1707520
between	O
items	O
such	O
as	O
health	B-C0018738
promotion	I-C0018738
actions	B-C3266814
,	O
satisfaction	B-C0022397
with	O
diagnostic	B-C0524922
equipment	I-C0524922
,	O
and	O
satisfaction	B-C0022397
with	O
maintenance	B-C4035913
equipment	I-C4035913
.	O
	
the	O
present	O
study	B-C2603343
revealed	O
a	O
higher	B-C0205250
level	B-C0441889
of	O
satisfaction	B-C0022397
among	O
professionals	B-C2698884
with	O
graduate	B-C0013630
studies	I-C0013630
human	B-C0162791
resources	I-C0162791
policy	I-C0162791
and	O
activities	B-C0441655
developed	B-C0332253
and	O
civil	B-C0401892
servants	I-C0401892
wage	B-C0036064
policy	B-C0242456
and	O
work	B-C0237852
schedule	I-C0237852
.	O
	
the	O
relevance	B-C2347946
of	O
this	O
study	B-C2603343
lies	O
on	O
the	O
important	O
role	O
that	O
health	B-C1704312
professionals	I-C1704312
play	O
on	O
the	O
health	B-C0018747
care	I-C0018747
network	I-C0018747
.	O
	
additionally	O
,	O
the	O
study	B-C2603343
of	O
satisfaction	B-C0022397
level	B-C0441889
can	O
provide	O
a	O
search	O
for	O
improvements	B-C2986411
,	O
considering	O
that	O
satisfied	B-C4084799
professionals	B-C2698884
not	O
only	O
improve	B-C0184511
service	B-C0871201
quality	I-C0871201
,	O
but	O
also	O
show	B-C0517173
greater	I-C0517173
creativity	I-C0517173
,	O
commitment	B-C0870312
,	O
and	O
application	B-C0185125
of	O
laparoscopic	B-C0031150
lumbar	B-C0408632
discectomy	I-C0408632
and	O
artificial	B-C2144940
disc	I-C2144940
replacement	I-C2144940
at	O
least	O
two	O
years	O
of	O
follow-up	B-C1522577
this	O
prospective	B-C0033522
observational	B-C1518527
study	I-C1518527
included	O
22	O
patients	B-C0030705
who	O
were	O
diagnosed	B-C0011900
with	O
symptomatic	B-C0231220
degenerative	B-C0158266
disc	I-C0158266
disease	I-C0158266
treated	O
via	O
artificial	B-C2144940
disc	I-C2144940
replacement	I-C2144940
adr	B-C2144940
with	O
a	O
laparoscopic	B-C0031150
technique	B-C0449851
.	O
	
the	O
current	O
study	B-C2603343
aimed	B-C1947946
to	O
assess	B-C1516048
the	O
safety	B-C0036043
and	O
efficacy	B-C1280519
of	O
adr	B-C2144940
using	O
a	O
laparoscopic	B-C0031150
technique	B-C0449851
for	O
lumbar	B-C0281899
disc	I-C0281899
herniation	I-C0281899
.	O
	
symptomatic	B-C0231220
degenerative	B-C0158266
disc	I-C0158266
disease	I-C0158266
is	O
the	O
major	O
cause	O
of	O
low	B-C0024031
back	I-C0024031
pain	I-C0024031
with	O
lumbar	B-C0024090
segmental	B-C0205122
instability	B-C1444783
.	O
	
adr	B-C2144940
has	O
increased	B-C0205217
in	O
popularity	B-C0679970
as	O
an	O
alternative	B-C0683466
treatment	I-C0683466
for	O
lumbar	B-C0281899
disc	I-C0281899
herniation	I-C0281899
.	O
	
however	O
,	O
the	O
traditional	B-C0443324
approach	B-C0449445
to	O
spinal	B-C0920347
surgery	I-C0920347
carries	O
the	O
risk	B-C0035647
of	O
catastrophic	B-C0007397
bleeding	B-C0019080
from	O
injury	B-C3263723
to	O
major	O
vessels	B-C0005847
,	O
as	O
well	O
as	O
iatrogenic	B-C0439669
injury	B-C3263723
to	O
the	O
viscera	B-C0042779
and	O
associated	B-C1285145
structures	I-C1285145
.	O
	
therefore	O
,	O
laparoscopic	B-C0031150
lumbar	B-C0408632
discectomy	I-C0408632
and	O
adr	B-C2144940
may	O
represent	B-C1882932
a	O
useful	O
alternative	B-C1523987
.	O
	
twenty-two	O
patients	B-C0030705
8	O
males	B-C0086582
and	O
14	O
females	B-C0086287
who	O
were	O
diagnosed	B-C0011900
with	O
symptomatic	B-C0231220
degenerative	B-C0158266
disc	I-C0158266
disease	I-C0158266
were	O
included	O
in	O
this	O
study	B-C2603343
.	O
	
seven	O
cases	B-C0868928
involved	O
the	O
l4/5	O
level	O
,	O
and	O
15	O
cases	B-C0868928
involved	O
the	O
l5/s1	O
level	O
.	O
	
all	O
patients	B-C0030705
were	O
ineffective	B-C3242229
after	O
at	O
least	O
6	O
months	O
of	O
conservative	B-C0459914
treatments	I-C0459914
all	O
patients	B-C0030705
were	O
informed	O
of	O
the	O
surgery	B-C0543467
before	O
the	O
operation	B-C0543467
and	O
provided	O
consent	B-C1511481
.	O
	
three-dimensional	B-C0450363
computed	B-C1536105
tomographic	I-C1536105
angiography	I-C1536105
3d	B-C0450363
-	O
cta	B-C1536105
of	O
the	O
iliac	B-C0020889
great	O
blood	B-C0005847
vessels	I-C0005847
was	O
completed	B-C0205197
before	O
the	O
surgery	B-C0543467
.	O
	
all	O
surgical	B-C0543467
procedures	I-C0543467
were	O
performed	O
under	O
a	O
laparoscope	B-C0023036
.	O
	
all	O
patients	B-C0030705
were	O
followed	B-C1522577
up	I-C1522577
.	O
	
all	O
surgeries	B-C0543467
were	O
successfully	B-C1272703
completed	B-C0205197
.	O
	
the	O
average	B-C1510992
operation	B-C0543467
time	B-C0040223
was	O
120	O
minutes	O
range	B-C1514721
110-150	O
min	O
,	O
and	O
the	O
average	B-C1510992
hemorrhage	B-C0019080
was	O
145	O
ml	O
range	B-C1514721
80-360	O
ml	O
.	O
	
all	O
cases	B-C0868928
underwent	O
x-rays	B-C0043299
at	O
3	O
days	O
,	O
3	O
months	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
and	O
the	O
final	O
postoperative	B-C0032786
follow-up	B-C1522577
.	O
	
the	O
outcome	B-C1274040
indicated	O
that	O
there	O
was	O
no	O
mobilization	B-C0300926
,	O
displacement	B-C2347509
,	O
or	O
subsidence	B-C3805266
in	O
all	O
patients	B-C0030705
with	O
the	O
exception	B-C1705847
of	O
one	O
case	B-C0868928
with	O
prosthesis	B-C2930543
migration	I-C2930543
.	O
	
the	O
follow-up	B-C1522577
time	O
was	O
43.8	O
months	O
range	B-C1514721
24-64	O
months	O
.	O
	
the	O
mean	B-C0444504
visual	B-C2960751
analog	I-C2960751
scale	I-C2960751
vas	B-C2960751
and	O
oswestry	B-C2960603
scores	I-C2960603
were	O
decreased	B-C0205216
postoperatively	B-C0032790
.	O
	
the	O
mean	B-C0444504
improvement	B-C2986411
rate	B-C1521828
of	O
the	O
vas	B-C2960751
score	I-C2960751
was	O
73.5	O
.	O
	
lumbar	B-C0024090
adr	B-C2144940
using	O
a	O
laparoscope	B-C0023036
represents	O
a	O
novel	O
,	O
minimally	B-C2711297
invasive	I-C2711297
treatment	B-C0039798
for	O
symptomatic	B-C0231220
degenerative	B-C0158266
disc	I-C0158266
disease	I-C0158266
and	O
severe	B-C0205082
lumbar	B-C3662826
discogenic	I-C3662826
pain	I-C3662826
.	O
	
low	B-C1401894
literacy	I-C1401894
and	O
written	B-C0033081
drug	I-C0033081
information	I-C0033081
information-seeking	B-C0392349
,	O
leaflet	B-C3273178
evaluation	B-C1550157
and	O
preferences	B-C0558295
,	O
and	O
roles	O
for	O
images	B-C1704922
background	O
low-literate	B-C1518028
patients	B-C0030705
are	O
at	O
risk	B-C0035647
to	O
misinterpret	O
written	B-C0033081
drug	I-C0033081
information	I-C0033081
.	O
	
for	O
the	O
co-	O
design	O
of	O
targeted	O
patient	B-C1955348
information	I-C1955348
,	O
it	O
is	O
key	O
to	O
involve	O
this	O
group	B-C1257890
in	O
determining	O
their	O
communication	B-C0009454
barriers	I-C0009454
and	O
information	B-C1533716
needs	O
.	O
	
objective	O
to	O
gain	O
insight	O
into	O
how	O
people	B-C0027361
with	O
low	B-C1401894
literacy	I-C1401894
use	O
and	O
evaluate	O
written	B-C0033081
drug	I-C0033081
information	I-C0033081
,	O
and	O
to	O
identify	O
ways	O
in	O
which	O
they	O
feel	O
the	O
patient	B-C0030705
leaflet	B-C3273178
can	O
be	O
improved	O
,	O
and	O
in	O
particular	O
how	O
images	B-C1704922
could	O
be	O
used	O
.	O
	
setting	O
food	B-C1561598
banks	I-C1561598
and	O
an	O
education	B-C0036375
institution	I-C0036375
for	O
dutch	B-C0376241
language	I-C0376241
training	B-C0220931
in	O
the	O
netherlands	B-C0027778
.	O
	
method	O
semi-structured	O
focus	B-C0016400
groups	I-C0016400
and	O
individual	B-C0237401
interviews	B-C0021822
were	O
held	O
with	O
low-literate	B-C1518028
participants	I-C1518028
n	O
=	O
45	O
.	O
	
the	O
thematic	B-C1254372
framework	I-C1254372
approach	I-C1254372
was	O
used	O
for	O
analysis	O
to	O
identify	O
themes	O
in	O
the	O
data	B-C1511726
.	O
	
main	O
outcome	B-C1274040
measure	O
low-literate	B-C1518028
people's	I-C1518028
experience	B-C1533716
with	O
patient	B-C1955348
information	I-C1955348
leaflets	B-C3273178
,	O
ideas	B-C1254370
for	O
improvements	B-C2986411
,	O
and	O
perceptions	B-C0030971
on	O
possible	O
uses	O
for	O
visuals	B-C0234621
.	O
	
results	O
patient	B-C1955348
information	I-C1955348
leaflets	B-C3273178
were	O
considered	O
discouraging	O
to	O
use	O
,	O
and	O
information	B-C1533716
difficult	O
to	O
find	O
and	O
understand	B-C0162340
.	O
	
many	O
rely	O
on	O
alternative	O
information	B-C0683836
sources	I-C0683836
.	O
	
the	O
leaflet	B-C3273178
should	O
be	O
shorter	O
,	O
and	O
improved	O
in	O
terms	O
of	O
organisation	B-C1300196
,	O
legibility	B-C0870803
and	O
readability	B-C0871211
.	O
	
participants	B-C0679646
thought	O
images	B-C1704922
could	O
increase	O
the	O
leaflet's	B-C3273178
appeal	O
,	O
help	O
ask	O
questions	B-C1522634
,	O
provide	O
an	O
overview	B-C0814812
,	O
help	O
understand	O
textual	B-C1527021
information	B-C1533716
,	O
aid	O
recall	B-C0034770
,	O
reassure	O
,	O
and	O
even	O
lead	O
to	O
increased	O
confidence	B-C1704726
,	O
empowerment	B-C0679959
and	O
feeling	O
of	O
safety	B-C0036043
.	O
	
conclusion	O
already	O
at	O
the	O
stages	O
of	O
paying	O
attention	O
to	O
the	O
leaflet	B-C3273178
and	O
maintaining	O
interest	O
in	O
the	O
message	O
,	O
low-literate	B-C1518028
patients	I-C1518028
experience	B-C0596545
barriers	B-C0009454
in	I-C0009454
the	I-C0009454
communication	I-C0009454
process	O
through	O
written	B-C0033081
drug	I-C0033081
information	I-C0033081
.	O
	
short	O
,	O
structured	O
,	O
visual	B-C0234621
/	O
textual	B-C1527021
explanations	B-C0681841
can	O
lower	O
the	O
motivational	O
threshold	O
to	O
use	O
the	O
leaflet	B-C3273178
,	O
improve	B-C0184511
understanding	B-C0162340
,	O
and	O
empower	O
the	O
low-literate	B-C1518028
target	I-C1518028
group	I-C1518028
.	O
	
establishment	O
and	O
application	O
of	O
a	O
flow	B-C0016263
cytometry	I-C0016263
-based	O
method	B-C0025663
for	O
detecting	B-C0442726
histone	B-C1156200
acetylation	I-C1156200
levels	B-C0441889
histone	B-C1512474
deacetylase	I-C1512474
inhibitors	I-C1512474
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
aids	B-C0001175
and	O
other	O
diseases	B-C0012634
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	B-C0003392
drugs	I-C0003392
developed	O
in	O
recent	O
years	O
.	O
	
however	O
,	O
there	O
is	O
still	O
a	O
lack	B-C0332268
of	O
a	O
unified	B-C1706076
and	O
reliable	B-C3858758
method	B-C0025663
for	O
detecting	B-C0442726
histone	B-C1156200
acetylation	I-C1156200
levels	B-C0441889
in	O
basic	B-C0681833
and	O
clinical	B-C0008972
research	I-C0008972
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
developed	O
a	O
flow	B-C0016263
cytometry	I-C0016263
-based	O
method	B-C0025663
to	O
detect	B-C1511790
histone	O
acetylation	O
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
on	O
ice	O
vs	O
.	O
	
room	O
temperature	O
,	O
permeabilization	O
method	O
intracellular	O
vs	O
.	O
	
nuclear	O
,	O
antibody	O
dose	O
antibody	O
titration	O
and	O
antibody	O
incubation	O
time	O
time	O
gradient	O
using	O
whole	O
blood	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
	
in	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	O
in	O
in	O
vitro	O
experiment	O
and	O
clinical	O
trial	O
of	O
chidamide	O
the	O
only	O
china	O
fda	O
approved	O
hdaci	O
,	O
the	O
result	O
of	O
which	O
confirmed	O
that	O
the	O
flow	O
cytometry	O
-based	O
method	O
for	O
detecting	O
histone	O
acetylation	O
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	O
which	O
can	O
be	O
used	O
in	O
basic	O
and	O
clinical	O
research	I-C0008972
performance	B-C1882330
and	O
safety	B-C0086139
of	O
collagenated	B-C0181075
xenogeneic	I-C0181075
bone	I-C0181075
block	I-C0181075
for	O
lateral	B-C0002387
alveolar	I-C0002387
ridge	I-C0002387
augmentation	I-C0002387
and	O
staged	B-C0021107
implant	I-C0021107
placement	I-C0021107
.	O
	
a	O
monocenter	B-C2826346
,	O
prospective	I-C2826346
single-arm	I-C2826346
clinical	I-C2826346
study	I-C2826346
to	O
assess	B-C0184514
the	O
clinical	B-C2826199
safety	I-C2826199
and	O
performance	B-C1882330
of	O
collagenated	B-C0181075
xenogeneic	I-C0181075
bone	I-C0181075
block	I-C0181075
cxbb	B-C0181075
for	O
lateral	B-C0002387
alveolar	I-C0002387
ridge	I-C0002387
augmentation	I-C0002387
and	O
two-stage	B-C0574055
implant	B-C0021107
placement	I-C0021107
.	O
	
in	O
ten	O
patients	B-C0030705
exhibiting	B-C0449450
a	O
single	B-C0205171
-	O
tooth	B-C0040426
gap	B-C3887622
,	O
the	O
surgical	B-C0543467
procedure	I-C0543467
included	B-C2700399
the	O
preparation	B-C1521827
of	O
mucoperiosteal	B-C1881914
flaps	I-C1881914
,	O
a	O
rigid	B-C0185023
fixation	I-C0185023
of	O
cxbb	B-C0181075
geistlich	B-C0282574
bio-graft	I-C0282574
using	O
an	O
osteosynthesis	B-C0005975
screw	I-C0005975
,	O
and	O
contour	B-C0876954
augmentation	B-C1293122
.	O
	
after	O
24	O
weeks	O
of	O
submerged	B-C0043240
healing	I-C0043240
,	O
the	O
primary	B-C2986535
endpoint	I-C2986535
was	O
defined	O
as	O
the	O
final	B-C3853528
ridge	B-C0447361
width	B-C0487742
sufficient	B-C0205410
to	O
place	O
an	O
adequately	B-C0205410
dimensioned	B-C0439534
titanium	B-C2165380
implant	I-C2165380
at	O
the	O
respective	O
sites	B-C0205145
.	O
	
secondary	B-C3274440
outcomes	I-C3274440
included	B-C2700399
,	O
for	O
example	O
,	O
the	O
gain	B-C1517378
in	O
ridge	B-C0447361
width	B-C0487742
mm	O
.	O
	
clinical	B-C2347800
parameters	I-C2347800
e.g	O
,	O
bleeding	B-C2698524
on	I-C2698524
probing	I-C2698524
-	O
bop	B-C2698524
,	O
probing	B-C1317646
depth	I-C1317646
-	O
pd	B-C1317646
,	O
mucosal	B-C0333047
recession	I-C0333047
-	O
mr	B-C0333047
were	O
assessed	B-C1516048
immediately	O
after	O
the	O
cementation	B-C0458893
of	I-C0458893
the	I-C0458893
crown	I-C0458893
and	O
at	O
the	O
final	B-C0204309
visit	I-C0204309
.	O
	
at	O
24	O
weeks	O
,	O
implant	B-C0021107
placement	I-C0021107
could	O
be	O
achieved	B-C1706701
in	O
8	O
of	O
10	O
patients	B-C0030705
exhibiting	B-C0449450
a	O
mean	B-C0444504
gain	B-C1517378
in	O
ridge	B-C0447361
width	B-C0487742
mean	B-C0444504
sd	B-C0871420
of	O
3.88	O
1.75	O
mm	O
.	O
	
histological	B-C0002809
analysis	B-C0936012
has	O
pointed	O
to	O
a	O
homogeneous	B-C0439713
osseous	B-C0262950
organization	B-C1300196
of	O
cxbb	B-C0181075
.	O
	
the	O
changes	B-C0392747
of	O
mean	B-C0444504
bop	B-C2698524
,	O
pd	B-C1317646
,	O
and	O
mr	B-C0333047
values	B-C1522609
at	O
the	O
final	B-C0204309
visit	I-C0204309
amounted	B-C1265611
to	O
16.62	O
32.02	O
,	O
0.04	O
0.21	O
mm	O
,	O
and	O
-0	O
0.12	O
mm	O
,	O
respectively	O
.	O
	
cxbb	B-C0181075
may	O
be	O
successfully	B-C0679864
used	O
to	O
support	B-C1521721
lateral	B-C0002387
alveolar	I-C0002387
ridge	I-C0002387
augmentation	I-C0002387
and	O
two-stage	B-C0574055
implant	B-C0021107
placement	I-C0021107
.	O
	
the	O
link	O
between	O
self-perceptions	B-C0242498
of	O
aging	B-C0001811
,	O
cancer	B-C0006826
view	O
and	O
physical	B-C0205485
and	O
mental	B-C0025353
health	I-C0025353
of	O
older	B-C3826770
people	I-C3826770
with	O
cancer	B-C0006826
a	B-C0010362
cross-sectional	I-C0010362
study	I-C0010362
older	B-C3826770
people	I-C3826770
may	O
suffer	O
from	O
stigmas	B-C0011570
linked	O
to	O
cancer	B-C0006826
and	O
aging	B-C0001811
.	O
	
although	O
some	O
studies	B-C2603343
suggested	O
that	O
a	O
negative	B-C0205160
view	B-C0449911
of	O
cancer	B-C0006826
may	O
increase	O
the	O
level	B-C1319226
of	I-C1319226
depression	I-C1319226
,	O
such	O
an	O
association	O
has	O
never	O
been	O
studied	B-C2603343
in	O
the	O
elderly	B-C0001792
population	I-C0001792
.	O
	
similarly	O
,	O
even	O
though	O
it	O
is	O
established	O
that	O
a	O
negative	B-C0205160
self-perception	B-C0242498
of	O
aging	B-C0001811
has	O
deleterious	O
consequences	B-C0686907
on	O
mental	B-C0025353
and	O
physical	B-C4060919
health	I-C4060919
in	O
normal	O
aging	B-C0001811
,	O
the	O
influence	O
in	O
pathological	B-C1521733
contexts	B-C0449255
,	O
such	O
as	O
oncology	B-C0027651
,	O
has	O
not	O
been	O
studied	O
.	O
	
the	O
main	O
aim	O
of	O
this	O
study	O
is	O
thus	O
to	O
analyze	B-C0936012
the	O
effect	O
of	O
these	O
two	O
stigmas	B-C0011570
on	O
the	O
health	B-C0018684
of	O
elderly	B-C0001792
oncology	B-C0027651
patients	B-C0030705
.	O
	
101	O
patients	B-C0030705
suffering	O
from	O
a	O
cancer	B-C0006826
breast	B-C0006142
,	O
gynecological	B-C0017411
,	O
lung	B-C0242379
or	O
hematological	B-C0018939
were	O
seen	O
as	O
soon	O
as	O
possible	O
after	O
their	O
diagnosis	B-C0011900
.	O
	
their	O
self-perception	B-C0242498
of	O
age	B-C0001779
,	O
cancer	B-C0006826
view	O
and	O
health	B-C0018684
physical	B-C4060919
and	O
mental	B-C0025353
was	O
assessed	O
.	O
	
multiple	O
regressions	B-C0684321
showed	O
that	O
patients	B-C0030705
with	O
a	O
more	O
negative	B-C0205160
self-perception	B-C0242498
of	O
aging	B-C0001811
and/or	O
more	O
negative	B-C0205160
cancer	B-C0006826
view	O
reported	O
poorer	B-C2700379
global	B-C1456573
health	I-C1456573
.	O
	
we	O
also	O
observed	O
that	O
negative	B-C0205160
self-perception	B-C0242498
of	O
aging	B-C0001811
was	O
associated	B-C0332281
with	I-C0332281
worse	O
physical	B-C4060919
and	O
mental	B-C0025353
health	I-C0025353
,	O
whereas	O
negative	B-C0205160
cancer	B-C0006826
views	O
were	O
only	O
linked	O
to	O
worse	O
mental	B-C0025353
health	I-C0025353
.	O
	
no	O
interaction	O
was	O
observed	O
between	O
these	O
two	O
stigmas	B-C0011570
,	O
suggesting	O
that	O
their	O
action	O
is	O
independent	B-C0085862
.	O
	
older	O
patients	B-C0030705
with	O
cancer	B-C0006826
face	O
double	O
stigmatization	B-C0038330
,	O
due	O
to	O
negative	B-C0205160
self-perception	B-C0242498
of	O
aging	B-C0001811
and	O
cancer	B-C0006826
,	O
and	O
these	O
stigmas	B-C0011570
have	O
impacts	O
on	O
global	O
and	O
mental	B-C0025353
health	I-C0025353
.	O
	
self-perception	B-C0242498
of	O
aging	B-C0001811
is	O
also	O
linked	O
to	O
physical	B-C4060919
health	I-C4060919
.	O
	
longitudinal	B-C0023981
studies	I-C0023981
will	O
be	O
necessary	O
to	O
analyze	B-C0936012
the	O
direction	O
of	O
the	O
association	O
between	O
this	O
double	O
stigmatization	B-C0038330
and	O
the	O
aortic	B-C0549113
root	I-C0549113
natural	B-C0175860
history	I-C0175860
after	O
root-sparing	B-C0729662
ascending	I-C0729662
replacement	I-C0729662
in	O
nonsyndromic	B-C2677304
aneurysmal	B-C0030705
patients	I-C0030705
leaving	O
native	B-C0302891
aortic	B-C0040300
tissue	I-C0040300
in	B-C0444498
situ	I-C0444498
in	O
root-sparing	B-C0729662
ascending	I-C0729662
aortic	I-C0729662
replacement	I-C0729662
raises	O
concern	B-C2699424
regarding	O
potential	B-C3245505
later	B-C0205087
need	B-C0027552
for	O
root	B-C0549113
reoperation	B-C0035110
or	O
for	O
the	O
potential	B-C3245505
occurrence	B-C2745955
of	O
localized	B-C0392752
dissections	B-C0340643
or	O
rupture	B-C3203359
in	O
the	O
residual	B-C1609982
root	B-C0549113
.	O
	
the	O
purpose	B-C0681832
of	I-C0681832
this	I-C0681832
study	I-C0681832
was	O
to	O
evaluate	B-C0184514
the	O
natural	B-C0018270
growth	I-C0018270
of	O
the	O
aortic	B-C0549113
root	I-C0549113
after	O
root-sparing	B-C0729662
aortic	I-C0729662
replacement	I-C0729662
.	O
	
in	O
all	O
,	O
102	O
consecutive	B-C1707491
patients	B-C0030705
mean	B-C0444504
age	B-C0001779
61.8	O
12.5	O
years	B-C0439234
60%	O
male	B-C0025266
who	O
had	O
undergone	O
root-sparing	B-C0729662
aortic	I-C0729662
replacement	I-C0729662
had	O
sufficient	B-C0205410
retrievable	B-C1533716
information	I-C1533716
regarding	O
their	O
aortic	B-C0549113
root	I-C0549113
diameter	B-C1301886
at	O
postoperative	B-C0032790
baseline	B-C1442488
and	O
follow-up	B-C1522577
imaging	B-C0079595
by	O
computed	B-C0040405
tomography	I-C0040405
or	O
echocardiography	B-C0013516
.	O
	
the	O
annual	B-C0332181
growth	B-C0449249
rate	I-C0449249
was	O
evaluated	B-C1516048
and	O
also	O
compared	B-C1707455
according	O
to	O
the	O
influence	B-C4054723
of	O
valve	B-C0332437
morphology	I-C0332437
and	O
concomitant	B-C0521115
aortic	B-C0003506
valve	I-C0003506
replacement	I-C0003506
.	O
	
furthermore	O
,	O
the	O
years	B-C0439234
of	O
natural	B-C0175860
history	I-C0175860
that	O
would	O
require	B-C1514873
for	O
root	B-C0549113
enlargement	B-C2711450
to	O
meet	O
a	O
50	O
mm	B-C0439200
threshold	B-C0449864
of	O
the	O
root	B-C0549113
diameter	B-C1301886
were	O
calculated	B-C1441506
.	O
	
the	O
estimated	B-C0750572
growth	B-C0449249
rate	I-C0449249
of	O
the	O
aortic	B-C0549113
root	I-C0549113
after	O
root-sparing	B-C0729662
aortic	I-C0729662
replacement	I-C0729662
is	O
between	O
0.27	O
and	O
0.51	O
mm	B-C0439200
per	B-C0439508
year	I-C0439508
mean	B-C0444504
0.41	O
mm	B-C0439200
,	O
varying	O
according	O
to	O
the	O
underlying	B-C1301886
diameter	I-C1301886
and	O
therefore	O
fivefold	O
less	B-C0439092
than	I-C0439092
other	O
aortic	B-C0225914
regions	I-C0225914
.	O
	
accordingly	O
,	O
a	O
root	B-C1298820
aneurysm	I-C1298820
indicating	O
reoperation	B-C0035110
would	O
not	O
be	O
expected	B-C1517001
for	O
29.1	O
years	B-C0439234
on	O
average	B-C1510992
.	O
	
only	O
patients	B-C0030705
with	O
a	O
diameter	B-C1301886
of	O
45	O
mm	B-C0439200
or	O
more	O
are	O
at	B-C1444641
risk	I-C1444641
for	O
reoperation	B-C0035110
,	O
and	O
not	O
until	B-C1720302
at	O
least	O
after	B-C0687676
10.4	O
years	B-C0439234
have	B-C2828386
passed	I-C2828386
.	O
	
neither	B-C4284892
the	O
valve	B-C0332437
morphology	I-C0332437
p	O
=	O
0.62	O
nor	O
concomitant	B-C0521115
aortic	B-C0003506
valve	I-C0003506
replacement	I-C0003506
p	O
=	O
0.86	O
influenced	B-C4054723
rate	B-C1521828
of	O
root	B-C1866956
dilation	I-C1866956
.	O
	
in	O
nonsyndromic	B-C2677304
patients	B-C0030705
,	O
the	O
aortic	B-C0549113
root	I-C0549113
is	O
the	O
slowest	B-C0439834
growing	B-C0018270
portion	B-C0449719
of	O
the	O
thoracic	B-C1522460
aorta	I-C1522460
.	O
	
leaving	O
the	O
native	B-C0302891
root	B-C0549113
,	O
as	O
in	O
root-sparing	B-C0729662
ascending	I-C0729662
aortic	I-C0729662
replacement	I-C0729662
,	O
is	O
a	O
safe	B-C0449445
approach	I-C0449445
regarding	O
secondary	B-C0549113
root	I-C0549113
intervention	B-C0184661
for	O
aortic	B-C0549113
root	I-C0549113
diameters	B-C1301886
of	O
45	O
mm	B-C0439200
physical	B-C0015259
exercise	I-C0015259
for	O
late-life	B-C2362314
depression	B-C0011581
effects	B-C1280500
on	O
heart	B-C0018810
rate	I-C0018810
variability	B-C2827666
late-life	B-C2362314
major	B-C1269683
depression	I-C1269683
is	O
associated	B-C0332281
with	I-C0332281
increased	B-C0205217
cardiovascular	B-C1113685
risk	I-C1113685
and	O
impaired	B-C0018799
autonomic	I-C0018799
control	I-C0018799
of	I-C0018799
the	I-C0018799
heart	I-C0018799
,	O
as	O
evident	O
from	O
reduced	B-C0392756
heart	B-C0018810
rate	I-C0018810
variability	B-C2827666
hrv	B-C2827666
.	O
	
moreover	O
,	O
antidepressant	B-C0003289
drug	I-C0003289
therapy	B-C0087111
also	O
might	O
be	O
associated	B-C0332281
with	I-C0332281
further	O
reductions	B-C0392756
of	O
hrv	B-C2827666
.	O
	
in	O
the	O
seeds	B-C2603343
study	I-C2603343
,	O
we	O
investigated	O
whether	O
sertraline	B-C0074393
associated	B-C0332281
with	I-C0332281
physical	B-C0015259
exercise	I-C0015259
protocols	O
led	O
to	O
improvements	B-C2986411
of	O
hrv	B-C2827666
,	O
compared	O
with	O
antidepressant	B-C0003289
drug	I-C0003289
therapy	B-C0087111
alone	O
.	O
	
single-blind	B-C0037181
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
.	O
	
psychiatric	B-C1548378
consultation	I-C1548378
-liaison	O
program	O
for	O
primary	B-C0033137
care	I-C0033137
.	O
	
patients	B-C0030705
aged	O
65-85	O
years	O
with	O
major	B-C1269683
depression	I-C1269683
,	O
recruited	O
from	O
primary	B-C0033137
care	I-C0033137
.	O
	
sertraline	B-C0074393
plus	O
structured	O
,	O
tailored	B-C0681860
group	I-C0681860
physical	B-C0015259
exercise	I-C0015259
s	B-C0681860
+	I-C0681860
ex	I-C0681860
versus	O
sertraline	B-C0074393
alone	O
s	O
for	O
24	O
weeks	B-C0439230
.	O
	
hrv	B-C2827666
indices	B-C0918012
rr	O
,	O
percentage	B-C0392762
of	I-C0392762
nn	I-C0392762
intervals	I-C0392762
greater	I-C0392762
than	I-C0392762
50	I-C0392762
msec	I-C0392762
pnn50	B-C0392762
,	O
square	B-C0392762
root	I-C0392762
of	I-C0392762
the	I-C0392762
mean	I-C0392762
squared	I-C0392762
differences	I-C0392762
of	I-C0392762
successive	I-C0392762
nn	I-C0392762
intervals	I-C0392762
rmssd	B-C0392762
,	O
standard	B-C0871420
deviation	I-C0871420
of	O
heart	B-C0018810
rate	I-C0018810
sdhr	B-C0871420
,	O
standard	B-C0871420
deviation	I-C0871420
of	I-C0871420
the	I-C0871420
nn	I-C0871420
interval	I-C0871420
sdnn	B-C0871420
,	O
high-frequency	B-C0392762
band	I-C0392762
hf	B-C0392762
,	O
low-frequency	B-C0392762
band	I-C0392762
lf	B-C0392762
,	O
and	O
their	O
ratio	B-C0456603
lf/hf	B-C0456603
were	O
measured	B-C0444706
at	O
baseline	B-C1442488
,	O
week	B-C0439230
12	O
,	O
and	O
week	B-C0439230
24	O
.	O
	
psychiatric	B-C0846574
and	O
medical	B-C0582103
assessments	I-C0582103
.	O
	
participants	B-C0679646
displayed	O
significant	O
improvements	B-C2986411
of	O
most	O
hrv	B-C2827666
indices	B-C0918012
over	O
time	O
,	O
irrespective	O
of	O
the	O
group	O
assignment	O
pnn50	B-C0392762
,	O
rmssd	B-C0392762
,	O
sdhr	B-C0871420
,	O
sdnn	B-C0871420
,	O
hf	B-C0392762
,	O
lf	B-C0392762
,	O
and	O
lf/hf	B-C0456603
.	O
	
moreover	O
,	O
patients	B-C0030705
in	O
the	O
s	B-C0681860
+	I-C0681860
ex	I-C0681860
group	I-C0681860
displayed	O
greater	O
increases	B-C0442805
of	O
different	O
hrv	B-C2827666
indices	B-C0918012
rr	B-C0392762
,	O
pnn50	B-C0392762
,	O
rmssd	B-C0392762
,	O
sdhr	B-C0871420
,	O
sdnn	B-C0871420
,	O
hf	B-C0392762
,	O
and	O
lf	B-C0392762
compared	O
with	O
those	O
in	O
the	O
s	B-C0681860
group	I-C0681860
.	O
	
the	O
combination	B-C0205195
of	O
structured	O
physical	B-C0015259
exercise	I-C0015259
and	O
sertraline	B-C0074393
might	O
exert	O
positive	B-C1446409
effects	B-C1280500
on	O
the	O
autonomic	B-C0232164
control	I-C0232164
of	I-C0232164
the	I-C0232164
heart	I-C0232164
among	O
older	O
patients	B-C0030705
with	O
major	B-C1269683
depression	I-C1269683
.	O
	
genome-wide	B-C0008630
snp	I-C0008630
linkage	I-C0008630
mapping	I-C0008630
and	O
qtl	B-C0597336
analysis	B-C0796344
for	O
fiber	B-C1260603
quality	B-C0332306
and	O
yield	B-C0392762
traits	B-C0599883
in	O
the	O
upland	B-C0010196
cotton	I-C0010196
recombinant	B-C1514783
inbred	I-C1514783
lines	I-C1514783
population	O
it	O
is	O
of	O
significance	O
to	O
discover	O
genes	B-C0017337
related	O
to	O
fiber	B-C1260603
quality	B-C0332306
and	O
yield	B-C0392762
traits	B-C0599883
and	O
tightly	O
linked	O
markers	B-C0017393
for	O
marker-assisted	B-C0017395
selection	I-C0017395
mas	B-C0017395
in	O
cotton	B-C0010196
breeding	B-C4042898
.	O
	
in	O
this	O
study	O
,	O
188	B-C0010196
f8	I-C0010196
recombinant	B-C1514783
inbred	I-C1514783
lines	I-C1514783
rils	B-C1514783
,	O
derived	O
from	O
a	O
intraspecific	B-C0205369
cross	B-C4042898
between	O
hs46	B-C0010196
and	O
marcabucag8us-1-88	B-C0010196
were	O
genotyped	B-C0017431
by	O
the	O
cotton	B-C0010196
63k	O
single	B-C3536614
nucleotide	I-C3536614
polymorphism	I-C3536614
snp	I-C3536614
assay	I-C3536614
.	O
	
field	B-C0868962
trials	I-C0868962
were	O
conducted	O
in	O
sanya	B-C0681784
,	O
hainan	I-C0681784
province	I-C0681784
,	O
during	O
the	O
2014-2015	O
cropping	B-C4042899
seasons	B-C0036497
under	O
standard	B-C1442989
conditions	B-C0348080
.	O
	
results	O
revealed	O
significant	B-C0237881
differences	B-C1705242
p	O
<	O
0.05	O
among	O
rils	B-C1514783
,	O
environments	B-C0014406
and	O
replications	B-C1883725
for	O
fiber	B-C1260603
quality	B-C0332306
and	O
yield	B-C0392762
traits	B-C0599883
.	O
	
broad-sense	O
heritabilities	B-C0439660
of	O
all	O
traits	B-C0599883
including	O
fiber	B-C1260603
length	B-C1444754
,	O
fiber	B-C1260603
uniformity	B-C0205375
,	O
micronaire	B-C0205556
,	O
fiber	B-C1260603
elongation	B-C0018270
,	O
fiber	B-C1260603
strength	B-C0039526
,	O
boll	B-C0010197
weight	B-C0043100
,	O
and	O
lint	B-C4019096
percentage	B-C0439165
ranged	O
from	O
0.26	O
to	O
0.66	O
.	O
	
a	O
1784.28	O
cm	B-C0582522
centimorgans	B-C0582522
linkage	B-C0008630
map	I-C0008630
,	O
harboring	O
2618	O
polymorphic	B-C1882417
snp	B-C0752046
markers	B-C0017393
,	O
was	O
constructed	O
,	O
which	O
had	O
0.68	O
cm	B-C0582522
per	O
marker	B-C0017393
density	O
.	O
	
seventy-one	O
quantitative	B-C0597336
trait	I-C0597336
locus	I-C0597336
qtls	B-C0597336
for	O
fiber	B-C1260603
quality	B-C0332306
and	O
yield	B-C0392762
traits	B-C0599883
were	O
detected	O
on	O
21	O
chromosomes	B-C1135923
,	O
explaining	O
4.70	O
phenotypic	B-C0031437
variance	B-C1711260
,	O
in	O
which	O
16	O
were	O
identified	O
as	O
stable	B-C0205360
qtls	B-C0597336
across	O
two	O
environments	B-C0014406
.	O
	
meanwhile	O
,	O
12	O
certain	O
regions	B-C1953345
were	O
investigated	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
one	O
hotspot	B-C2986491
or	O
more	O
cluster	B-C0017258
traits	B-C0599883
,	O
mainly	O
focused	O
on	O
chr05	B-C1135923
,	O
chr09	B-C1135923
,	O
chr10	B-C1135923
,	O
chr14	B-C1135923
,	O
chr19	B-C1135923
,	O
and	O
chr20	B-C1135923
.	O
	
nineteen	O
pairs	O
of	O
epistatic	B-C0017344
qtls	B-C0597336
e-qtls	B-C0597336
were	O
identified	O
,	O
of	O
which	O
two	O
pairs	O
involved	O
in	O
two	O
additive	B-C0442796
qtls	B-C0597336
.	O
	
these	O
additive	B-C0442796
qtls	B-C0597336
,	O
e-qtls	B-C0597336
,	O
and	O
qtl	B-C0597336
clusters	B-C0017258
were	O
tightly	O
linked	O
to	O
snp	B-C0752046
markers	B-C0017393
,	O
which	O
may	O
serve	O
as	O
target	B-C1521840
regions	B-C1953345
for	O
map-based	B-C0598888
cloning	I-C0598888
,	O
gene	B-C2717881
discovery	I-C2717881
,	O
and	O
mas	B-C0017395
in	O
cotton	B-C0010196
breeding	B-C4042898
.	O
	
effects	B-C1280500
of	O
an	O
early	O
intervention	B-C0184661
using	O
human	B-C0086418
amniotic	B-C0002630
epithelial	B-C0014597
cells	I-C0014597
in	O
a	O
copd	B-C0024117
rat	B-C0034716
model	B-C0026336
the	O
study	B-C2603343
aimed	O
to	O
investigate	B-C1292732
the	O
effect	B-C1280500
of	O
an	O
early	O
intervention	B-C0184661
using	O
human	B-C0086418
amniotic	B-C0002630
epithelial	B-C0014597
cell	I-C0014597
haec	B-C0014597
in	O
a	O
rat	B-C0034716
model	B-C0026336
of	O
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disease	I-C0024117
copd	B-C0024117
.	O
	
twenty-four	O
specific	B-C0162470
pathogen-free	I-C0162470
wistar	B-C0034716
rats	I-C0034716
were	O
randomized	B-C0206034
to	O
the	O
control	B-C0009932
,	O
copd	B-C0024117
,	O
and	O
copd	B-C0024117
+	O
haec	B-C0014597
groups	B-C0441833
.	O
	
copd	B-C0024117
was	O
established	O
by	O
intratracheal	B-C1555389
lps	B-C0023810
injection	O
combined	O
with	O
smoke	B-C0037366
fumigation	B-C0016804
over	O
30	O
days	B-C0439228
.	O
	
on	O
the	O
first	O
day	B-C0439228
of	O
model	B-C0026336
establishment	O
rats	B-C0034716
in	O
the	O
aec	B-C0014597
group	B-C0441833
also	O
received	O
intratracheal	B-C1555389
instillation	I-C1555389
of	O
500	O
haecs	B-C0014597
isolated	O
from	O
the	O
placenta	B-C0032043
of	O
healthy	B-C3898900
donors	B-C0013018
.	O
	
the	O
mean	B-C1444754
linear	I-C1444754
intercept	I-C1444754
mli	B-C1444754
and	O
mean	B-C0237753
alveolar	I-C0237753
number	I-C0237753
man	B-C0237753
were	O
used	O
to	O
assess	O
the	O
degree	O
of	O
lung	B-C0034067
emphysema	I-C0034067
.	O
	
il-8	B-C0079633
was	O
measured	O
using	O
a	O
radioimmunoassay	B-C0034580
,	O
surfactant	B-C0084692
protein	I-C0084692
d	I-C0084692
sp-d	B-C0084692
was	O
measured	O
by	O
elisa	B-C0014441
,	O
and	O
matrix	B-C0172537
metalloproteinase	I-C0172537
mmp	I-C0172537
and	O
mmp8	B-C0172956
expression	B-C1171362
was	O
assessed	O
by	O
pcr	B-C0032520
.	O
	
smoke	B-C0037366
fumigation	B-C0016804
combined	O
to	O
lps	B-C0023810
injection	O
successfully	O
established	O
a	O
copd	B-C0024117
rat	B-C0034716
model	B-C0026336
with	O
significant	O
emphysema	B-C0034067
and	O
airway	B-C0021368
inflammation	I-C0021368
,	O
elevated	B-C3163633
mli	B-C1444754
and	O
man	B-C0237753
,	O
elevated	B-C3163633
systemic	B-C0205373
and	O
lung	B-C0024109
tissue	B-C0040300
levels	B-C0441889
of	O
il-8	B-C0079633
and	O
sp-d	B-C0084692
p<0	O
,	O
and	O
high	O
expression	B-C1171362
of	O
mmp2	B-C0172537
and	O
mmp8	B-C0172956
.	O
	
rats	B-C0034716
in	O
the	O
copd	B-C0024117
+	O
haec	B-C0014597
group	B-C0441833
exhibited	O
alleviated	B-C0392756
lung	B-C0024109
damage	B-C0010957
,	O
mli	B-C1444754
and	O
man	B-C0237753
p<0	O
,	O
reduced	B-C0392756
systemic	B-C0205373
and	O
lung	B-C0024109
tissue	B-C0040300
levels	B-C0441889
of	O
il-8	B-C0079633
and	O
sp-d	B-C0084692
p<0	O
and	O
mmp2	B-C0172537
and	O
mmp8	B-C0172956
expression	B-C1171362
p<0	O
.	O
	
early	O
intervention	B-C0184661
using	O
haecs	B-C0014597
could	O
delay	O
disease	B-C0242656
progression	I-C0242656
in	O
rats	B-C0034716
with	O
systematic	B-C0220922
identification	B-C0020792
of	O
pharmacological	B-C0007992
targets	B-C1521840
from	O
small-molecule	B-C1328819
phenotypic	B-C0373483
screens	I-C0373483
phenotypic	B-C0031437
drug	B-C0920472
discovery	I-C0920472
offers	O
some	O
advantages	B-C0681074
over	O
target	B-C1521840
-	O
based	B-C1527178
methods	B-C0025663
,	O
mainly	O
because	O
it	O
allows	O
drug	B-C0013227
leads	I-C0013227
to	O
be	O
tested	B-C0039593
in	O
systems	B-C0449913
that	O
more	B-C0205172
closely	B-C3810854
model	B-C0026339
distinct	B-C2963144
disease	B-C0231294
states	I-C0231294
.	O
	
however	O
,	O
a	O
potential	B-C3245505
disadvantage	B-C0205556
is	O
the	O
difficulty	B-C0332218
of	O
linking	B-C2986575
the	O
observed	B-C1441672
phenotype	B-C0031437
to	O
a	O
specific	B-C0205369
cellular	B-C0007634
target	B-C1521840
.	O
	
to	O
address	O
this	O
problem	B-C0033213
,	O
we	O
developed	B-C1527148
depick	B-C0037589
,	O
a	O
computational	B-C1880157
target	O
de-convolution	B-C1707643
tool	B-C2827396
to	O
determine	B-C1148554
targets	B-C1521840
specifically	B-C0205369
linked	B-C2986575
to	O
small-molecule	B-C1328819
phenotypic	B-C0373483
screens	I-C0373483
.	O
	
we	O
applied	B-C1632850
depick	B-C0037589
to	O
eight	O
publicly	B-C0678367
available	O
screens	B-C0302765
and	O
predicted	B-C0681842
59	O
drug	B-C0013227
target	B-C1521840
-	O
phenotype	B-C0031437
associations	B-C0439849
.	O
	
in	O
addition	O
to	O
literature	B-C0023866
-	O
based	B-C1527178
evidence	B-C3887511
for	O
our	O
predictions	B-C0681842
,	O
we	O
provide	B-C1999230
experimental	B-C1517586
support	B-C1521721
for	O
seven	O
predicted	B-C0681842
associations	B-C0439849
.	O
	
interestingly	B-C0543488
,	O
our	O
analysis	B-C0936012
led	O
to	O
the	O
discovery	B-C1880355
of	O
a	O
previously	B-C0205156
unrecognized	B-C4288068
connection	B-C0449379
between	O
the	O
wnt	B-C1520113
signaling	I-C1520113
pathway	I-C1520113
and	O
an	O
aromatase	B-C0003805
,	O
cyp19a1	B-C3254086
.	O
	
these	O
results	B-C0683954
demonstrate	B-C0443289
that	O
the	O
depick	B-C0037589
approach	O
can	O
not	O
only	O
accelerate	B-C0521110
target	B-C1521840
de-convolution	B-C1707643
but	O
also	O
aid	B-C1269765
in	O
discovery	B-C1880355
of	O
new	O
functionally	B-C0205245
relevant	B-C2347946
biological	B-C0205460
relationships	B-C0439849
.	O
	
'	O
yarn	B-C1512347
with	O
me'	O
applying	O
clinical	B-C1512347
yarning	I-C1512347
to	O
improve	O
clinician	B-C0871685
-	O
patient	B-C0030705
communication	B-C0009452
in	O
aboriginal	B-C0935542
health	B-C0086388
care	I-C0086388
although	O
successful	O
communication	B-C0009452
is	O
at	O
the	O
heart	O
of	O
the	O
clinical	B-C0009818
consultation	I-C0009818
,	O
communication	B-C0009452
between	O
aboriginal	B-C0935542
patients	B-C0030705
and	O
practitioners	B-C0017319
such	O
as	O
doctors	B-C0031831
,	O
nurses	B-C0028661
and	O
allied	B-C0002122
health	I-C0002122
professionals	I-C0002122
,	O
continues	O
to	O
be	O
problematic	B-C0033213
and	O
is	O
arguably	O
the	O
biggest	O
barrier	O
to	O
the	O
delivery	O
of	O
successful	O
health	B-C0086388
care	I-C0086388
to	O
aboriginal	B-C0935542
people	I-C0935542
.	O
	
this	O
paper	O
presents	O
an	O
overarching	B-C0282574
framework	I-C0282574
for	O
practitioners	B-C0017319
to	O
help	O
them	O
reorientate	O
their	O
communication	B-C0009452
with	O
aboriginal	B-C0935542
patients	B-C0030705
using	O
'	O
clinical	B-C1512347
yarning	I-C1512347
'	O
.	O
	
clinical	B-C1512347
yarning	I-C1512347
is	O
a	O
patient	B-C0030705
-centred	O
approach	O
that	O
marries	O
aboriginal	B-C0935542
cultural	B-C0009452
communication	I-C0009452
preferences	O
with	O
biomedical	B-C1879848
understandings	O
of	O
health	B-C0679215
and	I-C0679215
disease	I-C0679215
.	O
	
clinical	B-C1512347
yarning	I-C1512347
consists	O
of	O
three	O
interrelated	O
areas	O
the	O
social	B-C0728831
yarn	B-C1512347
,	O
in	O
which	O
the	O
practitioner	B-C0017319
aims	O
to	O
find	O
common	O
ground	O
and	O
develop	O
the	O
interpersonal	B-C0021797
relationship	I-C0021797
the	O
diagnostic	B-C0348026
yarn	B-C1512347
,	O
in	O
which	O
the	O
practitioner	B-C0017319
facilitates	O
the	O
patient's	B-C0030705
health	B-C1254370
story	I-C1254370
while	O
interpreting	O
it	O
through	O
a	O
biomedical	B-C1879848
or	O
scientific	B-C0947630
lens	I-C0947630
and	O
the	O
management	O
yarn	B-C1512347
,	O
that	O
employs	B-C1254370
stories	I-C1254370
and	O
metaphors	B-C0302829
as	O
tools	O
for	O
patients	B-C0030705
to	O
help	O
them	O
understand	O
a	O
health	B-C0243095
issue	I-C0243095
so	O
a	O
collaborative	B-C0681804
management	I-C0681804
approach	I-C0681804
can	O
be	O
adopted	O
.	O
	
there	O
is	O
cultural	B-C0220814
and	O
research	B-C0242481
evidence	B-C3887511
that	O
supports	O
this	O
approach	O
.	O
	
clinical	B-C1512347
yarning	I-C1512347
has	O
the	O
potential	O
to	O
improve	O
outcomes	B-C1274040
for	O
patients	B-C0030705
and	O
effect	O
of	O
single-dose	B-C1960417
carbapenem	B-C0006968
exposure	B-C0743284
on	O
transcriptional	B-C0017262
expression	I-C0017262
of	O
blandm-1	B-C3699343
and	O
mexa	B-C0376623
in	O
pseudomonas	B-C0033809
aeruginosa	I-C0033809
the	O
therapeutic	B-C0302350
option	I-C0302350
of	O
a	O
carbapenem	B-C0006968
antibiotic	I-C0006968
is	O
compromised	O
in	O
pseudomonas	B-C0033809
aeruginosa	I-C0033809
owing	O
both	O
to	O
acquired	B-C1155281
and	O
intrinsic	B-C0949669
resistance	I-C0949669
mechanisms	O
.	O
	
in	O
recent	O
years	O
,	O
new	B-C2973511
delhi	I-C2973511
metallo-β-lactamase	I-C2973511
has	O
been	O
the	O
focus	O
as	O
a	O
predominant	O
carbapenem	B-C0949285
resistance	I-C0949285
determinant	I-C0949285
.	O
	
however	O
,	O
it	O
is	O
unclear	O
which	O
of	O
the	O
mechanisms	O
might	O
be	O
adopted	O
by	O
a	O
p	B-C0033809
.	O
	
aeruginosa	I-C0033809
strain	B-C1518614
possessing	O
both	O
blandm-1	B-C3699343
and	O
an	O
overexpressed	B-C0017262
mexab-oprm	B-C0029073
system	O
during	O
carbapenem	B-C0006968
therapy	B-C0338237
.	O
	
this	O
study	O
investigated	O
the	O
interplay	O
of	O
both	O
mechanisms	O
in	O
clinical	B-C1764827
isolates	I-C1764827
of	O
p	B-C0033809
.	O
	
aeruginosa	I-C0033809
when	O
exposed	O
to	O
meropenem	B-C0066005
.	O
	
five	O
strains	B-C1518614
were	O
used	O
i	O
strain	B-C0017262
overexpressing	I-C0017262
mexab-oprm	B-C0029073
but	O
with	O
no	B-C0332197
blandm-1	B-C3699343
ii	O
strain	O
harbouring	O
blandm-1	B-C3699343
but	O
expressing	B-C0017262
mexab-oprm	B-C0029073
at	O
basal	O
level	O
iii	O
strain	B-C1518614
possessing	O
blandm-1	B-C3699343
and	O
overexpressing	B-C0017262
mexab-oprm	B-C0029073
iv	O
p	B-C4164297
.	O
	
aeruginosa	I-C4164297
pao1	I-C4164297
and	O
v	O
p	B-C4164297
.	O
	
aeruginosa	I-C4164297
k2733-pao1	I-C4164297
δmexab-oprm	B-C0029073
δmexcd-oprj	B-C0029073
δmexef-oprn	B-C0029073
δmexxy-oprm	B-C0029073
into	O
which	O
blandm-1	B-C3699343
was	O
cloned	B-C0598888
.	O
	
strains	B-C1518614
were	O
incubated	O
in	O
luria-bertani	B-C2919900
broth	I-C2919900
with	O
and	O
without	O
1μg/ml	O
meropenem	B-C0066005
.	O
	
total	B-C4086963
rna	I-C4086963
was	O
isolated	O
at	O
45-min	O
intervals	O
and	O
was	O
immediately	O
reverse	B-C0035380
transcribed	I-C0035380
to	O
cdna	B-C0006556
.	O
	
this	O
was	O
repeated	O
for	O
6h	O
.	O
	
quantitative	B-C3179034
real-time	I-C3179034
pcr	I-C3179034
was	O
performed	O
for	O
both	O
resistance	B-C1517585
mechanisms	I-C1517585
.	O
	
meropenem	B-C0066005
exposure	B-C0743284
did	O
not	O
significantly	O
elevate	B-C0040649
transcription	I-C0040649
of	O
either	O
the	O
blandm-1	B-C3699343
or	O
mexa	B-C0376623
gene	I-C0376623
.	O
	
however	O
,	O
an	O
interesting	O
finding	O
was	O
that	O
upon	O
single-dose	B-C1960417
exposure	B-C0743284
to	I-C0743284
carbapenem	I-C0743284
,	O
the	O
efflux	B-C3824504
pump	I-C3824504
system	I-C3824504
played	O
a	O
major	O
role	B-C0220921
in	I-C0220921
bacterial	I-C0220921
survival	I-C0220921
compared	O
with	O
ndm-1	B-C2973511
.	O
	
this	O
study	O
gives	O
an	O
insight	O
into	O
the	O
bacterial	B-C0683154
response	I-C0683154
to	I-C0683154
carbapenem	I-C0683154
antibiotic	I-C0683154
when	O
two	O
different	O
resistance	B-C1517585
mechanisms	I-C1517585
coexist	O
.	O
	
this	O
type	O
of	O
study	O
would	O
be	O
helpful	O
in	O
designing	O
future	O
inducible	B-C0205263
expression	B-C0017262
of	O
both	O
ermb	B-C0017337
and	O
ermt	B-C0017337
conferred	O
high	B-C0205250
macrolide	B-C3160879
resistance	I-C3160879
in	O
streptococcus	B-C1459658
gallolyticus	I-C1459658
subsp	I-C1459658
.	O
	
pasteurianus	I-C1459658
isolates	B-C1518614
in	O
china	B-C0008115
streptococcus	B-C1459658
gallolyticus	I-C1459658
subsp	I-C1459658
.	O
	
pasteurianus	I-C1459658
is	O
an	O
under-recognized	O
pathogen	B-C0450254
and	O
zoonotic	B-C1690490
agent	I-C1690490
causing	O
opportunistic	B-C0029118
infections	I-C0029118
in	O
humans	B-C0086418
.	O
	
despite	O
increasing	O
recognition	B-C0205396
of	O
this	O
subspecies	B-C1459658
as	O
a	O
cause	O
for	O
human	B-C0086418
infectious	B-C0004623
diseases	I-C0004623
,	O
limited	O
information	O
is	O
known	O
about	O
its	O
antibiotic	B-C0949669
resistance	I-C0949669
mechanism	B-C0441712
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
aim	O
to	O
identify	O
the	O
molecular	B-C1148560
mechanism	I-C1148560
underlying	O
the	O
high	O
macrolide	B-C3160879
resistance	I-C3160879
of	O
six	O
s	B-C1459658
.	O
	
gallolyticus	I-C1459658
subsp	I-C1459658
.	O
	
pasteurianus	I-C1459658
isolates	B-C1518614
from	O
dead	B-C1306577
ducklings	B-C0013268
collected	O
in	O
several	O
natural	O
outbreaks	O
in	O
china	B-C0008115
during	O
2010-2013	O
.	O
	
all	O
isolates	B-C1518614
exhibited	O
multi-drug	B-C0242640
resistance	I-C0242640
including	O
high	O
macrolide	B-C3160879
resistance	I-C3160879
mic	B-C1304747
1024	O
mg/l	O
for	O
erythromycin	O
,	O
and	O
512	O
mg/l	O
for	O
clarithromycin	O
.	O
	
efflux-encoding	O
mefa	O
and	O
mefe	O
genes	O
were	O
not	O
detectable	O
in	O
these	O
isolates	O
.	O
	
the	O
presence	O
of	O
23s	O
rrna	O
mutations	O
in	O
specific	O
isolates	O
did	O
not	O
significantly	O
change	O
macrolide	O
mic	B-C1304747
s	O
.	O
	
no	O
nucleotide	O
substitutions	O
were	O
found	O
in	O
genes	O
encoding	O
ribosomal	O
proteins	O
l4	O
or	O
l22	O
.	O
	
the	O
ermb	O
and	O
ermt	O
genes	O
were	O
found	O
in	O
the	O
genomes	O
of	O
all	O
isolates	O
.	O
	
these	O
two	O
genes	O
were	O
acquired	O
independently	O
in	O
one	O
highly	O
virulent	O
isolate	O
al101002	O
,	O
and	O
clustered	O
with	O
tn916	O
and	O
is1216	O
,	O
respectively	O
.	O
	
the	O
expression	O
of	O
both	O
ermb	O
and	O
ermt	O
in	O
all	O
isolates	O
was	O
erythromycin	B-C0014806
inducible	O
and	O
yielded	O
comparable	O
macrolide	O
mics	O
in	O
all	O
six	O
isolates	O
.	O
	
taken	O
together	O
,	O
inducible	O
expression	O
of	O
both	O
ermb	O
and	O
ermt	O
conferred	O
high	O
macrolide	O
resistance	O
in	O
these	O
s	O
.	O
	
gallolyticus	O
subsp	O
.	O
	
pasterianus	O
isolates	O
.	O
	
our	O
findings	O
reveal	O
new	O
macrolide	O
resistance	O
features	O
in	O
s	O
.	O
	
gallolyticus	O
subsp	O
.	O
	
pasteurianus	O
by	O
both	O
ermb	O
and	O
ermt	B-C0017337
bilateral	B-C0238767
c1	B-C0025080
laminar	I-C0025080
hooks	I-C0025080
combined	O
with	O
c2	B-C1961768
pedicle	I-C1961768
screw	I-C1961768
fixation	B-C0185023
in	O
the	O
treatment	B-C0087111
of	O
atlantoaxial	B-C0263905
subluxation	I-C0263905
after	O
grisel	B-C0263885
syndrome	I-C0263885
many	O
etiologies	B-C0015127
can	O
lead	O
to	O
atlantoaxial	B-C0263905
subluxaion	I-C0263905
.	O
	
in	O
grisel	B-C0263885
syndrome	I-C0263885
gs	B-C0263885
,	O
this	O
subluxation	B-C0263905
occurs	O
spontaneously	B-C0205359
after	O
inflammatory	B-C0333348
processes	B-C1522240
of	O
the	O
head	B-C0018670
and	O
neck	B-C0027530
.	O
	
diagnosis	B-C0011900
is	O
typically	O
based	O
on	O
clinical	B-C0262926
history	I-C0262926
and	O
a	O
strong	O
suspicion	B-C0242114
of	O
this	O
syndrome	B-C0039082
.	O
	
nonsurgical	B-C0087111
treatment	I-C0087111
most	O
often	O
resolves	B-C2699488
the	O
symptoms	B-C1457887
however	O
,	O
in	O
some	O
cases	B-C0868928
surgical	B-C0543467
treatment	I-C0543467
is	O
necessary	O
to	O
repair	B-C0374711
the	O
subluxation	B-C0263905
.	O
	
various	O
surgical	B-C0011918
techniques	I-C0011918
and	O
instrumentation	B-C0348000
systems	I-C0348000
have	O
been	O
used	O
to	O
treat	B-C0087111
atlantoaxial	B-C0263905
subluxation	I-C0263905
,	O
although	O
there	O
is	O
no	O
consensus	B-C0376298
regarding	O
the	O
best	O
treatment	B-C0087111
method	I-C0087111
for	O
the	O
pediatric	B-C1521725
population	B-C1257890
.	O
	
to	O
describe	O
a	O
case	B-C0868928
of	O
atlantoaxial	B-C0263905
subluxation	I-C0263905
in	O
a	O
child	B-C0008059
with	O
gs	B-C0263885
treated	B-C0332154
surgically	B-C0543467
with	O
an	O
alternative	B-C1523987
construct	B-C0025080
.	O
	
this	O
is	O
a	O
case	B-C0085973
report	I-C0085973
and	O
literature	B-C0282441
review	I-C0282441
.	O
	
our	O
case	B-C0085973
study	I-C0085973
involves	O
a	O
5-	O
year	B-C0439234
-old	O
girl	B-C0870604
with	O
a	O
6-	O
month	B-C0439231
history	B-C0332119
of	O
unresolved	B-C0443342
fielding	B-C0263905
type	I-C0263905
ii	I-C0263905
atlantoaxial	I-C0263905
subluxation	I-C0263905
caused	O
by	O
gs	B-C0263885
.	O
	
despite	O
conservative	B-C0459914
treatment	I-C0459914
,	O
the	O
patient's	B-C0030705
symptoms	B-C1457887
continued	B-C0549178
to	O
progress	B-C1280477
.	O
	
after	O
two	O
failed	B-C0231175
closed	B-C0441610
reduction	I-C0441610
attempts	B-C1516084
,	O
open	B-C2370853
reduction	I-C2370853
and	O
c1-c2	B-C0037935
fusion	I-C0037935
were	O
performed	B-C0884358
with	O
atlas	B-C0181209
laminar	I-C0181209
hook	I-C0181209
and	O
axis	B-C0301559
pedicle	I-C0301559
polyaxial	I-C0301559
screws	I-C0301559
.	O
	
a	O
literature	B-C0282441
review	I-C0282441
of	O
the	O
surgical	B-C0543467
treatment	I-C0543467
of	O
gs	B-C0263885
was	O
also	O
performed	B-C0884358
.	O
	
after	O
surgery	B-C0038895
,	O
the	O
patient	B-C0030705
exhibited	O
full	O
clinical	B-C0205210
and	O
functional	B-C0599766
recovery	I-C0599766
with	O
complete	B-C2699488
resolution	I-C2699488
of	O
symptoms	B-C1457887
.	O
	
at	O
the	O
36-	O
month	B-C0439231
follow-up	B-C1522577
examination	B-C0582103
,	O
there	O
was	O
continual	B-C0439598
evidence	B-C3887511
of	O
satisfactory	B-C0438110
reduction	B-C0441610
and	O
fusion	B-C1293131
.	O
	
no	O
complications	B-C0009566
were	O
observed	B-C1441672
.	O
	
upon	O
completion	B-C0205197
of	O
the	O
literature	B-C0282441
review	I-C0282441
,	O
eight	O
gs	B-C0263885
cases	B-C0868928
were	O
found	O
to	O
have	O
been	O
treated	B-C1522326
surgically	B-C0543467
with	O
the	O
minimum	O
patient	B-C0030705
age	B-C0001779
being	O
9	O
years	B-C0439234
.	O
	
conservative	B-C0459914
management	I-C0459914
of	O
gs	B-C0263885
is	O
the	O
most	O
common	B-C0205214
and	O
effective	B-C1704419
treatment	B-C0087111
however	O
,	O
a	O
few	O
surgical	B-C0868928
cases	I-C0868928
have	O
been	O
reported	B-C0700287
in	O
the	O
literature	B-C0023866
with	O
good	O
results	B-C1274040
.	O
	
satisfactory	B-C0438110
clinical	B-C2985631
results	I-C2985631
and	O
fusion	B-C1293131
at	O
36	O
months	B-C0439231
post	B-C0241311
surgery	I-C0241311
were	O
seen	O
in	O
a	O
pediatric	B-C1521725
patient	B-C0030705
with	O
atlantoaxial	B-C0263905
subluxation	I-C0263905
and	O
instability	B-C1444783
using	O
atlas	B-C0181209
laminar	I-C0181209
hook	I-C0181209
and	O
axis	B-C0301559
pedicle	I-C0301559
polyaxial	I-C0301559
screws	I-C0301559
.	O
	
caries	B-C0333519
with	O
dental	B-C0026618
fluorosis	I-C0026618
and	O
oral	B-C1830927
health	I-C1830927
behaviour	I-C1830927
among	O
12-year	B-C0439234
school	B-C0260267
children	I-C0260267
in	O
moderate-fluoride	B-C0009462
drinking	I-C0009462
water	I-C0009462
community	I-C0009462
in	O
quetta	B-C0017446
,	O
pakistan	B-C0030211
to	O
determine	O
the	O
prevalence	B-C0033105
of	O
dental	B-C0011334
caries	I-C0011334
and	O
its	O
relationship	B-C0439849
with	O
dental	B-C0026618
fluorosis	I-C0026618
,	O
oral	B-C1830927
health	I-C1830927
behaviour	I-C1830927
and	O
dietary	B-C4019289
behaviour	I-C4019289
among	O
12-year	B-C0439234
school	B-C0260267
children	I-C0260267
in	O
moderate-fluoride	B-C0009462
drinking	I-C0009462
water	I-C0009462
community	I-C0009462
in	O
quetta	B-C0017446
,	O
pakistan	B-C0030211
.	O
	
cross-sectional	B-C0010362
study	I-C0010362
.	O
	
government	B-C0036375
and	O
private	B-C0036375
schools	I-C0036375
of	O
quetta	B-C0017446
,	O
from	O
november	B-C3828767
2012	O
to	O
february	B-C3830166
2013	O
.	O
	
atotal	O
of	O
349	O
children	B-C0008059
aged	O
12-year	B-C0439234
from	O
14	O
randomly	O
selected	O
schools	B-C0036375
were	O
included	O
.	O
	
the	O
data	B-C0010995
collection	I-C0010995
was	O
done	O
on	O
questionnaire	B-C0034394
designed	O
for	O
children	B-C0008059
.	O
	
dental	B-C0011334
caries	I-C0011334
status	B-C0449438
was	O
examined	O
by	O
using	O
who	O
criteria	O
.	O
	
dental	O
caries	O
was	O
found	O
in	O
81	O
children	O
23.2	O
with	O
mean	O
dmft	O
0.61	O
.	O
	
boys	O
had	O
1.6	O
times	O
more	O
chance	O
to	O
have	O
dental	O
caries	O
than	O
girls	O
.	O
	
dental	O
fluorosis	O
was	O
found	O
in	O
63.6	O
of	O
children	O
with	O
majority	O
of	O
moderate	O
degree	O
50.5	O
.	O
	
dental	O
fluorosis	O
status	B-C0449438
was	O
found	O
significantly	O
associated	O
with	O
dental	O
caries	O
status	O
in	O
children	O
.	O
	
the	O
children	O
who	O
had	O
mild	O
,	O
moderate	O
and	O
severe	O
fluorosis	O
,	O
had	O
4	O
times	O
more	O
chances	O
to	O
develop	O
caries	O
than	O
those	O
who	O
did	O
not	O
have	O
fluorosis	O
.	O
	
there	O
was	O
no	O
significant	O
association	O
between	O
children's	O
caries	O
status	O
and	O
use	O
of	O
paste	O
,	O
brushing	O
habit	O
,	O
miswak	O
,	O
and	O
visit	O
to	O
the	O
dentist	O
.	O
	
the	O
use	O
of	O
pastries	O
and	O
juices	O
had	O
a	O
direct	O
relation	O
with	O
the	O
children's	O
dental	O
caries	O
status	O
.	O
	
dental	O
caries	O
in	O
children	O
of	O
quetta	O
is	O
not	O
so	O
much	O
frequent	O
as	O
compared	O
to	O
the	O
fluoride	O
deficient	O
countries	O
.	O
	
however	O
,	O
the	O
high	O
prevalence	O
of	O
moderate	O
dental	O
fluorosis	O
and	O
consumption	O
of	O
pastries	O
and	O
juices	O
resulted	O
in	O
dental	O
caries	I-C0011334
proteomics	B-C0751973
analysis	B-C0002778
of	O
the	O
endogenous	B-C0205227
,	O
constitutive	O
,	O
leaf	B-C0242724
sumoylome	B-C0872079
sumoylation	B-C1157990
is	O
a	O
post-translational	B-C0033666
modification	I-C0033666
which	O
regulates	B-C1327622
a	O
number	O
of	O
critical	B-C1511545
biological	B-C3714634
processes	I-C3714634
in	O
,	O
for	O
example	O
mammals	B-C0024660
,	O
yeast	B-C0043393
and	O
plants	B-C0032098
.	O
	
in	O
order	O
to	O
fully	O
understand	B-C0162340
the	O
functional	B-C0935657
effects	I-C0935657
of	O
sumoylation	B-C1157990
an	O
essential	B-C0205224
first	O
step	O
is	O
the	O
identification	B-C0020792
of	O
endogenous	B-C0205227
targets	B-C1521840
for	O
sumoylation	B-C1157990
.	O
	
here	O
we	O
report	B-C0684224
the	O
results	B-C1274040
of	O
using	O
a	O
recently	O
developed	O
proteomic	B-C0872252
approach	I-C0872252
based	O
on	O
the	O
use	O
of	O
3d	B-C0450363
gels	B-C0017243
to	O
identify	O
the	O
endogenous	B-C0205227
sumo	B-C0911575
targets	B-C1521840
in	O
leaves	B-C0242724
of	O
solanum	B-C1145678
tuberosum	I-C1145678
.	O
	
by	O
using	O
3d	B-C0450363
gels	B-C0017243
we	O
avoid	O
the	O
problem	O
of	O
co-migration	B-C1254366
of	O
proteins	B-C0033684
,	O
which	O
is	O
a	O
major	B-C0205164
limitation	B-C0449295
of	O
2d	B-C1705052
gels	B-C0017243
,	O
and	O
we	O
enable	O
the	O
use	O
of	O
the	O
highly	B-C0439822
sensitive	I-C0439822
cydye	B-C0016320
dige	I-C0016320
fluor	I-C0016320
saturation	I-C0016320
dyes	I-C0016320
.	O
	
using	O
this	O
new	O
method	O
we	O
have	O
identified	B-C0205396
39	O
individual	B-C0033684
proteins	I-C0033684
as	O
probable	B-C0033204
sumo	B-C0911575
targets	B-C1521840
in	O
leaves	B-C0242724
of	O
solanum	B-C1145678
tuberosum	I-C1145678
.	O
	
the	O
advantages	O
of	O
this	O
method	B-C0871511
compared	O
with	O
other	O
approaches	B-C1292724
are	O
discussed	O
,	O
and	O
possible	B-C0332149
future	B-C0016884
developments	B-C1527148
are	O
outlined	O
.	O
	
the	O
authors	B-C3812881
have	O
no	O
conflicts	B-C0079152
of	I-C0079152
interest	I-C0079152
to	O
declare	O
.	O
	
all	O
authors	B-C3812881
have	O
approved	B-C0205540
the	O
manuscript	B-C0600659
and	O
agree	B-C3641827
with	O
submission	B-C1515022
to	O
journal	B-C0162443
of	I-C0162443
proteomics	I-C0162443
.	O
	
antenatal	B-C2828394
consultation	B-C0009818
following	B-C0332282
limb	B-C0206762
malformation	I-C0206762
discovery	B-C1880355
using	O
ultrasound	B-C0041618
scan	I-C0041618
our	O
unit	B-C0019988
has	O
been	O
providing	B-C1999230
antenatal	B-C2828394
consultations	B-C0009818
for	O
30	O
years	O
following	B-C0332282
the	O
discovery	B-C1880355
of	O
limb	B-C0206762
malformation	I-C0206762
with	O
the	O
fetus	B-C0015965
.	O
	
each	O
of	O
these	O
consultations	B-C0009818
is	O
specific	B-C0205369
and	O
carried	B-C2733037
out	I-C2733037
by	O
a	O
multi-professional	B-C0086390
team	I-C0086390
.	O
	
it	O
requires	B-C1514873
a	O
physical	O
and	O
rehabilitation	B-C1306847
doctor	B-C0031831
,	O
an	O
orthopedic	B-C0334891
surgeon	I-C0334891
,	O
an	O
occupational	B-C0028807
therapist	I-C0028807
for	O
upper	B-C1404175
limb	I-C1404175
malformation	I-C1404175
,	O
a	O
physiotherapist	B-C2362565
for	O
lower	B-C1404177
malformation	I-C1404177
and	O
a	O
psychologist	B-C0033908
.	O
	
this	O
multidisciplinary	B-C0242479
consultation	B-C0009818
is	O
unique	B-C1710548
because	O
of	O
each	O
pregnancy	B-C0032961
story	O
,	O
because	O
of	O
each	O
patient	B-C0030705
life	B-C0681455
story	I-C0681455
but	O
also	O
because	O
of	O
the	O
words	O
used	O
by	O
the	O
sonologist	B-C1522486
when	O
announcing	O
the	O
diagnosis	B-C0011900
.	O
	
we	O
deal	O
with	O
couples	B-C0010222
shocked	B-C0436570
by	O
the	O
prenatal	B-C0033053
diagnosis	I-C0033053
.	O
	
we	O
help	O
them	O
get	O
acceptance	B-C0000899
of	O
the	O
child	B-C0008059
to	O
be	O
born	O
and	O
to	O
forget	O
about	O
their	O
imaginary	B-C0025361
child	B-C0008059
.	O
	
medical	B-C0850397
information	I-C0850397
is	O
often	O
perceived	B-C0030971
as	O
being	O
"""a"	O
surfeit	B-C0205556
of	O
information	B-C1533716
""""	O
difficult	B-C0332218
to	O
handle	O
by	O
the	O
couple	B-C0010222
stunned	B-C4061448
by	O
the	O
overwhelming	B-C0205556
diagnosis	B-C0011900
.	O
	
we	O
must	O
stress	O
that	O
it	O
is	O
critical	B-C1511545
to	O
not	O
only	O
have	O
a	O
good	O
medical	B-C0517733
description	I-C0517733
of	O
the	O
malformations	B-C0000768
and	O
potential	B-C0087111
treatments	I-C0087111
but	O
also	O
a	O
good	O
psychological	B-C0600015
support	I-C0600015
parents	B-C0030551
personal	B-C1519021
life	B-C0681455
story	I-C0681455
,	O
self-defense	B-C0011142
mechanism	I-C0011142
,	O
guilt	B-C0018379
feeling	I-C0018379
.	O
	
the	O
ethical	B-C1136353
aspect	I-C1136353
of	O
this	O
consultation	B-C0009818
is	O
also	O
important	B-C3898777
.	O
	
team	B-C0086390
members	B-C0680022
must	O
be	O
as	O
neutral	B-C4050008
as	O
possible	B-C0332149
in	O
their	O
assessments	B-C0220825
in	O
order	O
to	O
let	O
the	O
couple	B-C0010222
take	O
the	O
final	O
decision	B-C0679006
the	O
continuation	B-C0805733
of	O
the	O
pregnancy	B-C0032961
or	O
a	O
request	B-C1272683
of	O
voluntary	B-C0439656
termination	B-C0392535
of	I-C0392535
pregnancy	I-C0392535
.	O
	
these	O
prenatal	B-C0678804
consultations	B-C0009818
highlight	O
the	O
importance	B-C0205556
of	O
the	O
multidisciplinary	B-C0205556
global	B-C2348867
care	B-C0086388
.	O
	
bending	B-C0870077
rules	I-C0870077
the	O
shape	B-C0332479
of	O
the	O
perceptual	B-C0030971
generalisation	B-C0017324
gradient	B-C0812409
is	O
sensitive	B-C0332324
to	O
inference	B-C0870077
rules	I-C0870077
generalising	B-C0017326
what	O
is	O
learned	B-C0023185
about	O
one	O
stimulus	B-C0234402
to	O
other	O
but	O
perceptually	B-C0030971
related	O
stimuli	B-C0234402
is	O
a	O
basic	O
behavioural	B-C0004927
phenomenon	B-C1882365
.	O
	
we	O
evaluated	B-C0220825
whether	O
a	O
rule	B-C0870077
learning	B-C0023185
mechanism	B-C0441712
may	O
serve	O
to	O
explain	O
such	O
generalisation	B-C0017324
.	O
	
to	O
this	O
end	O
,	O
we	O
assessed	B-C1516048
whether	O
inference	B-C0870077
rules	I-C0870077
communicated	B-C0566001
through	O
verbal	B-C1254363
instructions	I-C1254363
affect	O
generalisation	B-C0017324
.	O
	
expectancy	B-C0679138
ratings	B-C0871208
,	O
but	O
not	O
valence	O
ratings	B-C0871208
,	O
proved	O
sensitive	B-C0332324
to	O
this	O
manipulation	B-C0018578
.	O
	
in	O
addition	O
to	O
revealing	O
a	O
role	B-C1704326
for	O
inference	B-C0870077
rules	I-C0870077
in	O
generalisation	B-C0017324
,	O
our	O
study	B-C2603343
has	O
clinical	B-C0205210
implications	B-C0205245
as	O
well	O
.	O
	
more	O
specifically	O
,	O
we	O
argue	O
that	O
targeting	B-C1521840
inference	B-C0870077
rules	I-C0870077
might	O
prove	O
to	O
be	O
an	O
effective	O
strategy	B-C0679199
to	O
affect	O
the	O
excessive	B-C0442802
generalisation	B-C0017324
that	O
is	O
often	O
observed	O
in	O
neuroticism	B-C1842981
and	O
fatigue	B-C0015672
3	B-C1442461
months	I-C1442461
after	O
ischemic	B-C0948008
stroke	I-C0948008
a	O
cross-sectional	B-C0010362
study	I-C0010362
to	O
examine	B-C0332128
the	O
relation	O
between	O
neuroticism	B-C1842981
and	O
fatigue	B-C0015672
in	O
chinese	B-C0008115
patients	B-C0030705
with	O
stroke	B-C0038454
.	O
	
cross-sectional	B-C0010362
study	I-C0010362
.	O
	
acute	B-C0205178
stroke	B-C0587502
unit	I-C0587502
.	O
	
survivors	B-C0206194
of	O
ischemic	B-C0948008
stroke	I-C0948008
n=191	O
recruited	O
from	O
the	O
acute	B-C0205178
stroke	B-C0587502
unit	I-C0587502
between	O
may	O
1	O
,	O
2010	O
,	O
and	O
september	O
1	O
,	O
2011	O
.	O
	
not	O
applicable	O
.	O
	
the	O
personality	B-C0233849
trait	I-C0233849
of	O
neuroticism	B-C1842981
was	O
measured	B-C0444706
with	O
the	O
neuroticism	B-C1842981
subscale	B-C0459443
of	O
the	O
chinese	B-C0008115
version	B-C0333052
of	O
the	O
neo	B-C0031213
five-factor	I-C0031213
inventory	I-C0031213
.	O
	
the	O
level	B-C0441889
of	O
fatigue	B-C0015672
was	O
measured	B-C0444706
with	O
the	O
fatigue	B-C2733557
assessment	I-C2733557
scale	I-C2733557
.	O
	
the	O
national	B-C3472496
institutes	I-C3472496
of	I-C3472496
health	I-C3472496
stroke	I-C3472496
scale	I-C3472496
,	O
geriatric	B-C0451184
depression	I-C0451184
scale	I-C0451184
,	O
barthel	B-C0451019
index	I-C0451019
,	O
and	O
mini-mental	B-C0451306
state	I-C0451306
examination	I-C0451306
were	O
administered	B-C1521801
to	O
obtain	O
demographic	B-C0011298
and	O
clinical	B-C2708733
information	I-C2708733
.	O
	
fatigue	B-C3813323
severity	I-C3813323
3	B-C1442461
months	I-C1442461
after	O
stroke	B-C0038454
positively	O
correlated	B-C1707520
with	O
geriatric	B-C0451184
depression	I-C0451184
scale	I-C0451184
and	O
neo	B-C0031213
five-factor	I-C0031213
inventory	I-C0031213
neuroticism	B-C1842981
scores	B-C0449820
and	O
negatively	B-C0205160
correlated	B-C1707520
with	O
the	O
barthel	B-C1642833
index	I-C1642833
score	I-C1642833
.	O
	
neuroticism	B-C1842981
,	O
independent	B-C1299583
of	O
depressive	B-C0086132
symptoms	I-C0086132
,	O
is	O
a	O
predictor	O
of	O
fatigue	B-C3813323
severity	I-C3813323
3	B-C1442461
months	I-C1442461
after	O
stroke	B-C0038454
.	O
	
interventions	O
such	O
as	O
psychological	B-C0205486
screening	B-C3484370
programs	I-C3484370
are	O
warranted	O
for	O
early	O
detection	B-C1511790
of	O
patients	B-C0030705
at	O
high	B-C0332167
risk	I-C0332167
of	I-C0332167
poststroke	B-C2938940
depression	I-C2938940
.	O
	
hematological	B-C0243095
,	O
biochemical	B-C0243095
,	O
and	O
toxicopathic	B-C0243095
effects	I-C0243095
of	O
subchronic	B-C4053983
acetamiprid	B-C1142891
toxicity	B-C0600688
in	O
wistar	B-C0034716
rats	I-C0034716
acetamiprid	B-C1142891
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
neonicotinoids	B-C1997222
.	O
	
this	O
study	O
investigates	B-C1292732
toxic	B-C0600688
effects	I-C0600688
of	O
repeated	O
oral	B-C1527415
administration	I-C1527415
of	O
three	O
doses	B-C0178602
of	O
acetamiprid	B-C1142891
1/20	O
,	O
1/10	O
,	O
and	O
1/5	O
of	O
ld50	B-C0023378
during	O
60	O
days	B-C0439228
.	O
	
for	O
this	O
,	O
male	B-C0086582
wistar	B-C0034716
rats	I-C0034716
were	O
divided	O
into	O
four	O
different	O
groups	B-C0441833
.	O
	
hematological	B-C0243095
,	O
biochemical	B-C0243095
,	O
and	O
toxicopathic	B-C0243095
effects	I-C0243095
of	O
acetamiprid	B-C1142891
were	O
evaluated	B-C0220825
.	O
	
according	O
to	O
the	O
results	O
,	O
a	O
significant	O
decrease	B-C0547047
in	O
the	O
body	B-C0043094
weight	I-C0043094
gain	I-C0043094
at	O
the	O
highest	O
dose	B-C0178602
1/5	O
of	O
ld50	B-C0023378
of	O
acetamiprid	B-C1142891
was	O
noticed	O
.	O
	
an	O
increase	B-C0442805
in	O
the	O
relative	O
liver	B-C0023884
weight	B-C0043100
was	O
also	O
observed	O
at	O
this	O
dose	B-C0178602
level	B-C0441889
.	O
	
the	O
hematological	B-C0729650
constituents	I-C0729650
were	O
affected	O
.	O
	
a	O
significant	O
decrease	B-C0547047
in	O
rbc	B-C0014792
,	O
hgb	B-C0019046
,	O
and	O
hct	B-C0518014
in	O
rats	B-C0034716
treated	B-C1522326
with	O
higher	O
doses	B-C0178602
of	O
acetamiprid	B-C1142891
1/10	O
and	O
1/5	O
of	O
ld50	B-C0023378
was	O
noted	O
.	O
	
however	O
,	O
a	O
significant	O
increase	B-C0442805
in	O
wbc	B-C0023516
and	O
plt	B-C0005821
were	O
observed	O
at	O
the	O
same	O
doses	B-C0178602
.	O
	
furthermore	O
,	O
acetamiprid	B-C1142891
induced	B-C4279912
liver	I-C4279912
toxicity	I-C4279912
measured	O
by	O
the	O
increased	B-C0205217
activities	B-C0243102
of	O
aspartate	B-C0004002
aminotransferase	I-C0004002
ast	B-C0004002
,	O
alanine	B-C0001899
aminotransferase	I-C0001899
alt	B-C0001899
,	O
alkaline	B-C0002059
phosphates	I-C0002059
alps	B-C0002059
,	O
and	O
lactate	B-C0022917
dehydrogenase	I-C0022917
ldh	B-C0022917
which	O
may	O
be	O
due	O
to	O
the	O
loss	B-C1517945
of	O
hepatic	B-C2331083
membrane	I-C2331083
architecture	I-C2331083
and	O
hepatocellular	B-C0151763
damage	I-C0151763
.	O
	
in	O
addition	O
,	O
exposure	B-C0332157
to	I-C0332157
acetamiprid	B-C1142891
resulted	O
in	O
a	O
significant	O
decrease	B-C0547047
in	O
the	O
levels	B-C0441889
of	O
superoxide	B-C0038838
dismutase	I-C0038838
and	O
catalase	B-C0007367
activities	B-C0243102
p	O
0.01	O
with	O
concomitant	B-C0521115
increase	B-C0442805
in	O
lipid	B-C0023775
peroxidation	I-C0023775
in	O
rat	B-C0034716
liver	B-C0023884
.	O
	
these	O
findings	B-C0243095
highlight	O
the	O
subchronic	B-C4053983
hepatotoxicity	B-C0235378
of	O
sustained	B-C1710261
delivery	I-C1710261
of	O
vincristine	B-C0042679
inside	O
an	O
orthotopic	B-C0574893
mouse	B-C1522023
sarcoma	I-C1522023
model	O
decreases	B-C0547047
tumor	B-C0598934
growth	I-C0598934
sarcoma	B-C1261473
accounts	O
for	O
20%	O
of	O
solid	B-C0280100
tumors	I-C0280100
in	O
children	B-C0008059
.	O
	
surgery	B-C0543467
has	O
significant	O
morbidity	B-C0026538
.	O
	
we	O
hypothesized	O
that	O
delivering	O
chemotherapy	B-C3665472
directly	O
into	O
tumors	B-C0027651
through	O
sustained	B-C1710261
release	I-C1710261
silk	B-C0074529
systems	O
could	O
slow	O
tumor	B-C0598934
growth	I-C0598934
.	O
	
human	B-C0086418
ewing	B-C0553580
sarcoma	I-C0553580
cells	B-C0334227
a673	I-C0334227
were	O
cultured	B-C0430400
with	O
vincristine	B-C0042679
and	O
doxorubicin	B-C0013089
to	O
determine	O
half	B-C0600495
maximal	I-C0600495
inhibitory	I-C0600495
concentration	I-C0600495
ic50	B-C0600495
.	O
	
cells	B-C0334227
were	O
injected	O
into	O
mouse	B-C0025929
hind	B-C1522391
leg	I-C1522391
to	O
create	O
orthotopic	B-C0574893
tumors	B-C0027651
.	O
	
tumor	B-C0475276
volumes	I-C0475276
were	O
measured	O
using	O
ultrasound	B-C0041618
.	O
	
when	O
volume	O
reached	O
>250mm	O
interventions	B-C0184661
included	O
implantation	B-C0021107
of	O
drug-free	B-C0683584
silk	B-C0074529
foam	O
control	B-C0009932
-f	O
,	O
doxorubicin	B-C0013089
400μg	O
foam	O
dox400	B-C0013089
-f	O
,	O
vincristine	B-C0042679
50μg	O
foam	O
vin50	B-C0042679
-f	O
,	O
drug-free	B-C0683584
silk	B-C0074529
gel	B-C1382104
control	B-C0009932
-g	O
,	O
vincristine	B-C0042679
50μg	O
gel	B-C1382104
vin50	B-C0042679
-g	O
,	O
or	O
single	O
dose	O
intravenous	B-C0348016
vincristine	B-C0042679
50μg	O
vin50	B-C0042679
-iv	O
.	O
	
end-point	B-C2349179
was	O
volume>1000mm	O
.	O
	
kaplan	B-C1720943
meier	I-C1720943
and	O
anova	B-C0002780
were	O
used	O
.	O
	
ic50	B-C0600495
for	O
vincristine	B-C0042679
and	O
doxorubicin	B-C0013089
was	O
0.5ng	O
and	O
200ng/ml	O
,	O
respectively	O
.	O
	
there	O
was	O
no	O
difference	O
between	O
dox400	B-C0013089
-f	O
6	O
1days	B-C0439228
to	O
end	B-C2349179
point	I-C2349179
dtep	B-C2349179
and	O
control	B-C0009932
-f	O
5	O
dtep	B-C2349179
.	O
	
vin50	B-C0042679
-f	O
12.4	O
dtep	B-C2349179
had	O
slower	B-C4086857
growth	I-C4086857
compared	O
to	O
control	B-C0009932
-f	O
p<0	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
vin50	B-C0042679
-f	O
and	O
vin50	B-C0042679
-iv	O
14	O
dtep	B-C2349179
.	O
	
growth	B-C4086857
was	I-C4086857
slowest	I-C4086857
with	O
vin50	B-C0042679
-g	O
,	O
28	O
dtep	B-C2349179
compared	O
to	O
all	O
other	O
treatment	O
groups	O
p<0	O
.	O
	
sustained	B-C1710261
delivery	I-C1710261
of	O
vincristine	B-C0042679
inside	O
the	O
sarcoma	B-C1261473
tumor	B-C0027651
with	O
silk	B-C0074529
gel	B-C1382104
decreased	B-C0547047
tumor	B-C0598934
growth	I-C0598934
.	O
	
applying	O
this	O
intratumoral	B-C1831733
treatment	I-C1831733
strategy	O
may	O
potentially	O
decrease	B-C0547047
the	O
extent	O
of	O
surgical	B-C0728940
excision	I-C0728940
.	O
	
spinal	B-C0037949
load	B-C1318107
in	O
nurses	B-C0028661
during	O
emergency	B-C0013956
lifting	B-C0206244
of	O
obese	B-C0028754
patients	B-C0030705
preliminary	B-C1548161
results	I-C1548161
nurses	B-C0028661
are	O
exposed	O
to	O
the	O
risk	B-C0035647
of	O
injury	B-C3263722
while	O
handling	B-C1832073
patients	B-C0030705
.	O
	
this	O
is	O
particularly	O
true	O
for	O
obese	B-C0028754
patients	B-C0030705
.	O
	
the	O
goal	B-C0018017
of	O
this	O
paper	O
is	O
to	O
estimate	B-C0750572
the	O
spinal	B-C0037949
loads	B-C1318107
and	O
the	O
related	O
risk	B-C0035647
of	O
injury	B-C3263722
to	O
nurses	B-C0028661
while	O
lifting	B-C0206244
obese	B-C0028754
patients	B-C0030705
from	O
the	O
floor	B-C0016249
with	O
a	O
bariatric	B-C0183235
sheet	I-C0183235
during	O
a	O
hospital	B-C0019994
emergency	B-C0013956
.	O
	
six	O
male	B-C0086582
nurses	B-C0028661
participated	O
in	O
this	O
study	B-C2603343
.	O
	
the	O
biomechanical	B-C0430022
analysis	I-C0430022
focused	O
on	O
the	O
lifting	B-C0206244
strategy	O
.	O
	
thirty	O
obese	B-C0028754
in-patients	B-C0021562
were	O
enrolled	O
to	O
take	O
part	O
in	O
the	O
experimental	B-C0681814
study	I-C0681814
and	O
divided	O
into	O
three	O
groups	B-C0441833
according	O
to	O
their	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
.	O
	
three-dimensional	B-C0430022
motion	I-C0430022
analysis	I-C0430022
was	O
conducted	O
using	O
an	O
optoelectronic	B-C0025080
system	I-C0025080
.	O
	
the	O
trunk	B-C0460005
kinematics	B-C0600169
and	O
the	O
loading	B-C1318107
on	O
the	O
spines	B-C0037949
of	O
the	O
operating	O
nurses	B-C0028661
were	O
computed	B-C1441526
.	O
	
our	O
data	B-C1511726
showed	O
that	O
when	O
the	O
nurse	B-C0028661
was	O
operating	O
from	O
the	O
central	O
handle	O
,	O
his	O
trunk	B-C0460005
was	O
more	O
flexed	B-C0231452
at	O
the	O
end	O
of	O
the	O
lift	B-C0206244
with	O
a	O
reduced	B-C0392756
range	B-C2607871
of	I-C2607871
motion	I-C2607871
.	O
	
the	O
values	B-C1522609
were	O
higher	B-C0205250
when	O
the	O
nurse	B-C0028661
lifted	O
patients	B-C0030705
with	O
higher	B-C0205250
bmis	B-C1305855
.	O
	
all	O
kinetic	B-C1706312
parameters	I-C1706312
and	O
tension	B-C0026841
in	O
the	O
lumbar	B-C0224323
muscles	I-C0224323
at	O
the	O
end	O
of	O
the	O
movement	B-C0026649
were	O
characterised	O
by	O
lower	B-C0205251
values	B-C1522609
for	O
the	O
nurse	B-C0028661
placed	O
beside	O
the	O
patient's	B-C0030705
head	B-C0018670
or	O
feet	B-C0016504
if	O
compared	O
to	O
the	O
operator	O
positioned	O
beside	O
the	O
central	O
handle	O
in	O
all	O
patient	B-C0030705
groups	I-C0030705
.	O
	
our	O
preliminary	O
data	B-C1511726
suggest	O
that	O
only	O
the	O
reaction	O
load	B-C1318107
on	O
the	O
spine	B-C0037949
of	O
the	O
nurse	B-C0028661
holding	O
the	O
central	O
handle	O
,	O
closest	O
to	O
the	O
patient's	B-C0030705
centre	O
of	O
mass	O
,	O
seems	O
to	O
exceed	O
the	O
recommended	B-C0034866
safety	B-C0036043
limits	B-C0439801
.	O
	
expectations	B-C0679138
for	O
the	O
methodology	B-C3266812
and	O
translation	B-C0242481
of	O
animal	B-C0003048
research	I-C0003048
a	O
survey	B-C0038951
of	O
the	O
general	B-C0683971
public	I-C0683971
,	O
medical	B-C0038495
students	I-C0038495
and	O
animal	B-C0003062
researchers	B-C0035173
in	O
north	B-C0028405
america	I-C0028405
to	O
determine	O
what	O
are	O
considered	O
acceptable	B-C1879533
standards	B-C0038137
for	O
animal	B-C0003048
research	I-C0003048
ar	B-C0003048
methodology	B-C3266812
and	O
translation	B-C1521828
rate	I-C1521828
to	O
humans	B-C0086418
,	O
a	O
validated	O
survey	B-C0038951
was	O
sent	O
to	O
a	O
a	O
sample	O
of	O
the	O
general	B-C0683971
public	I-C0683971
,	O
via	O
sampling	B-C1552679
survey	I-C1552679
international	I-C1552679
ssi	B-C1552679
canada	B-C0006823
,	O
amazon	B-C1552679
mechanical	I-C1552679
turk	I-C1552679
amt	B-C1552679
usa	B-C0041703
,	O
a	O
canadian	B-C0006823
city	I-C0006823
festival	B-C0015922
cf	B-C0015922
and	O
a	O
canadian	B-C0006823
children's	B-C0020017
hospital	I-C0020017
ch	B-C0020017
b	O
a	O
sample	O
of	O
medical	B-C0038495
students	I-C0038495
two	O
first-year	O
classes	O
and	O
c	O
a	O
sample	O
of	O
scientists	B-C0402112
corresponding	O
authors	B-C3812881
and	O
academic	B-C1510747
paediatricians	B-C0237433
.	O
	
there	O
were	O
1379	O
responses	B-C0871261
from	O
the	O
general	B-C0683971
public	I-C0683971
sample	O
ssi	B-C1552679
,	O
n	O
=	O
557	O
amt	B-C1552679
,	O
n	O
=	O
590	O
cf	B-C0015922
,	O
n	O
=	O
195	O
ch	B-C0020017
,	O
n	O
=	O
102	O
,	O
205/330	O
62%	O
medical	B-C0038495
student	I-C0038495
responses	B-C0871261
,	O
and	O
23/323	O
7%	O
,	O
too	O
few	O
to	O
report	O
scientist	B-C0402112
responses	B-C0871261
.	O
	
asked	O
about	O
methodological	B-C0815254
quality	I-C0815254
,	O
most	O
of	O
the	O
general	B-C0683971
public	I-C0683971
and	O
medical	B-C0038495
student	I-C0038495
respondents	B-C0282122
expect	O
that	O
ar	B-C0003048
is	O
of	O
high	B-C0332306
quality	I-C0332306
e.g	O
.	O
	
anaesthesia	B-C0002903
and	O
analgesia	B-C0002766
are	O
monitored	O
,	O
even	O
overnight	O
,	O
and	O
'humane'	O
euthanasia	B-C0015187
,	O
optimal	B-C2698651
statistical	B-C0681864
design	I-C0681864
,	O
comprehensive	B-C1880156
literature	B-C0282441
review	I-C0282441
,	O
randomisation	B-C0034656
and	O
blinding	B-C0150108
,	O
are	O
performed	O
,	O
and	O
costs	B-C0010186
and	O
difficulty	O
are	O
not	O
acceptable	B-C1879533
justifications	B-C0392360
for	O
lower	B-C0332306
quality	I-C0332306
e.g	O
.	O
	
costs	B-C0010186
of	O
expert	O
consultation	B-C0009818
,	O
or	O
more	O
laboratory	B-C0025106
staff	I-C0025106
.	O
	
asked	O
about	O
their	O
expectations	B-C0679138
of	O
translation	B-C0242481
to	O
humans	B-C0086418
of	O
toxicity	B-C0600688
,	O
carcinogenicity	B-C0858970
,	O
teratogenicity	B-C0232910
and	O
treatment	B-C0039798
findings	B-C2607943
,	O
most	O
expect	O
translation	B-C0242481
more	O
than	O
60%	O
of	O
the	O
time	O
.	O
	
if	O
translation	B-C0242481
occurred	O
less	O
than	O
20%	O
of	O
the	O
time	O
,	O
a	O
minority	B-C0026192
disagreed	O
that	O
this	O
would	O
"""significantly"	O
reduce	O
your	O
support	O
for	O
ar	B-C0003048
""""	O
.	O
	
medical	B-C0038495
students	I-C0038495
were	O
more	O
supportive	B-C1521721
of	O
ar	B-C0003048
,	O
even	O
if	O
translation	B-C0242481
occurred	O
less	O
than	O
20%	O
of	O
the	O
time	O
.	O
	
expectations	B-C0679138
for	O
ar	B-C0003048
are	O
much	O
higher	O
than	O
empirical	B-C1511726
data	I-C1511726
predicting	B-C0681842
violence	B-C0042693
and	O
recidivism	B-C0680458
in	O
a	O
large	O
sample	O
of	O
males	B-C0086582
on	O
probation	B-C0687758
or	O
parole	B-C0814701
this	O
study	B-C2603343
evaluated	B-C1550157
the	O
utility	O
of	O
items	O
and	O
scales	O
from	O
the	O
iowa	B-C0022037
violence	B-C0042693
and	O
victimization	B-C0376695
instrument	B-C0038951
in	O
a	O
sample	O
of	O
1961	O
males	B-C0086582
from	O
the	O
state	O
of	O
iowa	B-C0022037
who	O
were	O
on	O
probation	B-C0687758
or	O
released	B-C0425147
from	I-C0425147
prison	I-C0425147
to	O
parole	B-C0814701
supervision	B-C1273870
.	O
	
this	O
is	O
the	O
first	O
study	B-C2603343
to	O
examine	O
the	O
potential	B-C3245505
of	O
the	O
iowa	B-C0022037
violence	B-C0042693
and	O
victimization	B-C0376695
instrument	B-C0038951
to	O
predict	B-C0681842
criminal	B-C0680468
offenses	I-C0680468
.	O
	
the	O
males	B-C0086582
were	O
followed	O
for	O
30	O
months	B-C0439231
immediately	O
following	O
their	O
admission	B-C0457453
to	O
probation	B-C0687758
or	O
parole	B-C0814701
.	O
	
auc	B-C0376690
analyses	B-C0936012
indicated	O
fair	O
to	O
good	O
predictive	B-C0681890
power	O
for	O
the	O
iowa	B-C0022037
violence	B-C0042693
and	O
victimization	B-C0376695
instrument	B-C0038951
for	O
charges	O
of	O
violence	B-C0042693
and	O
victimization	B-C0376695
,	O
but	O
chance	O
predictive	B-C0681890
power	O
for	O
drug	B-C0680484
offenses	I-C0680484
.	O
	
notably	O
,	O
both	O
scales	O
of	O
the	O
instrument	B-C0038951
performed	O
equally	O
well	O
at	O
the	O
30-	O
month	B-C0439231
follow-up	B-C1522577
.	O
	
items	O
on	O
the	O
iowa	B-C0022037
violence	B-C0042693
and	O
victimization	B-C0376695
instrument	B-C0038951
not	O
only	O
predicted	B-C0681842
violence	B-C0042693
,	O
but	O
are	O
straightforward	O
to	O
score	O
.	O
	
violence	B-C0042693
management	O
strategies	O
are	O
discussed	O
as	O
they	O
relate	O
to	O
the	O
current	B-C0521116
findings	B-C2607943
,	O
including	O
the	O
potential	B-C3245505
to	O
expand	B-C0205229
the	O
measure	O
to	O
other	O
jurisdictions	B-C0680647
and	O
prognostic	B-C1514474
significance	I-C1514474
of	O
non-hpv16	B-C0017431
genotypes	I-C0017431
in	O
oropharyngeal	B-C0280313
squamous	I-C0280313
cell	I-C0280313
carcinoma	I-C0280313
recent	O
studies	O
have	O
found	O
that	O
cases	O
with	O
oropharyngeal	B-C0280313
squamous	I-C0280313
cell	I-C0280313
carcinoma	I-C0280313
opscc	B-C0280313
positive	B-C4288937
for	O
hpv16	B-C3872681
genotype	I-C3872681
have	O
better	B-C0332272
overall	B-C4086681
survival	I-C4086681
compared	B-C1707455
with	O
cases	O
positive	O
for	O
other	O
hpv	B-C0807283
genotypes	I-C0807283
.	O
	
we	O
sought	O
to	O
further	O
replicate	B-C1883725
these	O
studies	O
and	O
determine	O
if	O
this	O
relationship	O
is	O
modified	B-C0205349
by	I-C0205349
expression	B-C1171362
of	O
p16	B-C0249880
tumor	I-C0249880
suppressor	I-C0249880
protein	I-C0249880
.	O
	
we	O
identified	O
238	O
opscc	B-C0280313
cases	O
from	O
the	O
carolina	B-C1516225
head	I-C1516225
and	I-C1516225
neck	I-C1516225
cancer	I-C1516225
study	I-C1516225
chance	B-C1516225
study	O
,	O
a	O
population	B-C1709599
based	I-C1709599
case-control	I-C1709599
study	I-C1709599
.	O
	
tumors	B-C0027651
that	O
tested	O
positive	B-C4288937
solely	I-C4288937
for	O
hpv16	B-C3872681
genotype	I-C3872681
and	O
no	O
other	O
genotypes	B-C0017431
with	O
pcr	B-C0032520
were	O
classified	B-C0008902
as	O
hpv16-positive	B-C4288937
.	O
	
tumors	B-C0027651
positive	B-C4288937
for	I-C4288937
any	O
other	O
high-risk	B-C0332167
hpv	B-C3872595
genotype	I-C3872595
were	O
classified	B-C0008902
as	O
non-hpv16-positive	B-C4288937
.	O
	
expression	B-C1171362
of	O
p16	B-C0249880
in	O
the	O
tumor	B-C0027651
was	O
determined	B-C0521095
with	O
immunohistochemistry	B-C0021044
.	O
	
follow-up	O
time	O
was	O
calculated	O
from	O
the	O
date	B-C2316983
of	I-C2316983
diagnosis	I-C2316983
to	O
date	B-C1148348
of	I-C1148348
death	I-C1148348
or	O
december	O
31	O
,	O
2013	O
.	O
	
overall	B-C4086681
survival	I-C4086681
was	O
compared	O
with	O
the	O
kaplan-meier	B-C1720944
curves	I-C1720944
and	O
log-rank	B-C0242928
test	I-C0242928
.	O
	
hazard	B-C2985465
ratios	I-C2985465
hr	B-C2985465
adjusted	O
for	O
smoking	B-C0037369
,	O
alcohol	B-C0001948
use	I-C0001948
,	O
sex	B-C0079399
,	O
race	B-C0034510
,	O
and	O
age	B-C0001779
was	O
calculated	O
with	O
the	O
cox	B-C0010235
proportional	I-C0010235
hazard	I-C0010235
regression	I-C0010235
.	O
	
cases	O
with	O
hpv16-positive	B-C4288937
opscc	B-C0280313
had	O
better	B-C0332272
overall	B-C4086681
survival	I-C4086681
than	O
cases	O
with	O
non-hpv16-positive	B-C4288937
opscc	B-C0280313
log-rank	O
p-value	O
0.010	O
.	O
	
when	O
restricted	O
to	O
opscc	B-C0280313
cases	O
positive	B-C1446409
for	O
p16	B-C1171362
expression	I-C1171362
,	O
the	O
same	O
trend	B-C1521798
continued	O
log-rank	O
p-value	O
0.002	O
.	O
	
in	O
the	O
adjusted	O
model	O
,	O
cases	O
with	O
non-hpv16-positive	B-C4288937
opscc	B-C0280313
had	O
greater	B-C0332167
risk	I-C0332167
of	I-C0332167
death	B-C1306577
compared	O
to	O
cases	O
with	O
hpv16-positive	B-C4288937
tumors	B-C0027651
hr	B-C2985465
1.92	O
95%	O
ci	O
1.03	O
,	O
3.60	O
.	O
	
this	O
finding	B-C0243095
indicates	B-C1444656
that	O
hpv	B-C0021344
genotyping	B-C2368152
carries	O
valuable	B-C1514474
prognostic	I-C1514474
significance	I-C1514474
in	O
addition	O
to	O
p16	B-C0249880
status	B-C0449438
and	O
future	O
survival	O
studies	O
of	O
opscc	B-C0280313
should	O
take	O
into	O
account	O
differing	O
hpv	B-C0807283
genotypes	I-C0807283
.	O
	
randomized	B-C0206034
trials	I-C0206034
of	O
the	O
teen	B-C0205653
outreach	B-C0871024
program	I-C0871024
in	O
louisiana	B-C0024024
and	O
rochester	B-C0017446
,	O
new	B-C0027976
york	I-C0027976
to	O
evaluate	B-C0220825
the	O
teen	B-C0205653
outreach	B-C0871024
program	I-C0871024
,	O
a	O
pregnancy	B-C0679784
prevention	I-C0679784
program	B-C0679717
,	O
in	O
2	O
community	B-C0009462
-based	O
settings	O
.	O
	
we	O
evaluated	B-C0220825
the	O
teen	B-C0205653
outreach	B-C0871024
program	I-C0871024
,	O
a	O
9-month	O
positive	B-C1709697
youth	I-C1709697
development	I-C1709697
program	I-C1709697
,	O
in	O
3	O
cohorts	B-C0599755
of	O
youths	B-C0087178
from	O
2012	O
to	O
2015	O
in	O
2	O
states	B-C1301808
.	O
	
in	O
louisiana	B-C0024024
,	O
7	O
agencies	B-C0237463
participated	O
in	O
an	O
individualized	B-C1881197
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
,	O
with	O
youths	B-C0087178
randomly	O
assigned	O
to	O
a	O
treatment	B-C0087111
or	O
control	B-C0009932
condition	I-C0009932
.	O
	
fourteen	O
agencies	B-C0237463
in	O
rochester	B-C0017446
,	O
new	B-C0027976
york	I-C0027976
,	O
participated	O
in	O
a	O
cluster	B-C1704332
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
.	O
	
we	O
found	O
no	B-C3842396
differences	I-C3842396
between	O
the	O
intervention	B-C0184661
and	O
control	B-C0009932
youths	I-C0009932
on	O
delay	B-C0205421
of	O
sexual	B-C0036864
onset	B-C0332162
in	O
louisiana	B-C0024024
adjusted	B-C0028873
odds	I-C0028873
ratio	I-C0028873
aor	B-C0028873
=	O
0.80	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
=	O
0.62	O
,	O
1.03	O
or	O
in	O
rochester	B-C0017446
,	O
new	B-C0027976
york	I-C0027976
aor	B-C0028873
=	O
0.89	O
95%	O
ci	B-C0009667
=	O
0.45	O
,	O
1.77	O
,	O
or	O
for	O
sex	B-C0009253
with	O
no	O
effective	O
means	O
of	O
birth	B-C0009871
control	I-C0009871
louisiana	B-C0024024
,	O
aor	B-C0028873
=	O
1.18	O
95%	O
ci	B-C0009667
=	O
0.78	O
,	O
1.78	O
rochester	B-C0017446
,	O
aor	B-C0028873
=	O
0.41	O
95%	O
ci	B-C0009667
=	O
0.13	O
,	O
1.27	O
after	O
controlling	B-C2239193
for	O
relevant	O
covariates	B-C1705098
.	O
	
we	O
found	O
no	B-C1513916
short-term	B-C0443303
effects	B-C1280500
for	O
the	O
offer	O
of	O
the	O
intervention	B-C0184661
.	O
	
research	B-C0035168
might	O
be	O
needed	O
for	O
the	O
long-term	B-C0023983
and	O
intermediate	B-C1280500
impacts	I-C1280500
of	O
youth	B-C1709697
development	I-C1709697
programs	I-C1709697
on	O
these	O
and	O
other	O
adolescent	B-C0205653
risk	B-C0086931
behaviors	I-C0086931
.	O
	
a	O
single	B-C1883016
session	I-C1883016
of	O
exhaustive	B-C0015259
exercise	I-C0015259
markedly	O
decreases	B-C0547047
circulating	B-C0175630
levels	O
of	O
guanidinoacetic	B-C0061626
acid	I-C0061626
in	O
healthy	B-C3898900
men	B-C0025266
and	O
women	B-C0043210
we	O
evaluated	B-C0220825
the	O
effects	B-C1704420
of	I-C1704420
exercise	B-C0015259
on	O
circulating	B-C0175630
concentrations	B-C0457929
of	O
guanidinoacetic	B-C0061626
acid	I-C0061626
gaa	B-C0061626
and	O
creatine	B-C0010286
in	O
23	O
healthy	B-C3661466
volunteers	I-C3661466
subjected	O
to	O
running	B-C0035953
to	O
exhaustion	B-C0392674
and	O
free-weight	B-C0015259
bench-press	I-C0015259
to	O
volitional	B-C0026606
failure	I-C0026606
.	O
	
blood	B-C0005767
was	O
taken	O
before	O
and	O
following	O
each	O
exercise	B-C0015259
session	B-C1883016
.	O
	
running	B-C0035953
induced	B-C0205263
a	O
significant	O
decrease	B-C0547047
in	O
serum	B-C0229671
gaa	B-C0061626
by	O
20.1	O
p	O
<	O
0.001	O
,	O
while	O
free-weight	B-C0015259
exercise	I-C0015259
reduced	B-C0392756
gaa	B-C0061626
by	O
11.7	O
p	O
<	O
0.001	O
,	O
suggesting	O
the	O
possible	O
use	O
of	O
serum	B-C0229671
gaa	B-C0061626
as	O
a	O
novel	O
biomarker	B-C0005516
of	O
anti-helminthic	B-C0003158
activity	B-C0205177
of	O
momordica	B-C0330482
charantia	I-C0330482
l	I-C0330482
.	O
	
against	O
fasciola	B-C3662687
hepatica	I-C3662687
eggs	I-C3662687
after	O
twelve	O
days	B-C0439228
of	O
incubation	B-C1439852
in	B-C1533691
vitro	I-C1533691
fasciolosis	B-C0015652
,	O
a	O
parasitic	B-C0030499
disease	I-C0030499
caused	O
by	O
the	O
trematode	B-C0040818
fasciola	B-C0015648
hepatica	I-C0015648
underreported	O
is	O
expanding	O
both	O
in	O
human	B-C0086418
and	O
animal	B-C1318101
population	I-C1318101
,	O
throughout	O
the	O
world	B-C2700280
.	O
	
the	O
constant	O
use	O
of	O
synthetic	B-C0259849
drugs	I-C0259849
to	O
treat	B-C0087111
this	O
condition	B-C0012634
has	O
led	O
to	O
the	O
natural	B-C0086685
selection	I-C0086685
of	O
resistant	B-C0332325
strains	B-C1518614
of	O
the	O
parasite	B-C0030498
.	O
	
hence	O
,	O
there	O
is	O
a	O
growing	O
focus	O
on	O
the	O
potential	O
anti-helminthic	B-C0003158
properties	B-C1292721
of	O
medicinal	B-C0032100
plants	I-C0032100
and	O
phytopharmaceuticals	B-C0577749
.	O
	
the	O
current	O
study	B-C2603343
assessed	O
the	O
potential	O
anti-fasciolicide	B-C0205245
action	B-C3266814
of	O
momordica	B-C0330482
charantia	I-C0330482
leaf	B-C0242724
extracts	B-C0032081
and	O
fractions	B-C1264633
on	O
the	O
eggs	B-C3662687
of	I-C3662687
f	I-C3662687
.	O
	
hepatica	I-C3662687
parasites	I-C3662687
.	O
	
the	O
lyophilized	B-C0205222
crude	B-C1258023
extract	I-C1258023
ce	B-C1258023
of	O
m	B-C0330482
.	O
	
charantia	I-C0330482
leaves	I-C0330482
and	O
its	O
sub-fractions	B-C1264633
,	O
obtained	O
from	O
liquid-liquid	B-C3178840
partitioning	I-C3178840
with	O
organic	B-C0360100
solvents	I-C0360100
,	O
were	O
analysed	B-C0936012
by	O
high	B-C0008562
performance	I-C0008562
liquid	I-C0008562
chromatography	I-C0008562
hplc	B-C0008562
,	O
suspended	B-C1553389
in	O
1%	O
dmso	B-C0012403
and	O
used	O
in	B-C1533691
in	O
vitro	I-C1533691
tests	B-C0022885
.	O
	
quadruplicates	B-C0205175
of	O
50	O
f	B-C3662687
.	O
	
hepatica	I-C3662687
eggs	I-C3662687
were	O
incubated	B-C1439852
at	O
23	O
with	O
m	B-C0330482
.	O
	
charantia	I-C0330482
leaf	B-C0242724
ce	B-C1258023
in	O
different	O
concentrations	B-C1446561
.	O
	
after	O
12	O
days	B-C0439228
no	O
larvae	B-C0023047
were	O
formed	O
in	O
eggs	B-C3662687
incubated	B-C1439852
with	O
ce	B-C1258023
concentrations	B-C1446561
above	O
12.5mg	O
.	O
	
eggs	B-C3662687
incubated	B-C1439852
with	O
ce	B-C1258023
sub-fractions	B-C1264633
at	O
concentrations	B-C1446561
of	O
1000	O
,	O
100	O
,	O
10	O
,	O
1	O
,	O
0.1	O
,	O
0.01μg	O
affected	B-C0392760
embryonic	B-C0013936
development	I-C0013936
,	O
with	O
n-butanol	B-C0089147
presenting	O
the	O
strongest	O
inhibition	B-C3463820
of	O
miracidia	B-C0023047
formation	B-C1522492
.	O
	
in	O
contrast	O
,	O
on	O
the	O
12th	O
day	O
,	O
90%	O
of	O
the	O
miracidia	B-C0023047
hatched	B-C0598016
in	O
the	O
control	B-C0009932
experiments	I-C0009932
using	O
0.03	O
dmso	B-C0012403
whereas	O
embryogenesis	B-C0013936
was	O
completely	O
abolished	B-C2746065
with	O
any	O
concentration	B-C1446561
of	O
albendazole	B-C0051091
sulphoxide	I-C0051091
abz	B-C0051091
.	O
	
chemical	B-C3495389
analysis	I-C3495389
of	O
the	O
ce	B-C1258023
and	O
sub-fractions	B-C1264633
revealed	O
a	O
prominent	O
presence	O
of	O
flavonoids	B-C0596577
.	O
	
hplc-ms	B-C3641325
confirmed	O
quercetin	B-C0034392
to	O
be	O
one	O
of	O
the	O
main	O
flavonoids	B-C0596577
present	O
in	O
the	O
ce	B-C1258023
and	O
the	O
n-butanol	B-C0089147
subfraction	B-C1264633
.	O
	
this	O
is	O
the	O
first	O
study	B-C2603343
to	O
analyse	B-C0936012
the	O
potential	O
anti-fasciolicide	B-C0205245
action	B-C3266814
of	O
m	B-C0330482
.	O
	
charantia	I-C0330482
leaf	B-C0242724
ce	B-C1258023
and	O
dabigatran	B-C2348066
a	O
new	O
oral	B-C0354604
anticoagulant	I-C0354604
.	O
	
guidelines	B-C0162791
to	O
follow	O
in	O
oral	B-C0524861
surgery	I-C0524861
procedures	I-C0524861
.	O
	
a	O
systematic	O
review	B-C0282441
of	I-C0282441
the	I-C0282441
literature	I-C0282441
dabigatran	B-C2348066
is	O
a	O
newly	O
commercialized	O
drug	B-C1254351
that	O
is	O
replacing	O
other	O
anticoagulants	B-C0003280
in	O
the	O
prevention	O
of	O
venous	B-C1861172
thromboembolism	I-C1861172
,	O
stroke	B-C0038454
and	O
systemic	B-C0149876
arterial	I-C0149876
valve	I-C0149876
embolism	I-C0149876
.	O
	
it	O
acts	O
directly	O
on	O
thrombin	B-C0040018
presenting	O
in	O
a	O
dynamic	O
and	O
predictable	O
way	O
,	O
which	O
does	O
not	O
require	O
monitoring	O
these	O
patients	B-C0030705
.	O
	
therefore	O
,	O
we	O
consider	O
the	O
need	O
to	O
assess	O
whether	O
their	O
use	O
increases	B-C0442805
the	O
risk	B-C3251812
of	I-C3251812
bleeding	I-C3251812
involved	O
before	O
any	O
dental	B-C0011331
treatment	I-C0011331
.	O
	
we	O
performed	O
a	O
systematic	O
review	O
with	O
a	O
bibliographic	B-C0260071
search	I-C0260071
in	O
pubmed	B-C1138432
/	O
medline	B-C0025141
along	O
with	O
the	O
cochrane	B-C0023625
library	I-C0023625
.	O
	
we	O
excluded	O
articles	O
dealing	O
with	O
all	O
anticoagulants	B-C0003280
other	O
than	O
dabigatran	B-C2348066
,	O
and	O
works	O
about	O
surgical	B-C0543467
treatments	I-C0543467
in	O
anatomical	B-C0923870
locations	I-C0923870
other	O
than	O
the	O
oral	B-C0226896
cavity	I-C0226896
.	O
	
we	O
included	O
a	O
total	O
of	O
13	O
papers	O
of	O
which	O
1	O
was	O
a	O
randomized	B-C0206034
clinical	I-C0206034
trial	I-C0206034
,	O
9	O
narrative	B-C0815257
literature	I-C0815257
reviews	I-C0815257
,	O
1	O
case	B-C0150093
series	I-C0150093
,	O
2	O
clinical	B-C1706256
cases	I-C1706256
and	O
1	O
expert	B-C0600219
opinion	I-C0600219
.	O
	
because	O
we	O
did	O
not	O
obtain	O
any	O
properly	O
designed	O
clinical	B-C0008976
trials	I-C0008976
,	O
we	O
were	O
unable	O
to	O
conduct	O
a	O
meta-analysis	B-C0920317
.	O
	
currently	O
,	O
there	O
is	O
no	O
consensus	B-C0376298
on	O
the	O
procedure	B-C0543467
to	O
be	O
followed	O
in	O
patients	B-C0030705
taking	O
dabigatran	B-C2348066
.	O
	
however	O
,	O
all	O
authors	O
agree	O
to	O
treat	O
each	O
case	O
individually	O
in	O
accordance	O
to	O
the	O
risk	B-C0035647
of	O
embolism	B-C0013922
,	O
postoperative	B-C0032788
bleeding	I-C0032788
and	O
renal	B-C0232804
function	I-C0232804
.	O
	
also	O
,	O
it	O
is	O
necessary	O
to	O
perform	O
minimally	O
invasive	B-C4048276
interventions	I-C4048276
,	O
and	O
take	O
the	O
appropriate	O
local	O
anti-hemolytic	B-C0199176
measures	I-C0199176
.	O
	
did	O
fidelis	B-C0282574
projects	B-C1709701
contribute	B-C1880177
to	O
the	O
detection	B-C0442726
of	O
new	O
smear	B-C2019329
-	O
positive	B-C1514241
pulmonary	B-C0041327
tuberculosis	I-C0041327
cases	O
in	O
china	B-C0008115
setting	O
the	O
first	B-C0282574
phase	I-C0282574
of	I-C0282574
the	I-C0282574
fund	I-C0282574
for	I-C0282574
innovative	I-C0282574
dots	I-C0282574
expansion	I-C0282574
through	I-C0282574
local	I-C0282574
initiatives	I-C0282574
to	I-C0282574
stop	I-C0282574
tb	I-C0282574
fidelis	B-C0282574
projects	B-C1709701
in	O
china	B-C0008115
started	O
in	O
2003	O
.	O
	
objective	O
to	O
determine	O
whether	O
the	O
fidelis	B-C0282574
projects	B-C1709701
contribute	B-C1880177
d	O
to	O
the	O
increased	B-C0205217
case	B-C0868928
detection	B-C0442726
rate	B-C1521828
for	O
new	O
smear	B-C2019329
-	O
positive	B-C1514241
pulmonary	B-C0041327
tuberculosis	I-C0041327
ptb	B-C0041327
in	O
china	B-C0008115
.	O
	
methods	O
we	O
compared	B-C1707455
the	O
case	B-C1521828
notification	I-C1521828
rates	I-C1521828
cnrs	B-C1521828
in	O
the	O
intervention	B-C0439234
year	I-C0439234
with	O
those	O
of	O
the	O
previous	B-C0205156
year	B-C0439234
in	O
the	O
fidelis	B-C0282574
areas	B-C0017446
,	O
then	O
compared	B-C1707455
the	O
difference	B-C1705242
between	O
the	O
cnrs	B-C1521828
of	O
the	O
intervention	B-C0439234
year	I-C0439234
and	O
the	O
previous	B-C0205156
year	B-C0439234
in	O
the	O
fidelis	B-C0282574
areas	B-C0017446
with	O
those	O
in	O
the	O
non-fi-delis	B-C0243095
areas	B-C0017446
within	O
the	O
province	B-C1514578
.	O
	
results	O
there	O
was	O
an	O
increase	B-C0442805
in	O
the	O
cnr	B-C1521828
in	O
the	O
intervention	B-C0439234
year	I-C0439234
compared	B-C1707455
with	O
the	O
previous	B-C0205156
year	B-C0439234
for	O
all	O
the	O
project	B-C1709701
sites	O
.	O
	
the	O
differences	B-C1705242
between	O
the	O
cnr	B-C1521828
in	O
the	O
intervention	B-C0439234
year	I-C0439234
and	O
the	O
previous	B-C0205156
year	B-C0439234
ranged	B-C1514721
from	O
6.4	O
to	O
31.1	O
per	O
100	O
000	O
population	B-C1257890
in	O
the	O
fidelis	B-C0282574
areas	B-C0017446
and	O
from	O
2.9	O
to	O
20.4	O
000	O
in	O
the	O
non-fidelis	B-C0243095
areas	B-C0017446
.	O
	
differences	B-C1705242
-in-	O
differences	B-C1705242
analysis	B-C0936012
shows	O
that	O
the	O
differences	B-C1705242
in	O
the	O
cnrs	B-C1521828
in	O
the	O
fidelis	B-C0282574
areas	B-C0017446
were	O
not	O
statistically	B-C0237881
significantly	I-C0237881
different	B-C1705242
from	O
those	O
in	O
the	O
non-	O
fidelis	B-C0282574
areas	B-C0017446
p	O
=	O
0.393	O
.	O
	
conclusion	O
the	O
fidelis	B-C0282574
projects	B-C1709701
may	O
have	O
contributed	B-C1880177
to	O
the	O
increase	B-C0442805
in	O
case	B-C0868928
detection	B-C0442726
of	O
new	O
smear	B-C2019329
-	O
positive	B-C1514241
ptb	B-C0041327
in	O
china	B-C0008115
,	O
but	O
the	O
level	B-C0441889
of	O
evidence	B-C3887511
is	O
liver	B-C0163315
fatty	I-C0163315
acid	I-C0163315
binding	I-C0163315
protein	I-C0163315
deficiency	B-C0011155
provokes	O
oxidative	B-C0242606
stress	I-C0242606
,	O
inflammation	B-C0021368
,	O
and	O
apoptosis	B-C0162638
-mediated	O
hepatotoxicity	B-C0235378
induced	B-C0205263
by	O
pyrazinamide	B-C0034239
in	O
zebrafish	B-C0043457
larvae	B-C0023047
pyrazinamide	B-C0034239
pza	B-C0034239
is	O
an	O
essential	B-C0205224
antitubercular	B-C0003448
drug	I-C0003448
,	O
but	O
little	O
is	O
still	O
known	O
about	O
its	O
hepatotoxicity	B-C0235378
potential	B-C3245505
.	O
	
this	O
study	O
examined	O
the	O
effects	B-C1704420
of	I-C1704420
pza	B-C0034239
exposure	B-C0332157
on	O
zebrafish	B-C0043457
danio	B-C0043457
rerio	I-C0043457
larvae	B-C0023047
and	O
the	O
mechanisms	O
underlying	O
its	O
hepatotoxicity	B-C0235378
.	O
	
a	O
transgenic	B-C0282641
line	I-C0282641
of	O
zebrafish	B-C0043457
larvae	B-C0023047
that	O
expressed	B-C1171362
enhanced	B-C1258415
green	I-C1258415
fluorescent	I-C1258415
protein	I-C1258415
egfp	B-C1258415
in	O
the	O
liver	B-C0023884
was	O
incubated	B-C1439852
with	O
1	O
,	O
2.5	O
,	O
and	O
5	O
mm	O
pza	B-C0034239
from	O
72	O
h	O
postfertilization	B-C0015914
hpf	O
.	O
	
different	O
endpoints	B-C2349179
such	O
as	O
mortality	B-C0205848
,	O
morphology	B-C0700329
changes	B-C0392747
in	O
the	O
size	B-C1450569
and	O
shape	B-C0332479
of	O
the	O
liver	B-C0023884
,	O
histological	B-C0019638
changes	B-C0392747
,	O
transaminase	B-C0919834
analysis	I-C0919834
and	O
apoptosis	B-C0162638
,	O
markers	B-C0005516
of	O
oxidative	B-C0242606
and	O
genetic	B-C0012860
damage	I-C0012860
,	O
as	O
well	O
as	O
the	O
expression	B-C0017262
of	O
certain	O
genes	B-C0017337
were	O
selected	O
to	O
evaluate	B-C0220825
pza	B-C0034239
-	O
induced	B-C0205263
hepatotoxicity	B-C0235378
.	O
	
our	O
results	O
confirm	B-C0750484
the	O
manner	O
of	O
pza	B-C0034239
dose-dependent	B-C1512045
hepatotoxicity	B-C0235378
.	O
	
pza	B-C0034239
was	O
found	O
to	O
induce	B-C0205263
marked	B-C1706089
injury	B-C3263723
in	O
zebrafish	B-C0043457
larvae	B-C0023047
,	O
such	O
as	O
liver	B-C0391996
atrophy	I-C0391996
,	O
elevations	B-C0438717
of	I-C0438717
transaminase	I-C0438717
levels	I-C0438717
,	O
oxidative	B-C0242606
stress	I-C0242606
,	O
and	O
hepatocyte	B-C3269241
apoptosis	I-C3269241
.	O
	
to	O
further	O
understand	O
the	O
mechanism	O
behind	O
pza	B-C0034239
-	O
induced	B-C0205263
hepatotoxicity	B-C0235378
,	O
changes	B-C0392747
in	O
gene	B-C3244092
expression	I-C3244092
levels	I-C3244092
in	O
zebrafish	B-C0043457
larvae	B-C0023047
exposed	B-C0332157
to	I-C0332157
pza	B-C0034239
for	O
72	O
h	O
postexposure	B-C0332157
hpe	O
were	O
determined	O
.	O
	
the	O
results	O
of	O
this	O
study	O
demonstrated	O
that	O
pza	B-C0034239
decreased	B-C0205216
the	O
expression	B-C3244092
levels	I-C3244092
of	O
liver	B-C0163315
fatty	I-C0163315
acid	I-C0163315
binding	I-C0163315
protein	I-C0163315
l-fabp	B-C0163315
and	O
its	O
target	B-C1332838
gene	I-C1332838
,	O
peroxisome	B-C0166415
proliferator-activated	I-C0166415
receptor	I-C0166415
α	I-C0166415
ppar-α	B-C0166415
,	O
and	O
provoked	O
more	O
severe	B-C0205082
oxidative	B-C0242606
stress	I-C0242606
and	O
hepatitis	B-C0019158
via	O
the	O
upregulation	B-C0041904
of	O
inflammatory	B-C0010813
cytokines	I-C0010813
such	O
as	O
tumor	B-C1456820
necrosis	I-C1456820
factor	I-C1456820
alpha	I-C1456820
tnf-α	B-C1456820
and	O
transforming	B-C0040690
growth	I-C0040690
factor	I-C0040690
β	I-C0040690
tgf-β	B-C0040690
.	O
	
these	O
findings	O
suggest	O
that	O
l-fabp	B-C0163315
-mediated	O
ppar-α	B-C0166415
downregulation	B-C0949469
appears	O
to	O
be	O
a	O
hepatotoxic	B-C3549372
response	I-C3549372
resulting	O
from	O
zebrafish	B-C0043457
larva	B-C0023047
liver	B-C0227525
cell	I-C0227525
apoptosis	B-C0162638
,	O
and	O
l-fabp	B-C0163315
can	O
be	O
used	O
as	O
a	O
biomarker	B-C0005516
for	O
the	O
early	B-C0596473
detection	I-C0596473
of	O
pza	B-C0034239
-	O
induced	B-C0205263
liver	B-C0151763
damage	I-C0151763
in	O
zebrafish	B-C0043457
larvae	B-C0023047
.	O
	
smooth	B-C0205357
versus	O
textured	B-C0205556
surfaces	B-C0205148
feature	B-C2348519
-based	O
category	B-C0683312
selectivity	B-C1707391
in	O
human	B-C0086418
visual	B-C0042817
cortex	I-C0042817
in	O
fmri	B-C0376335
studies	I-C0376335
,	O
human	B-C0086418
lateral	B-C0028785
occipital	I-C0028785
lo	I-C0028785
cortex	I-C0028785
is	O
thought	O
to	O
respond	O
selectively	O
to	O
images	B-C1704922
of	O
objects	B-C0347997
,	O
compared	B-C1707455
with	O
nonobjects	B-C1551338
.	O
	
however	O
,	O
it	O
remains	O
unresolved	B-C0443342
whether	O
all	O
objects	B-C0347997
evoke	O
equivalent	B-C0205163
levels	B-C0441889
of	O
activity	B-C0441655
in	O
lo	B-C0028785
,	O
and	O
,	O
if	O
not	O
,	O
which	O
image	B-C2346469
features	I-C2346469
produce	O
stronger	B-C0442821
activation	B-C1879547
.	O
	
here	O
,	O
we	O
used	O
an	O
unbiased	B-C3161035
parametric	I-C3161035
texture	I-C3161035
model	I-C3161035
to	O
predict	B-C0681842
preferred	B-C0234402
versus	O
nonpreferred	B-C0234402
stimuli	I-C0234402
in	O
lo	B-C0028785
.	O
	
observation	B-C0302523
and	O
psychophysical	B-C1274040
results	I-C1274040
showed	O
that	O
predicted	B-C0681842
preferred	B-C0558295
stimuli	B-C0234402
both	O
objects	B-C0347997
and	O
nonobjects	B-C1551338
had	O
smooth	B-C0205357
rather	O
than	O
textured	B-C0205556
surfaces	B-C0205148
.	O
	
these	O
predictions	B-C0681842
were	O
confirmed	B-C0521093
using	O
fmri	B-C0376335
,	O
for	O
objects	B-C0347997
and	O
nonobjects	B-C1551338
.	O
	
similar	O
preferences	B-C0558295
were	O
also	O
found	O
in	O
the	O
fusiform	B-C3536733
face	I-C3536733
area	I-C3536733
ffa	B-C3536733
.	O
	
consistent	B-C0332290
with	I-C0332290
this	O
1	O
ffa	B-C3536733
and	O
lo	B-C0028785
responded	O
more	O
strongly	O
to	O
nonfreckled	B-C0205556
smooth	B-C0205357
faces	B-C0205148
,	O
compared	B-C1707455
with	O
otherwise	O
identical	O
freckled	B-C0016689
textured	B-C0205556
faces	B-C0205148
and	O
2	O
strong	O
functional	B-C0205245
connections	B-C0449379
were	O
found	O
between	O
lo	B-C0028785
and	O
ffa	B-C3536733
.	O
	
thus	O
,	O
lo	B-C0028785
and	O
ffa	B-C3536733
may	O
be	O
part	O
of	O
an	O
information	B-C1533716
-	O
processing	B-C1709694
stream	O
distinguished	O
by	O
feature	B-C2348519
-based	O
category	B-C0683312
selectivity	B-C1707391
smooth	B-C0205357
>	O
high-fructose	B-C1445913
diet	I-C1445913
is	O
as	O
detrimental	O
as	O
high-fat	B-C0521974
diet	I-C0521974
in	O
the	O
induction	B-C0857127
of	O
insulin	B-C0021655
resistance	I-C0021655
and	O
diabetes	B-C0011847
mediated	O
by	O
hepatic	B-C0205054
/	O
pancreatic	B-C0030274
endoplasmic	B-C3178870
reticulum	I-C3178870
er	I-C3178870
stress	I-C3178870
in	O
the	O
context	B-C0449255
of	O
high	B-C0205250
human	B-C0086418
consumption	B-C0457083
of	O
fructose	B-C0016745
diets	B-C0012155
,	O
there	O
is	O
an	O
imperative	O
need	B-C0027552
to	O
understand	B-C0162340
how	O
dietary	B-C2699635
fructose	B-C0556134
intake	I-C0556134
influence	B-C4054723
cellular	B-C0007634
and	O
molecular	B-C1521991
mechanisms	B-C0441712
and	O
thereby	O
affect	B-C1280500
β-cell	B-C1969875
dysfunction	I-C1969875
and	O
insulin	B-C0021655
resistance	I-C0021655
.	O
	
while	O
evidence	B-C3887511
exists	B-C2987476
for	O
a	O
relationship	B-C0439849
between	O
high	B-C0205250
-	O
fat	B-C0015677
-	O
induced	B-C0205263
insulin	B-C0021655
resistance	I-C0021655
and	O
metabolic	B-C0025517
disorders	I-C0025517
,	O
there	O
is	O
lack	B-C0332268
of	I-C0332268
studies	B-C2603343
in	O
relation	O
to	O
high-fructose	B-C1445913
diet	I-C1445913
.	O
	
therefore	O
,	O
we	O
attempted	O
to	O
study	B-C2603343
the	O
effect	B-C1280500
of	O
different	B-C1705242
diets	B-C0012155
viz	O
,	O
high-fat	B-C0521974
diet	I-C0521974
hfd	B-C0521974
,	O
high-fructose	B-C1445913
diet	I-C1445913
hfs	B-C1445913
,	O
and	O
a	O
combination	B-C0205195
hfs	B-C1445913
+	O
hfd	B-C0521974
diet	B-C0012155
on	O
glucose	B-C1326961
homeostasis	I-C1326961
and	O
insulin	B-C0920563
sensitivity	I-C0920563
in	O
male	B-C0086582
wistar	B-C0034716
rats	I-C0034716
compared	B-C1707455
to	O
control	B-C1511501
animals	I-C1511501
fed	B-C2987508
with	O
normal	B-C0205307
pellet	B-C1998480
diet	B-C0012155
.	O
	
investigations	B-C1292732
include	O
oral	B-C0029161
glucose	I-C0029161
tolerance	I-C0029161
test	I-C0029161
,	O
insulin	B-C0236287
tolerance	I-C0236287
test	I-C0236287
,	O
histopathology	B-C0430445
by	O
h	B-C0523207
and	O
masson's	B-C1294297
trichrome	I-C1294297
staining	I-C1294297
,	O
mrna	B-C1515670
expression	I-C1515670
by	O
real-time	B-C1709846
pcr	I-C1709846
,	O
protein	B-C1882495
expression	I-C1882495
by	O
western	B-C0949466
blot	I-C0949466
,	O
and	O
caspase-3	B-C1150132
activity	I-C1150132
by	O
colorimetry	B-C0009407
.	O
	
rats	B-C0034721
subjected	O
to	O
high-fat	B-C0521974
/	O
fructose	B-C1445913
diets	I-C1445913
became	O
glucose	B-C0017725
intolerant	B-C0231200
,	O
insulin-resistant	B-C0021655
,	O
and	O
dyslipidemic	B-C0243095
.	O
	
compared	B-C1707455
to	O
control	B-C1511501
animals	I-C1511501
,	O
rats	B-C0034721
subjected	O
to	O
different	B-C1705242
combination	B-C0205195
of	O
fat	B-C0521974
/	O
fructose	B-C1445913
diets	I-C1445913
showed	O
increased	B-C0205217
mrna	B-C1515670
and	O
protein	B-C1171362
expression	I-C1171362
of	O
a	O
battery	O
of	O
er	B-C3178870
stress	I-C3178870
markers	B-C0008963
both	O
in	O
pancreas	B-C0030274
and	O
liver	B-C0023884
.	O
	
transcription	B-C0040648
factors	I-C0040648
of	O
β-cell	B-C0007613
function	I-C0007613
insig1	B-C1447572
,	O
srebp1c	B-C0537474
and	O
pdx1	B-C1528563
as	O
well	O
as	O
hepatic	B-C0205054
gluconeogenesis	B-C0017715
foxo1	B-C0250455
and	O
pepck	B-C4042244
were	O
adversely	B-C0879626
affected	I-C0879626
in	O
diet	B-C0012155
-	O
induced	B-C0205263
insulin-resistant	B-C0021655
rats	B-C0034721
.	O
	
the	O
convergence	B-C2700387
of	O
chronic	B-C0205191
er	B-C3178870
stress	I-C3178870
towards	O
apoptosis	B-C0162638
in	O
pancreas	B-C0030274
/	O
liver	B-C0023884
was	O
also	O
indicated	B-C1444656
by	O
increased	B-C0205217
levels	B-C0441889
of	O
chop	B-C0035696
mrna	I-C0035696
increased	B-C0205217
activity	O
of	O
both	O
jnk	B-C1150587
and	O
caspase-3	B-C1150132
in	O
rats	B-C0034721
subjected	O
to	O
high-fat	B-C0521974
/	O
fructose	B-C1445913
diets	I-C1445913
.	O
	
our	O
study	B-C2603343
exposes	O
the	O
experimental	B-C1517586
support	B-C1521721
in	O
that	O
high-fructose	B-C1445913
diet	I-C1445913
is	O
equally	B-C0205163
detrimental	O
in	O
causing	B-C0678227
metabolic	B-C0025517
disorders	I-C0025517
.	O
	
immature	B-C0205252
stages	B-C1306673
and	O
larval	B-C0562676
chaetotaxy	B-C1515222
of	O
notofairchildia	B-C1082670
stenygros	I-C1082670
quate	O
alexander	O
diptera	B-C0012578
psychodidae	B-C0033888
bruchomyiinae	B-C1082670
some	O
authors	O
have	O
hypothesized	O
that	O
bruchomyiinae	B-C1082670
is	O
"""the"	O
most	O
plesiomorphic	B-C1711207
subfamily	I-C1711207
of	O
psychodidae	B-C0033888
""""	O
and	O
its	O
members	B-C1551338
"""are"	O
among	O
the	O
most	O
primitive	B-C0205225
living	B-C0376558
diptera	B-C0012578
""""	O
.	O
	
although	O
bruchomyiinae	B-C1082670
is	O
of	O
no	B-C1513916
medical	B-C0205476
importance	B-C3898777
,	O
it	O
is	O
of	O
great	O
evolutionary	B-C0015219
significance	B-C0750502
,	O
having	O
long	O
been	O
placed	O
as	O
the	O
sister	B-C0008903
group	I-C0008903
of	O
phlebotominae	B-C1123010
.	O
	
in	O
general	O
,	O
species	B-C1705920
of	O
this	O
subfamily	B-C1711207
are	O
rarely	O
collected	O
in	O
their	O
natural	B-C0557745
environment	I-C0557745
therefore	O
,	O
adults	B-C0563200
and	O
,	O
even	O
more	O
so	O
,	O
the	O
immature	B-C0205252
stages	B-C1306673
of	O
these	O
flies	B-C0012578
are	O
poorly	O
known	O
.	O
	
we	O
describe	O
the	O
egg	B-C0562677
,	O
larvae	B-C0562676
and	O
pupae	B-C0034120
of	O
notofairchildia	B-C1082670
stenygros	I-C1082670
and	O
provide	O
nomenclatural	B-C0600281
notes	I-C0600281
on	O
larval	B-C0562676
chaetotaxy	B-C1515222
based	O
on	O
analyses	O
using	O
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
sem	B-C0026020
and	O
optic	B-C0596569
microscopy	I-C0596569
.	O
	
the	O
morphology	B-C0332437
of	O
immature	B-C0205252
nt	B-C1082670
.	O
	
stenygros	I-C1082670
is	O
compared	O
with	O
other	O
bruchomyiinae	B-C1082670
and	O
psychodidae	B-C0033888
species	B-C1705920
,	O
especially	O
with	O
species	B-C1705920
of	O
phlebotominae	B-C1123010
that	O
are	O
superficially	O
similar	B-C2348205
to	O
bruchomyiinae	B-C1082670
.	O
	
results	B-C0683954
of	O
this	O
study	B-C2603343
revealed	O
striking	O
morphological	B-C0543482
differences	B-C1705242
between	O
the	O
immature	B-C0205252
stages	B-C1306673
of	O
bruchomyiinae	B-C1082670
and	O
phlebotominae	B-C1123010
the	O
former	O
are	O
lacking	O
abdominal	B-C0000726
pseudopods	B-C0033827
and	O
microtrichia	B-C0018494
on	O
the	O
cephalic	B-C0205096
integument	B-C0037267
,	O
both	O
of	O
which	O
are	O
present	O
in	O
the	O
larvae	B-C0562676
of	O
phlebotominae	B-C1123010
.	O
	
these	O
morphological	B-C0543482
differences	B-C1705242
observed	O
in	O
the	O
immature	B-C0205252
stages	B-C1306673
between	O
members	B-C1551338
of	O
the	O
two	O
subfamilies	B-C1711207
support	O
the	O
findings	B-C0243095
of	O
recent	O
molecular	B-C2236970
studies	I-C2236970
indicating	O
that	O
bruchomyiinae	B-C1082670
and	O
phlebtominae	B-C1704307
are	O
evolutionarily	B-C0015219
not	B-C1546988
closely	I-C1546988
related	I-C1546988
.	O
	
notofairchildia	B-C1082670
stenygros	I-C1082670
is	O
now	O
the	O
fourth	B-C0205438
species	B-C1705920
of	O
bruchomyiinae	B-C1082670
for	O
which	O
the	O
immature	B-C0205252
stages	B-C1306673
initial	O
clinical	B-C0456984
results	I-C0456984
with	O
the	O
thermocool	B-C0490683
smarttouch	I-C0490683
surround	I-C0490683
flow	I-C0490683
catheter	I-C0490683
the	O
biosense	B-C0490683
webster	I-C0490683
thermocool	I-C0490683
smarttouch	I-C0490683
surround	I-C0490683
flow	I-C0490683
stsf	I-C0490683
catheter	I-C0490683
is	O
a	O
recently	O
developed	O
ablation	B-C0547070
catheter	B-C0085590
incorporating	O
surround	B-C0232177
flow	I-C0232177
sf	B-C0232177
technology	B-C0039421
to	O
ensure	O
efficient	O
cooling	O
and	O
force	O
sensing	O
to	O
quantify	B-C1709793
tissue	B-C0040300
contact	B-C0332158
.	O
	
in	O
our	O
unit	O
,	O
it	O
superseded	O
the	O
thermocool	B-C0490683
sf	I-C0490683
catheter	I-C0490683
from	O
the	O
time	O
of	O
its	O
introduction	O
in	O
may	O
2015	O
.	O
	
procedure	B-C0087111
-related	O
data	B-C1511726
were	O
collected	O
prospectively	O
for	O
the	O
first	O
100	O
ablation	B-C0547070
procedures	I-C0547070
performed	O
in	O
our	O
department	O
using	O
the	O
stsf	B-C0490683
catheter	I-C0490683
.	O
	
from	O
a	O
database	B-C0242356
of	O
654	O
procedures	B-C0087111
performed	O
in	O
our	O
unit	O
using	O
the	O
sf	B-C0490683
catheter	I-C0490683
,	O
we	O
selected	O
one	O
to	O
match	O
each	O
stsf	B-C0087111
procedure	I-C0087111
,	O
matching	O
for	O
procedure	B-C0455713
type	I-C0455713
,	O
operator	B-C1705274
experience	B-C0596545
,	O
patient	B-C0001779
age	I-C0001779
,	O
and	O
gender	B-C0079399
.	O
	
the	O
groups	B-C0681860
were	O
well	O
matched	O
for	O
patient	B-C0001779
age	I-C0001779
,	O
gender	B-C0079399
,	O
and	O
procedure	B-C0455713
type	I-C0455713
.	O
	
procedure	B-C1442476
duration	I-C1442476
was	O
similar	O
in	O
both	O
groups	B-C0681860
mean	O
225.5	O
vs	O
.	O
	
221.4	O
min	O
,	O
iqr	B-C1711350
106.5	O
vs	O
.	O
	
91.5	O
,	O
p	O
=	O
0.55	O
,	O
but	O
fluoroscopy	B-C4029016
duration	I-C4029016
was	O
shorter	B-C1806781
in	O
the	O
stsf	B-C0681860
group	I-C0681860
mean	O
25.8	O
vs	O
.	O
	
30.0	O
,	O
iqr	B-C1711350
19.6	O
vs	O
.	O
	
18.5	O
,	O
p	O
=	O
0.03	O
.	O
	
no	B-C4032686
complication	I-C4032686
occurred	O
in	O
the	O
stsf	B-C0681860
group	I-C0681860
.	O
	
complications	B-C0009566
occurred	O
in	O
two	O
cases	B-C1706256
in	O
the	O
sf	B-C0681860
group	I-C0681860
one	O
pericardial	B-C0031039
effusion	I-C0031039
requiring	O
drainage	B-C0013103
and	O
one	O
need	O
for	O
permanent	B-C0205355
pacing	B-C0199640
.	O
	
complete	B-C3897822
procedural	I-C3897822
success	I-C3897822
was	O
achieved	O
in	O
98	O
cases	B-C1706256
in	O
the	O
stsf	B-C0681860
group	I-C0681860
and	O
94	O
cases	B-C1706256
in	O
the	O
sf	B-C0681860
group	I-C0681860
p	O
=	O
0.15	O
.	O
	
the	O
composite	O
endpoint	O
of	O
procedure	O
failure	B-C0086138
or	O
acute	B-C0205178
complication	B-C0009566
was	O
less	O
common	O
in	O
the	O
stsf	B-C0681860
group	I-C0681860
2	O
vs	O
.	O
	
8	O
,	O
p	O
=	O
0.05	O
.	O
	
the	O
stsf	B-C0490683
catheter	I-C0490683
is	O
safe	O
and	O
effective	B-C1704419
in	O
treating	B-C1522326
a	O
range	O
of	O
arrhythmias	B-C0003811
.	O
	
compared	O
with	O
the	O
sf	B-C0490683
catheter	I-C0490683
,	O
it	O
shows	O
a	O
trend	O
towards	O
improved	O
safety	B-C0036043
-	O
efficacy	B-C1280519
low	B-C0024032
birth	I-C0024032
weight	I-C0024032
and	O
features	B-C2348519
of	O
neuroticism	B-C1842981
and	O
mood	B-C0525045
disorder	I-C0525045
in	O
83	O
545	O
participants	B-C0679646
of	O
the	O
uk	B-C0041700
biobank	B-C0206512
cohort	B-C0599755
low	B-C0024032
birth	I-C0024032
weight	I-C0024032
has	O
been	O
inconsistently	O
associated	O
with	O
risk	B-C0035647
of	O
developing	O
affective	B-C0001723
disorders	I-C0001723
,	O
including	O
major	B-C1269683
depressive	I-C1269683
disorder	I-C1269683
mdd	B-C1269683
.	O
	
to	O
date	O
,	O
studies	B-C2603343
investigating	B-C1292732
possible	O
associations	B-C0439849
between	O
birth	B-C0005612
weight	I-C0005612
and	O
bipolar	B-C0005586
disorder	I-C0005586
bd	B-C0005586
,	O
or	O
personality	B-C0233849
traits	I-C0233849
known	O
to	O
predispose	B-C0220898
to	O
affective	B-C0001723
disorders	I-C0001723
such	O
as	O
neuroticism	B-C1842981
,	O
have	O
not	O
been	O
conducted	O
in	O
large	O
cohorts	B-C0599755
.	O
	
to	O
assess	B-C1516048
whether	O
very	B-C0282666
low	I-C0282666
birth	I-C0282666
weight	I-C0282666
<1500	O
g	O
and	O
low	B-C0024032
birth	I-C0024032
weight	I-C0024032
1500-2490	O
g	O
were	O
associated	B-C0332281
with	I-C0332281
higher	B-C0564512
neuroticism	I-C0564512
scores	B-C0449820
assessed	B-C1516048
in	O
middle	B-C0026062
age	I-C0026062
,	O
and	O
lifetime	B-C0598779
history	I-C0598779
of	O
either	O
mdd	B-C1269683
or	O
bd	B-C0005586
.	O
	
we	O
controlled	O
for	O
possible	O
confounding	B-C0009673
factors	I-C0009673
.	O
	
retrospective	B-C1514923
cohort	B-C0009247
study	I-C0009247
using	O
baseline	B-C1442488
data	B-C1511726
on	O
the	O
83	O
545	O
uk	B-C0041700
biobank	B-C0206512
participants	B-C0679646
with	O
detailed	O
mental	B-C0025353
health	I-C0025353
and	O
birth	B-C0005612
weight	I-C0005612
data	B-C1511726
.	O
	
main	O
outcomes	B-C1274040
were	O
prevalent	O
mdd	B-C1269683
and	O
bd	B-C0005586
,	O
and	O
neuroticism	B-C1842981
assessed	B-C1516048
using	O
the	O
eysenck	B-C0034394
personality	I-C0034394
inventory	I-C0034394
neuroticism	I-C0034394
scale	I-C0034394
-	I-C0034394
revised	I-C0034394
epin-r	B-C0034394
.	O
	
referent	O
to	O
normal	B-C0456136
birth	I-C0456136
weight	I-C0456136
,	O
very	B-C0282666
low	I-C0282666
/	O
low	B-C0024032
birth	I-C0024032
weight	I-C0024032
were	O
associated	O
with	O
higher	B-C0564512
neuroticism	I-C0564512
scores	B-C0449820
,	O
increased	B-C0205217
mdd	B-C1269683
and	O
bd	B-C0005586
.	O
	
the	O
associations	B-C0439849
between	O
birth	B-C0005612
weight	I-C0005612
category	B-C0683312
and	O
mdd	B-C1269683
were	O
partially	O
mediated	O
by	O
higher	B-C0564512
neuroticism	I-C0564512
.	O
	
these	O
findings	B-C0683954
suggest	O
that	O
intrauterine	B-C0694756
programming	B-C1720850
may	O
play	O
a	O
role	B-C1705810
in	O
lifetime	B-C4071830
vulnerability	B-C1821973
to	O
affective	B-C0001723
disorders	I-C0001723
.	O
	
dna	B-C0920681
annealing	I-C0920681
by	O
redβ	B-C0766456
is	O
insufficient	O
for	O
homologous	B-C0599773
recombination	I-C0599773
and	O
the	O
additional	O
requirements	O
involve	O
intra-	B-C0678593
and	I-C0678593
inter-molecular	I-C0678593
interactions	I-C0678593
single	B-C0033684
strand	I-C0033684
annealing	I-C0033684
proteins	I-C0033684
ssaps	B-C0033684
like	O
redβ	B-C0766456
initiate	O
homologous	B-C0599773
recombination	I-C0599773
by	O
annealing	B-C0006556
complementary	I-C0006556
dna	I-C0006556
strands	I-C0006556
.	O
	
we	O
show	O
that	O
c-terminally	B-C1514568
truncated	I-C1514568
redβ	B-C0766456
,	O
whilst	O
still	O
able	O
to	O
promote	O
annealing	B-C0920681
and	O
nucleoprotein	B-C1158503
filament	I-C1158503
formation	I-C1158503
,	O
is	O
unable	O
to	O
mediate	O
homologous	B-C0599773
recombination	I-C0599773
.	O
	
mutations	B-C0026882
of	O
the	O
c-terminal	B-C1514562
domain	I-C1514562
were	O
evaluated	O
using	O
both	O
single	B-C0012935
-	O
and	O
double	B-C0311474
stranded	I-C0311474
ss	B-C0012935
and	O
ds	B-C0311474
substrates	O
in	O
recombination	B-C0034865
assays	B-C0005507
.	O
	
mutations	B-C0012878
of	O
critical	B-C0002520
amino	I-C0002520
acids	I-C0002520
affected	O
either	O
dsdna	B-C0311474
recombination	B-C1158522
or	O
both	O
ssdna	B-C0012935
and	O
dsdna	B-C1158522
recombination	I-C1158522
indicating	O
two	O
separable	O
functions	O
,	O
one	O
of	O
which	O
is	O
critical	O
for	O
dsdna	B-C1158522
recombination	I-C1158522
and	O
the	O
second	O
for	O
recombination	B-C1158522
per	O
se	O
.	O
	
as	O
evaluated	O
by	O
co-immunoprecipitation	B-C1449705
experiments	I-C1449705
,	O
the	O
dsdna	B-C1158522
recombination	I-C1158522
function	I-C1158522
relates	O
to	O
the	O
redα	B-C0033684
-	O
redβ	B-C0766456
protein-protein	B-C0872079
interaction	I-C0872079
,	O
which	O
requires	O
not	O
only	O
contacts	O
in	O
the	O
c-terminal	B-C1514562
domain	I-C1514562
but	O
also	O
a	O
region	O
near	O
the	O
n-terminus	B-C1514562
.	O
	
because	O
the	O
nucleoprotein	B-C1158503
filament	I-C1158503
formed	I-C1158503
with	O
c-terminally	B-C1514568
truncated	I-C1514568
redβ	B-C0766456
has	O
altered	O
properties	O
,	O
the	O
second	O
c-terminal	B-C1149341
function	I-C1149341
could	O
be	O
due	O
to	O
an	O
interaction	B-C1511658
required	O
for	O
functional	B-C0205245
filaments	B-C0025979
.	O
	
alternatively	O
the	O
second	O
c-terminal	B-C1149341
function	I-C1149341
could	O
indicate	O
a	O
requirement	O
for	O
a	O
redβ	B-C0766456
-	O
host	B-C1659605
factor	I-C1659605
interaction	I-C1659605
.	O
	
these	O
data	O
further	O
advance	O
the	O
model	O
for	O
red	B-C0599773
recombination	I-C0599773
and	O
the	O
proposition	O
that	O
redβ	B-C0766456
and	O
rad52	B-C0663124
ssaps	B-C0033684
multi-drug-resistant	B-C0242640
acinetobacter	B-C2828037
calcoaceticus-acinetobacter	I-C2828037
baumannii	I-C2828037
complex	I-C2828037
infection	B-C3714514
outbreak	B-C0012652
in	O
dogs	B-C0012984
and	O
cats	B-C0007450
in	O
a	O
veterinary	B-C0019996
hospital	I-C0019996
members	O
of	O
the	O
acinetobacter	B-C2828037
calcoaceticus-acinetobacter	I-C2828037
baumannii	I-C2828037
complex	I-C2828037
cause	O
severe	B-C0205082
outbreaks	B-C0012652
in	O
humans	B-C0086418
,	O
and	O
are	O
increasingly	B-C0442805
reported	B-C0700287
in	O
animals	B-C0003062
.	O
	
a	O
retrospective	B-C0035363
study	I-C0035363
,	O
describing	O
a	O
severe	B-C0205082
outbreak	B-C0012652
in	O
dogs	B-C0012984
and	O
cats	B-C0007450
caused	O
by	O
a	O
multidrug	B-C4076168
resistant	I-C4076168
member	I-C4076168
of	O
the	O
acinetobacter	B-C2828037
calcoaceticus-acinetobacter	I-C2828037
baumannii	I-C2828037
complex	I-C2828037
in	O
a	O
veterinary	B-C0019996
hospital	I-C0019996
,	O
between	O
july	O
2010	O
and	O
november	O
2012	O
.	O
	
the	O
study	B-C2603343
included	B-C0332257
19	O
dogs	B-C0012984
and	O
4	O
cats	B-C0007450
.	O
	
acinetobacter	B-C2828037
calcoaceticus-acinetobacter	I-C2828037
baumannii	I-C2828037
complex	I-C2828037
bacteria	I-C2828037
were	O
isolated	B-C0205409
from	O
urine	B-C0042036
9	O
animals	B-C0003062
,	O
respiratory	B-C0035237
tract	I-C0035237
11	O
,	O
tissues	B-C0040300
3	O
and	O
blood	B-C0005767
1	O
.	O
	
the	O
most	B-C0205393
common	B-C0205214
infection	B-C3714514
-	O
associated	B-C0449380
findings	I-C0449380
included	B-C0332257
fever	B-C0015967
,	O
purulent	B-C0333274
discharge	I-C0333274
from	O
endotracheal	B-C0336630
tubes	I-C0336630
,	O
hypotension	B-C0020649
,	O
and	O
neutropaenia	B-C0221023
.	O
	
infection	B-C3714514
s	O
led	O
to	O
pneumonia	B-C0032285
,	O
urinary	B-C0042029
tract	I-C0042029
infection	I-C0042029
,	O
cellulitis	B-C0007642
and	O
sepsis	B-C0243026
.	O
	
infection	B-C3714514
was	O
transmitted	B-C0242781
in	O
the	O
intensive	B-C0021708
care	I-C0021708
unit	I-C0021708
,	O
where	O
22	O
of	O
23	O
animals	B-C0003062
were	O
initially	B-C0205265
hospitalised	B-C0184666
.	O
	
the	O
mortality	B-C0205848
rate	I-C0205848
was	O
70%	O
16	O
of	O
23	O
animals	B-C0003062
,	O
and	O
was	O
higher	B-C0205250
in	O
cases	O
of	O
respiratory	B-C0035243
infection	I-C0035243
compared	B-C1707455
to	O
other	O
infections	B-C3714514
.	O
	
aggressive	O
environmental	B-C0014406
cleaning	B-C1947930
and	O
disinfection	B-C0012683
,	O
with	O
staff	B-C0588974
education	I-C0588974
for	O
personal	B-C0564673
hygiene	I-C0564673
and	O
antisepsis	B-C0003424
,	O
sharply	O
decreased	B-C0205216
the	O
infection	B-C3714514
incidence	B-C0021149
.	O
	
health	B-C0018684
care	I-C0018684
-	O
associated	B-C0332281
outbreaks	B-C0012652
with	O
multidrug	B-C0242640
resistant	I-C0242640
acinetobacter	B-C2828037
calcoaceticus-acinetobacter	I-C2828037
baumannii	I-C2828037
complex	I-C2828037
in	O
dogs	B-C0012984
and	O
cats	B-C0007450
are	O
potentially	O
highly	B-C0205250
fatal	B-C1302234
and	O
difficult	B-C0332218
to	O
eradicate	B-C2728502
,	O
warranting	O
monitoring	B-C1283169
,	O
antiseptic	B-C3536839
techniques	B-C0449851
and	O
judicious	O
antibiotic	B-C0003232
use	B-C0457083
.	O
	
manipulation	O
of	O
an	O
existing	O
crystal	B-C0444626
form	I-C0444626
unexpectedly	B-C0243095
results	I-C0243095
in	O
interwoven	B-C1510464
packing	I-C1510464
networks	I-C1510464
with	O
pseudo-translational	B-C1254362
symmetry	I-C1254362
nonribosomal	B-C0535847
peptide	I-C0535847
synthetases	I-C0535847
nrpss	B-C0535847
are	O
multimodular	B-C0014442
enzymes	I-C0014442
that	O
synthesize	B-C1883254
a	O
myriad	B-C0439064
of	O
diverse	B-C0567416
molecules	I-C0567416
.	O
	
tailoring	B-C1514562
domains	I-C1514562
have	O
been	O
co-opted	O
into	O
nrpss	B-C0535847
to	O
introduce	O
further	O
variety	O
into	O
nonribosomal	B-C0030956
peptide	I-C0030956
products	I-C0030956
.	O
	
linear	B-C0018160
gramicidin	I-C0018160
synthetase	I-C0018160
contains	B-C2700400
a	O
unique	O
formylation	B-C1159286
-	O
tailoring	B-C1514562
domain	I-C1514562
in	O
its	O
initiation	B-C1709061
module	I-C1709061
f-a	B-C1159286
-	O
pcp	B-C1514562
.	O
	
the	O
structure	O
of	O
the	O
f-a	B-C1159286
di-domain	B-C1514562
has	O
previously	O
been	O
determined	O
in	O
a	O
crystal	B-C0444626
form	I-C0444626
which	O
had	O
large	O
solvent	B-C0037638
channels	B-C0439799
and	O
no	B-C0178587
density	I-C0178587
for	O
the	O
minor	O
asub	B-C1514562
subdomain	I-C1514562
.	O
	
an	O
attempt	O
was	O
made	O
to	O
take	O
advantage	O
of	O
this	O
packing	B-C2828395
by	O
removing	B-C1883720
the	O
asub	B-C1514562
subdomain	I-C1514562
from	O
the	O
construct	O
f-a	B-C1159286
δ	O
sub	B-C1514562
in	O
order	O
to	O
produce	O
a	O
crystal	B-C0444626
that	O
could	O
accommodate	O
the	O
pcp	B-C1514562
domain	I-C1514562
.	O
	
in	O
the	O
resulting	O
crystal	B-C0444626
the	O
original	B-C1510464
packing	I-C1510464
network	I-C1510464
was	O
still	O
present	O
,	O
but	O
a	O
second	B-C1510464
network	I-C1510464
with	O
the	O
same	O
packing	B-C2828395
and	O
almost	O
no	O
contact	O
with	O
the	O
original	B-C1510464
network	I-C1510464
took	O
the	O
place	O
of	O
the	O
solvent	B-C0037638
channels	B-C0439799
and	O
changed	O
the	O
space	B-C0444626
group	I-C0444626
of	I-C0444626
the	I-C0444626
crystal	I-C0444626
.	O
	
folate	B-C0178638
-based	O
single	B-C0597452
cell	I-C0597452
screening	I-C0597452
using	O
surface	B-C0037815
enhanced	I-C0037815
raman	I-C0037815
microimaging	I-C0037815
recent	O
progress	O
in	O
nanotechnology	B-C0872323
and	O
its	O
application	O
to	O
biomedical	B-C0005540
settings	I-C0005540
have	O
generated	O
great	O
advantages	O
in	O
dealing	O
with	O
early	B-C2350269
cancer	I-C2350269
diagnosis	I-C2350269
.	O
	
the	O
identification	O
of	O
the	O
specific	O
properties	O
of	O
cancer	B-C0334227
cells	I-C0334227
,	O
such	O
as	O
the	O
expression	B-C0597360
of	O
particular	O
plasma	B-C0007603
membrane	I-C0007603
molecular	B-C1513401
receptors	I-C1513401
,	O
has	O
become	O
crucial	O
in	O
revealing	O
the	O
presence	O
and	O
in	O
assessing	B-C3650728
the	I-C3650728
stage	I-C3650728
of	I-C3650728
development	I-C3650728
of	I-C3650728
the	I-C3650728
disease	I-C3650728
.	O
	
here	O
we	O
report	O
a	O
single	B-C0597452
cell	I-C0597452
screening	I-C0597452
approach	O
based	O
on	O
surface	B-C0037815
enhanced	I-C0037815
raman	I-C0037815
scattering	I-C0037815
sers	I-C0037815
microimaging	I-C0037815
.	O
	
we	O
fabricated	O
a	O
sers-labelled	O
nanovector	O
based	O
on	O
the	O
biofunctionalization	O
of	O
gold	O
nanoparticles	O
with	O
folic	O
acid	O
.	O
	
after	O
treating	O
the	O
cells	O
with	O
the	O
nanovector	O
,	O
we	O
were	O
able	O
to	O
distinguish	O
three	O
different	O
cell	O
populations	O
from	O
different	O
cell	O
lines	O
cancer	O
hela	O
and	O
pc-3	O
,	O
and	O
normal	O
hacat	O
lines	O
,	O
suitably	O
chosen	O
for	O
their	O
different	O
expressions	O
of	O
folate	O
binding	O
proteins	O
.	O
	
the	O
nanovector	O
,	O
indeed	O
,	O
binds	O
much	O
more	O
efficiently	O
on	O
cancer	O
cell	O
lines	O
than	O
on	O
normal	O
ones	O
,	O
resulting	O
in	O
a	O
higher	O
sers	B-C0037815
signal	O
measured	O
on	O
cancer	O
cells	O
.	O
	
these	O
results	O
pave	O
the	O
way	O
for	O
applications	O
in	O
single	O
cell	O
diagnostics	O
and	O
,	O
potentially	O
,	O
in	O
theranostics	B-C4046052
self-reported	B-C2700446
occupational	B-C0521168
injuries	I-C0521168
among	O
industrial	B-C0021267
beef	B-C0175923
slaughterhouse	B-C0000715
workers	B-C1527116
in	O
the	O
midwestern	B-C0026081
united	I-C0026081
states	I-C0026081
although	O
workers	B-C1527116
in	O
meatpacking	B-C0025019
facilities	I-C0025019
in	O
the	O
united	B-C0041703
states	I-C0041703
experience	O
high	B-C1521828
rates	I-C1521828
of	O
occupational	B-C0521168
injury	I-C0521168
,	O
their	O
injury	B-C3263723
experiences	O
have	O
received	O
limited	O
research	B-C0035168
attention	O
.	O
	
prior	O
research	B-C0242481
indicates	I-C0242481
underreporting	B-C0700287
in	O
injury	B-C1822478
rates	I-C1822478
in	O
this	O
industry	B-C0021267
as	O
well	O
significant	O
variation	O
in	O
injury	B-C1822478
rates	I-C1822478
among	O
facilities	O
.	O
	
to	O
add	O
detail	O
to	O
the	O
rates	O
and	O
circumstances	O
surrounding	O
occupational	B-C0521168
injury	I-C0521168
among	O
meatpacking	B-C0025019
workers	B-C1527116
,	O
we	O
conducted	O
a	O
cross-sectional	B-C0010362
study	I-C0010362
of	O
workers	B-C1527116
employed	O
at	O
an	O
industrial	B-C0025019
beefpacking	I-C0025019
plant	I-C0025019
in	O
nebraska	B-C0027523
,	O
united	B-C0041703
states	I-C0041703
n	O
=	O
137	O
and	O
interviewed	O
workers	B-C1527116
about	O
recent	O
injury	B-C3263723
experiences	O
.	O
	
we	O
assessed	O
frequency	O
,	O
cause	O
and	O
nature	O
of	O
self-reported	B-C2700446
injury	B-C3263723
.	O
	
we	O
estimated	O
annual	B-C1708485
incidence	I-C1708485
rates	I-C1708485
of	O
self-reported	B-C2700446
injuries	B-C3263723
using	O
the	O
osha	B-C0041731
formula	B-C0489829
and	O
compared	O
these	O
rates	O
to	O
industry-wide	B-C1511726
data	I-C1511726
.	O
	
we	O
also	O
evaluated	O
psychological	B-C0815107
distress	I-C0815107
in	O
this	O
workforce	O
as	O
measured	O
by	O
the	O
kessler-6	B-C4300240
scale	I-C4300240
to	O
assess	O
whether	O
distress	B-C0231303
was	O
associated	B-C0332281
with	I-C0332281
recent	O
occupational	B-C0521168
injury	I-C0521168
.	O
	
in	O
this	O
study	O
,	O
15.1	O
of	O
workers	O
experienced	O
occupational	O
injuries	O
that	O
required	O
time	O
off	O
work	O
,	O
job	O
transfer	O
,	O
or	O
restriction	O
during	O
the	O
past	O
three	O
months	O
.	O
	
the	O
estimated	O
annual	O
incidence	O
rate	O
was	O
15.2	O
injuries	O
per	O
100	O
full-time	O
workers	O
for	O
these	O
injuries	O
at	O
this	O
plant	O
.	O
	
rushing	O
was	O
identified	O
as	O
the	O
cause	O
of	O
nearly	O
50%	O
of	O
injuries	O
,	O
and	O
repetitive	O
work	O
as	O
the	O
cause	O
of	O
an	O
additional	O
20%	O
of	O
injuries	O
.	O
	
use	O
of	O
metal	O
mesh	O
sleeves	O
por	O
0.10	O
p	O
=	O
0.008	O
and	O
metal	O
mesh	O
gloves	O
por	O
0.41	O
p	O
=	O
0.05	O
were	O
associated	O
with	O
reduced	O
risk	O
of	O
injury	B-C3263723
.	O
	
use	O
of	O
a	O
carbon	O
steel	O
for	O
knife	O
sharpening	O
por	O
5.2	O
p	O
=	O
0.02	O
was	O
associated	O
with	O
elevated	O
risk	O
of	O
moderate	O
and	O
severe	O
injury	O
.	O
	
there	O
were	O
no	O
associations	O
between	O
self-reported	O
occupational	O
injury	O
and	O
overall	O
measures	O
of	O
psychological	O
distress	O
.	O
	
self-reported	O
incidence	O
rate	O
of	O
severe	O
injury	O
in	O
this	O
plant	O
was	O
more	O
than	O
twice	O
official	O
industry	O
estimates	O
.	O
	
worker	O
self-reports	O
may	O
illustrate	O
key	O
areas	O
for	O
injury	O
prevention	I-C0150638
the	O
effect	B-C1280500
of	O
l-arginine	B-C0003765
on	O
dural	B-C0043240
healing	I-C0043240
after	O
experimentally	O
induced	B-C0205263
dural	B-C0013313
defect	B-C1457869
in	O
a	O
rat	B-C0034693
model	B-C0026339
incomplete	B-C0205257
repair	B-C0043240
of	O
the	O
dura	B-C0013313
mater	I-C0013313
may	O
result	B-C1274040
in	O
numerous	B-C0439064
complications	B-C0009566
such	O
as	O
cerebrospinal	B-C0023182
fluid	I-C0023182
leakage	I-C0023182
and	O
meningitis	B-C0025289
.	O
	
for	O
this	O
reason	O
,	O
accurate	B-C0443131
repair	B-C0043240
of	O
the	O
dura	B-C0013313
mater	I-C0013313
is	O
essential	B-C0205224
.	O
	
in	O
this	O
study	O
,	O
the	O
effect	B-C1280500
of	O
systemic	B-C0205373
and	O
local	B-C0205276
supplementation	B-C2348609
of	O
l-arginine	B-C0003765
on	O
dural	B-C0043240
healing	I-C0043240
was	O
evaluated	O
.	O
	
thirty	O
male	B-C0086582
wistar	B-C0034716
rats	I-C0034716
were	O
used	O
and	O
divided	B-C0332849
into	O
control	B-C0009932
,	O
local	B-C0205276
,	O
and	O
systemic	B-C0205373
l-arginine	B-C0003765
groups	B-C0441833
,	O
with	O
10	O
rats	B-C0034716
in	O
each	O
.	O
	
in	O
each	O
group	B-C0441833
,	O
a	O
5-mm	O
experimental	B-C0184898
incision	I-C0184898
was	O
made	O
at	O
the	O
lumbar	B-C2330954
segment	I-C2330954
of	I-C2330954
the	I-C2330954
dura	I-C2330954
mater	I-C2330954
and	O
cerebrospinal	B-C0023182
fluid	I-C0023182
leakage	I-C0023182
was	O
induced	B-C0205263
.	O
	
each	O
group	B-C0441833
was	O
divided	B-C0332849
into	O
2	O
subgroups	B-C1515021
and	O
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	B-C0439230
,	O
the	O
rats	B-C0034716
were	O
killed	B-C0015187
and	O
the	O
damaged	B-C1883709
segments	B-C0441635
of	O
the	O
dura	B-C0013313
were	O
separated	B-C0443299
,	O
histologically	B-C0205462
evaluated	O
and	O
the	O
dural	B-C0043240
healing	I-C0043240
indicators	B-C1522602
including	O
cell	B-C0007634
types	I-C0007634
,	O
granulation	B-C0018180
tissue	I-C0018180
formation	B-C1522492
,	O
collagen	B-C0009325
deposit	B-C0333562
,	O
and	O
vascularization	B-C0042382
were	O
compared	B-C1707455
between	O
groups	B-C0441833
.	O
	
the	O
systematic	B-C0220922
supplementation	B-C2348609
of	O
l-arginine	B-C0003765
showed	O
a	O
significant	B-C0750502
effect	B-C1280500
in	O
dural	B-C0043240
healing	I-C0043240
compared	B-C1707455
with	O
the	O
control	B-C0009932
group	I-C0009932
.	O
	
after	O
the	O
first	O
week	B-C0439230
,	O
granulation	B-C0018180
formation	B-C1522492
increased	B-C0205217
considerably	O
p	O
<	O
0.031	O
,	O
and	O
after	O
6	O
weeks	B-C0439230
,	O
collagen	B-C0009325
deposition	B-C0333562
and	O
neovascularization	B-C0027686
were	O
significantly	O
different	B-C1705242
compared	B-C1707455
with	O
the	O
control	B-C0009932
group	I-C0009932
p	O
<	O
0.030	O
p	O
<	O
0.009	O
.	O
	
in	O
comparison	B-C1707455
between	O
different	B-C1705242
groups	B-C0441833
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	B-C0439230
,	O
maximum	B-C0806909
changes	B-C0392747
in	O
healing	B-C0043240
indicators	B-C1522602
were	O
observed	B-C1441672
in	O
the	O
systemic	B-C0205373
group	B-C0441833
and	O
the	O
least	O
variations	B-C0205419
were	O
related	O
to	O
the	O
control	B-C0009932
group	I-C0009932
.	O
	
the	O
systemic	B-C0205373
supplementation	B-C2348609
of	O
l-arginine	B-C0003765
may	O
accelerate	B-C0521110
dural	B-C0043240
healing	I-C0043240
by	O
increasing	B-C0442808
the	O
level	B-C0441889
of	O
granulation	B-C0018180
tissue	I-C0018180
formation	B-C1522492
,	O
collagen	B-C0009325
deposition	B-C0333562
,	O
and	O
birth	B-C1254363
preparedness	I-C1254363
and	I-C1254363
complication	I-C1254363
readiness	I-C1254363
practice	I-C1254363
and	O
associated	B-C0439849
factors	B-C1521761
among	O
pregnant	B-C0033011
women	I-C0033011
,	O
northwest	B-C0015024
ethiopia	I-C0015024
background	O
.	O
	
little	O
is	O
known	O
about	O
birth	B-C1254363
preparedness	I-C1254363
and	I-C1254363
complication	I-C1254363
readiness	I-C1254363
bpcr	B-C1254363
plan	B-C1301732
in	O
resource	O
limited	O
settings	O
to	O
decrease	O
maternal	B-C0024923
mortality	I-C0024923
.	O
	
therefore	O
,	O
this	O
study	B-C2603343
was	O
done	O
to	O
assess	B-C0184514
the	O
status	B-C0449438
of	O
bpcr	B-C1254363
and	O
associated	B-C0439849
factors	B-C1521761
among	O
pregnant	B-C0033011
women	I-C0033011
in	O
south	B-C0015024
wollo	I-C0015024
,	O
northwest	B-C0015024
ethiopia	I-C0015024
,	O
by	O
involving	O
819	O
pregnant	B-C0033011
women	I-C0033011
from	O
march	O
to	O
april	O
,	O
2014	O
.	O
	
data	B-C1511726
were	O
collected	O
by	O
using	O
pretested	O
interviewer	B-C0021821
administered	B-C0034394
questionnaire	I-C0034394
and	O
analyzed	B-C0936012
using	O
a	O
computer	B-C0037585
program	I-C0037585
of	O
spss	B-C0333052
version	I-C0333052
20.00	I-C0333052
.	O
	
results	B-C1274040
.	O
	
pregnant	B-C0033011
women	I-C0033011
who	O
were	O
prepared	B-C4082130
for	O
at	O
least	O
three	O
elements	B-C3812827
of	O
bpcr	B-C1254363
were	O
24.1	O
.	O
	
pregnant	B-C0033011
women	I-C0033011
knowing	O
at	O
least	O
three	O
key	O
danger	B-C0037088
signs	I-C0037088
during	O
pregnancy	B-C0032961
,	O
delivery	B-C0005615
,	O
and	O
postnatal	B-C0871109
period	I-C0871109
were	O
23.2	O
,	O
22.6	O
,	O
and	O
9.6	O
,	O
respectively	O
.	O
	
women	B-C0043210
having	O
secondary	B-C0683860
education	I-C0683860
and	O
higher	O
were	O
6.20	O
95%	O
ci	B-C0009667
=	O
1.36	O
,	O
28.120	O
times	O
more	O
likely	O
to	O
be	O
prepared	B-C4082130
than	O
illiterates	B-C0020899
.	O
	
women	B-C0043210
having	O
a	O
lifetime	B-C0598779
history	I-C0598779
of	O
stillbirth	B-C0595939
5.80	O
1.13	O
,	O
29.63	O
,	O
attending	B-C1999232
anc	B-C0033052
for	O
last	O
child	B-C0008059
pregnancy	B-C0032961
5.44	O
2.07	O
,	O
14.27	O
,	O
participating	B-C0679823
in	O
community	B-C0009462
bpcr	B-C1254363
group	B-C0237576
discussion	I-C0237576
4.36	O
1.17	O
,	O
16.26	O
,	O
and	O
having	O
their	O
male	B-C0086582
partner	B-C0682323
involved	O
in	O
bpcr	B-C1254363
counseling	B-C0010210
during	O
anc	B-C0033052
follow-up	B-C1522577
4.45	O
1.95	O
,	O
10.16	O
were	O
more	O
likely	O
to	O
be	O
prepared	B-C4082130
.	O
	
conclusions	B-C1707478
.	O
	
bpcr	B-C1254363
was	O
very	O
low	O
and	O
should	O
be	O
strengthened	O
through	O
health	B-C1512347
communication	I-C1512347
by	O
involving	O
partner	B-C0682323
in	O
bpcr	B-C1254363
counseling	B-C0010210
.	O
	
fluoranthene	B-C0060514
degradation	B-C0005482
and	O
binding	B-C1167622
mechanism	B-C0441712
study	B-C2603343
based	O
on	O
the	O
active-site	B-C0205681
structure	B-C0678594
of	O
ring-hydroxylating	B-C0599874
dioxygenase	I-C0599874
in	O
microbacterium	B-C4153571
paraoxydans	I-C4153571
jpm1	I-C4153571
in	O
this	O
study	B-C2603343
,	O
a	O
gram-positive	B-C0018154
fluoranthene-degrading	I-C0018154
bacterial	I-C0018154
strain	B-C1518614
was	O
isolated	B-C0205409
from	O
crude	B-C0031264
oil	I-C0031264
in	O
dagang	B-C3179127
oilfield	I-C3179127
and	O
identified	B-C0205396
as	O
microbacterium	B-C4153571
paraoxydans	I-C4153571
jpm1	I-C4153571
by	O
the	O
analysis	B-C0936012
of	O
16s	B-C3537372
rdna	I-C3537372
sequence	B-C0004793
.	O
	
after	O
25	O
days	B-C0439228
of	O
incubation	B-C1439852
,	O
the	O
strain	B-C1518614
jpm1	B-C4153571
could	O
degrade	O
91.78	O
%	O
of	O
the	O
initial	B-C0205265
amount	B-C1265611
of	O
fluoranthene	B-C0060514
.	O
	
moreover	O
,	O
four	O
metabolites	B-C0870883
9-fluorenone-1-carboxylic	B-C0574031
acid	I-C0574031
,	O
9-fluorenone	B-C0050227
,	O
phthalic	B-C0070968
acid	I-C0070968
,	O
and	O
benzoic	B-C0053225
acid	I-C0053225
were	O
detected	O
in	O
the	O
culture	B-C0010454
solution	I-C0010454
.	O
	
the	O
gene	B-C0004793
sequence	I-C0004793
encoding	B-C2700640
the	O
aromatic-ring-hydroxylating	B-C0599874
dioxygenase	I-C0599874
was	O
amplified	B-C0017256
in	O
the	O
strain	B-C1518614
jpm1	B-C4153571
by	O
pcr	B-C0032520
.	O
	
based	O
on	O
the	O
translated	O
protein	B-C0002518
sequence	I-C0002518
,	O
a	O
homology	B-C1512489
modeling	I-C1512489
method	I-C1512489
was	O
applied	O
to	O
build	O
the	O
crystal	B-C0444626
structure	I-C0444626
of	O
dioxygenase	B-C0599874
.	O
	
subsequently	O
,	O
the	O
interaction	B-C1704675
mechanism	B-C0441712
between	O
fluoranthene	B-C0060514
and	O
the	O
active	B-C0205681
site	I-C0205681
of	O
dioxygenase	B-C0599874
was	O
simulated	B-C0679083
and	O
analyzed	B-C0936012
by	O
molecular	B-C3494273
docking	I-C3494273
.	O
	
consequently	O
,	O
a	O
feasible	O
degrading	B-C0005482
pathway	B-C1704259
of	O
fluoranthene	B-C0060514
in	O
the	O
strain	B-C1518614
jpm1	B-C4153571
was	O
proposed	O
based	O
on	O
the	O
metabolites	B-C0870883
and	O
the	O
interaction	B-C0237688
analyses	I-C0237688
.	O
	
additionally	O
,	O
the	O
thermodynamic	B-C0936012
analysis	I-C0936012
showed	O
that	O
the	O
strain	B-C1518614
jpm1	B-C4153571
had	O
high	B-C0205250
tolerance	B-C1704410
for	O
fluoranthene	B-C0060514
,	O
and	O
the	O
influence	B-C4054723
of	O
fluoranthene	B-C0060514
for	O
the	O
bacterial	B-C0004611
growth	B-C0018270
activity	O
was	O
negligible	B-C0332269
under	O
100	O
to	O
400	O
mg	O
l	O
concentrations	B-C1446561
.	O
	
taken	O
together	O
,	O
this	O
study	B-C2603343
indicates	O
that	O
the	O
strain	B-C1518614
jpm1	B-C4153571
has	O
high	O
potential	B-C3245505
for	O
further	O
study	B-C2603343
in	O
bioremediation	B-C0598015
of	O
polycyclic	B-C0032458
aromatic	I-C0032458
hydrocarbon	I-C0032458
pah	B-C0032458
contaminated	B-C0205279
sites	B-C0205145
.	O
	
ultrasonography	B-C0041618
for	O
acute	B-C0003615
appendicitis	I-C0003615
-	O
the	O
way	O
it	O
looks	O
today	O
despite	O
sophisticated	O
physical	B-C0031809
examination	I-C0031809
and	O
laboratory	B-C0022885
support	I-C0022885
,	O
diagnosis	B-C0011900
of	O
acute	B-C0003615
appendicitis	I-C0003615
remained	O
challenging	O
in	O
clinical	B-C0205897
practice	I-C0205897
with	O
a	O
negative	B-C0003611
appendectomy	I-C0003611
rate	B-C1521828
of	O
15	O
-	O
30	O
%	O
.	O
	
as	O
a	O
remarkable	O
clue	O
and	O
as	O
early	O
as	O
1986	O
,	O
ultrasonography	B-C0041618
us	B-C0041618
has	O
been	O
proven	O
a	O
reliable	B-C3858758
diagnostic	B-C0086143
method	I-C0086143
that	O
is	O
also	O
explicitly	O
helpful	O
in	O
difficult	O
cases	O
with	O
atypical	B-C0205182
presentation	B-C0449450
and	O
enables	O
to	O
rule	B-C0332196
out	I-C0332196
many	O
differential	B-C0011906
diagnoses	I-C0011906
recent	O
publications	B-C0034036
emphasized	O
the	O
role	O
of	O
multidetector	B-C3179130
computed	I-C3179130
tomography	I-C3179130
ct	B-C3179130
resulting	O
in	O
a	O
significant	O
reduction	O
of	O
false	B-C0205558
negative	I-C0205558
findings	I-C0205558
at	O
operation	B-C0543467
.	O
	
extensive	B-C0205231
as	O
well	O
as	O
uncritical	B-C0441485
application	I-C0441485
of	O
this	O
method	O
even	O
in	O
children	B-C0008059
inevitably	O
causes	O
substantial	O
radiation	B-C0418228
exposure	I-C0418228
,	O
a	O
sequel	O
to	O
either	O
pure	O
ignorance	O
or	O
unqualified/	O
inadequate	B-C0205412
performance	B-C1882330
of	O
us	B-C0041618
in	O
this	O
particular	O
situation	O
,	O
which	O
in	O
turn	O
can	O
be	O
considered	O
sequel	O
to	O
either	O
egocentric	B-C0564559
or	O
economic	B-C0013557
preponderance	B-C0220900
recent	O
data	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
us	B-C0041618
and	O
ct	B-C3179130
in	O
acute	B-C0003615
appendicitis	I-C0003615
.	O
	
therefore	O
,	O
1	O
generation	O
after	O
us	B-C0041618
with	I-C0041618
graded	I-C0041618
compression	I-C0041618
was	O
etched	O
in	O
stone	O
as	O
the	O
method	O
of	O
choice	O
for	O
diagnosing	B-C0011900
acute	B-C0003615
appendicitis	I-C0003615
puylaert	O
,	O
a	O
visual	B-C0234621
arousal	B-C0003808
fostering	B-C0242298
its	O
role	O
and	O
performance	O
in	O
clinical	B-C0008964
medicine	I-C0008964
mesenchymal	B-C1257975
stem	I-C1257975
cells	I-C1257975
enhance	B-C2349975
the	O
oncolytic	B-C1518581
effect	B-C1280500
of	O
newcastle	B-C0027984
disease	I-C0027984
virus	I-C0027984
in	O
glioma	B-C0017638
cells	B-C0007634
and	O
glioma	B-C0017638
stem	B-C0038250
cells	I-C0038250
via	O
the	O
secretion	B-C0036536
of	O
trail	B-C0385242
newcastle	B-C0027984
disease	I-C0027984
virus	I-C0027984
ndv	B-C0027984
is	O
an	O
avian	B-C0206540
paramyxovirus	I-C0206540
,	O
which	O
selectively	O
exerts	B-C0015264
oncolytic	B-C1518581
effects	B-C1280500
in	O
cancer	B-C0334227
cells	I-C0334227
.	O
	
mesenchymal	B-C1257975
stem	I-C1257975
cells	I-C1257975
mscs	B-C1257975
have	O
been	O
reported	O
to	O
affect	O
tumor	B-C0598934
growth	I-C0598934
and	O
deliver	B-C1705822
anti-tumor	B-C0003392
agents	I-C0003392
to	O
experimental	B-C1517586
glioblastoma	B-C0017636
gbm	B-C0017636
.	O
	
here	O
,	O
we	O
explored	O
the	O
effects	B-C1704420
of	I-C1704420
ndv	B-C0027984
-	O
infected	B-C0439663
mscs	B-C1257975
derived	O
from	O
different	O
sources	B-C0449416
,	O
on	O
glioma	B-C0017638
cells	B-C0007634
and	O
glioma	B-C0017638
stem	B-C0038250
cells	I-C0038250
gscs	B-C0038250
and	O
the	O
mechanisms	B-C0441712
involved	O
in	O
their	O
effects	B-C1280500
.	O
	
the	O
glioma	B-C0017638
cell	B-C0085983
lines	I-C0085983
a172	B-C0085983
and	O
u87	B-C0085983
and	O
primary	B-C0205225
gscs	B-C0038250
that	O
were	O
generated	B-C3146294
from	O
gbm	B-C0017636
tumors	B-C0027651
were	O
used	O
in	O
this	O
study	B-C0681814
.	O
	
mscs	B-C1257975
derived	B-C1441547
from	O
bone	B-C0005953
marrow	I-C0005953
,	O
adipose	B-C0001527
tissue	I-C0001527
or	O
umbilical	B-C0041633
cord	I-C0041633
were	O
infected	B-C0439663
with	O
ndv	B-C0027984
mth-68/h	B-C0965740
.	O
	
the	O
ability	B-C0085732
of	O
these	O
cells	B-C0007634
to	O
deliver	B-C1705822
the	O
virus	B-C0042776
to	O
glioma	B-C0017638
cell	B-C0085983
lines	I-C0085983
and	O
gscs	B-C0038250
and	O
the	O
effects	B-C1704420
of	I-C1704420
ndv	B-C0027984
-	O
infected	B-C0439663
mscs	B-C1257975
on	O
cell	B-C0007587
death	I-C0007587
and	O
on	O
the	O
stemness	B-C0205556
and	O
self-renewal	B-C1155711
of	O
gscs	B-C0038250
were	O
examined	B-C0332128
.	O
	
the	O
mechanisms	B-C0441712
involved	B-C1314939
in	O
the	O
cytotoxic	B-C1511636
effects	B-C1704420
of	I-C1704420
the	O
ndv	B-C0027984
-	O
infected	B-C0439663
mscs	B-C1257975
and	O
their	O
influence	B-C4054723
on	O
the	O
radiation	B-C0034537
sensitivity	I-C0034537
of	O
gscs	B-C0038250
were	O
examined	B-C0332128
as	O
well	O
.	O
	
ndv	B-C0027984
induced	B-C0205263
a	O
dose-dependent	B-C1512045
cell	B-C0007587
death	I-C0007587
in	O
glioma	B-C0017638
cells	B-C0007634
and	O
a	O
low	B-C0205251
level	B-C0441889
of	O
apoptosis	B-C0162638
and	O
inhibition	B-C3463820
of	O
self-renewal	B-C1155711
in	O
gscs	B-C0038250
.	O
	
mscs	B-C1257975
derived	B-C1441547
from	O
bone	B-C0005953
marrow	I-C0005953
,	O
adipose	B-C0001527
and	O
umbilical	B-C0041633
cord	I-C0041633
that	O
were	O
infected	B-C0439663
with	O
ndv	B-C0027984
delivered	B-C1705822
the	O
virus	B-C0042776
to	O
co-cultured	B-C0282547
glioma	B-C0017638
cells	B-C0007634
and	O
gscs	B-C0038250
.	O
	
conditioned	B-C0162518
medium	I-C0162518
of	O
ndv	B-C0027984
-	O
infected	B-C0439663
mscs	B-C1257975
induced	B-C0205263
higher	B-C0205250
level	B-C0441889
of	O
apoptosis	B-C0162638
in	O
the	O
tumor	B-C0597032
cells	I-C0597032
compared	B-C1707455
with	O
the	O
apoptosis	B-C0162638
induced	B-C0205263
by	O
their	O
direct	B-C1707758
infection	I-C1707758
with	O
similar	B-C2348205
virus	B-C2713348
titers	I-C2713348
.	O
	
these	O
results	B-C0683954
suggest	B-C1705535
that	O
factor	B-C1521761
secreted	B-C1327616
by	O
the	O
infected	B-C0439663
mscs	B-C1257975
sensitized	B-C0312864
the	O
glioma	B-C0017638
cells	B-C0007634
to	O
the	O
cytotoxic	B-C1511636
effects	B-C1704420
of	I-C1704420
ndv	B-C0027984
.	O
	
we	O
identified	B-C0205396
trail	B-C0385242
as	O
a	O
mediator	B-C0205556
of	O
the	O
cytotoxic	B-C1511636
effects	B-C1704420
of	I-C1704420
the	O
infected	B-C0439663
mscs	B-C1257975
and	O
demonstrated	B-C0205556
that	O
trail	B-C0385242
synergized	O
with	O
ndv	B-C0027984
in	O
the	O
induction	B-C0205263
of	O
cell	B-C0007587
death	I-C0007587
in	O
glioma	B-C0017638
cells	B-C0007634
and	O
gscs	B-C0038250
.	O
	
moreover	O
,	O
conditioned	B-C0348080
medium	B-C0439536
of	O
infected	B-C0439663
mscs	B-C1257975
enhanced	B-C2349975
the	O
sensitivity	O
of	O
gscs	B-C0038250
to	O
γ-radiation	B-C0017011
.	O
	
ndv	B-C0027984
-	O
infected	B-C0439663
umbilical	B-C0041633
cord	I-C0041633
-	O
derived	B-C1441547
mscs	B-C1257975
may	O
provide	O
a	O
novel	B-C0205314
effective	B-C1704419
therapeutic	B-C0302350
approach	B-C0449445
for	O
targeting	B-C1521840
gscs	B-C0038250
and	O
gbm	B-C0017636
and	O
for	O
sensitizing	O
these	O
tumors	B-C0027651
to	O
importance	B-C3898777
of	O
ecological	B-C0870460
factors	I-C0870460
and	O
colony	B-C0441833
handling	B-C1832073
for	O
optimizing	B-C2698650
health	B-C0018759
status	I-C0018759
of	O
apiaries	B-C3273359
in	O
mediterranean	B-C0240321
ecosystems	B-C0162358
we	O
analyzed	B-C0936012
six	O
apiaries	B-C3273359
in	O
several	O
natural	B-C0557745
environments	I-C0557745
with	O
a	O
mediterranean	B-C0240321
ecosystem	B-C0162358
in	O
madrid	B-C0037747
,	O
central	B-C0037747
spain	I-C0037747
,	O
in	O
order	O
to	O
understand	B-C0162340
how	O
landscape	B-C0870781
and	O
management	B-C0680830
characteristics	B-C1521970
may	O
influence	B-C4054723
apiary	B-C3273359
health	B-C0018684
and	O
bee	B-C0004923
production	O
in	O
the	O
long	B-C0443252
term	I-C0443252
.	O
	
we	O
focused	B-C1285542
on	O
five	O
criteria	B-C0243161
habitat	B-C0871648
quality	B-C0332306
,	O
landscape	B-C0870781
heterogeneity	B-C0019409
,	O
climate	B-C0008946
,	O
management	B-C0680830
and	O
health	B-C0018684
,	O
as	O
well	O
as	O
30	O
subcriteria	B-C0243161
,	O
and	O
we	O
used	O
the	O
analytic	B-C0035177
hierarchy	I-C0035177
process	I-C0035177
ahp	B-C0035177
to	O
rank	B-C0699794
them	O
according	O
to	O
relevance	B-C2347946
.	O
	
habitat	B-C0871648
quality	B-C0332306
proved	O
to	O
have	O
the	O
highest	O
relevance	B-C2347946
,	O
followed	O
by	O
beehive	B-C3273359
management	B-C0680830
.	O
	
within	O
habitat	B-C0871648
quality	B-C0332306
,	O
the	O
following	O
subcriteria	B-C0243161
proved	O
to	O
be	O
most	O
relevant	B-C2347946
orographic	B-C1880371
diversity	I-C1880371
,	O
elevation	B-C0702240
range	B-C1514721
and	O
important	B-C3898777
plant	B-C0032098
species	B-C1705920
located	B-C0332285
1.5	O
km	O
from	O
the	O
apiary	B-C3273359
.	O
	
the	O
most	O
important	B-C3898777
subcriteria	B-C0243161
under	O
beehive	B-C3273359
management	B-C0680830
were	O
honey	B-C0019906
production	B-C0033268
,	O
movement	O
of	O
the	O
apiary	B-C3273359
to	O
a	O
location	B-C0450429
with	O
a	O
higher	O
altitude	B-C0002349
and	O
wax	B-C0004924
renewal	B-C0205245
.	O
	
temperature	B-C0039476
was	O
the	O
most	O
important	O
subcriterion	B-C0243161
under	O
climate	B-C0008946
,	O
while	O
pathogen	B-C0450254
and	O
varroa	B-C0323623
loads	B-C0243095
were	O
the	O
most	O
significant	B-C0750502
under	O
health	B-C0018684
.	O
	
two	O
of	O
the	O
six	O
apiaries	B-C3273359
showed	O
the	O
best	B-C1299381
values	I-C1299381
in	O
the	O
ahp	B-C0035177
analysis	B-C0936012
and	O
showed	O
annual	B-C0332181
honey	B-C0019906
production	B-C0033268
of	O
70	O
and	O
28	O
kg/	O
colony	B-C0441833
.	O
	
this	O
high	O
productivity	B-C0033269
was	O
due	O
primarily	O
to	O
high	O
elevation	B-C0702240
range	B-C1514721
and	O
high	O
orographic	B-C1880371
diversity	I-C1880371
,	O
which	O
favored	O
high	O
habitat	B-C0871648
quality	B-C0332306
.	O
	
in	O
addition	O
,	O
one	O
of	O
these	O
apiaries	B-C3273359
showed	O
the	O
best	B-C1299381
value	I-C1299381
for	O
beehive	B-C3273359
management	B-C0680830
,	O
while	O
the	O
other	O
showed	O
the	O
best	B-C1299381
value	I-C1299381
for	O
health	B-C0018684
,	O
reflected	O
in	O
the	O
low	B-C0205251
pathogen	B-C0450254
load	B-C0243095
and	O
low	B-C0205251
average	B-C1510992
number	B-C0237753
of	O
viruses	B-C0042776
.	O
	
these	O
results	B-C1274040
highlight	O
the	O
importance	B-C3898777
of	O
environmental	B-C0870460
factors	I-C0870460
and	O
good	O
sanitary	B-C0205245
practices	I-C0205245
to	O
maximize	O
apiary	B-C3273359
health	B-C0018684
and	O
honey	B-C0019906
productivity	B-C0033269
.	O
	
chordoma	B-C1266174
dedifferentiation	I-C1266174
after	O
proton	B-C2169187
beam	I-C2169187
therapy	I-C2169187
a	O
case	B-C0007320
report	I-C0007320
and	O
review	B-C0282441
of	I-C0282441
the	I-C0282441
literature	I-C0282441
chordoma	B-C0008487
is	O
a	O
rare	B-C0522498
invasive	B-C0205281
bone	B-C0005967
tumor	I-C0005967
that	O
may	O
occur	O
anywhere	O
along	O
the	O
neuraxis	B-C1522496
.	O
	
a	O
total	O
of	O
three	O
primary	B-C0205225
histological	B-C0027652
varieties	I-C0027652
have	O
been	O
identified	B-C0205396
conventional	B-C0008487
,	O
chondroid	B-C1266173
,	O
and	O
dedifferentiated	B-C1266174
.	O
	
we	O
report	B-C0684224
a	O
case	B-C1706256
of	O
an	O
8-year-old	O
white	B-C0007457
girl	B-C0870604
who	O
presented	O
with	O
conventional	B-C0008487
chordoma	I-C0008487
,	O
was	O
treated	B-C0332154
with	O
surgical	B-C0015252
resection	I-C0015252
and	O
mixed	B-C0205430
proton	B-C0729603
and	O
photon	B-C3539769
beam	I-C3539769
therapy	I-C3539769
,	O
and	O
had	O
a	O
recurrence	B-C0034897
in	O
the	O
resection	B-C1515091
cavity	I-C1515091
2.5	O
years	O
later	O
with	O
dedifferentiated	B-C1266174
morphology	I-C1266174
.	O
	
the	O
recurrent	B-C0521158
tumor	I-C0521158
did	O
not	O
express	B-C1171362
brachyury	B-C0170844
,	O
a	O
recently	B-C0332185
identified	B-C0205396
protein	B-C0033684
specific	B-C0205369
to	O
tissue	B-C0040300
of	O
notochordal	B-C0028439
origin	B-C0439659
.	O
	
the	O
short	B-C1806781
time	B-C1948053
period	I-C1948053
between	O
radiation	B-C2169187
therapy	I-C2169187
and	O
dedifferentiation	B-C2248595
,	O
low	B-C0445550
dose	I-C0445550
of	O
photons	B-C0086805
,	O
and	O
rarity	B-C0522498
of	O
dedifferentiated	B-C2164487
skull	I-C2164487
base	I-C2164487
chordomas	I-C2164487
in	O
pediatric	B-C1521725
patients	B-C0030705
should	O
alert	B-C3665546
clinicians	B-C0871685
to	O
the	O
possibility	B-C0332149
of	O
chordoma	B-C1266174
dedifferentiation	I-C1266174
after	O
proton	B-C2169187
beam	I-C2169187
therapy	I-C2169187
.	O
	
volumetric	B-C0430022
absorptive	I-C0430022
microsampling	I-C0430022
at	O
home	B-C0442519
as	O
an	O
alternative	B-C1523987
tool	B-C0336791
for	O
the	O
monitoring	B-C1283169
of	O
hba1c	B-C0019018
in	O
diabetes	B-C0011847
patients	B-C0030705
microsampling	B-C0449851
techniques	I-C0449851
have	O
several	O
advantages	O
over	O
traditional	O
blood	B-C0005834
collection	I-C0005834
.	O
	
dried	B-C3178862
blood	I-C3178862
spot	I-C3178862
dbs	I-C3178862
sampling	I-C3178862
and	O
blood	B-C0005834
collection	I-C0005834
with	O
heparinized	B-C0184108
capillaries	I-C0184108
are	O
the	O
standard	B-C1442989
techniques	B-C0022885
.	O
	
volumetric	B-C0430022
absorptive	I-C0430022
microsampling	I-C0430022
vams	B-C0430022
is	O
a	O
novel	O
technique	B-C0022885
that	O
collects	O
a	O
fixed	O
volume	B-C0449468
of	O
blood	B-C0005767
by	O
applying	O
an	O
absorbent	O
tip	B-C3282898
to	O
a	O
blood	B-C0005767
drop	I-C0005767
.	O
	
in	O
the	O
present	O
study	B-C2603343
we	O
explored	O
the	O
feasibility	O
of	O
hba1c	B-C0019018
monitoring	B-C1283169
with	O
vams	B-C0430022
sampling	I-C0430022
at	O
home	B-C0442519
and	O
analysis	B-C0936012
in	O
the	O
laboratory	B-C0022877
.	O
	
diabetic	B-C0011847
patients	B-C0030705
were	O
enrolled	O
in	O
this	O
study	B-C2603343
during	O
consultation	B-C0009818
with	O
the	O
endocrinologist	B-C0259863
.	O
	
a	O
venous	B-C0444255
adults	B-C0001675
or	O
capillary	B-C0444254
children	I-C0444254
sample	I-C0444254
was	O
taken	O
for	O
immediate	O
hba1c	B-C0019018
analysis	B-C0936012
.	O
	
dbs	B-C3178862
n=1	O
and	O
dried	B-C0430022
vams	I-C0430022
n=2	O
were	O
collected	O
at	O
home	B-C0442519
and	O
sent	O
to	O
the	O
laboratory	B-C0022877
.	O
	
for	O
25	O
pediatric	B-C1521725
patients	B-C0030705
one	O
vams	B-C0430022
was	O
collected	O
during	O
consultation	B-C0009818
for	O
immediate	O
analysis	B-C0936012
without	O
drying	O
,	O
referred	O
to	O
as	O
""""	O
wet	B-C0430022
vams	I-C0430022
""""	O
.	O
	
hba1c	B-C0019018
analyses	B-C0936012
were	O
performed	O
on	O
a	O
tosoh	B-C0179038
hlc-723	I-C0179038
g8	I-C0179038
high-performance	I-C0179038
liquid	I-C0179038
chromatography	I-C0179038
hplc	I-C0179038
analyzer	I-C0179038
.	O
	
the	O
median	O
time	O
between	O
sampling	B-C0430022
at	O
home	B-C0442519
and	O
analysis	B-C0936012
was	O
3	O
days	B-C0439228
.	O
	
results	B-C1274040
of	O
hba1c	B-C0019018
in	O
dried	O
vams	B-C0430022
showed	O
a	O
poor	O
agreement	O
with	O
venous	B-C0444255
/	O
capillary	B-C0444254
blood	I-C0444254
collected	O
in	O
hospital	B-C0019994
concordance	B-C1707429
correlation	I-C1707429
coefficient	I-C1707429
ccc	B-C1707429
=0	O
.	O
	
similar	O
observations	O
were	O
found	O
with	O
standard	B-C1442989
dbs	B-C3178862
.	O
	
an	O
excellent	O
agreement	O
was	O
obtained	O
between	O
hba1c	B-C0019018
results	B-C1274040
on	O
wet	B-C0430022
vams	I-C0430022
ccc	B-C1707429
=0	O
and	O
standard	B-C1442989
blood	B-C0178913
samples	I-C0178913
.	O
	
patients	B-C0030705
experienced	O
vams	B-C0430022
and	O
dbs	B-C3178862
as	O
easy	B-C0332219
and	O
convenient	B-C3831015
to	O
use	B-C0457083
.	O
	
utilizing	O
equipment	B-C0014672
standard	B-C1442989
available	O
in	O
the	O
clinical	B-C0205210
laboratory	B-C0022877
,	O
the	O
use	O
of	O
home	B-C0442519
-sampled	O
dried	B-C0430022
vams	I-C0430022
and	O
dbs	B-C3178862
is	O
not	O
a	O
reliable	O
tool	O
for	O
the	O
monitoring	B-C1283169
of	O
hba1c	B-C0019018
.	O
	
however	O
,	O
perfect	O
agreement	O
between	O
hba1c	B-C0019018
measured	O
on	O
wet	B-C0430022
vams	I-C0430022
and	O
capillary	B-C0444254
microsamples	I-C0444254
are	O
eyes	B-C0015392
a	O
mirror	B-C0870904
of	O
the	O
soul	B-C1510643
what	O
eye	B-C0015392
wrinkles	B-C2729169
reveal	B-C0443289
about	O
a	O
horse's	B-C0019944
emotional	B-C0935620
state	I-C0935620
finding	O
valid	B-C2349099
indicators	B-C1522602
of	O
emotional	B-C0935620
states	I-C0935620
is	O
one	O
of	O
the	O
biggest	O
challenges	O
in	O
animal	B-C0003061
welfare	I-C0003061
science	I-C0003061
.	O
	
here	O
,	O
we	O
investigated	B-C1292732
in	O
horses	B-C0019944
whether	O
variation	B-C0205419
in	O
the	O
expression	B-C0700364
of	O
eye	B-C0015392
wrinkles	B-C2729169
caused	O
by	O
contraction	B-C1140999
of	O
the	O
inner	B-C0015420
eyebrow	I-C0015420
raiser	O
reflects	B-C0558058
emotional	B-C0849912
valence	I-C0849912
.	O
	
by	O
confronting	O
horses	B-C0019944
with	O
positive	B-C1446409
and	O
negative	B-C0205160
conditions	B-C0348080
,	O
we	O
aimed	O
to	O
induce	B-C0205263
positive	B-C1446409
and	O
negative	B-C0205160
emotional	B-C0935620
states	I-C0935620
,	O
hypothesising	B-C1512571
that	O
positive	B-C1446409
emotions	B-C0013987
would	O
reduce	B-C0392756
whereas	O
negative	B-C0205160
emotions	B-C0013987
would	O
increase	B-C0442805
eye	B-C0015392
wrinkle	B-C2729169
expression	B-C0700364
.	O
	
sixteen	O
horses	B-C0019944
were	O
individually	O
exposed	B-C0332157
in	O
a	O
balanced	B-C0205415
order	O
to	O
two	O
positive	B-C1446409
grooming	B-C0018249
,	O
food	B-C0679106
anticipation	I-C0679106
and	O
two	O
negative	B-C0205160
condition	B-C0348080
s	O
food	B-C0016452
competition	B-C0679932
,	O
waving	B-C0441655
a	O
plastic	B-C3273359
bag	I-C3273359
.	O
	
each	O
condition	B-C0348080
lasted	O
for	O
60	O
seconds	B-C0457385
and	O
was	O
preceded	O
by	O
a	O
60	O
second	B-C0457385
control	B-C0205390
phase	I-C0205390
.	O
	
throughout	O
both	O
phases	B-C0205390
,	O
pictures	B-C0441468
of	O
the	O
eyes	B-C0015392
were	O
taken	O
,	O
and	O
for	O
each	O
horse	B-C0019944
four	O
pictures	B-C0441468
per	O
condition	B-C0348080
and	O
phase	B-C0205390
were	O
randomly	B-C1707391
selected	I-C1707391
.	O
	
pictures	B-C0441468
were	O
scored	O
in	O
random	B-C1705176
order	I-C1705176
and	O
by	O
two	O
experimenters	B-C0870526
blind	B-C0150108
to	O
condition	B-C0348080
and	O
phase	B-C0205390
for	O
six	O
outcome	B-C0086749
measures	I-C0086749
qualitative	B-C0205556
impression	B-C1998467
,	O
eyelid	B-C0015426
shape	B-C0332479
,	O
markedness	B-C1706089
of	O
the	O
wrinkles	B-C2729169
,	O
presence	B-C0150312
of	O
eye	B-C0036410
white	I-C0036410
,	O
number	B-C0237753
of	O
wrinkles	B-C2729169
,	O
and	O
the	O
angle	B-C0205143
between	O
the	O
line	O
through	O
the	O
eyeball	B-C0015392
and	O
the	O
highest	B-C1522410
wrinkle	B-C2729169
.	O
	
the	O
angle	B-C0205143
decreased	B-C0205216
during	O
grooming	B-C0018249
and	O
increased	B-C0205217
during	O
food	B-C0016452
competition	B-C0679932
compared	B-C1707455
to	O
control	B-C0205390
phase	I-C0205390
s	O
,	O
whereas	O
the	O
two	O
phases	B-C0205390
did	O
not	O
differ	O
during	O
food	B-C0679106
anticipation	I-C0679106
and	O
the	O
plastic	B-C3273359
bag	I-C3273359
condition	B-C0348080
.	O
	
no	B-C1301751
effects	I-C1301751
on	O
the	O
other	O
outcome	B-C0086749
measures	I-C0086749
were	O
detected	B-C0442726
.	O
	
taken	O
together	O
,	O
we	O
have	O
defined	O
a	O
set	O
of	O
measures	B-C0079809
to	O
assess	B-C1516048
eye	B-C0015392
wrinkle	B-C2729169
expression	B-C0700364
reliably	O
,	O
of	O
which	O
one	O
measure	B-C0079809
was	O
affected	B-C0392760
by	O
the	O
conditions	B-C0348080
the	O
horses	B-C0019944
were	O
exposed	B-C0332157
to	I-C0332157
.	O
	
variation	B-C0205419
in	O
eye	B-C0015392
wrinkle	B-C2729169
expression	B-C0700364
might	O
provide	B-C0359589
valuable	O
information	B-C1533716
on	O
horse	B-C0019944
welfare	B-C0003061
but	O
further	O
validation	B-C1519941
of	O
specific	B-C0205369
measures	B-C0079809
across	O
different	B-C1705242
conditions	B-C0348080
effective	B-C1704419
mercury	B-C0025424
bioremoval	B-C1883720
from	O
aqueous	B-C3255993
solution	I-C3255993
,	O
and	O
its	O
electrochemical	B-C0259857
determination	I-C0259857
this	O
work	O
proposed	O
mercury	B-C0025424
elimination	B-C1883720
using	O
agricultural	B-C0001829
waste	B-C0043045
allium	B-C1262904
cepa	I-C1262904
l	I-C1262904
the	O
biomass	B-C0005535
removed	B-C0849355
99.4	O
of	O
mercury	B-C0025424
,	O
following	O
a	O
pseudo-second	B-C0022702
order	I-C0022702
kinetics	I-C0022702
r	O
=	O
0.9999	O
.	O
	
the	O
langmuir	B-C0876936
model	I-C0876936
was	O
adequately	B-C0205411
fitted	O
to	O
the	O
adsorption	B-C1254366
isotherm	I-C1254366
,	O
thereby	O
obtaining	O
the	O
maximum	B-C0806909
mercury	B-C0025424
adsorption	B-C0001674
capacity	B-C1516240
of	O
111.1	O
0.3	O
mg	O
g	O
.	O
	
the	O
biomass	B-C0005535
showed	O
high	B-C0205250
density	B-C0178587
of	O
strong	B-C0442821
mercury	B-C0025424
chelating	B-C0007974
groups	I-C0007974
,	O
thus	O
making	O
it	O
economically	B-C0013557
attractive	B-C2346874
.	O
	
also	O
,	O
the	O
implementation	B-C1708476
of	O
a	O
mercury	B-C0025424
-	O
selective	B-C0201747
electrode	I-C0201747
for	O
continuous	B-C0549178
determination	B-C1148554
in	O
real	B-C1550177
time	I-C1550177
is	O
proposed	B-C1553874
this	O
electrode	B-C1705652
replaces	B-C1550539
techniques	B-C0449851
like	O
atomic	B-C0037806
absorption	I-C0037806
spectroscopy	I-C0037806
,	O
thus	O
it	O
can	O
be	O
applied	O
to	O
real	B-C1550177
time	I-C1550177
studies	B-C2603343
.	O
	
this	O
work	O
therefore	O
presents	O
a	O
new	O
perspective	B-C0449851
for	O
removing	B-C1883720
mercury	B-C0025424
from	O
contaminated	B-C0043056
water	I-C0043056
for	O
environmental	B-C3853059
remediation	I-C3853059
.	O
	
modeling	B-C0870071
nurse-patient	B-C0578393
assignments	I-C0578393
considering	O
patient	B-C3494263
acuity	I-C3494263
and	O
travel	B-C0040802
distance	B-C0012751
metrics	B-C0242485
balancing	B-C0205415
workload	B-C0085122
among	O
nurses	B-C0028661
on	O
a	O
hospital	B-C0019988
unit	I-C0019988
is	O
important	O
for	O
the	O
satisfaction	B-C0242428
and	O
safety	B-C0036043
of	O
nurses	B-C0028661
and	O
patients	B-C0030705
.	O
	
to	O
balance	B-C0205415
nurse	B-C0028661
workloads	B-C0085122
,	O
direct	B-C1947931
patient	B-C0017313
care	I-C0017313
activities	I-C0017313
,	O
indirect	B-C0439852
patient	B-C0017313
care	I-C0017313
activities	I-C0017313
,	O
and	O
non-patient	B-C1254363
care	I-C1254363
activities	I-C1254363
that	O
occur	O
throughout	O
a	O
shift	B-C0333051
must	O
be	O
considered	O
.	O
	
the	O
layout	O
of	O
a	O
hospital	B-C0019988
unit	I-C0019988
and	O
the	O
location	B-C0450429
of	O
a	O
nurse's	B-C0028661
assigned	B-C1516050
patients	B-C0030705
relative	B-C0205345
to	O
other	O
resources	B-C0035201
on	O
the	O
unit	B-C0019988
are	O
also	O
important	B-C1521761
factors	I-C1521761
in	O
achieving	B-C1272277
workload	B-C0085122
balance	B-C0205415
.	O
	
in	O
most	O
hospitals	B-C0019994
,	O
a	O
unit	O
charge	O
nurse	B-C0028661
is	O
responsible	B-C1273518
for	O
the	O
shift	B-C0333051
assignment	B-C1516050
of	O
patients	B-C0030705
to	O
nurses	B-C0028661
based	O
on	O
experience	B-C0596545
and	O
past	B-C0237607
practices	I-C0237607
.	O
	
the	O
nurse-patient	B-C0578393
assignment	I-C0578393
process	B-C1522240
is	O
also	O
often	O
a	O
manual	B-C1522240
process	I-C1522240
in	O
which	O
the	O
charge	O
nurse	B-C0028661
must	O
sort	B-C1947906
through	O
multiple	B-C0243161
decision	I-C0243161
criteria	I-C0243161
in	O
a	O
limited	O
amount	O
of	O
time	B-C0040223
.	O
	
in	O
this	O
paper	O
,	O
a	O
methodology	B-C3266812
for	O
the	O
construction	O
of	O
balanced	B-C0205415
nurse-patient	B-C0578393
workload	I-C0578393
assignments	I-C0578393
is	O
proposed	B-C1553874
.	O
	
through	O
the	O
illustration	O
of	O
this	O
methodology	B-C3266812
new	O
scoring	B-C0449820
metrics	B-C0242485
are	O
developed	B-C1527148
using	O
measures	B-C0079809
currently	O
available	B-C0470187
on	O
,	O
or	O
from	O
,	O
the	O
hospital	B-C0019988
unit	I-C0019988
.	O
	
it	O
was	O
demonstrated	B-C0205245
that	O
the	O
complex	B-C0205539
scheduling	I-C0205539
problem	B-C0033213
can	O
be	O
captured	O
.	O
	
while	O
the	O
methodology	B-C3266812
was	O
illustrated	O
for	O
a	O
scheduling	B-C0205539
problem	B-C0033213
commonly	O
encountered	O
on	O
a	O
hospital	B-C0019988
unit	I-C0019988
,	O
the	O
approach	B-C0449445
can	O
be	O
adapted	O
to	O
other	O
workforce	B-C0024752
scheduling	B-C0205539
problems	B-C0033213
in	O
which	O
measures	B-C0079809
of	O
workload	B-C0085122
are	O
required	B-C1514873
and	O
composed	O
of	O
elements	B-C1254372
imposed	O
by	O
the	O
work	B-C0162579
environment	I-C0162579
,	O
variability	B-C2827666
within	O
the	O
required	B-C1514873
tasks	B-C3540678
,	O
and	O
a	O
measurable	B-C1513040
perception	B-C0030971
of	O
the	O
relative	B-C0205345
intensity	B-C0522510
of	O
the	O
work	B-C1254372
elements	I-C1254372
.	O
	
effect	B-C1704420
of	I-C1704420
alpha	B-C0023791
lipoic	I-C0023791
acid	I-C0023791
on	O
in	B-C1533691
vitro	I-C1533691
development	B-C0678723
of	O
bovine	B-C3667982
secondary	B-C0737234
preantral	I-C0737234
follicles	I-C0737234
the	O
present	O
study	B-C2603343
aimed	O
to	O
evaluate	B-C0220825
the	O
in	B-C1533691
vitro	I-C1533691
effect	B-C1704420
of	I-C1704420
alpha	B-C0023791
lipoic	I-C0023791
acid	I-C0023791
ala	B-C0023791
addition	O
to	O
the	O
culture	B-C0010454
medium	I-C0010454
on	O
the	O
development	B-C0678723
of	O
the	O
bovine	B-C3667982
secondary	B-C0737234
preantral	I-C0737234
follicles	I-C0737234
.	O
	
bovine	B-C3667982
secondary	B-C0737234
preantral	I-C0737234
follicles	I-C0737234
were	O
collected	B-C1516698
and	O
divided	B-C0332849
into	O
two	O
groups	B-C0441833
depending	O
on	O
their	O
size	B-C0456389
80-100	O
μm	O
and	O
100-110	O
μm	O
.	O
	
they	O
were	O
cultured	O
in	B-C1533691
vitro	I-C1533691
for	O
15	O
days	O
d	O
using	O
different	O
media	B-C0010454
including	O
at	O
three	O
different	O
doses	B-C0178602
of	O
ala	B-C0023791
.	O
	
the	O
genes	B-C0017262
expression	I-C0017262
levels	B-C0441889
of	O
follicle-stimulating	B-C1414828
hormone	I-C1414828
beta-subunit	I-C1414828
fshr	B-C1414828
,	O
insulin-like	B-C1334089
growth	I-C1334089
factor	I-C1334089
igf-1	B-C1334089
,	O
activin	B-C0017337
,	O
luteinizing	B-C1416843
hormone/choriogonadotropin	I-C1416843
receptor	I-C1416843
,	O
bone	B-C1332430
morphogenetic	I-C1332430
protein	I-C1332430
receptor	I-C1332430
type	I-C1332430
ia	I-C1332430
,	O
transforming	B-C1424583
growth	I-C1424583
factor	I-C1424583
beta	I-C1424583
receptor	I-C1424583
1	I-C1424583
,	O
growth	B-C1333668
differentiation	I-C1333668
factor	I-C1333668
9	I-C1333668
,	O
bcl2-associated	B-C0812198
x	I-C0812198
protein	I-C0812198
bax	B-C0812198
,	O
and	O
c-myc	B-C0079068
were	O
studied	O
using	O
real-time	B-C1709846
polymerase	I-C1709846
chain	I-C1709846
reaction	I-C1709846
.	O
	
the	O
protein	B-C1171362
expression	I-C1171362
levels	B-C0441889
of	O
fshr	B-C0034806
,	O
igf-1	B-C0021665
,	O
and	O
bax	B-C0219474
were	O
measured	O
using	O
western	B-C0949466
blot	I-C0949466
analysis	I-C0949466
.	O
	
the	O
results	B-C1254595
of	O
the	O
present	O
work	O
revealed	O
that	O
in	B-C1533691
vitro	I-C1533691
addition	O
of	O
ala	B-C0023791
-	O
induced	B-C0205263
significant	B-C0750502
increase	B-C1155901
in	I-C1155901
the	I-C1155901
growth	I-C1155901
and	O
development	B-C0678723
of	O
secondary	B-C0737234
preantral	I-C0737234
follicles	I-C0737234
throughout	O
the	O
culture	B-C0430400
period	B-C1948053
as	O
compared	B-C1707455
to	O
control	B-C0009932
.	O
	
the	O
fshr	B-C1414828
,	O
igf-1	B-C1334089
,	O
luteinizing	B-C1416843
hormone/choriogonadotropin	I-C1416843
receptor	I-C1416843
,	O
bone	B-C1332430
morphogenetic	I-C1332430
protein	I-C1332430
receptor	I-C1332430
type	I-C1332430
ia	I-C1332430
,	O
transforming	B-C1424583
growth	I-C1424583
factor	I-C1424583
beta	I-C1424583
receptor	I-C1424583
1	I-C1424583
,	O
growth	B-C1333668
differentiation	I-C1333668
factor	I-C1333668
9	I-C1333668
,	O
and	O
activin	B-C0017337
a	I-C0017337
genes	I-C0017337
were	O
upregulated	B-C0041904
in	O
ala	B-C0023791
-	O
treated	B-C1522326
follicles	B-C0737234
as	O
compared	B-C1707455
to	O
the	O
control	B-C0009932
.	O
	
on	O
contrary	O
,	O
preapoptotic	B-C0017337
genes	I-C0017337
bax	B-C0812198
and	O
c-myc	B-C0079068
were	O
downregulated	B-C0013081
in	O
treated	B-C1522326
follicles	B-C0737234
compared	B-C1707455
to	O
control	B-C0009932
ones	O
.	O
	
the	O
protein	B-C0428479
levels	I-C0428479
of	O
fshr	B-C0034806
and	O
igf-1	B-C0021665
were	O
highly	O
expressed	B-C1171362
in	O
treated	B-C1522326
follicles	B-C0737234
compared	B-C1707455
to	O
control	B-C0009932
however	O
,	O
bax	B-C0219474
protein	I-C0219474
was	O
downregulated	B-C0013081
in	O
the	O
treated	B-C1522326
follicles	B-C0737234
groups	B-C0441833
.	O
	
the	O
addition	O
of	O
ala	B-C0023791
to	O
the	O
culture	B-C0010454
medium	I-C0010454
enhances	B-C2349975
secondary	B-C0737234
preantral	I-C0737234
follicles	I-C0737234
development	B-C0678723
and	O
how	O
should	O
proxies	B-C1521761
of	O
cognitive	B-C2936352
reserve	I-C2936352
be	O
evaluated	B-C0220825
in	O
a	O
population	B-C1257890
of	O
healthy	B-C3898900
older	B-C0001792
adults	I-C0001792
while	O
some	O
tools	B-C1516602
have	O
been	O
developed	O
to	O
estimate	B-C0750572
an	O
individual's	B-C0027361
cognitive	B-C2936352
reserve	I-C2936352
cr	B-C2936352
,	O
no	O
study	O
has	O
assessed	B-C1516048
the	O
adequacy	B-C0205410
of	O
the	O
method	O
used	O
for	O
assessing	O
these	O
cr	B-C2936352
proxy	B-C1521761
indicators	O
.	O
	
therefore	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
most	O
appropriate	B-C1548787
method	O
to	O
estimate	B-C0750572
cr	B-C2936352
by	O
comparing	O
two	O
approaches	O
1	O
the	O
common	B-C0205214
assessment	B-C0220825
of	O
cr	B-C2936352
proxies	B-C1521761
in	O
the	O
literature	B-C0023866
e.g	O
.	O
	
years	B-C4054327
of	I-C4054327
education	I-C4054327
and	O
2	O
the	O
calculation	B-C1441506
of	O
a	O
comprehensive	B-C1880156
index	B-C0918012
based	O
on	O
most	B-C1299394
significant	I-C1299394
parameters	B-C0449381
used	O
in	O
the	O
estimation	B-C0680844
of	O
cr	B-C2936352
.	O
	
data	O
on	O
cr	B-C2936352
proxies	B-C1521761
i.e	O
.	O
	
education	B-C0013621
,	O
occupation	B-C0028811
,	O
and	O
leisure	B-C0023292
activities	I-C0023292
were	O
obtained	O
in	O
a	O
sample	O
of	O
204	O
older	B-C0001792
adults	I-C0001792
.	O
	
regression	B-C0034980
analyses	I-C0034980
were	O
used	O
to	O
develop	O
the	O
two	O
indices	B-C0918012
of	O
cr	B-C2936352
i.e	O
.	O
	
icr-standard	B-C0918012
and	O
icr-detailed	B-C0918012
and	O
to	O
determine	O
which	O
index	B-C0918012
best	O
represented	O
the	O
level	O
of	O
one's	O
cr	B-C2936352
.	O
	
the	O
icr-standard	B-C0918012
was	O
calculated	B-C1441506
using	O
a	O
combination	B-C0205195
of	O
the	O
three	O
most	O
common	B-C0205214
measures	B-C0079809
of	O
reserve	B-C2936352
in	O
the	O
literature	B-C0023866
number	B-C4054327
of	I-C4054327
schooling	I-C4054327
years	I-C4054327
,	O
complexity	B-C0439855
of	O
the	O
primary	O
occupation	B-C0028811
,	O
and	O
amount	O
of	O
current	B-C0521116
participation	B-C0679823
in	O
stimulating	B-C1948023
activities	B-C0441655
.	O
	
the	O
icr-detailed	B-C0918012
was	O
calculated	B-C1441506
using	O
the	O
most	B-C1299394
significant	I-C1299394
parameters	B-C0449381
established	O
in	O
initial	B-C0205265
analyses	B-C0936012
of	O
cr	B-C2936352
highest	B-C4264309
level	I-C4264309
of	I-C4264309
education	I-C4264309
combined	B-C0205195
with	O
the	O
number	O
of	O
training	B-C0040607
courses	I-C0040607
,	O
last	B-C1517741
occupation	B-C0028811
,	O
and	O
amount	B-C1265611
of	O
current	O
participation	B-C0679823
in	O
social	B-C2371613
and	O
intellectual	B-C0013652
activities	I-C0013652
.	O
	
the	O
comparison	B-C1707455
of	O
both	O
indices	B-C0918012
showed	O
that	O
higher	O
levels	O
of	O
icr-standard	B-C0918012
and	O
icr-detailed	B-C0918012
were	O
associated	B-C0332281
with	I-C0332281
a	O
greater	B-C1704243
minimization	B-C0392756
of	O
the	O
effects	B-C1704420
of	I-C1704420
age	B-C0001779
on	O
cognition	B-C0009240
.	O
	
however	O
,	O
the	O
icr-detailed	B-C0918012
was	O
more	O
strongly	O
associated	B-C0332281
to	O
this	O
minimization	B-C0392756
than	O
the	O
icr-standard	B-C0918012
,	O
suggesting	O
that	O
the	O
icr-detailed	B-C0918012
best	O
reflect	O
one's	O
cr	B-C2936352
.	O
	
this	O
study	O
is	O
the	O
first	O
to	O
show	O
that	O
it	O
is	O
of	O
great	B-C0549177
importance	B-C3898777
to	O
question	O
methods	O
measuring	B-C0444706
cr	B-C2936352
proxies	B-C1521761
in	O
order	O
to	O
develop	O
a	O
clinical	B-C1516602
tool	I-C1516602
allowing	O
a	O
comprehensive	B-C1880156
and	O
accurate	B-C0443131
estimation	B-C0680844
of	O
discordance	B-C3639994
in	O
pathology	B-C0807321
report	I-C0807321
after	O
central	B-C2347585
pathology	I-C2347585
review	I-C2347585
implications	O
for	O
breast	B-C0006142
cancer	I-C0006142
adjuvant	B-C0677850
treatment	I-C0677850
pathological	B-C1521733
predictive	B-C0683956
factors	I-C0683956
are	O
the	O
most	O
important	O
markers	B-C0005516
when	O
selecting	O
early	O
breast	B-C0006142
cancer	I-C0006142
adjuvant	B-C0677850
therapy	I-C0677850
.	O
	
in	O
randomized	B-C0206034
clinical	I-C0206034
trials	I-C0206034
the	O
variability	B-C2827666
in	O
pathology	B-C0807321
report	I-C0807321
after	O
central	B-C2347585
pathology	I-C2347585
review	I-C2347585
is	O
noteworthy	O
.	O
	
we	O
evaluated	O
the	O
discordance	B-C3639994
rate	B-C1521828
dr	B-C1521828
and	O
inter-rater	B-C0870740
agreement	I-C0870740
between	O
local	B-C0205276
and	O
central	B-C0205099
histopathological	B-C0684224
report	I-C0684224
and	O
the	O
clinical	B-C0205210
implication	O
on	O
treatment	B-C4061230
decision	I-C4061230
.	O
	
a	O
retrospective	B-C0035363
analysis	I-C0035363
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	B-C1458155
cancer	I-C1458155
tumors	I-C1458155
diagnosed	O
by	O
local	B-C0334866
pathologists	I-C0334866
and	O
subsequently	O
reviewed	B-C1709940
at	O
the	O
pathology	B-C0587487
division	I-C0587487
of	O
european	B-C1708333
institute	I-C1708333
of	I-C1708333
oncology	I-C1708333
.	O
	
the	O
inter-rater	B-C0870740
agreement	I-C0870740
k	O
between	O
local	O
and	O
central	B-C0030664
pathology	I-C0030664
was	O
calculated	O
for	O
ki-67	B-C0208804
,	O
grading	B-C0441799
,	O
hormone	B-C0019929
receptors	I-C0019929
er	B-C0034804
/	O
pgr	B-C0034833
and	O
her2/neu	B-C1512413
.	O
	
the	O
bland-altman	B-C0242481
plots	I-C0242481
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
ki-67	B-C0208804
,	O
er	B-C0034804
and	O
pgr	B-C0034833
.	O
	
dr	B-C1521828
was	O
calculated	O
for	O
er	B-C0034804
/	O
pgr	B-C0034833
and	O
her2	B-C0069515
.	O
	
from	O
2007	O
to	O
2013	O
,	O
187	O
pathology	B-C0444061
specimens	I-C0444061
from	O
10	O
cancer	B-C1513817
centers	I-C1513817
were	O
reviewed	B-C1709940
.	O
	
substantial	O
agreement	O
was	O
observed	O
for	O
er	B-C0034804
k0.612	O
95%	O
ci	B-C0009667
,	O
0538-0	O
,	O
pgr	B-C0034833
k0.659	O
95%	O
ci	B-C0009667
,	O
0580-0	O
,	O
ki-67	B-C0208804
k0.609	O
95%	O
ci	B-C0009667
,	O
0.534	O
and	O
grading	B-C0441799
k0.669	O
95%	O
ci	B-C0009667
,	O
0.569	O
.	O
	
moderate	O
agreement	O
was	O
found	O
for	O
her2	B-C0069515
k0.546	O
95%	O
ci	B-C0009667
,	O
0444-0	O
.	O
	
dr	B-C1521828
was	O
9.5	O
negativity	O
to	O
positivity	O
and	O
31.7	O
positivity	O
to	O
negativity	O
for	O
her2	B-C0069515
and	O
26.2	O
negativity	O
to	O
positivity	O
and	O
12.5	O
positivity	O
to	O
negativity	O
for	O
er	B-C0034804
/	O
pgr	B-C0034833
.	O
	
according	O
to	O
changes	O
in	O
her2	B-C0069515
and	O
er	B-C0034804
/	O
pgr	B-C0034833
status	O
,	O
23	O
12.2	O
and	O
33	O
17.6	O
systemic	B-C0205373
prescription	B-C0033080
were	O
respectively	O
modified	O
.	O
	
in	O
our	O
retrospective	B-C0035363
analysis	I-C0035363
,	O
central	B-C2347585
pathological	I-C2347585
review	I-C2347585
has	O
a	O
significant	O
impact	O
in	O
the	O
decision-making	B-C2364257
process	I-C2364257
in	O
early	O
breast	B-C0006142
cancer	I-C0006142
,	O
as	O
shown	O
in	O
clinical	B-C0008976
trials	I-C0008976
.	O
	
implementing	B-C1708476
non-invasive	B-C0205303
prenatal	B-C0033053
diagnosis	I-C0033053
nipd	B-C0033053
in	O
a	O
national	B-C0022877
health	I-C0022877
service	I-C0022877
laboratory	I-C0022877
from	O
dominant	B-C1527180
to	O
recessive	B-C0678943
disorders	B-C0012634
our	O
uk	B-C0022877
national	I-C0022877
health	I-C0022877
service	I-C0022877
regional	I-C0022877
genetics	I-C0022877
laboratory	I-C0022877
offers	O
nipd	B-C0033053
for	O
autosomal	B-C0443147
dominant	I-C0443147
and	O
de	B-C1515568
novo	I-C1515568
conditions	B-C0348080
achondroplasia	B-C0001080
,	O
thanataphoric	B-C0039743
dysplasia	I-C0039743
,	O
apert	B-C0001193
syndrome	I-C0001193
,	O
paternal	B-C0337493
mutation	B-C0026882
exclusion	B-C0680251
for	O
cystic	B-C0010674
fibrosis	I-C0010674
and	O
a	O
range	O
of	O
bespoke	B-C0683443
tests	I-C0683443
.	O
	
nipd	B-C0033053
avoids	O
the	O
risks	B-C0035648
associated	B-C0332281
with	I-C0332281
invasive	B-C0430022
testing	I-C0430022
,	O
making	O
prenatal	B-C0033053
diagnosis	I-C0033053
more	B-C0205172
accessible	O
to	O
families	B-C0015576
at	O
high	B-C0205250
genetic	B-C1517512
risk	I-C1517512
.	O
	
however	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	B-C0443196
diagnosis	B-C0011900
for	O
autosomal	B-C0265388
recessive	I-C0265388
diseases	I-C0265388
,	O
which	O
is	O
complicated	B-C0231242
by	O
the	O
predominance	B-C0332251
of	O
the	O
maternal	B-C0026591
mutant	B-C0596988
allele	B-C0002085
in	O
the	O
cell-free	B-C4289789
dna	I-C4289789
sample	B-C2347026
and	O
thus	O
requires	O
a	O
variety	B-C2346866
of	O
different	B-C1705242
approaches	B-C0449445
.	O
	
validation	B-C1519941
and	O
diagnostic	B-C0348026
implementation	B-C1708476
for	O
nipd	B-C0033053
of	O
congenital	B-C0001627
adrenal	I-C0001627
hyperplasia	I-C0001627
cah	B-C0001627
is	O
further	O
complicated	B-C0231242
by	O
presence	B-C0150312
of	O
a	O
pseudogene	B-C0033799
that	O
requires	O
a	O
different	B-C1705242
approach	B-C0449445
.	O
	
we	O
have	O
used	O
an	O
assay	B-C0005507
targeting	B-C1521840
approximately	B-C0332232
6700	O
heterozygous	B-C0019425
snps	B-C0752046
around	O
the	O
cah	B-C1413861
gene	I-C1413861
cyp21a2	B-C1413861
to	O
construct	O
the	O
high-risk	B-C0332167
parental	B-C0030551
haplotypes	B-C0018591
and	O
tested	O
this	O
approach	B-C0449445
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	B-C0242538
of	O
the	O
parental	B-C0030551
alleles	B-C0002085
can	O
be	O
correctly	O
identified	B-C0205396
using	O
nipd	B-C0033053
.	O
	
we	O
are	O
evaluating	O
various	O
measures	B-C0079809
of	O
the	O
fetal	B-C0015965
fraction	O
to	O
help	O
determine	O
inheritance	B-C0242538
of	O
parental	B-C0030551
mutations	B-C0026882
.	O
	
we	O
are	O
currently	O
exploring	O
the	O
utility	B-C3827682
of	O
an	O
nipd	B-C0033053
multi-disorder	B-C0022885
panel	I-C0022885
for	O
autosomal	B-C0265388
recessive	I-C0265388
disease	I-C0265388
,	O
to	O
make	O
testing	B-C0039593
more	O
widely	O
applicable	B-C1706839
to	O
families	B-C0015576
with	O
a	O
variety	O
of	O
serious	B-C0205404
genetic	B-C0019247
conditions	I-C0019247
.	O
	
silk	B-C4050636
fibroin	I-C4050636
based	O
carrier	B-C0013161
system	I-C0013161
for	O
delivery	B-C1705822
of	O
fibrinogen	B-C0016006
and	O
thrombin	B-C0040018
as	O
coagulant	B-C0009117
supplements	B-C2348609
the	O
control	B-C2587213
of	O
bleeding	B-C0019080
is	O
one	O
of	O
the	O
most	O
important	O
interventions	B-C0184661
after	O
a	O
traumatic	B-C3263723
injury	I-C3263723
.	O
	
hemostatic	B-C0019120
devices	I-C0019120
delivering	B-C0677249
blood	B-C0302148
clotting	I-C0302148
accelerating	O
agents	B-C0009117
such	O
as	O
fibrinogen	B-C0016006
are	O
increasingly	B-C0442808
used	O
due	O
to	O
their	O
efficacy	B-C1280519
and	O
their	O
ease	O
of	O
application	B-C0185125
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
describe	O
a	O
method	B-C0025663
to	O
incorporate	B-C0243126
the	O
coagulant	B-C0009117
supplements	B-C2348609
fibrinogen	B-C0016006
and	O
thrombin	B-C0040018
in	O
silk	B-C4050636
protein	I-C4050636
sponges	B-C0441126
by	O
mixing	O
the	O
coagulants	B-C0009117
with	O
an	O
aqueous	B-C0043047
silk	B-C0074529
solution	O
,	O
followed	O
by	O
molding	B-C0022885
,	O
freeze-drying	B-C0016698
and	O
water	B-C0022885
annealing	I-C0022885
.	O
	
in	O
this	O
combination	B-C0205195
system	B-C0449913
we	O
demonstrate	O
the	O
delivery	B-C1705822
of	O
fibrinogen	B-C0016006
while	O
maintaining	O
its	O
hemostatic	B-C0019116
potential	I-C0019116
.	O
	
concentration	B-C1264681
ratios	I-C1264681
of	O
silk	B-C0074529
to	O
fibrinogen	B-C0016006
of	O
1.0	O
,	O
2.3	O
and	O
3.0	O
were	O
used	O
.	O
	
the	O
thrombin	B-C0040018
-induced	O
fibrin	B-C0015982
polymeric	B-C0032521
network	B-C1882071
filled	O
the	O
space	O
in	O
and	O
next	O
to	O
the	O
silk	B-C0074529
spongy	B-C0678594
structure	I-C0678594
but	O
also	O
remained	O
interconnected	B-C0683595
to	O
the	O
silk	B-C0074529
,	O
providing	O
an	O
intact	B-C0205266
network	B-C1882071
.	O
	
the	O
mechanical	B-C1880022
characterization	I-C1880022
of	O
the	O
fibrinogen-releasing	B-C1283071
silk	B-C0074529
sponges	B-C0441126
before	O
and	O
after	O
the	O
induction	B-C0205263
of	O
the	O
fibrinogen	B-C0016006
polymerization	B-C0314672
demonstrated	O
that	O
the	O
fibrin	B-C0015982
network	B-C1882071
resulted	O
in	O
reduced	B-C0392756
permanent	B-C0205355
deformation	B-C0333067
from	O
21.1	O
to	O
6.5	O
,	O
19.6	O
to	O
5.7	O
and	O
12.7	O
to	O
9.4	O
for	O
the	O
2.8	O
,	O
1.5	O
and	O
0.8	O
fibrinogen	B-C0016006
-containing	O
silk	B-C0074529
sponges	B-C0441126
,	O
respectively	O
.	O
	
moreover	O
,	O
the	O
fibrin	B-C0015982
formation	B-C1522492
lead	O
to	O
a	O
more	O
linear	B-C0205132
elastic	B-C0013764
behavior	I-C0013764
over	O
longer	O
strain	O
ranges	O
.	O
	
in	O
combination	O
,	O
the	O
calcein-am	B-C0252016
/	O
pi	B-C0033470
stainings	B-C0038128
and	O
mtt	B-C2986858
assay	I-C2986858
results	O
indicate	O
uniform	B-C0205375
cell	B-C0007577
adhesion	I-C0007577
on	O
the	O
surface	B-C0205148
and	O
cytocompatibility	B-C1524057
of	O
the	O
silk	B-C0074529
/	O
fibrin	B-C0015982
sponges	B-C0441126
,	O
respectively	O
.	O
	
moreover	O
,	O
the	O
co-delivery	B-C1705822
of	O
thrombin	B-C0040018
with	O
fibrinogen	B-C0016006
via	O
silk	B-C0074529
as	O
carrier	B-C0013161
material	I-C0013161
is	O
described	O
,	O
offering	O
a	O
more	O
mechanically	B-C0443254
robust	B-C2986815
and	O
durable	B-C0205556
system	I-C0205556
while	O
preserving	B-C0728887
hemostatic	B-C0019116
features	I-C0019116
of	O
the	O
coagulant	B-C0009117
substances	I-C0009117
for	O
the	O
generation	B-C3146294
of	O
hemostatic	B-C0019120
devices	I-C0019120
.	O
	
adoptively	O
transferred	O
natural	B-C0022688
killer	I-C0022688
cells	I-C0022688
maintain	O
long-term	O
antitumor	B-C0243095
activity	I-C0243095
by	O
epigenetic	B-C0242614
imprinting	I-C0242614
and	O
cd4	B-C0039215
t	I-C0039215
cell	I-C0039215
help	O
natural	B-C0022688
killer	I-C0022688
nk	I-C0022688
cell	I-C0022688
infusions	B-C0574032
can	O
induce	O
remissions	O
in	O
subsets	O
of	O
patients	B-C0030705
with	O
different	O
types	O
of	O
cancer	B-C0006826
.	O
	
the	O
optimal	O
strategies	O
for	O
nk	B-C0022688
cell	I-C0022688
activation	B-C1326120
prior	O
to	O
infusion	B-C0574032
are	O
still	O
under	O
debate	O
.	O
	
there	O
is	O
recent	O
evidence	O
that	O
nk	B-C0022688
cells	I-C0022688
can	O
acquire	O
long-term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	B-C0079189
il-12	B-C0123759
/	O
15	B-C0254610
/	O
18	B-C0383327
.	O
	
the	O
mechanisms	O
supporting	O
the	O
maintenance	O
of	O
long-term	O
nk	B-C0022688
cell	I-C0022688
antitumor	B-C0243095
activity	I-C0243095
are	O
incompletely	O
under-stood	O
.	O
	
here	O
,	O
we	O
show	O
that	O
nk	B-C0022688
cells	I-C0022688
preactivated	O
in	B-C3850137
vitro	I-C3850137
with	O
il-12	B-C0123759
/	O
15	B-C0254610
/	O
18	B-C0383327
,	O
but	O
not	O
with	O
il-15	B-C0254610
alone	O
,	O
maintained	O
high	O
antitumor	B-C0243095
activity	I-C0243095
even	O
1	B-C1254367
mo	I-C1254367
after	O
transfer	O
into	O
lymphopenic	B-C0024312
rag-2	B-C1419248
γc	O
mice	B-C0026809
.	O
	
the	O
nk	B-C0022688
cell	I-C0022688
intrinsic	O
ability	O
for	O
ifnγ	B-C0021745
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non-coding	B-C0021920
sequence	I-C0021920
cns	B-C0021920
1	O
in	O
the	O
ifng	B-C1334085
locus	B-C1708726
,	O
previously	O
shown	O
to	O
enhance	O
transcription	B-C0040649
of	O
ifng	B-C1334085
.	O
	
in	O
a	O
xenograft	B-C0012644
melanoma	I-C0012644
mouse	I-C0012644
model	I-C0012644
,	O
human	B-C0086418
il-12	B-C0123759
/	O
15	B-C0254610
/	O
18	B-C0383327
-preactivated	O
nk	B-C0022688
cells	I-C0022688
rejected	O
tumors	B-C0027651
more	O
efficiently	O
.	O
	
in	O
rag-2	B-C1419248
γc	O
mice	B-C0026809
,	O
co-transfer	O
of	O
cd4	B-C0039215
t	I-C0039215
cells	I-C0039215
further	O
improved	O
the	O
long-term	O
competence	O
of	O
nk	B-C0022688
cells	I-C0022688
for	O
ifnγ	B-C0021745
production	O
that	O
was	O
dependent	O
on	O
il-2	B-C0021756
.	O
	
cd4	B-C0039215
t	I-C0039215
cell	I-C0039215
activation	B-C1326120
during	O
homeostatic	B-C1326161
proliferation	I-C1326161
required	O
macrophages	B-C0024432
and	O
further	O
promoted	O
the	O
long-term	O
nk	B-C0022688
cell	I-C0022688
antitumor	B-C0243095
activity	I-C0243095
.	O
	
thus	O
,	O
nk	B-C0022688
cells	I-C0022688
can	O
"""remember"""	O
a	O
previous	O
exposure	O
to	O
cytokines	B-C0079189
by	O
epigenetic	B-C0242614
imprinting	I-C0242614
resulting	O
in	O
a	O
remarkable	O
stability	O
of	O
the	O
ifnγ	B-C0021745
-producing	O
phenotype	B-C0031437
after	O
adoptive	O
transfer	O
.	O
	
in	O
addition	O
,	O
our	O
results	O
support	O
combination	O
of	O
cytokine	B-C0079189
-preactivated	O
nk	B-C0022688
cells	I-C0022688
with	O
cd4	B-C0039215
t	I-C0039215
cell	I-C0039215
activation	B-C1326120
upon	O
lymphopenic	B-C0024312
conditioning	O
to	O
achieve	O
long-term	O
nk	B-C0022688
cell	I-C0022688
effector	O
function	O
for	O
cancer	B-C0278348
immunotherapy	I-C0278348
.	O
	
survey	B-C0018762
of	O
neonatal	B-C0021709
intensive	I-C0021709
care	I-C0021709
unit	I-C0021709
nurse	B-C0028661
attitudes	B-C0004271
toward	O
therapeutic	B-C0020674
hypothermia	I-C0020674
treatment	I-C0020674
the	O
traumatic	B-C0332663
experiences	O
of	O
parent	B-C0030551
s	O
of	O
babies	B-C0021270
treated	B-C0332293
with	I-C0332293
therapeutic	B-C0020674
hypothermia	I-C0020674
th	B-C0020674
have	O
been	O
described	O
.	O
	
no	O
research	B-C0035168
has	O
assessed	B-C1516048
neonatal	B-C0021709
intensive	I-C0021709
care	I-C0021709
unit	I-C0021709
nicu	B-C0021709
nurse	B-C0028661
experience	O
in	O
providing	O
care	O
to	O
hypothermic	B-C0020672
babies	B-C0021270
and	O
emotional	O
support	O
to	O
their	O
parents	B-C0030551
.	O
	
to	O
assess	O
nicu	B-C0021709
nurse	B-C0028661
attitudes	B-C0004271
to	O
the	O
provision	O
of	O
th	B-C0020674
with	O
respect	O
to	O
perceptions	B-C0030971
about	O
baby	B-C0021270
pain	B-C0030193
/	O
sedation	B-C0344106
,	O
need	O
for	O
nurse	B-C0028661
and	O
parent	B-C0030551
education	B-C0013621
,	O
decision	B-C0011109
making	I-C0011109
about	O
initiation	B-C1704686
of	O
th	B-C0020674
,	O
and	O
barriers	O
to	O
best	O
care	O
.	O
	
a	O
survey	B-C0018762
was	O
electronically	O
sent	O
to	O
219	O
nurses	B-C0028661
at	O
2	O
affiliated	O
academic	O
level	O
iii	O
nicus	B-C0021709
1	O
rural	O
and	O
1	O
urban	O
location	O
.	O
	
there	O
were	O
17	O
questions	O
where	O
responses	B-C1706817
were	O
selected	O
from	O
a	O
preset	O
list	O
and	O
7	O
opportunities	O
for	O
nurses	B-C0028661
to	O
provide	O
free	O
text	O
responses	B-C1706817
.	O
	
the	O
response	B-C1706817
rate	O
was	O
38%	O
n	O
=	O
83	O
.	O
	
overwhelming	B-C0522501
similarities	O
between	O
the	O
urban	B-C0020029
and	O
rural	B-C0020023
institutions	I-C0020023
were	O
found	O
with	O
nicu	B-C0021709
nurses	B-C0028661
expressing	O
understanding	O
of	O
the	O
indications	O
for	O
initiating	O
th	B-C0020674
,	O
agreement	O
that	O
th	B-C0020674
improves	O
long-term	B-C0443252
outcomes	B-C0085415
and	O
that	O
the	O
benefits	O
of	O
th	B-C0020674
outweigh	O
the	O
risks	O
.	O
	
nurses	B-C0028661
at	O
the	O
urban	B-C0020029
institution	I-C0020029
more	O
frequently	O
expressed	O
concerns	O
surrounding	O
inadequate	O
treatment	B-C0087111
of	O
baby	B-C0021270
pain	B-C0030193
/	O
sedation	B-C0344106
,	O
and	O
nurses	B-C0028661
at	O
both	O
institutions	B-C0337951
strongly	O
emphasized	O
the	O
need	O
for	O
more	O
nurse	B-C0028661
and	O
parent	B-C0030551
education	B-C0013621
about	O
th	B-C0020674
and	O
improved	O
timeliness	O
of	O
decision	B-C0011109
making	I-C0011109
for	O
initiation	B-C1704686
of	O
th	B-C0020674
.	O
	
nicu	B-C0021709
nurses	B-C0028661
specifically	O
want	O
to	O
learn	O
more	O
about	O
outcomes	B-C0085415
of	O
babies	B-C0021270
after	O
treatment	B-C0087111
with	O
th	B-C0020674
and	O
feel	O
that	O
parents	B-C0030551
need	O
more	O
education	B-C0013621
about	O
th	B-C0020674
.	O
	
research	B-C0035168
is	O
urgently	O
needed	O
to	O
better	O
understand	O
the	O
implications	O
of	O
th	B-C0020674
treatment	I-C0020674
for	O
parent	B-C0030551
-	O
baby	B-C0021270
pharmacological	B-C0199242
venous	I-C0199242
thromboembolism	I-C0199242
prophylaxis	I-C0199242
in	O
meningioma	B-C0025286
patients	B-C0030705
should	O
it	O
be	O
earlier	O
than	O
clinical	B-C0695275
practice	I-C0695275
we	O
read	O
the	O
report	B-C2936319
by	O
çeltikçi	O
et	O
al	O
in	O
the	O
turkish	B-C1552762
neurosurgery	I-C1552762
with	O
great	O
interest	O
.	O
	
in	O
this	O
single-center	O
retrospective	B-C0035363
study	I-C0035363
,	O
they	O
analysed	O
449	O
intracranial	B-C0349604
meningioma	I-C0349604
patients	B-C0030705
underwent	O
open	B-C4283938
surgery	I-C4283938
.	O
	
they	O
stated	O
that	O
venous	B-C1861172
thromboembolism	I-C1861172
vte	B-C1861172
had	O
been	O
seen	O
in	O
21	O
4.6	O
of	O
their	O
patients	B-C0030705
.	O
	
this	O
is	O
an	O
important	O
issue	O
because	O
vte	B-C1861172
,	O
including	O
deep	B-C0149871
vein	I-C0149871
thrombosis	I-C0149871
dvt	B-C0149871
and	O
pulmonary	B-C0034065
embolism	I-C0034065
pe	B-C0034065
,	O
is	O
the	O
most	O
common	O
overall	O
complication	B-C0009566
in	O
meningioma	B-C1096493
surgery	I-C1096493
and	O
is	O
fatal	O
in	O
up	O
to	O
one	O
third	O
of	O
patients	B-C0030705
2	O
.	O
	
we	O
suppose	O
that	O
prophylaxis	B-C0199176
of	O
vte	B-C1861172
is	O
most	O
effective	O
when	O
mechanical	O
and	O
pharmacological	B-C0420172
prophylaxis	I-C0420172
are	O
combined	O
.	O
	
we	O
consider	O
that	O
there	O
key	O
some	O
practical	O
questions	O
to	O
be	O
answered	O
for	O
a	O
proper	O
clinical	B-C0205245
extrapolation	I-C0205245
.	O
	
best	B-C0282574
next-generation	B-C1254367
biomedical	B-C0282574
entity	I-C0282574
search	I-C0282574
tool	I-C0282574
for	O
knowledge	B-C0376554
discovery	B-C1880355
from	O
biomedical	B-C0025120
literature	I-C0025120
as	O
the	O
volume	B-C1690016
of	O
publications	B-C0034036
rapidly	B-C0456962
increases	B-C0205217
,	O
searching	B-C1706202
for	O
relevant	B-C2347946
information	B-C1533716
from	O
the	O
literature	B-C0023866
becomes	O
more	O
challenging	B-C0243095
.	O
	
to	O
complement	O
standard	B-C1442989
search	B-C2348167
engines	I-C2348167
such	O
as	O
pubmed	B-C1138432
,	O
it	O
is	O
desirable	B-C0205556
to	O
have	O
an	O
advanced	B-C2348167
search	I-C2348167
tool	I-C2348167
that	O
directly	B-C1947931
returns	B-C0332156
relevant	B-C2347946
biomedical	B-C0205556
entities	B-C1551338
such	O
as	O
targets	B-C0085104
,	O
drugs	B-C0013227
,	O
and	O
mutations	B-C0026882
rather	O
than	O
a	O
long	O
list	O
of	O
articles	O
.	O
	
some	O
existing	B-C0243095
tools	B-C0037589
submit	B-C1515023
a	O
query	B-C1522634
to	O
pubmed	B-C1138432
and	O
process	B-C1522240
retrieved	O
abstracts	B-C0600678
to	O
extract	O
information	B-C1533716
at	O
query	B-C1522634
time	B-C0040223
,	O
resulting	B-C1274040
in	O
a	O
slow	B-C0439834
response	O
time	B-C0040223
and	O
limited	B-C0439801
coverage	B-C1999244
of	O
only	O
a	O
fraction	B-C1264633
of	I-C1264633
the	O
pubmed	B-C1138432
corpus	I-C1138432
.	O
	
other	O
tools	B-C0037589
preprocess	B-C1882455
the	O
pubmed	B-C1138432
corpus	I-C1138432
to	O
speed	O
up	O
the	O
response	O
time	B-C0040223
however	O
,	O
they	O
are	O
not	O
constantly	B-C1948059
updated	B-C1519814
,	O
and	O
thus	O
produce	B-C0678227
outdated	B-C3645590
results	B-C1274040
.	O
	
further	O
,	O
most	O
existing	O
tools	B-C0037589
cannot	O
process	B-C1522240
sophisticated	B-C0205556
queries	B-C1522634
such	O
as	O
searches	B-C1706202
for	O
mutations	B-C0026882
that	O
co-occur	B-C1709305
with	O
query	B-C1522634
terms	O
in	O
the	O
literature	B-C0023866
.	O
	
to	O
address	O
these	O
problems	B-C0033213
,	O
we	O
introduce	B-C1292748
best	B-C0282574
,	O
a	O
biomedical	B-C0282574
entity	I-C0282574
search	I-C0282574
tool	I-C0282574
.	O
	
best	B-C0282574
returns	B-C0332156
,	O
as	O
a	O
result	B-C1274040
,	O
a	O
list	O
of	O
10	O
different	B-C1705242
types	O
of	O
biomedical	B-C0205556
entities	B-C1551338
including	B-C0332257
genes	B-C0017337
,	O
diseases	B-C0012634
,	O
drugs	B-C0013227
,	O
targets	B-C0085104
,	O
transcription	B-C0040648
factors	I-C0040648
,	O
mirnas	B-C1101610
,	O
and	O
mutations	B-C0026882
that	O
are	O
relevant	B-C2347946
to	O
a	O
user's	O
query	B-C1522634
.	O
	
to	O
the	O
best	O
of	O
our	O
knowledge	B-C0376554
,	O
best	B-C0282574
is	O
the	O
only	O
system	B-C0449913
that	O
processes	B-C1522240
free	O
text	B-C1527021
queries	B-C1522634
and	O
returns	B-C0332156
up-to-date	B-C0243095
results	B-C1274040
in	O
real	B-C1550177
time	I-C1550177
including	B-C0332257
mutation	B-C0026882
information	B-C1533716
in	O
the	O
results	B-C1274040
.	O
	
best	B-C0282574
alanine	B-C0001898
to	O
serine	B-C0036720
variant	B-C0205419
at	O
position	O
986	O
of	O
calcium	B-C0249742
sensing	I-C0249742
receptor	I-C0249742
and	O
colorectal	B-C1527249
cancer	I-C1527249
risk	B-C0035647
with	O
regard	O
to	O
the	O
effect	B-C1280500
of	O
calcium	B-C0006675
against	O
colorectal	B-C1527249
cancer	I-C1527249
crc	B-C1527249
and	O
considering	O
the	O
key	O
role	B-C1705810
of	O
calcium	B-C0249742
sensing	I-C0249742
receptor	I-C0249742
casr	B-C0249742
in	O
calcium	B-C3653518
homeostasis	I-C3653518
,	O
this	O
study	O
investigated	B-C1292732
whether	O
casr	B-C1413136
gene	I-C1413136
rs1801725	B-C0678941
or	O
a986s	B-C0678941
variant	I-C0678941
was	O
associated	B-C0332281
with	I-C0332281
susceptibility	B-C1264642
to	O
crc	B-C1527249
risk	B-C0035647
.	O
	
this	O
study	O
was	O
conducted	O
as	O
a	O
case-control	B-C0007328
study	I-C0007328
and	O
303	O
cases	B-C0868928
with	O
crc	B-C1527249
and	O
354	O
controls	B-C0009932
were	O
enrolled	O
.	O
	
all	O
657	O
subjects	B-C0681850
were	O
genotyped	B-C0017431
for	O
casr	B-C1413136
gene	I-C1413136
a986s	B-C0678941
variant	I-C0678941
using	O
pcr	B-C0032520
-	O
rflp	B-C3714764
method	I-C3714764
.	O
	
no	B-C1273937
significant	I-C1273937
difference	B-C1705242
was	O
observed	B-C1441672
for	O
the	O
a986s	B-C0678941
variant	I-C0678941
of	O
casr	B-C1413136
gene	I-C1413136
in	O
either	O
genotype	B-C0017431
or	O
allele	B-C0017270
frequencies	I-C0017270
between	O
the	O
cases	B-C0868928
and	O
the	O
controls	B-C0009932
and	O
this	O
lack	B-C0332268
of	O
difference	B-C1705242
remained	O
non-significant	O
even	O
after	O
adjustment	B-C0456081
for	O
age	B-C0001779
,	O
bmi	B-C1305855
,	O
sex	B-C1522384
,	O
smoking	B-C1519386
status	I-C1519386
,	O
and	O
family	B-C0241889
history	I-C0241889
of	O
crc	B-C1527249
.	O
	
no	B-C0332125
evidence	I-C0332125
for	O
the	O
effect	B-C1280500
modification	B-C3840684
of	O
the	O
association	B-C0439849
a986s	B-C0678941
variant	I-C0678941
and	O
crc	B-C1527249
by	O
bmi	B-C1305855
,	O
sex	B-C1522384
,	O
or	O
tumor	B-C0475445
site	I-C0475445
was	O
also	O
observed	B-C1441672
.	O
	
furthermore	O
,	O
the	O
risk	B-C0035647
of	O
obesity	B-C0028754
in	O
relation	B-C0439849
to	O
the	O
a986s	B-C0678941
variant	I-C0678941
in	O
the	O
controls	B-C0009932
and	O
the	O
cases	B-C0868928
was	O
separately	O
analyzed	B-C0936012
and	O
we	O
observed	O
no	B-C3842396
significant	I-C3842396
difference	I-C3842396
between	O
normal	B-C2712185
weight	I-C2712185
bmi	B-C1305855
<	O
25kg/m	O
and	O
overweight	B-C0497406
/	O
obese	B-C0028754
bmi	B-C1305855
25kg/m	O
subjects	B-C0681850
.	O
	
our	O
findings	B-C0243095
do	O
not	O
support	O
a	O
role	O
for	O
effect	B-C1280500
of	O
the	O
casr	B-C1413136
gene	I-C1413136
a986s	B-C0678941
variant	I-C0678941
on	O
crc	B-C1527249
risk	B-C0035647
nevertheless	O
,	O
this	O
finding	B-C0243095
requires	O
confirmation	B-C0750484
and	O
the	O
role	B-C1705810
of	O
the	O
gene	B-C0678941
variant	I-C0678941
in	O
carcinogenesis	B-C0596263
needs	O
to	O
be	O
further	O
treatment	B-C0087111
of	O
erythematotelangiectatic	B-C1449852
rosacea	I-C1449852
with	O
the	O
fractionation	B-C3161031
of	O
high-fluence	B-C0205212
,	O
long-pulsed	O
595-nm	O
pulsed	B-C1289859
dye	I-C1289859
laser	I-C1289859
various	O
lasers	B-C0023089
have	O
been	O
used	O
for	O
the	O
treatment	B-C0087111
of	O
erythematotelangiectatic	B-C1449852
rosacea	I-C1449852
etr	B-C1449852
that	O
does	O
not	O
respond	O
to	O
systemic	B-C1515119
or	O
topical	B-C0150349
therapy	I-C0150349
.	O
	
the	O
pulsed	B-C1289859
dye	I-C1289859
lasers	I-C1289859
pdls	B-C1289859
are	O
an	O
effective	O
option	O
for	O
etr	B-C1449852
,	O
and	O
the	O
purpuragenic	B-C0034150
fluence	B-C0376249
proved	O
to	O
be	O
superior	O
until	O
now	O
.	O
	
given	O
that	O
purpura	B-C0034150
and	O
subsequent	O
possible	O
postinflammatory	B-C0333616
hyperpigmentation	I-C0333616
pih	B-C0333616
are	O
occasionally	O
unbearable	O
in	O
some	O
patients	B-C0030705
,	O
and	O
several	O
studies	O
using	O
the	O
low	O
nonpurpuragenic	B-C0243095
fluence	B-C0376249
were	O
reported	O
.	O
	
to	O
deliver	O
the	O
sufficient	O
high	B-C0205212
fluence	I-C0205212
of	O
a	O
pdl	B-C1289859
without	O
generating	O
purpura	B-C0034150
,	O
we	O
designed	O
the	O
fractionation	B-C3161031
of	O
high	B-C0205212
fluence	I-C0205212
using	O
five	O
passes	O
and	O
longer	O
pulse	O
duration	O
6	O
milliseconds	O
of	O
a	O
pdl	B-C1289859
in	O
succession	O
.	O
	
a	O
total	O
of	O
eight	O
patients	B-C0030705
with	O
etr	B-C1449852
were	O
enrolled	O
in	O
this	O
study	O
all	O
patients	B-C0030705
were	O
treated	O
with	O
pdl	B-C1289859
10	O
times	O
at	O
2-week	O
intervals	O
.	O
	
erythema	B-C0041834
and	O
telangiectasia	B-C0039446
scores	O
,	O
as	O
well	O
as	O
improvement	O
,	O
were	O
assessed	O
by	O
two	O
physicians	B-C0031831
using	O
the	O
digital	B-C3899375
photographs	I-C3899375
.	O
	
moderate-to-marked	O
improvement	O
was	O
achieved	O
in	O
most	O
of	O
the	O
patients	B-C0030705
,	O
and	O
erythema	B-C0041834
and	O
telangiectasia	B-C0039446
scores	O
were	O
significantly	O
decreased	O
.	O
	
purpura	B-C0034150
and	O
pih	B-C0333616
were	O
not	O
reported	O
in	O
all	O
patients	B-C0030705
.	O
	
the	O
fractionation	B-C3161031
of	O
high-fluence	B-C0205212
,	O
long-pulsed	O
595	O
nm	O
pdl	B-C1289859
is	O
a	O
very	O
safe	O
and	O
effective	O
treatment	B-C0087111
for	O
propulsion	B-C0679199
strategy	I-C0679199
in	O
the	O
gait	B-C0016928
of	O
primary	B-C0033145
school	I-C0033145
children	B-C0008059
the	O
effect	B-C1280500
of	O
age	B-C0001779
and	O
speed	B-C0678536
the	O
strategy	B-C0679199
used	O
to	O
generate	B-C3146294
power	B-C3854080
for	O
forward	O
propulsion	B-C0026649
in	O
walking	B-C0080331
and	O
running	B-C0035953
has	O
recently	O
been	O
highlighted	O
as	O
a	O
marker	B-C0005516
of	O
gait	B-C0016928
maturation	B-C0678723
and	O
elastic	B-C1442080
energy	I-C1442080
recycling	B-C0334213
.	O
	
this	O
study	B-C2603343
investigated	B-C0220825
ankle	B-C0003086
and	O
hip	B-C0019552
power	B-C3854080
generation	B-C3146294
as	O
a	O
propulsion	B-C0679199
strategy	I-C0679199
ps	B-C0679199
during	O
the	O
late	B-C2019827
stance	I-C2019827
/	O
early	B-C2039052
swing	I-C2039052
phases	I-C2039052
of	O
walking	B-C0080331
and	O
running	B-C0035953
in	O
typically	B-C0870861
developing	I-C0870861
td	B-C0870861
children	B-C0008059
15	O
six	O
to	O
nine	O
years	B-C0439234
17	O
nine	O
to	O
13	O
years	B-C0439234
using	O
three-dimensional	B-C0450363
gait	B-C0558820
analysis	I-C0558820
.	O
	
peak	B-C0444505
ankle	B-C0003086
power	B-C3854080
generation	B-C3146294
at	O
push-off	B-C0444505
peaka2	B-C0444505
,	O
peak	B-C0444505
hip	B-C0019552
power	B-C3854080
generation	B-C3146294
in	O
early	B-C2039052
swing	I-C2039052
peakh3	B-C0444505
and	O
propulsion	B-C0679199
strategy	I-C0679199
ps	B-C0679199
peaka2	B-C0444505
/	O
peaka2+peakh3	B-C0444505
were	O
calculated	B-C0444686
to	O
provide	O
the	O
relative	O
contribution	O
of	O
ankle	B-C0003086
power	B-C3854080
to	O
total	O
propulsion	B-C0026649
.	O
	
mean	B-C0444504
ps	B-C0679199
values	B-C0042295
decreased	B-C0205216
as	O
speed	B-C0678536
increased	B-C0205217
for	O
comfortable	B-C0080331
walking	I-C0080331
p<0	O
,	O
fast	B-C0456962
walking	B-C0080331
p<0	O
and	O
fast	B-C0456962
running	B-C0035953
p<0	O
,	O
and	O
less	O
consistently	O
during	O
jogging	B-C0022400
p=0	O
.	O
	
ps	B-C0679199
varied	O
with	O
age	B-C0001779
p<0	O
only	O
during	O
fast	B-C0456962
walking	B-C0080331
.	O
	
at	O
any	O
speed	B-C0678536
of	O
fast	B-C0456962
walking	B-C0080331
,	O
older	B-C1455726
children	I-C1455726
generated	B-C3146294
more	O
peaka2	B-C0444505
p=0	O
and	O
less	O
peakh3	B-C0444505
p=0	O
than	O
younger	B-C0728836
children	I-C0728836
.	O
	
while	O
the	O
kinetics	B-C0022702
of	O
running	B-C0035953
propulsion	B-C0026649
appear	O
to	O
be	O
developed	O
by	O
age	B-C0001779
six	O
years	B-C0439234
,	O
the	O
skills	B-C0678856
of	O
fast	B-C0456962
walking	B-C0080331
appeared	O
to	O
require	O
additional	O
neuromuscular	B-C1979768
maturity	B-C0678732
.	O
	
these	O
findings	B-C0243095
support	O
the	O
concept	O
that	O
running	B-C0035953
is	O
a	O
skill	B-C0678856
that	O
matures	B-C0678723
early	B-C1279919
for	O
td	B-C0870861
children	B-C0008059
.	O
	
the	O
relationship	B-C0439849
between	O
anthropometry	B-C0003188
and	O
body	B-C0005885
composition	I-C0005885
from	O
computed	B-C0040405
tomography	I-C0040405
the	O
mediators	O
of	O
atherosclerosis	B-C0004153
in	O
south	B-C1519427
asians	I-C1519427
living	B-C0376558
in	O
america	B-C0002454
study	O
few	O
studies	O
examine	O
the	O
relationships	B-C0439849
between	O
anthropometry	B-C0003188
and	O
the	O
body	B-C0005885
composition	I-C0005885
measures	O
they	O
approximate	O
,	O
or	O
whether	O
they	O
differ	O
by	O
sex	B-C1522384
,	O
and	O
no	O
studies	O
have	O
examined	O
these	O
relationships	B-C0439849
in	O
south	B-C1519427
asians	I-C1519427
living	O
in	O
the	O
us	B-C0041703
.	O
	
we	O
conducted	O
a	O
cross-sectional	B-C0010362
study	I-C0010362
of	O
871	O
participants	B-C0679646
in	O
the	O
mediators	O
of	O
atherosclerosis	B-C0004153
in	O
south	B-C1519427
asians	I-C1519427
living	B-C0376558
in	O
america	B-C0002454
masala	B-C2603343
study	I-C2603343
who	O
had	O
bmi	B-C1305855
<	O
40	O
kg/m	O
and	O
underwent	O
abdominal	B-C0412620
ct	I-C0412620
scans	I-C0412620
for	O
measurement	B-C0242485
of	O
visceral	B-C1563740
and	O
subcutaneous	B-C0222331
fat	I-C0222331
.	O
	
linear	B-C0023733
regression	I-C0023733
was	O
used	O
to	O
model	B-C3161035
the	O
associations	O
between	O
anthropometric	B-C2598146
measures	I-C2598146
and	O
naturally	O
log-transformed	O
body	B-C0005885
composition	I-C0005885
measures	O
.	O
	
all	O
measures	O
of	O
anthropometry	B-C0003188
,	O
except	O
height	B-C0005890
,	O
were	O
significantly	O
associated	B-C0332281
with	I-C0332281
visceral	B-C1563740
fat	I-C1563740
and	O
had	O
a	O
significant	B-C0750502
non-linear	O
component	O
p	O
<	O
05	O
.	O
	
the	O
only	O
associations	O
for	O
visceral	B-C1563740
fat	I-C1563740
that	O
exhibited	O
significant	B-C0750502
heterogeneity	B-C0019409
by	O
sex	B-C1522384
were	O
waist	B-C0455829
circumference	I-C0455829
%	O
difference	O
in	O
visceral	B-C1563740
fat	I-C1563740
slope	O
women	B-C0043210
1.92	O
,	O
men	B-C0025266
2.74	O
,	O
p	O
=	O
007	O
for	O
interaction	O
and	O
waist-to-hip	B-C0205682
ratio	I-C0205682
women	B-C0043210
25.9	O
,	O
men	B-C0025266
717.4	O
,	O
p	O
<	O
001	O
.	O
	
except	O
for	O
height	B-C0005890
,	O
all	O
measures	O
of	O
anthropometry	B-C0003188
were	O
significantly	O
associated	B-C0332281
with	I-C0332281
subcutaneous	B-C0222331
fat	I-C0222331
,	O
had	O
a	O
significant	B-C0750502
quadratic	O
component	O
,	O
and	O
significant	B-C0750502
heterogeneity	B-C0019409
by	O
sex	B-C1522384
weight	B-C0005910
kg	O
2.74	O
for	O
women	B-C0043210
,	O
4.08	O
for	O
men	B-C0025266
bmi	B-C1305855
kg/m	O
10.3	O
,	O
14.0	O
waist	B-C0455829
circumference	I-C0455829
cm	O
1.51	O
,	O
3.36	O
hip	B-C0562350
circumference	I-C0562350
cm	O
2.53	O
,	O
4.50	O
with	O
p	O
<	O
001	O
for	O
each	O
.	O
	
in	O
masala	O
participants	B-C0679646
,	O
the	O
relationships	B-C0439849
of	O
anthropometric	B-C2598146
measures	I-C2598146
with	O
visceral	B-C1563740
and	O
subcutaneous	B-C0222331
fat	I-C0222331
appear	O
similar	O
to	O
other	O
race	B-C0034510
/	O
ethnic	B-C0015031
groups	I-C0015031
,	O
but	O
with	O
weaker	B-C1762617
non-linearity	O
and	O
heterogeneity	B-C0019409
by	O
sex	B-C1522384
.	O
	
given	O
these	O
results	O
,	O
researchers	B-C0035173
should	O
consider	O
separate	O
models	O
by	O
sex	B-C1522384
for	O
us	O
south	B-C1519427
asians	I-C1519427
when	O
approximating	O
subcutaneous	B-C0222331
fat	I-C0222331
or	O
when	O
using	O
waist	B-C0455829
circumference	I-C0455829
to	O
approximate	O
visceral	B-C1563740
fat	I-C1563740
.	O
	
active	B-C0205177
packaging	B-C0030176
of	O
chicken	B-C0677521
meats	I-C0677521
with	O
modified	B-C0392747
atmosphere	B-C0935443
including	O
oxygen	B-C0030054
scavengers	B-C1254355
the	O
effects	B-C1704420
of	I-C1704420
modified	B-C0392747
atmosphere	B-C0935443
packaging	B-C0030176
map	B-C0935443
-70%	O
co2	B-C0007012
/30%	O
n2	B-C0028158
and	O
iron	B-C0302583
-based	O
oxygen	B-C0030054
scavengers	B-C1254355
os	B-C1254355
with	O
various	O
absorption	O
capacities	O
ageless	O
ss100	O
,	O
ss300	O
,	O
and	O
ss500	O
as	O
an	O
active	O
packaging	B-C0178791
system	I-C0178791
on	O
microbiological	B-C0025953
and	O
oxidative	B-C0311404
changes	B-C0392747
in	O
chicken	B-C0677521
thigh	I-C0677521
meats	I-C0677521
were	O
evaluated	O
during	O
refrigerated	B-C1698986
storage	I-C1698986
4	O
for	O
19	O
d	O
at	O
3-	O
day	B-C0439228
intervals	B-C1272706
.	O
	
total	B-C0392762
aerobic	I-C0392762
mesophilic	I-C0392762
bacteria	I-C0392762
counts	I-C0392762
exceeded	O
the	O
acceptability	B-C0392762
limit	I-C0392762
at	O
d	O
7	O
in	O
the	O
control	B-C0009932
group	I-C0009932
without	O
map	B-C0935443
air	B-C0001861
,	O
and	O
at	O
d	O
19	O
in	O
map	B-C0935443
and	O
os	B-C1254355
containing	O
samples	B-C0370003
.	O
	
os	B-C1254355
utilization	B-C0042153
resulted	O
in	O
around	O
1.5	O
and	O
1.0	O
log	O
unit	O
reductions	B-C0392756
in	O
pseudomonas	B-C0033808
spp	I-C0033808
.	O
	
counts	B-C0439157
at	O
d	O
7	O
and	O
d	O
10	O
of	O
storage	B-C1698986
,	O
respectively	O
,	O
as	O
compared	O
with	O
air	B-C0001861
and	O
map	B-C0935443
groups	B-C0441833
p	O
<	O
0.05	O
.	O
	
map	B-C0935443
and	O
os	B-C1254355
groups	B-C0441833
had	O
fewer	O
p	O
<	O
0.05	O
coliform	B-C0805715
counts	I-C0805715
than	O
did	O
the	O
air	B-C0001861
group	B-C0441833
,	O
with	O
an	O
approximately	O
1.0	O
log	O
reduction	B-C0392756
observed	O
at	O
d	O
10	O
.	O
	
although	O
in	O
some	O
cases	B-C0868928
os	B-C1254355
utilization	B-C0042153
resulted	O
in	O
lower	O
tbars	B-C0162781
values	B-C1522609
and	O
carbonyl	B-C0456205
and	O
sulphydryl	B-C0456205
contents	I-C0456205
,	O
particularly	O
during	O
later	O
stages	B-C1306673
of	O
refrigerated	B-C1698986
storage	I-C1698986
as	O
compared	O
to	O
air	B-C0001861
and	O
map	B-C0935443
groups	B-C0441833
,	O
in	O
general	O
,	O
these	O
effects	B-C1280500
were	O
not	O
always	O
apparent	O
.	O
	
the	O
results	O
of	O
this	O
study	O
suggested	O
that	O
map	B-C0935443
suppressed	B-C1260953
microbiological	B-C2911660
growth	I-C2911660
and	O
retarded	O
lipid	B-C2612546
and	O
protein	B-C1159301
oxidation	I-C1159301
in	O
chicken	B-C0677521
thigh	I-C0677521
meats	I-C0677521
,	O
with	O
a	O
9-	O
day	B-C0439228
shelf-life	B-C4279909
extention	O
with	O
insignificant	O
effects	B-C1704420
of	I-C1704420
os	B-C1254355
.	O
	
multidrug	B-C0242640
resistance	I-C0242640
of	O
acinetobacter	B-C0314787
baumannii	I-C0314787
in	O
ladoke	B-C0019994
akintola	I-C0019994
university	I-C0019994
teaching	I-C0019994
hospital	I-C0019994
,	O
osogbo	B-C0028075
,	O
nigeria	I-C0028075
acinetobacter	B-C0314787
baumannii	I-C0314787
is	O
a	O
ubiquitous	O
pathogen	B-C0450254
that	O
has	O
emerged	O
as	O
a	O
major	O
cause	O
of	O
healthcare-associated	B-C0010356
infections	I-C0010356
at	O
ladoke	B-C0019994
akintola	I-C0019994
university	I-C0019994
teaching	I-C0019994
hospital	I-C0019994
.	O
	
isolates	B-C3494793
were	O
assayed	B-C1510438
according	O
to	O
standard	B-C0442711
protocol	I-C0442711
.	O
	
the	O
isolates	B-C3494793
were	O
subjected	O
to	O
molecular	B-C1513384
techniques	I-C1513384
to	O
detect	O
blaoxa	B-C1442492
,	O
blatem	I-C1442492
,	O
blactx-m	I-C1442492
,	O
and	I-C1442492
blashv	I-C1442492
genes	I-C1442492
in	O
strains	B-C0314787
of	O
the	O
a	B-C0314787
.	O
	
baumannii	I-C0314787
isolates	B-C3494793
.	O
	
the	O
prevalence	O
of	O
a	B-C0314787
.	O
	
baumannii	I-C0314787
was	O
8.5	O
and	O
was	O
most	O
prevalent	O
among	O
patients	B-C0030705
in	O
the	O
age	B-C0027362
group	I-C0027362
51-60	O
36%	O
the	O
male	B-C0086582
patients	B-C0030705
63.6	O
were	O
more	O
infected	B-C0439663
than	O
their	O
female	B-C0086287
counterparts	O
.	O
	
patients	B-C0030705
72.7	O
in	O
the	O
intensive	B-C0021708
care	I-C0021708
unit	I-C0021708
icu	B-C0021708
were	O
most	O
infected	B-C0439663
with	O
this	O
organism	B-C0029235
.	O
	
the	O
isolates	B-C3494793
showed	O
100%	O
resistance	B-C4281815
to	O
both	O
amikacin	B-C0002499
and	O
ciprofloxacin	B-C0008809
and	O
90.9	O
to	O
both	O
ceftriaxone	B-C0007561
and	O
ceftazidime	B-C0007559
,	O
while	O
resistance	B-C4281815
to	O
the	O
other	O
antibiotics	B-C0003232
used	O
in	O
this	O
study	B-C2603343
were	O
piperacillin	B-C0031955
81.8	O
,	O
imipenem	B-C0066005
72.7	O
,	O
gentamycin	B-C3854019
72.2	O
,	O
and	O
meropenem	B-C0066005
63.6	O
.	O
	
none	O
of	O
the	O
isolates	B-C3494793
was	O
,	O
however	O
,	O
resistant	B-C4281815
to	O
colistin	B-C0002499
.	O
	
pcr	B-C0032520
results	B-C0456984
showed	O
that	O
blaoxa	B-C1442492
,	O
blatem	I-C1442492
,	O
and	I-C1442492
blactx-m	I-C1442492
genes	I-C1442492
were	O
positive	B-C1446409
in	O
some	O
isolates	B-C3494793
,	O
while	O
blashv	B-C1442492
was	O
not	B-C0442737
detected	I-C0442737
in	O
any	O
of	O
the	O
isolates	B-C3494793
.	O
	
this	O
study	B-C2603343
has	O
revealed	B-C0443289
that	O
the	O
strains	B-C0314787
of	O
a	B-C0314787
.	O
	
baumannii	I-C0314787
isolated	B-C0205409
are	O
multiple	B-C0242640
drug	I-C0242640
resistant	I-C0242640
.	O
	
regular	O
monitoring	B-C1283169
,	O
judicious	O
prescription	B-C0033080
,	O
and	O
early	O
detection	B-C1511790
of	O
resistance	B-C4281815
to	O
these	O
antibiotics	B-C0003232
are	O
,	O
therefore	O
,	O
necessary	O
to	O
check	O
further	O
dissemination	O
of	O
the	O
dataset	B-C0150098
of	O
the	O
molecular	B-C2717775
dynamics	I-C2717775
simulations	I-C2717775
of	O
bilayers	B-C0205556
consisting	O
of	O
short	O
amyloidogenic	B-C0030956
peptide	I-C0030956
vdswnvlvag	B-C0002518
from	O
bgl2p-glucantransferase	B-C0014442
of	O
s	B-C0036025
.	O
	
cerevisiae	I-C0036025
cell	B-C0007623
wall	I-C0007623
the	O
amyloidogenic	B-C0030956
peptide	I-C0030956
vdswnvlvag	B-C0002518
from	O
bgl2p-glucantransferase	B-C0014442
of	O
saccharomyces	B-C0036025
cerevisiae	I-C0036025
cell	B-C0007623
wall	I-C0007623
and	O
its	O
modifying	O
analog	B-C0243071
veswnvlvag	B-C0002518
were	O
taken	O
for	O
the	O
construction	O
of	O
four	B-C0205450
types	O
of	O
bilayers	B-C0205556
which	O
differ	O
by	O
orientation	B-C1704322
of	O
the	O
peptides	B-C0030956
in	O
the	O
layers	B-C0205556
and	O
of	O
the	O
layers	B-C0205556
relative	O
to	O
each	O
other	O
.	O
	
these	O
bilayers	B-C0205556
were	O
used	O
as	O
starting	O
models	B-C3161035
for	O
the	O
molecular	B-C0596957
dynamics	I-C0596957
md	B-C0596957
at	O
three	O
charge	O
states	O
neutral	O
,	O
ph3	O
,	O
and	O
ph5	O
.	O
	
the	O
changes	B-C0392747
of	O
the	O
fraction	O
of	O
secondary	B-C0162807
structure	I-C0162807
during	O
1	O
ns	O
simulations	B-C0679083
were	O
received	O
for	O
96	O
md	O
trajectories	O
.	O
	
the	O
data	B-C1511726
article	B-C1706852
contains	O
the	O
necessary	O
information	B-C1533716
for	O
the	O
construction	O
of	O
models	B-C3161035
of	O
β-strands	B-C0600383
organization	B-C1300196
in	O
the	O
oligomer	B-C0599219
structure	B-C0678594
.	O
	
these	O
results	B-C1274040
were	O
used	O
in	O
the	O
associated	O
research	B-C1706852
article	I-C1706852
""""	O
structural	B-C0026349
model	I-C0026349
of	O
amyloid	B-C1449651
fibrils	I-C1449651
for	O
amyloidogenic	B-C0030956
peptide	I-C0030956
from	O
bgl2p-glucantransferase	B-C0014442
of	O
s	B-C0036025
.	O
	
cerevisiae	I-C0036025
cell	B-C0007623
wall	I-C0007623
and	O
its	O
modifying	O
analog	B-C0243071
.	O
	
new	O
morphology	B-C0332437
of	O
amyloid	B-C1449651
fibrils	I-C1449651
straight	B-C0036186
configuration	I-C0036186
saphenous	I-C0036186
vein	I-C0036186
transposition	B-C1293442
to	O
popliteal	B-C0032649
artery	I-C0032649
for	O
vascular	B-C0750138
access	I-C0750138
the	O
saphenous	B-C0036186
vein	I-C0036186
is	O
commonly	O
used	O
as	O
a	O
vascular	B-C0740038
graft	I-C0740038
in	O
peripheral	B-C0489868
artery	I-C0489868
surgery	B-C0543467
but	O
rarely	B-C0522498
used	O
for	O
vascular	B-C0750138
access	I-C0750138
.	O
	
the	O
literature	B-C0023866
on	O
straight	B-C0036186
configuration	I-C0036186
saphenous	I-C0036186
vein	I-C0036186
transposition	B-C1293442
to	O
the	O
popliteal	B-C0032649
artery	I-C0032649
is	O
scarce	B-C0522498
.	O
	
here	O
we	O
present	O
two	O
cases	O
of	O
straight	B-C0036186
configuration	I-C0036186
saphenous	I-C0036186
vein	I-C0036186
transposition	B-C1293442
to	O
the	O
popliteal	B-C0032649
artery	I-C0032649
for	O
vascular	B-C0750138
access	I-C0750138
,	O
the	O
surgical	B-C0011918
technique	I-C0011918
and	O
respective	O
follow-up	B-C1522577
.	O
	
two	O
young	B-C0238598
men	B-C0025266
,	O
aged	O
29	O
and	O
36	O
years	B-C0439234
,	O
were	O
chosen	O
for	O
lower-limb	B-C0457913
vascular	I-C0457913
access	I-C0457913
for	O
hemodialysis	B-C0019004
.	O
	
the	O
first	O
patient	B-C0030705
was	O
paraplegic	B-C0030486
since	O
birth	O
.	O
	
he	O
used	O
his	O
arms	O
to	O
move	O
so	O
upper	B-C0749854
extremity	I-C0749854
vascular	I-C0749854
access	I-C0749854
was	O
avoided	O
.	O
	
the	O
second	O
patient	B-C0030705
presented	O
with	O
an	O
infected	B-C0439663
upper	B-C0749781
extremity	I-C0749781
arteriovenous	I-C0749781
graft	I-C0749781
avg	B-C0749781
and	O
after	O
multiple	O
closed	B-C0587267
avfs	B-C0003855
he	O
had	O
no	O
more	O
available	O
arm	B-C0042449
veins	I-C0042449
.	O
	
both	O
patients	B-C0030705
received	B-C1514756
autologous	B-C0439859
lower	B-C4266545
extremity	I-C4266545
straight	B-C0036186
configuration	I-C0036186
saphenous	I-C0036186
vein	I-C0036186
transpositions	B-C1293442
to	O
the	O
popliteal	B-C0032649
artery	I-C0032649
under	O
spinal	B-C0002928
anesthesia	I-C0002928
in	O
may	O
and	O
october	O
2012	O
,	O
respectively	O
.	O
	
cannulation	B-C0917707
of	O
the	O
fistula	B-C0080304
was	O
allowed	O
after	O
one	O
month	B-C0439231
.	O
	
there	O
were	O
no	B-C0231243
early	I-C0231243
complications	I-C0231243
.	O
	
slight	B-C0038999
swelling	I-C0038999
on	O
the	O
leg	B-C1140621
appeared	B-C0700364
in	O
one	O
of	O
the	O
patients	B-C0030705
.	O
	
both	O
fistulas	B-C0080304
were	O
still	O
functional	B-C0205245
after	O
36	O
and	O
32	O
months	B-C0439231
,	O
respectively	O
.	O
	
the	O
straight	B-C0036186
configuration	I-C0036186
saphenous	I-C0036186
vein	I-C0036186
transposition	B-C1293442
to	O
popliteal	B-C0032649
artery	I-C0032649
is	O
simple	O
to	O
perform	O
,	O
offers	O
a	O
long	B-C0441635
and	I-C0441635
straight	I-C0441635
segment	I-C0441635
for	O
cannulation	B-C0917707
and	O
may	O
be	O
a	O
suitable	O
autologous	B-C0439859
vascular	B-C0750138
access	I-C0750138
in	O
selected	O
inhibited	B-C0311403
temperament	B-C0039474
and	O
hippocampal	B-C0019564
volume	B-C1113695
in	O
offspring	B-C0680063
of	O
parents	B-C0030551
with	O
bipolar	B-C0005586
disorder	I-C0005586
prior	O
studies	O
have	O
suggested	B-C1705535
that	O
inhibited	B-C0311403
temperament	B-C0039474
may	O
be	O
associated	B-C0332281
with	I-C0332281
an	O
increased	B-C0205217
risk	B-C0035647
for	O
developing	O
anxiety	B-C0003469
or	O
mood	B-C0525045
disorder	I-C0525045
,	O
including	O
bipolar	B-C0005586
disorder	I-C0005586
.	O
	
however	O
,	O
the	O
neurobiological	O
basis	O
for	O
this	O
increased	B-C0205217
risk	B-C0035647
is	O
unknown	B-C0439673
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-C0332128
temperament	B-C0039474
in	O
symptomatic	B-C0231220
and	O
asymptomatic	B-C0231221
child	B-C0008059
offspring	B-C0680063
of	O
parents	B-C0030551
with	O
bipolar	B-C0005586
disorder	I-C0005586
obd	B-C0005586
and	O
to	O
investigate	B-C1292732
whether	O
inhibited	B-C0311403
temperament	O
is	O
associated	O
with	O
aberrant	O
hippocampal	O
volumes	O
compared	O
with	O
healthy	O
control	O
hc	O
youth	O
.	O
	
the	O
obd	O
group	O
consisted	O
of	O
45	O
youth	O
,	O
24	O
of	O
whom	O
had	O
current	O
psychiatric	O
symptoms	O
obd	O
and	O
21	O
without	O
any	O
psychiatric	O
symptoms	O
obd	O
,	O
and	O
were	O
compared	O
with	O
24	O
hc	O
youth	O
.	O
	
temperament	O
characteristics	O
were	O
measured	O
by	O
using	O
the	O
revised	O
dimensions	O
of	O
temperament	O
survey	O
.	O
	
magnetic	O
resonance	O
imaging	O
was	O
used	O
to	O
measure	O
hippocampal	O
volumes	O
.	O
	
the	O
association	O
between	O
temperament	O
and	O
hippocampal	O
volumes	O
was	O
tested	O
by	O
using	O
multiple	O
regression	O
analysis	O
.	O
	
compared	O
with	O
the	O
obd	O
group	O
,	O
the	O
obd	O
group	O
had	O
significantly	O
more	O
inhibited	B-C0311403
temperament	B-C0039474
traits	O
,	O
less	O
flexibility	O
,	O
more	O
negative	O
mood	O
,	O
and	O
less	O
regular	O
rhythm	O
in	O
their	O
daily	O
routines	O
.	O
	
in	O
contrast	O
,	O
the	O
obd	O
group	O
was	O
more	O
likely	O
to	O
approach	O
novel	O
situations	O
compared	O
with	O
obd	O
or	O
hc	O
groups	O
.	O
	
within	O
the	O
obd	O
group	O
,	O
a	O
more	O
inhibited	O
temperament	O
was	O
associated	B-C0332281
with	I-C0332281
smaller	O
right	O
hippocampal	O
volumes	O
.	O
	
in	O
this	O
study	O
,	O
symptomatic	O
obd	O
were	O
characterized	O
by	O
an	O
inhibited	O
temperament	O
that	O
was	O
inversely	O
correlated	O
with	O
hippocampal	O
volume	O
.	O
	
additional	O
longitudinal	O
studies	O
are	O
needed	O
to	O
determine	O
whether	O
inverse	O
correlations	O
between	O
hippocampal	O
volume	O
and	O
inhibited	O
temperament	O
represent	O
early	O
markers	O
of	O
risk	O
for	O
later	O
developing	O
bipolar	O
disorder	I-C0005586
dynamic	B-C0729333
disorder	B-C0205556
can	O
explain	O
non-exponential	B-C0392762
kinetics	B-C0022702
of	O
fast	O
protein	B-C1655065
mechanical	I-C1655065
unfolding	I-C1655065
protein	B-C1655065
unfolding	I-C1655065
often	O
does	O
not	O
obey	O
a	O
simple	O
two-state	O
behavior	O
.	O
	
previous	O
single	B-C4279975
molecule	I-C4279975
force	I-C4279975
spectroscopy	I-C4279975
studies	B-C0947630
demonstrated	O
stretched	B-C0205556
exponential	I-C0205556
kinetics	B-C0022702
of	O
protein	B-C1655065
unfolding	I-C1655065
under	O
a	O
constant	B-C0441722
pulling	I-C0441722
force	I-C0441722
,	O
the	O
molecular	B-C1521991
origin	B-C0439659
of	O
which	O
remains	O
subject	O
to	O
debate	O
.	O
	
we	O
here	O
set	O
out	O
to	O
extensively	O
sample	O
the	O
mechanical	B-C1655065
unfolding	I-C1655065
of	O
ubiquitin	B-C0041538
and	O
nug2	B-C0033684
by	O
molecular	B-C2717775
dynamics	I-C2717775
md	I-C2717775
simulations	I-C2717775
.	O
	
both	O
proteins	B-C0033684
show	O
kinetics	B-C0022702
best	O
fit	O
by	O
stretched	B-C0205556
exponentials	I-C0205556
,	O
with	O
stretching	B-C1711342
exponents	I-C1711342
similar	O
to	O
those	O
found	O
in	O
experiments	B-C0681814
,	O
even	O
though	O
static	O
disorder	O
is	O
absent	B-C0332197
in	O
our	O
short	O
md	B-C2717775
simulations	I-C2717775
.	O
	
instead	O
,	O
we	O
can	O
ascribe	O
non-exponential	B-C0392762
kinetics	B-C0022702
to	O
dynamic	B-C0729333
disorder	B-C0205556
,	O
due	O
to	O
conformational	B-C0026377
fluctuations	B-C0231241
on	O
the	O
nanosecond	B-C1254367
timescale	I-C1254367
.	O
	
our	O
study	B-C2603343
highlights	O
the	O
general	O
role	O
of	O
dynamic	B-C0729333
disorder	B-C0205556
in	O
protein	B-C0022702
kinetics	I-C0022702
on	O
a	O
broad	O
range	O
of	O
time	B-C1254367
scales	I-C1254367
even	O
including	O
those	O
probed	O
in	O
md	B-C2717775
simulations	I-C2717775
.	O
	
identification	O
and	O
functional	O
analysis	O
of	O
the	O
gtpv	B-C0206574
bidirectional	B-C1706937
promoter	B-C0033413
region	I-C0033413
the	O
goat	B-C0206574
pox	I-C0206574
chick	I-C0206574
embryo-attenuated	I-C0206574
virus	I-C0206574
gtpv	B-C0206574
has	O
been	O
developed	O
as	O
an	O
effective	O
vaccine	B-C0042210
that	O
can	O
elicit	O
protective	O
immune	B-C0301872
responses	I-C0301872
.	O
	
it	O
possesses	O
a	O
large	O
genome	B-C0017428
and	O
a	O
robust	O
ability	O
to	O
express	B-C0017262
exogenous	B-C0205228
genes	B-C0017337
.	O
	
thus	O
,	O
this	O
virus	B-C0206574
is	O
an	O
ideal	B-C1512612
vector	B-C0599566
for	O
recombinant	B-C0034862
live	I-C0034862
vaccines	I-C0034862
for	O
infectious	B-C0009450
diseases	I-C0009450
in	O
ruminant	B-C0035950
animals	I-C0035950
.	O
	
in	O
this	O
study	O
,	O
we	O
identified	O
a	O
novel	O
bidirectional	B-C1706937
promoter	B-C0033413
region	I-C0033413
of	O
gtpv	B-C0206574
through	O
screening	O
named	O
pbvv	B-C0086860
.	O
	
pbvv	B-C0086860
is	O
located	O
between	O
etf-l	B-C0082367
and	O
vitf-3	B-C0040648
,	O
which	O
are	O
transcribed	B-C0040649
in	O
opposite	B-C1521805
directions	B-C0449738
.	O
	
a	O
new	O
recombinant	B-C0206574
goat	I-C0206574
pox	I-C0206574
virus	I-C0206574
rgtpv	B-C0206574
was	O
constructed	O
,	O
in	O
which	O
duplicate	O
pbvv	B-C0086860
was	O
used	O
as	O
a	O
promoter	B-C0086860
element	O
to	O
enhance	B-C2349975
brucella	B-C1621913
omp31	I-C1621913
expression	B-C1171362
,	O
and	O
duplicate	O
pbvv	B-C0086860
-	O
was	O
used	O
as	O
a	O
promoter	B-C0086860
element	I-C0086860
to	O
regulate	O
enhanced	B-C1258415
green	I-C1258415
fluorescent	I-C1258415
protein	I-C1258415
egfp	B-C1258415
at	O
the	O
same	O
time	O
as	O
the	O
selection	O
marker	O
.	O
	
pbvv	B-C0086860
promoter	I-C0086860
activity	O
was	O
compared	O
to	O
that	O
of	O
the	O
p7.5	B-C0086860
promoter	I-C0086860
of	O
vaccinia	B-C0042216
virus	I-C0042216
,	O
as	O
measured	O
by	O
egfp	B-C1258415
expression	B-C1171362
the	O
fluorescence	B-C0026022
intensity	I-C0026022
of	O
egfp	B-C1258415
expressed	B-C1171362
in	O
cells	B-C0007634
was	O
confirmed	O
by	O
fluorescence	B-C0026022
microscopy	I-C0026022
and	O
flow	B-C0016263
cytometry	I-C0016263
.	O
	
pbvv	B-C0086860
promoter	I-C0086860
activity	O
was	O
measured	O
by	O
brucella	B-C1621913
omp31	I-C1621913
expression	B-C1171362
.	O
	
interaction	O
with	O
the	O
anti-brucella-omp31	B-C0003250
monoclonal	I-C0003250
antibody	I-C0003250
was	O
confirmed	O
by	O
western	B-C0005863
blotting	I-C0005863
,	O
and	O
omp31	B-C1621913
mrna	B-C1515670
expression	I-C1515670
was	O
assessed	O
by	O
qrt-pcr	B-C1514628
.	O
	
the	O
results	O
of	O
this	O
study	O
will	O
be	O
useful	O
for	O
the	O
further	O
study	O
of	O
effective	B-C1704419
multivalent	B-C1514218
vaccines	I-C1514218
based	O
on	O
rgtpv	B-C0206574
.	O
	
this	O
study	O
also	O
provides	O
a	O
theoretical	O
basis	O
for	O
overcoming	O
the	O
problem	O
of	O
low	O
expression	B-C1171362
of	O
exogenous	B-C0205228
genes	B-C0017337
.	O
	
psychometric	B-C0033920
analysis	I-C0033920
of	O
the	O
patient	B-C1879301
health	I-C1879301
questionnaire	I-C1879301
in	O
danish	B-C0011318
patients	B-C0030705
with	O
an	O
implantable	B-C0162589
cardioverter	I-C0162589
defibrillator	I-C0162589
the	O
defib-women	B-C0681876
study	I-C0681876
to	O
assess	O
the	O
psychometric	B-C0033920
properties	I-C0033920
of	O
the	O
patient	B-C4083201
health	I-C4083201
questionnaire	I-C4083201
phq-9	B-C4083201
,	O
a	O
measure	B-C0079809
of	O
depressive	B-C0086132
symptoms	I-C0086132
,	O
in	O
a	O
large	B-C0549177
danish	B-C0011318
national	B-C0599755
cohort	I-C0599755
of	O
patients	B-C0030705
with	O
heart	B-C0018799
disease	I-C0018799
,	O
implanted	B-C0021107
with	O
an	O
implantable	B-C0162589
cardioverter	I-C0162589
defibrillator	I-C0162589
icd	B-C0162589
,	O
using	O
item	B-C0870753
response	I-C0870753
theory	I-C0870753
.	O
	
a	O
prospective	B-C0599755
cohort	I-C0599755
of	O
patients	B-C0030705
implanted	B-C0021107
with	O
an	O
icd	B-C0162589
n=1531	O
80.4	O
men	B-C0025266
completed	O
the	O
phq-9	B-C4083201
at	O
the	O
time	O
of	O
implant	B-C0021107
.	O
	
data	B-C1511726
were	O
analyzed	B-C0936012
using	O
two	O
item	B-C0870753
response	I-C0870753
theory	I-C0870753
models	I-C0870753
,	O
the	O
partial	B-C0026348
credit	I-C0026348
model	I-C0026348
and	O
the	O
generalized	B-C0026348
partial	I-C0026348
credit	I-C0026348
model	I-C0026348
.	O
	
the	O
analysis	B-C0936012
showed	O
disordered	B-C1706817
response	I-C1706817
thresholds	B-C0449864
in	O
eight	O
of	O
nine	O
items	B-C0871791
for	O
the	O
partial	B-C0026348
credit	I-C0026348
model	I-C0026348
and	O
five	O
of	O
nine	O
items	B-C0871791
for	O
the	O
generalized	B-C0026348
partial	I-C0026348
credit	I-C0026348
model	I-C0026348
,	O
indicating	O
that	O
respondents	B-C0282122
have	O
difficulty	B-C0332218
discriminating	B-C0012632
between	O
response	B-C1706817
options	O
.	O
	
when	O
collapsing	O
response	B-C1706817
options	B-C1518601
2	O
and	O
3	O
,	O
the	O
rescored	B-C0449820
phq-9	B-C4083201
had	O
a	O
better	O
fit	O
to	O
both	O
models	B-C0026348
.	O
	
the	O
unidimensionality	B-C0205556
and	O
the	O
precision	B-C1706245
of	O
the	O
rescored	B-C0449820
phq-9	B-C4083201
were	O
confirmed	O
.	O
	
items	B-C0871509
did	O
not	O
have	O
any	O
differential	B-C0205245
functioning	I-C0205245
dif	B-C0205245
across	O
educational	B-C0013658
level	I-C0013658
,	O
age	B-C0001779
,	O
indication	B-C3146298
for	O
icd	B-C0162589
implantation	B-C0021107
,	O
and	O
severity	B-C0439793
of	O
heart	B-C0018801
failure	I-C0018801
that	O
influence	B-C4054723
depression	B-C0011570
outcomes	B-C1274040
in	O
patients	B-C0030705
with	O
an	O
icd	B-C0162589
.	O
	
one	O
item	O
exhibited	O
dif	B-C0205245
by	O
gender	B-C0079399
.	O
	
three	O
items	B-C0871509
did	O
not	O
fit	O
the	O
partial	B-C0026348
credit	I-C0026348
model	I-C0026348
,	O
but	O
the	O
generalized	B-C0026348
partial	I-C0026348
credit	I-C0026348
model	I-C0026348
could	O
be	O
fitted	O
to	O
the	O
full	O
item	B-C0871509
set	I-C0871509
.	O
	
the	O
unidimensionality	B-C0205556
and	O
reliability	B-C2347947
of	O
the	O
danish	B-C0010969
version	I-C0010969
of	O
the	O
phq-9	B-C4083201
were	O
confirmed	B-C0750484
.	O
	
however	O
,	O
the	O
associated	B-C0332281
consequences	B-C0686907
of	O
the	O
number	O
of	O
response	B-C1706817
options	B-C1518601
3-point	O
versus	O
4-point	O
likert	B-C0451267
scale	I-C0451267
need	O
to	O
be	O
further	O
examined	B-C0332128
for	O
the	O
phq-9	B-C4083201
both	O
as	O
a	O
screening	B-C1710032
tool	B-C0037589
and	O
outcome	B-C0086749
measure	I-C0086749
.	O
	
geographical	B-C0935553
variations	I-C0935553
in	O
incidence	B-C0021149
,	O
management	B-C0376636
and	O
survival	B-C0038954
of	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
in	O
a	O
western	B-C0454664
country	I-C0454664
information	B-C1533716
on	O
the	O
incidence	B-C0021149
,	O
management	B-C0376636
,	O
and	O
prognosis	B-C0033325
of	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
hcc	B-C2239176
is	O
derived	O
from	O
population	B-C2348150
samples	I-C2348150
,	O
regional	B-C0205147
data	B-C1511726
,	O
or	O
registries	B-C0034975
.	O
	
comprehensive	B-C1880156
national	B-C1555720
evaluations	B-C0220825
within	O
a	O
given	O
country	B-C0454664
are	O
lacking	B-C0332268
.	O
	
this	O
study	B-C2603343
aimed	O
to	O
investigate	B-C1292732
regional	B-C0205147
variations	B-C0205419
in	O
hcc	B-C2239176
care	B-C1947933
within	O
france	B-C0016674
.	O
	
this	O
observational	B-C1518527
study	I-C1518527
analysed	O
data	B-C1511726
from	O
french	B-C1556084
administrative	B-C0242356
databases	I-C0242356
for	O
more	O
than	O
30	O
patients	B-C0030705
with	O
hcc	B-C2239176
diagnosed	B-C0011900
between	O
2009	O
and	O
2012	O
,	O
and	O
followed-up	O
until	O
2013	O
.	O
	
the	O
incidence	B-C0021149
of	O
hcc	B-C2239176
,	O
access	B-C0444454
to	O
surgery	B-C0543467
,	O
and	O
survival	B-C0038954
,	O
at	O
both	O
the	O
national	B-C0681788
level	I-C0681788
and	O
two	O
geographical	B-C0681784
levels	I-C0681784
the	O
21	O
french	B-C0454828
regions	I-C0454828
and	O
95	O
french	B-C1556084
departments	B-C1704729
into	O
which	O
france	B-C0016674
is	O
divided	B-C2919030
administratively	I-C2919030
,	O
were	O
determined	O
.	O
	
the	O
influence	B-C4054723
on	O
outcome	B-C1274040
of	O
the	O
structure	O
of	O
the	O
hospital	B-C0019994
where	O
hcc	B-C2239176
was	O
first	O
managed	B-C1273870
was	O
assessed	B-C1516048
.	O
	
at	O
the	O
national	B-C0681788
level	I-C0681788
,	O
the	O
median	B-C2986586
survival	I-C2986586
was	O
9.4	O
months	B-C0439231
and	O
only	O
22.8	O
of	O
patients	B-C0030705
had	O
curative	B-C1273390
treatment	I-C1273390
.	O
	
there	O
were	O
marked	O
variations	O
between	O
regions	B-C0017446
and	O
departments	B-C1704729
in	O
incidence	B-C0021149
,	O
access	B-C0444454
to	O
curative	B-C1273390
treatment	I-C1273390
range	O
1.3	O
and	O
8.1	O
respectively	O
,	O
and	O
in	O
median	B-C2986586
survival	I-C2986586
range	B-C1514721
5.7	O
and	O
4.3	O
months	B-C0439231
respectively	O
.	O
	
the	O
administrative	B-C0001554
type	I-C0001554
and	O
annual	B-C0332181
hcc	B-C2239176
-	O
caseload	B-C0814777
of	O
the	O
hospital	B-C0019994
where	O
patients	B-C0030705
were	O
first	O
admitted	B-C0184666
also	O
had	O
an	O
independent	B-C0085862
influence	B-C4054723
on	O
treatment	B-C0087111
and	O
survival	B-C0038954
.	O
	
despite	O
full	O
insurance	B-C0376629
coverage	I-C0376629
for	O
all	O
citizens	B-C0682134
,	O
national	B-C1555720
measures	B-C0079809
to	O
reduce	B-C0242503
inequities	I-C0242503
in	O
the	O
management	B-C0376636
of	O
cancer	B-C1516213
patients	I-C1516213
,	O
standardised	O
recommendations	B-C0034866
for	O
hcc	B-C2239176
surveillance	B-C0038842
and	O
management	B-C0376636
,	O
the	O
percentage	B-C0439165
of	O
patients	B-C0030705
undergoing	O
curative	B-C1273390
treatment	I-C1273390
and	O
their	O
survival	B-C0038954
may	O
vary	O
four-fold	O
depending	O
on	O
their	O
postcode	B-C0421454
.	O
	
the	O
hospital	B-C0019994
in	O
which	O
patients	B-C0030705
are	O
first	O
managed	B-C1273870
has	O
a	O
clear	O
influence	B-C4054723
on	O
accessibility	B-C0814423
to	O
both	O
good	B-C1947933
care	I-C1947933
and	O
survival	B-C0038954
.	O
	
population-based	B-C1709599
studies	I-C1709599
have	O
highlighted	O
large	O
and	O
sometimes	O
unexpected	O
differences	O
between	O
countries	B-C0454664
in	O
the	O
survival	B-C0038954
of	O
patients	B-C0030705
with	O
malignancy	B-C4282132
.	O
	
as	O
these	O
differences	O
are	O
considered	O
to	O
indicate	O
the	O
overall	O
effectiveness	B-C1280519
of	O
health	B-C1456613
systems	I-C1456613
,	O
in	O
addition	O
to	O
the	O
incidence	B-C0021149
of	O
the	O
cancer	B-C0006826
or	O
quality	B-C0332306
of	O
registration	B-C1514821
,	O
variations	O
within	O
a	O
given	O
country	B-C0454664
should	O
be	O
minimal	B-C0547040
.	O
	
however	O
,	O
similar	O
to	O
between	O
countries	B-C0454664
differences	O
,	O
this	O
study	B-C2603343
shows	O
differences	O
within	O
the	O
same	O
country	B-C0454664
in	O
the	O
incidence	B-C0021149
,	O
curative	B-C1273390
treatment	I-C1273390
rate	B-C1521828
,	O
and	O
survival	B-C0038954
of	O
patients	B-C0030705
with	O
hcc	B-C2239176
.	O
	
evidence	B-C3887511
that	O
access	O
to	O
care	B-C1947933
and	O
survival	B-C0038954
varies	O
within	O
a	O
country	B-C0454664
can	O
strengthen	B-C0205556
the	I-C0205556
impetus	I-C0205556
for	O
government	B-C0018104
and	O
clinicians	B-C0871685
to	O
address	O
these	O
identification	B-C0205396
of	O
potential	O
predictive	B-C0681890
markers	B-C0008963
of	O
dexamethasone	B-C0011777
resistance	B-C0013203
in	O
childhood	B-C0231335
acute	B-C0023449
lymphoblastic	I-C0023449
leukemia	I-C0023449
response	B-C0683154
to	O
dexamethasone	B-C0011777
dexa	B-C0011777
,	O
as	O
a	O
hallmark	B-C1254351
drug	I-C1254351
in	O
the	O
treatment	B-C0039798
of	O
childhood	B-C0231335
acute	B-C0023449
lymphoblastic	I-C0023449
leukemia	I-C0023449
all	B-C0023449
,	O
is	O
one	O
of	O
the	O
pivotal	O
prognostic	B-C1514474
factors	I-C1514474
in	O
the	O
prediction	B-C0033325
of	I-C0033325
outcome	I-C0033325
in	O
all	B-C0023449
.	O
	
identification	B-C0205396
of	O
predictive	B-C0681890
markers	B-C0008963
of	O
chemoresistance	B-C0013203
is	O
beneficial	O
to	O
selecting	O
of	O
the	O
best	O
therapeutic	B-C0040808
protocol	I-C0040808
with	O
the	O
lowest	O
effect	B-C0879626
adverse	I-C0879626
.	O
	
hence	O
,	O
we	O
aimed	O
to	O
find	O
drug	B-C0085104
targets	I-C0085104
using	O
the	O
2de	B-C0013860
/	O
ms	B-C0037813
proteomics	B-C0022885
study	I-C0022885
of	O
a	O
dexa	B-C0011777
-	O
resistant	B-C0007600
cell	I-C0007600
line	I-C0007600
reh	B-C0007600
as	O
a	O
model	B-C0026336
for	O
poor	O
dexa	B-C0011777
responding	O
patients	B-C0030705
before	O
and	O
after	O
drug	B-C0013216
treatment	I-C0013216
.	O
	
using	O
the	O
proteomic	B-C0022885
methods	I-C0022885
,	O
three	O
differentially	O
expressed	B-C1171362
proteins	B-C0033684
were	O
detected	B-C0442726
,	O
including	O
voltage	B-C0753015
dependent	I-C0753015
anion	I-C0753015
channel	I-C0753015
1	I-C0753015
vdac1	B-C0753015
,	O
sorting	B-C1741224
nexin	I-C1741224
3	I-C1741224
snx3	B-C1741224
,	O
and	O
prefoldin	B-C1743484
subunit	I-C1743484
6	I-C1743484
pfdn6	B-C1743484
.	O
	
we	O
observed	O
low	O
expression	B-C1171362
of	O
three	O
proteins	B-C0033684
after	O
dexa	B-C0011777
treatment	B-C0039798
in	O
reh	B-C0007600
cells	I-C0007600
.	O
	
we	O
subsequently	O
verified	O
low	O
expression	B-C1171362
of	O
resulted	O
proteins	B-C0033684
at	O
the	O
mrna	B-C0035696
level	B-C0441889
using	O
the	O
quantitative	B-C2733022
pcr	I-C2733022
method	I-C2733022
.	O
	
these	O
proteins	B-C0033684
are	O
promising	O
proteins	B-C0033684
because	O
of	O
their	O
important	O
roles	B-C1705810
in	O
drug	B-C0013203
resistance	I-C0013203
and	O
regulation	B-C1148568
of	I-C1148568
apoptosis	I-C1148568
vdac1	B-C0753015
,	O
protein	B-C0599895
trafficking	I-C0599895
snx3	B-C1741224
,	O
and	O
protein	B-C0162847
folding	I-C0162847
pfdn6	B-C1743484
.	O
	
additionally	O
,	O
mrna	B-C0035696
expression	B-C3244092
level	I-C3244092
of	O
these	O
proteins	B-C0033684
was	O
assessed	B-C1516048
in	O
17	O
bone	B-C0438737
marrow	I-C0438737
samples	I-C0438737
from	O
children	B-C0008059
with	O
newly	B-C1518321
diagnosed	I-C1518321
all	B-C0023449
and	O
7	O
non-cancerous	B-C0370003
samples	I-C0370003
as	O
controls	B-C0009932
.	O
	
the	O
results	O
indicated	O
that	O
independent	O
of	O
the	O
molecular	B-C0449560
subtypes	I-C0449560
of	O
leukemia	B-C0023418
,	O
mrna	B-C0035696
expression	B-C1171362
of	O
vdac1	B-C0753015
,	O
snx3	B-C1741224
,	O
and	O
pfdn6	B-C1743484
decreased	O
in	O
all	B-C0023449
samples	B-C0370003
compared	O
with	O
non-cancerous	B-C0370003
samples	I-C0370003
particularly	O
in	O
vdac1	B-C0753015
p	O
<	O
0.001	O
.	O
	
additionally	O
,	O
mrna	B-C0035696
expression	B-C1171362
of	O
three	O
proteins	B-C0033684
was	O
also	O
declined	O
in	O
high-risk	B-C0332167
samples	B-C0370003
compared	O
with	O
standard	B-C1442989
risk	B-C0035647
cases	B-C0868928
.	O
	
these	O
results	O
demonstrated	O
diagnostic	B-C0348026
and	O
prognostic	B-C0220901
value	B-C0042295
of	O
these	O
proteins	B-C0033684
in	O
childhood	B-C0231335
all	B-C0023449
.	O
	
furthermore	O
,	O
investigation	B-C0220825
of	O
protein-protein	B-C0872079
interaction	I-C0872079
using	O
string	B-C1547402
database	B-C0242356
indicated	O
that	O
these	O
proteins	B-C0033684
involved	O
in	O
the	O
signaling	B-C0037080
pathway	I-C0037080
of	O
nr3c1	B-C1370369
as	O
dexamethasone	B-C0011777
target	B-C0243095
.	O
	
in	O
conclusion	O
,	O
our	O
proteomic	B-C0022885
study	I-C0022885
in	O
dexa	B-C0011777
resistant	B-C0013203
leukemic	B-C1517806
cells	I-C1517806
revealed	O
vdac1	B-C0753015
,	O
snx3	B-C1741224
,	O
and	O
pfdn6	B-C1743484
are	O
promising	O
proteins	B-C0033684
that	O
might	O
serve	O
as	O
potential	O
biomarkers	B-C0005516
of	O
prognosis	B-C0033325
and	O
chemotherapy	B-C3665472
in	O
childhood	B-C0231335
all	B-C0023449
.	O
	
benthic	B-C0282574
injury	I-C0282574
dose-response	I-C0282574
models	I-C0282574
for	O
polychlorinated	B-C0032447
biphenyl	I-C0032447
-	O
contaminated	B-C0205279
sediment	B-C1550099
using	O
equilibrium	B-C0282574
partitioning	I-C0282574
the	O
study	B-C2603343
goal	O
was	O
to	O
develop	O
a	O
sediment	B-C1550099
polychlorinated	B-C0032447
biphenyl	I-C0032447
pcb	B-C0032447
dose-response	B-C0282574
model	I-C0282574
based	O
on	O
benthic	B-C0599636
invertebrate	I-C0599636
effects	O
to	O
pcbs	B-C0032447
.	O
	
the	O
authors	O
used	O
an	O
equilibrium	B-C0282574
partitioning	I-C0282574
eqp	I-C0282574
approach	I-C0282574
to	O
generate	O
predicted	O
pcb	B-C0032447
sediment	B-C1550099
effect	O
concentrations	B-C0457929
largely	O
aroclor	B-C0052391
1254	I-C0052391
associated	O
with	O
a	O
gradient	B-C0812409
of	O
toxic	B-C0600688
effects	I-C0600688
in	O
benthic	B-C0599636
organisms	I-C0599636
from	O
effects	O
observed	O
in	O
aquatic	B-C0563034
toxicity	B-C0600688
studies	B-C2603343
.	O
	
the	O
present	O
study	B-C2603343
differs	O
from	O
all	O
other	O
eqp	B-C0282574
collective	O
sediment	B-C1550099
investigations	O
in	O
that	O
the	O
authors	O
examined	O
a	O
common	O
dose-response	B-C0678790
gradient	B-C0812409
of	O
effects	O
for	O
pcbs	B-C0032447
rather	O
than	O
a	O
single	O
,	O
protective	O
value	O
.	O
	
the	O
authors	O
reviewed	O
the	O
chronic	B-C0205191
aquatic	B-C0563034
toxicity	B-C0600688
literature	B-C0023866
to	O
identify	O
measured	O
aqueous	B-C0599956
pcb	B-C0032447
concentrations	B-C0457929
and	O
associated	O
benthic	B-C0599636
invertebrate	I-C0599636
effects	O
.	O
	
the	O
authors	O
control-normalized	O
the	O
aquatic	B-C0563034
toxic	B-C0600688
effect	I-C0600688
data	B-C1511726
and	O
expressed	O
results	O
from	O
various	O
studies	B-C2603343
as	O
a	O
common	B-C0025867
metric	I-C0025867
,	O
percent	B-C0392762
injury	I-C0392762
.	O
	
then	O
,	O
they	O
calculated	O
organic	B-C0007011
carbon	I-C0007011
-normalized	O
sediment	B-C1550099
pcb	B-C0032447
concentrations	B-C0457929
mg/kg	O
organic	B-C0007011
carbon	I-C0007011
from	O
the	O
aqueous	B-C0599956
pcb	B-C0032447
toxicity	B-C0600688
data	B-C0150098
set	I-C0150098
using	O
eqp	B-C0282574
theory	O
based	O
on	O
the	O
us	B-C0041712
environmental	I-C0041712
protection	I-C0041712
agency's	I-C0041712
epiweb	B-C0037585
4.1	I-C0037585
derivation	O
of	O
the	O
water-organic	B-C1518903
carbon	I-C1518903
partition	I-C1518903
coefficient	I-C1518903
koc	B-C1518903
.	O
	
lastly	O
,	O
the	O
authors	O
constructed	O
a	O
nonlinear	O
dose-response	B-C0282574
numerical	I-C0282574
model	I-C0282574
for	O
these	O
synoptic	O
sediment	B-C1550099
pcb	B-C0032447
concentrations	B-C0457929
and	O
biological	B-C1511145
effects	I-C1511145
y	O
=	O
100/1	O
+	O
10	O
hill	O
slope	O
ec50	O
=	O
median	B-C1446561
effective	I-C1446561
concentration	I-C1446561
.	O
	
these	O
models	B-C0282574
were	O
used	O
to	O
generate	O
"""look-up"""	O
tables	B-C1706074
reporting	O
percent	B-C0392762
injury	I-C0392762
in	O
benthic	B-C1253910
biota	I-C1253910
for	O
a	O
range	O
of	O
aroclor	B-C0052391
-specific	O
sediment	B-C1550099
concentrations	B-C0457929
.	O
	
for	O
example	O
,	O
the	O
model	B-C0282574
using	O
the	O
epiweb	B-C0037585
koc	B-C1518903
estimate	O
predicts	O
mean	B-C0392762
benthic	I-C0392762
injury	I-C0392762
of	O
23.3	O
,	O
46.0	O
,	O
70.6	O
,	O
87.1	O
,	O
and	O
95%	O
for	O
hypothetical	O
sediment	B-C1550099
concentrations	B-C0457929
of	O
1	O
mg/kg	O
,	O
2	O
mg/kg	O
,	O
4	O
mg/kg	O
,	O
8	O
mg/kg	O
,	O
and	O
16	O
mg/kg	O
dry	O
weight	O
of	O
aroclor	B-C0052391
1254	I-C0052391
,	O
respectively	O
at	O
1%	O
organic	B-C0007011
carbon	I-C0007011
.	O
	
the	O
authors	O
recommend	O
the	O
model	B-C0282574
presented	O
for	O
screening	O
but	O
suggest	O
,	O
when	O
possible	O
,	O
determining	O
a	O
site-specific	B-C0449604
koc	B-C1518903
that	O
,	O
along	O
with	O
the	O
tables	B-C1706074
and	O
equations	B-C0552449
,	O
allows	O
users	O
to	O
create	O
their	O
own	O
protective	O
dose-response	B-C0678790
sediment	B-C1550099
concentration	B-C0457929
.	O
	
extract	B-C0032081
of	I-C0032081
caulis	I-C0032081
spatholobi	I-C0032081
,	O
a	O
novel	O
blocker	O
targeting	O
tumor	O
cell	O
induced	O
platelet	O
aggregation	O
,	O
inhibits	O
breast	O
cancer	O
metastasis	O
metastasis	O
of	O
breast	O
cancer	O
is	O
the	O
vital	O
step	O
for	O
malignant	O
progression	O
.	O
	
during	O
such	O
a	O
process	O
,	O
hematogenous	O
metastasis	O
is	O
an	O
indispensable	O
approach	O
for	O
the	O
dissemination	O
of	O
cancer	O
cells	O
.	O
	
a	O
platelet	O
,	O
contributes	O
to	O
hypercoagulable	O
state	O
,	O
and	O
is	O
also	O
identified	O
the	O
crucial	O
factor	O
in	O
the	O
coagulation	O
system	O
for	O
supporting	O
metastasis	O
.	O
	
therefore	O
,	O
the	O
relationship	O
of	O
a	O
platelet	O
and	O
a	O
tumor	O
cell	O
plays	O
a	O
critical	O
role	O
in	O
tumor	O
cell	O
metastasis	O
.	O
	
consequently	O
,	O
inhibiting	O
tumor	O
cell	O
induced	O
platelet	O
aggregation	O
tcipa	O
is	O
recongnized	O
as	O
a	O
crucial	O
target	O
on	O
suppression	O
of	O
tumor	O
metastasis	O
such	O
as	O
aspirin	O
asa	O
.	O
	
under	O
such	O
circumstance	O
,	O
here	O
we	O
report	O
that	O
,	O
through	O
dissociating	O
the	O
tumor	O
t	O
complex	O
,	O
80%	O
ethanol	O
extracts	O
of	O
caulis	B-C0242767
spatholobi	I-C0242767
set	O
successfully	O
alleviated	O
the	O
hypercoagulation	O
state	O
,	O
thereby	O
reducing	O
tumor	O
metastasis	O
and	O
improving	O
the	O
prospects	O
of	O
survival	O
in	O
breast	O
cancer	O
cell	O
model	O
.	O
	
through	O
mtt	O
and	O
anti	O
assay	O
stimulated	O
by	O
adp	O
,	O
we	O
detected	O
the	O
optimum	O
treatment	O
time	O
and	O
the	O
optimum	O
dose	O
of	O
set	O
.	O
	
by	O
using	O
confocal	O
microscopy	O
,	O
we	O
observed	O
that	O
set	O
can	O
strongly	O
block	O
the	O
formation	O
of	O
t	O
complex	O
i	O
n	O
vitro	O
.	O
	
the	O
result	O
was	O
further	O
quantified	O
and	O
confirmed	O
by	O
the	O
facs	O
analysis	O
.	O
	
the	O
fluorescent	O
value	O
of	O
t	O
complex	O
was	O
obviously	O
decreased	O
in	O
the	O
drug	O
groups	O
.	O
	
in	O
vivo	O
,	O
4t1	O
cells	O
were	O
injected	O
through	O
the	O
mouse	O
tail	O
vein	O
for	O
dynamic	O
visualization	O
by	O
small	O
animal	O
imaging	O
system	O
.	O
	
the	O
metastatic	O
intensity	O
was	O
quantified	O
and	O
the	O
survival	O
curve	O
was	O
analyzed	O
.	O
	
additionally	O
,	O
general	O
observation	O
and	O
hematoxylin	O
and	O
eosin	O
h	O
staining	O
of	O
lung	O
tissue	O
was	O
performed	O
.	O
	
set	O
exerted	O
an	O
obvious	O
effect	O
on	O
the	O
inhibition	O
of	O
metastasis	O
and	O
increasing	O
the	O
survival	O
rate	O
of	O
mice	O
.	O
	
for	O
the	O
molecular	O
mechanism	O
study	O
of	O
anti	O
,	O
zymography	O
and	O
r	O
t	O
assay	O
preliminarily	O
revealed	O
the	O
molecular	O
mechanism	O
of	O
set	O
in	O
the	O
regulation	O
of	O
p	O
t	O
interaction	O
.	O
	
collectively	O
,	O
through	O
drug	O
efficacy	O
identification	O
and	O
pharmacological	O
revealing	O
,	O
we	O
have	O
obtained	O
a	O
promising	O
candidate	O
for	O
the	O
interference	O
of	O
breast	O
metastasis	O
by	O
suppressing	O
tcipa	O
,	O
which	O
will	O
be	O
beneficial	O
for	O
clinical	O
cancer	O
treatment	I-C0040223
generalized	B-C0014548
epilepsy	I-C0014548
and	O
myoclonic	B-C0014550
seizures	I-C0014550
in	O
22q11.2	B-C0012236
deletion	I-C0012236
syndrome	I-C0012236
prompted	O
by	O
the	O
observations	O
of	O
juvenile	B-C0270853
myoclonic	I-C0270853
epilepsy	I-C0270853
jme	B-C0270853
in	O
22q11.2	B-C0012236
deletion	I-C0012236
syndrome	I-C0012236
22q11ds	B-C0012236
and	O
recurrent	B-C1511518
copy	I-C1511518
number	I-C1511518
variants	I-C1511518
in	O
genetic	B-C0017399
generalized	B-C0014548
epilepsy	I-C0014548
gge	B-C0014548
,	O
we	O
searched	O
for	O
further	O
evidence	O
supporting	O
a	O
possible	O
correlation	B-C1707520
of	O
22q11ds	B-C0012236
with	O
gge	B-C0014548
and	O
with	O
myoclonic	B-C0014550
seizures	I-C0014550
.	O
	
through	O
routine	B-C0086143
diagnostics	I-C0086143
,	O
we	O
identified	O
3	O
novel	O
individuals	B-C0027361
with	O
the	O
seemingly	O
uncommon	B-C0522498
combination	B-C0205195
of	O
22q11ds	B-C0012236
and	O
jme	B-C0270853
.	O
	
we	O
subsequently	O
screened	B-C0220908
the	O
literature	B-C0023866
for	O
reports	B-C0684224
focussing	O
on	O
the	O
epilepsy	B-C0031437
phenotype	I-C0031437
in	O
22q11ds	B-C0012236
.	O
	
we	O
additionally	O
screened	B-C0220908
a	O
database	B-C0242356
of	O
173	O
22q11ds	B-C0012236
patients	B-C0030705
and	O
identified	O
a	O
fourth	O
individual	B-C0027361
with	O
jme	B-C0270853
as	O
well	O
as	O
2	O
additional	O
cases	B-C0868928
with	O
gge	B-C0014548
.	O
	
we	O
describe	O
6	O
novel	B-C0205314
and	O
22	O
published	B-C0034037
cases	B-C0868928
with	O
co-occurrence	B-C0243095
of	O
22q11ds	B-C0012236
and	O
gge	B-C0014548
.	O
	
in	O
many	O
patients	B-C0030705
,	O
gge	B-C0014548
was	O
associated	B-C0332281
with	I-C0332281
myoclonic	B-C0014550
seizures	I-C0014550
allowing	O
for	O
a	O
diagnosis	B-C0011900
of	O
jme	B-C0270853
in	O
at	O
least	O
6	O
individuals	B-C0027361
.	O
	
seventeen	O
of	O
the	O
173	O
22q11ds	B-C0012236
cases	B-C0868928
10%	O
had	O
a	O
diagnosis	B-C0011900
of	O
either	O
focal	B-C0014547
or	O
generalized	B-C0014548
epilepsy	I-C0014548
.	O
	
in	O
these	O
cases	B-C0868928
,	O
focal	B-C0014547
epilepsy	I-C0014547
could	O
often	O
be	O
attributed	O
to	O
syndrome-associated	B-C0020598
hypocalcaemia	I-C0020598
,	O
cerebral	B-C2937358
bleeds	I-C2937358
,	O
or	O
structural	B-C3280971
brain	I-C3280971
anomalies	I-C3280971
.	O
	
however	O
,	O
the	O
cause	O
of	O
gge	B-C0014548
remained	O
unclear	O
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
describe	O
and	O
review	O
28	O
individuals	B-C0027361
with	O
22q11ds	B-C0012236
and	O
gge	B-C0014548
especially	O
jme	B-C0270853
,	O
showing	O
that	O
both	O
disorders	B-C0012634
frequently	B-C0243095
co-occur	I-C0243095
.	O
	
compared	O
to	O
the	O
reported	B-C0220900
prevalence	I-C0220900
of	O
15-21%	O
,	O
in	O
our	O
case	B-C0150093
series	I-C0150093
only	O
10%	O
of	O
22q11ds	B-C0012236
individuals	B-C0027361
were	O
found	O
to	O
have	O
epilepsy	B-C0014544
,	O
often	O
gge	B-C0014548
.	O
	
since	O
22q11.2	B-C1521104
does	O
not	O
contain	O
convincing	O
gge	B-C0014548
candidate	B-C1332838
genes	I-C1332838
,	O
we	O
discuss	O
the	O
possibility	O
of	O
an	O
aetiological	B-C0015127
correlation	B-C1707520
through	O
a	O
possibly	O
disturbed	O
interaction	O
with	O
the	O
gabab	B-C0052887
receptor	I-C0052887
.	O
	
normal	B-C0441889
levels	I-C0441889
of	O
urinary	B-C0042036
cc16	B-C1505089
protein	I-C1505089
.	O
	
comments	B-C0282574
on	I-C0282574
beamer	I-C0282574
et	I-C0282574
al	I-C0282574
.	O
	
association	I-C0282574
of	O
children's	B-C0008059
urinary	B-C0042036
cc16	B-C1505089
levels	B-C0262923
with	O
arsenic	B-C0373548
concentrations	I-C0373548
in	O
multiple	B-C1254372
environmental	I-C1254372
media	I-C1254372
.	O
	
int	O
.	O
	
j	O
.	O
	
environ	O
.	O
	
res	O
.	O
	
public	O
health	O
2016	O
,	O
13	O
,	O
521	O
in	O
1937	O
,	O
max	B-C0086418
clara	I-C0086418
described	O
a	O
new	O
type	O
of	O
cell	B-C0007634
in	O
the	O
human	B-C0086418
lung	B-C0024109
,	O
which	O
was	O
later	O
determined	O
to	O
be	O
an	O
exocrine	B-C0230676
secretory	I-C0230676
cell	I-C0230676
type	I-C0230676
containing	I-C0230676
granules	I-C0230676
composed	O
of	O
proteins	B-C0033684
diverse	O
colletotrichum	B-C0320203
species	I-C0320203
cause	O
anthracnose	B-C0032080
of	O
tea	B-C0032098
plants	I-C0032098
camellia	B-C0949852
sinensis	I-C0949852
l	I-C0949852
o	I-C0949852
.	O
	
kuntze	I-C0949852
in	O
china	B-C0008115
anthracnose	B-C0032080
caused	O
by	O
colletotrichum	B-C0320203
is	O
one	O
of	O
the	O
most	O
severe	O
diseases	B-C0032080
that	O
can	O
afflict	O
camellia	B-C0949852
sinensis	I-C0949852
.	O
	
however	O
,	O
research	B-C0035168
on	O
the	O
diversity	B-C1880371
and	O
geographical	B-C0681686
distribution	I-C0681686
of	O
colletotrichum	B-C0320203
in	O
china	B-C0008115
remain	O
limited	O
.	O
	
in	O
this	O
study	B-C0681814
,	O
106	O
colletotrichum	B-C0320203
isolates	B-C1764827
were	O
collected	B-C1516698
from	O
diseased	B-C0032080
leaves	B-C0242724
of	O
ca	B-C0949852
.	O
	
sinensis	I-C0949852
cultivated	O
in	O
the	O
15	O
main	O
tea	B-C1518533
production	I-C1518533
provinces	B-C1514578
in	O
china	B-C0008115
.	O
	
multi-locus	B-C1519068
phylogenetic	I-C1519068
analysis	I-C1519068
coupled	O
with	O
morphological	B-C1294314
identification	I-C1294314
showed	O
that	O
the	O
collected	B-C1516698
isolates	B-C1764827
belonged	O
to	O
11	O
species	B-C1705920
,	O
including	O
6	O
known	O
species	B-C1705920
c	B-C2642537
.	O
	
camelliae	I-C2642537
,	O
c	B-C2803492
.	O
	
cliviae	I-C2803492
,	O
c	B-C2813833
.	O
	
fioriniae	I-C2813833
,	O
c	B-C2804746
.	O
	
fructicola	I-C2804746
,	O
c	B-C3397324
.	O
	
karstii	I-C3397324
,	O
and	O
c	B-C2804749
.	O
	
siamense	I-C2804749
,	O
3	O
new	O
record	B-C1705920
species	I-C1705920
c	B-C3584139
.	O
	
aenigma	I-C3584139
,	O
c	B-C3746379
.	O
	
endophytica	I-C3746379
,	O
and	O
c	B-C2790917
.	O
	
truncatum	I-C2790917
,	O
1	O
novel	O
species	B-C1705920
c	B-C0016832
.	O
	
wuxiense	I-C0016832
,	O
and	O
1	O
indistinguishable	O
strain	B-C1518614
,	O
herein	O
described	O
as	O
colletotrichum	B-C0320203
sp	I-C0320203
.	O
	
of	O
these	O
species	B-C1705920
,	O
c	B-C2642537
.	O
	
camelliae	I-C2642537
and	O
c	B-C2804746
.	O
	
fructicola	I-C2804746
were	O
the	O
dominant	O
species	B-C1705920
causing	O
anthracnose	B-C0032080
in	O
ca	B-C0949852
.	O
	
sinensis	I-C0949852
.	O
	
in	O
addition	O
,	O
our	O
study	B-C0681814
provided	O
further	O
evidence	B-C3887511
that	O
phylogenetic	B-C1519068
analysis	I-C1519068
using	O
a	O
combination	O
of	O
apmat	B-C0162326
and	I-C0162326
gs	I-C0162326
sequences	I-C0162326
can	O
be	O
used	O
to	O
effectively	O
resolve	O
the	O
taxonomic	B-C0008903
relationships	B-C0439849
within	O
the	O
c	B-C1531932
.	O
	
gloeosporioides	I-C1531932
species	B-C1705920
complex	I-C1705920
.	O
	
finally	O
,	O
pathogenicity	B-C1136169
tests	B-C0022885
suggested	O
that	O
c	B-C2642537
.	O
	
camelliae	I-C2642537
,	O
c	B-C3584139
.	O
	
aenigma	I-C3584139
,	O
and	O
c	B-C3746379
.	O
	
endophytica	I-C3746379
are	O
more	O
invasive	B-C0205281
than	O
other	O
species	B-C1705920
after	O
the	O
inoculation	B-C2987620
of	O
the	O
leaves	B-C0242724
of	O
ca	B-C0949852
.	O
	
sinensis	I-C0949852
.	O
	
atp	B-C0001480
release	B-C1283071
from	O
bladder	B-C0227692
urothelium	I-C0227692
and	O
serosa	B-C0036760
in	O
a	O
rat	O
model	B-C0012644
of	O
partial	B-C0005694
bladder	I-C0005694
outlet	I-C0005694
obstruction	I-C0005694
overactive	B-C0878773
bladder	I-C0878773
is	O
one	O
of	O
the	O
major	O
health	B-C0243095
problem	I-C0243095
especially	O
in	O
elderly	B-C0001792
people	I-C0001792
.	O
	
adenosine	B-C0001480
triphosphate	I-C0001480
atp	B-C0001480
is	O
released	B-C1283071
from	O
urinary	B-C0227599
bladder	I-C0227599
cells	I-C0227599
and	O
acts	O
as	O
a	O
smooth	B-C1155937
muscle	I-C1155937
contraction	I-C1155937
and	O
sensory	B-C0597440
signal	I-C0597440
in	O
micturition	B-C0042034
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
atp	B-C0001480
release	O
in	O
the	O
pathophysiology	B-C0277785
of	O
overactive	B-C0878773
bladder	I-C0878773
.	O
	
to	O
assess	O
the	O
relationship	O
between	O
atp	B-C0001480
and	O
overactive	B-C0878773
bladder	I-C0878773
,	O
we	O
used	O
a	O
partial	B-C0005694
bladder	I-C0005694
outlet	I-C0005694
obstruction	I-C0005694
pboo	B-C0005694
model	B-C0012644
in	O
rats	B-C0034693
.	O
	
the	O
bladder	B-C0005682
caused	O
several	O
changes	O
by	O
pboo	B-C0005694
an	O
increase	B-C0442805
in	O
bladder	B-C0005682
weight	B-C0043100
,	O
hypertrophy	B-C0020564
of	O
sub-urothelium	B-C0227598
and	O
sub-serosal	B-C0036760
area	I-C0036760
,	O
and	O
frequent	O
non	B-C1518422
-	O
voiding	B-C0232850
bladder	I-C0232850
contraction	I-C0232850
during	O
urine	B-C0042036
storage	O
.	O
	
basal	B-C0205112
atp	B-C0001480
release	O
from	O
urothelium	B-C0227692
and	O
serosa	B-C0036760
of	O
pboo	B-C0005694
rats	B-C0034693
was	O
significantly	O
higher	O
than	O
that	O
of	O
normal	O
rats	B-C0034693
.	O
	
distention	B-C0005687
induced	O
atp	B-C0001480
release	B-C1283071
from	O
urothelium	B-C0227692
of	O
normal	O
and	O
pboo	B-C0005694
rats	B-C0034693
had	O
no	O
significant	O
change	O
.	O
	
however	O
,	O
distention	B-C0005687
-	O
induced	B-C0205263
atp	B-C0001480
release	B-C1283071
from	O
serosa	B-C0036760
of	O
pboo	B-C0005694
rats	B-C0034693
was	O
higher	O
than	O
that	O
of	O
normal	O
.	O
	
these	O
findings	O
may	O
identify	O
atp	B-C0001480
especially	O
released	B-C1283071
from	O
serosa	B-C0036760
as	O
one	O
of	O
causes	O
of	O
non	B-C1518422
-	O
voiding	B-C0232850
contractions	I-C0232850
and	O
overactive	B-C0878773
bladder	I-C0878773
symptoms	B-C1457887
.	O
	
determining	O
putative	B-C0012656
vectors	I-C0012656
of	O
the	O
bogia	B-C0032080
coconut	I-C0032080
syndrome	I-C0032080
phytoplasma	B-C1004784
using	O
loop-mediated	B-C3539922
isothermal	I-C3539922
amplification	I-C3539922
of	O
single-insect	B-C0016452
feeding	I-C0016452
media	I-C0016452
phytoplasmas	B-C1004784
are	O
insect	B-C3179193
vectored	I-C3179193
mollicutes	I-C3179193
responsible	O
for	O
disease	B-C0012634
in	O
many	O
economically	O
important	O
crops	B-C0032098
.	O
	
determining	O
which	O
insect	B-C0021585
species	I-C0021585
are	O
vectors	B-C0012656
of	O
a	O
given	O
phytoplasma	B-C1004784
is	O
important	O
for	O
managing	O
disease	B-C0012634
but	O
is	O
methodologically	O
challenging	O
because	O
disease-free	B-C0032098
plants	I-C0032098
need	O
to	O
be	O
exposed	O
to	O
large	O
numbers	O
of	O
insects	B-C0021585
,	O
often	O
over	O
many	O
months	B-C0439231
.	O
	
a	O
relatively	O
new	O
method	O
to	O
detect	O
likely	O
transmission	B-C1521797
involves	O
molecular	B-C0752096
testing	I-C0752096
for	O
phytoplasma	B-C1004784
dna	B-C0012854
in	O
sucrose	B-C0376597
solution	B-C0037633
that	O
insects	B-C0021585
have	O
fed	B-C2987508
upon	O
.	O
	
in	O
this	O
study	B-C2603343
we	O
combined	O
this	O
feeding	B-C0022885
medium	I-C0022885
method	I-C0022885
with	O
a	O
loop-mediated	B-C3539922
isothermal	I-C3539922
amplification	I-C3539922
lamp	I-C3539922
assay	I-C3539922
to	O
study	O
627	O
insect	B-C0021585
specimens	B-C2347026
of	O
11	O
hemiptera	B-C0018992
taxa	I-C0018992
sampled	O
from	O
sites	O
in	O
papua	B-C0030375
new	I-C0030375
guinea	I-C0030375
affected	O
by	O
bogia	B-C0032080
coconut	I-C0032080
syndrome	I-C0032080
bcs	B-C0032080
.	O
	
the	O
lamp	B-C3539922
assay	I-C3539922
detected	O
phytoplasma	B-C1004784
dna	B-C0012854
from	O
the	O
feeding	B-C0016452
solution	I-C0016452
and	O
head	B-C0018670
tissue	B-C0040300
of	O
insects	B-C0021585
from	O
six	O
taxa	B-C1515221
belonging	O
to	O
four	O
families	O
derbidae	B-C1063109
,	O
lophopidae	B-C1063149
,	O
flatidae	B-C1003013
and	O
ricaniidae	B-C1063157
.	O
	
two	O
other	O
taxa	B-C1515221
yielded	O
positives	O
only	O
from	O
the	O
heads	B-C0018670
and	O
the	O
remainder	O
tested	O
negative	O
.	O
	
these	O
results	O
demonstrate	O
the	O
utility	O
of	O
combining	O
single-insect	B-C0022885
feeding	I-C0022885
medium	I-C0022885
tests	I-C0022885
with	O
lamp	B-C3539922
assays	I-C3539922
to	O
identify	O
putative	B-C0012656
vectors	I-C0012656
that	O
can	O
be	O
the	O
subject	O
of	O
transmission	B-C1521797
tests	B-C0039593
and	O
to	O
better	O
understand	O
phytoplasma	B-C1004784
pathosystems	B-C0030664
.	O
	
non-toxigenic	B-C0445099
environmental	B-C0014406
vibrio	B-C0318248
cholerae	I-C0318248
o1	I-C0318248
strain	B-C1518614
from	O
haiti	B-C0018510
provides	B-C1999230
evidence	B-C3887511
of	O
pre-pandemic	B-C1615608
cholera	B-C0008354
in	O
hispaniola	B-C0454978
vibrio	B-C0042629
cholerae	I-C0042629
is	O
ubiquitous	B-C2348867
in	O
aquatic	B-C0563034
environments	I-C0563034
,	O
with	O
environmental	B-C0014406
toxigenic	B-C0445332
v	B-C0318248
.	O
	
cholerae	I-C0318248
o1	I-C0318248
strains	B-C1518614
serving	B-C1519269
as	O
a	O
source	B-C0449416
for	O
recurrent	B-C2945760
cholera	B-C0008354
epidemics	I-C0008354
and	O
pandemic	B-C1615608
disease	B-C0012634
.	O
	
however	O
,	O
a	O
number	O
of	O
questions	O
remain	O
about	O
long-term	B-C0443252
survival	B-C0220921
and	O
evolution	O
of	O
v	B-C0042629
.	O
	
cholerae	I-C0042629
strains	B-C1518614
within	O
these	O
aquatic	B-C0563034
environmental	I-C0563034
reservoirs	B-C0442537
.	O
	
through	O
monitoring	B-C0014416
of	O
the	O
haitian	B-C0018510
aquatic	B-C0563034
environment	I-C0563034
following	O
the	O
2010	O
cholera	B-C0008354
epidemic	I-C0008354
,	O
we	O
isolated	B-C0205409
two	B-C0205448
novel	B-C0205314
non-toxigenic	B-C0445099
ctxa/b	B-C0017337
-	O
negative	B-C0205160
vibrio	B-C0318248
cholerae	I-C0318248
o1	I-C0318248
.	O
	
these	O
two	B-C0205448
isolates	B-C1764827
underwent	O
whole-genome	B-C3640076
sequencing	I-C3640076
and	O
were	O
investigated	B-C1292732
through	B-C0332273
comparative	B-C1707455
genomics	B-C0887950
and	O
bayesian	B-C0242196
coalescent	I-C0242196
analysis	I-C0242196
.	O
	
these	O
isolates	B-C1764827
cluster	O
in	O
the	O
evolutionary	O
tree	B-C0040811
with	O
strains	B-C1518614
responsible	O
for	O
clinical	B-C0205210
cholera	B-C0008354
,	O
possessing	B-C3154893
genomic	B-C0017428
components	I-C0017428
of	O
6	O
and	O
7	O
pandemic	B-C1615608
lineages	B-C1881379
,	O
and	O
diverge	B-C0443299
from	O
""""	O
modern	B-C0521116
""""	O
cholera	B-C0008354
strains	B-C1518614
around	O
1548	O
c.e	O
.	O
	
95%	O
hpd	O
1532-1555	O
.	O
	
vibrio	B-C0017258
pathogenicity	I-C0017258
island	I-C0017258
vpi	B-C0017258
was	O
present	B-C0150312
however	O
,	O
sxt/r391-family	B-C0017258
ice	I-C0017258
and	O
vpi-2	B-C0017258
were	O
absent	B-C0332197
.	O
	
rugose	B-C0031437
phenotype	I-C0031437
conversion	B-C0439836
and	O
vibriophage	B-C0042776
resistance	B-C4281815
evidenced	B-C0332120
adaption	O
for	O
persistence	B-C0546816
in	O
aquatic	B-C0563034
environments	I-C0563034
.	O
	
the	O
identification	B-C0205396
of	O
v	B-C0318248
.	O
	
cholerae	I-C0318248
o1	I-C0318248
strains	B-C1518614
in	O
the	O
haitian	B-C0018510
environment	B-C0563034
,	O
which	O
predate	O
the	O
first	O
reported	B-C0011000
cholera	B-C0008354
pandemic	B-C1615608
in	O
1817	O
,	O
broadens	O
our	O
understanding	B-C0162340
of	O
the	O
history	B-C0019665
of	O
pandemics	B-C1615608
.	O
	
it	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
and	O
similar	B-C2348205
environmental	B-C0563034
strains	B-C1518614
could	O
acquire	B-C1706701
virulence	B-C0220936
genes	B-C0017337
from	O
the	O
2010	O
haitian	B-C0018510
epidemic	B-C0014499
clone	B-C1522642
,	O
including	O
the	O
cholera	B-C0008356
toxin	I-C0008356
producing	B-C0678227
ctxϕ	B-C0008356
.	O
	
the	O
pre-eclampsia	B-C0032914
ontology	B-C1707788
a	O
disease	B-C1707788
ontology	I-C1707788
representing	O
the	O
domain	O
knowledge	O
specific	O
to	O
pre-eclampsia	B-C0032914
pre-eclampsia	B-C0032914
pe	B-C0032914
is	O
a	O
clinical	B-C0221444
syndrome	I-C0221444
characterized	O
by	O
new-onset	B-C0745129
hypertension	I-C0745129
and	O
proteinuria	B-C0033687
at	O
20	B-C1998040
weeks	I-C1998040
of	I-C1998040
gestation	I-C1998040
,	O
and	O
is	O
a	O
leading	O
cause	B-C0015127
of	O
maternal	B-C3656218
and	O
perinatal	B-C0848215
morbidity	I-C0848215
and	O
mortality	B-C0205848
.	O
	
previous	O
studies	O
have	O
gathered	O
abundant	B-C2346714
data	B-C1511726
about	O
pe	B-C0032914
such	O
as	O
risk	B-C0035648
factors	I-C0035648
and	O
pathological	B-C0205469
findings	I-C0205469
.	O
	
however	O
,	O
most	O
of	O
these	O
data	B-C1511726
are	O
not	O
semantically	O
structured	O
.	O
	
clinical	B-C1516606
data	I-C1516606
on	O
pe	B-C0032914
patients	B-C0030705
are	O
often	O
generated	O
with	O
semantic	B-C0036612
heterogeneity	B-C0019409
such	O
as	O
using	O
disparate	B-C0028275
terminology	I-C0028275
to	O
describe	O
the	O
same	O
phenomena	B-C1882365
.	O
	
in	O
clinical	B-C0008972
studies	I-C0008972
,	O
interoperability	O
of	O
heterogenic	B-C1512426
clinical	B-C1516606
data	I-C1516606
is	O
required	O
in	O
various	O
situations	B-C0868928
.	O
	
in	O
such	O
a	O
situation	B-C0868928
,	O
it	O
is	O
necessary	O
to	O
develop	O
an	O
interoperable	O
and	O
standardized	O
semantic	B-C0036612
framework	B-C1254372
to	O
research	B-C0035168
the	O
pathology	B-C0205469
of	O
pe	B-C0032914
more	O
comprehensively	O
and	O
to	O
achieve	O
interoperability	O
of	O
heterogenic	B-C1512426
clinical	B-C1516606
data	I-C1516606
of	O
pe	B-C0032914
patients	B-C0030705
.	O
	
in	O
this	O
study	O
,	O
we	O
developed	O
an	O
ontology	B-C1707788
representing	O
clinical	B-C0683325
features	I-C0683325
,	O
treatments	B-C0087111
,	O
genetic	B-C0814299
factors	I-C0814299
,	O
environmental	B-C0686732
factors	I-C0686732
,	O
and	O
other	O
aspects	B-C1879746
of	O
the	O
current	O
knowledge	O
in	O
the	O
domain	O
of	O
pe	B-C0032914
.	O
	
we	O
call	O
this	O
pre-eclampsia	B-C0032914
ontology	B-C1707788
""""	O
peo	B-C1707788
""""	O
.	O
	
to	O
achieve	O
interoperability	O
with	O
other	O
ontologies	B-C1707788
,	O
the	O
core	O
structure	O
of	O
peo	B-C1707788
was	O
compliant	O
with	O
the	O
hierarchy	O
of	O
the	O
basic	B-C1518584
formal	I-C1518584
ontology	I-C1518584
bfo	B-C1518584
.	O
	
the	O
peo	B-C1707788
incorporates	O
a	O
wide	O
range	O
of	O
key	O
concepts	B-C0178566
and	O
terms	B-C1515273
of	O
pe	B-C0032914
from	O
clinical	B-C0008972
and	O
biomedical	B-C0005540
research	I-C0005540
in	O
structuring	O
the	O
knowledge	O
base	O
that	O
is	O
specific	O
to	O
pe	B-C0032914
therefore	O
,	O
peo	B-C1707788
is	O
expected	O
to	O
enhance	B-C2349975
pe	B-C0032914
-specific	O
information	B-C0079623
retrieval	I-C0079623
and	O
knowledge	O
discovery	O
in	O
both	O
clinical	B-C0008972
and	O
biomedical	B-C0005540
research	I-C0005540
fields	B-C0683945
.	O
	
predictors	B-C2698872
and	O
moderators	B-C1881878
of	O
spontaneous	B-C0205359
pretend	B-C2371970
play	I-C2371970
in	O
children	B-C0008059
with	O
and	O
without	O
autism	B-C1510586
spectrum	I-C1510586
disorder	I-C1510586
although	O
pretend	B-C2371970
play	I-C2371970
has	O
long	O
been	O
linked	O
to	O
children's	B-C0008059
normative	B-C0205307
cognitive	B-C0679035
development	I-C0679035
,	O
inconsistent	B-C0442809
findings	B-C0243095
call	O
for	O
greater	O
rigor	O
in	O
examining	B-C1292732
this	O
relation	B-C0439849
lillard	O
et	O
al	O
,	O
2013	O
.	O
	
spontaneous	B-C0205359
pretend	B-C2371970
play	I-C2371970
is	O
often	O
impacted	O
in	O
atypical	B-C0205182
development	B-C0243107
,	O
notably	O
in	O
autism	B-C1510586
spectrum	I-C1510586
disorder	I-C1510586
asd	B-C1510586
.	O
	
since	O
asd	B-C1510586
traits	B-C0599883
exist	O
along	O
a	O
continuum	B-C0595960
in	O
the	O
general	B-C0683971
population	I-C0683971
,	O
investigating	B-C1292732
how	O
pretend	B-C2371970
play	I-C2371970
varies	O
across	O
the	O
range	O
of	O
asd	B-C1510586
symptoms	B-C1457887
by	O
indexing	O
variations	B-C0205419
in	O
asd	B-C1510586
traits	B-C0599883
in	O
both	O
typically	O
developing	O
and	O
asd	B-C1510586
populations	B-C1257890
may	O
provide	O
insight	O
into	O
how	O
asd	B-C1510586
symptoms	B-C1457887
may	O
influence	O
the	O
relation	B-C0439849
between	O
pretend	B-C2371970
play	I-C2371970
and	O
associated	O
processes	O
in	O
cognitive	B-C0679035
development	I-C0679035
.	O
	
this	O
study	B-C2603343
used	O
rigorous	B-C0870991
observational	I-C0870991
methods	I-C0870991
to	O
assess	O
spontaneous	B-C0205359
pretend	B-C2371970
play	I-C2371970
.	O
	
specifically	O
,	O
5-	O
min	B-C0439232
free-play	B-C1254363
sessions	I-C1254363
with	O
two	O
discrete	B-C0443299
toy	B-C0040565
sets	O
were	O
double-coded	O
by	O
blinded	B-C1707428
coders	I-C1707428
coder	O
assignment	O
counterbalanced	O
.	O
	
key	O
facets	O
of	O
pretense	B-C0025361
development	I-C0025361
attribution	B-C0871161
of	I-C0871161
pretend	I-C0871161
properties	I-C0871161
app	B-C0871161
,	O
object	B-C1706204
substitution	I-C1706204
os	B-C1706204
,	O
imaginary	B-C0025361
objects	I-C0025361
were	O
examined	B-C1292732
.	O
	
these	O
facets	O
of	O
pretend	B-C2371970
play	I-C2371970
production	B-C0025361
were	O
then	O
analyzed	B-C0936012
in	O
relation	B-C0439849
to	O
asd	B-C1510586
symptoms	B-C1457887
,	O
as	O
well	O
as	O
plausible	O
,	O
long-theorized	O
correlates	O
theory	B-C0935573
of	I-C0935573
mind	I-C0935573
tom	B-C0935573
,	O
verbal	B-C1145677
ability	I-C1145677
,	O
familiarity	B-C0600269
,	O
and	O
interest	B-C0543488
in	O
specific	B-C0205369
toys	B-C0040565
.	O
	
forty	O
children	B-C0008059
mage	O
=	O
6	O
,	O
sdage	O
=	O
1.45	O
29	O
males	B-C0086582
,	O
six	O
of	O
whom	O
met	O
the	O
threshold	B-C0449864
for	O
asd	B-C1510586
diagnosis	B-C0011900
via	O
parent	B-C0030551
-reported	O
asd	B-C1510586
symptoms	B-C1457887
,	O
participated	O
in	O
play	B-C1254363
sessions	I-C1254363
and	O
completed	O
measures	B-C0079809
of	O
verbal	B-C0582577
iq	I-C0582577
and	O
tom	B-C0935573
.	O
	
besides	O
the	O
measure	B-C0079809
of	O
child	B-C0008059
asd	B-C1510586
symptoms	B-C1457887
,	O
parents	B-C0030551
completed	O
a	O
survey	B-C0038951
of	O
their	O
child's	B-C0008059
interest	B-C0543488
in	O
and	O
familiarity	B-C0600269
with	O
the	O
play	B-C1254363
session	I-C1254363
toys	B-C0040565
.	O
	
overall	O
,	O
greater	O
tom	B-C0935573
predicted	B-C0681842
more	O
app	B-C0871161
,	O
and	O
more	O
interest	B-C0543488
in	O
the	O
toys	B-C0040565
presented	O
predicted	B-C0681842
more	O
os	B-C1706204
.	O
	
in	O
terms	O
of	O
overall	O
pretend	B-C2371970
play	I-C2371970
production	B-C0025361
,	O
two	O
results	O
were	O
counterintuitive	O
.	O
	
first	O
,	O
among	O
children	B-C0008059
with	O
more	O
asd	B-C1510586
symptoms	B-C1457887
,	O
verbal	B-C1145677
ability	I-C1145677
marginally	O
negatively	O
predicted	B-C0681842
pretend	B-C2371970
play	I-C2371970
production	B-C0025361
.	O
	
second	O
,	O
among	O
children	B-C0008059
with	O
fewer	O
asd	B-C1510586
symptoms	B-C1457887
,	O
tom	B-C0935573
negatively	O
predicted	B-C0681842
pretend	B-C2371970
play	I-C2371970
production	B-C0025361
.	O
	
further	O
probing	O
revealed	O
that	O
the	O
negative	O
effect	O
of	O
asd	B-C1510586
symptoms	B-C1457887
on	O
pretend	B-C2371970
play	I-C2371970
was	O
simultaneously	O
moderated	O
by	O
both	O
variables	O
low	O
tom	B-C0935573
and	O
high	O
verbal	B-C1145677
ability	I-C1145677
both	O
related	O
to	O
less	O
pretend	B-C2371970
play	I-C2371970
production	O
among	O
children	B-C0008059
with	O
more	O
asd	B-C1510586
symptoms	B-C1457887
.	O
	
implications	O
for	O
assessment	O
and	O
subsequent	O
treatment	B-C0087111
for	O
pretend	B-C0085732
ability	I-C0085732
among	O
children	B-C0008059
with	O
varying	O
degrees	O
of	O
asd	B-C1510586
symptoms	B-C1457887
,	O
allelic	B-C0002085
diversity	B-C1880371
in	O
an	O
nlr	B-C0017337
gene	I-C0017337
bph9	B-C0017337
enables	O
rice	B-C1140671
to	O
combat	O
planthopper	B-C0600234
variation	B-C0042333
brown	B-C0600234
planthopper	I-C0600234
bph	B-C0600234
,	O
nilaparvata	B-C1051066
lugens	I-C1051066
stål	I-C1051066
,	O
is	O
one	O
of	O
the	O
most	O
devastating	O
insect	B-C0021585
pests	B-C0869004
of	O
rice	B-C1140671
oryza	B-C1140671
sativa	I-C1140671
l	I-C1140671
.	O
	
currently	O
,	O
30	O
bph	B-C0600234
-	O
resistance	B-C2945710
genes	I-C2945710
have	O
been	O
genetically	O
defined	O
,	O
most	O
of	O
which	O
are	O
clustered	O
on	O
specific	O
chromosome	B-C1953345
regions	I-C1953345
.	O
	
here	O
,	O
we	O
describe	O
molecular	B-C0009017
cloning	I-C0009017
and	O
characterization	B-C1880022
of	O
a	O
bph	B-C0600234
-	O
resistance	B-C2945710
gene	I-C2945710
,	O
bph9	B-C0017337
,	O
mapped	O
on	O
the	O
long	B-C1276871
arm	I-C1276871
of	I-C1276871
rice	I-C1276871
chromosome	I-C1276871
12	I-C1276871
12l	O
.	O
	
bph9	B-C0017337
encodes	O
a	O
rare	O
type	O
of	O
nucleotide-binding	B-C1148916
and	O
leucine-rich	B-C1517773
repeat	I-C1517773
nlr	B-C1517773
protein	B-C0033684
that	O
localizes	O
to	O
the	O
endomembrane	B-C1167315
system	I-C1167315
and	O
causes	O
a	O
cell	B-C0007587
death	I-C0007587
phenotype	B-C0031437
.	O
	
bph9	B-C0017337
activates	O
salicylic	B-C0036079
acid	I-C0036079
-	O
and	O
jasmonic	B-C0064138
acid	I-C0064138
-	O
signaling	B-C0037080
pathways	I-C0037080
in	O
rice	B-C1140671
plants	B-C0032098
and	O
confers	O
both	O
antixenosis	B-C1254365
and	O
antibiosis	B-C0003219
to	O
bph	B-C0600234
.	O
	
we	O
further	O
demonstrated	O
that	O
the	O
eight	O
bph	B-C0600234
-	O
resistance	B-C2945710
genes	I-C2945710
that	O
are	O
clustered	O
on	O
chromosome	B-C0008633
12l	I-C0008633
,	O
including	O
the	O
widely	O
used	O
bph1	B-C0017337
,	O
are	O
allelic	O
with	O
each	O
other	O
.	O
	
to	O
honor	O
the	O
priority	O
in	O
the	O
literature	B-C0023866
,	O
we	O
thus	O
designated	O
this	O
locus	B-C1708726
as	O
bph1/9	B-C0017337
these	O
eight	O
genes	B-C0017337
can	O
be	O
classified	O
into	O
four	O
allelotypes	B-C0002085
,	O
bph1/9-1	B-C0017337
,	O
-2	B-C0017337
,	O
-7	B-C0017337
,	O
and	O
-9	B-C0017337
these	O
allelotypes	B-C0002085
confer	O
varying	O
levels	B-C0441889
of	O
resistance	B-C1514892
to	O
different	O
biotypes	B-C0449562
of	O
bph	B-C0600234
.	O
	
the	O
coding	B-C0079941
region	I-C0079941
of	O
bph1/9	B-C0017337
shows	O
a	O
high	O
level	O
of	O
diversity	B-C1880371
in	O
rice	B-C1140671
germplasm	I-C1140671
.	O
	
homologous	O
fragments	O
of	O
the	O
nucleotide-binding	B-C1148916
nb	B-C1148916
and	O
leucine-rich	B-C1517773
repeat	I-C1517773
lrr	B-C1517773
domains	B-C1514562
exist	O
,	O
which	O
might	O
have	O
served	O
as	O
a	O
repository	B-C3847505
for	O
generating	O
allele	B-C0002085
diversity	B-C1880371
.	O
	
our	O
findings	O
reveal	O
a	O
rice	B-C1140671
plant	B-C0032098
strategy	O
for	O
modifying	O
the	O
genetic	B-C0017399
information	I-C0017399
to	O
gain	O
the	O
upper	O
hand	O
in	O
the	O
struggle	O
against	O
insect	B-C0021585
herbivores	B-C0562691
.	O
	
further	O
exploration	O
of	O
natural	O
allelic	B-C0042333
variation	I-C0042333
and	O
artificial	B-C0242481
shuffling	I-C0242481
within	O
this	O
gene	B-C0017337
may	O
allow	O
breeding	B-C0006159
to	O
be	O
tailored	O
to	O
control	O
emerging	O
biotypes	B-C0449562
of	O
nontoxic	B-C1518413
formulations	B-C0439962
of	O
scintillation	B-C0678573
nanocrystals	B-C1721058
for	O
use	O
as	O
x-ray	B-C0040405
computed	I-C0040405
tomography	I-C0040405
contrast	B-C0009924
agents	I-C0009924
x-ray	B-C0040405
computed	I-C0040405
tomography	I-C0040405
ct	B-C0040405
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	B-C2986496
,	O
clinical	B-C0205210
in	B-C1515655
vivo	I-C1515655
imaging	B-C0079595
techniques	I-C0079595
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
x-ray	B-C0183263
device	I-C0183263
and	O
contrast	B-C1979874
enhancement	B-C0969683
technologies	I-C0969683
.	O
	
the	O
present	O
study	B-C2603343
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	B-C0077513
tungstates	I-C0077513
such	O
as	O
cawo4	B-C0054486
are	O
promising	O
contrast	B-C0009924
agents	I-C0009924
for	O
x-ray	B-C0043299
,	O
radiation	B-C0851346
,	O
and	O
ct	B-C0040405
imaging	I-C0040405
,	O
because	O
of	O
the	O
high	O
x-ray	B-C0043299
mass	B-C0599946
attenuation	I-C0599946
of	O
tungsten	B-C0041383
w	B-C0041383
.	O
	
we	O
have	O
developed	O
a	O
method	O
of	O
formulation	B-C0439962
,	O
in	O
which	O
cawo4	B-C0054486
cwo	B-C0054486
nanoparticles	B-C1450054
nps	B-C1450054
are	O
encapsulated	B-C0205223
within	O
a	O
biocompatible	O
poly	B-C0257395
glycol-b-d	I-C0257395
acid	I-C0257395
peg-pla	I-C0257395
block	I-C0257395
copolymer	I-C0257395
bcp	I-C0257395
capsule	I-C0257395
.	O
	
we	O
show	O
that	O
these	O
peg-pla	B-C0257395
-	O
encapsulated	B-C0205223
cwo	B-C1450054
nps	I-C1450054
170	O
10	O
nm	O
hydrodynamic	O
diameter	O
produce	O
a	O
higher	O
ct	B-C0040405
contrast	B-C1979874
by	O
a	O
factor	O
of	O
about	O
2	O
than	O
commercial	O
iodine	B-C0021968
-based	O
radiocontrast	B-C0009924
agents	I-C0009924
e.g	O
,	O
iohexol	B-C0022005
at	O
identical	O
molar	O
concentrations	O
of	O
w	B-C0041383
or	O
i	B-C0021968
atoms	B-C0567415
.	O
	
peg-pla	B-C0257395
-	O
coated	B-C1522408
cwo	B-C1450054
nps	I-C1450054
are	O
chemically	O
stable	O
and	O
completely	O
nontoxic	B-C1518413
.	O
	
it	O
was	O
confirmed	O
that	O
the	O
maximum	B-C0752079
tolerated	I-C0752079
dose	I-C0752079
mtd	B-C0752079
of	O
this	O
material	B-C0520510
in	O
mice	B-C0026809
is	O
significantly	O
higher	O
250	O
50	O
mg	O
per	O
kg	O
body	B-C0005910
weight	I-C0005910
following	O
a	O
single	O
intravenous	B-C0013125
iv	I-C0013125
administration	I-C0013125
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	B-C0086140
-	O
coated	B-C1522408
iron	B-C0060240
oxide	I-C0060240
nanoparticles	B-C1450054
that	O
are	O
currently	O
used	O
clinically	B-C0205210
as	O
mri	B-C0024485
contrast	B-C0009924
agents	I-C0009924
mtd	B-C0752079
in	O
mice	B-C0026809
168	O
mg/kg	O
per	O
dose	B-C0178602
iv	O
.	O
	
iv-	O
injected	B-C0449894
peg-pla	B-C0257395
/	O
cwo	B-C1450054
nps	I-C1450054
caused	O
no	B-C1513916
histopathologic	B-C0677043
damage	B-C1883709
in	O
major	O
excretory	B-C0178784
organs	I-C0178784
heart	B-C0018787
,	O
liver	B-C0023884
,	O
lungs	B-C0024109
,	O
spleen	B-C0037993
,	O
and	O
kidney	B-C0022646
.	O
	
when	O
an	O
iv	O
dose	B-C0178602
of	O
100	O
mg/kg	O
was	O
given	O
to	O
mice	B-C0026809
,	O
the	O
blood	B-C0005775
circulation	I-C0005775
half-life	B-C0018517
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90%	O
of	O
the	O
nps	B-C1450054
were	O
cleared	O
from	O
the	O
mice	B-C0026809
within	O
24	O
h	O
via	O
the	O
renal	B-C0022646
and	O
hepatobiliary	B-C1711359
systems	I-C1711359
.	O
	
when	O
intratumorally	B-C1517565
administered	I-C1517565
,	O
peg-pla	B-C0257395
-	O
coated	B-C1522408
cwo	B-C1450054
nps	I-C1450054
showed	O
complete	O
retention	O
in	O
a	O
tumor-bearing	B-C2986594
mouse	I-C2986594
model	I-C2986594
measurements	O
were	O
made	O
up	O
to	O
1	O
week	B-C0439230
.	O
	
these	O
results	O
suggest	O
that	O
peg-pla	B-C0257395
-	O
coated	B-C1522408
cwo	B-C1450054
nps	I-C1450054
are	O
promising	O
materials	B-C0520510
for	O
use	O
in	O
ct	B-C0040405
contrast	B-C1979874
.	O
	
albumin	B-C0001924
-bioinspired	O
gd	B-C0016911
cus	B-C0056599
nanotheranostic	B-C0304231
agent	I-C0304231
for	O
in	B-C1515655
vivo	I-C1515655
photoacoustic	B-C3897929
/	O
magnetic	O
resonance	O
imaging	O
-guided	O
tumor	O
-targeted	O
photothermal	O
therapy	O
photothermal	O
therapy	O
ptt	O
is	O
attracting	O
increasing	O
interest	O
and	O
becoming	O
more	O
widely	O
used	O
for	O
skin	O
cancer	O
therapy	O
in	O
the	O
clinic	O
,	O
as	O
a	O
result	O
of	O
its	O
noninvasiveness	O
and	O
low	O
systemic	O
adverse	O
effects	O
.	O
	
however	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
biocompatible	O
ptt	O
agents	O
,	O
which	O
enable	O
accurate	O
imaging	O
,	O
monitoring	O
,	O
and	O
diagnosis	O
.	O
	
herein	O
,	O
a	O
biocompatible	O
gd	O
-integrated	O
cus	O
nanotheranostic	O
agent	O
gd	O
cus	O
bsa	O
was	O
synthesized	O
via	O
a	O
facile	O
and	O
environmentally	O
friendly	O
biomimetic	O
strategy	O
,	O
using	O
bovine	O
serum	O
albumin	O
bsa	O
as	O
a	O
biotemplate	O
at	O
physiological	O
temperature	O
.	O
	
the	O
as-prepared	O
gd	O
cus	O
bsa	O
nanoparticles	O
nps	O
with	O
ultrasmall	O
sizes	O
ca	O
.	O
	
9	O
nm	O
exhibited	O
high	O
photothermal	O
conversion	O
efficiency	O
and	O
good	O
photostability	O
under	O
near-infrared	O
nir	O
laser	O
irradiation	O
.	O
	
with	O
doped	O
gd	O
species	O
and	O
strong	O
tunable	O
nir	O
absorbance	O
,	O
gd	O
cus	O
bsa	O
nps	O
demonstrate	O
prominent	O
tumor-contrasted	O
imaging	O
performance	O
both	O
on	O
the	O
photoacoustic	O
and	O
magnetic	O
resonance	O
imaging	O
modalities	O
.	O
	
the	O
subsequent	O
gd	O
cus	O
bsa	O
-mediated	O
ptt	O
result	O
shows	O
high	O
therapy	O
efficacy	O
as	O
a	O
result	O
of	O
their	O
potent	O
nir	O
absorption	O
and	O
high	O
photothermal	O
conversion	O
efficiency	O
.	O
	
the	O
immune	O
response	O
triggered	O
by	O
gd	O
cus	O
bsa	O
-mediated	O
ptt	O
is	O
preliminarily	O
explored	O
.	O
	
in	O
addition	O
,	O
toxicity	O
studies	O
in	O
vitro	O
and	O
in	O
vivo	O
verify	O
that	O
gd	O
cus	O
bsa	O
nps	O
qualify	O
as	O
biocompatible	O
agents	O
.	O
	
a	O
biodistribution	O
study	O
demonstrated	O
that	O
the	O
nps	O
can	O
undergo	O
hepatic	O
clearance	O
from	O
the	O
body	O
.	O
	
this	O
study	O
highlights	O
the	O
practicality	O
and	O
versatility	O
of	O
albumin	O
-mediated	O
biomimetic	O
mineralization	O
of	O
a	O
nanotheranostic	O
agent	O
and	O
also	O
suggests	O
that	O
bioinspired	O
gd	O
cus	O
bsa	O
nps	O
possess	O
promising	O
imaging	O
guidance	O
and	O
effective	O
tumor	O
ablation	O
properties	O
,	O
with	O
high	O
spatial	O
resolution	O
and	O
deep	O
tissue	O
penetration	I-C0205556
family	B-C0015576
and	O
healthcare	B-C1704312
professionals	I-C1704312
'	O
perceptions	B-C0030971
of	O
a	O
pilot	O
hospice	B-C0085555
at	O
home	B-C0442519
programme	B-C0679897
for	O
children	B-C0008059
a	O
qualitative	O
study	B-C2603343
parents	B-C0030551
commonly	O
report	O
a	O
significant	O
improvement	B-C2986411
in	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
following	O
the	O
provision	B-C1283218
of	O
hospice	B-C0085555
and	O
supportive	B-C0344211
care	I-C0344211
and	O
have	O
identified	O
a	O
need	O
for	O
such	O
a	O
service	B-C0018747
in	O
the	O
home	B-C0442519
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
understand	O
the	O
experiences	O
of	O
families	B-C0015576
receiving	O
a	O
nurse	B-C0028661
led	O
pilot	O
hospice	B-C0085555
at	O
home	B-C0442519
programme	B-C0679897
and	O
the	O
experiences	B-C0596545
of	O
healthcare	B-C1704312
professionals	I-C1704312
delivering	O
and	O
engaging	O
with	O
the	O
programme	B-C0679897
.	O
	
an	O
exploratory	O
,	O
qualitative	O
study	B-C2603343
was	O
conducted	O
,	O
including	O
telephone	B-C0021823
interviews	I-C0021823
with	O
parents	B-C0030551
and	O
focus	B-C0016400
groups	I-C0016400
and	O
individual	B-C0237401
interviews	B-C0021822
with	O
healthcare	B-C1704312
professionals	I-C1704312
.	O
	
all	O
parents	B-C0030551
of	O
families	B-C0015576
who	O
received	O
the	O
programme	B-C0679897
of	O
care	B-C0086388
between	O
june	O
2014	O
and	O
september	O
2015	O
and	O
healthcare	B-C1704312
professionals	I-C1704312
delivering	O
and	O
engaging	O
with	O
the	O
programme	B-C0679897
were	O
invited	O
to	O
participate	O
.	O
	
seven	O
parents	B-C0030551
participated	O
in	O
telephone	B-C0021823
interviews	I-C0021823
.	O
	
four	O
focus	B-C0016400
groups	I-C0016400
took	O
place	O
,	O
two	O
with	O
external	B-C1257890
stakeholders	I-C1257890
18	O
participants	B-C0679646
in	O
total	O
,	O
one	O
with	O
in-patient	B-C0030705
hospice	B-C0025106
staff	I-C0025106
13	O
participants	B-C0679646
and	O
one	O
with	O
the	O
hospice	B-C0085555
at	O
home	O
team	O
8	O
participants	B-C0679646
.	O
	
two	O
additional	O
interviews	B-C0021822
took	O
place	O
with	O
individual	B-C0237401
stakeholders	B-C1257890
who	O
were	O
unable	O
to	O
attend	O
a	O
scheduled	O
focus	B-C0016400
group	I-C0016400
.	O
	
themes	O
from	O
interviews	B-C0021822
with	O
parents	B-C0030551
focused	O
on	O
the	O
value	O
of	O
having	O
consistent	O
and	O
expert	O
care	B-C0086388
.	O
	
the	O
findings	O
from	O
healthcare	B-C1704312
professionals	I-C1704312
centred	O
on	O
communication	B-C0009452
within	O
and	O
across	O
services	B-C0018747
,	O
education	B-C0582584
and	I-C0582584
training	I-C0582584
and	O
lone	B-C0043227
working	I-C0043227
.	O
	
the	O
pilot	O
hospice	B-C0085555
at	O
home	B-C0442519
programme	B-C0679897
was	O
welcomed	O
by	O
all	O
those	O
who	O
took	O
part	O
in	O
the	O
study	B-C2603343
.	O
	
the	O
programme	B-C0679897
may	O
be	O
improved	O
by	O
enhanced	O
clarification	B-C2986669
of	O
roles	O
,	O
enhanced	O
access	O
to	O
multi-disciplinary	O
services	B-C0018747
,	O
greater	O
communication	B-C0009452
across	O
services	B-C0018747
and	O
improved	O
information	O
provision	O
to	O
functional	B-C0205245
1	B-C3253155
scaffold	B-C1254350
design	B-C1707689
of	O
fluorescent	B-C0016321
probes	I-C0016321
for	O
kinesin	B-C1173400
spindle	I-C1173400
protein	I-C1173400
ksp	B-C1173400
1	B-C3253155
is	O
a	O
compact	O
fluorescent	B-C0016321
chromophore	B-C0596335
.	O
	
in	O
this	O
study	B-C2603343
,	O
triazapentalene	B-C3253155
was	O
used	O
to	O
modify	O
a	O
series	O
of	O
biphenyl-type	B-C0005580
inhibitors	B-C0033671
of	O
kinesin	B-C1173400
spindle	I-C1173400
protein	I-C1173400
ksp	B-C1173400
to	O
develop	O
fluorescent	B-C0016321
probes	I-C0016321
for	O
the	O
intracellular	B-C0178719
visualization	B-C0234621
of	O
this	O
protein	B-C0033684
.	O
	
microscopic	B-C0205288
studies	B-C2603343
demonstrated	O
that	O
these	O
novel	B-C0205314
triazapentalene	B-C3253155
-	O
labeled	B-C1708632
compounds	B-C1706082
exhibited	O
inhibitory	B-C3463820
activity	B-C0205177
towards	O
ksp	B-C1173400
in	O
cultured	B-C0007635
cells	I-C0007635
and	O
provided	O
important	O
information	B-C1533716
concerning	O
the	O
intracellular	B-C0178719
distribution	B-C1704711
.	O
	
c4b	B-C0056193
binding	I-C0056193
protein	I-C0056193
negatively	B-C0013081
regulates	I-C0013081
tlr1	B-C0971363
/	O
2	B-C0754728
response	B-C0871261
tlr2	B-C0754728
associates	B-C0332281
with	I-C0332281
tlr1	B-C0971363
and	O
recognizes	O
microbial	B-C0599840
lipoproteins	B-C0023820
.	O
	
pam3csk4	B-C1698795
,	O
a	O
triacylated	B-C0023820
lipoprotein	I-C0023820
,	O
is	O
anchored	B-C1624581
to	O
the	O
extracellular	B-C1517050
domain	I-C1517050
of	O
tlr1	B-C0971363
and	O
tlr2	B-C0754728
and	O
induces	B-C0205263
pro-inflammatory	B-C0021368
signals	B-C3537152
.	O
	
here	O
we	O
show	O
that	O
c4b	B-C0056193
binding	I-C0056193
protein	I-C0056193
c4bp	B-C0056193
,	O
which	O
is	O
a	O
complement	B-C1305430
pathway	I-C1305430
inhibitor	B-C1999216
,	O
is	O
a	O
tlr2	B-C0754728
-associated	O
molecule	O
.	O
	
immunoprecipitation	B-C0021069
assay	I-C0021069
using	O
anti-tlr2	B-C0021054
mab	I-C0021054
shows	O
that	O
c4bp	B-C0056193
binds	B-C1167622
to	I-C1167622
tlr2	B-C0754728
.	O
	
in	O
c4bp-deficient	B-C1413001
mice	B-C0206745
,	O
pam3csk4	B-C1698795
-	O
induced	B-C0205263
il-6	B-C0021760
levels	B-C0441889
were	O
increased	B-C0205217
compared	B-C1707455
with	O
wild	B-C0025929
type	I-C0025929
mice	I-C0025929
.	O
	
in	O
c4bp	B-C0056193
-	O
expressing	B-C1171362
cells	B-C0007634
,	O
pam3csk4	B-C1698795
-	O
induced	B-C0205263
il-8	B-C1819461
production	I-C1819461
was	O
reduced	B-C0392756
depending	O
on	O
the	O
c4bp	B-C0056193
expression	B-C3244092
levels	I-C3244092
.	O
	
these	O
results	O
reveal	B-C0443289
the	O
important	O
role	O
of	O
c4bp	B-C0056193
in	O
negative	B-C0013081
regulation	I-C0013081
of	O
tlr1	B-C0971363
/	O
2	B-C0754728
-	O
dependent	B-C0079189
pro-inflammatory	B-C0021368
cytokine	B-C1327413
production	I-C1327413
.	O
	
furthermore	O
,	O
using	O
a	O
fluorescent	B-C0016321
conjugated	I-C0016321
pam3csk4	B-C1698795
,	O
we	O
show	O
that	O
c4bp	B-C0056193
blocks	B-C0332206
the	O
binding	B-C1167622
of	I-C1167622
pam3csk4	B-C1698795
to	O
tlr1	B-C0971363
/	O
2	B-C0754728
.	O
	
finally	O
,	O
we	O
show	O
that	O
exogenous	B-C0205228
c4bp	B-C0056193
also	O
inhibits	B-C3463820
pam3csk4	B-C1698795
-	O
induced	B-C1511122
signaling	I-C1511122
leading	O
to	O
il-8	B-C1819461
production	I-C1819461
.	O
	
our	O
results	O
indicate	O
c4bp	B-C0056193
binding	B-C1167622
to	I-C1167622
tlr2	B-C0754728
and	O
consequent	B-C3845876
neutralization	B-C2987668
of	O
its	O
activity	B-C1152633
otherwise	O
inducing	O
pro-inflammatory	B-C0021368
cytokine	B-C1327413
production	I-C1327413
.	O
	
c4bp	B-C0056193
is	O
a	O
negative	B-C0013081
regulator	I-C0013081
of	O
tlr1	B-C0971363
/	O
2	B-C0754728
activity	B-C1152633
.	O
	
effect	B-C1280500
of	O
emodin	B-C0013982
on	O
mobility	B-C0037083
signal	I-C0037083
transduction	I-C0037083
system	I-C0037083
of	O
gallbladder	B-C0016976
smooth	B-C1267092
muscle	I-C1267092
in	O
guinea	B-C0085979
pig	I-C0085979
with	O
cholelithiasis	B-C0008350
to	O
study	B-C2603343
the	O
effect	B-C1280500
of	O
emodin	B-C0013982
on	O
protein	B-C1171362
and	O
gene	B-C0017262
expressions	I-C0017262
of	O
the	O
massagers	B-C0815029
in	O
mobility	B-C0037083
signal	I-C0037083
transduction	I-C0037083
system	I-C0037083
of	O
cholecyst	B-C0016976
smooth	B-C0596981
muscle	I-C0596981
cells	I-C0596981
in	O
guinea	B-C0085979
pig	I-C0085979
with	O
cholesterol	B-C0333018
calculus	I-C0333018
.	O
	
the	O
guinea	B-C0085979
pigs	I-C0085979
were	O
randomly	O
divided	O
into	O
4	O
groups	B-C0441833
,	O
such	O
as	O
control	B-C0009932
group	I-C0009932
,	O
gall-stone	B-C1392480
gs	B-C1392480
group	B-C0441833
,	O
emodin	B-C0013982
group	B-C0441833
and	O
ursodeoxycholic	B-C0042105
acid	I-C0042105
ua	B-C0042105
group	B-C0441833
.	O
	
cholesterol	B-C0333018
calculus	I-C0333018
models	B-C0026336
were	O
induced	O
in	O
guinea	B-C0085979
pigs	I-C0085979
of	O
gs	B-C1392480
,	O
emodin	B-C0013982
and	O
ua	B-C0042105
groups	B-C0441833
by	O
lithogenic	B-C0012155
diet	I-C0012155
,	O
while	O
emodin	B-C0013982
or	O
ua	B-C0042105
were	O
given	O
to	O
the	O
corresponding	O
group	B-C0441833
for	O
7	O
weeks	B-C0439230
.	O
	
the	O
histomorphological	B-C0332437
and	O
ultrastructure	B-C0041623
change	B-C0392747
of	O
gallbladder	B-C0016976
were	O
detected	B-C0442726
by	O
microscope	B-C0181839
and	O
electron	B-C0181845
microscope	I-C0181845
,	O
the	O
content	O
of	O
plasma	B-C0032105
cholecystokinin	B-C0008328
cck	B-C0008328
and	O
ca	B-C0596235
were	O
analyzed	B-C0936012
successively	O
by	O
radioimmunoassay	B-C0034580
and	O
flow	B-C0016263
cytometry	I-C0016263
.	O
	
the	O
protein	B-C0033684
and	O
mrna	B-C0035696
of	O
gsα	B-C0086903
,	O
giα	B-C0086706
and	O
cap	B-C0073423
in	O
cholecyst	B-C0016976
cells	B-C0596981
were	O
determined	B-C0521095
by	I-C0521095
western	B-C0005863
blotting	I-C0005863
and	O
real	B-C1709846
time	I-C1709846
polymerase	I-C1709846
chain	I-C1709846
reaction	I-C1709846
rt-pcr	B-C1709846
.	O
	
emodin	B-C0013982
or	O
ua	B-C0042105
can	O
relieve	O
pathogenic	B-C3816499
changes	B-C0392747
in	O
epithelial	B-C0014597
cells	I-C0014597
and	O
muscle	B-C0596981
cells	I-C0596981
in	O
gallbladder	B-C0016976
of	O
guinea	B-C0085979
pig	I-C0085979
with	O
cholesterol	B-C0333018
calculus	I-C0333018
by	O
microscope	B-C0181839
and	O
transmission	B-C0262880
electron	I-C0262880
microscope	I-C0262880
.	O
	
in	O
the	O
cholecyst	B-C0016976
cells	B-C0596981
of	O
gs	B-C1392480
group	B-C0441833
,	O
cck	B-C0008328
levels	B-C0441889
in	O
plasma	B-C0032105
and	O
ca	B-C0596235
decreased	B-C0205216
,	O
the	O
protein	B-C0033684
and	O
mrna	B-C0035696
of	O
gs	B-C1392480
were	O
down-regulated	B-C0013081
,	O
the	O
protein	B-C0033684
and	O
mrna	B-C0035696
of	O
gi	B-C0086706
and	O
cap	B-C0073423
were	O
up-regulated	B-C0041904
.	O
	
emodin	B-C0013982
significantly	B-C0750502
decreased	B-C0205216
the	O
formative	B-C1522492
rate	B-C1521828
of	O
gallstone	B-C1392480
,	O
improved	O
the	O
pathogenic	B-C3816499
change	B-C0392747
in	O
epithelial	B-C0014597
cells	I-C0014597
and	O
muscle	B-C0596981
cells	I-C0596981
,	O
increased	O
cck	B-C0008328
levels	B-C0441889
in	O
plasma	B-C0032105
and	O
ca	B-C0596235
in	O
cholecyst	B-C0016976
cells	B-C0596981
,	O
enhanced	O
the	O
protein	B-C0033684
and	O
mrna	B-C0035696
of	O
gs	B-C0086903
in	O
cholecyst	B-C0016976
cells	B-C0596981
,	O
reduced	B-C0392756
the	O
protein	B-C0033684
and	O
mrna	B-C0035696
of	O
gi	B-C0086706
and	O
cap	B-C0073423
in	O
cholecyst	B-C0016976
cells	B-C0596981
in	O
guinea	B-C0085979
pig	I-C0085979
with	O
cholesterol	B-C0333018
calculus	I-C0333018
.	O
	
the	O
dysfunction	B-C3887504
of	O
gallbladder	B-C0232772
contraction	I-C0232772
gives	O
rise	O
to	O
the	O
disorders	B-C0012634
of	O
mobility	B-C0037083
signal	I-C0037083
transduction	I-C0037083
system	I-C0037083
in	O
cholecyst	B-C0016976
smooth	B-C0596981
muscle	I-C0596981
cells	I-C0596981
,	O
including	B-C0332257
low	O
content	O
of	O
plasma	B-C0032105
cck	B-C0008328
and	O
ca	B-C0596235
in	O
cholecyst	B-C0016976
cells	B-C0596981
,	O
abnormal	B-C0311448
protein	I-C0311448
and	O
mrna	B-C0035696
of	O
gs	B-C0086903
,	O
gi	B-C0086706
and	O
cap	B-C0073423
.	O
	
emodin	B-C0013982
can	O
enhance	B-C2349975
the	O
contractibility	B-C0232772
of	I-C0232772
gallbladder	I-C0232772
and	O
alleviate	B-C0547047
cholestasis	B-C0008370
by	O
regulating	B-C1327622
plasma	B-C0032105
cck	B-C0008328
levels	B-C0441889
,	O
ca	B-C0596235
in	O
cholecyst	B-C0016976
cells	B-C0596981
and	O
the	O
protein	B-C0033684
and	O
mrna	B-C0035696
of	O
gs	B-C0086903
,	O
gi	B-C0086706
and	O
quantification	B-C1709793
of	O
urinary	B-C1524119
mono-hydroxylated	B-C0870883
metabolites	I-C0870883
of	O
polycyclic	B-C0032458
aromatic	I-C0032458
hydrocarbons	I-C0032458
by	O
on-line	B-C1720880
solid	I-C1720880
phase	I-C1720880
extraction	I-C1720880
-	O
high	B-C4054772
performance	I-C4054772
liquid	I-C4054772
chromatography-tandem	I-C4054772
mass	I-C4054772
spectrometry	I-C4054772
human	B-C0086418
exposure	B-C0332157
to	I-C0332157
polycyclic	B-C0032458
aromatic	I-C0032458
hydrocarbons	I-C0032458
pahs	B-C0032458
can	O
be	O
assessed	B-C1516048
through	O
monitoring	B-C1283169
of	O
urinary	B-C1524119
mono-hydroxylated	B-C0032458
pahs	I-C0032458
oh-pahs	B-C0032458
.	O
	
gas	B-C0008555
chromatography	I-C0008555
gc	B-C0008555
has	O
been	O
widely	O
used	O
to	O
separate	B-C0443299
oh-pahs	B-C0032458
before	O
quantification	B-C1709793
by	O
mass	B-C0037813
spectrometry	I-C0037813
in	O
biomonitoring	B-C0005517
studies	B-C2603343
.	O
	
however	O
,	O
because	O
gc	B-C0008555
requires	O
derivatization	B-C0449851
,	O
it	O
can	O
be	O
time	B-C3827829
consuming	I-C3827829
.	O
	
we	O
developed	B-C1527148
an	O
on-line	B-C1720880
solid	I-C1720880
phase	I-C1720880
extraction	I-C1720880
coupled	B-C1948027
to	O
isotope	B-C0022262
dilution	B-C1948037
-	O
high	B-C4054772
performance	I-C4054772
liquid	I-C4054772
chromatography-tandem	I-C4054772
mass	I-C4054772
spectrometry	I-C4054772
on-line-spe	B-C1720880
-	O
hplc-ms	B-C4054772
/	O
ms	B-C0037813
method	B-C0025663
for	O
the	O
quantification	B-C1709793
in	O
urine	B-C0042036
of	O
1-oh-naphthalene	B-C0027375
,	O
2-oh-naphthalene	B-C0027375
,	O
2-oh-fluorene	B-C0060517
,	O
3-oh-fluorene	B-C0060517
,	O
1-oh-phenanthrene	B-C0031367
,	O
the	O
sum	O
of	O
2-oh	B-C0031367
and	O
3-oh-phenanthrene	B-C0031367
,	O
4-oh-phenanthrene	B-C0031367
,	O
and	O
1-oh-pyrene	B-C0072667
.	O
	
the	O
method	B-C0025663
,	O
which	O
employed	B-C0557351
a	O
96-	O
well	B-C4283957
plate	I-C4283957
platform	I-C4283957
and	O
on-line	B-C1720880
spe	I-C1720880
,	O
showed	O
good	B-C2346484
sensitivity	I-C2346484
i.e	O
,	O
limits	B-C0439801
of	O
detection	B-C1511790
ranged	B-C1514721
from	O
0.007	O
to	O
0.09	O
ng/ml	O
and	O
used	O
only	O
100	O
μl	O
of	O
urine	B-C0042036
.	O
	
accuracy	B-C0443131
,	O
calculated	B-C1443182
from	O
the	O
recovery	B-C0237820
percentage	B-C0439165
at	O
three	O
spiking	B-C0348018
levels	B-C0441889
,	O
varied	B-C0205419
from	O
94	O
to	O
113	O
%	O
,	O
depending	B-C1701901
on	O
the	O
analyte	B-C0443354
.	O
	
the	O
inter	B-C1548610
-	O
and	O
intra	B-C0347985
-	O
day	B-C1561539
precision	I-C1561539
,	O
calculated	B-C1443182
from	O
20	O
repeated	B-C0205341
measurements	B-C0242485
of	O
two	O
quality	B-C0034378
control	I-C0034378
materials	B-C0520510
,	O
varied	B-C0205419
from	O
5.2	O
to	O
16.7	O
%	O
.	O
	
adequate	B-C0205411
method	B-C0025663
performance	B-C1882330
was	O
also	O
confirmed	B-C0521093
by	I-C0521093
acceptable	B-C1879533
recovery	B-C0237820
83-102	O
%	O
of	O
two	O
nist	B-C0021622
standard	B-C0034925
reference	I-C0034925
materials	B-C0520510
3672	O
and	O
3673	O
.	O
	
this	O
high-throughput	B-C0872047
on-line-spe	B-C1720880
-	O
hplc-ms	B-C4054772
/	O
ms	B-C0037813
method	B-C0025663
can	O
be	O
applied	O
in	O
large	B-C0549177
-	O
scale	B-C1522412
epidemiological	B-C0002783
studies	I-C0002783
.	O
	
graphical	B-C0870616
abstract	I-C0870616
example	O
lc-ms	B-C1883002
chromatogram	I-C1883002
of	O
urinary	B-C1524119
mono-hydroxylated	B-C0032458
pah	I-C0032458
metabolites	B-C0870883
.	O
	
utility	B-C0205245
and	O
applicability	B-C0205245
of	O
the	O
"""childhood"	B-C0282574
obesity	I-C0282574
risk	I-C0282574
"evaluation"""	I-C0282574
core	I-C0282574
in	O
predicting	O
obesity	B-C0028754
in	O
childhood	B-C0231335
and	O
adolescence	B-C0001578
in	O
greece	B-C0018226
from	O
early	B-C1279919
life	B-C0376558
the	O
""""	O
national	O
action	O
plan	O
for	O
public	O
health	O
""""	O
early	B-C1279919
identification	B-C0150323
of	O
infants	B-C0021270
being	O
at	O
high	B-C0332167
risk	I-C0332167
to	O
become	O
obese	B-C0028754
at	O
their	O
later	B-C0205087
childhood	B-C0231335
or	O
adolescence	B-C0001578
can	O
be	O
of	O
vital	O
importance	O
in	O
any	O
obesity	B-C0028754
prevention	B-C2700409
initiative	B-C1287154
.	O
	
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
utility	B-C0205245
and	O
applicability	B-C0205245
of	O
the	O
"""childhood"	B-C0282574
obesity	I-C0282574
risk	I-C0282574
evaluation	I-C0282574
core	I-C0282574
index	I-C0282574
as	O
a	O
screening	B-C1710032
tool	B-C0336791
for	O
the	O
early	B-C1279919
prediction	B-C0681842
of	O
obesity	B-C0028754
in	O
childhood	B-C0231335
and	O
adolescence	B-C0001578
.	O
	
anthropometric	B-C1511726
,	O
socio-demographic	B-C1511726
data	I-C1511726
were	O
collected	B-C1516695
cross-sectionally	B-C0205556
and	O
retrospectively	B-C1514923
from	O
a	O
representative	O
sample	B-C0370003
of	O
5946	O
children	B-C0008059
,	O
and	O
adolescents	B-C0205653
and	O
were	O
combined	O
for	O
calculating	B-C1441506
the	O
core-index	B-C0282574
score	I-C0282574
.	O
	
logistic	B-C0681925
regression	I-C0681925
analyses	I-C0681925
were	O
performed	O
to	O
examine	O
the	O
associations	B-C0439849
of	O
the	O
core-index	B-C0282574
score	I-C0282574
with	O
obesity	B-C0028754
by	O
gender	B-C0079399
and	O
age	B-C0027362
group	I-C0027362
,	O
and	O
cut-off	B-C0242481
point	I-C0242481
analysis	I-C0242481
was	O
also	O
applied	O
to	O
identify	O
the	O
optimal	B-C2698651
value	B-C1522609
of	O
the	O
core-index	B-C0282574
score	I-C0282574
that	O
differentiates	B-C0205615
obese	B-C0028754
from	O
non-obese	B-C0008059
children	I-C0008059
.	O
	
mean	B-C0282574
core-index	I-C0282574
score	I-C0282574
in	O
the	O
total	B-C0439810
sample	B-C0370003
was	O
3.06	O
sd	B-C0871420
1.92	O
units	O
range	O
0-11	O
units	O
.	O
	
each	O
unit	O
increase	B-C0442805
in	O
the	O
core-index	B-C0282574
score	I-C0282574
was	O
found	O
to	O
be	O
associated	B-C0332281
with	I-C0332281
a	O
30	O
%	O
95	O
%	O
c.i	B-C0009667
.	O
	
1.24	O
increased	B-C0205217
likelihood	B-C0033204
for	O
obesity	B-C0028754
in	O
childhood	B-C0231335
or	O
adolescence	B-C0001578
,	O
while	O
the	O
optimal	B-C2698651
cut-off	B-C0392762
value	I-C0392762
of	O
the	O
core-index	B-C0282574
score	I-C0282574
that	O
predicted	B-C0681842
obesity	B-C0028754
with	O
the	O
highest	B-C1522410
possible	O
sensitivity	B-C0036668
and	I-C0036668
specificity	I-C0036668
was	O
found	O
to	O
be	O
3.5	O
.	O
	
the	O
present	O
study	O
supports	O
the	O
utility	B-C0205245
and	O
applicability	B-C0205245
of	O
the	O
core-index	B-C0282574
as	O
a	O
screening	B-C1710032
tool	B-C0336791
for	O
the	O
early	B-C1279919
identification	B-C0150323
of	O
infants	B-C0021270
that	O
are	O
potentially	O
at	O
a	O
higher	B-C0332167
risk	I-C0332167
for	O
becoming	O
obese	B-C0028754
at	O
their	O
childhood	B-C0231335
and	O
adolescence	B-C0001578
.	O
	
this	O
tool	B-C0336791
could	O
be	O
routinely	O
used	O
by	O
health	B-C1704312
professionals	I-C1704312
to	O
identify	O
infants	B-C0021270
at	O
high	B-C0332167
risk	I-C0332167
and	O
provide	O
appropriate	O
counselling	B-C0010210
to	O
their	O
parents	B-C0030551
and	O
caregivers	B-C0085537
so	O
as	O
to	O
maximize	O
the	O
effectiveness	B-C1280519
of	O
early	B-C1279919
obesity	B-C0028754
prevention	B-C2700409
initiatives	B-C1287154
.	O
	
what	O
is	O
known	O
childhood	B-C0231335
obesity	B-C0028754
has	O
reached	O
epidemic	B-C1709707
proportions	I-C1709707
worldwide	O
.	O
	
certain	O
perinatal	B-C0243095
and	O
socio-demographic	B-C0243095
indices	I-C0243095
that	O
were	O
previously	O
identified	B-C0205396
as	O
correlates	O
of	O
childhood	B-C0231335
obesity	B-C0028754
in	O
children	B-C0008059
were	O
combined	O
to	O
develop	O
the	O
core-index	B-C0282574
,	O
a	O
screening	B-C1710032
tool	B-C0336791
that	O
estimates	O
obesity	B-C0028754
risk	B-C0035647
in	O
9-13	O
year-old	B-C1510829
children	B-C0008059
.	O
	
what	O
is	O
new	O
the	O
utility	B-C0205245
and	O
applicability	B-C0205245
of	O
the	O
core-index	B-C0282574
as	O
screening	B-C1710032
tool	B-C0336791
can	O
be	O
extended	O
to	O
the	O
age	B-C0001779
range	O
of	O
6-15	O
years	B-C1510829
.	O
	
the	O
core-index	B-C0282574
is	O
a	O
cost-effective	B-C0205556
screening	B-C1710032
tool	B-C0336791
that	O
can	O
assist	O
health	B-C1704312
professionals	I-C1704312
in	O
initiating	O
obesity	B-C0028754
preventive	B-C0033107
measures	I-C0033107
from	O
early	B-C1279919
life	B-C0376558
.	O
	
methodology	B-C3266812
development	B-C1527148
on	O
aquatic	B-C0563034
environmental	I-C0563034
assessment	B-C0220825
the	O
water	B-C0282574
framework	I-C0282574
directive	I-C0282574
aims	B-C1947946
at	O
reaching	O
the	O
good	O
ecological	B-C0162358
status	B-C0449438
of	O
the	O
surface	B-C0205148
and	O
ground	B-C0596631
water	I-C0596631
bodies	I-C0596631
lászló	O
et	O
al	O
.	O
	
microchem	O
j	O
85	O
,	O
2007	O
.	O
	
the	O
paper	O
deals	O
with	O
quality	B-C0332306
evaluation	B-C0220825
of	O
waters	B-C0043047
with	O
special	B-C0205555
focus	O
on	O
the	O
water	B-C0043047
chemistry	B-C0079107
parameters	B-C0549193
as	O
defined	O
in	O
the	O
water	B-C0282574
framework	I-C0282574
directive	I-C0282574
and	O
pertaining	O
legal	B-C0680575
regulations	I-C0680575
.	O
	
the	O
purpose	B-C1285529
of	O
this	O
paper	O
is	O
to	O
devise	O
a	O
quantitative	B-C0392762
type	O
of	O
water	B-C0043047
quality	B-C0332306
assessment	B-C0220825
method	B-C0025663
which	O
could	O
provide	B-C1999230
rapid	B-C0456962
,	O
accurate	B-C0443131
,	O
and	O
reliable	B-C3858758
information	B-C1533716
on	O
the	O
quality	B-C0332306
of	O
the	O
surface	B-C0205148
waters	B-C0043047
by	O
using	O
water	B-C0043047
chemistry	B-C0079107
parameters	B-C0549193
.	O
	
quality	B-C0332306
classes	B-C0456387
have	O
been	O
defined	B-C0442825
for	O
every	O
water	B-C0043047
chemistry	B-C0079107
parameter	B-C0549193
in	O
light	O
of	O
the	O
legal	B-C0752073
limit	I-C0752073
values	I-C0752073
of	O
the	O
water	B-C0043047
parameters	B-C0549193
.	O
	
in	O
addition	O
to	O
this	O
,	O
weight	B-C0392762
indices	I-C0392762
were	O
calculated	B-C1443182
on	O
the	O
basis	O
of	O
the	O
outcome	B-C1274040
of	O
the	O
paired	B-C0086766
comparison	I-C0086766
of	O
water	B-C0043047
chemistry	B-C0079107
parameters	B-C0549193
and	O
normalized	B-C1882115
matrix	B-C1704640
.	O
	
this	O
was	O
followed	O
by	O
the	O
parametric	B-C0681933
level	I-C0681933
analysis	I-C0681933
of	O
the	O
water	B-C0043047
chemistry	B-C0079107
parameters	B-C0549193
,	O
and	O
finally	O
,	O
the	O
aquatic	B-C0282574
environment	I-C0282574
index	I-C0282574
aei	B-C0282574
was	O
calculated	B-C1443182
,	O
which	O
provided	B-C1999230
general	B-C0332118
information	I-C0332118
on	O
the	O
quality	B-C0332306
of	O
water	B-C0043047
regarding	O
the	O
water	B-C0043047
chemistry	B-C0079107
parameters	B-C0549193
.	O
	
the	O
method	B-C0025663
was	O
illustrated	O
on	O
lake	B-C0337049
balaton	B-C0017446
,	O
hungary	B-C0020174
in	O
which	O
case	O
water	B-C0043047
samples	B-C0370003
taken	O
from	O
balatonfüred	B-C0017446
city	I-C0017446
lake	B-C0337049
area	B-C0017446
were	O
analyzed	B-C0936012
and	O
evaluated	B-C0220825
with	O
the	O
method	B-C0025663
wdr26	B-C4307325
promotes	B-C0033414
mitophagy	B-C1820119
of	O
cardiomyocytes	B-C0225828
induced	B-C0205263
by	O
hypoxia	B-C0242184
through	O
parkin	B-C1570554
translocation	B-C0599893
myocardial	B-C0151744
ischemia	I-C0151744
is	O
a	O
heart	B-C0018787
condition	B-C0348080
caused	O
by	O
reduction	B-C0392756
of	O
blood	B-C0232338
flow	I-C0232338
to	O
the	O
heart	B-C0018787
,	O
preventing	O
heart	B-C0018787
from	O
receiving	B-C1514756
enough	O
oxygen	B-C0030054
.	O
	
myocardial	B-C0151744
ischemia	I-C0151744
is	O
the	O
most	O
common	O
cause	B-C0007465
of	I-C0007465
death	I-C0007465
globally	B-C0205246
.	O
	
heart	B-C0018787
ischemic	B-C0376466
preconditioning	I-C0376466
ipc	B-C0376466
has	O
a	O
protective	B-C1280500
effect	I-C1280500
against	O
myocardial	B-C0225828
cell	I-C0225828
death	B-C0007587
induced	B-C0205263
by	O
ischemia	B-C0022116
and	O
ischemia-reperfusion	B-C0035126
injury	I-C0035126
.	O
	
wdr26	B-C4307325
has	O
recently	O
been	O
identified	B-C0205396
as	O
a	O
protein	B-C0033684
that	O
is	O
increased	B-C0205217
following	O
rat	B-C0034693
cardiac	B-C0018787
ipc	B-C0376466
.	O
	
wdr26	B-C4307325
can	O
promote	B-C0033414
the	O
proliferation	B-C0596290
of	O
h9c2	B-C0007634
cells	I-C0007634
and	O
protect	O
cardiomyocytes	B-C0225828
against	O
oxidative	B-C0242606
stress	I-C0242606
through	O
inhibiting	B-C3463820
apoptosis	B-C0162638
.	O
	
however	O
,	O
its	O
role	B-C1705810
in	O
myocardial	B-C0151744
ischemia	I-C0151744
is	O
unclear	O
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
explore	O
the	O
role	O
of	O
wdr26	B-C4307325
in	O
myocardial	B-C0151744
ischemia	I-C0151744
and	O
h9c2	B-C0007634
cell	I-C0007634
hypoxia	B-C0242184
.	O
	
our	O
results	B-C1274040
showed	O
that	O
wdr26	B-C4307325
is	O
induced	B-C0205263
by	O
myocardial	B-C0151744
ischemia	I-C0151744
and	O
h9c2	B-C0007634
cell	I-C0007634
hypoxia	B-C0242184
.	O
	
wdr26	B-C4307325
protects	O
h9c2	B-C0007634
cells	I-C0007634
against	O
hypoxia	B-C0242184
injury	B-C3263722
through	O
inhibiting	B-C3463820
ldh	B-C0022917
release	O
and	O
increasing	O
cell	B-C0007620
viability	I-C0007620
.	O
	
wdr26	B-C4307325
promotes	B-C0033414
hypoxia	B-C0242184
-	O
induced	B-C0205263
autophagy	B-C0004391
in	O
hypoxia	B-C0242184
of	O
h9c2	B-C0007634
cells	I-C0007634
.	O
	
we	O
further	O
demonstrated	O
that	O
in	O
h9c2	B-C0007634
cell	I-C0007634
hypoxia	B-C0242184
,	O
wdr26	B-C4307325
increases	B-C0442805
mitochondrial	B-C1720920
membrane	I-C1720920
potential	I-C1720920
,	O
thereby	O
increases	B-C0442805
parkin	B-C1570554
translocation	B-C0599893
of	O
mitochondria	B-C0026237
.	O
	
after	O
parkin	B-C1570554
is	O
translocated	B-C0599893
at	O
mitochondria	B-C0026237
,	O
wdr26	B-C4307325
can	O
increase	B-C0442805
mitochondria	B-C0026237
l	O
protein	B-C1816438
ubiquitination	I-C1816438
in	O
hypoxia	B-C0242184
of	O
h9c2	B-C0007634
cells	I-C0007634
.	O
	
wdr26	B-C4307325
is	O
a	O
mediator	O
of	O
response	O
to	O
hypoxia	B-C0242184
,	O
and	O
wdr26	B-C4307325
plays	O
an	O
important	O
role	O
in	O
hypoxia	B-C0242184
-mediated	O
autophagy	B-C0004391
and	O
mitophagy	B-C1820119
.	O
	
this	O
study	B-C2603343
provides	O
novel	B-C0205314
insights	O
into	O
the	O
protective	O
role	O
of	O
wdr26	B-C4307325
in	O
cardiomyocyte	B-C0225828
injury	B-C3263722
during	O
hypoxia	B-C0242184
.	O
	
wdr26	B-C4307325
may	O
serve	O
as	O
a	O
potential	O
target	B-C1521840
for	O
the	O
treatment	B-C0087111
of	O
myocardial	B-C0151744
ischemia	I-C0151744
.	O
	
impact	B-C4049986
of	O
antibiotic	B-C0003232
de-escalation	B-C3651014
on	O
clinical	B-C1274040
outcomes	I-C1274040
in	O
community-acquired	B-C0456394
pneumococcal	B-C0032300
pneumonia	I-C0032300
although	O
antibiotic	B-C0003232
de-escalation	B-C3651014
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	B-C0392756
selection	O
pressure	O
,	O
adverse	B-C0041755
drug	I-C0041755
effects	I-C0041755
and	O
costs	B-C0085123
,	O
evidence	B-C3887511
supporting	O
this	O
practice	O
in	O
community-acquired	B-C0032300
pneumococcal	I-C0032300
pneumonia	I-C0032300
capp	B-C0032300
is	O
lacking	B-C0332268
.	O
	
we	O
carried	O
out	O
a	O
retrospective	B-C1514923
analysis	B-C0936012
of	O
prospectively	O
collected	O
data	B-C1511726
of	O
a	O
cohort	B-C0599755
of	O
hospitalized	B-C0001585
adults	I-C0001585
with	O
capp	B-C0032300
.	O
	
pneumococcal	B-C0032300
aetiology	B-C1314792
was	O
established	B-C0443211
in	O
patients	B-C0030705
with	O
one	O
or	O
more	O
positive	B-C0159125
cultures	I-C0159125
for	O
streptococcus	B-C0038410
pneumoniae	I-C0038410
obtained	O
from	O
blood	B-C0005767
,	O
sterile	B-C0005889
fluids	I-C0005889
or	O
sputum	B-C0038056
,	O
and/or	O
a	O
positive	B-C1446409
urinary	B-C1319561
antigen	I-C1319561
test	I-C1319561
.	O
	
de-escalation	B-C3651014
therapy	I-C3651014
was	O
considered	O
when	O
the	O
initial	O
antibiotic	B-C0338237
therapy	I-C0338237
was	O
narrowed	O
to	O
penicillin	B-C0220892
,	O
amoxicillin	B-C0002645
or	O
amoxicillin/clavulanate	B-C0054066
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-C0184666
.	O
	
the	O
primary	O
outcomes	B-C1274040
were	O
30	O
day	B-C0439228
mortality	B-C0205848
and	O
length	B-C3826195
of	I-C3826195
hospital	I-C3826195
stay	I-C3826195
los	B-C3826195
.	O
	
adjustment	B-C0456081
for	O
confounders	O
was	O
performed	B-C0884358
with	O
multivariate	B-C0026777
and	O
propensity	B-C2718044
score	I-C2718044
analyses	B-C0936012
.	O
	
of	O
1410	O
episodes	O
of	O
capp	B-C0032300
,	O
antibiotic	B-C0003232
de-escalation	B-C3651014
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-C0184666
was	O
performed	B-C0884358
in	O
166	O
cases	B-C0868928
.	O
	
after	O
adjustment	B-C0456081
,	O
antibiotic	B-C0003232
de-escalation	B-C3651014
was	O
not	O
associated	B-C0332281
with	I-C0332281
a	O
higher	O
risk	B-C0035647
of	O
mortality	B-C0205848
or	B-C0028873
=	O
0.83	O
,	O
95%	O
ci	B-C0009667
=	O
0.24	O
,	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective	B-C0679688
factor	I-C0679688
for	O
prolonged	B-C0439590
los	B-C3826195
above	O
the	O
median	B-C0876920
or	B-C0028873
=	O
0.46	O
,	O
95%	O
ci	B-C0009667
=	O
0.30	O
.	O
	
similar	O
results	B-C1274040
were	O
found	O
in	O
patients	B-C0030705
classified	O
into	O
high-risk	B-C0332167
pneumonia	B-C0032285
severity	O
index	O
classes	O
iv-v	O
,	O
those	O
with	O
clinical	B-C1444783
instability	I-C1444783
and	O
those	O
with	O
bacteraemia	B-C0004610
.	O
	
no	B-C3842396
significant	I-C3842396
differences	I-C3842396
were	O
documented	B-C1301725
in	O
adverse	B-C0041755
drug	I-C0041755
reactions	I-C0041755
or	O
readmission	B-C0184666
<30	O
days	B-C0439228
.	O
	
antibiotic	B-C0003232
de-escalation	B-C3651014
seems	O
to	O
be	O
safe	O
and	O
effective	B-C1704419
in	O
reducing	B-C0392756
the	O
duration	B-C0449238
of	O
los	B-C3826195
,	O
and	O
did	O
not	O
adversely	B-C0879626
affect	I-C0879626
outcomes	B-C1274040
of	O
patients	B-C0030705
with	O
capp	B-C0032300
,	O
even	O
those	O
with	O
bacteraemia	B-C0004610
and	O
severe	B-C0012634
disease	I-C0012634
,	O
and	O
those	O
who	O
were	O
clinically	B-C0443343
unstable	I-C0443343
.	O
	
radiation	B-C0851346
-	O
induced	B-C0205263
parotid	B-C0341045
gland	I-C0341045
atrophy	I-C0341045
in	O
patients	B-C0030705
with	O
head	B-C0278996
and	I-C0278996
neck	I-C0278996
cancer	I-C0278996
after	O
carbon-ion	B-C3494442
radiotherapy	I-C3494442
this	O
study	B-C0008972
aimed	O
to	O
clarify	B-C2986669
the	O
relationship	B-C0439849
between	O
dosimetric	B-C0034603
factors	B-C1521761
and	O
parotid	B-C0341045
gland	I-C0341045
pg	I-C0341045
atrophy	I-C0341045
after	O
carbon	B-C3494442
ion	I-C3494442
radiotherapy	I-C3494442
c-ion	B-C3494442
rt	I-C3494442
.	O
	
fifty-four	O
patients	B-C0030705
with	O
head	B-C0018671
and	I-C0018671
neck	I-C0018671
tumours	I-C0018671
were	O
enrolled	O
and	O
93	O
irradiated	O
pgs	B-C0030580
were	O
analyzed	O
.	O
	
thirty	O
and	O
24	O
patients	B-C0030705
were	O
treated	B-C0332293
with	I-C0332293
total	B-C0034620
doses	I-C0034620
relative	B-C3825732
biological	I-C3825732
effectiveness	I-C3825732
rbe	B-C3825732
of	O
57.6	O
gy	O
and	O
64.0	O
gy	O
,	O
respectively	O
,	O
in	O
16	O
fractions	O
.	O
	
pg	B-C0030580
volumes	B-C0449468
were	O
measured	B-C2700258
using	O
computed	B-C1551337
tomographic	I-C1551337
images	I-C1551337
obtained	O
before	O
c-ion	B-C3494442
rt	I-C3494442
and	O
every	O
3-6	O
months	B-C0439231
thereafter	O
.	O
	
the	O
median	B-C0876920
follow-up	B-C1522577
period	B-C1948053
was	O
46.4	O
months	B-C0439231
range	B-C1514721
=24	O
months	B-C0439231
.	O
	
univariate	B-C0683962
analysis	I-C0683962
showed	O
that	O
pg	B-C0030580
volumes	B-C0449468
receiving	O
more	O
than	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
gy	O
rbe	B-C3825732
v5	B-C0449468
,	O
v10	B-C0449468
,	O
v15	B-C0449468
and	O
v20	B-C0449468
,	O
respectively	O
,	O
mean	B-C0444504
dose	B-C0034620
,	O
and	O
maximum	B-C0806909
dose	B-C0034620
were	O
significantly	O
associated	B-C0332281
with	I-C0332281
pg	B-C0341045
atrophy	I-C0341045
.	O
	
multivariate	B-C0026777
analysis	I-C0026777
indicated	O
that	O
only	O
v5	B-C0449468
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
atrophy	B-C0341045
.	O
	
increasing	B-C0442808
v5	B-C0449468
was	O
a	O
significant	O
risk	B-C0035648
factor	I-C0035648
for	O
pg	B-C0341045
atrophy	I-C0341045
after	O
c-ion	B-C3494442
rt	I-C3494442
.	O
	
il-27	B-C1706289
is	O
essential	O
for	O
suppression	B-C0021079
of	O
experimental	B-C1517586
allergic	B-C0155877
asthma	I-C0155877
by	O
the	O
tlr7	B-C1579758
/	O
8	B-C1579755
agonist	B-C2987634
r848	B-C3642356
resiquimod	B-C0965594
different	O
models	B-C0684309
of	I-C0684309
experimental	I-C0684309
allergic	B-C0155877
asthma	I-C0155877
have	O
shown	O
that	O
the	O
tlr7	B-C1579758
/	O
8	B-C1579755
agonist	B-C2987634
resiquimod	B-C0965594
r848	B-C3642356
is	O
a	O
potential	O
inhibitor	B-C1999216
of	O
type	B-C0242633
2	I-C0242633
helper	I-C0242633
cell	I-C0242633
-driven	O
inflammatory	B-C1155266
responses	I-C1155266
.	O
	
however	O
,	O
the	O
mechanisms	O
mediating	O
its	O
therapeutic	B-C1527144
effects	I-C1527144
are	O
not	O
fully	O
understood	O
.	O
	
using	O
a	O
model	B-C0684309
of	I-C0684309
experimental	I-C0684309
allergic	B-C0155877
asthma	I-C0155877
,	O
we	O
show	O
that	O
induction	B-C0857127
of	O
il-27	B-C1706289
by	O
r848	B-C3642356
is	O
critical	O
for	O
the	O
observed	O
ameliorative	B-C0332272
effects	O
.	O
	
r848	B-C3642356
significantly	O
inhibited	B-C0311403
all	O
hallmarks	B-C1512330
of	O
experimental	B-C1517586
allergic	B-C0155877
asthma	I-C0155877
,	O
including	O
airway	B-C0004096
hyperreactivity	I-C0004096
,	O
eosinophilic	B-C0333930
airway	B-C0458827
inflammation	B-C0021368
,	O
mucus	B-C0155872
hypersecretion	I-C0155872
,	O
and	O
ag	B-C0003320
-	O
specific	B-C0358334
ig	I-C0358334
production	B-C0003261
.	O
	
whereas	O
r848	B-C3642356
significantly	O
reduced	O
il-5	B-C0021759
,	O
il-13	B-C0214743
,	O
and	O
il-17	B-C0384648
,	O
it	O
induced	O
ifn-γ	B-C3539881
and	O
il-27	B-C1706289
.	O
	
neutralization	B-C2987668
of	O
il-27	B-C1706289
completely	O
reversed	O
the	O
therapeutic	B-C1527144
effect	I-C1527144
of	O
r848	B-C3642356
in	O
the	O
experimental	B-C1517586
asthma	B-C0004096
model	B-C0684309
,	O
demonstrating	O
dependence	O
of	O
r848	B-C3642356
-mediated	O
suppression	B-C0021079
on	O
il-27	B-C1706289
.	O
	
in	B-C1533691
vitro	I-C1533691
,	O
r848	B-C3642356
induced	B-C0857127
production	O
of	O
il-27	B-C1706289
by	O
murine	B-C0026809
alveolar	B-C0085236
macrophages	I-C0085236
and	O
dendritic	B-C0011306
cells	I-C0011306
and	O
enhanced	B-C2349975
expression	B-C1171362
of	O
programmed	B-C4300350
death-ligand	I-C4300350
1	I-C4300350
,	O
whose	O
expression	B-C1171362
on	O
monocytes	B-C0085236
and	O
dendritic	B-C0011306
cells	I-C0011306
has	O
been	O
shown	O
to	O
regulate	B-C1327622
peripheral	B-C3179073
tolerance	I-C3179073
in	O
both	O
murine	B-C0026809
and	O
human	B-C0086418
studies	O
.	O
	
moreover	O
,	O
in	B-C1533691
vitro	I-C1533691
il-27	B-C1706289
enhanced	B-C2349975
secretion	B-C1327616
of	O
ifn-γ	B-C3539881
whereas	O
it	O
inhibited	B-C0311403
il-5	B-C0021759
and	O
il-13	B-C0214743
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
th2	B-C0242633
responses	O
.	O
	
taken	O
together	O
,	O
our	O
study	O
proves	O
that	O
r848	B-C3642356
-mediated	O
suppression	B-C0021079
of	O
experimental	B-C1517586
asthma	B-C0004096
is	O
dependent	O
on	O
il-27	B-C1706289
.	O
	
these	O
data	O
provide	O
evidence	O
of	O
a	O
central	O
role	O
of	O
il-27	B-C1706289
for	O
the	O
control	O
of	O
th2	B-C0242633
-mediated	O
allergic	B-C1504369
diseases	I-C1504369
.	O
	
a	O
comparison	O
of	O
functional	B-C0205245
outcomes	O
in	O
patients	B-C0030705
undergoing	O
revision	B-C1997575
arthroscopic	I-C1997575
repair	I-C1997575
of	O
massive	O
rotator	B-C0263912
cuff	I-C0263912
tears	I-C0263912
with	O
and	O
without	B-C0332288
arthroscopic	B-C0443142
suprascapular	B-C3515385
nerve	I-C3515385
release	I-C3515385
this	O
study	O
was	O
designed	O
to	O
compare	O
functional	B-C0205245
outcomes	O
in	O
patients	B-C0030705
undergoing	O
revision	B-C1997575
repair	I-C1997575
of	O
massive	O
rotator	B-C0263912
cuff	I-C0263912
tears	I-C0263912
retracted	B-C1254362
medial	I-C1254362
to	O
the	O
glenoid	B-C1261046
with	O
goutallier	B-C0026846
grade	I-C0026846
4	I-C0026846
atrophy	I-C0026846
and	O
concomitant	O
release	B-C3515385
of	I-C3515385
the	I-C3515385
suprascapular	I-C3515385
nerve	I-C3515385
to	O
a	O
similar	O
group	O
of	O
patients	B-C0030705
with	O
grade	B-C0026846
3	I-C0026846
atrophy	I-C0026846
undergoing	O
revision	B-C1997575
rotator	I-C1997575
cuff	I-C1997575
repair	I-C1997575
rtcr	B-C1997575
without	O
nerve	B-C3515385
release	I-C3515385
.	O
	
we	O
hypothesized	O
that	O
patients	B-C0030705
undergoing	O
nerve	B-C3515385
release	I-C3515385
would	O
have	O
more	O
favorable	O
functional	B-C0205245
outcomes	O
as	O
measured	O
by	O
the	O
modified	O
university	B-C1883464
of	I-C1883464
california	I-C1883464
at	O
los	B-C0024015
angeles	I-C0024015
shoulder	B-C0681889
rating	I-C0681889
scale	I-C0681889
ucla	B-C0681889
.	O
	
twenty-two	O
patients	B-C0030705
underwent	O
revision	B-C1997575
repair	I-C1997575
of	O
massive	O
rotator	B-C0263912
cuff	I-C0263912
tears	I-C0263912
with	O
release	B-C3515385
of	I-C3515385
the	I-C3515385
suprascapular	I-C3515385
nerve	I-C3515385
at	O
the	O
suprascapular	B-C0816410
notch	I-C0816410
.	O
	
we	O
compared	O
total	O
preoperative	B-C0445204
,	O
postoperative	B-C0032790
,	O
and	O
change	O
in	O
ucla	B-C0237855
score	I-C0237855
in	O
these	O
patients	B-C0030705
to	O
a	O
similar	O
group	B-C1257890
of	O
22	O
patients	B-C0030705
undergoing	O
revision	B-C1997575
rtcr	I-C1997575
without	B-C0332288
suprascapular	B-C3515385
nerve	I-C3515385
release	I-C3515385
.	O
	
additionally	O
,	O
ucla	O
subscores	O
between	O
the	O
two	O
groups	B-C1257890
were	O
compared	O
preoperatively	B-C0445204
and	O
at	O
final	O
follow-up	B-C1522577
.	O
	
the	O
average	O
preoperative	B-C0445204
ucla	B-C0237855
score	I-C0237855
in	O
the	O
nerve-release	B-C1257890
group	I-C1257890
was	O
7.91	O
,	O
and	O
final	O
follow-up	B-C1522577
average	O
was	O
27.86	O
average	O
3.05	O
grades	O
of	O
strength	O
were	O
recovered	O
.	O
	
in	O
the	O
comparison	O
group	B-C1257890
,	O
average	O
preoperative	B-C0445204
ucla	B-C0237855
score	I-C0237855
was	O
11.77	O
,	O
and	O
final	O
follow-up	B-C1522577
average	O
was	O
29.09	O
average	O
1.32	O
grades	O
of	O
strength	O
were	O
recovered	O
.	O
	
the	O
average	O
preoperative	B-C0445204
ucla	B-C0237855
score	I-C0237855
was	O
significantly	O
worse	O
in	O
the	O
nerve-release	B-C1257890
group	I-C1257890
p=0	O
.	O
	
the	O
average	O
postoperative	B-C0032790
ucla	B-C0237855
score	I-C0237855
was	O
not	O
significantly	O
different	O
p=0	O
between	O
the	O
groups	B-C1257890
,	O
indicating	O
a	O
better	O
improvement	O
in	O
the	O
nerve-release	B-C1257890
group	I-C1257890
with	O
significantly	O
greater	O
improvement	O
in	O
active	O
forward	O
flexion	B-C0231452
,	O
strength	B-C0517349
,	O
and	O
pain	B-C0451615
relief	I-C0451615
.	O
	
patients	B-C0030705
who	O
underwent	O
concomitant	O
release	B-C3515385
of	I-C3515385
the	I-C3515385
suprascapular	I-C3515385
nerve	I-C3515385
during	O
revision	B-C1997575
rtcr	I-C1997575
had	O
greater	O
overall	O
improvement	O
as	O
noted	O
in	O
pain	B-C0451615
relief	I-C0451615
,	O
active	B-C0231452
forward	I-C0231452
flexion	I-C0231452
,	O
and	O
strength	B-C0517349
,	O
than	O
a	O
comparable	O
group	B-C1257890
without	B-C0332288
nerve	B-C3515385
release	I-C3515385
.	O
	
fading	B-C0205216
with	B-C0332311
time	I-C0332311
of	O
pd-l1	B-C4300350
immunoreactivity	B-C0597879
in	O
non-small	B-C0007131
cells	I-C0007131
lung	I-C0007131
cancer	I-C0007131
tissues	B-C0040300
a	O
methodological	B-C0025662
study	I-C0025662
blockade	B-C0332206
of	O
inhibitory	B-C1155874
immune	I-C1155874
checkpoints	I-C1155874
is	O
currently	O
arising	O
as	O
a	O
potential	O
immunologic	B-C0205470
option	B-C1518601
for	O
tumor	B-C0920425
therapy	I-C0920425
.	O
	
inhibition	B-C3463820
of	O
programmed	B-C2986635
cell	I-C2986635
death	I-C2986635
protein	I-C2986635
1	I-C2986635
and/or	O
its	O
specific	O
ligand	B-C0023688
programmed	B-C4300350
death-ligand	I-C4300350
1	I-C4300350
pd-l1	B-C4300350
was	O
effective	O
in	O
clinical	B-C0008976
trials	I-C0008976
in	O
advanced	B-C0205179
melanoma	B-C0025202
,	O
non-small	B-C0007131
cell	I-C0007131
lung	I-C0007131
cancer	I-C0007131
nsclc	B-C0007131
bladder	B-C0005695
and	O
kidney	B-C1378703
cancer	I-C1378703
.	O
	
the	O
predictive	O
role	O
of	O
the	O
immunohistochemical	B-C1441616
ihc	B-C1441616
expression	B-C1171362
of	O
pd-l1	B-C4300350
is	O
highly	O
debated	O
.	O
	
different	O
reagents	B-C0034760
,	O
clones	B-C1522642
,	O
cutoffs	O
of	O
cell	B-C0007634
expression	B-C1171362
and	O
subjective	B-C0439655
interpretation	B-C0438231
of	O
pd-l1	B-C4300350
immunoreactivity	B-C0597879
in	O
epithelial	B-C0014597
cells	I-C0014597
and	O
lymphocytes	B-C0024264
are	O
the	O
main	O
issue	B-C0033213
.	O
	
in	O
this	O
study	O
we	O
selected	O
58	O
consecutive	O
nsclc	B-C0007131
surgical	B-C1292533
specimens	I-C1292533
that	O
underwent	O
pathologic	B-C4086729
examination	I-C4086729
from	O
january	B-C3829466
2014	O
to	O
july	B-C3829447
2015	O
.	O
	
using	O
a	O
tissue	O
microarray	B-C1449575
approach	I-C1449575
we	O
evaluated	O
the	O
ihc	B-C1441616
expression	I-C1441616
of	O
pd-l1	B-C4300350
in	O
tumor-infiltrating	B-C0079722
lymphocytes	I-C0079722
and	O
tumor	B-C0597032
cells	I-C0597032
tcs	B-C0597032
and	O
compared	O
the	O
ich	B-C1441616
staining	I-C1441616
with	O
tumor	B-C1516204
histology	I-C1516204
,	O
grade	B-C0919553
and	O
the	O
age	O
of	O
the	O
tissue	B-C0040300
blocks	I-C0040300
.	O
	
the	O
main	O
new	O
finding	B-C0243095
was	O
the	O
fading	B-C0205216
of	O
pd-l1	B-C4300350
ihc	B-C1441616
expression	I-C1441616
in	O
tcs	B-C0597032
in	O
tissues	B-C0040300
processed	O
in	O
2014	O
compared	O
with	O
2015	O
.	O
	
pd-l1	B-C4300350
expression	B-C0017262
in	O
tumor-infiltrating	B-C0079722
lymphocytes	I-C0079722
in	O
the	O
2	O
years	B-C0439234
was	O
similar	B-C2348205
.	O
	
we	O
also	O
found	O
a	O
significant	B-C1299395
higher	I-C1299395
immunoreactivity	B-C0597879
of	O
tcs	B-C0597032
in	O
high	B-C0205082
grade	I-C0205082
nsclc	B-C0007131
and	O
in	O
the	O
squamous	B-C0007137
carcinoma	I-C0007137
histotype	B-C0449574
compared	O
with	O
low	B-C1282907
grade	I-C1282907
tumors	B-C0019638
and	O
the	O
adenocarcinoma	B-C0001418
histology	B-C0019638
p=0	O
.	O
	
we	O
demonstrated	O
that	O
the	O
ihc	B-C1441616
evaluation	I-C1441616
of	O
pd-l1	B-C4300350
in	O
nsclc	B-C0007131
archival	B-C0040300
tissues	I-C0040300
is	O
feasible	O
and	O
can	O
be	O
implemented	O
in	O
a	O
routine	O
pathology	B-C0030664
setting	I-C0030664
,	O
but	O
it	O
should	O
be	O
carefully	O
assessed	O
in	O
tissue	B-C0040300
blocks	I-C0040300
older	O
than	O
1	O
differential	B-C1705242
transcriptome	B-C3178810
expression	B-C0017262
in	O
human	B-C0086418
nucleus	B-C0028633
accumbens	I-C0028633
as	O
a	O
function	O
of	O
loneliness	B-C0023974
loneliness	B-C0023974
is	O
associated	B-C0332281
with	I-C0332281
impaired	B-C0684336
mental	B-C0025353
and	O
physical	B-C0018684
health	I-C0018684
.	O
	
studies	O
of	O
lonely	B-C0237401
individuals	I-C0237401
reported	O
differential	B-C1519516
expression	I-C1519516
of	O
inflammatory	B-C0333348
genes	B-C0017337
in	O
peripheral	B-C0205100
leukocytes	B-C0023516
and	O
diminished	B-C0205216
activation	B-C0017255
in	O
brain	B-C0006104
reward	B-C1273723
regions	I-C1273723
such	O
as	O
nucleus	B-C0028633
accumbens	I-C0028633
,	O
but	O
could	O
not	O
address	O
gene	B-C0017262
expression	I-C0017262
in	O
the	O
human	B-C0086418
brain	B-C0006104
.	O
	
here	O
,	O
we	O
examined	O
genome-wide	B-C0017262
rna	I-C0017262
expression	I-C0017262
in	O
post-mortem	B-C0004398
nucleus	B-C0028633
accumbens	I-C0028633
from	O
donors	B-C0013018
n=26	O
with	O
known	O
loneliness	B-C0023974
measures	B-C0079809
.	O
	
loneliness	B-C0023974
was	O
associated	B-C0332281
with	I-C0332281
1710	O
differentially	B-C1519595
expressed	I-C1519595
transcripts	I-C1519595
and	O
genes	B-C0017337
from	O
1599	O
genes	B-C0017337
degs	B-C0017337
false	B-C1880720
discovery	I-C1880720
rate	I-C1880720
p<0	O
,	O
fold	O
change	O
|2|	O
,	O
controlling	O
for	O
confounds	O
previously	O
associated	B-C0332281
with	I-C0332281
behavioral	B-C0004927
processes	I-C0004927
,	O
neurological	B-C0027765
disease	I-C0027765
,	O
psychological	B-C0004936
disorders	I-C0004936
,	O
cancer	B-C0006826
,	O
organismal	B-C0029235
injury	B-C0178314
and	O
skeletal	B-C0263661
and	O
muscular	B-C0026848
disorders	I-C0026848
,	O
as	O
well	O
as	O
networks	B-C1882071
of	O
upstream	B-C0522505
rna	B-C0017362
regulators	I-C0017362
.	O
	
furthermore	O
,	O
a	O
number	O
of	O
degs	B-C0017337
were	O
associated	B-C0332281
with	I-C0332281
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
genes	B-C0017337
that	O
was	O
correlated	B-C1707520
with	O
loneliness	B-C0023974
in	O
this	O
sample	B-C0370003
,	O
although	O
gene	B-C1880945
expression	I-C1880945
analyses	I-C1880945
controlled	O
for	O
ad	B-C0002395
diagnosis	B-C0011900
.	O
	
these	O
results	O
identify	O
novel	O
targets	B-C1521840
for	O
future	O
mechanistic	B-C0242481
studies	I-C0242481
of	O
gene	B-C0017337
networks	O
in	O
nucleus	B-C0028633
accumbens	I-C0028633
and	O
gene	B-C0017263
regulatory	I-C0017263
mechanisms	I-C0017263
across	O
a	O
variety	O
of	O
diseases	B-C0012634
exacerbated	O
by	O
loneliness	B-C0023974
.	O
	
molecular	B-C0034036
psychiatry	I-C0034036
advance	I-C0034036
online	I-C0034036
publication	I-C0034036
,	O
1	O
november	B-C3828767
overall	O
quality	B-C0871161
properties	I-C0871161
of	O
kiwifruit	B-C0440282
treated	B-C0332293
by	I-C0332293
cinnamaldehyde	B-C0055754
and	O
citral	B-C0055809
microbial	B-C0599840
,	O
antioxidant	B-C1148564
capacity	I-C1148564
during	O
cold	B-C0010405
storage	I-C0010405
this	O
work	O
was	O
undertaken	O
to	O
evaluate	B-C0220825
the	O
microbiological	B-C0025953
characteristics	B-C1521970
and	O
antioxidant	B-C1148564
and	O
physiological	B-C0031843
activities	I-C0031843
in	O
kiwifruits	B-C0440282
actinida	B-C0971874
deliciosa	I-C0971874
var	O
.	O
	
qinmei	O
with/without	O
cinnamaldehyde	B-C0055754
c1	O
and	O
citral	B-C0055809
c2	O
fumigation	B-C0016804
treatments	B-C1522326
5	O
μl/l	O
during	O
0	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
d	O
of	O
storage	B-C1698986
at	O
4	O
c	O
.	O
	
essential	B-C0028908
oils	I-C0028908
eos	B-C0028908
treatment	B-C1522326
lowered	O
the	O
total	O
viable	B-C0750480
counts	I-C0750480
,	O
yeast	B-C0043393
,	O
and	O
mold	B-C0369241
to	O
1.54	O
,	O
2.36	O
,	O
and	O
2.05	O
log	O
cfu/g	O
,	O
respectively	O
.	O
	
moreover	O
,	O
eos	B-C0028908
improved	O
the	O
antioxidant	B-C1148564
activities	I-C1148564
of	O
kiwifruit	B-C0440282
.	O
	
they	O
enhanced	B-C2349975
phenolics	B-C0359916
and	O
flavonoids	B-C0596577
content	O
in	O
fruit	B-C0016767
tissue	B-C1514137
by	O
49.48	O
at	O
day	O
3	O
and	O
56.93	O
at	O
day	O
6	O
,	O
respectively	O
.	O
	
in	O
addition	O
,	O
ascorbic	B-C0003968
acid	I-C0003968
in	O
treated	B-C1522326
groups	B-C0441833
had	O
the	O
lower	O
losing	O
rate	B-C1521828
.	O
	
similarly	O
,	O
mda	B-C0024643
malondialdehyde	B-C0024643
,	O
h2	B-C0020281
o2	I-C0020281
hydrogen	B-C0020281
peroxide	I-C0020281
,	O
and	O
o2	B-C0038836
superoxide	B-C0038836
anion	I-C0038836
production	O
were	O
effectively	B-C1704419
decreased	B-C0205216
in	O
the	O
range	O
of	O
27.27	O
to	O
54.38	O
.	O
	
physicochemical	B-C1521970
characteristics	I-C1521970
showed	O
that	O
kiwifruits	B-C0440282
from	O
treated	B-C1522326
group	B-C0441833
maintained	O
higher	O
levels	O
of	O
flesh	B-C0009393
luminosity	I-C0009393
and	O
firmness	B-C1545487
.	O
	
eos	B-C0028908
also	O
decreased	B-C0205216
the	O
levels	O
of	O
reducing	B-C0026492
sugar	I-C0026492
by	O
45.97	O
at	O
day	O
3	O
,	O
and	O
increased	B-C0205217
the	O
content	O
of	O
soluble	B-C0033684
protein	I-C0033684
and	O
hydrolyzed	O
amino	B-C0002520
acid	I-C0002520
.	O
	
therefore	O
,	O
postharvest	O
eos	B-C0028908
treatment	B-C1522326
has	O
positive	B-C1280500
effects	I-C1280500
on	O
delaying	O
senescence	B-C3546449
and	O
enhancing	B-C2349975
antioxidant	B-C1148564
capacities	I-C1148564
in	O
anti-inflammatory	B-C1515999
effect	I-C1515999
of	O
yu-ping-feng-san	B-C1676720
via	O
tgf-β1	B-C1704256
signaling	B-C3158357
suppression	I-C3158357
in	O
rat	B-C0034721
model	B-C0012644
of	O
copd	B-C0024117
yu-ping-feng-san	B-C1676720
ypfs	B-C1676720
is	O
a	O
classical	O
traditional	O
chinese	B-C0013227
medicine	I-C0013227
that	O
is	O
widely	O
used	O
for	O
treatment	B-C1522326
of	O
the	O
diseases	B-C0012634
in	O
respiratory	B-C0035237
systems	I-C0035237
,	O
including	O
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disease	I-C0024117
copd	B-C0024117
recognized	O
as	O
chronic	B-C1290886
inflammatory	I-C1290886
disease	I-C1290886
.	O
	
however	O
,	O
the	O
molecular	B-C3537153
mechanism	I-C3537153
remains	O
unclear	O
.	O
	
here	O
we	O
detected	O
the	O
factors	O
involved	O
in	O
transforming	B-C1704256
growth	I-C1704256
factor	I-C1704256
beta	I-C1704256
1	I-C1704256
tgf-β1	B-C1704256
smad2	B-C1566792
signaling	B-C0037080
pathway	I-C0037080
and	O
inflammatory	B-C0079189
cytokines	I-C0079189
,	O
to	O
clarify	O
whether	O
ypfs	B-C1676720
could	O
attenuate	B-C0599946
inflammatory	B-C1155266
response	I-C1155266
dependent	O
on	O
tgf-β1	B-C1704256
/	O
smad2	B-C1566792
signaling	B-C3537152
in	O
copd	B-C0024117
rats	B-C0034721
or	O
cigarette	B-C0239059
smoke	I-C0239059
extract	I-C0239059
cse	B-C0239059
treated	B-C1522326
human	B-C0086418
bronchial	B-C1711178
epithelial	I-C1711178
beas-2b	I-C1711178
cells	I-C1711178
.	O
	
the	O
copd	B-C0024117
rat	B-C0034721
model	B-C0012644
was	O
established	O
by	O
exposure	B-C0332157
to	O
cigarette	B-C0239059
smoke	I-C0239059
and	O
intratracheal	B-C1555389
instillation	I-C1555389
of	O
lipopolysaccharide	B-C0023810
,	O
ypfs	B-C1676720
was	O
administered	O
to	O
the	O
animals	B-C0003062
.	O
	
the	O
efficacy	B-C1280519
of	O
ypfs	B-C1676720
was	O
evaluated	O
by	O
comparing	O
the	O
severity	B-C0439793
of	O
pulmonary	B-C0030660
pathological	I-C0030660
damage	I-C0030660
,	O
pro-inflammation	B-C0079189
cytokines	I-C0079189
,	O
collagen	B-C0017337
related	I-C0017337
genes	I-C0017337
and	O
the	O
activation	B-C1879547
of	O
tgf-β1	B-C1704256
/	O
smad2	B-C1566792
signaling	B-C0037080
pathway	I-C0037080
.	O
	
furthermore	O
,	O
cse	B-C0239059
-	O
treated	B-C1522326
cells	B-C0007634
were	O
employed	O
to	O
confirm	O
whether	O
the	O
effect	B-C1280500
of	O
ypfs	B-C1676720
was	O
dependent	O
on	O
the	O
tgf-β1	B-C1704256
/	O
smad2	B-C1566792
signaling	B-C3537152
via	O
knockdown	B-C2350567
smad2	B-C1334468
si-rna	B-C1099354
,	O
or	O
pretreatment	B-C3539076
with	O
the	O
inhibitor	B-C1999216
of	O
tgf-β1	B-C1704256
.	O
	
administration	O
of	O
ypfs	B-C1676720
effectively	O
alleviated	O
injury	B-C0273115
of	I-C0273115
lung	I-C0273115
,	O
suppressed	B-C1260953
releasing	O
of	O
pro-inflammatory	B-C0079189
cytokines	I-C0079189
and	O
collagen	B-C0333584
deposition	I-C0333584
in	O
copd	B-C0024117
animals	B-C0003062
p<0	O
,	O
whereas	O
exogenous	B-C1704256
tgf-β1	I-C1704256
promoted	O
releasing	O
of	O
il-1β	B-C0021753
,	O
il-6	B-C0021760
,	O
tnfα	B-C1456820
p<0	O
.	O
	
administration	O
ypfs	B-C1676720
reduced	O
inflammatory	B-C1155266
response	I-C1155266
significantly	O
,	O
also	O
down-regulated	B-C0013081
tgf-β1	B-C1704256
/	O
smad2	B-C1566792
signaling	B-C3537152
in	B-C1515655
vivo	I-C1515655
and	O
in	B-C1533691
vitro	I-C1533691
.	O
	
unexpectedly	O
,	O
knockdown	B-C2350567
smad2	B-C1334468
or	O
inhibition	B-C3463820
of	O
tgf-β1	B-C1704256
abolished	O
anti-inflammatory	B-C1515999
effect	I-C1515999
of	O
ypfs	B-C1676720
in	O
cse	B-C0239059
-	O
treated	B-C1522326
cells	B-C0007634
.	O
	
ypfs	B-C1676720
accomplished	O
anti-inflammatory	B-C1515999
effects	I-C1515999
mainly	O
by	O
suppressing	B-C1260953
phosphorylation	B-C0031715
of	O
smad2	B-C1566792
,	O
tgf-β1	B-C1704256
/	O
smad2	B-C1566792
signaling	B-C0037080
pathway	I-C0037080
was	O
required	O
for	O
ypfs	B-C1676720
-mediated	O
anti-inflammation	B-C1515999
in	O
copd	B-C0024117
rats	B-C0034721
or	O
cse	B-C0239059
-	O
treated	B-C1522326
beas-2b	B-C1711178
cells	I-C1711178
.	O
	
the	O
association	B-C0439849
between	O
maternal	B-C1858460
hydronephrosis	B-C0020295
and	O
acute	B-C0205178
flank	B-C0016199
pain	I-C0016199
during	O
pregnancy	B-C0032961
a	O
prospective	B-C0033522
pilot-study	B-C0031928
maternal	B-C1858460
hydronephrosis	B-C0020295
may	O
cause	O
flank	B-C0016199
pain	I-C0016199
during	O
pregnancy	B-C0032961
.	O
	
we	O
aimed	B-C1947946
to	O
investigate	B-C1292732
the	O
association	O
between	O
maternal	B-C1858460
hydronephrosis	B-C0020295
and	O
flank	B-C0016199
pain	I-C0016199
intensity	B-C1320357
.	O
	
from	O
2014	O
to	O
2015	O
,	O
all	O
consecutive	B-C1707491
women	B-C0043210
with	O
singleton	B-C0032961
pregnancies	I-C0032961
,	O
who	O
presented	O
at	O
our	O
tertiary	O
center	O
due	O
to	O
acute	B-C0205178
flank	B-C0016199
pain	I-C0016199
,	O
were	O
prospectively	B-C0033522
evaluated	B-C0220825
by	O
renal	B-C0022646
ultrasonography	B-C0041618
and	O
pain	B-C0030193
questionnaires	B-C0034394
.	O
	
a	O
visual	B-C0042815
analogue	I-C0042815
scale	I-C0042815
was	O
used	O
to	O
assess	O
pain	B-C1320357
intensity	I-C1320357
.	O
	
the	O
study	B-C2603343
had	O
90%	O
power	O
to	O
detect	O
a	O
significant	B-C0750502
correlation	B-C1707520
between	O
hydronephrosis	B-C0020295
and	O
flank	B-C0016199
pain	I-C0016199
spearman's	B-C1710141
test	I-C1710141
.	O
	
a	O
total	O
of	O
51	O
consecutive	B-C1707491
women	B-C0043210
with	O
left-sided	B-C0443246
13.7	O
,	O
right-sided	B-C0444532
64.7	O
or	O
bilateral	B-C0238767
21.6	O
pain	B-C0030193
were	O
enrolled	O
.	O
	
the	O
mean	B-C0444504
gestational	B-C0017504
age	I-C0017504
of	O
these	O
women	B-C0043210
,	O
who	O
presented	O
due	O
to	O
their	O
pain	B-C0030193
,	O
was	O
27.5	O
6.8	O
weeks	B-C0439230
at	O
the	O
time	O
of	O
consultation	B-C0009818
.	O
	
the	O
mean	B-C0444504
vas	B-C1508029
score	I-C1508029
was	O
7.6	O
2.2	O
.	O
	
in	O
43/51	O
84.3	O
women	B-C0043210
,	O
hydronephrosis	B-C0020295
was	O
found	O
on	O
renal	B-C0022646
sonograms	O
.	O
	
no	O
correlation	B-C1707520
was	O
found	O
between	O
the	O
grade	O
of	O
hydronephrosis	B-C0020295
and	O
pain	B-C1320357
intensity	I-C1320357
p	O
=	O
0.466	O
r=	O
-0	O
.	O
	
women	B-C0043210
delivered	O
at	O
a	O
mean	B-C0444504
gestational	B-C0017504
age	I-C0017504
of	O
38.1	O
2.4	O
weeks	B-C0439230
and	O
their	O
infants	B-C0021270
had	O
a	O
mean	B-C0444504
birthweight	B-C0005612
of	O
3138	O
677	O
g	O
.	O
	
hydronephrosis	B-C0020295
is	O
a	O
common	O
finding	B-C0243095
among	O
pregnant	B-C0033011
women	I-C0033011
with	O
acute	B-C0205178
flank	B-C0016199
pain	I-C0016199
.	O
	
the	O
grade	O
of	O
hydronephrosis	B-C0020295
does	O
not	O
affect	O
pain	B-C1320357
intensity	I-C1320357
.	O
	
this	O
study	B-C2603343
suggests	O
normal	B-C0232989
pregnancy	I-C0232989
outcomes	B-C0032972
in	O
these	O
simulating	B-C0679083
the	O
potential	B-C3245505
role	B-C1705810
of	O
media	B-C0681284
coverage	I-C0681284
and	O
infected	B-C0439663
bats	B-C0008139
in	O
the	O
2014	O
ebola	B-C0282687
outbreak	B-C0012652
multiple	O
epidemiological	B-C1516907
models	B-C0026336
have	O
been	O
developed	B-C1527148
to	O
model	O
the	O
transmission	B-C0040722
dynamics	I-C0040722
of	O
ebola	B-C0282687
virus	I-C0282687
ebov	I-C0282687
disease	I-C0282687
in	O
west	B-C0001747
africa	I-C0001747
in	O
2014	O
because	O
the	O
severity	B-C0392364
of	O
the	O
epidemic	B-C0014499
is	O
commonly	O
overestimated	O
.	O
	
a	O
compartmental	B-C2986731
model	I-C2986731
that	O
incorporates	O
the	O
media	B-C4049986
impact	I-C4049986
and	O
the	O
effect	B-C1280500
of	O
infected	B-C0439663
bats	B-C0008139
was	O
constructed	O
and	O
calibrated	B-C0006751
using	O
data	B-C1511726
reported	O
until	O
the	O
end	O
of	O
2014	O
.	O
	
the	O
final	O
cumulative	B-C1511559
number	B-C0205848
of	I-C0205848
deaths	I-C0205848
and	O
confirmed	B-C0750484
cases	B-C1706256
were	O
estimated	B-C0750572
to	O
be	O
1.0921	O
95%	O
ci	B-C0009667
9.7706	O
and	O
1.5193	O
95%	O
ci	B-C0009667
1.3593	O
,	O
respectively	O
.	O
	
the	O
epidemic	B-C0014499
was	O
estimated	B-C0750572
to	O
end	O
on	O
june	O
2015	O
,	O
which	O
was	O
similar	B-C2348205
to	O
the	O
data	B-C1511726
reported	B-C0700287
by	O
the	O
world	B-C0043237
health	I-C0043237
organization	I-C0043237
.	O
	
a	O
sensitivity	B-C0936012
analysis	I-C0936012
indicated	B-C1444656
that	O
an	O
increase	B-C0442805
of	O
either	O
the	O
media	B-C4049986
impact	I-C4049986
or	O
the	O
number	B-C0237753
of	O
infectious	B-C1550587
bats	B-C0008139
that	O
are	O
captured	O
daily	B-C0332173
can	O
increase	B-C0442805
the	O
cumulative	B-C1511559
number	B-C0237753
of	O
confirmed	B-C0750484
cases	B-C1706256
/	O
deaths	B-C0205848
.	O
	
of	O
the	O
considered	O
epidemiological	B-C1516907
parameters	I-C1516907
,	O
only	O
the	O
media	B-C0681284
coverage	I-C0681284
can	O
significantly	O
reduce	O
both	O
the	O
peak	B-C3840073
time	I-C3840073
and	O
the	O
value	B-C1522609
of	O
the	O
cumulative	B-C1511559
confirmed	B-C0750484
cases	B-C1706256
/	O
deaths	B-C0205848
.	O
	
thus	O
,	O
we	O
propose	O
'the	O
cumulative	B-C1511559
confirmed	B-C0750484
cases	B-C1706256
and	O
deaths	B-C0205848
'	O
as	O
another	O
media	B-C0009458
mechanism	B-C0441712
.	O
	
in	O
conclusion	O
,	O
the	O
media	B-C4049986
impact	I-C4049986
contributed	O
to	O
the	O
control	B-C0243148
of	O
the	O
2014	O
ebola	B-C0282687
outbreak	B-C0012652
,	O
and	O
infectious	B-C1550587
bats	B-C0008139
may	O
be	O
a	O
potential	B-C3245505
source	B-C0449416
of	O
the	O
body	B-C0242821
diffusion	B-C0598801
weighted	I-C0598801
imaging	I-C0598801
using	O
non-cpmg	B-C0079595
fast	I-C0079595
spin	I-C0079595
echo	I-C0079595
ss-fse	B-C0079595
is	O
a	O
fast	B-C0456962
technique	B-C0079595
that	O
does	O
not	O
suffer	O
from	O
off-resonance	B-C2828093
distortions	B-C2919017
to	O
the	O
degree	O
that	O
epi	B-C0162734
does	O
.	O
	
unlike	O
epi	B-C0162734
,	O
ss-fse	B-C0079595
is	O
ill-suited	O
to	O
diffusion	B-C0598801
weighted	I-C0598801
imaging	I-C0598801
dwi	B-C0598801
due	O
to	O
the	O
carr-purcell-meiboom-geill	B-C0243095
cpmg	I-C0243095
condition	I-C0243095
.	O
	
non-cpmg	B-C0243095
phase	B-C0205390
cycling	B-C1511572
does	O
accommodate	O
ss-fse	B-C0079595
and	O
dwi	B-C0598801
but	O
places	B-C0442504
constraints	B-C0443288
on	O
reconstruction	B-C0205245
,	O
which	O
are	O
resolved	B-C3714811
here	O
through	O
parallel	B-C0079595
imaging	I-C0079595
.	O
	
additionally	O
,	O
improved	B-C0184511
echo	B-C0205360
stability	I-C0205360
can	O
be	O
achieved	O
by	O
using	O
short	B-C0439593
duration	I-C0439593
and	O
highly	O
selective	O
diverse	B-C1880371
radiofrequency	B-C2347883
pulses	B-C1710082
.	O
	
here	O
,	O
signal-to-noise	B-C2986823
ratio	I-C2986823
snr	B-C2986823
comparisons	O
between	O
epi	B-C0162734
and	O
ncpmg	B-C0243095
ss-fse	B-C0079595
acquisitions	B-C1708464
and	O
reconstruction	B-C0449851
techniques	I-C0449851
give	O
similar	B-C2348205
values	B-C0042295
.	O
	
diffusion	B-C0598801
imaging	I-C0598801
with	O
ncpmg	B-C0243095
ss-fse	B-C0079595
gives	O
similar	B-C2348205
snr	B-C2986823
to	O
an	O
epi	B-C0162734
acquisition	B-C1708464
,	O
though	O
apparent	B-C3890194
diffusion	I-C3890194
coefficient	I-C3890194
values	B-C0042295
are	O
higher	B-C0205250
than	O
seen	O
with	O
epi	B-C0162734
.	O
	
in	B-C1515655
vivo	I-C1515655
images	B-C1704922
have	O
good	O
image	B-C0806487
quality	I-C0806487
with	O
little	O
distortion	B-C2919017
.	O
	
this	O
method	O
has	O
the	O
ability	O
to	O
capture	O
distortion	B-C2919017
-	O
free	B-C0332296
dwi	B-C0598801
images	B-C1704922
near	O
areas	B-C0205146
of	O
significant	B-C0750502
off-resonance	B-C2828093
as	O
well	O
as	O
preserve	O
adequate	O
snr	B-C2986823
.	O
	
parallel	B-C0079595
imaging	I-C0079595
and	O
diverse	B-C1880371
refocusing	O
rf	B-C2347883
pulses	B-C1708464
allow	O
shorter	B-C1254367
etl	I-C1254367
compared	O
to	O
previous	O
implementations	B-C1708476
and	O
thus	O
reduces	B-C0392756
phase	B-C0205390
encode	B-C2700640
direction	B-C0449738
blur	B-C1511231
and	O
sar	B-C1155281
accumulation	B-C4055506
.	O
	
modification	B-C0392747
of	O
mechanical	B-C0871161
properties	I-C0871161
,	O
polymerization	B-C0314672
temperature	B-C0039476
,	O
and	O
handling	B-C0040223
time	I-C0040223
of	O
polymethylmethacrylate	B-C0005533
cement	B-C0005934
for	O
enhancing	O
applicability	B-C4048755
in	O
vertebroplasty	B-C1303192
polymethylmethacrylate	B-C0005533
pmma	B-C0005533
bone	B-C0005934
cement	I-C0005934
is	O
a	O
popular	O
bone	B-C0262950
void	B-C0229984
filler	B-C0005934
for	O
vertebroplasty	B-C1303192
.	O
	
however	O
,	O
the	O
use	O
of	O
pmma	B-C0005533
has	O
some	O
drawbacks	O
,	O
including	O
the	O
material's	B-C0005479
excessive	O
stiffness	B-C0018599
,	O
exothermic	B-C0314672
polymerization	I-C0314672
,	O
and	O
short	B-C1806781
handling	B-C0040223
time	I-C0040223
.	O
	
this	O
study	B-C2603343
aimed	O
to	O
create	O
an	O
ideal	O
modified	B-C0392747
bone	B-C0005934
cement	I-C0005934
to	O
solve	O
the	O
above-mentioned	O
problems	B-C0033213
.	O
	
modified	B-C0392747
bone	B-C0005934
cements	I-C0005934
were	O
prepared	B-C1521827
by	O
combining	O
pmma	B-C0005533
with	O
three	O
different	O
volume	B-C0560268
fractions	I-C0560268
of	O
castor	B-C0007343
oil	I-C0007343
5%	O
,	O
10%	O
,	O
and	O
15%	O
.	O
	
the	O
peak	B-C0444505
polymerization	B-C0314672
temperatures	B-C0039476
,	O
times	O
to	O
achieve	O
the	O
peak	B-C0444505
polymerization	B-C0314672
temperature	B-C0039476
,	O
porosities	B-C0080037
,	O
densities	B-C0178587
,	O
modulus	B-C2350289
and	O
maximum	B-C0806909
compression	B-C0376507
strengths	I-C0376507
of	O
standard	B-C1442989
without	O
castor	B-C0007343
oil	I-C0007343
,	O
and	O
modified	B-C0392747
cements	B-C0005934
were	O
investigated	B-C1292732
following	O
storage	O
at	O
ambient	B-C0428692
temperature	I-C0428692
22	O
or	O
under	O
precooling	B-C0678568
conditions	B-C0348080
3	O
.	O
	
six	O
specimens	B-C0370003
were	O
tested	O
in	O
each	O
group	O
of	O
the	O
aforementioned	O
parameters	B-C0549193
.	O
	
increasing	B-C0205217
castor	B-C0007343
oil	I-C0007343
content	O
and	O
precooling	B-C0678568
treatment	B-C1522326
effectively	O
decreased	B-C0205216
the	O
peak	B-C0444505
polymerization	B-C0314672
temperatures	B-C0039476
and	O
increased	B-C0205217
the	O
duration	B-C0449238
to	O
achieve	O
the	O
peak	B-C0444505
polymerization	B-C0314672
temperature	B-C0039476
p	O
<	O
0.05	O
.	O
	
furthermore	O
,	O
the	O
mechanical	B-C0871161
properties	I-C0871161
of	O
the	O
material	B-C0005479
,	O
including	O
density	B-C0178587
,	O
modulus	B-C2350289
,	O
and	O
maximum	B-C0806909
compression	B-C0376507
strength	I-C0376507
,	O
decreased	B-C0205216
with	O
increasing	B-C0205217
castor	B-C0007343
oil	I-C0007343
content	B-C0456205
.	O
	
however	O
,	O
preparation	B-C1521827
temperature	B-C0039476
room	B-C0428692
temperature	I-C0428692
versus	O
precooling	B-C0678568
had	O
no	O
significant	O
effect	O
p	O
>	O
0.05	O
on	O
these	O
mechanical	B-C0871161
properties	I-C0871161
.	O
	
in	O
conclusion	O
,	O
the	O
addition	O
of	O
castor	B-C0007343
oil	I-C0007343
to	O
pmma	B-C0005533
followed	O
by	O
precooling	B-C0678568
created	O
an	O
ideal	O
modified	B-C0392747
bone	B-C0005934
cement	I-C0005934
with	O
a	O
low	O
modulus	B-C2350289
,	O
low	O
polymerization	B-C0314672
temperature	B-C0039476
,	O
and	O
long	O
handling	B-C0040223
time	I-C0040223
,	O
enhancing	O
its	O
applicability	B-C4048755
and	O
safety	B-C0036043
for	O
a	O
case	B-C0868928
of	O
retrograde	B-C0400855
intussusception	I-C0400855
at	O
roux-en-y	B-C0002804
anastomosis	I-C0002804
10	O
years	O
after	O
total	B-C0017118
gastrectomy	I-C0017118
review	B-C0282441
of	I-C0282441
the	I-C0282441
literature	I-C0282441
a	O
63-year-	O
old	B-C0086582
man	I-C0086582
,	O
who	O
had	O
undergone	O
total	B-C0017118
gastrectomy	I-C0017118
and	O
roux-en-y	B-C0372024
reconstruction	I-C0372024
for	O
gastric	B-C0699791
cancer	I-C0699791
10	O
years	O
previously	O
,	O
was	O
admitted	B-C0184666
to	O
our	O
hospital	B-C0019994
with	O
complaints	B-C0871764
of	O
abdominal	B-C0000737
pain	I-C0000737
,	O
palpable	B-C0522499
abdominal	B-C0000735
tumor	I-C0000735
,	O
and	O
hematemesis	B-C0018926
.	O
	
on	B-C0809949
admission	I-C0809949
,	O
the	O
abdominal	B-C0232498
tenderness	I-C0232498
was	O
improving	B-C1272745
and	O
no	O
abdominal	B-C0000735
tumor	I-C0000735
was	O
palpable	B-C0522499
.	O
	
mild	B-C0021368
inflammatory	I-C0021368
changes	O
and	O
anemia	B-C0002871
were	O
noted	O
on	O
blood	B-C3826648
examination	I-C3826648
.	O
	
abdominal	B-C0000726
computed	B-C0040405
tomography	I-C0040405
revealed	O
a	O
tumor	B-C0027651
with	O
a	O
layered	B-C0205556
structure	I-C0205556
in	O
the	O
left	B-C0000726
abdomen	I-C0000726
.	O
	
the	O
patient	B-C0030705
was	O
diagnosed	B-C0011900
with	O
intestinal	B-C0021843
obstruction	I-C0021843
secondary	O
to	O
intussusception	B-C0021933
,	O
and	O
surgery	B-C0543467
was	O
performed	B-C0884358
.	O
	
retrograde	B-C0400855
intussusception	I-C0400855
was	O
found	O
at	O
the	O
site	O
of	O
the	O
y	B-C0002805
anastomosis	I-C0002805
.	O
	
we	O
conducted	O
manual	B-C0185114
reduction	I-C0185114
using	O
the	O
hutchinson	B-C0087111
procedure	I-C0087111
.	O
	
the	O
intestinal	B-C0021853
color	B-C0009393
after	O
the	O
reduction	B-C0441610
was	O
good	O
,	O
and	O
no	O
intestinal	B-C1096244
resection	I-C1096244
was	O
required	B-C1514873
.	O
	
postoperative	B-C4304804
recovery	I-C4304804
was	O
uneventful	O
,	O
and	O
the	O
patient	B-C0030705
was	O
discharged	B-C0030685
12	O
days	O
after	O
surgery	B-C0543467
.	O
	
reports	B-C0684224
of	O
jejunal	B-C0022378
intussusception	B-C0021933
after	O
total	B-C0017118
gastrectomy	I-C0017118
with	O
roux-en-y	B-C0372024
reconstruction	I-C0372024
are	O
relatively	O
rare	O
.	O
	
here	O
,	O
we	O
report	O
a	O
case	O
of	O
jejunal	B-C0022378
intussusception	B-C0021933
after	O
total	B-C0017118
gastrectomy	I-C0017118
with	O
roux-en-y	B-C0372024
reconstruction	I-C0372024
.	O
	
brassinosteroid	B-C0038317
-	O
induced	B-C0205263
changes	B-C0392747
of	O
lipid	B-C0023779
composition	B-C0243176
in	O
leaves	B-C0242724
of	O
pisum	B-C1262903
sativum	I-C1262903
l	I-C1262903
.	O
	
during	O
senescence	B-C1326530
the	O
effect	B-C1704420
of	I-C1704420
steroid	B-C0038317
phytohormone	B-C0032082
24-epibrassinolide	B-C0243833
ebr	B-C0243833
on	O
the	O
composition	B-C0243176
of	O
some	O
lipid	B-C0023779
classes	B-C0456387
free	B-C0015688
fatty	I-C0015688
acids	I-C0015688
,	O
triacylglycerols	B-C0041004
and	O
galactolipids	B-C0060960
in	O
detached	B-C0687118
pea	B-C1262903
leaves	B-C0242724
was	O
studied	O
for	O
the	O
first	O
time	O
.	O
	
ebr	B-C0243833
0.1μm	O
promoted	O
senescence	B-C1326530
and	O
increased	B-C0205217
the	O
content	B-C0456205
of	O
14	O
,	O
16	O
and	O
18	O
free	B-C0015688
fatty	I-C0015688
acids	I-C0015688
as	O
well	O
as	O
18	O
and	O
18	O
bound	O
to	O
triacylglycerols	B-C0041004
in	O
the	O
detached	B-C0687118
leaves	B-C0242724
in	O
contrast	O
to	O
mock-treated	B-C0242724
leaves	I-C0242724
.	O
	
the	O
content	B-C0456205
of	O
all	O
identified	B-C0205396
fatty	B-C0015684
acids	I-C0015684
bound	O
to	O
galactolipids	B-C0060960
decreased	B-C0205216
in	O
the	O
detached	B-C0687118
leaves	B-C0242724
treated	B-C1522326
with	O
ebr	B-C0243833
compared	O
to	O
that	O
in	O
mock-treated	B-C0242724
leaves	I-C0242724
.	O
	
these	O
findings	B-C2607943
suggest	O
that	O
free	B-C0015688
fatty	I-C0015688
acids	I-C0015688
are	O
liberated	O
from	O
polar	B-C0813983
lipids	B-C0023779
and	O
then	O
undergo	O
esterification	B-C2612539
to	O
neutral	B-C0023779
lipids	I-C0023779
in	O
the	O
detached	B-C0687118
leaves	B-C0242724
upon	O
ebr	B-C0243833
treatment	B-C1522326
.	O
	
we	O
propose	O
that	O
steroid	B-C0038317
phytohormones	B-C0032082
may	O
be	O
involved	O
into	O
regulation	B-C1327622
of	O
leaf	B-C0242724
senescence	B-C1326530
via	O
alteration	B-C1515926
of	O
cell	B-C0007634
lipid	B-C0023779
composition	B-C0243176
.	O
	
posterior	B-C1265659
dislocation	I-C1265659
of	O
the	O
sternoclavicular	B-C0038291
joint	I-C0038291
report	B-C0684224
of	O
two	O
cases	B-C0868928
the	O
authors	O
report	B-C0684224
the	O
cases	B-C0868928
of	O
two	O
young	B-C0332239
patients	B-C0030705
who	O
had	O
suffered	O
a	O
sporting	B-C0337205
accident	I-C0337205
with	O
posterior	B-C1265659
traumatic	I-C1265659
dislocation	I-C1265659
of	O
sternoclavicular	B-C0038291
joint	I-C0038291
.	O
	
in	O
one	O
of	O
the	O
patients	B-C0030705
closed	B-C0185500
reduction	I-C0185500
was	O
accomplished	O
by	O
keeping	O
the	O
limb	B-C0015385
in	O
a	O
sling	B-C0183346
.	O
	
the	O
second	O
patient	B-C0030705
,	O
after	O
reduction	B-C1293152
was	O
done	O
,	O
presented	O
recurrence	B-C0034897
of	O
the	O
dislocation	B-C1265659
,	O
thus	O
requiring	O
surgical	B-C0543467
treatment	I-C0543467
.	O
	
it	O
is	O
important	O
to	O
observe	O
the	O
relevance	B-C2347946
of	O
computed	B-C0040405
tomography	I-C0040405
to	O
help	O
diagnosing	B-C1704656
,	O
as	O
well	O
as	O
monitoring	O
the	O
reduction	B-C1293152
procedure	I-C1293152
.	O
	
the	O
objective	O
of	O
this	O
study	B-C2603343
was	O
to	O
demonstrate	O
two	O
different	O
types	O
of	O
treatment	B-C0087111
in	O
a	O
rare	B-C0522498
injury	B-C3263722
such	O
as	O
the	O
posterior	B-C1265659
dislocation	I-C1265659
of	O
sternoclavicular	B-C0038291
joint	I-C0038291
.	O
	
using	O
a	O
graphical	B-C1254363
risk	I-C1254363
tool	I-C1254363
to	O
examine	O
willingness	B-C0243095
to	I-C0243095
take	I-C0243095
migraine	B-C0149931
prophylactic	B-C0199176
medications	B-C0013227
many	O
migraine	B-C0149931
sufferers	B-C0030705
use	O
daily	B-C0332173
prophylactic	B-C0199176
therapy	I-C0199176
to	O
reduce	O
the	O
frequency	B-C0439603
of	O
their	O
headache	B-C0018681
attacks	O
.	O
	
the	O
food	B-C0041714
and	I-C0041714
drug	I-C0041714
administration	I-C0041714
has	O
approved	B-C0205540
several	B-C0439064
different	O
medications	B-C0013227
for	O
migraine	B-C0149931
prophylaxis	B-C0199176
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	B-C0030705
perceive	O
these	O
treatments	B-C0087111
to	O
provide	O
clinically	B-C0750502
significant	I-C0750502
benefits	B-C0814225
given	O
their	O
side	B-C0879626
effect	I-C0879626
profiles	B-C1979963
.	O
	
three	O
hundred	O
headache	B-C0018681
sufferers	B-C0030705
were	O
recruited	O
from	O
the	O
community	B-C0009462
and	O
local	B-C0205276
headache	B-C0018681
clinics	B-C0442592
using	O
print	B-C0033161
and	O
television	B-C0039461
advertising	B-C0001690
.	O
	
participants	B-C0679646
reported	O
experiencing	O
problematic	O
headache	B-C0018681
attacks	O
with	O
a	O
median	B-C0876920
iqr	O
frequency	B-C0439603
of	O
7.0	O
4-13	O
headache	B-C0018681
days	B-C0556971
per	I-C0556971
month	I-C0556971
.	O
	
these	O
sufferers	B-C0030705
participated	O
in	O
a	O
cross-sectional	B-C0010362
,	O
single-site	I-C0010362
,	O
study	I-C0010362
that	O
used	O
a	O
specially	O
designed	O
computer	O
assessment	O
task	O
.	O
	
participants	B-C0679646
were	O
instructed	O
on	O
the	O
probability	B-C0033204
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	B-C0879626
effects	I-C0879626
for	O
several	B-C0439064
blinded	B-C0150108
medication	B-C0013227
profiles	B-C1979963
divalproex	B-C0886883
sodium	I-C0886883
,	O
venlafaxine	B-C0078569
,	O
gabapentin	B-C0060926
,	O
propranolol	B-C0033497
,	O
and	O
topiramate	B-C0076829
.	O
	
after	O
learning	O
the	O
likelihood	B-C0033204
of	O
experiencing	O
side	B-C0879626
effect	I-C0879626
profiles	B-C1979963
of	O
each	O
medication	B-C0013227
,	O
participants	B-C0679646
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	B-C0243095
to	I-C0243095
take	I-C0243095
the	O
medication	B-C0013227
for	O
a	O
given	O
headache	B-C0018681
reduction	B-C0392756
level	B-C0441889
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	B-C0556971
per	I-C0556971
month	I-C0556971
.	O
	
the	O
side	B-C0879626
effect	I-C0879626
profile	B-C1979963
for	O
divalproex	B-C0886883
sodium	I-C0886883
was	O
associated	B-C0332281
with	I-C0332281
the	O
smallest	B-C0243095
willingness	I-C0243095
to	I-C0243095
take	I-C0243095
,	O
with	O
gabapentin	B-C0060926
,	O
propranolol	B-C0033497
,	O
and	O
topiramate	B-C0076829
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O
	
however	O
,	O
<60%	O
of	O
participants	B-C0679646
reported	O
willingness	B-C0243095
to	I-C0243095
take	I-C0243095
any	O
of	O
these	O
medications	B-C0013227
even	O
if	O
they	O
provided	O
a	O
50%	O
reduction	B-C0392756
in	O
headache	B-C0018681
frequency	B-C0439603
.	O
	
several	B-C0439064
general	O
predictors	B-C2698872
of	O
willingness	B-C0243095
to	I-C0243095
take	I-C0243095
were	O
observed	O
including	O
high	B-C0205250
headache	B-C0018681
-related	O
disability	B-C0231170
,	O
depressive	B-C0086132
symptoms	I-C0086132
,	O
and	O
pain	B-C0002771
medication	I-C0002771
concerns	B-C2699424
including	O
fear	B-C0015726
of	O
tolerance	B-C0220929
.	O
	
these	O
findings	B-C0243095
suggest	O
that	O
if	O
properly	O
informed	B-C1522154
of	O
the	O
side	B-C0879626
effect	I-C0879626
profiles	B-C1979963
of	O
these	O
medications	B-C0013227
,	O
many	O
patients	B-C0030705
might	O
opt	O
for	O
other	O
genome-wide	B-C2350277
detection	I-C2350277
of	O
selective	B-C0017393
signatures	I-C0017393
in	O
chicken	B-C0008051
through	O
high	B-C0752046
density	I-C0752046
snps	I-C0752046
chicken	B-C0008051
is	O
recognized	O
as	O
an	O
excellent	O
model	B-C0026339
for	O
studies	O
of	O
genetic	B-C0314603
mechanism	B-C0441712
of	O
phenotypic	B-C0031437
and	O
genomic	B-C0017428
evolution	B-C0015219
,	O
with	O
large	O
effective	O
population	B-C0032683
size	I-C0032683
and	O
strong	O
human	B-C0086418
-driven	O
selection	B-C1707391
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
performed	O
extended	B-C0545278
haplotype	I-C0545278
homozygosity	I-C0545278
ehh	B-C0545278
tests	O
to	O
identify	O
significant	O
core	B-C0004793
regions	I-C0004793
employing	O
600k	O
snp	B-C0752046
chicken	B-C0008051
chip	B-C3897601
in	O
an	O
f2	B-C0441833
population	I-C0441833
of	O
1	O
hens	B-C0005595
,	O
which	O
was	O
derived	O
from	O
reciprocal	B-C0010364
crosses	I-C0010364
between	O
white	B-C0008051
leghorn	I-C0008051
and	O
dongxiang	B-C0008051
chicken	I-C0008051
.	O
	
results	O
indicated	O
that	O
a	O
total	O
of	O
49	O
core	B-C0004793
regions	I-C0004793
with	O
an	O
average	O
length	B-C1444754
of	O
9.79	O
kb	O
were	O
identified	B-C0205396
,	O
which	O
occupied	O
approximately	O
52.15	O
of	O
genome	B-C0017428
across	O
all	O
autosomes	B-C0596142
,	O
and	O
806	O
significant	O
core	B-C0004793
regions	I-C0004793
attracted	O
us	O
mostly	O
.	O
	
genes	B-C0017337
in	O
candidate	B-C0004793
regions	I-C0004793
may	O
experience	O
positive	B-C2347644
selection	I-C2347644
and	O
were	O
considered	O
to	O
have	O
possible	O
influence	O
on	O
beneficial	O
economic	B-C0205556
traits	I-C0205556
.	O
	
a	O
panel	B-C0441833
of	O
genes	B-C0017337
including	O
aasdhppt	B-C1422497
,	O
gdpd5	B-C1539559
,	O
par3	B-C1414507
,	O
sox6	B-C1424266
,	O
gpc1	B-C1415193
and	O
a	O
signal	B-C0037080
pathway	I-C0037080
of	O
akt1	B-C0812228
were	O
detected	B-C0442726
with	O
the	O
most	O
extreme	O
p-values	B-C1709380
.	O
	
further	O
enrichment	B-C0936012
analyses	I-C0936012
indicated	O
that	O
these	O
genes	B-C0017337
were	O
associated	B-C0332281
with	I-C0332281
immune	B-C1817756
function	I-C1817756
,	O
sensory	B-C1160370
organ	I-C1160370
development	I-C1160370
and	O
neurogenesis	B-C0814002
,	O
and	O
may	O
have	O
experienced	O
positive	B-C2347644
selection	I-C2347644
in	O
chicken	B-C0008051
.	O
	
moreover	O
,	O
some	O
of	O
core	B-C0004793
regions	I-C0004793
exactly	O
overlapped	O
with	O
genes	B-C0017337
excavated	O
in	O
our	O
previous	O
gwas	B-C2350277
,	O
suggesting	O
that	O
these	O
genes	B-C0017337
have	O
undergone	O
positive	B-C2347644
selection	I-C2347644
may	O
affect	O
egg	B-C0013710
production	B-C0441655
.	O
	
findings	B-C2607943
in	O
our	O
study	O
could	O
draw	O
a	O
comparatively	O
integrate	O
genome-wide	B-C0079435
map	I-C0079435
of	O
selection	B-C0017393
signature	I-C0017393
in	O
the	O
chicken	B-C0008051
genome	B-C0017428
,	O
and	O
would	O
be	O
worthy	O
for	O
explicating	O
the	O
genetic	B-C0314603
mechanisms	B-C0441712
of	O
phenotypic	B-C0031437
diversity	B-C1880371
in	O
poultry	B-C0032850
breeding	B-C0006159
.	O
	
high-throughput	O
genotyping	B-C3178894
with	O
taqman	B-C3178894
allelic	I-C3178894
discrimination	I-C3178894
and	O
allele-specific	B-C3178894
genotyping	I-C3178894
assays	I-C3178894
real-time	B-C1709846
pcr	I-C1709846
-based	O
genotyping	B-C3178894
methods	I-C3178894
,	O
such	O
as	O
taqman	B-C3178894
allelic	I-C3178894
discrimination	I-C3178894
assays	I-C3178894
and	O
allele-specific	B-C3178894
genotyping	I-C3178894
,	O
are	O
particularly	O
useful	B-C3827682
when	O
screening	B-C0813145
a	O
handful	O
of	O
single	B-C0752046
nucleotide	I-C0752046
polymorphisms	I-C0752046
in	O
hundreds	O
of	O
samples	B-C0370003
either	O
derived	O
from	O
different	B-C1705242
individuals	B-C0027361
,	O
tissues	B-C0040300
,	O
or	O
pre	B-C0332152
-	O
amplified	B-C0683230
dna	I-C0683230
.	O
	
although	O
real-time	B-C1709846
pcr	I-C1709846
-	O
based	B-C1527178
methods	B-C0025663
such	O
as	O
taqman	B-C3178894
are	O
well-established	B-C0443211
,	O
alternative	B-C1523987
methods	B-C0025663
,	O
like	O
allele-specific	B-C3178894
genotyping	I-C3178894
,	O
are	O
powerful	O
alternatives	B-C1523987
,	O
especially	O
for	O
genotyping	B-C3178894
short	B-C1519302
tandem	I-C1519302
repeat	I-C1519302
str	B-C1519302
length	B-C1444754
polymorphisms	B-C0032529
.	O
	
here	O
,	O
we	O
describe	O
all	O
relevant	B-C2347946
aspects	B-C1521970
when	O
developing	B-C1527148
an	O
assay	B-C1510438
for	O
a	O
new	O
snp	B-C0752046
or	O
str	B-C1519302
using	O
either	O
taqman	B-C3178894
or	O
allele-specific	B-C3178894
genotyping	I-C3178894
,	O
respectively	O
,	O
such	O
as	O
primer	B-C0206416
and	O
probe	B-C0012893
design	O
,	O
optimization	B-C2698650
of	O
reaction	B-C0443286
conditions	B-C0348080
,	O
the	O
experimental	B-C3178894
procedure	I-C3178894
for	I-C3178894
typing	I-C3178894
hundreds	O
of	O
samples	B-C0370003
,	O
and	O
finally	O
the	O
data	B-C1511726
evaluation	B-C0220825
.	O
	
our	O
goal	B-C0018017
is	O
to	O
provide	B-C1999230
a	O
guideline	B-C0162791
for	O
developing	B-C1527148
genotyping	B-C3178894
assays	I-C3178894
using	O
these	O
two	O
approaches	B-C1292724
that	O
render	O
reliable	O
and	O
reproducible	B-C1514863
genotype	B-C3178894
calls	I-C3178894
involving	B-C1314939
minimal	B-C0547040
optimization	B-C2698650
.	O
	
the	O
role	O
of	O
p2x7	B-C0386482
receptors	I-C0386482
in	O
a	O
rodent	B-C0035804
pcp	B-C0031381
-	O
induced	B-C0205263
schizophrenia	B-C0036341
model	B-C0012644
p2x7	B-C0386482
receptors	I-C0386482
p2x7rs	B-C0386482
are	O
ligand-gated	B-C0815090
ion	I-C0815090
channels	I-C0815090
sensitive	B-C0332324
to	O
extracellular	B-C0521119
atp	B-C0001480
.	O
	
here	O
we	O
examined	B-C0332128
for	O
the	O
first	O
time	O
the	O
role	O
of	O
p2x7r	B-C0386482
in	O
an	O
animal	B-C0599779
model	I-C0599779
of	O
schizophrenia	B-C0036341
.	O
	
using	O
the	O
pcp	B-C0031381
induced	B-C0205263
schizophrenia	B-C0036341
model	B-C0012644
we	O
show	O
that	O
both	O
genetic	B-C1511760
deletion	I-C1511760
and	O
pharmacological	B-C0205464
inhibition	B-C3463820
of	O
p2x7rs	B-C0386482
alleviate	B-C1301676
schizophrenia-like	B-C0243095
behavioral	B-C0004927
alterations	B-C1515926
.	O
	
in	O
p2rx7+/+	B-C1418215
mice	B-C0025929
,	O
pcp	B-C0031381
induced	B-C0205263
hyperlocomotion	B-C3540840
,	O
stereotype	B-C0038271
behavior	I-C0038271
,	O
ataxia	B-C0004134
and	O
social	B-C0424095
withdrawal	I-C0424095
.	O
	
in	O
p2x7	B-C1418215
receptor	I-C1418215
deficient	B-C0011155
mice	B-C0206745
p2rx7-/-	B-C1418215
,	O
the	O
social	B-C0037420
interactions	I-C0037420
were	O
increased	B-C0205217
,	O
whereas	O
the	O
pcp	B-C0031381
induced	B-C0205263
hyperlocomotion	B-C3540840
and	O
stereotype	B-C0038271
behavior	I-C0038271
were	O
alleviated	B-C1301676
.	O
	
the	O
selective	O
p2x7	B-C2936582
receptor	I-C2936582
antagonist	I-C2936582
jnj-47965567	B-C2936582
partly	O
replicated	O
the	O
effect	B-C1280500
of	I-C1280500
gene	B-C1511760
deficiency	I-C1511760
on	O
pcp	B-C0031381
-	O
induced	B-C0205263
behavioral	B-C0542299
changes	I-C0542299
and	O
counteracted	O
pcp	B-C0031381
-	O
induced	B-C0205263
social	B-C0424095
withdrawal	I-C0424095
.	O
	
we	O
also	O
show	O
that	O
pcp	B-C0031381
treatment	B-C1522326
upregulates	B-C0041904
and	O
increases	B-C0442805
the	O
functional	B-C0205245
responsiveness	B-C0205342
of	O
p2x7rs	B-C0386482
in	O
the	O
prefrontal	B-C0162783
cortex	I-C0162783
of	O
young	B-C0238598
adult	I-C0238598
animals	B-C0003062
.	O
	
the	O
amplitude	B-C0678555
of	O
nmda	B-C0080093
evoked	B-C1444748
currents	B-C1705970
recorded	O
from	O
layer	B-C0206441
v	I-C0206441
pyramidal	I-C0206441
neurons	I-C0206441
of	O
cortical	B-C0007776
slices	O
were	O
slightly	O
decreased	B-C0205216
by	O
both	O
genetic	B-C1511760
deletion	I-C1511760
of	O
p2rx7	B-C1418215
and	O
by	O
jnj-47965567	B-C2936582
.	O
	
pcp	B-C0031381
induced	B-C0205263
alterations	B-C1515926
in	O
mrna	B-C1515670
expression	I-C1515670
encoding	O
schizophrenia-related	B-C0036341
genes	B-C0017337
,	O
such	O
as	O
nr2a	B-C1415299
,	O
nr2b	B-C1415300
,	O
neuregulin	B-C0626201
1	I-C0626201
,	O
nr1	B-C0914905
and	O
gaba	B-C1565610
α1	I-C1565610
subunit	O
were	O
absent	B-C0332197
in	O
the	O
pfc	O
of	O
young	B-C0238598
adult	I-C0238598
p2rx7-/-	B-C1418215
animals	B-C1517490
.	O
	
our	O
findings	B-C0243095
point	O
to	O
p2x7r	B-C0386482
as	O
a	O
potential	B-C3245505
therapeutic	B-C0302350
target	B-C1521840
in	O
the	O
flavor	B-C0982164
and	O
nutritional	B-C1521739
characteristic	B-C1521970
of	O
four	O
strawberry	B-C0457802
varieties	B-C1883525
cultured	B-C0001829
in	O
soilless	B-C0439861
system	I-C0439861
strawberry	B-C0457802
fruits	I-C0457802
cv	B-C0457802
.	O
	
benihoppe	I-C0457802
,	O
tochiotome	B-C0457802
,	O
sachinoka	B-C0457802
,	O
and	O
guimeiren	B-C0457802
were	O
harvested	O
and	O
evaluated	O
the	O
flavor	B-C0982164
and	O
nutritional	B-C1521739
parameters	B-C0549193
.	O
	
by	O
principal	B-C0429865
component	I-C0429865
analysis	I-C0429865
and	O
hierarchical	B-C1881045
clustering	I-C1881045
analysis	I-C1881045
,	O
differences	O
were	O
observed	O
based	O
on	O
the	O
volatile	B-C2350439
compounds	I-C2350439
composition	B-C0243176
,	O
sugar	B-C0242209
and	O
acid	B-C0369760
concentration	B-C1446561
,	O
sweetness	B-C0678582
,	O
and	O
total	B-C0242209
soluble	I-C0242209
sugars	I-C0242209
/	O
total	B-C0369760
organic	I-C0369760
acids	I-C0369760
of	O
the	O
four	O
varieties	B-C1883525
.	O
	
a	O
total	O
of	O
37	O
,	O
48	O
,	O
65	O
,	O
and	O
74	O
volatile	B-C2350439
compounds	I-C2350439
were	O
identified	B-C0205396
and	O
determined	B-C0521095
in	O
cv	B-C0457802
.	O
	
benihoppe	I-C0457802
,	O
tochiotome	B-C0457802
,	O
sachinoka	B-C0457802
,	O
and	O
guimeiren	B-C0457802
strawberry	I-C0457802
fruits	I-C0457802
extracted	B-C0185115
by	O
head-space	B-C1720881
solid-phase	I-C1720881
microextraction	I-C1720881
hs-spme	B-C1720881
,	O
respectively	O
.	O
	
esters	B-C0014898
significantly	O
dominated	O
the	O
chemical	B-C0243176
composition	I-C0243176
of	O
the	O
four	O
varieties	B-C1883525
.	O
	
furaneol	B-C0378287
was	O
detected	O
in	O
cultivars	B-C0032098
of	O
sachinoka	B-C0457802
and	O
guimeiren	B-C0457802
,	O
but	O
mesifuran	B-C0457802
was	O
only	O
found	O
in	O
cv	B-C0457802
.	O
	
tochiotome	I-C0457802
.	O
	
tochiotome	B-C0457802
and	O
sachinoka	B-C0457802
showed	O
higher	O
content	B-C1446561
of	O
linalool	B-C0064997
and	O
e	B-C0955941
.	O
	
sachinoka	B-C0457802
showed	O
the	O
highest	B-C0205250
content	B-C1446561
of	O
total	B-C0242209
sugars	I-C0242209
and	O
total	B-C0369760
acids	I-C0369760
.	O
	
guimeiren	B-C0457802
showed	O
higher	O
sweetness	B-C0678582
index	B-C0918012
than	O
the	O
other	O
three	O
cultivars	B-C0032098
.	O
	
firmness	B-C1545487
of	O
tochiotome	B-C0457802
was	O
highest	B-C0205250
among	O
all	O
the	O
varieties	B-C1883525
.	O
	
the	O
highest	B-C0205250
total	B-C0392762
soluble	I-C0392762
solids	I-C0392762
tss	I-C0392762
value	I-C0392762
was	O
found	O
in	O
cv	B-C0457802
.	O
	
sachinoka	I-C0457802
,	O
followed	O
by	O
the	O
guimeiren	B-C0457802
and	O
tochiotome	B-C0457802
varieties	B-C1883525
.	O
	
sachinoka	B-C0457802
had	O
the	O
highest	B-C0205250
titratable	B-C0368606
acidity	I-C0368606
ta	I-C0368606
value	I-C0368606
.	O
	
the	O
content	B-C1446561
of	O
ascorbic	B-C0003968
acid	I-C0003968
asa	B-C0003968
of	O
cv	B-C0457802
.	O
	
tochiotome	I-C0457802
was	O
higher	B-C0205250
than	O
the	O
others	O
,	O
but	O
there	O
was	O
no	B-C1273937
significant	I-C1273937
difference	B-C1705241
in	O
cultivars	B-C0032098
of	O
benihoppe	B-C0457802
,	O
tochiotome	B-C0457802
,	O
and	O
sachinoka	B-C0457802
.	O
	
fructose	B-C0016745
and	O
glucose	B-C0017725
were	O
the	O
major	O
sugars	B-C0242209
in	O
all	O
cultivars	B-C0032098
.	O
	
citric	B-C0055819
acid	I-C0055819
was	O
the	O
major	O
organic	B-C0369760
acid	I-C0369760
in	O
cv	B-C0457802
.	O
	
tochiotome	I-C0457802
,	O
cv	B-C0457802
.	O
	
sachinoka	I-C0457802
,	O
and	O
cv	B-C0457802
.	O
	
guimeiren	I-C0457802
.	O
	
tochiotome	B-C0457802
had	O
higher	B-C0205250
ratios	B-C0456603
of	O
tss	B-C1635078
/	O
ta	B-C0368606
and	O
total	B-C0242209
sugars	I-C0242209
/	O
total	B-C0369760
organic	I-C0369760
acids	I-C0369760
than	O
others	O
,	O
arising	O
from	O
its	O
lower	O
acid	B-C0369760
content	B-C1446561
.	O
	
the	O
order	O
of	O
the	O
comprehensive	B-C0449820
evaluation	I-C0449820
score	I-C0449820
was	O
sachinoka	B-C0457802
>	O
guimeiren	B-C0457802
>	O
tochiotome	B-C0457802
>	O
prognostic	B-C0449821
value	I-C0449821
of	O
glut-1	B-C0168458
expression	B-C1171362
in	O
oral	B-C0585362
squamous	I-C0585362
cell	I-C0585362
carcinoma	I-C0585362
a	O
prisma-compliant	B-C0282574
meta-analysis	I-C0282574
a	O
variety	O
of	O
studies	B-C2603343
have	O
evaluated	B-C0220825
the	O
correlation	B-C1707520
between	O
glucose	B-C0168458
transporter-1	I-C0168458
glut-1	B-C0168458
expression	B-C1171362
and	O
prognosis	B-C0033325
of	O
oral	B-C0585362
squamous	I-C0585362
cell	I-C0585362
carcinoma	I-C0585362
oscc	B-C0585362
however	O
,	O
the	O
results	B-C1274040
were	O
inconsistent	B-C0442809
and	O
inconclusive	B-C1629507
.	O
	
a	O
meta-analysis	B-C0920317
was	O
performed	O
to	O
assess	B-C0184514
the	O
prognostic	B-C0220901
significance	B-C0750502
of	O
glut-1	B-C0168458
in	O
oscc	B-C0585362
.	O
	
electronic	B-C3841595
databases	I-C3841595
of	O
pubmed	B-C1138432
,	O
embase	B-C0282574
,	O
and	O
web	B-C0282574
of	I-C0282574
science	I-C0282574
were	O
searched	O
for	O
relevant	B-C2603343
studies	I-C2603343
.	O
	
the	O
last	O
search	O
was	O
updated	O
on	O
july	B-C3829447
2016	O
.	O
	
odds	B-C0028873
ratio	I-C0028873
or	B-C0028873
and	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
were	O
pooled	O
to	O
evaluate	B-C0220825
the	O
relationship	B-C1705630
between	O
glut-1	B-C0168458
and	O
clinical	B-C3810252
features	I-C3810252
and	O
hazard	B-C2985465
ratio	I-C2985465
hr	B-C2985465
and	O
95%	O
ci	B-C0009667
were	O
combined	O
to	O
measure	B-C0079809
the	O
effect	B-C1280500
of	O
glut-1	B-C0168458
on	O
overall	B-C4086681
survival	I-C4086681
os	B-C4086681
.	O
	
p	O
value	O
<	O
0.05	O
was	O
considered	O
as	O
statistically	B-C0237881
significant	I-C0237881
.	O
	
a	O
total	O
of	O
13	O
studies	B-C2603343
with	O
1301	O
subjects	B-C0080105
were	O
included	O
for	O
meta-analysis	B-C0920317
.	O
	
the	O
pooled	B-C1511726
data	I-C1511726
showed	O
that	O
high	O
glut-1	B-C0168458
expression	B-C1171362
was	O
associated	B-C0332281
with	I-C0332281
advanced	B-C1300072
tumor	I-C1300072
stages	I-C1300072
n	O
=	O
7	O
,	O
or	B-C0028873
=	O
2.99	O
,	O
95%	O
ci	B-C0009667
2.01	O
,	O
p	O
<	O
0.001	O
,	O
higher	B-C0441800
tumor	I-C0441800
grade	I-C0441800
n	O
=	O
5	O
,	O
or	B-C0028873
=	O
3.34	O
,	O
95%	O
ci	B-C0009667
1.12	O
,	O
p	O
=	O
0.031	O
,	O
tumor	B-C0475440
size	I-C0475440
n	O
=	O
5	O
,	O
or	B-C0028873
=	O
3.36	O
,	O
95%	O
ci	B-C0009667
2.04	O
,	O
p	O
<	O
0.001	O
,	O
lymph	B-C0332397
node	I-C0332397
metastasis	I-C0332397
n	O
=	O
5	O
,	O
or	B-C0028873
=	O
3.15	O
,	O
95%	O
ci	B-C0009667
1.89	O
,	O
p	O
<	O
0.001	O
,	O
tobacco	B-C0543414
use	I-C0543414
n	O
=	O
3	O
,	O
or	B-C0028873
=	O
2.18	O
,	O
95%	O
ci	B-C0009667
1.18	O
,	O
p	O
=	O
0.013	O
,	O
and	O
distant	B-C1302548
metastasis	I-C1302548
n	O
=	O
2	O
,	O
or	B-C0028873
=	O
3.06	O
,	O
95%	O
ci	B-C0009667
1.19	O
,	O
p	O
=	O
0.02	O
.	O
	
furthermore	O
,	O
increased	B-C0205217
glut-1	B-C0168458
expression	B-C1171362
was	O
also	O
correlated	B-C1707520
with	O
shorter	B-C4086681
os	I-C4086681
n	O
=	O
8	O
,	O
hr	B-C2985465
=	O
1.88	O
,	O
95%	O
ci	B-C0009667
1.51	O
,	O
p	O
<	O
0.001	O
.	O
	
no	O
significant	B-C0206086
publication	I-C0206086
bias	I-C0206086
was	O
detected	B-C0442726
in	O
this	O
meta-analysis	B-C0920317
.	O
	
glut-1	B-C0168458
overexpression	B-C1514559
was	O
in	O
connection	O
with	O
aggressive	B-C3810252
clinical	I-C3810252
features	I-C3810252
and	O
worse	B-C4086681
os	I-C4086681
in	O
oscc	B-C0585362
.	O
	
however	O
,	O
further	O
studies	B-C2603343
are	O
still	O
needed	O
to	O
verify	O
whether	O
glut-1	B-C0168458
could	O
serve	O
as	O
a	O
prognostic	B-C0220901
biomarker	B-C0005516
for	O
biogeography	B-C2936603
and	O
character	O
evolution	B-C0282688
of	O
the	O
ciliate	B-C0008781
genus	B-C1708235
euplotes	B-C0085343
spirotrichea	B-C1004715
,	O
euplotia	B-C0085343
,	O
with	O
description	B-C0678257
of	O
euplotes	B-C0085343
curdsi	I-C0085343
sp	I-C0085343
.	O
	
nov	I-C0085343
ciliates	B-C0008781
comprise	O
a	O
diverse	B-C1880371
and	O
ecologically	B-C0870460
important	B-C3898777
phylum	B-C1709533
of	O
unicellular	B-C0597305
protists	I-C0597305
.	O
	
one	O
of	O
the	O
most	O
specious	O
and	O
best-defined	O
genera	B-C1708235
is	O
euplotes	B-C0085343
,	O
which	O
constitutes	O
more	O
than	O
70	O
morphospecies	B-C1705920
,	O
many	O
of	O
which	O
have	O
never	O
been	O
molecularly	B-C0039593
tested	I-C0039593
.	O
	
the	O
increasing	O
number	O
of	O
described	O
euplotes	B-C0085343
taxa	B-C1515221
emphasizes	O
the	O
importance	O
for	O
detailed	O
characterizations	B-C1880022
of	O
new	O
ones	O
,	O
requiring	O
standardized	O
morphological	B-C0543482
observations	B-C0302523
,	O
sequencing	B-C1561491
of	O
molecular	B-C0005516
markers	I-C0005516
and	O
careful	O
comparison	B-C1707455
with	O
previous	O
literature	B-C0023866
.	O
	
here	O
we	O
describe	O
euplotes	B-C0085343
curdsi	I-C0085343
sp	I-C0085343
.	O
	
nov	I-C0085343
distinguishable	B-C0205615
by	O
the	O
combination	B-C0205195
of	O
the	O
following	O
features	B-C2348519
45-65	O
μm	O
length	B-C1444754
,	O
oval	B-C0332437
or	I-C0332437
elongated	I-C0332437
shape	I-C0332437
with	O
both	O
ends	O
rounded	O
,	O
narrow	B-C0332437
peristome	I-C0332437
with	O
25-34	O
adoral	B-C0332437
membranelles	I-C0332437
,	O
conspicuous	B-C0596901
paroral	I-C0596901
membrane	I-C0596901
,	O
double-eurystomus	B-C0332437
dorsal	I-C0332437
argyrome	I-C0332437
type	I-C0332437
,	O
6-7	O
dorsolateral	B-C0332437
kineties	I-C0332437
and	O
10	O
frontoventral	B-C0332437
cirri	I-C0332437
.	O
	
three	O
populations	B-C0032659
of	O
the	O
novel	O
species	B-C1705920
have	O
been	O
found	O
in	O
brackish	B-C0337056
and	O
marine	B-C0017446
samples	I-C0017446
in	O
the	O
mediterranean	B-C0025138
and	O
the	O
white	B-C0017446
sea	I-C0017446
.	O
	
we	O
provide	O
the	O
ssu	B-C0017337
rrna	I-C0017337
gene	I-C0017337
sequences	B-C1517495
of	O
these	O
populations	B-C0032659
,	O
and	O
an	O
updated	O
phylogeny	B-C0031797
of	O
the	O
genus	B-C1708235
euplotes	B-C0085343
.	O
	
using	O
the	O
molecular	B-C1521991
phylogenetic	B-C0205556
tree	I-C0205556
,	O
we	O
inferred	O
aspects	B-C1879746
of	O
the	O
biogeographical	B-C0019665
history	I-C0019665
of	O
the	O
genus	B-C1708235
and	O
the	O
evolution	B-C0282688
of	O
its	O
most	O
important	O
taxonomic	B-C0008903
characters	B-C1521970
in	O
order	O
to	O
provide	O
a	O
frame	O
for	O
future	O
descriptions	B-C0678257
.	O
	
ultimately	O
,	O
these	O
data	B-C1511726
reveal	O
recurrent	B-C2945760
trends	B-C1521798
of	O
freshwater	B-C0016710
invasion	O
and	O
highlight	O
the	O
dynamic	O
,	O
yet	O
convergent	O
,	O
morphological	B-C0543482
evolution	B-C0282688
of	O
comparative	B-C2718022
effectiveness	I-C2718022
of	O
treatments	B-C0087111
for	O
chronic	B-C0457949
low	I-C0457949
back	I-C0457949
pain	I-C0457949
a	O
multiple	B-C4277638
treatment	I-C4277638
comparison	I-C4277638
analysis	I-C4277638
a	O
systematic	B-C1955832
review	I-C1955832
and	O
network	B-C4277638
meta-analysis	I-C4277638
.	O
	
to	O
determine	O
current	B-C2827774
treatment	I-C2827774
options	I-C2827774
of	O
chronic	B-C0457949
low	I-C0457949
back	I-C0457949
pain	I-C0457949
lbp	B-C0457949
as	O
defined	O
by	O
randomized	B-C0206035
controlled	I-C0206035
trials	I-C0206035
rcts	B-C0206035
and	O
to	O
compare	B-C1707455
effectiveness	B-C1280519
of	O
those	O
treatments	B-C0087111
using	O
a	O
mixed-treatment	B-C4277638
comparison	I-C4277638
mtc	B-C4277638
.	O
	
it	O
is	O
important	O
to	O
provide	O
an	O
evidence-based	B-C3887511
assessment	B-C0220825
of	O
the	O
treatment	B-C0683525
options	I-C0683525
that	O
exist	O
for	O
lbp	B-C0457949
.	O
	
a	O
systematic	B-C0035168
search	I-C0035168
of	O
rcts	B-C0206035
was	O
conducted	O
in	O
medline	B-C0025141
and	O
the	O
cochrane	B-C0023621
collaboration	I-C0023621
library	I-C0023621
from	O
1990	O
to	O
2014	O
.	O
	
from	O
the	O
selected	B-C2603343
studies	I-C2603343
,	O
we	O
extracted	O
preoperative	B-C0445204
and	O
postoperative	B-C0032790
odi	B-C2960603
and	O
vas	B-C2732809
back	I-C2732809
pain	I-C2732809
scores	I-C2732809
,	O
additional	B-C2081627
surgeries	I-C2081627
,	O
and	O
complications	B-C0009566
.	O
	
standard	B-C4277638
and	I-C4277638
network	I-C4277638
meta-analytic	I-C4277638
techniques	I-C4277638
were	O
used	O
.	O
	
twelve	O
rcts	B-C0206035
were	O
included	O
in	O
the	O
analysis	B-C0936012
5	O
total	B-C2144940
disk	I-C2144940
replacement	I-C2144940
tdr	B-C2144940
versus	O
fusion	B-C0186045
1	O
tdr	B-C2144940
versus	O
exercise	B-C1522704
and	O
cognitive	B-C0009244
behavioral	I-C0009244
therapy	I-C0009244
cbt	B-C0009244
5	O
fusion	B-C0186045
versus	O
exercise	B-C1522704
and	O
cbt	B-C0009244
and	O
1	O
fusion	B-C0186045
versus	O
physical	B-C0949766
therapy	I-C0949766
pt	B-C0949766
.	O
	
on	O
the	O
basis	O
of	O
mtc	B-C4277638
,	O
with	O
respect	O
to	O
odi	B-C2960603
change	I-C2960603
scores	I-C2960603
,	O
the	O
pooled	B-C1705241
mean	I-C1705241
difference	I-C1705241
favoring	O
fusion	B-C0186045
over	O
exercise	B-C1522704
and	O
cbt	B-C0009244
was	O
2.0	O
points	O
95%	O
ci	O
,	O
-1	O
to	O
4.8	O
.	O
	
the	O
pooled	B-C1705241
mean	I-C1705241
difference	I-C1705241
favoring	O
tdr	B-C2144940
over	O
exercise	B-C1522704
and	O
cbt	B-C0009244
was	O
6.4	O
points	O
95%	O
ci	O
,	O
3.2	O
.	O
	
the	O
pooled	B-C1705241
mean	I-C1705241
difference	I-C1705241
favoring	O
fusion	B-C0186045
over	O
pt	B-C0949766
was	O
8.8	O
points	O
95%	O
ci	O
,	O
4.1	O
.	O
	
the	O
pooled	B-C1705241
mean	I-C1705241
differences	I-C1705241
favoring	O
tdr	B-C2144940
over	O
fusion	B-C0186045
was	O
4.4	O
points	O
95%	O
ci	O
,	O
2.37	O
.	O
	
for	O
pt	B-C0949766
versus	O
structured	B-C1522704
exercise	I-C1522704
with	O
cbt	B-C0009244
,	O
the	O
pooled	B-C1705241
mean	I-C1705241
difference	I-C1705241
favoring	O
exercise	B-C1522704
with	O
cbt	B-C0009244
over	O
pt	B-C0949766
was	O
6.8	O
points	O
95%	O
ci	O
,	O
1.5	O
.	O
	
for	O
tdr	B-C2144940
versus	O
pt	B-C0949766
,	O
the	O
pooled	B-C1705241
mean	I-C1705241
difference	I-C1705241
favoring	O
tdr	B-C2144940
over	O
pt	B-C0949766
was	O
13.2	O
points	O
95%	O
ci	O
,	O
8.0	O
.	O
	
additional	O
surgery	B-C1521828
rates	I-C1521828
were	O
similar	O
between	O
treatment	B-C0683525
options	I-C0683525
.	O
	
all	O
4	O
treatments	B-C0087111
provided	O
some	O
benefit	B-C0814225
to	O
patients	B-C0030705
with	O
chronic	B-C0457949
lbp	I-C0457949
.	O
	
according	O
to	O
the	O
mtc	B-C4277638
analysis	I-C4277638
,	O
tdr	B-C2144940
may	O
be	O
the	O
most	B-C1704419
effective	I-C1704419
treatment	B-C0087111
and	O
pt	B-C0949766
the	O
least	B-C1704419
effective	I-C1704419
treatment	B-C0087111
for	O
chronic	B-C0457949
lbp	I-C0457949
.	O
	
this	O
review	B-C0282443
is	O
based	O
on	O
a	O
limited	B-C0449788
number	I-C0449788
of	O
rct	B-C0206035
studies	I-C0206035
and	O
does	O
not	O
support	O
any	O
1	O
treatment	B-C0087111
modality	B-C0695347
for	O
all	O
a	O
novel	O
selective	O
inhibitor	B-C0014432
of	O
delta-5	B-C0057338
desaturase	I-C0057338
lowers	O
insulin	B-C0021655
resistance	I-C0021655
and	O
reduces	B-C1262477
body	I-C1262477
weight	I-C1262477
in	O
diet	B-C0012155
-induced	O
obese	B-C0028754
c57bl/6j	B-C1521751
mice	I-C1521751
obesity	B-C0028754
is	O
now	O
recognized	O
as	O
a	O
state	O
of	O
chronic	O
low-grade	O
inflammation	B-C0021368
and	O
is	O
called	O
as	O
metabolic	B-C0311400
inflammation	B-C0021368
.	O
	
delta-5	B-C0057338
desaturase	I-C0057338
d5d	B-C0057338
is	O
an	O
enzyme	B-C0014442
that	O
metabolizes	O
dihomo-γ-linolenic	B-C0000658
acid	I-C0000658
dgla	B-C0000658
to	O
arachidonic	B-C0003695
acid	I-C0003695
aa	B-C0003695
.	O
	
thus	O
,	O
d5d	B-C0057338
inhibition	B-C1524081
increases	O
dgla	B-C0000658
precursor	O
to	O
anti-inflammatory	B-C1515999
eicosanoids	B-C0013725
while	O
decreasing	O
aa	B-C0003695
precursor	O
to	O
pro-inflammatory	O
eicosanoids	B-C0013725
,	O
and	O
could	O
result	O
in	O
synergistic	B-C2986495
improvement	B-C2986411
in	O
the	O
low-grade	O
inflammatory	O
state	O
.	O
	
here	O
,	O
we	O
demonstrate	O
reduced	B-C0392756
insulin	B-C0021655
resistance	I-C0021655
and	O
the	O
anti-obesity	B-C0376607
effect	O
of	O
a	O
d5d	B-C0057338
selective	O
inhibitor	O
compound-326	B-C1254351
,	O
an	O
orally	B-C0442027
active	O
small-molecule	B-C1328819
,	O
in	O
a	O
high-fat	B-C0453819
diet	I-C0453819
-induced	O
obese	B-C0025933
dio	I-C0025933
mouse	I-C0025933
model	B-C0012644
.	O
	
in	O
vivo	O
d5d	B-C0057338
inhibition	B-C1524081
was	O
confirmed	O
by	O
determining	O
changes	O
in	O
blood	B-C0005767
aa	B-C0003695
/	O
dgla	B-C0000658
profiles	B-C2022317
.	O
	
in	O
dio	B-C0025933
mice	I-C0025933
,	O
chronic	O
treatment	O
with	O
compound-326	B-C1254351
lowered	O
insulin	B-C0021655
resistance	I-C0021655
and	O
caused	O
body	B-C1262477
weight	I-C1262477
loss	I-C1262477
without	O
significant	O
impact	O
on	O
cumulative	O
calorie	B-C4281687
intake	I-C4281687
.	O
	
decreased	O
macrophage	B-C4014887
infiltration	I-C4014887
into	I-C4014887
adipose	I-C4014887
tissue	I-C4014887
was	O
expected	O
from	O
mrna	B-C0872262
analysis	I-C0872262
.	O
	
increased	O
daily	O
energy	B-C0014272
expenditure	I-C0014272
was	O
also	O
observed	O
following	O
administration	B-C1533734
of	O
compound-326	B-C1254351
,	O
in	O
line	O
with	O
sustained	O
body	B-C1262477
weight	I-C1262477
loss	I-C1262477
.	O
	
these	O
data	O
indicate	O
that	O
the	O
novel	O
d5d	B-C0057338
selective	O
inhibitor	B-C0014432
,	O
compound-326	B-C1254351
,	O
will	O
be	O
a	O
new	O
class	O
of	O
drug	O
for	O
the	O
treatment	O
of	O
obese	B-C0028754
and	O
diabetic	B-C0011847
patients	B-C0030705
.	O
	
blood	B-C0184104
collection	I-C0184104
tubes	I-C0184104
and	O
storage	B-C3640194
temperature	I-C3640194
should	O
be	O
evaluated	O
when	O
using	O
the	O
siemens	B-C3831595
advia	I-C3831595
centaur	I-C3831595
xp	I-C3831595
for	O
measuring	B-C2984945
25-hydroxyvitamin	I-C2984945
d	I-C2984945
a	O
significant	O
bias	O
was	O
found	O
when	O
using	O
the	O
siemens	B-C3831595
advia	I-C3831595
centaur	I-C3831595
xp	I-C3831595
system	O
for	O
measurement	B-C2984945
of	I-C2984945
25-hydroxyvitamin	I-C2984945
d	I-C2984945
25ohd	B-C0535968
with	O
vacuette	B-C0184104
tubes	I-C0184104
with	I-C0184104
serum	I-C0184104
clot	I-C0184104
activator	I-C0184104
and	I-C0184104
gel	I-C0184104
.	O
	
here	O
,	O
we	O
examined	O
whether	O
other	O
commonly	O
used	O
tubes	B-C0184104
or	O
temperatures	B-C0039476
affected	O
25ohd	B-C2984945
results	I-C2984945
obtained	O
with	O
the	O
siemens	B-C3831595
advia	I-C3831595
centaur	I-C3831595
xp	I-C3831595
system	O
.	O
	
serum	B-C0229671
was	O
collected	O
into	O
five	O
types	O
of	O
vacuum	B-C0184104
blood	I-C0184104
collection	I-C0184104
tubes	I-C0184104
from	O
three	O
manufacturers	O
,	O
and	O
25ohd	B-C2984945
was	I-C2984945
analyzed	I-C2984945
using	O
the	O
siemens	B-C3831595
advia	I-C3831595
centaur	I-C3831595
xp	I-C3831595
system	O
and	O
liquid	B-C4049918
chromatography	I-C4049918
tandem	I-C4049918
mass	I-C4049918
spectrometry	I-C4049918
lc-ms/ms	B-C4049918
immediately	O
or	O
after	O
storage	O
at	O
4	O
or	O
-80	O
for	O
48	O
h	O
.	O
	
significantly	B-C4055638
higher	I-C4055638
25ohd	B-C2984945
values	I-C2984945
were	O
found	O
when	O
using	O
the	O
siemens	B-C3831595
advia	I-C3831595
centaur	I-C3831595
xp	I-C3831595
system	O
with	O
vacuette	B-C0184104
tubes	I-C0184104
with	I-C0184104
serum	I-C0184104
clot	I-C0184104
activator	I-C0184104
and	I-C0184104
gel	I-C0184104
and	O
vacuette	B-C0184104
tubes	I-C0184104
with	I-C0184104
clot	I-C0184104
activator	I-C0184104
but	O
no	O
gel	O
compared	O
with	O
vacuette	B-C0184104
tubes	I-C0184104
with	O
no	O
additives	O
.	O
	
the	O
25ohd	B-C2984945
values	I-C2984945
in	O
all	O
of	O
these	O
tubes	O
were	O
not	O
significantly	O
different	O
from	O
those	O
obtained	O
by	O
lc-ms/ms	B-C4049918
.	O
	
moreover	O
,	O
after	O
storage	O
at	O
-80	O
for	O
48	O
h	O
,	O
the	O
values	O
obtained	O
in	O
improvevacuter	B-C0184104
tubes	I-C0184104
with	I-C0184104
serum	I-C0184104
clot	I-C0184104
activator	I-C0184104
and	I-C0184104
ge	I-C0184104
l	O
significantly	B-C4055637
increased	I-C4055637
,	O
with	O
a	O
mean	O
bias	O
of	O
74.6	O
compared	O
with	O
the	O
values	O
before	O
storage	O
,	O
on	O
analysis	O
with	O
the	O
siemens	B-C3831595
advia	I-C3831595
centaur	I-C3831595
xp	I-C3831595
system	O
.	O
	
vacuette	B-C0184104
tubes	I-C0184104
containing	O
additives	O
significantly	O
affect	O
the	O
accuracy	O
of	O
25ohd	B-C2984945
results	I-C2984945
obtained	O
using	O
the	O
siemens	B-C3831595
advia	I-C3831595
centaur	I-C3831595
xp	I-C3831595
system	O
.	O
	
additionally	O
,	O
the	O
composition	O
of	O
serum	B-C0229671
collected	O
in	O
improvevacuter	B-C0184104
tubes	I-C0184104
was	O
affected	O
by	O
freezing	B-C0016701
,	O
resulting	O
in	O
different	O
measurements	O
when	O
using	O
the	O
siemens	O
25ohd	B-C0535968
assay	B-C3273359
platform	I-C3273359
.	O
	
evolution	B-C0015219
of	O
fitness	B-C3824713
cost-neutral	B-C0243095
mutant	B-C0596988
pfcrt	B-C0962247
conferring	O
p	B-C0032150
.	O
	
falciparum	I-C0032150
4-aminoquinoline	B-C0048060
drug	B-C0013203
resistance	I-C0013203
is	O
accompanied	O
by	O
altered	B-C0392747
parasite	B-C0030498
metabolism	B-C0025519
and	O
digestive	B-C1167024
vacuole	I-C1167024
physiology	B-C0031842
southeast	B-C0003983
asia	I-C0003983
is	O
an	O
epicenter	O
of	O
multidrug-resistant	B-C0242640
plasmodium	B-C0032150
falciparum	I-C0032150
strains	I-C0032150
.	O
	
selective	O
pressures	O
on	O
the	O
subcontinent	O
have	O
recurrently	O
produced	O
several	O
allelic	B-C0002085
variants	B-C0678941
of	O
parasite	B-C0030498
drug	B-C0013203
resistance	I-C0013203
genes	B-C0017337
,	O
including	O
the	O
p	B-C0017337
.	O
	
falciparum	I-C0017337
chloroquine	I-C0017337
resistance	I-C0017337
transporter	I-C0017337
pfcrt	B-C0017337
.	O
	
despite	O
significant	O
reductions	B-C0441610
in	O
the	O
deployment	B-C2825812
of	O
the	O
4-aminoquinoline	B-C0048060
drug	B-C1254351
chloroquine	B-C0008269
cq	B-C0008269
,	O
which	O
selected	O
for	O
the	O
mutant	B-C0678941
pfcrt	B-C0017337
alleles	B-C0002085
that	O
halted	O
cq	B-C0008269
efficacy	B-C1280519
decades	O
ago	O
,	O
the	O
parasite	B-C0030498
pfcrt	B-C0017337
locus	B-C1708726
is	O
continuously	O
evolving	O
.	O
	
this	O
is	O
highlighted	O
by	O
the	O
presence	O
of	O
a	O
highly	B-C0205250
mutated	B-C0026882
allele	B-C0002085
,	O
cam734	B-C0017337
pfcrt	I-C0017337
,	O
which	O
has	O
acquired	O
the	O
singular	O
ability	O
to	O
confer	O
parasite	B-C0030498
cq	B-C0008269
resistance	B-C0013203
without	O
an	O
associated	O
fitness	B-C3824713
cost	B-C4049986
.	O
	
here	O
,	O
we	O
used	O
pfcrt	B-C0017337
-specific	O
zinc-finger	B-C0597094
nucleases	I-C0597094
to	O
genetically	B-C0205239
dissect	I-C0205239
this	O
allele	B-C0002085
in	O
the	O
pathogenic	B-C3816499
setting	O
of	O
asexual	B-C3714514
blood-stage	I-C3714514
infection	I-C3714514
.	O
	
comparative	B-C0683941
analysis	I-C0683941
of	O
drug	B-C0013203
resistance	I-C0013203
and	O
growth	B-C0018270
profiles	O
of	O
recombinant	B-C0030498
parasites	I-C0030498
that	O
express	B-C0017262
cam734	B-C0017337
or	O
variants	B-C0678941
thereof	O
,	O
dd2	B-C0017337
the	O
most	O
common	O
southeast	B-C0003983
asian	I-C0003983
variant	B-C0678941
,	O
or	O
wild-type	B-C1883559
pfcrt	B-C0017337
,	O
revealed	O
previously	O
unknown	O
roles	O
for	O
pfcrt	B-C0962247
mutations	B-C0026882
in	O
modulating	O
parasite	B-C0030498
susceptibility	O
to	O
multiple	O
antimalarial	B-C0003374
agents	I-C0003374
.	O
	
these	O
results	O
were	O
generated	O
in	O
the	O
gc03	B-C0017337
strain	B-C1518614
,	O
used	O
in	O
multiple	O
earlier	O
pfcrt	B-C0017337
studies	B-C2603343
,	O
and	O
might	O
differ	O
in	O
natural	O
isolates	O
harboring	O
this	O
allele	B-C0002085
.	O
	
results	O
presented	O
herein	O
show	O
that	O
cam734	B-C0017337
-mediated	O
cq	B-C0008269
resistance	B-C0013203
is	O
dependent	O
on	O
the	O
rare	O
a144f	B-C0026882
mutation	B-C0026882
that	O
has	O
not	O
been	O
observed	O
beyond	O
southeast	B-C0003983
asia	I-C0003983
,	O
and	O
reveal	O
distinct	O
impacts	B-C4049986
of	O
this	O
and	O
other	O
cam734	B-C0017337
-specific	O
mutations	B-C0026882
on	O
cq	B-C0008269
resistance	B-C0013203
and	O
parasite	B-C0030498
growth	B-C0449249
rates	I-C0449249
.	O
	
biochemical	B-C0005507
assays	I-C0005507
revealed	O
a	O
broad	O
impact	B-C4049986
of	O
mutant	B-C0596988
pfcrt	B-C0962247
isoforms	B-C0597298
on	O
parasite	B-C0030498
metabolism	B-C0025519
,	O
including	O
nucleoside	B-C0597106
triphosphate	I-C0597106
levels	B-C0441889
,	O
hemoglobin	B-C1157963
catabolism	I-C1157963
and	O
disposition	O
of	O
heme	B-C0018966
,	O
as	O
well	O
as	O
digestive	B-C1167024
vacuole	I-C1167024
volume	B-C0449468
and	O
ph	B-C0020283
.	O
	
results	O
from	O
our	O
study	O
provide	O
new	O
insights	O
into	O
the	O
complex	B-C4246449
molecular	I-C4246449
basis	I-C4246449
and	O
physiological	B-C0205463
impact	B-C4049986
of	O
pfcrt	B-C0962247
-mediated	O
antimalarial	B-C0003374
drug	B-C0013203
resistance	I-C0013203
,	O
and	O
inform	O
ongoing	O
efforts	O
to	O
characterize	O
novel	O
pfcrt	B-C0017337
alleles	B-C0002085
that	O
can	O
undermine	O
the	O
efficacy	B-C1280519
of	O
first-line	O
antimalarial	B-C0003374
drug	I-C0003374
regimens	B-C0040808
.	O
	
effect	B-C1280500
of	O
nutritionally	B-C0392209
induced	I-C0392209
hyperlipidaemia	B-C0020473
on	O
in	B-C1533691
vitro	I-C1533691
bovine	B-C3667982
embryo	B-C0013935
quality	O
depends	O
on	O
the	O
type	O
of	O
major	O
fatty	B-C0015684
acid	I-C0015684
in	O
the	O
diet	B-C0012155
the	O
present	O
study	B-C2603343
examined	B-C0332128
whether	O
the	O
effects	B-C1704420
of	I-C1704420
dietary	B-C0012155
-induced	O
hyperlipidaemia	B-C0020473
on	O
preimplantation	B-C1446949
embryo	I-C1446949
development	I-C1446949
depend	O
on	O
the	O
predominant	O
fatty	B-C0015684
acid	I-C0015684
fa	B-C0015684
type	O
in	O
the	O
diet	B-C0012155
.	O
	
in	O
a	O
combined	O
in	B-C1515655
vivo	I-C1515655
-	O
in	B-C1533691
vitro	I-C1533691
bovine	B-C3667982
model	B-C0599779
,	O
two	O
groups	O
of	O
cows	B-C0007452
n=3	O
in	O
each	O
group	O
were	O
fed	B-C3853577
with	O
three	O
diets	B-C0012155
consecutively	O
4	O
weeks	O
feeding	B-C2987508
for	O
each	O
1	O
a	O
maintenance	B-C0012155
control	I-C0012155
diet	I-C0012155
cont	B-C0012155
2	O
a	O
high	B-C0205250
-	O
starch	B-C0311120
diet	B-C0012155
rich	O
in	O
saturated	B-C0597423
fat	I-C0597423
sat	B-C0597423
and	O
3	O
a	O
high	B-C0205250
-	O
starch	B-C0311120
diet	B-C0012155
rich	O
in	O
omega-3	B-C0015689
unsaturated	B-C0012172
fat	I-C0012172
unsat	B-C0012172
.	O
	
two	O
feeding	B-C2987508
sequences	B-C1519249
were	O
used	O
to	O
test	O
for	O
carry-over	O
effects	O
group	O
a	O
was	O
fed	B-C3853577
cont	B-C0012155
,	O
sat1	B-C0597423
and	O
then	O
unsat2	B-C0012172
,	O
whereas	O
group	O
b	O
was	O
fed	B-C3853577
cont	B-C0012155
,	O
unsat1	B-C0012172
and	O
then	O
sat2	B-C0597423
.	O
	
serum	B-C0229671
was	O
collected	O
after	O
each	O
dietary	B-C0012155
period	B-C1948053
,	O
analysed	B-C0936012
and	O
tested	B-C0039593
in	O
bovine	B-C3667982
in	B-C1533691
vitro	I-C1533691
embryo	B-C0920489
culture	I-C0920489
.	O
	
introducing	O
sat	B-C0597423
and	O
unsat	B-C0012172
diets	B-C0012155
induced	O
hyperlipidaemia	B-C0020473
specifically	O
hypercholesterolaemia	B-C0020443
and	O
elevated	O
free	B-C0015688
fas	I-C0015688
and	O
reduced	O
insulin	B-C0920563
sensitivity	I-C0920563
.	O
	
carry-over	O
effects	O
in	O
serum	B-C0229671
metabolites	B-C0870883
and	O
fa	B-C0202009
profile	I-C0202009
were	O
dependent	O
on	O
the	O
diet	B-C0012155
and	O
feeding	B-C2987508
sequence	B-C1519249
.	O
	
sat1	B-C0597423
and	O
sat2	B-C0597423
serum	B-C0229671
decreased	O
blastocyst	B-C1281743
rates	O
and	O
altered	O
blastocyst	B-C1281743
mrna	B-C1515670
expression	I-C1515670
related	O
to	O
apoptosis	B-C0162638
and	O
oxidative	B-C0242606
stress	I-C0242606
.	O
	
unsat1	B-C0012172
and	O
unsat2	B-C0012172
serum	B-C0229671
resulted	O
in	O
normal	O
embryo	B-C0013935
development	O
and	O
quality	B-C0332306
.	O
	
other	O
in	B-C1533691
vitro	I-C1533691
effects	O
depended	O
on	O
the	O
sequence	B-C1519249
of	O
feeding	B-C2987508
.	O
	
in	O
conclusion	O
,	O
substitution	B-C1706204
of	O
saturated	B-C0597423
fat	I-C0597423
with	O
omega-3	B-C0015689
fat	I-C0015689
in	O
a	O
high-caloric	B-C0301590
diet	I-C0301590
induced	O
hyperlipidaemia	B-C0020473
with	O
an	O
fa	B-C0202009
profile	I-C0202009
yielding	O
similar	O
rates	O
and	O
quality	O
of	O
blastocysts	B-C1281743
compared	O
with	O
normolipidaemic	B-C0009932
controls	I-C0009932
.	O
	
draft	B-C2348746
genome	I-C2348746
sequence	I-C2348746
of	O
the	O
soil	B-C0037592
isolate	B-C1764827
lysinibacillus	B-C1095838
fusiformis	I-C1095838
m5	I-C1095838
,	O
a	O
potential	B-C3245505
hypoxanthine	B-C0020684
producer	O
lysinibacillus	B-C1095838
fusiformis	I-C1095838
strain	I-C1095838
m5	I-C1095838
is	O
a	O
potential	B-C3245505
hypoxanthine	B-C0020684
producer	O
that	O
was	O
isolated	B-C1764827
from	O
clay	B-C0055863
soil	B-C0037592
.	O
	
here	O
,	O
we	O
present	O
the	O
draft	B-C2348746
genome	I-C2348746
sequence	I-C2348746
that	O
was	O
annotated	B-C2936606
in	O
order	O
to	O
facilitate	O
future	O
studies	B-C2603343
of	O
l	B-C1095838
.	O
	
fusiformis	I-C1095838
m5	I-C1095838
.	O
	
impact	B-C4049986
of	O
clinical	B-C0008976
trial	I-C0008976
results	B-C0456984
on	O
the	O
temporal	B-C2362314
trends	B-C0040833
of	O
carotid	B-C0014099
endarterectomy	I-C0014099
and	O
stenting	B-C2348535
from	O
2002	O
to	O
2014	O
randomized	B-C0206034
trials	I-C0206034
provide	O
conflicting	B-C1705242
data	B-C1511726
for	O
the	O
efficacy	B-C1280519
of	O
carotid-artery	B-C2348535
stenting	I-C2348535
compared	O
with	O
endarterectomy	B-C0014098
.	O
	
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
impact	B-C4049986
of	O
conflicting	B-C1705242
clinical	B-C1096775
trial	I-C1096775
publications	I-C1096775
on	O
the	O
utilization	B-C0815187
rates	O
of	O
carotid	O
revascularization	O
procedures	O
.	O
	
we	O
conducted	O
a	O
population-level	O
time-series	O
analysis	O
of	O
all	O
individuals	O
who	O
underwent	O
carotid	O
endarterectomy	O
and	O
stenting	O
in	O
ontario	O
,	O
canada	O
2002-2014	O
.	O
	
the	O
primary	O
analysis	O
examined	O
temporal	O
changes	O
in	O
the	O
rates	O
of	O
carotid	O
revascularization	O
procedures	O
after	O
publications	O
of	O
major	O
randomized	O
trials	O
.	O
	
secondary	O
analyses	O
examined	O
changes	O
in	O
overall	O
and	O
age	O
,	O
sex	O
,	O
carotid-artery	O
symptom	O
,	O
and	O
operator	O
specialty-specific	O
procedure	O
rates	O
.	O
	
a	O
total	O
of	O
16	O
772	O
patients	O
were	O
studied	O
14	O
394	O
endarterectomy	O
86%	O
2378	O
stenting	O
14%	O
.	O
	
the	O
overall	O
rate	O
of	O
carotid	O
revascularization	O
decreased	O
from	O
6.0	O
procedures	O
per	O
100	O
000	O
individuals	O
40	O
years	O
old	O
in	O
april	O
2002	O
to	O
4.3	O
procedures	O
in	O
the	O
first	O
quarter	O
of	O
2014	O
29%	O
decrease	O
p<0	O
.	O
	
the	O
rate	O
of	O
endarterectomy	O
decreased	O
by	O
36%	O
p<0	O
,	O
whereas	O
the	O
rate	O
of	O
carotid-artery	O
stenting	O
increased	O
by	O
72%	O
p=0	O
.	O
	
we	O
observed	O
a	O
marked	O
increase	O
p=0	O
in	O
stenting	O
after	O
publication	O
of	O
the	O
sapphire	O
trial	O
stenting	O
and	O
angioplasty	O
with	O
protection	O
in	O
patients	O
at	O
high	O
risk	O
for	O
endarterectomy	O
in	O
2004	O
,	O
whereas	O
stenting	O
remained	O
relatively	O
unchanged	O
after	O
subsequent	O
randomized	O
trials	O
published	O
in	O
2006	O
p=0	O
and	O
2010	O
p=0	O
.	O
	
in	O
contrast	O
,	O
endarterectomy	O
decreased	O
after	O
trials	O
published	O
in	O
2006	O
p=0	O
and	O
2010	O
p=0	O
.	O
	
although	O
the	O
overall	O
rates	O
of	O
carotid	O
revascularization	O
and	O
endarterectomy	O
have	O
fallen	O
since	O
2002	O
,	O
the	O
rate	O
of	O
carotid-artery	O
stenting	O
has	O
risen	O
since	O
the	O
publication	O
of	O
stenting	O
-favorable	O
sapphire	O
trial	O
.	O
	
subsequent	O
conflicting	O
randomized	O
trials	O
were	O
associated	O
with	O
a	O
decreasing	O
rate	O
of	O
carotid	O
endarterectomy	I-C0014099
electronic	B-C4279906
tongues	I-C4279906
to	O
assess	O
wine	B-C0043188
sensory	B-C0445254
descriptors	B-C0282354
this	O
work	B-C0043227
reports	B-C0684224
the	O
application	B-C4048755
of	O
an	O
electronic	B-C4279906
tongue	I-C4279906
as	O
a	O
tool	B-C0336791
towards	O
the	O
analysis	B-C0936012
of	O
wine	B-C0043188
in	O
tasks	O
such	O
as	O
its	O
discrimination	B-C0242568
based	O
on	O
the	O
maturing	B-C0205286
in	O
barrels	B-C3273359
or	O
the	O
prediction	B-C0681842
of	O
the	O
global	B-C2348867
scores	B-C0449820
assigned	O
by	O
a	O
sensory	B-C0027363
panel	I-C0027363
.	O
	
to	O
this	O
aim	O
,	O
red	B-C0349371
wine	I-C0349371
samples	B-C0370003
were	O
first	O
analysed	B-C0936012
with	O
the	O
voltammetric	B-C0183210
sensor	I-C0183210
array	I-C0183210
,	O
without	O
performing	O
any	O
sample	B-C0370003
pretreatment	B-C3539076
.	O
	
afterwards	O
,	O
obtained	O
responses	B-C0443286
were	O
preprocessed	B-C1522240
employing	O
fast	B-C0002045
fourier	I-C0002045
transform	I-C0002045
fft	B-C0002045
for	O
the	O
compression	B-C0728907
and	O
reduction	B-C0392756
of	O
signal	B-C1710082
complexity	B-C0439855
,	O
and	O
obtained	O
coefficients	B-C1707429
were	O
then	O
used	O
as	O
inputs	B-C1708517
to	O
build	O
the	O
qualitative	B-C0205556
and	O
quantitative	B-C0392762
models	B-C0026336
employing	O
either	O
linear	B-C0012630
discriminant	I-C0012630
analysis	I-C0012630
lda	B-C0012630
or	O
partial	B-C0034980
least	I-C0034980
squares	I-C0034980
regression	I-C0034980
pls	B-C0034980
,	O
respectively	O
.	O
	
satisfactory	O
results	B-C0683954
were	O
obtained	O
overall	O
,	O
with	O
a	O
classification	B-C0008902
rate	B-C1521828
of	O
100%	O
in	O
the	O
discrimination	B-C0242568
of	O
the	O
type	O
of	O
barrel	B-C3273359
used	O
during	O
wine	B-C0043188
maturing	B-C0205286
,	O
a	O
normalized	B-C0079809
nrmse	I-C0079809
of	O
0.077	O
in	O
the	O
estimation	O
of	O
ageing	B-C0001811
time	B-C0040223
months	B-C0439231
or	O
0.11	O
in	O
the	O
prediction	B-C0681842
of	O
the	O
scores	B-C0449820
0-10	O
from	O
a	O
trained	B-C0027363
sensory	I-C0027363
panel	I-C0027363
all	O
for	O
the	O
external	O
test	B-C0039593
subset	B-C1515021
.	O
	
toward	O
optimizing	B-C2698650
dental	B-C0392413
implant	I-C0392413
performance	O
surface	B-C0205148
characterization	B-C1880022
of	O
ti	B-C0040302
and	O
tizr	B-C4041873
implant	B-C0440216
materials	I-C0440216
targeting	B-C1521840
understanding	O
enhanced	B-C2349975
osseointegration	B-C0079949
kinetics	B-C0022702
,	O
the	O
goal	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
characterize	B-C1880022
the	O
surface	B-C0205148
morphology	B-C0332437
and	O
composition	B-C0486616
of	O
ti	B-C0040302
and	O
tizr	B-C4041873
dental	B-C0392413
implant	I-C0392413
substrates	B-C3891814
subjected	O
to	O
one	O
of	O
two	O
surface	B-C0205148
treatments	B-C1522326
developed	O
by	O
straumann	O
.	O
	
these	O
two	O
treatments	B-C1522326
are	O
typically	O
known	O
as	O
sla	B-C0392413
and	O
slactive	B-C0392413
,	O
with	O
the	O
latter	O
resulting	O
in	O
more	O
rapid	B-C0456962
osseointegration	B-C0079949
.	O
	
a	O
range	O
of	O
techniques	B-C0449851
was	O
applied	B-C4048755
to	O
characterize	B-C1880022
four	O
different	B-C1705242
substrate	B-C0205148
/	O
surface	B-C0205148
treatment	B-C1522326
combinations	B-C0205195
tisla	B-C0392413
,	O
tislactive	B-C0392413
,	O
tizrsla	B-C0392413
,	O
and	O
tizrslactive	B-C0392413
.	O
	
contact	B-C0332158
angle	B-C0205143
measurements	B-C0242485
establish	O
establish	O
their	O
hydrophilic	B-C0475370
/	O
hydrophobic	B-C0598629
nature	O
.	O
	
surface	B-C0205148
morphology	B-C0332437
was	O
probed	O
with	O
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
.	O
	
x-ray	B-C0043301
diffraction	I-C0043301
,	O
raman	B-C0037815
μ-spectroscopy	I-C0037815
,	O
and	O
x-ray	B-C2700282
photoelectron	I-C2700282
spectroscopy	I-C2700282
were	O
used	O
to	O
elucidate	O
the	O
composition	B-C0486616
of	O
the	O
near-	O
surface	B-C0205148
region	O
.	O
	
consistent	B-C0332290
with	I-C0332290
previous	B-C0205156
work	O
,	O
surface	B-C0205148
morphology	B-C0332437
was	O
found	O
to	O
differ	B-C1705242
only	O
at	O
the	O
nanoscale	B-C1553036
,	O
with	O
both	O
slactive	B-C0392413
substrates	B-C3891814
displaying	B-C0870432
nano	B-C1553036
-	O
protrusions	B-C0333056
.	O
	
spectroscopic	B-C0037812
data	B-C1511726
indicate	O
that	O
all	O
substrates	B-C3891814
exhibit	O
surface	B-C0205148
films	B-C1522408
of	O
titanium	B-C0145999
oxide	I-C0145999
displaying	O
near	O
tio2	B-C0145999
stoichiometry	B-C0597526
.	O
	
raman	B-C0037815
μ-spectroscopy	I-C0037815
reveals	B-C0443289
that	O
amorphous	B-C1979848
tio2	B-C0145999
is	O
most	O
likely	O
the	O
only	O
phase	B-C0205390
present	B-C0150312
on	O
tisla	B-C0392413
,	O
whilst	O
rutile	B-C0141060
-	O
tio2	B-C0145999
is	O
also	O
evidenced	B-C3887511
on	O
tislactive	B-C0392413
,	O
tizrsla	B-C0392413
,	O
and	O
tizrslactive	B-C0392413
.	O
	
for	O
tizr	B-C4041873
alloy	B-C0002154
substrates	B-C3891814
,	O
there	O
is	O
no	O
evidence	B-C3887511
of	O
discrete	B-C0443299
phases	B-C0205390
of	O
oxidized	B-C0030011
zr	B-C0043506
.	O
	
x-ray	B-C2700282
photoelectron	I-C2700282
spectra	I-C2700282
demonstrate	O
that	O
all	O
samples	B-C0370003
are	O
terminated	B-C1692758
by	O
adventitious	B-C1517294
carbon	B-C0007009
,	O
with	O
it	O
being	O
somewhat	O
thicker	B-C1280412
1nm	O
on	O
tisla	B-C0392413
and	O
tizrsla	B-C0392413
.	O
	
given	O
previous	B-C0205156
in	B-C0681829
vivo	I-C0681829
studies	I-C0681829
,	O
acquired	B-C0439661
data	B-C1511726
suggest	O
that	O
both	O
nanoscale	B-C1553036
protrusions	B-C0333056
,	O
and	O
a	O
thinner	B-C0205168
layer	B-C1522408
of	O
adventitious	B-C1517294
carbon	B-C0007009
contribute	B-C1880177
to	O
the	O
more	O
rapid	B-C0456962
osseointegration	B-C0079949
of	O
slactive	B-C0392413
dental	B-C0392413
implants	I-C0392413
.	O
	
composition	B-C0486616
of	O
the	O
surface	B-C0205148
oxide	B-C0030015
layer	B-C1522408
is	O
apparently	O
less	B-C0547044
important	B-C3898777
in	O
determining	O
osseointegration	B-C0079949
kinetics	B-C0022702
.	O
	
cocaine	B-C0009170
use	B-C1524063
reverses	B-C1555029
striatal	B-C0027880
plasticity	I-C0027880
produced	B-C0678227
during	B-C0347984
cocaine	B-C0009170
seeking	O
relapse	B-C0035020
is	O
a	O
two	B-C0205448
-	O
component	B-C1705248
process	B-C1522240
consisting	O
of	O
a	O
highly	B-C0205250
motivated	B-C0026605
drug-seeking	O
phase	B-C0205390
that	O
,	O
if	O
successful	O
,	O
is	O
followed	B-C0332283
by	I-C0332283
a	O
drug-using	B-C0242510
phase	B-C0205390
resulting	B-C0332294
in	I-C0332294
temporary	B-C0205374
satiation	B-C0036239
.	O
	
in	O
rodents	B-C0035804
,	O
cue-induced	O
drug	O
seeking	O
requires	B-C1514873
transient	B-C0206249
synaptic	I-C0206249
potentiation	I-C0206249
t-sp	B-C0206249
of	O
cortical	B-C0039062
glutamatergic	I-C0039062
synapses	I-C0039062
on	O
nucleus	B-C0028633
accumbens	I-C0028633
core	B-C0444669
medium	B-C0682698
spiny	I-C0682698
neurons	I-C0682698
,	O
but	O
it	O
is	O
unknown	B-C0439673
how	O
achieving	O
drug	B-C0242510
use	I-C0242510
affects	B-C0001721
this	O
plasticity	B-C0027880
.	O
	
we	O
modeled	B-C3714583
the	O
two	O
phases	B-C0205390
of	O
relapse	B-C0035020
after	O
extinction	B-C0015347
from	O
cocaine	B-C0009170
self-administration	B-C0036589
to	O
assess	B-C1516048
how	O
cocaine	B-C0009170
use	O
affects	B-C0001721
t-sp	B-C0206249
associated	B-C0332281
with	I-C0332281
cue-induced	O
drug	O
seeking	O
.	O
	
rats	B-C0034721
were	O
trained	O
to	O
self-administer	B-C0036589
cocaine	B-C0009170
n	O
=	O
96	O
or	O
were	O
used	O
as	O
yoked	B-C1710702
-	O
saline	B-C0036082
control	B-C1511501
animals	I-C1511501
n	O
=	O
21	O
.	O
	
after	O
extinction	B-C0015347
,	O
reinstatement	B-C0678335
was	O
initiated	B-C1704686
by	O
10	O
minutes	B-C0439232
of	O
cue-induced	O
drug	O
seeking	O
,	O
followed	B-C0332283
by	I-C0332283
45	O
minutes	B-C0439232
with	O
contingent	B-C1701901
cocaine	B-C0009170
access	B-C1554204
,	O
after	O
which	O
cocaine	B-C0009170
was	O
discontinued	B-C1444662
and	O
unreinforced	B-C0243095
lever	I-C0243095
pressing	I-C0243095
ensued	I-C0243095
.	O
	
three	B-C0205449
measures	B-C0079809
of	O
t-sp	B-C0206249
were	O
assayed	B-C1510438
during	B-C0347984
reinstatement	B-C0678335
dendritic	B-C0872341
spine	I-C0872341
morphology	B-C0332437
,	O
alpha-amino-3-hydroxy-5-methyl-4-isoxazole	B-C0051318
propionic	I-C0051318
acid	I-C0051318
ampa	B-C0051318
to	O
n-methyl-d-aspartate	B-C0079883
nmda	B-C0079883
ratios	B-C0456603
,	O
and	O
matrix	B-C0025543
metalloproteinase	I-C0025543
activity	B-C0243102
.	O
	
we	O
found	B-C0243095
that	O
cocaine	B-C0009170
use	O
for	O
10	O
minutes	B-C0439232
collapsed	B-C0392748
all	O
three	B-C0205449
measures	B-C0079809
of	O
cue-potentiated	O
t-sp	B-C0206249
back	O
to	O
baseline	B-C1442488
.	O
	
moreover	O
,	O
when	O
cocaine	B-C0009170
use	O
was	O
discontinued	B-C1444662
45	O
minutes	B-C0439232
later	O
,	O
dendritic	B-C0872341
spine	I-C0872341
morphology	B-C0332437
and	O
ampa	B-C0051318
to	O
nmda	B-C0079883
ratios	B-C0456603
were	O
restored	O
as	O
animals	B-C0003062
became	O
motivated	B-C0026605
to	O
engage	O
unrewarded	O
lever	B-C0243095
pressing	I-C0243095
.	O
	
nonreinforced	O
drug	O
seeking	O
was	O
positively	B-C1446409
correlated	B-C1707520
with	O
changes	B-C0392747
in	O
spine	B-C2752558
morphology	B-C0332437
,	O
and	O
cocaine	B-C0009170
access	B-C1554204
reversed	B-C1555029
this	O
relationship	B-C0439849
.	O
	
using	O
a	O
novel	B-C0205314
modification	B-C0392747
of	O
the	O
reinstatement	B-C0678335
paradigm	B-C0681797
,	O
we	O
show	O
that	O
achieving	O
cocaine	B-C0009170
use	O
reversed	B-C1555029
the	O
synaptic	B-C1254358
plasticity	I-C1254358
underpinning	O
the	O
motivation	B-C0026605
to	O
seek	O
the	O
delicaflavone	B-C1254351
induces	B-C0205263
autophagic	B-C1326207
cell	I-C1326207
death	I-C1326207
in	O
lung	B-C0684249
cancer	I-C0684249
via	O
akt	B-C1515844
/	O
mtor	B-C1515673
/	O
p70s6k	B-C0073337
signaling	B-C0037080
pathway	I-C0037080
searching	O
for	O
potential	B-C3245505
anticancer	B-C0003392
agents	I-C0003392
from	O
natural	B-C0449416
sources	I-C0449416
is	O
an	O
effective	B-C1704419
strategy	O
for	O
developing	O
novel	B-C0205314
chemotherapeutic	B-C0729502
agents	I-C0729502
.	O
	
in	O
this	O
study	B-C2603343
,	O
data	B-C1511726
supporting	O
the	O
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
anticancer	B-C0243095
effects	I-C0243095
of	O
delicaflavone	B-C1254351
,	O
a	O
rarely	O
occurring	O
biflavonoid	B-C0596577
from	O
selaginella	B-C1210298
doederleinii	I-C1210298
,	O
were	O
reported	O
.	O
	
delicaflavone	B-C1254351
exhibited	O
favorable	B-C3640814
anticancer	B-C0243095
properties	B-C0243178
,	O
as	O
shown	O
by	O
the	O
mtt	B-C2986858
assay	I-C2986858
and	O
xenograft	B-C1520166
model	I-C1520166
of	O
human	B-C0086418
non-small	B-C0007131
cell	I-C0007131
lung	I-C0007131
cancer	I-C0007131
in	O
male	B-C0086582
balb/c	B-C0025929
nude	I-C0025929
mice	I-C0025929
without	O
observable	O
adverse	B-C0559546
effect	I-C0559546
.	O
	
by	O
transmission	B-C0678118
electron	I-C0678118
microscopy	I-C0678118
with	O
acridine	B-C0001185
orange	I-C0001185
and	O
cyto-id	B-C0004391
detection	O
dyes	B-C0013343
,	O
western	B-C0949466
blot	I-C0949466
analysis	B-C0936012
,	O
and	O
rt-pcr	B-C1709846
assay	I-C1709846
,	O
we	O
confirmed	O
that	O
delicaflavone	B-C1254351
induces	B-C0205263
autophagic	B-C1326207
cell	I-C1326207
death	I-C1326207
by	O
increasing	B-C0442808
the	O
ratio	O
of	O
lc3-ii	B-C3711208
to	O
lc3-i	B-C3714087
,	O
which	O
are	O
autophagy-related	B-C4277731
proteins	I-C4277731
,	O
and	O
promoting	B-C0033414
the	O
generation	B-C3146294
of	O
acidic	B-C0029219
vesicular	I-C0029219
organelles	I-C0029219
and	O
autolysosomes	B-C0230822
in	O
the	O
cytoplasm	B-C0010834
of	O
human	O
lung	B-C0684249
cancer	I-C0684249
a549	B-C4277577
and	O
pc-9	B-C0007634
cells	I-C0007634
in	O
a	O
time	B-C0040223
-	O
and	O
dose-dependent	B-C1512045
manner	O
.	O
	
delicaflavone	B-C1254351
downregulated	B-C0013081
the	O
expression	B-C2697945
of	I-C2697945
phospho-akt	I-C2697945
,	O
phospho-mtor	B-C0033684
,	O
and	O
phospho-p70s6k	B-C0033684
in	O
a	O
time	B-C0040223
-	O
and	O
dose-dependent	B-C1512045
manner	O
,	O
suggesting	B-C1705535
that	O
it	O
induced	B-C0205263
autophagy	B-C0004391
by	O
inhibiting	B-C3463820
the	O
akt	B-C1515844
/	O
mtor	B-C1515673
/	O
p70s6k	B-C0073337
pathway	B-C0037080
in	O
a549	B-C4277577
and	O
pc-9	B-C0007634
cells	I-C0007634
.	O
	
delicaflavone	B-C1254351
is	O
a	O
potential	B-C3245505
anticancer	B-C0003392
agent	I-C0003392
that	O
can	O
induce	B-C0205263
autophagic	B-C1326207
cell	I-C1326207
death	I-C1326207
in	O
human	B-C0086418
non-small	B-C0007131
cell	I-C0007131
lung	I-C0007131
cancer	I-C0007131
via	O
the	O
akt	B-C1515844
/	O
mtor	B-C1515673
/	O
p70s6k	B-C0073337
signaling	B-C0037080
pathway	I-C0037080
.	O
	
delicaflavone	B-C1254351
showed	O
anti-lung	B-C0243095
cancer	I-C0243095
effects	I-C0243095
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
.	O
	
delicaflavone	B-C1254351
induced	B-C0205263
autophagic	B-C1326207
cell	I-C1326207
death	I-C1326207
via	O
akt	B-C1515844
/	O
mtor	B-C1515673
/	O
p70s6k	B-C0073337
signaling	B-C0037080
pathway	I-C0037080
.	O
	
delicaflavone	B-C1254351
did	O
not	O
show	O
observable	O
side	B-C0879626
effects	I-C0879626
in	O
a	O
xenograft	B-C1520166
mouse	I-C1520166
model	I-C1520166
.	O
	
delicaflavone	B-C1254351
may	O
represent	O
a	O
potential	B-C3245505
therapeutic	B-C0304231
agent	I-C0304231
for	O
lung	B-C0684249
cancer	I-C0684249
.	O
	
delicaflavone	B-C1254351
showed	O
anti-lung	B-C0243095
cancer	I-C0243095
effects	I-C0243095
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
.	O
	
delicaflavone	B-C1254351
induced	O
autophagic	B-C1326207
cell	I-C1326207
death	I-C1326207
via	O
akt	B-C1515844
/	O
mtor	B-C1515673
/	O
p70s6k	B-C0073337
signaling	B-C0037080
pathway	I-C0037080
.	O
	
delicaflavone	B-C1254351
did	O
not	O
show	O
observable	O
side	B-C0879626
effects	I-C0879626
in	O
a	O
xenograft	B-C1520166
mouse	I-C1520166
model	I-C1520166
.	O
	
delicaflavone	B-C1254351
may	O
represent	O
a	O
potential	B-C3245505
therapeutic	B-C0304231
agent	I-C0304231
for	O
lung	B-C0684249
cancer	I-C0684249
.	O
	
determinants	B-C1521761
of	O
on-road	B-C0442650
driving	B-C0004379
in	O
multiple	B-C0026769
sclerosis	I-C0026769
to	O
investigate	B-C1292732
the	O
cognitive	B-C1516691
,	O
visual	B-C0234621
,	O
and	O
motor	B-C0521654
deficits	I-C0521654
underlying	O
poor	O
performance	O
on	O
different	O
dimensions	B-C0233849
of	O
on-road	B-C0442650
driving	B-C0004379
in	O
individuals	B-C0237401
with	O
multiple	B-C0026769
sclerosis	I-C0026769
ms	B-C0026769
.	O
	
prospective	O
cross-sectional	B-C0010362
study	I-C0010362
.	O
	
ms	B-C3839267
clinic	I-C3839267
and	O
driving	B-C0004379
simulator	B-C0679083
lab	B-C0022877
.	O
	
active	B-C0684312
drivers	I-C0684312
n=102	O
with	O
various	O
types	O
of	O
ms	B-C0026769
.	O
	
not	O
applicable	O
.	O
	
off-road	B-C0442650
cognitive	B-C1516691
,	O
visual	B-C0234621
,	O
and	O
motor	B-C0234130
functions	I-C0234130
,	O
as	O
well	O
as	O
13	O
specific	B-C0205369
driving	B-C0683900
skills	I-C0683900
.	O
	
these	O
skills	B-C0683900
were	O
categorized	B-C0871968
into	O
hierarchic	B-C0009085
clusters	I-C0009085
of	O
operational	B-C3241922
,	O
tactical	B-C0683900
,	O
visuo-integrative	B-C0234621
,	O
and	O
mixed	B-C0683900
driving	I-C0683900
.	O
	
stepwise	B-C0034980
regression	I-C0034980
analysis	I-C0034980
was	O
used	O
to	O
determine	O
the	O
off-road	B-C0442650
functions	O
influencing	O
performance	O
on	O
the	O
on-road	B-C0442650
test	B-C0039593
and	O
each	O
cluster	B-C1704332
.	O
	
visuospatial	B-C0814069
function	I-C0814069
p=	O
,	O
inhibition	B-C0021467
p=	O
,	O
binocular	B-C0429540
acuity	I-C0429540
p=	O
,	O
vertical	B-C1301505
visual	I-C1301505
field	I-C1301505
p=	O
,	O
and	O
stereopsis	B-C0011586
p=	O
best	O
determined	O
variance	B-C1711260
in	O
total	O
on-road	B-C0442650
score	B-C0449820
unadjusted	O
r	O
.	O
	
attentional	B-C4274597
shift	I-C4274597
p=	O
,	O
stereopsis	B-C0011586
p=	O
,	O
glare	B-C1321305
recovery	I-C1321305
p=	O
,	O
and	O
use	O
of	O
assistive	B-C0036605
devices	I-C0036605
p=	O
best	O
predicted	O
the	O
operational	B-C0009085
cluster	I-C0009085
unadjusted	O
r	O
.	O
	
visuospatial	B-C0814069
function	I-C0814069
p=	O
,	O
inhibition	B-C0021467
p=	O
,	O
reasoning	B-C0684328
p=	O
,	O
binocular	B-C0429540
acuity	I-C0429540
p=	O
,	O
and	O
stereopsis	B-C0011586
p=	O
best	O
determined	O
the	O
tactical	B-C0009085
cluster	I-C0009085
unadjusted	O
r	O
.	O
	
the	O
visuo-integrative	B-C0026347
mode	I-C0026347
l	O
unadjusted	O
r	O
comprised	O
binocular	B-C0429540
acuity	I-C0429540
p=	O
and	O
stereopsis	B-C0011586
p=	O
.	O
	
inhibition	B-C0021467
p=	O
and	O
binocular	B-C0429540
acuity	I-C0429540
p=	O
provided	O
the	O
best	O
model	B-C0026348
of	O
the	O
mixed	B-C0009085
cluster	I-C0009085
unadjusted	O
r	O
.	O
	
our	O
results	O
provide	O
more	O
insights	O
into	O
the	O
specific	O
impairments	B-C0221099
that	O
influence	O
different	O
dimensions	O
of	O
on-road	B-C0442650
driving	B-C0004379
and	O
may	O
be	O
used	O
as	O
a	O
framework	O
for	O
targeted	B-C1521840
driving	B-C0004379
intervention	B-C0599917
programs	I-C0599917
in	O
netarsudil	B-C1254351
increases	B-C0442805
outflow	B-C0430894
facility	I-C0430894
in	O
human	B-C0086418
eyes	B-C0015392
through	O
multiple	B-C0439064
mechanisms	B-C0441712
netarsudil	B-C1254351
is	O
a	O
rho	B-C0033671
kinase/norepinephrine	I-C0033671
transporter	I-C0033671
inhibitor	I-C0033671
currently	O
in	O
phase	B-C0282461
3	I-C0282461
clinical	I-C0282461
development	I-C0282461
for	O
glaucoma	B-C0017601
treatment	B-C0087111
.	O
	
we	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	B-C0870883
,	O
netarsudil-m1	B-C1254351
,	O
on	O
outflow	B-C0430894
facility	I-C0430894
c	B-C0430894
,	O
outflow	B-C1254359
hydrodynamics	B-C2936194
,	O
and	O
morphology	B-C0332437
of	O
the	O
conventional	B-C0439858
outflow	B-C1705987
pathway	I-C1705987
in	O
enucleated	B-C1396718
human	I-C1396718
eyes	I-C1396718
.	O
	
paired	B-C1709450
human	B-C0086418
eyes	B-C0015392
n	O
=	O
5	O
were	O
perfused	B-C0031001
with	O
either	O
0.3	O
μm	O
netarsudil-m1	B-C1254351
or	O
vehicle	B-C0042444
solution	I-C0042444
at	O
constant	B-C0033095
pressure	I-C0033095
15	O
mm	O
hg	O
.	O
	
after	O
3	O
hours	B-C0439227
,	O
fluorescent	B-C0026032
microspheres	I-C0026032
were	O
added	O
to	O
perfusion	B-C0031001
media	B-C0009924
to	O
trace	B-C1552622
the	O
outflow	B-C1254359
patterns	I-C1254359
before	O
perfusion	B-C0031001
-	O
fixation	B-C0185023
.	O
	
the	O
percentage	B-C1444754
effective	I-C1444754
filtration	I-C1444754
length	I-C1444754
pefl	B-C1444754
was	O
calculated	O
from	O
the	O
measured	B-C0444706
lengths	B-C1444754
of	O
tracer	B-C1522485
distribution	B-C1704711
in	O
the	O
trabecular	B-C0040573
meshwork	I-C0040573
tm	B-C0040573
,	O
episcleral	B-C0226616
veins	I-C0226616
esvs	B-C0226616
,	O
and	O
along	O
the	O
inner	B-C1254362
wall	I-C1254362
iw	B-C1254362
of	O
schlemm's	B-C0229108
canal	I-C0229108
after	O
global	B-C2348867
and	O
confocal	B-C0242842
imaging	I-C0242842
.	O
	
morphologic	B-C1260954
changes	I-C1260954
along	O
the	O
trabecular	B-C0040573
outflow	B-C1705987
pathway	I-C1705987
were	O
investigated	O
by	O
confocal	B-C0242842
,	O
light	B-C0430389
,	O
and	O
electron	B-C0026019
microscopy	I-C0026019
.	O
	
perfusion	B-C0031001
with	O
netarsudil-m1	B-C1254351
significantly	B-C0750502
increased	B-C0205217
c	B-C0430894
when	O
compared	O
to	O
baseline	O
51%	O
,	O
p	O
<	O
0.01	O
and	O
to	O
paired	B-C1709450
controls	O
102%	O
,	O
p	O
<	O
0.01	O
,	O
as	O
well	O
as	O
significantly	B-C0750502
increased	B-C0205217
pefl	B-C1444754
in	O
both	O
iw	B-C1254362
p	O
<	O
0.05	O
and	O
esvs	B-C0226616
p	O
<	O
0.01	O
.	O
	
in	O
treated	O
eyes	B-C0015392
,	O
pefl	B-C1444754
was	O
significantly	B-C0750502
higher	O
in	O
esvs	B-C0226616
than	O
in	O
the	O
iw	B-C1254362
p	O
<	O
0.01	O
and	O
was	O
associated	B-C0332281
with	I-C0332281
increased	B-C0205217
cross-sectional	B-C0205146
area	I-C0205146
of	O
esvs	B-C0226616
p	O
<	O
0.01	O
.	O
	
percentage	B-C1444754
effective	I-C1444754
filtration	I-C1444754
length	I-C1444754
in	O
esvs	B-C0226616
positively	O
correlated	O
with	O
the	O
percentage	O
change	O
in	O
c	B-C0430894
r2	O
=	O
0.58	O
,	O
p	O
=	O
0.01	O
.	O
	
a	O
significant	B-C0750502
increase	B-C0442805
in	O
juxtacanalicular	B-C0009780
connective	I-C0009780
tissue	I-C0009780
jct	B-C0009780
thickness	B-C1280412
p	O
<	O
0.05	O
was	O
found	O
in	O
treated	O
eyes	B-C0015392
compared	O
to	O
controls	O
.	O
	
netarsudil	B-C1254351
acutely	B-C0205178
increased	B-C0205217
c	B-C0430894
by	O
expansion	O
of	O
the	O
jct	B-C0009780
and	O
dilating	O
the	O
esvs	B-C0226616
,	O
which	O
led	O
to	O
redistribution	B-C0332620
of	O
aqueous	O
outflow	B-C1254359
through	O
a	O
larger	B-C0205146
area	I-C0205146
of	O
the	O
iw	B-C1254362
and	O
geographical	B-C0681784
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
health	B-C1171307
disparities	I-C1171307
in	O
prostate	B-C0376358
cancer	I-C0376358
treatment	B-C0087111
variation	B-C1705242
in	O
prostate	B-C0376358
cancer	I-C0376358
is	O
common	O
,	O
and	O
it	O
is	O
driven	O
by	O
clinical	B-C0205210
and	O
clinician	B-C0871685
factors	B-C1521761
,	O
patient	B-C0376409
preferences	I-C0376409
,	O
availability	B-C0470187
of	I-C0470187
resources	B-C0018741
,	O
and	O
access	B-C0444454
to	O
physicians	B-C0031831
and	O
treating	B-C0018704
facilities	I-C0018704
.	O
	
most	O
research	B-C0035168
on	O
treatment	B-C0087111
disparities	B-C1705242
in	O
men	B-C0025266
with	O
prostate	B-C0376358
cancer	I-C0376358
has	O
focused	O
on	O
race	B-C0034510
and	O
socioeconomic	B-C0037464
factors	I-C0037464
.	O
	
however	O
,	O
the	O
geography	B-C0017444
of	O
disparities	B-C1705242
-	O
capturing	O
racial	B-C0682075
and	O
socioeconomic	B-C0682194
differences	I-C0682194
based	O
on	O
where	O
patients	B-C0376409
live	B-C2982691
-	O
can	O
provide	O
insight	O
into	O
barriers	B-C4045969
to	O
care	B-C0086388
and	O
help	O
identify	O
outlier	O
areas	B-C0681784
in	O
which	O
access	B-C0444454
to	O
care	B-C0086388
,	O
health	B-C0018741
resources	I-C0018741
,	O
or	O
both	O
are	O
more	O
pronounced	O
.	O
	
research	B-C0035168
regarding	O
treatment	B-C0087111
patterns	B-C0449774
and	O
disparities	B-C1705242
in	O
prostate	B-C0376358
cancer	I-C0376358
using	O
the	O
geographical	B-C0815319
information	I-C0815319
system	I-C0815319
gis	B-C0815319
was	O
searched	B-C1706202
.	O
	
studies	B-C2603343
were	O
limited	O
to	O
english-language	B-C0376245
articles	B-C1706852
and	O
research	B-C0035168
focused	O
on	O
us	B-C0041703
populations	B-C1257890
.	O
	
a	O
total	O
of	O
43	O
articles	B-C1706852
were	O
found	O
of	O
those	O
,	O
30	O
provided	O
information	B-C1533716
about	O
or	O
used	O
spatial	B-C0037775
or	O
geographical	B-C0681784
analyses	B-C0936012
to	O
assess	B-C1516048
and	O
describe	O
differences	B-C1705242
or	O
disparities	B-C1705242
in	O
prostate	B-C0376358
cancer	I-C0376358
and	O
its	O
treatment	B-C0087111
.	O
	
two	O
additional	O
gis	B-C0815319
resources	O
were	O
included	O
.	O
	
the	O
research	B-C0035168
on	O
geographical	B-C0681784
and	O
spatial	B-C1521761
determinants	I-C1521761
of	O
prostate	B-C0376358
cancer	I-C0376358
disparities	B-C1705242
was	O
reviewed	B-C1709940
.	O
	
we	O
also	O
examined	O
geographical	B-C0681784
analyses	B-C0936012
at	O
the	O
state	B-C0683927
level	I-C0683927
,	O
focusing	O
on	O
florida	B-C0016253
.	O
	
overall	O
,	O
we	O
described	O
a	O
geographical	B-C0681784
framework	O
to	O
disparities	B-C1705242
that	O
affect	O
men	B-C0025266
with	O
prostate	B-C0376358
cancer	I-C0376358
and	O
reviewed	B-C1709940
existing	O
published	O
evidence	B-C3887511
supporting	O
the	O
interplay	O
of	O
geographical	B-C0681784
factors	B-C1521761
and	O
disparities	B-C1705242
in	O
prostate	B-C0376358
cancer	I-C0376358
.	O
	
disparities	B-C1705242
in	O
prostate	B-C0376358
cancer	I-C0376358
are	O
common	B-C0205214
and	O
persistent	B-C0205322
,	O
and	O
notable	O
differences	O
in	O
treatment	B-C0087111
are	O
observable	O
across	O
racial	O
and	O
socioeconomic	O
strata	O
.	O
	
geographical	B-C0681784
analysis	B-C0936012
provides	O
additional	O
information	B-C1533716
about	O
where	O
disparate	B-C1705242
groups	B-C1257890
live	B-C2982691
and	O
also	O
helps	O
to	O
map	B-C0024779
access	B-C0444454
to	O
care	B-C0086388
.	O
	
this	O
information	B-C1533716
can	O
be	O
used	O
by	O
public	B-C2826212
health	I-C2826212
officials	I-C2826212
,	O
health-systems	B-C0018707
administrators	I-C0018707
,	O
clinicians	B-C0871685
,	O
and	O
policymakers	B-C0242170
to	O
better	O
understand	O
and	O
respond	O
to	O
geographical	B-C0681784
barriers	B-C4045969
that	O
contribute	O
to	O
disparities	B-C1955989
in	I-C1955989
care	I-C1955989
.	O
	
the	O
novel	O
mir-9600	B-C1101610
suppresses	B-C1260953
tumor	B-C0178874
progression	I-C0178874
and	O
promotes	O
paclitaxel	B-C0144576
sensitivity	B-C0205556
in	O
non-small-cell	B-C0007131
lung	I-C0007131
cancer	I-C0007131
through	O
altering	B-C1515926
stat3	B-C1367307
expression	B-C0017262
micrornas	B-C1101610
have	O
been	O
identified	B-C0205396
to	O
be	O
involved	O
in	O
center	B-C1300072
stage	I-C1300072
of	O
cancer	B-C1516164
biology	I-C1516164
.	O
	
they	O
accommodate	O
cell	B-C0596290
proliferation	I-C0596290
and	O
migration	B-C1622501
by	O
negatively	B-C0205160
regulate	B-C0017263
gene	I-C0017263
expression	I-C0017263
either	O
by	O
hampering	O
the	O
translation	B-C0678935
of	O
targeted	B-C0035696
mrnas	I-C0035696
or	O
by	O
promoting	O
their	O
degradation	B-C0243125
.	O
	
we	O
characterized	B-C1880022
and	O
identified	B-C0205396
the	O
novel	O
mir-9600	B-C1101610
and	O
its	O
target	B-C1521840
in	O
human	B-C0086418
non-small-cell	B-C0007131
lung	I-C0007131
cancer	I-C0007131
nsclc	B-C0007131
.	O
	
our	O
results	O
demonstrated	O
that	O
the	O
mir-9600	B-C1101610
were	O
downregulated	B-C0013081
in	O
nsclc	B-C0007131
tissues	B-C0040300
and	O
cells	B-C0007634
.	O
	
it	O
is	O
confirmed	O
that	O
signal	B-C1367307
transducer	I-C1367307
and	I-C1367307
activator	I-C1367307
of	I-C1367307
transcription	I-C1367307
3	I-C1367307
stat3	B-C1367307
,	O
a	O
putative	B-C0017337
target	I-C0017337
gene	I-C0017337
,	O
is	O
directly	O
inhibited	B-C0311403
by	O
mir-9600	B-C1101610
.	O
	
the	O
mir-9600	B-C1101610
markedly	O
suppressed	B-C1260953
the	O
protein	B-C1171362
expression	I-C1171362
of	O
stat3	B-C1367307
,	O
but	O
with	O
no	B-C3694175
significant	I-C3694175
influence	B-C4054723
in	O
corresponding	O
mrna	B-C0035696
levels	B-C0441889
,	O
and	O
the	O
direct	O
combination	O
of	O
mir-9600	B-C1101610
and	O
stat3	B-C1367307
was	O
confirmed	O
by	O
a	O
luciferase	O
reporter	O
assay	O
.	O
	
mir-9600	B-C1101610
inhibited	B-C0311403
cell	B-C0007595
growth	I-C0007595
,	O
hampered	O
expression	B-C1171362
of	O
cell	B-C0007586
cycle	I-C0007586
-related	O
proteins	B-C0033684
and	O
inhibited	B-C0311403
cell	B-C1622501
migration	I-C1622501
and	O
invasion	B-C2699153
in	O
human	B-C0086418
nsclc	B-C0007131
cell	B-C0085983
lines	I-C0085983
.	O
	
further	O
,	O
mir-9600	B-C1101610
significantly	O
suppressed	B-C1260953
tumor	B-C0598934
growth	I-C0598934
in	O
nude	B-C0025932
mice	I-C0025932
.	O
	
similarly	O
,	O
mir-9600	B-C1101610
impeded	O
tumorigenesis	B-C0007621
and	O
metastasis	B-C4255448
through	O
directly	O
targeting	B-C1148560
stat3	B-C1367307
.	O
	
furthermore	O
,	O
we	O
identified	B-C0205396
that	O
mir-9600	B-C1101610
augmented	O
paclitaxel	B-C0144576
and	O
cisplatin	B-C0008838
sensitivity	B-C0205556
by	O
downregulating	B-C0013081
stat3	B-C1367307
and	O
promoting	O
chemotherapy	B-C3665472
-	O
induced	B-C0205263
apoptosis	B-C0162638
.	O
	
these	O
data	O
demonstrate	O
that	O
mir-9600	B-C1101610
might	O
be	O
a	O
useful	O
and	O
novel	O
therapeutic	B-C0302350
target	B-C1521840
for	O
beneficial	B-C0683156
effects	I-C0683156
of	O
natural	B-C3651790
eggshell	I-C3651790
membrane	I-C3651790
nem	B-C3651790
on	O
multiple	O
indices	O
of	O
arthritis	B-C0003864
in	O
collagen-induced	B-C0971858
arthritic	I-C0971858
rats	B-C0034721
this	O
study	B-C2603343
was	O
performed	O
to	O
evaluate	B-C0220825
the	O
potential	B-C1280519
efficacy	I-C1280519
of	O
natural	B-C3651790
eggshell	I-C3651790
membrane	I-C3651790
nem	B-C3651790
in	O
collagen-induced	B-C0971858
arthritic	I-C0971858
rats	B-C0034721
,	O
a	O
well-established	O
rodent	B-C1519106
model	I-C1519106
of	I-C1519106
inflammation	I-C1519106
and	O
rheumatoid	B-C0003873
arthritis	I-C0003873
.	O
	
rats	B-C0034721
with	O
developing	O
type	B-C0971858
ii	I-C0971858
collagen-induced	I-C0971858
arthritis	I-C0971858
cia	B-C0971858
were	O
treated	O
once	O
daily	B-C0332173
by	O
oral	B-C2698653
gavage	I-C2698653
on	O
study	B-C2826182
days	I-C2826182
-14	O
to	O
17	O
with	O
vehicle	B-C0042444
or	O
nem	B-C3651790
52	O
mg/kg	O
body	B-C0005910
weight	I-C0005910
.	O
	
rats	B-C0034721
were	O
euthanized	B-C2983562
on	O
study	B-C2826182
day	I-C2826182
17	O
.	O
	
efficacy	B-C1280519
was	O
assessed	B-C1516048
by	O
daily	B-C0332173
ankle	B-C0003086
caliper	B-C0175720
measurements	B-C0242485
,	O
ankle	O
diameter	O
expressed	O
as	O
area	O
under	O
the	O
curve	O
aucd0-17	O
,	O
and	O
histopathologic	O
evaluation	O
of	O
ankles	O
and	O
knees	O
.	O
	
serum	O
biomarkers	O
of	O
cartilage	O
function	O
and	O
inflammation	O
collagen	O
type	O
ii	O
c-telopeptide	O
ctxii	O
,	O
cartilage	O
oligomeric	O
matrix	O
protein	O
comp	O
,	O
and	O
alpha-2-macroglobulin	O
a2m	O
were	O
measured	O
by	O
elisa	O
.	O
	
treatment	O
with	O
nem	O
resulted	O
in	O
significant	O
beneficial	O
effects	O
on	O
the	O
daily	O
ankle	O
diameter	O
measurements	B-C0242485
and	O
ankle	B-C0003086
diameter	B-C1301886
auc	O
.	O
	
ankle	O
and	O
knee	O
histopathology	O
scores	O
were	O
significantly	O
reduced	O
36%	O
and	O
43%	O
reduction	O
of	O
summed	O
individual	O
histopathology	O
scores	O
for	O
ankle	O
and	O
knee	O
,	O
respectively	O
p	O
<	O
0.05	O
toward	O
normal	O
for	O
rats	O
given	O
nem	O
compared	O
to	O
vehicle	O
controls	O
.	O
	
the	O
percent	O
reduction	O
of	O
serum	O
ctxii	O
,	O
comp	O
,	O
and	O
a2m	O
in	O
nem	O
-	O
treated	O
rats	O
ranged	O
from	O
30%	O
to	O
72%	O
p	O
<	O
0.05	O
.	O
	
nem	O
significantly	O
improved	O
multiple	O
aspects	O
of	O
inflammatory	O
arthritis	O
including	O
inflammation	O
,	O
pannus	O
,	O
cartilage	O
damage	O
,	O
bone	O
resorption	O
,	O
and	O
periosteal	O
bone	O
formation	O
.	O
	
this	O
study	O
provides	O
further	O
support	O
for	O
the	O
use	O
of	O
ctxii	O
,	O
comp	O
,	O
and	O
a2m	O
as	O
relevant	O
biomarkers	O
that	O
were	O
responsive	O
to	O
nem	B-C3651790
mimicking	O
the	O
cell	B-C3161472
membrane	I-C3161472
bio-inspired	B-C0872312
simultaneous	B-C0521115
functions	O
with	O
monovalent	B-C0678553
anion	B-C0003075
selectivity	B-C1707391
and	O
antifouling	B-C0243178
properties	I-C0243178
of	O
anion	B-C0003075
exchange	O
membrane	B-C0025256
a	O
new	O
bio-inspired	B-C0872312
method	I-C0872312
was	O
applied	O
in	O
this	O
study	O
to	O
simultaneously	B-C0521115
improve	O
the	O
monovalent	B-C0678553
anion	B-C0003075
selectivity	B-C1707391
and	O
antifouling	B-C0243178
properties	I-C0243178
of	O
anion	B-C0003075
exchange	O
membranes	B-C0025256
aems	O
.	O
	
three-layer	O
architecture	O
was	O
developed	O
by	O
deposition	O
of	O
polydopamine	B-C3252413
pda	B-C3252413
and	O
electro-deposition	O
of	O
n-o-sulfonic	B-C0162969
acid	I-C0162969
benzyl	I-C0162969
chitosan	I-C0162969
nsbc	B-C0162969
.	O
	
the	O
innermost	B-C0205102
and	O
outermost	B-C0205101
layers	B-C1561572
were	O
pda	B-C3252413
with	O
different	O
deposition	O
time	O
.	O
	
the	O
middle	B-C0444598
layer	B-C1561572
was	O
prepared	O
by	O
nsbc	B-C0162969
.	O
	
fourier	B-C0206055
transform	I-C0206055
infrared	I-C0206055
spectroscopy	I-C0206055
and	O
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
confirmed	O
that	O
pda	B-C3252413
and	O
nsbc	B-C0162969
were	O
successfully	O
modified	O
on	O
the	O
surfaces	O
of	O
aems	O
.	O
	
the	O
contact	O
angle	O
of	O
the	O
membranes	B-C0025256
indicated	O
an	O
improved	O
hydrophilicity	B-C0475370
of	O
the	O
modified	O
membranes	B-C0025256
.	O
	
a	O
series	O
of	O
electrodialysis	B-C0683122
experiments	I-C0683122
in	O
which	O
cl	B-C0596019
/	O
so4	B-C3536965
separation	O
was	O
studied	O
,	O
demonstrating	O
the	O
monovalent	B-C0678553
anion	B-C0003075
selectivity	B-C1707391
of	O
the	O
samples	O
.	O
	
the	O
cl	B-C0596019
/	O
so4	B-C3536965
permselectivity	B-C0031164
of	O
the	O
modified	O
membranes	B-C0025256
can	O
reach	O
up	O
to	O
2.20	O
,	O
higher	O
than	O
that	O
of	O
the	O
commercial	B-C0025256
membrane	I-C0025256
only	O
0.78	O
during	O
90	O
minutes	O
in	O
electrodialysis	B-C0683122
ed	B-C0683122
.	O
	
the	O
increase	O
value	O
of	O
the	O
resistance	O
of	O
the	O
membranes	B-C0025256
was	O
also	O
measured	O
to	O
evaluate	O
the	O
antifouling	B-C0243178
properties	I-C0243178
.	O
	
sodium	B-C0142877
dodecyl	I-C0142877
benzene	I-C0142877
sulfonate	I-C0142877
sdbs	B-C0142877
was	O
used	O
as	O
the	O
fouling	B-C3826310
material	O
in	O
the	O
ed	B-C0683122
process	O
and	O
the	O
membrane	B-C0025256
area	O
resistance	O
of	O
modified	B-C0025256
membrane	I-C0025256
the	O
loop	B-C1514562
2	I-C1514562
region	I-C1514562
of	O
ribosomal	B-C0073335
protein	I-C0073335
us5	I-C0073335
influences	O
spectinomycin	B-C0001268
sensitivity	B-C0427965
,	O
translational	B-C3824282
fidelity	I-C3824282
,	O
and	O
ribosome	B-C1156140
biogenesis	I-C1156140
ribosomal	B-C0073335
protein	I-C0073335
us5	I-C0073335
is	O
an	O
essential	B-C1705248
component	I-C1705248
of	O
the	O
small	B-C1167012
ribosomal	I-C1167012
subunit	I-C1167012
that	O
is	O
involved	O
in	O
subunit	B-C1156143
assembly	I-C1156143
,	O
maintenance	B-C3824282
of	I-C3824282
translational	I-C3824282
fidelity	I-C3824282
,	O
and	O
the	O
ribosome's	B-C0035553
response	B-C0871261
to	O
the	O
antibiotic	B-C0001268
spectinomycin	I-C0001268
.	O
	
while	O
many	O
of	O
the	O
characterized	O
us5	B-C0026882
mutations	I-C0026882
that	O
affect	O
decoding	B-C1148560
map	O
to	O
its	O
interface	B-C1148560
with	O
us4	B-C0073333
,	O
more	O
recent	O
work	O
has	O
shown	O
that	O
residues	B-C1709915
distant	O
from	O
the	O
us4-us5	B-C1148560
interface	I-C1148560
can	O
also	O
affect	O
the	O
decoding	B-C1522240
process	I-C1522240
.	O
	
we	O
targeted	O
one	O
such	O
interface-remote	B-C1254362
area	I-C1254362
,	O
the	O
loop	B-C1514562
2	I-C1514562
region	I-C1514562
residues	B-C1709915
20	O
to	O
31	O
,	O
for	O
mutagenesis	B-C0079866
in	O
escherichia	B-C0014834
.	O
	
coli	I-C0014834
and	O
generated	O
21	O
unique	B-C0596988
mutants	I-C0596988
.	O
	
a	O
majority	O
of	O
the	O
loop	B-C1514562
2	I-C1514562
alterations	O
confer	O
resistance	B-C4281815
to	O
spectinomycin	B-C0001268
and	O
affect	O
the	O
fidelity	B-C3824282
of	I-C3824282
translation	I-C3824282
.	O
	
however	O
,	O
only	O
a	O
minority	O
show	O
altered	O
rrna	B-C0035701
processing	O
or	O
ribosome	B-C1156140
biogenesis	I-C1156140
defects	B-C1457869
.	O
	
multiplex	B-C0205556
social	B-C0728831
ecological	B-C0565987
network	B-C0242481
analysis	I-C0242481
reveals	B-C0443289
how	O
social	B-C0037400
changes	I-C0037400
affect	B-C0392760
community	B-C0009462
robustness	B-C2986815
more	O
than	O
resource	B-C0178640
depletion	B-C0392756
network	B-C0242481
analysis	I-C0242481
provides	B-C1999230
a	O
powerful	O
tool	O
to	O
analyze	O
complex	B-C0439855
influences	B-C4054723
of	O
social	B-C0680343
and	O
ecological	B-C0565987
structures	I-C0565987
on	O
community	B-C0009462
and	O
household	B-C0020052
dynamics	O
.	O
	
most	O
network	B-C0242481
studies	I-C0242481
of	O
social	B-C0728831
-	O
ecological	B-C0162358
systems	I-C0162358
use	O
simple	B-C0205352
,	O
undirected	O
,	O
unweighted	B-C1882071
networks	I-C1882071
.	O
	
we	O
analyze	O
multiplex	B-C0205556
,	O
directed	B-C0449738
,	O
and	O
weighted	B-C1882071
networks	I-C1882071
of	O
subsistence	B-C0024501
food	B-C0016452
flows	O
collected	B-C1516695
in	O
three	O
small	O
indigenous	B-C1512704
communities	B-C0009462
in	O
arctic	B-C0003740
alaska	B-C0001905
potentially	O
facing	O
substantial	O
economic	B-C0013557
and	O
ecological	B-C0565987
changes	B-C0392747
.	O
	
our	O
analysis	O
of	O
plausible	O
future	B-C0016884
scenarios	B-C0683579
suggests	O
that	O
changes	B-C0392747
to	O
social	B-C0728831
relations	B-C0439849
and	O
key	O
households	B-C0020052
have	O
greater	O
effects	B-C1280500
on	O
community	B-C0009462
robustness	B-C2986815
than	O
changes	B-C0392747
to	O
specific	B-C0205369
wild	B-C0178640
food	I-C0178640
resources	I-C0178640
.	O
	
heavy	B-C0872279
resistance	I-C0872279
training	I-C0872279
in	O
hypoxia	B-C0242184
enhances	B-C2349975
1rm	B-C4054321
squat	B-C0241236
performance	B-C0597198
purpose	O
to	O
determine	O
if	O
heavy	B-C0872279
resistance	I-C0872279
training	I-C0872279
in	O
hypoxia	B-C0242184
ihrt	B-C0872279
is	O
more	O
effective	B-C1704419
at	O
improving	B-C1272745
strength	B-C0237897
,	O
power	B-C0424581
,	O
and	O
increasing	B-C0442808
lean	B-C0424678
mass	I-C0424678
than	O
the	O
same	O
training	B-C2673163
in	O
normoxia	O
.	O
	
methods	O
a	O
pair-matched	B-C0085145
,	O
placebo-controlled	B-C0599724
study	I-C0599724
design	B-C1707689
included	O
20	O
resistance-trained	B-C0872279
participants	B-C0679646
assigned	O
to	O
ihrt	B-C0872279
fio2	B-C2370852
0.143	O
or	O
placebo	B-C0009932
fio2	B-C2370852
0.20	O
,	O
n	O
=	O
10	O
per	O
group	B-C0681860
.	O
	
participants	B-C0679646
were	O
matched	B-C1708943
for	O
strength	B-C0237897
and	O
training	B-C0872279
.	O
	
both	B-C1706086
groups	B-C0681860
performed	B-C0884358
20	O
sessions	B-C1883016
over	O
7	O
weeks	B-C0439230
either	O
with	O
ihrt	B-C0872279
or	O
placebo	B-C0009932
.	O
	
all	O
participants	B-C0679646
were	O
tested	B-C0039593
for	O
1rm	B-C4054321
,	O
20-m	B-C3842775
sprint	B-C0454374
,	O
body	B-C0005885
composition	I-C0005885
,	O
and	O
countermovement	B-C0221189
jump	I-C0221189
pre	B-C0332152
-	O
,	O
mid	B-C1254367
-	O
,	O
and	O
post	B-C0687676
-	O
training	B-C0872279
and	O
compared	B-C1707455
via	O
magnitude	B-C1704240
-	O
based	B-C1527178
inferences	B-C0679201
.	O
	
presentation	O
of	O
results	O
groups	B-C0681860
were	O
not	B-C3845108
clearly	I-C3845108
different	B-C1705242
for	O
any	O
test	B-C0039593
at	O
baseline	B-C1442488
.	O
	
training	B-C0872279
improved	B-C0184511
both	B-C1706086
absolute	B-C0205344
ihrt	B-C0872279
13.1	O
3.9	O
,	O
effect	B-C0814843
size	I-C0814843
es	B-C0814843
0.60	O
,	O
placebo	B-C0009932
9.8	O
4.7	O
,	O
es	B-C0814843
0.31	O
and	O
relative	B-C0205345
1rm	B-C4054321
ihrt	B-C0872279
13.4	O
5.1	O
,	O
es	B-C0814843
0.76	O
,	O
placebo	B-C0009932
9.7	O
5.3	O
,	O
es	B-C0814843
0.48	O
at	O
mid	O
.	O
	
similarly	O
,	O
at	O
post	B-C0687676
both	B-C1706086
groups	B-C0681860
increased	B-C0205217
absolute	B-C0205344
ihrt	B-C0872279
20.7	O
7.6	O
,	O
es	B-C0814843
0.74	O
,	O
placebo	B-C0009932
14.1	O
6.0	O
,	O
es	B-C0814843
0.58	O
and	O
relative	B-C0205345
1rm	B-C4054321
ihrt	B-C0872279
21.6	O
8.5	O
,	O
es	B-C0814843
1.08	O
,	O
placebo	B-C0009932
13.2	O
6.4	O
,	O
es	B-C0814843
0.78	O
.	O
	
importantly	O
,	O
the	O
change	B-C0392747
in	O
ihrt	B-C0872279
was	O
greater	B-C1704243
than	O
placebo	B-C0009932
at	O
mid	O
for	O
both	B-C1706086
absolute	B-C0205344
4.4	O
greater	B-C1704243
change	B-C0392747
,	O
90%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
1.0	O
,	O
es	B-C0814843
0.21	O
,	O
and	O
relative	B-C0205345
strength	B-C0237897
5.6	O
greater	B-C1704243
change	B-C0392747
,	O
90%	O
ci	B-C0009667
1.0	O
,	O
es	B-C0814843
0.31	O
relative	B-C0205345
.	O
	
there	O
was	O
also	O
a	O
greater	B-C1704243
change	B-C0392747
for	O
ihrt	B-C0872279
at	O
post	O
for	O
both	B-C1706086
absolute	B-C0205344
7.0	O
greater	B-C1704243
change	B-C0392747
,	O
90%	O
ci	B-C0009667
1.3	O
,	O
es	B-C0814843
0.33	O
,	O
and	O
relative	B-C0205345
1rm	B-C4054321
9.2	O
greater	B-C1704243
change	B-C0392747
,	O
90%	O
ci	B-C0009667
1.6	O
,	O
es	B-C0814843
0.49	O
.	O
	
only	O
ihrt	B-C0872279
increased	B-C0205217
countermovement	B-C0221189
jump	I-C0221189
peak	B-C0444505
power	B-C0424581
at	O
post	B-C0687676
4.9	O
,	O
es	B-C0814843
0.35	O
,	O
however	O
the	O
difference	B-C1705242
between	O
ihrt	B-C0872279
and	O
placebo	B-C0009932
was	O
unclear	B-C3845108
2.7	O
,	O
90%	O
ci	B-C0009667
-2	O
,	O
es	B-C0814843
0.20	O
with	O
no	B-C3845108
clear	I-C3845108
differences	B-C1705242
in	O
speed	B-C0678536
or	O
body	B-C0005885
composition	I-C0005885
throughout	O
.	O
	
conclusion	O
heavy	B-C0872279
resistance	I-C0872279
training	I-C0872279
in	O
hypoxia	B-C0242184
is	O
more	O
effective	B-C1704419
than	O
placebo	B-C0009932
for	O
improving	B-C1272745
absolute	B-C0205344
and	O
relative	B-C0205345
strength	B-C0237897
.	O
	
ultrasonography	B-C0041618
and	O
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
evaluation	B-C0220825
of	O
pediatric	B-C1521725
spinal	B-C0266498
anomalies	I-C0266498
spinal	B-C0080178
dysraphisms	I-C0080178
are	O
congenital	B-C0000768
abnormalities	I-C0000768
of	O
the	O
spine	B-C0037949
due	O
to	O
imperfect	O
fusion	B-C0332466
of	O
midline	B-C0549183
mesenchymal	B-C1513143
,	O
bony	B-C0443157
and	O
neural	B-C3714606
structures	B-C0678594
.	O
	
imaging	B-C0011923
plays	O
a	O
vital	O
role	O
in	O
their	O
evaluation	B-C0220825
as	O
significant	O
portion	O
of	O
patients	B-C0030705
may	O
present	O
with	O
concurrent	B-C0205420
anomalies	B-C0000768
that	O
need	O
to	O
be	O
corrected	B-C0205202
simultaneously	B-C0521115
to	O
avoid	O
repeat	B-C0035110
surgeries	I-C0035110
.	O
	
the	O
aims	O
of	O
the	O
study	B-C2603343
were	O
to	O
evaluate	B-C0220825
spinal	B-C0080178
dysraphisms	I-C0080178
using	O
usg	B-C0041618
and	O
mri	B-C0024485
and	O
to	O
correlate	B-C1707520
imaging	B-C0011923
findings	B-C2607943
with	O
operative	B-C1882154
findings	B-C2607943
in	O
patients	B-C0030705
undergoing	O
surgery	B-C0543467
.	O
	
hospital	B-C0019994
based	O
observational	B-C1518527
study	I-C1518527
conducted	O
over	O
a	O
period	B-C1948053
of	O
year	B-C0439234
.	O
	
38	O
cases	B-C1706256
of	O
both	O
sexes	B-C1522384
and	O
below	O
12	O
years	B-C0439234
of	O
age	B-C0001779
with	O
spinal	B-C0080178
dysraphism	I-C0080178
were	O
studied	O
.	O
	
usg	B-C0041618
was	O
performed	O
in	O
29	O
cases	B-C1706256
where	O
acoustic	B-C1254362
window	I-C1254362
was	O
available	O
for	O
proper	O
evaluation	B-C0220825
.	O
	
mri	B-C0024485
was	O
performed	O
in	O
all	O
cases	B-C1706256
.	O
	
usg	B-C0041618
findings	B-C2607943
were	O
compared	O
with	O
mri	B-C0024485
findings	B-C2607943
and	O
operative	B-C1882154
follow	B-C3274571
up	I-C3274571
was	O
taken	O
in	O
23	O
cases	B-C1706256
who	O
underwent	O
operative	B-C0150270
management	I-C0150270
.	O
	
results	O
were	O
analysed	B-C0936012
using	O
percentage	B-C0439165
and	O
arithmetic	B-C0392762
mean	I-C0392762
.	O
	
39.47	O
%	O
cases	B-C1706256
were	O
male	B-C0086582
and	O
60.53	O
%	O
cases	B-C1706256
were	O
female	B-C0086287
.	O
	
neonatal	B-C0935562
period	I-C0935562
was	O
the	O
most	O
common	O
presenting	O
age	B-C0027362
group	I-C0027362
.	O
	
closed	B-C0587267
spinal	B-C0080178
dysraphism	I-C0080178
63.16	O
was	O
more	O
common	O
than	O
open	B-C0175566
36.84	O
.	O
	
79.31	O
cases	B-C1706256
showed	O
full	O
agreement	O
between	O
spinal	B-C0521329
usg	B-C0041618
and	O
mri	B-C0024485
examinations	B-C0582103
and	O
6	O
out	O
of	O
20.69	O
showed	O
partial	O
agreement	O
.	O
	
on	O
operative	B-C1882154
correlation	B-C1707520
,	O
usg	B-C0041618
findings	B-C2607943
were	O
confirmatory	B-C0750484
in	O
91.30	O
cases	B-C1706256
and	O
mri	B-C0024485
findings	B-C2607943
were	O
confirmatory	B-C0750484
in	O
100%	O
cases	B-C1706256
.	O
	
usg	B-C0041618
can	O
be	O
used	O
as	O
the	O
initial	O
modality	B-C1275506
for	O
evaluation	B-C0220825
of	O
spinal	B-C0080178
dysraphism	I-C0080178
as	O
well	O
as	O
for	O
screening	B-C1710032
of	O
suspected	B-C0750491
cases	B-C1706256
.	O
	
mri	B-C0024485
is	O
indicated	O
to	O
confirm	O
abnormal	B-C0205161
usg	B-C0041618
findings	B-C2607943
,	O
which	O
shows	O
all	O
concurrent	B-C0205420
abnormalities	B-C0000768
and	O
also	O
provides	O
additional	O
anatomical	B-C0220784
details	B-C1522508
relevant	O
to	O
surgical	B-C0599880
planning	I-C0599880
.	O
	
bora	B-C1824391
-dependent	O
plk1	B-C1579259
regulation	B-C1158894
a	O
new	O
weapon	O
for	O
cancer	B-C0920425
therapy	I-C0920425
the	O
mitotic	B-C1579259
kinase	I-C1579259
polo	I-C1579259
like	I-C1579259
kinase	I-C1579259
1	I-C1579259
plk1	B-C1579259
is	O
overexpressed	B-C1514559
in	O
many	O
cancers	B-C1512773
and	I-C1512773
its	I-C1512773
inhibition	I-C1512773
slows	B-C1156236
down	I-C1156236
proliferation	I-C1156236
and	O
increases	B-C2248382
apoptosis	I-C2248382
in	O
cancer	B-C0334227
cell	I-C0334227
lines	I-C0334227
.	O
	
understanding	O
how	O
plk1	B-C1819041
is	I-C1819041
activated	I-C1819041
is	O
therefore	O
crucial	O
for	O
the	O
development	O
of	O
novel	O
plk1	B-C1449702
inhibitors	I-C1449702
with	O
anticancer	B-C0003392
properties	I-C0003392
.	O
	
we	O
recently	O
identified	O
a	O
conserved	O
regulatory	B-C0678662
loop	I-C0678662
leading	O
to	O
plk1	B-C1819041
activation	I-C1819041
that	O
involves	O
cyclin-dependent	B-C2353787
kinase	I-C2353787
1	I-C2353787
cdk1	B-C2353787
.	O
	
activation	B-C0162493
of	I-C0162493
transcription	I-C0162493
enforces	O
the	O
formation	O
of	O
distinct	O
nuclear	B-C0230595
bodies	I-C0230595
in	O
zebrafish	B-C0043457
embryos	B-C0013935
nuclear	B-C0230595
bodies	I-C0230595
are	O
cellular	B-C2335889
compartments	I-C2335889
that	O
lack	B-C0332268
lipid	B-C0023768
bilayers	I-C0023768
and	O
harbor	O
specific	B-C0205369
rnas	B-C0035668
and	O
proteins	B-C0033684
.	O
	
recent	O
proposals	O
that	O
nuclear	B-C0230595
bodies	I-C0230595
form	O
through	O
liquid-liquid	O
phase	O
separation	O
leave	O
the	O
question	O
of	O
how	O
different	O
nuclear	B-C0230595
bodies	I-C0230595
maintain	O
their	O
distinct	O
identities	O
unanswered	O
.	O
	
here	O
we	O
investigate	B-C1292732
cajal	B-C0751972
bodies	I-C0751972
cbs	B-C0751972
,	O
histone	B-C2752281
locus	I-C2752281
bodies	I-C2752281
hlbs	B-C2752281
and	O
nucleoli	B-C0007609
-	O
involved	O
in	O
assembly	O
of	O
the	O
splicing	B-C0314666
machinery	I-C0314666
,	O
histone	B-C1158725
mrna	I-C1158725
3'	I-C1158725
end	I-C1158725
processing	I-C1158725
,	O
and	O
rrna	B-C1156152
processing	I-C1156152
,	O
respectively	O
-	O
in	O
the	O
embryos	B-C0013935
of	O
the	O
zebrafish	B-C0043457
,	O
danio	B-C0043457
rerio	I-C0043457
.	O
	
we	O
take	O
advantage	O
of	O
the	O
transcriptional	O
silence	O
of	O
the	O
1-cell	O
embryo	B-C0013935
and	O
follow	O
nuclear	B-C0230595
body	I-C0230595
appearance	O
as	O
zygotic	B-C0043544
transcription	B-C0040649
becomes	O
activated	B-C1879547
.	O
	
cbs	B-C0751972
are	O
present	O
from	O
fertilization	B-C0015914
onwards	O
,	O
while	O
hlb	B-C2752281
and	O
nucleolar	B-C0007609
components	B-C0243092
formed	O
foci	B-C0205234
several	O
hours	O
later	O
when	O
histone	B-C0019652
genes	B-C0017337
and	O
rdna	B-C0012933
became	O
active	B-C0205177
.	O
	
hlb	B-C2752281
formation	O
was	O
blocked	B-C0332206
by	O
transcription	B-C1514673
inhibition	I-C1514673
,	O
suggesting	O
nascent	B-C1519595
histone	I-C1519595
transcripts	I-C1519595
recruit	O
hlb	B-C2752281
components	B-C0243092
like	O
u7	B-C0162464
snrnp	I-C0162464
.	O
	
surprisingly	O
,	O
we	O
found	O
that	O
u7	O
base-pairing	B-C0600436
with	O
nascent	B-C1519595
histone	I-C1519595
transcripts	I-C1519595
was	O
not	O
required	O
for	O
localization	B-C1158693
to	O
hlbs	B-C2752281
.	O
	
rather	O
,	O
the	O
type	O
of	O
sm	O
ring	O
assembled	O
on	O
u7	O
determined	O
its	O
targeting	O
to	O
hlbs	B-C2752281
or	O
cbs	B-C0751972
the	O
spliceosomal	O
sm	O
ring	O
targeted	O
snrnas	B-C0035709
to	O
cbs	B-C0751972
while	O
the	O
specialized	O
u7	O
sm-ring	O
localized	O
to	O
hlbs	B-C2752281
,	O
demonstrating	O
the	O
contribution	B-C1880177
of	O
protein	B-C0033684
constituents	B-C0729650
to	O
the	O
distinction	O
among	O
nuclear	B-C0230595
bodies	I-C0230595
.	O
	
thus	O
,	O
nucleolar	B-C0007609
,	O
hlb	B-C2752281
,	O
and	O
cb	B-C0751972
components	B-C0243092
can	O
mix	O
in	O
early	B-C1279919
embryogenesis	B-C0013936
when	O
transcription	B-C0040649
is	O
naturally	O
or	O
artificially	O
silenced	O
.	O
	
these	O
data	O
support	O
a	O
model	O
in	O
which	O
transcription	B-C0040649
of	O
specific	B-C0205369
gene	B-C1708726
loci	I-C1708726
nucleates	O
nuclear	B-C0230595
body	I-C0230595
components	B-C0243092
with	O
high	O
specificity	B-C0037791
and	O
fidelity	O
to	O
perform	O
distinct	O
regulatory	B-C1704735
functions	B-C0031843
.	O
	
variation	B-C0699810
in	I-C0699810
the	I-C0699810
age	I-C0699810
of	O
first	B-C0035150
reproduction	I-C0035150
different	B-C0205556
strategies	I-C0205556
or	O
individual	B-C0332306
quality	I-C0332306
although	O
age	B-C0001779
at	O
first	B-C0035150
reproduction	I-C0035150
is	O
a	O
key	O
demographic	B-C0011292
parameter	I-C0011292
that	O
is	O
probably	O
under	O
high	B-C0460139
selective	I-C0460139
pressure	I-C0460139
,	O
it	O
is	O
highly	O
variable	B-C0439828
and	O
the	O
cause	O
of	O
this	O
variability	B-C2827666
is	O
not	O
well	O
understood	O
.	O
	
two	O
non-exclusive	O
hypotheses	B-C1512571
may	O
explain	O
such	O
variability	B-C2827666
.	O
	
it	O
could	O
be	O
the	O
expression	B-C0565975
of	O
different	O
individual	B-C0205556
strategies	I-C0205556
,	O
i.e	O
,	O
different	O
allocation	B-C1706778
strategies	I-C1706778
in	O
fitness	B-C0031812
components	I-C0031812
,	O
or	O
the	O
consequences	O
of	O
individual	B-C0021228
difference	I-C0021228
in	O
intrinsic	B-C0205102
quality	I-C0205102
,	O
i.e	O
,	O
some	O
individuals	B-C0237401
always	O
doing	O
better	O
than	O
others	O
in	O
all	O
fitness	B-C0031812
components	I-C0031812
.	O
	
we	O
tested	B-C0039593
these	O
hypotheses	B-C1512571
in	O
the	O
wandering	B-C0325368
albatross	I-C0325368
investigating	O
relationships	B-C0439849
between	O
the	O
age	B-C0001779
at	O
first	B-C0035150
reproduction	I-C0035150
and	O
subsequent	O
adult	B-C0001675
demographic	B-C0011298
traits	B-C0599883
.	O
	
using	O
finite	B-C0870071
mixture	I-C0870071
capture	I-C0870071
recapture	I-C0870071
modeling	I-C0870071
,	O
we	O
demonstrate	O
that	O
the	O
age	B-C0001779
at	O
first	B-C0035150
reproduction	I-C0035150
is	O
negatively	B-C1513916
related	O
to	O
both	O
reproductive	B-C0035150
performances	B-C0597198
and	O
adult	B-C0001675
survival	B-C0038952
,	O
suggesting	O
that	O
individual	B-C0332306
quality	I-C0332306
was	O
an	O
important	O
factor	O
explaining	O
variation	B-C2827666
in	O
the	O
age	B-C0001779
at	O
first	B-C0035150
reproduction	I-C0035150
.	O
	
our	O
results	O
suggest	O
that	O
age	B-C0001779
at	O
first	B-C0006159
breeding	I-C0006159
is	O
a	O
good	O
predictor	B-C2698872
of	O
quality	B-C0332306
in	O
this	O
long-lived	O
seabird	B-C0325368
species	I-C0325368
.	O
	
heterogeneity	B-C0019409
of	O
colorectal	B-C1527249
cancer	I-C1527249
risk	B-C0035647
by	O
tumour	B-C0027651
characteristics	B-C1521970
large	O
prospective	B-C0033522
study	I-C0033522
of	O
uk	B-C0041700
women	B-C0043210
associations	B-C0439849
between	O
behavioural	B-C0004927
and	O
other	O
personal	B-C1519021
factors	B-C1521761
and	O
colorectal	B-C1527249
cancer	I-C1527249
risk	B-C0035647
have	O
been	O
reported	O
to	O
vary	O
by	O
tumour	B-C0027651
characteristics	B-C1521970
,	O
but	O
evidence	O
is	O
inconsistent	O
.	O
	
in	O
a	O
large	O
uk	B-C0041700
-based	O
prospective	B-C0033522
study	I-C0033522
we	O
examined	O
associations	O
of	O
14	O
postulated	O
risk	B-C0035648
factors	I-C0035648
with	O
colorectal	B-C1527249
cancer	I-C1527249
risk	B-C0035647
overall	O
,	O
and	O
across	O
three	O
anatomical	B-C0005898
sites	I-C0005898
and	O
four	O
morphological	B-C0543482
subtypes	B-C0449560
.	O
	
among	O
1.3	O
million	O
women	B-C0043210
,	O
18	O
incident	O
colorectal	B-C1527249
cancers	I-C1527249
were	O
identified	O
during	O
13.8	O
sd	O
3.4	O
years	O
follow-up	B-C1522577
via	O
record	O
linkage	O
to	O
national	B-C0805443
cancer	I-C0805443
registry	I-C0805443
data	B-C1511726
.	O
	
cox	B-C0010235
regression	I-C0010235
yielded	O
adjusted	O
relative	B-C0242492
risks	I-C0242492
.	O
	
statistical	B-C0237881
significance	I-C0237881
was	O
assessed	O
using	O
correction	O
for	O
multiple	O
testing	O
.	O
	
overall	O
,	O
colorectal	B-C1527249
cancer	I-C1527249
risk	B-C0035647
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
height	B-C0005890
,	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
,	O
smoking	B-C0037369
,	O
alcohol	B-C0001948
intake	I-C0001948
,	O
physical	B-C0026606
activity	I-C0026606
,	O
parity	B-C0030563
and	O
menopausal	B-C0282402
hormone	I-C0282402
therapy	I-C0282402
use	O
.	O
	
for	O
smoking	B-C0037369
there	O
was	O
substantial	O
heterogeneity	B-C0019409
across	O
morphological	B-C0543482
types	B-C0332307
relative	B-C0242492
risks	I-C0242492
around	O
two	O
or	O
greater	O
were	O
seen	O
in	O
current	O
smokers	B-C0337664
both	O
for	O
signet	B-C0333727
ring	I-C0333727
cell	I-C0333727
and	O
for	O
neuroendocrine	B-C0206754
tumours	I-C0206754
.	O
	
obese	B-C0028754
women	B-C0043210
were	O
also	O
at	B-C3843761
higher	I-C3843761
risk	I-C3843761
for	O
signet	B-C0333727
ring	I-C0333727
cell	I-C0333727
tumours	B-C0027651
.	O
	
for	O
adenocarcinomas	B-C0001418
,	O
the	O
large	O
majority	O
of	O
colorectal	B-C1527249
cancers	I-C1527249
in	O
the	O
cohort	B-C0599755
,	O
all	O
risk	B-C0035648
factor	I-C0035648
associations	B-C0439849
were	O
weak	O
.	O
	
there	O
was	O
little	O
or	O
no	O
heterogeneity	B-C0019409
in	O
risk	B-C0035647
between	O
tumours	B-C0027651
of	O
the	O
right	B-C1305188
colon	I-C1305188
,	O
left	B-C0227388
colon	I-C0227388
and	O
rectum	B-C0034896
for	O
any	O
of	O
the	O
14	O
factors	B-C0035648
examined	O
.	O
	
these	O
epidemiological	B-C0014507
findings	B-C0243095
complement	O
an	O
emerging	O
picture	O
from	O
molecular	B-C0946228
studies	I-C0946228
of	O
possible	O
different	O
developmental	B-C0458003
pathways	B-C1705987
for	O
different	O
tumour	B-C0027651
types	B-C0332307
.	O
	
impact	B-C4049986
of	O
alcohol	B-C0001948
use	I-C0001948
on	O
eeg	B-C0013819
dynamics	I-C0013819
of	O
response	B-C1510574
inhibition	I-C1510574
a	O
cotwin	B-C0242481
control	I-C0242481
analysis	I-C0242481
research	O
indicates	O
that	O
alcohol	B-C0678254
misuse	I-C0678254
is	O
associated	B-C0332281
with	I-C0332281
behavioral	B-C0424296
disinhibition	I-C0424296
,	O
but	O
the	O
neurophysiological	B-C1327471
mechanisms	I-C1327471
governing	O
this	O
relationship	B-C0439849
remain	O
largely	O
unknown	O
.	O
	
recent	O
work	O
suggests	O
that	O
successful	O
inhibition	B-C1510574
and	O
cognitive	B-C0392335
control	I-C0392335
involve	O
electrophysiological	B-C0850293
theta-band	I-C0850293
dynamics	I-C0850293
,	O
including	O
medial	B-C2951740
frontal	I-C2951740
cortex	I-C2951740
mfc	B-C2951740
power	B-C1254358
enhancement	I-C1254358
and	O
functional	B-C1254358
connectivity	I-C1254358
between	O
the	O
mfc	B-C2951740
and	O
dorsal	B-C4019080
prefrontal	I-C4019080
cortex	I-C4019080
dpfc	B-C4019080
regions	O
,	O
which	O
may	O
be	O
disrupted	O
by	O
alcohol	B-C0678254
misuse	I-C0678254
.	O
	
in	O
addition	O
,	O
research	O
suggests	O
that	O
,	O
compared	O
to	O
men	B-C0025266
,	O
women	B-C0043210
are	O
at	O
heightened	O
risk	B-C0035647
of	O
experiencing	O
the	O
negative	O
physical	B-C0871083
and	O
neurocognitive	B-C0871178
correlates	I-C0871178
of	O
drinking	B-C0001948
.	O
	
the	O
present	O
study	B-C2603343
tested	O
the	O
hypothesis	O
that	O
alcohol	B-C0678254
misuse	I-C0678254
has	O
a	O
deleterious	B-C0879626
effect	I-C0879626
on	O
theta-band	B-C0204631
response	B-C1510574
inhibition	I-C1510574
eeg	B-C0013819
dynamics	I-C0013819
in	O
a	O
sample	B-C1257890
of	O
300	O
24-year-old	O
same-sex	O
twins	B-C0041427
.	O
	
a	O
cotwin	B-C0035171
control	I-C0035171
ctc	I-C0035171
design	I-C0035171
was	O
used	O
to	O
disentangle	O
premorbid	O
risk	B-C0035647
for	O
alcohol	B-C0001948
use	I-C0001948
from	O
the	O
causal	B-C1280500
effects	I-C1280500
of	O
alcohol	B-C4038778
exposure	I-C4038778
.	O
	
drinking	B-C0001948
was	O
negatively	O
associated	B-C0332281
with	I-C0332281
theta-band	B-C0204631
mfc	B-C1254358
power	I-C1254358
and	O
mfc	B-C2951740
-	O
dpfc	B-C4019080
connectivity	B-C0229984
during	O
response	B-C1510574
inhibition	I-C1510574
,	O
and	O
this	O
effect	B-C1280500
was	O
stronger	O
among	O
women	B-C0043210
.	O
	
the	O
ctc	B-C0242481
analysis	I-C0242481
suggested	O
that	O
,	O
for	O
women	B-C0043210
,	O
reduced	O
nogo-related	O
theta-band	B-C0204631
mfc	B-C1254358
power	I-C1254358
and	O
mfc	B-C2951740
-	O
dpfc	B-C4019080
connectivity	B-C0229984
were	O
both	O
consistent	O
with	O
the	O
potential	O
deleterious	B-C0879626
causal	I-C0879626
effects	I-C0879626
of	O
alcohol	B-C4038778
exposure	I-C4038778
.	O
	
these	O
findings	O
suggest	O
that	O
diminished	B-C0205216
theta-band	B-C0204631
mfc	B-C1254358
power	I-C1254358
and	O
mfc	B-C2951740
-	O
dpfc	B-C4019080
connectivity	B-C0229984
may	O
be	O
neurophysiological	B-C1327471
mechanisms	I-C1327471
underlying	O
alcohol-related	B-C0424296
disinhibition	I-C0424296
.	O
	
although	O
preliminary	O
,	O
these	O
results	O
suggest	O
that	O
normative	B-C0243095
levels	I-C0243095
of	O
alcohol	B-C0001948
use	I-C0001948
during	O
emerging	O
adulthood	B-C0700597
have	O
potential	O
sex-specific	O
causal	B-C1280500
effects	I-C1280500
on	O
response	B-C1510574
inhibition	I-C1510574
eeg	B-C0013819
dynamics	I-C0013819
,	O
neutrophil	B-C0027950
and	O
monocyte	B-C0026473
function	B-C0007613
in	O
patients	B-C0030705
with	O
chronic	B-C0524910
hepatitis	I-C0524910
c	I-C0524910
undergoing	O
antiviral	B-C0280274
therapy	I-C0280274
with	O
regimens	B-C0040808
containing	O
protease	B-C0033607
inhibitors	I-C0033607
with	O
and	O
without	O
interferon	B-C0021747
real-life	B-C1511726
data	I-C1511726
showed	O
an	O
increased	B-C0205217
incidence	B-C0021149
of	O
bacterial	B-C0004623
infections	I-C0004623
in	O
patients	B-C0030705
with	O
advanced	O
liver	B-C0023895
disease	I-C0023895
receiving	B-C1514756
a	O
protease	B-C0033607
inhibitor	I-C0033607
pi	B-C0033607
antiviral	B-C0040808
regimen	I-C0040808
against	O
hepatitis	B-C0220847
c	I-C0220847
hcv	B-C0220847
.	O
	
however	O
,	O
the	O
causes	O
of	O
this	O
event	O
are	O
unknown	O
.	O
	
we	O
hypothesized	O
that	O
pis	B-C0033607
might	O
impair	O
innate	B-C0020969
immune	I-C0020969
responses	I-C0020969
through	O
the	O
inhibition	B-C1524081
of	I-C1524081
proteases	I-C1524081
participating	O
in	O
the	O
anti-bacterial	B-C0544570
functions	I-C0544570
of	O
neutrophils	B-C0027950
and	O
monocytes	B-C0026473
.	O
	
the	O
aims	O
of	O
the	O
study	B-C1706256
were	O
to	O
assess	B-C0184514
phagocytic	B-C0085416
and	I-C0085416
oxidative	I-C0085416
burst	I-C0085416
capacity	B-C1516240
in	O
neutrophils	B-C0027950
and	O
monocytes	B-C0026473
obtained	O
from	O
patients	B-C0030705
receiving	B-C1514756
a	O
pi	B-C0033607
containing-	O
antiviral	B-C0040808
regimen	I-C0040808
,	O
and	O
to	O
determine	O
cytokine	B-C1327414
secretion	I-C1327414
after	O
neutrophil	B-C0027950
stimulation	B-C0007613
with	O
flagellin	B-C0016194
.	O
	
forty	O
patients	B-C0030705
with	O
chronic	B-C0524910
hcv	I-C0524910
80%	O
with	O
cirrhosis	B-C0023890
were	O
enrolled	O
in	O
the	O
study	B-C1706256
,	O
28	O
received	B-C1514756
triple	B-C0087111
therapy	I-C0087111
group	B-C0441835
a	I-C0441835
with	O
pegylated-interferon	B-C0021747
and	O
ribavirin	B-C0035525
for	O
4	O
weeks	B-C0439230
followed	O
by	O
the	O
addition	O
of	O
a	O
pi	B-C0033607
telaprevir	B-C1876229
,	O
boceprevir	B-C1738934
or	O
simeprevir	B-C2605855
,	O
and	O
12	O
patients	B-C0030705
received	B-C1514756
an	O
interferon	B-C0021747
-free	O
regimen	O
group	O
b	O
with	O
simeprevir	O
and	O
sofosbuvir	O
.	O
	
phagocytosis	O
and	O
oxidative	O
burst	O
capacity	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
of	O
therapy	O
.	O
	
in	O
neutrophils	O
from	O
group	O
a	O
patients	O
,	O
oxidative	O
burst	O
rate	O
and	O
oxidative	O
enzymatic	O
activity	O
per	O
cell	O
significantly	O
decreased	O
throughout	O
the	O
study	O
period	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.010	O
,	O
respectively	O
.	O
	
pairwise	O
comparisons	O
showed	O
a	O
decrease	O
between	O
baseline	O
and	O
week	O
4	O
and	O
8	O
of	O
therapy	O
.	O
	
no	O
differences	O
were	O
observed	O
after	O
the	O
introduction	O
of	O
the	O
pi	O
.	O
	
the	O
oxidative	O
enzymatic	O
activity	O
per	O
cell	O
in	O
monocytes	O
significantly	O
decrease	O
during	O
the	O
study	O
period	O
p	O
=	O
0.042	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	O
p	O
=	O
0.037	O
in	O
patients	O
from	O
group	O
a	O
.	O
	
none	O
of	O
these	O
findings	O
were	O
observed	O
in	O
group	O
b	O
patients	O
.	O
	
cytokine	O
secretion	O
did	O
not	O
significantly	O
change	O
during	O
the	O
study	O
in	O
both	O
groups	O
.	O
	
in	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	B-C0040808
rather	O
than	O
the	O
pi	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	O
and	O
monocyte	O
phagocytic	O
and	O
oxidative	O
burst	O
capacity	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
hcv	O
-related	O
advanced	O
liver	O
fibrosis	I-C0239946
child	B-C0524343
death	I-C0524343
and	O
maternal	B-C1858460
psychosis-like	B-C0033975
experiences	I-C0033975
in	O
44	O
low-	B-C0024045
and	O
middle-income	B-C0870890
countries	B-C0454664
the	O
role	O
of	O
depression	B-C0011570
studies	O
on	O
the	O
effect	O
of	O
child	B-C0524343
death	I-C0524343
on	O
the	O
mental	B-C0025353
wellbeing	I-C0025353
of	O
women	B-C0043210
in	O
low-	B-C0024045
and	O
middle-income	B-C0870890
countries	B-C0454664
lmics	B-C0454664
are	O
scarce	O
despite	O
the	O
high	O
child	B-C0008083
mortality	I-C0008083
rates	O
.	O
	
thus	O
,	O
the	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
association	B-C0439849
between	O
child	B-C0524343
death	I-C0524343
and	O
psychosis-like	B-C0033975
experiences	I-C0033975
ples	B-C0033975
,	O
as	O
well	O
as	O
the	O
role	O
of	O
depression	B-C0011570
in	O
this	O
association	B-C0439849
.	O
	
data	B-C0010100
from	O
44	O
lmics	B-C0454664
which	O
participated	O
in	O
the	O
world	B-C0018762
health	I-C0018762
survey	I-C0018762
whs	B-C0018762
were	O
analyzed	O
.	O
	
a	O
total	O
of	O
59	O
women	B-C0043210
who	O
ever	O
gave	O
birth	B-C0005615
,	O
aged	O
18-49	O
years	B-C0439234
,	O
without	O
a	O
self-reported	B-C0681906
lifetime	B-C4071830
psychosis	B-C0596905
diagnosis	I-C0596905
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O
	
the	O
world	B-C3481515
mental	I-C3481515
health	I-C3481515
survey	I-C3481515
version	O
of	O
the	O
composite	B-C0451085
international	I-C0451085
diagnostic	I-C0451085
interview	I-C0451085
cidi	B-C0451085
was	O
used	O
to	O
establish	O
the	O
diagnosis	B-C1704656
of	O
past	O
12-	O
month	B-C0439231
dsm-iv	B-C0220952
depression	B-C0011570
,	O
and	O
assess	O
four	O
positive	B-C0871189
psychotic	I-C0871189
symptoms	I-C0871189
.	O
	
depression	B-C0011570
was	O
defined	O
as	O
self-reported	B-C0681906
lifetime	B-C4071830
depression	B-C0596905
diagnosis	I-C0596905
and/or	O
past	O
12-	O
month	B-C0439231
depression	B-C0011570
.	O
	
multivariable	O
logistic	B-C0681925
regression	I-C0681925
analyses	I-C0681925
were	O
performed	O
.	O
	
after	O
adjustment	O
for	O
potential	B-C0009673
confounders	I-C0009673
,	O
women	B-C0043210
who	O
experienced	O
child	B-C0524343
death	I-C0524343
had	O
higher	O
odds	O
for	O
all	O
types	O
of	O
ples	B-C0033975
when	O
unadjusted	O
for	O
depression	B-C0011570
or	B-C0028873
1.20	O
p<0	O
and	O
depression	B-C0011570
or	B-C0028873
=1	O
95%	O
ci	B-C0009667
=1	O
.	O
	
when	O
adjusted	O
for	O
depression	B-C0011570
,	O
only	O
delusion	B-C0233685
of	I-C0233685
control	I-C0233685
was	O
strongly	O
associated	B-C0332281
with	I-C0332281
child	B-C0524343
death	I-C0524343
or	B-C0028873
=1	O
95%	O
ci	B-C0009667
=1	O
.	O
	
child	B-C0524343
death	I-C0524343
may	O
be	O
an	O
important	O
determinant	O
of	O
mental	B-C0025353
wellbeing	I-C0025353
among	O
women	B-C0043210
in	O
lmics	B-C0454664
.	O
	
given	O
the	O
known	O
adverse	B-C3858647
health	I-C3858647
outcomes	I-C3858647
associated	B-C0332281
with	I-C0332281
ples	B-C0033975
and	O
depression	B-C0011570
,	O
as	O
well	O
as	O
the	O
co-occurrence	O
of	O
these	O
symptoms	B-C1457887
,	O
mental	B-C0184643
health	I-C0184643
care	I-C0184643
may	O
be	O
particularly	O
important	O
for	O
mothers	B-C0026591
who	O
have	O
experienced	O
child	B-C0848031
loss	I-C0848031
in	O
prednisolone	B-C0032950
is	O
associated	B-C0332281
with	I-C0332281
a	O
worse	B-C0740400
lipid	I-C0740400
profile	I-C0740400
than	O
hydrocortisone	B-C0020268
in	O
patients	B-C0030705
with	O
adrenal	B-C0001623
insufficiency	I-C0001623
prednisolone	B-C0032950
is	O
used	O
as	O
glucocorticoid	B-C0017710
replacement	B-C0279033
therapy	I-C0279033
for	O
adrenal	B-C0001623
insufficiency	I-C0001623
ai	B-C0001623
.	O
	
recent	O
data	B-C1511726
indicate	O
that	O
its	O
use	O
in	O
ai	B-C0001623
is	O
associated	B-C0332281
with	I-C0332281
low	O
bone	B-C0005938
mineral	I-C0005938
density	I-C0005938
.	O
	
data	B-C1511726
on	O
risk	B-C0035648
factors	I-C0035648
for	O
cardiovascular	B-C0007222
disease	I-C0007222
in	O
patients	B-C0030705
with	O
ai	B-C0001623
treated	B-C1522326
with	O
prednisolone	B-C0032950
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	B-C0007465
of	O
excess	O
mortality	B-C0205848
.	O
	
we	O
aimed	O
to	O
address	O
this	O
question	O
using	O
real-world	O
data	B-C1511726
from	O
the	O
european	B-C0282574
adrenal	I-C0282574
insufficiency	I-C0282574
registry	I-C0282574
eu-air	B-C0282574
.	O
	
eu-air	B-C0282574
,	O
comprising	O
of	O
19	O
centres	B-C0475309
across	O
germany	B-C0017480
,	O
the	O
netherlands	B-C0027778
,	O
sweden	B-C0038995
and	O
the	O
uk	B-C0041700
,	O
commenced	O
enrolling	O
patients	B-C0030705
with	O
ai	B-C0001623
in	O
august	O
2012	O
.	O
	
patients	B-C0030705
receiving	O
prednisolone	B-C0032950
3-6	O
mg/day	O
,	O
n	O
=	O
50	O
or	O
hydrocortisone	B-C0020268
15-30	O
mg/day	O
,	O
n	O
=	O
909	O
were	O
identified	B-C0205396
and	O
grouped	B-C0439745
at	O
a	O
ratio	O
of	O
1	O
prednisolone	B-C0032950
hydrocortisone	B-C0020268
by	O
matching	O
for	O
gender	B-C0079399
,	O
age	B-C0001779
,	O
duration	B-C0449238
and	O
type	B-C0457464
of	I-C0457464
disease	I-C0457464
.	O
	
data	B-C1511726
from	O
baseline	B-C1442488
and	O
follow-up	B-C1522577
visits	B-C1512346
were	O
analysed	O
.	O
	
data	B-C1511726
from	O
patients	B-C0030705
with	O
congenital	B-C0001627
adrenal	I-C0001627
hyperplasia	I-C0001627
were	O
excluded	B-C2828389
.	O
	
significantly	O
higher	O
mean	B-C0392762
s.d	I-C0392762
.	O
	
total	I-C0392762
6.3	O
1.6	O
vs	O
5.4	O
1.1	O
mmol/l	O
p	O
=	O
0.003	O
and	O
low-density	B-C0023824
lipoprotein	I-C0023824
ldl	I-C0023824
cholesterol	I-C0023824
levels	O
3.9	O
1.4	O
vs	O
3.2	O
1.0	O
mmol/l	O
p	O
=	O
0.013	O
were	O
identified	O
in	O
47	O
patients	O
on	O
prednisolone	O
vs	O
141	O
receiving	O
hydrocortisone	O
at	O
baseline	O
and	O
at	O
follow-up	O
p	O
=	O
0.005	O
and	O
p	O
=	O
0.006	O
,	O
respectively	O
.	O
	
hba1c	O
,	O
high-density	O
lipoprotein	O
and	O
triglyceride	O
levels	O
,	O
body	O
mass	O
index	O
,	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
and	O
waist	O
circumference	O
were	O
not	O
significantly	O
different	O
.	O
	
this	O
is	O
the	O
first	O
matched	O
analysis	O
of	O
its	O
kind	O
.	O
	
significantly	O
higher	O
ldl	B-C0023823
levels	B-C0441889
in	O
patients	O
receiving	O
prednisolone	O
relative	O
to	O
hydrocortisone	O
could	O
predict	O
a	O
higher	O
relative	O
risk	O
of	O
cardiovascular	O
disease	O
in	O
the	O
former	O
group	B-C0441833
oxytocin	B-C0030095
reduces	B-C0392756
face	B-C0015450
processing	B-C1709694
time	B-C0040223
but	O
leaves	B-C0205556
recognition	B-C0524637
accuracy	B-C0443131
and	O
eye	B-C0015392
-	O
gaze	B-C0553544
unaffected	B-C2986417
previous	B-C0205156
studies	B-C0681814
have	O
found	O
that	O
oxytocin	B-C0030095
oxt	B-C0030095
can	O
improve	B-C0184511
the	O
recognition	B-C0524637
of	O
emotional	B-C0849912
facial	B-C0015457
expressions	I-C0015457
it	O
has	O
been	O
proposed	B-C1553874
that	O
this	O
effect	B-C1280500
is	O
mediated	B-C0086597
by	O
an	O
increase	B-C0442805
in	O
attention	B-C0004268
to	O
the	O
eye-region	B-C0446453
of	O
faces	B-C0015450
.	O
	
nevertheless	O
,	O
evidence	B-C3887511
in	O
support	O
of	O
this	O
claim	O
is	O
inconsistent	B-C0442809
,	O
and	O
few	B-C0205388
studies	B-C0681814
have	O
directly	B-C1947931
tested	B-C0039593
the	O
effect	B-C1280500
of	O
oxytocin	B-C0030095
on	O
emotion	B-C0013987
recognition	B-C0524637
via	O
altered	B-C0392747
eye	B-C0015392
-	O
gaze	B-C0553544
methods	B-C0025663
in	O
a	O
double-blind	B-C0013072
,	O
within	B-C0332285
-	O
subjects	B-C0080105
,	O
randomized	B-C0681814
control	I-C0681814
experiment	I-C0681814
,	O
40	O
healthy	B-C3898900
male	B-C0025266
participants	I-C0025266
received	B-C1514756
24	O
iu	B-C0439453
intranasal	B-C0001560
oxt	B-C0030095
and	O
placebo	B-C1696465
in	O
two	O
identical	B-C0205280
experimental	B-C1517586
sessions	B-C1883016
separated	B-C0443299
by	O
a	O
2-	O
week	B-C0439230
interval	B-C1272706
.	O
	
visual	B-C0589102
attention	I-C0589102
to	O
the	O
eye-region	B-C0446453
was	O
assessed	B-C1516048
on	O
both	O
occasions	O
while	O
participants	B-C0679646
completed	B-C0205197
a	O
static	B-C0441463
facial	B-C0015450
emotion	B-C0013987
recognition	B-C0524637
task	B-C3540678
using	O
medium	B-C0522510
intensity	I-C0522510
facial	B-C0015457
expressions	I-C0015457
.	O
	
although	O
oxt	B-C0030095
had	O
no	B-C1301751
effect	I-C1301751
on	O
emotion	B-C0013987
recognition	B-C0524637
accuracy	B-C0443131
,	O
recognition	B-C0524637
performance	B-C1882330
was	O
improved	B-C0184511
because	O
face	B-C0015450
processing	B-C1709694
was	O
faster	B-C0456962
across	O
emotions	B-C0013987
under	O
the	O
influence	B-C4054723
of	O
oxt	B-C0030095
.	O
	
this	O
effect	B-C1280500
was	O
marginally	B-C1947914
significant	B-C0750502
p<	O
.	O
	
consistent	B-C0332290
with	I-C0332290
a	O
previous	B-C0205156
study	B-C0681814
using	O
dynamic	B-C0234402
stimuli	I-C0234402
,	O
oxt	B-C0030095
had	O
no	B-C1301751
effect	I-C1301751
on	O
eye	B-C0015392
-	O
gaze	B-C0553544
patterns	B-C0449774
when	O
viewing	B-C0449911
static	B-C0441463
emotional	B-C0849912
faces	B-C0015450
and	O
this	O
was	O
not	O
related	O
to	O
recognition	B-C0524637
accuracy	B-C0443131
or	O
face	B-C0015450
processing	B-C1709694
time	B-C0040223
.	O
	
these	O
findings	B-C0243095
suggest	B-C1705535
that	O
oxt	B-C0030095
-	O
induced	B-C0205263
enhanced	B-C2349975
facial	B-C0015450
emotion	B-C0013987
recognition	B-C0524637
is	O
not	O
necessarily	O
mediated	B-C0086597
by	O
an	O
increase	B-C0442805
in	O
attention	B-C0004268
to	O
the	O
eye-region	B-C0446453
of	O
faces	B-C0015450
,	O
as	O
previously	B-C0205156
assumed	B-C3242379
.	O
	
we	O
discuss	O
several	B-C0443302
methodological	B-C3266812
issues	B-C0033213
which	O
may	O
explain	O
discrepant	B-C0243095
findings	I-C0243095
and	O
suggest	B-C1705535
the	O
effect	B-C1280500
of	O
oxt	B-C0030095
on	O
visual	B-C0589102
attention	I-C0589102
may	O
differ	O
depending	O
on	O
task	B-C3540678
requirements	B-C1514873
.	O
	
new	O
directions	O
for	O
psychiatric	B-C0204512
rehabilitation	I-C0204512
in	O
the	O
usa	B-C0041703
american	B-C0596070
researchers	B-C0035173
have	O
led	O
the	O
world	B-C2700280
in	O
developing	B-C1527148
,	O
evaluating	B-C0220825
,	O
and	O
disseminating	B-C0205221
evidence	B-C3887511
-based	O
psychiatric	B-C0204512
rehabilitation	I-C0204512
practices	B-C1510541
for	O
people	B-C0027361
with	O
serious	B-C0205404
mental	B-C0004936
illness	I-C0004936
.	O
	
paradoxically	O
,	O
however	O
,	O
the	O
usa	B-C0041703
lags	O
behind	O
most	O
industrialized	B-C0282613
nations	I-C0282613
in	O
providing	O
access	B-C0018748
to	O
high-quality	B-C0034379
mental	B-C0025355
health	I-C0025355
and	O
psychiatric	B-C3526598
services	I-C3526598
.	O
	
this	O
essay	B-C0684224
examines	O
several	O
evidence-based	B-C1510541
practices	I-C1510541
developed	O
in	O
the	O
usa	B-C0041703
,	O
the	O
spread	O
of	O
these	O
practices	B-C0034024
,	O
the	O
barriers	B-C3260965
to	O
ensuring	O
availability	B-C0018748
to	O
people	B-C0027361
who	O
could	O
benefit	B-C0086387
from	O
these	O
services	B-C0025355
,	O
and	O
some	O
promising	O
directions	O
for	O
overcoming	B-C2983310
the	O
barriers	B-C3260965
.	O
	
factors	B-C1521761
influencing	O
the	O
growth	O
and	O
sustainment	B-C0024501
of	O
effective	B-C1704419
client	B-C0008942
-centred	O
practices	B-C0034024
include	O
the	O
availability	B-C0470187
of	O
adequate	B-C0243098
and	I-C0243098
stable	I-C0243098
funding	I-C0243098
,	O
committed	B-C0023181
leadership	I-C0023181
,	O
and	O
the	O
influence	B-C4054723
of	O
vested	O
interests	O
.	O
	
two	O
strategies	O
for	O
promoting	B-C0033414
the	O
spread	B-C0332261
and	O
sustainment	B-C0024501
of	O
well-implemented	B-C1510541
evidence-based	I-C1510541
practices	I-C1510541
are	O
the	O
adoption	B-C1708476
of	O
fidelity	B-C0680011
scales	I-C0680011
and	O
learning	B-C0023185
communities	B-C0009462
.	O
	
modifiable	B-C0392747
healthy	B-C4277664
lifestyle	I-C4277664
behaviors	I-C4277664
10-year	O
health	B-C1550208
outcomes	I-C1550208
from	O
a	O
health	B-C0018738
promotion	I-C0018738
program	I-C0018738
previous	O
studies	O
have	O
examined	O
the	O
impact	B-C4049986
of	I-C4049986
healthy	B-C4277664
lifestyle	I-C4277664
choices	I-C4277664
on	O
health-related	B-C1550208
outcomes	I-C1550208
however	O
,	O
given	O
their	O
fragmented	B-C1708096
,	O
often	O
cross-sectional	B-C0010362
nature	I-C0010362
,	O
assessing	B-C1160858
the	I-C1160858
relative	I-C1160858
impact	I-C1160858
of	O
daily	O
modifiable	B-C0392747
behaviors	B-C0004927
on	O
overall	O
long-term	B-C0443252
outcomes	B-C1550208
,	O
particularly	O
for	O
a	O
diverse	O
working	B-C1527116
adult	I-C1527116
population	I-C1527116
,	O
remains	B-C0205556
challenging	I-C0205556
.	O
	
relationships	O
between	O
ten	O
self-reported	B-C2700446
healthy	B-C4277664
lifestyle	I-C4277664
behaviors	I-C4277664
and	O
health	B-C1550208
outcomes	I-C1550208
during	O
the	O
subsequent	O
9	O
years	O
in	O
a	O
cohort	B-C0599755
of	O
10	O
participants	B-C0679646
enrolled	O
during	O
2003	O
in	O
a	O
voluntary	B-C0439656
workplace	B-C0162579
wellness	B-C0043113
program	I-C0043113
were	O
assessed	O
.	O
	
cox	B-C0010235
proportional-hazards	I-C0010235
models	I-C0010235
computed	B-C2985465
hazard	I-C2985465
ratios	I-C2985465
hrs	B-C2985465
for	O
lifestyle	B-C0023676
characteristics	I-C0023676
associated	O
with	O
time	B-C0040223
to	O
one	O
of	O
seven	O
self-reported	B-C2700446
chronic	B-C0008679
diseases	I-C0008679
or	O
death	B-C0011065
.	O
	
data	B-C4019276
were	I-C4019276
collected	I-C4019276
between	O
2003	O
and	O
2012	O
and	O
analyzed	O
between	O
2014	O
and	O
2016	O
.	O
	
behaviors	B-C0004927
that	O
most	O
significantly	O
affected	O
future	B-C0086749
outcomes	I-C0086749
were	O
low-fat	B-C0242970
diet	I-C0242970
,	O
aerobic	B-C0001701
exercise	I-C0001701
,	O
nonsmoking	B-C0812017
,	O
and	O
adequate	B-C2364286
sleep	I-C2364286
.	O
	
a	O
dose-response	B-C4284887
effect	I-C4284887
was	O
seen	O
between	O
dietary	B-C0425440
fat	I-C0425440
intake	I-C0425440
and	O
hypertension	B-C0020538
,	O
obesity	B-C0028754
,	O
diabetes	B-C0011847
,	O
heart	B-C0018799
disease	I-C0018799
,	O
and	O
hypercholesterolemia	B-C0020443
.	O
	
after	O
dietary	B-C0425440
fat	I-C0425440
intake	I-C0425440
,	O
aerobic	B-C0001701
exercise	I-C0001701
was	O
the	O
next	O
most	O
significant	O
behavior	B-C0004927
associated	O
with	O
development	B-C0086750
of	I-C0086750
outcomes	I-C0086750
.	O
	
compared	O
with	O
sedentary	B-C0205254
participants	B-C0679646
,	O
those	O
who	O
exercised	B-C0015259
4	O
days	O
per	O
week	O
were	O
less	O
likely	O
to	O
develop	O
new-onset	B-C0743128
diabetes	I-C0743128
hr	B-C2985465
=0	O
,	O
95%	O
ci	B-C0009667
=0	O
,	O
0.48	O
heart	B-C0018799
disease	I-C0018799
hr	B-C2985465
=0	O
,	O
95%	O
ci	B-C0009667
=0	O
,	O
0.80	O
and	O
hypercholesterolemia	B-C0020443
hr	B-C2985465
=0	O
,	O
95%	O
ci	B-C0009667
=0	O
,	O
0.74	O
.	O
	
low-fat	B-C0242970
diet	I-C0242970
and	O
adequate	B-C2364286
sleep	I-C2364286
were	O
more	O
significant	O
than	O
commonly	O
promoted	O
healthy	B-C4277664
behaviors	I-C4277664
,	O
such	O
as	O
eating	B-C0814440
a	I-C0814440
daily	I-C0814440
breakfast	I-C0814440
.	O
	
modifiable	B-C0392747
lifestyle	B-C0023676
behaviors	I-C0023676
targeted	O
in	O
health	B-C0018738
promotion	I-C0018738
programs	I-C0018738
should	O
be	O
prioritized	O
in	O
an	O
evidence-based	B-C1510541
manner	I-C1510541
.	O
	
top	O
priorities	O
for	O
workplace	B-C0162579
health	B-C0018738
promotion	I-C0018738
should	O
include	O
low-fat	B-C0242970
diet	I-C0242970
,	O
aerobic	B-C0001701
exercise	I-C0001701
,	O
nonsmoking	B-C0812017
,	O
and	O
adequate	B-C2364286
sleep	I-C2364286
.	O
	
diazoxide	B-C0012022
prevents	B-C1292733
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
and	O
mitochondrial	B-C1096176
damage	I-C1096176
,	O
leading	O
to	O
anti-hypertrophic	B-C0243095
effects	I-C0243095
pathological	B-C0205469
cardiac	B-C1383860
hypertrophy	I-C1383860
is	O
characterized	B-C1880022
by	O
wall	B-C0446987
thickening	B-C0205400
or	O
chamber	B-C0729936
enlargement	B-C0020564
of	O
the	O
heart	B-C0018787
in	O
response	O
to	O
pressure	B-C4284008
or	O
volume	B-C0449468
overload	O
,	O
respectively	O
.	O
	
this	O
condition	B-C0348080
will	O
,	O
initially	O
,	O
improve	B-C0184511
the	O
organ	B-C0178784
contractile	B-C1258017
function	I-C1258017
,	O
but	O
if	O
sustained	B-C0443318
will	O
render	O
dysfunctional	B-C3887504
mitochondria	B-C0026237
and	O
oxidative	B-C0242606
stress	I-C0242606
.	O
	
mitochondrial	B-C0764439
atp-sensitive	I-C0764439
k	I-C0764439
channels	I-C0764439
mitokatp	B-C0764439
modulate	B-C0443264
the	O
redox	B-C0030012
status	I-C0030012
of	O
the	O
cell	B-C0007634
and	O
protect	B-C1545588
against	O
several	O
cardiac	B-C0018787
insults	B-C1883709
.	O
	
here	O
,	O
we	O
tested	O
the	O
hypothesis	B-C1512571
that	O
mitokatp	B-C0764439
opening	B-C1882151
using	O
diazoxide	B-C0012022
will	O
avoid	O
isoproterenol	B-C0022245
-	O
induced	B-C0205263
cardiac	B-C1383860
hypertrophy	I-C1383860
in	B-C1515655
vivo	I-C1515655
by	O
decreasing	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
ros	B-C0162772
production	O
and	O
mitochondrial	B-C0026237
ca	B-C0596235
-	O
induced	B-C0205263
swelling	B-C0038999
.	O
	
to	O
induce	B-C0205263
cardiac	B-C1383860
hypertrophy	I-C1383860
,	O
swiss	B-C0162416
mice	I-C0162416
were	O
treated	B-C1522326
intraperitoneally	B-C0442120
with	O
isoproterenol	B-C0022245
30	O
mg/kg/	O
day	B-C0439228
for	O
8	O
days	B-C0439228
.	O
	
diazoxide	B-C0012022
5	O
mg/kg/	O
day	B-C0439228
was	O
used	O
to	O
open	O
mitokatp	B-C0764439
and	O
5-hydroxydecanoate	B-C0098450
5	O
mg/kg/	O
day	B-C0439228
was	O
administrated	O
as	O
a	O
mitokatp	B-C0764439
blocker	B-C0870261
.	O
	
isoproterenol	B-C0022245
-	O
treated	B-C1522326
mice	B-C0025929
had	O
elevated	B-C3163633
heart	B-C0018787
weight	B-C0043100
/	O
tibia	B-C1279118
length	B-C1444754
ratios	B-C0456603
and	O
increased	B-C0205217
myocyte	B-C0225828
cross-sectional	B-C0243095
areas	I-C0243095
.	O
	
additionally	O
,	O
hypertrophic	B-C0333959
hearts	B-C0018787
produced	O
higher	B-C0205250
levels	B-C0441889
of	O
h2o2	B-C0020281
and	O
had	O
lower	O
glutathione	B-C1151528
peroxidase	I-C1151528
activity	I-C1151528
.	O
	
in	O
contrast	O
,	O
mitokatp	B-C0764439
opening	B-C1882151
with	O
diazoxide	B-C0012022
blocked	B-C0332206
all	O
isoproterenol	B-C0022245
effects	B-C1280500
in	O
a	O
manner	O
reversed	B-C1555029
by	O
5-hydroxydecanoate	B-C0098450
.	O
	
isolated	B-C0205409
mitochondria	B-C0026237
from	O
isoproterenol	B-C0022245
-	O
induced	B-C0205263
hypertrophic	B-C0333959
hearts	B-C0018787
had	O
increased	B-C0205217
susceptibility	B-C0231204
to	O
ca	B-C0596235
-	O
induced	B-C0205263
swelling	B-C0038999
secondary	O
to	O
mitochondrial	B-C0908146
permeability	I-C0908146
transition	I-C0908146
pore	I-C0908146
opening	B-C1882151
.	O
	
mitokatp	B-C0764439
opening	B-C1882151
was	O
accompanied	O
by	O
lower	O
ca	B-C0596235
-	O
induced	B-C0205263
mitochondrial	B-C0026244
swelling	I-C0026244
,	O
an	O
effect	B-C1280500
blocked	B-C0332206
by	O
5-hydroxydecanoate	B-C0098450
.	O
	
our	O
results	O
suggest	O
that	O
mitokatp	B-C0764439
opening	B-C1882151
negatively	B-C0205160
regulates	B-C1327622
cardiac	B-C1383860
hypertrophy	I-C1383860
by	O
avoiding	O
oxidative	B-C0311404
impairment	B-C0221099
and	O
mitochondrial	B-C1096176
damage	I-C1096176
.	O
	
anticholinergic	B-C0242896
premedication	B-C0033045
to	O
prevent	O
bradycardia	B-C0428977
in	O
combined	O
spinal	B-C0002928
anesthesia	I-C0002928
and	O
dexmedetomidine	B-C0113293
sedation	B-C0344106
a	O
randomized	B-C0206034
,	O
double-blind	B-C0013072
,	O
placebo-controlled	B-C0599724
study	I-C0599724
when	O
dexmedetomidine	B-C0113293
is	O
used	O
in	O
patients	B-C0030705
undergoing	O
spinal	B-C0002928
anesthesia	I-C0002928
,	O
high	O
incidence	B-C0220856
of	O
bradycardia	B-C0428977
in	O
response	O
to	O
parasympathetic	B-C0030510
activation	B-C1879547
is	O
reported	O
.	O
	
therefore	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	B-C1280519
of	O
atropine	B-C0004259
premedication	B-C0033045
for	O
preventing	B-C1292733
the	O
incidence	B-C0220856
of	O
bradycardia	B-C0428977
and	O
the	O
hemodynamic	B-C0019010
effect	I-C0019010
on	O
patients	B-C0030705
undergoing	O
spinal	B-C0002928
anesthesia	I-C0002928
with	O
sedation	B-C0344106
by	O
dexmedetomidine	B-C0113293
.	O
	
randomized	B-C0206034
,	O
double-blind	B-C0013072
,	O
placebo-controlled	B-C0599724
study	I-C0599724
.	O
	
operating	B-C0029064
room	I-C0029064
.	O
	
one	O
hundred	O
fourteen	O
patients	B-C0113293
age	O
range	O
,	O
2-65	O
years	B-C1510829
american	B-C0037459
society	I-C0037459
of	I-C0037459
anesthesiology	I-C0037459
class	I-C0037459
i-ii	I-C0037459
participated	O
in	O
this	O
study	B-C2603343
,	O
willing	O
to	O
be	O
sedated	O
and	O
to	O
undergo	O
spinal	B-C0002928
anesthesia	I-C0002928
.	O
	
the	O
patients	B-C0113293
were	O
divided	O
into	O
2	O
groups	B-C0681860
group	B-C0681860
a	I-C0681860
and	O
group	B-C0681860
c	I-C0681860
.	O
	
after	O
performing	O
spinal	B-C0002928
anesthesia	I-C0002928
,	O
dexmedetomidine	B-C0113293
was	O
infused	B-C0574032
at	O
a	O
loading	B-C0678767
dose	I-C0678767
of	O
0.6	O
μg/kg	O
for	O
10	O
minutes	B-C0439232
,	O
followed	O
by	O
an	O
infusion	B-C0574032
at	O
0.25	O
μg/	O
h	O
.	O
	
simultaneously	O
with	O
the	O
loading	B-C0678767
dose	I-C0678767
of	O
dexmedetomidine	B-C0113293
,	O
patients	B-C0113293
in	O
group	B-C0681860
a	I-C0681860
received	O
an	O
intravenous	B-C1522229
bolus	I-C1522229
of	O
0.5	O
mg	O
atropine	B-C0004259
,	O
whereas	O
patients	B-C0113293
in	O
group	B-C0681860
c	I-C0681860
received	O
an	O
intravenous	B-C2064712
normal	I-C2064712
saline	I-C2064712
bolus	B-C1511237
.	O
	
data	B-C1511726
on	O
administration	B-C1533734
of	O
atropine	B-C0004259
and	O
ephedrine	B-C0014479
were	O
collected	O
.	O
	
hemodynamic	B-C4281788
data	B-C1511726
including	O
heart	B-C0018810
rate	I-C0018810
,	O
systolic	B-C0871470
blood	I-C0871470
pressure	I-C0871470
,	O
diastolic	B-C0428883
blood	I-C0428883
pressure	I-C0428883
dbp	B-C0428883
,	O
and	O
mean	B-C0428886
blood	I-C0428886
pressure	I-C0428886
mbp	B-C0428886
were	O
also	O
recorded	O
.	O
	
the	O
incidence	B-C0220856
of	O
bradycardia	B-C0428977
requiring	O
atropine	B-C0004259
treatment	B-C0087111
was	O
significantly	B-C4055637
higher	I-C4055637
in	O
group	B-C0681860
c	I-C0681860
than	O
group	B-C0681860
a	I-C0681860
p=	O
.	O
	
however	O
,	O
the	O
incidence	B-C0220856
of	O
hypotension	B-C0020649
needing	O
ephedrine	B-C0014479
treatment	B-C0087111
showed	O
no	B-C3842396
significant	I-C3842396
difference	I-C3842396
between	O
the	O
2	O
groups	B-C0681860
p=	O
.	O
	
systolic	B-C0871470
blood	I-C0871470
pressure	I-C0871470
and	O
heart	B-C0018810
rate	I-C0018810
showed	O
no	B-C3842396
significant	I-C3842396
differences	I-C3842396
between	O
the	O
2	O
groups	B-C0681860
p=	O
and	O
464	O
,	O
respectively	O
.	O
	
however	O
,	O
group	B-C0681860
a	I-C0681860
showed	O
significant	O
increases	B-C0205217
in	O
dbp	B-C0428883
and	O
mbp	B-C0428886
,	O
and	O
group	B-C0681860
c	I-C0681860
did	O
not	O
p=	O
and	O
008	O
,	O
respectively	O
.	O
	
prophylactic	B-C0199176
atropine	B-C0004259
reduces	O
the	O
incidence	B-C0220856
of	O
bradycardia	B-C0428977
in	O
patients	B-C0113293
undergoing	O
spinal	B-C0002928
anesthesia	I-C0002928
with	O
dexmedetomidine	B-C0113293
sedation	B-C0344106
.	O
	
however	O
,	O
dbp	B-C0428883
and	O
mbp	B-C0428886
showed	O
significant	O
increases	B-C0205217
in	O
patients	B-C0113293
when	O
prophylactic	B-C0199176
atropine	B-C0004259
was	O
administrated	B-C1533734
.	O
	
therefore	O
,	O
atropine	B-C0004259
premedication	B-C0033045
should	O
be	O
administered	B-C1533734
downregulation	B-C0013081
of	O
endothelial	B-C1563722
transient	I-C1563722
receptor	I-C1563722
potential	I-C1563722
vanilloid	I-C1563722
type	I-C1563722
4	I-C1563722
channel	I-C1563722
and	O
small-conductance	B-C1571638
of	I-C1571638
ca2+-activated	I-C1571638
k+	I-C1571638
channels	I-C1571638
underpins	O
impaired	B-C0221099
endothelium-dependent	B-C0082428
hyperpolarization	I-C0082428
in	O
hypertension	B-C0020538
endothelium-dependent	B-C0082428
hyperpolarization	I-C0082428
edh	B-C0082428
responses	B-C1704632
are	O
impaired	B-C0221099
in	O
hypertension	B-C0020538
,	O
but	O
the	O
underlying	O
mechanisms	B-C0441712
have	O
not	O
yet	O
been	O
determined	O
.	O
	
the	O
activation	B-C1879547
of	O
small-	B-C1571638
and	O
intermediate-conductance	B-C1571649
of	I-C1571649
ca	I-C1571649
k	I-C1571649
channels	I-C1571649
skca	B-C1571638
and	O
ikca	B-C1571649
underpins	O
edh	B-C0082428
-mediated	O
responses	B-C1704632
.	O
	
it	O
was	O
recently	O
reported	B-C0684224
that	O
ca	B-C3158761
influx	I-C3158761
through	O
endothelial	B-C1563722
transient	I-C1563722
receptor	I-C1563722
potential	I-C1563722
vanilloid	I-C1563722
type	I-C1563722
4	I-C1563722
channel	I-C1563722
trpv4	B-C1563722
is	O
a	O
prerequisite	B-C0679209
for	O
the	O
activation	B-C1879547
of	O
skca	B-C1571638
/	O
ikca	B-C1571649
in	O
endothelial	B-C0225336
cells	I-C0225336
in	O
specific	O
beds	O
.	O
	
here	O
,	O
we	O
attempted	B-C1516084
to	O
determine	O
whether	O
the	O
impairment	B-C0221099
of	O
edh	B-C0082428
in	O
hypertension	B-C0020538
is	O
attributable	O
to	O
the	O
dysfunction	B-C3887504
of	O
trpv4	B-C1563722
and	O
s	B-C1571638
/	O
ikca	B-C1571649
,	O
using	O
isolated	O
superior	B-C0162861
mesenteric	I-C0162861
arteries	I-C0162861
of	O
20-week-old	O
stroke-prone	B-C0034705
spontaneously	I-C0034705
hypertensive	I-C0034705
rats	I-C0034705
shrsp	B-C0034705
and	O
age-matched	O
wistar-kyoto	B-C0034709
wky	I-C0034709
rats	I-C0034709
.	O
	
in	O
the	O
wky	B-C0034709
arteries	B-C0003842
,	O
edh	B-C0082428
-mediated	O
responses	B-C1704632
were	O
reduced	B-C0392756
by	O
a	O
combination	B-C0205195
of	O
skca	B-C1571638
/	O
ikca	B-C1571649
blockers	B-C0870261
apamin	B-C0003521
plus	O
tram-34	B-C0916207
1-	B-C0916207
and	O
by	O
the	O
blockade	B-C0332206
of	O
trpv4	B-C1563722
with	O
the	O
selective	O
antagonist	B-C0243076
rn-1734	B-C2744078
or	O
hc-067047	B-C3493142
.	O
	
in	O
the	O
shrsp	B-C0034705
arteries	B-C0003842
,	O
edh-mediated	B-C0082428
hyperpolarization	I-C0082428
and	O
relaxation	B-C0035028
were	O
significantly	B-C0750502
impaired	B-C0221099
when	O
compared	O
with	O
wky	B-C0034709
.	O
	
gsk1016790a	B-C2604031
,	O
a	O
selective	O
trpv4	B-C1563722
activator	B-C0243192
,	O
evoked	O
robust	O
hyperpolarization	B-C2262820
and	O
relaxation	B-C0035028
in	O
wky	B-C0034709
arteries	B-C0003842
.	O
	
in	O
contrast	O
,	O
in	O
shrsp	B-C0034705
arteries	B-C0003842
,	O
the	O
gsk1016790a	B-C2604031
-evoked	O
hyperpolarization	B-C2262820
was	O
small	O
and	O
relaxation	B-C0035028
was	O
absent	B-C0332197
.	O
	
hyperpolarization	B-C2262820
and	O
relaxation	B-C0035028
to	O
cyclohexyl-	B-C2976731
,	O
a	O
selective	O
skca	B-C1571638
activator	B-C0243192
,	O
were	O
marginally	B-C1947914
decreased	B-C0205216
in	O
shrsp	B-C0034705
arteries	B-C0003842
compared	O
with	O
wky	B-C0034709
arteries	B-C0003842
.	O
	
the	O
expression	B-C1171362
of	O
endothelial	B-C1563722
trpv4	I-C1563722
and	O
skca	B-C1571638
protein	O
was	O
significantly	B-C4055638
decreased	I-C4055638
in	O
the	O
shrsp	B-C0034705
mesenteric	B-C0162861
arteries	I-C0162861
compared	O
with	O
those	O
of	O
wky	B-C0034709
,	O
whereas	O
function	B-C0542341
and	O
expression	B-C1171362
of	O
ikca	B-C1571649
were	O
preserved	O
in	O
shrsp	B-C0034705
arteries	B-C0003842
.	O
	
these	O
findings	B-C0243095
suggest	O
that	O
edh	B-C0082428
-mediated	O
responses	B-C1704632
are	O
impaired	B-C0221099
in	O
superior	B-C0162861
mesenteric	I-C0162861
arteries	I-C0162861
of	O
shrsp	B-C0034705
because	O
of	O
a	O
reduction	B-C0441610
in	O
both	O
trpv4	B-C1563722
and	O
skca	B-C1571638
input	B-C1708517
to	O
bioavailability	B-C1706947
and	O
health	B-C0679809
risk	I-C0679809
assessment	I-C0679809
of	O
potentially	B-C3245505
toxic	B-C0032346
elements	I-C0032346
in	O
thriasio	B-C0017446
plain	I-C0017446
,	O
near	I-C0017446
athens	I-C0017446
,	O
greece	B-C0018226
elevated	O
concentrations	B-C1446561
of	O
potentially	B-C3245505
toxic	B-C0032346
elements	I-C0032346
ptes	B-C0032346
are	O
usually	O
found	O
in	O
areas	B-C3846701
of	I-C3846701
intense	I-C3846701
industrial	I-C3846701
activity	I-C3846701
.	O
	
thriasio	B-C0017446
plain	I-C0017446
is	O
a	O
plain	B-C0017446
near	I-C0017446
athens	I-C0017446
,	O
greece	B-C0018226
,	O
where	O
most	O
of	O
the	O
heavy	B-C0524640
industry	I-C0524640
of	O
the	O
country	O
has	O
been	O
situated	O
for	O
decades	O
,	O
but	O
it	O
also	O
is	O
a	O
residential	B-C0442506
and	O
horticultural	B-C4300640
area	B-C0205146
.	O
	
we	O
aimed	O
at	O
measuring	O
the	O
levels	O
of	O
ptes	B-C0032346
in	O
soils	B-C0037592
and	O
indigenous	O
plant	O
species	O
and	O
assessing	O
the	O
health	O
risk	O
associated	O
with	O
direct	O
soil	O
ingestion	O
.	O
	
samples	O
of	O
soils	B-C0037592
at	O
roadsides	O
and	O
growing	O
plants	O
were	O
collected	O
from	O
31	O
sites	O
of	O
that	O
area	O
.	O
	
concentrations	O
of	O
al	O
,	O
as	O
,	O
cd	O
,	O
co	O
,	O
cr	O
,	O
cu	O
,	O
fe	O
,	O
mn	O
,	O
mo	O
,	O
ni	O
,	O
pb	O
,	O
v	O
and	O
zn	O
were	O
measured	O
in	O
both	O
soils	O
as	O
pseudo-total	O
and	O
aerial	O
plant	O
tissues	O
.	O
	
we	O
found	O
that	O
as	O
,	O
cd	O
,	O
cr	O
,	O
cu	O
,	O
ni	O
,	O
pb	O
and	O
zn	O
were	O
higher	O
than	O
maximum	O
regulatory	O
limits	O
.	O
	
element	O
concentrations	O
in	O
plants	O
were	O
rather	O
lower	O
than	O
expected	O
,	O
probably	O
because	O
indigenous	B-C0302891
plants	O
have	O
developed	O
excluder	O
behaviour	O
over	O
time	O
.	O
	
copper	O
and	O
zn	O
soil	O
-to-	O
plant	B-C0032098
coefficients	O
were	O
highest	O
among	O
the	O
other	O
elements	O
for	O
cu	O
this	O
was	O
unexpected	O
,	O
and	O
probably	O
associated	O
with	O
recent	O
cu	O
-	O
releasing	O
industrial	O
activity	O
.	O
	
risk	O
assessment	O
analysis	O
indicated	O
that	O
as	O
was	O
the	O
element	O
contributing	O
more	O
than	O
50	O
%	O
of	O
the	O
health	O
risk	O
related	O
to	O
direct	O
soil	O
ingestion	O
,	O
followed	O
by	O
cr	O
,	O
pb	O
,	O
and	O
,	O
surprisingly	O
,	O
mn	O
.	O
	
we	O
concluded	O
that	O
in	O
a	O
multi	O
-	O
element	O
contamination	O
situation	O
,	O
elevated	O
risk	O
of	O
ptes	O
such	O
as	O
as	O
,	O
cr	O
and	O
pb	O
may	O
reduce	O
the	O
tolerance	O
limits	O
of	O
exposure	O
to	O
less-	O
toxic	O
elements	O
here	O
,	O
mn	B-C0024706
nutrients	B-C0678695
influence	O
the	O
thermal	B-C1254359
ecophysiology	I-C1254359
of	O
an	O
intertidal	B-C1254362
macroalga	B-C0036500
multiple	B-C0597530
stressors	I-C0597530
or	O
multiple	B-C1254370
drivers	I-C1254370
urbanization	B-C0041938
of	O
coastlines	B-C0681784
is	O
leading	O
to	O
increased	O
introduction	O
of	O
nutrients	B-C0678695
from	O
the	O
terrestrial	B-C0014406
environment	I-C0014406
to	O
nearshore	B-C0871648
habitats	I-C0871648
.	O
	
while	O
such	O
nutrient	B-C0678695
influxes	O
can	O
be	O
detrimental	O
to	O
coastal	B-C0681784
marine	B-C0599383
organisms	I-C0599383
due	O
to	O
increased	O
eutrophication	B-C0015191
and	O
subsequent	O
reduced	B-C0392756
oxygen	B-C0030054
,	O
they	O
could	O
also	O
have	O
positive	B-C1280500
effects	I-C1280500
i.e	O
,	O
increased	O
food	B-C0016452
availability	B-C0470187
on	O
species	B-C1705920
that	O
are	O
nitrogen-limited	B-C0028158
such	O
as	O
macroalgae	B-C0036500
.	O
	
nutrient	B-C0678695
enrichment	B-C1254366
in	O
this	O
environment	B-C0014406
thus	O
has	O
the	O
potential	B-C3245505
to	O
counteract	O
some	O
of	O
the	O
negative	B-C4049986
impacts	I-C4049986
of	O
increasing	B-C0442808
temperatures	B-C0039476
,	O
at	O
least	O
for	O
some	O
species	B-C1705920
.	O
	
characterizing	O
the	O
physiological	B-C1254359
response	I-C1254359
of	O
organisms	B-C0029235
to	O
simultaneous	B-C0205420
changes	B-C0392747
in	O
multiple	B-C1254370
drivers	I-C1254370
such	O
as	O
these	O
is	O
an	O
important	O
first	O
step	O
in	O
predicting	O
how	O
global	B-C2348867
climate	B-C2718051
change	I-C2718051
may	O
lead	O
to	O
ecological	B-C0162358
responses	B-C0871261
at	O
more	O
local	B-C0683925
levels	I-C0683925
.	O
	
we	O
evaluated	O
how	O
nutrient	B-C0678695
enrichment	B-C1254366
i.e	O
,	O
nitrogen	B-C0028158
availability	B-C0470187
affected	O
the	O
growth	B-C0018270
of	O
fucus	B-C1083174
vesiculosus	I-C1083174
,	O
a	O
foundational	O
macroalgal	B-C0036500
species	B-C0036500
in	O
the	O
north	B-C0004166
atlantic	I-C0004166
rocky	I-C0004166
intertidal	I-C0004166
zone	I-C0004166
,	O
and	O
found	O
that	O
nutrient	B-C0678695
-enriched	O
algal	B-C2698828
blades	I-C2698828
showed	O
a	O
significant	O
increase	O
in	O
tissue	B-C1621966
growth	I-C1621966
compared	O
to	O
individuals	B-C0441833
grown	O
under	O
ambient	B-C1879688
conditions	O
.	O
	
we	O
further	O
quantified	O
net	O
photosynthesis	B-C0031764
by	O
ambient	O
and	O
nutrient	B-C0678695
-enriched	O
tissues	B-C1514137
at	O
saturating	B-C1282930
irradiance	I-C1282930
over	O
a	O
range	O
of	O
temperature	B-C0039476
conditions	O
6-30	O
.	O
	
respiration	B-C0035203
was	O
unaffected	O
by	O
nutrient	B-C0678695
treatment	B-C1522326
however	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
photosynthetic	B-C0031764
oxygen	B-C0030054
production	O
for	O
nutrient	B-C0678695
-enriched	O
tissue	B-C1514137
compared	O
to	O
ambient	B-C1879688
,	O
but	O
only	O
at	O
elevated	B-C3163633
18	O
temperatures	B-C0039476
.	O
	
this	O
study	B-C2603343
contributes	O
to	O
a	O
growing	O
body	O
of	O
literature	B-C0023866
showing	O
the	O
complexity	O
of	O
responses	B-C0871261
to	I-C0871261
changes	I-C0871261
in	O
multiple	B-C1254370
drivers	I-C1254370
,	O
and	O
highlights	O
the	O
importance	O
of	O
studying	B-C2603343
the	O
impacts	B-C0282165
of	O
global	B-C2348867
climate	B-C2718051
change	I-C2718051
within	O
the	O
context	O
of	O
more	O
local	O
environmental	B-C0014406
conditions	B-C0348080
.	O
	
a	O
trial	B-C0008976
to	O
determine	O
whether	O
septic	B-C0036983
shock	I-C0036983
-	O
reversal	B-C0443290
is	O
quicker	B-C0456962
in	O
pediatric	B-C1521725
patients	B-C0030705
randomized	B-C0034656
to	O
an	O
early	B-C1279919
goal-directed	B-C1271494
fluid-sparing	I-C1271494
strategy	I-C1271494
versus	O
usual	B-C0511425
care	I-C0511425
squeeze	B-C0008976
study	B-C2348563
protocol	I-C2348563
for	O
a	O
pilot	B-C0206035
randomized	I-C0206035
controlled	I-C0206035
trial	I-C0206035
current	B-C0521116
pediatric	B-C1521725
septic	B-C0036983
shock	I-C0036983
resuscitation	B-C0035273
guidelines	B-C0162791
from	O
the	O
american	B-C1708333
college	I-C1708333
of	I-C1708333
critical	I-C1708333
care	I-C1708333
medicine	I-C1708333
focus	O
on	O
the	O
early	B-C1279919
and	O
goal-directed	B-C1271494
administration	I-C1271494
of	O
intravascular	B-C0442123
fluid	B-C0005889
followed	O
by	O
vasoactive	B-C1980011
medication	B-C0013227
infusions	B-C0574032
for	O
persistent	B-C0205322
and	O
fluid-refractory	B-C0349412
shock	I-C0349412
.	O
	
however	O
,	O
accumulating	B-C4055506
adult	B-C0001675
and	O
pediatric	B-C1521725
data	B-C1511726
suggest	O
that	O
excessive	B-C0442802
fluid	B-C0522792
administration	I-C0522792
is	O
associated	O
with	O
worse	B-C1457868
patient	B-C0030705
outcomes	B-C1274040
and	O
even	O
increased	B-C2749787
risk	I-C2749787
of	I-C2749787
death	I-C2749787
.	O
	
the	O
optimal	B-C1265611
amount	I-C1265611
of	O
intravascular	B-C0442123
fluid	B-C0005889
required	O
in	O
early	B-C1279919
pediatric	B-C1521725
septic	B-C0036983
shock	I-C0036983
resuscitation	B-C0035273
prior	O
to	O
the	O
initiation	B-C1704686
of	O
vasoactive	B-C1980011
support	I-C1980011
remains	O
unanswered	O
.	O
	
the	O
squeeze	B-C0008976
pilot	I-C0008976
trial	I-C0008976
is	O
a	O
pragmatic	B-C0871858
,	O
two-arm	B-C0242481
,	O
parallel-group	B-C2826345
,	O
open-label	B-C1709323
,	O
prospective	B-C0206035
pilot	I-C0206035
randomized	I-C0206035
controlled	I-C0206035
trial	I-C0206035
.	O
	
participants	B-C0679646
are	O
children	B-C0008059
aged	B-C0001779
29	O
days	B-C0439228
to	O
under	O
18	O
years	B-C0439234
with	O
suspected	B-C0750491
or	O
confirmed	B-C0750484
septic	B-C0036983
shock	I-C0036983
and	O
a	O
need	O
for	O
ongoing	O
resuscitation	B-C0035273
.	O
	
eligible	O
participants	B-C0679646
are	O
enrolled	B-C1516879
under	O
an	O
exception	B-C1705847
to	O
consent	B-C1511481
process	B-C1522240
and	O
randomly	B-C0439605
assigned	B-C1516050
via	O
concealed	B-C0443189
allocation	B-C1706778
to	O
either	O
the	O
usual	B-C0511425
care	I-C0511425
control	B-C0009932
or	O
fluid	B-C0035273
sparing	I-C0035273
intervention	I-C0035273
resuscitation	I-C0035273
strategy	I-C0035273
.	O
	
the	O
primary	B-C0205225
objective	B-C0018017
of	O
this	O
pilot	B-C0008976
trial	I-C0008976
is	O
to	O
determine	O
feasibility	B-C0015730
,	O
based	O
on	O
the	O
ability	O
to	O
enroll	B-C1516879
participants	B-C0679646
and	O
to	O
adhere	O
to	O
the	O
study	B-C2348563
protocol	I-C2348563
.	O
	
the	O
primary	B-C3274433
outcome	I-C3274433
measure	I-C3274433
by	O
which	O
success	B-C0679864
will	O
be	O
determined	O
is	O
participant	B-C0679646
enrollment	B-C1516879
rate	B-C1521828
"""pass"""	O
defined	O
as	O
at	O
least	O
two	O
participants	B-C0679646
/	O
site	B-C0205145
/	O
month	B-C0439231
,	O
recognizing	O
that	O
enrollment	B-C1516879
may	O
be	O
slower	O
during	O
the	O
run-in	O
phase	O
.	O
	
secondary	O
objectives	B-C0018017
include	O
assessing	O
1	O
appropriateness	B-C0814634
of	O
eligibility	B-C1516637
criteria	I-C1516637
,	O
and	O
2	O
completeness	B-C0439812
of	O
clinical	B-C1274040
outcomes	I-C1274040
to	O
inform	O
the	O
endpoints	B-C2349179
for	O
the	O
planned	B-C1301732
multisite	B-C0206012
trial	I-C0206012
.	O
	
to	O
support	O
the	O
nested	B-C0008972
translational	I-C0008972
study	I-C0008972
,	O
squeeze-d	B-C0008972
,	O
we	O
will	O
also	O
evaluate	O
the	O
feasibility	B-C0015730
of	O
describing	O
cell-free	B-C4289789
dna	I-C4289789
a	O
procoagulant	B-C1292267
molecule	I-C1292267
with	O
prognostic	B-C0220901
utility	I-C0220901
in	O
blood	B-C0178913
samples	I-C0178913
obtained	O
from	O
children	B-C0008059
enrolled	B-C1516879
into	O
the	O
squeeze	B-C0008976
pilot	I-C0008976
trial	I-C0008976
at	O
baseline	B-C1442488
and	O
at	O
24	O
h	O
.	O
	
the	O
optimal	O
degree	B-C0449286
of	O
fluid	B-C0005889
resuscitation	B-C0035273
and	O
the	O
timing	B-C0449243
of	O
initiation	B-C1704686
of	O
vasoactive	B-C1980011
support	I-C1980011
in	O
order	O
to	O
achieve	O
recommended	O
therapeutic	B-C0302350
targets	B-C1521840
in	O
children	B-C0008059
with	O
septic	B-C0036983
shock	I-C0036983
remains	O
unanswered	O
.	O
	
no	O
prospective	B-C0033522
study	I-C0033522
to	O
date	B-C0011008
has	O
examined	O
this	O
important	O
question	B-C1522634
for	O
children	B-C0008059
in	O
developed	B-C0282613
countries	I-C0282613
including	O
canada	B-C0006823
.	O
	
recruitment	B-C2949735
for	O
the	O
squeeze	B-C0008976
pilot	I-C0008976
trial	I-C0008976
opened	B-C3483819
on	O
6	O
january	O
2014	O
.	O
	
findings	B-C0243095
will	O
inform	O
the	O
feasibility	B-C0015730
of	O
the	O
planned	B-C1301732
multicenter	B-C0206012
trial	I-C0206012
to	O
answer	O
our	O
overall	B-C1561607
research	B-C0681799
question	I-C0681799
.	O
	
entropy-driven	B-C0443286
reactions	I-C0443286
in	O
living	B-C0376558
cells	B-C0007634
for	O
assay	B-C1510438
let-7a	B-C1101610
microrna	I-C1101610
imaging	B-C0079595
of	O
microrna	B-C1101610
mirna	B-C1101610
in	O
living	B-C0376558
cells	B-C0007634
could	O
facilitate	O
the	O
monitoring	B-C0005517
of	O
the	O
expression	B-C0017262
and	O
distribution	B-C1704711
of	O
mirna	B-C1101610
and	O
research	B-C0035168
on	O
mirna	B-C1101610
-related	O
diseases	B-C0012634
.	O
	
given	O
the	O
low	O
expression	B-C3244092
levels	I-C3244092
and	O
even	O
down-regulation	B-C0013081
of	O
cellular	B-C0007634
mirna	B-C1101610
that	O
is	O
associated	B-C0332281
with	I-C0332281
some	O
diseases	B-C0012634
,	O
enzyme	B-C0014442
-	O
free	B-C0332296
amplification	B-C0887815
strategies	I-C0887815
are	O
imperative	O
for	O
intracellular	B-C0178719
mirna	B-C1101610
assay	B-C1510438
.	O
	
in	O
this	O
work	O
,	O
we	O
report	O
an	O
entropy-driven	B-C0443286
reaction	I-C0443286
for	O
amplification	B-C0887815
assay	B-C1510438
mirna	B-C1101610
with	O
a	O
detection	B-C2718050
limit	I-C2718050
of	O
0.27	O
pm	O
.	O
	
the	O
resulting	O
signal	B-C1710082
amplification	B-C1521871
provides	O
excellent	O
recognition	O
and	O
signal	B-C1710082
enhancement	B-C2349975
of	O
specific	B-C0205369
mirna	B-C1101610
s	O
in	O
living	B-C0376558
cells	B-C0007634
.	O
	
this	O
method	O
supplies	O
accurate	B-C0443131
information	B-C1533716
regarding	O
cellular	B-C0007634
mirna	B-C1101610
-related	O
biological	B-C3714634
events	I-C3714634
and	O
provides	O
a	O
new	O
tool	O
for	O
highly	B-C0439822
sensitive	I-C0439822
and	O
simultaneous	B-C0521115
imaging	B-C0079595
of	O
multiple	B-C0439064
low-level	O
biomarkers	B-C0005516
,	O
thereby	O
improving	O
the	O
accuracy	B-C0598285
of	O
early	B-C0596473
disease	I-C0596473
diagnosis	I-C0596473
.	O
	
iterative	B-C1854293
development	B-C1527148
and	O
evaluation	B-C0220825
of	O
a	O
pharmacogenomic	B-C1138555
-guided	O
clinical	B-C0525070
decision	I-C0525070
support	I-C0525070
system	I-C0525070
for	O
warfarin	B-C0366686
dosing	I-C0366686
pharmacogenomic	B-C1138555
-guided	O
dosing	B-C0178602
has	O
the	O
potential	O
to	O
improve	O
patient	B-C0030705
outcomes	O
but	O
its	O
implementation	B-C1708476
has	O
been	O
met	O
with	O
clinical	B-C0205210
challenges	B-C0805586
.	O
	
our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	B-C0220825
a	O
clinical	B-C0525070
decision	I-C0525070
support	I-C0525070
system	I-C0525070
cdss	B-C0525070
for	O
pharmacogenomic	B-C1138555
-guided	O
warfarin	B-C0366686
dosing	I-C0366686
designed	B-C1707689
for	O
physicians	B-C0031831
and	O
pharmacists	B-C0031323
.	O
	
twelve	O
physicians	B-C0031831
and	O
pharmacists	B-C0031323
completed	O
6	O
prescribing	B-C0278329
tasks	B-C3540678
using	O
simulated	B-C3825675
patient	I-C3825675
scenarios	B-C0683579
in	O
two	O
iterations	B-C1854293
development	B-C1527148
and	O
validation	B-C1519941
phases	B-C0205390
of	O
a	O
newly	O
developed	O
pharmacogenomic	B-C1138555
-driven	O
cdss	B-C0525070
prototype	B-C0205556
.	O
	
for	O
each	O
scenario	B-C0683579
,	O
usability	B-C1510648
was	O
measured	B-C0444706
via	O
efficiency	B-C0013682
,	O
recorded	B-C0034869
as	O
time	B-C1316026
to	I-C1316026
task	I-C1316026
completion	I-C1316026
,	O
and	O
participants	B-C0679646
'	O
perceived	B-C0030971
satisfaction	B-C0242428
which	O
were	O
compared	O
using	O
kruskal-wallis	B-C0282574
and	I-C0282574
mann	I-C0282574
whitney	I-C0282574
u	I-C0282574
tests	I-C0282574
,	O
respectively	O
.	O
	
debrief	O
interviews	O
were	O
conducted	O
and	O
qualitatively	B-C0022885
analyzed	I-C0022885
.	O
	
usability	B-C1510648
findings	O
from	O
the	O
first	O
i.e	O
.	O
	
development	B-C1527148
iteration	B-C1854293
were	O
incorporated	O
into	O
the	O
cdss	B-C0525070
design	B-C1707689
for	O
the	O
second	B-C0457385
i.e	O
.	O
	
validation	B-C1519941
iteration	B-C1854293
.	O
	
during	O
the	O
cdss	B-C0525070
validation	B-C1519941
iteration	B-C1854293
,	O
participants	B-C0679646
took	O
more	O
time	B-C1316026
to	I-C1316026
complete	I-C1316026
tasks	I-C1316026
with	O
a	O
median	B-C0549183
iqr	O
of	O
183	O
124-247	O
seconds	B-C0457385
versus	O
101	O
73.5	O
seconds	B-C0457385
in	O
the	O
development	B-C1527148
iteration	B-C1854293
p=0	O
.	O
	
this	O
increase	B-C0442805
in	O
time	B-C0871530
on	I-C0871530
task	I-C0871530
was	O
due	O
to	O
the	O
increase	B-C0442805
in	O
time	B-C0040223
spent	O
in	O
the	O
cdss	B-C0525070
corresponding	O
to	O
several	O
design	B-C1707689
changes	O
.	O
	
efficiency	B-C0013682
differences	O
that	O
were	O
observed	O
between	O
pharmacists	B-C0031323
and	O
physicians	B-C0031831
in	O
the	O
development	B-C1527148
iteration	B-C1854293
were	O
eliminated	O
in	O
the	O
validation	B-C1519941
iteration	B-C1854293
.	O
	
the	O
increased	B-C0205217
use	O
of	O
the	O
cdss	B-C0525070
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
cdss	B-C0525070
recommended	O
doses	B-C0178602
in	O
the	O
validation	B-C1519941
iteration	B-C1854293
4%	O
in	O
the	O
first	O
iteration	B-C1854293
vs	O
.	O
	
37.5	O
in	O
the	O
second	B-C0457385
iteration	B-C1854293
,	O
p<0	O
.	O
	
overall	O
satisfaction	B-C0242428
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	B-C1854293
but	O
the	O
qualitative	B-C0022885
analysis	I-C0022885
revealed	O
greater	O
trust	O
in	O
the	O
second	B-C0457385
prototype	B-C0205556
.	O
	
a	O
pharmacogenomic	B-C1138555
-guided	O
cdss	B-C0525070
has	O
been	O
developed	O
using	O
warfarin	B-C0043031
as	O
the	O
test	O
drug	B-C1254351
.	O
	
the	O
final	O
cdss	B-C0525070
prototype	B-C0205556
was	O
trusted	O
by	O
prescribers	O
and	O
significantly	O
increased	B-C0205217
the	O
time	B-C0040223
using	O
the	O
tool	B-C0871532
and	O
acceptance	O
of	O
the	O
recommended	O
doses	B-C0178602
.	O
	
this	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	B-C1138555
into	O
cdss	B-C0525070
design	B-C1707689
for	O
clinical	B-C1516634
testing	I-C1516634
.	O
	
pedicle	B-C1961768
screw	I-C1961768
combined	B-C0205195
with	O
lateral	B-C0005975
mass	I-C0005975
screw	I-C0005975
fixation	B-C0185023
in	O
the	O
treatment	B-C0087111
of	O
basilar	B-C3887851
invagination	I-C3887851
and	O
congenital	B-C0022738
c2-c3	I-C0022738
fusion	I-C0022738
clinical	B-C4084924
evaluation	I-C4084924
of	O
a	O
surgical	B-C0543467
fixation	B-C0185023
technique	B-C0449851
featuring	O
combined	B-C0205195
use	O
of	O
pedicle	B-C1961768
screw	I-C1961768
and	O
lateral	B-C0005975
mass	I-C0005975
screw	I-C0005975
lms	B-C0005975
.	O
	
introduction	O
of	O
a	O
novel	O
technique	B-C0449851
for	O
the	O
treatment	B-C0087111
of	O
congenital	B-C0022738
c2-c3	I-C0022738
fusion	I-C0022738
and	O
basilar	B-C3887851
invagination	I-C3887851
bi	B-C3887851
.	O
	
posterior	B-C0205095
occipitocervical	B-C0027530
fixation	B-C0185023
using	O
c2	B-C1961768
pedicle	I-C1961768
screw	I-C1961768
was	O
widely	O
used	O
for	O
bi	B-C3887851
.	O
	
however	O
,	O
in	O
cases	B-C0868928
where	O
bi	B-C3887851
is	O
concurrent	B-C0205420
with	O
congenital	B-C0022738
c2-c3	I-C0022738
fusion	I-C0022738
,	O
the	O
c2	B-C0456605
pedicles	I-C0456605
tend	O
to	O
be	O
thinner	B-C0205168
than	O
that	O
in	O
normal	B-C0205307
population	B-C1257890
and	O
hence	O
more	O
likely	O
to	O
fail	B-C0231175
.	O
	
we	O
prompted	O
to	O
tackle	O
the	O
issue	B-C0033213
by	O
combining	B-C0205195
the	O
pedicle	B-C1961768
screw	I-C1961768
with	O
the	O
additional	O
use	O
of	O
lms	B-C0005975
in	O
attempt	O
to	O
strengthen	B-C0808080
the	O
fixation	B-C0185023
.	O
	
twenty-five	O
patients	B-C0030705
who	O
underwent	O
combined	B-C0205195
pedicle	B-C1961768
screw	I-C1961768
with	O
lms	B-C0005975
fixation	B-C0185023
were	O
retrospectively	B-C0035363
studied	I-C0035363
.	O
	
the	O
instrument	B-C0348000
position	B-C0733755
,	O
fusion	B-C0699952
status	B-C0449438
,	O
and	O
complications	B-C0009566
were	O
analyzed	B-C0936012
.	O
	
none	O
had	O
spinal	B-C0037929
cord	I-C0037929
or	O
vertebral	B-C0433912
artery	I-C0433912
injury	I-C0433912
.	O
	
the	O
average	O
follow-up	B-C1522577
time	B-C0040223
was	O
20	O
months	B-C0439231
.	O
	
solid	O
fusion	B-C0699952
was	O
achieved	O
in	O
23	O
patients	B-C0030705
92%	O
as	O
detected	O
radiologically	B-C0043299
.	O
	
two	O
cases	B-C0868928
suffered	O
from	O
recurred	B-C0034897
bi	B-C3887851
and	O
instrument	B-C0348000
failure	B-C0162643
but	O
eventually	O
achieved	O
solid	O
fusion	B-C0699952
between	O
the	O
occiput	B-C0230005
and	O
c2	B-C0456605
was	O
after	O
revision	B-C0558347
.	O
	
among	O
all	O
25	O
patients	B-C0030705
,	O
4	O
suffered	O
from	O
complications	B-C0009566
including	O
instrument	B-C0348000
s	O
failure	B-C0162643
,	O
cerebrospinal	B-C0023182
fluid	I-C0023182
leakage	I-C0023182
,	O
and	O
intracranial	B-C0524466
infection	B-C3714514
.	O
	
the	O
clinical	B-C0205210
outcome	B-C1274040
indicates	O
that	O
the	O
technique	B-C0449851
is	O
reliable	O
for	O
the	O
treatment	B-C0087111
of	O
bi	B-C3887851
with	O
congenital	B-C0022738
c2-c3	I-C0022738
fusion	I-C0022738
.	O
	
co-occurrence	B-C2745955
and	O
clustering	B-C0012641
of	O
health	B-C0018684
conditions	B-C0348080
at	O
age	B-C0001779
11	O
cross-sectional	B-C0010362
findings	B-C2607943
from	O
the	O
millennium	B-C0009247
cohort	I-C0009247
study	I-C0009247
to	O
identify	O
patterns	O
of	O
co-occurrence	B-C2745955
and	O
clustering	B-C0012641
of	O
6	O
common	O
adverse	B-C0877248
health	B-C0018684
conditions	B-C0348080
in	O
11-	O
year	B-C1510829
-old	O
children	B-C0008059
and	O
explore	O
differences	B-C1705242
by	O
sociodemographic	B-C0011292
factors	I-C0011292
.	O
	
nationally	O
representative	O
prospective	B-C1709709
cohort	I-C1709709
study	I-C1709709
.	O
	
children	B-C0008059
born	O
in	O
the	O
uk	B-C0041700
between	O
2000	O
and	O
2002	O
.	O
	
11	O
399	O
11-	O
year	B-C1510829
-old	O
singleton	B-C1313913
children	B-C0008059
for	O
whom	O
data	B-C1511726
on	O
all	O
6	O
health	B-C0018684
conditions	B-C0348080
and	O
sociodemographic	B-C1533716
information	I-C1533716
were	O
available	O
complete	B-C0205197
cases	B-C0868928
.	O
	
prevalence	B-C0220900
,	O
co-occurrence	B-C2745955
and	O
clustering	B-C0012641
of	O
6	O
common	O
health	B-C0018684
conditions	B-C0348080
wheeze	B-C0043144
eczema	B-C0013595
long-standing	B-C0221423
illness	I-C0221423
excluding	O
wheeze	B-C0043144
and	O
eczema	B-C0013595
injury	B-C3263723
socioemotional	B-C0013985
difficulties	I-C0013985
measured	O
using	O
strengths	B-C3472494
and	I-C3472494
difficulties	I-C3472494
questionnaire	I-C3472494
and	O
unfavourable	B-C0005910
weight	I-C0005910
thin	B-C0041667
/	O
overweight	B-C0497406
/	O
obese	B-C0028754
vs	O
normal	B-C0005910
.	O
	
42.4	O
of	O
children	B-C0008059
had	O
2	O
or	O
more	O
adverse	B-C0877248
health	B-C0018684
conditions	B-C0348080
co-occurrence	B-C2745955
.	O
	
co-occurrence	B-C2745955
was	O
more	O
common	O
in	O
boys	B-C0870221
and	O
children	B-C0008059
from	O
lower	O
income	B-C0021162
households	B-C0020052
.	O
	
latent	B-C0936012
class	I-C0936012
analysis	I-C0936012
identified	O
6	O
classes	B-C0456387
'	O
normative	B-C0205307
'	O
57.4	O
'	O
atopic	B-C0392707
burdened	B-C2828008
'	O
14.0	O
'	O
socioemotional	B-C0013985
burdened	I-C0013985
'	O
11.0	O
'	O
unfavourable	B-C0005910
weight	I-C0005910
/	O
injury	B-C3263723
'	O
7.7	O
'	O
eczema	B-C0013595
/	O
injury	B-C3263723
'	O
6.0	O
and	O
'	O
eczema	B-C0013595
/	O
unfavourable	B-C0005910
weight	I-C0005910
'	O
3.9	O
.	O
	
as	O
with	O
co-occurrence	B-C2745955
,	O
class	B-C0456387
membership	B-C0680038
differed	O
by	O
sociodemographic	B-C0011292
factors	I-C0011292
boys	B-C0870221
,	O
children	B-C0008059
of	O
mothers	B-C0026591
with	O
lower	O
educational	B-C0013658
attainment	I-C0013658
and	O
children	B-C0008059
from	O
lower	O
income	B-C0021162
households	B-C0020052
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
socioemotional	B-C0013985
burdened	I-C0013985
'	O
class	B-C0456387
.	O
	
children	B-C0008059
of	O
mothers	B-C0026591
with	O
higher	O
educational	B-C0013658
attainment	I-C0013658
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
normative	B-C0205307
'	O
and	O
'	O
eczema	B-C0013595
/	O
unfavourable	B-C0005910
weight	I-C0005910
'	O
classes	B-C0456387
.	O
	
co-occurrence	B-C2745955
of	O
adverse	B-C0877248
health	B-C0018684
conditions	B-C0348080
at	O
age	B-C0001779
11	O
is	O
common	O
and	O
is	O
associated	B-C0332281
with	I-C0332281
adverse	B-C0877248
socioeconomic	B-C0748878
circumstances	B-C1254372
.	O
	
holistic	B-C0019844
,	O
child	B-C0008059
focused	O
care	B-C1947933
,	O
particularly	O
in	O
boys	B-C0870221
and	O
those	O
in	O
lower	O
income	B-C0021162
groups	B-C0441833
,	O
may	O
help	O
to	O
prevent	B-C2700409
and	O
reduce	B-C0392756
co-occurrence	B-C2745955
in	O
later	B-C0205087
childhood	B-C0231335
and	O
genomic	B-C0017428
characterization	B-C1880022
of	O
a	O
wild-bird	B-C0325328
-	O
origin	B-C0243095
pigeon	B-C0325912
paramyxovirus	B-C0027984
type	I-C0027984
1	I-C0027984
ppmv-1	B-C0027984
first	O
isolated	B-C0205409
in	O
the	O
northwest	B-C0008115
region	I-C0008115
of	I-C0008115
china	I-C0008115
pigeon	B-C0325912
paramyxovirus	B-C0027984
type-1	I-C0027984
ppmv-1	B-C0027984
is	O
an	O
enzootic	B-C0598394
in	O
pigeon	B-C0325912
flocks	B-C1633987
and	O
causes	O
severe	B-C0205082
economic	B-C0681022
losses	I-C0681022
in	O
the	O
poultry	B-C0032850
industry	B-C0021267
in	O
many	O
countries	B-C0454664
.	O
	
a	O
ppmv-1	B-C0027984
isolate	B-C1764827
,	O
abbreviated	O
as	O
ppmv-1/ql-01/ch/15	B-C0027984
,	O
was	O
isolated	B-C0205409
from	O
a	O
great	O
spotted	O
woodpecker	B-C0326243
in	O
the	O
northwest	B-C0008115
region	I-C0008115
of	I-C0008115
china	I-C0008115
in	O
2015	O
.	O
	
the	O
complete	O
genome	B-C0017428
was	O
sequenced	B-C3854164
,	O
and	O
the	O
results	B-C1274040
showed	O
that	O
the	O
virus	B-C0042776
genome	B-C0017428
was	O
15	O
nt	O
in	O
length	B-C1444754
,	O
in	O
the	O
gene	B-C0887940
arrangement	I-C0887940
3'-np-p-m-f-hn-l-5'	I-C0887940
.	O
	
several	O
amino	B-C0002520
acid	I-C0002520
mutations	B-C0026882
were	O
identified	B-C0205396
in	O
the	O
functional	B-C1514562
domains	I-C1514562
of	O
the	O
f	B-C0162768
and	O
hn	B-C0019822
proteins	I-C0019822
.	O
	
the	O
pathogenicity	B-C1136169
index	I-C1136169
of	O
the	O
isolate	B-C1764827
was	O
evaluated	B-C0220825
,	O
and	O
the	O
mean	B-C1301931
death	I-C1301931
time	I-C1301931
mdt	B-C1301931
was	O
72	O
h	O
and	O
the	O
intracerebral	B-C1136169
pathogenicity	I-C1136169
index	I-C1136169
icpi	B-C1136169
was	O
0.925	O
,	O
indicating	O
that	O
this	O
isolate	B-C1764827
was	O
mesogenic	B-C0205556
.	O
	
sequencing	B-C1294197
results	B-C1274040
showed	O
that	O
it	O
had	O
a	O
virulent	B-C1520022
newcastle	B-C0027984
disease	I-C0027984
virus	I-C0027984
cleavage	B-C0002518
motif	I-C0002518
112	I-C0002518
at	O
the	O
fusion	B-C0162768
protein	I-C0162768
cleavage	B-C0002518
site	I-C0002518
.	O
	
morbidity	B-C0026538
and	O
mortality	B-C0205848
were	O
70%	O
and	O
50%	O
,	O
after	O
inoculation	B-C2987620
of	O
pigeons	B-C0325912
,	O
whereas	O
this	O
virus	B-C0042776
was	O
nonpathogenic	B-C0243095
in	O
chickens	B-C0008051
.	O
	
different	O
immune	B-C0301872
responses	I-C0301872
of	O
pigeons	B-C0325912
and	O
chickens	B-C0008051
were	O
induced	B-C0205263
in	B-C1515655
vivo	I-C1515655
,	O
which	O
led	O
to	O
different	O
hi	B-C2229730
serum	I-C2229730
antibody	I-C2229730
titers	I-C2229730
.	O
	
the	O
results	B-C1274040
of	O
phylogenetic	B-C1519068
and	O
evolutionary	B-C0936012
distance	I-C0936012
analysis	I-C0936012
showed	O
that	O
this	O
ppmv-1	B-C0027984
strain	B-C1518614
belonged	O
to	O
sub-genotype	B-C0441756
via	I-C0441756
in	O
class	B-C0441886
ii	I-C0441886
.	O
	
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
identification	B-C0599616
and	O
analysis	B-C0936012
of	O
ppmv-1	B-C0027984
co-circulation	B-C0237318
among	O
wild	B-C0325328
birds	I-C0325328
and	O
domestic	B-C0999232
pigeon	I-C0999232
flocks	B-C1633987
in	O
china	B-C0008115
.	O
	
the	O
data	B-C1511726
from	O
this	O
study	B-C2603343
highlight	O
the	O
important	O
role	O
of	O
wild	B-C0325328
birds	I-C0325328
in	O
the	O
dissemination	B-C0205221
of	O
ppmv-1	B-C0027984
and	O
provide	O
useful	O
references	B-C1514811
for	O
improving	B-C1272745
our	O
understanding	O
of	O
the	O
distribution	B-C0037775
and	O
evolution	B-C0015219
of	O
ppmv-1	B-C0027984
in	O
memory	B-C0679057
consolidation	I-C0679057
effects	B-C1280500
on	O
memory	B-C0025361
stabilization	I-C0025361
and	O
item	B-C0025361
integration	I-C0025361
in	O
older	B-C0001792
adults	I-C0001792
this	O
study	B-C2603343
examined	O
the	O
differential	B-C1274040
effects	I-C1274040
of	O
aging	B-C0001811
on	O
consolidation	B-C0679057
processes	I-C0679057
that	O
strengthen	O
newly	O
acquired	O
memory	B-C0870873
traces	I-C0870873
in	O
veridical	O
form	O
memory	B-C0025361
stabilization	I-C0025361
versus	O
consolidation	B-C0679057
processes	I-C0679057
that	O
are	O
responsible	O
for	O
integrating	B-C0025361
these	O
memory	B-C0870873
traces	I-C0870873
into	O
an	O
existing	O
body	O
of	O
knowledge	B-C0376554
item	B-C0025361
integration	I-C0025361
.	O
	
older	B-C0001792
adults	I-C0001792
learned	B-C0023185
13	O
nonwords	B-C0282574
and	O
were	O
tested	O
on	O
their	O
memory	B-C0025260
for	O
the	O
nonwords	B-C0282574
,	O
and	O
on	O
whether	O
these	O
nonwords	B-C0282574
impacted	O
upon	O
processing	O
of	O
similar-sounding	O
english	B-C0376245
words	B-C0282574
immediately	O
and	O
24	O
hours	B-C0439227
later	O
.	O
	
participants	B-C0679646
accurately	O
recognized	O
the	O
nonwords	B-C0282574
immediately	O
,	O
but	O
showed	O
significant	O
decreases	O
in	O
delayed	O
recognition	B-C0524637
and	O
recall	B-C0034770
.	O
	
in	O
comparison	O
,	O
the	O
nonwords	B-C0282574
impacted	O
upon	O
processing	B-C1709694
of	O
similar-sounding	B-C0282574
words	I-C0282574
only	O
in	O
the	O
delayed	B-C0451414
test	I-C0451414
.	O
	
together	O
,	O
these	O
findings	O
suggest	O
that	O
memory	B-C0679057
consolidation	I-C0679057
processes	I-C0679057
may	O
be	O
more	O
evident	O
in	O
item	B-C0025361
integration	I-C0025361
than	O
memory	B-C0025361
stabilization	I-C0025361
processes	I-C0025361
for	O
new	O
declarative	O
memories	B-C0025260
in	O
older	B-C0001792
adults	I-C0001792
.	O
	
mucosa	B-C0026727
-	O
associated	B-C0332281
biohydrogenating	B-C0445623
microbes	I-C0445623
protect	O
the	O
simulated	O
colon	B-C3888384
microbiome	B-C1956108
from	O
stress	B-C0038435
associated	B-C0332281
with	I-C0332281
high	B-C1446561
concentrations	I-C1446561
of	O
poly-unsaturated	B-C2362518
fat	I-C2362518
polyunsaturated	B-C0032615
fatty	I-C0032615
acids	I-C0032615
pufas	B-C0032615
may	O
affect	O
colon	B-C3888384
microbiome	B-C1956108
homeostasis	B-C0019868
by	O
exerting	B-C0015264
specific	B-C0205369
antimicrobial	B-C0003232
effects	B-C1280500
and/or	O
interfering	O
with	O
mucosal	B-C0026727
biofilm	B-C1561572
formation	B-C1522492
at	O
the	O
gut	B-C0836209
mucosal	I-C0836209
interface	I-C0836209
.	O
	
we	O
used	O
standardized	B-C1439852
batch	I-C1439852
incubations	I-C1439852
and	O
the	O
mucosal-simulator	B-C0282574
of	I-C0282574
the	I-C0282574
human	I-C0282574
microbial	I-C0282574
intestinal	I-C0282574
ecosystem	I-C0282574
m-shime	B-C0282574
to	O
show	O
the	O
in	B-C1533691
vitro	I-C1533691
luminal	B-C0524461
and	O
mucosal	B-C0026727
effects	B-C1704420
of	I-C1704420
the	O
main	O
pufa	B-C0032615
in	O
the	O
western	B-C3849996
diet	I-C3849996
,	O
linoleic	B-C0023749
acid	I-C0023749
la	B-C0023749
.	O
	
high	B-C1446561
concentrations	I-C1446561
of	O
la	B-C0023749
were	O
found	O
to	O
decrease	B-C0547047
butyrate	B-C0006521
production	B-C0205245
and	O
faecalibacterium	B-C0317558
prausnitzii	I-C0317558
numbers	O
dependent	O
on	O
la	B-C0023749
biohydrogenation	B-C0020286
to	O
vaccenic	B-C0301702
acid	I-C0301702
va	B-C0301702
and	O
stearic	B-C0038229
acid	I-C0038229
sa	B-C0038229
.	O
	
in	O
faecal	B-C0015733
batch	B-C1439852
incubations	I-C1439852
,	O
la	B-C0023749
biohydrogenation	B-C0020286
and	O
butyrate	B-C0006521
production	B-C0205245
were	O
positively	B-C1707520
correlated	I-C1707520
and	O
sa	B-C0038229
did	O
not	O
inhibit	B-C3463820
butyrate	B-C0006521
production	B-C0205245
.	O
	
in	O
the	O
m-shime	B-C0282574
,	O
addition	O
of	O
a	O
mucosal	B-C0026727
environment	B-C0014406
stimulated	B-C1948023
biohydrogenation	B-C0020286
to	O
sa	B-C0038229
and	O
protected	O
f	B-C0317558
.	O
	
prausnitzii	I-C0317558
from	O
inhibition	B-C3463820
by	O
la	B-C0023749
.	O
	
this	O
was	O
probably	O
due	O
to	O
the	O
preference	B-C0558295
of	O
two	O
biohydrogenating	B-C0020286
genera	B-C1708235
roseburia	B-C0995401
and	O
pseudobutyrivibrio	B-C1012458
for	O
the	O
mucosal	B-C0026727
niche	O
.	O
	
co-culture	B-C0282547
batch	B-C1439852
incubations	I-C1439852
using	O
roseburia	B-C1667633
hominis	I-C1667633
and	O
f	B-C0317558
.	O
	
prausnitzii	I-C0317558
validated	B-C1519941
these	O
observations	B-C0302523
.	O
	
correlations	B-C1707520
networks	B-C1882071
further	O
uncovered	O
the	O
central	O
role	O
of	O
roseburia	B-C0995401
and	O
pseudobutyrivibrio	B-C1012458
in	O
protecting	O
luminal	B-C0524461
and	O
mucosal	B-C3496041
shime	I-C3496041
microbiota	I-C3496041
from	O
la	B-C0023749
-	O
induced	B-C0038435
stress	I-C0038435
.	O
	
our	O
results	B-C1274040
confirm	O
how	O
cross-shielding	B-C1704675
interactions	I-C1704675
provide	O
resilience	O
to	O
the	O
microbiome	B-C1956108
and	O
demonstrate	O
the	O
importance	B-C3898777
of	O
biohydrogenating	B-C0020286
,	O
mucosal	B-C0026727
bacteria	B-C0004611
for	O
recovery	B-C0237820
from	O
la	B-C0023749
stress	B-C0038435
.	O
	
genetic	B-C0314603
parameters	B-C0449381
for	O
tick	B-C0750480
count	I-C0750480
and	O
udder	B-C0242386
health	B-C0018684
in	O
commercial	B-C0680536
and	O
indigenous	B-C1512704
ewes	B-C0699762
in	O
south	B-C0037712
africa	I-C0037712
the	O
genetics	B-C0314603
of	O
tick	B-C0040196
infestation	I-C0040196
in	O
sheep	B-C0036945
need	O
study	O
,	O
as	O
host	B-C4281815
resistance	I-C4281815
often	O
forms	O
part	O
of	O
integrated	O
pest	B-C0031249
control	I-C0031249
programs	I-C0031249
.	O
	
repeated	O
udder	B-C0242386
health	B-C1550208
scores	I-C1550208
,	O
site-specific	B-C0449604
tick	B-C0750480
count	I-C0750480
,	O
mating	B-C1260875
weight	B-C0043100
and	O
reproduction	B-C0035150
records	B-C0034869
n=879-1204	O
were	O
recorded	O
annually	O
from	O
2010	O
to	O
2015	O
on	O
ewes	B-C0699762
of	O
the	O
indigenous	B-C1512704
namaqua	B-C1269178
afrikaner	I-C1269178
na	B-C1269178
fat-tailed	B-C1704650
breed	I-C1704650
,	O
as	O
well	O
as	O
the	O
commercial	B-C0680536
dorper	B-C1296152
and	O
sa	B-C1269346
mutton	I-C1269346
merino	I-C1269346
samm	I-C1269346
breeds	I-C1269346
.	O
	
udder	B-C0242386
s	O
were	O
scored	B-C0449820
subjectively	O
on	O
a	O
1-5	O
scale	O
1	O
-	O
udder	B-C0242386
intact	B-C0205266
and	O
5	O
-	O
udder	B-C0242386
damaged	B-C0010957
severely	I-C0010957
and	O
ticks	B-C0040196
were	O
counted	B-C0750480
on	O
three	B-C1545955
locations	I-C1545955
.	O
	
the	O
body	B-C1545955
sites	I-C1545955
counted	B-C0750480
were	O
the	O
head	B-C0229962
and	I-C0229962
thoracic	I-C0229962
limb	I-C0229962
htltc	B-C0229962
,	O
udder-pelvic	B-C1268092
limb	I-C1268092
upltc	B-C1268092
and	O
perineum-breech-tail	B-C0039259
pbttc	B-C0039259
.	O
	
these	O
counts	B-C0750480
were	O
also	O
totaled	O
for	O
a	O
total	B-C0750480
tick	I-C0750480
count	I-C0750480
ttc	B-C0750480
.	O
	
reproduction	B-C0035150
traits	B-C0599883
were	O
number	O
of	O
lambs	B-C1123019
weaned	B-C0043084
per	O
ewe	B-C0243095
lambed	I-C0243095
and	O
total	O
weight	O
of	O
lamb	B-C0043084
weaned	I-C0043084
per	O
ewe	B-C0243095
lambed	I-C0243095
.	O
	
udder	B-C0242386
health	B-C1550208
scores	I-C1550208
of	O
na	B-C1269178
ewes	B-C0699762
were	O
lower	O
than	O
those	O
of	O
dorpers	B-C1296152
,	O
which	O
in	O
turn	O
had	O
lower	O
scores	O
than	O
samm	B-C1269346
ewes	B-C0699762
.	O
	
na	B-C1269178
ewes	B-C0699762
had	O
lower	O
values	O
for	O
htltc	B-C0229962
,	O
upltc	B-C1268092
and	O
ttc	B-C0750480
than	O
the	O
commercial	B-C0680536
breeds	B-C1704650
,	O
but	O
higher	O
values	O
for	O
pbttc	B-C0039259
than	O
dorpers	B-C1296152
.	O
	
heritability	B-C4062865
estimates	B-C0750572
amounted	O
to	O
0.26	O
for	O
htltc	B-C0229962
,	O
0.53	O
for	O
upltc	B-C1268092
,	O
0.07	O
for	O
pbttc	B-C0039259
,	O
0.44	O
for	O
ttc	B-C0750480
and	O
0.61	O
for	O
udder	B-C0242386
health	B-C1550208
score	I-C1550208
.	O
	
animal	B-C0871648
permanent	I-C0871648
environment	I-C0871648
also	O
affected	O
pbttc	B-C0039259
0.14	O
.	O
	
significant	B-C0678931
genetic	I-C0678931
correlations	I-C0678931
were	O
found	O
between	O
the	O
htltc	B-C0229962
and	O
upltc	B-C1268092
0.47	O
,	O
upltc	B-C1268092
and	O
udder	B-C0242386
health	B-C1550208
score	I-C1550208
0.52	O
,	O
htltc	B-C0229962
and	O
upltc	B-C1268092
0.24	O
as	O
well	O
as	O
upltc	B-C1268092
and	O
pbttc	B-C0039259
-0	O
.	O
	
heavier	O
ewes	B-C0699762
had	O
higher	O
upltc	B-C1268092
0.38	O
,	O
ttc	B-C0750480
0.33	O
and	O
impaired	B-C0221099
udder	B-C0242386
health	B-C0018684
0.21	O
.	O
	
udder	B-C0242386
health	B-C1550208
score	I-C1550208
s	O
and	O
tick	B-C0750480
counts	I-C0750480
at	O
all	O
sites	O
were	O
not	O
related	O
to	O
reproduction	B-C0035150
traits	B-C0599883
.	O
	
the	O
indigenous	B-C1512704
na	B-C1269178
breed	B-C1704650
outperformed	O
the	O
commercial	B-C0680536
breeds	B-C1704650
with	O
lower	O
values	O
for	O
htltc	B-C0229962
,	O
upltc	B-C1268092
,	O
ttc	B-C0750480
and	O
a	O
better	O
udder	B-C0242386
health	B-C1550208
score	I-C1550208
.	O
	
mechanisms	O
contributing	O
to	O
the	O
better	O
performance	O
of	O
the	O
na	B-C1269178
breed	B-C1704650
under	O
pastoral	B-C0030643
conditions	I-C0030643
and	O
the	O
scope	O
for	O
selection	O
for	O
tick	B-C0040196
tolerance	B-C1704410
within	O
breeds	B-C1704650
starvation	B-C0038187
-	O
and	O
antibiotics	B-C0003232
-induced	O
formation	B-C0007613
of	O
persister	B-C0563199
cells	I-C0563199
in	O
pseudomonas	B-C0033809
aeruginosa	I-C0033809
planktonic	B-C0032071
stationary	B-C0430402
and	I-C0430402
exponential	I-C0430402
cultures	I-C0430402
of	O
pseudomonas	B-C0033809
aeruginosa	I-C0033809
are	O
highly	B-C0332325
resistant	I-C0332325
to	O
killing	B-C1306577
by	O
bactericidal	B-C0003232
antimicrobials	I-C0003232
because	O
of	O
the	O
presence	O
of	O
persisters	B-C0563199
,	O
cells	B-C0563199
that	O
are	O
multidrug	B-C0013220
tolerant	I-C0013220
and	O
play	O
a	O
key	O
role	O
in	O
the	O
recalcitrance	B-C0205245
of	O
biofilm	B-C0081786
infections	B-C3714514
.	O
	
the	O
aim	O
of	O
this	O
study	B-C0085973
was	O
to	O
investigate	B-C1292732
the	O
formation	B-C0007613
of	O
persister	B-C0563199
cells	I-C0563199
in	O
p	B-C0033809
.	O
	
aeruginosa	I-C0033809
stationary	B-C0430402
vs	O
.	O
	
exponential	B-C0430402
cultures	I-C0430402
using	O
different	B-C1705242
class	B-C0456387
antimicrobials	B-C0003232
.	O
	
the	O
susceptibilities	B-C1264642
of	O
p	B-C0033809
.	O
	
aeruginosa	I-C0033809
pao1	I-C0033809
wild-type	I-C0033809
and	O
mutant	B-C1518614
strains	I-C1518614
to	O
antimicrobials	B-C0003232
were	O
determined	O
by	O
standard	B-C2827874
microtiter	I-C2827874
broth	I-C2827874
dilution	I-C2827874
method	I-C2827874
.	O
	
in	O
order	O
to	O
determine	O
persister	B-C0563199
formation	B-C0007613
,	O
dose	B-C1512045
-	O
and	O
time	B-C0040223
-dependent	O
killing	B-C0022885
experiments	I-C0022885
were	O
performed	B-C0884358
with	O
antibiotics	B-C0003232
.	O
	
ceftazidime	B-C0007559
cephalosporin	B-C3536856
showed	O
little	O
efficacy	B-C1280519
against	O
either	O
culture	B-C0430402
.	O
	
stationary-phase	B-C0563199
cells	I-C0563199
were	O
more	O
tolerant	B-C0013220
to	O
imipenem	B-C0020933
carbapenem	B-C0006968
than	O
exponential	B-C0563199
cells	I-C0563199
,	O
leaving	O
a	O
small	O
fraction	B-C1264633
of	I-C1264633
persisters	B-C0563199
at	O
high	B-C0205250
imipenem	B-C0020933
concentration	B-C0392762
in	O
both	O
populations	B-C1257890
.	O
	
polymyxin	B-C0032535
b	I-C0032535
polymyxin	B-C0032539
appeared	O
to	O
be	O
ineffective	O
at	O
low	B-C0392762
concentrations	I-C0392762
against	O
both	O
cell	B-C1257890
populations	I-C1257890
.	O
	
very	O
high	O
polymyxin	B-C0032535
b	I-C0032535
concentration	B-C0392762
completely	O
eradicated	O
exponential	B-C0563199
cells	I-C0563199
and	O
regrowth	B-C0205245
was	O
seen	O
in	O
a	O
stationary	B-C1257890
population	I-C1257890
.	O
	
stationary	B-C0563199
cells	I-C0563199
were	O
more	O
tolerant	B-C0013220
to	O
tobramycin	B-C0040341
aminoglycoside	B-C0002556
than	O
exponential	B-C0563199
cells	I-C0563199
but	O
a	O
higher	B-C0392762
concentration	I-C0392762
of	O
tobramycin	B-C0040341
completely	O
eliminated	B-C0849355
survivors	B-C0441833
.	O
	
ciprofloxacin	B-C0008809
fluoroquinolone	B-C0949665
at	O
a	O
low	B-C0392762
concentration	I-C0392762
resulted	O
in	O
killing	B-C1306577
of	O
both	O
cultures	B-C0430402
of	O
p	B-C0033809
.	O
	
aeruginosa	I-C0033809
,	O
producing	O
persisters	B-C0563199
that	O
were	O
invulnerable	O
to	O
killing	B-C1306577
.	O
	
stationary	B-C0563199
cells	I-C0563199
appear	O
to	O
be	O
somewhat	O
more	O
tolerant	B-C0013220
than	O
exponential	B-C0563199
cells	I-C0563199
in	O
all	O
of	O
these	O
assays	B-C0005507
.	O
	
we	O
also	O
showed	O
that	O
nutrient	B-C0678695
deprivation	B-C0871712
serine	B-C0036720
starvation	B-C0038187
regulated	O
by	O
stringent	B-C0149784
and	I-C0149784
general	I-C0149784
stress	I-C0149784
response	I-C0149784
,	O
contribute	O
to	O
the	O
increased	B-C0151956
tolerance	I-C0151956
of	O
p	B-C0033809
.	O
	
aeruginosa	I-C0033809
exponential	B-C0563199
and	I-C0563199
stationary	I-C0563199
planktonic	I-C0563199
cells	I-C0563199
via	O
production	B-C0007613
of	O
chaetomium	B-C1225414
thermophilum	I-C1225414
formate	B-C0016570
dehydrogenase	I-C0016570
has	O
high	O
activity	O
in	O
the	O
reduction	B-C0301630
of	O
hydrogen	B-C0973231
carbonate	I-C0973231
hco3	B-C0973231
-	I-C0973231
to	O
formate	B-C0220832
while	O
formate	B-C0016570
dehydrogenases	I-C0016570
fdhs	B-C0016570
have	O
been	O
used	O
for	O
cofactor	B-C0178555
recycling	B-C0282114
in	O
chemoenzymatic	B-C1511130
synthesis	I-C1511130
,	O
the	O
ability	O
of	O
fdh	B-C0016570
to	O
reduce	O
co2	B-C0007012
could	O
also	O
be	O
utilized	O
in	O
the	O
conversion	B-C0439836
of	O
co2	B-C0007012
to	O
useful	O
products	B-C1514468
via	O
formate	B-C0220832
hcoo	B-C0220832
.	O
	
in	O
this	O
study	O
,	O
we	O
investigated	B-C1292732
the	O
reduction	B-C0301630
of	O
co2	B-C0007012
in	O
the	O
form	O
of	O
hydrogen	B-C0973231
carbonate	I-C0973231
hco3	B-C0973231
to	O
formate	B-C0220832
by	O
fdhs	B-C0016570
from	O
candida	B-C1011924
methylica	I-C1011924
cmfdh	B-C0016570
and	O
chaetomium	B-C1225414
thermophilum	I-C1225414
ctfdh	B-C0016570
in	O
a	O
nadh	B-C0027289
-dependent	O
reaction	B-C0443286
.	O
	
the	O
catalytic	B-C0243102
performance	I-C0243102
with	O
hco3	B-C0973231
as	O
a	O
substrate	B-C3891814
was	O
evaluated	O
by	O
measuring	B-C0444706
the	O
kinetic	B-C1254367
rates	I-C1254367
and	O
conducting	O
productivity	B-C1510438
assays	I-C1510438
.	O
	
ctfdh	B-C0016570
showed	O
a	O
higher	O
efficiency	B-C0013682
in	O
converting	B-C0439836
hco3	B-C0973231
to	O
formate	B-C0220832
than	O
cmfdh	B-C0016570
,	O
whereas	O
cmfdh	B-C0016570
was	O
better	O
in	O
the	O
oxidation	B-C0030011
of	O
formate	B-C0220832
.	O
	
the	O
ph	B-C0020283
optimum	O
of	O
the	O
reduction	B-C0301630
was	O
at	O
ph	B-C0020283
7-8	O
.	O
	
however	O
,	O
the	O
high	B-C1446561
concentrations	I-C1446561
of	O
hco3	B-C0973231
reduced	O
the	O
reaction	B-C0678608
rate	I-C0678608
.	O
	
ctfdh	B-C0016570
was	O
modeled	O
in	O
the	O
presence	O
of	O
hco3	B-C0973231
showing	O
that	O
it	O
fits	O
to	O
the	O
active	B-C0205681
site	I-C0205681
.	O
	
the	O
active	B-C0205681
site	I-C0205681
setting	O
for	O
hydride	B-C1148560
transfer	I-C1148560
in	O
co2	B-C0007012
reduction	B-C0301630
was	O
modeled	O
.	O
	
the	O
hydride	B-C1148560
donated	I-C1148560
by	O
nadh	B-C0027289
would	O
form	O
a	O
favorable	O
contact	O
to	O
the	O
carbon	B-C0007009
atom	I-C0007009
of	O
hco3	B-C0973231
,	O
resulting	O
in	O
a	O
surplus	O
of	O
electrons	B-C0013852
within	O
the	O
molecule	B-C0567416
.	O
	
this	O
would	O
cause	O
the	O
complex	O
formed	O
by	O
hydrogen	B-C0973231
carbonate	I-C0973231
and	O
the	O
hydride	B-C0003075
to	O
break	O
into	O
formate	B-C0220832
and	O
hydroxide	B-C0220853
ions	I-C0220853
.	O
	
evaluation	B-C0015196
of	O
an	O
international	B-C1512888
educational	B-C0150562
programme	I-C0150562
for	O
health	B-C1704312
care	I-C1704312
professionals	I-C1704312
on	O
best	O
practice	O
in	O
the	O
management	B-C1273870
of	O
a	O
perinatal	B-C0178795
death	B-C0011065
improving	B-C0150562
perinatal	I-C0150562
mortality	I-C0150562
review	I-C0150562
and	I-C0150562
outcomes	I-C0150562
via	I-C0150562
education	I-C0150562
improve	B-C0150562
stillbirths	B-C0595939
and	O
neonatal	B-C0410916
deaths	I-C0410916
are	O
devastating	B-C0441471
events	I-C0441471
for	O
both	O
parents	B-C0030551
and	O
clinicians	B-C0205210
and	O
are	O
global	B-C1456573
public	I-C1456573
health	I-C1456573
concerns	B-C2699424
.	O
	
careful	O
clinical	B-C1516615
management	I-C1516615
after	O
these	O
deaths	B-C0011065
is	O
required	O
,	O
including	O
appropriate	O
investigation	B-C0220825
and	O
assessment	B-C0220825
to	O
determine	O
cause	O
s	O
to	O
prevent	O
future	O
losses	O
,	O
and	O
to	O
improve	O
bereavement	B-C0085882
care	I-C0085882
for	O
families	B-C0015576
.	O
	
an	O
educational	B-C0150562
programme	I-C0150562
for	O
health	B-C1704312
care	I-C1704312
professionals	I-C1704312
working	O
in	O
maternal	B-C1858460
and	O
child	B-C0008078
health	I-C0008078
has	O
been	O
designed	O
to	O
address	O
these	O
needs	O
according	O
to	O
the	O
perinatal	B-C0162791
society	I-C0162791
of	I-C0162791
australia	I-C0162791
and	I-C0162791
new	I-C0162791
zealand	I-C0162791
guideline	I-C0162791
for	I-C0162791
perinatal	I-C0162791
mortality	I-C0162791
improving	B-C0150562
perinatal	I-C0150562
mortality	I-C0150562
review	I-C0150562
and	I-C0150562
outcomes	I-C0150562
via	I-C0150562
education	I-C0150562
improve	B-C0150562
.	O
	
the	O
programme	B-C0150562
has	O
a	O
major	O
focus	O
on	O
stillbirth	B-C0595939
and	O
is	O
delivered	O
as	O
six	O
interactive	B-C0559197
skills	I-C0559197
-based	O
stations	B-C1883167
.	O
	
we	O
aimed	O
to	O
determine	O
participants	B-C0679646
'	O
pre-	B-C0150562
and	O
post-programme	B-C0150562
knowledge	B-C0376554
of	O
and	O
confidence	B-C1704726
in	O
the	O
management	B-C1273870
of	O
perinatal	B-C0178795
deaths	B-C0011065
,	O
along	O
with	O
satisfaction	B-C0242428
with	O
the	O
programme	B-C0150562
.	O
	
we	O
also	O
aimed	O
to	O
determine	O
suitability	O
for	O
international	B-C1512888
use	O
.	O
	
the	O
improve	B-C0150562
programme	I-C0150562
was	O
delivered	O
to	O
health	B-C1704312
professionals	I-C1704312
in	O
maternity	B-C0020010
hospitals	I-C0020010
in	O
all	O
seven	O
australian	B-C0004340
states	B-C1301808
and	O
territories	B-C0681784
and	O
modified	O
for	O
use	O
internationally	B-C1512888
with	O
piloting	O
in	O
vietnam	B-C0042658
,	O
fiji	B-C0016080
,	O
and	O
the	O
netherlands	B-C0027778
with	O
the	O
assistance	B-C0010210
of	O
the	O
international	B-C1708333
stillbirth	I-C1708333
alliance	I-C1708333
,	O
isa	B-C1708333
.	O
	
modifications	O
were	O
made	O
to	O
programme	B-C0282574
materials	I-C0282574
in	O
consultation	B-C0009818
with	O
local	O
teams	O
and	O
included	O
translation	B-C0040712
for	O
the	O
vietnam	B-C0150562
programme	I-C0150562
.	O
	
participants	B-C0679646
completed	O
pre-	B-C0150562
and	O
post-programme	B-C0150562
evaluation	B-C0015196
questionnaires	B-C0034394
on	O
knowledge	B-C0376554
and	O
confidence	B-C1704726
on	O
six	O
key	O
components	O
of	O
perinatal	B-C0178795
death	B-C0011065
management	B-C1273870
as	O
well	O
as	O
a	O
satisfaction	B-C0034394
questionnaire	I-C0034394
.	O
	
over	O
the	O
period	O
may	O
2012	O
to	O
may	O
2015	O
,	O
30	O
improve	B-C0150562
workshops	B-C0242262
were	O
conducted	O
,	O
including	O
26	O
with	O
758	O
participants	B-C0679646
in	O
australia	B-C0004340
and	O
four	O
with	O
136	O
participants	B-C0679646
internationally	B-C1512888
.	O
	
evaluations	B-C0015196
showed	O
a	O
significant	B-C0750502
improvement	B-C2936612
between	O
pre-	B-C0150562
and	O
post-programme	B-C0150562
knowledge	B-C0376554
and	O
confidence	B-C1704726
in	O
all	O
six	O
stations	B-C1883167
and	O
overall	O
,	O
and	O
a	O
high	O
degree	O
of	O
satisfaction	B-C0242428
in	O
all	O
settings	B-C0162579
.	O
	
the	O
improve	B-C0150562
programme	I-C0150562
has	O
been	O
well	O
received	O
in	O
australia	B-C0004340
and	O
in	O
three	O
different	O
international	B-C1512888
settings	B-C0162579
and	O
is	O
now	O
being	O
made	O
available	O
through	O
isa	B-C1708333
.	O
	
future	O
research	B-C0035168
is	O
required	O
to	O
determine	O
whether	O
the	O
immediate	O
improvements	B-C2936612
in	O
knowledge	B-C0376554
are	O
sustained	B-C0443318
with	O
less	O
causes	O
of	O
death	B-C0011065
being	O
classified	O
as	O
unknown	O
,	O
changes	B-C0205897
in	I-C0205897
clinical	I-C0205897
practice	I-C0205897
and	O
improvement	B-C2936612
in	O
parents'	B-C0030551
experiences	O
with	O
care	B-C1947933
.	O
	
the	O
suitability	O
for	O
this	O
programme	B-C0150562
in	O
low-income	B-C1331016
countries	B-C0454664
experiences	O
of	O
support	O
in	O
working	O
toward	O
personal	B-C1519021
recovery	B-C2004454
goals	B-C0018017
a	O
collaborative	B-C0681804
,	O
qualitative	B-C0949415
study	I-C0949415
recovery	B-C2004454
can	O
be	O
understood	O
as	O
a	O
subjective	B-C1522240
process	I-C1522240
guided	O
by	O
personal	B-C1519021
expectations	B-C0679138
,	O
goals	B-C0018017
and	O
hopes	B-C0392347
.	O
	
the	O
aim	O
of	O
the	O
study	B-C2603343
was	O
to	O
explore	O
how	O
persons	B-C0027361
using	O
a	O
community	B-C0475309
mental	I-C0475309
health	I-C0475309
centre	I-C0475309
cmhc	B-C0475309
experienced	O
that	O
their	O
expectations	B-C0679138
for	O
treatment	B-C0087111
,	O
and	O
goals	B-C0018017
and	O
hopes	B-C0392347
for	O
recovery	B-C2004454
were	O
supported	O
by	O
the	O
health	B-C1704312
professionals	I-C1704312
during	O
treatment	B-C0087111
.	O
	
employing	O
a	O
hermeneutic	B-C0870642
-phenomenological	O
approach	O
,	O
eight	O
service	B-C0030705
users	I-C0030705
were	O
interviewed	O
about	O
their	O
expectations	B-C0679138
for	O
treatment	B-C0087111
and	O
their	O
goals	B-C0018017
and	O
hopes	B-C0392347
for	O
recovery	B-C2004454
at	O
the	O
start	O
of	O
their	O
contact	O
with	O
health	B-C1704312
professionals	I-C1704312
at	O
a	O
cmhc	B-C0475309
.	O
	
two	O
years	B-C0439234
later	O
,	O
they	O
were	O
re-interviewed	O
about	O
their	O
experiences	O
of	O
treatment	B-C0087111
and	O
support	O
from	O
the	O
health	B-C1704312
professionals	I-C1704312
in	O
their	O
work	O
towards	O
these	O
goals	B-C0018017
and	O
hopes	B-C0392347
.	O
	
a	O
collaborative	B-C0282116
approach	I-C0282116
was	O
adopted	O
.	O
	
a	O
co-researcher	B-C0035173
with	O
lived	O
experience	O
took	O
part	O
in	O
all	O
stages	O
of	O
the	O
study	B-C2603343
.	O
	
data	B-C1511726
were	O
analysed	O
by	O
means	O
of	O
a	O
data	B-C1511726
-driven	O
stepwise	O
approach	O
in	O
line	O
with	O
thematic	B-C0936012
analysis	I-C0936012
.	O
	
five	O
themes	O
reflecting	O
how	O
participants	B-C0679646
experienced	O
support	O
from	O
health	B-C1704312
professionals	I-C1704312
at	O
the	O
cmhc	B-C0475309
in	O
their	O
work	O
towards	O
their	O
recovery	B-C2004454
goals	B-C0018017
were	O
elicited	O
,	O
as	O
follows	O
developing	B-C0205556
an	I-C0205556
understanding	I-C0205556
of	I-C0205556
oneself	I-C0205556
and	O
one's	O
mental	B-C1446377
health	I-C1446377
problems	I-C1446377
learning	O
how	O
to	O
change	O
feelings	B-C1527305
and	O
behaviours	B-C0004927
being	B-C0243095
'pushed'	I-C0243095
into	I-C0243095
social	I-C0243095
arenas	I-C0243095
finding	B-C0243095
helpful	I-C0243095
medication	I-C0243095
and	O
counselling	B-C0010210
in	O
family	B-C0851511
,	O
practical	B-C0243095
and	O
financial	B-C0243095
issues	I-C0243095
.	O
	
the	O
participants	B-C0679646
'	O
expectations	B-C0679138
about	O
counselling	B-C0010210
with	O
regard	O
to	O
longer-term	O
family	B-C0851511
,	O
practical	B-C0243095
,	O
and	O
financial	B-C0243095
challenges	I-C0243095
were	O
insufficiently	O
met	O
by	O
the	O
cmhc	B-C0475309
.	O
	
in	O
the	O
experience	O
of	O
the	O
service	B-C0030705
users	I-C0030705
,	O
recovery	B-C2004454
occurred	O
within	O
the	O
context	O
of	O
their	O
everyday	B-C0376558
life	I-C0376558
with	O
or	O
without	O
the	O
support	O
of	O
their	O
professional	B-C1704312
helpers	B-C0341652
.	O
	
to	O
facilitate	O
recovery	B-C2004454
,	O
health	B-C1704312
professionals	I-C1704312
should	O
acknowledge	O
the	O
service	B-C0030705
user's	I-C0030705
personal	B-C1519021
goals	B-C0018017
and	O
hopes	B-C0392347
and	O
take	O
a	O
more	O
comprehensive	O
and	O
longer-term	O
approach	O
to	O
his	O
or	O
her	O
needs	B-C0027552
and	O
desires	B-C0871633
.	O
	
acknowledging	O
and	O
facilitating	O
recovery	B-C2004454
goals	B-C0018017
by	O
offering	O
counselling	B-C0010210
with	O
regard	O
to	O
family	B-C0851511
,	O
practical	B-C0243095
and	O
financial	B-C0243095
issues	I-C0243095
pathogenesis	B-C0699748
of	O
copd	B-C0024117
and	O
asthma	B-C0004096
asthma	B-C0004096
and	O
copd	B-C0024117
remain	O
two	O
diseases	B-C0035242
of	I-C0035242
the	I-C0035242
respiratory	I-C0035242
tract	I-C0035242
with	O
unmet	B-C3274904
medical	B-C0205476
needs	B-C0027552
.	O
	
this	O
review	B-C0282443
considers	O
the	O
current	O
state	O
of	O
play	O
with	O
respect	O
to	O
what	O
is	O
known	O
about	O
the	O
underlying	O
pathogenesis	B-C0699748
of	O
these	O
two	O
chronic	B-C1290886
inflammatory	I-C1290886
diseases	I-C1290886
of	O
the	O
lung	B-C0024109
.	O
	
the	O
review	B-C0282443
highlights	O
why	O
they	O
are	O
different	O
conditions	B-C0348080
requiring	O
different	O
approaches	O
to	O
treatment	B-C0087111
and	O
provides	O
a	O
backdrop	O
for	O
the	O
subsequent	O
chapters	O
in	O
this	O
volume	O
discussing	O
recent	O
advances	O
in	O
the	O
pharmacology	B-C0031330
and	O
treatment	B-C0087111
of	O
asthma	B-C0004096
and	O
antigen	B-C1536991
specificity	I-C1536991
determines	O
anti-red	B-C0003241
blood	I-C0003241
cell	I-C0003241
igg-fc	I-C0003241
alloantibody	I-C0003241
glycosylation	B-C0017982
and	O
thereby	O
severity	B-C0439793
of	O
haemolytic	B-C0014761
disease	I-C0014761
of	I-C0014761
the	I-C0014761
fetus	I-C0014761
and	I-C0014761
newborn	I-C0014761
haemolytic	B-C0014761
disease	I-C0014761
of	I-C0014761
the	I-C0014761
fetus	I-C0014761
and	I-C0014761
newborn	I-C0014761
hdfn	B-C0014761
is	O
a	O
severe	O
disease	B-C0012634
in	O
which	O
fetal	B-C0015965
red	B-C0014792
blood	I-C0014792
cells	I-C0014792
rbc	B-C0014792
are	O
destroyed	B-C1948029
by	O
maternal	B-C0729663
anti-rbc	I-C0729663
igg	I-C0729663
alloantibodies	I-C0729663
.	O
	
hdfn	B-C0014761
is	O
most	O
often	O
caused	O
by	O
anti-d	B-C0140430
but	O
may	O
also	O
occur	O
due	B-C0678226
to	I-C0678226
anti-k	B-C0313239
,	O
-c	B-C0432626
-	O
or	O
-e	B-C0947659
.	O
	
we	O
recently	O
found	O
n-linked	B-C1622430
glycosylation	I-C1622430
of	O
anti-d	B-C0140430
to	O
be	O
skewed	O
towards	O
low	B-C0205251
fucosylation	B-C3271553
,	O
thereby	O
increasing	B-C0442808
the	O
affinity	B-C0003255
to	O
igg-fc	B-C1521898
receptor	I-C1521898
iiia	I-C1521898
and	O
iiib	B-C0966831
,	O
which	O
correlated	B-C1707520
with	O
hdfn	B-C0014761
disease	B-C0012634
severity	B-C0439793
.	O
	
here	O
,	O
we	O
analysed	O
230	O
pregnant	B-C0033011
women	I-C0033011
with	O
anti-c	B-C0432626
,	O
-e	B-C0947659
or	O
-k	B-C0313239
alloantibodies	B-C0022144
from	O
a	O
prospective	O
screening	B-C0422390
cohort	I-C0422390
and	O
investigated	B-C1292732
the	O
type	O
of	O
fc-tail	B-C0376322
glycosylation	I-C0376322
of	O
these	O
antibodies	B-C0003241
in	O
relation	O
to	O
the	O
trigger	B-C1444748
of	O
immunisation	B-C0020971
and	O
pregnancy	B-C0032972
outcome	I-C0032972
.	O
	
anti-c	B-C0432626
,	O
-e	B-C0947659
and	O
-k	B-C0313239
show	O
-	O
independent	B-C0332291
of	I-C0332291
the	O
event	B-C0441471
that	O
had	O
led	O
to	O
immunisation	B-C0020971
-	O
a	O
different	B-C1705242
kind	O
of	O
fc-glycosylation	B-C0376322
compared	O
to	O
that	O
of	O
the	O
total	O
igg	B-C0020852
fraction	O
,	O
but	O
with	O
less	O
pronounced	O
differences	O
compared	O
to	O
anti-d	O
.	O
	
high	O
fc-galactosylation	O
and	O
sialylation	O
of	O
anti-c	O
correlated	O
with	O
hdfn	O
disease	O
severity	O
,	O
while	O
low	O
anti-k	O
fc-fucosylation	O
correlated	O
with	O
severe	O
fetal	O
anaemia	O
.	O
	
igg-fc	O
glycosylation	O
of	O
anti-rbc	O
antibodies	O
is	O
shaped	O
depending	O
on	O
the	O
antigen	O
.	O
	
these	O
features	O
influence	O
their	O
clinical	O
potency	O
and	O
may	O
therefore	O
be	O
used	O
to	O
predict	O
severity	O
and	O
identify	O
those	O
needing	O
treatment	B-C0039798
shout	O
louder	O
about	O
poor	B-C0871051
pay	I-C0871051
it	O
seems	O
increasingly	O
clear	O
to	O
me	O
that	O
the	O
nhs	B-C0027462
pay	B-C0871051
campaign	B-C0680899
is	O
not	O
making	O
waves	O
either	O
in	O
the	O
nhs	B-C0027462
or	O
with	O
the	O
sars	B-C1175175
-	O
cov	B-C0010076
fusion	O
peptides	B-C0030956
induce	O
membrane	B-C0596901
surface	B-C0205148
ordering	B-C1254362
and	O
curvature	B-C1254362
viral	B-C1721020
membrane	I-C1721020
fusion	I-C1721020
is	O
an	O
orchestrated	O
process	O
triggered	O
by	O
membrane-anchored	B-C1622010
viral	B-C0042716
fusion	I-C0042716
glycoproteins	I-C0042716
.	O
	
the	O
s2	B-C3658241
subunit	B-C0599220
of	O
the	O
spike	B-C3658241
glycoprotein	I-C3658241
from	O
severe	B-C1175175
acute	I-C1175175
respiratory	I-C1175175
syndrome	I-C1175175
sars	B-C1175175
coronavirus	B-C0010076
cov	B-C0010076
contains	O
internal	B-C1514562
domains	I-C1514562
called	O
fusion	B-C0030956
peptides	I-C0030956
fp	B-C0030956
that	O
play	O
essential	O
roles	O
in	O
virus	B-C1537068
entry	I-C1537068
.	O
	
although	O
membrane	B-C0025246
fusion	I-C0025246
has	O
been	O
broadly	O
studied	B-C2603343
,	O
there	O
are	O
still	O
major	O
gaps	O
in	O
the	O
molecular	B-C1521991
details	O
of	O
lipid	B-C0023779
rearrangements	B-C0596965
in	O
the	O
bilayer	B-C0023768
during	O
fusion	B-C0030956
peptide	I-C0030956
-	O
membrane	B-C0596901
interactions	B-C1704675
.	O
	
here	O
we	O
employed	O
differential	B-C0006780
scanning	I-C0006780
calorimetry	I-C0006780
dsc	B-C0006780
and	O
electron	B-C0013845
spin	I-C0013845
resonance	I-C0013845
esr	B-C0013845
to	O
gather	O
information	O
on	O
the	O
membrane	B-C0025246
fusion	I-C0025246
mechanism	B-C0441712
promoted	B-C0033414
by	O
two	O
putative	O
sars	B-C1175175
fps	B-C0030956
.	O
	
dsc	B-C0006780
data	B-C1511726
showed	O
the	O
peptides	B-C0030956
strongly	O
perturb	O
the	O
structural	B-C0678594
integrity	B-C0205266
of	O
anionic	B-C1622418
vesicles	I-C1622418
and	O
support	O
the	O
hypothesis	B-C1512571
that	O
the	O
peptides	B-C0030956
generate	O
opposing	O
curvature	B-C1254362
stresses	O
on	O
phosphatidylethanolamine	B-C0031618
membranes	B-C0596901
.	O
	
esr	B-C0013845
showed	O
that	O
both	O
fps	B-C0030956
increase	O
lipid	B-C0023779
packing	B-C2828395
and	O
head	O
group	O
ordering	B-C1254362
as	O
well	O
as	O
reduce	O
the	O
intramembrane	B-C0596901
water	B-C0392762
content	I-C0392762
for	O
anionic	B-C0596901
membranes	I-C0596901
.	O
	
therefore	O
,	O
bending	O
moment	O
in	O
the	O
bilayer	B-C0023768
could	O
be	O
generated	O
,	O
promoting	O
negative	O
curvature	B-C1254362
.	O
	
the	O
significance	B-C0750502
of	O
the	O
ordering	B-C1280500
effect	I-C1280500
,	O
membrane	B-C0596901
dehydration	B-C1963090
,	O
changes	O
in	O
the	O
curvature	B-C1254362
properties	O
and	O
the	O
possible	O
role	O
of	O
negatively	O
charged	O
phospholipids	B-C0031676
in	O
helping	O
to	O
overcome	O
the	O
high	O
kinetic	O
barrier	O
involved	O
in	O
the	O
different	O
stages	O
of	O
the	O
sars	B-C1175175
-	O
cov	B-C0010076
-mediated	O
membrane	B-C0025246
fusion	I-C0025246
elucidating	O
a	O
chemical	O
defense	B-C1154988
mechanism	I-C1154988
of	O
antarctic	B-C0920736
sponges	B-C0032699
a	O
computational	B-C4297010
study	I-C4297010
in	O
2000	O
,	O
a	O
novel	O
secondary	B-C0870883
metabolite	I-C0870883
erebusinone	B-C0870883
,	O
ereb	B-C0870883
was	O
isolated	O
from	O
the	O
antarctic	B-C0920736
sea	B-C4102027
sponge	I-C4102027
,	O
isodictya	B-C4102027
erinacea	I-C4102027
.	O
	
the	O
bioactivity	B-C0005520
of	O
ereb	B-C0870883
was	O
investigated	O
,	O
and	O
it	O
was	O
found	O
to	O
inhibit	B-C3463820
molting	B-C0282576
when	O
fed	O
to	O
the	O
arthropod	B-C0003903
species	I-C0003903
orchomene	B-C3780008
plebs	I-C3780008
.	O
	
xanthurenic	B-C0078610
acid	I-C0078610
xa	B-C0078610
is	O
a	O
known	O
endogenous	B-C0205227
molt	B-C1704735
regulator	I-C1704735
present	O
in	O
arthropods	B-C0003903
.	O
	
experimental	O
studies	O
have	O
confirmed	O
that	O
xa	B-C0078610
inhibits	B-C3463820
molting	B-C0282576
by	O
binding	B-C1167622
to	O
either	O
or	O
both	O
of	O
two	O
p450	B-C0010762
enzymes	I-C0010762
cyp315a1	B-C0010762
or	O
cyp314a1	B-C0010762
that	O
are	O
responsible	O
for	O
the	O
final	O
two	O
hydroxylations	B-C0020365
in	O
the	O
production	O
of	O
the	O
molt-inducing	B-C0019932
hormone	I-C0019932
,	O
20-hydroxyecdysone	B-C0013495
20e	B-C0013495
.	O
	
the	O
lack	O
of	O
crystal	B-C0444626
structures	I-C0444626
and	O
biochemical	B-C0430027
assays	I-C0430027
for	O
cyp315a1	B-C0010762
or	O
cyp314a1	B-C0010762
,	O
has	O
prevented	O
further	O
experimental	O
exploration	B-C0936012
of	O
xa	B-C0078610
and	O
ereb's	B-C0870883
molt	B-C0282576
inhibition	B-C3463820
mechanisms	B-C0441712
.	O
	
herein	O
,	O
a	O
wide	O
array	O
of	O
computational	B-C1516769
techniques	I-C1516769
-	O
homology	B-C1512489
modeling	I-C1512489
,	O
molecular	B-C2717775
dynamics	I-C2717775
simulations	I-C2717775
,	O
binding	B-C1149343
site	I-C1149343
bioinformatics	B-C1140694
,	O
flexible	B-C1522290
receptor-flexible	I-C1522290
ligand	I-C1522290
docking	I-C1522290
,	O
and	O
molecular	O
mechanics-generalized	O
born	B-C0002045
surface	I-C0002045
area	I-C0002045
calculations	I-C0002045
-	O
have	O
been	O
employed	O
to	O
elucidate	O
the	O
structure-function	B-C0038477
relationships	I-C0038477
between	O
the	O
aforementioned	O
p450s	B-C0010762
and	O
the	O
two	O
described	O
small	O
molecule	O
inhibitors	B-C0243077
ereb	B-C0870883
and	O
xa	B-C0078610
.	O
	
results	O
indicate	O
that	O
ereb	B-C0870883
likely	O
targets	O
cyp315a1	B-C0010762
by	O
interacting	O
with	O
a	O
network	O
of	O
aromatic	B-C1254350
residues	I-C1254350
in	O
the	O
binding	B-C1149343
site	I-C1149343
,	O
while	O
xa	B-C0078610
may	O
inhibit	O
both	O
cyp315a1	B-C0010762
and	O
cyp314a1	B-C0010762
because	O
of	O
its	O
aromatic	B-C1254350
,	O
as	O
well	O
as	O
charged	B-C0022023
nature	I-C0022023
.	O
	
the	O
anatomical	B-C0026779
mummies	I-C0026779
of	O
mombello	B-C0681784
detection	B-C0442726
of	O
cocaine	B-C0009170
,	O
nicotine	B-C0028040
,	O
and	O
caffeine	B-C0006644
in	O
the	O
hair	B-C0018494
of	O
psychiatric	B-C0748064
patients	I-C0748064
of	O
the	O
early	O
20th	O
century	O
the	O
mombello	B-C0020021
psychiatric	I-C0020021
hospital	I-C0020021
in	O
limbiate	B-C0681784
,	O
near	O
milan	B-C0681784
,	O
replaced	O
the	O
old	O
senavra	B-C0019994
hospital	I-C0019994
as	O
the	O
psychiatric	B-C0020021
hospital	I-C0020021
for	O
the	O
province	B-C0681784
of	I-C0681784
milan	I-C0681784
in	O
the	O
19th	O
century	O
.	O
	
during	O
the	O
early	O
20th	O
century	O
,	O
bodies	B-C0242821
of	O
several	O
mombello	B-C0748064
patients	I-C0748064
were	O
dissected	B-C0205239
and	O
preserved	B-C0033085
by	O
giuseppe	B-C0086418
paravicini	I-C0086418
,	O
an	O
anatomist	B-C0334865
who	O
operated	O
within	O
the	O
asylum	B-C0870166
.	O
	
the	O
aim	B-C1947946
of	O
the	O
present	O
study	B-C0008972
was	O
to	O
examine	O
and	O
memorialize	O
this	O
important	O
assemblage	B-C0010995
.	O
	
to	O
this	O
end	O
,	O
we	O
were	O
allowed	O
to	O
sample	B-C2347026
the	O
head	B-C1261040
hair	I-C1261040
of	O
six	O
such	O
preparations	B-C1521827
for	O
toxicological	B-C0205472
analysis	B-C0936012
.	O
	
by	O
means	O
of	O
high	B-C0008562
performance	I-C0008562
liquid	I-C0008562
chromatography	I-C0008562
,	O
cocaine	B-C0009170
and	O
its	O
main	O
metabolite	B-C0870883
,	O
benzoylecgonine	B-C0053258
,	O
were	O
detected	B-C0442726
in	O
two	O
out	O
of	O
six	O
hair	B-C2347026
samples	I-C2347026
.	O
	
the	O
concentrations	B-C1446561
for	O
cocaine	B-C0009170
were	O
0.151	O
and	O
0.09ng	O
and	O
for	O
benzoylecgonine	B-C0053258
0.103	O
and	O
0.147ng	O
,	O
respectively	O
.	O
	
given	O
that	O
cocaine	B-C0009170
was	O
a	O
commonly	O
used	O
medicine	B-C0013227
,	O
beginning	O
in	O
the	O
mid-19th	O
century	O
and	O
persisting	O
into	O
the	O
20th	O
century	O
,	O
it	O
is	O
not	O
surprising	O
that	O
some	O
patients	B-C0020021
may	O
have	O
ingested	B-C0232478
this	O
drug	B-C0013227
.	O
	
in	O
addition	O
to	O
the	O
detection	B-C0442726
of	O
cocaine	B-C0009170
,	O
these	O
analyses	B-C0936012
also	O
provided	O
evidence	O
of	O
nicotine	B-C0028040
and	O
caffeine	B-C0006644
intake	B-C1512806
.	O
	
terahertz	B-C2350265
identification	I-C2350265
and	O
quantification	B-C1709793
of	O
neurotransmitter	B-C0027908
and	O
neurotrophy	B-C0027754
mixture	I-C0027754
terahertz	B-C2350265
spectroscopy	I-C2350265
has	O
been	O
widely	O
used	O
for	O
investigating	B-C1292732
the	O
fingerprint	B-C0016128
spectrum	I-C0016128
of	O
different	O
substances	B-C0439861
.	O
	
for	O
cancerous	B-C0006826
tissues	B-C0040300
,	O
the	O
greatest	O
difficulty	O
is	O
the	O
absorption	B-C2825050
peaks	O
of	O
various	O
substances	B-C0439861
contained	O
in	O
tissues	B-C0040300
overlap	B-C1948020
with	O
each	O
other	O
,	O
which	O
are	O
hard	O
to	O
identify	O
and	O
quantitative	B-C0392762
analyze	B-C0936012
.	O
	
as	O
a	O
result	O
,	O
it	O
is	O
very	O
hard	O
to	O
measure	O
the	O
presence	O
of	O
cancer	B-C0334227
cell	I-C0334227
and	O
then	O
to	O
diagnose	B-C0011900
accurately	B-C0443131
.	O
	
in	O
this	O
paper	O
,	O
we	O
select	O
three	O
typical	O
neurotransmitters	B-C0027908
γ-aminobutyric	B-C0016904
acid	I-C0016904
,	O
l-glutamic	B-C0061472
acid	I-C0061472
,	O
dopamine	B-C0282151
hydrochloride	I-C0282151
and	O
two	O
typical	O
metabolites	B-C0870883
inositol	B-C0021547
and	O
creatine	B-C0010286
in	O
neurons	B-C0027882
to	O
measure	O
their	O
terahertz	B-C2350265
spectra	I-C2350265
with	O
different	O
mixture	B-C0456603
ratios	I-C0456603
.	O
	
by	O
choosing	O
characteristic	B-C1521970
absorption	B-C2825050
peaks	O
,	O
removing	O
baseline	B-C1442488
and	O
using	O
the	O
least	B-C0023189
square	I-C0023189
method	I-C0023189
,	O
we	O
can	O
identify	O
the	O
components	O
and	O
proportions	B-C1709707
of	O
each	O
mixture	O
,	O
where	O
the	O
goodness	B-C0870608
of	I-C0870608
fit	I-C0870608
to	O
practical	O
situation	O
is	O
up	O
to	O
94%	O
.	O
	
these	O
results	O
provide	O
important	O
evidences	O
for	O
identifying	O
nerve	B-C0027908
substances	I-C0027908
and	O
obtaining	O
exact	O
quantitative	B-C0392762
analysis	B-C0936012
.	O
	
comparing	O
the	O
bulking	O
effect	O
of	O
calcium	B-C0115137
hydroxyapatite	I-C0115137
and	O
deflux	B-C0299556
injection	B-C0021485
into	O
the	O
bladder	B-C0227716
neck	I-C0227716
for	O
improvement	B-C2986411
of	O
urinary	B-C0042024
incontinence	I-C0042024
in	O
bladder	B-C1838703
exstrophy-epispadias	I-C1838703
complex	I-C1838703
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	O
the	O
efficacy	B-C1280519
of	O
the	O
endoscopic	B-C3522839
injection	I-C3522839
of	O
calcium	B-C0115137
hydroxyapatite	I-C0115137
caha	B-C0115137
into	O
the	O
bladder	B-C0227716
neck	I-C0227716
bn	B-C0227716
region	O
of	O
patients	B-C0030705
with	O
urinary	B-C0042024
incontinence	I-C0042024
and	O
bladder	B-C1838703
exstrophy-epispadias	I-C1838703
complex	I-C1838703
beec	B-C1838703
.	O
	
we	O
designed	O
a	O
retrospective	B-C2985505
cohort	I-C2985505
study	I-C2985505
in	O
which	O
we	O
retrospectively	B-C0035363
studied	I-C0035363
medical	B-C0184826
charts	I-C0184826
of	O
female	B-C0086287
and	O
male	B-C0086582
patients	B-C0030705
of	O
beec	B-C1838703
who	O
had	O
undergone	O
caha	B-C0115137
or	O
deflux	B-C0299556
injection	B-C0021485
for	O
continence	B-C1536613
improvement	I-C1536613
between	O
2009	O
and	O
2014	O
.	O
	
sixteen	O
incontinent	B-C0021167
patients	B-C0030705
with	O
a	O
mean	O
sd	O
age	O
of	O
8.09	O
3.5	O
years	O
received	O
an	O
endoscopic	B-C3522839
submucosal	I-C3522839
injection	I-C3522839
of	O
5.4	O
ml	O
of	O
pure	O
caha	B-C0115137
powder	O
with	O
autologous	B-C0439859
plasma	B-C0032105
group	O
a	O
.	O
	
patients	B-C0030705
in	O
group	O
b	O
n	O
=	O
21	O
,	O
control	B-C0009932
group	I-C0009932
,	O
with	O
a	O
mean	O
sd	O
age	O
of	O
7.51	O
2.8	O
years	O
received	O
deflux	B-C0299556
injection	B-C0021485
5.1	O
ml	O
.	O
	
the	O
mean	O
follow-up	B-C1522577
after	O
injection	B-C0021485
was	O
38	O
5.2	O
and	O
33	O
4.1	O
months	O
in	O
groups	O
a	O
and	O
b	O
,	O
respectively	O
.	O
	
no	O
post-injection	B-C0274425
complication	I-C0274425
was	O
detected	B-C0442726
in	O
none	O
of	O
the	O
patients	B-C0030705
during	O
the	O
follow-up	B-C1522577
.	O
	
eleven	O
patients	B-C0030705
68.75	O
in	O
group	O
a	O
became	O
socially	O
dry	B-C1512080
following	O
1-2	O
injections	B-C0021485
,	O
the	O
degree	O
of	O
incontinence	B-C0021167
was	O
improved	O
in	O
4	O
patients	B-C0030705
25%	O
,	O
and	O
there	O
was	O
no	B-C0442739
change	I-C0442739
in	O
one	O
patient	B-C0030705
6.25	O
.	O
	
however	O
,	O
deflux	B-C0299556
injection	B-C0021485
resulted	O
in	O
complete	B-C1512080
dryness	I-C1512080
in	O
14	O
66.66	O
,	O
improvement	B-C2986411
in	O
the	O
degree	O
of	O
incontinence	B-C0021167
in	O
5	O
23.81	O
and	O
no	B-C0442739
change	I-C0442739
in	O
2	O
patients	B-C0030705
9.52	O
,	O
leading	O
to	O
no	B-C3842396
significant	I-C3842396
difference	I-C3842396
in	O
continence	B-C0442964
achievement	I-C0442964
between	O
caha	B-C0115137
and	O
deflux	B-C0299556
groups	O
p	O
=	O
0.9	O
.	O
	
the	O
statistical	B-C0871424
analysis	I-C0871424
was	O
not	B-C3842396
significantly	I-C3842396
different	I-C3842396
in	O
terms	O
of	O
bladder	B-C0429807
capacity	I-C0429807
p	O
=	O
0.7	O
or	O
q	O
max	O
p	O
=	O
0.8	O
.	O
	
the	O
preliminary	B-C1548161
results	I-C1548161
of	O
this	O
study	B-C2603343
revealed	B-C0443289
that	O
caha	B-C0115137
may	O
be	O
applied	O
as	O
an	O
affordable	O
bulking	B-C1320234
agent	I-C1320234
in	O
treatment	B-C0087111
of	O
urinary	B-C0042024
incontinence	I-C0042024
in	O
opportunities	B-C0683937
for	O
genomic	B-C0017428
prediction	B-C0681842
for	O
fertility	B-C0015895
using	O
endocrine	B-C0014136
and	O
classical	B-C0443177
fertility	B-C0015895
traits	B-C0599883
in	O
dairy	B-C0007452
cattle	I-C0007452
endocrine	B-C0014136
fertility	B-C0015895
traits	B-C0599883
,	O
defined	O
from	O
progesterone	B-C0033308
concentration	B-C1446561
levels	B-C0441889
in	O
milk	B-C0026131
,	O
have	O
been	O
suggested	O
as	O
alternative	B-C1523987
indicators	B-C1522602
for	O
fertility	B-C0015895
in	O
dairy	B-C0007452
cows	I-C0007452
because	O
they	O
are	O
less	O
biased	O
by	O
farm	B-C0557759
management	B-C1273870
decisions	B-C0679006
and	O
more	O
directly	O
reflect	O
a	O
cow	B-C0007452
's	O
reproductive	B-C0035150
physiology	B-C0031843
than	O
classical	B-C0443177
traits	B-C0599883
derived	O
from	O
insemination	B-C0021586
and	O
calving	O
data	B-C1511726
.	O
	
to	O
determine	O
the	O
potential	O
use	B-C1524063
of	I-C1524063
endocrine	B-C0014136
fertility	B-C0015895
traits	B-C0599883
in	O
genomic	B-C0017428
evaluations	B-C0015195
,	O
the	O
improvement	B-C2986411
in	O
accuracy	B-C0443131
from	O
using	O
endocrine	B-C0014136
fertility	B-C0015895
traits	B-C0599883
concurrent	B-C0205420
with	O
classical	B-C0443177
traits	B-C0599883
in	O
the	O
genomic	B-C0017428
prediction	B-C0681842
of	O
fertility	B-C0015895
was	O
quantified	B-C1709793
.	O
	
the	O
impact	B-C4049986
of	O
recording	O
all	O
traits	B-C0599883
on	O
all	O
training	O
animals	B-C0003062
was	O
also	O
investigated	B-C1292732
.	O
	
endocrine	B-C0014136
and	O
classical	B-C0443177
fertility	B-C0015895
records	O
were	O
available	O
on	O
5	O
lactations	B-C0022925
from	O
2	O
holstein	B-C0324069
cows	I-C0324069
in	O
ireland	B-C0022067
,	O
the	O
netherlands	B-C0027778
,	O
sweden	B-C0038995
,	O
and	O
the	O
united	B-C0041700
kingdom	I-C0041700
.	O
	
the	O
endocrine	B-C0014136
traits	B-C0599883
were	O
commencement	B-C1254358
of	I-C1254358
luteal	I-C1254358
activity	I-C1254358
c-la	B-C1254358
and	O
proportion	B-C1709707
of	O
samples	B-C0370003
with	O
luteal	B-C1254358
activity	I-C1254358
pla	B-C0370003
the	O
classical	B-C0443177
trait	B-C0599883
was	O
the	O
interval	B-C1272706
from	O
calving	O
to	O
first	O
service	O
cfs	O
.	O
	
the	O
interval	B-C1272706
from	O
c-la	B-C1254358
to	O
first	O
service	O
c-lafs	O
,	O
which	O
is	O
a	O
combination	O
of	O
an	O
endocrine	B-C0014136
trait	B-C0599883
and	O
a	O
classical	B-C0443177
trait	B-C0599883
,	O
was	O
also	O
investigated	B-C1292732
.	O
	
the	O
target	B-C1521840
breeding	B-C1521840
goal	I-C1521840
trait	B-C0599883
for	O
fertility	B-C0015895
was	O
cfs	O
or	O
c-lafs	O
,	O
whereas	O
c-la	B-C1254358
and	O
pla	B-C0370003
served	O
as	O
predictor	B-C2698872
traits	B-C0599883
.	O
	
genomic	B-C0017428
ebv	I-C0017428
gebv	B-C0017428
for	O
fertility	B-C0015895
were	O
derived	O
using	O
genomic	B-C1710191
blup	I-C1710191
in	O
bivariate	B-C0026336
models	I-C0026336
with	O
85	O
snp	B-C0752046
.	O
	
genomic	O
ebv	O
for	O
the	O
separate	O
fertility	B-C0015895
traits	B-C0599883
were	O
also	O
computed	O
,	O
in	O
univariate	B-C0026336
models	I-C0026336
.	O
	
the	O
accuracy	B-C0443131
of	O
gebv	B-C0017428
was	O
evaluated	O
by	O
5-fold	O
cross-validation	B-C0681935
.	O
	
the	O
highest	O
accuracy	B-C0443131
of	O
gebv	B-C0017428
was	O
achieved	O
using	O
bivariate	B-C0681927
predictions	B-C0681842
,	O
where	O
both	O
an	O
endocrine	B-C0014136
fertility	B-C0015895
trait	B-C0599883
and	O
the	O
classical	B-C0443177
fertility	B-C0015895
trait	B-C0599883
were	O
used	O
.	O
	
accuracy	B-C0443131
of	O
gebv	B-C0017428
for	O
predicting	B-C0681842
adjusted	O
phenotypes	B-C0031437
for	O
cfs	O
in	O
the	O
univariate	B-C0026336
model	I-C0026336
was	O
0.04	O
,	O
but	O
when	O
predicting	B-C0681842
cfs	O
using	O
a	O
bivariate	B-C0026336
model	I-C0026336
with	O
c-la	B-C1254358
,	O
the	O
accuracy	B-C0443131
increased	B-C0205217
to	O
0.14	O
when	O
all	O
training	B-C0003062
animals	I-C0003062
were	O
phenotyped	B-C0031437
for	O
c-la	B-C1254358
and	O
or	O
not	O
for	O
cfs	O
.	O
	
on	O
phenotyping	B-C0031437
all	O
training	B-C0003062
animals	I-C0003062
for	O
both	O
c-la	B-C1254358
and	O
cfs	O
,	O
accuracy	B-C0443131
for	O
cfs	O
increased	B-C0205217
to	O
0.18	O
however	O
,	O
when	O
validation	B-C1519941
animals	B-C0003062
were	O
also	O
phenotyped	B-C0031437
for	O
c-la	B-C1254358
,	O
there	O
was	O
no	B-C1513916
substantial	B-C0442805
increase	I-C0442805
in	O
accuracy	B-C0443131
.	O
	
when	O
predicting	B-C0681842
cfs	O
in	O
bivariate	B-C0681927
analysis	I-C0681927
with	O
pla	B-C0370003
,	O
accuracy	B-C0443131
ranged	O
from	O
0.07	O
to	O
0.14	O
.	O
	
this	O
first	O
study	B-C2603343
on	O
genomic	B-C0017428
predictions	B-C0681842
for	O
fertility	B-C0015895
using	O
endocrine	B-C0014136
traits	B-C0599883
suggests	O
some	O
improvement	B-C2986411
in	O
the	O
accuracy	B-C0443131
of	O
prediction	B-C0681842
over	O
using	O
only	O
the	O
classical	B-C0443177
traits	B-C0599883
.	O
	
further	O
studies	B-C2603343
with	O
larger	B-C0549177
training	B-C1257890
populations	I-C1257890
may	O
show	O
greater	B-C1704243
improvements	B-C2986411
.	O
	
a	O
microfluidic	B-C1257867
platform	O
to	O
design	B-C1707689
crosslinked	B-C1450054
hyaluronic	I-C1450054
acid	I-C1450054
nanoparticles	I-C1450054
chanps	B-C1450054
for	O
enhanced	B-C1707501
mri	I-C1707501
recent	B-C0332185
advancements	B-C3854260
in	O
imaging	B-C0011923
diagnostics	I-C0011923
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	B-C1450053
that	O
entrap	O
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
mri	B-C0024485
contrast	B-C0009924
agents	I-C0009924
cas	B-C0009924
,	O
without	O
the	O
need	O
to	O
chemically	B-C0220806
modify	B-C0392747
the	O
clinically	B-C0205210
approved	B-C0205540
compounds	B-C1706082
.	O
	
nevertheless	O
,	O
the	O
exploitation	O
of	O
microfluidic	B-C1257867
platforms	I-C1257867
for	O
their	O
controlled	B-C2587213
and	O
continuous	B-C0549178
production	B-C1883254
is	O
still	O
missing	O
.	O
	
here	O
,	O
a	O
microfluidic	B-C1257867
platform	I-C1257867
is	O
used	O
to	O
synthesize	B-C1883254
crosslinked	B-C1450054
hyaluronic	I-C1450054
acid	I-C1450054
nanoparticles	I-C1450054
chanps	B-C1450054
in	O
which	O
a	O
clinically	B-C0205210
relevant	B-C2347946
mri	B-C0024485
-	O
cas	B-C0009924
,	O
gadolinium	B-C0060933
diethylenetriamine	I-C0060933
penta-acetic	I-C0060933
acid	I-C0060933
gd-dtpa	B-C0060933
,	O
is	O
entrapped	O
.	O
	
this	O
microfluidic	B-C1257867
process	B-C1522240
facilitates	O
a	O
high	O
degree	B-C0441889
of	O
control	B-C2587213
over	O
particle	B-C1450054
synthesis	B-C1883254
,	O
enabling	O
the	O
production	B-C1883254
of	O
monodisperse	B-C1450054
particles	I-C1450054
as	O
small	O
as	O
35	O
nm	O
.	O
	
furthermore	O
,	O
the	O
interference	B-C0521102
of	O
gd-dtpa	B-C0060933
during	O
polymer	B-C0032521
precipitation	B-C0032931
is	O
overcome	O
by	O
finely	O
tuning	O
process	B-C1522240
parameters	B-C0549193
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic-lipophilic	B-C0392762
balance	I-C0392762
hlb	B-C0392762
of	O
surfactants	B-C0038891
and	O
ph	B-C0020283
conditions	B-C0348080
.	O
	
for	O
both	O
production	B-C1883254
strategies	O
proposed	O
to	O
design	B-C1707689
gd	B-C0060933
-loaded	O
chanps	B-C1450054
,	O
a	O
boosting	O
of	O
the	O
relaxation	B-C2697937
rate	I-C2697937
t1	I-C2697937
is	O
observed	O
since	O
a	O
t1	B-C2697937
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μm	O
of	O
gd	B-C0060933
-loaded	O
chanps	B-C1450054
while	O
a	O
similar	O
value	B-C1522609
is	O
reached	O
with	O
100	O
μm	O
of	O
the	O
relevant	B-C2347946
clinical	B-C0205210
gd-dtpa	B-C0060933
in	O
solution	B-C0037633
.	O
	
the	O
advanced	O
microfluidic	B-C1257867
platform	O
to	O
synthesize	O
intravascularly	B-C0442123
-	O
injectable	B-C1272883
and	O
completely	O
biocompatible	B-C0063083
hydrogel	I-C0063083
nanoparticles	B-C1450054
entrapping	O
clinically	B-C0205210
approved	B-C0205540
cas	B-C0009924
enables	O
the	O
implementation	B-C1708476
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	B-C1704338
and	O
therapy	B-C0087111
applications	B-C4048755
.	O
	
arthrobacter	B-C0003876
ginkgonis	I-C0003876
sp	I-C0003876
.	O
	
nov	I-C0003876
,	O
an	O
actinomycete	B-C0600148
isolated	B-C0205409
from	O
rhizosphere	B-C2936389
of	O
ginkgo	B-C0330206
biloba	I-C0330206
l	I-C0330206
a	O
gram-stain-positive	B-C0855278
,	O
aerobic	B-C1510824
actinobacterial	B-C0600148
strain	I-C0600148
designated	O
syp-a7299t	B-C0003876
,	O
which	O
displayed	O
a	O
rod-coccus	B-C0562679
growth	I-C0562679
lifecycle	I-C0562679
,	O
was	O
isolated	B-C0205409
from	O
the	O
rhizosphere	B-C2936389
of	O
ginkgo	B-C0330206
biloba	I-C0330206
l	I-C0330206
.	O
	
phylogenetic	B-C1519068
analyses	I-C1519068
based	O
on	O
16s	B-C0035899
rrna	I-C0035899
gene	I-C0035899
sequences	I-C0035899
indicated	O
that	O
strain	B-C0003876
syp-a7299t	I-C0003876
belongs	O
to	O
the	O
genus	B-C1708235
arthrobacter	B-C0003876
and	O
is	O
most	O
closely	O
related	O
to	O
arthrobacter	B-C2762206
halodurans	I-C2762206
jsm	I-C2762206
078085t	I-C2762206
97.4	O
%	O
16s	B-C0035899
rrna	I-C0035899
gene	I-C0035899
sequence	I-C0035899
similarity	B-C2348205
.	O
	
the	O
dna	B-C0012854
-	O
dna	B-C0012854
relatedness	B-C0392762
value	I-C0392762
between	O
strain	B-C0003876
syp-a7299t	I-C0003876
and	O
a	B-C2762206
.	O
	
halodurans	I-C2762206
jsm	I-C2762206
078085t	I-C2762206
was	O
37	O
%	O
2.9	O
.	O
	
the	O
cell-wall	B-C0007623
peptidoglycan	B-C0030958
was	O
a4α	B-C0030958
,	O
and	O
glucose	B-C0017725
and	O
galactose	B-C0016945
were	O
whole-cell	B-C0242209
sugars	I-C0242209
.	O
	
the	O
polar	B-C0023779
lipids	I-C0023779
consisted	O
of	O
diphosphatidylglycerol	B-C0574031
,	O
phosphatidylglycerol	B-C0031614
,	O
phosphatidylinositol	B-C0031621
,	O
two	O
glycolipids	B-C0017950
and	O
an	O
unknown	O
polar	B-C0023779
lipid	I-C0023779
.	O
	
the	O
major	O
menaquinone	B-C0086605
were	O
mk-8	B-C0084980
72	O
%	O
and	O
mk-9	B-C0127520
28	O
%	O
,	O
and	O
the	O
predominant	O
cellular	B-C0015684
fatty	I-C0015684
acids	I-C0015684
were	O
anteiso-c15	B-C0646611
0	I-C0646611
,	O
iso-c15	B-C0044840
0	I-C0044840
and	O
anteiso-c17	B-C0044862
0	I-C0044862
.	O
	
the	O
dna	B-C0012854
g+c	B-C1135899
content	I-C1135899
was	O
68.9	O
mol%	O
.	O
	
based	O
on	O
the	O
morphological	B-C0543482
,	O
physiological	B-C0205463
,	O
biochemical	B-C0205474
and	O
chemotaxonomic	B-C0205245
characters	I-C0205245
presented	O
in	O
this	O
study	O
,	O
strain	B-C0003876
syp-a7299t	I-C0003876
represents	O
a	O
novel	O
species	B-C1705920
of	O
the	O
genus	B-C1708235
arthrobacter	B-C0003876
,	O
for	O
which	O
the	O
name	O
arthrobacter	B-C0003876
ginkgonis	I-C0003876
sp	I-C0003876
.	O
	
nov	I-C0003876
.	O
	
is	O
proposed	O
.	O
	
the	O
type	B-C1518614
strain	I-C1518614
is	O
syp-a7299t	B-C0003876
=dsm	B-C0003876
100491t=kctc	I-C0003876
39	I-C0003876
592t	I-C0003876
.	O
	
decoding	B-C0870395
the	O
interactions	B-C1373094
regulating	B-C0243148
the	O
active	B-C0679217
state	I-C0679217
mechanics	B-C0376706
of	O
eukaryotic	B-C0684063
protein	B-C0033640
kinases	I-C0033640
eukaryotic	B-C0684063
protein	B-C0033640
kinases	I-C0033640
regulate	B-C0243148
most	O
cellular	B-C0007613
functions	I-C0007613
by	O
phosphorylating	B-C1158886
targeted	B-C1521840
protein	B-C0033684
substrates	B-C3891814
through	B-C0332273
a	O
highly	B-C0205250
conserved	B-C0443318
catalytic	B-C0243092
core	I-C0243092
.	O
	
in	O
the	O
active	B-C0679217
state	I-C0679217
,	O
the	O
catalytic	B-C0243092
core	I-C0243092
oscillates	B-C0695434
between	O
open	B-C0175566
,	O
intermediate	B-C0205103
,	O
and	O
closed	B-C0677512
conformations	B-C0033625
.	O
	
currently	B-C0521116
,	O
the	O
intramolecular	B-C1373094
interactions	I-C1373094
that	O
regulate	B-C0243148
the	O
active	B-C0679217
state	I-C0679217
mechanics	B-C0376706
are	O
not	B-C0205556
well	I-C0205556
understood	I-C0205556
.	O
	
here	O
,	O
using	O
camp-dependent	B-C0010531
protein	I-C0010531
kinase	I-C0010531
as	O
a	O
representative	B-C1882932
model	B-C0026336
coupled	B-C1948027
with	O
biochemical	B-C0205474
,	O
biophysical	B-C1511162
,	O
and	O
computational	B-C1516769
techniques	I-C1516769
,	O
we	O
define	O
a	O
set	O
of	O
highly	B-C0205250
conserved	B-C2347858
electrostatic	B-C0683119
and	O
hydrophobic	B-C0678607
interactions	I-C0678607
working	O
harmoniously	B-C0699798
to	O
regulate	B-C0243148
these	O
mechanics	B-C0376706
.	O
	
these	O
include	B-C0332257
the	O
previously	B-C0205156
identified	B-C0205396
salt	B-C0023745
bridge	I-C0023745
between	O
a	O
lysine	B-C0024337
from	O
the	O
β3-strand	B-C0600383
and	O
a	O
glutamate	B-C0220839
from	O
the	O
αc-helix	B-C0162805
as	O
well	O
as	O
an	O
electrostatic	B-C0683119
interaction	I-C0683119
between	O
the	O
phosphorylated	B-C0031715
activation	B-C1879547
loop	B-C0445022
and	O
αc-helix	B-C0162805
and	O
an	O
ensemble	B-C0444667
of	O
hydrophobic	B-C0598629
residues	B-C1709915
of	O
the	O
regulatory	O
spine	O
and	O
shell	O
.	O
	
moreover	O
,	O
for	O
over	O
three	O
decades	B-C2981279
it	O
was	O
thought	O
that	O
the	O
highly	B-C0205250
conserved	B-C0443318
β3	B-C0600383
-lysine	O
was	O
essential	O
for	O
phosphoryl	O
transfer	O
,	O
but	O
our	O
findings	O
show	O
that	O
the	O
β3	B-C0024337
-lysine	I-C0024337
is	O
not	O
required	O
for	O
phosphoryl	O
transfer	O
but	O
is	O
essential	B-C0205224
for	O
the	O
active	O
state	O
mechanics	B-C0376706
acute	B-C0205178
clinical	B-C0205210
adverse	B-C0392615
radiation	I-C0392615
effects	I-C0392615
after	O
gamma	B-C2960266
knife	I-C2960266
surgery	I-C2960266
for	O
vestibular	B-C0027859
schwannomas	I-C0027859
objective	O
vestibular	B-C0027859
schwannomas	I-C0027859
vss	B-C0027859
represent	O
a	O
common	O
indication	O
of	O
gamma	B-C2960266
knife	I-C2960266
surgery	I-C2960266
gks	B-C2960266
.	O
	
while	O
most	O
studies	B-C2603343
focus	O
on	O
the	O
long-term	B-C0443252
morbidity	B-C0178685
and	O
adverse	B-C0392615
radiation	I-C0392615
effects	I-C0392615
ares	B-C0392615
,	O
none	O
describe	O
the	O
acute	B-C0205178
clinical	B-C0205210
ares	B-C0392615
that	O
might	O
appear	O
on	O
a	O
short-term	B-C0443303
basis	O
.	O
	
these	O
types	O
of	O
events	O
are	O
investigated	B-C1292732
,	O
and	O
their	O
incidence	B-C0021149
,	O
type	B-C0332307
,	O
and	O
outcomes	B-C0086750
are	O
reported	B-C0684224
in	O
the	O
present	O
paper	O
.	O
	
methods	O
the	O
included	O
patients	B-C0030705
were	O
treated	B-C1522326
between	O
july	O
2010	O
and	O
march	O
2016	O
,	O
underwent	O
at	O
least	O
6	O
months	B-C0439231
of	O
follow-up	B-C1522577
,	O
and	O
presented	O
with	O
a	O
disabling	B-C0596452
symptom	B-C1457887
during	O
the	O
first	O
6	O
months	B-C0439231
after	O
gks	B-C2960266
that	O
affected	B-C0392760
their	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
.	O
	
the	O
timing	O
of	O
appearance	O
,	O
as	O
well	O
as	O
the	O
type	O
of	O
main	O
symptom	B-C1457887
and	O
outcome	B-C0086750
,	O
were	O
noted	O
.	O
	
the	O
prescribed	B-C0278329
dose	B-C0178602
was	O
12	O
gy	O
at	O
the	O
margin	O
.	O
	
results	O
thirty-five	O
22%	O
of	O
159	O
patients	B-C0030705
who	O
fulfilled	O
the	O
inclusion	B-C1512693
criteria	O
had	O
acute	B-C0205178
clinical	B-C0205210
ares	B-C0392615
.	O
	
the	O
mean	B-C0444504
followup	B-C1522577
period	O
was	O
30	O
months	B-C0439231
range	B-C1514721
6-49	O
months	B-C0439231
.	O
	
the	O
mean	B-C0444504
time	O
of	O
appearance	O
was	O
37.9	O
days	B-C0439228
median	B-C0876920
31	O
days	B-C0439228
range	B-C1514721
3-110	O
days	B-C0439228
.	O
	
in	O
patients	B-C0030705
with	O
de	B-C1515568
novo	I-C1515568
symptoms	B-C1457887
,	O
the	O
more	O
frequent	O
symptoms	B-C1457887
were	O
vertigo	B-C0042571
n	O
=	O
4	O
11.4	O
and	O
gait	B-C0575081
disturbance	I-C0575081
n	O
=	O
3	O
8.6	O
.	O
	
the	O
exacerbation	B-C0235874
of	O
a	O
preexisting	O
symptom	B-C1457887
was	O
more	O
frequently	O
related	O
to	O
hearing	B-C3887873
loss	I-C3887873
n	O
=	O
10	O
28.6	O
,	O
followed	O
by	O
gait	B-C0575081
disturbance	I-C0575081
n	O
=	O
7	O
20%	O
and	O
vertigo	B-C0042571
n	O
=	O
3	O
,	O
8.6	O
.	O
	
in	O
the	O
univariate	B-C0683962
logistic	B-C0681925
regression	I-C0681925
analysis	I-C0681925
,	O
the	O
following	O
factors	B-C1521761
were	O
statistically	B-C0237881
significant	I-C0237881
age	B-C0001779
p	O
=	O
0.002	O
odds	B-C0028873
ratio	I-C0028873
or	B-C0028873
0.96	O
,	O
hearing	O
at	O
baseline	B-C1442488
by	O
gardner-robertson	B-C0451213
gr	B-C0451213
class	O
p	O
=	O
0.006	O
or	B-C0028873
0.21	O
,	O
pure	B-C0392762
tone	I-C0392762
average	I-C0392762
at	O
baseline	B-C1442488
p	O
=	O
0.006	O
or	B-C0028873
0.97	O
,	O
and	O
koos	B-C0349674
grade	I-C0349674
at	O
baseline	B-C1442488
with	O
koos	B-C0349674
grade	I-C0349674
i	I-C0349674
used	O
as	O
a	O
reference	O
for	O
koos	B-C0349674
grade	I-C0349674
ii	I-C0349674
,	O
or	B-C0028873
0.17	O
and	O
p	O
=	O
0.002	O
for	O
koos	B-C0349674
grade	I-C0349674
iii	I-C0349674
,	O
or	B-C0028873
0.42	O
and	O
p	O
=	O
0.05	O
.	O
	
the	O
following	O
were	O
not	O
statistically	B-C0237881
significant	I-C0237881
but	O
showed	O
a	O
tendency	O
toward	O
significance	O
the	O
number	O
of	O
isocenters	B-C1881275
p	O
=	O
0.06	O
or	B-C0028873
0.94	O
and	O
the	O
maximal	B-C0806909
dose	B-C0178602
received	O
by	O
the	O
cochlea	B-C0009197
p	O
=	O
0.07	O
or	B-C0028873
0.74	O
.	O
	
fractional	B-C0034980
polynomial	I-C0034980
regression	I-C0034980
analysis	I-C0034980
showed	O
a	O
nonlinear	O
relationship	O
between	O
the	O
outcome	B-C0086750
and	O
the	O
radiation	B-C0560131
dose	I-C0560131
rate	I-C0560131
minimum	O
reached	O
at	O
a	O
cutoff	O
of	O
2.5	O
gy/minute	O
and	O
the	O
maximal	B-C0806909
vestibular	B-C0042606
dose	B-C0178602
maximum	O
reached	O
at	O
a	O
cutoff	O
of	O
8	O
gy	O
,	O
but	O
the	O
small	O
sample	B-C0242618
size	I-C0242618
precludes	B-C0332206
a	O
detailed	O
analysis	B-C0936012
of	O
the	O
former	O
.	O
	
the	O
clinical	B-C0205210
acute	B-C0205178
ares	B-C0392615
disappeared	O
in	O
32	O
91.4	O
patients	B-C0030705
during	O
the	O
first	O
6	O
months	B-C0439231
after	O
appearance	O
.	O
	
permanent	O
and	O
somewhat	O
disabling	B-C0596452
morbidity	B-C0178685
was	O
found	O
in	O
3	O
cases	B-C1706256
1.9	O
from	O
the	O
whole	O
series	O
1	O
each	O
with	O
complete	B-C0581883
hearing	I-C0581883
loss	I-C0581883
gr	B-C0451213
class	I-C0451213
i	I-C0451213
before	O
and	O
v	B-C0451213
after	O
,	O
hemifacial	B-C0278152
spasm	I-C0278152
persistent	B-C0205322
but	O
alleviated	O
,	O
and	O
dysgeusia	B-C0013378
.	O
	
conclusions	O
acute	B-C0205178
effects	B-C1280500
after	O
radiosurgery	B-C0085203
for	O
vs	B-C0027859
are	O
not	O
rare	O
.	O
	
they	O
concern	O
predominantly	O
de	B-C1515568
novo	I-C1515568
vertigo	B-C0042571
and	O
gait	B-C0575081
disturbance	I-C0575081
and	O
the	O
exacerbation	B-C0235874
of	O
preexistent	O
hearing	B-C3887873
loss	I-C3887873
.	O
	
in	O
de	B-C1515568
novo	I-C1515568
vestibular	B-C0042606
symptom	B-C1457887
s	O
,	O
a	O
vestibular	B-C0042606
dose	B-C0178602
of	O
more	O
than	O
8	O
gy	O
is	O
thought	O
to	O
play	O
a	O
role	O
.	O
	
in	O
most	O
cases	B-C1706256
,	O
none	O
of	O
these	O
effects	B-C1280500
are	O
permanent	O
,	O
and	O
they	O
will	O
ultimately	O
improve	O
or	O
disappear	O
with	O
steroid	B-C0149783
therapy	I-C0149783
.	O
	
permanent	O
ares	B-C0392615
remain	O
very	O
long-chain	B-C0015689
n-3	I-C0015689
pufa	I-C0015689
supplied	B-C1999230
by	O
the	O
usual	B-C3538928
diet	B-C0012155
decrease	B-C0547047
plasma	B-C0038233
stearoyl-coa	I-C0038233
desaturase	I-C0038233
index	B-C0918012
in	O
non-hypertriglyceridemic	B-C0243095
older	B-C0001792
adults	I-C0001792
at	O
high	O
vascular	B-C0005847
risk	B-C0035647
the	O
activity	B-C0243102
of	O
stearoyl-coa	B-C2002916
desaturase-1	I-C2002916
scd1	B-C2002916
,	O
the	O
central	B-C0014442
enzyme	I-C0014442
in	O
the	O
synthesis	B-C1883254
of	O
monounsaturated	B-C0015687
fatty	I-C0015687
acids	I-C0015687
mufa	B-C0015687
,	O
has	O
been	O
associated	B-C0332281
with	I-C0332281
de	B-C1515568
novo	I-C1515568
lipogenesis	B-C1563744
.	O
	
in	O
experimental	B-C0086272
models	I-C0086272
scd1	B-C2002916
is	O
down-regulated	B-C0013081
by	O
polyunsaturated	B-C0032615
fatty	I-C0032615
acids	I-C0032615
pufa	B-C0032615
,	O
but	O
clinical	B-C0008972
studies	I-C0008972
are	O
scarce	O
.	O
	
the	O
effect	B-C1280500
of	O
long-chain	B-C0015689
n-3	I-C0015689
pufa	I-C0015689
lcn-3pufa	B-C0015689
supplied	B-C1999230
by	O
the	O
regular	B-C0012155
diet	I-C0012155
,	O
in	O
the	O
absence	B-C0332197
of	O
fatty	B-C0453017
fish	I-C0453017
or	O
fish	B-C0556145
oil	I-C0556145
supplementation	B-C0242295
,	O
remains	O
to	O
be	O
explored	O
.	O
	
we	O
related	B-C0439849
1-y	O
changes	B-C0392747
in	O
plasma	B-C2002916
scd1	I-C2002916
index	B-C0918012
,	O
as	O
assessed	B-C1516048
by	O
the	O
c16	B-C0069966
/	O
c16	B-C0030234
ratio	B-C0456603
,	O
to	O
both	O
adiposity	B-C1563743
traits	B-C0599883
and	O
nutrient	B-C1287879
intake	I-C1287879
changes	B-C0392747
in	O
a	O
sub-cohort	B-C0599755
n	O
=	O
243	O
of	O
non-hypertriglyceridemic	B-C0243095
subjects	B-C0080105
of	O
the	O
predimed	B-C0008976
prevención	I-C0008976
con	I-C0008976
dieta	I-C0008976
mediterranea	I-C0008976
trial	I-C0008976
.	O
	
after	O
adjustment	O
for	O
confounders	O
,	O
including	O
changes	B-C0392747
in	O
fasting	B-C0015663
triglycerides	B-C0041004
,	O
plasma	B-C2002916
scd1	I-C2002916
index	B-C0918012
increased	B-C0205217
in	O
parallel	O
with	O
body	B-C0005910
weight	I-C0005910
0.221	O
95%	O
confidence	B-C0009667
interval	I-C0009667
,	O
0.021	O
to	O
0.422	O
,	O
p	O
=	O
0.031	O
and	O
bmi	B-C1305855
0.115	O
0.027	O
to	O
0.202	O
,	O
p	O
=	O
0.011	O
.	O
	
additionally	O
,	O
dietary	B-C0012155
lcn-3pufa	B-C0015689
but	O
not	O
mufa	B-C0015687
or	O
plant-derived	B-C1318902
pufa	I-C1318902
were	O
associated	B-C0332281
with	I-C0332281
decreased	B-C0205216
plasma	B-C2002916
scd1	I-C2002916
index	B-C0918012
-0	O
-1	O
to	O
-0	O
,	O
p	O
=	O
0.033	O
,	O
for	O
each	O
1	O
g/d-	O
increase	B-C0442805
in	O
lcn-3pufa	B-C0015689
.	O
	
no	O
associations	B-C0439849
were	O
found	O
for	O
other	O
food	B-C0016452
groups	B-C0441833
,	O
but	O
there	O
was	O
a	O
trend	O
for	O
fatty	B-C0453017
fish	I-C0453017
intake	B-C1512806
-0	O
-0	O
to	O
0.012	O
,	O
p	O
=	O
0.085	O
,	O
for	O
each	O
10	O
g/d-	O
increase	B-C0442805
.	O
	
our	O
data	B-C1511726
add	O
clinical	B-C0205210
evidence	B-C3887511
on	O
the	O
down-regulation	B-C0013081
of	O
plasma	B-C2002916
scd1	I-C2002916
index	B-C0918012
by	O
lcn-3pufa	B-C0015689
in	O
the	O
context	B-C0449255
of	O
realistic	O
changes	B-C0392747
in	O
fish	B-C0016163
consumption	B-C2983605
in	O
the	O
customary	B-C3538928
,	O
non-supplemented	B-C0243095
diet	B-C0012155
.	O
	
distinct	B-C2333134
cortical	I-C2333134
and	I-C2333134
sub-cortical	I-C2333134
neurogenic	I-C2333134
domains	I-C2333134
for	O
gabaergic	B-C1816494
interneuron	B-C0021792
precursor	B-C1709634
transcription	B-C0040648
factors	I-C0040648
nkx2.1	B-C1452466
,	O
olig2	B-C2347389
and	O
coup-tfii	B-C1506576
in	O
early	O
fetal	B-C0521457
human	B-C0086418
telencephalon	B-C0231028
the	O
extent	O
of	O
similarities	B-C2348205
and	O
differences	B-C1705242
between	O
cortical	B-C1818464
gabaergic	I-C1818464
interneuron	I-C1818464
generation	I-C1818464
in	O
rodent	B-C0035804
and	O
primate	B-C0033147
telencephalon	B-C0231028
remains	O
contentious	O
.	O
	
we	O
examined	O
expression	B-C1171362
of	O
three	O
interneuron	B-C0021792
precursor	B-C1709634
transcription	B-C0040648
factors	I-C0040648
,	O
alongside	O
other	O
markers	B-C0005516
,	O
using	O
immunohistochemistry	B-C0021044
on	O
8-12	O
post-conceptional	B-C3827345
weeks	I-C3827345
pcw	B-C3827345
human	B-C0086418
telencephalon	B-C0231028
sections	O
.	O
	
nkx2.1	B-C1452466
,	O
olig2	B-C2347389
,	O
and	O
coup-tfii	B-C1506576
expression	B-C1171362
occupied	O
distinct	O
although	O
overlapping	O
neurogenic	B-C0027882
domains	I-C0027882
which	O
extended	O
into	O
the	O
cortex	B-C0007776
and	O
revealed	O
three	O
cge	B-C1268212
compartments	I-C1268212
lateral	B-C0205093
,	O
medial	B-C0205098
,	O
and	O
ventral	B-C1704448
.	O
	
nkx2.1	B-C1452466
expression	B-C1171362
was	O
very	O
largely	O
confined	O
to	O
the	O
mge	B-C1268212
,	O
medial	B-C0205098
cge	B-C1268212
,	O
and	O
ventral	B-C1704448
septum	B-C0936188
confirming	O
that	O
,	O
at	O
this	O
developmental	B-C0870411
stage	I-C0870411
,	O
interneuron	B-C0021792
generation	O
from	O
nkx2.1	B-C1452466
+	O
precursor	B-C1709634
s	O
closely	O
resembles	O
the	O
process	O
observed	O
in	O
rodents	B-C0035804
.	O
	
olig2	B-C2347389
immunoreactivity	B-C0597879
was	O
observed	O
in	O
gabaergic	B-C0815002
cells	I-C0815002
of	O
the	O
proliferative	B-C0596290
zones	B-C1710706
of	O
the	O
mge	B-C1268212
and	O
septum	B-C0936188
,	O
but	O
not	O
necessarily	O
co-expressed	O
with	O
nkx2.1	B-C1452466
,	O
and	O
olig2	B-C2347389
expression	B-C1171362
was	O
also	O
extensively	O
seen	O
in	O
the	O
lge	B-C1268212
,	O
cge	B-C1268212
,	O
and	O
cortex	B-C0007776
.	O
	
at	O
8	O
pcw	B-C3827345
,	O
olig2	B-C2347389
+	O
cells	B-C0815002
were	O
only	O
present	O
in	O
the	O
medial	B-C0205098
and	O
anterior	B-C0205094
cortical	B-C0007776
wall	I-C0007776
suggesting	O
a	O
migratory	B-C0232901
pathway	B-C1705987
for	O
interneuron	B-C0021792
precursor	B-C1709634
s	O
via	O
the	O
septum	B-C0936188
into	O
the	O
medial	B-C0205098
cortex	B-C0007776
.	O
	
by	O
12	O
pcw	B-C3827345
,	O
olig2	B-C2347389
+	O
cells	B-C0815002
were	O
present	O
throughout	O
the	O
cortex	B-C0007776
and	O
many	O
were	O
actively	O
dividing	B-C0332849
but	O
without	O
co-expressing	O
cortical	B-C0007776
progenitor	B-C0038250
markers	B-C0005516
.	O
	
dividing	O
coup-tfii	B-C1506576
+	O
progenitor	B-C0038250
cells	I-C0038250
were	O
localized	B-C0392752
to	O
ventral	B-C1704448
cge	B-C1268212
as	O
previously	O
described	O
but	O
were	O
also	O
numerous	O
in	O
adjacent	O
ventral	B-C1704448
cortex	B-C0007776
in	O
both	O
the	O
cases	O
,	O
coup-tfii	B-C1506576
was	O
co-expressed	O
with	O
pax6	B-C4308210
in	O
proliferative	B-C0596290
zones	B-C1710706
and	O
tbr1	B-C3501502
or	O
calretinin	B-C0054544
in	O
post-	O
mitotic	B-C1513354
cortical	B-C2333134
neurons	I-C2333134
.	O
	
thus	O
coup-tfii	B-C1506576
+	O
progenitors	B-C0038250
gave	O
rise	O
to	O
pyramidal	B-C0206441
cells	I-C0206441
,	O
but	O
also	O
interneurons	B-C0021792
which	O
not	O
only	O
migrated	B-C0232902
posteriorly	O
into	O
the	O
cortex	B-C0007776
from	O
ventral	B-C1704448
cge	B-C1268212
but	O
also	O
anteriorly	B-C0205094
via	O
the	O
primary	B-C0206695
neuroendocrine	I-C0206695
carcinoma	I-C0206695
of	O
the	O
breast	B-C0006141
a	O
single	B-C0596545
center	I-C0596545
experience	I-C0596545
and	O
review	B-C0282441
of	I-C0282441
the	I-C0282441
literature	I-C0282441
neuroendocrine	B-C0206695
carcinoma	I-C0206695
of	O
the	O
breast	B-C0006141
is	O
an	O
extremely	B-C0205403
rare	B-C0522498
tumor	B-C0027651
.	O
	
a	O
standard	B-C1442989
treatment	B-C0087111
has	O
yet	O
to	O
be	O
established	B-C0443211
because	O
only	O
a	O
few	O
cases	B-C1706256
have	O
been	O
reported	O
in	O
literature	B-C0023866
.	O
	
the	O
authors	B-C3812881
report	O
five	O
cases	B-C1706256
observed	O
from	O
january	B-C3829466
2007	O
to	O
december	B-C3830550
2014	O
and	O
a	O
review	B-C0282441
of	I-C0282441
literature	I-C0282441
.	O
	
four	O
patients	B-C0030705
underwent	O
quadrantectomy	B-C0337354
and	O
in	O
two	O
cases	B-C1706256
axillary	B-C0024203
nodal	I-C0024203
dissection	I-C0024203
and	O
only	O
one	O
to	O
mastectomy	B-C0024881
with	O
axillary	B-C0024203
nodal	I-C0024203
dissection	I-C0024203
.	O
	
tumor	B-C0475440
size	I-C0475440
was	O
from	O
t1	B-C0475372
to	O
t2	B-C0475373
with	O
n0	B-C0441959
to	O
n1	B-C0441962
,	O
according	O
tnm	B-C0809869
classification	I-C0809869
.	O
	
pathological	B-C0444061
specimens	I-C0444061
were	O
stained	B-C2986582
with	O
hematoxylin	B-C0018964
and	O
eosin	B-C0021212
and	O
an	O
immunohistochemical	B-C1441616
panel	B-C0441833
of	O
antibodies	B-C0813154
neuron-specific	B-C0003320
enolase	I-C0003320
,	O
chromogranin	B-C0486578
,	O
synaptophysin	B-C0487636
,	O
estrogen	B-C1545287
and	O
progesterone	B-C1545448
receptors	I-C1545448
,	O
c-erb	B-C0003320
and	O
ki-67	B-C0208804
.	O
	
all	O
cases	B-C1706256
showed	O
markers	B-C0162490
positivity	O
to	O
neuron-specific	B-C0003320
enolase	I-C0003320
,	O
chromogranin	B-C0486578
,	O
synaptophysin	B-C0487636
and	O
estrogen	B-C1545287
and	O
progesterone	B-C1545448
receptors	I-C1545448
were	O
found	O
.	O
	
ki-67	B-C0208804
was	O
higher	O
than	O
40%	O
in	O
four	O
patients	B-C0030705
.	O
	
adjuvant	B-C0085533
chemotherapy	I-C0085533
was	O
administrated	B-C1533734
in	O
patients	B-C0030705
with	O
ki-67	B-C0208804
>10%	O
every	O
patients	B-C0030705
were	O
treated	B-C1522326
with	O
radiotherapy	B-C1522449
and	O
with	O
hormonal	B-C0279025
therapy	I-C0279025
too	O
.	O
	
although	O
neuroendocrine	B-C3544078
breast	I-C3544078
tumor	I-C3544078
is	O
considered	O
a	O
distinct	O
entity	B-C1551338
,	O
the	O
best	O
treatment	B-C0087111
seems	O
to	O
be	O
correlate	B-C1707520
to	O
the	O
size	B-C0475440
of	I-C0475440
tumor	I-C0475440
and	O
to	O
the	O
lymph	B-C0024204
node	I-C0024204
status	B-C0449438
and	O
to	O
ki-67	B-C0208804
index	B-C0600653
like	O
the	O
common	O
breast	B-C0678222
cancer	I-C0678222
.	O
	
diagnosis	B-C0011900
,	O
neuroendocrine	B-C0206695
breast	I-C0206695
carcinoma	I-C0206695
.	O
	
a	O
new	O
parametric	B-C3161035
model	I-C3161035
to	O
assess	B-C1516048
delay	B-C0205421
and	O
compression	B-C0392756
of	O
mortality	B-C0205848
a	O
decrease	B-C0547047
in	O
mortality	B-C0205848
across	O
all	O
ages	B-C0001779
causes	O
a	O
shift	O
of	O
the	O
age	B-C0001779
pattern	B-C0449774
of	O
mortality	B-C0205848
,	O
or	O
mortality	B-C0205848
delay	B-C0205421
,	O
while	O
differences	B-C1705242
in	O
the	O
rate	B-C1521828
of	O
decrease	B-C0547047
across	O
ages	B-C0001779
cause	O
a	O
change	O
in	O
the	O
shape	B-C0332479
of	O
the	O
age-at-death	B-C1546180
distribution	B-C1704711
,	O
mortality	B-C0205848
compression	B-C0392756
or	O
expansion	B-C0442805
.	O
	
evidence	B-C3887511
exists	O
for	O
both	O
compression	B-C0392756
and	O
delay	B-C0205421
of	O
mortality	B-C0205848
.	O
	
existing	O
parametric	B-C3161035
models	I-C3161035
to	O
describe	O
the	O
full	O
age	B-C0001779
pattern	B-C0449774
of	O
mortality	B-C0205848
are	O
not	O
able	O
to	O
capture	O
mortality	B-C0205848
delay	B-C0205421
versus	O
mortality	B-C0205848
compression	B-C0392756
.	O
	
more	O
recent	O
models	B-C3161035
that	O
assess	O
delay	B-C0205421
versus	O
compression	B-C0392756
mostly	O
focused	O
on	O
the	O
adult	B-C0001675
or	O
old	B-C1999167
ages	I-C1999167
alone	O
and	O
did	O
not	O
distinguish	O
mortality	B-C0205848
compression	B-C0392756
below	O
and	O
above	O
the	O
modal	B-C0001779
age	I-C0001779
at	O
death	B-C1306577
,	O
although	O
they	O
represent	O
different	B-C1705242
mechanisms	B-C0441712
.	O
	
this	O
paper	B-C1706852
presents	O
a	O
new	O
parametric	B-C3161035
model	I-C3161035
that	O
describes	O
the	O
full	O
age	B-C0001779
pattern	B-C0449774
of	O
mortality	B-C0205848
and	O
assesses	O
compression	B-C0392756
-	O
at	O
different	B-C1705242
stages	B-C0680083
of	I-C0680083
life	I-C0680083
-	O
and	O
delay	B-C0205421
of	O
mortality	B-C0205848
the	O
code	B-C3161035
model	I-C3161035
.	O
	
the	O
model	B-C3161035
includes	O
10	O
parameters	B-C0549193
,	O
of	O
which	O
five	O
are	O
constant	B-C1948059
over	O
time	B-C0040223
.	O
	
the	O
five	O
time	B-C0040223
-varying	O
parameters	B-C0549193
reflect	O
delay	B-C0205421
of	O
mortality	B-C0205848
and	O
compression	B-C0392756
of	O
mortality	B-C0205848
in	O
infancy	B-C0231330
,	O
adolescence	B-C0001578
,	O
young	B-C0680085
adulthood	I-C0680085
,	O
late	B-C0700597
adulthood	I-C0700597
,	O
and	O
old	B-C1999167
age	I-C1999167
.	O
	
the	O
model	B-C3161035
describes	O
infant	B-C0021270
and	O
background	O
mortality	B-C0205848
by	O
two	O
simple	O
functions	B-C0542341
,	O
uses	O
a	O
mixed	B-C0023965
logistic	I-C0023965
model	I-C0023965
with	O
different	B-C1705242
slopes	B-C0807955
in	O
adult	B-C0001675
,	O
middle	B-C0026062
,	O
and	O
old	B-C1999167
age	I-C1999167
,	O
and	O
includes	O
the	O
modal	B-C0001779
age	I-C0001779
at	O
death	B-C1306577
as	O
a	O
parameter	B-C0549193
to	O
account	O
for	O
the	O
delay	B-C0205421
in	O
mortality	B-C0205848
.	O
	
applying	O
the	O
code	B-C3161035
model	I-C3161035
to	O
age	B-C0001779
-	O
specific	B-C0205369
probabilities	B-C0033204
of	O
death	B-C1306577
for	O
japanese	B-C1556094
,	O
french	B-C1556084
,	O
american	B-C0596070
,	O
and	O
danish	B-C1257890
men	B-C0025266
and	O
women	B-C0043210
between	O
1950	O
and	O
2010	O
showed	O
a	O
very	O
good	O
fit	O
of	O
the	O
full	O
age	B-C0001779
pattern	B-C0449774
of	O
mortality	B-C0205848
.	O
	
delay	B-C0205421
of	O
mortality	B-C0205848
explained	O
about	O
two-thirds	O
of	O
the	O
increase	B-C0442805
in	O
life	B-C0023671
expectancy	I-C0023671
at	O
birth	B-C0005615
,	O
whereas	O
compression	B-C0392756
of	O
mortality	B-C0205848
due	O
to	O
mortality	B-C0282251
declines	I-C0282251
in	O
young	B-C4061789
age	I-C4061789
explained	O
about	O
one-third	O
.	O
	
no	O
strong	O
compression	B-C0392756
of	O
mortality	B-C0205848
in	O
late	B-C0700597
adulthood	I-C0700597
age	I-C0700597
was	O
observed	O
.	O
	
mortality	B-C0205848
compression	B-C0392756
in	O
old	B-C1999167
age	I-C1999167
has	O
had	O
a	O
small	O
negative	O
impact	O
on	O
life	B-C0023671
expectancy	I-C0023671
.	O
	
the	O
code	B-C3161035
model	I-C3161035
proved	O
a	O
valid	O
instrument	O
for	O
describing	O
the	O
full	O
age	B-C0001779
pattern	B-C0449774
of	O
mortality	B-C0205848
and	O
for	O
disentangling	O
the	O
effects	O
of	O
mortality	B-C0205848
delay	B-C0205421
and	O
compression	B-C0392756
-	O
at	O
different	B-C1705242
stages	B-C0680083
of	I-C0680083
life	I-C0680083
-	O
on	O
the	O
increase	B-C0442805
in	O
life	B-C0023671
expectancy	I-C0023671
.	O
	
prevalence	B-C0033105
of	O
hypothyroidism	B-C0020676
in	O
andalusia	B-C0037747
,	O
spain	I-C0037747
,	O
determined	O
by	O
thyroid	B-C0040135
hormone	I-C0040135
comsumption	B-C0678263
hypothyroidism	B-C0020676
is	O
the	O
most	O
common	O
condition	O
linked	O
to	O
a	O
hormone	B-C0599750
deficiency	I-C0599750
,	O
nevertheless	O
data	O
on	O
its	O
prevalence	B-C0033105
are	O
scarce	O
in	O
spain	B-C0037747
.	O
	
for	O
that	O
reason	O
,	O
we	O
have	O
estimated	O
its	O
prevalence	B-C0033105
through	O
the	O
registration	B-C1514821
of	O
patients	B-C0030705
who	O
had	O
used	O
thyroid	B-C0040135
hormones	I-C0040135
in	O
andalusia	B-C0037747
south	I-C0037747
spain	I-C0037747
.	O
	
data	O
of	O
patients	B-C0030705
who	O
had	O
withdrawn	O
levothyroxine	B-C1881373
under	O
the	O
public	O
system	O
during	O
2014	O
from	O
the	O
base	O
of	O
the	O
andalusian	B-C0018747
health	I-C0018747
service	I-C0018747
were	O
considered	O
.	O
	
prevalence	B-C0033105
were	O
calculated	O
with	O
confidence	B-C0009667
intervals	I-C0009667
of	O
95%	O
for	O
each	O
management	B-C0683738
area	I-C0683738
,	O
stratified	O
by	O
sex	B-C1522384
and	O
age	B-C0027362
groups	I-C0027362
,	O
and	O
differences	O
between	O
them	O
were	O
evaluated	B-C0220825
.	O
	
321	O
people	B-C0027361
98%	O
older	O
than	O
18	O
years	O
and	O
83%	O
female	B-C0086287
were	O
identified	O
as	O
levothyroxine	B-C1881373
users	O
and	O
a	O
prevalence	B-C0033105
of	O
hypothyroidism	B-C0020676
of	O
3.95	O
95%	O
ci	B-C0009667
3.94	O
was	O
estimated	O
for	O
the	O
general	O
population	B-C1257890
.	O
	
the	O
condition	O
was	O
more	O
common	O
in	O
females	B-C0086287
,	O
in	O
the	O
older	O
18	O
years	O
7.81	O
95%	O
ci	B-C0009667
7.80	O
to	O
7.82	O
compared	O
to	O
males	B-C0086582
1.75	O
95%	O
ci	B-C0009667
1.73	O
with	O
a	O
ratio	O
of	O
4.5	B-C1254367
.	O
	
it	O
increases	O
in	O
the	O
population	B-C1257890
of	O
women	B-C0043210
older	O
than	O
45	O
years	O
,	O
10.32	O
95%	O
ci	B-C0009667
10.30	O
and	O
in	O
the	O
over	O
60	O
years	O
11.37	O
95%	O
ci	B-C0009667
11.35	O
.	O
	
the	O
prevalence	B-C0033105
in	O
adult	B-C0001675
women	B-C0043210
in	O
the	O
western	B-C1514578
provinces	I-C1514578
is	O
7.38	O
95%	O
ci	B-C0009667
7.36	O
,	O
in	O
the	O
eastern	B-C1514578
provinces	I-C1514578
8.59	O
95%	O
ci	B-C0009667
8.57	O
and	O
in	O
coastal	B-C0017446
areas	I-C0017446
6.70	O
95%	O
ci	B-C0009667
6.68	O
compared	O
to	O
the	O
mountainous	B-C1257890
ones	I-C1257890
,	O
which	O
is	O
8.91	O
95%	O
ci	B-C0009667
8.88	O
.	O
	
the	O
results	O
denote	O
a	O
high	B-C1512456
prevalence	I-C1512456
of	O
hypothyroidism	B-C0020676
in	O
the	O
adult	B-C0001675
population	B-C1257890
of	O
andalusia	B-C0037747
compared	O
to	O
the	O
nearby	O
countries	B-C0454664
,	O
with	O
a	O
clear	O
increased	O
associated	B-C0332281
with	I-C0332281
females	B-C0086287
and	O
age	B-C0001779
.	O
	
furthermore	O
,	O
the	O
prevalence	B-C0033105
of	O
the	O
illness	B-C0221423
presents	O
also	O
a	O
geographically-related	B-C0681784
variability	B-C2827666
.	O
	
disease	B-C1384960
activity	I-C1384960
and	O
increased	B-C0332167
risk	I-C0332167
of	I-C0332167
cardiovascular	B-C0376297
death	I-C0376297
among	O
patients	B-C0030705
with	O
psoriatic	B-C0003872
arthritis	I-C0003872
recent	O
studies	O
indicate	O
increased	O
cardiovascular	B-C1301700
cv	I-C1301700
morbidity	I-C1301700
and	O
mortality	B-C0376297
in	O
patients	B-C0030705
with	O
psoriatic	B-C0003872
arthritis	I-C0003872
psa	B-C0003872
,	O
but	O
results	O
are	O
inconsistent	O
.	O
	
this	O
prompted	O
our	O
investigation	O
of	O
the	O
mortality	B-C0205848
rate	I-C0205848
,	O
cause	B-C0007465
of	I-C0007465
death	I-C0007465
,	O
and	O
incidence	O
of	O
acute	O
cv	B-C1320716
events	I-C1320716
in	O
patients	B-C0030705
from	O
northern	B-C1709269
sweden	B-C0038995
with	O
psa	B-C0003872
.	O
	
patients	B-C0030705
with	O
established	O
psa	B-C0003872
464	O
were	O
included	O
.	O
	
to	O
calculate	O
standardized	B-C1710186
mortality	I-C1710186
ratio	I-C1710186
smr	B-C1710186
and	O
standardized	B-C2828391
incidence	I-C2828391
ratio	I-C2828391
sir	B-C2828391
for	O
cv	B-C1320716
events	I-C1320716
,	O
data	O
were	O
extracted	O
from	O
the	O
national	B-C0282574
causes	I-C0282574
of	I-C0282574
death	I-C0282574
register	I-C0282574
and	O
the	O
national	B-C0282574
inpatient	I-C0282574
care	I-C0282574
register	I-C0282574
in	O
sweden	B-C0038995
,	O
and	O
compared	O
with	O
the	O
general	B-C0683971
population	I-C0683971
.	O
	
the	O
study	O
period	O
was	O
1995-2011	O
.	O
	
to	O
study	O
the	O
effect	O
of	O
inflammatory	B-C0333348
activity	O
,	O
a	O
composite	O
disease	B-C4065474
activity	I-C4065474
index	I-C4065474
dai	B-C4065474
was	O
used	O
.	O
	
the	O
smr	B-C1710186
95%	O
ci	O
for	O
overall	B-C0026565
mortality	I-C0026565
and	O
diseases	B-C0728936
of	I-C0728936
the	I-C0728936
circulatory	I-C0728936
system	I-C0728936
international	B-C0870733
classification	I-C0870733
of	I-C0870733
diseases	I-C0870733
,	O
10th	O
edition	O
i00-i99	O
was	O
1.22	O
0.89	O
and	O
1.64	O
1.02	O
,	O
respectively	O
.	O
	
in	O
regression	B-C0034980
analysis	I-C0034980
,	O
dai	B-C4065474
was	O
significantly	O
associated	O
with	O
death	B-C1306577
or	O
1.99	O
,	O
95%	O
ci	O
1.41	O
when	O
adjusted	O
for	O
age	O
and	O
sex	O
p	O
<	O
0.001	O
,	O
and	O
remained	O
significant	O
after	O
stratifying	B-C0205363
patients	B-C0030705
into	O
the	O
2	O
major	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
diseases	B-C0728936
of	I-C0728936
the	I-C0728936
circulatory	I-C0728936
system	I-C0728936
and	O
malignant	B-C0006826
neoplasms	I-C0006826
.	O
	
peripheral	B-C1704436
and	O
axial	B-C3805913
disease	I-C3805913
was	O
associated	O
with	O
death	B-C1306577
or	O
4.02	O
,	O
95%	O
ci	O
1.84	O
,	O
p	O
<	O
0.001	O
compared	O
with	O
peripheral	B-C1704436
disease	I-C1704436
only	O
.	O
	
the	O
sir	B-C2828391
95%	O
ci	O
for	O
a	O
cv	B-C1320716
event	I-C1320716
myocardial	B-C0027051
infarction	I-C0027051
or	O
stroke	B-C0018843
was	O
0.597	O
0.40	O
this	O
association	O
was	O
only	O
significant	O
in	O
men	B-C0025266
.	O
	
patients	B-C0030705
with	O
psa	B-C0003872
had	O
a	O
small	O
but	O
significant	O
increase	O
in	O
smr	B-C1710186
for	O
death	B-C1306577
due	O
to	O
diseases	B-C0728936
of	I-C0728936
the	I-C0728936
circulatory	I-C0728936
system	I-C0728936
compared	O
with	O
the	O
general	B-C0683971
population	I-C0683971
.	O
	
among	O
patients	B-C0030705
,	O
death	B-C1306577
was	O
associated	O
with	O
dai	B-C4065474
,	O
as	O
well	O
as	O
axial	B-C3805913
involvement	I-C3805913
in	O
combination	O
with	O
peripheral	B-C1704436
disease	I-C1704436
,	O
indicating	O
more	O
aggressive	O
disease	B-C4086242
phenotypes	I-C4086242
.	O
	
histomorphometric	B-C0200760
and	O
transcriptome	B-C3178810
evaluation	B-C0220825
of	O
early	O
healing	B-C1321023
bone	I-C1321023
treated	B-C0332293
with	I-C0332293
a	O
novel	B-C0205314
human	B-C0011429
particulate	I-C0011429
dentin	I-C0011429
powder	B-C0032861
human	B-C0011429
particulate	I-C0011429
dentin	I-C0011429
hpd	B-C0011429
shows	O
potential	B-C3245505
as	O
an	O
alternative	B-C1523987
bone	B-C0005976
grafting	I-C0005976
material	B-C0181074
.	O
	
however	O
,	O
the	O
mechanism	B-C0441712
of	O
bone	B-C1321023
healing	I-C1321023
at	O
the	O
molecular	B-C1521991
level	B-C0441889
after	O
grafting	B-C1961139
with	O
hpd	B-C0011429
is	O
unclear	O
.	O
	
this	O
study	B-C2603343
assessed	B-C1516048
the	O
histological	B-C0205462
and	O
global	B-C2348867
gene	B-C0017262
expression	I-C0017262
of	O
bone	B-C0391978
tissues	I-C0391978
grafted	B-C0700106
with	O
hpd	B-C0011429
.	O
	
the	O
hpd	B-C0011429
was	O
prepared	B-C4082130
to	O
250-500	O
µm	O
in	O
size	O
.	O
	
x-ray	B-C0043301
diffraction	I-C0043301
xrd	B-C0043301
and	O
energy	B-C2699997
dispersive	I-C2699997
x-ray	I-C2699997
spectroscopy	I-C2699997
edx	B-C2699997
were	O
performed	B-C0884358
to	O
confirm	B-C1456348
the	O
crystal	B-C0444626
structure	I-C0444626
,	O
organic	B-C0029224
compound	I-C0029224
residues	B-C1709915
,	O
and	O
surface	B-C0332437
morphology	I-C0332437
,	O
respectively	O
.	O
	
bony	B-C0443157
defects	B-C1457869
were	O
created	B-C1706214
on	O
the	O
heads	B-C0018670
of	O
24	O
new	B-C0324547
zealand	I-C0324547
white	I-C0324547
rabbits	I-C0324547
.	O
	
sterilized	B-C0205556
hpd	B-C0011429
was	O
used	O
as	O
the	O
grafting	B-C0181074
material	I-C0181074
.	O
	
the	O
quality	B-C0332306
and	O
quantity	B-C1265611
of	O
new	B-C0029433
bone	I-C0029433
formation	I-C0029433
was	O
evaluated	B-C0220825
using	O
micro-ct	B-C2350281
and	O
histologic	B-C0205462
analyses	B-C0936012
during	B-C0347984
the	O
8	O
week	O
experimental	B-C1517586
periods	B-C1948053
.	O
	
for	O
microarray	B-C0022885
assay	I-C0022885
,	O
bone	B-C0391978
tissue	I-C0391978
and	O
blood	B-C0178913
samples	I-C0178913
were	O
taken	O
at	O
3	O
,	O
5	O
and	O
7	O
d	O
post-implantation	B-C1254367
.	O
	
the	O
results	B-C0456984
of	O
xrd	B-C0043301
and	O
edx	B-C2699997
showed	O
that	O
hpd	B-C0011429
exhibited	O
physical	B-C0597237
and	O
chemical	B-C0243178
properties	I-C0243178
similar	B-C2348205
to	O
natural	B-C0205296
hydroxyapatite	B-C0020326
.	O
	
new	B-C0029433
bone	I-C0029433
formation	I-C0029433
was	O
observed	B-C1441672
after	O
hpd	B-C0011429
implantation	B-C0021107
compared	B-C1707455
to	O
the	O
controls	B-C0009932
,	O
as	O
shown	O
on	O
hematoxylin	B-C0523207
and	I-C0523207
eosin	I-C0523207
staining	I-C0523207
and	O
micro-ct	B-C2350281
.	O
	
the	O
bone	B-C1317149
volume	I-C1317149
of	O
hpd	B-C0011429
treated	B-C1522326
animals	B-C0003062
was	O
higher	B-C0205250
than	O
that	O
of	O
the	O
control	B-C0009932
group	I-C0009932
at	O
all	O
observation	B-C0302523
times	B-C1632851
.	O
	
microarray	B-C1449575
analysis	I-C1449575
showed	O
that	O
vascular	B-C1621270
development	I-C1621270
coupled	O
with	O
immune	B-C0439662
and	O
inflammatory	B-C0333348
related	O
genes	B-C0017337
were	O
expressed	B-C0017262
in	O
the	O
early	B-C2363430
healing	B-C0043240
stage	B-C0205390
.	O
	
the	O
gene	B-C3839127
coding	I-C3839127
for	O
the	O
il-1	B-C3536785
antagonist	I-C3536785
,	O
il1rn	B-C1416402
,	O
was	O
expressed	B-C0017262
to	O
inhibit	B-C0021469
the	O
inflammatory	B-C1155266
response	I-C1155266
,	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
ccl2	B-C1337092
gene	I-C1337092
was	O
activated	B-C1879547
to	O
2.3	O
times	O
the	O
normal	B-C0205307
level	B-C0441889
.	O
	
bmp2	B-C1332424
,	O
runx2	B-C1419771
,	O
col1a	B-C0017337
,	O
and	O
opn	B-C1420369
expression	B-C0017262
were	O
also	O
up-regulated	B-C0041904
.	O
	
ccl2	B-C1337092
predominated	B-C0332251
in	O
osteoblastogenesis	B-C1159974
of	O
the	O
hpd	B-C0011429
-	O
treated	B-C1522326
bony	B-C0443157
defect	B-C1457869
in	O
the	O
early	B-C2363430
stage	I-C2363430
of	O
healing	B-C0043240
.	O
	
hpd	B-C0011429
accelerated	B-C0521110
bone	B-C0005972
regeneration	I-C0005972
and	O
augmentation	B-C0332509
.	O
	
these	O
results	B-C0456984
suggested	B-C1705535
that	O
hpd	B-C0011429
provided	B-C1999230
potential	B-C3245505
as	O
a	O
bone	B-C0005976
graft	I-C0005976
resource	B-C0178514
during	B-C0347984
the	O
bone	B-C0262950
healing	B-C2004454
process	I-C2004454
.	O
	
'you	O
can't	O
be	O
a	O
person	B-C0027361
and	O
a	O
docto	B-C0031831
r'	O
the	O
work-life	B-C4277700
balance	I-C4277700
of	O
doctors	B-C0031831
in	O
training	B-C0220931
-a	O
qualitative	B-C0949415
study	I-C0949415
investigate	B-C1292732
the	O
work-life	B-C4277700
balance	I-C4277700
of	O
doctors	B-C0031831
in	O
training	B-C0220931
in	O
the	O
uk	B-C0041700
from	O
the	O
perspectives	O
of	O
trainers	B-C0453962
and	O
trainees	O
.	O
	
qualitative	B-C0205556
semistructured	O
focus	O
groups	O
and	O
interviews	B-C0021822
with	O
trainees	O
and	O
trainers	B-C0453962
.	O
	
postgraduate	B-C0871106
medical	I-C0871106
training	I-C0871106
in	O
london	B-C0023973
,	O
yorkshire	B-C0017446
and	O
humber	B-C0017446
,	O
kent	B-C0454861
,	O
surrey	B-C0454877
and	O
sussex	B-C0017446
,	O
and	O
wales	B-C0043015
during	O
the	O
junior	B-C0031831
doctor	I-C0031831
contract	B-C0332522
dispute	B-C0680226
at	O
the	O
end	O
of	O
2015	O
.	O
	
part	O
of	O
a	O
larger	O
general	B-C0029246
medical	I-C0029246
council	I-C0029246
study	B-C2603343
about	O
the	O
fairness	O
of	O
postgraduate	B-C0871106
medical	I-C0871106
training	I-C0871106
.	O
	
96	O
trainees	O
and	O
41	O
trainers	B-C0453962
.	O
	
trainees	O
comprised	O
uk	B-C0041700
graduates	B-C0588053
and	O
international	B-C0016553
medical	I-C0016553
graduates	I-C0016553
,	O
across	O
all	O
stages	O
of	O
training	B-C0220931
in	O
6	O
specialties	B-C0037778
general	B-C0086343
practice	I-C0086343
,	O
medicine	B-C0025118
,	O
obstetrics	B-C1274104
and	I-C1274104
gynaecology	I-C1274104
,	O
psychiatry	B-C0033873
,	O
radiology	B-C0034599
,	O
surgery	B-C0038894
and	O
foundation	B-C0016617
.	O
	
postgraduate	B-C0871106
training	I-C0871106
was	O
characterised	O
by	O
work-life	B-C4277572
imbalance	I-C4277572
.	O
	
long	B-C0205166
hours	B-C0439227
at	O
work	B-C0043227
were	O
typically	O
supplemented	O
with	O
revision	B-C0439617
and	O
completion	B-C1554962
of	O
the	O
e-portfolio	B-C0205556
.	O
	
trainees	O
regularly	O
moved	O
workplaces	B-C0162579
which	O
could	O
disrupt	B-C0332454
their	O
personal	B-C0682273
lives	I-C0682273
and	O
sometimes	O
led	O
to	O
separation	B-C0599245
from	O
friends	B-C0079382
and	O
family	B-C0015576
.	O
	
this	O
made	O
it	O
challenging	O
to	O
cope	B-C0009967
with	O
personal	O
pressures	O
,	O
the	O
stresses	B-C0038443
of	O
which	O
could	O
then	O
impinge	O
on	O
learning	B-C0023185
and	O
training	B-C0220931
,	O
while	O
also	O
leaving	B-C1706081
trainees	O
with	O
a	O
lack	B-C0332268
of	O
social	B-C0037438
support	I-C0037438
outside	O
work	O
to	O
buffer	O
against	O
the	O
considerable	O
stresses	B-C0038443
of	O
training	B-C0220931
.	O
	
low	B-C0205251
morale	B-C0438698
and	O
harm	B-C0438698
to	O
well-being	B-C1821407
resulted	O
in	O
some	O
trainees	O
feeling	B-C1527305
dehumanised	B-C1135946
.	O
	
work-life	B-C4277572
imbalance	I-C4277572
was	O
particularly	O
severe	B-C0205082
for	O
those	O
with	O
children	B-C0008059
and	O
especially	O
women	B-C0043210
who	O
faced	O
a	O
lack	B-C0332268
of	O
less-than	B-C0439092
-	O
full-time	B-C2584323
positions	I-C2584323
and	O
discriminatory	B-C0012632
attitudes	B-C0004271
.	O
	
female	B-C0086287
trainees	O
frequently	O
talked	B-C0234856
about	O
having	O
to	O
choose	B-C1707391
a	O
specialty	B-C0037778
they	O
felt	O
was	O
more	O
conducive	O
to	O
a	O
work-life	B-C4277700
balance	I-C4277700
such	O
as	O
general	B-C0086343
practice	I-C0086343
.	O
	
the	O
proposed	O
junior	B-C0031831
doctor	I-C0031831
contract	B-C0332522
was	O
felt	O
to	O
exacerbate	B-C0436331
existing	B-C0205556
problems	B-C0033213
.	O
	
a	O
lack	B-C0332268
of	O
work-life	B-C4277700
balance	I-C4277700
in	O
postgraduate	B-C0871106
medical	I-C0871106
training	I-C0871106
negatively	B-C3853545
impacted	B-C0333125
on	O
trainees	O
'	O
learning	B-C0023185
and	O
well-being	B-C1821407
.	O
	
women	B-C0043210
with	O
children	B-C0008059
were	O
particularly	O
affected	B-C0392760
,	O
suggesting	O
this	O
group	B-C0441833
would	O
benefit	B-C0814225
the	O
greatest	B-C0205393
from	O
changes	B-C0392747
to	O
improve	B-C0184511
the	O
work-life	B-C4277700
balance	I-C4277700
reappraisal	B-C1254363
modulates	O
attentional	B-C4277667
bias	I-C4277667
to	O
angry	B-C0002957
faces	O
heightened	O
attentional	O
bias	O
to	O
emotional	O
information	O
is	O
one	O
of	O
the	O
main	O
characteristics	O
of	O
disorders	O
related	O
to	O
emotion	O
dysregulation	O
such	O
as	O
anxiety	O
,	O
depression	O
,	O
and	O
substance	O
abuse	O
.	O
	
although	O
reappraisal	O
,	O
an	O
emotion	O
regulation	O
strategy	O
,	O
is	O
known	O
to	O
effectively	O
modulate	O
subjective	O
experience	O
of	O
emotions	O
,	O
it	O
remains	O
unknown	O
whether	O
reappraisal	O
can	O
alter	O
attentional	O
biases	O
to	O
emotional	O
information	O
.	O
	
in	O
the	O
current	O
research	O
,	O
we	O
investigated	O
the	O
influence	O
of	O
instruction-induced	O
state	O
reappraisal	O
study	O
1	O
and	O
trait	O
reappraisal	O
study	O
2	O
on	O
attentional	O
biases	O
to	O
happy	O
and	O
angry	O
faces	O
.	O
	
in	O
study	O
1	O
,	O
healthy	O
young	O
women	O
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
three	O
groups	O
up	O
-	O
,	O
down	O
-	O
,	O
and	O
no-regulation	O
.	O
	
participants	O
were	O
instructed	O
to	O
reappraise	O
their	O
emotions	O
to	O
increase	O
and	O
decrease	O
emotional	O
experience	O
while	O
viewing	O
an	O
emotionally	O
negative	O
film	O
clip	O
.	O
	
attentional	O
bias	O
was	O
assessed	O
with	O
a	O
dot-probe	O
task	O
with	O
pictures	O
of	O
angry	O
and	O
happy	O
facial	O
expressions	O
.	O
	
in	O
study	O
2	O
,	O
a	O
separate	O
group	O
of	O
healthy	O
young	O
men	O
and	O
women	O
participated	O
.	O
	
participants	O
'	O
trait	O
reappraisal	O
and	O
suppression	O
as	O
well	O
as	O
state	O
and	O
trait	O
anxiety	O
were	O
assessed	O
.	O
	
a	O
dot-probe	O
task	O
was	O
completed	O
by	O
all	O
participants	O
.	O
	
statistical	O
tests	O
in	O
study	O
1	O
revealed	O
that	O
participants	O
who	O
reappraised	O
to	O
decrease	O
negative	O
emotions	O
while	O
viewing	O
an	O
emotionally	O
negative	O
film	O
clip	O
had	O
reduced	O
attentional	O
bias	O
to	O
subsequently	O
presented	O
angry	O
faces	O
compared	O
to	O
participants	O
who	O
reappraised	O
to	O
increase	O
negative	O
emotions	O
.	O
	
multiple	O
regression	O
analyses	O
in	O
study	O
2	O
revealed	O
that	O
trait	O
reappraisal	O
predicted	O
slower	O
orienting	O
toward	O
angry	O
faces	O
,	O
whereas	O
state	O
anxiety	O
predicted	O
slower	O
disengagement	O
from	O
angry	O
faces	O
.	O
	
interestingly	O
,	O
trait	O
suppression	O
predicted	O
slower	O
disengagement	O
from	O
happy	O
faces	O
.	O
	
taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
both	O
instruction-induced	O
state	O
reappraisal	O
and	O
trait	O
reappraisal	O
are	O
linked	O
to	O
reduced	O
attentional	O
bias	O
to	O
negative	O
information	O
and	O
contribute	O
to	O
better	O
understanding	O
of	O
how	O
everyday	O
emotion	O
regulation	O
styles	O
contribute	O
to	O
attentional	O
processing	O
of	O
emotional	O
information	B-C1533716
graded	B-C0008902
structure	I-C0008902
in	O
sexual	B-C0036864
definitions	B-C1704788
categorizations	B-C0008902
of	O
having	O
""""	O
had	B-C0243095
sex	I-C0243095
""""	O
and	O
virginity	B-C0282349
loss	B-C0745777
among	O
homosexual	B-C0019898
and	O
heterosexual	B-C1527360
men	B-C0025266
and	O
women	B-C0043210
definitions	B-C1704788
of	O
sexual	B-C0036864
behavior	I-C0036864
display	O
a	O
robust	O
hierarchy	B-C0019523
of	O
agreement	O
regarding	O
whether	O
or	O
not	O
acts	B-C0441655
should	O
be	O
classed	O
as	O
,	O
for	O
example	O
,	O
sex	B-C0009253
or	O
virginity	B-C0282349
loss	B-C0745777
.	O
	
the	O
current	O
research	B-C0035168
offers	O
a	O
theoretical	B-C0871935
explanation	B-C0681841
for	O
this	O
hierarchy	B-C0019523
,	O
proposing	O
that	O
sexual	B-C0036864
definitions	B-C1704788
display	O
graded	B-C0008902
categorical	I-C0008902
structure	I-C0008902
,	O
arising	O
from	O
goodness	O
of	O
membership	B-C0680038
judgments	B-C0022423
.	O
	
moderation	B-C1881878
of	O
this	O
graded	B-C0008902
structure	I-C0008902
is	O
also	O
predicted	O
,	O
with	O
the	O
focus	O
here	O
on	O
how	O
sexual	B-C0205949
orientation	I-C0205949
identity	B-C0424215
affects	O
sexual	B-C0036864
definitions	B-C1704788
.	O
	
a	O
total	O
of	O
300	O
18-	O
to	O
30-	O
year	B-C1510829
-old	O
participants	B-C0679646
completed	O
an	O
online	B-C0038951
survey	I-C0038951
,	O
rating	B-C0871208
18	O
behaviors	B-C0004927
for	O
how	O
far	O
each	O
constitutes	O
having	O
""""	O
had	B-C0243095
sex	I-C0243095
""""	O
and	O
virginity	B-C0282349
loss	B-C0745777
.	O
	
participants	B-C0679646
fell	O
into	O
one	O
of	O
four	O
groups	B-C0681860
heterosexual	B-C1527360
male	B-C0025266
or	O
female	B-C0043210
,	O
gay	B-C0242657
male	I-C0242657
or	O
lesbian	B-C1533642
.	O
	
the	O
predicted	O
ratings	B-C0871208
hierarchy	B-C0019523
emerged	O
,	O
in	O
which	O
bidirectional	B-C0036864
genital	I-C0036864
acts	I-C0036864
were	O
rated	B-C0871208
significantly	O
higher	B-C0205250
than	O
unidirectional	B-C0036864
or	O
nonpenetrative	B-C0563018
contact	I-C0563018
,	O
which	O
was	O
in	O
turn	O
rated	B-C0871208
significantly	O
higher	B-C0205250
than	O
acts	B-C0441655
involving	O
no	B-C0243095
genital	I-C0243095
contact	I-C0243095
.	O
	
moderation	B-C1881878
of	O
graded	B-C0008902
structure	I-C0008902
was	O
also	O
in	O
line	O
with	O
predictions	B-C0681842
.	O
	
compared	O
to	O
the	O
other	O
groups	B-C0681860
,	O
the	O
lesbian	B-C0681860
group	I-C0681860
significantly	O
upgraded	O
ratings	B-C0871208
of	O
genital	B-C0036864
contact	I-C0036864
that	O
was	O
either	O
unidirectional	B-C0036864
or	O
nonpenetrative	B-C0563018
.	O
	
there	O
was	O
also	O
evidence	B-C3887511
of	O
upgrading	O
by	O
the	O
gay	B-C0242657
male	I-C0242657
sample	O
of	O
anal	B-C0556628
intercourse	I-C0556628
ratings	B-C0871208
.	O
	
these	O
effects	B-C1280500
are	O
theorized	O
to	O
reflect	O
group	B-C0681860
-level	O
variation	B-C0205419
in	O
experience	B-C0596545
,	O
contextual	B-C0004271
perspective	I-C0004271
,	O
and	O
identity	B-C0424215
-management	O
.	O
	
the	O
implications	B-C3146298
of	O
the	O
findings	B-C0243095
in	O
relation	O
to	O
previous	O
research	B-C0035168
are	O
discussed	O
.	O
	
it	O
is	O
suggested	O
that	O
a	O
graded	B-C0008902
structure	I-C0008902
approach	O
can	O
greatly	O
benefit	B-C0814225
future	O
research	B-C0035168
into	O
sexual	B-C0036864
definitions	B-C1704788
,	O
by	O
permitting	O
variable	O
definitions	B-C1704788
effects	O
of	O
soybean	B-C4076257
isoflavone	I-C4076257
on	O
intestinal	B-C0021853
antioxidant	B-C1148564
capacity	I-C1148564
and	O
cytokines	B-C0079189
in	O
young	O
piglets	B-C0039005
fed	B-C2987508
oxidized	B-C0030011
fish	B-C0016157
oil	I-C0016157
to	O
investigate	O
the	O
effect	O
of	O
glycitein	B-C0253391
,	O
a	O
synthetic	B-C1883254
soybean	B-C4076257
isoflavone	I-C4076257
isf	B-C4076257
,	O
on	O
the	O
intestinal	B-C0021853
antioxidant	B-C1148564
capacity	I-C1148564
,	O
morphology	B-C0332437
,	O
and	O
cytokine	B-C0079189
content	O
in	O
young	O
piglets	B-C0039005
fed	B-C2987508
oxidized	B-C0030011
fish	B-C0016157
oil	I-C0016157
,	O
72	O
4-d-old	O
male	O
piglets	B-C0039005
were	O
assigned	O
to	O
three	O
treatments	B-C0001563
.	O
	
the	O
control	B-C0009932
group	I-C0009932
was	O
fed	B-C2987508
a	O
basal	B-C2983588
diet	I-C2983588
containing	O
fresh	B-C0443224
fish	B-C0016157
oil	I-C0016157
,	O
and	O
the	O
other	O
two	O
groups	O
received	O
the	O
same	O
diet	O
except	O
for	O
the	O
substitution	O
with	O
the	O
same	O
dosage	B-C0178602
of	O
oxidized	B-C0030011
fish	B-C0016157
oil	I-C0016157
alone	O
or	O
with	O
isf	B-C4076257
oxidized	B-C0030011
fish	B-C0016157
oil	I-C0016157
plus	O
isf	B-C4076257
.	O
	
after	O
21	O
d	O
of	O
feeding	B-C2987508
,	O
supplementation	B-C0242297
of	O
oxidized	B-C0030011
fish	B-C0016157
oil	I-C0016157
increased	O
the	O
levels	O
of	O
malondialdehyde	B-C0024643
mda	B-C0024643
,	O
oxidized	B-C0061516
glutathione	I-C0061516
gssg	B-C0061516
,	O
interleukin-1β	B-C0021753
il-1β	B-C0021753
,	O
tumor	B-C1456820
necrosis	I-C1456820
factor-α	I-C1456820
tnf-α	B-C1456820
,	O
interleukin-2	B-C0021756
il-2	B-C0021756
,	O
nuclear	B-C0079904
factor	I-C0079904
κ	I-C0079904
b	I-C0079904
nf-κb	B-C0079904
,	O
inducible	B-C0132555
nitric	I-C0132555
oxide	I-C0132555
synthase	I-C0132555
inos	B-C0132555
,	O
no	B-C0028128
,	O
and	O
caspase-3	B-C0291573
in	O
jejunal	B-C0227308
mucosa	I-C0227308
,	O
and	O
decreased	O
the	O
villous	B-C0227266
height	B-C0489786
in	O
duodenum	B-C0013303
and	O
the	O
levels	O
of	O
secretory	B-C0020838
immunoglobulin	I-C0020838
a	I-C0020838
siga	B-C0020838
and	O
il-4	B-C0021758
in	O
the	O
jejunal	B-C0227308
mucosa	I-C0227308
compared	O
with	O
supplementation	B-C0242297
with	O
fresh	B-C0443224
oil	B-C0016157
.	O
	
the	O
addition	O
of	O
oxidized	B-C0030011
fish	B-C0016157
oil	I-C0016157
plus	O
isf	B-C4076257
partially	O
alleviated	O
this	O
negative	O
effect	O
.	O
	
the	O
addition	O
of	O
oxidized	B-C0030011
fish	B-C0016157
oil	I-C0016157
plus	O
isf	B-C4076257
increased	O
the	O
villous	B-C0227266
height	B-C0489786
and	O
levels	O
of	O
siga	B-C0020838
and	O
il-4	B-C0021758
in	O
jejunal	B-C0227308
mucosa	I-C0227308
,	O
but	O
decreased	O
the	O
levels	O
of	O
il-1β	B-C0021753
and	O
il-2	B-C0021756
in	O
jejunal	B-C0227308
mucosa	I-C0227308
p<0	O
compared	O
with	O
oxidized	B-C0030011
fish	B-C0016157
oil	I-C0016157
.	O
	
collectively	O
,	O
these	O
results	O
show	O
that	O
dietary	B-C0242297
supplementation	I-C0242297
of	O
isf	B-C4076257
could	O
partly	O
alleviate	O
the	O
negative	O
effect	O
of	O
oxidized	B-C0030011
fish	B-C0016157
oil	I-C0016157
by	O
improving	O
the	O
intestinal	B-C0021853
morphology	I-C0021853
as	O
well	O
as	O
the	O
antioxidant	B-C1148564
capacity	I-C1148564
and	O
immune	B-C1817756
function	I-C1817756
in	O
young	O
piglets	B-C0039005
.	O
	
evolution	B-C3825184
enhanced	B-C2349975
footing	B-C1527178
for	O
snake	B-C0037382
limb	B-C1517884
development	I-C1517884
two	O
groups	O
have	O
studied	O
the	O
loss	B-C1517945
of	O
limbs	B-C0015385
in	O
snake	B-C0037382
evolution	B-C3825184
by	O
focusing	O
on	O
a	O
long-distance	B-C0456966
cis-acting	B-C1516561
enhancer	I-C1516561
of	O
sonic	B-C1335824
hedgehog	I-C1335824
.	O
	
they	O
find	O
a	O
progressive	B-C0205329
degeneration	B-C1880269
of	O
binding	B-C1514535
sites	I-C1514535
for	O
key	O
transcription	B-C0040648
factors	I-C0040648
,	O
mirroring	O
the	O
progressive	B-C0205329
limblessness	B-C0205556
occurring	B-C1709305
in	O
these	O
dynamin-related	B-C0669938
protein	I-C0669938
1	I-C0669938
mediates	B-C0205245
low	B-C0017725
glucose	I-C0017725
-	O
induced	B-C0205263
endothelial	B-C0856169
dysfunction	I-C0856169
in	O
human	B-C0086418
arterioles	B-C0003847
intensive	O
glycemic	B-C1327622
regulation	I-C1327622
has	O
resulted	O
in	O
an	O
increased	B-C0205217
incidence	B-C0021149
of	O
hypoglycemia	B-C0020615
.	O
	
hypoglycemic	B-C0020615
burden	B-C2828008
correlates	O
with	O
adverse	B-C0001688
cardiovascular	B-C0161816
complications	I-C0161816
and	O
contributes	O
acutely	B-C0205178
and	O
chronically	B-C0205191
to	O
endothelial	B-C0856169
dysfunction	I-C0856169
.	O
	
prior	O
data	B-C1511726
indicate	O
that	O
mitochondrial	B-C4021734
dysfunction	I-C4021734
contributes	O
to	O
hypoglycemia	B-C0020615
-	O
induced	B-C0205263
endothelial	B-C0856169
dysfunction	I-C0856169
,	O
but	O
the	O
mechanisms	B-C0441712
behind	O
this	O
linkage	B-C0205245
remain	O
unknown	B-C0439673
.	O
	
we	O
attempt	O
to	O
determine	O
whether	O
clinically	B-C0205210
relevant	B-C2347946
low-glucose	B-C0017725
lg	B-C0017725
exposures	B-C0332157
acutely	B-C0205178
induce	B-C0205263
endothelial	B-C0856169
dysfunction	I-C0856169
through	O
activation	B-C1879547
of	O
the	O
mitochondrial	B-C0230871
fission	I-C0230871
process	I-C0230871
.	O
	
characterization	B-C1880022
of	O
mitochondrial	B-C0243095
morphology	I-C0243095
was	O
carried	O
out	O
in	O
cultured	B-C0205245
endothelial	B-C0225336
cells	I-C0225336
by	O
using	O
confocal	B-C0242842
microscopy	I-C0242842
.	O
	
isolated	B-C0205409
human	B-C0086418
arterioles	B-C0003847
were	O
used	O
to	O
explore	O
the	O
effect	B-C1280500
lg	B-C0017725
-	O
induced	B-C0205263
mitochondrial	B-C0230871
fission	I-C0230871
has	O
on	O
the	O
formation	B-C1522492
of	O
detrimental	B-C1537052
reactive	I-C1537052
oxygen	I-C1537052
species	I-C1537052
ros	B-C1537052
,	O
bioavailability	B-C0005508
of	O
nitric	B-C0028128
oxide	I-C0028128
no	B-C0028128
,	O
and	O
endothelial-dependent	B-C1258036
vascular	I-C1258036
relaxation	I-C1258036
.	O
	
fluorescence	B-C0026022
microscopy	I-C0026022
was	O
employed	O
to	O
visualize	O
changes	B-C0392747
in	O
mitochondrial	B-C0026237
ros	B-C1537052
and	O
no	B-C0028128
levels	B-C0441889
and	O
videomicroscopy	B-C0242940
applied	O
to	O
measure	B-C0079809
vasodilation	B-C0042401
response	B-C0205245
.	O
	
pharmacological	B-C0205464
disruption	B-C0332453
of	O
the	O
profission	B-C0033684
protein	I-C0033684
drp1	B-C0669938
with	O
mdivi-1	B-C2933581
during	O
lg	B-C0017725
exposure	B-C0332157
reduced	B-C0392756
mitochondrial	B-C0230871
fragmentation	I-C0230871
among	O
vascular	B-C1257792
endothelial	I-C1257792
cells	I-C1257792
lg	B-C0017725
0.469	O
lg	B-C0017725
+	O
mdivi-1	B-C2933581
0.276	O
p	O
=	O
0.003	O
,	O
prevented	B-C1292733
formation	B-C1522492
of	O
vascular	B-C0005847
ros	B-C1537052
lg	B-C0017725
2.036	O
lg	B-C0017725
+	O
mdivi-1	B-C2933581
1.774	O
p	O
=	O
0.005	O
,	O
increased	B-C0205217
the	O
presence	B-C0150312
of	O
no	B-C0028128
lg	B-C0017725
1.352	O
lg	B-C0017725
+	O
mdivi-1	B-C2933581
1.502	O
p	O
=	O
0.048	O
,	O
and	O
improved	B-C0184511
vascular	B-C0042401
dilation	I-C0042401
response	B-C0205245
to	O
acetylcholine	B-C0001041
lg	B-C0017725
31.6	O
lg	B-C0017725
+	O
mdivi-1	B-C2933581
78.5	O
at	O
maximum	B-C0806909
dose	B-C0178602
p	O
<	O
0.001	O
.	O
	
additionally	O
,	O
decreased	B-C0205216
expression	B-C1171362
of	O
drp1	B-C0669938
via	O
sirna	B-C1099354
knockdown	B-C2350567
during	O
lg	B-C0017725
conditions	B-C0348080
also	O
improved	B-C0184511
vascular	B-C1258036
relaxation	I-C1258036
.	O
	
exposure	B-C0332157
to	I-C0332157
lg	B-C0017725
imparts	O
endothelial	B-C0856169
dysfunction	I-C0856169
coupled	B-C1948027
with	O
altered	B-C0392747
mitochondrial	B-C0026237
phenotypes	B-C0031437
among	O
isolated	B-C0205409
human	B-C0086418
arterioles	B-C0003847
.	O
	
disruption	B-C0332453
of	O
drp1	B-C0669938
and	O
subsequent	B-C0332282
mitochondrial	B-C0230871
fragmentation	I-C0230871
events	O
prevents	B-C1292733
impaired	B-C0221099
vascular	B-C0042401
dilation	I-C0042401
,	O
restores	B-C0205245
mitochondrial	B-C0026237
phenotype	B-C0031437
,	O
and	O
implicates	O
mitochondrial	B-C0230871
fission	I-C0230871
as	O
a	O
primary	B-C0205225
mediator	B-C0205556
of	O
lg	B-C0017725
-	O
induced	B-C0205263
endothelial	B-C0856169
dysfunction	I-C0856169
new	O
noteworthy	O
acute	B-C0205178
low-glucose	B-C0017725
exposure	B-C0332157
induces	B-C0205263
mitochondrial	B-C0230871
fragmentation	I-C0230871
in	O
endothelial	B-C0225336
cells	I-C0225336
via	O
drp1	B-C0669938
and	O
is	O
associated	B-C0332281
with	I-C0332281
impaired	B-C0221099
endothelial	B-C0225336
function	B-C0007613
in	O
human	B-C0086418
arterioles	B-C0003847
.	O
	
targeting	B-C0599894
of	O
drp1	B-C0669938
prevents	B-C1292733
fragmentation	B-C0230871
,	O
improves	O
vasofunction	B-C1254358
,	O
and	O
may	O
provide	O
a	O
therapeutic	B-C0302350
target	B-C1521840
for	O
improving	O
cardiovascular	B-C0161816
complications	I-C0161816
among	O
diabetics	B-C0241863
listen	O
to	O
this	O
article's	O
corresponding	O
podcast	O
a	O
16	O
yin	B-C0017337
yang	I-C0017337
gene	B-C0017262
expression	I-C0017262
ratio	B-C0456603
signature	B-C1708225
for	O
er+	B-C2938924
/	O
node-	B-C3160889
breast	I-C3160889
cancer	I-C3160889
breast	B-C0006142
cancer	I-C0006142
is	O
one	O
of	O
the	O
leading	O
causes	B-C0015127
of	O
cancer	B-C0006826
death	B-C0011065
in	O
women	B-C0043210
.	O
	
it	O
is	O
a	O
complex	B-C0439855
and	O
heterogeneous	B-C0019409
disease	B-C0012634
with	O
different	O
clinical	B-C0205210
outcomes	B-C0085415
.	O
	
stratifying	B-C0205363
patients	B-C0030705
into	O
subgroups	B-C1515021
with	O
different	O
outcomes	B-C0085415
could	O
help	O
guide	O
clinical	B-C4042877
decision	I-C4042877
making	I-C4042877
.	O
	
in	O
this	O
study	B-C0008972
,	O
we	O
used	O
two	O
opposing	O
groups	B-C0441833
of	O
genes	B-C0017337
,	O
yin	B-C0017337
and	I-C0017337
yang	I-C0017337
,	O
to	O
develop	O
a	O
prognostic	B-C1511294
expression	B-C0017262
ratio	B-C0456603
signature	B-C1708225
.	O
	
using	O
the	O
metabric	B-C0242356
cohort	B-C0086027
we	O
identified	O
a16-	O
gene	B-C1708225
signature	I-C1708225
capable	O
of	O
stratifying	B-C0205363
breast	B-C0006142
cancer	I-C0006142
patients	B-C0030705
into	O
four	O
risk	B-C3166291
levels	I-C3166291
with	O
intention	O
that	O
low-risk	B-C3538919
patients	B-C0030705
would	O
not	O
undergo	O
adjuvant	B-C1522673
systemic	B-C1515119
therapy	I-C1515119
,	O
intermediate	B-C0205103
-	O
low-risk	B-C3538919
patients	B-C0030705
will	O
be	O
treated	B-C0332293
with	I-C0332293
hormonal	B-C0279025
therapy	I-C0279025
only	O
,	O
and	O
intermediate	B-C0205103
-high-	O
and	O
high-risk	B-C0684030
groups	I-C0684030
will	O
be	O
treated	B-C0332293
by	O
chemotherapy	B-C3665472
in	O
addition	O
to	O
the	O
hormonal	B-C0279025
therapy	I-C0279025
.	O
	
the	O
16-	O
gene	B-C1708225
signature	I-C1708225
for	O
four	O
risk	B-C3166291
level	I-C3166291
stratifications	B-C0008902
of	O
breast	B-C0006142
cancer	I-C0006142
patients	B-C0030705
has	O
been	O
validated	B-C1519941
using	O
14	O
independent	O
datasets	B-C0150098
.	O
	
notably	O
,	O
the	O
low-risk	B-C3538919
group	B-C1257890
n	O
=	O
51	O
of	O
205	O
estrogen	B-C2938924
receptor-positive	I-C2938924
and	O
node	B-C3160889
negative	I-C3160889
er+	B-C2938924
/	O
node-	B-C3160889
patients	B-C0030705
from	O
three	O
different	O
datasets	B-C0150098
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	B-C0677850
therapy	I-C0677850
had	O
100%	O
15-	O
year	B-C0439234
disease-specific	B-C2986538
survival	I-C2986538
rate	I-C2986538
.	O
	
the	O
concordance	B-C0918012
index	I-C0918012
of	O
ymr	B-C2698560
for	O
er+	B-C2938924
/	O
node	B-C3160889
negative	I-C3160889
patients	B-C0030705
is	O
close	O
to	O
the	O
commercially	B-C0680536
available	O
signatures	B-C1708225
.	O
	
however	O
,	O
ymr	B-C2698560
showed	O
more	O
significance	B-C0750502
hr	B-C2985465
=	O
3.7	O
,	O
p	O
=	O
8.7e	O
in	O
stratifying	B-C0205363
er+	B-C2938924
/	O
node-	B-C3160889
subgroup	B-C1515021
than	O
oncotypedx	B-C2698560
hr	B-C2985465
=	O
2.7	O
,	O
p	O
=	O
1.3e	O
,	O
mammaprint	B-C2827401
hr	B-C2985465
=	O
2.5	O
,	O
p	O
=	O
5.8e	O
,	O
rors	B-C2698560
hr	B-C2985465
=	O
2.4	O
,	O
p	O
=	O
1.4e	O
,	O
and	O
npi	B-C2698560
hr	B-C2985465
=	O
2.6	O
,	O
p	O
=	O
1.2e	O
.	O
	
ymr	B-C2698560
signature	B-C1708225
may	O
be	O
developed	O
as	O
a	O
clinical	B-C0205210
tool	B-C0037589
to	O
select	O
a	O
subgroup	B-C1515021
of	O
low-risk	B-C3538919
er+	B-C2938924
/	O
node-	B-C3160889
patients	B-C0030705
who	O
do	O
not	O
require	O
any	O
adjuvant	B-C1522673
hormonal	B-C0279025
therapy	I-C0279025
aht	B-C0279025
.	O
	
risk	B-C0035648
factors	I-C0035648
associated	B-C0332281
with	I-C0332281
repeated	B-C0205341
hiv	B-C0459958
testing	I-C0459958
among	O
internet	B-C0282111
-using	O
men	B-C2827413
who	I-C2827413
have	I-C2827413
sex	I-C2827413
with	I-C2827413
men	I-C2827413
men	B-C2827413
who	I-C2827413
have	I-C2827413
sex	I-C2827413
with	I-C2827413
men	I-C2827413
msm	B-C2827413
represent	B-C1882932
a	O
disproportionately	B-C0205350
impacted	B-C0333125
risk	B-C0684030
group	I-C0684030
for	O
hiv	B-C0019682
incidence	B-C0021149
among	O
at-risk	B-C1444641
u.s	B-C0041703
.	O
	
few	O
studies	B-C2603343
have	O
identified	B-C0205396
risk	B-C0035648
factors	I-C0035648
associated	B-C0332281
with	I-C0332281
hiv	B-C0459958
testing	I-C0459958
frequency	B-C0871396
both	O
within	B-C0332285
and	O
outside	B-C0205101
of	O
traditional	O
health	B-C0086388
care	I-C0086388
settings	I-C0086388
.	O
	
msm	B-C2827413
enrolled	O
in	O
a	O
prospective	B-C1709709
cohort	I-C1709709
were	O
mailed	B-C0024492
at-home	B-C0025080
specimen	I-C0025080
collection	I-C0025080
kits	I-C0025080
and	O
followed	B-C1254367
for	O
a	O
year	B-C0439234
.	O
	
incidence	B-C0456603
density	I-C0456603
rate	I-C0456603
ratios	I-C0456603
idrr	B-C0456603
of	O
testing	B-C0039593
were	O
calculated	B-C1441506
,	O
and	O
generalized	B-C0205246
estimating	B-C0750572
equations	B-C0552449
were	O
used	O
to	O
analyze	O
the	O
association	B-C0439849
between	O
hiv	B-C0459958
testing	I-C0459958
and	O
behavioral	B-C0004927
factors	B-C1521761
.	O
	
the	O
incidence	B-C1708485
rate	I-C1708485
of	O
testing	B-C0039593
was	O
higher	B-C0205250
among	O
black	B-C0005680
msm	B-C2827413
than	O
white	B-C0007457
msm	B-C2827413
idrr	B-C0456603
1.3	O
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
1.1	O
,	O
1.5	O
and	O
higher	B-C0205250
among	O
msm	B-C2827413
who	O
reported	O
3+	O
condomless	B-C0848723
anal	O
intercourse	O
partners	O
cai	O
than	O
msm	O
who	O
reported	O
no	O
cai	O
idrr	O
1.6	O
,	O
95%	O
ci	O
1.3	O
,	O
2.0	O
.	O
	
increasing	O
availability	O
of	O
hiv	O
testing	O
outside	O
traditional	O
health	O
care	O
settings	O
,	O
including	O
at-home	O
testing	O
kits	O
,	O
in	O
conjunction	O
with	O
targeted	O
behavioral	O
interventions	O
and	O
biomedical	O
treatment	O
preventions	O
is	O
nursingstandard.com	B-C2349146
1	O
nurse	B-C0028661
donna	O
wood	O
has	O
been	O
suspended	B-C1705537
for	O
2	O
months	B-C0439231
by	O
the	O
nursing	B-C0033282
and	I-C0033282
midwifery	I-C0033282
council	I-C0033282
nmc	B-C0033282
for	O
concealing	B-C0443189
the	O
high	B-C0015967
temperature	I-C0015967
of	O
colleague	B-C0028661
pauline	O
cafferkey	O
,	O
who	O
later	O
developed	O
ebola	B-C0282687
.	O
	
read	O
more	O
theory	B-C0935573
of	I-C0935573
mind	I-C0935573
in	O
adolescents	B-C0205653
with	O
bipolar	B-C0005586
disorder	I-C0005586
in	O
euthymic	B-C0233475
phase	I-C0233475
using	O
the	O
strange	B-C0282574
stories	I-C0282574
test	I-C0282574
objective	O
this	O
study	O
evaluated	B-C0220825
the	O
theory	B-C0935573
of	I-C0935573
mind	I-C0935573
tom	B-C0935573
in	O
adolescents	B-C0205653
diagnosed	B-C0011900
with	O
bipolar	B-C0005586
disorder	I-C0005586
bd	B-C0005586
during	O
their	O
euthymic	B-C0233475
period	I-C0233475
compared	O
to	O
a	O
typically	B-C0441833
developing	I-C0441833
td	I-C0441833
group	I-C0441833
method	O
the	O
bd	B-C0005586
group	B-C0441833
consisted	O
of	O
thirty	O
11-18	O
year	O
old	O
inpatients	B-C0021562
in	O
euthymic	B-C0233475
phase	I-C0233475
.	O
	
the	O
td	B-C0441833
group	I-C0441833
included	O
30	O
age	B-C0001779
,	O
gender	B-C0079399
,	O
and	O
iq	B-C0456149
matched	O
volunteer	O
students	B-C0038492
.	O
	
to	O
assess	O
the	O
diagnosis	B-C0011900
and	O
comorbid	B-C0012634
disorders	I-C0012634
,	O
we	O
performed	O
the	O
semi-structured	B-C0681913
interview	I-C0681913
of	O
the	O
kiddie	B-C0681913
schedule	I-C0681913
for	I-C0681913
affective	I-C0681913
disorders	I-C0681913
and	I-C0681913
schizophrenia-present	I-C0681913
and	I-C0681913
lifetime	I-C0681913
version	I-C0681913
k-sads-pl	B-C0681913
for	O
the	O
bd	B-C0005586
adolescents	B-C0205653
.	O
	
to	O
evaluate	B-C0220825
the	O
severity	O
of	O
attention	B-C1263846
deficit	I-C1263846
hyperactivity	I-C1263846
disorder	I-C1263846
adhd	B-C1263846
and	O
mania	B-C0338831
,	O
conner's	B-C0681889
parent	I-C0681889
rating	I-C0681889
scale-revised	I-C0681889
version	I-C0681889
cprs-r	I-C0681889
,	O
and	O
young	B-C4087288
mania	I-C4087288
rating	I-C4087288
scale	I-C4087288
ymrs	B-C4087288
were	O
used	O
,	O
respectively	O
.	O
	
ravens	B-C0451407
progressive	I-C0451407
matrices	I-C0451407
was	O
conducted	O
to	O
evaluate	B-C0220825
intellectual	B-C0423898
ability	I-C0423898
in	O
the	O
both	O
groups	B-C0441833
.	O
	
happe	B-C0282574
strange	I-C0282574
stories	I-C0282574
test	I-C0282574
was	O
performed	O
to	O
assess	O
tom	B-C0935573
in	O
the	O
participants	B-C0679646
.	O
	
data	B-C1511726
were	O
analyzed	O
using	O
the	O
independent	O
t-test	B-C0871472
,	O
analysis	B-C0814908
of	I-C0814908
covariance	I-C0814908
,	O
and	O
pearson	B-C0010101
correlation	I-C0010101
analysis	I-C0010101
results	O
the	O
two	O
groups	B-C0441833
did	O
not	O
show	O
any	O
differences	O
in	O
comprehending	O
the	O
stories	O
however	O
,	O
the	O
bd	B-C0005586
group's	B-C0441833
mentalizing	B-C2959458
scores	I-C2959458
were	O
significantly	O
weaker	O
than	O
the	O
td	B-C0441833
group	I-C0441833
p<0	O
conclusion	O
the	O
tom	B-C0935573
impairments	B-C0221099
in	O
adolescents	B-C0205653
with	O
bd	B-C0005586
may	O
be	O
explained	O
as	O
a	O
trait	B-C0017393
marker	I-C0017393
which	O
may	O
lead	O
to	O
continuation	O
of	O
social	B-C0037431
problems	I-C0037431
even	O
during	O
remission	B-C0597370
structural	O
and	O
functional	O
characterization	O
of	O
the	O
tyw3	B-C0033684
/	O
taw3	B-C0033684
class	O
of	O
sam-dependent	B-C0969403
methyltransferases	I-C0969403
s-adenosylmethionine	B-C0969403
sam	I-C0969403
methyltransferases	I-C0969403
regulate	B-C1327622
a	O
wide	O
range	O
of	O
biological	B-C3714634
processes	I-C3714634
through	O
the	O
modification	B-C2752381
of	O
proteins	B-C0033684
,	O
nucleic	B-C0028606
acids	I-C0028606
,	O
polysaccharides	B-C0032594
,	O
as	O
well	O
as	O
various	O
metabolites	B-C0870883
.	O
	
tyw3	B-C0033684
/	O
taw3	B-C0033684
is	O
a	O
sam-dependent	B-C0969403
methyltransferase	I-C0969403
responsible	O
for	O
the	O
formation	O
of	O
a	O
trna	B-C1158758
modification	I-C1158758
known	O
as	O
wybutosine	B-C1171957
and	O
its	O
derivatives	O
that	O
are	O
required	O
for	O
accurate	O
decoding	B-C1519614
in	O
protein	B-C0597295
synthesis	I-C0597295
.	O
	
here	O
,	O
we	O
report	O
the	O
crystal	B-C0230587
structure	I-C0230587
of	O
taw3	B-C0033684
,	O
a	O
homolog	O
of	O
tyw3	B-C0033684
from	O
sulfolobus	B-C0995927
solfataricus	I-C0995927
,	O
which	O
revealed	O
a	O
novel	O
α/β	B-C0162847
fold	I-C0162847
.	O
	
the	O
sequence	O
motif	O
s/t	B-C0002518
and	O
invariant	O
aspartate	B-C0085845
and	O
histidine	B-C0019602
,	O
conserved	O
in	O
tyw3	B-C0033684
/	O
taw3	B-C0033684
,	O
cluster	B-C1704332
to	O
form	O
the	O
catalytic	B-C0175921
center	O
.	O
	
these	O
structural	B-C1510464
and	O
sequence	B-C0002518
features	O
indicate	O
that	O
tyw3	B-C0033684
/	O
taw3	B-C0033684
proteins	O
constitute	O
a	O
distinct	O
class	O
of	O
sam-dependent	B-C0969403
methyltransferases	I-C0969403
.	O
	
using	O
site-directed	B-C0079870
mutagenesis	I-C0079870
along	O
with	O
in	B-C0017381
vivo	I-C0017381
complementation	I-C0017381
assays	I-C0017381
combined	O
with	O
mass	B-C0037813
spectrometry	I-C0037813
as	O
well	O
as	O
ligand	B-C1522290
docking	I-C1522290
and	O
cofactor	B-C1323251
binding	I-C1323251
assays	B-C1510438
,	O
we	O
have	O
identified	O
the	O
active	B-C0205681
site	I-C0205681
of	O
tyw3	B-C0033684
and	O
residues	O
essential	O
for	O
cofactor	B-C1323251
binding	I-C1323251
and	O
methyltransferase	B-C1152247
activity	I-C1152247
.	O
	
developmental	B-C0458003
profile	B-C1979963
and	O
diagnoses	B-C1704656
in	O
children	B-C0008059
presenting	O
with	O
motor	B-C3898226
stereotypies	I-C3898226
motor	B-C3898226
stereotypies	I-C3898226
represent	O
a	O
typical	O
example	O
of	O
the	O
difficulty	B-C0332218
in	O
distinguishing	O
non-clinical	B-C0004927
behaviors	I-C0004927
physiological	B-C0031843
and	O
transient	B-C0205374
from	O
symptoms	B-C1457887
or	O
among	O
different	O
disorders	B-C0012634
""""	O
primary	B-C4302136
stereotypies	I-C4302136
""""	O
associated	B-C0332281
with	I-C0332281
autistic	B-C1510586
spectrum	I-C1510586
disorder	I-C1510586
asd	B-C1510586
,	O
intellectual	B-C3714756
disabilities	I-C3714756
,	O
genetic	B-C0567439
syndromes	I-C0567439
,	O
and	O
sensory	B-C4062750
impairment	I-C4062750
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
obtain	B-C1301820
an	O
accurate	O
assessment	B-C0220825
on	O
the	O
relationship	B-C0439849
between	O
stereotypies	B-C0038273
and	O
neurodevelopmental	B-C1535926
disorders	I-C1535926
.	O
	
we	O
studied	B-C2603343
23	O
children	B-C0008059
3	O
girls	B-C0870604
,	O
aged	B-C0001779
36-95	O
months	B-C0439231
,	O
who	O
requested	O
a	O
consultation	B-C0009818
due	O
to	O
the	O
persistence	B-C0518691
or	O
increased	B-C0205217
severity	B-C0392364
of	O
motor	B-C3898226
stereotypies	I-C3898226
.	O
	
none	O
of	O
the	O
patients	B-C0030705
had	O
a	O
previous	O
diagnosis	B-C1704656
of	O
asd	B-C1510586
.	O
	
the	O
assessment	B-C0220825
included	O
the	O
motor	B-C0349674
severity	I-C0349674
stereotypy	I-C0349674
scale	I-C0349674
msss	B-C0349674
,	O
the	O
repetitive	B-C0475483
behavior	I-C0475483
scale-revised	I-C0475483
rbs-r	B-C0475483
,	O
the	O
raven's	B-C4305179
colored	I-C4305179
progressive	I-C4305179
matrices	I-C4305179
,	O
the	O
child	B-C0870266
behavior	I-C0870266
checklist	I-C0870266
for	O
ages	B-C0001779
1½-5	O
or	O
4-18	O
cbcl	B-C0870266
,	O
the	O
social	B-C0349674
responsiveness	I-C0349674
scale	I-C0349674
srs	B-C0349674
,	O
and	O
the	O
autism	B-C0282574
diagnostic	I-C0282574
observation	I-C0282574
schedule-second	I-C0282574
edition	I-C0282574
ados	B-C0282574
2	I-C0282574
.	O
	
all	O
patients	B-C0030705
were	O
showing	O
motor	B-C3898226
stereotypies	I-C3898226
for	O
periods	B-C1948053
of	I-C1948053
time	I-C1948053
varying	O
from	O
6	O
to	O
77	O
months	B-C0439231
.	O
	
the	O
msss	B-C0349674
showed	O
that	O
each	O
child	B-C0870604
had	O
a	O
limited	B-C0439801
number	B-C0237753
of	O
stereotypies	B-C0038273
their	O
frequency	B-C0871396
and	O
intensity	B-C0522510
were	O
mild	B-C2945599
.	O
	
the	O
interference	B-C0521102
of	O
stereotypies	B-C0038273
was	O
variable	B-C0439828
the	O
impairment	B-C0221099
in	O
daily	O
life	B-C0376558
was	O
mild	B-C2945599
.	O
	
the	O
rbs-r	B-C0475483
scores	B-C0449820
were	O
positive	O
for	O
the	O
subscale	O
of	O
""""	O
stereotypic	B-C0038271
behaviors	I-C0038271
""""	O
in	O
all	O
children	B-C0008059
.	O
	
moreover	O
,	O
several	O
children	B-C0008059
presented	O
other	O
repetitive	B-C1827547
behaviors	I-C1827547
,	O
mainly	O
""""	O
ritualistic	B-C2266670
behavior	I-C2266670
""""	O
and	O
""""	O
sameness	B-C1827547
behavior	I-C1827547
""""	O
all	O
patients	B-C0030705
showed	O
a	O
normal	B-C4231661
cognitive	I-C4231661
level	I-C4231661
.	O
	
the	O
cbcl	B-C0870266
evidenced	B-C3887511
behavioral	B-C0233514
problems	I-C0233514
in	O
22%	O
of	O
the	O
children	B-C0008059
internalizing	B-C1457887
problems	I-C1457887
,	O
attention	B-C0004268
,	O
and	O
withdrawn	B-C2825032
were	O
the	O
main	O
complaints	O
.	O
	
on	O
the	O
srs	B-C0349674
,	O
all	O
but	O
one	O
of	O
the	O
tested	B-C0039593
patients	B-C0030705
obtained	B-C1301820
clinical	B-C3533165
scores	I-C3533165
in	O
the	O
clinical	B-C0205210
range	B-C1514721
for	O
at	O
least	O
one	O
area	O
.	O
	
on	O
the	O
ados	B-C0282574
2	I-C0282574
,	O
4	O
patients	B-C0030705
obtained	B-C1301820
scores	B-C0449820
indicating	O
a	O
moderate	B-C0205081
level	B-C0441889
of	O
asd	B-C1510586
symptoms	B-C1457887
,	O
4	O
had	O
a	O
mild	B-C2945599
level	B-C0441889
,	O
and	O
15	O
showed	O
no	O
or	O
minimal	O
signs	B-C0037088
of	O
asd	B-C1510586
.	O
	
motor	B-C3898226
stereotypies	I-C3898226
in	O
children	B-C0008059
with	O
normal	B-C4231661
cognitive	I-C4231661
level	I-C4231661
represent	O
a	O
challenging	O
diagnostic	B-C0348026
issue	B-C0033213
for	O
which	O
a	O
finely	O
tailored	B-C0870097
assessment	B-C0220825
is	O
mandatory	O
in	O
order	O
to	O
define	O
a	O
precise	O
developmental	B-C0458003
profile	B-C2003903
.	O
	
thus	O
,	O
careful	O
and	O
cautious	O
use	O
of	O
standardized	B-C0237892
tests	I-C0237892
is	O
warranted	O
to	O
avoid	O
misdiagnosis	B-C0679838
.	O
	
furthermore	O
,	O
it	O
is	O
hard	O
to	O
consider	O
motor	B-C3898226
stereotypies	I-C3898226
,	O
even	O
the	O
primary	O
ones	O
,	O
exclusively	O
as	O
a	O
movement	B-C0026650
disorder	I-C0026650
.	O
	
left	B-C0225897
ventricular	I-C0225897
rotational	B-C0445237
mechanics	B-C0376706
in	O
infants	B-C0021270
with	O
hypoxic	B-C0752304
ischemic	I-C0752304
encephalopathy	I-C0752304
and	O
preterm	B-C4048294
infants	I-C4048294
at	O
36	O
weeks	B-C0439230
postmenstrual	B-C3828508
age	I-C3828508
a	O
comparison	B-C1707455
with	O
healthy	B-C3898900
term	B-C0009932
controls	I-C0009932
there	O
is	O
a	O
paucity	O
of	O
data	B-C1511726
on	O
left	B-C0225897
ventricle	I-C0225897
lv	B-C0225897
rotational	B-C0031842
physiology	I-C0031842
in	O
neonates	B-C0021289
.	O
	
we	O
aimed	O
to	O
assess	O
rotational	B-C0445237
mechanics	B-C0376706
in	O
infants	B-C0021270
with	O
hypoxic	B-C0752304
ischemic	I-C0752304
encephalopathy	I-C0752304
hie	B-C0752304
and	O
premature	B-C4048294
infants	I-C4048294
<32	O
weeks	B-C0439230
at	O
36	O
weeks	B-C0439230
postmenstrual	B-C3828508
age	I-C3828508
pma	B-C3828508
preterm	B-C1257890
group	I-C1257890
and	O
compare	B-C1707455
them	O
with	O
healthy	B-C3898900
term	B-C0009932
controls	I-C0009932
term	B-C0009932
controls	I-C0009932
.	O
	
we	O
also	O
compared	B-C1707455
the	O
parameters	B-C0549193
in	O
preterm	B-C4048294
infants	I-C4048294
with	O
and	O
without	O
chronic	B-C0746102
lung	I-C0746102
disease	I-C0746102
cld	B-C0746102
.	O
	
echocardiography	B-C0013516
was	O
performed	O
within	O
48	O
hours	B-C0439227
of	O
birth	B-C0005615
or	O
at	O
36	O
weeks	B-C0439230
pma	B-C3828508
.	O
	
lv	B-C0225897
basal	B-C0205112
and	O
apical	O
rotation	B-C0035868
,	O
twist	B-C0231467
and	O
torsion	O
=	O
twist	B-C0231467
/	O
lv	B-C1444754
length	I-C1444754
,	O
twist	B-C1521828
rate	I-C1521828
lvtr	B-C1521828
,	O
and	O
untwist	B-C1521828
rate	I-C1521828
lvutr	B-C1521828
were	O
measured	O
.	O
	
one-way	B-C1709320
anova	I-C1709320
was	O
used	O
to	O
compare	B-C1707455
values	B-C0042295
.	O
	
there	O
was	O
no	O
difference	O
in	O
gestation	B-C0032961
40.0	O
39.1	O
vs	O
39.9	O
39.0	O
,	O
p>	O
or	O
birthweight	B-C0005612
3.7	O
3.4	O
vs	O
3.5	O
3.2	O
,	O
p>	O
between	O
the	O
hie	B-C0752304
group	B-C1257890
n=16	O
and	O
term	B-C0009932
controls	I-C0009932
n=30	O
.	O
	
the	O
preterm	B-C1257890
group	I-C1257890
n=35	O
had	O
a	O
gestation	B-C0032961
and	O
weight	B-C0043100
of	O
36.0	O
34.6	O
weeks	B-C0439230
and	O
2.3	O
2.0	O
kg	O
.	O
	
the	O
hie	B-C0752304
group	O
had	O
lower	O
twist	B-C0231467
,	O
torsion	O
,	O
lvtr	B-C1521828
,	O
and	O
lvutr	B-C1521828
than	O
the	O
other	O
two	O
groups	O
.	O
	
the	O
preterm	B-C1257890
group	I-C1257890
had	O
a	O
more	O
negative	O
clockwise	B-C3831073
basal	B-C0205112
rotation	B-C0035868
while	O
the	O
term	B-C1257890
group	I-C1257890
had	O
a	O
more	O
positive	O
counterclockwise	B-C3830994
apical	B-C0205111
rotation	B-C0035868
.	O
	
preterm	B-C4048294
infants	I-C4048294
with	O
cld	B-C0746102
had	O
higher	O
apical	B-C0205111
rotation	B-C0035868
,	O
twist	B-C0231467
,	O
and	O
torsion	O
when	O
compared	B-C1707455
to	O
infants	B-C0021270
without	O
cld	B-C0746102
.	O
	
infants	B-C0021270
with	O
hie	B-C0752304
have	O
reduced	O
rotational	B-C0445237
mechanics	B-C0376706
.	O
	
preterm	B-C4048294
infants	I-C4048294
at	O
36	O
weeks	B-C0439230
pma	B-C3828508
have	O
comparable	B-C1707455
measurements	B-C0242485
of	O
twist	B-C0231467
to	O
term	B-C0456128
infants	I-C0456128
.	O
	
this	O
is	O
achieved	O
by	O
predominant	O
basal	B-C0205112
rather	O
than	O
apical	O
rotation	O
.	O
	
infants	O
with	O
cld	O
have	O
increased	O
apical	O
rotation	B-C0035868
comparing	B-C1707455
the	O
effects	B-C1704420
of	I-C1704420
different	B-C1705242
dynamic	B-C0454281
sitting	I-C0454281
strategies	I-C0454281
in	O
wheelchair	B-C0438917
seating	I-C0438917
on	O
lumbar-pelvic	B-C0024090
angle	I-C0024090
prolonged	B-C0439590
static	B-C4270719
sitting	I-C4270719
in	O
a	O
wheelchair	B-C0043143
is	O
associated	B-C0332281
with	I-C0332281
an	O
increased	B-C0205217
risk	B-C0035647
of	O
lower	B-C0024031
back	I-C0024031
pain	I-C0024031
.	O
	
the	O
wheelchair	B-C0438917
seating	I-C0438917
system	I-C0438917
is	O
a	O
key	B-C1521761
factor	I-C1521761
of	O
this	O
risk	B-C0035647
because	O
it	O
affects	O
spinal	B-C0521329
loading	B-C0205245
in	O
the	O
sitting	B-C0277814
position	I-C0277814
.	O
	
in	O
this	O
study	B-C2603343
,	O
7	O
dynamic	B-C0454281
sitting	I-C0454281
strategies	I-C0454281
dsss	B-C0454281
are	O
examined	B-C0332128
lumbar	B-C0454281
prominent	I-C0454281
dynamic	I-C0454281
sitting	I-C0454281
lpds	B-C0454281
,	O
back	B-C0454281
reclined	I-C0454281
dynamic	I-C0454281
sitting	I-C0454281
brds	B-C0454281
,	O
femur	B-C0454281
upward	I-C0454281
dynamic	I-C0454281
sitting	I-C0454281
fuds	B-C0454281
,	O
lumbar	B-C0454281
prominent	I-C0454281
with	I-C0454281
back	I-C0454281
reclined	I-C0454281
dynamic	I-C0454281
sitting	I-C0454281
lbds	B-C0454281
,	O
lumbar	B-C0454281
prominent	I-C0454281
with	I-C0454281
femur	I-C0454281
upward	I-C0454281
dynamic	I-C0454281
sitting	I-C0454281
lfds	B-C0454281
,	O
back	B-C0454281
reclined	I-C0454281
with	I-C0454281
femur	I-C0454281
upward	I-C0454281
dynamic	I-C0454281
sitting	I-C0454281
bfds	B-C0454281
,	O
and	O
lumbar	B-C0454281
prominent	I-C0454281
with	I-C0454281
back	I-C0454281
reclined	I-C0454281
with	I-C0454281
femur	I-C0454281
upward	I-C0454281
dynamic	I-C0454281
sitting	I-C0454281
lbfds	B-C0454281
.	O
	
the	O
objective	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
analyze	B-C0936012
the	O
biomechanical	B-C3658372
effects	B-C1704420
of	I-C1704420
these	O
sitting	B-C0454281
strategies	I-C0454281
on	O
lumbar-pelvic	B-C0024090
angles	I-C0024090
.	O
	
twenty	O
able-bodied	B-C0424576
participants	B-C0679646
were	O
recruited	B-C0205245
for	O
the	O
study	B-C2603343
.	O
	
all	O
participants	B-C0679646
performed	B-C0884358
lpds	B-C0454281
,	O
brds	B-C0454281
,	O
fuds	B-C0454281
,	O
lbds	B-C0454281
,	O
lfds	B-C0454281
,	O
bfds	B-C0454281
,	O
and	O
lbfds	B-C0454281
in	O
a	O
random	B-C0439605
order	B-C1705176
.	O
	
all	O
lumbar-pelvic	B-C0024090
angle	I-C0024090
parameters	B-C0549193
,	O
including	O
the	O
static	B-C0441463
lumbar	B-C0024090
angle	I-C0024090
,	O
static	B-C0441463
pelvic	B-C0030797
angle	I-C0030797
,	O
lumbar	B-C0575375
range	I-C0575375
of	I-C0575375
motion	I-C0575375
,	O
and	O
pelvic	B-C0243095
range	I-C0243095
of	I-C0243095
motion	I-C0243095
were	O
measured	B-C0444706
and	O
compared	B-C1707455
.	O
	
results	B-C1274040
show	O
that	O
lbds	B-C0454281
and	O
lbfds	B-C0454281
enabled	B-C1171285
the	O
most	O
beneficial	B-C0205556
lumbar	B-C1286136
movements	I-C1286136
,	O
although	O
the	O
difference	B-C1705242
between	O
the	O
2	O
strategies	B-C0679199
was	O
nonsignificant	B-C1273937
.	O
	
brds	B-C0454281
and	O
bfds	B-C0454281
enabled	B-C1171285
the	O
most	O
beneficial	B-C0205556
pelvic	B-C0454470
movements	I-C0454470
,	O
although	O
the	O
difference	B-C1705242
between	O
the	O
2	O
strategies	B-C0679199
was	O
nonsignificant	B-C1273937
.	O
	
among	O
all	O
the	O
upright	O
dsss	B-C0454281
,	O
lpds	B-C0454281
and	O
lfds	B-C0454281
enabled	B-C1171285
the	O
most	O
beneficial	B-C0205556
lumbar	B-C1286136
and	O
pelvic	B-C0454470
movements	I-C0454470
,	O
although	O
no	B-C1273937
significant	I-C1273937
difference	B-C1705242
was	O
observed	B-C1441672
between	O
these	O
2	O
strategies	B-C0679199
.	O
	
we	O
identified	B-C0205396
the	O
effects	B-C1280500
and	O
differences	B-C1705242
among	O
7	O
dsss	B-C0454281
on	O
lumbar-pelvic	B-C0024090
angles	I-C0024090
.	O
	
wheelchair	B-C0853966
users	I-C0853966
can	O
choose	B-C1707391
the	O
most	O
suitable	B-C3900053
dss	B-C0454281
that	O
meets	B-C1550543
their	O
needs	B-C0027552
.	O
	
these	O
findings	B-C0243095
may	O
serve	O
as	O
a	O
reference	B-C1706462
for	O
practicing	B-C0017319
physicians	I-C0017319
or	O
wheelchair	B-C0853966
users	I-C0853966
to	O
choose	B-C1707391
an	O
appropriate	B-C1548787
dynamic	O
wheelchair	B-C0438917
seating	I-C0438917
source	O
apportionment	O
and	O
heavy	B-C0347988
metal	I-C0347988
health	B-C0679809
risk	I-C0679809
hmhr	B-C0679809
quantification	B-C1709793
from	O
sources	B-C0449416
in	O
a	O
southern	B-C1710133
city	B-C0008848
in	O
china	B-C0008115
,	O
using	O
an	O
me2	B-C0037585
-	O
hmhr	B-C0679809
model	B-C0596657
heavy	B-C0347988
metals	I-C0347988
cr	B-C0008574
,	O
co	B-C0009148
,	O
ni	B-C0028013
,	O
as	B-C0003818
,	O
cd	B-C0006632
,	O
and	O
pb	B-C0023175
can	O
be	O
bound	O
to	O
pm	B-C1720884
adversely	B-C0879626
affecting	I-C0879626
human	B-C0086418
health	B-C0018684
.	O
	
quantifying	O
the	O
source	B-C0449416
impacts	O
on	O
heavy	B-C0347988
metals	I-C0347988
can	O
provide	O
source	B-C0449416
-	O
specific	B-C0205369
estimates	O
of	O
the	O
heavy	B-C0347988
metal	I-C0347988
health	B-C0679809
risk	I-C0679809
hmhr	B-C0679809
to	O
guide	O
effective	B-C1704419
development	O
of	O
strategies	O
to	O
reduce	O
such	O
risks	B-C0035647
from	O
exposure	B-C0332157
to	I-C0332157
heavy	B-C0347988
metals	I-C0347988
in	O
pm2.5	B-C1720884
particulate	B-C1720884
matter	I-C1720884
pm	B-C1720884
with	O
aerodynamic	B-C1301886
diameter	I-C1301886
less	O
than	O
or	O
equal	O
to	O
2.5	O
μm	O
.	O
	
in	O
this	O
study	O
,	O
a	O
method	O
combining	O
multilinear	B-C0037585
engine	I-C0037585
2	I-C0037585
me2	B-C0037585
and	O
a	O
risk	B-C0086930
assessment	I-C0086930
model	B-C0596657
is	O
developed	O
to	O
more	O
effectively	O
quantify	B-C1709793
source	B-C0449416
contributions	B-C1880177
to	O
hmhr	B-C0679809
,	O
including	O
heavy	B-C0347988
metal	I-C0347988
non-cancer	B-C1513916
risk	I-C1513916
non-hmcr	B-C1513916
and	O
cancer	B-C0596244
risk	I-C0596244
hmcr	B-C0596244
.	O
	
the	O
combined	O
model	B-C0596657
called	O
me2-hmhr	B-C0596657
has	O
two	O
steps	O
step1	O
,	O
source	B-C0449416
contributions	B-C1880177
to	O
heavy	B-C0347988
metals	I-C0347988
are	O
estimated	O
by	O
employing	O
the	O
me2	B-C0037585
model	B-C0596657
step2	O
,	O
the	O
source	B-C0449416
contributions	B-C1880177
in	O
step	O
1	O
are	O
introduced	O
into	O
the	O
risk	B-C0086930
assessment	I-C0086930
model	B-C0596657
to	O
calculate	O
the	O
source	B-C0449416
contributions	B-C1880177
to	O
hmhr	B-C0679809
.	O
	
the	O
approach	O
was	O
applied	O
to	O
huzou	B-C0008115
,	O
china	B-C0008115
and	O
five	O
significant	O
sources	B-C0449416
were	O
identified	O
.	O
	
soil	B-C0037592
dust	B-C0013330
is	O
the	O
largest	O
source	B-C0449416
of	O
non-hmcr	B-C1513916
.	O
	
for	O
hmcr	B-C0596244
,	O
the	O
source	B-C0449416
contributions	B-C1880177
of	O
soil	B-C0037592
dust	B-C0013330
,	O
coal	B-C0009131
combustion	B-C0681531
,	O
cement	B-C2220339
dust	I-C2220339
,	O
vehicle	O
,	O
and	O
secondary	O
sources	O
are	O
1.0	O
10	O
,	O
3.7	O
10	O
,	O
2.7	O
10	O
,	O
1.6	O
10	O
and	O
1.9	O
10	O
,	O
respectively	O
.	O
	
the	O
soil	O
dust	B-C0013330
is	O
the	O
largest	O
contributor	O
to	O
hmcr	O
,	O
being	O
driven	O
by	O
the	O
high	O
impact	O
of	O
soil	O
dust	O
on	O
pm2.5	O
and	O
the	O
abundance	O
of	O
heavy	O
metals	O
in	O
soil	O
dust	B-C0013330
aspirin	B-C0004057
suppresses	B-C1260953
growth	B-C0018270
in	O
pi3k	B-C1335212
-	O
mutant	B-C0678941
breast	B-C0678222
cancer	I-C0678222
by	O
activating	B-C0599177
ampk	B-C2350345
and	O
inhibiting	B-C3463820
mtorc1	B-C2975458
signaling	O
despite	O
the	O
high	O
incidence	B-C0021149
of	O
oncogenic	B-C0029016
mutations	B-C0026882
in	O
pik3ca	B-C1335212
,	O
the	O
gene	B-C3839127
encoding	I-C3839127
the	O
catalytic	B-C0600499
subunit	I-C0600499
of	O
pi3k	B-C0044602
,	O
pi3k	B-C0044602
inhibitors	B-C0014432
have	O
yielded	O
little	O
clinical	B-C1333602
benefit	I-C1333602
for	O
breast	B-C0678222
cancer	I-C0678222
patients	B-C0030705
.	O
	
recent	B-C0332185
epidemiologic	B-C0002783
studies	I-C0002783
have	O
suggested	B-C1705535
a	O
therapeutic	B-C0302350
benefit	B-C0814225
from	O
aspirin	B-C0004057
intake	O
in	O
cancers	B-C0006826
harboring	O
oncogenic	B-C0044602
pik3ca	I-C0044602
here	O
,	O
we	O
show	O
that	O
mutant	B-C0678941
pik3ca	B-C0044602
-	O
expressing	B-C0017262
breast	B-C1512505
cancer	I-C1512505
cells	I-C1512505
have	O
greater	O
sensitivity	B-C0332324
to	O
aspirin	B-C0004057
-mediated	O
growth	B-C0007595
suppression	B-C0007613
than	O
their	O
wild-type	B-C1883559
counterparts	O
.	O
	
aspirin	B-C0004057
decreased	B-C0205216
viability	B-C0007620
and	O
anchorage-independent	B-C1515979
growth	I-C1515979
of	O
mutant	B-C0678941
pik3ca	B-C0044602
breast	B-C1512505
cancer	I-C1512505
cells	I-C1512505
independently	B-C1299583
of	O
its	O
effects	B-C1280500
on	O
cox-2	B-C0387583
and	O
nf-κb	B-C0079904
.	O
	
we	O
ascribed	O
the	O
effects	B-C1704420
of	I-C1704420
aspirin	B-C0004057
to	O
amp-activated	B-C2350345
protein	I-C2350345
kinase	I-C2350345
ampk	B-C2350345
activation	B-C0599177
,	O
mtorc1	B-C2975459
inhibition	B-C1519312
,	O
and	O
autophagy	B-C0004391
induction	O
.	O
	
in	O
vivo	O
,	O
oncogenic	B-C0029016
pik3ca	B-C0044602
-driven	O
mouse	B-C0025929
mammary	B-C1458155
tumors	I-C1458155
treated	B-C1522326
daily	O
with	O
aspirin	B-C0004057
resulted	O
in	O
decreased	B-C0205216
tumor	B-C0598934
growth	I-C0598934
kinetics	B-C0022702
,	O
whereas	O
combination	B-C0205195
therapy	B-C0087111
of	O
aspirin	B-C0004057
and	O
a	O
pi3k	B-C0044602
inhibitor	B-C1999216
further	O
attenuated	B-C0599946
tumor	B-C0598934
growth	I-C0598934
.	O
	
our	O
study	O
supports	O
the	O
evaluation	B-C0220825
of	O
aspirin	B-C0004057
and	O
pi3k	B-C0044602
pathway	O
inhibitors	B-C1254351
as	O
a	O
combination	B-C0205195
therapy	B-C0087111
for	O
targeting	B-C1521840
breast	B-C0678222
cancer	I-C0678222
.	O
	
prevalence	B-C0683919
of	O
psychiatric	B-C3841734
disorders	I-C3841734
among	O
female	B-C0086287
juvenile	B-C0022443
offenders	I-C0022443
inmates	B-C0033167
of	O
juvenile	B-C1708333
developmental	I-C1708333
centers	I-C1708333
are	O
the	O
special	B-C0205555
group	B-C1257890
of	O
youth	B-C0087178
population	B-C1257890
who	O
are	O
in	O
conflict	B-C0009671
with	O
law	B-C0728724
.	O
	
they	O
are	O
vulnerable	B-C0332324
to	O
psychiatric	B-C1404970
illness	I-C1404970
.	O
	
the	O
objective	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
see	O
the	O
prevalence	B-C0683919
and	O
type	B-C0332307
of	O
psychiatric	B-C3841734
disorders	I-C3841734
in	O
institutionalized	B-C0562359
female	B-C0086287
juvenile	B-C0022443
offenders	I-C0022443
and	O
non-offenders	B-C1257890
of	O
same	B-C0445247
age	B-C0001779
,	O
sex	B-C1522384
and	O
socioeconomic	B-C0086996
group	I-C0086996
in	O
the	O
community	B-C0009462
.	O
	
the	O
association	B-C0004083
of	O
mental	B-C0004936
disorders	I-C0004936
was	O
examined	B-C0332128
in	O
43	O
female	B-C0086287
inmates	B-C0033167
of	O
juvenile	B-C1708333
development	I-C1708333
centers	I-C1708333
and	O
43	O
randomly	B-C0439605
selected	B-C1707391
comparison	B-C1707455
subjects	B-C0681850
in	O
community	B-C0009462
.	O
	
one	B-C1254363
stage-structured	I-C1254363
assessment	I-C1254363
of	O
psychopathology	B-C0033927
was	O
carried	O
out	O
by	O
using	O
a	O
structured	B-C1300196
and	O
valid	B-C2349099
bangla	B-C0023008
version	B-C0333052
of	O
the	O
development	B-C1254363
and	I-C1254363
well-being	I-C1254363
assessment	I-C1254363
dawba	B-C1254363
.	O
	
development	B-C1254363
and	I-C1254363
well-being	I-C1254363
assessment	I-C1254363
generated	O
psychiatric	B-C0205487
diagnosis	B-C0011900
was	O
assigned	O
based	O
on	O
icd-10	B-C1137110
diagnostic	B-C0679228
criteria	I-C0679228
for	O
research	B-C0035168
.	O
	
the	O
result	B-C0683954
revealed	B-C0443289
that	O
,	O
of	O
those	O
who	O
were	O
in	O
conflict	B-C0009671
with	O
law	B-C0728724
,	O
93%	O
had	O
mental	B-C0004936
disorder	I-C0004936
,	O
whereas	O
14%	O
of	O
non-offenders	B-C1257890
had	O
psychiatric	B-C3841734
disorder	I-C3841734
.	O
	
among	O
the	O
offenders	B-C0699726
with	O
psychiatric	B-C3841734
disorders	I-C3841734
,	O
most	O
of	O
them	O
32.6	O
suffered	O
from	O
major	B-C1269683
depressive	I-C1269683
disorder	I-C1269683
mdd	B-C1269683
,	O
followed	O
by	O
combined	B-C0205195
mdd	B-C1269683
post	B-C0038436
traumatic	I-C0038436
stress	I-C0038436
disorder	I-C0038436
ptsd	B-C0038436
.	O
	
on	O
the	O
other	O
hand	O
,	O
among	O
the	O
non-offenders	B-C1257890
with	O
psychiatric	B-C3841734
disorder	I-C3841734
9.3	O
suffered	O
from	O
mdd	B-C1269683
.	O
	
it	O
can	O
be	O
concluded	B-C1707478
that	O
considerable	B-C4288581
psychiatric	B-C3841734
disorders	I-C3841734
are	O
prevalent	B-C0683919
among	O
the	O
female	B-C0086287
juvenile	B-C0022443
offenders	I-C0022443
with	O
comparison	B-C1707455
to	O
non-offenders	B-C1257890
.	O
	
broad	B-C0332464
-based	O
replication	B-C0681825
study	I-C0681825
could	O
confirm	B-C1456348
these	O
association	B-C0439849
between	O
neutrophil	B-C0027950
-to-	O
lymphocyte	B-C0024264
ratio	B-C0456603
and	O
differentiated	B-C1337013
thyroid	I-C1337013
cancer	I-C1337013
a	O
meta-analysis	B-C0920317
the	O
association	B-C0439849
between	O
neutrophil	B-C0027950
-to-	O
lymphocyte	B-C0024264
ratio	B-C0456603
nlr	B-C0456603
and	O
differentiated	B-C1337013
thyroid	I-C1337013
cancer	I-C1337013
dtc	B-C1337013
is	O
undecided	O
.	O
	
to	O
rectify	O
this	O
question	O
,	O
we	O
conducted	B-C0884358
a	O
systematic	B-C0220922
meta-analysis	B-C0920317
based	O
on	O
7	O
prospective	B-C0033522
cohort	I-C0033522
studies	I-C0033522
published	B-C1704324
between	O
2013	O
and	O
2015	O
,	O
comprising	O
7349	O
patients	B-C0030705
.	O
	
six	O
of	O
these	O
cohorts	B-C0599755
included	O
pretreatment	B-C3539076
baseline	B-C1442488
nlr	B-C0456603
data	B-C1511726
for	O
patients	B-C0030705
with	O
thyroid	B-C0040137
nodules	I-C0040137
.	O
	
the	O
meta-analysis	B-C0920317
of	O
these	O
6	O
cohorts	B-C0599755
showed	O
that	O
the	O
nlr	B-C0456603
of	O
patients	B-C0030705
with	O
dtc	B-C1337013
4617	O
cases	B-C1706256
was	O
statistically	B-C0237881
similar	O
to	O
patients	B-C0030705
with	O
benign	B-C0749467
nodules	I-C0749467
only	O
1666	O
cases	B-C1706256
,	O
with	O
a	O
mean	O
difference	O
md	O
of	O
0.19	O
95%	O
ci	B-C0009667
-0	O
to	O
0.46	O
i	O
=	O
93%	O
p	B-C1709380
<	O
0.001	O
.	O
	
no	O
significant	O
difference	O
in	O
nlr	B-C0456603
was	O
found	O
between	O
patients	B-C0030705
with	O
dtc	B-C1337013
and	O
patients	B-C0030705
with	O
benign	B-C0749467
nodules	I-C0749467
.	O
	
two	O
studies	B-C0947630
addressed	O
an	O
association	B-C0439849
between	O
nlr	B-C0456603
and	O
papillary	B-C0238463
thyroid	I-C0238463
carcinoma	I-C0238463
in	O
patients	B-C0030705
stratified	B-C0205363
by	O
age	B-C0001779
<45	O
and	O
45	O
years	B-C1510829
496	O
and	O
891	O
cases	B-C1706256
,	O
respectively	O
the	O
pooled	O
md	O
was	O
0.09	O
95%	O
ci	B-C0009667
-0	O
to	O
0.55	O
i	O
=	O
92.2	O
,	O
p	B-C1709380
<	O
0.001	O
.	O
	
an	O
elevated	B-C3163633
nlr	B-C0456603
seems	O
not	O
a	O
reliable	B-C3858758
indicator	B-C1522602
of	O
progressing	B-C0205329
dtc	B-C1337013
in	O
patients	B-C0030705
with	O
goiters	B-C0018021
,	O
and	O
there	O
was	O
no	O
difference	O
in	O
nlr	B-C0456603
between	O
patients	B-C0030705
aged	B-C0001779
<45	O
years	B-C1510829
and	O
those	O
aged	B-C0001779
45	O
years	B-C1510829
.	O
	
well-designed	O
and	O
large-scale	O
investigations	B-C0220825
are	O
warranted	O
to	O
understand	O
the	O
value	O
of	O
nlr	B-C0456603
in	O
the	O
prognosis	B-C0011900
of	O
transcriptomic	B-C3178810
insights	O
into	O
the	O
allelopathic	B-C3658358
effects	B-C1704420
of	I-C1704420
the	O
garlic	B-C0993630
allelochemical	B-C0220806
diallyl	B-C0057693
disulfide	I-C0057693
on	O
tomato	B-C0242772
roots	B-C0242726
garlic	B-C0993630
is	O
an	O
allelopathic	B-C3658358
crop	B-C0242775
that	O
can	O
alleviate	O
the	O
obstacles	O
to	O
continuous	B-C0549178
cropping	B-C4042899
of	O
vegetable	B-C0242775
crops	I-C0242775
.	O
	
diallyl	B-C0057693
disulfide	I-C0057693
dads	B-C0057693
,	O
one	O
of	O
the	O
most	O
important	O
allelochemicals	B-C0220806
in	O
garlic	B-C0993630
,	O
promotes	B-C0033414
tomato	B-C0242772
root	B-C1524120
growth	I-C1524120
.	O
	
therefore	O
,	O
the	O
global	B-C2348867
transcriptome	B-C3178810
profiles	B-C1956267
of	O
dads	B-C0057693
-	O
treated	B-C1522326
tomato	B-C0242772
roots	B-C0242726
over	O
time	O
were	O
investigated	B-C1292732
to	O
reveal	O
the	O
potential	B-C3245505
growth-promoting	B-C0682777
mechanisms	I-C0682777
.	O
	
we	O
detected	B-C0442726
1828	O
,	O
1296	O
and	O
1190	O
differentially	B-C0017262
expressed	I-C0017262
genes	B-C0017337
degs	B-C0017337
in	O
the	O
4	O
,	O
24	O
and	O
48	O
h	O
samples	O
,	O
respectively	O
.	O
	
most	O
degs	B-C0017337
involved	O
in	O
assimilatory	B-C2612332
sulfate	I-C2612332
reduction	I-C2612332
and	O
glutathione	B-C1158188
metabolism	I-C1158188
were	O
up-regulated	B-C0041904
after	O
short-term	B-C0443303
4	O
h	O
dads	B-C0057693
treatment	B-C1522326
.	O
	
in	O
addition	O
,	O
increased	B-C3267013
activity	I-C3267013
of	I-C3267013
defensive	I-C3267013
enzymes	I-C3267013
and	O
up-regulation	B-C0041904
of	O
six	O
peroxidase	B-C0017337
genes	I-C0017337
were	O
observed	B-C1441672
,	O
suggesting	O
that	O
dads	B-C0057693
could	O
induce	B-C0205263
tomato	B-C0242772
resistance	B-C4281815
.	O
	
in	O
plant-pathogen	B-C1752856
interactions	I-C1752856
,	O
degs	B-C0017337
related	O
to	O
calcium	B-C0600431
signaling	I-C0600431
were	O
primarily	O
inhibited	B-C0311403
,	O
while	O
those	O
encoding	B-C2700640
pathogenesis-related	B-C0070140
proteins	I-C0070140
were	O
primarily	O
up-regulated	B-C0041904
.	O
	
although	O
plant	B-C0032098
hormone	B-C0596715
synthesis	I-C0596715
and	O
signal	B-C0037083
transduction	I-C0037083
were	O
both	O
significantly	B-C0392760
affected	I-C0392760
by	O
dads	B-C0057693
,	O
the	O
expression	B-C0017262
trends	B-C1521798
of	O
the	O
genes	B-C0017337
in	O
these	O
two	O
pathways	B-C1704259
were	O
conflicting	O
.	O
	
this	O
research	B-C0035168
provides	O
comprehensive	B-C1880156
information	B-C1533716
concerning	O
the	O
changes	B-C0392747
in	O
the	O
tomato	B-C0242772
root	B-C0242726
transcriptome	B-C3178810
affected	B-C0392760
by	O
dads	B-C0057693
and	O
may	O
help	O
direct	O
further	O
studies	B-C2603343
on	O
dads	B-C0057693
-	O
responsive	B-C0205342
genes	B-C0017337
to	O
enhance	B-C2349975
the	O
current	B-C0521116
understanding	O
of	O
the	O
mechanisms	B-C0678659
by	O
which	O
dads	B-C0057693
alleviates	O
the	O
obstacles	O
to	O
continuous	B-C0549178
cropping	B-C4042899
.	O
	
mitotic	B-C1513354
phosphotyrosine	B-C0070948
network	B-C0868995
analysis	I-C0868995
reveals	O
that	O
tyrosine	B-C1519726
phosphorylation	I-C1519726
regulates	O
polo-like	B-C0290178
kinase	I-C0290178
1	I-C0290178
plk1	B-C0290178
tyrosine	B-C1519726
phosphorylation	I-C1519726
is	O
closely	O
associated	B-C0332281
with	I-C0332281
cell	B-C0596290
proliferation	I-C0596290
.	O
	
during	O
the	O
cell	B-C0007586
cycle	I-C0007586
,	O
serine	B-C1519253
and	I-C1519253
threonine	I-C1519253
phosphorylation	I-C1519253
plays	O
the	O
leading	O
role	O
,	O
and	O
such	O
phosphorylation	B-C0031715
events	O
are	O
most	O
dynamic	B-C0729333
during	O
the	O
mitotic	B-C3893712
phase	I-C3893712
of	O
the	O
cell	B-C0007586
cycle	I-C0007586
.	O
	
however	O
,	O
mitotic	B-C1513354
phosphotyrosine	B-C0070948
is	O
not	O
well	O
characterized	O
.	O
	
although	O
a	O
few	O
functionally	B-C0542341
-	O
relevant	B-C2347946
mitotic	B-C1513354
phosphotyrosine	B-C0070948
sites	B-C0205145
have	O
been	O
characterized	B-C1880022
,	O
evidence	O
suggests	O
that	O
this	O
modification	B-C0392747
may	O
be	O
more	O
prevalent	B-C0220900
than	O
previously	O
appreciated	O
.	O
	
here	O
,	O
we	O
examined	B-C0332128
tyrosine	B-C1519726
phosphorylation	I-C1519726
in	O
mitotic	B-C0230518
human	I-C0230518
cells	I-C0230518
including	O
those	O
on	O
spindle-associated	B-C0033684
proteins	I-C0033684
database	B-C1328866
mining	I-C1328866
confirmed	O
2000	O
mitotic	B-C1513354
phosphotyrosine	B-C0070948
sites	B-C0205145
,	O
and	O
network	B-C0868995
analysis	I-C0868995
revealed	O
a	O
number	O
of	O
subnetworks	O
that	O
were	O
enriched	O
in	O
tyrosine-phosphorylated	B-C0033684
proteins	I-C0033684
,	O
including	O
components	O
of	O
the	O
kinetochore	B-C0242609
or	O
spindle	B-C1166795
and	O
src	B-C0282625
family	I-C0282625
kinases	I-C0282625
.	O
	
we	O
identified	O
polo-like	B-C0290178
kinase	I-C0290178
1	I-C0290178
plk1	B-C0290178
,	O
a	O
major	O
signaling	B-C3537152
hub	O
in	O
the	O
spindle	B-C1166795
subnetwork	B-C1882071
,	O
as	O
phosphorylated	B-C1519061
at	O
the	O
conserved	O
tyr	B-C0041485
in	O
the	O
kinase	B-C1519724
domain	I-C1519724
.	O
	
substitution	B-C0525038
of	O
tyr	B-C0041485
with	O
a	O
phosphomimetic	B-C1254350
residue	I-C1254350
eliminated	O
plk1	B-C0290178
activity	B-C1537044
in	B-C1533691
vitro	I-C1533691
and	O
in	O
cells	B-C0007634
.	O
	
further	O
analysis	B-C0936012
showed	O
that	O
tyr	B-C0041485
phosphorylation	B-C0031715
reduced	O
the	O
phosphorylation	B-C1158892
of	I-C1158892
thr	I-C1158892
in	O
the	O
activation	B-C0445022
loop	I-C0445022
,	O
a	O
phosphorylation	B-C0031715
event	O
necessary	O
for	O
plk1	B-C0290178
activity	B-C1537044
.	O
	
our	O
data	O
indicate	O
that	O
mitotic	B-C1513354
tyrosine	B-C1519726
phosphorylation	I-C1519726
regulated	O
a	O
key	O
serine/threonine	B-C0072402
kinase	I-C0072402
hub	O
in	O
mitotic	B-C0230518
cells	I-C0230518
and	O
suggested	O
that	O
spatially	O
separating	O
tyrosine	B-C1519726
phosphorylation	I-C1519726
events	O
can	O
reveal	O
previously	O
unrecognized	B-C4288068
regulatory	B-C1514829
events	I-C1514829
and	O
complexes	B-C0439855
associated	O
with	O
specific	O
structures	B-C0243092
of	O
the	O
cell	B-C0007586
cycle	I-C0007586
.	O
	
divided	B-C0332849
and	O
sliding	B-C0332246
superficial	B-C0226130
temporal	I-C0226130
artery	I-C0226130
flap	B-C0038925
for	O
primary	B-C0205225
donor-site	B-C1444716
closure	B-C0185003
superficial	B-C0226130
temporal	I-C0226130
artery	I-C0226130
sta	B-C0226130
flaps	B-C0038925
are	O
often	O
used	O
for	O
reconstruction	B-C0524865
of	O
hair-bearing	B-C0005898
areas	I-C0005898
.	O
	
however	O
,	O
primary	B-C0441503
closure	I-C0441503
of	O
the	O
donor	B-C1444716
site	I-C1444716
is	O
not	O
easy	O
when	O
the	O
size	B-C0456389
of	O
the	O
necessary	O
skin	B-C1123023
island	I-C1123023
is	O
relatively	O
large	B-C0549177
.	O
	
in	O
such	O
cases	O
,	O
skin	B-C0040748
grafts	I-C0040748
are	O
needed	O
at	O
the	O
donor	B-C1444716
site	I-C1444716
,	O
resulting	O
in	O
baldness	B-C0002170
.	O
	
we	O
have	O
solved	O
this	O
issue	O
by	O
applying	O
the	O
divided	B-C0332849
and	O
sliding	B-C0332246
flap	B-C0038925
technique	B-C0449851
,	O
which	O
was	O
first	O
reported	O
for	O
primary	B-C0441503
donor-site	I-C0441503
closure	I-C0441503
of	O
a	O
latissimus	B-C0224362
dorsi	I-C0224362
musculocutaneous	I-C0224362
flap	B-C0038925
.	O
	
we	O
applied	O
this	O
technique	B-C0449851
to	O
the	O
hair-bearing	B-C0226130
sta	I-C0226130
flap	B-C0038925
,	O
where	O
primary	B-C0441503
donor-site	I-C0441503
closure	I-C0441503
is	O
extremely	O
beneficial	O
for	O
preventing	B-C2700409
baldness	B-C0002170
consequent	O
to	O
skin	B-C0037297
grafting	I-C0037297
.	O
	
the	O
sta	B-C0226130
flap	B-C0038925
was	O
divided	B-C0332849
into	O
3	O
,	O
and	O
creation	B-C1706214
of	O
large	O
flap	B-C0038925
was	O
possible	O
.	O
	
therefore	O
,	O
we	O
concluded	O
that	O
the	O
divided	B-C0332849
and	O
sliding	B-C0332246
sta	B-C0226130
flap	B-C0038925
could	O
at	O
least	O
partially	O
solve	O
the	O
donor-site	B-C1444716
problem	B-C0033213
.	O
	
although	O
further	O
investigation	B-C0220825
is	O
necessary	O
to	O
validate	B-C1519941
the	O
maximum	B-C0806909
possible	B-C0332149
flap	B-C0038925
size	B-C0456389
,	O
this	O
technique	B-C0449851
may	O
be	O
applicable	O
to	O
at	O
least	O
small	B-C0700321
defects	B-C0243067
that	O
are	O
common	O
after	O
skin	B-C0007114
cancer	I-C0007114
ablation	B-C0547070
or	O
influence	B-C4054723
of	O
surface	B-C0038884
properties	I-C0038884
on	O
adhesion	B-C0441722
forces	I-C0441722
and	O
attachment	B-C1947904
of	O
streptococcus	B-C0038409
mutans	I-C0038409
to	O
zirconia	B-C0078814
in	B-C1533691
vitro	I-C1533691
zirconia	B-C0078814
is	O
becoming	O
a	O
prevalent	B-C0520510
material	I-C0520510
in	O
dentistry	B-C0011438
.	O
	
however	O
,	O
any	O
foreign	B-C0016542
bodies	I-C0016542
inserted	B-C0441587
may	O
provide	O
new	O
niches	O
for	O
the	O
bacteria	B-C0004611
in	O
oral	B-C0226896
cavity	I-C0226896
.	O
	
the	O
object	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
effect	B-C1280500
of	O
surface	B-C0038884
properties	I-C0038884
including	O
surface	B-C4313424
roughness	I-C4313424
and	O
hydrophobicity	B-C0598629
on	O
the	O
adhesion	B-C0175633
and	O
biofilm	B-C1325881
formation	I-C1325881
of	O
streptococcus	B-C0038409
mutans	I-C0038409
s	B-C0038409
.	O
	
mutans	I-C0038409
to	O
zirconia	B-C0078814
.	O
	
atomic	B-C0242849
force	I-C0242849
microscopy	I-C0242849
was	O
employed	O
to	O
determine	O
the	O
zirconia	B-C0078814
surface	B-C0205148
morphology	B-C0332437
and	O
the	O
adhesion	B-C0441722
forces	I-C0441722
between	O
the	O
s	B-C0038409
.	O
	
mutans	I-C0038409
and	O
zirconia	B-C0078814
.	O
	
the	O
results	B-C1274040
showed	O
that	O
the	O
surface	B-C4313424
roughness	I-C4313424
was	O
nanoscale	B-C0392762
and	O
significantly	O
different	B-C1705242
among	O
tested	B-C0441833
groups	I-C0441833
p	O
<	O
0.05	O
coarse	B-C0205194
23.94	O
2.52	O
nm	O
>	O
medium	B-C0439536
17.00	O
3.81	O
nm	O
>	O
fine	B-C0205232
11.89	O
1.68	O
nm	O
.	O
	
the	O
contact	B-C0205143
angles	I-C0205143
of	O
the	O
coarse	B-C0441833
group	I-C0441833
were	O
the	O
highest	O
,	O
followed	O
by	O
the	O
medium	B-C0439536
and	O
the	O
fine	B-C0441833
groups	I-C0441833
.	O
	
increasing	O
the	O
surface	B-C4313424
roughness	I-C4313424
and	O
hydrophobicity	B-C0598629
resulted	O
in	O
an	O
increase	O
of	O
adhesion	B-C0441722
forces	I-C0441722
and	O
early	O
attachment	B-C1947904
2	O
h	O
and	O
4	O
h	O
of	O
s	B-C0038409
.	O
	
mutans	I-C0038409
on	O
the	O
zirconia	B-C0078814
but	O
no	O
influence	B-C4054723
on	O
the	O
further	O
development	B-C1527148
of	O
biofilm	B-C0081786
6	O
h	O
h	O
.	O
	
our	O
findings	O
suggest	O
that	O
the	O
surface	B-C4313424
roughness	I-C4313424
in	O
nanoscale	B-C0392762
and	O
hydrophobicity	B-C0598629
of	O
zirconia	B-C0078814
had	O
influence	B-C4054723
on	O
the	O
s	B-C0038409
.	O
	
mutans	I-C0038409
initial	O
adhesion	B-C0441722
force	I-C0441722
and	O
early	O
attachment	B-C1947904
instead	O
of	O
whole	O
stages	O
of	O
biofilm	B-C1325881
formation	I-C1325881
.	O
	
the	O
relationship	O
between	O
thiamine	B-C0039840
and	O
two	O
symbioses	B-C0039029
root	B-C1720942
nodule	I-C1720942
symbiosis	B-C0039029
and	O
arbuscular	B-C1138420
mycorrhiza	I-C1138420
lotus	B-C1940771
japonicus	I-C1940771
thic	B-C0017337
is	O
expressed	B-C0017262
in	O
all	O
organs	B-C0032098
,	O
and	O
the	O
encoded	B-C0033684
protein	I-C0033684
catalyzes	B-C0007382
thiamine	B-C1157735
biosynthesis	I-C1157735
.	O
	
loss	B-C0243095
of	I-C0243095
function	I-C0243095
produces	O
chlorosis	B-C0008272
,	O
a	O
typical	O
thiamine	B-C0039840
-deficiency	O
phenotype	B-C0031437
,	O
and	O
mortality	B-C0205848
.	O
	
to	O
investigate	O
thiamine's	B-C0039840
role	O
in	O
symbiosis	B-C0039029
,	O
we	O
focused	O
on	O
thi1	B-C0017337
,	O
a	O
thiamine-biosynthesis	B-C0017337
gene	I-C0017337
expressed	B-C0017262
in	O
roots	B-C0242726
,	O
nodules	B-C1720942
,	O
and	O
seeds	B-C0036563
.	O
	
the	O
thi1	B-C0678941
mutant	I-C0678941
had	O
green	B-C0242724
leaves	I-C0242724
,	O
but	O
formed	O
small	B-C0700321
nodules	B-C1720942
and	O
immature	B-C0205252
seeds	B-C0036563
.	O
	
these	O
phenotypes	B-C0031437
were	O
rescued	O
by	O
thi1	B-C0017337
complementation	B-C0178654
and	O
by	O
exogenous	B-C0205228
thiamine	B-C0039840
.	O
	
thus	O
,	O
thi1	B-C0017337
is	O
required	O
for	O
nodule	B-C1720942
enlargement	B-C0542341
and	O
seed	B-C2265562
maturation	I-C2265562
.	O
	
on	O
the	O
other	O
hand	O
,	O
colonization	B-C4289767
by	O
arbuscular	B-C1138420
mycorrhiza	I-C1138420
am	B-C1138420
fungus	B-C0016832
rhizophagus	B-C2664655
irregularis	I-C2664655
was	O
not	O
affected	O
in	O
the	O
thi1	B-C0678941
mutant	I-C0678941
or	O
by	O
exogenous	B-C0205228
thiamine	B-C0039840
.	O
	
however	O
,	O
spores	B-C0038029
of	O
r	B-C2664655
.	O
	
irregularis	I-C2664655
stored	O
more	O
thiamine	B-C0039840
than	O
the	O
source	O
host	B-C0868970
plants	I-C0868970
,	O
despite	O
lacking	O
thiamine	B-C0017337
biosynthesis	I-C0017337
genes	I-C0017337
.	O
	
therefore	O
,	O
disturbance	O
of	O
the	O
thiamine	B-C0039840
supply	O
would	O
affect	O
progeny	B-C0680063
phenotypes	B-C0031437
such	O
as	O
spore	B-C1159442
formation	I-C1159442
and	O
hyphal	B-C1156247
growth	I-C1156247
.	O
	
further	O
investigation	O
will	O
be	O
required	O
to	O
elucidate	O
thiamine's	B-C0039840
effect	O
on	O
bilateral	B-C0238767
sternal	B-C0038293
infusion	B-C0574032
of	O
ropivacaine	B-C0073571
and	O
length	B-C0023303
of	I-C0023303
stay	I-C0023303
in	O
icu	B-C0021708
after	O
cardiac	B-C0018821
surgery	I-C0018821
with	O
increased	B-C0205217
respiratory	B-C0548981
risk	I-C0548981
a	O
randomised	B-C0206035
controlled	I-C0206035
trial	I-C0206035
the	O
continuous	O
bilateral	B-C0238767
infusion	B-C0574032
of	O
a	O
local	B-C0002934
anaesthetic	I-C0002934
solution	B-C0525069
around	O
the	O
sternotomy	B-C0185792
wound	B-C0043250
bilateral	B-C0238767
sternal	B-C0038293
is	O
an	O
innovative	O
technique	B-C0449851
for	O
reducing	B-C0392756
pain	B-C0030193
after	O
sternotomy	B-C0185792
.	O
	
to	O
assess	O
the	O
effects	B-C1280500
of	O
the	O
technique	B-C0449851
on	O
the	O
need	O
for	O
intensive	B-C0085559
care	I-C0085559
in	O
cardiac	B-C0741926
patients	I-C0741926
at	O
increased	B-C0205217
risk	B-C0035647
of	O
respiratory	B-C0161818
complications	I-C0161818
.	O
	
randomised	B-C0206035
,	O
observer-blind	I-C0206035
controlled	I-C0206035
trial	I-C0206035
.	O
	
single	O
centre	O
,	O
french	B-C0020028
university	I-C0020028
hospital	I-C0020028
.	O
	
in	O
total	O
,	O
120	O
adults	B-C0001675
scheduled	O
for	O
open-heart	B-C0189745
surgery	I-C0189745
,	O
with	O
one	O
of	O
the	O
following	O
conditions	O
age	B-C0001779
more	O
than	O
75	O
years	B-C0439234
,	O
bmi	B-C1305855
>30	O
kg	O
m	O
,	O
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disease	I-C0024117
,	O
active	B-C1266863
smoking	I-C1266863
habit	I-C1266863
.	O
	
either	O
a	O
bilateral	B-C0238767
sternal	B-C0038293
infusion	B-C0574032
of	O
0.2	O
ropivacaine	B-C0073571
3	O
ml	O
h	O
through	O
each	O
catheter	B-C0085590
'intervention'	B-C2986530
group	I-C2986530
,	O
or	O
standardised	B-C1947933
care	I-C1947933
only	O
'control'	B-C0009932
group	I-C0009932
.	O
	
analgesia	B-C3202977
was	O
provided	O
with	O
paracetamol	B-C0000970
and	O
self-administered	B-C1519231
intravenous	B-C1522726
morphine	B-C0026549
.	O
	
the	O
length	B-C1254367
of	I-C1254367
time	I-C1254367
to	O
readiness	B-C1318963
for	O
discharge	B-C0030685
from	O
icu	B-C0021708
,	O
blindly	O
assessed	B-C1516048
by	O
a	O
committee	B-C2699414
of	O
experts	B-C0009817
.	O
	
no	B-C1301751
effect	I-C1301751
was	O
found	O
between	O
groups	B-C0441833
for	O
the	O
primary	B-C3274433
outcome	I-C3274433
p	O
=	O
0.680	O
,	O
intention	B-C2718028
to	I-C2718028
treat	I-C2718028
the	O
median	B-C0042295
values	I-C0042295
were	O
42.4	O
and	O
37.7	O
h	O
,	O
respectively	O
for	O
the	O
control	B-C0009932
and	O
intervention	B-C2986530
groups	I-C2986530
p	O
=	O
0.873	O
.	O
	
similar	O
nonsignificant	O
trends	O
were	O
noted	O
for	O
other	O
postoperative	B-C0241311
delays	B-C0205421
.	O
	
significant	O
effects	B-C1280500
favouring	O
the	O
intervention	B-C0184661
were	O
noted	O
for	O
dynamic	B-C0030193
pain	I-C0030193
,	O
patient	B-C0030702
satisfaction	I-C0030702
,	O
occurrence	B-C2219665
of	I-C2219665
nausea	I-C2219665
and	O
vomiting	B-C0042963
,	O
occurrence	B-C2745955
of	O
delirium	B-C0011206
or	O
mental	B-C0009676
confusion	I-C0009676
and	O
occurrence	B-C2745955
of	O
pulmonary	B-C0281169
complications	I-C0281169
.	O
	
in	O
12	O
patients	B-C0030705
,	O
although	O
no	O
symptoms	B-C1457887
actually	O
occurred	O
,	O
the	O
total	O
ropivacaine	O
plasma	O
level	O
exceeded	O
the	O
lowest	O
value	O
for	O
which	O
neurological	B-C0235031
symptoms	I-C0235031
have	O
been	O
observed	O
in	O
healthy	B-C1708335
volunteers	I-C1708335
.	O
	
because	O
of	O
a	O
small	B-C0814843
size	I-C0814843
effect	I-C0814843
,	O
and	O
despite	O
significant	O
analgesic	B-C0948482
effects	I-C0948482
,	O
this	O
strategy	O
failed	O
to	O
reduce	O
the	O
time	B-C0040223
spent	O
in	O
icu	B-C0021708
.	O
	
eudract	B-C4289562
n	O
2012-005225-69	O
clinicaltrials.gov	B-C4086204
pupil	B-C0517965
sizes	I-C0517965
scale	B-C0349674
with	O
attentional	B-C0589051
load	I-C0589051
and	O
task	B-C3540678
experience	B-C0596545
in	O
a	O
multiple	B-C0439064
object	B-C0347997
tracking	B-C0546881
task	B-C3540678
previous	O
studies	O
have	O
related	O
changes	B-C0392747
in	O
attentional	B-C0589051
load	I-C0589051
to	O
pupil	B-C0517965
size	I-C0517965
modulations	B-C0443264
.	O
	
however	O
,	O
studies	O
relating	O
changes	B-C0392747
in	O
attentional	B-C0589051
load	I-C0589051
and	O
task	B-C3540678
experience	B-C0596545
on	O
a	O
finer	O
scale	B-C0349674
to	O
pupil	B-C0517965
size	I-C0517965
modulations	B-C0443264
are	O
scarce	O
.	O
	
here	O
,	O
we	O
investigated	B-C1292732
how	O
these	O
changes	B-C0392747
affect	B-C0001721
pupil	B-C0517965
sizes	I-C0517965
.	O
	
to	O
manipulate	B-C0018578
attentional	B-C0589051
load	I-C0589051
,	O
participants	B-C0679646
covertly	O
tracked	B-C0546881
between	O
zero	B-C0919414
and	O
five	B-C0205451
objects	B-C0347997
among	O
several	O
randomly	B-C0439605
moving	O
objects	B-C0347997
on	O
a	O
computer	B-C0009622
screen	B-C1705053
.	O
	
to	O
investigate	B-C1292732
effects	B-C1704420
of	I-C1704420
task	B-C3540678
experience	B-C0596545
,	O
the	O
experiment	O
was	O
conducted	O
on	O
three	B-C0205449
consecutive	B-C1707491
days	B-C0439228
.	O
	
we	O
found	O
that	O
pupil	B-C0517965
sizes	I-C0517965
increased	O
with	O
each	O
increment	B-C1705117
in	O
attentional	B-C0589051
load	I-C0589051
.	O
	
across	O
days	B-C0439228
,	O
we	O
found	O
systematic	B-C0220922
pupil	B-C0517965
size	I-C0517965
reductions	B-C0392756
.	O
	
we	O
compared	O
the	O
model	B-C0870608
fit	I-C0870608
for	O
predicting	O
pupil	B-C0517965
size	I-C0517965
modulations	B-C0443264
using	O
attentional	B-C0589051
load	I-C0589051
,	O
task	B-C3540678
experience	B-C0596545
,	O
and	O
task	B-C0039333
performance	I-C0039333
as	O
predictors	B-C2698872
.	O
	
we	O
found	O
that	O
a	O
model	B-C3161035
which	O
included	O
attentional	B-C0589051
load	I-C0589051
and	O
task	B-C3540678
experience	B-C0596545
as	O
predictors	B-C2698872
had	O
the	O
best	O
model	B-C0870608
fit	I-C0870608
while	O
adding	O
performance	B-C0039333
as	O
a	O
predictor	B-C2698872
to	O
this	O
model	B-C3161035
reduced	O
the	O
overall	O
model	B-C0870608
fit	I-C0870608
.	O
	
overall	O
,	O
results	B-C1274040
suggest	O
that	O
pupillometry	B-C0260180
provides	O
a	O
viable	B-C0443348
metric	B-C0025867
for	O
precisely	O
assessing	O
attentional	B-C0589051
load	I-C0589051
and	O
task	B-C3540678
experience	B-C0596545
in	O
visuospatial	B-C0814069
tasks	B-C3540678
.	O
	
back	O
to	O
the	O
roots	O
deep	O
view	O
into	O
the	O
evolutionary	B-C0282688
history	B-C0019665
of	O
adp-ribosylation	B-C0596043
opened	O
by	O
the	O
dna	B-C0012854
-	O
targeting	B-C1521840
toxin	B-C0040549
-	O
antitoxin	B-C0003445
module	B-C1709061
dartg	I-C1709061
in	O
this	O
issue	O
of	O
molecular	B-C1513407
cell	I-C1513407
,	O
jankevicius	O
et	O
al	O
.	O
	
2016	O
characterize	O
the	O
dartg	B-C1709061
toxin	B-C0040549
-	O
antitoxin	B-C0003445
module	B-C1709061
in	O
which	O
the	O
dart	B-C0014442
toxin	B-C0040549
adp-ribosylates	B-C0596043
single-stranded	B-C0012935
dna	I-C0012935
and	O
the	O
darg	B-C0033684
antitoxin	B-C0003445
counteracts	B-C0443286
dart	B-C0014442
by	O
direct	O
binding	B-C1167622
and	O
by	O
enzymatic	B-C0014442
remova	B-C1883720
l	O
of	O
the	O
growth	B-C0668195
differentiation	I-C0668195
factor	I-C0668195
15	I-C0668195
is	O
a	O
myomitokine	B-C0574031
governing	B-C3157768
systemic	I-C3157768
energy	I-C3157768
homeostasis	I-C3157768
reduced	B-C0392756
mitochondrial	B-C1325653
electron	I-C1325653
transport	I-C1325653
chain	I-C1325653
activity	B-C0441655
promotes	B-C0033414
longevity	B-C0023980
and	O
improves	B-C0184511
energy	B-C3157043
homeostasis	I-C3157043
via	O
cell-autonomous	B-C0007613
and	O
-	O
non-autonomous	B-C0007613
factors	I-C0007613
in	O
multiple	B-C0026339
model	I-C0026339
systems	I-C0026339
.	O
	
this	O
mitohormetic	B-C3178757
effect	B-C1280500
is	O
thought	O
to	O
involve	O
the	O
mitochondrial	B-C2612628
unfolded	I-C2612628
protein	I-C2612628
response	I-C2612628
upr	B-C2612628
,	O
an	O
adaptive	B-C0149784
stress-response	I-C0149784
pathway	B-C1705987
activated	B-C1879547
by	O
mitochondrial	B-C0026237
proteotoxic	B-C0449430
stress	I-C0449430
.	O
	
using	O
mice	B-C0025929
with	O
skeletal	B-C0242692
muscle-specific	I-C0242692
deficiency	B-C0011155
of	O
crif1	B-C2352141
muscle-specific	B-C0026845
knockout	B-C0206745
mko	B-C0206745
,	O
an	O
integral	B-C0033684
protein	I-C0033684
of	O
the	O
large	B-C1166894
mitoribosomal	I-C1166894
subunit	I-C1166894
39s	B-C2611782
,	O
we	O
identified	O
growth	B-C0668195
differentiation	I-C0668195
factor	I-C0668195
15	I-C0668195
gdf15	B-C0668195
as	O
a	O
upr	B-C2612628
-associated	O
cell-non-autonomous	B-C0007613
myomitokine	B-C0574031
that	O
regulates	B-C3157768
systemic	I-C3157768
energy	I-C3157768
homeostasis	I-C3157768
.	O
	
mko	B-C0206745
mice	I-C0206745
were	O
protected	B-C1545588
against	O
obesity	B-C0028754
and	O
sensitized	B-C1325847
to	O
insulin	B-C0021641
,	O
an	O
effect	O
associated	B-C0332281
with	I-C0332281
elevated	B-C3163633
gdf15	B-C0668195
secretion	B-C1159339
after	O
upr	B-C2612628
activation	B-C1879547
.	O
	
in	O
ob/ob	B-C0206745
mice	I-C0206745
,	O
administration	O
of	O
recombinant	B-C0034861
gdf15	B-C0668195
decreased	B-C0205216
body	B-C0005910
weight	I-C0005910
and	O
improved	B-C0184511
insulin	B-C0920563
sensitivity	I-C0920563
,	O
which	O
was	O
attributed	O
to	O
elevated	B-C3163633
oxidative	B-C0282636
metabolism	I-C0282636
and	O
lipid	B-C0023773
mobilization	I-C0023773
in	O
the	O
liver	B-C0023884
,	O
muscle	B-C0026845
,	O
and	O
adipose	B-C0001527
tissue	I-C0001527
.	O
	
thus	O
,	O
gdf15	B-C0668195
is	O
a	O
potent	B-C3245505
mitohormetic	B-C3178757
signal	B-C3537152
that	O
safeguards	O
against	O
the	O
onset	B-C0243095
of	I-C0243095
obesity	I-C0243095
and	O
insulin	B-C0021655
resistance	I-C0021655
.	O
	
synthesis	B-C1883254
and	O
characterization	B-C1880022
of	O
acetylated	B-C0002732
amylose	I-C0002732
and	O
development	B-C1527148
of	O
inclusion	B-C1254350
complexes	I-C1254350
with	O
rifampicin	B-C0035608
amylose	B-C0002732
am	B-C0002732
tends	O
to	O
form	O
single	O
helical	O
inclusion	B-C1254350
complexes	I-C1254350
with	O
suitable	O
agents	B-C0450442
.	O
	
these	O
complexes	B-C1704241
are	O
considered	B-C0750591
promising	O
biomaterial	B-C0005479
carrier	O
since	O
the	O
guest	B-C0567416
molecules	I-C0567416
can	O
be	O
released	B-C0391871
later	B-C0205087
,	O
leading	O
to	O
many	O
applications	B-C0205245
,	O
especially	O
in	O
the	O
pharmaceutical	B-C0013185
industry	I-C0013185
.	O
	
rifampicin	B-C0035608
rif	B-C0035608
has	O
long	O
been	O
recognized	O
as	O
an	O
active	B-C0205177
drug	B-C1254351
against	O
mycobacterium	B-C0026926
tuberculosis	I-C0026926
,	O
however	O
,	O
the	O
administration	B-C1533734
of	O
rif	B-C0035608
in	O
high	O
dosages	B-C0178602
can	O
originate	O
unwanted	O
side-effects	B-C0001688
.	O
	
due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	B-C0302891
amylose	B-C0002732
am	B-C0002732
in	O
the	O
formation	B-C1522492
of	O
complexes	B-C1704241
is	O
limited	O
by	O
their	O
low	O
water	B-C0597682
solubility	I-C0597682
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	B-C0449286
of	O
substitution	B-C1706204
ds	B-C1706204
,	O
allowing	O
solubilizing	B-C0037628
0.5gl	O
acetylated	B-C0002732
amylose	I-C0002732
ama	B-C0002732
in	O
water	B-C0043047
at	O
neutral	B-C1882074
ph	I-C1882074
,	O
in	O
opposition	O
to	O
that	O
observed	B-C1441672
with	O
native	B-C0302891
amylose	B-C0002732
trace	B-C0442822
solubility	B-C0037628
.	O
	
the	O
resulting	O
acetylated	B-C0002732
amylose	I-C0002732
was	O
characterized	B-C1880022
by	O
means	O
of	O
fourier	B-C0206055
transform	I-C0206055
infrared	I-C0206055
ft-ir	I-C0206055
spectroscopy	I-C0206055
and	O
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
sem	B-C0026020
.	O
	
ft-ir	B-C0206055
results	B-C1274040
indicated	B-C1444656
that	O
the	O
acetylation	B-C0001038
of	O
anhydroglucose	B-C0017725
units	B-C0439148
of	O
amylose	B-C0002732
corresponds	O
to	O
a	O
low	B-C0205251
ds	B-C1706204
,	O
whereas	O
sem	B-C0026020
results	B-C1274040
suggested	O
that	O
the	O
smooth	B-C0205148
surfaces	I-C0205148
of	O
amylose	B-C0002732
granules	B-C3853628
were	O
changed	B-C0392747
into	O
rougher	O
surfaces	B-C0205148
after	O
acetylation	B-C0001038
.	O
	
ultraviolet	B-C0260250
absorption	I-C0260250
spectroscopy	I-C0260250
uv-vis	B-C0260250
analysis	B-C0936012
confirmed	B-C0521093
the	O
formation	B-C1522492
and	O
allowed	O
the	O
quantification	B-C1709793
of	O
both	O
native	B-C0302891
am	B-C0002732
-	O
rif	B-C0035608
and	O
acetylated	O
ama	B-C0002732
-	O
rif	B-C0035608
amylose	B-C0002732
inclusion	B-C1254350
complexes	I-C1254350
.	O
	
their	O
characterization	B-C1880022
in	O
solution	B-C0037633
was	O
performed	B-C0884358
by	O
dynamic	B-C1882368
light	I-C1882368
scattering	I-C1882368
dls	B-C1882368
and	O
zeta	B-C0597697
potential	I-C0597697
zp	B-C0597697
measurements	B-C0242485
.	O
	
the	O
average	B-C0456389
size	I-C0456389
of	O
inclusion	B-C1254350
complexes	I-C1254350
as	O
determined	B-C0521095
by	I-C0521095
dls	B-C1882368
,	O
ranged	B-C1514721
between	O
70	O
and	O
100nm	O
.	O
	
besides	O
,	O
zp	B-C0597697
analysis	B-C0936012
showed	O
that	O
both	O
complexes	B-C1704241
are	O
more	O
stable	B-C0205360
in	O
the	O
presence	B-C0150312
of	O
rif	B-C0035608
.	O
	
this	O
study	O
may	O
lead	O
to	O
the	O
development	B-C1527148
of	O
an	O
effective	B-C1704419
method	O
for	O
the	O
preparation	B-C1521827
of	O
amylose	B-C0002732
inclusion	B-C1254350
complexes	I-C1254350
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	B-C1517331
application	B-C0205245
in	O
drug	B-C0085104
delivery	I-C0085104
systems	I-C0085104
.	O
	
selective	B-C1707391
reaching	B-C2584321
in	O
macaques	B-C0024398
evidence	B-C3887511
for	O
action	B-C3266814
-centred	O
attention	B-C0004268
when	O
a	O
monkey	B-C0026447
selects	B-C1707391
a	O
piece	O
of	O
food	B-C0016452
lying	O
on	O
the	O
ground	O
from	O
among	O
other	B-C0205394
viable	B-C0443348
objects	B-C0347997
in	O
the	O
near	B-C1706276
vicinity	B-C0205146
,	O
only	O
the	O
desired	B-C0871633
item	B-C0016452
governs	B-C0243148
the	O
particular	O
pattern	B-C0449774
and	O
direction	B-C0449738
of	O
the	O
animal's	B-C0003062
reaching	B-C2584321
action	B-C3266814
.	O
	
it	O
would	O
seem	O
then	O
that	O
selection	B-C1707391
is	O
an	O
important	B-C3898777
component	B-C1552020
controlling	B-C2587213
the	O
animal's	B-C0003062
action	B-C3266814
.	O
	
but	O
,	O
we	O
may	O
ask	O
,	O
is	O
the	O
selection	B-C1707391
process	B-C1522240
in	O
such	O
cases	B-C0868928
impervious	O
to	O
the	O
presence	B-C3854307
of	O
other	B-C0205394
objects	B-C0347997
that	O
could	O
constitute	B-C1522492
potential	B-C3245505
obstacles	B-C0347997
to	O
or	O
constraints	B-C0443288
on	O
movement	B-C0026649
execution	B-C1705848
and	O
if	O
it	O
is	O
,	O
in	O
fact	O
,	O
pervious	B-C0205326
to	O
other	B-C0205394
objects	B-C0347997
,	O
do	O
they	O
have	O
a	O
direct	B-C1947931
influence	B-C4054723
on	O
the	O
organization	B-C0029237
of	O
the	O
response	B-C0871261
the	O
kinematics	B-C0600169
of	O
macaques	B-C0024398
'	O
reaching	B-C2584321
movements	B-C0026649
were	O
examined	B-C0332128
by	O
the	O
current	B-C0521116
study	B-C2603343
that	O
analysed	B-C0936012
some	O
exemplars	O
as	O
they	O
selectively	B-C1707391
reached	B-C2584321
to	O
grasp	B-C0220843
a	O
food	B-C0016452
item	I-C0016452
in	O
the	O
absence	B-C0332197
as	O
well	O
as	O
in	O
the	O
presence	B-C3854307
of	O
potential	B-C3245505
obstacles	B-C0347997
i.e	O
,	O
stones	B-C0347997
that	O
could	O
affect	B-C0001721
the	O
arm	B-C0446516
trajectory	B-C0449738
.	O
	
changes	B-C0392747
in	O
movement	B-C0026649
parameterization	B-C0681933
were	O
noted	B-C4288581
in	O
temporal	B-C2362314
measures	B-C0079809
,	O
such	O
as	O
movement	B-C0026649
time	B-C0040223
,	O
as	O
well	O
as	O
in	O
spatial	B-C1254362
ones	I-C1254362
,	O
such	O
as	O
paths	O
of	O
trajectory	B-C0449738
.	O
	
generally	O
speaking	O
,	O
the	O
presence	B-C3854307
of	O
stones	B-C0347997
in	O
the	O
vicinity	B-C0205146
of	O
the	O
acting	B-C0001241
hand	B-C0018563
stalled	B-C1947925
the	O
reaching	B-C2584321
movement	B-C0026649
and	O
affected	B-C0001721
the	O
arm	B-C0446516
trajectory	B-C0449738
as	O
the	O
hand	B-C0018563
veered	B-C1277225
away	I-C1277225
from	O
the	O
stone	B-C0347997
even	O
when	O
it	O
was	O
not	B-C1518422
a	O
physical	B-C0205485
obstacle	B-C0347997
.	O
	
we	O
concluded	O
that	O
nearby	B-C1706276
objects	B-C0347997
evoke	O
a	O
motor	B-C1285623
response	I-C1285623
in	O
macaques	B-C0024398
,	O
and	O
the	O
attentional	B-C0004268
mechanisms	B-C0441712
that	O
allow	O
for	O
a	O
successful	B-C1272703
action	B-C3266814
selection	B-C1707391
are	O
revealed	B-C0443289
in	O
the	O
reaching	B-C2584321
path	B-C0449738
.	O
	
the	O
data	B-C1511726
outlined	O
here	O
concur	O
with	O
human	B-C0086418
studies	B-C2603343
indicating	B-C0392360
that	O
potential	B-C3245505
obstacles	B-C0347997
are	O
internally	B-C0205102
represented	B-C1882932
,	O
a	O
finding	B-C0243095
implying	O
basic	B-C1527178
cognitive	B-C1516691
operations	B-C3241922
allowing	O
for	O
action	B-C3266814
selection	B-C1707391
in	O
a	O
novel	B-C0205314
method	B-C0025663
for	O
interactive	B-C1704675
multi-objective	B-C1571702
dose-guided	B-C1561964
patient	I-C1561964
positioning	I-C1561964
in	O
intensity-modulated	B-C1512814
radiation	I-C1512814
therapy	I-C1512814
imrt	B-C1512814
,	O
3d	O
in-room	O
imaging	B-C0011923
data	B-C1511726
is	O
typically	O
utilized	O
for	O
accurate	B-C0443131
patient	B-C0548501
alignment	I-C0548501
on	O
the	O
basis	O
of	O
anatomical	B-C0504075
landmarks	I-C0504075
.	O
	
in	O
the	O
presence	O
of	O
non-rigid	O
anatomical	B-C0392747
changes	I-C0392747
,	O
it	O
is	O
often	O
not	O
obvious	O
which	O
patient	B-C0449850
position	I-C0449850
is	O
most	O
suitable	O
.	O
	
thus	O
,	O
dose	B-C0178602
-guided	O
patient	B-C0548501
alignment	I-C0548501
is	O
an	O
interesting	O
approach	O
to	O
use	O
available	O
in-room	O
imaging	B-C0011923
data	B-C1511726
for	O
up-to-date	O
dose	B-C0178602
calculation	B-C1441506
,	O
aimed	O
at	O
finding	B-C0243095
the	O
position	O
that	O
yields	O
the	O
optimal	B-C2698651
dose	B-C0178602
distribution	B-C1704711
.	O
	
this	O
contribution	O
presents	O
the	O
first	O
implementation	O
of	O
dose	B-C0178602
-guided	O
patient	B-C0548501
alignment	I-C0548501
as	O
multi-criteria	O
optimization	O
problem	O
.	O
	
user-defined	O
clinical	B-C0205210
objectives	B-C0018017
are	O
employed	O
for	O
setting	O
up	O
a	O
multi-objective	B-C1571702
problem	O
.	O
	
using	O
pre-calculated	O
dose	B-C0178602
distributions	B-C1704711
at	O
a	O
limited	O
number	O
of	O
patient	B-C0086388
shifts	I-C0086388
and	O
dose	B-C0178602
interpolation	B-C3494285
,	O
a	O
continuous	O
space	O
of	O
pareto-efficient	B-C0086388
patient	I-C0086388
shifts	I-C0086388
becomes	O
accessible	O
.	O
	
pareto	O
sliders	O
facilitate	O
interactive	B-C1704675
browsing	O
of	O
the	O
possible	O
shifts	O
with	O
real-time	O
dose	B-C0178602
display	O
to	O
the	O
user	O
.	O
	
dose	B-C0178602
interpolation	B-C3494285
accuracy	B-C0443131
is	O
validated	O
and	O
the	O
potential	O
of	O
multi-objective	B-C1571702
dose-guided	B-C1561964
positioning	I-C1561964
demonstrated	O
for	O
three	O
head	B-C0278996
and	I-C0278996
neck	I-C0278996
h	B-C0278996
and	O
three	O
prostate	B-C0600139
cancer	I-C0600139
patients	B-C0030705
.	O
	
dose-guided	B-C1561964
positioning	I-C1561964
is	O
compared	B-C1707455
to	O
replanning	O
for	O
all	O
cases	O
.	O
	
a	O
delineated	O
replanning	O
ct	B-C0040405
served	O
as	O
surrogate	O
for	O
in-room	O
imaging	B-C0011923
data	B-C1511726
.	O
	
dose	B-C0178602
interpolation	B-C3494285
accuracy	B-C0443131
was	O
high	B-C0205250
.	O
	
using	O
a	O
formula	O
see	O
text	O
dose	B-C0178602
difference	O
criterion	O
,	O
a	O
median	O
pass-rate	O
of	O
95.7	O
for	O
h	B-C0278996
and	O
99.6	O
for	O
prostate	B-C0600139
cases	I-C0600139
was	O
determined	O
in	O
a	O
comparison	B-C1707455
to	O
exact	O
dose	B-C0178602
calculations	B-C1441506
.	O
	
for	O
all	O
patients	B-C0030705
,	O
dose-guided	B-C1561964
positioning	I-C1561964
allowed	O
to	O
find	O
a	O
clinically	O
preferable	O
dose	B-C0178602
distribution	B-C1704711
compared	B-C1707455
to	O
bony	B-C1706765
anatomy	I-C1706765
based	I-C1706765
alignment	I-C1706765
.	O
	
for	O
all	O
h	B-C0278996
cases	O
,	O
mean	O
dose	B-C0178602
to	O
the	O
spared	O
parotid	B-C0030580
glands	I-C0030580
was	O
below	O
formula	O
see	O
text	O
up	O
to	O
formula	O
see	O
text	O
with	O
bony	B-C1706765
alignment	I-C1706765
and	O
clinical	B-C0454198
target	I-C0454198
volume	I-C0454198
ctv	B-C0454198
formula	O
see	O
text	O
above	O
99.1	O
compared	B-C1707455
to	O
95.1	O
.	O
	
for	O
all	O
prostate	B-C0600139
patients	B-C0030705
,	O
ctv	B-C0454198
formula	O
see	O
text	O
was	O
above	O
98.9	O
compared	B-C1707455
to	O
88.5	O
and	O
formula	O
see	O
text	O
to	O
the	O
rectum	O
below	O
formula	O
see	O
text	O
compared	B-C1707455
to	O
56.1	O
.	O
	
replanning	O
yielded	O
improved	O
results	O
for	O
the	O
h	B-C0278996
cases	O
.	O
	
for	O
the	O
prostate	B-C0600139
cases	I-C0600139
,	O
differences	O
to	O
dose-guided	B-C1561964
positioning	I-C1561964
clinical	B-C2985631
and	O
radiological	B-C0043299
outcome	B-C1274040
following	O
pneumothorax	B-C0032326
after	O
endoscopic	B-C0375931
lung	I-C0375931
volume	I-C0375931
reduction	I-C0375931
with	O
valves	B-C0042296
valve	B-C0042296
implantation	B-C0021107
has	O
evolved	O
as	O
a	O
therapy	B-C0087111
for	O
patients	B-C0030705
with	O
advanced	B-C0205179
emphysema	B-C0034067
.	O
	
although	O
it	O
is	O
a	O
minimally	B-C0282624
invasive	I-C0282624
treatmen	I-C0282624
t	O
,	O
it	O
is	O
associated	B-C0332281
with	I-C0332281
complications	B-C0009566
,	O
the	O
most	O
common	B-C0205214
being	O
pneumothorax	B-C0032326
.	O
	
pneumothorax	B-C0032326
occurs	O
due	O
to	O
the	O
rapid	B-C0456962
target	B-C1521840
lobe	B-C0225752
volume	B-C0524689
reduction	I-C0524689
and	O
may	O
be	O
a	O
predictor	B-C2698872
of	O
clinical	B-C0205210
benefit	B-C0814225
despite	O
this	O
complication	B-C0009566
.	O
	
the	O
objective	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
conduct	O
an	O
exploratory	B-C3899452
data	I-C3899452
analysis	I-C3899452
of	O
patients	B-C0030705
who	O
developed	O
a	O
pneumothorax	B-C0032326
following	O
endoscopic	B-C0087111
valve	I-C0087111
therapy	I-C0087111
for	O
emphysema	B-C0034067
.	O
	
this	O
study	B-C2603343
performed	B-C0884358
a	O
retrospective	B-C0035363
evaluation	I-C0035363
of	O
pneumothorax	B-C0032326
management	B-C0376636
and	O
the	O
impact	B-C4049986
of	O
pneumothorax	B-C0032326
on	O
clinical	B-C2985631
outcomes	I-C2985631
in	O
70	O
patients	B-C0030705
following	O
valve	B-C0087111
therapy	I-C0087111
in	O
381	O
consecutive	B-C1707491
patients	B-C0030705
.	O
	
pneumothorax	B-C0032326
rate	B-C0026538
following	O
valve	B-C0087111
therapy	I-C0087111
was	O
18%	O
.	O
	
pneumothorax	B-C0032326
management	B-C0376636
consisted	O
of	O
chest	B-C0189476
tube	I-C0189476
insertion	I-C0189476
,	O
valve	B-C0042296
removal	B-C0015252
,	O
and	O
surgical	B-C0549433
intervention	I-C0549433
in	O
87%	O
61/70	O
,	O
44%	O
31/70	O
,	O
and	O
19%	O
13/70	O
of	O
the	O
patients	B-C0030705
,	O
respectively	O
.	O
	
despite	O
pneumothorax	B-C0032326
,	O
patients	B-C0030705
experienced	O
modest	B-C0205081
but	O
significant	B-C0750502
improvements	B-C2986411
in	O
lung	B-C0231921
function	I-C0231921
parameters	B-C0549193
forced	B-C0016529
expiratory	I-C0016529
volume	I-C0016529
in	O
1	O
second	O
55	O
ml	O
,	O
residual	B-C0035190
volume	I-C0035190
-390	O
ml	O
,	O
total	B-C0040509
lung	I-C0040509
capacity	I-C0040509
-348	O
all	O
p<0	O
.	O
	
persistent	B-C0205322
lobar	B-C0004144
atelectasis	I-C0004144
3	O
months	O
after	O
recovering	B-C1709864
from	O
pneumothorax	B-C0032326
,	O
which	O
was	O
associated	B-C0332281
with	I-C0332281
relevant	B-C2347946
clinical	B-C0205210
improvement	B-C2986411
,	O
was	O
observed	B-C1441672
in	O
only	O
21%	O
15/70	O
of	O
the	O
patients	B-C0030705
.	O
	
pneumothorax	B-C0032326
is	O
a	O
frequent	B-C0332183
severe	B-C0205082
complication	B-C0009566
following	O
valve	B-C0087111
therapy	I-C0087111
that	O
requires	O
further	O
intervention	B-C0184661
.	O
	
nevertheless	O
,	O
the	O
pneumothorax	B-C0032326
does	O
not	O
impair	B-C0221099
the	O
clinical	B-C0449440
status	I-C0449440
in	O
the	O
majority	O
of	O
patients	B-C0030705
.	O
	
patients	B-C0030705
with	O
lobar	B-C0004144
atelectasis	I-C0004144
benefit	B-C0814225
after	O
recovering	B-C1709864
from	O
pneumothorax	B-C0032326
in	O
terms	O
of	O
lung	B-C0231921
function	I-C0231921
parameters	B-C0549193
.	O
	
3mo	B-C0026336
a	O
model	B-C0026336
for	O
music	B-C0026867
-	O
based	B-C1527178
biofeedback	B-C0005491
in	O
the	O
domain	B-C1880389
of	O
sports	B-C0038039
and	O
motor	B-C0234130
rehabilitation	B-C0034992
,	O
it	O
is	O
of	O
major	B-C0205164
importance	B-C3898777
to	O
regulate	B-C1327622
and	O
control	B-C2587213
physiological	B-C0031845
processes	I-C0031845
and	O
physical	B-C0026597
motion	I-C0026597
in	O
most	B-C0205393
optimal	B-C2698651
ways	O
.	O
	
for	O
that	O
purpose	B-C1285529
,	O
real-time	B-C1550177
auditory	B-C0596134
feedback	I-C0596134
of	O
physiological	B-C0205463
and	O
physical	B-C0205485
information	B-C1533716
based	B-C1527178
on	O
sound	B-C0037709
signals	I-C0037709
,	O
often	O
termed	O
""""	O
sonification	B-C0449851
""""	O
has	O
been	O
proven	B-C0456369
particularly	O
useful	B-C3827682
.	O
	
however	O
,	O
the	O
use	B-C0457083
of	O
music	B-C0026867
in	O
biofeedback	B-C0005491
systems	B-C0449913
has	O
been	O
much	O
less	B-C0439092
explored	B-C1280903
.	O
	
in	O
the	O
current	B-C0521116
article	B-C1706852
,	O
we	O
assert	O
that	O
the	O
use	B-C0457083
of	O
music	B-C0026867
,	O
and	O
musical	B-C0026867
principles	B-C0178566
,	O
can	O
have	O
a	O
major	B-C0205164
added	O
value	B-C1554112
,	O
on	O
top	O
of	O
mere	B-C0547040
sound	B-C0037709
signals	I-C0037709
,	O
to	O
the	O
benefit	B-C0814225
of	O
psychological	B-C0205486
and	O
physical	B-C0205485
optimization	B-C2698650
of	O
sports	B-C0038039
and	O
motor	B-C0234130
rehabilitation	B-C0034992
tasks	B-C3540678
.	O
	
in	O
this	O
article	B-C1706852
,	O
we	O
present	B-C0449450
the	O
3mo	B-C0026336
model	I-C0026336
to	O
describe	O
three	O
main	B-C1542147
functions	B-C0542341
of	O
music	B-C0026867
that	O
contribute	B-C1880177
to	O
these	O
benefits	B-C0814225
.	O
	
these	O
functions	B-C0542341
relate	O
the	O
power	B-C0808080
of	O
music	B-C0026867
to	O
motivate	B-C0026605
,	O
and	O
to	O
monitor	B-C1283169
and	O
modify	B-C0392747
physiological	B-C0205463
and	O
physical	B-C0205485
processes	B-C1522240
.	O
	
the	O
model	B-C0026336
brings	O
together	O
concepts	B-C0178566
and	O
theories	B-C0871935
related	O
to	O
human	B-C0086418
sensorimotor	B-C0237434
interaction	I-C0237434
with	O
music	B-C0026867
,	O
and	O
specifies	B-C1521902
the	O
underlying	O
psychological	B-C0205486
and	O
physiological	B-C0205463
principles	B-C0178566
.	O
	
this	O
3mo	B-C0026336
model	I-C0026336
is	O
intended	B-C1283828
to	O
provide	B-C1999230
a	O
conceptual	B-C1254372
framework	I-C1254372
that	O
guides	B-C0681464
future	B-C0016884
research	B-C0035168
on	O
musical	B-C0026867
biofeedback	B-C0005491
systems	B-C0449913
in	O
the	O
domain	B-C1880389
of	O
sports	B-C0038039
and	O
motor	B-C0234130
rehabilitation	B-C0034992
.	O
	
analysis	B-C0002778
of	O
tilianin	B-C0966451
and	O
acacetin	B-C0100994
in	O
agastache	B-C1008095
rugosa	I-C1008095
by	O
high-performance	B-C0008562
liquid	I-C0008562
chromatography	I-C0008562
with	O
ionic	B-C1720867
liquids	I-C1720867
-	O
ultrasound	B-C0220934
based	O
extraction	B-C0684295
ionic	B-C1720867
liquid	I-C1720867
1-butyl-3-methylimidazolium	B-C1956443
bromide	I-C1956443
-	O
methanol	B-C0001963
-based	O
ultrasonic	B-C0220934
-assisted	O
extraction	B-C0684295
iluae	B-C0684295
was	O
used	O
to	O
extract	B-C0684295
tilianin	B-C0966451
and	O
acacetin	B-C0100994
from	O
the	O
aerial	B-C1136056
parts	I-C1136056
of	O
agastache	B-C1008095
rugose	I-C1008095
a	B-C1008095
.	O
	
rugose	I-C1008095
,	O
and	O
simultaneously	O
determined	O
by	O
reversed	B-C2717789
phase	I-C2717789
high	I-C2717789
performance	I-C2717789
liquid	I-C2717789
chromatographic	I-C2717789
rp-hplc	B-C2717789
method	O
with	O
ultraviolet	B-C0449335
detection	I-C0449335
rp-hplc-uv	B-C0449335
.	O
	
an	O
inertsustain	B-C1705246
rp-c18	I-C1705246
column	I-C1705246
was	O
used	O
with	O
the	O
mobile	B-C3469601
phase	I-C3469601
consisting	O
of	O
methanol	B-C0001963
and	O
0.2	O
acetic	B-C0000983
acid	I-C0000983
as	O
gradient	B-C0812409
elution	B-C1441565
at	O
the	O
detection	B-C0449819
wavelength	I-C0449819
of	O
332	O
nm	O
.	O
	
the	O
flow	B-C2826285
rate	I-C2826285
was	O
0.8	O
ml/min	O
,	O
and	O
the	O
column	B-C1705246
temperature	B-C0039476
was	O
30	O
c	O
.	O
	
under	O
the	O
optimized	B-C2698650
conditions	B-C0348080
,	O
tilianin	B-C0966451
and	O
acacetin	B-C0100994
displayed	O
good	O
linearity	O
in	O
the	O
ranges	O
of	O
0.0595	O
and	O
0.0585	O
μg/ml	O
,	O
respectively	O
,	O
with	O
the	O
average	O
recoveries	O
being	O
96.93	O
and	O
97.88	O
,	O
respectively	O
.	O
	
the	O
method	B-C0449851
of	O
iluae	B-C0684295
was	O
compared	O
with	O
the	O
traditional	B-C0449851
methods	I-C0449851
,	O
it	O
exhibited	O
higher	B-C0205250
efficiency	B-C0013682
,	O
higher	B-C0205250
reproducibility	B-C1514863
and	O
environmental	B-C0014406
friendly	I-C0014406
in	O
analyzing	O
the	O
active	B-C0205177
compounds	B-C1706082
in	O
traditional	B-C0025124
chinese	I-C0025124
medicines	I-C0025124
tcms	B-C0025124
.	O
	
evaluation	B-C0220825
of	O
mif	B-C1334507
-173	I-C1334507
g/c	I-C1334507
polymorphism	B-C0678951
in	O
turkish	B-C0549217
patients	B-C0030705
with	O
ankylosing	B-C0038013
spondylitis	I-C0038013
ankylosing	B-C0038013
spondylitis	I-C0038013
as	B-C0038013
is	O
a	O
chronic	B-C1290886
inflammatory	I-C1290886
disease	I-C1290886
mainly	O
affecting	O
the	O
spine	B-C0037949
and	O
sacroiliac	B-C0036036
joints	I-C0036036
.	O
	
macrophage	B-C0024429
migration	I-C0024429
inhibitory	I-C0024429
mif	I-C0024429
factor	I-C0024429
is	O
a	O
regulatory	B-C1704735
cytokine	B-C0079189
that	O
inhibits	B-C3463820
random	O
immune	B-C1326500
cell	I-C1326500
migration	I-C1326500
.	O
	
mif	B-C1334507
gene	I-C1334507
promoter	B-C0314621
polymorphisms	B-C0678951
play	O
a	O
role	O
in	O
the	O
progression	B-C0242656
of	O
several	O
inflammatory	B-C1290884
disorders	I-C1290884
.	O
	
to	O
investigate	B-C1292732
the	O
relationship	O
between	O
the	O
mif	B-C1334507
gene	I-C1334507
-173	I-C1334507
g/c	I-C1334507
single-nucleotide	B-C0752046
polymorphism	I-C0752046
snp	B-C0752046
and	O
as	B-C0038013
.	O
	
cross-sectional	B-C0010362
study	I-C0010362
.	O
	
in	O
this	O
study	B-C2603343
,	O
a	O
total	O
of	O
161	O
as	B-C0038013
and	O
194	O
normal	B-C3898900
controls	B-C0009932
were	O
recruited	O
.	O
	
the	O
mif	B-C1334507
gene	I-C1334507
-173	I-C1334507
g/c	I-C1334507
snp	B-C0752046
was	O
analyzed	B-C0936012
by	O
polymerase	B-C0032520
chain	I-C0032520
reaction	I-C0032520
using	O
the	O
restriction	B-C3714764
fragment	I-C3714764
length	I-C3714764
polymorphism	I-C3714764
method	I-C3714764
.	O
	
there	O
was	O
no	O
significant	B-C0750502
difference	O
between	O
groups	B-C1257890
in	O
terms	O
of	O
genotype	B-C0017431
distribution	O
p>0	O
.	O
	
when	O
wild-type	B-C1883559
g/g	B-C0017431
and	O
g/c+c/c	B-C0017431
genotypes	I-C0017431
are	O
compared	O
in	O
terms	O
of	O
clinical	B-C0683325
characteristics	I-C0683325
,	O
there	O
is	O
a	O
significant	B-C0750502
difference	O
between	O
the	O
average	O
age	B-C0001779
and	O
the	O
duration	B-C0872146
of	I-C0872146
disease	I-C0872146
in	O
as	B-C0038013
patients	B-C0030705
p<0	O
.	O
	
no	O
significant	B-C0750502
relationship	O
between	O
as	B-C0038013
disease	B-C0012634
and	O
mif	B-C1334507
-173	I-C1334507
g/c	I-C1334507
polymorphism	B-C0678951
was	O
found	O
.	O
	
mif	B-C1334507
-173	I-C1334507
g/c	I-C1334507
polymorphism	B-C0678951
c	B-C0002085
allele	I-C0002085
may	O
affect	O
the	O
time	O
of	O
onset	O
and	O
the	O
duration	B-C0872146
of	I-C0872146
disease	I-C0872146
in	O
as	B-C0038013
patients	B-C0030705
.	O
	
mechanisms	O
of	O
global	B-C2348867
cerebral	B-C0006114
edema	I-C0006114
formation	O
in	O
aneurysmal	B-C0751530
subarachnoid	I-C0751530
hemorrhage	I-C0751530
a	O
growing	O
body	O
of	O
clinical	B-C0205210
literature	B-C0023866
emphasizes	O
the	O
impact	O
of	O
cerebral	B-C0006114
edema	I-C0006114
in	O
early	B-C0270611
brain	I-C0270611
injury	I-C0270611
following	O
aneurysmal	B-C0751530
subarachnoid	I-C0751530
hemorrhage	I-C0751530
asah	B-C0751530
.	O
	
aneurysm	B-C0162869
rupture	I-C0162869
itself	O
initiates	O
global	B-C2348867
cerebral	B-C0006114
edema	I-C0006114
in	O
up	O
to	O
two	O
thirds	O
of	O
cases	O
.	O
	
although	O
cerebral	B-C0006114
edema	I-C0006114
is	O
not	O
a	O
universal	O
feature	O
of	O
asah	B-C0751530
,	O
it	O
portends	O
a	O
poor	O
clinical	B-C0449259
course	I-C0449259
,	O
with	O
quantitative	B-C0034384
analysis	I-C0034384
revealing	O
a	O
direct	O
correlation	O
between	O
cerebral	B-C0006114
edema	I-C0006114
and	O
poor	B-C3806166
outcome	I-C3806166
,	O
including	O
mortality	O
and	O
cognitive	O
deficits	O
.	O
	
mechanistically	O
,	O
global	B-C2348867
cerebral	B-C0006114
edema	I-C0006114
has	O
been	O
linked	O
to	O
global	B-C2348867
ischemia	B-C0022116
at	O
the	O
time	O
of	O
aneurysm	B-C0162869
rupture	I-C0162869
,	O
dysfunction	B-C3887504
of	O
autoregulation	B-C0019868
,	O
blood	B-C2937287
breakdown	I-C2937287
products	B-C1514468
,	O
neuroinflammation	B-C1408627
,	O
and	O
hyponatremia	B-C0020625
/	O
endocrine	B-C4025823
abnormalities	I-C4025823
.	O
	
at	O
a	O
molecular	B-C1521991
level	B-C0441889
,	O
several	O
culprits	O
have	O
been	O
identified	O
,	O
including	O
aquaporin-4	B-C0292777
,	O
matrix	B-C0165519
metalloproteinase-9	I-C0165519
,	O
sur1	B-C3711621
-	O
trpm4	B-C1384655
cation	I-C1384655
channels	I-C1384655
,	O
vascular	B-C1171892
endothelial	I-C1171892
growth	I-C1171892
factor	I-C1171892
,	O
bradykinin	B-C0006100
,	O
and	O
others	O
.	O
	
here	O
,	O
we	O
review	O
these	O
cellular	B-C0007634
and	O
molecular	B-C1521991
mechanisms	O
of	O
global	B-C2348867
cerebral	B-C0006114
edema	I-C0006114
formation	O
in	O
asah	B-C0751530
.	O
	
given	O
the	O
importance	O
of	O
edema	B-C0013604
to	O
the	O
outcome	O
of	O
patients	B-C0030705
with	O
asah	B-C0751530
and	O
its	O
status	B-C0449438
as	O
a	O
highly	O
modifiable	O
pathological	B-C0030660
process	I-C0030660
,	O
a	O
better	O
understanding	O
of	O
cerebral	B-C0006114
edema	I-C0006114
in	O
asah	B-C0751530
promises	O
to	O
hasten	O
the	O
development	O
of	O
medical	B-C0418981
therapies	I-C0418981
to	O
improve	O
outcomes	O
in	O
this	O
frequently	O
devastating	B-C0332663
disease	B-C0012634
.	O
	
biliary	B-C0005423
phospholipids	B-C0031676
sustain	B-C0443318
enterocyte	B-C0682610
proliferation	B-C0596290
and	O
intestinal	B-C0021841
tumor	I-C0021841
progression	B-C0178874
via	O
nuclear	B-C0206588
receptor	I-C0206588
lrh1	B-C1448055
in	O
mice	B-C0025929
the	O
proliferative-	O
crypt	B-C3686613
compartment	I-C3686613
of	O
the	O
intestinal	B-C0226890
epithelium	I-C0226890
is	O
enriched	O
in	O
phospholipids	B-C0031676
and	O
accumulation	B-C4055506
of	O
phospholipids	B-C0031676
has	O
been	O
described	O
in	O
colorectal	B-C0009404
tumors	I-C0009404
.	O
	
here	O
we	O
hypothesize	O
that	O
biliary	B-C0005423
phospholipid	B-C0031676
flow	B-C0806140
could	O
directly	O
contribute	O
to	O
the	O
proliferative	B-C1514485
power	I-C1514485
of	O
normal	B-C0682610
and	O
dysplastic	B-C1512101
enterocytes	I-C1512101
.	O
	
we	O
used	O
abcb4	B-C1412071
-/-	O
mice	B-C0025929
which	O
lack	O
biliary	B-C0005423
phospholipid	B-C0031676
secretion	B-C0036536
.	O
	
we	O
first	O
show	O
that	O
abcb4	B-C1412071
-/-	O
mice	B-C0025929
are	O
protected	B-C1545588
against	O
intestinal	B-C0021853
tumorigenesis	B-C0007621
.	O
	
at	O
the	O
molecular	B-C1521991
level	B-C0441889
,	O
the	O
transcriptional	B-C1148759
activity	I-C1148759
of	O
the	O
nuclear	B-C0206588
receptor	I-C0206588
liver	B-C1448055
receptor	I-C1448055
homolog-1	I-C1448055
lrh1	B-C1448055
is	O
reduced	B-C0392756
in	O
abcb4	B-C1412071
-/-	O
mice	B-C0025929
and	O
its	O
re-activation	B-C4086768
re-establishes	O
a	O
tumor	B-C0027651
burden	B-C2828008
comparable	O
to	O
control	B-C0009932
mice	B-C0025929
.	O
	
feeding	B-C2987508
abcb4	B-C1412071
-/-	O
mice	B-C0025929
a	O
diet	B-C0242295
supplemented	I-C0242295
with	O
phospholipids	B-C0031676
completely	O
overcomes	B-C2983310
the	O
intestinal	B-C0021841
tumor	I-C0021841
protective	O
phenotype	B-C0031437
,	O
thus	O
corroborating	O
the	O
hypothesis	O
that	O
the	O
absence	B-C0332197
of	O
biliary	B-C0005423
phospholipids	B-C0031676
and	O
not	O
lack	O
of	O
abcb4	B-C1412071
gene	I-C1412071
per	O
se	O
is	O
responsible	O
for	O
the	O
protection	B-C1545588
.	O
	
in	O
turn	O
,	O
phospholipids	B-C0031676
cannot	O
re-establish	O
intestinal	B-C0021853
tumorigenesis	B-C0007621
in	O
abcb4	B-C1412071
-/-	O
mice	B-C0025929
crossed	O
with	O
mice	B-C0025929
with	O
intestinal	B-C0021853
specific	B-C0205369
ablation	B-C0547070
of	O
lrh1	B-C1448055
,	O
a	O
nuclear	B-C0887829
hormone	I-C0887829
receptor	I-C0887829
that	O
is	O
activates	B-C1879547
by	O
phospholipids	B-C0031676
.	O
	
our	O
data	B-C1511726
identify	O
the	O
key	O
role	O
of	O
biliary	B-C0005423
phospholipids	B-C0031676
in	O
sustaining	O
intestinal	B-C0021839
mucosa	I-C0021839
proliferation	B-C1514485
and	O
tumor	B-C0178874
progression	I-C0178874
through	O
the	O
activation	B-C1879547
of	O
nuclear	B-C0206588
receptor	I-C0206588
lrh1	B-C1448055
.	O
	
metalloproteinase	B-C0025543
meprin	B-C1622778
α	I-C1622778
regulates	O
migration	B-C1622501
and	O
invasion	B-C1269955
of	O
human	B-C0086418
hepatocarcinoma	B-C2239176
cells	B-C0334227
and	O
is	O
a	O
mediator	O
of	O
the	O
oncoprotein	B-C0029005
reptin	B-C1120857
hepatocellular	B-C2239176
carcinoma	I-C2239176
is	O
associated	B-C0332281
with	I-C0332281
a	O
high	B-C0205250
rate	B-C1521828
of	O
intra-hepatic	B-C0205054
invasion	B-C1269955
that	O
carries	O
a	O
poor	B-C0278252
prognosis	I-C0278252
.	O
	
meprin	B-C1622778
alpha	I-C1622778
mep1a	B-C1622778
is	O
a	O
secreted	B-C1327616
metalloproteinase	B-C0025543
with	O
many	O
substrates	O
relevant	O
to	O
cancer	B-C1269955
invasion	I-C1269955
.	O
	
we	O
found	O
that	O
mep1a	B-C1622778
was	O
a	O
target	B-C1521840
of	O
reptin	B-C1120857
,	O
a	O
protein	B-C0029005
that	I-C0029005
is	I-C0029005
oncogenic	I-C0029005
in	O
hcc	B-C2239176
.	O
	
we	O
studied	O
mep1a	B-C1622778
regulation	B-C1327622
by	O
reptin	B-C1120857
,	O
its	O
role	O
in	O
hcc	B-C2239176
,	O
and	O
whether	O
it	O
mediates	O
reptin	B-C1120857
oncogenic	B-C0007090
effects	B-C1280500
.	O
	
mepa	B-C1622778
and	O
reptin	B-C1120857
expression	B-C1171362
was	O
measured	O
in	O
human	B-C0086418
hcc	B-C2239176
by	O
qrt-pcr	B-C1514628
and	O
in	O
cultured	B-C0007635
cells	I-C0007635
by	O
pcr	B-C0032520
,	O
western	B-C0949466
blot	I-C0949466
and	O
enzymatic	B-C0681902
activity	I-C0681902
measurements	I-C0681902
.	O
	
cell	B-C0007595
growth	I-C0007595
was	O
assessed	B-C1516048
by	O
counting	B-C0007584
and	O
mts	B-C2986858
assay	I-C2986858
.	O
	
cell	B-C1622501
migration	I-C1622501
was	O
measured	O
in	O
boyden	B-C3874231
chambers	I-C3874231
and	O
wound	B-C0043240
healing	I-C0043240
assays	B-C0005507
,	O
and	O
cell	B-C1269955
invasion	I-C1269955
in	O
boyden	B-C3874231
chambers	I-C3874231
.	O
	
silencing	B-C0598496
reptin	B-C1419774
decreased	B-C0205216
mep1a	B-C1622778
expression	B-C1171362
and	O
activity	B-C0441655
,	O
without	O
affecting	O
meprin	B-C1451346
β	I-C1451346
.	O
	
mep1a	B-C1622778
,	O
but	O
not	O
meprin	B-C1451346
β	I-C1451346
,	O
was	O
overexpressed	B-C1514559
in	O
a	O
series	O
of	O
242	O
human	B-C0086418
hcc	B-C2239176
2.04	O
fold	O
,	O
p	O
<	O
0.0001	O
,	O
and	O
a	O
high	B-C0205250
expression	B-C1171362
correlated	B-C1707520
with	O
a	O
poor	B-C0278252
prognosis	I-C0278252
.	O
	
mep1a	B-C1622778
and	O
reptin	B-C1120857
expressions	B-C1171362
were	O
positively	O
correlated	B-C1707520
r	O
=	O
0.39	O
,	O
p	O
<	O
0.0001	O
.	O
	
silencing	B-C0598496
mep1a	B-C1417113
had	O
little	O
effect	O
on	O
cell	B-C0596290
proliferation	I-C0596290
,	O
but	O
decreased	B-C0205216
cell	B-C1622501
migration	I-C1622501
and	O
invasion	B-C1269955
of	O
huh7	B-C0007601
and	O
hep3b	B-C0007601
cells	I-C0007601
.	O
	
conversely	O
,	O
overexpression	B-C1514559
of	O
mep1a	B-C1622778
or	O
addition	O
of	O
recombinant	B-C1514798
mep1a	B-C1622778
increased	B-C0205217
migration	B-C1622501
and	O
invasion	B-C1269955
.	O
	
finally	O
,	O
overexpression	B-C1514559
of	O
mep1a	B-C1622778
restored	O
a	O
normal	B-C0205307
cell	B-C1622501
migration	I-C1622501
in	O
cells	B-C0334227
where	O
reptin	B-C1120857
was	O
depleted	B-C0333668
.	O
	
mep1a	B-C1622778
is	O
overexpressed	B-C1514559
in	O
most	O
hcc	B-C2239176
and	O
induces	B-C0205263
hcc	B-C2239176
cell	B-C1622501
migration	I-C1622501
and	O
invasion	B-C1269955
.	O
	
mep1a	B-C1622778
expression	B-C1171362
is	O
regulated	O
by	O
reptin	B-C1120857
,	O
and	O
mep1a	B-C1622778
mediates	O
reptin	B-C1120857
-	O
induced	B-C0205263
migration	B-C1622501
.	O
	
overall	O
,	O
we	O
suggest	O
that	O
mep1a	B-C1622778
may	O
be	O
a	O
useful	O
target	B-C1521840
in	O
psychosocial	B-C0033963
impact	I-C0033963
on	O
families	B-C0015576
with	O
an	O
infant	B-C0021270
with	O
a	O
hypoplastic	B-C0152101
left	I-C0152101
heart	I-C0152101
syndrome	I-C0152101
during	B-C1254367
and	I-C1254367
after	I-C1254367
the	I-C1254367
interstage	I-C1254367
monitoring	I-C1254367
period	I-C1254367
-	O
a	O
prospective	B-C0033522
mixed-method	I-C0033522
study	I-C0033522
to	O
investigate	O
parents'	B-C0596545
experiences	I-C0596545
,	O
coping	B-C0009967
ability	I-C0009967
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
while	O
monitoring	B-C0030695
their	O
sick	B-C0260101
child	I-C0260101
with	O
hypoplastic	B-C0152101
left	I-C0152101
heart	I-C0152101
syndrome	I-C0152101
at	O
home	B-C0442519
.	O
	
interstage	B-C0030695
home	I-C0030695
monitoring	I-C0030695
for	O
children	B-C0008059
with	O
hypoplastic	B-C0152101
left	I-C0152101
heart	I-C0152101
syndrome	I-C0152101
reduces	O
interstage	O
mortality	B-C0008083
between	O
norwood	B-C2242650
stages	I-C2242650
i	I-C2242650
and	I-C2242650
ii	I-C2242650
.	O
	
little	O
is	O
known	O
about	O
the	O
psychosocial	B-C0033963
impact	I-C0033963
of	O
interstage	B-C0030695
home	I-C0030695
monitoring	I-C0030695
.	O
	
prospective	B-C0033522
mixed-method	I-C0033522
study	I-C0033522
.	O
	
this	O
study	O
assessed	O
the	O
psychosocial	B-C0033963
impact	I-C0033963
on	O
parents	B-C0030551
during	O
interstage	B-C0030695
home	I-C0030695
monitoring	I-C0030695
.	O
	
this	O
contains	O
for	O
quantitative	B-C0034384
assessment	I-C0034384
the	O
short	B-C1714475
form	I-C1714475
health	I-C1714475
survey	I-C1714475
questionnaire	I-C1714475
and	O
the	O
impact	O
of	O
family	B-C0243095
scale	I-C0243095
administered	I-C0243095
one	O
and	O
five	O
weeks	O
following	O
discharge	B-C0030685
before	B-C1254367
and	I-C1254367
after	I-C1254367
stage	I-C1254367
ii	I-C1254367
.	O
	
for	O
qualitative	B-C0034375
assessment	I-C0034375
,	O
semi-structured	B-C0681913
interviews	I-C0681913
focussing	O
on	O
the	O
postdischarge	B-C1320368
coping	B-C0474179
strategies	I-C0474179
were	O
conducted	O
twice	O
,	O
five	O
weeks	O
after	B-C1320368
hospital	I-C1320368
discharge	I-C1320368
before	B-C1254367
and	I-C1254367
after	I-C1254367
stage	I-C1254367
ii	I-C1254367
.	O
	
ten	O
infants	B-C0021270
eight	O
males	B-C0086582
with	O
hypoplastic	B-C0152101
left	I-C0152101
heart	I-C0152101
syndrome	I-C0152101
n	O
=	O
7	O
or	O
other	O
types	O
of	O
univentricular	B-C0018798
heart	I-C0018798
malformations	I-C0018798
n	O
=	O
3	O
,	O
and	O
their	O
parents	B-C0030551
nine	O
mother/father	B-C0030551
two-	O
parent	B-C0030551
households	B-C0020052
,	O
one	O
single	B-C0337491
mother	I-C0337491
were	O
included	O
.	O
	
there	O
were	O
no	B-C0243095
interstage	I-C0243095
deaths	I-C0243095
.	O
	
mental	B-C0025353
health	I-C0025353
composite	B-C4055211
summary	I-C4055211
scores	I-C4055211
were	O
low	O
in	O
both	O
parents	B-C0030551
mothers	B-C0026591
40	O
9	O
fathers	B-C0015671
40	O
9	O
and	O
lowest	O
for	O
the	O
item	O
'	O
vitality	B-C0424589
'	O
mothers	B-C0026591
37	O
19	O
fathers	B-C0015671
43	O
25	O
before	B-C1254367
and	I-C1254367
after	I-C1254367
stage	I-C1254367
ii	I-C1254367
.	O
	
impact	O
of	O
family	B-C0243095
scale	I-C0243095
values	I-C0243095
showed	O
higher	O
daily	O
and	O
social	B-C2828008
burdens	I-C2828008
for	O
mothers	B-C0026591
.	O
	
'becoming	O
a	O
family'	O
was	O
the	O
most	O
important	O
task	O
as	O
coping	B-C0474179
strategy	I-C0474179
to	O
equilibrate	O
the	O
fragile	B-C0233459
emotional	I-C0233459
balance	I-C0233459
.	O
	
the	O
parents	B-C0030551
judged	O
interstage	B-C0030695
home	I-C0030695
monitoring	I-C0030695
as	O
a	O
protective	B-C0184661
intervention	I-C0184661
.	O
	
although	O
psychosocial	B-C0033963
burden	I-C0033963
before	B-C1254367
and	I-C1254367
after	I-C1254367
stage	I-C1254367
ii	I-C1254367
remains	O
high	O
,	O
becoming	O
a	O
family	B-C0015576
is	O
an	O
essential	O
experience	O
for	O
parents	B-C0030551
and	O
confirms	O
their	O
parenthood	B-C0337469
.	O
	
healthcare	B-C0018724
professionals	I-C0018724
must	O
be	O
aware	O
of	O
parents	B-C0030551
'	O
needs	O
during	O
this	O
vulnerable	B-C1254367
interstage	I-C1254367
period	I-C1254367
and	O
to	O
provide	O
psychosocial	B-C0542298
and	O
nursing	B-C0028678
support	I-C0028678
.	O
	
rates	B-C1521828
and	O
predictors	B-C2698872
of	O
injury	B-C0178314
in	O
a	O
population	B-C0032659
-	O
based	B-C1527178
cohort	B-C0599755
of	O
people	B-C0027361
living	B-C0376558
with	O
hiv	B-C0019693
injuries	B-C0178314
are	O
responsible	O
for	O
10%	O
of	O
the	O
global	B-C2348867
burden	B-C2828008
of	O
disease	B-C0012634
however	O
,	O
the	O
epidemiology	B-C0014508
of	O
injury	B-C0178314
among	O
people	B-C0019693
living	I-C0019693
with	I-C0019693
hiv	I-C0019693
plhiv	B-C0019693
has	O
not	B-C3841798
been	I-C3841798
well	I-C3841798
elucidated	B-C2986669
.	O
	
this	O
study	B-C2603343
seeks	O
to	O
characterize	B-C1880022
rates	B-C1521828
and	O
predictors	B-C2698872
of	O
injury	B-C0178314
among	O
plhiv	B-C0019693
compared	B-C1707455
to	O
the	O
general	B-C0683971
population	I-C0683971
in	O
british	B-C0006193
columbia	I-C0006193
bc	B-C0006193
,	O
canada	B-C0006823
.	O
	
a	O
population	B-C0032659
-	O
based	B-C1527178
dataset	B-C0150098
was	O
created	B-C1707531
via	O
linkage	B-C0242239
between	B-C0205103
the	O
bc	B-C1708333
centre	I-C1708333
for	I-C1708333
excellence	I-C1708333
in	I-C1708333
hiv/aids	I-C1708333
and	O
populationdatabc	B-C1511726
.	O
	
plhiv	B-C0019693
aged	B-C0001779
20	B-C0439234
years	I-C0439234
and	O
older	B-C0580836
were	O
compared	B-C1707455
to	O
a	O
random	B-C0439605
10%	O
sample	B-C0370003
of	O
the	O
adult	B-C0001675
general	B-C0683971
population	I-C0683971
.	O
	
the	O
international	B-C1512888
classification	B-C0008902
of	O
diseases	B-C0012634
9	O
and	O
10	O
codes	O
were	O
used	B-C1524063
to	O
classify	B-C0008902
unintentional	B-C0151736
and	O
intentional	B-C0151737
injuries	I-C0151737
based	B-C1527178
on	O
the	O
external	B-C1407879
cause	I-C1407879
of	O
the	O
injury	B-C0178314
from	O
1996	O
to	O
2013	O
.	O
	
generalized	B-C0026348
estimating	I-C0026348
equation	I-C0026348
gee	B-C0026348
poisson	B-C0023962
regression	I-C0023962
models	I-C0023962
were	O
fit	O
to	O
estimate	B-C0750572
the	O
effect	B-C1280500
of	O
hiv	B-C0019693
status	B-C0449438
on	O
rates	B-C1521828
of	O
unintentional	B-C0151736
and	O
intentional	B-C0151737
injury	I-C0151737
,	O
and	O
to	O
identify	B-C0205396
correlates	B-C1707520
of	O
injury	B-C0178314
among	O
plhiv	B-C0019693
.	O
	
the	O
crude	O
incidence	B-C1708485
rate	I-C1708485
of	O
unintentional	B-C0151736
injury	I-C0151736
was	O
18.56	O
person	B-C0027361
-	O
years	B-C0439234
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
17.77	O
among	O
plhiv	B-C0019693
and	O
8.51	O
person	B-C0027361
-	O
years	B-C0439234
95%	O
ci	B-C0009667
8.42	O
in	O
the	O
general	B-C0683971
population	I-C0683971
.	O
	
among	O
plhiv	B-C0019693
,	O
13.45	O
of	O
deaths	B-C1306577
were	O
due	B-C0678226
to	I-C0678226
injury	B-C0178314
,	O
compared	B-C1707455
to	O
5.52	O
of	O
deaths	B-C1306577
in	O
the	O
general	B-C0683971
population	I-C0683971
.	O
	
in	O
adjusted	O
models	B-C0026348
,	O
plhiv	B-C0019693
were	O
more	O
likely	O
to	O
report	B-C0700287
unintentional	B-C0151736
incidence	B-C1708485
rate	I-C1708485
ratio	B-C0456603
1.42	O
,	O
95%	O
ci	B-C0009667
1.32	O
and	O
intentional	B-C0151737
injury	I-C0151737
incidence	B-C1708485
rate	I-C1708485
ratio	B-C0456603
1.93	O
,	O
95%	O
ci	B-C0009667
1.70	O
compared	B-C1707455
to	O
the	O
general	B-C0683971
population	I-C0683971
.	O
	
we	O
identified	B-C0205396
elevated	B-C3163633
rates	B-C1521828
of	O
intentional	B-C0151737
and	O
unintentional	B-C0151736
injury	I-C0151736
among	O
plhiv	B-C0019693
.	O
	
injuries	B-C0178314
are	O
largely	B-C0549177
preventable	B-C1547273
as	O
such	O
,	O
targeted	B-C1521840
efforts	O
are	O
needed	B-C0027552
to	O
decrease	B-C0547047
the	O
burden	B-C2828008
of	O
injury	B-C0178314
-	O
related	B-C0439849
disability	B-C0231170
and	O
death	B-C1306577
among	O
trek-1	B-C0754471
k2p2.1	I-C0754471
k	I-C0754471
channels	I-C0754471
are	O
suppressed	B-C1260953
in	O
patients	B-C0030705
with	O
atrial	B-C0004238
fibrillation	I-C0004238
and	O
heart	B-C0018801
failure	I-C0018801
and	O
provide	B-C1999230
therapeutic	B-C0302350
targets	I-C0302350
for	O
rhythm	B-C0243148
control	I-C0243148
atrial	B-C0004238
fibrillation	I-C0004238
af	B-C0004238
is	O
the	O
most	O
common	O
cardiac	B-C0003811
arrhythmia	I-C0003811
.	O
	
concomitant	B-C0018801
heart	I-C0018801
failure	I-C0018801
hf	B-C0018801
poses	O
a	O
particular	O
therapeutic	B-C0302350
challenge	B-C1315011
and	O
is	O
associated	O
with	O
prolonged	B-C0439590
atrial	B-C0034954
electrical	I-C0034954
refractoriness	I-C0034954
compared	O
with	O
non-failing	B-C0018787
hearts	I-C0018787
.	O
	
we	O
hypothesized	O
that	O
downregulation	B-C0013081
of	O
atrial	B-C1371280
repolarizing	I-C1371280
trek-1	B-C0754471
k2p2.1	I-C0754471
k	I-C0754471
channels	I-C0754471
contributes	B-C1880177
to	O
electrical	B-C3658220
remodeling	I-C3658220
during	O
af	B-C0004238
with	O
hf	B-C0018801
,	O
and	O
that	O
trek-1	B-C1517499
gene	I-C1517499
transfer	I-C1517499
would	O
provide	O
rhythm	B-C0243148
control	I-C0243148
via	O
normalization	B-C1882115
of	O
atrial	B-C0428938
effective	I-C0428938
refractory	I-C0428938
periods	I-C0428938
in	O
this	O
af	B-C0004238
subset	B-C2986480
.	O
	
in	O
patients	B-C0030705
with	O
chronic	B-C0694539
af	I-C0694539
and	O
hf	B-C0018801
,	O
atrial	B-C0754471
trek-1	I-C0754471
mrna	B-C0035696
levels	B-C0441889
were	O
reduced	O
by	O
82%	O
left	B-C0225860
atrium	I-C0225860
and	O
81%	O
right	B-C0225844
atrium	I-C0225844
compared	O
with	O
sinus	B-C0232201
rhythm	I-C0232201
sr	B-C0232201
subjects	B-C0080105
.	O
	
human	B-C0086418
findings	B-C0243095
were	O
recapitulated	O
in	O
a	O
porcine	B-C0026336
model	I-C0026336
of	O
atrial	B-C0004238
tachypacing-induced	I-C0004238
af	I-C0004238
and	O
reduced	B-C0392756
left	B-C0080310
ventricular	I-C0080310
function	I-C0080310
.	O
	
trek-1	B-C0754471
mrna	B-C0035696
-66%	O
and	O
protein	B-C0754471
-61%	O
was	O
suppressed	B-C1260953
in	O
af	B-C0004238
animals	B-C0003062
at	O
14-day	O
follow-up	O
compared	B-C1707455
with	O
sr	B-C0232201
controls	O
.	O
	
downregulation	B-C0013081
of	O
repolarizing	B-C1371280
trek-1	B-C0754471
channels	I-C0754471
was	O
associated	O
with	O
prolongation	B-C0439590
of	O
atrial	B-C0428938
effective	I-C0428938
refractory	I-C0428938
periods	I-C0428938
versus	O
baseline	B-C1442488
conditions	O
,	O
consistent	B-C0332290
with	I-C0332290
prior	B-C0332152
observations	B-C0302523
in	O
humans	B-C0086418
with	O
hf	B-C0018801
.	O
	
in	O
a	O
preclinical	B-C1709630
therapeutic	B-C0302350
approach	I-C0302350
,	O
pigs	B-C0039005
were	O
randomized	B-C0034656
to	O
either	O
atrial	B-C0017296
ad-trek-1	I-C0017296
gene	I-C0017296
therapy	I-C0017296
or	O
sham	B-C0032042
treatment	I-C0032042
.	O
	
gene	B-C1517499
transfer	I-C1517499
effectively	B-C1280519
increased	B-C0205217
trek-1	B-C0754471
protein	I-C0754471
levels	B-C0441889
and	O
attenuated	B-C0599946
atrial	B-C0428938
effective	I-C0428938
refractory	I-C0428938
period	I-C0428938
prolongation	B-C0439590
in	O
the	O
porcine	B-C0026336
af	I-C0026336
model	I-C0026336
.	O
	
ad-trek-1	B-C0754471
increased	O
the	O
sr	B-C0232201
prevalence	B-C0033105
to	O
62%	O
during	O
follow-up	O
in	O
af	B-C0004238
animals	B-C0003062
,	O
compared	B-C1707455
to	O
35%	O
in	O
the	O
untreated	O
af	B-C0004238
group	O
.	O
	
in	O
conclusion	B-C1707478
,	O
trek-1	B-C0754471
downregulation	B-C0013081
and	O
rhythm	B-C0243148
control	I-C0243148
by	O
ad-trek-1	B-C1517499
transfer	I-C1517499
suggest	B-C1705535
mechanistic	B-C0087111
and	I-C0087111
potential	I-C0087111
therapeutic	I-C0087111
significance	B-C0750502
of	O
trek-1	B-C0754471
channels	I-C0754471
in	O
a	O
subgroup	B-C1515021
of	O
af	B-C0004238
patients	B-C0030705
with	O
hf	B-C0018801
and	O
prolonged	B-C0439590
atrial	B-C0428938
effective	I-C0428938
refractory	I-C0428938
periods	I-C0428938
.	O
	
functional	B-C0205245
correction	I-C0205245
of	O
ionic	O
remodeling	O
through	O
trek-1	B-C0017296
gene	I-C0017296
therapy	I-C0017296
represents	O
a	O
novel	B-C0205314
paradigm	B-C0681797
to	O
optimize	O
and	O
specify	O
af	B-C0004238
a	O
rasch	B-C0871207
rating	I-C0871207
scale	I-C0871207
analysis	B-C0936012
of	O
the	O
presence	B-C0150312
of	O
nursing	B-C0028677
scale	B-C0681889
-	O
rn	B-C0687673
the	O
phenomenon	B-C1882365
of	O
nursing	B-C0028677
presence	B-C0150312
encompasses	O
the	O
emotional	B-C0849912
connection	B-C0449379
between	O
nurse	B-C0028661
and	O
patient	B-C0030705
,	O
and	O
technical	B-C0449851
skills	I-C0449851
performed	B-C0884358
by	O
the	O
nurse	B-C0028661
.	O
	
the	O
presence	B-C0150312
of	O
nursing	B-C0028677
scale	B-C0681889
-	O
rn	B-C0687673
version	B-C0333052
pons	B-C0681889
-	O
rn	B-C0687673
was	O
developed	B-C1527148
to	O
measure	B-C0079809
nurses'	B-C0028661
perceptions	B-C0030971
of	O
their	O
ability	B-C0085732
to	O
be	O
present	B-C0150312
to	O
their	O
patients	B-C0030705
.	O
	
this	O
study	B-C2603343
summarizes	B-C1706244
the	O
process	B-C1522240
of	O
re-evaluation	B-C0681840
of	O
the	O
psychometric	B-C0033920
properties	I-C0033920
of	O
the	O
pons	B-C0681889
-	O
rn	B-C0687673
instrument	O
.	O
	
a	O
sample	B-C1257890
of	O
76	O
registered	B-C0687673
nurses	I-C0687673
providing	B-C1999230
direct	B-C1947931
patient	B-C0017313
care	I-C0017313
responded	B-C2911692
to	O
the	O
31-	O
item	B-C1551338
questionnaire	B-C0034394
.	O
	
the	O
rasch	B-C0871207
rating	I-C0871207
scale	I-C0871207
model	I-C0871207
was	O
used	O
for	O
assessing	B-C0184514
construct	B-C0681897
validity	I-C0681897
of	O
pons	B-C0681889
-	O
rn	B-C0687673
data	B-C1511726
.	O
	
a	O
principal	B-C0429865
component	I-C0429865
analysis	I-C0429865
pca	B-C0429865
of	O
residuals	B-C1609982
supported	B-C1521721
appropriateness	B-C0814634
of	O
the	O
subscales	B-C0459443
defined	O
by	O
a	O
2-dimensional	B-C1705052
structure	B-C0678594
.	O
	
the	O
results	B-C0683954
of	O
item	B-C1551338
and	O
person	B-C0027361
fit	B-C2349186
analysis	B-C0936012
,	O
rating	B-C0681889
scale	I-C0681889
functioning	B-C0205245
analysis	B-C0936012
and	O
reliability	B-C0814892
analysis	I-C0814892
have	O
demonstrated	B-C0443289
that	O
the	O
thirty-one	O
item	B-C1551338
presence	B-C0150312
of	O
nursing	B-C0028677
scale	B-C0681889
-	O
rn	B-C0687673
instrument	O
yielded	O
measures	B-C0079809
with	O
high	B-C0205250
validity	B-C0814892
and	I-C0814892
reliability	I-C0814892
as	O
two	O
sub-scales	B-C0459443
.	O
	
jou	O
elastin	B-C0013765
is	O
differentially	B-C2755857
regulated	I-C2755857
by	O
pressure	B-C1956078
therapy	I-C1956078
in	O
a	O
porcine	B-C3665571
model	B-C0599779
of	O
hypertrophic	B-C0162810
scar	I-C0162810
beneficial	B-C1280500
effects	I-C1280500
of	O
pressure	B-C1956078
therapy	I-C1956078
for	O
hypertrophic	B-C0162810
scars	I-C0162810
have	O
been	O
reported	O
,	O
but	O
the	O
mechanisms	B-C0441712
of	O
action	O
are	O
not	O
fully	O
understood	O
.	O
	
this	O
study	B-C2603343
evaluated	O
elastin	B-C0013765
and	O
its	O
contribution	O
to	O
scar	B-C0162810
pliability	B-C0242808
.	O
	
the	O
relationship	B-C0439849
between	O
changes	O
in	O
vancouver	B-C0349674
scar	I-C0349674
scale	I-C0349674
vss	B-C0349674
scores	B-C0449820
of	O
pressure-treated	B-C1956078
scars	B-C0162810
and	O
differential	O
regulation	O
of	O
elastin	B-C0013765
was	O
assessed	O
.	O
	
hypertrophic	B-C0162810
scars	I-C0162810
were	O
created	O
and	O
assessed	O
weekly	B-C0332174
using	O
vss	B-C0349674
and	O
biopsy	B-C0005558
procurement	B-C0243095
.	O
	
pressure	B-C1956078
treatment	I-C1956078
began	O
on	O
day	B-C0439228
70	O
postinjury	B-C1254367
.	O
	
treated	B-C0087111
scars	B-C0162810
were	O
compared	B-C1707455
with	O
untreated	O
shams	B-C0032042
.	O
	
treatment	B-C0087111
lasted	O
2	O
weeks	B-C0439230
,	O
through	O
day	B-C0439228
84	O
,	O
and	O
scars	B-C0162810
were	O
assessed	O
weekly	B-C0332174
through	O
day	B-C0439228
126	O
.	O
	
transcript	B-C1519595
and	O
protein	B-C0428479
levels	I-C0428479
of	O
elastin	B-C0013765
were	O
quantified	B-C1709793
.	O
	
pressure	B-C1956078
treatment	I-C1956078
resulted	O
in	O
lower	O
vss	B-C0349674
scores	B-C0449820
compared	B-C1707455
with	O
sham-treated	B-C0032042
scars	B-C0162810
.	O
	
pliability	B-C0242808
vssp	B-C0242808
was	O
a	O
key	O
contributor	O
to	O
this	O
difference	O
.	O
	
at	O
day	B-C0439228
70	O
pretreatment	B-C3539076
,	O
vssp	B-C0242808
=	O
2	O
.	O
	
without	B-C0032042
treatment	I-C0032042
,	O
sham-treated	B-C0032042
scars	B-C0162810
became	O
less	O
pliable	B-C0242808
,	O
while	O
pressure-treated	B-C1956078
scars	B-C0162810
became	O
more	O
pliable	B-C0242808
.	O
	
the	O
percentage	O
of	O
elastin	B-C0013765
in	O
scars	B-C0162810
at	O
day	B-C0439228
70	O
was	O
higher	O
than	O
in	O
uninjured	B-C1123023
skin	I-C1123023
.	O
	
following	O
treatment	B-C0087111
,	O
the	O
percentage	O
of	O
elastin	B-C0013765
increased	B-C0205217
and	O
continued	O
to	O
increase	B-C0442805
through	O
day	B-C0439228
126	O
.	O
	
untreated	O
sham	B-C0032042
scars	B-C0162810
did	O
not	O
show	O
a	O
similar	O
increase	B-C0442805
.	O
	
quantification	B-C1709793
of	O
verhoeff-van	B-C1294321
gieson	I-C1294321
staining	I-C1294321
corroborated	O
the	O
findings	B-C0243095
and	O
immunofluorescence	B-C0079603
revealed	O
the	O
alignment	B-C1706765
of	O
elastin	B-C0013765
fibers	I-C0013765
.	O
	
pressure	B-C1956078
treatment	I-C1956078
results	O
in	O
increased	B-C0205217
protein	B-C1171362
level	I-C1171362
expression	I-C1171362
of	O
elastin	B-C0013765
compared	B-C1707455
with	O
sham	B-C0032042
-untreated	O
scars	B-C0162810
.	O
	
these	O
findings	B-C0243095
further	O
characterize	O
the	O
extracellular	B-C0015350
matrix's	I-C0015350
response	O
to	O
the	O
application	O
of	O
pressure	B-C0033095
as	O
a	O
scar	B-C0162810
treatment	B-C0087111
,	O
which	O
will	O
contribute	O
to	O
the	O
refinement	O
of	O
rehabilitation	B-C0034992
practices	O
and	O
ultimately	O
improvements	B-C2986411
in	O
functional	B-C0205245
and	O
psychosocial	B-C0542298
outcomes	B-C1274040
for	O
epigenome-wide	B-C2350277
analysis	I-C2350277
links	O
smad3	B-C0919432
methylation	B-C0376452
at	O
birth	B-C0005615
to	O
asthma	B-C0264408
in	I-C0264408
children	I-C0264408
of	O
asthmatic	B-C0004096
mothers	B-C0026591
the	O
timing	O
and	O
mechanisms	B-C0441712
of	O
asthma	B-C0004096
inception	B-C1522492
remain	O
imprecisely	O
defined	O
.	O
	
although	O
epigenetic	B-C1516924
mechanisms	B-C0441712
likely	O
contribute	O
to	O
asthma	B-C0004096
pathogenesis	B-C0699748
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
asthma	B-C0004096
inception	B-C1522492
.	O
	
we	O
sought	O
to	O
assess	B-C0184514
whether	O
the	O
trajectory	O
to	O
asthma	B-C0004096
begins	O
already	O
at	O
birth	B-C0005615
and	O
whether	O
epigenetic	B-C1516924
mechanisms	B-C0441712
,	O
specifically	O
dna	B-C0376452
methylation	I-C0376452
,	O
contribute	O
to	O
asthma	B-C0004096
inception	B-C1522492
.	O
	
we	O
used	O
the	O
methylated	B-C1328856
cpg	I-C1328856
island	I-C1328856
recovery	I-C1328856
assay	I-C1328856
chip	I-C1328856
to	O
survey	B-C0038951
dna	B-C0376452
methylation	I-C0376452
in	O
cord	B-C0162371
blood	I-C0162371
mononuclear	B-C0806987
cells	I-C0806987
from	O
36	O
children	B-C0008059
18	O
nonasthmatic	B-C0080105
and	O
18	O
asthmatic	B-C0004096
subjects	B-C0080105
by	O
age	B-C0001779
9	O
years	B-C0439234
from	O
the	O
infant	B-C0021270
immune	B-C0439662
study	B-C2603343
iis	B-C2603343
,	O
an	O
unselected	O
birth	B-C0005615
cohort	B-C0599755
closely	O
monitored	O
for	O
asthma	B-C0004096
for	O
a	O
decade	O
.	O
	
smad3	B-C0919432
methylation	B-C0376452
in	O
iis	B-C2603343
n	O
=	O
60	O
and	O
in	O
2	O
replication	B-C0598312
cohorts	B-C0599755
the	O
manchester	B-C0681784
asthma	B-C0004096
and	O
allergy	B-C0945823
study	I-C0945823
n	O
=	O
30	O
and	O
the	O
childhood	B-C0264408
origins	I-C0264408
of	I-C0264408
asthma	I-C0264408
study	B-C2603343
n	O
=	O
28	O
was	O
analyzed	B-C0936012
by	O
using	O
bisulfite	B-C3831347
sequencing	I-C3831347
or	O
illumina	B-C0022885
450k	I-C0022885
arrays	I-C0022885
.	O
	
cord	B-C0162371
blood	I-C0162371
mononuclear	B-C0806987
cell	I-C0806987
-derived	O
il-1β	B-C1702300
levels	B-C0441889
were	O
measured	B-C0444706
by	O
means	O
of	O
elisa	B-C0014441
.	O
	
neonatal	B-C0021289
immune	B-C0439662
cells	B-C0007634
harbored	O
589	O
differentially	O
methylated	B-C0004793
regions	I-C0004793
that	O
distinguished	O
iis	B-C2603343
children	B-C1257890
who	O
did	O
and	O
did	O
not	O
have	O
asthma	B-C0004096
by	O
age	B-C0001779
9	O
years	B-C0439234
.	O
	
in	O
all	O
3	O
cohorts	B-C0599755
methylation	B-C0376452
in	O
smad3	B-C0919432
,	O
the	O
most	O
connected	O
node	O
within	O
the	O
network	O
of	O
asthma	B-C0004096
-	O
associated	B-C0332281
,	O
differentially	O
methylated	B-C0004793
regions	I-C0004793
,	O
was	O
selectively	O
increased	B-C0205217
in	O
asthmatic	B-C0264408
children	B-C0008059
of	O
asthmatic	B-C0004096
mothers	B-C0026591
and	O
was	O
associated	B-C0332281
with	I-C0332281
childhood	B-C0264408
asthma	I-C0264408
risk	B-C0035647
.	O
	
moreover	O
,	O
smad3	B-C0919432
methylation	B-C0376452
in	O
iis	B-C2603343
neonates	B-C0021289
with	O
maternal	B-C0026591
asthma	B-C0004096
was	O
strongly	O
and	O
positively	O
associated	B-C0332281
with	I-C0332281
neonatal	B-C0021289
production	O
of	O
il-1β	B-C1702300
,	O
an	O
innate	B-C0243042
inflammatory	I-C0243042
mediator	I-C0243042
.	O
	
the	O
trajectory	O
to	O
childhood	B-C0264408
asthma	I-C0264408
begins	O
at	O
birth	B-C0005615
and	O
involves	O
epigenetic	B-C1516924
modifications	B-C0392747
in	O
immunoregulatory	B-C0678889
and	O
proinflammatory	B-C0333348
pathways	B-C1704259
.	O
	
maternal	B-C0026591
asthma	B-C0004096
influences	O
epigenetic	B-C1516924
mechanisms	B-C0441712
that	O
contribute	O
to	O
the	O
inception	B-C1522492
clinical	B-C0205210
correlates	B-C1707520
of	O
faecal	B-C0015732
incontinence	I-C0015732
in	O
systemic	B-C0036421
sclerosis	I-C0036421
identifying	O
therapeutic	B-C0679624
avenues	I-C0679624
the	O
aim	O
was	O
to	O
establish	O
the	O
prevalence	B-C0683921
and	O
severity	B-C0392364
of	O
faecal	B-C0015732
incontinence	I-C0015732
fi	B-C0015732
in	O
ssc	B-C0036421
,	O
its	O
association	B-C0439849
with	O
other	O
intestinal	B-C0021853
manifestations	B-C0205319
and	O
potential	B-C3245505
predictors	B-C2698872
of	O
fi	B-C0015732
,	O
and	O
its	O
impact	B-C4049986
on	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
.	O
	
a	O
multicentre	O
,	O
cross-sectional	B-C0010362
study	I-C0010362
of	O
298	O
ssc	B-C0036421
subjects	B-C0030705
followed	O
in	O
the	O
canadian	B-C1708333
scleroderma	I-C1708333
research	I-C1708333
group	I-C1708333
cohort	B-C0599755
was	O
performed	O
using	O
validated	O
questionnaires	B-C0034394
jorge-wexner	B-C0349674
score	I-C0349674
an	O
fi	B-C0015732
severity	B-C0681887
scale	I-C0681887
,	O
bristol	B-C4084861
stool	I-C4084861
scale	I-C4084861
a	O
visual	O
scale	O
of	O
stool	B-C0426740
consistency	I-C0426740
and	O
fi	B-C0015732
quality-of-life	B-C0451401
scale	I-C0451401
.	O
	
constipation	B-C0009806
was	O
defined	O
by	O
the	O
rome	B-C0679228
iii	I-C0679228
criteria	I-C0679228
.	O
	
associations	B-C0439849
between	O
the	O
jorge-wexner	B-C0349674
score	I-C0349674
and	O
other	O
clinical	B-C1836458
variables	I-C1836458
were	O
determined	O
using	O
multivariate	B-C0034980
regression	I-C0034980
analyses	I-C0034980
.	O
	
eighty-one	O
27.2	O
subjects	B-C0030705
had	O
fi	B-C0015732
,	O
which	O
was	O
mild	B-C2945599
in	O
37	O
12.4	O
and	O
moderate	B-C1299393
to	I-C1299393
severe	I-C1299393
in	O
44	O
14.8	O
.	O
	
most	O
patients	B-C0030705
had	O
well-formed	O
stools	B-C0015733
,	O
111	O
38.8	O
reported	O
constipation	B-C0009806
and	O
38	O
13.4	O
had	O
been	O
previously	B-C0205156
treated	B-C1522326
for	O
small	B-C3160854
intestinal	I-C3160854
bacterial	I-C3160854
overgrowth	I-C3160854
sibo	B-C3160854
.	O
	
variables	B-C0439828
independently	B-C0085862
associated	B-C0332281
with	I-C0332281
fi	B-C0015732
were	O
loose	B-C2129214
vs	O
well-formed	O
stools	B-C0015733
odds	B-C0028873
ratio	I-C0028873
or	B-C0028873
=	O
7.01	O
,	O
95%	O
ci	B-C0009667
2.09	O
,	O
23.51	O
,	O
constipation	B-C0009806
or	B-C0028873
=	O
3.64	O
,	O
95%	O
ci	B-C0009667
1.61	O
,	O
8.27	O
,	O
p	B-C1709380
=	O
0.002	O
,	O
history	B-C0683519
of	O
sibo	B-C3160854
or	B-C0028873
=	O
2.97	O
,	O
95%	O
ci	B-C0009667
1.06	O
,	O
8.27	O
and	O
urinary	B-C0042024
incontinence	I-C0042024
or	B-C0028873
=	O
2.45	O
,	O
95%	O
ci	B-C0009667
1.14	O
,	O
5.27	O
.	O
	
quality	B-C0034380
of	I-C0034380
life	I-C0034380
measured	B-C0444706
with	O
the	O
fi	B-C0015732
quality-of-life	B-C0451401
scale	I-C0451401
was	O
inversely	B-C0439850
correlated	B-C1707520
with	O
fi	B-C0015732
severity	B-C0521117
correlation	B-C1707520
coefficients	B-C1707429
between	O
-0	O
and	O
-0	O
,	O
p	B-C1709380
<	O
0.001	O
.	O
	
fi	B-C0015732
was	O
common	B-C0205214
and	O
often	O
severe	B-C0205082
in	O
ssc	B-C0036421
.	O
	
loose	B-C2129214
stools	I-C2129214
,	O
sibo	B-C3160854
,	O
constipation	B-C0009806
and	O
urinary	B-C0042024
incontinence	I-C0042024
were	O
strongly	B-C0442821
associated	B-C0332281
with	I-C0332281
fi	B-C0015732
.	O
	
other	O
than	O
targeting	B-C1521840
anorectal	B-C3870603
dysfunction	B-C0277785
,	O
concomitant	B-C0521115
treatment	B-C0087111
of	O
clinical	B-C0205210
correlates	B-C1707520
could	O
lead	O
to	O
improvement	B-C2986411
in	O
fi	B-C0015732
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
in	O
from	O
training	B-C0220931
to	O
practice	B-C0033284
the	O
impact	B-C4049986
of	O
engage	B-C1708333
,	O
ireland's	B-C0022067
national	B-C0040607
men's	I-C0040607
health	I-C0040607
training	I-C0040607
programme	I-C0040607
ireland's	B-C0022067
national	B-C0027458
men's	I-C0027458
health	I-C0027458
policy	I-C0027458
recommended	B-C0034866
developing	O
training	B-C0040607
programmes	I-C0040607
tailored	B-C2986593
to	O
the	O
needs	B-C0027552
of	O
those	O
working	B-C0043227
in	O
health	B-C1704312
and	O
allied	B-C0002122
health	I-C0002122
professionals	I-C0002122
and	O
engage	B-C1708333
was	O
developed	O
to	O
meet	O
that	O
recommendation	B-C0034866
.	O
	
this	O
study	B-C2603343
evaluated	B-C0220825
the	O
impact	B-C4049986
of	O
engage	B-C1708333
on	O
frontline	B-C0679886
service	I-C0679886
providers'	I-C0679886
self-reported	B-C1948177
knowledge	I-C1948177
,	O
skills	B-C0678856
,	O
capacity	B-C1516240
and	O
practice	B-C0033284
up	O
to	O
5-months	O
post	B-C0687676
training	B-C0220931
.	O
	
between	O
2012	O
and	O
2015	O
,	O
engage	B-C1708333
trainers	B-C0453962
n	O
=	O
57	O
delivered	O
62	O
1-day	O
training	B-C0040607
programmes	I-C0040607
to	O
810	O
participants	B-C0679646
.	O
	
this	O
study	B-C2603343
was	O
conducted	O
on	O
a	O
subset	B-C1515021
of	O
those	O
training	B-C0220931
days	O
n	O
=	O
26	O
and	O
participants	B-C0679646
.	O
	
quantitative	B-C0392762
methodologies	B-C0038949
were	O
used	O
to	O
collect	O
pre	O
n	O
=	O
295	O
,	O
post	B-C0687676
n	O
=	O
295	O
and	O
5-month	O
post	B-C0687676
n	O
=	O
128	O
training	B-C0220931
questionnaire	B-C0034394
data	O
.	O
	
overall	B-C1561607
,	O
participants	B-C0679646
were	O
highly	O
satisfied	B-C4084799
with	O
the	O
training	B-C0220931
immediately	B-C0205253
post	B-C0687676
training	B-C0220931
8.60	O
1.60	O
out	O
of	O
10	O
and	O
at	O
5-month	O
follow	B-C0589120
up	I-C0589120
8.06	O
1.43	O
out	O
of	O
10	O
.	O
	
participants'	B-C0679646
self-reported	B-C1948177
level	I-C1948177
of	I-C1948177
knowledge	I-C1948177
,	O
skill	B-C0678856
and	O
capacity	B-C1516240
in	O
identifying	O
priorities	B-C0439607
,	O
engaging	O
men	B-C0025266
and	O
influencing	B-C4054723
practice	B-C0033284
beyond	O
their	O
own	O
organisation	B-C0029236
increased	B-C0205217
immediately	B-C0205253
following	O
training	B-C0220931
p	O
<	O
0.001	O
and	O
,	O
with	O
the	O
exception	B-C1705847
of	O
improving	B-C1272745
capacity	B-C1516240
to	O
engage	O
men	B-C0025266
and	O
influencing	B-C4054723
practice	B-C0033284
beyond	O
their	O
organisation	B-C0029236
,	O
these	O
improvements	B-C2936612
were	O
sustained	B-C0443318
at	O
5-month	O
post	B-C0687676
training	B-C0220931
p	O
<	O
0.001	O
.	O
	
the	O
vast	O
majority	B-C0680220
of	O
service	B-C0679886
providers	I-C0679886
93.4	O
reported	B-C0700287
that	O
engage	B-C1708333
had	O
impacted	B-C4049986
their	O
work	B-C0043227
practice	B-C0033284
up	O
to	O
5-month	O
post	B-C0687676
training	B-C0220931
.	O
	
the	O
findings	B-C0243095
suggest	B-C1705535
that	O
engage	B-C1708333
has	O
succeeded	B-C0243095
in	O
improving	B-C1272745
service	B-C0679886
providers'	I-C0679886
capacity	B-C1516240
to	O
engage	O
and	O
work	B-C0043227
with	O
men	B-C0025266
improving	B-C1272745
gender	B-C0079399
competency	B-C0086035
in	O
the	O
delivery	O
of	O
health	B-C0018684
and	O
health	B-C0018747
related	I-C0018747
services	I-C0018747
may	O
increase	B-C0205217
the	O
utilisation	B-C0042155
of	O
such	O
services	B-C0018747
by	O
men	B-C0025266
and	O
thereby	O
improve	B-C0184511
health	B-C0085565
outcomes	I-C0085565
for	O
double	B-C1511667
strand	I-C1511667
break	I-C1511667
induction	B-C0205263
and	O
kinetics	B-C0022702
indicate	O
preserved	O
hypersensitivity	B-C0020517
in	O
keratinocytes	B-C0022567
to	O
subtherapeutic	B-C0302350
doses	B-C0178602
for	O
7	O
weeks	B-C0439230
of	O
radiotherapy	B-C1522449
previously	O
we	O
reported	O
that	O
hyper-radiosensitivity	B-C0034537
hrs	B-C0034537
was	O
evidenced	O
by	O
quantifying	B-C1709793
dna	B-C3159064
double	I-C3159064
strand	I-C3159064
break	I-C3159064
dsb	I-C3159064
foci	I-C3159064
in	O
epidermis	B-C0014520
biopsies	B-C0005558
collected	O
after	O
delivering	O
radiotherapeutic	B-C0034619
one	O
and	O
five	O
dose	B-C0178602
fractions	I-C0178602
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
determine	O
whether	O
hrs	B-C0034537
was	O
preserved	O
throughout	O
a	O
7-	O
week	B-C0439230
radiotherapy	B-C1522449
treatment	B-C0087111
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	B-C3159064
decline	O
and	O
foci	B-C3159064
persistence	O
between	O
dose	B-C0178602
fractions	I-C0178602
.	O
	
42	O
patients	B-C0030705
with	O
prostate	B-C0600139
cancer	I-C0600139
received	O
7-	O
week	B-C0439230
fractionated	O
radiotherapy	B-C1522449
treatment	I-C1522449
rt	B-C1522449
with	O
daily	O
dose	B-C0178602
fractions	I-C0178602
of	O
0.05	O
to	O
the	O
skin	B-C1123023
.	O
	
before	O
rt	B-C1522449
,	O
and	O
at	O
several	O
times	O
throughout	O
treatment	B-C0087111
,	O
skin	B-C0150866
biopsies	I-C0150866
n=452	O
were	O
collected	O
at	O
30min	O
,	O
and	O
2	O
,	O
3	O
,	O
24	O
,	O
and	O
72h	O
after	O
dose	B-C0178602
fractions	I-C0178602
.	O
	
dsb-foci	B-C3159064
markers	B-C0012872
,	O
γh2ax	B-C1415406
and	O
53bp1	B-C1420865
,	O
were	O
labelled	O
in	O
epidermal	B-C0014520
keratinocytes	B-C0022567
with	O
immunofluorescence	B-C0016318
and	O
immunohistochemical	B-C1508788
staining	I-C1508788
.	O
	
foci	O
were	O
counted	O
both	O
with	O
digital	B-C2348290
image	I-C2348290
analysis	I-C2348290
and	O
manually	O
.	O
	
hrs	B-C0034537
in	O
keratinocytes	B-C0022567
was	O
evidenced	O
by	O
the	O
dose-response	B-C0678790
relationships	I-C0678790
of	O
dsb	B-C3159064
foci	I-C3159064
,	O
observed	O
throughout	O
the	O
treatment	B-C0454268
course	I-C0454268
,	O
independent	B-C0332291
of	I-C0332291
sampling	B-C0441621
time	B-C0040223
and	O
quantification	B-C1709793
method	B-C0025663
.	O
	
foci	B-C3159064
observed	O
at	O
24h	O
after	O
dose	B-C0178602
fractions	I-C0178602
indicated	O
considerable	O
dsb	B-C1511667
persistence	O
.	O
	
accordingly	O
,	O
foci	B-C3159064
significantly	O
accumulated	O
after	O
5	O
consecutive	O
dose	B-C0178602
fractions	I-C0178602
.	O
	
for	O
doses	B-C0178602
below	O
0.3gy	O
,	O
persistent	O
foci	B-C3159064
could	O
be	O
observed	O
even	O
at	O
72h	O
after	O
damage	B-C0012860
induction	B-C0205263
.	O
	
a	O
comparison	B-C1707455
of	O
γh2ax	B-C1415406
and	O
53bp1	B-C1420865
quantifications	B-C1709793
in	O
double-staine	B-C2986582
d	O
biopsies	B-C0005558
showed	O
similar	O
hrs	B-C0034537
dose-response	B-C0678790
relationships	I-C0678790
.	O
	
these	O
results	O
represented	O
the	O
first	O
evidence	B-C3887511
of	O
preserved	O
hrs	B-C0034537
,	O
assessed	B-C1516048
by	O
γh2ax	B-C1415406
-	O
and	O
53bp1	B-C1420865
-labelled	O
dsb	B-C3159064
foci	I-C3159064
,	O
throughout	O
a	O
7-	O
week	B-C0439230
treatment	B-C0454268
course	I-C0454268
with	O
daily	B-C0332173
repeated	O
subtherapeutic	B-C0302350
dose	B-C0178602
fractions	I-C0178602
.	O
	
ct	B-C1536105
angiography	I-C1536105
for	O
planning	B-C1301732
transcatheter	B-C3509486
aortic	I-C3509486
valve	I-C3509486
replacement	I-C3509486
using	O
automated	B-C0392762
tube	I-C0392762
voltage	I-C0392762
selection	I-C0392762
image	B-C0806487
quality	I-C0806487
and	O
radiation	B-C0851346
exposure	B-C0332157
to	O
assess	B-C0184514
image	B-C0806487
quality	I-C0806487
and	O
accuracy	B-C0598285
of	O
ct	B-C1536105
angiography	I-C1536105
cta	B-C1536105
for	O
transcatheter	B-C3509486
aortic	I-C3509486
valve	I-C3509486
replacement	I-C3509486
tavr	B-C3509486
planning	B-C1301732
performed	O
with	O
3rd	B-C0040405
generation	I-C0040405
dual-source	I-C0040405
ct	I-C0040405
dsct	B-C0040405
.	O
	
we	O
evaluated	O
125	O
patients	B-C0030705
who	O
underwent	O
tavr	B-C3509486
-	O
planning	B-C1301732
cta	B-C1536105
on	O
3rd	B-C0040405
generation	I-C0040405
dsct	I-C0040405
.	O
	
a	O
two-part	B-C0008971
protocol	I-C0008971
was	O
performed	O
including	O
retrospectively	B-C1514923
ecg-gated	B-C1634617
coronary	I-C1634617
cta	I-C1634617
ccta	B-C1634617
and	O
prospectively	B-C0205556
ecg-triggered	B-C1536105
aortoiliac	I-C1536105
cta	I-C1536105
using	O
60ml	O
of	O
contrast	B-C0009924
medium	I-C0009924
.	O
	
automated	B-C0392762
tube	I-C0392762
voltage	I-C0392762
selection	I-C0392762
and	O
advanced	B-C2986769
iterative	I-C2986769
reconstruction	I-C2986769
were	O
applied	O
.	O
	
effective	B-C4019308
dose	I-C4019308
ed	B-C4019308
,	O
signal-to-noise	B-C2986823
snr	B-C2986823
and	O
contrast-to-noise	B-C0392762
ratios	I-C0392762
cnr	B-C0392762
were	O
calculated	O
.	O
	
five-point	B-C0282574
scales	I-C0282574
were	O
used	O
for	O
subjective	B-C0439655
image	B-C1297895
quality	I-C1297895
analysis	I-C1297895
.	O
	
in	O
patients	B-C0030705
who	O
underwent	O
tavr	B-C3509486
,	O
sizing	B-C0449381
parameters	I-C0449381
were	O
obtained	O
.	O
	
image	B-C0806487
quality	I-C0806487
was	O
rated	O
good	O
to	O
excellent	O
in	O
97.6	O
of	O
ccta	B-C1634617
and	O
100%	O
of	O
aortoiliac	B-C1536105
ctas	I-C1536105
.	O
	
cta	B-C1536105
studies	B-C0008972
at	O
>100kv	O
showed	O
decreased	B-C0205216
objective	B-C1571702
image	B-C0806487
quality	I-C0806487
compared	O
to	O
70-100kv	O
snr	B-C2986823
,	O
all	O
p	O
cnr	B-C0392762
,	O
all	O
p	O
.	O
	
mean	B-C0444504
ed	B-C4019308
increased	B-C0205217
continuously	O
from	O
70	O
to	O
>100kv	O
ccta	B-C1634617
4.5	O
,	O
all	O
p	O
aortoiliac	B-C1536105
cta	I-C1536105
2.4	O
,	O
all	O
p	O
.	O
	
in	O
39	O
patients	B-C0030705
tavr	B-C3509486
was	O
performed	O
and	O
annulus	B-C0225957
diameter	B-C1301886
was	O
within	O
the	O
recommended	O
range	O
in	O
all	O
patients	B-C0030705
.	O
	
no	B-C1513916
severe	B-C0205082
cardiac	B-C0161816
or	O
vascular	B-C0009566
complications	I-C0009566
were	O
noted	O
.	O
	
3rd	B-C0040405
generation	I-C0040405
dsct	I-C0040405
provides	O
diagnostic	B-C0348026
image	B-C0806487
quality	I-C0806487
in	O
tavr	B-C3509486
-	O
planning	B-C1301732
cta	B-C1536105
and	O
facilitates	O
reliable	O
assessment	B-C0220825
of	O
tavr	B-C3509486
device	B-C0025080
and	O
delivery	B-C1705822
option	O
while	O
reducing	B-C0392756
radiation	B-C4019308
dose	I-C4019308
.	O
	
a	O
giant	B-C0017526
aneurysmal	B-C0152244
bone	I-C0152244
cyst	I-C0152244
in	O
the	O
mandibular	B-C0024688
condyle	I-C0024688
aneurysmal	B-C0152244
bone	I-C0152244
cyst	I-C0152244
abc	B-C0152244
is	O
a	O
rare	B-C0522498
,	O
rapidly	B-C0456962
expanding	B-C0205229
,	O
locally	B-C1517927
destructive	B-C1948029
,	O
and	O
easily	B-C0332219
misdiagnosed	B-C0679838
lesion	B-C0221198
.	O
	
an	O
abc	B-C0152244
of	O
the	O
condyle	B-C0024688
is	O
rare	B-C0522498
.	O
	
this	O
report	O
presents	O
a	O
25-	O
year	B-C0439234
-	O
old	B-C0580836
female	B-C0086287
with	O
a	O
giant	B-C0017526
abc	B-C0152244
in	O
the	O
left	B-C0205091
mandibular	I-C0205091
condyle	I-C0205091
.	O
	
this	O
patient	O
was	O
treated	O
with	O
surgical	O
resection	O
of	O
the	O
affected	O
bone	O
and	O
immediate	O
mandibular	B-C0024688
reconstruction	O
using	O
autologous	O
bone	O
.	O
	
follow-up	O
to	O
date	O
showed	O
no	O
signs	O
of	O
recurrence	O
.	O
	
the	O
clinical	O
feature	O
,	O
imaging	O
finding	O
,	O
pathogenesis	O
,	O
and	O
treatment	O
methods	O
of	O
abcs	O
are	O
association	B-C0439849
between	O
postpartum	B-C0221074
depression	I-C0221074
and	O
the	O
practice	B-C0032893
of	O
exclusive	B-C0242205
breastfeeding	I-C0242205
in	O
the	O
first	O
three	O
months	B-C0439231
of	O
life	B-C0376558
to	O
investigate	B-C1292732
the	O
association	B-C0439849
between	O
postpartum	B-C0221074
depression	I-C0221074
and	O
the	O
occurrence	B-C2745955
of	O
exclusive	B-C0242205
breastfeeding	I-C0242205
.	O
	
this	O
is	O
a	O
cross-sectional	B-C0010362
study	I-C0010362
conducted	O
in	O
the	O
states	B-C1301808
of	O
the	O
northeast	B-C0017446
region	I-C0017446
,	O
during	O
the	O
vaccination	B-C4279933
campaign	I-C4279933
in	O
2010	O
.	O
	
the	O
sample	O
consisted	O
of	O
2583	O
mother	B-C0026591
-	O
child	B-C0008059
pairs	B-C1709450
,	O
with	O
children	B-C0008059
aged	B-C0001779
from	O
15	O
days	B-C0439228
to	O
3	O
months	B-C0439231
.	O
	
the	O
edinburgh	B-C0451144
postnatal	I-C0451144
depression	I-C0451144
scale	I-C0451144
was	O
used	O
to	O
screen	B-C0220908
for	O
postpartum	B-C0221074
depression	I-C0221074
.	O
	
the	O
outcome	B-C1274040
was	O
lack	B-C0332268
of	O
exclusive	B-C0242205
breastfeeding	I-C0242205
,	O
defined	O
as	O
the	O
occurrence	B-C2745955
of	O
this	O
practice	B-C1254370
in	O
the	O
24h	O
preceding	B-C0332152
the	O
interview	B-C0021822
.	O
	
postpartum	B-C0221074
depression	I-C0221074
was	O
the	O
explanatory	B-C0681885
variable	I-C0681885
of	O
interest	O
and	O
the	O
covariates	B-C0814913
were	O
socioeconomic	B-C0037464
and	O
demographic	B-C0011292
conditions	I-C0011292
maternal	B-C0024922
health	I-C0024922
care	I-C0024922
prenatal	B-C0033052
,	O
delivery	B-C0011209
,	O
and	O
postnatal	B-C0032782
care	I-C0032782
and	O
the	O
child's	B-C0205556
biological	I-C0205556
factors	I-C0205556
.	O
	
multivariate	B-C0026777
logistic	I-C0026777
regression	I-C0026777
analysis	I-C0026777
was	O
conducted	O
to	O
control	O
for	O
possible	O
confounding	B-C0009673
factors	I-C0009673
.	O
	
exclusive	B-C0242205
breastfeeding	I-C0242205
was	O
observed	B-C1441672
in	O
50.8	O
of	O
the	O
infants	B-C0021270
and	O
11.8	O
of	O
women	B-C0043210
had	O
symptoms	B-C1457887
of	O
postpartum	B-C0221074
depression	I-C0221074
.	O
	
in	O
the	O
multivariate	B-C0026777
logistic	I-C0026777
regression	I-C0026777
analysis	I-C0026777
,	O
a	O
higher	O
chance	O
of	O
exclusive	B-C0242205
breastfeeding	I-C0242205
absence	B-C0332197
was	O
found	O
among	O
mothers	B-C0026591
with	O
symptoms	B-C1457887
of	O
postpartum	B-C0221074
depression	I-C0221074
or=1	O
p<0	O
,	O
among	O
younger	B-C2349001
subjects	I-C2349001
or=1	O
p<0	O
,	O
those	O
who	O
reported	O
receiving	O
benefits	B-C0814225
from	O
the	O
bolsa	B-C0681136
família	I-C0681136
program	I-C0681136
or=1	O
p=0	O
,	O
and	O
those	O
started	O
antenatal	B-C0033052
care	I-C0033052
later	O
during	O
pregnancy	B-C0032961
or=2	O
p=0	O
.	O
	
postpartum	B-C0221074
depression	I-C0221074
contributed	O
to	O
reducing	B-C0392756
the	O
practice	B-C1254370
of	O
exclusive	B-C0242205
breastfeeding	I-C0242205
.	O
	
therefore	O
,	O
this	O
disorder	B-C0012634
should	O
be	O
included	O
in	O
the	O
prenatal	B-C0033052
and	O
early	B-C0233066
postpartum	I-C0233066
support	B-C0282451
guidelines	I-C0282451
for	O
breastfeeding	B-C0006147
,	O
especially	O
in	O
low	B-C1328812
socioeconomic	I-C1328812
status	I-C1328812
women	B-C0043210
.	O
	
evidence	B-C0332120
of	I-C0332120
toothpick	B-C3273359
groove	B-C1184482
formation	B-C1522492
in	O
neandertal	B-C3178755
anterior	B-C0205094
and	O
posterior	B-C0205095
teeth	B-C0040426
during	O
the	O
microscopic	B-C0026018
examination	I-C0026018
of	O
the	O
neandertal	B-C3178755
dentitions	B-C0011443
from	O
el	B-C0017446
sidrón	I-C0017446
spain	B-C0037747
and	O
hortus	B-C0017446
france	B-C0016674
,	O
we	O
found	O
unusual	B-C2700116
fine	O
parallel	O
microstriations	B-C1254365
on	O
the	O
mesial	B-C1708982
and	O
distal	B-C0205108
sides	I-C0205108
of	O
all	O
tooth	B-C0040426
types	O
,	O
near	O
the	O
cervix	B-C0446455
.	O
	
as	O
its	O
appearance	O
was	O
similar	B-C2348205
to	O
toothpick	B-C3273359
grooves	B-C1184482
described	O
in	O
other	O
homo	B-C1300203
species	I-C1300203
,	O
it	O
could	O
correspond	O
to	O
early	B-C2363430
stages	I-C2363430
on	O
its	O
formation	B-C1522492
.	O
	
to	O
test	O
this	O
hypothesis	O
we	O
developed	O
an	O
experimental	B-C0237832
replication	I-C0237832
of	O
a	O
groove	B-C1184482
using	O
grass	B-C0018210
stalks	B-C2700372
.	O
	
comparisons	B-C1707455
between	O
204	O
isolated	B-C0205409
neandertal	B-C3178755
teeth	B-C0040426
and	O
the	O
two	O
experimental	B-C1517586
dental	B-C0226984
specimens	B-C0370003
corroborate	O
that	O
the	O
marks	B-C0037088
correspond	O
to	O
initial	B-C2363430
stages	I-C2363430
of	O
toothpick	B-C3273359
groove	B-C1184482
formation	B-C1522492
,	O
and	O
we	O
propose	O
a	O
five-grade	B-C0349674
recording	I-C0349674
scale	I-C0349674
that	O
summarized	O
the	O
groove	B-C1184482
formation	B-C1522492
process	I-C1522492
.	O
	
using	O
this	O
new	O
recording	O
procedure	O
,	O
we	O
found	O
that	O
hortus	B-C0017446
individuals	B-C0027361
have	O
higher	O
incidence	B-C0021149
of	O
this	O
trait	O
eight	O
individuals	B-C0027361
out	O
of	O
nine	O
than	O
the	O
el	B-C0017446
sidrón	I-C0017446
individuals	B-C0027361
nine	O
out	O
of	O
11	O
.	O
	
toothpick	B-C3273359
grooves	B-C1184482
from	O
el	B-C0017446
sidrón	I-C0017446
show	O
the	O
earliest	B-C2363430
stages	I-C2363430
of	O
development	B-C1527148
,	O
whereas	O
the	O
grooves	B-C1184482
found	O
on	O
hortus	B-C0017446
neandertals	B-C3178755
were	O
well-developed	B-C0205556
.	O
	
toothpick	B-C3273359
grooves	B-C1184482
were	O
also	O
found	O
in	O
21	O
incisors	B-C0021156
and	O
canines	B-C0010482
.	O
	
these	O
differences	B-C1705242
could	O
be	O
due	O
to	O
the	O
more	O
advanced	O
occlusal	B-C0447303
dental	B-C2717979
wear	I-C2717979
in	O
hortus	B-C0017446
individuals	B-C0027361
,	O
maybe	O
age	B-C0001779
-related	O
and	O
with	O
a	O
more	O
meat	B-C0025017
-based	O
diet	B-C0012155
maybe	O
favoring	O
the	O
inclusion	O
of	O
food	B-C0016452
debris	B-C0440266
and	O
thus	O
probing	B-C0449851
as	O
the	O
cleaning	B-C1947930
methodology	I-C1947930
.	O
	
our	O
results	O
allow	O
the	O
identification	B-C0205396
and	O
characterization	B-C1880022
of	O
incipient	B-C0205256
toothpick	B-C3273359
grooves	B-C1184482
on	O
the	O
human	B-C0086418
fossil	B-C0016614
record	B-C0034869
and	O
contribute	B-C1880177
to	O
increase	B-C0442805
our	O
knowledge	B-C0376554
on	O
neandertals	B-C3178755
behavioral	B-C0018464
and	O
oral	B-C0424439
care	I-C0424439
habits	I-C0424439
.	O
	
thsd7a	B-C2745341
expression	B-C1171362
in	O
human	B-C0086418
cancer	B-C0006826
we	O
recently	O
described	O
a	O
case	O
of	O
a	O
thrombospondin	B-C2745341
type-1	I-C2745341
domain	I-C2745341
containing	I-C2745341
7a	I-C2745341
thsd7a	B-C2745341
associated	O
membranous	B-C4054536
nephropathy	I-C4054536
in	O
a	O
female	B-C0150905
patient	I-C0150905
who	O
was	O
synchronously	B-C0439580
suffering	B-C0751408
from	O
a	O
thsd7a	B-C2745341
-	O
positive	B-C1514241
malignancy	B-C0205282
.	O
	
we	O
here	O
investigated	O
the	O
role	O
of	O
thsd7a	B-C2745341
as	O
a	O
new	O
potential	O
tumor	B-C0041361
antigen	I-C0041361
by	O
evaluating	O
over	O
20	O
000	O
tissue	B-C2316370
spots	I-C2316370
in	O
more	O
than	O
70	O
different	O
tumor	B-C1276705
entities	I-C1276705
by	O
immunohistochemistry	B-C0021044
using	O
tissue	B-C1519522
microarrays	I-C1519522
.	O
	
thsd7a	B-C2745341
expression	B-C1171362
was	O
highly	O
variable	O
in	O
different	B-C0027651
neoplasias	I-C0027651
with	O
differing	O
staining	B-C0449778
patterns	I-C0449778
.	O
	
both	O
gain	B-C0243095
and	I-C0243095
loss	I-C0243095
of	O
thsd7a	B-C2745341
expression	B-C1171362
compared	O
to	O
expression	B-C1171362
status	I-C1171362
in	O
non-tumor	B-C0040300
tissue	I-C0040300
were	O
linked	O
to	O
tumor-specific	B-C0041365
markers	I-C0041365
in	O
the	O
different	O
tumor	B-C1276705
entities	I-C1276705
and	O
were	O
of	O
prognostic	B-C0449821
value	I-C0449821
.	O
	
the	O
potential	O
role	O
of	O
thsd7a	B-C2745341
in	O
tumor	B-C1850355
development	I-C1850355
and	O
therapy	B-C4087167
civil	B-C0680324
society	I-C0680324
-driven	O
drug	B-C0815220
policy	I-C0815220
reform	I-C0815220
for	O
health	B-C0018684
and	O
human	B-C0037440
welfare	I-C0037440
-	O
india	B-C0021201
the	O
lack	B-C0332268
of	O
adequate	B-C0205411
access	O
to	O
opioids	B-C0242402
in	O
india	B-C0021201
as	O
analgesics	B-C0002771
and	O
for	O
agonist	B-C2987634
therapies	B-C0087111
,	O
forces	O
millions	O
to	O
live	O
with	O
severe	B-C0205082
unalleviated	B-C0030193
pain	I-C0030193
,	O
or	O
languish	B-C1762617
with	O
suffering	B-C0683278
associated	O
with	O
drug	B-C1510472
dependence	I-C1510472
.	O
	
although	O
india	B-C0021201
is	O
a	O
major	O
opium	B-C0029112
exporter	B-C0402574
,	O
the	O
excessively	O
prohibitive	B-C0683610
1985	O
narcotics	B-C0027413
law	I-C0027413
formulated	O
to	O
control	B-C0243148
harmful	B-C0013146
use	I-C0013146
of	I-C0013146
drugs	I-C0013146
,	O
impeded	O
the	O
availability	B-C0470187
and	O
access	B-C0444454
to	O
opioids	B-C0242402
for	O
medical	B-C0678312
and	O
scientific	B-C0683933
purposes	B-C1285529
.	O
	
amendment	B-C0680532
of	O
this	O
law	B-C1947938
in	O
2014	O
established	O
a	O
new	O
national	B-C0220868
regulatory	I-C0220868
framework	I-C0220868
for	O
improved	O
access	B-C0444454
to	O
essential	B-C0205224
opioid	B-C0002772
analgesics	I-C0002772
.	O
	
this	O
article	O
reflects	O
on	O
key	O
elements	O
and	O
processes	O
that	O
led	O
to	O
this	O
landmark	O
achievement	B-C0001072
.	O
	
unlike	O
quick	O
timelines	O
associated	O
with	O
effecting	O
policy	B-C0815220
reforms	I-C0815220
for	O
law	B-C0162469
enforcement	I-C0162469
,	O
realizing	O
the	O
2014	O
drug	B-C0683727
policy	I-C0683727
change	O
primarily	O
to	O
mitigate	B-C1553901
human	B-C0683278
suffering	I-C0683278
,	O
was	O
a	O
22-year-long	O
process	O
.	O
	
the	O
most	O
exacting	O
challenges	O
included	O
recognizing	O
the	O
multilayered	B-C0037431
complexities	I-C0037431
of	O
the	O
prior	O
policy	B-C0242456
framework	I-C0242456
and	O
understanding	O
their	O
adverse	B-C0205169
impact	B-C0814716
on	O
field	O
practices	O
to	O
chart	O
an	O
appropriate	O
and	O
viable	O
path	O
for	O
reform	B-C0206597
.	O
	
the	O
evolution	O
of	O
an	O
informal	O
civil	B-C0680411
society	I-C0680411
movement	I-C0680411
involving	O
health	B-C1704312
care	I-C1704312
professionals	I-C1704312
,	O
lawyers	B-C0086530
,	O
media	B-C4054555
,	O
policy	B-C0870132
analysts	I-C0870132
,	O
government	B-C0242304
officials	I-C0242304
,	O
and	O
the	O
public	B-C0034035
was	O
pivotal	O
in	O
addressing	O
these	O
challenges	B-C0805586
and	O
garnering	O
momentum	O
for	O
reform	B-C0680438
.	O
	
the	O
success	B-C0597535
of	O
the	O
effort	O
for	O
improving	O
access	B-C0018748
to	O
opioid	B-C0242402
medications	B-C0150270
was	O
underpinned	O
by	O
a	O
three-pronged	O
strategy	O
of	O
1	O
persuading	O
the	O
executive	B-C0335161
arm	I-C0335161
of	I-C0335161
the	I-C0335161
government	I-C0335161
to	O
take	O
interim	B-C2827738
enabling	O
measures	B-C0033107
2	O
leveraging	O
judicial	B-C0178362
intervention	I-C0178362
through	O
public	B-C0034035
interest	B-C0021729
litigation	B-C0079706
and	O
3	O
crafting	B-C0242440
a	I-C0242440
viable	I-C0242440
policy	I-C0242440
document	I-C0242440
for	O
legislative	B-C0680796
approval	I-C0680796
and	O
implementation	B-C1708476
.	O
	
we	O
hope	O
our	O
findings	O
are	O
useful	O
for	O
realizing	O
drug	B-C0683727
policy	I-C0683727
reforms	I-C0683727
,	O
given	O
the	O
current	O
transformed	O
global	B-C2348867
policy	B-C0242456
mandates	B-C0814715
emphasizing	O
humanitarian	B-C0037440
,	O
healthcare	B-C0086388
,	O
and	O
quality-of-life	B-C0034380
considerations	B-C0518609
.	O
	
efficacy	B-C1280519
of	O
synbiotics	B-C2936470
for	O
treatment	B-C0087111
of	O
bacillary	B-C1527298
dysentery	I-C1527298
in	O
children	B-C0008059
a	O
double-blind	B-C0013072
,	O
randomized	B-C0206035
,	O
placebo-controlled	B-C0599724
study	I-C0599724
bacillary	B-C1527298
dysentery	I-C1527298
is	O
a	O
major	O
cause	O
of	O
children's	B-C0008059
admission	B-C0184666
to	I-C0184666
hospitals	I-C0184666
.	O
	
to	O
assess	B-C0184514
the	O
probiotic	B-C0525033
and	O
prebiotic	B-C2717875
synbiotics	B-C2936470
effects	B-C1280500
in	O
children	B-C0008059
with	O
dysentery	B-C0013369
in	O
a	O
randomized	B-C0206034
clinical	I-C0206034
trial	I-C0206034
,	O
200	O
children	B-C0008059
with	O
dysentery	B-C0013369
were	O
studied	O
in	O
2	O
groups	B-C0441833
the	O
synbiotic	B-C2936470
group	B-C0441833
received	O
1	O
tablet	B-C0039225
/day	B-C0439505
of	O
synbiotic	B-C2936470
for	O
3-5	O
days	B-C0439228
and	O
the	O
placebo	B-C1696465
group	B-C0441833
received	O
placebo	B-C1696465
tablets	B-C0039225
identical	O
tablet	B-C0039225
form	O
like	O
probiotics	B-C0525033
.	O
	
the	O
standard	B-C1442989
treatment	B-C0087111
was	O
administered	B-C1521801
for	O
all	O
patients	B-C0030705
.	O
	
duration	B-C0449238
of	O
hospitalization	B-C0019993
,	O
dysentery	B-C0013369
,	O
fever	B-C0015967
,	O
and	O
the	O
weight	B-C1262477
loss	I-C1262477
were	O
assessed	B-C1516048
in	O
each	O
group	B-C0441833
.	O
	
it	O
was	O
concluded	O
that	O
there	O
was	O
no	B-C3842396
significant	I-C3842396
difference	I-C3842396
in	O
both	O
groups	B-C0441833
in	O
the	O
baseline	B-C1442488
characteristics	B-C1521970
.	O
	
the	O
mean	B-C0449238
duration	I-C0449238
of	O
dysentery	B-C0013369
reduced	B-C0392756
p	O
<	O
0.05	O
.	O
	
the	O
mean	B-C0449238
duration	I-C0449238
of	O
fever	B-C0015967
has	O
been	O
significantly	O
reduced	B-C0392756
in	O
the	O
synbiotic	B-C2936470
group	B-C0441833
1.64	O
0.87	O
days	B-C0439228
in	O
comparison	B-C1707455
to	O
the	O
placebo	B-C1696465
group	B-C0441833
2.13	O
0.94	O
days	B-C0439228
p	O
<	O
0.001	O
.	O
	
average	B-C1265611
amount	I-C1265611
of	O
weight	B-C1262477
loss	I-C1262477
was	O
significantly	O
lower	O
in	O
the	O
synbiotic	B-C2936470
group	B-C0441833
in	O
comparison	B-C1707455
to	O
that	O
in	O
the	O
placebo	B-C1696465
group	B-C0441833
129.5	O
23.388	O
grams	O
and	O
278	O
28.385	O
grams	O
,	O
resp	O
p	O
<	O
0.001	O
.	O
	
there	O
was	O
no	B-C3842396
significant	I-C3842396
difference	I-C3842396
in	O
the	O
mean	B-C0449238
duration	I-C0449238
of	O
hospitalization	B-C0019993
in	O
both	O
groups	B-C0441833
p	O
>	O
0.05	O
.	O
	
the	O
use	O
of	O
synbiotics	B-C2936470
as	O
an	O
adjuvant	B-C0677850
therapy	I-C0677850
to	O
the	O
standard	B-C1442989
treatment	B-C0087111
of	O
dysentery	B-C0013369
significantly	O
reduces	B-C0392756
the	O
duration	B-C0449238
of	O
dysentery	B-C0013369
,	O
fever	B-C0015967
,	O
and	O
rate	B-C1262477
of	I-C1262477
weight	I-C1262477
losses	I-C1262477
.	O
	
the	O
trial	B-C0008976
is	O
registered	B-C1514821
effect	B-C1280500
of	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
mellitus	I-C0011860
on	O
the	O
pharmacokinetics	B-C0031328
and	O
transplacental	B-C0678748
transfer	I-C0678748
of	O
nifedipine	B-C0028066
in	O
hypertensive	B-C0020538
pregnant	B-C0033011
women	I-C0033011
diabetes	B-C0011849
mellitus	I-C0011849
can	O
inhibit	B-C3463820
cytochrome	B-C1142644
p450	I-C1142644
3a4	I-C1142644
,	O
an	O
enzyme	B-C0014442
responsible	O
for	O
the	O
metabolism	B-C0683140
of	O
nifedipine	B-C0028066
,	O
used	O
for	O
the	O
treatment	B-C0087111
of	O
hypertension	B-C0020538
in	O
pregnant	B-C0033011
women	I-C0033011
.	O
	
we	O
aimed	B-C1947946
to	O
assess	B-C0184514
the	O
effect	B-C1280500
of	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
mellitus	I-C0011860
t2dm	B-C0011860
on	O
the	O
pharmacokinetics	B-C0031328
,	O
placental	B-C0678748
transfer	I-C0678748
and	O
distribution	O
of	O
nifedipine	B-C0028066
in	O
amniotic	B-C0002638
fluid	I-C0002638
in	O
hypertensive	B-C0020538
pregnant	B-C0033011
women	I-C0033011
.	O
	
the	O
study	B-C2603343
was	O
conducted	O
in	O
12	O
hypertensive	B-C0020538
pregnant	B-C0033011
women	I-C0033011
control	B-C0009932
group	I-C0009932
cg	B-C0009932
and	O
10	O
hypertensive	B-C0020538
pregnant	B-C0033011
women	I-C0033011
with	O
t2dm	B-C0011860
taking	O
slow-release	O
nifedipine	B-C0028066
20	O
mg	O
,	O
12/12	O
h	O
.	O
	
on	O
the	O
34th	O
week	B-C0439230
of	O
gestation	B-C0032961
,	O
serial	O
blood	B-C0178913
samples	I-C0178913
were	O
collected	O
0-12	O
h	O
after	O
administration	B-C1533734
of	O
the	O
medication	B-C0013227
.	O
	
at	B-C3263555
delivery	I-C3263555
,	O
samples	B-C0178913
of	O
maternal	B-C0026591
and	O
fetal	B-C0015925
blood	I-C0015925
and	O
amniotic	B-C0002638
fluid	I-C0002638
were	O
collected	O
for	O
determination	B-C1148554
of	O
nifedipine	B-C0028066
distribution	O
in	O
these	O
compartments	O
.	O
	
the	O
median	B-C0876920
pharmacokinetic	B-C0031328
parameters	B-C0549193
of	O
cg	B-C0009932
were	O
peak	B-C0683150
plasma	I-C0683150
concentration	I-C0683150
cmax	B-C0683150
26.41	O
ng	O
ml	O
,	O
time	B-C2348796
to	I-C2348796
reach	I-C2348796
cmax	I-C2348796
tmax	B-C2348796
1.79	O
h	O
,	O
area	B-C0376690
under	I-C0376690
the	I-C0376690
plasma	I-C0376690
concentration	I-C0376690
vs	O
.	O
	
time	B-C2986848
curve	I-C2986848
from	O
0-12	O
h	O
auc	B-C0376690
0-12	O
235.99	O
ng.h	O
ml	O
,	O
half-life	B-C0018517
t½	O
4.34	O
h	O
,	O
volume	B-C0683148
of	I-C0683148
distribution	I-C0683148
divided	O
by	O
bioavailability	B-C0005508
vd	B-C0683148
/	O
f	B-C0005508
560.96	O
l	O
,	O
and	O
clt	B-C0683152
/	O
f	B-C0005508
84.77	O
l	O
h	O
.	O
	
the	O
parameters	B-C0549193
for	O
t2dm	B-C0011860
group	B-C1257890
were	O
cmax	B-C0683150
23.52	O
ng	O
ml	O
,	O
tmax	B-C2348796
1.48	O
h	O
,	O
auc	B-C0376690
0-12	O
202.23	O
ng.h	O
ml	O
,	O
t½	O
5.00	O
h	O
,	O
vd	B-C0683148
/	O
f	B-C0005508
609.40	O
l	O
,	O
and	O
apparent	O
total	B-C0683152
clearance	I-C0683152
clt	B-C0683152
/	O
f	B-C0005508
98.94	O
l	O
h	O
.	O
	
the	O
ratios	B-C0456603
of	O
plasma	B-C0683150
concentrations	I-C0683150
of	O
nifedipine	B-C0028066
in	O
the	O
umbilical	B-C0041637
vein	I-C0041637
,	O
intervillous	B-C0230968
space	I-C0230968
and	O
amniotic	B-C0002638
fluid	I-C0002638
to	O
those	O
in	O
the	O
maternal	B-C0026591
vein	O
for	O
cg	B-C0009932
and	O
t2dm	B-C0011860
were	O
0.53	O
and	O
0.44	O
,	O
0.78	O
and	O
0.87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	B-C0002638
fluid	I-C0002638
/	O
maternal	B-C0026591
plasma	B-C0032105
ratio	B-C0456603
of	O
0.05	O
for	O
both	O
groups	B-C1257890
.	O
	
the	O
ratios	B-C0456603
of	O
plasma	B-C0683150
concentrations	I-C0683150
in	O
the	O
umbilical	B-C0041632
artery	I-C0041632
to	O
those	O
in	O
the	O
umbilical	B-C0041637
vein	I-C0041637
were	O
0.82	O
for	O
cg	B-C0009932
and	O
0.88	O
for	O
t2dm	B-C0011860
.	O
	
there	O
was	O
no	O
influence	B-C4054723
of	O
t2dm	B-C0011860
on	O
the	O
pharmacokinetics	B-C0031328
or	O
placental	B-C0678748
transfer	I-C0678748
of	O
nifedipine	B-C0028066
in	O
hypertensive	B-C0020538
women	B-C0043210
with	O
controlled	B-C2911690
diabetes	B-C0011847
.	O
	
results	B-C1274040
of	O
an	O
international	B-C0033267
postmarketing	I-C0033267
surveillance	I-C0033267
study	I-C0033267
of	O
pl-vegf165	B-C1254351
safety	B-C0036043
and	O
efficacy	B-C1280519
in	O
210	O
patients	B-C0030705
with	O
peripheral	B-C1704436
arterial	I-C1704436
disease	I-C1704436
the	O
effective	O
treatment	B-C0087111
of	O
chronic	B-C0205191
lower	B-C0023216
limb	I-C0023216
ischemia	B-C0022116
is	O
one	O
of	O
the	O
most	O
challenging	O
issues	O
confronting	O
vascular	B-C0586909
surgeons	I-C0586909
.	O
	
current	O
pharmacological	B-C0205464
therapies	B-C0087111
play	O
an	O
auxiliary	O
role	O
and	O
cannot	O
prevent	O
disease	B-C0242656
progression	I-C0242656
,	O
and	O
new	O
treatment	B-C0087111
methods	I-C0087111
are	O
needed	O
.	O
	
pl-vegf165	B-C1254351
,	O
a	O
gene	B-C0017296
therapy	I-C0017296
drug	B-C1254351
,	O
was	O
approved	O
in	O
russia	B-C0035970
for	O
the	O
treatment	B-C0087111
of	O
atherosclerotic	B-C0333482
peripheral	B-C1704436
arterial	I-C1704436
disease	I-C1704436
pad	B-C1704436
after	O
clinical	B-C0008972
studies	I-C0008972
in	O
2011	O
.	O
	
the	O
study	B-C2603343
drug	B-C1254351
is	O
an	O
original	O
gene	B-C0012931
construction	I-C0012931
in	O
which	O
pl-vegf165	B-C1254351
1.2	O
mg	O
is	O
the	O
active	B-C0574031
substance	I-C0574031
.	O
	
this	O
postmarketing	B-C0033267
surveillance	I-C0033267
study	I-C0033267
was	O
undertaken	O
to	O
evaluate	O
the	O
safety	B-C0036043
identification	O
of	O
uncommon	O
side	B-C0879626
effects	I-C0879626
and	O
efficacy	B-C1280519
of	O
gene	B-C0017296
therapy	I-C0017296
in	O
patients	B-C0030705
in	O
routine	O
clinical	B-C0205897
practice	I-C0205897
.	O
	
in	O
total	O
,	O
210	O
patients	B-C0030705
with	O
stage	B-C1306673
ii-iii	I-C1306673
chronic	B-C0205191
limb	B-C0015385
ischemia	B-C0022116
according	O
to	O
the	O
fontaine	B-C0282574
classification	I-C0282574
modified	O
by	O
av	O
pokrovsky	O
in	O
33	O
healthcare	B-C0018704
facilities	I-C0018704
in	O
russia	B-C0035970
and	O
the	O
ukraine	B-C0041580
were	O
enrolled	O
in	O
the	O
study	B-C2603343
.	O
	
the	O
control	B-C0009932
group	I-C0009932
n	O
=	O
60	O
received	O
conservative	B-C0459914
therapy	I-C0459914
without	O
prostaglandins	B-C0033554
and	O
prostacyclins	B-C0205911
,	O
and	O
the	O
treatment	B-C1257890
group	I-C1257890
n	O
=	O
150	O
received	O
treatment	B-C0087111
with	O
pl-vegf165	B-C1254351
as	O
two	O
intramuscular	B-C0021492
injections	I-C0021492
for	O
a	O
total	O
dose	B-C0178602
of	O
2.4	O
mg	O
.	O
	
pain-free	B-C0243095
walking	I-C0243095
distance	I-C0243095
pwd	B-C0243095
the	O
primary	O
efficacy	B-C1280519
criterion	O
for	O
fontaine	B-C0282574
stages	B-C1306673
ii-iii	I-C1306673
,	O
blood	B-C0243095
flow	I-C0243095
linear	I-C0243095
velocity	I-C0243095
bflv	B-C0243095
,	O
and	O
ankle-brachial	B-C1328319
index	I-C1328319
abi	B-C1328319
were	O
monitored	O
for	O
6	O
months	B-C0439231
.	O
	
the	O
safety	B-C0036043
of	O
pl-vegf165	B-C1254351
gene	B-C1517499
transfer	I-C1517499
in	O
terms	O
of	O
the	O
trial	B-C4255259
protocol	I-C4255259
was	O
initially	O
evaluated	O
6	O
months	B-C0439231
after	O
the	O
start	O
of	O
the	O
study	O
adverse	B-C0877248
events	I-C0877248
aes	B-C0877248
and	O
serious	B-C0877248
adverse	I-C0877248
events	I-C0877248
saes	B-C0877248
were	O
recorded	O
during	O
both	O
routine	O
visits	B-C0008952
and	O
unscheduled	O
requests	O
for	O
medical	B-C3825410
care	I-C3825410
.	O
	
overall	O
,	O
pwd	B-C0243095
increased	O
by	O
177%	O
,	O
from	O
100.3	O
6.9	O
to	O
277.1	O
16.2	O
m	O
p	O
=	O
0.0001	O
,	O
in	O
the	O
treatment	B-C1257890
group	I-C1257890
,	O
whereas	O
the	O
mean	B-C0444504
value	O
was	O
unchanged	O
in	O
the	O
control	B-C0009932
group	I-C0009932
p	O
=	O
0.218	O
.	O
	
both	O
bflv	B-C0243095
and	O
abi	B-C1328319
values	I-C1328319
increased	O
by	O
24%	O
p	O
=	O
0.0001	O
in	O
the	O
treatment	B-C1257890
group	I-C1257890
but	O
decreased	O
in	O
the	O
control	B-C0009932
group	I-C0009932
.	O
	
the	O
greatest	O
therapeutic	B-C1527144
effect	I-C1527144
was	O
observed	O
for	O
stage	B-C0205578
iii	I-C0205578
disease	B-C0012634
pwd	B-C0243095
increased	O
by	O
683%	O
p	O
=	O
0.0001	O
.	O
	
no	B-C1513916
angiogenic	B-C0087111
therapy	I-C0087111
-related	O
aes	B-C0877248
or	O
side	B-C0879626
effects	I-C0879626
were	O
recorded	O
,	O
and	O
target	O
limb	B-C0949591
salvage	I-C0949591
was	O
96	O
and	O
97%	O
in	O
the	O
treatment	B-C1257890
and	O
control	B-C0009932
groups	I-C0009932
,	O
respectively	O
.	O
	
the	O
results	B-C1274040
obtained	O
in	O
this	O
study	B-C2603343
are	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
the	O
phase	B-C1706096
iib	I-C1706096
/	O
iii	B-C0282461
registration	O
clinical	B-C0008972
study	I-C0008972
completed	O
in	O
2011	O
.	O
	
pl-vegf165	B-C1254351
intramuscular	B-C0442117
gene	B-C1517499
transfer	I-C1517499
is	O
an	O
effective	O
treatment	B-C0087111
for	O
moderate	O
to	O
severe	O
claudication	B-C1456822
due	O
to	O
chronic	B-C0205191
lower	B-C0023216
limb	I-C0023216
ischemia	B-C0022116
in	O
routine	O
clinical	B-C0205897
practice	I-C0205897
.	O
	
psychological	B-C0033898
factors	I-C0033898
associated	B-C0332281
with	I-C0332281
nafld	B-C0400966
/	O
nash	B-C3241937
a	O
systematic	B-C1955832
review	I-C1955832
nonalcoholic	B-C0400966
fatty	I-C0400966
liver	I-C0400966
disease	I-C0400966
nafld	B-C0400966
represents	O
one	O
of	O
the	O
most	O
common	O
chronic	B-C0341439
liver	I-C0341439
diseases	I-C0341439
worldwide	O
.	O
	
so	O
far	O
,	O
the	O
pathogenesis	B-C0699748
of	O
nafld	B-C0400966
and	O
its	O
more	O
severe	B-C0205082
variant	O
nonalcoholic	B-C3241937
steatohepatitis	I-C3241937
nash	B-C3241937
is	O
yet	O
unclear	O
,	O
with	O
many	O
mechanisms	B-C0441712
being	O
proposed	O
as	O
possible	O
causes	O
.	O
	
this	O
article	O
aims	O
to	O
review	B-C1552617
the	O
psychological	B-C0033898
factors	I-C0033898
associated	B-C0332281
with	I-C0332281
nafld	B-C0400966
/	O
nash	B-C3241937
.	O
	
three	O
main	O
categories	O
of	O
factors	B-C1521761
have	O
been	O
investigated	B-C1292732
emotional	B-C0849912
,	O
cognitive	B-C1516691
and	O
behavioral	B-C0004927
.	O
	
five	O
electronic	B-C3841595
databases	I-C3841595
were	O
searched	O
,	O
limited	O
to	O
studies	O
published	O
in	O
the	O
english	B-C0376245
language	I-C0376245
,	O
during	O
the	O
period	B-C1948053
2005-2015	O
pubmed	B-C1138432
,	O
thomson	B-C0242356
isi	I-C0242356
-	I-C0242356
web	I-C0242356
of	I-C0242356
science	I-C0242356
,	O
scopus	B-C0242356
,	O
proquest	B-C0242356
,	O
and	O
sciencedirect	B-C0242356
.	O
	
results	O
indicated	O
the	O
most	O
relevant	O
emotional	B-C0849912
factors	B-C1521761
to	O
be	O
depression	B-C0011570
and	O
anxiety	B-C0003467
.	O
	
the	O
areas	O
of	O
investigation	B-C1292732
for	O
cognitive	B-C0392335
functioning	I-C0392335
concern	O
those	O
contents	B-C0456205
and	O
processes	B-C1522240
related	O
to	O
the	O
ability	O
to	O
initiate	B-C1704686
and	O
maintain	O
lifestyle	B-C0870811
changes	I-C0870811
.	O
	
the	O
most	O
important	O
behavioral	B-C0004927
factors	B-C1521761
identified	O
are	O
physical	B-C0026606
activity	I-C0026606
,	O
nutrition	B-C1442959
/	O
food	B-C0013470
intake	I-C0013470
and	O
substance	B-C0439861
consumption	B-C1947907
coffee	B-C0009237
,	O
alcohol	B-C0001967
,	O
cigarettes	B-C0677453
.	O
	
some	O
of	O
the	O
factors	B-C1521761
identified	O
act	O
as	O
protective	B-C0679688
factors	I-C0679688
,	O
other	O
as	O
vulnerability	B-C0035648
factors	I-C0035648
.	O
	
nafld	B-C0400966
/	O
nash	B-C3241937
may	O
be	O
considered	O
a	O
cognitive-behavioral	B-C0556006
disease	I-C0556006
,	O
the	O
most	O
effective	O
management	B-C0376636
being	O
lifestyle	B-C0870811
changes	I-C0870811
,	O
with	O
emphasis	O
on	O
diet	B-C0012155
and	O
an	O
approach	O
to	O
functionally	O
relevant	O
clustering	B-C1522242
of	O
the	O
protein	B-C0033684
universe	I-C0033684
active	B-C1522242
site	I-C1522242
profile-based	I-C1522242
clustering	I-C1522242
of	O
protein	B-C1510464
structures	I-C1510464
and	O
sequences	B-C0002518
protein	B-C1527118
function	I-C1527118
identification	O
remains	O
a	O
significant	O
problem	O
.	O
	
solving	O
this	O
problem	O
at	O
the	O
molecular	B-C0935587
functional	I-C0935587
level	I-C0935587
would	O
allow	O
mechanistic	O
determinant	O
identification-	O
amino	B-C0002520
acids	I-C0002520
that	O
distinguish	O
details	O
between	O
functional	B-C1254370
families	I-C1254370
within	O
a	O
superfamily	B-C1254370
.	O
	
active	B-C0242481
site	I-C0242481
profiling	I-C0242481
was	O
developed	O
to	O
identify	O
mechanistic	O
determinants	O
.	O
	
dasp	B-C2348167
and	O
dasp2	B-C2348167
were	O
developed	O
as	O
tools	O
to	O
search	O
sequence	B-C0950141
databases	I-C0950141
using	O
active	B-C0242481
site	I-C0242481
profiling	I-C0242481
.	O
	
here	O
,	O
tulip	B-C0025663
two-level	B-C0025663
iterative	I-C0025663
clustering	I-C0025663
process	I-C0025663
is	O
introduced	O
as	O
an	O
iterative	O
,	O
divisive	O
clustering	B-C1522242
process	I-C1522242
that	O
utilizes	O
active	B-C0242481
site	I-C0242481
profiling	I-C0242481
to	O
separate	O
structurally	O
characterized	O
superfamily	B-C1254370
members	O
into	O
functionally	O
relevant	O
clusters	B-C1704332
.	O
	
underlying	O
tulip	B-C0025663
is	O
the	O
observation	O
that	O
functionally	B-C1254370
relevant	I-C1254370
families	I-C1254370
curated	O
by	O
structure-function	B-C0242356
linkage	I-C0242356
database	I-C0242356
,	O
sfld	B-C0242356
self-identify	O
in	O
dasp2	B-C2348167
searches	O
clusters	B-C1704332
containing	O
multiple	B-C1254370
functional	I-C1254370
families	I-C1254370
do	O
not	O
.	O
	
each	O
tulip	B-C0025663
iteration	O
produces	O
candidate	O
clusters	B-C1704332
,	O
each	O
evaluated	O
to	O
determine	O
if	O
it	O
self-identifies	O
using	O
dasp2	B-C2348167
.	O
	
if	O
so	O
,	O
it	O
is	O
deemed	O
a	O
functionally	B-C1254370
relevant	I-C1254370
group	I-C1254370
.	O
	
divisive	O
clustering	B-C1522242
continues	O
until	O
each	O
structure	O
is	O
either	O
a	O
functionally	B-C1254370
relevant	I-C1254370
group	I-C1254370
member	O
or	O
a	O
singlet	O
.	O
	
tulip	B-C0025663
is	O
validated	O
on	O
enolase	B-C0031691
and	O
glutathione	B-C0017837
transferase	I-C0017837
structures	B-C0596527
,	O
superfamilies	B-C1254370
well-curated	O
by	O
sfld	B-C0242356
.	O
	
correlation	B-C1707520
is	O
strong	O
small	O
numbers	O
of	O
structures	B-C0678594
prevent	O
statistically	B-C0871424
significant	I-C0871424
analysis	I-C0871424
.	O
	
tulip	B-C0025663
-identified	O
enolase	B-C0031691
clusters	B-C1704332
are	O
used	O
in	O
dasp2	B-C0598211
genbank	I-C0598211
searches	O
to	O
identify	O
sequences	B-C0002518
sharing	O
functional	O
site	O
features	O
.	O
	
analysis	O
shows	O
a	O
true	O
positive	O
rate	O
of	O
96%	O
,	O
false	O
negative	O
rate	O
of	O
4%	O
,	O
and	O
maximum	O
false	O
positive	O
rate	O
of	O
4%	O
.	O
	
f-measure	B-C0079809
and	O
performance	B-C0936012
analysis	I-C0936012
on	O
the	O
enolase	B-C0031691
search	O
results	O
and	O
comparison	O
to	O
gemma	B-C0025663
and	O
sci-phy	B-C0025663
demonstrate	O
that	O
tulip	B-C0025663
avoids	O
the	O
over-division	O
problem	O
of	O
these	O
methods	O
.	O
	
mechanistic	O
determinants	O
for	O
enolase	B-C0031691
families	I-C0031691
are	O
evaluated	O
and	O
shown	O
to	O
correlate	O
well	O
with	O
literature	B-C0023866
early	B-C1279919
high	B-C2584312
school	I-C2584312
engagement	I-C2584312
in	O
students	B-C0038492
with	O
attention/deficit	B-C1263846
hyperactivity	I-C1263846
disorder	I-C1263846
students	B-C0038492
with	O
attention/deficit	B-C1263846
hyperactivity	I-C1263846
disorder	I-C1263846
adhd	B-C1263846
continue	O
to	O
languish	O
behind	O
their	O
peers	B-C0679739
with	O
regard	O
to	O
academic	B-C0700132
achievement	I-C0700132
and	O
education	B-C0013658
attainment	I-C0013658
.	O
	
school	B-C2584312
engagement	I-C2584312
is	O
potentially	O
modifiable	O
,	O
and	O
targeting	O
engagement	B-C2584312
may	O
be	O
a	O
means	O
to	O
improve	O
education	B-C0013621
outcomes	B-C1274040
.	O
	
to	O
investigate	O
school	B-C2584312
engagement	I-C2584312
for	O
students	B-C0038492
with	O
adhd	B-C1263846
during	O
the	O
crucial	O
high	B-C0871305
school	I-C0871305
transition	I-C0871305
period	B-C1948053
and	O
to	O
identify	O
factors	O
associated	O
with	O
low	B-C0243095
school	I-C0243095
engagement	I-C0243095
.	O
	
participants	B-C0679646
are	O
adolescents	B-C0205653
12-15	O
years	B-C0439234
in	O
the	O
first	O
and	O
third	O
year	B-C0439234
of	O
high	B-C0599395
school	I-C0599395
with	O
diagnosed	B-C1704656
adhd	B-C1263846
n	O
=	O
130	O
.	O
	
participants	B-C0679646
were	O
recruited	O
from	O
21	O
paediatric	B-C0030755
practices	B-C0205897
.	O
	
cross-sectional	B-C0010362
study	I-C0010362
assessing	O
school	B-C2584312
engagement	I-C2584312
.	O
	
data	B-C1511726
were	O
collected	O
through	O
direct	O
assessment	B-C0220825
and	O
child	B-C0008059
,	O
parent	B-C0030551
,	O
and	O
teacher	B-C0221457
surveys	B-C0038951
.	O
	
school	B-C2584312
engagement	I-C2584312
is	O
measured	O
as	O
student	B-C0871447
attitudes	I-C0871447
to	O
school	B-C0036375
cognitive	B-C0009240
and	O
emotional	B-C0013987
and	O
suspension	B-C4272256
rates	B-C1521828
behavioural	B-C0004927
.	O
	
multivariable	B-C0034980
regression	I-C0034980
analyses	I-C0034980
examined	O
student	B-C0038492
,	O
family	B-C0015576
,	O
and	O
school	B-C0814325
factors	I-C0814325
affecting	O
engagement	B-C2584312
.	O
	
in	O
comparison	O
with	O
state	O
data	O
,	O
students	B-C0038492
with	O
adhd	B-C1263846
in	O
the	O
first	O
year	B-C0439234
of	O
high	B-C0599395
school	I-C0599395
were	O
less	O
motivated	O
p	O
<	O
01	O
and	O
less	O
connected	O
to	O
peers	B-C0679739
p	O
<	O
01	O
.	O
	
overall	O
,	O
there	O
was	O
no	O
discordance	O
in	O
third	O
year	B-C0439234
attitudes	B-C0004271
.	O
	
there	O
were	O
high	B-C0243095
rates	I-C0243095
of	I-C0243095
suspension	I-C0243095
in	O
both	O
years	B-C0439234
in	O
comparison	O
to	O
state-wide	O
suspensions	B-C4272256
21%	O
vs	O
.	O
	
6%	O
,	O
p	O
<	O
01	O
.	O
	
explanatory	O
factors	O
for	O
poor	O
attitudes	B-C0004271
include	O
adolescent	B-C0205653
depression	B-C0011570
,	O
poor	O
adolescent	B-C0205653
supervision	B-C0038842
,	O
and	O
devaluing	B-C0564495
education	B-C0013621
.	O
	
conduct	B-C0684326
problems	I-C0684326
and	O
increased	O
hyperactivity	B-C0424295
were	O
related	O
to	O
increased	B-C0243095
likelihood	I-C0243095
of	I-C0243095
being	I-C0243095
suspended	I-C0243095
,	O
whilst	O
higher	O
cognitive	B-C0392334
ability	I-C0392334
,	O
family	B-C0015576
socio-economic	B-C0086996
status	I-C0086996
,	O
and	O
independent	O
schools	B-C0036375
reduced	O
risk	B-C0035647
.	O
	
potentially	O
modifiable	O
individual	B-C0237401
and	O
family	B-C0015576
factors	B-C4035944
including	O
adolescent	B-C0205653
depression	B-C0011570
,	O
behavioural	B-C0233514
problems	I-C0233514
,	O
education	B-C0013621
values	B-C0042295
,	O
and	O
family	B-C0015576
supervision	B-C0038842
could	O
be	O
targeted	O
to	O
better	O
manage	O
the	O
high	B-C0871305
school	I-C0871305
transition	I-C0871305
for	O
students	B-C0038492
with	O
proliferation	B-C0596290
-related	O
activity	O
in	O
endothelial	B-C0225336
cells	I-C0225336
is	O
enhanced	B-C2349975
by	O
micropower	O
plasma	B-C0017110
nonthermal	B-C0752188
plasma	I-C0752188
has	O
received	O
a	O
lot	O
of	O
attention	O
as	O
a	O
medical	B-C0679624
treatment	I-C0679624
technique	I-C0679624
in	O
recent	O
years	O
.	O
	
it	O
can	O
easily	O
create	O
various	O
reactive	B-C0162772
chemical	I-C0162772
species	I-C0162772
ros	B-C0162772
and	O
is	O
harmless	O
to	O
living	B-C0242821
body	I-C0242821
.	O
	
although	O
plasma	B-C0017110
at	O
gas	O
-	O
liquid	O
interface	O
has	O
a	O
potential	O
for	O
a	O
biomedical	O
application	O
,	O
the	O
interactions	O
between	O
the	O
gas	O
-	O
liquid	O
plasma	B-C0017110
and	O
living	O
cells	O
remain	O
unclear	O
.	O
	
here	O
,	O
we	O
show	O
characteristics	O
of	O
a	O
micropower	O
plasma	O
with	O
0.018	O
w	O
of	O
the	O
power	O
input	O
,	O
generated	O
at	O
gas	B-C0017110
-	O
liquid	B-C0302908
interface	B-C1254362
.	O
	
we	O
also	O
provide	O
the	O
evidence	O
of	O
plasma	O
-induced	O
enhancement	O
in	O
proliferation	O
activity	O
of	O
endothelial	O
cells	O
.	O
	
the	O
plasma	O
produced	O
h2o2	O
,	O
hno2	O
,	O
and	O
hno3	O
in	O
phosphate	O
buffered	O
saline	O
containing	O
mg	O
and	O
ca	O
pbs	O
+	O
,	O
and	O
their	O
concentration	O
increased	O
linearly	O
during	O
600-second	O
discharge	O
.	O
	
the	O
value	O
of	O
ph	O
in	O
pbs	O
+	O
against	O
the	O
plasma	O
discharge	O
time	O
was	O
stable	O
at	O
about	O
7.0	O
.	O
	
temperature	O
in	O
pbs	O
+	O
rose	O
monotonically	O
,	O
and	O
its	O
rise	O
was	O
up	O
to	O
0.8	O
at	O
the	O
bottom	O
of	O
a	O
cell-cultured	O
dish	O
by	O
the	O
plasma	O
discharge	O
for	O
600	O
s	O
.	O
	
short-time	O
treatment	O
of	O
the	O
plasma	O
enhanced	O
proliferation	O
activity	O
of	O
endothelial	O
cells	O
.	O
	
in	O
contrast	O
,	O
the	O
treatment	O
of	O
h2o2	O
does	O
not	O
enhance	O
the	O
cell	O
proliferation	O
.	O
	
thus	O
,	O
the	O
ros	O
production	O
and	O
the	O
nuclear	O
factor-kappa	O
b	O
nf-κb	O
activation	O
due	O
to	O
the	O
plasma	O
treatment	O
might	O
be	O
related	O
to	O
enhancement	O
of	O
the	O
cell	O
proliferation	O
.	O
	
our	O
results	O
may	O
potentially	O
provide	O
the	O
basis	O
for	O
developing	O
the	O
biomedical	B-C0752188
applications	O
using	O
the	O
gas	O
-	O
liquid	O
plasma	B-C0017110
ph	B-C0020283
-dependent	O
transmembrane	B-C1148560
activity	I-C1148560
of	O
peptide	B-C0030956
-functionalized	O
gold	B-C0018026
nanostars	I-C0018026
for	O
computed	B-C0040405
tomography	I-C0040405
/	O
photoacoustic	B-C3897929
imaging	I-C3897929
and	O
photothermal	B-C0454527
therapy	I-C0454527
progress	B-C1280477
in	O
multifunctional	B-C1450053
nanomaterials	I-C1450053
for	O
tumor	B-C0920425
therapy	I-C0920425
mostly	O
depends	O
on	O
the	O
development	B-C1527148
of	O
tumor	B-C0027651
-	O
targeting	B-C1521840
delivery	B-C0087111
strategies	I-C0087111
.	O
	
one	O
approach	B-C1292724
is	O
to	O
explore	O
a	O
ph	B-C0020283
-responsive	O
strategy	B-C0449851
to	O
target	B-C1521840
the	O
slightly	O
acidic	B-C2936626
solid	I-C2936626
tumor	I-C2936626
microenvironment	I-C2936626
.	O
	
a	O
novel	O
class	O
of	O
ph	B-C2606266
low	I-C2606266
insertion	I-C2606266
peptides	I-C2606266
phlips	B-C2606266
with	O
ph	B-C0020283
-dependent	O
transmembrane	B-C1148560
activity	I-C1148560
can	O
fold	B-C0332462
and	O
rapidly	O
insert	B-C0205245
into	O
the	O
lipid	B-C0023768
bilayer	I-C0023768
of	O
tumor	B-C0597032
cells	I-C0597032
triggered	O
by	O
acidity	B-C1254365
,	O
facilitating	O
the	O
cellular	B-C1254366
internalization	I-C1254366
of	O
nanomaterials	B-C1450053
synchronously	B-C0439580
.	O
	
here	O
,	O
we	O
innovatively	O
decorated	O
gold	B-C0018026
nanostars	I-C0018026
gnss	B-C0018026
with	O
phlips	B-C2606266
gns	B-C0018026
-	O
phlip	B-C2606266
to	O
improve	O
their	O
targeting	B-C1521840
ability	O
and	O
photothermal	B-C0454527
therapeutic	I-C0454527
ptt	B-C0454527
efficiency	B-C0013682
.	O
	
the	O
obtained	O
gns	B-C0018026
-	O
phlip	B-C2606266
exhibited	O
the	O
excellent	O
characteristics	B-C1521970
of	O
uniform	O
size	B-C0456389
and	O
good	O
biocompatibility	B-C0596177
.	O
	
as	O
compared	O
to	O
gns	B-C0018026
-	O
mpeg	B-C0066763
,	O
the	O
cellular	B-C1254366
internalization	I-C1254366
of	O
gns	B-C0018026
-	O
phlip	B-C2606266
was	O
1-fold	O
higher	O
after	O
a	O
2	O
h	O
incubation	O
with	O
cells	B-C0007634
in	O
media	B-C1705217
at	O
ph	B-C0020283
6.4	O
than	O
at	O
ph	B-C0020283
7.4	O
.	O
	
moreover	O
,	O
the	O
tumor	B-C0027651
accumulation	B-C4055506
of	O
the	O
gns	B-C0018026
-	O
phlip	B-C2606266
was	O
3-fold	O
higher	O
than	O
that	O
of	O
gns	B-C0018026
-	O
mpeg	B-C0066763
after	O
intravenous	B-C0021494
injection	I-C0021494
into	O
mcf-7	B-C0596890
breast	B-C1458155
tumor	I-C1458155
animal	B-C0012644
models	I-C0012644
for	O
24	O
h	O
.	O
	
furthermore	O
,	O
gns	B-C0018026
-	O
phlip	B-C2606266
exhibited	O
stronger	O
signals	B-C1710082
than	O
the	O
gns	B-C0018026
-	O
mpeg	B-C0066763
through	O
computed	B-C0040405
tomography	I-C0040405
ct	B-C0040405
and	O
photoacoustic	B-C3897929
pa	I-C3897929
imaging	I-C3897929
.	O
	
simultaneously	O
,	O
the	O
desirable	O
targeting	B-C1521840
efficiency	B-C0013682
significantly	O
improved	O
the	O
ptt	B-C0454527
efficacy	B-C1280519
to	O
tumors	B-C0027651
,	O
with	O
low	O
side	B-C0879626
effects	I-C0879626
on	O
normal	O
tissues	B-C0040300
.	O
	
the	O
results	O
clearly	O
demonstrate	O
that	O
the	O
gns	B-C0018026
-	O
phlip	B-C2606266
successfully	O
took	O
advantage	O
of	O
the	O
tumor	B-C0027651
-	O
targeting	B-C1521840
ability	O
of	O
phlips	B-C2606266
and	O
the	O
good	O
characteristics	B-C1521970
of	O
gns	B-C0018026
s	O
,	O
which	O
may	O
contribute	O
to	O
the	O
study	O
of	O
tumor	O
imaging	O
and	O
therapy	B-C0087111
stepwise	O
cyclopropanation	B-C1511131
on	O
the	O
polycyclopropanated	B-C3179052
polyketide	I-C3179052
formation	O
in	O
jawsamycin	B-C0003240
biosynthesis	B-C0005572
jawsamycin	B-C0003240
is	O
a	O
polyketide	B-C3179052
-	O
nucleoside	B-C0028621
hybrid	O
with	O
a	O
unique	O
polycyclopropane	B-C0010587
moiety	O
on	O
a	O
single	O
polyketide	B-C3179052
chain	I-C3179052
.	O
	
the	O
unexpected	O
isolation	O
of	O
cyclopropane	B-C0010587
deficient	O
jawsamycin	B-C0003240
analogs	O
allowed	O
us	O
to	O
propose	O
a	O
stepwise	O
cyclopropanation	B-C1511131
mechanism	B-C0441712
for	O
the	O
enzymatic	B-C0014442
synthesis	B-C0005572
of	O
this	O
polyketide	B-C3179052
.	O
	
the	O
concise	O
timing	O
of	O
the	O
cyclopropanation	B-C1511131
could	O
be	O
regulated	O
by	O
a	O
delicate	O
balance	O
between	O
reaction	B-C0678608
rates	I-C0678608
of	O
the	O
condensation	B-C0596312
and	O
cyclopropanation	B-C1511131
reactions	I-C1511131
.	O
	
initial	O
experience	O
with	O
laparoscopic	B-C0519801
radical	I-C0519801
antegrade	I-C0519801
modular	I-C0519801
pancreatosplenectomy	I-C0519801
for	O
left-sided	B-C0346647
pancreatic	I-C0346647
cancer	I-C0346647
in	O
a	O
single	O
institution	B-C2607850
technical	O
aspects	O
and	O
oncological	B-C0679250
outcomes	I-C0679250
laparoscopic	B-C0751429
surgery	I-C0751429
has	O
been	O
performed	O
less	O
frequently	O
in	O
the	O
era	O
of	O
pancreatic	B-C0346647
cancer	I-C0346647
due	O
to	O
technical	B-C1710348
difficulties	I-C1710348
and	O
concerns	O
about	O
oncological	B-C0027651
safety	B-C0036043
.	O
	
radical	B-C0842939
antegrade	I-C0842939
modular	I-C0842939
pancreatosplenectomy	I-C0842939
ramps	B-C0842939
is	O
expected	O
to	O
be	O
helpful	O
to	O
obtain	O
a	O
negative	B-C1709157
margin	I-C1709157
during	O
radical	B-C0184919
lymph	I-C0184919
node	I-C0184919
dissection	I-C0184919
.	O
	
we	O
hypothesized	O
that	O
it	O
would	O
also	O
be	O
favorable	B-C3640814
as	O
a	O
laparoscopic	B-C0393360
application	I-C0393360
due	O
to	O
unique	O
features	O
.	O
	
fifteen	O
laparoscopic	B-C0031150
ramps	B-C0842939
for	O
well-selected	O
patients	B-C0030705
with	O
left-sided	B-C0346647
pancreatic	I-C0346647
cancer	I-C0346647
were	O
performed	O
from	O
july	O
2011	O
to	O
april	O
2016	O
.	O
	
five	O
trocars	B-C0041158
were	O
usually	O
used	O
,	O
and	O
the	O
operative	B-C0543467
procedures	I-C0543467
and	O
range	B-C0242382
of	I-C0242382
dissection	I-C0242382
were	O
similar	O
to	O
or	O
the	O
same	O
as	O
those	O
of	O
open	O
ramps	B-C0842939
described	O
by	O
strasberg	B-C0805191
.	O
	
all	O
medical	O
records	O
and	O
follow-up	B-C1704685
data	I-C1704685
were	O
reviewed	O
and	O
analyzed	O
.	O
	
all	O
patients	B-C0030705
had	O
pancreatic	B-C1335302
ductal	I-C1335302
adenocarcinoma	I-C1335302
.	O
	
mean	O
operative	B-C3494201
time	I-C3494201
was	O
219.3	O
53.8	O
min	O
,	O
and	O
estimated	B-C1443559
blood	I-C1443559
loss	I-C1443559
was	O
250	O
70	O
ml	O
.	O
	
the	O
length	B-C0023303
of	I-C0023303
postoperative	I-C0023303
hospital	I-C0023303
stay	I-C0023303
was	O
6.1	O
1.2	O
days	O
,	O
and	O
postoperative	B-C0032787
morbidities	B-C0026538
developed	O
in	O
two	O
patients	B-C0030705
13.3	O
with	O
urinary	B-C0080274
retention	I-C0080274
.	O
	
the	O
median	O
number	O
of	O
retrieved	O
lymph	B-C0024204
nodes	I-C0024204
was	O
18.1	O
6.2	O
and	O
all	O
had	O
negative	B-C1709157
margins	I-C1709157
.	O
	
median	O
follow-up	B-C1522577
time	O
was	O
46.0	O
months	O
,	O
and	O
the	O
3-year	O
disease	B-C0242793
free	I-C0242793
survival	I-C0242793
and	O
overall	B-C0038954
survival	I-C0038954
rates	I-C0038954
were	O
56.3	O
and	O
74.1	O
,	O
respectively	O
.	O
	
our	O
early	O
experience	O
with	O
laparoscopic	B-C0031150
ramps	B-C0842939
achieved	O
feasible	O
perioperative	B-C1518988
results	O
accompanied	O
by	O
acceptable	O
survival	B-C0038954
outcomes	I-C0038954
.	O
	
laparoscopic	B-C0031150
ramps	B-C0842939
could	O
be	O
a	O
safe	O
and	O
oncologically	B-C0027651
feasible	B-C3831015
procedure	I-C3831015
in	O
well-selected	O
patients	B-C0030705
with	O
left-sided	B-C0346647
pancreatic	I-C0346647
cancer	I-C0346647
.	O
	
individual	B-C0237401
classification	B-C0008902
of	O
strong	B-C0442821
risk	B-C0035647
attitudes	B-C0004271
an	O
application	O
across	O
lottery	B-C0392762
types	B-C0332307
and	O
age	B-C0027362
groups	I-C0027362
empirical	B-C1880496
evaluations	B-C1292732
of	O
risk	B-C0035647
attitudes	B-C0004271
often	O
rely	O
on	O
a	O
weak	B-C1762617
definition	B-C1704788
of	O
risk	B-C0035647
that	O
concerns	O
preferences	O
towards	O
risky	B-C0035647
and	O
riskless	B-C1518601
options	I-C1518601
e.g	O
,	O
a	O
lottery	B-C0392762
vs	O
.	O
	
a	O
sure	O
outcome	B-C1274040
.	O
	
a	O
large	O
body	O
of	O
work	O
has	O
shown	O
that	O
individuals	B-C0237401
tend	O
to	O
be	O
weak	B-C1762617
risk	B-C0035647
averse	O
in	O
choice	B-C1707391
contexts	B-C0449255
involving	O
risky	B-C0035647
and	O
riskless	B-C1517378
gains	I-C1517378
but	O
weak	B-C1762617
risk	B-C0035647
seeking	O
in	O
contexts	B-C0449255
involving	O
losses	B-C1517945
,	O
a	O
phenomenon	B-C1882365
known	O
as	O
the	O
reflection	B-C1882365
effect	I-C1882365
.	O
	
recent	O
attempts	O
to	O
evaluate	O
age	B-C0699810
differences	I-C0699810
in	O
risk	B-C0035647
attitudes	B-C0004271
have	O
relied	O
on	O
this	O
weak	B-C1762617
definition	B-C1704788
,	O
testing	O
whether	O
the	O
reflection	B-C1882365
effect	I-C1882365
increases	B-C0442805
or	O
diminishes	B-C0205216
as	O
we	O
grow	O
older	B-C1254367
.	O
	
the	O
present	O
work	O
argues	O
that	O
weak	B-C1762617
risk	B-C0035647
attitudes	B-C0004271
have	O
limited	O
generalizability	B-C0205556
and	O
proposes	O
the	O
use	B-C1524063
of	I-C1524063
a	O
strong	B-C0442821
definition	O
of	O
risk	O
that	O
is	O
concerned	O
with	O
preferences	O
towards	O
options	O
with	O
the	O
same	O
expected	O
value	O
but	O
different	O
degrees	O
of	O
risk	O
i.e	O
,	O
outcome	O
variance	O
.	O
	
a	O
reanalysis	O
of	O
previously-published	O
data	O
and	O
the	O
results	O
from	O
a	O
new	O
study	O
show	O
that	O
only	O
a	O
minority	O
of	O
individuals	O
manifests	O
the	O
reflection	O
effect	O
under	O
a	O
strong	B-C0442821
definition	B-C1704788
of	O
risk	B-C0035647
,	O
and	O
that	O
,	O
when	O
facing	O
certain	O
lottery	O
-	O
pair	O
types	O
,	O
older	O
adults	O
appear	O
to	O
be	O
more	O
risk	O
seeking	O
than	O
younger	O
adults	I-C0001792
treating	B-C1522326
the	O
binge	B-C0596170
or	O
the	O
fat	B-C0015665
body	I-C0015665
representations	B-C1882932
of	O
fatness	B-C4024583
in	O
a	O
gold	B-C0150110
standard	I-C0150110
psychological	B-C0205486
treatment	B-C0814280
manual	I-C0814280
for	O
binge	B-C0596170
eating	I-C0596170
disorder	I-C0596170
this	O
article	O
reports	B-C0700287
the	O
results	B-C0456984
of	O
a	O
foucauldian	B-C0086418
-informed	O
discourse	B-C0870428
analysis	I-C0870428
exploring	O
representations	B-C1882932
of	O
fatness	B-C4024583
embedded	O
within	O
an	O
empirically	B-C1880496
based	O
psychological	B-C0205486
treatment	B-C0814280
manual	I-C0814280
for	O
binge	B-C0596170
eating	I-C0596170
disorder	I-C0596170
,	O
a	O
condition	B-C0348080
characterized	B-C1880022
by	O
overvaluation	O
of	O
weight	B-C0005910
and	O
shape	B-C0348078
.	O
	
analyses	B-C0936012
indicate	B-C1444656
that	O
the	O
manual	B-C0024763
prioritizes	O
weight	B-C1262477
loss	I-C1262477
with	O
relatively	B-C0205345
less	O
emphasis	O
placed	O
on	O
treating	B-C1522326
the	O
diagnostic	B-C0348026
symptoms	B-C1457887
and	O
underlying	O
mechanisms	B-C0441712
of	O
binge	B-C0596170
eating	I-C0596170
disorder	I-C0596170
.	O
	
we	O
raise	O
critical	B-C3869780
concerns	I-C3869780
about	O
these	O
observations	B-C0302523
and	O
link	O
our	O
findings	B-C0243095
to	O
mainstream	O
psychology's	B-C0033909
adoption	O
of	O
the	O
medical	B-C0205556
framing	I-C0205556
of	O
fatness	B-C4024583
as	O
obesity	B-C0028754
within	O
the	O
""""	O
gold	B-C0150110
standard	I-C0150110
""""	O
approach	O
to	O
intervention	B-C1273869
.	O
	
we	O
recommend	O
that	O
psychology	B-C0033909
as	O
a	O
discipline	B-C0237070
abandons	O
the	O
weight	B-C1262477
loss	I-C1262477
imperative	O
associated	B-C0332281
with	I-C0332281
binge	B-C0596170
eating	I-C0596170
disorder	I-C0596170
and	O
fat	B-C0015665
bodies	I-C0015665
.	O
	
we	O
recommend	O
that	O
practitioners	B-C0017319
locate	O
the	O
problem	B-C0033213
of	O
fat	B-C0036938
shame	I-C0036938
in	O
society	B-C0037455
as	O
opposed	O
to	O
the	O
individual	B-C0237401
person's	O
body	B-C0242821
and	O
provide	B-C1999230
individuals	B-C0237401
with	O
tools	O
to	O
identify	O
and	O
resist	O
fat	B-C0277787
stigma	I-C0277787
and	O
oppression	B-C0235132
,	O
rather	O
than	O
provide	B-C1999230
them	O
with	O
tools	O
to	O
reshape	O
their	O
high	O
diversity	B-C1880371
of	O
planctomycetes	B-C1222577
in	O
soils	B-C0037592
of	O
two	O
lichen	B-C0023657
-dominated	O
sub-arctic	B-C0003740
ecosystems	B-C0162358
of	O
northwestern	B-C1709274
siberia	B-C0037045
a	O
wide	O
variety	O
of	O
terrestrial	B-C0562020
ecosystems	B-C0162358
in	O
tundra	B-C3850151
have	O
a	O
ground	O
vegetation	O
cover	O
composed	O
of	O
reindeer	O
lichens	B-C0023657
genera	B-C1708235
cladonia	B-C1080962
and	O
cetraria	B-C1094116
.	O
	
the	O
microbial	B-C0599840
communities	O
of	O
two	O
lichen	B-C0023657
-dominated	O
ecosystems	B-C0162358
typical	O
of	O
the	O
sub-arctic	B-C0003740
zone	I-C0003740
of	O
northwestern	B-C1709274
siberia	B-C0037045
,	O
that	O
is	O
a	O
forested	B-C0086312
tundra	B-C3850151
soil	B-C0037592
and	O
a	O
shallow	B-C0017446
acidic	I-C0017446
peatland	I-C0017446
,	O
were	O
examined	O
in	O
our	O
study	B-C2603343
.	O
	
as	O
revealed	O
by	O
molecular	O
analyses	O
,	O
soil	B-C0037592
and	O
peat	B-C0030739
layers	O
just	O
beneath	O
the	O
lichen	B-C0023657
cover	O
were	O
abundantly	O
colonized	B-C4289767
by	O
bacteria	B-C0004611
from	O
the	O
phylum	B-C1709533
planctomycetes	B-C1222577
.	O
	
highest	O
abundance	O
of	O
planctomycetes	B-C1222577
detected	O
by	O
fluorescence	B-C0016315
in	B-C0162788
situ	I-C0162788
hybridization	I-C0162788
was	O
in	O
the	O
range	O
2.2	O
10	O
cells	B-C0392762
per	I-C0392762
gram	I-C0392762
of	I-C0392762
wet	I-C0392762
weight	I-C0392762
.	O
	
16s	B-C3537372
rrna	I-C3537372
gene	B-C0017337
fragments	I-C0017337
from	O
the	O
planctomycetes	B-C1222577
comprised	O
8-13%	O
of	O
total	O
16s	B-C3537372
rrna	I-C3537372
gene	B-C0017337
reads	O
retrieved	O
using	O
illumina	B-C1553778
pair-end	I-C1553778
sequencing	I-C1553778
from	O
the	O
soil	B-C0037592
and	O
peat	B-C0030739
samples	I-C0030739
.	O
	
lichen	B-C0023657
-associated	O
assemblages	O
of	O
planctomycetes	B-C1222577
displayed	O
unexpectedly	O
high	O
diversity	B-C1880371
,	O
with	O
a	O
total	O
of	O
89	O
reads	O
representing	O
1723	O
operational	B-C0683955
taxonomic	I-C0683955
units	I-C0683955
determined	O
at	O
97%	O
sequence	B-C1710052
identity	I-C1710052
.	O
	
the	O
soil	B-C0037592
of	O
forested	O
tundra	B-C3850151
was	O
dominated	O
by	O
uncultivated	O
members	O
of	O
the	O
family	B-C1704727
planctomycetaceae	B-C0995267
53-71%	O
of	O
total	O
planctomycetes	B-C1222577
-like	O
reads	O
,	O
while	O
sequences	B-C0162326
affiliated	O
with	O
the	O
phycisphaera-related	B-C2791840
group	I-C2791840
wd2101	I-C2791840
recently	O
assigned	O
to	O
the	O
order	B-C1705177
tepidisphaerales	B-C4087581
were	O
most	O
abundant	O
in	O
peat	B-C0030739
28-51%	O
of	O
total	O
reads	O
.	O
	
representatives	O
of	O
the	O
isosphaera	B-C0995268
-	O
singulisphaera	B-C2291815
group	I-C2291815
14-28%	O
of	O
total	O
reads	O
and	O
the	O
lineages	B-C1881379
defined	O
by	O
the	O
genera	B-C1708235
gemmata	B-C0995258
1-4%	O
and	O
planctopirus	B-C4103516
-	O
rubinisphaera	B-C4103506
1-3%	O
were	O
present	O
in	O
both	O
habitats	B-C0871648
.	O
	
two	O
strains	O
of	O
singulisphaera-like	B-C0004611
bacteria	I-C0004611
were	O
isolated	O
from	O
studied	O
soil	B-C0037592
and	O
peat	B-C0030739
samples	I-C0030739
.	O
	
these	O
planctomycetes	B-C1222577
displayed	O
good	O
tolerance	O
of	O
low	B-C0009264
temperatures	I-C0009264
4-15	O
and	O
were	O
capable	O
of	O
growth	B-C0018270
on	O
a	O
number	O
of	O
polysaccharides	B-C0032594
,	O
including	O
lichenan	B-C0064959
,	O
a	O
characteristic	O
component	O
of	O
lichen	B-C0023657
-derived	O
relationship	B-C0439849
between	O
polycythemia	B-C0032461
and	O
in-hospital	B-C0085556
mortality	I-C0085556
in	O
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disease	I-C0024117
patients	B-C0030705
with	O
low-risk	B-C3538919
pulmonary	B-C0034065
embolism	I-C0034065
pulmonary	B-C0034065
embolism	I-C0034065
pe	B-C0034065
is	O
frequent	B-C0332183
in	O
subjects	B-C0080105
with	O
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disease	I-C0024117
copd	B-C0024117
and	O
associated	B-C0332281
with	I-C0332281
high	O
mortality	B-C0079320
.	O
	
this	O
multi-center	B-C0035363
retrospective	I-C0035363
study	I-C0035363
was	O
performed	O
to	O
investigate	B-C1292732
if	O
secondary	O
polycythemia	B-C0032461
is	O
associated	B-C0332281
with	I-C0332281
in-hospital	B-C0085556
mortality	I-C0085556
in	O
copd	B-C0024117
patients	B-C0030705
with	O
low-risk	B-C3538919
pe	B-C0034065
.	O
	
we	O
identified	O
copd	B-C0024117
patients	B-C0030705
with	O
proven	O
pe	B-C0034065
between	O
october	O
,	O
2005	O
and	O
october	O
,	O
2015	O
.	O
	
patients	B-C0030705
in	O
risk	O
classes	O
iii-v	O
on	O
the	O
basis	O
of	O
the	O
pesi	B-C0243095
score	I-C0243095
were	O
excluded	O
.	O
	
we	O
extracted	O
demographic	B-C0011298
,	O
clinical	B-C0205210
and	O
laboratory	B-C0677075
information	I-C0677075
at	O
the	O
time	B-C3854259
of	I-C3854259
admission	I-C3854259
from	O
medical	B-C0025102
records	I-C0025102
.	O
	
all	O
subjects	B-C0080105
were	O
followed	O
until	O
hospital	B-C0586003
discharge	I-C0586003
to	O
identify	O
all-cause	O
mortality	B-C0079320
.	O
	
we	O
enrolled	O
629	O
consecutive	O
patients	B-C0030705
with	O
copd	B-C0024117
and	O
pe	B-C0034065
at	O
low	B-C3538919
risk	I-C3538919
132	O
of	O
them	O
21.0	O
with	O
and	O
497	O
79.0	O
without	O
secondary	O
polycythemia	B-C0032461
.	O
	
compared	O
with	O
those	O
without	O
polycythemia	B-C0032461
,	O
the	O
polycythemia	B-C0032461
group	O
had	O
significantly	B-C4055638
lower	I-C4055638
forced	B-C2238302
expiratory	I-C2238302
volume	I-C2238302
in	I-C2238302
one	I-C2238302
second	I-C2238302
fev1	I-C2238302
level	I-C2238302
0.9	O
vs	O
.	O
	
1.4	O
,	O
p=0	O
,	O
lower	B-C2363807
pao2	I-C2363807
and	O
spo2	B-C2317096
as	O
well	O
as	O
higher	B-C0391839
paco2	I-C0391839
p=0	O
,	O
p=0	O
and	O
p=0	O
,	O
respectively	O
.	O
	
copd	B-C0024117
patients	B-C0030705
with	O
polycythemia	B-C0032461
had	O
a	O
higher	B-C0205250
proportion	B-C1709707
of	O
arrhythmia	B-C0003811
in	O
electrocardiogram	B-C0013798
ecg	B-C0013798
49.5	O
vs	O
.	O
	
35.7	O
,	O
p=0	O
,	O
a	O
longer	O
hospital	B-C0392762
duration	I-C0392762
time	I-C0392762
15.3	O
vs	O
.	O
	
9.7	O
,	O
p=0	O
,	O
a	O
higher	B-C0205250
mechanical	B-C2223989
ventilation	I-C2223989
rate	I-C2223989
noninvasive	B-C2986496
and	O
invasive	B-C0205281
,	O
51.7	O
vs	O
.	O
	
30.3	O
,	O
p=0	O
and	O
31.0	O
vs	O
.	O
	
7.9	O
,	O
p=0	O
,	O
respectively	O
,	O
and	O
a	O
higher	B-C0205250
in-hospital	B-C0085556
mortality	I-C0085556
12.1	O
vs	O
.	O
	
6.6	O
,	O
p=0	O
.	O
	
multivariate	B-C0681925
logistic	I-C0681925
regression	I-C0681925
analysis	I-C0681925
revealed	O
that	O
polycythemia	B-C0032461
was	O
associated	B-C0332281
with	I-C0332281
mortality	B-C0079320
in	O
copd	B-C0024117
patients	B-C0030705
with	O
low-risk	B-C3538919
pe	B-C0034065
adjusted	O
or	O
1.11	O
95%	O
ci	O
,	O
1.04	O
.	O
	
polycythemia	B-C0032461
is	O
an	O
independent	O
risk	B-C0035648
factor	I-C0035648
for	O
all-cause	O
in-hospital	B-C0085556
mortality	I-C0085556
in	O
copd	B-C0024117
patients	B-C0030705
with	O
pe	B-C0034065
at	O
low	B-C3538919
risk	I-C3538919
.	O
	
masitinib	B-C2351398
for	O
treatment	B-C0087111
of	O
severely	B-C0205082
symptomatic	B-C0231220
indolent	B-C0272203
systemic	I-C0272203
mastocytosis	I-C0272203
a	O
randomised	B-C0034656
,	O
placebo-controlled	B-C1706408
,	O
phase	B-C0282461
3	I-C0282461
study	I-C0282461
indolent	B-C0272203
systemic	I-C0272203
mastocytosis	I-C0272203
,	O
including	O
the	O
subvariant	B-C0205556
of	O
smouldering	B-C3897042
systemic	I-C3897042
mastocytosis	I-C3897042
,	O
is	O
a	O
lifelong	B-C4274169
condition	O
associated	B-C0332281
with	I-C0332281
reduced	B-C1963786
quality	I-C1963786
of	I-C1963786
life	I-C1963786
.	O
	
masitinib	B-C2351398
inhibits	B-C3463820
kit	B-C0033640
and	O
lyn	B-C1442804
kinases	I-C1442804
that	O
are	O
involved	O
in	O
indolent	B-C0272203
systemic	I-C0272203
mastocytosis	I-C0272203
pathogenesis	B-C0699748
.	O
	
we	O
aimed	O
to	O
assess	O
safety	B-C1705187
and	O
efficacy	B-C1707887
of	O
masitinib	B-C2351398
versus	O
placebo	B-C1696465
in	O
severely	B-C0436345
symptomatic	I-C0436345
patients	B-C0030705
who	O
were	O
unresponsive	B-C0205269
to	O
optimal	B-C2698651
symptomatic	B-C0231220
treatments	B-C0087111
.	O
	
in	O
this	O
randomised	B-C0034656
,	O
double-blind	B-C0013072
,	O
placebo-controlled	B-C1706408
,	O
phase	B-C0282461
3	I-C0282461
study	I-C0282461
,	O
we	O
enrolled	O
adults	B-C0001675
aged	B-C0001779
18-75	O
years	O
with	O
indolent	B-C0272203
or	O
smouldering	B-C3897042
systemic	I-C3897042
mastocytosis	I-C3897042
,	O
according	O
to	O
who	B-C0043237
classification	B-C0008902
or	O
documented	B-C0920316
mastocytosis	B-C0024899
based	O
on	O
histological	B-C0449574
criteria	I-C0449574
,	O
at	O
50	O
centres	O
in	O
15	O
countries	B-C0454664
.	O
	
we	O
excluded	O
patients	B-C0030705
with	O
cutaneous	B-C0221912
or	O
non-severe	O
systemic	B-C0221013
mastocytosis	I-C0221013
after	O
a	O
protocol	B-C1507394
amendment	I-C1507394
.	O
	
patients	B-C0030705
were	O
centrally	O
randomised	B-C0034656
1	O
to	O
receive	O
either	O
oral	B-C1527415
masitinib	B-C2351398
6	O
mg/kg	O
per	O
day	O
over	O
24	O
weeks	O
with	O
possible	O
extension	O
or	O
matched	O
placebo	B-C1696465
with	O
minimisation	O
according	O
to	O
severe	B-C0436345
symptoms	I-C0436345
.	O
	
the	O
primary	B-C2986535
endpoint	I-C2986535
was	O
cumulative	O
response	B-C0521982
75%	O
improvement	B-C2986411
from	O
baseline	B-C1442488
within	O
weeks	O
8-24	O
in	O
at	O
least	O
one	O
severe	B-C0436345
baseline	I-C0436345
symptom	I-C0436345
from	O
the	O
following	O
pruritus	B-C0033774
score	B-C0449820
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
hamilton	B-C0451203
rating	I-C0451203
scale	I-C0451203
for	I-C0451203
depression	I-C0451203
of	O
19	O
or	O
more	O
,	O
or	O
fatigue	B-C2733557
impact	I-C2733557
scale	I-C2733557
of	O
75	O
or	O
more	O
.	O
	
we	O
assessed	O
treatment	B-C0087113
effect	I-C0087113
using	O
repeated	O
measures	O
methodology	B-C0086912
for	O
rare	B-C0678236
diseases	I-C0678236
via	O
the	O
generalised	B-C0282574
estimating	I-C0282574
equation	I-C0282574
model	I-C0282574
in	O
a	O
modified	O
intention-to-treat	B-C2718028
population	B-C1257890
,	O
including	O
all	O
participants	B-C0679646
assigned	O
to	O
treatment	B-C0087111
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non-treatment-related	B-C0243095
cause	I-C0243095
.	O
	
we	O
assessed	O
safety	B-C1705187
in	O
all	O
patients	B-C0030705
who	O
received	O
at	O
least	O
one	O
dose	B-C0870450
of	O
study	B-C0013175
drug	I-C0013175
.	O
	
this	O
trial	B-C0008976
is	O
registered	O
with	O
clinicaltrials.gov	B-C0008976
,	O
number	I-C0008976
nct00814073	I-C0008976
.	O
	
between	O
feb	B-C3830166
19	O
,	O
2009	O
,	O
and	O
july	B-C3829447
15	O
,	O
2015	O
,	O
135	O
patients	B-C0030705
were	O
randomly	B-C0814868
assigned	I-C0814868
to	O
masitinib	B-C2351398
n=71	O
or	O
placebo	B-C1696465
n=64	O
.	O
	
by	O
24	O
weeks	B-C0439230
,	O
masitinib	B-C2351398
was	O
associated	B-C0332281
with	I-C0332281
a	O
cumulative	O
response	B-C0521982
of	O
18	O
in	O
the	O
primary	B-C2986535
endpoint	I-C2986535
122	O
responses	B-C0521982
of	O
656	O
possible	O
responses	B-C0521982
weighted	B-C0205556
generalised	I-C0205556
estimating	I-C0205556
equation	I-C0205556
compared	O
with	O
7	O
for	O
placebo	B-C1696465
48	O
of	O
656	O
difference	O
11	O
odds	B-C0028873
ratio	I-C0028873
3	O
95%	O
ci	O
1	O
p=0	O
.	O
	
frequent	B-C0332183
severe	B-C1519255
adverse	I-C1519255
events	I-C1519255
>4%	O
difference	O
from	O
placebo	B-C1696465
were	O
diarrhoea	B-C0011991
eight	O
11%	O
of	O
70	O
in	O
the	O
masitinib	B-C2351398
group	B-C0441833
vs	O
one	O
2%	O
of	O
63	O
in	O
the	O
placebo	B-C1696465
group	B-C0441833
,	O
rash	O
four	O
6%	O
vs	O
none	O
,	O
and	O
asthenia	B-C0004093
four	O
6%	O
vs	O
one	O
2%	O
.	O
	
the	O
most	O
frequent	B-C0332183
serious	B-C1519255
adverse	I-C1519255
events	I-C1519255
were	O
diarrhoea	B-C0011991
three	O
patients	B-C0030705
4%	O
vs	O
one	O
2%	O
and	O
urticaria	B-C0042109
two	O
3%	O
vs	O
none	O
,	O
and	O
no	O
life-threatening	B-C2826244
toxicities	B-C0600688
occurred	O
.	O
	
one	O
patient	B-C0030705
in	O
the	O
placebo	B-C1696465
group	B-C0441833
died	B-C1546956
unrelated	B-C1704623
to	O
study	B-C3161471
treatment	I-C3161471
.	O
	
these	O
study	B-C0683954
findings	I-C0683954
indicate	O
that	O
masitinib	B-C2351398
is	O
an	O
effective	B-C1704419
and	O
well	O
tolerated	B-C1254351
agent	I-C1254351
for	O
the	O
treatment	B-C0087111
of	O
severely	B-C0436345
symptomatic	I-C0436345
indolent	B-C0272203
or	O
smouldering	B-C3897042
systemic	I-C3897042
mastocytosis	I-C3897042
.	O
	
attributable	B-C0814766
risk	I-C0814766
of	O
ambient	B-C1879688
pm10	B-C1720884
on	O
daily	O
mortality	B-C0205848
and	O
years	B-C2713320
of	I-C2713320
life	I-C2713320
lost	I-C2713320
in	O
chengdu	B-C0681784
,	O
china	B-C0008115
attributable	B-C0814766
risk	I-C0814766
is	O
an	O
important	O
indicator	O
for	O
planning	B-C0018727
and	O
evaluating	B-C0557980
public	I-C0557980
health	I-C0557980
interventions	I-C0557980
.	O
	
however	O
,	O
most	O
current	O
measures	O
of	O
the	O
attributable	B-C0814766
risk	I-C0814766
of	O
air	B-C0001869
pollutants	I-C0001869
have	O
not	O
considered	O
temporal	B-C0449235
relationships	I-C0449235
between	O
exposure	B-C0332157
and	O
risk	B-C0035647
.	O
	
more	O
importantly	O
,	O
limited	O
information	O
is	O
available	O
regarding	O
the	O
attributable	B-C0814766
risk	I-C0814766
due	O
to	O
ambient	B-C1879688
air	B-C0001869
pollutants	I-C0001869
in	O
basin	B-C0681784
regions	I-C0681784
like	O
the	O
sichuan	B-C0681784
basin	I-C0681784
,	O
china	B-C0008115
.	O
	
to	O
quantify	O
the	O
association	O
between	O
pm10	B-C1720884
and	O
deaths	B-C1306577
in	O
the	O
basin	B-C0681784
region	I-C0681784
,	O
we	O
used	O
a	O
measure	O
proposed	O
recently	O
within	O
the	O
framework	O
of	O
the	O
distributed	B-C0392762
lag	I-C0392762
non-linear	I-C0392762
model	I-C0392762
to	O
estimate	O
the	O
attributable	B-C0814766
risk	I-C0814766
in	O
chengdu	B-C0681784
,	O
china	B-C0008115
.	O
	
meanwhile	O
,	O
we	O
examined	O
the	O
association	B-C0439849
between	O
pm10	B-C1720884
and	O
years	B-C2713320
of	I-C2713320
life	I-C2713320
lost	I-C2713320
yll	B-C2713320
.	O
	
our	O
analysis	B-C0936012
showed	O
that	O
population-attributable	B-C1264633
fractions	I-C1264633
for	O
non-accidental	B-C0521130
,	O
respiratory	B-C0521346
,	O
and	O
cardiovascular	B-C0205848
mortality	I-C0205848
were	O
0.569	O
95%	O
ci	O
-3	O
,	O
4.374	O
,	O
0.695	O
95%	O
ci	O
-5	O
,	O
6.457	O
,	O
and	O
0.631	O
95%	O
ci	O
-6	O
,	O
7.390	O
,	O
respectively	O
.	O
	
on	O
average	O
,	O
a	O
1μg/m	O
increase	O
in	O
pm10	B-C1720884
was	O
associated	O
with	O
cumulative	B-C0442805
increases	I-C0442805
of	O
0.26893	O
,	O
0.30437	O
,	O
and	O
0.21924	O
yll	B-C2713320
for	O
non-accidental	B-C0521130
,	O
respiratory	B-C0521346
,	O
and	O
cardiovascular	B-C0205848
mortality	I-C0205848
,	O
respectively	O
,	O
referring	O
to	O
20μg/m	O
.	O
	
in	O
addition	O
,	O
we	O
found	O
an	O
inverse	B-C0449774
u-shaped	I-C0449774
pattern	I-C0449774
for	O
the	O
cumulative	B-C0035647
risk	I-C0035647
with	O
350μg/m	O
as	O
the	O
reverse	O
point	O
.	O
	
with	O
a	O
1μg/m	O
increase	O
in	O
pm10	B-C1720884
,	O
yll	B-C2713320
changed	O
more	O
significantly	O
than	O
mortality	B-C0205848
.	O
	
moreover	O
,	O
pm10	B-C1720884
demonstrated	O
remarkable	O
effects	B-C1280500
on	O
yll	B-C2713320
among	O
men	B-C0025266
and	O
the	O
far-infrared	B-C1289903
protects	B-C1545588
vascular	B-C1257792
endothelial	I-C1257792
cells	I-C1257792
from	O
advanced	B-C0162574
glycation	I-C0162574
end	I-C0162574
products	I-C0162574
-	O
induced	B-C0205263
injury	B-C0178314
via	O
plzf	B-C1674035
-mediated	O
autophagy	B-C0004391
in	O
diabetic	B-C0085243
mice	I-C0085243
the	O
accumulation	O
of	O
advanced	B-C0162574
glycation	I-C0162574
end	I-C0162574
products	I-C0162574
ages	B-C0162574
in	O
diabetic	B-C0011847
patients	B-C0030705
induces	B-C0205263
vascular	B-C0014261
endothelial	I-C0014261
injury	B-C0178314
.	O
	
promyelocytic	B-C1674035
leukemia	I-C1674035
zinc	I-C1674035
finger	I-C1674035
protein	I-C1674035
plzf	B-C1674035
is	O
a	O
transcription	B-C0040648
factor	I-C0040648
that	O
can	O
be	O
activated	B-C2253861
by	O
low-temperature	B-C0009264
far-infrared	B-C1289903
fir	B-C1289903
irradiation	B-C1282930
to	O
exert	B-C3714634
beneficial	I-C3714634
effects	I-C3714634
on	O
the	O
vascular	B-C0014261
endothelium	I-C0014261
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
we	O
investigated	B-C1292732
the	O
influence	B-C4054723
of	O
fir	B-C1289903
-	O
induced	B-C0205263
plzf	B-C1674035
activation	B-C2253861
on	O
age	B-C0162574
-	O
induced	B-C0205263
endothelial	B-C0014261
injury	B-C0178314
both	B-C1706086
in	B-C0681828
vitro	I-C0681828
and	O
in	B-C0681829
vivo	I-C0681829
.	O
	
fir	B-C1289903
irradiation	B-C1282930
inhibited	B-C0311403
age	B-C0162574
-	O
induced	B-C0205263
apoptosis	B-C0162638
in	O
human	B-C3179121
umbilical	I-C3179121
vein	I-C3179121
endothelial	I-C3179121
cells	I-C3179121
huvecs	B-C3179121
.	O
	
plzf	B-C1674035
activation	B-C2253861
increased	B-C0205217
the	O
expression	B-C1171362
of	O
phosphatidylinositol-3	B-C2936824
kinases	I-C2936824
pi3k	B-C2936824
,	O
which	O
are	O
important	B-C3898777
kinases	B-C0031727
in	O
the	O
autophagic	B-C0004391
signaling	B-C0037080
pathway	I-C0037080
.	O
	
fir	B-C1289903
-	O
induced	B-C0205263
plzf	B-C1674035
activation	B-C2253861
led	O
to	O
autophagy	B-C0004391
in	O
huvec	B-C3179121
,	O
which	O
was	O
mediated	O
through	B-C0332273
the	O
upregulation	B-C0041904
of	O
pi3k	B-C2936824
.	O
	
immunofluorescence	B-C0016318
staining	B-C0487602
showed	O
that	O
ages	B-C0162574
were	O
engulfed	O
by	O
huvecs	B-C3179121
and	O
localized	B-C0392752
to	O
lysosomes	B-C0024369
.	O
	
fir	B-C1289903
-	O
induced	B-C0205263
autophagy	B-C0004391
promoted	B-C0033414
ages	B-C0162574
degradation	B-C0243125
in	O
huvecs	B-C3179121
.	O
	
in	O
nicotinamide	B-C0028027
/	O
streptozotocin	B-C0038432
-	O
induced	B-C0205263
diabetic	B-C0085243
mice	I-C0085243
,	O
fir	B-C1289903
therapy	B-C0087111
reduced	B-C0392756
serum	B-C0217068
ages	I-C0217068
and	O
ages	B-C0162574
deposition	B-C0333562
at	O
the	O
vascular	B-C0014261
endothelium	I-C0014261
.	O
	
fir	B-C1289903
therapy	B-C0087111
also	O
reduced	B-C0392756
diabetes	B-C0011847
-	O
induced	B-C0205263
inflammatory	B-C4087233
markers	I-C4087233
in	O
the	O
vascular	B-C0014261
endothelium	I-C0014261
and	O
improved	B-C0184511
vascular	B-C0014261
endothelial	I-C0014261
function	B-C1254358
.	O
	
these	O
protective	B-C3179279
effects	I-C3179279
of	O
fir	B-C1289903
therapy	B-C0087111
were	O
not	B-C0442737
found	I-C0442737
in	O
plzf	B-C1674035
-	O
knockout	B-C0206745
mice	I-C0206745
.	O
	
our	O
data	B-C1511726
suggest	B-C1705535
that	O
fir	B-C1289903
-	O
induced	B-C0205263
plzf	B-C1674035
activation	B-C2253861
in	O
vascular	B-C1257792
endothelial	I-C1257792
cells	I-C1257792
protects	O
the	O
vascular	B-C0014261
endothelium	I-C0014261
in	O
diabetic	B-C0085243
mice	I-C0085243
from	O
age	B-C0162574
-	O
induced	B-C0205263
injury	B-C0178314
.	O
	
ultrasonic	B-C0729619
computed	I-C0729619
tomography	I-C0729619
imaging	I-C0729619
of	O
iron	B-C3652446
oxide	I-C3652446
nanoparticles	I-C3652446
iron	B-C3652446
oxide	I-C3652446
nanoparticles	I-C3652446
ionps	B-C3652446
are	O
becoming	O
increasingly	B-C0442805
used	O
and	O
intensively	B-C1292732
investigated	I-C1292732
in	O
the	O
field	B-C1521738
of	O
medical	B-C0025086
imaging	I-C0025086
.	O
	
they	O
are	O
currently	B-C0521116
fda	B-C0041714
approved	B-C0205540
for	O
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
mri	B-C0024485
,	O
and	O
it	O
would	O
be	O
highly	B-C0205250
desirable	O
to	O
visualize	B-C0234621
them	O
by	O
ultrasound	B-C1456803
as	O
well	O
.	O
	
previous	B-C0205156
reports	B-C0684224
using	O
the	O
conventional	B-C0439858
ultrasound	B-C0203325
b-scan	I-C0203325
pulse-echo	I-C0203325
imaging	I-C0203325
technique	I-C0203325
have	O
shown	O
very	O
limited	B-C0439801
detectability	B-C3830527
of	O
these	O
particles	B-C0597177
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C0681814
is	O
to	O
explore	O
the	O
feasibility	B-C3827682
of	O
imaging	B-C0011923
ionps	B-C3652446
using	O
the	O
through-transmission	B-C3266812
ultrasound	I-C3266812
methodology	I-C3266812
and	O
demonstrate	O
their	O
detectability	O
using	O
ultrasonic	B-C0430022
computed	I-C0430022
tomography	I-C0430022
uct	B-C0430022
.	O
	
commercially	O
available	O
ionps	B-C3652446
were	O
acoustically	B-C0001166
analysed	B-C0936012
to	O
quantify	B-C1709793
their	O
effect	B-C1280500
on	O
the	O
speed	B-C0678536
of	O
sound	B-C0037709
sos	B-C0037709
and	O
acoustic	B-C0001166
attenuation	B-C0599946
as	O
a	O
function	B-C0542341
of	O
concentration	B-C1446561
.	O
	
next	O
,	O
through-transmission	B-C0430022
projection	I-C0430022
and	O
uct	B-C0729619
imaging	I-C0729619
were	O
performed	B-C0884358
on	O
a	O
breast	B-C0006141
mimicking	O
phantom	O
and	O
on	O
an	O
ex	O
vivo	O
tissue	O
model	O
,	O
to	O
which	O
ionps	O
were	O
injected	O
.	O
	
finally	O
,	O
an	O
mri	O
scan	O
was	O
performed	O
to	O
verify	O
that	O
the	O
same	O
particles	O
examined	O
in	O
the	O
ultrasound	O
experiment	O
can	O
be	O
imaged	O
by	O
magnetic	O
resonance	O
,	O
using	O
the	O
same	O
clinically	O
relevant	O
concentrations	O
.	O
	
the	O
results	O
have	O
shown	O
a	O
consistent	O
concentration	O
dependent	O
speed	O
of	O
sound	O
increase	O
1.86	O
formula	O
see	O
text	O
rise	O
per	O
100	O
µg	O
ml	O
ionps	O
.	O
	
imaging	O
based	O
on	O
this	O
property	O
has	O
shown	O
a	O
substantial	O
contrast-to-noise	O
ratio	O
improvement	O
up	O
to	O
5	O
fold	O
,	O
p	O
<	O
0.01	O
.	O
	
the	O
sos	O
-related	O
effect	O
generated	O
a	O
well	O
discernible	O
image	O
contrast	O
and	O
allowed	O
the	O
detection	O
of	O
the	O
particles	O
existence	O
and	O
location	O
,	O
in	O
both	O
raster-scan	O
projection	O
and	O
uct	O
imaging	O
.	O
	
conversely	O
,	O
no	O
significant	O
change	O
in	O
the	O
acoustic	O
attenuation	O
coefficient	O
was	O
noted	O
.	O
	
based	O
on	O
these	O
findings	O
,	O
it	O
is	O
concluded	O
that	O
ionps	O
can	O
be	O
used	O
as	O
an	O
effective	O
sos	O
-	O
based	O
contrast	O
agent	O
,	O
potentially	O
useful	O
for	O
ultrasonic	O
breast	B-C0597204
imaging	O
.	O
	
furthermore	O
,	O
the	O
particle	O
offers	O
the	O
capacity	O
of	O
significantly	O
enhancing	O
diagnosis	O
accuracy	O
using	O
multimodal	O
mri	O
-	O
ultrasound	O
imaging	O
capabilities	B-C2698977
genetically	B-C0314603
encoded	B-C2700640
calcium	B-C0596234
indicators	I-C0596234
for	O
studying	O
long-term	B-C0443252
calcium	B-C0006675
dynamics	B-C0596957
during	O
apoptosis	B-C0162638
intracellular	B-C1820193
calcium	I-C1820193
release	I-C1820193
is	O
essential	B-C0205224
for	O
regulating	B-C0596286
almost	O
all	O
cellular	B-C0007613
functions	I-C0007613
.	O
	
specific	B-C0205369
spatio-temporal	B-C3494293
patterns	B-C0449774
of	O
cytosolic	B-C1383501
calcium	B-C0006675
elevations	B-C3163633
are	O
critical	B-C1511545
determinants	B-C1521761
of	O
cell	B-C1540661
fate	I-C1540661
in	O
response	O
to	O
pro-apoptotic	B-C1516044
cellular	B-C0007634
stressors	B-C0597530
.	O
	
as	O
the	O
apoptotic	B-C1159821
program	I-C1159821
can	O
take	O
hours	B-C0439227
or	O
days	B-C0439228
,	O
measurement	B-C0242485
of	O
long-term	B-C0443252
calcium	B-C0006675
dynamics	B-C0596957
are	O
essential	B-C0205224
for	O
understanding	B-C0162340
the	O
mechanistic	B-C0441712
role	B-C1705810
of	O
calcium	B-C0006675
in	O
apoptotic	B-C0162638
cell	I-C0162638
death	I-C0162638
.	O
	
due	O
to	O
the	O
technical	B-C0449851
limitations	B-C0449295
of	O
using	O
calcium	B-C0006675
-	O
sensitive	B-C0332324
dyes	B-C0013343
to	O
measure	B-C0079809
cytosolic	B-C1383501
calcium	B-C0006675
little	O
is	O
known	O
about	O
long-term	B-C0443252
calcium	B-C0006675
dynamics	B-C0596957
in	O
living	B-C0007634
cells	I-C0007634
after	O
treatment	B-C0087111
with	O
apoptosis	B-C0162638
-	O
inducing	B-C0205263
drugs	B-C0013227
.	O
	
genetically	B-C0314603
encoded	B-C2700640
calcium	B-C0596234
indicators	I-C0596234
could	O
potentially	O
overcome	B-C2983310
some	O
of	O
the	O
limitations	B-C0449295
of	O
calcium	B-C0006675
-	O
sensitive	B-C0332324
dyes	B-C0013343
.	O
	
here	O
,	O
we	O
compared	O
the	O
performance	B-C1882330
of	O
the	O
genetically	B-C0314603
encoded	B-C2700640
calcium	B-C0006675
indicators	B-C0021212
gcamp6s	B-C0596234
and	O
gcamp6f	B-C0596234
with	O
the	O
ratiometric	B-C0016320
dye	I-C0016320
fura-2	B-C0079389
.	O
	
gcamp6s	B-C0596234
performed	O
as	O
well	O
or	O
better	O
than	O
fura-2	B-C0079389
in	O
detecting	O
agonist	B-C2987634
-	O
induced	B-C0205263
calcium	B-C0006675
transients	B-C0205374
.	O
	
we	O
then	O
examined	O
the	O
utility	B-C0457083
of	O
gcamp6s	B-C0596234
for	O
continuously	B-C0549178
measuring	B-C0444706
apoptotic	B-C1516044
calcium	B-C0201925
release	I-C0201925
over	O
the	O
course	B-C0750729
of	O
ten	O
hours	B-C0439227
after	O
treatment	B-C0087111
with	O
staurosporine	B-C0075193
.	O
	
we	O
found	O
that	O
gcamp6s	B-C0596234
was	O
suitable	O
for	O
measuring	B-C0444706
apoptotic	B-C1516044
calcium	B-C0201925
release	I-C0201925
over	O
long	O
time	O
courses	B-C0750729
and	O
revealed	O
significant	B-C0750502
heterogeneity	B-C0019409
in	O
calcium	B-C0201925
release	I-C0201925
dynamics	B-C0596957
in	O
individual	O
cells	B-C0007634
challenged	O
with	O
staurosporine	B-C0075193
.	O
	
our	O
results	O
suggest	O
gcamp6s	B-C0596234
is	O
an	O
excellent	B-C1961136
indicator	B-C0021212
for	O
monitoring	B-C1283169
long-term	B-C0443252
changes	B-C0392747
cytosolic	B-C1383501
calcium	B-C0006675
during	O
staphylococcus	B-C1680786
pseudintermedius	I-C1680786
human	B-C0086418
infection	B-C3714514
cases	B-C0868928
in	O
spain	B-C0037747
dog	B-C0012984
-to-	O
human	B-C0086418
transmission	B-C0242781
staphylococcus	B-C1680786
pseudintermedius	I-C1680786
is	O
an	O
opportunistic	B-C0450254
pathogen	I-C0450254
that	O
has	O
been	O
identified	B-C0205396
as	O
infectious	B-C0314732
agent	I-C0314732
or	O
colonizer	B-C2747813
mainly	O
in	O
dogs	B-C0012984
.	O
	
s	B-C1680786
.	O
	
pseudintermedius	I-C1680786
has	O
been	O
also	O
detected	B-C0442726
in	O
humans	B-C0086418
and	O
more	O
specifically	O
in	O
people	B-C0027361
in	O
contact	B-C0332158
with	I-C0332158
dogs	B-C0012984
.	O
	
in	O
this	O
study	B-C0681814
,	O
the	O
possible	B-C0332149
s	B-C1680786
.	O
	
pseudintermedius	I-C1680786
pet	B-C0031268
-to-	O
human	B-C0086418
transmission	B-C0242781
was	O
analyzed	B-C0936012
in	O
four	O
clinical	B-C0205210
human	B-C0086418
cases	B-C0868928
.	O
	
two	O
patients	B-C0030705
were	O
dog	B-C0012984
owners	B-C1704784
and	O
s	B-C1680786
.	O
	
pseudintermedius	I-C1680786
was	O
also	O
detected	B-C0442726
as	O
colonizer	B-C2747813
in	O
these	O
healthy	B-C3898900
animals	B-C0003062
.	O
	
s	B-C1680786
.	O
	
pseudintermedius	I-C1680786
isolates	B-C1764827
from	O
patients	B-C0030705
and	O
dogs	B-C0012984
of	O
the	O
same	O
household	B-C0020052
showed	O
identical	B-C0205280
pulsed-field	B-C0085117
gel	I-C0085117
electrophoresis	I-C0085117
patterns	B-C0449774
,	O
sequence	B-C2359784
types	I-C2359784
sts	B-C2359784
,	O
and	O
antimicrobial	B-C1456627
resistance	I-C1456627
phenotypes	B-C0678920
and	I-C0678920
genotypes	I-C0678920
,	O
and	O
were	O
methicillin	B-C0079830
susceptible	I-C0079830
.	O
	
resistance	B-C4281815
to	O
erythromycin	B-C0014806
,	O
clindamycin	B-C0008947
,	O
tetracycline	B-C0039644
,	O
trimetoprim-sulfamethoxazole	B-C0041044
,	O
and/or	O
ciprofloxacin	B-C0008809
was	O
identified	B-C0205396
among	O
s	B-C1680786
.	O
	
pseudintermedius	I-C1680786
strains	B-C1518614
.	O
	
the	O
lineages	B-C1881379
st241	B-C2359784
and	O
the	O
new	O
st521	B-C2359784
were	O
detected	B-C0442726
in	O
the	O
strains	B-C1518614
of	O
the	O
two	O
dog	B-C0012984
-	O
owner	B-C1704784
patients	B-C0030705
,	O
respectively	O
.	O
	
the	O
strains	B-C1518614
from	O
the	O
other	B-C0205394
two	O
patients	B-C0030705
presented	B-C0449450
two	O
new	O
sts	B-C2359784
,	O
st719	B-C2359784
and	O
st720	B-C2359784
.	O
	
to	O
our	O
knowledge	B-C0376554
,	O
this	O
is	O
the	O
first	O
description	B-C0678257
of	O
human	B-C0086418
infections	B-C3714514
caused	O
by	O
s	B-C1680786
.	O
	
pseudintermedius	I-C1680786
in	O
tango	B-C0282574
-	O
a	O
screening	B-C0220908
tool	I-C0220908
to	O
identify	O
comorbidities	B-C0009488
on	O
the	O
causal	B-C0282654
pathway	I-C0282654
of	O
nocturia	B-C0028734
to	O
develop	O
a	O
robust	B-C1710032
screening	I-C1710032
metric	I-C1710032
for	O
use	O
in	O
identifying	O
non-lower	O
urinary	B-C0042027
tract	I-C0042027
comorbidities	B-C0009488
pertinent	O
to	O
the	O
multidisciplinary	B-C0729737
assessment	I-C0729737
of	O
patients	B-C0030705
with	O
nocturia	B-C0028734
.	O
	
variables	B-C0439828
having	O
a	O
significant	O
risk	O
association	B-C0332281
with	I-C0332281
nocturia	B-C0028734
of	O
greater	O
than	O
once	O
per	O
night	B-C0240526
were	O
identified	O
.	O
	
discriminating	B-C0205235
items	O
from	O
validated	O
and	O
reliable	O
tools	B-C0220908
measuring	O
these	O
comorbidities	B-C0009488
were	O
identified	O
.	O
	
a	O
self-completed	O
57-item	O
questionnaire	B-C0034394
was	O
developed	O
and	O
a	O
medical	B-C0205476
checklist	B-C1707357
and	O
pertinent	O
clinical	B-C3266594
measures	I-C3266594
added	O
.	O
	
pre-determined	O
criteria	O
were	O
applied	O
to	O
retain	O
or	O
remove	O
items	O
in	O
the	O
development	O
of	O
the	O
short-form	B-C2964478
sf	B-C2964478
screening	B-C0220908
tool	I-C0220908
.	O
	
the	O
tool	B-C0220908
was	O
administered	O
to	O
252	O
individuals	B-C0237401
with	O
nocturia	B-C0028734
who	O
were	O
attending	O
either	O
a	O
tertiary	O
level	O
sleep	B-C0037313
,	O
continence	B-C0442964
,	O
falls	B-C0085639
or	O
rehabilitation	B-C0587660
service	I-C0587660
for	O
routine	B-C0262500
care	I-C0262500
.	O
	
data	B-C4019276
collected	I-C4019276
were	O
subjected	O
to	O
descriptive	B-C0678257
analysis	I-C0678257
criteria	O
were	O
applied	O
to	O
reduce	O
the	O
number	O
of	O
items	O
.	O
	
using	O
pre-determined	O
domains	O
,	O
a	O
nocturia	B-C0028734
screening	B-C1710032
metric	I-C1710032
,	O
entitled	O
tango	B-C0282574
,	O
was	O
generated	O
.	O
	
the	O
acronym	O
tango	B-C0282574
stands	O
for	O
targeting	B-C1521840
the	O
individual's	B-C0015127
aetiology	I-C0015127
of	O
nocturia	B-C0028734
to	O
guide	O
outcomes	O
.	O
	
the	O
demographic	B-C0683970
characteristics	I-C0683970
of	O
the	O
sample	O
are	O
described	O
,	O
along	O
with	O
item	O
endorsement	O
levels	O
.	O
	
the	O
statistical	B-C0871424
and	O
structural	B-C0026349
framework	I-C0026349
to	O
justify	O
deleting	O
or	O
retaining	O
of	O
items	O
from	O
the	O
tango	B-C0282574
long-form	O
to	O
the	O
sf	B-C2964478
is	O
presented	O
.	O
	
the	O
resultant	O
tango	B-C0282574
-	O
sf	B-C2964478
patient	B-C0030705
-completed	O
nocturia	B-C0028734
screening	B-C0220908
tool	I-C0220908
is	O
reported	O
.	O
	
a	O
novel	O
all-cause	O
diagnostic	B-C0348026
metric	O
for	O
identifying	O
co-existing	O
morbidities	B-C0026538
of	O
clinical	B-C0683325
relevance	I-C0683325
to	O
nocturia	B-C0028734
in	O
patients	B-C0030705
who	O
present	O
across	O
disciplines	B-C0237070
and	O
medical	B-C0037778
specialties	I-C0037778
has	O
been	O
developed	O
.	O
	
tango	B-C0282574
has	O
the	O
potential	O
to	O
improve	O
practice	O
and	O
smooth	B-C0242503
inequalities	I-C0242503
associated	B-C0332281
with	I-C0332281
a	O
siloed	O
approach	O
to	O
assessment	B-C0220825
and	O
subsequent	O
care	B-C1947933
of	O
patients	B-C0030705
with	O
probabilistic	B-C0033204
acute	B-C0205178
risk	B-C0086930
assessment	I-C0086930
of	O
cumulative	B-C2986588
exposure	I-C2986588
to	O
organophosphorus	B-C0360429
and	O
carbamate	B-C0360422
pesticides	I-C0360422
from	O
dietary	B-C0042440
vegetables	I-C0042440
and	O
fruits	B-C0016767
in	O
shanghai	B-C0681784
populations	B-C1257890
organophosphorus	B-C0360429
pesticides	I-C0360429
ops	B-C0360429
and	O
carbamate	B-C0360422
pesticides	I-C0360422
cps	B-C0360422
are	O
among	O
the	O
most	O
widely	O
used	O
pesticides	B-C0031253
in	O
china	B-C0008115
,	O
playing	O
a	O
major	O
role	O
in	O
protecting	B-C1545588
agricultural	B-C0242775
commodities	I-C0242775
.	O
	
in	O
this	O
study	O
,	O
we	O
determined	B-C0521095
the	O
cumulative	B-C2986588
acute	I-C2986588
exposure	I-C2986588
to	O
ops	B-C0360429
and	O
cps	B-C0360422
of	O
shanghai	B-C0681784
residents	B-C2347958
from	O
vegetables	B-C0042440
and	O
fruits	B-C0016767
vfs	B-C0016452
.	O
	
the	O
food	B-C2983605
consumption	I-C2983605
data	B-C1511726
were	O
obtained	B-C1301820
from	O
the	O
shanghai	B-C0038951
food	I-C0038951
consumption	I-C0038951
survey	I-C0038951
shfcs	B-C0038951
of	O
2012-14	O
including	O
a	O
total	O
of	O
1973	O
participants	B-C0679646
aged	B-C0001779
2-90	O
years	B-C0439234
.	O
	
the	O
pesticide	B-C0031251
residue	I-C0031251
data	B-C1511726
were	O
obtained	B-C1301820
from	O
the	O
shanghai	B-C0681784
monitoring	B-C1283169
programme	B-C3484370
during	O
2008-11	O
with	O
34	O
organophosphates	B-C0360429
and	O
11	O
carbamates	B-C0360422
analysed	O
in	O
a	O
total	O
of	O
5335	O
samples	B-C0444315
of	O
vfs	B-C0016452
.	O
	
a	O
probabilistic	B-C0033204
approach	O
was	O
performed	B-C0884358
as	O
recommended	B-C0034866
by	O
the	O
efsa	B-C0282574
,	O
using	O
the	O
optimistic	B-C3161035
model	I-C3161035
with	O
non-detects	O
set	O
as	O
zero	B-C0919414
and	O
with	O
processing	B-C0016487
factors	B-C1521761
pfs	B-C1521761
being	O
used	O
and	O
the	O
pessimistic	B-C3161035
model	I-C3161035
with	O
non-detects	O
replaced	B-C1299987
by	I-C1299987
limit	B-C2718050
of	I-C2718050
detection	I-C2718050
lod	B-C2718050
and	O
without	B-C0332288
pfs	B-C1521761
.	O
	
we	O
used	O
the	O
relative	B-C0025663
potency	I-C0025663
factor	I-C0025663
rpf	I-C0025663
method	I-C0025663
to	O
normalise	O
the	O
various	O
pesticides	B-C0031253
to	O
the	O
index	B-C1706082
compound	I-C1706082
ic	B-C1706082
of	O
methamidophos	B-C0066080
and	O
chlorpyrifos	B-C0013328
separately	B-C0443299
.	O
	
only	O
in	O
the	O
pessimistic	B-C3161035
model	I-C3161035
using	O
methamidophos	B-C0066080
as	O
the	O
ic	B-C1706082
was	O
there	O
was	O
small	O
risk	B-C0035647
of	O
exposure	B-C0332157
exceeding	O
the	O
arfd	B-C0454255
3	O
µg	O
kg	O
bw	O
day	B-C0439228
-	O
in	O
the	O
populations	B-C1257890
of	O
preschool	B-C0008100
children	I-C0008100
0.029	O
,	O
school-age	B-C2827631
children	I-C2827631
0.022	O
and	O
adults	B-C0001675
0.002	O
.	O
	
there	O
were	O
no	B-C4036089
risk	I-C4036089
of	O
exposure	B-C0332157
exceeding	O
the	O
arfd	B-C0454255
of	O
methamidophos	B-C0066080
in	O
the	O
optimistic	B-C3161035
model	I-C3161035
and	O
of	O
chlorpyrifos	B-C0013328
100	O
µg	O
kg	O
bw	O
day	B-C0439228
-	O
in	O
both	O
optimistic	B-C0564470
and	O
pessimistic	B-C3161035
models	I-C3161035
in	O
all	O
three	O
populations	B-C1257890
.	O
	
considering	O
the	O
chinese	B-C2242848
habits	I-C2242848
of	O
overwhelmingly	O
eating	B-C0013470
processed	B-C0344355
food	I-C0344355
vegetables	B-C0042440
being	O
cooked	B-C0335326
,	O
and	O
fruits	B-C0016767
being	O
washed	B-C1548982
or	O
peeled	B-C0441602
,	O
we	O
conclude	O
that	O
little	O
acute	B-C0205178
risk	B-C0035647
was	O
found	O
for	O
the	O
exposure	B-C0332157
to	I-C0332157
vf	B-C0016452
-	O
sourced	B-C0449416
ops	B-C0360429
and	O
cps	B-C0360422
in	O
modem	B-C0700032
a	O
comprehensive	B-C1880156
approach	B-C0449445
to	O
modelling	B-C0870071
outcome	B-C0085415
and	O
costs	B-C0010186
impacts	B-C4049986
of	O
interventions	B-C0184661
for	O
dementia	B-C0497327
.	O
	
protocol	B-C0442711
paper	B-C0030351
the	O
modem	B-C0700032
project	I-C0700032
a	O
comprehensive	B-C1880156
approach	B-C0449445
to	O
modelling	B-C0870071
outcome	B-C0085415
and	O
costs	B-C0010186
impacts	B-C4049986
of	O
interventions	B-C0184661
for	O
dementia	B-C0497327
explores	O
how	O
changes	B-C0392747
in	O
arrangements	O
for	O
the	O
future	B-C0016884
treatment	B-C0087111
and	O
care	B-C1947933
of	O
people	B-C0027361
living	O
with	O
dementia	B-C0497327
,	O
and	O
support	B-C0344211
for	O
family	B-C0015576
and	O
other	O
unpaid	B-C0557361
carers	B-C1305660
,	O
could	O
result	B-C1274040
in	O
better	O
outcomes	B-C0085415
and	O
more	O
efficient	B-C0442799
use	B-C1524063
of	I-C1524063
resources	B-C0035201
.	O
	
modem	B-C0700032
starts	O
with	O
a	O
systematic	B-C0220922
mapping	B-C1283195
of	O
the	O
literature	B-C0023866
on	O
effective	B-C1704419
and	O
potentially	O
cost	B-C0010186
-	O
effective	B-C1704419
interventions	B-C0184661
in	O
dementia	B-C0497327
care	B-C1947933
.	O
	
those	O
findings	B-C2607943
,	O
as	O
well	O
as	O
data	B-C1511726
from	O
a	O
cohort	B-C0599755
,	O
will	O
then	O
be	O
used	O
to	O
model	B-C3161035
the	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
and	O
cost	B-C0010186
impacts	B-C4049986
of	O
making	O
these	O
evidence	B-C3887511
-based	O
interventions	B-C0184661
more	O
widely	O
available	B-C0470187
in	O
england	B-C0014282
over	O
the	O
period	B-C1948053
from	O
now	O
to	O
2040	O
.	O
	
modelling	B-C0870071
will	O
use	O
a	O
suite	O
of	O
models	B-C3161035
,	O
combining	B-C0205195
microsimulation	B-C0869023
and	O
macrosimulation	B-C0869023
methods	I-C0869023
,	O
modelling	B-C0870071
the	O
costs	B-C0010186
and	O
outcomes	B-C0085415
of	O
care	B-C1947933
,	O
both	O
for	O
an	O
individual	B-C0027361
over	O
the	O
life-course	B-C1510618
from	O
the	O
point	O
of	O
dementia	B-C0497327
diagnosis	I-C0497327
,	O
and	O
for	O
individuals	B-C0027361
and	O
england	B-C0014282
as	O
a	O
whole	B-C0444667
in	O
a	O
particular	O
year	O
.	O
	
project	B-C0700032
outputs	O
will	O
include	O
an	O
online	B-C0683828
dementia	B-C0282574
evidence	I-C0282574
toolkit	I-C0282574
,	O
making	O
evidence	B-C3887511
summaries	B-C1706244
and	O
a	O
literature	B-C0023866
database	B-C0242356
available	B-C0470187
free	O
to	O
anyone	O
,	O
papers	B-C0030351
in	O
academic	B-C0162443
journals	I-C0162443
and	O
other	O
written	O
outputs	O
,	O
and	O
a	O
modem	B-C3161035
legacy	I-C3161035
model	I-C3161035
,	O
which	O
will	O
enable	O
local	B-C0679924
commissioners	I-C0679924
of	O
services	B-C0557854
to	O
apply	O
the	O
model	B-C3161035
to	O
their	O
own	O
populations	B-C1257890
.	O
	
modelling	B-C0870071
the	O
effects	B-C1704420
of	I-C1704420
evidence	B-C3887511
-based	O
cost	B-C0010186
-	O
effective	B-C1704419
interventions	B-C0184661
and	O
making	O
this	O
information	B-C1533716
widely	O
available	B-C0470187
has	O
the	O
potential	B-C3245505
to	O
improve	B-C0184511
the	O
health	B-C0018684
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
both	O
of	O
people	B-C0027361
with	O
dementia	B-C0497327
and	O
their	O
carers	B-C1305660
,	O
while	O
ensuring	O
that	O
resources	B-C0035201
assessment	B-C0936012
of	O
neuroanatomical	B-C0220784
and	O
behavioural	B-C0815123
effects	I-C0815123
of	O
in	B-C2827729
ovo	I-C2827729
methylmercury	B-C0025794
exposure	B-C0332157
in	O
zebra	B-C0326833
finches	I-C0326833
taeniopygia	B-C0326833
guttata	I-C0326833
methylmercury	B-C0025794
mehg	B-C0025794
readily	O
crosses	B-C2828360
the	O
blood	B-C0005854
brain	I-C0005854
barrier	I-C0005854
and	O
is	O
a	O
known	B-C0205309
neuro	B-C0205494
-	O
toxicant	B-C0599787
.	O
	
mehg	B-C0025794
accumulation	B-C4055506
in	O
the	O
brain	B-C0006104
causes	B-C0015127
histopathological	B-C0243140
alterations	B-C0392747
,	O
neurobehavioral	B-C2986478
changes	B-C0392747
,	O
and	O
impairments	B-C0221099
to	O
cognitive	B-C1516691
motor	B-C0234130
functions	I-C0234130
in	O
mammalian	B-C0024660
models	B-C0012644
.	O
	
however	O
,	O
in	O
birds	B-C0005595
the	O
neurotoxic	B-C0235032
effects	I-C0235032
of	O
mehg	B-C0025794
on	O
the	O
developing	O
pre	B-C0332152
-	O
hatching	B-C0598016
brain	B-C0006104
and	O
consequent	B-C3845876
behavioral	B-C0542299
alterations	I-C0542299
in	O
adult	B-C0001675
birds	B-C0005595
have	O
not	B-C1518422
received	B-C1514756
much	O
attention	B-C0004268
.	O
	
moreover	O
,	O
passerine	B-C0600537
birds	I-C0600537
are	O
poorly	B-C0205169
represented	B-C1882932
in	O
mehg	B-C0025794
neurotoxicology	B-C0597059
studies	B-C2603343
in	O
comparison	B-C1707455
to	O
other	O
avian	B-C0005595
orders	B-C3858829
.	O
	
hence	O
in	O
this	O
study	B-C2603343
,	O
we	O
used	B-C1524063
the	O
egg	B-C0013710
injection	B-C0456651
method	I-C0456651
to	O
investigate	B-C1292732
the	O
long	B-C0023983
term	I-C0023983
effects	I-C0023983
of	O
in	B-C2827729
ovo	I-C2827729
mehg	B-C0025794
exposure	B-C0332157
on	O
brain	B-C0006104
histopathology	B-C0243140
and	O
courtship	B-C0237550
behavior	I-C0237550
in	O
a	O
model	B-C0012644
songbird	B-C0600538
species	B-C1705920
,	O
the	O
zebra	B-C0326833
finch	I-C0326833
taeniopygia	B-C0326833
guttata	I-C0326833
.	O
	
egg	B-C0013710
treatment	B-C1522326
groups	B-C0681860
included	B-C0332257
a	O
low	B-C0205251
mehg	B-C0025794
dose	B-C0178602
of	O
0.2μg	O
hg	B-C0025424
g	O
egg	B-C0013710
,	O
a	O
high	B-C0205250
mehg	B-C0025794
dose	B-C0178602
of	O
3.2μg	O
hg	B-C0025424
g	O
egg	B-C0013710
,	O
and	O
a	O
vehicle	B-C0042444
control	I-C0042444
water	B-C0043047
.	O
	
no	B-C0853204
adverse	I-C0853204
effects	I-C0853204
of	O
in	B-C2827729
ovo	I-C2827729
mehg	B-C0025794
treatment	B-C1522326
were	O
detected	B-C0442726
on	O
courtship	B-C0237548
song	O
quality	O
or	O
on	O
mating	O
behavior	O
in	O
experimental	O
males	O
at	O
sexually	O
maturity	O
which	O
would	O
suggest	O
that	O
observable	O
neurobehavioral	O
effects	O
of	O
mehg	O
exposure	O
may	O
depend	O
on	O
the	O
timing	O
of	O
exposure	O
during	O
offspring	O
development	O
.	O
	
however	O
,	O
neuroanatomical	O
analysis	O
indicated	O
an	O
increase	O
in	O
telencephalon	O
volume	O
with	O
increased	O
mehg	O
concentrations	O
which	O
may	O
suggest	O
a	O
prolonged	O
inflammatory	O
response	O
in	O
this	O
region	O
of	O
the	O
brain	I-C1273723
evaluation	B-C0220825
of	O
the	O
condom	B-C0349674
barriers	I-C0349674
scale	I-C0349674
for	O
young	B-C0238598
black	B-C2827413
men	I-C2827413
who	I-C2827413
have	I-C2827413
sex	I-C2827413
with	I-C2827413
men	I-C2827413
reliability	B-C0035036
and	I-C0035036
validity	I-C0035036
of	O
3	O
subscales	B-C0349674
reliable	B-C0035037
and	O
valid	B-C2349099
scale	B-C0349674
measures	B-C0086749
of	O
barriers	B-C0004764
to	O
condom	B-C0679782
use	I-C0679782
are	O
not	O
available	O
for	O
young	B-C0238598
black	B-C2827413
men	I-C2827413
who	I-C2827413
have	I-C2827413
sex	I-C2827413
with	I-C2827413
men	I-C2827413
ybmsm	B-C2827413
.	O
	
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
condom	B-C0349674
barriers	I-C0349674
scales	I-C0349674
for	O
application	O
with	O
ybmsm	B-C2827413
.	O
	
a	O
clinic-based	B-C0205210
sample	B-C2347026
of	O
600	O
ybmsm	B-C2827413
completed	O
a	O
computer-assisted	B-C2362103
self-interview	B-C0021822
.	O
	
the	O
primary	O
measure	B-C0086749
was	O
a	O
14-item	O
abbreviated	B-C0282574
version	I-C0282574
of	O
the	O
condom	B-C0349674
barriers	I-C0349674
scale	I-C0349674
.	O
	
reliability	B-C0035037
and	O
criterion	B-C2699472
validity	I-C2699472
were	O
assessed	O
.	O
	
all	O
3	O
subscales	B-C0349674
were	O
reliable	B-C0035037
partner	B-C0036911
-related	O
barriers	B-C0004764
cronbach	B-C0392762
α	I-C0392762
=0	O
,	O
sensation	B-C0036658
-related	O
barriers	B-C0004764
α=0	O
,	O
and	O
motivation	B-C0026605
-related	O
barriers	B-C0004764
α	O
=0	O
.	O
	
a	O
complete	B-C0517435
absence	I-C0517435
of	I-C0517435
barriers	I-C0517435
was	O
common	O
47.0	O
partner	B-C0036911
-related	O
,	O
30.7	O
sensation	B-C0036658
-related	O
,	O
and	O
46.5	O
motivation	B-C0026605
-related	O
.	O
	
dichotomized	O
subscales	B-C0349674
were	O
significantly	B-C0237881
associated	B-C0332281
with	I-C0332281
reporting	O
any	O
condomless	B-C0420844
insertive	B-C0233979
anal	B-C0282347
sex	I-C0282347
all	O
ps	B-C0392762
<	O
0.001	O
and	O
any	O
condomless	B-C0420844
receptive	B-C0544683
anal	B-C0282347
sex	I-C0282347
all	O
ps	B-C0392762
<	O
0.001	O
.	O
	
the	O
subscales	B-C0349674
were	O
significantly	B-C0237881
associated	B-C0332281
with	I-C0332281
these	O
measures	B-C0086749
of	O
condomless	B-C0420844
sex	B-C0009253
preserved	O
at	O
a	O
continuous	B-C0549178
level	B-C0441889
all	O
ps	B-C0392762
<0	O
,	O
except	O
for	O
sensation	B-C0036658
barriers	B-C0004764
associated	B-C0332281
with	I-C0332281
condomless	B-C0420844
receptive	O
anal	B-C0282347
sex	I-C0282347
=	O
0.03	O
.	O
	
further	O
,	O
the	O
subscales	B-C0349674
were	O
significantly	B-C0237881
associated	B-C0332281
with	I-C0332281
reporting	O
any	O
condom	B-C0679782
use	I-C0679782
problems	B-C1546466
all	O
ps	B-C0392762
<0	O
and	O
a	O
measure	B-C0086749
of	O
condomless	B-C0420844
oral	B-C0282348
sex	I-C0282348
all	O
ps	B-C0392762
<0	O
,	O
except	O
for	O
partner	B-C0036911
-related	O
barriers	B-C0004764
=0	O
.	O
	
finally	O
,	O
the	O
sensation	B-C0036658
-related	O
barriers	B-C0004764
subscale	B-C0349674
was	O
significantly	B-C0237881
associated	B-C0332281
with	I-C0332281
testing	O
positive	B-C1514241
for	O
chlamydia	B-C0008148
and/or	O
gonorrhea	B-C0018081
p=0	O
.	O
	
the	O
3	O
identified	O
subscales	B-C0349674
yielded	O
adequate	O
reliability	B-C0035037
and	O
strong	O
evidence	O
of	O
validity	B-C0042284
,	O
thereby	O
suggesting	O
the	O
utility	O
of	O
these	O
brief	O
measures	B-C0086749
for	O
use	O
in	O
observational	B-C1518527
and	O
experimental	B-C0681814
research	I-C0681814
with	O
variation	B-C0042333
in	O
the	O
intensity	B-C0522510
of	O
selection	B-C0036576
on	O
codon	B-C0009221
bias	B-C0242568
over	O
time	B-C0040223
causes	O
contrasting	B-C0449774
patterns	I-C0449774
of	O
base	B-C0004790
composition	I-C0004790
evolution	B-C0015219
in	O
drosophila	B-C0013138
four-fold	O
degenerate	B-C1880269
coding	B-C0079941
sites	I-C0079941
form	O
a	O
major	O
component	O
of	O
the	O
genome	B-C0017428
,	O
and	O
are	O
often	O
used	O
to	O
make	O
inferences	O
about	O
selection	B-C0036576
and	O
demography	B-C0011292
,	O
so	O
that	O
understanding	O
their	O
evolution	B-C0015219
is	O
important	O
.	O
	
despite	O
previous	O
efforts	O
,	O
many	O
questions	O
regarding	O
the	O
causes	O
of	O
base	B-C0004790
composition	I-C0004790
changes	B-C0392747
at	O
these	O
sites	B-C0079941
in	O
drosophila	B-C0013138
remain	O
unanswered	O
.	O
	
to	O
shed	O
further	O
light	O
on	O
this	O
issue	B-C0033213
,	O
we	O
obtained	O
a	O
new	O
whole-genome	B-C3242346
polymorphism	I-C3242346
data	I-C3242346
set	I-C3242346
from	O
d	B-C0998507
.	O
	
simulans	I-C0998507
.	O
	
we	O
analyzed	B-C0936012
samples	B-C0444241
from	O
the	O
putatively	O
ancestral	O
range	O
of	O
d	B-C0998507
.	O
	
simulans	I-C0998507
,	O
as	O
well	O
as	O
an	O
existing	O
polymorphism	B-C3242346
data	I-C3242346
set	I-C3242346
from	O
an	O
african	O
population	O
of	O
d	B-C0013139
.	O
	
melanogaster	I-C0013139
.	O
	
by	O
using	O
d	B-C0998511
.	O
	
yakuba	I-C0998511
as	O
an	O
outgroup	B-C0871022
,	O
we	O
found	O
clear	O
evidence	B-C3887511
for	O
selection	B-C0036576
on	O
4-fold	O
sites	B-C0079941
along	O
both	O
lineages	B-C0282637
over	O
a	O
substantial	B-C1948053
period	I-C1948053
,	O
with	O
the	O
intensity	B-C0522510
of	O
selection	B-C0036576
increasing	O
with	O
gc	B-C1135899
content	I-C1135899
.	O
	
based	O
on	O
an	O
explicit	O
model	B-C0026339
of	O
base	B-C0004790
composition	I-C0004790
evolution	B-C0015219
,	O
we	O
suggest	O
that	O
the	O
observed	B-C1441672
at-	O
biased	B-C0242568
substitution	B-C0449774
pattern	I-C0449774
in	O
both	O
lineages	B-C0282637
is	O
probably	O
due	O
to	O
an	O
ancestral	B-C0392756
reduction	I-C0392756
in	O
selection	B-C0036576
intensity	B-C0522510
,	O
and	O
is	O
unlikely	O
to	O
be	O
the	O
result	B-C0456984
of	O
an	O
increase	B-C0442805
in	O
mutational	B-C0026882
bias	B-C0242568
towards	O
at	O
alone	O
.	O
	
by	O
using	O
two	O
polymorphism-based	B-C0796451
methods	I-C0796451
for	O
estimating	B-C0750572
selection	B-C0036576
coefficients	B-C1707429
over	O
different	O
timescales	O
,	O
we	O
show	O
that	O
the	O
selection	B-C0036576
intensity	B-C0522510
on	O
codon	B-C0009221
usage	O
has	O
been	O
rather	O
stable	B-C0205360
in	O
d	B-C0998507
.	O
	
simulans	I-C0998507
in	O
the	O
recent	O
past	O
,	O
but	O
the	O
long-term	B-C0443252
estimates	B-C0750572
in	O
d	B-C0013139
.	O
	
melanogaster	I-C0013139
are	O
much	O
higher	B-C0205250
than	O
the	O
short-term	B-C0443303
ones	O
,	O
indicating	O
a	O
continuing	B-C0549178
decline	B-C0282251
in	O
selection	B-C0036576
intensity	B-C0522510
,	O
to	O
such	O
an	O
extent	B-C0439792
that	O
the	O
short-term	B-C0443303
estimates	B-C0750572
suggest	O
that	O
selection	B-C0036576
is	O
only	O
active	B-C0205177
in	O
the	O
most	O
gc	B-C1135899
-rich	O
parts	O
of	O
the	O
genome	B-C0017428
.	O
	
finally	O
,	O
we	O
provide	O
evidence	B-C3887511
for	O
complex	B-C0439855
evolutionary	B-C0449774
patterns	I-C0449774
in	O
the	O
putatively	O
neutral	B-C0021920
short	I-C0021920
introns	I-C0021920
,	O
which	O
cannot	O
be	O
explained	O
by	O
the	O
standard	B-C0034925
gc	B-C1135899
-	O
biased	B-C0242568
gene	B-C0017259
conversion	I-C0017259
model	B-C0026339
.	O
	
these	O
results	B-C0456984
reveal	O
a	O
dynamic	B-C0729333
picture	O
of	O
base	B-C0004790
composition	I-C0004790
evolution	B-C0015219
.	O
	
a	O
case	B-C0868928
of	O
koch's	B-C0041330
spine	I-C0041330
treated	B-C1522326
with	O
modified	B-C0392747
transpedicular	B-C0010468
vertebral	I-C0010468
curettage	I-C0010468
and	O
posterior	B-C0205095
fixation	B-C0185023
a	O
novel	O
technique	B-C0449851
tuberculosis	B-C0041296
tb	B-C0041296
is	O
a	O
chronic	B-C0205191
granulomatous	B-C1610637
infection	I-C1610637
caused	O
by	O
acid-fast	B-C0026926
mycobacterium	I-C0026926
tuberculosis	I-C0026926
bacilli	I-C0026926
.	O
	
spinal	B-C0444534
involvement	I-C0444534
occurs	O
in	O
less	O
than	O
one	O
percent	O
of	O
tb	B-C0041296
.	O
	
spinal	B-C0041330
tb	I-C0041330
pott's	B-C0041330
disease	I-C0041330
accounts	O
for	O
50%	O
of	O
skeletal	B-C0041329
tb	I-C0041329
.	O
	
though	O
it	O
most	O
commonly	O
affects	O
the	O
thoracolumbar	B-C0224591
junction	I-C0224591
,	O
it	O
can	O
occur	O
at	O
any	O
level	B-C0441889
of	O
the	O
spine	B-C0037949
.	O
	
early	O
diagnosis	B-C0011900
and	O
treatment	B-C0087111
is	O
mandatory	O
in	O
order	O
to	O
avoid	O
neurological	B-C0235029
complications	I-C0235029
and	O
spinal	B-C0575157
deformity	I-C0575157
.	O
	
we	O
report	B-C0684224
a	O
case	B-C0868928
of	O
a	O
young	B-C0332239
female	B-C0086287
with	O
tuberculosis	B-C0041330
of	O
d12-l1	B-C0507384
who	O
was	O
treated	B-C1522326
with	O
posterior	B-C0205095
decompression	B-C1829459
using	O
a	O
modified	B-C0392747
transpedicular	B-C0010468
approach	I-C0010468
and	O
posterior	B-C0205095
instrumentation	B-C0356967
with	O
a	O
successful	O
a	O
comparison	B-C1707455
of	O
two	O
comorbidity	B-C1516737
indices	I-C1516737
for	O
predicting	B-C0681842
inpatient	B-C0021562
rehabilitation	B-C0034991
outcomes	B-C0085415
comorbid	B-C1275743
conditions	I-C1275743
are	O
important	O
in	O
health	B-C0086388
care	I-C0086388
.	O
	
the	O
best	O
comorbidity	B-C1516737
index	I-C1516737
for	O
predicting	B-C0681842
the	O
impact	B-C4049986
of	O
comorbidities	B-C0009488
on	O
rehabilitation	B-C0034991
outcomes	B-C0085415
has	O
not	O
been	O
determined	B-C0521095
.	O
	
compare	B-C1707455
the	O
associations	B-C0439849
of	O
comorbidity	B-C0009488
measured	B-C0444706
using	O
the	O
charlson	B-C1516737
comorbidity	I-C1516737
index	I-C1516737
cci	B-C1516737
and	O
the	O
cumulative	B-C0681889
index	I-C0681889
rating	I-C0681889
scale	I-C0681889
cirs	B-C0681889
with	O
key	O
rehabilitation	B-C0034991
outcomes	B-C0085415
.	O
	
aim	O
was	O
to	O
determine	B-C0521095
whether	O
either	O
of	O
these	O
comorbidity	B-C1516737
indices	I-C1516737
helped	O
explain	O
the	O
variation	B-C0205419
in	O
key	O
rehabilitation	B-C0034991
outcomes	B-C0085415
.	O
	
prospective	B-C1709709
open-cohort	I-C1709709
study	I-C1709709
.	O
	
inpatient	B-C0021562
rehabilitation	B-C0034991
ward	B-C1305702
,	O
melbourne	B-C0004340
,	O
australia	B-C0004340
.	O
	
adults	B-C0001675
admitted	B-C0184666
for	O
inpatient	B-C0021562
rehabilitation	B-C0034991
n=280	O
.	O
	
the	O
main	O
outcomes	B-C0085415
were	O
demographic	B-C0011292
e.g	O
.	O
	
age	B-C0001779
,	O
gender	B-C0079399
,	O
discharge	B-C0030685
destination	B-C0079220
and	O
clinical	B-C0205210
outcomes	B-C0085415
reason	B-C0566251
for	O
rehabilitation	B-C0034991
,	O
length	B-C0023303
of	I-C0023303
stay	I-C0023303
,	O
functional	B-C0451172
independence	I-C0451172
measure	I-C0451172
,	O
cci	B-C1516737
and	O
cirs	B-C0681889
.	O
	
a	O
series	O
of	O
regression	B-C0034980
analyses	I-C0034980
were	O
performed	B-C0884358
to	O
determine	B-C0521095
the	O
influence	B-C4054723
of	O
comorbidity	B-C0009488
on	O
three	O
dependent	B-C0871711
variables	I-C0871711
los	B-C0023303
in	O
rehabilitation	B-C0034991
2	O
the	O
change	B-C0443172
in	O
functional	B-C0451172
independence	I-C0451172
measure-motor	I-C0451172
score	B-C0449820
between	O
rehabilitation	B-C0034991
discharge	B-C0030685
and	O
admission	B-C0184666
and	O
3	O
the	O
discharge	B-C0030685
destination	B-C0079220
home	B-C0442519
vs	O
other	O
.	O
	
the	O
mean	B-C0444504
age	B-C0001779
was	O
57.7	O
years	B-C0439234
,	O
there	O
were	O
slightly	O
more	O
females	B-C0086287
51%	O
,	O
most	O
95%	O
patients	B-C0030705
previously	B-C0205156
lived	B-C0425078
at	I-C0425078
home	I-C0425078
with	O
family	B-C0015576
or	O
other	O
relatives	B-C0080103
63%	O
.	O
	
the	O
most	O
common	O
reason	B-C0566251
for	O
rehabilitation	B-C0034991
was	O
orthopaedic	B-C1136201
or	O
other	O
conditions	B-C0348080
52%	O
and	O
most	O
80%	O
people	B-C0027361
were	O
discharged	B-C0030685
home	B-C0442519
.	O
	
the	O
median	O
los	B-C0023303
was	O
27	O
days	B-C0439228
.	O
	
there	O
were	O
100	O
35.7	O
patients	B-C0030705
who	O
had	O
no	O
comorbidity	B-C0009488
recorded	B-C0034869
using	O
the	O
cci	B-C1516737
,	O
112	O
40.0	O
and	O
26	O
9.3	O
who	O
three	O
or	O
more	O
.	O
	
all	O
patients	B-C0030705
had	O
at	O
least	O
one	O
comorbidity	B-C0009488
recorded	B-C0034869
with	O
the	O
cirs	B-C0681889
,	O
and	O
264	O
94.3	O
had	O
3	O
or	O
more	O
comorbidities	B-C0009488
.	O
	
there	O
was	O
little	O
or	O
no	O
difference	B-C1705242
between	O
the	O
cci	B-C1516737
or	O
cirs	B-C0681889
in	O
terms	O
of	O
their	O
ability	B-C0085732
to	O
explain	O
the	O
variance	B-C1711260
in	O
los	B-C0023303
adjusted	O
r2	B-C2827748
=0	O
with	O
and	O
without	O
comorbidities	B-C0009488
,	O
change	B-C0443172
in	O
disability	B-C0231170
during	O
rehabilitation	B-C0034991
adjusted	O
r2	B-C2827748
=0	O
-	O
0.33	O
with	O
and	O
without	O
comorbidities	B-C0009488
or	O
the	O
discharge	B-C0030685
destination	B-C0079220
auc=0	O
without	O
comorbidities	B-C0009488
0.73	O
-	O
0.74	O
with	O
comorbidities	B-C0009488
beyond	O
that	O
accounted	O
for	O
by	O
demographic	B-C0011292
and	O
clinical	B-C2708733
information	I-C2708733
.	O
	
neither	O
the	O
cirs	B-C0681889
nor	O
the	O
cci	B-C1516737
in	O
our	O
patient	B-C0030705
sample	B-C0370003
provide	B-C1999230
additional	O
information	B-C1533716
that	O
explains	O
the	O
impact	B-C4049986
of	O
comorbidities	B-C0009488
on	O
key	O
rehabilitation	B-C0034991
outcomes	B-C0085415
.	O
	
further	O
research	B-C0035168
is	O
needed	O
to	O
determine	B-C0521095
the	O
most	O
appropriate	B-C1548787
measure	B-C0079809
of	O
comorbidity	B-C0009488
of	O
relevance	B-C2347946
to	O
inpatient	B-C0021562
rehabilitation	B-C0034991
outcomes	B-C0085415
.	O
	
internet	B-C3842705
gaming	I-C3842705
disorder	B-C0004936
explains	O
unique	B-C1711260
variance	I-C1711260
in	O
psychological	B-C0815107
distress	I-C0815107
and	O
disability	B-C0231170
after	O
controlling	O
for	O
comorbid	B-C1275743
depression	B-C0011570
,	O
ocd	B-C0028768
,	O
adhd	B-C1263846
,	O
and	O
anxiety	B-C0003467
this	O
study	B-C2603343
extends	O
knowledge	B-C0376554
about	O
the	O
relationship	B-C0439849
of	O
internet	B-C0004936
gaming	I-C0004936
disorder	I-C0004936
igd	B-C0004936
to	O
other	O
established	O
mental	B-C0004936
disorders	I-C0004936
by	O
exploring	O
comorbidities	B-C0009488
with	O
anxiety	B-C0003467
,	O
depression	B-C0011570
,	O
attention	B-C1263846
deficit	I-C1263846
hyperactivity	I-C1263846
disorder	I-C1263846
adhd	B-C1263846
,	O
and	O
obsessive	B-C0028768
compulsive	I-C0028768
disorder	I-C0028768
ocd	B-C0028768
,	O
and	O
assessing	B-C0184514
whether	O
igd	B-C0004936
accounts	O
for	O
unique	B-C1711260
variance	I-C1711260
in	O
distress	B-C0231303
and	O
disability	B-C0231170
.	O
	
an	O
online	B-C0038951
survey	I-C0038951
was	O
completed	O
by	O
a	O
convenience	B-C0150095
sample	I-C0150095
that	O
engages	O
in	O
internet	B-C3842705
gaming	I-C3842705
n	O
=	O
404	O
.	O
	
participants	B-C0679646
meeting	B-C1254372
criteria	I-C1254372
for	O
igd	B-C0004936
based	O
on	O
the	O
personal	B-C0242481
internet	I-C0242481
gaming	I-C0242481
disorder	I-C0242481
evaluation-9	I-C0242481
pie-9	B-C0242481
reported	O
higher	B-C0009488
comorbidity	I-C0009488
with	O
depression	B-C0011570
,	O
ocd	B-C0028768
,	O
adhd	B-C1263846
,	O
and	O
anxiety	B-C0003467
compared	O
with	O
those	O
who	O
did	O
not	O
meet	O
the	O
igd	B-C0004936
criteria	B-C0243161
.	O
	
igd	B-C0004936
explained	O
a	O
small	O
proportion	B-C1709707
of	O
unique	B-C1711260
variance	I-C1711260
in	O
distress	B-C0231303
1%	O
and	O
disability	B-C0231170
3%	O
.	O
	
igd	B-C0004936
accounted	O
for	O
a	O
larger	B-C1709707
proportion	I-C1709707
of	O
unique	B-C1711260
variance	I-C1711260
in	O
disability	B-C0231170
than	O
anxiety	B-C0003467
and	O
adhd	B-C1263846
,	O
and	O
a	O
similar	O
proportion	B-C1709707
to	O
depression	B-C0011570
.	O
	
replications	B-C1883725
with	O
clinical	B-C2349001
samples	I-C2349001
using	O
longitudinal	B-C1707689
designs	I-C1707689
and	O
structured	B-C0681913
diagnostic	I-C0681913
interviews	I-C0681913
what	O
is	O
the	O
real	B-C0237400
impact	B-C4049986
of	O
urinary	B-C0042024
incontinence	I-C0042024
on	O
female	B-C1112442
sexual	I-C1112442
dysfunction	I-C1112442
a	O
case	B-C0007328
control	I-C0007328
study	I-C0007328
urinary	B-C0042024
incontinence	I-C0042024
ui	B-C0042024
has	O
been	O
associated	B-C0332281
with	I-C0332281
negative	B-C0205160
effects	B-C1280500
on	O
women's	B-C0043210
sexuality	B-C0036915
.	O
	
women's	B-C0043210
sexuality	B-C0036915
and	O
sexual	B-C0278092
function	I-C0278092
are	O
a	O
complex	B-C0439855
issue	B-C0033213
,	O
and	O
the	O
role	B-C1705810
of	O
ui	B-C0042024
is	O
not	B-C0205257
completely	I-C0205257
clear	O
.	O
	
to	O
assess	B-C1516048
the	O
impact	B-C4049986
of	O
ui	B-C0042024
on	O
female	B-C0278098
sexual	I-C0278098
function	I-C0278098
by	O
comparing	B-C1707455
this	O
population	B-C1257890
with	O
a	O
control	B-C0009932
group	I-C0009932
of	O
continent	B-C0443192
women	B-C0043210
.	O
	
we	O
performed	O
a	O
case-control	B-C0007328
study	I-C0007328
from	O
august	O
2012	O
to	O
september	O
2013	O
.	O
	
we	O
evaluated	B-C0220825
continent	B-C0443192
and	O
incontinent	B-C0231238
women	B-C0043210
age	B-C0001779
range	B-C1514721
=	O
30-70	O
years	O
for	O
their	O
sexuality	B-C0036915
.	O
	
all	O
patients	B-C0030705
were	O
evaluated	B-C0220825
by	O
anamnesis	B-C0021055
,	O
physical	B-C0031809
examination	I-C0031809
,	O
and	O
self-report	B-C2700446
quality-of-life	B-C0451149
questionnaires	I-C0451149
.	O
	
in	O
addition	O
,	O
incontinent	B-C0231238
women	B-C0043210
underwent	O
a	O
1-hour	O
pad	B-C0430973
test	I-C0430973
.	O
	
patients	B-C0030705
without	O
sexual	B-C0036864
activity	I-C0036864
were	O
evaluated	B-C0220825
for	O
the	O
role	B-C1705810
of	O
ui	B-C0042024
in	O
their	O
sexual	B-C0036899
abstinence	I-C0036899
.	O
	
sexual	B-C0036899
abstinence	I-C0036899
was	O
defined	O
as	O
the	O
absence	B-C3840693
of	I-C3840693
sexual	I-C3840693
activity	I-C3840693
for	O
more	O
than	O
6	O
months	O
.	O
	
all	O
sexually	B-C0241028
active	I-C0241028
women	B-C0043210
completed	O
the	O
self-report	B-C2700446
sexuality	B-C0036915
quotient	B-C2347741
-	O
female	B-C0086287
version	B-C0333052
sq-f	O
questionnaire	B-C0034394
.	O
	
a	O
total	O
of	O
356	O
women	B-C0043210
were	O
included	O
in	O
the	O
study	B-C2603343
incontinent	B-C0231238
,	O
n	O
=	O
243	O
continent	B-C0443192
,	O
n	O
=	O
113	O
.	O
	
sexual	B-C0036899
abstinence	I-C0036899
was	O
found	O
in	O
162	O
women	B-C0043210
45%	O
.	O
	
incontinent	B-C0231238
women	B-C0043210
presented	O
a	O
higher	B-C1512456
prevalence	I-C1512456
p	O
<	O
001	O
of	O
sexual	B-C0036899
abstinence	I-C0036899
than	O
their	O
counterparts	B-C0682323
129	O
53%	O
and	O
33	O
29.2	O
,	O
respectively	O
.	O
	
age	B-C0001779
,	O
marital	B-C0024819
status	I-C0024819
,	O
and	O
ui	B-C0042024
were	O
found	O
to	O
be	O
isolated	B-C0205409
predictive	B-C0683956
factors	I-C0683956
for	O
more	O
sexual	B-C0036899
abstinence	I-C0036899
in	O
incontinent	B-C0231238
women	B-C0043210
.	O
	
sexually	B-C0241028
active	I-C0241028
women	B-C0043210
incontinent	B-C0231238
,	O
n	O
=	O
114	O
continent	B-C0443192
,	O
n	O
=	O
80	O
presented	O
similar	O
demographic	B-C0011298
data	B-C1511726
.	O
	
despite	O
a	O
similar	O
frequency	B-C0439603
of	O
sexual	B-C0036864
activity	I-C0036864
,	O
incontinent	B-C0231238
women	B-C0043210
had	O
less	O
sexual	B-C1409687
desire	I-C1409687
,	O
foreplay	B-C0558138
,	O
harmony	B-C0699798
with	O
a	O
partner	B-C3887537
,	O
sexual	B-C1331418
comfort	I-C1331418
,	O
and	O
sexual	B-C0871356
satisfaction	I-C0871356
than	O
their	O
counterparts	O
.	O
	
women	B-C0043210
with	O
greater	B-C1704243
urinary	B-C3897214
leakage	I-C3897214
during	O
the	O
1-hour	O
pad	B-C0430973
test	I-C0430973
weight	B-C0043100
>	O
11	O
g	O
had	O
the	O
worst	O
sexual	B-C0278092
function	I-C0278092
sq-f	O
score	B-C0449820
.	O
	
women	B-C0043210
with	O
ui	B-C0042024
were	O
more	O
likely	O
to	O
be	O
sexual	B-C0036899
abstinent	I-C0036899
than	O
continent	B-C0443192
women	B-C0043210
.	O
	
furthermore	O
,	O
women	B-C0043210
with	O
ui	B-C0042024
showed	O
less	O
sexual	B-C1409687
desire	I-C1409687
,	O
sexual	B-C1331418
comfort	I-C1331418
,	O
and	O
sexual	B-C0871356
satisfaction	I-C0871356
than	O
their	O
counterparts	B-C0682323
despite	O
having	O
a	O
similar	O
frequency	B-C0439603
of	O
sexual	B-C0036864
activity	I-C0036864
.	O
	
salvianolic	B-C3252265
acids	I-C3252265
for	O
injection	B-C1272883
safi	B-C1272883
suppresses	B-C1260953
inflammatory	B-C1155266
responses	I-C1155266
in	O
activated	B-C1879547
microglia	B-C0206116
to	O
attenuate	B-C0599946
brain	B-C0270611
damage	I-C0270611
in	O
focal	B-C0917798
cerebral	I-C0917798
ischemia	I-C0917798
inflammatory	B-C0021368
reactions	I-C0021368
induced	O
by	O
microglia	B-C0206116
in	O
the	O
brain	B-C0006104
play	O
crucial	O
roles	B-C1705810
in	O
ischemia	B-C0007786
/	O
reperfusion	B-C3854511
i/r	I-C3854511
cerebral	I-C3854511
injuries	I-C3854511
.	O
	
microglia	B-C0206116
activation	B-C1879547
has	O
been	O
shown	O
to	O
be	O
closely	O
related	O
to	O
tlr4	B-C2247725
/	O
nf-κb	B-C1513838
signal	I-C1513838
pathways	I-C1513838
.	O
	
salvianolic	B-C3252265
acids	I-C3252265
for	O
injection	B-C1272883
safi	B-C1272883
have	O
been	O
used	O
in	O
clinical	B-C0205897
practice	I-C0205897
to	O
treat	B-C1522326
ischemic	B-C0948008
stroke	I-C0948008
with	O
reported	B-C0700287
neuroprotective	B-C0815279
effects	I-C0815279
however	O
,	O
the	O
underlying	O
mechanisms	B-C0441712
are	O
still	O
uncertain	O
.	O
	
first	O
,	O
we	O
studied	B-C2603343
the	O
effect	B-C1280500
of	O
safi	B-C1272883
on	O
inflammatory	B-C1155266
responses	I-C1155266
in	O
lps	B-C0023810
-	O
stimulated	B-C1948023
bv-2	B-C4075604
microglia	B-C0206116
.	O
	
then	O
,	O
to	O
discover	B-C1880355
whether	O
the	O
beneficial	B-C0814225
in	B-C0681828
vitro	I-C0681828
effects	B-C1280500
of	O
safi	B-C1272883
lead	O
to	O
in	B-C0681829
vivo	I-C0681829
therapeutic	B-C1527144
effect	I-C1527144
s	O
,	O
an	O
mcao	B-C0740391
middle	B-C0740391
cerebral	I-C0740391
artery	I-C0740391
occlusion	I-C0740391
rat	B-C0034721
model	B-C0012644
was	O
further	O
employed	B-C0557351
to	O
elucidate	O
the	O
probable	O
mechanism	B-C0441712
of	O
safi	B-C1272883
in	O
treating	B-C1522326
ischemic	B-C0948008
stroke	I-C0948008
.	O
	
rats	B-C0034721
in	O
the	O
safi	B-C1272883
group	B-C0441833
were	O
given	O
safi	B-C1272883
23	O
or	O
46mg/kg	O
before	O
i	B-C0917798
/	O
r	B-C3854511
injury	I-C3854511
.	O
	
the	O
results	B-C1274040
showed	O
that	O
safi	B-C1272883
treatment	B-C1522326
significantly	B-C4055638
decreased	I-C4055638
neuroinflammation	B-C0021368
and	O
the	O
infarction	B-C0021308
volume	B-C0449468
compared	O
with	O
the	O
vehicle	B-C0042444
group	B-C0441833
.	O
	
activation	B-C1879547
of	O
microglia	B-C0206116
cells	I-C0206116
was	O
reduced	B-C0392756
,	O
and	O
tlr4	B-C2247725
/	O
nf-κb	B-C1513838
signals	I-C1513838
,	O
which	O
were	O
markedly	O
inhibited	B-C0311403
by	O
safi	B-C1272883
treatment	B-C1522326
in	O
ischemic	B-C0475224
hemisphere	B-C0228174
,	O
were	O
accompanied	O
by	O
reduced	B-C0392756
expression	B-C1171362
and	O
release	B-C0680255
of	O
cytokines	B-C0079189
il-1β	B-C0021753
and	O
il-6	B-C0021760
.	O
	
this	O
study	B-C2603343
provides	O
evidence	B-C3887511
that	O
safi	B-C1272883
effectively	B-C1704419
protects	O
the	O
brain	B-C0006104
after	O
cerebral	B-C0917798
ischemia	I-C0917798
,	O
which	O
may	O
be	O
caused	O
by	O
attenuating	B-C0599946
inflammation	B-C0021368
in	O
dynamics	B-C3826426
of	O
bacterial	B-C0521009
class	B-C1040746
bacilli	I-C1040746
in	O
the	O
deepest	B-C0337049
valley	I-C0337049
lake	I-C0337049
of	O
kashmir	B-C0681784
-the	O
manasbal	B-C0337049
lake	I-C0337049
in	O
recognition	O
of	O
the	O
importance	O
of	O
bacteria	B-C0004611
as	O
ecological	B-C0021212
indicators	I-C0021212
of	O
the	O
aquatic	B-C0162358
systems	I-C0162358
a	O
comprehensive	B-C0936012
and	I-C0936012
systematic	I-C0936012
analysis	I-C0936012
was	O
carried	O
out	O
on	O
manasbal	B-C0337049
lake	I-C0337049
,	O
the	O
deepest	B-C0337049
spring	I-C0337049
fed	I-C0337049
valley	I-C0337049
lake	I-C0337049
of	O
kashmir	B-C0681784
.	O
	
the	O
main	O
objective	O
envisaged	O
was	O
to	O
analyze	B-C0936012
bacterial	B-C2936393
community	I-C2936393
composition	I-C2936393
bcc	B-C2936393
and	O
for	O
this	O
purpose	O
systematic	B-C1710275
and	O
regular	B-C0597681
sampling	I-C0597681
of	I-C0597681
waters	I-C0597681
from	O
ten	O
different	O
sampling	O
stations	O
,	O
predetermined	O
in	O
the	O
lake	O
according	O
to	O
differences	O
in	O
degree	O
of	O
human	O
interference	O
and	O
also	O
as	O
zones	O
of	O
special	O
ecological	O
interests	O
were	O
selected	O
.	O
	
the	O
isolated	O
species	O
were	O
identified	O
according	O
to	O
bergey's	O
manual	O
specification	O
by	O
examining	O
their	O
micro	O
and	O
macro	O
morphological	O
characteristics	O
and	O
biochemical	O
characteristics	O
on	O
different	O
culture	O
media	O
.	O
	
further	O
confirmation	O
was	O
done	O
by	O
sequencing	O
the	O
16s	O
rrna	O
gene	O
by	O
using	O
universal	O
bacterial	O
primers	O
27f	O
and	O
1429r	O
.	O
	
from	O
all	O
the	O
sampling	O
stations	O
the	O
class	O
bacilli	O
showed	O
a	O
maximum	O
relative	O
abundance	O
with	O
a	O
contribution	O
of	O
16	O
bacterial	O
species	O
.	O
	
the	O
whole	O
process	O
resulted	O
in	O
the	O
identification	O
of	O
bacillus	O
aerius	O
,	O
bacillus	O
altitudinis	O
,	O
bacillus	O
anthracis	O
,	O
bacillus	O
cereus	O
,	O
bacillus	O
ginsengisoli	O
,	O
bacillus	O
pumilus	O
,	O
bacillus	O
safensis	O
,	O
bacillus	O
stratosphericus	O
,	O
bacillus	O
subtilis	O
,	O
bacillus	O
tequilensis	O
,	O
bacillus	O
thermocopriae	O
,	O
bacillus	O
thuringiensis	O
,	O
brevibacillus	O
agri	O
strain	O
,	O
lysinibacillus	O
boronitolerans	O
,	O
lysinibacillus	O
pakistanensis	O
and	O
lysinibacillus	O
sphaericus	I-C0314884
a	O
new	O
angle	B-C0205143
and	O
its	O
relationship	O
with	O
early	O
fixation	B-C0410837
failure	I-C0410837
of	O
femoral	B-C0015806
neck	I-C0015806
fractures	I-C0015806
treated	O
with	O
three	O
cannulated	B-C0005975
compression	I-C0005975
screws	I-C0005975
the	O
pauwels	O
angle	B-C0205143
has	O
been	O
used	O
widely	O
,	O
however	O
an	O
accurate	O
evaluation	O
of	O
this	O
angle	O
is	O
difficult	O
because	O
of	O
deformity	B-C0302142
of	O
the	O
affected	B-C0392760
lower	B-C0023216
extremity	I-C0023216
.	O
	
therefore	O
we	O
designed	O
a	O
new	O
measurement	B-C0242485
of	O
the	O
orientation	B-C1704322
of	O
femoral	B-C0015806
neck	I-C0015806
fracture	I-C0015806
and	O
applied	O
this	O
in	O
a	O
retrospective	B-C0035363
study	I-C0035363
to	O
assess	O
1	O
its	O
reproducibility	B-C1514863
,	O
2	O
its	O
advantages	O
compared	O
with	O
the	O
pauwels	O
angle	O
,	O
3	O
its	O
relationship	O
with	O
the	O
short-term	B-C0033325
prognosis	I-C0033325
treated	B-C1522326
with	O
three	O
cannulated	B-C0005975
compression	I-C0005975
screws	I-C0005975
.	O
	
this	O
new	O
measurement	B-C0242485
is	O
reproducible	O
and	O
has	O
some	O
reference	O
meaning	O
for	O
the	O
treatment	B-C0087111
of	O
femoral	B-C0015806
neck	I-C0015806
fractures	I-C0015806
.	O
	
two	O
hundred	O
and	O
twenty-eight	O
patients	B-C0030705
with	O
femoral	B-C0015806
neck	I-C0015806
fractures	I-C0015806
treated	O
with	O
three	O
cannulated	B-C0005975
compression	I-C0005975
screws	I-C0005975
were	O
retrospectively	B-C0936012
analyzed	I-C0936012
.	O
	
the	O
vn	O
angle	B-C0205143
,	O
which	O
was	O
the	O
angle	O
between	O
the	O
fracture	B-C1254362
line	I-C1254362
and	O
the	O
vertical	B-C0205128
of	O
the	O
neck	B-C1522496
axis	I-C1522496
,	O
and	O
the	O
pauwels	O
angle	O
were	O
measured	O
respectively	O
.	O
	
the	O
method	O
of	O
icc	B-C1707429
was	O
performed	O
to	O
assess	O
the	O
reproducibility	B-C1514863
of	O
the	O
two	O
angles	B-C0205143
,	O
and	O
the	O
absolute	O
value	O
of	O
difference	O
in	O
pre-operative	B-C0445204
and	O
post-operative	B-C0032790
radiographs	B-C1306645
was	O
used	O
to	O
evaluate	O
the	O
uniformity	O
of	O
the	O
two	O
angles	B-C0205143
.	O
	
these	O
fractures	B-C0016658
were	O
divided	O
into	O
four	O
groups	B-C0441833
according	O
to	O
vn	O
angle	O
vn<0	O
n=92	O
,	O
0	O
n=82	O
,	O
10	O
n=26	O
,	O
vn	O
n=28	O
,	O
and	O
the	O
short-term	O
within	O
6	O
months	B-C0439231
fixation	B-C0016641
results	O
of	O
radiographs	B-C1306645
in	O
these	O
fractures	B-C0016658
were	O
evaluated	O
.	O
	
the	O
icc	B-C1707429
of	O
the	O
vn	O
angle	O
and	O
the	O
pauwels	O
angle	O
in	O
pre-operative	B-C0445204
radiographs	B-C1306645
were	O
0.937	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
0.922	O
and	O
0.942	O
respectively	O
95%	O
ci	B-C0009667
0.914	O
,	O
indicating	O
both	O
angles	B-C0205143
had	O
a	O
good	O
inter-rater	B-C1514863
reproducibility	I-C1514863
.	O
	
however	O
,	O
there	O
was	O
a	O
great	O
difference	O
between	O
the	O
pauwels	O
angle	O
in	O
pre-operative	B-C0445204
and	O
post-operative	B-C0032790
radiographs	B-C1306645
p=0	O
,	O
the	O
absolute	O
difference	O
was	O
10.66	O
range	O
1.72	O
,	O
while	O
no	O
statistical	O
difference	O
for	O
the	O
vn	O
angle	O
p=0	O
and	O
the	O
absolute	O
difference	O
was	O
2.20	O
range	O
0.05	O
.	O
	
the	O
overall	O
fixation	B-C0410837
failure	I-C0410837
rate	B-C1521828
which	O
was	O
defined	O
as	O
screw	B-C0410830
loosening	I-C0410830
,	O
varus	O
collapse	O
,	O
obvious	O
fracture	B-C0585059
displacement	I-C0585059
or	O
femoral	B-C0015815
neck	I-C0015815
shortening	O
was	O
11.84	O
,	O
and	O
the	O
mean	O
failure	O
rates	O
according	O
to	O
vn	O
angles	O
were	O
respectively	O
0%	O
,	O
3.24	O
95%	O
ci	B-C0009667
1.64	O
,	O
22.69	O
95%	O
ci	B-C0009667
16.43	O
,	O
65.45	O
95%	O
ci	B-C0009667
59.36	O
.	O
	
the	O
mean	O
failure	B-C1521828
rates	I-C1521828
of	O
fractures	B-C0016658
according	O
to	O
post-operative	B-C0032790
pauwels	O
angle	O
<30	O
,	O
30-50	O
,	O
>50	O
were	O
respectively	O
0%	O
,	O
1.46	O
95%	O
ci	B-C0009667
1.42	O
and	O
36.24	O
95%	O
ci	B-C0009667
34.93	O
.	O
	
the	O
vn	O
angle	O
has	O
a	O
good	O
inter-rater	B-C1514863
reproducibility	I-C1514863
,	O
a	O
higher	O
reliability	O
than	O
the	O
pauwels	O
angle	O
and	O
is	O
closely	O
related	O
to	O
the	O
short-term	B-C0033325
prognosis	I-C0033325
of	O
femoral	B-C0015806
neck	I-C0015806
fractures	I-C0015806
treated	O
with	O
cannulated	B-C0005975
compression	I-C0005975
screws	I-C0005975
.	O
	
retirement	B-C0035345
crisis	B-C0231224
warnings	B-C1550014
becoming	O
a	O
reality	B-C0871222
the	O
figures	B-C0237753
are	O
startling	B-C0243095
the	O
number	O
of	O
nhs	B-C0027461
staff	B-C0028698
applying	O
to	O
retire	B-C0035345
has	O
surged	B-C0442805
by	O
a	O
quarter	O
since	O
2012	O
.	O
	
the	O
potential	O
consequences	B-C0686907
are	O
alarming	B-C0205404
a	O
serious	O
shortage	B-C0392762
of	O
nurses	B-C0028661
and	O
other	O
healthcare	B-C1704312
professionals	I-C1704312
now	O
seems	O
the	O
burden	B-C0162698
of	O
mental	B-C0004936
disorders	I-C0004936
in	O
the	O
eastern	B-C0282645
mediterranean	I-C0282645
region	I-C0282645
,	O
1990-2013	O
the	O
eastern	B-C0282645
mediterranean	I-C0282645
region	I-C0282645
emr	B-C0282645
is	O
witnessing	O
an	O
increase	B-C0442805
in	O
chronic	B-C0008679
disorders	I-C0008679
,	O
including	O
mental	B-C0004936
illness	I-C0004936
.	O
	
with	O
ongoing	O
unrest	O
,	O
this	O
is	O
expected	O
to	O
rise	O
.	O
	
this	O
is	O
the	O
first	O
study	B-C0008972
to	O
quantify	O
the	O
burden	B-C0162698
of	O
mental	B-C0004936
disorders	I-C0004936
in	O
the	O
emr	B-C0282645
.	O
	
we	O
used	O
data	B-C1511726
from	O
the	O
global	B-C4277729
burden	I-C4277729
of	I-C4277729
disease	I-C4277729
study	I-C4277729
gbd	B-C4277729
2013	O
.	O
	
dalys	B-C4300518
disability-adjusted	B-C4300518
life	I-C4300518
years	I-C4300518
allow	O
assessment	B-C0220825
of	O
both	O
premature	B-C1855073
mortality	I-C1855073
years	B-C2713320
of	I-C2713320
life	I-C2713320
lost	I-C2713320
-	O
ylls	B-C2713320
and	O
nonfatal	O
outcomes	O
years	B-C1254367
lived	I-C1254367
with	I-C1254367
disability	I-C1254367
-	O
ylds	B-C1254367
.	O
	
dalys	B-C4300518
are	O
computed	O
by	O
adding	O
ylls	B-C2713320
and	O
ylds	B-C1254367
for	O
each	O
age-sex-country	O
group	O
.	O
	
in	O
2013	O
,	O
mental	B-C0004936
disorders	I-C0004936
contributed	O
to	O
5.6	O
of	O
the	O
total	B-C0162698
disease	I-C0162698
burden	I-C0162698
in	O
the	O
emr	B-C0282645
1894	O
dalys	B-C4300518
/100	O
population	B-C1257890
2519	O
dalys	B-C4300518
/100	O
2590/100	O
males	B-C0086582
,	O
2426/100	O
females	B-C0086287
in	O
high-income	B-C0948433
countries	O
,	O
1884	O
dalys	O
/100	O
1618/100	O
males	O
,	O
2157/100	O
females	O
in	O
middle-income	O
countries	O
,	O
1607	O
dalys	O
/100	O
1500/100	O
males	O
,	O
1717/100	O
females	O
in	O
low-income	O
countries	O
.	O
	
females	O
had	O
a	O
greater	O
proportion	O
of	O
burden	O
due	O
to	O
mental	O
disorders	O
than	O
did	O
males	O
of	O
equivalent	O
ages	O
,	O
except	O
for	O
those	O
under	O
15	O
years	O
of	O
age	O
.	O
	
the	O
highest	O
proportion	O
of	O
dalys	O
occurred	O
in	O
the	O
25-49	O
age	O
group	O
,	O
with	O
a	O
peak	O
in	O
the	O
35-39	O
years	O
age	O
group	O
5344	O
dalys	O
/100	O
.	O
	
the	O
burden	O
of	O
mental	O
disorders	O
in	O
emr	O
increased	O
from	O
1726	O
dalys	O
/100	O
in	O
1990	O
to	O
1912	O
dalys	O
/100	O
in	O
2013	O
10.8	O
increase	O
.	O
	
within	O
the	O
mental	O
disorders	O
group	O
in	O
emr	O
,	O
depressive	O
disorders	O
accounted	O
for	O
most	O
dalys	O
,	O
followed	O
by	O
anxiety	O
disorders	O
.	O
	
among	O
emr	O
countries	O
,	O
palestine	O
had	O
the	O
largest	O
burden	O
of	O
mental	O
disorders	O
.	O
	
nearly	O
all	O
emr	O
countries	O
had	O
a	O
higher	O
mental	O
disorder	O
burden	O
compared	O
to	O
the	O
global	O
level	O
.	O
	
our	O
findings	O
call	O
for	O
emr	O
ministries	O
of	O
health	O
to	O
increase	O
provision	O
of	O
mental	O
health	O
services	O
and	O
to	O
address	O
the	O
stigma	O
of	O
mental	O
illness	O
.	O
	
moreover	O
,	O
our	O
results	O
showing	O
the	O
accelerating	O
burden	O
of	O
mental	O
health	O
are	O
alarming	O
as	O
the	O
region	O
is	O
seeing	O
an	O
increased	O
level	O
of	O
instability	O
.	O
	
indeed	O
,	O
mental	O
health	O
problems	O
,	O
if	O
not	O
properly	O
addressed	O
,	O
will	O
lead	O
to	O
an	O
increased	O
burden	O
of	O
diseases	O
in	O
the	O
region	B-C0017446
like	O
father	B-C0015671
,	O
like	O
daughter	B-C0011011
-	O
inherited	B-C0439660
cutis	B-C0282160
aplasia	I-C0282160
occurring	O
in	O
a	O
family	B-C0015576
with	O
marfan	B-C0024796
syndrome	I-C0024796
a	O
case	B-C0085973
report	I-C0085973
we	O
present	O
the	O
case	B-C0868928
of	O
a	O
newborn	B-C0021289
with	O
co-occurrence	B-C2745955
of	O
marfan	B-C0024796
syndrome	I-C0024796
and	O
aplasia	B-C0282160
cutis	I-C0282160
congenita	I-C0282160
acc	B-C0282160
and	O
a	O
family	B-C0241889
history	I-C0241889
significant	B-C0750502
for	O
marfan	B-C0024796
syndrome	I-C0024796
and	O
acc	B-C0282160
in	O
the	O
father	B-C0015671
.	O
	
this	O
case	B-C0868928
details	B-C1522508
a	O
previously	O
unreported	O
mutation	B-C0026882
in	O
marfan	B-C0024796
syndrome	I-C0024796
and	O
describes	O
a	O
novel	O
coinheritance	B-C0728826
of	O
marfan	B-C0024796
syndrome	I-C0024796
and	O
hyperandrogenemia	B-C1299574
in	O
women	B-C0043210
with	O
polycystic	B-C0032460
ovary	I-C0032460
syndrome	I-C0032460
prevalence	B-C0220900
,	O
characteristics	B-C1521970
and	O
association	B-C0332281
with	I-C0332281
body	B-C1305855
mass	I-C1305855
index	I-C1305855
hyperandrogenemia	B-C1299574
is	O
one	O
of	O
the	O
major	O
diagnostic	B-C0348026
features	O
for	O
the	O
diagnosis	B-C0011900
of	O
polycystic	B-C0032460
ovary	I-C0032460
syndrome	I-C0032460
pcos	B-C0032460
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	B-C0750572
the	O
prevalence	B-C0220900
and	O
the	O
characteristics	B-C1521970
of	O
hyperandrogenemia	B-C1299574
in	O
women	B-C0043210
with	O
pcos	B-C0032460
and	O
to	O
investigate	B-C1292732
the	O
association	O
of	O
clinical	B-C0205210
and	O
biochemical	B-C0205474
characteristics	B-C1521970
with	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
according	O
to	O
the	O
presence	B-C0150312
of	O
hyperandrogenemia	B-C1299574
.	O
	
we	O
studied	O
266	O
women	B-C0043210
diagnosed	B-C0011900
with	O
pcos	B-C0032460
.	O
	
hyperandrogenemia	B-C1299574
was	O
defined	O
by	O
testosterone	B-C0039601
t	B-C0039601
and/or	O
free	B-C0443483
testosterone	I-C0443483
ft	B-C0443483
and/or	O
4	B-C4284099
androstenedione	I-C4284099
δ4-a	B-C4284099
higher	O
than	O
75%	O
of	O
the	O
upper	O
limits	O
of	O
each	O
hormone	B-C0019932
.	O
	
patients	B-C0030705
were	O
stratified	B-C0205363
in	O
two	O
groups	B-C1257890
according	O
to	O
a	O
bmi	B-C1305855
threshold	B-C0449864
of	O
25	O
kg/m2	O
.	O
	
hyperandrogenemia	B-C1299574
was	O
present	B-C0150312
in	O
78.2	O
of	O
the	O
patients	B-C0030705
.	O
	
elevated	B-C3163633
levels	O
of	O
t	B-C0039601
were	O
found	O
in	O
58.4	O
,	O
while	O
elevated	B-C3163633
levels	O
of	O
ft	B-C0443483
and	O
δ4-a	B-C4284099
were	O
found	O
in	O
42.5	O
and	O
34.1	O
of	O
patients	B-C0030705
.	O
	
in	O
normal	B-C2712185
weight	I-C2712185
women	B-C0043210
bmi	B-C1305855
25	O
kg/m2	O
with	O
hyperandrogenemia	B-C1299574
lower	O
values	O
of	O
hip	B-C0562350
circumference	I-C0562350
and	O
homa-ir	B-C3639411
and	O
increased	B-C0205217
levels	O
of	O
t	B-C0039601
,	O
ft	B-C0443483
,	O
δ4-a	B-C4284099
,	O
17-hydroxyprogesterone	B-C0045010
17-ohp	B-C0045010
,	O
dehydroepiandrosterone	B-C0057277
sulfate	I-C0057277
dheas	B-C0057277
,	O
white	B-C0023516
blood	I-C0023516
cells	I-C0023516
wbc	B-C0023516
and	O
neutrophils	B-C0027950
were	O
observed	O
compared	O
to	O
women	B-C0043210
without	O
hyperandrogenemia	B-C1299574
.	O
	
also	O
,	O
in	O
overweight	B-C0497406
women	B-C0043210
higher	O
levels	O
of	O
t	B-C0039601
,	O
ft	B-C0443483
,	O
δ4-a	B-C4284099
,	O
17-ohp	B-C0045010
,	O
dheas	B-C0057277
and	O
cortisol	B-C0020268
were	O
measured	B-C0444706
,	O
while	O
lower	O
thyroid-stimulating	B-C0202230
hormone	I-C0202230
tsh	I-C0202230
levels	I-C0202230
were	O
comparable	O
to	O
women	B-C0043210
without	O
hyperandrogenemia	B-C1299574
.	O
	
this	O
study	O
showed	O
high	O
prevalence	B-C0220900
of	O
hyperandrogenemia	B-C1299574
in	O
pcos	B-C0032460
women	B-C0043210
.	O
	
women	B-C0043210
with	O
bmi	B-C1305855
25	O
kg/m2	O
have	O
significant	B-C0750502
differences	O
in	O
androgens	B-C0002844
,	O
wbc	B-C0023516
,	O
neutrophils	B-C0027950
and	O
homa-ir	B-C3639411
and	O
women	B-C0043210
with	O
bmi	B-C1305855
25	O
kg/m2	O
in	O
androgens	B-C0002844
,	O
tsh	B-C2825077
and	O
cortisol	B-C0020268
according	O
to	O
the	O
presence	B-C0150312
or	O
not	O
of	O
a	O
course	B-C0750729
-based	O
approach	B-C0449445
to	O
the	O
doctor	B-C0031831
of	O
nursing	B-C0008967
practice	I-C0008967
project	I-C0008967
supporting	O
student	B-C0038492
growth	O
from	O
concept	B-C0178566
to	O
completion	B-C0205197
we	O
describe	O
a	O
course	B-C0750729
-based	O
approach	B-C0449445
to	O
the	O
doctor	B-C0031831
of	O
nursing	B-C0008967
practice	I-C0008967
project	I-C0008967
in	O
which	O
students	B-C0038492
work	B-C0043227
in	O
groups	B-C0441833
of	O
8	O
to	O
12	O
with	O
a	O
faculty	B-C0015535
member	I-C0015535
to	O
complete	B-C0205197
individual	O
final	O
projects	B-C1709701
that	O
require	O
a	O
minimum	B-C1524031
of	O
360	O
practicum	B-C0032929
hours	B-C0439227
in	O
3-	O
semester	B-C2348178
-long	O
courses	B-C0750729
.	O
	
project	B-C0871489
teams	I-C0871489
include	O
agency	B-C0237463
or	O
community	B-C0009462
-based	O
mentors	B-C0025369
.	O
	
project	B-C0243095
findings	I-C0243095
are	O
disseminated	B-C0205221
through	O
written	B-C0684224
and	O
oral	B-C0684224
reports	I-C0684224
.	O
	
this	O
approach	B-C0449445
preserves	O
faculty	B-C0015535
resources	B-C0024752
and	O
provides	O
students	B-C0038492
with	O
mentoring	B-C4255266
,	O
opportunities	B-C1254370
for	O
reflection	B-C0037397
,	O
and	O
time	B-C0040223
for	O
project	B-C1527148
development	I-C1527148
.	O
	
clinical	B-C0205210
and	O
angiographic	B-C0002978
correlation	B-C1707520
of	O
high-sensitivity	B-C0006560
c-reactive	I-C0006560
protein	I-C0006560
with	O
acute	B-C1303258
st	I-C1303258
elevation	I-C1303258
myocardial	I-C1303258
infarction	I-C1303258
vascular	B-C0947751
inflammation	I-C0947751
and	O
associated	O
ongoing	O
inflammatory	B-C1155266
responses	I-C1155266
are	O
considered	O
as	O
the	O
critical	O
culprits	O
in	O
the	O
pathogenesis	B-C0699748
of	O
acute	B-C0205178
atherothrombotic	B-C1963943
events	B-C0441471
such	O
as	O
acute	B-C0948089
coronary	I-C0948089
syndrome	I-C0948089
acs	B-C0948089
and	O
myocardial	B-C0027051
infarction	I-C0027051
mi	B-C0027051
.	O
	
st	B-C1536220
segment	I-C1536220
elevation	I-C1536220
myocardial	I-C1536220
infarction	I-C1536220
stemi	B-C1536220
is	O
considered	O
as	O
one	O
of	O
the	O
prominent	O
clinical	B-C0205210
forms	B-C0348078
of	O
acs	B-C0948089
.	O
	
moreover	O
,	O
c-reactive	B-C0006560
protein	I-C0006560
crp	B-C0006560
is	O
an	O
important	O
acute	B-C0001347
phase	I-C0001347
prsotein	I-C0001347
,	O
which	O
may	O
be	O
estimated	O
using	O
high-sensitivity	B-C3839560
methods	I-C3839560
hs-crp	B-C3839560
,	O
and	O
its	O
elevated	B-C3163633
level	B-C0428528
in	O
body	B-C0005889
fluids	I-C0005889
reflects	O
chronic	B-C0021376
inflammatory	I-C0021376
status	B-C0449438
.	O
	
the	O
circulating	O
hs-crp	B-C3839560
level	B-C0428528
has	O
been	O
proposed	O
as	O
a	O
promising	O
inflammatory	B-C0021368
marker	B-C0005516
of	O
coronary	B-C0010054
artery	I-C0010054
disease	I-C0010054
cad	B-C0010054
.	O
	
the	O
present	O
study	B-C2603343
investigated	B-C1292732
the	O
correlation	B-C1707520
of	O
hs-crp	B-C3839560
level	B-C0428528
with	O
clinical	B-C0205210
and	O
angiographic	B-C0002978
features	B-C2348519
of	O
stemi	B-C1536220
,	O
various	O
other	O
traditional	O
risk	B-C0035648
factors	I-C0035648
,	O
complications	B-C0009566
of	O
myocardial	B-C0027051
infarction	I-C0027051
and	O
angiographically	B-C0750502
significant	I-C0750502
cad	B-C0010054
.	O
	
out	O
of	O
190	O
patients	B-C0030705
with	O
stemi	B-C1536220
that	O
were	O
analyzed	B-C0936012
,	O
the	O
interval	B-C1272706
between	O
symptom	B-C4086878
onset	I-C4086878
and	O
reperfusion	B-C0035124
therapy	I-C0035124
window	B-C1948053
period	I-C1948053
varied	O
from	O
0.5	O
to	O
24	O
h	B-C0439227
.	O
	
the	O
hs-crp	B-C3839560
value	O
was	O
found	O
to	O
be	O
higher	O
in	O
non-diabetic	B-C0030705
patients	I-C0030705
0.61	O
mg/dl	O
compared	B-C1707455
with	O
diabetic	B-C0011847
patients	B-C0030705
0.87	O
mg/dl	O
.	O
	
moreover	O
,	O
a	O
significant	O
correlation	B-C1707520
between	O
hs-crp	B-C3839560
and	O
hs-troponin	B-C3827339
t	I-C3827339
was	O
also	O
recorded	O
p<0	O
.	O
	
however	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
hs-crp	B-C3839560
values	B-C0042295
in	O
patients	B-C0030705
with	O
or	O
without	O
mortality	B-C0205848
.	O
	
it	O
is	O
considered	O
that	O
the	O
present	O
study	B-C2603343
will	O
increase	O
the	O
understanding	O
of	O
atherosclerosis	B-C0004153
in	O
general	O
and	O
may	O
also	O
have	O
clinical	B-C1254363
applications	I-C1254363
in	O
the	O
targeting	O
of	O
therapy	B-C0087111
for	O
this	O
harmful	O
bioelectrochemical	B-C2350499
anaerobic	B-C3641081
sewage	B-C0597443
treatment	I-C0597443
technology	B-C0039421
for	O
arctic	B-C0003740
communities	B-C0009462
this	O
study	B-C2603343
describes	O
a	O
novel	O
wastewater	B-C0450237
treatment	B-C1522326
technology	B-C0039421
suitable	O
for	O
small	O
remote	B-C0205157
northern	B-C1709269
communities	B-C0009462
.	O
	
the	O
technology	B-C0039421
is	O
based	B-C1527178
on	O
an	O
enhanced	B-C2349975
biodegradation	B-C0005482
of	O
organic	B-C0302333
carbon	I-C0302333
through	O
a	O
combination	O
of	O
anaerobic	B-C3641081
methanogenic	B-C0025621
and	O
microbial	B-C0599840
electrochemical	B-C2350499
bioelectrochemical	B-C2350499
degradation	B-C0243125
processes	I-C0243125
leading	O
to	O
biomethane	B-C0029224
production	B-C1522492
.	O
	
the	O
microbial	B-C0599840
electrochemical	B-C2350499
degradation	B-C0243125
is	O
achieved	O
in	O
a	O
membraneless	B-C0243095
flow	I-C0243095
-through	O
bioanode	B-C0003103
-	O
biocathode	B-C0007441
setup	O
operating	B-C3242339
at	O
an	O
applied	B-C4048755
voltage	B-C0598352
below	O
the	O
water	B-C0043047
electrolysis	B-C0013829
threshold	B-C0449864
.	O
	
laboratory	B-C0022877
wastewater	B-C0450237
treatment	B-C1522326
tests	B-C0392366
conducted	O
through	O
a	O
broad	B-C0332464
range	I-C0332464
of	O
mesophilic	B-C0205081
and	O
psychrophilic	B-C0009264
temperatures	I-C0009264
5-23	O
c	O
using	O
synthetic	B-C2004457
wastewater	B-C0450237
showed	O
a	O
biochemical	B-C3826658
oxygen	I-C3826658
demand	I-C3826658
bod5	B-C3826658
removal	B-C1883720
efficiency	B-C0013682
of	O
90-97%	O
and	O
an	O
effluent	B-C1546612
bod5	B-C3826658
concentration	B-C1446561
as	O
low	O
as	O
7	O
mg	O
l	O
.	O
	
an	O
electricity	B-C0013790
consumption	B-C0457083
of	O
0.6	O
kwh	O
kg	O
of	O
chemical	B-C2936287
oxygen	I-C2936287
demand	I-C2936287
cod	B-C2936287
removed	B-C0849355
was	O
observed	B-C1441672
.	O
	
low	B-C0205251
energy	B-C1442080
consumption	B-C0457083
coupled	O
with	O
enhanced	B-C2349975
methane	B-C0025617
production	B-C1522492
led	O
to	O
a	O
net	O
positive	B-C1446409
energy	B-C1442080
balance	B-C0205415
in	O
the	O
bioelectrochemical	B-C2350499
treatment	B-C1522326
system	B-C0449913
.	O
	
impact	B-C4049986
of	O
femoral	B-C0015801
artery	I-C0015801
puncture	B-C0034117
using	O
digital	B-C0002979
subtraction	I-C0002979
angiography	I-C0002979
and	O
road	B-C1283195
mapping	I-C1283195
on	O
vascular	B-C1393529
and	O
bleeding	B-C0019080
complications	B-C0009566
after	O
transfemoral	O
transcatheter	B-C3509486
aortic	I-C3509486
valve	I-C3509486
implantation	I-C3509486
the	O
use	O
of	O
large	B-C0549177
-	O
diameter	B-C1301886
sheaths	O
carries	O
the	O
risk	B-C0035647
of	O
significant	O
vascular	B-C1393529
and	O
bleeding	B-C0019080
complications	B-C0009566
after	O
transfemoral	O
transcatheter	B-C3509486
aortic	I-C3509486
valve	I-C3509486
implantation	I-C3509486
tavi	B-C3509486
.	O
	
in	O
this	O
analysis	B-C0936012
,	O
we	O
sought	O
to	O
assess	B-C0184514
the	O
impact	B-C4049986
of	O
a	O
modified	O
femoral	B-C0015801
artery	I-C0015801
puncture	B-C0034117
technique	B-C0449851
using	O
digital	B-C0002979
subtraction	I-C0002979
angiography	I-C0002979
dsa	B-C0002979
and	O
road	B-C1283195
mapping	I-C1283195
during	O
transfemoral	O
tavi	B-C3509486
on	O
periprocedural	B-C1141861
vascular	B-C0005847
and	O
bleeding	B-C0019080
events	O
.	O
	
this	O
is	O
a	O
retrospective	O
analysis	B-C0936012
of	O
transfemoral	O
tavi	B-C3509486
patients	B-C0030705
included	O
in	O
a	O
prospective	B-C0242356
institutional	I-C0242356
database	I-C0242356
.	O
	
the	O
modified	O
femoral	B-C0015801
artery	I-C0015801
puncture	B-C0034117
technique	B-C0449851
using	O
dsa	B-C0002979
-derived	O
road	B-C1283195
mapping	I-C1283195
guidance	O
was	O
introduced	O
in	O
october	O
2012	O
.	O
	
before	O
the	O
introduction	O
of	O
this	O
technique	B-C0449851
,	O
vascular	B-C0005847
puncture	B-C0034117
was	O
acquired	O
based	O
on	O
an	O
integration	O
of	O
angiographic	B-C0002978
data	B-C1511726
,	O
the	O
bony	B-C0443157
iliofemoral	B-C1279169
landmarks	B-C0504075
and	O
a	O
radiopaque	B-C0181739
object	I-C0181739
.	O
	
consecutive	O
patients	B-C0030705
who	O
underwent	O
tavi	B-C3509486
with	O
the	O
road	B-C1283195
mapping	I-C1283195
technique	B-C0449851
rm	B-C0441833
group	I-C0441833
,	O
n=160	O
were	O
compared	O
with	O
consecutive	O
patients	B-C0030705
who	O
underwent	O
tavi	B-C3509486
without	O
road	B-C1283195
mapping	I-C1283195
control	B-C0009932
group	I-C0009932
,	O
n=160	O
prior	O
to	O
its	O
introduction	O
.	O
	
a	O
standardised	O
strategy	O
of	O
periprocedural	B-C0003281
anticoagulation	I-C0003281
was	O
adopted	O
in	O
both	O
groups	B-C0441833
as	O
well	O
as	O
the	O
use	O
of	O
a	O
single	B-C0025080
suture-based	I-C0025080
closure	I-C0025080
device	I-C0025080
.	O
	
all	O
endpoints	B-C2349179
were	O
defined	O
according	O
to	O
the	O
varc-2	B-C0282574
criteria	I-C0282574
for	O
event	O
definition	O
.	O
	
the	O
mean	O
age	O
in	O
the	O
rm	B-C0441833
group	I-C0441833
was	O
80	O
years	B-C0439234
compared	O
to	O
81	O
years	B-C0439234
in	O
the	O
control	B-C0009932
group	I-C0009932
p=0	O
,	O
and	O
females	B-C0086287
were	O
equally	O
distributed	O
between	O
both	O
groups	B-C0441833
63.1	O
vs	O
.	O
	
58.1	O
,	O
p=0	O
.	O
	
the	O
baseline	B-C3164744
logistic	I-C3164744
euroscore	I-C3164744
was	O
20.7	O
vs	O
.	O
	
24.9	O
in	O
the	O
rm	B-C0441833
and	O
control	B-C0009932
group	I-C0009932
,	O
respectively	O
p=0	O
.	O
	
notably	O
,	O
sheath	B-C0456389
size	I-C0456389
was	O
significantly	O
larger	O
in	O
the	O
rm	B-C0441833
compared	O
to	O
the	O
control	B-C0009932
group	I-C0009932
due	O
to	O
the	O
more	O
frequent	O
use	O
of	O
the	O
20	O
fr	O
sheath	O
23.8	O
vs	O
.	O
	
1.8	O
,	O
p<0	O
,	O
respectively	O
associated	B-C0332281
with	I-C0332281
the	O
more	O
frequent	O
implantation	B-C0021107
of	O
the	O
29	O
mm	O
edwards	O
sapien	O
xt	O
valve	O
in	O
the	O
rm	B-C0441833
group	I-C0441833
43.8	O
vs	O
.	O
	
7%	O
,	O
respectively	O
,	O
p<0	O
.	O
	
despite	O
the	O
latter	O
finding	O
,	O
both	O
major	O
vascular	B-C1393529
complications	I-C1393529
and	O
major	O
bleeding	B-C0019080
at	O
30	O
days	B-C0439228
were	O
significantly	O
lower	B-C0205251
in	O
the	O
rm	B-C0441833
group	I-C0441833
compared	O
to	O
the	O
control	B-C0009932
group	I-C0009932
4.3	O
vs	O
.	O
	
11.8	O
,	O
p=0	O
,	O
and	O
14.4	O
vs	O
.	O
	
25.6	O
,	O
p=0	O
.	O
	
an	O
analysis	B-C0936012
limited	O
to	O
access	O
site-related	O
complications	B-C0009566
also	O
revealed	O
lower	O
events	O
in	O
the	O
road	B-C0441833
map	I-C0441833
group	I-C0441833
but	O
did	O
not	O
reach	O
statistical	B-C0237881
significance	I-C0237881
8.1	O
vs	O
.	O
	
13.8	O
,	O
p=0	O
.	O
	
other	O
forms	O
of	O
vascular	B-C1393529
and	O
bleeding	B-C0019080
complications	B-C0009566
as	O
well	O
as	O
all-cause	B-C0178686
mortality	I-C0178686
were	O
comparable	O
in	O
both	O
groups	B-C0441833
.	O
	
a	O
modified	O
femoral	B-C0015801
artery	I-C0015801
puncture	B-C0034117
technique	B-C0449851
using	O
dsa	B-C0002979
and	O
road	B-C1283195
mapping	I-C1283195
was	O
associated	B-C0332281
with	I-C0332281
a	O
reduction	O
in	O
major	O
vascular	B-C1393529
and	O
bleeding	B-C0019080
complications	B-C0009566
after	O
transfemoral	O
tavi	B-C3509486
,	O
and	O
provides	O
a	O
simple	B-C0205352
and	O
effective	B-C1704419
strategy	O
for	O
potentially	O
improving	O
patient	B-C2987124
outcomes	I-C2987124
.	O
	
differential	B-C1705242
roles	B-C1552020
of	O
axin1	B-C1438871
and	O
axin2	B-C1454580
in	O
tankyrase	B-C0963182
inhibitor-induced	B-C0014432
formation	B-C1522492
of	O
degradasomes	B-C1180347
and	O
β-catenin	B-C0105770
degradation	B-C0243125
inhibition	B-C1524081
of	O
the	O
tankyrase	B-C0963182
enzymes	I-C0963182
tnks1	B-C1504783
and	O
tnks2	B-C1448153
has	O
recently	O
been	O
shown	O
to	O
induce	O
highly	B-C0205250
dynamic	B-C0729333
assemblies	B-C0872376
of	O
β-catenin	B-C0105770
destruction	B-C1704241
complex	I-C1704241
components	B-C1179435
known	O
as	O
degradasomes	B-C1180347
,	O
which	O
promote	B-C0033414
degradation	B-C0243125
of	O
β-catenin	B-C0105770
and	O
reduced	B-C0392756
wnt	B-C1520113
signaling	I-C1520113
activity	B-C0205177
in	O
colorectal	B-C1527249
cancer	I-C1527249
cells	B-C0007634
.	O
	
axin1	B-C1438871
and	O
axin2	B-C1454580
/	O
conductin	B-C1454580
,	O
the	O
rate-limiting	B-C0489879
factors	B-C1521761
for	O
the	O
stability	B-C0205360
and	O
function	B-C0542341
of	O
endogenous	B-C0205227
destruction	B-C1704241
complexes	I-C1704241
,	O
are	O
stabilized	B-C0184512
upon	O
tnks	B-C0963182
inhibition	B-C1524081
due	O
to	O
abrogated	O
degradation	B-C0243125
of	O
axin	B-C3178961
by	O
the	O
proteasome	B-C1180347
.	O
	
since	O
the	O
role	B-C1552020
of	O
axin1	B-C1438871
versus	O
axin2	B-C1454580
as	O
scaffolding	B-C0033684
proteins	I-C0033684
in	O
the	O
wnt	B-C1520113
signaling	I-C1520113
pathway	I-C1520113
still	O
remains	B-C1527428
incompletely	B-C0205257
understood	B-C0162340
,	O
we	O
sought	O
to	O
elucidate	O
their	O
relative	B-C0205345
contribution	B-C1880177
in	O
the	O
formation	B-C1522492
of	O
degradasomes	B-C1180347
,	O
as	O
these	O
protein	B-C0033684
assemblies	B-C0872376
most	O
likely	O
represent	O
the	O
morphological	B-C0543482
and	O
functional	B-C0205245
correlates	B-C1707520
of	O
endogenous	B-C0205227
β-catenin	B-C0105770
destruction	B-C1704241
complexes	I-C1704241
.	O
	
in	O
sw480	B-C0007634
colorectal	B-C1527249
cancer	I-C1527249
cells	B-C0007634
treated	B-C1522326
with	O
the	O
tankyrase	B-C0014432
inhibitor	I-C0014432
tnksi	B-C0014432
g007-lk	B-C3658785
we	O
found	B-C0150312
that	O
axin1	B-C1438871
was	O
not	O
required	O
for	O
degradasome	B-C1180347
formation	B-C1522492
.	O
	
in	O
contrast	O
,	O
the	O
formation	B-C1522492
of	O
degradasomes	B-C1180347
as	O
well	O
as	O
their	O
capacity	B-C1516240
to	O
degrade	B-C0243125
β-catenin	B-C0105770
were	O
considerably	B-C0750591
impaired	B-C0221099
in	O
g007-lk-treated	B-C3658785
cells	B-C0007634
depleted	O
of	O
axin2	B-C1454580
.	O
	
these	O
findings	B-C0243095
give	O
novel	B-C0205314
insights	B-C0233820
into	O
differential	B-C1705242
functional	B-C1705810
roles	I-C1705810
of	O
axin1	B-C1438871
versus	O
axin2	B-C1454580
in	O
the	O
β-catenin	B-C0105770
destruction	B-C1704241
complex	I-C1704241
.	O
	
mri	B-C0024485
-based	O
prostate	B-C0376358
cancer	I-C0376358
detection	B-C0011900
with	O
high-level	B-C0683878
representation	I-C0683878
and	O
hierarchical	B-C0699032
classification	B-C0008902
extracting	O
the	O
high-level	B-C0683878
feature	I-C0683878
representation	I-C0683878
by	O
using	O
deep	B-C0870951
neural	I-C0870951
networks	I-C0870951
for	O
detection	B-C0011900
of	O
prostate	B-C0376358
cancer	I-C0376358
,	O
and	O
then	O
based	O
on	O
high-level	B-C0683878
feature	I-C0683878
representation	I-C0683878
constructing	O
hierarchical	B-C0699032
classification	B-C0008902
to	O
refine	O
the	O
detection	B-C0011900
results	B-C1274040
.	O
	
high-level	B-C0683878
feature	I-C0683878
representation	I-C0683878
is	O
first	O
learned	O
by	O
a	O
deep	B-C0870951
learning	I-C0870951
network	I-C0870951
,	O
where	O
multiparametric	B-C4304904
mr	I-C4304904
images	B-C1704922
are	O
used	O
as	O
the	O
input	O
data	B-C1511726
.	O
	
then	O
,	O
based	O
on	O
the	O
learned	O
high-level	B-C2346469
features	I-C2346469
,	O
a	O
hierarchical	B-C0699032
classification	B-C0008902
method	B-C0025663
is	O
developed	O
,	O
where	O
multiple	B-C0282574
random	I-C0282574
forest	I-C0282574
classifiers	I-C0282574
are	O
iteratively	B-C1707689
constructed	I-C1707689
to	O
refine	O
the	O
detection	B-C0011900
results	B-C1274040
of	O
prostate	B-C0376358
cancer	I-C0376358
.	O
	
the	O
experiments	B-C0681814
were	O
carried	O
on	O
21	O
real	O
patient	B-C0030705
subjects	O
,	O
and	O
the	O
proposed	O
method	B-C0025663
achieves	O
an	O
averaged	O
section-based	B-C0220825
evaluation	I-C0220825
sbe	B-C0220825
of	O
89.90	O
,	O
an	O
averaged	O
sensitivity	B-C0332324
of	O
91.51	O
,	O
and	O
an	O
averaged	O
specificity	B-C0037791
of	O
88.47	O
.	O
	
the	O
high-level	B-C2346469
features	I-C2346469
learned	O
from	O
our	O
proposed	O
method	B-C0025663
can	O
achieve	O
better	O
performance	B-C1882330
than	O
the	O
conventional	B-C0205214
handcrafted	B-C2346469
features	I-C2346469
e.g	O
,	O
lbp	B-C2346469
and	O
haar-like	B-C2346469
features	I-C2346469
in	O
detecting	B-C0011900
prostate	B-C0376358
cancer	I-C0376358
regions	B-C0005898
,	O
also	O
the	O
context	B-C0449255
features	B-C2348519
obtained	O
from	O
the	O
proposed	O
hierarchical	B-C0699032
classification	B-C0008902
approach	O
are	O
effective	B-C1704419
in	O
refining	O
cancer	B-C0006826
detection	B-C0011900
result	B-C1274040
.	O
	
quantitative	B-C0006117
susceptibility	I-C0006117
mapping	I-C0006117
using	O
structural	B-C0020912
feature	I-C0020912
based	I-C0020912
collaborative	I-C0020912
reconstruction	I-C0020912
sfcr	B-C0020912
in	O
the	O
human	B-C0086418
brain	B-C0006104
the	O
reconstruction	B-C0020912
of	O
mr	B-C0917874
quantitative	B-C0006117
susceptibility	I-C0006117
mapping	I-C0006117
qsm	B-C0006117
from	O
local	B-C0205390
phase	I-C0205390
measurements	B-C0242485
is	O
an	O
ill	O
posed	O
inverse	O
problem	O
and	O
different	O
regularization	B-C0205245
strategies	I-C0205245
incorporating	O
a	O
priori	B-C0332152
information	B-C1533716
extracted	O
from	O
magnitude	B-C1704240
and	O
phase	B-C1704922
images	I-C1704922
have	O
been	O
proposed	B-C1553874
.	O
	
however	O
,	O
the	O
anatomy	B-C0700276
observed	O
in	O
magnitude	B-C1704240
and	O
phase	B-C1704922
images	I-C1704922
does	O
not	O
always	O
coincide	O
spatially	O
with	O
that	O
in	O
susceptibility	B-C0024779
maps	I-C0024779
,	O
which	O
could	O
give	O
erroneous	B-C1547323
estimation	B-C0750572
in	O
the	O
reconstructed	B-C0024779
susceptibility	I-C0024779
map	I-C0024779
.	O
	
in	O
this	O
paper	O
,	O
we	O
develop	O
a	O
structural	B-C0020912
feature	I-C0020912
based	I-C0020912
collaborative	I-C0020912
reconstruction	I-C0020912
sfcr	B-C0020912
method	O
for	O
qsm	B-C0006117
including	O
both	O
magnitude	B-C1704240
and	O
susceptibility	B-C1547045
based	O
information	B-C1533716
.	O
	
the	O
sfcr	B-C0020912
algorithm	B-C0002045
is	O
composed	O
of	O
two	O
consecutive	B-C1261552
steps	I-C1261552
corresponding	O
to	O
complementary	O
reconstruction	B-C3161035
models	I-C3161035
,	O
each	O
with	O
a	O
structural	B-C0678594
feature	I-C0678594
based	O
l1	O
norm	B-C0443288
constraint	I-C0443288
and	O
a	O
voxel	O
fidelity	O
based	O
l2	O
norm	B-C0443288
constraint	I-C0443288
,	O
which	O
allows	O
both	O
the	O
structure	B-C0678594
edges	O
and	O
tiny	O
features	B-C2348519
to	O
be	O
recovered	O
,	O
whereas	O
the	O
noise	B-C0028263
and	O
artifacts	B-C0085089
could	O
be	O
reduced	O
.	O
	
in	O
the	O
m-step	B-C1261552
,	O
the	O
initial	O
susceptibility	B-C0024779
map	I-C0024779
is	O
reconstructed	B-C0020912
by	O
employing	O
a	O
k-space	O
based	O
compressed	B-C3161035
sensing	I-C3161035
model	I-C3161035
incorporating	O
magnitude	B-C1704240
prior	O
.	O
	
in	O
the	O
s-step	B-C1261552
,	O
the	O
susceptibility	B-C0024779
map	I-C0024779
is	O
fitted	O
in	O
spatial	B-C1254362
domain	I-C1254362
using	O
weighted	O
constraints	B-C0443288
derived	O
from	O
the	O
initial	O
susceptibility	B-C0024779
map	I-C0024779
from	O
the	O
m-step	B-C1261552
.	O
	
simulations	B-C0679083
and	O
in	B-C1515655
vivo	I-C1515655
human	B-C0086418
experiments	B-C0681814
at	O
7t	O
mri	B-C0024485
show	O
that	O
the	O
sfcr	B-C0020912
method	O
provides	O
high	O
quality	B-C0332306
susceptibility	B-C0024779
maps	I-C0024779
with	O
improved	O
rmse	B-C0871425
and	O
mssim	B-C0871425
.	O
	
finally	O
,	O
the	O
susceptibility	B-C1547045
values	O
of	O
deep	O
gray	B-C0018220
matter	I-C0018220
are	O
analyzed	O
in	O
multiple	B-C0582540
head	I-C0582540
positions	I-C0582540
,	O
with	O
the	O
supine	B-C0038846
position	I-C0038846
most	O
approximate	O
to	O
the	O
gold	O
standard	O
cosmos	B-C0449913
result	B-C1274040
.	O
	
high	B-C0205250
hba1c	B-C0019018
at	O
onset	B-C0332162
cannot	O
be	O
used	O
as	O
a	O
predictor	B-C2698872
for	O
future	O
metabolic	B-C1513158
control	I-C1513158
for	O
the	O
individual	B-C0237401
child	B-C0008059
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
mellitus	I-C0011854
to	O
study	O
how	O
metabolic	B-C1513158
control	I-C1513158
at	O
onset	B-C0332162
of	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
correlates	O
to	O
metabolic	B-C1513158
control	I-C1513158
and	O
clinical	B-C0205210
parameters	B-C0449381
during	O
childhood	B-C0231335
until	O
transition	B-C2700061
from	O
pediatric	B-C3839839
care	I-C3839839
to	O
adult	B-C0001675
diabetes	B-C0150544
care	I-C0150544
.	O
	
data	B-C1511726
at	O
onset	B-C0332162
,	O
three	O
months	B-C0439231
,	O
one	O
,	O
three	O
,	O
and	O
five	O
years	B-C0439234
after	O
diagnosis	B-C0011900
and	O
at	O
transition	B-C2700061
,	O
on	O
hba1c	B-C0019018
and	O
clinical	B-C0205210
parameters	B-C0449381
,	O
on	O
8084	O
patients	B-C0030705
in	O
the	O
swedish	B-C0282574
pediatric	I-C0282574
quality	I-C0282574
registry	I-C0282574
,	O
swediabkids	I-C0282574
,	O
were	O
used	O
.	O
	
of	O
these	O
patients	B-C0030705
,	O
26%	O
had	O
been	O
referred	O
to	O
adult	B-C0001675
diabetes	B-C0150544
care	I-C0150544
by	O
2014	O
.	O
	
children	B-C0008059
with	O
hba1c	B-C0019018
<	O
72	O
mmol/mol	O
8.7	O
20%	O
of	O
patients	B-C0030705
,	O
low	B-C0205251
group	B-C1257890
at	O
diagnosis	B-C0011900
continued	O
to	O
have	O
good	O
metabolic	B-C1513158
control	I-C1513158
during	O
childhood	B-C0231335
,	O
in	O
contrast	O
to	O
children	B-C0008059
with	O
hba1c	B-C0019018
>	O
114	O
mmol/mol	O
12.6	O
20%	O
of	O
patients	B-C0030705
,	O
high	B-C0205250
group	B-C1257890
at	O
diagnosis	B-C0011900
,	O
who	O
continued	O
to	O
have	O
high	B-C0205250
hba1c	B-C0019018
at	O
follow-up	B-C1522577
.	O
	
for	O
the	O
individual	B-C0237401
,	O
there	O
was	O
no	B-C1273937
significant	I-C1273937
correlation	B-C1707520
between	O
high	B-C0205250
hba1c	B-C0019018
at	O
onset	B-C0332162
and	O
during	O
follow-up	B-C1522577
.	O
	
during	O
follow-up	B-C1522577
,	O
children	B-C0008059
in	O
the	O
high	B-C0205250
group	B-C1257890
were	O
more	O
often	O
smokers	B-C0337664
,	O
less	O
physically	B-C0556453
active	I-C0556453
,	O
and	O
more	O
often	O
had	O
retinopathy	B-C0035309
than	O
children	B-C0008059
in	O
the	O
low	B-C0205251
group	B-C1257890
p	O
<	O
01	O
,	O
01	O
,	O
03	O
respectively	O
.	O
	
high	B-C0205250
hba1c	B-C0019018
at	O
onset	B-C0332162
was	O
associated	B-C0332281
with	I-C0332281
high	B-C0205250
hba1c	B-C0019018
during	O
follow-up	B-C1522577
on	O
a	O
group	B-C1257890
level	O
,	O
but	O
it	O
cannot	O
be	O
used	O
as	O
a	O
predictor	B-C2698872
of	O
future	O
metabolic	B-C1513158
control	I-C1513158
on	O
an	O
individual	B-C0237401
level	O
.	O
	
these	O
results	O
emphasize	O
the	O
important	O
work	O
done	O
by	O
the	O
diabetes	B-C0011847
team	B-C0871489
in	O
the	O
first	O
years	O
after	O
diagnosis	B-C0011900
.	O
	
it	O
is	O
important	O
to	O
continuously	O
set	O
high	B-C0205250
goals	B-C0018017
for	O
the	O
achievement	B-C0001072
of	O
tight	O
metabolic	B-C1513158
control	I-C1513158
,	O
in	O
order	O
to	O
decrease	B-C0547047
the	O
risk	B-C0035647
of	O
microvascular	B-C3837959
complications	I-C3837959
.	O
	
photosensitizer	B-C0162713
decorated	B-C1254366
red	B-C0014792
blood	I-C0014792
cells	I-C0014792
as	O
an	O
ultra-sensitive	B-C0085104
light-responsive	I-C0085104
drug	I-C0085104
delivery	I-C0085104
system	I-C0085104
red	B-C0014792
blood	I-C0014792
cells	I-C0014792
rbcs	B-C0014792
,	O
the	O
most	O
abundant	B-C2346714
type	O
of	O
cells	B-C0007634
in	O
our	O
blood	B-C0005767
,	O
have	O
shown	O
promises	O
as	O
a	O
natural	B-C1254365
drug	I-C1254365
delivery	I-C1254365
system	I-C1254365
dds	B-C1254365
with	O
inherent	O
biocompatibility	B-C0596177
.	O
	
herein	O
,	O
we	O
uncover	O
that	O
a	O
photosensitizer	B-C0162713
,	O
chlorin	B-C0055367
e6	I-C0055367
ce6	B-C0055367
,	O
could	O
be	O
decorated	B-C1254366
into	O
the	O
membrane	B-C0596901
of	O
rbcs	B-C0014792
upon	O
simple	O
mixing	B-C1720722
,	O
without	O
affecting	O
the	O
membrane	B-C0596901
integrity	B-C1947912
and	O
stability	B-C0205360
in	O
dark	O
.	O
	
upon	O
light	B-C0023693
irradiation	B-C1282930
with	O
a	O
rather	O
low	O
power	O
density	B-C0178587
,	O
the	O
generated	B-C3146294
singlet	B-C0074565
oxygen	I-C0074565
by	O
ce6	B-C0055367
as	O
the	O
result	B-C0940920
of	I-C0940920
photodynamic	I-C0940920
effect	I-C0940920
would	O
lead	O
to	O
rather	O
efficient	O
disruption	B-C0332453
of	O
rbc	B-C0014792
membrane	B-C0596901
.	O
	
with	O
doxorubicin	B-C0013089
dox	B-C0013089
,	O
a	O
typical	O
chemotherapy	O
drug	O
,	O
as	O
the	O
model	O
,	O
we	O
engineer	O
a	O
unique	O
type	O
of	O
light-responsive	O
rbc-based	O
dds	O
by	O
decorating	O
ce6	O
on	O
the	O
cell	O
membrane	O
and	O
loading	O
dox	B-C0013089
inside	O
cells	O
.	O
	
the	O
light	O
triggered	O
cell	O
membrane	O
break	O
down	O
would	O
thus	O
trigger	O
instant	O
release	O
of	O
dox	O
,	O
enabling	O
light-controlled	O
chemotherapy	B-C3665472
with	O
great	O
specificity	O
.	O
	
beyond	O
that	O
,	O
our	O
rbc	O
system	O
could	O
also	O
be	O
utilized	O
for	O
loading	O
of	O
larger	O
biomolecules	O
such	O
as	O
enzymes	O
,	O
whose	O
release	O
as	O
well	O
as	O
catalytic	O
function	O
is	O
also	O
controlled	O
by	O
light	O
.	O
	
our	O
work	O
thus	O
presents	O
a	O
unique	O
type	O
of	O
biocompatible	O
cell-based	O
dds	O
that	O
can	O
be	O
precisely	O
controlled	O
by	O
mild	O
external	O
stimuli	O
,	O
promising	O
not	O
only	O
for	O
cancer	O
therapy	O
but	O
also	O
for	O
other	O
potential	O
applications	O
in	O
biotechnologies	B-C0005574
validation	B-C1519941
of	O
the	O
neogen	B-C0015846
fentanyl	I-C0015846
elisa	B-C0014441
kit	O
for	O
blood	B-C0005767
and	O
urine	B-C0042036
the	O
neogen	B-C0015846
fentanyl	I-C0015846
ready-to-use	O
enzyme-linked	B-C0014441
immunosorbent	I-C0014441
assay	I-C0014441
kit	O
was	O
validated	O
following	O
the	O
scientific	B-C1257890
working	I-C1257890
group	I-C1257890
for	O
forensic	B-C1721026
toxicology	I-C1721026
standard	B-C0086343
practices	I-C0086343
for	O
method	O
validation	B-C1519941
in	O
forensic	B-C1721026
toxicology	I-C1721026
laboratory	B-C4291774
guidelines	I-C4291774
.	O
	
two	O
decision	O
points	O
,	O
0.5	O
and	O
1	O
ng/ml	O
,	O
were	O
successfully	O
validated	O
for	O
whole	B-C0370231
blood	I-C0370231
.	O
	
for	O
urine	B-C0042036
,	O
two	O
decision	O
points	O
,	O
1	O
and	O
5	O
ng/ml	O
,	O
were	O
also	O
successfully	O
validated	O
.	O
	
the	O
validation	B-C1519941
included	O
the	O
evaluation	B-C0220825
of	O
sensitivity	B-C1511883
,	O
precision	B-C1706245
,	O
specificity	B-C0037791
,	O
carryover	B-C0205556
,	O
plate	B-C0205556
drift	I-C0205556
,	O
ruggedness/robustness	O
and	O
a	O
case	O
sample	O
evaluation	B-C0220825
.	O
	
the	O
empirically	O
determined	O
limit	B-C2718050
of	I-C2718050
detection	I-C2718050
was	O
0.25	O
ng/ml	O
for	O
blood	B-C0005767
and	O
0.5	O
ng/ml	O
for	O
urine	B-C0042036
.	O
	
precision	B-C1706245
was	O
determined	O
at	O
five	O
different	O
concentrations	B-C1446561
ranging	O
from	O
0.25	O
to	O
1.5	O
ng/ml	O
with	O
15	O
replicates	B-C1883725
at	O
each	O
level	O
for	O
whole	B-C0370231
blood	I-C0370231
and	O
demonstrated	O
a	O
<2	O
coefficient	B-C0681921
of	I-C0681921
variation	I-C0681921
cv	B-C0681921
.	O
	
in	O
urine	B-C0042036
,	O
the	O
cv	B-C0681921
was	O
<5	O
at	O
six	O
different	O
concentrations	B-C1446561
from	O
0.5	O
to	O
7.5	O
ng/ml	O
with	O
15	O
replicates	B-C1883725
at	O
each	O
level	O
.	O
	
cross-reactivity	B-C0010357
was	O
evaluated	B-C0220825
for	O
norfentanyl	B-C0214194
,	O
acetyl	B-C3700366
fentanyl	I-C3700366
,	O
4-anilino-n-phenethylpiperidine	B-C2713534
,	O
beta-hydroxythiofentanyl	B-C4305828
,	O
butyryl	B-C4305826
fentanyl	I-C4305826
and	O
furanyl	B-C0015846
fentanyl	I-C0015846
.	O
	
everolimus	B-C0541315
for	O
treatment	B-C0087111
of	O
pseudomyogenic	B-C0018915
hemangioendothelioma	I-C0018915
pseudomyogenic	B-C0018915
hemangioendothelioma	I-C0018915
pmh	B-C0018915
is	O
a	O
recently	O
described	O
vascular	B-C0282607
neoplasm	I-C0282607
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft	B-C0225317
tissue	I-C0225317
of	O
the	O
distal	O
extremities	O
of	O
young	B-C0238598
adults	I-C0238598
.	O
	
metastatic	B-C1522484
pmh	B-C0018915
can	O
be	O
fatal	B-C1302234
and	O
there	O
are	O
no	O
effective	B-C1704419
medications	B-C0013227
.	O
	
we	O
describe	O
a	O
case	B-C1706256
of	O
a	O
15-year-old	O
boy	B-C0870221
with	O
metastatic	B-C1522484
pmh	B-C0018915
,	O
who	O
responded	B-C0521982
to	I-C0521982
treatment	I-C0521982
with	O
everolimus	B-C0541315
,	O
a	O
mammalian	B-C2746052
target	I-C2746052
of	I-C2746052
rapamycin	I-C2746052
inhibitor	I-C2746052
.	O
	
immunohistochemistry	B-C0021044
showed	O
that	O
mammalian	B-C1307407
target	I-C1307407
of	I-C1307407
rapamycin	I-C1307407
was	O
expressed	B-C1171362
in	O
pmh	B-C0018915
biopsy	B-C0677862
specimens	I-C0677862
,	O
which	O
may	O
explain	O
the	O
reduction	B-C0392756
in	O
pmh	B-C0018915
tumor	B-C0475440
size	I-C0475440
following	O
opposing	O
roles	B-C1521970
of	O
acetylation	B-C0001038
and	O
phosphorylation	B-C0031715
in	O
lifr	B-C0125607
-	O
dependent	B-C3244310
self-renewal	B-C1155711
growth	B-C0018270
signaling	B-C0037080
in	O
mouse	B-C4042879
embryonic	I-C4042879
stem	I-C4042879
cells	I-C4042879
lif	B-C0125606
promotes	O
self-renewal	B-C1155711
of	O
mouse	B-C4042879
embryonic	I-C4042879
stem	I-C4042879
cells	I-C4042879
mescs	B-C4042879
,	O
and	O
in	O
its	O
absence	B-C0332268
,	O
the	O
cells	B-C0007634
differentiate	B-C2945687
.	O
	
lif	B-C0125606
binds	O
to	O
the	O
lif	B-C0125607
receptor	I-C0125607
lifr	B-C0125607
and	O
activates	B-C1879547
the	O
jak-stat3	B-C0037080
pathway	I-C0037080
,	O
but	O
it	O
remains	B-C0439673
unknown	I-C0439673
how	O
the	O
receptor	B-C1523873
complex	I-C1523873
triggers	B-C1444748
differentiation	B-C2945687
or	O
self-renewal	B-C1155711
.	O
	
here	O
,	O
we	O
report	O
that	O
the	O
lifr	B-C0125607
cytoplasmic	B-C1511625
domain	I-C1511625
contains	O
a	O
self-renewal	B-C1155711
domain	B-C1880389
within	O
the	O
juxtamembrane	B-C1622525
region	I-C1622525
and	O
a	O
differentiation	B-C2945687
domain	B-C1880389
within	O
the	O
c-terminal	B-C1707271
region	I-C1707271
.	O
	
the	O
differentiation	B-C2945687
domain	B-C1880389
contains	O
four	O
spxx	B-C0030956
repeats	I-C0030956
that	O
are	O
phosphorylated	B-C0031715
by	O
mapk	B-C0752312
to	O
restrict	B-C0443288
stat3	B-C2248236
activation	I-C2248236
the	O
self-renewal	B-C1155711
domain	B-C1880389
is	O
characterized	O
by	O
a	O
3k	B-C0660452
motif	I-C0660452
that	O
is	O
acetylated	B-C0001038
by	O
p300	O
.	O
	
in	O
mescs	B-C4042879
,	O
acetyl-	O
lifr	B-C0125607
undergoes	O
homodimerization	B-C1512485
,	O
leading	O
to	O
stat3	B-C0253050
hypo-	B-C1879547
or	I-C1879547
hyper-activation	I-C1879547
depending	B-C3244310
on	O
the	O
presence	B-C0150312
or	O
absence	B-C0332197
of	O
gp130	B-C0082758
.	O
	
lifr	B-C0125607
-	O
activated	B-C1879547
stat3	B-C0253050
restricts	B-C0443288
differentiation	B-C2945687
via	O
cytokine	B-C0079189
induction	B-C0205263
.	O
	
thus	O
,	O
lifr	B-C0125607
acetylation	B-C0001038
and	O
serine	B-C1519253
phosphorylation	I-C1519253
differentially	B-C2945687
promote	O
stem	B-C0038250
cell	I-C0038250
self-renewal	B-C1155711
and	O
interprofessional	B-C0021799
primary	B-C0033137
care	I-C0033137
team	B-C0589031
meetings	I-C0589031
a	O
qualitative	B-C0205556
approach	B-C0449445
comparing	O
observations	B-C0302523
with	O
personal	B-C1519021
opinions	B-C0683292
the	O
number	O
of	O
people	B-C0027361
with	O
multiple	B-C3266262
chronic	I-C3266262
conditions	I-C3266262
requiring	O
primary	B-C0018747
care	I-C0018747
services	I-C0018747
increases	B-C0442805
.	O
	
professionals	B-C0679924
from	O
different	O
disciplines	B-C0013996
collaborate	B-C0282116
and	O
coordinate	B-C0700114
care	B-C1947933
to	O
deal	O
with	O
the	O
complex	O
health	B-C0086388
care	I-C0086388
needs	I-C0086388
.	O
	
there	O
is	O
lack	B-C0332268
of	O
information	B-C1533716
on	O
current	O
practices	O
regarding	O
interprofessional	B-C0021799
team	B-C0589031
ipt	I-C0589031
meetings	I-C0589031
.	O
	
this	O
study	B-C2603343
aimed	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
process	O
of	O
interprofessional	B-C0021799
collaboration	B-C0282116
in	O
primary	B-C0033137
care	I-C0033137
team	B-C0589031
meetings	I-C0589031
in	O
the	O
netherlands	B-C0027778
by	O
observing	O
the	O
current	B-C0033284
practice	I-C0033284
and	O
exploring	O
personal	B-C1519021
opinions	B-C0683292
.	O
	
qualitative	B-C0949415
study	I-C0949415
involving	O
observations	B-C0302523
of	O
team	B-C0589031
meeting	I-C0589031
s	O
and	O
interviews	B-C0683518
with	O
participants	B-C0679646
.	O
	
eight	O
different	O
ipt	B-C0589031
meetings	I-C0589031
n	O
=	O
8	O
in	O
different	O
primary	B-C0033137
care	I-C0033137
practices	I-C0033137
were	O
observed	O
by	O
means	O
of	O
video	B-C0042650
recordings	I-C0042650
.	O
	
experiences	B-C0596545
were	O
explored	O
by	O
conducting	O
individual	O
semi-structured	B-C0681913
interviews	I-C0681913
n	O
=	O
60	O
with	O
participants	B-C0679646
i.e	O
.	O
	
health	B-C0018724
care	I-C0018724
professionals	I-C0018724
from	O
different	O
disciplines	B-C0013996
of	O
the	O
observed	O
team	B-C0589031
meetings	I-C0589031
.	O
	
the	O
data	B-C1511726
were	O
analysed	B-C0936012
by	O
means	O
of	O
content	B-C0681915
analysis	I-C0681915
.	O
	
most	O
participants	B-C0679646
expressed	O
favourable	O
opinions	B-C0683292
about	O
their	O
team	B-C0589031
meetings	I-C0589031
.	O
	
however	O
,	O
observations	B-C0302523
showed	O
that	O
team	B-C0589031
meetings	I-C0589031
were	O
more	O
or	O
less	O
hectic	O
,	O
and	O
lacked	B-C0332268
a	O
clear	O
structure	O
and	O
team	B-C1711307
coordinator	I-C1711307
or	O
leader	B-C0401960
.	O
	
there	O
appears	O
to	O
be	O
a	O
discrepancy	B-C1290905
between	O
findings	B-C0243095
from	O
observations	B-C0302523
and	O
interviews	B-C0021822
.	O
	
from	O
the	O
interviews	B-C0021822
,	O
four	O
main	O
themes	O
were	O
extracted	O
1	O
team	B-C1257890
structure	I-C1257890
and	I-C1257890
composition	I-C1257890
,	O
2	O
patient-centredness	B-C0243024
,	O
3	O
interaction	B-C0021797
and	O
4	O
attitude	B-C0004271
and	O
motivation	B-C0026605
.	O
	
ipt	B-C0589031
meetings	I-C0589031
could	O
benefit	O
from	O
improvements	B-C2986411
in	O
structure	O
,	O
patient-centredness	B-C0243024
and	O
leadership	B-C0023181
by	O
the	O
chairpersons	B-C1524106
.	O
	
given	O
the	O
discrepancy	B-C1290905
between	O
observations	B-C0302523
and	O
interviews	B-C0021822
,	O
it	O
would	O
appear	O
useful	O
to	O
improve	B-C2986411
team	B-C1551024
members	I-C1551024
'	O
awareness	B-C0004448
of	O
aspects	B-C1879746
that	O
could	O
be	O
improved	B-C2986411
before	O
training	B-C0220931
them	O
in	O
dealing	O
with	O
specific	O
urachal	B-C2931202
carcinoma	I-C2931202
report	B-C0684224
of	O
two	O
cases	B-C1706256
and	O
review	B-C0699752
of	I-C0699752
the	O
literature	B-C0023866
urachal	B-C2931202
carcinoma	I-C2931202
is	O
a	O
rare	B-C0522498
tumor	B-C0027651
that	O
most	O
commonly	O
occurs	O
in	O
ovaries	B-C0029939
and	O
less	B-C3843156
often	I-C3843156
in	O
the	O
adnexal	B-C0001575
region	B-C0005898
and	O
urinary	B-C1508753
system	I-C1508753
.	O
	
we	O
herein	O
present	B-C0449450
two	O
cases	B-C1706256
of	O
urachal	B-C2931202
carcinoma	I-C2931202
one	O
case	B-C1706256
was	O
a	O
32-year-old	O
male	B-C0025266
patient	B-C0030705
who	O
presented	B-C0449450
with	O
painless	B-C0473235
hematuria	I-C0473235
with	O
blood	B-C0302148
clots	I-C0302148
for	O
1	O
month	B-C0439231
,	O
whereas	O
the	O
other	O
case	B-C1706256
was	O
a	O
50-year-old	O
woman	B-C0043210
who	O
presented	B-C0449450
with	O
gross	B-C0473237
hematuria	I-C0473237
with	O
mild	B-C2945599
dysuria	B-C0013428
,	O
urgency	B-C0085606
and	I-C0085606
frequent	I-C0085606
urination	I-C0085606
for	O
1	O
year	B-C0439234
.	O
	
following	O
surgical	B-C0728940
resection	I-C0728940
,	O
the	O
two	O
patients	B-C0030705
were	O
diagnosed	B-C0011900
with	O
urachal	B-C2931201
adenocarcinoma	I-C2931201
mixed	B-C0205430
type	B-C0332307
and	O
urachal	B-C2931201
mucinous	I-C2931201
adenocarcinoma	I-C2931201
,	O
respectively	O
,	O
based	O
on	O
the	O
histopathological	B-C0243140
examination	B-C0582103
.	O
	
a	O
review	B-C0699752
of	I-C0699752
previously	O
published	B-C0034037
cases	B-C1706256
and	O
relevant	B-C2347946
literature	B-C0023866
is	O
also	O
presented	B-C0449450
.	O
	
the	O
aim	B-C1947946
of	O
the	O
present	B-C0150312
study	B-C0008972
was	O
to	O
help	O
understand	B-C0162340
this	O
disease	B-C0027651
better	B-C0332272
,	O
in	O
order	O
to	O
reduce	B-C0392756
the	O
rate	B-C1521828
of	O
clinical	B-C0205210
and	O
pathological	B-C1521733
misdiagnosis	B-C0679838
.	O
	
a	O
recombinant	B-C0017387
human	B-C0086418
anti-platelet	B-C0370058
scfv	I-C0370058
antibody	I-C0370058
produced	O
in	O
pichia	O
pastoris	O
for	O
atheroma	O
targeting	O
cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
system	O
are	O
key	O
factors	O
in	O
the	O
progression	O
of	O
atherosclerotic	O
plaque	O
,	O
leading	O
to	O
plaque	O
instability	O
and	O
rupture	O
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	O
events	O
such	O
as	O
coronary	O
artery	O
disease	O
,	O
cerebrovascular	O
disease	O
and	O
peripheral	O
arterial	O
disease	O
.	O
	
here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	O
of	O
a	O
recombinant	O
single-chain	O
variable	O
fragment	O
scfv	B-C1883036
derived	O
from	O
a	O
human	O
anti-αiibβ3	O
antibody	O
huab	O
selected	O
to	O
target	O
atheromatous	O
lesions	O
for	O
the	O
presence	O
of	O
platelets	O
.	O
	
indeed	O
,	O
platelets	O
within	O
atheroma	O
plaques	O
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	O
,	O
in	O
platelet	O
-	O
leucocyte	O
aggregates	O
and	O
in	O
thrombi	O
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	O
of	O
atherosclerotic	O
progression	O
.	O
	
the	O
dna	O
sequence	O
that	O
encodes	O
the	O
anti-αiibβ3	O
teg4	O
scfv	O
previously	O
obtained	O
from	O
a	O
phage-display	O
selection	O
on	O
activated	O
platelets	O
,	O
was	O
inserted	O
into	O
the	O
eukaryote	O
vector	O
ppiczαa	O
in	O
fusion	O
with	O
a	O
tag	O
sequence	O
encoding	O
2	O
cysteines	O
useable	O
for	O
specific	O
probes	O
grafting	O
experiments	O
.	O
	
the	O
recombinant	O
protein	O
was	O
expressed	O
at	O
high	O
yields	O
in	O
pichia	B-C0997362
pastoris	I-C0997362
30	O
mg/l	O
culture	O
.	O
	
the	O
advantage	O
of	O
p	O
.	O
	
pastoris	O
as	O
an	O
expression	O
system	O
is	O
the	O
production	O
and	O
secretion	O
of	O
recombinant	O
proteins	O
in	O
the	O
supernatant	O
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scfv	O
are	O
produced	O
in	O
the	O
cytoplasm	O
of	O
bacteria	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	O
.	O
	
the	O
improved	O
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	O
active	O
scfv	O
fragments	O
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	O
-directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	O
of	O
atherosclerotic	O
plaques	O
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	O
risk	O
of	O
instability	B-C1444783
identification	B-C0205396
of	O
mir-21-5p	B-C1101610
as	O
a	O
functional	B-C0017362
regulator	I-C0017362
of	O
mesothelin	B-C1334533
expression	B-C0017262
using	O
microrna	B-C1101610
capture	O
affinity	B-C1510827
coupled	B-C1948027
with	O
next	B-C2936622
generation	I-C2936622
sequencing	I-C2936622
micrornas	B-C1101610
mirnas	B-C1101610
are	O
small	B-C0887909
non-coding	I-C0887909
rnas	I-C0887909
that	O
regulate	B-C0017263
mrna	B-C1515670
expression	I-C1515670
mainly	O
by	O
silencing	B-C0598496
target	B-C1521840
transcripts	B-C1519595
via	O
binding	B-C1167622
to	O
mirna	B-C0314659
recognition	I-C0314659
elements	I-C0314659
mres	I-C0314659
in	O
the	O
3'untranslated	B-C0600600
region	I-C0600600
3'utr	B-C0600600
.	O
	
the	O
identification	B-C0205396
of	O
bona	B-C2323869
fide	I-C2323869
targets	B-C1521840
is	O
challenging	O
for	O
researchers	B-C0243095
working	I-C0243095
on	O
the	O
functional	B-C0205245
aspect	I-C0205245
of	O
mirnas	B-C1101610
.	O
	
recently	O
,	O
we	O
developed	O
a	O
method	B-C0449851
mir-catch	I-C0449851
based	O
on	O
biotinylated	B-C1159274
dna	B-C0012854
antisense	B-C0079925
oligonucleotides	I-C0079925
that	O
capture	O
the	O
mrna	B-C0035696
of	O
interest	O
and	O
facilitates	O
the	O
characterisation	O
of	O
mirnas	B-C1523523
interactions	I-C1523523
in	O
a	O
physiological	B-C1325880
cellular	I-C1325880
context	O
.	O
	
here	O
,	O
the	O
mir-catch	B-C0449851
technique	I-C0449851
was	O
applied	O
to	O
the	O
mesothelin	B-C1334533
msln	I-C1334533
gene	I-C1334533
and	O
coupled	B-C1948027
with	O
next	B-C2936622
generation	I-C2936622
sequencing	I-C2936622
ngs	B-C2936622
,	O
to	O
identify	O
mirnas	B-C1101610
that	O
regulate	B-C0017263
msln	B-C1334533
mrna	I-C1334533
and	O
that	O
may	O
be	O
responsible	O
for	O
its	O
increased	O
protein	B-C0428479
levels	I-C0428479
found	O
in	O
malignant	B-C0812413
pleural	I-C0812413
mesothelioma	I-C0812413
mpm	B-C0812413
.	O
	
biotinylated	B-C1159274
msln	B-C1334533
oligos	I-C1334533
were	O
employed	O
to	O
isolate	O
mirna	B-C1099355
mrna	I-C1099355
complexes	I-C1099355
from	O
a	O
normal	O
cell	B-C0007600
line	I-C0007600
met-5a	I-C0007600
which	O
expresses	B-C1171362
low	O
levels	O
of	O
msln	B-C0380162
.	O
	
mirnas	B-C1101610
targeting	B-C1521840
the	O
msln	B-C1334533
mrna	I-C1334533
were	O
identified	O
by	O
ngs	B-C2936622
and	O
mir-21-5p	B-C1101610
and	O
mir-100-5p	B-C1101610
were	O
selected	O
for	O
further	O
validation	B-C0936012
analyses	I-C0936012
.	O
	
mir-21-5p	B-C1101610
was	O
shown	O
to	O
be	O
able	O
to	O
modulate	B-C0443264
msln	B-C1334533
expression	B-C0017262
in	O
mirna	B-C1101610
mimic	B-C0393040
experiments	B-C0681814
in	O
a	O
panel	O
of	O
malignant	B-C0334227
and	O
non-malignant	O
cell	B-C0007600
lines	I-C0007600
.	O
	
further	O
mirna	B-C1101610
inhibitor	B-C1999216
experiments	B-C0681814
and	O
luciferase	B-C0024075
assays	B-C0005507
in	O
mero-14	B-C0007634
cells	I-C0007634
validated	O
mir-21-5p	B-C1101610
as	O
a	O
true	O
regulator	B-C0017362
of	O
msln	B-C1334533
.	O
	
moreover	O
,	O
in	B-C0681828
vitro	I-C0681828
experiments	I-C0681828
showed	O
that	O
treatment	B-C0087111
with	O
mir-21-5p	B-C1101610
mimic	B-C0393040
reduced	O
proliferation	B-C1514485
of	O
mpm	B-C0812413
cell	B-C0007600
lines	I-C0007600
.	O
	
altogether	O
,	O
this	O
work	O
shows	O
that	O
the	O
mir-catch	B-C0449851
technique	I-C0449851
,	O
coupled	B-C1948027
with	O
ngs	B-C2936622
and	O
in	B-C1533691
vitro	I-C1533691
validation	B-C1519941
,	O
represents	O
a	O
reliable	O
method	B-C0449851
to	O
identify	O
native	O
mirna	B-C1523523
interactions	I-C1523523
.	O
	
mir-21-5p	B-C1101610
is	O
suggested	O
as	O
novel	O
regulator	B-C0017362
of	O
msln	B-C1334533
with	O
a	O
possible	O
functional	B-C0205245
role	I-C0205245
in	O
cellular	B-C0007595
growth	I-C0007595
.	O
	
zoonotic	B-C1628327
and	O
non-zoonotic	B-C0243095
parasites	B-C0030498
of	O
wild	B-C0445392
rodents	B-C0035804
in	O
turkman	B-C0022065
sahra	I-C0022065
,	O
northeastern	I-C0022065
iran	I-C0022065
this	O
study	B-C2603343
was	O
conducted	O
to	O
collect	B-C0010995
informative	I-C0010995
data	I-C0010995
on	O
the	O
parasitic	B-C0747256
infection	I-C0747256
of	O
wild	B-C0445392
rodents	B-C0035804
,	O
emphasizing	O
on	O
finding	B-C0243095
parasites	B-C0030498
,	O
which	O
have	O
medical	B-C0205476
importance	B-C3898777
to	O
human	B-C0086418
.	O
	
during	O
2012-2014	O
,	O
a	O
total	B-C4288115
number	I-C4288115
of	O
91	O
wild	B-C0445392
rodents	B-C0035804
were	O
captured	B-C0205245
from	O
rural	B-C0178837
areas	I-C0178837
of	O
turkmen	B-C0022065
sahra	I-C0022065
,	O
golestan	I-C0022065
province	I-C0022065
,	O
using	O
handmade	B-C0699733
traps	I-C0699733
.	O
	
animals	B-C0003062
were	O
anesthetized	B-C1720436
,	O
surveyed	B-C0038951
for	O
any	O
ectoparasite	B-C0562634
and	O
then	O
their	O
carcasses	B-C0229961
were	O
carefully	O
dissected	B-C0205239
for	O
examination	B-C0332128
of	O
endoparsites	B-C0320225
.	O
	
four	O
species	B-C1705920
of	O
rodents	B-C0035804
including	B-C0332257
mus	B-C0025914
musculus	I-C0025914
52.75	O
,	O
rattus	B-C0034693
norvegicus	I-C0034693
38.46	O
,	O
rhombomys	B-C1646173
opimus	I-C1646173
4.40	O
and	O
meriones	B-C1681293
libycus	I-C1681293
4.40	O
were	O
captured	B-C0205245
.	O
	
parasitic	B-C1384353
infestation	I-C1384353
was	O
detected	B-C0442726
in	O
38.5	O
of	O
sampled	B-C0870078
rodents	B-C0035804
.	O
	
parasite	B-C1384353
infestation	I-C1384353
rates	B-C1521828
of	O
sampled	B-C0870078
rodents	B-C0035804
was	O
hymenolepis	B-C0322197
diminuta	I-C0322197
=	O
7.7	O
,	O
cryptosporidium	B-C1744526
spp	I-C1744526
=	O
6.6	O
,	O
trichuris	B-C0684063
spp	I-C0684063
=	O
5.5	O
,	O
cysticercus	B-C0322189
fasciolaris	I-C0322189
=	O
2.20	O
,	O
angiostrongylus	B-C1641848
spp	I-C1641848
=	O
2.20	O
,	O
capillaria	B-C0006896
sp	I-C0006896
=	O
1.09	O
,	O
rhipicephalus	B-C0323464
spp	I-C0323464
.	O
	
=	O
8.70	O
,	O
nosopsyllus	B-C0323233
fasciatus	I-C0323233
=	O
1.09	O
,	O
and	O
laelaps	B-C3012304
nuttalli	I-C3012304
=	O
3.29	O
.	O
	
among	O
10	O
genera	B-C1708235
/	O
species	B-C1705920
of	O
identified	B-C0205396
parasites	B-C0030498
,	O
at	O
least	O
8	O
of	O
them	O
were	O
zoonotic	B-C1628327
with	O
public	B-C3244304
health	I-C3244304
importance	B-C3898777
.	O
	
l	B-C3012304
.	O
	
nuttalli	I-C3012304
and	O
n	B-C0323233
.	O
	
fasciatus	I-C0323233
were	O
the	O
only	O
two	O
non-zoonotic	B-C0243095
detected	B-C0442726
parasites	B-C0030498
in	O
this	O
survey	B-C0038951
.	O
	
harboring	B-C0332257
a	O
wide	B-C0332464
variety	O
of	O
zoonotic	B-C1628327
parasites	B-C0030498
in	O
sampled	B-C0870078
wild	B-C0445392
rodents	B-C0035804
particularly	B-C0205369
when	O
they	O
live	O
nearby	B-C1706276
villages	B-C0562518
,	O
represents	O
a	O
potential	B-C3245505
risk	B-C0035647
to	O
native	B-C0079891
inhabitants	I-C0079891
.	O
	
hence	O
,	O
controlling	B-C2587213
rodents	B-C0035804
'	O
population	B-C1257890
in	O
residential	B-C0442506
regions	I-C0442506
and	O
improving	B-C0184511
awareness	B-C0004448
of	O
local	B-C0205276
people	B-C0027361
about	O
the	O
risk	B-C0035647
of	O
disease	B-C0242781
transmission	I-C0242781
through	O
rodents	B-C0035804
seems	O
to	O
be	O
entirely	O
creative	O
approach	O
for	O
successful	B-C1272703
aging	B-C0001811
a	O
pilot	B-C0031928
study	I-C0031928
of	O
an	O
intergenerational	B-C0598500
health	B-C0043113
promotion	I-C0043113
program	I-C0043113
to	O
develop	O
and	O
evaluate	B-C0220825
the	O
effectiveness	B-C1280519
of	O
an	O
intergenerational	B-C0598500
health	B-C0043113
promotion	I-C0043113
program	I-C0043113
.	O
	
this	O
was	O
an	O
action	O
research	B-C0700032
project	I-C0700032
.	O
	
a	O
total	B-C0439810
of	O
34	O
participants	B-C0679646
attended	O
the	O
12-	O
week	B-C0439230
program	B-C0043113
and	O
completed	B-C0205197
the	O
pre-test	B-C0032919
and	I-C0032919
post-test	I-C0032919
.	O
	
there	O
were	O
16	O
middle-aged	B-C0205847
and	O
nine	O
older	B-C0001792
adults	I-C0001792
recruited	B-C2949735
from	O
a	O
district	O
of	O
taipei	B-C0017446
,	O
and	O
nine	O
young	B-C0238598
adults	I-C0238598
recruited	B-C2949735
from	O
the	O
principal	B-C1521895
investigator's	I-C1521895
university	B-C0041740
.	O
	
the	O
""""	O
attitudes	B-C0282574
toward	I-C0282574
aging	I-C0282574
scale	I-C0282574
""""	O
and	O
the	O
""""	O
spiritual	B-C0282574
health	I-C0282574
scale	I-C0282574
""""	O
were	O
two	O
assessment	B-C0220825
instruments	B-C0282574
used	O
in	O
the	O
study	B-C2603343
.	O
	
the	O
results	B-C0683954
showed	O
that	O
there	O
were	O
significant	B-C0750502
improvements	B-C2986411
in	O
the	O
attitudes	B-C0282574
toward	I-C0282574
aging	I-C0282574
scale	I-C0282574
for	O
the	O
young	B-C0238598
adult	I-C0238598
group	B-C0441833
aged	O
18-29	O
years	B-C1510829
and	O
in	O
the	O
spiritual	B-C0282574
health	I-C0282574
scale	I-C0282574
for	O
the	O
older	B-C0001792
adult	I-C0001792
group	B-C0441833
aged	B-C0001779
65-80	O
years	B-C1510829
.	O
	
the	O
evaluation	B-C0220825
showed	O
that	O
participants	B-C0679646
were	O
satisfied	B-C0242428
with	O
the	O
program	B-C0043113
.	O
	
the	O
results	B-C0683954
of	O
the	O
present	O
study	O
provide	O
future	O
directions	O
for	O
successful	B-C1272703
aging	B-C0001811
and	O
intergenerational	B-C0598500
learning	B-C0013621
.	O
	
signs	B-C0037088
of	O
dysarthria	B-C0013362
in	O
adults	B-C0001675
with	O
22q11.2	B-C0012236
deletion	I-C0012236
syndrome	I-C0012236
the	O
aim	O
of	O
the	O
study	B-C2603343
was	O
to	O
investigate	O
how	O
adults	B-C0001675
with	O
22q11.2	B-C0012236
deletion	I-C0012236
syndrome	I-C0012236
22q11ds	B-C0012236
performed	O
on	O
dysarthria	B-C0013362
and	O
intelligibility	B-C0589416
tests	B-C0683443
compared	B-C1707455
with	O
a	O
control	B-C0009932
group	I-C0009932
.	O
	
ten	O
participants	B-C0679646
with	O
confirmed	O
22q11.2	B-C2910370
deletion	I-C2910370
,	O
five	O
males	B-C0086582
and	O
five	O
females	B-C0086287
with	O
a	O
mean	O
age	B-C0001779
of	O
31	O
years	B-C0439234
range	O
19-49	O
,	O
were	O
compared	B-C1707455
with	O
a	O
control	B-C0009932
group	I-C0009932
matched	O
for	O
gender	B-C0079399
and	O
age	B-C0001779
five	O
males	B-C0086582
and	O
five	O
females	B-C0086287
,	O
mean	O
age	B-C0001779
32	O
years	B-C0439234
,	O
range	O
19-49	O
.	O
	
assessment	B-C1516048
of	O
non-verbal	B-C0430022
and	I-C0430022
verbal	I-C0430022
tasks	I-C0430022
reflecting	O
respiration	B-C0035203
,	O
phonation	B-C0031577
,	O
oral	B-C0563145
motor	I-C0563145
function	I-C0563145
,	O
velopharyngeal	B-C4027435
function	I-C4027435
,	O
articulation	B-C0234830
,	O
and	O
prosody	B-C0233743
was	O
performed	O
as	O
well	O
as	O
the	O
swedish	B-C0451496
test	I-C0451496
of	I-C0451496
intelligibility	I-C0451496
sti	B-C0451496
.	O
	
all	O
assessments	B-C1516048
were	O
made	O
by	O
two	O
raters	O
inter-rater	B-C0870740
and	O
intra-rater	B-C0392762
reliability	I-C0392762
was	O
acceptable	O
.	O
	
the	O
participants	B-C0679646
with	O
22q11ds	B-C0012236
had	O
significantly	O
more	O
problems	B-C0033213
than	O
the	O
control	B-C0009932
group	I-C0009932
on	O
all	O
investigated	O
dimensions	O
except	O
the	O
sti	B-C0451496
.	O
	
overall	O
,	O
the	O
severity	O
of	O
their	O
speech	B-C0243095
deviation	I-C0243095
was	O
rated	B-C0871208
as	O
mild	O
to	O
moderate	O
.	O
	
the	O
largest	O
difficulties	O
were	O
found	O
regarding	O
speech	B-C0037817
respiration	B-C0035203
,	O
phonation	B-C0031577
,	O
oral	B-C0563145
motor	I-C0563145
function	I-C0563145
,	O
and	O
velopharyngeal	B-C4027435
function	I-C4027435
.	O
	
the	O
results	O
of	O
the	O
present	O
study	B-C2603343
suggest	O
that	O
a	O
neurological	B-C1314792
etiology	I-C1314792
could	O
be	O
added	O
to	O
the	O
previously	O
described	O
structural	B-C1314792
etiology	I-C1314792
explaining	O
the	O
speech	B-C0233715
difficulties	I-C0233715
found	O
in	O
22q11ds	B-C0012236
.	O
	
signs	B-C0037088
of	O
difficulties	O
in	O
both	O
speech	B-C0025361
motor	I-C0025361
planning	I-C0025361
and	O
speech	B-C0025361
motor	I-C0025361
programming	I-C0025361
were	O
found	O
.	O
	
further	O
studies	B-C2603343
are	O
needed	O
to	O
confirm	O
the	O
results	B-C1274040
,	O
as	O
are	O
studies	B-C2603343
of	O
the	O
association	O
between	O
structural	B-C1866933
brain	I-C1866933
abnormalities	I-C1866933
and	O
neurological	B-C1457887
speech	I-C1457887
symptoms	I-C1457887
.	O
	
for	O
clinical	B-C1285529
purposes	I-C1285529
,	O
it	O
is	O
important	O
that	O
clinicians	B-C0871685
have	O
knowledge	O
about	O
the	O
variable	O
speech	B-C0478143
symptoms	I-C0478143
that	O
may	O
occur	O
in	O
individuals	B-C0237401
with	O
22q11ds	B-C0012236
and	O
that	O
they	O
be	O
aware	O
of	O
the	O
complexity	O
of	O
the	O
etiology	B-C1314792
of	O
such	O
speech	B-C0478143
symptoms	I-C0478143
.	O
	
sulfur	B-C0038774
and	O
zinc	B-C0043481
availability	B-C0470187
from	O
co-granulated	B-C3853628
zn	B-C0043481
-enriched	O
elemental	B-C0038774
sulfur	I-C0038774
fertilizers	B-C0015919
acidification	B-C2987513
by	O
oxidation	B-C0030011
of	O
elemental	B-C0038774
sulfur	I-C0038774
es	B-C0038774
can	O
solubilize	O
zno	B-C0043491
,	O
providing	O
slow	B-C0439834
release	B-C1283071
of	O
both	O
sulfur	B-C0038774
s	B-C0038774
and	O
zinc	B-C0043481
zn	B-C0043481
in	O
soil	O
.	O
	
for	O
this	O
study	O
,	O
a	O
new	O
granular	B-C3853628
fertilizer	B-C0015919
with	O
es	B-C0038774
and	O
zno	B-C0043491
was	O
produced	O
and	O
evaluated	B-C1516048
.	O
	
the	O
effect	B-C1280500
of	O
incorporating	O
microorganisms	B-C0445623
or	O
a	O
carbon	B-C0007009
source	B-C0449416
in	O
the	O
granule	B-C3853628
was	O
also	O
evaluated	B-C1516048
.	O
	
four	O
granulated	B-C3853628
es-zn	B-C1289929
fertilizers	I-C1289929
with	O
and	O
without	B-C0332288
s-oxidizing	B-C0445623
microorganisms	I-C0445623
,	O
a	O
commercial	O
es	O
pastille	O
,	O
znso4	B-C0078794
,	O
and	O
zno	B-C0043491
were	O
applied	O
to	O
the	O
center	B-C0205099
of	O
petri	B-C1322960
dishes	I-C1322960
containing	O
two	O
contrasting	B-C1979874
ph	B-C0020283
soils	B-C0037592
.	O
	
soil	B-C0037592
ph	B-C0020283
,	O
cacl2	B-C0006686
-extractable	O
s	B-C0038774
and	O
zn	B-C0043481
,	O
and	O
remaining	O
es	B-C0038774
were	O
evaluated	B-C1516048
at	O
30	O
and	O
60	O
days	O
in	O
two	O
soil	B-C0037592
sections	I-C0037592
0-5	O
and	O
5-9	O
mm	O
from	O
the	O
fertilizer	B-C0015919
application	B-C0205145
site	I-C0205145
.	O
	
a	O
visualization	B-C0022885
test	I-C0022885
was	O
performed	O
to	O
evaluate	O
zn	B-C0043481
diffusion	B-C0012222
over	O
time	O
.	O
	
a	O
significant	B-C0750502
ph	B-C0728725
decrease	I-C0728725
was	O
observed	B-C1441672
in	O
the	O
acidic	B-C0001128
soil	B-C0037592
for	O
all	O
es-zn	B-C1289929
fertilizer	I-C1289929
treatments	B-C1522326
and	O
in	O
the	O
alkaline	B-C1979842
soil	B-C0037592
for	O
the	O
acidithiobacillus	B-C0039878
thiooxidans	I-C0039878
-	O
inoculated	B-C0427946
treatment	I-C0427946
only	O
.	O
	
in	O
agreement	O
with	O
zn	B-C0043481
visualization	B-C0022885
tests	I-C0022885
,	O
extractable-	O
zn	B-C0043481
concentrations	B-C1446561
were	O
higher	B-C0205250
from	O
the	O
point	O
of	O
application	O
in	O
the	O
acidic	B-C0001128
62.9	O
mg	O
dm	O
compared	O
to	O
the	O
alkaline	B-C1979842
soil	B-C0037592
5.5	O
mg	O
dm	O
.	O
	
elemental	B-C1159425
s	I-C1159425
oxidation	I-C1159425
was	O
greater	B-C1704243
in	O
the	O
acidic	B-C0001128
soil	B-C0037592
20.9	O
than	O
slightly	O
alkaline	B-C1979842
soil	B-C0037592
12%	O
.	O
	
the	O
es-zn	B-C1289929
granular	I-C1289929
fertilizers	I-C1289929
increased	B-C0205217
s	B-C0038774
and	O
zn	B-C0043481
concentrations	B-C1446561
in	O
soil	B-C0037592
and	O
can	O
provide	O
a	O
strategically	O
slow	B-C0439834
release	B-C1283071
of	O
nutrients	B-C0678695
to	O
the	O
impact	B-C4049986
of	O
blood	B-C0005841
transfusions	I-C0005841
on	O
survival	B-C0038952
of	O
locally	B-C1517927
advanced	B-C0205179
cervical	B-C4048328
cancer	I-C4048328
patients	B-C0030705
undergoing	O
neoadjuvant	B-C4272610
chemotherapy	I-C4272610
plus	O
radical	B-C0543467
surgery	I-C0543467
transfusions	B-C0005841
represent	O
one	O
of	O
the	O
main	O
progresses	B-C1272688
of	O
modern	B-C0242324
medicine	I-C0242324
.	O
	
however	O
,	O
accumulating	O
evidence	B-C3887511
supports	O
that	O
transfusions	B-C0005841
correlate	O
with	O
worse	O
survival	B-C0038952
outcomes	B-C0085415
in	O
patients	B-C0030705
affected	B-C0392760
by	O
solid	B-C0006826
cancers	I-C0006826
.	O
	
in	O
the	O
present	O
study	B-C0008972
,	O
we	O
aimed	B-C1947946
to	O
investigate	B-C1292732
the	O
effects	O
of	O
perioperative	B-C1518988
blood	B-C0005841
transfusion	I-C0005841
in	O
locally	B-C1517927
advanced	B-C0205179
cervical	B-C4048328
cancer	I-C4048328
.	O
	
data	O
of	O
consecutive	O
patients	B-C0030705
affected	B-C0392760
by	O
locally	B-C1517927
advanced	B-C0205179
cervical	B-C4048328
cancer	I-C4048328
scheduled	O
to	O
undergo	O
neoadjuvant	B-C4272610
chemotherapy	I-C4272610
plus	O
radical	B-C0543467
surgery	I-C0543467
were	O
retrospectively	B-C0035363
searched	B-C1706202
to	O
test	B-C0039593
the	O
impact	B-C4049986
of	O
perioperative	B-C1518988
transfusions	B-C0005841
on	O
survival	B-C0038952
outcomes	B-C0085415
.	O
	
five-	O
year	B-C0439234
survival	B-C0038952
outcomes	B-C0085415
were	O
evaluated	O
using	O
kaplan-meier	B-C2827659
and	O
cox	B-C0010234
models	I-C0010234
.	O
	
the	O
study	B-C0008972
included	O
275	O
patients	B-C0030705
.	O
	
overall	O
,	O
170	O
62%	O
patients	B-C0030705
had	O
blood	B-C0005841
transfusion	I-C0005841
.	O
	
via	O
univariate	B-C0683962
analysis	I-C0683962
,	O
we	O
observed	B-C1441672
that	O
transfusion	B-C0005841
correlated	O
with	O
an	O
increased	O
risk	B-C0035647
of	O
developing	B-C0332253
recurrence	B-C1458156
hazard	B-C2985465
ratio	I-C2985465
hr	B-C2985465
,	O
2.2	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
,	O
1.09	O
p	B-C0033204
=	O
0.02	O
.	O
	
other	O
factors	O
associated	O
with	O
5-	O
year	B-C0439234
disease-free	B-C0242793
survival	I-C0242793
were	O
noncomplete	B-C3272974
clinical	B-C4055223
response	I-C4055223
after	O
neoadjuvant	B-C4272610
chemotherapy	I-C4272610
hr	B-C2985465
,	O
2.99	O
95%	O
ci	B-C0009667
,	O
0.92	O
p	B-C0033204
=	O
0.06	O
and	O
pathological	B-C4050242
p	B-C0033204
=	O
0.03	O
response	B-C4050242
at	O
neoadjuvant	B-C4272610
chemotherapy	I-C4272610
as	O
well	O
as	O
parametrial	B-C1518890
p	B-C0033204
=	O
0.004	O
,	O
vaginal	B-C0042232
p	B-C0033204
<	O
0.001	O
,	O
and	O
lymph	B-C0024204
node	I-C0024204
p	B-C0033204
=	O
0.002	O
involvements	O
.	O
	
however	O
,	O
via	O
multivariate	B-C0026777
analysis	I-C0026777
,	O
only	O
vaginal	B-C0042232
hr	B-C2985465
,	O
3.07	O
95%	O
ci	B-C0009667
,	O
1.20	O
p	B-C0033204
=	O
0.01	O
and	O
lymph	B-C0024204
node	I-C0024204
involvements	O
hr	B-C2985465
,	O
2.4	O
95%	O
ci	B-C0009667
,	O
1.00	O
p	B-C0033204
=	O
0.05	O
correlate	O
with	O
worse	O
disease-free	O
survival	O
.	O
	
no	O
association	O
with	O
worse	O
outcomes	O
was	O
observed	O
for	O
patients	O
undergoing	O
blood	O
transfusion	O
hr	O
,	O
2.71	O
95%	O
ci	O
,	O
0.91	O
p	B-C0033204
=	O
0.07	O
.	O
	
looking	O
at	O
factors	O
influencing	O
overall	O
survival	O
,	O
we	O
observed	O
that	O
lymph	O
node	O
status	O
p	O
=	O
0.01	O
and	O
vaginal	O
involvement	O
p	O
=	O
0.06	O
were	O
independently	O
associated	O
with	O
survival	O
.	O
	
the	O
role	O
of	O
blood	O
transfusions	O
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	O
in	O
laac	O
patients	O
treated	O
by	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	O
surgery	O
remains	O
unclear	O
further	O
prospective	O
studies	O
are	O
tissue	B-C0040300
reservoirs	O
of	O
antiviral	B-C0243095
t	B-C1817907
cell	I-C1817907
immunity	I-C1817907
in	O
persistent	O
human	B-C0086418
cmv	B-C0010823
infection	I-C0010823
t	B-C0039194
cell	I-C0039194
responses	B-C0301872
to	O
viruses	B-C0042776
are	O
initiated	O
and	O
maintained	O
in	O
tissue	B-C0040300
sites	O
however	O
,	O
knowledge	O
of	O
human	B-C0086418
antiviral	B-C0243095
t	B-C0039194
cells	I-C0039194
is	O
largely	O
derived	O
from	O
blood	B-C0005767
.	O
	
cytomegalovirus	B-C0010825
cmv	B-C0010825
persists	O
in	O
most	O
humans	B-C0086418
,	O
requires	O
t	B-C1817907
cell	I-C1817907
immunity	I-C1817907
to	O
control	O
,	O
yet	O
tissue	B-C0040300
immune	B-C0301872
responses	I-C0301872
remain	O
undefined	O
.	O
	
here	O
,	O
we	O
investigated	O
human	B-C0086418
cmv	B-C0010825
-specific	O
t	O
cells	O
,	O
virus	O
persistence	O
and	O
cmv	B-C0010825
-associated	O
t	B-C0039194
cell	O
homeostasis	O
in	O
blood	O
,	O
lymphoid	O
,	O
mucosa	O
l	O
and	O
secretory	O
tissues	O
of	O
44	O
cmv	O
seropositive	O
and	O
28	O
seronegative	O
donors	O
.	O
	
cmv	O
-specific	O
t	O
cells	I-C0039194
were	O
maintained	O
in	O
distinct	O
distribution	O
patterns	O
,	O
highest	O
in	O
blood	O
,	O
bone	O
marrow	O
bm	O
,	O
or	O
lymph	O
nodes	O
ln	O
,	O
with	O
the	O
frequency	O
and	O
function	O
in	O
blood	O
distinct	O
from	O
tissues	O
.	O
	
cmv	O
genomes	O
were	O
detected	O
predominantly	O
in	O
lung	O
and	O
also	O
in	O
spleen	O
,	O
bm	O
,	O
blood	O
and	O
ln	O
.	O
	
high	O
frequencies	O
of	O
activated	O
cmv	O
-specific	O
t	O
cells	O
were	O
found	O
in	O
blood	O
and	O
bm	O
samples	O
with	O
low	O
virus	B-C0042776
detection	O
,	O
whereas	O
in	O
lung	O
,	O
cmv	O
-specific	O
t	O
cells	O
were	O
present	O
along	O
with	O
detectable	O
virus	O
.	O
	
in	O
lns	O
,	O
cmv	O
-specific	O
t	O
cells	O
exhibited	O
quiescent	O
phenotypes	O
independent	O
of	O
virus	O
.	O
	
overall	O
,	O
t	O
cell	O
differentiation	O
was	O
enhanced	O
in	O
sites	O
of	O
viral	O
persistence	B-C1547035
with	O
age	O
.	O
	
together	O
,	O
our	O
results	O
suggest	O
tissue	O
t	O
cell	O
reservoirs	O
for	O
cmv	B-C0010825
control	O
shaped	O
by	O
both	O
viral	O
and	O
tissue	O
-	O
intrinsic	O
factors	O
,	O
with	O
global	O
effects	O
on	O
homeostasis	O
of	O
tissue	O
t	B-C0039194
cells	O
over	O
the	O
lifespan	B-C0870809
lipid	B-C0523744
levels	I-C0523744
and	O
risk	B-C0035647
of	O
recurrent	B-C1735901
venous	I-C1735901
thrombosis	I-C1735901
results	B-C1274040
from	O
the	O
mega	B-C0016441
follow-up	I-C0016441
study	I-C0016441
essentials	O
the	O
role	O
of	O
lipid	B-C0523744
levels	I-C0523744
in	O
the	O
risk	B-C0035647
of	O
recurrent	B-C1735901
venous	I-C1735901
thrombosis	I-C1735901
is	O
unclear	B-C3845108
.	O
	
lipids	B-C0023779
were	O
assessed	B-C1516048
in	O
patients	B-C0030705
with	O
a	O
first	O
venous	B-C0042487
thrombosis	I-C0042487
n	O
=	O
2106	O
followed	B-C0332283
for	O
6.9	O
years	B-C0439234
.	O
	
lipids	B-C0023779
were	O
not	O
associated	B-C0332281
with	I-C0332281
recurrence	B-C0034897
,	O
overall	O
or	O
in	O
patients	B-C0030705
with	O
unprovoked	O
first	O
events	B-C0441471
.	O
	
testing	B-C0523744
lipid	I-C0523744
levels	I-C0523744
is	O
not	O
useful	B-C3827682
to	O
identify	B-C0205396
patients	B-C0030705
at	O
an	O
increased	B-C0205217
risk	B-C0035647
of	O
recurrence	B-C0034897
.	O
	
background	O
knowledge	O
of	O
risk	B-C0035648
factors	I-C0035648
for	O
recurrent	B-C1735901
venous	I-C1735901
thrombosis	I-C1735901
may	O
guide	O
decisions	O
on	O
duration	B-C0449238
of	O
anticoagulation	B-C0003281
.	O
	
the	O
association	B-C0439849
between	O
lipid	B-C0523744
levels	I-C0523744
and	O
first	O
venous	B-C0042487
thrombosis	I-C0042487
has	O
been	O
studied	O
extensively	O
.	O
	
however	O
,	O
data	B-C1511726
on	O
the	O
role	O
of	O
lipids	B-C0023779
in	O
the	O
risk	B-C0035647
of	O
recurrence	B-C0034897
are	O
scarce	O
.	O
	
objective	O
to	O
assess	B-C1516048
the	O
association	B-C0439849
between	O
lipid	B-C0523744
levels	I-C0523744
and	O
recurrent	B-C1735901
venous	I-C1735901
thrombosis	I-C1735901
.	O
	
patients	B-C0030705
/methods	O
patients	B-C0030705
with	O
a	O
first	O
venous	B-C0042487
thrombosis	I-C0042487
from	O
the	O
mega	B-C0016441
study	I-C0016441
were	O
included	B-C0332257
.	O
	
follow-up	B-C1522577
started	B-C1272689
at	O
the	O
date	B-C0011008
of	O
end	B-C0444930
of	O
anticoagulant	B-C0150457
treatment	I-C0150457
.	O
	
percentile	B-C1264641
categories	B-C0683312
of	O
total	B-C0543421
/	O
low-density	B-C0023824
lipoprotein	I-C0023824
/	O
high-density	B-C0023822
lipoprotein	I-C0023822
cholesterol	I-C0023822
,	O
triglycerides	B-C0041004
and	O
apolipoproteins	B-C0003593
b	I-C0003593
and	O
a1	B-C0085201
were	O
established	B-C0443211
<	O
10th	O
,	O
10th-25th	O
,	O
25th-75th	O
reference	B-C0034925
,	O
75th-90th	O
,	O
>	O
90th	O
percentile	B-C1264641
.	O
	
lipids	B-C0023779
were	O
measured	B-C0444706
at	O
least	O
3	O
months	B-C0439231
after	O
discontinuing	B-C1444662
anticoagulation	B-C0003281
.	O
	
results	B-C1274040
of	O
2106	O
patients	B-C0030705
followed	O
for	O
a	O
median	O
of	O
6.9	O
years	B-C0439234
,	O
326	O
developed	O
recurrence	B-C0034897
incidence	B-C1708485
rate	I-C1708485
,	O
2.7	O
patient	B-C0030705
-	O
years	B-C0439234
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
,	O
2.5	O
.	O
	
with	O
hazard	B-C2985465
ratios	I-C2985465
ranging	B-C1514721
from	O
0.88	O
95%	O
ci	B-C0009667
,	O
0.55	O
to	O
1.33	O
95%	O
ci	B-C0009667
,	O
0.86	O
in	O
the	O
highest	O
percentile	B-C1264641
category	B-C0683312
vs	O
.	O
	
the	O
reference	B-C0034925
,	O
we	O
found	O
no	O
association	B-C0439849
across	O
percentile	B-C1264641
categories	B-C0683312
between	O
recurrence	B-C0034897
and	O
lipid	B-C0523744
levels	I-C0523744
in	O
age-	B-C0001779
and	O
sex	B-C0079399
-adjusted	O
models	B-C0026339
,	O
nor	O
after	O
further	B-C1517331
adjustments	B-C0456081
for	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
,	O
diabetes	B-C0011847
,	O
estrogen	B-C0014939
and	O
statin	B-C0360714
use	B-C0457083
,	O
and	O
duration	B-C0449238
of	O
anticoagulation	B-C0003281
.	O
	
subgroup	B-C1515021
analyses	B-C0936012
stratified	B-C0205363
by	O
unprovoked	O
or	O
provoked	B-C1444748
first	O
events	B-C0441471
,	O
location	B-C0450429
deep	B-C0149871
vein	I-C0149871
thrombosis	I-C0149871
or	O
pulmonary	B-C0034065
embolism	I-C0034065
and	O
sex	B-C0079399
also	O
did	O
not	O
reveal	B-C0443289
an	O
association	B-C0439849
with	O
any	O
of	O
the	O
lipid	B-C0523744
levels	I-C0523744
studied	O
.	O
	
conclusions	O
testing	B-C0523744
lipid	I-C0523744
levels	I-C0523744
did	O
not	O
identify	B-C0205396
patients	B-C0030705
at	O
an	O
increased	B-C0205217
risk	B-C0035647
of	O
recurrent	B-C1735901
venous	I-C1735901
thrombosis	I-C1735901
in	O
this	O
study	B-C2603343
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	B-C0441471
,	O
and	O
these	O
should	O
not	O
influence	B-C4054723
decisions	O
on	O
duration	B-C0449238
of	O
insecticidal	B-C0596781
effects	I-C0596781
of	O
deltamethrin	B-C0057233
in	O
laboratory	B-C0022877
and	O
field	B-C1521738
populations	B-C0032659
of	O
culicoides	B-C0010446
species	I-C0010446
how	O
effective	O
are	O
host	B-C1167395
-	O
contact	B-C0392367
reduction	B-C0392756
methods	B-C0242481
in	O
india	B-C0021201
bluetongue	B-C0005867
virus	I-C0005867
btv	B-C0005867
is	O
transmitted	B-C0242781
by	O
culicoides	B-C0010446
biting	B-C0007747
midges	I-C0007747
and	O
causes	O
bluetongue	B-C0005866
bt	B-C0005866
,	O
a	O
clinical	B-C0012634
disease	I-C0012634
observed	O
primarily	O
in	O
sheep	B-C0036945
.	O
	
bt	B-C0005866
has	O
a	O
detrimental	B-C0879626
effect	I-C0879626
on	O
subsistence	O
farmers	B-C0221460
in	O
india	B-C0021201
,	O
where	O
hyperendemic	B-C0277550
outbreaks	I-C0277550
impact	O
on	O
smallholdings	O
in	O
the	O
southern	B-C1301808
states	I-C1301808
of	O
the	O
country	B-C0454664
.	O
	
in	O
this	O
study	O
,	O
we	O
establish	O
a	O
reliable	O
method	B-C0242481
for	O
testing	O
the	O
toxic	B-C0600688
effects	I-C0600688
of	O
deltamethrin	B-C0057233
on	O
culicoides	B-C0010446
and	O
then	O
compare	O
deltamethrin	B-C0057233
with	O
traditional	B-C3824729
control	I-C3824729
methods	I-C3824729
used	O
by	O
farmers	B-C0221460
in	O
india	B-C0021201
.	O
	
effects	O
of	O
deltamethrin	B-C0057233
were	O
initially	O
tested	O
using	O
a	O
colonised	B-C0456178
strain	I-C0456178
of	O
culicoides	B-C0322767
nubeculosus	I-C0322767
meigen	I-C0322767
and	O
a	O
modified	O
world	B-C0043237
health	I-C0043237
organisation	I-C0043237
exposure	B-C0005507
assay	I-C0005507
.	O
	
this	O
method	B-C0242481
was	O
then	O
applied	O
to	O
field	B-C1521738
populations	B-C0032659
of	O
culicoides	B-C0010446
spp	I-C0010446
.	O
	
in	O
india	B-C0021201
.	O
	
the	O
field	B-C1521738
population	B-C0032659
of	O
c	B-C0322770
.	O
	
oxystoma	I-C0322770
in	O
india	B-C0021201
had	O
a	O
greater	O
lc50	O
0.012	O
0.009	O
for	O
deltamethrin	B-C0057233
than	O
laboratory-reared	B-C0022885
c.nubeculosus	B-C0322767
0.0013	O
0.0002	O
.	O
	
exposure	O
of	O
c	B-C0322767
.	O
	
nubeculosus	I-C0322767
to	O
deltamethrin	B-C0057233
at	O
higher	O
ambient	B-C0428692
temperatures	I-C0428692
resulted	O
in	O
greater	O
rates	O
of	O
knockdown	O
but	O
a	O
lower	O
mortality	B-C0205848
rate	I-C0205848
at	O
24	O
h	O
post-exposure	O
.	O
	
behavioural	B-C0005507
assays	I-C0005507
with	O
c	B-C0322767
.	O
	
nubeculosus	I-C0322767
in	O
who	B-C0043237
tubes	B-C1561954
provided	O
evidence	O
for	O
contact	O
irritancy	O
and	O
spatial	O
repellence	O
caused	O
by	O
deltamethrin	B-C0057233
.	O
	
the	O
field	B-C1521738
experiments	B-C0681814
in	O
india	B-C0021201
,	O
however	O
,	O
provided	O
no	O
evidence	O
for	O
repellent	B-C0544309
or	O
toxic	B-C0600688
effects	I-C0600688
of	O
deltamethrin	B-C0057233
.	O
	
traditional	B-C0242481
methods	I-C0242481
such	O
as	O
the	O
application	B-C4048755
of	O
neem	B-C0068484
oil	I-C0068484
and	O
burning	B-C1254366
of	O
neem	B-C1060234
leaves	B-C0242724
also	O
provided	O
no	B-C1513916
protection	B-C1545588
.	O
	
our	O
study	O
demonstrates	O
that	O
field	B-C1521738
-collected	O
culicoides	B-C0010446
in	O
india	B-C0021201
are	O
less	O
susceptible	O
to	O
deltamethrin	B-C0057233
exposure	O
than	O
laboratory-bred	B-C0022885
c	B-C0322767
.	O
	
nubeculosus	I-C0322767
and	O
traditional	B-C0242481
methods	I-C0242481
of	O
insect	B-C0021569
control	I-C0021569
do	O
not	O
provide	O
protection	B-C1545588
to	O
sheep	B-C0036945
.	O
	
these	O
low	O
levels	O
of	O
susceptibility	B-C1326888
to	O
deltamethrin	B-C0057233
have	O
not	O
been	O
recorded	O
before	O
in	O
field	B-C1521738
populations	B-C0032659
of	O
culicoides	B-C0010446
and	O
suggest	O
resistance	B-C0021575
to	O
synthetic	B-C1254351
pyrethrioids	I-C1254351
.	O
	
alternative	O
insect	B-C0021569
control	I-C0021569
methods	B-C0242481
,	O
in	O
addition	O
to	O
vaccination	B-C0042196
,	O
may	O
be	O
needed	O
to	O
protect	O
indian	B-C0021201
livestock	B-C2936506
from	O
btv	B-C0005867
transmission	B-C0242781
.	O
	
correlation	B-C1707520
of	O
the	O
lipid	B-C0023779
profile	B-C1979963
,	O
bmi	B-C1305855
and	O
bone	B-C0005938
mineral	I-C0005938
density	I-C0005938
in	O
postmenopausal	B-C0206159
women	B-C0043210
to	O
the	O
reduction	B-C0392756
of	O
bone	B-C0005938
density	I-C0005938
and	O
osteoporosis	B-C0029456
in	O
postmenopausal	B-C0206159
women	B-C0043210
contribute	O
elevated	B-C3163633
lipid	B-C0023779
parameters	B-C0449381
and	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
.	O
	
the	O
goal	O
of	O
our	O
study	B-C2603343
was	O
to	O
determine	O
the	O
correlation	B-C1707520
between	O
lipid	B-C0023779
parameters	B-C0449381
,	O
bmi	B-C1305855
and	O
osteoporosis	B-C0029456
in	O
postmenopausal	B-C0206159
women	B-C0043210
.	O
	
the	O
study	B-C2603343
was	O
carried	O
out	O
by	O
matched	B-C1708943
type	B-C0332307
between	O
experimental	B-C1517586
group	B-C0441833
and	O
controls	B-C0009932
.	O
	
the	O
experimental	B-C1517586
group	B-C0441833
consisted	O
of	O
100	O
females	B-C0043210
at	O
postmenopausal	B-C0206159
age	B-C0001779
,	O
in	O
which	O
by	O
the	O
dexa	B-C1510486
method	I-C1510486
was	O
diagnosed	B-C0011900
osteoporosis	B-C0029456
at	O
the	O
department	O
of	O
endocrinology	O
,	O
diabetes	O
and	O
metabolic	O
diseases	O
,	O
university	B-C0000872
medical	I-C0000872
center	I-C0000872
of	I-C0000872
rs	I-C0000872
during	O
2015-2016	O
,	O
while	O
the	O
control	B-C0009932
group	I-C0009932
consisted	O
of	O
100	O
females	B-C0043210
in	O
a	O
postmenopausal	B-C0206159
age	B-C0001779
but	O
without	O
diagnosed	B-C0011900
osteoporosis	B-C0029456
.	O
	
the	O
groups	B-C0441833
were	O
matched	B-C1708943
by	O
age	B-C0001779
2	O
years	B-C1510829
.	O
	
to	O
all	O
participants	B-C0679646
of	O
the	O
study	B-C2603343
were	O
carried	O
out	O
biochemical	B-C0005774
analysis	I-C0005774
of	I-C0005774
blood	I-C0005774
,	O
or	O
the	O
analysis	B-C0936012
of	O
the	O
lipid	B-C0023779
profile	B-C1979963
that	O
included	O
total	B-C0543421
cholesterol	I-C0543421
,	O
ldl	B-C0023824
cholesterol	I-C0023824
,	O
triglycerides	B-C0041004
tg	B-C0041004
and	O
hdl	B-C0023822
cholesterol	I-C0023822
,	O
and	O
was	O
determined	O
the	O
values	B-C0042295
of	O
bmi	B-C1305855
and	O
waist	B-C0455829
circumference	I-C0455829
wc	B-C0455829
.	O
	
analysis	B-C0936012
of	O
the	O
data	B-C1511726
of	O
our	O
research	B-C0035168
shows	O
that	O
by	O
the	O
univariate	B-C0206031
logistic	I-C0206031
regression	I-C0206031
the	O
values	B-C0042295
of	O
lipid	B-C0023779
parameters	B-C0449381
total	B-C0543421
cholesterol	I-C0543421
p=0	O
,	O
ldl	B-C0023824
p=0	O
and	O
tg	B-C0041004
p=0	O
were	O
significantly	B-C0750502
associated	B-C0332281
with	I-C0332281
osteoporosis	B-C0029456
,	O
while	O
in	O
multivariate	B-C0023965
logistic	I-C0023965
model	I-C0023965
only	O
total	B-C0543421
cholesterol	I-C0543421
p=	O
0.018	O
was	O
found	O
as	O
an	O
independent	B-C0085862
risk	B-C0035648
factor	I-C0035648
for	O
osteoporosis	B-C0029456
in	O
postmenopausal	B-C0206159
women	B-C0043210
.	O
	
bmi	B-C1305855
values	B-C0042295
were	O
not	B-C1513916
statistically	B-C0237881
significantly	I-C0237881
associated	B-C0332281
with	I-C0332281
osteoporosis	B-C0029456
p=0	O
.	O
	
on	O
the	O
decrease	B-C0547047
in	O
bone	B-C0005938
mineral	I-C0005938
density	I-C0005938
and	O
osteoporosis	B-C0029456
in	O
postmenopausal	B-C0206159
women	B-C0043210
influence	O
many	O
risk	B-C0035648
factors	I-C0035648
whose	O
identification	B-C0205396
has	O
the	O
aim	O
to	O
develop	O
more	O
effective	B-C1704419
prevention	B-C2700409
of	O
this	O
disease	B-C0029456
in	O
the	O
heterotopic	B-C0029396
ossification	I-C0029396
after	O
the	O
use	O
of	O
recombinant	B-C1445625
human	I-C1445625
bone	I-C1445625
morphogenetic	I-C1445625
protein-7	I-C1445625
to	O
present	O
the	O
incidence	B-C0021149
of	O
heterotopic	B-C0029396
ossification	I-C0029396
after	O
the	O
use	O
of	O
recombinant	B-C1445625
human	I-C1445625
bone	I-C1445625
morphogenetic	I-C1445625
protein-7	I-C1445625
rhbmp-7	B-C1445625
for	O
the	O
treatment	B-C0087111
of	O
nonunions	B-C3897107
.	O
	
bone	B-C0053932
morphogenetic	I-C0053932
proteins	I-C0053932
bmps	B-C0053932
promote	O
bone	B-C0029433
formation	I-C0029433
by	O
auto-induction	B-C1148560
.	O
	
recombinant	B-C1445625
human	I-C1445625
bmp-7	I-C1445625
in	O
combination	O
with	O
bone	B-C0181075
grafts	I-C0181075
was	O
used	O
in	O
84	O
patients	B-C0030705
for	O
the	O
treatment	B-C0087111
of	O
long	B-C3897107
bone	I-C3897107
nonunions	I-C3897107
.	O
	
all	O
patients	B-C0030705
were	O
evaluated	B-C0220825
radiographicaly	B-C0841672
for	O
the	O
development	B-C1527148
of	O
heterotopic	B-C0029396
ossification	I-C0029396
during	O
the	O
standard	B-C1442989
assessment	B-C0220825
for	O
the	O
nonunion	B-C3897107
healing	B-C0043240
.	O
	
in	O
all	O
patients	B-C0030705
80.9	O
with	O
radiographic	B-C0444708
signs	B-C0037088
of	O
heterotopic	B-C0029396
ossification	I-C0029396
,	O
a	O
ct	B-C0040405
scan	I-C0040405
was	O
performed	O
.	O
	
nonunion	B-C3897107
site	B-C0205145
palpation	B-C0030247
and	O
rom	B-C1562926
evaluation	I-C1562926
of	O
the	O
adjacent	B-C0205117
joints	B-C0022417
were	O
also	O
carried	O
out	O
.	O
	
factors	B-C1521761
related	O
to	O
the	O
patient	B-C0030705
age	B-C0001779
,	O
gender	B-C0079399
,	O
the	O
nonunion	B-C3897107
location	B-C0450429
,	O
size	B-C0456389
,	O
chronicity	B-C0547045
,	O
number	B-C2700391
of	I-C2700391
previous	I-C2700391
procedures	I-C2700391
,	O
infection	B-C3714514
,	O
surrounding	B-C1282914
tissues	B-C0040300
condition	B-C0348080
and	O
the	O
surgical	B-C0543467
procedure	I-C0543467
graft	B-C0181074
and	O
fixation	B-C0185023
type	B-C0332307
,	O
amount	B-C1265611
of	O
rhbmp-7	B-C1445625
were	O
correlated	B-C1707520
with	O
the	O
development	B-C1527148
of	O
heterotopic	B-C0029396
ossification	I-C0029396
and	O
statistical	B-C0871424
analysis	I-C0871424
with	O
pearsons	B-C0237913
χ	I-C0237913
2	I-C0237913
test	I-C0237913
was	O
performed	O
.	O
	
eighty	O
point	O
nine	O
percent	O
of	O
the	O
nonunions	B-C3897107
treated	B-C1522326
with	O
rhbmp-7	B-C1445625
,	O
healed	B-C0205249
with	O
no	O
need	O
for	O
further	O
procedures	B-C2700391
.	O
	
heterotopic	B-C0029396
bone	I-C0029396
formation	I-C0029396
occurred	O
in	O
15	O
of	O
84	O
patients	B-C0030705
17.8	O
and	O
it	O
was	O
apparent	O
in	O
the	O
routine	O
radiological	B-C0220825
evaluation	I-C0220825
of	O
the	O
nonunion	B-C3897107
site	O
,	O
in	O
a	O
mean	B-C0040223
time	I-C0040223
of	O
5.5	O
mo	O
after	O
the	O
rhbmp-7	B-C1445625
application	B-C4048755
range	O
3-12	O
.	O
	
the	O
heterotopic	B-C0029396
ossification	I-C0029396
was	O
located	O
at	O
the	O
femur	B-C0015811
in	O
8	O
cases	B-C1706256
,	O
at	O
the	O
tibia	B-C1279118
in	O
6	O
,	O
and	O
at	O
the	O
humerus	B-C0020164
in	O
οne	O
patient	B-C0030705
.	O
	
in	O
4	O
patients	B-C0030705
a	O
palpable	B-C0746412
mass	I-C0746412
was	O
present	O
and	O
only	O
in	O
one	O
patient	B-C0030705
,	O
with	O
a	O
para-articular	B-C3897107
knee	I-C3897107
nonunion	I-C3897107
treated	B-C1522326
with	O
rhbmp-7	B-C1445625
,	O
the	O
size	B-C0456389
of	O
heterotopic	B-C0029396
ossification	I-C0029396
affected	O
the	O
knee	B-C0576094
range	I-C0576094
of	I-C0576094
motion	I-C0576094
.	O
	
all	O
the	O
patients	B-C0030705
with	O
heterotopic	B-C0029396
ossification	I-C0029396
were	O
male	B-C0086582
.	O
	
statistical	B-C0871424
analysis	I-C0871424
proved	O
that	O
patient's	B-C0030705
gender	B-C0079399
was	O
the	O
only	O
important	O
factor	B-C1521761
for	O
the	O
development	B-C1527148
of	O
heterotopic	B-C0029396
ossification	I-C0029396
p	O
=	O
0.007	O
.	O
	
heterotopic	B-C0029396
ossification	I-C0029396
after	O
the	O
use	O
of	O
rhbmp-7	B-C1445625
in	O
nonunions	B-C3897107
was	O
common	O
but	O
it	O
did	O
not	O
compromise	O
the	O
final	O
clinical	B-C1274040
outcome	I-C1274040
in	O
most	O
cases	B-C1706256
,	O
and	O
affected	O
only	O
male	B-C0086582
patients	B-C0030705
.	O
	
hypocretin/orexin	B-C1113688
peptides	I-C1113688
excite	B-C0549255
rat	B-C0034693
neuroendocrine	B-C0027912
dopamine	B-C1512035
neurons	I-C1512035
through	O
orexin	B-C0671880
2	I-C0671880
receptor	I-C0671880
-mediated	O
activation	B-C1879547
of	O
a	O
mixed	B-C0205430
cation	B-C0007447
current	B-C0162585
hypocretin/orexin	B-C1113688
h/o	B-C1113688
neurons	B-C0027882
of	O
the	O
lateral	B-C0020654
hypothalamus	I-C0020654
are	O
compelling	B-C0815217
modulator	B-C0027361
candidates	I-C0027361
for	O
the	O
chronobiology	B-C0008716
of	O
neuroendocrine	B-C0027912
output	B-C1709366
and	O
,	O
as	O
a	O
consequence	B-C0686907
,	O
hormone	B-C0815016
release	I-C0815016
from	O
the	O
anterior	B-C0032008
pituitary	I-C0032008
.	O
	
here	O
we	O
investigate	O
the	O
effects	B-C1280500
of	O
h/o	B-C1113688
peptides	I-C1113688
upon	O
tuberoinfundibular	B-C1512035
dopamine	I-C1512035
tida	I-C1512035
neurons	I-C1512035
-	O
cells	B-C0007634
which	O
control	B-C0243148
,	O
via	O
inhibition	B-C3463820
,	O
the	O
pituitary	B-C0032005
secretion	B-C2611224
of	I-C2611224
prolactin	I-C2611224
.	O
	
in	O
whole	B-C0242624
cell	I-C0242624
recordings	I-C0242624
performed	B-C0884358
in	O
male	B-C0086582
rat	B-C0034693
hypothalamic	B-C0449445
slices	I-C0449445
,	O
application	O
of	O
h/o-a	B-C0671870
,	O
as	O
well	O
as	O
h/o-b	B-C0671872
,	O
excited	B-C0549255
oscillating	O
tida	B-C1512035
neurons	I-C1512035
,	O
inducing	B-C0205263
a	O
reversible	B-C0205343
depolarising	B-C1395184
switch	O
from	O
phasic	B-C1254362
to	I-C1254362
tonic	I-C1254362
discharge	I-C1254362
.	O
	
the	O
h/o	B-C1113688
-	O
induced	B-C0205263
inward	B-C0439786
current	B-C0162585
underpinning	B-C1521721
this	O
effect	B-C1280500
was	O
post-synaptic	B-C1167384
as	O
it	O
endured	O
in	O
the	O
presence	B-C0150312
of	O
tetrodotoxin	B-C0039705
,	O
appeared	B-C0700364
to	O
be	O
carried	O
by	O
a	O
na	B-C0037492
-	O
dependent	B-C0851827
transient	B-C1563722
receptor	I-C1563722
potential-like	I-C1563722
channel	I-C1563722
as	O
it	O
was	O
blocked	B-C0332206
by	O
2-apb	B-C0669933
and	O
was	O
diminished	B-C0205216
by	O
removal	B-C1883720
of	O
extracellular	B-C0521119
na	B-C0037492
,	O
and	O
was	O
a	O
consequence	B-C0686907
of	I-C0686907
ox2r	B-C0671880
receptor	I-C0671880
activation	B-C1879547
as	O
it	O
was	O
blocked	B-C0332206
by	O
the	O
ox2r	B-C0671880
receptor	I-C0671880
antagonist	B-C0243076
tcs	B-C3492123
ox2	I-C3492123
29	I-C3492123
,	O
but	O
not	O
the	O
ox1r	B-C0597357
receptor	I-C0597357
antagonist	B-C0243076
sb	B-C1097132
334867	I-C1097132
.	O
	
application	B-C0185125
of	O
the	O
hormone	B-C0019932
,	O
melatonin	B-C0025219
,	O
failed	B-C0231175
to	O
alter	B-C0392747
tida	B-C1512035
membrane	B-C0025251
potential	I-C0025251
or	O
oscillatory	B-C0695434
activity	I-C0695434
.	O
	
this	O
first	O
description	B-C0678257
of	O
the	O
electrophysiological	B-C0850293
effects	I-C0850293
of	O
h/os	B-C1113688
upon	O
the	O
tida	B-C1512035
network	I-C1512035
identifies	B-C0205396
cellular	B-C3537153
mechanisms	I-C3537153
that	O
may	O
contribute	B-C1880177
to	O
the	O
circadian	B-C0008810
rhythmicity	I-C0008810
of	O
prolactin	B-C2611224
secretion	I-C2611224
.	O
	
improving	B-C1272745
exchange	O
with	O
consumers	B-C1707496
within	O
mental	B-C0178740
health	I-C0178740
organizations	I-C0178740
recognizing	O
mental	B-C0004936
ill	I-C0004936
health	I-C0004936
experience	O
as	O
a	O
'sneaky	O
,	O
special	O
degree'	O
stigmatizing	B-C0277787
views	O
towards	O
consumers	B-C1707496
may	O
be	O
held	O
even	O
by	O
those	O
working	B-C0043227
within	O
mental	B-C0178740
health	I-C0178740
organizations	I-C0178740
.	O
	
contemporary	O
mental	B-C3244237
health	I-C3244237
policies	I-C3244237
require	O
organizations	B-C0920545
to	O
work	B-C0043227
collaboratively	B-C0282116
with	O
consumers	B-C1707496
in	O
producing	B-C0678227
and	O
delivering	B-C0011211
services	B-C0557854
.	O
	
using	O
social	B-C0683615
exchange	I-C0683615
theory	I-C0683615
,	O
which	O
emphasises	O
mutual	B-C1709100
exchange	B-C0678640
to	O
maximise	B-C0806909
benefits	B-C0814225
in	O
partnership	B-C0680453
,	O
the	O
current	B-C0521116
study	B-C2603343
explores	O
the	O
perspectives	B-C0678958
of	O
those	O
working	B-C0043227
within	O
organizations	B-C0920545
that	O
have	O
some	O
level	B-C0441889
of	O
consumer	B-C1707496
leadership	B-C0023181
.	O
	
interviews	B-C0021822
were	O
conducted	O
with	O
14	O
participants	B-C0679646
from	O
a	O
range	B-C1514721
of	O
mental	B-C0178740
health	I-C0178740
organizations	I-C0178740
.	O
	
data	B-C1511726
were	O
transcribed	O
,	O
and	O
analyzed	B-C0936012
using	O
thematic	B-C0936012
analytic	I-C0936012
and	O
discursive	B-C4068735
psychological	B-C0033903
techniques	I-C0033903
.	O
	
findings	B-C0243095
suggest	O
stigma	B-C0277787
is	O
still	O
prevalent	O
even	O
in	O
organizations	B-C0920545
that	O
have	O
consumers	B-C1707496
in	O
leadership	B-C0023181
positions	I-C0023181
,	O
and	O
consumers	B-C1707496
are	O
often	O
perceived	B-C0030971
as	O
less	O
able	O
to	O
work	B-C0043227
in	O
mental	B-C0178740
health	I-C0178740
organizations	I-C0178740
than	O
non-consumers	O
.	O
	
several	O
discourses	B-C2584313
challenged	O
such	O
a	O
view	O
-	O
showing	O
how	O
consumers	B-C1707496
bring	O
value	O
to	O
mental	B-C0178740
health	I-C0178740
organizations	I-C0178740
through	O
their	O
expertise	O
in	O
the	O
mental	B-C0178740
health	I-C0178740
system	I-C0178740
,	O
and	O
their	O
ability	B-C0085732
to	O
provide	O
safety	B-C0150755
and	O
support	B-C0037438
to	O
other	O
consumers	B-C1707496
.	O
	
through	O
a	O
social	B-C0683615
exchange	I-C0683615
theory	I-C0683615
lens	O
,	O
the	O
authors	B-C3812881
call	O
for	O
organizations	B-C0920545
to	O
challenge	O
stigma	B-C0277787
and	O
promote	B-C0033414
the	O
value	O
that	O
consumers	B-C1707496
can	O
bring	O
to	O
maximize	B-C0806909
mutual	B-C1709100
benefits	B-C0814225
.	O
	
does	O
sex	B-C1522384
really	O
matter	O
explaining	O
intraspecies	B-C1705920
variation	B-C0205419
in	O
ocean	B-C0028814
acidification	B-C2987513
responses	B-C0871261
ocean	B-C0028814
acidification	B-C2987513
oa	B-C2987513
poses	O
a	O
major	B-C0749385
threat	I-C0749385
to	O
marine	O
ecosystems	B-C0162358
globally	B-C2348867
,	O
having	O
significant	B-C0750502
ecological	B-C0162358
and	O
economic	B-C0013557
importance	B-C3898777
.	O
	
the	O
number	B-C0237753
and	O
complexity	B-C0237523
of	O
experiments	B-C0681814
examining	B-C0332128
the	O
effects	B-C1704420
of	I-C1704420
oa	B-C2987513
has	O
substantially	B-C0750502
increased	B-C0205217
over	O
the	O
past	B-C1444637
decade	B-C2981279
,	O
in	O
an	O
attempt	B-C1516084
to	O
address	B-C1547607
multi-stressor	B-C0597530
interactions	B-C1704675
and	O
long-term	B-C0443252
responses	B-C0871261
in	O
an	O
increasing	B-C0442808
range	B-C1514721
of	O
aquatic	B-C0596121
organisms	I-C0596121
.	O
	
however	O
,	O
differences	B-C1705242
in	O
the	O
response	B-C0871261
of	O
males	B-C0086582
and	O
females	B-C0086287
to	O
elevated	B-C0858343
pco2	I-C0858343
have	O
been	O
investigated	B-C1292732
in	O
fewer	B-C0205388
than	O
4%	O
of	O
studies	O
to	O
date	B-C0011008
,	O
often	O
being	O
precluded	O
by	O
the	O
difficulty	B-C0332218
of	O
determining	O
sex	B-C1522384
non-destructively	B-C1254370
,	O
particularly	O
in	O
early	B-C0680083
life	I-C0680083
stages	I-C0680083
.	O
	
here	O
we	O
highlight	O
that	O
sex	B-C1522384
can	O
significantly	B-C0750502
impact	B-C4049986
organism	B-C0029235
responses	B-C0871261
to	O
oa	B-C2987513
,	O
differentially	O
affecting	B-C0392760
physiology	B-C0031843
,	O
reproduction	B-C0035150
,	O
biochemistry	B-C0205474
and	O
ultimately	B-C0220921
survival	I-C0220921
.	O
	
what	O
is	O
more	O
,	O
these	O
impacts	B-C4049986
do	O
not	O
always	O
conform	O
to	O
ecological	B-C0871935
theory	I-C0871935
based	O
on	O
differential	B-C0443199
resource	B-C0086914
allocation	I-C0086914
towards	O
reproduction	B-C0035150
,	O
which	O
would	O
predict	B-C0681842
females	B-C0086287
to	O
be	O
more	O
sensitive	B-C0332324
to	O
oa	B-C2987513
owing	O
to	O
the	O
higher	O
production	B-C0220812
cost	I-C0220812
of	O
eggs	B-C0029974
compared	B-C1707455
with	O
sperm	B-C0037868
.	O
	
therefore	O
,	O
non-	O
sex	B-C1522384
-	O
specific	B-C2603343
studies	I-C2603343
may	O
overlook	O
subtle	O
but	O
ecologically	O
significant	B-C0750502
differences	B-C1705242
in	O
the	O
responses	B-C0871261
of	O
males	B-C0086582
and	O
females	B-C0086287
to	O
oa	B-C2987513
,	O
with	O
consequences	B-C0686907
for	O
forecasting	B-C0220831
the	O
fate	O
of	O
natural	B-C0205296
populations	B-C1257890
in	O
a	O
near-future	B-C0016884
ocean	B-C0028814
.	O
	
computational	B-C4297010
analysis	I-C4297010
of	O
conserved	B-C0444764
coil	I-C0444764
functional	B-C1709915
residues	I-C1709915
in	O
the	O
mitochondrial	B-C3863348
genomic	I-C3863348
sequences	I-C3863348
of	O
dermatophytes	B-C0011635
dermatophyte	B-C0011635
is	O
a	O
group	O
of	O
closely	O
related	O
fungi	B-C0016832
that	O
have	O
the	O
capacity	O
to	O
invade	B-C1517574
keratinized	B-C0232387
tissue	B-C0040300
of	O
humans	B-C0086418
and	O
other	O
animals	B-C0003062
.	O
	
the	O
infection	B-C3714514
known	O
as	O
dermatophytosis	B-C0011636
,	O
caused	O
by	O
members	O
of	O
the	O
genera	B-C1708235
microsporum	B-C0026033
,	O
trichophyton	B-C0040933
,	O
and	O
epidermophyton	B-C0014529
includes	O
infection	B-C3714514
to	O
the	O
groin	B-C0018246
tinea	B-C1384589
cruris	I-C1384589
,	O
beard	B-C0221982
tinea	B-C2349994
barbae	I-C2349994
,	O
scalp	B-C0036270
tinea	B-C0040250
capitis	I-C0040250
,	O
feet	B-C0016504
tinea	B-C0040259
pedis	I-C0040259
,	O
glabrous	B-C1180283
skin	I-C1180283
tinea	B-C0040252
corporis	I-C0040252
,	O
nail	B-C0027342
tinea	B-C0040261
unguium	I-C0040261
,	O
and	O
hand	B-C0018563
tinea	B-C0153246
manuum	I-C0153246
.	O
	
the	O
identification	O
of	O
evolutionary	B-C0015219
relationship	B-C0439849
between	O
these	O
three	B-C1708235
genera	I-C1708235
of	O
dermatophyte	B-C0011635
is	O
epidemiologically	B-C1516907
important	I-C1516907
to	O
understand	O
their	O
pathogenicity	B-C1136169
.	O
	
mitochondrial	B-C0012929
dna	I-C0012929
evolves	B-C0282688
more	B-C0456962
rapidly	I-C0456962
than	O
a	O
nuclear	B-C1179920
dna	I-C1179920
due	O
to	O
higher	O
rate	B-C3178846
of	I-C3178846
mutation	I-C3178846
but	O
is	O
very	O
less	B-C0392760
affected	I-C0392760
by	O
genetic	B-C0034865
recombination	I-C0034865
,	O
making	O
it	O
an	O
important	B-C2827396
tool	I-C2827396
for	O
phylogenetic	B-C1519068
studies	I-C1519068
.	O
	
thus	O
,	O
here	O
we	O
present	O
a	O
novel	O
scheme	O
to	O
identify	O
the	O
conserved	B-C0444764
coil	I-C0444764
functional	B-C1709915
residues	I-C1709915
of	O
trichophyton	B-C0040935
rubrum	I-C0040935
,	O
trichophyton	B-C0040934
mentagrophytes	I-C0040934
,	O
epidermophyton	B-C0014530
floccosum	I-C0014530
and	O
microsporum	B-C0319950
canis	I-C0319950
.	O
	
protein	B-C0079941
coding	I-C0079941
sequences	I-C0079941
of	O
the	O
mitochondrial	B-C1819716
genome	I-C1819716
were	O
aligned	O
for	O
their	O
similar	B-C0162326
sequences	I-C0162326
and	O
homology	B-C1512489
modelling	I-C1512489
was	O
performed	O
for	O
structure	B-C1510464
and	O
pocket	B-C0599218
identification	B-C0936012
.	O
	
the	O
results	O
obtained	O
from	O
comparative	B-C0683941
analysis	I-C0683941
of	O
the	O
protein	B-C0002518
sequences	I-C0002518
revealed	O
the	O
presence	O
of	O
functionally	O
active	B-C0205681
sites	I-C0205681
in	O
all	O
the	O
species	O
of	O
the	O
genera	B-C1708235
trichophyton	B-C0040933
and	O
microsporum	B-C0026033
.	O
	
however	O
in	O
epidermophyton	B-C0014530
floccosum	I-C0014530
it	O
was	O
observed	O
in	O
three	O
protein	B-C0002518
sequences	I-C0002518
of	O
the	O
five	O
studied	O
.	O
	
the	O
absence	O
of	O
these	O
conserved	B-C0444764
coil	I-C0444764
functional	B-C1709915
residues	I-C1709915
in	O
e	B-C0014530
.	O
	
floccusum	I-C0014530
may	O
be	O
correlated	O
with	O
lesser	B-C0030657
infectivity	I-C0030657
of	O
this	O
organism	B-C0029235
.	O
	
the	O
functional	B-C1709915
residues	I-C1709915
identified	O
in	O
the	O
present	O
study	O
could	O
be	O
responsible	O
for	O
the	O
disease	B-C0012634
and	O
thus	O
can	O
act	O
as	O
putative	B-C1521840
target	I-C1521840
sites	I-C1521840
for	O
drug	B-C0013171
designing	I-C0013171
.	O
	
non-intubated	B-C0087111
subxiphoid	B-C4039027
uniportal	B-C4304660
video-assisted	I-C4304660
thoracoscopic	I-C4304660
thymectomy	I-C4304660
using	O
glasses-free	O
3d	O
vision	O
trans-sternal	O
thymectomy	B-C0040071
has	O
long	O
been	O
accepted	O
as	O
the	O
standard	O
surgical	O
procedure	O
for	O
thymic	O
masses	O
.	O
	
recently	O
,	O
minimally	O
invasive	O
methods	O
,	O
such	O
as	O
video-assisted	O
thoracoscopic	O
surgery	O
vats	O
and	O
,	O
even	O
more	O
recently	O
,	O
non-intubated	O
anesthesia	O
,	O
have	O
emerged	O
.	O
	
these	O
methods	O
provide	O
advantages	O
including	O
reductions	O
in	O
surgical	O
trauma	O
,	O
postoperative	O
associated	O
pain	O
,	O
and	O
in	O
regards	O
to	O
vats	O
,	O
provide	O
certain	O
cosmetic	O
benefits	O
.	O
	
considering	O
these	O
advantages	O
,	O
we	O
herein	O
present	O
a	O
case	O
of	O
subxiphoid	O
uniportal	O
vats	O
for	O
thymic	O
mass	O
using	O
a	O
glasses-free	B-C0243095
3d	B-C0450363
thoracoscopic	O
display	O
system	I-C0871584
trends	B-C0040833
in	O
dietary	B-C1286104
intake	I-C1286104
among	O
adults	B-C0001675
with	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
nhanes	B-C0376344
1988-2012	O
dietary	B-C0012155
recommendations	B-C0034866
for	O
adults	B-C0001675
with	O
diabetes	B-C0011860
are	O
to	O
follow	O
a	O
healthy	B-C0452415
diet	I-C0452415
in	O
appropriate	O
portion	B-C3658326
sizes	I-C3658326
.	O
	
we	O
determined	O
recent	O
trends	B-C0040833
in	O
energy	B-C0006777
and	O
nutrient	B-C0006777
intakes	I-C0006777
among	O
a	O
nationally	O
representative	O
sample	O
of	O
us	B-C0041703
adults	B-C0001675
with	O
and	O
without	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
.	O
	
participants	B-C0679646
were	O
adults	B-C0001675
aged	B-C0001779
20	O
years	B-C0439234
from	O
the	O
cross-sectional	B-C0376344
national	I-C0376344
health	I-C0376344
and	I-C0376344
nutrition	I-C0376344
examination	I-C0376344
surveys	I-C0376344
,	O
1988-2012	O
n	O
=	O
49	O
770	O
.	O
	
diabetes	B-C0011860
was	O
determined	O
by	O
self-report	B-C2700446
of	O
a	O
physician's	B-C0031831
diagnosis	B-C0011900
n	O
=	O
4885	O
.	O
	
intake	B-C0006777
of	I-C0006777
energy	I-C0006777
and	O
nutrients	B-C0678695
were	O
determined	O
from	O
a	O
24-	O
h	B-C0439227
recall	O
by	O
participants	B-C0679646
of	O
all	O
food	B-C0016452
consumed	O
.	O
	
linear	B-C0023733
regression	I-C0023733
was	O
used	O
to	O
test	B-C0039593
for	O
trends	B-C0040833
in	O
mean	O
intake	B-C1286104
over	O
time	B-C0040223
for	O
all	O
participants	B-C0679646
and	O
by	O
demographic	B-C0683970
characteristics	I-C0683970
.	O
	
among	O
adults	B-C0001675
with	O
diabetes	B-C0011860
,	O
overall	O
total	O
energy	B-C0006777
intake	I-C0006777
increased	B-C0205217
between	O
1988-1994	O
and	O
2011-2012	O
1689	B-C0439259
kcal	I-C0439259
versus	O
1895	B-C0439259
kcal	I-C0439259
ptrend	O
<	O
0.001	O
with	O
evidence	O
of	O
a	O
plateau	B-C2964353
between	O
2003-2006	O
and	O
2011-2012	O
.	O
	
in	O
2007-2012	O
,	O
energy	B-C0006777
intake	I-C0006777
was	O
greater	O
for	O
younger	B-C0238598
than	O
older	B-C0001792
adults	I-C0001792
,	O
for	O
men	B-C0025266
than	O
women	B-C0043210
,	O
and	O
for	O
non-hispanic	B-C0221786
whites	I-C0221786
versus	O
non-hispanic	B-C0085756
blacks	I-C0085756
.	O
	
there	O
was	O
no	O
change	O
in	O
the	O
percentage	B-C0439165
of	O
calories	B-C1556156
from	O
carbohydrate	B-C0453802
,	O
total	B-C0012171
fat	I-C0012171
or	O
protein	B-C0453858
.	O
	
percentage	B-C0439165
of	O
calories	B-C1556156
from	O
saturated	B-C0682953
fat	I-C0682953
was	O
similar	O
across	O
study	B-C2603343
periods	B-C1948053
but	O
remained	O
above	O
recommendations	B-C0034866
11.2	O
in	O
2011-2012	O
.	O
	
fibre	B-C0474451
intake	I-C0474451
significantly	O
decreased	O
and	O
remained	O
below	O
recommendations	B-C0034866
ptrend	O
=	O
0.002	O
.	O
	
sodium	B-C0037570
,	O
cholesterol	B-C0008395
and	O
calcium	B-C0006726
intakes	B-C1286104
increased	B-C0205217
.	O
	
there	O
was	O
no	O
change	O
in	O
energy	B-C0006777
intake	I-C0006777
among	O
adults	B-C0001675
without	O
diabetes	B-C0011860
and	O
dietary	B-C0012155
trends	B-C0040833
were	O
similar	O
to	O
those	O
with	O
diabetes	B-C0011860
.	O
	
future	O
data	B-C1511726
are	O
needed	O
to	O
confirm	O
a	O
plateau	B-C2964353
in	O
energy	B-C0006777
intake	I-C0006777
among	O
adults	B-C0001675
with	O
diabetes	B-C0011860
,	O
although	O
the	O
opportunity	O
exists	O
to	O
increase	B-C0442805
fibre	B-C0012173
and	O
reduce	B-C0547047
saturated	B-C0682953
fat	I-C0682953
.	O
	
clonal	B-C1522642
and	O
serotype	B-C0449943
dynamics	B-C3826426
of	O
serogroup	B-C1532752
6	I-C1532752
isolates	B-C1764827
causing	O
invasive	B-C1320214
pneumococcal	I-C1320214
disease	I-C1320214
in	O
portugal	B-C0032729
1999-2012	O
although	O
serogroup	B-C1532752
6	I-C1532752
was	O
among	O
the	O
first	O
to	O
be	O
recognized	O
among	O
streptococcus	B-C0038410
pneumoniae	I-C0038410
,	O
several	O
new	O
serotypes	B-C0449943
were	O
identified	B-C0205396
since	O
the	O
introduction	B-C0579004
of	O
pneumococcal	B-C0206515
conjugate	I-C0206515
vaccines	I-C0206515
pcvs	B-C0206515
.	O
	
a	O
decrease	B-C0547047
of	O
the	O
6b-2	B-C0205419
variant	I-C0205419
among	O
invasive	B-C1320214
pneumococcal	I-C1320214
disease	I-C1320214
ipd	B-C1320214
,	O
but	O
not	O
6b-1	B-C0205419
,	O
was	O
noted	O
post	B-C0687676
conjugate	B-C0206515
vaccine	I-C0206515
introduction	B-C0579004
,	O
underpinned	O
by	O
a	O
decrease	B-C0547047
of	O
cc273	B-C1764827
isolates	I-C1764827
.	O
	
serotype	B-C3697188
6c	I-C3697188
was	O
associated	B-C0332281
with	I-C0332281
adult	B-C0001675
ipd	B-C1320214
and	O
increased	B-C0205217
in	O
this	O
age	B-C0027362
group	I-C0027362
representing	O
two	O
lineages	B-C0282637
cc315	B-C0282637
and	O
cc395	B-C0282637
,	O
while	O
the	O
same	O
lineages	B-C0282637
expressed	B-C1171362
other	O
serogroup	B-C1532752
6	I-C1532752
serotypes	B-C0449943
in	O
children	B-C0008059
.	O
	
taken	O
together	O
,	O
these	O
findings	B-C2607943
suggest	O
a	O
potential	O
cross-protection	B-C2717886
of	O
pcvs	B-C0206515
against	O
serotype	B-C3697188
6c	I-C3697188
ipd	B-C1320214
among	O
vaccinated	B-C1519885
children	B-C0008059
but	O
not	O
among	O
adults	B-C0001675
.	O
	
serotype	B-C2732283
6a	I-C2732283
became	O
the	O
most	O
important	O
serogroup	B-C1532752
6	I-C1532752
serotype	B-C0449943
in	O
children	B-C0008059
but	O
it	O
decreased	B-C0205216
in	O
adult	B-C0001675
ipd	B-C1320214
.	O
	
no	O
other	O
serogroup	B-C1532752
6	I-C1532752
serotypes	B-C0449943
were	O
detected	B-C0442726
,	O
so	O
available	O
phenotypic	B-C0031437
or	O
simple	O
genotypic	B-C0017431
assays	B-C1510438
remain	O
adequate	B-C0205411
for	O
distinguishing	O
serotypes	B-C0449943
within	O
serogroup	B-C1532752
6	I-C1532752
isolates	B-C1764827
.	O
	
minimally	B-C2711297
invasive	I-C2711297
percutaneous	B-C0162428
nephrolithotomy	I-C0162428
improves	O
stone-free	O
rates	O
for	O
impacted	B-C0333125
proximal	B-C0205107
ureteral	B-C0041952
stones	I-C0041952
a	O
systematic	B-C1955832
review	I-C1955832
and	O
meta-analysis	B-C0920317
urinary	B-C0451641
stones	I-C0451641
are	O
common	O
medical	B-C0205476
disorders	B-C0012634
and	O
the	O
treatment	B-C1522326
of	O
impacted	B-C0041952
proximal	I-C0041952
ureteral	I-C0041952
stones	I-C0041952
ipus	O
is	O
still	O
a	O
challenge	O
for	O
urologists	O
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
minimally	O
invasive	O
percutaneous	O
nephrolithotomy	O
mi	O
-	O
pcnl	O
and	O
ureteroscopic	O
lithotripsy	O
url	O
in	O
the	O
treatment	O
of	O
ipus	O
via	O
a	O
meta-analysis	O
.	O
	
we	O
collected	O
studies	O
using	O
pubmed	O
,	O
embase	O
,	O
and	O
cochrane	O
library	O
from	O
1978	O
to	O
november	O
2016	O
and	O
analyzed	O
them	O
using	O
stata	O
12.0	O
and	O
revman	O
5.3	O
.	O
	
odds	O
ratios	O
or	O
s	O
and	O
standard	O
mean	O
difference	O
smd	O
were	O
calculated	O
for	O
binary	O
and	O
continuous	O
variables	O
respectively	O
,	O
accompanied	O
with	O
95%	O
confidence	O
intervals	O
cis	O
.	O
	
all	O
study	O
procedures	O
followed	O
the	O
prisma	O
guidelines	O
.	O
	
five	O
prospective	O
studies	O
were	O
included	O
in	O
our	O
meta-analysis	O
,	O
with	O
242	O
mi	O
-	O
pcnl	O
and	O
256	O
url	O
cases	O
.	O
	
mi	O
-	O
pcnl	O
was	O
associated	O
with	O
a	O
longer	O
postoperative	O
hospital	O
stay	O
than	O
url	O
smd	O
,	O
3.14	O
95%	O
ci	O
,	O
1.27	O
to	O
5.55	O
.	O
	
however	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
operative	O
time	O
smd	O
,	O
-0	O
95%	O
ci	O
,	O
-3	O
to	O
2.38	O
.	O
	
in	O
addition	O
,	O
mi	O
-	O
pcnl	O
had	O
higher	O
initial	O
or	O
,	O
11.12	O
95%	O
ci	O
,	O
5.56	O
to	O
22.24	O
and	O
overall	O
stone-free	O
rates	O
or	O
,	O
8.70	O
95%	O
ci	O
,	O
3.23	O
to	O
23.45	O
than	O
url	O
,	O
along	O
with	O
lower	O
possibilities	O
of	O
surgical	O
conversion	O
or	O
,	O
0.11	O
95%	O
ci	O
,	O
0.03	O
to	O
0.49	O
and	O
postoperative	O
shock	O
wave	O
lithotripsy	O
or	O
,	O
0.06	O
95%	O
ci	O
,	O
0.02	O
to	O
0.18	O
.	O
	
regarding	O
complications	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
mi	O
-	O
pcnl	O
and	O
url	O
or	O
,	O
1.39	O
95%	O
ci	O
,	O
0.93	O
to	O
2.10	O
,	O
except	O
for	O
hematuria	O
or	O
,	O
4.80	O
95%	O
ci	O
,	O
1.45	O
to	O
15.94	O
.	O
	
mi	O
-	O
pcnl	O
is	O
optimal	O
and	O
should	O
be	O
considered	O
as	O
the	O
preferred	O
treatment	O
method	O
for	O
ipus	O
,	O
as	O
it	O
has	O
better	O
efficacy	O
and	O
a	O
safety	O
profile	O
similar	O
to	O
that	O
of	O
url	O
.	O
	
however	O
,	O
further	O
high	O
quality	O
studies	O
with	O
larger	O
sample	O
size	O
are	O
required	O
in	O
future	B-C0016884
predictive	B-C0683956
factors	I-C0683956
for	O
long-term	B-C0443252
outcome	B-C1274040
of	O
subthalamic	B-C0152355
nucleus	I-C0152355
deep	B-C0394162
brain	I-C0394162
stimulation	I-C0394162
for	O
parkinson's	B-C0030567
disease	I-C0030567
despite	O
the	O
recognition	O
of	O
the	O
usefulness	B-C3827682
of	O
subthalamic	B-C0152355
nucleus	I-C0152355
deep	B-C0394162
brain	I-C0394162
stimulation	I-C0394162
stn	B-C0152355
-	O
dbs	B-C0394162
for	O
the	O
treatment	B-C1522326
of	O
parkinson's	B-C0030567
disease	I-C0030567
pd	B-C0030567
,	O
preoperative	B-C0445204
predictive	B-C0683956
factors	I-C0683956
for	O
the	O
long-term	B-C0443252
outcome	B-C1274040
of	O
stn	B-C0152355
-	O
dbs	B-C0394162
are	O
not	B-C1518422
sufficiently	B-C0205410
established	B-C0443211
.	O
	
we	O
performed	O
this	O
study	B-C2603343
to	O
determine	O
such	O
predictive	B-C0683956
factors	I-C0683956
.	O
	
the	O
subjects	B-C0681850
were	O
66	O
patients	B-C0030705
who	O
were	O
classified	B-C0008902
into	O
two	B-C0205448
groups	B-C0681860
on	O
the	O
basis	B-C1527178
of	O
their	O
activities	B-C0001288
of	I-C0001288
daily	I-C0001288
living	I-C0001288
adl	B-C0001288
evaluated	O
five	B-C0439234
years	I-C0439234
after	B-C0687676
the	O
stn	B-C0152355
-	O
dbs	B-C0394162
surgery	B-C0543467
33	O
patients	B-C0030705
were	O
assigned	B-C1516050
to	O
the	O
independent	B-C0332291
adl	B-C0001288
group	B-C0681860
group	B-C0681860
i	I-C0681860
and	O
the	O
remaining	O
33	O
patients	B-C0030705
to	O
the	O
dependent	B-C3244310
adl	B-C0001288
group	B-C0681860
group	B-C0681860
d	I-C0681860
.	O
	
group	B-C0681860
i	I-C0681860
patients	B-C0030705
showed	O
a	O
schwab	B-C4034311
and	I-C4034311
england	I-C4034311
s	I-C4034311
scale	I-C4034311
score	O
of	O
more	O
than	O
70	O
during	O
the	O
off-period	O
,	O
indicating	O
that	O
these	O
patients	O
can	O
maintain	O
their	O
independent	O
adl	O
all	O
the	O
time	O
.	O
	
group	O
d	O
patients	O
showed	O
a	O
score	O
of	O
70	O
or	O
lower	O
during	O
the	O
off-period	O
,	O
indicating	O
that	O
these	O
patients	O
cannot	O
maintain	O
their	O
independent	O
adl	O
for	O
an	O
entire	O
day	O
.	O
	
we	O
studied	O
the	O
differences	O
in	O
the	O
preoperative	O
state	O
between	O
these	O
two	O
groups	O
.	O
	
statistically	O
significant	O
differences	O
were	O
noted	O
in	O
pd	O
onset	O
age	O
,	O
age	O
at	O
surgery	O
,	O
preoperative	O
unified	O
parkinson's	O
disease	O
rating	O
scale	O
updrs	O
part	O
i	O
score	O
,	O
part	O
ii	O
score	O
,	O
total	O
subscore	O
for	O
axial	O
symptoms	O
in	O
part	O
iii	O
,	O
mini-mental	O
state	O
examination	O
mmse	O
score	O
and	O
s	B-C4034311
score	B-C0449820
.	O
	
multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
significant	O
independent	O
variables	O
related	O
to	O
long-term	O
independent	O
adl	O
were	O
the	O
age	O
at	O
surgery	O
,	O
mmse	O
score	O
and	O
preoperative	O
s	O
scale	O
score	O
during	B-C0347984
the	O
off-period	B-C1948053
.	O
	
the	O
pd	O
onset	O
age	O
,	O
age	O
at	O
surgery	O
,	O
preoperative	O
high	O
-	O
level	O
adl	O
,	O
cognitive	O
function	O
,	O
and	O
axial	O
symptoms	O
are	O
important	O
predictive	O
factors	O
for	O
the	O
long-term	O
outcome	O
of	O
stn	O
-	O
dbs	B-C0394162
who	O
persuades	B-C3825845
who	O
an	O
analysis	B-C0936012
of	O
persuasion	B-C3825845
choices	B-C0008300
related	O
to	O
antibiotic	B-C0003232
-	O
free	B-C1996904
food	B-C0016452
personal	B-C0086792
communication	I-C0086792
,	O
in	O
which	O
one	O
person	B-C0027361
persuades	B-C3825845
another	O
to	O
engage	O
in	O
a	O
particular	O
behavior	B-C0004927
,	O
is	O
one	O
means	O
through	O
which	O
behaviors	B-C0004927
spread	B-C0332261
.	O
	
to	O
better	O
understand	B-C0162340
how	O
personal	B-C0086792
communication	I-C0086792
spreads	B-C0332261
behavior	B-C0004927
,	O
we	O
investigated	B-C1292732
adults'	B-C0001675
n	O
=	O
228	O
likelihood	B-C0033204
of	O
persuading	B-C3825845
others	O
in	O
a	O
fictitious	O
social	B-C0150775
network	I-C0150775
to	O
buy	B-C0870238
antibiotic	B-C0003232
-	O
free	B-C1996904
food	B-C0016452
,	O
and	O
who	O
they	O
attempted	B-C1516084
to	O
persuade	B-C3825845
,	O
based	O
on	O
behavioral	B-C0004927
determinants	B-C1521761
,	O
homophily	B-C0205556
,	O
and	O
superdiffuser	B-C0205556
traits	B-C0037401
.	O
	
for	O
potential	B-C3245505
consumers	B-C1707496
,	O
the	O
findings	B-C0243095
showed	O
that	O
behavioral	B-C0004927
determinants	B-C1521761
,	O
behavioral	B-C0004927
intentions	B-C0162425
,	O
and	O
mavenism	B-C0205556
predicted	B-C0681842
intentions	B-C0162425
to	O
persuade	B-C3825845
others	O
.	O
	
homophily	B-C0205556
,	O
mavenism	B-C0205556
,	O
and	O
connectivity	B-C0205245
predicted	B-C0681842
patterns	B-C0449774
of	O
interpersonal	B-C0021797
persuasion	B-C3825845
.	O
	
for	O
vegetarians	B-C0042441
without	O
homophily	B-C0205556
in	O
action	B-C3266814
,	O
behavioral	B-C0004927
determinants	B-C1521761
and	O
mavenism	B-C0205556
predicted	B-C0681842
persuasion	B-C3825845
intentions	B-C0162425
.	O
	
persuasiveness	B-C3825845
was	O
associated	B-C0332281
with	I-C0332281
targeting	B-C1521840
more	O
network	B-C0150775
members	B-C0680022
mavenism	B-C0205556
was	O
associated	B-C0332281
with	I-C0332281
selecting	O
structurally	B-C0678594
central	B-C0205099
members	B-C0680022
.	O
	
modeling	B-C0870071
the	O
flux	B-C2348693
of	O
metabolites	B-C0870883
in	O
the	O
juvenile	B-C0022439
hormone	I-C0022439
biosynthesis	B-C0220781
pathway	B-C1704259
using	O
generalized	B-C0026336
additive	I-C0026336
models	I-C0026336
and	O
ordinary	B-C0282574
differential	I-C0282574
equations	I-C0282574
juvenile	B-C0022439
hormone	I-C0022439
jh	B-C0022439
regulates	O
development	B-C1527148
and	O
reproductive	B-C0036887
maturation	I-C0036887
in	O
insects	B-C0021585
.	O
	
the	O
corpora	B-C0010085
allata	I-C0010085
ca	B-C0010085
from	O
female	B-C0086287
adult	B-C0026584
mosquitoes	I-C0026584
synthesize	O
fluctuating	B-C0231241
levels	B-C0441889
of	O
jh	B-C0022439
,	O
which	O
have	O
been	O
linked	O
to	O
the	O
ovarian	B-C1160265
development	I-C1160265
and	O
are	O
influenced	O
by	O
nutritional	B-C1521739
signals	B-C0037083
.	O
	
the	O
rate	B-C1521828
of	O
jh	B-C0022439
biosynthesis	B-C0220781
is	O
controlled	O
by	O
the	O
rate	B-C1521828
of	O
flux	B-C2348693
of	O
isoprenoids	B-C0682996
in	O
the	O
pathway	B-C1704259
,	O
which	O
is	O
the	O
outcome	O
of	O
a	O
complex	O
interplay	O
of	O
changes	B-C0392747
in	O
precursor	B-C3891814
pools	O
and	O
enzyme	B-C0014442
levels	B-C0441889
.	O
	
a	O
comprehensive	B-C1880156
study	B-C2603343
of	O
the	O
changes	B-C0392747
in	O
enzymatic	B-C0243102
activities	I-C0243102
and	O
precursor	B-C3891814
pool	O
sizes	O
have	O
been	O
previously	O
reported	O
for	O
the	O
mosquito	B-C0026584
aedes	B-C0322859
aegypti	I-C0322859
jh	B-C0022439
biosynthesis	B-C0220781
pathway	B-C1704259
.	O
	
in	O
the	O
present	O
studies	B-C2603343
,	O
we	O
used	O
two	O
different	O
quantitative	B-C0681919
approaches	I-C0681919
to	O
describe	O
and	O
predict	O
how	O
changes	B-C0392747
in	O
the	O
individual	O
metabolic	B-C0311400
reactions	B-C0443286
in	O
the	O
pathway	B-C1704259
affect	O
jh	B-C0022439
synthesis	B-C0220781
.	O
	
first	O
,	O
we	O
constructed	O
generalized	B-C0026336
additive	I-C0026336
models	I-C0026336
gams	B-C0026336
that	O
described	O
the	O
association	O
between	O
changes	B-C0392747
in	O
specific	O
metabolite	B-C0870883
concentrations	B-C0457929
with	O
changes	B-C0392747
in	O
enzymatic	B-C0243102
activities	I-C0243102
and	O
substrate	B-C3891814
concentrations	B-C0457929
.	O
	
changes	B-C0392747
in	O
substrate	B-C3891814
concentrations	B-C0457929
explained	O
50%	O
or	O
more	O
of	O
the	O
model	B-C0026336
deviances	O
in	O
7	O
of	O
the	O
13	O
metabolic	B-C0311400
steps	B-C1261552
analyzed	B-C0936012
.	O
	
addition	O
of	O
information	O
on	O
enzymatic	B-C0243102
activities	I-C0243102
almost	O
always	O
improved	O
the	O
fitness	B-C2349186
of	O
gams	B-C0026336
built	O
solely	O
based	O
on	O
substrate	B-C3891814
concentrations	B-C0457929
.	O
	
gams	B-C0026336
were	O
validated	O
using	O
experimental	B-C1517586
data	B-C1511726
that	O
were	O
not	O
included	O
when	O
the	O
model	O
was	O
built	O
.	O
	
in	O
addition	O
,	O
a	O
system	O
of	O
ordinary	B-C0282574
differential	I-C0282574
equations	I-C0282574
ode	B-C0282574
was	O
developed	O
to	O
describe	O
the	O
instantaneous	O
changes	B-C0392747
in	O
metabolites	B-C0870883
as	O
a	O
function	B-C0542341
of	O
the	O
levels	B-C0441889
of	O
enzymatic	B-C0243102
catalytic	I-C0243102
activities	I-C0243102
.	O
	
the	O
results	B-C1274040
demonstrated	O
the	O
ability	O
of	O
the	O
models	B-C0026336
to	O
predict	O
changes	B-C0392747
in	O
the	O
flux	B-C2348693
of	O
metabolites	B-C0870883
in	O
the	O
jh	B-C0022439
pathway	B-C1704259
,	O
and	O
can	O
be	O
used	O
in	O
the	O
future	O
to	O
design	B-C1707689
and	O
validate	B-C1519941
experimental	B-C1517586
manipulations	B-C0205245
of	O
jh	B-C0022439
synthesis	B-C0220781
.	O
	
associations	B-C0439849
between	O
human	B-C0885503
breast	I-C0885503
milk	I-C0885503
hormones	B-C0019932
and	O
adipocytokines	B-C1955907
and	O
infant	B-C0205714
growth	I-C0205714
and	O
body	B-C0005885
composition	I-C0005885
in	O
the	O
first	B-C3280927
6	I-C3280927
months	I-C3280927
of	I-C3280927
life	I-C3280927
much	O
is	O
to	O
be	O
learnt	O
about	O
human	B-C0885503
breast	I-C0885503
milk	I-C0885503
hbm	B-C0885503
.	O
	
the	O
purpose	O
of	O
this	O
study	O
is	O
to	O
extend	O
our	O
knowledge	O
of	O
hbm	B-C0885503
by	O
investigating	O
the	O
role	O
of	O
maternal	B-C1858460
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
,	O
sex	B-C0079399
and	O
stage	B-C0022925
of	I-C0022925
lactation	I-C0022925
month	O
1	O
vs	O
.	O
	
6	O
on	O
hbm	B-C0885503
insulin	B-C0021641
,	O
glucose	B-C0017725
,	O
leptin	B-C0299583
,	O
il-6	B-C0021760
and	O
tnf-α	B-C1456820
and	O
their	O
associations	B-C0439849
with	O
infant	B-C0021270
body	B-C0005885
composition	I-C0005885
.	O
	
thirty-seven	O
exclusively	O
breastfeeding	B-C1623041
infants	I-C1623041
n	O
=	O
37	O
16	O
,	O
21	O
,	O
and	O
their	O
mothers	B-C1623040
19-47	O
kg	O
m	O
were	O
studied	O
at	O
1	O
and	O
6	O
months	O
of	O
lactation	B-C0022925
.	O
	
infants	B-C0021270
had	O
body	B-C1285593
composition	I-C1285593
measured	I-C1285593
using	O
dual-energy	B-C1510486
x-ray	I-C1510486
absorptiometry	I-C1510486
and	O
hbm	B-C0885503
collected	O
.	O
	
a	O
significant	O
interaction	B-C1704675
between	O
maternal	B-C1858460
bmi	B-C1305855
and	O
infant	B-C0079399
sex	I-C0079399
on	O
insulin	B-C0202098
levels	I-C0202098
p	O
=	O
0.0322	O
was	O
observed	O
such	O
that	O
insulin	B-C0428405
was	I-C0428405
229%	I-C0428405
higher	I-C0428405
in	O
obese	B-C0028754
mothers	B-C0026591
nursing	O
female	B-C2222300
infants	I-C2222300
than	O
in	O
normal	B-C2712185
weight	I-C2712185
mothers	B-C0026591
nursing	B-C0006147
female	O
infants	O
and	O
179%	O
higher	O
than	O
obese	O
mothers	O
nursing	B-C0006147
male	O
infants	O
.	O
	
for	O
leptin	O
,	O
a	O
significant	O
association	O
with	O
bmi	O
category	O
was	O
observed	O
p	O
<	O
0.0001	O
such	O
that	O
overweight	O
and	O
obese	O
mothers	O
had	O
96.5	O
and	O
315.1	O
higher	O
leptin	O
levels	O
than	O
normal	O
weight	O
mothers	O
,	O
respectively	O
.	O
	
leptin	O
was	O
also	O
found	O
to	O
have	O
a	O
significant	O
p	O
=	O
0.0004	O
33.7	O
decrease	O
from	O
months	O
1	O
to	O
6	O
,	O
controlling	O
for	O
bmi	O
category	O
and	O
sex	O
.	O
	
a	O
significant	O
inverse	O
relationship	O
between	O
month	O
1	O
leptin	O
levels	O
and	O
infant	O
length	O
p	O
=	O
0.0257	O
,	O
percent	O
fat	O
p	O
=	O
0.0223	O
,	O
total	O
fat	O
mass	O
p	O
=	O
0.0226	O
and	O
trunk	O
fat	O
mass	O
p	O
=	O
0.0111	O
at	O
month	O
6	O
was	O
also	O
found	O
.	O
	
no	O
associations	O
or	O
interactions	O
were	O
observed	O
for	O
glucose	O
,	O
tnf-α	O
or	O
il-6	O
.	O
	
these	O
data	O
demonstrate	O
that	O
maternal	O
bmi	O
,	O
infant	O
sex	O
and	O
stage	O
of	O
lactation	O
affect	O
the	O
compositional	O
make-up	O
of	O
insulin	O
and	O
leptin	B-C0299583
aryl	B-C0596123
hydrocarbon	I-C0596123
receptor	I-C0596123
ahr	I-C0596123
rs2066853	I-C0596123
gene	B-C0678951
polymorphism	I-C0678951
association	O
with	O
infertile	B-C0021359
oligoasthenoteratozoospermic	B-C0028960
men	B-C0025266
and	O
seminal	B-C1519232
oxidative	B-C0242606
stress	I-C0242606
this	O
study	O
aimed	O
to	O
assess	O
the	O
association	O
between	O
aryl	B-C0596123
hydrocarbon	I-C0596123
receptor	I-C0596123
ahr	I-C0596123
rs2066853	I-C0596123
gene	B-C0678951
polymorphism	I-C0678951
with	O
infertile	B-C0021359
oligoasthenoteratozoospermic	B-C0028960
oat	B-C0028960
men	B-C0025266
and	O
seminal	B-C1519232
oxidative	B-C0242606
stress	I-C0242606
os	B-C0242606
.	O
	
a	O
total	O
of	O
170	O
egyptian	B-C0025266
men	I-C0025266
were	O
allocated	O
according	O
to	O
their	O
semen	B-C0202533
analysis	I-C0202533
into	O
fertile	B-C0015895
normozoospermic	B-C4231237
controls	I-C4231237
n	O
=	O
50	O
and	O
infertile	B-C0021359
oat	B-C0028960
men	B-C0025266
n	O
=	O
120	O
.	O
	
they	O
were	O
subjected	O
to	O
history	B-C0199182
taking	I-C0199182
,	O
clinical	B-C1274016
examination	I-C1274016
,	O
semen	B-C0202533
analysis	I-C0202533
,	O
estimation	B-C0750572
of	O
seminal	B-C1519232
glutathione	B-C0017822
peroxidase	I-C0017822
gpx	B-C0017822
,	O
and	O
malondialdehyde	B-C0024643
mda	B-C0024643
.	O
	
ahr	B-C0596123
rs2066853	I-C0596123
gene	B-C0678951
polymorphism	I-C0678951
was	O
identified	O
in	O
the	O
blood	B-C0005767
by	O
pcr	B-C0032520
-	O
rflp	B-C0035268
.	O
	
comparing	O
infertile	B-C0021359
oat	B-C0028960
men	B-C0025266
with	O
fertile	B-C0015895
controls	B-C0009932
,	O
ahr	B-C0596123
rs2066853	I-C0596123
genotypes	B-C0017431
showed	O
decreased	B-C0205216
prevalence	B-C0033105
for	O
wild	B-C1883559
homozygous	B-C0019904
genotype	I-C0019904
gg	I-C0019904
35.8	O
vs	O
56%	O
and	O
for	O
heterozygous	B-C0019425
genotype	I-C0019425
ga	I-C0019425
17.5	O
vs	O
30%	O
and	O
an	O
increased	B-C0205217
prevalence	B-C0033105
for	O
homozygous	B-C0019904
genotype	I-C0019904
aa	I-C0019904
46.7	O
vs	O
14%	O
.	O
	
distribution	O
of	O
alleles	B-C0002085
of	O
ahr	B-C0596123
rs2066853	I-C0596123
among	O
oat	B-C0028960
men	B-C0025266
compared	O
with	O
fertile	B-C0015895
men	B-C0025266
showed	O
decreased	B-C0205216
prevalence	B-C0033105
of	O
g	B-C0002085
allele	I-C0002085
44.6	O
vs	O
71%	O
and	O
an	O
increased	B-C0205217
prevalence	B-C0033105
of	O
a	B-C0002085
allele	I-C0002085
55.4	O
vs	O
29%	O
.	O
	
seminal	B-C1519232
mda	B-C0024643
demonstrated	O
significant	O
increase	B-C0205217
whereas	O
seminal	B-C1519232
gpx	B-C0017822
demonstrated	O
significant	O
decrease	B-C0205216
in	O
cases	O
with	O
aa	B-C0019904
and	O
ga	B-C0019425
/	O
aa	B-C0019904
genotypes	I-C0019904
compared	O
to	O
cases	O
with	O
gg	B-C0019904
genotype	I-C0019904
.	O
	
it	O
is	O
concluded	O
that	O
there	O
is	O
a	O
significant	O
association	O
between	O
ahr	B-C0596123
rs2066853	I-C0596123
genotype	B-C0017431
polymorphism	B-C0678951
with	O
decreased	B-C0205216
sperm	B-C0037868
parameters	O
as	O
well	O
as	O
increased	B-C0205217
seminal	B-C1519232
oxidative	B-C0242606
stress	I-C0242606
in	O
infertile	B-C0021359
oat	B-C0028960
men	B-C0025266
.	O
	
associations	B-C0439849
of	O
gender	B-C0079399
and	O
a	O
proxy	B-C0600420
of	O
female	B-C0086287
menopausal	B-C1513126
status	I-C1513126
with	O
histological	B-C0205462
features	B-C2348519
of	O
drug-induced	B-C0860207
liver	I-C0860207
injury	I-C0860207
gender	B-C0079399
and	O
menopause	B-C0025320
may	O
contribute	O
to	O
type	B-C0332307
and	O
severity	B-C0439793
of	O
drug-induced	B-C0860207
liver	I-C0860207
injury	I-C0860207
dili	B-C0860207
by	O
influencing	B-C4054723
host	B-C1167395
responses	B-C1704632
to	O
injury	B-C3263723
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
assess	B-C1516048
the	O
associations	B-C0439849
of	O
gender	B-C0079399
and	O
female	B-C0086287
age	B-C0001779
50	O
a	O
proxy	B-C0600420
of	O
menopause	B-C0025320
with	O
histological	B-C0205462
features	B-C2348519
of	O
liver	B-C0160390
injury	I-C0160390
in	O
212	O
adults	B-C0001675
enrolled	O
in	O
the	O
drug-induced	B-C0860207
liver	I-C0860207
injury	I-C0860207
network	B-C1882071
dilin	B-C1882071
registry	B-C0034975
.	O
	
all	O
participants	B-C0679646
had	O
a	O
causality	B-C0015127
score	B-C0449820
of	O
at	O
least	O
'	O
probable	B-C0332148
'	O
,	O
a	O
liver	B-C0193388
biopsy	I-C0193388
within	O
30	O
days	O
of	O
dili	B-C0860207
onset	O
,	O
and	O
no	O
prior	O
chronic	B-C0341439
liver	I-C0341439
disease	I-C0341439
.	O
	
biochemical	B-C0205474
and	O
histological	B-C0205462
injury	B-C3263723
types	B-C0332307
were	O
classified	O
as	O
hepatocellular	B-C0151763
or	O
cholestatic/mixed	B-C1737228
injury	I-C1737228
.	O
	
the	O
cohort	B-C0599755
was	O
divided	B-C0332849
into	O
three	O
gender	B-C0079399
/	O
age	B-C0001779
categories	B-C0683312
men	B-C0025266
41.0	O
,	O
women	B-C0043210
<50	O
years	O
27.4	O
and	O
women	B-C0043210
50	O
years	O
of	O
age	B-C0001779
31.6	O
.	O
	
interaction	B-C1704675
of	O
gender	B-C0079399
and	O
age	B-C0001779
category	B-C0683312
50	O
or	O
not	O
was	O
assessed	B-C1516048
.	O
	
hepatocellular	B-C0151763
injury	I-C0151763
was	O
more	O
prevalent	O
in	O
women	B-C0043210
<50	O
years	O
vs	O
.	O
	
others	O
p=	O
.	O
	
after	O
adjusting	O
for	O
biochemical	B-C0205474
injury	B-C3263723
types	B-C0332307
,	O
black	B-C0005680
race	I-C0005680
and	O
possible	B-C0332149
ageing	B-C0001811
effects	B-C1280500
,	O
more	O
severe	B-C0205082
interface	O
hepatitis	B-C0019158
was	O
noted	O
in	O
biopsies	B-C0005558
of	O
women	B-C0043210
<50	O
years	O
compared	B-C1707455
to	O
those	O
of	O
men	B-C0025266
and	O
women	B-C0043210
50	O
years	O
p=	O
and	O
p=	O
respectively	O
.	O
	
compared	B-C1707455
to	O
those	O
of	O
men	B-C0025266
,	O
biopsies	B-C0005558
of	O
women	B-C0043210
showed	O
greater	B-C1704243
plasma	B-C0391861
cell	I-C0391861
infiltration	I-C0391861
,	O
hepatocyte	B-C3269241
apoptosis	I-C3269241
,	O
hepatocyte	B-C0227525
rosettes	B-C0035863
and	O
lobular	B-C0205417
disarray	O
but	O
less	O
iron	B-C0302583
-	O
positive	B-C1514241
hepatocytes	B-C0227525
and	O
histological	B-C0205462
cholestasis	B-C0008370
p<	O
.	O
	
these	O
associations	B-C0439849
persisted	O
after	O
excluding	O
cases	B-C0868928
of	O
amoxicillin/clavulanic	B-C0054066
acid	I-C0054066
,	O
anabolic	B-C0002744
steroids	I-C0002744
or	O
nitrofurantoin	B-C0028156
dili	B-C0860207
which	O
showed	O
gender	B-C0079399
-specific	O
distributions	B-C1704711
.	O
	
gender	B-C0079399
and	O
a	O
proxy	B-C0600420
of	O
menopause	B-C0025320
were	O
associated	B-C0332281
with	I-C0332281
various	O
features	B-C2348519
of	O
inflammation	B-C0021368
and	O
injury	B-C3263723
in	O
a	O
novel	O
potent	O
anticancer	B-C0003392
compound	I-C0003392
optimized	O
from	O
a	O
natural	B-C0205296
oridonin	B-C0069639
scaffold	O
induces	O
apoptosis	B-C0162638
and	O
cell	B-C1155873
cycle	I-C1155873
arrest	I-C1155873
through	O
the	O
mitochondrial	B-C1513340
pathway	I-C1513340
the	O
cytotoxicity	B-C0596402
of	O
the	O
natural	B-C0205296
ent-kaurene	B-C1254351
diterpenoid	I-C1254351
,	O
oridonin	B-C0069639
,	O
has	O
been	O
extensively	O
studied	O
.	O
	
however	O
,	O
the	O
application	O
of	O
oridonin	B-C0069639
for	O
cancer	B-C0920425
therapy	I-C0920425
was	O
hampered	O
primarily	O
by	O
its	O
moderate	B-C0678792
potency	I-C0678792
.	O
	
in	O
this	O
study	O
,	O
a	O
series	O
of	O
oridonin	B-C0069639
a-ring	B-C0002776
modified	I-C0002776
analogues	I-C0002776
,	O
and	I-C0002776
their	I-C0002776
derivatives	I-C0002776
bearing	O
various	O
substituents	B-C1254350
on	I-C1254350
14-oh	I-C1254350
position	I-C1254350
,	O
were	O
designed	O
,	O
synthesized	B-C1883254
,	O
and	O
evaluated	B-C0220825
for	O
anticancer	B-C0003392
efficacy	B-C1280519
.	O
	
some	O
of	O
the	O
derivatives	B-C0243072
were	O
significantly	O
more	O
potent	O
than	O
oridonin	B-C0069639
against	O
both	O
drug	B-C1254351
-	O
sensitive	B-C0332324
and	O
drug-resistant	B-C0013203
cancer	B-C0334227
cells	I-C0334227
.	O
	
the	O
most	O
potent	O
compound	B-C0003392
,	O
13p	I-C0003392
,	O
was	O
200-fold	B-C1254367
more	O
efficacious	B-C1280519
than	O
oridonin	B-C0069639
in	O
mcf-7	B-C0596890
cancer	I-C0596890
cells	I-C0596890
.	O
	
furthermore	O
,	O
13p	B-C0003392
induced	O
apoptosis	B-C0162638
and	O
cell	B-C1155873
cycle	I-C1155873
arrest	I-C1155873
at	O
the	O
g2/m	B-C1517347
phase	I-C1517347
.	O
	
a	O
decrease	O
in	O
mitochondrial	B-C1720920
membrane	I-C1720920
potential	I-C1720920
and	O
an	O
increase	O
in	O
bax/bcl-2	B-C0219474
ratio	O
,	O
accompanied	O
by	O
activated	B-C4290004
caspase-3	I-C4290004
cleavage	B-C0597304
,	O
were	O
observed	O
in	O
mcf-7	B-C0596890
cells	I-C0596890
after	O
treatment	B-C0087111
with	O
13p	B-C0003392
,	O
suggesting	O
that	O
the	O
mitochondrial	B-C1513340
pathway	I-C1513340
was	O
involved	O
in	O
the	O
13p	B-C0003392
-mediated	O
apoptosis	B-C0162638
.	O
	
moreover	O
,	O
13p	B-C0003392
significantly	O
inhibited	O
tumor	B-C0598934
growth	I-C0598934
in	O
mouse	B-C0025929
xenograft	B-C1520166
models	I-C1520166
and	O
had	O
no	B-C0857329
observable	I-C0857329
toxic	I-C0857329
effect	I-C0857329
.	O
	
stromal	B-C1336512
alterations	I-C1336512
in	O
ovarian	B-C0029925
cancers	I-C0029925
via	O
wavelength	B-C0449819
dependent	B-C0851827
second	B-C0026018
harmonic	I-C0026018
generation	I-C0026018
microscopy	I-C0026018
and	O
optical	B-C0596837
scattering	I-C0596837
ovarian	B-C0029925
cancer	I-C0029925
remains	O
the	O
most	O
deadly	O
gynecological	B-C0018417
cancer	B-C0006826
with	O
a	O
poor	O
aggregate	O
survival	B-C0038954
rate	I-C0038954
however	O
,	O
the	O
specific	B-C2986538
rates	I-C2986538
are	O
highly	O
dependent	B-C0851827
on	O
the	O
stage	O
of	O
the	O
disease	B-C0012634
upon	O
diagnosis	B-C0011900
.	O
	
current	O
screening	B-C0220908
and	O
imaging	B-C1512629
tools	I-C1512629
are	O
insufficient	O
to	O
detect	O
early	B-C0221198
lesions	I-C0221198
and	O
are	O
not	O
capable	O
of	O
differentiating	O
the	O
subtypes	B-C0872379
of	O
ovarian	B-C0029925
cancer	I-C0029925
that	O
may	O
benefit	O
from	O
specific	O
treatments	B-C0087111
.	O
	
as	O
an	O
alternative	O
to	O
current	O
screening	B-C0220908
and	O
imaging	B-C1512629
tools	I-C1512629
,	O
we	O
utilized	O
wavelength	B-C0449819
dependent	B-C0851827
collagen	B-C0009325
-specific	O
second	B-C0026018
harmonic	I-C0026018
generation	I-C0026018
shg	I-C0026018
imaging	I-C0026018
microscopy	I-C0026018
and	O
optical	B-C0027692
scattering	I-C0027692
measurements	I-C0027692
to	O
probe	O
the	O
structural	B-C1510464
differences	B-C1705242
in	O
the	O
extracellular	B-C0015350
matrix	I-C0015350
ecm	B-C0015350
of	O
normal	O
stroma	B-C0927195
,	O
benign	B-C0086692
tumors	I-C0086692
,	O
endometrioid	B-C0474809
tumors	I-C0474809
,	O
and	O
low	B-C3839184
and	O
high-grade	B-C3839280
serous	I-C3839280
tumors	I-C3839280
.	O
	
the	O
shg	B-C0026018
signatures	B-C1704864
of	O
the	O
emission	O
directionality	O
and	O
conversion	B-C0439836
efficiency	B-C0013682
as	O
well	O
as	O
the	O
optical	B-C0596837
scattering	I-C0596837
are	O
related	O
to	O
the	O
organization	B-C1300196
of	O
collagen	B-C0009325
on	O
the	O
sub-micron	B-C0439201
size	B-C0282574
scale	I-C0282574
and	O
encode	O
structural	B-C1510464
information	B-C1533716
.	O
	
the	O
wavelength	B-C0449819
dependence	B-C0851827
of	O
these	O
readouts	O
adds	O
additional	O
characterization	O
of	O
the	O
size	B-C0456389
and	O
distribution	B-C1704711
of	O
collagen	B-C1179626
fibrils	I-C1179626
/	O
fibers	B-C0225325
relative	O
to	O
the	O
interrogating	O
wavelengths	B-C0449819
.	O
	
we	O
found	O
a	O
strong	O
wavelength	B-C0449819
dependence	B-C0851827
of	O
these	O
metrics	B-C0015350
that	O
are	O
related	O
to	O
significant	O
structural	B-C1510464
differences	B-C1705242
in	O
the	O
collagen	B-C0009325
organization	B-C1300196
and	O
are	O
consistent	O
with	O
the	O
dualistic	O
classification	B-C0008902
of	O
type	B-C0476122
i	I-C0476122
and	I-C0476122
ii	I-C0476122
serous	I-C0476122
tumors	I-C0476122
.	O
	
moreover	O
,	O
type	B-C0474809
i	I-C0474809
endometrioid	I-C0474809
tumors	I-C0474809
have	O
strongly	O
differing	O
ecm	B-C0015350
architecture	O
than	O
the	O
serous	B-C0476122
malignancies	I-C0476122
.	O
	
the	O
shg	B-C0026018
metrics	B-C0015350
and	O
optical	B-C0027692
scattering	I-C0027692
measurements	I-C0027692
were	O
used	O
to	O
form	O
a	O
linear	B-C3161035
discriminant	I-C3161035
model	I-C3161035
to	O
classify	O
the	O
tissues	B-C0040300
,	O
and	O
we	O
obtained	O
high	O
accuracy	O
>90%	O
between	O
high-grade	B-C3839280
serous	I-C3839280
tumors	I-C3839280
from	O
the	O
other	O
tissue	B-C2713035
types	I-C2713035
.	O
	
high-grade	B-C3839280
serous	I-C3839280
tumors	I-C3839280
account	O
for	O
70%	O
of	O
ovarian	B-C0029925
cancers	I-C0029925
,	O
and	O
this	O
delineation	O
has	O
potential	O
clinical	O
applications	O
in	O
terms	O
of	O
supplementing	O
histological	B-C0679557
analysis	I-C0679557
,	O
understanding	O
the	O
etiology	B-C1314792
,	O
as	O
well	O
as	O
development	O
of	O
an	O
in	B-C0681829
vivo	I-C0681829
screening	B-C0220908
tool	I-C0220908
.	O
	
shg	B-C0026018
and	O
optical	B-C0027692
scattering	I-C0027692
measurements	I-C0027692
provide	O
sub-resolution	O
information	B-C1533716
and	O
when	O
combined	O
provide	O
superior	B-C0430022
diagnostic	I-C0430022
power	I-C0430022
over	O
clinical	B-C0011923
imaging	I-C0011923
modalities	B-C1275506
.	O
	
additionally	O
the	O
measurements	B-C0242485
are	O
able	O
to	O
delineate	O
the	O
different	O
subtypes	B-C0872379
of	O
ovarian	B-C0029925
cancer	I-C0029925
and	O
may	O
potentially	O
assist	O
in	O
treatment	B-C0040808
protocols	I-C0040808
.	O
	
understanding	O
the	O
altered	B-C1515926
collagen	B-C0009325
assembly	O
can	O
supplement	O
histological	B-C0679557
analysis	I-C0679557
and	O
provide	O
new	O
insight	O
into	O
the	O
etiology	B-C1314792
.	O
	
these	O
methods	O
could	O
become	O
an	O
in	B-C0681829
vivo	I-C0681829
screening	B-C0220908
tool	I-C0220908
for	O
earlier	O
detection	O
which	O
is	O
important	O
since	O
ovarian	B-C1140680
malignancies	I-C1140680
can	O
metastasize	B-C0027627
while	O
undetectable	O
by	O
current	O
clinical	B-C0011923
imaging	I-C0011923
the	O
role	O
of	O
metal-on-metal	B-C3494213
bearings	I-C3494213
in	O
total	B-C0040508
hip	I-C0040508
arthroplasty	I-C0040508
and	O
hip	B-C1719285
resurfacing	I-C1719285
review	B-C0282443
article	I-C0282443
the	O
current	O
role	O
of	O
metal-on-metal	B-C3494213
mom	I-C3494213
bearings	I-C3494213
in	O
hip	B-C0186193
arthroplasty	I-C0186193
remains	O
controversial	O
.	O
	
the	O
low	O
wear	O
offered	O
by	O
mom	B-C3494213
bearings	I-C3494213
compared	O
to	O
metal-on-polyethylene	B-C3880938
and	O
the	O
possibility	O
of	O
a	O
lower	B-C3538919
risk	I-C3538919
of	I-C3538919
dislocation	B-C0012691
with	O
larger	B-C0205556
head	I-C0205556
sizes	I-C0205556
,	O
encouraged	O
a	O
trend	B-C1521798
towards	O
the	O
re-introduction	B-C0376495
of	O
the	O
mom	B-C3494213
bearing	I-C3494213
couple	O
.	O
	
however	O
,	O
recent	O
evidence	B-C3887511
has	O
shown	O
that	O
not	O
all	O
designs	O
of	O
the	O
mom	B-C3494213
bearing	I-C3494213
have	O
been	O
successful	B-C1272703
.	O
	
the	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
provide	O
an	O
update	O
on	O
the	O
use	O
of	O
mom	B-C3494213
bearings	I-C3494213
and	O
address	O
the	O
following	O
issues	O
1	O
the	O
reintroduction	B-C0376495
of	O
metal-on-metal	B-C3494213
bearings	I-C3494213
in	O
total	B-C0040508
hip	I-C0040508
arthroplasty	I-C0040508
,	O
2	O
the	O
failure	O
of	O
metal-on-metal	B-C3494213
bearings	I-C3494213
in	O
stemmed	B-C0040508
total	I-C0040508
hip	I-C0040508
arthroplasty	I-C0040508
,	O
3	O
the	O
role	O
of	O
metal-on-metal	B-C1955625
hip	I-C1955625
resurfacing	I-C1955625
in	O
modern	O
orthopaedics	B-C0029355
and	O
4	O
metal-on-metal	B-C1955625
hip	I-C1955625
resurfacing	I-C1955625
versus	O
total	B-C0040508
hip	I-C0040508
arthroplasty	I-C0040508
.	O
	
a	O
literature	B-C0023866
search	O
strategy	B-C0679199
was	O
conducted	O
using	O
various	O
search	O
terms	O
in	O
medline	B-C0025141
and	O
embase	B-C0242356
.	O
	
the	O
highest	O
quality	B-C1706852
articles	I-C1706852
that	O
met	O
the	O
inclusion	B-C1512693
criteria	I-C1512693
and	O
best	O
answered	O
the	O
topics	O
of	O
focus	O
of	O
this	O
review	B-C0282443
were	O
selected	O
.	O
	
key	O
search	O
terms	O
included	O
'	O
metal-on-metal	B-C3494213
'	O
,	O
'	O
total	B-C0040508
hip	I-C0040508
arthroplasty	I-C0040508
'	O
and	O
'	O
hip	B-C1719285
resurfacing	I-C1719285
'	O
.	O
	
the	O
initial	O
search	O
retrieved	O
1240	O
articles	B-C1706852
.	O
	
twenty-two	O
articles	B-C1706852
were	O
selected	O
and	O
used	O
in	O
the	O
review	B-C0282443
.	O
	
metal-on-metal	B-C3881498
hip	I-C3881498
resurfacing	I-C3881498
is	O
still	O
a	O
suitable	O
treatment	B-C0087111
option	O
in	O
specific	B-C0205369
patient	B-C2361270
populations	I-C2361270
with	O
the	O
appropriate	B-C1548787
implant	B-C0021107
design	I-C0021107
and	O
surgical	O
skill	O
,	O
while	O
stemmed	O
metal-on-metal	B-C3881498
total	I-C3881498
hip	I-C3881498
arthroplasty	I-C3881498
should	O
be	O
avoided	O
in	O
all	B-C2361270
patient	I-C2361270
populations	I-C2361270
.	O
	
continued	O
follow-up	B-C1522577
of	O
patients	B-C0030705
undergoing	O
metal-on-metal	B-C1955625
hip	I-C1955625
resurfacing	I-C1955625
is	O
critical	B-C1511545
in	O
order	O
to	O
further	O
understand	O
the	O
long-term	B-C0443252
outcomes	B-C0085415
of	O
these	O
patients	B-C0030705
and	O
why	O
certain	O
complications	B-C0009566
morphogenetic	B-C0026559
alterations	B-C1515926
of	O
alternaria	B-C0320062
alternata	I-C0320062
exposed	B-C0332157
to	I-C0332157
dicarboximide	B-C0392419
fungicide	I-C0392419
,	O
iprodione	B-C0123904
fungicide-resistant	B-C0332325
alternaria	B-C0320062
alternata	I-C0320062
impede	O
the	O
practical	O
control	B-C2587213
of	O
the	O
alternaria	B-C0026946
diseases	I-C0026946
in	O
crop	B-C0242775
fields	B-C0001829
.	O
	
this	O
study	O
aimed	O
to	O
investigate	B-C1292732
cytological	B-C0205471
fungicide	B-C0392419
resistance	B-C1514892
mechanisms	B-C0441712
of	O
a	B-C0320062
.	O
	
alternata	I-C0320062
against	O
dicarboximide	B-C0392419
fungicide	I-C0392419
iprodione	B-C0123904
.	O
	
a	B-C0320062
.	O
	
alternata	I-C0320062
isolated	B-C0205409
from	O
cactus	B-C0330340
brown	B-C1705203
spot	I-C1705203
was	O
cultured	B-C0200954
on	O
potato-dextrose	B-C1254353
agar	I-C1254353
pda	B-C1254353
with	O
or	O
without	B-C0332288
iprodione	B-C0123904
,	O
and	O
the	O
fungal	B-C0200954
cultures	I-C0200954
with	O
different	B-C1705242
growth	B-C0018270
characteristics	B-C1521970
from	O
no	B-C3686837
,	O
initial	B-C0205265
and	O
full	B-C0443225
growth	B-C0018270
were	O
observed	B-C1441672
by	O
light	B-C0430389
and	O
electron	B-C0026019
microscopy	I-C0026019
.	O
	
mycelia	B-C0949695
began	O
to	O
grow	B-C0018270
from	O
one	B-C1649476
day	I-C1649476
after	I-C1649476
incubation	I-C1649476
dai	B-C1649476
and	O
continued	B-C0549178
to	O
be	O
in	O
full	B-C0443225
growth	B-C0018270
control-growth	B-C0018270
,	O
con-g	B-C0018270
on	O
pda	B-C1254353
without	O
fungicide	B-C0392419
,	O
while	O
on	O
pda	B-C1254353
with	O
iprodione	B-C0123904
,	O
no	B-C3686837
fungal	I-C3686837
growth	I-C3686837
iprodione-no	B-C3686837
growth	I-C3686837
,	O
ipr-n	B-C3686837
occurred	O
for	O
the	O
first	O
3	O
dai	B-C1649476
,	O
but	O
once	O
the	O
initial	B-C0205265
growth	B-C0018270
iprodione-initial	B-C0018270
growth	I-C0018270
,	O
ipr-i	B-C0018270
began	O
at	O
4-5	O
dai	B-C1254367
,	O
the	O
colonies	B-C1947989
grew	O
and	O
expanded	B-C0205229
continuously	B-C0549178
to	O
be	O
in	O
full	B-C0443225
growth	B-C0018270
iprodione-growth	B-C0018270
,	O
ipr-g	B-C0018270
,	O
suggesting	O
ipr-i	B-C0018270
may	O
be	O
a	O
turning	O
moment	O
of	O
the	O
morphogenetic	B-C0026559
changes	B-C0392747
resisting	B-C1514892
fungicidal	B-C1321381
toxicity	B-C0040539
.	O
	
con-g	B-C0018270
formed	O
multicellular	B-C0038029
conidia	I-C0038029
with	O
cell	B-C3826300
walls	I-C3826300
and	O
septa	B-C0243092
and	O
intact	B-C0205266
dense	B-C0439794
cytoplasm	B-C0010834
.	O
	
in	O
ipr-n	B-C3686837
,	O
fungal	B-C0016832
sporulation	B-C2613267
was	O
inhibited	B-C0311403
by	O
forming	O
mostly	O
undeveloped	B-C0243095
unicellular	B-C0038029
conidia	I-C0038029
with	O
degraded	B-C0243095
and	O
necrotic	B-C0027540
cytoplasm	B-C0010834
.	O
	
however	O
,	O
in	O
ipr-i	B-C0018270
,	O
conspicuous	B-C1265925
cellular	I-C1265925
changes	I-C1265925
occurred	O
during	O
sporulation	B-C2613267
by	O
forming	O
multicellular	B-C0038029
conidia	I-C0038029
with	O
double	B-C0205400
layered	I-C0205400
thickened	B-C0205400
cell	B-C3826300
walls	I-C3826300
and	O
accumulation	B-C4055506
of	O
proliferated	B-C1514485
lipid	B-C0230704
bodies	I-C0230704
in	O
the	O
conidial	B-C0038029
cytoplasm	B-C0010834
,	O
which	O
may	O
inhibit	B-C0311403
the	O
penetration	B-C0205321
of	O
the	O
fungicide	B-C0392419
into	O
conidial	B-C0038029
cells	B-C0007634
,	O
reducing	O
fungicide	B-C0392419
-	O
associated	B-C0332281
toxicity	B-C0040539
,	O
and	O
may	O
be	O
utilized	O
as	O
energy	B-C1442080
and	O
nutritional	B-C1521739
sources	B-C0449416
,	O
respectively	O
,	O
for	O
the	O
further	O
fungal	B-C0016832
growth	B-C0018270
to	O
form	O
mature	B-C0205286
colonies	B-C1947989
as	O
in	O
ipr-g	B-C0018270
that	O
formed	O
multicellular	B-C0038029
conidia	I-C0038029
with	O
cell	B-C3826300
walls	I-C3826300
and	O
intact	B-C0205266
cytoplasm	B-C0010834
with	O
lipid	B-C0230704
bodies	I-C0230704
as	O
in	O
limits	O
of	O
the	O
possible	O
diagnostic	B-C1551337
image	I-C1551337
quality	B-C0806487
in	O
coronary	B-C0085532
angiography	I-C0085532
with	O
third-generation	B-C0040405
dual-source	I-C0040405
ct	I-C0040405
the	O
usage	B-C0457083
of	O
coronary	B-C1634617
ct	I-C1634617
angiography	I-C1634617
cta	B-C1634617
is	O
appropriate	O
in	O
patients	B-C0030705
with	O
acute	B-C0522051
or	O
chronic	B-C1740831
chest	I-C1740831
pain	I-C1740831
however	O
the	O
diagnostic	B-C0598285
accuracy	I-C0598285
may	O
be	O
challenged	O
with	O
increased	O
agatston	B-C0449820
score	I-C0449820
as	B-C0449820
,	O
increased	O
heart	B-C0018810
rate	I-C0018810
,	O
arrhythmia	B-C0003811
and	O
severe	B-C0028756
obesity	I-C0028756
.	O
	
thus	O
,	O
we	O
aim	O
to	O
determine	O
the	O
potential	O
of	O
the	O
recently	O
introduced	O
third-generation	B-C0040405
dual-source	I-C0040405
ct	I-C0040405
dsct	B-C0040405
for	O
cta	B-C1634617
in	O
a	O
'real-life'	O
clinical	B-C3176918
setting	I-C3176918
.	O
	
two	O
hundred	O
and	O
sixty-eight	O
consecutive	O
patients	B-C0030705
age	O
67	O
10	O
years	O
bmi	B-C1305855
27	O
5	O
kg/m²	O
61%	O
male	B-C0025266
undergoing	O
clinically	O
indicated	O
cta	B-C1634617
with	O
dsct	B-C0040405
were	O
included	O
in	O
the	O
retrospective	B-C0936012
single-center	I-C0936012
analysis	I-C0936012
.	O
	
a	O
contrast-enhanced	B-C0150098
volume	I-C0150098
dataset	I-C0150098
was	O
acquired	O
in	O
sequential	B-C0441633
ssm	B-C0441633
n	O
=	O
151	O
or	O
helical	B-C0441633
scan	I-C0441633
mode	I-C0441633
hsm	B-C0441633
n	O
=	O
117	O
.	O
	
coronary	B-C1283333
segments	I-C1283333
were	O
classified	O
in	O
diagnostic	B-C0806487
or	O
non-diagnostic	B-C0806487
image	I-C0806487
quality	I-C0806487
.	O
	
a	O
subset	O
underwent	O
invasive	B-C0002971
angiography	I-C0002971
to	O
determine	O
the	O
diagnostic	B-C0598285
accuracy	I-C0598285
of	O
cta	B-C1634617
.	O
	
ssm	B-C0441633
96.8	O
6%	O
and	O
hsm	B-C0441633
97.5	O
8%	O
provided	O
no	O
significant	O
differences	O
in	O
the	O
overall	O
diagnostic	B-C1551337
image	I-C1551337
quality	B-C0806487
.	O
	
however	O
,	O
as	B-C0449820
had	O
significant	O
influence	B-C4054723
on	O
diagnostic	B-C1551337
image	I-C1551337
quality	B-C0806487
exclusively	O
in	O
ssm	B-C0441633
b	O
=	O
0.003	O
p	O
=	O
0.0001	O
,	O
but	O
not	O
in	O
hsm	B-C0441633
.	O
	
diagnostic	B-C1551337
image	I-C1551337
quality	B-C0806487
significantly	O
decreased	O
in	O
ssm	B-C0441633
in	O
patients	B-C0030705
with	O
as	B-C0449820
2	O
p	O
=	O
0.03	O
.	O
	
ssm	B-C0441633
sensitivity	B-C1511883
93.9	O
specificity	B-C0037791
96.7	O
ppv	B-C1514243
88.6	O
npv	B-C1513918
98.3	O
and	O
hsm	B-C0441633
sensitivity	B-C1511883
97.4	O
specificity	B-C0037791
94.3	O
ppv	B-C1514243
86.0	O
npv	B-C1513918
99.0	O
provided	O
comparable	O
diagnostic	B-C0598285
accuracy	I-C0598285
p	O
=	O
n.s	O
.	O
	
ssm	B-C0441633
yielded	O
significantly	O
lower	O
radiation	B-C4019308
doses	I-C4019308
as	O
compared	O
to	O
hsm	B-C0441633
2.1	O
2.0	O
vs	O
.	O
	
5.1	O
3.3	O
msv	O
p	O
=	O
0.0001	O
in	O
age	B-C0599755
and	O
bmi	B-C1305855
-matched	O
cohorts	B-C0599755
.	O
	
ssm	B-C0441633
in	O
third-generation	B-C0040405
dsct	I-C0040405
enables	O
significant	O
dose	B-C0178602
savings	O
and	O
provides	O
robust	O
diagnostic	B-C1551337
image	I-C1551337
quality	B-C0806487
in	O
patients	B-C0030705
with	O
as	B-C0449820
2000	O
independent	O
of	O
heart	B-C0018810
rate	I-C0018810
,	O
heart	B-C0232187
rhythm	I-C0232187
or	O
antagonistic	B-C1148560
self-organizing	B-C0376678
patterning	I-C0376678
systems	O
control	B-C2587213
maintenance	B-C2371947
and	O
regeneration	B-C0034963
of	O
the	O
anteroposterior	B-C0442212
axis	B-C1522496
in	O
planarians	B-C0032068
planarian	B-C0032068
flatworms	B-C0032211
maintain	B-C2371947
their	O
body	B-C1268086
plan	O
in	O
the	O
face	O
of	O
constant	O
internal	O
turnover	O
and	O
can	O
regenerate	B-C0334213
from	O
arbitrary	B-C1264693
tissue	B-C0040300
fragments	B-C0486805
.	O
	
both	O
phenomena	B-C1882365
require	O
self-maintaining	B-C0024501
and	O
self-organizing	B-C0376678
patterning	I-C0376678
mechanisms	B-C0441712
,	O
the	O
molecular	B-C1521991
mechanisms	B-C0441712
of	O
which	O
remain	O
poorly	O
understood	O
.	O
	
we	O
show	O
that	O
a	O
morphogenic	B-C1152630
gradient	B-C0812409
of	O
canonical	B-C3178960
wnt	I-C3178960
signaling	I-C3178960
patterns	O
gene	B-C0017262
expression	I-C0017262
along	O
the	O
planarian	B-C0032068
anteroposterior	B-C0442212
a/p	B-C0442212
axis	B-C1522496
.	O
	
our	O
results	B-C0683954
demonstrate	O
that	O
gradient	B-C0812409
formation	B-C1522492
likely	O
occurs	O
autonomously	B-C0332291
in	O
the	O
tail	B-C0039259
and	O
that	O
an	O
autoregulatory	B-C0019868
module	O
of	O
wnt	B-C0753137
-mediated	O
wnt	B-C0935995
expression	B-C1171362
both	O
shapes	O
the	O
gradient	B-C0812409
at	O
steady	B-C0678587
state	I-C0678587
and	O
governs	O
its	O
re-establishment	O
during	O
regeneration	B-C0034963
.	O
	
functional	B-C0205245
antagonism	B-C1148560
between	O
the	O
tail	B-C0039259
wnt	B-C0753137
gradient	B-C0812409
and	O
an	O
unknown	B-C0439673
head	B-C0018670
patterning	B-C0376678
system	O
further	O
determines	O
the	O
spatial	B-C0037775
proportions	B-C1709707
of	O
the	O
planarian	B-C0032068
a/p	B-C0442212
axis	B-C1522496
and	O
mediates	O
mutually	B-C1709100
exclusive	B-C1548966
molecular	B-C1148560
fate	I-C1148560
choices	O
during	B-C0347984
regeneration	B-C0034963
.	O
	
overall	O
,	O
our	O
results	B-C0683954
suggest	O
that	O
the	O
planarian	B-C0032068
a/p	B-C0442212
axis	B-C1522496
is	O
patterned	O
by	O
self-organizing	B-C0376678
patterning	I-C0376678
systems	O
deployed	B-C2825812
from	O
either	O
end	O
that	O
are	O
functionally	B-C0205245
coupled	B-C1948027
by	O
mutual	B-C1709100
antagonism	B-C1148560
.	O
	
characterization	B-C1880022
and	O
ectopic	B-C1512167
expression	I-C1512167
of	O
cowri1	B-C1517488
,	O
an	O
ap2/erebp	B-C1517488
domain-containing	O
transcription	B-C0040648
factor	I-C0040648
from	O
coconut	B-C0009210
cocos	B-C0009210
nucifera	I-C0009210
l	I-C0009210
endosperm	B-C2717855
,	O
changes	O
the	O
seeds	B-C0036563
oil	B-C0032085
content	O
in	O
transgenic	B-C0085245
arabidopsis	B-C0162740
thaliana	I-C0162740
and	O
rice	B-C1140671
oryza	B-C1140671
sativa	I-C1140671
l	I-C1140671
coconut	B-C0009210
cocos	B-C0009210
nucifera	I-C0009210
l	I-C0009210
is	O
a	O
key	O
tropical	B-C0041183
crop	B-C0242775
and	O
a	O
member	O
of	O
the	O
monocotyledonous	B-C1704727
family	I-C1704727
arecaceae	B-C0682477
palmaceae	B-C0682477
.	O
	
few	O
genes	B-C0017337
and	O
related	O
metabolic	B-C0025519
processes	I-C0025519
involved	O
in	O
coconut	B-C0009210
endosperm	B-C2717855
development	O
have	O
been	O
investigated	B-C1292732
.	O
	
in	O
this	O
study	B-C2603343
,	O
a	O
new	O
member	O
of	O
the	O
wri1	B-C1517488
gene	B-C1517488
family	I-C1517488
was	O
isolated	O
from	O
coconut	B-C0009210
endosperm	B-C2717855
and	O
was	O
named	O
cowri1	B-C1517488
.	O
	
its	O
transcriptional	B-C0040649
activities	B-C0441655
and	O
interactions	B-C1704675
with	O
the	O
acetyl-coa	B-C0001022
carboxylase	I-C0001022
bccp2	B-C0213275
promoter	B-C0086860
of	O
cowri1	B-C1517488
were	O
confirmed	O
by	O
the	O
yeast	B-C0599647
two-hybrid	I-C0599647
and	O
yeast	B-C0599647
one-hybrid	I-C0599647
approaches	O
,	O
respectively	O
.	O
	
functional	O
characterization	B-C1880022
was	O
carried	O
out	O
through	O
seed	B-C0036563
-specific	O
expression	B-C0017262
in	O
arabidopsis	B-C0162741
and	O
endosperm	B-C2717855
-specific	O
expression	B-C0017262
in	O
rice	B-C1140671
.	O
	
in	O
transgenic	B-C0085245
arabidopsis	B-C0162741
,	O
high	O
over-expressions	B-C0017262
of	O
cowri1	B-C1517488
in	O
seven	O
independent	O
t2	B-C0085245
lines	B-C1140671
were	O
detected	O
by	O
quantitative	B-C3179034
real-time	I-C3179034
pcr	I-C3179034
.	O
	
the	O
relative	O
mrna	B-C0035696
accumulation	O
of	O
genes	B-C0017337
encoding	B-C2700640
enzymes	B-C0014442
involved	O
in	O
either	O
fatty	B-C0596562
acid	I-C0596562
biosynthesis	I-C0596562
or	O
triacylglycerols	B-C0041004
assembly	O
bccp2	B-C0017337
,	O
kasi	B-C0017337
,	O
mat	B-C0017337
,	O
enr	B-C0017337
,	O
fata	B-C0017337
,	O
and	O
gpdh	B-C0017337
were	O
also	O
assayed	B-C0005507
in	O
mature	O
seeds	B-C0036563
.	O
	
furthermore	O
,	O
lipid	B-C0023779
and	O
fatty	B-C0015684
acids	I-C0015684
c16	B-C0030234
and	O
c18	B-C0038228
significantly	O
increased	O
.	O
	
in	O
two	O
homozygous	B-C0019904
t2	B-C0085245
transgenic	B-C0085245
rice	B-C1140671
lines	I-C1140671
g5	B-C1140671
and	O
g2	B-C1140671
,	O
different	O
cowri1	B-C1517488
expression	B-C0017262
levels	O
were	O
detected	O
,	O
but	O
no	O
cowri1	B-C1517488
transcripts	B-C1519595
were	O
detected	O
in	O
the	O
wild	B-C1883559
type	I-C1883559
.	O
	
analyses	B-C0936012
of	O
the	O
seed	B-C0036563
oil	B-C0032085
content	O
,	O
starch	B-C0038179
content	O
,	O
and	O
total	O
protein	B-C0033684
content	O
indicated	O
that	O
the	O
two	O
t2	B-C0085245
transgenic	B-C0085245
lines	I-C0085245
showed	O
a	O
significant	O
increase	O
p	O
<	O
0.05	O
in	O
seed	B-C0036563
oil	B-C0032085
content	O
.	O
	
the	O
transgenic	B-C0085245
lines	I-C0085245
also	O
showed	O
a	O
significant	O
increase	O
in	O
starch	B-C0038179
content	O
,	O
whereas	O
total	O
protein	B-C0033684
content	O
decreased	O
significantly	O
.	O
	
further	O
analysis	B-C0936012
of	O
the	O
fatty	B-C0015684
acid	I-C0015684
composition	O
revealed	O
that	O
palmitic	B-C0030234
acid	I-C0030234
c16	B-C0030234
and	O
linolenic	B-C0125903
acid	I-C0125903
c18	B-C0125903
increased	O
significantly	O
in	O
the	O
seeds	B-C0036563
of	O
the	O
transgenic	B-C0085245
rice	B-C1140671
lines	I-C1140671
,	O
but	O
oleic	B-C0028928
acid	I-C0028928
c18	B-C0028928
tooth	B-C0040434
discoloration	I-C0040434
resulting	B-C0678226
from	O
a	O
nano	B-C1553036
zinc	B-C0043492
oxide-eugenol	I-C0043492
sealer	B-C0676273
a	O
desirable	O
quality	B-C0332306
of	O
any	O
endodontic	B-C0676273
sealer	I-C0676273
is	O
its	O
ability	O
to	O
be	O
tooth	B-C0475833
color	I-C0475833
friendly	B-C2700214
.	O
	
therefore	O
the	O
aim	O
of	O
the	O
present	O
study	B-C2603343
was	O
to	O
evaluate	O
the	O
tooth	B-C0040434
discoloration	I-C0040434
potential	B-C3245505
of	O
a	O
nano	B-C1553036
zinc	B-C0043492
oxide-eugenol	I-C0043492
nzoe	B-C0043492
sealer	B-C0676273
.	O
	
in	O
order	O
to	O
evaluate	O
tooth	B-C0040434
discoloration	I-C0040434
,	O
the	O
pulp	B-C0034099
chamber	I-C0034099
of	O
60	O
human	B-C0086418
maxillary	B-C0021156
central	I-C0021156
and	O
lateral	B-C0021156
incisors	I-C0021156
were	O
filled	B-C1708059
with	O
one	O
of	O
the	O
sealers	B-C0676273
,	O
naming	O
ah-26	B-C0051001
resin-based	B-C0051001
sealer	I-C0051001
,	O
pulpdent	B-C0072601
sealer	B-C0676273
zoe	B-C0043492
-based	O
and	O
a	O
nzoe	B-C0043492
experimental	O
sealer	B-C0676273
.	O
	
color	B-C0009393
measurements	B-C0242485
was	O
assessed	O
at	O
the	O
baseline	B-C1442488
before	B-C1524072
placement	I-C1524072
of	O
sealers	B-C0676273
t0	O
,	O
24	O
h	B-C0439227
t1	O
and	O
72	O
h	B-C0439227
t2	O
h	B-C0439227
,	O
1-	O
week	B-C0439230
t3	O
,	O
and	O
1-	O
month	B-C0439231
t4	O
after	O
the	O
placement	O
of	O
sealers	B-C0676273
using	O
the	O
easy	B-C0183400
shade	I-C0183400
spectrophotometer	I-C0183400
.	O
	
data	B-C1511726
were	O
analyzed	B-C0936012
in	O
spss	B-C0037585
software	I-C0037585
using	O
one-way	B-C1709320
anova	I-C1709320
,	O
and	O
repeated	O
measured	O
anova	B-C0002780
.	O
	
no	O
significant	O
differences	O
were	O
observed	B-C1441672
when	O
the	O
paired	B-C0282574
comparison	I-C0282574
test	I-C0282574
was	O
performed	O
p>0	O
.	O
	
the	O
tested	O
nzoe	B-C0043492
sealer	B-C0676273
had	O
similar	O
tooth	B-C0040434
discoloration	I-C0040434
potential	B-C3245505
in	O
comparison	B-C1707455
with	O
ah-26	B-C0051001
and	O
zoe	B-C0043492
sealer	B-C0676273
.	O
	
on	O
the	O
identity	B-C0017390
of	O
the	O
palearctic	B-C0681784
species	B-C1705920
of	O
the	O
wolf	B-C0323749
spider	I-C0323749
genus	B-C1708235
<i>	O
trebacosa	B-C3409647
</i>	O
lycosidae	O
in	O
this	O
paper	O
we	O
propose	O
trebacosa	O
brunhesi	O
villepoux	O
,	O
2007	O
as	O
a	O
junior	O
synonym	O
of	O
trebacosa	O
europaea	O
szinetár	O
kan-csal	O
,	O
2007	O
based	O
on	O
the	O
examination	O
of	O
specimens	O
from	O
all	O
the	O
localities	O
from	O
where	O
those	O
species	O
are	O
known	O
.	O
	
illustration	O
of	O
the	O
type	O
species	O
of	O
the	O
genus	O
,	O
trebacosa	O
marxi	O
stone	O
,	O
1890	O
and	O
specimens	O
from	O
all	O
known	O
localities	O
of	O
t	O
.	O
	
europaea	O
are	O
given	O
to	O
show	O
both	O
the	O
inter-	O
and	O
the	O
intraspecific	O
differences	O
of	O
the	O
genus	O
.	O
	
scanning	O
electron	O
micrographs	O
were	O
used	O
to	O
illustrate	O
the	O
detailed	O
structure	O
of	O
the	O
female's	O
genitalia	I-C0017421
a	O
numerical	B-C0237753
study	B-C2603343
on	O
the	O
application	O
of	O
the	O
functionally	B-C3273359
graded	I-C3273359
materials	I-C3273359
in	O
the	O
stent	B-C0038257
design	B-C1707689
undesirable	B-C1883420
deformation	B-C2919017
of	O
the	O
stent	B-C0038257
can	O
induce	O
a	O
significant	B-C0178324
amount	O
of	O
injure	B-C3263723
not	O
only	O
to	O
the	O
blood	B-C0005847
vessel	I-C0005847
but	O
also	O
to	O
the	O
plaque	B-C0332461
.	O
	
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
reduce/minimize	B-C0243095
these	O
undesirable	B-C1883420
deformations	B-C2919017
by	O
the	O
application	O
of	O
functionally	B-C3273359
graded	I-C3273359
materials	I-C3273359
fgm	B-C3273359
.	O
	
to	O
do	O
this	O
,	O
finite	B-C3826344
element	I-C3826344
fe	I-C3826344
method	I-C3826344
was	O
employed	B-C0557351
to	O
simulate	B-C0679083
the	O
expansion	B-C0442805
of	O
a	O
stent	B-C0038257
and	O
the	O
corresponding	O
displacement	B-C2347509
of	O
the	O
stenosis	B-C1261287
plaque	B-C0332461
.	O
	
three	O
hyperelastic	B-C0450146
plaque	B-C0332461
types	O
as	O
well	O
as	O
five	O
elastoplastic	B-C0441289
stents	I-C0441289
were	O
simulated	O
.	O
	
dogboning	B-C0001688
,	O
foreshortening	B-C0243095
,	O
maximum	B-C0806909
stress	B-C0038435
in	O
the	O
plaque	B-C0332461
,	O
and	O
the	O
pressure	B-C0033095
which	O
is	O
needed	O
to	O
fully	O
expand	B-C0205229
the	O
stent	B-C0038257
for	O
different	O
stent	B-C0038257
materials	B-C0520510
,	O
were	O
acquired	O
.	O
	
while	O
all	O
fgms	B-C3273359
had	O
lower	B-C0547044
dogboning	B-C0001688
in	O
comparison	O
to	O
the	O
stents	B-C0038257
made	O
of	O
the	O
uniform	B-C0205375
materials	B-C0520510
,	O
the	O
stent	B-C0038257
with	O
the	O
lowest	B-C1708760
heterogeneous	B-C0918012
index	I-C0918012
displayed	O
the	O
lowest	B-C1708760
amount	O
of	O
dogboning	B-C0001688
.	O
	
steel	B-C0038239
stent	B-C0038257
showed	O
the	O
lowest	B-C1708760
foreshortening	B-C0243095
and	O
fully	O
expansion	B-C4049814
pressure	I-C4049814
but	O
the	O
difference	B-C1705241
was	O
much	O
lower	B-C0547044
than	O
that	O
the	O
one	O
for	O
dogboning	B-C0001688
.	O
	
therefore	O
,	O
the	O
fgm	B-C3273359
with	O
the	O
heterogeneous	B-C0918012
index	I-C0918012
of	O
0.5	O
is	O
expected	O
to	O
exhibit	O
the	O
most	O
suitable	B-C3900053
results	B-C1274040
.	O
	
in	O
addition	O
,	O
the	O
results	B-C1274040
revealed	O
that	O
the	O
material	B-C0520510
parameters	B-C0549193
has	O
crucial	B-C1511545
effects	B-C1280500
on	O
the	O
deformation	B-C2919017
of	O
the	O
stent	B-C0038257
and	O
,	O
as	O
a	O
result	B-C1274040
,	O
as	O
a	O
design	B-C1707689
point	O
of	O
view	O
the	O
fgm	B-C3273359
parameters	B-C0549193
can	O
be	O
tailored	O
to	O
achieve	O
the	O
goal	O
of	O
the	O
biomechanical	B-C0009563
optimization	B-C2698650
.	O
	
women's	B-C0043210
perspectives	O
on	O
human	B-C0021344
papillomavirus	I-C0021344
self-sampling	B-C0080142
in	O
the	O
context	O
of	O
the	O
uk	B-C0041700
cervical	B-C0007874
screening	B-C1254363
programme	I-C1254363
testing	B-C0039593
for	O
human	B-C0021344
papillomavirus	I-C0021344
hpv	B-C0021344
is	O
being	O
incorporated	O
into	O
the	O
cervical	B-C0007874
screening	B-C1254363
programme	I-C1254363
,	O
with	O
the	O
probable	O
future	O
introduction	O
of	O
hpv	B-C0021344
as	O
a	O
primary	O
test	O
and	O
a	O
possibility	O
of	O
hpv	B-C0021344
self-sampling	B-C0080142
.	O
	
in	O
anticipation	O
of	O
this	O
development	O
,	O
we	O
sought	O
to	O
inform	O
future	O
policy	B-C0242456
and	O
practice	B-C0237607
by	O
identifying	O
potential	B-C3245505
barriers	B-C4296486
to	O
hpv	B-C0021344
self-sampling	B-C0080142
.	O
	
a	O
cross-sectional	B-C0010362
survey	I-C0010362
of	O
194	O
women	B-C0043210
aged	O
20-64	O
years	O
was	O
conducted	O
.	O
	
logistic	B-C0681925
regression	I-C0681925
analysis	I-C0681925
was	O
used	O
to	O
identify	O
determinants	B-C1521761
of	O
self-sampling	B-C0080142
intentions	O
.	O
	
a	O
purposive	O
subsample	O
of	O
19	O
women	B-C0043210
who	O
reported	O
low	O
self-sampling	B-C0080142
intentions	O
were	O
interviewed	O
.	O
	
interviews	B-C0021822
were	O
framework-analysed	O
.	O
	
most	O
survey	B-C0038951
participants	B-C0679646
n=133	O
,	O
69.3	O
intended	O
to	O
hpv	B-C0021344
self-sample	O
.	O
	
lower	B-C0205556
intention	B-C0162425
was	O
associated	B-C0332281
with	I-C0332281
lower	B-C0205556
self-efficacy	O
or=24	O
,	O
p	O
,	O
lower	B-C0205556
education	B-C0013621
or=6	O
,	O
p	O
and	O
lower	B-C0205556
perceived	B-C0030971
importance	O
of	O
hpv	B-C0021344
as	O
a	O
cause	O
of	O
cervical	B-C0302592
cancer	I-C0302592
or=2	O
,	O
p	O
.	O
	
interviews	B-C0021822
revealed	O
personal	B-C1519021
and	O
system-related	O
barriers	B-C4296486
.	O
	
personal	B-C1519021
barriers	B-C4296486
included	O
a	O
lack	O
of	O
knowledge	B-C0376554
about	O
hpv	B-C0021344
self-sampling	B-C0080142
,	O
women's	B-C0043210
low	B-C0558092
confidence	I-C0558092
in	O
their	O
ability	O
to	O
self-sample	O
correctly	O
and	O
low	B-C0558092
confidence	I-C0558092
in	O
the	O
subsequent	O
results	O
.	O
	
system-related	O
factors	O
included	O
a	O
lack	B-C0558092
of	I-C0558092
confidence	I-C0558092
in	O
the	O
rationale	O
for	O
modifying	O
the	O
current	O
cervical	B-C0007874
screening	B-C1254363
programme	I-C1254363
,	O
and	O
concerns	O
about	O
sample	B-C0370003
contamination	B-C2349974
and	O
identity	B-C3658363
theft	I-C3658363
.	O
	
insights	O
gained	O
from	O
this	O
research	B-C0035168
can	O
be	O
used	O
to	O
guide	O
further	O
enquiry	O
into	O
the	O
possibility	O
of	O
hpv	B-C0021344
self-sampling	B-C0080142
and	O
to	O
help	O
inform	O
future	O
policy	B-C0242456
and	O
practice	B-C0237607
.	O
	
personal	B-C1519021
and	O
system-related	B-C0243095
barriers	I-C0243095
including	O
low	B-C0558092
confidence	I-C0558092
in	O
the	O
reasons	O
for	O
changing	O
current	O
cervical	B-C0007874
screening	B-C1710032
provision	O
need	O
to	O
be	O
addressed	O
,	O
should	O
hpv	B-C0021344
self-sampling	B-C0080142
be	O
incorporated	O
into	O
the	O
cervical	B-C0007874
screening	B-C1254363
programme	I-C1254363
.	O
	
n-terminal	B-C1706793
hypothesis	B-C1512571
for	O
alzheimer's	B-C0002395
disease	I-C0002395
although	O
the	O
amyloid	B-C0002716
abeta	B-C0078939
peptide	I-C0078939
,	O
aβ	B-C0078939
hypothesis	B-C1512571
is	O
25	O
years	B-C0439234
old	O
,	O
is	O
the	O
dominant	B-C1527180
model	B-C3161035
of	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
pathogenesis	B-C0699748
,	O
and	O
guides	O
the	O
development	B-C1527148
of	O
potential	O
treatments	B-C0087111
,	O
it	O
is	O
still	O
controversial	B-C0680243
.	O
	
one	O
possible	O
reason	O
is	O
a	O
lack	B-C0332268
of	O
a	O
mechanistic	B-C0441712
path	I-C0441712
from	O
the	O
cleavage	B-C0439861
products	I-C0439861
of	O
the	O
amyloid	B-C0085151
precursor	I-C0085151
protein	I-C0085151
app	B-C0085151
such	O
as	O
soluble	B-C1948047
aβ	B-C3484390
monomer	I-C3484390
and	O
soluble	O
molecular	B-C1521991
fragments	B-C0332255
to	O
the	O
deleterious	B-C1280500
effects	I-C1280500
on	O
synaptic	B-C0597545
form	I-C0597545
and	O
function	B-C0542341
.	O
	
from	O
a	O
review	B-C0699752
of	I-C0699752
the	O
recent	O
literature	B-C0023866
and	O
our	O
own	O
published	B-C0034036
work	I-C0034036
including	O
aggregation	B-C0022702
kinetics	I-C0022702
and	O
structural	B-C0678594
morphology	B-C0332437
,	O
aβ	B-C0078939
clearance	B-C0449297
,	O
molecular	B-C1521991
simulations	B-C0679083
,	O
long-term	B-C0206249
potentiation	I-C0206249
measurements	B-C0242485
with	O
inhibition	B-C2259198
binding	I-C2259198
,	O
and	O
the	O
binding	B-C1167622
of	O
a	O
commercial	O
monoclonal	B-C0003250
antibody	I-C0003250
,	O
aducanumab	B-C4043101
,	O
we	O
hypothesize	B-C1512571
that	O
the	O
n-terminal	B-C1706793
domains	I-C1706793
of	O
neurotoxic	B-C0260049
aβ	B-C0078939
oligomers	I-C0078939
are	O
implicated	O
in	O
causing	B-C0678227
the	O
generation	B-C3146294
of	O
high-quality	B-C0332306
swath	B-C0282574
acquisition	B-C1706701
data	B-C1511726
for	O
label-free	B-C0243095
quantitative	B-C0392762
proteomics	B-C0872252
studies	I-C0872252
using	O
tripletof	B-C0183396
mass	I-C0183396
spectrometers	I-C0183396
data	B-C1511726
-	O
independent	B-C0332291
acquisition	B-C1706701
is	O
a	O
powerful	O
mass	B-C0037813
spectrometry	I-C0037813
technique	I-C0037813
that	O
enables	O
comprehensive	O
ms	B-C0037813
and	O
ms/ms	B-C0599748
analysis	B-C0936012
of	O
all	O
detectable	B-C3830527
species	B-C1551338
,	O
providing	O
an	O
information	B-C1533716
rich	O
data	B-C1511726
file	O
that	O
can	O
be	O
mined	B-C1328866
deeply	O
.	O
	
here	O
,	O
we	O
describe	O
how	O
to	O
acquire	B-C1706701
high-quality	B-C0332306
swath	B-C0282574
acquisition	B-C1706701
data	B-C1511726
to	O
be	O
used	O
for	O
large	B-C0549177
quantitative	B-C0392762
proteomic	B-C0872252
studies	I-C0872252
.	O
	
we	O
specifically	O
focus	O
on	O
using	O
variable	B-C0439828
sized	B-C0456389
q1	B-C0282574
windows	I-C0282574
for	O
acquisition	B-C1706701
of	O
ms/ms	B-C0599748
data	B-C1511726
for	O
generating	B-C3146294
higher	O
specificity	B-C0037791
quantitative	B-C0392762
data	B-C1511726
.	O
	
a	O
new	O
light	O
on	O
alkaptonuria	B-C0002066
a	O
fourier-transform	B-C0596777
infrared	I-C0596777
microscopy	I-C0596777
ftirm	B-C0596777
and	O
low	B-C0026022
energy	I-C0026022
x-ray	I-C0026022
fluorescence	I-C0026022
microscopy	I-C0026022
lexrf	B-C0026022
correlative	B-C1511524
study	I-C1511524
on	O
a	O
rare	B-C0678236
disease	I-C0678236
alkaptonuria	B-C0002066
aku	B-C0002066
is	O
an	O
ultra-rare	B-C0678236
disease	I-C0678236
associated	B-C0332281
to	O
the	O
lack	B-C0332268
of	O
an	O
enzyme	B-C0014442
involved	O
in	O
tyrosine	B-C1156678
catabolism	I-C1156678
.	O
	
this	O
deficiency	B-C0011155
results	O
in	O
the	O
accumulation	B-C4055506
of	O
homogentisic	B-C0019881
acid	I-C0019881
hga	B-C0019881
in	O
the	O
form	O
of	O
ochronotic	B-C0028818
pigment	I-C0028818
in	O
joint	B-C0022417
cartilage	B-C0007301
,	O
leading	O
to	O
a	O
severe	B-C0205082
arthropathy	B-C0022408
.	O
	
secondary	B-C0002726
amyloidosis	I-C0002726
has	O
been	O
also	O
unequivocally	B-C4053896
assessed	B-C1516048
as	O
a	O
comorbidity	B-C0009488
of	O
aku	B-C0002066
arthropathy	B-C0022408
.	O
	
composition	O
of	O
ochronotic	B-C0028818
pigment	I-C0028818
and	O
how	O
it	O
is	O
structurally	B-C0678594
related	O
to	O
amyloid	B-C0002716
is	O
still	O
unknown	O
.	O
	
we	O
exploited	O
synchrotron	B-C0599746
radiation	I-C0599746
infrared	B-C0596777
and	O
x-ray	B-C0026022
fluorescence	I-C0026022
microscopies	I-C0026022
in	O
combination	O
with	O
conventional	O
bio-assays	B-C0005507
and	O
analytical	B-C0936012
tools	O
to	O
characterize	O
chemical	B-C0243176
composition	I-C0243176
and	O
morphology	B-C0332437
of	O
aku	B-C0002066
cartilage	B-C0007301
.	O
	
we	O
evinced	B-C0205319
that	O
aku	B-C0002066
cartilage	B-C0007301
is	O
characterized	O
by	O
proteoglycans	B-C0033692
depletion	B-C0333668
,	O
increased	B-C0595879
sodium	I-C0595879
levels	I-C0595879
,	O
accumulation	B-C4055506
of	O
lipids	B-C0023779
in	O
the	O
peri-lacunar	B-C0229984
regions	I-C0229984
and	O
amyloid	B-C0002716
formation	B-C1522492
.	O
	
we	O
also	O
highlighted	O
an	O
increase	B-C0442805
of	O
aromatic	B-C1510940
compounds	I-C1510940
and	O
oxygen-containing	B-C0684299
species	I-C0684299
,	O
depletion	B-C0333668
in	O
overall	O
magnesium	B-C0024467
content	B-C1264655
although	O
localized	B-C0392752
in	O
the	O
peri-lacunar	B-C0229984
region	I-C0229984
and	O
the	O
presence	B-C0150312
of	O
calcium	B-C0006681
carbonate	I-C0006681
fragments	O
in	O
proximity	B-C1514583
of	O
cartilage	B-C0225370
lacunae	I-C0225370
.	O
	
we	O
highlighted	O
common	B-C0205214
features	O
between	O
aku	B-C0002066
and	O
arthropathy	B-C0022408
,	O
but	O
also	O
specific	O
signatures	O
of	O
the	O
disease	B-C0012634
,	O
like	O
presence	B-C0150312
of	O
amyloids	B-C0002716
and	O
peculiar	B-C0205161
calcifications	B-C1533591
.	O
	
our	O
analyses	B-C0936012
provide	O
a	O
unified	O
picture	O
of	O
aku	B-C0002066
cartilage	B-C0007301
,	O
shedding	O
a	O
new	O
light	O
on	O
the	O
disease	B-C0012634
and	O
opening	O
new	B-C0205314
perspectives	O
.	O
	
ochronotic	B-C0028818
pigment	I-C0028818
is	O
a	O
hallmark	O
of	O
aku	B-C0002066
and	O
responsible	O
of	O
tissue	B-C1623047
degeneration	I-C1623047
.	O
	
conventional	O
bio-assays	B-C0005507
have	O
not	O
yet	O
clarified	O
its	O
composition	B-C0243176
and	O
its	O
structural	B-C0678594
relationship	B-C0439849
with	O
amyloids	B-C0002716
.	O
	
the	O
present	B-C0521116
work	B-C0035168
proposes	O
new	O
strategies	O
for	O
filling	O
the	O
aforementioned	O
gap	O
that	O
encompass	O
the	O
integration	B-C0243126
of	O
new	O
analytical	B-C0936012
approaches	O
with	O
standardized	B-C1442989
analyses	B-C0936012
.	O
	
unbiased	B-C1711255
estimates	I-C1711255
of	O
cerebrospinal	B-C0007806
fluid	I-C0007806
β-amyloid	B-C0169424
1-42	I-C0169424
cutoffs	B-C1442160
in	O
a	O
large	O
memory	B-C0442592
clinic	I-C0442592
population	B-C1257890
we	O
sought	O
to	O
define	O
a	O
cutoff	B-C1442160
for	O
β-amyloid	B-C0169424
1-42	I-C0169424
in	O
cerebrospinal	B-C0007806
fluid	I-C0007806
csf	B-C0007806
,	O
a	O
key	O
marker	B-C0005516
for	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
,	O
with	O
data-driven	B-C3899452
gaussian	B-C0026348
mixture	I-C0026348
modeling	I-C0026348
in	O
a	O
memory	B-C0442592
clinic	I-C0442592
population	B-C1257890
.	O
	
we	O
performed	O
a	O
combined	O
cross-sectional	B-C0010362
and	O
prospective	B-C1709709
cohort	I-C1709709
study	I-C1709709
.	O
	
we	O
selected	O
2462	O
subjects	B-C2349001
with	O
subjective	B-C0234985
cognitive	I-C0234985
decline	I-C0234985
,	O
mild	B-C1270972
cognitive	I-C1270972
impairment	I-C1270972
,	O
ad	B-C0002395
-type	O
dementia	B-C0497327
,	O
and	O
dementia	B-C0497327
other	O
than	O
ad	B-C0002395
from	O
the	O
amsterdam	B-C0681784
dementia	B-C0497327
cohort	B-C0599755
.	O
	
we	O
defined	O
csf	B-C0007806
β-amyloid	B-C0169424
1-42	I-C0169424
cutoffs	B-C1442160
by	O
data-driven	B-C3899452
gaussian	B-C0026348
mixture	I-C0026348
modeling	I-C0026348
in	O
the	O
total	B-C3258257
population	I-C3258257
and	O
in	O
subgroups	B-C1515021
based	O
on	O
clinical	B-C0332140
diagnosis	I-C0332140
,	O
age	B-C0001779
,	O
and	O
apolipoprotein	B-C1446118
e	I-C1446118
apoe	I-C1446118
genotype	I-C1446118
.	O
	
we	O
investigated	B-C1292732
whether	O
abnormal	B-C0205161
β-amyloid	B-C0169424
1-42	I-C0169424
as	O
defined	O
by	O
the	O
data-driven	B-C3899452
cutoff	B-C1442160
could	O
better	O
predict	B-C0681842
progression	B-C0449258
to	O
ad	B-C0002395
-type	O
dementia	B-C0497327
than	O
abnormal	B-C0205161
β-amyloid	B-C0169424
1-42	I-C0169424
defined	O
by	O
a	O
clinical	B-C0332140
diagnosis	I-C0332140
-based	O
cutoff	B-C1442160
using	O
cox	B-C0010235
proportional	I-C0010235
hazards	I-C0010235
regression	I-C0010235
.	O
	
in	O
the	O
total	O
group	B-C0441833
of	O
patients	B-C0030705
,	O
we	O
found	O
a	O
cutoff	B-C1442160
for	O
abnormal	B-C0205161
csf	B-C0007806
β-amyloid	B-C0169424
1-42	I-C0169424
of	O
680	O
pg/ml	O
95%	O
ci	B-C0009667
660-705	O
pg/ml	O
.	O
	
similar	O
cutoffs	B-C1442160
were	O
found	O
within	O
diagnostic	B-C0011900
and	O
apoe	B-C1446118
genotype	I-C1446118
subgroups	B-C1515021
.	O
	
the	O
cutoff	B-C1442160
was	O
higher	B-C0205250
in	O
elderly	B-C0001792
subjects	B-C2349001
than	O
in	O
younger	O
subjects	B-C2349001
.	O
	
the	O
data-driven	B-C3899452
cutoff	B-C1442160
was	O
higher	B-C0205250
than	O
our	O
clinical	B-C0332140
diagnosis	I-C0332140
-based	O
cutoff	B-C1442160
and	O
had	O
a	O
better	O
predictive	B-C0681890
accuracy	B-C0443131
for	O
progression	B-C0449258
to	O
ad	B-C0002395
-type	O
dementia	B-C0497327
in	O
nondemented	O
subjects	B-C2349001
hr	B-C2985465
7.6	O
versus	O
5.2	O
,	O
p	B-C1709380
<	O
0.01	O
.	O
	
mixture	B-C0026348
modeling	I-C0026348
is	O
a	O
robust	B-C2986815
method	B-C0025663
to	O
determine	O
cutoffs	B-C1442160
for	O
csf	B-C0007806
β-amyloid	B-C0169424
1-42	I-C0169424
.	O
	
it	O
might	O
better	O
capture	O
biological	B-C0205460
changes	B-C0392747
that	O
are	O
related	O
to	O
ad	B-C0002395
than	O
cutoffs	B-C1442160
based	O
on	O
clinical	B-C0332140
diagnosis	I-C0332140
.	O
	
identification	B-C0205396
of	O
the	O
anti-mycobacterial	B-C0360390
functional	B-C0205245
properties	B-C0871161
of	O
piperidinol	B-C1254351
derivatives	I-C1254351
tuberculosis	B-C0041296
tb	B-C0041296
remains	O
a	O
major	O
global	B-C2348867
health	B-C0018684
threat	B-C0749385
and	O
is	O
now	O
the	O
leading	O
cause	B-C0007465
of	I-C0007465
death	I-C0007465
from	O
a	O
single	O
infectious	B-C0314732
agent	I-C0314732
worldwide	B-C2348867
.	O
	
the	O
current	O
tb	B-C0041296
drug	B-C0013227
regimen	B-C0040808
is	O
inadequate	B-C0205412
,	O
and	O
new	O
anti-tubercular	B-C1254351
agents	I-C1254351
are	O
urgently	O
required	O
to	O
be	O
able	O
to	O
successfully	O
combat	O
the	O
increasing	O
prevalence	B-C0220900
of	O
drug-resistant	B-C0206525
tb	I-C0206525
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
a	O
piperidinol	B-C1254351
compound	I-C1254351
derivative	I-C1254351
that	O
is	O
highly	O
active	B-C0205177
against	O
the	O
mycobacterium	B-C0026926
tuberculosis	I-C0026926
bacillus	B-C0004587
.	O
	
the	O
antibacterial	B-C0279516
properties	B-C0871161
of	O
the	O
piperidinol	B-C1254351
compound	I-C1254351
and	O
its	O
corresponding	O
bis-mannich	B-C0024728
base	I-C0024728
analogue	B-C0243071
were	O
evaluated	B-C0220825
against	O
m	B-C0317761
.	O
	
smegmatis	I-C0317761
and	O
gram-negative	B-C0018150
organisms	I-C0018150
.	O
	
cytotoxicity	B-C0596402
studies	B-C2603343
were	O
undertaken	O
in	O
order	O
to	O
determine	O
the	O
selectivity	B-C0918012
index	I-C0918012
for	O
these	O
compounds	B-C1254351
.	O
	
spontaneous	O
resistant	B-C0332325
mutants	B-C0596988
of	O
m	B-C0317761
.	O
	
smegmatis	I-C0317761
were	O
generated	O
against	O
the	O
piperidinol	B-C1254351
and	O
corresponding	O
bis-mannich	B-C1254351
base	I-C1254351
lead	I-C1254351
derivatives	I-C1254351
and	O
whole	O
genome	B-C1328887
sequencing	I-C1328887
employed	O
to	O
determine	O
the	O
genetic	B-C4277689
modifications	I-C4277689
that	O
lead	O
to	O
selection	O
pressure	O
in	O
the	O
presence	O
of	O
these	O
compounds	B-C1254351
.	O
	
the	O
piperidinol	B-C1254351
and	O
the	O
bis-mannich	B-C1254351
base	I-C1254351
analogue	I-C1254351
were	O
found	O
to	O
be	O
selective	O
for	O
mycobacteria	B-C0026912
and	O
rapidly	O
kill	O
this	O
organism	B-C0029235
with	O
a	O
cytotoxicity	B-C0596402
selectivity	B-C0918012
index	I-C0918012
for	O
mycobacteria	B-C0026912
of	O
>30-fold	O
.	O
	
whole	O
genome	B-C1328887
sequencing	I-C1328887
of	O
m	B-C0317761
.	O
	
smegmatis	I-C0317761
strains	B-C1518614
resistant	B-C0332325
to	O
the	O
lead	B-C1254351
compounds	I-C1254351
led	O
to	O
the	O
identification	B-C0205396
of	O
a	O
number	O
of	O
single	B-C0752046
nucleotide	I-C0752046
polymorphisms	I-C0752046
indicating	O
multiple	O
targets	O
.	O
	
our	O
results	B-C0683954
indicate	O
that	O
the	O
piperidinol	B-C1254351
moiety	I-C1254351
represents	O
an	O
attractive	O
compound	B-C1254351
class	I-C1254351
in	O
the	O
pursuit	O
of	O
novel	O
anti-tubercular	B-C1254351
agents	I-C1254351
.	O
	
metatranscriptomics	B-C0752248
reveals	O
the	O
active	O
bacterial	B-C0004611
and	O
eukaryotic	B-C0004611
fibrolytic	I-C0004611
communities	I-C0004611
in	O
the	O
rumen	B-C0035946
of	O
dairy	B-C3687529
cow	I-C3687529
fed	O
a	O
mixed	B-C0205430
diet	B-C0012155
ruminants	B-C0035950
have	O
a	O
unique	O
ability	O
to	O
derive	O
energy	B-C1442080
from	O
the	O
degradation	B-C0243125
of	O
plant	B-C0032098
polysaccharides	B-C0032594
through	O
the	O
activity	B-C0441655
of	O
the	O
rumen	B-C0035946
microbiota	B-C1000792
.	O
	
although	O
this	O
process	B-C1522240
is	O
well	O
studied	O
in	B-C1533691
vitro	I-C1533691
,	O
knowledge	O
gaps	O
remain	O
regarding	O
the	O
relative	O
contribution	O
of	O
the	O
microbiota	B-C1000792
members	I-C1000792
and	O
enzymes	B-C0014442
in	B-C1515655
vivo	I-C1515655
.	O
	
the	O
present	O
study	O
used	O
rna-sequencing	B-C0917793
to	O
reveal	O
both	O
the	O
expression	B-C0017262
of	O
genes	B-C0017337
encoding	O
carbohydrate-active	B-C0014442
enzymes	I-C0014442
cazymes	B-C0014442
by	O
the	O
rumen	B-C0035946
microbiota	B-C1000792
of	O
a	O
lactating	B-C3687529
dairy	I-C3687529
cow	I-C3687529
and	O
the	O
microorganisms	B-C0445623
forming	O
the	O
fiber	B-C1260603
-degrading	O
community	B-C0009462
.	O
	
functional	B-C0936012
analysis	I-C0936012
identified	O
12	O
cazymes	B-C0014442
,	O
accounting	O
for	O
1%	O
of	O
the	O
transcripts	B-C1519595
.	O
	
the	O
cazyme	B-C0014442
profile	O
was	O
dominated	O
by	O
families	O
gh94	B-C0055033
cellobiose-phosphorylase	B-C0055033
,	O
gh13	B-C0002712
amylase	B-C0002712
,	O
gh43	B-C0062220
and	O
gh10	B-C0062220
hemicellulases	B-C0062220
,	O
gh9	B-C1260229
and	O
gh48	B-C1260229
cellulases	B-C1260229
,	O
pl11	B-C0032491
pectinase	B-C0032491
as	O
well	O
as	O
gh2	B-C0014442
and	O
gh3	B-C0014442
oligosaccharidases	B-C0014442
.	O
	
our	O
data	O
support	O
the	O
pivotal	O
role	O
of	O
the	O
most	O
characterized	O
fibrolytic	B-C0004611
bacteria	I-C0004611
prevotella	B-C0242946
,	O
ruminocccus	B-C0318074
and	O
fibrobacter	B-C0995400
,	O
and	O
highlight	O
a	O
substantial	O
,	O
although	O
most	O
probably	O
underestimated	O
,	O
contribution	B-C1880177
of	O
fungi	B-C0016832
and	O
ciliate	B-C0008781
protozoa	I-C0008781
to	O
polysaccharide	B-C0032594
degradation	B-C0243125
.	O
	
particularly	O
these	O
results	O
may	O
motivate	O
further	O
exploration	O
of	O
the	O
role	O
and	O
the	O
functions	O
of	O
protozoa	B-C0033739
in	O
the	O
rumen	B-C0035946
.	O
	
moreover	O
,	O
an	O
important	O
part	O
of	O
the	O
fibrolytic	B-C0004611
bacterial	I-C0004611
community	I-C0004611
remains	O
to	O
be	O
characterized	O
since	O
one	O
third	O
of	O
the	O
cazyme	B-C0014442
transcripts	B-C1519595
originated	O
from	O
distantly	O
related	O
strains	B-C0004611
.	O
	
these	O
findings	O
are	O
used	O
to	O
highlight	O
limitations	O
of	O
current	O
metatranscriptomics	B-C0752248
approaches	O
to	O
understand	O
the	O
functional	O
rumen	B-C0035946
microbial	B-C0445623
community	I-C0445623
fine	B-C1283195
mapping	I-C1283195
of	O
carbon	B-C0017337
assimilation	I-C0017337
rate	I-C0017337
8	I-C0017337
,	O
a	O
quantitative	B-C0597336
trait	I-C0597336
locus	I-C0597336
for	O
flag	B-C0242724
leaf	I-C0242724
nitrogen	B-C0028158
content	B-C0456205
,	O
stomatal	B-C1955855
conductance	B-C0392762
and	O
photosynthesis	B-C0031764
in	O
rice	B-C1140671
increasing	B-C0442808
the	O
rate	B-C1521828
of	O
leaf	B-C0031764
photosynthesis	I-C0031764
is	O
one	O
important	O
approach	O
for	O
increasing	O
grain	B-C0392762
yield	I-C0392762
in	O
rice	B-C1140671
oryza	B-C1140671
sativa	I-C1140671
.	O
	
exploiting	O
the	O
natural	O
variation	B-C0205419
in	O
co2	B-C1521828
assimilation	I-C1521828
rate	I-C1521828
a	O
between	O
rice	B-C1140671
cultivars	I-C1140671
using	O
quantitative	B-C1514626
genetics	I-C1514626
is	O
one	O
promising	O
means	O
to	O
identify	O
genes	B-C0017337
contributing	O
to	O
higher	O
photosynthesis	B-C0031764
.	O
	
in	O
this	O
study	O
,	O
we	O
determined	O
precise	O
location	B-C0450429
of	O
carbon	B-C0017337
assimilation	I-C0017337
rate	I-C0017337
8	I-C0017337
car8	B-C0017337
by	O
crossing	B-C0010366
a	O
high-yielding	O
indica	B-C1659274
cultivar	I-C1659274
with	O
a	O
japanese	B-C0022341
commercial	B-C0680536
cultivar	B-C0032098
.	O
	
fine	B-C1283195
mapping	I-C1283195
suggested	O
that	O
car8	B-C0017337
encodes	B-C2700640
a	O
putative	B-C0033684
heme	I-C0033684
activator	I-C0033684
protein	I-C0033684
3	I-C0033684
oshap3	B-C0033684
subunit	O
of	O
a	O
ccaat-box-binding	B-C0526260
transcription	I-C0526260
factor	I-C0526260
called	O
oshap3h	B-C0017337
.	O
	
sequencing	B-C1328887
analysis	I-C1328887
revealed	O
that	O
the	O
indica	B-C1659274
allele	B-C0002085
of	O
car8	B-C0017337
has	O
a	O
1-bp	B-C0162773
deletion	I-C0162773
at	O
322	O
bp	B-C0600436
from	O
the	O
start	B-C0242610
codon	I-C0242610
,	O
resulting	O
in	O
a	O
truncated	B-C1144558
protein	I-C1144558
of	O
125	O
amino	B-C0002520
acids	I-C0002520
.	O
	
in	O
addition	O
,	O
car8	B-C0017337
is	O
identical	B-C0205280
to	O
dth8	B-C0017337
/	O
ghd8	B-C0017337
/	O
lhd1	B-C0017337
,	O
which	O
was	O
reported	O
to	O
control	O
rice	B-C1140671
flowering	B-C1820370
date	B-C0011008
.	O
	
the	O
increase	B-C0442805
of	O
a	B-C1521828
is	O
largely	O
due	O
to	O
an	O
increase	B-C0442805
of	O
rubp	B-C1521828
regeneration	I-C1521828
rate	I-C1521828
via	O
increased	B-C0205217
leaf	B-C0242724
nitrogen	B-C0028158
content	B-C0456205
,	O
and	O
partially	O
explained	O
by	O
reduced	B-C0392756
stomatal	B-C1955855
limitation	B-C0449295
via	O
increased	B-C0205217
stomatal	B-C1955855
conductance	B-C0392762
relative	O
to	O
a	B-C1521828
.	O
	
this	O
allele	B-C0002085
also	O
increases	O
hydraulic	B-C0205556
conductivity	I-C0205556
,	O
which	O
would	O
promote	B-C0033414
higher	O
stomatal	B-C1955855
conductance	B-C0392762
.	O
	
this	O
indicates	O
that	O
car8	B-C0017337
affects	O
multiple	O
physiological	B-C0031843
aspects	I-C0031843
relating	O
to	O
photosynthesis	B-C0031764
.	O
	
the	O
detailed	O
analysis	B-C0936012
of	O
molecular	B-C1148560
functions	I-C1148560
of	O
car8	B-C0017337
would	O
help	O
to	O
understand	O
the	O
association	B-C0439849
between	O
photosynthesis	B-C0031764
and	O
flowering	B-C1820370
and	O
demonstrate	O
specific	O
genetic	B-C0314603
mechanisms	B-C0441712
that	O
can	O
be	O
exploited	O
to	O
improve	B-C0184511
photosynthesis	B-C0031764
in	O
rice	B-C1140671
and	O
potentially	O
other	O
allogeneic	B-C2242529
stem	I-C2242529
cell	I-C2242529
transplantation	I-C2242529
for	O
adult	B-C0001675
patients	B-C0030705
with	O
acute	B-C0023449
lymphoblastic	I-C0023449
leukemia	I-C0023449
who	O
had	O
central	B-C4050309
nervous	I-C4050309
system	I-C4050309
involvement	I-C4050309
a	O
study	B-C2603343
from	O
the	O
adult	B-C0001675
all	B-C0023449
working	B-C1883562
group	I-C1883562
of	O
the	O
japan	B-C0022341
society	B-C0037455
for	O
hematopoietic	B-C1705576
cell	I-C1705576
transplantation	I-C1705576
the	O
prognosis	B-C0033325
for	O
adult	B-C0001675
acute	B-C0023449
lymphoblastic	I-C0023449
leukemia	I-C0023449
all	B-C0023449
patients	B-C0030705
with	O
central	B-C4050309
nervous	I-C4050309
system	I-C4050309
cns	I-C4050309
involvement	I-C4050309
cns+	B-C4050309
who	O
received	O
allogeneic	B-C1705576
hematopoietic	I-C1705576
stem	I-C1705576
cell	I-C1705576
transplantation	I-C1705576
allo-sct	B-C1705576
remains	O
unclear	O
.	O
	
we	O
retrospectively	B-C1514923
compared	O
the	O
outcomes	B-C0085415
of	O
allo-sct	B-C1705576
for	O
patients	B-C0030705
with	O
cns	B-C4050309
involvement	I-C4050309
and	O
for	O
patients	B-C0030705
without	B-C0332288
cns	B-C4050309
involvement	I-C4050309
cns-	B-C4050309
using	O
a	O
database	B-C0242356
in	O
japan	B-C0022341
.	O
	
the	O
eligibility	O
criteria	B-C0243161
for	O
this	O
study	B-C2603343
were	O
as	O
follows	O
diagnosis	B-C1704656
of	O
all	B-C0023449
,	O
aged	O
more	O
than	O
16	O
years	B-C1510829
,	O
allo-sct	B-C1705576
between	O
2005	O
and	O
2012	O
,	O
and	O
first	B-C0205435
sct	B-C1705576
.	O
	
data	B-C1511726
for	O
2582	O
patients	B-C0030705
including	O
136	O
cns+	B-C0030705
patients	I-C0030705
and	O
2446	O
cns-	B-C0030705
patients	I-C0030705
were	O
used	O
for	O
analyses	B-C0936012
.	O
	
as	O
compared	O
with	O
cns-	B-C0030705
patients	I-C0030705
,	O
cns+	B-C0030705
patients	I-C0030705
were	O
younger	B-C0332239
,	O
had	O
worse	B-C1457868
disease	B-C0012634
status	B-C0449438
at	O
sct	B-C1705576
and	O
had	O
poorer	O
performance	B-C1518965
status	I-C1518965
ps	B-C1518965
at	O
sct	B-C1705576
p	O
<	O
0.01	O
.	O
	
incidence	B-C0021149
of	O
relapse	B-C0035020
was	O
higher	O
in	O
cns+	B-C0030705
patients	I-C0030705
p	O
=	O
0.02	O
,	O
and	O
incidence	B-C0021149
of	O
cns	B-C3714787
relapse	B-C0035020
was	O
also	O
higher	O
p	O
<	O
0.01	O
.	O
	
the	O
probability	B-C0033204
of	O
3-	O
year	B-C0439234
overall	B-C4086681
survival	I-C4086681
os	B-C4086681
was	O
better	O
in	O
cns-	B-C0030705
patients	I-C0030705
p	O
<	O
0.01	O
by	O
univariate	B-C0683962
analysis	I-C0683962
.	O
	
however	O
,	O
in	O
patients	B-C0030705
who	O
received	B-C1514756
sct	B-C1705576
in	O
cr	B-C0677874
,	O
there	O
was	O
no	B-C3842396
difference	I-C3842396
in	O
the	O
probability	B-C0033204
of	O
os	B-C4086681
between	O
cns+	B-C4050309
and	O
cns-	B-C4050309
patients	B-C0030705
p	O
=	O
0.38	O
and	O
cns	B-C4050309
involvement	I-C4050309
did	O
not	O
have	O
an	O
unfavorable	B-C3640815
effect	B-C1280500
on	O
os	B-C4086681
by	O
multivariate	B-C0026777
analysis	I-C0026777
.	O
	
cns+	B-C0030705
patients	I-C0030705
who	O
achieved	O
cr	B-C0677874
showed	O
os	B-C4086681
comparable	O
to	O
that	O
of	O
cns-	B-C0030705
patients	I-C0030705
.	O
	
silent	B-C1328742
strain	I-C1328742
of	I-C1328742
caregiving	I-C1328742
exploring	O
the	O
best	B-C0035648
predictors	I-C0035648
of	O
distress	B-C0231303
in	O
family	B-C0086279
carers	I-C0086279
of	O
geriatric	B-C0870602
patients	I-C0870602
the	O
aim	O
of	O
this	O
article	O
was	O
to	O
identify	O
the	O
best	B-C0035648
predictors	I-C0035648
of	O
distress	B-C0231303
suffered	I-C0231303
by	O
family	B-C0086279
carers	I-C0086279
fcs	B-C0086279
of	O
geriatric	B-C0870602
patients	I-C0870602
.	O
	
a	O
cross-sectional	B-C0010362
study	I-C0010362
of	O
100	O
fc	B-C0086279
-	O
geriatric	B-C0870602
patient	I-C0870602
dyads	B-C0870454
was	O
conducted	O
.	O
	
the	O
negative	B-C0243095
impact	I-C0243095
of	I-C0243095
care	I-C0243095
nioc	B-C0243095
subscale	B-C0459443
of	O
the	O
cope	B-C0392762
index	I-C0392762
was	O
dichotomized	O
to	O
identify	O
lower	B-C4075362
stress	I-C4075362
score	O
of	O
15	O
on	O
the	O
scale	O
and	O
higher	B-C4075362
stress	I-C4075362
score	O
of	O
16	O
on	O
the	O
scale	O
exerted	O
on	O
fcs	B-C0086279
by	O
the	O
process	B-C2735110
of	I-C2735110
providing	I-C2735110
care	I-C2735110
.	O
	
the	O
set	O
of	O
explanatory	B-C0681841
variables	B-C2673413
comprised	O
a	O
wide	O
range	O
of	O
sociodemographic	B-C0011292
and	O
care-related	B-C0086388
attributes	I-C0086388
,	O
including	O
patient-related	B-C0243095
results	I-C0243095
from	O
comprehensive	O
geriatric	B-C0017463
assessments	I-C0017463
and	O
disease	B-C0012634
profiles	B-C0747306
.	O
	
the	O
best	O
combination	O
of	O
explanatory	B-C0681841
variables	B-C2673413
that	O
provided	O
the	O
highest	B-C0681890
predictive	I-C0681890
powe	I-C0681890
r	O
for	O
distress	B-C0231303
among	O
fcs	B-C0086279
in	O
the	O
multiple	B-C0681925
logistic	I-C0681925
regression	I-C0681925
lr	I-C0681925
model	I-C0681925
was	O
determined	O
according	O
to	O
statistical	O
information	O
criteria	O
.	O
	
the	O
statistical	O
robustness	O
of	O
the	O
observed	O
relationships	O
and	O
the	O
discriminative	O
power	O
of	O
the	O
model	O
were	O
verified	O
with	O
the	O
cross-validation	O
method	O
.	O
	
the	O
mean	O
age	O
of	O
fcs	O
was	O
57.2	O
10.6	O
years	O
,	O
whereas	O
that	O
of	O
geriatric	O
patients	O
was	O
81.7	O
6.4	O
years	O
.	O
	
despite	O
the	O
broad	O
initial	O
set	O
of	O
potential	O
explanatory	O
variables	O
,	O
only	O
five	O
predictors	O
were	O
jointly	O
selected	O
for	O
the	O
best	O
statistical	O
model	O
.	O
	
a	O
higher	O
level	O
of	O
distress	O
was	O
independently	O
predicted	O
by	O
lower	O
self-evaluation	O
of	O
health	O
worse	O
self-appraisal	O
of	O
coping	O
well	O
as	O
a	O
caregiver	O
lower	O
sense	O
of	O
general	O
support	O
more	O
hours	O
of	O
care	O
per	O
week	O
and	O
the	O
motor	O
retardation	O
of	O
the	O
cared	O
-for	O
person	O
measured	O
with	O
the	O
speed	O
of	O
the	O
timed	O
up	O
and	O
go	O
tug	O
test	O
.	O
	
worse	O
performance	O
on	O
the	O
tug	O
test	O
was	O
only	O
the	O
patient	O
-related	O
predictor	O
of	O
distress	O
among	O
the	O
variables	O
examined	O
as	O
contributors	O
to	O
the	O
higher	O
nioc	O
.	O
	
enhancing	O
the	O
mobility	O
of	O
geriatric	O
patients	O
through	O
suitably	O
tailored	O
kinesitherapeutic	O
methods	O
during	O
their	O
hospital	O
stay	O
may	O
mitigate	O
the	O
burden	O
endured	O
by	O
fcs	B-C0086279
microbiological	B-C0025953
and	O
clinical	B-C0683325
characteristics	I-C0683325
of	O
hypermucoviscous	B-C0001699
klebsiella	I-C0001699
pneumoniae	I-C0001699
isolates	B-C1764827
associated	B-C0332281
with	I-C0332281
invasive	B-C4285937
infections	I-C4285937
in	O
china	B-C0008115
a	O
distinctive	B-C0039082
syndrome	I-C0039082
caused	B-C0015127
by	I-C0015127
hypermucoviscous	B-C0001699
klebsiella	I-C0001699
pneumoniae	I-C0001699
hmkp	B-C0001699
including	O
pyogenic	B-C0267830
liver	I-C0267830
abscess	I-C0267830
pla	B-C0267830
is	O
now	O
becoming	O
a	O
globally	B-C0872315
emerging	I-C0872315
disease	I-C0872315
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
22.8	O
84/369	O
of	O
k	B-C0001699
.	O
	
pneumoniae	I-C0001699
clinical	O
isolates	B-C1764827
associated	B-C0332281
with	I-C0332281
various	B-C0332307
types	I-C0332307
of	O
invasive	B-C4285937
infections	I-C4285937
were	O
identified	O
as	O
hmkp	B-C0001699
,	O
with	O
45.2	O
associated	B-C0332281
with	I-C0332281
pla	B-C0267830
.	O
	
multivariate	B-C0026777
regression	I-C0026777
analysis	I-C0026777
showed	O
that	O
male	B-C0150904
patients	I-C0150904
with	O
41-50	O
years	B-C0439234
,	O
pla	B-C0267830
,	O
diabetes	B-C0011849
mellitus	I-C0011849
,	O
and	O
hypertension	B-C0020538
were	O
independent	B-C0085862
risk	B-C0035648
factors	I-C0035648
for	O
hmkp	B-C0948802
infections	I-C0948802
.	O
	
k2	B-C0449547
42.9	O
,	O
36/84	O
was	O
the	O
most	O
common	O
capsular	B-C0205151
serotype	B-C0449943
among	O
hmkp	B-C0001699
isolates	B-C1764827
,	O
followed	O
by	O
k1	B-C0449547
23.8	O
,	O
20/84	O
.	O
	
seventy-five	B-C0439165
percentage	I-C0439165
of	O
k1	B-C0449547
hmkp	B-C0001699
isolates	B-C1764827
were	O
associated	B-C0332281
with	I-C0332281
pla	B-C0267830
,	O
while	O
k2	B-C0449547
hmkp	B-C0001699
isolates	B-C1764827
accounted	B-C0750591
for	O
more	B-C0332307
types	I-C0332307
of	O
invasive	B-C4285937
infections	I-C4285937
.	O
	
the	O
positive	B-C1446409
rates	B-C1521828
of	O
iuta	B-C0017337
,	O
mrkd	B-C0017337
,	O
aerobactin	B-C0017337
,	O
iron	B-C0017337
,	O
and	O
rmpa	B-C0017337
among	O
hmkp	B-C0001699
isolates	B-C1764827
were	O
significantly	B-C4055637
higher	I-C4055637
than	O
those	O
among	O
non-hmkp	B-C0001699
isolates	B-C1764827
p	O
<	O
0.05	O
.	O
	
there	O
was	O
a	O
correlation	B-C1707520
between	O
maga	B-C0017337
,	O
ybts	B-C0017337
,	O
alls	B-C0017337
,	O
and	O
wcag	B-C0017337
and	O
k1	B-C0449547
isolates	B-C1764827
.	O
	
interestingly	O
,	O
mrkd	B-C0017337
was	O
exclusively	B-C0442726
detected	I-C0442726
among	O
hmkp	B-C0001699
32.1	O
,	O
27/84	O
and	O
k2	B-C0449547
isolates	B-C1764827
65.9	O
,	O
27/41	O
.	O
	
all	O
k1	B-C0449547
and	O
k2	B-C0449547
hmkp	B-C0001699
and	O
non-hmkp	B-C0001699
isolates	B-C1764827
were	O
positive	B-C1446409
for	O
rmpa	B-C0017337
.	O
	
aerobactin	B-C0017337
was	O
found	B-C0150312
among	O
95.0	O
and	O
97.5	O
of	O
k1	B-C0449547
and	O
k2	B-C0449547
isolates	B-C1764827
.	O
	
st23	B-C0449943
was	O
found	B-C0150312
to	O
be	O
the	O
most	B-C0332183
prevalent	I-C0332183
st	B-C0449943
among	O
69	O
hmkp	B-C0001699
isolates	B-C1764827
with	O
k1	B-C0449547
,	O
k2	B-C0449547
,	O
k5	B-C0449547
,	O
k20	B-C0449547
,	O
and	O
k57	B-C0449547
27.5	O
,	O
19/69	O
and	O
was	O
only	O
found	B-C0150312
among	O
k1	B-C0449547
isolates	B-C1764827
.	O
	
st65	B-C0449943
was	O
the	O
second	O
most	B-C0332183
prevalent	I-C0332183
st	B-C0449943
26.1	O
,	O
18/69	O
and	O
was	O
also	O
only	O
found	B-C0150312
among	O
k2	B-C0449547
isolates	B-C1764827
.	O
	
st23-k1	B-C0449547
hmkp	B-C0001699
isolates	B-C1764827
84.2	O
,	O
16/19	O
were	O
associated	B-C0332281
with	I-C0332281
pla	B-C0267830
,	O
while	O
st65-k2	B-C0449547
isolates	B-C1764827
were	O
correlated	B-C1707520
with	O
more	O
types	B-C0457463
of	I-C0457463
infections	I-C0457463
relative	O
to	O
st23-k1	B-C0449547
isolates	B-C1764827
.	O
	
pfge	B-C0085117
results	B-C1274040
showed	O
that	O
the	O
homology	B-C2697616
of	O
84	O
hmkp	B-C0001699
isolates	B-C1764827
was	O
diverse	B-C1880371
.	O
	
only	O
five	B-C0205451
pfge	B-C0085117
clusters	B-C1704332
with	O
more	O
than	O
75%	O
similarity	B-C2348205
accounted	B-C0750591
for	O
more	O
than	O
three	B-C0205449
isolates	B-C1764827
.	O
	
these	O
five	B-C0205451
pfge	B-C0085117
clusters	B-C1704332
only	O
accounted	B-C0750591
for	O
35	O
41.7	O
,	O
35/84	O
isolates	B-C1764827
.	O
	
in	O
conclusion	O
,	O
our	O
study	B-C2603343
first	O
found	B-C0150312
that	O
hypertension	B-C0020538
and	O
male	B-C0150904
patients	I-C0150904
with	O
41-50	O
years	B-C0439234
old	B-C0580836
were	O
independent	B-C0085862
risk	B-C0035648
factors	I-C0035648
.	O
	
the	O
composition	B-C0486616
of	O
st	B-C0449943
types	I-C0449943
and	O
pfge	B-C0085117
clusters	B-C1704332
among	O
k	B-C0001699
.	O
	
pneumoniae	I-C0001699
k2	B-C0449547
isolates	B-C1764827
was	O
more	O
diverse	B-C1880371
than	O
k1	B-C0449547
isolates	B-C1764827
.	O
	
k1	B-C0449547
and	O
k2	B-C0449547
hmkp	B-C0001699
isolates	B-C1764827
had	O
respective	O
specific	B-C2003903
profiles	I-C2003903
of	O
virulence	B-C0042765
-	O
associated	B-C0750490
genes	B-C0017337
.	O
	
haemoglobinopathies	B-C0019045
and	O
β-thalassaemia	B-C0005283
among	O
the	O
tribals	B-C0040881
working	B-C0043227
in	O
the	O
tea	B-C0039400
gardens	B-C4019428
of	O
assam	B-C0681784
,	O
india	B-C0021201
prevalence	B-C0220900
of	O
haemoglobinopathies	B-C0019045
and	O
β-thalassaemia	B-C0005283
are	O
very	B-C0205250
high	I-C0205250
in	O
india	B-C0021201
but	O
information	B-C1533716
about	O
its	O
status	O
among	O
the	O
tribals	B-C0040881
working	B-C0043227
in	O
the	O
tea	B-C0039400
gardens	B-C4019428
of	O
assam	B-C0681784
is	O
very	B-C0205251
less	I-C0205251
.	O
	
the	O
present	O
study	B-C2603343
was	O
carried	O
out	O
to	O
determine	O
the	O
prevalence	B-C0220900
of	O
haemoglobinopathies	B-C0019045
and	O
β-thalassaemia	B-C0005283
among	O
the	O
tribals	B-C0040881
working	B-C0043227
in	O
the	O
tea	B-C0039400
gardens	B-C4019428
of	O
assam	B-C0681784
.	O
	
a	O
total	O
1204	O
samples	O
from	O
the	O
tribals	B-C0040881
working	B-C0043227
in	O
tea	B-C0039400
gardens	B-C4019428
of	O
assam	B-C0681784
were	O
analysed	B-C0936012
for	O
both	O
complete	B-C0009555
blood	I-C0009555
count	I-C0009555
cbc	B-C0009555
and	O
high	B-C0008562
pressure	I-C0008562
liquid	I-C0008562
chromatography	I-C0008562
hplc	B-C0008562
for	O
detection	B-C1511790
of	O
haemoglobinopathies	B-C0019045
and	O
β-thalassaemia	B-C0005283
.	O
	
this	O
study	B-C2603343
showed	O
that	O
the	O
prevalence	B-C0220900
of	O
sickle	B-C0002895
cell	I-C0002895
anaemia	I-C0002895
and	O
β-thalassaemia	B-C0005283
were	O
very	B-C0205250
high	I-C0205250
among	O
this	O
population	B-C1257890
.	O
	
our	O
results	B-C1274040
indicated	B-C1444656
a	O
higher	O
prevalence	B-C0220900
of	O
β-thalassaemia	B-C0005283
3.07	O
among	O
the	O
munda	B-C0015031
ethnic	I-C0015031
group	I-C0015031
and	O
higher	O
prevalence	B-C0220900
of	O
sickle	B-C0002895
cell	I-C0002895
anaemia	I-C0002895
4.73	O
among	O
the	O
lohar	B-C0015031
ethnic	I-C0015031
group	I-C0015031
.	O
	
this	O
was	O
the	O
first	O
study	B-C2603343
to	O
report	O
the	O
presence	B-C0150312
of	O
hbe	B-C0019024
among	O
the	O
tribals	B-C0040881
working	B-C0043227
in	O
the	O
tea	B-C0039400
gardens	B-C4019428
of	O
assam	B-C0681784
.	O
	
based	O
on	O
the	O
present	O
findings	B-C0243095
,	O
sickle	B-C0002895
cell	I-C0002895
anaemia	I-C0002895
and	O
β-thalassaemia	B-C0005283
were	O
major	O
health	B-C0018684
problem	B-C0033213
for	O
the	O
tribals	B-C0040881
working	B-C0043227
in	O
the	O
tea	B-C0039400
gardens	B-C4019428
of	O
assam	B-C0681784
.	O
	
proper	O
diagnostic	B-C0011929
facilities	I-C0011929
for	O
haemoglobinopathy	B-C0019045
and	O
thalassaemia	B-C0039730
should	O
be	O
established	B-C0443211
in	O
these	O
areas	B-C0205146
,	O
including	O
establishment	O
of	O
haemoglobinopathy	B-C0019045
and	O
thalassaemia	B-C0039730
database	B-C0242356
collection	B-C1516698
,	O
haematological	B-C0022877
analysis	I-C0022877
laboratories	I-C0022877
,	O
genetic	B-C0442592
counselling	I-C0442592
clinics	I-C0442592
,	O
prenatal	B-C0565990
diagnosis	I-C0565990
centres	I-C0565990
and	O
neonatal	B-C0565990
screening	I-C0565990
centres	I-C0565990
.	O
	
long	B-C0443252
term	I-C0443252
outcome	B-C1274040
in	O
patients	B-C0030705
with	O
esophageal	B-C1654920
stenting	I-C1654920
for	O
cancer	B-C0152018
esophagus	I-C0152018
-	O
our	O
experience	O
at	O
a	O
rural	B-C0020023
hospital	I-C0020023
of	O
punjab	B-C0681784
,	O
india	B-C0021201
cancer	B-C0152018
of	I-C0152018
the	I-C0152018
esophagus	I-C0152018
is	O
among	O
the	O
leading	O
cause	B-C0085978
of	O
cancer	B-C1516192
deaths	I-C1516192
in	O
punjab	B-C0681784
,	O
india	B-C0021201
.	O
	
patients	B-C0030705
generally	O
present	B-C0150312
with	O
dysphagia	B-C0011168
as	O
their	O
first	O
symptom	B-C1457887
and	O
more	O
often	O
they	O
have	O
advanced	B-C0679246
disease	I-C0679246
at	O
the	O
time	B-C0040223
of	O
presentation	B-C0449450
to	O
a	O
tertiary	B-C0587437
care	I-C0587437
centre	I-C0587437
.	O
	
palliative	B-C1285158
procedures	I-C1285158
have	O
important	B-C3898777
roles	O
in	O
this	O
setting	O
.	O
	
stenting	B-C2348535
is	O
the	O
best	O
option	B-C1518601
to	O
palliate	B-C1285530
the	O
symptoms	B-C1457887
of	O
dysphagia	B-C0011168
,	O
from	O
which	O
patient	B-C0030705
is	O
suffering	B-C0518881
the	I-C0518881
most	I-C0518881
.	O
	
to	O
know	O
the	O
success	B-C0679864
rate	B-C1521828
,	O
early	B-C0231243
and	O
long	B-C0443252
term	I-C0443252
complications	B-C0009566
and	O
mortality	B-C0205848
in	O
esophageal	B-C1654920
stenting	I-C1654920
,	O
when	O
it	O
was	O
done	O
in	O
malignant	B-C0341129
esophageal	I-C0341129
stricture	I-C0341129
patients	B-C0030705
.	O
	
one	B-C1704407
hundred	I-C1704407
patients	B-C0030705
,	O
who	O
had	O
undergone	O
esophageal	B-C1654920
stenting	I-C1654920
from	O
january	B-C3829466
2012	O
to	O
january	B-C3829466
2015	O
,	O
were	O
included	B-C0332257
in	O
the	O
study	B-C2603343
.	O
	
we	O
retrospectively	B-C0035363
analysed	I-C0035363
the	O
data	B-C1511726
for	O
patient	B-C0030705
characteristics	B-C1521970
,	O
causes	B-C1314792
of	O
non-operability	B-C0205187
,	O
early	B-C0231243
and	O
long	B-C0443252
term	I-C0443252
complications	B-C0009566
,	O
re-interventions	B-C0184661
,	O
efficacy	B-C1280519
and	O
mortality	B-C0205848
.	O
	
out	O
of	O
100	O
patients	B-C0030705
,	O
indications	B-C3146298
for	O
stenting	B-C2348535
were	O
locally	O
advanced	B-C0679246
disease	I-C0679246
not	O
amenable	B-C3900053
to	O
surgery	B-C0543467
52%	O
,	O
metastatic	B-C2939420
disease	I-C2939420
35%	O
,	O
cva	B-C0038454
1%	O
,	O
cardiac	B-C0262402
and	O
respiratory	B-C1659989
problem	I-C1659989
8%	O
,	O
un-willing	O
for	O
surgery	B-C0543467
in	O
5%	O
of	O
patients	B-C0030705
.	O
	
majority	O
of	O
patients	B-C0030705
94%	O
had	O
squamous	B-C0007137
cell	I-C0007137
carcinoma	I-C0007137
,	O
while	O
only	O
6%	O
had	O
adenocarcinoma	B-C0001418
.	O
	
84%	O
of	O
patients	B-C0030705
presented	B-C0449450
with	O
dysphagia	B-C0011168
with	O
or	O
without	O
chest	B-C0008031
pain	I-C0008031
and	O
recurrent	B-C3553459
cough	I-C3553459
while	O
16%	O
had	O
recurrent	B-C0750325
vomiting	I-C0750325
.	O
	
58%	O
had	O
dysphagia	B-C0011168
to	O
liquids	B-C0302908
and	O
solids	B-C0302909
and	O
17%	O
had	O
complete	B-C0011168
dysphagia	I-C0011168
.	O
	
after	O
stenting	B-C2348535
93%	O
had	O
significant	B-C0750502
improvement	B-C2986411
in	O
dysphagia	B-C0011168
score	B-C0449820
from	O
median	O
of	O
3	O
to	O
1	O
.	O
	
post	B-C3272301
procedure	I-C3272301
stay	B-C0023303
was	O
3.61	O
days	B-C0439228
.	O
	
one	O
patient	B-C0030705
had	O
procedure	B-C0184661
related	O
major	O
complication	B-C0009566
in	O
the	O
form	O
of	O
post	B-C0919874
procedural	I-C0919874
bleed	I-C0919874
after	O
16	O
days	B-C0439228
of	O
stenting	B-C2348535
leading	O
to	O
death	B-C1306577
of	O
that	O
patient	B-C0030705
.	O
	
minor	B-C0558080
complications	B-C0009566
were	O
present	B-C0150312
in	O
52	O
patients	B-C0030705
treated	B-C1522326
conservatively	O
not	O
affecting	B-C0392760
the	O
efficacy	B-C1280519
of	O
procedure	B-C0184661
.	O
	
these	O
include	B-C2700399
pain	B-C0030193
after	O
stenting	B-C2348535
38%	O
,	O
stent	B-C0028778
obstruction	I-C0028778
23%	O
and	O
stent	B-C4087543
migration	I-C4087543
6%	O
.	O
	
all	O
the	O
minor	B-C0558080
complications	B-C0009566
were	O
treated	B-C1522326
conservatively	O
except	B-C0332300
in	O
six	O
patients	B-C0030705
in	O
whom	O
re-stenting	B-C2348535
was	O
done	O
.	O
	
esophageal	B-C1654920
stenting	I-C1654920
is	O
relatively	O
safe	O
procedure	B-C0184661
with	O
short	O
stay	B-C0023303
of	O
the	O
patient	B-C0030705
in	O
the	O
hospital	B-C0019994
.	O
	
although	O
,	O
it	O
helps	O
in	O
alleviating	O
patients	B-C0030705
'	O
morbidity	B-C0026538
very	O
effectively	B-C1704419
and	O
reliably	O
,	O
there	O
are	O
many	O
technical	B-C1710348
glitches	I-C1710348
,	O
which	O
needs	O
to	O
be	O
kept	O
into	O
account	O
and	O
patient	B-C0030705
should	O
be	O
properly	O
counseled	B-C0600047
before	O
the	O
procedure	B-C0184661
to	O
prevent	B-C1292733
and	O
manage	B-C2587213
post	B-C3272301
procedure	I-C3272301
complications	B-C0009566
treatment	B-C0039798
of	O
carcinoma	B-C0686217
in	I-C0686217
situ	I-C0686217
of	I-C0686217
the	I-C0686217
glans	I-C0686217
penis	I-C0686217
with	O
topical	B-C3215046
imiquimod	I-C3215046
followed	O
by	O
carbon	B-C0392251
dioxide	I-C0392251
laser	I-C0392251
excision	B-C0728940
different	B-C1705242
approaches	B-C1292724
have	O
been	O
described	B-C1552738
in	O
published	O
studies	O
for	O
carcinoma	B-C0686217
in	I-C0686217
situ	I-C0686217
cis	I-C0686217
of	I-C0686217
the	I-C0686217
glans	I-C0686217
penis	I-C0686217
erythroplasia	B-C0154089
of	I-C0154089
queyrat	I-C0154089
,	O
including	B-C0332257
topical	B-C1519552
chemotherapy	I-C1519552
or	O
immunotherapy	B-C0021083
and	O
laser	B-C0441543
or	O
surgical	B-C0728940
excision	I-C0728940
.	O
	
we	O
evaluated	B-C0728940
the	O
efficacy	B-C1280519
of	O
topical	B-C3215046
imiquimod	I-C3215046
iq	B-C3215046
followed	O
by	O
carbon	B-C0392251
dioxide	I-C0392251
laser	I-C0392251
ablation	B-C0348007
of	O
the	O
lesion	B-C0221198
.	O
	
from	O
2010	O
to	O
2015	O
,	O
10	O
patients	B-C0522476
affected	I-C0522476
by	O
cis	B-C0686217
of	O
the	O
glans	B-C1550261
were	O
treated	B-C0332293
by	O
iq	B-C3215046
,	O
followed	O
by	O
carbon	B-C0392251
dioxide	I-C0392251
laser	I-C0392251
ablation	B-C0348007
.	O
	
for	O
every	O
patient	B-C0030705
,	O
we	O
performed	B-C0884358
histologic	B-C0019637
examination	I-C0019637
before	B-C0332152
and	O
after	B-C0687676
iq	B-C3215046
.	O
	
local	O
toxicity	B-C0013221
and	O
adverse	B-C0879626
effects	I-C0879626
were	O
recorded	O
.	O
	
after	B-C2709088
treatment	I-C2709088
,	O
histologic	B-C0019637
examination	I-C0019637
showed	O
no	B-C0332652
residual	I-C0332652
tumor	I-C0332652
in	O
6	O
patients	B-C0030705
complete	B-C4050307
response	I-C4050307
cr	B-C4050307
,	O
stable	B-C0677946
disease	I-C0677946
in	O
2	O
patients	B-C0030705
,	O
and	O
progressive	B-C1335499
disease	I-C1335499
in	O
2	O
patients	B-C0030705
.	O
	
those	O
with	O
a	O
cr	B-C4050307
had	O
human	B-C0021344
papillomavirus	I-C0021344
-	O
related	B-C0439849
lesions	B-C0221198
,	O
and	O
they	O
had	O
no	B-C1513916
experienced	O
relapses	B-C0035020
after	B-C0687676
a	O
mean	O
follow-up	B-C1522577
of	O
26	O
months	B-C0439231
.	O
	
the	O
2	O
patients	B-C0030705
with	O
progressive	B-C1335499
disease	I-C1335499
underwent	O
total	O
penectomy	B-C0194708
.	O
	
all	O
patients	B-C0030705
were	O
alive	B-C2584946
at	O
the	O
last	O
follow-up	B-C0260832
examination	I-C0260832
.	O
	
all	O
patients	B-C0030705
experienced	O
a	O
mild	B-C2945599
local	O
toxicity	B-C0013221
burning	B-C0085624
erythema	I-C0085624
but	O
no	B-C1513916
major	B-C0205164
adverse	B-C0879626
effects	I-C0879626
.	O
	
local	O
treatment	B-C0039798
with	O
iq	B-C3215046
for	O
glans	B-C1550261
cis	B-C0686217
is	O
effective	B-C1704419
mainly	O
for	O
human	B-C0021344
papillomavirus	I-C0021344
-	O
related	B-C0439849
lesions	B-C0221198
.	O
	
the	O
present	O
study	O
is	O
the	O
first	O
to	O
record	O
the	O
histologic	B-C0019637
examination	I-C0019637
findings	O
before	B-C0332152
and	O
after	B-C0687676
iq	B-C3215046
treatment	B-C0039798
.	O
	
the	O
small	O
number	O
of	O
patients	B-C0030705
,	O
owing	O
to	O
the	O
rarity	B-C0522498
of	O
this	O
disease	B-C0012634
,	O
was	O
the	O
main	O
limitation	B-C0449295
of	O
the	O
present	O
study	O
.	O
	
iq	B-C3215046
must	O
be	O
used	O
carefully	O
,	O
and	O
a	O
close	O
follow-up	B-C1522577
protocol	B-C0442711
is	O
mandatory	B-C0683517
because	O
of	O
the	O
lack	B-C0332268
of	O
long-term	B-C0443252
efficacy	B-C1280519
progressive	B-C0205329
subcortical	B-C0815275
calcifications	B-C1533591
secondary	O
to	O
venous	B-C0340766
hypertension	I-C0340766
in	O
an	O
intracranial	B-C0524466
dural	B-C0752156
arteriovenous	I-C0752156
fistula	I-C0752156
intracranial	B-C0524466
dural	B-C0752156
arteriovenous	I-C0752156
fistulas	I-C0752156
davf	B-C0752156
are	O
acquired	B-C1711164
lesions	I-C1711164
,	O
with	O
the	O
most	O
commonly	O
reported	B-C0700287
findings	B-C0243095
on	O
ct	B-C0040405
haemorrhage	B-C0019080
or	O
focal	B-C0006114
oedema	I-C0006114
.	O
	
we	O
describe	O
a	O
case	O
of	O
progressive	B-C0205329
subcortical	B-C0815275
calcification	B-C1533591
on	O
ct	B-C0040405
secondary	O
to	O
venous	B-C0340766
hypertension	I-C0340766
from	O
a	O
high	O
grade	O
effects	O
of	O
static	B-C0010405
cold	I-C0010405
storage	I-C0010405
and	O
hypothermic	B-C0193410
machine	I-C0193410
perfusion	I-C0193410
on	O
oxidative	B-C0696141
stress	I-C0696141
factors	I-C0696141
,	O
adhesion	B-C1720822
molecules	I-C1720822
,	O
and	O
zinc	B-C2700330
finger	I-C2700330
transcription	I-C2700330
factor	I-C2700330
proteins	I-C2700330
before	O
and	O
after	O
liver	B-C0023911
transplantation	I-C0023911
background	O
this	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
static	B-C0010405
cold	I-C0010405
storage	I-C0010405
scs	B-C0010405
and	O
hypothermic	B-C0193410
machine	I-C0193410
perfusion	I-C0193410
hmp	B-C0193410
on	O
the	O
oxidative	B-C0696141
stress	I-C0696141
factors	I-C0696141
osf	B-C0696141
,	O
adhesion	B-C1720822
molecules	I-C1720822
am	B-C1720822
,	O
and	O
zinc	B-C2700330
finger	I-C2700330
transcription	I-C2700330
factor	I-C2700330
snail	B-C2700330
before	O
and	O
after	O
liver	B-C0023911
transplantation	I-C0023911
.	O
	
material	O
and	O
methods	O
experimental	O
dogs	B-C0012984
were	O
randomly	O
divided	O
into	O
donor	B-C0262458
group	B-C0441833
a	O
,	O
scs	B-C0010405
group	B-C0441833
b	O
,	O
and	O
hmp	B-C0193410
group	B-C0441833
c	O
n=30	O
groups	B-C0441833
.	O
	
livers	B-C0023911
retrieved	I-C0023911
from	O
group	B-C0441833
a	O
were	O
transplanted	B-C0023911
into	O
group	B-C0441833
b	O
after	O
scs	B-C0010405
,	O
and	O
the	O
livers	B-C0023884
sampled	O
from	O
group	B-C0441833
b	O
were	O
transplanted	B-C0023911
into	O
group	B-C0441833
c	O
after	O
hmp	B-C0193410
.	O
	
the	O
dogs	O
in	O
group	B-C0441833
a	O
were	O
euthanized	B-C3686530
and	O
discarded	O
,	O
and	O
the	O
livers	B-C0023884
sampled	O
from	O
group	B-C0441833
c	O
were	O
used	O
for	O
other	O
experiments	O
.	O
	
twenty	O
dogs	B-C0012984
with	O
successful	O
liver	B-C0023911
transplants	I-C0023911
were	O
randomly	O
selected	O
from	O
groups	B-C0441833
b	O
and	O
c	O
for	O
analysis	O
.	O
	
results	O
during	O
the	O
liver	B-C0023884
sampling	B-C0036150
process	I-C0036150
,	O
the	O
levels	O
of	O
osf	B-C0696141
,	O
am	B-C1720822
,	O
and	O
snail	O
between	O
the	O
2	O
groups	B-C0441833
showed	O
no	B-C3842396
significant	I-C3842396
differences	I-C3842396
p>0	O
before	O
the	O
transplantation	B-C0040732
,	O
the	O
levels	O
of	O
chemokine	B-C3180772
cxcl14	I-C3180772
and	O
snail	B-C2700330
between	O
the	O
2	O
groups	B-C0441833
showed	O
no	B-C3842396
significant	I-C3842396
differences	I-C3842396
p>0	O
,	O
and	O
compared	O
with	O
group	B-C0441833
b	O
,	O
hif-1α	O
and	O
p-selectin	B-C0134835
in	O
group	B-C0441833
c	O
were	O
lower	O
p<0	O
60	O
min	O
after	O
the	O
transplantation	B-C0040732
,	O
hif-1α	B-C1528324
,	O
chemokine	B-C3180772
cxcl14	I-C3180772
,	O
p-selectin	B-C0134835
,	O
and	O
snail	B-C2700330
in	O
group	B-C0441833
c	O
were	O
lower	O
than	O
that	O
in	O
group	B-C0441833
b	O
p<0	O
.	O
	
conclusions	O
hmp	B-C0193410
can	O
significantly	O
reduce	O
the	O
levels	O
of	O
osf	B-C0696141
and	O
inflammatory	B-C0333348
factors	I-C0333348
,	O
which	O
is	O
conducive	B-C0243095
for	O
liver	B-C0023911
transplantation	I-C0023911
.	O
	
physiology	B-C0031843
of	O
respiratory	B-C4314646
disturbances	I-C4314646
in	O
muscular	B-C0026850
dystrophies	I-C0026850
muscular	B-C0026850
dystrophy	I-C0026850
is	O
a	O
group	O
of	O
inherited	O
myopathies	B-C0026848
characterised	O
by	O
progressive	B-C0205329
skeletal	B-C0541794
muscle	I-C0541794
wasting	I-C0541794
,	O
including	O
of	O
the	O
respiratory	B-C0035231
muscles	I-C0035231
.	O
	
respiratory	B-C1145670
failure	I-C1145670
,	O
i.e	O
.	O
	
when	O
the	O
respiratory	B-C0035237
system	I-C0035237
fails	B-C0231175
in	O
its	O
gas	B-C0678852
exchange	I-C0678852
functions	I-C0678852
,	O
is	O
a	O
common	O
feature	B-C2348519
in	O
muscular	B-C0026850
dystrophy	I-C0026850
,	O
being	O
the	O
main	O
cause	O
of	O
death	B-C1306577
,	O
and	O
it	O
is	O
a	O
consequence	B-C0686907
of	I-C0686907
lung	B-C0024109
failure	B-C1145670
,	O
pump	B-C1145670
failure	I-C1145670
or	O
a	O
combination	O
of	O
the	O
two	O
.	O
	
the	O
former	O
is	O
due	O
to	O
recurrent	B-C2945760
aspiration	B-C0700198
,	O
the	O
latter	O
to	O
progressive	B-C0205329
weakness	B-C1836141
of	I-C1836141
respiratory	I-C1836141
muscles	I-C1836141
and	O
an	O
increase	B-C0442805
in	O
the	O
load	O
against	O
which	O
they	O
must	O
contract	B-C0678852
.	O
	
in	O
fact	O
,	O
both	O
the	O
resistive	B-C0205556
and	I-C0205556
elastic	I-C0205556
components	I-C0205556
of	O
the	O
work	O
of	O
breathing	B-C0035203
increase	B-C0442805
due	O
to	O
airway	B-C0001883
obstruction	I-C0001883
and	O
chest	B-C0205076
wall	I-C0205076
and	O
lung	B-C0024109
stiffening	B-C0427008
,	O
respectively	O
.	O
	
the	O
respiratory	B-C4314646
disturbances	I-C4314646
in	O
muscular	B-C0026850
dystrophy	I-C0026850
are	O
restrictive	B-C3806472
pulmonary	I-C3806472
function	I-C3806472
,	O
hypoventilation	B-C3203358
,	O
altered	O
thoracoabdominal	B-C0444467
pattern	O
,	O
hypercapnia	B-C0020440
,	O
dyspnoea	B-C0013404
,	O
impaired	B-C0548979
regulation	I-C0548979
of	I-C0548979
breathing	I-C0548979
,	O
inefficient	B-C0455777
cough	I-C0455777
and	O
sleep	B-C0037315
disordered	I-C0037315
breathing	I-C0037315
.	O
	
they	O
can	O
be	O
present	O
at	O
different	O
rates	O
according	O
to	O
the	O
type	O
of	O
muscular	B-C0026850
dystrophy	I-C0026850
and	O
its	O
progression	B-C0242656
,	O
leading	O
to	O
different	O
onset	O
of	O
each	O
symptom	B-C1457887
,	O
prognosis	B-C0033325
and	O
degree	B-C0243095
of	I-C0243095
respiratory	I-C0243095
involvement	I-C0243095
.	O
	
a	O
common	O
feature	B-C2348519
of	O
muscular	B-C0026850
dystrophy	I-C0026850
is	O
respiratory	B-C1145670
failure	I-C1145670
,	O
i.e	O
.	O
	
the	O
inability	O
of	O
the	O
respiratory	B-C0035237
system	I-C0035237
to	O
provide	O
proper	O
oxygenation	B-C0597398
and	O
carbon	B-C0221102
dioxide	I-C0221102
elimination	I-C0221102
in	O
the	O
lung	B-C0024109
,	O
respiratory	B-C1145670
failure	I-C1145670
is	O
caused	O
by	O
recurrent	B-C2945760
aspiration	B-C0700198
,	O
and	O
leads	O
to	O
hypoxaemia	B-C0700292
and	O
hypercarbia	B-C0020440
.	O
	
ventilatory	B-C0398353
failure	I-C0398353
in	O
muscular	B-C0026850
dystrophy	I-C0026850
is	O
caused	O
by	O
increased	B-C0205217
respiratory	B-C0243095
load	I-C0243095
and	O
respiratory	B-C1836141
muscles	I-C1836141
weakness	I-C1836141
.	O
	
respiratory	B-C0243095
load	I-C0243095
increases	B-C0442805
in	O
muscular	B-C0026850
dystrophy	I-C0026850
because	O
scoliosis	B-C0036439
makes	O
chest	B-C0429679
wall	I-C0429679
compliance	I-C0429679
decrease	B-C0547047
,	O
atelectasis	B-C0004144
and	O
fibrosis	B-C0016059
make	O
lung	B-C0024112
compliance	I-C0024112
decrease	B-C0547047
,	O
and	O
airway	B-C0001883
obstruction	I-C0001883
makes	O
airway	B-C4048282
resistance	I-C4048282
increase	B-C0442805
the	O
consequences	B-C0686907
of	I-C0686907
respiratory	B-C1145670
pump	I-C1145670
failure	I-C1145670
are	O
restrictive	B-C3806472
pulmonary	I-C3806472
function	I-C3806472
,	O
hypoventilation	B-C3203358
,	O
altered	O
thoracoabdominal	B-C0444467
pattern	O
,	O
hypercapnia	B-C0020440
,	O
dyspnoea	B-C0013404
,	O
impaired	B-C0548979
regulation	I-C0548979
of	I-C0548979
breathing	I-C0548979
,	O
inefficient	B-C0455777
cough	I-C0455777
and	O
sleep	B-C0037315
disordered	I-C0037315
breathing	I-C0037315
.	O
	
to	O
understand	O
the	O
mechanisms	B-C0457994
leading	O
to	O
respiratory	B-C4314646
disturbances	I-C4314646
in	O
patients	B-C0030705
with	O
muscular	B-C0026850
dystrophy	I-C0026850
to	O
understand	O
the	O
impact	O
of	O
respiratory	B-C4314646
disturbances	I-C4314646
in	O
patients	B-C0030705
with	O
muscular	B-C0026850
dystrophy	I-C0026850
to	O
provide	O
a	O
brief	O
description	B-C3259023
of	O
the	O
main	O
forms	O
of	O
muscular	B-C0026850
dystrophy	I-C0026850
with	O
their	O
respiratory	B-C0243095
implications	I-C0243095
.	O
	
significance	B-C0750502
of	O
uterine	B-C0153574
corpus	I-C0153574
tumor	I-C0153574
invasion	B-C1269955
in	O
early-stage	B-C1517886
cervical	B-C0007847
cancer	I-C0007847
to	O
examine	O
characteristics	B-C1521970
and	O
survival	B-C0038952
outcomes	B-C1274040
of	O
women	B-C0043210
with	O
surgically-treated	B-C0543467
cervical	B-C0007847
cancer	I-C0007847
exhibiting	O
uterine	B-C0153574
corpus	I-C0153574
tumor	I-C0153574
invasion	B-C1269955
.	O
	
we	O
utilized	O
the	O
surveillance	B-C0242638
,	O
epidemiology	I-C0242638
,	O
and	I-C0242638
end	I-C0242638
results	I-C0242638
program	I-C0242638
to	O
identify	O
cervical	B-C0007847
cancer	I-C0007847
patients	B-C0030705
who	O
underwent	O
hysterectomy	B-C0020699
between	O
1973	O
and	O
2003	O
.	O
	
logistic	B-C0681925
regression	I-C0681925
models	I-C0681925
were	O
used	O
to	O
identify	O
risk	B-C0035648
factors	I-C0035648
for	O
uterine	B-C0153574
corpus	I-C0153574
tumor	I-C0153574
invasion	B-C1269955
on	O
multivariable	B-C0026777
analysis	I-C0026777
.	O
	
association	B-C0439849
of	O
uterine	B-C0153574
corpus	I-C0153574
tumor	I-C0153574
invasion	B-C1269955
and	O
cause-specific	B-C1707318
survival	I-C1707318
css	B-C1707318
from	O
cervical	B-C0007847
cancer	I-C0007847
was	O
examined	O
with	O
cox	B-C0034980
proportional	I-C0034980
hazard	I-C0034980
regression	I-C0034980
models	I-C0034980
on	O
multivariable	B-C0026777
analysis	I-C0026777
.	O
	
we	O
identified	O
837	O
4.9	O
cases	O
of	O
uterine	B-C0153574
corpus	I-C0153574
invasion	B-C1269955
and	O
16	O
95.1	O
cases	O
of	O
non-invasion	B-C0205303
.	O
	
median	B-C0876920
follow-up	B-C1522577
time	B-C0040223
was	O
14.0	O
years	O
.	O
	
there	O
were	O
1642	O
deaths	B-C0011065
due	O
to	O
cervical	B-C0007847
cancer	I-C0007847
.	O
	
uterine	B-C0153574
corpus	I-C0153574
invasion	B-C1269955
was	O
independently	B-C0085862
associated	B-C0332281
with	I-C0332281
older	B-C0001779
age	I-C0001779
,	O
non-squamous	B-C4048239
histology	I-C4048239
,	O
high-grade	B-C1334017
tumors	I-C1334017
,	O
large	B-C0475440
tumor	I-C0475440
size	I-C0475440
,	O
and	O
nodal	B-C0443268
metastasis	B-C0027627
on	O
multivariable	B-C0026777
analysis	I-C0026777
all	O
,	O
p	O
<	O
0.001	O
.	O
	
on	O
univariable	B-C0683962
analysis	I-C0683962
,	O
uterine	B-C0153574
corpus	I-C0153574
tumor	I-C0153574
invasion	B-C1269955
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
decreased	B-C0205216
css	B-C1707318
compared	O
to	O
the	O
non-invasion	B-C0205303
5-year	O
rates	O
,	O
79.0	O
versus	O
94.5	O
,	O
p	O
<	O
0.001	O
.	O
	
after	O
controlling	B-C2239193
for	O
other	O
significant	B-C0750502
prognostic	B-C1514474
factors	I-C1514474
,	O
uterine	B-C0153574
corpus	I-C0153574
tumor	I-C0153574
invasion	B-C1269955
remained	O
an	O
independent	B-C0085862
prognostic	B-C1514474
factor	I-C1514474
for	O
decreased	B-C0205216
css	B-C1707318
adjusted-hazard	B-C2985465
ratio	I-C2985465
1.45	O
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
1.21	O
.	O
	
among	O
stage	B-C0475385
t1b	I-C0475385
cases	O
n	O
=	O
6730	O
,	O
uterine	B-C0153574
corpus	I-C0153574
tumor	I-C0153574
invasion	B-C1269955
remained	O
an	O
independent	B-C0085862
prognostic	B-C1514474
factor	I-C1514474
for	O
decreased	B-C0205216
css	B-C1707318
adjusted-hazard	B-C2985465
ratio	I-C2985465
1.95	O
,	O
95%ci	O
1.47	O
.	O
	
uterine	B-C0153574
corpus	I-C0153574
tumor	I-C0153574
invasion	B-C1269955
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
decreased	B-C0205216
css	B-C1707318
in	O
stage	B-C0730458
t1b1	I-C0730458
disease	B-C0153574
74.5	O
versus	O
90.7	O
,	O
p	O
<	O
0.001	O
and	O
in	O
stage	B-C0730459
t1b2	I-C0730459
disease	B-C0153574
67.0	O
versus	O
79.5	O
,	O
p	O
=	O
0.01	O
.	O
	
uterine	B-C0153574
corpus	I-C0153574
tumor	I-C0153574
invasion	B-C1269955
is	O
an	O
independent	B-C0085862
prognostic	B-C1514474
factor	I-C1514474
for	O
decreased	B-C0205216
survival	B-C0038952
of	O
women	B-C0043210
with	O
early-stage	B-C1517886
cervical	B-C0007847
cancer	I-C0007847
.	O
	
efficient	O
gene	B-C0242613
targeting	I-C0242613
in	O
non-homologous	B-C2984257
end-joining	I-C2984257
-deficient	O
lipomyces	B-C1002871
starkeyi	I-C1002871
strains	B-C1518614
microbial	B-C0599840
lipids	B-C0023779
are	O
sustainable	O
feedstock	O
for	O
the	O
production	B-C0033268
of	O
oleochemicals	B-C0220806
and	O
biodiesel	B-C2717894
.	O
	
oleaginous	B-C0043393
yeasts	I-C0043393
have	O
recently	O
been	O
proposed	O
as	O
alternative	B-C1523987
lipid	B-C0023779
producers	B-C0043393
to	O
plants	B-C0032098
and	O
animals	B-C0003062
to	O
promote	O
sustainability	O
in	O
the	O
chemical	B-C0007983
and	O
fuel	B-C0021267
industries	I-C0021267
.	O
	
the	O
oleaginous	B-C0043393
yeast	I-C0043393
lipomyces	B-C1002871
starkeyi	I-C1002871
has	O
great	O
industrial	O
potential	O
as	O
an	O
excellent	O
lipid	B-C0023779
producer	B-C0043393
.	O
	
however	O
,	O
improvement	O
of	O
its	O
lipid	B-C0023779
productivity	B-C0441655
is	O
essential	O
for	O
the	O
cost-effective	B-C0033268
production	I-C0033268
of	O
oleochemicals	B-C0220806
and	O
fuels	B-C0556991
.	O
	
genetic	B-C0017387
and	O
metabolic	B-C3179022
engineering	I-C3179022
of	O
l	B-C1002871
.	O
	
starkeyi	I-C1002871
via	O
gene	O
manipulation	O
techniques	O
may	O
result	O
in	O
improvements	O
in	O
lipid	B-C0023779
production	B-C0033268
and	O
our	O
understanding	O
of	O
the	O
mechanisms	B-C0441712
behind	O
lipid	B-C0023779
biosynthesis	B-C0005572
pathways	I-C0005572
.	O
	
we	O
previously	O
described	O
an	O
integrative	B-C0205245
transformation	I-C0205245
system	I-C0205245
using	O
a	O
drug	B-C1254351
-resistant	O
marker	B-C0017393
for	O
l	B-C1002871
.	O
	
starkeyi	I-C1002871
.	O
	
however	O
,	O
gene-targeting	B-C0242613
frequencies	B-C0017270
were	O
very	O
low	O
because	O
non-homologous	B-C0034865
recombination	I-C0034865
is	O
probably	O
predominant	O
in	O
l	B-C1002871
.	O
	
starkeyi	I-C1002871
.	O
	
genetic	B-C0017387
engineering	I-C0017387
tools	I-C0017387
for	O
l	B-C1002871
.	O
	
starkeyi	I-C1002871
have	O
not	O
been	O
sufficiently	O
developed	O
.	O
	
in	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
genetic	B-C0017387
tool	I-C0017387
and	O
its	O
application	B-C0205245
in	O
l	B-C1002871
.	O
	
starkeyi	I-C1002871
.	O
	
to	O
develop	O
a	O
highly	O
efficient	O
gene-targeting	B-C0242613
system	I-C0242613
for	O
l	B-C1002871
.	O
	
starkeyi	I-C1002871
,	O
we	O
constructed	O
a	O
series	O
of	O
mutants	B-C0678941
by	O
disrupting	B-C0332454
genes	B-C0017337
for	O
lsku70p	B-C0033684
,	O
lsku80p	B-C0033684
,	O
and/or	O
lslig4p	B-C0033684
,	O
which	O
share	O
homology	B-C2697616
with	O
other	O
yeasts	B-C0043393
ku70p	B-C0033684
,	O
ku80p	B-C0033684
,	O
and	O
lig4p	B-C0033684
,	O
respectively	O
,	O
being	O
involved	O
in	O
non-homologous	B-C2984257
end-joining	I-C2984257
pathway	I-C2984257
.	O
	
deletion	B-C0017260
of	O
the	O
lslig4	B-C0017337
gene	I-C0017337
dramatically	O
improved	O
the	O
homologous	B-C0034865
recombination	I-C0034865
efficiency	B-C0013682
80.0	O
at	O
the	O
lsura3	B-C0017337
locus	B-C1708726
compared	O
with	O
that	O
in	O
the	O
wild-type	B-C1883559
strain	B-C1518614
1.4	O
,	O
when	O
2000-bp	B-C0004793
homologous	I-C0004793
flanking	I-C0004793
regions	I-C0004793
were	O
used	O
.	O
	
the	O
homologous	B-C0034865
recombination	I-C0034865
efficiencies	B-C0013682
of	O
the	O
double	O
mutant	B-C0678941
l	B-C0678941
sku70	I-C0678941
and	O
the	O
triple	O
mutant	B-C0678941
lsku70	B-C0678941
were	O
also	O
markedly	O
enhanced	O
.	O
	
therefore	O
,	O
the	O
l	B-C1002871
.	O
	
starkeyi	I-C1002871
lslig4	B-C0678941
background	O
strains	B-C1518614
have	O
promise	O
as	O
efficient	O
recipient	B-C1518614
strains	I-C1518614
for	O
genetic	B-C0017387
and	O
metabolic	B-C3179022
engineering	I-C3179022
approaches	B-C1292724
in	O
this	O
evaluating	O
clinical	B-C0205210
,	O
dietary	B-C0012155
and	O
psychological	B-C0205486
risk	B-C0035648
factors	I-C0035648
for	O
relapse	B-C0035020
of	O
ulcerative	B-C0009324
colitis	I-C0009324
in	O
clinical	B-C0205210
,	O
endoscopic	B-C0442418
and	O
histological	B-C0205462
remission	B-C0597370
the	O
literature	O
on	O
possible	O
factors	O
that	O
could	O
trigger	O
a	O
relapse	B-C0035020
in	O
patients	B-C0030705
with	O
ulcerative	B-C0009324
colitis	I-C0009324
uc	B-C0009324
in	O
clinical	B-C0205210
,	O
endoscopic	B-C0442418
and	O
histological	B-C0205462
remission	B-C0597370
on	O
long	O
term	O
follow	B-C1522577
up	I-C1522577
is	O
scarce	O
.	O
	
to	O
determine	O
the	O
relapse	B-C0035020
rate	O
in	O
patients	B-C0030705
with	O
uc	B-C0009324
in	O
clinical	B-C0205210
,	O
endoscopic	B-C0442418
and	O
histological	B-C0205462
remission	B-C0597370
and	O
identify	O
factors	O
that	O
may	O
influence	O
the	O
risk	B-C0035647
of	O
relapse	B-C0035020
.	O
	
patients	B-C0030705
with	O
uc	B-C0009324
in	O
clinical	B-C0205210
,	O
endoscopic	B-C0442418
and	O
histological	B-C0205462
remission	B-C0597370
were	O
enrolled	O
between	O
january-july	O
2010	O
and	O
followed	B-C1522577
up	I-C1522577
for	O
1	O
year	B-C0439234
to	O
determine	O
the	O
effect	O
of	O
clinical	B-C0205210
,	O
dietary	B-C0012155
and	O
psychological	B-C0205486
factors	B-C0035648
on	O
relapse	B-C0035020
.	O
	
information	O
regarding	O
factors	O
that	O
may	O
affect	O
relapse	B-C0035020
such	O
as	O
infection	B-C3714514
,	O
antibiotic	B-C0003232
or	O
nsaids	B-C0003211
use	O
and	O
any	O
other	O
factor	O
which	O
the	O
patient	B-C0030705
felt	O
important	O
,	O
and	O
compliance	B-C1321605
with	O
medications	B-C2081612
was	O
obtained	O
.	O
	
97	O
patients	B-C0030705
59	O
males	B-C0025266
,	O
mean	O
age	B-C0001779
39	O
+	O
11.9	O
years	B-C0439234
were	O
followed	B-C1522577
up	I-C1522577
for	O
a	O
mean	O
duration	O
of	O
9	O
+	O
2.3	O
months	B-C0439231
.	O
	
18	O
relapsed	B-C0035020
with	O
the	O
median	O
time	O
to	O
relapse	B-C0035020
being	O
3.5	O
months	B-C0439231
.	O
	
on	O
univariate	B-C0683962
analysis	I-C0683962
more	O
relapsers	O
had	O
significantly	O
higher	O
nsaids	B-C0003211
use	O
within	O
15	O
days	B-C0439228
of	O
relapse	B-C0035020
,	O
respiratory	B-C0035243
tract	I-C0035243
infection	I-C0035243
within	O
4	O
weeks	B-C0439230
,	O
use	O
of	O
steroids	B-C0038317
more	O
than	O
once	O
in	O
past	O
,	O
higher	O
consumption	B-C1947907
of	O
calcium	B-C0006675
,	O
riboflavin	B-C0035527
,	O
vitamin	B-C0042839
a	I-C0042839
and	O
lower	O
consumption	B-C1947907
of	O
sugars	B-C0242209
.	O
	
on	O
multivariate	B-C0026777
analysis	I-C0026777
,	O
nsaids	B-C0003211
use	O
hr	O
intake	B-C1512806
of	O
vitamin	B-C0042839
a	I-C0042839
hr	O
were	O
statistically	O
significant	O
predictors	B-C2698872
of	O
relapse	B-C0035020
.	O
	
with	O
a	O
relapse	B-C0035020
rate	O
of	O
18.6	O
over	O
a	O
follow	B-C1522577
up	I-C1522577
of	O
9	O
months	B-C0439231
in	O
patients	B-C0030705
with	O
uc	B-C0009324
in	O
clinical	B-C0205210
,	O
endoscopic	B-C0442418
and	O
histological	B-C0205462
remission	B-C0597370
,	O
independent	O
predictors	B-C2698872
of	O
relapse	B-C0035020
were	O
history	O
of	O
nsaids	B-C0003211
use	O
within	O
15	O
days	B-C0439228
of	O
relapse	B-C0035020
and	O
higher	O
intake	O
of	O
vitamin	B-C0042839
a	I-C0042839
.	O
	
high	O
performance	O
reduction	B-C0301630
of	O
h2o2	B-C0020281
with	O
an	O
electron	B-C0013846
transport	I-C0013846
decaheme	B-C0010749
cytochrome	I-C0010749
on	O
a	O
porous	O
ito	B-C0669925
electrode	B-C1705652
the	O
decaheme	B-C0010749
cytochrome	I-C0010749
mtrc	I-C0010749
from	O
shewanella	B-C1028266
oneidensis	I-C1028266
mr-1	I-C1028266
immobilized	B-C0014444
on	O
an	O
ito	B-C0669925
electrode	B-C1705652
displays	O
unprecedented	O
h2o2	B-C0020281
reduction	B-C0301630
activity	O
.	O
	
although	O
mtrc	B-C0010749
showed	O
lower	O
peroxidase	B-C1151518
activity	I-C1151518
in	O
solution	O
compared	O
to	O
horseradish	B-C0019941
peroxidase	I-C0019941
,	O
the	O
ten	O
heme	B-C0018966
cofactors	B-C0009235
enable	O
excellent	O
electronic	B-C0683826
communication	I-C0683826
and	O
a	O
superior	O
activity	O
on	O
the	O
electrode	B-C1705652
surface	O
.	O
	
a	O
hierarchical	O
ito	B-C0669925
electrode	B-C1705652
enabled	O
optimal	O
immobilization	B-C1254366
of	O
mtrc	B-C0010749
and	O
a	O
high	O
current	B-C2349035
density	I-C2349035
of	O
1	O
ma	O
cm	O
at	O
0.4	O
v	O
vs	O
she	B-C1705652
could	O
be	O
obtained	O
at	O
ph	O
6.5	O
eonset	O
=	O
0.72	O
v	O
.	O
	
uv-visible	B-C1883416
and	O
resonance	B-C0037815
raman	I-C0037815
spectroelectrochemical	I-C0037815
studies	I-C0037815
suggest	O
the	O
formation	O
of	O
a	O
high	O
valent	O
iron-oxo	O
species	O
as	O
the	O
catalytic	B-C0007382
intermediate	O
.	O
	
our	O
findings	O
demonstrate	O
the	O
potential	B-C3245505
of	O
multiheme	B-C0010749
cytochromes	I-C0010749
to	O
catalyze	B-C0007382
technologically	B-C0681539
relevant	O
reactions	O
and	O
establish	O
mtrc	B-C0010749
as	O
a	O
new	O
benchmark	O
in	O
biotechnological	B-C0005574
h2o2	B-C0020281
reduction	B-C0301630
with	O
scope	O
for	O
applications	O
in	O
fuel	B-C3273359
cells	I-C3273359
and	O
ophthalmic	B-C0015411
manifestations	I-C0015411
of	O
facial	B-C0015450
dog	B-C0259797
bites	I-C0259797
in	O
children	B-C0008059
to	O
characterize	O
ophthalmic	B-C0015411
manifestations	I-C0015411
and	O
periocular	B-C4290297
injuries	I-C4290297
of	O
pediatric	B-C1521725
facial	B-C0015450
dog	B-C0259797
bites	I-C0259797
.	O
	
a	O
retrospective	B-C1514923
review	B-C0282443
of	O
all	O
children	B-C0008059
younger	B-C0332239
than	O
18	O
years	B-C0439234
who	O
sought	O
medical	B-C0205476
attention	B-C0004268
after	O
a	O
dog	B-C0259797
bite	I-C0259797
to	O
the	O
face	B-C0015450
between	O
january	B-C3829466
1	O
,	O
2003	O
and	O
may	B-C3812381
22	O
,	O
2014	O
was	O
performed	B-C0884358
at	O
a	O
large	B-C0205372
tertiary	I-C0205372
pediatric	B-C0020017
hospital	I-C0020017
.	O
	
data	B-C1511726
on	O
type	B-C0332307
and	O
location	B-C0552513
of	I-C0552513
injury	I-C0552513
,	O
surgical	B-C0549433
intervention	I-C0549433
,	O
and	O
complications	B-C1264516
were	O
collected	B-C1516698
.	O
	
a	O
total	B-C0439810
of	O
1	O
children	B-C0008059
aged	B-C0001779
0.19	O
to	O
17	O
years	B-C0439234
were	O
identified	B-C0205396
with	O
dog	B-C0259797
bite	I-C0259797
s	O
.	O
	
dog	O
bite	O
s	O
to	O
the	O
face	O
occurred	O
in	O
most	O
patients	O
n	O
=	O
1	O
,	O
414	O
71%	O
.	O
	
of	O
those	O
children	O
with	O
facial	O
dog	B-C0259797
bite	I-C0259797
injuries	O
,	O
230	O
16%	O
suffered	O
ophthalmic	O
manifestations	O
.	O
	
the	O
average	O
age	O
was	O
4.3	O
years	O
.	O
	
eyelid	O
injuries	O
occurred	O
in	O
227	O
99%	O
of	O
children	O
,	O
47	O
20%	O
sustained	O
canalicular	O
system	O
injuries	O
,	O
3	O
1.3	O
suffered	O
corneal	O
abrasions	O
,	O
and	O
2	O
patients	O
sustained	O
facial	O
nerve	O
injury	O
resulting	O
in	O
lagophthalmos	O
.	O
	
no	O
patients	O
suffered	O
vision	O
loss	O
.	O
	
complications	O
occurred	O
in	O
32	O
patients	O
14%	O
,	O
with	O
the	O
most	O
common	O
being	O
epiphora	O
in	O
9	O
patients	O
28%	O
,	O
upper	O
eyelid	O
ptosis	O
in	O
8	O
25%	O
,	O
and	O
prominent	O
scar	O
formation	O
in	O
4	O
patients	O
13%	O
.	O
	
thirteen	O
children	O
5.7	O
needed	O
one	O
or	O
more	O
secondary	O
procedure	O
to	O
correct	O
complications	O
.	O
	
the	O
authors	O
report	O
the	O
clinical	O
features	O
and	O
management	O
on	O
the	O
largest	O
series	O
of	O
ophthalmic	O
and	O
periocular	O
injuries	O
associated	O
with	O
pediatric	O
facial	O
dog	O
bite	O
s	I-C0259797
.	O
	
these	O
injuries	O
occur	O
in	O
about	O
1	O
in	O
6	O
dog	O
bite	O
s	O
to	O
the	O
face	O
and	O
primarily	O
involve	O
the	O
ocular	O
adnexa	O
.	O
	
despite	O
early	O
and	O
appropriate	O
surgical	O
management	O
,	O
complications	O
and	O
the	O
need	O
for	O
revision	O
surgery	O
are	O
relatively	O
common	B-C1522138
blastocystis	B-C3106936
subtyping	I-C3106936
and	O
its	O
association	O
with	O
intestinal	B-C0021832
parasites	I-C0021832
in	O
children	B-C0008059
from	O
different	O
geographical	B-C3245499
regions	I-C3245499
of	I-C3245499
colombia	I-C3245499
blastocystis	B-C0005707
is	O
a	O
common	O
enteric	B-C4289767
protist	I-C4289767
colonizing	I-C4289767
probably	O
more	O
than	O
1	O
billion	O
people	B-C0027361
with	O
a	O
large	O
variety	O
of	O
non-human	B-C1167395
hosts	I-C1167395
.	O
	
remarkable	O
genetic	B-C0042333
diversity	I-C0042333
has	O
been	O
observed	O
,	O
leading	O
to	O
the	O
subdivision	B-C1708235
of	I-C1708235
the	I-C1708235
genus	I-C1708235
into	O
multiple	B-C0449560
subtypes	I-C0449560
st	B-C0449560
,	O
some	O
of	O
which	O
are	O
exclusively	O
found	O
in	O
non-human	B-C1167395
hosts	I-C1167395
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
distribution	O
of	O
blastocystis	B-C3106936
sts	I-C3106936
/	O
18s	B-C0002085
alleles	I-C0002085
in	O
symptomatic	B-C0231220
abdominal	B-C0000737
pain	I-C0000737
,	O
anal	B-C0033775
pruritus	I-C0033775
,	O
diarrhea	B-C0011991
,	O
headache	B-C0018681
,	O
nauseas	B-C0027497
and/or	O
vomit	B-C0042963
and	O
asymptomatic	B-C0231221
children	B-C0008059
from	O
nine	O
geographical	B-C3245499
regions	I-C3245499
of	I-C3245499
colombia	I-C3245499
.	O
	
a	O
total	O
of	O
2026	O
fecal	B-C0455051
samples	I-C0455051
were	O
collected	O
as	O
part	O
of	O
a	O
national	B-C0681817
survey	I-C0681817
to	O
estimate	O
the	O
frequency	O
of	O
intestinal	B-C0021832
parasites	I-C0021832
in	O
children	B-C0008059
.	O
	
a	O
set	O
of	O
256	O
samples	O
that	O
were	O
blastocystis	B-C0005707
positive	I-C0005707
was	O
finally	O
selected	O
.	O
	
the	O
samples	O
were	O
submitted	O
to	O
dna	B-C3839098
extraction	I-C3839098
,	O
real	B-C1709846
time	I-C1709846
pcr	I-C1709846
and	O
sequencing	B-C1294197
using	O
blastocystis	B-C3687300
-specific	O
primers	B-C0206415
targeting	O
the	O
small	B-C1167012
subunit	I-C1167012
rrna	B-C0035899
gene	I-C0035899
for	O
st	B-C1261145
identification	I-C1261145
.	O
	
dna	B-C0012854
of	O
ascaris	B-C0003955
lumbricoides	I-C0003955
16.4	O
,	O
trichuris	B-C0040913
trichiura	I-C0040913
8.2	O
,	O
hookworms	B-C1265425
necator	B-C0002826
americanus	I-C0002826
/	O
ancylostoma	B-C0162314
duodenale	I-C0162314
7.3	O
,	O
giardia	B-C0017535
duodenalis	I-C0017535
23.1	O
,	O
entamoeba	B-C1285568
complex	I-C1285568
82%	O
,	O
entamoeba	B-C0320420
coli	I-C0320420
55%	O
,	O
hymenolepis	B-C0322196
nana	I-C0322196
0.8	O
,	O
endolimax	B-C0320452
nana	I-C0320452
33.2	O
and	O
neobalantidium	B-C0004694
coli	I-C0004694
2.7	O
was	O
detected	O
in	O
the	O
blastocystis	B-C0005707
-	O
positive	B-C1514241
samples	I-C1514241
.	O
	
we	O
detected	O
st1	B-C3106801
21.4	O
,	O
st2	B-C3106925
19.5	O
,	O
st3	B-C3106933
55.5	O
,	O
st4	B-C3961358
0.8	O
,	O
st6	B-C3106938
2%	O
and	O
st7	B-C3106936
0.8	O
alleles	B-C0002085
1	O
,	O
2	O
,	O
4	O
,	O
81	O
,	O
82	O
and	O
83	O
for	O
st1	B-C3106801
alleles	B-C0002085
9	O
,	O
11	O
,	O
12	O
,	O
15	O
,	O
67	O
,	O
71	O
and	O
73	O
for	O
st2	B-C3106925
alleles	B-C0002085
34	O
,	O
36	O
,	O
38	O
,	O
45	O
,	O
49	O
,	O
55	O
,	O
134	O
and	O
128	O
for	O
st3	B-C3106933
allele	B-C0002085
42	O
for	O
st4	B-C3961358
allele	B-C0002085
122	O
for	O
st6	B-C3106938
,	O
and	O
allele	B-C0002085
142	O
for	O
st7	B-C3106936
.	O
	
further	O
studies	O
implementing	O
high-resolution	B-C1719039
molecular	B-C0005516
markers	I-C0005516
are	O
necessary	O
to	O
understand	O
the	O
dynamics	O
of	O
blastocystis	B-C0005707
transmission	B-C1521797
and	O
the	O
role	O
of	O
this	O
stramenopila	B-C1004618
in	O
health	B-C0679215
and	I-C0679215
disease	I-C0679215
.	O
	
did	O
municipal	B-C1550151
solid	I-C1550151
waste	I-C1550151
landfill	B-C0599634
have	O
obvious	O
influence	B-C4054723
on	O
polychlorinated	B-C4277576
dibenzo-p-dioxins	I-C4277576
and	O
polychlorinated	B-C4277574
dibenzofurans	I-C4277574
pcdd	B-C4277576
/	O
fs	B-C4277574
in	O
ambient	B-C0001861
air	I-C0001861
a	O
case	B-C0085973
study	I-C0085973
in	O
east	B-C0008115
china	I-C0008115
municipal	B-C1550151
solid	I-C1550151
waste	I-C1550151
msw	B-C1550151
landfill	B-C0599634
was	O
a	O
main	O
way	O
to	O
disposal	B-C1707797
of	O
msw	B-C1550151
and	O
almost	O
95%	O
of	O
msw	B-C1550151
was	O
disposed	B-C1707797
by	O
landfills	B-C0599634
in	O
the	O
world	B-C2700280
.	O
	
in	O
order	O
to	O
understand	O
the	O
influence	B-C4054723
of	O
msw	B-C1550151
landfill	B-C0599634
on	O
polychlorinated	B-C4277576
dibenzo-p-dioxins	I-C4277576
and	O
polychlorinated	B-C4277574
dibenzofurans	I-C4277574
pcdd	B-C4277576
/	O
fs	B-C4277574
in	O
surrounding	B-C0935443
atmosphere	I-C0935443
,	O
42	O
ambient	B-C0001861
air	I-C0001861
samples	O
were	O
collected	O
and	O
analyzed	B-C0936012
from	O
surrounding	B-C0205145
sites	I-C0205145
,	O
background	B-C0205145
site	I-C0205145
,	O
upwind	B-C0205145
site	I-C0205145
and	O
downwind	B-C0205145
site	I-C0205145
of	O
a	O
msw	B-C1550151
landfill	B-C0599634
in	O
east	B-C0008115
china	I-C0008115
.	O
	
the	O
results	O
of	O
present	O
study	B-C2603343
were	O
summarized	O
as	O
follows	O
.	O
	
1	O
the	O
total	O
concentrations	B-C1446561
of	O
pcdd	B-C4277576
/	O
fs	B-C4277574
pcdd	B-C4277576
/	O
fs	B-C4277574
in	O
ambient	B-C0001861
air	I-C0001861
from	O
surrounding	B-C0205145
sites	I-C0205145
,	O
background	B-C0205145
site	I-C0205145
,	O
upwind	B-C0205145
site	I-C0205145
and	O
downwind	B-C0205145
site	I-C0205145
were	O
2.215	O
,	O
2.058	O
,	O
2.617	O
and	O
1.822	O
,	O
respectively	O
.	O
	
2	O
the	O
toxic	B-C1446561
equivalent	I-C1446561
concentrations	I-C1446561
teq	B-C1446561
of	O
pcdd	B-C4277576
/	O
fs	B-C4277574
in	O
ambient	B-C0001861
air	I-C0001861
from	O
surrounding	B-C0205145
sites	I-C0205145
,	O
background	B-C0205145
site	I-C0205145
,	O
upwind	B-C0205145
site	I-C0205145
and	O
downwind	B-C0205145
site	I-C0205145
were	O
0.103	O
,	O
0.096	O
,	O
0.120	O
and	O
0.108	O
i-teqnm	O
,	O
respectively	O
.	O
	
3	O
the	O
congener	B-C1979963
profiles	I-C1979963
,	O
pcdd	B-C4277576
/	O
fs	B-C4277574
and	O
teq	B-C1446561
between	O
background	B-C0935443
atmosphere	I-C0935443
and	O
surrounding	B-C0935443
atmosphere	I-C0935443
of	O
landfill	B-C0599634
did	O
not	O
show	O
statistically	B-C0237881
significant	I-C0237881
difference	O
.	O
	
4	O
the	O
pcdd	B-C4277576
/	O
fs	B-C4277574
and	O
teq	B-C1446561
in	O
ambient	B-C0001861
air	I-C0001861
of	O
downwind	B-C0205145
site	I-C0205145
were	O
not	O
higher	O
than	O
that	O
of	O
upwind	B-C0205145
site	I-C0205145
,	O
suggesting	O
that	O
studied	O
landfill	B-C0599634
did	O
not	O
have	O
obvious	O
influence	B-C4054723
on	O
pcdd	B-C4277576
/	O
fs	B-C4277574
in	O
ambient	B-C0001861
air	I-C0001861
from	O
downwind	B-C0205145
site	I-C0205145
.	O
	
5	O
the	O
95th	O
percentile	B-C1264641
carcinogenic	B-C0596244
risk	I-C0596244
cr	B-C0596244
of	O
pcdd	B-C4277576
/	O
fs	B-C4277574
in	O
ambient	B-C0001861
air	I-C0001861
from	O
s	O
urrounding	B-C0205145
sites	I-C0205145
,	O
background	B-C0205145
site	I-C0205145
,	O
upwind	B-C0205145
site	I-C0205145
and	O
downwind	B-C0205145
site	I-C0205145
were	O
8.03	O
,	O
7.57	O
,	O
9.69	O
and	O
8.15	O
,	O
respectively	O
,	O
which	O
were	O
much	B-C0443151
lower	I-C0443151
than	I-C0443151
the	I-C0443151
threshold	I-C0443151
value	I-C0443151
of	O
cr	B-C0596244
10	O
,	O
suggesting	O
that	O
studied	O
landfill	B-C0599634
did	O
not	O
influence	B-C4054723
the	O
cr	B-C0596244
of	O
pcdd	B-C4277576
/	O
fs	B-C4277574
in	O
surrounding	B-C0935443
atmosphere	I-C0935443
and	O
negligible	O
cancer	B-C0596244
risk	I-C0596244
occurred	O
.	O
	
6	O
the	O
non-carcinogenic	B-C4036089
risk	I-C4036089
non-cr	B-C4036089
analysis	B-C0936012
indicated	O
that	O
landfill	B-C0599634
did	O
not	O
have	O
influence	B-C4054723
on	O
the	O
non-cr	B-C4036089
of	O
pcdd	B-C4277576
/	O
fs	B-C4277574
in	O
surrounding	B-C0935443
atmosphere	I-C0935443
and	O
no	O
obvious	O
non-carcinogenic	B-C1301751
effects	I-C1301751
methodological	B-C1879746
considerations	I-C1879746
for	O
designing	O
a	O
community	B-C0009462
water	B-C0016323
fluoridation	I-C0016323
cessation	B-C1880019
study	B-C2603343
high-quality	B-C0814847
,	O
up-to-date	O
research	B-C0242481
on	O
community	B-C0009462
water	B-C0016323
fluoridation	I-C0016323
cwf	B-C0016323
,	O
and	O
especially	O
on	O
the	O
implications	O
of	O
cwf	B-C0016323
cessation	B-C1880019
for	O
dental	B-C0011365
health	I-C0011365
,	O
is	O
limited	O
.	O
	
although	O
cwf	B-C0016323
cessation	B-C1880019
studies	B-C2603343
have	O
been	O
conducted	O
,	O
they	O
are	O
few	O
in	O
number	O
one	O
of	O
the	O
major	O
reasons	O
is	O
the	O
methodological	B-C0237523
complexity	I-C0237523
of	O
conducting	O
such	O
a	O
study	B-C2603343
.	O
	
this	O
article	O
draws	O
on	O
a	O
systematic	B-C1955832
review	I-C1955832
of	O
existing	O
cessation	B-C1880019
studies	B-C2603343
n=15	O
to	O
explore	O
methodological	B-C1879746
considerations	I-C1879746
of	O
conducting	O
cwf	B-C0016323
cessation	B-C1880019
studies	B-C2603343
in	O
future	B-C0016884
.	O
	
we	O
review	O
nine	O
important	O
methodological	B-C1879746
aspects	I-C1879746
study	B-C0035171
design	I-C0035171
,	O
comparison	B-C0009462
community	I-C0009462
,	O
target	B-C0039309
population	I-C0039309
,	O
time	B-C0872291
frame	I-C0872291
,	O
sampling	B-C0449370
strategy	I-C0449370
,	O
clinical	B-C1522602
indicators	I-C1522602
,	O
assessment	B-C0935549
criteria	I-C0935549
,	O
covariates	O
and	O
biomarkers	B-C0005516
and	O
provide	O
recommendations	B-C2936699
for	O
planning	B-C0018727
future	B-C0016884
cwf	B-C0016323
cessation	B-C1880019
studies	B-C2603343
that	O
examine	O
effects	O
on	O
dental	B-C0011334
caries	I-C0011334
.	O
	
there	O
is	O
no	O
one	O
ideal	O
study	B-C0035171
design	I-C0035171
to	O
answer	O
a	O
research	B-C0681799
question	I-C0681799
.	O
	
however	O
,	O
recommendations	B-C0034866
proposed	O
regarding	O
methodological	B-C1879746
aspects	I-C1879746
to	O
conduct	O
an	O
epidemiological	B-C0002783
study	I-C0002783
to	O
observe	O
the	O
effects	O
of	O
cwf	B-C0016323
cessation	B-C1880019
on	O
dental	B-C0011334
caries	I-C0011334
,	O
coupled	O
with	O
our	O
identification	O
of	O
important	O
methodological	O
gaps	O
,	O
will	O
be	O
useful	O
for	O
researchers	B-C0035173
who	O
are	O
looking	O
to	O
optimize	B-C2698650
resources	B-C0035201
to	O
conduct	O
such	O
a	O
study	B-C2603343
central	B-C0027149
myxoma	I-C0027149
/	O
myxofibroma	B-C0205766
of	O
the	O
jaws	B-C0022359
a	O
clinico	B-C0442592
-	O
epidemiologic	B-C0014508
review	B-C0282443
myxomas	B-C0027149
are	O
a	O
group	O
of	O
benign	B-C0205183
rare	B-C4054123
tumors	I-C4054123
of	O
connective-tissue	B-C0009780
origin	B-C0439659
that	O
occur	O
in	O
both	O
hard	B-C0040300
central	I-C0040300
and	O
soft	B-C0225317
tissues	I-C0225317
of	O
the	O
body	B-C0242821
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C0008972
is	O
to	O
highlight	O
our	O
experience	O
in	O
the	O
management	O
of	O
central	B-C1404550
myxoma	I-C1404550
of	I-C1404550
the	I-C1404550
jaw	I-C1404550
,	O
with	O
emphasis	O
on	O
its	O
clinic	B-C0442592
-	O
epidemiologic	B-C0014508
features	O
as	O
seen	O
in	O
our	O
environment	B-C0014406
.	O
	
all	O
patients	B-C0030705
who	O
were	O
managed	O
for	O
central	B-C1404550
myxoma	I-C1404550
of	I-C1404550
the	I-C1404550
jaw	I-C1404550
at	O
the	O
oral	B-C1704729
and	I-C1704729
maxillofacial	I-C1704729
surgery	I-C1704729
department	I-C1704729
of	O
a	O
regional	B-C0020027
university	I-C0020027
teaching	I-C0020027
hospital	I-C0020027
between	O
september	O
1997	O
and	O
october	O
2015	O
were	O
retrospectively	B-C0035363
studied	I-C0035363
.	O
	
details	O
sourced	O
included	O
age	B-C0001779
,	O
sex	B-C1522384
,	O
site	B-C0475445
of	I-C0475445
tumor	I-C0475445
,	O
duration	B-C0449238
,	O
signs/symptoms	B-C3540840
,	O
treatment	B-C0580351
given	I-C0580351
,	O
and	O
complications	B-C0009566
.	O
	
data	B-C1511726
were	O
analyzed	B-C0936012
using	O
statistical	B-C0037585
package	I-C0037585
for	I-C0037585
social	I-C0037585
sciences	I-C0037585
spss	I-C0037585
version	I-C0037585
16	I-C0037585
spss	B-C0683757
inc	I-C0683757
chicago	B-C0008044
,	O
il	B-C0020898
,	O
usa	B-C0041703
and	O
microsoft	B-C0037585
excel	I-C0037585
2007	I-C0037585
microsoft	B-C0683757
,	O
redmond	B-C0008848
,	O
wa	B-C0043038
,	O
usa	B-C0041703
.	O
	
results	B-C1274040
from	O
descriptive	B-C2828391
statistics	I-C2828391
were	O
represented	O
in	O
the	O
form	O
of	O
tables	B-C1706074
and	O
charts	B-C0684240
,	O
with	O
a	O
test	B-C0392366
for	I-C0392366
significance	I-C0392366
ρ	O
using	O
pearson	B-C0008041
chi-square	I-C0008041
χ	O
set	O
at	O
0.05	O
.	O
	
a	O
total	O
of	O
16	O
patients	B-C0030705
were	O
managed	O
within	O
the	O
period	B-C1948053
reviewed	B-C1709940
,	O
consisting	O
of	O
10	O
62.5	O
females	B-C0086287
and	O
six	O
37.5	O
males	B-C0086582
,	O
giving	O
a	O
male-to-female	B-C0682069
ratio	I-C0682069
of	O
1	O
.	O
	
the	O
ages	B-C0001779
of	O
patients	B-C0030705
ranged	B-C1514721
from	O
5	O
to	O
70	O
years	B-C1510829
,	O
with	O
a	O
mean	O
of	O
27.06	O
years	B-C1510829
.	O
	
the	O
mandible	B-C0024687
accounted	O
for	O
nine	O
56.3	O
cases	B-C0868928
and	O
the	O
maxilla	B-C0024947
for	O
six	O
37.5	O
cases	B-C0868928
,	O
while	O
a	O
combination	B-C0205195
of	O
the	O
maxilla	B-C0024947
and	O
the	O
zygoma	B-C1269549
were	O
involved	O
in	O
one	O
6.3	O
case	B-C0868928
.	O
	
bucco-lingual	B-C0229962
or	O
bucco-palatal	B-C0229962
expansion	B-C0205229
were	O
the	O
most	O
common	O
presentation	O
six	O
46.2	O
cases	B-C0868928
each	O
.	O
	
histological	B-C0205462
assessment	B-C0220825
of	O
tissue	B-C1292533
specimens	I-C1292533
showed	O
that	O
fibromyxoma	B-C0205766
accounted	B-C0085978
for	O
seven	O
43.8	O
cases	B-C0868928
,	O
while	O
the	O
remaining	O
nine	O
56.3	O
cases	B-C0868928
were	O
diagnosed	B-C0011900
as	O
myxoma	B-C0027149
.	O
	
all	O
patients	B-C0030705
had	O
jaw	B-C2090639
resections	I-C2090639
,	O
and	O
these	O
consisted	O
of	O
mandibulectomies	B-C0185566
in	O
nine	O
60.0	O
patients	B-C0030705
and	O
maxillectomies	B-C0407722
in	O
six	O
40.0	O
patients	B-C0030705
.	O
	
the	O
duration	B-C4019086
of	I-C4019086
hospital	I-C4019086
stay	I-C4019086
ranged	B-C1514721
from	O
5	O
to	O
29	O
days	B-C0439228
,	O
with	O
a	O
mean	O
of	O
17.86	O
days	B-C0439228
.	O
	
complications	B-C0009566
were	O
noted	O
in	O
three	O
patients	B-C0030705
,	O
and	O
all	O
were	O
surgical	B-C0038941
wound	I-C0038941
infections	I-C0038941
.	O
	
most	O
patients	B-C0030705
in	O
our	O
environment	B-C0014406
present	O
late	O
with	O
large	B-C0475278
tumors	I-C0475278
and	O
are	O
usually	O
not	O
compliant	O
with	O
follow-up	B-C1522577
review	B-C1552617
.	O
	
thus	O
,	O
a	O
radical	B-C0439807
approach	O
is	O
favored	O
in	O
most	O
pediatric	B-C1521725
hypovitaminosis	B-C0042870
d	I-C0042870
molecular	O
perspectives	B-C1879746
and	O
clinical	B-C0683325
implications	B-C1707478
vitamin	B-C0042866
d	I-C0042866
,	O
a	O
secosteroid	B-C0036532
,	O
is	O
essential	B-C0205224
for	O
the	O
development	B-C0678723
and	O
maintenance	B-C0024501
of	O
healthy	B-C3898900
bone	B-C0262950
in	O
both	O
the	O
adult	B-C0001675
and	O
pediatric	B-C1521725
populations	B-C1257890
.	O
	
low	B-C1611820
level	I-C1611820
of	O
25-hydroxy	B-C0006657
vitamin	I-C0006657
d	I-C0006657
25-	B-C0006657
is	O
highly	O
prevalent	O
in	O
children	B-C0008059
worldwide	O
and	O
has	O
been	O
linked	O
to	O
various	O
adverse	B-C0879626
health	B-C1550208
outcomes	I-C1550208
including	O
rickets	B-C0035579
,	O
osteomalacia	B-C0029442
,	O
osteomalacic	B-C0410213
myopathy	I-C0410213
,	O
sarcopenia	B-C0872084
,	O
and	O
weakness	B-C3714552
,	O
growth	B-C0151686
retardation	I-C0151686
,	O
hypocalcemia	B-C0020598
,	O
seizure	B-C0036572
and	O
tetany	B-C0039621
,	O
autism	B-C0004352
,	O
cardiovascular	B-C0007222
diseases	I-C0007222
,	O
diabetes	B-C0011849
mellitus	I-C0011849
,	O
cancers	B-C0006826
prostate	B-C0376358
,	O
colon	B-C0009375
,	O
breast	B-C0006142
,	O
infectious	B-C0009450
diseases	I-C0009450
viral	B-C0042769
,	O
tuberculosis	B-C0041296
,	O
and	O
autoimmune	B-C0004364
diseases	I-C0004364
,	O
such	O
as	O
multiple	B-C0026769
sclerosis	I-C0026769
and	O
hashimoto's	B-C0677607
thyroiditis	I-C0677607
.	O
	
risk	B-C0035648
factors	I-C0035648
for	O
hypovitaminosis	B-C0042870
d	I-C0042870
are	O
people	B-C0027361
with	O
darker	B-C0037290
skin	I-C0037290
pigmentation	I-C0037290
,	O
use	B-C1524063
of	O
sunscreen	B-C0038818
,	O
insufficient	B-C0205412
ultraviolet	B-C0564461
b	I-C0564461
exposure	B-C0332157
,	O
prematurity	B-C0021294
,	O
living	B-C0337646
in	I-C0337646
northern	I-C0337646
latitudes	I-C0337646
,	O
malnutrition	B-C0162429
,	O
obesity	B-C0028754
,	O
exclusive	B-C0242205
breastfeeding	I-C0242205
,	O
low	B-C0243095
maternal	I-C0243095
vitamin	I-C0243095
d	I-C0243095
level	I-C0243095
,	O
certain	O
medications	B-C0013227
,	O
drinking	B-C0684271
unfortified	B-C0349374
cow's	I-C0349374
milk	I-C0349374
,	O
liver	B-C0085605
failure	I-C0085605
,	O
chronic	B-C0403447
renal	I-C0403447
insufficiency	I-C0403447
,	O
cystic	B-C0010674
fibrosis	I-C0010674
,	O
asthma	B-C0004096
,	O
and	O
sickle	B-C1399386
cell	I-C1399386
hemoglobinopathy	I-C1399386
.	O
	
this	O
review	B-C0282443
highlights	O
and	O
summarizes	O
the	O
molecular	O
perspectives	O
of	O
vitamin	B-C0042870
d	I-C0042870
deficiency	I-C0042870
and	O
its	O
potential	O
adverse	B-C0879626
health	B-C1550208
outcomes	I-C1550208
in	O
pediatric	B-C1521725
age	B-C0027362
groups	I-C0027362
.	O
	
the	O
recommended	B-C0516913
treatment	I-C0516913
regimen	I-C0516913
is	O
beyond	O
the	O
scope	O
of	O
this	O
causes	O
of	O
ecological	B-C0565987
gradients	B-C0812409
in	O
leaf	B-C0242724
margin	B-C0205284
entirety	B-C0439751
evaluating	B-C0015196
the	O
roles	B-C1705810
of	O
biomechanics	B-C0005537
,	O
hydraulics	B-C1518533
,	O
vein	B-C0449829
geometry	I-C0449829
,	O
and	O
bud	B-C2700462
packing	B-C2828395
a	O
recent	B-C0332185
commentary	B-C0282411
by	O
edwards	O
et	O
al	O
.	O
	
am	O
.	O
	
j	O
.	O
	
bot	O
.	O
	
103	O
975-978	O
proposed	B-C1553874
that	O
constraints	B-C0443288
imposed	O
by	O
the	O
packing	B-C2828395
of	O
young	B-C0332239
leaves	B-C0242724
in	O
buds	B-C2700462
could	O
explain	O
the	O
positive	B-C1446409
association	B-C0750490
between	O
non-entire	B-C0205556
leaf	B-C0242724
margins	B-C0205284
and	O
latitude	B-C1627936
but	O
did	O
not	O
thoroughly	O
consider	B-C0750591
alternative	B-C1523987
explanations	B-C0681841
.	O
	
we	O
review	B-C1552617
the	O
logic	B-C0023963
and	O
evidence	B-C3887511
underlying	O
six	O
major	B-C0205164
hypotheses	B-C1512571
for	O
the	O
functional	B-C0205245
significance	B-C0750502
of	O
marginal	B-C0205284
teeth	B-C0242724
,	O
involving	O
putative	B-C0750591
effects	B-C1280500
on	O
1	O
leaf	B-C0242724
cooling	B-C0678568
,	O
2	O
optimal	B-C2698651
support	O
and	O
supply	O
of	O
the	O
areas	B-C0205146
served	O
by	O
major	B-C0205164
veins	B-C0042449
,	O
3	O
enhanced	B-C0205217
leaf	B-C0242724
-	O
margin	B-C0205284
photosynthesis	B-C0031764
,	O
4	O
hydathodal	B-C0007613
function	I-C0007613
,	O
5	O
defense	B-C1880266
against	B-C0521124
herbivores	B-C0562691
,	O
and	O
6	O
bud	B-C2700462
packing	B-C2828395
.	O
	
theoretical	B-C0871935
and	O
empirical	B-C1880496
problems	B-C0033213
undermine	O
all	O
hypotheses	B-C1512571
except	B-C0332300
the	O
support-supply	B-C1512571
hypothesis	I-C1512571
,	O
which	O
implies	O
that	O
thinner	B-C0205168
leaves	B-C0242724
should	O
have	O
non-entire	B-C0205556
margins	B-C0205284
.	O
	
phylogenetically	B-C0871077
structured	B-C0936012
analyses	I-C0936012
across	O
angiosperms	B-C0330208
,	O
the	O
el	B-C0681784
yunque	I-C0681784
flora	B-C0314761
,	O
and	O
the	O
genus	B-C1708235
viburnum	B-C0969714
all	O
demonstrate	O
that	O
non-entire	B-C0205556
margins	B-C0205284
are	O
indeed	B-C2984081
more	O
common	B-C0205214
in	O
thinner	B-C0205168
leaves	B-C0242724
.	O
	
across	O
angiosperms	B-C0330208
,	O
the	O
association	B-C0750490
of	O
leaf	B-C0242724
thickness	B-C1280412
with	O
non-entire	B-C0205556
leaf	B-C0242724
margins	B-C0205284
is	O
stronger	B-C0442821
than	O
that	O
of	O
latitude	B-C1627936
.	O
	
we	O
outline	B-C0600661
a	O
synthetic	B-C3161035
model	I-C3161035
showing	O
how	O
biomechanics	B-C0005537
,	O
hydraulics	B-C1518533
,	O
vein	B-C0042449
geometry	B-C0449829
,	O
rates	B-C0449249
of	O
leaf	B-C0242724
expansion	B-C0007595
,	O
and	O
length	O
of	O
development	B-C1527148
within	O
resting	B-C0679218
buds	B-C2700462
,	O
all	O
tied	O
to	O
leaf	B-C0242724
thickness	B-C1280412
,	O
drive	B-C1287104
patterns	B-C0449774
in	O
the	O
distribution	B-C0037775
of	O
entire	B-C0439751
vs	O
.	O
	
non-entire	B-C0205556
leaf	B-C0242724
margins	B-C0205284
.	O
	
our	O
model	B-C3161035
accounts	O
for	O
dominance	B-C0870441
of	O
entire	B-C0439751
margins	B-C0205284
in	O
the	O
tropics	B-C0681784
,	O
mediterranean	B-C0282645
scrub	I-C0282645
,	O
and	O
tundra	B-C3850151
,	O
non-entire	B-C0205556
margins	B-C0205284
in	O
cold	B-C0009264
temperate	I-C0009264
deciduous	B-C0086312
forests	I-C0086312
and	O
tropical	B-C0681784
vines	B-C0330100
and	O
early-successional	B-C0040811
trees	I-C0040811
,	O
and	O
entire	B-C0439751
leaf	B-C0242724
margins	B-C0205284
in	O
monocots	B-C0331451
.	O
	
spinose-toothed	B-C0242724
leaves	I-C0242724
should	O
be	O
favored	O
in	O
short-statured	B-C0349588
evergreen	B-C0040811
trees	I-C0040811
and	O
shrubs	B-C0446286
,	O
primarily	O
in	O
mediterranean	B-C0282645
scrub	I-C0282645
and	O
related	O
semiarid	B-C0871648
habitats	I-C0871648
.	O
	
viral	B-C1520007
vector	I-C1520007
biosafety	B-C1443933
in	O
laboratory	B-C0003048
animal	I-C0003048
research	I-C0003048
viral	B-C1520007
vector	I-C1520007
research	B-C0035168
presents	B-C0449450
unique	B-C1710548
occupational	B-C0079920
health	I-C0079920
and	O
safety	B-C0036043
challenges	B-C0805586
to	O
institutions	B-C2607850
due	O
to	O
the	O
rapid	B-C0456962
development	B-C1527148
ofboth	O
in	B-C1515655
vivo	I-C1515655
and	O
in	B-C1533691
vitro	I-C1533691
gene-editing	B-C4277689
technologies	I-C4277689
.	O
	
risks	B-C0035647
to	O
human	B-C0086418
and	O
animal	B-C0003062
health	B-C0018684
make	O
it	O
incumbent	B-C3898777
on	O
institutions	B-C2607850
to	O
appropriately	B-C1548787
evaluate	B-C0220825
viral	B-C1520007
vector	I-C1520007
usage	B-C0457083
in	O
research	B-C0035168
on	O
the	O
basis	B-C1527178
of	O
available	B-C0470187
information	B-C1533716
and	O
governmental	B-C0034982
regulations	I-C0034982
and	O
guidelines	B-C0162791
here	O
we	O
review	B-C1552617
the	O
factors	B-C1521761
related	O
to	O
risk	B-C0086930
assessment	I-C0086930
regarding	O
viral	B-C1520007
vector	I-C1520007
usage	B-C0457083
in	O
animals	B-C0003062
and	O
the	O
relevant	B-C2347946
regulatory	B-C1301746
documents	I-C1301746
associated	B-C0332281
with	I-C0332281
this	O
research	B-C0035168
,	O
and	O
we	O
highlight	O
the	O
most	B-C0205393
commonly	B-C0205214
used	O
viral	B-C1520007
vectors	I-C1520007
in	O
research	B-C0035168
today	O
.	O
	
this	O
review	B-C1552617
is	O
particularly	B-C0205369
focused	B-C1285542
on	O
the	O
background	B-C1706907
,	O
use	O
in	O
research	B-C0035168
and	O
associated	B-C0332281
health	B-C0018684
and	O
environmental	B-C0686732
risks	I-C0686732
related	B-C0439849
to	O
adenoviral	B-C0001483
,	O
adeno-associated	B-C1564874
viral	I-C1564874
,	O
lentiviral	B-C0079679
,	O
and	O
herpesviral	B-C0019369
vectors	B-C1520007
.	O
	
liver	B-C0019158
inflammation	I-C0019158
relates	O
to	O
decreased	B-C0205216
canalicular	B-C0005393
bile	B-C0618375
transporter	I-C0618375
expression	B-C1171362
in	O
pediatric	B-C1521725
onset	B-C0206132
intestinal	B-C0012634
failure	I-C0012634
although	O
liver	B-C0023895
disease	I-C0023895
is	O
a	O
major	O
complication	B-C0009566
of	O
parenteral	B-C0030547
nutrition	I-C0030547
pn	B-C0030547
for	O
intestinal	B-C0012634
failure	I-C0012634
if	B-C0012634
,	O
its	O
pathogenesis	B-C0699748
remains	O
unclear	O
.	O
	
we	O
investigated	B-C1292732
potential	O
molecular	B-C1521991
mechanisms	B-C0441712
of	O
liver	B-C0160390
injury	I-C0160390
in	O
pediatric	B-C1521725
onset	B-C0206132
if	B-C0012634
.	O
	
liver	B-C0023884
expression	B-C1171362
of	O
canalicular	B-C0005393
phospholipid	B-C0031676
abcb4	B-C1260069
,	O
bile	B-C0005390
acid	I-C0005390
abcb11	B-C1313221
,	O
and	O
sterol	B-C0038323
abcg5/8	B-C0971221
transporters	B-C0007292
,	O
their	O
upstream	B-C0033684
regulators	I-C0033684
lxr	B-C4277606
and	O
fxr	B-C1173940
as	O
well	O
as	O
pro-inflammatory	B-C0079189
cytokines	I-C0079189
interleukin-6	B-C0021760
il6	B-C0021760
and	O
tumor	B-C0041368
necrosis	I-C0041368
factor	I-C0041368
tnf	B-C0041368
were	O
investigated	B-C1292732
among	O
patients	B-C0030705
with	O
if	B-C0012634
age	B-C0001779
median	O
3.8	O
iqr	B-C1711350
1.2	O
to	O
11	O
in	O
relation	O
to	O
biochemical	B-C0205474
and	O
histologic	B-C0205462
liver	B-C0160390
injury	I-C0160390
,	O
pn	B-C0030547
,	O
serum	B-C0229671
plant	B-C0031866
sterols	I-C0031866
,	O
fibroblast	B-C1431711
growth	I-C1431711
factor	I-C1431711
19	I-C1431711
,	O
and	O
α-tocopherol	B-C0969677
.	O
	
patients	B-C0030705
receiving	O
pn	B-C0030547
currently	O
n	O
=	O
18	O
showed	O
more	O
advanced	O
liver	B-C0160390
injury	I-C0160390
than	O
patients	B-C0030705
after	O
weaning	B-C0043084
off	O
pn	B-C0030547
n	O
=	O
30	O
.	O
	
histologic	B-C0205462
portal	B-C2748698
inflammation	I-C2748698
strongly	O
segregated	O
pn	B-C0030547
-	O
dependent	B-C3244310
44%	O
from	O
weaned	B-C0043084
off	O
patients	B-C0030705
3%	O
,	O
p	O
=	O
0.001	O
and	O
coupled	O
with	O
progression	B-C0242656
of	O
cholestasis	B-C0008370
and	O
liver	B-C0239946
fibrosis	I-C0239946
.	O
	
patients	B-C0030705
with	O
portal	B-C2748698
inflammation	I-C2748698
demonstrated	O
markedly	O
induced	O
liver	B-C0023884
rna	B-C0040649
expression	I-C0040649
of	O
il6	B-C1334122
and	O
tnf	B-C0812246
,	O
repression	B-C0920533
of	O
fxr	B-C1173940
and	O
its	O
canalicular	B-C0005393
bile	B-C0618375
transporter	I-C0618375
target	O
gene	B-C0017337
rna	B-C0040649
expression	I-C0040649
,	O
including	O
abcb4	B-C1412071
and	O
abcb11	B-C1412070
as	O
well	O
as	O
decreased	B-C0205216
protein	B-C1171362
expression	I-C1171362
of	O
abcb11	B-C1313221
and	O
abcb4	B-C1260069
.	O
	
furthermore	O
,	O
upregulation	B-C0041904
of	O
lxr	B-C4277606
and	O
abcg5/8	B-C1422255
rna	B-C0040649
expression	I-C0040649
was	O
suppressed	B-C1260953
in	O
patients	B-C0030705
with	O
portal	B-C2748698
inflammation	I-C2748698
.	O
	
current	O
pn	B-C0030547
,	O
increased	B-C0205217
serum	B-C0229671
levels	B-C0441889
of	O
plant	B-C0031866
sterols	I-C0031866
stigmasterol	B-C0038329
,	O
avenasterol	B-C0031866
,	O
and	O
sitosterol	B-C0220914
along	O
with	O
serum	B-C0229671
citrulline	B-C0008864
,	O
a	O
marker	B-C0005516
of	O
enterocyte	B-C0682610
mass	I-C0682610
,	O
predicted	O
portal	B-C2748698
inflammation	I-C2748698
.	O
	
in	O
pediatric	B-C1521725
onset	B-C0206132
if	B-C0012634
,	O
current	O
pn	B-C0030547
delivery	O
synergistically	O
with	O
intestinal	B-C0021853
compromise	B-C2945640
promote	O
liver	B-C0019158
inflammation	I-C0019158
,	O
which	O
associates	B-C0332281
with	O
progression	B-C0242656
of	O
biochemical	B-C0205474
and	O
histologic	B-C0205462
liver	B-C0160390
injury	I-C0160390
,	O
while	O
reducing	B-C0392756
expression	B-C1171362
of	O
canalicular	B-C0005393
bile	B-C0618375
transporters	I-C0618375
.	O
	
impaired	B-C0518456
mobility	I-C0518456
,	O
depressed	B-C0344315
mood	I-C0344315
,	O
cognitive	B-C0338656
impairment	I-C0338656
and	O
polypharmacy	B-C2922974
are	O
independently	O
associated	O
with	O
disability	B-C0231170
in	O
older	O
cancer	B-C0006826
outpatients	B-C0029921
the	O
prospective	O
physical	B-C0424594
frailty	I-C0424594
in	O
elderly	B-C0001792
cancer	B-C1516213
patients	I-C1516213
pf	B-C0424594
-	O
ec	B-C1516213
cohort	B-C0009247
study	I-C0009247
to	O
assess	O
the	O
prevalence	O
of	O
disability	B-C0231170
and	O
the	O
oncologic	B-C4294904
factors	I-C4294904
associated	O
with	O
disability	B-C0231170
in	O
older	O
outpatients	B-C0029921
with	O
cancer	B-C0006826
.	O
	
the	O
physical	B-C0424594
frailty	I-C0424594
in	O
elderly	B-C0001792
cancer	B-C1516213
patients	I-C1516213
pf	B-C0424594
-	O
ec	B-C1516213
study	O
france	B-C0016674
is	O
a	O
prospective	B-C1709709
bicentric	I-C1709709
observational	I-C1709709
cohort	I-C1709709
study	I-C1709709
.	O
	
two	O
hundred	O
and	O
ninety	O
outpatients	B-C0029921
with	O
cancer	B-C0006826
were	O
included	O
.	O
	
a	O
cross-sectional	B-C0010362
analysis	I-C0010362
of	O
oncologic	B-C4294904
factors	I-C4294904
and	O
geriatric	B-C1704440
variables	B-C0439828
associated	O
with	O
disability	B-C0231170
that	O
were	O
collected	O
using	O
a	O
comprehensive	B-C1880156
geriatric	B-C0017463
assessment	I-C0017463
cga	B-C0017463
was	O
conducted	O
.	O
	
disability	B-C0231170
was	O
defined	O
as	O
impairment	B-C0221099
in	O
activities	B-C0001288
of	I-C0001288
daily	I-C0001288
living	I-C0001288
adl	B-C0001288
and/or	O
instrumental	B-C1290928
activities	I-C1290928
of	I-C1290928
daily	I-C1290928
living	I-C1290928
iadl	B-C1290928
,	O
simplified	O
to	O
four	O
items	O
.	O
	
univariate	B-C0683962
and	O
multivariate	B-C0026777
logistic	B-C0023965
models	I-C0023965
of	O
disabled	B-C0018576
patients	I-C0018576
were	O
performed	O
.	O
	
the	O
three	O
final	O
multivariate	B-C0026777
models	B-C0023965
were	O
compared	O
using	O
the	O
area	O
under	O
the	O
receiver	B-C0035787
operating	I-C0035787
characteristic	I-C0035787
curve	I-C0035787
auc	B-C0376690
/	O
roc	B-C0035787
of	O
the	O
logistic	B-C0023965
model	I-C0023965
.	O
	
the	O
mean	O
age	O
was	O
80.6years	O
,	O
and	O
51%	O
of	O
the	O
patients	O
were	O
women	B-C0043210
with	O
various	O
types	O
of	O
cancer	B-C0006826
.	O
	
the	O
prevalence	O
of	O
disability	B-C0231170
was	O
67.6	O
.	O
	
no	O
oncologic	B-C4294904
factors	I-C4294904
cancer	B-C0872338
site	I-C0872338
,	O
cancer	B-C1704231
extension	I-C1704231
were	O
associated	O
with	O
disability	B-C0231170
.	O
	
impaired	B-C0518456
mobility	I-C0518456
,	O
poor	B-C0598463
functional	I-C0598463
status	I-C0598463
,	O
depressive	B-C0344315
mood	I-C0344315
,	O
cognitive	B-C0338656
impairment	I-C0338656
and	O
polypharmacy	B-C2922974
were	O
independently	O
associated	O
with	O
disability	B-C0231170
p<0	O
.	O
	
the	O
auc/roc	O
of	O
the	O
final	O
models	O
was	O
similar	O
.	O
	
disability	B-C0231170
was	O
highly	O
prevalent	O
in	O
older	O
cancer	B-C0006826
outpatients	B-C0029921
before	O
cancer	B-C0920425
treatment	I-C0920425
but	O
was	O
not	O
associated	O
with	O
oncologic	B-C4294904
factors	I-C4294904
.	O
	
impaired	B-C0518456
mobility	I-C0518456
,	O
depressed	B-C0344315
mood	I-C0344315
,	O
cognitive	B-C0338656
impairment	I-C0338656
and	O
polypharmacy	B-C2922974
were	O
the	O
geriatric	O
variables	O
significantly	O
and	O
independently	O
associated	O
with	O
disability	B-C0231170
.	O
	
identifying	O
these	O
factors	O
prior	O
to	O
cancer	B-C0920425
treatment	I-C0920425
could	O
enable	O
the	O
implementation	O
of	O
corrective	B-C1947976
actions	I-C1947976
to	O
improve	O
patient	B-C1516213
autonomy	B-C0598368
before	O
treatment	B-C0920425
and	O
during	O
synthesis	B-C0007987
,	O
sar	B-C0038477
and	O
molecular	B-C3494273
docking	I-C3494273
study	B-C2603343
of	O
novel	O
non-β-lactam	B-C0014432
inhibitors	I-C0014432
of	O
tem	B-C0597979
type	I-C0597979
β-lactamase	I-C0597979
the	O
novel	O
classes	O
of	O
acylated	B-C1254351
phenoxyanilide	I-C1254351
and	O
thiourea	B-C1254351
compounds	I-C1254351
were	O
investigated	B-C1292732
for	O
their	O
ability	O
to	O
inhibit	B-C1524081
tem	B-C0597979
type	I-C0597979
β-lactamase	I-C0597979
enzyme	I-C0597979
.	O
	
two	O
compounds	B-C1254351
4g	I-C1254351
and	O
5c	B-C1254351
reveal	O
the	O
inhibition	B-C1524081
potency	B-C1710560
in	O
micromolar	B-C0439194
range	O
and	O
show	O
their	O
action	B-C3266814
by	O
non-covalent	B-C1167622
binding	I-C1167622
in	O
the	O
vicinity	O
of	O
the	O
tem-171	B-C0597979
active	B-C0205681
site	I-C0205681
.	O
	
the	O
structure	B-C0038477
activity	I-C0038477
relationship	I-C0038477
around	O
carbon	B-C0596310
chain	I-C0596310
length	I-C0596310
and	O
different	O
substituents	B-C0680963
in	I-C0680963
ortho-	I-C0680963
and	I-C0680963
para-positions	I-C0680963
of	O
acylated	B-C1254351
phenoxyanilide	I-C1254351
as	O
well	O
as	O
molecular	B-C0600115
modelling	I-C0600115
study	B-C2603343
metabolic	B-C4054530
responses	I-C4054530
of	O
the	O
growing	O
daphnia	B-C1005664
similis	I-C1005664
to	O
chronic	B-C0205191
agnps	B-C1721060
exposure	O
as	O
revealed	O
by	O
gc-q-tof/ms	B-C0599827
and	O
lc-q-tof/ms	B-C0599827
silver	B-C0037125
nanoparticles	B-C1721060
agnps	B-C1721060
are	O
one	O
of	O
the	O
most	O
widely	O
used	O
nanomaterials	B-C1450053
.	O
	
their	O
fast-growing	B-C4086299
utilization	O
has	O
increased	B-C0205217
the	O
occurrence	O
of	O
agnps	B-C1721060
in	O
the	O
environment	B-C0014406
,	O
posing	O
potential	O
health	B-C0035647
and	I-C0035647
ecological	I-C0035647
risks	I-C0035647
.	O
	
in	O
this	O
study	O
,	O
we	O
conducted	O
chronic	B-C1136118
toxicity	I-C1136118
tests	I-C1136118
and	O
investigated	O
the	O
metabolic	B-C0870883
changes	B-C0392747
of	O
the	O
growing	O
daphna	B-C1005664
similis	I-C1005664
with	O
exposure	B-C0332157
to	I-C0332157
0	O
,	O
0.02	O
,	O
and	O
1	O
ppb	O
agnps	B-C1721060
,	O
using	O
non-targeted	B-C0037813
mass	I-C0037813
spectrometry	I-C0037813
-based	O
metabolomics	B-C1328813
.	O
	
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
baseline	B-C1442488
metabolite	B-C0870883
change	B-C0392747
of	O
a	O
common	O
aquatic	B-C0596121
organism	I-C0596121
daphnia	B-C0010979
crustacean	I-C0010979
through	O
its	O
life-cycle	B-C0023675
.	O
	
the	O
results	O
show	O
a	O
dynamic	B-C0243095
kinetic	I-C0243095
pattern	I-C0243095
of	O
the	O
growing	O
daphnia's	B-C0010979
metabolome	B-C2350399
underwent	O
a	O
cycle	B-C0023675
from	O
day	B-C0439228
0	O
to	O
day	B-C0439228
21	O
,	O
with	O
the	O
level	B-C0441889
of	O
metabolites	B-C0870883
gradually	O
increasing	B-C0442808
from	O
day	B-C0439228
0	O
to	O
day	B-C0439228
13	O
,	O
before	O
falling	O
back	O
to	O
the	O
baseline	B-C1442488
level	B-C0441889
of	O
day	B-C0439228
0	O
on	O
day	B-C0439228
21	O
.	O
	
as	O
for	O
the	O
samples	B-C0370003
exposed	B-C0332157
to	I-C0332157
environmental	B-C0392762
concentrations	I-C0392762
of	O
agnps	B-C1721060
,	O
although	O
without	O
morphological	B-C0243095
or	I-C0243095
structural	I-C0243095
changes	I-C0243095
,	O
numerous	O
metabolite	B-C0870883
changes	B-C0392747
occurred	O
abruptly	O
during	O
the	O
first	O
10	O
days	B-C0439228
,	O
and	O
these	O
changes	B-C0392747
reached	O
steady	B-C0678587
state	I-C0678587
by	O
day	B-C0439228
13	O
.	O
	
the	O
significant	O
changes	B-C0392747
in	O
certain	O
metabolites	B-C0870883
,	O
such	O
as	O
amino	B-C0002520
acids	I-C0002520
serine	B-C0036720
,	O
threonine	B-C0040005
and	O
tyrosine	B-C0041485
,	O
sugars	B-C0242209
d-allose	B-C0894158
and	O
fatty	B-C0015684
acids	I-C0015684
arachidonic	B-C0003695
acid	I-C0003695
revealed	O
new	O
insights	O
into	O
how	O
these	O
metabolites	B-C0870883
in	O
daphnia	B-C0010979
respond	O
to	O
chronic	B-C0205191
agnps	B-C1721060
stress	B-C0038442
.	O
	
these	O
findings	B-C2607943
highlight	O
the	O
capability	B-C2698977
of	O
metabolomics	B-C1328813
to	O
discover	O
early	O
metabolic	B-C4054530
responses	I-C4054530
to	O
environmental	B-C0014406
silver	B-C0037125
nanoparticles	B-C1721060
.	O
	
evaluating	O
the	O
relative	B-C0035023
effectiveness	I-C0035023
of	O
high-intensity	B-C4081854
and	O
low-intensity	B-C0392762
models	I-C0392762
of	O
behaviour	B-C0542299
change	I-C0542299
communication	B-C1274143
interventions	I-C1274143
for	O
abortion	B-C0156543
care-seeking	B-C0018695
in	O
bihar	B-C0681784
and	O
jharkhand	B-C0681784
,	O
india	B-C0021201
a	O
cross-sectional	B-C0010362
study	I-C0010362
this	O
study	O
aimed	O
to	O
compare	O
the	O
effectiveness	B-C1280519
of	O
a	O
high-intensity	B-C4081854
model	I-C4081854
him	B-C4081854
and	O
a	O
low-intensity	B-C0392762
model	I-C0392762
lim	B-C0392762
of	O
behaviour	B-C0542299
change	I-C0542299
communication	B-C1274143
interventions	I-C1274143
in	O
bihar	B-C0681784
and	O
jharkhand	B-C0681784
states	O
of	O
india	B-C0021201
designed	O
to	O
improve	O
women's	B-C0043210
knowledge	B-C1948177
and	O
usage	O
of	O
safe	B-C0156543
abortion	I-C0156543
services	O
,	O
as	O
well	O
as	O
the	O
dose	B-C0683160
effect	I-C0683160
of	O
intervention	B-C0184661
exposure	O
.	O
	
we	O
conducted	O
two	O
cross-sectional	B-C0010362
household	I-C0010362
surveys	I-C0010362
among	O
married	B-C0555047
women	B-C0043210
aged	B-C0001779
15-49	O
years	O
in	O
intervention	B-C0184661
and	O
comparison	O
districts	B-C0681784
.	O
	
difference-in-difference	B-C0392762
models	I-C0392762
were	O
used	O
to	O
assess	O
the	O
efficacy	B-C1280519
of	O
the	O
intervention	B-C0184661
,	O
adjusting	O
for	O
sociodemographic	B-C0243095
characteristics	I-C0243095
.	O
	
although	O
both	O
intervention	B-C0184661
types	O
improved	O
abortion	B-C0156543
knowledge	B-C0376554
,	O
the	O
him	B-C4081854
intervention	B-C0184661
was	O
more	O
effective	O
in	O
improving	O
comprehensive	B-C0376554
knowledge	I-C0376554
about	O
abortion	B-C0156543
.	O
	
in	O
particular	O
,	O
there	O
were	O
improvements	O
in	O
knowledge	B-C0376554
on	O
legality	B-C0000812
of	I-C0000812
abortion	I-C0000812
aor=2	O
95%	O
ci	O
1.6	O
to	O
2.9	O
and	O
nearby	O
sources	O
of	O
safe	B-C3697217
abortion	I-C3697217
care	I-C3697217
aor=1	O
95%	O
ci	O
1.2	O
to	O
1.3	O
.	O
	
higher	O
level	O
of	O
exposure	O
to	O
abortion-related	O
messages	O
was	O
related	O
to	O
more	O
accurate	O
knowledge	B-C0376554
about	O
abortion	B-C0156543
within	O
both	O
intervention	B-C0184661
groups	O
.	O
	
evidence	O
was	O
mixed	O
on	O
changes	O
in	O
abortion	B-C0156543
care-seeking	B-C0018695
behaviour	B-C0004927
.	O
	
more	O
work	O
is	O
needed	O
to	O
ensure	O
that	O
women	B-C0043210
seek	O
safe	B-C0156543
abortion	I-C0156543
services	O
in	O
lieu	O
of	O
informal	O
services	O
that	O
may	O
be	O
more	O
likely	O
to	O
lead	O
to	O
postabortion	B-C0851640
complications	I-C0851640
.	O
	
tissue	B-C0040300
microrna	B-C1101610
profiles	O
as	O
diagnostic	B-C1511876
and	O
prognostic	B-C1514475
biomarkers	I-C1514475
in	O
patients	B-C0030705
with	O
resectable	B-C0015252
pancreatic	B-C1335302
ductal	I-C1335302
adenocarcinoma	I-C1335302
and	O
periampullary	B-C1335377
cancers	I-C1335377
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
validate	O
previously	O
described	O
diagnostic	B-C0348026
and	O
prognostic	B-C0220901
microrna	B-C1101610
expression	B-C1956267
profiles	I-C1956267
in	O
tissue	B-C0040300
samples	O
from	O
patients	B-C0030705
with	O
pancreatic	B-C0235974
cancer	I-C0235974
and	O
other	O
periampullary	B-C1335377
cancers	I-C1335377
.	O
	
expression	B-C0017262
of	O
46	O
selected	O
micrornas	B-C1101610
was	O
studied	O
in	O
formalin	B-C0949307
-fixed	O
paraffin-embedded	B-C1519524
tissue	I-C1519524
from	O
patients	B-C0030705
with	O
resected	B-C0015252
pancreatic	B-C1335302
ductal	I-C1335302
adenocarcinoma	I-C1335302
n	O
=	O
165	O
,	O
ampullary	B-C0262401
cancer	I-C0262401
n=59	O
,	O
duodenal	B-C0541912
cancer	I-C0541912
n	O
=	O
6	O
,	O
distal	B-C0205108
common	B-C0740277
bile	I-C0740277
duct	I-C0740277
cancer	I-C0740277
n	O
=	O
21	O
,	O
and	O
gastric	B-C0024623
cancer	I-C0024623
n	O
=	O
20	O
chronic	B-C0149521
pancreatitis	I-C0149521
n	O
=	O
39	O
and	O
normal	B-C0940731
pancreas	I-C0940731
n	O
=	O
35	O
.	O
	
the	O
micrornas	B-C1101610
were	O
analyzed	O
by	O
pcr	B-C0032520
using	O
the	O
fluidigm	B-C0282574
platform	I-C0282574
.	O
	
twenty-two	O
micrornas	B-C1101610
were	O
significantly	O
differently	O
expressed	B-C0017262
in	O
patients	B-C0030705
with	O
pancreatic	B-C0235974
cancer	I-C0235974
when	O
compared	O
to	O
healthy	B-C2986479
controls	I-C2986479
and	O
chronic	B-C0149521
pancreatitis	I-C0149521
patients	B-C0030705
17	O
mirnas	B-C1101610
were	O
upregulated	B-C0041904
mir-21-5p	B-C1537719
,	O
-	O
23a-3p	B-C1842758
,	O
-	O
31-5p	B-C1537742
,	O
-	O
34c-5p	B-C1537747
,	O
-	O
93-3p	B-C1537750
,	O
-	O
135b-3p	B-C1537788
,	O
-	O
155-5p	B-C1537811
,	O
-	O
186-5p	B-C1537820
,	O
-	O
196b-5p	B-C1537832
,	O
-	O
203	B-C1537841
,	O
-	O
205-5p	B-C4284346
,	O
-	O
210	B-C1537846
,	O
-	O
222-3p	B-C1537860
,	O
-	O
451	B-C1826031
,	O
-	O
492	B-C1826046
,	O
-	O
614	B-C1826193
,	O
and	O
mir-622	B-C1826201
and	O
5	O
were	O
downregulated	B-C0013081
mir-122-5p	B-C1865068
,	O
-	O
130b-3p	B-C1537780
,	O
-	O
216b	B-C2239687
,	O
-	O
217	B-C1537853
,	O
and	O
mir-375	B-C1537896
.	O
	
micrornas	B-C1101610
were	O
grouped	O
into	O
diagnostic	B-C0348026
indices	O
of	O
varying	O
complexity	B-C0439855
.	O
	
ten	O
micrornas	B-C1101610
associated	B-C0332281
with	I-C0332281
prognosis	B-C0033325
were	O
identified	O
let-7	B-C1621390
g	I-C1621390
,	O
mir-29a-5p	B-C1835841
,	O
-	O
34a-5p	B-C1537745
,	O
-	O
125a-3p	B-C1537770
,	O
-	O
146a-5p	B-C1826002
,	O
-	O
187	B-C1537821
,	O
-	O
205-5p	B-C4284346
,	O
-	O
212-3p	B-C1537848
,	O
-	O
222-5p	B-C1537860
,	O
and	O
mir-450b-5p	B-C2239697
.	O
	
prognostic	B-C0033326
indices	I-C0033326
based	O
on	O
differences	O
in	O
expression	B-C0017262
of	O
2	O
different	O
micrornas	B-C1101610
were	O
constructed	O
for	O
pancreatic	B-C0235974
and	O
ampullary	B-C0262401
cancer	I-C0262401
combined	O
and	O
separately	O
30	O
,	O
5	O
,	O
and	O
21	O
indices	O
.	O
	
the	O
study	B-C2603343
confirms	O
that	O
pancreatic	B-C0235974
cancer	I-C0235974
tissue	B-C0040300
has	O
a	O
microrna	B-C1101610
expression	B-C1956267
profile	I-C1956267
that	O
is	O
different	O
from	O
that	O
of	O
other	O
periampullary	B-C1335377
cancers	I-C1335377
,	O
chronic	B-C0149521
pancreatitis	I-C0149521
,	O
and	O
normal	B-C0940731
pancreas	I-C0940731
.	O
	
we	O
identified	O
prognostic	B-C0220901
micrornas	B-C1101610
and	O
microrna	B-C1101610
indices	O
that	O
were	O
associated	B-C0332281
with	I-C0332281
shorter	O
overall	B-C4086681
survival	I-C4086681
in	O
patients	B-C0030705
with	O
radically	O
resected	B-C0015252
pancreatic	B-C0235974
cancer	I-C0235974
.	O
	
effectiveness	B-C1280519
of	O
workers	B-C1527116
'	O
general	B-C0420142
health	I-C0420142
examination	I-C0420142
in	O
korea	B-C0022771
by	O
health	B-C1254363
examination	I-C1254363
period	I-C1254363
and	O
compliance	B-C3714738
retrospective	B-C2985505
cohort	I-C2985505
study	I-C2985505
using	O
nationwide	O
data	O
our	O
study	O
evaluated	B-C0220825
the	O
effectiveness	B-C1280519
of	O
the	O
workers	B-C1527116
'	O
general	B-C0420142
health	I-C0420142
examination	I-C0420142
by	O
health	B-C1254363
examination	I-C1254363
period	I-C1254363
and	O
compliance	B-C3714738
.	O
	
a	O
retrospective	B-C2985505
cohort	I-C2985505
of	O
the	O
health	B-C1254363
examination	I-C1254363
participants	B-C0679646
in	O
2006	O
baseline	O
year	O
n	O
was	O
used	O
.	O
	
we	O
identified	O
newly	O
occurring	O
cardio	B-C0007222
-	O
cerebrovascular	B-C0007820
disease	I-C0007820
over	O
7	O
years	O
from	O
2007	O
to	O
2013	O
.	O
	
after	O
stratification	B-C1514983
by	O
age	B-C0001779
,	O
sex	B-C1522384
,	O
and	O
national	B-C0027452
health	I-C0027452
insurance	I-C0027452
type	I-C0027452
,	O
we	O
identified	O
7	O
years'	O
cumulative	B-C1511559
incidence	B-C0021149
of	O
cardio	B-C0007222
-	O
cerebrovascular	B-C0007820
disease	I-C0007820
by	O
health	B-C1254363
examination	I-C1254363
compliance	B-C3714738
and	O
estimated	O
its	O
relative	O
risk	O
by	O
health	B-C1254363
examination	I-C1254363
period	I-C1254363
and	O
compliance	B-C3714738
.	O
	
the	O
compliant	B-C1257890
group	I-C1257890
presented	O
a	O
lower	O
cumulative	B-C1511559
incidence	B-C0021149
of	O
cardio	B-C0007222
-	O
cerebrovascular	B-C0007820
disease	I-C0007820
than	O
the	O
non-compliant	B-C1257890
group	I-C1257890
this	O
result	O
was	O
consistent	O
across	O
sex	B-C1522384
,	O
working	B-C0043227
age	B-C0001779
40s	O
and	O
50s	O
,	O
and	O
workplace	B-C0162579
policyholder	B-C1551367
.	O
	
relative	O
risk	O
of	O
cardio	B-C0007222
-	O
cerebrovascular	B-C0007820
disease	I-C0007820
by	O
health	B-C1254363
examination	I-C1254363
period	I-C1254363
1	O
and	O
2	O
years	O
showed	O
statistically	B-C0237881
significant	I-C0237881
results	O
in	O
ischemic	B-C0151744
heart	I-C0151744
disease	I-C0151744
for	O
male	O
participants	B-C0679646
.	O
	
of	O
men	B-C0025266
in	O
their	O
40s	O
,	O
office	B-C2230102
workers	I-C2230102
over	O
a	O
2-year	O
period	O
presented	O
statistically	O
higher	B-C0332167
relative	I-C0332167
risk	I-C0332167
of	I-C0332167
ischemic	B-C0151744
heart	I-C0151744
disease	I-C0151744
than	O
non-office	B-C1527116
workers	I-C1527116
over	O
a	O
1-year	O
period	O
1.03	O
95%	O
confidence	B-C0009667
interval	I-C0009667
,	O
1.02	O
.	O
	
however	O
,	O
there	O
were	O
no	O
consistent	O
results	O
in	O
ischemic	B-C0475224
cerebrovascular	B-C0007820
disease	I-C0007820
and	O
hemorrhagic	B-C0333275
cerebrovascular	B-C0007820
disease	I-C0007820
for	O
men	B-C0025266
or	O
cardio	B-C0007222
-	O
cerebrovascular	B-C0007820
disease	I-C0007820
for	O
women	B-C0043210
.	O
	
a	O
1-year	O
period	O
of	O
workers	B-C1527116
'	O
general	B-C0420142
health	I-C0420142
examinations	I-C0420142
in	O
non-office	B-C1527116
workers	I-C1527116
had	O
a	O
more	O
significant	O
prevention	B-C0199176
effect	O
on	O
ischemic	B-C0151744
heart	I-C0151744
disease	I-C0151744
than	O
a	O
2-year	O
period	O
in	O
office	B-C2230102
workers	I-C2230102
among	O
working	O
age	B-C0001779
40s-50s	O
men	B-C0025266
.	O
	
it	O
is	O
,	O
however	O
,	O
necessary	O
to	O
consider	O
that	O
prevention	B-C0199176
of	O
cardio	B-C0007222
-	O
cerebrovascular	B-C0007820
disease	I-C0007820
can	O
be	O
partially	O
explained	O
by	O
their	O
occupational	B-C0521127
characteristics	I-C0521127
rather	O
than	O
by	O
health	B-C1254363
examination	I-C1254363
period	I-C1254363
.	O
	
calibration	B-C0006751
of	O
self-report	B-C2700446
measures	B-C0079809
of	O
physical	B-C0026606
activity	I-C0026606
and	O
sedentary	B-C3824706
behavior	I-C3824706
calibration	B-C0006751
equations	B-C0552449
offer	O
potential	B-C3245505
to	O
improve	B-C1272747
the	O
accuracy	B-C4035952
and	O
utility	O
of	O
self-report	B-C2700446
measures	B-C0079809
of	O
physical	B-C0026606
activity	I-C0026606
pa	B-C0026606
and	O
sedentary	B-C3824706
behavior	I-C3824706
sb	B-C3824706
by	O
re-scaling	B-C1947916
potentially	B-C3245505
biased	O
estimates	B-C0750572
.	O
	
the	O
present	O
study	O
evaluates	O
calibration	B-C0006751
models	B-C0026348
designed	O
to	O
estimate	B-C0750572
pa	B-C0026606
and	O
sb	B-C3824706
in	O
a	O
representative	B-C1299385
sample	O
of	O
adults	B-C0001675
from	O
the	O
physical	B-C0026606
activity	I-C0026606
measurement	B-C0376688
survey	I-C0376688
pams	B-C0376688
.	O
	
participants	B-C0679646
in	O
the	O
pams	B-C0376688
project	O
completed	O
replicate	O
single	O
day	O
trials	B-C0681815
that	O
involved	O
wearing	O
a	O
sensewear	B-C1301852
armband	I-C1301852
swa	I-C1301852
monitor	B-C0596972
for	O
24	B-C0439584
hours	I-C0439584
followed	O
by	O
a	O
telephone	B-C0021823
administered	B-C1519231
24-hour	O
physical	B-C1254363
activity	I-C1254363
recall	I-C1254363
par	B-C1254363
.	O
	
comprehensive	O
statistical	B-C0026348
model	I-C0026348
selection	O
and	O
validation	B-C2984648
procedures	B-C2700391
were	O
used	O
to	O
develop	O
and	O
test	O
separate	O
calibration	B-C0006751
models	B-C0026348
designed	O
to	O
predict	B-C0681843
objectively	B-C0683957
-	O
measured	B-C0079809
sb	B-C3824706
and	O
moderate	B-C0026606
to	I-C0026606
vigorous	I-C0026606
pa	I-C0026606
mvpa	B-C0026606
from	O
self-reported	B-C2700446
par	B-C1254363
data	O
.	O
	
equivalence	B-C0814870
testing	O
was	O
used	O
to	O
evaluate	O
the	O
equivalence	B-C0814870
of	O
the	O
model-	O
predicted	B-C0681843
values	O
with	O
the	O
objective	B-C0683957
measures	B-C0079809
in	O
a	O
separate	O
holdout	O
sample	O
.	O
	
the	O
final	O
prediction	O
model	O
for	O
both	O
sb	B-C3824706
and	O
mvpa	B-C0026606
included	O
reported	O
time	O
spent	O
in	O
sb	B-C3824706
and	O
mvpa	B-C0026606
,	O
as	O
well	O
as	O
terms	O
capturing	O
sex	B-C1522384
,	O
age	B-C3172266
,	O
education	B-C0424927
,	O
and	O
bmi	B-C1305855
.	O
	
cross-validation	B-C0681935
analyses	B-C0002780
on	O
an	O
independent	O
sample	O
exhibited	O
high	O
correlations	O
with	O
observed	O
sb	B-C3824706
r	O
=	O
0.72	O
and	O
mvpa	B-C0026606
r	O
=	O
0.75	O
.	O
	
equivalence	B-C0814870
testing	O
demonstrated	O
that	O
the	O
model-	O
predicted	B-C0681843
values	O
were	O
statistically	B-C0237881
equivalent	O
to	O
the	O
corresponding	O
objective	B-C0683957
values	O
for	O
both	O
sb	B-C3824706
and	O
mvpa	B-C0026606
.	O
	
the	O
results	O
demonstrate	O
that	O
simple	O
regression	B-C0034980
models	B-C0026348
can	O
be	O
used	O
to	O
statistically	B-C0237881
adjust	O
for	O
over	O
or	O
underestimation	O
in	O
self-report	B-C2700446
measures	B-C0079809
among	O
different	O
segments	O
of	O
the	O
population	B-C1257890
.	O
	
the	O
models	B-C0026348
produced	O
group	O
estimates	B-C0750572
from	O
the	O
par	B-C1254363
that	O
were	O
statistically	B-C0237881
equivalent	O
to	O
the	O
observed	O
time	O
spent	O
in	O
sb	B-C3824706
and	O
mvpa	B-C0026606
obtained	O
from	O
the	O
objective	O
swa	B-C1301852
monitor	B-C0596972
however	O
additional	O
work	O
is	O
needed	O
to	O
correct	O
for	O
estimates	B-C0750572
of	O
individual	B-C0946284
behavior	I-C0946284
.	O
	
human	B-C0086418
amnion	B-C1305379
epithelial	B-C0014597
cells	I-C0014597
rescue	O
cell	B-C0007587
death	I-C0007587
via	O
immunomodulation	B-C1963758
of	O
microglia	B-C0206116
in	O
a	O
mouse	B-C2986594
model	I-C2986594
of	O
perinatal	B-C2347482
brain	I-C2347482
injury	I-C2347482
human	B-C0086418
amnion	B-C1305379
epithelial	B-C0014597
cells	I-C0014597
haecs	B-C0014597
are	O
clonogenic	B-C0392762
and	O
have	O
been	O
proposed	O
to	O
reduce	B-C0205216
inflammatory	B-C0021368
-	O
induced	B-C0205263
tissue	B-C0037578
injury	I-C0037578
.	O
	
perturbation	B-C0332453
of	O
the	O
immune	B-C0301872
response	I-C0301872
is	O
implicated	O
in	O
the	O
pathogenesis	B-C0699748
of	O
perinatal	B-C2347482
brain	I-C2347482
injury	I-C2347482
modulating	B-C0443264
this	O
response	B-C0301872
could	O
thus	O
be	O
a	O
novel	B-C0205314
therapy	B-C0087111
for	O
treating	B-C1522326
or	O
preventing	O
such	O
injury	B-C2347482
.	O
	
the	O
immunomodulatory	B-C1963758
properties	O
of	O
haecs	B-C0014597
have	O
been	O
shown	O
in	O
other	O
animal	B-C0599779
models	I-C0599779
,	O
but	O
a	O
detailed	O
investigation	B-C0220825
of	O
the	O
effects	B-C1280500
on	O
brain	B-C0006104
immune	B-C0439662
cells	B-C0007634
following	O
injury	B-C2347482
has	O
not	O
been	O
undertaken	O
.	O
	
here	O
,	O
we	O
investigate	B-C0220825
the	O
effects	B-C1280500
of	O
haecs	B-C0014597
on	O
microglia	B-C0206116
,	O
the	O
first	O
immune	B-C0301872
responders	I-C0301872
to	O
injury	B-C2347482
within	O
the	O
brain	B-C0006104
.	O
	
we	O
generated	O
a	O
mouse	B-C2986594
model	I-C2986594
combining	O
neonatal	B-C2939425
inflammation	B-C0021368
and	O
perinatal	B-C0178795
hyperoxia	B-C0242706
,	O
both	O
of	O
which	O
are	O
risk	B-C0035648
factors	I-C0035648
associated	O
with	O
perinatal	B-C2347482
brain	I-C2347482
injury	I-C2347482
.	O
	
on	O
embryonic	B-C0013936
day	B-C0439228
16	O
we	O
administered	B-C1533734
lipopolysaccharide	B-C0023810
lps	B-C0023810
,	O
or	O
saline	B-C0036082
control	B-C1550141
,	O
intra-amniotically	B-C1512912
to	O
c57bl/6	B-C1521751
j	I-C1521751
mouse	I-C1521751
pups	I-C1521751
.	O
	
on	O
postnatal	B-C0443281
day	B-C0439228
p	O
,	O
lps	B-C0023810
pups	B-C1521751
were	O
placed	O
in	O
hyperoxia	B-C0242706
65%	O
oxygen	B-C0030054
and	O
control	B-C0009932
pups	I-C0009932
in	O
normoxia	B-C0311411
for	O
14	O
days	B-C0439228
.	O
	
pups	B-C1521751
were	O
given	O
either	O
haecs	B-C0014597
or	O
saline	B-C0036082
intravenously	B-C1737200
on	O
p4	O
.	O
	
at	O
p14	O
,	O
relative	O
to	O
controls	B-C0009932
,	O
lps	B-C0023810
and	O
hyperoxia	B-C0242706
pups	B-C1521751
had	O
reduced	B-C0205216
body	B-C0005910
weight	I-C0005910
,	O
increased	B-C0205217
density	B-C0178587
of	O
apoptotic	B-C1516044
cells	B-C0007634
tunel	B-C1515232
in	O
the	O
cortex	B-C0007776
,	O
striatum	B-C0010097
and	O
white	B-C0682708
matter	I-C0682708
,	O
astrocytes	B-C0004112
gfap	B-C0017626
in	O
the	O
white	B-C0682708
matter	I-C0682708
and	O
activated	B-C1515877
microglia	B-C0206116
cd68	B-C0215872
in	O
the	O
cortex	B-C0007776
and	O
striatum	B-C0010097
,	O
but	O
no	O
change	O
in	O
total	O
microglia	B-C0206116
density	B-C0178587
iba1	B-C0312586
.	O
	
haec	B-C0014597
administration	B-C1533734
rescued	O
the	O
decreased	B-C0205216
body	B-C0005910
weight	I-C0005910
and	O
reduced	B-C0205216
apoptosis	B-C0162638
and	O
astrocyte	B-C0004112
areal	B-C1999244
coverage	I-C1999244
in	O
the	O
white	B-C0682708
matter	I-C0682708
,	O
but	O
increased	B-C0205217
the	O
density	B-C0178587
of	O
total	O
and	O
activated	B-C1515877
microglia	B-C0206116
.	O
	
we	O
then	O
stimulated	O
primary	B-C0205225
microglia	B-C0206116
cd45	B-C1435882
low	O
cd11b	B-C1136310
+	O
with	O
lps	B-C0023810
for	O
24	O
h	O
,	O
followed	O
by	O
co-culture	B-C0282547
with	O
haec	B-C0014597
conditioned	B-C0162518
medium	I-C0162518
for	O
48	O
h	O
.	O
	
haec	B-C0014597
conditioned	B-C0162518
medium	I-C0162518
increased	B-C0205217
microglial	B-C0206116
phagocytic	B-C0031308
activity	I-C0031308
,	O
decreased	B-C0205216
microglia	B-C0206116
apoptosis	B-C0162638
and	O
decreased	B-C0205216
m1	B-C0024426
activation	I-C0024426
markers	I-C0024426
cd86	B-C1528561
.	O
	
stimulating	O
haecs	B-C0014597
for	O
24	O
h	O
with	O
lps	B-C0023810
did	O
not	O
alter	O
release	B-C1963578
of	O
cytokines	B-C0079189
known	O
to	O
modulate	B-C0443264
microglia	B-C0206116
activity	B-C0441655
.	O
	
these	O
data	B-C1511726
demonstrate	O
that	O
haecs	B-C0014597
can	O
directly	O
immunomodulate	B-C1963758
brain	B-C0006104
microglia	B-C0206116
,	O
probably	O
via	O
release	B-C1963578
of	O
trophic	B-C1579754
factors	I-C1579754
.	O
	
this	O
observation	B-C0302523
offers	O
promise	O
that	O
haecs	B-C0014597
may	O
afford	O
therapeutic	B-C0087111
utility	I-C0087111
in	O
the	O
management	B-C0376636
of	O
perinatal	B-C2347482
brain	I-C2347482
injury	I-C2347482
.	O
	
identification	B-C0205396
of	O
predictive	O
dna	B-C0376452
methylation	I-C0376452
biomarkers	B-C0041366
for	O
chemotherapy	B-C3665472
response	B-C0521982
in	O
colorectal	B-C1527249
cancer	I-C1527249
resistance	B-C0013203
to	O
5-fluorouracil	B-C0016360
5-fu	B-C0016360
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	B-C1522326
of	O
colorectal	B-C1527249
cancer	I-C1527249
crc	B-C1527249
and	O
posed	O
an	O
increased	O
risk	B-C2986492
of	I-C2986492
recurrence	I-C2986492
.	O
	
dna	B-C0376452
methylation	I-C0376452
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	B-C0920474
for	O
recurrent	B-C0277556
disease	I-C0277556
and	O
its	O
contribution	B-C1880177
to	O
the	O
development	O
of	O
drug	B-C0013203
resistance	I-C0013203
remains	O
to	O
be	O
clarified	B-C2986669
.	O
	
this	O
study	B-C0008972
aimed	O
to	O
determine	O
the	O
methylation	B-C0376452
phenotype	B-C0031437
in	O
crc	B-C1527249
for	O
identification	B-C0205396
of	O
predictive	O
markers	B-C0041366
for	O
chemotherapy	B-C3665472
response	B-C0521982
.	O
	
we	O
performed	O
dna	B-C0376452
methylation	I-C0376452
profiling	B-C2003903
on	O
43	O
non-recurrent	B-C0439597
and	O
five	O
recurrent	B-C2945760
crc	B-C1527249
patients	B-C0030705
using	O
the	O
illumina	B-C1880239
infinium	I-C1880239
humanmethylation450	I-C1880239
beadchip	I-C1880239
assay	I-C1880239
.	O
	
in	O
addition	O
,	O
crc	B-C1527249
cells	B-C0334227
with	O
different	O
genetic	B-C4042916
backgrounds	I-C4042916
,	O
response	B-C0521982
to	O
5-fu	B-C0016360
and	O
global	B-C0376452
methylation	I-C0376452
levels	B-C0441889
ht29	B-C0282639
and	O
sw48	B-C0085983
were	O
treated	B-C1522326
with	O
5-fu	B-C0016360
and	O
dna	B-C0376452
methylation	I-C0376452
inhibitor	B-C1999216
5-aza-2'-deoxycytidine	B-C0049065
5-azadc	B-C0049065
.	O
	
the	O
singular	O
and	O
combined	O
effects	B-C1280500
of	O
these	O
two	O
drug	B-C1254351
classes	B-C0456387
on	O
cell	B-C0007620
viability	I-C0007620
and	O
global	B-C0376452
methylation	I-C0376452
profiles	B-C1979963
were	O
investigated	O
.	O
	
our	O
genome-wide	B-C2350277
methylation	I-C2350277
study	I-C2350277
on	O
the	O
clinical	B-C0205210
specimens	B-C0370003
showed	O
that	O
recurrent	B-C2945760
crcs	B-C1527249
exhibited	O
higher	O
methylation	B-C0376452
levels	B-C0441889
compared	O
to	O
non-recurrent	B-C0439597
crcs	B-C1527249
.	O
	
we	O
identified	B-C0205396
4787	O
significantly	O
differentially	O
methylated	B-C0017337
genes	I-C0017337
p	O
<	O
0.05	O
3112	O
genes	B-C0017337
were	O
hyper	B-C0243095
-	O
while	O
1675	O
genes	B-C0017337
were	O
hypomethylated	B-C0243095
in	O
the	O
recurrent	B-C2945760
group	B-C0441833
compared	O
to	O
the	O
non-recurrent	B-C0439597
.	O
	
fifty	O
eight	O
and	O
47	O
of	O
the	O
significantly	O
hypermethylated	B-C0017337
and	I-C0017337
hypomethylated	I-C0017337
genes	I-C0017337
have	O
an	O
absolute	O
recurrent	B-C2945760
/	O
non-recurrent	B-C0439597
methylation	B-C0376452
difference	O
of	O
20%	O
.	O
	
most	O
of	O
the	O
hypermethylated	B-C0017337
genes	I-C0017337
were	O
involved	O
in	O
the	O
mapk	B-C1518102
signaling	I-C1518102
pathway	I-C1518102
which	O
is	O
a	O
key	O
regulator	B-C1704735
for	O
apoptosis	B-C0162638
while	O
the	O
hypomethylated	B-C0017337
genes	I-C0017337
were	O
involved	O
in	O
the	O
pi3k-akt	B-C0037080
signaling	I-C0037080
pathway	I-C0037080
and	O
proliferation	B-C1514485
process	I-C1514485
.	O
	
we	O
also	O
demonstrate	O
that	O
5-azadc	B-C0049065
treatment	B-C1522326
enhanced	O
response	B-C0521982
to	O
5-fu	B-C0016360
which	O
resulted	O
in	O
significant	O
growth	B-C1512773
inhibition	I-C1512773
compared	O
to	O
5-fu	B-C0016360
alone	O
in	O
hypermethylated	B-C0085983
cell	I-C0085983
lines	I-C0085983
sw48	I-C0085983
.	O
	
in	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	B-C0017337
in	O
recurrent	B-C2945760
crcs	B-C1527249
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	B-C0087111
targets	B-C1521840
for	O
patients	B-C0030705
with	O
chemoresistance	B-C0013203
.	O
	
we	O
postulate	O
that	O
aberrant	B-C0443127
methylation	B-C0376452
of	O
ccnei	B-C0017337
,	O
ccndbp1	B-C1413177
,	O
pon3	B-C1418756
,	O
ddx43	B-C1425700
,	O
and	O
chl1	B-C1413393
in	O
crc	B-C1527249
might	O
be	O
associated	B-C0332281
with	I-C0332281
the	O
recurrence	B-C0034897
of	O
crc	B-C1527249
and	O
5-azadc	B-C0049065
-mediated	O
restoration	O
of	O
5-fu	B-C0016360
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
mapk	B-C1518102
signaling	I-C1518102
pathway	I-C1518102
.	O
	
effect	B-C1280500
of	O
successive	B-C1533734
administration	I-C1533734
of	O
vancomycin	B-C0042313
and	O
amikacin	B-C0002499
on	O
auditory	B-C0018767
function	I-C0018767
of	O
immature	B-C0596750
animals	I-C0596750
effect	B-C1280500
of	O
successive	B-C1533734
administration	I-C1533734
vancomycin	B-C0042313
and	O
amikacin	B-C0002499
in	O
therapeutic	B-C0302350
doses	B-C0178602
on	O
immature	B-C0205252
auditory	B-C0587901
organ	I-C0587901
was	O
compared	B-C1707455
to	O
single	B-C0205171
administration	B-C3469597
of	O
the	O
same	B-C0445247
drugs	B-C1254351
in	O
chronic	B-C0205191
experiments	B-C0205664
on	O
immature	B-C0205252
rabbits	B-C3887509
by	O
recording	B-C2355580
of	O
short-latency	B-C0242465
auditory	B-C0085854
brainstem	I-C0085854
response	I-C0085854
abr	B-C0085854
and	O
distortion	B-C0430676
product	I-C0430676
otoacoustic	I-C0430676
emission	I-C0430676
dpoae	B-C0430676
.	O
	
drug	B-C3469597
administration	I-C3469597
always	O
increased	B-C0205217
significantly	O
the	O
abr	B-C0085854
peak	O
i	O
threshold	B-C0004312
.	O
	
ototoxic	B-C0235280
antibiotics	B-C0003232
did	O
not	O
change	O
dpoae	B-C0430676
,	O
but	O
selectively	O
affected	B-C0392760
activity	B-C3668946
of	O
outer	B-C1518683
hair	I-C1518683
cells	I-C1518683
.	O
	
no	B-C1513916
enhancement	B-C2349975
of	O
the	O
ototoxic	B-C0235280
effects	I-C0235280
was	O
observed	B-C1441672
after	O
successive	B-C1533734
administration	I-C1533734
of	O
the	O
two	O
water	B-C0043047
safety	B-C0036043
in	O
healthcare	B-C0018704
facilities	I-C0018704
.	O
	
the	O
vieste	B-C0282574
charter	I-C0282574
the	O
study	B-C0035173
group	I-C0035173
on	O
hospital	B-C0019994
hygiene	B-C0020405
of	O
the	O
italian	B-C1274109
society	I-C1274109
of	I-C1274109
hygiene	I-C1274109
,	O
preventive	I-C1274109
medicine	I-C1274109
and	I-C1274109
public	I-C1274109
health	I-C1274109
gisio-siti	B-C1274109
and	O
the	O
local	B-C1274109
health	I-C1274109
authority	I-C1274109
of	O
foggia	B-C0017446
,	O
apulia	B-C0017446
,	O
italy	B-C0022277
,	O
after	O
the	O
national	B-C0086047
convention	I-C0086047
"""safe"	O
water	B-C0043047
in	O
healthcare	B-C0018704
facilities	I-C0018704
""""	O
held	O
in	O
vieste-pugnochiuso	B-C0017446
on	O
27-28	O
may	O
2016	O
,	O
present	O
the	O
""""	O
vieste	B-C0282574
charter	I-C0282574
""""	O
,	O
drawn	O
up	O
in	O
collaboration	B-C0282116
with	O
experts	B-C0009817
from	O
the	O
national	B-C0920537
institute	I-C0920537
of	I-C0920537
health	I-C0920537
and	O
the	B-C0683710
ministry	I-C0683710
of	I-C0683710
health	I-C0683710
.	O
	
this	O
paper	O
considers	O
the	O
risk	B-C0035648
factors	I-C0035648
that	O
may	O
affect	B-C2237113
the	O
water	B-C0043047
safety	B-C0036043
in	O
healthcare	B-C0018704
facilities	I-C0018704
and	O
reports	O
the	O
current	O
regulatory	B-C0282574
frameworks	I-C0282574
governing	O
the	O
management	B-C1254363
of	I-C1254363
installations	I-C1254363
and	O
the	O
quality	B-C0332306
of	O
the	O
water	B-C0043047
.	O
	
the	O
authors	O
promote	O
a	O
careful	O
analysis	O
of	O
the	O
risks	B-C0035647
that	O
characterize	O
the	O
health	B-C0018704
facilities	I-C0018704
,	O
for	O
the	O
control	O
of	O
which	O
specific	O
actions	O
are	O
recommended	O
in	O
various	O
areas	O
,	O
including	O
water	B-C0871600
safety	I-C0871600
plans	I-C0871600
approval	O
of	O
treatments	B-C1522326
healthcare	B-C0018704
facilities	I-C0018704
responsibility	B-C0678341
,	O
installation	O
and	O
maintenance	B-C0024501
of	O
facilities	B-C0018704
multidisciplinary	B-C0449445
approach	I-C0449445
education	B-C0013621
and	O
research	B-C0035168
regional	B-C0700114
and	I-C0700114
national	I-C0700114
coordination	I-C0700114
communication	B-C0009452
.	O
	
in	B-C1515655
vivo	I-C1515655
three-dimensional	B-C0450363
patellar	B-C0030647
mechanics	B-C0376706
normal	B-C0205307
knees	B-C0022742
compared	B-C1707455
with	O
domed	B-C0444914
and	O
anatomic	B-C0220784
patellar	B-C0030647
components	B-C1708963
patellofemoral	B-C0447801
complications	B-C1171258
are	O
a	O
major	O
cause	O
of	O
revision	B-C0035110
surgery	I-C0035110
following	B-C0332282
total	B-C0086511
knee	I-C0086511
arthroplasty	I-C0086511
tka	B-C0086511
.	O
	
high	B-C0205250
forces	B-C0441722
occurring	O
at	O
the	O
patellofemoral	B-C0447801
articulation	I-C0447801
coupled	B-C1948027
with	O
a	O
small	B-C0700321
patellofemoral	B-C0447801
contact	B-C0205146
area	I-C0205146
pose	O
substantial	O
design	B-C1707689
challenges	O
.	O
	
in	O
this	O
study	B-C2603343
,	O
the	O
three-dimensional	B-C0450363
3d	B-C0450363
in	B-C1515655
vivo	I-C1515655
mechanics	B-C0376706
of	O
domed	B-C0444914
and	O
anatomically	B-C0220784
shaped	B-C0332479
patellar	B-C0030647
components	B-C1708963
were	O
compared	B-C1707455
with	O
those	O
of	O
native	B-C0302891
patellae	B-C0030647
.	O
	
ten	O
normal	B-C0205307
knees	B-C0022742
,	O
10	O
treated	B-C0332293
with	I-C0332293
an	O
lcs-ps	B-C0086511
low	I-C0086511
contact	I-C0086511
stress-posterior	I-C0086511
stabilized	I-C0086511
tka	I-C0086511
anatomically	B-C0220784
shaped	B-C0332479
patellar	B-C0030647
component	B-C1708963
,	O
and	O
10	O
treated	B-C0332293
with	I-C0332293
a	O
pfc	B-C0086511
sigma	I-C0086511
rp-ps	I-C0086511
press-fit	I-C0086511
condylar	I-C0086511
sigma	I-C0086511
rotating	I-C0086511
platform-posterior	I-C0086511
stabilized	I-C0086511
tka	I-C0086511
domed	B-C0444914
patellar	B-C0030647
component	B-C1708963
were	O
analyzed	B-C0936012
under	O
fluoroscopic	B-C0016356
surveillance	B-C0220920
while	O
the	O
patient	B-C0030705
performed	B-C0884358
a	O
weight-bearing	B-C0085086
deep	B-C0205125
knee	B-C0243095
bend	I-C0243095
from	O
full	B-C0443225
knee	B-C2237139
extension	I-C2237139
to	O
maximum	B-C0806909
knee	B-C0240114
flexion	I-C0240114
.	O
	
relevant	O
bone	O
geometries	O
were	O
segmented	B-C0441635
out	O
from	O
computed	B-C0412645
tomography	I-C0412645
ct	B-C0412645
scans	B-C0441633
,	O
and	O
computer-assisted-design	B-C0162517
cad	B-C0162517
models	B-C3161035
of	O
the	O
implanted	B-C0021102
components	B-C1708963
were	O
obtained	O
from	O
the	O
manufacturer	O
.	O
	
three-dimensional	B-C0450363
patellofemoral	B-C0447801
kinematics	B-C0600169
were	O
obtained	O
using	O
a	O
3d	B-C0450363
-to-	O
2d	B-C1705052
registration	O
process	O
.	O
	
contact	B-C0376706
mechanics	I-C0376706
were	O
calculated	B-C1441506
using	O
a	O
distance	B-C0024779
map	I-C0024779
between	O
the	O
articulating	B-C0030647
patellar	I-C0030647
and	O
femoral	B-C0828554
surfaces	I-C0828554
.	O
	
both	O
patellar	B-C0030647
component	B-C1708963
designs	O
exhibited	O
good	B-C0205170
rotational	B-C0600169
kinematics	I-C0600169
and	O
tracked	O
well	O
within	O
the	O
femoral	B-C0223886
trochlea	I-C0223886
when	O
compared	B-C1707455
with	O
the	O
normal	B-C0205307
patella	B-C0030647
.	O
	
the	O
contact	B-C0205146
areas	I-C0205146
in	O
the	O
tka	B-C0086511
groups	B-C0441833
peaked	O
at	O
60	O
of	O
knee	B-C0240114
flexion	I-C0240114
mean	B-C0444504
and	O
standard	B-C0871420
deviation	I-C0871420
,	O
201	O
63.4	O
mm	O
for	O
the	O
lcs-ps	B-C0441833
group	I-C0441833
and	O
218	O
95.4	O
mm	O
for	O
the	O
sigma	B-C0441833
rp-ps	I-C0441833
group	I-C0441833
,	O
and	O
the	O
areas	B-C0205146
were	O
substantially	O
smaller	B-C0547044
than	O
those	O
previously	O
reported	B-C0684224
for	O
the	O
normal	B-C0205307
patella	B-C0030647
.	O
	
contact	B-C3714763
points	I-C3714763
in	O
the	O
tka	B-C0086511
groups	B-C0441833
stayed	O
close	O
to	O
the	O
center	B-C0205099
of	O
the	O
patellar	B-C0030647
components	B-C1708963
.	O
	
both	O
designs	B-C1707689
performed	B-C0884358
satisfactorily	B-C0205410
,	O
although	O
patellofemoral	B-C0447801
contact	B-C0205146
areas	I-C0205146
were	O
reduced	B-C0392756
in	O
comparison	B-C1707455
with	O
those	O
in	O
the	O
native	B-C0302891
patella	B-C0030647
.	O
	
assessment	B-C1516048
of	O
the	O
extravascular	B-C0162589
implantable	I-C0162589
defibrillator	I-C0162589
feasibility	B-C0443348
of	O
substernal	B-C1285520
ventricular	I-C1285520
pacing	I-C1285520
the	O
objective	B-C0018017
of	O
this	O
study	B-C0681814
was	O
to	O
assess	B-C1516048
feasibility	B-C0443348
of	O
ventricular	B-C1285520
pacing	I-C1285520
and	O
thresholds	B-C0449864
from	O
within	B-C0332285
the	O
substernal	B-C0230145
space	I-C0230145
to	O
examine	O
a	O
new	B-C0205314
extravascular	B-C0162589
icd	I-C0162589
configuration	B-C0449830
with	O
pacing	B-C1285520
capabilities	B-C2698977
.	O
	
in	O
patients	B-C0030705
undergoing	O
midline	B-C1282959
sternotomy	I-C1282959
,	O
a	O
duodecapolar	B-C0085590
diagnostic	I-C0085590
pacing	I-C0085590
catheter	I-C0085590
was	O
positioned	B-C0733755
in	O
the	O
substernal	B-C0230145
space	I-C0230145
anterior	B-C0205094
to	O
the	O
pericardium	B-C0031050
,	O
and	O
a	O
cutaneous	B-C0241148
patch	I-C0241148
in	O
left	B-C0450414
lateral	I-C0450414
position	I-C0450414
.	O
	
different	B-C1705242
unipolar	B-C0443340
and	O
bipolar	B-C0443156
pacing	B-C1285520
configurations	B-C0449830
were	O
assessed	B-C1516048
.	O
	
strength-duration	B-C0022885
curves	I-C0022885
were	O
performed	B-C0884358
to	O
identify	O
the	O
optimal	B-C2698651
output	B-C0204709
,	O
starting	O
at	O
25	O
ma	B-C0450172
with	O
a	O
pulse	B-C0487742
width	I-C0487742
of	O
10	O
milliseconds	B-C0439223
.	O
	
eight	O
patients	B-C0030705
with	O
mean	B-C0444504
age	B-C0001779
69	O
9	O
years	B-C0439234
were	O
included	B-C0332257
.	O
	
in	O
5	O
,	O
ventricular	B-C1522565
capture	O
was	O
achieved	O
in	O
1	O
configuration	B-C0449830
.	O
	
the	O
mean	B-C0444504
bipolar	B-C0443156
pacing	B-C1285520
thresholds	B-C0449864
at	O
pw	O
10	O
,	O
5	O
,	O
3	O
,	O
1	O
milliseconds	B-C0439223
were	O
12.4	O
3.7	O
ma	B-C0450172
5	O
patients	B-C0030705
,	O
13.3	O
5.8	O
ma	B-C0450172
3	O
patients	B-C0030705
,	O
18.3	O
5.7	O
ma	B-C0450172
3	O
patients	B-C0030705
,	O
and	O
25	O
0	O
ma	B-C0450172
2	O
patients	B-C0030705
,	O
respectively	O
.	O
	
the	O
60-mm	O
electrode	B-C0013812
spacing	B-C1710137
was	O
the	O
most	O
successful	B-C1272703
bipolar	B-C0443156
configuration	B-C0449830
.	O
	
unipolar	B-C0443340
pacing	B-C1285520
was	O
successful	B-C1272703
in	O
3	O
out	O
of	O
4	O
patients	B-C0030705
with	O
mean	B-C0444504
thresholds	B-C0449864
of	O
10	O
0	O
ma	B-C0450172
at	O
10	O
milliseconds	B-C0439223
3	O
patients	B-C0030705
,	O
15	O
0	O
ma	B-C0450172
at	O
5	O
milliseconds	B-C0439223
3	O
patients	B-C0030705
,	O
16.7	O
2.9	O
ma	B-C0450172
at	O
3	O
milliseconds	B-C0439223
3	O
patients	B-C0030705
,	O
and	O
20	O
7.1	O
ma	B-C0450172
at	O
1	O
milliseconds	B-C0439223
2	O
patients	B-C0030705
.	O
	
ventricular	B-C1285520
pacing	I-C1285520
from	O
the	O
substernal	O
space	O
in	O
patients	O
with	O
midline	O
sternotomy	O
is	O
feasible	O
.	O
	
closed	O
sternum	O
studies	O
are	O
needed	O
to	O
determine	O
pacing	B-C1285520
thresholds	O
more	O
accurately	B-C0443131
effects	B-C1280500
of	O
a	O
specific	B-C0439861
blend	I-C0439861
of	O
essential	B-C0028910
oils	I-C0028910
on	O
apparent	B-C0750489
nutrient	B-C0678695
digestion	B-C0012238
,	O
rumen	B-C0035946
fermentation	B-C0015852
and	O
rumen	B-C0035946
microbial	B-C0599840
populations	I-C0599840
in	O
sheep	B-C0036945
fed	O
a	O
50	O
alfalfa	B-C2827434
hay	I-C2827434
concentrate	B-C0012155
diet	I-C0012155
an	O
experiment	B-C0205664
was	O
conducted	O
to	O
investigate	B-C1292732
the	O
effects	B-C1280500
of	O
a	O
specific	O
mixture	B-C0439962
of	O
essential	B-C0028910
oils	I-C0028910
meo	B-C0028910
,	O
containing	O
thyme	B-C0304119
,	O
clove	B-C0028906
and	O
cinnamon	B-C0301249
eo	I-C0301249
,	O
on	O
rumen	B-C0035946
microbial	B-C0015852
fermentation	I-C0015852
,	O
nutrient	B-C0678695
apparent	B-C0750489
digestibility	B-C0243095
and	O
blood	B-C0005767
metabolites	B-C0870883
in	O
fistulated	B-C0036945
sheep	I-C0036945
.	O
	
six	O
sheep	B-C0036945
fitted	O
with	O
ruminal	B-C0302142
fistulas	I-C0302142
were	O
used	O
in	O
a	O
repeated	B-C0282574
measurement	I-C0282574
design	I-C0282574
with	O
two	O
24-d	O
periods	B-C0439531
to	O
investigate	O
the	O
effect	B-C1280500
of	O
adding	O
meo	B-C0028910
at	O
0	O
control	O
,	O
0.8	O
,	O
and	O
1.6	O
ml/d	O
on	O
apparent	B-C0750489
nutrient	B-C0678695
digestibility	B-C0243095
,	O
rumen	B-C0035946
fermentation	B-C0015852
characteristics	B-C1521970
,	O
rumen	B-C0035946
microbial	B-C0599840
population	I-C0599840
and	O
blood	B-C0005767
chemical	B-C0870883
metabolites	I-C0870883
.	O
	
animals	B-C0003062
were	O
fed	O
with	O
a	O
50	O
alfalfa	B-C2827434
hay	I-C2827434
concentrate	B-C0012155
diet	I-C0012155
.	O
	
ruminal	B-C0020283
ph	I-C0020283
,	O
total	O
volatile	B-C0015691
fatty	I-C0015691
acids	I-C0015691
vfa	B-C0015691
concentration	B-C0392762
,	O
molar	B-C0392762
proportion	I-C0392762
of	I-C0392762
individual	I-C0392762
vfa	B-C0015691
,	O
acetate	B-C0392762
propionate	I-C0392762
ratio	I-C0392762
and	O
methane	B-C1855163
production	I-C1855163
were	O
not	O
affected	O
with	O
meo	B-C0028910
.	O
	
relative	O
to	O
the	O
control	B-C0009932
,	O
small	B-C0030956
peptides	I-C0030956
plus	O
amino	O
acid	O
nitrogen	O
and	O
large	O
peptides	O
nitrogen	O
concentration	O
in	O
rumen	O
fluid	O
were	O
not	O
affected	O
with	O
meo	O
supplementation	O
while	O
,	O
rumen	O
fluid	O
ammonia	O
nitrogen	O
concentration	O
at	O
0	O
and	O
6	O
h	O
after	O
morning	O
feeding	O
in	O
sheep	O
fed	O
with	O
1.6	O
ml/d	O
of	O
meo	O
was	O
lower	O
p<0	O
compared	O
to	O
the	O
control	O
and	O
0.8	O
ml/d	O
of	O
meo	O
.	O
	
at	O
0	O
h	O
after	O
morning	O
feeding	O
,	O
ammonia	O
nitrogen	O
concentration	O
was	O
higher	O
p<0	O
in	O
sheep	O
fed	O
0.8	O
ml/d	O
of	O
meo	O
relative	O
to	O
1.6	O
ml/d	O
and	O
control	O
diet	O
.	O
	
ruminal	O
protozoa	O
and	O
hyper	O
ammonia	O
producing	O
hap	O
bacteria	O
counts	O
were	O
not	O
affected	O
by	O
addition	O
of	O
meo	O
in	O
the	O
diet	O
.	O
	
relative	O
to	O
the	O
control	O
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
red	O
and	O
white	O
blood	O
cells	O
,	O
hemoglobin	O
,	O
hematocrit	O
,	O
glucose	O
,	O
beta-hydroxybutyric	O
acid	O
,	O
cholesterol	O
,	O
total	O
protein	O
,	O
albumin	O
,	O
blood	O
urea	O
nitrogen	O
and	O
aspartate	O
aminotransferase	O
and	O
alanine	O
aminotransferase	O
concentration	O
.	O
	
apparent	O
total	O
tract	O
digestibility	O
of	O
dry	O
matter	O
,	O
crude	O
proten	O
,	O
organic	O
matter	O
,	O
and	O
neutral	O
detergent	O
fiber	O
were	O
not	O
influenced	O
by	O
meo	O
supplementation	O
.	O
	
the	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
supplementation	O
of	O
meo	O
may	O
have	O
limited	O
effects	O
on	O
apparent	O
nutrient	O
digestibility	O
,	O
ruminal	O
fermentation	O
and	O
protozoa	O
and	O
hap	O
bacteria	O
count	O
,	O
blood	O
cells	O
and	O
metabolites	B-C0870883
high	B-C0872186
throughput	I-C0872186
selection	B-C1707391
of	O
antibiotic-resistant	B-C0949285
transgenic	B-C0085245
arabidopsis	B-C0162741
plants	I-C0162741
kanamycin	B-C0022487
resistance	B-C0949285
is	O
the	O
most	B-C0205393
frequently	B-C0332183
used	O
antibiotic-resistance	B-C0949285
marker	B-C0005516
for	O
arabidopsis	B-C0162741
transformations	B-C3714584
,	O
however	O
,	O
this	O
method	B-C0025663
frequently	B-C0332183
causes	O
escape	B-C0014832
of	O
untransformed	B-C0032098
plants	I-C0032098
,	O
particularly	O
at	O
the	O
high	B-C0205250
seedling	B-C0242437
density	B-C0178587
during	O
the	O
selection	B-C1707391
.	O
	
here	O
we	O
developed	B-C1527148
a	O
robust	B-C2986815
high	B-C0205250
-	O
density	B-C0178587
selection	B-C1707391
method	B-C0025663
using	O
top	B-C1704458
agar	B-C0001771
for	O
arabidopsis	B-C0162740
thaliana	I-C0162740
.	O
	
top	B-C1704458
agar	B-C0001771
effectively	B-C1704419
suppressed	B-C0443189
growth	B-C0220844
of	O
untransformed	B-C0330098
wild-type	I-C0330098
plants	I-C0330098
on	O
selection	B-C1707391
media	B-C0010454
at	O
high	B-C0205250
density	B-C0178587
.	O
	
survival	B-C0038952
of	O
the	O
transformed	B-C3714584
plants	B-C0032098
during	O
the	O
selection	B-C1707391
were	O
confirmed	B-C0750484
by	O
production	O
of	O
green	B-C0332583
true	B-C0205238
leaves	B-C0242724
and	O
expression	B-C0017262
of	O
a	O
firefly	B-C0311727
luciferase	I-C0311727
reporter	B-C0206414
gene	I-C0206414
.	O
	
top	B-C1704458
agar	B-C0001771
method	B-C0025663
allowed	O
selection	B-C1707391
using	O
a	O
large	B-C0549177
amount	B-C1265611
of	O
seeds	B-C0036563
in	O
arabidopsis	B-C0162741
transformation	B-C3714584
.	O
	
limb	B-C0015385
remote	B-C2936234
ischaemic	I-C2936234
postconditioning	I-C2936234
-	O
induced	B-C0205263
elevation	B-C0205217
of	O
fibulin-5	B-C1452861
confers	O
neuroprotection	B-C0598958
to	O
rats	B-C0034721
with	O
cerebral	B-C0917798
ischaemia	I-C0917798
/	O
reperfusion	B-C0035126
injury	I-C0035126
activation	B-C1879547
of	O
the	O
akt	B-C1515844
pathway	I-C1515844
limb	B-C0015385
remote	B-C2936234
ischaemic	I-C2936234
postconditioning	I-C2936234
ripostc	B-C2936234
is	O
an	O
effective	O
and	O
well-acknowledged	O
treatment	B-C0087111
for	O
brain	B-C2945681
ischaemia	I-C2945681
injury	I-C2945681
.	O
	
the	O
present	O
study	B-C2603343
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
fibulin-5	B-C1452861
in	O
the	O
neuroprotection	B-C0598958
of	O
ripostc	B-C2936234
against	O
cerebral	B-C0917798
ischaemia	I-C0917798
/	O
reperfusion	B-C0035126
i/r	I-C0035126
injury	I-C0035126
in	O
rats	B-C0034721
.	O
	
the	O
middle	B-C0740391
cerebral	I-C0740391
artery	I-C0740391
occlusion	I-C0740391
mcao	B-C0740391
model	B-C0026339
was	O
established	O
in	O
rats	B-C0034721
and	O
then	O
ripostc	B-C2936234
was	O
carried	O
out	O
by	O
three	O
cycles	O
of	O
10	O
minutes	B-C0439232
occlusion	B-C0740391
/10	O
minutes	B-C0439232
release	O
of	O
the	O
bilateral	B-C0238767
femoral	B-C0015801
artery	I-C0015801
at	O
the	O
beginning	O
of	O
the	O
reperfusion	B-C0035124
.	O
	
to	O
downregulate	B-C0013081
the	O
fibulin-5	B-C1452861
level	B-C0441889
,	O
fibulin-5	B-C1099354
sirna	I-C1099354
was	O
injected	B-C1533685
into	O
the	O
lateral	B-C0152279
ventricle	I-C0152279
24	O
hours	B-C0439227
before	O
mcao	B-C0740391
.	O
	
according	O
to	O
our	O
present	O
study	B-C2603343
,	O
ripostc	B-C2936234
attenuated	B-C0599946
cerebral	B-C0917798
i	I-C0917798
/	O
r	B-C0035126
injury	I-C0035126
by	O
decreasing	B-C0442797
infarct	B-C0021308
volume	B-C0449468
,	O
improving	O
neurobehavioral	B-C0449820
score	I-C0449820
and	O
suppressing	B-C1260953
blood	B-C0005854
brain	I-C0005854
barrier	I-C0005854
bbb	B-C0005854
leakage	B-C0015376
.	O
	
moreover	O
,	O
the	O
mrna	B-C0035696
and	O
protein	B-C0428479
levels	I-C0428479
of	O
fibulin-5	B-C1452861
were	O
upregulated	B-C0041904
by	O
ripostc	B-C2936234
at	O
24	O
hours	B-C0439227
and	O
72	O
hours	B-C0439227
after	O
reperfusion	B-C0035124
.	O
	
downregulation	B-C0013081
of	O
fibulin-5	B-C1452861
attenuated	B-C0599946
the	O
neuroprotection	B-C0598958
of	O
ripostc	B-C2936234
.	O
	
finally	O
,	O
the	O
result	O
showed	O
that	O
fibulin-5	B-C1452861
was	O
upregulated	B-C0041904
by	O
ripostc	B-C2936234
via	O
activation	B-C1879547
of	O
the	O
pi3k/akt	B-C1515844
pathway	I-C1515844
.	O
	
taken	O
together	O
,	O
these	O
results	B-C1274040
provide	O
evidence	B-C3887511
that	O
upregulation	B-C0041904
of	O
fibulin-5	B-C1452861
is	O
involved	O
in	O
the	O
beneficial	O
effect	O
of	O
ripostc	B-C2936234
against	O
cerebral	B-C0917798
i	I-C0917798
/	O
r	B-C0035126
injury	I-C0035126
.	O
	
optomechanical	B-C0443254
control	I-C0443254
of	O
quantum	B-C0392762
yield	I-C0392762
in	O
trans-cis	B-C0596342
ultrafast	I-C0596342
photoisomerization	I-C0596342
of	O
a	O
retinal	B-C0035331
chromophore	B-C0596335
model	B-C0026336
the	O
quantum	B-C0392762
yield	I-C0392762
of	O
a	O
photochemical	B-C2350502
reaction	I-C2350502
is	O
one	O
of	O
the	O
most	O
fundamental	B-C1265611
quantities	I-C1265611
in	O
photochemistry	B-C0031739
,	O
as	O
it	O
measures	O
the	O
efficiency	O
of	O
the	O
transduction	B-C0376451
of	I-C0376451
light	I-C0376451
energy	I-C0376451
into	I-C0376451
chemical	I-C0376451
energy	I-C0376451
.	O
	
nature	B-C0349590
has	O
evolved	O
photoreceptors	B-C0031760
in	O
which	O
the	O
reactivity	B-C0678596
of	O
a	O
chromophore	B-C0596335
is	O
enhanced	O
by	O
its	O
molecular	B-C0014406
environment	I-C0014406
to	O
achieve	O
high	O
quantum	B-C0392762
yields	I-C0392762
.	O
	
the	O
retinal	B-C0035331
chromophore	B-C0596335
sterically	O
constrained	O
inside	O
rhodopsin	B-C0035499
proteins	I-C0035499
represents	O
an	O
outstanding	O
example	O
of	O
such	O
a	O
control	O
.	O
	
in	O
a	O
more	O
general	O
framework	O
,	O
mechanical	B-C0563538
forces	I-C0563538
acting	O
on	O
a	O
molecular	B-C1521991
system	I-C1521991
can	O
strongly	O
modify	O
its	O
reactivity	B-C0678596
.	O
	
herein	O
,	O
we	O
show	O
that	O
the	O
exertion	O
of	O
tensile	B-C0039526
forces	I-C0039526
on	O
a	O
simplified	O
retinal	B-C0035331
chromophore	B-C0596335
model	B-C0026336
provokes	O
a	O
substantial	B-C0205556
and	I-C0205556
regular	I-C0205556
increase	I-C0205556
in	O
the	O
trans-to-cis	B-C0596342
photoisomerization	I-C0596342
quantum	B-C0392762
yield	I-C0392762
in	O
a	O
counterintuitive	O
way	O
,	O
as	O
these	O
extension	O
forces	O
facilitate	O
the	O
formation	O
of	O
the	O
more	O
compressed	O
cis	B-C1254350
photoisomer	I-C1254350
.	O
	
a	O
rationale	B-C2699007
for	O
the	O
mechanochemical	B-C2350457
effect	I-C2350457
on	O
this	O
photoisomerization	B-C2350502
mechanism	I-C2350502
quality	B-C0332306
of	O
nursing	B-C0028694
intensity	I-C0028694
data	I-C0028694
inter-rater	B-C0870740
reliability	I-C0870740
of	O
the	O
patient	B-C0030705
classification	B-C0008902
after	O
two	B-C2981279
decades	I-C2981279
in	O
clinical	B-C0205210
use	B-C0457083
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
measure	B-C0079809
the	O
inter-rater	B-C0870740
reliability	I-C0870740
of	O
the	O
oulu	B-C0008902
patient	I-C0008902
classification	I-C0008902
and	O
to	O
discuss	O
existing	O
methods	B-C0025664
of	O
reliability	B-C0237829
testing	I-C0237829
.	O
	
the	O
oulu	B-C0008902
patient	I-C0008902
classification	I-C0008902
,	O
part	O
of	O
the	O
rafaela	B-C0282574
system	I-C0282574
,	O
has	O
been	O
developed	O
to	O
assist	B-C1269765
nursing	B-C0454680
managers	I-C0454680
with	O
the	O
proper	O
allocation	B-C1706778
of	O
nursing	B-C0028682
resources	B-C0018741
.	O
	
due	O
to	O
the	O
increased	B-C0205217
intensity	B-C0522510
of	O
inpatient	B-C0019993
care	I-C0019993
during	O
recent	O
years	B-C0439234
,	O
there	O
is	O
a	O
need	O
for	O
the	O
reliability	B-C0237829
testing	I-C0237829
of	O
the	O
classification	B-C0008902
,	O
which	O
has	O
been	O
in	O
clinical	B-C0205210
use	B-C0457083
for	O
20	O
years	B-C0439234
.	O
	
retrospective	B-C1514923
statistical	B-C0038208
study	I-C0038208
.	O
	
to	O
test	B-C0237829
inter-rater	B-C0870740
reliability	I-C0870740
,	O
a	O
pair	O
of	O
nurses	B-C0028661
classified	B-C0008902
the	O
same	O
patients	B-C0030705
,	O
without	O
knowledge	O
of	O
each	O
other's	O
ratings	B-C0871208
,	O
as	O
a	O
part	O
of	O
annually	B-C0332181
conducted	O
standardization	B-C0038136
.	O
	
data	B-C1511726
on	O
the	O
parallel	B-C0008902
classifications	I-C0008902
n	O
=	O
19	O
was	O
obtained	B-C1301820
from	O
inpatient	B-C0021562
units	O
n	O
=	O
32	O
with	O
different	B-C1705242
specialties	B-C0037778
at	O
a	O
university	B-C0020028
hospital	I-C0020028
in	O
finland	B-C0016132
during	O
2010-2015	O
.	O
	
parallel	B-C0008902
classification	I-C0008902
practices	B-C4035713
were	O
also	O
analysed	O
.	O
	
the	O
reliability	B-C2347947
of	O
the	O
overall	O
classification	B-C0008902
and	O
its	O
subareas	O
were	O
calculated	B-C1441506
using	O
suitable	O
statistical	B-C1707429
coefficients	I-C1707429
.	O
	
inter-rater	B-C0870740
reliability	I-C0870740
coefficients	B-C1707429
were	O
a	O
reliable	O
or	O
almost	O
perfect	O
means	O
of	O
considering	O
the	O
nursing	B-C0028682
intensity	B-C0522510
category	B-C0683312
and	O
various	O
practices	B-C4035713
,	O
but	O
there	O
were	O
detectable	B-C0442726
differences	B-C1705242
between	O
subareas	O
.	O
	
the	O
lowest	O
agreement	B-C0205556
levels	B-C0441889
occurred	B-C1709305
in	O
the	O
subareas	O
'	O
planning	B-C3863893
and	I-C3863893
coordination	I-C3863893
of	I-C3863893
nursing	I-C3863893
care	I-C3863893
'	O
and	O
'	O
guiding	B-C1254363
of	I-C1254363
care	I-C1254363
/	O
continued	B-C0009853
care	I-C0009853
and	O
emotional	B-C0600015
support	I-C0600015
'	O
.	O
	
there	O
is	O
a	O
need	O
to	O
develop	O
the	O
descriptions	B-C0678257
of	O
subareas	O
and	O
to	O
clarify	B-C2986669
the	O
related	O
concepts	B-C0178566
.	O
	
precise	O
nursing	B-C0184600
documentation	I-C0184600
can	O
promote	B-C0033414
a	O
high	O
level	B-C0441889
of	O
agreement	B-C0205556
and	O
reliable	O
results	B-C1274040
.	O
	
the	O
traditional	O
overall	O
proportion	O
of	O
agreement	B-C0205556
does	O
not	O
provide	O
an	O
adequate	O
picture	O
of	O
reliability	O
-	O
weighted	O
kappa	B-C1707429
coefficients	I-C1707429
water	B-C4302493
pipe	I-C4302493
shisha	O
,	O
hookah	O
,	O
arghile	O
smoking	B-C0037369
and	O
secondhand	B-C0375734
tobacco	I-C0375734
smoke	I-C0375734
effects	B-C1280500
on	O
cyp1a2	B-C1620185
and	O
cyp2a6	B-C3884187
phenotypes	B-C0031437
as	O
measured	O
by	O
caffeine	B-C0042014
urine	I-C0042014
test	I-C0042014
public	B-C0085098
policies	I-C0085098
to	O
stop	O
or	O
reduce	O
cigarette	B-C0700219
smoking	I-C0700219
and	O
exposure	B-C0332157
to	O
secondhand	B-C0375734
smoke	I-C0375734
and	O
associated	B-C0243083
diseases	I-C0243083
have	O
yielded	O
successful	O
results	O
over	O
the	O
past	O
decade	O
.	O
	
yet	O
,	O
the	O
growing	O
worldwide	O
popularity	O
of	O
another	O
form	O
of	O
tobacco	B-C0543414
consumption	I-C0543414
,	O
water	B-C4302493
pipe	I-C4302493
smoking	B-C0037369
,	O
has	O
received	O
relatively	O
less	O
attention	O
.	O
	
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
study	O
to	O
date	O
has	O
evaluated	O
the	O
effects	O
of	O
water	B-C4302493
pipe	I-C4302493
smoking	B-C0037369
on	O
cytochrome	B-C1149063
p450	I-C1149063
cyp450	I-C1149063
activities	I-C1149063
and	O
drug	B-C0687133
interaction	I-C0687133
potential	B-C3245505
in	O
humans	B-C0086418
,	O
whereas	O
only	O
limited	O
information	O
is	O
available	O
on	O
the	O
impact	O
of	O
secondhand	B-C0375734
smoke	I-C0375734
on	O
drug	B-C0683140
metabolism	I-C0683140
.	O
	
in	O
a	O
sample	O
of	O
99	O
healthy	B-C1708335
volunteers	I-C1708335
28	O
water	B-C3697029
pipe	I-C3697029
smokers	I-C3697029
,	O
30	O
secondhand	B-C0375734
tobacco	I-C0375734
smoke	I-C0375734
exposed	O
persons	B-C0027361
,	O
and	O
41	O
controls	B-C0009932
,	O
we	O
systematically	B-C1707455
compared	I-C1707455
cyp1a2	B-C1620185
and	O
cyp2a6	B-C3884187
enzyme	B-C0243102
activities	I-C0243102
in	B-C1515655
vivo	I-C1515655
using	O
caffeine	B-C0042014
urine	I-C0042014
test	I-C0042014
.	O
	
the	O
median	O
self-reported	B-C2700446
duration	B-C0449238
of	O
water	B-C4302493
pipe	I-C4302493
smoking	B-C0037369
was	O
7.5	O
h	B-C0439227
/	O
week	B-C0439230
and	O
3	O
years	B-C0439234
of	O
exposure	B-C0332157
in	O
total	O
.	O
	
the	O
secondhand	B-C0375734
smoke	I-C0375734
group	B-C1257890
had	O
a	O
median	O
of	O
14	O
h	B-C0439227
of	O
self-reported	B-C2700446
weekly	B-C0332174
exposure	B-C0332157
to	O
tobacco	B-C0439994
smoke	I-C0439994
indoor	O
where	O
a	O
minimum	O
of	O
five	O
cigarettes	B-C0677453
were	O
smoked	B-C0239059
/	O
hour	B-C0439227
for	O
a	O
total	O
of	O
3.5	O
years	B-C0439234
median	O
.	O
	
analysis	B-C0936012
of	O
variance	B-C1711260
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
cyp1a2	B-C1620185
and	O
cyp2a6	B-C3884187
activities	B-C0243102
among	O
the	O
three	O
study	B-C2603343
groups	B-C1257890
p	O
>	O
0.05	O
.	O
	
nor	O
was	O
there	O
a	O
significant	O
association	O
between	O
the	O
extent	O
of	O
water	B-C4302493
pipe	I-C4302493
or	O
secondhand	B-C0375734
smoke	I-C0375734
exposure	B-C0332157
and	O
the	O
cyp1a2	B-C1620185
and	O
cyp2a6	B-C3884187
activities	B-C0243102
p	O
>	O
0.05	O
.	O
	
further	O
analysis	B-C0936012
in	O
a	O
subsample	O
with	O
smoke	O
exposure	B-C0332157
more	O
than	O
the	O
median	O
values	O
also	O
did	O
not	O
reveal	O
a	O
significant	O
difference	O
from	O
the	O
controls	B-C0009932
.	O
	
although	O
we	O
do	O
not	O
rule	O
out	O
an	O
appreciable	O
possible	O
impact	O
of	O
water	B-C4302493
pipe	I-C4302493
smoke	O
and	O
secondhand	B-C0375734
smoke	I-C0375734
on	O
in	B-C1515655
vivo	I-C1515655
activities	B-C0243102
of	O
these	O
two	O
drug	B-C0683140
metabolism	I-C0683140
pathways	B-C1704259
,	O
variability	O
in	O
smoke	O
constituents	B-C0729650
from	O
different	O
tobacco	B-C0543414
consumption	I-C0543414
methods	O
e.g	O
,	O
water	B-C4302493
pipe	I-C4302493
might	O
affect	O
drug	B-C0683140
metabolism	I-C0683140
in	O
ways	O
that	O
might	O
differ	O
from	O
that	O
of	O
cigarette	B-C0239059
smoke	I-C0239059
.	O
	
further	O
studies	B-C2603343
in	O
larger	O
prospective	O
samples	O
are	O
recommended	O
to	O
evaluate	O
water	B-C4302493
pipe	I-C4302493
and	O
secondhand	B-C0375734
tobacco	I-C0375734
smoke	I-C0375734
effects	O
on	O
cyp450	B-C0010762
function	O
,	O
particularly	O
at	O
higher	O
smoke	B-C0439994
exposure	B-C0332157
how	O
do	O
wettability	B-C0162598
,	O
zeta	B-C0597697
potential	I-C0597697
and	O
hydroxylation	B-C0020365
degree	O
affect	O
the	O
biological	O
response	O
of	O
biomaterials	O
it	O
is	O
well	O
known	O
that	O
composition	O
,	O
electric	O
charge	O
,	O
wettability	O
and	O
roughness	O
of	O
implant	O
surfaces	O
have	O
great	O
influence	O
on	O
their	O
interaction	O
with	O
the	O
biological	O
fluids	O
and	O
tissues	O
,	O
but	O
systematic	O
studies	O
of	O
different	O
materials	O
in	O
the	O
same	O
experimental	O
conditions	O
are	O
still	O
lacking	O
in	O
the	O
scientific	O
literature	O
.	O
	
the	O
aim	O
of	O
this	O
research	O
is	O
to	O
investigate	O
the	O
correlations	O
between	O
some	O
surface	O
characteristics	O
wettability	O
,	O
zeta	O
potential	O
and	O
hydroxylation	B-C0243095
degree	I-C0243095
and	O
the	O
biological	B-C0243095
response	I-C0243095
protein	O
adsorption	O
,	O
blood	O
wettability	O
,	O
cell	O
and	O
bacterial	O
adhesion	O
to	O
some	O
model	O
biomaterials	B-C0005479
.	O
	
the	O
resulting	O
knowledge	O
can	O
be	O
applied	O
for	O
the	O
development	O
of	O
future	O
innovative	O
surfaces	O
for	O
implantable	O
biomaterials	O
.	O
	
roughness	O
was	O
not	O
considered	O
as	O
a	O
variable	O
because	O
it	O
is	O
a	O
widely	O
explored	O
feature	O
smooth	O
surfaces	O
prepared	O
by	O
a	O
controlled	O
protocol	O
were	O
compared	O
in	O
order	O
to	O
have	O
no	O
roughness	O
effects	O
.	O
	
three	O
oxides	O
zro2	O
,	O
al2o3	O
,	O
sio2	O
,	O
three	O
metals	O
316lss	O
steel	O
,	O
ti	O
,	O
nb	O
and	O
two	O
polymers	O
corona	O
treated	O
polystyrene	O
for	O
cell	O
culture	O
and	O
untreated	O
polystyrene	O
for	O
bacteria	O
culture	O
,	O
widely	O
used	O
for	O
biomedical	O
applications	O
,	O
were	O
considered	O
.	O
	
the	O
surfaces	O
were	O
characterized	O
by	O
contact	O
profilometry	O
,	O
sem	O
-	O
eds	O
,	O
xps	O
,	O
ftir	O
,	O
zeta	O
potential	O
and	O
wettability	O
with	O
different	O
fluids	O
.	O
	
protein	O
adsorption	O
,	O
blood	O
wettability	O
,	O
bacterial	O
and	O
cell	O
adhesion	O
were	O
evaluated	O
in	O
order	O
to	O
investigate	O
the	O
correlations	O
between	O
the	O
surface	O
physiochemical	O
properties	O
and	O
biological	O
responses	O
.	O
	
from	O
a	O
methodological	O
standpoint	O
,	O
xps	O
and	O
electrokinetic	O
measurements	O
emerged	O
as	O
the	O
more	O
suitable	O
techniques	O
respectively	O
for	O
the	O
evaluation	O
of	O
hydroxylation	O
degree	O
and	O
surface	O
charge	O
/	O
isoelectric	O
point	O
.	O
	
moreover	O
,	O
determination	O
of	O
wettability	O
by	O
blood	O
appeared	O
a	O
specific	O
and	O
crucial	O
test	O
,	O
the	O
results	O
of	O
which	O
are	O
not	O
easily	O
predictable	O
by	O
using	O
other	O
type	O
of	O
tests	O
.	O
	
hydroxylation	O
degree	O
resulted	O
correlated	O
to	O
the	O
wettability	O
by	O
water	O
,	O
but	O
not	O
directly	O
to	O
surface	O
charge	O
.	O
	
wetting	O
tests	O
with	O
different	O
media	O
showed	O
the	O
possibility	O
to	O
highlight	O
some	O
differences	O
among	O
look-alike	O
materials	O
.	O
	
a	O
dependence	O
of	O
protein	O
absorption	O
on	O
hydroxylation	O
degree	O
,	O
charge	O
and	O
wettability	O
was	O
evidenced	O
and	O
its	O
maximum	O
was	O
registered	O
for	O
surfaces	O
with	O
low	O
wettability	O
in	O
both	O
water	O
based	O
and	O
protein	O
containing	O
media	O
and	O
a	O
moderate	O
surface	O
charge	O
.	O
	
as	O
far	O
as	O
bacterial	O
adhesion	O
is	O
concerned	O
,	O
no	O
effect	O
of	O
surface	O
charge	O
or	O
protein	O
adsorption	O
was	O
evidenced	O
,	O
while	O
the	O
presence	O
of	O
a	O
high	O
acid	O
component	O
of	O
the	O
surface	O
energy	O
appeared	O
significant	O
.	O
	
finally	O
,	O
the	O
combination	O
of	O
hydroxylation	O
degree	O
,	O
wettability	O
,	O
surface	O
charge	O
and	O
energy	O
polar	O
component	O
emerged	O
as	O
a	O
key	O
parameter	O
for	O
cell	O
adhesion	O
and	O
viability	B-C0007620
persistent	B-C0205322
effects	B-C1280500
of	O
pre-columbian	B-C0032659
plant	B-C0032098
domestication	B-C0175819
on	O
amazonian	B-C0086312
forest	I-C0086312
composition	B-C0486616
the	O
extent	O
to	O
which	O
pre-columbian	B-C0032659
societies	B-C0037455
altered	O
amazonian	B-C0086312
landscapes	B-C0870781
is	O
hotly	O
debated	O
.	O
	
we	O
performed	O
a	O
basin-wide	B-C0936012
analysis	I-C0936012
of	O
pre-columbian	B-C0032659
impacts	B-C4049986
on	O
amazonian	B-C0086312
forests	I-C0086312
by	O
overlaying	O
known	O
archaeological	B-C0205145
sites	I-C0205145
in	O
amazonia	B-C0681784
with	O
the	O
distributions	O
and	O
abundances	B-C2346714
of	O
85	O
woody	B-C0040811
species	B-C1705920
domesticated	B-C0175819
by	O
pre-columbian	B-C0032659
peoples	B-C0027361
.	O
	
domesticated	B-C0175819
species	B-C1705920
are	O
five	O
times	O
more	O
likely	O
than	O
nondomesticated	B-C1705920
species	I-C1705920
to	O
be	O
hyperdominant	B-C1527180
.	O
	
across	O
the	O
basin	O
,	O
the	O
relative	O
abundance	B-C2346714
and	O
richness	B-C0205556
of	O
domesticated	B-C0175819
species	B-C1705920
increase	O
in	O
forests	B-C0086312
on	O
and	O
around	O
archaeological	B-C0205145
sites	I-C0205145
.	O
	
in	O
southwestern	B-C0681784
and	I-C0681784
eastern	I-C0681784
amazonia	I-C0681784
,	O
distance	O
to	O
archaeological	B-C0205145
sites	I-C0205145
strongly	O
influences	O
the	O
relative	O
abundance	B-C2346714
and	O
richness	O
of	O
domesticated	B-C0175819
species	B-C1705920
.	O
	
our	O
analyses	B-C0936012
indicate	O
that	O
modern	O
tree	B-C0040811
communities	B-C0009462
in	O
amazonia	B-C0681784
are	O
structured	O
to	O
an	O
important	O
extent	O
by	O
a	O
long	O
history	B-C0019665
of	O
plant	B-C0032098
domestication	B-C0175819
by	O
amazonian	B-C0086312
peoples	B-C0027361
.	O
	
halogenated	B-C1959882
phenolic	I-C1959882
compounds	I-C1959882
in	O
wild	B-C0016163
fish	I-C0016163
from	O
canadian	B-C0006823
areas	I-C0006823
of	O
concern	B-C2699424
concentrations	O
of	O
halogenated	B-C1959882
phenolic	I-C1959882
compounds	I-C1959882
were	O
measured	O
in	O
the	O
plasma	B-C0032105
of	O
brown	B-C0328325
bullhead	I-C0328325
ameiurus	B-C0328325
nebulosus	I-C0328325
from	O
4	O
canadian	B-C0006823
areas	I-C0006823
of	O
concern	B-C2699424
aocs	B-C0006823
,	O
to	O
assess	O
exposure	O
to	O
suspected	O
thyroid	B-C0040132
-	O
disrupting	B-C1568245
chemicals	I-C1568245
.	O
	
hydroxylated	B-C0032447
polychlorinated	I-C0032447
biphenyls	I-C0032447
oh-pcbs	B-C0032447
were	O
detected	O
in	O
every	O
sample	O
collected	O
in	O
3	O
of	O
the	O
aocs	B-C0006823
the	O
detection	B-C1511790
frequency	B-C0439603
was	O
lower	O
in	O
samples	O
from	O
the	O
detroit	B-C0337050
river	I-C0337050
aoc	B-C0006823
.	O
	
the	O
oh-pcbs	B-C0032447
most	O
frequently	O
detected	O
were	O
pentachloro	B-C0678518
,	O
hexachloro	I-C0678518
,	O
and	I-C0678518
heptachloro	I-C0678518
congeners	I-C0678518
,	O
which	O
are	O
structurally	O
similar	O
to	O
thyroid	B-C0040135
hormones	I-C0040135
.	O
	
pentachlorophenol	B-C0030855
pcp	B-C0030855
was	O
detected	O
at	O
highest	O
concentrations	O
1.8	O
ng/g	O
in	O
fish	B-C0016163
from	O
prince	B-C3203003
edward	I-C3203003
bay	I-C3203003
,	O
the	O
bay	B-C3203003
of	I-C3203003
quinte	I-C3203003
lake	I-C3203003
reference	I-C3203003
site	I-C3203003
,	O
and	O
hillman	B-C0475311
marsh	I-C0475311
the	B-C0475311
wheatley	I-C0475311
harbour	I-C0475311
reference	I-C0475311
site	I-C0475311
,	O
suggesting	O
local	O
sources	B-C2728510
of	I-C2728510
contamination	I-C2728510
.	O
	
elevated	B-C0524230
pcp	I-C0524230
concentrations	I-C0524230
were	O
also	O
detected	O
in	O
the	O
plasma	B-C0032105
of	O
brown	B-C0328325
bullhead	I-C0328325
from	O
exposed	O
sites	O
in	O
the	O
toronto	B-C0006823
and	I-C0006823
region	I-C0006823
aoc	I-C0006823
0.4	O
ng/g	O
.	O
	
triclosan	B-C0040958
was	O
consistently	O
detected	O
in	O
the	O
toronto	B-C0006823
and	I-C0006823
region	I-C0006823
aoc	I-C0006823
0.05	O
ng/g	O
,	O
consistent	O
with	O
wastewater	B-C0450237
emission	O
.	O
	
greater	O
concentrations	O
were	O
occasionally	O
detected	O
in	O
the	O
plasma	B-C0032105
of	O
brown	B-C0328325
bullhead	I-C0328325
from	O
the	O
bay	B-C3203003
of	I-C3203003
quinte	I-C3203003
aoc	B-C0006823
.	O
	
concentrations	O
of	O
polybrominated	B-C2350562
diphenyl	I-C2350562
ethers	I-C2350562
were	O
highest	O
in	O
the	O
toronto	B-C0006823
and	I-C0006823
region	I-C0006823
aoc	I-C0006823
,	O
and	O
at	O
2	O
of	O
the	O
bay	B-C3203003
of	I-C3203003
quinte	I-C3203003
aoc	B-C0006823
exposed	O
sites	O
near	O
trenton	B-C0006823
and	I-C0006823
belleville	I-C0006823
.	O
	
distribution	B-C0449775
patterns	I-C0449775
reflected	O
the	O
properties	B-C0243178
and	O
usage	B-C0457083
of	O
the	O
compounds	O
under	O
investigation	B-C0683933
and	O
the	O
characteristics	B-C1521970
of	O
each	O
aoc	B-C0006823
.	O
	
the	O
genetic	B-C0314603
basis	O
for	O
variation	B-C0042333
in	O
resistance	B-C1514892
to	O
infection	B-C3714514
in	O
the	O
drosophila	B-C0013139
melanogaster	I-C0013139
genetic	I-C0013139
reference	I-C0013139
panel	I-C0013139
individuals	B-C0027361
vary	O
extensively	O
in	O
the	O
way	O
they	O
respond	O
to	O
disease	B-C0012634
but	O
the	O
genetic	B-C0314603
basis	O
of	O
this	O
variation	B-C0042333
is	O
not	O
fully	O
understood	O
.	O
	
we	O
found	O
substantial	O
individual	B-C0027361
variation	B-C0042333
in	O
resistance	B-C1514892
and	O
tolerance	B-C1704410
to	O
the	O
fungal	B-C0997672
pathogen	I-C0997672
metarhizium	I-C0997672
anisopliae	I-C0997672
ma549	I-C0997672
using	O
the	O
drosophila	B-C0013139
melanogaster	I-C0013139
genetic	I-C0013139
reference	I-C0013139
panel	I-C0013139
dgrp	B-C0013139
.	O
	
in	O
addition	O
,	O
we	O
found	O
that	O
host	B-C0520990
defense	I-C0520990
to	O
ma549	B-C0997672
was	O
correlated	O
with	O
defense	B-C1880266
to	O
the	O
bacterium	B-C0004611
pseudomonas	B-C0033809
aeruginosa	I-C0033809
pa14	I-C0033809
,	O
and	O
several	O
previously	O
published	O
dgrp	B-C0013139
phenotypes	B-C0031437
including	O
oxidative	B-C0242606
stress	I-C0242606
sensitivity	B-C0332324
,	O
starvation	B-C0038187
stress	B-C0678683
resistance	I-C0678683
,	O
hemolymph	B-C0019051
glucose	B-C0337438
levels	I-C0337438
,	O
and	O
sleep	B-C0037313
indices	B-C0918012
.	O
	
we	O
identified	O
polymorphisms	B-C0032529
associated	B-C0332281
with	I-C0332281
differences	B-C1705242
between	O
lines	O
in	O
both	O
their	O
mean	B-C0086595
survival	I-C0086595
times	I-C0086595
and	O
microenvironmental	B-C4072789
plasticity	B-C0678558
,	O
suggesting	O
that	O
lines	O
differ	B-C1705242
in	O
their	O
ability	B-C0085732
to	O
adapt	B-C0392673
to	O
variable	B-C0439828
pathogen	B-C0450254
exposures	B-C0332157
.	O
	
the	O
majority	O
of	O
polymorphisms	B-C0032529
increasing	B-C0442808
resistance	B-C1514892
to	O
ma549	B-C0997672
were	O
sex	B-C0242568
biased	I-C0242568
,	O
located	O
in	O
non-coding	B-C0021920
regions	I-C0021920
,	O
had	O
moderately	O
large	O
effect	B-C1280500
and	O
were	O
rare	O
,	O
suggesting	O
that	O
there	O
is	O
a	O
general	O
cost	O
to	O
defense	B-C1880266
.	O
	
nevertheless	O
,	O
host	B-C0520990
defense	I-C0520990
was	O
not	O
negatively	O
correlated	B-C1707520
with	O
overall	O
longevity	B-C0023980
and	O
fecundity	B-C0015895
.	O
	
in	O
contrast	O
to	O
ma549	B-C0997672
,	O
minor	B-C0002085
alleles	I-C0002085
were	O
concentrated	O
in	O
the	O
most	O
pa14	B-C0033809
-	O
susceptible	B-C0231204
as	O
well	O
as	O
the	O
most	O
pa14	B-C0033809
-	O
resistant	B-C1514892
lines	O
.	O
	
a	O
pathway	B-C1705987
based	O
analysis	B-C0936012
revealed	O
a	O
network	O
of	O
pa14	B-C0033809
and	O
ma549	B-C0997672
-	O
resistance	B-C1514892
genes	B-C0017337
that	O
are	O
functionally	B-C0205245
connected	O
through	O
processes	B-C1522240
that	O
encompass	O
phagocytosis	B-C0031308
and	O
engulfment	B-C1159764
,	O
cell	B-C1516353
mobility	I-C1516353
,	O
intermediary	B-C0025519
metabolism	I-C0025519
,	O
protein	B-C1158886
phosphorylation	I-C1158886
,	O
axon	B-C2984268
guidance	I-C2984268
,	O
response	B-C1155291
to	I-C1155291
dna	I-C1155291
damage	I-C1155291
,	O
and	O
drug	B-C0683140
metabolism	I-C0683140
.	O
	
functional	B-C0205245
testing	B-C0039593
with	O
insertional	B-C0079868
mutagenesis	I-C0079868
lines	O
indicates	O
that	O
12/13	O
candidate	B-C0017337
genes	I-C0017337
tested	B-C0039593
influence	B-C4054723
susceptibility	B-C0231204
to	O
ma549	B-C0997672
.	O
	
many	O
candidate	B-C0017337
genes	I-C0017337
have	O
homologs	B-C0162774
identified	O
in	O
studies	B-C0008972
of	O
human	B-C0086418
disease	B-C0012634
,	O
suggesting	O
that	O
genes	B-C0017337
affecting	O
variation	B-C0042333
in	O
susceptibility	B-C0231204
are	O
conserved	O
across	O
surrogate	B-C4053457
inaccuracy	B-C0443236
in	O
predicting	O
older	B-C0001792
adults'	I-C0001792
desire	B-C0871633
for	O
life-sustaining	B-C0871803
interventions	I-C0871803
in	O
the	O
event	O
of	O
decisional	B-C0679006
incapacity	B-C3176592
is	O
it	O
due	O
in	O
part	O
to	O
erroneous	B-C1547323
quality-of-life	B-C0281588
assessments	I-C0281588
family	B-C0086282
members	I-C0086282
are	O
often	O
called	O
upon	O
to	O
make	O
decisions	B-C0679006
for	O
an	O
incapacitated	O
relative	B-C0080103
.	O
	
yet	O
they	O
have	O
difficulty	O
predicting	O
a	O
loved	O
one's	O
desire	B-C0871633
to	O
receive	O
treatments	B-C0087111
in	O
hypothetical	O
situations	O
.	O
	
we	O
tested	O
the	O
hypothesis	O
that	O
this	O
difficulty	O
could	O
in	O
part	O
be	O
explained	O
by	O
discrepant	O
quality-of-life	B-C0281588
assessments	I-C0281588
.	O
	
the	O
data	B-C1511726
come	O
from	O
235	O
community-dwelling	B-C4045975
adults	B-C0001675
aged	O
70	O
years	B-C0439234
and	O
over	O
who	O
rated	O
their	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
and	O
desire	B-C0871633
for	O
specified	O
interventions	B-C0184661
in	O
four	O
health	B-C0683314
states	I-C0683314
current	B-C0683314
state	I-C0683314
,	O
mild	B-C2945599
to	O
moderate	B-C0205081
stroke	B-C0038454
,	O
incurable	O
brain	B-C0006118
cancer	I-C0006118
,	O
and	O
severe	B-C0205082
dementia	B-C0497327
.	O
	
all	O
ratings	B-C0871208
were	O
made	O
on	O
likert-type	B-C0451267
scales	I-C0451267
.	O
	
using	O
identical	O
rating	B-C0681889
scales	I-C0681889
,	O
a	O
surrogate	B-C4053457
chosen	O
by	O
the	O
older	B-C0001792
adult	I-C0001792
was	O
asked	O
to	O
predict	O
the	O
latter's	O
responses	O
.	O
	
linear	O
mixed	O
models	O
were	O
fitted	O
to	O
determine	O
whether	O
differences	O
in	O
quality-of-life	B-C0034380
ratings	B-C0871208
between	O
the	O
older	B-C0001792
adult	I-C0001792
and	O
surrogate	B-C4053457
were	O
associated	O
with	O
surrogates'	B-C4053457
inaccuracy	B-C0443236
in	O
predicting	O
desire	B-C0871633
for	O
treatment	B-C0087111
.	O
	
the	O
difference	O
in	O
quality-of-life	B-C0034380
ratings	B-C0871208
was	O
a	O
significant	O
predictor	B-C2698872
of	O
prediction	O
inaccuracy	B-C0443236
for	O
the	O
three	O
hypothetical	O
health	B-C0683314
states	I-C0683314
p	O
<	O
0.01	O
and	O
nearly	O
significant	O
for	O
the	O
current	B-C0683314
health	I-C0683314
state	I-C0683314
p	O
=	O
0.077	O
.	O
	
all	O
regression	B-C1707429
coefficients	I-C1707429
were	O
negative	B-C0205160
,	O
implying	O
that	O
the	O
more	O
the	O
surrogate	B-C4053457
overestimated	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
compared	O
to	O
the	O
older	B-C0001792
adult	I-C0001792
,	O
the	O
more	O
he	O
or	O
she	O
overestimated	O
the	O
older	B-C0001792
adult	I-C0001792
's	O
desire	B-C0871633
to	O
be	O
treated	O
.	O
	
discrepant	O
quality-of-life	B-C0034380
ratings	B-C0871208
are	O
associated	O
with	O
surrogates'	B-C4053457
difficulty	O
in	O
predicting	O
desire	B-C0871633
for	O
life-sustaining	B-C0871803
interventions	I-C0871803
in	O
hypothetical	O
situations	O
.	O
	
this	O
finding	O
underscores	O
the	O
importance	O
of	O
discussing	O
anticipated	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
in	O
states	O
of	O
cognitive	B-C0234985
decline	I-C0234985
,	O
to	O
better	O
prepare	O
family	B-C0086282
members	I-C0086282
for	O
making	O
difficult	O
decisions	B-C0679006
gain-of-function	B-C0026882
mutation	I-C0026882
in	O
scn5a	B-C1419864
causes	O
ventricular	B-C0085612
arrhythmias	I-C0085612
and	O
early	B-C1833334
onset	I-C1833334
atrial	B-C0004238
fibrillation	I-C0004238
mutations	B-C0026882
in	O
scn5a	B-C1419864
,	O
the	O
gene	B-C0017337
encoding	B-C2700640
the	O
α-subunit	O
of	O
the	O
cardiac	B-C0018787
sodium	B-C0037492
channel	I-C0037492
nav1.5	I-C0037492
,	O
are	O
associated	O
with	O
a	O
broad	O
spectrum	B-C2827424
of	O
inherited	B-C0439660
cardiac	B-C0003811
arrhythmia	I-C0003811
disorders	I-C0003811
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
identify	O
the	O
genetic	B-C0314603
and	O
functional	B-C1521761
determinants	I-C1521761
underlying	O
a	O
dutch	B-C0013331
family	B-C0015576
that	O
presented	O
with	O
a	O
combined	O
phenotype	B-C0031437
of	O
ventricular	B-C0085612
arrhythmias	I-C0085612
with	O
a	O
likely	O
adrenergic	B-C0599756
component	B-C1705248
,	O
either	O
in	O
isolation	B-C0205409
or	O
in	O
combination	B-C0205195
with	O
a	O
mildly	O
decreased	O
heart	B-C0232164
function	I-C0232164
and	O
early	B-C1833334
onset	I-C1833334
<55	O
years	B-C0439234
atrial	B-C0004238
fibrillation	I-C0004238
.	O
	
we	O
performed	O
next	O
generation	B-C0079411
sequencing	B-C0162326
in	O
the	O
proband	B-C1948021
of	O
a	O
two-	O
generation	B-C0079411
dutch	B-C0013331
family	B-C0015576
and	O
demonstrated	O
a	O
novel	O
missense	B-C0599155
mutation	I-C0599155
in	O
scn5a-	B-C1419864
which	O
co-segregated	O
with	O
the	O
clinical	B-C0205210
phenotype	B-C0031437
in	O
the	O
family	B-C0015576
.	O
	
we	O
functionally	B-C0205245
evaluated	O
the	O
putative	O
genetic	B-C0314603
defect	B-C1457869
by	O
patch	B-C0920630
clamp	I-C0920630
electrophysiological	B-C0850293
studies	I-C0850293
in	O
human	B-C0868971
embryonic	I-C0868971
kidney	B-C0553257
cells	I-C0553257
transfected	B-C0040669
with	O
mutant	B-C0596988
or	O
wild-type	B-C1419864
nav1.5	I-C1419864
.	O
	
the	O
current	B-C1705970
inactivation	B-C0544461
was	O
slower	O
and	O
recovery	O
from	O
inactivation	B-C0544461
was	O
faster	O
in	O
scn5a-m1851v	B-C0037492
channels	I-C0037492
.	O
	
the	O
voltage	B-C0598352
dependence	B-C3244310
of	O
inactivation	B-C0544461
was	O
shifted	O
towards	O
more	O
positive	B-C1446409
potentials	B-C3245505
and	O
consequently	O
,	O
a	O
larger	O
ttx	B-C0039705
-	O
sensitive	B-C0332324
window	B-C1705970
current	I-C1705970
was	O
observed	O
in	O
scn5a-m1851v	B-C0037492
channels	I-C0037492
.	O
	
furthermore	O
,	O
a	O
higher	O
upstroke	B-C0439830
velocity	I-C0439830
was	O
observed	O
for	O
the	O
scn5a-m1851v	B-C0037492
channels	I-C0037492
,	O
while	O
the	O
depolarization	B-C0598352
voltage	I-C0598352
was	O
more	O
negative	B-C0205160
,	O
both	O
indicating	O
increased	O
excitability	O
.	O
	
this	O
mutation	B-C0026882
leads	O
to	O
a	O
gain-of-function	B-C0441712
mechanism	I-C0441712
based	O
on	O
increased	O
channel	B-C0037492
availability	O
and	O
increased	O
window	B-C1705970
current	I-C1705970
,	O
fitting	O
the	O
observed	O
clinical	B-C0205210
phenotype	B-C0031437
of	O
likely	O
adrenergic-induced	O
ventricular	B-C0085612
arrhythmias	I-C0085612
and	O
atrial	B-C0004238
fibrillation	I-C0004238
.	O
	
these	O
findings	B-C0243095
further	O
expand	O
the	O
range	O
of	O
cardiac	B-C0003811
arrhythmias	I-C0003811
associated	O
with	O
mutations	B-C0026882
in	O
the	O
cancer	B-C0006826
warburg	B-C1520120
effect	I-C1520120
may	O
be	O
a	O
testable	B-C0332265
example	B-C1707959
of	O
the	O
minimum	B-C1524031
entropy	B-C0376522
production	B-C0392762
rate	I-C0392762
principle	B-C0178566
cancer	B-C0334227
cells	I-C0334227
consume	B-C0205245
more	O
glucose	B-C0017725
by	O
glycolytic	B-C1158288
fermentation	I-C1158288
to	O
lactate	B-C0376261
than	O
by	O
respiration	B-C0035203
,	O
a	O
characteristic	B-C1521970
known	O
as	O
the	O
warburg	B-C1520120
effect	I-C1520120
.	O
	
in	O
contrast	O
with	O
the	O
34	O
moles	B-C0439189
of	O
atp	B-C0001480
produced	O
by	O
respiration	B-C0035203
,	O
fermentation	B-C0015852
produces	O
two	O
moles	B-C0439189
of	O
atp	B-C0001480
per	O
mole	B-C0439189
of	O
glucose	B-C0017725
consumed	B-C0205245
,	O
which	O
poses	O
a	O
puzzle	O
on	O
the	O
function	B-C0542341
of	O
the	O
warburg	B-C1520120
effect	I-C1520120
.	O
	
productions	B-C0205245
of	O
free	B-C0678591
energy	I-C0678591
δg	B-C1637382
,	O
enthalpy	B-C0599530
δh	B-C1710184
and	O
entropy	B-C0376522
δs	B-C1710185
per	O
mole	B-C0439189
linearly	B-C0205132
vary	O
with	O
the	O
fraction	B-C1264633
x	I-C1264633
of	I-C1264633
glucose	B-C0017725
consumed	B-C0205245
by	O
fermentation	B-C0015852
that	O
is	O
frequently	B-C0332183
estimated	B-C0750572
around	O
0.9	O
.	O
	
hence	O
,	O
calculation	B-C1441506
shows	O
that	O
,	O
in	O
respect	O
to	O
pure	B-C0237400
respiration	B-C0035203
,	O
the	O
predominant	O
fermentative	B-C0015852
metabolism	B-C0025519
decreases	B-C0547047
around	O
10%	O
the	O
production	B-C0205245
of	O
entropy	B-C0376522
per	O
mole	B-C0439189
of	O
glucose	B-C0017725
consumed	B-C0205245
in	O
cancer	B-C0334227
cells	I-C0334227
.	O
	
we	O
hypothesize	B-C1512571
that	O
increased	B-C0205217
fermentation	B-C0015852
could	O
allow	O
cancer	B-C0334227
cells	I-C0334227
to	O
accomplish	B-C0205556
the	O
prigogine	B-C0282574
theorem	I-C0282574
of	O
the	O
trend	B-C1521798
to	O
minimize	B-C0392762
the	O
rate	B-C1521828
of	O
production	B-C0205245
of	O
entropy	B-C0376522
.	O
	
according	O
the	O
theorem	B-C0282574
,	O
open	B-C0007634
cellular	I-C0007634
systems	I-C0007634
near	O
the	O
steady	B-C0678587
state	I-C0678587
could	O
evolve	B-C1280477
to	O
minimize	B-C0392762
the	O
rates	B-C1521828
of	O
entropy	B-C0376522
production	B-C0205245
that	O
may	O
be	O
reached	O
by	O
modified	B-C0184511
replicating	B-C1883725
cells	B-C0007634
producing	O
entropy	B-C0376522
at	O
low	O
rate	B-C1521828
.	O
	
remarkably	O
,	O
at	O
co2	B-C0007012
concentrations	B-C1446561
above	O
930	O
ppm	B-C0439187
,	O
glucose	B-C0017725
respiration	B-C0035203
produces	O
less	O
entropy	B-C0376522
than	O
fermentation	B-C0015852
,	O
which	O
suggests	O
experimental	B-C1517586
tests	B-C0022885
to	O
validate	B-C1456348
the	O
hypothesis	B-C1512571
of	O
minimization	B-C0392762
of	O
the	O
rate	B-C1521828
of	O
entropy	B-C0376522
production	B-C0205245
through	O
the	O
warburg	B-C1520120
effect	I-C1520120
.	O
	
potential	B-C3245505
drug-drug	B-C0687133
interactions	I-C0687133
among	O
prescriptions	B-C0033080
for	O
elderly	B-C0001792
patients	B-C0030705
in	O
primary	B-C0033137
health	I-C0033137
care	I-C0033137
elderly	B-C0001792
patients	B-C0030705
are	O
at	O
high	B-C0332167
risk	I-C0332167
from	O
drug-drug	B-C0687133
interactions	I-C0687133
ddis	B-C0687133
.	O
	
this	O
study	B-C2603343
evaluates	B-C0220825
the	O
potential	B-C3245505
ddis	B-C0687133
in	O
turkish	O
elderly	B-C0001792
patients	B-C0030705
at	O
a	O
primary	B-C0033137
health	I-C0033137
care	I-C0033137
outpatient	B-C0029916
clinic	I-C0029916
.	O
	
online	B-C0242356
database	I-C0242356
systems	I-C0242356
were	O
used	O
to	O
examine	O
ddis	B-C0687133
on	O
the	O
prescriptions	B-C0033080
of	O
patients	B-C0030705
n	O
=	O
1206	O
.	O
	
the	O
clinical	B-C1836458
severity	I-C1836458
of	O
ddis	B-C0687133
was	O
classified	O
by	O
the	O
lexi-interact	B-C0242356
online	I-C0242356
database	I-C0242356
.	O
	
of	O
the	O
5059	O
prescriptions	B-C0033080
,	O
33%	O
were	O
found	O
to	O
have	O
ddis	B-C0687133
.	O
	
we	O
detected	B-C0442726
29	O
0.9	O
a	O
,	O
380	O
11.8	O
b	O
,	O
2494	O
77.7	O
c	O
,	O
289	O
9%	O
d	O
,	O
and	O
18	O
0.6	O
x	O
risk	O
rating	O
category	O
ddis	B-C0687133
among	O
the	O
prescriptions	B-C0033080
.	O
	
prescriptions	B-C0033080
of	O
female	O
patients	B-C0030705
and	O
patients	B-C0030705
aged	O
between	O
65	O
and	O
72	O
years	O
showed	O
significantly	B-C4055637
higher	I-C4055637
number	O
of	O
ddis	B-C0687133
.	O
	
the	O
frequency	B-C0205212
of	O
ddis	B-C0687133
increased	B-C0205217
both	O
with	O
the	O
number	O
of	O
drugs	B-C1254351
and	O
combined	O
preparations	O
per	O
prescription	B-C0033080
.	O
	
acetylsalicylic	B-C0004057
acid	I-C0004057
and	O
salbutamol	B-C0001927
were	O
the	O
most	O
frequently	B-C0332183
prescribed	B-C0278329
drugs	B-C1254351
contributing	O
to	O
clinically	B-C0243095
important	I-C0243095
ddis	B-C0687133
.	O
	
additionally	O
,	O
acetylsalicylic	B-C0004057
acid	I-C0004057
and	O
escitalopram	B-C1099456
,	O
which	O
interact	B-C1704675
with	O
each	O
other	O
,	O
were	O
found	O
on	O
the	O
list	O
of	O
beers	B-C4042847
criteria	I-C4042847
.	O
	
the	O
most	O
predicted	B-C1333602
clinical	I-C1333602
outcomes	I-C1333602
of	O
ddis	B-C0687133
were	O
increase	O
in	O
therapeutic	B-C2348767
efficacy	I-C2348767
and	O
adverse	B-C0559546
/	O
toxic	B-C0542243
reactions	I-C0542243
.	O
	
conclusions	O
prediction	B-C0681842
of	O
ddis	B-C0687133
in	O
elderly	B-C0001792
patients	B-C0030705
will	O
provide	O
better	O
prescribing	B-C0033080
and	O
drug	B-C0678800
safety	I-C0678800
.	O
	
use	O
of	O
nonsteroidal	B-C0003211
anti-inflammatory	I-C0003211
agents	I-C0003211
,	O
selective	B-C0360105
serotonin	I-C0360105
reuptake	I-C0360105
inhibitors	I-C0360105
,	O
and	O
beta-2	B-C2936789
adrenergic	I-C2936789
receptor	I-C2936789
agonists	I-C2936789
discontinued	B-C1444662
splenogonadal	B-C0266636
fusion	I-C0266636
and	O
bilateral	B-C1261504
empty	I-C1261504
scrotum	I-C1261504
in	O
an	O
18-	O
month	B-C1510828
-old	O
boy	B-C0870221
splenogonadal	B-C0266636
fusion	I-C0266636
is	O
a	O
rare	B-C0522498
benign	O
congenital	B-C0000768
anomaly	I-C0000768
defined	O
as	O
the	O
presence	O
of	O
splenic	B-C0771377
tissue	I-C0771377
adherent	B-C0334154
to	O
gonads	B-C0018067
.	O
	
it	O
was	O
first	O
described	O
in	O
1883	O
by	O
bostroem	B-C0086418
,	O
a	O
german	B-C1556085
pathologist	B-C0334866
.	O
	
we	O
present	O
a	O
case	B-C1706256
of	O
an	O
18-	O
month	B-C1510828
-old	O
boy	B-C0870221
who	O
was	O
referred	O
as	O
a	O
case	B-C1706256
of	O
bilateral	B-C1261504
empty	I-C1261504
scrotum	I-C1261504
since	O
birth	O
.	O
	
during	O
routine	B-C0205547
laparoscopic	B-C0521291
exploration	B-C1280903
,	O
right	B-C0228039
vas	I-C0228039
deferens	I-C0228039
and	O
testicular	B-C4266473
vessels	I-C4266473
were	O
entering	O
the	O
right	B-C0932530
internal	I-C0932530
inguinal	I-C0932530
ring	I-C0932530
so	O
right	B-C0230318
inguinal	I-C0230318
exploration	B-C1280903
was	O
done	O
,	O
which	O
revealed	O
blind	B-C0243095
ending	I-C0243095
vas	B-C0042360
deferens	I-C0042360
and	O
testicular	B-C4266473
vessels	I-C4266473
and	O
the	O
left	B-C0227998
testis	I-C0227998
was	O
found	O
intra-abdominally	B-C1512910
near	O
the	O
left	O
internal	B-C1512866
ring	I-C1512866
with	O
a	O
mass	B-C0577573
on	O
its	O
upper	B-C0227991
pole	I-C0227991
.	O
	
wedge	B-C0192152
biopsy	I-C0192152
was	O
taken	O
from	O
the	O
upper	B-C0227991
pole	I-C0227991
of	I-C0227991
the	I-C0227991
testicle	I-C0227991
site	B-C1515974
of	O
the	O
mass	B-C0577573
for	O
tissue	B-C1546905
diagnosis	I-C1546905
followed	O
by	O
orchidopexy	B-C0194907
.	O
	
histology	B-C0344441
showed	O
splenic	B-C0771377
tissue	I-C0771377
.	O
	
although	O
splenogonadal	B-C0266636
fusion	I-C0266636
is	O
a	O
rare	B-C0522498
condition	B-C0012634
,	O
surgeons	B-C0582175
should	O
be	O
aware	O
of	O
this	O
rare	B-C0678236
disease	I-C0678236
entity	O
to	O
avoid	O
unnecessary	B-C0376708
aggressive	O
interventions	B-C0808232
such	O
as	O
real-world	B-C4049986
impact	I-C4049986
of	O
non-breast	B-C1408354
cancer-specific	I-C1408354
death	I-C1408354
on	O
overall	B-C4086681
survival	I-C4086681
in	O
resectable	B-C1514888
breast	B-C0006142
cancer	I-C0006142
the	O
real-world	O
occurrence	B-C1521828
rate	I-C1521828
of	O
non-breast	B-C1408354
cancer-specific	I-C1408354
death	I-C1408354
non-bcsd	B-C1408354
and	O
its	O
impact	B-C4049986
on	O
patients	B-C0030705
with	O
breast	B-C0006142
cancer	I-C0006142
are	O
poorly	O
recognized	O
.	O
	
women	B-C0043210
with	O
resectable	B-C1514888
breast	B-C0006142
cancer	I-C0006142
from	O
1990	O
to	O
2007	O
in	O
the	O
surveillance	B-C0242638
,	O
epidemiology	I-C0242638
,	O
and	I-C0242638
end	I-C0242638
results	I-C0242638
database	I-C0242638
n	O
=	O
199	O
were	O
analyzed	B-C0936012
.	O
	
the	O
outcome	B-C1274040
events	B-C0441471
of	O
breast	B-C0006142
cancer	I-C0006142
were	O
classified	O
as	O
breast	B-C1516192
cancer-specific	I-C1516192
death	I-C1516192
bcsd	B-C1516192
,	O
non-bcsd	B-C1408354
,	O
or	O
survival	B-C0038952
.	O
	
binary	B-C0206031
logistics	I-C0206031
was	O
used	O
to	O
estimate	B-C0750572
the	O
occurrence	B-C1521828
rates	I-C1521828
of	O
non-bcsd	B-C1408354
and	O
bcsd	B-C1516192
with	O
different	O
clinicopathological	B-C1521761
factors	I-C1521761
.	O
	
the	O
gray	B-C0282574
method	I-C0282574
was	O
used	O
to	O
measure	B-C0079809
the	O
cumulative	B-C0021149
incidence	I-C0021149
of	O
non-bcsd	B-C1408354
and	O
bcsd	B-C1516192
.	O
	
the	O
ratio	B-C0456603
of	O
non-bcsds	B-C1408354
to	O
all	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
and	O
stacked	B-C3272897
cumulative	B-C0021149
incidence	I-C0021149
function	B-C0681493
plots	I-C0681493
were	O
used	O
to	O
present	O
the	O
impact	B-C4049986
of	O
non-bcsd	B-C1408354
on	O
overall	B-C4086681
survival	I-C4086681
os	B-C4086681
.	O
	
models	B-C0010235
of	I-C0010235
cox	I-C0010235
proportional	I-C0010235
hazards	I-C0010235
regression	I-C0010235
and	O
competing	B-C0034980
risk	I-C0034980
regression	I-C0034980
were	O
compared	O
to	O
highlight	O
the	O
suitable	B-C3161035
model	I-C3161035
.	O
	
there	O
were	O
12	O
non-bcsds	B-C1408354
6.44	O
and	O
28	O
bcsds	B-C1516192
14.39	O
.	O
	
the	O
oldest	B-C0027362
age	I-C0027362
group	I-C0027362
>62	O
years	O
,	O
black	B-C0005680
race	I-C0005680
,	O
and	O
a	O
single	B-C4060922
or	I-C4060922
divorced	I-C4060922
marital	I-C4060922
status	I-C4060922
were	O
associated	B-C0332281
with	I-C0332281
more	O
non-bcsds	B-C1408354
.	O
	
with	O
adjustments	O
for	O
age	B-C0001779
,	O
a	O
hormone	B-C1562029
receptor-positive	I-C1562029
hor+	I-C1562029
status	I-C1562029
was	O
no	O
longer	O
related	O
to	O
increased	B-C0205217
non-bcsd	B-C1408354
s	O
.	O
	
in	O
patients	B-C0030705
with	O
grade	B-C0012634
1	I-C0012634
,	O
stage	I-C0012634
i	I-C0012634
disease	I-C0012634
and	O
an	O
hor+	B-C1562029
status	I-C1562029
as	O
well	O
as	O
the	O
oldest	O
subgroup	O
,	O
a	O
great	O
dilution	O
of	O
non-bcsd	B-C1408354
on	O
all	O
causes	B-C0007465
of	I-C0007465
death	I-C0007465
could	O
be	O
observed	O
,	O
and	O
this	O
led	O
to	O
incorrect	B-C3845771
interpretations	I-C3845771
.	O
	
the	O
inaccuracy	B-C0443236
,	O
caused	O
by	O
the	O
commonly	O
used	O
cox	B-C0010235
proportional	I-C0010235
hazards	I-C0010235
model	I-C0010235
,	O
could	O
be	O
corrected	O
by	O
a	O
competing	B-C0034980
risk	I-C0034980
model	I-C0034980
.	O
	
os	B-C4086681
was	O
largely	O
impaired	B-C0221099
by	O
non-bcsd	B-C1408354
during	O
early	O
breast	B-C0006142
cancer	I-C0006142
.	O
	
for	O
some	O
future	O
clinical	B-C0008976
trial	I-C0008976
planning	B-C1254363
,	O
especially	O
for	O
the	O
oldest	B-C0001795
patients	B-C0030705
and	O
those	O
with	O
hor+	B-C1562029
breast	B-C0006142
cancer	I-C0006142
,	O
non-bcsd	B-C1408354
should	O
be	O
considered	O
a	O
competing	B-C0814316
risk	I-C0814316
event	I-C0814316
.	O
	
cancer	O
2017	O
.	O
	
2017	O
american	B-C0002455
cancer	I-C0002455
society	I-C0002455
.	O
	
hip	B-C0019552
segmentation	B-C2697664
from	O
mri	B-C0024485
volumes	O
in	O
infants	B-C0021270
for	O
ddh	B-C0019555
diagnosis	B-C0011900
and	O
treatment	B-C0599880
planning	I-C0599880
diagnosis	B-C0011900
and	O
surgical	B-C1515089
management	I-C1515089
of	O
developmental	B-C0019555
dysplasia	I-C0019555
of	I-C0019555
the	I-C0019555
hip	I-C0019555
ddh	B-C0019555
relies	O
on	O
physical	B-C0031809
examination	I-C0031809
and	O
2d	O
ultrasound	B-C0041618
scanning	I-C0041618
.	O
	
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
mri	B-C0024485
can	O
be	O
used	O
to	O
complement	O
existing	O
techniques	B-C0449851
and	O
could	O
be	O
advantageous	O
in	O
treatment	B-C0599880
planning	I-C0599880
due	O
to	O
its	O
larger	O
field	O
of	O
view	O
.	O
	
in	O
this	O
paper	O
we	O
propose	O
a	O
semi-automatic	B-C0205554
method	B-C0025663
to	O
segment	B-C3161035
surface	I-C3161035
models	I-C3161035
of	O
the	O
acetabulum	B-C0000962
from	O
mri	B-C0024485
images	B-C1551337
.	O
	
the	O
method	B-C0025663
incorporates	O
clinical	B-C0205210
knowledge	B-C0376554
in	O
the	O
form	O
of	O
intensity	B-C0876936
priors	I-C0876936
which	O
are	O
integrated	O
into	O
a	O
random	B-C0002045
walker	I-C0002045
rw	I-C0002045
formulation	I-C0002045
.	O
	
we	O
use	O
a	O
modified	B-C0392747
rw	B-C0002045
framework	O
which	O
compensates	B-C0205432
for	O
incomplete	B-C0205257
or	O
blurred	B-C0205556
boundaries	B-C2828371
in	O
the	O
image	B-C1551337
by	O
using	O
information	B-C1533716
from	O
neighboring	B-C1254362
slices	I-C1254362
in	O
the	O
sequence	B-C1519249
incorporated	O
as	O
node	B-C0392762
weights	I-C0392762
.	O
	
we	O
conducted	O
a	O
pilot	B-C0031928
study	I-C0031928
to	O
evaluate	B-C0220825
the	O
segmentation	B-C2697664
on	O
a	O
set	O
of	O
10	O
infant	B-C0021270
hip	B-C0019552
mri	B-C0024485
sequences	B-C1519249
using	O
a	O
1.5	O
tesla	O
mr	B-C0183115
scanner	I-C0183115
.	O
	
contours	B-C0876954
obtained	O
from	O
the	O
semi-automated	B-C0205554
segmentation	B-C2697664
were	O
compared	B-C1707455
against	O
manually	B-C3842330
segmented	B-C2697664
hip	B-C0019552
contours	B-C0876954
using	O
dice	B-C0456603
ratio	I-C0456603
dr	B-C0456603
,	O
hausdorff	B-C0012751
distance	I-C0012751
hd	B-C0012751
and	O
root	B-C2347976
mean	I-C2347976
square	I-C2347976
rms	B-C2347976
distance	O
.	O
	
the	O
proposed	O
method	B-C0025663
gave	O
values	O
of	O
dr	B-C0456603
=	O
0.84	O
0.5	O
,	O
hd	B-C0012751
=3	O
0.7	O
,	O
rms	B-C2347976
=1	O
0.3	O
and	O
dr	B-C0456603
=0	O
0.2	O
,	O
hd	B-C0012751
=3	O
0.1	O
,	O
rms	B-C2347976
=	O
2.0	O
0.6	O
for	O
right	B-C0834313
and	O
left	B-C0834314
acetabular	I-C0834314
contours	I-C0834314
respectively	O
which	O
was	O
higher	B-C0205250
than	O
the	O
corresponding	O
values	O
obtained	O
from	O
conventional	B-C0439858
rw	B-C0002045
segmentation	B-C2697664
.	O
	
the	O
execution	B-C1705848
time	B-C0040223
of	O
the	O
segmentation	B-C2697664
algorithm	B-C0002045
was	O
less	O
than	O
4	O
seconds	B-C0457385
on	O
a	O
3.5	O
ghz	O
automated	O
basal	B-C0007117
cell	I-C0007117
carcinoma	I-C0007117
detection	O
in	O
high-definition	B-C0920367
optical	I-C0920367
coherence	I-C0920367
tomography	I-C0920367
basal	B-C0007117
cell	I-C0007117
carcinoma	I-C0007117
bcc	B-C0007117
is	O
the	O
most	O
common	O
non-melanoma	B-C0699893
skin	I-C0699893
cancer	I-C0699893
.	O
	
conventional	O
diagnosis	O
of	O
bcc	B-C0007117
requires	O
invasive	B-C0205281
biopsies	B-C0005558
.	O
	
recently	O
,	O
a	O
high-definition	B-C0920367
optical	I-C0920367
coherence	I-C0920367
tomography	I-C0920367
hd-oct	B-C0920367
technique	O
has	O
been	O
developed	O
,	O
which	O
provides	O
a	O
non-invasive	B-C0205303
in	B-C1708481
vivo	I-C1708481
imaging	I-C1708481
method	I-C1708481
of	O
skin	B-C1123023
.	O
	
good	O
agreements	O
of	O
bcc	B-C0007117
features	O
between	O
hd-oct	B-C0920367
images	B-C1551337
and	O
histopathological	B-C0243140
architecture	I-C0243140
have	O
been	O
found	O
.	O
	
therefore	O
it	O
is	O
possible	O
to	O
automatically	O
detect	O
bcc	B-C0007117
using	O
hd-oct	B-C0920367
.	O
	
this	O
paper	O
presents	O
a	O
novel	O
bcc	B-C0007117
detection	B-C0430022
method	I-C0430022
that	O
consists	O
of	O
four	O
steps	O
graph	O
based	O
skin	B-C1180212
surface	I-C1180212
segmentation	B-C0700381
,	O
surface	B-C0016203
flattening	I-C0016203
,	O
deep	O
feature	O
extraction	O
and	O
the	O
bcc	B-C0007117
classification	O
.	O
	
the	O
effectiveness	B-C1280519
of	O
the	O
proposed	O
method	O
is	O
well	O
demonstrated	O
on	O
a	O
dataset	O
of	O
5	O
images	O
.	O
	
it	O
can	O
therefore	O
serve	O
as	O
an	O
automatic	O
tool	O
for	O
screening	O
fall	B-C0085639
risk	B-C0035648
factors	I-C0035648
analysis	B-C0936012
based	O
on	O
sample	B-C0376522
entropy	I-C0376522
of	O
plantar	B-C0230463
kinematic	B-C1254365
signal	B-C1710082
during	O
stance	B-C2019827
phase	I-C2019827
falls	B-C0085639
are	O
a	O
multi-causal	B-C1882365
phenomenon	I-C1882365
with	O
a	O
complex	B-C0439855
interaction	B-C1704675
.	O
	
the	O
aim	O
of	O
our	O
research	B-C0035168
is	O
to	O
study	B-C2603343
the	O
effect	B-C1280500
of	O
multiple	B-C0439064
variables	B-C0439828
for	O
potential	B-C3245505
risk	B-C1268740
of	I-C1268740
falls	I-C1268740
and	O
construct	B-C2827421
an	O
elderly	B-C3161035
fall	I-C3161035
risk	I-C3161035
assessment	I-C3161035
model	I-C3161035
based	O
on	O
demographics	B-C0011298
data	B-C1511726
and	O
gait	B-C2045693
characteristics	I-C2045693
.	O
	
a	O
total	O
of	O
101	O
subjects	B-C2349001
,	O
whom	O
belong	O
to	O
malianwa	B-C0442658
street	I-C0442658
,	O
aged	B-C0001779
above	O
50	O
years	B-C1510829
old	I-C1510829
and	O
participated	B-C0679823
in	O
questionnaire	B-C0034394
survey	B-C0038951
.	O
	
participants	B-C0679646
were	O
classified	O
into	O
three	O
groups	B-C0441833
high	B-C0684030
,	O
medium	B-C2348561
and	O
low	B-C3538919
risk	I-C3538919
group	B-C0441833
according	O
to	O
the	O
score	B-C0449820
of	O
elderly	B-C0349674
fall	I-C0349674
risk	I-C0349674
assessment	I-C0349674
scale	I-C0349674
.	O
	
in	O
addition	O
,	O
the	O
data	B-C1511726
of	O
ground	B-C0336996
reaction	I-C0336996
force	I-C0336996
grf	B-C0336996
and	O
ground	B-C1254365
reaction	I-C1254365
moment	I-C1254365
grm	B-C1254365
was	O
record	B-C2355580
when	O
they	O
performed	B-C0884358
walking	B-C0080331
at	O
comfortable	B-C1822395
state	I-C1822395
.	O
	
the	O
demographic	B-C0683970
variables	B-C0439828
,	O
sample	B-C0376522
entropy	I-C0376522
of	O
grf	B-C0336996
and	O
grm	B-C1254365
,	O
and	O
impulse	B-C1705241
difference	I-C1705241
of	O
bilateral	B-C4299794
foot	I-C4299794
were	O
considered	O
as	O
potential	B-C3245505
explanatory	B-C0681841
variables	B-C0439828
of	O
risk	B-C0086930
assessment	I-C0086930
model	B-C3161035
.	O
	
firstly	O
,	O
we	O
investigated	B-C1292732
whether	O
different	O
groups	B-C0441833
could	O
present	O
difference	B-C1705241
in	O
every	O
variable	B-C0439828
.	O
	
statistical	B-C1705241
differences	I-C1705241
were	O
found	B-C0150312
for	O
the	O
following	O
variables	B-C0439828
age	B-C0001779
p=2	O
impulse	B-C1705241
difference	I-C1705241
p=0	O
sample	B-C0376522
entropy	I-C0376522
of	O
grf	B-C0336996
in	O
vertical	B-C0205128
direction	B-C0449738
p=0	O
sample	B-C0376522
entropy	I-C0376522
of	O
grm	B-C1254365
in	O
anterior-posterior	B-C1999039
direction	B-C0449738
p=0	O
.	O
	
finally	O
,	O
the	O
multiple	B-C0439064
regression	B-C0034980
analysis	I-C0034980
results	B-C1274040
indicated	B-C1444656
that	O
age	B-C0001779
,	O
impulse	B-C1705241
difference	I-C1705241
and	O
sample	B-C0376522
entropy	I-C0376522
of	O
resultant	O
grm	B-C1254365
could	O
identify	O
individuals	B-C0237401
who	O
had	O
different	O
levels	B-C1532976
of	I-C1532976
fall	I-C1532976
risk	I-C1532976
.	O
	
therefore	O
,	O
those	O
results	B-C1274040
could	O
potentially	B-C3245505
be	O
useful	B-C3827682
in	O
the	O
fall	B-C1532976
risk	I-C1532976
assessment	I-C1532976
and	O
monitor	B-C0150369
the	O
state	B-C1442792
of	O
physical	B-C0516981
function	I-C0516981
in	O
elderly	B-C0001792
population	I-C0001792
.	O
	
endurance	B-C0518031
based	O
personalized	B-C0282574
fitness	I-C0282574
planner	I-C0282574
endurance	B-C0518031
is	O
an	O
important	B-C3898777
factor	B-C1521761
of	O
cardiovascular	B-C2981722
fitness	I-C2981722
indicating	O
the	O
capacity	B-C1516240
of	O
an	O
individual	B-C0237401
to	O
perform	B-C0884358
exercise	B-C0015259
for	O
a	O
longer	B-C0449238
duration	I-C0449238
with	O
increased	B-C0205217
intensity	B-C0522510
.	O
	
various	O
subject	B-C0205369
specific	I-C0205369
and	O
exercise	B-C0015259
related	O
parameters	B-C0549193
affect	O
endurance	B-C0518031
of	O
an	O
individual	B-C0237401
.	O
	
in	O
this	O
work	O
,	O
we	O
propose	O
a	O
statistical	B-C1710191
technique	I-C1710191
to	O
model	B-C3161035
endurance	B-C0518031
as	O
a	O
function	O
of	O
these	O
factors	B-C1521761
incorporating	O
the	O
serial	O
dependence	O
of	O
observations	B-C0302523
generated	O
by	O
individuals	B-C0237401
over	B-C0040223
time	I-C0040223
.	O
	
the	O
proposed	B-C1553874
model	B-C3161035
provides	O
a	O
device	B-C0025080
to	O
predict	O
future	O
endurance	B-C0518031
of	O
a	O
test	O
subject	B-C0681850
following	O
particular	O
exercise	B-C0454291
regime	I-C0454291
.	O
	
this	O
facilitates	O
a	O
test	B-C1548600
user	I-C1548600
with	O
a	O
fitness	B-C0282574
planner	I-C0282574
with	O
the	O
provision	O
to	O
fix	O
exercise	B-C0454291
regimes	I-C0454291
to	O
reach	O
a	O
set	O
fitness	B-C1456706
goal	B-C0018017
.	O
	
heart	B-C0018810
rate	I-C0018810
variability	B-C2827666
as	O
a	O
biomarker	B-C0005516
for	O
sedation	B-C0235195
depth	I-C0235195
estimation	B-C0750572
in	O
icu	B-C0021708
patients	B-C0030705
an	O
automated	B-C0596139
patient-specific	I-C0596139
system	I-C0596139
to	O
classify	O
the	O
level	B-C2226609
of	I-C2226609
sedation	I-C2226609
in	O
icu	B-C0021708
patients	B-C0030705
using	O
heart	B-C0018810
rate	I-C0018810
variability	B-C2827666
signal	B-C1710082
is	O
presented	B-C0449450
in	O
this	O
paper	B-C0282420
.	O
	
ecg	B-C0013798
from	O
70	O
mechanically	B-C0199470
ventilated	I-C0199470
adult	B-C0001675
patients	B-C0030705
with	O
administered	B-C1521801
sedatives	B-C0036557
in	O
an	O
icu	B-C0021708
setting	I-C0021708
were	O
used	O
to	O
develop	O
a	O
support	B-C2699740
vector	I-C2699740
machine	I-C2699740
based	O
system	O
for	O
sedation	B-C0235195
depth	I-C0235195
monitoring	B-C1283169
using	O
several	O
heart	B-C0018810
rate	I-C0018810
variability	B-C2827666
measures	B-C0079809
.	O
	
a	O
leave-one-subject-out	B-C0681935
cross	I-C0681935
validation	I-C0681935
was	O
used	O
for	O
classifier	B-C4291659
training	B-C0040607
and	O
performance	B-C1882330
evaluations	B-C0220825
.	O
	
the	O
proposed	O
patient-specific	B-C0596139
system	I-C0596139
provided	B-C1999230
a	O
sensitivity	B-C0036667
,	O
specificity	B-C0037791
and	O
an	O
auc	B-C0376690
of	O
64%	O
,	O
84.8	O
and	O
0.72	O
,	O
respectively	O
.	O
	
it	O
is	O
hoped	O
that	O
with	O
the	O
help	O
of	O
additional	O
physiological	B-C0205463
signals	B-C1710082
the	O
proposed	O
patient	B-C0030705
-	O
specific	B-C0205369
sedation	B-C2226609
level	I-C2226609
prediction	B-C0681842
system	B-C0449913
could	O
lead	O
to	O
a	O
fully	O
automated	B-C0596139
multimodal	I-C0596139
system	I-C0596139
to	O
assist	O
clinical	B-C0205210
staff	B-C0851286
in	O
icus	B-C0021708
to	O
interpret	B-C1285553
the	O
sedation	B-C2226609
level	I-C2226609
of	O
the	O
reliability	B-C0035036
and	I-C0035036
validity	I-C0035036
of	O
the	O
diabetes	B-C0012158
eating	I-C0012158
problem	I-C0012158
survey-revised	I-C0012158
on	O
turkish	B-C0549217
children	B-C0008059
and	O
adolescents	B-C0205653
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
mellitus	I-C0011854
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
examine	B-C1292732
the	O
reliability	B-C0035036
and	I-C0035036
validity	I-C0035036
of	O
turkish	B-C0549217
version	B-C0333052
of	O
diabetes	B-C0012158
eating	I-C0012158
problem	I-C0012158
survey-revised	I-C0012158
deps-r	B-C0012158
for	O
children	B-C0008059
and	O
adolescent	B-C0205653
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
mellitus	I-C0011854
.	O
	
a	O
total	O
of	O
200	O
children	B-C0008059
and	O
adolescents	B-C0205653
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
,	O
ages	B-C0001779
9-18	O
years	B-C0439234
,	O
completed	O
the	O
deps-r	B-C0012158
turkish	B-C0549217
version	B-C0333052
.	O
	
in	O
addition	O
to	O
tests	B-C0039593
of	O
validity	B-C2349101
,	O
confirmatory	B-C0870334
factor	I-C0870334
analysis	I-C0870334
was	O
conducted	O
to	O
investigate	B-C1292732
the	O
factor	B-C0870541
structure	I-C0870541
of	O
the	O
16-item	O
turkish	B-C0549217
version	B-C0333052
of	O
deps-r	B-C0012158
.	O
	
the	O
turkish	B-C0549217
version	B-C0333052
of	O
deps-r	B-C0012158
demonstrated	O
satisfactory	B-C0205410
cronbach's	B-C0870731
0.847	O
and	O
was	O
significantly	O
correlated	B-C1707520
with	O
ag	B-C0001779
e	O
r=0	O
p<0	O
,	O
hemoglobin	B-C1261236
a1c	I-C1261236
levels	I-C1261236
r=0	O
p<0	O
and	O
bmi	B-C1305855
-	O
sds	B-C0449820
r=0	O
p<0	O
indicating	O
criterion	B-C2699472
validity	I-C2699472
.	O
	
median	O
deps-r	B-C0012158
scores	B-C0449820
of	O
turkish	B-C0549217
version	B-C0333052
for	O
the	O
total	O
samples	B-C1257890
,	O
females	B-C0086287
and	O
males	B-C0086582
were	O
as	O
follows	O
11.0	O
,	O
11.5	O
and	O
10.5	O
respectively	O
.	O
	
disturbed	B-C4062871
eating	I-C4062871
behaviors	I-C4062871
and	O
insulin	B-C0021641
restriction	B-C0443288
were	O
associated	O
with	O
poor	O
metabolic	B-C1513158
control	I-C1513158
.	O
	
a	O
short	O
,	O
self-administered	B-C1519231
diabetes	B-C0011854
specific	O
screening	B-C1710032
tool	O
for	O
disordered	B-C4062871
eating	I-C4062871
behavior	I-C4062871
can	O
be	O
used	O
routinely	O
in	O
the	O
clinical	B-C0205210
care	B-C0086388
of	O
adolescents	B-C0205653
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
.	O
	
the	O
turkish	B-C0549217
version	B-C0333052
of	O
deps-r	B-C0012158
is	O
a	O
valid	O
screening	B-C1710032
tool	O
for	O
disordered	B-C4062871
eating	I-C4062871
behaviors	I-C4062871
in	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
and	O
it	O
is	O
potentially	O
important	O
to	O
early	O
detect	O
disordered	B-C4062871
eating	I-C4062871
behaviors	I-C4062871
.	O
	
a	O
comparison	B-C1707455
of	O
the	O
localization	B-C0475264
of	O
rectal	B-C0007113
carcinomas	I-C0007113
according	O
to	O
the	O
general	B-C0205246
rules	B-C0870077
of	O
the	O
japanese	B-C0008902
classification	I-C0008902
of	I-C0008902
colorectal	I-C0008902
carcinoma	I-C0008902
jccrc	B-C0008902
and	O
western	B-C1705493
guidelines	B-C0162791
the	O
aim	B-C1947946
of	O
this	O
study	O
was	O
to	O
compare	B-C1707455
the	O
localization	B-C0475264
of	O
rectal	B-C0007113
cancers	I-C0007113
as	O
classified	B-C0008902
according	O
to	O
the	O
general	B-C0205246
rules	B-C0870077
of	O
the	O
japanese	B-C0008902
classification	I-C0008902
of	I-C0008902
colorectal	I-C0008902
carcinoma	I-C0008902
jccrc	B-C0008902
and	O
also	O
according	O
to	O
the	O
european	B-C1708333
society	I-C1708333
for	I-C1708333
medical	I-C1708333
oncology	I-C1708333
esmo	B-C1708333
and	O
the	O
national	B-C1513893
comprehensive	I-C1513893
cancer	I-C1513893
network	I-C1513893
nccn	B-C1513893
guidelines	B-C0162791
,	O
which	O
are	O
based	O
on	O
rigid	B-C0014245
endoscopic	I-C0014245
measurements	B-C0242485
.	O
	
the	O
medical	B-C0025102
records	I-C0025102
of	O
patients	B-C0030705
scheduled	B-C0205539
to	O
receive	B-C1514756
curative	B-C1511562
surgery	I-C1511562
for	O
histologically	B-C0205462
proven	O
rectal	B-C0149978
adenocarcinoma	I-C0149978
during	B-C0347984
2009-2015	O
were	O
investigated	B-C1292732
n	O
=	O
230	O
.	O
	
rigid	B-C0033251
proctoscopy	I-C0033251
was	O
performed	B-C0884358
in	O
patients	B-C0030705
with	O
rectal	B-C0007113
cancer	I-C0007113
located	B-C0332285
in	I-C0332285
the	O
upper	B-C1282910
ra	B-C1282910
or	O
lower	B-C0441994
rb	B-C0441994
division	B-C1293097
using	O
double-contrast	B-C0412118
barium	I-C0412118
enema	I-C0412118
.	O
	
the	O
median	B-C0876920
values	O
of	O
height	B-C0489786
from	O
the	O
anal	B-C0227423
verge	I-C0227423
were	O
7.5	O
cm	O
range	B-C1514721
2-12	O
and	O
3	O
cm	O
0-9	O
on	O
rigid	B-C0033251
proctoscopy	I-C0033251
for	O
cancers	B-C0006826
assigned	B-C1516050
as	O
ra	B-C1282910
and	O
rb	B-C0441994
,	O
respectively	O
.	O
	
all	O
159	O
cancers	B-C0006826
at	O
ra	B-C1282910
or	O
rb	B-C0441994
were	O
located	B-C0332285
within	B-C0332285
12	O
cm	O
from	O
the	O
anal	B-C0227423
verge	I-C0227423
by	O
rigid	B-C0033251
proctoscopy	I-C0033251
,	O
while	O
only	O
79.7	O
of	O
ra	B-C1282910
or	O
82.1	O
of	O
rb	B-C0441994
cancers	B-C0006826
were	O
located	B-C0332285
in	I-C0332285
the	O
mid	B-C0444598
5.1	O
cm	O
or	O
low	B-C0205251
5	O
cm	O
rectum	B-C0034896
,	O
respectively	O
.	O
	
ra	B-C1282910
and	O
rb	B-C0441994
cancers	B-C0006826
are	O
deemed	O
to	O
be	O
rectal	B-C0007113
cancers	I-C0007113
according	O
to	O
nccn	B-C1513893
guidelines	B-C0162791
,	O
but	O
these	O
classifications	B-C0008902
are	O
not	O
interchangeable	O
with	O
mid-	B-C0444598
and	O
low	B-C0205251
-	O
rectal	B-C0007113
cancers	I-C0007113
,	O
respectively	O
,	O
according	O
to	O
the	O
esmo	B-C1708333
guidelines	B-C0162791
.	O
	
natural	B-C2936208
orifice	I-C2936208
transluminal	I-C2936208
endoscopic	I-C2936208
surgery	I-C2936208
with	O
a	O
snake-mechanism	B-C0441712
using	O
a	O
movable	B-C1709769
pulley	I-C1709769
natural	B-C2936208
orifice	I-C2936208
transluminal	I-C2936208
endoscopic	I-C2936208
surgery	I-C2936208
is	O
an	O
emerging	O
technique	B-C0449851
.	O
	
we	O
aimed	O
to	O
develop	B-C1527148
an	O
advanced	B-C0205179
surgical	B-C3204163
robot	I-C3204163
mechanism	B-C0441712
for	O
natural	B-C2936206
orifice	I-C2936206
surgery	I-C2936206
.	O
	
we	O
propose	O
the	O
active-controlled	B-C1710360
overtube-type	I-C1710360
platform	I-C1710360
with	O
multiple	O
channels	B-C0439799
for	O
an	O
endoscopic	B-C0179535
camera	I-C0179535
and	O
surgical	B-C0543467
tools	B-C0336791
.	O
	
to	O
make	O
such	O
a	O
platform	B-C1710360
,	O
we	O
suggest	B-C1705535
an	O
advanced	B-C0205179
snake	B-C0441712
mechanism	I-C0441712
comprising	O
movable	B-C1709769
pulleys	I-C1709769
to	O
make	O
a	O
snake	B-C0441712
mechanism	I-C0441712
with	O
multiple	O
degrees	B-C0205245
of	I-C0205245
freedom	I-C0205245
and	O
high	O
operating	O
force	O
.	O
	
the	O
stiffness	B-C0205556
and	O
maneuverability	B-C0205556
of	O
the	O
active-controlled	B-C1710360
platform	I-C1710360
appeared	O
satisfactory	B-C0205410
.	O
	
using	O
prototypes	B-C3161035
and	O
ex	B-C2348480
vivo	I-C2348480
experiments	B-C0681814
,	O
we	O
confirmed	O
that	O
the	O
mechanism	B-C0441712
was	O
suitable	O
for	O
a	O
snake-like	B-C0336537
robotic	I-C0336537
platform	B-C1710360
for	O
natural	B-C2936206
orifice	I-C2936206
surgery	I-C2936206
.	O
	
the	O
suggested	B-C1705535
snake	B-C0441712
mechanism	I-C0441712
using	O
movable	B-C1709769
pulleys	I-C1709769
has	O
the	O
advantages	O
of	O
stiffness	B-C0205556
and	O
maneuverability	B-C0205556
.	O
	
this	O
new	O
mechanism	B-C0441712
can	O
be	O
an	O
alternative	B-C1523987
platform	B-C1710360
for	O
natural	B-C2936206
orifice	I-C2936206
surgery	I-C2936206
.	O
	
real	O
role	O
of	O
β-blockers	B-C0001645
in	O
regression	B-C0597370
of	O
left	B-C0455825
ventricular	I-C0455825
mass	I-C0455825
in	O
hypertension	B-C0020538
patients	B-C0030705
bayesian	B-C0026348
network	I-C0026348
meta-analysis	B-C0920317
left	B-C0149721
ventricular	I-C0149721
hypertrophy	I-C0149721
lvh	B-C0149721
is	O
commonly	O
present	O
in	O
patients	B-C0030705
with	O
hypertension	B-C0020538
ht	B-C0020538
.	O
	
according	O
to	O
the	O
expert	B-C1301746
consensus	I-C1301746
document	I-C1301746
from	O
american	B-C0596070
,	O
angiotensin-converting	B-C0003015
enzyme	I-C0003015
inhibitor	I-C0003015
acei	B-C0003015
and	O
angiotensin	B-C0815017
receptor	I-C0815017
blockers	I-C0815017
arbs	B-C0815017
were	O
recommended	O
as	O
1st-line	O
therapeutic	B-C0013227
drugs	I-C0013227
.	O
	
however	O
,	O
none	O
noticed	O
the	O
different	O
efficacy	B-C1280519
between	O
fat-soluble	B-C0304516
and	I-C0304516
selective	I-C0304516
β1-receptor	I-C0304516
blockers	I-C0304516
fs-β-b	B-C0304516
and	O
other	O
β-blockers	B-C0001645
on	O
regression	B-C0597370
of	O
lvh	B-C0149721
before	O
.	O
	
the	O
aim	O
of	O
this	O
analysis	B-C0920317
was	O
to	O
compare	B-C1707455
the	O
efficacy	B-C1280519
of	O
fs-β-b	B-C0304516
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	B-C0003364
drugs	I-C0003364
acei	B-C0003015
,	O
arbs	B-C0815017
,	O
calcium	B-C0006684
channel	I-C0006684
blockers	I-C0006684
ccbs	B-C0006684
,	O
and	O
diuretics	B-C0012798
on	O
regression	B-C0597370
of	O
lvh	B-C0149721
.	O
	
relative	B-C0205345
trials	B-C0008976
were	O
identified	O
in	O
the	O
pubmed	B-C1138432
,	O
web	B-C2349146
of	I-C2349146
science	I-C2349146
,	O
ovid	B-C0282443
ebm	I-C0282443
reviews	I-C0282443
and	O
cochrane	B-C0242356
databases	I-C0242356
,	O
and	O
the	O
relevant	O
papers	B-C1706852
were	O
examined	B-C1292732
.	O
	
we	O
performed	O
both	O
traditional	O
and	O
bayesian	B-C0026348
meta-analysis	B-C0920317
of	O
randomized	B-C0206035
controlled	I-C0206035
trials	I-C0206035
rcts	B-C0206035
about	O
the	O
regression	B-C0597370
of	O
lvh	B-C0149721
.	O
	
sensitivity	B-C0936012
analysis	I-C0936012
and	O
regression	B-C0034980
analysis	I-C0034980
were	O
performed	O
to	O
explore	O
possible	O
sources	O
of	O
heterogeneity	B-C0019409
.	O
	
inconsistency	B-C0936012
analysis	I-C0936012
was	O
performed	O
to	O
check	O
whether	O
the	O
analysis	B-C0920317
of	O
the	O
trials	B-C0008976
in	O
the	O
network	B-C0026348
was	O
indeed	O
consistent	B-C0332290
.	O
	
a	O
total	O
of	O
41	O
rcts	B-C0206035
involving	O
2566	O
patients	B-C0030705
with	O
ht	B-C0020538
and	O
lvh	B-C0149721
were	O
included	O
in	O
this	O
analysis	B-C0920317
.	O
	
bayesian	B-C0026348
network	I-C0026348
meta-analysis	B-C0920317
indicated	O
no	O
statistically	B-C0237881
significant	I-C0237881
differences	O
between	O
these	O
groups	B-C0441833
fs-β-b	B-C0304516
and	O
acei	B-C0003015
md	O
,	O
-7	O
95%	O
ci	B-C0009667
,	O
-14	O
,	O
1.27	O
fs-β-b	B-C0304516
and	O
arb	B-C0815017
md	O
,	O
-2	O
95%	O
cl	B-C0009667
,	O
-12	O
,	O
6.31	O
.	O
	
although	O
fs-β-b	B-C0304516
showed	O
greater	O
efficacy	B-C1280519
when	O
compared	B-C1707455
with	O
diuretic	B-C0012798
md	O
,	O
13.04	O
95%	O
ci	B-C0009667
,	O
3.38	O
,	O
22.59	O
or	O
ccb	B-C0006684
md	O
,	O
10.90	O
95%	O
ci	B-C0009667
,	O
1.98	O
,	O
19.49	O
.	O
	
the	O
probabilities	B-C0033204
of	O
being	O
among	O
the	O
most	O
efficacious	B-C1280519
treatments	B-C0087111
were	O
fs-β-b	B-C0304516
72%	O
,	O
arb	B-C0815017
27%	O
,	O
acei	B-C0003015
0.01	O
,	O
ccb	B-C0006684
0.00	O
,	O
and	O
diuretic	B-C0012798
0.00	O
.	O
	
evidence	O
from	O
our	O
analysis	B-C0920317
reveals	O
that	O
fs-β-b	B-C0304516
have	O
potential	O
to	O
become	O
1st-line	O
therapeutic	B-C0013227
drugs	I-C0013227
in	O
ht	B-C0020538
and	O
lvh	B-C0149721
patients	B-C0030705
.	O
	
however	O
,	O
the	O
real	O
efficacy	B-C1280519
of	O
fs-β-b	B-C0304516
on	O
regression	B-C0597370
of	O
lvh	B-C0149721
should	O
be	O
confirmed	O
by	O
further	O
large	O
,	O
high	O
quality	B-C0332306
trials	B-C0008976
improved	B-C0184511
risk	B-C0035647
stratification	B-C1514983
for	O
patients	B-C0030705
with	O
high-grade	O
urothelial	B-C2145472
carcinoma	I-C2145472
following	O
application	O
of	O
the	O
paris	B-C0030561
system	B-C0449913
for	O
reporting	B-C0700287
urinary	B-C2979983
cytology	I-C2979983
the	O
paris	B-C0030561
system	B-C0449913
for	O
reporting	B-C0700287
urinary	B-C2979983
cytology	I-C2979983
tps	B-C2979983
requires	O
4	O
cytomorphologic	B-C0243092
criteria	B-C0243161
for	O
a	O
definitive	O
diagnosis	B-C0011900
of	O
high-grade	B-C2145472
urothelial	I-C2145472
carcinoma	I-C2145472
hguc	B-C2145472
in	O
urinary	B-C2979983
tract	I-C2979983
cytology	I-C2979983
utc	B-C2979983
specimens	B-C0370003
an	O
elevated	B-C3163633
nuclear-to-cytoplasmic	B-C0333907
n/c	I-C0333907
ratio	I-C0333907
at	O
or	O
above	O
0.7	O
,	O
markedly	O
atypical	B-C0205182
nuclear	B-C0007610
borders	B-C0205284
,	O
moderate	B-C0205081
to	O
severe	B-C0205082
hyperchromasia	B-C0333910
,	O
and	O
coarse	B-C1868540
chromatin	I-C1868540
.	O
	
however	O
,	O
malignant	B-C0205282
utc	B-C2979983
specimens	B-C0370003
often	O
contain	O
degenerative	B-C1880269
changes	B-C0392747
,	O
and	O
this	O
limits	O
the	O
number	O
of	O
malignant	B-C0334227
cells	I-C0334227
meeting	O
all	O
4	O
tps	B-C2979983
cytomorphologic	B-C0243092
criteria	B-C0243161
.	O
	
one	O
hundred	O
twelve	O
utc	B-C2979983
specimens	B-C0370003
from	O
patients	B-C0030705
with	O
a	O
subsequent	O
diagnosis	B-C0011900
of	O
hguc	B-C2145472
were	O
reviewed	B-C1709940
and	O
reclassified	B-C0205542
according	O
to	O
tps	B-C2979983
criteria	B-C0243161
.	O
	
the	O
presence	B-C0150312
of	O
tps	B-C2979983
cytomorphologic	B-C0243092
criteria	B-C0243161
for	O
hguc	B-C2145472
in	O
each	O
specimen	B-C0370003
was	O
recorded	O
,	O
as	O
was	O
the	O
proportion	O
of	O
atypical	B-C0205182
cells	B-C0007634
meeting	O
all	O
4	O
criteria	B-C0243161
.	O
	
the	O
number	O
of	O
specimens	B-C0370003
definitively	O
diagnosed	B-C0011900
as	O
hguc	B-C2145472
did	O
not	O
significantly	B-C0750502
change	B-C0392747
upon	O
reclassification	B-C0008902
.	O
	
however	O
,	O
approximately	B-C0332232
40%	O
of	O
indeterminate	B-C0205258
specimens	B-C0370003
21	O
of	O
51	O
were	O
reclassified	B-C0205542
into	O
a	O
higher	O
risk	B-C0035647
category	B-C0683312
.	O
	
the	O
most	O
restrictive	O
cytomorphologic	B-C0243092
criterion	O
was	O
an	O
n/c	B-C0333907
ratio	I-C0333907
of	O
0.7	O
or	O
higher	O
seen	O
in	O
78%	O
of	O
specimens	B-C0370003
,	O
and	O
approximately	B-C0332232
half	O
of	O
specimens	B-C0370003
containing	O
all	O
4	O
cytomorphologic	O
criteria	O
did	O
not	O
meet	O
tps	O
's	O
numerical	O
criterion	O
for	O
hguc	O
at	O
least	O
5	O
malignant	O
cells	O
.	O
	
in	O
the	O
majority	O
of	O
specimens	B-C0370003
qualifying	O
for	O
hguc	O
by	O
tps	O
standards	O
,	O
only	O
a	O
small	O
fraction	O
of	O
atypical	O
cells	O
10%-20%	O
met	O
all	O
the	O
criteria	O
.	O
	
when	O
applied	O
to	O
malignant	O
utc	O
specimens	O
,	O
tps	O
criteria	O
improved	O
specimen	O
risk	O
stratification	O
by	O
upgrading	O
approximately	O
40%	O
of	O
indeterminate	O
specimens	O
into	O
higher	O
risk	O
categories	O
while	O
not	O
significantly	O
changing	O
the	O
frequency	O
of	O
hguc	O
diagnoses	O
.	O
	
cancer	O
cytopathol	O
2017	O
.	O
	
2017	O
american	O
cancer	O
society	I-C0002455
questionable	O
diagnostic	B-C0348026
benefit	B-C0814225
of	O
the	O
commercially	O
available	O
panel	O
of	O
bee	B-C0004920
venom	I-C0004920
components	B-C1705248
for	O
many	O
years	B-C0439234
,	O
only	O
the	O
major	O
allergen	B-C0002092
rapi	B-C0002092
m	I-C0002092
1	I-C0002092
has	O
been	O
available	O
on	O
the	O
immunocap	B-C0282574
system	I-C0282574
for	O
routine	O
diagnosis	B-C0011900
of	O
bee	B-C1828283
venom	I-C1828283
bv	I-C1828283
allergy	I-C1828283
.	O
	
now	O
,	O
there	O
are	O
five	O
components	B-C1705248
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	B-C1511883
and	O
specificity	B-C1511884
of	O
rapi	B-C0002092
m	I-C0002092
1	I-C0002092
,	O
2	B-C0002092
,	O
3	B-C0002092
,	O
5	B-C0002092
,	O
and	O
10	B-C0002092
in	O
bv-allergic	B-C1828283
patients	B-C0030705
.	O
	
we	O
further	O
evaluated	O
the	O
sensitivity	B-C1511883
of	O
rapi	B-C0002092
m	I-C0002092
1	I-C0002092
and	O
2	B-C0002092
of	O
an	O
alternative	O
platform	O
and	O
investigated	B-C1292732
possible	O
differences	O
in	O
the	O
sensitization	B-C1325847
profile	O
between	O
monosensitization	B-C1325847
and	O
clinically	O
relevant	O
double	B-C1325847
sensitization	I-C1325847
.	O
	
analysis	B-C0936012
of	O
the	O
whole	O
panel	O
of	O
bv	B-C0004920
allergens	B-C0002092
of	O
the	O
cap	B-C0282574
system	I-C0282574
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	B-C1511883
than	O
analysis	B-C0936012
of	O
the	O
combination	O
of	O
rapi	B-C0002092
m	I-C0002092
1	I-C0002092
and	O
2	B-C0002092
of	O
the	O
immulite	B-C3829562
71.6	O
vs	O
85.8	O
.	O
	
sensitization	B-C1325847
rate	B-C1521828
of	O
rapi	B-C0002092
m	I-C0002092
5	I-C0002092
was	O
more	O
than	O
doubled	O
in	O
double-sensitized	B-C1325847
patients	B-C0030705
,	O
while	O
there	O
was	O
no	O
difference	O
for	O
rapi	B-C0002092
m	I-C0002092
2	I-C0002092
.	O
	
the	O
benefit	B-C0814225
of	O
the	O
commercially	O
available	O
panel	O
of	O
bv	B-C0004920
components	B-C1705248
is	O
questionable	O
,	O
due	O
to	O
the	O
insufficient	B-C0231180
sensitivity	B-C1511883
and	O
still	O
unavailable	O
important	O
cross-reacting	B-C0010357
allergens	B-C0002092
.	O
	
orai1	B-C4255013
-mediated	O
antimicrobial	B-C1136254
secretion	B-C0036537
from	O
pancreatic	B-C0227578
acini	I-C0227578
shapes	O
the	O
gut	B-C4018878
microbiome	I-C4018878
and	O
regulates	B-C1155268
gut	B-C0699819
innate	B-C0020969
immunity	I-C0020969
the	O
gut	B-C4018878
microbiome	I-C4018878
participates	O
in	O
numerous	O
physiologic	B-C1254359
functions	I-C1254359
and	O
communicates	B-C0566001
intimately	O
with	O
the	O
host	B-C1167395
immune	B-C0020962
system	I-C0020962
.	O
	
antimicrobial	B-C4084937
peptides	I-C4084937
are	O
critica	B-C1511545
l	O
components	B-C1179435
of	O
intestinal	B-C0021853
innate	B-C0020969
immunity	I-C0020969
.	O
	
we	O
report	O
a	O
prominent	B-C0205402
role	O
for	O
antimicrobials	B-C1819788
secreted	I-C1819788
by	O
pancreatic	B-C0227578
acini	I-C0227578
in	O
shaping	O
the	O
gut	B-C4018878
microbiome	I-C4018878
that	O
is	O
essential	O
for	O
intestinal	B-C0021853
innate	B-C0020969
immunity	I-C0020969
,	O
barrier	B-C1254358
function	I-C1254358
,	O
and	O
survival	B-C0220921
.	O
	
deletion	B-C1880274
of	O
the	O
ca	B-C1823405
channel	I-C1823405
orai1	I-C1823405
in	O
pancreatic	B-C0227578
acini	I-C0227578
of	O
adult	O
mice	B-C0026809
resulted	O
in	O
60%-70%	O
mortality	B-C0026565
within	O
3	O
weeks	O
.	O
	
despite	O
robust	O
activation	B-C1817386
of	I-C1817386
the	I-C1817386
intestinal	I-C1817386
innate	I-C1817386
immune	I-C1817386
response	I-C1817386
,	O
mice	B-C0026809
lacking	O
acinar	B-C0332207
orai1	B-C1823405
exhibited	O
intestinal	B-C0021853
bacterial	B-C0521009
outgrowth	B-C0007613
and	O
dysbiosis	B-C4287543
,	O
ultimately	O
causing	O
systemic	B-C0205373
translocation	B-C0599718
,	O
inflammation	B-C0021368
,	O
and	O
death	B-C0011065
.	O
	
while	O
digestive	B-C0544420
enzyme	I-C0544420
supplementation	B-C0948571
was	O
ineffective	B-C3242229
,	O
treatments	B-C0087111
constraining	O
bacterial	B-C0521009
outgrowth	B-C0007613
purified	B-C1998793
liquid	B-C0301571
diet	I-C0301571
,	O
broad-spectrum	B-C0003232
antibiotics	I-C0003232
rescued	O
survival	B-C0220921
,	O
feeding	B-C2987508
,	O
and	O
weight	B-C0043094
gain	I-C0043094
.	O
	
pancreatic	B-C1306845
levels	I-C1306845
of	O
cathelicidin	B-C0671062
-related	O
antimicrobial	B-C4084937
peptide	I-C4084937
cramp	B-C4084937
were	O
reduced	B-C0392756
,	O
and	O
supplement	B-C2348609
of	O
synthetic	O
cramp	B-C4084937
prevented	O
intestinal	B-C0021831
disease	I-C0021831
.	O
	
these	O
findings	B-C0243095
reveal	O
a	O
critical	B-C1511545
role	O
for	O
antimicrobial	B-C1136254
pancreatic	B-C0232787
secretion	I-C0232787
in	O
gut	B-C0699819
innate	B-C0020969
immunity	I-C0020969
.	O
	
palliative	B-C0030231
care	I-C0030231
with	O
attachment	B-C1947904
hybrid	B-C3642532
removable	I-C3642532
prosthesis	I-C3642532
abutment	B-C0545406
injury	B-C0178314
,	O
unsatisfactory	B-C0439856
aesthetics	B-C0014901
and	O
lesser	O
retention	B-C0011397
exist	O
with	O
the	O
cast	B-C0545391
partial	I-C0545391
denture	I-C0545391
.	O
	
though	O
these	O
constraints	O
exist	O
in	O
the	O
removable	B-C0011463
partial	I-C0011463
denture	I-C0011463
rpd	B-C0011463
it	O
is	O
still	O
widely	O
used	O
because	O
of	O
the	O
simplicity	O
in	O
design	B-C0011395
,	O
fabrication	B-C1254366
,	O
economics	B-C0013557
and	O
patient	B-C4277744
comfort	I-C4277744
.	O
	
this	O
clinical	B-C1299495
report	I-C1299495
describes	O
a	O
hybrid	O
rpd	B-C0011463
technique	B-C0449851
which	O
uses	O
extra	O
coronal	B-C0205123
attachment	B-C1947904
that	O
reduces	B-C0392756
the	O
limitations	O
and	O
provides	O
better	O
comfort	B-C1331418
for	O
the	O
cxcl5	B-C1955899
plays	O
a	O
promoting	O
role	O
in	O
osteosarcoma	B-C0029463
cell	B-C0027627
migration	I-C0027627
and	I-C0027627
invasion	I-C0027627
in	O
autocrine	B-C0596138
-	O
and	O
paracrine	B-C0597170
-dependent	O
manners	O
cxcl5	B-C1955899
,	O
a	O
cxc-type	B-C0282553
chemokine	I-C0282553
,	O
is	O
an	O
important	O
attractant	O
for	O
granulocytic	B-C0018183
immune	I-C0018183
cells	I-C0018183
by	O
binding	B-C1149468
to	I-C1149468
its	I-C1149468
receptor	I-C1149468
cxcr2	I-C1149468
.	O
	
recently	O
,	O
cxcl5	B-C1955899
/	O
cxcr2	B-C0527994
has	O
been	O
found	O
to	O
play	O
an	O
oncogenic	B-C0029005
role	O
in	O
many	O
human	B-C0086418
cancers	B-C0006826
.	O
	
however	O
,	O
the	O
exact	O
role	O
of	O
cxcl5	B-C1955899
in	O
osteosarcoma	B-C0029463
cell	B-C0027627
migration	I-C0027627
and	I-C0027627
invasion	I-C0027627
has	O
not	O
been	O
revealed	O
.	O
	
here	O
we	O
found	O
that	O
the	O
protein	B-C1171362
expression	I-C1171362
of	O
cxcl5	B-C1955899
was	O
significantly	O
increased	B-C0205217
in	O
osteosarcoma	B-C0029463
tissues	B-C0040300
compared	O
with	O
that	O
in	O
matched	B-C0040300
adjacent	I-C0040300
nontumor	I-C0040300
tissues	I-C0040300
.	O
	
moreover	O
,	O
the	O
expression	B-C1171362
of	O
cxcl5	B-C1435946
was	O
significantly	O
associated	O
with	O
advanced	B-C0205563
clinical	I-C0205563
stage	I-C0205563
and	O
metastasis	B-C4255448
.	O
	
further	O
investigation	O
showed	O
that	O
the	O
cxcl5	B-C1955899
expression	B-C3244092
levels	I-C3244092
were	O
also	O
significantly	O
increased	B-C0205217
in	O
osteosarcoma	B-C0029463
cell	B-C0085983
lines	I-C0085983
,	O
including	O
saos-2	B-C0085983
,	O
mg63	B-C0085983
,	O
u2os	B-C0085983
,	O
and	O
sw1353	B-C0085983
,	O
when	O
compared	O
with	O
those	O
in	O
normal	B-C0029418
osteoblast	I-C0029418
hfob1.19	B-C0029418
cells	I-C0029418
.	O
	
u2os	B-C0085983
cells	I-C0085983
were	O
further	O
transfected	B-C0314641
with	O
cxcl5	B-C1332819
-	O
specific	B-C1099354
sirna	I-C1099354
or	O
overexpression	B-C1514559
plasmid	B-C0032136
.	O
	
knockdown	B-C2350567
of	O
cxcl5	B-C1332819
significantly	O
suppressed	B-C1260953
u2os	B-C0085983
cell	B-C0027627
migration	I-C0027627
and	I-C0027627
invasion	I-C0027627
.	O
	
on	O
the	O
contrary	O
,	O
overexpression	B-C1514559
of	O
cxlc5	B-C1955899
remarkably	O
promoted	O
the	O
migration	B-C0027627
and	I-C0027627
invasion	I-C0027627
of	O
u2os	B-C0085983
cells	I-C0085983
.	O
	
interestingly	O
,	O
both	O
exogenous	B-C0205228
cxcl5	B-C1955899
treatment	B-C0039798
and	O
the	O
conditioned	O
medium	O
of	O
cxcl5	B-C1955899
-	O
overexpressing	B-C1514559
hfob1.19	B-C0029418
cells	I-C0029418
could	O
also	O
enhance	O
the	O
migration	B-C0027627
and	I-C0027627
invasion	I-C0027627
of	O
u2os	B-C0085983
cells	I-C0085983
,	O
suggesting	O
that	O
the	O
promoting	O
role	O
of	O
cxcl5	B-C1955899
in	O
u2os	B-C0085983
cell	B-C0027627
migration	I-C0027627
and	I-C0027627
invasion	I-C0027627
is	O
also	O
in	O
a	O
paracrine	B-C0597170
-dependent	O
manner	O
.	O
	
according	O
to	O
these	O
data	O
,	O
our	O
study	O
demonstrates	O
that	O
cxcl5	B-C1955899
is	O
upregulated	O
in	O
osteosarcoma	B-C0029463
and	O
may	O
play	O
an	O
oncogenic	B-C0029005
role	O
in	O
osteosarcoma	B-C0029463
metastasis	B-C4255448
.	O
	
therefore	O
,	O
cxcl5	B-C1955899
may	O
become	O
a	O
potential	B-C3245505
therapeutic	B-C0205245
target	I-C0205245
for	O
osteosarcoma	B-C0029463
treatment	B-C0039798
.	O
	
integrating	B-C1881786
molecular	B-C1521991
qtl	B-C0597336
data	B-C1511726
into	O
genome-wide	B-C2350277
genetic	I-C2350277
association	I-C2350277
analysis	I-C2350277
probabilistic	B-C0033204
assessment	B-C1292732
of	O
enrichment	B-C2986411
and	O
colocalization	B-C0475264
we	O
propose	O
a	O
novel	O
statistical	B-C0026348
framework	I-C0026348
for	O
integrating	B-C1881786
the	O
result	B-C1274040
from	O
molecular	B-C1521991
quantitative	B-C0597336
trait	I-C0597336
loci	I-C0597336
qtl	B-C0597336
mapping	B-C1283195
into	O
genome-wide	B-C2350277
genetic	I-C2350277
association	I-C2350277
analysis	I-C2350277
of	O
complex	B-C0439855
traits	B-C0599883
,	O
with	O
the	O
primary	O
objectives	O
of	O
quantitatively	B-C0392762
assessing	B-C1292732
the	O
enrichment	B-C2986411
of	O
the	O
molecular	B-C1521991
qtls	B-C0597336
in	O
complex	B-C0439855
trait	B-C0599883
-	O
associated	B-C0332281
genetic	B-C0678941
variants	I-C0678941
and	O
the	O
colocalizations	B-C0475264
of	O
the	O
two	O
types	B-C0332307
of	O
association	B-C0439849
signals	B-C1710082
.	O
	
we	O
introduce	O
a	O
natural	B-C0242198
bayesian	I-C0242198
hierarchical	I-C0242198
model	I-C0242198
that	O
treats	O
the	O
latent	O
association	B-C0439849
status	O
of	O
molecular	B-C1521991
qtls	B-C0597336
as	O
snp	B-C0752046
-	O
level	B-C0441889
annotations	O
for	O
candidate	O
snps	B-C0752046
of	O
complex	B-C0439855
traits	B-C0599883
.	O
	
we	O
detail	O
a	O
computational	B-C1880157
procedure	B-C2700391
to	O
seamlessly	O
perform	O
enrichment	B-C2986411
,	O
fine-mapping	B-C1283195
and	O
colocalization	B-C0475264
analyses	B-C0936012
,	O
which	O
is	O
a	O
distinct	B-C2348519
feature	I-C2348519
compared	B-C1707455
to	O
the	O
existing	O
colocalization	B-C0475264
analysis	B-C0936012
procedures	B-C2700391
in	O
the	O
literature	B-C0023866
.	O
	
the	O
proposed	O
approach	B-C0449445
is	O
computationally	B-C1880157
efficient	B-C0442799
and	O
requires	O
only	O
summary	B-C1706244
-	O
level	B-C0441889
statistics	B-C2828391
.	O
	
we	O
evaluate	B-C1292732
and	O
demonstrate	O
the	O
proposed	O
computational	B-C1880157
approach	B-C0449445
through	O
extensive	B-C0205231
simulation	B-C0009609
studies	B-C2603343
and	O
analyses	B-C0936012
of	O
blood	B-C0596192
lipid	I-C0596192
data	B-C1511726
and	O
the	O
whole	B-C0370231
blood	I-C0370231
eqtl	B-C0597336
data	B-C1511726
from	O
the	O
gtex	B-C4289040
project	I-C4289040
.	O
	
in	O
addition	O
,	O
a	O
useful	O
utility	B-C0025663
from	O
our	O
proposed	O
method	B-C0025663
enables	O
the	O
computation	B-C1880157
of	O
expected	O
colocalization	B-C0475264
signals	B-C1710082
using	O
simple	O
characteristics	B-C1521970
of	O
the	O
association	B-C0439849
data	B-C1511726
.	O
	
using	O
this	O
utility	B-C0025663
,	O
we	O
further	O
illustrate	O
the	O
importance	O
of	O
enrichment	B-C2986411
analysis	B-C0936012
on	O
the	O
ability	O
to	O
discover	O
colocalized	B-C0475264
signals	B-C1710082
and	O
the	O
potential	B-C3245505
limitations	B-C0449295
of	O
currently	O
available	O
molecular	B-C1521991
qtl	B-C0597336
data	B-C1511726
.	O
	
the	O
software	B-C0037585
pipeline	O
that	O
implements	O
the	O
proposed	O
computation	B-C1880157
procedures	B-C2700391
,	O
enloc	B-C0242356
,	O
is	O
freely	O
available	O
at	O
engineering	B-C0017387
the	O
ribosomal	B-C0012933
dna	I-C0012933
in	O
a	O
megabase	B-C0872017
synthetic	I-C0872017
chromosome	I-C0872017
we	O
designed	O
and	O
synthesized	O
a	O
976	B-C0872017
pair	I-C0872017
linear	I-C0872017
chromosome	I-C0872017
,	O
synxii	B-C0872017
,	O
based	O
on	O
native	O
chromosome	B-C0008642
xii	I-C0008642
in	O
saccharomyces	B-C0036025
cerevisiae	I-C0036025
synxii	B-C0872017
was	O
assembled	O
using	O
a	O
two-step	B-C0449851
method	I-C0449851
,	O
specified	O
by	O
successive	O
megachunk	B-C0017387
integration	I-C0017387
and	O
meiotic	B-C0017387
recombination-mediated	I-C0017387
assembly	I-C0017387
,	O
producing	O
a	O
functional	B-C0205245
chromosome	B-C0008642
in	O
s	B-C0036025
.	O
	
cerevisiae	I-C0036025
.	O
	
minor	B-C1457869
growth	I-C1457869
defect	I-C1457869
""""	O
bugs	B-C1457869
""""	O
detected	B-C0442726
in	O
synxii	B-C0872017
,	O
caused	O
by	O
deletion	B-C0017260
of	O
trna	B-C0035711
genes	B-C0017337
,	O
were	O
rescued	O
by	O
introducing	O
an	O
ectopic	B-C0017337
copy	I-C0017337
of	O
a	O
single	B-C0035711
trna	I-C0035711
gene	B-C0017337
.	O
	
the	O
ribosomal	B-C0017258
gene	I-C0017258
cluster	I-C0017258
rdna	B-C0017258
on	O
synxii	B-C0872017
was	O
left	O
intact	O
during	O
the	O
assembly	B-C0017387
process	I-C0017387
and	O
subsequently	O
replaced	O
by	O
a	O
modified	B-C0392747
rdna	B-C0017258
unit	O
used	O
to	O
regenerate	B-C0334213
rdna	B-C0017258
at	O
three	O
distinct	O
chromosomal	B-C0008633
locations	I-C0008633
.	O
	
the	O
signature	O
sequences	B-C0004793
within	O
rdna	B-C0017258
,	O
which	O
can	O
be	O
used	O
to	O
determine	O
species	B-C1705920
identity	B-C0243095
,	O
were	O
swapped	O
to	O
generate	O
a	O
saccharomyces	B-C0036024
synxii	B-C0872017
strain	B-C1518614
that	O
would	O
be	O
identified	B-C0205396
as	O
saccharomyces	B-C1504647
bayanus	I-C1504647
by	O
standard	B-C1442989
reversible	O
humidity	B-C0020167
sensitive	B-C0332324
clothing	B-C0009072
for	O
personal	B-C0262758
thermoregulation	I-C0262758
two	O
kinds	O
of	O
humidity	B-C0020167
-	O
induced	B-C0205263
,	O
bendable	O
smart	B-C0009072
clothing	I-C0009072
have	O
been	O
designed	B-C3274373
to	I-C3274373
reversibly	I-C3274373
adapt	I-C3274373
their	O
thermal	B-C1708520
insulation	I-C1708520
functionality	I-C1708520
.	O
	
the	O
first	O
design	O
mimics	O
the	O
pores	B-C0221956
in	O
human	B-C1123023
skin	I-C1123023
,	O
in	O
which	O
pre-cut	O
flaps	O
open	O
to	O
produce	O
pores	B-C0221956
in	O
nafion	B-C0068361
sheets	B-C0039717
when	O
humidity	B-C0020167
increases	O
,	O
as	O
might	O
occur	O
during	O
human	B-C0038990
sweating	I-C0038990
thus	O
permitting	O
air	B-C0042491
flow	I-C0042491
and	O
reducing	O
both	O
the	O
humidity	B-C0020167
level	O
and	O
the	O
apparent	B-C0039476
temperature	I-C0039476
.	O
	
like	O
the	O
smart	O
human	B-C0221956
sweating	I-C0221956
pores	I-C0221956
,	O
the	O
flaps	O
can	O
close	O
automatically	O
after	O
the	O
perspiration	B-C0038990
to	O
keep	O
the	O
wearer	B-C0009072
warm	I-C0009072
.	O
	
the	O
second	O
design	O
involves	O
thickness	B-C1280412
adjustable	B-C0009072
clothes	I-C0009072
by	O
inserting	O
the	O
bent	B-C0039717
polymer	I-C0039717
sheets	I-C0039717
between	O
two	O
fabrics	B-C0039717
.	O
	
as	O
the	O
humidity	B-C0020167
increases	O
,	O
the	O
sheets	B-C0039717
become	O
thinner	O
,	O
thus	O
reducing	O
the	O
gap	O
between	O
the	O
two	O
fabrics	B-C0039717
to	O
reduce	O
the	O
thermal	B-C0205245
insulation	I-C0205245
.	O
	
the	O
insulation	B-C1708520
layer	I-C1708520
can	O
recover	O
its	O
original	O
thickness	B-C1280412
upon	O
humidity	B-C0020167
reduction	O
to	O
restore	O
its	O
warmth-preservation	B-C0392197
function	O
.	O
	
such	O
humidity	B-C0020167
sensitive	B-C0332324
smart	O
polymer	B-C0039717
materials	I-C0039717
can	O
be	O
utilized	O
to	O
adjust	O
personal	B-C1331418
comfort	I-C1331418
,	O
and	O
be	O
effective	O
in	O
reducing	B-C0243095
energy	I-C0243095
consumption	I-C0243095
for	O
building	O
heating	B-C0205245
or	I-C0205245
cooling	I-C0205245
with	O
numerous	O
smart	B-C1707689
design	I-C1707689
.	O
	
development	B-C0243107
of	O
an	O
automaton	B-C0026336
model	I-C0026336
of	O
rotational	B-C0441655
activity	I-C0441655
driving	O
atrial	B-C0004238
fibrillation	I-C0004238
atrial	B-C0004238
fibrillation	I-C0004238
af	B-C0004238
is	O
difficult	O
to	O
treat	B-C0087111
effectively	B-C1704419
,	O
owing	O
to	O
uncertainty	B-C0087130
in	O
where	O
to	O
best	O
ablate	B-C0162563
to	O
eliminate	B-C0441655
arrhythmogenic	B-C0085611
substrate	B-C3891814
.	O
	
a	O
model	B-C0026336
providing	O
insight	O
into	O
the	O
electrical	B-C0442828
activation	B-C1879547
events	B-C0441471
would	O
be	O
useful	O
to	O
guide	O
catheter	B-C0162559
ablation	I-C0162559
strategy	I-C0162559
.	O
	
method	O
a	O
two-dimensional	B-C1705052
,	O
576	B-C0336537
node	I-C0336537
automaton	I-C0336537
was	O
developed	O
to	O
simulate	B-C0441655
atrial	B-C0018792
electrical	O
activity	O
.	O
	
the	O
substrate	O
field	O
was	O
altered	O
by	O
the	O
presence	O
of	O
differing	O
refractory	O
period	O
at	O
varying	O
locations	O
.	O
	
fibrosis	O
was	O
added	O
in	O
the	O
form	O
of	O
short	O
,	O
randomly	O
positioned	O
lines	O
of	O
conduction	O
block	O
.	O
	
larger	O
areas	O
of	O
block	O
were	O
used	O
to	O
simulate	O
ablation	O
lesions	O
.	O
	
anisotropy	O
was	O
imposed	O
in	O
a	O
2	O
ratio	O
.	O
	
a	O
premature	O
electrical	O
impulse	O
from	O
one	O
of	O
four	O
grid	O
corners	O
was	O
utilized	O
to	O
initiate	O
activation	O
.	O
	
rotational	O
activity	O
was	O
uninducible	O
when	O
refractory	O
patch	O
dimensions	O
were	O
less	O
than	O
20	O
.	O
	
for	O
larger	O
refractory	O
regions	O
,	O
a	O
single	O
premature	O
stimulus	O
was	O
capable	O
of	O
inducing	O
an	O
average	O
of	O
1.19	O
rotors	O
,	O
which	O
often	O
formed	O
near	O
the	O
patch	O
edges	O
.	O
	
a	O
maximum	O
of	O
5	O
rotors	O
formed	O
when	O
refractory	O
patch	O
dimensions	O
approached	O
the	O
size	O
of	O
the	O
entire	O
left	O
atrial	B-C0596673
virtual	O
field	O
.	O
	
rotors	O
formed	O
along	O
a	O
refractory	O
patch	O
edge	O
,	O
after	O
wavefront	O
arrival	O
was	O
delayed	O
at	O
turning	O
points	O
or	O
due	O
to	O
the	O
presence	O
of	O
a	O
fiber	O
cluster	O
of	O
sufficient	O
size	O
.	O
	
however	O
,	O
rotational	O
activity	O
could	O
also	O
occur	O
around	O
a	O
large	O
fiber	O
cluster	O
without	O
the	O
need	O
of	O
spatially	O
variable	O
refractoriness	O
.	O
	
when	O
obstacles	O
to	O
conduction	O
were	O
lacking	O
in	O
size	O
,	O
nascent	O
rotors	O
drifted	O
and	O
either	O
extinguished	O
,	O
or	O
stabilized	O
upon	O
anchoring	O
at	O
a	O
sufficiently	O
large	O
fiber	O
cluster	O
elsewhere	O
in	O
the	O
field	O
.	O
	
transient	O
rotors	O
terminated	O
when	O
traversing	O
a	O
region	O
with	O
differing	O
refractory	O
periods	O
,	O
if	O
no	O
obstacle	O
to	O
conduction	O
was	O
present	O
to	O
sufficiently	O
delay	O
wavefront	O
arrival	O
beyond	O
the	O
longest	O
refractory	O
period	O
.	O
	
other	O
rotors	O
were	O
annihilated	O
when	O
a	O
nearby	O
rotor	O
with	O
faster	O
spin	O
rate	O
gradually	O
interrupted	O
the	O
activation	O
pathway	O
.	O
	
elimination	O
of	O
anchors	O
by	O
removal	O
,	O
or	O
by	O
simulated	O
ablation	O
over	O
a	O
sufficient	O
region	O
,	O
prevented	O
rotor	O
onset	O
at	O
a	O
particular	O
location	O
where	O
it	O
would	O
otherwise	O
form	O
.	O
	
the	O
presence	O
of	O
obstacles	O
to	O
conduction	O
and	O
spatial	O
differences	O
in	O
refractory	O
period	O
are	O
important	O
parameters	O
for	O
initiating	O
and	O
maintaining	O
rotational	O
activity	O
in	O
this	O
simulation	O
of	O
an	O
atrial	O
substrate	B-C3891814
multimodal	B-C1513743
brain	I-C1513743
imaging	I-C1513743
with	O
magnetoencephalography	B-C0024489
a	O
method	B-C0430022
for	O
measuring	B-C0242485
blood	B-C0005823
pressure	I-C0005823
and	O
cardiorespiratory	B-C0871665
oscillations	I-C0871665
studies	B-C2603343
with	O
magnetoencephalography	B-C0024489
meg	B-C0024489
are	O
still	O
quite	O
rarely	O
combined	O
simultaneously	O
with	O
methods	B-C0430022
that	O
can	O
provide	O
a	O
metabolic	B-C0025520
dimension	I-C0025520
to	O
meg	B-C0024489
investigation	B-C0220825
s	O
.	O
	
in	O
addition	O
,	O
continuous	O
blood	B-C3826646
pressure	I-C3826646
measurements	I-C3826646
which	O
comply	O
with	O
meg	B-C0024489
compatibility	O
requirements	O
are	O
lacking	O
.	O
	
for	O
instance	O
,	O
by	O
combining	O
methods	B-C0430022
reflecting	O
neurovascular	B-C1828265
status	I-C1828265
one	O
could	O
obtain	O
more	O
information	O
on	O
low	B-C0205213
frequency	I-C0205213
fluctuations	B-C0231239
that	O
have	O
recently	O
gained	O
increasing	O
interest	O
as	O
a	O
mediator	O
of	O
functional	B-C1707489
connectivity	I-C1707489
within	O
brain	B-C2951780
networks	I-C2951780
.	O
	
this	O
paper	O
presents	O
a	O
multimodal	B-C1513743
brain	I-C1513743
imaging	I-C1513743
setup	O
,	O
capable	O
to	O
non-invasively	B-C0205303
and	O
continuously	O
measure	O
cerebral	B-C0006104
hemodynamic	B-C0019010
,	O
cardiorespiratory	B-C0846599
and	O
blood	B-C0005823
pressure	I-C0005823
oscillations	B-C0871665
simultaneously	O
with	O
meg	B-C0024489
.	O
	
in	O
the	O
setup	O
,	O
all	O
methods	B-C0430022
apart	O
from	O
meg	B-C0024489
rely	O
on	O
the	O
use	O
of	O
fibre	B-C0015979
optics	I-C0015979
.	O
	
in	O
particular	O
,	O
we	O
present	O
a	O
method	B-C0430022
for	O
measuring	B-C0242485
of	O
blood	B-C0005823
pressure	I-C0005823
and	O
cardiorespiratory	B-C0871665
oscillations	I-C0871665
continuously	O
with	O
meg	B-C0024489
.	O
	
the	O
potential	B-C3245505
of	O
this	O
type	O
of	O
multimodal	B-C1513743
setup	O
for	O
brain	B-C0035168
research	I-C0035168
is	O
demonstrated	O
by	O
our	O
preliminary	O
studies	O
on	O
human	B-C0086418
,	O
showing	O
effects	B-C1704420
of	I-C1704420
mild	B-C0020440
hypercapnia	I-C0020440
,	O
gathered	O
simultaneously	O
with	O
the	O
presented	O
effect	B-C1704420
of	I-C1704420
peritoneal	B-C0031148
lavage	I-C0031148
solution	B-C0037633
temperature	B-C0039476
on	O
body	B-C0005903
temperature	I-C0005903
in	O
anaesthetised	B-C1720436
cats	B-C0007450
and	O
small	O
dogs	B-C0012984
a	O
prospective	B-C0033522
,	O
randomised	B-C0206034
,	O
non-blinded	B-C0242481
,	O
clinical	B-C0008972
study	I-C0008972
to	O
assess	O
the	O
effect	B-C1704420
of	I-C1704420
peritoneal	B-C0031148
lavage	I-C0031148
using	O
warmed	B-C0687712
fluid	B-C0302908
on	O
body	B-C0005903
temperature	I-C0005903
in	O
anesthetised	B-C1720436
cats	B-C0007450
and	O
dogs	B-C0012984
of	O
less	O
than	O
10	O
kg	O
body	B-C0518010
mass	I-C0518010
undergoing	O
coeliotomy	B-C0023038
.	O
	
a	O
standardised	B-C0442711
anaesthetic	I-C0442711
protocol	I-C0442711
was	O
used	O
.	O
	
oesophageal	B-C3161742
and	O
rectal	B-C0489749
temperatures	I-C0489749
were	O
measured	B-C0444706
at	O
various	B-C1552717
time	I-C1552717
points	I-C1552717
.	O
	
at	O
the	O
end	O
of	O
surgery	B-C0543467
,	O
group	B-C0030705
1	I-C0030705
patients	I-C0030705
n=10	O
were	O
lavaged	B-C0022100
with	O
200	O
ml/kg	O
sterile	B-C0232920
isotonic	B-C0445115
saline	I-C0445115
at	O
34	O
and	O
group	B-C1642385
2	O
n=10	O
at	O
40	O
.	O
	
groups	B-C1642385
were	O
similar	O
with	O
respect	O
to	O
age	B-C0596090
,	O
mass	B-C1306372
,	O
body	B-C3687361
condition	I-C3687361
and	O
surgical	B-C0184898
incision	I-C0184898
length	O
.	O
	
duration	B-C0449238
of	O
anaesthesia	B-C0002921
,	O
surgical	B-C0543467
procedures	I-C0543467
and	O
peritoneal	B-C0031148
lavage	I-C0031148
was	O
similar	O
between	O
groups	B-C1642385
.	O
	
linear	B-C0023733
regression	I-C0023733
showed	O
no	B-C0243095
significant	I-C0243095
change	I-C0243095
in	O
oesophageal	B-C3161742
temperature	I-C3161742
during	O
the	O
lavage	B-C0022100
period	B-C1948053
for	O
group	B-C1642385
1	O
p=0	O
,	O
but	O
a	O
significant	O
increase	O
for	O
group	B-C0030705
2	I-C0030705
patients	I-C0030705
p<0	O
,	O
with	O
mean	B-C0444504
temperature	B-C0450031
changes	I-C0450031
of	O
-0	O
from	O
36.3	O
to	O
35.9	O
and	O
+0	O
from	O
35.4	O
to	O
36.3	O
,	O
respectively	O
.	O
	
similar	O
results	B-C0459422
were	O
found	O
for	O
rectal	B-C0489749
temperature	I-C0489749
,	O
with	O
mean	B-C0444504
changes	O
of	O
-0	O
and	O
+0	O
p=0	O
and	O
0.045	O
,	O
respectively	O
.	O
	
the	O
use	O
of	O
isotonic	B-C0022260
crystalloid	B-C0056562
solution	I-C0056562
for	O
peritoneal	B-C0031148
lavage	I-C0031148
at	O
a	O
temperature	B-C0039476
of	O
40	O
significantly	O
warms	B-C0687712
small	B-C0030705
animal	I-C0030705
patients	I-C0030705
,	O
when	O
applied	O
in	O
a	O
clinical	B-C3176918
setting	I-C3176918
,	O
compared	O
with	O
lavage	B-C0022100
bioengineered	B-C2717958
3d	B-C0450363
models	B-C0026339
for	O
studying	B-C2603343
human	B-C0086418
cell	B-C0007634
-	O
tuberculosis	B-C0026926
interactions	B-C1704675
in	B-C1515655
vivo	I-C1515655
animal	B-C0599779
models	I-C0599779
have	O
intrinsic	O
limitations	O
for	O
studying	B-C2603343
relationships	B-C0439849
between	O
tuberculosis	B-C0026926
and	O
its	O
host	B-C1167395
and	O
there	O
is	O
a	O
need	O
for	O
alternative	O
,	O
in	B-C1533691
vitro	I-C1533691
cellular	B-C0026339
models	I-C0026339
.	O
	
a	O
microsphere	B-C0026032
-based	O
3d	B-C0450363
in	B-C1533691
vitro	I-C1533691
culture	B-C1516329
system	I-C1516329
of	O
mycobacterium	B-C0026926
tuberculosis	I-C0026926
-infected	O
human	B-C0086418
blood	B-C0005767
mononuclear	B-C0806987
cells	I-C0806987
was	O
reported	O
to	O
address	O
specific	O
aspects	O
of	O
host	B-C1167395
-	O
pathogen	B-C0450254
interactions	B-C1704675
.	O
	
perspectives	B-C1254370
on	O
cardiovascular	B-C0007226
effects	B-C1704420
of	I-C1704420
incretin	B-C1562292
-based	O
drugs	B-C1254351
from	O
bedside	O
to	O
bench	O
,	O
return	O
trip	O
recently	O
,	O
cardiovascular	B-C0007226
outcome	B-C1274040
trials	B-C0008976
with	O
glucose	B-C0017725
-lowering	O
drugs	B-C1254351
used	O
in	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
mellitus	I-C0011860
,	O
namely	O
glucagon-like	B-C0378073
peptide-1	I-C0378073
receptor	I-C0378073
agonists	B-C0243192
glp-1ra	B-C0243192
,	O
liraglutide	B-C1456408
and	O
semaglutide	B-C3885068
,	O
showed	O
a	O
reduction	B-C0547047
in	O
cardiovascular	B-C1320716
events	I-C1320716
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	B-C0008976
with	O
other	O
incretin	B-C1562292
-based	O
drugs	B-C1254351
,	O
such	O
as	O
lixisenatide	B-C2973895
or	O
with	O
dipeptidyl	B-C1827106
peptidase-4	I-C1827106
inhibitors	I-C1827106
dpp4i	B-C1827106
.	O
	
mechanisms	B-C0441712
underlying	O
the	O
observed	O
cardiovascular	B-C0007226
differences	B-C1705242
between	O
dpp4i	B-C1827106
and	O
glp1-ra	B-C0243192
,	O
and	O
across	O
individual	O
glp1-ra	B-C0243192
are	O
poorly	O
understood	O
.	O
	
this	O
review	B-C0282443
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	B-C3887511
from	O
experimental	B-C0681814
and	O
mechanistic	B-C0681814
studies	I-C0681814
on	O
the	O
action	B-C3266814
of	O
glp1-ra	B-C0243192
and	O
dpp4i	B-C1827106
on	O
the	O
cardiovascular	B-C0007226
system	I-C0007226
,	O
both	O
deriving	O
from	O
clinical	B-C0011001
and	O
pre-clinical	B-C0011001
sources	I-C0011001
.	O
	
the	O
results	B-C1274040
of	O
cardiovascular	B-C0007226
outcome	B-C1274040
trials	B-C0008976
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	B-C0681814
preclinical	B-C1516606
data	I-C1516606
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	B-C0018801
failure	I-C0018801
results	B-C1274040
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	B-C1512571
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	B-C2607943
of	O
cardioprotection	B-C0205245
of	O
incretin	B-C1562292
-based	O
drugs	B-C1254351
.	O
	
in	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	B-C1562292
cardiovascular	B-C0007226
effects	B-C1704420
of	I-C1704420
a	O
direct	O
cardiac	B-C0018787
action	B-C3266814
of	O
glp-1	B-C0061355
metabolites	B-C0870883
through	O
glp-1	B-C0378073
receptor	I-C0378073
-independent	O
pathways	B-C1704259
,	O
and	O
of	O
dpp4	B-C0081937
substrates	B-C3891814
other	O
than	O
role	O
of	O
breast	B-C0344104
magnetic	I-C0344104
resonance	I-C0344104
imaging	I-C0344104
in	O
predicting	B-C0681842
residual	B-C1609982
lobular	B-C0279563
carcinoma	I-C0279563
in	I-C0279563
situ	I-C0279563
after	O
initial	B-C0205265
excision	B-C0728940
breast	B-C0344104
magnetic	I-C0344104
resonance	I-C0344104
mr	I-C0344104
imaging	I-C0344104
is	O
a	O
useful	O
screening	B-C0199230
modality	B-C0695347
in	O
detecting	B-C1511790
suspicious	B-C4050405
lesions	B-C0221198
in	O
patients	B-C0030705
with	O
a	O
history	B-C0262926
of	O
lobular	B-C0279563
carcinoma	I-C0279563
in	I-C0279563
situ	I-C0279563
lcis	B-C0279563
.	O
	
this	O
study	B-C2603343
aimed	B-C1947946
to	O
evaluate	B-C0220825
the	O
effectiveness	B-C1280519
of	O
breast	B-C0344104
mr	I-C0344104
imaging	I-C0344104
in	O
detecting	B-C1511790
remnant	B-C3272697
lcis	B-C0279563
lesions	B-C0221198
after	B-C0687676
initial	B-C0205265
excision	B-C0728940
.	O
	
between	O
2011	O
and	O
2015	O
,	O
29	O
patients	B-C0030705
with	O
lcis	B-C0279563
who	O
underwent	B-C2586066
initial	B-C0205265
excision	B-C0728940
were	O
enrolled	O
.	O
	
breast	B-C0080264
ultrasonography	I-C0080264
and	O
breast	B-C0344104
mr	I-C0344104
imaging	I-C0344104
was	O
conducted	O
after	B-C0687676
initial	B-C0205265
excision	B-C0728940
.	O
	
imaging	B-C1287399
findings	I-C1287399
were	O
compared	B-C1707455
with	O
pathologic	B-C0030660
results	B-C1274040
.	O
	
there	O
were	O
nine	O
31.0	O
cases	B-C1706256
with	O
positive	B-C1709603
margins	I-C1709603
after	B-C0687676
initial	B-C0205265
excision	B-C0728940
they	O
were	O
lcis	B-C0279563
n=8	O
and	O
atypical	B-C1368920
lobular	I-C1368920
hyperplasia	I-C1368920
n=1	O
.	O
	
residual	B-C1609982
lesions	B-C0221198
were	O
identified	B-C0205396
in	O
12	O
cases	B-C1706256
they	O
were	O
invasive	B-C0279565
lobular	I-C0279565
carcinoma	I-C0279565
n=1	O
3.4	O
,	O
lcis	B-C0279563
n=9	O
31.0	O
,	O
atypical	B-C1368920
lobular	I-C1368920
hyperplasia	I-C1368920
n=1	O
3.4	O
,	O
and	O
papillary	B-C0334242
carcinoma	I-C0334242
in	I-C0334242
situ	I-C0334242
n=1	O
3.4	O
.	O
	
prior	B-C0332152
to	O
the	O
second	B-C0205436
operation	B-C0543467
,	O
these	O
lesions	B-C0221198
could	O
be	O
detected	O
in	O
seven	O
cases	B-C1706256
using	O
ultrasonography	B-C0080264
sensitivity	B-C1511883
,	O
53.3	O
specificity	B-C1511884
,	O
100%	O
and	O
in	O
10	O
cases	B-C1706256
using	O
breast	B-C0344104
mr	I-C0344104
imaging	I-C0344104
sensitivity	B-C1511883
,	O
83.3	O
specificity	B-C1511884
,	O
100%	O
.	O
	
breast	B-C0344104
mr	I-C0344104
imaging	I-C0344104
showed	O
higher	B-C0205250
sensitivity	B-C1511883
than	O
breast	B-C0080264
ultrasonography	I-C0080264
in	O
detecting	B-C1511790
remnant	B-C3272697
lcis	B-C0279563
lesions	B-C0221198
.	O
	
if	O
a	O
suspicious	B-C4050405
lesion	B-C0221198
was	O
found	O
using	O
breast	B-C0344104
mr	I-C0344104
imaging	I-C0344104
,	O
a	O
second	B-C0205436
operation	B-C0543467
should	O
be	O
considered	B-C0750591
because	O
of	O
the	O
possibility	B-C0332149
of	O
multifocality	B-C2986663
,	O
even	O
if	O
lcis	B-C0279563
was	O
confirmed	B-C0750484
at	O
the	O
initial	B-C0205265
operation	B-C0543467
.	O
	
construction	B-C0007987
of	O
fused	B-C1254350
polyheterocycles	I-C1254350
through	O
sequential	B-C1705294
4	B-C0598128
+	I-C0598128
2	I-C0598128
and	I-C0598128
3	I-C0598128
+	I-C0598128
2	I-C0598128
cycloadditions	I-C0598128
a	O
method	O
for	O
pd	B-C0030230
-	O
catalyzed	B-C0007382
aerobic	B-C1510824
oxidative	B-C0030011
reaction	I-C0030011
of	O
quinazolinones	B-C1720912
and	O
alkynes	B-C0002078
has	O
been	O
developed	O
for	O
sequential	B-C1705294
4	B-C0598128
+	I-C0598128
2	I-C0598128
and	I-C0598128
3	I-C0598128
+	I-C0598128
2	I-C0598128
cycloadditions	I-C0598128
to	O
assemble	B-C1706853
a	O
novel	B-C0205314
fused-polycyclic	B-C1254350
system	I-C1254350
containing	O
tetrahydropyridine	B-C0044607
and	O
dihydrofuran	B-C0029224
rings	I-C0029224
.	O
	
the	O
reaction	B-C0596319
process	I-C0596319
involves	O
c-h	B-C0813982
and	I-C0813982
n-h	I-C0813982
bond	I-C0813982
functionalization	O
for	O
the	O
formation	B-C1522492
of	O
tetrahydropyridine	B-C0044607
and	O
an	O
oxygen	B-C0030054
radical	I-C0030054
cyclization	B-C0010546
for	O
the	O
dihydrofuran	B-C0029224
ring	I-C0029224
.	O
	
this	O
atom	B-C0567415
-	O
and	O
step-	O
economical	B-C0013556
synthesis	I-C0013556
is	O
highly	O
efficient	O
and	O
has	O
good	O
substrate	B-C3891814
tolerance	B-C1704410
,	O
which	O
provides	O
a	O
new	O
approach	O
for	O
the	O
construction	B-C0007987
of	O
polycyclic	B-C1254350
molecules	I-C1254350
with	O
potential	O
pharmaceutical	B-C0008003
interest	I-C0008003
.	O
	
biological	B-C0205460
basis	B-C1874451
of	O
radiation	B-C0034533
protection	I-C0034533
needs	O
rejuvenation	B-C0035016
human	B-C0086418
beings	I-C0086418
encounter	O
radiation	B-C0851346
in	O
many	O
different	O
situations	O
-	O
from	O
proximity	B-C1514583
to	O
radioactive	B-C0034552
waste	I-C0034552
sites	B-C0205145
to	O
participation	B-C0679823
in	O
medical	B-C0199171
procedures	I-C0199171
using	O
x-rays	B-C0043309
etc	O
.	O
	
limits	O
for	O
radiation	B-C0015333
exposures	I-C0015333
are	O
legally	B-C0851285
regulated	I-C0851285
however	O
,	O
current	O
radiation	B-C0034533
protection	I-C0034533
policy	B-C0242456
does	O
not	O
explicitly	O
acknowledge	O
that	O
biological	B-C0205460
,	O
cellular	B-C0178539
and	O
molecular	B-C1521991
effects	B-C1704420
of	I-C1704420
low	B-C0445550
doses	I-C0445550
and	O
low	O
dose	B-C1512044
rates	I-C1512044
of	O
radiation	B-C0851346
differ	O
from	O
effects	O
induced	O
by	O
medium	O
and	O
high	B-C0444956
dose	I-C0444956
radiation	B-C0015333
exposures	I-C0015333
.	O
	
recent	O
technical	B-C1527148
developments	I-C1527148
in	O
biology	B-C0005532
and	O
medicine	B-C0025118
,	O
from	O
single	B-C0597452
cell	I-C0597452
techniques	I-C0597452
to	O
big	B-C4297010
data	I-C4297010
computational	I-C4297010
research	I-C4297010
,	O
have	O
enabled	O
new	O
approaches	B-C1292724
for	O
study	B-C2603343
of	O
biology	B-C0005532
of	O
low	B-C0445550
doses	I-C0445550
of	O
radiation	B-C0851346
.	O
	
results	O
of	O
the	O
work	O
done	O
so	O
far	O
support	B-C1521721
the	O
idea	B-C1947946
that	O
low	B-C0445550
doses	I-C0445550
of	O
radiation	B-C0851346
have	O
effects	O
that	O
differ	O
from	O
those	O
associated	B-C0332281
with	I-C0332281
high	B-C0444956
dose	I-C0444956
exposures	B-C0014412
this	O
work	O
,	O
however	O
,	O
is	O
far	O
from	O
sufficient	B-C0205410
for	O
the	O
development	B-C1527148
of	O
a	O
new	O
theoretical	B-C0282574
framework	I-C0282574
needed	O
for	O
the	O
understanding	O
of	O
low	B-C0445550
dose	I-C0445550
radiation	B-C0015333
exposures	I-C0015333
.	O
	
mechanistic	O
understanding	O
of	O
radiation	B-C4281532
effects	I-C4281532
at	O
low	B-C0445550
doses	I-C0445550
is	O
necessary	O
in	O
order	O
to	O
develop	O
better	O
radiation	B-C0034533
protection	I-C0034533
policy	B-C0242456
.	O
	
gleason	B-C0332326
grade	I-C0332326
grouping	I-C0332326
of	O
prostate	B-C0600139
cancer	I-C0600139
is	O
of	O
prognostic	B-C1514474
value	I-C1514474
in	O
asian	B-C0078988
men	B-C0025266
the	O
international	B-C1708333
society	I-C1708333
of	I-C1708333
urological	I-C1708333
pathology	I-C1708333
made	O
recommendations	O
for	O
the	O
use	O
of	O
grade	B-C0332326
groups	I-C0332326
gg	B-C0332326
originally	O
described	O
by	O
epstein	B-C1547383
and	O
colleagues	B-C0681088
over	O
gleason	B-C3203027
score	I-C3203027
gs	B-C3203027
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	B-C0425382
by	O
the	O
who	B-C4267671
classification	I-C4267671
in	O
2016	O
.	O
	
the	O
majority	O
of	O
studies	B-C2603343
validating	O
this	O
revision	B-C0439617
have	O
been	O
in	O
caucasian	B-C0043157
populations	I-C0043157
.	O
	
we	O
therefore	O
asked	O
whether	O
the	O
new	O
gg	B-C0332326
system	I-C0332326
was	O
retrospectively	O
associated	O
with	O
biochemical	B-C0242793
disease-free	I-C0242793
survival	I-C0242793
in	O
a	O
mixed-ethnicity	B-C0015031
cohort	B-C0599755
of	O
asian	B-C0078988
men	B-C0025266
.	O
	
a	O
total	O
of	O
680	O
radical	B-C0194810
prostatectomies	I-C0194810
rps	B-C0194810
from	O
2005	O
to	O
2014	O
were	O
included	O
.	O
	
gs	B-C3203027
from	O
initial	O
biopsy	B-C0005558
and	O
rp	B-C0194810
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	B-C0868928
to	O
gg	B-C0332326
,	O
defined	O
as	O
1	O
gs	B-C3203027
6	O
2	O
gs	B-C3203027
3+4=7	O
3	O
gs	B-C3203027
4+3=7	O
4	O
gs	B-C3203027
4+4=8/5+3=8/3+5=8	O
and	O
5	O
gs	B-C3203027
9-10	O
.	O
	
biochemical	B-C2985506
recurrence	I-C2985506
was	O
defined	O
as	O
two	O
consecutive	O
post-	O
rp	B-C0194810
prostate-specific	B-C0138741
antigen	I-C0138741
psa	B-C0138741
levels	O
of	O
>0	O
ng/ml	O
after	O
post-	O
rp	B-C0194810
psa	B-C0138741
reaching	O
the	O
nadir	B-C1708760
of	O
<0	O
ng/ml	O
.	O
	
our	O
data	B-C1511726
showed	O
that	O
kaplan-meier	B-C1720943
analysis	I-C1720943
revealed	O
significant	O
differences	O
in	O
biochemical	B-C2985506
recurrence	I-C2985506
within	O
gleason	B-C0332326
gg	I-C0332326
based	O
on	O
either	O
biopsy	B-C0005558
or	O
prostatectomy	B-C0033573
scoring	B-C0449820
.	O
	
multivariate	B-C0026777
analysis	I-C0026777
further	O
confirmed	O
that	O
a	O
higher	O
gg	B-C0332326
was	O
significantly	O
associated	O
with	O
risk	B-C0035647
of	O
biochemical	B-C2985506
recurrence	I-C2985506
.	O
	
this	O
gg	B-C0332326
system	I-C0332326
had	O
a	O
higher	O
prognostic	B-C0449821
discrimination	B-C2945687
for	O
both	O
initial	O
biopsy	B-C0005558
and	O
rp	B-C0194810
than	O
gs	B-C3203027
.	O
	
our	O
study	B-C2603343
validates	B-C1519941
the	O
use	O
of	O
the	O
revised	B-C0439617
and	O
updated	B-C1519814
gg	B-C0332326
system	I-C0332326
in	O
a	O
mixed-ethnicity	B-C0015031
population	I-C0015031
of	O
asian	B-C0078988
men	B-C0025266
.	O
	
higher	O
gg	B-C0332326
was	O
significantly	O
associated	O
with	O
increased	O
risk	B-C0035647
of	O
biochemical	B-C2985506
recurrence	I-C2985506
.	O
	
we	O
therefore	O
recommend	O
its	O
use	O
to	O
inform	O
clinical	B-C1516615
management	I-C1516615
for	O
patients	B-C0030705
with	O
prostate	B-C0600139
cancer	I-C0600139
.	O
	
membrane	B-C3161472
nanoclusters	B-C1704332
of	O
fcγri	B-C0123263
segregate	O
from	O
inhibitory	B-C3463820
sirpα	B-C0671702
upon	O
activation	B-C2248379
of	I-C2248379
human	I-C2248379
macrophages	I-C2248379
signal	B-C0037083
integration	I-C0037083
between	O
activating	B-C1879547
fc	B-C0034805
receptors	I-C0034805
and	O
inhibitory	B-C3463820
signal	B-C0671702
regulatory	I-C0671702
protein	I-C0671702
α	I-C0671702
sirpα	B-C0671702
controls	O
macrophage	B-C0024432
phagocytosis	B-C0031308
.	O
	
here	O
,	O
using	O
dual-color	B-C0430389
direct	I-C0430389
stochastic	I-C0430389
optical	I-C0430389
reconstruction	I-C0430389
microscopy	I-C0430389
,	O
we	O
report	O
that	O
fcγ	B-C0123263
receptor	I-C0123263
i	I-C0123263
fcγri	B-C0123263
,	O
fcγrii	B-C0796385
,	O
and	O
sirpα	B-C0671702
are	O
not	O
homogeneously	B-C1881065
distributed	O
at	O
macrophage	B-C0024432
surfaces	B-C0699040
but	O
are	O
organized	O
in	O
discrete	B-C0443299
nanoclusters	B-C1704332
,	O
with	O
a	O
mean	O
radius	O
of	O
71	O
11	O
nm	O
,	O
60	O
6	O
nm	O
,	O
and	O
48	O
3	O
nm	O
,	O
respectively	O
.	O
	
nanoclusters	B-C1704332
of	O
fcγri	B-C0123263
,	O
but	O
not	O
fcγrii	B-C0796385
,	O
are	O
constitutively	O
associated	B-C0332281
with	I-C0332281
nanoclusters	B-C1704332
of	O
sirpα	B-C0671702
,	O
within	O
62	O
5	O
nm	O
,	O
mediated	O
by	O
the	O
actin	B-C0025979
cytoskeleton	I-C0025979
.	O
	
upon	O
fc	B-C0034805
receptor	I-C0034805
activation	B-C1514758
,	O
src-family	B-C0282625
kinase	I-C0282625
signaling	B-C1154413
leads	O
to	O
segregation	O
of	O
fcγri	B-C0123263
and	O
sirpα	B-C0671702
nanoclusters	B-C1704332
to	O
be	O
197	O
3	O
nm	O
apart	O
.	O
	
co-ligation	B-C0314675
of	O
sirpα	B-C0671702
with	O
cd47	B-C1506697
abrogates	O
nanocluster	B-C1704332
segregation	O
.	O
	
if	O
the	O
balance	O
of	O
signals	B-C0037083
favors	O
activation	B-C1879547
,	O
fcγri	B-C0123263
nanoclusters	B-C1704332
reorganize	B-C0680829
into	O
periodically	B-C0332182
spaced	O
concentric	B-C1254362
rings	I-C1254362
.	O
	
thus	O
,	O
a	O
nanometer	B-C0439202
-	O
and	O
micron-scale	B-C0439201
reorganization	B-C0680829
of	O
activating	B-C1879547
and	O
inhibitory	B-C3463820
receptors	B-C0597357
occurs	O
at	O
the	O
surface	O
of	O
human	B-C0024432
macrophages	I-C0024432
concurrent	B-C0205420
with	O
signal	B-C0037083
integration	I-C0037083
.	O
	
firecracker	B-C0336696
eye	B-C3544170
exposure	I-C3544170
experimental	B-C0681814
study	I-C0681814
and	O
simulation	B-C0679083
understanding	O
the	O
mechanisms	B-C0441712
of	O
traumatic	B-C0332663
ocular	B-C0015408
injury	I-C0015408
is	O
helpful	O
to	O
make	O
accurate	B-C0443131
diagnoses	B-C0011900
before	O
the	O
symptoms	B-C1457887
emerge	O
and	O
to	O
develop	O
specific	O
eye	B-C3826373
protection	I-C3826373
.	O
	
the	O
comprehension	B-C0162340
of	O
the	O
dynamics	B-C3826426
of	O
primary	B-C0205225
blast	B-C0005700
injury	I-C0005700
mechanisms	B-C0441712
is	O
a	O
challenging	O
issue	B-C0033213
.	O
	
the	O
question	O
is	O
whether	O
the	O
pressure	B-C0033095
wave	B-C0678544
propagation	B-C1254366
and	O
reflection	B-C4054089
alone	O
could	O
cause	B-C0085978
ocular	B-C4061128
damage	I-C4061128
.	O
	
to	O
date	O
,	O
there	O
are	O
dissenting	B-C0012742
opinions	B-C0871010
and	O
no	O
conclusive	B-C2828146
evidence	B-C3887511
thereupon	O
.	O
	
a	O
previous	O
numerical	B-C0220825
investigation	I-C0220825
of	O
blast	B-C0337026
trauma	B-C3714660
highlighted	O
the	O
dynamic	B-C0729333
effect	B-C1280500
of	O
pressure	B-C0033095
propagation	B-C1254366
and	O
its	O
amplification	B-C1521871
by	O
the	O
geometry	B-C0449829
of	O
the	O
bony	B-C1266926
orbit	I-C1266926
,	O
inducing	B-C0205263
a	O
resonance	B-C0459800
cavity	B-C0029180
effect	B-C1280500
and	O
a	O
standing	B-C0678544
wave	I-C0678544
hazardous	B-C0337044
for	O
eye	B-C0015392
tissues	B-C0040300
.	O
	
the	O
objective	O
of	O
the	O
current	O
work	O
is	O
to	O
find	O
experimental	B-C1517586
evidence	B-C3887511
of	O
the	O
numerically	B-C0243174
identified	B-C0205396
phenomenon	B-C1882365
.	O
	
therefore	O
,	O
tests	B-C0392366
aimed	O
at	O
evaluating	B-C0220825
the	O
response	B-C0871261
of	O
porcine	B-C3665571
eyes	B-C0015392
to	O
blast	B-C0337026
overpressure	B-C0033095
generated	O
by	O
firecrackers	B-C0336696
explosion	B-C0015329
were	O
performed	B-C0884358
.	O
	
the	O
orbital	B-C0029180
cavity	I-C0029180
effect	B-C1280500
was	O
considered	O
mounting	O
the	O
enucleated	B-C1396718
eyes	I-C1396718
inside	O
a	O
dummy	O
orbit	B-C0029180
.	O
	
the	O
experimental	B-C1517586
measurements	B-C0242485
obtained	B-C1301820
during	O
the	O
explosion	B-C0015329
tests	B-C0392366
presented	O
in	O
this	O
paper	B-C0282420
corroborate	B-C1456348
the	O
numerical	B-C3887511
evidence	I-C3887511
of	O
a	O
high-frequency	B-C0205212
pressure	B-C0033095
amplification	B-C1521871
,	O
enhancing	B-C2349975
the	O
loading	O
on	O
the	O
ocular	B-C0015392
tissues	B-C0040300
,	O
attributable	B-C0596130
to	O
the	O
orbital	B-C4243627
bony	I-C4243627
walls	I-C4243627
surrounding	O
the	O
the	O
platelet-activating	B-C0071234
receptor	I-C0071234
c-type	B-C2354438
lectin	I-C2354438
receptor-2	I-C2354438
plays	O
an	O
essential	O
role	B-C1705810
in	O
liver	B-C0023907
regeneration	I-C0023907
after	O
partial	B-C0193398
hepatectomy	I-C0193398
in	O
mice	B-C0025929
essentials	O
regeneration	B-C0023907
role	B-C1705810
of	O
c-type	B-C2354438
lectin	I-C2354438
receptor-2	I-C2354438
clec-2	B-C2354438
after	O
70%	B-C0193398
hepatectomy	I-C0193398
hpx	B-C0193398
was	O
investigated	O
.	O
	
wild-type	B-C1883559
or	O
clec-2	B-C0017337
deleted	B-C0017260
from	O
platelets	B-C0005821
of	O
chimeric	B-C0025929
mice	I-C0025929
flko	B-C0025929
underwent	O
hpx	B-C0193398
.	O
	
the	O
liver/body	B-C2983636
weight	I-C2983636
ratio	I-C2983636
was	O
significantly	O
lower	O
in	O
the	O
flko	B-C0025929
than	O
in	O
the	O
wild-type	B-C1520150
.	O
	
clec-2	B-C2354438
plays	O
an	O
essential	O
role	B-C1705810
in	O
liver	B-C0023907
regeneration	I-C0023907
after	O
hpx	B-C0193398
.	O
	
background	O
and	O
aim	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	B-C1705810
of	O
c-type	B-C2354438
lectin	I-C2354438
receptor	I-C2354438
clec	I-C2354438
in	O
liver	B-C0023907
regeneration	I-C0023907
following	O
partial	B-C0193398
liver	I-C0193398
resection	I-C0193398
in	O
mice	B-C0025929
.	O
	
materials	O
and	O
methods	O
irradiated	O
chimeric	B-C0025929
mice	I-C0025929
transplanted	B-C0700106
with	O
fetal	B-C0521457
liver	B-C0227525
cells	I-C0227525
from	O
wild-type	B-C1520150
wt	I-C1520150
mice	I-C1520150
,	O
clec-2	B-C0017337
-	O
deleted	B-C0017260
ko	O
mice	B-C0025929
or	O
mice	B-C0025929
with	O
clec-2	B-C0017337
deleted	B-C0017260
specifically	O
from	O
platelets	B-C0005821
flko	O
were	O
generated	B-C3146294
.	O
	
mice	B-C0025929
underwent	O
70%	B-C0193398
partial	I-C0193398
hepatectomy	I-C0193398
ph	B-C0193398
.	O
	
immunohistochemical	B-C0487602
staining	I-C0487602
was	O
performed	O
to	O
investigate	O
the	O
expression	B-C1171362
of	O
the	O
endogenous	B-C0205227
ligand	B-C0023688
for	O
clec-2	B-C2354438
,	O
podoplanin	B-C3537357
.	O
	
the	O
accumulation	B-C0007613
of	O
platelets	B-C0005821
in	O
the	O
liver	B-C0023884
was	O
also	O
quantified	B-C1709793
.	O
	
the	O
hepatic	B-C0205054
expression	B-C1171362
of	O
the	O
il-6	B-C0021760
/	O
gp130	B-C0017968
and	O
stat3	B-C0253050
,	O
akt	B-C0164786
and	O
erk1/2	B-C0600388
was	O
also	O
examined	O
.	O
	
results	O
the	O
liver/body	B-C2983636
weight	I-C2983636
ratio	I-C2983636
and	O
expression	B-C1171362
of	O
all	O
cell	B-C0596290
proliferation	I-C0596290
markers	B-C1611701
were	O
significantly	O
lower	O
in	O
the	O
flko	B-C0025929
group	I-C0025929
than	O
in	O
the	O
wt	B-C1520150
group	I-C1520150
.	O
	
the	O
expression	B-C1171362
of	O
phosphorylated	B-C0164786
p	I-C0164786
akt	I-C0164786
and	O
perk1	B-C0600388
/2	O
was	O
similar	O
in	O
the	O
wt	B-C1520150
and	O
flko	B-C0025929
groups	I-C0025929
.	O
	
on	O
the	O
other	O
hand	O
,	O
the	O
expression	B-C1171362
of	O
pstat3	B-C0253050
and	O
il-6	B-C0021760
was	O
significantly	O
stronger	O
in	O
the	O
wt	B-C1520150
group	I-C1520150
than	O
in	O
the	O
flko	B-C0025929
group	I-C0025929
.	O
	
the	O
expression	B-C1171362
of	O
podoplanin	B-C3537357
was	O
detected	O
in	O
the	O
hepatic	B-C0227523
sinusoids	I-C0227523
of	O
both	O
groups	B-C0441833
.	O
	
however	O
,	O
the	O
extent	O
to	O
which	O
platelets	B-C0005821
accumulated	O
in	O
hepatic	B-C0227523
sinusoids	I-C0227523
was	O
significantly	O
less	O
in	O
the	O
flko	B-C0025929
group	I-C0025929
than	O
in	O
the	O
wt	B-C1520150
group	I-C1520150
.	O
	
conclusion	O
clec-2	B-C2354438
was	O
involved	O
in	O
hepatic	B-C0023907
regeneration	I-C0023907
after	O
liver	B-C0019144
resection	I-C0019144
and	O
clec-2	B-C2354438
-related	O
liver	B-C0023907
regeneration	I-C0023907
was	O
attributed	O
to	O
the	O
interaction	O
between	O
platelets	B-C0005821
and	O
sinusoidal	B-C0682624
endothelial	B-C0225336
cells	I-C0225336
.	O
	
temporal	B-C1254367
stability	B-C0205360
of	O
heavy	B-C0556345
drinking	I-C0556345
days	O
and	O
drinking	B-C0001948
reductions	B-C0441610
among	O
heavy	B-C0337678
drinkers	I-C0337678
in	O
the	O
combine	B-C2603343
study	I-C2603343
recently	O
,	O
the	O
food	B-C0041714
and	I-C0041714
drug	I-C0041714
administration	I-C0041714
fda	B-C0041714
proposed	O
to	O
expand	B-C0205229
the	O
options	O
for	O
primary	B-C0205225
end	B-C2349179
points	I-C2349179
in	O
the	O
development	B-C1527148
of	O
medications	B-C2081612
for	O
alcohol	B-C0001956
use	I-C0001956
disorder	I-C0001956
to	O
include	O
either	O
abstinence	B-C3843422
from	O
alcohol	B-C0001967
or	O
a	O
nonabstinent	B-C0243095
outcome	B-C1274040
no	O
heavy	B-C0556345
drinking	I-C0556345
days	O
with	O
a	O
heavy	B-C0556345
drinking	I-C0556345
day	O
defined	B-C1704788
as	O
more	O
than	O
3	O
drinks	B-C0001967
per	O
day	O
for	O
women	B-C0043210
and	O
more	O
than	O
4	O
drinks	B-C0001967
per	O
day	O
for	O
men	B-C0025266
>3/>4	O
cutoff	B-C1442160
.	O
	
the	O
fda	B-C0041714
also	O
suggested	B-C1705535
that	O
6	O
months	B-C0439231
would	O
be	O
the	O
most	O
appropriate	B-C1548787
length	B-C1706316
for	I-C1706316
a	I-C1706316
clinical	I-C1706316
trial	I-C1706316
to	O
demonstrate	O
the	O
stability	B-C0205360
of	O
this	O
nonabstinent	B-C0243095
drinking	B-C0001948
outcome	B-C1274040
.	O
	
however	O
,	O
few	O
alcohol	O
clinical	B-C0008976
trials	I-C0008976
have	O
examined	B-C0332128
the	O
stability	B-C0205360
of	O
nonheavy	B-C0556344
drinking	I-C0556344
during	B-C0347984
and	O
after	B-C0001758
treatment	I-C0001758
.	O
	
in	O
a	O
secondary	B-C0683944
analysis	I-C0683944
of	O
the	O
combine	B-C2603343
study	I-C2603343
data	B-C1511726
n	O
=	O
1	O
,	O
we	O
examined	B-C0332128
transitions	B-C2700061
in	O
heavy	B-C0556345
drinking	I-C0556345
days	O
during	B-C0454268
the	I-C0454268
course	I-C0454268
of	I-C0454268
treatment	I-C0454268
months	B-C0439231
1	O
through	O
4	O
,	O
during	B-C0347984
the	O
transition	B-C2700061
out	O
of	O
treatment	B-C0087111
months	B-C0439231
4	O
through	O
7	O
,	O
and	O
up	O
to	O
12	O
months	B-C0439231
afterward	O
months	B-C0439231
13	O
through	O
16	O
using	O
latent	B-C0681946
variable	I-C0681946
mixture	I-C0681946
models	I-C0681946
.	O
	
heavy	B-C0556345
drinking	I-C0556345
and	O
nonheavy	B-C0556344
drinking	I-C0556344
were	O
relatively	O
stable	B-C0205360
in	O
consecutive	B-C1707491
months	B-C0439231
minimum	B-C1524031
agreement	O
kappa	O
=	O
0.64	O
for	O
months	B-C0439231
1	O
to	O
2	O
.	O
	
most	O
individuals	B-C0237401
were	O
stable	B-C0205360
low-risk	B-C3538919
drinkers	B-C0556338
/	O
abstainers	B-C0682156
or	O
heavy	B-C0337678
drinkers	I-C0337678
by	O
the	O
end	O
of	O
treatment	B-C0087111
,	O
as	O
characterized	B-C1880022
by	O
a	O
10%	O
probability	B-C0033204
or	O
less	O
of	O
transitioning	B-C2700061
out	O
of	O
either	O
a	O
no	O
heavy	B-C0556345
drinking	I-C0556345
state	B-C1442792
or	O
a	O
heavy	B-C0556345
drinking	I-C0556345
state	B-C1442792
.	O
	
more	O
than	O
two-thirds	O
of	O
the	O
heavy	B-C0337678
drinkers	I-C0337678
who	O
exceeded	O
the	O
heavy	B-C0556345
drinking	I-C0556345
threshold	B-C0449864
during	B-C2709058
treatment	I-C2709058
reported	B-C0700287
,	O
on	O
average	B-C1510992
,	O
a	O
64%	O
reduction	B-C0441610
in	O
drinking	B-C0556327
frequency	I-C0556327
and	O
a	O
38%	O
reduction	B-C0441610
in	O
drinking	B-C0001948
intensity	O
from	O
pretreatment	B-C3539076
drinking	B-C0001948
levels	B-C0441889
.	O
	
the	O
results	B-C0456984
show	O
stability	B-C0205360
of	O
no	O
heavy	B-C0556345
drinking	I-C0556345
as	O
an	O
outcome	B-C1274040
within	O
the	O
first	O
4	O
months	B-C0439231
of	O
treatment	B-C0087111
and	O
that	O
the	O
>3/>4	O
drink	B-C0001967
cutoff	B-C1442160
may	O
mask	O
substantial	O
reductions	B-C0441610
in	O
alcohol	B-C0001948
consumption	I-C0001948
among	O
some	O
patients	B-C0030705
.	O
	
future	O
studies	B-C2603343
should	O
explore	O
the	O
clinical	B-C0205210
utility	O
of	O
reduction	B-C0441610
end	B-C2349179
points	I-C2349179
.	O
	
oral	B-C0029162
health	I-C0029162
in	O
transition	B-C2700061
the	O
hadza	B-C1257890
foragers	I-C1257890
of	O
tanzania	B-C0039298
conventional	B-C0439858
wisdom	O
holds	O
that	O
a	O
decline	B-C0547047
in	O
oral	B-C0029162
health	I-C0029162
accompanies	O
the	O
transition	B-C2700061
from	O
hunting	B-C4255216
and	O
gathering	B-C2371489
to	O
agriculture	B-C0001829
,	O
given	O
increased	B-C0205217
consumption	B-C1947907
of	O
carbohydrates	B-C0012170
.	O
	
this	O
widely	O
touted	O
example	B-C1707959
of	O
the	O
mismatch	B-C1881865
between	O
our	O
biology	B-C0005532
and	O
modern	B-C0023676
lifestyle	I-C0023676
has	O
been	O
intuited	O
largely	O
from	O
the	O
bioarchaeological	B-C0034869
record	I-C0034869
of	O
the	O
neolithic	B-C2948499
revolution	I-C2948499
in	O
the	O
new	B-C2700280
world	I-C2700280
.	O
	
recent	O
studies	B-C2603343
of	O
other	O
populations	B-C0032659
have	O
,	O
however	O
,	O
challenged	O
the	O
universality	O
of	O
this	O
assertion	B-C1301625
.	O
	
here	O
,	O
we	O
present	O
the	O
first	O
comprehensive	B-C1880156
study	B-C2603343
of	O
oral	B-C0029162
health	I-C0029162
among	O
a	O
living	B-C1257890
population	I-C1257890
in	O
transition	B-C2700061
from	O
the	O
bush	B-C0330099
to	O
village	B-C0023676
life	I-C0023676
,	O
the	O
hadza	B-C1257890
hunter	B-C0239971
-	O
gatherers	B-C1257890
of	O
tanzania	B-C0039298
,	O
to	O
test	O
the	O
hypothesis	B-C1512571
that	O
the	O
shift	B-C2700061
from	O
foraging	B-C2752984
to	O
farming	B-C0001829
,	O
or	O
agricultural	B-C0001827
intensification	I-C0001827
,	O
inevitably	O
leads	O
to	O
increased	B-C0205217
periodontal	B-C0031090
disease	I-C0031090
,	O
caries	B-C0011334
,	O
and	O
orthodontic	B-C0332276
disorders	B-C0012634
.	O
	
our	O
results	B-C1274040
showed	O
that	O
women	B-C0043210
living	B-C0337645
in	O
villages	B-C0562518
consuming	B-C1947907
a	O
mostly	O
agricultural	B-C0242775
diet	B-C0012155
exhibited	O
more	O
caries	B-C0011334
and	O
periodontal	B-C0031090
disease	I-C0031090
than	O
those	O
living	B-C0337645
in	O
the	O
bush	B-C0330099
consuming	B-C1947907
a	O
mostly	O
wild-food	B-C0012155
diet	I-C0012155
.	O
	
furthermore	O
,	O
men	B-C0025266
living	B-C0337645
in	O
the	O
bush	B-C0330099
consuming	B-C1947907
mostly	O
a	O
wild-food	B-C0012155
diet	I-C0012155
had	O
more	O
than	O
those	O
living	B-C0337645
in	O
the	O
village	B-C0562518
consuming	B-C1947907
a	O
mostly	O
agricultural	B-C0242775
diet	B-C0012155
.	O
	
these	O
findings	B-C0243095
are	O
explained	O
by	O
the	O
high	B-C0205250
incidence	B-C0021149
of	O
maize	B-C1138842
consumption	B-C1947907
in	O
village	B-C0562518
settings	O
,	O
along	O
with	O
previously	O
recognized	O
variation	B-C0205419
in	O
rate	B-C1521828
of	O
caries	B-C0011334
between	O
men	B-C0025266
and	O
women	B-C0043210
.	O
	
the	O
unexpected	O
discovery	O
of	O
high	B-C0205250
caries	B-C0011334
incidences	B-C0021149
for	O
men	B-C0025266
in	O
the	O
bush	B-C0330099
is	O
likely	O
explained	O
by	O
heavy	O
reliance	O
on	O
honey	B-C0019906
,	O
and	O
perhaps	O
differential	O
access	O
to	O
tobacco	B-C0008038
and	O
marijuana	B-C0024808
.	O
	
these	O
data	B-C1511726
support	O
the	O
notions	O
that	O
mechanisms	B-C0441712
of	O
cariogenesis	B-C0011334
are	O
multifactorial	B-C1837655
and	O
that	O
the	O
relationships	B-C0439849
between	O
oral	B-C0029162
health	I-C0029162
and	O
the	O
shift	B-C2700061
from	O
a	O
predominantly	O
wild-food	B-C0012155
diet	I-C0012155
to	O
one	O
dominated	O
by	O
cultigens	B-C0242775
the	O
r2r3myb	B-C0040648
vvmybpa1	B-C0040648
from	O
grape	B-C0682492
reprograms	O
the	O
phenylpropanoid	B-C1156966
pathway	I-C1156966
in	O
tobacco	B-C0740009
flowers	B-C0330090
this	O
work	O
shows	O
that	O
,	O
in	O
tobacco	B-C0740009
,	O
the	O
ectopic	B-C1512167
expression	I-C1512167
of	O
vvmybpa1	B-C0040648
,	O
a	O
grape	B-C0682492
regulator	B-C1704735
of	O
proanthocyanidin	B-C0072018
biosynthesis	O
,	O
up-	B-C1157519
or	I-C1157519
down-regulates	I-C1157519
different	O
branches	O
of	O
the	O
phenylproanoid	B-C1156966
pathway	I-C1156966
,	O
in	O
a	O
structure-specific	O
fashion	O
.	O
	
proanthocyanidins	B-C0072018
are	O
flavonoids	B-C0596577
of	O
paramount	O
importance	O
for	O
animal	B-C3668949
and	O
human	B-C0012155
diet	I-C0012155
.	O
	
research	B-C0035168
interest	O
increasingly	O
tilts	O
towards	O
generating	O
crops	B-C0242775
enriched	O
with	O
these	O
health	B-C0018684
-promoting	O
compounds	B-C0205198
.	O
	
flavonoids	B-C0596577
synthesis	B-C1883254
is	O
regulated	O
by	O
the	O
mbw	B-C1167128
transcriptional	B-C1167128
complex	I-C1167128
,	O
made	O
of	O
r2r3myb	B-C0040648
,	O
bhlh	B-C0288972
and	O
wd40	B-C0040648
proteins	I-C0040648
,	O
with	O
the	O
myb	B-C0040648
components	O
liable	O
for	O
channeling	B-C0439799
the	O
complex	B-C1704241
towards	O
specific	O
branches	O
of	O
the	O
pathway	B-C1704259
.	O
	
hence	O
,	O
using	O
tobacco	B-C0740009
as	O
a	O
model	B-C0026336
,	O
here	O
,	O
we	O
tested	B-C0039593
if	O
the	O
ectopic	B-C1512167
expression	I-C1512167
of	O
the	O
proanthocyanidin	B-C0072018
regulator	B-C1704735
vvmybpa1	B-C0040648
from	O
grape	B-C0682492
induces	B-C0205263
the	O
biosynthesis	B-C0005572
of	O
these	O
compounds	B-C0205198
in	O
not-naturally	O
committed	B-C0301868
cells	I-C0301868
.	O
	
here	O
,	O
we	O
show	O
,	O
via	O
targeted	O
transcriptomic	B-C0040649
and	O
metabolic	B-C0311400
analyses	B-C0936012
of	O
primary	O
transgenic	B-C0085245
lines	I-C0085245
and	O
their	O
progeny	B-C0680063
,	O
that	O
vvmybpa1	B-C0040648
alters	O
the	O
phenylpropanoid	B-C1156966
pathway	I-C1156966
in	O
tobacco	B-C0740009
floral	B-C0330090
organs	I-C0330090
,	O
in	O
a	O
structure-specific	O
fashion	O
.	O
	
we	O
also	O
report	O
that	O
a	O
modest	O
vvmybpa1	B-C0040648
expression	B-C1171362
is	O
sufficient	O
to	O
induce	O
the	O
expression	B-C1171362
of	O
both	O
proanthocyanidin	B-C0072018
-specific	O
and	O
early	B-C0017337
genes	I-C0017337
of	O
the	O
phenylpropanoid	B-C1156966
pathway	I-C1156966
.	O
	
consequently	O
,	O
proanthocyanidins	B-C0072018
and	O
chlorogenic	B-C0008240
acids	I-C0008240
are	O
induced	O
or	O
de	B-C1515568
novo	I-C1515568
synthetised	O
in	O
floral	B-C0330090
limbs	I-C0330090
,	O
tubes	I-C0330090
and	O
stamens	B-C1136236
.	O
	
other	O
phenylpropanoid	B-C1156966
branches	I-C1156966
are	O
conversely	O
induced	O
or	O
depleted	B-C0333668
according	O
to	O
the	O
floral	B-C0330090
structure	I-C0330090
.	O
	
our	O
study	O
documents	O
a	O
novel	B-C0205314
and	O
distinct	O
function	O
of	O
vvmybpa1	B-C0040648
with	O
respect	O
to	O
other	O
mybs	B-C0040648
regulating	O
proanthocyanidins	B-C0072018
.	O
	
present	O
findings	B-C2607943
may	O
have	O
major	O
implications	O
in	O
designing	B-C0679199
strategies	I-C0679199
for	O
enriching	O
crops	B-C0242775
with	O
health	B-C0018684
-promoting	O
genome-wide	B-C2350277
association	I-C2350277
mapping	I-C2350277
in	O
winter	B-C0004755
barley	I-C0004755
for	O
grain	B-C0086369
yield	B-C0392762
and	O
culm	B-C0242767
cell	B-C0007623
wall	I-C0007623
polymer	B-C0683005
content	B-C1264655
using	O
the	O
high-throughput	O
compp	B-C0022885
technique	I-C0022885
a	O
collection	B-C1516698
of	O
112	O
winter	B-C0004755
barley	I-C0004755
varieties	I-C0004755
hordeum	B-C0331554
vulgare	I-C0331554
l	I-C0331554
was	O
grown	B-C0597252
in	O
the	O
field	B-C1254362
for	O
two	O
years	B-C0439234
2008/09	O
and	O
2009/10	O
in	O
northern	B-C1709269
italy	B-C0022277
and	O
grain	B-C0086369
and	O
straw	B-C4047917
yields	B-C0392762
recorded	O
.	O
	
in	O
the	O
first	O
year	B-C0439234
of	O
the	O
trial	O
,	O
a	O
severe	O
attack	O
of	O
barley	B-C1000417
yellow	I-C1000417
mosaic	I-C1000417
virus	I-C1000417
baymv	B-C1000417
strongly	O
influenced	B-C4054723
final	O
performances	B-C1882330
with	O
an	O
average	B-C1510992
reduction	B-C0392756
of	O
50%	O
for	O
grain	B-C0086369
and	O
straw	B-C4047917
harvested	B-C0205245
in	O
comparison	B-C1707455
to	O
the	O
second	B-C0205436
year	B-C0439234
.	O
	
the	O
genetic	B-C1285573
determination	I-C1285573
gd	B-C1285573
for	O
grain	B-C0086369
yield	B-C0392762
was	O
0.49	O
and	O
0.70	O
,	O
for	O
the	O
two	O
years	B-C0439234
respectively	O
,	O
and	O
for	O
straw	B-C4047917
yield	B-C0392762
gd	B-C1285573
was	O
low	O
in	O
2009	O
0.09	O
and	O
higher	O
in	O
2010	O
0.29	O
.	O
	
cell	B-C0007623
wall	I-C0007623
polymers	B-C0683005
in	O
culms	B-C0242767
were	O
quantified	O
by	O
means	O
of	O
the	O
monoclonal	O
antibodies	O
lm6	O
,	O
lm11	O
,	O
jim13	O
and	O
bs-400-3	O
and	O
the	O
carbohydrate-binding	O
module	O
cbm3a	O
using	O
the	O
high-throughput	O
compp	O
technique	O
.	O
	
of	O
these	O
,	O
lm6	O
,	O
which	O
detects	O
arabinan	O
components	O
,	O
showed	O
a	O
relatively	O
high	O
gd	O
in	O
both	O
years	O
and	O
a	O
significantly	O
negative	O
correlation	O
with	O
grain	O
yield	O
gyld	O
.	O
	
overall	O
,	O
heritability	O
h2	O
was	O
calculated	O
for	O
gyld	O
,	O
lm6	O
and	O
jim	O
and	O
resulted	O
to	O
be	O
0.42	O
,	O
0.32	O
and	O
0.20	O
,	O
respectively	O
.	O
	
a	O
total	O
of	O
4	O
snps	O
from	O
the	O
9k	O
iselect	O
array	O
were	O
used	O
in	O
the	O
study	O
for	O
the	O
analysis	O
of	O
population	O
structure	O
,	O
linkage	O
disequilibrium	O
ld	O
and	O
genome-wide	O
association	O
study	O
gwas	O
.	O
	
marker-trait	O
associations	O
mta	O
were	O
analyzed	O
for	O
grain	O
yield	O
and	O
cell	O
wall	O
determination	O
by	O
lm6	O
and	O
jim13	O
as	O
these	O
were	O
the	O
traits	O
showing	O
significant	O
correlations	O
between	O
the	O
years	O
.	O
	
a	O
single	O
qtl	O
for	O
gyld	O
containing	O
three	O
mtas	O
was	O
found	O
on	O
chromosome	O
3h	O
located	O
close	O
to	O
the	O
hv-eif4e	O
gene	O
,	O
which	O
is	O
known	O
to	O
regulate	O
resistance	O
to	O
baymv	O
.	O
	
subsequently	O
the	O
qtl	O
was	O
shown	O
to	O
be	O
tightly	O
linked	O
to	O
rym4	O
,	O
a	O
locus	O
for	O
resistance	O
to	O
the	O
virus	O
.	O
	
gwas	O
on	O
arabinans	O
quantified	O
by	O
lm6	O
resulted	O
in	O
the	O
identification	O
of	O
major	O
qtls	O
closely	O
located	O
on	O
3h	O
and	O
hypotheses	O
regarding	O
putative	O
candidate	O
genes	O
were	O
formulated	O
through	O
the	O
study	O
of	O
gene	O
expression	O
levels	O
based	O
on	O
bioinformatics	O
the	O
prevalence	B-C0220900
and	O
clinical	B-C0205210
relevance	B-C2347946
of	O
asa	B-C0004057
nonresponse	B-C4282382
after	O
cardiac	B-C0018821
surgery	I-C0018821
we	O
aimed	O
to	O
identify	O
the	O
prevalence	B-C0220900
of	O
acetylsalicylic	B-C0004057
acid	I-C0004057
asa	B-C0004057
nonresponse	B-C4282382
in	O
patients	B-C0030705
after	O
coronary	B-C0010055
artery	I-C0010055
bypass	I-C0010055
graft	I-C0010055
cabg	I-C0010055
surgery	I-C0010055
and	O
the	O
possible	O
consequences	B-C0686907
for	O
the	O
rate	O
of	O
major	O
cardiovascular	B-C1320716
events	I-C1320716
.	O
	
this	O
prospective	B-C0033522
,	O
observational	B-C1518527
,	O
bicentric	B-C0009247
cohort	I-C0009247
study	I-C0009247
was	O
conducted	O
in	O
two	O
german	B-C0019994
university	I-C0019994
hospitals	I-C0019994
.	O
	
a	O
total	O
of	O
400	O
patients	B-C0030705
200	O
in	O
each	O
study	O
center	O
undergoing	O
elective	B-C0206058
cabg	B-C0010055
surgery	I-C0010055
were	O
enrolled	O
after	O
written	O
informed	O
consent	O
.	O
	
platelet	B-C1254881
function	I-C1254881
was	O
analyzed	O
on	O
day	O
3	O
d3	O
and	O
day	O
5	O
d5	O
postoperatively	B-C0032790
following	O
stimulation	O
with	O
arachidonic	B-C0003695
acid	I-C0003695
aspitest	B-C0032184
and	O
with	O
thrombin	B-C0219419
receptor-activating	I-C0219419
peptide	I-C0219419
6	I-C0219419
traptest	B-C0032184
using	O
multiple	B-C0032184
electrode	I-C0032184
aggregometry	I-C0032184
multiplate	B-C0032184
.	O
	
individuals	O
with	O
an	O
aspitest	B-C0032184
40	O
au	O
were	O
categorized	O
as	O
asa	B-C0004057
nonresponders	B-C0919875
.	O
	
a	O
1-year	O
follow-up	B-C1522577
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	B-C1320716
events	I-C1320716
,	O
hospital	B-C0184666
admissions	I-C0184666
,	O
or	O
deaths	B-C1306577
related	O
to	O
cardiovascular	B-C0007222
disease	I-C0007222
.	O
	
the	O
prevalence	B-C0220900
of	O
asa	B-C0004057
nonresponse	B-C4282382
was	O
51.5	O
on	O
d3	O
,	O
and	O
it	O
significantly	B-C0750502
increased	B-C0205217
to	O
71.3	O
on	O
d5	O
p	O
=	O
0049	O
.	O
	
the	O
area	O
under	O
the	O
aggregation	B-C3828533
curve	I-C3828533
in	O
the	O
traptest	B-C0032184
p	O
<	O
0001	O
,	O
the	O
platelet	B-C0032181
count	I-C0032181
on	O
d5	O
p	O
=	O
009	O
,	O
and	O
the	O
cardiopulmonary	B-C0429123
bypass	I-C0429123
time	I-C0429123
p	O
=	O
01	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
asa	B-C0004057
nonresponse	B-C4282382
.	O
	
a	O
1-year	O
follow-up	B-C1522577
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end	B-C2349179
point	I-C2349179
with	O
no	O
difference	O
between	O
asa	B-C0004057
responders	B-C0919876
and	O
nonresponders	B-C0919875
.	O
	
this	O
study	B-C0008972
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	B-C1518988
asa	B-C0004057
nonresponse	B-C4282382
in	O
patients	B-C0030705
following	O
cabg	B-C0010055
.	O
	
no	O
effect	O
on	O
the	O
incidence	O
of	O
cardiovascular	B-C1320716
events	I-C1320716
was	O
recorded	O
in	O
the	O
1-year	O
follow-up	B-C1522577
.	O
	
therefore	O
,	O
a	O
randomized	B-C0206034
dosage	I-C0206034
adjustment	I-C0206034
trial	I-C0206034
should	O
elucidate	O
whether	O
a	O
tailored	O
asa	B-C0004057
treatment	B-C1533734
after	O
cabg	B-C0010055
surgery	I-C0010055
genome	B-C2348746
sequences	I-C2348746
of	O
mycobacteriophages	B-C0026911
jane	I-C0026911
and	I-C0026911
sneeze	I-C0026911
,	O
new	O
members	O
of	O
cluster	O
g	O
jane	O
and	O
sneeze	O
are	O
newly	O
isolated	B-C0205409
phages	B-C0004651
of	O
mycobacterium	B-C0317761
smegmatis	I-C0317761
mc	I-C0317761
from	O
hillsborough	B-C3812217
,	O
nj	B-C0027971
,	O
and	O
palo	B-C0017446
verde	I-C0017446
,	O
costa	B-C0010182
rica	I-C0010182
,	O
respectively	O
.	O
	
both	O
are	O
cluster	O
g	O
,	O
subcluster	O
g1	O
mycobacteriophages	B-C0026911
.	O
	
notable	O
nucleotide	B-C0028630
differences	B-C1705242
exist	O
between	O
genomes	B-C0017428
in	O
the	O
right	O
half	O
,	O
including	O
the	O
presence	O
of	O
mycobacteriophage	B-C0026911
mobile	B-C1257903
element	I-C1257903
1	I-C1257903
effect	B-C1280500
of	O
punica	B-C1001173
granatum	I-C1001173
fruit	B-C0016767
peel	I-C0016767
on	O
glucose-6-phosphate	B-C0017757
dehydrogenase	I-C0017757
and	O
malate	B-C0024544
dehydrogenase	I-C0024544
in	O
amphistome	B-C0684063
gastrothylax	B-C3006520
indicus	I-C3006520
increasing	B-C0442808
anthelmintic	B-C0003158
resistance	B-C0013203
and	O
the	O
impact	B-C4049986
of	O
conventional	O
anthelmintics	B-C0003158
on	O
the	O
environment	B-C0014406
,	O
it	O
is	O
important	O
to	O
look	O
for	O
alternative	O
strategies	O
against	O
helminth	B-C0018893
parasite	I-C0018893
in	O
sheep	B-C0036945
.	O
	
important	O
lipogenic	B-C0014442
enzymes	I-C0014442
like	O
glucose-6-phosphate	B-C0017757
dehydrogenase	I-C0017757
g-6-pdh	B-C0017757
and	O
malate	B-C0024544
dehydrogenase	I-C0024544
mdh	B-C0024544
show	O
subcellular	B-C3893246
distribution	B-C0449775
pattern	I-C0449775
.	O
	
activity	B-C0243102
of	O
g-6-pdh	B-C0017757
was	O
largely	O
restricted	O
to	O
cytosolic	B-C1511625
fraction	I-C1511625
while	O
mdh	B-C0024544
was	O
found	O
in	O
both	O
cytosolic	B-C1511625
and	O
mitochondrial	B-C0026237
fraction	I-C0026237
in	O
gastrothylax	B-C3006520
indicus	I-C3006520
.	O
	
following	O
in	B-C1533691
vitro	I-C1533691
treatment	B-C1522326
with	O
ethanolic	B-C0001962
and	O
aqueous	B-C2828366
extracts	I-C2828366
of	O
punica	B-C1001173
granatum	I-C1001173
fruit	B-C0016767
peel	I-C0016767
and	O
commercial	O
anthelmintic	B-C0003158
,	O
albendazole	B-C0001911
g-6-pdh	B-C0017757
activity	B-C0243102
was	O
decreased	B-C0392756
by	O
19-32	O
%	O
,	O
whereas	O
mdh	B-C0024544
was	O
suppressed	B-C1260953
by	O
24-41	O
%	O
,	O
compared	O
to	O
the	O
respective	O
control	B-C1550141
.	O
	
albendazole	B-C0001911
was	O
quite	O
effective	B-C1704419
when	O
compared	O
with	O
negative	B-C1947986
control	I-C1947986
and	O
both	O
the	O
extracts	B-C2828366
.	O
	
the	O
results	B-C1274040
indicate	O
that	O
phytochemicals	B-C0577749
of	O
plant	B-C0032098
may	O
act	O
as	O
potential	B-C3245505
vermifuge	B-C0003158
or	O
remitting	B-C2919482
seronegative	I-C2919482
symmetrical	I-C2919482
synovitis	I-C2919482
with	I-C2919482
pitting	I-C2919482
edema	I-C2919482
appearance	O
on	O
fdg	B-C4271885
pet/ct	I-C4271885
remitting	B-C2919482
seronegative	I-C2919482
symmetrical	I-C2919482
synovitis	I-C2919482
with	I-C2919482
pitting	I-C2919482
edema	I-C2919482
rs3pe	B-C2919482
is	O
a	O
rare	B-C0678236
condition	I-C0678236
in	O
the	O
elderly	B-C0001792
and	O
can	O
appear	O
as	O
a	O
first	O
presentation	O
of	O
various	O
types	B-C0332307
of	O
rheumatic	B-C0035435
and	O
malignant	B-C0442867
diseases	I-C0442867
.	O
	
we	O
presented	O
a	O
62-	O
year	B-C0439234
-old	O
man	B-C0025266
with	O
the	O
diagnosis	B-C0011900
of	O
rs3pe	B-C2919482
based	O
on	O
the	O
clinical	B-C0037088
sign	I-C0037088
and	O
laboratory	B-C1705214
data	I-C1705214
.	O
	
because	O
of	O
the	O
possibility	O
of	O
associated	O
malignancies	B-C0006826
in	O
rs3pe	B-C2919482
,	O
fdg	B-C4271885
pet/ct	I-C4271885
was	O
performed	O
to	O
exclude	O
occult	B-C0027667
tumors	I-C0027667
.	O
	
the	O
images	B-C1704254
showed	O
multiple	B-C0439064
,	O
symmetrically	B-C0332516
,	O
diffusely	B-C0205219
increased	B-C0205217
f-fdg	B-C0046056
uptake	B-C0243144
in	O
the	O
soft	B-C0225317
tissue	I-C0225317
around	O
joints	B-C0022417
and	O
bones	B-C0262950
in	O
the	O
shoulders	B-C0037004
,	O
hips	B-C0019552
,	O
knees	B-C0022742
,	O
and	O
parks	B-C0562547
as	O
social	B-C0728831
and	O
cultural	B-C0220814
spaces	B-C1883067
among	O
u.s	B-C0041703
-	O
and	O
foreign	B-C1517294
-	O
born	B-C0005615
latinas	B-C0949335
parks	B-C0562547
provide	O
opportunities	B-C0814559
for	O
people	B-C0027361
to	O
engage	O
in	O
activities	B-C0441655
that	O
can	O
promote	B-C0033414
physical	B-C0205485
and	O
emotional	B-C0849912
well-being	B-C0018684
.	O
	
using	O
focus	B-C0016400
groups	I-C0016400
and	O
personal	B-C1519021
interviews	B-C0021822
conducted	O
in	O
selected	O
neighborhoods	O
of	O
a	O
northeastern	B-C1709272
city	B-C0008848
with	O
a	O
high	B-C0205250
rate	B-C1521828
of	O
obesity	B-C0028754
,	O
we	O
examined	B-C0332128
perceptions	B-C0030971
of	O
barriers	B-C1254370
and	O
facilitators	B-C0205556
regarding	O
the	O
use	B-C1524063
of	I-C1524063
parks	B-C0562547
and	O
park	B-C0562547
features	B-C2348519
that	O
would	O
promote	B-C0033414
physical	B-C0026606
activity	I-C0026606
among	O
latina	B-C0949335
women	B-C0043210
n	O
=	O
39	O
.	O
	
foreign	B-C1517294
-	O
born	B-C0005615
latinas	B-C0949335
emphasized	O
the	O
environmental	B-C0014406
characteristics	B-C1521970
of	O
parks	B-C0562547
and	O
the	O
types	B-C0332307
of	O
amenities	B-C1547538
that	O
can	O
support	O
preferred	O
cultural	B-C0441655
and	O
social	B-C2371613
activities	I-C2371613
,	O
while	O
u.s	B-C0041703
.	O
	
-	O
born	B-C0005615
latinas	B-C0949335
emphasized	O
the	O
use	O
of	O
parks	B-C0562547
for	O
physical	B-C0026606
activity	I-C0026606
and	O
weight	B-C0005910
management	B-C0441655
.	O
	
most	O
striking	O
were	O
the	O
different	O
ways	O
in	O
which	O
foreign	B-C1517294
-	O
born	B-C0005615
participants	B-C0679646
conceptualized	B-C0589138
parks	B-C0562547
as	O
sociocultural	B-C1254362
family	I-C1254362
centers	I-C1254362
,	O
extending	O
more	O
common	B-C0205214
conceptualizations	B-C0589138
centered	O
on	O
exercise	B-C0015259
or	O
individual	B-C0027361
health	B-C0018684
gain	B-C1517378
.	O
	
these	O
findings	B-C2607943
suggest	O
the	O
need	O
for	O
new	B-C0205314
policies	B-C0242456
that	O
incorporate	O
culturally	B-C0220814
specific	B-C0205369
park	B-C0562547
programming	B-C1704769
to	O
promote	B-C0033414
national	O
goals	B-C0018017
of	O
increasing	B-C0442808
levels	B-C0441889
of	O
physical	B-C0026606
activity	I-C0026606
for	O
the	O
impact	B-C4049986
of	O
childhood	B-C0008060
maltreatment	I-C0008060
on	O
the	O
differential	B-C0443199
efficacy	B-C1280519
of	O
cbasp	B-C0033968
versus	O
escitalopram	B-C1099456
in	O
patients	B-C0030705
with	O
chronic	B-C0581391
depression	I-C0581391
a	O
secondary	B-C0683944
analysis	I-C0683944
childhood	B-C0008060
maltreatment	I-C0008060
cm	B-C0008060
has	O
been	O
indicated	B-C1444656
as	O
a	O
predictor	B-C2698872
of	O
a	O
differential	B-C0443199
response	B-C0871261
to	O
antidepressant	B-C1096649
treatment	I-C1096649
with	O
psychotherapy	B-C0033968
compared	B-C1707455
to	O
medication	B-C0013227
.	O
	
in	O
this	O
secondary	B-C0683944
analysis	I-C0683944
,	O
we	O
investigated	B-C1292732
whether	O
the	O
presence	B-C3854307
of	O
cm	B-C0008060
results	B-C1274040
in	O
a	O
differential	B-C0443199
indication	B-C3146298
for	O
the	O
cognitive	B-C0033968
behavioral	I-C0033968
analysis	I-C0033968
system	I-C0033968
of	I-C0033968
psychotherapy	I-C0033968
cbasp	B-C0033968
or	O
escitalopram	B-C1099456
plus	O
clinical	B-C1516615
management	I-C1516615
esc	B-C1099456
.	O
	
sixty	O
patients	B-C0030705
with	O
chronic	B-C0581391
depression	I-C0581391
were	O
randomized	B-C0034656
to	O
either	O
22	O
sessions	B-C1883017
of	O
cbasp	B-C0033968
or	O
esc	B-C1099456
over	O
the	O
course	B-C0750729
of	O
8	B-C0439230
weeks	I-C0439230
of	O
acute	B-C0205178
and	O
20	B-C0439230
weeks	I-C0439230
of	O
extended	B-C0231448
treatment	B-C0087111
at	O
2	O
german	B-C0017480
treatment	B-C0337950
sites	I-C0337950
.	O
	
cm	B-C0008060
was	O
assessed	B-C1516048
using	O
the	O
childhood	B-C0231335
trauma	B-C1510467
questionnaire	B-C0034394
and	O
the	O
clinician	B-C0871685
rated	B-C0871208
early	B-C0282574
trauma	I-C0282574
inventory	I-C0282574
.	O
	
intention-to-treat	B-C2718028
analyses	I-C2718028
were	O
used	O
to	O
examine	O
the	O
impact	B-C4049986
of	O
cm	B-C0008060
on	O
depression	B-C0011570
,	O
global	B-C0017644
functioning	I-C0017644
,	O
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
.	O
	
the	O
presence	B-C3854307
of	O
cm	B-C0008060
did	O
not	O
result	B-C1274040
in	O
significant	B-C0750502
differences	B-C1705242
in	O
treatment	B-C0521982
response	I-C0521982
to	O
cbasp	B-C0033968
or	O
esc	B-C1099456
on	O
any	O
outcome	B-C0086749
measure	I-C0086749
after	O
28	B-C0439230
weeks	I-C0439230
of	O
treatment	B-C0087111
independent	B-C0332291
of	I-C0332291
the	O
type	O
of	O
cm	B-C0008060
assessment	B-C0220825
.	O
	
after	O
8	B-C0439230
weeks	I-C0439230
,	O
a	O
significant	B-C0750502
cm	B-C0008060
treatment	B-C0087111
interaction	B-C1704675
was	O
found	B-C0150312
for	O
scores	B-C0449820
on	O
the	O
montgomery-asberg	B-C4054475
depression	I-C4054475
rating	I-C4054475
scale	I-C4054475
.	O
	
patients	B-C0030705
with	O
a	O
history	B-C0262926
of	O
cm	B-C0008060
receiving	B-C1514756
cbasp	B-C0033968
had	O
a	O
significantly	B-C4055638
lower	I-C4055638
response	B-C0237629
rate	I-C0237629
compared	B-C1707455
to	O
patients	B-C0030705
without	O
cm	B-C0008060
and	O
to	O
those	O
receiving	B-C1514756
esc	B-C1099456
after	O
8	B-C0439230
weeks	I-C0439230
.	O
	
conclusively	B-C2828146
,	O
cbasp	B-C0033968
and	O
esc	B-C1099456
are	O
equally	O
effective	B-C1704419
treatment	B-C0087111
options	O
for	O
the	O
difficult	B-C0332218
to	O
treat	B-C1522326
subgroup	B-C1515021
of	O
patients	B-C0030705
with	O
chronic	B-C0581391
depression	I-C0581391
and	O
a	O
history	B-C0262926
of	O
cm	B-C0008060
.	O
	
cm	B-C0008060
may	O
be	O
a	O
predictor	B-C2698872
of	O
a	O
longer	B-C0205166
latency	B-C0023103
of	O
treatment	B-C0521982
response	I-C0521982
in	O
the	O
case	B-C0868928
of	O
psychotherapy	B-C0033968
.	O
	
cbasp	B-C0033968
and	O
escitalopram	B-C1099456
are	O
equally	O
effective	B-C1704419
treatment	B-C0087111
options	O
for	O
chronic	B-C0581391
depression	I-C0581391
.	O
	
both	O
treatments	B-C0087111
are	O
also	O
equally	O
effective	B-C1704419
for	O
the	O
difficult	B-C0332218
to	O
treat	B-C1522326
subgroup	B-C1515021
of	O
patients	B-C0030705
with	O
chronic	B-C0581391
depression	I-C0581391
and	O
a	O
history	B-C0262926
of	O
childhood	B-C0008060
maltreatment	I-C0008060
.	O
	
childhood	B-C0008060
maltreatment	I-C0008060
may	O
result	B-C1274040
in	O
a	O
longer	B-C0205166
latency	B-C0023103
of	O
treatment	B-C0521982
response	I-C0521982
in	O
the	O
case	B-C0868928
of	O
a	O
role	O
for	O
the	O
locus	B-C0023951
coeruleus	I-C0023951
in	O
the	O
analgesic	B-C0948482
efficacy	I-C0948482
of	O
n-acetylaspartylglutamate	B-C0067685
peptidase	I-C0067685
gcpii	B-C0067685
inhibitors	B-C0014432
zj43	B-C1451894
and	O
2-pmpa	B-C0910831
n-acetylaspartylglutamate	B-C0130693
naag	B-C0130693
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	B-C0027908
in	O
the	O
mammalian	B-C0024660
nervous	B-C0027763
system	I-C0027763
.	O
	
naag	B-C0130693
activates	B-C1879547
a	O
group	B-C0532371
ii	I-C0532371
metabotropic	I-C0532371
glutamate	I-C0532371
receptor	I-C0532371
mglur3	B-C0532371
and	O
is	O
inactivated	O
by	O
an	O
extracellular	B-C0067685
enzyme	I-C0067685
,	O
glutamate	I-C0067685
carboxypeptidase	I-C0067685
ii	I-C0067685
gcpii	B-C0067685
in	B-C1515655
vivo	I-C1515655
.	O
	
inhibitors	B-C0014432
of	I-C0014432
this	I-C0014432
enzyme	I-C0014432
are	O
analgesic	B-C0002771
in	O
animal	B-C0599779
models	I-C0599779
of	O
inflammatory	B-C0234251
,	O
neuropathic	B-C3714625
and	O
bone	B-C0279530
cancer	I-C0279530
pain	B-C0030193
.	O
	
naag	B-C0130693
and	O
gcpii	B-C0067685
are	O
present	O
in	O
the	O
locus	B-C0023951
coeruleus	I-C0023951
,	O
a	O
center	O
for	O
the	O
descending	O
noradrenergic	B-C0599861
inhibitory	B-C3463820
pain	O
system	O
.	O
	
in	O
the	O
formalin	B-C0949307
footpad	B-C2985236
model	B-C0012644
,	O
systemic	B-C0205373
treatment	B-C0039798
with	O
gcpii	B-C0014432
inhibitors	I-C0014432
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B-C0234251
pain	I-C0234251
response	B-C0871261
and	O
increases	O
release	O
of	O
spinal	B-C0521329
noradrenaline	B-C0028351
.	O
	
this	O
analgesic	B-C0948482
efficacy	I-C0948482
is	O
blocked	B-C0332206
by	O
systemic	B-C0205373
injection	B-C0021485
of	O
a	O
group	B-C0532371
ii	I-C0532371
mglur	I-C0532371
antagonist	B-C1254351
,	O
by	O
intrathecal	B-C0021896
spinal	I-C0021896
injection	I-C0021896
of	O
an	O
alpha	B-C0304513
2	I-C0304513
adrenergic	I-C0304513
receptor	I-C0304513
antagonist	I-C0304513
and	O
by	O
microinjection	B-C0025991
of	O
an	O
α-amino-3-hydroxy-5-methylisoxazole-4-propionic	B-C1254351
acid	I-C1254351
ampa	I-C1254351
receptor	I-C1254351
antagonist	I-C1254351
directly	O
into	O
the	O
contralateral	B-C0441988
locus	B-C0023951
coeruleus	I-C0023951
.	O
	
footpad	B-C2985236
inflammation	B-C0021368
increases	O
release	O
of	O
glutamate	B-C0017789
in	O
the	O
contralateral	B-C0441988
locus	B-C0023951
coeruleu	I-C0023951
s	O
and	O
systemic	B-C0205373
treatment	B-C0039798
with	O
a	O
gcpii	B-C0014432
inhibitor	I-C0014432
blocks	B-C0332206
this	O
increase	O
.	O
	
direct	B-C1947931
injection	B-C0021485
of	O
gcpii	B-C0014432
inhibitors	I-C0014432
into	O
the	O
contralateral	B-C0441988
or	O
ipsilatera	B-C0441989
l	O
locus	B-C0023951
coeruleus	I-C0023951
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B-C0234251
pain	I-C0234251
response	B-C0871261
in	O
a	O
dose-dependent	B-C1512045
manner	O
and	O
the	O
contralateral	B-C0441988
effect	B-C1280500
also	O
is	O
blocked	B-C0332206
by	O
intrathecal	B-C0021896
injection	I-C0021896
of	O
an	O
alpha	B-C0304513
2	I-C0304513
adrenergic	I-C0304513
receptor	I-C0304513
antagonist	I-C0304513
.	O
	
these	O
data	O
support	O
the	O
hypothesis	B-C1512571
that	O
the	O
analgesic	B-C0948482
efficacy	I-C0948482
of	O
systemically	O
administered	O
gcpii	B-C0014432
inhibitors	I-C0014432
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	B-C0441988
l	O
locus	B-C0023951
coeruleus	I-C0023951
via	O
group	B-C0532371
ii	I-C0532371
mglur	I-C0532371
,	O
ampa	B-C1528634
and	O
alpha	B-C0001639
2	I-C0001639
adrenergic	I-C0001639
receptors	I-C0001639
.	O
	
association	B-C0439849
of	O
physical	B-C0026606
activity	I-C0026606
on	O
body	B-C0005885
composition	I-C0005885
,	O
cardiometabolic	B-C0035648
risk	I-C0035648
factors	I-C0035648
,	O
and	O
prevalence	B-C0220900
of	O
cardiovascular	B-C0007222
disease	I-C0007222
in	O
the	O
korean	B-C1556095
population	I-C1556095
from	O
the	O
fifth	O
korea	B-C0022771
national	B-C0376344
health	I-C0376344
and	I-C0376344
nutrition	I-C0376344
examination	I-C0376344
survey	I-C0376344
,	O
2008-2011	O
data	B-C1511726
regarding	O
associations	B-C0439849
among	O
physical	B-C0026606
activity	I-C0026606
pa	B-C0026606
level	B-C0441889
,	O
body	B-C0005885
composition	I-C0005885
,	O
and	O
prevalence	B-C0220900
of	O
cardiovascular	B-C0007222
diseases	I-C0007222
in	O
asian	B-C0032659
populations	I-C0032659
are	O
rare	B-C0522498
.	O
	
the	O
international	B-C0034394
physical	I-C0034394
activity	I-C0034394
questionnaire	I-C0034394
ipaq	B-C0034394
was	O
utilized	O
to	O
estimate	B-C0750572
pa	B-C0026606
levels	B-C0441889
and	O
analyze	B-C0936012
the	O
association	B-C0439849
of	O
pa	B-C0026606
level	B-C0441889
with	O
various	O
body	B-C0005885
composition	I-C0005885
parameters	B-C0549193
and	O
the	O
prevalence	B-C0220900
of	O
cardiovascular	B-C0007222
diseases	I-C0007222
by	O
using	O
data	B-C1511726
from	O
the	O
korean	B-C0022771
national	B-C0376344
health	I-C0376344
and	I-C0376344
nutrition	I-C0376344
examination	I-C0376344
survey	I-C0376344
from	O
2008	O
to	O
2011	O
.	O
	
moderate	B-C0205081
and	O
high	B-C0205250
pa	B-C0026606
levels	B-C0441889
were	O
associated	B-C0439849
with	O
lower	B-C1518029
prevalence	I-C1518029
of	O
hypertension	B-C0020538
and	O
diabetes	B-C0011849
mellitus	I-C0011849
,	O
and	O
lower	B-C0205251
concentrations	B-C1446561
of	O
serum	B-C4076066
ferritin	I-C4076066
,	O
parathyroid	B-C4314193
hormone	I-C4314193
,	O
and	O
alkaline	B-C1860130
phosphatase	I-C1860130
.	O
	
sarcopenia	B-C0872084
low	B-C0205251
vs	O
.	O
	
moderate	B-C0205081
vs	O
.	O
	
high	B-C0205250
pa	B-C0026606
group	B-C0441833
14.3	O
vs	O
.	O
	
10.5	O
vs	O
.	O
	
7.3	O
,	O
p	B-C1709380
=	O
0.001	O
,	O
underweight	B-C0041667
5.7	O
vs	O
.	O
	
4.9	O
vs	O
.	O
	
3.5	O
,	O
p	O
=	O
0.001	O
,	O
and	O
central	B-C0311277
obesity	I-C0311277
7.8	O
vs	O
.	O
	
6.9	O
vs	O
.	O
	
6.3	O
,	O
p	O
=	O
0.002	O
were	O
more	O
often	O
observed	B-C1441672
in	O
the	O
low	B-C0205251
pa	B-C0026606
group	B-C0441833
.	O
	
the	O
prevalence	B-C0220900
rates	B-C1521828
of	O
cardiovascular	B-C0007222
diseases	I-C0007222
were	O
lower	B-C0205251
in	O
the	O
moderate	B-C0205081
odds	B-C0028873
ratio	I-C0028873
or	B-C0028873
,	O
0.822	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
,	O
0.737	O
p	B-C1709380
=	O
0.001	O
and	O
high	B-C0205250
activity	B-C0026606
groups	B-C0441833
or	B-C0028873
,	O
0.663	O
95%	O
ci	B-C0009667
,	O
0.589	O
p	B-C1709380
=	O
0.001	O
than	O
in	O
the	O
low	B-C0205251
activity	B-C0026606
group	B-C0441833
,	O
even	O
after	O
adjusting	O
for	O
age	B-C0001779
,	O
sex	B-C0079399
,	O
smoking	B-C0037369
,	O
underlying	B-C0012634
disease	I-C0012634
,	O
and	O
general	B-C0028754
or	O
abdominal	B-C0311277
obesity	I-C0311277
and	O
muscle	B-C0240417
mass	I-C0240417
.	O
	
regular	B-C0815170
physical	I-C0815170
activity	I-C0815170
was	O
associated	B-C0439849
with	O
a	O
low	B-C1518029
prevalence	I-C1518029
of	O
cardiovascular	B-C0007222
diseases	I-C0007222
stroke	B-C0018843
,	O
myocardial	B-C0027051
infarction	I-C0027051
,	O
stable	B-C0340288
angina	I-C0340288
,	O
and	O
chronic	B-C1561643
renal	I-C1561643
disease	I-C1561643
,	O
which	O
was	O
independent	B-C0332291
of	I-C0332291
body	B-C0005885
composition	I-C0005885
and	O
conventional	O
risk	B-C0035648
factors	I-C0035648
in	O
the	O
korean	B-C1556095
population	I-C1556095
,	O
with	O
a	O
positive	B-C1446409
dose-response	B-C0678790
relationship	I-C0678790
.	O
	
treated	B-C0087111
prevalence	B-C0033105
of	O
attention-deficit/hyperactivity	B-C1263846
disorder	I-C1263846
increased	B-C0205217
from	O
2009	O
to	O
2015	O
among	O
school-aged	B-C2827631
children	I-C2827631
and	O
adolescents	B-C0205653
in	O
the	O
united	B-C0041703
states	I-C0041703
the	O
purpose	B-C1285529
of	O
this	O
brief	O
is	O
to	O
describe	B-C1552738
changes	B-C0392747
in	O
the	O
treated	B-C0087111
prevalence	B-C0033105
of	O
medically	B-C0205476
managed	B-C0184516
attention-deficit/hyperactivity	B-C1263846
disorder	I-C1263846
adhd	B-C1263846
among	O
insured	B-C1548605
school-aged	B-C2827631
children	I-C2827631
and	O
adolescents	B-C0205653
in	O
the	O
united	B-C0041703
states	I-C0041703
from	O
2009	O
to	O
2015	O
.	O
	
we	O
examine	B-C0332128
the	O
differences	B-C1705241
between	O
those	O
with	O
employer-sponsored	B-C3824871
insurance	I-C3824871
esi	B-C3824871
and	O
with	O
medicaid	B-C0021682
insurance	I-C0021682
.	O
	
we	O
utilized	O
two	O
large	O
longitudinal	B-C0205127
administrative	B-C0150098
datasets	I-C0150098
containing	O
medical	B-C0205476
and	O
drug	B-C0013227
claims	B-C3824919
data	B-C1511726
on	O
individuals	B-C0237401
with	O
esi	B-C3824871
and	O
medicaid	B-C0021682
insurance	I-C0021682
from	O
truven	B-C0242356
health	I-C0242356
marketscan	I-C0242356
administrative	I-C0242356
claims	I-C0242356
databases	I-C0242356
.	O
	
treated	B-C0087111
prevalence	B-C0033105
was	O
measured	B-C0444706
as	O
the	O
percentage	B-C0439165
of	O
school-aged	B-C2827631
children	I-C2827631
and	O
adolescents	B-C0205653
enrolled	O
in	O
a	O
calendar	B-C0456586
year	I-C0456586
who	O
met	O
the	O
criteria	B-C0243161
for	O
medically	B-C0205476
managed	B-C0184516
adhd	B-C1263846
in	O
the	O
same	O
calendar	B-C0456586
year	I-C0456586
.	O
	
subjects	B-C0080105
were	O
eligible	B-C1548635
for	O
inclusion	B-C1512693
if	O
they	O
were	O
aged	B-C0001779
6-17	O
years	B-C0439234
and	O
were	O
continuously	B-C0549178
enrolled	O
during	O
a	O
calendar	B-C0456586
year	I-C0456586
.	O
	
the	O
annual	B-C0332181
prevalence	B-C0033105
of	O
treated	B-C0087111
adhd	B-C1263846
among	O
school-aged	B-C2827631
children	I-C2827631
and	O
adolescents	B-C0205653
with	O
esi	B-C3824871
increased	B-C0205217
from	O
4.5	O
in	O
2009	O
to	O
6.7	O
in	O
2015	O
.	O
	
among	O
those	O
with	O
medicaid	B-C0021682
it	O
increased	B-C0205217
from	O
11.3	O
in	O
2009	O
to	O
13.3	O
in	O
2012	O
,	O
and	O
fell	O
after	O
2012	O
,	O
remaining	O
steady	B-C0205361
from	O
2013	O
through	O
2015	O
.	O
	
treated	B-C0087111
prevalence	B-C0033105
of	O
adhd	B-C1263846
increased	B-C0205217
continuously	B-C0549178
over	O
time	B-C0040223
among	O
school-aged	B-C2827631
children	I-C2827631
and	O
adolescents	B-C0205653
with	O
esi	B-C3824871
,	O
but	O
declined	B-C0205216
slightly	O
after	O
2012	O
among	O
those	O
in	O
the	O
medicaid	B-C0021682
sample	I-C0021682
.	O
	
acute	B-C0205178
macular	B-C0271051
edema	I-C0271051
and	O
peripapillary	B-C0442163
soft	B-C0205358
exudate	B-C0015388
after	O
pancreas	B-C0030275
transplantation	I-C0030275
with	O
accelerated	B-C0521110
progression	B-C0242656
of	O
diabetic	B-C0011884
retinopathy	I-C0011884
the	O
effect	O
of	O
pancreas	B-C0030275
transplantation	I-C0030275
on	O
diabetic	B-C0011884
retinopathy	I-C0011884
remains	O
inconclusive	B-C1629507
.	O
	
herein	O
,	O
we	O
report	O
six	O
patients	B-C0030705
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
mellitus	I-C0011854
dm	B-C0011854
who	O
underwent	O
pancreas	B-C0030275
transplantation	I-C0030275
and	O
developed	O
acute	B-C0205178
macular	B-C0271051
edema	I-C0271051
and	O
peripapillary	B-C0442163
soft	B-C0205358
exudate	B-C0015388
with	O
rapid	B-C0456962
progression	B-C0242656
to	O
proliferative	B-C0154830
diabetic	I-C0154830
retinopathy	I-C0154830
.	O
	
in	O
this	O
retrospective	B-C0035363
observational	I-C0035363
study	I-C0035363
,	O
diabetic	B-C0011847
patients	B-C0030705
who	O
underwent	O
pancreas	B-C0030275
transplantation	I-C0030275
in	O
a	O
single	B-C0205171
medical	B-C0565990
center	I-C0565990
and	O
developed	O
symptomatic	B-C0231220
acute	B-C0205178
macular	B-C0271051
edema	I-C0271051
and	O
peripapillary	B-C0442163
soft	B-C0205358
exudate	B-C0015388
within	B-C0332285
3	B-C1442461
months	I-C1442461
after	B-C0687676
the	O
operation	B-C0543467
were	O
enrolled	O
.	O
	
the	O
complete	B-C0205197
ophthalmic	B-C0449259
course	I-C0449259
and	O
medical	B-C0025102
records	I-C0025102
of	O
the	O
patients	B-C0030705
were	O
retrospectively	B-C1514923
reviewed	B-C1709940
.	O
	
diabetic	B-C0011884
retinopathy	I-C0011884
and	O
progression	B-C0242656
following	B-C0332282
treatment	B-C0087111
after	O
pancreas	B-C0030275
transplantation	I-C0030275
were	O
measured	B-C0444706
.	O
	
six	O
chinese	B-C0152035
women	B-C0043210
with	O
type	B-C0011854
1	I-C0011854
dm	I-C0011854
were	O
enrolled	O
in	O
this	O
study	B-C2603343
.	O
	
mean	O
hemoglobin	B-C0019018
hb	I-C0019018
a1c	I-C0019018
was	O
13.4	O
prior	O
to	O
transplantation	B-C0030275
and	O
decreased	B-C0205216
rapidly	B-C0456962
to	O
6.5	O
within	B-C0332285
2	B-C1442456
months	I-C1442456
postsurgery	B-C0032790
.	O
	
the	O
patients	B-C0030705
had	O
no	B-C1518422
or	O
mild	B-C2945599
pretransplant	B-C0040733
diabetic	B-C0011884
retinopathy	I-C0011884
and	O
developed	O
acute	B-C0205178
symptomatic	B-C0231220
macular	B-C0271051
edema	I-C0271051
and	O
peripapillary	B-C0442163
soft	B-C0205358
exudate	B-C0015388
in	O
both	B-C0229118
eyes	I-C0229118
after	O
pancreas	B-C0030275
transplantation	I-C0030275
.	O
	
all	O
macular	B-C0271051
edema	I-C0271051
resolved	B-C3714811
either	O
with	O
or	O
without	B-C0332288
treatment	B-C0087111
.	O
	
five	O
cases	B-C0868928
progressed	B-C0242656
to	O
proliferative	B-C0154830
diabetic	I-C0154830
retinopathy	I-C0154830
and	O
received	B-C1709850
panretinal	B-C0730064
photocoagulation	I-C0730064
.	O
	
diabetic	B-C0011884
retinopathy	I-C0011884
remained	O
stable	B-C0205360
in	O
all	B-C0444868
eyes	B-C0015392
after	B-C0687676
treatment	B-C0087111
,	O
and	O
the	O
visual	B-C0234621
prognosis	B-C0278250
was	I-C0278250
good	I-C0278250
,	O
except	B-C0332300
in	O
one	B-C0205447
eye	B-C0015392
that	O
had	O
macular	B-C0332574
branch	B-C0006123
retinal	I-C0006123
artery	I-C0006123
occlusion	I-C0006123
with	O
foveal	B-C0016622
involvement	B-C1314939
.	O
	
acute	B-C0205178
macular	B-C0271051
edema	I-C0271051
after	O
pancreas	B-C0030275
transplantation	I-C0030275
has	O
a	O
favorable	B-C3640814
treatment	B-C0085415
outcome	I-C0085415
despite	O
rapid	O
progression	B-C0242656
to	O
proliferative	B-C0154830
diabetic	I-C0154830
retinopathy	I-C0154830
.	O
	
high	B-C0205250
pretransplant	B-C0040733
hba1c	B-C0019018
and	O
abrupt	B-C1276802
blood	B-C0005802
sugar	I-C0005802
normalization	B-C0205245
may	O
be	O
related	O
to	O
the	O
disease	B-C0242656
course	I-C0242656
.	O
	
anger	B-C0002957
and	O
aggression	B-C0001807
in	O
borderline	B-C0006012
personality	I-C0006012
disorder	I-C0006012
and	O
attention	B-C1263846
deficit	I-C1263846
hyperactivity	I-C1263846
disorder	I-C1263846
-	O
does	O
stress	B-C0038435
matter	O
the	O
impact	B-C4049986
of	O
stress	B-C0038435
on	O
anger	B-C0002957
and	O
aggression	B-C0001807
in	O
borderline	B-C0006012
personality	I-C0006012
disorder	I-C0006012
bpd	B-C0006012
and	O
attention	B-C1263846
deficit	I-C1263846
hyperactivity	I-C1263846
disorder	I-C1263846
adhd	B-C1263846
has	O
not	O
been	O
thoroughly	O
investigated	B-C1292732
.	O
	
the	O
goal	O
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
different	O
aspects	O
of	O
anger	B-C0002957
and	O
aggression	B-C0001807
in	O
patients	B-C0030705
with	O
these	O
disorders	B-C0012634
.	O
	
twenty-nine	O
unmedicated	B-C0243095
female	B-C0086287
bpd	B-C0006012
patients	B-C0030705
,	O
28	O
adhd	B-C1263846
patients	B-C0030705
and	O
30	O
healthy	B-C2986479
controls	I-C2986479
hc	B-C2986479
completed	O
self-reports	B-C2700446
measuring	B-C0444706
trait	B-C0599883
anger	B-C0002957
,	O
aggression	B-C0001807
and	O
emotion	B-C2370884
regulation	I-C2370884
capacities	O
.	O
	
a	O
modified	O
version	O
of	O
the	O
point	B-C0681797
subtraction	I-C0681797
aggression	I-C0681797
paradigm	I-C0681797
and	O
a	O
state	B-C0242481
anger	I-C0242481
measurement	I-C0242481
were	O
applied	O
under	O
resting	B-C0348080
and	O
stress	B-C0348080
conditions	I-C0348080
.	O
	
stress	B-C0038435
was	O
induced	B-C0205263
by	O
the	O
mannheim	B-C3494508
multicomponent	I-C3494508
stress	I-C3494508
test	I-C3494508
mmst	B-C3494508
.	O
	
both	O
patient	B-C0030705
groups	O
scored	B-C0449820
significantly	O
higher	O
on	O
all	O
self-report	B-C2700446
measures	B-C0444706
compared	B-C1707455
to	O
hcs	B-C2986479
.	O
	
compared	B-C1707455
to	O
adhd	B-C1263846
patients	B-C0030705
,	O
bpd	B-C0006012
patients	B-C0030705
reported	O
higher	O
trait	B-C0599883
aggression	B-C0001807
and	O
hostility	B-C0020039
,	O
a	O
stronger	O
tendency	O
to	O
express	O
anger	B-C0002957
when	O
provoked	O
and	O
to	O
direct	O
anger	B-C0002957
inwardly	O
.	O
	
furthermore	O
,	O
bpd	B-C0006012
patients	B-C0030705
exhibited	O
higher	O
state	O
anger	B-C0002957
than	O
hcs	B-C2986479
and	O
adhd	B-C1263846
patients	B-C0030705
under	O
both	O
conditions	O
and	O
showed	O
a	O
stress-dependent	B-C0205245
anger	B-C0002957
increase	O
.	O
	
at	O
the	O
behavioral	B-C0004927
level	I-C0004927
,	O
no	O
significant	O
effects	O
were	O
found	O
.	O
	
in	O
bpd	B-C0006012
patients	B-C0030705
,	O
aggression	B-C0001807
and	O
anger	B-C0002957
were	O
positively	O
correlated	O
with	O
emotion	B-C2370884
regulation	I-C2370884
deficits	B-C2987487
.	O
	
our	O
findings	B-C0243095
suggest	O
a	O
significant	O
impact	B-C4049986
of	O
stress	B-C0038435
on	O
self-perceived	O
state	O
anger	B-C0002957
in	O
bpd	B-C0006012
patients	B-C0030705
but	O
not	O
on	O
aggressive	B-C0001807
behavior	I-C0001807
towards	O
others	O
in	O
females	B-C0086287
with	O
bpd	B-C0006012
or	O
adhd	B-C1263846
.	O
	
however	O
,	O
it	O
appears	O
to	O
be	O
pronounced	O
inwardly	O
directed	O
anger	B-C0002957
which	O
is	O
of	O
clinical	B-C0205210
importance	B-C3898777
in	O
bpd	B-C0006012
patients	B-C0030705
.	O
	
interferon	B-C1334085
gamma	I-C1334085
and	O
interleukin	B-C1334098
10	I-C1334098
polymorphisms	B-C0678951
in	O
chinese	B-C0152035
children	B-C0008059
with	O
hemophagocytic	B-C0024291
lymphohistiocytosis	I-C0024291
the	O
aim	O
of	O
the	O
study	B-C2603343
is	O
to	O
investigate	B-C1292732
the	O
association	O
of	O
interferon	B-C1334085
gamma	I-C1334085
ifn-γ	B-C1334085
and	O
interleukin-10	B-C1334098
il-10	B-C1334098
gene	B-C0017337
single	B-C0752046
nucleotide	I-C0752046
polymorphisms	I-C0752046
with	O
the	O
susceptibility	B-C0012655
of	O
hemophagocytic	B-C0024291
lymphohistiocytosis	I-C0024291
hlh	B-C0024291
in	O
chinese	B-C0152035
children	B-C0008059
without	B-C0332123
known	I-C0332123
family	I-C0332123
history	I-C0332123
of	I-C0332123
hlh	B-C0024291
.	O
	
forty	O
children	B-C0008059
with	O
hlh	B-C0024291
and	O
160	O
age	B-C0001779
-	O
and	O
gender	B-C0079399
-matched	O
healthy	B-C2986479
controls	I-C2986479
from	O
xuzhou	B-C0019994
children's	I-C0019994
hospital	I-C0019994
were	O
enrolled	O
in	O
the	O
study	B-C2603343
.	O
	
serum	B-C0229671
ifn-γ	B-C3539881
and	O
il-10	B-C0085295
levels	O
were	O
measured	B-C0444706
by	O
enzyme	B-C0014441
linked-immunosorbent	I-C0014441
assay	I-C0014441
.	O
	
polymorphisms	B-C0678951
of	O
the	O
ifn-γ	B-C1334085
gene	I-C1334085
at	O
position	O
+874	O
and	O
+2109	O
,	O
and	O
il-10	B-C1334098
at	O
position	O
-1082	O
were	O
analyzed	B-C2963401
by	O
allele	B-C0002085
-	O
specific	B-C0205369
pcr	B-C0032520
.	O
	
median	B-C0229671
serum	I-C0229671
concentrations	B-C1446561
of	O
ifn	B-C3539881
-γ	I-C3539881
and	O
il-10	B-C0085295
were	O
significantly	B-C4055637
higher	I-C4055637
in	O
children	B-C0008059
with	O
hlh	B-C0024291
compared	B-C1707455
to	O
healthy	B-C2986479
controls	I-C2986479
.	O
	
the	O
frequencies	B-C0439603
of	O
ifn-γ	B-C1334085
+874	O
t/a	B-C0017431
and	I-C0017431
t/t	I-C0017431
genotypes	I-C0017431
,	O
as	O
well	O
as	O
t	B-C0002085
allele	I-C0002085
,	O
were	O
significantly	B-C4055637
higher	I-C4055637
in	O
the	O
hlh	B-C0024291
group	O
compared	B-C1707455
with	O
those	O
in	O
the	O
control	B-C0009932
group	I-C0009932
.	O
	
the	O
frequencies	B-C0439603
of	O
il-10	B-C1334098
-1082	O
g/a	B-C0017431
genotype	I-C0017431
and	O
g	B-C0002085
allele	I-C0002085
were	O
significantly	B-C4055637
increased	I-C4055637
in	O
hlh	B-C0024291
patients	B-C0030705
compared	B-C1707455
with	O
healthy	B-C2986479
controls	I-C2986479
.	O
	
no	B-C1273937
significant	I-C1273937
difference	B-C3842396
was	O
found	O
in	O
the	O
distribution	B-C1704711
of	O
ifn-γ	B-C1334085
+2109	O
g/a	B-C0017431
genotypes	I-C0017431
between	O
children	B-C0008059
with	O
hlh	B-C0024291
and	O
controls	B-C0243148
.	O
	
this	O
study	B-C2603343
presents	B-C0150312
preliminary	B-C0439611
evidence	B-C3887511
for	O
the	O
association	O
between	O
ifn	B-C1334085
+874	O
t/a	B-C0017431
,	O
t/t	I-C0017431
,	O
il-10	B-C1334098
-1082	O
a/g	B-C0017431
genotypes	I-C0017431
,	O
and	O
hlh	B-C0024291
susceptibility	B-C0012655
in	O
chinese	B-C0152035
children	B-C0008059
with	O
data	B-C1511726
-driven	O
implementation	B-C1708476
of	O
alarm	B-C0336648
reduction	B-C0392756
interventions	B-C0184661
in	O
a	O
cardiovascular	B-C0587446
surgical	I-C0587446
icu	I-C0587446
alarm	B-C4035921
fatigue	I-C4035921
in	O
the	O
icu	B-C0021708
setting	B-C3176918
has	O
been	O
well	O
documented	B-C1301725
in	O
the	O
literature	B-C0023866
.	O
	
the	O
icu's	B-C0021708
high-intensity	B-C4081854
environment	B-C0014406
requires	O
staff's	B-C0851286
vigilant	B-C0043012
attention	B-C0004268
,	O
and	O
distraction	B-C4060717
from	O
false	B-C0205237
and	O
non-actionable	O
alarms	B-C0336648
pulls	O
staff	B-C0851286
away	O
from	O
important	O
tasks	B-C3540678
,	O
creates	O
dissatisfaction	B-C0870433
,	O
and	O
is	O
a	O
potential	O
patient	B-C1113679
safety	I-C1113679
risk	B-C0035647
if	O
alarms	B-C0336648
are	O
missed	B-C1705492
or	O
ignored	B-C1554079
.	O
	
this	O
project	O
was	O
intended	O
to	O
improve	O
patient	B-C1113679
safety	I-C1113679
by	O
optimizing	O
alarm	B-C0336648
systems	B-C0449913
in	O
a	O
cardiovascular	B-C0587446
surgical	I-C0587446
intensive	I-C0587446
care	I-C0587446
unit	I-C0587446
cvsicu	B-C0587446
.	O
	
specific	O
aims	O
were	O
to	O
examine	B-C0332128
nurses	B-C0028661
'	O
attitudes	B-C0004271
toward	O
clinical	B-C0205210
alarm	B-C0336648
signals	B-C1710082
,	O
assess	O
nurses	B-C0028661
'	O
ability	O
to	O
discriminate	O
audible	B-C1706857
alarm	I-C1706857
signals	B-C1710082
,	O
and	O
implement	B-C1708476
a	O
bundled	O
set	O
of	O
best	B-C3179154
practices	I-C3179154
for	O
monitor	B-C2091666
alarm	I-C2091666
reduction	B-C0392756
without	O
undermining	O
patient	B-C1113679
safety	I-C1113679
.	O
	
cvsicu	B-C0587446
nurses	B-C0028661
completed	O
an	O
alarm	B-C0336648
perception	B-C0038951
survey	I-C0038951
and	O
participated	O
in	O
alarm	B-C0336648
discriminability	B-C0039593
testing	I-C0039593
.	O
	
nurse	B-C2361339
survey	I-C2361339
data	I-C2361339
and	O
baseline	B-C1442488
monitor	O
alarm	B-C0336648
data	B-C1511726
were	O
used	O
to	O
select	O
targeted	B-C1521840
alarm	B-C0336648
reduction	B-C0392756
interventions	B-C0184661
,	O
which	O
were	O
progressively	O
phased	O
in	O
.	O
	
monitor	O
alarm	B-C0336648
data	B-C1511726
and	O
cardiorespiratory	B-C1320716
event	I-C1320716
data	B-C1511726
were	O
trended	O
over	O
one	O
year	B-C0439234
.	O
	
five	O
of	O
the	O
most	O
frequent	O
cvsicu	B-C0587446
monitor	B-C2091666
alarm	I-C2091666
types-	O
pulse	B-C0034108
oximetry	I-C0034108
,	O
heart	B-C0018810
rate	I-C0018810
,	O
systolic	B-C0277882
and	O
diastolic	B-C0235222
blood	I-C0235222
pressure	I-C0235222
,	O
pulse	B-C0034108
oximetry	I-C0034108
sensor	B-C0183210
,	O
and	O
ventricular	B-C0042514
tachycardia	I-C0042514
>	O
2-were	O
targeted	B-C1521840
.	O
	
after	O
implementation	B-C1708476
,	O
there	O
was	O
a	O
61%	O
reduction	B-C0392756
in	O
average	O
alarms	B-C0336648
per	O
monitored	O
bed	B-C0004916
and	O
a	O
downward	O
trend	O
in	O
cardiorespiratory	B-C1320716
events	I-C1320716
.	O
	
to	O
reduce	B-C0392756
alarm	B-C4035921
fatigue	I-C4035921
it	O
is	O
important	O
to	O
decrease	B-C0547047
alarm	B-C0336648
burden	B-C2828008
through	O
targeted	B-C1521840
interventions	B-C0184661
.	O
	
methods	O
to	O
reduce	O
non-actionable	O
alarms	B-C0336648
include	O
adding	O
short	O
delays	B-C0205421
to	O
allow	O
alarm	B-C0336648
self-correction	B-C1947976
,	O
adjusting	O
default	O
alarm	B-C0336648
threshold	B-C0449864
limits	B-C0439801
,	O
providing	O
alarm	B-C0336648
notification	B-C0422202
through	O
a	O
secondary	B-C0025080
device	I-C0025080
,	O
and	O
teaching	B-C0220924
staff	B-C0851286
to	O
optimize	O
alarm	B-C0336648
settings	O
for	O
individual	B-C0237401
patients	B-C0030705
.	O
	
the	O
ncam1	B-C1334863
gene	I-C1334863
set	I-C1334863
is	O
linked	O
to	O
depressive	B-C0086132
symptoms	I-C0086132
and	O
their	O
brain	B-C0006104
structural	I-C0006104
correlates	B-C0871083
in	O
healthy	B-C0237401
individuals	I-C0237401
depressive	B-C0086132
symptoms	I-C0086132
exist	O
on	O
a	O
continuum	O
,	O
the	O
far	O
end	O
of	O
which	O
is	O
found	O
in	O
depressive	B-C0011581
disorders	I-C0011581
.	O
	
utilizing	O
the	O
continuous	B-C0037812
spectrum	I-C0037812
of	O
depressive	B-C0086132
symptoms	I-C0086132
may	O
therefore	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
biological	B-C0243095
underpinnings	I-C0243095
of	O
depression	B-C0011570
.	O
	
gene	B-C0796344
set	I-C0796344
enrichment	I-C0796344
analysis	I-C0796344
gsea	B-C0796344
is	O
an	O
important	O
tool	O
for	O
the	O
identification	O
of	O
gene	B-C0017337
groups	I-C0017337
linked	O
to	O
complex	B-C0678922
traits	I-C0678922
,	O
and	O
was	O
applied	O
in	O
the	O
present	O
study	O
on	O
genome-wide	B-C2350277
association	I-C2350277
study	I-C2350277
gwas	B-C2350277
data	B-C3483981
of	I-C3483981
depression	I-C3483981
scores	I-C3483981
and	O
their	O
brain-level	B-C0006104
structural	I-C0006104
correlates	B-C0871083
in	O
healthy	B-C0237401
young	I-C0237401
individuals	I-C0237401
.	O
	
on	O
symptom	B-C1319166
level	I-C1319166
i.e	O
.	O
	
depression	B-C3483981
scores	I-C3483981
,	O
robust	B-C2986815
enrichment	O
was	O
identified	O
for	O
two	O
gene	B-C0017337
sets	I-C0017337
ncam1	B-C1334863
interactions	B-C0596610
and	O
collagen	B-C2246343
formation	I-C2246343
.	O
	
depression	B-C3483981
scores	I-C3483981
were	O
also	O
associated	B-C0332281
with	I-C0332281
decreased	B-C0205216
fractional	B-C0085406
anisotropy	I-C0085406
fa	B-C0085406
-	O
a	O
brain	B-C0152381
white	I-C0152381
matter	I-C0152381
property	I-C0152381
-	O
within	B-C0152325
the	I-C0152325
forceps	I-C0152325
minor	I-C0152325
and	O
the	O
left	B-C2337627
superior	I-C2337627
temporal	I-C2337627
longitudinal	I-C2337627
fasciculus	I-C2337627
.	O
	
within	O
each	O
of	O
these	O
tracts	O
,	O
mean	B-C0085406
fa	I-C0085406
value	O
of	O
depression	B-C3483981
score	I-C3483981
-	O
associated	B-C2700259
voxels	I-C2700259
was	O
used	O
as	O
a	O
phenotype	B-C0031437
in	O
a	O
subsequent	O
gsea	B-C0796344
.	O
	
the	O
ncam1	B-C1334863
interactions	B-C0596610
gene	B-C0017337
set	I-C0017337
was	O
significantly	O
enriched	O
in	O
these	O
tracts	O
.	O
	
by	O
linking	O
the	O
ncam1	B-C1334863
interactions	B-C0596610
gene	B-C0017337
set	I-C0017337
to	O
depression	B-C3483981
scores	I-C3483981
and	O
their	O
structural	B-C0006104
brain	I-C0006104
correlates	B-C0871083
in	O
healthy	B-C1708335
participants	I-C1708335
,	O
the	O
current	O
study	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
molecular	B-C0243095
underpinnings	I-C0243095
of	O
depressive	B-C0086132
symptomatology	I-C0086132
.	O
	
the	O
burden	O
of	O
hpv	B-C0021344
-related	O
diseases	B-C0012634
in	O
italy	B-C0022277
,	O
2001-12	O
human	B-C0343641
papillomavirus	I-C0343641
hpv	I-C0343641
infection	I-C0343641
is	O
the	O
main	O
cause	O
of	O
cervical	B-C0007847
cancer	I-C0007847
and	O
plays	O
a	O
relevant	O
role	O
in	O
the	O
development	B-C1527148
of	O
genital	B-C1398518
warts	I-C1398518
and	O
of	O
the	O
cancer	B-C0006826
of	O
penis	B-C0030851
and	O
anus	B-C0003461
,	O
head	B-C0018670
/	O
neck	B-C0027530
,	O
oropharynx	B-C0521367
and	O
genitourinary	B-C0042066
system	I-C0042066
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
is	O
the	O
evaluation	B-C1292732
of	O
hospitalizations	B-C0019993
due	O
to	O
hpv-related	B-C0343641
pathologies	I-C0343641
in	O
2001-12	O
in	O
italy	B-C0022277
.	O
	
the	O
national	B-C0586003
hospital	I-C0586003
discharge	I-C0586003
forms	B-C0376315
were	O
provided	O
by	O
the	O
ministry	B-C1274109
of	I-C1274109
health	I-C1274109
.	O
	
the	O
hpv	B-C0021344
-related	O
hospitalizations	B-C0019993
were	O
identified	O
using	O
specific	O
diagnostic	B-C0348026
codes	B-C0805701
,	O
accordingly	O
to	O
the	O
icd-9-cm	B-C1137112
coding	B-C2347818
system	I-C2347818
.	O
	
the	O
proportion	O
of	O
hospitalizations	B-C0019993
of	O
potentially	O
hpv-related	B-C0343641
pathologies	I-C0343641
,	O
obtained	O
from	O
the	O
literature	B-C0023866
,	O
was	O
evaluated	B-C1292732
as	O
well	O
as	O
the	O
hospitalization	B-C1521828
rates	I-C1521828
hr	B-C1521828
and	O
their	O
trend	B-C1521798
over	O
time	B-C0040223
.	O
	
uterine	B-C0007847
cervical	I-C0007847
cancer	I-C0007847
and	O
cin	B-C0851140
iii	I-C0851140
accounted	O
for	O
40%	O
of	O
hospitalizations	B-C0019993
hr	B-C1521828
15.6	O
000	O
and	O
17.6	O
000	O
,	O
respectively	O
.	O
	
head	B-C0018670
/	O
neck	B-C0027530
and	O
oropharynx	B-C0521367
pathologies	B-C1521733
accounted	O
for	O
24.5	O
of	O
cases	B-C0868928
hr	B-C1521828
16/100	O
000	O
and	O
3.9	O
000	O
,	O
in	O
males	B-C0086582
and	O
females	B-C0086287
,	O
respectively	O
,	O
followed	O
by	O
genital	B-C1398518
warts	I-C1398518
17.3	O
of	O
hospitalizations	B-C0019993
hr	B-C1521828
7.5	O
000	O
in	O
males	B-C0086582
and	O
8.52	O
000	O
in	O
females	B-C0086287
,	O
anal	B-C0153446
8.1	O
of	O
hospitalizations	B-C0019993
,	O
genitourinary	B-C0751569
7.7	O
and	O
penis	B-C0153601
cancers	I-C0153601
2.2	O
.	O
	
the	O
study	B-C2603343
,	O
even	O
if	O
limited	O
to	O
the	O
evaluation	B-C1292732
of	O
hospitalizations	B-C0019993
,	O
points	O
out	O
how	O
hpv-related	B-C0343641
pathologies	I-C0343641
continue	O
to	O
be	O
a	O
relevant	O
public	B-C0018684
health	I-C0018684
issue	B-C0033213
in	O
italy	B-C0022277
with	O
a	O
high	O
impact	B-C4049986
on	O
the	O
discovery	B-C1880355
of	O
potent	B-C0205556
and	O
selective	B-C0205556
kynurenine	B-C0064449
3-monooxygenase	I-C0064449
inhibitors	B-C0014432
for	O
the	O
treatment	B-C0087111
of	O
acute	B-C0001339
pancreatitis	I-C0001339
a	O
series	B-C0205549
of	O
potent	B-C0205556
,	O
competitive	B-C0205556
and	O
highly	B-C0205250
selective	B-C0205556
kynurenine	B-C0064449
monooxygenase	I-C0064449
inhibitors	B-C0014432
have	O
been	O
discovered	B-C1880355
via	O
a	O
substrate	B-C3891814
-based	O
approach	B-C0449445
for	O
the	O
treatment	B-C0087111
of	O
acute	B-C0001339
pancreatitis	I-C0001339
.	O
	
the	O
lead	B-C1522538
compound	B-C1706082
demonstrated	O
good	B-C0205170
cellular	B-C0007634
potency	B-C0205556
and	O
clear	O
pharmacodynamic	B-C0851347
activity	B-C0441655
in	B-C1515655
vivo	I-C1515655
.	O
	
draft	B-C0017428
genome	I-C0017428
sequence	B-C0314659
of	O
providencia	B-C0315286
stuartii	I-C0315286
ps71	I-C0315286
,	O
a	O
multidrug-resistant	B-C0242640
strain	B-C1518614
associated	B-C0332281
with	I-C0332281
nosocomial	B-C0205721
infections	I-C0205721
in	O
greece	B-C0018226
providencia	B-C0315286
stuartii	I-C0315286
is	O
frequently	B-C0332183
associated	B-C0332281
with	I-C0332281
nosocomial	B-C0205721
outbreaks	I-C0205721
and	O
displays	O
intrinsic	B-C0205102
resistance	B-C4281815
to	O
many	O
commonly	B-C0205214
used	O
antimicrobials	B-C1136254
.	O
	
we	O
report	O
here	O
the	O
draft	B-C0017428
genome	I-C0017428
sequence	B-C0314659
of	O
a	O
p	B-C0315286
.	O
	
stuartii	I-C0315286
strain	I-C0315286
carrying	O
acquired	B-C0439661
resistance	B-C2945710
genes	I-C2945710
conferring	O
panresistance	B-C4281815
to	O
cephalosporins	B-C3536856
blashv-5	B-C0017337
and	O
blaveb-1	B-C0017337
,	O
carbapenems	B-C0006968
blavim-1	B-C0017337
,	O
and	O
aminoglycosides	B-C0002556
rmtb	B-C0017337
involved	O
in	O
an	O
outbreak	B-C0012652
in	O
greek	B-C0018226
hospitals	B-C0019994
.	O
	
impact	B-C4049986
of	O
diabetic	B-C0011880
ketoacidosis	I-C0011880
management	B-C0376636
in	O
the	O
medical	B-C2711734
intensive	I-C2711734
care	I-C2711734
unit	I-C2711734
after	O
order	B-C0282574
set	I-C0282574
implementation	B-C1708476
to	O
determine	O
the	O
rate	B-C1521828
of	O
compliance	B-C0525058
to	O
the	O
2006	O
and	O
2009	O
ada	B-C0162791
dka	I-C0162791
guidelines	I-C0162791
in	O
the	O
medical	B-C2711734
intensive	I-C2711734
care	I-C2711734
unit	I-C2711734
micu	B-C2711734
at	O
a	O
large	O
academic	B-C0000872
medical	I-C0000872
centre	I-C0000872
after	O
the	O
implementation	B-C1708476
of	O
a	O
computerised	B-C0282574
dka	I-C0282574
order	I-C0282574
set	I-C0282574
and	O
protocol	B-C0008971
.	O
	
retrospective	B-C1514923
chart	B-C0282443
review	I-C0282443
of	O
adult	B-C0030705
patients	I-C0030705
with	O
dka	B-C0011880
admitted	B-C0809949
to	O
the	O
micu	B-C2711734
.	O
	
results	O
of	O
pre-order	B-C0282574
set	I-C0282574
pre	B-C0282574
were	O
compared	O
to	O
those	O
of	O
data	O
post-order	B-C0282574
set	I-C0282574
post	B-C0282574
.	O
	
the	O
primary	B-C1274040
outcome	I-C1274040
was	O
a	O
composite	O
administration	B-C1533734
of	O
intravenous	B-C2317423
fluid	I-C2317423
resuscitation	I-C2317423
in	O
the	O
first	O
24	O
h	O
,	O
insulin	B-C0021641
bolus	B-C1511237
and	O
initial	B-C0205265
insulin	B-C0021641
infusion	B-C2964135
rate	I-C2964135
.	O
	
twelve	O
of	O
60	O
patients	B-C0030705
20%	O
in	O
the	O
pre	B-C0681860
group	I-C0681860
received	O
treatment	B-C0087111
compliant	B-C0566588
with	O
the	O
2006	O
guidelines	B-C0162791
versus	O
14	O
of	O
55	O
patients	B-C0030705
25.5	O
in	O
the	O
post	B-C0681860
group	I-C0681860
or	B-C0028873
1.22	O
95%	O
ci	B-C0009667
0.44	O
to	O
3.4	O
,	O
p	O
=	O
0.51	O
.	O
	
compliance	B-C0525058
to	O
the	O
2009	O
guidelines	B-C0162791
was	O
significantly	B-C4055637
higher	I-C4055637
in	O
the	O
post	B-C0681860
group	I-C0681860
31.7	O
versus	O
65.5	O
,	O
or	B-C0028873
4.44	O
95%	O
ci	B-C0009667
1.8	O
to	O
10.92	O
,	O
p	O
=	O
0.0004	O
.	O
	
compliance	B-C0525058
for	O
individual	O
components	O
was	O
26.7	O
versus	O
70.9	O
for	O
fluid	B-C0150238
resuscitation	I-C0150238
p	O
=	O
0.0001	O
,	O
55%	O
versus	O
49.1	O
for	O
insulin	B-C0021641
bolus	B-C1511237
p	O
=	O
0.58	O
and	O
60%	O
versus	O
81.3	O
for	O
initial	B-C0205265
insulin	B-C0021641
infusion	B-C2964135
rate	I-C2964135
p	O
=	O
0.014	O
,	O
respectively	O
.	O
	
time	B-C0040223
to	O
dka	B-C0011880
resolution	B-C2699488
was	O
decreased	B-C0205216
p	O
=	O
0.04	O
,	O
and	O
hypoglycaemia	B-C0020615
was	O
increased	B-C0205217
p	O
=	O
0.0022	O
.	O
	
implementation	B-C1708476
of	O
a	O
computerised	B-C0282574
dka	I-C0282574
order	I-C0282574
set	I-C0282574
and	O
protocol	B-C0008971
was	O
associated	B-C0332281
with	I-C0332281
improved	B-C0184511
compliance	B-C0525058
to	O
the	O
2009	O
ada	B-C0162791
dka	I-C0162791
guidelines	I-C0162791
,	O
24-h	O
fluid	B-C0150238
resuscitation	I-C0150238
,	O
initial	B-C0205265
insulin	B-C0021641
infusion	B-C2964135
rate	I-C2964135
,	O
time	B-C0040223
to	O
dka	B-C0011880
resolution	B-C2699488
and	O
appropriate	O
transition	B-C2700061
to	O
subcutaneous	B-C0443315
insulin	B-C0021641
.	O
	
however	O
,	O
patients	B-C0030705
in	O
the	O
post	B-C0681860
implementation	I-C0681860
group	I-C0681860
were	O
more	O
likely	O
to	O
exhibit	O
hypoglycaemia	B-C0020615
.	O
	
construction	O
of	O
an	O
acetylcholinesterase	B-C0001044
sensor	B-C0600364
based	O
on	O
synthesized	B-C2713587
paramagnetic	I-C2713587
nanoparticles	I-C2713587
,	O
a	O
simple	O
tool	O
for	O
neurotoxic	B-C0260049
compounds	I-C0260049
assay	B-C1510438
magnetic	B-C2713587
particles	I-C2713587
mps	B-C2713587
have	O
been	O
widely	O
used	O
in	O
biological	B-C0205245
applications	I-C0205245
in	O
recent	O
years	O
as	O
a	O
carrier	O
for	O
various	O
molecules	B-C0567416
.	O
	
their	O
big	O
advantage	O
is	O
in	O
repeated	O
use	O
of	O
immobilized	B-C1254366
molecules	B-C0567416
including	O
enzymes	B-C0014442
.	O
	
acetylcholinesterase	B-C0001044
ache	B-C0001044
is	O
an	O
enzyme	B-C0014442
playing	O
crucial	O
role	O
in	O
neurotransmission	B-C0027793
and	O
the	O
enzyme	B-C0014442
is	O
targeted	B-C1521840
by	O
various	O
molecules	B-C0567416
like	O
alzheimer's	B-C0002395
drugs	B-C1254351
,	O
pesticides	B-C0031253
and	O
warfare	B-C1113670
agents	I-C1113670
.	O
	
in	O
this	O
work	O
,	O
an	O
electrochemical	B-C0600364
biosensor	I-C0600364
having	O
ache	B-C0001044
immobilized	B-C0014444
onto	O
mps	B-C2713587
and	O
stabilized	B-C0184512
through	O
glutaraldehyde	B-C0017814
ga	I-C0017814
molecule	I-C0017814
was	O
proposed	O
for	O
assay	B-C1510438
of	O
the	O
neurotoxic	B-C0260049
compounds	I-C0260049
.	O
	
the	O
prepared	B-C1450054
nanoparticles	I-C1450054
were	O
modified	B-C0205349
by	I-C0205349
pure	B-C0001044
ache	I-C0001044
and	O
they	O
were	O
used	O
for	O
the	O
measurement	B-C0242485
anti-alzheimer's	B-C0243095
drug	B-C1254351
galantamine	B-C0016967
and	O
carbamate	B-C0360422
pesticide	I-C0360422
carbofuran	B-C0006995
with	O
limit	B-C1549649
of	O
detection	B-C0442726
1.5	O
µm	O
and	O
20	O
nm	O
,	O
respectively	O
.	O
	
all	O
measurements	B-C0242485
were	O
carried	O
out	O
using	O
screen-printed	B-C0600364
sensor	I-C0600364
with	O
carbon	B-C0007009
working	B-C0013812
,	O
silver	B-C0037125
reference	B-C4067887
,	O
and	O
carbon	B-C0007009
auxiliary	B-C0013812
electrode	I-C0013812
.	O
	
standard	B-C1510438
ellman's	I-C1510438
assay	I-C1510438
was	O
used	O
for	O
validation	B-C1519941
measurement	B-C0242485
of	O
both	O
inhibitors	B-C0243077
.	O
	
part	O
of	O
this	O
work	O
was	O
the	O
elimination	B-C1883720
of	O
reversible	B-C0205343
inhibitors	B-C0243077
represented	O
by	O
galantamine	B-C0016967
from	O
the	O
active	B-C0205681
site	I-C0205681
of	O
ache	B-C0001044
.	O
	
for	O
this	O
purpose	O
,	O
we	O
used	O
a	O
lower	B-C2003888
ph	B-C0020283
to	O
get	O
the	O
original	B-C0205313
activity	B-C0441655
of	O
ache	B-C0001044
after	O
inhibition	B-C3463820
by	O
galantamine	B-C0016967
.	O
	
we	O
also	O
observed	B-C1441672
decarbamylation	B-C1254366
of	O
the	O
ache	B-C0001044
-	O
carbofuran	B-C0006995
adduct	B-C0596040
.	O
	
influence	O
of	O
organic	B-C0360100
solvents	I-C0360100
to	O
ache	B-C0001044
as	O
well	O
as	O
repeatability	O
of	O
measurement	B-C0242485
with	O
mps	B-C2713587
with	O
ache	B-C0001044
alanine	B-C0001899
aminotransferase	I-C0001899
is	O
a	O
marker	B-C0005516
of	O
lipotoxicity	B-C0039082
consequences	B-C0686907
and	O
hyperandrogenemia	B-C1299574
in	O
women	B-C0043210
with	O
polycystic	B-C0032460
ovary	I-C0032460
syndrome	I-C0032460
several	O
studies	B-C2603343
have	O
reported	O
higher	O
levels	O
of	O
alanine	B-C0001899
aminotransferase	I-C0001899
alt	B-C0001899
in	O
women	B-C0043210
with	O
polycystic	B-C0032460
ovary	I-C0032460
syndrome	I-C0032460
pcos	B-C0032460
compared	O
with	O
control	B-C0009932
subjects	I-C0009932
.	O
	
plasma	B-C1272112
alt	I-C1272112
levels	I-C1272112
are	O
considered	O
a	O
marker	B-C0005516
of	O
hepatic	B-C0205054
lipotoxicity	B-C0039082
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	B-C0205054
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	B-C0015695
steatosis	I-C0015695
and	O
hepatic	B-C0205054
insulin	B-C0021655
resistance	I-C0021655
.	O
	
retrospective	B-C0282574
chart	I-C0282574
review	O
aiming	O
to	O
assess	O
,	O
in	O
pcos	B-C0032460
women	B-C0043210
,	O
the	O
relationship	O
between	O
alt	B-C1272112
levels	I-C1272112
and	O
measures	O
of	O
lipotoxicity	B-C0039082
consequences	B-C0686907
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	B-C0428568
and	O
using	O
the	O
oral	B-C0029161
glucose	I-C0029161
tolerance	I-C0029161
test	I-C0029161
.	O
	
women	B-C0043210
n	O
=	O
132	O
with	O
pcos	B-C0032460
,	O
were	O
in	O
average	O
27.9	O
years	B-C0439234
of	O
age	B-C0001779
,	O
with	O
a	O
mean	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
of	O
34.1	O
kg/m	O
and	O
49%	O
had	O
a	O
metabolic	B-C0039082
syndrome	I-C0039082
mets	B-C0039082
.	O
	
alt	B-C1272112
levels	I-C1272112
were	O
significantly	O
correlated	O
with	O
homeostatic	B-C3639411
model	I-C3639411
assessment	I-C3639411
for	I-C3639411
insulin	I-C3639411
resistance	I-C3639411
r	O
=	O
0.42	O
,	O
p	O
<	O
0.001	O
,	O
hdl-c	B-C0023822
r	O
=	O
-0	O
,	O
p	O
<	O
0.001	O
,	O
matsuda	B-C0918012
index	I-C0918012
-0	O
,	O
p	O
<	O
0.001	O
,	O
insulin	B-C0430022
secretion-sensitivity	I-C0430022
index-2	I-C0430022
-0	O
,	O
p	O
=	O
0.043	O
,	O
and	O
free	B-C0443483
testosterone	I-C0443483
0.38	O
,	O
p	O
<	O
0.001	O
,	O
but	O
not	O
with	O
fasting	B-C1261430
glucose	I-C1261430
and	O
triglyceride	B-C0428475
levels	I-C0428475
.	O
	
alt	B-C0001899
cutoff	O
24	O
iu/l	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	B-C1261430
glucose	I-C1261430
p	O
=	O
0.021	O
and	O
triglyceride	B-C0428475
levels	I-C0428475
p	O
=	O
0.041	O
,	O
and	O
detected	O
more	O
women	B-C0043210
with	O
the	O
mets	B-C0039082
59.2	O
vs	O
.	O
	
36.1	O
,	O
p	O
=	O
0.008	O
and	O
whole-body	B-C0021655
insulin	I-C0021655
resistance	I-C0021655
matsuda	B-C0918012
index	I-C0918012
<12	O
l	O
,	O
85.3	O
vs	O
.	O
	
51.9	O
,	O
p	O
=	O
0.004	O
.	O
	
plasma	B-C1272112
alt	I-C1272112
levels	I-C1272112
seem	O
to	O
be	O
a	O
strong	O
predictor	B-C2698872
not	O
only	O
of	O
liver	B-C0023884
lipotoxicity	B-C0039082
but	O
also	O
of	O
systemic	B-C0039082
lipotoxic	I-C0039082
consequences	B-C0686907
and	O
hyperandrogenemia	B-C1299574
in	O
women	B-C0043210
with	O
pcos	B-C0032460
.	O
	
although	O
it	O
requires	O
validation	B-C1519941
in	O
another	O
study	B-C2603343
,	O
an	O
alt	B-C0001899
cutoff	O
of	O
24	O
iu/l	O
may	O
help	O
clinicians	B-C0871685
identify	O
women	B-C0043210
with	O
increased	O
metabolic	B-C2321263
risks	I-C2321263
.	O
	
opioid	B-C0242402
use	O
in	O
chronic	B-C0150055
pain	I-C0150055
patients	B-C0030705
with	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
a	O
systematic	B-C1955832
review	I-C1955832
to	O
investigate	O
the	O
prevalence	B-C0220900
of	O
chronic	B-C0150055
pain	I-C0150055
and	O
opioid	B-C0242402
management	B-C1611232
among	O
patients	B-C0030705
with	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
ckd	B-C1561643
.	O
	
systematic	B-C1955832
review	I-C1955832
.	O
	
a	O
systematic	O
search	O
was	O
performed	O
,	O
including	O
citations	O
from	O
1960	O
to	O
may	O
2015	O
.	O
	
the	O
review	O
highlights	O
methodological	B-C0815254
quality	I-C0815254
assessment	I-C0815254
of	O
the	O
selected	O
studies	B-C0085973
prevalence	B-C0220900
of	O
pain	B-C0030193
type	B-C0332307
,	O
dose	B-C0678766
,	O
and	O
reason	O
for	O
opioid	B-C0242402
use	O
effectiveness	B-C1280519
of	O
pain	B-C1304888
control	I-C1304888
and	O
associated	O
adverse	B-C0879626
effects	I-C0879626
of	O
opioids	B-C0242402
in	O
ckd	B-C1561643
patients	B-C0030705
.	O
	
twelve	O
of	O
131	O
articles	O
met	O
inclusion	B-C1512693
criteria	I-C1512693
.	O
	
there	O
were	O
no	O
randomized	B-C0282440
controlled	I-C0282440
trials	I-C0282440
rct	B-C0282440
evaluable	O
,	O
and	O
12	O
were	O
observational	B-C3658316
studies	I-C3658316
.	O
	
out	O
of	O
12	O
studies	B-C0085973
,	O
four	O
were	O
of	O
high	B-C0205250
quality	B-C0332306
,	O
six	O
were	O
of	O
moderate	B-C0439536
quality	B-C0332306
,	O
and	O
the	O
remaining	O
two	O
were	O
low	B-C0205251
-	O
quality	B-C0332306
studies	B-C0085973
.	O
	
the	O
studies	B-C0085973
were	O
from	O
different	O
countries	B-C0454664
with	O
sample	B-C0242618
size	I-C0242618
ranging	O
from	O
10	O
to	O
12	O
.	O
	
several	O
studies	B-C0085973
showed	O
a	O
high	O
prevalence	B-C0220900
of	O
chronic	B-C0205191
uncontrolled	B-C0747149
pain	I-C0747149
.	O
	
the	O
effectiveness	O
of	O
different	O
categories	O
of	O
opioids	B-C0242402
,	O
dose	B-C0678766
,	O
duration	B-C0920470
,	O
and	O
commonly	O
prescribed	B-C0278329
opioids	B-C0242402
varied	O
across	O
studies	B-C0085973
.	O
	
based	O
on	O
a	O
systematic	B-C1955832
review	I-C1955832
of	O
the	O
current	O
literature	O
,	O
there	O
is	O
fair	O
evidence	O
for	O
the	O
high	O
prevalence	B-C0220900
of	O
chronic	B-C0150055
pain	I-C0150055
among	O
patients	B-C0030705
with	O
ckd	B-C1561643
,	O
which	O
is	O
not	O
being	O
effectively	O
managed	O
,	O
probably	O
due	O
to	O
underprescription	B-C0679863
of	O
analgesics	B-C0002771
or	O
opioids	B-C0242402
in	O
the	O
ckd	B-C1561643
population	B-C2361270
.	O
	
clinicians	B-C0871685
are	O
in	O
need	O
of	O
additional	O
and	O
well-designed	O
randomized	B-C0282440
control	I-C0282440
trials	I-C0282440
that	O
focus	O
on	O
the	O
indications	O
for	O
opioid	B-C0242402
therapy	B-C0087111
,	O
appropriate	O
opioid	B-C0242402
doses	B-C0678766
and	O
dosing	B-C0678766
intervals	B-C0031084
,	O
outcomes	O
with	O
adequacy	B-C0814633
of	O
symptom	B-C1274136
control	I-C1274136
,	O
and	O
reporting	O
on	O
the	O
incidence	O
of	O
adverse	B-C0879626
side	I-C0879626
effects	I-C0879626
.	O
	
cognitive	B-C0338656
impairment	I-C0338656
in	O
first-episode	B-C0439615
drug-naïve	B-C0030705
patients	I-C0030705
with	O
schizophrenia	B-C0036341
relationships	B-C0439849
with	O
serum	B-C0683149
concentrations	I-C0683149
of	O
brain-derived	B-C0107103
neurotrophic	I-C0107103
factor	I-C0107103
and	O
glial	B-C0207072
cell	I-C0207072
line-derived	I-C0207072
neurotrophic	I-C0207072
factor	I-C0207072
evidence	O
suggests	O
that	O
brain-derived	B-C0107103
neurotrophic	I-C0107103
factor	I-C0107103
bdnf	B-C0107103
and	O
glial	B-C0207072
cell	I-C0207072
line	I-C0207072
-derived	I-C0207072
neurotrophic	I-C0207072
factor	I-C0207072
gdnf	B-C0207072
are	O
important	O
in	O
the	O
regulation	B-C1326639
of	I-C1326639
synaptic	I-C1326639
plasticity	I-C1326639
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
cognitive	B-C0871689
processes	I-C0871689
in	O
psychiatric	B-C0004936
disorders	I-C0004936
.	O
	
our	O
work	O
aimed	O
at	O
exploring	O
the	O
associations	B-C0439849
between	O
serum	B-C0229671
bdnf	B-C0107103
and	O
gdnf	B-C0207072
levels	O
and	O
cognitive	B-C0392335
functions	I-C0392335
in	O
first-episode	B-C0030705
drug-naïve	I-C0030705
fedn	I-C0030705
patients	I-C0030705
with	O
schizophrenia	B-C0036341
.	O
	
the	O
bdnf	B-C0107103
and	O
gdnf	B-C0207072
levels	O
of	O
58	O
fedn	B-C0030705
patients	I-C0030705
and	O
55	O
age	B-C0001779
-	O
and	O
sex	B-C1522384
-matched	O
healthy	B-C2986479
controls	I-C2986479
were	O
measured	O
and	O
test	B-C0681850
subjects	I-C0681850
were	O
examined	O
using	O
several	O
neurocognitive	B-C0872227
tests	I-C0872227
including	O
the	O
verbal	B-C0033905
fluency	I-C0033905
test	I-C0033905
vft	B-C0033905
,	O
the	O
trail	B-C0040604
making	I-C0040604
test	I-C0040604
tmt	B-C0040604
,	O
the	O
digit	B-C0451577
span	I-C0451577
test	I-C0451577
dst	B-C0451577
,	O
and	O
the	O
stroop	B-C2718024
test	I-C2718024
.	O
	
patients	B-C0030705
performed	O
significantly	O
worse	O
than	O
controls	B-C0009932
in	O
nearly	O
all	O
neurocognitive	B-C0872227
performances	I-C0872227
except	O
the	O
forward	O
subscale	O
part	O
of	O
the	O
dst	B-C0451577
.	O
	
bdnf	B-C0107103
levels	B-C0441889
were	O
inversely	O
correlated	O
to	O
tmt-part	B-C0237855
b	I-C0237855
scores	I-C0237855
and	O
positively	O
correlated	O
to	O
vft-action	B-C0033905
in	O
the	O
fedn	O
group	O
.	O
	
gdnf	B-C0207072
levels	B-C0441889
showed	O
a	O
positive	O
correlation	O
with	O
vft-action	B-C0237855
scores	I-C0237855
and	O
a	O
negative	O
correlation	O
with	O
tmt-part	B-C0237855
b	I-C0237855
scores	I-C0237855
of	O
these	O
patients	B-C0030705
.	O
	
current	O
data	O
suggests	O
that	O
cognitive	B-C0338656
dysfunction	I-C0338656
widely	O
exists	O
in	O
the	O
early	B-C2363430
stages	I-C2363430
of	O
schizophrenia	B-C0036341
.	O
	
bdnf	B-C0107103
and	O
gdnf	B-C0207072
may	O
be	O
jointly	O
contributed	O
to	O
the	O
pathological	B-C1521733
mechanisms	B-C0441712
involved	O
in	O
cognitive	B-C0338656
impairment	I-C0338656
in	O
fedn	B-C0030705
patients	I-C0030705
with	O
comprehensive	B-C1880156
functional	B-C0936012
analysis	I-C0936012
of	O
large	O
lists	O
of	O
genes	B-C0017337
and	O
proteins	B-C0033684
the	O
interpretation	B-C0459471
of	O
high	B-C0150098
dimensional	I-C0150098
datasets	I-C0150098
resulting	O
from	O
genomic	B-C0681814
and	O
proteomic	B-C0681814
experiments	I-C0681814
in	O
a	O
timely	O
and	O
efficient	O
manner	O
is	O
challenging	O
.	O
	
cluego	B-C0037585
software	I-C0037585
is	O
a	O
cytoscape	B-C3658280
app	I-C3658280
that	O
extracts	O
representative	O
functional	O
biological	B-C0205460
information	B-C1533716
for	O
large	O
lists	O
of	O
genes	B-C0017337
or	O
proteins	B-C0033684
.	O
	
the	O
functional	B-C0936012
enrichment	I-C0936012
analysis	I-C0936012
is	O
based	O
on	O
the	O
latest	O
publicly	O
available	O
data	B-C1511726
from	O
multiple	O
annotation	B-C1706814
and	O
ontology	B-C1518584
resources	B-C0035201
that	O
can	O
be	O
automatically	B-C0205554
accessed	B-C0444454
through	O
cluego	B-C0037585
.	O
	
predefined	B-C4281677
settings	I-C4281677
for	O
the	O
selection	B-C1707391
of	O
the	O
terms	B-C1705313
are	O
provided	O
to	O
facilitate	O
the	O
analysis	B-C0936012
.	O
	
results	B-C1274040
are	O
visualized	O
as	O
networks	B-C1882071
in	O
which	O
gene	B-C1138831
ontology	I-C1138831
go	B-C1138831
terms	O
and	O
pathways	B-C1705987
are	O
grouped	O
based	O
on	O
their	O
biological	O
role	O
.	O
	
many	O
species	B-C1705920
are	O
now	O
supported	O
by	O
cluego	B-C0037585
and	O
additional	O
organisms	B-C0029235
are	O
added	O
on	O
demand	O
.	O
	
cluego	B-C0037585
can	O
be	O
used	O
together	O
with	O
the	O
cluepedia	B-C3658280
app	I-C3658280
to	O
enable	O
the	O
visualization	O
of	O
protein-protein	B-C0872079
interactions	I-C0872079
within	O
or	O
between	O
management	B-C1536570
of	O
precipitated	B-C3274502
opiate	I-C3274502
withdrawal	I-C3274502
syndrome	I-C3274502
induced	B-C0205263
by	O
nalmefene	B-C0068377
mistakenly	O
prescribed	B-C0278329
in	O
opiate	B-C0376196
-	O
dependent	B-C0581116
patients	I-C0581116
a	O
review	B-C0282443
for	O
clinicians	B-C0871685
nalmefene	B-C0068377
,	O
a	O
long-acting	B-C3536879
µ-opioid	I-C3536879
antagonist	I-C3536879
approved	B-C0205540
to	O
treat	B-C1522326
alcohol	B-C0001956
use	I-C0001956
disorder	I-C0001956
,	O
is	O
occasionally	B-C1998882
mistakenly	O
prescribed	B-C0278329
to	O
opiate	B-C0376196
-	O
dependent	B-C0581116
or	O
opioid	B-C0242402
-	O
treated	B-C1522326
patients	B-C0030705
.	O
	
we	O
review	B-C1552617
recent	O
literature	B-C0023866
on	O
drug-drug	B-C0687133
interactions	I-C0687133
between	O
nalmefene	B-C0068377
and	O
opioids	B-C0242402
that	O
lead	O
to	O
precipitated	B-C0029104
opioid	I-C0029104
withdrawal	I-C0029104
,	O
and	O
focus	O
on	O
its	O
management	B-C1536570
and	O
planning	B-C1301732
for	O
care	B-C0017313
at	O
discharge	B-C0030685
.	O
	
areas	O
covered	O
this	O
article	O
provides	O
a	O
brief	O
and	O
comprehensive	B-C3494708
review	I-C3494708
of	O
management	O
of	O
precipitated	B-C3274502
opioid	I-C3274502
withdrawal	I-C3274502
syndrome	I-C3274502
when	O
nalmefene	B-C0068377
is	O
associated	B-C0332281
with	I-C0332281
an	O
opioid	B-C0242402
,	O
whether	O
misused	B-C1997897
or	O
legally	B-C1301860
prescribed	B-C0278329
.	O
	
expert	B-C0600219
opinion	I-C0600219
when	O
treating	B-C1522326
an	O
opiate	B-C0376196
-	O
dependent	B-C0581116
patient	I-C0581116
with	O
co-occurring	O
alcohol	B-C0001956
use	I-C0001956
disorder	I-C0001956
,	O
both	O
conditions	B-C0348080
need	O
to	O
be	O
a	O
focus	O
of	O
clinical	B-C0205210
attention	I-C0205210
.	O
	
new	B-C0205314
drugs	B-C0013227
for	O
alcohol	B-C0001956
use	I-C0001956
disorder	I-C0001956
have	O
been	O
approved	B-C0205540
,	O
but	O
must	O
be	O
given	O
cautiously	O
and	O
with	O
a	O
full	O
understanding	O
of	O
their	O
potential	B-C3245505
drug-drug	B-C0687133
interactions	I-C0687133
with	O
opioid	B-C0242402
medications	B-C4284232
.	O
	
opiate	B-C0376196
-	O
dependent	B-C0581116
patients	I-C0581116
should	O
be	O
intensively	O
monitored	O
for	O
risk	B-C0035648
factors	I-C0035648
of	O
alcohol	B-C0001956
use	I-C0001956
disorder	I-C0001956
and	O
should	O
be	O
continuously	O
motivated	O
for	O
treatment	B-C0814469
maintenance	I-C0814469
.	O
	
when	O
nalmefene	B-C0068377
is	O
administered	B-C0806914
to	O
opiate	B-C0376196
-	O
dependent	B-C0581116
patients	I-C0581116
,	O
acute	B-C0205178
opioid	B-C3274502
withdrawal	I-C3274502
syndrome	I-C3274502
may	O
occur	B-C1709305
.	O
	
management	B-C1536570
of	O
precipitated	O
acute	B-C0205178
opioid	B-C0029104
withdrawal	I-C0029104
may	O
include	B-C2700399
short	O
or	O
long-acting	B-C1373059
µ-opioid	I-C1373059
agonists	I-C1373059
during	O
hospitalization	B-C0019993
,	O
in	O
addition	O
to	O
supportive	B-C0344211
treatment	I-C0344211
.	O
	
the	O
best	O
management	B-C1610129
of	O
polydrug	B-C0556390
abusers	I-C0556390
is	O
based	O
on	O
a	O
multidisciplinary	B-C0729737
approach	I-C0729737
,	O
which	O
should	O
be	O
pursued	O
and	O
improved	B-C0184511
through	B-C0332273
continuing	B-C1553904
medical	I-C1553904
education	I-C1553904
.	O
	
discovering	O
key	O
residues	B-C1709915
of	O
dengue	B-C0011315
virus	I-C0011315
ns2b-ns3-protease	B-C1612175
new	O
binding	B-C0005456
sites	I-C0005456
for	O
antiviral	B-C0042771
inhibitors	I-C0042771
design	O
the	O
ns2b-ns3	B-C1612175
protease	I-C1612175
is	O
essential	O
for	O
the	O
dengue	B-C0011315
virus	I-C0011315
denv	B-C0011315
replication	B-C1514849
process	I-C1514849
.	O
	
this	O
complex	B-C1167179
constitutes	O
a	O
target	B-C1521840
for	O
efficient	O
antiviral	B-C0003451
discovery	B-C1880355
because	O
a	O
drug	B-C1254351
could	O
inhibit	O
the	O
viral	B-C1159314
polyprotein	I-C1159314
processing	I-C1159314
.	O
	
furthermore	O
,	O
since	O
the	O
protease	B-C1947941
is	O
highly	O
conserved	B-C0009802
between	O
the	O
four	O
dengue	B-C0011315
virus	I-C0011315
serotypes	B-C0449943
,	O
it	O
is	O
probable	O
that	O
a	O
drug	B-C1254351
would	O
be	O
equally	O
effective	O
against	O
all	O
of	O
them	O
.	O
	
in	O
this	O
article	O
,	O
a	O
strategy	O
is	O
reported	O
that	O
allowed	O
us	O
to	O
identify	O
influential	B-C0021399
residues	B-C1709915
on	O
the	O
function	O
of	O
the	O
dengue	B-C0011315
ns2b-ns3	B-C1612175
protease	I-C1612175
.	O
	
moreover	O
,	O
this	O
is	O
a	O
strategy	O
that	O
could	O
be	O
applied	O
to	O
virtually	O
any	O
protein	B-C0033684
for	O
the	O
search	O
of	O
alternative	O
influential	B-C0021399
residues	B-C1709915
,	O
and	O
for	O
non-competitive	B-C0815027
inhibitor	I-C0815027
development	B-C1527148
.	O
	
first	O
,	O
we	O
incorporated	O
several	O
features	O
derived	O
from	O
computational	B-C0376528
alanine	B-C0001898
scanning	B-C1517890
mutagenesis	I-C1517890
,	O
sequence	B-C0314659
,	O
structure	B-C0009802
conservation	I-C0009802
,	O
and	O
other	O
structure	B-C0678594
-based	O
characteristics	B-C1521970
.	O
	
second	O
,	O
these	O
features	O
were	O
used	O
as	O
variables	O
to	O
obtain	O
a	O
multilayer	B-C0870951
perceptron	I-C0870951
model	I-C0870951
to	O
identify	O
defined	O
groups	B-C0441833
clusters	O
of	O
key	O
residues	B-C1709915
as	O
possible	O
candidate	O
pockets	O
for	O
binding	B-C0005456
sites	I-C0005456
of	O
new	O
leads	O
on	O
the	O
denv	B-C0011315
protease	B-C1947941
.	O
	
the	O
identified	O
residues	B-C1709915
included	O
i	O
amino	B-C0002520
acids	I-C0002520
close	O
to	O
the	O
beta	B-C0162806
sheet	I-C0162806
-loop-	O
beta	B-C0162806
sheet	I-C0162806
known	O
to	O
be	O
important	O
in	O
its	O
closed	B-C0033625
conformation	I-C0033625
for	O
ns2b	B-C1612175
ii	O
residues	B-C1709915
close	O
to	O
the	O
active	B-C0205681
site	I-C0205681
,	O
iii	O
several	O
residues	B-C1709915
evenly	O
spread	O
on	O
the	O
ns2b-ns3	B-C1612175
contact	O
surface	O
,	O
and	O
iv	O
some	O
inner	O
residues	B-C1709915
most	O
likely	O
related	O
to	O
the	O
overall	O
stability	B-C0205360
of	O
the	O
protease	B-C1947941
.	O
	
in	O
addition	O
,	O
we	O
found	O
concordance	O
on	O
our	O
list	O
of	O
residues	B-C1709915
with	O
previously	O
identified	O
amino	B-C0002520
acids	I-C0002520
part	O
of	O
a	O
highly	O
conserved	O
peptide	B-C0030956
studied	O
for	O
vaccine	B-C0597634
development	I-C0597634
.	O
	
association	B-C0439849
of	O
toll-like	B-C1411976
receptor	I-C1411976
4	I-C1411976
on	O
human	B-C0086418
monocyte	B-C0026473
subsets	B-C1515021
and	O
vulnerability	B-C1821973
characteristics	B-C1521970
of	O
coronary	B-C0018787
plaque	B-C0332461
as	O
assessed	B-C1516048
by	O
64-slice	B-C3179130
multidetector	I-C3179130
computed	I-C3179130
tomography	I-C3179130
although	O
toll-like	B-C1411976
receptor	I-C1411976
4	I-C1411976
tlr-4	B-C1411976
is	O
involved	O
in	O
monocyte	B-C1155075
activation	I-C1155075
in	O
patients	B-C0030705
with	O
accelerated	B-C0521110
forms	O
of	O
atherosclerosis	B-C0004153
,	O
the	O
relationship	B-C0439849
between	O
the	O
expression	B-C0597360
of	O
tlr-4	B-C1411976
on	O
circulating	B-C0175630
monocyte	B-C0026473
s	O
and	O
coronary	B-C0018787
plaque	B-C0332461
vulnerability	B-C1821973
has	O
not	O
previously	O
been	O
evaluated	B-C0220825
.	O
	
we	O
investigated	O
this	O
relationship	B-C0439849
using	O
64-slice	B-C3179130
multidetector	I-C3179130
computed	I-C3179130
tomography	I-C3179130
mdct	B-C3179130
in	O
patients	B-C0030705
with	O
stable	B-C0340288
angina	I-C0340288
pectoris	I-C0340288
sap	B-C0340288
and	O
results	O
enrolled	O
65	O
patients	B-C0030705
with	O
sap	B-C0340288
who	O
underwent	O
mdct	B-C3179130
.	O
	
three	O
monocyte	B-C0026473
subsets	B-C1515021
cd14	B-C0026473
,	O
cd14	B-C0026473
,	O
and	O
cd14	B-C0026473
and	O
expression	B-C0597360
of	O
tlr-4	B-C1411976
were	O
measured	O
by	O
flow	B-C0016263
cytometry	I-C0016263
.	O
	
intracoronary	B-C0018787
plaques	B-C0332461
were	O
assessed	B-C1516048
by	O
64-slice	B-C3179130
mdct	I-C3179130
.	O
	
we	O
defined	O
vulnerability	B-C1821973
of	O
intracoronary	B-C0018787
plaques	B-C0332461
according	O
to	O
the	O
presence	O
of	O
positive	B-C3854505
remodeling	I-C3854505
remodeling	B-C0243095
index	I-C0243095
>1	O
and/or	O
low	O
ct	B-C0040405
attenuation	B-C2986722
<35	O
hu	O
.	O
	
the	O
circulating	B-C0175630
cd14	B-C0026473
more	O
frequently	O
expressed	B-C0597360
tlr-4	B-C1411976
than	O
cd14	B-C0026473
and	O
cd14	B-C0026473
p<0	O
.	O
	
the	O
relative	O
proportion	O
of	O
the	O
expression	B-C0597360
of	O
tlr-4	B-C1411976
on	O
cd14	B-C0026473
was	O
significantly	O
greater	O
in	O
patients	B-C0030705
with	O
vulnerable	B-C0332461
plaque	I-C0332461
compared	O
with	O
those	O
without	O
10.4	O
4.1	O
%	O
vs	O
.	O
	
4.5	O
2.8	O
%	O
,	O
p=0	O
.	O
	
in	O
addition	O
,	O
the	O
relative	O
proportion	O
of	O
tlr-4	B-C1411976
expression	B-C0597360
on	O
cd14	B-C0026473
positively	O
correlated	B-C1707520
with	O
the	O
remodeling	B-C0243095
index	I-C0243095
r=0	O
,	O
p=0	O
and	O
negatively	O
correlated	B-C1707520
with	O
ct	B-C0040405
attenuation	B-C2986722
value	I-C2986722
r=-0	O
,	O
p=0	O
.	O
	
upregulation	B-C0949479
of	O
tlr-4	B-C1411976
on	O
cd14	B-C0026473
might	O
be	O
associated	B-C0332281
with	I-C0332281
coronary	B-C0018787
plaque	B-C0332461
vulnerability	B-C1821973
in	O
patients	B-C0030705
with	O
delta-frequency	B-C0429299
stimulation	B-C1948023
of	O
cerebellar	B-C0007765
projections	B-C0348018
can	O
compensate	B-C0205432
for	O
schizophrenia	B-C0036341
-related	O
medial	B-C4062322
frontal	I-C4062322
dysfunction	I-C4062322
schizophrenia	B-C0036341
involves	O
abnormalities	B-C1704258
in	O
the	O
medial	B-C0016733
frontal	I-C0016733
cortex	I-C0016733
that	O
lead	O
to	O
cognitive	B-C0009241
deficits	I-C0009241
.	O
	
here	O
we	O
investigate	B-C1292732
a	O
novel	B-C0205314
strategy	B-C0679199
to	O
normalize	B-C1882115
medial	B-C2951740
frontal	I-C2951740
brain	I-C2951740
activity	B-C0443158
by	O
stimulating	B-C1948023
cerebellar	B-C0007765
projections	B-C0348018
.	O
	
we	O
used	O
an	O
interval	B-C0872291
timing	I-C0872291
task	O
to	O
study	B-C2603343
elementary	O
cognitive	B-C0025361
processing	I-C0025361
that	O
requires	O
both	O
frontal	B-C0016733
and	O
cerebellar	B-C2953133
networks	I-C2953133
that	O
are	O
disrupted	B-C0332454
in	O
patients	B-C0030705
with	O
schizophrenia	B-C0036341
.	O
	
we	O
report	O
three	O
novel	B-C0205314
findings	B-C0243095
.	O
	
first	O
,	O
patients	B-C0030705
with	O
schizophrenia	B-C0036341
had	O
dysfunctional	O
delta	B-C0011227
rhythms	I-C0011227
between	O
1-4	O
hz	O
in	O
the	O
medial	B-C0016733
frontal	I-C0016733
cortex	I-C0016733
.	O
	
we	O
explored	O
cerebellar	B-C0007765
-	O
frontal	B-C0016733
interactions	B-C1704675
in	O
animal	B-C0599779
models	I-C0599779
and	O
found	O
that	O
both	O
frontal	B-C0016733
and	O
cerebellar	B-C0682702
neurons	I-C0682702
were	O
modulated	B-C0443264
during	O
interval	B-C0872291
timing	I-C0872291
and	O
had	O
delta-frequency	B-C0429299
interactions	B-C1704675
.	O
	
finally	O
,	O
delta-frequency	B-C0429299
optogenetic	B-C3494301
stimulation	B-C1948023
of	O
thalamic	B-C0039729
synaptic	B-C0206181
terminals	I-C0206181
of	O
lateral	B-C0205093
cerebellar	B-C0007765
projection	B-C0348018
neurons	B-C0027882
rescued	O
timing	O
performance	O
as	O
well	O
as	O
medial	B-C2951740
frontal	I-C2951740
activity	B-C0443158
in	O
a	O
rodent	B-C1519106
model	I-C1519106
of	O
schizophrenia-related	B-C0036341
frontal	B-C4062322
dysfunction	I-C4062322
.	O
	
these	O
data	B-C1511726
provide	O
insight	O
into	O
how	O
the	O
cerebellum	B-C0007765
influences	B-C4054723
medial	B-C4248854
frontal	I-C4248854
networks	I-C4248854
and	O
the	O
role	O
of	O
the	O
cerebellum	B-C0007765
in	O
cognitive	B-C0025361
processing	I-C0025361
.	O
	
variables	B-C0439828
associated	B-C0332281
with	I-C0332281
unplanned	B-C0205556
general	B-C0001675
adult	I-C0001675
icu	B-C0583239
admission	I-C0583239
in	O
hospitalised	B-C0870668
patients	I-C0870668
protocol	B-C0442711
for	O
a	O
systematic	B-C0220922
review	B-C1552617
failure	B-C0231175
to	O
promptly	O
identify	B-C0205396
deterioration	B-C0868945
in	O
hospitalised	B-C0870668
patients	I-C0870668
is	O
associated	B-C0332281
with	I-C0332281
delayed	B-C0205421
admission	B-C0583239
to	I-C0583239
intensive	I-C0583239
care	I-C0583239
units	I-C0583239
icus	B-C0021708
and	O
poor	B-C2700379
outcomes	B-C0085415
.	O
	
existing	B-C2987476
vital	B-C0518766
sign	I-C0518766
-based	O
early	B-C0449820
warning	I-C0449820
score	I-C0449820
ews	B-C0449820
algorithms	B-C0002045
do	O
not	O
have	O
a	O
sufficiently	B-C0205410
high	B-C0205250
positive	B-C3812269
predictive	B-C1514307
value	I-C1514307
to	O
be	O
used	O
for	O
automated	B-C0205554
activation	B-C1879547
of	O
an	O
icu	B-C0021708
outreach	B-C0586969
team	I-C0586969
.	O
	
incorporating	B-C0332257
additional	O
patient	B-C2707520
data	I-C2707520
might	O
improve	B-C0184511
the	O
predictive	B-C0681890
power	B-C3854080
of	O
ews	B-C0449820
algorithms	B-C0002045
however	O
,	O
it	O
is	O
currently	B-C0521116
not	O
known	O
which	O
patient	B-C2707520
data	I-C2707520
or	O
variables	B-C0439828
are	O
most	O
predictive	B-C0681890
of	O
icu	B-C0583239
admission	I-C0583239
.	O
	
we	O
describe	O
the	O
protocol	B-C0442711
for	O
a	O
systematic	B-C0220922
review	B-C1552617
of	O
variables	B-C0439828
associated	B-C0332281
with	I-C0332281
icu	B-C0583239
admission	I-C0583239
.	O
	
medline	B-C0242356
,	O
embase	B-C0242356
,	O
cinahl	B-C0242356
and	O
the	O
cochrane	B-C0242356
library	I-C0242356
,	O
including	B-C0332257
cochrane	B-C0242356
database	I-C0242356
of	I-C0242356
systematic	I-C0242356
reviews	I-C0242356
and	O
the	O
cochrane	B-C0282574
central	I-C0282574
register	I-C0282574
of	I-C0282574
controlled	I-C0282574
trials	I-C0282574
central	B-C0282574
will	O
be	O
searched	B-C1706202
for	O
studies	B-C2603343
that	O
assess	B-C0184514
the	O
association	B-C0439849
of	O
routinely	B-C0205547
recorded	B-C0034869
variables	B-C0439828
associated	B-C0332281
with	I-C0332281
subsequent	B-C0332282
unplanned	B-C0205556
icu	B-C0583239
admission	I-C0583239
.	O
	
only	O
studies	B-C2603343
involving	B-C1314939
adult	B-C0001675
patients	B-C0030705
admitted	B-C0184666
to	I-C0184666
general	B-C0205246
icus	B-C0021708
will	O
be	O
included	B-C0332257
.	O
	
we	O
will	O
extract	B-C0849355
data	B-C1511726
relating	B-C0332281
to	I-C0332281
the	O
statistical	B-C0010101
association	I-C0010101
between	O
icu	B-C0583239
admission	I-C0583239
and	O
predictor	B-C0681842
variables	B-C0439828
,	O
the	O
quality	B-C0332306
of	O
the	O
studies	B-C2603343
and	O
the	O
generalisability	B-C0205246
of	O
the	O
findings	B-C0243095
.	O
	
the	O
results	B-C1274040
of	O
this	O
review	B-C1552617
will	O
aid	B-C1269765
the	O
development	B-C1527148
of	O
future	O
models	B-C3161035
which	O
predict	B-C0681842
the	O
risk	B-C0035647
of	O
unplanned	B-C0205556
icu	B-C0583239
admission	I-C0583239
.	O
	
diagnosis	B-C0011900
of	O
retinal	B-C0035298
health	B-C0018684
in	O
digital	B-C0200189
fundus	I-C0200189
images	I-C0200189
using	O
continuous	B-C2936326
wavelet	I-C2936326
transform	I-C2936326
cwt	B-C2936326
and	O
entropies	B-C0376522
vision	B-C0042789
is	O
paramount	O
to	O
humans	B-C0086418
to	O
lead	O
an	O
active	O
personal	B-C1519021
and	O
professional	B-C2698884
life	I-C2698884
.	O
	
the	O
prevalence	B-C0220900
of	O
ocular	B-C0015397
diseases	I-C0015397
is	O
rising	O
,	O
and	O
diseases	B-C0012634
such	O
as	O
glaucoma	B-C0017601
,	O
diabetic	B-C0011884
retinopathy	I-C0011884
dr	B-C0011884
and	O
age-related	B-C0242383
macular	I-C0242383
degeneration	I-C0242383
amd	B-C0242383
are	O
the	O
leading	B-C1522538
causes	B-C0015127
of	O
blindness	B-C0456909
in	O
developed	B-C0282613
countries	I-C0282613
.	O
	
identifying	O
these	O
diseases	B-C0012634
in	O
mass	B-C0024870
screening	I-C0024870
programmes	I-C0024870
is	O
time-consuming	B-C3827829
,	O
labor	B-C0043227
-intensive	O
and	O
the	O
diagnosis	B-C0011900
can	O
be	O
subjective	B-C0439655
.	O
	
the	O
use	O
of	O
an	O
automated	B-C0011905
computer	I-C0011905
aided	I-C0011905
diagnosis	I-C0011905
system	I-C0011905
will	O
reduce	O
the	O
time	O
taken	O
for	O
analysis	B-C0936012
and	O
will	O
also	O
reduce	O
the	O
inter-observer	B-C0021713
subjective	I-C0021713
variabilities	I-C0021713
in	O
image	B-C0020910
interpretation	I-C0020910
.	O
	
in	O
this	O
work	O
,	O
we	O
propose	O
one	O
such	O
system	O
for	O
the	O
automatic	B-C0205554
classification	B-C0008902
of	O
normal	B-C0205307
from	O
abnormal	B-C0205161
dr	B-C0011884
,	O
amd	B-C0242383
,	O
glaucoma	B-C0017601
images	B-C0237660
.	O
	
we	O
had	O
a	O
total	O
of	O
404	O
normal	B-C0205307
and	O
1082	O
abnormal	B-C0205161
fundus	B-C0200189
images	I-C0200189
in	O
our	O
database	B-C0242356
.	O
	
as	O
the	O
first	O
step	O
,	O
2d-continuous	B-C2936326
wavelet	I-C2936326
transform	I-C2936326
cwt	B-C2936326
decomposition	O
on	O
the	O
fundus	B-C0200189
images	I-C0200189
of	O
two	O
classes	O
was	O
performed	O
.	O
	
subsequently	O
,	O
energy	B-C1442080
features	O
and	O
various	O
entropies	B-C0376522
namely	O
yager	O
,	O
renyi	O
,	O
kapoor	O
,	O
shannon	O
,	O
and	O
fuzzy	O
were	O
extracted	O
from	O
the	O
decomposed	O
images	B-C0237660
.	O
	
then	O
,	O
adaptive	O
synthetic	O
sampling	B-C0449370
approach	I-C0449370
was	O
applied	O
to	O
balance	O
the	O
normal	B-C0205307
and	O
abnormal	B-C0205161
datasets	B-C0150098
.	O
	
next	O
,	O
the	O
extracted	O
features	O
were	O
ranked	O
according	O
to	O
the	O
significances	O
using	O
particle	B-C0282574
swarm	I-C0282574
optimization	I-C0282574
pso	B-C0282574
.	O
	
thereupon	O
,	O
the	O
ranked	O
and	O
selected	O
features	O
were	O
used	O
to	O
train	O
the	O
random	O
forest	O
classifier	O
using	O
stratified	B-C0205363
10-fold	O
cross	B-C0681935
validation	I-C0681935
.	O
	
overall	O
,	O
the	O
proposed	O
system	O
presented	O
a	O
performance	B-C3533080
rate	I-C3533080
of	O
92.48	O
,	O
and	O
a	O
sensitivity	B-C0036667
and	O
specificity	B-C0037791
of	O
89.37	O
and	O
95.58	O
respectively	O
using	O
15	O
features	O
.	O
	
this	O
novel	O
system	O
shows	O
promise	O
in	O
detecting	O
abnormal	B-C0205161
fundus	B-C0200189
images	I-C0200189
,	O
and	O
hence	O
,	O
could	O
be	O
a	O
valuable	O
adjunct	O
eye	B-C0015392
health	B-C0018684
screening	B-C0220908
tool	I-C0220908
that	O
could	O
be	O
employed	O
in	O
polyclinics	B-C0442592
,	O
and	O
thereby	O
reduce	O
the	O
workload	B-C0085122
of	O
specialists	B-C1611835
at	O
the	O
epigenetic	B-C1516924
landscape	I-C1516924
of	O
age	B-C0001779
-	O
related	B-C1552599
diseases	B-C0012634
the	O
geroscience	B-C1518533
perspective	B-C1254370
in	O
this	O
review	B-C0282443
,	O
we	O
summarize	O
current	O
knowledge	O
regarding	O
the	O
epigenetics	B-C1516924
of	O
age	B-C0001779
-	O
related	B-C1552599
diseases	B-C0012634
,	O
focusing	O
on	O
those	O
studies	B-C0008972
that	O
have	O
described	O
dna	B-C0376452
methylation	I-C0376452
landscape	I-C0376452
in	O
cardio-vascular	B-C0007222
diseases	I-C0007222
,	O
musculoskeletal	B-C0026861
function	I-C0026861
and	O
frailty	B-C0424594
.	O
	
we	O
stress	O
the	O
importance	O
of	O
adopting	O
the	O
conceptual	B-C1254372
framework	I-C1254372
of	O
""""	O
geroscience	B-C1518533
""""	O
,	O
which	O
starts	O
from	O
the	O
observation	O
that	O
advanced	B-C0001792
age	B-C0001779
is	O
the	O
major	O
risk	B-C0035648
factor	I-C0035648
for	O
several	O
of	O
these	O
pathologies	B-C0205469
and	O
aims	B-C1947946
at	O
identifying	O
the	O
mechanistic	B-C0439849
links	I-C0439849
between	O
aging	B-C0001811
and	O
age	B-C0001779
-	O
related	B-C1552599
diseases	B-C0012634
.	O
	
dna	B-C0376452
methylation	I-C0376452
undergoes	O
a	O
profound	O
remodeling	B-C0678692
during	O
aging	B-C0001811
,	O
which	O
includes	O
global	B-C2613367
hypomethylation	I-C2613367
of	O
the	O
genome	B-C0017428
,	O
hypermethylation	B-C1512554
at	O
specific	B-C0205369
loci	B-C0678933
and	O
an	O
increase	B-C0442805
in	O
inter-individual	B-C0042333
variation	I-C0042333
and	O
in	O
stochastic	B-C0038347
changes	B-C0392747
of	O
dna	B-C0376452
methylation	I-C0376452
values	B-C0042295
.	O
	
these	O
epigenetic	B-C1516924
modifications	B-C3840684
can	O
be	O
an	O
important	O
contributor	O
to	O
the	O
development	B-C1527148
of	O
age	B-C0001779
-	O
related	B-C1552599
diseases	B-C0012634
,	O
but	O
our	O
understanding	O
on	O
the	O
complex	B-C0439855
relationship	B-C0439849
between	O
the	O
epigenetic	B-C1516924
signatures	I-C1516924
of	O
aging	B-C0001811
and	O
age	B-C0001779
-	O
related	B-C1552599
disease	B-C0012634
is	O
still	O
poor	O
.	O
	
the	O
most	O
relevant	B-C2347946
results	B-C2825142
in	O
this	O
field	O
come	O
from	O
the	O
use	O
of	O
the	O
so	O
called	O
""""	O
epigenetics	B-C1516924
clocks	I-C1516924
""""	O
in	O
cohorts	B-C0599755
of	O
subjects	B-C0080105
affected	B-C0392760
by	O
age	B-C0001779
-	O
related	B-C1552599
diseases	B-C0012634
.	O
	
we	O
report	O
these	O
studies	B-C0008972
in	O
final	O
section	O
of	O
this	O
beneficial	B-C1280500
effects	I-C1280500
of	O
phyllanthus	B-C0950041
amarus	I-C0950041
against	O
high	B-C0012155
fructose	I-C0012155
diet	I-C0012155
induced	O
insulin	B-C0021655
resistance	I-C0021655
and	O
hepatic	B-C0242606
oxidative	I-C0242606
stress	I-C0242606
in	O
male	B-C0086582
wistar	B-C0034716
rats	I-C0034716
insulin	B-C0021655
resistance	I-C0021655
ir	B-C0021655
is	O
a	O
characteristic	O
feature	O
of	O
obesity	B-C0028754
,	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
mellitus	I-C0011860
,	O
and	O
cardiovascular	B-C0007222
diseases	I-C0007222
.	O
	
emerging	O
evidence	O
suggests	O
that	O
the	O
high-fructose	B-C0016745
consumption	B-C1947907
is	O
a	O
potential	B-C3245505
and	O
important	O
factor	B-C1521761
responsible	O
for	O
the	O
rising	B-C0220888
incidence	I-C0220888
of	O
ir	B-C0021655
.	O
	
the	O
present	O
study	B-C2603343
investigates	B-C1292732
the	O
beneficial	B-C1280500
effects	I-C1280500
of	O
aqueous	B-C2828366
extract	I-C2828366
of	O
phyllanthus	B-C0950041
amaru	I-C0950041
s	O
paae	B-C2828366
on	O
ir	B-C0021655
and	O
oxidative	B-C0242606
stress	I-C0242606
in	O
high-fructose	B-C0016745
hf	B-C0016745
fed	O
male	B-C0086582
wistar	B-C0034716
rats	I-C0034716
.	O
	
hf	B-C0012155
diet	I-C0012155
66%	O
of	O
fructose	O
and	O
paae	B-C2828366
200	O
mg/kg	O
body	O
weight/day	O
were	O
given	O
concurrently	B-C0205420
to	O
the	O
rats	B-C0034716
for	O
a	O
period	O
of	O
60	O
days	O
.	O
	
fructose-fed	B-C0205556
rats	B-C0034716
showed	O
weight	B-C0043094
gain	I-C0043094
,	O
hyperglycemia	B-C0020456
,	O
hyperinsulinemia	B-C0020459
,	O
impaired	B-C0271650
glucose	I-C0271650
tolerance	I-C0271650
,	O
impaired	B-C0920563
insulin	I-C0920563
sensitivity	I-C0920563
,	O
dyslipidemia	B-C0242339
,	O
hyperleptinemia	B-C0012634
,	O
and	O
hypoadiponectinemia	B-C2675519
p	O
<	O
0.05	O
after	O
60	O
days	O
.	O
	
co-administration	B-C1533734
of	O
paae	B-C2828366
along	O
with	O
hf	B-C0012155
diet	I-C0012155
significantly	O
ameliorated	O
all	O
these	O
alterations	B-C1515926
.	O
	
regarding	O
hepatic	B-C0205054
antioxidant	B-C1148564
status	I-C1148564
,	O
higher	O
lipid	B-C0023775
peroxidation	I-C0023775
and	O
protein	B-C1159301
oxidation	I-C1159301
,	O
lower	O
reduced	B-C0034917
glutathione	I-C0034917
levels	O
and	O
lower	B-C3890174
activities	I-C3890174
of	O
enzymatic	B-C0003402
antioxidants	I-C0003402
,	O
and	O
the	O
histopathological	B-C0243140
changes	I-C0243140
like	O
mild	O
to	O
severe	O
distortion	B-C2919017
of	O
the	O
normal	O
architecture	O
as	O
well	O
as	O
the	O
prominence	O
and	O
widening	O
of	O
the	O
liver	B-C0227523
sinusoids	I-C0227523
observed	O
in	O
the	O
hf	B-C0012155
diet	I-C0012155
-fed	O
rats	B-C0034716
were	O
significantly	O
prevented	O
by	O
paae	B-C2828366
treatment	B-C0087111
.	O
	
these	O
findings	O
indicate	O
that	O
paae	B-C2828366
is	O
beneficial	O
in	O
improving	O
insulin	B-C0920563
sensitivity	I-C0920563
and	O
attenuating	O
metabolic	B-C0025517
syndrome	I-C0025517
and	O
hepatic	B-C0242606
oxidative	I-C0242606
stress	I-C0242606
in	O
fructose-fed	B-C0205556
rats	B-C0034716
.	O
	
environmental	B-C1516998
factors	I-C1516998
and	O
hypertension	B-C0020538
environmental	B-C1516998
factors	I-C1516998
are	O
a	O
major	O
cause	O
of	O
poor	B-C0683321
health	I-C0683321
worldwide	B-C2700280
.	O
	
the	O
most	O
solid	O
evidence	B-C3887511
is	O
for	O
air	B-C0001873
pollution	I-C0001873
,	O
leading	O
to	O
increased	O
disability-adjusted	B-C4300518
life	I-C4300518
years	I-C4300518
.	O
	
outdoor	B-C0680182
temperature	B-C0039476
and	O
other	O
seasonal	B-C0036497
climate	B-C2718051
changes	I-C2718051
may	O
also	O
influence	O
cardiovascular	B-C3887460
health	B-C0018684
,	O
according	O
to	O
their	O
direct	O
modulation	O
of	O
air	B-C0001873
pollution	I-C0001873
.	O
	
moreover	O
,	O
an	O
increasing	O
body	O
of	O
evidence	B-C3887511
associates	O
environmental	B-C0014412
exposure	I-C0014412
to	O
noise	B-C0028263
with	O
poor	B-C0243095
cardiovascular	I-C0243095
outcome	I-C0243095
,	O
and	O
in	O
particular	O
with	O
hypertension	B-C0020538
.	O
	
this	O
review	O
is	O
aimed	O
at	O
reviewing	O
current	O
evidence	B-C3887511
about	O
the	O
role	O
of	O
these	O
environmental	B-C1516998
factors	I-C1516998
in	O
cardiovascular	B-C0007222
disease	I-C0007222
and	O
specifically	O
hypertension	B-C0020538
.	O
	
in	O
particular	O
,	O
the	O
impact	B-C4049986
of	O
air	B-C0001873
pollution	I-C0001873
,	O
with	O
its	O
short-term	B-C0443303
and	O
long-term	B-C0023983
effects	I-C0023983
,	O
the	O
outdoor	B-C0680182
temperature	B-C0039476
and	O
noise	B-C0686918
pollution	I-C0686918
will	O
be	O
investigated	O
.	O
	
people	B-C0027361
belonging	O
to	O
low	B-C0205251
social	B-C0037402
classes	I-C0037402
,	O
as	O
well	O
as	O
children	B-C0008059
,	O
women	B-C0043210
,	O
older	B-C3826770
people	I-C3826770
and	O
those	O
with	O
established	O
cardiovascular	B-C0007222
diseases	I-C0007222
,	O
seem	O
to	O
have	O
a	O
greater	O
susceptibility	B-C1264642
to	O
the	O
effects	B-C1280500
of	O
environmental	B-C0596519
stressors	I-C0596519
,	O
recalling	O
the	O
concept	B-C0178566
of	O
""""	O
environmental	B-C1254370
justice	I-C1254370
""""	O
.	O
	
the	O
accumulating	O
strong	O
scientific	O
evidence	B-C3887511
may	O
thus	O
support	O
public	B-C0680811
health	I-C0680811
policies	I-C0680811
aimed	O
at	O
reducing	O
social	B-C0680381
inequalities	I-C0680381
in	O
cardiovascular	B-C3887460
health	B-C0018684
.	O
	
the	O
effects	B-C1704420
of	I-C1704420
probiotic	B-C0525033
and	O
synbiotic	B-C2936470
supplementation	B-C0242296
on	O
metabolic	B-C0524620
syndrome	I-C0524620
indices	B-C0010439
in	O
adults	B-C0001675
at	O
risk	B-C0035647
of	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
study	B-C1507394
protocol	I-C1507394
for	O
a	O
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
the	O
incidence	B-C0021149
of	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
,	O
cardiovascular	B-C0007222
diseases	I-C0007222
,	O
and	O
obesity	B-C0028754
has	O
been	O
rising	B-C0442805
dramatically	O
however	O
,	O
their	O
pathogenesis	B-C0699748
is	O
particularly	O
intriguing	B-C0543488
.	O
	
recently	O
,	O
dysbiosis	B-C3658208
of	O
the	O
intestinal	B-C2985398
microbiota	I-C2985398
has	O
emerged	O
as	O
a	O
new	B-C0205314
candidate	B-C0392360
that	O
may	O
be	O
linked	O
to	O
metabolic	B-C0025517
diseases	I-C0025517
.	O
	
we	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	B-C2985398
microbiota	I-C2985398
by	O
probiotic	B-C0525033
or	O
synbiotic	B-C2936470
supplementation	B-C0242296
may	B-C1272747
improve	I-C1272747
metabolic	B-C0025517
dysfunction	I-C0025517
and	O
prevent	B-C0392756
diabetes	B-C0011847
in	O
prediabetics	B-C0362046
.	O
	
in	O
this	O
study	B-C2603343
,	O
a	O
synthesis	B-C1883254
and	O
study	B-C2603343
of	O
synbiotics	B-C2936470
will	O
be	O
carried	B-C0206243
out	O
for	O
the	O
first	O
time	O
in	O
iran	B-C0022065
.	O
	
in	O
a	O
randomized	B-C0206035
triple-blind	I-C0206035
controlled	I-C0206035
clinical	I-C0206035
trial	I-C0206035
,	O
120	O
adults	B-C0001675
with	O
impaired	B-C0271650
glucose	I-C0271650
tolerance	I-C0271650
based	O
on	O
the	O
inclusion	B-C1512693
criteria	I-C1512693
will	O
be	O
selected	B-C1707391
by	O
a	O
simple	O
random	B-C0439605
sampling	B-C0449370
method	I-C0449370
and	O
will	O
be	O
randomly	B-C0439605
allocated	B-C1706778
to	O
6	O
months	B-C0439231
of	O
6	O
g/d	O
probiotic	B-C0525033
,	O
synbiotic	B-C2936470
or	O
placebo	B-C1696465
.	O
	
the	O
fecal	B-C0015733
abundance	B-C2346714
of	O
bacteria	B-C0004611
,	O
blood	B-C0005823
pressure	I-C0005823
,	O
height	B-C0489786
,	O
weight	B-C0005910
,	O
and	O
waist	B-C0455829
and	O
hip	B-C0562350
circumferences	I-C0562350
will	O
be	O
measured	B-C0444706
at	O
baseline	B-C1442488
and	O
following	B-C0332282
treatment	B-C0087111
.	O
	
also	O
,	O
plasma	B-C0850354
lipid	I-C0850354
profiles	I-C0850354
,	O
hba1c	B-C0019018
,	O
fasting	B-C0583513
plasma	I-C0583513
glucose	I-C0583513
,	O
and	O
insulin	B-C0021641
levels	B-C0441889
,	O
will	O
be	O
measured	B-C0444706
and	O
insulin	B-C4049994
resistance	I-C4049994
homa-ir	B-C4049994
and	O
beta-cell	B-C4055385
function	I-C4055385
homa-b	B-C4055385
will	O
be	O
calculated	B-C1441506
at	O
baseline	B-C1442488
and	O
will	O
be	O
repeated	B-C0205341
at	O
months	B-C0439231
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O
	
the	O
data	B-C1511726
will	O
be	O
compared	B-C1707455
within	O
and	O
between	O
groups	B-C0681860
using	B-C1524063
statistical	B-C1710191
methods	I-C1710191
.	O
	
the	O
results	B-C1274040
of	O
this	O
trial	B-C0206035
could	O
contribute	B-C1880177
to	O
the	O
evidence-based	B-C0282451
clinical	I-C0282451
guidelines	I-C0282451
that	O
address	O
gut	B-C2985398
microbiota	I-C2985398
manipulation	B-C0087111
to	O
maximize	B-C0442805
health	B-C0086387
benefits	I-C0086387
in	O
prevention	B-C0199176
and	O
management	B-C0376636
of	O
metabolic	B-C0524620
syndrome	I-C0524620
in	O
prediabetes	B-C0362046
.	O
	
iranian	B-C0034975
registry	I-C0034975
of	O
clinical	B-C0008976
trials	I-C0008976
irct201511032321n2	B-C0282574
.	O
	
evaluation	B-C1516048
of	O
the	O
relationship	B-C0439849
between	O
the	O
static	B-C0441463
measurement	B-C0242485
of	O
transverse	B-C0230467
arch	I-C0230467
flexibility	B-C0242808
of	O
the	O
forefoot	B-C1510667
and	O
gait	B-C0016928
parameters	B-C0549193
in	O
healthy	B-C1708335
subjects	I-C1708335
purpose	B-C0681832
to	O
investigate	B-C1292732
the	O
relationship	B-C0439849
between	O
the	O
static	B-C0441463
measurement	B-C0242485
of	O
the	O
transverse	B-C0230467
arch	I-C0230467
of	O
the	O
forefoot	B-C1510667
,	O
using	O
a	O
3-dimensional	B-C0450363
3d	B-C0450363
foot	B-C4052629
scanner	I-C4052629
,	O
and	O
kinetics	B-C0022702
and	O
kinematics	B-C0600169
of	O
gait	B-C0016928
parameters	B-C0549193
in	O
the	O
sagittal	B-C0935598
plane	I-C0935598
.	O
	
subjects	B-C0080105
and	O
methods	B-C0025663
twenty	O
healthy	B-C1708335
subjects	I-C1708335
participated	O
in	O
this	O
study	B-C0681814
.	O
	
the	O
transverse	B-C0230467
arch	I-C0230467
of	O
the	O
forefoot	B-C1510667
was	O
measured	B-C0444706
under	O
three	O
conditions	B-C0348080
as	O
follows	O
condition	B-C0348080
1	O
,	O
sitting	B-C0277814
condition	B-C0348080
2	O
,	O
standing	B-C0231472
and	O
condition	B-C0348080
3	O
,	O
foot	B-C0016504
forward	B-C0439780
and	O
lower	B-C1140621
leg	I-C1140621
tilting	B-C1711426
anteriorly	B-C0205094
to	O
the	O
maximum	B-C0806909
position	B-C0733755
with	O
heel	B-C0018870
contact	B-C0332158
.	O
	
gait	B-C0016928
parameters	B-C0549193
were	O
recorded	B-C3853788
using	O
a	O
3d	B-C1704459
motion	I-C1704459
analysis	I-C1704459
system	I-C1704459
and	O
force	B-C0492768
plate	I-C0492768
.	O
	
correlation	B-C1707520
coefficients	B-C1707429
between	O
taf	B-C0242808
for	O
each	O
comparison	B-C1707455
of	O
conditions	B-C0348080
and	O
gait	B-C0016928
parameters	B-C0549193
were	O
calculated	B-C1441506
using	O
the	O
spearman	B-C0010101
correlation	I-C0010101
analysis	I-C0010101
.	O
	
results	B-C1274040
rates	B-C1521828
of	O
the	O
transverse	B-C0230467
arch	I-C0230467
of	O
the	O
forefoot	B-C1510667
width	B-C0487742
and	O
height	B-C0489786
between	O
condition	B-C0348080
2	O
and	O
condition	B-C0348080
3	O
were	O
significantly	B-C1707520
correlated	I-C1707520
with	O
the	O
anterior	B-C0205094
and	O
posterior	B-C0205095
component	B-C1705248
of	O
ground	B-C0441722
reaction	I-C0441722
forces	I-C0441722
,	O
the	O
hip	B-C0019558
joint	I-C0019558
extension	B-C0231448
angle	B-C0205143
,	O
and	O
the	O
ankle	B-C0003086
plantar	B-C0231784
flexion	I-C0231784
moment	I-C0231784
.	O
	
conclusion	B-C1707478
our	O
study's	B-C0681814
findings	B-C0243095
indicated	B-C1444656
that	O
increased	B-C0205217
stiffness	B-C0427008
of	O
the	O
transverse	B-C0230467
arch	I-C0230467
of	O
the	O
forefoot	B-C1510667
was	O
related	B-C0439849
to	O
the	O
increase	B-C0442805
in	O
ankle	B-C0003086
plantar	B-C0231784
moment	I-C0231784
,	O
and	O
decreased	B-C0205216
stiffness	B-C0427008
of	O
the	O
transverse	B-C0230467
arch	I-C0230467
of	O
the	O
forefoot	B-C1510667
was	O
related	B-C0439849
to	O
the	O
increase	B-C0442805
in	O
hip	B-C0019558
joint	I-C0019558
extension	B-C0231448
angle	B-C0205143
during	O
management	B-C0376636
and	O
case	B-C0543472
outcome	I-C0543472
of	O
gastric	B-C0267223
impaction	I-C0267223
in	O
four	O
raptors	B-C0600536
a	O
case	B-C0150093
series	I-C0150093
four	O
captive	O
raptors	B-C0600536
,	O
an	O
american	B-C0325583
kestrel	I-C0325583
falco	B-C0325583
sparverius	I-C0325583
,	O
peregrine	B-C0325581
falcon	I-C0325581
falco	B-C0325581
peregrinus	I-C0325581
,	O
golden	B-C0325569
eagle	I-C0325569
aquila	B-C0325569
chrysaetos	I-C0325569
,	O
and	O
barn	B-C0326063
owl	I-C0326063
tyto	B-C0326063
alba	I-C0326063
,	O
were	O
diagnosed	B-C0011900
with	O
ventricular	B-C2355627
and/or	O
proventricular	B-C0033745
foreign	B-C0232481
material	I-C0232481
impactions	B-C0333124
consisting	O
of	O
artificial	B-C3891814
turf	I-C3891814
substrate	I-C3891814
,	O
paper	B-C0030351
and	O
plastic	B-C0032162
substrate	I-C0032162
,	O
grass	B-C0018210
,	O
and	O
newspaper	B-C0027989
.	O
	
partial	B-C0003123
or	I-C0003123
total	I-C0003123
anorexia	I-C0003123
was	O
reported	O
in	O
all	O
birds	B-C0600536
and	O
decreased	B-C0205216
casting	B-C3519992
in	O
2	O
birds	B-C0600536
.	O
	
survey	B-C0038951
radiographs	B-C1306645
confirmed	O
presence	O
of	O
gastric	B-C0038351
enlargement	B-C1293134
in	O
all	O
4	O
birds	B-C0600536
.	O
	
the	O
kestrel	B-C0325582
and	O
eagle	B-C0325569
were	O
treated	B-C1522326
unsuccessfully	O
with	O
gastroscopy	B-C0017195
and	O
gastric	B-C0017134
lavage	I-C0017134
,	O
respectively	O
,	O
followed	O
by	O
surgical	B-C0549433
intervention	I-C0549433
to	O
remove	O
the	O
ventricular	B-C2355627
impactions	B-C0333124
.	O
	
both	O
birds	B-C0600536
died	B-C2826209
of	I-C2826209
undetermined	I-C2826209
causes	I-C2826209
after	B-C0032790
surgery	I-C0032790
.	O
	
the	O
peregrine	B-C0325581
falcon	I-C0325581
died	B-C1306577
before	B-C3179131
medical	I-C3179131
or	O
surgical	B-C0549433
intervention	I-C0549433
was	O
started	O
,	O
and	O
the	O
owl	B-C0326063
was	O
managed	O
successfully	O
with	O
oral	B-C1250025
mineral	I-C1250025
oil	I-C1250025
and	O
liquid	B-C0301571
diet	I-C0301571
to	O
facilitate	B-C0232481
egestion	I-C0232481
of	I-C0232481
the	I-C0232481
foreign	I-C0232481
material	I-C0232481
as	O
a	O
pellet	B-C1706128
.	O
	
lead	B-C0023176
poisoning	I-C0023176
was	O
suspected	O
as	O
the	O
predisposing	B-C0032946
cause	I-C0032946
for	O
foreign	B-C0232481
body	I-C0232481
ingestion	I-C0232481
in	O
the	O
eagle	B-C0325569
,	O
but	O
underlying	B-C0015127
causes	I-C0015127
for	O
pica	B-C0031873
in	O
the	O
other	O
birds	B-C0600536
were	O
not	B-C0521096
determined	I-C0521096
.	O
	
radiographs	B-C1306645
can	O
provide	O
useful	O
diagnostic	B-C0811871
information	I-C0811871
in	O
sick	B-C0221423
raptors	B-C0600536
that	O
exhibit	B-C0042963
vomiting	I-C0042963
or	O
changes	B-C0426587
in	I-C0426587
appetite	I-C0426587
or	O
casting	B-C3519992
frequency	I-C3519992
,	O
and	O
may	O
help	O
guide	O
treatment	B-C0087111
decisions	I-C0087111
of	O
impacted	B-C0333125
birds	B-C0600536
.	O
	
careful	O
consideration	B-C0518609
of	O
substrate	B-C3891814
,	O
enrichment	B-C3273359
items	I-C3273359
,	O
and	O
access	O
to	O
potential	B-C3245505
foreign	B-C0232481
material	I-C0232481
that	I-C0232481
could	I-C0232481
be	I-C0232481
ingested	I-C0232481
may	O
be	O
the	O
best	O
pre-emptive	O
management	B-C0376636
strategy	I-C0376636
in	O
captive	O
anti-inflammatory	B-C0243095
activity	B-C0441655
of	O
elaeagnus	B-C1006436
angustifolia	I-C1006436
fruit	B-C0772257
extract	I-C0772257
on	O
rat	B-C0034693
paw	B-C0687080
edema	B-C0013604
the	O
elaeagnus	B-C1006436
angustifolia	I-C1006436
fruit	B-C0016767
has	O
been	O
traditionally	O
used	O
in	O
iranian	B-C0022065
herbal	B-C2240391
medicine	I-C2240391
to	O
treat	B-C1522326
diarrhea	B-C0011991
and	O
rheumatoid	B-C0003873
arthritis	I-C0003873
.	O
	
in	O
the	O
present	O
study	O
,	O
the	O
effects	B-C1280500
of	O
e	B-C1006436
.	O
	
angustifolia	I-C1006436
fruit	B-C0772257
extract	I-C0772257
on	O
the	O
acute	B-C0205178
and	O
chronic	B-C0457343
phases	I-C0457343
of	O
formalin	B-C0949307
-	O
induced	B-C0205263
rat	B-C0034693
paw	B-C0687080
edema	B-C0013604
were	O
examined	B-C0332128
.	O
	
the	O
acute	B-C0205178
and	O
chronic	B-C0457343
anti-inflammatory	B-C0243095
effects	I-C0243095
of	O
e	B-C1006436
.	O
	
angustifolia	I-C1006436
fruit	B-C0772257
extract	I-C0772257
were	O
investigated	B-C1292732
through	O
the	O
subcutaneous	B-C0021499
injection	I-C0021499
of	O
100	O
μl	O
of	O
formalin	B-C0949307
2.5	O
into	O
a	O
rat's	B-C0034693
hind	O
paw	B-C0687080
.	O
	
thirty	B-C1442458
minutes	I-C1442458
before	O
the	O
procedure	B-C2700391
,	O
the	O
experimental	B-C1517586
groups	B-C0441833
were	O
treated	B-C1522326
intraperitoneally	B-C0442120
with	O
hydroalcoholic	B-C0772257
fruit	I-C0772257
extracts	I-C0772257
of	O
e	B-C1006436
.	O
	
angustifolia	I-C1006436
concentrations	B-C1264643
of	O
100	O
,	O
300	O
,	O
700	O
,	O
and	O
1000	O
mg/kg	O
sodium	B-C0037549
salicylate	I-C0037549
ss	B-C0037549
,	O
400	O
mg/kg	O
and	O
distilled	B-C0790233
water	I-C0790233
were	O
used	O
as	O
positive	B-C1446409
and	O
negative	B-C0205160
control	B-C0009932
groups	I-C0009932
,	O
respectively	O
.	O
	
treatment	B-C1522326
with	O
ss	B-C0037549
and	O
the	O
fruit	B-C0772257
extracts	I-C0772257
were	O
performed	B-C0884358
daily	B-C0332173
for	O
8	O
days	B-C0439228
,	O
and	O
the	O
degree	B-C0449286
of	O
edema	B-C0013604
was	O
measured	B-C0444706
by	O
using	O
mercury	B-C0025080
plethysmometer	I-C0025080
and	O
digital	B-C0175720
caliper	I-C0175720
.	O
	
in	O
the	O
acute	B-C0205178
anti-inflammatory	B-C0243095
study	B-C2603343
,	O
the	O
extract	B-C2828366
showed	O
a	O
significant	O
anti-inflammatory	B-C1515999
effect	I-C1515999
in	O
a	O
dose-dependent	B-C1512045
manner	O
.	O
	
the	O
results	B-C1274040
of	O
1000	O
mg/kg	O
of	O
the	O
extract	B-C2828366
was	O
significantly	O
different	B-C1705242
compared	B-C1707455
with	I-C1707455
the	O
negative	B-C0205160
control	B-C0009932
group	I-C0009932
p<0	O
and	O
was	O
comparable	O
to	O
sodium	B-C0037549
salicylate	I-C0037549
p<0	O
.	O
	
results	B-C1274040
from	O
the	O
chronic	B-C0457343
study	B-C2603343
suggested	B-C1705535
that	O
e	B-C1006436
.	O
	
angustifolia	I-C1006436
extract	B-C2828366
significantly	O
reduced	B-C0392756
paw	B-C0687080
edema	B-C0013604
and	O
inflammation	B-C0021368
in	O
a	O
dose-dependent	B-C1512045
manner	O
.	O
	
the	O
results	B-C1274040
also	O
showed	O
that	O
the	O
measurement	B-C0242485
by	O
digital	B-C0175720
caliper	I-C0175720
and	O
mercury	B-C0025080
plethysmometer	I-C0025080
were	O
both	O
reliable	O
and	O
might	O
be	O
applied	O
interchangeably	O
p<0	O
.	O
	
phytochemical	B-C0022885
tests	I-C0022885
indicated	O
that	O
the	O
hydroalcoholic	B-C0772257
fruit	I-C0772257
extract	I-C0772257
of	O
e	B-C1006436
.	O
	
angustifolia	I-C1006436
was	O
positive	B-C1446409
for	O
cardiac	B-C0007158
glycosides	I-C0007158
,	O
flavonoids	B-C0596577
,	O
terpenoids	B-C0039561
,	O
and	O
saponins	B-C0036189
.	O
	
based	O
on	O
our	O
findings	B-C0243095
,	O
the	O
e	B-C1006436
.	O
	
angustifolia	I-C1006436
fruit	B-C0772257
extract	I-C0772257
probably	O
has	O
acute	B-C0205178
and	O
chronic	B-C0457343
anti-inflammatory	B-C0243095
activities	B-C0441655
to	O
support	O
its	O
applications	O
in	O
folk	B-C0016419
medicine	I-C0016419
.	O
	
increased	B-C0205217
cerebral	B-C4277714
blood	I-C4277714
volume	I-C4277714
pulsatility	B-C0577317
during	O
head-down	B-C0242683
tilt	I-C0242683
with	O
elevated	B-C0020440
carbon	I-C0020440
dioxide	I-C0020440
the	O
spacecot	O
study	O
astronauts	O
aboard	O
the	O
international	O
space	O
station	O
iss	O
have	O
exhibited	O
hyperopic	O
shifts	O
,	O
posterior	O
eye	O
globe	O
flattening	O
,	O
dilated	O
optic	O
nerve	O
sheaths	O
,	O
and	O
even	O
optic	O
disc	O
swelling	O
from	O
spaceflight	O
.	O
	
elevated	O
intracranial	O
pressure	O
icp	O
consequent	O
to	O
cephalad	O
fluid	O
shifts	O
is	O
commonly	O
hypothesized	O
as	O
contributing	O
to	O
these	O
ocular	O
changes	O
.	O
	
head-down	O
tilt	O
hdt	O
is	O
frequently	O
utilized	O
as	O
an	O
earth	O
-based	O
analog	O
to	O
study	O
similar	O
fluid	O
shifts	O
.	O
	
sealed	O
environments	O
like	O
the	O
iss	O
also	O
exhibit	O
elevated	B-C0020440
carbon	I-C0020440
dioxide	I-C0020440
co2	O
,	O
a	O
potent	O
arteriolar	O
vasodilator	O
that	O
could	O
further	O
affect	O
cerebral	O
blood	O
volume	O
and	O
flow	O
,	O
intracranial	O
compliance	O
,	O
and	O
icp	O
.	O
	
a	O
collaborative	O
pilot	O
study	O
between	O
the	O
national	O
space	O
biomedical	O
research	O
institute	O
and	O
the	O
german	O
aerospace	O
center	O
tested	O
the	O
hypotheses	O
that	O
1	O
hdt	O
and	O
elevated	O
co2	O
physiologically	O
interact	O
,	O
and	O
2	O
cerebrovascular	O
pulsatility	O
is	O
related	O
to	O
hdt	O
and/or	O
elevated	O
co2	O
in	O
a	O
double-blind	O
crossover	O
study	O
n=6	O
,	O
we	O
measured	O
cerebral	O
blood	O
volume	O
cbv	O
pulsatility	O
via	O
near-infrared	O
spectroscopy	O
,	O
alongside	O
non-invasive	O
icp	O
and	O
intraocular	O
pressure	O
iop	O
during	O
28-hr	O
-12	O
hdt	O
at	O
both	O
nominal	O
0.04	O
and	O
elevated	O
0.5	O
ambient	O
co2	O
in	O
our	O
cohort	O
,	O
cbv	O
pulsatility	O
increased	O
significantly	O
over	O
time	O
at	O
cardiac	O
frequencies	O
0.031	O
μm/hr	O
increase	O
in	O
hbt	O
pulsatility	O
amplitude	O
and	O
mayer	O
wave	O
frequencies	O
0.019	O
μm/hr	O
increase	O
.	O
	
the	O
hdt	O
-	O
co2	O
interaction	O
on	O
pulsatility	O
was	O
not	O
robust	O
,	O
but	O
rather	O
driven	O
by	O
an	O
individual	O
.	O
	
significant	O
differences	O
between	O
atmospheres	O
were	O
not	O
detected	O
in	O
icp	O
or	O
iop	O
.	O
	
further	O
work	O
is	O
needed	O
to	O
reproduce	O
these	O
findings	O
in	O
a	O
larger	O
cohort	O
,	O
to	O
determine	O
whether	O
a	O
"""water"	O
"hammer"""	O
effect	O
in	O
cerebral	O
pulsatility	O
is	O
also	O
present	O
during	O
spaceflight	O
,	O
and	O
whether	O
it	O
is	O
associated	O
with	O
ocular	O
changes	O
in	O
astronauts	B-C0242688
shift	B-C1658633
work	I-C1658633
is	O
associated	B-C0332281
with	I-C0332281
metabolic	B-C0524620
syndrome	I-C0524620
in	O
young	B-C0332239
female	B-C0086287
korean	B-C1556095
workers	B-C1306056
shift	B-C1658633
work	I-C1658633
is	O
associated	B-C0332281
with	I-C0332281
health	B-C0021788
problems	I-C0021788
,	O
including	O
metabolic	B-C0524620
syndrome	I-C0524620
.	O
	
this	O
study	B-C2603343
investigated	O
the	O
association	B-C0439849
between	O
shift	B-C1658633
work	I-C1658633
and	O
metabolic	B-C0524620
syndrome	I-C0524620
in	O
young	B-C0332239
workers	B-C1306056
.	O
	
a	O
total	O
of	O
3	O
subjects	B-C0080105
aged	O
20-40	O
years	O
enrolled	O
in	O
the	O
2011-2012	O
korean	B-C1556095
national	B-C0376344
health	I-C0376344
and	I-C0376344
nutrition	I-C0376344
examination	I-C0376344
survey	I-C0376344
were	O
divided	O
into	O
shift	B-C0425104
and	O
day	B-C4316562
workers	I-C4316562
.	O
	
we	O
conducted	O
a	O
cross-sectional	B-C0010362
study	I-C0010362
and	O
calculated	B-C0444686
odds	B-C0028873
ratios	I-C0028873
using	O
multivariate	B-C0026777
logistic	B-C0681925
regression	I-C0681925
analysis	I-C0681925
in	O
order	O
to	O
examine	B-C0332128
the	O
association	B-C0439849
between	O
shift	B-C1658633
work	I-C1658633
and	O
metabolic	B-C0524620
syndrome	I-C0524620
.	O
	
the	O
prevalence	B-C0033105
of	O
metabolic	B-C0524620
syndrome	I-C0524620
was	O
14.3	O
and	O
7.1	O
among	O
male	B-C0086582
and	O
female	B-C0086287
shift	B-C0425104
workers	I-C0425104
,	O
respectively	O
.	O
	
after	O
adjusting	O
for	O
confounding	B-C0009673
factors	I-C0009673
,	O
shift	B-C1658633
work	I-C1658633
was	O
associated	B-C0332281
with	I-C0332281
metabolic	B-C0524620
syndrome	I-C0524620
in	O
female	B-C0086287
workers	B-C1306056
odds	B-C0028873
ratio	I-C0028873
,	O
2.53	O
95%	O
confidence	B-C0009667
interval	I-C0009667
,	O
1.12	O
to	O
5.70	O
.	O
	
shift	B-C1658633
work	I-C1658633
was	O
associated	B-C0332281
with	I-C0332281
metabolic	B-C0524620
syndrome	I-C0524620
in	O
young	B-C0332239
women	B-C0043210
.	O
	
timely	O
efforts	O
are	O
necessary	O
to	O
manage	B-C0184516
metabolic	B-C0524620
syndrome	I-C0524620
in	O
the	O
in	B-C1533691
vitro	I-C1533691
differentiation	B-C0007589
of	O
human	B-C0086418
pluripotent	B-C0872076
stem	I-C0872076
cells	I-C0872076
into	O
trophoblastic	B-C1519658
cells	I-C1519658
the	O
placenta	B-C0032043
is	O
the	O
first	O
organ	B-C0178784
to	O
develop	O
during	O
embryogenesis	B-C0013936
and	O
is	O
required	O
for	O
the	O
survival	B-C0038952
of	O
the	O
developing	O
embryo	B-C0013935
.	O
	
the	O
placenta	B-C0032043
is	O
comprised	O
of	O
various	O
trophoblastic	B-C1519658
cells	I-C1519658
that	O
differentiate	B-C0007589
from	O
the	O
extra-embryonic	B-C1326118
trophectoderm	I-C1326118
cells	I-C1326118
of	O
the	O
preimplantation	B-C1446949
blastocyst	B-C1281743
.	O
	
as	O
such	O
,	O
our	O
understanding	O
of	O
the	O
early	O
differentiation	B-C0007589
events	I-C0007589
of	O
the	O
human	B-C0086418
placenta	B-C0032043
is	O
limited	O
because	O
of	O
ethical	O
and	O
legal	O
restrictions	O
on	O
the	O
isolation	B-C0204727
and	O
manipulation	B-C0947647
of	O
human	B-C0086418
embryogenesis	B-C0013936
.	O
	
human	B-C0872076
pluripotent	I-C0872076
stem	I-C0872076
cells	I-C0872076
hpscs	B-C0872076
are	O
a	O
robust	O
model	B-C3161035
system	I-C3161035
for	O
investigating	O
human	B-C0020119
development	I-C0020119
and	O
can	O
also	O
be	O
differentiated	B-C0007589
in	B-C1533691
vitro	I-C1533691
into	O
trophoblastic	B-C1519658
cells	I-C1519658
that	O
express	O
markers	O
of	O
the	O
various	O
trophoblast	B-C1519658
cell	B-C0007634
types	I-C0007634
.	O
	
here	O
,	O
we	O
present	O
a	O
detailed	O
protocol	O
for	O
differentiating	B-C0007589
hpscs	B-C0872076
into	O
trophoblastic	B-C1519658
cells	I-C1519658
using	O
bone	B-C0033684
morphogenic	I-C0033684
protein	I-C0033684
4	I-C0033684
and	O
inhibitors	B-C1999216
of	O
the	O
activin	B-C0050668
/	O
nodal	B-C3271798
signaling	I-C3271798
pathways	I-C3271798
.	O
	
this	O
protocol	O
generates	O
various	O
trophoblast	B-C1519658
cell	B-C0007634
types	I-C0007634
that	O
can	O
be	O
transfected	B-C0040669
with	O
sirnas	B-C1099354
for	O
investigating	O
loss-of-function	O
phenotypes	B-C0031437
or	O
can	O
be	O
infected	B-C0439663
with	O
pathogens	B-C0450254
.	O
	
additionally	O
,	O
hpscs	B-C0872076
can	O
be	O
genetically	O
modified	O
and	O
then	O
differentiated	B-C0007589
into	O
trophoblast	B-C0041178
progenitors	B-C0038250
for	O
gain-of-function	O
analyses	O
.	O
	
this	O
in	B-C1533691
vitro	I-C1533691
differentiation	B-C0007589
method	I-C0007589
for	O
generating	O
human	B-C0086418
trophoblasts	B-C0041178
starting	O
from	O
hpscs	B-C0872076
overcomes	O
the	O
ethical	O
and	O
legal	O
restrictions	B-C0443288
of	O
working	O
with	O
early	O
human	B-C0086418
embryos	B-C0013935
,	O
and	O
this	O
system	O
can	O
be	O
used	O
for	O
a	O
variety	O
of	O
applications	O
,	O
including	O
drug	B-C0920472
discovery	I-C0920472
and	O
stem	B-C1514966
cell	I-C1514966
research	I-C1514966
.	O
	
metabolomics	B-C0870883
analysis	B-C0936012
of	O
anaphylactoid	B-C0340865
reaction	I-C0340865
reveals	B-C0443289
its	O
mechanism	B-C0441712
in	O
a	O
rat	B-C0034721
model	B-C0599779
anaphylactoid	B-C0340865
reactions	I-C0340865
,	O
accounting	O
for	O
more	O
than	O
77%	O
of	O
all	O
immune-mediated	B-C0301918
immediate	I-C0301918
hypersensitivity	I-C0301918
reactions	I-C0301918
,	O
have	O
become	O
a	O
serious	B-C0205404
threat	B-C0749385
to	O
public	B-C0699943
health	I-C0699943
,	O
but	O
their	O
effect	B-C1280500
mechanism	B-C0441712
is	O
not	B-C3845108
clear	I-C3845108
and	O
diagnostic	B-C0086143
tests	I-C0086143
are	O
limited	B-C0439801
.	O
	
comprehensive	B-C1880156
metabolite	B-C0870883
analysis	B-C0936012
may	O
reveal	B-C0443289
the	O
anaphylactoid	B-C1706805
effect	B-C1280500
mechanism	B-C0441712
systematically	B-C0220922
and	O
provide	B-C1999230
reference	B-C0034925
for	O
future	B-C0016884
diagnostic	B-C0348026
purposes	B-C1285529
.	O
	
plasma	B-C0032105
from	O
brown	B-C0034700
norway	I-C0034700
rats	I-C0034700
given	O
intravenous	B-C0021494
injection	I-C0021494
of	O
saline	B-C0036082
,	O
compound	B-C0009574
48/80	I-C0009574
2.5	O
ml/kg	O
or	O
ovalbumin	B-C0029923
20	O
ml/kg	O
in	O
20	O
s	O
for	O
the	O
first	O
time	O
was	O
used	B-C1524063
to	O
study	B-C2603343
the	O
effect	B-C1280500
mechanism	B-C0441712
of	O
anaphylactoid	B-C0340865
reactions	I-C0340865
through	O
metabolomics	B-C0870883
uplc-qtof-ms/ms	B-C0599748
.	O
	
metabolomics	B-C0870883
integrated	O
with	O
proteomics	B-C0242356
data	I-C0242356
were	O
used	B-C1524063
to	O
analyze	B-C0936012
the	O
anaphylactoid	B-C1706805
pathways	B-C1704259
by	O
metaboanalyst	B-C0037589
followed	B-C0332283
by	I-C0332283
integrated	O
pathway	B-C0868995
analysis	I-C0868995
.	O
	
thirty	O
metabolites	B-C0870883
were	O
identified	B-C0205396
through	O
the	O
metlin	B-C0242356
database	I-C0242356
by	O
ms/ms	B-C0599748
and	O
18	O
of	O
them	O
were	O
confirmed	B-C0521093
by	I-C0521093
authentic	B-C0034925
standards	I-C0034925
.	O
	
the	O
results	B-C1274040
showed	O
that	O
adenosine	B-C0001443
,	O
histamine	B-C0019588
,	O
n-acetylhistamine	B-C0067730
,	O
n	B-C0061063
,	O
malate	B-C0220873
and	O
xanthine	B-C0043314
are	O
important	B-C3898777
indices	O
for	O
anaphylactoid	B-C0340865
reactions	I-C0340865
.	O
	
it	O
could	O
be	O
concluded	O
that	O
the	O
effect	B-C1280500
mechanism	B-C0441712
is	O
mainly	O
composed	O
of	O
histidine	B-C1156823
metabolism	I-C1156823
,	O
arachidonic	B-C1158360
acid	I-C1158360
metabolism	I-C1158360
,	O
energy	B-C0014272
metabolism	I-C0014272
,	O
purine	B-C0920640
metabolism	I-C0920640
and	O
other	B-C0205394
small	B-C0700321
molecules	B-C0567416
through	B-C0332273
30	O
metabolites	B-C0870883
.	O
	
multiple	B-C0681925
linear	I-C0681925
regression	I-C0681925
analysis	I-C0681925
indicated	B-C1444656
that	O
not	B-C1518422
only	B-C0205171
histamine	B-C0019588
but	O
also	O
n	B-C0061063
and	O
arachidonic	B-C0003695
acid	I-C0003695
could	O
be	O
used	B-C1524063
to	O
evaluate	O
anaphylactoid	B-C1706805
symptoms	B-C1457887
of	O
animals	B-C0003062
.	O
	
furthermore	O
,	O
the	O
citrate	B-C1516586
cycle	I-C1516586
,	O
histidine	B-C1156823
metabolism	I-C1156823
and	O
arachidonic	B-C1158360
acid	I-C1158360
metabolism	I-C1158360
could	O
be	O
the	O
main	B-C1542147
pathways	B-C1704259
of	O
anaphylactoid	B-C0340865
reactions	I-C0340865
as	O
determined	B-C0521095
by	I-C0521095
metaboanalyst	B-C0037589
.	O
	
the	O
results	B-C1274040
may	O
provide	B-C1999230
a	O
reference	B-C1514811
to	O
improve	B-C0184511
diagnostic	B-C0598285
accuracy	I-C0598285
and	O
predict	B-C0681842
and	O
monitor	O
treatment	B-C0087113
efficacy	I-C0087113
in	O
anaphylactoid	B-C0340865
reactions	I-C0340865
in	O
the	O
clinical	B-C3176918
setting	I-C3176918
.	O
	
the	O
prevalence	B-C0683921
of	O
sleep	B-C0037315
apnea	I-C0037315
in	O
type	B-C0340647
b	I-C0340647
aortic	I-C0340647
dissection	I-C0340647
implications	O
for	O
false	B-C0205237
lumen	B-C0524461
thrombosis	B-C0040053
obstructive	B-C0520679
sleep	I-C0520679
apnea	I-C0520679
osa	B-C0520679
has	O
been	O
implicated	O
in	O
aortic	B-C0340643
dissection	I-C0340643
.	O
	
thrombosis	B-C0040053
of	O
the	O
false	B-C0205237
lumen	B-C0524461
is	O
associated	B-C0332281
with	I-C0332281
a	O
prognosis	B-C0033325
of	O
type	B-C0340647
b	I-C0340647
aortic	I-C0340647
dissection	I-C0340647
aod	B-C0340647
,	O
and	O
partial	B-C0333204
thrombosis	I-C0333204
has	O
been	O
reported	O
to	O
be	O
an	O
independent	O
predictor	B-C0683956
of	O
mortality	B-C0178686
.	O
	
this	O
study	B-C2603343
sought	O
to	O
explore	O
whether	O
the	O
severity	B-C0392364
of	O
osa	B-C0520679
is	O
associated	B-C0332281
with	I-C0332281
false	B-C0205237
lumen	B-C0524461
thrombosis	B-C0040053
.	O
	
in	O
this	O
observational	B-C1518527
study	I-C1518527
,	O
151	O
type	B-C0340647
b	I-C0340647
aod	I-C0340647
patients	B-C0030705
were	O
recruited	O
consecutively	O
from	O
2013	O
to	O
2015	O
.	O
	
the	O
status	O
of	O
the	O
false	B-C0205237
lumen	B-C0524461
was	O
classified	O
as	O
patent	O
,	O
partially	B-C0728938
thrombosed	B-C0040053
,	O
or	O
completely	O
thrombosed	B-C0040053
based	O
on	O
a	O
computer	B-C1536105
tomography	I-C1536105
angiography	I-C1536105
image	B-C1551337
.	O
	
patients	B-C0030705
were	O
divided	O
into	O
non-osa	B-C0681860
group	I-C0681860
apnea-hypopnea	B-C4083070
index	I-C4083070
ahi	B-C4083070
<	O
5	O
,	O
and	O
mild	B-C0681860
5	O
ahi	B-C4083070
15	O
,	O
moderate	B-C0681860
15	O
<	O
ahi	B-C4083070
30	O
,	O
and	O
severe	B-C0681860
osa	I-C0681860
groups	I-C0681860
ahi	B-C4083070
>	O
30	O
using	O
the	O
ahi	B-C4083070
.	O
	
the	O
prevalence	B-C0683921
of	O
osa	B-C0520679
in	O
type	B-C0340647
b	I-C0340647
dissection	I-C0340647
was	O
66.2	O
.	O
	
among	O
151	O
cases	B-C1706256
,	O
51	O
patients	B-C0030705
33.8	O
were	O
in	O
the	O
non-osa	B-C0681860
group	I-C0681860
,	O
56	O
37.1	O
were	O
in	O
the	O
mild	B-C0681860
group	I-C0681860
,	O
21	O
13.9	O
were	O
in	O
the	O
moderate	B-C0681860
group	I-C0681860
,	O
and	O
23	O
15.2	O
were	O
in	O
the	O
severe	B-C0681860
group	I-C0681860
.	O
	
additionally	O
,	O
a	O
partially	B-C0728938
thrombosed	B-C0040053
false	B-C0205237
lumen	B-C0524461
was	O
observed	O
in	O
88	O
patients	B-C0030705
58.3	O
.	O
	
multivariable	B-C0026777
analysis	I-C0026777
revealed	O
that	O
osa	B-C0520679
severity	B-C0392364
was	O
positively	B-C1446409
associated	B-C0332281
with	I-C0332281
partial	B-C0728938
thrombosis	B-C0040053
odds	B-C0028873
ratio	I-C0028873
,	O
1.784	O
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
1.182	O
,	O
p	O
=	O
006	O
after	O
adjusting	O
for	O
other	O
confounding	B-C0009673
factors	I-C0009673
.	O
	
osa	B-C0520679
was	O
present	O
in	O
two-thirds	O
of	O
patients	B-C0030705
with	O
type	B-C0340647
b	I-C0340647
aod	I-C0340647
.	O
	
the	O
severity	B-C0392364
of	O
osa	B-C0520679
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
an	O
increased	B-C0205217
risk	B-C0035647
of	O
partial	B-C0728938
false	B-C0205237
lumen	B-C0524461
thrombosis	B-C0040053
.	O
	
osa	B-C0520679
may	O
therefore	O
be	O
implicated	O
in	O
both	O
the	O
etiology	B-C1314792
and	O
prognosis	B-C0033325
of	O
contextual	B-C0542559
factors	I-C0542559
for	O
stunting	B-C0018273
among	O
children	B-C0008059
of	O
age	B-C0001779
6	O
to	O
24	O
months	B-C0439231
in	O
an	O
under-privileged	B-C0009462
community	I-C0009462
of	O
dhaka	B-C0004732
,	O
bangladesh	B-C0004732
to	O
determine	O
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
stunting	B-C0018273
among	O
children	B-C0008059
aged	B-C0001779
6	O
to	O
24	O
months	B-C0439231
in	O
a	O
slum	B-C0037345
of	O
dhaka	B-C0004732
,	O
bangladesh	B-C0004732
.	O
	
we	O
conducted	O
this	O
case	B-C0007328
control	I-C0007328
study	I-C0007328
during	O
november	O
2009	O
to	O
december	O
2012	O
.	O
	
children	B-C0008059
were	O
classified	O
as	O
case	O
if	O
length-for-age	B-C0871421
z-score	I-C0871421
laz	B-C0871421
was	O
<-2	O
and	O
as	O
control	B-C0009932
if	O
laz	B-C0871421
was	O
>-1	O
sd	O
.	O
	
the	O
logistic	B-C0681925
regression	I-C0681925
model	I-C0681925
was	O
used	O
to	O
find	O
the	O
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
stunting	B-C0018273
.	O
	
the	O
significant	O
risk	B-C0035648
factors	I-C0035648
for	O
stunting	B-C0018273
were	O
child's	B-C0008059
age	B-C0001779
>12	O
months	B-C0439231
,	O
maternal	B-C0026591
undernutrition	B-C0162429
,	O
mother's	B-C2924476
education	I-C2924476
<5	O
years	B-C0439234
,	O
consumption	B-C0684271
of	O
untreated	B-C0599638
drinking	I-C0599638
water	I-C0599638
and	O
monthly	B-C0332177
family	B-C0015576
income	B-C0021162
<100	O
usd	B-C1555442
.	O
	
the	O
findings	B-C0243095
of	O
this	O
study	B-C0007328
reiterated	O
the	O
role	O
of	O
maternal	B-C0026591
undernutrition	B-C0162429
and	O
less	B-C0013658
education	I-C0013658
,	O
consumption	B-C0684271
of	O
untreated	B-C0599638
drinking	I-C0599638
water	I-C0599638
and	O
poor	O
family	B-C0015576
income	B-C0021162
as	O
important	O
associated	B-C0332281
factors	B-C1521761
of	O
childhood	B-C0231335
stunting	B-C0018273
most	O
americans	B-C0596070
have	O
good	B-C3898900
health	I-C3898900
,	O
little	O
unmet	B-C4061640
need	I-C4061640
,	O
and	O
few	O
health	B-C3242647
care	I-C3242647
expenses	I-C3242647
the	O
distribution	O
of	O
health	B-C3242647
care	I-C3242647
expenditures	I-C3242647
remains	O
highly	O
concentrated	B-C0392762
,	O
but	O
most	O
americans	B-C0596070
use	O
few	O
health	B-C0018741
care	I-C0018741
resources	I-C0018741
and	O
have	O
low	O
out-of-pocket	B-C0680969
spending	I-C0680969
.	O
	
more	O
than	O
93	O
percent	O
of	O
""""	O
low	B-C1257890
spenders	I-C1257890
""""	O
those	O
in	O
the	O
bottom	O
half	O
of	O
the	O
population	B-C1257890
believe	O
they	O
have	O
received	B-C1514756
all	O
needed	O
care	B-C0086388
in	O
a	O
timely	B-C3827828
manner	O
.	O
	
the	O
low	O
spending	B-C0680969
by	O
the	O
majority	O
of	O
the	O
population	B-C1257890
has	O
remained	O
almost	O
unchanged	O
during	O
the	O
thirty-seven-	O
year	B-C0439234
period	B-C1948053
examined	B-C0332128
.	O
	
penile	B-C1536126
erosion	I-C1536126
in	O
a	O
paraplegic	B-C0030486
man	B-C0025266
with	O
indwelling	B-C0521197
urinary	I-C0521197
catheter	I-C0521197
and	O
scrotal	B-C0151609
edema	I-C0151609
the	O
chronic	B-C0205191
use	B-C1524063
of	I-C1524063
urinary	B-C0521197
indwelling	I-C0521197
catheters	I-C0521197
is	O
a	O
common	O
practice	O
in	O
the	O
setting	O
of	O
long-term	B-C0443252
patient	B-C0017313
care	I-C0017313
and	O
is	O
associated	O
with	O
numerous	O
complications	B-C0009566
.	O
	
more	O
awareness	B-C0004448
about	O
urogenital	B-C0042066
trauma	B-C3714660
from	O
urinary	B-C0042019
catheterization	I-C0042019
is	O
needed	O
,	O
as	O
it	O
is	O
as	O
common	O
as	O
symptomatic	B-C0231220
urinary	B-C0042029
tract	I-C0042029
infections	I-C0042029
.	O
	
there	O
are	O
a	O
number	O
of	O
preventable	B-C2700409
measures	I-C2700409
that	O
can	O
be	O
taken	O
to	O
decrease	B-C0547047
the	O
risk	B-C0035647
of	O
mechanical	B-C3714660
trauma	I-C3714660
to	O
the	O
urethra	B-C0041967
and	O
glans	B-C0227948
penis	I-C0227948
caused	O
by	O
chronic	B-C0205191
catheterization	B-C0007430
.	O
	
we	O
present	O
a	O
case	O
of	O
a	O
27-	O
year	B-C0439234
old	B-C0580836
paraplegic	B-C0030486
male	B-C0086582
needing	O
a	O
chronic	B-C0205191
indwelling	B-C0007439
catheter	I-C0007439
that	O
acquired	B-C0439661
ventral	B-C1704448
penile	B-C1536126
erosion	I-C1536126
while	O
being	O
cared	B-C1947933
for	O
in	O
the	O
icu	B-C0021708
setting	I-C0021708
.	O
	
modified	B-C0392747
anastomotic	B-C0677554
technique	I-C0677554
for	O
thoracolaparoscopic	B-C0472889
ivor-lewis	I-C0472889
esophagectomy	I-C0472889
early	B-C1279919
outcomes	B-C0085415
and	O
technical	B-C1522508
details	I-C1522508
thoracoscopic	B-C0192353
intrathoracic	I-C0192353
esophagogastrostomy	I-C0192353
is	O
a	O
technically	O
demanding	O
operation	O
these	O
technical	B-C0681521
requirements	I-C0681521
restrict	O
the	O
extensive	O
application	B-C1524063
of	I-C1524063
minimally	B-C0547040
invasive	B-C0205281
ivor-lewis	B-C0472889
esophagectomy	I-C0472889
.	O
	
in	O
an	O
attempt	O
to	O
reduce	B-C0547047
the	O
difficulty	O
of	O
this	O
surgical	B-C0543467
procedure	I-C0543467
,	O
this	O
study	O
developed	O
a	O
modified	B-C0392747
anastomotic	B-C0677554
technique	I-C0677554
for	O
thoracolaparoscopic	B-C0472889
ivor-lewis	I-C0472889
esophagectomy	I-C0472889
.	O
	
during	O
the	O
entirety	O
of	O
this	O
modified	B-C0392747
approach	B-C1292724
,	O
neither	O
technically	O
challenging	O
operations	B-C0543467
such	O
as	O
intrathoracic	B-C0009068
suturing	I-C0009068
or	O
knotting	B-C0087111
,	O
nor	O
special	O
instruments	B-C0348000
such	O
as	O
an	O
orvil	B-C0025080
system	I-C0025080
or	O
a	O
reverse-puncture	B-C0025080
head	I-C0025080
are	O
required	O
.	O
	
between	O
october	O
2015	O
and	O
january	O
2016	O
,	O
15	O
consecutive	B-C1707491
patients	B-C0030705
with	O
cancer	B-C0006826
in	O
the	O
distal	B-C0227191
third	I-C0227191
of	I-C0227191
the	I-C0227191
esophagus	I-C0227191
or	O
the	O
gastric	B-C0007144
cardia	I-C0007144
underwent	O
this	O
modified	B-C0392747
surgical	B-C0543467
procedure	I-C0543467
.	O
	
the	O
good	O
short-term	B-C0443303
outcomes	B-C0085415
that	O
were	O
achieved	O
suggest	O
that	O
the	O
modified	B-C0392747
anastomotic	B-C0677554
technique	I-C0677554
is	O
safe	O
and	O
feasible	O
for	O
thoracolaparoscopic	B-C0472889
ivor-lewis	I-C0472889
esophagectomy	I-C0472889
.	O
	
quantitative	B-C0681919
analysis	I-C0681919
of	O
cell	B-C0596290
proliferation	I-C0596290
by	O
a	O
dye	B-C0013341
dilution	I-C0013341
assay	I-C0013341
application	B-C4048755
to	O
cell	B-C0682523
lines	I-C0682523
and	O
cocultures	B-C0282547
cell	B-C0596290
proliferation	I-C0596290
represents	O
one	O
of	O
the	O
most	O
fundamental	O
processes	B-C3714634
in	I-C3714634
biological	I-C3714634
systems	I-C3714634
,	O
thus	O
the	O
quantitative	B-C0681919
analysis	I-C0681919
of	O
cell	B-C0596290
proliferation	I-C0596290
is	O
important	O
in	O
many	O
biological	B-C0005532
applications	B-C4048755
such	O
as	O
drug	B-C0373483
screening	I-C0373483
,	O
production	O
of	O
biologics	B-C0005522
,	O
and	O
assessment	B-C0220825
of	O
cytotoxicity	B-C0596402
.	O
	
conventional	B-C0439858
proliferation	B-C3899698
assays	I-C3899698
mainly	O
quantify	O
cell	B-C0007584
number	I-C0007584
based	O
on	O
a	O
calibration	B-C0006751
curve	I-C0006751
of	O
a	O
homogeneous	B-C1881065
cell	B-C0007634
population	I-C0007634
,	O
and	O
therefore	O
are	O
not	O
applicable	O
for	O
the	O
analysis	B-C0936012
of	O
cocultured	B-C0007635
cells	I-C0007635
.	O
	
moreover	O
,	O
these	O
assays	B-C0005507
measure	B-C0242485
cell	B-C0596290
proliferation	I-C0596290
indirectly	O
,	O
based	O
on	O
cellular	B-C1524026
metabolic	I-C1524026
activity	I-C1524026
or	O
dna	B-C0032246
content	I-C0032246
.	O
	
to	O
overcome	B-C2983310
these	O
shortcomings	O
,	O
a	O
dye	B-C0013341
dilution	I-C0013341
assay	I-C0013341
employing	O
fluorescent	B-C0016320
cell	I-C0016320
tracking	I-C0016320
dyes	I-C0016320
that	O
are	O
retained	B-C0333118
within	O
cells	B-C0007634
was	O
applied	O
and	O
was	O
diluted	B-C1948037
proportionally	B-C0205351
by	O
subsequent	O
cell	B-C0007590
divisions	I-C0007590
.	O
	
here	O
,	O
it	O
was	O
demonstrated	O
that	O
this	O
assay	B-C1510438
could	O
be	O
implemented	O
to	O
quantitatively	B-C0681919
analyze	I-C0681919
the	O
cell	B-C0596290
proliferation	I-C0596290
of	O
different	O
types	O
of	O
cell	B-C0682523
lines	I-C0682523
,	O
and	O
to	O
concurrently	B-C0205420
analyze	B-C0936012
the	O
proliferation	B-C1514485
of	O
two	O
types	O
of	O
cell	B-C0682523
lines	I-C0682523
in	O
coculture	B-C0282547
by	O
utilizing	O
cell	B-C2936595
tracking	I-C2936595
dyes	B-C0016320
with	O
different	O
spectral	B-C1883073
characteristics	B-C1521970
.	O
	
the	O
mean	B-C0392762
division	I-C0392762
time	I-C0392762
estimated	B-C0750572
by	O
the	O
dye	B-C0013341
dilution	I-C0013341
assay	I-C0013341
is	O
compared	O
with	O
the	O
population	B-C2986483
doubling	I-C2986483
time	I-C2986483
obtained	O
from	O
conventional	B-C0439858
methods	B-C0025663
and	O
values	B-C0456580
from	O
literature	B-C0023866
.	O
	
additionally	O
,	O
dye	B-C0016320
transfer	O
between	O
cocultured	B-C0007635
cells	I-C0007635
was	O
investigated	B-C1292732
and	O
it	O
was	O
found	O
that	O
it	O
is	O
a	O
characteristic	B-C1521970
of	O
the	O
cells	B-C0007634
rather	O
than	O
a	O
characteristic	B-C1521970
of	O
the	O
dye	B-C0016320
.	O
	
it	O
was	O
suggested	O
that	O
this	O
method	O
can	O
be	O
easily	O
combined	O
with	O
other	O
flow	B-C0016263
cytometric	I-C0016263
analyses	I-C0016263
of	O
cellular	B-C0007634
properties	B-C0871161
,	O
providing	O
valuable	B-C0205556
information	B-C1533716
on	O
cell	B-C0449438
status	I-C0449438
under	O
diverse	B-C1880371
conditions	B-C0348080
.	O
	
engineering	B-C0017387
and	O
in	B-C1515655
vivo	I-C1515655
applications	B-C4048755
of	O
riboswitches	B-C2936590
riboswitches	B-C2936590
are	O
common	B-C0205214
gene	B-C0017362
regulatory	I-C0017362
units	I-C0017362
mostly	O
found	O
in	O
bacteria	B-C0004611
that	O
are	O
capable	B-C2698977
of	O
altering	B-C1515926
gene	B-C0017262
expression	I-C0017262
in	O
response	B-C0871261
to	O
a	O
small	B-C1328819
molecule	I-C1328819
.	O
	
these	O
structured	B-C0035668
rna	I-C0035668
elements	I-C0035668
consist	O
of	O
two	O
modular	B-C1709061
subunits	B-C1711351
an	O
aptamer	B-C0599013
domain	I-C0599013
that	O
binds	B-C1167622
with	O
high	B-C0205250
specificity	B-C0037791
and	O
affinity	B-C1510827
to	O
a	O
target	B-C1521840
ligand	B-C0023688
and	O
an	O
expression	B-C0017262
platform	O
that	O
transduces	B-C0037083
ligand	B-C1517880
binding	I-C1517880
to	O
a	O
gene	B-C0017262
expression	I-C0017262
output	O
.	O
	
significant	B-C0750502
progress	B-C1280477
has	O
been	O
made	O
in	O
engineering	B-C0017387
novel	B-C0205314
aptamer	B-C0599013
domains	I-C0599013
for	O
new	B-C0205314
small	B-C1328819
molecule	I-C1328819
inducers	B-C3898767
of	O
gene	B-C0017262
expression	I-C0017262
.	O
	
modified	B-C0392747
expression	B-C0017262
platforms	O
have	O
also	O
been	O
optimized	B-C2698650
to	O
function	B-C0542341
when	O
fused	B-C0699952
with	O
both	O
natural	B-C0205296
and	O
synthetic	B-C2004457
aptamer	B-C0599013
domains	I-C0599013
.	O
	
as	O
this	O
field	B-C2346620
expands	O
,	O
the	O
use	O
of	O
these	O
privileged	B-C1547898
scaffolds	B-C0337143
has	O
permitted	O
the	O
development	B-C1527148
of	O
tools	B-C2827396
such	O
as	O
rna	B-C0035668
-based	O
fluorescent	B-C0016315
biosensors	B-C0600364
.	O
	
in	O
this	O
review	B-C0282443
,	O
we	O
summarize	B-C1552616
the	O
methods	B-C0025663
that	O
have	O
been	O
developed	O
to	O
engineer	B-C0578393
new	O
riboswitches	B-C2936590
and	O
highlight	O
applications	B-C4048755
of	O
natural	B-C0205296
and	O
synthetic	B-C2004457
riboswitches	B-C2936590
in	O
enzyme	B-C0033629
and	O
strain	B-C1879848
engineering	I-C1879848
,	O
in	O
controlling	O
gene	B-C0017262
expression	I-C0017262
and	O
cellular	B-C0007613
physiology	I-C0007613
,	O
and	O
in	O
real-time	B-C0079595
imaging	I-C0079595
of	O
cellular	B-C0870883
metabolites	I-C0870883
and	O
signals	B-C0037080
.	O
	
a	O
novel	B-C0205314
assay	B-C1510438
to	O
measure	B-C0079809
tertiary	B-C0597565
and	O
quaternary	B-C0578399
amines	I-C0578399
in	O
wastewater	B-C3494254
an	O
indicator	B-C1522602
for	O
ndma	B-C0012431
wastewater	B-C3494254
precursors	B-C1709634
this	O
study	B-C0947630
examined	B-C0332128
the	O
potential	B-C3245505
of	O
using	O
a	O
novel	B-C0205314
bulk	B-C1510438
amine	I-C1510438
assay	I-C1510438
as	O
an	O
approximation	B-C0332232
for	O
the	O
tertiary	B-C0597565
and	O
quaternary	B-C0578399
amine	I-C0578399
load	O
in	O
wastewaters	B-C3494254
and	O
surface	B-C0205148
water	B-C1550678
samples	I-C1550678
,	O
and	O
this	O
approximation	B-C0332232
was	O
compared	B-C1707455
to	O
n-nitrosodimethylamine	B-C0012431
ndma	B-C0012431
formation	B-C1522492
potential	B-C3245505
using	O
chloramines	B-C0008164
.	O
	
an	O
existing	O
colorimetric	B-C0009407
method	I-C0009407
was	O
examined	B-C0332128
and	O
optimized	O
for	O
the	O
detection	B-C0442726
of	O
amines	B-C0002508
in	O
environmental	B-C0014406
water	B-C1550678
samples	I-C1550678
.	O
	
the	O
method	B-C0871511
consists	O
of	O
liquid-liquid	B-C3178840
extraction	I-C3178840
followed	O
by	O
a	O
catalyzed	B-C0205245
reaction	B-C0596319
to	O
form	O
a	O
yet-	O
undefined	B-C0750600
product	B-C1514468
that	O
is	O
known	O
to	O
be	O
both	O
a	O
strong	B-C0442821
chromophore	B-C0596335
and	O
fluorophore	B-C0598447
.	O
	
previous	O
work	O
verified	O
that	O
this	O
reaction	B-C0596319
was	O
effectively	O
catalyzed	B-C0205245
by	O
a	O
number	B-C0237753
of	O
compounds	B-C0205198
containing	O
tertiary	B-C0597565
and	O
quaternary	B-C0578399
amine	I-C0578399
moieties	B-C3641152
.	O
	
many	O
tertiary	B-C0597565
and	O
quaternary	B-C0578399
compounds	I-C0578399
are	O
also	O
efficient	B-C0442799
producers	B-C0205245
of	O
ndma	B-C0012431
under	O
chloramination	B-C0002505
conditions	B-C0348080
,	O
and	O
a	O
linear	B-C1707520
correlation	I-C1707520
was	O
consequently	B-C3845876
derived	O
from	O
the	O
bulk	B-C1710082
amine	I-C1710082
signals	I-C1710082
vs	O
.	O
	
ndma	B-C0012431
formation	B-C1522492
potential	B-C3245505
in	O
various	O
wastewater	B-C3494254
samples	B-C0370003
r	O
=	O
0.74	O
n	O
=	O
24	O
p-value	O
<	O
0.05	O
.	O
	
the	O
results	O
provide	O
evidence	B-C3887511
that	O
approximately	B-C0332232
2%	O
of	O
the	O
tertiary	B-C0597565
and	O
quaternary	O
amines	O
measured	B-C0444706
can	O
form	O
ndma	B-C0012431
and	O
an	O
estimated	B-C0750572
0.01	O
of	O
nitrogen	B-C0028158
in	O
dissolved	B-C0002508
organic	I-C0002508
nitrogen	I-C0002508
originates	I-C0002508
from	O
these	O
bulk	B-C0002508
amines	I-C0002508
.	O
	
the	O
normalization	B-C1882115
of	O
ndma	B-C0012431
concentration	B-C1446561
by	O
the	O
amine	B-C0002508
measurement	B-C0242485
revealed	O
that	O
ozone	B-C0030106
effectively	B-C1704419
destroyed	B-C1948029
those	O
tertiary	B-C0597565
and	O
quaternary	B-C0578399
amine	I-C0578399
structures	B-C0678594
more	O
likely	O
to	O
form	O
ndma	B-C0012431
in	O
treated	B-C1522326
wastewater	B-C3494254
samples	B-C0370003
.	O
	
this	O
bulk	B-C1510438
amine	I-C1510438
assay	I-C1510438
illustrates	O
that	O
proxy	O
measurements	B-C0242485
of	O
tertiary	B-C0597565
and	O
quaternary	B-C0578399
amines	I-C0578399
can	O
be	O
linked	O
to	O
the	O
ndma	B-C0012431
formation	B-C1522492
potential	B-C3245505
of	O
a	O
given	O
sample	B-C0370003
,	O
and	O
this	O
approach	O
may	O
prove	O
useful	B-C3827682
as	O
a	O
characterizing	B-C1880022
tool	B-C0449851
for	O
ndma	B-C0012431
precursors	B-C1709634
in	O
chlamydia	B-C0085504
pneumoniae	I-C0085504
infection	B-C3714514
promotes	B-C0033414
vascular	B-C1257792
endothelial	I-C1257792
cell	I-C1257792
angiogenesis	B-C0302600
through	O
an	O
iqgap1	B-C0529338
-related	O
signaling	B-C0037080
pathway	I-C0037080
chlamydia	B-C0085504
pneumoniae	I-C0085504
c	B-C0085504
.	O
	
pneumoniae	I-C0085504
infection	B-C3714514
plays	O
a	O
potential	B-C1705810
role	I-C1705810
in	O
angiogenesis	B-C0302600
.	O
	
however	O
,	O
it	O
is	O
still	O
an	O
enigma	O
how	O
c	B-C0085504
.	O
	
pneumoniae	I-C0085504
is	O
involved	B-C1314939
in	O
this	O
process	B-C1522240
.	O
	
therefore	O
,	O
we	O
investigated	B-C1292732
the	O
effect	B-C1280500
of	O
c	B-C0085504
.	O
	
pneumoniae	I-C0085504
infection	B-C3714514
on	O
angiogenesis	B-C0302600
,	O
and	O
then	O
explored	O
the	O
roles	B-C1705810
of	O
iqgap1	B-C0529338
-related	O
signaling	B-C0037080
in	O
c	B-C0085504
.	O
	
pneumoniae	I-C0085504
infection	B-C3714514
-	O
induced	B-C0205263
angiogenesis	B-C0302600
.	O
	
c	B-C0085504
.	O
	
pneumoniae	I-C0085504
infection	B-C3714514
significantly	B-C2349975
enhanced	I-C2349975
angiogenesis	B-C0302600
as	O
assessed	B-C1516048
by	O
the	O
tube	B-C1510438
formation	I-C1510438
assay	I-C1510438
possibly	B-C0332149
by	O
inducing	B-C0205263
vascular	B-C1257792
endothelial	I-C1257792
cell	I-C1257792
vec	B-C1257792
migration	B-C0013975
in	O
the	O
wound	B-C0043240
healing	I-C0043240
and	O
transwell	B-C1510438
migration	I-C1510438
assays	I-C1510438
.	O
	
subsequently	B-C0332282
,	O
immunoprecipitation	B-C0021069
,	O
western	B-C0949466
blot	I-C0949466
and	O
tube	B-C1510438
formation	I-C1510438
assay	I-C1510438
results	B-C1254595
showed	O
that	O
the	O
phosphorylation	B-C1158886
of	O
both	O
iqgap1	B-C0529338
and	O
n-wasp	B-C0531254
was	O
required	B-C1514873
for	O
the	O
angiogenesis	B-C0302600
induced	B-C0205263
by	O
c	B-C0085504
.	O
	
pneumoniae	I-C0085504
infection	B-C3714514
.	O
	
our	O
co-immunoprecipitation	B-C1449705
study	B-C0681827
revealed	B-C0443289
that	O
iqgap1	B-C0529338
physically	O
associated	B-C0332281
with	I-C0332281
n-wasp	B-C0531254
after	O
c	B-C0085504
.	O
	
pneumoniae	I-C0085504
infection	B-C3714514
of	O
vecs	B-C1257792
.	O
	
actin	B-C1155982
polymerization	I-C1155982
assay	B-C1510438
further	O
showed	O
that	O
in	O
c	B-C0085504
.	O
	
pneumoniae	I-C0085504
-	O
infected	B-C0439663
vecs	B-C1257792
,	O
both	O
iqgap1	B-C0529338
and	O
n-wasp	B-C0531254
were	O
recruited	O
to	O
filamentous	B-C1180307
actin	I-C1180307
,	O
and	O
shared	O
some	O
common	B-C0205214
compartments	O
localized	B-C0392752
at	O
the	O
leading	B-C1621433
edge	I-C1621433
of	O
lamellipodia	B-C0230628
,	O
which	O
was	O
impaired	B-C0221099
after	O
the	O
depletion	B-C0333668
of	O
iqgap1	B-C0529338
by	O
using	O
the	O
small	B-C1099354
interference	I-C1099354
rna	I-C1099354
.	O
	
moreover	O
,	O
the	O
knockdown	B-C2350567
of	O
iqgap1	B-C1416471
also	O
significantly	B-C0205216
decreased	I-C0205216
n-wasp	B-C0531254
phosphorylation	B-C1158886
at	O
tyr256	B-C0041485
induced	B-C0205263
by	O
c	B-C0085504
.	O
	
pneumoniae	I-C0085504
infection	B-C3714514
.	O
	
we	O
conclude	B-C1707478
that	O
c	B-C0085504
.	O
	
pneumoniae	I-C0085504
infection	B-C3714514
promotes	B-C0033414
vec	B-C1257792
migration	B-C0013975
and	O
angiogenesis	B-C0302600
presumably	O
through	O
the	O
iqgap1	B-C0529338
-related	O
signaling	B-C0037080
pathway	I-C0037080
.	O
	
four-dimensional	B-C2347299
graded	B-C0441800
consciousness	B-C0234421
both	O
the	O
multidimensional	B-C2347299
phenomenon	B-C1882365
and	O
the	O
polysemous	B-C0205556
notion	I-C0205556
of	O
consciousness	B-C0234421
continue	O
to	O
prove	O
resistant	B-C0332325
to	O
consistent	B-C0332290
measurement	B-C0242485
and	O
unambiguous	B-C1704788
definition	I-C1704788
.	O
	
this	O
is	O
hardly	O
surprising	O
,	O
given	O
that	O
there	O
is	O
no	B-C0243095
agreement	I-C0243095
even	O
as	O
regards	O
the	O
most	O
fundamental	O
issues	B-C0033213
they	O
involve	O
.	O
	
one	O
of	O
the	O
basic	O
disagreements	B-C0012742
present	O
in	O
the	O
continuing	O
debate	B-C0870392
about	O
consciousness	B-C0234421
pertains	O
to	O
its	O
gradational	B-C0441800
nature	B-C0349590
.	O
	
the	O
general	O
aim	O
of	O
this	O
article	B-C1706852
is	O
to	O
show	O
how	O
consciousness	B-C0234421
might	O
be	O
graded	B-C0441800
and	O
multidimensional	B-C2347299
at	O
the	O
same	O
time	B-C0040223
.	O
	
we	O
therefore	O
focus	O
on	O
the	O
question	B-C1522634
of	O
what	O
it	O
is	O
,	O
exactly	O
,	O
that	O
is	O
or	O
could	O
be	O
graded	B-C0441800
in	O
cases	B-C0868928
of	O
consciousness	B-C0234421
,	O
and	O
how	O
we	O
can	O
measure	B-C0079809
it	O
.	O
	
ultimately	O
,	O
four	O
different	O
gradable	B-C0441800
aspects	B-C1879746
of	O
consciousness	B-C0234421
will	O
be	O
described	O
quality	B-C0332306
,	O
abstractness	B-C0679195
,	O
complexity	B-C0237521
and	O
usefulness	B-C3827682
,	O
which	O
belong	O
to	O
four	O
different	O
dimensions	B-C0439534
,	O
these	O
being	O
understood	O
,	O
respectively	O
,	O
as	O
phenomenal	B-C3898065
,	O
semantic	B-C0036612
,	O
physiological	B-C0205463
,	O
and	O
functional	B-C0542341
.	O
	
consequently	O
,	O
consciousness	B-C0234421
may	O
be	O
said	O
to	O
vary	O
with	O
respect	O
to	O
phenomenal	B-C3898065
quality	B-C0332306
,	O
semantic	B-C0036612
abstraction	B-C0679195
,	O
physiological	B-C0205463
complexity	B-C0237521
,	O
and	O
functional	B-C0542341
usefulness	B-C3827682
.	O
	
it	O
is	O
hoped	O
that	O
such	O
a	O
four-dimensional	B-C2347299
approach	O
will	O
help	O
to	O
clarify	O
and	O
justify	O
claims	O
about	O
the	O
hierarchical	B-C0349590
nature	I-C0349590
of	O
consciousness	B-C0234421
.	O
	
the	O
approach	B-C0449445
also	O
proves	O
explanatorily	O
advantageous	B-C3898777
,	O
as	O
it	O
enables	O
us	O
not	O
only	O
to	O
draw	O
attention	B-C0004268
to	O
certain	O
new	O
and	O
important	B-C3898777
differences	B-C1705242
in	O
respect	O
of	O
subjective	B-C0205556
measures	B-C0079809
of	O
awareness	B-C0004448
and	O
to	O
justify	O
how	O
a	O
given	O
creature	B-C0003062
may	O
be	O
ranked	B-C0699794
higher	B-C0205250
in	O
one	O
dimension	O
of	O
consciousness	B-C0234421
and	O
lower	O
in	O
terms	O
of	O
another	O
,	O
but	O
also	O
allows	O
for	O
innovative	B-C0681841
explanations	I-C0681841
of	O
a	O
variety	O
of	O
well-known	O
phenomena	B-C1882365
amongst	O
these	O
,	O
the	O
interpretations	B-C0459471
of	O
blindsight	B-C0205556
and	O
locked-in	B-C0023944
syndrome	I-C0023944
will	O
be	O
briefly	O
outlined	O
here	O
.	O
	
moreover	O
,	O
a	O
4d	B-C2347299
framework	O
makes	O
possible	O
many	O
predictions	B-C0681842
and	O
hypotheses	B-C1512571
that	O
may	O
be	O
experimentally	B-C0681814
tested	B-C0039593
we	O
point	O
out	O
a	O
few	O
such	O
possibilities	O
pertaining	O
to	O
interdimensional	B-C3244310
dependencies	I-C3244310
.	O
	
synthesis	B-C1883254
of	O
some	O
unique	O
carbamate	B-C0006948
derivatives	B-C0002776
bearing	O
2-furoyl-1-piperazine	B-C0566267
as	O
a	O
valuable	O
therapeutic	B-C1611640
agents	I-C1611640
the	O
aim	B-C1947946
of	O
the	O
research	B-C0242481
work	I-C0242481
was	O
to	O
synthesize	O
different	O
biologically	B-C0566267
active	I-C0566267
carbamate	B-C0006948
derivatives	B-C0002776
bearing	O
2-furoyl-1-piperazine	B-C0566267
and	O
having	O
modest	O
toxicity	B-C0600688
.	O
	
the	O
synthesis	B-C1883254
was	O
completed	O
as	O
a	O
multiple	B-C1519249
sequence	I-C1519249
.	O
	
the	O
structural	B-C0678594
confirmation	B-C0750484
of	O
all	O
the	O
synthesized	O
compounds	O
was	O
obtained	O
by	O
ei-ms	B-C4054904
,	O
ir	B-C0037807
and	O
1h-nmr	B-C3850001
spectral	O
data	O
.	O
	
the	O
enzyme	B-C1524081
inhibition	I-C1524081
and	O
antibacterial	B-C0243095
potential	I-C0243095
of	O
the	O
synthesized	B-C0566267
compounds	I-C0566267
was	O
evaluated	B-C0220825
.	O
	
to	O
find	O
the	O
utility	O
of	O
the	O
prepared	O
compounds	B-C0566267
as	O
possible	O
therapeutic	B-C1611640
agents	I-C1611640
their	O
cytotoxicity	B-C0596402
was	O
also	O
checked	O
.	O
	
all	O
the	O
compounds	B-C0566267
were	O
active	B-C0205177
against	O
acetylcholinesterase	B-C0001044
enzyme	I-C0001044
,	O
especially	O
12	B-C0566267
and	O
14	B-C0566267
showed	O
very	O
good	B-C0205170
inhibitory	B-C0234122
potential	I-C0234122
relative	O
to	O
eserine	B-C1314787
,	O
a	O
reference	B-C0034925
standard	I-C0034925
.	O
	
almost	O
all	O
the	O
compounds	B-C0566267
showed	O
good	O
activities	O
against	O
both	O
gram-positive	B-C0018154
and	O
gram-negative	B-C0018150
bacterial	I-C0018150
strains	I-C0018150
.	O
	
epidemiology	B-C0014507
and	O
outcomes	B-C0085565
of	O
injuries	B-C0178314
in	O
kenya	B-C0022558
a	O
multisite	B-C0681625
surveillance	I-C0681625
study	I-C0681625
injury	B-C0178314
is	O
a	O
leading	O
cause	O
of	O
disability	B-C0231170
and	O
death	B-C1306577
worldwide	O
,	O
accounting	O
for	O
over	O
5	O
million	O
deaths	B-C1306577
each	O
year	B-C0439234
.	O
	
the	O
injury	B-C0178314
burden	B-C2828008
is	O
higher	O
in	O
low-	B-C0454664
and	I-C0454664
middle-income	I-C0454664
countries	I-C0454664
where	O
more	O
than	O
90%	O
of	O
injury	B-C0178314
-related	O
deaths	O
occur	O
.	O
	
despite	O
this	O
burden	O
,	O
the	O
use	O
of	O
prospective	O
trauma	O
registries	O
to	O
describe	O
injury	B-C1306577
epidemiology	O
and	O
outcomes	O
is	O
limited	O
in	O
low-	O
and	O
middle-income	O
countries	O
.	O
	
kenya	O
lacks	O
robust	O
data	O
to	O
describe	O
injury	O
epidemiology	O
and	O
care	O
.	O
	
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
epidemiology	O
and	O
outcomes	O
of	O
injuries	O
at	O
4	O
referral	O
hospitals	O
in	O
kenya	O
using	O
hospital	O
-based	O
trauma	O
registries	O
.	O
	
from	O
january	O
2014	O
to	O
may	O
2015	O
,	O
all	O
injured	O
patients	O
presenting	O
to	O
the	O
casualty	O
departments	O
of	O
kenyatta	O
national	O
,	O
thika	O
level	O
5	O
,	O
machakos	O
level	O
5	O
,	O
and	O
meru	O
level	O
5	O
hospitals	O
were	O
enrolled	O
prospectively	O
.	O
	
data	O
collected	O
included	O
demographic	O
characteristics	O
,	O
type	O
of	O
prehospital	O
care	O
received	O
,	O
prehospital	O
time	O
,	O
injury	O
pattern	O
,	O
and	O
outcomes	O
.	O
	
a	O
total	O
of	O
14	O
patients	O
were	O
enrolled	O
in	O
our	O
study	O
.	O
	
patients	O
were	O
predominantly	O
male	O
76.1	O
and	O
young	O
mean	O
age	O
28	O
years	O
.	O
	
the	O
most	O
common	O
mechanisms	O
of	O
injury	O
were	O
road	O
traffic	O
injuries	O
36.8	O
,	O
falls	O
26.4	O
,	O
and	O
being	O
struck/hit	O
by	O
a	O
person	O
or	O
object	O
20.1	O
.	O
	
burn	O
was	O
the	O
most	O
common	O
mechanism	O
of	O
injury	O
in	O
the	O
age	O
category	O
under	O
5	O
years	O
.	O
	
body	O
regions	O
commonly	O
injured	O
were	O
lower	O
extremity	O
35.1	O
,	O
upper	O
extremity	O
33.4	O
,	O
and	O
head	O
26.0	O
.	O
	
the	O
overall	O
mortality	O
rate	O
was	O
2.4	O
.	O
	
significant	O
predictors	O
of	O
mortality	O
from	O
multivariate	O
analysis	O
were	O
glasgow	O
coma	O
scale	O
12	O
,	O
estimated	O
injury	O
severity	O
score	O
9	O
,	O
burns	O
,	O
and	O
gunshot	O
injuries	O
.	O
	
hospital	O
-based	O
trauma	O
registries	O
can	O
be	O
important	O
sources	O
of	O
data	O
to	O
study	O
the	O
epidemiology	O
of	O
injuries	O
in	O
low-	O
and	O
middle-income	O
countries	O
.	O
	
data	O
from	O
such	O
trauma	O
registries	O
can	O
highlight	O
key	O
needs	O
and	O
be	O
used	O
to	O
design	O
public	O
health	O
interventions	O
and	O
quality-of-care	O
improvement	O
programs	I-C1254363
a	O
child	B-C0008059
with	O
phenylketonuria	B-C0031485
and	O
focal	B-C0333497
segmental	I-C0333497
glomerulosclerosis	I-C0333497
,	O
the	O
bright	O
side	O
of	O
proteinuria	B-C0033687
phenylketonuria	B-C0031485
pku	B-C0031485
is	O
the	O
most	O
common	B-C0205214
inborn	B-C0002514
error	I-C0002514
of	I-C0002514
amino	I-C0002514
acid	I-C0002514
metabolism	I-C0002514
.	O
	
phenylalanine	B-C0031456
hydroxylase	I-C0031456
is	O
the	O
underlying	O
deficient	B-C0011155
enzyme	B-C0014442
.	O
	
if	O
left	O
untreated	B-C0332155
,	O
growth	B-C0878787
failure	I-C0878787
,	O
microcephaly	B-C0025958
,	O
global	B-C0557874
developmental	I-C0557874
delay	I-C0557874
,	O
seizures	B-C0036572
and	O
severe	B-C4294877
intellectual	I-C4294877
impairment	I-C4294877
would	O
characterize	B-C1880022
the	O
clinical	B-C0683325
picture	I-C0683325
of	O
pku	B-C0031485
.	O
	
on	O
the	O
other	O
side	O
of	O
protein	B-C0033684
homeostasis	B-C0019868
lies	O
nephrotic	B-C0027726
syndrome	I-C0027726
.	O
	
it	O
is	O
a	O
well-known	O
quantitative	B-C0392762
defect	B-C1457869
due	O
to	O
significant	B-C0750502
proteinuria	B-C0033687
.	O
	
focal	B-C0333497
segmental	I-C0333497
glomerulosclerosis	I-C0333497
fsgs	B-C0333497
is	O
a	O
special	B-C0205555
congenital	B-C1744681
variant	B-C0205419
affecting	B-C0392760
children	B-C0008059
and	O
adults	B-C0001675
.	O
	
hereby	O
,	O
we	O
describe	O
a	O
three-	O
year	O
old	O
male	B-C0086582
child	B-C0008059
who	O
presented	B-C0150312
with	O
generalized	B-C1850534
edema	I-C1850534
and	O
global	B-C0557874
developmental	I-C0557874
delay	I-C0557874
.	O
	
investigations	B-C1261322
revealed	B-C0443289
pku	B-C0031485
along	O
with	O
fsgs	B-C0333497
.	O
	
we	O
assume	O
that	O
congenital	B-C3501848
nephrosis	I-C3501848
ameliorated	B-C0184511
the	O
picture	O
of	O
pku	B-C0031485
,	O
and	O
had	O
a	O
salutary	B-C0205556
effect	I-C0205556
on	O
the	O
growth	B-C0018271
and	I-C0018271
development	I-C0018271
.	O
	
such	O
coexistence	O
between	O
pku	B-C0031485
and	O
fsgs	B-C0333497
gastrointestinal	B-C0017178
disorders	I-C0017178
in	O
curry-jones	B-C0795915
syndrome	I-C0795915
clinical	B-C0205210
and	O
molecular	B-C1521991
insights	B-C0233820
from	O
an	O
affected	B-C0392760
newborn	B-C0021289
curry-jones	B-C0795915
syndrome	I-C0795915
cjs	B-C0795915
is	O
a	O
pattern	B-C0449774
of	O
malformation	B-C0302142
that	O
includes	O
craniosynostosis	B-C0010278
,	O
pre-axial	B-C2751914
polysyndactyly	I-C2751914
,	O
agenesis	B-C0175754
of	I-C0175754
the	I-C0175754
corpus	I-C0175754
callosum	I-C0175754
,	O
cutaneous	B-C1704258
and	O
gastrointestinal	B-C0521362
abnormalities	O
.	O
	
a	O
recurrent	O
,	O
mosaic	O
mutation	O
of	O
smo	O
c.1234	O
c>t	O
p.leu412phe	O
causes	O
cjs	O
.	O
	
this	O
report	O
describes	O
the	O
gastrointestinal	B-C3824760
and	O
surgical	O
findings	O
in	O
a	O
baby	O
with	O
cjs	O
who	O
presented	O
with	O
abdominal	O
obstruction	O
and	O
reviews	O
the	O
spectrum	O
of	O
gastrointestinal	O
malformations	O
in	O
this	O
rare	O
disorder	O
.	O
	
a	O
41-	O
week	O
,	O
4	O
g	O
,	O
female	O
presented	O
with	O
craniosynostosis	O
,	O
pre-axial	O
polysyndactyly	O
,	O
and	O
cutaneous	O
findings	O
consistent	O
with	O
a	O
clinical	O
diagnosis	O
of	O
cjs	O
.	O
	
the	O
infant	O
developed	O
abdominal	O
distension	O
beginning	O
on	O
the	O
second	O
day	O
of	O
life	O
.	O
	
surgical	O
exploration	O
revealed	O
an	O
intestinal	O
malrotation	O
for	O
which	O
she	O
underwent	O
a	O
ladd	O
procedure	O
.	O
	
multiple	O
small	O
nodules	O
were	O
found	O
on	O
the	O
surface	O
of	O
the	O
small	O
and	O
large	O
bowel	O
in	O
addition	O
to	O
an	O
apparent	O
intestinal	O
duplication	O
that	O
seemed	O
to	O
originate	O
posterior	O
to	O
the	O
pancreas	O
.	O
	
histopathology	O
of	O
serosal	O
nodules	O
revealed	O
bundles	O
of	O
smooth	O
muscle	O
with	O
associated	O
ganglion	O
cells	O
.	O
	
molecular	O
analysis	O
demonstrated	O
the	O
smo	O
c.1234	O
c>t	O
mutation	O
in	O
varying	O
amounts	O
in	O
affected	O
skin	O
up	O
to	O
35%	O
and	O
intestinal	O
hamartoma	O
26%	O
.	O
	
gastrointestinal	O
features	O
including	O
structural	O
malformations	O
,	O
motility	O
disorders	O
,	O
and	O
upper	O
gi	O
bleeding	O
are	O
major	O
causes	O
of	O
morbidity	O
in	O
cjs	O
.	O
	
smooth	O
muscle	O
hamartomas	O
are	O
a	O
recognized	O
feature	O
of	O
children	O
with	O
cjs	O
typically	O
presenting	O
with	O
abdominal	O
obstruction	O
requiring	O
surgical	O
intervention	O
.	O
	
a	O
somatic	O
mutation	O
in	O
smo	O
likely	O
accounts	O
for	O
the	O
structural	O
malformations	O
and	O
predisposition	O
to	O
form	O
bowel	O
hamartomas	O
and	O
myofibromas	O
.	O
	
the	O
mutation	O
burden	O
in	O
the	O
involved	O
tissues	O
likely	O
accounts	O
for	O
the	O
variable	O
manifestations	I-C3150238
sella	B-C1866959
turcica	I-C1866959
bridging	I-C1866959
and	O
dental	B-C0262444
anomalies	I-C0262444
is	O
there	O
an	O
association	B-C0439849
sella	B-C1866959
turcica	I-C1866959
bridging	I-C1866959
stb	B-C1866959
,	O
or	O
calcification	B-C0006660
of	O
the	O
interclinoid	B-C0023685
ligament	I-C0023685
of	O
sella	B-C0036609
turcica	I-C0036609
,	O
has	O
been	O
reported	O
to	O
be	O
associated	B-C0332281
with	I-C0332281
some	O
dental	B-C0262444
anomalies	I-C0262444
palatal	B-C2749981
canine	I-C2749981
impaction	B-C0040456
and	O
transposition	B-C1319068
.	O
	
the	O
aim	O
of	O
the	O
study	B-C2603343
was	O
to	O
find	O
any	O
association	B-C0439849
between	O
canine	B-C2749981
impaction	B-C0040456
,	O
hyperdontia	B-C0040457
or	O
hypodontia	B-C0020608
and	O
sellar	B-C0036609
dimensions	B-C0439534
or	O
bridging	B-C1866959
.	O
	
lateral	B-C0205093
cephalometric	B-C0007723
radiographs	B-C1306645
from	O
78	O
patients	B-C0030705
with	O
impacted	B-C0040456
canines	B-C2749981
,	O
68	O
with	O
dental	B-C0399352
agenesis	I-C0399352
and	O
17	O
with	O
hyperdontia	B-C0040457
were	O
collected	O
.	O
	
linear	B-C0205132
dimensions	B-C0439534
of	O
sella	B-C0036609
turcica	I-C0036609
were	O
calculated	O
and	O
compared	O
to	O
those	O
of	O
a	O
control	B-C0009932
group	I-C0009932
47	O
individuals	B-C0237401
.	O
	
a	O
standardize	B-C0349674
scoring	I-C0349674
scale	I-C0349674
was	O
used	O
to	O
quantify	O
the	O
extent	O
of	O
stb	B-C1866959
from	O
each	O
radiographs	B-C1306645
.	O
	
the	O
frequency	B-C0439603
of	O
partial	B-C0728938
and	O
complete	B-C0205197
calcifications	B-C0006660
of	O
sella	B-C0036609
in	O
patients	B-C0030705
with	O
dental	B-C0262444
anomalies	I-C0262444
is	O
increased	B-C0205217
when	O
compared	O
to	O
controls	B-C0009932
.	O
	
stb	B-C1866959
can	O
influence	O
the	O
interclinoid	B-C0012751
distance	I-C0012751
but	O
does	O
not	O
affect	O
other	O
linear	B-C0205132
dimensions	B-C0439534
of	O
sella	B-C0036609
.	O
	
no	O
statistically	B-C0237881
significant	I-C0237881
difference	O
has	O
been	O
found	O
in	O
sellar	B-C0036609
dimensions	B-C0439534
and	O
stb	B-C1866959
expression	O
when	O
evaluating	O
radiographs	B-C1306645
at	O
different	O
ages	B-C0001779
.	O
	
stb	B-C1866959
is	O
frequently	O
found	O
in	O
patients	B-C0030705
with	O
dental	B-C0262444
abnormalities	I-C0262444
.	O
	
coxiella	B-C0010240
burnetii	I-C0010240
isolates	B-C1764827
originating	O
from	O
infected	B-C0007452
cattle	I-C0007452
induce	B-C0205263
a	O
more	O
pronounced	O
proinflammatory	B-C2247677
cytokine	I-C2247677
response	I-C2247677
compared	O
to	O
isolates	B-C1764827
from	O
infected	B-C1510458
goats	I-C1510458
and	O
sheep	B-C0036945
coxiella	B-C0010240
burnetii	I-C0010240
is	O
the	O
causative	B-C0449411
agent	I-C0449411
of	O
q	B-C0034362
fever	I-C0034362
.	O
	
although	O
the	O
prevalence	B-C0220900
of	O
c	B-C0010240
.	O
	
burnetii	I-C0010240
in	O
cattle	B-C0007452
is	O
much	O
higher	O
than	O
in	O
goats	B-C1510458
and	O
sheep	B-C0036945
,	O
infected	B-C0007452
cattle	I-C0007452
are	O
rarely	O
associated	B-C0332281
with	I-C0332281
human	B-C0086418
outbreaks	B-C0012652
.	O
	
we	O
investigated	B-C1292732
whether	O
the	O
immune	B-C0301872
response	I-C0301872
of	O
humans	B-C0086418
differs	O
after	O
contact	O
with	O
c	B-C0010240
.	O
	
burnetii	I-C0010240
isolates	B-C1764827
from	O
different	O
host	B-C1167395
origins	I-C1167395
or	O
with	O
different	O
multilocus	B-C1443925
variable	I-C1443925
number	I-C1443925
of	I-C1443925
tandem	I-C1443925
repeat	I-C1443925
analysis	I-C1443925
mlva	B-C1443925
genotypes	B-C0017431
.	O
	
cytokine	B-C2247677
responses	I-C2247677
were	O
measured	O
in	O
human	B-C0086418
peripheral	B-C1321301
blood	I-C1321301
mononuclear	I-C1321301
cells	I-C1321301
pbmcs	B-C1321301
stimulated	B-C1948023
with	O
16	O
c	B-C0010240
.	O
	
burnetii	I-C0010240
isolates	B-C1764827
with	O
known	O
mlva	B-C1443925
genotype	B-C0017431
from	O
goats	B-C1510458
,	O
sheep	B-C0036945
,	O
cattle	B-C0007452
,	O
acute	B-C0519066
and	O
chronic	B-C1443892
q	I-C1443892
fever	I-C1443892
patients	B-C0030705
.	O
	
coxiella	B-C0010240
burnetii	I-C0010240
isolates	B-C1764827
originating	O
from	O
cattle	B-C0007452
induce	B-C0205263
significantly	O
more	O
il-1β	B-C0021753
,	O
tnf-α	B-C0041368
and	O
il-22	B-C0961814
than	O
the	O
isolates	B-C1764827
from	O
goats	B-C1510458
,	O
sheep	B-C0036945
or	O
chronic	B-C1443892
q	I-C1443892
fever	I-C1443892
patients	B-C0030705
.	O
	
comparing	O
the	O
cytokine	B-C0079189
induction	B-C0205263
of	O
the	O
isolates	B-C1764827
based	O
on	O
their	O
mvla	B-C1443925
genotype	B-C0017431
did	O
not	O
reveal	O
differences	O
in	O
response	B-C2247677
between	O
the	O
mlva	B-C1443925
genotypes	B-C0017431
.	O
	
the	O
proinflammatory	B-C2247677
cytokine	I-C2247677
response	I-C2247677
induced	B-C0205263
in	O
human	B-C0086418
pbmcs	B-C1321301
by	O
c	B-C0010240
.	O
	
burnetii	I-C0010240
isolates	B-C1764827
from	O
cattle	B-C0007452
may	O
explain	O
the	O
low	O
incidence	B-C0021149
of	O
human	B-C0086418
q	B-C0034362
fever	I-C0034362
outbreaks	B-C0012652
caused	O
by	O
cattle	B-C0007452
.	O
	
the	O
cytokine	B-C0079189
profile	O
of	O
pbmcs	O
stimulated	O
with	O
c	O
.	O
	
burnetii	O
isolates	O
from	O
chronic	O
q	O
fever	O
patients	O
resembles	O
isolates	O
from	O
goats	O
.	O
	
furthermore	O
,	O
cytokine	B-C0392762
responses	O
seem	O
to	O
be	O
depending	O
on	O
host	O
origin	O
than	O
on	O
mlva	O
genotype	B-C0017431
a	O
novel	O
brca1-associated	B-C1368335
protein-1	I-C1368335
isoform	B-C0597298
affects	B-C4054723
response	B-C0871261
of	O
mesothelioma	B-C0025500
cells	I-C0025500
to	O
drugs	B-C0013227
impairing	B-C0221099
brca1	B-C1528558
-mediated	O
dna	B-C0012899
repair	I-C0012899
brca1	B-C1368335
associated	I-C1368335
protein1	I-C1368335
bap1	B-C1368335
is	O
a	O
tumor	B-C0597611
suppressor	I-C0597611
involved	O
in	O
multiple	B-C0439064
cellular	B-C0007613
processes	I-C0007613
such	O
as	O
transcriptional	B-C1158770
regulation	I-C1158770
,	O
chromatin	B-C1156197
modification	I-C1156197
by	O
deubiquitinating	B-C1157996
histone	B-C0147579
2a	I-C0147579
,	O
and	O
dna	B-C0012899
repair	I-C0012899
.	O
	
bap1	B-C1368335
mutations	B-C0026882
are	O
frequent	B-C0332183
in	O
malignant	B-C0812413
pleural	I-C0812413
mesothelioma	I-C0812413
mpm	B-C0812413
.	O
	
our	O
aim	B-C1947946
was	O
to	O
functionally	B-C0205245
characterize	B-C1521970
a	O
newly	O
identified	B-C0205396
isoform	B-C0597298
of	B-C1368335
bap1	I-C1368335
and	O
investigate	B-C1292732
the	O
effects	B-C1280500
of	O
its	O
expression	B-C0017262
on	O
drug	B-C0237865
sensitivity	I-C0237865
in	O
mpm	B-C0812413
.	O
	
expression	B-C0017262
of	O
bap1	B-C1368335
isoforms	O
was	O
detected	B-C0442726
by	O
quantitative	B-C2733022
polymerase	I-C2733022
chain	I-C2733022
reaction	I-C2733022
in	O
mpm	B-C0812413
and	O
normal	B-C0205307
mesothelium	B-C0086610
cell	B-C0007600
lines	I-C0007600
and	O
tumor	B-C0475358
and	O
nontumor	B-C1292533
samples	I-C1292533
.	O
	
histone	B-C0019646
h2a	I-C0019646
ubiquitination	B-C1156207
levels	B-C0441889
were	O
analyzed	B-C0936012
by	O
western	B-C0949466
blot	I-C0949466
after	O
acidic	B-C0684295
extraction	I-C0684295
of	O
core	B-C2987130
histones	I-C2987130
.	O
	
subcellular	B-C3893246
localization	B-C0475264
of	O
bap1	B-C1368335
isoforms	B-C0597298
was	O
examined	B-C0332128
by	O
immunofluorescence	B-C0079603
.	O
	
mpm	B-C0812413
cell	B-C0007620
survival	I-C0007620
in	O
response	B-C0871261
to	O
poly	B-C0032405
diphosphate-ribose	I-C0032405
polymerase	I-C0032405
parp	B-C0032405
and	O
dual	O
phosphoinositide	B-C0044602
3-kinase	I-C0044602
pi3k	B-C0044602
mammalian	B-C1307407
target	I-C1307407
of	I-C1307407
rapamycin	I-C1307407
mtor	B-C1307407
inhibitors	B-C0014432
was	O
analyzed	B-C0936012
by	O
in	B-C1515653
vitro	I-C1515653
assays	I-C1515653
.	O
	
we	O
have	O
identified	B-C0205396
a	O
novel	O
alternative	B-C1720834
splice	I-C1720834
isoform	I-C1720834
of	O
bap1	B-C1368335
bap1δ	B-C1332380
that	O
misses	O
part	O
of	O
the	O
catalytic	B-C0600499
domain	I-C0600499
.	O
	
cells	B-C0007634
transfected	B-C0040669
with	O
bap1δ	B-C1332380
showed	O
reduced	B-C0392756
deubiquitinating	B-C1157996
activity	I-C1157996
compared	B-C1707455
with	O
full-length	O
bap1	B-C1368335
.	O
	
the	O
expression	B-C0017262
of	O
bap1δ	B-C1332380
transcript	B-C1519595
is	O
more	O
abundant	B-C2346714
in	O
nontumor	B-C1292533
than	O
in	O
tumor	O
samples	O
.	O
	
mpm	B-C0812413
cell	B-C0085983
lines	I-C0085983
expressing	B-C0017262
more	O
than	O
20%	O
of	O
bap1δ	B-C1332380
are	O
more	O
sensitive	B-C0332324
to	O
olaparib	B-C2316164
a	O
parp1	B-C1567710
inhibitor	B-C0014432
cytotoxicity	B-C0596402
,	O
and	O
this	O
sensitivity	B-C0332324
is	O
enhanced	B-C2349975
when	O
olaparib	B-C2316164
treatment	B-C3887704
is	O
combined	B-C0205195
with	O
gdc0980	B-C2984520
a	O
dual	O
pi3k	B-C0044602
-	O
mtor	B-C1307407
inhibitor	B-C0014432
,	O
which	O
induces	B-C0205263
downregulation	B-C0013081
of	O
brca1	B-C1528558
.	O
	
these	O
observations	B-C0302523
suggest	O
that	O
bap1δ	B-C1332380
does	O
regulate	B-C3270705
dna	I-C3270705
damage	I-C3270705
response	I-C3270705
and	O
influences	B-C4054723
drug	B-C0237865
sensitivity	I-C0237865
.	O
	
it	O
might	O
therefore	O
be	O
relevant	B-C2347946
to	O
investigate	B-C1292732
whether	O
patients	B-C0030705
with	O
high	B-C0205250
expression	B-C0017262
of	O
bap1δ	B-C1332380
may	O
be	O
responsive	B-C0521982
to	O
parp	B-C0032405
/	O
pi3k	B-C0044602
-	O
mtor	B-C1307407
inhibitors	B-C0014432
.	O
	
cucurbitacin	B-C0056580
b	I-C0056580
protects	O
against	O
pressure	B-C0497233
overload	B-C0684338
induced	O
cardiac	B-C1383860
hypertrophy	I-C1383860
lack	O
of	O
effective	O
anti-cardiac	B-C1254351
hypertrophy	I-C1254351
drugs	I-C1254351
creates	O
a	O
major	O
cause	B-C0015127
for	O
the	O
increasing	O
prevalence	B-C0033105
of	O
heart	B-C0018801
failure	I-C0018801
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
anti-hypertrophy	B-C0243095
and	O
anti-fibrosis	B-C0243095
potential	B-C3245505
of	O
a	O
natural	B-C0032098
plant	I-C0032098
triterpenoid	B-C1519655
,	O
cucurbitacin	B-C0056580
b	I-C0056580
both	O
in	B-C0681828
vitro	I-C0681828
and	O
in	B-C0681829
vivo	I-C0681829
.	O
	
aortic	B-C0185014
banding	I-C0185014
ab	B-C0185014
was	O
performed	O
to	O
induce	O
cardiac	B-C1383860
hypertrophy	I-C1383860
.	O
	
after	O
1	O
week	O
of	O
surgery	B-C0543467
,	O
mice	B-C0025929
were	O
receive	O
cucurbitacin	B-C0056580
b	I-C0056580
treatment	B-C0087111
gavage	B-C2698653
,	O
0.2	O
mg/kg	O
body	B-C0005910
weight	I-C0005910
/2	O
day	O
.	O
	
after	O
4	O
weeks	O
of	O
ab	B-C0185014
,	O
cucurbitacin	B-C0056580
b	I-C0056580
demonstrated	O
a	O
strong	O
anti-hypertrophy	B-C0243095
and	O
-fibrosis	B-C0243095
ability	O
as	O
evidenced	O
by	O
decreased	O
of	O
heart	B-C0018787
weight	B-C0043100
,	O
myocardial	B-C0225828
cell	I-C0225828
cross-sectional	B-C2923394
area	I-C2923394
and	O
interstitial	B-C0240035
fibrosis	I-C0240035
,	O
ameliorated	O
of	O
systolic	B-C0039155
and	O
diastolic	B-C0012000
abnormalities	B-C0205161
,	O
normalized	O
in	O
gene	B-C0017262
expression	I-C0017262
of	O
hypertrophic	B-C0020564
and	O
fibrotic	B-C0334129
markers	B-C0005516
,	O
reserved	O
microvascular	B-C3272839
density	I-C3272839
in	O
pressure	B-C0497233
overload	B-C0684338
induced	O
hypertrophic	B-C0020564
mice	B-C0025929
.	O
	
cucurbitacin	B-C0056580
b	I-C0056580
also	O
showed	O
significant	O
hypertrophy	B-C0020564
inhibitory	B-C0243095
effect	I-C0243095
in	O
phenylephrine	B-C0031469
stimulated	B-C1948023
cardiomyocytes	B-C0225828
.	O
	
the	O
cucurbitacin	B-C0056580
b	I-C0056580
-mediated	O
mitigated	B-C1553901
cardiac	B-C1383860
hypertrophy	I-C1383860
was	O
attributable	O
to	O
the	O
increasing	O
level	O
of	O
autophagy	B-C0004391
,	O
which	O
was	O
associated	B-C0332281
with	I-C0332281
the	O
blockade	B-C0332206
of	O
akt	B-C0164786
/	O
mtor	B-C1453984
/	O
foxo3a	B-C1506134
signal	B-C0037080
pathway	I-C0037080
,	O
validated	O
by	O
sc79	B-C4307495
,	O
mk2206	B-C2933427
,	O
and	O
3-ma	B-C0047569
,	O
the	O
akt	B-C0164786
agonist	B-C2987634
,	O
inhibitor	B-C0243077
and	O
autophagy	B-C0004391
inhibitor	B-C0243077
in	B-C0681828
vitro	I-C0681828
.	O
	
the	O
overexpression	B-C1514559
of	O
constitutively	O
active	O
akt	B-C0164786
completely	O
abolished	O
the	O
cucurbitacin	B-C0056580
b	I-C0056580
-mediated	O
protection	O
of	O
cardiac	B-C1383860
hypertrophy	I-C1383860
in	O
human	B-C0086418
cardiomyocytes	B-C0225828
ac16	I-C0225828
.	O
	
collectively	O
,	O
our	O
findings	O
suggest	O
that	O
cucurbitacin	B-C0056580
b	I-C0056580
protects	O
against	O
cardiac	B-C1383860
hypertrophy	I-C1383860
through	O
increasing	O
the	O
autophagy	B-C0004391
level	O
in	O
cardiomyocytes	B-C0225828
,	O
which	O
is	O
associated	B-C0332281
with	I-C0332281
the	O
inhibition	B-C1519312
of	O
akt	B-C0164786
/	O
mtor	B-C1453984
/	O
foxo3a	B-C1506134
signal	B-C0037080
axis	I-C0037080
.	O
	
inflammatory	B-C0333348
and	O
oxidative	B-C0242606
stress	I-C0242606
markers	B-C0005516
in	O
experimental	B-C1517586
allergic	B-C0155877
asthma	I-C0155877
ovalbumin	B-C0029923
-	O
induced	B-C0205263
allergic	B-C0002390
lung	I-C0002390
inflammation	I-C0002390
ali	B-C0002390
is	O
a	O
condition	B-C0348080
believed	O
to	O
be	O
mediated	O
by	O
cytokines	B-C0079189
,	O
extracellular	B-C0015350
matrix	I-C0015350
remodeling	B-C1820201
,	O
and	O
redox	B-C0030012
imbalance	B-C1397014
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
evaluated	B-C0220825
pulmonary	B-C0231921
function	I-C0231921
together	O
with	O
inflammatory	B-C0333348
markers	B-C0005516
as	O
interleukin-4	B-C0021758
il-4	B-C0021758
,	O
myeloperoxidase	B-C0027021
mpo	B-C0027021
,	O
eosinophil	B-C0014467
cells	I-C0014467
,	O
and	O
redox	B-C0030012
markers	B-C0005516
in	O
the	O
lungs	B-C0024109
of	O
balb/c	B-C0025919
mice	I-C0025919
after	O
ovalbumin	B-C0029923
ova	B-C0029923
sensitization	B-C1325847
and	O
challenge	B-C0022885
.	O
	
our	O
results	B-C1274040
showed	O
an	O
increase	B-C0442805
in	O
bronchial	B-C0085129
hyperresponsiveness	I-C0085129
stimulated	B-C1948023
by	O
methacholine	B-C0600370
mch	B-C0600370
,	O
inflammatory	B-C0333348
cell	B-C0007613
influx	I-C0007613
,	O
especially	O
eosinophils	B-C0014467
together	O
with	O
an	O
increase	B-C0442805
of	O
high	B-C0019796
mobility	I-C0019796
group	I-C0019796
box	I-C0019796
1	I-C0019796
hmgb1	B-C0019796
and	O
altered	O
lipid	B-C0023775
peroxidation	I-C0023775
lp	B-C0023775
and	O
antioxidant	B-C0003402
defenses	B-C1880266
in	O
the	O
ova	B-C0029923
group	B-C0681860
compared	O
to	O
the	O
control	B-C0009932
group	I-C0009932
p	O
0.5	O
.	O
	
thus	O
,	O
we	O
demonstrated	O
that	O
ova	B-C0029923
-	O
induced	B-C0205263
ali	B-C0002390
altered	O
redox	B-C0030012
status	O
concomitantly	B-C0521115
with	O
impaired	B-C0221099
lung	B-C0035245
function	I-C0035245
,	O
which	O
was	O
associated	B-C0332281
with	I-C0332281
hmgb1	B-C0019796
expression	B-C1171362
and	O
proteolytic	B-C0597304
remodeling	B-C1820201
.	O
	
taken	O
together	O
all	O
results	B-C1274040
found	O
here	O
,	O
we	O
may	O
suggest	O
hmgb1	B-C0019796
is	O
an	O
important	B-C3898777
therapeutic	B-C0302350
target	B-C1521840
for	O
asthma	B-C0004096
,	O
once	O
orchestrates	B-C0205556
the	O
redox	B-C0030012
signaling	B-C3537152
,	O
inflammation	B-C0021368
,	O
and	O
remodeling	B-C3714634
that	O
contribute	O
to	O
the	O
disease	B-C0012634
development	B-C1527148
.	O
	
association	B-C0439849
among	O
prematurity	B-C0021294
<30	B-C0017504
weeks'	I-C0017504
gestational	I-C0017504
age	I-C0017504
,	O
blood	B-C0005823
pressure	I-C0005823
,	O
urinary	B-C1524119
albumin	B-C2362049
,	O
calcium	B-C0006675
,	O
and	O
phosphate	B-C0031603
in	O
early	B-C0599196
childhood	I-C0599196
there	O
is	O
a	O
paucity	O
of	O
data	B-C1511726
on	O
blood	B-C0005823
pressures	I-C0005823
bp	B-C0005823
,	O
urinary	B-C1524119
albumin	B-C2362049
,	O
and	O
mineral	B-C0026162
excretion	B-C0221102
in	O
early	B-C0599196
childhood	I-C0599196
in	O
contemporary	B-C1254367
cohorts	B-C0599755
of	O
extremely	B-C0205403
low	B-C0205251
gestational	B-C0017504
age	I-C0017504
ga	B-C0017504
neonates	B-C0021289
.	O
	
our	O
aim	O
was	O
to	O
compare	B-C1707455
bps	B-C0005823
and	O
the	O
urinary	B-C1524119
excretion	B-C0221102
of	O
albumin	B-C2362049
,	O
calcium	B-C0006675
,	O
and	O
phosphate	B-C0031603
in	O
preterm	B-C2964377
and	O
term-born	B-C0233324
cohorts	B-C0599755
in	O
early	B-C0599196
childhood	I-C0599196
.	O
	
this	O
was	O
a	O
prospective	B-C0033522
observational	I-C0033522
study	I-C0033522
conducted	O
at	O
a	O
single	B-C0205171
center	B-C0475309
,	O
involving	B-C1314939
children	B-C0008059
<5	B-C0001779
years	I-C0001779
age	I-C0001779
,	O
born	B-C0151526
preterm	I-C0151526
ga	B-C0460089
<30	I-C0460089
weeks	I-C0460089
or	O
at	B-C0233324
term	I-C0233324
37	B-C3536634
weeks'	I-C3536634
ga	I-C3536634
.	O
	
urinary	B-C0587185
albumin	I-C0587185
mg/l	O
,	O
calcium	B-C0428302
and	O
phosphate	B-C0428304
levels	I-C0428304
indexed	B-C0918012
to	O
creatinine	B-C0010294
mg/dl	O
,	O
and	O
bp	B-C0005823
were	O
measured	B-C0444706
.	O
	
the	O
median	B-C2939193
iqr	B-C1711350
follow-up	B-C1522577
age	B-C0001779
of	O
our	O
cohort	B-C0599755
n	O
=	O
106	O
was	O
30	O
16-48	O
months	B-C0439231
.	O
	
preterm-born	B-C4048294
children	I-C4048294
n	O
=	O
55	O
had	O
a	O
significantly	B-C4055638
lower	I-C4055638
mean	B-C0444504
ga	B-C0017504
and	O
birth	B-C0005612
weight	I-C0005612
and	O
higher	B-C0205250
mean	B-C0444504
systolic	B-C0871470
,	O
diastolic	B-C0428883
,	O
and	O
mean	B-C0428886
bps	I-C0428886
,	O
compared	B-C1707455
with	O
term	B-C0233324
n	O
=	O
51	O
controls	B-C0009932
.	O
	
a	O
significantly	B-C4055637
higher	I-C4055637
proportion	B-C1709707
of	O
preterm-born	B-C4048294
children	I-C4048294
weighed	B-C0005910
<10th	B-C3276033
centile	I-C3276033
and	O
had	O
systolic	B-C0871470
bp	I-C0871470
>95th	B-C0243095
centile	I-C0243095
at	O
follow-up	B-C1522577
.	O
	
albumin	B-C2362049
and	O
calcium	B-C0006675
excretion	B-C0221102
did	O
not	B-C3842396
differ	I-C3842396
between	O
the	O
groups	B-C0681860
median	B-C0876920
urine-phosphate	B-C2735243
creatinine	I-C2735243
ratios	I-C2735243
were	O
higher	B-C0205250
in	O
the	O
preterm	B-C4048294
group	I-C4048294
.	O
	
on	O
logistic	B-C0206031
regression	I-C0206031
,	O
lower	B-C0205251
ga	B-C0017504
and	O
younger	B-C0332239
age	B-C0001779
at	O
follow-up	B-C1522577
were	O
significantly	B-C0750502
associated	B-C0332281
with	I-C0332281
an	O
increased	B-C0205217
risk	B-C0035647
of	O
systolic	B-C0871470
and	O
diastolic	B-C0428883
bp	I-C0428883
above	O
the	O
95th	B-C0243095
centile	I-C0243095
male	B-C0086582
gender	I-C0086582
was	O
associated	B-C0332281
with	I-C0332281
decreased	B-C0205216
risk	B-C0035647
of	O
diastolic	B-C0235222
hypertension	I-C0235222
.	O
	
even	O
in	O
early	B-C0599196
childhood	I-C0599196
,	O
children	B-C4048294
born	I-C4048294
preterm	I-C4048294
had	O
significantly	B-C0750502
elevated	B-C3163633
bp	B-C0005823
,	O
compared	B-C1707455
with	O
their	O
term-born	B-C0233324
counterparts	B-C0009932
.	O
	
closer	O
monitoring	B-C1283169
of	O
bps	B-C0005823
in	O
this	O
population	B-C1257890
recombinant	B-C0034861
protein	B-C1514562
transduction	I-C1514562
domain	I-C1514562
-	O
cu/zn	B-C0010461
superoxide	I-C0010461
dismutase	I-C0010461
alleviates	B-C0392756
bone	B-C0279530
cancer	I-C0279530
pain	B-C0596240
via	O
peroxiredoxin	B-C0914290
4	I-C0914290
modulation	B-C1148560
and	O
antioxidation	B-C1148560
bone	B-C0279530
cancer	I-C0279530
pain	B-C0596240
bcp	B-C0596240
is	O
a	O
serious	B-C0205404
chronic	B-C0205191
clinical	B-C0348080
condition	I-C0348080
and	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
ros	B-C0162772
were	O
considered	B-C0750591
to	O
be	O
involved	B-C1314939
in	O
its	O
development	B-C1527148
and	O
persistency	B-C0205322
.	O
	
normally	B-C0205307
,	O
superoxide	B-C0038838
dismutase	I-C0038838
sod	B-C0038838
converts	O
superoxide	B-C0038836
anions	I-C0038836
to	O
hydrogen	B-C0020281
peroxide	I-C0020281
h2o2	B-C0020281
and	O
h2o2	B-C0020281
is	O
then	O
naturalized	O
to	O
be	O
water	B-C0043047
by	O
peroxiredoxin	B-C0914290
4	I-C0914290
.	O
	
we	O
reported	B-C0684224
previously	O
that	O
recombinant	B-C0034861
protein	B-C1514562
transduction	I-C1514562
domain	I-C1514562
ptd	B-C1514562
cu/zn	B-C0010461
sod	I-C0010461
effectively	B-C1704419
scavenged	B-C1148560
excessive	B-C0442802
ros	B-C0162772
and	O
prevented	B-C1292733
cardiomyocytes	B-C0225828
from	O
hypoxia-reoxygenation	B-C0542341
damage	B-C1883709
.	O
	
however	O
,	O
whether	O
ptd	B-C1514562
-	O
cu/zn	B-C0010461
sod	I-C0010461
would	O
prevent	B-C1292733
bcp	B-C0596240
development	B-C1527148
is	O
unknown	B-C0439673
.	O
	
in	O
the	O
current	B-C0521116
study	B-C0681814
,	O
we	O
found	B-C0150312
that	O
an	O
implanted	B-C0021102
carcinoma	B-C0007097
in	O
the	O
rat	B-C0034721
tibia	B-C0040184
induced	B-C0205263
remarkable	O
hyperalgesia	B-C0020429
,	O
increased	B-C0205217
h2o2	B-C0020281
levels	B-C0441889
and	O
decreased	B-C0205216
sod	B-C0038838
and	O
peroxiredoxin	B-C0914290
4	I-C0914290
levels	B-C0441889
.	O
	
after	O
administration	B-C1521801
of	O
recombinant	B-C0034861
ptd	B-C1514562
-	O
cu/zn	B-C0010461
sod	I-C0010461
to	O
these	O
tumor-burden	B-C1516167
rats	B-C0034721
,	O
their	O
hyperalgesia	B-C0020429
was	O
significantly	B-C0750502
attenuated	B-C0599946
and	O
peroxiredoxin	B-C0914290
4	I-C0914290
expression	B-C1171362
was	O
significantly	B-C4055637
increased	I-C4055637
.	O
	
in	B-C0332287
addition	I-C0332287
,	O
an	O
increased	B-C0205217
expression	B-C0597360
of	O
n-methyl-d-aspartic	B-C0080093
acid	I-C0080093
nmda	I-C0080093
receptors	I-C0080093
and	O
a	O
decreased	B-C0205216
expression	B-C0597360
of	O
γ-aminobutyric	B-C0206518
acid	I-C0206518
gaba	I-C0206518
receptors	I-C0206518
in	O
this	O
cancer	B-C0596240
pain	I-C0596240
were	O
prevented	B-C1292733
by	O
ptd	B-C1514562
-	O
cu/zn	B-C0010461
sod	I-C0010461
administration	B-C1521801
or	O
peroxiredoxin	B-C0914290
4	I-C0914290
overexpression	B-C1514559
.	O
	
our	O
data	B-C1511726
suggested	B-C1705535
that	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
,	O
at	O
least	O
in	O
part	O
,	O
play	O
a	O
role	B-C1705810
in	O
cancer	B-C0027627
metastatic	I-C0027627
pain	B-C0596240
development	B-C1527148
and	O
persistency	B-C0205322
which	O
can	O
be	O
attenuated	B-C0332161
by	I-C0332161
the	O
adminstration	B-C1521801
of	O
recombinant	B-C0034861
ptd	I-C0034861
-	O
cu/zn	B-C0010461
sod	I-C0010461
via	O
the	O
peroxiredoxin	B-C0914290
4	I-C0914290
modulation	B-C1148560
from	O
oxidative	B-C0242606
stress	I-C0242606
.	O
	
immune	B-C1844666
dysregulation	I-C1844666
in	O
offspring	B-C0680063
of	O
a	O
bipolar	B-C0005586
parent	B-C0030551
.	O
	
altered	O
serum	B-C0229671
levels	B-C0441889
of	O
immune	B-C0439662
growth	B-C0018284
factors	I-C0018284
at	O
adolescent	B-C0205653
age	I-C0205653
immune	B-C1844666
dysregulation	I-C1844666
plays	O
a	O
role	O
in	O
the	O
vulnerability	B-C1821973
for	O
mood	B-C0525045
disorders	I-C0525045
.	O
	
immune	B-C0439662
growth	B-C0018284
factors	I-C0018284
,	O
such	O
as	O
stem	B-C0143630
cell	I-C0143630
factor	I-C0143630
scf	B-C0143630
,	O
insulin-like	B-C0123257
growth	I-C0123257
factor-binding	I-C0123257
protein-2	I-C0123257
igf-bp2	B-C0123257
,	O
epidermal	B-C0242275
growth	I-C0242275
factor	I-C0242275
egf	B-C0242275
,	O
il-7	B-C0021761
and	O
scd25	B-C0487019
have	O
repeatedly	O
been	O
reported	O
altered	B-C0392747
in	O
patients	B-C0030705
with	O
mood	B-C0525045
disorders	I-C0525045
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
levels	B-C0441889
of	O
these	O
factors	B-C0018284
in	O
serum	B-C0229671
of	O
adolescent	B-C0205653
bipolar	B-C0005586
offspring	B-C0680063
,	O
who	O
have	O
a	O
heightened	B-C0442803
risk	B-C0035647
for	O
mood	B-C0525045
disorder	I-C0525045
development	B-C1527148
and	O
to	O
also	O
analyze	B-C0936012
the	O
data	B-C1511726
combined	O
with	O
previously	O
published	B-C1704324
data	I-C1704324
.	O
	
growth	B-C0018284
factors	I-C0018284
were	O
assessed	B-C1516048
by	O
cba	B-C0005507
/	O
elisa	B-C0014441
in	O
adolescent	B-C0205653
bipolar	B-C0005586
offspring	B-C0680063
n=96	O
,	O
mean	B-C0444504
age	B-C0001779
=16	O
years	B-C0439234
and	O
in	O
age	B-C0001779
-	O
and	O
gender	B-C0079399
-	O
matched	B-C1708943
healthy	B-C3898900
controls	B-C0009932
n=50	O
.	O
	
egf	B-C0242275
belonged	O
to	O
a	O
mutually	O
correlating	B-C1707520
cluster	B-C1704332
of	O
mainly	O
neurotrophic	B-C0132298
compounds	I-C0132298
including	O
s100b	B-C3711149
and	O
bdnf	B-C3486709
,	O
which	O
were	O
in	O
general	O
decreased	B-C0205216
in	O
serum	B-C0229671
.	O
	
il-7	B-C0021761
,	O
scf	B-C0143630
,	O
igf-bp2	B-C0123257
and	O
scd25	B-C0487019
,	O
belonged	O
to	O
a	O
different	O
mutually	O
correlating	B-C1707520
cluster	B-C1704332
of	O
immune	B-C0439662
growth	B-C0018284
factors	I-C0018284
,	O
which	O
were	O
in	O
general	O
increased	B-C0205217
igf-bp2	B-C0123257
significantly	B-C0750502
in	O
serum	B-C0229671
of	O
offspring	B-C0680063
without	O
a	O
mood	B-C0525045
disorder	I-C0525045
,	O
il-7	B-C0021761
and	O
scf	B-C0143630
in	O
serum	B-C0229671
of	O
offspring	B-C0680063
who	O
had	O
expirienced	B-C0596545
a	O
mood	B-C0525045
episode	I-C0525045
.	O
	
this	O
pattern	B-C0449774
of	O
de	B-C0547047
-	O
and	O
increases	B-C0442805
was	O
not	O
different	O
between	O
bipolar	B-C0005586
offspring	B-C0680063
that	O
developed	O
or	O
did	O
not	O
develop	O
a	O
mood	B-C0525045
disorder	I-C0525045
over	O
time	B-C0040223
,	O
apart	O
from	O
the	O
igf-bp2	B-C0123257
level	B-C0441889
,	O
which	O
was	O
near	O
significantly	B-C0750502
higher	O
in	O
offspring	B-C0680063
later	O
developing	O
a	O
mood	B-C0525045
disorder	I-C0525045
.	O
	
correlations	B-C1707520
with	O
the	O
previously	O
published	B-C1704324
immune-cellular	B-C4023612
abnormalities	I-C4023612
were	O
not	O
found	O
.	O
	
in	O
conclusion	B-C1707478
non-affected	O
adolescents	B-C0205653
at	O
familial	B-C0241888
mood	B-C0525045
disorder	I-C0525045
development	B-C1527148
risk	B-C0035647
were	O
characterized	B-C1880022
by	O
a	O
distinct	O
pattern	B-C0449774
of	O
a	O
series	O
of	O
compounds	B-C0018284
operating	O
in	O
a	O
network	B-C1882071
of	O
hematopoiesis	B-C0018951
,	O
neurogenesis	B-C0814002
and	O
enos	B-C0132555
s-nitrosylates	B-C1159123
β-actin	B-C0005186
on	O
cys374	B-C0010654
and	O
regulates	B-C1327623
pkc-θ	B-C0171420
at	O
the	O
immune	B-C1171348
synapse	I-C1171348
by	O
impairing	B-C0221099
actin	B-C1149245
binding	I-C1149245
to	O
profilin-1	B-C0525216
the	O
actin	B-C1155966
cytoskeleton	I-C1155966
coordinates	I-C1155966
the	I-C1155966
organization	I-C1155966
of	O
signaling	B-C0021054
microclusters	I-C0021054
at	O
the	O
immune	B-C1171348
synapse	I-C1171348
is	B-C1171348
however	O
,	O
the	O
mechanisms	B-C3537153
involved	O
remain	O
poorly	O
understood	O
.	O
	
we	O
show	O
here	O
that	O
nitric	B-C0028128
oxide	I-C0028128
no	B-C0028128
generated	O
by	O
endothelial	B-C0132555
nitric	I-C0132555
oxide	I-C0132555
synthase	I-C0132555
enos	B-C0132555
controls	O
the	O
coalescence	O
of	O
protein	B-C0171420
kinase	I-C0171420
c-θ	I-C0171420
pkc-θ	B-C0171420
at	O
the	O
central	B-C1171348
supramolecular	I-C1171348
activation	I-C1171348
cluster	I-C1171348
c-smac	B-C1171348
of	O
the	O
is	B-C1171348
.	O
	
enos	B-C0132555
translocated	B-C0599893
with	O
the	O
golgi	B-C0018042
to	O
the	O
is	B-C1171348
and	O
partially	O
colocalized	B-C0392752
with	O
f-actin	B-C1180307
around	O
the	O
c-smac	B-C1171348
.	O
	
this	O
resulted	O
in	O
reduced	O
actin	B-C1155982
polymerization	I-C1155982
and	O
centripetal	O
retrograde	B-C1709934
flow	I-C1709934
of	O
β-actin	B-C0005186
and	O
pkc-θ	B-C0171420
from	O
the	O
lamellipodium-like	B-C0230628
distal	B-C0205108
d	B-C1171348
,	O
promoting	B-C0033414
pkc-θ	B-C0171420
activation	B-C0014429
.	O
	
furthermore	O
,	O
enos	B-C0132555
-derived	O
no	B-C0028128
s-nitrosylated	B-C1159123
β-actin	B-C0005186
on	O
cys374	B-C0010654
and	O
impaired	B-C0221099
actin	B-C1149245
binding	I-C1149245
to	O
profilin-1	B-C0525216
pfn1	B-C0525216
,	O
as	O
confirmed	O
with	O
the	O
transnitrosylating	B-C3158785
agent	O
s-nitroso-l-cysteine	B-C0073896
cys-no	B-C0073896
.	O
	
the	O
importance	O
of	O
no	B-C0028128
and	O
the	O
formation	O
of	O
pfn1-actin	B-C1180347
complexes	I-C1180347
on	O
the	O
regulation	B-C1327623
of	O
pkc-θ	B-C0171420
was	O
corroborated	O
by	O
overexpression	B-C1514559
of	O
pfn1	B-C1456390
-	O
and	O
actin-binding	B-C1149245
defective	O
mutants	B-C0596988
of	O
β-actin	B-C1384510
c374s	I-C1384510
and	O
pfn1	B-C1456390
h119e	I-C1456390
,	O
respectively	O
,	O
which	O
reduced	O
the	O
coalescence	O
of	O
pkc-θ	B-C0171420
at	O
the	O
c-smac	B-C1171348
.	O
	
these	O
findings	O
unveil	O
a	O
novel	O
no	B-C0028128
-dependent	O
mechanism	B-C3537153
by	O
which	O
the	O
actin	B-C1155966
cytoskeleton	I-C1155966
controls	I-C1155966
the	I-C1155966
organization	I-C1155966
and	O
activation	B-C1879547
of	O
signaling	B-C0021054
microclusters	I-C0021054
at	O
the	O
dobutamine	B-C0949700
stress	I-C0949700
echocardiography	I-C0949700
impact	B-C4049986
of	O
abnormal	B-C0205161
blood	B-C1261540
potassium	I-C1261540
levels	I-C1261540
on	O
cardiac	B-C0003811
arrhythmias	I-C0003811
guidelines	B-C0162791
suggest	O
that	O
an	O
abnormal	B-C0205161
blood	B-C1261540
potassium	I-C1261540
level	I-C1261540
is	O
a	O
relative	O
contraindication	B-C0522473
to	O
performing	B-C0884358
dobutamine	B-C0949700
stress	I-C0949700
echocardiography	I-C0949700
dse	B-C0949700
.	O
	
however	O
,	O
this	O
has	O
not	O
been	O
previously	O
studied	O
.	O
	
we	O
reviewed	B-C1709940
a	O
consecutive	B-C2985408
series	I-C2985408
of	I-C2985408
patients	I-C2985408
who	O
had	O
potassium	B-C0032821
testing	B-C0039593
within	O
48	O
hours	B-C0439227
of	O
undergoing	O
dse	B-C0949700
for	O
the	O
evaluation	B-C0220825
of	O
myocardial	B-C0151744
ischemia	I-C0151744
over	O
a	O
10-	O
year	B-C0439234
period	B-C1948053
n	O
=	O
13	O
.	O
	
normal	O
potassium	B-C0032821
range	B-C1514721
in	O
our	O
laboratory	B-C0022877
is	O
3.6	O
mmol/l	O
.	O
	
hemolyzed	B-C0475880
samples	I-C0475880
were	O
not	O
included	O
.	O
	
the	O
association	B-C0439849
of	O
potassium	B-C0428289
levels	I-C0428289
with	O
the	O
development	B-C1527148
of	O
supraventricular	B-C0428974
and	O
ventricular	B-C0085612
arrhythmias	I-C0085612
was	O
assessed	B-C1516048
.	O
	
the	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	B-C0003811
was	O
very	O
low	B-C0205251
supraventricular	B-C0039240
tachycardia	I-C0039240
/	O
atrial	B-C0004238
fibrillation	I-C0004238
,	O
4.9	O
nonsustained	B-C2919575
ventricular	I-C2919575
tachycardia	I-C2919575
,	O
2.9	O
sustained	B-C0750197
ventricular	I-C0750197
tachycardia	I-C0750197
or	O
ventricular	B-C0042510
fibrillation	I-C0042510
,	O
0.1	O
,	O
confirming	O
the	O
overall	B-C0036043
safety	I-C0036043
of	O
dse	B-C0949700
.	O
	
most	O
arrhythmias	B-C0003811
88%	O
occurred	O
in	O
patients	B-C0030705
with	O
normal	O
potassium	B-C0428289
levels	I-C0428289
,	O
and	O
arrhythmia	B-C0003811
rates	B-C1521828
remained	O
low	B-C0205251
in	O
patients	B-C0030705
with	O
potassium	B-C0032821
abnormalities	B-C1704258
.	O
	
patients	B-C0030705
with	O
hyperkalemia	B-C0020461
had	O
a	O
lower	O
risk	B-C0035647
of	O
developing	O
mild	B-C2945599
odds	B-C0028873
ratio	I-C0028873
or	B-C0028873
,	O
0.39	O
95%	O
ci	B-C0009667
,	O
0.22	O
and	O
severe	B-C0205082
or	B-C0028873
,	O
0.13	O
95%	O
ci	B-C0009667
,	O
0.01	O
supraventricular	B-C0428974
arrhythmias	I-C0428974
as	O
well	O
as	O
mild	B-C2945599
ventricular	B-C0085612
arrhythmias	I-C0085612
or	B-C0028873
,	O
0.58	O
95%	O
ci	B-C0009667
,	O
0.40	O
.	O
	
even	O
though	O
events	O
were	O
rare	B-C0522498
,	O
patients	B-C0030705
with	O
severe	B-C0205082
hypokalemia	B-C0020621
potassium	B-C0428289
levels	I-C0428289
3.1	O
mmol/l	O
had	O
an	O
increased	B-C0205217
risk	B-C0035647
of	O
supraventricular	B-C0428974
arrhythmia	I-C0428974
and	O
ventricular	B-C0012634
ectopy	I-C0012634
.	O
	
dse	B-C0949700
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	B-C1704258
in	O
blood	B-C1261540
potassium	I-C1261540
concentrations	I-C1261540
,	O
and	O
hence	O
cancellation	O
of	O
dse	B-C0949700
in	O
patients	B-C0030705
with	O
potassium	B-C0032821
abnormalities	B-C1704258
does	O
not	O
appear	O
warranted	O
.	O
	
elevated	B-C3163633
potassium	B-C0428289
levels	I-C0428289
are	O
associated	B-C0332281
with	I-C0332281
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	B-C0428974
and	O
ventricular	B-C0085612
arrhythmias	I-C0085612
.	O
	
while	O
remaining	O
at	O
relatively	O
low	B-C0205251
risk	B-C0035647
,	O
patients	B-C0030705
with	O
very	O
low	B-C0205251
potassium	B-C0428289
levels	I-C0428289
3.1	O
mmol/l	O
at	O
the	O
time	O
of	O
dse	B-C0949700
have	O
a	O
modestly	O
increased	B-C0205217
risk	B-C0035647
of	O
arrhythmia	B-C0003811
.	O
	
consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	B-C0205082
hypokalemia	B-C0020621
prior	B-C0332152
to	O
anatomical	B-C0220784
subgroup	B-C1515021
analysis	B-C0936012
of	O
the	O
meridian	B-C0681784
cohort	B-C0599755
posterior	B-C3280768
fossa	I-C3280768
abnormalities	I-C3280768
to	O
assess	B-C0184514
the	O
diagnostic	B-C0348026
and	O
clinical	B-C0205210
contribution	B-C1880177
of	O
in	B-C0024485
utero	I-C0024485
magnetic	I-C0024485
resonance	I-C0024485
iumr	I-C0024485
imaging	I-C0024485
in	O
fetuses	B-C0015965
diagnosed	B-C0011900
with	O
abnormalities	B-C3280768
of	I-C3280768
the	I-C3280768
posterior	I-C3280768
fossa	I-C3280768
as	O
the	O
only	O
intracranial	B-C3809358
abnormality	I-C3809358
recognised	O
on	O
antenatal	B-C0080265
ultrasonography	I-C0080265
uss	B-C0080265
.	O
	
we	O
report	B-C0684224
a	O
sub-group	B-C1515021
analysis	B-C0936012
of	O
fetuses	B-C0015965
with	O
abnormalities	B-C3280768
of	I-C3280768
the	I-C3280768
posterior	I-C3280768
fossa	I-C3280768
diagnosed	B-C0011900
on	O
antenatal	B-C0080265
uss	I-C0080265
with	O
or	O
without	O
ventriculomegaly	B-C0743968
from	O
the	O
meridian	B-C0681784
cohort	B-C0599755
who	O
had	O
iumr	B-C0024485
imaging	I-C0024485
within	O
2	O
weeks	O
of	O
uss	B-C0080265
and	O
outcome	B-C0085415
reference	B-C1554143
data	I-C1554143
were	O
available	B-C0470187
.	O
	
the	O
diagnostic	B-C0598285
accuracy	I-C0598285
of	O
uss	B-C0080265
and	O
iumr	B-C0024485
are	O
reported	B-C0684224
as	O
well	O
as	O
indicators	B-C0021212
of	O
diagnostic	B-C0598285
confidence	I-C0598285
and	O
effects	B-C1280500
on	O
prognosis	B-C0033325
and	O
clinical	B-C1516615
management	I-C1516615
.	O
	
abnormalities	B-C3280768
confined	I-C3280768
to	I-C3280768
the	I-C3280768
posterior	I-C3280768
fossa	I-C3280768
according	O
to	O
uss	B-C0080265
were	O
found	O
in	O
81	O
fetuses	B-C0015965
67	O
with	O
parenchymal	B-C0682552
and	O
14	O
with	O
csf	B-C0007806
-containing	O
lesions	B-C0221198
.	O
	
the	O
overall	O
diagnostic	B-C0598285
accuracy	I-C0598285
for	O
detecting	B-C0442726
an	O
isolated	B-C0205409
posterior	B-C3280768
fossa	I-C3280768
abnormality	I-C3280768
was	O
65%	O
for	O
uss	B-C0080265
and	O
88%	O
for	O
iumr	B-C0024485
difference	B-C1705241
=	O
22%	O
,	O
95%	O
ci	O
14.0	O
to	O
30.5	O
,	O
p	O
<	O
0.0001	O
.	O
	
there	O
was	O
an	O
improvement	B-C2986411
in	O
'	O
appropriate	B-C1548787
'	O
diagnostic	B-C0598285
confidence	I-C0598285
as	O
assessed	B-C0184514
by	O
a	O
score	B-C0449820
-	O
based	B-C1527178
weighted	B-C0043100
average	B-C1510992
'	O
method	B-C0025663
p	O
<	O
0.0001	O
and	O
a	O
three-fold	O
reduction	B-C0441610
in	O
'high	B-C0205250
confidence	O
but	O
incorrect	B-C3827420
diagnoses	B-C0011900
'	O
was	O
achieved	O
by	O
using	O
iumr	B-C0024485
imaging	I-C0024485
.	O
	
the	O
prognostic	B-C0033325
information	I-C0033325
given	O
to	O
the	O
women	B-C0043210
after	O
iumr	B-C0024485
imaging	I-C0024485
changed	O
in	O
44%	O
of	O
cases	B-C1706256
and	O
the	O
overall	B-C1561607
effect	B-C1280500
of	O
iumr	B-C0024485
on	O
clinical	B-C1516615
management	I-C1516615
was	O
considered	O
to	O
be	O
'	O
significant	B-C0750502
'	O
,	O
'	O
major	B-C0205164
'	O
or	O
'	O
decisive	B-C0564585
'	O
in	O
35%	O
of	O
cases	B-C1706256
.	O
	
our	O
data	B-C1511726
suggests	O
that	O
any	O
woman	B-C0043210
whose	O
fetus	B-C0015965
has	O
a	O
posterior	B-C3280768
fossa	I-C3280768
abnormality	I-C3280768
as	O
the	O
only	O
intracranial	B-C3809358
finding	I-C3809358
on	O
uss	B-C0080265
should	O
have	O
iumr	B-C0024485
imaging	I-C0024485
for	O
further	O
evaluation	B-C0220825
.	O
	
this	O
is	O
on	O
the	O
basis	B-C1527178
of	O
improved	B-C0184511
diagnostic	B-C0598285
accuracy	I-C0598285
and	O
confidence	B-C0598285
which	O
has	O
substantial	B-C0205082
effects	B-C1280500
on	O
the	O
prognostic	B-C0033325
information	I-C0033325
given	O
to	O
women	B-C0043210
and	O
changes	O
in	O
clinical	B-C1516615
management	I-C1516615
.	O
	
design	B-C1707689
,	O
synthesis	B-C1883254
,	O
and	O
evaluation	B-C0220825
of	O
curcumin	B-C0010467
derivatives	B-C0243072
as	O
nrf2	B-C0289507
activators	B-C0599177
and	O
cytoprotectors	B-C0524828
against	O
oxidative	B-C3893307
death	I-C3893307
activation	B-C0599177
of	O
nuclear	B-C0289507
factor	I-C0289507
erythroid-2-related	I-C0289507
factor	I-C0289507
2	I-C0289507
nrf2	B-C0289507
has	O
been	O
proven	O
to	O
be	O
an	O
effective	O
means	O
to	O
prevent	O
the	O
development	O
of	O
cancer	B-C0006826
,	O
and	O
natural	O
curcumin	B-C0010467
stands	O
out	O
as	O
a	O
potent	O
nrf2	B-C0289507
activator	B-C0599177
and	O
cancer	B-C0006826
chemopreventive	B-C1516463
agent	I-C1516463
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
synthesized	O
a	O
series	O
of	O
curcumin	B-C0010467
analogs	B-C0243071
by	O
introducing	O
the	O
geminal	B-C1254350
dimethyl	I-C1254350
substituents	I-C1254350
on	I-C1254350
the	I-C1254350
active	I-C1254350
methylene	I-C1254350
group	I-C1254350
to	O
find	O
more	O
potent	O
nrf2	B-C0289507
activators	B-C0599177
and	O
cytoprotectors	B-C0524828
against	O
oxidative	B-C3893307
death	I-C3893307
.	O
	
the	O
geminally	B-C1254350
dimethylated	I-C1254350
and	O
catechol	B-C0054858
-type	O
curcumin	B-C0010467
analog	B-C0243071
compound	B-C1254351
3	I-C1254351
was	O
identified	O
as	O
a	O
promising	O
lead	B-C1254351
molecule	I-C1254351
in	O
terms	O
of	O
its	O
increased	O
stability	B-C0314668
and	O
cytoprotective	B-C0524828
activity	B-C0441655
against	O
the	O
tert-butyl	B-C0076150
hydroperoxide	I-C0076150
t-bhp	B-C0076150
death	B-C0007587
of	O
hepg2	B-C2717940
cells	I-C2717940
.	O
	
mechanism	B-C0441712
studies	B-C2603343
indicate	O
that	O
its	O
cytoprotective	B-C0524828
effects	B-C1280500
are	O
mediated	O
by	O
activating	B-C1879547
the	O
nrf2	B-C0289507
signaling	B-C0037080
pathway	I-C0037080
in	O
the	O
michael	B-C1254351
acceptor	I-C1254351
-	O
and	O
catechol	B-C0054858
-dependent	O
manners	O
.	O
	
additionally	O
,	O
we	O
verified	O
by	O
using	O
copper	B-C0009968
and	O
iron	B-C0302583
ion	B-C0022023
chelators	B-C0007974
that	O
the	O
two	O
metal	B-C0025552
ion	B-C0022023
-mediated	O
oxidations	B-C0030011
of	O
compound	B-C1254351
3	I-C1254351
to	O
its	O
corresponding	O
electrophilic	O
o-quinone	B-C0034435
,	O
contribute	O
significantly	O
to	O
its	O
nrf2	B-C0289507
-dependent	O
cytoprotection	B-C0524828
.	O
	
this	O
work	O
provides	O
an	O
example	O
of	O
successfully	O
designing	B-C1707689
natural	B-C0205296
curcumin	B-C0010467
-directed	O
nrf2	B-C0289507
activators	B-C0599177
by	O
a	O
stability	B-C0314668
-increasing	O
and	O
proelectrophilic	B-C1254365
safe	B-C0036043
with	O
self-injury	B-C0424366
a	O
practical	B-C0681464
guide	I-C0681464
to	O
understanding	B-C0162340
,	O
responding	B-C0004927
and	O
harm-reduction	B-C0679771
inckle	B-C0805191
kay	I-C0805191
safe	B-C0036043
with	O
self-injury	B-C0424366
a	O
practical	B-C0681464
guide	I-C0681464
to	O
understanding	B-C0162340
,	O
responding	B-C0004927
and	O
harm-reduction	B-C0679771
274pp	O
23.99	O
pccs	O
books	O
9781910919163	O
1910919160	O
formula	O
see	O
text	O
the	O
author	B-C3812881
begins	O
her	O
book	B-C0006002
with	O
a	O
concise	B-C1806781
exploration	B-C1292732
of	O
the	O
stereotypes	B-C0038272
and	O
truths	B-C0205238
of	O
self-harm	B-C0424366
.	O
	
in	O
the	O
following	O
seven	O
chapters	B-C0005990
,	O
she	O
sets	O
out	O
a	O
grounded	B-C1510611
and	O
often	O
challenging	B-C0449911
view	I-C0449911
of	O
how	O
self-harm	B-C0424366
is	O
understood	B-C0162340
from	O
differing	O
pre-hospital	B-C1254367
policies	B-C0242456
for	O
the	O
care	B-C0017313
of	I-C0017313
patients	I-C0017313
with	O
acute	B-C0948089
coronary	I-C0948089
syndromes	I-C0948089
in	O
india	B-C0021201
a	O
policy	B-C0242456
document	B-C1301746
analysis	B-C0936012
ischemic	B-C0002962
heart	I-C0002962
disease	I-C0002962
is	O
the	O
leading	B-C1522538
cause	B-C0007465
of	I-C0007465
death	I-C0007465
in	O
india	B-C0021201
.	O
	
in	O
high-income	B-C0948433
countries	B-C0454664
,	O
pre-hospital	B-C1444165
systems	I-C1444165
of	I-C1444165
care	I-C1444165
have	O
been	O
developed	O
to	O
manage	B-C0184516
acute	B-C0205178
manifestations	B-C1280464
of	I-C1280464
ischemic	B-C0002962
heart	I-C0002962
disease	I-C0002962
,	O
such	O
as	O
acute	B-C0948089
coronary	I-C0948089
syndrome	I-C0948089
acs	B-C0948089
.	O
	
however	O
,	O
it	O
is	O
unknown	B-C0439673
whether	O
guidelines	B-C0162791
,	O
policies	B-C0242456
,	O
regulations	B-C0851285
,	O
or	O
laws	B-C0023150
exist	B-C2987476
to	O
guide	O
pre-hospital	B-C1254367
acs	B-C0948089
care	B-C0086388
in	O
india	B-C0021201
.	O
	
we	O
undertook	O
a	O
nation-wide	B-C1254362
document	B-C1301746
analysis	B-C0936012
to	O
address	O
this	O
gap	O
in	O
knowledge	B-C0376554
.	O
	
from	O
november	B-C3828767
2014	O
to	O
may	B-C3812381
2016	O
,	O
we	O
searched	B-C1706202
for	O
publicly	B-C0205556
available	B-C0470187
emergency	B-C1527398
care	I-C1527398
guidelines	B-C0162791
and	O
legislation	B-C0600657
addressing	O
pre-hospital	B-C1254367
acs	B-C0948089
care	B-C0086388
in	O
all	O
29	O
indian	B-C0021201
states	B-C1301808
and	O
7	O
union	B-C0017446
territories	I-C0017446
via	O
internet	B-C0282111
search	B-C1706202
and	O
direct	B-C1947931
correspondence	B-C0282413
.	O
	
we	O
found	B-C0150312
two	O
documents	B-C1301746
addressing	O
pre-hospital	B-C1254367
acs	B-C0948089
care	B-C0086388
.	O
	
though	O
india	B-C0021201
has	O
legislation	B-C0814715
mandating	I-C0814715
acute	B-C0679878
care	I-C0679878
for	O
emergencies	B-C0013956
such	O
as	O
trauma	B-C3714660
,	O
regulations	B-C0851285
or	O
laws	B-C0023150
to	O
guide	O
pre-hospital	B-C1254367
acs	B-C0948089
care	B-C0086388
are	O
largely	O
absent	B-C0332197
.	O
	
policy	B-C0242170
makers	I-C0242170
urgently	B-C0439609
need	B-C0027552
to	O
develop	O
comprehensive	B-C1880156
,	O
multi-stakeholder	B-C0205556
policies	B-C0242456
for	O
pre-hospital	B-C1254367
emergency	B-C0013956
cardiovascular	B-C4273565
care	I-C4273565
in	O
lack	B-C0332268
of	O
antimicrobial	B-C1271650
efficacy	B-C1280519
of	O
mecetronium	B-C0771499
etilsulfate	I-C0771499
in	O
propanol	B-C0175804
-based	O
hand	B-C1330330
rubs	I-C1330330
for	O
surgical	B-C0543467
hand	B-C0018570
disinfection	I-C0018570
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
determine	O
if	O
mecetronium	B-C0771499
etilsulfate	I-C0771499
mes	B-C0771499
contributes	O
to	O
overall	O
efficacy	B-C1280519
in	O
surgical	B-C0543467
hand	B-C0018570
disinfection	I-C0018570
.	O
	
three	O
blinded	O
hand	B-C1330330
rubs	I-C1330330
45%	O
iso-propanol	B-C0022237
,	O
30%	O
n-propanol	B-C0001964
were	O
applied	B-C4048755
for	O
1.5	O
min	O
and	O
compared	B-C1707455
with	O
the	O
en	B-C1254351
12791	I-C1254351
reference	O
procedure	B-C2700391
crossover	B-C0242817
design	I-C0242817
.	O
	
one	O
commercial	B-C0680536
hand	B-C1330330
rub	I-C1330330
contained	O
0.2	O
mes	B-C0771499
,	O
and	O
the	O
two	O
other	O
hand	B-C1330330
rubs	I-C1330330
were	O
identical	B-C0205280
apart	O
from	O
0.2	O
mes	B-C0771499
.	O
	
none	O
of	O
the	O
formulations	B-C1705957
had	O
a	O
log10	B-C1690986
reduction	B-C0392756
after	O
3	O
h	O
that	O
was	O
significantly	O
better	B-C0332272
compared	B-C1707455
with	O
the	O
reference	O
procedure	B-C2700391
mean	B-C0444504
1.72	O
standard	B-C0871420
deviation	I-C0871420
1.15	O
.	O
	
the	O
antimicrobial	B-C1271650
contribution	B-C1880177
of	O
mes	B-C0771499
in	O
hand	B-C1330330
rubs	I-C1330330
skin	B-C0814024
conductance	I-C0814024
responses	B-C0871261
and	O
neural	B-C3714606
activations	B-C1879547
during	O
fear	B-C0015726
conditioning	B-C0009647
and	O
extinction	B-C0015347
recall	B-C0034770
across	O
anxiety	B-C0003469
disorders	I-C0003469
the	O
fear	B-C0015726
conditioning	B-C0009647
and	O
extinction	B-C0015347
neurocircuitry	B-C0596723
has	O
been	O
extensively	B-C0205231
studied	B-C2603343
in	O
healthy	B-C3898900
and	O
clinical	B-C0205210
populations	B-C1257890
,	O
with	O
a	O
particular	B-C0205234
focus	I-C0205234
on	O
posttraumatic	B-C0038436
stress	I-C0038436
disorder	I-C0038436
.	O
	
despite	O
significant	B-C0750502
overlap	B-C1948020
of	O
symptoms	B-C1457887
between	O
posttraumatic	B-C0038436
stress	I-C0038436
disorder	I-C0038436
and	O
anxiety	B-C0003469
disorders	I-C0003469
,	O
the	O
latter	O
has	O
received	B-C1514756
less	B-C0439092
attention	B-C0004268
.	O
	
given	O
that	O
dysregulated	O
fear	B-C0015726
levels	B-C0441889
characterize	B-C1880022
anxiety	B-C0003469
disorders	I-C0003469
,	O
examining	B-C0582103
the	O
neural	B-C3714606
correlates	B-C1707520
of	O
fear	B-C0015726
and	O
extinction	B-C0015347
learning	B-C0023185
may	O
shed	O
light	O
on	O
the	O
pathogenesis	B-C0699748
of	O
underlying	O
anxiety	B-C0003469
disorders	I-C0003469
.	O
	
to	O
investigate	B-C1292732
the	O
psychophysiological	B-C0018467
and	O
neural	B-C3714606
correlates	B-C1707520
of	O
fear	B-C0015726
conditioning	B-C0009647
and	O
extinction	B-C0015347
recall	B-C0034770
in	O
anxiety	B-C0003469
disorders	I-C0003469
and	O
to	O
document	B-C1301746
how	O
these	O
features	B-C2348519
differ	O
as	O
a	O
function	B-C0542341
of	O
multiple	B-C0439064
diagnoses	B-C0011900
or	O
anxiety	B-C0003467
severity	B-C0439793
.	O
	
this	O
investigation	B-C0220825
was	O
a	O
cross-sectional	B-C0010362
,	O
case-control	B-C0872128
,	O
functional	B-C0376335
magnetic	I-C0376335
resonance	I-C0376335
imaging	I-C0376335
study	B-C2603343
at	O
an	O
academic	B-C0000872
medical	I-C0000872
center	I-C0000872
.	O
	
participants	B-C0679646
were	O
healthy	B-C3898900
controls	B-C0009932
and	O
individuals	B-C0237401
with	O
at	O
least	O
1	O
of	O
the	O
following	B-C0332282
anxiety	B-C0003469
disorders	I-C0003469
generalized	B-C0270549
anxiety	I-C0270549
disorder	I-C0270549
,	O
social	B-C4237417
anxiety	I-C4237417
disorder	I-C4237417
,	O
specific	B-C0236801
phobia	I-C0236801
,	O
and	O
panic	B-C0030319
disorder	I-C0030319
.	O
	
the	O
study	B-C2603343
dates	B-C0011008
were	O
between	O
march	O
2013	O
and	O
may	O
2015	O
.	O
	
two-day	O
fear	B-C0015726
conditioning	B-C0009647
and	O
extinction	B-C0015347
paradigm	B-C0681797
.	O
	
skin	B-C0814024
conductance	I-C0814024
responses	B-C0871261
,	O
blood	B-C1655730
oxygenation	I-C1655730
level-dependent	I-C1655730
responses	B-C0871261
,	O
trait	B-C0599883
anxiety	B-C3483978
scores	I-C3483978
from	O
the	O
state	B-C0683457
trait	I-C0683457
anxiety	I-C0683457
inventory	I-C0683457
-	O
trait	B-C0599883
form	B-C0348078
,	O
and	O
functiona	B-C0542341
l	O
connectivity	B-C1707489
.	O
	
this	O
study	B-C2603343
included	B-C2700399
21	O
healthy	B-C3898900
controls	B-C0009932
10	O
women	B-C0043210
and	O
61	O
individuals	B-C0237401
with	O
anxiety	B-C0003469
disorders	I-C0003469
36	O
women	B-C0043210
.	O
	
p	B-C1709380
values	I-C1709380
reported	B-C0700287
for	O
the	O
neuroimaging	B-C0679575
results	B-C0456984
are	O
all	O
familywise	B-C0015576
error	B-C0743559
corrected	B-C0205202
.	O
	
skin	B-C0814024
conductance	I-C0814024
responses	B-C0871261
during	O
extinction	B-C0015347
recall	B-C0034770
did	O
not	O
differ	O
between	O
individuals	B-C0237401
with	O
anxiety	B-C0003469
disorders	I-C0003469
and	O
healthy	B-C3898900
controls	B-C0009932
ηp2	B-C0392762
=	O
0.001	O
,	O
p	O
=	O
79	O
,	O
where	O
ηp2	B-C0392762
is	O
partial	B-C0392762
eta	I-C0392762
squared	I-C0392762
.	O
	
the	O
anxiety	B-C0003467
group	B-C1257890
had	O
lower	B-C0205251
activation	B-C1879547
of	O
the	O
ventromedial	B-C3850122
prefrontal	I-C3850122
cortex	I-C3850122
vmpfc	B-C3850122
during	O
extinction	B-C0015347
recall	B-C0034770
ηp2	B-C0392762
=	O
0.178	O
,	O
p	O
=	O
02	O
.	O
	
a	O
similar	O
hypoactive	B-C0086439
pattern	B-C0449774
was	O
found	O
during	O
early	B-C1279919
conditioning	B-C0009647
ηp2	B-C0392762
=	O
0.106	O
,	O
p	O
=	O
009	O
.	O
	
the	O
vmpfc	B-C3850122
hypoactivation	B-C1879547
was	O
associated	B-C0332281
with	I-C0332281
anxiety	B-C0860603
symptom	I-C0860603
severity	B-C0439793
r	O
=	O
-0	O
,	O
p	O
=	O
01	O
for	O
conditioning	B-C0009647
and	O
r	O
=	O
-0	O
,	O
p	O
=	O
004	O
for	O
extinction	B-C0015347
recall	B-C0034770
and	O
the	O
number	B-C0237753
of	O
co-occuring	B-C1709305
anxiety	B-C0003469
disorders	I-C0003469
diagnosed	B-C0011900
ηp2	B-C0392762
=	O
0.137	O
,	O
p	O
=	O
009	O
for	O
conditioning	B-C0009647
and	O
ηp2	B-C0392762
=	O
0.227	O
,	O
p	O
=	O
004	O
for	O
extinction	B-C0015347
recall	B-C0034770
.	O
	
psychophysiological	B-C0018467
interaction	B-C0237688
analyses	I-C0237688
revealed	B-C0443289
that	O
the	O
fear	B-C0015726
network	B-C0598941
connectivity	I-C0598941
differed	O
between	O
healthy	B-C3898900
controls	B-C0009932
and	O
the	O
anxiety	B-C0003467
group	B-C1257890
during	O
fear	B-C0015726
learning	B-C0023185
ηp2	B-C0392762
range	B-C1514721
between	O
0.088	O
and	O
0.176	O
and	O
p	B-C1709380
range	B-C1514721
between	O
0.02	O
and	O
0.003	O
and	O
extinction	B-C0015347
recall	B-C0034770
ηp2	B-C0392762
range	B-C1514721
between	O
0.111	O
and	O
0.235	O
and	O
p	B-C1709380
range	B-C1514721
between	O
0.02	O
and	O
0.002	O
.	O
	
despite	O
no	O
skin	B-C0814024
conductance	I-C0814024
response	B-C0871261
group	B-C1257890
differences	B-C1705241
during	O
extinction	B-C0015347
recall	B-C0034770
,	O
brain	B-C0006104
activation	B-C1879547
patterns	B-C0449774
between	O
anxious	B-C0849801
and	O
healthy	B-C3898900
individuals	B-C0237401
differed	O
.	O
	
these	O
findings	B-C0243095
encourage	O
future	B-C0016884
studies	B-C2603343
to	O
examine	B-C0582103
the	O
conditions	B-C0348080
longitudinally	B-C0023981
and	O
in	O
the	O
context	B-C0449255
of	O
treatment	B-C0008976
trials	I-C0008976
to	O
improve	B-C0184511
and	O
guide	B-C1562629
therapeutics	I-C1562629
via	O
advanced	B-C0205179
neurobiological	B-C0027817
understanding	B-C0162340
of	O
each	O
extracellular	B-C3894683
vesicles	I-C3894683
from	O
bone	B-C0005953
marrow	I-C0005953
derived	O
mesenchymal	B-C1257975
stem	I-C1257975
cells	I-C1257975
protect	B-C1545588
against	O
murine	B-C0026809
hepatic	B-C0920569
ischemia	I-C0920569
-	O
reperfusion	O
injury	O
hepatic	O
ischemia-reperfusion	O
injury	O
iri	O
and	O
associated	O
inflammation	O
contributes	O
to	O
liver	O
dysfunction	O
and	O
complications	O
after	O
liver	O
surgery	O
and	O
transplantation	O
.	O
	
mesenchymal	O
stem	O
cells	O
msc	O
have	O
been	O
reported	O
to	O
reduce	O
hepatic	B-C4303160
iri	O
because	O
of	O
their	O
reparative	O
immunomodulatory	O
effects	O
in	O
injured	O
tissues	O
.	O
	
recent	O
studies	O
have	O
highlighted	O
beneficial	O
effects	O
of	O
extracellular	O
vesicles	O
from	O
mscs	O
msc	O
-	O
ev	O
on	O
tissue	O
injury	O
.	O
	
the	O
effects	O
of	O
systemically	O
administered	O
mouse	O
bone	O
marrow	O
derived	O
msc	O
-	O
ev	O
were	O
evaluated	O
in	O
an	O
experimental	O
murine	O
model	O
of	O
hepatic	O
iri	O
induced	O
by	O
cross	O
clamping	O
the	O
hepatic	O
artery	O
and	O
portal	O
vein	O
for	O
90	O
minutes	O
followed	O
by	O
reperfusion	O
for	O
periods	O
of	O
upto	O
6	O
hours	O
.	O
	
compared	O
with	O
controls	O
,	O
intravenous	O
administration	O
of	O
msc	O
-	O
ev	O
30	O
minutes	O
prior	O
to	O
iri	O
dramatically	O
reduced	O
the	O
extent	O
of	O
tissue	O
necrosis	O
,	O
decreased	O
caspase-3	O
positive	O
and	O
apoptotic	O
cells	O
,	O
and	O
reduced	O
serum	O
aminotransferase	O
levels	O
.	O
	
msc	O
-	O
ev	O
increased	O
hepatic	O
mrna	O
expression	O
of	O
nacht	O
,	O
lrr	O
and	O
pyd	O
domains-containing	O
protein	O
12	O
nlrp12	O
,	O
and	O
the	O
chemokine	O
c-x-c	O
motif	O
ligand	O
1	O
cxcl1	O
,	O
and	O
reduced	O
mrna	O
expression	O
of	O
several	O
inflammatory	O
cytokines	O
such	O
as	O
il-6	O
during	O
iri	O
.	O
	
msc	O
-	O
ev	O
increased	O
cell	O
viability	O
and	O
suppressed	O
both	O
oxidative	O
injury	O
and	O
nf-κb	O
activity	O
in	O
aml12	O
murine	O
hepatocytes	O
in	O
vitro	O
.	O
	
in	O
conclusion	O
,	O
the	O
administration	O
of	O
ev	O
derived	O
from	O
bone	O
marrow	O
derived	O
mscs	O
may	O
ameliorate	O
hepatic	O
iri	O
by	O
reducing	O
hepatic	O
injury	O
through	O
modulation	O
of	O
the	O
inflammatory	O
response	O
.	O
	
this	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
	
all	O
rights	O
nucleic	B-C0872232
acid	I-C0872232
detection	I-C0872232
with	O
crispr	B-C3658200
-	O
cas13a	B-C0599560
/	O
c2c2	B-C0599560
rapid	B-C0456962
,	O
inexpensive	O
,	O
and	O
sensitive	B-C0332324
nucleic	B-C0872232
acid	I-C0872232
detection	I-C0872232
may	O
aid	B-C1269765
point-of-care	B-C1547702
pathogen	B-C0450254
detection	B-C1511790
,	O
genotyping	B-C1285573
,	O
and	O
disease	B-C0012634
monitoring	B-C1283169
.	O
	
the	O
rna	B-C0035668
-guided	O
,	O
rna	B-C0035668
-	O
targeting	B-C1521840
clustered	B-C3658200
regularly	I-C3658200
interspaced	I-C3658200
short	I-C3658200
palindromic	I-C3658200
repeats	I-C3658200
crispr	B-C3658200
effector	B-C0599560
cas13a	B-C0599560
previously	O
known	O
as	O
c2c2	B-C0599560
exhibits	O
a	O
""""	O
collateral	B-C1948058
effect	B-C1280500
""""	O
of	O
promiscuous	O
ribonuclease	B-C1148840
activity	I-C1148840
upon	O
target	B-C1521840
recognition	B-C0599844
.	O
	
we	O
combine	B-C0205195
the	O
collateral	B-C1948058
effect	B-C1280500
of	O
cas13a	B-C0599560
with	O
isothermal	B-C3539922
amplification	I-C3539922
to	O
establish	B-C0443211
a	O
crispr	B-C3658200
-based	O
diagnostic	B-C0348026
crispr	B-C3658200
-	O
dx	B-C0348026
,	O
providing	O
rapid	B-C0456962
dna	B-C0012854
or	O
rna	B-C0035668
detection	B-C1511790
with	O
attomolar	B-C1511883
sensitivity	I-C1511883
and	O
single-base	B-C1704464
mismatch	B-C1881865
specificity	B-C0037791
.	O
	
we	O
use	O
this	O
cas13a	B-C0599560
-based	O
molecular	B-C1521991
detection	B-C1511790
platform	B-C1710360
,	O
termed	O
specific	B-C1710360
high-sensitivity	I-C1710360
enzymatic	I-C1710360
reporter	I-C1710360
unlocking	I-C1710360
sherlock	B-C1710360
,	O
to	O
detect	B-C0442726
specific	B-C0205369
strains	B-C1518614
of	O
zika	B-C0318793
and	O
dengue	B-C0011315
virus	I-C0011315
,	O
distinguish	O
pathogenic	B-C0450254
bacteria	B-C0004611
,	O
genotype	B-C0017431
human	B-C0086418
dna	B-C0012854
,	O
and	O
identify	B-C0205396
mutations	B-C0026882
in	O
cell-free	B-C0007625
tumor	B-C0012930
dna	I-C0012930
.	O
	
furthermore	O
,	O
sherlock	B-C1710360
reaction	B-C0443286
reagents	B-C0034760
can	O
be	O
lyophilized	B-C0016698
for	O
cold-chain	B-C0282332
independence	O
and	O
long-term	B-C0443252
storage	B-C1698986
and	O
be	O
readily	O
reconstituted	O
on	O
paper	O
for	O
field	B-C0869019
applications	I-C0869019
.	O
	
a	O
plea	O
for	O
thoracoscopic	B-C0039989
resection	B-C0015252
of	O
solitary	B-C2350019
pulmonary	I-C2350019
nodule	I-C2350019
in	O
cancer	B-C0006826
patients	B-C0030705
solitary	B-C2350019
pulmonary	I-C2350019
nodules	I-C2350019
spn	B-C2350019
are	O
frequently	O
detected	B-C0442726
in	O
cancer	B-C0006826
patients	B-C0030705
.	O
	
these	O
lesions	B-C0577916
are	O
often	O
considered	O
as	O
pulmonary	B-C0153676
metastases	I-C0153676
and	O
increasingly	B-C0442808
treated	B-C1522326
by	O
non-surgical	B-C0087111
techniques	I-C0087111
without	O
histological	B-C0205462
confirmation	B-C0750484
.	O
	
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
histological	B-C0205462
nature	B-C1262865
of	O
spn	B-C2350019
resected	B-C1521996
by	O
thoracoscopy	B-C0039989
and	O
to	O
identify	O
risk	B-C0035648
factors	I-C0035648
of	O
malignancy	B-C4282132
.	O
	
single-institution	B-C0035363
retrospective	I-C0035363
analysis	I-C0035363
of	O
all	O
consecutive	B-C1707491
patients	B-C0030705
with	O
previously	O
known	O
malignancies	B-C4282132
who	O
underwent	O
thoracoscopic	B-C0039989
resection	B-C0015252
of	O
spn	B-C2350019
with	O
unknown	B-C0439673
diagnosis	B-C0011900
between	O
2001	O
and	O
2014	O
.	O
	
one	O
hundred	O
and	O
forty	O
cancer	B-C0006826
patients	B-C0030705
underwent	O
thoracoscopic	B-C0039989
resection	B-C0015252
of	O
a	O
spn	B-C2350019
.	O
	
the	O
resected	B-C1521996
spn	B-C2350019
was	O
benign	B-C0205183
in	O
34	O
patients	B-C0030705
24.3	O
and	O
malignant	B-C0205282
in	O
106	O
patients	B-C0030705
.	O
	
the	O
latter	O
were	O
metastasis	B-C0027627
in	O
70	O
patients	B-C0030705
50%	O
and	O
a	O
primary	B-C0205225
lung	B-C0242379
cancer	I-C0242379
in	O
36	O
patients	B-C0030705
25.7	O
.	O
	
upon	O
univariate	B-C0683962
analysis	I-C0683962
,	O
malignancy	B-C4282132
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
age	B-C0001779
>60	O
years	B-C1510829
,	O
disease	B-C0012634
-free	O
interval	B-C1272706
24	O
months	B-C0439231
,	O
spn	B-C2350019
size	B-C0475440
>8	O
mm	O
,	O
upper	B-C0225756
lobe	I-C0225756
localization	B-C0475264
and	O
suvmax	B-C2986846
>	O
2.5	O
on	O
pet-ct	B-C1699633
.	O
	
upon	O
multivariate	B-C0026777
analysis	I-C0026777
,	O
upper	B-C0225756
lobe	I-C0225756
localization	B-C0475264
and	O
suvmax	B-C2986846
>	O
2.5	O
were	O
associated	B-C0332281
with	I-C0332281
malignancy	B-C4282132
.	O
	
smoking	B-C0037369
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
spn	B-C2350019
containing	O
primary	B-C0205225
lung	B-C0242379
cancer	I-C0242379
.	O
	
in	O
this	O
series	B-C0205549
,	O
only	O
50%	O
of	O
spn	B-C2350019
in	O
patients	B-C0030705
with	O
known	O
malignant	B-C0442867
disease	I-C0442867
were	O
pulmonary	B-C0153676
metastases	I-C0153676
and	O
25%	O
had	O
a	O
newly	B-C1518321
diagnosed	I-C1518321
nsclc	B-C0007131
.	O
	
smoking	B-C0037369
was	O
associated	B-C0332281
with	I-C0332281
primary	B-C0205225
lung	B-C0242379
cancer	I-C0242379
but	O
no	B-C1513916
other	O
predictor	B-C2698872
was	O
found	O
to	O
allow	O
the	O
distinction	O
between	O
pulmonary	B-C0153676
metastasis	I-C0153676
and	O
lung	B-C0242379
cancer	I-C0242379
.	O
	
these	O
results	O
endorse	O
the	O
need	O
of	O
histological	B-C0205462
confirmation	B-C0750484
of	O
spn	B-C2350019
in	O
patients	B-C0030705
with	O
previous	B-C0205156
malignancies	B-C4282132
to	O
avoid	O
diagnostic	B-C0348026
uncertainty	B-C0087130
and	O
suboptimal	B-C2984009
treatments	B-C0087111
.	O
	
reliability	B-C0205556
of	O
fear	B-C4040543
assessment	I-C4040543
in	O
growing	B-C3687568
pigs	B-C0039005
exposed	B-C0332157
to	I-C0332157
a	O
novel	B-C0205314
object	B-C0347997
test	B-C0039593
in	O
commercial	B-C0680536
conditions	B-C0348080
the	O
objective	B-C0018017
of	O
this	O
study	O
was	O
to	O
assess	B-C1516048
the	O
reliability	B-C0205556
and	O
feasibility	B-C0015730
of	O
a	O
novel	B-C0205314
object	B-C0347997
test	B-C0039593
assessing	B-C2364227
fear	I-C2364227
in	O
pigs	B-C0039005
in	O
commercial	B-C0680536
conditions	B-C0348080
.	O
	
a	O
total	O
of	O
18	O
commercial	B-C0680536
farms	B-C0557759
were	O
visited	O
,	O
and	O
321	O
pens	B-C0020057
housing	I-C0020057
4	O
growing	B-C3687568
pigs	B-C0039005
were	O
assessed	B-C1516048
.	O
	
three	O
balloons	B-C3273359
were	O
used	O
as	O
a	O
novel	B-C0039005
stimulus	B-C0234402
.	O
	
measures	B-C0079809
were	O
a	O
the	O
time	B-C0040223
it	O
took	O
for	O
the	O
first	O
pig	B-C0039005
to	O
contact	B-C0392367
1	O
of	O
the	O
balloons	B-C3273359
,	O
b	O
percentage	O
of	O
nonhuman	B-C0237798
animals	B-C0003062
watching	B-C2371283
the	O
balloons	B-C3273359
each	O
for	O
10	O
s	O
,	O
and	O
c	O
percentage	O
of	O
animals	B-C0003062
touching	B-C2584295
the	O
balloons	B-C3273359
during	O
periods	B-C1948053
of	O
5	O
s	O
.	O
	
the	O
time	B-C0040223
of	O
the	O
first	O
pig	B-C0039005
to	O
contact	B-C0392367
1	O
of	O
the	O
balloons	B-C3273359
ranged	B-C1514721
from	O
0	O
s	O
to	O
362	O
s	O
.	O
	
an	O
effect	B-C1280500
of	O
the	O
farm	B-C0557759
was	O
found	O
p	O
<	O
0001	O
for	O
contact	B-C0392367
latency	B-C0242465
,	O
ranging	B-C1514721
from	O
6.8	O
s	O
to	O
73.3	O
s	O
,	O
but	O
little	O
difference	B-C1705242
was	O
found	O
in	O
terms	O
of	O
intrafarm	B-C0557759
variability	B-C2827666
.	O
	
interobserver	B-C0870736
repeatability	I-C0870736
was	O
also	O
high	B-C0205250
in	O
this	O
measure	B-C0079809
,	O
ranging	B-C1514721
from	O
r	O
=	O
74	O
to	O
r	O
=	O
96	O
.	O
	
as	O
a	O
result	O
,	O
it	O
is	O
concluded	O
that	O
contact	B-C0392367
latency	B-C0242465
could	O
be	O
a	O
good	O
measure	B-C0079809
to	O
assess	B-C1516048
fear	B-C0015726
of	O
a	O
novel	O
stimulus	B-C0234402
in	O
commercial	B-C0680536
farms	B-C0557759
.	O
	
precise	O
prediction	B-C0681842
of	O
activators	B-C0751968
for	O
the	O
human	B-C0086418
constitutive	B-C0914906
androstane	I-C0914906
receptor	I-C0914906
using	O
structure	B-C0026383
-based	O
three-dimensional	B-C0887820
quantitative	I-C0887820
structure-activity	I-C0887820
relationship	I-C0887820
methods	B-C0025663
the	O
constitutive	B-C0914906
androstane	I-C0914906
receptor	I-C0914906
car	B-C0914906
,	O
nr1i3	B-C0663285
regulates	B-C2755857
the	I-C2755857
expression	I-C2755857
of	O
numerous	B-C0439064
drug-metabolizing	B-C0683140
enzymes	B-C0014442
and	O
transporters	B-C0007292
.	O
	
the	O
upregulation	B-C0041904
of	O
various	O
enzymes	B-C0014442
,	O
including	O
cyp2b6	B-C0534137
,	O
by	O
car	B-C0914906
activators	B-C0751968
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	B-C0205082
drug-drug	B-C0687133
interactions	I-C0687133
ddis	B-C0687133
.	O
	
to	O
date	O
,	O
however	O
,	O
few	O
effective	B-C1704419
computational	B-C1516769
approaches	I-C1516769
for	O
identifying	O
car	B-C0914906
activators	O
exist	O
.	O
	
in	O
this	O
study	O
,	O
we	O
aimed	O
to	O
develop	O
three-dimensional	B-C0887820
quantitative	I-C0887820
structure-activity	I-C0887820
relationship	I-C0887820
3d-qsar	B-C0887820
models	B-C3161035
to	O
predict	O
the	O
car	B-C0914906
activating	B-C1514758
potency	B-C3245505
of	O
compounds	B-C1254351
emerging	O
in	O
the	O
drug-discovery	B-C0920472
process	B-C1522240
.	O
	
models	B-C3161035
were	O
constructed	O
using	O
comparative	B-C1513380
molecular	I-C1513380
field	I-C1513380
analysis	I-C1513380
comfa	B-C1513380
based	O
on	O
the	O
molecular	B-C0567416
alignments	B-C1706765
of	O
ligands	B-C1517880
binding	I-C1517880
to	O
car	B-C0914906
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand-docking	B-C1522290
using	O
28	B-C1254351
compounds	I-C1254351
as	O
a	O
training	O
set	O
.	O
	
the	O
comfa	B-C1513380
model	B-C3161035
,	O
modified	B-C0205349
by	I-C0205349
adding	O
a	O
lipophilic	B-C0598631
parameter	B-C0598631
with	O
calculated	O
logd7.4	O
s+logd7	O
,	O
demonstrated	O
statistically	O
good	O
predictive	B-C1514307
ability	I-C1514307
r	O
=	O
0.99	O
,	O
q	O
=	O
0.74	O
.	O
	
we	O
also	O
confirmed	O
the	O
excellent	O
predictability	B-C0237793
of	O
the	O
3d-qsar	B-C0887820
model	B-C3161035
for	O
car	B-C0914906
activation	B-C1514758
r	O
=	O
0.71	O
using	O
seven	O
compounds	B-C1254351
as	O
a	O
test	O
set	O
for	O
external	B-C1519941
validation	I-C1519941
.	O
	
collectively	O
,	O
our	O
results	B-C1274040
indicate	O
that	O
the	O
3d-qsar	B-C0887820
model	B-C3161035
developed	O
in	O
this	O
study	O
provides	O
precise	B-C2828393
prediction	B-C0681842
of	O
car	B-C0914906
activating	B-C1514758
potency	B-C3245505
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	B-C1254351
candidates	I-C1254351
with	O
minimized	B-C1524031
ddi	B-C0687133
risk	B-C0035647
related	O
to	O
enzyme-induction	B-C0014431
in	O
the	O
early	B-C1279919
drug-discovery	B-C0920472
stage	B-C1306673
.	O
	
effects	B-C1704420
of	I-C1704420
sirna	B-C1099354
-mediated	O
suppression	B-C0038855
of	O
hpv-11	B-C0017376
l1	I-C0017376
expression	B-C0017262
on	O
the	O
proliferation	B-C0596290
and	O
apoptosis	B-C0162638
of	O
vaginal	B-C1987256
epithelial	I-C1987256
cells	I-C1987256
the	O
aim	B-C1947946
of	O
the	O
present	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
the	O
effects	B-C1704420
of	I-C1704420
human	B-C0343641
papillomavirus	I-C0343641
hpv	I-C0343641
infection	I-C0343641
on	O
the	O
gynecological	B-C1384956
disease	I-C1384956
of	O
vaginitis	B-C0042267
and	O
to	O
demonstrate	O
how	O
the	O
small	B-C1099354
interfering	I-C1099354
rna	I-C1099354
sirna	B-C1099354
method	O
may	O
be	O
used	O
for	O
hpv	B-C0021344
prevention	B-C0199176
in	O
the	O
clinic	B-C0442592
.	O
	
human	B-C0086418
vaginal	B-C1987256
epithelial	I-C1987256
cells	I-C1987256
were	O
transfected	B-C0040669
with	O
hpv-11	B-C0017376
l1	I-C0017376
expression	B-C0599566
vector	I-C0599566
and	O
sirna	B-C1099354
-	O
hpv-11	B-C0017376
l1	I-C0017376
vectors	B-C0017397
and	O
a	O
control	B-C0009932
group	I-C0009932
was	O
transfected	B-C0040669
with	O
scrambled	O
sirna	B-C1099354
.	O
	
cell	B-C0596290
proliferation	I-C0596290
in	O
each	O
group	O
was	O
analyzed	O
using	O
the	O
mtt	B-C1510438
assay	I-C1510438
and	O
the	O
expression	B-C1171362
of	O
apoptosis	B-C0162638
-associated	O
proteins	B-C0033684
was	O
measured	B-C0444706
by	O
western	B-C2121086
blot	I-C2121086
analysis	I-C2121086
.	O
	
compared	B-C1707455
with	O
the	O
control	B-C0009932
group	I-C0009932
,	O
hpv-11	B-C0017376
l1	I-C0017376
mrna	B-C0035696
and	O
protein	B-C0428479
levels	I-C0428479
were	O
significantly	O
increased	B-C0205217
following	O
transfection	B-C0040669
with	O
the	O
hpv-11	B-C0017376
l1	I-C0017376
expression	B-C0599566
vector	I-C0599566
in	O
cells	B-C0007634
p<0	O
,	O
but	O
this	O
result	O
was	O
significantly	O
reversed	O
by	O
silencing	B-C0598496
of	O
hpv-11	B-C0017376
l1	I-C0017376
p<0	O
.	O
	
in	O
addition	O
,	O
cell	B-C0596290
proliferation	I-C0596290
in	O
the	O
hpv-11	B-C0441833
group	I-C0441833
was	O
lower	B-C0205251
than	O
that	O
in	O
the	O
control	B-C0009932
group	I-C0009932
however	O
,	O
cell	B-C0596290
proliferation	I-C0596290
was	O
significantly	O
increased	B-C0205217
in	O
cells	B-C0007634
transfected	B-C0040669
with	O
silenced	B-C0598496
l1	B-C0017376
compared	O
with	O
that	O
in	O
the	O
control	B-C0009932
group	I-C0009932
p<0	O
.	O
	
furthermore	O
,	O
silencing	B-C0598496
of	O
hpv-11	B-C0017376
l1	I-C0017376
significantly	O
decreased	B-C0205216
caspase-3	B-C1413132
and	O
caspase-9	B-C1332668
expressions	B-C0017262
in	O
cells	B-C0007634
,	O
whereas	O
the	O
expression	B-C0017262
was	O
increased	B-C0205217
in	O
the	O
hpv-11	B-C0017376
l1	I-C0017376
group	O
p<0	O
.	O
	
the	O
present	O
study	B-C2603343
suggested	O
that	O
sirna	B-C1099354
-mediated	O
silencing	B-C0598496
of	O
hpv-11	B-C0017376
l1	I-C0017376
may	O
have	O
potential	O
therapeutic	B-C0278296
applications	I-C0278296
for	O
treating	O
gynecological	B-C1384956
diseases	I-C1384956
associated	B-C0332281
with	I-C0332281
hpv-11	B-C1093046
infection	B-C3714514
.	O
	
an	O
evaluation	B-C0220825
of	O
neuroendocrine	B-C0027912
dysfunction	B-C3887504
following	O
acute	B-C0205178
aneurysmal	B-C0751530
subarachnoid	I-C0751530
hemorrhage	I-C0751530
a	O
prospective	B-C0033522
study	I-C0033522
the	O
aim	B-C1947946
was	O
to	O
investigate	B-C1292732
the	O
incidence	O
and	O
pattern	B-C0449774
of	O
neuroendocrine	B-C0027912
changes	O
in	O
cases	B-C0030705
of	O
acute	B-C0205178
aneurysmal	B-C0751530
subarachnoid	I-C0751530
hemorrhage	I-C0751530
sah	B-C0751530
.	O
	
endocrine	B-C0014136
assessment	B-C0220825
was	O
performed	O
in	O
100	O
consecutive	O
cases	B-C0030705
of	O
acute	B-C0205178
aneurysmal	B-C0751530
sah	I-C0751530
presenting	O
within	O
7	O
days	B-C0439228
of	O
ictus	B-C0038454
.	O
	
the	O
gonadotropic	B-C0018061
,	O
somatotrophic	B-C0037663
,	O
thyrotropic	B-C0040160
,	O
and	O
corticotrophic	B-C0001655
axes	O
were	O
evaluated	B-C0220825
for	O
their	O
possible	O
dysfunction	B-C3887504
.	O
	
a	O
total	O
of	O
100	O
cases	B-C0030705
38	O
males	B-C0086582
,	O
62	O
females	B-C0086287
age	B-C0001779
range	B-C1514721
-	O
17-76	O
years	B-C1510829
mean	B-C0444504
age	B-C0001779
-	O
43.6	O
years	B-C1510829
of	O
acute	B-C0205178
sah	B-C0751530
were	O
studied	B-C0008972
.	O
	
the	O
aneurysms	B-C0002940
were	O
located	O
in	O
the	O
anterior	B-C0007818
circulation	I-C0007818
n	O
=	O
95	O
and	O
posterior	B-C0007818
circulation	I-C0007818
n	O
=	O
5	O
.	O
	
the	O
most	O
common	O
hormone	B-C0599750
deficiency	I-C0599750
was	O
of	O
growth	B-C0037663
hormone	I-C0037663
n	O
=	O
67	O
,	O
followed	O
by	O
gonadotrophin	B-C0018061
n	O
=	O
50	O
,	O
corticotrophin	B-C0001655
n	O
=	O
49	O
and	O
thyrotrophin	B-C0040160
n	O
=	O
35	O
.	O
	
hyperprolactinemia	B-C0020514
was	O
noted	O
in	O
10	O
cases	B-C0030705
.	O
	
one-pituitary	B-C0857439
hormone	I-C0857439
axis	I-C0857439
deficiency	I-C0857439
was	O
noted	O
in	O
26	O
cases	B-C0030705
while	O
67	O
cases	B-C0030705
had	O
two	O
or	O
more	O
pituitary	B-C0032015
hormone	I-C0032015
axes	O
dysfunction	B-C3887504
.	O
	
a	O
total	O
of	O
93	O
cases	B-C0030705
had	O
hormonal	B-C0019932
dysfunction	B-C3887504
in	O
one	O
or	O
more	O
pituitary	B-C0032015
hormone	I-C0032015
axes	I-C0032015
,	O
and	O
seven	O
cases	B-C0030705
had	O
no	O
hormonal	B-C0019932
dysfunction	B-C3887504
.	O
	
endocrine	B-C1397856
dysfunction	I-C1397856
occurs	O
in	O
93%	O
cases	B-C0030705
of	O
acute	B-C0205178
sah	B-C0751530
and	O
multiple	O
pituitary	B-C0032015
hormone	I-C0032015
axes	I-C0032015
dysfunction	B-C3887504
occurs	O
in	O
67%	O
cases	B-C0030705
.	O
	
it	O
is	O
suggested	O
that	O
hormonal	B-C0019932
evaluation	B-C0220825
should	O
be	O
considered	O
as	O
part	O
of	O
management	O
of	O
acute	B-C0205178
sah	B-C0751530
.	O
	
validity	B-C2349101
and	O
reliability	B-C2347947
of	O
fluoroscopy	B-C0016356
for	O
digital	B-C0012249
radiography	I-C0012249
a	O
new	O
way	O
to	O
evaluate	B-C0220825
diaphragmatic	B-C0011980
mobility	B-C0026597
fluoroscopy	B-C0016356
is	O
considered	O
the	O
most	O
accurate	O
method	B-C2911685
to	O
evaluate	B-C0220825
the	O
diaphragm	B-C0011980
,	O
yet	O
most	O
existing	O
methods	B-C2911685
for	O
measuring	O
diaphragmatic	B-C0011980
mobility	B-C0026597
using	O
fluoroscopy	B-C0016356
are	O
complex	O
.	O
	
to	O
assess	O
the	O
validity	B-C2349101
and	O
reliability	B-C2347947
of	O
a	O
new	O
evaluation	B-C2911685
method	I-C2911685
of	O
diaphragmatic	B-C0011980
motion	B-C0026597
using	O
fluoroscopy	B-C0016356
by	O
digital	B-C0012249
radiography	I-C0012249
of	O
healthy	B-C3898900
adults	B-C0001675
.	O
	
twenty-six	O
adults	B-C0001675
were	O
evaluated	B-C0220825
,	O
according	O
to	O
the	O
parameters	O
anthropometry	B-C0003188
and	O
pulmonary	B-C0024119
function	I-C0024119
test	I-C0024119
.	O
	
the	O
evaluation	B-C0220825
of	O
diaphragm	B-C0011980
mobility	B-C0026597
by	O
means	O
of	O
fluoroscopy	B-C0016356
by	O
digital	B-C0012249
radiography	I-C0012249
method	B-C2911685
was	O
randomly	O
conducted	O
by	O
two	O
raters	O
a	O
and	O
b	O
.	O
	
the	O
pearson	B-C0871052
correlation	I-C0871052
coefficient	I-C0871052
and	O
the	O
intraclass	B-C0392762
correlation	I-C0392762
coefficient	I-C0392762
icc	B-C0392762
were	O
used	O
to	O
assess	O
the	O
concurrent	O
validity	B-C2349101
.	O
	
the	O
inter-rater	O
and	O
intra-rater	O
reliability	B-C2347947
of	O
the	O
measurement	B-C0242485
of	O
diaphragmatic	B-C0011980
motion	B-C0026597
was	O
determined	O
using	O
icc	B-C0392762
and	O
a	O
confidence	O
interval	O
of	O
95%	O
.	O
	
there	O
was	O
a	O
relationship	B-C0439849
in	O
the	O
assessment	B-C0220825
of	O
the	O
concurrent	O
validity	B-C2349101
.	O
	
there	O
was	O
good	O
inter-rater	O
reliability	B-C2347947
for	O
right	O
hemidiaphragm	B-C1269845
mobility	B-C0026597
and	O
moderate	O
reliability	B-C2347947
for	O
left	B-C0929194
hemidiaphragm	I-C0929194
in	O
the	O
first	O
assessment	B-C0220825
.	O
	
in	O
the	O
second	O
assessment	B-C0220825
,	O
there	O
was	O
good	O
reliability	B-C2347947
for	O
the	O
mobility	B-C0026597
of	O
both	O
hemidiaphragms	B-C1269845
.	O
	
there	O
was	O
good	O
intra-rater	O
reliability	B-C2347947
in	O
the	O
mobility	B-C0026597
of	O
both	O
hemidiaphragms	B-C1269845
for	O
raters	O
a	O
and	O
b	O
.	O
	
the	O
evaluation	B-C0220825
of	O
diaphragmatic	B-C0011980
motion	B-C0026597
using	O
fluoroscopy	B-C0016356
by	O
digital	B-C0012249
radiography	I-C0012249
proved	O
to	O
be	O
a	O
valid	B-C2349099
and	O
reliable	B-C0205556
method	B-C2911685
of	O
healthy	B-C3898900
adults	B-C0001675
.	O
	
loss	B-C0243148
of	I-C0243148
control	I-C0243148
over	O
alcohol	B-C0813934
seeking	I-C0813934
in	O
rats	B-C0086893
depends	O
on	O
individual	B-C0237401
vulnerability	B-C1821973
and	O
duration	O
of	O
alcohol	B-C0001948
consumption	I-C0001948
experience	O
alcohol	B-C0001956
use	I-C0001956
disorder	I-C0001956
aud	B-C0001956
is	O
characterized	O
by	O
excessive	B-C0560219
alcohol	I-C0560219
use	I-C0560219
and	O
persistent	B-C0205322
alcohol	B-C0813934
seeking	I-C0813934
despite	O
knowledge	O
of	O
its	O
negative	O
consequences	O
.	O
	
importantly	O
,	O
aud	B-C0001956
typically	O
develops	O
after	O
chronic	B-C0205191
excessive	B-C0560219
alcohol	I-C0560219
use	I-C0560219
in	O
a	O
subgroup	B-C1515021
of	O
individuals	B-C0237401
who	O
drink	B-C3842894
alcohol	I-C3842894
,	O
suggesting	O
that	O
aud	B-C0001956
results	O
from	O
an	O
interaction	B-C1704675
between	O
individual	B-C0237401
vulnerability	B-C1821973
and	O
prolonged	B-C4038778
alcohol	I-C4038778
exposure	I-C4038778
.	O
	
the	O
present	O
study	B-C2603343
assessed	B-C1516048
the	O
contribution	O
of	O
prolonged	B-C4038778
exposure	I-C4038778
to	I-C4038778
alcohol	I-C4038778
and	O
individual	B-C0001948
levels	I-C0001948
of	I-C0001948
alcohol	I-C0001948
intake	I-C0001948
to	O
the	O
development	B-C1527148
of	O
loss	B-C0243148
of	I-C0243148
control	I-C0243148
over	O
alcohol	B-C0813934
seeking	I-C0813934
in	O
a	O
conditioned	B-C3161035
suppression	I-C3161035
model	I-C3161035
.	O
	
to	O
investigate	B-C1292732
the	O
impact	O
of	O
prolonged	B-C4038778
alcohol	I-C4038778
exposure	I-C4038778
,	O
conditioned	B-C1260953
suppression	I-C1260953
of	O
alcohol	B-C0813934
seeking	I-C0813934
was	O
assessed	B-C1516048
after	O
2	O
and	O
4	O
months	O
of	O
intermittent	B-C1254367
alcohol	I-C1254367
access	I-C1254367
iaa	B-C1254367
in	O
a	O
subgroup	B-C1515021
of	O
rats	B-C0086893
drinking	O
moderate	O
amounts	O
of	O
alcohol	O
.	O
	
we	O
observed	O
that	O
suppression	B-C1260953
of	O
alcohol	B-C0813934
seeking	I-C0813934
was	O
reduced	O
after	O
4	O
months	O
compared	O
with	O
2	O
months	O
of	O
iaa	B-C1254367
.	O
	
the	O
influence	B-C4054723
of	O
individual	O
levels	O
of	O
alcohol	B-C0001948
intake	I-C0001948
on	O
loss	B-C0243148
of	I-C0243148
control	I-C0243148
over	O
alcohol	B-C0813934
seeking	I-C0813934
was	O
subsequently	O
determined	B-C0521095
by	I-C0521095
assessing	B-C1516048
conditioned	B-C1260953
suppression	I-C1260953
in	O
subgroups	B-C1515021
of	O
low	B-C0205556
and	I-C0205556
high	I-C0205556
alcohol	I-C0205556
drinking	I-C0205556
rats	B-C0086893
.	O
	
unlike	O
the	O
low	B-C0205556
alcohol	I-C0205556
drinking	I-C0205556
rats	B-C0086893
,	O
the	O
high	B-C0205556
alcohol	I-C0205556
drinking	I-C0205556
rats	B-C0086893
showed	O
aversion-resistant	B-C0332325
alcohol	B-C0813934
seeking	I-C0813934
after	O
2	O
months	O
of	O
iaa	B-C1254367
,	O
although	O
both	O
groups	B-C0441833
showed	O
comparable	O
levels	O
of	O
conditioned	O
freezing	O
.	O
	
these	O
findings	O
show	O
that	O
the	O
development	O
of	O
loss	B-C0243148
of	I-C0243148
control	I-C0243148
over	O
alcohol	B-C0813934
seeking	I-C0813934
,	O
a	O
key	O
characteristic	O
of	O
aud	B-C0001956
in	O
humans	B-C0086418
,	O
is	O
dependent	O
on	O
both	O
the	O
extent	O
of	O
alcohol	B-C4038778
exposure	I-C4038778
and	O
the	O
individual's	B-C0237401
neural	B-C3714606
correlates	B-C0871178
of	O
experimental	B-C1517586
trauma	B-C3714660
memory	B-C0679061
retrieval	I-C0679061
traumatic	B-C0332663
memories	B-C0025260
such	O
as	O
intrusions	B-C4049623
and	O
flashbacks	B-C1821940
play	O
a	O
major	O
role	O
in	O
the	O
development	B-C1527148
and	O
maintenance	B-C0024501
of	O
post-traumatic	B-C0038436
stress	I-C0038436
disorder	I-C0038436
ptsd	B-C0038436
.	O
	
a	O
thorough	O
understanding	O
of	O
the	O
neural	B-C3714606
mechanisms	B-C0441712
underlying	O
traumatic	B-C0332663
memories	B-C0025260
is	O
indispensable	O
for	O
precise	O
diagnosis	B-C0011900
,	O
for	O
personalized	B-C1709510
treatment	B-C0087111
and	O
prevention	B-C0199176
.	O
	
in	O
particular	O
,	O
the	O
identification	B-C0205396
of	O
early	O
neural	B-C3714606
predictor	B-C0683956
variables	I-C0683956
for	O
intrusion	B-C4049623
development	B-C1527148
shortly	O
after	O
trauma	B-C3714660
exposure	B-C0332157
requires	O
detailed	O
investigation	B-C0220825
.	O
	
here	O
,	O
we	O
examined	B-C0332128
the	O
neural	B-C0871178
correlates	I-C0871178
of	O
early	O
experimental	B-C1517586
trauma	B-C3714660
memory	B-C0679061
retrieval	I-C0679061
in	O
a	O
traumatic	B-C0681797
film	I-C0681797
paradigm	I-C0681797
in	O
42	O
young	O
healthy	B-C3898900
females	B-C0086287
,	O
using	O
both	O
implicit	B-C0561768
and	O
explicit	B-C0561766
retrieval	B-C0679061
tasks	I-C0679061
.	O
	
we	O
show	O
that	O
implicit	B-C0561768
experimental	B-C1517586
trauma	B-C3714660
retrieval	B-C0679061
specifically	O
involved	O
the	O
retrosplenial	B-C4085586
cortex	I-C4085586
and	O
the	O
anterior	B-C0175190
cingulate	I-C0175190
cortex	I-C0175190
acc	B-C0175190
,	O
while	O
both	O
retrieval	B-C0679061
tasks	I-C0679061
resulted	O
in	O
trauma-related	B-C1144879
activity	B-C0441655
in	O
the	O
posterior	B-C0175191
cingulate	I-C0175191
cortex	I-C0175191
pcc	B-C0175191
and	O
the	O
precuneus	B-C1281018
.	O
	
importantly	O
,	O
neural	B-C3714606
activity	B-C0441655
early	O
after	O
experimental	B-C1517586
trauma	B-C3714660
exposure	B-C0332157
predicted	B-C0681842
later	O
intrusion	B-C4049623
development	B-C1527148
,	O
with	O
independent	B-C0085862
contributions	B-C1880177
from	O
activity	B-C0441655
in	O
the	O
retrosplenial	B-C4085586
cortex	I-C4085586
implicit	B-C0561768
retrieval	B-C0679061
and	O
the	O
pcc	B-C0175191
explicit	B-C0561766
retrieval	B-C0679061
.	O
	
additional	B-C1524062
analyses	B-C0936012
revealed	B-C0443289
a	O
stronger	O
connectivity	B-C1707489
between	O
the	O
bilateral	B-C0002708
amygdala	I-C0002708
and	O
the	O
supplementary	B-C3496173
motor	I-C3496173
area	I-C3496173
,	O
precentral	B-C0921005
and	O
paracentral	B-C0228203
lobule	I-C0228203
for	O
the	O
control	B-C0009932
group	I-C0009932
compared	O
to	O
the	O
experimental	B-C1517586
trauma	B-C3714660
group	B-C0441833
.	O
	
our	O
study	B-C0008972
gives	O
new	O
insights	O
in	O
the	O
neural	B-C3714606
correlates	B-C0871178
of	O
experimental	B-C1517586
trauma	B-C3714660
memory	B-C0679061
retrieval	I-C0679061
and	O
their	O
predictive	B-C1514307
value	I-C1514307
for	O
subsequent	B-C0332282
symptom	B-C1457887
development	B-C1527148
.	O
	
our	O
results	B-C1274040
could	O
provide	O
the	O
basis	O
for	O
personalized	B-C1709510
early	B-C0814494
treatment	I-C0814494
and	O
prevention	B-C2700409
of	O
ptsd	B-C0038436
.	O
	
targeting	B-C1159372
the	O
nrf2	B-C0289507
/	O
amyloid-beta	B-C1149161
liaison	I-C1149161
in	O
alzheimer's	B-C0002395
disease	I-C0002395
a	O
rational	B-C0010998
approach	I-C0010998
amyloid	B-C0002716
is	O
a	O
prominent	B-C0205402
feature	B-C2348519
of	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
.	O
	
yet	O
,	O
a	O
linear	B-C0205132
linkage	B-C0439849
between	O
amyloid-β	B-C0078939
peptide	I-C0078939
aβ	B-C0078939
and	O
the	O
disease	B-C0277793
onset	I-C0277793
and	O
progression	B-C0242656
has	O
recently	O
been	O
questioned	O
.	O
	
in	O
this	O
context	B-C0449255
,	O
the	O
crucial	O
partnership	B-C0439849
between	O
aβ	B-C1510880
and	O
nrf2	B-C1518762
pathways	I-C1518762
is	O
acquiring	B-C0439661
paramount	B-C0205250
importance	B-C3898777
,	O
offering	O
prospects	O
for	O
deciphering	B-C1285553
the	O
aβ	B-C0078939
-centered	O
disease	B-C0012634
network	B-C1882071
.	O
	
here	O
,	O
we	O
report	O
on	O
a	O
new	B-C0205314
class	O
of	O
antiaggregating	B-C0085826
agents	I-C0085826
rationally	O
designed	O
to	O
simultaneously	B-C0521115
activate	B-C0162493
transcription	I-C0162493
-based	O
antioxidant	B-C0003402
responses	B-C0683154
,	O
whose	O
lead	B-C1254351
1	I-C1254351
showed	O
interesting	O
properties	B-C0871161
in	O
a	O
preliminary	B-C0439611
investigation	O
.	O
	
relying	O
on	O
the	O
requirements	B-C0556043
of	O
aβ	B-C0078939
recognition	B-C0599844
,	O
we	O
identified	B-C0205396
the	O
catechol	B-C1254351
derivative	I-C1254351
12	I-C1254351
.	O
	
in	O
sh-sy5y	B-C0815000
neuroblastoma	I-C0815000
cells	I-C0815000
,	O
12	B-C1254351
combined	B-C0205195
remarkable	O
free	B-C0079381
radical	I-C0079381
scavenger	I-C0079381
properties	B-C0871161
to	O
the	O
ability	O
to	O
trigger	B-C1444748
the	O
nrf2	B-C1518762
pathway	I-C1518762
and	O
induce	B-C0017391
the	O
nrf2	B-C0289507
-	O
dependent	B-C3244310
defensive	B-C2164680
gene	B-C0919428
nqo1	I-C0919428
by	O
means	O
of	O
electrophilic	B-C1254365
activation	I-C1254365
of	O
the	O
transcriptional	B-C0040649
response	I-C0040649
.	O
	
moreover	O
,	O
12	O
prevented	O
the	O
formation	B-C1522492
of	O
cytotoxic	B-C1511636
stable	B-C0205360
oligomeric	B-C1254351
intermediates	I-C1254351
,	O
being	O
significantly	B-C0750502
more	B-C0205172
effective	B-C1704419
,	O
and	O
per	O
se	O
less	B-C0013221
toxic	I-C0013221
,	O
than	O
prototype	B-C1254351
1	I-C1254351
.	O
	
more	O
importantly	O
,	O
as	O
different	B-C1705242
chemical	B-C0243178
features	I-C0243178
were	O
exploited	O
to	O
regulate	B-C1523114
nrf2	I-C1523114
and	O
aβ	B-C0078939
activities	B-C1148560
,	O
the	O
two	O
pathways	B-C1704259
could	O
be	O
tuned	O
independently	O
.	O
	
these	O
findings	O
point	O
to	O
compound	B-C1254351
12	I-C1254351
and	O
its	O
derivatives	B-C1254351
as	O
promising	O
tools	O
for	O
investigating	O
the	O
therapeutic	B-C0302350
potential	B-C3245505
of	O
the	O
nrf2	B-C0289507
/	O
aβ	B-C0078939
cellular	B-C0007634
network	B-C1882071
,	O
laying	O
foundation	O
for	O
generating	B-C3146294
new	O
drug	B-C1254351
leads	I-C1254351
to	O
confront	O
young	B-C0332239
people	B-C0027361
,	O
mental	B-C0025353
health	I-C0025353
practitioners	B-C1306754
and	O
researchers	B-C0035173
co-produce	O
a	O
transition	B-C0282574
preparation	I-C0282574
programme	I-C0282574
to	O
improve	O
outcomes	B-C1274040
and	O
experience	B-C0596545
for	O
young	B-C0332239
people	B-C0027361
leaving	O
child	B-C0025355
and	I-C0025355
adolescent	I-C0025355
mental	I-C0025355
health	I-C0025355
services	I-C0025355
camhs	B-C0025355
in	O
the	O
uk	B-C0041700
young	B-C0332239
people	B-C0027361
attending	O
child	B-C0025355
and	I-C0025355
adolescent	I-C0025355
mental	I-C0025355
health	I-C0025355
services	I-C0025355
camhs	B-C0025355
are	O
required	O
to	O
move	O
on	O
,	O
either	O
through	O
discharge	B-C1548175
or	O
referral	B-C2585021
to	I-C2585021
an	O
adult	B-C0025355
service	I-C0025355
,	O
at	O
age	B-C0001779
17/18	O
,	O
a	O
period	B-C1948053
of	O
increased	B-C0205217
risk	B-C0035647
for	O
onset	B-C0332162
of	I-C0332162
mental	B-C1446377
health	I-C1446377
problems	I-C1446377
and	O
other	O
complex	B-C0439855
psychosocial	B-C0542298
and	O
physical	B-C0205485
changes	B-C0392747
.	O
	
camhs	B-C0025355
transitions	B-C2700061
are	O
often	O
poorly	O
managed	O
with	O
negative	B-C0205160
outcomes	B-C1274040
for	O
young	B-C0332239
people	B-C0027361
.	O
	
better	O
preparation	B-C1521827
may	O
improve	O
outcomes	B-C1274040
and	O
experience	B-C0596545
.	O
	
this	O
study	B-C0008972
aimed	O
to	O
co-produce	O
,	O
with	O
young	B-C0332239
people	B-C0027361
who	O
had	O
transitioned	B-C2700061
or	O
were	O
facing	O
transition	B-C2700061
from	O
camhs	B-C0025355
,	O
a	O
camhs	B-C0025355
transition	B-C0282574
preparation	I-C0282574
programme	I-C0282574
tpp	B-C0282574
,	O
deliverable	O
in	O
routine	B-C0205547
nhs	B-C0027462
settings	O
.	O
	
eighteen	O
young	B-C0332239
people	B-C0027361
,	O
aged	O
17-22	O
,	O
from	O
three	O
uk	B-C0041700
national	B-C0027462
health	I-C0027462
service	I-C0027462
nhs	B-C0027462
mental	O
health	O
foundation	O
trusts	O
participated	O
in	O
creative	O
,	O
participatory	B-C0242262
research	I-C0242262
workshops	I-C0242262
.	O
	
seven	O
parents	B-C0030551
completed	O
short	O
questionnaires	B-C0034394
.	O
	
thirty	O
clinical	B-C0025106
staff	I-C0025106
from	O
two	O
trusts	O
took	O
part	O
in	O
workshops	B-C0242262
to	O
ensure	O
deliverability	O
of	O
young	B-C0332239
people's	B-C0027361
ideas	B-C1254370
.	O
	
young	B-C0332239
people	B-C0027361
were	O
offered	O
co-research	B-C0683937
opportunities	I-C0683937
.	O
	
most	O
young	B-C0332239
people	B-C0027361
felt	O
anxious	B-C0003467
,	O
fearful	B-C0015726
and	O
uncertain	O
on	O
leaving	O
camhs	B-C0025355
and	O
perceived	B-C0030971
mental	B-C0025355
health	I-C0025355
services	I-C0025355
as	O
uncaring	O
.	O
	
participants	B-C0679646
outlined	O
transition	B-C2700061
procedures	B-C2700391
and	O
drafted	O
a	O
range	O
of	O
preparation	B-C0441655
activities	I-C0441655
,	O
centred	O
around	O
dedicated	O
transition	B-C2700061
peer	B-C0679740
support	I-C0679740
and	O
a	O
transition	B-C2700061
booklet	B-C0030258
,	O
which	O
should	O
be	O
offered	O
to	O
all	O
camhs	B-C0025355
leavers	B-C1257890
,	O
irrespective	O
of	O
discharge	B-C1548175
or	O
transfer	B-C3244299
to	O
an	O
adult	B-C0025355
service	I-C0025355
.	O
	
preparation	B-C1521827
should	O
aim	O
to	O
build	O
confidence	B-C1704726
to	O
help	O
young	B-C0332239
people	B-C0027361
take	O
responsibility	B-C0678341
for	O
themselves	O
and	O
flourish	O
in	O
the	O
adult	B-C0001675
world	B-C2700280
coping	O
or	O
getting	O
through	O
it	O
was	O
not	O
enough	O
.	O
	
some	O
clinicians	B-C0871685
also	O
felt	O
anxious	B-C0003467
at	O
transition	B-C2700061
and	O
recognised	O
the	O
potential	O
impact	B-C4049986
on	O
young	B-C0332239
people	B-C0027361
of	O
poor	O
communication	B-C0009452
and	O
lack	B-C0332268
of	O
understanding	O
between	O
services	B-C0025355
.	O
	
parents	B-C0030551
would	O
appreciate	O
help	O
to	O
support	B-C0037438
their	O
offspring	B-C0680063
during	O
the	O
transition	B-C2700061
period	B-C1948053
.	O
	
clinicians	B-C0871685
cited	O
lack	B-C0332268
of	O
funding	O
and	O
inflexible	O
nhs	B-C0027462
procedures	B-C2700391
and	O
policies	B-C0242456
as	O
potential	O
barriers	B-C0205556
to	O
the	O
implementation	B-C1708476
of	O
young	B-C0332239
people's	B-C0027361
ideas	B-C1254370
.	O
	
nine	O
young	B-C0332239
people	B-C0027361
took	O
up	O
co-research	B-C0683937
opportunities	I-C0683937
.	O
	
mental	B-C0025355
health	I-C0025355
services	I-C0025355
underestimate	O
the	O
anxiety	B-C0003467
of	O
camhs	B-C0025355
leavers	B-C1257890
.	O
	
young	B-C0332239
people	B-C0027361
have	O
clear	O
ideas	B-C1254370
about	O
the	O
preparation	B-C1521827
they	O
require	O
to	O
leave	O
camhs	B-C0025355
with	O
the	O
confidence	B-C1704726
to	O
take	O
responsibility	B-C0678341
for	O
their	O
own	O
health	B-C0086388
care	I-C0086388
.	O
	
close	O
collaboration	B-C0282116
of	O
nhs	B-C0027462
staff	B-C0851286
and	O
researchers	B-C0035173
facilitates	O
the	O
implementation	B-C1708476
of	O
research	B-C0035168
findings	B-C2607943
.	O
	
the	O
histone	B-C1571486
acetyltransferase	I-C1571486
gcn5	I-C1571486
positively	B-C1326165
regulates	I-C1326165
t	I-C1326165
cell	I-C1326165
activation	I-C1326165
histone	B-C0062773
acetyltransferases	I-C0062773
hats	B-C0062773
regulate	B-C1158770
inducible	I-C1158770
transcription	I-C1158770
in	O
multiple	B-C0439064
cellular	B-C1325880
processes	I-C1325880
and	O
during	O
inflammatory	B-C1155266
and	O
immune	B-C0301872
response	I-C0301872
.	O
	
however	O
,	O
the	O
functions	B-C1527118
of	O
general	B-C1571486
control	I-C1571486
nonrepressed-protein	I-C1571486
5	I-C1571486
gcn5	B-C1571486
,	O
an	O
evolutionarily	O
conserved	O
hat	B-C0062773
from	O
yeast	B-C0043393
to	O
human	B-C0086418
,	O
in	O
immune	B-C1327458
regulation	I-C1327458
remain	O
unappreciated	O
.	O
	
in	O
this	O
study	B-C0008972
,	O
we	O
conditionally	O
deleted	B-C0017260
gcn5	B-C1571486
encoded	B-C2700640
by	O
the	O
kat2a	B-C1415020
gene	I-C1415020
specifically	O
in	O
t	B-C0039194
lymphocytes	I-C0039194
by	O
crossing	B-C0010366
floxed	B-C1415020
gcn5	I-C1415020
and	O
lck-cre	B-C0919477
mice	B-C0025929
,	O
and	O
demonstrated	O
that	O
gcn5	B-C1571486
plays	O
important	B-C1705810
roles	I-C1705810
in	O
multiple	O
stages	B-C1306673
of	O
t	B-C0007613
cell	I-C0007613
functions	I-C0007613
including	O
development	B-C0815089
,	O
clonal	B-C1516670
expansion	I-C1516670
,	O
and	O
differentiation	B-C0007589
.	O
	
loss	B-C0243095
of	I-C0243095
gcn5	B-C1571486
functions	O
impaired	B-C4022557
t	I-C4022557
cell	I-C4022557
proliferation	I-C4022557
,	O
il-2	B-C1819447
production	I-C1819447
,	O
and	O
th1	B-C0242632
/	O
th17	B-C2936411
,	O
but	O
not	O
th2	B-C0242633
and	O
regulatory	B-C1155041
t	I-C1155041
cell	I-C1155041
differentiation	I-C1155041
.	O
	
gcn5	B-C1571486
is	O
recruited	O
onto	O
the	O
il-2	B-C0879590
promoter	B-C0086860
by	O
interacting	B-C1704675
with	O
the	O
nfat	B-C0288011
in	O
t	B-C0039194
cells	I-C0039194
upon	O
tcr	B-C0034790
stimulation	O
.	O
	
interestingly	O
,	O
instead	O
of	O
directly	O
acetylating	O
nfat	O
,	O
gcn5	O
catalyzes	O
histone	O
h3	O
lysine	O
h9	O
acetylation	O
to	O
promote	O
il-2	O
production	O
.	O
	
t	O
cell	O
-specific	O
suppression	O
of	O
gcn5	O
partially	O
protected	O
mice	O
from	O
myelin	O
oligodendrocyte	O
glycoprotein	O
-	O
induced	O
experimental	O
autoimmune	O
encephalomyelitis	O
,	O
an	O
experimental	O
model	O
for	O
human	O
multiple	O
sclerosis	O
.	O
	
our	O
study	O
reveals	O
previously	O
unknown	O
physiological	O
functions	O
for	O
gcn5	O
and	O
a	O
molecular	O
mechanism	O
underlying	O
these	O
functions	O
in	O
regulating	O
t	O
cell	O
immunity	O
.	O
	
hence	O
gcn5	O
may	O
be	O
an	O
important	O
new	O
target	O
for	O
autoimmune	O
disease	O
therapy	B-C0087111
minor	B-C0000768
physical	I-C0000768
anomalies	I-C0000768
and	O
dermatoglyphic	B-C0221916
signs	O
in	O
affective	B-C0525045
disorders	I-C0525045
a	O
systematic	B-C1955832
review	I-C1955832
the	O
increased	B-C0205217
prevalence	B-C0220900
of	O
minor	B-C0000768
physical	I-C0000768
anomalies	I-C0000768
mpas	B-C0000768
and	O
the	O
abnormalities	B-C0432333
of	I-C0432333
dermatoglyphic	I-C0432333
patterns	I-C0432333
may	O
be	O
physical	B-C0205485
manifestations	B-C0205319
of	O
neurodevelopmental	B-C0679378
disruption	I-C0679378
in	O
affective	B-C0525045
disorders	I-C0525045
.	O
	
this	O
paper	O
aims	O
to	O
review	B-C1955832
the	O
current	O
state	O
of	O
knowledge	O
on	O
the	O
frequency	B-C0439603
of	O
mpas	B-C0000768
and	O
dermatoglyphic	B-C0432333
abnormalities	I-C0432333
in	O
mood	B-C0525045
disorders	I-C0525045
.	O
	
a	O
medline	B-C0025141
,	O
psychinfo	B-C0242356
and	O
web	B-C0242356
of	I-C0242356
science	I-C0242356
search	I-C0242356
was	O
carried	O
out	O
to	O
collect	O
all	O
publications	B-C0034036
on	O
the	O
frequency	B-C0439603
of	O
mpas	B-C0000768
and	O
on	O
dermatoglyphic	B-C4025116
traits	I-C4025116
in	O
bipolar	B-C0005586
disorder	I-C0005586
and	O
unipolar	B-C0041696
depression	I-C0041696
.	O
	
24	O
studies	B-C2603343
on	O
mpas	B-C0000768
,	O
19	O
on	O
dermatoglyphics	B-C0011624
,	O
and	O
5	O
dealing	O
with	O
both	O
were	O
found	O
with	O
discrepant	B-C1290905
findings	B-C2607943
.	O
	
the	O
relative	B-C0205345
contribution	B-C1880177
of	O
neurodevelopmental	B-C0679378
retardation	I-C0679378
to	O
the	O
aetiology	B-C1314792
of	O
affective	B-C0525045
disorders	I-C0525045
remains	O
undetermined	O
,	O
the	O
field	O
is	O
open	O
for	O
further	O
research	B-C0035168
.	O
	
increased	B-C0442805
recognition	B-C0524637
of	O
neurodevelopmental	B-C0599855
processes	B-C1522240
in	O
the	O
origin	B-C0439659
of	O
affective	B-C0525045
disorders	I-C0525045
may	O
allow	O
for	O
earlier	O
and	O
more	O
effective	B-C1704419
intervention	B-C0184661
and	O
novel	B-C0035171
strategy	I-C0035171
to	O
expand	O
super-charged	B-C0022688
nk	I-C0022688
cells	I-C0022688
with	O
significant	B-C3245505
potential	I-C3245505
to	O
lyse	B-C0024348
and	O
differentiate	B-C0205615
cancer	B-C1956422
stem	I-C1956422
cells	I-C1956422
differences	B-C1705241
in	O
nk	B-C0007595
expansion	I-C0007595
and	O
function	B-C0542341
between	O
healthy	B-C1708335
and	O
cancer	B-C1516213
patients	I-C1516213
natural	B-C0022688
killer	I-C0022688
nk	I-C0022688
cells	I-C0022688
are	O
known	O
to	O
target	O
cancer	B-C1956422
stem	I-C1956422
cells	I-C1956422
and	O
undifferentiated	B-C0205698
tumors	I-C0205698
.	O
	
in	O
this	O
paper	O
,	O
we	O
provide	O
a	O
novel	B-C0035171
strategy	I-C0035171
for	O
expanding	O
large	O
numbers	O
of	O
super-charged	B-C0022688
nk	I-C0022688
cells	I-C0022688
with	O
significant	B-C3245505
potential	I-C3245505
to	O
lyse	B-C0024348
and	O
differentiate	B-C0205615
cancer	B-C1956422
stem	I-C1956422
cells	I-C1956422
and	O
demonstrate	O
the	O
differences	B-C1705241
in	O
the	O
dynamics	B-C3826426
of	O
nk	B-C0022688
cell	I-C0022688
expansion	B-C0007595
between	O
healthy	B-C0013018
donors	I-C0013018
and	O
cancer	B-C1516213
patients	I-C1516213
.	O
	
decline	B-C1849420
in	I-C1849420
cytotoxicity	I-C1849420
and	O
lower	B-C0441994
interferon	B-C3156720
ifn	I-C3156720
secretion	I-C3156720
by	O
osteoclast	B-C0029431
oc	B-C0029431
nk	B-C0022688
cells	I-C0022688
from	O
cancer	B-C1516213
patients	I-C1516213
correlates	O
with	O
faster	B-C0456962
expansion	B-C0007595
of	O
residual	O
contaminating	B-C0205279
t	B-C0039194
cells	I-C0039194
within	O
purified	B-C1998793
nk	B-C0022688
cells	I-C0022688
,	O
whereas	O
healthy	B-C0013018
donors	I-C0013018
'	O
ocs	B-C0029431
continue	O
expanding	O
super-charged	B-C0022688
nk	I-C0022688
cells	I-C0022688
while	O
limiting	O
t	B-C0039194
cell	I-C0039194
expansion	B-C0007595
for	O
up	O
to	O
60	O
days	B-C0439228
.	O
	
similar	O
to	O
patient	B-C0030705
nk	B-C0022688
cells	I-C0022688
,	O
nk	B-C0022688
cells	I-C0022688
from	O
tumor	B-C0027651
-bearing	O
blt-humanized	B-C2986594
mice	I-C2986594
promote	O
faster	B-C0456962
expansion	B-C0007595
of	O
residual	O
t	B-C2673541
cells	I-C2673541
resulting	I-C2673541
in	I-C2673541
decreased	I-C2673541
numbers	I-C2673541
and	O
function	B-C0542341
of	O
nk	B-C0022688
cells	I-C0022688
,	O
whereas	O
nk	B-C0022688
cells	I-C0022688
from	O
mice	B-C0025929
with	O
no	B-C1513916
tumor	B-C0027651
continue	O
expanding	B-C0007595
nk	B-C0022688
cells	I-C0022688
and	O
retain	O
their	O
cytotoxicity	B-C0596402
.	O
	
in	O
addition	O
,	O
dendritic	B-C0011306
cells	I-C0011306
dcs	B-C0011306
in	O
contrast	O
to	O
ocs	B-C0029431
are	O
found	O
to	O
promote	O
faster	B-C0456962
expansion	B-C0007595
of	O
residual	O
t	B-C0039194
cells	I-C0039194
within	O
purified	B-C1998793
nk	B-C0022688
cells	I-C0022688
resulting	O
in	O
the	O
decline	B-C2363838
in	I-C2363838
nk	I-C2363838
cell	I-C2363838
numbers	I-C2363838
from	O
healthy	B-C1708335
individuals	I-C1708335
.	O
	
addition	O
of	O
anti-cd3	B-C3831520
mab	I-C3831520
inhibits	O
t	B-C1155046
cell	I-C1155046
proliferation	I-C1155046
while	O
enhancing	B-C2349975
nk	B-C0022688
cell	I-C0022688
expansion	B-C0007595
however	O
,	O
expanding	B-C0007595
nk	B-C0022688
cells	I-C0022688
have	O
lower	B-C0441994
cytotoxicity	B-C0596402
but	O
higher	B-C0205250
secretion	B-C3156720
of	I-C3156720
ifn-γ	I-C3156720
.	O
	
expansion	B-C0007595
and	O
functional	B-C0205245
activation	B-C1879547
of	O
super-charged	B-C0022688
nk	I-C0022688
cells	I-C0022688
by	O
ocs	B-C0029431
is	O
dependent	B-C0851827
on	O
interleukin	B-C0123759
il	I-C0123759
and	O
il-15	B-C0254610
.	O
	
thus	O
,	O
in	O
this	O
report	O
,	O
we	O
not	O
only	O
provide	O
a	O
novel	B-C0035171
strategy	I-C0035171
to	O
expand	B-C0007595
super-charged	B-C0022688
nk	I-C0022688
cells	I-C0022688
,	O
but	O
also	O
demonstrate	O
that	O
rapid	B-C0007595
and	I-C0007595
sustained	I-C0007595
expansion	I-C0007595
of	O
residual	O
t	B-C0039194
cells	I-C0039194
within	O
the	O
purified	B-C1998793
nk	B-C0022688
cells	I-C0022688
during	O
expansion	B-C0007595
with	O
dcs	B-C0011306
or	O
ocs	B-C0029431
could	O
be	O
a	O
potential	B-C3245505
mechanism	B-C0441712
by	O
which	O
the	O
numbers	B-C0237753
and	O
function	B-C0542341
of	O
nk	B-C2363838
cells	I-C2363838
decline	I-C2363838
in	O
cancer	B-C1516213
patients	I-C1516213
and	O
in	O
blt-humanized	B-C2986594
mice	I-C2986594
.	O
	
extremely	B-C0205403
giant	B-C0238246
liver	I-C0238246
hemangioma	I-C0238246
50	O
cm	O
with	O
kasabach-merritt	B-C0221025
syndrome	I-C0221025
a	O
33-	O
year	B-C0439234
-	O
old	B-C0580836
male	B-C0086582
has	O
been	O
found	B-C0150312
with	O
a	O
giant	B-C0238246
liver	I-C0238246
hemangioma	I-C0238246
of	O
initial	B-C0205265
size	B-C0475440
29	O
cm	O
for	O
5	O
years	B-C0439234
.	O
	
he	O
received	B-C1514756
arterial	B-C3163695
embolization	I-C3163695
twice	B-C1948050
in	O
order	O
to	O
shrink	B-C0205230
the	O
tumor	B-C0027651
however	O
,	O
no	B-C1301751
effect	I-C1301751
was	O
obtained	B-C1301820
.	O
	
the	O
tumor	B-C0027651
had	O
rapidly	B-C0456962
grown	B-C2911660
to	O
50	O
cm	O
and	O
caused	O
abnormalities	B-C1704258
in	O
the	O
hematological	B-C0279810
and	O
coagulative	B-C0005778
systems	B-C0449913
.	O
	
preoperative	B-C0445204
computed	B-C0040405
tomography	I-C0040405
revealed	B-C0443289
that	O
the	O
right	B-C0205090
hepatic	B-C0019155
vein	I-C0019155
,	O
right	B-C0205090
hepatic	B-C0019145
artery	I-C0019145
,	O
and	O
right	B-C0205090
portal	B-C0032718
vein	I-C0032718
were	O
not	B-C4296884
involved	I-C4296884
by	O
the	O
hemangioma	B-C0018916
.	O
	
resection	B-C0728940
of	O
the	O
giant	B-C0238246
liver	I-C0238246
hemangioma	I-C0238246
was	O
successfully	B-C1272703
performed	B-C0884358
after	O
intraoperative	B-C0456904
intentional	B-C1283828
bloodletting	B-C0005857
with	O
concurrent	B-C0205420
blood	B-C0200591
salvage	I-C0200591
.	O
	
all	O
hematological	B-C0279810
and	O
coagulative	B-C0005778
abnormalities	B-C1704258
had	O
returned	B-C0332156
to	O
normal	B-C0205307
after	O
the	O
role	B-C1705810
of	O
cysteine	B-C0010654
residues	B-C1709915
in	O
regulation	B-C0518894
of	O
peptidyl-prolyl	B-C1150301
cis-trans	I-C1150301
isomerase	I-C1150301
activity	I-C1150301
of	O
wheat	B-C0043137
cyclophilin	B-C0917877
tacypa-1	B-C1418793
oxidative	B-C0311404
conditions	B-C0348080
result	O
in	O
inhibition	B-C3463820
of	O
peptidyl-prolyl	B-C1150301
cis-trans	I-C1150301
isomerase	I-C1150301
ppiase	I-C1150301
activity	I-C1150301
of	O
several	O
cyclophilins	B-C0917877
.	O
	
thiol	B-C0038734
groups	O
have	O
been	O
implicated	O
in	O
redox	B-C0030012
regulation	B-C0518894
of	O
these	O
proteins	B-C0033684
.	O
	
in	O
our	O
previous	O
study	O
,	O
we	O
proposed	O
that	O
activity	B-C0243102
of	O
wheat	B-C0043137
cyclophilin	B-C0917877
,	O
tacypa-1	B-C1418793
,	O
may	O
be	O
modulated	B-C0443264
through	O
a	O
novel	O
dual	O
mechanism	B-C0441712
of	O
redox	B-C0030012
regulation	B-C0518894
.	O
	
to	O
further	O
understand	O
the	O
regulation	B-C0518894
of	O
ppiase	B-C1150301
activity	I-C1150301
of	O
tacypa-1	B-C1418793
,	O
we	O
generated	O
mutants	B-C0596988
of	O
tacypa-1	B-C1418793
by	O
substituting	B-C1706204
cysteine	B-C0010654
residues	B-C1709915
at	O
positions	B-C0733755
-40	O
and	O
-122	O
with	O
serine	B-C0036720
,	O
and	O
at	O
-126	O
with	O
proline	B-C0033382
.	O
	
comparative	B-C0683941
analysis	I-C0683941
of	O
their	O
ppiase	B-C1150301
activity	I-C1150301
revealed	O
that	O
catalytic	B-C0007382
efficiencies	B-C0013682
kcat/km	O
of	O
tacypa-1c40s	B-C0136073
0.37	O
x	O
106	O
m-1	O
s-1	O
and	O
tacypa-1c122s	B-C0136073
0.31	O
x	O
106	O
m-1	O
s-1	O
were	O
significantly	B-C4055638
lower	I-C4055638
as	O
compared	O
to	O
the	O
native	O
tacypa-1	B-C0136073
1.33	O
x	O
106	O
m-1	O
s-1	O
,	O
whereas	O
kcat/km	O
of	O
the	O
double	O
mutant	B-C0596988
tacypa-1c40s/c122s	B-C0136073
was	O
significantly	B-C4055637
higher	I-C4055637
2.36	O
x	O
106	O
m-1	O
s-1	O
.	O
	
compared	O
to	O
wild-type	B-C1883559
tacypa-1	B-C1418793
,	O
the	O
different	O
mutants	B-C0596988
also	O
showed	O
differential	B-C0443199
sensitivity	B-C0332324
to	O
cu2+	B-C1177210
.	O
	
furthermore	O
,	O
the	O
results	B-C1274040
of	O
this	O
study	B-C2603343
also	O
revealed	B-C0443289
that	O
despite	O
lacking	B-C0332268
ppiase	B-C1150301
activity	I-C1150301
,	O
the	O
mutant	B-C0596988
tacypa-1c126p	B-C1418793
was	O
able	O
to	O
confer	O
partial	B-C0728938
protection	B-C1545588
against	O
heat	B-C0282498
stress	I-C0282498
.	O
	
these	O
observations	B-C0302523
suggest	O
that	O
the	O
mechanism	B-C0441712
of	O
tacypa-1	B-C1418793
-induced	O
thermotolerance	B-C3544386
may	O
also	O
involve	O
other	O
activities	B-C0441655
besides	O
cis	B-C0596342
to	I-C0596342
trans	I-C0596342
isomerisation	I-C0596342
,	O
which	O
needs	O
to	O
be	O
identified	B-C0205396
association	B-C0439849
of	O
exclusive	B-C0242205
breastfeeding	I-C0242205
duration	B-C0449238
with	O
systemic	B-C3646020
inflammation	I-C3646020
markers	B-C0005516
in	O
adolescents	B-C0205653
a	O
cross-sectional	B-C0010362
study	I-C0010362
breastfeeding	B-C2136514
duration	I-C2136514
has	O
been	O
associated	B-C0332281
with	I-C0332281
less	B-C0439092
low-grade	B-C1282907
inflammation	B-C0021368
in	O
healthy	B-C3898900
adolescents	B-C0205653
,	O
but	O
there	O
is	O
scarce	B-C0231180
information	B-C1533716
regarding	O
obese	B-C0028754
subjects	O
.	O
	
this	O
study	O
aimed	O
to	O
evaluate	O
whether	O
exclusive	B-C0242205
breastfeeding	I-C0242205
is	O
related	O
to	O
serum	B-C0683149
concentrations	I-C0683149
of	O
inflammatory	B-C0333348
markers	B-C0005516
in	O
a	O
population	B-C1257890
of	O
spanish	B-C0086409
adolescents	B-C0205653
.	O
	
a	O
cross-sectional	B-C0010362
study	I-C0010362
was	O
performed	B-C0884358
on	O
1	O
adolescents	B-C0205653
13.2	O
1.2	O
years	O
randomly	O
recruited	O
from	O
schools	B-C0036375
in	O
southeast	B-C1711190
spain	B-C0037747
.	O
	
data	B-C1511726
on	O
breastfeeding	B-C2136514
duration	I-C2136514
were	O
collected	B-C1516698
via	O
a	O
parental	B-C0034394
questionnaire	I-C0034394
.	O
	
interleukin-6	B-C0021760
il-6	B-C0021760
and	O
tumor	B-C1456820
necrosis	I-C1456820
factor-alpha	I-C1456820
tnf-α	B-C1456820
were	O
determined	B-C0521095
by	I-C0521095
enzyme-linked	B-C0014441
immunosorbent	I-C0014441
assay	I-C0014441
.	O
	
c-reactive	B-C0006560
protein	I-C0006560
crp	B-C0006560
was	O
determined	B-C0521095
by	I-C0521095
solid-phase	B-C0020980
chemiluminescent	I-C0020980
immunometric	I-C0020980
assay	I-C0020980
.	O
	
nonadjusted	O
and	O
adjusted	O
multivariate	B-C0026777
correlation	B-C0010101
analyses	I-C0010101
confirmed	B-C1456348
a	O
strong	B-C0442821
association	B-C0439849
p	O
<	O
001	O
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
between	O
the	O
three	O
markers	B-C0005516
of	O
inflammation	B-C0021368
and	O
exclusive	B-C0242205
breastfeeding	I-C0242205
duration	B-C0449238
.	O
	
no	B-C1273937
significant	I-C1273937
differences	B-C1705242
were	O
observed	B-C1441672
for	O
il-6	B-C0021760
,	O
tnf-α	B-C1456820
,	O
and	O
crp	B-C0006560
serum	B-C0683149
concentrations	I-C0683149
among	O
normal	B-C1285592
weight	I-C1285592
,	O
overweight	B-C0497406
,	O
and	O
obese	B-C0028754
adolescents	B-C0205653
,	O
except	B-C0332300
for	I-C0332300
il-6	B-C0021760
between	O
normal	B-C1285592
weight	I-C1285592
and	O
obese	B-C0028754
subjects	B-C0205653
.	O
	
likewise	O
,	O
no	B-C1273937
significant	I-C1273937
association	B-C0439849
was	O
found	B-C0150312
between	O
these	O
markers	B-C0005516
of	O
inflammation	B-C0021368
and	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
z-score	B-C0871421
.	O
	
we	O
found	B-C0150312
a	O
possible	B-C0332149
association	B-C0439849
between	O
inflammatory	B-C0333348
markers	B-C0005516
and	O
exclusive	B-C0242205
breastfeeding	I-C0242205
duration	B-C0449238
in	O
adolescents	B-C0205653
,	O
regardless	B-C3641650
of	O
their	O
bmi	B-C1305855
.	O
	
this	O
finding	B-C0243095
suggests	B-C1705535
that	O
increased	B-C0205217
body	B-C0005910
weight	I-C0005910
or	O
obesity	B-C0028754
might	O
not	O
mediate	O
the	O
association	B-C0439849
between	O
breastfeeding	B-C0006147
and	O
inflammation	B-C0021368
.	O
	
these	O
results	B-C1274040
contribute	O
to	O
the	O
understanding	B-C0162340
of	O
the	O
relationship	B-C0439849
between	O
breastfeeding	B-C0006147
and	O
inflammatory	B-C0333348
markers	B-C0005516
in	O
effect	B-C1280500
of	O
ultrasound	B-C1456803
and	O
enzymatic	B-C0014442
pre-treatment	B-C3539076
on	O
yield	B-C0392762
and	O
properties	B-C0871161
of	O
banana	B-C0004722
juice	B-C1268568
effect	B-C1280500
of	O
ultrasound	B-C1456803
and	O
enzymatic	B-C0014442
pre-treatments	B-C3539076
with	O
cellulase	B-C0007641
and	O
pectinase	B-C0032491
on	O
yield	B-C0392762
and	O
properties	B-C0871161
of	O
banana	B-C0004722
juice	B-C1268568
were	O
investigated	B-C1292732
.	O
	
a	O
two-level	B-C0681865
full	I-C0681865
factorial	I-C0681865
design	I-C0681865
was	O
employed	O
.	O
	
the	O
factors	O
selected	O
were	O
ultrasonication	B-C0040223
time	I-C0040223
0	O
and	O
30	O
min	B-C0439232
,	O
cellulase	B-C0007641
concentration	B-C0392762
0	O
and	O
0.2	O
and	O
pectinase	B-C0032491
concentration	B-C0392762
0	O
and	O
0.2	O
.	O
	
the	O
responses	O
studied	O
were	O
yield	B-C0392762
,	O
viscosity	B-C0042784
,	O
clarity	B-C3272888
,	O
total	B-C0392762
soluble	I-C0392762
solids	I-C0392762
tss	B-C0392762
and	O
ph	B-C0020283
.	O
	
it	O
was	O
observed	O
that	O
pectinase	B-C0032491
was	O
more	O
effective	B-C1704419
in	O
increasing	B-C0442808
the	O
yield	B-C0392762
of	O
juice	B-C1268568
compared	O
to	O
cellulase	B-C0007641
.	O
	
ultrasonic	B-C3539076
pre-treatment	I-C3539076
alone	O
did	O
not	B-C1513916
significantly	B-C0442805
increase	I-C0442805
the	O
yield	B-C0392762
of	O
juice	B-C1268568
.	O
	
when	O
ultrasound	B-C1456803
was	O
combined	O
with	O
pre-treatment	B-C3539076
with	O
both	O
the	O
enzymes	B-C0014442
maximum	B-C0392762
yield	I-C0392762
of	O
89.40	O
was	O
obtained	O
compared	O
to	O
47.30	O
in	O
the	O
control	B-C0009932
.	O
	
the	O
viscosity	B-C0042784
of	O
the	O
juice	B-C1268568
decreased	B-C0205216
with	O
addition	O
of	O
enzymes	B-C0014442
and	O
with	O
application	O
of	O
ultrasound	B-C1456803
.	O
	
the	O
clarity	B-C2963144
of	O
the	O
juice	B-C1268568
was	O
not	O
affected	O
by	O
cellulase	B-C0007641
treatment	B-C1522326
,	O
but	O
improved	B-C0184511
with	O
pectinase	B-C0032491
treatment	B-C1522326
.	O
	
ultrasonication	B-C1456803
alone	O
was	O
found	O
to	O
be	O
more	O
effective	B-C1704419
than	O
pectinase	B-C0032491
or	O
cellulase	B-C0007641
treatment	B-C1522326
in	O
improving	B-C1272745
the	O
clarity	B-C0486588
of	O
the	O
juice	B-C1268568
.	O
	
the	O
tss	B-C0392762
increased	B-C0205217
with	O
enzymatic	B-C0014442
treatment	B-C1522326
,	O
ultrasonication	B-C1456803
and	O
their	O
combination	O
.	O
	
ph	B-C0020283
was	O
not	O
affected	O
by	O
treatment	B-C1522326
type	O
,	O
but	O
was	O
found	O
to	O
be	O
lower	O
for	O
the	O
treated	B-C1522326
juices	B-C1268568
.	O
	
significant	B-C1707520
correlations	I-C1707520
electrocardiographic	B-C0428946
appearance	I-C0428946
of	O
aortic	B-C0003507
stenosis	I-C0003507
before	O
and	O
after	O
aortic	B-C0003506
valve	I-C0003506
replacement	I-C0003506
so	O
far	O
,	O
the	O
specific	O
appearance	O
of	O
qrs	B-C0429097
complex	I-C0429097
,	O
st-segment	B-C0429029
,	O
and	O
t	B-C0239242
wave	I-C0239242
was	O
observed	B-C1441672
in	O
aortic	B-C0003507
stenosis	I-C0003507
as	B-C0003507
.	O
	
s-wave	B-C0429094
dynamic	B-C0729333
change	B-C0392747
in	O
leads	B-C0441907
v1	I-C0441907
-	O
v3	B-C0449218
was	O
not	O
reported	O
in	O
as	B-C0003507
.	O
	
in	O
a	O
single-center	O
,	O
prospective	B-C0033522
study	I-C0033522
,	O
we	O
included	O
a	O
total	O
number	O
of	O
1.175	O
patients	B-C0030705
who	O
underwent	O
surgical	B-C0543467
aortic	B-C0003506
valve	I-C0003506
replacement	I-C0003506
avr	B-C0003506
.	O
	
we	O
conducted	O
3-year	O
gathering	O
of	O
patients	B-C0030705
with	O
symptomatic	B-C0231220
and	O
asymptomatic	B-C0231221
severe	O
as	B-C0003507
,	O
and	O
separated	O
them	O
by	O
hemodynamic	B-C0489528
stability	I-C0489528
into	O
groups	O
a	O
and	O
b	O
,	O
through	O
eflv	B-C0428772
of	O
more	O
or	O
less	O
than	O
50%	O
,	O
ava	B-C0428817
of	O
more	O
or	O
less	O
than	O
0.9	O
cm	O
,	O
pg	B-C0232117
between	O
55	O
and	O
75	O
mm	B-C0439475
hg	I-C0439475
or	O
over	O
75	O
mm	B-C0439475
hg	I-C0439475
,	O
and	O
end-diastolic	B-C2059470
lv	I-C2059470
dimension	I-C2059470
of	O
more	O
or	O
less	O
than	O
56	O
mm	O
.	O
	
we	O
evaluated	B-C0220825
the	O
impact	B-C4049986
of	O
s-wave	B-C0429094
magnitude	B-C1704240
in	O
right	B-C2729494
precordial	I-C2729494
leads	O
before	O
and	O
after	O
avr	B-C0003506
in	O
all	O
patients	B-C0030705
.	O
	
we	O
followed	O
s-wave	B-C0429094
changes	B-C0392747
in	O
electrocardiogram	B-C0013798
altogether	O
with	O
hemodynamic	B-C0204901
measurements	I-C0204901
derived	O
from	O
echocardiography	B-C0013516
.	O
	
analysis	B-C0936012
of	O
echocardiographic	B-C0013516
parameters	B-C0449381
,	O
measured	B-C0444706
in	O
patients	B-C0030705
before	O
surgery	B-C0543467
,	O
did	O
not	O
show	O
statistical	B-C0237881
significance	I-C0237881
between	O
asymptomatic	B-C0231221
and	O
symptomatic	B-C0231220
group	O
.	O
	
the	O
statistical	B-C0237881
significance	I-C0237881
was	O
observed	B-C1441672
in	O
the	O
change	B-C0392747
in	O
s-wave	B-C0429094
magnitude	B-C1704240
in	O
the	O
right	B-C2729494
precordial	I-C2729494
leads	O
in	O
both	O
subsets	O
of	O
patients	B-C0030705
before	O
avr	B-C0003506
.	O
	
we	O
found	O
statistically	B-C0237881
significant	I-C0237881
predictive	B-C1514307
value	I-C1514307
of	O
s-wave	B-C0429094
magnitude	B-C1704240
in	O
leads	B-C0441908
v2	I-C0441908
-	O
v3	B-C0449218
for	O
dependent	B-C0871711
variables	I-C0871711
pg	B-C0232117
and	O
end-diastolic	B-C2059470
lv	I-C2059470
dimension	I-C2059470
.	O
	
s-wave	B-C0429094
changes	O
in	O
right	B-C2729494
precordial	I-C2729494
leads	O
can	O
predict	O
increase	B-C0442805
in	O
pg	B-C0232117
and	O
critical	O
narrowing	O
of	O
ava	B-C0428817
,	O
suggestive	B-C0332299
of	I-C0332299
timely	O
referral	B-C2585524
for	I-C2585524
avr	B-C0003506
.	O
	
anemia	B-C0002871
complicating	B-C1522701
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
prevalence	B-C0220900
,	O
risk	B-C0035648
factors	I-C0035648
and	O
prognosis	B-C0033325
to	O
determine	O
the	O
prevalence	B-C0220900
,	O
risk	B-C0035648
factors	I-C0035648
and	O
prognosis	B-C0033325
of	O
anemia	B-C0002871
in	O
representative	B-C0030701
community-based	O
patients	B-C0030705
with	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
.	O
	
data	O
from	O
the	O
fremantle	B-C2603343
diabetes	I-C2603343
study	I-C2603343
phase	I-C2603343
ii	I-C2603343
fds2	B-C2603343
n=1551	O
,	O
mean	O
age	O
65.7years	O
,	O
51.9	O
males	B-C0086582
and	O
busselton	B-C2603343
diabetes	I-C2603343
study	I-C2603343
bds	B-C2603343
n=186	O
,	O
mean	O
age	O
70.2years	O
,	O
50.0	O
males	B-C0086582
cohorts	B-C0599755
,	O
and	O
from	O
186	O
matched	O
bds	B-C2603343
participants	B-C0679646
without	O
diabetes	B-C0011847
,	O
were	O
analyzed	B-C0936012
.	O
	
the	O
prevalence	B-C0220900
of	O
anemia	B-C0002871
hemoglobin	B-C0019046
130g/l	O
males	B-C0086582
,	O
120g/l	O
females	B-C0086287
was	O
determined	B-C0521095
in	O
each	O
sample	B-C0178913
.	O
	
in	O
fds2	B-C2603343
,	O
associates	O
of	O
anemia	B-C0002871
were	O
assessed	B-C1516048
using	O
multiple	O
logistic	B-C0206031
regression	I-C0206031
and	O
cox	B-C0010235
proportional	I-C0010235
hazards	I-C0010235
modeling	I-C0010235
identified	O
predictors	B-C0035648
of	O
death	B-C0011065
during	O
4.3	O
post-recruitment	O
.	O
	
the	O
prevalence	B-C0220900
of	O
anemia	B-C0002871
at	O
baseline	O
was	O
11.5	O
in	O
fds2	B-C2603343
participants	B-C0679646
,	O
17.8	O
in	O
bds	B-C2603343
type	O
2	O
patients	B-C0030705
and	O
5.4	O
in	O
bds	B-C2603343
participants	B-C0679646
without	O
diabetes	B-C0011847
.	O
	
in	O
fds2	B-C2603343
,	O
163	O
of	O
178	O
patients	B-C0030705
with	O
anemia	B-C0002871
91.6	O
had	O
at	O
least	O
one	O
other	O
risk	B-C0035648
factor	I-C0035648
serum	B-C0427408
vitamin	I-C0427408
b12	I-C0427408
<140pmol/l	O
,	O
serum	B-C0241012
ferritin	I-C0241012
<30μg/l	O
and/or	O
transferrin	B-C1277709
saturation	I-C1277709
<20%	O
,	O
serum	B-C0428413
testosterone	I-C0428413
<10nmol/l	O
males	B-C0086582
,	O
glitazone	B-C1257987
therapy	B-C0087111
,	O
estimated	B-C3811844
glomerular	I-C3811844
filtration	I-C3811844
rate	I-C3811844
egfr	B-C3811844
<60ml/min	O
1.73m	O
,	O
malignancy	B-C4282132
,	O
hemoglobinopathy	B-C0019045
.	O
	
more	O
anemic	B-C0857322
than	O
non-anemic	B-C0857322
fds2	B-C2603343
patients	B-C0030705
died	O
28.7	O
versus	O
8.0	O
p<0	O
.	O
	
after	O
adjustment	O
for	O
other	O
independent	O
predictors	B-C0035648
age	O
as	O
time-scale	O
,	O
male	O
sex	O
,	O
aboriginality	B-C1704258
,	O
marital	B-C0024819
status	I-C0024819
,	O
smoking	B-C0037369
,	O
egfr	B-C3811844
,	O
anemia	B-C0002871
was	O
associated	B-C0332281
with	I-C0332281
a	O
57%	O
increase	B-C0442805
in	O
mortality	O
p=0	O
.	O
	
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	B-C0002871
but	O
other	O
mostly	O
modifiable	O
risk	B-C0035648
factors	I-C0035648
are	O
usually	O
present	B-C0150312
.	O
	
anemia	B-C0002871
is	O
associated	B-C0332281
with	I-C0332281
an	O
increased	B-C2749787
risk	I-C2749787
of	I-C2749787
death	I-C2749787
after	O
adjustment	O
for	O
other	O
succinic	B-C0075429
acid	I-C0075429
production	B-C1883254
by	O
immobilized	B-C0282542
cultures	B-C0007585
using	O
spent	B-C0302908
sulphite	I-C0302908
liquor	I-C0302908
as	O
fermentation	B-C0015852
medium	B-C1705217
spent	B-C0010454
sulphite	I-C0010454
liquor	I-C0010454
ssl	B-C0010454
was	O
used	O
as	O
carbon	B-C0007009
source	B-C0449416
for	O
the	O
production	B-C1883254
of	O
succinic	B-C0075429
acid	I-C0075429
using	O
immobilized	B-C0282542
cultures	B-C0007585
of	O
actinobacillus	B-C1026661
succinogenes	I-C1026661
and	O
basfia	B-C3716734
succiniciproducens	I-C3716734
on	O
two	O
different	O
supports	B-C0439861
,	O
delignified	B-C3256315
cellulosic	I-C3256315
material	I-C3256315
dcm	B-C3256315
and	O
alginate	B-C0102137
beads	B-C0439861
.	O
	
fed-batch	B-C3179109
immobilized	I-C3179109
cultures	I-C3179109
with	O
a	B-C1026661
.	O
	
succinogenes	I-C1026661
in	O
alginates	B-C0102137
resulted	O
in	O
higher	B-C0205250
sugar	B-C0242209
to	O
succinic	B-C0075429
acid	I-C0075429
conversion	B-C0392762
yield	I-C0392762
0.81g	O
than	O
the	O
respective	O
yield	B-C0392762
achieved	O
0.65g	O
when	O
dcm	B-C3256315
immobilized	B-C0282542
cultures	B-C0007585
were	O
used	O
.	O
	
the	O
final	O
succinic	B-C0075429
acid	I-C0075429
concentration	B-C1446561
and	O
yield	B-C0392762
achieved	O
in	O
fed-batch	B-C3179109
with	O
immobilized	B-C0282542
cultures	B-C0007585
of	O
b	B-C3716734
.	O
	
succiniciproducens	I-C3716734
in	O
alginates	B-C0102137
45g/l	O
and	O
0.66g	O
were	O
higher	B-C0205250
than	O
a	B-C1026661
.	O
	
succinogenes	I-C1026661
immobilized	B-C0282542
cultures	B-C0007585
35.4g	O
and	O
0.61g	O
using	O
nano	B-C1553036
-	O
filtrated	B-C0302908
ssl	I-C0302908
as	O
fermentation	B-C0015852
medium	B-C1705217
.	O
	
immobilized	B-C0282542
cultures	B-C0007585
of	O
b	B-C3716734
.	O
	
succiniciproducens	I-C3716734
in	O
alginate	B-C0102137
beads	B-C0439861
were	O
reused	O
in	O
four	O
sequential	B-C3179109
fed-batch	I-C3179109
fermentations	B-C0015852
of	O
nano	B-C1553036
-	O
filtrated	B-C0010454
ssl	I-C0010454
leading	O
to	O
the	O
production	B-C1883254
of	O
64.7g	O
of	O
succinic	B-C0075429
acid	I-C0075429
with	O
a	O
yield	B-C0392762
range	O
of	O
0.42	O
and	O
productivity	B-C0033269
range	O
of	O
0.29	O
.	O
	
the	O
immobilized	B-C0282542
cultures	B-C0007585
improved	O
the	O
efficiency	B-C0013682
of	O
succinic	B-C0075429
acid	I-C0075429
production	B-C1883254
as	O
compared	B-C1707455
to	O
free	B-C0007585
cell	I-C0007585
cultures	I-C0007585
.	O
	
interventions	B-C1273869
to	O
improve	B-C0184511
grandparent	B-C0337471
caregivers'	B-C0086279
mental	B-C0025353
and	O
physical	B-C0517226
health	I-C0517226
an	O
integrative	B-C0282443
review	I-C0282443
the	O
aim	B-C1947946
of	O
this	O
integrative	B-C0282443
review	I-C0282443
is	O
to	O
appraise	O
grandparent	B-C0337471
caregiver	B-C0086279
interventions	B-C1273869
that	O
are	O
designed	O
to	O
improve	B-C0184511
their	O
physical	B-C0517226
and	O
mental	B-C0025353
health	I-C0025353
.	O
	
a	O
database	B-C0242356
search	B-C1706202
was	O
performed	O
to	O
identify	O
relevant	B-C2347946
studies	B-C2603343
published	B-C0034037
between	O
january	O
1	O
,	O
1980	O
,	O
and	O
december	O
31	O
,	O
2014	O
.	O
	
thirteen	O
publications	B-C0034036
,	O
including	O
11	O
studies	B-C2603343
,	O
met	O
all	O
inclusion	B-C1512693
and	O
exclusion	B-C0680251
criteria	I-C0680251
.	O
	
all	O
studies	B-C2603343
included	O
grandparent	B-C0337471
mental	B-C0025353
health	I-C0025353
outcomes	B-C1274040
with	O
fewer	O
focusing	O
on	O
physical	B-C0517226
health	I-C0517226
and	O
social	B-C0337609
relations	I-C0337609
.	O
	
improvements	B-C2986411
were	O
found	O
in	O
all	O
three	O
areas	B-C0205146
with	O
fewer	O
improvements	B-C2986411
seen	O
in	O
physical	B-C0517226
health	I-C0517226
.	O
	
however	O
,	O
small	B-C0814843
effect	I-C0814843
sizes	I-C0814843
were	O
seen	O
with	O
most	O
measures	B-C1879489
of	O
these	O
outcomes	B-C1274040
.	O
	
although	O
the	O
interventions	B-C1273869
led	O
to	O
positive	O
grandparent	B-C0337471
caregiver	B-C0086279
outcomes	O
,	O
the	O
studies	B-C2603343
were	O
limited	B-C0439801
by	O
their	O
design	B-C1707689
,	O
only	O
one	O
of	O
which	O
was	O
a	O
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
.	O
	
also	O
,	O
interventions	B-C1273869
did	O
not	O
consider	O
variations	B-C0205419
in	O
the	O
grandchild's	B-C0337548
or	O
parent's	B-C0030551
ages	B-C0001779
or	O
if	O
the	O
grandparent	B-C0337471
provided	O
primary	B-C0205225
or	O
shared	B-C0237876
care	B-C1947933
.	O
	
these	O
gaps	O
should	O
be	O
addressed	O
in	O
future	B-C0016884
research	B-C0035168
.	O
	
an	O
attenuated	B-C0599946
mycobacterium	B-C0026926
tuberculosis	I-C0026926
clinical	B-C0205210
strain	B-C1518614
with	O
a	O
defect	B-C1457869
in	O
esx-1	B-C1744314
secretion	B-C0036536
induces	O
minimal	B-C0547040
host	B-C1167395
immune	B-C0301872
responses	I-C0301872
and	O
pathology	B-C0030664
although	O
mycobacterium	B-C0026926
tuberculosis	I-C0026926
m.tb	I-C0026926
dk9897	I-C0026926
is	O
an	O
attenuated	B-C0599946
strain	B-C1518614
,	O
it	O
was	O
isolated	B-C0205409
from	O
a	O
patient	B-C0030705
with	O
extrapulmonary	B-C0679362
tuberculosis	I-C0679362
and	O
vaccination	B-C0042196
with	O
a	O
subunit	B-C0887892
vaccine	I-C0887892
h56	B-C0887892
induced	B-C0205263
poor	B-C0542537
protection	B-C1545588
against	O
it	O
.	O
	
both	O
attenuation	B-C0599946
and	O
lack	B-C0332268
of	O
protection	B-C1545588
are	O
because	O
m.tb	B-C0026926
dk9897	I-C0026926
cannot	O
secrete	B-C0036536
the	O
esxa	B-C1744314
virulence	B-C1136170
factor	I-C1136170
nor	O
induce	O
a	O
host	B-C0301872
response	I-C0301872
against	O
it	O
.	O
	
genome	B-C1328887
sequencing	I-C1328887
identified	O
a	O
frameshift	B-C0079380
mutation	I-C0079380
in	O
the	O
eccca1	B-C0017337
gene	I-C0017337
.	O
	
since	O
the	O
encoded	B-C2700640
eccca1	B-C1254349
protein	I-C1254349
provides	O
energy	B-C1442080
for	O
esx-1	B-C1744314
secretion	B-C0036536
,	O
it	O
suggested	O
a	O
defect	B-C1457869
in	O
the	O
esx-1	B-C1744314
type	B-C3159197
vii	I-C3159197
secretion	I-C3159197
system	I-C3159197
.	O
	
genetic	B-C0178654
complementation	I-C0178654
with	O
a	O
plasmid	B-C0032136
carrying	O
the	O
m.tb	B-C0026926
h37rv	I-C0026926
sequence	O
of	O
eccca1-ecccb1-pe35	B-C0012931
re-established	O
esxa	B-C1744314
secretion	B-C0036536
,	O
host	B-C1167395
specific	O
esxa	B-C1744314
t-cell	B-C0039194
responses	B-C0301872
,	O
and	O
increased	B-C0205217
strain	B-C1518614
virulence	B-C0042765
.	O
	
the	O
esx-1	B-C1744314
secretion	B-C0036536
defect	B-C1457869
prevents	B-C1292733
several	O
virulence	B-C1136170
factors	I-C1136170
from	O
being	O
functional	O
during	O
infection	B-C3714514
and	O
therefore	O
attenuates	B-C0599946
m.tb	B-C0026926
.	O
	
it	O
precludes	O
specific	O
t-cell	B-C0039194
responses	B-C0301872
against	O
strong	O
antigens	B-C0003320
and	O
we	O
found	O
very	O
little	O
in	B-C1515655
vivo	I-C1515655
cytokine	B-C1327413
production	I-C1327413
,	O
gross	B-C0428094
pathology	I-C0428094
or	O
granuloma	B-C1817882
formation	I-C1817882
in	O
lungs	B-C0024109
from	O
m.tb	B-C0026926
dk9897	I-C0026926
infected	B-C0237158
animals	I-C0237158
.	O
	
this	O
coincides	O
with	O
m.tb	B-C0026926
dk9897	I-C0026926
being	O
unable	O
to	O
disrupt	O
the	O
phagosome	B-C1166752
membrane	I-C1166752
and	O
make	O
contact	O
to	O
the	O
results	B-C0683954
for	O
patients	B-C0030705
with	O
sarcoma	B-C1261473
not	B-C1518425
otherwise	I-C1518425
specified	I-C1518425
and	O
other	O
diagnoses	B-C0011900
than	O
ewing	B-C0553580
sarcoma	I-C0553580
treated	B-C0332154
according	O
to	O
the	O
euro-ewing	B-C0008976
99	I-C0008976
trial	I-C0008976
euro-ewing	B-C0008976
99	I-C0008976
trial	I-C0008976
of	O
the	O
european	B-C1535514
ewing	B-C0553580
tumor	I-C0553580
working	B-C0043227
initiative	B-C1287154
of	O
national	B-C0015737
groups	B-C0441833
ee99	B-C1507394
was	O
an	O
international	B-C1512888
phase	B-C0282461
iii	I-C0282461
study	I-C0282461
in	O
patients	B-C0030705
with	O
ewing	B-C0553580
sarcoma	I-C0553580
.	O
	
the	O
german	B-C1708333
society	I-C1708333
of	I-C1708333
pediatric	I-C1708333
oncology	I-C1708333
and	I-C1708333
hematology	I-C1708333
gpoh	I-C1708333
data	I-C1708333
center	I-C1708333
registered	B-C1514821
and	O
followed	O
patients	B-C0030705
with	O
other	O
diagnoses	B-C0011900
than	O
ewing	B-C0553580
sarcoma	I-C0553580
who	O
were	O
treated	B-C0332154
according	O
to	O
the	O
ee99	B-C1507394
protocol	I-C1507394
in	O
an	O
additional	O
non-ewing	B-C0242356
database	I-C0242356
.	O
	
data	B-C1511726
of	O
27	O
patients	B-C0030705
with	O
other	O
diagnoses	B-C0011900
than	O
ewing	B-C0553580
sarcoma	I-C0553580
treated	B-C0332154
according	O
to	O
the	O
ee99	B-C1507394
protocol	I-C1507394
were	O
analyzed	B-C0936012
.	O
	
patients	B-C0030705
had	O
miscellaneous	B-C0205395
histologic	B-C0205462
diagnoses	B-C0011900
,	O
the	O
majority	B-C0205393
were	O
diagnosed	B-C0011900
with	O
sarcoma	B-C1261473
not	B-C1518425
otherwise	I-C1518425
specified	I-C1518425
nos	B-C1518425
arising	O
in	O
bone	B-C0391978
and	O
soft	B-C0225317
tissue	I-C0225317
63%	O
.	O
	
the	O
median	B-C0876920
age	B-C0001779
at	O
diagnosis	B-C0011900
was	O
16.9	O
years	O
range	O
4.5	O
.	O
	
localized	B-C0277565
disease	I-C0277565
was	O
diagnosed	B-C0011900
in	O
61.5	O
of	O
the	O
patients	B-C0030705
and	O
38.5	O
had	O
distant	B-C0027627
metastases	I-C0027627
at	O
time	O
of	O
primary	B-C0205225
diagnosis	B-C0011900
.	O
	
the	O
median	B-C0876920
follow-up	B-C1522577
time	B-C0040223
was	O
3.7	O
years	O
range	O
0.5	O
.	O
	
patients	B-C0030705
with	O
localized	B-C0277565
disease	I-C0277565
showed	O
a	O
3-year	O
event-free	B-C0242793
survival	I-C0242793
efs	B-C0242793
of	O
68%	O
,	O
compared	O
to	O
3-year	O
efs	B-C0242793
of	O
20%	O
in	O
patients	B-C0030705
with	O
metastases	B-C0027627
p	O
=	O
0.042	O
.	O
	
three-year	O
efs	B-C0242793
for	O
patients	B-C0030705
with	O
sarcoma	B-C1261473
nos	B-C1518425
was	O
52%	O
,	O
patients	B-C0030705
with	O
localized	B-C0277565
and	O
metastatic	B-C0027627
disease	I-C0027627
showed	O
3-year	O
efs	B-C0242793
of	O
66	O
and	O
20%	O
,	O
respectively	O
.	O
	
efs	B-C0242793
in	O
patients	B-C0030705
with	O
other	O
diagnoses	B-C0011900
than	O
ewing	B-C0553580
sarcoma	I-C0553580
treated	B-C0332154
according	O
to	O
ee99	B-C1507394
was	O
significantly	B-C0750502
higher	O
in	O
patients	B-C0030705
with	O
localized	B-C0277565
than	O
metastatic	B-C0027627
disease	I-C0027627
.	O
	
sarcomas	B-C1261473
of	O
soft	B-C0225317
tissue	I-C0225317
and	O
bone	B-C0391978
that	O
cannot	O
be	O
classified	B-C0008902
to	O
current	B-C0521116
diagnostic	B-C1550395
categories	I-C1550395
constitute	O
a	O
therapeutic	B-C0302350
challenge	B-C0805586
.	O
	
capsular	B-C0032595
polysaccharide	I-C0032595
types	B-C0332307
and	O
virulence-related	B-C0042765
traits	B-C0599883
of	O
epidemic	B-C0014499
kpc	B-C1855645
-	O
producing	B-C0678227
klebsiella	B-C0001699
pneumoniae	I-C0001699
isolates	B-C1764827
in	O
a	O
chinese	B-C0008115
university	B-C0020028
hospital	I-C0020028
klebsiella	B-C0001699
pneumoniae	I-C0001699
is	O
an	O
important	B-C3898777
human	B-C0086418
pathogen	B-C0450254
associated	B-C0332281
with	I-C0332281
a	O
variety	B-C2346866
of	O
diseases	B-C0012634
and	O
the	O
prevalence	B-C0220900
of	O
blakpc	B-C0017337
carrying	O
k	B-C0001699
.	O
	
pneumoniae	I-C0001699
kpc-kp	B-C0001699
is	O
rapidly	B-C0442808
increasing	I-C0442808
.	O
	
capsule	B-C0085229
is	O
an	O
important	B-C3898777
virulence	B-C1136170
factor	I-C1136170
in	O
k	B-C0001699
.	O
	
pneumoniae	I-C0001699
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
determined	O
to	O
first	O
systematically	B-C0220922
characterize	B-C1880022
capsular	B-C0032595
polysaccharide	I-C0032595
cps	B-C0032595
and	O
virulence	B-C0042765
traits	B-C0599883
in	O
kpc-kp	B-C0001699
strains	B-C1518614
.	O
	
a	O
total	O
of	O
56	O
kpc-kp	B-C0001699
isolates	B-C1764827
were	O
recovered	B-C0521108
from	O
clinical	B-C0370003
samples	I-C0370003
in	O
a	O
chinese	B-C0020028
hospital	I-C0020028
,	O
which	O
were	O
assigned	B-C1516050
to	O
clonal	B-C0282637
lineages	I-C0282637
by	O
multilocus	B-C2936544
sequence	I-C2936544
typing	I-C2936544
mlst	B-C2936544
.	O
	
capsule	B-C0085229
typing	B-C0441704
wzi	B-C1294197
sequencing	I-C1294197
and	O
wzc	B-C0032520
polymerase	I-C0032520
chain	I-C0032520
reaction	I-C0032520
pcr	B-C0032520
and	O
virulence	B-C0042765
genes	B-C0017337
were	O
characterized	B-C1880022
by	O
molecular	B-C0200924
approaches	I-C0200924
.	O
	
the	O
virulence	B-C0042765
of	O
these	O
strains	B-C1518614
was	O
determined	O
by	O
biofilm	B-C1325881
formation	I-C1325881
,	O
serum	B-C0229671
killing	B-C0599733
resistance	B-C4281815
,	O
phagocytosis	B-C0031308
,	O
and	O
infection	B-C3714514
models	B-C3161035
.	O
	
six	O
different	O
sts	B-C2359784
were	O
found	B-C0150312
among	O
56	O
kpc-kp	B-C0001699
isolates	B-C1764827
76.8	O
43	O
of	O
56	O
isolates	B-C1764827
belonged	O
to	O
st11	B-C2359784
,	O
6	B-C2359784
isolates	B-C1764827
belonged	O
to	O
st147	B-C2359784
,	O
4	O
isolates	B-C1764827
belonged	O
to	O
st15	B-C2359784
,	O
1	O
isolate	O
belonged	O
to	O
st1456	B-C2359784
,	O
1	O
isolate	O
belonged	O
to	O
st65	B-C2359784
,	O
and	O
1	O
isolate	O
was	O
st23	B-C2359784
.	O
	
based	O
on	O
the	O
wzi	B-C3708993
gene	I-C3708993
dna	I-C3708993
sequences	I-C3708993
and	O
wzc	B-C0032520
pcr	I-C0032520
,	O
these	O
56	O
strains	B-C1518614
were	O
classified	O
as	O
capsular	B-C0085229
type	B-C0332307
wzi47-k47	B-C0085229
n	O
=	O
37	O
,	O
wzi64-k64	B-C0085229
n	O
=	O
8	O
,	O
wzi8-k8	B-C0085229
n	O
=	O
4	O
,	O
wzi37-k37	B-C0085229
n	O
=	O
4	O
,	O
wzi53-k53	B-C0085229
n	O
=	O
1	O
,	O
wzi125-k2	B-C0085229
n	O
=	O
1	O
,	O
and	O
wzi1-k1	B-C0085229
n	O
=	O
1	O
.	O
	
heterogeneity	B-C0242960
was	O
detected	B-C0442726
in	O
biofilm	B-C1325881
formation	I-C1325881
and	O
phagocytosis	B-C0031308
among	O
different	O
cps	B-C0032595
types	B-C0332307
.	O
	
st11	B-C2359784
strains	B-C1518614
were	O
less	O
virulent	B-C1520022
than	O
other	O
st	B-C2359784
strains	B-C1518614
.	O
	
kpc-kp	B-C0001699
strains	B-C1518614
exhibit	O
variability	B-C2827666
of	O
virulence-associated	B-C0042765
traits	B-C0599883
.	O
	
differences	O
were	O
associated	O
with	O
the	O
st	B-C2359784
types	B-C0332307
and	O
interaction-driven	B-C1704675
distinctive	O
electronic	B-C0449830
states	I-C0449830
of	O
artificial	B-C0567415
atoms	I-C0567415
at	O
the	O
zno	B-C0043491
interface	B-C0205556
we	O
have	O
investigated	B-C1292732
the	O
electronic	B-C0449830
states	I-C0449830
of	O
planar	B-C1258084
quantum	I-C1258084
dots	I-C1258084
at	O
the	O
zno	B-C0043491
interface	B-C0205556
containing	O
a	O
few	O
interacting	B-C1704675
electrons	B-C0013852
in	O
an	O
externally	B-C4048755
applied	I-C4048755
magnetic	B-C0563533
field	I-C0563533
.	O
	
the	O
electron-electron	B-C0013852
interaction	B-C1704675
effects	B-C1280500
are	O
expected	O
to	O
be	O
much	B-C0442821
stronger	I-C0442821
in	O
this	O
case	B-C0868928
than	O
in	O
traditional	B-C0449913
semiconductor	I-C0449913
quantum	I-C0449913
systems	I-C0449913
,	O
such	O
as	O
in	O
gaas	B-C0061005
or	O
inas	B-C0172463
quantum	B-C1258084
dots	I-C1258084
.	O
	
in	O
order	O
to	O
highlight	O
that	O
stronger	B-C0442821
coulomb	B-C1280500
effects	I-C1280500
in	O
the	O
zno	B-C0043491
quantum	B-C1258084
dots	I-C1258084
,	O
we	O
have	O
compared	B-C1707455
the	O
energy	B-C1254366
spectra	I-C1254366
and	O
the	O
magnetization	B-C0563532
in	O
this	O
system	B-C0449913
to	O
those	O
of	O
the	O
inas	B-C0172463
quantum	B-C1258084
dots	I-C1258084
.	O
	
we	O
have	O
found	O
that	O
in	O
the	O
zno	B-C0043491
quantum	B-C1258084
dots	I-C1258084
the	O
signatures	O
of	O
stronger	B-C0442821
coulomb	B-C1704675
interaction	I-C1704675
manifests	B-C0205319
in	O
an	O
unique	B-C1710548
ground	B-C0449830
state	I-C0449830
that	O
has	O
very	O
different	B-C1705242
properties	B-C1882134
than	O
the	O
corresponding	O
ones	O
in	O
the	O
inas	B-C0172463
dot	B-C1258084
.	O
	
our	O
results	B-C1274040
for	O
the	O
magnetization	B-C0563532
also	O
exhibits	B-C0205556
behaviors	I-C0205556
never	B-C2003901
before	B-C0332152
observed	B-C1441672
in	O
a	O
quantum	B-C1258084
dot	I-C1258084
for	O
a	O
realistic	B-C0392762
set	I-C0392762
of	I-C0392762
parameters	I-C0392762
.	O
	
we	O
have	O
found	O
a	O
stronger	B-C0442821
temperature	B-C0039476
dependence	B-C0851827
and	O
other	O
unexpected	B-C2348519
features	I-C2348519
,	O
such	O
as	O
paramagnetic-like	B-C1254365
behavior	I-C1254365
at	O
high	B-C0039476
temperatures	I-C0039476
for	O
a	O
quantum-dot	B-C1258084
helium	B-C0018880
.	O
	
evaluation	B-C0220825
of	O
tobacco	B-C0680803
control	I-C0680803
policies	I-C0680803
in	O
san	B-C0036152
francisco	I-C0036152
homeless	B-C0019863
housing	B-C0687761
programs	I-C0687761
the	O
2014	O
surgeon	B-C0684224
general's	I-C0684224
report	I-C0684224
noted	B-C4288581
that	O
high	B-C0205250
smoking	B-C1822491
rates	I-C1822491
in	O
vulnerable	B-C0949366
populations	I-C0949366
such	O
as	O
the	O
homeless	B-C0019863
have	O
been	O
a	O
persistent	B-C0205322
public	B-C0678367
health	B-C1398682
problem	I-C1398682
smoking	B-C0037369
prevalence	B-C0683919
among	O
individuals	B-C0237401
experiencing	B-C0683573
homelessness	B-C0237154
exceeds	O
70%	O
.	O
	
historically	O
,	O
service	B-C0679886
providers	I-C0679886
for	O
the	O
homeless	B-C0019863
have	O
not	O
enacted	O
comprehensive	B-C1880156
tobacco	B-C0680803
control	I-C0680803
policies	I-C0680803
.	O
	
we	O
conducted	B-C1300196
a	O
qualitative	B-C0949415
study	I-C0949415
of	O
homeless	B-C0019863
housing	B-C0687761
programs	I-C0687761
in	O
san	B-C0036152
francisco	I-C0036152
.	O
	
administrators	B-C0085751
representing	B-C1882932
9	O
of	O
the	O
city's	O
11	O
homeless	B-C0586395
service	I-C0586395
agencies	I-C0586395
were	O
interviewed	B-C0021822
to	O
assess	B-C0184514
institutional	B-C0015003
smoking	B-C0037369
-related	O
policies	B-C0242456
and	O
cessation	B-C0085134
programs	B-C3484370
and	O
perceived	B-C0030971
barriers	B-C0679881
and	O
receptivity	B-C0205342
to	O
instituting	B-C1272753
tobacco	B-C0040329
control	B-C2587213
interventions	B-C0184661
.	O
	
respondents	B-C0282122
indicated	B-C1444656
that	O
although	O
most	O
programs	B-C3484370
had	O
adopted	B-C1272684
smoke	B-C0037366
-	O
free	B-C0332296
grounds	B-C1254362
and	O
some	O
had	O
eliminated	B-C0849355
evidence	B-C3887511
of	O
staff	B-C0851286
smoking	B-C0037369
,	O
the	O
smoking	B-C0037369
status	B-C0449438
of	O
clients	B-C0008942
was	O
assessed	B-C1516048
only	O
when	O
required	B-C1514873
by	O
funders	O
.	O
	
none	O
of	O
the	O
programs	B-C3484370
offered	B-C1444648
smoking	B-C0085134
cessation	I-C0085134
interventions	B-C0184661
.	O
	
most	O
administrators	B-C0085751
were	O
receptive	B-C0205342
to	O
adopting	B-C1272684
policies	B-C0242456
that	O
would	O
promote	B-C0033414
a	O
tobacco	B-C0040329
-	O
free	B-C0332296
culture	B-C0037455
however	O
,	O
they	O
noted	B-C4288581
that	O
their	O
clients	B-C0008942
had	O
unique	B-C1710548
challenges	B-C0805586
that	O
made	O
traditional	B-C0443324
smoking	B-C0085134
cessation	I-C0085134
programs	B-C3484370
unfeasible	O
.	O
	
homeless	B-C0019863
housing	B-C0687761
programs	I-C0687761
in	O
san	B-C0036152
francisco	I-C0036152
have	O
not	O
yet	O
adopted	B-C1272684
a	O
tobacco	B-C0040329
-	O
free	B-C0332296
culture	B-C0037455
.	O
	
existing	B-C2987476
policies	B-C0242456
were	O
created	B-C1706214
in	O
response	B-C0871261
to	O
external	B-C0205101
mandates	B-C1442085
,	O
and	O
smoking	B-C0085134
cessation	I-C0085134
programs	B-C3484370
may	O
need	O
to	O
be	O
modified	B-C0392747
in	O
order	O
to	O
effectively	B-C1704419
reach	O
identification	O
of	O
low	O
micromolar	B-C0439300
dual	O
inhibitors	B-C0014432
for	O
aldose	B-C0002003
reductase	I-C0002003
alr2	B-C0002003
and	O
poly	B-C0032405
adp-ribose	I-C0032405
polymerase	I-C0032405
parp-1	B-C0032405
using	O
structure	B-C0678594
based	O
design	B-C1707689
approach	O
clinical	B-C0008972
studies	I-C0008972
have	O
revealed	O
that	O
diabetic	B-C0011884
retinopathy	I-C0011884
is	O
a	O
multifactorial	O
disorder	B-C0012634
.	O
	
moreover	O
,	O
studies	O
also	O
suggest	O
that	O
alr2	B-C0002003
and	O
parp-1	B-C0032405
co-occur	O
in	O
retinal	B-C0035298
cells	B-C0007634
,	O
making	O
them	O
appropriate	O
targets	B-C1521840
for	O
the	O
treatment	B-C0087111
of	O
diabetic	B-C0011884
retinopathy	I-C0011884
.	O
	
to	O
find	O
the	O
dual	O
inhibitors	B-C0014432
of	O
alr2	B-C0002003
and	O
parp-1	B-C0032405
,	O
the	O
structure	B-C0678594
based	O
design	B-C1707689
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	B-C1521840
proteins	B-C0033684
.	O
	
a	O
series	O
of	O
novel	O
thiazolidine-2	B-C1568506
tzd	B-C1568506
derivatives	B-C1527240
were	O
therefore	O
rationally	O
designed	B-C1707689
,	O
synthesized	B-C1883254
and	O
their	O
in	B-C1533691
vitro	I-C1533691
inhibitory	B-C1152555
activities	I-C1152555
against	O
alr2	B-C0002003
and	O
parp-1	B-C0032405
were	O
evaluated	O
.	O
	
the	O
experimental	B-C2825142
results	I-C2825142
showed	O
that	O
compounds	B-C1254351
5b	I-C1254351
and	O
5f	B-C1254351
,	O
with	O
2-chloro	O
and	O
4-fluoro	O
substitutions	O
,	O
showed	O
biochemical	B-C0205474
activities	B-C0441655
in	O
micromolar	B-C0439300
and	O
submicromolar	B-C0439300
range	B-C1514721
ic50	B-C0600495
1.34	O
against	O
both	O
the	O
targeted	B-C1521840
enzymes	B-C0014442
.	O
	
the	O
structure-activity	B-C0038477
relationship	I-C0038477
elucidated	O
for	O
these	O
novel	O
inhibitors	B-C0014432
against	O
both	O
the	O
enzymes	B-C0014442
provide	O
new	O
insight	O
into	O
the	O
binding	B-C1167622
mode	B-C1513371
of	O
the	O
inhibitors	B-C0014432
to	O
the	O
active	B-C0205681
sites	I-C0205681
of	O
enzymes	B-C0014442
.	O
	
the	O
positive	B-C1446409
results	B-C0683954
of	O
the	O
biochemical	B-C0205474
assay	B-C0005507
suggest	O
that	O
these	O
compounds	B-C1254351
may	O
be	O
further	O
optimized	B-C2698650
and	O
utilized	B-C0042153
for	O
the	O
treatment	B-C0087111
of	O
diabetic	B-C0011884
retinopathy	I-C0011884
.	O
	
microbiology	B-C0085672
of	O
the	O
upper	B-C0225377
and	O
lower	B-C0231989
airways	I-C0231989
in	O
pediatric	B-C1521725
cystic	B-C0010674
fibrosis	I-C0010674
patients	B-C0030705
objective	O
to	O
evaluate	O
the	O
microbiology	O
of	O
the	O
upper	O
and	O
lower	O
airways	O
in	O
pediatric	B-C1521725
cystic	B-C0010674
fibrosis	I-C0010674
cf	B-C0010674
patients	B-C0030705
who	O
underwent	O
sinus	B-C0748725
surgery	I-C0748725
.	O
	
study	O
design	O
retrospective	B-C0035363
case	O
series	O
with	O
chart	O
review	O
.	O
	
setting	O
tertiary	B-C0337954
care	I-C0337954
children's	B-C0020017
hospital	I-C0020017
.	O
	
subjects	O
and	O
methods	O
a	O
total	O
of	O
201	O
paired	O
sinus	B-C2237356
and	O
pulmonary	B-C2020984
cultures	I-C2020984
from	O
105	O
cf	B-C0010674
patients	B-C0030705
were	O
identified	O
between	O
1996	O
and	O
2014	O
.	O
	
demographics	B-C0011289
and	O
culture	B-C0430400
results	B-C1274040
were	O
analyzed	B-C0681874
.	O
	
results	B-C1274040
the	O
mean	O
age	O
of	O
patients	B-C0030705
was	O
11.2	O
5.4	O
years	O
range	O
,	O
1-27	O
years	O
,	O
and	O
approximately	O
one-half	O
were	O
female	B-C0043210
.	O
	
methicillin	B-C0025643
-	O
sensitive	B-C0332324
staphylococcus	B-C0038172
aureus	I-C0038172
was	O
the	O
most	O
common	O
pathogen	B-C4267729
overall	O
.	O
	
a	O
significantly	O
higher	O
prevalence	B-C0683921
of	O
pseudomonas	B-C0033809
aeruginosa	I-C0033809
32%	O
for	O
pulmonary	B-C2020984
and	O
37%	O
for	O
sinus	B-C2237356
cultures	I-C2237356
was	O
observed	O
in	O
older	B-C1999167
patients	B-C0030705
versus	O
younger	B-C0238598
patients	B-C0030705
p	B-C0033105
<	O
001	O
.	O
	
there	O
was	O
low	O
to	O
moderate	B-C1881878
agreement	B-C1707520
between	O
sinus	B-C2237356
and	O
pulmonary	B-C2020984
cultures	I-C2020984
kappa	B-C0439099
statistic	B-C0220900
range	I-C0220900
,	O
0.03	O
.	O
	
the	O
prevalence	B-C0220900
of	O
methicillin-resistant	B-C1265292
s	I-C1265292
aureus	I-C1265292
mrsa	B-C1265292
increased	O
significantly	B-C0237881
for	O
lower	B-C2199769
respiratory	I-C2199769
tract	I-C2199769
culture	I-C2199769
from	O
5%	O
to	O
16%	O
and	O
sinus	B-C2237356
culture	I-C2237356
from	O
5%	O
to	O
27%	O
between	O
1996-2004	O
and	O
2010-2014	O
p	B-C0033105
=	O
016	O
and	O
p	B-C0033105
<	O
001	O
,	O
respectively	O
.	O
	
the	O
prevalence	B-C0220900
of	O
positive	B-C1514241
sinus	B-C2237356
cultures	I-C2237356
increased	O
from	O
40%	O
to	O
85%	O
between	O
1996-2004	O
and	O
2010-2014	O
p	B-C0033105
=	O
018	O
.	O
	
patients	B-C0030705
with	O
pulmonary	B-C2709248
mrsa	B-C1265292
were	O
more	O
likely	O
to	O
be	O
coinfected	B-C0275524
with	O
pulmonary	B-C2709248
p	B-C0033809
aeruginosa	I-C0033809
risk	B-C0242492
ratio	I-C0242492
,	O
2.4	O
95%	O
ci	B-C0009667
,	O
1.2	O
p	O
=	O
015	O
or	O
aspergillus	B-C0004037
fumigatus	I-C0004037
risk	B-C0242492
ratio	I-C0242492
,	O
2.2	O
95%	O
ci	B-C0009667
,	O
1.2	O
p	O
=	O
035	O
.	O
	
conclusions	O
there	O
is	O
low	O
to	O
moderate	B-C1881878
correlation	B-C1707520
between	O
pulmonary	B-C2709248
and	O
sinus	B-C0030471
pathogens	B-C4267729
in	O
cf	B-C0010674
patients	B-C0030705
.	O
	
this	O
is	O
important	O
to	O
consider	O
when	O
treating	B-C0087111
infections	B-C3714514
.	O
	
the	O
prevalence	B-C0220900
of	O
mrsa	B-C1265292
in	O
sinus	B-C2237356
cultures	I-C2237356
has	O
increased	O
over	O
time	O
and	O
warrants	O
further	O
the	O
role	O
of	O
mir-451	B-C2603907
in	O
the	O
switching	O
between	O
proliferation	B-C1514485
and	O
migration	B-C1533574
in	O
malignant	B-C0555198
glioma	I-C0555198
cells	B-C0007634
ampk	B-C0252214
signaling	B-C3537152
,	O
mtor	B-C1307407
modulation	B-C0443264
and	O
rac1	B-C0139880
activation	B-C0599177
required	O
glioblastoma	B-C1621958
multiforme	I-C1621958
gbm	B-C1621958
,	O
who	B-C0017636
grade	I-C0017636
iv	I-C0017636
astrocytoma	I-C0017636
,	O
is	O
the	O
most	O
common	O
primary	B-C0677930
neoplasm	I-C0677930
of	O
the	O
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
cns	B-C3714787
and	O
has	O
the	O
highest	O
malignancy	B-C4282132
and	O
mortality	B-C0205848
rates	I-C0205848
.	O
	
the	O
invasive	B-C0205281
nature	I-C0205281
of	O
gbm	B-C1621958
complicates	O
surgical	B-C0728940
resection	I-C0728940
and	O
restricts	O
chemotherapeutic	B-C0870057
access	I-C0870057
,	O
contributing	O
to	O
poor	O
patient	B-C0030705
prognosis	B-C0033325
.	O
	
the	O
migration	B-C1533574
of	O
tumor	B-C0597032
cells	I-C0597032
is	O
closely	O
related	O
to	O
the	O
tumor	B-C0597032
cell	I-C0597032
proliferation	B-C1514485
.	O
	
the	O
acquisition	B-C1706701
of	O
migratory	B-C0232901
capability	B-C2698977
,	O
in	O
addition	O
to	O
intracellular	B-C0178719
factors	B-C1521761
,	O
is	O
proposed	O
to	O
be	O
a	O
crucial	B-C0441712
mechanism	I-C0441712
during	O
the	O
progression	B-C0449258
of	O
invasion	B-C1269955
.	O
	
using	O
qrt-pcr	B-C1514628
analysis	B-C0936012
,	O
we	O
determined	O
that	O
the	O
expression	B-C0017262
of	O
mir-451	B-C1826031
in	O
glioma	B-C0017638
tissue	B-C0040300
was	O
lower	O
than	O
in	O
control	B-C0459385
brain	I-C0459385
tissue	I-C0459385
,	O
especially	O
in	O
the	O
central	B-C0205099
portions	B-C0449719
of	O
the	O
tumor	B-C0027651
.	O
	
in	O
glioma	B-C0017638
cell	B-C0085983
lines	I-C0085983
,	O
we	O
found	O
that	O
decreased	B-C0205216
mir-451	B-C1826031
expression	B-C0017262
suppressed	B-C1260953
tumor	B-C0597032
cell	I-C0597032
proliferation	B-C1514485
but	O
enhanced	O
migration	B-C1533574
with	O
a	O
concomitant	B-C0521115
low	O
level	O
of	O
cab39	B-C2715759
/	O
ampk	B-C0252214
/	O
mtor	B-C1307407
pathway	B-C1514528
activation	I-C1514528
and	O
high	O
level	O
of	O
rac1	B-C0139880
/	O
cofilin	B-C0056080
pathway	B-C1514528
activation	I-C1514528
,	O
respectively	O
.	O
	
notably	O
,	O
the	O
effect	O
of	O
mir-451	B-C2603907
on	O
cytological	B-C0205471
behavior	I-C0205471
and	O
on	O
the	O
activation	B-C0599177
of	O
mtor	B-C1307407
and	O
rac1	B-C0139880
was	O
limited	O
when	O
ampkα1	B-C1739697
expression	B-C1171362
was	O
knocked-down	O
with	O
a	O
synthetic	B-C1883254
shrna	B-C2930586
.	O
	
we	O
suggest	O
that	O
the	O
glioma	B-C0017638
microenvironment	B-C2936626
results	O
in	O
heterogeneity	B-C0019409
of	O
mir-451	B-C1826031
expression	B-C0017262
.	O
	
our	O
data	O
indicated	O
that	O
mir-451	B-C2603907
relays	O
environmental	O
signals	O
by	O
upregulating	B-C0041904
the	O
activity	O
of	O
ampk	B-C0252214
signaling	B-C3537152
,	O
thereby	O
modulating	B-C0443264
the	O
activation	B-C0599177
of	O
mtor	B-C1307407
and	O
rac1	B-C0139880
/	O
cofilin	B-C0056080
which	O
,	O
in	O
turn	O
,	O
play	O
key	O
roles	O
in	O
glioma	B-C0017638
cell	O
proliferation	B-C1514485
and	O
migration	B-C1533574
,	O
respectively	O
.	O
	
our	O
results	O
highlight	O
the	O
need	O
to	O
consider	O
opposing	O
roles	O
of	O
a	O
therapeutic	B-C0302350
target	O
which	O
,	O
while	O
suppressing	B-C1260953
tumor	B-C0597032
cell	I-C0597032
proliferation	B-C1514485
,	O
could	O
also	O
promote	O
cell	B-C0007634
infiltration	B-C0332448
.	O
	
comparison	B-C1707455
of	O
gasoline	B-C3273359
direct-injection	I-C3273359
gdi	B-C3273359
and	O
port	B-C3273359
fuel	I-C3273359
injection	I-C3273359
pfi	B-C3273359
vehicle	B-C0004380
emissions	I-C0004380
emission	B-C0004380
certification	B-C0007836
standards	B-C0038137
,	O
cold-start	B-C0243095
,	O
secondary	O
organic	B-C0747055
aerosol	B-C0001712
formation	B-C1522492
potential	B-C3245505
,	O
and	O
potential	B-C3245505
climate	B-C0008946
impacts	B-C4049986
recent	O
increases	B-C0205217
in	O
the	O
corporate	B-C0205556
average	B-C0870462
fuel	I-C0870462
economy	I-C0870462
standards	B-C0038137
have	O
led	O
to	O
widespread	B-C0205391
adoption	O
of	O
vehicles	B-C0175845
equipped	O
with	O
gasoline	B-C3273359
direct-injection	I-C3273359
gdi	B-C3273359
engines	B-C3273359
.	O
	
changes	O
in	O
engine	B-C3273359
technologies	B-C0039421
can	O
alter	O
emissions	B-C0004380
.	O
	
to	O
quantify	B-C1709793
these	O
effects	B-C1280500
,	O
we	O
measured	B-C0444706
gas-	B-C0017110
and	O
particle-phase	B-C1254350
emissions	B-C0004380
from	O
82	O
light-duty	B-C0205556
gasoline	B-C0017113
vehicles	B-C0175845
recruited	O
from	O
the	O
california	B-C0006754
in-use	O
fleet	O
tested	B-C0392366
on	O
a	O
chassis	B-C1707356
dynamometer	B-C3273359
using	O
the	O
cold-start	B-C0243095
unified	O
cycle	O
.	O
	
the	O
fleet	O
included	O
15	O
gdi	B-C3273359
vehicles	B-C0175845
,	O
including	O
8	O
gdis	B-C3273359
certified	B-C0007836
to	O
the	O
most-stringent	O
emissions	B-C0004380
standard	B-C0038137
,	O
superultra-low-emission	B-C0008902
vehicles	I-C0008902
sulev	B-C0008902
.	O
	
we	O
quantified	B-C1709793
the	O
effects	B-C1704420
of	I-C1704420
engine	B-C3273359
technology	B-C0039421
,	O
emission	B-C0004380
certification	B-C0007836
standards	B-C0038137
,	O
and	O
cold-start	B-C0243095
on	O
emissions	B-C0004380
.	O
	
for	O
vehicles	B-C0175845
certified	B-C0007836
to	O
the	O
same	O
emissions	B-C0004380
standard	B-C0038137
,	O
there	O
is	O
no	O
statistical	B-C0038215
difference	B-C1705241
of	O
regulated	O
gas-phase	B-C1254350
pollutant	B-C0599786
emissions	B-C0004380
between	O
pfis	B-C3273359
and	O
gdis	B-C3273359
.	O
	
however	O
,	O
gdis	B-C3273359
had	O
,	O
on	O
average	B-C1510992
,	O
a	O
factor	B-C1521761
of	O
2	O
higher	O
particulate	B-C1720884
matter	I-C1720884
pm	B-C1720884
mass	O
emissions	B-C0004380
than	O
pfis	B-C3273359
due	O
to	O
higher	O
elemental	B-C0007009
carbon	I-C0007009
ec	B-C0007009
emissions	B-C0004380
.	O
	
sulev	B-C0008902
certified	B-C0007836
gdis	B-C3273359
have	O
a	O
factor	B-C1521761
of	O
2	O
lower	O
pm	B-C1720884
mass	O
emissions	B-C0004380
than	O
gdis	B-C3273359
certified	B-C0007836
as	O
ultralow-emission	B-C0008902
vehicles	I-C0008902
3.0	O
1.1	O
versus	O
6.3	O
1.1	O
mg/mi	O
,	O
suggesting	O
improvements	B-C2986411
in	O
engine	B-C3273359
design	B-C1707689
and	O
calibration	B-C0006751
.	O
	
comprehensive	B-C1880156
organic	B-C0747055
speciation	O
revealed	B-C0443289
no	O
statistically	B-C0237881
significant	I-C0237881
differences	B-C1705241
in	O
the	O
composition	B-C0243176
of	O
the	O
volatile	B-C1963547
organic	B-C0029224
compounds	I-C0029224
emissions	B-C0004380
between	O
pfi	B-C3273359
and	O
gdis	B-C3273359
,	O
including	O
benzene	B-C0005036
,	O
toluene	B-C0040383
,	O
ethylbenzene	B-C0059792
,	O
and	O
xylenes	B-C0043368
btex	B-C0029224
.	O
	
therefore	O
,	O
the	O
secondary	O
organic	B-C0747055
aerosol	B-C0001712
and	O
ozone	B-C0030106
formation	B-C1522492
potential	B-C3245505
of	O
the	O
exhaust	B-C0178629
does	O
not	O
depend	O
on	O
engine	B-C3273359
technology	B-C0039421
.	O
	
cold-start	B-C0243095
contributes	B-C1880177
a	O
larger	B-C0549177
fraction	B-C1264633
of	I-C1264633
the	O
total	O
unified	O
cycle	O
emissions	B-C0004380
for	O
vehicles	B-C0175845
meeting	O
more-stringent	O
emission	B-C0004380
standards	B-C0038137
.	O
	
organic	B-C0747055
gas	B-C0017110
emissions	B-C0004380
were	O
the	O
most	O
sensitive	B-C0332324
to	O
cold-start	B-C0243095
compared	B-C1707455
to	O
the	O
other	O
pollutants	B-C0599786
tested	B-C0392366
here	O
.	O
	
there	O
were	O
no	O
statistically	B-C0237881
significant	I-C0237881
differences	B-C1705241
in	O
the	O
effects	B-C1704420
of	I-C1704420
cold-start	B-C0243095
on	O
gdis	B-C3273359
and	O
pfis	B-C3273359
.	O
	
for	O
our	O
test	O
fleet	O
,	O
the	O
measured	B-C0444706
14.5	O
decrease	B-C0205216
in	O
co2	B-C0007012
emissions	B-C0004380
from	O
gdis	B-C3273359
was	O
much	O
greater	B-C1704243
than	O
the	O
potential	B-C3245505
climate	B-C0008946
forcing	O
associated	B-C0332281
with	I-C0332281
higher	O
black	B-C0007010
carbon	I-C0007010
emissions	B-C0004380
.	O
	
thus	O
,	O
switching	O
from	O
pfi	B-C3273359
to	O
gdi	B-C3273359
vehicles	B-C0175845
will	O
likely	O
lead	O
to	O
a	O
reduction	B-C0392756
in	O
net	O
global	B-C0206217
warming	I-C0206217
.	O
	
trib3	B-C1259051
downregulation	B-C0013081
enhances	B-C2349975
doxorubicin	B-C0013089
-	O
induced	B-C0458082
cytotoxicity	B-C0596402
in	O
gastric	B-C0024623
cancer	I-C0024623
cells	B-C0334227
trib3	B-C1259051
,	O
which	O
is	O
a	O
pseudokinase	B-C0033684
known	O
to	O
regulate	B-C1327622
multiple	I-C1327622
pro-survival	I-C1327622
pathways	I-C1327622
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	B-C0087111
target	B-C1521840
for	O
the	O
treatment	B-C0920425
of	O
human	B-C0086418
tumors	B-C0027651
.	O
	
however	O
,	O
its	O
precise	O
role	O
in	O
cancer	B-C0006826
is	O
controversial	O
,	O
as	O
trib3	B-C1259051
protein	B-C0428479
levels	I-C0428479
have	O
been	O
associated	O
with	O
both	O
good	B-C0278250
and	O
poor	B-C0278252
prognosis	I-C0278252
in	O
cancer	B-C1516213
patients	I-C1516213
.	O
	
here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
trib3	B-C1259051
expression	B-C1171362
in	O
the	O
survival	B-C0007620
of	O
gastric	B-C0024623
cancer	I-C0024623
cells	B-C0334227
exposed	O
to	O
anticancer	B-C0003392
drugs	I-C0003392
.	O
	
we	O
found	O
that	O
the	O
tested	B-C0039593
anticancer	B-C0003392
drug	I-C0003392
,	O
doxorubicin	B-C0013089
,	O
induced	B-C0458082
cytotoxicity	B-C0596402
by	O
decreasing	O
trib3	B-C1540055
transcription	B-C0040649
,	O
which	O
was	O
followed	O
by	O
apoptotic	B-C0162638
cell	I-C0162638
death	I-C0162638
.	O
	
moreover	O
,	O
trib3	B-C1099354
sirna	I-C1099354
knockdown	B-C2350567
appeared	O
to	O
enhance	B-C2349975
doxorubicin	B-C0013089
-	O
induced	B-C0458082
apoptosis	B-C0162638
in	O
gastric	B-C0024623
cancer	I-C0024623
cells	B-C0334227
,	O
concurrently	O
with	O
altering	O
the	O
expression	B-C1171362
of	O
downstream	B-C0522506
apoptotic	B-C0763396
factors	I-C0763396
.	O
	
conversely	O
,	O
overexpression	B-C1514559
of	O
trib3	B-C1259051
significantly	O
protected	B-C0007634
cells	I-C0007634
against	O
doxorubicin	B-C0013089
-	O
induced	B-C0458082
apoptosis	B-C0162638
.	O
	
our	O
results	O
indicate	O
that	O
downregulation	B-C0013081
of	O
trib3	B-C1259051
appears	O
to	O
promote	B-C0033414
cell	B-C0007587
death	I-C0007587
and	O
enhance	B-C2349975
doxorubicin	B-C0013089
-	O
induced	B-C0458082
apoptosis	B-C0162638
,	O
supporting	O
the	O
anti-apoptotic	B-C2986514
role	O
of	O
trib3	B-C1259051
.	O
	
the	O
inductions	B-C0017391
of	O
three	O
classes	O
of	O
mapks	B-C0752312
failed	O
to	O
affect	O
doxorubicin	B-C0013089
-mediated	O
trib3	B-C1259051
downregulation	B-C0013081
,	O
while	O
trib3	B-C1259051
overexpression	B-C1514559
did	O
not	O
affect	O
doxorubicin	B-C0013089
-	O
induced	B-C0458082
mapk	B-C1155551
activation	I-C1155551
.	O
	
in	O
sum	O
,	O
our	O
findings	B-C2825141
indicate	O
that	O
trib3	B-C1259051
plays	O
an	O
anti-apoptotic	B-C2986514
role	O
in	O
doxorubicin	B-C0013089
-treated	O
gastric	B-C0024623
cancer	I-C0024623
cell	B-C0334227
lines	I-C0334227
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
trib3	B-C1259051
expression	B-C1171362
in	O
response	O
to	O
anticancer	B-C0003392
drugs	I-C0003392
,	O
such	O
as	O
doxorubicin	B-C0013089
,	O
irinotecan	B-C0123931
or	O
oxaliplatin	B-C0069717
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	B-C0920425
therapy	I-C0920425
.	O
	
digital	B-C0016129
myopericytoma	B-C1302808
a	O
case	B-C0007320
report	I-C0007320
and	O
systematic	B-C1955832
literature	I-C1955832
review	I-C1955832
a	O
myopericytoma	B-C1302808
mp	B-C1302808
is	O
an	O
exceedingly	O
rare	O
perivascular	B-C1335392
tumor	I-C1335392
of	O
unknown	B-C0743626
etiology	I-C0743626
.	O
	
given	O
their	O
potential	B-C3245505
for	O
mimicry	B-C0242943
and	O
malignancy	B-C4282132
,	O
mp	B-C1302808
tumors	I-C1302808
pose	O
a	O
unique	O
challenge	O
for	O
surgeons	B-C0582175
and	O
may	O
be	O
overlooked	O
on	O
differential	B-C0011906
diagnosis	I-C0011906
.	O
	
we	O
present	O
a	O
case	B-C0007320
report	I-C0007320
of	O
an	O
otherwise	O
healthy	B-C3898900
33-year-old	O
right-hand	B-C0344333
dominant	I-C0344333
male	B-C0025266
who	O
presented	O
to	O
our	O
outpatient	B-C0029916
clinic	I-C0029916
with	O
a	O
2-month	O
history	O
of	O
painless	B-C0234226
swelling	B-C0038999
and	O
erythema	B-C2071552
of	I-C2071552
the	I-C2071552
pulp	I-C2071552
of	I-C2071552
his	I-C2071552
left	I-C2071552
index	I-C2071552
finger	I-C2071552
.	O
	
subsequent	O
plain	B-C1306645
film	I-C1306645
x-ray	I-C1306645
showed	O
near-complete	B-C0205197
bony	B-C3810196
destruction	I-C3810196
of	O
his	O
distal	B-C0223821
phalanx	I-C0223821
.	O
	
pathological	B-C0030660
evaluation	B-C0220825
of	O
an	O
incisional	B-C0184922
biopsy	I-C0184922
showed	O
a	O
benign	B-C0086692
variant	I-C0086692
of	O
mp	B-C1302808
.	O
	
the	O
lesion	B-C0221198
was	O
treated	O
by	O
excision	B-C0728940
with	O
tumor	B-C0027651
shelling	B-C1283248
,	O
and	O
there	O
was	O
no	B-C0332125
evidence	I-C0332125
of	I-C0332125
recurrence	B-C0034897
81	O
days	O
postoperatively	B-C0032790
.	O
	
a	O
systematic	O
literature	O
review	O
of	O
the	O
management	B-C0376636
and	O
outcome	B-C0085415
of	O
all	O
known	O
cases	B-C0085973
of	O
hand	B-C0869996
and	I-C0869996
wrist	I-C0869996
mp	B-C1302808
gene	B-C0017262
expression	I-C0017262
reveals	O
evidence	B-C3887511
for	O
egfr	B-C0034802
-dependent	O
proximal-distal	B-C0015385
limb	I-C0015385
patterning	B-C0376678
in	O
a	O
myriapod	B-C0597910
evolution	B-C0015219
of	O
segmented	B-C0015385
limbs	I-C0015385
is	O
one	O
of	O
the	O
key	O
innovations	O
of	O
arthropoda	B-C0003903
,	O
allowing	O
development	O
of	O
functionally	O
specific	O
specialized	O
head	B-C0018670
and	O
trunk	B-C0460005
appendages	B-C0598782
,	O
a	O
major	O
factor	O
behind	O
their	O
unmatched	O
evolutionary	O
success	O
.	O
	
proximodistal	B-C0015385
limb	I-C0015385
patterning	B-C0376678
is	O
controlled	O
by	O
two	O
regulatory	B-C1720950
networks	I-C1720950
in	O
the	O
vinegar	B-C0598324
fly	I-C0598324
drosophila	B-C0013139
melanogaster	I-C0013139
,	O
and	O
other	O
insects	B-C0021585
.	O
	
the	O
first	O
is	O
represented	O
by	O
the	O
function	O
of	O
the	O
morphogens	B-C0566267
wingless	B-C0168282
wg	B-C0168282
and	O
decapentaplegic	B-C0082344
dpp	B-C0082344
the	O
second	O
by	O
the	O
egfr-signaling	B-C1155379
cascade	I-C1155379
.	O
	
while	O
the	O
role	O
of	O
wg	B-C0168282
and	O
dpp	B-C0082344
has	O
been	O
studied	B-C2603343
in	O
a	O
wide	O
range	O
of	O
arthropods	B-C0003903
representing	O
all	O
main	O
branches	O
,	O
that	O
is	O
,	O
pancrustacea	B-C1218615
=	O
hexapoda	B-C1095852
+	O
crustacea	B-C0010395
,	O
myriapoda	B-C0597910
and	O
chelicerata	B-C0998333
,	O
investigation	B-C1292732
of	O
the	O
potential	O
role	O
of	O
egfr-signaling	B-C1155379
is	O
restricted	O
to	O
insects	B-C0021585
hexapoda	B-C1095852
.	O
	
gene	B-C1880945
expression	I-C1880945
analysis	I-C1880945
of	O
egfr	B-C0034802
,	O
its	O
potential	B-C3245505
ligands	B-C0023688
,	O
and	O
putative	B-C0033684
downstream	I-C0033684
factors	I-C0033684
in	O
the	O
pill	B-C0323823
millipede	I-C0323823
glomeris	B-C1023180
marginata	I-C1023180
myriapoda	B-C0597910
diplopoda	B-C0323823
,	O
reveals	O
that-in	O
at	O
least	O
mandibulate	B-C1218616
arthropods	B-C0003903
-	O
egfr-signaling	B-C1155379
is	O
likely	O
a	O
conserved	O
regulatory	B-C0243095
mechanism	I-C0243095
in	O
proximodistal	B-C0015385
limb	I-C0015385
patterning	B-C0376678
.	O
	
pirfenidone	B-C0298067
normalizes	B-C0599112
the	O
tumor	B-C2936626
microenvironment	I-C2936626
to	O
improve	O
chemotherapy	B-C3665472
normalization	B-C0556530
of	O
the	O
tumor	B-C2936626
microenvironment	I-C2936626
by	O
selectively	O
targeting	B-C1521840
components	B-C0932050
of	O
the	O
tumor	B-C0027651
extracellular	B-C0015350
matrix	I-C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	B-C3245505
to	O
decompress	B-C1965697
tumor	B-C0027651
blood	B-C0005847
vessels	I-C0005847
,	O
increase	B-C0442805
vessel	B-C0005847
perfusion	B-C0599705
and	O
thus	O
,	O
improve	O
drug	B-C0087111
delivery	I-C0087111
and	O
the	O
efficacy	B-C0598333
of	O
cancer	B-C0920425
therapy	I-C0920425
.	O
	
therefore	O
,	O
we	O
now	O
need	O
to	O
identify	B-C0205396
safe	O
and	O
well	O
tolerated	B-C0243095
pharmaceutical	B-C1254351
agents	I-C1254351
that	O
are	O
able	O
to	O
remodel	O
the	O
microenvironment	B-C2936626
of	O
solid	B-C0280100
tumors	I-C0280100
and	O
enhance	B-C2349975
chemotherapy	B-C3665472
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
repurposed	O
pirfenidone	B-C0298067
,	O
a	O
clinically	B-C0205210
approved	B-C0205540
anti-fibrotic	B-C4031950
drug	I-C4031950
for	O
the	O
treatment	B-C0087111
of	O
idiopathic	B-C1800706
pulmonary	I-C1800706
fibrosis	I-C1800706
,	O
to	O
investigate	B-C1292732
its	O
possible	O
role	O
on	O
tumor	B-C2936626
microenvironment	I-C2936626
normalization	B-C0556530
.	O
	
using	O
two	O
orthotopic	B-C0574893
mammary	B-C0006141
tumor	B-C1710493
models	I-C1710493
we	O
demonstrate	O
that	O
pirfenidone	B-C0298067
reduces	B-C0547047
collagen	B-C0009325
and	O
hyaluronan	B-C0813622
levels	B-C0441889
and	O
,	O
as	O
a	O
result	B-C1274040
,	O
significantly	B-C0750502
increases	B-C0442805
blood	B-C0005847
vessel	I-C0005847
functionality	B-C0542341
and	O
perfusion	B-C0599705
and	O
improves	O
the	O
anti-tumor	B-C0598333
efficacy	I-C0598333
of	O
doxorubicin	B-C0013089
.	O
	
reduction	B-C0392756
of	O
extracellular	B-C0932050
matrix	I-C0932050
components	I-C0932050
were	O
mediated	O
via	O
tgfβ	B-C2984328
signaling	I-C2984328
pathway	I-C2984328
inhibition	B-C3463820
due	O
to	O
downregulation	B-C0013081
of	O
tgfβ1	B-C1366557
,	O
col1a1	B-C1332772
,	O
col3a1	B-C1413581
,	O
has2	B-C1415475
,	O
has3	B-C1415476
expression	B-C0017262
levels	B-C0441889
.	O
	
our	O
findings	B-C0243095
provide	O
evidence	B-C3887511
that	O
repurposing	O
pirfenidone	B-C0298067
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	B-C0035171
to	O
enhance	B-C2349975
drug	B-C0087111
delivery	I-C0087111
to	O
solid	B-C0280100
tumors	I-C0280100
by	O
normalizing	B-C0556530
the	O
tumor	B-C2936626
microenvironment	I-C2936626
.	O
	
serum	B-C0229671
vascular	B-C0169539
endothelial	I-C0169539
growth	I-C0169539
factor	I-C0169539
receptor-3	I-C0169539
levels	B-C1446561
in	O
patients	B-C0030705
with	O
esophageal	B-C0279626
squamous	I-C0279626
cell	I-C0279626
cancer	I-C0279626
esophageal	B-C0014859
cancer	I-C0014859
is	O
one	O
of	O
the	O
most	O
aggressive	O
tumors	B-C0017185
of	I-C0017185
the	I-C0017185
gastrointestinal	I-C0017185
tract	I-C0017185
.	O
	
in	O
this	O
study	O
,	O
we	O
quantified	O
the	O
serum	B-C0229671
vascular	B-C0169539
endothelial	I-C0169539
growth	I-C0169539
factor-3	I-C0169539
vegfr-3	B-C0169539
expression	B-C1171362
in	O
patients	B-C0030705
with	O
esophageal	B-C0279626
squamous	I-C0279626
cell	I-C0279626
carcinoma	I-C0279626
escc	B-C0279626
to	O
evaluate	O
the	O
role	O
of	O
vegfr-3	B-C0169539
in	O
escc	B-C0279626
.	O
	
ninety	O
five	O
patients	B-C0030705
with	O
escc	B-C0279626
were	O
studied	O
.	O
	
pre-therapy	B-C1882440
and	O
preoperative	B-C0445204
samples	B-C1550100
were	O
stored	O
and	O
elisa	B-C0014441
was	O
used	O
to	O
designate	O
the	O
concentrations	O
of	O
vegfr-3	B-C0169539
.	O
	
the	O
serum	B-C0683149
values	I-C0683149
of	O
vegfr-3	B-C0169539
were	O
significantly	O
higher	O
in	O
patients	B-C0030705
with	O
escc	B-C0279626
than	O
in	O
healthy	B-C3898900
donors	B-C0013018
p<0	O
.	O
	
the	O
results	O
imply	O
a	O
very	O
good	O
sensitivity	B-C1511883
of	O
vegfr-3	B-C0169539
in	O
escc	B-C0279626
.	O
	
vegfr-3	B-C0169539
may	O
be	O
a	O
good	O
diagnostic	B-C0348026
biomarker	B-C0005516
for	O
escc	B-C0279626
.	O
	
biomarker	B-C0005516
,	O
escc	B-C0279626
,	O
vegfr-3	B-C0169539
.	O
	
zinc	B-C0043481
and	O
wound	B-C0043240
healing	I-C0043240
a	O
review	B-C0699752
of	I-C0699752
zinc	B-C0043481
physiology	B-C0031843
and	O
clinical	B-C4048755
applications	I-C4048755
our	O
understanding	B-C0233820
of	O
the	O
role	O
of	O
zinc	B-C0043481
in	O
normal	O
human	B-C0086418
physiology	B-C0031843
is	O
constantly	B-C1948059
expanding	O
,	O
yet	O
there	O
are	O
major	O
gaps	B-C3887622
in	O
our	O
knowledge	O
with	O
regard	O
to	O
the	O
function	B-C0542341
of	O
zinc	B-C0043481
in	O
wound	B-C0043240
healing	I-C0043240
.	O
	
this	O
review	B-C0282443
aims	B-C1947946
to	O
provide	O
the	O
clinician	B-C0871685
with	O
sufficient	B-C0205410
understanding	O
of	O
zinc	B-C0043481
biology	B-C0005532
and	O
an	O
up-to-date	O
perspective	O
on	O
the	O
role	O
of	O
zinc	B-C0043481
in	O
wound	B-C0043240
healing	I-C0043240
.	O
	
zinc	B-C0043481
is	O
an	O
essential	O
ion	B-C0022023
that	O
is	O
crucial	O
for	O
maintenance	O
of	O
normal	O
physiology	B-C0031843
,	O
and	O
zinc	B-C0235950
deficiency	I-C0235950
has	O
many	O
manifestations	B-C0205319
ranging	O
from	O
delayed	B-C0205421
wound	B-C0043240
healing	I-C0043240
to	O
immune	B-C0021053
dysfunction	I-C0021053
and	O
impairment	B-C0221099
of	O
multiple	B-C0439064
sensory	B-C0682647
systems	I-C0682647
.	O
	
while	O
consensus	B-C0376298
has	O
been	O
reached	O
regarding	O
the	O
detrimental	B-C1280500
effects	I-C1280500
of	O
zinc	B-C0235950
deficiency	I-C0235950
on	O
wound	B-C0043240
healing	I-C0043240
,	O
there	O
is	O
considerable	O
discord	B-C0680238
in	O
the	O
literature	B-C0023866
on	O
the	O
optimal	B-C0025663
methods	I-C0025663
and	O
true	B-C0814225
benefits	I-C0814225
of	O
zinc	B-C0043481
receipt	O
of	O
thyroid	B-C0020676
hormone	I-C0020676
deficiency	I-C0020676
treatment	B-C0087111
and	O
risk	B-C0035647
of	O
herpes	B-C0019360
zoster	I-C0019360
thyroid	B-C0040135
hormone	I-C0040135
th	B-C0040135
has	O
been	O
suggested	O
to	O
control	O
herpes	B-C0019369
virus	I-C0019369
gene	B-C0017262
expression	I-C0017262
and	O
replication	B-C0598312
in	O
neurons	B-C0027882
via	O
epigenetics	B-C1516924
through	O
its	O
nuclear	B-C0206588
receptors	I-C0206588
.	O
	
it	O
has	O
previously	O
been	O
shown	O
that	O
patients	B-C0030705
with	O
hypothyroidism	B-C0020676
are	O
predisposed	O
to	O
herpes	B-C0019360
zoster	I-C0019360
hz	B-C0019360
,	O
suggesting	O
that	O
the	O
th	B-C0020676
deficiency	I-C0020676
may	O
be	O
a	O
risk	B-C0035648
factor	I-C0035648
for	O
varicella	B-C0042338
zoster	I-C0042338
virus	I-C0042338
vzv	B-C0042338
reactivation	B-C4086768
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
test	O
the	O
hypothesis	B-C1512571
that	O
th	B-C2986608
treatment	I-C2986608
will	O
ameliorate	O
the	O
complication	B-C0009566
of	O
hz	B-C0019360
.	O
	
this	O
study	B-C2603343
investigated	B-C1292732
the	O
hypothesis	B-C1512571
by	O
enquiring	O
into	O
a	O
comprehensive	B-C0242356
medical	I-C0242356
database	I-C0242356
at	O
kaiser	B-C1708333
permanente	I-C1708333
southern	I-C1708333
california	I-C1708333
kpsc	B-C1708333
to	O
verify	O
whether	O
patients	B-C0030705
taking	O
th	B-C0040135
medication	B-C2081612
experience	O
a	O
reduction	O
in	O
hz	B-C0019360
occurrence	O
.	O
	
it	O
was	O
shown	O
by	O
kaplan-meier	B-C1720943
analysis	I-C1720943
that	O
hypothyroidism	B-C0020676
patients	B-C0030705
taking	O
th	B-C0040135
medicines	B-C0013227
had	O
a	O
lower	O
risk	B-C0035647
of	O
hz	B-C0019360
.	O
	
the	O
fully	O
adjusted	O
analysis	B-C0936012
indicated	O
that	O
patients	B-C0030705
receiving	O
medication	B-C2081612
for	O
the	O
treatment	B-C0087111
of	O
th	B-C0020676
deficiency	I-C0020676
exhibited	O
a	O
reduced	O
risk	B-C0035647
of	O
hz	B-C0019360
hazard	B-C2985465
ratio	I-C2985465
0.60	O
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
0.51	O
.	O
	
this	O
lower	O
risk	B-C0035647
of	O
hz	B-C0019360
was	O
significant	O
in	O
all	O
age	B-C0027362
groups	I-C0027362
except	O
the	O
18-39	O
years	B-C0439234
cohort	B-C0599755
.	O
	
in	O
addition	O
,	O
female	B-C0086287
patients	B-C0030705
taking	O
th	B-C2986608
treatment	I-C2986608
exhibited	O
a	O
lower	O
risk	B-C0035647
than	O
their	O
male	B-C0086582
counterparts	O
.	O
	
together	O
these	O
findings	B-C0243095
support	O
the	O
hypothesis	B-C1512571
that	O
a	O
constant	O
level	O
of	O
th	B-C0040135
will	O
provide	O
a	O
degree	O
of	O
protection	O
from	O
contracting	O
hz	B-C0019360
.	O
	
more	O
studies	B-C2603343
are	O
underway	O
to	O
evaluate	B-C0262707
the	I-C0262707
laboratory	I-C0262707
data	I-C0262707
for	O
an	O
analysis	B-C0936012
of	O
hormonal	B-C0458083
effects	B-C1280500
on	O
peer	B-C0679739
exclusion	B-C2828389
during	O
the	O
pubertal	B-C1627769
transition	B-C2700061
the	O
role	O
of	O
social	B-C0683256
competence	I-C0683256
for	O
some	O
youth	B-C0087178
,	O
early	B-C0034013
puberty	I-C0034013
is	O
accompanied	O
by	O
peer	B-C0679739
exclusion	B-C2828389
.	O
	
yet	O
early	B-C1279919
developers	B-C1257890
may	O
experience	B-C0596545
less	O
peer	B-C0679739
exclusion	B-C2828389
if	O
they	O
have	O
social	B-C0683256
competence	I-C0683256
,	O
which	O
would	O
bolster	B-C1511253
their	O
ability	O
to	O
develop	B-C1527148
and	O
maintain	B-C0024501
positive	B-C1446409
relationships	B-C0439849
with	O
their	O
peers	B-C0679739
.	O
	
accordingly	O
,	O
the	O
present	B-C0150312
study	B-C2603343
tests	O
whether	O
pubertal	B-C1627769
timing	B-C0449243
and	O
tempo	B-C0876945
predicts	B-C0681842
decrements	B-C0392756
in	O
children's	B-C0008059
social	B-C0683256
competence	I-C0683256
and	O
whether	O
decrements	B-C0392756
in	O
social	B-C0683256
competence	I-C0683256
account	O
for	O
associations	B-C0332281
between	O
puberty	B-C0034011
timing	B-C0449243
and	O
tempo	B-C0876945
and	O
peer	B-C0679739
exclusion	B-C2828389
over	O
time	B-C0040223
.	O
	
longitudinal	B-C0023981
data	B-C1511726
were	O
drawn	O
from	O
1364	O
families	B-C0015576
48%	O
female	B-C0043210
76%	O
white	B-C0007457
m	O
=	O
9.32	O
years	B-C0439234
,	O
sd	O
=	O
48	O
,	O
at	O
wave	O
3	O
who	O
participated	B-C0679823
in	O
waves	O
3-5	O
i.e	O
,	O
grades	O
4-6	O
of	O
phase	B-C0282461
iii	I-C0282461
of	O
the	O
nichd	B-C1513896
-	O
seccyd	B-C0023981
.	O
	
the	O
results	B-C1274040
from	O
latent	B-C0814921
growth	I-C0814921
curve	I-C0814921
models	I-C0814921
indicated	O
that	O
earlier	B-C1279919
pubertal	B-C1627769
timing	B-C0449243
and	O
more	O
rapid	B-C0456962
pubertal	B-C1627769
tempo	B-C0876945
among	O
girls	B-C0870604
were	O
associated	B-C0332281
with	I-C0332281
high	B-C0205250
initial	B-C0205265
levels	B-C0441889
of	O
peer	B-C0679739
exclusion	B-C2828389
.	O
	
moreover	O
,	O
mediation	B-C0814912
analyses	I-C0814912
revealed	O
that	O
early	B-C1279919
developers'	B-C1257890
susceptibility	B-C1264642
to	O
peer	B-C0679739
exclusion	B-C2828389
was	O
associated	B-C0332281
with	I-C0332281
their	O
initial	B-C0205265
level	B-C0441889
of	O
social	B-C0683256
competence	I-C0683256
.	O
	
in	O
boys	B-C0870221
,	O
pubertal	B-C1627769
timing	B-C0449243
and	O
tempo	B-C0876945
were	O
not	O
directly	O
associated	B-C0332281
with	I-C0332281
peer	B-C0679739
exclusion	B-C2828389
instead	O
,	O
indirect	O
effects	B-C1704420
of	I-C1704420
pubertal	B-C1627769
timing	B-C0449243
on	O
peer	B-C0679739
exclusion	B-C2828389
intercept	B-C3146232
,	O
slope	B-C0807955
occurred	O
through	O
initial	B-C0205265
levels	B-C0441889
of	O
social	B-C0683256
competence	I-C0683256
.	O
	
on	O
average	B-C1510992
,	O
early	B-C1279919
developers'	B-C1257890
who	O
had	O
low	B-C0205251
levels	B-C0441889
of	O
social	B-C0683256
competence	I-C0683256
also	O
had	O
high	B-C0205250
initial	B-C0205265
levels	B-C0441889
of	O
peer	B-C0679739
exclusion	B-C2828389
but	O
experienced	B-C0596545
decrements	B-C0392756
in	O
peer	B-C0679739
exclusion	B-C2828389
over	O
time	O
.	O
	
the	O
association	B-C0332281
between	O
the	O
intercepts	B-C3146232
for	O
puberty	B-C0034011
and	O
peer	B-C0679739
exclusion	B-C2828389
and	O
the	O
slopes	B-C0807955
for	O
social	B-C0683256
competence	I-C0683256
and	O
peer	B-C0679739
exclusion	B-C2828389
were	O
stronger	B-C0442821
for	O
boys	B-C0870221
than	O
girls	B-C0870604
.	O
	
overall	O
,	O
our	O
findings	B-C0243095
suggest	O
that	O
early	B-C1279919
developers'	B-C1257890
susceptibility	B-C1264642
to	O
and	O
experiences	B-C0596545
of	O
peer	B-C0679739
exclusion	B-C2828389
are	O
associated	B-C0332281
with	I-C0332281
their	O
development	B-C1527148
of	O
social	B-C0683256
competence	I-C0683256
.	O
	
air	B-C0001873
pollution	I-C0001873
characteristics	B-C1521970
and	O
health	B-C0679809
risks	I-C0679809
in	O
henan	B-C1514578
province	I-C1514578
,	O
china	B-C0008115
events	O
of	O
severe	B-C0205082
air	B-C0001873
pollution	I-C0001873
occurred	O
frequently	O
in	O
china	B-C0008115
recently	O
,	O
thus	O
understanding	O
of	O
the	O
air	B-C0001873
pollution	I-C0001873
characteristics	B-C1521970
and	O
its	O
health	B-C0018684
risks	B-C0035647
is	O
very	O
important	O
.	O
	
in	O
this	O
work	O
,	O
we	O
analyzed	O
a	O
two-year	O
dataset	B-C0150098
march	O
2014	O
-	O
february	O
2016	O
including	O
daily	B-C0332173
concentrations	B-C1446561
of	O
six	O
criteria	O
pollutants	B-C0001869
pm2.5	B-C1720884
,	O
pm10	B-C1720884
,	O
co	B-C0007018
,	O
so2	B-C0038777
,	O
no2	B-C0028160
,	O
and	O
o3	B-C0030106
from	O
18	O
cities	O
in	O
henan	B-C1514578
province	I-C1514578
.	O
	
results	O
reveal	O
the	O
serious	O
air	B-C0001873
pollution	I-C0001873
status	B-C0449438
in	O
henan	B-C1514578
province	I-C1514578
,	O
especially	O
the	O
northern	B-C1709269
part	I-C1709269
,	O
and	O
zhengzhou	B-C0008848
is	O
the	O
city	B-C0008848
with	O
the	O
worst	B-C1522166
air	B-C2371710
quality	I-C2371710
.	O
	
annual	O
average	O
pm2.5	B-C1720884
concentrations	B-C1446561
exceed	O
the	O
second	O
grade	O
of	O
chinese	B-C0034925
ambient	I-C0034925
air	I-C0034925
quality	I-C0034925
standard	I-C0034925
75μg/m	O
at	O
both	O
2014	O
and	O
2015	O
.	O
	
pm2.5	B-C1720884
is	O
typically	O
the	O
major	O
pollutant	B-C0599786
,	O
but	O
ozone	B-C0030106
pollution	B-C0001873
can	O
be	O
significant	O
during	O
summer	B-C0241301
.	O
	
furthermore	O
,	O
as	O
the	O
commonly	O
used	O
air	B-C0918012
quality	I-C0918012
index	I-C0918012
aqi	B-C0918012
neglects	O
the	O
mutual	O
health	B-C0018684
effects	O
from	O
multiple	O
pollutants	B-C0599786
,	O
we	O
introduced	O
the	O
aggregate	B-C0918012
air	I-C0918012
quality	I-C0918012
index	I-C0918012
aaqi	B-C0918012
and	O
health-risk	B-C0918012
based	I-C0918012
air	I-C0918012
quality	I-C0918012
index	I-C0918012
haqi	B-C0918012
to	O
evaluate	B-C0679809
the	I-C0679809
health	I-C0679809
risks	I-C0679809
.	O
	
results	O
show	O
that	O
based	O
on	O
haqi	B-C0918012
,	O
the	O
current	O
aqi	B-C0918012
system	O
likely	O
significantly	O
underestimate	O
the	O
health	B-C0018684
risks	B-C0035647
of	O
air	B-C0001873
pollution	I-C0001873
,	O
highlighting	O
that	O
the	O
general	B-C0683971
public	I-C0683971
may	O
need	O
stricter	O
health	B-C1254363
protection	I-C1254363
measures	I-C1254363
.	O
	
the	O
population	B-C0032659
-weighted	O
two-year	O
average	O
haqi	B-C0918012
data	O
further	O
demonstrates	O
that	O
all	O
population	B-C0032659
in	O
the	O
studied	O
cities	B-C0008848
in	O
henan	B-C1514578
province	I-C1514578
live	O
with	O
polluted	B-C0001873
air	I-C0001873
-	O
72%	O
of	O
the	O
population	B-C0032659
is	O
exposed	B-C0332157
to	I-C0332157
air	B-C0001861
that	O
is	O
unhealthy	B-C0243095
for	O
sensitive	B-C0332324
people	B-C0027361
,	O
while	O
28%	O
of	O
people	B-C0027361
is	O
exposed	B-C0332157
to	I-C0332157
air	B-C0001861
that	O
can	O
be	O
harmful	O
to	O
healthy	B-C3898900
people	B-C0027361
and	O
the	O
health	B-C0018684
risks	B-C0035647
are	O
much	O
greater	O
during	O
winter	B-C0241737
than	O
during	O
other	O
seasons	B-C0036497
.	O
	
future	O
works	O
should	O
further	O
improve	O
the	O
haqi	B-C0918012
algorithm	B-C0002045
,	O
and	O
validate	O
the	O
links	O
between	O
the	O
clinical	B-C1516606
/	O
epidemiologic	B-C0014508
data	B-C0150098
and	O
the	O
haqi	B-C0918012
increased	B-C0205217
risk	B-C0035647
of	O
ptld	B-C0432487
in	O
lung	B-C2063401
transplant	I-C2063401
recipients	I-C2063401
with	O
cystic	B-C0010674
fibrosis	I-C0010674
post-transplant	B-C0432487
lymphoproliferative	I-C0432487
disease	I-C0432487
ptld	B-C0432487
is	O
an	O
important	O
cause	O
of	O
morbidity	B-C0026538
and	O
mortality	B-C0026566
following	O
lung	B-C0024128
transplantation	I-C0024128
.	O
	
recipients	B-C0376387
with	O
cystic	B-C0010674
fibrosis	I-C0010674
cf	B-C0010674
may	O
have	O
an	O
increased	B-C0205217
risk	B-C0035647
of	O
ptld	B-C0432487
although	O
the	O
literature	B-C0023866
is	O
limited	O
to	O
single	B-C0599755
center	I-C0599755
cohorts	I-C0599755
.	O
	
our	O
primary	O
aim	O
is	O
to	O
examine	O
ptld	B-C0432487
in	O
an	O
adult	B-C0001675
lung	B-C0024128
transplant	I-C0024128
population	B-C1257890
by	O
utilizing	O
the	O
international	B-C0282574
society	I-C0282574
for	I-C0282574
heart	I-C0282574
and	I-C0282574
lung	I-C0282574
transplantation	I-C0282574
registry	I-C0282574
.	O
	
we	O
studied	B-C2603343
30	O
adult	B-C0001675
recipients	B-C1709854
of	O
lung	B-C0024128
transplants	I-C0024128
performed	O
between	O
1999	O
and	O
2011	O
.	O
	
the	O
primary	O
outcome	B-C1274040
was	O
development	B-C1527148
of	O
and	O
time	B-C0040223
to	O
ptld	B-C0432487
.	O
	
in	O
addition	O
to	O
indication	O
for	O
transplant	B-C0040732
,	O
other	O
predictors	B-C2698872
examined	O
included	O
epstein-barr	B-C0014644
virus	I-C0014644
ebv	B-C0014644
and	O
cytomegalovirus	B-C0010825
cmv	B-C0010825
serostatus	B-C1300950
,	O
gender	B-C0079399
,	O
and	O
age	B-C0001779
.	O
	
outcomes	B-C1274040
were	O
assessed	B-C1516048
with	O
univariable	B-C0683962
and	O
multivariable	B-C0010235
cox	I-C0010235
proportional	I-C0010235
hazard	I-C0010235
models	I-C0010235
to	O
obtain	O
hazard	B-C2985465
ratios	I-C2985465
hr	B-C2985465
.	O
	
17%	O
of	O
the	O
cohort	B-C0599755
had	O
a	O
diagnosis	B-C0011900
of	O
cf	B-C0010674
.	O
	
ptld	B-C0432487
developed	O
in	O
2%	O
of	O
cf	B-C0010674
recipients	B-C0376387
compared	O
to	O
1%	O
for	O
non-cf	B-C2063401
recipients	I-C2063401
p<0	O
.	O
	
compared	O
to	O
non-cf	B-C2063401
recipients	I-C2063401
,	O
cf	B-C0010674
recipients	B-C0376387
had	O
higher	B-C0220900
prevalence	I-C0220900
of	O
ebv	B-C0014644
and	O
cmv	B-C2919629
seronegativity	I-C2919629
and	O
higher	B-C0220900
prevalences	I-C0220900
of	O
high	B-C0035647
risk	I-C0035647
ebv	B-C0014644
and	O
cmv	B-C0010825
mismatch	O
d+/r-	O
.	O
	
there	O
is	O
a	O
significant	O
association	O
between	O
cf	B-C0010674
and	O
the	O
development	B-C1527148
of	O
ptld	B-C0432487
hr	B-C2985465
1.66	O
95%	O
ci	O
1.30	O
.	O
	
stratified	B-C0026777
multivariable	I-C0026777
analysis	I-C0026777
controlling	O
for	O
age	B-C0001779
revealed	O
ebv	B-C0014644
negative	B-C1513916
non-cf	B-C2063401
recipients	I-C2063401
have	O
an	O
almost	O
2	O
fold	O
increased	B-C0205217
risk	B-C0035647
of	O
developing	O
ptld	B-C0432487
,	O
whereas	O
ebv	B-C0014644
negative	O
cf	B-C0010674
recipients	B-C0376387
had	O
an	O
almost	O
6.5	O
fold	O
increased	B-C0205217
risk	B-C0035647
.	O
	
cf	B-C0010674
recipients	B-C0376387
have	O
a	O
higher	O
risk	B-C0035647
for	O
ptld	B-C0432487
compared	O
to	O
non-cf	B-C2063401
recipients	I-C2063401
.	O
	
further	O
studies	B-C2603343
are	O
needed	O
to	O
account	O
for	O
additional	O
risk	B-C0035648
factors	I-C0035648
and	O
management	B-C0035649
in	O
this	O
population	B-C2063401
post-transplant	I-C2063401
.	O
	
methods	B-C0025663
,	O
tools	B-C0541506
and	O
current	B-C0521116
perspectives	B-C1254370
in	O
proteogenomics	B-C3897816
with	O
combined	O
technological	B-C0681519
advancements	I-C0681519
in	O
high-throughput	B-C2936625
next-generation	I-C2936625
sequencing	I-C2936625
and	O
deep	B-C0037813
mass	I-C0037813
spectrometry	I-C0037813
-based	O
proteomics	B-C0872252
,	O
proteogenomics	B-C3897816
,	O
i.e	O
,	O
the	O
integrative	B-C0936012
analysis	I-C0936012
of	O
proteomic	B-C1511726
and	I-C1511726
genomic	I-C1511726
data	I-C1511726
,	O
has	O
emerged	O
as	O
a	O
new	O
research	B-C0683945
field	I-C0683945
.	O
	
early	O
efforts	O
in	O
the	O
field	B-C0683945
were	O
focused	O
on	O
improving	O
protein	B-C0033684
identification	B-C0205396
using	O
sample-specific	B-C0282574
genomic	I-C0282574
and	O
transcriptomic	B-C0026382
sequencing	I-C0026382
data	I-C0026382
.	O
	
more	O
recently	O
,	O
integrative	B-C0936012
analysis	I-C0936012
of	O
quantitative	B-C0392762
measurements	B-C0242485
from	O
genomic	B-C0681814
and	I-C0681814
proteomic	I-C0681814
studies	I-C0681814
have	O
identified	B-C0205396
novel	O
insights	O
into	O
gene	B-C0017263
expression	I-C0017263
regulation	I-C0017263
,	O
cell	B-C0037083
signaling	I-C0037083
,	O
and	O
disease	B-C0012634
.	O
	
many	O
methods	B-C0025663
and	O
tools	B-C0541506
have	O
been	O
developed	O
or	O
adapted	O
to	O
enable	O
an	O
array	B-C1510941
of	O
integrative	B-C1292724
proteogenomic	I-C1292724
approaches	I-C1292724
and	O
in	O
this	O
article	B-C1706852
,	O
we	O
systematically	B-C0220922
classify	B-C0008902
published	B-C0034037
methods	B-C0025663
and	O
tools	B-C0541506
into	O
four	O
major	B-C1550395
categories	I-C1550395
,	O
1	O
sequence	B-C0004793
-centric	O
proteogenomics	O
2	O
analysis	O
of	O
proteogenomic	O
relationships	O
3	O
integrative	O
modeling	O
of	O
proteogenomic	O
data	O
and	O
4	O
data	O
sharing	O
and	O
visualization	O
.	O
	
we	O
provide	O
a	O
comprehensive	O
review	O
of	O
methods	O
and	O
available	O
tools	O
in	O
each	O
category	O
and	O
highlight	O
their	O
typical	O
applications	B-C0205245
plasma	B-C0032105
dna	B-C0012854
and	O
rna	B-C0035668
differentially	B-C1705242
impact	B-C4049986
coagulation	B-C0005778
during	O
abdominal	B-C1141926
sepsis	I-C1141926
-an	O
explorative	B-C2603343
study	I-C2603343
cell-free	B-C4289789
dna	I-C4289789
cfdna	B-C4289789
and	O
extracellular	B-C0521119
rna	B-C0035668
exrna	B-C0035668
are	O
both	O
suspected	B-C0750491
to	O
activate	B-C1515877
coagulation	B-C0005779
cascades	I-C0005779
in	O
sepsis	B-C0243026
.	O
	
therefore	O
,	O
our	O
study	B-C2603343
investigated	B-C1292732
the	O
influence	B-C4054723
of	O
plasmatic	B-C0032105
nucleic	B-C0028606
acids	I-C0028606
on	O
coagulation	B-C0005778
in	O
septic	B-C0333534
patients	B-C0030705
in	O
comparison	B-C1707455
to	O
patients	B-C0030705
after	O
major	O
abdominal	B-C0198482
surgery	I-C0198482
.	O
	
a	O
total	O
of	O
15	O
patients	B-C0030705
with	O
sepsis	B-C0243026
,	O
10	O
postoperative	B-C0032790
patients	B-C0030705
,	O
and	O
10	O
healthy	B-C1708335
volunteers	I-C1708335
were	O
included	B-C0332257
in	O
this	O
longitudinal	B-C0023981
study	I-C0023981
.	O
	
blood	B-C0005767
was	O
collected	B-C1516695
at	O
sepsis	B-C0243026
onset	B-C0277793
and	O
after	O
surgery	B-C0543467
respectively	O
,	O
as	O
well	O
as	O
after	O
24	O
,	O
72	O
and	O
168	O
h	O
.	O
	
levels	B-C0441889
of	O
cfdna	B-C4289789
and	O
exrna	B-C0035668
were	O
measured	B-C0444706
by	O
quantitative	B-C0392762
probe-based	B-C0182400
polymerase	B-C0032520
chain	I-C0032520
reaction	I-C0032520
.	O
	
in	O
addition	O
,	O
thromboelastography	B-C0040017
for	O
coagulation	B-C0005778
as	O
well	O
as	O
thromboaggregometry	B-C0022885
for	O
platelet	B-C1254881
function	I-C1254881
was	O
conducted	O
.	O
	
both	O
cfdna	B-C4289789
and	O
exrna	B-C0035668
were	O
elevated	B-C3163633
in	O
patients	B-C0030705
with	O
sepsis	B-C0243026
compared	B-C1707455
with	O
postoperative	B-C0032790
patients	B-C0030705
and	O
healthy	B-C1708335
volunteers	I-C1708335
.	O
	
while	O
higher	B-C0205250
exrna	B-C0035668
levels	B-C0441889
correlated	B-C1707520
with	O
a	O
faster	B-C2266672
clotting	I-C2266672
time	I-C2266672
and	O
more	O
stable	B-C0302148
clots	I-C0302148
,	O
cfdna	B-C4289789
correlated	B-C1707520
with	O
a	O
shorter	B-C2266672
clotting	I-C2266672
time	I-C2266672
but	O
also	O
less	O
fibrinolysis	B-C0016017
.	O
	
in	O
addition	O
,	O
higher	B-C0205250
cfdna	B-C4289789
seems	O
to	O
be	O
associated	B-C0332281
with	I-C0332281
kidney	B-C0151746
dysfunction	I-C0151746
as	O
well	O
as	O
with	O
general	O
markers	B-C0005516
of	O
cell	B-C0599732
damage	I-C0599732
lactate	B-C0022917
dehydrogenase	I-C0022917
and	O
lactate	B-C0376261
.	O
	
both	O
nucleic	B-C0028606
acid	I-C0028606
species	O
might	O
be	O
associated	B-C0332281
with	I-C0332281
different	B-C1705242
effects	B-C1280500
on	O
coagulation	B-C0005778
during	O
sepsis	B-C0243026
,	O
with	O
an	O
overall	B-C1561607
procoagulatory	B-C2917275
influence	B-C4054723
.	O
	
for	O
this	O
reason	O
,	O
individualized	B-C1881197
therapeutic	B-C0087111
approaches	I-C0087111
in	O
patients	B-C0030705
suffering	B-C0751408
from	O
coagulation	B-C0005778
-	O
associated	B-C0449380
organ	B-C0342953
dysfunction	I-C0342953
association	B-C0439849
of	O
fat	B-C3656665
mass	I-C3656665
and	O
obesity	B-C0028754
-	O
associated	B-C0332281
gene	B-C0678941
variant	I-C0678941
with	O
lifestyle	B-C0023676
factors	B-C1521761
and	O
body	B-C0344335
fat	I-C0344335
in	O
indian	B-C1524069
children	B-C0008059
common	O
intronic	B-C0678941
variants	I-C0678941
of	O
the	O
fat	B-C3656665
mass	I-C3656665
and	O
obesity	B-C0028754
-	O
associated	B-C0332281
fto	B-C1970415
gene	I-C1970415
have	O
been	O
associated	B-C0332281
with	I-C0332281
obesity	B-C0028754
-related	O
traits	B-C0599883
in	O
humans	B-C0086418
.	O
	
1	O
the	O
aim	O
of	O
this	O
study	B-C2603343
is	O
to	O
study	B-C2603343
the	O
distribution	O
of	O
fto	B-C1970415
gene	I-C1970415
variants	B-C0678941
across	O
different	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
categories	O
and	O
2	O
to	O
explore	O
the	O
association	B-C0439849
between	O
fto	B-C1970415
gene	I-C1970415
variants	B-C0678941
and	O
lifestyle	B-C0023676
factors	B-C1521761
in	O
obese	B-C0028754
and	O
normal	B-C2712185
weight	I-C2712185
indian	B-C1524069
children	B-C0008059
.	O
	
fifty-six	O
children	B-C0008059
26	O
boys	B-C0870221
,	O
mean	O
age	B-C0001779
10.3	O
2.2	O
years	B-C0439234
were	O
studied	B-C2603343
.	O
	
height	B-C0005890
,	O
weight	B-C0005910
,	O
and	O
waist	B-C0455829
and	O
hip	B-C0562350
circumference	I-C0562350
were	O
measured	B-C0444706
.	O
	
physical	B-C0026606
activity	I-C0026606
questionnaire	B-C4264334
and	O
food	B-C0016452
intake	B-C1512806
food	B-C2986698
frequency	I-C2986698
questionnaire	I-C2986698
were	O
assessed	B-C1516048
.	O
	
body	B-C1632383
fat	I-C1632383
percentage	I-C1632383
%bf	B-C1632383
was	O
measured	O
by	O
dual-energy	B-C1510486
x-ray	I-C1510486
absorptiometry	I-C1510486
.	O
	
fto	B-C0678941
allelic	I-C0678941
variants	I-C0678941
at	O
rs9939609	B-C1517493
site	I-C1517493
were	O
detected	O
by	O
sybr	B-C1709846
green	I-C1709846
amplification	I-C1709846
refractory	I-C1709846
mutation	I-C1709846
system	I-C1709846
real-time	I-C1709846
polymerase	I-C1709846
chain	I-C1709846
reaction	I-C1709846
using	O
allele	B-C0002085
-	O
specific	B-C0205369
primers	B-C0206415
.	O
	
generalized	B-C0023732
linear	I-C0023732
model	I-C0023732
was	O
used	O
to	O
investigate	B-C1292732
the	O
simultaneous	B-C0521115
influence	B-C4054723
of	O
genetic	B-C0314603
and	O
lifestyle	B-C0023676
factors	B-C1521761
on	O
%bf	B-C1632383
.	O
	
mean	O
height	B-C0005890
,	O
weight	B-C0005910
,	O
and	O
bmi	B-C1305855
of	O
normal	B-C0205307
and	O
obese	B-C0028754
children	B-C0008059
were	O
130.6	O
7.1	O
versus	O
143.2	O
15.6	O
,	O
24.0	O
5.2	O
versus	O
53.1	O
15.8	O
,	O
and	O
13.9	O
2.1	O
versus	O
25.3	O
3.2	O
,	O
respectively	O
.	O
	
the	O
frequency	O
of	O
aa	B-C0002085
allele	I-C0002085
was	O
57%	O
among	O
obese	B-C0028754
children	B-C0008059
and	O
35%	O
in	O
normal	B-C2712185
weight	I-C2712185
children	B-C0008059
.	O
	
children	B-C0008059
with	O
the	O
aa	B-C0002085
allele	I-C0002085
who	O
were	O
obese	B-C0028754
had	O
least	O
physical	B-C0026606
activity	I-C0026606
,	O
whereas	O
children	B-C0008059
with	O
at	B-C0002085
allele	I-C0002085
and	O
obesity	B-C0028754
had	O
the	O
highest	B-C1522410
intake	B-C4281687
of	I-C4281687
calories	I-C4281687
when	O
compared	B-C1707455
to	O
children	B-C0008059
who	O
had	O
at	B-C0002085
allele	I-C0002085
and	O
were	O
normal	B-C0205307
.	O
	
%bf	B-C1632383
was	O
positively	O
associated	B-C0332281
with	I-C0332281
aa	B-C0002085
alleles	I-C0002085
and	O
junk	B-C0681578
food	I-C0681578
intake	B-C1512806
and	O
negatively	O
with	O
healthy	B-C3898900
food	B-C0016452
intake	B-C1512806
and	O
moderate	O
physical	B-C0026606
activity	I-C0026606
.	O
	
healthy	B-C4277664
lifestyle	I-C4277664
with	O
high	O
physical	B-C0026606
activity	I-C0026606
and	O
diet	B-C0012155
low	B-C0205251
in	O
calories	B-C1556156
and	O
fat	B-C0012171
may	O
help	O
in	O
modifying	B-C0392747
the	O
risk	B-C0035647
imposed	O
by	O
fto	B-C0678941
variants	I-C0678941
in	O
museum	B-C0026863
specimen	B-C0370003
data	B-C1511726
reveal	O
emergence	O
of	O
a	O
plant	B-C0032080
disease	I-C0032080
may	O
be	O
linked	O
to	O
increases	B-C0442805
in	O
the	O
insect	B-C0021573
vector	I-C0021573
population	O
the	O
emergence	O
rate	O
of	O
new	O
plant	O
diseases	O
is	O
increasing	O
due	O
to	O
novel	O
introductions	O
,	O
climate	O
change	O
,	O
and	O
changes	O
in	O
vector	O
populations	O
,	O
posing	O
risks	O
to	O
agricultural	O
sustainability	O
.	O
	
assessing	O
and	O
managing	O
future	O
disease	O
risks	O
depends	O
on	O
understanding	O
the	O
causes	O
of	O
contemporary	O
and	O
historical	O
emergence	O
events	O
.	O
	
since	O
the	O
mid-1990s	O
,	O
potato	O
growers	O
in	O
the	O
western	O
united	O
states	O
,	O
mexico	O
,	O
and	O
central	O
america	O
have	O
experienced	O
severe	O
yield	O
loss	O
from	O
zebra	O
chip	O
disease	O
and	O
have	O
responded	O
by	O
increasing	O
insecticide	O
use	O
to	O
suppress	O
populations	O
of	O
the	O
insect	B-C1257890
vector	I-C1257890
,	O
the	O
potato	O
psyllid	O
,	O
bactericera	O
cockerelli	O
hemiptera	O
triozidae	O
.	O
	
despite	O
the	O
severe	O
nature	O
of	O
zebra	O
chip	O
outbreaks	O
,	O
the	O
causes	O
of	O
emergence	O
remain	O
unknown	O
.	O
	
we	O
tested	O
the	O
hypotheses	O
that	O
1	O
b	O
.	O
	
cockerelli	O
occupancy	O
has	O
increased	O
over	O
the	O
last	O
century	O
in	O
california	O
and	O
2	O
such	O
increases	O
are	O
related	O
to	O
climate	O
change	O
,	O
specifically	O
warmer	O
winters	O
.	O
	
we	O
compiled	O
a	O
dataset	O
of	O
87	O
museum	O
specimen	O
occurrence	O
records	O
across	O
the	O
order	O
hemiptera	O
collected	O
between	O
1900	O
and	O
2014	O
.	O
	
we	O
then	O
analyzed	O
changes	O
in	O
b	O
.	O
	
cockerelli	O
distribution	O
using	O
a	O
hierarchical	O
occupancy	O
model	O
using	O
changes	O
in	O
background	O
species	O
lists	O
to	O
correct	O
for	O
collecting	O
effort	O
.	O
	
we	O
found	O
evidence	O
that	O
b	O
.	O
	
cockerelli	O
occupancy	O
has	O
increased	O
over	O
the	O
last	O
century	O
.	O
	
however	O
,	O
these	O
changes	O
appear	O
to	O
be	O
unrelated	O
to	O
climate	O
changes	O
,	O
at	O
least	O
at	O
the	O
scale	O
of	O
our	O
analysis	O
.	O
	
to	O
the	O
extent	O
that	O
species	O
occupancy	O
is	O
related	O
to	O
abundance	O
,	O
our	O
analysis	O
provides	O
the	O
first	O
quantitative	O
support	O
for	O
the	O
hypothesis	O
that	O
b	O
.	O
	
cockerelli	O
population	I-C1257890
abundance	O
has	O
increased	O
,	O
but	O
further	O
work	O
is	O
needed	O
to	O
link	O
b	O
.	O
	
cockerelli	O
population	O
dynamics	O
to	O
zebra	O
chip	O
epidemics	O
.	O
	
finally	O
,	O
we	O
demonstrate	O
how	O
this	O
historical	O
macro-ecological	O
approach	O
provides	O
a	O
general	O
framework	O
for	O
comparative	O
risk	O
assessment	O
of	O
future	O
pest	O
and	O
insect	O
vector	O
outbreaks	O
.	O
	
this	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
	
all	O
rights	O
effect	B-C1280500
of	O
halotolerant	B-C0004611
rhizobacteria	I-C0004611
isolated	B-C0205409
from	O
halophytes	B-C2350261
on	O
the	O
growth	B-C0018270
of	O
sugar	B-C0330391
beet	I-C0330391
beta	B-C0330391
vulgaris	I-C0330391
l	I-C0330391
under	O
salt	B-C1154956
stress	I-C1154956
utilization	B-C0042153
of	O
rhizobacteria	B-C0004611
that	O
have	O
associated	B-C0332281
with	I-C0332281
plant	B-C0242726
roots	I-C0242726
in	O
harsh	B-C4068826
environments	B-C0014406
could	O
be	O
a	O
feasible	B-C0035171
strategy	I-C0035171
to	O
deal	O
with	O
limits	O
to	O
agricultural	B-C0001827
production	I-C0001827
caused	O
by	O
soil	B-C0037592
salinity	B-C1956027
.	O
	
halophytes	B-C2350261
occur	O
naturally	O
in	O
high	B-C0205250
-	O
salt	B-C0178838
environments	I-C0178838
,	O
and	O
their	O
roots	B-C0242726
may	O
be	O
associated	B-C0332281
with	I-C0332281
promising	O
microbial	B-C0599840
candidates	I-C0599840
for	O
promoting	B-C0033414
growth	B-C0018270
and	O
salt	B-C1752460
tolerance	I-C1752460
in	O
crops	B-C0242775
.	O
	
this	O
study	B-C2603343
aimed	O
to	O
isolate	B-C0205409
efficient	O
halotolerant	B-C2350260
plant	I-C2350260
-	O
growth	B-C0597252
-	O
promoting	B-C0033414
rhizobacterial	B-C0521009
strains	B-C1518614
from	O
halophytes	B-C2350261
and	O
evaluate	B-C1516048
their	O
activity	B-C0441655
and	O
effects	B-C1280500
on	O
sugar	B-C0330391
beet	I-C0330391
beta	B-C0330391
vulgaris	I-C0330391
l	I-C0330391
growth	B-C0018270
under	O
salinity	B-C1154956
stress	I-C1154956
.	O
	
a	O
total	O
of	O
23	O
isolates	B-C1764827
were	O
initially	O
screened	O
for	O
their	O
ability	B-C0085732
to	O
secrete	O
1-aminocyclopropane-1-carboxylate	B-C0044278
deaminase	I-C0044278
acd	B-C0044278
as	O
well	O
as	O
other	O
plant-growth	B-C0597252
-	O
promoting	B-C0033414
characteristics	B-C1521970
and	O
subsequently	O
identified	B-C0205396
by	O
sequencing	B-C1561491
the	O
16s	B-C3537372
rrna	I-C3537372
gene	B-C0017337
.	O
	
three	O
isolates	B-C1764827
,	O
identified	O
as	O
micrococcus	B-C2766719
yunnanensis	I-C2766719
,	O
planococcus	B-C1483193
rifietoensis	I-C1483193
and	O
variovorax	B-C0314842
paradoxus	I-C0314842
,	O
enhanced	B-C2349975
salt	B-C1154956
stress	I-C1154956
tolerance	B-C1704410
remarkably	O
in	O
sugar	B-C0330391
beet	I-C0330391
,	O
resulting	B-C0332294
in	I-C0332294
greater	B-C1704243
seed	B-C1160189
germination	I-C1160189
and	O
plant	B-C0032098
biomass	B-C0005535
,	O
higher	B-C0205250
photosynthetic	B-C0031764
capacity	B-C1516240
and	O
lower	B-C0205251
stress	B-C0038435
-	O
induced	B-C0205263
ethylene	B-C0015075
production	B-C0005572
at	O
different	B-C1705242
nacl	B-C0037494
concentrations	B-C1446561
50-125	O
mm	O
.	O
	
these	O
results	B-C1274040
demonstrate	O
that	O
salinity	B-C1956027
-	O
adapted	B-C0392673
,	O
acd	B-C0044278
-producing	O
bacteria	B-C0004611
isolated	B-C0205409
from	O
halophytes	B-C2350261
could	O
promote	B-C0033414
sugar	B-C0330391
beet	I-C0330391
growth	B-C0018270
under	O
saline	B-C1154956
stress	I-C1154956
conditions	I-C1154956
.	O
	
potential	B-C3245505
sunitinib	B-C1176020
-	O
induced	B-C0205263
coronary	B-C0205042
artery	I-C0205042
and	O
aortic	B-C0340643
dissections	I-C0340643
small-molecule	B-C0879484
multitargeted	I-C0879484
tyrosine	I-C0879484
kinase	I-C0879484
inhibitor	I-C0879484
tki	I-C0879484
therapy	I-C0879484
is	O
used	O
in	O
different	O
types	O
of	O
cancer	B-C0006826
.	O
	
these	O
drugs	B-C0013227
have	O
been	O
associated	B-C0332281
with	I-C0332281
cardiovascular	B-C0876994
toxicity	I-C0876994
,	O
including	O
aortic	B-C0340643
dissection	I-C0340643
.	O
	
to	O
our	O
knowledge	B-C0376554
,	O
this	O
is	O
the	O
first	B-C0040223
time	I-C0040223
that	O
a	O
coronary	B-C0340643
dissection	I-C0340643
potentially	B-C3245505
associated	B-C0332281
with	I-C0332281
a	O
tki	B-C0879484
treatment	I-C0879484
recovery	B-C0237820
of	I-C0237820
orthographic	B-C0871846
processing	B-C0025361
after	O
stroke	B-C0038454
a	O
longitudinal	B-C0023981
fmri	B-C0376335
study	O
an	O
intact	O
orthographic	B-C0871846
processing	B-C0025361
system	O
is	O
critical	O
for	O
normal	B-C1404290
reading	I-C1404290
and	I-C1404290
spelling	I-C1404290
.	O
	
here	O
we	O
investigate	O
the	O
neural	B-C3714606
changes	I-C3714606
associated	O
with	O
impairment	B-C0221099
and	O
subsequent	O
recovery	B-C0237820
of	O
the	O
orthographic	B-C0871846
lexical	B-C0871801
processing	I-C0871801
system	O
in	O
an	O
individual	O
with	O
an	O
ischemic	B-C0022116
left	B-C2062605
posterior	I-C2062605
cerebral	I-C2062605
artery	I-C2062605
pca	I-C2062605
stroke	I-C2062605
.	O
	
this	O
work	O
describes	O
a	O
longitudinal	B-C0023981
case	I-C0023981
study	I-C0023981
of	O
a	O
patient	O
,	O
whose	O
initials	O
are	O
mmy	B-C0086418
,	O
with	O
impairments	B-C0221099
in	O
orthographic	B-C0871846
lexical	B-C0871801
processing	I-C0871801
for	O
reading	B-C1404290
and	I-C1404290
spelling	I-C1404290
at	O
stroke	B-C0038454
onset	B-C0277793
,	O
and	O
who	O
recovered	O
these	O
skills	O
within	O
1	O
year	O
post	O
stroke	B-C0038454
.	O
	
we	O
tested	O
the	O
hypothesis	B-C1512571
that	O
this	O
acute	B-C0205178
impairment	B-C0221099
to	O
reading	B-C1404290
and	I-C1404290
spelling	I-C1404290
would	O
be	O
associated	O
with	O
a	O
selective	O
loss	B-C1517945
of	I-C1517945
neural	B-C3714606
activation	I-C3714606
in	O
the	O
left	B-C2337131
fusiform	I-C2337131
gyrus	I-C2337131
fg	B-C2337131
,	O
and	O
that	O
subsequent	O
recovery	O
would	O
be	O
associated	O
with	O
a	O
gain	B-C1517378
of	I-C1517378
neural	B-C3714606
activation	I-C3714606
in	O
this	O
region	O
.	O
	
mmy's	B-C0086418
case	O
provided	O
a	O
unique	O
opportunity	O
to	O
assess	O
the	O
selectivity	O
of	O
neural	B-C3714606
changes	I-C3714606
because	O
she	O
demonstrated	O
a	O
behavioral	B-C0004927
recovery	B-C2004454
of	I-C2004454
naming	I-C2004454
as	I-C2004454
well	I-C2004454
i.e	O
,	O
if	O
there	O
is	O
neural	B-C3714606
recovery	I-C3714606
for	O
reading	B-C1404290
and	I-C1404290
spelling	I-C1404290
,	O
but	O
not	O
naming	O
,	O
then	O
these	O
neural	B-C3714606
changes	I-C3714606
are	O
selective	O
to	O
the	O
recovery	O
of	O
orthographic	B-C0871846
processing	B-C0025361
.	O
	
to	O
test	O
our	O
hypothesis	O
,	O
we	O
examined	O
longitudinal	B-C0004939
behavioral	I-C0004939
and	O
functional	B-C0376335
magnetic	I-C0376335
resonance	I-C0376335
imaging	I-C0376335
fmri	B-C0376335
data	O
of	O
reading	B-C0586739
,	O
spelling	B-C0869025
,	O
and	O
visual	B-C0451342
object	I-C0451342
naming	I-C0451342
acquired	O
acutely	O
,	O
3	O
weeks	O
,	O
5	O
months	O
,	O
and	O
one	O
year	O
post	O
stroke	B-C0038454
.	O
	
in	O
confirmation	O
of	O
our	O
hypothesis	B-C1512571
,	O
the	O
loss	O
and	O
subsequent	O
gain	O
of	O
orthographic	B-C0871846
lexical	B-C0871801
processing	I-C0871801
was	O
associated	O
with	O
up-regulation	B-C0041904
of	O
neural	B-C3714606
activation	I-C3714606
in	O
areas	O
previously	O
associated	O
with	O
orthographic	B-C0871846
lexical	B-C0871801
processing	I-C0871801
i.e	O
,	O
the	O
left	B-C2953769
mid-fg	I-C2953769
and	O
inferior	B-C0152298
frontal	I-C0152298
junction	I-C0152298
ifj	B-C0152298
.	O
	
furthermore	O
,	O
these	O
neural	B-C3714606
changes	I-C3714606
were	O
found	O
to	O
be	O
selective	O
to	O
orthographic	B-C0871846
processing	B-C0025361
,	O
as	O
they	O
were	O
observed	O
for	O
reading	B-C0586739
and	O
spelling	B-C0869025
,	O
but	O
not	O
for	O
visual	B-C0451342
object	I-C0451342
naming	I-C0451342
within	O
the	O
left	B-C2953769
mid-fg	I-C2953769
.	O
	
this	O
work	O
shows	O
that	O
left	B-C2062605
pca	I-C2062605
stroke	I-C2062605
can	O
temporarily	O
and	O
selectively	O
disrupt	O
the	O
orthographic	B-C0871846
lexical	B-C0871801
processing	I-C0871801
system	O
,	O
not	O
only	O
in	O
the	O
posterior	B-C1254362
region	I-C1254362
adjacent	B-C0205117
to	O
the	O
stroke	B-C0038454
,	O
but	O
also	O
in	O
relatively	O
distant	B-C1254362
frontal	I-C1254362
orthographic	B-C0871846
processing	B-C0025361
nodal	B-C0443268
skip	B-C0560435
metastasis	B-C0596869
in	O
thoracic	B-C0861674
esophageal	I-C0861674
squamous	I-C0861674
cell	I-C0861674
carcinoma	I-C0861674
a	O
cohort	B-C0009247
study	I-C0009247
nodal	B-C0443268
skip	B-C0560435
metastasis	B-C0596869
is	O
a	O
prognostic	B-C1514474
factor	I-C1514474
in	O
some	O
sites	O
of	O
malignancies	B-C4282132
,	O
but	O
its	O
role	O
in	O
esophageal	B-C0014859
cancer	I-C0014859
is	O
still	O
unclear	B-C3845108
.	O
	
the	O
present	O
study	O
aimed	O
to	O
investigate	B-C1292732
occurrence	O
and	O
effect	B-C1280500
of	O
nodal	B-C0443268
skip	B-C0560435
metastases	O
in	O
thoracic	B-C0861674
esophageal	I-C0861674
squamous	I-C0861674
cell	I-C0861674
carcinoma	I-C0861674
.	O
	
all	O
578	O
patients	B-C0030705
undergoing	O
esophagectomy	B-C0085198
for	O
thoracic	B-C0861674
esophageal	I-C0861674
squamous	I-C0861674
cell	I-C0861674
carcinoma	I-C0861674
at	O
the	O
center	B-C1708333
for	I-C1708333
esophageal	I-C1708333
diseases	I-C1708333
located	O
in	O
padova	B-C0681784
between	O
january	B-C3829466
1992	O
and	O
december	B-C3830550
2010	O
were	O
retrospectively	B-C0035363
evaluated	I-C0035363
.	O
	
selection	B-C0242801
criteria	I-C0242801
were	O
r0	B-C0677874
resection	I-C0677874
,	O
pathological	B-C1521733
m0	B-C0445034
stage	I-C0445034
and	O
pathological	B-C1521733
lymph	B-C0806692
node	I-C0806692
involvement	I-C0806692
.	O
	
patients	B-C1516213
receiving	O
neoadjuvant	B-C0600558
therapy	I-C0600558
were	O
excluded	O
.	O
	
the	O
selection	O
identified	O
88	O
patients	B-C0030705
with	O
lymph	B-C0806692
node	I-C0806692
involvement	I-C0806692
confirmed	O
by	O
pathological	B-C1521733
evaluation	B-C0220825
.	O
	
sixteen	O
patients	B-C1516213
18.2	O
had	O
nodal	B-C0443268
skip	B-C0560435
metastasis	B-C0596869
.	O
	
adjusting	O
for	O
the	O
number	O
of	O
lymph	B-C0596869
node	I-C0596869
metastases	I-C0596869
,	O
patient	B-C1516213
with	O
nodal	B-C0443268
skip	B-C0560435
metastasis	B-C0596869
had	O
similar	O
5-year	O
overall	B-C4086681
survival	I-C4086681
14%	O
vs	O
.	O
	
13%	O
,	O
p	O
=	O
0.93	O
and	O
5-year	O
disease	B-C0242793
free	I-C0242793
survival	I-C0242793
14%	O
vs	O
.	O
	
9%	O
,	O
p	O
=	O
0.48	O
compared	O
to	O
patients	B-C0030705
with	O
both	O
peritumoral	B-C3897941
and	O
distant	B-C0443203
lymph	B-C0596869
node	I-C0596869
metastases	I-C0596869
.	O
	
the	O
risk	O
difference	O
of	O
nodal	B-C0443268
skip	B-C0560435
metastasis	B-C0596869
was	O
-24	O
95%	O
c.i	B-C0009667
.	O
	
-43	O
to	O
-5	O
in	O
patients	B-C0030705
with	O
more	O
than	O
one	O
lymph	B-C0596869
node	I-C0596869
metastasis	I-C0596869
compared	O
to	O
those	O
with	O
one	O
lymph	B-C0596869
node	I-C0596869
metastasis	I-C0596869
-2	O
95%	O
c.i	B-C0009667
.	O
	
-29	O
to	O
25.2	O
in	O
middle	B-C0444598
thoracic	B-C0227188
esophagus	I-C0227188
and	O
-23	O
95%	O
c.i	B-C0009667
.	O
	
-47	O
to	O
1.8	O
in	O
lower	B-C0441994
thoracic	B-C0227188
esophagus	I-C0227188
compared	O
to	O
upper	B-C1282910
thoracic	B-C0227188
esophagus	I-C0227188
18.1	O
95%	O
c.i	B-C0009667
.	O
	
3.2	O
to	O
33.0	O
in	O
clinical	B-C0205210
n0	B-C0441959
stage	I-C0441959
vs	O
.	O
	
clinical	B-C0205210
n+	B-C1272457
stage	I-C1272457
.	O
	
nodal	B-C0443268
skip	B-C0560435
metastasis	B-C0596869
is	O
a	O
common	O
pattern	O
of	O
metastatic	B-C0806692
lymph	I-C0806692
involvement	I-C0806692
in	O
thoracic	B-C0861674
esophageal	I-C0861674
squamous	I-C0861674
cell	I-C0861674
carcinoma	I-C0861674
.	O
	
however	O
,	O
neither	B-C4284892
overall	B-C4086681
survival	I-C4086681
nor	O
disease	B-C0242793
free	I-C0242793
survival	I-C0242793
are	O
associated	B-C0332281
with	I-C0332281
nodal	B-C0443268
skip	B-C0560435
metastasis	B-C0596869
association	B-C0439849
of	O
leukemia	B-C1366463
inhibitory	I-C1366463
factor	I-C1366463
gene	I-C1366463
polymorphism	B-C0678951
and	O
in	B-C1533691
vitro	I-C1533691
fertilization	B-C0015914
outcome	B-C1274040
in	O
a	O
population	B-C1257890
in	O
northern	B-C0022065
iran	I-C0022065
several	O
studies	B-C2603343
have	O
been	O
demonstrated	O
that	O
endometrial	B-C0227843
leukemia	B-C0125606
inhibitory	I-C0125606
factor	I-C0125606
lif	B-C0125606
is	O
important	O
in	O
embryo	B-C0029976
implantation	I-C0029976
.	O
	
lif	B-C0125606
is	O
a	O
secreted	O
glycoprotein	B-C0017968
with	O
a	O
variety	O
of	O
biological	B-C3714634
functions	I-C3714634
including	O
stimulation	B-C1948023
of	O
cell	B-C0596290
proliferation	I-C0596290
,	O
differentiation	B-C0007589
and	O
survival	B-C0007620
that	O
are	O
all	O
essential	B-C0205224
for	O
blastocyete	B-C0005705
development	B-C1527148
and	O
implantation	B-C0029976
.	O
	
the	O
lif	B-C0125607
receptor	I-C0125607
activates	B-C1879547
several	O
signaling	B-C0037080
pathways	I-C0037080
in	O
diverse	B-C0449475
cell	I-C0449475
types	I-C0449475
,	O
including	O
jak/stat	B-C2984327
,	O
mapk	B-C0752312
and	O
pi3-kinase	B-C0044602
pathways	B-C0037080
in	O
the	O
endometrium	B-C0014180
of	O
fertile	B-C0015895
woman	B-C0043210
.	O
	
it	O
has	O
been	O
suggested	O
that	O
the	O
initial	O
lower	O
expression	B-C1171362
of	O
lif	B-C0125606
in	O
proliferative	B-C0334094
phase	B-C0205390
may	O
be	O
one	O
of	O
the	O
causes	O
for	O
multiple	O
failure	B-C0231174
of	O
implantation	B-C0021107
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	O
the	O
association	B-C0439849
between	O
maternal	B-C1858460
genotype	B-C0017431
of	O
snp	B-C0752046
3951c/t	I-C0752046
lif	B-C0125606
and	O
in	B-C0015915
vitro	I-C0015915
fertilization	I-C0015915
and	O
embryo	B-C0013938
transfer	I-C0013938
ivf	B-C0015915
-	O
et	B-C0013938
outcome	B-C0085415
in	O
infertile	B-C0021359
women	B-C0043210
.	O
	
this	O
case-control	B-C0007328
study	I-C0007328
was	O
comprised	O
of	O
infertile	B-C0021359
patients	B-C0030705
n=70	O
and	O
women	B-C0043210
having	O
one	O
healthy	B-C0686744
child	I-C0686744
as	O
controls	B-C0009932
n=73	O
.	O
	
genotyping	B-C1285573
for	O
snp-3951c/t	B-C0752046
was	O
performed	O
by	O
pcr/rflp	B-C3714764
.	O
	
allele	B-C0002085
and	O
genotype	B-C0017431
distribution	B-C1704711
did	O
not	O
differ	O
significantly	O
between	O
patients	B-C0030705
and	O
controls	B-C0009932
p>0	O
.	O
	
the	O
lif	B-C0125606
genotype	B-C0017431
frequencies	B-C0017270
amongst	O
the	O
70	O
cases	B-C0868928
were	O
c/c	B-C0004793
=40%	O
,	O
c/t	B-C0004793
=52	O
and	O
t/t	B-C0004793
=7	O
the	O
c	O
and	O
t	O
allele	B-C0002085
frequencies	B-C0017270
were	O
66%	O
and	O
34%	O
,	O
respectively	O
.	O
	
the	O
lif	B-C0125606
genotype	B-C0017431
frequencies	B-C0017270
amongst	O
the	O
73	O
controls	B-C0009932
were	O
c/c	B-C0004793
=45	O
,	O
c/t	B-C0004793
=50	O
and	O
t/t	B-C0004793
=4	O
the	O
c	O
and	O
t	O
allele	B-C0002085
frequencies	B-C0017270
were	O
70%	O
and	O
30%	O
,	O
respectively	O
.	O
	
in	O
conclusion	O
,	O
the	O
results	B-C1274040
of	O
this	O
study	O
indicate	O
that	O
snp	B-C0752046
3951c/t	I-C0752046
of	O
lif	B-C0125606
may	O
not	O
be	O
associated	B-C0332281
with	I-C0332281
ivf	B-C0015915
-	O
et	B-C0013938
outcome	B-C0085415
in	O
this	O
population	B-C1257890
.	O
	
although	O
more	O
studies	B-C2603343
should	O
be	O
considered	O
with	O
larger	O
number	O
of	O
patients	B-C0030705
and	O
control	B-C0009932
subjects	I-C0009932
to	O
confirm	B-C1456348
our	O
anti	B-C0243095
angiogenic	I-C0243095
effect	I-C0243095
of	O
chebulagic	B-C0653267
acid	I-C0653267
involves	O
inhibition	B-C3463820
of	O
vegfr2	B-C3549205
and	O
gsk3β	B-C0037080
dependent	I-C0037080
signaling	I-C0037080
pathways	I-C0037080
inhibition	B-C3463820
of	O
angiogenesis	B-C0302600
is	O
a	O
useful	O
strategy	B-C0679716
to	O
prevent	B-C2700409
cancer	B-C1516170
growth	I-C1516170
,	O
which	O
targets	B-C1521840
new	O
vessels	B-C0005847
that	O
grow	O
to	O
nourish	O
actively	O
proliferating	B-C1514485
tumor	B-C0597032
cells	I-C0597032
.	O
	
endothelial	B-C0225336
cells	I-C0225336
can	O
use	O
a	O
number	O
of	O
different	O
pathways	B-C0037080
to	O
cause	O
angiogenesis	B-C0302600
and	O
each	O
step	O
in	O
these	O
pathways	B-C0037080
can	O
be	O
targeted	B-C1521840
.	O
	
the	O
use	O
of	O
multi	B-C1254351
targeted	I-C1254351
drugs	I-C1254351
is	O
gaining	O
much	O
importance	O
in	O
this	O
scenario	O
.	O
	
our	O
previous	O
results	O
have	O
shown	O
the	O
anti	B-C0243095
angiogenic	I-C0243095
effect	I-C0243095
of	O
chebulagic	B-C0653267
acid	I-C0653267
-	O
a	O
benzopyran	B-C0005078
tannin	B-C1456509
present	O
in	O
the	O
fruits	B-C0016767
of	O
terminalia	B-C1193061
chebula	I-C1193061
.	O
	
the	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
molecular	B-C3537153
mechanism	I-C3537153
of	O
the	O
anti	B-C0243095
angiogenic	I-C0243095
effect	I-C0243095
of	O
chebulagic	B-C0653267
acid	I-C0653267
.	O
	
results	O
of	O
our	O
investigations	O
using	O
molecular	B-C3494274
docking	I-C3494274
studies	I-C3494274
and	O
huvecs	B-C3179121
in	O
culture	B-C0007585
suggested	O
that	O
chebulagic	B-C0653267
acid	I-C0653267
inhibited	B-C3463820
gsk-3β	B-C0244988
dependent	B-C3244310
β-catenin	B-C0105770
phosphorylation	B-C1158886
,	O
an	O
important	O
mediator	O
of	O
ve-cadherin	B-C0300423
/	O
β-catenin	B-C0105770
signaling	B-C0037080
and	O
vegfr2	B-C3849882
phosphorylation	B-C1158886
which	O
is	O
an	O
important	O
step	O
involved	O
in	O
vegf	B-C3271788
signaling	I-C3271788
.	O
	
chebulagic	B-C0653267
acid	I-C0653267
inhibits	B-C3463820
angiogenesis	B-C0302600
by	O
blocking	B-C0332206
both	O
vegf	B-C1256770
/	O
vegfr2	B-C3849882
and	O
cell-cell	B-C0037080
contact	I-C0037080
dependent	I-C0037080
downstream	I-C0037080
signaling	I-C0037080
pathway	I-C0037080
.	O
	
identification	O
of	O
protective	O
b-cell	B-C0282581
epitopes	I-C0282581
within	O
the	O
novel	O
malaria	B-C0206255
vaccine	I-C0206255
candidate	O
p	B-C3849939
.	O
	
falciparum	I-C3849939
schizont	I-C3849939
egress	I-C3849939
antigen-1	I-C3849939
naturally	B-C0205296
-acquired	O
antibodies	B-C0003241
to	O
pfsea-1a	B-C3849939
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	B-C0024530
in	O
children	B-C0008059
.	O
	
vaccination	B-C0042196
of	O
mice	B-C0025929
with	O
pbsea-1a	B-C4040232
decreases	O
parasitemia	B-C0242723
and	O
prolongs	O
survival	O
following	O
plasmodium	B-C0032149
berghei	I-C0032149
anka	I-C0032149
challenge	O
.	O
	
to	O
enhance	O
the	O
immunogenicity	B-C4277607
of	O
pfsea-1a	B-C3849939
,	O
we	O
identified	O
five	O
linear	O
,	O
b-cell	B-C0282581
epitopes	I-C0282581
using	O
peptide	B-C0030956
microarrays	B-C1136348
probed	O
with	O
anti-sera	B-C0020960
from	O
rpfsea-1a	B-C3849939
-	O
vaccinated	B-C1519885
non-human	O
primates	B-C0033147
.	O
	
we	O
evaluated	B-C0220825
the	O
relationship	O
between	O
epitope	B-C0003316
-specific	O
antibody	B-C0003241
levels	O
and	O
protection	O
from	O
parasitemia	B-C0242723
in	O
a	O
longitudinal	O
treatment	B-C0087111
-	O
reinfection	B-C0205339
cohort	B-C0599755
in	O
western	B-C0022558
kenya	I-C0022558
.	O
	
antibodies	B-C0003241
to	O
three	O
epitopes	B-C0003316
were	O
associated	O
with	O
16-17%	O
decreased	O
parasitemia	B-C0242723
over	O
an	O
18-	O
week	B-C0439230
high	O
transmission	B-C1521797
season	O
.	O
	
we	O
are	O
currently	O
designing	O
immunogens	B-C0042213
to	O
enhance	O
antibody	B-C0003261
responses	I-C0003261
to	O
these	O
three	O
estrogen	B-C0014939
deficiency	B-C0011155
accelerates	B-C0521110
lumbar	B-C0507372
facet	I-C0507372
joints	I-C0507372
arthritis	B-C0003864
dramatic	O
increase	B-C0442805
in	O
the	O
prevalence	B-C0220900
of	O
lumbar	B-C0507372
facet	I-C0507372
joint	I-C0507372
lfj	B-C0507372
arthritis	B-C0003864
in	O
women	B-C0043210
around	O
the	O
age	B-C0001779
of	O
menopause	B-C0025320
indicates	O
a	O
protective	B-C0086939
role	I-C0086939
for	O
estrogen	B-C0014939
in	O
lfj	B-C0507372
arthritis	B-C0003864
.	O
	
to	O
date	O
,	O
there	O
is	O
no	B-C0332125
evidence	I-C0332125
for	O
this	O
indication	B-C3146298
and	O
the	O
mechanism	B-C0441712
of	O
such	O
an	O
effect	B-C1280500
remains	O
poorly	O
understood	O
.	O
	
in	O
this	O
study	B-C2603343
,	O
ovariectomized	B-C0025929
ovx	I-C0025929
mice	I-C0025929
were	O
used	O
to	O
mimic	O
the	O
estrogen	B-C0014939
-	O
deficient	B-C0011155
status	B-C0449438
of	O
post-menopausal	B-C0206159
women	B-C0043210
.	O
	
micro-ct	B-C2350281
and	O
immunohistochemistry	B-C0021044
was	O
employed	O
to	O
assess	B-C0184514
the	O
morphological	B-C0543482
and	O
molecular	B-C1521991
changes	B-C0392747
in	O
ovariectomy	B-C0029936
-	O
induced	B-C0205263
lfj	B-C0507372
arthritis	B-C0003864
.	O
	
the	O
results	B-C1274040
show	O
that	O
the	O
lfj	B-C0507372
subchondral	B-C0005938
bone	I-C0005938
mass	I-C0005938
was	O
significantly	O
decreased	B-C0205216
in	O
ovx	B-C0025929
mice	I-C0025929
,	O
with	O
increased	B-C0205217
cavities	B-C0229984
on	O
the	O
interface	B-C1254362
of	O
the	O
subchondral	B-C0262950
bone	I-C0262950
.	O
	
severe	B-C0205082
cartilage	B-C0007301
degradation	B-C0243125
was	O
observed	O
in	O
ovariectomy	B-C0029936
-	O
induced	B-C0205263
lfj	B-C0507372
arthritis	B-C0003864
.	O
	
increased	B-C0205217
blood	B-C0005847
vessels	I-C0005847
and	O
innervations	B-C1619351
were	O
also	O
found	O
in	O
degenerated	B-C0011164
lfj	B-C0507372
,	O
particularly	O
in	O
the	O
subchondral	B-C0262950
bone	I-C0262950
area	B-C0005898
.	O
	
17β-estradiol	B-C0014912
treatment	B-C0087111
efficiently	O
suppressed	B-C1260953
lfj	B-C0507372
subchondral	B-C0231544
bone	I-C0231544
turnover	I-C0231544
,	O
markedly	O
inhibited	B-C0311403
cartilage	B-C0007301
degradation	B-C0243125
,	O
and	O
increased	B-C0205217
blood	B-C0005847
vessel	I-C0005847
and	O
nerve	B-C0027747
ending	I-C0027747
growth	B-C0018270
in	O
degenerated	B-C0011164
lfj	B-C0507372
in	O
ovx	B-C0025929
mice	I-C0025929
.	O
	
our	O
study	B-C2603343
reveals	O
that	O
estrogen	B-C0014939
is	O
a	O
key	O
factor	B-C1521761
in	O
regulating	B-C0518894
lfj	I-C0518894
metabolism	I-C0518894
.	O
	
severe	B-C0205082
lfj	B-C0507372
degeneration	B-C0011164
occurs	O
when	O
estrogen	B-C0014939
is	O
absent	B-C0332197
in	B-C1515655
vivo	I-C1515655
.	O
	
collapsed	B-C0392748
subchondral	B-C0262950
bone	I-C0262950
may	O
be	O
the	O
initiation	B-C1704686
of	O
this	O
process	B-C1522240
,	O
and	O
estrogen	B-C0014935
replacement	I-C0014935
therapy	I-C0014935
can	O
effectively	O
prevent	O
degeneration	B-C0011164
of	O
lfj	B-C0507372
under	O
estrogen	B-C0014939
-	O
deficient	B-C0011155
conditions	B-C0348080
.	O
	
dexmedetomidine	B-C0113293
effect	B-C1280500
on	O
emergence	B-C0920253
agitation	I-C0920253
and	O
delirium	B-C0011206
in	O
children	B-C0008059
undergoing	O
laparoscopic	B-C2111384
hernia	I-C2111384
repair	I-C2111384
a	O
preliminary	B-C0439611
study	B-C2603343
objective	O
to	O
evaluate	O
the	O
safety	B-C0678800
and	O
efficacy	B-C1280519
of	O
dexmedetomidine	B-C0113293
dex	B-C0113293
to	O
prevent	O
emergence	B-C0920253
agitation	I-C0920253
ea	B-C0920253
and	O
delirium	B-C0011206
ed	B-C0011206
in	O
children	B-C0008059
undergoing	O
laparoscopic	B-C2111384
hernia	I-C2111384
repair	I-C2111384
under	O
general	B-C0002915
anesthesia	I-C0002915
.	O
	
methods	O
100	O
children	B-C0008059
1-5	O
years	B-C0439234
,	O
10-25	O
kg	O
were	O
randomized	B-C0034656
into	O
four	O
groups	B-C0441833
controls	B-C0009932
saline	B-C0036082
and	O
intravenous	B-C0348016
dex	B-C0113293
at	O
0.25	O
,	O
0.5	O
,	O
and	O
1.0	O
µg/kg	O
d1	B-C0178602
,	O
d2	B-C0178602
,	O
d3	B-C0178602
,	O
respectively	O
.	O
	
dex	B-C0113293
/	O
saline	B-C0036082
infusion	B-C0574032
was	O
started	O
following	O
anesthesia	B-C4049933
.	O
	
ea	B-C0920253
and	O
ed	B-C0011206
were	O
evaluated	O
on	O
a	O
5-point	B-C0282574
scale	I-C0282574
.	O
	
results	O
for	O
the	O
c	B-C0009932
,	O
d1	B-C0178602
,	O
d2	B-C0178602
,	O
and	O
d3	B-C0178602
groups	B-C0441833
,	O
respectively	O
,	O
ea	B-C0920253
frequencies	B-C0439603
were	O
45.8	O
,	O
30.4	O
,	O
12%	O
,	O
4%	O
ed	B-C0011206
frequencies	B-C0439603
29.1	O
,	O
13%	O
,	O
4%	O
,	O
4%	O
chipps	B-C1504479
scores	B-C0449820
8	O
,	O
6	O
,	O
3	O
,	O
3	O
sevoflurane	B-C0074414
doses	B-C0178602
from	O
13.2	O
3.4	O
controls	B-C0009932
to	O
9.4	O
3.5	O
ml	O
d3	B-C0178602
.	O
	
intervals	B-C1272706
until	O
mask	B-C0024861
removal	B-C1883720
/	O
spontaneous	B-C1882151
eye	I-C1882151
opening	I-C1882151
were	O
significantly	O
longer	B-C0205166
for	O
d2	B-C0178602
and	O
d3	B-C0178602
than	O
controls	B-C0009932
.	O
	
pacu	B-C0034871
stay	B-C3489408
was	O
longer	B-C0205166
for	O
d3	B-C0178602
.	O
	
conclusions	O
there	O
was	O
significantly	O
less	O
postoperative	B-C0032790
ea	B-C0920253
and	O
pain	B-C0030201
,	O
with	O
less	O
sevoflurane	B-C0074414
required	O
,	O
using	O
farnesylthiosalicylic	B-C0297002
acid	I-C0297002
-loaded	O
lipid-polyethylene	B-C1254351
glycol-polymer	I-C1254351
hybrid	I-C1254351
nanoparticles	I-C1254351
for	O
treatment	B-C0087111
of	O
glioblastoma	B-C0017636
we	O
aimed	O
to	O
develop	O
lipid-polyethylene	B-C1254351
glycol	I-C1254351
peg	I-C1254351
hybrid	I-C1254351
nanoparticles	I-C1254351
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	B-C0475358
tissue	I-C0475358
with	O
active	B-C1372955
ingredient	I-C1372955
,	O
a	O
new	O
generation	B-C0079411
antineoplastic	B-C0003392
drug	I-C0003392
,	O
farnesylthiosalicylic	B-C0297002
acid	I-C0297002
fta	B-C0297002
for	O
treatment	B-C0087111
of	O
glioblastoma	B-C0017636
.	O
	
farnesylthiosalicylic	B-C0297002
acid	I-C0297002
-loaded	O
poly	B-C1254351
acid	I-C1254351
distearoyl-glycerol-3-phospho-ethanolamine-n	I-C1254351
methoxy	I-C1254351
peg	I-C1254351
ammonium	I-C1254351
salt	I-C1254351
plga-dspe-peg	B-C1254351
with	O
or	O
without	O
1	B-C1254351
dotap	I-C1254351
hybrid	I-C1254351
nanoparticles	I-C1254351
has	O
been	O
prepared	B-C4082130
and	O
evaluated	B-C0220825
for	O
in-vitro	B-C0681828
characterization	I-C0681828
.	O
	
cytotoxicity	B-C0596402
of	O
fta-loaded	B-C0297002
nanoparticles	I-C0297002
along	O
with	O
its	O
efficacy	B-C0013682
on	O
rat	B-C0007634
glioma-2	I-C0007634
rg2	I-C0007634
cells	I-C0007634
was	O
also	O
evaluated	B-C0220825
both	O
in	B-C0681828
vitro	I-C0681828
in	O
comparison	O
with	O
non-malignant	B-C0007600
cell	I-C0007600
line	I-C0007600
,	O
l929	I-C0007600
and	O
in	B-C0681829
vivo	I-C0681829
.	O
	
scanning	B-C0523160
electron	I-C0523160
microscopy	I-C0523160
studies	I-C0523160
showed	O
that	O
all	O
formulations	B-C1705957
prepared	I-C1705957
had	O
smooth	B-C1182795
surface	I-C1182795
and	O
spherical	B-C0332501
in	I-C0332501
shape	I-C0332501
.	O
	
fta	B-C0297002
and	O
fta-loaded	B-C0297002
nanoparticles	I-C0297002
have	O
cytotoxic	B-C0596402
activity	I-C0596402
against	O
rg2	B-C0007600
glioma	I-C0007600
cell	I-C0007600
lines	I-C0007600
in	O
cell	B-C0681854
culture	I-C0681854
studies	I-C0681854
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
dotap	B-C1254351
.	O
	
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
and	O
histopathologic	B-C0677043
evaluation	B-C0220825
on	O
rg2	B-C0431085
tumour	I-C0431085
cells	I-C0431085
in	O
rat	B-C0012644
glioma	I-C0012644
model	I-C0012644
49	O
female	O
wistar	B-C0034716
rats	I-C0034716
,	O
250-300	O
g	O
comparing	O
intravenous	B-C0021494
and	O
intratumoral	B-C1517565
injections	I-C1517565
of	O
the	O
drug	B-C1254351
have	O
been	O
performed	O
and	O
fta-loaded	B-C0297002
nanoparticles	I-C0297002
reduced	O
tumour	B-C0475440
size	I-C0475440
significantly	O
in	O
in-vivo	B-C0681829
studies	I-C0681829
,	O
with	O
higher	O
efficiency	B-C0013682
of	O
intratumoral	B-C1517565
administration	I-C1517565
than	O
intravenous	B-C1522726
route	I-C1522726
.	O
	
farnesylthiosalicylic	B-C0297002
acid	I-C0297002
-loaded	O
plga-dspe-peg-dotap	B-C1254351
hybrid	I-C1254351
nanoparticles	I-C1254351
are	O
proven	O
to	O
be	O
effective	B-C1704419
against	O
glioblastoma	B-C0017636
in	O
both	O
in-vitro	B-C0681828
and	O
in-vivo	B-C0681829
experiments	I-C0681829
.	O
	
map	B-C0582587
learning	I-C0582587
and	O
working	B-C0025265
memory	I-C0025265
multimodal	O
learning	B-C0237896
strategies	I-C0237896
the	O
current	O
research	B-C0035168
investigated	O
whether	O
learning	B-C0582587
spatial	I-C0582587
information	B-C1533716
from	O
a	O
map	B-C0024779
involves	O
different	B-C1275506
modalities	I-C1275506
,	O
which	O
are	O
managed	O
by	O
discrete	O
components	O
in	O
working	B-C0025265
memory	I-C0025265
.	O
	
in	O
four	O
experiments	O
,	O
participants	B-C0679646
studied	O
a	O
map	O
either	O
while	O
performing	O
a	O
simultaneous	B-C0521115
interference	B-C0025361
task	I-C0025361
high	O
cognitive	B-C0870301
load	I-C0870301
or	O
without	B-C0025361
interference	I-C0025361
low	O
cognitive	B-C0870301
load	I-C0870301
.	O
	
the	O
modality	B-C0695347
of	O
interference	B-C0679066
varied	O
between	O
experiments	O
.	O
	
experiment	O
1	O
used	O
a	O
tapping	B-C0025361
task	I-C0025361
visuospatial	B-C0814069
,	O
experiment	O
2	O
a	O
backwards	B-C0025361
counting	I-C0025361
task	I-C0025361
verbal	B-C0439824
,	O
experiment	O
3	O
an	O
articulatory	B-C0003910
suppression	B-C0201782
task	I-C0201782
verbal	B-C0439824
and	O
experiment	O
4	O
an	O
n-back	B-C0025361
task	I-C0025361
central	B-C0025361
executive	I-C0025361
.	O
	
spatial	B-C0243095
recall	I-C0243095
was	O
assessed	B-C1516048
in	O
two	O
tests	O
,	O
directional	B-C0022423
judgements	I-C0022423
and	O
map	B-C0699866
drawing	I-C0699866
.	O
	
cognitive	B-C0870301
load	I-C0870301
was	O
found	O
to	O
affect	O
spatial	B-C0243095
recall	I-C0243095
detrimentally	O
regardless	B-C3641650
of	O
interference	B-C0679066
modality	B-C0695347
.	O
	
the	O
findings	O
suggest	O
that	O
when	O
learning	B-C0582587
maps	I-C0582587
people	O
use	O
a	O
multimodal	O
learning	B-C0237896
strategy	I-C0237896
,	O
utilising	O
resources	B-C0035201
from	O
all	O
components	O
of	O
working	B-C0025265
memory	I-C0025265
.	O
	
4-anilino-2-pyridylquinazolines	B-C0034407
and	O
-	O
pyrimidines	B-C0034289
as	O
highly	O
potent	B-C0442821
and	O
nontoxic	B-C1518413
inhibitors	B-C0243077
of	O
breast	B-C0761993
cancer	I-C0761993
resistance	I-C0761993
protein	I-C0761993
abcg2	B-C0761993
multidrug	B-C0242640
resistance	I-C0242640
mdr	B-C0242640
mediated	O
by	O
atp-binding	B-C0242738
cassette	I-C0242738
abc	I-C0242738
transport	I-C0242738
proteins	I-C0242738
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic	B-C3665472
treatment	I-C3665472
of	O
cancer	B-C0027651
and	O
might	O
be	O
overcome	B-C2983310
by	O
inhibition	B-C3463820
of	O
the	O
transporter	B-C0596902
.	O
	
because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	B-C0441712
involved	O
in	O
the	O
transport	B-C1519628
process	I-C1519628
,	O
in	O
particular	O
for	O
breast	B-C0761993
cancer	I-C0761993
resistance	I-C0761993
protein	I-C0761993
bcrp	B-C0761993
/	O
abcg2	B-C0761993
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	B-C0243077
of	O
abcg2	B-C0761993
.	O
	
in	O
this	O
study	O
,	O
we	O
investigated	B-C1292732
a	O
systematic	O
series	O
of	O
4-substituted-2-pyridylquinazolines	B-C0034407
in	O
terms	O
of	O
their	O
inhibitory	B-C3463820
potency	B-C3245505
as	O
well	O
as	O
selectivity	B-C0037791
toward	O
abcg2	B-C0761993
.	O
	
for	O
comparison	O
,	O
the	O
quinazoline	B-C0034407
scaffold	I-C0034407
was	O
reduced	O
to	O
the	O
significantly	O
smaller	O
4-methylpyrimidine	B-C0034289
basic	O
structure	O
.	O
	
furthermore	O
,	O
the	O
cytotoxicity	B-C0596402
and	O
the	O
ability	O
to	O
reverse	B-C1555029
mdr	B-C0242640
was	O
tested	O
with	O
the	O
chemotherapeutic	B-C0729502
agents	I-C0729502
sn-38	B-C0142710
and	O
mitoxantrone	B-C0026259
mx	B-C0026259
.	O
	
interaction	B-C1704675
of	O
the	O
compounds	B-C1706082
with	O
abcg2	B-C0761993
was	O
investigated	B-C1292732
by	O
a	O
colorimetric	B-C1531834
atpase	B-C0001473
assay	B-C2717977
.	O
	
enzyme	B-C1516893
kinetic	I-C1516893
studies	I-C1516893
were	O
carried	O
out	O
with	O
hoechst	B-C0062907
33342	I-C0062907
as	O
fluorescent	B-C0016320
dye	I-C0016320
and	O
substrate	B-C3891814
of	O
abcg2	B-C0761993
to	O
elucidate	O
the	O
compounds	B-C1706082
binding	B-C1145667
modes	I-C1145667
.	O
	
the	O
value	O
of	O
biosamples	B-C1706958
in	O
smoking	B-C0085134
cessation	I-C0085134
trials	B-C0008976
a	O
review	O
of	O
genetic	B-C0730319
,	O
metabolomic	B-C1328813
,	O
and	O
epigenetic	B-C1516924
findings	B-C0243095
evidence	O
is	O
emerging	O
that	O
certain	O
genotypes	B-C0017431
and	O
biomarkers	B-C0005516
are	O
associated	O
with	O
smoking	B-C0085134
cessation	I-C0085134
success	O
and	O
efficacy	O
of	O
smoking	B-C1095963
cessation	I-C1095963
treatments	I-C1095963
.	O
	
we	O
review	O
key	O
findings	O
that	O
open	O
potential	O
avenues	O
for	O
personalizing	O
smoking	B-C1095963
cessation	I-C1095963
treatment	I-C1095963
according	O
to	O
an	O
individual's	B-C0237401
genetic	B-C2986505
or	O
metabolic	B-C3853758
profile	I-C3853758
.	O
	
these	O
results	O
provide	O
important	O
incentive	B-C0021147
for	O
smoking	B-C0085134
cessation	I-C0085134
researchers	B-C0687734
to	O
collect	O
biosamples	B-C1706958
and	O
perform	O
genotyping	B-C1285573
in	O
research	B-C0681814
studies	I-C0681814
and	O
clinical	B-C0008976
trials	I-C0008976
.	O
	
acr	B-C1515941
appropriateness	B-C0243161
criteria	I-C0243161
radiologic	B-C0205483
management	B-C0376636
of	O
mesenteric	B-C1412000
ischemia	I-C1412000
mesenteric	B-C1412000
vascular	I-C1412000
insufficiency	I-C1412000
is	O
a	O
serious	O
medical	B-C3843040
condition	I-C3843040
that	O
may	O
lead	O
to	O
bowel	B-C0241950
infarction	I-C0241950
,	O
morbidity	B-C0026538
,	O
and	O
mortality	B-C0178686
that	O
may	O
approach	B-C0449445
50%	O
.	O
	
recommended	O
therapy	B-C0087111
for	O
acute	B-C0001363
mesenteric	I-C0001363
ischemia	I-C0001363
includes	O
aspiration	B-C0349707
embolectomy	B-C0162575
,	O
transcatheter	B-C0203005
thrombolysis	B-C0040044
,	O
and	O
angioplasty	B-C0162577
with	O
or	O
without	O
stenting	B-C2348535
for	O
the	O
treatment	B-C0087111
of	O
underlying	O
arterial	B-C0238397
stenosis	I-C0238397
.	O
	
nonocclusive	B-C3852986
mesenteric	I-C3852986
ischemia	I-C3852986
may	O
respond	O
to	O
transarterial	B-C0021439
infusion	I-C0021439
of	O
vasodilators	B-C0042402
such	O
as	O
nitroglycerin	B-C0017887
,	O
papaverine	B-C0030350
,	O
glucagon	B-C0017687
,	O
and	O
prostaglandin	B-C0002335
e1	I-C0002335
.	O
	
recommended	O
therapy	B-C0087111
for	O
chronic	B-C0311262
mesenteric	I-C0311262
ischemia	I-C0311262
includes	O
angioplasty	B-C0162577
with	O
or	O
without	O
stent	B-C0522776
placement	I-C0522776
and	O
,	O
if	O
an	O
endovascular	B-C1997114
approach	I-C1997114
is	O
not	O
possible	O
,	O
surgical	B-C1536078
bypass	I-C1536078
or	O
endarterectomy	B-C0014098
.	O
	
the	O
diagnosis	B-C0011900
of	O
median	B-C1861783
arcuate	I-C1861783
ligament	I-C1861783
syndrome	I-C1861783
is	O
controversial	O
,	O
but	O
surgical	B-C0543467
release	O
may	O
be	O
appropriate	O
depending	O
on	O
the	O
clinical	B-C0018759
situation	I-C0018759
.	O
	
venous	B-C0348013
mesenteric	B-C1412000
ischemia	I-C1412000
may	O
respond	O
to	O
systemic	B-C0205373
anticoagulation	B-C0003281
alone	O
.	O
	
transhepatic	B-C0589464
or	O
transjugular	B-C1254362
superior	B-C0226742
mesenteric	I-C0226742
vein	I-C0226742
catheterization	B-C2025545
and	I-C2025545
thrombolytic	I-C2025545
infusion	I-C2025545
can	O
be	O
offered	O
depending	O
on	O
the	O
severity	O
of	O
symptoms	B-C1457887
,	O
condition	B-C0683521
of	I-C0683521
the	I-C0683521
patient	I-C0683521
,	O
and	O
response	B-C0871261
to	O
systemic	B-C0205373
anticoagulation	B-C0003281
.	O
	
adjunct	B-C1719882
transjugular	B-C0339897
intrahepatic	I-C0339897
portosystemic	I-C0339897
shunt	I-C0339897
creation	I-C0339897
can	O
be	O
considered	O
for	O
outflow	O
improvement	B-C2986411
.	O
	
the	O
american	B-C1515941
college	I-C1515941
of	I-C1515941
radiology	I-C1515941
appropriateness	B-C0243161
criteria	I-C0243161
are	O
evidence-based	B-C1510541
guidelines	B-C0162791
for	O
specific	O
clinical	B-C0683521
conditions	I-C0683521
that	O
are	O
reviewed	B-C1709940
annually	B-C0332181
by	O
a	O
multidisciplinary	B-C1319406
expert	I-C1319406
panel	I-C1319406
.	O
	
the	O
guideline	B-C0162791
development	B-C1527148
and	O
revision	B-C0439617
include	O
an	O
extensive	B-C0936012
analysis	I-C0936012
of	O
current	O
medical	B-C0025120
literature	I-C0025120
from	O
peer-reviewed	B-C2985503
journals	I-C2985503
and	O
the	O
application	O
of	O
well-established	O
methodologies	B-C0086912
rand	B-C3826892
/	O
ucla	B-C4285296
appropriateness	B-C0814634
method	O
and	O
grading	B-C0282574
of	I-C0282574
recommendations	I-C0282574
assessment	I-C0282574
,	O
development	I-C0282574
,	O
and	I-C0282574
evaluation	I-C0282574
or	O
grade	B-C0282574
to	O
rate	O
the	O
appropriateness	B-C0814634
of	O
imaging	B-C0079595
and	O
treatment	B-C0087111
procedures	I-C0087111
for	O
specific	O
clinical	B-C0205210
scenarios	B-C0683579
.	O
	
in	O
those	O
instances	B-C1550608
where	O
evidence	B-C3887511
is	O
lacking	B-C0332268
or	O
equivocal	B-C0332241
,	O
expert	B-C0600219
opinion	I-C0600219
may	O
supplement	B-C2348609
the	O
available	O
evidence	B-C3887511
to	O
recommend	O
imaging	B-C0079595
or	O
blur	B-C1511231
perception	B-C0030971
throughout	O
the	O
visual	B-C0042826
field	I-C0042826
in	O
myopia	B-C0027092
and	O
emmetropia	B-C0234622
we	O
evaluated	B-C0220825
the	O
ability	B-C0085732
of	O
emmetropic	B-C0234622
and	O
myopic	B-C0027092
observers	B-C0870992
to	O
detect	B-C0442726
and	O
discriminate	B-C0205235
blur	B-C1511231
across	O
the	O
retina	B-C0035298
under	O
monocular	B-C0042797
or	O
binocular	B-C0042794
viewing	I-C0042794
conditions	B-C0348080
.	O
	
we	O
recruited	B-C2949735
39	O
young	B-C0332239
23-30	O
years	O
healthy	B-C0686750
adults	I-C0686750
n	O
=	O
19	O
myopes	B-C0027092
with	O
best-corrected	B-C4072794
visual	B-C0042812
acuity	I-C0042812
0.0	O
logmar	B-C0007963
20/20	I-C0007963
or	O
better	B-C0332272
in	O
each	O
eye	B-C0015392
and	O
no	B-C0243095
binocular	I-C0243095
or	O
accommodative	B-C0042790
dysfunction	I-C0042790
.	O
	
monocular	B-C0042797
and	O
binocular	B-C0042794
blur	B-C1511231
discrimination	B-C0205235
thresholds	B-C0449864
were	O
measured	B-C0444706
as	O
a	O
function	B-C1705273
of	O
pedestal	B-C1511231
blur	I-C1511231
using	O
naturalistic	B-C0205296
stimuli	B-C0234402
with	O
an	O
adaptive	B-C0430872
4afc	I-C0430872
procedure	I-C0430872
.	O
	
stimuli	B-C0234402
were	O
presented	B-C0449450
in	O
a	O
46	O
diameter	B-C1301886
window	O
at	O
40	O
cm	O
.	O
	
gaussian	B-C1511231
blur	I-C1511231
pedestals	I-C1511231
were	O
confined	B-C0443288
to	O
an	O
annulus	B-C3273359
at	O
either	O
0	O
,	O
4	O
,	O
8	O
,	O
or	O
12	O
eccentricity	B-C0871265
,	O
with	O
a	O
blur	B-C1511231
increment	B-C1705117
applied	B-C4048755
to	O
only	O
one	B-C1631280
quadrant	I-C1631280
of	O
the	O
image	B-C1704922
.	O
	
the	O
adaptive	B-C0430872
procedure	I-C0430872
efficiently	B-C0442799
estimated	B-C0750572
a	O
dipper	B-C0243095
shaped	I-C0243095
blur	B-C1511231
discrimination	B-C0205235
threshold	B-C0449864
function	B-C1705273
with	O
two	B-C0205448
parameters	B-C0549193
intrinsic	B-C0205102
blur	B-C1511231
and	O
blur	B-C1511231
sensitivity	B-C0332324
.	O
	
the	O
amount	B-C1265611
of	O
intrinsic	B-C0205102
blur	B-C1511231
increased	B-C0205217
for	O
retinal	B-C0871265
eccentricities	I-C0871265
beyond	O
4	O
p	O
<	O
0.001	O
and	O
was	O
lower	B-C2003888
in	O
binocular	B-C0042794
than	O
monocular	B-C0042797
conditions	B-C0348080
p	O
<	O
0.001	O
,	O
but	O
was	O
similar	B-C2348205
across	O
refractive	B-C0870812
groups	B-C0441833
p	O
=	O
0.47	O
.	O
	
blur	B-C1511231
sensitivity	B-C0332324
decreased	B-C0205216
with	O
retinal	B-C0871265
eccentricity	I-C0871265
p	O
<	O
0.001	O
and	O
was	O
highest	B-C1522410
for	O
binocular	B-C0042794
viewing	O
,	O
but	O
only	O
for	O
central	B-C0678899
vision	I-C0678899
p	O
<	O
0.05	O
.	O
	
myopes	B-C0027092
showed	O
worse	B-C1457868
blur	B-C1511231
sensitivity	B-C0332324
than	O
emmetropes	B-C0234622
monocularly	B-C0042797
p	O
<	O
0.05	O
but	O
not	O
binocularly	B-C0042794
p	O
=	O
0.66	O
.	O
	
as	O
expected	O
,	O
blur	B-C1511231
perception	B-C0030971
worsens	B-C1457868
in	O
the	O
visual	B-C0234628
periphery	I-C0234628
and	O
binocular	B-C0042794
summation	B-C0234108
is	O
most	O
evident	B-C0750489
in	O
central	B-C0678899
vision	I-C0678899
.	O
	
furthermore	O
,	O
myopes	B-C0027092
exhibit	O
a	O
monocular	B-C0042797
impairment	B-C0221099
in	O
blur	B-C1511231
sensitivity	B-C0332324
that	O
improves	B-C0184511
under	O
binocular	B-C0042794
conditions	B-C0348080
.	O
	
implications	B-C0679201
for	O
the	O
development	B-C1527148
of	O
myopia	B-C0027092
risk	B-C0035648
factors	I-C0035648
of	O
neurological	B-C1536136
deterioration	I-C1536136
in	O
patients	B-C0030705
with	O
cerebral	B-C0007785
infarction	I-C0007785
due	O
to	O
large-artery	B-C2711237
atherosclerosis	I-C2711237
in	O
some	O
patients	B-C0030705
with	O
acute	B-C0205178
ischemic	B-C0948008
stroke	I-C0948008
,	O
neurological	B-C1536136
deterioration	I-C1536136
nd	B-C1536136
is	O
observed	B-C1441672
,	O
and	O
it	O
is	O
difficult	B-C0332218
to	O
predict	B-C0681842
at	O
the	O
time	B-C3854259
of	I-C3854259
admission	I-C3854259
.	O
	
especially	O
in	O
some	O
patients	B-C0030705
with	O
large-artery	B-C2711237
atherosclerosis	I-C2711237
laa	B-C2711237
,	O
aggressive	B-C0580822
medical	B-C0237726
treatments	I-C0237726
and	O
surgical	B-C4035998
interventions	I-C4035998
might	O
be	O
helpful	B-C3898897
to	O
prevent	O
nd	B-C1536136
.	O
	
therefore	O
,	O
we	O
investigated	B-C1292732
factors	B-C0014501
associated	B-C0332281
with	I-C0332281
nd	B-C1536136
in	O
patients	B-C0030705
with	O
laa	B-C2711237
.	O
	
we	O
studied	B-C2603343
patients	B-C0030705
with	O
laa	B-C2711237
who	O
were	O
admitted	B-C0184666
to	I-C0184666
our	I-C0184666
hospital	I-C0184666
.	O
	
we	O
divided	B-C0332849
them	O
into	O
2	O
groups	B-C0441833
with	O
group	B-C0441833
1	O
and	O
without	O
deterioration	B-C0234985
group	B-C0441833
2	O
,	O
and	O
evaluated	B-C0220825
their	O
medical	B-C0025102
records	I-C0025102
,	O
risk	B-C0035648
factors	I-C0035648
,	O
and	O
radiological	B-C0929225
findings	B-C0243095
,	O
such	O
as	O
number	O
of	O
diffusion	B-C0012222
-	O
positive	B-C1514241
lesion	B-C0221198
and	O
degree	B-C4034225
of	I-C4034225
stenosis	I-C4034225
.	O
	
our	O
study	B-C2348561
population	I-C2348561
consisted	O
of	O
171	O
patients	B-C0030705
71	O
41.5	O
did	O
and	O
100	O
58.5	O
did	O
not	O
suffer	B-C0683278
deterioration	B-C0234985
.	O
	
by	O
univariate	B-C0683962
analysis	I-C0683962
,	O
blood	B-C0005823
pressure	I-C0005823
bp	B-C0005823
,	O
heart	B-C0018810
rate	I-C0018810
,	O
national	B-C4269147
institutes	I-C4269147
of	I-C4269147
health	I-C4269147
stroke	I-C4269147
scale	I-C4269147
nihss	I-C4269147
score	I-C4269147
,	O
number	O
of	O
diffusion	B-C0012222
-	O
positive	B-C1514241
lesion	B-C0221198
,	O
count	B-C0014772
of	I-C0014772
red	I-C0014772
blood	I-C0014772
cell	I-C0014772
,	O
high-density	B-C0023821
lipoprotein	I-C0023821
,	O
and	O
degree	B-C4034225
of	I-C4034225
stenosis	I-C4034225
differed	O
significantly	B-C0750502
between	O
the	O
2	O
groups	B-C0441833
.	O
	
by	O
multivariate	B-C0026777
analysis	I-C0026777
,	O
systolic	B-C0871470
bp	I-C0871470
170	O
mm	O
hg	O
,	O
odds	B-C0028873
ratio	I-C0028873
7.20	O
,	O
p	O
<	O
was	O
associated	B-C0332281
with	I-C0332281
nd	B-C1536136
.	O
	
furthermore	O
,	O
number	O
of	O
diffusion-weighted	B-C0598801
image	I-C0598801
dwi	B-C0598801
positive	B-C1514241
lesion	B-C0221198
8	O
,	O
degree	B-C4034225
of	I-C4034225
stenosis	I-C4034225
>80	O
,	O
and	O
nihss	B-C4269147
score	I-C4269147
4	O
were	O
also	O
independent	B-C0085862
factors	B-C0014501
associated	B-C0332281
with	I-C0332281
nd	B-C1536136
.	O
	
high	B-C0020538
bp	I-C0020538
,	O
severity	B-C0439793
of	O
neurological	B-C0521654
deficit	I-C0521654
at	O
the	O
time	B-C3854259
of	I-C3854259
admission	I-C3854259
,	O
and	O
radiological	B-C0929225
findings	B-C0243095
,	O
such	O
as	O
degree	B-C4034225
of	I-C4034225
stenosis	I-C4034225
and	O
number	O
of	O
dwi	B-C0598801
-	O
positive	B-C1514241
lesion	B-C0221198
,	O
are	O
independently	B-C0243095
associated	B-C0332281
with	I-C0332281
nd	B-C1536136
in	O
patients	B-C0030705
with	O
development	B-C1527148
and	O
validation	B-C1519941
of	O
an	O
easy-to-use	O
risk	B-C0086930
assessment	I-C0086930
tool	I-C0086930
for	O
cumulative	O
low	B-C0230102
back	I-C0230102
loading	B-C1318107
the	O
lifting	B-C0005479
fatigue	I-C0005479
failure	I-C0005479
tool	I-C0005479
lifft	B-C0005479
recent	O
evidence	O
suggests	O
that	O
musculoskeletal	B-C0026857
disorders	I-C0026857
msds	B-C0026857
may	O
be	O
the	O
result	O
of	O
a	O
fatigue	B-C0015672
failure	B-C0231174
process	I-C0231174
in	O
affected	B-C0392760
tissues	B-C0040300
.	O
	
this	O
paper	O
describes	O
a	O
new	O
low	B-C1318107
back	I-C1318107
exposure	I-C1318107
assessment	B-C0005479
tool	I-C0005479
the	O
lifting	B-C0005479
fatigue	I-C0005479
failure	I-C0005479
tool	I-C0005479
lifft	B-C0005479
,	O
which	O
estimates	O
a	O
""""	O
daily	B-C2348070
dose	I-C2348070
""""	O
of	O
cumulative	B-C1511559
loading	B-C1318107
on	O
the	O
low	B-C0230102
back	I-C0230102
using	O
fatigue	B-C0015672
failure	B-C0231174
principles	B-C0178566
.	O
	
only	O
three	O
variables	B-C0439828
are	O
necessary	O
to	O
derive	O
the	O
cumulative	B-C1511559
load	B-C1318107
associated	B-C0332281
with	I-C0332281
a	O
lifting	B-C0206244
task	B-C3540678
the	O
weight	B-C0043100
of	I-C0043100
the	I-C0043100
load	I-C0043100
,	O
the	O
maximum	O
horizontal	B-C0012751
distance	I-C0012751
from	O
the	O
spine	B-C0037949
to	B-C1318107
the	I-C1318107
load	I-C1318107
,	O
and	O
the	O
number	O
of	O
repetitions	B-C0205341
for	O
tasks	B-C0039333
performed	I-C0039333
during	O
the	O
workday	B-C0680192
.	O
	
the	O
new	B-C0005479
tool	I-C0005479
was	O
validated	B-C1519941
using	O
two	O
existing	O
epidemiological	B-C1516907
databases	B-C0242356
the	O
lumbar	B-C0575375
motion	I-C0575375
monitor	O
lmm	O
database	O
,	O
and	O
a	O
database	O
from	O
a	O
u.s	O
.	O
	
automotive	O
manufacturer	O
.	O
	
the	O
lifft	O
cumulative	O
damage	O
metric	O
explained	O
92%	O
of	O
the	O
deviance	O
in	O
low	O
back	O
disorders	O
lbds	O
in	O
the	O
lmm	O
database	O
and	O
72-95%	O
of	O
the	O
deviance	O
in	O
low	O
back	O
outcomes	O
in	O
the	O
automotive	O
database	O
depending	O
on	O
the	O
outcome	O
measure	O
.	O
	
thus	O
,	O
lifft	O
is	O
practitioner	O
friendly	O
and	O
its	O
cumulative	O
damage	O
metric	O
highly	O
related	O
to	O
low	O
back	O
outcomes	I-C0085415
genetic	B-C0042333
diversity	I-C0042333
in	O
various	O
accessions	B-C1510755
of	O
pineapple	B-C0946573
ananas	B-C0946573
comosus	I-C0946573
l	I-C0946573
merr	I-C0946573
using	O
issr	B-C0039290
and	O
ssr	B-C1519302
markers	B-C0012872
inter	B-C0039290
simple	I-C0039290
sequence	I-C0039290
repeat	I-C0039290
issr	B-C0039290
and	O
simple	B-C1519302
sequence	I-C1519302
repeat	I-C1519302
ssr	B-C1519302
markers	B-C0012872
were	O
used	O
to	O
assess	O
the	O
genetic	B-C0042333
diversity	I-C0042333
of	O
36	O
pineapple	B-C0946573
accessions	B-C1510755
that	O
were	O
introduced	O
from	O
10	O
countries	B-C0454664
/	O
regions	B-C0017446
.	O
	
thirteen	O
issr	B-C0039290
primers	B-C0206415
amplified	B-C1441475
96	O
bands	O
,	O
of	O
which	O
91	O
93.65	O
were	O
polymorphic	B-C1882417
,	O
whereas	O
20	O
ssr	B-C1519302
primers	B-C0206415
amplified	B-C1441475
73	O
bands	O
,	O
of	O
which	O
70	O
96.50	O
were	O
polymorphic	B-C1882417
.	O
	
nei's	B-C0282574
gene	I-C0282574
diversity	I-C0282574
h	B-C0282574
=	O
0.28	O
,	O
shannon's	B-C0918012
information	I-C0918012
index	I-C0918012
i	B-C0918012
=	O
0.43	O
,	O
and	O
polymorphism	B-C0282574
information	I-C0282574
content	I-C0282574
pic	B-C0282574
=	O
0.29	O
generated	O
using	O
the	O
ssr	B-C1519302
primers	B-C0206415
were	O
higher	O
than	O
that	O
with	O
issr	B-C0039290
primers	B-C0206415
h	B-C0282574
=	O
0.23	O
,	O
i	B-C0918012
=	O
0.37	O
,	O
pic	B-C0282574
=	O
0.24	O
,	O
thereby	O
suggesting	O
that	O
the	O
ssr	B-C1519302
system	I-C1519302
is	O
more	O
efficient	O
than	O
the	O
issr	B-C0039290
system	I-C0039290
in	O
assessing	O
genetic	B-C0042333
diversity	I-C0042333
in	O
various	O
pineapple	B-C0946573
accessions	B-C1510755
.	O
	
mean	O
genetic	B-C0314603
similarities	B-C2348205
were	O
0.74	O
,	O
0.61	O
,	O
and	O
0.69	O
,	O
as	O
determined	O
using	O
issr	B-C0039290
,	O
ssr	B-C1519302
,	O
and	O
combined	O
issr	B-C0039290
/	O
ssr	B-C1519302
,	O
respectively	O
.	O
	
these	O
results	O
suggest	O
that	O
the	O
genetic	B-C0042333
diversity	I-C0042333
among	O
pineapple	B-C0946573
accessions	B-C1510755
is	O
very	O
high	O
.	O
	
we	O
clustered	B-C1881045
the	O
36	O
pineapple	B-C0946573
accessions	B-C1510755
into	O
three	O
or	O
five	O
groups	O
on	O
the	O
basis	O
of	O
the	O
phylogenetic	B-C1519069
trees	I-C1519069
constructed	O
based	O
on	O
the	O
results	O
of	O
issr	B-C0039290
,	O
ssr	B-C1519302
,	O
and	O
combined	O
issr	B-C0039290
/	O
ssr	B-C1519302
analyses	B-C0936012
using	O
the	O
unweighted	B-C0025663
pair-group	I-C0025663
with	I-C0025663
arithmetic	I-C0025663
averaging	I-C0025663
upgma	I-C0025663
method	I-C0025663
.	O
	
the	O
results	O
of	O
principal	B-C0429865
components	I-C0429865
analysis	I-C0429865
pca	B-C0429865
also	O
supported	O
the	O
upgma	B-C0025663
clustering	B-C1881045
.	O
	
these	O
results	O
will	O
be	O
useful	O
not	O
only	O
for	O
the	O
scientific	O
conservation	O
and	O
management	O
of	O
pineapple	B-C0946573
germplasm	B-C4046074
but	O
also	O
for	O
the	O
improvement	O
of	O
the	O
current	O
pineapple	B-C0946573
breeding	B-C4042898
strategies	I-C4042898
.	O
	
advanced	B-C1999167
age	I-C1999167
is	O
not	O
a	O
barrier	B-C0443288
to	O
creating	O
a	O
functional	B-C0205245
arteriovenous	B-C1541850
fistula	I-C1541850
a	O
retrospective	B-C0035363
study	I-C0035363
arteriovenous	B-C1541850
fistulas	I-C1541850
avfs	B-C1541850
are	O
the	O
recommended	O
form	O
of	O
vascular	B-C0750138
access	I-C0750138
for	O
hemodialysis	B-C0019004
.	O
	
however	O
,	O
controversy	B-C0680243
exists	O
regarding	O
whether	O
avfs	B-C1541850
are	O
suitable	O
for	O
elderly	B-C0001792
patients	B-C0030705
.	O
	
single-center	B-C0035363
retrospective	I-C0035363
review	I-C0035363
to	O
investigate	B-C1292732
the	O
impact	B-C4049986
of	O
age	B-C0001779
on	O
avf	B-C1541850
outcomes	B-C1274040
.	O
	
five	O
hundred	O
and	O
twenty-five	O
patients	B-C0030705
with	O
avf	B-C1541850
creation	B-C1706214
were	O
stratified	B-C0205363
based	O
on	O
age	B-C0001779
<65	B-C0027362
,	O
65-75	B-C0027362
,	O
and	O
>75	B-C0027362
years	B-C0439234
.	O
	
avf	B-C1541850
outcomes	B-C1274040
including	O
primary	B-C0205225
failure	B-C0231174
,	O
avf	B-C1541850
patency	B-C0042377
primary	B-C0205225
,	O
secondary	B-C0175668
,	O
and	O
functional	B-C0205245
,	O
and	O
avf	B-C1541850
complications	B-C0009566
were	O
studied	O
for	O
3	O
years	B-C0439234
following	O
avf	B-C1541850
creation	B-C1706214
.	O
	
the	O
cohort	B-C0599755
was	O
63%	O
male	B-C0025266
,	O
44%	O
caucasian	B-C0043157
,	O
and	O
55%	O
had	O
diabetes	B-C0011847
or	O
cardiovascular	B-C0007222
disease	I-C0007222
.	O
	
39%	O
were	O
aged	B-C0001779
<65	B-C0027362
years	B-C0439234
,	O
33%	O
65-75	B-C0027362
years	B-C0439234
,	O
and	O
28%	O
were	O
aged	B-C0001779
>75	B-C0027362
years	B-C0439234
.	O
	
no	O
differences	O
in	O
rates	O
of	O
primary	B-C0205225
failure	B-C0231174
,	O
loss	O
of	O
primary	B-C0205225
patency	B-C0042377
,	O
complications	B-C0009566
,	O
or	O
need	O
for	O
intervention	B-C0184661
were	O
observed	O
between	O
age	B-C0027362
groups	I-C0027362
.	O
	
there	O
was	O
a	O
significant	O
association	B-C0439849
of	O
age	B-C0001779
with	O
secondary	B-C0175668
patency	B-C0042377
and	O
functional	B-C0205245
patency	B-C0042377
,	O
with	O
age	B-C0001779
>75	B-C0027362
being	O
an	O
independent	O
risk	B-C0035648
factor	I-C0035648
for	O
shortened	B-C1282927
lifespan	B-C1254367
of	O
the	O
fistula	O
.	O
	
for	O
patients	B-C0030705
aged	B-C0001779
>75	B-C0027362
years	B-C0439234
,	O
secondary	B-C0175668
patency	B-C0042377
at	O
3	O
years	B-C0439234
was	O
64%	O
compared	O
to	O
75%-78%	O
for	O
younger	B-C0332239
patients	B-C0030705
.	O
	
functional	B-C0205245
patency	B-C0042377
at	O
2	O
years	B-C0439234
was	O
69%	O
for	O
those	O
aged	B-C0001779
>75	B-C0027362
years	B-C0439234
compared	O
to	O
78%-81%	O
for	O
younger	B-C0332239
patients	B-C0030705
.	O
	
we	O
found	O
no	O
difference	O
in	O
avf	B-C1541850
maturation	B-C1254042
,	O
primary	B-C0205225
patency	B-C0042377
,	O
complications	B-C0009566
,	O
or	O
interventions	B-C0184661
in	O
those	O
over	O
the	O
age	B-C0001779
of	O
75	B-C0027362
compared	O
to	O
younger	B-C0332239
counterparts	O
.	O
	
while	O
secondary	B-C0175668
and	O
functional	B-C0205245
patency	B-C0042377
rates	B-C1521828
were	O
significantly	O
lower	O
in	O
those	O
aged	B-C0001779
>75	B-C0027362
years	B-C0439234
,	O
the	O
magnitude	O
of	O
difference	O
is	O
likely	O
not	O
clinically	O
relevant	O
.	O
	
therefore	O
,	O
we	O
recommend	O
that	O
advanced	B-C1999167
age	I-C1999167
alone	O
should	O
not	O
preclude	O
patients	B-C0030705
from	O
avf	B-C1541850
creation	B-C1706214
.	O
	
a	O
modified	B-C0392747
esbl	B-C0486433
nordmann/dortet/poirel-based	O
protocol	O
to	O
optimize	O
early	O
sepsis	O
management	O
we	O
evaluated	O
a	O
modification	O
of	O
a	O
colorimetric	O
test	O
recently	O
described	O
by	O
dortet	O
et	O
al	O
.	O
	
2015	O
for	O
the	O
rapid	O
detection	O
of	O
esbl	B-C0022885
-producing	O
enterobacteriaceae	O
directly	O
from	O
positive	O
blood	O
cultures	O
that	O
requires	O
less	O
manipulation	O
,	O
materials	O
and	O
hands-on	O
time	O
.	O
	
the	O
simplified	O
protocol	O
showed	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100%	O
and	O
95.7	O
the	O
use	O
of	O
informativity	O
in	O
the	O
development	B-C1527148
of	O
robust	B-C0042720
viromics	I-C0042720
-based	O
examinations	B-C0242481
metagenomics	B-C2717799
-based	O
studies	O
have	O
provided	O
insight	O
into	O
many	O
of	O
the	O
complex	O
microbial	B-C0599840
communities	I-C0599840
responsible	O
for	O
maintaining	B-C0184640
life	I-C0184640
on	I-C0184640
this	I-C0184640
planet	I-C0184640
.	O
	
sequencing	B-C0487717
efforts	O
often	O
uncover	O
novel	O
genetic	B-C0017272
content	I-C0017272
this	O
is	O
most	O
evident	O
for	O
phage	B-C0004651
communities	I-C0004651
,	O
in	O
which	O
upwards	O
of	O
90%	O
of	O
all	O
sequences	B-C0162801
exhibit	O
no	O
similarity	O
to	O
any	O
sequence	B-C0162801
in	O
current	O
data	B-C3847505
repositories	I-C3847505
.	O
	
for	O
the	O
small	B-C1264633
fraction	I-C1264633
that	O
can	O
be	O
identified	O
,	O
the	O
top	O
blast	B-C2698333
hit	O
is	O
generally	O
posited	O
as	O
being	O
representative	B-C1882932
of	O
a	O
viral	B-C0597651
taxon	I-C0597651
present	O
in	O
the	O
sample	O
of	O
origin	O
.	O
	
homology	B-C2697616
-based	O
classification	B-C0008902
,	O
however	O
,	O
can	O
be	O
misleading	O
as	O
sequence	B-C0026382
repositories	I-C0026382
capture	O
but	O
a	O
small	B-C1264633
fraction	I-C1264633
of	O
phage	B-C0004651
diversity	I-C0004651
.	O
	
furthermore	O
,	O
lateral	B-C0205093
gene	B-C1517499
transfer	I-C1517499
is	O
pervasive	B-C0205391
within	O
phage	B-C0004651
communities	I-C0004651
.	O
	
as	O
such	O
,	O
the	O
presence	O
of	O
a	O
particular	B-C0017337
gene	I-C0017337
may	O
not	O
be	O
indicative	O
of	O
the	O
presence	O
of	O
a	O
particular	B-C0042776
viral	I-C0042776
species	I-C0042776
.	O
	
rather	O
,	O
it	O
is	O
just	O
that	O
an	O
indication	B-C3146298
of	O
the	O
presence	O
of	O
a	O
specific	B-C0017337
gene	I-C0017337
.	O
	
to	O
circumvent	O
this	O
limitation	B-C0449295
,	O
we	O
have	O
developed	O
a	O
new	O
method	O
for	O
the	O
analysis	B-C3854164
of	I-C3854164
viral	I-C3854164
metagenomic	I-C3854164
datasets	I-C3854164
.	O
	
blast	B-C2698333
hits	O
are	O
weighted	O
,	O
integrating	B-C2359783
the	I-C2359783
sequence	I-C2359783
identity	I-C2359783
and	O
length	B-C0080143
of	I-C0080143
alignments	I-C0080143
as	O
well	O
as	O
a	O
taxonomic	B-C0008903
signal	I-C0008903
,	O
such	O
that	O
each	B-C0017337
gene	I-C0017337
is	O
evaluated	O
with	O
respect	O
to	O
its	O
information	B-C1533716
content	I-C1533716
.	O
	
through	O
this	O
quantifiable	B-C0025867
metric	I-C0025867
,	O
predictions	B-C0681842
of	O
viral	B-C1956108
community	I-C1956108
structure	O
can	O
be	O
made	O
with	O
confidence	O
.	O
	
as	O
a	O
proof-of-concept	B-C1254370
,	O
the	O
approach	O
presented	O
here	O
was	O
implemented	B-C1708476
and	O
applied	O
to	O
seven	O
freshwater	B-C2717745
viral	I-C2717745
metagenomes	I-C2717745
.	O
	
while	O
providing	O
a	O
robust	B-C2986815
method	I-C2986815
for	O
evaluating	O
viral	B-C2717799
metagenomic	I-C2717799
data	I-C2717799
,	O
the	O
tool	B-C0037589
is	O
versatile	B-C0205556
and	O
can	O
easily	O
be	O
customized	B-C1880202
to	O
investigations	B-C1261322
of	O
any	O
environment	B-C0014406
or	O
presence	B-C0150312
of	I-C0150312
citrinin	B-C0008861
in	O
grains	B-C0007757
and	O
its	O
possible	B-C0332149
health	B-C0018684
effects	B-C1280500
citrinin	B-C0008861
is	O
a	O
mycotoxin	B-C0026955
produced	B-C0205245
by	O
several	O
species	B-C1705920
of	O
the	O
genera	B-C0004034
aspergillus	I-C0004034
,	O
penicillium	B-C0030843
and	O
monascus	B-C0997448
and	O
it	O
occurs	B-C1709305
mainly	O
in	O
stored	B-C0007757
grain	I-C0007757
.	O
	
citrinin	B-C0008861
is	O
generally	O
formed	B-C0205431
after	O
harvest	B-C0205245
and	O
occurs	B-C1709305
mainly	O
in	O
stored	B-C0007757
grains	I-C0007757
,	O
it	O
also	O
occurs	B-C1709305
in	O
other	B-C0541488
plant	I-C0541488
products	I-C0541488
.	O
	
often	O
,	O
the	O
co-occurrence	B-C2745955
with	O
other	O
mycotoxins	B-C0026955
is	O
observed	B-C1441672
,	O
especially	O
ochratoxin	B-C0069299
a	I-C0069299
,	O
which	O
is	O
usually	O
associated	B-C0332281
with	I-C0332281
endemic	B-C0004698
nephropathy	I-C0004698
.	O
	
at	O
the	O
european	B-C0015179
union	I-C0015179
level	B-C0441889
,	O
systematic	B-C0220922
monitoring	B-C1283169
of	O
citrinin	B-C0008861
in	O
grains	B-C0007757
began	O
with	O
the	O
aim	B-C1947946
of	O
determining	B-C0205556
its	O
highest	O
permissible	B-C1265611
amount	I-C1265611
in	O
food	B-C0016452
.	O
	
thus	O
,	O
far	O
the	O
systematic	B-C0220922
monitoring	B-C1283169
of	O
the	O
above	B-C0008861
mentioned	I-C0008861
mycotoxin	I-C0008861
in	O
croatia	B-C0010343
is	O
yet	O
to	O
begin	B-C0439659
.	O
	
the	O
main	B-C0018017
goal	I-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
determine	B-C0205556
the	O
presence	B-C0150312
of	I-C0150312
citrinin	B-C0008861
in	O
grains	B-C0007757
sampled	B-C0870078
in	O
the	O
area	B-C0205146
of	O
međimurje	B-C0079170
,	O
osijek-baranja	B-C0079170
,	O
vukovar-srijem	B-C0079170
and	O
brod-posavina	B-C0079170
county	I-C0079170
.	O
	
for	O
the	O
purpose	B-C1285529
of	O
identification	B-C0205396
and	O
quantification	B-C1709793
of	O
citrinin	B-C0008861
,	O
high	B-C4054775
performance	I-C4054775
liquid	I-C4054775
chromatograph	I-C4054775
hplc	I-C4054775
with	I-C4054775
fluorescence	I-C4054775
was	O
used	B-C1273517
calibration	B-C0006751
curve	I-C0006751
k	O
>	O
0.999	O
intra	B-C3176771
assay	I-C3176771
cv	I-C3176771
=	O
2.1	O
inter	B-C3176771
assay	I-C3176771
cv	I-C3176771
=	O
4.3	O
loq	B-C1709793
<	O
1	O
μg/kg	O
.	O
	
from	O
the	O
area	B-C0205146
of	O
međimurje	B-C0079170
county	I-C0079170
,	O
10	O
samples	B-C0370003
of	O
corn	B-C1138842
and	O
10	O
samples	B-C0370003
of	O
wheat	B-C0043137
were	O
analyzed	B-C0936012
.	O
	
none	O
of	O
the	O
samples	B-C0370003
contained	B-C2700400
citrinin	B-C0008861
<1	O
μg/kg	O
.	O
	
from	O
the	O
area	B-C0205146
of	O
osijek-baranja	B-C0079170
and	O
vukovar-srijem	B-C0079170
county	I-C0079170
,	O
15	O
samples	B-C0370003
from	O
each	O
county	B-C0079170
were	O
analyzed	B-C0936012
.	O
	
the	O
mean	B-C0444504
value	I-C0444504
for	O
the	O
samples	B-C0370003
of	O
osijek-baranja	B-C0079170
county	I-C0079170
was	O
19.63	O
μg/kg	O
median	B-C2348144
=15	O
μg/kg	O
,	O
while	O
for	O
vukovar-srijem	B-C0079170
county	I-C0079170
the	O
mean	B-C0444504
value	I-C0444504
of	O
citrinin	B-C0008861
was	O
14	O
μg/kg	O
median	B-C2348144
=1	O
μg/kg	O
.	O
	
from	O
5	O
analyzed	B-C0936012
samples	B-C0370003
from	O
brod-posavina	B-C0079170
county	I-C0079170
,	O
one	O
of	O
the	O
samples	B-C0370003
contained	B-C2700400
citrinin	B-C0008861
in	O
the	O
amount	B-C1265611
of	O
23.8	O
μg/kg	O
,	O
while	O
the	O
registered	B-C1514821
amount	B-C1265611
s	O
in	O
the	O
other	O
samples	B-C0370003
were	O
<1	O
μg/kg	O
.	O
	
the	O
results	B-C1274040
show	O
that	O
grains	B-C0007757
from	O
several	B-C0439064
counties	B-C0079170
contain	B-C2700400
certain	O
amounts	B-C1265611
of	O
citrinin	B-C0008861
possibly	O
indicating	B-C1444656
a	O
significant	B-C0750502
intake	B-C1512806
of	O
citrinin	B-C0008861
in	O
humans	B-C0086418
.	O
	
it	O
must	O
be	O
stated	O
that	O
grains	B-C0007757
and	O
grain-based	B-C0016452
products	I-C0016452
are	O
the	O
basis	O
of	O
everyday	B-C0332173
diet	B-C0012155
of	O
all	O
age	B-C0027362
groups	I-C0027362
,	O
especially	O
small	B-C0008059
children	I-C0008059
,	O
where	O
higher	B-C0205250
intake	B-C1512806
of	O
citrinin	B-C0008861
can	O
occur	B-C1709305
.	O
	
consequently	O
,	O
we	O
emphasize	B-C0205556
the	O
need	O
for	O
systematic	B-C0220922
analysis	B-C0936012
of	O
larger	B-C1265611
amount	I-C1265611
of	O
samples	B-C0370003
,	O
from	O
both	O
large	B-C0007757
grains	I-C0007757
and	O
small	B-C0007757
grains	I-C0007757
,	O
especially	O
in	O
the	O
area	B-C0205146
of	O
brod-posavina	B-C0079170
county	I-C0079170
,	O
in	O
order	O
to	O
obtain	O
more	O
realistic	O
notion	O
of	O
citrinin	B-C0008861
contamination	B-C2349974
of	O
grains	B-C0007757
and	O
to	O
asses	B-C1516048
the	O
health	B-C0018684
risk	B-C0035647
in	O
recurrent	B-C0026882
noncoding	I-C0026882
regulatory	I-C0026882
mutations	I-C0026882
in	O
pancreatic	B-C1335302
ductal	I-C1335302
adenocarcinoma	I-C1335302
the	O
contributions	B-C1880177
of	O
coding	B-C0026882
mutations	I-C0026882
to	O
tumorigenesis	B-C0007621
are	O
relatively	O
well	O
known	O
however	O
,	O
little	O
is	O
known	O
about	O
somatic	B-C0544886
alterations	I-C0544886
in	O
noncoding	B-C0021920
dna	I-C0021920
.	O
	
here	O
we	O
describe	O
gecco	O
genomic	O
enrichment	O
computational	O
clustering	O
operation	O
to	O
analyze	O
somatic	B-C0544886
noncoding	I-C0544886
alterations	I-C0544886
in	O
308	O
pancreatic	B-C1335302
ductal	I-C1335302
adenocarcinomas	I-C1335302
pdas	B-C1335302
and	O
identify	O
commonly	O
mutated	B-C0004793
regulatory	I-C0004793
regions	I-C0004793
.	O
	
we	O
find	O
recurrent	B-C0026882
noncoding	I-C0026882
mutations	I-C0026882
to	O
be	O
enriched	O
in	O
pda	B-C1335302
pathways	B-C1704259
,	O
including	O
axon	B-C2984268
guidance	I-C2984268
and	O
cell	B-C0007577
adhesion	I-C0007577
,	O
and	O
newly	O
identified	B-C0205396
processes	B-C1522240
,	O
including	O
transcription	B-C0040649
and	O
homeobox	B-C0017347
genes	I-C0017347
.	O
	
we	O
identified	B-C0205396
mutations	B-C0026882
in	O
protein	B-C1514535
binding	I-C1514535
sites	I-C1514535
correlating	O
with	O
differential	B-C0443199
expression	B-C0017262
of	O
proximal	B-C0205107
genes	B-C0017337
and	O
experimentally	O
validated	O
effects	B-C1704420
of	I-C1704420
mutations	B-C0026882
on	O
expression	B-C0017262
.	O
	
we	O
developed	O
an	O
expression	B-C0392762
modulation	I-C0392762
score	I-C0392762
that	O
quantifies	B-C1709793
the	O
strength	B-C0808080
of	O
gene	B-C0017263
regulation	I-C0017263
imposed	O
by	O
each	O
class	O
of	O
regulatory	B-C0017362
elements	I-C0017362
,	O
and	O
found	O
the	O
strongest	O
elements	B-C0017362
were	O
most	O
frequently	O
mutated	O
,	O
suggesting	O
a	O
selective	O
advantage	O
.	O
	
our	O
detailed	O
single-cancer	B-C0022885
analysis	I-C0022885
of	O
noncoding	B-C0026882
alterations	I-C0026882
identifies	O
regulatory	B-C0026882
mutations	I-C0026882
as	O
candidates	B-C0205556
for	O
diagnostic	B-C1511876
and	O
prognostic	B-C1514475
markers	I-C1514475
,	O
and	O
suggests	O
new	O
mechanisms	B-C0441712
for	O
tumor	B-C0007621
evolution	I-C0007621
.	O
	
distal	B-C0205108
posterior	B-C0149576
cerebral	I-C0149576
artery	I-C0149576
revascularization	B-C0007794
for	O
a	O
fusiform	B-C0332493
pca	B-C0149576
aneurysm	B-C0002940
a	O
lesson	O
learned	O
the	O
need	O
for	O
revascularization	B-C0007794
with	O
proximal	B-C0205107
posterior	B-C0149576
cerebral	I-C0149576
artery	I-C0149576
occlusion	B-C0028790
in	O
the	O
treatment	B-C1522326
of	O
giant	B-C0751004
and	O
fusiform	B-C0333099
aneurysms	I-C0333099
is	O
unclear	O
.	O
	
while	O
early	O
series	O
demonstrated	O
only	O
about	O
a	O
10%	O
chance	O
of	O
infarction	B-C0021308
following	O
posterior	B-C0149576
cerebral	I-C0149576
artery	I-C0149576
occlusion	B-C0028790
,	O
recently	O
several	O
authors	B-C3812881
have	O
advocated	O
a	O
bypass	B-C0741847
prior	O
to	O
parent	O
vessel	B-C0005847
sacrifice	O
in	O
all	O
cases	O
.	O
	
we	O
present	O
the	O
case	O
of	O
an	O
adult	O
man	O
with	O
a	O
fusiform	B-C0333099
aneurysm	I-C0333099
of	O
the	O
right	O
posterior	B-C0149576
cerebral	I-C0149576
artery	I-C0149576
at	O
the	O
p2-p3	B-C0682580
junction	I-C0682580
.	O
	
he	O
clinically	B-C3640841
failed	I-C3640841
a	O
balloon	B-C3697458
test	I-C3697458
occlusion	I-C3697458
preoperatively	B-C0445204
and	O
therefore	O
underwent	O
an	O
occipital	B-C0226117
artery	I-C0226117
to	O
distal	B-C0205108
posterior	B-C0149576
cerebral	I-C0149576
artery	I-C0149576
bypass	B-C0741847
with	O
subsequent	O
endovascular	B-C2223520
occlusion	I-C2223520
of	I-C2223520
the	I-C2223520
parent	I-C2223520
vessel	I-C2223520
and	O
aneurysm	B-C0002940
.	O
	
despite	O
the	O
fact	O
that	O
the	O
immediate	O
and	O
6	O
month	O
follow	B-C1522577
up	I-C1522577
cerebral	B-C0007767
angiography	I-C0007767
confirmed	O
a	O
patent	O
bypass	B-C0741847
,	O
the	O
patient	B-C0030705
still	O
developed	O
a	O
posterior	B-C0149576
cerebral	I-C0149576
artery	I-C0149576
territory	B-C0038454
stroke	I-C0038454
.	O
	
we	O
believe	O
this	O
case	O
demonstrates	O
that	O
successful	O
distal	B-C0205108
revascularization	B-C0007794
in	O
the	O
setting	O
of	O
proximal	B-C0205107
posterior	B-C0149576
cerebral	I-C0149576
artery	I-C0149576
occlusion	B-C0028790
does	O
not	O
guarantee	O
against	O
cerebral	B-C0917798
ischemia	I-C0917798
and	O
infarction	B-C0021308
even	O
in	O
those	O
patients	B-C0030705
that	O
fail	O
a	O
test	B-C3697458
occlusion	I-C3697458
.	O
	
when	O
is	O
a	O
test	B-C0237855
score	I-C0237855
fair	B-C2911689
for	O
the	O
individual	B-C0237401
who	O
is	O
being	O
tested	B-C0392366
effects	B-C1704420
of	I-C1704420
different	O
scoring	B-C0036449
procedures	I-C0036449
across	O
multiple	B-C0439064
attempts	B-C1516084
when	O
testing	B-C0039593
a	O
motor	B-C0026612
skill	I-C0026612
task	B-C3540678
tests	B-C0392366
or	O
test	B-C0392366
batteries	I-C0392366
used	O
for	O
assessing	B-C1516048
motor	B-C0026612
skills	I-C0026612
,	O
either	O
in	O
research	B-C0681814
studies	I-C0681814
or	O
in	O
clinical	B-C0008976
settings	I-C0008976
,	O
apply	O
a	O
variety	O
of	O
procedures	B-C0025664
for	O
scoring	B-C0036449
performances	B-C0597198
,	O
including	O
everything	O
from	O
one	O
to	O
ten	O
attempts	B-C1516084
,	O
of	O
which	O
the	O
best	O
is	O
scored	B-C0449820
or	O
an	O
average	B-C1510992
is	O
computed	B-C1441526
.	O
	
the	O
rationale	O
behind	O
scoring	B-C0036449
procedures	B-C0025664
is	O
rarely	O
stated	O
,	O
and	O
it	O
seems	O
that	O
the	O
number	O
of	O
attempts	B-C1516084
allowed	O
is	O
decided	O
without	O
much	O
qualification	O
from	O
research	B-C0035168
.	O
	
it	O
is	O
uncertain	O
whether	O
procedures	B-C0025664
fairly	O
capture	O
an	O
individual's	B-C0237401
skill	B-C0026612
level	B-C0441889
.	O
	
thus	O
,	O
the	O
validity	O
of	O
the	O
tests	B-C0392366
may	O
be	O
compromised	O
.	O
	
the	O
present	O
study	B-C2603343
tested	B-C0392366
24	O
young	O
female	B-C0043210
soccer	B-C0037393
players	B-C0335104
on	O
the	O
juggling	B-C0034872
of	O
a	O
soccer	B-C0336986
ball	I-C0336986
.	O
	
they	O
were	O
given	O
10	O
attempts	B-C1516084
,	O
and	O
trials	B-C0681815
were	O
scored	B-C0449820
according	O
to	O
nine	O
different	O
procedures	B-C0025664
including	O
the	O
'	O
best	B-C1522427
of	I-C1522427
'	O
or	O
'	O
mean	B-C0444504
of	I-C0444504
'	O
either	O
one	O
,	O
two	O
,	O
three	O
,	O
five	O
,	O
or	O
ten	O
attempts	B-C1516084
.	O
	
individual	B-C0237401
raw	B-C0449820
scores	I-C0449820
differed	O
widely	O
across	O
trials	B-C0681815
,	O
but	O
no	B-C1301751
general	I-C1301751
effect	I-C1301751
of	O
trials	B-C0681815
was	O
found	O
.	O
	
the	O
mean	B-C0392762
sd	I-C0392762
percentage	I-C0392762
difference	I-C0392762
between	O
the	O
lowest	B-C1708760
and	O
highest	B-C1522410
scores	B-C0449820
was	O
27.7	O
,	O
with	O
17	O
players	B-C0335104
71%	O
demonstrating	O
a	O
significant	B-C0750502
change	O
from	O
lowest	B-C1708760
to	O
highest	B-C1522410
score	B-C0449820
.	O
	
correlations	B-C1707520
between	O
raw	B-C0449820
scores	I-C0449820
were	O
low	B-C0205251
across	O
trials	B-C0681815
,	O
while	O
they	O
were	O
generally	O
higher	B-C0205250
across	O
scoring	B-C0036449
procedures	B-C0025664
.	O
	
the	O
first	O
trial	B-C0681815
was	O
significantly	B-C0750502
different	B-C1705242
from	O
the	O
remaining	O
both	O
as	O
a	O
raw	B-C0449820
score	I-C0449820
and	O
as	O
scoring	B-C0036449
procedure	B-C0025664
.	O
	
the	O
mean	B-C0392762
percentage	I-C0392762
difference	I-C0392762
between	O
best-of-two	B-C0449820
and	O
best-of-ten	B-C0449820
scores	I-C0449820
was	O
95%	O
,	O
with	O
50	O
%	O
of	O
the	O
players	B-C0335104
demonstrating	O
a	O
significant	B-C0750502
difference	B-C1705242
between	O
the	O
two	O
scoring	B-C0036449
procedures	B-C0025664
.	O
	
no	B-C3842396
significant	I-C3842396
differences	I-C3842396
were	O
found	O
across	O
mean-of-rule	B-C0449820
scorings	I-C0449820
.	O
	
best-of-rule	B-C0449820
and	O
mean-of-rule	B-C0449820
scorings	I-C0449820
were	O
significantly	B-C0750502
different	B-C1705242
except	O
for	O
the	O
best-of-two	B-C0449820
vs	O
.	O
	
mean-of-two	B-C0449820
.	O
	
the	O
mean	B-C0392762
difference	I-C0392762
between	O
highest	B-C1522410
and	O
lowest	B-C1708760
rank	B-C0699794
across	O
players	B-C0335104
was	O
6.7	O
3.6	O
,	O
with	O
individual	B-C0237401
rankings	B-C0699794
within	O
the	O
group	B-C1257890
varying	O
33%	O
on	O
average	O
across	O
procedures	B-C0025664
.	O
	
one	O
player	O
moved	O
from	O
3rd	O
to	O
23rd	O
place	O
because	O
of	O
procedural	B-C0025664
differences	B-C1705242
.	O
	
therefore	O
,	O
it	O
is	O
concluded	O
that	O
scoring	B-C0036449
procedures	B-C0025664
affect	O
results	B-C0456984
and	O
may	O
have	O
an	O
impact	O
on	O
test	B-C0456984
outcomes	I-C0456984
.	O
	
this	O
may	O
present	O
consequences	O
for	O
decision-making	O
from	O
test	B-C0456984
results	I-C0456984
,	O
such	O
as	O
diagnosing	B-C0011900
and	O
selection	O
of	O
intervention	B-C0184661
groups	B-C0441833
.	O
	
we	O
hope	O
that	O
our	O
results	O
would	O
inspire	O
further	O
research	B-C0035168
into	O
the	O
scoring	B-C0036449
procedures	B-C0025664
of	O
the	O
vast	O
amount	O
of	O
tests	B-C0392366
a	O
fast	B-C0002045
peak-searching	I-C0002045
algorithm	I-C0002045
for	O
ultrasonic	B-C3163956
elastography	I-C3163956
tissue	B-C2316047
axial	I-C2316047
strain	I-C2316047
estimation	I-C2316047
with	I-C2316047
ultrasound	I-C2316047
elastography	I-C2316047
has	O
become	O
a	O
hot	O
field	O
in	O
recent	O
years	O
.	O
	
however	O
,	O
for	O
keypoints	O
tracking-based	B-C0002045
elastography	I-C0002045
algorithms	I-C0002045
,	O
locating	B-C0243095
extrema	B-C0205556
in	O
multimodal	O
ultrasonic	B-C0220934
radiofrequency	B-C2347883
signals	B-C1710082
is	O
still	O
a	O
challenging	O
problem	B-C0033213
.	O
	
in	O
this	O
paper	O
,	O
a	O
new	O
method	O
is	O
proposed	B-C1553874
to	O
locate	B-C0243095
the	O
local	O
maxima	B-C0806909
and	O
minima	B-C1524031
of	O
the	O
rf	B-C2347883
signals	B-C1710082
directly	O
without	O
derivation	B-C1441547
operation	B-C3241922
.	O
	
this	O
algorithm	B-C0002045
can	O
accurately	O
locate	B-C0243095
extrema	B-C0205556
even	O
if	O
disturbed	O
peaks	B-C0444505
resulting	O
from	O
different	O
noise	B-C0028263
exist	O
.	O
	
furthermore	O
,	O
the	O
new	O
algorithm	B-C0002045
can	O
speed	O
up	O
approximately	O
79%	O
of	O
the	O
implementation	B-C1708476
process	O
as	O
compared	B-C1707455
with	O
the	O
standard	B-C0242481
cross-correlation	I-C0242481
method	I-C0242481
on	O
the	O
same	O
computing	B-C1880157
platform	O
.	O
	
in	O
addition	O
,	O
the	O
elastographic	O
signal-to-noise	B-C2986823
ratio	I-C2986823
and	O
the	O
contrast-to-noise	B-C0392762
ratio	I-C0392762
audiovisual	B-C1254359
integration	B-C0679019
supports	O
face	B-C0015450
-	O
name	B-C1547383
associative	B-C0679045
memory	B-C0025260
formation	I-C0025260
prior	O
multisensory	B-C0445254
experience	B-C0596545
influences	O
how	O
we	O
perceive	O
our	O
environment	B-C0014406
,	O
and	O
hence	O
how	O
memories	B-C0025260
are	O
encoded	O
for	O
subsequent	O
retrieval	B-C0679061
.	O
	
this	O
study	B-C2603343
investigated	O
if	O
audiovisual	B-C1254359
av	B-C1254359
integration	B-C0679019
and	O
associative	B-C0679045
memory	B-C0025260
formation	I-C0025260
rely	O
on	O
overlapping	O
or	O
distinct	O
processes	O
.	O
	
our	O
functional	O
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
results	O
demonstrate	O
that	O
the	O
neural	B-C0027882
mechanisms	B-C0441712
underlying	O
av	B-C1254359
integration	B-C0679019
and	O
associative	B-C0679045
memory	B-C0025260
overlap	B-C1948020
substantially	O
.	O
	
in	O
particular	O
,	O
activity	B-C0441655
in	O
anterior	B-C3499005
superior	I-C3499005
temporal	I-C3499005
sulcus	I-C3499005
sts	B-C1281074
is	O
increased	O
during	O
av	B-C1254359
integration	B-C0679019
and	O
also	O
determines	O
the	O
success	O
of	O
novel	O
av	B-C1254359
face	B-C0015450
-	O
name	B-C1547383
association	O
formation	O
.	O
	
dynamic	B-C0681944
causal	I-C0681944
modeling	I-C0681944
results	O
further	O
demonstrate	O
how	O
the	O
anterior	B-C3499005
sts	I-C3499005
interacts	O
with	O
the	O
associative	B-C0679045
memory	B-C0025260
system	I-C0025260
to	O
facilitate	O
successful	O
memory	B-C0025260
formation	I-C0025260
for	O
av	B-C1254359
face	B-C0015450
-	O
name	B-C1547383
associations	B-C0679045
.	O
	
specifically	O
,	O
the	O
connection	O
of	O
fusiform	B-C0228243
gyrus	I-C0228243
to	O
anterior	B-C3499005
sts	I-C3499005
is	O
enhanced	O
while	O
the	O
reverse	O
connection	O
is	O
reduced	O
when	O
participants	B-C0679646
subsequently	O
remembered	B-C0034770
both	O
face	B-C0015450
and	O
name	B-C1547383
.	O
	
collectively	O
,	O
our	O
results	O
demonstrate	O
how	O
multisensory	B-C0445254
associative	B-C0679045
memories	B-C0025260
can	O
be	O
formed	O
for	O
subsequent	O
liquid	B-C4049918
chromatography-tandem	I-C4049918
mass	I-C4049918
spectrometry	I-C4049918
quantification	B-C1709793
of	O
acetamiprid	B-C1142891
and	O
thiacloprid	B-C0962702
residues	B-C1254354
in	O
butterbur	B-C1019150
grown	O
under	O
regulated	B-C0014406
conditions	I-C0014406
an	O
analytical	B-C0178476
method	I-C0178476
was	O
developed	O
to	O
quantify	B-C1709793
the	O
residual	B-C1254354
levels	B-C0441889
of	O
the	O
neonicotinoid	B-C1997222
insecticides	I-C1997222
,	O
acetamiprid	B-C1142891
and	O
thiacloprid	B-C0962702
,	O
in	O
field-incurred	B-C0443318
butterbur	B-C1019150
samples	B-C0370003
using	O
liquid	B-C4049918
chromatography-tandem	I-C4049918
mass	I-C4049918
spectrometry	I-C4049918
lc-ms/ms	B-C4049918
.	O
	
samples	B-C0370003
were	O
extracted	B-C0684295
with	O
acetonitrile	B-C0050456
and	O
partitioned	O
with	O
dichloromethane	B-C0025748
.	O
	
after	O
partitioning	O
,	O
purification	B-C1998793
was	O
conducted	O
using	O
a	O
florisil	B-C1504285
cartridge	I-C1504285
.	O
	
linearity	B-C0205132
of	O
a	O
matrix-matched	B-C0006751
calibration	I-C0006751
curve	I-C0006751
of	O
the	O
two	O
compounds	B-C1254354
over	O
a	O
concentration	B-C1446561
range	B-C1514721
of	O
0.004	O
was	O
excellent	O
,	O
with	O
determination	B-C2827748
coefficients	I-C2827748
r	B-C2827748
.	O
	
the	O
limits	B-C2718050
of	I-C2718050
detection	I-C2718050
lod	B-C2718050
and	O
quantitation	B-C1709793
loq	B-C1709793
for	O
both	O
acetamiprid	B-C1142891
and	O
thiacloprid	B-C0962702
were	O
0.0006	O
and	O
0.002mg	O
,	O
respectively	O
.	O
	
the	O
average	O
recoveries	O
for	O
acetamiprid	B-C1142891
and	O
thiacloprid	B-C0962702
at	O
two	O
spiking	B-C0441889
levels	I-C0441889
0.02	O
and	O
0.1mg	O
,	O
i.e	O
,	O
10	O
loq	B-C1709793
and	O
50	O
loq	B-C1709793
were	O
between	O
78.23	O
to	O
82.17	O
,	O
with	O
relative	B-C0871420
standard	I-C0871420
deviations	I-C0871420
rsds	B-C0871420
.	O
	
the	O
method	B-C0178476
was	O
successfully	O
applied	O
to	O
field-incurred	B-C0443318
samples	B-C0370003
treated	B-C1522326
with	O
a	O
commercial	B-C0680536
pesticide	B-C0031253
product	I-C0031253
,	O
either	O
once	O
zero	O
or	O
7	O
days	B-C0439228
before	O
harvest	B-C0205245
or	O
twice	O
0	O
and	O
7	O
,	O
7	O
and	O
14	O
,	O
or	O
14	O
and	O
21	O
days	B-C0439228
before	O
harvest	B-C0205245
.	O
	
the	O
highest	O
and	O
lowest	O
residues	B-C1254354
were	O
obtained	O
for	O
the	O
7	O
and	O
0	O
days	B-C0439228
'	O
treatment	B-C1522326
and	O
the	O
21	O
and	O
14	O
days	B-C0439228
'	O
treatment	B-C1522326
,	O
respectively	O
.	O
	
the	O
developed	O
method	B-C0178476
is	O
simple	O
and	O
accurate	B-C0443131
and	O
can	O
be	O
extrapolated	O
to	O
other	O
leafy	B-C0042440
vegetables	I-C0042440
.	O
	
percentile	B-C1264641
categorization	B-C0008902
of	O
qt	B-C1287082
interval	I-C1287082
as	O
an	O
approach	B-C0449445
for	O
identifying	B-C0557971
adult	B-C0001675
patients	B-C0030705
at	O
risk	B-C0035647
for	O
cardiovascular	B-C2926098
death	I-C2926098
the	O
results	O
from	O
studies	O
of	O
the	O
association	O
of	O
qt	B-C0151878
prolongation	I-C0151878
with	O
cardiovascular	B-C2926098
death	I-C2926098
cvd	B-C2926098
have	O
been	O
inconsistent	B-C0442809
.	O
	
the	O
purpose	B-C0681832
of	I-C0681832
this	I-C0681832
study	I-C0681832
was	O
to	O
compare	B-C1707455
the	O
major	O
correction	B-C0392762
formulas	I-C0392762
to	O
percentile	B-C1532337
values	I-C1532337
of	O
qt	B-C0860814
for	O
heart	B-C0018810
rate	I-C0018810
ranges	B-C1514721
as	O
to	O
their	O
ability	B-C0085732
to	O
remove	B-C1883720
the	O
relationship	B-C0439849
of	O
qt	B-C0860814
to	O
heart	B-C0018810
rate	I-C0018810
and	O
to	O
predict	O
cvd	B-C2926098
.	O
	
participants	B-C0679646
were	O
16	O
veterans	B-C0042610
who	O
had	O
an	O
initial	O
ecg	B-C0013798
at	O
the	O
veterans	B-C0282574
affairs	I-C0282574
medical	I-C0282574
center	I-C0282574
,	O
palo	B-C3827373
alto	I-C3827373
,	O
between	O
march	B-C3829202
31	O
,	O
1987	O
,	O
and	O
december	B-C3830550
20	O
,	O
1999	O
,	O
and	O
were	O
followed	O
for	O
cvd	B-C2926098
.	O
	
the	O
4	O
major	O
correction	B-C0392762
formulas	I-C0392762
bazett	B-C1882512
,	O
fridericia	B-C1882513
,	O
framingham	B-C0392762
,	O
and	O
hodges	B-C0392762
were	O
used	O
to	O
correct	O
qt	B-C1287082
interval	I-C1287082
.	O
	
in	O
addition	O
,	O
the	O
percentiles	B-C1264641
for	O
heart	B-C0018810
rate	I-C0018810
ranges	B-C1514721
as	O
proposed	O
by	O
schwartz	B-C0086418
were	O
calculated	O
.	O
	
during	O
median	B-C2939193
follow-up	O
of	O
17.8	O
years	B-C1510829
,	O
455	O
cvd	B-C2926098
events	O
occurred	O
.	O
	
when	O
compared	O
to	O
the	O
other	O
equations	B-C0552449
,	O
qtc	O
bazett	O
had	O
the	O
greatest	O
dependence	O
on	O
heart	B-C0018810
rate	I-C0018810
r	O
=	O
0.18	O
.	O
	
the	O
hazard	B-C2985465
ratio	I-C2985465
95%	O
confidence	B-C0009667
interval	I-C0009667
for	O
cvd	B-C2926098
was	O
2.08	O
1.28	O
for	O
the	O
98th	O
percentile	B-C1264641
of	O
qt	B-C1287082
interval	I-C1287082
by	O
heart	B-C0018810
rate	I-C0018810
ranges	B-C1514721
,	O
2.05	O
1.27	O
for	O
qtc	B-C1882512
bazett	I-C1882512
,	O
1.39	O
0.44	O
for	O
qtc	B-C0392762
fridericia	O
,	O
1.05	O
0.26	O
for	O
qtc	O
hodges	I-C0392762
,	O
and	O
1.12	O
0.28	O
for	O
qtc	B-C0392762
framingham	I-C0392762
.	O
	
the	O
hazard	O
ratio	O
of	O
qtc	B-C1882512
bazett	I-C1882512
was	O
significantly	B-C4055637
higher	I-C4055637
than	O
the	O
other	O
formulas	B-C0489829
except	O
for	O
the	O
98th	O
percentile	B-C1264641
method	O
.	O
	
the	O
framingham	B-C0392762
,	O
hodges	B-C0392762
,	O
and	O
fridericia	B-C0392762
equations	I-C0392762
remove	B-C1883720
the	O
effect	B-C1280500
of	O
heart	B-C0018810
rate	I-C0018810
on	O
qt	B-C1287082
interval	I-C1287082
significantly	O
better	O
than	O
the	O
bazett	B-C0392762
equation	I-C0392762
.	O
	
using	O
qt-interval	B-C1287082
percentiles	B-C1264641
based	O
on	O
heart	B-C0018810
rate	I-C0018810
provides	O
a	O
consistent	O
approach	B-C0449445
both	O
for	O
identifying	O
those	O
whose	O
qt	B-C1287082
intervals	I-C1287082
prolong	O
due	O
to	O
drugs	B-C3687832
or	O
other	O
stressors	B-C0597530
and	O
for	O
assessing	O
cvd	B-C2926098
risk	B-C0035647
.	O
	
how	O
should	O
i	O
study	O
for	O
the	O
exam	B-C0681376
self-regulated	B-C1510634
learning	I-C1510634
strategies	B-C0237896
and	O
achievement	B-C0237912
in	O
introductory	B-C0005532
biology	I-C0005532
in	O
college	B-C0557806
introductory	B-C0036397
science	I-C0036397
courses	B-C0013652
,	O
students	B-C0038492
are	O
challenged	O
with	O
mastering	O
large	O
amounts	O
of	O
disciplinary	B-C0205556
content	I-C0205556
while	O
developing	O
as	O
autonomous	B-C0815096
and	O
effective	B-C1704419
learners	B-C0038492
.	O
	
self-regulated	B-C1510634
learning	I-C1510634
srl	B-C1510634
is	O
the	O
process	O
of	O
setting	O
learning	B-C2010704
goals	I-C2010704
,	O
monitoring	O
progress	B-C1280477
toward	O
them	O
,	O
and	O
applying	O
appropriate	O
study	B-C0237896
strategies	I-C0237896
.	O
	
srl	B-C1510634
characterizes	O
successful	O
,	O
"""expert"""	O
learners	B-C0038492
,	O
and	O
develops	O
with	O
time	O
and	O
practice	O
.	O
	
in	O
a	O
large	O
,	O
undergraduate	B-C0683865
introductory	B-C0005532
biology	I-C0005532
course	B-C0013652
,	O
we	O
investigated	O
1	O
what	O
srl	B-C1510634
strategies	B-C0237896
students	B-C0038492
reported	O
using	O
the	O
most	O
when	O
studying	O
for	O
exams	B-C0681376
,	O
2	O
which	O
strategies	B-C0237896
were	O
associated	O
with	O
higher	O
achievement	B-C0001072
and	O
with	O
grade	B-C0441800
improvement	B-C0184511
on	O
exams	B-C0681376
,	O
and	O
3	O
what	O
study	O
approaches	O
students	B-C0038492
proposed	O
to	O
use	O
for	O
future	O
exams	B-C0681376
.	O
	
higher	B-C0205250
-	O
achieving	B-C0001072
students	B-C0038492
,	O
and	O
students	B-C0038492
whose	O
exam	B-C0681376
grades	B-C0441800
improved	B-C0184511
in	O
the	O
first	B-C3843058
half	I-C3843058
of	O
the	O
semester	B-C2348178
,	O
reported	O
using	O
specific	O
cognitive	B-C0009240
and	O
metacognitive	B-C0870885
strategies	I-C0870885
significantly	O
more	O
frequently	B-C0332183
than	O
their	O
lower	B-C2003888
-	O
achieving	B-C0001072
peers	B-C0679739
.	O
	
lower	B-C2003888
-	O
achieving	B-C0001072
students	B-C0038492
more	O
frequently	B-C0332183
reported	O
that	O
they	O
did	O
not	O
implement	O
their	O
planned	O
strategies	B-C0237896
or	O
,	O
if	O
they	O
did	O
,	O
still	O
did	O
not	O
improve	O
their	O
outcomes	B-C1274040
.	O
	
these	O
results	O
suggest	O
that	O
many	O
students	B-C0038492
entering	O
introductory	B-C0005532
biology	I-C0005532
have	O
limited	B-C0439801
knowledge	B-C0013621
of	O
srl	B-C1510634
strategies	B-C0237896
and/or	O
limited	B-C0439801
ability	O
to	O
implement	O
them	O
,	O
which	O
can	O
impact	B-C4049986
their	O
achievement	B-C0237912
.	O
	
course	B-C0013652
-specific	O
interventions	B-C0242687
that	O
promote	O
srl	B-C1510634
development	O
should	O
be	O
considered	O
as	O
integral	O
pedagogical	B-C1510624
tools	I-C1510624
,	O
aimed	O
at	O
fostering	B-C0242298
development	O
of	O
students	B-C0038492
'	O
lifelong	B-C4274169
learning	B-C0871370
skills	I-C0871370
.	O
	
characterising	B-C1880022
bias	B-C0242568
in	O
regulatory	B-C0035647
risk	I-C0035647
and	O
decision	B-C0011108
analysis	I-C0011108
an	O
analysis	B-C0936012
of	O
heuristics	B-C0597916
applied	O
in	O
health	B-C0752189
technology	I-C0752189
appraisal	B-C1254363
,	O
chemicals	B-C0220806
regulation	B-C0851285
,	O
and	O
climate	B-C2718051
change	I-C2718051
governance	B-C0441655
in	O
many	O
environmental	B-C0237095
and	O
public	B-C3244304
health	I-C3244304
domains	I-C3244304
,	O
heuristic	B-C0597916
methods	I-C0597916
of	O
risk	B-C0035647
and	O
decision	B-C0011108
analysis	I-C0011108
must	O
be	O
relied	O
upon	O
,	O
either	O
because	O
problem	B-C0033213
structures	I-C0033213
are	O
ambiguous	O
,	O
reliable	O
data	B-C1511726
is	O
lacking	B-C0332268
,	O
or	O
decisions	B-C0679006
are	O
urgent	O
.	O
	
this	O
introduces	O
an	O
additional	O
source	B-C0449416
of	O
uncertainty	B-C0087130
beyond	O
model	B-C3161035
and	O
measurement	B-C0681899
error	I-C0681899
-	O
uncertainty	B-C0087130
stemming	O
from	O
relying	O
on	O
inexact	O
inference	B-C0870077
rules	I-C0870077
.	O
	
here	O
we	O
identify	B-C0205245
and	O
analyse	B-C1524024
heuristics	B-C0597916
used	O
to	O
prioritise	O
risk	B-C0035647
objects	B-C1518526
,	O
to	O
discriminate	B-C0205235
between	O
signal	B-C1710082
and	O
noise	B-C0028263
,	O
to	O
weight	B-C0043100
evidence	B-C3887511
,	O
to	O
construct	O
models	B-C3161035
,	O
to	O
extrapolate	O
beyond	O
datasets	B-C0150098
,	O
and	O
to	O
make	O
policy	B-C0242456
.	O
	
some	O
of	O
these	O
heuristics	B-C0597916
are	O
based	O
on	O
causal	O
generalisations	B-C0205556
,	O
yet	O
can	O
misfire	O
when	O
these	O
relationships	B-C0439849
are	O
presumed	O
rather	O
than	O
tested	O
e.g	O
.	O
	
surrogates	B-C4053457
in	O
clinical	B-C0008976
trials	I-C0008976
.	O
	
others	O
are	O
conventions	B-C0205556
designed	O
to	O
confer	O
stability	B-C0205360
to	O
decision	B-C0011108
analysis	I-C0011108
,	O
yet	O
which	O
may	O
introduce	O
serious	O
error	B-C0743559
when	O
applied	O
ritualistically	O
e.g	O
.	O
	
significance	B-C0039593
testing	I-C0039593
.	O
	
some	O
heuristics	B-C0597916
can	O
be	O
traced	O
back	O
to	O
formal	O
justifications	B-C0392360
,	O
but	O
only	O
subject	O
to	O
strong	O
assumptions	B-C1254370
that	O
are	O
often	O
violated	O
in	O
practical	B-C0205245
applications	I-C0205245
.	O
	
heuristic	B-C0597916
decision	B-C0870077
rules	I-C0870077
e.g	O
.	O
	
feasibility	B-C0870077
rules	I-C0870077
in	O
principle	O
act	O
as	O
surrogates	B-C4053457
for	O
utility	B-C0205556
maximisation	I-C0205556
or	O
distributional	B-C1704711
concerns	B-C2699424
,	O
yet	O
in	O
practice	B-C1254372
may	O
neglect	O
costs	B-C0010187
and	I-C0010187
benefits	I-C0010187
,	O
be	O
based	O
on	O
arbitrary	B-C1264693
thresholds	B-C0449864
,	O
and	O
be	O
prone	O
to	O
gaming	O
.	O
	
we	O
highlight	O
the	O
problem	B-C0033213
of	O
rule-entrenchment	B-C1254366
,	O
where	O
analytical	B-C1707391
choices	I-C1707391
that	O
are	O
in	O
principle	O
contestable	O
are	O
arbitrarily	O
fixed	O
in	O
practice	B-C1254372
,	O
masking	O
uncertainty	B-C0087130
and	O
potentially	O
introducing	O
bias	B-C0242568
.	O
	
strategies	B-C0679199
for	O
making	O
risk	B-C0035647
and	O
decision	B-C0011108
analysis	I-C0011108
more	O
rigorous	O
include	O
formalising	O
the	O
assumptions	B-C1254370
and	O
scope	B-C1710028
conditions	B-C1254370
under	O
which	O
heuristics	B-C0597916
should	O
be	O
applied	O
testing	B-C0039593
rather	O
than	O
presuming	O
their	O
underlying	O
empirical	B-C0392360
or	O
theoretical	B-C0392360
justifications	I-C0392360
using	O
sensitivity	B-C0036667
analysis	B-C0936012
,	O
simulations	B-C0679083
,	O
multiple	B-C0242481
bias	I-C0242481
analysis	I-C0242481
,	O
and	O
deductive	B-C0282574
systems	I-C0282574
of	I-C0282574
inference	I-C0282574
e.g	O
.	O
	
directed	B-C1706232
acyclic	I-C1706232
graphs	I-C1706232
to	O
characterise	O
rule	B-C0870077
uncertainty	B-C0087130
and	O
refine	O
heuristics	B-C0597916
adopting	O
""""	O
recovery	B-C1519193
schemes	I-C1519193
""""	O
to	O
correct	O
for	O
known	O
biases	B-C0242568
and	O
basing	O
decision	B-C0870077
rules	I-C0870077
on	O
clearly	O
articulated	O
values	B-C0042295
and	O
evidence	B-C3887511
,	O
rather	O
than	O
multicentric	B-C1334815
castleman	I-C1334815
disease	I-C1334815
of	O
hyaline	B-C0020191
vascular	B-C0005847
variant	B-C0205419
presenting	O
with	O
unusual	B-C2700116
systemic	B-C0205373
manifestations	B-C1280464
a	O
case	B-C0007320
report	I-C0007320
castleman	B-C1334815
disease	I-C1334815
is	O
a	O
rare	B-C0522498
lymphoproliferative	B-C0024314
disorder	I-C0024314
presenting	O
with	O
localized	B-C0392752
or	O
disseminated	B-C0205221
lymphadenopathy	B-C0497156
and	O
systemic	B-C0205373
manifestations	B-C1280464
.	O
	
it	O
can	O
be	O
categorized	B-C0008902
in	O
numerous	B-C0439064
ways	O
,	O
such	O
as	O
unicentric	B-C0017531
versus	O
multicentric	B-C1334815
,	O
histopathological	B-C0243140
variants	B-C0205419
hyaline	B-C0020191
-	O
vascular	B-C0005847
,	O
plasma	B-C0032112
cell	I-C0032112
,	O
and	O
mixed	B-C0205419
,	O
or	O
subtypes	B-C0872379
based	O
on	O
causative	B-C0449411
viral	B-C0042769
infections	I-C0042769
human	B-C0019682
immunodeficiency	I-C0019682
virus	I-C0019682
,	O
human	B-C0376526
herpesvirus-8	I-C0376526
,	O
or	O
kaposi	B-C0376526
sarcoma	I-C0376526
herpesvirus	I-C0376526
.	O
	
presentation	O
ranges	O
from	O
asymptomatic	B-C0231221
to	O
symptoms	B-C1457887
involving	O
multiple	B-C0439064
organs	B-C0178784
.	O
	
even	O
though	O
the	O
exact	O
mechanism	B-C0441712
of	O
pathogenesis	B-C0699748
is	O
unknown	O
,	O
treatment	B-C1522326
is	O
directed	B-C1879741
toward	O
possible	O
etiologies	B-C0015127
such	O
as	O
interleukin-6	B-C0021760
,	O
cluster	B-C0054946
of	I-C0054946
differentiation	I-C0054946
20	I-C0054946
,	O
and	O
viral	B-C0521026
agents	I-C0521026
.	O
	
a	O
36-	O
year	B-C0439234
-old	O
sri	B-C1553327
lankan	I-C1553327
woman	B-C0043210
presented	O
with	O
generalized	O
body	B-C0577596
swelling	I-C0577596
and	O
foamy	B-C2188715
urine	I-C2188715
of	O
2	O
weeks	B-C0439230
'	O
duration	B-C0449238
.	O
	
examination	B-C0582103
revealed	O
pallor	B-C0030232
generalized	B-C1850534
edema	I-C1850534
axillary	B-C0004454
,	O
cervical	B-C0205064
,	O
and	O
inguinal	B-C0578736
lymphadenopathy	I-C0578736
hypertension	B-C0020538
and	O
hepatomegaly	B-C0019209
.	O
	
investigations	B-C1261322
showed	O
bicytopenia	B-C1142446
,	O
nephrotic	B-C0445118
range	I-C0445118
proteinuria	I-C0445118
with	O
hypoalbuminemia	B-C0239981
,	O
hypogammaglobulinemia	B-C0086438
,	O
and	O
features	B-C2348519
of	O
hyaline	B-C0020191
-	O
vascular	B-C0005847
type	B-C0332307
castleman	B-C1334815
disease	I-C1334815
in	O
a	O
lymph	B-C0193842
node	I-C0193842
biopsy	I-C0193842
.	O
	
she	O
was	O
managed	B-C0086583
with	O
rituximab	B-C0393022
and	O
had	O
good	O
clinical	B-C0205210
improvement	B-C2986411
.	O
	
castleman	B-C1334815
disease	I-C1334815
has	O
a	O
broad	B-C0332464
spectrum	B-C2827424
of	O
clinical	B-C0205210
manifestations	B-C1280464
,	O
disease	B-C0012634
pathogeneses	B-C0699748
,	O
and	O
associations	B-C0205556
and/or	O
complications	B-C0009566
.	O
	
medical	B-C0205476
professionals	B-C1704312
need	O
to	O
be	O
familiar	O
with	O
this	O
spectrum	B-C2827424
because	O
timely	O
diagnosis	B-C0011900
and	O
aggressive	B-C2985566
targeted	I-C2985566
therapy	I-C2985566
are	O
the	O
cornerstones	O
of	O
managing	O
these	O
the	O
ages-reykjavik	B-C0004171
study	I-C0004171
atlases	I-C0004171
non-linear	B-C0206165
multi-spectral	B-C1705542
template	I-C1705542
and	O
atlases	B-C0004171
for	O
studies	B-C2603343
of	O
the	O
ageing	B-C0001811
brain	B-C0006104
quantitative	B-C0034384
analyses	I-C0034384
of	O
brain	B-C0006104
structures	B-C0678594
from	O
magnetic	B-C0024485
resonance	I-C0024485
mr	B-C0024485
image	B-C0024485
data	B-C1511726
are	O
often	O
performed	O
using	O
automatic	B-C0205554
segmentation	B-C2697664
algorithms	B-C0002045
.	O
	
many	O
of	O
these	O
algorithms	B-C0002045
rely	O
on	O
templates	B-C1705542
and	O
atlases	B-C0004171
in	O
a	O
common	O
coordinate	B-C1183514
space	I-C1183514
.	O
	
most	O
freely	B-C1996904
available	B-C0470187
brain	B-C0006104
atlases	B-C0004171
are	O
generated	O
from	O
relatively	O
young	B-C0332239
individuals	B-C0027361
and	O
not	O
always	O
derived	O
from	O
well-defined	O
cohort	B-C0009247
studies	I-C0009247
.	O
	
in	O
this	O
paper	O
,	O
we	O
introduce	O
a	O
publicly	B-C0678367
available	B-C0470187
multi-spectral	B-C1705542
template	I-C1705542
with	O
corresponding	O
tissue	B-C0040300
probability	B-C0033204
atlases	B-C0004171
and	O
regional	B-C0205147
atlases	B-C0004171
,	O
optimised	B-C2698650
to	O
use	O
in	O
studies	B-C2603343
of	O
ageing	B-C0001811
cohorts	B-C0599755
mean	O
age	O
75	O
5	O
years	O
.	O
	
furthermore	O
,	O
we	O
provide	O
validation	B-C1519941
data	B-C1511726
from	O
a	O
regional	B-C0205147
segmentation	B-C2697664
pipeline	O
to	O
assure	O
the	O
integrity	B-C1947912
of	O
the	O
comparative	B-C0683941
and	O
evolutionary	B-C0936012
analysis	I-C0936012
of	O
an	O
adapter	B-C1417530
molecule	I-C1417530
myd88	I-C1417530
in	O
invertebrate	B-C0021948
metazoans	B-C2713498
the	O
myeloid	B-C1417530
differentiation	I-C1417530
factor	I-C1417530
88	I-C1417530
myd88	B-C1417530
is	O
an	O
essential	O
adapter	O
in	O
toll-like	B-C0670896
receptor	I-C0670896
tlr	B-C0670896
signalling	B-C0037083
pathways	I-C0037083
,	O
with	O
tlr	B-C0670896
the	O
first	O
pattern-recognition	B-C1564907
receptor	I-C1564907
prr	B-C1564907
that	O
was	O
discovered	O
in	O
drosophila	B-C0013138
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
a	O
myd88	B-C1417530
gene	I-C1417530
was	O
identified	B-C0205396
and	O
characterized	B-C1880022
from	O
a	O
commercially	O
important	O
shellfish	B-C1304606
,	O
scapharca	B-C3346701
subcrenata	I-C3346701
,	O
including	O
a	O
death	B-C1511738
domain	I-C1511738
and	O
tir	B-C1956034
domain	I-C1956034
conserved	O
within	O
other	O
molluscs	B-C0026391
.	O
	
furthermore	O
,	O
comparative	B-C0796358
genomic	I-C0796358
evidence	I-C0796358
revealed	O
that	O
myd88	B-C1417530
was	O
of	O
different	B-C1705242
lengths	B-C1444754
and	O
contained	O
quantitative	B-C0392762
exon	B-C0015295
and	O
intron	B-C0021920
regions	I-C0021920
,	O
which	O
might	O
be	O
involved	O
in	O
specific	B-C0441712
mechanisms	I-C0441712
.	O
	
to	O
further	O
explore	O
the	O
phylogenetic	B-C1519068
relationships	I-C1519068
of	O
invertebrate	B-C0021948
metazoan	B-C2713498
myd88	B-C1417530
,	O
we	O
applied	O
mrbayes	B-C0037589
and	I-C0037589
phyml	I-C0037589
software	I-C0037589
to	O
construct	B-C2827421
phylogenetic	B-C1519069
trees	I-C1519069
using	O
bayesian	B-C0242196
and	O
maximum	B-C0024970
likelihood	I-C0024970
approaches	I-C0024970
,	O
respectively	O
,	O
which	O
suggested	O
that	O
the	O
myd88	B-C1417530
of	O
arthropoda	B-C0003903
was	O
closely	O
related	O
to	O
lower	B-C0205251
invertebrates	B-C0021948
,	O
in	O
contrast	B-C1979874
to	O
morphological	B-C0543482
taxonomy	B-C0087066
.	O
	
finally	O
,	O
we	O
investigated	B-C1292732
the	O
evolutionary	B-C0015219
patterns	I-C0015219
and	O
location	O
of	O
positive	B-C0678933
selection	I-C0678933
sites	I-C0678933
psss	B-C0678933
in	O
the	O
myd88	B-C1417530
gene	I-C1417530
from	O
arthropoda	B-C0003903
,	O
mollusca	B-C0026391
and	O
insecta	B-C0021585
using	O
paml	B-C0037589
software	I-C0037589
with	O
the	O
maximum	B-C0025663
likelihood	I-C0025663
method	I-C0025663
.	O
	
the	O
data	B-C1511726
showed	O
that	O
positive	B-C0678933
selection	I-C0678933
sites	I-C0678933
were	O
detected	B-C0442726
in	O
these	O
groups	B-C1257890
,	O
and	O
partial	B-C0002518
sites	I-C0002518
were	O
located	O
in	O
the	O
tir	B-C1956034
domain	I-C1956034
but	O
were	O
not	B-C0442737
found	I-C0442737
in	O
the	O
death	B-C1511738
domain	I-C1511738
.	O
	
to	O
summarize	O
,	O
in	O
this	O
study	B-C2603343
,	O
we	O
report	O
on	O
the	O
diversification	B-C0680948
of	O
myd88	B-C1417530
in	O
invertebrate	B-C0021948
metazoans	B-C2713498
,	O
the	O
specific	B-C0205369
evolutionary	B-C0015219
position	I-C0015219
of	O
arthropoda	B-C0003903
myd88	B-C1417530
,	O
and	O
the	O
positive	B-C1446409
selection	B-C0036576
pressures	I-C0036576
on	O
myd88	B-C1417530
of	O
arthropoda	B-C0003903
,	O
mollusca	B-C0026391
and	O
insecta	B-C0021585
.	O
	
these	O
results	B-C1274040
are	O
a	O
valuable	B-C1880177
contribution	I-C1880177
to	O
understand	O
and	O
clarify	B-C2986669
the	O
evolutionary	B-C0015219
pattern	I-C0015219
of	O
tlr	B-C0670896
/	O
myd88	B-C1417530
signalling	B-C0037083
pathways	I-C0037083
in	O
invertebrate	B-C0021948
and	O
vertebrate	B-C0042567
taxa	I-C0042567
.	O
	
rubinstein-taybi	B-C0035934
syndrome	I-C0035934
associated	B-C0332281
with	I-C0332281
pituitary	B-C0346308
macroadenoma	I-C0346308
a	O
case	B-C0085973
report	I-C0085973
rubinstein-taybi	B-C0035934
syndrome	I-C0035934
rsts	B-C0035934
is	O
an	O
autosomal	B-C3899989
dominant	I-C3899989
disorder	I-C3899989
that	O
is	O
classically	O
characterized	B-C1880022
by	O
prenatal	B-C2828394
and	O
postnatal	B-C0443281
growth	B-C0151686
restriction	I-C0151686
,	O
microcephaly	B-C0025958
,	O
dysmorphic	B-C0432072
craniofacial	I-C0432072
features	I-C0432072
,	O
broad	B-C0426891
thumbs	I-C0426891
and	O
toes	B-C1865038
,	O
and	O
intellectual	B-C3714756
disability	I-C3714756
.	O
	
we	O
describe	O
the	O
first	O
reported	O
case	O
of	O
a	O
pituitary	B-C0346308
macroadenoma	I-C0346308
associated	B-C0332281
with	I-C0332281
rsts	B-C0035934
.	O
	
a	O
39-year-old	O
caucasian	B-C0043157
female	B-C0043210
with	O
a	O
past	B-C0455458
medical	I-C0455458
history	I-C0455458
of	O
rsts	B-C0035934
diagnosed	B-C0011900
at	O
age	B-C0001779
two	O
was	O
found	O
to	O
have	O
a	O
gadolinium	B-C0016911
-enhancing	O
pituitary	B-C0342419
mass	I-C0342419
on	O
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
mri	B-C0024485
of	O
the	O
brain	B-C0006104
three	O
years	B-C0439234
ago	O
during	O
workup	O
for	O
migraine-like	B-C0018681
headaches	I-C0018681
.	O
	
subsequent	O
serial	O
imaging	B-C0011923
showed	O
radiographic	B-C3887511
evidence	I-C3887511
of	O
growth	B-C0018270
up	O
to	O
11.5	O
x	O
14.0	O
x	O
10.0	O
mm	O
in	O
size	B-C0456389
.	O
	
the	O
pituitary	B-C0032005
sellar	B-C0221198
lesion	I-C0221198
was	O
resected	B-C0015252
through	O
an	O
endoscopic	B-C0442418
transnasal	B-C3897344
transsphenoidal	B-C0205508
approach	I-C0205508
and	O
was	O
found	O
to	O
be	O
a	O
thyrotroph	B-C0346303
adenoma	I-C0346303
.	O
	
rsts	B-C0035934
is	O
a	O
rare	B-C0522498
,	O
neurodevelopmental	B-C1535926
genetic	B-C0019247
disease	I-C0019247
where	O
most	O
patients	B-C0018576
with	I-C0018576
disabilities	I-C0018576
survive	B-C0038952
into	O
adulthood	B-C0700597
.	O
	
the	O
disorder	B-C0012634
is	O
associated	B-C0332281
with	I-C0332281
an	O
increased	B-C0205217
predisposition	B-C0220898
for	O
development	B-C1527148
of	O
nervous	B-C0027766
system	I-C0027766
tumors	I-C0027766
,	O
including	O
pituitary	B-C0032000
adenomas	I-C0032000
.	O
	
the	O
clinico-	O
radiological	B-C0039431
paradox	B-C0221733
of	O
cognitive	B-C0392335
function	I-C0392335
and	O
mri	B-C0024485
burden	B-C2828008
of	O
white	B-C0682708
matter	I-C0682708
lesions	B-C0221198
in	O
people	B-C0027361
with	O
multiple	B-C0026769
sclerosis	I-C0026769
a	O
systematic	B-C1955832
review	I-C1955832
and	O
meta-analysis	B-C0282458
moderate	B-C0205081
correlation	B-C1707520
exists	O
between	O
the	O
imaging	B-C2984008
quantification	I-C2984008
of	O
brain	B-C0006104
white	B-C0682708
matter	I-C0682708
lesions	B-C0221198
and	O
cognitive	B-C1516691
performance	B-C0597198
in	O
people	B-C0027361
with	O
multiple	B-C0026769
sclerosis	I-C0026769
ms	B-C0026769
.	O
	
this	O
may	O
reflect	O
the	O
greater	O
importance	O
of	O
other	O
features	B-C2348519
,	O
including	O
subvisible	O
pathology	B-C0030664
,	O
or	O
methodological	B-C3266812
limitations	B-C0449295
of	O
the	O
primary	B-C0205225
literature	B-C0023866
.	O
	
to	O
summarise	O
the	O
cognitive	B-C1516691
clinico-	O
radiological	B-C0039431
paradox	B-C0221733
and	O
explore	O
the	O
potential	B-C3245505
methodological	B-C3266812
factors	B-C1521761
that	O
could	O
influence	O
the	O
assessment	B-C1516048
of	O
this	O
relationship	B-C0439849
.	O
	
systematic	B-C1955832
review	I-C1955832
and	O
meta-analysis	B-C0282458
of	O
primary	B-C0205225
research	B-C0035168
relating	O
cognitive	B-C0392335
function	I-C0392335
to	O
white	B-C0682708
matter	I-C0682708
lesion	B-C0221198
burden	B-C2828008
.	O
	
fifty	O
papers	B-C0030351
met	O
eligibility	B-C1512693
criteria	I-C1512693
for	O
review	B-C0282443
,	O
and	O
meta-analysis	B-C0282458
of	O
overall	O
results	B-C1274040
was	O
possible	O
in	O
thirty-two	O
2050	O
participants	B-C0679646
.	O
	
aggregate	B-C0205418
correlation	B-C1707520
between	O
cognition	B-C0009240
and	O
t2	B-C0475373
lesion	B-C0221198
burden	B-C2828008
was	O
r	O
=	O
-0	O
95%	O
confidence	B-C0009667
interval	I-C0009667
-0	O
,	O
-0	O
.	O
	
wide	O
methodological	B-C3266812
variability	B-C2827666
was	O
seen	O
,	O
particularly	O
related	O
to	O
key	O
factors	B-C1521761
in	O
the	O
cognitive	B-C1516691
data	B-C1511726
capture	O
and	O
image	B-C0200765
analysis	I-C0200765
techniques	I-C0200765
.	O
	
resolving	O
the	O
persistent	O
clinico-	O
radiological	B-C0039431
paradox	B-C0221733
will	O
likely	O
require	O
simultaneous	O
evaluation	B-C0220825
of	O
multiple	B-C0439064
components	B-C1705248
of	O
the	O
complex	B-C0439855
pathology	B-C0030664
using	O
optimum	B-C2698651
measurement	B-C0242485
techniques	B-C0449851
for	O
both	O
cognitive	B-C1516691
and	O
mri	B-C0024485
feature	B-C2348519
quantification	B-C1709793
.	O
	
we	O
recommend	O
a	O
consensus	B-C0376298
initiative	O
to	O
support	O
common	O
standards	B-C1442989
for	O
image	B-C0200765
analysis	I-C0200765
in	O
ms	B-C0026769
,	O
enabling	O
benchmarking	B-C0525063
while	O
also	O
supporting	O
ongoing	O
long	B-C3494264
non-coding	I-C3494264
rna	I-C3494264
snhg6	B-C1822801
as	O
a	O
potential	O
biomarker	B-C0041365
for	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
long	B-C3494264
non-coding	I-C3494264
rnas	I-C3494264
lncrnas	B-C3494264
refer	O
to	O
all	O
non-protein	B-C0887909
coding	I-C0887909
transcripts	B-C1519595
longer	O
than	O
200	O
nucleotides	B-C0028630
.	O
	
their	O
critical	O
roles	O
in	O
different	O
biological	B-C0205460
pathways	B-C1705987
have	O
been	O
already	O
well	O
established	O
.	O
	
altered	O
expression	B-C0017262
of	O
lncrnas	B-C3494264
can	O
be	O
involved	O
in	O
the	O
cancer	B-C0598935
initiation	I-C0598935
and/or	O
progression	B-C0178874
.	O
	
since	O
patients	B-C0030705
with	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
hcc	B-C2239176
are	O
usually	O
diagnosed	B-C0011900
in	O
late	B-C1279941
stages	I-C1279941
,	O
developing	O
diagnostic	B-C0920688
methods	I-C0920688
seems	O
to	O
be	O
essential	O
.	O
	
in	O
this	O
study	B-C2603343
,	O
the	O
expression	B-C0017262
levels	O
of	O
different	O
lncrnas	B-C3494264
were	O
systematically	O
analysed	B-C0936012
in	O
different	O
genomic	B-C0150098
and	O
transcriptome	B-C0150098
datasets	I-C0150098
.	O
	
the	O
analyses	B-C0936012
showed	O
that	O
snhg6	B-C1822801
is	O
among	O
the	O
lncrnas	B-C3494264
with	O
distinctive	O
dysregulation	B-C0017263
of	O
expression	B-C0017262
and	O
copy	O
number	O
variation	O
in	O
hcc	B-C2239176
tumors	I-C2239176
compared	O
with	O
normal	B-C0040300
tissues	I-C0040300
.	O
	
the	O
results	O
also	O
suggest	O
that	O
the	O
dysregulation	B-C0017263
of	O
snhg6	B-C1822801
is	O
highly	O
cancer	B-C0006826
type	O
specific	O
.	O
	
through	O
co-occurrence	O
analyses	B-C0936012
,	O
we	O
found	O
that	O
snhg6	B-C1822801
and	O
its	O
related	O
co-expressed	B-C0017262
genes	B-C0017337
on	O
8q	B-C1515445
are	O
involved	O
in	O
the	O
structural	B-C0678594
integrity	B-C1947912
of	O
ribosome	B-C0035553
and	O
translation	B-C1519614
.	O
	
this	O
comprehensive	B-C1880156
in	B-C3489666
silico	I-C3489666
analysis	B-C0936012
,	O
provides	O
a	O
resource	O
for	O
investigating	B-C1292732
snhg6	B-C1822801
in	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
and	O
lays	O
the	O
groundwork	O
for	O
design	O
of	O
next	O
expressional	B-C0017262
divergence	B-C0443204
of	O
insect	B-C0021585
gox	B-C1415468
genes	I-C1415468
from	O
specialist	O
to	O
generalist	O
glucose	B-C0017735
oxidase	I-C0017735
insect	B-C0021585
herbivores	I-C0021585
often	O
secrete	B-C1327616
glucose	B-C0017735
oxidase	I-C0017735
gox	B-C0017735
onto	O
plants	B-C0032098
to	O
counteract	B-C1947978
plant	B-C0032098
defenses	B-C1880266
and	O
potential	B-C3245505
pathogens	B-C0450254
.	O
	
whether	O
generalist	O
herbivores	B-C0021585
always	O
have	O
significantly	B-C4055637
higher	I-C4055637
gox	B-C0017735
activities	B-C0441655
than	O
their	O
specialist	O
counterparts	B-C1947978
at	O
any	O
comparable	O
stage	O
or	O
conditions	O
and	O
how	O
this	O
is	O
realized	O
remain	O
unknown	O
.	O
	
to	O
address	O
these	O
two	O
general	O
questions	O
,	O
we	O
subjected	O
larvae	B-C0023047
of	O
a	O
pair	O
of	O
sister	O
species	B-C1705920
differed	O
mainly	O
in	O
host	O
range	O
,	O
the	O
generalist	O
helicoverpa	B-C1002429
armigera	I-C1002429
and	O
its	O
specialist	O
counterpart	B-C1947978
helicoverpa	B-C1093556
assulta	I-C1093556
,	O
to	O
the	O
same	O
sets	O
of	O
stage	O
,	O
protein	B-C0033684
to	O
digestible	B-C0012238
carbohydrate	B-C0453802
p	O
ratio	O
,	O
allelochemical	B-C1135843
or	O
host	B-C0868970
plant	I-C0868970
treatments	B-C1522326
for	O
simultaneous	O
analyses	O
of	O
gox	B-C1415468
transcripts	B-C1519595
and	O
activities	B-C0441655
in	O
their	O
labial	B-C0226928
glands	I-C0226928
.	O
	
gox	B-C1415468
activity	B-C0441655
and	O
transcripts	B-C1519595
are	O
upregulated	B-C0041904
concurrently	O
with	O
food	B-C0016452
ingestion	B-C0232478
and	O
body	B-C0231256
growth	I-C0231256
,	O
downregulated	B-C0013081
with	O
stopping	O
ingestion	B-C0232478
and	O
wandering	B-C0233569
for	O
pupation	B-C1326578
in	O
both	O
species	B-C1705920
.	O
	
the	O
three	O
tested	O
host	B-C0868970
plants	I-C0868970
upregulated	B-C0041904
gox	B-C1415468
transcripts	B-C1519595
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
gox	B-C1415468
activity	B-C0441655
in	O
both	O
species	B-C1705920
.	O
	
there	O
were	O
significant	O
differences	O
in	O
both	O
gox	B-C1415468
transcripts	B-C1519595
and	O
activity	B-C0441655
elicited	O
by	O
allelochemicals	B-C1135843
,	O
but	O
only	O
in	O
gox	B-C1415468
transcripts	B-C1519595
by	O
p	O
ratios	O
in	O
both	O
species	B-C1705920
.	O
	
gox	B-C0017735
activities	B-C0441655
were	O
higher	O
in	O
h	B-C1002429
.	O
	
armigera	I-C1002429
than	O
h	B-C1093556
.	O
	
assulta	I-C1093556
in	O
all	O
the	O
comparable	O
treatments	O
,	O
but	O
gox	B-C1415468
transcripts	B-C1519595
were	O
significantly	B-C4055637
higher	I-C4055637
either	O
in	O
generalists	O
or	O
in	O
specialists	O
,	O
depending	O
on	O
the	O
developmental	B-C0870411
stages	I-C0870411
,	O
host	B-C0868970
plants	I-C0868970
,	O
p	O
ratio	O
and	O
allelochemicals	B-C1135843
they	O
encounter	B-C1947978
.	O
	
these	O
data	B-C1511726
indicate	O
that	O
the	O
greater	B-C1704243
gox	B-C0017735
activity	B-C0441655
in	O
generalist	O
herbivores	B-C0021585
is	O
not	O
achieved	O
by	O
greater	B-C1704243
transcription	B-C0040649
rate	O
,	O
but	O
by	O
greater	O
transcript	B-C1519595
stability	O
,	O
greater	O
translation	B-C1519614
rate	O
,	O
better	B-C0014439
enzyme	I-C0014439
stability	I-C0014439
propranolol	B-C0033497
effects	O
on	O
decompression	B-C0011119
sickness	I-C0011119
in	O
a	O
simulated	O
dissub	B-C0221094
rescue	B-C0242857
in	O
swine	B-C1135183
disabled	B-C0221094
submarine	I-C0221094
dissub	B-C0221094
survivors	B-C1171334
may	O
face	O
elevated	B-C0020440
co2	I-C0020440
levels	I-C0020440
and	O
inert	B-C0545273
gas	I-C0545273
saturation	I-C0545273
,	O
putting	O
them	O
at	O
risk	O
for	O
co2	B-C0007012
toxicity	B-C0040539
and	O
decompression	B-C0011119
sickness	I-C0011119
dcs	B-C0011119
.	O
	
propranolol	B-C0033497
was	O
shown	O
to	O
reduce	B-C0201930
co2	I-C0201930
production	I-C0201930
in	O
an	O
experimental	O
dissub	B-C0221094
model	B-C0026336
in	O
humans	B-C0086418
but	O
its	O
effects	O
on	O
dcs	B-C0011119
in	O
a	O
dissub	B-C0221094
rescue	B-C0242857
scenario	I-C0242857
are	O
unknown	O
.	O
	
a	O
100%	O
oxygen	B-C0035203
prebreathe	I-C0035203
opb	B-C0035203
reduces	O
dcs	B-C0011119
incidence	O
and	O
severity	O
and	O
is	O
incorporated	O
into	O
some	O
dissub	B-C0221094
rescue	B-C0242857
protocols	I-C0242857
.	O
	
we	O
used	O
a	O
swine	B-C1135183
model	I-C1135183
of	O
dissub	B-C0221094
rescue	B-C0242857
to	O
study	O
the	O
effect	O
of	O
propranolol	B-C0033497
on	O
dcs	B-C0011119
incidence	O
and	O
mortality	B-C0205848
with	O
and	O
without	O
an	O
opb	B-C0035203
.	O
	
in	O
experiment	O
1	O
,	O
male	B-C0086582
yorkshire	B-C0324292
swine	I-C0324292
70	O
kg	O
were	O
pressurized	B-C0033095
to	O
2.8	O
ata	O
for	O
22	O
h	O
.	O
	
propranolol	B-C0033497
1.0	O
mg	O
kg-1	O
iv	O
was	O
administered	B-C1521801
at	I-C1521801
21.25	O
h	O
.	O
	
at	O
22	O
h	O
,	O
the	O
animal	B-C0003062
was	O
rapidly	B-C1965697
decompressed	I-C1965697
and	O
observed	O
for	O
dcs	B-C0011119
type	O
,	O
onset	B-C0449244
time	I-C0449244
,	O
and	O
mortality	B-C0205848
.	O
	
experimental	O
animals	B-C0003062
n	O
=	O
21	O
69	O
4.1	O
kg	O
,	O
prop1.0	B-C0033497
,	O
were	O
compared	O
to	O
prop1.0	B-C0033497
-	O
opb45	B-C0035203
n	O
=	O
8	O
69	O
2.8	O
kg	O
with	O
the	O
same	O
dive	B-C0178599
profile	O
,	O
except	O
for	O
a	O
45	O
min	O
opb	B-C0035203
prior	O
to	O
decompression	B-C1965697
.	O
	
in	O
experiment	O
2	O
,	O
the	O
same	O
methodology	B-C3266812
was	O
used	O
with	O
the	O
following	O
changes	O
swine	B-C1135183
pressurized	B-C0033095
to	O
2.8	O
ata	O
for	O
28	O
h	O
experimental	O
group	O
n	O
=	O
25	O
67	O
3.3	O
kg	O
,	O
prop0.5	B-C0033497
bis	O
,	O
propranolol	B-C0033497
0.5	O
mg	O
kg-1	O
bis	O
twice	O
iv	O
was	O
administered	B-C1521801
at	I-C1521801
22	O
h	O
and	O
26	O
h	O
.	O
	
control	B-C1511501
animals	I-C1511501
n	O
=	O
25	O
67	O
3.9	O
kg	O
received	O
normal	B-C0445115
saline	I-C0445115
.	O
	
opb	B-C0035203
reduced	B-C0205848
mortality	I-C0205848
in	O
prop1.0	B-C0033497
-	O
obp45	B-C0035203
compared	O
to	O
prop1.0	B-C0033497
0%	O
vs	O
.	O
	
71%	O
.	O
	
prop0.5	B-C0033497
bis	O
had	O
increased	B-C0205848
mortality	I-C0205848
compared	O
to	O
control	O
60-%	O
vs	O
.	O
	
4%	O
.	O
	
administration	O
of	O
beta	B-C0001645
blockers	I-C0001645
prior	O
to	O
saturation	B-C1965697
decompression	I-C1965697
appears	O
to	O
increase	O
dcs	B-C0011119
and	O
worsen	B-C0205848
mortality	I-C0205848
in	O
a	O
swine	B-C1135183
model	B-C0026336
however	O
,	O
their	O
effects	O
in	O
bounce	B-C0178599
diving	I-C0178599
gut	B-C4018878
microbiota	I-C4018878
-mediated	O
protection	B-C1545588
against	O
diarrheal	B-C0011991
infections	B-C3714514
the	O
mammalian	B-C0024660
gut	B-C4018878
microbiota	I-C4018878
is	O
a	O
highly	O
abundant	O
and	O
diverse	O
microbial	B-C0445623
community	B-C0009462
that	O
resides	B-C2982691
in	O
the	O
gastrointestinal	B-C0017189
tract	I-C0017189
.	O
	
one	O
major	O
benefit	O
that	O
the	O
gut	B-C4018878
microbiota	I-C4018878
provides	O
to	O
its	O
host	B-C1167395
is	O
colonization	B-C4289767
resistance	B-C4281815
-the	O
ability	O
to	O
prevent	B-C0205245
colonization	B-C4289767
by	O
foreign	B-C0445623
microbes	I-C0445623
,	O
including	O
diarrheal	B-C0011991
pathogens	B-C0450254
such	O
as	O
clostridium	B-C0079134
difficile	I-C0079134
,	O
salmonella	B-C0036126
enterica	I-C0036126
serovar	I-C0036126
typhimurium	I-C0036126
and	O
diarrheagenic	B-C1264842
escherichia	I-C1264842
coli	I-C1264842
.	O
	
we	O
conducted	O
a	O
literature	B-C0282441
review	I-C0282441
of	O
the	O
effects	B-C1704420
of	I-C1704420
the	O
gut	B-C4018878
microbiota	I-C4018878
on	O
infection	B-C3714514
by	O
diarrheal	B-C0011991
pathogens	B-C0450254
.	O
	
we	O
used	O
pubmed	B-C1138432
to	O
search	O
for	O
relevant	O
articles	B-C1706852
published	O
before	O
july	O
2016	O
,	O
as	O
well	O
as	O
incorporated	O
data	B-C1511726
from	O
our	O
laboratory	B-C0022877
.	O
	
the	O
gut	B-C4018878
microbiota	I-C4018878
provides	O
protection	B-C1545588
from	O
diarrheal	B-C0011991
infections	B-C3714514
both	O
by	O
direct	B-C1947931
inhibition	B-C3463820
of	O
pathogens	B-C0450254
and	O
by	O
indirect	B-C0439852
effects	B-C1280500
on	O
host	B-C1167395
functions	B-C0542341
.	O
	
direct	B-C1947931
effects	B-C1704420
of	I-C1704420
the	O
microbiota	B-C4018878
on	O
diarrheal	B-C0011991
pathogens	B-C0450254
include	O
competing	O
for	O
nutrients	B-C0678695
and	O
producing	O
metabolites	B-C0870883
that	O
inhibit	B-C0205245
pathogen	B-C0450254
growth	B-C0018270
or	O
virulence	B-C0042765
.	O
	
indirect	B-C0439852
effects	B-C1704420
of	I-C1704420
the	O
gut	B-C4018878
microbiota	I-C4018878
include	O
promoting	O
maintenance	B-C0024501
of	O
the	O
gut	B-C0232577
mucosal	I-C0232577
barrier	I-C0232577
and	O
stimulating	O
innate	B-C0020969
and	O
adaptive	B-C0678209
immunity	I-C0678209
.	O
	
human	B-C0086418
epidemiological	B-C0002783
studies	I-C0002783
and	O
experimental	B-C1517586
infections	B-C3714514
of	O
laboratory	B-C0003064
animals	I-C0003064
both	O
demonstrate	O
that	O
antibiotic	B-C0338237
treatment	I-C0338237
can	O
alter	O
the	O
gut	B-C4018878
microbial	I-C4018878
community	B-C0009462
and	O
thereby	O
reduce	O
colonization	B-C4289767
resistance	B-C4281815
against	O
diarrheal	B-C0011991
pathogens	B-C0450254
.	O
	
further	O
research	B-C0035168
might	O
lead	O
to	O
the	O
development	B-C1527148
of	O
next-generation	B-C0525033
probiotics	I-C0525033
that	O
could	O
be	O
used	O
to	O
bolster	O
colonization	B-C4289767
resistance	B-C4281815
and	O
thus	O
prevent	B-C0205245
travellers'	B-C0277528
diarrheal	I-C0277528
.	O
	
ecotoxicity	B-C0600688
testing	B-C0039593
and	O
environmental	B-C4076706
risk	I-C4076706
assessment	I-C4076706
of	O
iron	B-C0302583
nanomaterials	B-C1450053
for	O
sub-surface	O
remediation	B-C3853059
-	O
recommendations	B-C0034866
from	O
the	O
fp7	B-C0700032
project	I-C0700032
nanorem	I-C0700032
nanoremediation	B-C3853059
with	O
iron	B-C0302583
fe	B-C0302583
nanomaterials	B-C1450053
opens	O
new	O
doors	O
for	O
treating	B-C1522326
contaminated	B-C0205279
soil	B-C0037592
and	O
groundwater	B-C0043047
,	O
but	O
is	O
also	O
accompanied	O
by	O
new	O
potential	B-C0035647
risks	I-C0035647
as	O
large	O
quantities	O
of	O
engineered	B-C1450053
nanomaterials	I-C1450053
are	O
introduced	O
into	O
the	O
environment	B-C0014406
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
have	O
assessed	B-C1516048
the	O
ecotoxicity	B-C0600688
of	O
four	O
engineered	O
fe	B-C0302583
nanomaterials	B-C1450053
,	O
specifically	O
,	O
nano-goethite	B-C0300269
,	O
trap-ox	B-C0302583
fe-zeolites	I-C0302583
,	O
carbo-iron	B-C0302583
and	O
fermeg12	B-C0302583
,	O
developed	O
within	O
the	O
european	B-C0700032
fp7	I-C0700032
project	I-C0700032
nanorem	I-C0700032
for	O
sub-surface	O
remediation	B-C3853059
towards	O
a	O
test	B-C0022885
battery	I-C0022885
consisting	O
of	O
eight	O
ecotoxicity	B-C0600688
tests	B-C0022885
on	O
bacteria	B-C0004611
v	B-C0318276
.	O
	
fisheri	I-C0318276
,	O
e	B-C0014834
.	O
	
coli	I-C0014834
,	O
algae	B-C0002028
p	B-C1089415
.	O
	
subcapitata	I-C1089415
,	O
chlamydomonas	B-C0008155
sp	I-C0008155
,	O
crustaceans	B-C0010395
d	B-C1081963
.	O
	
magna	I-C1081963
,	O
worms	B-C0018893
e	B-C0524676
.	O
	
fetida	I-C0524676
,	O
l	B-C0998692
.	O
	
variegatus	I-C0998692
and	O
plants	B-C0032098
r	B-C0996771
.	O
	
sativus	I-C0996771
,	O
l	B-C0331557
.	O
	
multiflorum	I-C0331557
.	O
	
the	O
tested	O
materials	O
are	O
commercially	O
available	O
and	O
include	O
fe	B-C0060240
oxide	I-C0060240
and	O
nanoscale	B-C0302583
zero	I-C0302583
valent	I-C0302583
iron	I-C0302583
nzvi	B-C0302583
,	O
but	O
also	O
hybrid	O
products	O
with	O
fe	B-C0302583
loaded	O
into	O
a	O
matrix	B-C1704640
.	O
	
all	O
but	O
one	O
material	B-C0520510
,	O
a	O
ball	B-C0302583
milled	I-C0302583
nzvi	I-C0302583
fermeg12	B-C0302583
,	O
showed	O
no	B-C1513916
toxicity	I-C1513916
in	O
the	O
test	B-C0022885
battery	I-C0022885
when	O
tested	O
in	O
concentrations	B-C1446561
up	O
to	O
100	O
mg/l	O
,	O
which	O
is	O
the	O
cutoff	B-C1442160
for	O
hazard	B-C0598697
labeling	B-C2827499
in	O
chemicals	B-C0851285
regulation	I-C0851285
in	O
europe	B-C0015176
.	O
	
however	O
it	O
should	O
be	O
noted	O
that	O
fe	B-C0302583
nanomaterials	B-C1450053
proved	O
challenging	O
to	O
test	O
adequately	O
due	O
to	O
their	O
turbidity	B-C0301633
,	O
aggregation	B-C0332621
and	O
sedimentation	B-C1384604
behavior	I-C1384604
in	O
aqueous	B-C0599956
media	B-C1705217
.	O
	
this	O
paper	O
provides	O
a	O
number	O
of	O
recommendations	B-C0034866
concerning	O
future	B-C0039593
testing	I-C0039593
of	O
fe	B-C0302583
nanomaterials	B-C1450053
and	O
discusses	O
environmental	B-C4076706
risk	I-C4076706
assessment	I-C4076706
grade	B-C0008902
group	I-C0008902
underestimation	B-C0243095
in	O
prostate	B-C0194804
biopsy	I-C0194804
predictive	B-C0683956
factors	I-C0683956
and	O
outcomes	B-C1518681
in	O
candidates	B-C1257890
for	O
active	B-C1827061
surveillance	I-C1827061
we	O
intended	O
to	O
analyze	O
the	O
outcomes	B-C1518681
and	O
predictive	B-C0683956
factors	I-C0683956
for	O
underestimating	O
the	O
prostate	B-C0376358
cancer	I-C0376358
pca	B-C0376358
grade	B-C0008902
group	I-C0008902
gg	B-C0008902
from	O
prostate	B-C0194804
biopsies	I-C0194804
in	O
a	O
large	O
monocentric	B-C0599755
cohort	I-C0599755
of	O
patients	B-C0030705
treated	B-C1522326
by	O
minimally	B-C0194810
invasive	I-C0194810
radical	I-C0194810
prostatectomy	I-C0194810
rp	B-C0194810
.	O
	
using	O
a	O
monocentric	B-C0242356
prospectively	I-C0242356
maintained	I-C0242356
database	I-C0242356
,	O
we	O
included	O
3062	O
patients	B-C0030705
who	O
underwent	O
minimally	B-C0194810
invasive	I-C0194810
rp	I-C0194810
between	O
2006	O
and	O
2013	O
.	O
	
we	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	B-C1518681
associated	B-C0332281
with	I-C0332281
a	O
gg	B-C0008902
upgrade	O
from	O
biopsy	B-C0005558
to	O
rp	B-C0194810
.	O
	
multivariate	B-C0206031
logistic	I-C0206031
regression	I-C0206031
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	B-C1450294
to	O
predict	O
upgrading	O
for	O
gg1	B-C0008902
.	O
	
biopsy	B-C0005558
gg	B-C0008902
was	O
upgraded	O
after	O
rp	B-C0194810
in	O
51.5	O
of	O
cases	O
.	O
	
patients	B-C0030705
upgraded	O
from	O
gg1	B-C0008902
to	O
gg2	B-C0008902
or	O
gg3	B-C0008902
after	O
rp	B-C0194810
had	O
a	O
longer	B-C0040223
time	I-C0040223
to	O
biochemical	B-C2985506
recurrence	I-C2985506
than	O
those	O
with	O
gg2	B-C0008902
or	O
gg3	B-C0008902
respectively	O
,	O
on	O
both	O
biopsy	B-C0005558
and	O
rp	B-C0194810
,	O
but	O
a	O
shorter	B-C0040223
time	I-C0040223
to	O
biochemical	B-C2985506
recurrence	I-C2985506
than	O
those	O
who	O
remained	O
gg1	B-C0008902
after	O
rp	O
p	O
<	O
0001	O
.	O
	
in	O
multivariate	B-C0026777
analyses	I-C0026777
,	O
variables	B-C1705098
predicting	O
upgrading	O
for	O
gg1	B-C0008902
pca	B-C0376358
were	O
age	B-C0001779
p	O
=	O
0014	O
,	O
abnormal	B-C1384593
digital	I-C1384593
rectal	I-C1384593
examination	I-C1384593
p	O
<	O
0001	O
,	O
prostate	B-C0033572
-specific	O
antigen	O
density	O
p	O
<	O
0001	O
,	O
percentage	O
of	O
positive	O
cores	O
p	O
<	O
0001	O
,	O
and	O
body	O
mass	O
index	O
p	O
=	O
037	O
.	O
	
a	O
nomogram	O
was	O
generated	O
and	O
validated	O
internally	O
.	O
	
biopsy	O
grading	O
system	O
is	O
misleading	O
in	O
approximately	O
50%	O
of	O
cases	O
.	O
	
upgrading	O
gg	O
from	O
biopsy	O
to	O
rp	O
may	O
have	O
consequences	O
on	O
clinical	O
outcomes	O
.	O
	
a	O
nomogram	O
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	O
of	O
needing	O
to	O
upgrade	O
gg1	O
patients	O
at	O
their	O
initial	O
evaluation	B-C0220825
characterization	B-C1880022
of	O
electrocorticogram	B-C0430797
high	B-C0205250
-	O
gamma	B-C0017011
signal	B-C1710082
in	O
response	B-C0871261
to	O
varying	B-C1705242
upper	B-C1140618
extremity	I-C1140618
movement	B-C0026649
velocity	B-C0439830
the	O
mechanism	B-C0441712
by	O
which	O
the	O
human	B-C0086418
primary	B-C3495441
motor	I-C3495441
cortex	I-C3495441
m1	B-C3495441
encodes	B-C2700640
upper	B-C1140618
extremity	I-C1140618
movement	B-C0026649
kinematics	B-C0600169
is	O
not	O
fully	O
understood	O
.	O
	
for	O
example	O
,	O
human	B-C0086418
electrocorticogram	B-C0430797
ecog	B-C0430797
signals	B-C1710082
have	O
been	O
shown	O
to	O
modulate	B-C0443264
with	O
upper	B-C1140618
extremity	I-C1140618
movement	B-C0026649
s	O
however	O
,	O
this	O
relationship	B-C0439849
has	O
not	O
been	O
explicitly	B-C2963144
characterized	B-C1880022
.	O
	
to	O
address	O
this	O
issue	B-C0033213
,	O
we	O
recorded	B-C3853788
high	B-C0205250
-	O
density	B-C0178587
ecog	B-C0430797
signals	B-C1710082
from	O
patients	B-C0030705
undergoing	O
epilepsy	B-C0014544
surgery	B-C0543467
evaluation	B-C0220825
as	O
they	O
performed	B-C0884358
elementary	B-C0013878
upper	B-C1140618
extremity	I-C1140618
movements	B-C0026649
while	O
systematically	B-C0220922
varying	B-C1705242
movement	B-C0026649
speed	B-C0678536
and	O
duration	B-C0449238
.	O
	
specifically	B-C0205369
,	O
subjects	B-C0681850
performed	B-C0884358
intermittent	B-C0205267
pincer	B-C0429273
grasp	I-C0429273
/	O
release	B-C0391871
,	O
elbow	B-C2215879
flexion	I-C2215879
/	O
extension	B-C0231448
,	O
and	O
shoulder	B-C0575546
flexion	I-C0575546
/	O
extension	B-C0231448
at	O
slow	B-C0439834
,	O
moderate	B-C0205081
,	O
and	O
fast	B-C0456962
speeds	B-C0678536
.	O
	
in	O
all	O
movements	B-C0026649
,	O
bursts	B-C4296482
of	O
power	B-C3854080
in	O
the	O
high	B-C0205250
-	O
see	O
text	O
band	O
80-160	O
hz	O
were	O
observed	B-C1441672
in	O
m1	B-C3495441
.	O
	
in	O
addition	B-C0332287
,	O
the	O
amplitude	B-C2346753
of	O
these	O
power	B-C3854080
bursts	B-C4296482
and	O
the	O
area	B-C0205146
of	O
m1	B-C3495441
with	O
elevated	B-C3163633
high	B-C0205250
-	O
see	O
text	O
activity	B-C0441655
were	O
directly	B-C1947931
proportional	B-C0205351
to	O
the	O
movement	B-C0026649
speed	B-C0678536
.	O
	
likewise	O
,	O
the	O
duration	B-C0449238
of	O
elevated	B-C3163633
high	B-C0205250
-	O
see	O
text	O
activity	B-C0441655
increased	B-C0205217
with	O
movement	B-C0026649
duration	B-C0449238
.	O
	
based	B-C1527178
on	O
linear	B-C0023733
regression	I-C0023733
,	O
m1	B-C3495441
high	B-C0205250
-	O
see	O
text	O
power	B-C3854080
amplitude	B-C2346753
and	O
duration	B-C0449238
covaried	B-C0205419
with	O
movement	B-C0026649
speed	B-C0678536
and	O
duration	B-C0449238
,	O
respectively	O
,	O
with	O
an	O
average	B-C1510992
formula	O
see	O
text	O
of	O
formula	O
see	O
text	O
and	O
formula	O
see	O
text	O
.	O
	
these	O
findings	B-C0243095
indicate	B-C3146298
that	O
the	O
encoding	B-C2700640
of	O
upper	B-C1140618
extremity	I-C1140618
movement	B-C0026649
speed	B-C0678536
by	O
m1	B-C3495441
high	B-C0205250
-	O
see	O
text	O
activity	B-C0441655
is	O
primarily	B-C0205225
linear	B-C0205132
.	O
	
also	O
,	O
the	O
fact	O
that	O
this	O
activity	B-C0441655
remained	O
elevated	B-C3163633
throughout	O
a	O
movement	B-C0026649
suggests	O
that	O
m1	B-C3495441
does	O
not	O
merely	O
generate	O
transient	B-C0205374
instructions	B-C1442085
for	O
a	O
specific	B-C0205369
movement	B-C0026649
duration	B-C0449238
,	O
but	O
instead	O
is	O
responsible	O
for	O
the	O
entirety	B-C0444667
of	O
the	O
movement	B-C0026649
.	O
	
finally	O
,	O
the	O
spatial	B-C0037775
distribution	I-C0037775
of	O
high	B-C0205250
-	O
see	O
text	O
activity	B-C0441655
suggests	O
the	O
presence	B-C0150312
of	O
a	O
recruitment	B-C2949735
phenomenon	B-C1882365
in	O
which	O
higher	B-C0205250
speeds	B-C0678536
or	O
increased	B-C0205217
muscle	B-C0026845
activity	B-C0441655
involve	O
activation	B-C1879547
of	O
larger	O
m1	B-C3495441
area	B-C0205146
fatty	B-C0015684
acids	I-C0015684
have	O
different	B-C1705242
adipogenic	B-C0596843
differentiation	I-C0596843
potentials	B-C3245505
in	O
stromal	B-C0162597
vascular	I-C0162597
cells	I-C0162597
isolated	B-C0205409
from	O
abdominal	B-C1563742
fat	I-C1563742
in	O
laying	B-C1622979
hens	B-C0008051
this	O
study	B-C2603343
was	O
conducted	O
to	O
examine	O
the	O
effects	B-C1704420
of	I-C1704420
fatty	B-C0015684
acids	I-C0015684
fa	B-C0015684
with/without	O
chicken	B-C1440440
serum	I-C1440440
cs	B-C1440440
on	O
the	O
expression	B-C0017262
of	O
adipogenic	B-C0596843
transcripts	B-C1519595
and	O
adipogenesis	B-C0596843
in	O
chicken	B-C0008051
stromal	B-C0162597
vascular	I-C0162597
cells	I-C0162597
svc	B-C0162597
.	O
	
in	O
experiment	O
1	O
,	O
svc	B-C0162597
were	O
grown	O
in	O
dmem	B-C1665363
containing	O
10%	O
fbs	B-C3812213
control	B-C0009932
and	O
treated	B-C1522326
with	O
300	O
µm	O
oleic	B-C0028928
acid	I-C0028928
ola	B-C0028928
+	O
fbs	B-C3812213
,	O
linoleic	B-C0023749
acid	I-C0023749
lna	B-C0023749
+	O
fbs	B-C3812213
,	O
palmitic	B-C0030234
acid	I-C0030234
pam	B-C0030234
+	O
fbs	B-C3812213
,	O
or	O
stearic	B-C0038229
acid	I-C0038229
sta	B-C0038229
+	O
fbs	B-C3812213
for	O
48	O
h	O
.	O
	
in	O
experiment	O
2	O
,	O
cells	B-C0007634
were	O
grown	O
in	O
dmem	B-C1665363
containing	O
5%	O
cs	B-C1440440
and	O
treated	B-C1522326
with	O
300	O
µm	O
ola	B-C0028928
cs	B-C1440440
+	O
ola	B-C0028928
,	O
pam	B-C0030234
cs	B-C1440440
+	O
pam	B-C0030234
,	O
sta	B-C0038229
cs	B-C1440440
+	O
sta	B-C0038229
or	O
200	O
µm	O
lna	B-C0023749
cs	B-C1440440
+	O
lna	B-C0023749
for	O
48	O
h	O
.	O
	
adipogenesis	B-C0596843
was	O
determined	O
using	O
oil	B-C1294000
red	I-C1294000
o	I-C1294000
staining	I-C1294000
and	O
glycerol-3-phosphate	B-C1151278
dehydrogenase	I-C1151278
gpdh	I-C1151278
activity	I-C1151278
.	O
	
the	O
proportion	O
of	O
ola	B-C0028928
,	O
pam	B-C0030234
,	O
or	O
sta	B-C0038229
was	O
increased	B-C0205217
p	O
<	O
0.05	O
in	O
svc	B-C0162597
grown	O
in	O
either	O
fbs	B-C3812213
or	O
cs	B-C1440440
with	O
ola	B-C0028928
,	O
pam	B-C0030234
or	O
sta	B-C0038229
.	O
	
adipogenesis	B-C0596843
was	O
induced	B-C0205263
in	O
fbs	B-C3812213
+	O
ola	B-C0028928
,	O
fbs	B-C3812213
+	O
lna	B-C0023749
,	O
fbs	B-C3812213
+	O
pam	B-C0030234
,	O
fbs	B-C3812213
+	O
sta	B-C0038229
,	O
cs	B-C1440440
+	O
ola	B-C0028928
,	O
cs	B-C1440440
+	O
lna	B-C0023749
,	O
cs	B-C1440440
+	O
pam	B-C0030234
,	O
or	O
cs	B-C1440440
+	O
sta	B-C0038229
compared	O
to	O
fbs	B-C3812213
.	O
	
gpdh	B-C1151278
activity	I-C1151278
was	O
significantly	B-C4055637
higher	I-C4055637
in	O
fbs	B-C3812213
+	O
ola	B-C0028928
and	O
fbs	B-C3812213
+	O
lna	B-C0023749
than	O
one	O
in	O
fbs	B-C3812213
.	O
	
compared	O
to	O
fbs	B-C3812213
,	O
the	O
expression	B-C0017262
of	O
fabp4	B-C1333527
mrna	B-C0035696
increased	B-C0205217
p	O
<	O
0.05	O
in	O
fbs	B-C3812213
+	O
ola	B-C0028928
,	O
fbs	B-C3812213
+	O
lna	B-C0023749
,	O
or	O
fbs	B-C3812213
+	O
pam	B-C0030234
,	O
whereas	O
that	O
of	O
c/ebpα	B-C1413322
,	O
c/ebpβ	B-C1413323
,	O
and	O
atgl	B-C1538686
increased	B-C0205217
p	O
<	O
0.05	O
in	O
fbs	B-C3812213
+	O
ola	B-C0028928
or	O
fbs	B-C3812213
+	O
lna	B-C0023749
cells	B-C0007634
.	O
	
expression	B-C0017262
of	O
fabp4	B-C1333527
and	O
c/ebpβ	B-C1413323
mrna	B-C0035696
was	O
higher	B-C0205250
in	O
cs	B-C1440440
,	O
cs	B-C1440440
+	O
ola	B-C0028928
,	O
cs	B-C1440440
+	O
lna	B-C0023749
,	O
cs	B-C1440440
+	O
pam	B-C0030234
,	O
or	O
cs	B-C1440440
+	O
sta	B-C0038229
compared	B-C1707455
with	O
fbs	B-C3812213
,	O
whereas	O
the	O
expression	B-C0017262
of	O
atgl	B-C1538686
and	O
c/ebpα	B-C1413322
was	O
higher	B-C0205250
in	O
cs	B-C1440440
,	O
cs	B-C1440440
+	O
ola	B-C0028928
,	O
or	O
cs	B-C1440440
+	O
lna	B-C0023749
than	O
fbs	B-C3812213
cells	B-C0007634
.	O
	
in	O
conclusion	O
,	O
these	O
results	B-C2825142
showed	O
that	O
fa	B-C0015684
have	O
different	B-C1705242
potentials	B-C3245505
to	O
induce	B-C0205263
adipogenesis	B-C0596843
,	O
lna	B-C0023749
is	O
the	O
most	O
potent	B-C3245505
among	O
the	O
tested	O
fa	B-C0015684
,	O
and	O
these	O
potentials	B-C3245505
can	O
be	O
improved	O
in	O
the	O
presence	B-C0150312
of	O
a	O
novel	B-C0205314
rapid	B-C0456962
analysis	B-C0936012
using	O
mass	B-C0037813
spectrometry	I-C0037813
to	O
evaluate	O
downstream	B-C0522506
refolding	B-C0162847
of	O
recombinant	B-C0904505
human	I-C0904505
insulin-like	I-C0904505
growth	I-C0904505
factor-1	I-C0904505
mecasermin	B-C0904505
mecasermin	B-C0904505
is	O
used	O
to	O
treat	O
elevated	B-C0020456
blood	I-C0020456
sugar	I-C0020456
as	O
well	O
as	O
growth	B-C0037663
hormone	I-C0037663
-	O
resistant	B-C0332325
laron-type	B-C0271568
dwarfism	I-C0271568
.	O
	
mecasermin	B-C0904505
isolated	O
from	O
inclusion	B-C0007637
bodies	I-C0007637
in	O
extracts	O
of	O
e.coli	B-C0014834
must	O
be	O
refolded	O
to	O
acquire	O
sufficient	O
activity	O
.	O
	
however	O
,	O
there	O
is	O
no	O
rapid	B-C0456962
analytical	B-C0178476
method	I-C0178476
for	O
monitoring	O
refolding	B-C0162847
during	O
the	O
purification	B-C0597301
process	O
.	O
	
we	O
prepared	O
mecasermin	B-C0904505
drug	B-C0013227
product	I-C0013227
,	O
in-process	O
samples	B-C0370003
during	O
the	O
oxidation	B-C0030011
of	O
mecasermin	B-C0904505
,	O
forced-reduced	O
mecasermin	B-C0904505
,	O
and	O
aerially	O
oxidized	O
mecasermin	B-C0904505
after	O
forced	O
reduction	B-C0301630
.	O
	
desalted	O
mecasermin	B-C0904505
samples	B-C0370003
were	O
analyzed	O
using	O
maldi-isd	B-C0282597
.	O
	
the	O
peak	B-C0392762
intensity	I-C0392762
ratio	I-C0392762
of	O
product	O
to	O
precursor	O
ion	O
was	O
determined	O
.	O
	
the	O
charge	B-C0205556
state	I-C0205556
distribution	I-C0205556
csd	B-C0205556
of	O
mecasermin	B-C0904505
ions	O
was	O
evaluated	O
using	O
esi-ms	B-C0596495
coupled	O
with	O
sec-mode	O
hplc	B-C0008562
.	O
	
the	O
drift	B-C0392762
time	I-C0392762
and	O
collision	B-C0392762
cross-sectional	I-C0392762
areas	I-C0392762
ccs	B-C0392762
of	O
mecasermin	B-C0904505
ions	O
were	O
evaluated	O
using	O
esi-ims-ms	B-C0022885
coupled	B-C1948027
with	O
sec-mode	O
hplc	B-C0008562
.	O
	
maldi-isd	B-C0282597
data	O
,	O
csd	B-C0392762
values	I-C0392762
determined	O
using	O
esi-ms	B-C0596495
,	O
and	O
the	O
ccs	B-C0392762
acquired	O
using	O
esi-ims-ms	B-C0022885
revealed	O
the	O
relationship	B-C0439849
between	O
the	O
folded	B-C0332462
and	O
unfolded	B-C1254362
proteoforms	B-C1510464
of	O
forced-reduced	O
mecasermin	B-C0904505
and	O
aerially	O
oxidized	O
mecasermin	B-C0904505
with	O
the	O
free-sh	B-C0392762
protein	I-C0392762
ratio	I-C0392762
of	O
mecasermin	B-C0904505
drug	B-C0013227
product	I-C0013227
.	O
	
the	O
collision	B-C0392762
cross-sectional	I-C0392762
area	I-C0392762
,	O
which	O
is	O
determined	O
using	O
esi-ims-ms	B-C0022885
,	O
provided	O
proteoform	B-C1510464
information	O
through	O
rapid	B-C0456962
monitoring	O
<2	O
min	O
of	O
in-process	O
samples	B-C0370003
during	O
the	O
manufacture	O
of	O
mecasermin	B-C0904505
.	O
	
esi-ims-ms	B-C0022885
coupled	O
with	O
sec-mode	O
hplc	B-C0008562
is	O
a	O
rapid	B-C0456962
and	O
robust	B-C2986815
method	O
for	O
analyzing	O
the	O
free-sh	B-C0392762
protein	I-C0392762
ratio	I-C0392762
of	O
mecasermin	B-C0904505
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	B-C1510464
changes	O
during	O
the	O
oxidation	B-C0030011
of	O
mecasermin	B-C0904505
.	O
	
esi-ims-ms	B-C0022885
is	O
applicable	O
as	O
a	O
process	O
analytical	O
technology	O
tool	O
for	O
identifying	O
the	O
""""	O
critical	B-C1511545
quality	B-C0332306
attributes	B-C1882133
""""	O
and	O
implementing	O
""""	O
quality	B-C0332306
by	O
design	B-C1707689
""""	O
for	O
manufacturing	O
regulated	B-C0017263
intron	B-C0021920
removal	B-C1883720
integrates	O
motivational	B-C3825945
state	I-C3825945
and	O
experience	B-C0596545
myriad	O
experiences	B-C0596545
produce	O
transient	B-C0025265
memory	I-C0025265
,	O
yet	O
,	O
contingent	O
on	O
the	O
internal	B-C0025361
state	I-C0025361
of	O
the	O
organism	B-C0029235
and	O
the	O
saliency	O
of	O
the	O
experience	B-C0596545
,	O
only	O
some	O
memories	B-C0025260
persist	O
over	O
time	B-C0040223
.	O
	
how	O
experience	B-C0596545
and	O
internal	B-C0025361
state	I-C0025361
influence	B-C4054723
the	O
duration	B-C0449238
of	O
memory	B-C0025260
at	O
the	O
molecular	O
level	O
remains	O
unknown	O
.	O
	
a	O
self-assembled	B-C0205418
aggregated	I-C0205418
state	O
of	O
drosophila	B-C0949989
orb2a	I-C0949989
protein	I-C0949989
is	O
required	O
specifically	O
for	O
long-lasting	B-C0423909
memory	I-C0423909
.	O
	
we	O
report	O
that	O
in	O
the	O
adult	B-C1440070
fly	I-C1440070
brain	B-C0006104
the	O
mrna	B-C0035696
encoding	B-C2700640
orb2a	B-C0949989
protein	I-C0949989
exists	O
in	O
an	O
unspliced	B-C0026661
non-protein-coding	I-C0026661
form	I-C0026661
.	O
	
the	O
convergence	B-C2700387
of	O
experience	B-C0596545
and	O
internal	B-C0013126
drive	I-C0013126
transiently	O
increases	B-C0442805
the	O
spliced	B-C0035696
protein-coding	I-C0035696
orb2a	I-C0035696
mrna	I-C0035696
.	O
	
a	O
screen	O
identified	O
pasilla	B-C1100909
,	O
the	O
fly	B-C1440070
ortholog	O
of	O
mammalian	B-C0024660
nova-1	B-C0033684
/	O
2	B-C0033684
,	O
as	O
a	O
mediator	B-C1363844
of	O
orb2a	B-C0035696
mrna	I-C0035696
processing	B-C0314627
.	O
	
a	O
single-nucleotide	B-C0028630
substitution	B-C0596324
in	O
the	O
intronic	B-C0021920
region	O
that	O
reduces	B-C0392756
pasilla	B-C1100909
binding	B-C0033618
and	O
intron	B-C0021920
removal	B-C1883720
selectively	O
impairs	B-C0221099
long-term	B-C0423909
memory	I-C0423909
.	O
	
we	O
posit	O
that	O
pasilla	B-C1100909
-mediated	O
processing	B-C0314627
of	O
unspliced	B-C0035696
orb2a	I-C0035696
mrna	I-C0035696
integrates	O
experience	B-C0596545
and	O
internal	B-C0025361
state	I-C0025361
to	O
control	O
orb2a	B-C0949989
protein	I-C0949989
abundance	B-C2346714
and	O
long-term	B-C0423909
memory	I-C0423909
formation	B-C1522492
.	O
	
the	O
flashe	B-C0038951
study	I-C0038951
survey	B-C0038951
development	B-C1527148
,	O
dyadic	B-C0870454
perspectives	O
,	O
and	O
participant	B-C0679646
characteristics	B-C1521970
the	O
national	B-C1513882
cancer	I-C1513882
institute	I-C1513882
developed	O
the	O
family	B-C0015608
life	I-C0015608
,	O
activity	B-C0441655
,	O
sun	B-C0038817
,	O
health	B-C0018684
,	O
and	O
eating	B-C0013470
flashe	B-C0038951
study	B-C0038951
to	O
examine	O
multiple	O
cancer	B-C0281206
preventive	I-C0281206
behaviors	B-C0018687
within	O
parent	B-C0030551
-	O
adolescent	B-C0205653
dyads	B-C0870454
.	O
	
the	O
purpose	O
of	O
creating	O
flashe	B-C0038951
was	O
to	O
enable	O
the	O
examination	O
of	O
physical	B-C0026606
activity	I-C0026606
,	O
diet	B-C0012155
,	O
and	O
other	O
cancer	B-C0281206
preventive	I-C0281206
behaviors	I-C0281206
and	O
potential	O
correlates	O
among	O
parent	B-C0030551
-	O
adolescent	B-C0205653
dyads	B-C0870454
.	O
	
flashe	B-C0038951
surveys	I-C0038951
were	O
developed	O
from	O
a	O
process	O
involving	O
literature	B-C0282441
reviews	I-C0282441
,	O
scientific	B-C0036397
input	B-C1708517
from	O
experts	B-C0009817
in	O
the	O
field	O
,	O
cognitive	B-C0204471
testing	I-C0204471
,	O
and	O
usability	O
testing	O
.	O
	
this	O
cross-sectional	B-C0010362
,	O
web-based	B-C2603343
study	I-C2603343
of	O
parents	B-C0030551
and	O
their	O
adolescent	B-C0205653
children	B-C0680063
aged	O
12-17	O
years	O
was	O
administered	B-C1621583
between	O
april	B-C3715024
and	O
october	B-C3828732
2014	O
.	O
	
the	O
nationwide	O
sample	O
consisted	O
of	O
1	O
parent	B-C0030551
-	O
adolescent	B-C0205653
dyads	B-C0870454
1	O
parents	B-C0030551
and	O
1	O
adolescents	B-C0205653
who	O
returned	O
all	O
flashe	B-C0038951
surveys	I-C0038951
.	O
	
flashe	B-C0038951
assessed	O
parent	B-C0030551
and	O
adolescent	B-C0205653
reports	O
of	O
several	O
intrapersonal	O
and	O
interpersonal	B-C3476070
domains	O
including	O
psychosocial	B-C0033963
variables	I-C0033963
,	O
parenting	B-C0085092
,	O
and	O
the	O
community	B-C0563116
and	O
home	B-C0442519
environments	I-C0442519
.	O
	
on	O
a	O
subset	O
of	O
example	O
flashe	B-C0038951
items	O
across	O
these	O
domains	O
,	O
responses	B-C1547656
of	O
parents	B-C0030551
and	O
adolescents	B-C0205653
within	O
the	O
same	O
dyads	B-C0870454
were	O
positively	O
and	O
significantly	O
correlated	B-C0010100
r	O
=0	O
.	O
	
analyses	O
were	O
run	O
in	O
2015-2016	O
.	O
	
flashe	B-C0038951
data	O
present	O
multiple	O
opportunities	O
for	O
studying	O
research	B-C0681799
questions	I-C0681799
among	O
individuals	B-C0027361
or	O
dyads	B-C0870454
,	O
including	O
the	O
ability	B-C0085732
to	O
examine	O
similarity	B-C2348205
between	O
parents	B-C0030551
and	O
adolescents	B-C0205653
on	O
many	O
constructs	O
relevant	O
to	O
cancer	B-C0281206
preventive	I-C0281206
behaviors	I-C0281206
.	O
	
flashe	B-C0038951
data	O
are	O
publicly	O
available	O
for	O
researchers	B-C0035173
and	O
practitioners	B-C0017319
to	O
help	O
advance	O
research	B-C0035168
on	O
cancer	B-C0281206
preventive	I-C0281206
health	B-C0018687
behaviors	I-C0018687
.	O
	
sex	B-C0036866
differences	I-C0036866
in	O
the	O
effect	B-C1704420
of	I-C1704420
chronic	B-C1510527
mild	I-C1510527
stress	I-C1510527
on	O
mouse	B-C0025929
prefrontal	B-C0162783
cortical	I-C0162783
bdnf	B-C0107103
levels	O
a	O
role	O
of	O
major	O
ovarian	B-C0729511
hormones	I-C0729511
depression	B-C0011570
induced	B-C0205263
by	O
stress	B-C0038435
is	O
affected	O
by	O
sex	B-C1522384
,	O
age	B-C0001779
and	O
hormonal	B-C0458083
status	O
of	O
the	O
animal	B-C0003062
and	O
also	O
by	O
duration	B-C0449238
and	O
type	O
of	O
the	O
stressors	B-C0597530
.	O
	
moreover	O
,	O
higher	O
prevalence	O
of	O
depression	B-C0011570
and	O
comorbidities	B-C0009488
in	O
women	B-C0043210
than	O
men	B-C0025266
implies	O
the	O
need	O
to	O
include	O
the	O
sex	B-C1522384
variable	O
in	O
studies	O
on	O
animal	B-C0599779
models	I-C0599779
of	O
depression	B-C0011570
.	O
	
the	O
present	O
study	O
was	O
therefore	O
initiated	O
to	O
evaluate	O
the	O
effect	B-C1704420
of	I-C1704420
sex	B-C1522384
and	O
ovarian	B-C0729511
hormones	I-C0729511
on	O
depression	B-C0011570
-like	O
phenotypes	B-C0031437
in	O
mice	B-C0025929
exposed	O
to	O
a	O
21-day	O
chronic	B-C1510527
variable	I-C1510527
mild	I-C1510527
stress	I-C1510527
cvms	B-C1510527
paradigm	B-C0242481
.	O
	
adult	B-C0001675
male	B-C0086582
,	O
intact	B-C3687560
female	I-C3687560
and	O
,	O
ovariectomized	B-C3687559
ovx	I-C3687559
female	I-C3687559
mice	B-C0025929
exposed	O
to	O
cvms	B-C1510527
displayed	O
despair	O
behavior	B-C0004927
,	O
a	O
depression	B-C0011570
-like	O
phenotype	B-C0031437
,	O
in	O
all	O
the	O
groups	O
.	O
	
however	O
,	O
intact	B-C3687560
females	I-C3687560
alone	O
,	O
but	O
not	O
males	B-C0086582
and	O
ovx	B-C3687559
females	I-C3687559
,	O
showed	O
anhedonia	B-C0178417
,	O
another	O
depression	B-C0011570
-like	O
phenotype	B-C0031437
.	O
	
at	O
the	O
molecular	B-C0596958
level	I-C0596958
,	O
the	O
expression	B-C1171362
of	O
brain-derived	B-C0107103
neurotrophic	I-C0107103
factor	I-C0107103
bdnf	B-C0107103
,	O
a	O
neuropeptide	B-C0027895
associated	B-C0332281
with	I-C0332281
depression	B-C0011570
,	O
and	O
few	O
other	O
stress	B-C0038435
-specific	O
genes	B-C0017337
crh	B-C1366488
,	O
nr3c1	B-C1334899
,	O
cart	B-C1824528
,	O
and	O
npy	B-C1417815
were	O
measured	O
in	O
the	O
prefrontal	B-C0162783
cortex	I-C0162783
pfc	B-C0162783
region	O
of	O
the	O
reward	O
circuitry	O
.	O
	
there	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
bdnf	B-C0107103
protein	B-C1171362
expression	I-C1171362
along	O
with	O
an	O
increase	O
in	O
the	O
mrna	B-C1515670
expression	I-C1515670
of	O
crh	B-C1366488
,	O
nr3c1	B-C1334899
,	O
cart	B-C1824528
,	O
and	O
npy	B-C1417815
in	O
intact	B-C3687560
females	I-C3687560
,	O
but	O
not	O
in	O
the	O
other	O
two	O
groups	O
of	O
mice	B-C0025929
.	O
	
ovx	B-C3687559
females	I-C3687559
resembled	O
males	B-C0086582
in	O
behavioral	B-C0243095
and	O
molecular	B-C4054479
responses	I-C4054479
to	O
cvms	B-C1510527
.	O
	
17β-estradiol	B-C0014912
e2	B-C0014912
administration	B-C1533734
,	O
not	O
progesterone	B-C0033308
p4	B-C0033308
,	O
to	O
ovx	B-C3687559
female	I-C3687559
stress	B-C0038435
mice	B-C0025929
,	O
mitigated	O
despair	O
and	O
enhanced	O
hedonic	O
capacity	O
with	O
an	O
increased	O
expression	B-C1171362
of	O
bdnf	B-C0107103
in	O
pfc	B-C0162783
.	O
	
this	O
study	O
strengthens	O
the	O
evidence	O
for	O
the	O
beneficial	O
effects	B-C1704420
of	I-C1704420
e2	B-C0014912
administration	B-C1533734
in	O
stress	B-C0038435
development	B-C1527148
and	O
evaluation	B-C0015194
of	O
the	O
adhd	B-C1263846
cognitions	O
scale	O
for	O
adults	O
the	O
clinical	O
literature	O
on	O
adhd	B-C0451081
in	O
adults	O
suggests	O
that	O
""""	O
overly	O
positive	O
""""	O
or	O
optimistic	O
cognitions	O
may	O
contribute	O
to	O
impairment	O
and	O
failure	O
to	O
use	O
self-regulation	O
skills	O
in	O
this	O
population	O
,	O
yet	O
the	O
research	O
literature	O
on	O
this	O
topic	O
is	O
limited	O
.	O
	
we	O
developed	O
the	O
adhd	O
cognitions	I-C0451081
scale	I-C0451081
acs	O
,	O
a	O
brief	O
self-report	O
measure	O
of	O
adhd	O
-related	O
thoughts	O
,	O
and	O
evaluated	O
its	O
psychometric	O
properties	O
.	O
	
we	O
collected	O
self-report	O
measures	O
,	O
inculding	O
the	O
acs	O
,	O
from	O
two	O
large	O
community	O
samples	O
ns	O
=	O
262	O
,	O
304	O
.	O
	
the	O
measure	O
demonstrated	O
a	O
one-factor	O
solution	O
that	O
replicated	O
in	O
the	O
second	O
sample	O
.	O
	
evidence	O
of	O
good	O
internal	O
consistency	O
and	O
also	O
convergent	O
and	O
divergent	O
validity	O
was	O
obtained	O
for	O
both	O
samples	O
.	O
	
scores	O
on	O
the	O
acs	O
correlated	O
with	O
functional	O
impairment	O
,	O
time	O
management	O
problems	O
,	O
and	O
avoidant	O
coping	O
strategies	O
.	O
	
with	O
additional	O
study	O
,	O
the	O
acs	O
may	O
be	O
useful	O
to	O
identify	O
and	O
track	O
maladaptive	O
adhd	O
-related	O
cognitions	O
during	O
cognitive-behavioral	O
treatment	O
,	O
and	O
to	O
further	O
study	O
the	O
role	O
of	O
these	O
thoughts	O
in	O
adhd	O
-related	O
impairment	B-C0221099
visual	B-C0234621
confidence	B-C1704726
visual	B-C0234621
confidence	B-C1704726
refers	O
to	O
an	O
observer's	B-C0870992
ability	B-C0085732
to	O
judge	B-C0022423
the	O
accuracy	B-C0443131
of	O
her	O
perceptual	B-C0679006
decisions	I-C0679006
.	O
	
even	O
though	O
confidence	B-C1704726
judgments	B-C0022423
have	O
been	O
recorded	O
since	O
the	O
early	O
days	O
of	O
psychophysics	B-C0033930
,	O
only	O
recently	O
have	O
they	O
been	O
recognized	O
as	O
essential	O
for	O
a	O
deeper	O
understanding	O
of	O
visual	B-C0042830
perception	I-C0042830
.	O
	
the	O
reluctance	O
to	O
study	O
visual	B-C0234621
confidence	B-C1704726
may	O
have	O
come	O
in	O
part	O
from	O
obtaining	O
convincing	O
experimental	B-C3887511
evidence	I-C3887511
in	O
favor	O
of	O
metacognitive	B-C0589513
abilities	I-C0589513
rather	O
than	O
just	O
perceptual	B-C0312418
sensitivity	I-C0312418
.	O
	
some	O
effort	O
has	O
thus	O
been	O
dedicated	O
to	O
offer	O
different	O
experimental	B-C0681797
paradigms	I-C0681797
to	O
study	B-C2603343
visual	B-C0234621
confidence	B-C1704726
in	O
humans	B-C0086418
and	O
nonhuman	B-C0003062
animals	I-C0003062
.	O
	
to	O
understand	O
the	O
origins	B-C0439659
of	O
confidence	B-C1704726
judgments	B-C0022423
,	O
investigators	B-C0035173
have	O
developed	O
two	O
competing	O
frameworks	O
.	O
	
the	O
approach	O
based	O
on	O
signal	B-C0011114
decision	I-C0011114
theory	I-C0011114
is	O
popular	O
but	O
fails	B-C0231175
to	O
account	O
for	O
response	B-C0034746
times	I-C0034746
.	O
	
in	O
contrast	O
,	O
the	O
approach	O
based	O
on	O
accumulation	O
of	O
evidence	B-C3887511
models	B-C3161035
naturally	O
includes	O
the	O
dynamics	B-C3826426
of	O
perceptual	B-C0679006
decisions	I-C0679006
.	O
	
these	O
models	B-C3161035
can	O
explain	O
a	O
range	O
of	O
results	B-C1274040
,	O
including	O
the	O
apparently	O
paradoxical	B-C0205310
dissociation	B-C0086168
between	O
performance	B-C0597198
and	O
confidence	B-C1704726
grapevine	B-C0682492
subtilase	B-C0767764
family	I-C0767764
update	O
on	O
new	O
sequences	B-C0004793
and	O
nomenclature	B-C0600281
proposal	I-C0600281
in	O
grapevine	B-C0682492
,	O
serine	B-C2717971
peptidases	I-C2717971
from	O
the	O
subtilase	B-C0767764
family	I-C0767764
were	O
recently	O
associated	O
to	O
plasmopara	B-C1091290
viticola	I-C1091290
resistance	B-C4281815
.	O
	
this	O
family	O
in	O
grapevine	B-C0682492
,	O
first	O
characterized	O
in	O
2014	O
,	O
was	O
re-analyzed	B-C0936012
last	O
year	O
and	O
82	O
subtilase	B-C0767764
genes	B-C0017337
were	O
identified	O
.	O
	
however	O
,	O
in	O
november	O
of	O
2016	O
,	O
the	O
national	B-C1705803
center	I-C1705803
for	I-C1705803
biotechnology	I-C1705803
information	I-C1705803
database	B-C0242356
ncbi	B-C1705803
made	O
a	O
new	O
public	O
release	O
of	O
the	O
grapevine	B-C0682492
genome	B-C2936606
annotation	I-C2936606
based	O
on	O
new	O
sequencing	B-C0026382
data	I-C0026382
and	O
better	O
prediction	B-C0681842
algorithms	B-C0002045
.	O
	
as	O
a	O
consequence	B-C0686907
,	O
some	O
gene	B-C2936606
annotations	I-C2936606
and	O
lengths	O
changed	O
.	O
	
here	O
we	O
present	O
an	O
update	O
to	O
the	O
grapevine	B-C0682492
subtilase	B-C0767764
gene	B-C1517488
family	I-C1517488
sequences	B-C0004793
sbt	B-C0767764
,	O
namely	O
sequence	B-C0600091
identifiers	I-C0600091
,	O
bioinformatic	B-C1140694
predictions	B-C0681842
and	O
recommend	O
a	O
nomenclature	B-C0600281
for	O
the	O
grapevine	B-C0682492
sbt	B-C0767764
genes	B-C0017337
.	O
	
our	O
results	B-C0456984
show	O
that	O
grapevine	B-C0682492
subtilase	B-C0767764
gene	B-C1517488
family	I-C1517488
is	O
now	O
constituted	O
by	O
87	O
subtilase	B-C0767764
genes	B-C0017337
encoding	B-C2700640
for	O
109	O
subtilase	B-C0767764
proteins	I-C0767764
and	O
,	O
despite	O
the	O
reported	O
alterations	B-C0596611
,	O
expression	B-C0017262
data	B-C1511726
on	O
subtilases	B-C0767764
associated	O
to	O
grapevine	B-C0682492
resistance	B-C4281815
to	O
p	B-C1091290
.	O
	
viticola	I-C1091290
pathosystem	B-C0450254
did	O
not	O
suffer	O
any	O
shared	B-C3179495
decision	I-C3179495
making	I-C3179495
and	O
the	O
promise	B-C1555307
of	O
a	O
respectful	O
and	O
equitable	O
healthcare	B-C0018696
system	I-C0018696
in	O
peru	B-C0031238
peru	B-C0031238
has	O
achieved	O
sustained	B-C0282113
development	I-C0282113
in	O
the	O
last	O
two	O
decades	B-C2981279
.	O
	
however	O
,	O
despite	O
this	O
achievement	O
,	O
it	O
has	O
not	O
been	O
matched	O
with	O
improvements	B-C2936612
in	O
the	O
quality	B-C0870471
of	I-C0870471
education	I-C0870471
and	O
health	B-C0034379
investment	O
in	O
both	O
sectors	B-C0009433
is	O
among	O
the	O
lowest	O
in	O
the	O
region	B-C0017446
.	O
	
this	O
situation	O
perpetuates	O
huge	O
gaps	B-C4277599
in	O
infrastructure	B-C1254363
and	O
also	O
conditions	O
a	O
poor	B-C1401894
literacy	I-C1401894
level	I-C1401894
of	O
the	O
population	B-C1257890
specifically	O
in	O
health	B-C0018684
.	O
	
currently	O
,	O
there	O
is	O
a	O
fragmented	O
model	B-C3161035
of	O
patient	B-C0017313
care	I-C0017313
,	O
in	O
which	O
the	O
systems	B-C0018696
are	O
exclusive	O
of	O
each	O
other	O
.	O
	
they	O
do	O
not	O
cooperate	B-C0392337
or	O
communicate	B-C0009452
with	O
each	O
other	O
and	O
if	O
there	O
is	O
no	O
vertical	O
communication	B-C0009452
within	O
the	O
system	B-C0018696
,	O
preventing	O
referral	B-C0034927
of	I-C0034927
patients	I-C0034927
directly	O
from	O
the	O
basic	B-C1547668
level	I-C1547668
to	O
the	O
complex	B-C1547668
level	I-C1547668
of	O
care	B-C0017313
when	O
needed	O
.	O
	
in	O
addition	O
,	O
there	O
has	O
been	O
no	O
progress	O
in	O
the	O
development	B-C1527148
of	O
an	O
empathetic	O
,	O
respectful	O
or	O
person-centered	B-C1254363
clinical	I-C1254363
practice	I-C1254363
instead	O
,	O
economic	B-C0013557
,	O
social	B-C0728831
and	O
educational	B-C0013652
differences	O
perpetuate	O
a	O
paternalistic	O
clinical	B-C1254363
practice	I-C1254363
.	O
	
the	O
task	O
of	O
orienting	O
medical	B-C0220931
training	I-C0220931
towards	O
the	O
development	B-C1527148
of	O
humanism	B-C0020156
is	O
pending	O
.	O
	
the	O
patient	B-C0030705
is	O
the	O
center	O
of	O
the	O
medical	B-C0079816
act	I-C0079816
and	O
the	O
main	O
objective	O
of	O
doctors'	B-C0031831
actions	O
.	O
	
a	O
humanistic	B-C1947933
care	I-C1947933
approach	I-C1947933
will	O
not	O
only	O
empower	O
the	O
person	B-C0027361
in	O
the	O
clinical	O
encounter	O
-	O
to	O
participate	O
and	O
make	O
decisions	O
related	O
to	O
his/her	O
health	B-C0086388
care	I-C0086388
-	O
but	O
it	O
will	O
allow	O
us	O
to	O
move	O
towards	O
an	O
empathetic	O
,	O
caring	B-C0150499
,	O
respectful	B-C0679133
and	O
kind	O
model	B-C3161035
of	O
clinical	B-C1254363
practice	I-C1254363
.	O
	
identification	O
of	O
markers	B-C0005516
for	O
quiescent	B-C3686820
pancreatic	B-C2936598
stellate	I-C2936598
cells	I-C2936598
in	O
the	O
normal	B-C0205307
human	B-C0086418
pancreas	B-C0030274
pancreatic	B-C2936598
stellate	I-C2936598
cells	I-C2936598
pscs	B-C2936598
play	O
a	O
central	O
role	O
as	O
source	O
of	O
fibrogenic	B-C0007634
cells	I-C0007634
in	O
pancreatic	B-C0235974
cancer	I-C0235974
and	O
chronic	B-C0149521
pancreatitis	I-C0149521
.	O
	
in	O
contrast	O
to	O
quiescent	B-C3686820
hepatic	B-C2340138
stellate	I-C2340138
cells	I-C2340138
qhscs	B-C2340138
,	O
a	O
specific	O
marker	B-C0005516
for	O
quiescent	B-C3686820
pscs	B-C2936598
qpscs	B-C2936598
that	O
can	O
be	O
used	O
in	O
formalin-fixed	B-C2711483
and	I-C2711483
paraffin	I-C2711483
embedded	I-C2711483
ffpe	I-C2711483
normal	I-C2711483
human	I-C2711483
pancreatic	I-C2711483
tissue	I-C2711483
has	O
not	O
been	O
identified	O
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
a	O
marker	O
enabling	O
the	O
identification	O
of	O
qpscs	B-C2936598
in	O
normal	B-C0205307
human	B-C0086418
ffpe	B-C2711483
pancreatic	I-C2711483
tissue	I-C2711483
.	O
	
immunohistochemical	B-C1441616
ihc	B-C1441616
,	O
double-ihc	B-C1441616
,	O
immunofluorescence	B-C0079603
if	B-C0079603
and	O
double-if	B-C0079603
analyses	I-C0079603
were	O
carried	O
out	O
using	O
a	O
tissue	B-C1519522
microarray	I-C1519522
consisting	O
of	O
cores	O
with	O
normal	B-C0205307
human	B-C0086418
pancreatic	B-C0587009
tissue	I-C0587009
.	O
	
cores	O
with	O
normal	B-C0205307
human	B-C0086418
liver	B-C0023884
served	O
as	O
control	B-C0009932
.	O
	
antibodies	B-C0003241
directed	O
against	O
adipophilin	B-C1505480
,	O
α-sma	B-C2716282
,	O
cd146	B-C0386212
,	O
crbp-1	B-C1872428
,	O
cytoglobin	B-C1450216
,	O
desmin	B-C0011696
,	O
gfap	B-C0017626
,	O
nestin	B-C3711758
,	O
s100a4	B-C0287850
and	O
vinculin	B-C1454484
were	O
examined	O
,	O
with	O
special	O
emphasis	O
on	O
their	O
expression	O
in	O
periacinar	B-C0442156
cells	B-C0007634
in	O
the	O
normal	B-C0205307
human	B-C0086418
pancreas	B-C0030274
and	O
perisinusoidal	B-C0227531
cells	I-C0227531
in	O
the	O
normal	B-C0205307
human	B-C0086418
liver	B-C0023884
.	O
	
the	O
immunolabelling	B-C0079609
capacity	B-C1516240
was	O
evaluated	O
according	O
to	O
a	O
semiquantitative	B-C2986822
scoring	I-C2986822
system	I-C2986822
.	O
	
double-if	B-C0079603
of	O
the	O
markers	B-C0005516
of	O
interest	O
together	O
with	O
markers	B-C0005516
for	O
other	O
periacinar	B-C0442156
cells	B-C0007634
was	O
performed	O
.	O
	
moreover	O
,	O
the	O
utility	O
of	O
histochemical	B-C1508788
stains	I-C1508788
for	O
the	O
identification	O
of	O
human	B-C0086418
qpscs	B-C2936598
was	O
examined	O
,	O
and	O
their	O
ultrastructure	B-C0041623
was	O
revisited	O
by	O
electron	B-C0013842
microscopy	I-C0013842
.	O
	
adipophilin	B-C1505480
,	O
crbp-1	B-C1872428
,	O
cytoglobin	B-C1450216
and	O
vinculin	B-C1454484
were	O
expressed	O
in	O
qhscs	B-C2340138
in	O
the	O
liver	B-C0023884
,	O
whereas	O
cytoglobin	B-C1450216
and	O
adipophilin	B-C1505480
were	O
expressed	O
in	O
qpscs	B-C2936598
in	O
the	O
pancreas	B-C0030274
.	O
	
adipophilin	B-C1505480
immunohistochemistry	B-C0021044
was	O
highly	O
dependent	O
on	O
the	O
preanalytical	B-C0872291
time	I-C0872291
interval	I-C0872291
pati	B-C0872291
from	O
removal	O
of	O
the	O
tissue	B-C0040300
to	O
formalin	B-C3536615
fixation	I-C3536615
.	O
	
cytoglobin	B-C1450216
,	O
s100a4	B-C0287850
and	O
vinculin	B-C1454484
were	O
expressed	O
in	O
periacinar	B-C0442156
fibroblasts	B-C0016030
fbs	B-C0016030
.	O
	
the	O
other	O
examined	O
markers	B-C0005516
were	O
negative	O
in	O
human	B-C0086418
qpscs	B-C2936598
.	O
	
our	O
data	O
indicate	O
that	O
cytoglobin	B-C1450216
and	O
adipophilin	B-C1505480
are	O
markers	B-C0005516
of	O
qpscs	B-C2936598
in	O
the	O
normal	B-C0205307
human	B-C0086418
pancreas	B-C0030274
.	O
	
however	O
,	O
the	O
use	O
of	O
adipophilin	B-C1505480
as	O
a	O
qpsc	B-C2936598
marker	O
may	O
be	O
limited	O
due	O
to	O
its	O
high	O
dependence	O
on	O
optimal	O
pati	B-C0872291
.	O
	
cytoglobin	B-C1450216
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
a	O
sensitive	O
marker	B-C0005516
for	O
qpscs	B-C2936598
but	O
is	O
expressed	O
in	O
fbs	B-C0016030
biomagnetic	B-C0596176
monitoring	I-C0596176
of	O
atmospheric	B-C0683932
pollution	I-C0683932
a	O
review	B-C0699752
of	I-C0699752
magnetic	B-C0563532
signatures	O
from	O
biological	B-C0600364
sensors	I-C0600364
biomagnetic	B-C0596176
monitoring	I-C0596176
of	O
atmospheric	B-C0683932
pollution	I-C0683932
is	O
a	O
growing	O
application	O
in	O
the	O
field	O
of	O
environmental	B-C0014406
magnetism	B-C0563532
.	O
	
particulate	B-C1720884
matter	I-C1720884
pm	B-C1720884
in	O
atmospheric	B-C0683932
pollution	I-C0683932
contains	O
readily-	O
measurable	B-C1513040
concentrations	O
of	O
magnetic	B-C0439876
minerals	I-C0439876
.	O
	
biological	B-C0205460
surfaces	B-C0205148
,	O
exposed	O
to	O
atmospheric	B-C0683932
pollution	I-C0683932
,	O
accumulate	O
magnetic	B-C0563532
particles	B-C0597177
over	O
time	O
,	O
providing	O
a	O
record	O
of	O
location	B-C0450429
-	O
specific	B-C0205369
,	O
time-integrated	B-C1961029
air	B-C2371710
quality	I-C2371710
information	B-C1533716
.	O
	
this	O
review	B-C0282443
summarizes	O
current	O
knowledge	O
of	O
biological	B-C0600364
material	I-C0600364
'	O
sensors	B-C0600364
'	O
used	O
for	O
biomagnetic	B-C0596176
monitoring	I-C0596176
purposes	O
.	O
	
our	O
work	O
addresses	O
the	O
range	O
of	O
magnetic	B-C0563532
properties	I-C0563532
reported	O
for	O
lichens	B-C0023657
,	O
mosses	B-C0282635
,	O
leaves	B-C0242724
,	O
bark	B-C0949119
,	O
trunk	B-C2700369
wood	I-C2700369
,	O
insects	B-C0021585
,	O
crustaceans	B-C1704306
,	O
mammal	B-C0024660
and	O
human	B-C0440744
tissues	I-C0440744
their	O
associations	O
with	O
atmospheric	B-C0001869
pollutant	I-C0001869
species	I-C0001869
pm	B-C1720884
,	O
nox	B-C0028167
,	O
trace	B-C0040577
elements	I-C0040577
,	O
pahs	B-C0032458
the	O
pros	B-C0243095
and	I-C0243095
cons	I-C0243095
of	O
biomagnetic	B-C0596176
monitoring	I-C0596176
of	O
atmospheric	B-C0683932
pollution	I-C0683932
current	O
challenges	O
for	O
large-scale	B-C0814860
implementation	I-C0814860
of	O
biomagnetic	B-C0596176
monitoring	I-C0596176
and	O
future	B-C0016884
perspectives	O
.	O
	
a	O
summary	O
table	O
is	O
presented	O
,	O
with	O
the	O
aim	O
of	O
aiding	O
researchers	B-C0035173
and	O
policy	B-C0242170
makers	I-C0242170
in	O
selecting	O
the	O
most	O
suitable	O
biological	B-C0600364
sensor	I-C0600364
for	O
their	O
intended	O
biomagnetic	B-C0596176
monitoring	I-C0596176
role	O
of	O
infrared	B-C0260249
spectroscopy	I-C0260249
and	O
imaging	B-C0079595
in	O
cancer	B-C0006826
diagnosis	B-C0011900
ftir	B-C0206055
imaging	B-C0079595
has	O
been	O
used	O
to	O
diagnose	B-C0011900
and	O
differentiate	B-C0205615
the	O
molecular	B-C1521991
differences	B-C1705242
between	O
normal	B-C0040300
and	O
diseased	B-C0012634
tissues	B-C0040300
.	O
	
the	O
differences	B-C1705242
correspond	O
to	O
the	O
distribution	B-C1704711
and	O
structure	B-C0678594
of	O
lipids	B-C0023779
,	O
proteins	B-C0033684
,	O
nucleic	B-C0028606
acids	I-C0028606
as	O
well	O
as	O
other	O
metabolites	B-C0870883
.	O
	
these	O
differences	B-C1705242
depended	O
on	O
the	O
type	B-C0872066
and	O
the	O
grade	O
of	O
cancer	B-C0006826
.	O
	
the	O
sensitivity	B-C0332324
of	O
chemotherapy	B-C3665472
drugs	B-C1254351
on	O
individual	B-C0237401
specific	O
was	O
also	O
discussed	O
.	O
	
here	O
,	O
we	O
emphasize	O
that	O
ftir	B-C0206055
spectroscopy	I-C0206055
and	O
imaging	B-C0079595
can	O
be	O
considered	O
as	O
a	O
promising	O
technique	B-C0449851
and	O
will	O
find	O
its	O
place	O
on	O
the	O
detection	B-C1511790
of	O
this	O
dreadful	B-C0012634
disease	I-C0012634
because	O
of	O
high	B-C1441604
sensitivity	I-C1441604
,	O
accuracy	B-C4035952
and	O
inexpensive	O
technique	B-C0449851
.	O
	
now	O
the	O
medical	B-C1562642
community	I-C1562642
started	O
using	O
and	O
accepting	O
this	O
technique	B-C0449851
for	O
early	B-C2363430
stage	I-C2363430
cancer	B-C0006826
detection	B-C1511790
.	O
	
but	O
,	O
this	O
technique	B-C0449851
endures	O
several	O
challenges	B-C0805586
on	O
its	O
application	O
into	O
the	O
diagnosis	B-C0011900
of	O
cancer	B-C0006826
in	O
regards	O
of	O
sample	B-C3824791
preparations	I-C3824791
,	O
data	B-C0262707
interpretation	I-C0262707
,	O
and	O
data	B-C0010992
analysis	I-C0010992
.	O
	
in	O
general	O
,	O
more	O
research	B-C0035168
is	O
needed	O
in	O
this	O
field	O
and	O
it	O
is	O
necessary	O
to	O
understand	O
the	O
morphology	B-C0332437
and	O
biology	B-C0005532
of	O
the	O
sample	O
before	O
using	O
the	O
spectroscopy	B-C0206055
and	O
imaging	B-C0079595
because	O
invaluable	B-C1511545
information	B-C1533716
the	O
clasp2	B-C1566863
protein	B-C3178902
interaction	I-C3178902
network	I-C3178902
in	O
adipocytes	B-C0206131
links	O
clip2	B-C2350719
to	O
agap3	B-C0061928
,	O
clasp2	B-C1566863
to	O
g2l1	B-C0033684
,	O
mark2	B-C0299851
,	O
and	O
soga1	B-C0026045
,	O
and	O
identifies	O
soga1	B-C0026045
as	O
a	O
microtubule-associated	B-C0026045
protein	I-C0026045
clasp2	B-C1566863
is	O
a	O
microtubule-associated	B-C0026045
protein	I-C0026045
that	O
undergoes	O
insulin	B-C0021641
-	O
stimulated	B-C0599177
phosphorylation	B-C1158886
and	O
co-localization	B-C0475264
with	O
reorganized	B-C0680829
actin	B-C0001271
and	O
glut4	B-C0166441
at	O
the	O
plasma	B-C0007603
membrane	I-C0007603
.	O
	
to	O
gain	B-C1517378
insight	B-C0233820
to	O
the	O
role	B-C1705810
of	O
clasp2	B-C1566863
in	O
this	O
system	B-C0597714
,	O
we	O
developed	B-C1527148
and	O
successfully	B-C1272703
executed	B-C1705848
a	O
streamlined	B-C0205357
interactome	B-C0872079
approach	B-C0444454
and	O
built	O
a	O
clasp2	B-C1566863
protein	B-C3178902
network	I-C3178902
in	O
3t3-l1	B-C1257743
adipocytes	I-C1257743
.	O
	
using	O
two	O
different	B-C1705242
commercially	B-C0680536
available	B-C0470187
antibodies	B-C0003241
for	O
clasp2	B-C1566863
and	O
an	O
antibody	B-C0003241
for	O
epitope	B-C0003316
-tagged	O
,	O
overexpressed	B-C1171362
clasp2	B-C1566863
,	O
we	O
performed	B-C0884358
multiple	B-C0439064
affinity	B-C0008551
purification	I-C0008551
coupled	B-C1948027
with	O
mass	B-C0037813
spectrometry	I-C0037813
ap	B-C0008551
-	O
ms	B-C0037813
experiments	B-C0681814
in	O
combination	B-C0205195
with	O
label-free	B-C0475878
quantitative	B-C0392762
proteomics	B-C0872252
and	O
analyzed	B-C0936012
the	O
data	B-C1511726
with	O
the	O
bioinformatics	B-C1140694
tool	B-C0037589
significance	B-C3203917
analysis	I-C3203917
of	I-C3203917
interactome	I-C3203917
saint	B-C3203917
.	O
	
we	O
discovered	B-C1880355
that	O
clasp2	B-C1566863
co-immunoprecipitates	B-C0301871
co-ips	B-C0301871
the	O
novel	O
protein	B-C0033684
soga1	B-C0026045
,	O
the	O
microtubule-associated	B-C3542416
protein	I-C3542416
kinase	I-C3542416
mark2	B-C0299851
,	O
and	O
the	O
microtubule	B-C0026046
/	O
actin	B-C0001271
-	O
regulating	B-C1327622
protein	B-C0033684
g2l1	B-C0033684
.	O
	
the	O
gtpase-activating	B-C0061928
proteins	I-C0061928
agap1	B-C1173678
and	O
agap3	B-C0061928
were	O
also	O
enriched	O
in	O
the	O
clasp2	B-C1566863
interactome	B-C0872079
,	O
although	O
subsequent	B-C0332282
agap3	B-C0061928
and	O
clip2	B-C2350719
interactome	B-C0872079
analysis	B-C0936012
suggests	O
a	O
preference	B-C0558295
of	O
agap3	B-C0061928
for	O
clip2	B-C2350719
.	O
	
follow-up	O
mark2	B-C0299851
interactome	B-C0872079
analysis	B-C0936012
confirmed	B-C0750484
reciprocal	B-C1882911
co-ip	B-C0301871
of	O
clasp2	B-C1566863
and	O
also	O
revealed	O
mark2	B-C0299851
can	O
co-ip	B-C0301871
soga1	B-C0026045
,	O
glycogen	B-C0017932
synthase	I-C0017932
,	O
and	O
glycogenin	B-C1612135
.	O
	
investigating	B-C1292732
the	O
soga1	B-C0026045
interactome	B-C0872079
confirmed	B-C0750484
soga1	B-C0026045
can	O
reciprocal	B-C1882911
co-ip	B-C0301871
both	O
clasp2	B-C1566863
and	O
mark2	B-C0299851
as	O
well	O
as	O
glycogen	B-C0017932
synthase	I-C0017932
and	O
glycogenin	B-C1612135
.	O
	
soga1	B-C0026045
was	O
confirmed	B-C0750484
to	O
colocalize	B-C0392752
with	O
clasp2	B-C1566863
and	O
also	O
with	O
tubulin	B-C0041348
,	O
which	O
identifies	O
soga1	B-C0026045
as	O
a	O
new	O
microtubule-associated	B-C0026045
protein	I-C0026045
.	O
	
these	O
results	B-C0683954
introduce	O
the	O
metabolic	B-C0597299
function	I-C0597299
of	O
these	O
proposed	B-C1553874
novel	O
protein	B-C3178902
networks	I-C3178902
and	O
their	O
relationship	B-C0439849
with	O
microtubules	B-C0026046
as	O
new	O
fields	O
of	O
cytoskeleton	B-C0010853
-	O
associated	B-C0332281
protein	B-C0026376
biology	I-C0026376
.	O
	
